

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 26, 2005, 15:11:57 ; Search time 76 Seconds
(without alignments)
3.625 Million cell updates/sec

Title: nm000201

Perfect score: 2986

Sequence: 1 GCGCCCGAGTCGAGCTGAG.....ATAAAGTTTCTCAACTGCC 2986

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 2288 seqs, 46127 residues

Total number of hits satisfying chosen parameters: 4576

Minimum DB seq length: 18

Maximum DB seq length: 26

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 2293 summaries

Database : rng201.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	26	0.9	26	1	Human intercellula
C 2	26	0.9	26	1	Intercellular adhe
C 3	26	0.9	26	1	Low adenosine anti
C 4	26	0.9	26	1	Human ICAM-1 polyn
C 5	26	0.9	26	1	Human ICAM-1 antis
C 6	26	0.9	26	1	Human ICAM-1 DNA f
C 7	24	0.8	24	1	ICAM-1 primer PCR
C 8	24	0.8	24	1	ICAM-1 primer PCR
C 9	24	0.8	24	1	ICAM-related gene
C 10	24	0.8	24	1	ICAM-1 primer PCR
C 11	24	0.8	24	1	Human intercellula
C 12	24	0.8	24	1	Human ICAM-4 DNA C
C 13	24	0.8	24	1	Human ICAM-4 DNA C
C 14	24	0.8	24	1	Human ICAM-4 DNA C
C 15	24	0.8	24	1	Human ICAM-4 DNA C
C 16	24	0.8	24	1	Human ICAM-4 antis
C 17	24	0.8	24	1	Human ICAM-4 sense
C 18	24	0.8	24	1	Human ICAM-4 PCR p
C 19	24	0.8	24	1	Human ICAM-4 PCR p
C 20	24	0.8	24	1	Human ICAM-R cDNA
C 21	24	0.8	24	1	Human ICAM-R cDNA
C 22	24	0.8	24	1	PCR primer for hum
C 23	24	0.8	24	1	PCR primer for hum
C 24	24	0.8	24	1	Intercellular adhe
C 25	24	0.8	24	1	Human ICAM-1 oligo
C 26	24	0.8	24	1	Human ICAM-1 oligo
C 27	24	0.8	24	1	Primer for human I
C 28	24	0.8	24	1	Primer for human I
C 29	24	0.8	24	1	Primer for human I
C 30	24	0.8	24	1	Primer for human I
C 31	24	0.8	24	1	Low adenosine anti
C 32	24	0.8	24	1	Human ICAM-1 domai
C 33	24	0.8	24	1	Human ICAM-1 domai

C	34	24	0.8	24	1	AAA971108	PCR primer H-1/D3 (
C	35	24	0.8	24	1	AAA971107	PCR primer H-1/D3 (
C	36	24	0.8	24	1	AAA12098	Human ICAM-1 DNA f
C	37	24	0.8	24	1	AAA12094	Human ICAM-1 DNA f
C	38	24	0.8	24	1	AAA12096	Human ICAM-1 DNA f
C	39	24	0.8	24	1	AAA08253	Human ICAM-1 oligo
C	40	24	0.8	24	1	AAA08254	Human ICAM-1 oligo
C	41	24	0.8	24	1	AAFI9512	Human ICAM-1 polyn
C	42	24	0.8	24	1	ABK09296	Intercellular adhe
C	43	24	0.8	24	1	ABK09297	Intercellular adhe
C	44	24	0.8	24	1	ABK66439	Human gene specifi
C	45	24	0.8	24	1	ABZ79520	ICAM-1 probe seque
C	46	24	0.8	24	1	ADG25673	Human ICAM-1 domai
C	47	24	0.8	24	1	ADG25674	Human ICAM-1 domai
C	48	24	0.8	24	1	ABZ95206	Human ICAM-1 antis
C	49	24	0.8	24	1	ABD19148	Human ICAM-1 DNA f
C	50	23.4	0.8	25	1	ABQ82716	ICAM-1 mutagenic o
C	51	23.4	0.8	25	1	ADR31134	Human ICAM-1 mutag
C	52	23.4	0.8	25	1	ADR96971	Human ICAM-1 mutag
C	53	23	0.8	23	1	AAT76146	Human intercellula
C	54	23	0.8	23	1	AAT76148	Human intercellula
C	55	23	0.8	23	1	AAV33943	Intercellular adhe
C	56	23	0.8	23	1	AAV33945	Intercellular adhe
C	57	23	0.8	23	1	AAA33388	Low adenosine anti
C	58	23	0.8	23	1	AAA33386	Low adenosine anti
C	59	23	0.8	23	1	AAF19508	Human ICAM-1 polyn
C	60	23	0.8	23	1	AAF19510	Human ICAM-1 polyn
C	61	23	0.8	23	1	ABZ95204	Human ICAM-1 antis
C	62	23	0.8	23	1	ABZ95202	Human ICAM-1 antis
C	63	23	0.8	23	1	ABD19144	Human ICAM-1 DNA f
C	64	23	0.8	23	1	ABD19146	Human ICAM-1 DNA f
C	65	23	0.8	23	1	ADJ76669	ICAM1 forward PCR
C	66	23	0.8	23	1	ADP45898	Extend primer 95 u
C	67	23	0.8	23	1	ADQ14963	CD54 probe seqid 8
C	68	23	0.8	24	1	ADP45898	Human ICAM-1 antis
C	69	23	0.8	25	1	ABU57035	Human ICAM-1 antis
C	70	22.4	0.8	24	1	ACF05122	Human genomic DNA
C	71	22.4	0.8	24	1	ACF35685	Human TGNP promote
C	72	22	0.7	22	1	AAT76144	Human intercellula
C	73	22	0.7	22	1	AAV38622	Human ICAM-1, E-se
C	74	22	0.7	22	1	AAA33383	Low adenosine anti
C	75	22	0.7	22	1	AAFI9505	Human ICAM-1 polyn
C	76	22	0.7	22	1	AAI68676	ICAM-1 triple heli
C	77	22	0.7	22	1	AAI68674	ICAM-1 triple heli
C	78	22	0.7	22	1	ABZ95199	Human ICAM-1 antis
C	79	22	0.7	22	1	ABD19141	Human ICAM-1 DNA f
C	80	22	0.7	22	1	ADJ78611	Chimeric ICAM-1 tr
C	81	22	0.7	22	1	ADL66997	Multiplex PCR prim
C	82	22	0.7	22	1	ADQ14962	CD54 reverse trans
C	83	22	0.7	22	1	ADQ14961	CD54 reverse trans
C	84	22	0.7	22	1	ADP45859	Extend primer 51 u
C	85	21.8	0.7	25	1	AAH40163	SNP specific SNPE
C	86	21.8	0.7	25	1	AAH40159	SNP specific SNPE
C	87	21.4	0.7	24	1	ABK90209	Human transcriptio
C	88	21.4	0.7	25	1	AAH40155	SNP specific SNPE
C	89	21	0.7	21	1	AAQ22631	Antisense oligonuc
C	90	21	0.7	21	1	AAQ44514	Antisense oligonuc
C	91	21	0.7	21	1	AAT01741	Peptide Nucleic ac
C	92	21	0.7	21	1	AAT30213	Antisense oligonuc
C	93	21	0.7	21	1	AAT80604	Antisense oligonuc
C	94	21	0.7	21	1	AAT58076	ICAM-1 antisense o
C	95	21	0.7	21	1	AAT58080	ICAM-1 antisense o
C	96	21	0.7	21	1	AAT58081	ICAM-1 antisense o
C	97	21	0.7	21	1	AAT58079	ICAM-1 antisense o
C	98	21	0.7	21	1	AAT58078	ICAM-1 antisense o
C	99	21	0.7	21	1	AAT76151	Human intercellula
C	100	21	0.7	21	1	AAV38621	Human ICAM-1, E-se
C	101	21	0.7	21	1	AAV38612	Human ICAM-1, E-se
C	102	21	0.7	21	1	AAV38614	Human ICAM-1, E-se
C	103	21	0.7	21	1	AAV38616	Human ICAM-1, E-se
C	104	21	0.7	21	1	AAV38615	Human ICAM-1, E-se
C	105	21	0.7	21	1	AAV38615	Intercellular adhe
C	106	21	0.7	21	1	AAV38615	Antisense oligonuc

c 107	21	0.7	21	1	AAI18670	Cellular adhesion	180	21	0.7	21	1	ADQ82842	Human ICAM-1 oligo
c 108	21	0.7	21	1	AAI09079	Tumour necrosis fa	181	21	0.7	21	1	ADQ82779	Human ICAM-1 oligo
c 109	21	0.7	21	1	AAI23579	Deletion sequence	182	21	0.7	21	1	ADQ82789	Human ICAM-1 oligo
c 110	21	0.7	21	1	AAA33391	Low adenosine anti	183	21	0.7	21	1	ADQ82801	Human ICAM-1 oligo
c 111	21	0.7	21	1	AAZ49338	ICAM-1 targeted a	184	21	0.7	21	1	ADQ82803	Human ICAM-1 oligo
c 112	21	0.7	21	1	AAI19513	Human ICAM-1 polyn	185	21	0.7	21	1	ADQ82810	Human ICAM-1 oligo
c 113	21	0.7	21	1	AAZ48895	Human ICAM-1 antis	186	21	0.7	21	1	ADQ82833	Human ICAM-1 oligo
c 114	21	0.7	21	1	AAF96034	Human gene single	187	21	0.7	21	1	ADQ82806	Human ICAM-1 oligo
c 115	21	0.7	21	1	AAF96035	Human gene single	188	21	0.7	21	1	ADQ82815	Human ICAM-1 oligo
c 116	21	0.7	21	1	AAF87790	Human intracellular	189	21	0.7	21	1	ADQ82817	Human ICAM-1 oligo
c 117	21	0.7	21	1	ABZ79519	ICAM-1 reverse pri	190	21	0.7	21	1	ADQ82825	Human ICAM-1 oligo
c 118	21	0.7	21	1	ADC38977	Human ICAM-1 targe	191	21	0.7	21	1	ADQ82837	Human ICAM-1 oligo
c 119	21	0.7	21	1	ADZ89981	Intracellular adhe	192	21	0.7	21	1	ADQ82838	Human ICAM-1 oligo
c 120	21	0.7	21	1	ADD56653	Human gene express	193	21	0.7	21	1	ADQ82841	Human ICAM-1 oligo
c 121	21	0.7	21	1	ADD56652	Human gene express	194	21	0.7	21	1	ADQ82786	Human ICAM-1 oligo
c 122	21	0.7	21	1	ADDF70305	ICAM antisense oli	195	21	0.7	21	1	ADQ82797	Human ICAM-1 oligo
c 123	21	0.7	21	1	ADDF70359	ICAM antisense oli	196	21	0.7	21	1	ADQ82799	Human ICAM-1 oligo
c 124	21	0.7	21	1	ABZ95207	Human ICAM-1 antis	197	21	0.7	21	1	ADQ82820	Human ICAM-1 oligo
c 125	21	0.7	21	1	ABD19149	Human ICAM-1 DNA f	198	21	0.7	21	1	ADQ82829	Human ICAM-1 oligo
c 126	21	0.7	21	1	AD156732	Human ICAM-1 G496	199	21	0.7	21	1	ADQ82839	Human ICAM-1 oligo
c 127	21	0.7	21	1	AD156734	Human ICAM-1 A496G	200	21	0.7	21	1	ADQ82768	Human ICAM-1 oligo
c 128	21	0.7	21	1	ADI82247	RTQ PCR probe for	201	21	0.7	21	1	ADQ82777	Human ICAM-1 oligo
c 129	21	0.7	21	1	ADI82246	RTQ PCR primer #1	202	21	0.7	21	1	ADQ82778	Human ICAM-1 oligo
c 130	21	0.7	21	1	ADI82248	RTQ PCR primer #2	203	21	0.7	21	1	ADQ82792	Human ICAM-1 oligo
c 131	21	0.7	21	1	ADJ76671	ICAM1 probe SEQ ID	204	21	0.7	21	1	ADQ82807	Human ICAM-1 oligo
c 132	21	0.7	21	1	ADM46454	Antisense oligonuc	205	21	0.7	21	1	ADQ82821	Human ICAM-1 oligo
c 133	21	0.7	21	1	ADQ03877	Human ICAM-specifi	206	21	0.7	21	1	ADQ82774	Human ICAM-1 oligo
c 134	21	0.7	21	1	ADQ16477	Oligonucleotide.	207	21	0.7	21	1	ADQ82782	Human ICAM-1 oligo
c 135	21	0.7	21	1	ADQ16469	Modified oligonuc	208	21	0.7	21	1	ADQ82788	Human ICAM-1 oligo
c 136	21	0.7	21	1	ADQ88550	Murine ICAM-1 anti	209	21	0.7	21	1	ADQ82804	Human ICAM-1 oligo
c 137	21	0.7	21	1	ADQ88606	Oligomer 77 used c	210	21	0.7	21	1	ADQ82826	Human ICAM-1 oligo
c 138	21	0.7	21	1	ADQ82771	Human ICAM-1 oligo	211	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 139	21	0.7	21	1	ADQ82794	Human ICAM-1 oligo	212	21	0.7	21	1	ADQ82811	Human ICAM-1 oligo
c 140	21	0.7	21	1	ADQ82812	Human ICAM-1 oligo	213	21	0.7	21	1	ADQ82813	Human ICAM-1 oligo
c 141	21	0.7	21	1	ADQ82814	Human ICAM-1 oligo	214	21	0.7	21	1	ADQ82822	Human ICAM-1 oligo
c 142	21	0.7	21	1	ADQ82783	Human ICAM-1 oligo	215	21	0.7	21	1	ADQ82804	Human ICAM-1 oligo
c 143	21	0.7	21	1	ADQ82790	Human ICAM-1 oligo	216	21	0.7	21	1	ADQ82826	Human ICAM-1 oligo
c 144	21	0.7	21	1	ADQ82793	Human ICAM-1 oligo	217	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 145	21	0.7	21	1	ADQ82828	Human ICAM-1 oligo	218	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 146	21	0.7	21	1	ADQ82832	Human ICAM-1 oligo	219	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 147	21	0.7	21	1	ADQ82840	Human ICAM-1 oligo	220	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 148	21	0.7	21	1	ADQ82769	Human ICAM-1 oligo	221	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 149	21	0.7	21	1	ADQ82776	Human ICAM-1 oligo	222	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 150	21	0.7	21	1	ADQ82800	Human ICAM-1 oligo	223	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 151	21	0.7	21	1	ADQ82802	Human ICAM-1 oligo	224	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 152	21	0.7	21	1	ADQ82772	Human ICAM-1 oligo	225	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 153	21	0.7	21	1	ADQ82785	Human ICAM-1 oligo	226	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 154	21	0.7	21	1	ADQ82787	Human ICAM-1 oligo	227	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 155	21	0.7	21	1	ADQ82795	Human ICAM-1 oligo	228	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 156	21	0.7	21	1	ADQ82809	Human ICAM-1 oligo	229	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 157	21	0.7	21	1	ADQ82830	Human ICAM-1 oligo	230	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 158	21	0.7	21	1	ADQ82835	Human ICAM-1 oligo	231	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 159	21	0.7	21	1	ADQ82805	Human ICAM-1 oligo	232	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 160	21	0.7	21	1	ADQ82824	Human ICAM-1 oligo	233	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 161	21	0.7	21	1	ADQ82755	ICAM-1 siRNA antis	234	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 162	21	0.7	21	1	ADQ82827	Human ICAM-1 oligo	235	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 163	21	0.7	21	1	ADQ82831	Human ICAM-1 oligo	236	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 164	21	0.7	21	1	ADQ82836	Human ICAM-1 oligo	237	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 165	21	0.7	21	1	ADQ82773	Human ICAM-1 oligo	238	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 166	21	0.7	21	1	ADQ82775	Human ICAM-1 oligo	239	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 167	21	0.7	21	1	ADQ82784	Human ICAM-1 oligo	240	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 168	21	0.7	21	1	ADQ82798	Human ICAM-1 oligo	241	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 169	21	0.7	21	1	ADQ82796	Human ICAM-1 oligo	242	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 170	21	0.7	21	1	ADQ82808	Human ICAM-1 oligo	243	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 171	21	0.7	21	1	ADQ82823	Human ICAM-1 oligo	244	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 172	21	0.7	21	1	ADQ82753	ICAM-1 siRNA antis	245	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 173	21	0.7	21	1	ADQ82816	Human ICAM-1 oligo	246	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 174	21	0.7	21	1	ADQ82818	Human ICAM-1 oligo	247	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 175	21	0.7	21	1	ADQ82770	Human ICAM-1 oligo	248	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 176	21	0.7	21	1	ADQ82780	Human ICAM-1 oligo	249	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 177	21	0.7	21	1	ADQ82781	Human ICAM-1 oligo	250	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 178	21	0.7	21	1	ADQ82819	Human ICAM-1 oligo	251	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo
c 179	21	0.7	21	1	ADQ82834	Human ICAM-1 oligo	252	21	0.7	21	1	ADQ82791	Human ICAM-1 oligo

C 253	20.4	0.7	22	1	AAT65727	Repeat sequence fr	C 326	20	0.7	20	1	AAT01749	Peptide Nucleic ac
C 254	20.4	0.7	22	1	AAV38895	ICAM inhibiting an	C 327	20	0.7	20	1	AAT01747	Peptide Nucleic ac
C 255	20.4	0.7	22	1	AAV08924	Antisense thiol-de	C 328	20	0.7	20	1	AAT01750	Peptide Nucleic ac
C 256	20.4	0.7	22	1	AAV95048	Protein production	C 329	20	0.7	20	1	AAT01754	Peptide Nucleic ac
C 257	20.4	0.7	22	1	AAD20067	Antisense oligo fo	C 330	20	0.7	20	1	AAT01763	Peptide Nucleic ac
C 258	20.4	0.7	22	1	ADB88579	Frizzled-4 (FZD4)	C 331	20	0.7	20	1	AAT01746	Peptide Nucleic ac
C 259	20.4	0.7	22	1	ADH69177	PIOD2 PCR primer #	C 332	20	0.7	20	1	AAT01764	Peptide Nucleic ac
260	20.4	0.7	22	1	AAQ33663	Microsatellite seg	C 333	20	0.7	20	1	AAT01740	Peptide Nucleic ac
261	20.4	0.7	23	1	AAQ33773	Microsatellite seg	C 334	20	0.7	20	1	AAT01751	Peptide Nucleic ac
262	20.4	0.7	23	1	AAQ33885	Microsatellite seg	C 335	20	0.7	20	1	AAT01745	Peptide Nucleic ac
263	20.4	0.7	23	1	AAT66105	Repeat sequence fo	C 336	20	0.7	20	1	AAT01761	Peptide Nucleic ac
C 264	20.4	0.7	23	1	AAE60472	Oligonucleotide cl	C 337	20	0.7	20	1	AAQ81115	Peptide Nucleic ac
265	20.4	0.7	24	1	AAQ34158	Sequence of a micr	C 338	20	0.7	20	1	AAQ81119	Peptide Nucleic ac
266	20.4	0.7	24	1	AAQ34074	Microsatellite seg	C 339	20	0.7	20	1	AAAT1968	Antisense oligonuc
267	20.4	0.7	24	1	AAQ33707	Microsatellite seg	C 340	20	0.7	20	1	AAQ88741	Human ICAM modifie
C 268	20.4	0.7	24	1	AAT66096	Repeat sequence fo	C 341	20	0.7	20	1	AAQ88742	Human ICAM modifie
269	20.4	0.7	24	1	AAH46015	Synthetic oligonuc	C 342	20	0.7	20	1	AAQ44449	Antisense oligonuc
270	20.4	0.7	24	1	AAF99862	Immunostimulatory	C 343	20	0.7	20	1	AAT44450	Antisense oligonuc
271	20.4	0.7	24	1	ABL55369	Human leucine zipp	C 344	20	0.7	20	1	AAT44450	ICAM antisense com
272	20.4	0.7	24	1	ABS78584	Angiogenesis inhib	C 345	20	0.7	20	1	AAT44251	ICAM antisense com
273	20.4	0.7	24	1	ABZ25854	Human basic transc	C 346	20	0.7	20	1	AAQ33922	ICAM expression in
274	20.4	0.7	24	1	ACH03377	Immunostimulatory	C 347	20	0.7	20	1	AAQ33923	ICAM expression in
275	20.4	0.7	24	1	ADB37364	Immunostimulatory	C 348	20	0.7	20	1	AAT30226	Antisense oligonuc
276	20.4	0.7	24	1	ADH93896	Human gene PCR pri	C 349	20	0.7	20	1	AAT30227	Antisense oligonuc
C 277	20.4	0.7	24	1	ADQ81094	Sheep prion protei	C 350	20	0.7	20	1	AAT30222	Antisense oligonuc
C 278	20.4	0.7	24	1	ADQ81099	Sheep prion protei	C 351	20	0.7	20	1	AAT30228	Antisense oligonuc
C 279	20.4	0.7	24	1	ADQ81051	Cow prion protein	C 352	20	0.7	20	1	AAT30211	Antisense oligonuc
C 280	20.4	0.7	24	1	ADR16077	Human PARP DNA 85-	C 353	20	0.7	20	1	AAT30221	Antisense oligonuc
281	20.2	0.7	25	1	AAH37431	SNP specific SNPE	C 354	20	0.7	20	1	AAT30225	Antisense oligonuc
C 282	20	0.7	20	1	AAQ22630	Antisense oligonuc	C 355	20	0.7	20	1	AAT30225	Antisense oligonuc
C 283	20	0.7	20	1	AAQ22639	Antisense oligonuc	C 356	20	0.7	20	1	AAT30222	Antisense oligonuc
C 284	20	0.7	20	1	AAQ22636	Antisense oligonuc	C 357	20	0.7	20	1	AAT30228	Antisense oligonuc
C 285	20	0.7	20	1	AAQ22652	Antisense oligonuc	C 358	20	0.7	20	1	AAT30221	Antisense oligonuc
C 286	20	0.7	20	1	AAQ22643	Antisense oligonuc	C 359	20	0.7	20	1	AAT30215	Antisense oligonuc
C 287	20	0.7	20	1	AAQ22650	Antisense oligonuc	C 360	20	0.7	20	1	AAT30224	Antisense oligonuc
C 288	20	0.7	20	1	AAQ22641	Antisense oligonuc	C 361	20	0.7	20	1	AAT30219	Antisense oligonuc
C 289	20	0.7	20	1	AAQ22635	Antisense oligonuc	C 362	20	0.7	20	1	AAT30210	Antisense oligonuc
C 290	20	0.7	20	1	AAQ22640	Antisense oligonuc	C 363	20	0.7	20	1	AAT30223	Antisense oligonuc
C 291	20	0.7	20	1	AAQ22642	Antisense oligonuc	C 364	20	0.7	20	1	AAT30220	Antisense oligonuc
C 292	20	0.7	20	1	AAQ22638	Antisense oligonuc	C 365	20	0.7	20	1	AAT30223	Antisense oligonuc
C 293	20	0.7	20	1	AAQ22644	Antisense oligonuc	C 366	20	0.7	20	1	AAT30223	Antisense oligonuc
C 294	20	0.7	20	1	AAQ22651	Antisense oligonuc	C 367	20	0.7	20	1	AAQ22651	Phosphonomonoester
C 295	20	0.7	20	1	AAQ22653	Antisense oligonuc	C 368	20	0.7	20	1	AAQ22651	Phosphonomonoester
C 296	20	0.7	20	1	AAQ22637	Antisense oligonuc	C 369	20	0.7	20	1	AAQ22637	Phosphorothioate o
C 297	20	0.7	20	1	AAQ22654	Antisense oligonuc	C 370	20	0.7	20	1	AAQ22637	PCR primer SR1 use
C 298	20	0.7	20	1	AAQ22338	DNA for modulation	C 371	20	0.7	20	1	AAQ22638	ISIS-2302, ICAM-1
C 299	20	0.7	20	1	AAQ40559	2' functionalised	C 372	20	0.7	20	1	AAQ40559	Human B7-2 targett
C 300	20	0.7	20	1	AAQ40557	Cytidine based ami	C 373	20	0.7	20	1	AAQ40557	Modified oligonuc
C 301	20	0.7	20	1	AAQ72765	ICAM-1 mRNA 5'end.	C 374	20	0.7	20	1	AAQ40557	Modified oligonuc
C 302	20	0.7	20	1	AAQ44518	Antisense oligonuc	C 375	20	0.7	20	1	AAQ40557	Antisense molecule
C 303	20	0.7	20	1	AAQ44519	Antisense oligonuc	C 376	20	0.7	20	1	AAQ40557	Anti-CMV oligonuc
C 304	20	0.7	20	1	AAQ44523	Antisense oligonuc	C 377	20	0.7	20	1	AAQ40557	Fully modified pho
C 305	20	0.7	20	1	AAQ44520	Antisense oligonuc	C 378	20	0.7	20	1	AAQ40557	Fully modified pho
C 306	20	0.7	20	1	AAQ44582	Antisense oligonuc	C 379	20	0.7	20	1	AAQ40557	Fully modified pho
C 307	20	0.7	20	1	AAQ44513	Antisense oligonuc	C 380	20	0.7	20	1	AAQ40557	Antisense oligonuc
C 308	20	0.7	20	1	AAQ44521	Antisense oligonuc	C 381	20	0.7	20	1	AAQ40557	Phosphorothioate 2
C 309	20	0.7	20	1	AAQ44583	Antisense oligonuc	C 382	20	0.7	20	1	AAQ40557	ICAM-1 antisense o
C 310	20	0.7	20	1	AAQ44590	Antisense oligonuc	C 383	20	0.7	20	1	AAQ40557	ICAM-1 antisense o
C 311	20	0.7	20	1	AAQ44585	Antisense oligonuc	C 384	20	0.7	20	1	AAQ40557	Phosphorothioate o
C 312	20	0.7	20	1	AAQ44589	Antisense oligonuc	C 385	20	0.7	20	1	AAQ40557	Antisense oligonuc
C 313	20	0.7	20	1	AAQ44594	Antisense oligonuc	C 386	20	0.7	20	1	AAQ40557	Antisense oligonuc
C 314	20	0.7	20	1	AAQ44522	Antisense oligonuc	C 387	20	0.7	20	1	AAQ40557	Antisense oligonuc
C 315	20	0.7	20	1	AAQ44565	Antisense oligonuc	C 388	20	0.7	20	1	AAQ40557	Antisense oligonuc
C 316	20	0.7	20	1	AAQ44598	Antisense oligonuc	C 389	20	0.7	20	1	AAQ40557	Antisense oligonuc
C 317	20	0.7	20	1	AAQ44543	Antisense oligonuc	C 390	20	0.7	20	1	AAQ40557	Antisense oligonuc
C 318	20	0.7	20	1	AAQ44524	Antisense oligonuc	C 391	20	0.7	20	1	AAQ40557	Cellular adhesion
C 319	20	0.7	20	1	AAQ44587	Antisense oligonuc	C 392	20	0.7	20	1	AAQ40557	Human ICAM-1 anti
C 320	20	0.7	20	1	AAQ45153	Oligonucleotide us	C 393	20	0.7	20	1	AAQ40557	Rat intercellular
C 321	20	0.7	20	1	AAT01762	Peptide Nucleic ac	C 394	20	0.7	20	1	AAQ40557	Tumour necrosis fa
C 322	20	0.7	20	1	AAT01748	Peptide Nucleic ac	C 395	20	0.7	20	1	AAQ40557	Deletion sequence
C 323	20	0.7	20	1	AAT01760	Peptide Nucleic ac	C 396	20	0.7	20	1	AAQ40557	Phosphorothioate o
C 324	20	0.7	20	1	AAT01766	Peptide Nucleic ac	C 397	20	0.7	20	1	AAQ40557	ICAM-1 targeted PS
C 325	20	0.7	20	1	AAT01753	Peptide Nucleic ac	C 398	20	0.7	20	1	AAQ40557	ICAM-1 targeted PS

C 399	20	0.7	20	1	AAZ58227	ICAM-1 targeted PS	C 472	20	0.7	20	1	AAZ48905	Human ICAM-1 antis
C 400	20	0.7	20	1	AAZ58230	ICAM-1 targeted PS	C 473	20	0.7	20	1	AAZ48921	Human ICAM-1 antis
C 401	20	0.7	20	1	AAZ57446	Phosphorothioate o	C 474	20	0.7	20	1	AAZ48897	Human ICAM-1 antis
C 402	20	0.7	20	1	AAA96410	Primer used to amp	C 475	20	0.7	20	1	AAZ48904	Human ICAM-1 antis
C 403	20	0.7	20	1	AAZ90212	Phosphorothioate h	C 476	20	0.7	20	1	AAZ48919	Human ICAM-1 antis
C 404	20	0.7	20	1	AAA40808	Human TNFalpha ant	C 477	20	0.7	20	1	AAZ48908	Human ICAM-1 antis
C 405	20	0.7	20	1	AAA40800	Control antisense	C 478	20	0.7	20	1	AAZ48875	Human ICAM-1 antis
C 406	20	0.7	20	1	AAZ95215	2'-modified oligon	C 479	20	0.7	20	1	AAZ57157	ICAM targeting pho
C 407	20	0.7	20	1	AAZ95212	2'-modified oligon	C 480	20	0.7	20	1	AAZ57150	Phosphorothioate 2
C 408	20	0.7	20	1	AAA58336	Synthetic 3'-P-O-a	C 481	20	0.7	20	1	AAA50200	2'-Methoxyethoxy-m
C 409	20	0.7	20	1	AAZ59000	Sequence of a phos	C 482	20	0.7	20	1	AAA94747	Oligonucleotide #1
C 410	20	0.7	20	1	AAZ61387	2'-O-modified ribo	C 483	20	0.7	20	1	AAZ94540	Example biological
C 411	20	0.7	20	1	AAZ61389	2'-O-modified ribo	C 484	20	0.7	20	1	AAZ71631	Phosphorothioate 2
C 412	20	0.7	20	1	AAZ48638	ICAM-1 antisense i	C 485	20	0.7	20	1	AAZ99217	ICAM-1 target phos
C 413	20	0.7	20	1	AAZ48637	ICAM-1 antisense i	C 486	20	0.7	20	1	AAZ73477	Forward primer #10
C 414	20	0.7	20	1	AAA14454	ICAM-1 targeting	C 487	20	0.7	20	1	AAZ32820	ICAM-1 antisense o
C 415	20	0.7	20	1	AAA12077	Human ICAM-1 antis	C 488	20	0.7	20	1	ABA04587	Oligonucleotide #7
C 416	20	0.7	20	1	AAA12081	Human ICAM-1 antis	C 489	20	0.7	20	1	AAZ56197	Human ICAM-1 phosp
C 417	20	0.7	20	1	AAA12083	Human ICAM-1 antis	C 490	20	0.7	20	1	AAZ23804	Oligo #4 used to p
C 418	20	0.7	20	1	AAA12078	Human ICAM-1 antis	C 491	20	0.7	20	1	AAZ60943	Anti-ICAM-1 oligon
C 419	20	0.7	20	1	AAA12088	Human ICAM-1 antis	C 492	20	0.7	20	1	AAZ60945	Anti-ICAM-1 oligon
C 420	20	0.7	20	1	AAA12073	Human ICAM-1 antis	C 493	20	0.7	20	1	AAZ60944	Anti-ICAM-1 oligon
C 421	20	0.7	20	1	AAA12076	Human ICAM-1 antis	C 494	20	0.7	20	1	AAZ75800	3' untranslated re
C 422	20	0.7	20	1	AAA12092	Human ICAM-1 antis	C 495	20	0.7	20	1	AAD13419	Human ICAM-1 targe
C 423	20	0.7	20	1	AAA12084	Human ICAM-1 antis	C 496	20	0.7	20	1	AAZ31596	Oligonucleotide ta
C 424	20	0.7	20	1	AAA12075	Human ICAM-1 antis	C 497	20	0.7	20	1	AAZ31599	Oligonucleotide ta
C 425	20	0.7	20	1	AAA12079	Human ICAM-1 antis	C 498	20	0.7	20	1	AAZ11376	Phosphorothioate o
C 426	20	0.7	20	1	AAA12084	Human ICAM-1 antis	C 499	20	0.7	20	1	AAZ77810	ICAM-1 antisense o
C 427	20	0.7	20	1	AAA12065	Human ICAM-1 antis	C 500	20	0.7	20	1	AAZ92894	Human ABC1 transcr
C 428	20	0.7	20	1	AAA12072	Human ICAM-1 antis	C 501	20	0.7	20	1	AAZ11587	Fully modified pho
C 429	20	0.7	20	1	AAA12086	Human ICAM-1 antis	C 502	20	0.7	20	1	AAZ28597	Phosphorothioate o
C 430	20	0.7	20	1	AAA12090	Human ICAM-1 antis	C 503	20	0.7	20	1	AAZ89460	Human ICAM-1 antis
C 431	20	0.7	20	1	AAA12068	Human ICAM-1 antis	C 504	20	0.7	20	1	AAZ09545	FITC-labeled ICAM
C 432	20	0.7	20	1	AAA12071	Human ICAM-1 antis	C 505	20	0.7	20	1	AAH46458	Oligonucleotide #7
C 433	20	0.7	20	1	AAA12082	Human ICAM-1 antis	C 506	20	0.7	20	1	AAH46464	Oligonucleotide #1
C 434	20	0.7	20	1	AAA12089	Human ICAM-1 antis	C 507	20	0.7	20	1	AAH46452	Oligonucleotide #2
C 435	20	0.7	20	1	AAA12087	Human ICAM-1 antis	C 508	20	0.7	20	1	AAH25746	Human type II RNas
C 436	20	0.7	20	1	AAA12074	Human ICAM-1 antis	C 509	20	0.7	20	1	AAZ88206	Modified phospho
C 437	20	0.7	20	1	AAA12080	Human ICAM-1 antis	C 510	20	0.7	20	1	AAZ20914	Phosphorothioate o
C 438	20	0.7	20	1	AAA12083	Human ICAM-1 antis	C 511	20	0.7	20	1	AAH49228	Anti-ICAM oligonuc
C 439	20	0.7	20	1	AAA12085	Human ICAM-1 antis	C 512	20	0.7	20	1	AAH49229	Anti-ICAM oligonuc
C 440	20	0.7	20	1	AAA12091	Human ICAM-1 antis	C 513	20	0.7	20	1	AAZ87785	DNA 20-mer ASO (an
C 441	20	0.7	20	1	AAA12069	Human ICAM-1 antis	C 514	20	0.7	20	1	AAZ87786	Human intracellular
C 442	20	0.7	20	1	AAA12099	Human ICAM-1 antis	C 515	20	0.7	20	1	AAZ87788	Human intracellular
C 443	20	0.7	20	1	AAA12087	Human ICAM-1 antis	C 516	20	0.7	20	1	AAZ87791	Human intracellular
C 444	20	0.7	20	1	AAA12066	Human ICAM-1 antis	C 517	20	0.7	20	1	AAZ87789	Human intracellular
C 445	20	0.7	20	1	AAA12070	Human ICAM-1 antis	C 518	20	0.7	20	1	AAZ87787	Oligonucleotide IS
C 446	20	0.7	20	1	AAZ40363	Antisense inhibito	C 519	20	0.7	20	1	ABK12804	Intracellular-adhe
C 447	20	0.7	20	1	AAZ47918	ICAM-1 phosphoroth	C 520	20	0.7	20	1	ABL01636	ICAM-1 targeted an
C 448	20	0.7	20	1	AAA14945	PCR primer SRI use	C 521	20	0.7	20	1	ABL01637	ICAM-1 targeted an
C 449	20	0.7	20	1	AAA10247	2-aminoadenosine-c	C 522	20	0.7	20	1	ABL01635	ICAM-1 targeted an
C 450	20	0.7	20	1	AAZ98648	Therapeutic antise	C 523	20	0.7	20	1	ABL01635	ICAM-1 targeted an
C 451	20	0.7	20	1	AAZ48119	ICAM-1 targeting a	C 524	20	0.7	20	1	ABX87928	Antisense oligonuc
C 452	20	0.7	20	1	AAZ49336	ICAM-1 targetted p	C 525	20	0.7	20	1	ABA97491	ICAM-1 targeted an
C 453	20	0.7	20	1	AAZ49330	ICAM-1 targetted p	C 526	20	0.7	20	1	ABA97490	ICAM-1 targeted an
C 454	20	0.7	20	1	AAZ49337	ICAM-1 targetted p	C 527	20	0.7	20	1	ABA97492	ICAM-1 targeted 2=
C 455	20	0.7	20	1	AAA93139	Clone vc68-1 secre	C 528	20	0.7	20	1	ABA91946	ICAM-1 targeted 2=
C 456	20	0.7	20	1	AAA06838	Nucleotide sequenc	C 529	20	0.7	20	1	ABA91948	ICAM-1 targeted 2=
C 457	20	0.7	20	1	AAA14472	Synthetic oligonuc	C 530	20	0.7	20	1	ABV73951	Methylated antisen
C 458	20	0.7	20	1	AAZ48918	Human ICAM-1 antis	C 531	20	0.7	20	1	ABV73947	Antisense oligonuc
C 459	20	0.7	20	1	AAZ48910	Human ICAM-1 antis	C 532	20	0.7	20	1	ABL90980	ICAM-1 mediated in
C 460	20	0.7	20	1	AAZ48917	Human ICAM-1 antis	C 533	20	0.7	20	1	ABL46182	Human ICAM-1 antis
C 461	20	0.7	20	1	AAZ48916	Human ICAM-1 antis	C 534	20	0.7	20	1	ABL46180	Human ICAM-1 antis
C 462	20	0.7	20	1	AAZ48907	Human ICAM-1 antis	C 535	20	0.7	20	1	ABL46181	Human ICAM-1 antis
C 463	20	0.7	20	1	AAZ48884	Human ICAM-1 antis	C 536	20	0.7	20	1	ABL46178	Human ICAM-1 antis
C 464	20	0.7	20	1	AAZ48889	Human ICAM-1 antis	C 537	20	0.7	20	1	ABL57312	Phosphorothioate a
C 465	20	0.7	20	1	AAZ48892	Human ICAM-1 antis	C 538	20	0.7	20	1	ABK86103	Human ICAM-1 oligo
C 466	20	0.7	20	1	AAZ48902	Human ICAM-1 antis	C 539	20	0.7	20	1	ABK90764	Oligomeric compoun
C 467	20	0.7	20	1	AAZ48906	Human ICAM-1 antis	C 540	20	0.7	20	1	ABK90760	Oligomeric compoun
C 468	20	0.7	20	1	AAZ48909	Human ICAM-1 antis	C 541	20	0.7	20	1	ABK15435	Human ICAM-1 antis
C 469	20	0.7	20	1	AAZ48903	Human ICAM-1 antis	C 542	20	0.7	20	1	ABK15435	Human ICAM-1 antis
C 470	20	0.7	20	1	AAZ48887	Human ICAM-1 antis	C 543	20	0.7	20	1	ABK15447	Human ICAM-1 antis
C 471	20	0.7	20	1	AAZ48901	Human ICAM-1 antis	C 544	20	0.7	20	1	ABK15441	Human ICAM-1 antis

C 545	20	0.7	20	1	ABK15437	Human ICAM-1 antis	C 618	20	0.7	20	1	AB298430	Human ICAM oligonu
C 546	20	0.7	20	1	ABK15438	Human ICAM-1 antis	C 619	20	0.7	20	1	AB298448	Human ICAM oligonu
C 547	20	0.7	20	1	ABK15443	Human ICAM-1 antis	C 620	20	0.7	20	1	AB298470	Human ICAM oligonu
C 548	20	0.7	20	1	ABK15439	Human ICAM-1 antis	C 621	20	0.7	20	1	AB298474	Human ICAM oligonu
C 549	20	0.7	20	1	ABK15445	Human ICAM-1 antis	C 622	20	0.7	20	1	AB298494	Human ICAM oligonu
C 550	20	0.7	20	1	ABK15442	Human ICAM-1 antis	C 623	20	0.7	20	1	AB298503	Human ICAM oligonu
C 551	20	0.7	20	1	ABK15440	Human ICAM-1 antis	C 624	20	0.7	20	1	AB298509	Human ICAM oligonu
C 552	20	0.7	20	1	AAL46755	ICAM antisense oli	C 625	20	0.7	20	1	AB298518	Human ICAM oligonu
C 553	20	0.7	20	1	AAL46756	ICAM antisense oli	C 626	20	0.7	20	1	AB298552	Human ICAM oligonu
C 554	20	0.7	20	1	ABA00065	Antisense oligonuc	C 627	20	0.7	20	1	AB298558	Human ICAM oligonu
C 555	20	0.7	20	1	ABK91305	Oligonucleotide, I	C 628	20	0.7	20	1	AB298584	Human ICAM oligonu
C 556	20	0.7	20	1	ABK91307	Oligonucleotide, I	C 629	20	0.7	20	1	AB298408	Human ICAM oligonu
C 557	20	0.7	20	1	ABK91301	Oligonucleotide, I	C 630	20	0.7	20	1	AB298428	Human ICAM oligonu
C 558	20	0.7	20	1	AAD22784	Human ICAM-1 antis	C 631	20	0.7	20	1	AB298455	Human ICAM oligonu
C 559	20	0.7	20	1	AAD22890	Human ICAM-1 antis	C 632	20	0.7	20	1	AB298461	Human ICAM oligonu
C 560	20	0.7	20	1	ACC49158	ICAM-1 inhibitory	C 633	20	0.7	20	1	AB298484	Human ICAM oligonu
C 561	20	0.7	20	1	ACC49159	ICAM-1 inhibitory	C 634	20	0.7	20	1	AB298485	Human ICAM oligonu
C 562	20	0.7	20	1	AB277539	Nucleotide sequenc	C 635	20	0.7	20	1	AB298486	Human ICAM oligonu
C 563	20	0.7	20	1	AB279518	ICAM-1 forward pri	C 636	20	0.7	20	1	AB298500	Human ICAM oligonu
C 564	20	0.7	20	1	ACC59002	Human ICAM-1 antis	C 637	20	0.7	20	1	AB298506	Human ICAM oligonu
C 565	20	0.7	20	1	ACD27443	Human ICAM-1 targe	C 638	20	0.7	20	1	AB298526	Human ICAM oligonu
C 566	20	0.7	20	1	ACD27441	Human ICAM-1 targe	C 639	20	0.7	20	1	AB298529	Human ICAM oligonu
C 567	20	0.7	20	1	ACD27445	Human ICAM-1 targe	C 640	20	0.7	20	1	AB298536	Human ICAM oligonu
C 568	20	0.7	20	1	ACD27437	Human ICAM-1 targe	C 641	20	0.7	20	1	AB298542	Human ICAM oligonu
C 569	20	0.7	20	1	ACD27440	Human ICAM-1 targe	C 642	20	0.7	20	1	AB298549	Human ICAM oligonu
C 570	20	0.7	20	1	ACD27442	Human ICAM-1 targe	C 643	20	0.7	20	1	AB298555	Human ICAM oligonu
C 571	20	0.7	20	1	ACD27447	Human ICAM-1 targe	C 644	20	0.7	20	1	AB298566	Human ICAM oligonu
C 572	20	0.7	20	1	ACD27435	Human ICAM-1 targe	C 645	20	0.7	20	1	AB298585	Human ICAM oligonu
C 573	20	0.7	20	1	ACD27439	Human ICAM-1 targe	646	20	0.7	20	1	AB299055	Human PDE4C oligon
C 574	20	0.7	20	1	ACD27438	Human ICAM-1 targe	C 647	20	0.7	20	1	AB298396	Human ICAM oligonu
C 575	20	0.7	20	1	ACD67194	Derivatised oligon	C 648	20	0.7	20	1	AB298399	Human ICAM oligonu
C 576	20	0.7	20	1	ACD67192	Derivatised oligon	C 649	20	0.7	20	1	AB298410	Human ICAM oligonu
C 577	20	0.7	20	1	ACC58504	Oligonucleotide OD	C 650	20	0.7	20	1	AB298417	Human ICAM oligonu
C 578	20	0.7	20	1	ACC58503	Oligonucleotide OD	C 651	20	0.7	20	1	AB298422	Human ICAM oligonu
C 579	20	0.7	20	1	ACD27755	Peptide linked oli	C 652	20	0.7	20	1	AB298460	Human ICAM oligonu
580	20	0.7	20	1	ACC85089	Human ICAM-1 cDNA	C 653	20	0.7	20	1	AB298464	Human ICAM oligonu
C 581	20	0.7	20	1	ADA24219	Human ICAM-1 antis	C 654	20	0.7	20	1	AB298467	Human ICAM oligonu
C 582	20	0.7	20	1	ACD05028	Tumour necrosis fa	C 655	20	0.7	20	1	AB298469	Human ICAM oligonu
C 583	20	0.7	20	1	ACD05036	Tumour necrosis fa	C 656	20	0.7	20	1	AB298475	Human ICAM oligonu
C 584	20	0.7	20	1	ADC24654	Antisense DNA #2 t	C 657	20	0.7	20	1	AB298476	Human ICAM oligonu
C 585	20	0.7	20	1	ADC38983	Human ICAM-1 targe	C 658	20	0.7	20	1	AB298481	Human ICAM oligonu
C 586	20	0.7	20	1	ADC38989	Human ICAM-1 targe	C 659	20	0.7	20	1	AB298483	Human ICAM oligonu
C 587	20	0.7	20	1	ADC38990	Human ICAM-1 targe	C 660	20	0.7	20	1	AB298489	Human ICAM oligonu
C 588	20	0.7	20	1	ADC39059	Human ICAM-1 targe	C 661	20	0.7	20	1	AB298495	Human ICAM oligonu
C 589	20	0.7	20	1	ADC38996	Human ICAM-1 targe	C 662	20	0.7	20	1	AB298496	Human ICAM oligonu
C 590	20	0.7	20	1	ADC38981	Human ICAM-1 targe	C 663	20	0.7	20	1	AB298519	Human ICAM oligonu
C 591	20	0.7	20	1	ADC38988	Human ICAM-1 targe	C 664	20	0.7	20	1	AB298547	Human ICAM oligonu
C 592	20	0.7	20	1	ADC38999	Human ICAM-1 targe	C 665	20	0.7	20	1	AB298561	Human ICAM oligonu
C 593	20	0.7	20	1	ADC39058	Human ICAM-1 targe	C 666	20	0.7	20	1	AB298563	Human ICAM oligonu
C 594	20	0.7	20	1	ADC38976	Human ICAM-1 targe	C 667	20	0.7	20	1	AB298568	Human ICAM oligonu
C 595	20	0.7	20	1	ADC38982	Human ICAM-1 targe	C 668	20	0.7	20	1	AB298574	Human ICAM oligonu
C 596	20	0.7	20	1	ADC38984	Human ICAM-1 targe	C 669	20	0.7	20	1	AB298581	Human ICAM oligonu
C 597	20	0.7	20	1	ADC38997	Human ICAM-1 targe	C 670	20	0.7	20	1	AB298582	Human ICAM oligonu
C 598	20	0.7	20	1	ADC38985	Human ICAM-1 targe	C 671	20	0.7	20	1	AB298411	Human ICAM oligonu
C 599	20	0.7	20	1	ADC38986	Human ICAM-1 targe	C 672	20	0.7	20	1	AB298492	Human ICAM oligonu
C 600	20	0.7	20	1	ADC38998	Human ICAM-1 targe	C 673	20	0.7	20	1	AB298493	Human ICAM oligonu
C 601	20	0.7	20	1	ADC38987	Human ICAM-1 targe	C 674	20	0.7	20	1	AB298498	Human ICAM oligonu
C 602	20	0.7	20	1	ADC39000	Human ICAM-1 targe	C 675	20	0.7	20	1	AB298531	Human ICAM oligonu
C 603	20	0.7	20	1	AAD58980	Human ICAM-1 antis	C 676	20	0.7	20	1	AB298533	Human ICAM oligonu
C 604	20	0.7	20	1	AAD59033	Antisense oligonuc	C 677	20	0.7	20	1	AB298560	Human ICAM oligonu
C 605	20	0.7	20	1	AAD58979	Human ICAM-1 antis	C 678	20	0.7	20	1	AB298562	Human ICAM oligonu
C 606	20	0.7	20	1	ADP82093	Phosphorothioate m	C 679	20	0.7	20	1	AB298567	Human ICAM oligonu
C 607	20	0.7	20	1	ADP27755	ICAM-1 targeted ol	C 680	20	0.7	20	1	AB298570	Human ICAM oligonu
C 608	20	0.7	20	1	ADP99241	Modified oligomeri	C 681	20	0.7	20	1	AB298434	Human ICAM oligonu
C 609	20	0.7	20	1	ADP99244	Modified oligomeri	C 682	20	0.7	20	1	AB298447	Human ICAM oligonu
C 610	20	0.7	20	1	ADP99242	Modified oligomeri	C 683	20	0.7	20	1	AB298472	Human ICAM oligonu
C 611	20	0.7	20	1	ADP82816	Immunostimulant OD	C 684	20	0.7	20	1	AB298501	Human ICAM oligonu
C 612	20	0.7	20	1	ADP82817	Immunostimulant OD	C 685	20	0.7	20	1	AB298505	Human ICAM oligonu
613	20	0.7	20	1	ADG42098	Human ICAM-1 RT-PC	C 686	20	0.7	20	1	AB298523	Human ICAM oligonu
C 614	20	0.7	20	1	ADG64776	Human ICAM-1 speci	C 687	20	0.7	20	1	AB298556	Human ICAM oligonu
C 615	20	0.7	20	1	AAD50285	Cholesterol-Dialk	C 688	20	0.7	20	1	AB298379	Human ICAM oligonu
C 616	20	0.7	20	1	AB298387	Human ICAM oligonu	C 689	20	0.7	20	1	AB298394	Human ICAM oligonu
C 617	20	0.7	20	1	AB298418	Human ICAM oligonu	C 690	20	0.7	20	1	AB298412	Human ICAM oligonu

C 691	20	0.7	20	1	ABZ98413	Human ICAM oligonu	C 764	20	0.7	20	1	ABZ98550	Human ICAM oligonu
C 692	20	0.7	20	1	ABZ98431	Human ICAM oligonu	C 765	20	0.7	20	1	ABZ98564	Human ICAM oligonu
C 693	20	0.7	20	1	ABZ98437	Human ICAM oligonu	C 766	20	0.7	20	1	ABZ98391	Human ICAM oligonu
C 694	20	0.7	20	1	ABZ98446	Human ICAM oligonu	C 767	20	0.7	20	1	ABZ98392	Human ICAM oligonu
C 695	20	0.7	20	1	ABZ98456	Human ICAM oligonu	C 768	20	0.7	20	1	ABZ98397	Human ICAM oligonu
C 696	20	0.7	20	1	ABZ98462	Human ICAM oligonu	C 769	20	0.7	20	1	ABZ98416	Human ICAM oligonu
C 697	20	0.7	20	1	ABZ98482	Human ICAM oligonu	C 770	20	0.7	20	1	ABZ98429	Human ICAM oligonu
C 698	20	0.7	20	1	ABZ98512	Human ICAM oligonu	C 771	20	0.7	20	1	ABZ98433	Human ICAM oligonu
C 699	20	0.7	20	1	ABZ98530	Human ICAM oligonu	C 772	20	0.7	20	1	ABZ98463	Human ICAM oligonu
C 700	20	0.7	20	1	ABZ98535	Human ICAM oligonu	C 773	20	0.7	20	1	ABZ98488	Human ICAM oligonu
C 701	20	0.7	20	1	ABZ98553	Human ICAM oligonu	C 774	20	0.7	20	1	ABZ98504	Human ICAM oligonu
C 702	20	0.7	20	1	ABZ98388	Human ICAM oligonu	C 775	20	0.7	20	1	ABZ98524	Human ICAM oligonu
C 703	20	0.7	20	1	ABZ98424	Human ICAM oligonu	C 776	20	0.7	20	1	ABZ98525	Human ICAM oligonu
C 704	20	0.7	20	1	ABZ98435	Human ICAM oligonu	C 777	20	0.7	20	1	ABZ98540	Human ICAM oligonu
C 705	20	0.7	20	1	ABZ98443	Human ICAM oligonu	C 778	20	0.7	20	1	ABZ98551	Human ICAM oligonu
C 706	20	0.7	20	1	ABZ98502	Human ICAM oligonu	C 779	20	0.7	20	1	ABZ98576	Human ICAM oligonu
C 707	20	0.7	20	1	ABZ98507	Human ICAM oligonu	C 780	20	0.7	20	1	ABZ98577	Human ICAM oligonu
C 708	20	0.7	20	1	ABZ98377	Human ICAM oligonu	C 781	20	0.7	20	1	ABZ98580	Human ICAM oligonu
C 709	20	0.7	20	1	ABZ98390	Human ICAM oligonu	C 782	20	0.7	20	1	ABZ98385	Human ICAM oligonu
C 710	20	0.7	20	1	ABZ98330	Human ICAM oligonu	C 783	20	0.7	20	1	ABZ98389	Human ICAM oligonu
C 711	20	0.7	20	1	ABZ98404	Human ICAM oligonu	C 784	20	0.7	20	1	ABZ98402	Human ICAM oligonu
C 712	20	0.7	20	1	ABZ98415	Human ICAM oligonu	C 785	20	0.7	20	1	ABZ98403	Human ICAM oligonu
C 713	20	0.7	20	1	ABZ98432	Human ICAM oligonu	C 786	20	0.7	20	1	ABZ98419	Human ICAM oligonu
C 714	20	0.7	20	1	ABZ98449	Human ICAM oligonu	C 787	20	0.7	20	1	ABZ98423	Human ICAM oligonu
C 715	20	0.7	20	1	ABZ98465	Human ICAM oligonu	C 788	20	0.7	20	1	ABZ98426	Human ICAM oligonu
C 716	20	0.7	20	1	ABZ98466	Human ICAM oligonu	C 789	20	0.7	20	1	ABZ98435	Human ICAM oligonu
C 717	20	0.7	20	1	ABZ98477	Human ICAM oligonu	C 790	20	0.7	20	1	ABZ98459	Human ICAM oligonu
C 718	20	0.7	20	1	ABZ98508	Human ICAM oligonu	C 791	20	0.7	20	1	ABZ98479	Human ICAM oligonu
C 719	20	0.7	20	1	ABZ98517	Human ICAM oligonu	C 792	20	0.7	20	1	ABZ98513	Human ICAM oligonu
C 720	20	0.7	20	1	ABZ98554	Human ICAM oligonu	C 793	20	0.7	20	1	ABZ98528	Human ICAM oligonu
C 721	20	0.7	20	1	ABZ98559	Human ICAM oligonu	C 794	20	0.7	20	1	ABZ98538	Human ICAM oligonu
C 722	20	0.7	20	1	ABZ98584	Human ICAM oligonu	C 795	20	0.7	20	1	ABZ98571	Human ICAM oligonu
C 723	20	0.7	20	1	ABZ98330	Human ICAM oligonu	C 796	20	0.7	20	1	ABZ98579	Human ICAM oligonu
C 724	20	0.7	20	1	ABZ98382	Human ICAM oligonu	C 797	20	0.7	20	1	ABZ98405	Human ICAM oligonu
C 725	20	0.7	20	1	ABZ98400	Human ICAM oligonu	C 798	20	0.7	20	1	ABZ98407	Human ICAM oligonu
C 726	20	0.7	20	1	ABZ98427	Human ICAM oligonu	C 799	20	0.7	20	1	ABZ98414	Human ICAM oligonu
C 727	20	0.7	20	1	ABZ98468	Human ICAM oligonu	C 800	20	0.7	20	1	ABZ98420	Human ICAM oligonu
C 728	20	0.7	20	1	ABZ98491	Human ICAM oligonu	C 801	20	0.7	20	1	ABZ98473	Human ICAM oligonu
C 729	20	0.7	20	1	ABZ98527	Human ICAM oligonu	C 802	20	0.7	20	1	ABZ98490	Human ICAM oligonu
C 730	20	0.7	20	1	ABZ98535	Human ICAM oligonu	C 803	20	0.7	20	1	ABZ98514	Human ICAM oligonu
C 731	20	0.7	20	1	ABZ98544	Human ICAM oligonu	C 804	20	0.7	20	1	ABZ98515	Human ICAM oligonu
C 732	20	0.7	20	1	ABZ98565	Human ICAM oligonu	C 805	20	0.7	20	1	ABZ98520	Human ICAM oligonu
C 733	20	0.7	20	1	ABZ98386	Human ICAM oligonu	C 806	20	0.7	20	1	ABZ98532	Human ICAM oligonu
C 734	20	0.7	20	1	ABZ98395	Human ICAM oligonu	C 807	20	0.7	20	1	ABZ98545	Human ICAM oligonu
C 735	20	0.7	20	1	ABZ98398	Human ICAM oligonu	C 808	20	0.7	20	1	ABZ98546	Human ICAM oligonu
C 736	20	0.7	20	1	ABZ98401	Human ICAM oligonu	C 809	20	0.7	20	1	ABZ98557	Human ICAM oligonu
C 737	20	0.7	20	1	ABZ98438	Human ICAM oligonu	C 810	20	0.7	20	1	ABZ98572	Human ICAM oligonu
C 738	20	0.7	20	1	ABZ98441	Human ICAM oligonu	C 811	20	0.7	20	1	ABZ98578	Human ICAM oligonu
C 739	20	0.7	20	1	ABZ98442	Human ICAM oligonu	C 812	20	0.7	20	1	ABZ98421	Human ICAM oligonu
C 740	20	0.7	20	1	ABZ98453	Human ICAM oligonu	C 813	20	0.7	20	1	ABZ98436	Human ICAM oligonu
C 741	20	0.7	20	1	ABZ98457	Human ICAM oligonu	C 814	20	0.7	20	1	ABZ98451	Human ICAM oligonu
C 742	20	0.7	20	1	ABZ98458	Human ICAM oligonu	C 815	20	0.7	20	1	ABZ98452	Human ICAM oligonu
C 743	20	0.7	20	1	ABZ98479	Human ICAM oligonu	C 816	20	0.7	20	1	ABZ98478	Human ICAM oligonu
C 744	20	0.7	20	1	ABZ98521	Human ICAM oligonu	C 817	20	0.7	20	1	ABZ98480	Human ICAM oligonu
C 745	20	0.7	20	1	ABZ98534	Human ICAM oligonu	C 818	20	0.7	20	1	ABZ98487	Human ICAM oligonu
C 746	20	0.7	20	1	ABZ98559	Human ICAM oligonu	C 819	20	0.7	20	1	ABZ98499	Human ICAM oligonu
C 747	20	0.7	20	1	ABZ98378	Human ICAM oligonu	C 820	20	0.7	20	1	ABZ98510	Human ICAM oligonu
C 748	20	0.7	20	1	ABZ98381	Human ICAM oligonu	C 821	20	0.7	20	1	ABZ98511	Human ICAM oligonu
C 749	20	0.7	20	1	ABZ98406	Human ICAM oligonu	C 822	20	0.7	20	1	ABZ98543	Human ICAM oligonu
C 750	20	0.7	20	1	ABZ98444	Human ICAM oligonu	C 823	20	0.7	20	1	ABZ75966	ICAM-1 gene target
C 751	20	0.7	20	1	ABZ98454	Human ICAM oligonu	C 824	20	0.7	20	1	ABZ75967	ICAM-1 gene target
C 752	20	0.7	20	1	ABZ98471	Human ICAM oligonu	C 825	20	0.7	20	1	ACC49170	ICAM-1 inhibitory
C 753	20	0.7	20	1	ABZ98541	Human ICAM oligonu	C 826	20	0.7	20	1	ACC49169	ICAM-1 inhibitory
C 754	20	0.7	20	1	ABZ98553	Human ICAM oligonu	C 827	20	0.7	20	1	ABX13929	Oligonucleotide wi
C 755	20	0.7	20	1	ABZ98553	Human ICAM oligonu	C 828	20	0.7	20	1	ABD31411	Human ICAM-derived
C 756	20	0.7	20	1	ABZ98553	Human ICAM oligonu	C 829	20	0.7	20	1	ABD31495	Human ICAM-derived
C 757	20	0.7	20	1	ABZ98409	Human ICAM oligonu	C 830	20	0.7	20	1	ABD31516	Human ICAM-derived
C 758	20	0.7	20	1	ABZ98445	Human ICAM oligonu	C 831	20	0.7	20	1	ABD31531	Human ICAM-derived
C 759	20	0.7	20	1	ABZ98450	Human ICAM oligonu	C 832	20	0.7	20	1	ABD31551	Human ICAM-derived
C 760	20	0.7	20	1	ABZ98516	Human ICAM oligonu	C 833	20	0.7	20	1	ABD31568	Human ICAM-derived
C 761	20	0.7	20	1	ABZ98522	Human ICAM oligonu	C 834	20	0.7	20	1	ABD31570	Human ICAM-derived
C 762	20	0.7	20	1	ABZ98537	Human ICAM oligonu	C 835	20	0.7	20	1	ABD31596	Human ICAM-derived
C 763	20	0.7	20	1	ABZ98539	Human ICAM oligonu	C 836	20	0.7	20	1	ABD31426	Human ICAM-derived

C 983	20	0.7	20	1	ABD31436	Human ICAM-derived	ci1056	20	0.7	20	1	ADJ60424	Oligonucleotide as
C 984	20	0.7	20	1	ABD31483	Human ICAM-derived	ci1057	20	0.7	20	1	ADJ60435	Oligonucleotide as
C 985	20	0.7	20	1	ABD31498	Human ICAM-derived	ci1058	20	0.7	20	1	ADJ60231	Oligonucleotide as
C 986	20	0.7	20	1	ABD31504	Human ICAM-derived	ci1059	20	0.7	20	1	ADJ60244	Oligonucleotide as
C 987	20	0.7	20	1	ABD31511	Human ICAM-derived	ci1060	20	0.7	20	1	ADJ60258	Oligonucleotide as
C 988	20	0.7	20	1	ABD31518	Human ICAM-derived	ci1061	20	0.7	20	1	ADJ60266	Oligonucleotide as
C 989	20	0.7	20	1	ABD31534	Human ICAM-derived	ci1062	20	0.7	20	1	ADJ60272	Oligonucleotide as
C 990	20	0.7	20	1	ABD31542	Human ICAM-derived	ci1063	20	0.7	20	1	ADJ60279	Oligonucleotide as
C 991	20	0.7	20	1	ABD31557	Human ICAM-derived	ci1064	20	0.7	20	1	ADJ60311	Oligonucleotide as
C 992	20	0.7	20	1	ABD31557	Human ICAM-derived	ci1065	20	0.7	20	1	ADJ60314	Oligonucleotide as
C 993	20	0.7	20	1	ABD31571	Human ICAM-derived	ci1066	20	0.7	20	1	ADJ60320	Oligonucleotide as
C 994	20	0.7	20	1	ABD31410	Human ICAM-derived	ci1067	20	0.7	20	1	ADJ60324	Oligonucleotide as
C 995	20	0.7	20	1	ABD31454	Human ICAM-derived	ci1068	20	0.7	20	1	ADJ60326	Oligonucleotide as
C 996	20	0.7	20	1	ABD31466	Human ICAM-derived	ci1069	20	0.7	20	1	ADJ60341	Oligonucleotide as
C 997	20	0.7	20	1	ABD31469	Human ICAM-derived	ci1070	20	0.7	20	1	ADJ60345	Oligonucleotide as
C 998	20	0.7	20	1	ABD31473	Human ICAM-derived	ci1071	20	0.7	20	1	ADJ60362	Oligonucleotide as
C 999	20	0.7	20	1	ABD31527	Human ICAM-derived	ci1072	20	0.7	20	1	ADJ60379	Oligonucleotide as
C1000	20	0.7	20	1	ABD31529	Human ICAM-derived	ci1073	20	0.7	20	1	ADJ60432	Oligonucleotide as
C1001	20	0.7	20	1	ABD31537	Human ICAM-derived	ci1074	20	0.7	20	1	ADJ60277	Oligonucleotide as
C1002	20	0.7	20	1	ABD31561	Human ICAM-derived	ci1075	20	0.7	20	1	ADJ60321	Oligonucleotide as
C1003	20	0.7	20	1	ABD31584	Human ICAM-derived	ci1076	20	0.7	20	1	ADJ60347	Oligonucleotide as
C1004	20	0.7	20	1	ABD31587	Human ICAM-derived	ci1077	20	0.7	20	1	ADJ60359	Oligonucleotide as
C1005	20	0.7	20	1	ABD31588	Human ICAM-derived	ci1078	20	0.7	20	1	ADJ60361	Oligonucleotide as
C1006	20	0.7	20	1	ABD31611	Human ICAM-derived	ci1079	20	0.7	20	1	ADJ60370	Oligonucleotide as
C1007	20	0.7	20	1	ABD31611	Human ICAM-derived	ci1080	20	0.7	20	1	ADJ60392	Oligonucleotide as
C1008	20	0.7	20	1	ABD31422	Human ICAM-derived	ci1081	20	0.7	20	1	ADJ60402	Oligonucleotide as
C1009	20	0.7	20	1	ABD31429	Human ICAM-derived	ci1082	20	0.7	20	1	ADJ60406	Oligonucleotide as
C1010	20	0.7	20	1	ABD31431	Human ICAM-derived	ci1083	20	0.7	20	1	ADJ60408	Oligonucleotide as
C1011	20	0.7	20	1	ABD31449	Human ICAM-derived	ci1084	20	0.7	20	1	ADJ60260	Oligonucleotide as
C1012	20	0.7	20	1	ABD31460	Human ICAM-derived	ci1085	20	0.7	20	1	ADJ60271	Oligonucleotide as
C1013	20	0.7	20	1	ABD31461	Human ICAM-derived	ci1086	20	0.7	20	1	ADJ60284	Oligonucleotide as
C1014	20	0.7	20	1	ABD31451	Human ICAM-derived	ci1087	20	0.7	20	1	ADJ60306	Oligonucleotide as
C1015	20	0.7	20	1	ABD31500	Human ICAM-derived	ci1088	20	0.7	20	1	ADJ60307	Oligonucleotide as
C1016	20	0.7	20	1	ABD31510	Human ICAM-derived	ci1089	20	0.7	20	1	ADJ60312	Oligonucleotide as
C1017	20	0.7	20	1	ABD31512	Human ICAM-derived	ci1090	20	0.7	20	1	ADJ60316	Oligonucleotide as
C1018	20	0.7	20	1	ABD31522	Human ICAM-derived	ci1091	20	0.7	20	1	ADJ60356	Oligonucleotide as
C1019	20	0.7	20	1	ABD31579	Human ICAM-derived	ci1092	20	0.7	20	1	ADJ60369	Oligonucleotide as
C1020	20	0.7	20	1	ABD31599	Human ICAM-derived	ci1093	20	0.7	20	1	ADJ60388	Oligonucleotide as
C1021	20	0.7	20	1	ABD31604	Human ICAM-derived	ci1094	20	0.7	20	1	ADJ60227	Oligonucleotide as
C1022	20	0.7	20	1	ABD31607	Human ICAM-derived	ci1095	20	0.7	20	1	ADJ60235	Oligonucleotide as
1023	20	0.7	20	1	ABD32086	Human PDE4C-derive	ci1096	20	0.7	20	1	ADJ60247	Oligonucleotide as
C1024	20	0.7	20	1	ABD31430	Human ICAM-derived	ci1097	20	0.7	20	1	ADJ60303	Oligonucleotide as
C1025	20	0.7	20	1	ABD31451	Human ICAM-derived	ci1098	20	0.7	20	1	ADJ60360	Oligonucleotide as
C1026	20	0.7	20	1	ABD31486	Human ICAM-derived	ci1099	20	0.7	20	1	ADJ60364	Oligonucleotide as
C1027	20	0.7	20	1	ABD31509	Human ICAM-derived	ci1100	20	0.7	20	1	ADJ60374	Oligonucleotide as
C1028	20	0.7	20	1	ABD31533	Human ICAM-derived	ci1101	20	0.7	20	1	ADJ60385	Oligonucleotide as
C1029	20	0.7	20	1	ABD31539	Human ICAM-derived	ci1102	20	0.7	20	1	ADJ60387	Oligonucleotide as
C1030	20	0.7	20	1	ABD31576	Human ICAM-derived	ci1103	20	0.7	20	1	ADJ60411	Oligonucleotide as
C1031	20	0.7	20	1	ABD31583	Human ICAM-derived	ci1104	20	0.7	20	1	ADJ60428	Oligonucleotide as
C1032	20	0.7	20	1	ABD31586	Human ICAM-derived	ci1105	20	0.7	20	1	ADJ60234	Oligonucleotide as
C1033	20	0.7	20	1	ABD31615	Human ICAM-derived	ci1106	20	0.7	20	1	ADJ60248	Oligonucleotide as
C1034	20	0.7	20	1	ADE90158	Human ICAM-1 anti	ci1107	20	0.7	20	1	ADJ60294	Oligonucleotide as
C1035	20	0.7	20	1	ADE39677	Oligonucleotide OD	ci1108	20	0.7	20	1	ADJ60309	Oligonucleotide as
C1036	20	0.7	20	1	ADE39676	Oligonucleotide OD	ci1109	20	0.7	20	1	ADJ60333	Oligonucleotide as
C1037	20	0.7	20	1	ADF42913	Methylated immunos	ci1110	20	0.7	20	1	ADJ60337	Oligonucleotide as
C1038	20	0.7	20	1	ADF42918	Methylated immunos	ci1111	20	0.7	20	1	ADJ60338	Oligonucleotide as
1039	20	0.7	20	1	ADF56727	Human ICAM-1 A241	ci1112	20	0.7	20	1	ADJ60343	Oligonucleotide as
C1040	20	0.7	20	1	ADI33382	Labelled ISIS 2302	ci1113	20	0.7	20	1	ADJ60352	Oligonucleotide as
C1041	20	0.7	20	1	ADI29042	Oligonucleotide #2	ci1114	20	0.7	20	1	ADJ60355	Oligonucleotide as
C1042	20	0.7	20	1	ADJ60230	Oligonucleotide as	ci1115	20	0.7	20	1	ADJ60363	Oligonucleotide as
C1043	20	0.7	20	1	ADJ60232	Oligonucleotide as	ci1116	20	0.7	20	1	ADJ60366	Oligonucleotide as
C1044	20	0.7	20	1	ADJ60243	Oligonucleotide as	ci1117	20	0.7	20	1	ADJ60381	Oligonucleotide as
C1045	20	0.7	20	1	ADJ60261	Oligonucleotide as	ci1118	20	0.7	20	1	ADJ60389	Oligonucleotide as
C1046	20	0.7	20	1	ADJ60286	Oligonucleotide as	ci1119	20	0.7	20	1	ADJ60405	Oligonucleotide as
C1047	20	0.7	20	1	ADJ60298	Oligonucleotide as	ci1120	20	0.7	20	1	ADJ60420	Oligonucleotide as
C1048	20	0.7	20	1	ADJ60292	Oligonucleotide as	ci1121	20	0.7	20	1	ADJ60229	Oligonucleotide as
C1049	20	0.7	20	1	ADJ60301	Oligonucleotide as	ci1122	20	0.7	20	1	ADJ60239	Oligonucleotide as
C1050	20	0.7	20	1	ADJ60304	Oligonucleotide as	ci1123	20	0.7	20	1	ADJ60241	Oligonucleotide as
C1051	20	0.7	20	1	ADJ60336	Oligonucleotide as	ci1124	20	0.7	20	1	ADJ60245	Oligonucleotide as
C1052	20	0.7	20	1	ADJ60354	Oligonucleotide as	ci1125	20	0.7	20	1	ADJ60249	Oligonucleotide as
C1053	20	0.7	20	1	ADJ60357	Oligonucleotide as	ci1126	20	0.7	20	1	ADJ60250	Oligonucleotide as
C1054	20	0.7	20	1	ADJ60380	Oligonucleotide as	ci1127	20	0.7	20	1	ADJ60264	Oligonucleotide as
C1055	20	0.7	20	1	ADJ60416	Oligonucleotide as	ci1128	20	0.7	20	1	ADJ60268	Oligonucleotide as

c1129	20	0.7	20	1	ADJ60305	Oligonucleotide as	c1202	20	0.7	20	1	ADJ60413	Oligonucleotide as
c1130	20	0.7	20	1	ADJ60332	Oligonucleotide as	c1203	20	0.7	20	1	ADJ60425	Oligonucleotide as
c1131	20	0.7	20	1	ADJ60334	Oligonucleotide as	c1204	20	0.7	20	1	ADJ60434	Oligonucleotide as
c1132	20	0.7	20	1	ADJ60342	Oligonucleotide as	c1205	20	0.7	20	1	ADJ60236	Oligonucleotide as
c1133	20	0.7	20	1	ADJ60382	Oligonucleotide as	c1206	20	0.7	20	1	ADJ60259	Oligonucleotide as
c1134	20	0.7	20	1	ADJ60383	Oligonucleotide as	c1207	20	0.7	20	1	ADJ60287	Oligonucleotide as
c1135	20	0.7	20	1	ADJ60228	Oligonucleotide as	c1208	20	0.7	20	1	ADJ60293	Oligonucleotide as
c1136	20	0.7	20	1	ADJ60237	Oligonucleotide as	c1209	20	0.7	20	1	ADJ60325	Oligonucleotide as
c1137	20	0.7	20	1	ADJ60252	Oligonucleotide as	c1210	20	0.7	20	1	ADJ60365	Oligonucleotide as
c1138	20	0.7	20	1	ADJ60282	Oligonucleotide as	c1211	20	0.7	20	1	ADJ60367	Oligonucleotide as
c1139	20	0.7	20	1	ADJ60300	Oligonucleotide as	c1212	20	0.7	20	1	ADJ60394	Oligonucleotide as
c1140	20	0.7	20	1	ADJ60302	Oligonucleotide as	c1213	20	0.7	20	1	ADJ60397	Oligonucleotide as
c1141	20	0.7	20	1	ADJ60319	Oligonucleotide as	c1214	20	0.7	20	1	ADJ60414	Oligonucleotide as
c1142	20	0.7	20	1	ADJ60340	Oligonucleotide as	c1215	20	0.7	20	1	ADJ60419	Oligonucleotide as
c1143	20	0.7	20	1	ADJ60353	Oligonucleotide as	c1216	20	0.7	20	1	ADJ60238	Oligonucleotide as
c1144	20	0.7	20	1	ADJ60375	Oligonucleotide as	c1217	20	0.7	20	1	ADJ60240	Oligonucleotide as
c1145	20	0.7	20	1	ADJ60412	Oligonucleotide as	c1218	20	0.7	20	1	ADJ60351	Oligonucleotide as
c1146	20	0.7	20	1	ADJ60421	Oligonucleotide as	c1219	20	0.7	20	1	ADJ60356	Oligonucleotide as
c1147	20	0.7	20	1	ADJ60422	Oligonucleotide as	c1220	20	0.7	20	1	ADJ60265	Oligonucleotide as
c1148	20	0.7	20	1	ADJ60940	Oligonucleotide as	c1221	20	0.7	20	1	ADJ60349	Oligonucleotide as
c1149	20	0.7	20	1	ADJ60276	Oligonucleotide as	c1222	20	0.7	20	1	ADJ60368	Oligonucleotide as
c1150	20	0.7	20	1	ADJ60278	Oligonucleotide as	c1223	20	0.7	20	1	ADJ60378	Oligonucleotide as
c1151	20	0.7	20	1	ADJ60285	Oligonucleotide as	c1224	20	0.7	20	1	ADJ60410	Oligonucleotide as
c1152	20	0.7	20	1	ADJ60235	Oligonucleotide as	c1225	20	0.7	20	1	ADJ60418	Oligonucleotide as
c1153	20	0.7	20	1	ADJ60310	Oligonucleotide as	c1226	20	0.7	20	1	ADJ60433	Oligonucleotide as
c1154	20	0.7	20	1	ADJ60313	Oligonucleotide as	c1227	20	0.7	20	1	ADJ60297	Oligonucleotide as
c1155	20	0.7	20	1	ADJ60315	Oligonucleotide as	c1228	20	0.7	20	1	ADJ60299	Oligonucleotide as
c1156	20	0.7	20	1	ADJ60331	Oligonucleotide as	c1229	20	0.7	20	1	ADJ60318	Oligonucleotide as
c1157	20	0.7	20	1	ADJ60344	Oligonucleotide as	c1230	20	0.7	20	1	ADJ60322	Oligonucleotide as
c1158	20	0.7	20	1	ADJ60346	Oligonucleotide as	c1231	20	0.7	20	1	ADJ60323	Oligonucleotide as
c1159	20	0.7	20	1	ADJ60395	Oligonucleotide as	c1232	20	0.7	20	1	ADJ60335	Oligonucleotide as
c1160	20	0.7	20	1	ADJ60417	Oligonucleotide as	c1233	20	0.7	20	1	ADJ60350	Oligonucleotide as
c1161	20	0.7	20	1	ADJ60242	Oligonucleotide as	c1234	20	0.7	20	1	ADJ60377	Oligonucleotide as
c1162	20	0.7	20	1	ADJ60246	Oligonucleotide as	c1235	20	0.7	20	1	ADJ60409	Oligonucleotide as
c1163	20	0.7	20	1	ADJ60253	Oligonucleotide as	c1236	20	0.7	20	1	ADJ60415	Oligonucleotide as
c1164	20	0.7	20	1	ADJ60255	Oligonucleotide as	c1237	20	0.7	20	1	ADJ60263	Oligonucleotide as
c1165	20	0.7	20	1	ADJ60257	Oligonucleotide as	c1238	20	0.7	20	1	ADJ60270	Oligonucleotide as
c1166	20	0.7	20	1	ADJ60280	Oligonucleotide as	c1239	20	0.7	20	1	ADJ60283	Oligonucleotide as
c1167	20	0.7	20	1	ADJ60281	Oligonucleotide as	c1240	20	0.7	20	1	ADJ60327	Oligonucleotide as
c1168	20	0.7	20	1	ADJ60291	Oligonucleotide as	c1241	20	0.7	20	1	ADJ60371	Oligonucleotide as
c1169	20	0.7	20	1	ADJ60329	Oligonucleotide as	c1242	20	0.7	20	1	ADJ60376	Oligonucleotide as
c1170	20	0.7	20	1	ADJ60351	Oligonucleotide as	c1243	20	0.7	20	1	ADJ60390	Oligonucleotide as
c1171	20	0.7	20	1	ADJ60358	Oligonucleotide as	c1244	20	0.7	20	1	ADJ60393	Oligonucleotide as
c1172	20	0.7	20	1	ADJ60398	Oligonucleotide as	c1245	20	0.7	20	1	ADJ60403	Oligonucleotide as
c1173	20	0.7	20	1	ADJ60400	Oligonucleotide as	c1246	20	0.7	20	1	ADJ60404	Oligonucleotide as
c1174	20	0.7	20	1	ADJ60427	Oligonucleotide as	c1247	20	0.7	20	1	ADJ60407	Oligonucleotide as
c1175	20	0.7	20	1	ADJ60430	Oligonucleotide as	c1248	20	0.7	20	1	ADJ60429	Oligonucleotide as
c1176	20	0.7	20	1	ADJ60431	Oligonucleotide as	c1249	20	0.7	20	1	ADJ77768	Modified antisense
c1177	20	0.7	20	1	ADJ60254	Oligonucleotide as	c1250	20	0.7	20	1	ADJ77765	Modified antisense
c1178	20	0.7	20	1	ADJ60262	Oligonucleotide as	c1251	20	0.7	20	1	ADJ77766	Modified antisense
c1179	20	0.7	20	1	ADJ60269	Oligonucleotide as	c1252	20	0.7	20	1	ADJ54197	Human B7-2 DNA con
c1180	20	0.7	20	1	ADJ60275	Oligonucleotide as	c1253	20	0.7	20	1	ADJ69872	Sulphurised oligon
c1181	20	0.7	20	1	ADJ60286	Oligonucleotide as	c1254	20	0.7	20	1	ADJ69878	Sulphurised oligon
c1182	20	0.7	20	1	ADJ60308	Oligonucleotide as	c1255	20	0.7	20	1	ADJ69879	Sulphurised oligon
c1183	20	0.7	20	1	ADJ60372	Oligonucleotide as	c1256	20	0.7	20	1	ADJ69884	Sulphurised oligon
c1184	20	0.7	20	1	ADJ60373	Oligonucleotide as	c1257	20	0.7	20	1	ADJ65128	Antisense oligonuc
c1185	20	0.7	20	1	ADJ60386	Oligonucleotide as	c1258	20	0.7	20	1	ADJ65130	Antisense oligonuc
c1186	20	0.7	20	1	ADJ60399	Oligonucleotide as	c1259	20	0.7	20	1	ADJ64657	Antisense oligonuc
c1187	20	0.7	20	1	ADJ60423	Oligonucleotide as	c1260	20	0.7	20	1	ADJ64657	Antisense oligonuc
c1188	20	0.7	20	1	ADJ60426	Oligonucleotide as	c1261	20	0.7	20	1	ADJ64675	Antisense oligonuc
c1189	20	0.7	20	1	ADJ60257	Oligonucleotide as	c1262	20	0.7	20	1	ADJ64673	Antisense oligonuc
c1190	20	0.7	20	1	ADJ60273	Oligonucleotide as	c1263	20	0.7	20	1	ADJ64653	Antisense oligonuc
c1191	20	0.7	20	1	ADJ60274	Oligonucleotide as	c1264	20	0.7	20	1	ADJ64659	Antisense oligonuc
c1192	20	0.7	20	1	ADJ60298	Oligonucleotide as	c1265	20	0.7	20	1	ADJ64656	Antisense oligonuc
c1193	20	0.7	20	1	ADJ60317	Oligonucleotide as	c1266	20	0.7	20	1	ADJ64662	Antisense oligonuc
c1194	20	0.7	20	1	ADJ60328	Oligonucleotide as	c1267	20	0.7	20	1	ADJ64673	Antisense oligonuc
c1195	20	0.7	20	1	ADJ60330	Oligonucleotide as	c1268	20	0.7	20	1	ADJ64674	Antisense oligonuc
c1196	20	0.7	20	1	ADJ60339	Oligonucleotide as	c1269	20	0.7	20	1	ADJ64677	Antisense oligonuc
c1197	20	0.7	20	1	ADJ60348	Oligonucleotide as	c1270	20	0.7	20	1	ADJ64658	Antisense oligonuc
c1198	20	0.7	20	1	ADJ60384	Oligonucleotide as	c1271	20	0.7	20	1	ADJ64676	Antisense oligonuc
c1199	20	0.7	20	1	ADJ60391	Oligonucleotide as	c1272	20	0.7	20	1	ADJ64661	Antisense oligonuc
c1200	20	0.7	20	1	ADJ60396	Oligonucleotide as	c1273	20	0.7	20	1	ADJ64660	Antisense oligonuc
c1201	20	0.7	20	1	ADJ60401	Oligonucleotide as	c1274	20	0.7	20	1	ADJ64664	Antisense oligonuc

c1421	20	0.7	20	1	AD045849	Human oligonucleot	c1494	20	0.7	20	1	ADP87902	2',5'-oligoadenyli
c1422	20	0.7	20	1	AD045858	Human oligonucleot	c1495	20	0.7	20	1	ADP87905	2',5'-oligoadenyli
c1423	20	0.7	20	1	AD045893	Human oligonucleot	c1496	20	0.7	20	1	AD085919	Antisense oligonuc
c1424	20	0.7	20	1	AD045905	Human oligonucleot	1497	20	0.7	20	1	ADP08716	Extend primer 53 u
c1425	20	0.7	20	1	AD045908	Human oligonucleot	1498	20	0.7	20	1	ADP45836	Extend primer 28 u
c1426	20	0.7	20	1	AD045906	Human oligonucleot	c1499	20	0.7	20	1	ADQ16468	Modified oligonuc
c1427	20	0.7	20	1	AD045913	Human oligonucleot	c1500	20	0.7	20	1	ADQ75054	Ligand conjugated
c1428	20	0.7	20	1	AD045746	Human oligonucleot	c1501	20	0.7	20	1	ADQ76194	Chemokine modulati
c1429	20	0.7	20	1	AD045748	Human oligonucleot	c1502	20	0.7	20	1	ADQ29110	Human ICAM-1 anti
c1430	20	0.7	20	1	AD045750	Human oligonucleot	c1503	20	0.7	20	1	ADQ29118	Human ICAM-1 anti
c1431	20	0.7	20	1	AD045753	Human oligonucleot	c1504	20	0.7	20	1	ADQ88549	Murine ICAM-1 anti
c1432	20	0.7	20	1	AD045780	Human oligonucleot	c1505	20	0.7	20	1	ADQ14892	CD54 RNase H depen
c1433	20	0.7	20	1	AD045782	Human oligonucleot	c1506	20	0.7	20	1	ADQ14896	CD54 RNase H depen
c1434	20	0.7	20	1	AD045783	Human oligonucleot	c1507	20	0.7	20	1	ADQ14913	CD54 RNase H depen
c1435	20	0.7	20	1	AD045788	Human oligonucleot	c1508	20	0.7	20	1	ADQ14897	CD54 RNase H depen
c1436	20	0.7	20	1	AD045791	Human oligonucleot	c1509	20	0.7	20	1	ADQ14903	CD54 RNase H depen
c1437	20	0.7	20	1	AD045802	Human oligonucleot	c1510	20	0.7	20	1	ADQ14909	CD54 RNase H depen
c1438	20	0.7	20	1	AD045805	Human oligonucleot	c1511	20	0.7	20	1	ADQ14881	CD54 RNase H depen
c1439	20	0.7	20	1	AD045830	Human oligonucleot	c1512	20	0.7	20	1	ADQ14889	CD54 RNase H depen
c1440	20	0.7	20	1	AD045857	Human oligonucleot	c1513	20	0.7	20	1	ADQ14911	CD54 RNase H depen
c1441	20	0.7	20	1	AD045868	Human oligonucleot	c1514	20	0.7	20	1	ADQ14899	CD54 RNase H depen
c1442	20	0.7	20	1	AD045878	Human oligonucleot	c1515	20	0.7	20	1	ADQ14891	CD54 RNase H depen
c1443	20	0.7	20	1	AD045897	Human oligonucleot	c1516	20	0.7	20	1	ADQ14900	CD54 RNase H depen
c1444	20	0.7	20	1	AD045910	Human oligonucleot	c1517	20	0.7	20	1	ADQ14908	CD54 RNase H depen
c1445	20	0.7	20	1	AD045919	Human oligonucleot	c1518	20	0.7	20	1	ADQ14912	CD54 RNase H depen
c1446	20	0.7	20	1	AD045922	Human oligonucleot	c1519	20	0.7	20	1	ADQ14882	CD54 RNase H depen
c1447	20	0.7	20	1	AD045727	Human oligonucleot	c1520	20	0.7	20	1	ADQ14883	CD54 RNase H depen
c1448	20	0.7	20	1	AD045745	Human oligonucleot	c1521	20	0.7	20	1	ADQ14893	CD54 RNase H depen
c1449	20	0.7	20	1	AD045757	Human oligonucleot	c1522	20	0.7	20	1	ADQ14894	CD54 RNase H depen
c1450	20	0.7	20	1	AD045775	Human oligonucleot	c1523	20	0.7	20	1	ADQ14879	CD54 RNase H depen
c1451	20	0.7	20	1	AD045794	Human oligonucleot	c1524	20	0.7	20	1	ADQ14902	CD54 RNase H depen
c1452	20	0.7	20	1	AD045798	Human oligonucleot	c1525	20	0.7	20	1	ADQ14914	CD54 RNase H depen
c1453	20	0.7	20	1	AD045800	Human oligonucleot	c1526	20	0.7	20	1	ADQ14888	CD54 RNase H depen
c1454	20	0.7	20	1	AD045803	Human oligonucleot	c1527	20	0.7	20	1	ADQ14890	CD54 RNase H depen
c1455	20	0.7	20	1	AD045817	Human oligonucleot	c1528	20	0.7	20	1	ADQ14904	CD54 RNase H depen
c1456	20	0.7	20	1	AD045824	Human oligonucleot	c1529	20	0.7	20	1	ADQ14906	CD54 RNase H depen
c1457	20	0.7	20	1	AD045904	Human oligonucleot	c1530	20	0.7	20	1	ADQ14907	CD54 RNase H depen
c1458	20	0.7	20	1	AD045911	Human oligonucleot	c1531	20	0.7	20	1	ADQ14915	CD54 RNase H depen
c1459	20	0.7	20	1	AD045739	Human oligonucleot	c1532	20	0.7	20	1	ADQ14915	CD54 RNase H depen
c1460	20	0.7	20	1	AD045761	Human oligonucleot	c1533	20	0.7	20	1	ADQ14880	CD54 RNase H depen
c1461	20	0.7	20	1	AD045809	Human oligonucleot	c1534	20	0.7	20	1	ADQ14885	CD54 RNase H depen
c1462	20	0.7	20	1	AD045830	Human oligonucleot	c1535	20	0.7	20	1	ADQ14898	CD54 RNase H depen
c1463	20	0.7	20	1	AD045884	Human oligonucleot	c1536	20	0.7	20	1	ADQ14877	CD54 RNase H depen
c1464	20	0.7	20	1	AD045895	Human oligonucleot	c1537	20	0.7	20	1	ADQ14884	CD54 RNase H depen
c1465	20	0.7	20	1	AD045899	Human oligonucleot	c1538	20	0.7	20	1	ADQ14886	CD54 RNase H depen
c1466	20	0.7	20	1	AD045900	Human oligonucleot	c1539	20	0.7	20	1	ADQ14895	CD54 RNase H depen
c1467	20	0.7	20	1	AD045901	Human oligonucleot	c1540	20	0.7	20	1	ADQ14901	CD54 RNase H depen
c1468	20	0.7	20	1	AD045914	Human oligonucleot	c1541	20	0.7	20	1	ADQ14905	CD54 RNase H depen
c1469	20	0.7	20	1	AD045794	Human oligonucleot	c1542	20	0.7	20	1	ADQ14916	CD54 RNase H depen
c1470	20	0.7	20	1	AD045754	Human oligonucleot	c1543	20	0.7	20	1	ADQ14878	CD54 RNase H depen
c1471	20	0.7	20	1	AD045765	Human oligonucleot	c1544	20	0.7	20	1	ADQ14887	CD54 RNase H depen
c1472	20	0.7	20	1	AD045766	Human oligonucleot	c1545	20	0.7	20	1	ADQ14886	CD54 RNase H depen
c1473	20	0.7	20	1	AD045816	Human oligonucleot	c1546	20	0.7	20	1	ADQ14895	CD54 RNase H depen
c1474	20	0.7	20	1	AD045823	Human oligonucleot	c1547	20	0.7	20	1	ADQ14906	CD54 RNase H depen
c1475	20	0.7	20	1	AD045830	Human oligonucleot	c1548	20	0.7	20	1	ADQ14907	CD54 RNase H depen
c1476	20	0.7	20	1	AD045860	Human oligonucleot	c1549	20	0.7	20	1	ADQ14916	CD54 RNase H depen
c1477	20	0.7	20	1	AD045871	Human oligonucleot	c1550	20	0.7	20	1	ADQ14877	CD54 RNase H depen
c1478	20	0.7	20	1	AD045879	Human oligonucleot	c1551	20	0.7	20	1	ADQ14884	CD54 RNase H depen
c1479	20	0.7	20	1	AD045885	Human oligonucleot	c1552	20	0.7	20	1	ADQ14886	CD54 RNase H depen
c1480	20	0.7	20	1	AD045887	Human oligonucleot	c1553	20	0.7	20	1	ADQ14895	CD54 RNase H depen
c1481	20	0.7	20	1	AD045894	Human oligonucleot	c1554	20	0.7	20	1	ADQ14901	CD54 RNase H depen
c1482	20	0.7	20	1	AD045916	Human oligonucleot	c1555	20	0.7	20	1	ADQ14905	CD54 RNase H depen
c1483	20	0.7	20	1	AD045729	Human oligonucleot	c1556	20	0.7	20	1	ADQ14878	CD54 RNase H depen
c1484	20	0.7	20	1	AD045764	Human oligonucleot	c1557	20	0.7	20	1	ADQ14887	CD54 RNase H depen
c1485	20	0.7	20	1	AD045769	Human oligonucleot	c1558	20	0.7	20	1	ADQ14886	CD54 RNase H depen
c1486	20	0.7	20	1	AD045796	Human oligonucleot	c1559	20	0.7	20	1	ADQ14895	CD54 RNase H depen
c1487	20	0.7	20	1	AD045812	Human oligonucleot	c1560	20	0.7	20	1	ADQ14906	CD54 RNase H depen
c1488	20	0.7	20	1	AD045851	Human oligonucleot	c1561	20	0.7	20	1	ADQ14916	CD54 RNase H depen
c1489	20	0.7	20	1	AD045863	Human oligonucleot	c1562	20	0.7	20	1	ADQ14877	CD54 RNase H depen
c1490	20	0.7	20	1	AD045885	Human oligonucleot	c1563	20	0.7	20	1	ADQ14884	CD54 RNase H depen
c1491	20	0.7	20	1	AD045876	Human oligonucleot	c1564	20	0.7	20	1	ADQ14895	CD54 RNase H depen
c1492	20	0.7	20	1	AD045899	Human oligonucleot	c1565	20	0.7	20	1	ADQ14901	CD54 RNase H depen
c1493	20	0.7	20	1	ADP87907	2',5'-oligoadenyli	c1566	20	0.7	20	1	ADP89463	Human ICAM-1 modif

1567	20	0.7	25	1	AAEP9464	Human ICAM-1 antisense	19	0.6	19	1	AAH49230	Anti-ICAM oligonucleotide
1568	19.8	0.7	23	1	ADP69447	5' anchored (ISSR) PCR primer for human	19	0.6	19	1	ABL01638	ICAM-1 targeted an
1569	19.8	0.7	24	1	AAZ77676	Ras GTP enzyme-act	19	0.6	19	1	ABK09295	Interleukin adhe
1570	19.8	0.7	24	1	ABV77671	Murine tricarboxyl	19	0.6	19	1	ABA97493	ICAM-1 targeted an
1571	19.6	0.7	24	1	ABZ70239	SNP flanking sequ	19	0.6	19	1	AAI46757	ICAM antisense oli
1572	19.8	0.7	21	1	AACT73438	Microsatellite seq	19	0.6	19	1	AAJ52577	Interleukin adhe
1573	19.4	0.6	21	1	AAQ33891	Microsatellite seq	19	0.6	19	1	ACD67155	Derivatised oligon
1574	19.4	0.6	21	1	AAQ34015	Microsatellite seq	19	0.6	19	1	ACC85090	Human ICAM-1 cDNA
1575	19.4	0.6	21	1	AAQ33879	Microsatellite seq	19	0.6	19	1	ADH82094	Phosphorothioate m
1576	19.4	0.6	21	1	AAJ90296	Oligonucleotide RT	19	0.6	19	1	ADG25672	Human ICAM-1 probe
1577	19.4	0.6	21	1	AAJ65738	Repeat sequence fr	19	0.6	19	1	ABZ95200	Human ICAM-1 antis
1578	19.4	0.6	21	1	AAH866419	PCR primer PDZK5.6	19	0.6	19	1	ADL25033	Intestinal epithel
1579	19.4	0.6	21	1	AAH46013	Synthetic oligonuc	19	0.6	19	1	ABD19142	Human ICAM-1 DNA f
1580	19.4	0.6	21	1	AAH46014	Synthetic oligonuc	19	0.6	19	1	ADJ65124	Antisense oligonuc
1581	19.4	0.6	21	1	AAJ99702	Immunostimulatory	19	0.6	19	1	ADQ22992	Human CD54 gene an
1582	19.4	0.6	21	1	AAH37973	SNP specific upper	19	0.6	19	1	ADP46421	siRNA 3 targeted t
1583	19.4	0.6	21	1	ABJ78423	Angiogenesis inhib	19	0.6	19	1	ADP46419	siRNA 2 targeted t
1584	19.4	0.6	21	1	ADH47846	NOV14 probe, SEQ I	19	0.6	19	1	ADP46420	siRNA 2 targeted t
1585	19.4	0.6	21	1	ACF64055	IFNAR1 forward PCR	19	0.6	19	1	ADP46422	siRNA 4 targeted t
1586	19.4	0.6	21	1	ACH03241	Immunostimulatory	19	0.6	19	1	ADP45848	Extend primer 40 u
1587	19.4	0.6	21	1	ADH37204	Immunostimulatory	19	0.6	19	1	ADQ82757	Human ICAM-1 oligo
1588	19.4	0.6	21	1	ADH59619	Non-nucleotide pro	19	0.6	19	1	ADQ82764	Human ICAM-1 oligo
1589	19.4	0.6	21	1	ADP68377	DNA probe used to	19	0.6	19	1	ADQ82768	Human ICAM-1 oligo
1590	19.4	0.6	21	1	ADL25728	Human NOVX gene, p	19	0.6	19	1	ADQ82763	Human ICAM-1 oligo
1591	19.4	0.6	22	1	AAQ33675	Microsatellite seq	19	0.6	19	1	ADQ82751	Human ICAM-1 oligo
1592	19.4	0.6	22	1	AAQ34038	Microsatellite seq	19	0.6	19	1	ADQ82766	Human ICAM-1 oligo
1593	19.4	0.6	22	1	AAQ34080	Microsatellite seq	19	0.6	19	1	ADQ82760	Human ICAM-1 oligo
1594	19.4	0.6	22	1	AAQ33991	Microsatellite seq	19	0.6	19	1	ADQ82762	Human ICAM-1 oligo
1595	19.4	0.6	22	1	AAI64448	SSR motif #8. Uni	19	0.6	19	1	ADQ82761	Human ICAM-1 oligo
1596	19.4	0.6	22	1	ADO81143	Prior protein poly	19	0.6	19	1	ADQ82756	Human ICAM-1 oligo
1597	19.4	0.6	22	1	ADO81098	Sheep prion protei	19	0.6	19	1	ADQ82755	Human ICAM-1 oligo
1598	19.4	0.6	24	1	AAH39074	SNP specific lower	19	0.6	19	1	ADQ82767	Human ICAM-1 oligo
1599	19.4	0.6	24	1	ADR44221	Caenorhabditis ele	19	0.6	19	1	AAQ85815	Anti-ICAM 2'-O-alk
1600	19.2	0.6	24	1	AAJ98498	H. discus derived	19	0.6	20	1	AAQ85815	Human telomerase R
1601	19.2	0.6	24	1	AAH48127	Ribonucleotide red	19	0.6	20	1	AAZ37713	Human mdm2 phospho
1602	19.2	0.6	24	1	AAJ24627	Primer for a polym	19	0.6	20	1	AAZ21805	Exemplary oligonuc
1603	19.2	0.6	24	1	AAJ24635	Primer for polymor	19	0.6	20	1	AAZ21805	Human RANK antise
1604	19.2	0.6	24	1	AAH23170	Nitric oxide synth	19	0.6	20	1	AAJ31817	Human mdm2 antise
1605	19.2	0.6	24	1	ABQ83629	Human mPer3-10.01	19	0.6	20	1	AAJ31817	Human mdm2 antise
1606	19.2	0.6	24	1	ABQ83626	Human thyroglobuli	19	0.6	20	1	AAJ31817	Human mdm2 antise
1607	19.2	0.6	24	1	ABZ21100	Zinc finger protei	19	0.6	20	1	AAJ31817	Human mdm2 antise
1608	19.2	0.6	24	1	ABK89466	Human large protei	19	0.6	20	1	AAJ31817	Human mdm2 antise
1609	19.2	0.6	24	1	AAJ16055	Human microtubulin	19	0.6	20	1	AAJ31817	Human mdm2 antise
1610	19.2	0.6	24	1	ABJ42396	Histidyl-tRNA synt	19	0.6	20	1	AAJ31817	Human mdm2 antise
1611	19.2	0.6	24	1	ABQ75907	Human I1 factor OR	19	0.6	20	1	AAJ31817	Human mdm2 antise
1612	19.2	0.6	24	1	ABA01638	Human tyrosinase 1	19	0.6	20	1	AAJ31817	Human mdm2 antise
1613	19.2	0.6	24	1	ABJ10945	Human zinc finger	19	0.6	20	1	AAJ31817	Human mdm2 antise
1614	19.2	0.6	24	1	ABJ10945	7s ribosomal RNA (19	0.6	20	1	AAJ31817	Human mdm2 antise
1615	19	0.6	19	1	AAQ47007	Probe (Icam 1-3) f	19	0.6	20	1	AAJ31817	Human mdm2 antise
1616	19	0.6	19	1	AAQ97342	Probe used for ide	19	0.6	20	1	AAJ31817	Human mdm2 antise
1617	19	0.6	19	1	AAQ88743	Human ICAM modifi	19	0.6	20	1	AAJ31817	Human mdm2 antise
1618	19	0.6	19	1	AAI44451	Antisense oligonuc	19	0.6	20	1	AAJ31817	Human mdm2 antise
1619	19	0.6	19	1	AAJ44252	ICAM antisense com	19	0.6	20	1	AAJ31817	Human mdm2 antise
1620	19	0.6	19	1	AAJ33924	ICAM expression in	19	0.6	20	1	AAJ31817	Human mdm2 antise
1621	19	0.6	19	1	AAJ24206	Phosphononoester	19	0.6	20	1	AAJ31817	Human mdm2 antise
1622	19	0.6	19	1	AAJ24206	Oligonucleotide IS	19	0.6	20	1	AAJ31817	Human mdm2 antise
1623	19	0.6	19	1	AAJ76145	Human intercellula	19	0.6	20	1	AAJ31817	Human mdm2 antise
1624	19	0.6	19	1	AAJ54842	Probe icam 1-3 use	19	0.6	20	1	AAJ31817	Human mdm2 antise
1625	19	0.6	19	1	AAJ28151	Deletion derivativ	19	0.6	20	1	AAJ31817	Human mdm2 antise
1626	19	0.6	19	1	AAJ56364	Human ICAM-R cDNA	19	0.6	20	1	AAJ31817	Human mdm2 antise
1627	19	0.6	19	1	AAJ69141	ICAM-R cDNA screen	19	0.6	20	1	AAJ31817	Human mdm2 antise
1628	19	0.6	19	1	AAJ21854	Primer for ICAM im	19	0.6	20	1	AAJ31817	Human mdm2 antise
1629	19	0.6	19	1	AAJ33384	Low adenosine anti	19	0.6	20	1	AAJ31817	Human mdm2 antise
1630	19	0.6	19	1	AAJ24278	Human ICAM oligonu	19	0.6	20	1	AAJ31817	Human mdm2 antise
1631	19	0.6	19	1	AAJ27847	ICAM-1 3' non-codi	19	0.6	20	1	AAJ31817	Human mdm2 antise
1632	19	0.6	19	1	AAJ97106	PCR primer Icam 1-	19	0.6	20	1	AAJ31817	Human mdm2 antise
1633	19	0.6	19	1	AAJ08852	Human ICAM oligonu	19	0.6	20	1	AAJ31817	Human mdm2 antise
1634	19	0.6	19	1	AAJ19506	Human ICAM-1 poly	19	0.6	20	1	AAJ31817	Human mdm2 antise
1635	19	0.6	19	1	AAJ73490	Reverse primer #10	19	0.6	20	1	AAJ31817	Human mdm2 antise
1636	19	0.6	19	1	AAJ73482	Reverse primer #10	19	0.6	20	1	AAJ31817	Human mdm2 antise
1637	19	0.6	19	1	AAJ60946	Anti-ICAM-1 oligon	19	0.6	20	1	AAJ31817	Human mdm2 antise
1638	19	0.6	19	1	AAJ37310	SNP specific lower	19	0.6	20	1	AAJ31817	Human mdm2 antise
1639	19	0.6	19	1	AAJ91943	Human ICAM-R probe	19	0.6	20	1	AAJ31817	Human mdm2 antise

c1713	18.4	0.6	20	1	AAFG2932	Human PEPCK-cytoso	ci786	18.4	0.6	20	1	ADM15498	Human mPGES-1 chim
c1714	18.4	0.6	20	1	AAH28355	DNA oligomer #5.	ci787	18.4	0.6	20	1	ADM14129	Human mPGES-1 chim
1715	18.4	0.6	20	1	AAH48201	Antibody binding o	ci788	18.4	0.6	20	1	ADM14134	Human mPGES-1 chim
c1716	18.4	0.6	20	1	AAI64445	SSR motif #5. Uni	ci789	18.4	0.6	20	1	ADM14296	Human mPGES-1 chim
1717	18.4	0.6	20	1	AAI64449	SSR motif #9. Uni	ci790	18.4	0.6	20	1	ADM14298	Human mPGES-1 chim
c1718	18.4	0.6	20	1	AAS29481	Human mdm2 antisen	ci791	18.4	0.6	20	1	ADM15453	Human mPGES-1 chim
c1719	18.4	0.6	20	1	AAS67840	Human casein kinas	ci792	18.4	0.6	20	1	ADM14131	Human mPGES-1 chim
1720	18.4	0.6	20	1	AAAL45125	Oligonucleotide sy	ci793	18.4	0.6	20	1	ADM15408	Human mPGES-1 chim
c1721	18.4	0.6	20	1	ABA96307	Oligonucleotide SE	ci794	18.4	0.6	20	1	ADM14133	Human mPGES-1 chim
1722	18.4	0.6	20	1	ABA96306	Oligonucleotide SE	ci795	18.4	0.6	20	1	ADM14133	Human mPGES-1 chim
1723	18.4	0.6	20	1	ABK68939	Human phosphorilas	ci796	18.4	0.6	20	1	ADM14772	Human mPGES-1 chim
c1724	18.4	0.6	20	1	ACC55324	Human ADAMTS13 Sfs	ci797	18.4	0.6	20	1	ADM15478	Human mPGES-1 chim
c1725	18.4	0.6	20	1	ABZ24438	Oligonucleotide (C	ci798	18.4	0.6	20	1	ADM14295	Human mPGES-1 chim
1726	18.4	0.6	20	1	ABZ24439	Oligonucleotide (T	ci799	18.4	0.6	20	1	ADM13952	Human mPGES-1 chim
1727	18.4	0.6	20	1	ADD26665	Polynucleotide (ds	ci800	18.4	0.6	20	1	ADM13988	Human mPGES-1 chim
c1728	18.4	0.6	20	1	ADD21677	Human mdm2 antisen	ci801	18.4	0.6	20	1	ADM14427	Human mPGES-1 chim
c1729	18.4	0.6	20	1	ADG42099	Human ICAM-1 RT-PC	ci802	18.4	0.6	20	1	ADM14814	Human mPGES-1 chim
1730	18.4	0.6	20	1	ABZ98011	Human RANTES oligo	ci803	18.4	0.6	20	1	ADO45368	Human oligonucleot
1731	18.4	0.6	20	1	ABZ98012	Human RANTES oligo	ci804	18.4	0.6	20	1	ADO45263	Human oligonucleot
1732	18.4	0.6	20	1	ABZ98014	Human RANTES oligo	ci805	18.4	0.6	20	1	ADO45779	Human oligonucleot
1733	18.4	0.6	20	1	ABZ97908	Human RANTES oligo	ci806	18.4	0.6	20	1	ADO45369	Human oligonucleot
1734	18.4	0.6	20	1	ABZ98003	Human RANTES oligo	ci807	18.4	0.6	20	1	ADO45778	Human oligonucleot
1735	18.4	0.6	20	1	ABZ98013	Human RANTES oligo	ci808	18.4	0.6	20	1	ADO45366	Human oligonucleot
1736	18.4	0.6	20	1	ABZ99088	Human PDE4C oligon	ci809	18.4	0.6	20	1	ADO46462	Human oligonucleot
c1737	18.4	0.6	20	1	ABZ98439	Human ICAM oligonu	ci810	18.4	0.6	20	1	ADO45358	Human oligonucleot
c1738	18.4	0.6	20	1	ABZ98440	Human ICAM oligonu	ci811	18.4	0.6	20	1	ADO45367	Human oligonucleot
c1739	18.4	0.6	20	1	ACA88946	Selection and ampl	ci812	18.4	0.6	20	1	ADO81052	Human oligonucleot
1740	18.4	0.6	20	1	ABD30939	Human RANTES-deriv	ci813	18.4	0.6	20	1	ADO81097	Cow prion protein
1741	18.4	0.6	20	1	ABD31043	Human RANTES-deriv	ci814	18.4	0.6	20	1	ADO52210	Human inhibitor of
1742	18.4	0.6	20	1	ABD31044	Human RANTES-deriv	ci815	18.4	0.6	20	1	ADO52274	Human inhibitor of
1743	18.4	0.6	20	1	ABD31045	Human RANTES-deriv	ci816	18.4	0.6	20	1	ADP45826	Extend primer 18 u
1744	18.4	0.6	20	1	ABD31042	Human RANTES-deriv	ci817	18.4	0.6	20	1	ADP45838	Extend primer 30 u
1745	18.4	0.6	20	1	ABD31034	Human RANTES-deriv	ci818	18.4	0.6	20	1	ADQ80464	dsDNA epitope comp
c1746	18.4	0.6	20	1	ABD31471	Human ICAM-derived	ci819	18.4	0.6	20	1	ADQ80463	dsDNA epitope sequ
c1747	18.4	0.6	20	1	ABD31470	Human ICAM-derived	ci820	18.4	0.6	20	1	ADT01088	Novel mutant prote
1748	18.4	0.6	20	1	ADJ321179	Human PDE4C-derive	ci821	18.4	0.6	20	1	ADT00235	Novel mutant prote
1749	18.4	0.6	20	1	ADJ56729	Human ICAM-1 G241A	ci822	18.4	0.6	21	1	ABN88973	Phosphorothioate 2
1750	18.4	0.6	20	1	ADJ59878	Oligonucleotide as	ci823	18.4	0.6	22	1	AAH31456	Human Alu segment
1751	18.4	0.6	20	1	ADJ59868	Oligonucleotide as	ci824	18.4	0.6	22	1	AAH31456	SNP specific upper
1752	18.4	0.6	20	1	ADJ59877	Oligonucleotide as	ci825	18.4	0.6	23	1	AAH39005	Human chromosome 1
1753	18.4	0.6	20	1	ADJ59876	Oligonucleotide as	ci826	18.4	0.6	23	1	ADH79601	Human p53 forward
c1754	18.4	0.6	20	1	ADJ60289	Oligonucleotide as	ci827	18.4	0.6	23	1	ADH44542	Primer #1 to ampli
1755	18.4	0.6	20	1	ADJ60290	Oligonucleotide as	ci828	18.2	0.6	19	1	AAQ25869	3' Alu primer. Sy
c1756	18.4	0.6	20	1	ADJ60973	Oligonucleotide as	ci829	18.2	0.6	19	1	AAQ48683	PCR primer alu 2 f
1757	18.4	0.6	20	1	ADJ59773	Oligonucleotide as	ci830	18.2	0.6	19	1	AAQ48683	Human Alu segment
1758	18.4	0.6	20	1	ADJ59876	Oligonucleotide as	ci831	18.2	0.6	19	1	AAQ48683	SNP specific upper
1759	18.4	0.6	20	1	ADJ96297	Human breast cance	ci832	18.2	0.6	19	1	AAQ48683	Human p53 forward
c1760	18.4	0.6	20	1	ADJ96333	Human breast cance	ci833	18.2	0.6	19	1	AAQ48683	Primer #1 to ampli
1761	18.4	0.6	20	1	ADJ96333	Human breast cance	ci834	18.2	0.6	19	1	AAQ48683	3' Alu primer. Sy
c1762	18.4	0.6	20	1	ADJ96457	Human breast cance	ci835	18.2	0.6	19	1	AAQ48683	PCR primer alu 2 f
c1763	18.4	0.6	20	1	ADJ96457	Human breast cance	ci836	18.2	0.6	19	1	AAQ48683	Human Alu segment
c1764	18.4	0.6	20	1	ADM13954	Human mPGES-1 chim	ci837	18.2	0.6	19	1	AAQ48683	SNP specific upper
c1765	18.4	0.6	20	1	ADM14456	Human mPGES-1 chim	ci838	18.2	0.6	19	1	AAQ48683	Human p53 forward
c1766	18.4	0.6	20	1	ADM14546	Human mPGES-1 chim	ci839	18.2	0.6	19	1	AAQ48683	Primer #1 to ampli
c1767	18.4	0.6	20	1	ADM14167	Human mPGES-1 chim	ci840	18.2	0.6	19	1	AAQ48683	3' Alu primer. Sy
c1768	18.4	0.6	20	1	ADM14413	Human mPGES-1 chim	ci841	18.2	0.6	19	1	AAQ48683	PCR primer alu 2 f
c1769	18.4	0.6	20	1	ADM14566	Human mPGES-1 chim	ci842	18.2	0.6	19	1	AAQ48683	Human Alu segment
c1770	18.4	0.6	20	1	ADM14345	Human mPGES-1 chim	ci843	18.2	0.6	19	1	AAQ48683	SNP specific upper
c1771	18.4	0.6	20	1	ADM14426	Human mPGES-1 chim	ci844	18.2	0.6	19	1	AAQ48683	Human p53 forward
c1772	18.4	0.6	20	1	ADM14501	Human mPGES-1 chim	ci845	18.2	0.6	19	1	AAQ48683	Primer #1 to ampli
c1773	18.4	0.6	20	1	ADM13951	Human mPGES-1 chim	ci846	18.2	0.6	19	1	AAQ48683	3' Alu primer. Sy
c1774	18.4	0.6	20	1	ADM14130	Human mPGES-1 chim	ci847	18.2	0.6	19	1	AAQ48683	PCR primer alu 2 f
c1775	18.4	0.6	20	1	ADM14166	Human mPGES-1 chim	ci848	18.2	0.6	19	1	AAQ48683	Human Alu segment
c1776	18.4	0.6	20	1	ADM14399	Human mPGES-1 chim	ci849	18.2	0.6	19	1	AAQ48683	SNP specific upper
c1777	18.4	0.6	20	1	ADM15236	Human mPGES-1 chim	ci850	18.2	0.6	19	1	AAQ48683	Human p53 forward
c1778	18.4	0.6	20	1	ADM13989	Human mPGES-1 chim	ci851	18.2	0.6	19	1	AAQ48683	Primer #1 to ampli
c1779	18.4	0.6	20	1	ADM14297	Human mPGES-1 chim	ci852	18.2	0.6	19	1	AAQ48683	3' Alu primer. Sy
c1780	18.4	0.6	20	1	ADM14346	Human mPGES-1 chim	ci853	18.2	0.6	19	1	AAQ48683	PCR primer alu 2 f
c1781	18.4	0.6	20	1	ADM14695	Human mPGES-1 chim	ci854	18.2	0.6	19	1	AAQ48683	Human Alu segment
c1782	18.4	0.6	20	1	ADM15080	Human mPGES-1 chim	ci855	18.2	0.6	19	1	AAQ48683	SNP specific upper
c1783	18.4	0.6	20	1	ADM14132	Human mPGES-1 chim	ci856	18.2	0.6	19	1	AAQ48683	Human p53 forward
c1784	18.4	0.6	20	1	ADM13953	Human mPGES-1 chim	ci857	18.2	0.6	19	1	AAQ48683	Primer #1 to ampli
c1785	18.4	0.6	20	1	ADM14344	Human mPGES-1 chim	ci858	18.2	0.6	19	1	AAQ48683	3' Alu primer. Sy

C1859	18	0.6	18	1	AAV238620	Human ICAM-1, E-se	C1932	18	0.6	19	1	AAV28149	Oligonucleotide IS
C1860	18	0.6	18	1	AAV06904	Modified oligonucleotide	C1933	18	0.6	19	1	AAV06847	ICAM-1 antisense d
C1861	18	0.6	18	1	AAV06894	Peptide-nucleic acid	C1934	18	0.6	19	1	AAV01233	Forward PCR primer
C1862	18	0.6	18	1	AAV73853	ICAM-1 DNA target	C1935	18	0.6	19	1	ADP70310	ICAM antisense oli
C1863	18	0.6	18	1	AAV74297	ICAM-1 antisense o	C1936	18	0.6	19	1	ADP70302	ICAM antisense oli
C1864	18	0.6	18	1	AAV69140	ICAM-R cDNA screen	C1937	18	0.6	19	1	ADP70355	ICAM antisense oli
C1865	18	0.6	18	1	AAV21853	Primer for ICAM im	C1938	18	0.6	19	1	ACA58212	Human familial bip
C1866	18	0.6	18	1	AAV24277	Human ICAM oligonu	C1939	18	0.6	19	1	ADH89039	Human POLYX PCR p
C1867	18	0.6	18	1	AAV97105	PCR primer ICAM 1-	C1940	18	0.6	19	1	AHQ16474	Modified oligonucleotide
C1868	18	0.6	18	1	AAV07354	Human ICAM-1 antis	C1941	18	0.6	19	1	ADQ88555	Murine ICAM-1 anti
C1869	18	0.6	18	1	AAV07353	Human ICAM-1 antis	C1942	18	0.6	20	1	ADP23802	Oligo #2 used to p
C1870	18	0.6	18	1	AAV08251	Human ICAM oligonu	C1943	18	0.6	20	1	ADP23803	Oligo #3 used to p
C1871	18	0.6	18	1	AAV24887	Human ICAM-1 antis	C1944	18	0.6	20	1	ADP52338	Human IFNGR2 antis
C1872	18	0.6	18	1	AAV24888	Human ICAM-1 antis	C1945	18	0.6	20	1	AAV61524	Human inhibitor-ka
C1873	18	0.6	18	1	AAV24889	Human ICAM-1 antis	C1946	18	0.6	20	1	ADP69468	3' - 5' DNA sequen
C1874	18	0.6	18	1	AAV24890	Human ICAM-1 antis	C1947	18	0.6	20	1	ADH77439	Human PTPN12 antis
C1875	18	0.6	18	1	AAV24892	Human ICAM-1 antis	C1948	18	0.6	20	1	ADP23802	Oligo #2 used to p
C1876	18	0.6	18	1	AAV24894	Human ICAM-1 antis	C1949	18	0.6	20	1	ADP23803	Oligo #3 used to p
C1877	18	0.6	18	1	AAV24889	Human ICAM-1 antis	C1950	18	0.6	20	1	ADP75052	Human IFNGR2 antis
C1878	18	0.6	18	1	AAV24887	Human ICAM-1 antis	C1951	18	0.6	20	1	ADP75053	Human inhibitor-ka
C1879	18	0.6	18	1	AAV24885	Human ICAM-1 antis	C1952	17.8	0.6	19	1	ABX93650	Human alu-specific
C1880	18	0.6	18	1	AAV24889	Human ICAM-1 antis	C1953	17.8	0.6	19	1	ABX95026	Human alu-specific
C1881	18	0.6	18	1	AAV24893	Human ICAM-1 antis	C1954	17.8	0.6	21	1	AAV95063	3' - 5' DNA sequen
C1882	18	0.6	18	1	AAV24883	Human ICAM-1 antis	C1955	17.8	0.6	21	1	AAQ33789	Microsatellite seq
C1883	18	0.6	18	1	AAV24891	Human ICAM-1 antis	C1956	17.8	0.6	21	1	AAQ27760	PCR primer for hum
C1884	18	0.6	18	1	AAV24881	Human ICAM-1 antis	C1957	17.8	0.6	21	1	ABX97829	Human NADPH quinon
C1885	18	0.6	18	1	AAV24888	Human ICAM-1 antis	C1958	17.8	0.6	21	1	ABX97831	Human NADPH quinon
C1886	18	0.6	18	1	AAV24886	Human ICAM-1 antis	C1959	17.8	0.6	21	1	ACAS4779	Degenerate PCR pri
C1887	18	0.6	18	1	AAV24883	Human ICAM-1 antis	C1960	17.8	0.6	21	1	ABV75846	Human NF-kappaB as
C1888	18	0.6	18	1	AAV24887	Human ICAM-1 antis	C1961	17.8	0.6	22	1	AAQ33716	Human NF-kappaB RA
C1889	18	0.6	18	1	AAV24889	Human ICAM-1 antis	C1962	17.8	0.6	22	1	AAQ33716	Microsatellite seq
C1890	18	0.6	18	1	AAV24889	Human ICAM-1 antis	C1963	17.8	0.6	22	1	AAV71942	Primer detects mar
C1891	18	0.6	18	1	AAV73474	Reverse primer #10	C1964	17.8	0.6	22	1	AAV72014	Primer detects mar
C1892	18	0.6	18	1	AAV73471	Forward primer #10	C1965	17.8	0.6	22	1	AAV64456	SSR motif #16. Un
C1893	18	0.6	18	1	AAV73473	Reverse primer #10	C1966	17.4	0.6	19	1	AAQ33728	Human DISC1/DISC2
C1894	18	0.6	18	1	AAV73486	Reverse primer #10	C1967	17.4	0.6	19	1	AAQ33728	Microsatellite seq
C1895	18	0.6	18	1	AAV91942	Human ICAM-R probe	C1968	17.4	0.6	19	1	AAQ97343	Probe used for ide
C1896	18	0.6	18	1	ABK092294	Inter cellular adhe	C1969	17.4	0.6	19	1	AAV66093	Compound simple se
C1897	18	0.6	18	1	ABV46179	Human ICAM-1 antis	C1970	17.4	0.6	19	1	AAV91272	Repeat sequence fo
C1898	18	0.6	18	1	ADP93488	Human ICAM-1 antis	C1971	17.4	0.6	19	1	AAV57826	ICAM-1 Arg-241 all
C1899	18	0.6	18	1	ACD67112	Human ICAM-1 antis	C1972	17.4	0.6	19	1	AAV289471	Human chromosome 1
C1900	18	0.6	18	1	ACD67112	Derivatised oligon	C1973	17.4	0.6	19	1	AAV289472	SSA primer 3 for a
C1901	18	0.6	18	1	ACD67112	ICAM-1 specific an	C1974	17.4	0.6	19	1	AAV289472	SSA primer 4 for a
C1902	18	0.6	18	1	ACD67112	Derivatised oligon	C1975	17.4	0.6	19	1	AAV48211	Reverse PCR primer
C1903	18	0.6	18	1	ADP38978	Human ICAM-1 targe	C1976	17.4	0.6	19	1	AAV48211	Heterologous inser
C1904	18	0.6	18	1	ADP38978	Human ICAM-1 targe	C1977	17.4	0.6	19	1	AAV48211	Heterologous inser
C1905	18	0.6	18	1	ADP38978	Human ICAM-1 targe	C1978	17.4	0.6	19	1	AAV48211	Human alu sequence
C1906	18	0.6	18	1	ADP70291	ICAM antisense oli	C1979	17.4	0.6	19	1	ADP69517	Human chromosome 1
C1907	18	0.6	18	1	ADP70291	ICAM antisense oli	C1980	17.4	0.6	19	1	ADP69517	ISSR-related PCR p
C1908	18	0.6	18	1	ADP70332	ICAM antisense oli	C1981	17.4	0.6	19	1	ADP69517	Human VEGFR1 short
C1909	18	0.6	18	1	ADP70334	ICAM antisense oli	C1982	17.4	0.6	19	1	ADP69517	Human VEGFR1 short
C1910	18	0.6	18	1	ADP70303	ICAM antisense oli	C1983	17.4	0.6	19	1	ADP69517	Selection and ampl
C1911	18	0.6	18	1	ADG32591	Murine TRPV trans	C1984	17.4	0.6	19	1	ADN34364	Lower strand of cy
C1912	18	0.6	18	1	ADG32591	Human ICAM-1 probe	C1985	17.4	0.6	19	1	ADN34364	Upper strand of cy
C1913	18	0.6	18	1	ADG32591	Antisense oligonuc	C1986	17.4	0.6	19	1	ADH71084	Human beta micros
C1914	18	0.6	18	1	ADG32591	Antisense oligonuc	C1987	17.4	0.6	19	1	ADP09402	Extend primer 24 u
C1915	18	0.6	18	1	ADG32591	Antisense oligonuc	C1988	17.4	0.6	19	1	ADP45856	Extend primer 48 u
C1916	18	0.6	18	1	ADG32591	Antisense oligonuc	C1989	17.4	0.6	19	1	ADP45856	Extend primer 47 u
C1917	18	0.6	18	1	ADG32591	ICAM-1 specific an	C1990	17.4	0.6	19	1	ADP45856	Human glucose-6-ph
C1918	18	0.6	18	1	ADP45890	Extend primer 82 u	C1991	17.4	0.6	19	1	ADP45890	Human glucose-6-ph
C1919	18	0.6	18	1	ADP45890	Extend primer 58 u	C1992	17.4	0.6	19	1	ADP45890	Hepatitis C virus
C1920	18	0.6	18	1	ADP45890	Extend primer 57 u	C1993	17.4	0.6	20	1	ADP45890	Compound simple se
C1921	18	0.6	18	1	ADP45890	Modified oligonucleotide	C1994	17.4	0.6	20	1	ADP45890	H. discus derived
C1922	18	0.6	18	1	ADP45890	Modified oligonucleotide	C1995	17.4	0.6	20	1	ADP45890	Human RANK antise
C1923	18	0.6	18	1	ADP45890	2'-protected-amine	C1996	17.4	0.6	20	1	ADP45890	Human caspase 8 m
C1924	18	0.6	18	1	ADP45890	Modified oligonucleotide	C1997	17.4	0.6	20	1	ADP45890	Human tumour-assoc
C1925	18	0.6	18	1	ADP45890	Murine ICAM-1 anti	C1998	17.4	0.6	20	1	ADP45890	Human caspase-8 an
C1926	18	0.6	18	1	ADP45890	Murine ICAM-1 targe	C1999	17.4	0.6	20	1	ADP45890	Human oligonucleot
C1927	18	0.6	18	1	ADP45890	Murine ICAM-1 targe	C2000	17.4	0.6	20	1	ADP45890	Human RANTES oligo
C1928	18	0.6	18	1	ADP45890	Murine ICAM-1 anti	C2001	17.4	0.6	20	1	ADP45890	Human RANTES-deriv
C1929	18	0.6	18	1	ADP45890	Murine ICAM-1 targe	C2002	17.4	0.6	20	1	ADP45890	Human transglutami
C1930	18	0.6	18	1	ADP45890	Human autoimmu d	C2003	17.4	0.6	20	1	ADP45890	Oligonucleotide as
C1931	18	0.6	19	1	AAQ45144	Oligonucleotide us	C2004	17.4	0.6	20	1	ADP45890	Human mPGES-1 chim

C2005	17.4	0.6	20	1	ADMI14675	Human mPGES-1 chim	2078	16.8	0.6	20	1	ABZ97900	Human RANTES oligo
C2006	17.4	0.6	20	1	ADMI15440	Human mPGES-1 chim	C2079	16.8	0.6	20	1	ABZ89853	Human oligonucleot
C2007	17.4	0.6	20	1	ADMI14780	Human mPGES-1 chim	C2080	16.8	0.6	20	1	ADL24992	Intestinal epithel
C2008	17.4	0.6	20	1	ADMI15146	Human mPGES-1 chim	C2081	16.8	0.6	20	1	ABD26083	AA463249-derived o
C2009	17.4	0.6	20	1	ADMI15318	Human mPGES-1 chim	C2082	16.8	0.6	20	1	ABD30931	Human RANTES-deriv
C2010	17.4	0.6	20	1	ADMI15318	Human mPGES-1 chim	C2083	16.8	0.6	20	1	ABD31032	Human RANTES-deriv
C2011	17.4	0.6	21	1	AA05264	Human oligonucleot	C2084	16.8	0.6	20	1	ABD28946	N58473-derived oli
C2012	17.4	0.6	21	1	AA05264	CA repeat fluorogre	C2085	16.8	0.6	20	1	ADH71020	Cosmid C215 repeat
C2013	17.4	0.6	21	1	AA05264	Human inflammatory	C2086	16.8	0.6	20	1	ADJ53542	Human PP3CB DNA a
C2014	17.2	0.6	19	1	AA076248	Human chromosome 1	C2087	16.8	0.6	20	1	ADJ53600	Human PP3CB DNA a
C2015	17	0.6	18	1	AA085814	Generic primer fro	C2088	16.8	0.6	20	1	ADJ59866	Oligonucleotide as
C2016	17	0.6	18	1	AA085813	Anti-ICAM 2'-O-alk	C2089	16.8	0.6	20	1	ADJ59765	Oligonucleotide as
C2017	17	0.6	18	1	AA085813	Human ICAM-1 antis	C2090	16.8	0.6	20	1	ADK70840	5' mRNA DNA prepar
C2018	17	0.6	18	1	AA085813	Human CARC/PPGT pr	C2091	16.8	0.6	20	1	ADJ10322	Human protein tyro
C2019	17	0.6	18	1	ADJ56979	Human autoimmun d	C2092	16.8	0.6	20	1	ADJ10322	Phosphorothioate a
C2020	17	0.6	19	1	AA085821	Anti-ICAM 2'-O-alk	C2093	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2021	17	0.6	19	1	AA085821	Primer Alu 3' used	C2094	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2022	17	0.6	19	1	AA085821	SNP specific upper	C2095	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2023	17	0.6	19	1	AA085821	STR marker 21-32S	C2096	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2024	17	0.6	19	1	ADP09291	Extend primer 86 u	C2097	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2025	17	0.6	20	1	AA045156	Oligonucleotide us	C2098	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2026	17	0.6	20	1	ABX10634	Synthetic phosphor	C2099	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2027	17	0.6	20	1	ADA20965	Mouse BAX chimeric	C2100	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2028	17	0.6	20	1	ABZ99108	Human PDE4C oligon	C2101	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2029	17	0.6	20	1	ABZ32139	Human PDE4C-deri	C2102	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2030	17	0.6	20	1	ADJ60993	Oligonucleotide as	C2103	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2031	17	0.6	20	1	ADJ60993	Human mPGES-1 chim	C2104	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2032	17	0.6	20	1	ADJ60993	Human mPGES-1 chim	C2105	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2033	17	0.6	20	1	ADJ60993	Human mPGES-1 chim	C2106	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2034	17	0.6	20	1	ADJ60993	Human mPGES-1 chim	C2107	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2035	16.8	0.6	20	1	AA033171	Human oligonucleot	C2108	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2036	16.8	0.6	20	1	AA033171	Human oligonucleot	C2109	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2037	16.8	0.6	20	1	AA033171	Human oligonucleot	C2110	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2038	16.8	0.6	20	1	AA033171	Human oligonucleot	C2111	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2039	16.8	0.6	20	1	AA033171	Human oligonucleot	C2112	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2040	16.8	0.6	20	1	AA033171	Human oligonucleot	C2113	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2041	16.8	0.6	20	1	AA033171	Human oligonucleot	C2114	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2042	16.8	0.6	20	1	AA033171	Human oligonucleot	C2115	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2043	16.8	0.6	20	1	AA033171	Human oligonucleot	C2116	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2044	16.8	0.6	20	1	AA033171	Human oligonucleot	C2117	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2045	16.8	0.6	20	1	AA033171	Human oligonucleot	C2118	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2046	16.8	0.6	20	1	AA033171	Human oligonucleot	C2119	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2047	16.8	0.6	20	1	AA033171	Human oligonucleot	C2120	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2048	16.8	0.6	20	1	AA033171	Human oligonucleot	C2121	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2049	16.8	0.6	20	1	AA033171	Human oligonucleot	C2122	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2050	16.8	0.6	20	1	AA033171	Human oligonucleot	C2123	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2051	16.8	0.6	20	1	AA033171	Human oligonucleot	C2124	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2052	16.8	0.6	20	1	AA033171	Human oligonucleot	C2125	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2053	16.8	0.6	20	1	AA033171	Human oligonucleot	C2126	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2054	16.8	0.6	20	1	AA033171	Human oligonucleot	C2127	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2055	16.8	0.6	20	1	AA033171	Human oligonucleot	C2128	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2056	16.8	0.6	20	1	AA033171	Human oligonucleot	C2129	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2057	16.8	0.6	20	1	AA033171	Human oligonucleot	C2130	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2058	16.8	0.6	20	1	AA033171	Human oligonucleot	C2131	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2059	16.8	0.6	20	1	AA033171	Human oligonucleot	C2132	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2060	16.8	0.6	20	1	AA033171	Human oligonucleot	C2133	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2061	16.8	0.6	20	1	AA033171	Human oligonucleot	C2134	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2062	16.8	0.6	20	1	AA033171	Human oligonucleot	C2135	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2063	16.8	0.6	20	1	AA033171	Human oligonucleot	C2136	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2064	16.8	0.6	20	1	AA033171	Human oligonucleot	C2137	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2065	16.8	0.6	20	1	AA033171	Human oligonucleot	C2138	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2066	16.8	0.6	20	1	AA033171	Human oligonucleot	C2139	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2067	16.8	0.6	20	1	AA033171	Human oligonucleot	C2140	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2068	16.8	0.6	20	1	AA033171	Human oligonucleot	C2141	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2069	16.8	0.6	20	1	AA033171	Human oligonucleot	C2142	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2070	16.8	0.6	20	1	AA033171	Human oligonucleot	C2143	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2071	16.8	0.6	20	1	AA033171	Human oligonucleot	C2144	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2072	16.8	0.6	20	1	AA033171	Human oligonucleot	C2145	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2073	16.8	0.6	20	1	AA033171	Human oligonucleot	C2146	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2074	16.8	0.6	20	1	AA033171	Human oligonucleot	C2147	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2075	16.8	0.6	20	1	AA033171	Human oligonucleot	C2148	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2076	16.8	0.6	20	1	AA033171	Human oligonucleot	C2149	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim
C2077	16.8	0.6	20	1	AA033171	Human oligonucleot	C2150	16.8	0.6	20	1	ADJ10322	Human mPGES-1 chim

2151	16.4	0.5	19	1	ADRS0945	Human glucose-6-ph
2152	16.4	0.5	19	1	ADT00288	Novel mutant prote
2153	16.4	0.5	20	1	AAQ49455	Primer for detecti
2154	16.4	0.5	20	1	AAQ93404	Equine clone 595-1
2155	16.4	0.5	20	1	AAQ93403	Equine clone 595-1
2156	16.4	0.5	20	1	AAT66046	Primer #1 to ampli
2157	16.4	0.5	20	1	AAZ37726	Human mdm2 phospho
2158	16.4	0.5	20	1	AAQ04029	Equine allele poly
2159	16.4	0.5	20	1	AAQ04030	Equine allele poly
2160	16.4	0.5	20	1	AAA93472	Primer used to amp
2161	16.4	0.5	20	1	AAZ98449	H. discus derived
2162	16.4	0.5	20	1	AAF80880	Human mdm2 phospho
2163	16.4	0.5	20	1	AAH20695	Human telomeric re
2164	16.4	0.5	20	1	AAZ94935	Human mdm2 antisen
2165	16.4	0.5	20	1	ABX80012	EST polymorphic DN
2166	16.4	0.5	20	1	ACC79697	7S cloning forward
2167	16.4	0.5	20	1	ACC47049	Mouse phospholipas
2168	16.4	0.5	20	1	AAI61525	Human inhibitor-ka
2169	16.4	0.5	20	1	ADC89591	Human COREST antis
2170	16.4	0.5	20	1	ADD21691	Human mdm2 antisen
2171	16.4	0.5	20	1	ABZ97901	Human RANTES oligo
2172	16.4	0.5	20	1	ABZ97918	Human RANTES oligo
2173	16.4	0.5	20	1	ABZ88525	Human oligonucleot
2174	16.4	0.5	20	1	ABD30949	Human RANTES-deriv
2175	16.4	0.5	20	1	ABD30932	Human RANTES-deriv
2176	16.4	0.5	20	1	ABD24755	AI122689-derived o
2177	16.4	0.5	20	1	ADJ59766	Oligonucleotide as
2178	16.4	0.5	20	1	ADJ59783	Oligonucleotide as
2179	16.4	0.5	20	1	ADMI5187	Human mPGES-1 chim
2180	16.4	0.5	20	1	ADMI5454	Human mPGES-1 chim
2181	16.4	0.5	20	1	ADMI4984	Human mPGES-1 chim
2182	16.4	0.5	20	1	ADMI5240	Human mPGES-1 chim
2183	16.4	0.5	20	1	ADMI4526	Human oligonucleot
2184	16.4	0.5	20	1	ADO45235	Human oligonucleot
2185	16.4	0.5	20	1	ADO45273	Human oligonucleot
2186	16.4	0.5	20	1	ADN06467	Human FLAP related
2187	16.4	0.5	20	1	ADP31860	Oestrogen-responsi
2188	16.4	0.5	20	1	ADP31785	Oestrogen-responsi
2189	16.4	0.5	20	1	ADQ14953	Corest intron targ
2190	16.4	0.5	20	1	ADQ94486	Human 5-lipoxigena
2191	16.4	0.5	20	1	ADT01119	Novel mutant prote
2192	16	0.5	18	1	AAZ77487	US5912147 primer 3
2193	16	0.5	18	1	AAZ77486	US5912147 primer 3
2194	16	0.5	18	1	AAZ77488	US5912147 primer 3
2195	16	0.5	18	1	ADO48792	Human neuropilin 1
2196	16	0.5	18	1	ADR32335	Rat KDR cytosolic
2197	16	0.5	18	1	ADRS7967	Nucleotide #4 for
2198	16	0.5	19	1	ADR82260	Hepatitis C virus
2199	16	0.5	19	1	ADR82257	Hepatitis C virus
2200	16	0.5	19	1	ADR82261	Hepatitis C virus
2201	16	0.5	19	1	ADR82258	Hepatitis C virus
2202	16	0.5	19	1	ADR82256	Hepatitis C virus
2203	16	0.5	19	1	ADR82259	Hepatitis C virus
2204	16	0.5	20	1	AAH20694	Human telomeric re
2205	16	0.5	20	1	ADMI5337	Human mPGES-1 chim
2206	16	0.5	20	1	ADMI5017	Human mPGES-1 chim
2207	16	0.5	20	1	ADT00407	Novel mutant prote
2208	15.8	0.5	19	1	AAQ82623	Chromosome 11 (loc
2209	15.8	0.5	19	1	AAZ35377	Interspersed repea
2210	15.8	0.5	19	1	ADZ43498	Human IDE PCR prim
2211	15.8	0.5	19	1	ACA88902	Human familial bip
2212	15.8	0.5	19	1	ACA58281	Human fibrocystin
2213	15.8	0.5	19	1	ADM77315	Human fibrocystin
2214	15.8	0.5	19	1	ADO14391	Human interleukin-
2215	15.8	0.5	19	1	ADO14519	Human interleukin-
2216	15.8	0.5	19	1	ADO14515	Human interleukin-
2217	15.8	0.5	19	1	ADO14387	Human interleukin-
2218	15.8	0.5	19	1	ADH53976	Human neurodegener
2219	15.8	0.5	19	1	ADM66491	Human short tandem
2220	15.8	0.5	19	1	ADR80868	Human glucose-6-ph
2221	15.4	0.5	18	1	AAZ77458	US5912147 primer 2
2222	15.4	0.5	18	1	AAZ77457	US5912147 primer 1
2223	15.4	0.5	18	1	ABK27429	Colon cancer assoc

ALIGNMENTS

RESULT 1

AAAT76149/c
ID AAT76149 standard; DNA; 26 BP.

XX
AC AAT76149;

XX
DT 12-SEP-1997 (first entry)

XX
DE Human intercellular adhesion molecule-1 antisense oligonucleotide.

XX
KW Asthma; airway epithelium; adenosine free; cystic fibrosis;
chronic obstructive pulmonary disease; bronchitis; ss.

XX
OS Synthetic.

XX
PN WO9640162-A1.

XX
PD 19-DEC-1996.

XX
PF 06-JUN-1996; 96WO-US009306.

XX
PR 07-JUN-1995; 95US-00474497.

XX
PA (UYEC-) UNIV EAST CAROLINA.

XX
PI Nyce JW, Metzger WJ;

XX
DR WPI; 1997-051871/05.

XX
PT Treatment of airway diseases such as asthma - by topically applying
adenosine-free antisense oligo:nucleotide to airway epithelium of
subject.

XX
PS Claim 5; Page 28; 7lpp; English.

CC A method for treating airway disease in a subject has been produced,
CC which involves the topical administration of an essentially adenosine
CC free antisense oligonucleotide (ON) to the airway epithelium of the
CC subject. The present sequence is an antisense oligonucleotide HSCAM1AS7
CC specific for the human intercellular adhesion molecule-1 (ICAM-1). The
CC method can be used to treat airway diseases such as cystic fibrosis,
CC asthma, chronic obstructive pulmonary disease, bronchitis and other
CC airway diseases characterised by an inflammatory response. By eliminating
CC adenosine from the antisense ON, its liberation upon antisense
CC degradation is prevented, thereby preventing adenosine- induced
CC bronchoconstriction in patients with hyper-reactive airways

XX
SQ Sequence 26 BP; 0 A; 5 C; 10 G; 11 T; 0 U; 0 Other;

Query Match 0.9%; Score 26; DB 1; Length 26;

Best Local Similarity 100.0%; Pred. No. 87;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1599 ACAACAGGCCCAAAAGGACCCCA 1624

DB 26 ACAACAGGCCCAAAAGGACCCCA 1

RESULT 2

AAAX53946/c

ID AAX53946 standard; DNA; 26 BP.

XX
AC AAX53946;

XX
DT 05-JUL-1999 (first entry)

XX
DE Intercellular adhesion molecule-1 (ICAM-1) antisense oligonucleotide.

XX
KW Antisense oligonucleotide; multiple target; antisense treatment;
impaired respiration; inflammation; lung disease;

XX
KW pulmonary vasoconstriction; inflammation; allergic rhinitis;

KW acute asthma; allergy; asthma; impeded respiration;
KW respiratory distress syndrome; pain; cystic fibrosis;
KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
XX prostate cancer; ss.

XX
OS Synthetic.

XX
PN WO9913886-A1.

XX
PD 25-MAR-1999.

XX
PF 17-SEP-1998; 98WO-US019419.

XX
PR 17-SEP-1997; 97US-0059160P.

XX
PR 09-JUN-1998; 98US-00093972.

XX
PA (UYEC-) UNIV EAST CAROLINA.

XX
PI Nyce JW;

XX
DR WPI; 1999-229400/19.

XX
PT New antisense oligonucleotides used in treatment of, e.g. pulmonary
vasoconstriction.

XX
PS Disclosure; Page 47; 120pp; English.

CC The specification describes antisense oligonucleotides (AAX52869-X55271)
CC directed against at least 2 mRNAs selected from target genes, coding and
CC non-coding regions of RNAs corresponding to target genes, gene initiation
CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-
CC -end and the juxta-section between coding and non-coding regions and all
CC segments of RNAs encoding proteins associated with one or more diseases,
CC conditions or mixtures. The antisense oligonucleotides may be derived
CC from sequences AAX5272-74. These multiple target oligonucleotides
CC (specifically AAX55180-271) can be used for the antisense treatment of
CC diseases and conditions. Typical diseases and conditions are those
CC associated with impaired respiration and inflammation, including lung
CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
CC acute asthma, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
CC well as all types of cancers which may metastasize or have metastasized
CC to the lungs, including breast and prostate cancer

XX
SQ Sequence 26 BP; 0 A; 5 C; 10 G; 11 T; 0 U; 0 Other;

Query Match 0.9%; Score 26; DB 1; Length 26;

Best Local Similarity 100.0%; Pred. No. 87;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1599 ACAACAGGCCCAAAAGGACCCCA 1624

DB 26 ACAACAGGCCCAAAAGGACCCCA 1

RESULT 3

AAA33389/c

ID AAA33389 standard; DNA; 26 BP.

XX
AC AAA33389;

XX
DT 28-JUL-2000 (first entry)

XX
DE Low adenosine antisense oligonucleotide SEQ ID NO:1078.

XX
KW Human; adenosine receptor; low adenosine antisense oligonucleotide;

KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cycostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX Homo sapiens.
 OS
 XX
 XX WO200009525-A2.
 XX
 XX PD 24-FEB-2000.
 XX
 XX PF 03-AUG-1999; 99WO-US017712.
 XX
 XX PR 03-AUG-1998; 98US-0095212P.
 XX
 XX PA (UYEC-) UNIV EAST CAROLINA.
 XX
 XX PI Nyce JW;
 XX
 XX DR WPI; 2000-205971/18.
 XX
 XX PT New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers.
 XX
 XX PS Claim 18; Page 400; 1343pp; English.
 XX
 XX CC The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cycostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impaired respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasize to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
 CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
 CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
 CC AAA33992) are specifically claimed ONs from the present invention. N.B.
 CC Sequences given in the disclosure of the present invention do not match
 CC up with their corresponding SEQ ID NO: sequences given in the sequence
 CC listing
 XX
 XX SQ Sequence 26 BP; 0 A; 5 C; 10 G; 11 T; 0 U; 0 Other;
 Query Match 0.9%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 87;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1599 ACAACAGGCCCAAAAGGAGCCCA 1624
 |||||
 DB 26 ACAACAGGCCCAAAAGGAGCCCA 1
 |||||
 RESULT 4
 AAF19511/c
 ID AAF19511 standard; DNA; 26 BP.
 XX
 AC AAF19511;
 Query Match 0.9%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 87;
 XX
 XX DT 14-MAR-2001 (first entry)
 XX
 XX DE Human ICAM-1 polynucleotide fragment #1078.
 XX
 XX KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cycostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX
 XX OS Homo sapiens.
 XX
 XX PN WO2000062736-A2.
 XX
 XX PD 26-OCT-2000.
 XX
 XX PF 24-MAR-2000; 2000WO-US008020.
 XX
 XX PR 06-APR-1999; 99US-0127958P.
 XX
 XX XX (UYEC-) UNIV EAST CAROLINA.
 PA (NYCE/) NYCE J W.
 XX
 XX PI Nyce JW;
 XX
 XX DR WPI; 2000-679539/66.
 XX
 XX PT Low adenosine (A) content antisense oligonucleotides which do not trigger
 PT adenosine receptors during metabolism, useful e.g. for treating cancers
 and respiratory obstructions.
 XX
 XX PS Claim 14; Page 145; 1592pp; English.
 XX
 XX CC The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
 CC surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention
 XX
 XX SQ Sequence 26 BP; 0 A; 5 C; 10 G; 11 T; 0 U; 0 Other;
 Query Match 0.9%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 87;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1599 ACAACAGGCCCAAAAGGGACCCCA 1624
 DB 26 ACAACAGGCCCAAAAGGGACCCCA 1

RESULT 5
 ABZ95205/c
 ID ABZ95205 standard; DNA; 26 BP.
 XX
 AC ABZ95205;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human ICAM-1 antisense fragment no.1070.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 DR WPI; 2003-229219/22.
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiqunone.
 XX
 PS Disclosure; SEQ ID NO 10447; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiqunone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytotatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiqunone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 26 BP; 0 A; 5 C; 10 G; 11 T; 0 U; 0 Other;

Query Match 0.9%; Score 26; DB 1; Length 26;
 Best Local Similarity 100.0%; Pred. No. 87;

Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1599 ACAACAGGCCCAAAAGGGACCCCA 1624
 DB 26 ACAACAGGCCCAAAAGGGACCCCA 1

RESULT 6
 ABD19147/c
 ID ABD19147 standard; DNA; 26 BP.
 XX
 AC ABD19147;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-1 DNA fragment 1070.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytotatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 10447; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary

CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 26 BP; 0 A; 5 C; 10 G; 11 T; 0 U; 0 Other;

Query Match 0.9%; Score 26; DB 1; Length 26;

Best Local Similarity 100.0%; Pred. No. 87;
 Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1599 ACAACAGGCCCAAAAGGACCCCA 1624

DB 26 ACAACAGGCCCAAAAGGACCCCA 1

RESULT 7

AAQ55328/c
 ID AAQ55328 standard; DNA; 24 BP.

XX AC AAQ55328;

DT 25-MAR-2003 (revised)

DT 12-JUN-1994 (first entry)

XX ICAM-1 primer PCR 3.1.

XX ICAM-1; intercellular adhesion molecule-1; human rhinovirus; HRV; probe;
 KW primer; polymerase chain reaction; PCR; hybridization; ss.

XX Synthetic.

XX WO9400485-A1.

PD 06-JAN-1994.

XX 22-JUN-1993; 93WO-US0005972.

XX 22-JUN-1992; 92US-00903069.

XX (MILE) MILES INC.

XX Greve JM, McClelland A;

XX WPI; 1994-026146/03.

PT Multimeric forms of inter-cellular adhesion mol. (ICAM) - displaying
 PT enhanced binding of human rhinovirus and able to reduce its infectivity.

XX Example; Page 18; 70pp; English.

XX Oligonucleotides AAQ55327-35 were used to create forms of ICAM-1
 CC (AAR48038) that facilitate cross-linking and multimerization. The primers
 CC given in AAQ55336-39 were used to clone ICAM(185)/IgG immunoadhesin
 CC fusion protein. ICA(453)/IgG fusion (AAR48037) in encoded by sequence
 CC AAQ55340. Mutein AAQ55342, a mutated form of AAQ55340, encodes tICAM(452)
 CC cysteine mutant terminated at residue 452. Probe AAQ55341 was used for
 CC HRV identification. (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 24 BP; 2 A; 3 C; 11 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 24; DB 1; Length 24;

Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1633 AACACACAGCCACGCTCCCTGA 1656

DB 24 AACACACAGCCACGCTCCCTGA 1

RESULT 8

AAQ55327
 ID AAQ55327 standard; DNA; 24 BP.

XX AC AAQ55327;

DT 25-MAR-2003 (revised)

DT 12-JUN-1994 (first entry)

XX ICAM-1 primer PCR 5.1.

XX ICAM-1; intercellular adhesion molecule-1; human rhinovirus; HRV; probe;
 KW primer; polymerase chain reaction; PCR; hybridization; ss.

XX Synthetic.

XX WO9400485-A1.

XX 06-JAN-1994.

XX 22-JUN-1993; 93WO-US0005972.

XX 22-JUN-1992; 92US-00903069.

XX (MILE) MILES INC.

XX Greve JM, McClelland A;

XX WPI; 1994-026146/03.

PT Multimeric forms of inter-cellular adhesion mol. (ICAM) - displaying
 PT enhanced binding of human rhinovirus and able to reduce its infectivity.

XX Example; Page 18; 70pp; English.

XX Oligonucleotides AAQ55327-35 were used to create forms of ICAM-1
 CC (AAR48038) that facilitate cross-linking and multimerization. The primers
 CC given in AAQ55336-39 were used to clone ICAM(185)/IgG immunoadhesin
 CC fusion protein. ICA(453)/IgG fusion (AAR48037) in encoded by sequence
 CC AAQ55340. Mutein AAQ55342, a mutated form of AAQ55340, encodes tICAM(452)
 CC cysteine mutant terminated at residue 452. Probe AAQ55341 was used for
 CC HRV identification. (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 24 BP; 3 A; 13 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.8%; Score 24; DB 1; Length 24;

Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCCGAGCGCCCGGCC 81

DB 1 ATGGCTCCCGAGCGCCCGGCC 24

RESULT 9

AAT84255/c

ID AAT84255 standard; cDNA; 24 BP.

XX AC AAT84255;

DT 05-NOV-1997 (first entry)

XX ICAM-related gene antisense PCR primer H-1/D3 AS.

XX ICAM-4; intercellular adhesion molecule-4; neuropathology; human;

KW antibody; diagnosis; stroke; polymerase chain reaction; PCR; primer; ss.

XX Synthetic.

XX WO9640916-A1.

XX 19-DEC-1996.

PF 06-JUN-1996; 96WO-US0009146.
 XX
 PR 07-JUN-1995; 95US-00481130.
 XX
 PA (ICOS-) ICOS CORP.
 XX
 PI Kilgannon PD, Gallatin WM;
 XX WPI; 1997-108644/10.
 DR
 XX Inter-cellular adhesion molecule-4 gene and promoter - used to develop
 PT prods. for, e.g. screening for neuro:pathology or, for neuronal directed
 PT expression of proteins.
 XX
 PS Example 10; Page 34; 97pp; English.
 XX
 CC This antisense primer, designated H-1/D3 AS, is designed to be
 CC complementary to human intercellular adhesion molecule ICAM-1 domain 3.
 CC It was used with a sense primer (AAT84254), also based on ICAM-1 domain
 CC 3, to amplify DNA from a human p1 library. 2 Clones were identified that
 CC contained approx. 75-95 bp genomic DNA inserts. A 7.0 kb BamHI fragment
 CC was used to screen a human hippocampus cDNA library, yielding clone #34.
 CC This was used to screen a human cerebral cortex library, yielding clone
 CC 16-1. Overlapping clones #34 and 16-1 were used to produce a full-length
 CC sequence (AAT84246) coding for novel rat ICAM-4 (AAW00931)
 XX
 SQ Sequence 24 BP; 1 A; 7 C; 7 G; 9 T; 0 U; 0 Other;
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 942 GAACACAGAGCCAGGAGACTGCA 965
 DB 24 GAACACAGAGCCAGGAGACTGCA 1
 RESULT 10
 AAT84254
 ID AAT84254 standard; cDNA; 24 BP.
 XX
 AC AAT84254;
 XX
 DT 05-NOV-1997 (first entry)
 XX
 DE ICAM-related gene sense PCR primer H-1/D3 S.
 XX
 KW ICAM-4; intercellular adhesion molecule-4; neuropathology; human;
 KW antibody; diagnosis; stroke; polymerase chain reaction; PCR; primer; ss.
 XX
 OS Synthetic.
 XX
 PN WO9640916-A1.
 XX
 PD 19-DEC-1996.
 XX
 PF 06-JUN-1996; 96WO-US0009146.
 XX
 PR 07-JUN-1995; 95US-00481130.
 XX
 PA (ICOS-) ICOS CORP.
 XX
 PI Kilgannon PD, Gallatin WM;
 XX WPI; 1997-108644/10.
 DR
 XX Inter-cellular adhesion molecule-4 gene and promoter - used to develop
 PT prods. for, e.g. screening for neuro:pathology or, for neuronal directed
 PT expression of proteins.
 XX
 PS Example 10; Page 34; 97pp; English.
 XX
 CC This sense primer, designated H-1/D3 S, is designed to be complementary

CC to human intercellular adhesion molecule ICAM-1 domain 3. It was used
 CC with an antisense primer (AAT84255), also based on ICAM-1 domain 3, to
 CC amplify DNA from a human p1 library. 2 Clones were identified that
 CC contained approx. 75-95 bp genomic DNA inserts. A 7.0 kb BamHI fragment
 CC was used to screen a human hippocampus cDNA library, yielding clone #34.
 CC This was used to screen a human cerebral cortex library, yielding clone
 CC 16-1. Overlapping clones #34 and 16-1 were used to produce a full-length
 CC sequence (AAT84246) coding for novel rat ICAM-4 (AAW00931)
 XX
 SQ Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX

QY 729 CCGGGTCTTAGAGGTGGACACGCA 752
 DB 1 CCGGGTCTTAGAGGTGGACACGCA 24
 RESULT 11
 AAT76150/c
 ID AAT76150 standard; DNA; 24 BP.
 XX
 AC AAT76150;
 XX
 DT 12-SEP-1997 (first entry)
 XX
 DE Human intercellular adhesion molecule-1 antisense oligonucleotide.
 XX
 KW Asthma; airway epithelium; adenosine free; cystic fibrosis;
 KW chronic obstructive pulmonary disease; bronchitis; ss.
 XX
 OS Synthetic.
 XX
 PN WO9640162-A1.
 XX
 PD 19-DEC-1996.
 XX
 PF 06-JUN-1996; 96WO-US009306.
 XX
 PR 07-JUN-1995; 95US-00474497.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 PI Nyce JW, Metzger WJ;
 XX
 DR WPI; 1997-051871/05.
 XX
 PT Treatment of airway diseases such as asthma - by topically applying
 PT adenosine-free antisense oligo:nucleotide to airway epithelium of
 PT subject.
 XX
 PS Claim 5; Page 28; 71pp; English.
 XX
 CC A method for treating airway disease in a subject has been produced,
 CC which involves the topical administration of an essentially adenosine
 CC free antisense oligonucleotide (ON) to the airway epithelium of the
 CC subject. The present sequence is an antisense oligonucleotide HSICAMIAS8
 CC specific for the human intercellular adhesion molecule-1 (CAM-1). The
 CC method can be used to treat airway diseases such as cystic fibrosis,
 CC asthma, chronic obstructive pulmonary disease, bronchitis and other
 CC airway diseases characterised by an inflammatory response. By eliminating
 CC adenosine from the antisense ON, its liberation upon antisense
 CC degradation is prevented, thereby preventing adenosine- induced
 CC bronchoconstriction in patients with hyper-reactive airways
 XX
 SQ Sequence 24 BP; 0 A; 4 C; 10 G; 10 T; 0 U; 0 Other;
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY      1626 GAAACCGAACACACAGCCACGCC 1649
Db      ||||||||||||||||||||||||
        24 GAAACCGAACACACAGCCACGCC 1

RESULT 12
AAV34672
ID      AAV34672 standard; DNA; 24 BP.
XX
AC
XX
XX
XX      28-AUG-1998 (first entry)
XX
DE      Human ICAM-4 DNA cloning sense primer (H-1/D3 S).
XX
KW      ICAM-4; intercellular adhesion molecule polypeptide; modulator;
KW      monoclonal antibody; MAb; PCR primer; human; ss.
XX
OS      Synthetic.
OS      Homo sapiens.
XX
PN      US5773293-A.
XX
PD      30-JUN-1998.
XX
PF      07-JUN-1995; 95US-00485604.
XX
PR      27-JAN-1992; 92US-00827689.
PR      26-MAY-1992; 92US-00889724.
PR      05-JUN-1992; 92US-00894061.
PR      22-JAN-1993; 93US-00009266.
PR      05-AUG-1993; 93US-00102852.
PR      18-MAY-1994; 94US-00245295.
XX
XX      (ICOS-) ICOS CORP.
XX
XX      Kilgannon PD, Gallatin WM;
XX
XX      WPI; 1998-387016/33.
XX
XX      New hybridomas producing monoclonal antibodies specific for intracellular
XX      adhesion molecule 4 - used to e.g. identify ICAM 4 expressing cells, to
XX      assay or purify ICAM 4 and as ICAM 4 modulators.
XX
XX      Example 10; Col 19; 42pp; English.
XX
XX      This primer is complementary to the human intercellular adhesion molecule
XX      polypeptide (ICAM)-1 domain 3 and is used for the cloning of human ICAM-
XX      4. The invention provides hybridomas 127A, 127H and 173E, corresponding
XX      to ATCC numbers HB 11905, 11911 and 11912, respectively, and monoclonal
XX      antibodies (MAb) secreted by them. The MAbs are specific for ICAM-4,
XX      which is expressed almost exclusively in the brain, with low level
XX      expression in the spleen. They are used to characterise binding sites in
XX      ICAM-4, to purify ICAM-4, in immunising compositions for production of
XX      anti-idiotypes, to identify cells that express ICAM-4 on the surface. The
XX      MAbs can also be used to modulate ligand/receptor activity involving ICAM
XX      -4 (particularly its effector functions in (non-) specific immune
XX      responses) and as immunoassay reagent for detection and quantitation of
XX      ICAM-4 on cells or in body fluids
XX
XX      Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX      Query Match      0.8%; Score 24; DB 1; Length 24;
XX      Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX      Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      729 CCGGGTCCTAGAGTGGACACGCA 752
Db      ||||||||||||||||||||||||
        1 CCGGGTCCTAGAGTGGACACGCA 24

RESULT 13
AAV34673/c

```

```

ID      AAV34673 standard; DNA; 24 BP.
XX
AC      AAV34673;
XX
XX      28-AUG-1998 (first entry)
XX
DE      Human ICAM-4 DNA cloning antisense primer (H-1/D3 AS).
XX
KW      ICAM-4; intercellular adhesion molecule polypeptide; modulator;
KW      monoclonal antibody; MAb; PCR primer; human; ss.
XX
XX      Synthetic.
XX      Homo sapiens.
XX
PN      US5773293-A.
XX
PD      30-JUN-1998.
XX
PF      07-JUN-1995; 95US-00485604.
XX
PR      27-JAN-1992; 92US-00827689.
PR      26-MAY-1992; 92US-00889724.
PR      05-JUN-1992; 92US-00894061.
PR      22-JAN-1993; 93US-00009266.
PR      05-AUG-1993; 93US-00102852.
PR      18-MAY-1994; 94US-00245295.
XX
XX      (ICOS-) ICOS CORP.
XX
XX      Kilgannon PD, Gallatin WM;
XX
XX      WPI; 1998-387016/33.
XX
XX      New hybridomas producing monoclonal antibodies specific for intracellular
XX      adhesion molecule 4 - used to e.g. identify ICAM 4 expressing cells, to
XX      assay or purify ICAM 4 and as ICAM 4 modulators.
XX
XX      Example 10; Col 19; 42pp; English.
XX
XX      This primer is complementary to the human intercellular adhesion molecule
XX      polypeptide (ICAM)-1 domain 3 and is used for the cloning of human ICAM-
XX      4. The invention provides hybridomas 127A, 127H and 173E, corresponding
XX      to ATCC numbers HB 11905, 11911 and 11912, respectively, and monoclonal
XX      antibodies (MAb) secreted by them. The MAbs are specific for ICAM-4,
XX      which is expressed almost exclusively in the brain, with low level
XX      expression in the spleen. They are used to characterise binding sites in
XX      ICAM-4, to purify ICAM-4, in immunising compositions for production of
XX      anti-idiotypes, to identify cells that express ICAM-4 on the surface. The
XX      MAbs can also be used to modulate ligand/receptor activity involving ICAM
XX      -4 (particularly its effector functions in (non-) specific immune
XX      responses) and as immunoassay reagent for detection and quantitation of
XX      ICAM-4 on cells or in body fluids
XX
XX      Sequence 24 BP; 1 A; 7 C; 7 G; 9 T; 0 U; 0 Other;
XX
XX      Query Match      0.8%; Score 24; DB 1; Length 24;
XX      Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX      Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      942 GAACCCAGAGCCAGGAGACTGCA 965
Db      ||||||||||||||||||||||||
        24 GAACCCAGAGCCAGGAGACTGCA 1

RESULT 14
AAV54844/c
ID      AAV54844 standard; DNA; 24 BP.
XX
AC      AAV54844;
XX
XX      25-MAR-2003 (revised)
XX      18-NOV-1998 (first entry)
XX
XX

```

DE PCR primer H-1/D3(AS) used to amplify a 230 bp fragment of ICAM-1.
 XX
 KW Human; ICAM-R; intercellular adhesion molecule; adhesion; treatment;
 KW inflammatory condition; asthma; tumour growth; metastasis;
 KW viral infection; PCR primer; ss.
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN US5811517-A.
 XX
 PD 22-SEP-1998.
 XX
 XX 07-JUN-1995; 95US-00483389.
 XX
 PR 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 05-AUG-1994; 94US-00286754.
 XX
 PA (ICOS-) ICOS CORP.
 XX
 PI Vazeux R, Gallatin WM;
 XX
 DR WPI; 1998-530940/45.
 XX
 PT DNA encoding mutant ICAM-R poly:peptide(s) - useful for diagnosis and
 PT treatment of cell adhesion based disease conditions e.g. inflammation or
 PT asthma.
 XX
 PS Example 5; Col 16; 11lpp; English.
 XX
 CC PCR primers AAV54843-44 are used to amplify a 230 bp fragment of ICAM-1
 CC (intercellular adhesion molecule-1) domain 3. The product is used as a
 CC probe to isolate ICAM-R. ICAMs are polypeptides that are expressed on
 CC blood vessel endothelial cell surfaces and are involved in the adhesion
 CC events in various conditions. ICAM-R variants (see AAW71264-69) can be
 CC used to treat or monitor inflammatory conditions involving specific or
 CC non-specific immune responses, asthma, tumour growth and/or metastasis and
 CC viral infections. The ICAM variants are produced recombinantly, from
 CC expression libraries of mutated sequences, and the ones that are claimed
 CC are the ones that have been found to be especially involved in adhesion
 CC events. They can also be used to raise antibodies, also for use as
 CC therapeutic or diagnostic agents. (Updated on 25-MAR-2003 to correct PR
 CC field.)
 XX
 SQ Sequence 24 BP; 1 A; 7 C; 7 G; 9 T; 0 U; 0 Other;
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 942 GAACACAGAGCCAGGAGACTGCA 965
 Db 24 GAACACAGAGCCAGGAGACTGCA 1
 RESULT 15
 AAV54843
 ID AAV54843 standard; DNA; 24 BP.
 XX
 AC AAV54843;
 XX
 XX 25-MAR-2003 (revised)
 DT 18-NOV-1998 (first entry)
 XX
 DE PCR primer H-1/D3(S) used to amplify a 230 bp fragment of ICAM-1.
 XX
 KW Human; ICAM-R; intercellular adhesion molecule; adhesion; treatment;
 KW inflammatory condition; asthma; tumour growth; metastasis;

KW viral infection; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN US5811517-A.
 XX
 PD 22-SEP-1998.
 XX
 XX 07-JUN-1995; 95US-00483389.
 XX
 PR 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 05-AUG-1994; 94US-00286754.
 XX
 PA (ICOS-) ICOS CORP.
 XX
 PI Vazeux R, Gallatin WM;
 XX
 DR WPI; 1998-530940/45.
 XX
 PT DNA encoding mutant ICAM-R poly:peptide(s) - useful for diagnosis and
 PT treatment of cell adhesion based disease conditions e.g. inflammation or
 PT asthma.
 XX
 PS Example 5; Col 16; 11lpp; English.
 XX
 CC PCR primers AAV54843-44 are used to amplify a 230 bp fragment of ICAM-1
 CC (intercellular adhesion molecule-1) domain 3. The product is used as a
 CC probe to isolate ICAM-R. ICAMs are polypeptides that are expressed on
 CC blood vessel endothelial cell surfaces and are involved in the adhesion
 CC events in various conditions. ICAM-R variants (see AAW71264-69) can be
 CC used to treat or monitor inflammatory conditions involving specific or
 CC non-specific immune responses, asthma, tumour growth and/or metastasis and
 CC viral infections. The ICAM variants are produced recombinantly, from
 CC expression libraries of mutated sequences, and the ones that are claimed
 CC are the ones that have been found to be especially involved in adhesion
 CC events. They can also be used to raise antibodies, also for use as
 CC therapeutic or diagnostic agents. (Updated on 25-MAR-2003 to correct PR
 CC field.)
 XX
 SQ Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 729 CCGGCTCCTAGAGTGGACACGCA 752
 Db 1 CCGGCTCCTAGAGTGGACACGCA 24
 RESULT 16
 AAV19346/c
 ID AAV19346 standard; cDNA; 24 BP.
 XX
 AC AAV19346;
 XX
 XX 21-JUL-1998 (first entry)
 DT
 XX
 DE Human ICAM-4 antisense primer H-1/D3 AS.
 XX
 KW Intracellular adhesion molecule; ICAM; probe; hybridisation; primer;
 KW reverse transcription; RT-PCR; RACE; rapid amplification of cDNA ends;
 KW immunogen; antibody; human; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX

```

PN US5700658-A.
XX
PD 23-DEC-1997.
XX
XX 18-MAY-1994; 94US-00245295.
XX
XX 27-JAN-1992; 92US-00827689.
PR 26-MAY-1992; 92US-00889724.
PR 05-JUN-1992; 92US-00894061.
PR 22-JAN-1993; 93US-00009266.
PR 05-AUG-1993; 93US-00102852.
XX
XX (ICOS-) ICOS CORP.
XX
XX Kilgannon PD, Gallatin WM;
XX WPI; 1998-062375/06.
XX
XX DNA encoding ICAM-4 - useful for transforming cells and producing
XX recombinant ICAM-4.
XX
XX Example 9; Col 18; 30pp; English.
XX
XX Primers AAV19345-46 amplified a fragment of the gene encoding the human
XX intracellular adhesion molecule 4 (ICAM-4) gene. The primers were
XX designed based on the sequence of the human ICAM-1 domain 3. The
XX amplification reaction resulted in the isolation of a 7.0 kb BamHI
XX fragment that hybridised with rat ICAM-4 sequence (AAV19326) under high
XX stringency conditions. Cells expressing ICAM-4 can be used as immunogens
XX for antibody production and to produce recombinant ICAM-4, which can also
XX be used for antibody production. The DNA can also be used in
XX hybridisation assays to detect expression of ICAM-4 in cells
XX
XX Sequence 24 BP; 1 A; 7 C; 7 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 24; DB 1; Length 24;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 942 GAACACAGAGCCAGGAGACTGCA 965
DB 24 GAACACAGAGCCAGGAGACTGCA 1
|||||
RESULT 17
AAV19345
ID AAV19345 standard; cDNA; 24 BP.
XX
XX AAV19345;
XX
XX 21-JUL-1998 (first entry)
XX
XX Human ICAM-4 sense primer H-1/D3 S.
XX
XX Intracellular adhesion molecule; ICAM; probe; hybridisation; primer;
XX reverse transcription; RT-PCR; RACE; rapid amplification of cDNA ends;
XX immunogen; antibody; human; ss.
XX
XX Synthetic.
XX OS Homo sapiens.
XX
XX US5700658-A.
XX
XX 23-DEC-1997.
XX
XX 18-MAY-1994; 94US-00245295.
XX
XX 27-JAN-1992; 92US-00827689.
PR 26-MAY-1992; 92US-00889724.
PR 05-JUN-1992; 92US-00894061.
PR 22-JAN-1993; 93US-00009266.
PR 05-AUG-1993; 93US-00102852.
XX

```

```

PA (ICOS-) ICOS CORP.
XX
XX Kilgannon PD, Gallatin WM;
XX
XX WPI; 1998-062375/06.
XX
XX DNA encoding ICAM-4 - useful for transforming cells and producing
XX recombinant ICAM-4.
XX
XX Example 9; Col 18; 30pp; English.
XX
XX Primers AAV19345-46 amplified a fragment of the gene encoding the human
XX intracellular adhesion molecule 4 (ICAM-4) gene. The primers were
XX designed based on the sequence of the human ICAM-1 domain 3. The
XX amplification reaction resulted in the isolation of a 7.0 kb BamHI
XX fragment that hybridised with rat ICAM-4 sequence (AAV19326) under high
XX stringency conditions. Cells expressing ICAM-4 can be used as immunogens
XX for antibody production and to produce recombinant ICAM-4, which can also
XX be used for antibody production. The DNA can also be used in
XX hybridisation assays to detect expression of ICAM-4 in cells
XX
XX Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 24; DB 1; Length 24;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 729 CCGGGTCTCTAGAGGTGGACACGCA 752
DB 1 CCGGGTCTCTAGAGGTGGACACGCA 24
|||||
RESULT 18
AAV11675/c
ID AAV11675 standard; cDNA; 24 BP.
XX
XX AAV11675;
XX
XX 04-AUG-1998 (first entry)
XX
XX Human ICAM-4 PCR primer H-1/D3 AS.
XX
XX ICAM-4; intercellular adhesion molecule; human; neuron-specific;
XX promoter; hippocampus; antibody; cell-cell interaction; PCR primer; ss.
XX
XX Synthetic.
XX OS Homo sapiens.
XX
XX US5753502-A.
XX
XX 19-MAY-1998.
XX
XX 06-JUN-1996; 96US-00656984.
XX
XX 05-AUG-1993; 93US-00102852.
PR 18-MAY-1994; 94US-00245295.
PR 07-JUN-1995; 95US-00481130.
XX
XX (ICOS-) ICOS CORP.
XX
XX Kilgannon PD, Gallatin WM;
XX
XX WPI; 1998-311408/27.
XX
XX ICAM-4 gene promoter - for directing gene expression in neuronal cells.
XX Example 10; Col 19; 47pp; English.
XX
XX AAV11666-V11675 are PCR primers used in a method to isolate a human
XX neuron-specific intercellular adhesion molecule, ICAM-4 gene promoter.
XX This promoter specifically promotes gene transcription in neuronal cells
XX especially hippocampal cells. Recombinant proteins can also be used to
XX raise antibodies against ICAM-4. The ICAM-4 DNA sequences and its
XX

```

```

CC recombinant production are new tools in the elucidation of cell-cell
XX interactions
SQ Sequence 24 BP; 1 A; 7 C; 7 G; 9 T; 0 U; 0 Other;

Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACCCAGAGCCAGGAGACTGCA 965
Db 24 GAACCCAGAGCCAGGAGACTGCA 1

RESULT 19
AAV11674
ID AAV11674 standard; cDNA; 24 BP.
XX
AC AAV11674;
XX
DT 04-AUG-1998 (first entry)
XX
DE Human ICAM-4 PCR primer H-1/D3 S.
XX
KW ICAM-4; intercellular adhesion molecule; human; neuron-specific;
KW promoter; hippocampus; antibody; cell-cell interaction; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5753502-A.
XX
PD 19-MAY-1998.
XX
PF 06-JUN-1996; 96US-00656984.
XX
PR 05-AUG-1993; 93US-00102852.
PR 18-MAY-1994; 94US-00245295.
PR 07-JUN-1995; 95US-00481130.
XX
PA (ICOS-) ICOS CORP.
XX
PI Kilgannon PD, Gallatin WM;
XX
PF WPI; 1998-311408/27.
XX
PT ICAM-4 gene promoter - for directing gene expression in neuronal cells.
XX
PS Example 10; Col 19; 47pp; English.
XX
CC AAV11666-V11675 are PCR primers used in a method to isolate a human
CC neuron-specific intercellular adhesion molecule, ICAM-4 gene promoter.
CC This promoter specifically promotes gene transcription in neuronal cells
CC especially hippocampal cells. Recombinant proteins can also be used to
CC raise antibodies against ICAM-4. The ICAM-4 DNA sequences and its
CC recombinant production are new tools in the elucidation of cell-cell
CC interactions
XX
SQ Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;

Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCTAGAGGTGGACACGCA 752
Db 1 CCGGGTCTAGAGGTGGACACGCA 24

RESULT 20
AAV56366/c
ID AAV56366 standard; DNA; 24 BP.
XX

```

```

AC AAV56366;
XX
DT 20-NOV-1998 (first entry)
XX
DE Human ICAM-R cDNA primer H-1/D3 (AS).
XX
KW Intercellular adhesion molecule; ICAM-R; human; modulator; 14.3.3 family;
KW HSI-beta; tubulin; inhibitor; stimulator; effector; immune response;
KW inflammation; disorder; T cell activation; macrophage; Crohn's disease;
KW adult respiratory distress syndrome; stroke; multiple sclerosis; asthma;
KW rheumatoid arthritis; tumour growth; human immune deficiency virus;
KW infection; diabetes; graft vs. host disease; passive immunisation;
KW primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5773218-A.
XX
PD 30-JUN-1998.
XX
PF 07-JUN-1995; 95US-00482882.
XX
PR 27-JAN-1992; 92US-00827689.
PR 26-MAY-1992; 92US-00889724.
PR 05-JUN-1992; 92US-00894061.
PR 22-JAN-1993; 93US-00009266.
PR 26-JAN-1993; 93WO-US000787.
PR 05-AUG-1993; 93US-00102852.
PR 05-AUG-1994; 94US-00286754.
XX
PA (ICOS-) ICOS CORP.
XX
PI Gallatin WM, Vazeux R;
XX
PF WPI; 1998-386989/33.
XX
PT Identifying compounds that modulate interaction of intracellular adhesion
PT molecule R - with ligands HSI-beta and tubulin using two-hybrid assay,
PT useful for treating inflammation, T cell activation etc.
XX
PS Example 5; Col 101-102; 108pp; English.
XX
CC AAV56349-V56366 are primers and probes used in the isolation of a novel
CC human intercellular adhesion molecule, ICAM-R. This sequence is used in a
CC method which investigates modulators of the interaction between ICAM-R
CC and the 14.3.3 family member HSI-beta and tubulin. An anti-ICAM-R
CC antibody optionally coupled to toxin or radionuclide, or an ICAM-R
CC peptide, can block, inhibit or stimulate ligand/receptor interactions
CC involving ICAM-R, particularly its effector functions involved in
CC (non)specific immune responses. ICAM-R related agents may be used to
CC treat or monitor inflammation, disorders involving T cell activation or
CC macrophages, e.g. adult respiratory distress syndrome, stroke, Crohn's
CC disease, multiple sclerosis, rheumatoid arthritis, asthma, tumour growth,
CC human immune deficiency virus infection, diabetes, graft vs. host disease
CC and many others. Antibodies may also be used for passive immunisation,
CC for purifying, detecting or quantifying ICAM-R and for identifying ICAM-R
CC expressing cells
XX
SQ Sequence 24 BP; 1 A; 7 C; 7 G; 9 T; 0 U; 0 Other;

Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACCCAGAGCCAGGAGACTGCA 965
Db 24 GAACCCAGAGCCAGGAGACTGCA 1

RESULT 21
AAV56365
ID AAV56365 standard; DNA; 24 BP.

```


XX AAV56365;
 AC
 XX 20-NOV-1998 (first entry)
 DT
 XX Human ICAM-R cDNA primer H-1/D3(S).
 DE
 XX Intercellular adhesion molecule; ICAM-R; human; modulator; 14.3.3 family;
 KW HSI-beta; tubulin; inhibitor; stimulator; effector; immune response;
 KW inflammation; disorder; T cell activation; macrophage; Crohn's disease;
 KW adult respiratory distress syndrome; stroke; multiple sclerosis; asthma;
 KW rheumatoid arthritis; tumour growth; human immune deficiency virus;
 KW infection; diabetes; graft vs. host disease; passive immunisation;
 KW primer; ss.
 XX
 XX Synthetic.
 OS Homo sapiens.
 XX US5773218-A.
 XX
 XX 30-JUN-1998.
 PD
 XX 07-JUN-1995; 95US-00482882.
 PF
 XX 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 03-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 05-AUG-1994; 94US-00286754.
 XX
 XX (ICOS-) ICOS CORP.
 PA
 XX Gallatin WM, Vazeux R;
 PI WPI; 1998-386989/33.
 XX
 XX Identifying compounds that modulate interaction of intracellular adhesion
 PT molecule R - with ligands HSI-beta and tubulin using two-hybrid assay,
 PT useful for treating inflammation, T cell activation etc.
 XX
 XX Example 5; Col 101-102; 108pp; English.
 PS
 XX AAV56349-V56366 are primers and probes used in the isolation of a novel
 CC human intercellular adhesion molecule, ICAM-R. This sequence is used in a
 CC method which investigates modulators of the interaction between ICAM-R
 CC and the 14.3.3 family member HSI-beta and tubulin. An anti-ICAM-R
 CC antibody optionally coupled to toxin or radionuclide, or an ICAM-R
 CC peptide, can block, inhibit or stimulate ligand/receptor interactions
 CC involving ICAM-R, particularly its effector functions involved in
 CC (non)specific immune responses. ICAM-R related agents may be used to
 CC treat or monitor inflammation, disorders involving T cell activation or
 CC macrophages, e.g. adult respiratory distress syndrome, stroke, Crohn's
 CC disease, multiple sclerosis, rheumatoid arthritis, asthma, tumour growth,
 CC human immune deficiency virus infection, diabetes, graft vs. host disease
 CC and many others. Antibodies may also be used for passive immunisation,
 CC for purifying, detecting or quantifying ICAM-R and for identifying ICAM-R
 CC expressing cells
 XX
 XX Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCTAGAGTGGACACGCA 752
 |||||
 Db 1 CCGGGTCTAGAGTGGACACGCA 24

RESULT 22
 AAX36502/c

ID AAX36502 standard; cDNA; 24 BP.
 XX
 AC AAX36502;
 XX
 DT 07-JUL-1999 (first entry)
 XX
 XX PCR primer for human ICAM-4 coding sequence.
 DE
 XX ICAM-4; neuropathology screening; intracellular adhesion molecule-4;
 KW cerebral ischaemia; epilepsy; AIDS stage determination; diagnosis;
 KW Alzheimer's disease; Pick's disease; diffuse cortical Lewy body disease;
 KW frontal lobe degeneration; Parkinson's disease; Huntington's disease;
 KW depression; schizophrenia; psychosis; infection; vasculitis; tumour;
 KW metabolic disorder; nutritional disorder; toxic encephalopathy;
 KW PCR primer; ss.
 XX
 XX Synthetic.
 OS Homo sapiens.
 XX WO9918441-A1.
 XX
 XX 15-APR-1999.
 PD
 XX 02-OCT-1998; 98WO-US020876.
 PF
 XX 02-OCT-1997; 97US-00942867.
 PR
 XX (ICOS-) ICOS CORP.
 PA
 XX Kilgannon PD, Gallatin WM;
 PI WPI; 1999-264102/22.
 DR
 XX Screening for neuropathology in individuals by quantifying the
 PT concentration of circulating intercellular adhesion molecule designated
 PT ICAM-4.
 XX
 XX Example 10; Page 35; 101pp; English.
 PS
 XX This sequence is a PCR primer for a human ICAM-4 coding sequence. The
 CC invention relates to a method of screening for neuropathology in an
 CC individual, comprising quantitating the concentration of circulating
 CC intracellular adhesion molecule-4 (ICAM-4). Anti-ICAM-4 antibodies of the
 CC invention are used to purify ICAM-4, and for the modulation of
 CC ligand/receptor binding activities involving ICAM-4. The methods
 CC can be used to screen for neuropathies, e.g. cerebral ischaemia (i.e.
 CC stroke) resulting from various disorders such as thrombosis, embolism,
 CC cerebral aneurysmal haemorrhage, vasospasm, etc. Quantification of
 CC circulating ICAM-4 can also distinguish between various forms of epilepsy
 CC and may also permit determination of the stage of AIDS progression.
 CC Quantification of circulating ICAM-4 can also be useful for diagnosis for
 CC Alzheimer's disease, and other cortical dementia such as Pick's disease,
 CC diffuse cortical Lewy body disease, frontal lobe degeneration, as well as
 CC subcortical dementia such as Parkinson's disease, Huntington's disease,
 CC and progressive supranuclear, and a number of primary psychiatric
 CC disorders such as depression, schizophrenia, and psychosis, and
 CC nongenetic dementia arising from infections, vasculitis, metabolic and
 CC nutritional disorders (e.g. thyroid, vitamin B12 deficiency), toxic
 CC encephalopathies (e.g. exposure to carbon monoxide, or heavy metals) and
 CC tumours
 XX
 XX Sequence 24 BP; 1 A; 7 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACACGAGCCAGGACACTGCA 965
 |||||
 Db 24 GAACACGAGCCAGGACACTGCA 1

RESULT 23

AAAX36501
ID AAX36501 standard; cDNA; 24 BP.
AC AAX36501;
XX
XX
XX 07-JUL-1999 (first entry)
DT
DE
DE PCR primer for human ICAM-4 coding sequence.
XX
XX ICAM-4; neuropathology screening; intracellular adhesion molecule-4;
KW cerebral ischaemia; epilepsy; AIDS stage determination; diagnosis;
KW Alzheimer's disease; Pick's disease; diffuse cortical Lewy body disease;
KW frontal lobe degeneration; Parkinson's disease; Huntington's disease;
KW depression; schizophrenia; psychosis; infection; vasculitis; tumour;
KW metabolic disorder; nutritional disorder; toxic encephalopathy;
KW PCR primer; ss.
XX
XX Synthetic.
OS
OS Homo sapiens.
XX
XX WO9918441-A1.
XX
XX 15-APR-1999.
PD
XX 02-OCT-1998; 98WO-US020876.
PF
XX 02-OCT-1997; 97US-00942867.
PR
XX (ICOS-) ICOS CORP.
PA
XX Kilgannon PD, Gallatin WM;
PI
XX WPI; 1999-264102/22.
XX
XX Screening for neuropathology in individuals by quantifying the
PT concentration of circulating intracellular adhesion molecule designated
PT ICAM-4.
XX
XX Example 10; Page 35; 101pp; English.
XX
XX This sequence is a PCR primer for a human ICAM-4 coding sequence. The
CC invention relates to a method of screening for neuropathology in an
CC individual, comprising quantitating the concentration of circulating
CC intracellular adhesion molecule-4 (ICAM-4). Anti-ICAM-4 antibodies of the
CC invention are used to purify ICAM-4, and for the modulation of
CC ligand/receptor binding activities involving ICAM-4. The methods
CC can be used to screen for neuropathies, e.g. cerebral ischaemia (i.e.
CC stroke) resulting from various disorders such as thrombosis, embolism,
CC cerebral aneurysmal haemorrhage, vasospasm, etc. Quantification of
CC circulating ICAM-4 can also distinguish between various forms of epilepsy
CC and may also permit determination of the stage of AIDS progression.
CC Quantification of circulating ICAM-4 can also be useful for diagnosis for
CC Alzheimer's disease, and other cortical dementia such as Pick's disease,
CC diffuse cortical Lewy body disease, frontal lobe degeneration, as well as
CC subcortical dementia such as Parkinson's disease, Huntington's disease,
CC and progressive supranuclear, and a number of primary psychiatric
CC disorders such as depression, schizophrenia, and psychosis, and
CC nongenetic dementia arising from infections, vasculitis, metabolic and
CC nutritional disorders (e.g. thyroid, vitamin B12 deficiency), toxic
CC encephalopathies (e.g. exposure to carbon monoxide, or heavy metals) and
CC tumours
XX
SQ Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 729 CCGGGTCTAGAGTGGACACGCA 752
DB 1 CCGGGTCTAGAGTGGACACGCA 24

RESULT 24
AAX53947/c
ID AAX53947 standard; DNA; 24 BP.
XX
XX AAX53947;
AC
XX
XX 05-JUL-1999 (first entry)
DT
DE
DE Inter cellular adhesion molecule-1 (ICAM-1) antisense oligonucleotide.
XX
XX Antisense oligonucleotide; multiple target; antisense treatment;
KW impaired respiration; inflammation; lung disease;
KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
KW acute asthma; allergy; asthma; impeded respiration;
KW respiratory distress syndrome; pain; cystic fibrosis;
KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
KW prostate cancer; ss.
XX
XX Synthetic.
OS
XX WO9913886-A1.
PN
XX
XX 25-MAR-1999.
PD
XX
XX 17-SEP-1998; 98WO-US019419.
PF
XX
XX 17-SEP-1997; 97US-0059160P.
PR
XX 09-JUN-1998; 98US-00093972.
PR
XX (UYEC-) UNIV EAST CAROLINA.
PA
XX
XX Nyce JW;
PI
XX
XX WPI; 1999-229400/19.
DR
XX
XX New antisense oligonucleotides used in treatment of, e.g. pulmonary
PT vasoconstriction.
PT
XX Disclosure; Page 47; 120pp; English.
XX
XX The specification describes antisense oligonucleotides (AAX52869-X55271)
CC directed against at least 2 mRNAs selected from target genes, coding and
CC non-coding regions of RNAs corresponding to target genes, gene initiation
CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-
CC end and the juxta-section between coding and non-coding regions and all
CC segments of RNAs encoding proteins associated with one or more diseases,
CC conditions or mixtures. The antisense oligonucleotides may be derived
CC from sequences AAX55272-74. These multiple target oligonucleotides
CC (specifically AAX55180-271) can be used for the antisense treatment of
CC diseases and conditions. Typical diseases and conditions are those
CC associated with impaired respiration and inflammation, including lung
CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
CC acute asthma, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
CC well as all types of cancers which may metastasize or have metastasized
CC to the lungs, including breast and prostate cancer
XX
SQ Sequence 24 BP; 0 A; 4 C; 10 G; 10 T; 0 U; 0 Other;
Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1626 GAAACCGAACACACAGCCGCGC 1649
DB 24 GAAACCGAACACACAGCCGCGC 1

```

RESULT 25
AAV69142
ID AAV69142 standard; DNA; 24 BP.
AC AAV69142;
XX
DT 17-FEB-1999 (first entry)
XX
DE Human ICAM-1 oligonucleotide H-1/D3 (S).
XX
KW Inter cellular adhesion molecule polypeptide; ICAM-R; humanised; ICR 1.1;
KW ICR 8.1; monoclonal antibody; therapeutic; inflammatory; asthma; tumour;
KW graft-versus-host disease; viral infection; toxin; radionuclide; probe;
KW neovascularisation site; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5837822-A.
XX
PD 17-NOV-1998.
XX
PF 07-JUN-1995; 95US-00487113.
XX
PR 27-JAN-1992; 92US-00827689.
PR 26-MAY-1992; 92US-00889724.
PR 05-JUN-1992; 92US-00894061.
PR 22-JAN-1993; 93US-00009266.
PR 26-JAN-1993; 93WO-US000787.
PR 05-AUG-1993; 93US-00102852.
XX
PA (ICOS-) ICOS CORP.
XX
PI Vazeux R, Gallatin WM;
XX
DR WPI; 1999-023535/02.
XX
PT Humanised antibodies specific for intercellular adhesion molecule
PT polypeptide - useful for therapeutic or diagnostic purposes.
XX
PS Example 5; Col 16; 116pp; English.
XX
CC Human ICAM-1 oligos AAV69142 and AAV69143 are used in the course of the
CC invention for screening and amplifying a cDNA encoding human
CC intercellular adhesion molecule polypeptide (ICAM-R). The invention
CC relates to humanised ICR 1.1 and ICR 8.1 antibodies targeted to the ICAM-
CC R polypeptide. Antibodies specific for ICAM's are potentially useful as
CC therapeutic compounds, for treating e.g. immune-mediated inflammatory
CC conditions (e.g. graft-versus-host disease), asthma, tumours or viral
CC infections. Monoclonal antibodies specific for ICAM-R, or their
CC conjugates formed with e.g. toxins or radionuclides are useful for
CC therapeutically targeting or detecting neovascularisation sites
XX
SQ Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 729 CCGGGTCTAGAGGTGGACACGCA 752
Db 1 CCGGGTCTAGAGGTGGACACGCA 24
RESULT 26
AAV69143/c
ID AAV69143 standard; DNA; 24 BP.
XX
AC AAV69143;
XX
DT 17-FEB-1999 (first entry)
XX
DE Human ICAM-1 oligonucleotide H-1/D3 (AS).
XX
KW Inter cellular adhesion molecule polypeptide; ICAM-R; humanised; ICR 1.1;
KW ICR 8.1; monoclonal antibody; therapeutic; inflammatory; asthma; tumour;
KW graft-versus-host disease; viral infection; toxin; radionuclide; probe;
KW neovascularisation site; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN US5837822-A.
XX
PD 17-NOV-1998.
XX
PF 07-JUN-1995; 95US-00487113.
XX
PR 27-JAN-1992; 92US-00827689.
PR 26-MAY-1992; 92US-00889724.
PR 05-JUN-1992; 92US-00894061.
PR 22-JAN-1993; 93US-00009266.
PR 26-JAN-1993; 93WO-US000787.
PR 05-AUG-1993; 93US-00102852.
XX
PA (ICOS-) ICOS CORP.
XX
PI Vazeux R, Gallatin WM;
XX
DR WPI; 1999-023535/02.
XX
PT Humanised antibodies specific for intercellular adhesion molecule
PT polypeptide - useful for therapeutic or diagnostic purposes.
XX
PS Example 5; Col 16; 116pp; English.
XX
CC Human ICAM-1 oligos AAV69142 and AAV69143 are used in the course of the
CC invention for screening and amplifying a cDNA encoding human
CC intercellular adhesion molecule polypeptide (ICAM-R). The invention
CC relates to humanised ICR 1.1 and ICR 8.1 antibodies targeted to the ICAM-
CC R polypeptide. Antibodies specific for ICAM's are potentially useful as
CC therapeutic compounds, for treating e.g. immune-mediated inflammatory
CC conditions (e.g. graft-versus-host disease), asthma, tumours or viral
CC infections. Monoclonal antibodies specific for ICAM-R, or their
CC conjugates formed with e.g. toxins or radionuclides are useful for
CC therapeutically targeting or detecting neovascularisation sites
XX
SQ Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 942 GAACACGAGCCAGGAGACTGCA 965
Db 24 GAACACGAGCCAGGAGACTGCA 1
RESULT 27
AAV21857/c
ID AAV21857 standard; DNA; 24 BP.
XX
AC AAV21857;
XX
DT 14-MAY-1999 (first entry)
XX
DE Primer for human ICAM-1.
XX
KW ICAM; immunoglobulin-like loop; intercellular adhesion molecule receptor;
KW alpha d/CD18; antibody; immunisation; inflammatory response; asthma;
KW tumour growth; viral infection; therapy; primer; ss.
XX
OS Synthetic.
OS Homo sapiens.

```

```

XX PN US5880268-A.
XX PD
XX PF 09-MAR-1999.
XX PF 07-JUN-1995; 95US-00483932.
XX PR 27-JAN-1992; 92US-00827689.
XX PR 26-MAY-1992; 92US-00889724.
XX PR 05-JUN-1992; 92US-00894061.
XX PR 22-JAN-1993; 93US-00009266.
XX PR 26-JAN-1993; 93WO-US000787.
XX PR 05-AUG-1993; 93US-00102852.
XX PR 05-AUG-1994; 94US-00286754.
XX PA (ICOS-) ICOS CORP.
XX PI Vazeux R, Gallatin WM;
XX PI WPI; 1999-204041/17.
XX DR
XX PT New intercellular adhesion molecule receptor (ICAM-R) specific antibodies
XX PT - useful for modulating ligand/receptor binding and biological activities
XX PT involving ICAM-R, especially those of the specific and non-specific
XX PT immune systems.
XX PS
XX PS Example 5; Col 16; 108pp; English.
XX CC
XX CC This sequence is a primer for DNA encoding human ICAM-R. The invention
XX CC relates to antibodies (Ab) which bind specifically to the intercellular
XX CC adhesion molecule receptor (ICAM-R), inhibiting the interaction between
XX CC ICAM-R and alpha d/CD18. Abs with specific ICAM-R binding are useful in
XX CC compositions for immunisation, and for purifying ICAM-R polypeptides and
XX CC identifying cells expressing ICAM-R on their cell surface, modulating
XX CC ligand/receptor binding and biological activities involving ICAM-R.
XX CC especially inflammatory responses of the specific immune system, the non-
XX CC specific immune system, monitoring and treating asthma, tumour growth,
XX CC and/or metastasis, and viral infection (e.g. HIV infection). In
XX CC particular diseases involving an essential T cell activation (e.g.
XX CC asthma, psoriasis, diabetes, graft vs. host disease, tissue transplant
XX CC rejection, and multiple sclerosis) may be treated with anti-ICAM-R
XX CC antibodies. The Abs specifically bind to and identify ICAM-R and disrupt
XX CC ICAM-R to cell adhesion molecule, especially alpha d/CD18 binding
XX CC
XX SQ Sequence 24 BP; 1 A; 7 C; 7 G; 9 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 942 GAACGAGCGCAGGAGACTGCA 965
Db 24 GAACGAGCGCAGGAGACTGCA 1
RESULT 28
AA21856
ID AAX21856 standard; DNA; 24 BP.
XX AC
XX AC AAX21856;
XX DT
XX DT 14-MAY-1999 (first entry)
XX DE
XX DE Primer for human ICAM-1.
XX KW ICAM; immunoglobulin-like loop; intercellular adhesion molecule receptor;
XX KW alpha d/CD18; antibody; immunisation; inflammatory response; asthma;
XX KW tumour growth; viral infection; therapy; primer; ss.
XX OS
XX OS Synthetic.
XX OS Homo sapiens.
XX PN US5880268-A.
XX
XX PN US5880268-A.
XX PD
XX PF 09-MAR-1999.
XX PF 07-JUN-1995; 95US-00483932.
XX PR 27-JAN-1992; 92US-00827689.
XX PR 26-MAY-1992; 92US-00889724.
XX PR 05-JUN-1992; 92US-00894061.
XX PR 22-JAN-1993; 93US-00009266.
XX PR 26-JAN-1993; 93WO-US000787.
XX PR 05-AUG-1993; 93US-00102852.
XX PR 05-AUG-1994; 94US-00286754.
XX PA (ICOS-) ICOS CORP.
XX PI Vazeux R, Gallatin WM;
XX PI WPI; 1999-204041/17.
XX DR
XX PT New intercellular adhesion molecule receptor (ICAM-R) specific antibodies
XX PT - useful for modulating ligand/receptor binding and biological activities
XX PT involving ICAM-R, especially those of the specific and non-specific
XX PT immune systems.
XX PS
XX PS Example 5; Col 16; 108pp; English.
XX CC
XX CC This sequence is a primer for DNA encoding human ICAM-R. The invention
XX CC relates to antibodies (Ab) which bind specifically to the intercellular
XX CC adhesion molecule receptor (ICAM-R), inhibiting the interaction between
XX CC ICAM-R and alpha d/CD18. Abs with specific ICAM-R binding are useful in
XX CC compositions for immunisation, and for purifying ICAM-R polypeptides and
XX CC identifying cells expressing ICAM-R on their cell surface, modulating
XX CC ligand/receptor binding and biological activities involving ICAM-R.
XX CC especially inflammatory responses of the specific immune system, the non-
XX CC specific immune system, monitoring and treating asthma, tumour growth,
XX CC and/or metastasis, and viral infection (e.g. HIV infection). In
XX CC particular diseases involving an essential T cell activation (e.g.
XX CC asthma, psoriasis, diabetes, graft vs. host disease, tissue transplant
XX CC rejection, and multiple sclerosis) may be treated with anti-ICAM-R
XX CC antibodies. The Abs specifically bind to and identify ICAM-R and disrupt
XX CC ICAM-R to cell adhesion molecule, especially alpha d/CD18 binding
XX CC
XX SQ Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 729 CCGGGTCTTAGAGGTGACACGCA 752
Db 1 CCGGGTCTTAGAGGTGACACGCA 24
RESULT 29
AAV08993/C
ID AAV08993 standard; cDNA; 24 BP.
XX AC
XX AC AAV08993;
XX DT
XX DT 02-MAR-1999 (first entry)
XX DE
XX DE Primer for human ICAM-4 coding sequence.
XX KW ICAM-4; human; neuronal; intercellular adhesion molecule-4; PCR primer;
XX KW ss.
XX OS
XX OS Synthetic.
XX OS Homo sapiens.
XX PN US5852170-A.
XX XX
XX XX 22-DEC-1998.
XX

```

PF 07-JUN-1995; 95US-00487595.
 XX
 PR 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 05-AUG-1993; 93US-00102852.
 PR 18-MAY-1994; 94US-00245295.
 XX
 PA (ICOS-) ICOS CORP.
 XX
 PI Kilgannon PD, Gallatin WM;
 XX
 DR WPI; 1999-080500/07.
 XX
 PT Human neuronal ICAM-4 polypeptide - useful for antibody production or in
 PT screening assays.
 XX
 PS Example 10; Col 19; 42pp; English.
 XX
 CC This sequence represents a primer for the DNA encoding the human neuronal
 CC intercellular adhesion molecule-4 (ICAM-4) protein. This sequence was
 CC used to isolate the human ICAM-4 protein of the invention. ICAM-4 fusion
 CC proteins can be used to produce anti-ICAM-4 antibodies. ICAM-4
 CC polypeptides can be used in screening assays for antibodies or other
 CC compounds that modulate ICAM-4 activity
 XX
 SQ Sequence 24 BP; 1 A; 7 C; 7 G; 9 T; 0 U; 0 Other;
 XX
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 942 GAACACGAGCCAGGAGACTGCA 965
 Db 24 GAACACGAGCCAGGAGACTGCA 1
 RESULT 30
 AAV08992
 ID AAV08992 standard; cDNA; 24 BP.
 XX
 AC AAV08992;
 XX
 DT 02-MAR-1999 (first entry)
 XX
 DE Primer for human ICAM-4 coding sequence.
 XX
 KW ICAM-4; human; neuronal; intercellular adhesion molecule-4; PCR primer;
 KW ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN US5852170-A.
 XX
 PD 22-DEC-1998.
 XX
 PF 07-JUN-1995; 95US-00487595.
 XX
 PR 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 05-AUG-1993; 93US-00102852.
 PR 18-MAY-1994; 94US-00245295.
 XX
 PA (ICOS-) ICOS CORP.
 XX
 PI Kilgannon PD, Gallatin WM;
 XX
 DR WPI; 1999-080500/07.
 XX

PT Human neuronal ICAM-4 polypeptide - useful for antibody production or in
 PT screening assays.
 XX
 PS Example 10; Col 19; 42pp; English.
 XX
 CC This sequence represents a primer for the DNA encoding the human neuronal
 CC intercellular adhesion molecule-4 (ICAM-4) protein. This sequence was
 CC used to isolate the human ICAM-4 protein of the invention. ICAM-4 fusion
 CC proteins can be used to produce anti-ICAM-4 antibodies. ICAM-4
 CC polypeptides can be used in screening assays for antibodies or other
 CC compounds that modulate ICAM-4 activity
 XX
 SQ Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 729 CCGGGTCTAGAGGTGGACACGCA 752
 Db 1 CCGGGTCTAGAGGTGGACACGCA 24
 RESULT 31
 AAA33390/c
 ID AAA33390 standard; DNA; 24 BP.
 XX
 AC AAA33390;
 XX
 DT 28-JUL-2000 (first entry)
 XX
 DE Low adenosine antisense oligonucleotide SEQ ID NO:1079.
 XX
 KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200009525-A2.
 XX
 PD 24-FEB-2000.
 XX
 PF 03-AUG-1999; 99WO-US017712.
 XX
 PR 03-AUG-1998; 98US-0095212P.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 PI Nyce JW;
 XX
 DR WPI; 2000-205971/18.
 XX
 PT New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers.
 XX
 PS Claim 18; Page 400; 1343pp; English.
 XX
 CC The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating

CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impeded respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONS reduces side effects. The A-containing ONS break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
 CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
 CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
 CC AAA33992) are specifically claimed ONS from the present invention. N.B.
 CC Sequences given in the disclosure of the present invention do not match
 CC up with their corresponding SEQ ID NO: sequences given in the sequence
 CC listing

XX SQ Sequence 24 BP; 0 A; 4 C; 10 G; 10 T; 0 U; 0 Other;
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1626 GAAACCGAACACACACAGCCACGCC 1649
 |||||
 Db 24 GAAACCGAACACACACAGCCACGCC 1

RESULT 32
 AAZ24280/C
 ID AAZ24280 standard; DNA; 24 BP.
 XX AC AAZ24280;
 XX DT 16-FEB-2000 (first entry)
 XX DE Human ICAM-1 domain 3 oligonucleotide H-1/D3(AS).
 XX KW ICAM-R; human; intercellular adhesion molecule; phosphorylation;
 XX KW protein kinase C; modulator; primer; ICAM-1: ss.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN US5989843-A.
 XX PD 23-NOV-1999.
 XX PF 27-SEP-1996; 96US-00720420.
 XX PR 27-JAN-1992; 92US-00827689.
 XX PR 26-MAY-1992; 92US-00889724.
 XX PR 05-JUN-1992; 92US-00894061.
 XX PR 22-JAN-1993; 93US-00009266.
 XX PR 26-JAN-1993; 93WO-US000787.
 XX PR 05-AUG-1993; 93US-00102852.
 XX PR 07-JUN-1995; 95US-00487113.
 XX PA (ICOS-) ICOS CORP.
 XX PI Gallatin WM, Vazeux R;
 XX WPI; 2000-022778/02.

XX Identifying modulators of protein kinase C phosphorylation of human
 XX intercellular adhesion molecule polypeptide.

XX Example 5; Col 119-120; 122pp; English.

XX This invention describes a novel method for identifying a compound that
 CC modulates phosphorylation of human intercellular adhesion molecule
 CC polypeptide (ICAM-R) by protein kinase C isoform. The method comprises:

CC (a) exposing a purified peptide consisting of the cytoplasmic domain of
 CC ICAM-R to protein kinase C isoform and labeled adenosine triphosphate in
 CC the presence and absence of a test compound; (b) measuring labeled
 CC phosphate transferred to the peptide; and (c) identifying a test compound
 CC that affects transfer of the labeled phosphate as a modulator compound.
 CC The method is useful for identifying compounds that modulate the
 CC phosphorylation of human intercellular adhesion molecule polypeptide
 CC which might form the basis for the development of therapeutic and
 CC diagnostic agents. This sequence represents a primer used in the method
 CC of the invention

XX SQ Sequence 24 BP; 1 A; 7 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACGAGCCGAGGACACACTGCA 965
 |||||
 Db 24 GAACGAGCCGAGGACACACTGCA 1

RESULT 33
 AAZ24279
 ID AAZ24279 standard; DNA; 24 BP.
 XX AC AAZ24279;
 XX DT 16-FEB-2000 (first entry)
 XX DE Human ICAM-1 domain 3 oligonucleotide H-1/D3(S).
 XX KW ICAM-R; human; intercellular adhesion molecule; phosphorylation;
 XX KW protein kinase C; modulator; primer; ICAM-1: ss.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN US5989843-A.
 XX PD 23-NOV-1999.
 XX PF 27-SEP-1996; 96US-00720420.
 XX PR 27-JAN-1992; 92US-00827689.
 XX PR 26-MAY-1992; 92US-00889724.
 XX PR 05-JUN-1992; 92US-00894061.
 XX PR 22-JAN-1993; 93US-00009266.
 XX PR 26-JAN-1993; 93WO-US000787.
 XX PR 05-AUG-1993; 93US-00102852.
 XX PR 07-JUN-1995; 95US-00487113.
 XX PA (ICOS-) ICOS CORP.
 XX PI Gallatin WM, Vazeux R;
 XX WPI; 2000-022778/02.

XX Identifying modulators of protein kinase C phosphorylation of human
 XX intercellular adhesion molecule polypeptide.

XX Example 5; Col 119-120; 122pp; English.

XX This invention describes a novel method for identifying a compound that
 CC modulates phosphorylation of human intercellular adhesion molecule
 CC polypeptide (ICAM-R) by protein kinase C isoform. The method comprises:
 CC (a) exposing a purified peptide consisting of the cytoplasmic domain of
 CC ICAM-R to protein kinase C isoform and labeled adenosine triphosphate in
 CC the presence and absence of a test compound; (b) measuring labeled
 CC phosphate transferred to the peptide; and (c) identifying a test compound
 CC that affects transfer of the labeled phosphate as a modulator compound.
 CC The method is useful for identifying compounds that modulate the
 CC phosphorylation of human intercellular adhesion molecule polypeptide

CC which might form the basis for the development of therapeutic and
 CC diagnostic agents. This sequence represents a primer used in the method
 CC of the invention
 XX
 SQ Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 729 CCGGGTCCTAGAGGTGGACACGCA 752
 Db 1 CCGGGTCCTAGAGGTGGACACGCA 24
 RESULT 34
 AAA97108/c
 ID AAA97108 standard; DNA; 24 BP.
 XX
 AC AAA97108;
 XX
 DT 19-DEC-2000 (first entry)
 XX
 DE PCR primer H-1/D3(AS) used to amplify ICAM-1 domain 3.
 XX
 KW Anti-human immunodeficiency virus; HIV; cytostatic; ICAM-R; ARDS; stroke;
 KW intercellular adhesion molecule; immunoglobulin heavy chain; septicemia;
 KW inflammatory conditions; glomerulonephritis; arthritis; dermatosis;
 KW haemodialysis; leukapheresis; ulcerative colitis; Crohn's disease;
 KW necrotising enterocolitis; atherosclerosis; psoriasis; asthma;
 KW transplant rejection; diabetes; tumour; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6100383-A.
 XX
 PD 08-AUG-2000.
 XX
 PF 07-JUN-1995; 95US-00475680.
 XX
 PR 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 28-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 05-AUG-1994; 94US-00286754.
 XX
 PA (ICOS-) ICOS CORP.
 XX
 PI Gallatin WM, Vazeux R;
 XX
 DR WPI; 2000-542449/49.
 XX
 PT Hybrid fusion proteins comprising intercellular adhesion molecule or its
 PT variants useful, for treating inflammatory conditions, Crohn's disease,
 PT atherosclerosis and diabetes.
 XX
 PS Example 5; Col 16; 109pp; English.
 XX
 CC This invention relates to a hybrid fusion protein comprising an
 CC intercellular adhesion molecule (ICAM-R) amino acid fragment at its amino
 CC terminus and a constant domain of an immunoglobulin heavy chain at its
 CC carboxy terminus. ICAM-R polypeptides are useful for treating and
 CC monitoring inflammatory conditions such as adult respiratory distress
 CC syndrome, multiple organ injury syndrome secondary to septicemia or
 CC trauma, reperfusion injury of tissue, acute glomerulonephritis, reactive
 CC arthritis, dermatosis, stroke, thermal injury, haemodialysis,
 CC leukapheresis, ulcerative colitis, Crohn's disease, necrotising
 CC enterocolitis, granulocyte transfusion associated syndrome,
 CC atherosclerosis and cytokine induced toxicity. ICAM-R polypeptides are
 CC also useful for treating conditions resulting from a response of the
 CC specific immune system in a mammal e.g. psoriasis, organ/tissue

CC transplant rejection and autoimmune diseases including Raynaud's
 CC syndrome, autoimmune thyroiditis, multiple sclerosis, rheumatoid
 CC arthritis, diabetes and lupus erythematosus. ICAM-R products and ICAM-R
 CC related products are also useful in monitoring and treating asthma,
 CC tumour growth and/or metastasis, and viral infection (e.g. HIV
 CC infection). Sequences AAA97090 and AAB13036 represent the human ICAM-R
 CC DNA and protein sequences. Sequences AAA97091-A97112 represent ICAM-R DNA
 CC fragments, PCR primers and probes, all used in the identification of the
 CC ICAM-R DNA sequence. AAA97113-A97123 and AAA97129-A97152 represent
 CC primers used in the production of humanised anti-ICAM-R antibody ICR-8.1,
 CC and fragments of the humanised antibody. Sequences AAA97124-A97128,
 CC AAA97132, AAA97144 represent ICR-8.1 sequences. Sequences AAA97153-A97176
 CC excluding AAA97155-A97156 represent primers used in the production of
 CC humanised anti-ICAM-R antibody ICR-1.1, and fragments of the humanised
 CC antibody. Sequences AAA97155-A97156 and AAB13047-B13048 represent murine
 CC ICR-1.1 sequences. DNA and peptide sequences used in the production of
 CC the chimeric protein of the invention include AAA97177-A97188 and
 CC AAB13050-B13051
 XX
 SQ Sequence 24 BP; 1 A; 7 C; 7 G; 9 T; 0 U; 0 Other;
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 942 GAACACGAGCCGAGGAGACTGCA 965
 Db 24 GAACACGAGCCGAGGAGACTGCA 1
 RESULT 35
 AAA97107
 ID AAA97107 standard; DNA; 24 BP.
 XX
 AC AAA97107;
 XX
 DT 19-DEC-2000 (first entry)
 XX
 DE PCR primer H-1/D3(S) used to amplify ICAM-1 domain 3.
 XX
 KW Anti-human immunodeficiency virus; HIV; cytostatic; ICAM-R; ARDS; stroke;
 KW intercellular adhesion molecule; immunoglobulin heavy chain; septicemia;
 KW inflammatory conditions; glomerulonephritis; arthritis; dermatosis;
 KW haemodialysis; leukapheresis; ulcerative colitis; Crohn's disease;
 KW necrotising enterocolitis; atherosclerosis; psoriasis; asthma;
 KW transplant rejection; diabetes; tumour; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6100383-A.
 XX
 PD 08-AUG-2000.
 XX
 PF 07-JUN-1995; 95US-00475680.
 XX
 PR 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 05-AUG-1994; 94US-00286754.
 XX
 PA (ICOS-) ICOS CORP.
 XX
 PI Gallatin WM, Vazeux R;
 XX
 DR WPI; 2000-542449/49.
 XX
 PT Hybrid fusion proteins comprising intercellular adhesion molecule or its
 PT variants useful, for treating inflammatory conditions, Crohn's disease,
 PT atherosclerosis and diabetes.

Example 5; Col 16; 109pp; English.

PS This invention relates to a hybrid fusion protein comprising an
XX intercellular adhesion molecule (ICAM-R) amino acid fragment at its amino
CC terminus and a constant domain of an immunoglobulin heavy chain at its
CC carboxy terminus. ICAM-R polypeptides are useful for treating and
CC monitoring inflammatory conditions such as adult respiratory distress
CC syndrome, multiple organ injury syndrome secondary to septicemia or
CC trauma, reperfusion injury of tissue, acute glomerulonephritis, reactive
CC arthritis, dermatosis, stroke, thermal injury, haemodialysis,
CC leukapheresis, ulcerative colitis, Crohn's disease, necrotising
CC enterocolitis, granulocyte transfusion associated syndrome,
CC atherosclerosis and cytokine induced toxicity. ICAM-R polypeptides are
CC also useful for treating conditions resulting from a response of the
CC specific immune system in a mammal e.g. psoriasis, organ/tissue
CC transplant rejection and autoimmune diseases including Raynaud's
CC syndrome, autoimmune thyroiditis, multiple sclerosis, rheumatoid
CC arthritis, diabetes and lupus erythematosus. ICAM-R products and ICAM-R
CC related products are also useful in monitoring and treating asthma,
CC tumour growth and/or metastasis, and viral infection (e.g. HIV
CC infection). Sequences AAA97090 and AAB13036 represent the human ICAM-R
CC DNA and protein sequences. Sequences AAA97091-A97112 represent ICAM-R
CC fragments, PCR primers and probes, all used in the identification of the
CC ICAM-R DNA sequence. AAA97113-A97123 and AAA97129-A97152 represent
CC primers used in the production of humanised anti-ICAM-R antibody ICR-8.1,
CC and fragments of the humanised antibody. Sequences AAA97124-A97128,
CC AAA97132, AAA97144 represent ICR-8.1 sequences. Sequences AAA97153-A97176
CC excluding AAA97155-A97156 represent primers used in the production of
CC humanised anti-ICAM-R antibody ICR-1.1, and fragments of the humanised
CC antibody. Sequences AAA97155-A97156 and AAB13047-B13048 represent murine
CC ICR-1.1 sequences. DNA and peptide sequences used in the production of
CC the chimeric protein of the invention include AAA97177-A97188 and
CC AAB13050-B13051
XX

SQ Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCTAGAGTGGACACGCA 752
DB 1 CCGGGTCTAGAGTGGACACGCA 24

RESULT 36
AAA12098
ID AAA12098 standard; DNA; 24 BP.

XX AAA12098;

AC AAA12098;

XX 07-AUG-2000 (first entry)

DE Human ICAM-1 DNA fragment #6.

XX Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
KW antitussive gene therapy; inflammatory disease; virus infection;
KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
KW graft-versus-host reaction; neurodermatitis; gum disease; ss.

XX Homo sapiens.

OS Homo sapiens.

XX WO200018907-A2.

XX 06-APR-2000.

XX 21-SEP-1999; 99WO-EF006972.

XX 25-SEP-1998; 98DE-01044111.

PR 04-DEC-1998; 98DE-01056138.

PR 08-JUN-1999; 99DE-01026110.

XX (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.

XX Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;

XX WPI; 2000-293146/25.

DR Novel antisense nucleic acids targeted to specific sequences within the
XX ICAM-1 gene, useful for treating inflammation and metastasis.

PT Disclosure; Page 27; 28pp; German.

XX This invention describes novel antisense nucleic acids (I) targeted
XX against a specific nucleic acid sequence within human ICAM-1. The
CC products of the invention have cytostatic, anti-inflammatory,
CC dermatological, antiviral, antirheumatic, antiarthritic,
CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
CC can be used for antisense therapy; gene therapy. The antisense nucleic
CC acids or vectors are used to inhibit or eliminate acute or chronic
CC inflammatory diseases of humans, virus infection, metastasis,
CC inflammation of the skin, mobilization of hematopoietic stem cells,
CC coughs and all biological processes under the influence of ICAM-1,
CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
CC rejection, graft-versus-host reaction after bone marrow transplantation,
CC psoriasis, asthma and neurodermatitis. In particular, the antisense
CC nucleic acids are used to treat acute or chronic inflammation of gum
CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
CC expression. The antisense nucleic acids or vectors can be used to
CC suppress immune reactions against gene therapy using viral or non-viral
CC vectors in mammals. The antisense nucleic acids may also be used in kits
CC to diagnose ICAM-1 associated disturbances. AAA12093-A12098 represent
CC fragments of human ICAM-1 DNA which is used in the method of the
CC invention
XX

SQ Sequence 24 BP; 9 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1837 AAAACACTAGGCCACGCATCTGAT 1860
DB 1 AAAACACTAGGCCACGCATCTGAT 24

RESULT 37

AAA12094

ID AAA12094 standard; DNA; 24 BP.

XX AAA12094;

XX 07-AUG-2000 (first entry)

DE Human ICAM-1 DNA fragment #2.

XX Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
KW antitussive gene therapy; inflammatory disease; virus infection;
KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
KW graft-versus-host reaction; neurodermatitis; gum disease; ss.

XX Homo sapiens.

OS Homo sapiens.

XX WO200018907-A2.

XX 06-APR-2000.

XX 21-SEP-1999; 99WO-EF006972.

XX 25-SEP-1998; 98DE-01044111.

PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.

XX
 XX Patzel V, Kronenwett R, Steidl U, Haas R, Sczakiel G;
 XX WPI; 2000-293146/25.
 DR

XX Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 PT

XX Disclosure; Page 26; 28pp; German.
 XX

CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12093-Al2098 represent
 CC fragments of human ICAM-1 DNA which is used in the method of the
 CC invention
 CC

XX Sequence 24 BP; 3 A; 11 C; 5 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 45 CCTCAGCCTCGCTATGGCTCCAG 68
 Db 1 CCTCAGCCTCGCTATGGCTCCAG 24

RESULT 38

AAA12096
 ID AAA12096 standard; DNA; 24 BP.

XX AAA12096;

XX 07-AUG-2000 (first entry)

XX Human ICAM-1 DNA fragment #4.

XX Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.

XX Homo sapiens.

XX WO200018907-A2.

XX 06-APR-2000.

XX 21-SEP-1999; 99WO-EP006972.

XX

PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX

PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.

XX Patzel V, Kronenwett R, Steidl U, Haas R, Sczakiel G;
 XX WPI; 2000-293146/25.
 DR

XX Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 PT

XX Disclosure; Page 26; 28pp; German.
 XX

CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12093-Al2098 represent
 CC fragments of human ICAM-1 DNA which is used in the method of the
 CC invention
 CC

XX Sequence 24 BP; 8 A; 8 C; 6 G; 2 T; 0 U; 0 Other;
 SQ

Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1205 ACAAGAACCCAGACCCGGAGCTTC 1228
 Db 1 ACAAGAACCCAGACCCGGAGCTTC 24

RESULT 39

AAA08253

ID AAA08253 standard; DNA; 24 BP.

XX AAA08253;

XX 28-JUN-2000 (first entry)

XX Human ICAM-1 oligonucleotide probe SEQ ID NO:23.

XX Human; ICAM-R; chromosome 19; intracellular adhesion molecule receptor;
 KW CAM; ICAM-1; ICAM-2; humanised; antibody; mutagenic; PCR primer; probe;
 KW chimeric; vulnary; nephropathic; antipsoriatic; antiarthritic; cerebroprotective;
 KW antitumor; antiarteriosclerotic; immunosuppressive; antidiabetic;
 KW neuroprotective; antithyroid; dermatological; antiasthmatic; cytostatic;
 KW antiviral; antinflammatory; anti-HIV; vasotropic; antipsoriatic;
 KW immunomodulator; cell adhesion mediator; antirheumatic;
 KW inflammatory condition; immunisation; immune response; ss.

XX Homo sapiens.

XX US6040176-A.

XX 21-MAR-2000.

XX

PF 12-SEP-1996; 96US-00714017.
 XX 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 05-AUG-1994; 94US-00286754.
 XX (ICOS-) ICOS CORP.
 PA Gallatin WM, Vazeux R;
 PI WPI; 2000-270138/23.
 XX Novel monoclonal antibody directed against ICAM-R proteins useful for
 PT treating acute glomerulonephritis, ulcerative colitis, psoriasis,
 PT rheumatoid arthritis, diabetes, multiple sclerosis, asthma and viral
 PT infection.
 XX Example 5; Col 16; 117pp; English.
 XX The present invention describes a monoclonal antibody (Mab) (I), produced
 CC by the hybridoma cell line 81K2F (ATCC HB 11692). Also described are: (1)
 CC a hybridoma cell line 81K2F; and (2) a Mab (II), that competes with (I)
 CC for binding to ICAM-R (intracellular adhesion molecule receptor) (III).
 CC (II) mimics the activity of natural binding proteins through which
 CC intercellular and intracellular activities of (III) are modulated. (II)
 CC is also used for modulating the immune responses. (I) is used for
 CC immunisation as well as for purifying (III). They are also useful in
 CC modulating the ligand/receptor binding biological activity involving
 CC (III) especially those effector functions of (III) involved in specific
 CC and non-specific immune system responses. Inflammatory conditions which
 CC may be treated or monitored with related products of (III) include
 CC conditions resulting from a response of the non-specific immune system in
 CC a mammal e.g. adult respiratory distress syndrome, multiple organ injury
 CC syndrome secondary to septicemia or trauma, reperfusion injury of tissue,
 CC acute glomerulonephritis, reactive arthritis, stroke, ulcerative colitis
 CC and atherosclerosis, and conditions resulting from a response of the
 CC specific immune system in a mammal, e.g. psoriasis, organ/tissue
 CC transplantation rejection, autoimmune diseases such as autoimmune
 CC thyroiditis, multiple sclerosis, rheumatoid arthritis, diabetes and lupus
 CC erythematosus. AAA08236 to AAA08334, and AAY82435 to AAY82451 represent
 CC sequences used in the exemplification of the present invention
 XX Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 729 CCGGGTCTAGAGGTGGACACGCA 752
 DB 1 CCGGGTCTAGAGGTGGACACGCA 24
 RESULT 40
 AAA08254/c
 ID AAA08254 standard; DNA; 24 BP.
 XX AAA08254;
 AC
 XX 28-JUN-2000 (first entry)
 DT Human ICAM-1 oligonucleotide probe SEQ ID NO:24.
 XX Human; ICAM-R; chromosome 19; intracellular adhesion molecule receptor;
 KW CAM; ICAM-1; ICAM-2; humanised; antibody; mutagenic; PCR primer; probe;
 KW chimeric; vulnarary; nephropathic; antiarthritic; cerebroprotective;
 KW antitumor; antiarteriosclerotic; immunosuppressive; antidiabetic;
 KW neuroprotective; antithyroid; dermatological; antiaathmatic; cytostatic;
 KW antiviral; antiinflammatory; anti-HIV; vasotropic; antipsoriatic;

KW immunomodulator; cell adhesion mediator; antirheumatic;
 KW inflammatory condition; immunisation; immune response; ss.
 OS Homo sapiens.
 XX US6040176-A.
 XX 21-MAR-2000.
 XX 12-SEP-1996; 96US-00714017.
 XX 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 05-AUG-1994; 94US-00286754.
 XX (ICOS-) ICOS CORP.
 PA Gallatin WM, Vazeux R;
 PI WPI; 2000-270138/23.
 XX Novel monoclonal antibody directed against ICAM-R proteins useful for
 PT treating acute glomerulonephritis, ulcerative colitis, psoriasis,
 PT rheumatoid arthritis, diabetes, multiple sclerosis, asthma and viral
 PT infection.
 XX Example 5; Col 16; 117pp; English.
 XX The present invention describes a monoclonal antibody (Mab) (I), produced
 CC by the hybridoma cell line 81K2F (ATCC HB 11692). Also described are: (1)
 CC a hybridoma cell line 81K2F; and (2) a Mab (II), that competes with (I)
 CC for binding to ICAM-R (intracellular adhesion molecule receptor) (III).
 CC (II) mimics the activity of natural binding proteins through which
 CC intercellular and intracellular activities of (III) are modulated. (II)
 CC is also used for modulating the immune responses. (I) is used for
 CC immunisation as well as for purifying (III). They are also useful in
 CC modulating the ligand/receptor binding biological activity involving
 CC (III) especially those effector functions of (III) involved in specific
 CC and non-specific immune system responses. Inflammatory conditions which
 CC may be treated or monitored with related products of (III) include
 CC conditions resulting from a response of the non-specific immune system in
 CC a mammal e.g. adult respiratory distress syndrome, multiple organ injury
 CC syndrome secondary to septicemia or trauma, reperfusion injury of tissue,
 CC acute glomerulonephritis, reactive arthritis, stroke, ulcerative colitis
 CC and atherosclerosis, and conditions resulting from a response of the
 CC specific immune system in a mammal, e.g. psoriasis, organ/tissue
 CC transplantation rejection, autoimmune diseases such as autoimmune
 CC thyroiditis, multiple sclerosis, rheumatoid arthritis, diabetes and lupus
 CC erythematosus. AAA08236 to AAA08334, and AAY82435 to AAY82451 represent
 CC sequences used in the exemplification of the present invention
 XX Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 942 GAACACAGAGCCAGGACACTGCA 965
 DB 24 GAACACAGAGCCAGGACACTGCA 1
 RESULT 41
 AAF19512/c
 ID AAF19512 standard; DNA; 24 BP.
 XX AAF19512;
 AC
 XX 14-MAR-2001 (first entry)

XX DE Human ICM-1 polynucleotide fragment #1079.

XX KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;

XX KW human; airway disorder; bronchoconstriction; lung inflammation;

XX KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;

XX KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;

XX KW respiratory obstruction; pulmonary obstruction; impeded respiration;

XX KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;

XX KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;

XX KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;

XX KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;

XX KW cancer; ss.

XX OS Homo sapiens.

XX PN WO200062736-A2.

XX PD 26-OCT-2000.

XX PF 24-MAR-2000; 2000WO-US008020.

XX PR 06-APR-1999; 99US-0127958P.

XX PA (UYEC-) UNIV EAST CAROLINA.

XX PA (NYCE/) NYCE J W.

XX PI Nyce JW;

XX PN WPI; 2000-679539/66.

XX DR Low adenosine (A) content antisense oligonucleotides which do not trigger

XX PT adenosine receptors during metabolism, useful e.g. for treating cancers

XX PT and respiratory obstructions.

XX PS Claim 14; Page 145; 1592pp; English.

XX CC The present invention describes low adenosine (A) content antisense

XX CC oligonucleotides and compositions (I) comprising them. In the antisense

XX CC oligonucleotides the A is replaced by a 'Universal' or alternative base.

XX CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,

XX CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.

XX CC The antisense oligonucleotides and (I) can be used to down-regulate the

XX CC expression and or activity of target polypeptides associated with

XX CC lung/respiratory disorders and malignancies, such as stimulating and

XX CC activating peptide factors and transmitters, transcription factors,

XX CC immunoglobulins and antibodies, antibody receptors, cytokines and

XX CC chemokines, endogenously produced specific and non-specific enzymes,

XX CC binding proteins, adhesion molecules and their receptors, cytokine and

XX CC chemokine receptors, adenosine receptors, bradykinin receptors, central

XX CC nervous system (CNS) and peripheral nervous and non-nervous system

XX CC receptors, CNS and peripheral nervous and non-nervous system peptide

XX CC transmitters, defensins, growth factors, vasoactive peptides and

XX CC receptors, binding proteins and malignancy associated proteins. The

XX CC antisense oligonucleotides may be used in this way to treat disorders

XX CC including respiratory obstruction (especially pulmonary obstruction

XX CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or

XX CC surfactant hypoproduction which are associated with a disease or

XX CC condition selected from pulmonary vasoconstriction, inflammation,

XX CC allergies, asthma, impeded respiration, respiratory distress syndrome

XX CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary

XX CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),

XX CC pulmonary transplantation rejection, pulmonary infections, bronchitis,

XX CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide

XX CC fragments and antisense oligonucleotides used in the exemplification of

XX CC the present invention

XX SQ Sequence 24 BP; 0 A; 4 C; 10 G; 10 T; 0 U; 0 Other;

Query Match 0.8%; Score 24; DB 1; Length 24;

Best Local Similarity 100.0%; Pred. No. 1.6e-02;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1626 GAAACCGACACACACGCGCC 1649

DB 24 GAAACCGACACACACGCGCC 1

RESULT 42

ABK09296

ID ABK09296 standard; DNA; 24 BP.

XX AC ABK09296;

XX DT 30-DEC-2002 (first entry)

XX DE Intercellular adhesion molecule, ICAM-R PCR primer H-1/D3(S).

XX KW Human; intercellular adhesion molecule; ICAM; antiinflammatory; stroke;

XX KW antibacterial; vulnery; vasotropic; nephrotropic; antiarthritis;

XX KW cerebroprotective; dermatological; antitumor; immunosuppressive; tumor;

XX KW antipsoriatic; antiarteriosclerotic; neuroprotective; antithyroid;

XX KW virucide; antirheumatic; antidiabetic; antiasthmatic; cytostatic; asthma;

XX KW hybridoma cell line; ATCC HB 12190; inflammation; septicemia; trauma;

XX KW adult respiratory distress syndrome; multiple organ injury syndrome;

XX KW tissue reperfusion injury; acute glomerulonephritis; arthritis; vaccine;

XX KW dermatosis; thermal injury; haemodialysis; PCR primer; psoriasis;

XX KW Crohn's disease; ulcerative colitis; multiple sclerosis; infection; ss.

XX OS Homo sapiens.

XX PN US2001029293-A1.

XX PD 11-OCT-2001.

XX PF 03-JAN-2001; 2001US-00753436.

XX PR 27-JAN-1992; 92US-00827689.

XX PR 26-MAY-1992; 92US-00889724.

XX PR 05-JUN-1992; 92US-00894061.

XX PR 22-JAN-1993; 93US-00092266.

XX PR 26-JAN-1993; 93WO-US000787.

XX PR 05-AUG-1993; 93US-00102852.

XX PR 07-JUN-1995; 95US-00487113.

XX PR 24-AUG-1999; 99US-00382289.

XX PA (ICOS-) ICOS CORP.

XX PI Gallatin WM, Vazeux R;

XX DR WPI; 2002-009992/01.

XX PT Novel hybridoma cell line useful for producing monoclonal antibody for

XX PT treating inflammatory conditions, immune system disorders and infectious

XX PT diseases, is deposited under specified ATCC accession number.

XX PS Page 9; Example 5; 126pp; English.

XX CC The invention relates to a novel hybridoma cell line (I) ATCC HB 12190.

XX CC (I) is useful for producing an intercellular adhesion molecule (ICAM).

XX CC monoclonal antibody (II). (II) is useful for treating inflammatory

XX CC conditions including adult respiratory distress syndrome, multiple organ

XX CC injury, syndrome secondary to septicemia or trauma, tissue reperfusion

XX CC injury, acute glomerulonephritis, reactive arthritis, dermatosis with

XX CC acute inflammatory components, stroke, thermal injury, haemodialysis,

XX CC leukopheresis, ulcerative colitis, Crohn's disease, necrotising

XX CC enterocolitis, granulocyte transfusion associated syndrome, diabetes,

XX CC atherosclerosis, cytokine-induced toxicity, psoriasis, organ/tissue

XX CC transplant rejection, autoimmune diseases including Raynaud's syndrome,

XX CC autoimmune thyroiditis, multiple sclerosis, rheumatoid arthritis, lupus

XX CC erythematous asthma, tumour growth and/or metastasis, viral infection,

XX CC tissue transplant rejection, graft versus host disease and multiple

XX CC sclerosis. (II) is also useful for immunisation, for purifying ICAM-R

XX CC polypeptides and for identifying cells that display the polypeptides on

XX CC their surfaces. AAS09279-AAS09380 represent ICAM coding sequences, PCR

XX CC primers and related sequences of the invention

XX SQ Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 729 CCGGGTCTAGAGGTGGACACGCA 752
 |||||
 Db 1 CCGGGTCTAGAGGTGGACACGCA 24

RESULT 43
 ABK09297/c
 ID ABK09297 standard; DNA; 24 BP.
 AC ABK09297;
 XX
 XX
 DT 30-DEC-2002 (first entry)
 XX
 DE Intercellular adhesion molecule, ICAM-R PCR primer H-1/D3(AS).
 XX
 KW Human; intercellular adhesion molecule; ICAM; antiinflammatory; stroke;
 KW antibacterial; vulnery; vasotropic; nephrotropic; antiarthritic;
 KW cerebroprotective; dermatological; antiulcer; immunosuppressive; tumour;
 KW antipsoriatic; antiarteriosclerotic; neuroprotective; antithyroid;
 KW viricide; antirheumatic; antidiabetic; antiasthmatic; cytotstatic; asthma;
 KW hybridoma cell line; ATCC HB 12190; inflammation; septicemia; trauma;
 KW adult respiratory distress syndrome; multiple organ injury syndrome;
 KW tissue reperfusion injury; acute glomerulonephritis; arthritis; vaccine;
 KW dermatosis; thermal injury; haemodialysis; PCR primer; psoriasis;
 KW Crohn's disease; ulcerative colitis; multiple sclerosis; infection; ss.
 XX
 OS Homo sapiens.
 XX
 XX
 PN US2001029293-A1.
 XX
 PD 11-OCT-2001.
 XX
 XX
 PF 03-JAN-2001; 2001US-00753436.
 XX
 PR 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 07-JUN-1995; 95US-00487113.
 PR 24-AUG-1999; 99US-00382289.
 XX
 PA (ICOS-) ICOS CORP.
 XX
 XX Gallatin WM, Vazeux R;
 PI WPI; 2002-009992/01.
 XX
 DR Novel hybridoma cell line useful for producing monoclonal antibody for
 PT treating inflammatory conditions, immune system disorders and infectious
 PT diseases, is deposited under specified ATCC accession number.
 XX
 XX Page 9; Example 5; 126pp; English.
 PS
 XX The invention relates to a novel hybridoma cell line (I) ATCC HB 12190.
 CC (I) is useful for producing an intercellular adhesion molecule (ICAM)
 CC monoclonal antibody (II). (II) is useful for treating inflammatory
 CC conditions including adult respiratory distress syndrome, multiple organ
 CC injury syndrome secondary to septicemia or trauma, tissue reperfusion
 CC injury, acute glomerulonephritis, reactive arthritis, dermatosis with
 CC acute inflammatory components, stroke, thermal injury, haemodialysis,
 CC leukopenia, ulcerative colitis, Crohn's disease, necrotising
 CC enterocolitis, granulocyte transfusion associated syndrome, diabetes,
 CC atherosclerosis, cytokine-induced toxicity, psoriasis, organ/tissue
 CC transplant rejection, autoimmune diseases including Raynaud's syndrome,
 CC

CC autoimmune thyroiditis, multiple sclerosis, rheumatoid arthritis, lupus
 CC erythematous, asthma, tumour growth and/or metastasis, viral infection,
 CC tissue transplant rejection, graft versus host disease and multiple
 CC sclerosis. (II) is also useful for immunisation, for purifying ICAM-R
 CC polypeptides and for identifying cells that display the polypeptides on
 CC their surfaces. AAS09279-AAS09380 represent ICAM coding sequences, PCR
 CC primers and related sequences of the invention
 XX
 SQ Sequence 24 BP; 1 A; 7 C; 7 G; 9 T; 0 U; 0 Other;
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 942 GAACACAGCCAGGACACTGCA 965
 |||||
 Db 24 GAACACAGCCAGGACACTGCA 1

RESULT 44
 ABK66439
 ID ABK66439 standard; DNA; 24 BP.
 XX
 XX
 AC ABK66439;
 XX
 DT 02-JUL-2002 (first entry)
 XX
 DE Human gene specific PCR primer #527.
 XX
 KW Primer; ss; DNA microarray; differential expression analysis; human.
 KW Homo sapiens.
 XX
 OS Homo sapiens.
 XX
 PN US6352829-B1.
 XX
 PD 05-MAR-2002.
 XX
 XX
 PF 05-JAN-1999; 99US-00225928.
 XX
 XX
 PR 21-MAY-1997; 97US-00859998.
 XX
 XX (CLON-) CLONTECH LAB INC.
 PA
 XX
 PI Chenchik A, Jokhadze G, Bibilashvili R;
 XX
 XX WPI; 2002-314699/35.
 XX
 PT Producing sub-population of labeled nucleic acids, useful for analyzing
 PT differences in RNA profiles between several different physiological
 PT sources, using set of distinct gene specific primers.
 XX
 XX Example 3; SEQ ID NO 527; 11pp; English.
 PS
 XX The invention relates to producing a sub-population of labeled nucleic
 CC acids (NAs) comprising contacting a NA sample from a physiological
 CC source, with a pool of 50 distinct gene specific primers under suitable
 CC conditions to enzymatically generate sub-population of NAs, where each
 CC gene specific primer has a sequence complementary to a distinct mRNA, and
 CC each labeled NA is generated using a single gene specific primer. The
 CC method is useful for producing a sub-population of labeled NAs which is
 CC useful for analysing the differences in the RNA profiles between several
 CC different physiological sources, where the method comprises producing
 CC subpopulation of labeled NAs for the different physiological sources,
 CC comprising the populations for each physiological source to identify
 CC differences in the population, where the comparison is preferably
 CC performed by hybridising the labeled NAs for each of the distinct
 CC physiological sources to an array of probe NAs stably associated with the
 CC surface of a substrate to produce a hybridisation pattern for each of the
 CC sources, and comparing the patterns for each of the sources, where
 CC differential gene expression assays are utilised in differential
 CC expression analysis of diseased a normal tissue e.g. neoplastic a normal
 CC tissue, or different tissue or subtype types. The present sequence is a
 CC human gene specific PCR primer used in the method of the invention. Note:

CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from USPTO
 CC at http.wipo.segdata.uspto.gov/sequence.html?DocID=635282981

XX Sequence 24 BP; 2 A; 6 C; 9 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1220 GGGAGCTTCGTGTCCTGATGGCC 1243

DB 1 GGGAGCTTCGTGTCCTGATGGCC 24

RESULT 45
 ABZ79520
 ID ABZ79520 standard; DNA; 24 BP.
 XX AC ABZ79520;
 XX DT 10-MAY-2003 (first entry)
 XX DE ICAM-1 probe sequence # SEQ ID 25.
 XX KW AK155 receptor; cytokine receptor; inflammation; Crohn's disease;
 KW autoimmune disease; multiple sclerosis; rheumatoid arthritis; psoriasis;
 KW asthma; allergy; diabetes mellitus; Sjogren's syndrome;
 KW transplant rejection; angiogenesis; cancer; probe; ss.
 XX OS Unidentified.
 XX PN WO2003002717-A2.
 XX PD 09-JAN-2003.
 XX PF 27-JUN-2002; 2002WO-US020489.
 XX PR 28-JUN-2001; 2001US-0302176P.
 XX PR 03-JAN-2002; 2002US-0345690P.
 XX PA (SCHE) SCHERING CORP.
 XX PA (FINK/) FINKENSCHER H.
 XX PI Finkenschers H, De Waal Malefyt R, Nagalakshmi ML, Moore K;
 XX WPI; 2003-278256/27.

XX New cells recombinantly altered to express an exogenous AK155 cytokine
 PT receptor, useful for identifying agents for treating AK155-mediated
 PT diseases, e.g. inflammation, angiogenesis or cancer.
 XX Example 2; Page 51; 100pp; English.
 XX The present invention relates to a cell recombinantly altered to express
 CC an exogenous AK155 cytokine receptor comprising alpha and beta subunits.
 CC The cytokine receptor, when expressed in Ba/F3 cells, binds to AK155 and
 CC stimulates binding of STAT3 to interferon (IFN) gamma-activated
 CC sequences. The cell is useful in expressing AK155 cytokine receptor which
 CC may be used for identifying therapeutic agents useful for treating AK155-
 CC mediated conditions or diseases, such as inflammation (e.g. Crohn's
 CC disease), autoimmune diseases (e.g. multiple sclerosis, rheumatoid
 CC arthritis, psoriasis, asthma, allergies, diabetes mellitus, Sjogren's
 CC syndrome), transplant rejection, angiogenesis, and cancer. The current
 CC sequence represents an ICAM-1 probe sequence

XX Sequence 24 BP; 4 A; 9 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 971 TGACCATCTACAGCTTTCCGGCGC 994

DB 1 TGACCATCTACAGCTTTCCGGCGC 24

RESULT 46

ADG25673

ID ADG25673 standard; DNA; 24 BP.

XX AC ADG25673;

XX DT 26-FEB-2004 (first entry)

XX DE Human ICAM-1 domain 3 PCR primer H-1/D3 S.

XX KW Human; intercellular adhesion molecule; ICAM-R; hybridoma cell line;
 KW ATCC HB 12190; monoclonal antibody; CD11b; nonspecific immune system;
 KW adult respiratory distress syndrome; multiple organ injury syndrome;
 KW septicemia; trauma; reperfusion injury; acute glomerulonephritis;
 KW reactive arthritis; dermatosis with acute inflammatory component; stroke;
 KW thermal injury; haemodialysis; leukapheresis; ulcerative colitis;
 KW Crohn's disease; necrotising enterocolitis;
 KW granulocyte transfusion associated syndrome; atherosclerosis;
 KW cytokine-induced toxicity; specific immune system; psoriasis;
 KW organ transplant rejection; autoimmune disease; Raynaud's syndrome;
 KW autoimmune thyroiditis; experimental autoimmune encephalomyelitis; EAE;
 KW multiple sclerosis; rheumatoid arthritis; diabetes; lupus erythematosus;
 KW asthma; tumour growth; metastasis; viral infection; HIV infection;
 KW immunogen; ss; primer; probe.
 XX OS Homo sapiens.
 XX PN US2003199423-A1.
 XX PD 23-OCT-2003.
 XX PF 05-JUN-2002; 2002US-00163942.
 XX PR 27-JAN-1992; 92US-00827689.
 XX PR 26-MAY-1992; 92US-00889724.
 XX PR 05-JUN-1992; 92US-00894061.
 XX PR 22-JAN-1993; 93US-00009266.
 XX PR 26-JAN-1993; 93WO-US000787.
 XX PR 05-AUG-1993; 93US-00102852.
 XX PR 07-JUN-1995; 95US-00487113.
 XX PR 24-AUG-1999; 99US-00382289.
 XX PR 03-JAN-2001; 2001US-00753436.

XX (GALL/) GALLATIN W M.

XX (VAZE/) VAZEUX R.

XX Gallatin WM, Vazeux R;

XX WPI; 2003-900201/82.

XX Hybridoma cell line for production of monoclonal antibodies useful for
 PT treating e.g. asthma and arthritis.

XX Example 5; SEQ ID NO 23; 127pp; English.

XX The invention relates to a hybridoma cell line ATCC HB 12190 producing a
 CC monoclonal antibody against human intercellular adhesion molecule
 CC polypeptide (ICAM-R). Also included are a monoclonal antibody produced by
 CC the hybridoma cell line, identification of a compound that modulates the
 CC interaction of binding partners intercellular adhesion molecule
 CC polypeptide (ICAM-R) and CD11b (involving: immobilising ICAM-R or CD11b,
 CC detectably labelling the non-immobilised binding partner, contacting the
 CC immobilised binding partner with the labelled binding partner in the
 CC presence and absence of test compound, detecting the label bound to the
 CC immobilised binding partner and identifying a modulating compound as a
 CC test compound that affects the label bound in the presence of the test
 CC compound in comparison to the label bound in the absence of the test
 CC compound) and identification of a compound that modulates phosphorylation
 CC of ICAM-R by protein kinase C isoform (involving: exposing ICAM-R peptide

comprising amino acids 482-518 of ADG25651 to protein kinase C isoform
 CC and labelled phosphate in the presence and absence of a test compound,
 CC measuring labelled phosphate transferred to the ICAM-R peptide and
 CC identifying a test compound that affects transfer of the labelled
 CC phosphate as a modulator compound). The hybridoma cell line ATCC HB 12190
 CC is useful in the production of monoclonal antibodies useful for
 CC identifying compounds and for the treatment of conditions resulting from
 CC a response of the nonspecific immune system in a mammal (e.g. adult
 CC respiratory distress syndrome, multiple organ injury syndrome secondary
 CC to septicemia, multiple organ injury syndrome secondary to trauma,
 CC reperfusion injury of tissue, acute glomerulonephritis, reactive
 CC arthritis, dermatosis with acute inflammatory components, stroke, thermal
 CC injury, haemodialysis, leukapheresis, ulcerative colitis, Crohn's
 CC disease, necrotising enterocolitis, granulocyte transfusion associated
 CC syndrome, atherosclerosis and cytokine-induced toxicity) and conditions
 CC resulting from a response of the specific immune system in a mammal (e.g.
 CC psoriasis, organ/tissue transplant rejection and autoimmune diseases
 CC including Raynaud's syndrome, autoimmune thyroiditis, experimental
 CC autoimmune encephalomyelitis (EAE), multiple sclerosis, rheumatoid
 CC arthritis, diabetes or lupus erythematosus), asthma, tumour growth and/or
 CC metastasis and viral infection (e.g. HIV infection). The monoclonal
 CC antibodies are readily available using immunogens comprising cells
 CC naturally expressing intercellular adhesion molecule polypeptide (ICAM-R)
 CC or its variants and display ligand/receptor binding biological activities
 CC and/or immunological properties specific to ICAM-R. The present sequence
 CC is a primer or probe used in the isolation of nucleic acids encoding
 CC human ICAM-R.
 XX
 SQ Sequence 24 BP; 5 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 729 CCGGGTCTAGAGGTGGACACGCA 752
 DB 1 CCGGGTCTAGAGGTGGACACGCA 24
 RESULT 47
 ADG25674/C
 ID ADG25674 standard; DNA; 24 BP.
 XX
 AC ADG25674;
 XX
 XX
 DT 26-FEB-2004 (first entry)
 XX
 XX Human ICAM-1 domain 3 PCR primer H-1/D3 AS.
 DE
 XX Human; intercellular adhesion molecule; ICAM-R; hybridoma cell line;
 KW ATCC HB 12190; monoclonal antibody; CD11b; nonspecific immune system;
 KW adult respiratory distress syndrome; multiple organ injury syndrome;
 KW septicemia; trauma; reperfusion injury; acute glomerulonephritis;
 KW reactive arthritis; dermatosis with acute inflammatory component; stroke;
 KW thermal injury; haemodialysis; leukapheresis; ulcerative colitis;
 KW Crohn's disease; necrotising enterocolitis;
 KW granulocyte transfusion associated syndrome; atherosclerosis;
 KW cytokine-induced toxicity; specific immune system; psoriasis;
 KW organ transplant rejection; autoimmune disease; Raynaud's syndrome;
 KW autoimmune thyroiditis; experimental autoimmune encephalomyelitis; EAE;
 KW multiple sclerosis; rheumatoid arthritis; diabetes; lupus erythematosus;
 KW asthma; tumour growth; metastasis; viral infection; HIV infection;
 KW immunogen; ss; primer; probe.
 XX
 OS Homo sapiens.
 XX
 XX US2003199423-A1.
 XX
 XX 23-OCT-2003.
 XX
 XX 05-JUN-2002; 2002US-00163942.
 XX
 XX 27-JAN-1992; 92US-00827689.

PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 23-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US0000787.
 PR 03-AUG-1993; 93US-00102852.
 PR 07-JUN-1995; 95US-00487113.
 PR 24-AUG-1999; 99US-00382289.
 PR 03-JAN-2001; 2001US-00753436.
 XX (GALL/) GALLATIN W M.
 PA (VAZE/) VAZEUX R.
 XX
 XX Gallatin WM, Vazeux R;
 PI
 XX WPI; 2003-900201/82.
 DR
 XX Hybridoma cell line for production of monoclonal antibodies useful for
 PT treating e.g. asthma and arthritis.
 PT
 XX Example 5; SEQ ID NO 24; 127pp; English.
 XX
 CC The invention relates to a hybridoma cell line ATCC HB 12190 producing a
 CC monoclonal antibody against human intercellular adhesion molecule
 CC polypeptide (ICAM-R). Also included are a monoclonal antibody produced by
 CC the hybridoma cell line, identification of a compound that modulates the
 CC interaction of binding partners intercellular adhesion molecule
 CC polypeptide (ICAM-R) and CD11b (involving; immobilising ICAM-R or CD11b,
 CC detectably labelling the non-immobilised binding partner, contacting the
 CC immobilised binding partner with the labelled binding partner in the
 CC presence and absence of test compound, detecting the label bound to the
 CC immobilised binding partner and identifying a modulating compound as a
 CC test compound that affects the label bound in the presence of the test
 CC compound in comparison to the label bound in the absence of the test
 CC compound) and identification of a compound that modulates phosphorylation
 CC of ICAM-R by protein kinase C isoform (involving: exposing ICAM-R peptide
 CC comprising amino acids 482-518 of ADG25651 to protein kinase C isoform
 CC and labelled phosphate in the presence and absence of a test compound,
 CC measuring labelled phosphate transferred to the ICAM-R peptide and
 CC identifying a test compound that affects transfer of the labelled
 CC phosphate as a modulator compound). The hybridoma cell line ATCC HB 12190
 CC is useful in the production of monoclonal antibodies useful for
 CC identifying compounds and for the treatment of conditions resulting from
 CC a response of the nonspecific immune system in a mammal (e.g. adult
 CC respiratory distress syndrome, multiple organ injury syndrome secondary
 CC to septicemia, multiple organ injury syndrome secondary to trauma,
 CC reperfusion injury of tissue, acute glomerulonephritis, reactive
 CC arthritis, dermatosis with acute inflammatory components, stroke, thermal
 CC injury, haemodialysis, leukapheresis, ulcerative colitis, Crohn's
 CC disease, necrotising enterocolitis, granulocyte transfusion associated
 CC syndrome, atherosclerosis and cytokine-induced toxicity) and conditions
 CC resulting from a response of the specific immune system in a mammal (e.g.
 CC psoriasis, organ/tissue transplant rejection and autoimmune diseases
 CC including Raynaud's syndrome, autoimmune thyroiditis, experimental
 CC autoimmune encephalomyelitis (EAE), multiple sclerosis, rheumatoid
 CC arthritis, diabetes or lupus erythematosus), asthma, tumour growth and/or
 CC metastasis and viral infection (e.g. HIV infection). The monoclonal
 CC antibodies are readily available using immunogens comprising cells
 CC naturally expressing intercellular adhesion molecule polypeptide (ICAM-R)
 CC or its variants and display ligand/receptor binding biological activities
 CC and/or immunological properties specific to ICAM-R. The present sequence
 CC is a primer or probe used in the isolation of nucleic acids encoding
 CC human ICAM-R.
 XX
 SQ Sequence 24 BP; 1 A; 7 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACACGACCCAGGACACTGCA 965

DB 24 GAACACGACCCAGGACACTGCA 1

```

RESULT 48
ABZ95206/c
ID ABZ95206 standard; DNA; 24 BP.
XX AC
XX ABZ95206;
XX DT
XX 17-OCT-2003 (first entry)
XX DE
XX Human ICAM-1 antisense fragment no.1071.
XX KW
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.
XX OS
XX Homo sapiens.
XX PN
XX WO200285308-A2.
XX PD
XX 31-OCT-2002.
XX PF
XX 23-APR-2002; 2002WO-US013135.
XX PR
XX 24-APR-2001; 2001US-0286137P.
XX PA
XX (EPIG-) EPIGENESIS PHARM INC.
XX PI
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX DR
XX Pharmaceutical composition for treating ailments associated with impaired
XX respiration, has oligo(s) antisense to specific gene(s) or its
XX corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX ubiquinone.
XX PS
XX Disclosure; SEQ ID NO 10448; 872pp; English.
XX CC
XX The invention relates to a novel pharmaceutical composition, which has a
XX first active agent comprising an oligonucleotide antisense to the
XX initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX junctions of genes encoding a polypeptide associated with lung and/or
XX nasal airway dysfunction and a second active agent comprising an
XX antiinflammatory steroid and ubiquinone. A composition of the invention
XX has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX immunosuppressive, and cytostatic activity. The composition may have a
XX use in antisense gene therapy. The composition is useful for treating or
XX preventing a respiratory, lung or malignant disease or condition, also
XX for enhancing the prophylactic or therapeutic respiratory effect of an
XX antiinflammatory steroid in a subject, for reducing or depleting levels
XX of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX receptor, producing bronchodilation, increasing levels of ubiquinone or
XX lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX lung inflammation, lung allergies, or a respiratory disease or condition.
XX Note: The sequence data for this patent is not represented in the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX SQ
XX Sequence 24 BP; 0 A; 4 C; 10 G; 10 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 24; DB 1; Length 24;
XX Best Local Similarity 100.0%; Pred. No. 1.6e+02;
XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1626 GAAACCGAACACACAGCCAGCC 1649
DB 24 GAAACCGAACACACAGCCAGCC 1

```

```

RESULT 49
ABD19148/c
ID ABD19148 standard; DNA; 24 BP.
XX AC
XX ABD19148;
XX DT
XX 29-JUL-2004 (first entry)
XX DE
XX Human ICAM-1 DNA fragment 1071.
XX KW
XX Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ds.
XX OS
XX Homo sapiens.
XX PN
XX WO200285309-A2.
XX PD
XX 31-OCT-2002.
XX PF
XX 23-APR-2002; 2002WO-US013143.
XX PR
XX 24-APR-2001; 2001US-0286036P.
XX PA
XX (EPIG-) EPIGENESIS PHARM INC.
XX PI
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX DR
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX PS
XX Claim 15; SEQ ID NO 10448; 763pp; English.
XX CC
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposcretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has antiallergic, antiinflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory
XX distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX hypertension, emphysema, chronic obstructive pulmonary disease, cancer.
XX transplantation rejection, pulmonary infections, bronchitis or cancer.
XX The reduced adenosine content of the anti-sense oligos corresponding to
XX thymidines present in the target RNA serves to prevent the breakdown of
XX the oligonucleotides into products that free adenosine into the system
XX e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to

```

CC prevent any unwanted effects due to it
 XX Sequence 24 BP; 0 A; 4 C; 10 G; 10 T; 0 U; 0 Other;
 SQ Query Match 0.8%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 1.6e+02;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1626 GAAACCGACACACACAGCCACGCC 1649
 DB 24 GAAACCGACACACACAGCCACGCC 1

RESULT 50
 ABQ82716
 ID ABQ82716 standard; DNA; 25 BP.
 XX
 AC ABQ82716;
 XX
 DT 03-JAN-2003 (first entry)
 XX
 XX ICAM-1 mutagenic oligonucleotide #2.
 XX
 XX Intercellular adhesion molecule-1; ICAM-1; virucide; vaccine;
 KW viral infection; rhinoviral infection; mutagenic; ss.
 XX
 OS Synthetic.
 XX
 PN US6436403-B1.
 XX
 PD 20-AUG-2002.
 XX
 PF 07-JUN-1995; 95US-00479557.
 XX
 PR 16-MAR-1989; 89US-00324073.
 PR 22-DEC-1989; 89US-00454292.
 PR 27-APR-1990; 90US-00514033.
 PR 15-OCT-1993; 93US-00136408.
 PR 11-APR-1995; 95US-00420720.
 XX
 PA (BLOO-) CENT BLOOD RES INC.
 XX
 PI Springer TA, Staunton DE;
 XX
 DR WPI; 2002-722107/78.
 XX
 PT Pharmaceutical composition comprising a virus bound to a functional
 PT derivative of intercellular adhesion molecule-1, useful as vaccine for
 PT preventing viral infection, preferably rhinoviral infection in a subject.
 XX
 PS Example 2; Col 20; 37pp; English.
 XX
 CC The present invention describes a pharmaceutical composition (I)
 CC comprising a virus bound to a functional derivative of intercellular
 CC adhesion molecule-1 (ICAM)-1 in a mixture with a pharmaceutically
 CC acceptable carrier, where the functional derivative comprises amino acids
 CC 1-451 of the ICAM-1 amino acid sequence (S1) given in ABP53764, having
 CC homologous domains, followed by a phenylalanine (F). Optionally, (I)
 CC comprises a virus bound to a functional derivative of ICAM-1 in a mixture
 CC with a carrier, where the functional derivative contains an amino acid
 CC substitution chosen from S3/T, K8/E, R13/K, G15/SA, Y52/F, S61/I,
 CC Q62PW/API, M64/I, Y66/T, N68/K, D71/E, S74/A, T75/A, R88V/EA, E90/Q,
 CC L91/A, N118/Q, R125/E, E127/R, K 128/R, V136GE/GVK, N156/E, A178/G,
 CC A189T/SI, D203TQ/TAD and Y452E/F. (I) has virucide activity and can be
 CC used in vaccines. (I) is useful for preventing viral infection in an
 CC individual, preferably rhinoviral infection. The present sequence
 CC represents a mutagenic oligonucleotide for ICAM-1, which is used in an
 CC example from the present invention
 XX
 SQ Sequence 25 BP; 7 A; 10 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 23.4; DB 1; Length 25;
 Best Local Similarity 96.0%; Pred. No. 1.8e+02;
 Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1550 TCAGCACGTACCTCTATACCGCCA 1574
 DB 1 TCAGCACGTACCTCTATACCGCCA 25

RESULT 51
 ADR31134
 ID ADR31134 standard; DNA; 25 BP.
 XX
 AC ADR31134;
 XX
 DT 04-NOV-2004 (first entry)
 XX
 XX Human ICAM-1 mutagenic primer #2.
 DE
 XX ss; viral infection; major serotype rhinovirus;
 KW intercellular adhesion molecule; ICAM-1; antiviral therapy; primer;
 KW mutagenic.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN US6777191-B1.
 XX
 PD 17-AUG-2004.
 XX
 PF 07-JUN-1995; 95US-00474387.
 XX
 PR 16-MAR-1989; 89US-00324073.
 PR 22-DEC-1989; 89US-00454292.
 PR 27-APR-1990; 90US-00514033.
 PR 15-OCT-1993; 93US-00136408.
 PR 11-APR-1995; 95US-00420720.
 XX
 PA (BLOO-) CENT BLOOD RES INC.
 XX
 PI Springer TA, Staunton DE;
 XX
 DR WPI; 2004-623513/60.
 XX
 CC Diagnosing presence of viral infection, by contacting suspected
 CC biological sample with labeled soluble intercellular adhesion molecule-1
 CC functional derivative, and determining presence of complexes of
 CC functional derivative and virus.
 XX
 PS Example 2; Col 20; 37pp; English.
 XX
 CC This invention describes a novel method of diagnosing the presence of
 CC viral infection (especially caused by major serotype rhinovirus). The
 CC method involves contacting a biological sample suspected of containing a
 CC virus with a detectably labelled and soluble intercellular adhesion
 CC molecule (ICAM)-1 functional derivative which forms detectable complexes
 CC of ICAM-1 functional derivative and virus. The soluble functional
 CC derivative of ICAM-1 lacks a transmembrane domain and comprises domains
 CC -2 of ICAM-1, or a variant of domains 1-2 of ICAM-1. The method can be
 CC used for treating viral infection in an individual in need of treatment
 CC by using a functional derivative of ICAM-1, an anti-idiotypic antibody to
 CC anti-ICAM antibody, or antibody to ICAM-1 for antiviral therapy. The
 CC method enables identification of the serotype (or subspecies) of the
 CC virus. This sequence represents a mutagenic primer which introduces the
 CC Y4476TAG mutation which results in a truncated ICAM-1 (Dcyt-).
 XX
 SQ Sequence 25 BP; 7 A; 10 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 23.4; DB 1; Length 25;
 Best Local Similarity 96.0%; Pred. No. 1.8e+02;
 Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1550 TCAGCACGTACCTCTATACCGCCA 1574
 DB 1 TCAGCACGTACCTCTATACCGCCA 25


```

RESULT 52
ADR96971
ID ADR96971 standard; DNA; 25 BP.
XX
AC ADR96971;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human ICAM-1 mutagenic primer #2.
XX
ss: viral infection; major serotype rhinovirus;
KW intercellular adhesion molecule; ICAM-1; antiviral therapy; primer;
KW mutagenic.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN US6797270-B1.
XX
PD 28-SEP-2004.
XX
PF 11-APR-1995; 95US-00420720.
XX
PR 16-MAR-1989; 89US-00324073.
PR 22-DEC-1989; 89US-00454292.
PR 27-APR-1990; 90US-00514033.
PR 15-OCT-1993; 93US-00136408.
XX
PA (BLOO-) CENT BLOOD RES INC.
XX
PI Springer TA, Staunton DE;
XX
DR WPI; 2004-687765/67.
XX
PT Reducing human rhinovirus infectivity in a subject or host cell, by
PT contacting the virus with an intercellular adhesion molecule-1 soluble
PT fragment or administering to the subject a composition comprising the
PT soluble fragment.
XX
PS Example 2; Col 20; 36pp; English.
XX
CC This invention describes a novel method of diagnosing the presence of
CC viral infection (especially caused by major serotype rhinovirus). The
CC method involves contacting a biological sample suspected of containing a
CC virus with a detectably labelled and soluble intercellular adhesion
CC molecule (ICAM)-1 functional derivative which forms detectable complexes
CC of ICAM-1 functional derivative and virus. The soluble functional
CC derivative of ICAM-1 lacks a transmembrane domain and comprises domains 1
CC -2 of ICAM-1, or a variant of domains 1-2 of ICAM-1. The method can be
CC used for treating viral infection in an individual in need of treatment
CC by using a functional derivative of ICAM-1, an anti-idiotypic antibody to
CC anti-ICAM antibody, or antibody to ICAM-1 for antiviral therapy. The
CC method enables identification of the subserotype (or subspecies) of the
CC virus. This sequence represents a mutagenic primer which introduces the
CC Y4476TAG mutation which results in a truncated ICAM-1 (Dcvt-).
XX
SQ Sequence 25 BP; 7 A; 10 C; 4 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.8e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1550 TCAGCAGCTACTCTCTATAACCGCCA 1574
DB 1 TCAGCAGCTACTCTCTAGAACCGCCA 25
XX
RESULT 53
AAT76146/c
ID AAT76146 standard; DNA; 23 BP.
XX

```

```

AC AAT76146;
XX
DT 12-SEP-1997 (first entry)
XX
DE Human intercellular adhesion molecule-1 antisense oligonucleotide.
XX
KW Asthma; airway epithelium; adenosine free; cystic fibrosis;
KW chronic obstructive pulmonary disease; bronchitis; ss.
XX
OS Synthetic.
XX
PN WO9640162-A1.
XX
PD 19-DEC-1996.
XX
PF 06-JUN-1996; 96WO-US009306.
XX
PR 07-JUN-1995; 95US-00474497.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
PI Nyce JW, Metzger WJ;
XX
DR WPI; 1997-051871/05.
XX
PT Treatment of airway diseases such as asthma - by topically applying
PT adenosine-free antisense oligonucleotide to airway epithelium of
PT subject.
XX
PS Claim 5; Page 27; 71pp; English.
XX
CC A method for treating airway disease in a subject has been produced,
CC which involves the topical administration of an essentially adenosine
CC free antisense oligonucleotide (ON) to the airway epithelium of the
CC subject. The present sequence is an antisense oligonucleotide HSCAM1AS4
CC specific for the human intercellular adhesion molecule-1 (CAM-1). The
CC method can be used to treat airway diseases such as cystic fibrosis,
CC asthma, chronic obstructive pulmonary disease, bronchitis and other
CC airway diseases characterised by an inflammatory response. By eliminating
CC adenosine from the antisense ON, its liberation upon antisense
CC degradation is prevented, thereby preventing adenosine- induced
CC bronchoconstriction in patients with hyper-reactive airways
XX
SQ Sequence 23 BP; 0 A; 9 C; 6 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 939 GGGGAACACAGAGCCAGGAGACAC 961
DB 23 GGGGAACACAGAGCCAGGAGACAC 1
XX
RESULT 54
AAT76148/c
ID AAT76148 standard; DNA; 23 BP.
XX
AC AAT76148;
XX
DT 12-SEP-1997 (first entry)
XX
DE Human intercellular adhesion molecule-1 antisense oligonucleotide.
XX
KW Asthma; airway epithelium; adenosine free; cystic fibrosis;
KW chronic obstructive pulmonary disease; bronchitis; ss.
XX
OS Synthetic.
XX
PN WO9640162-A1.
XX
PD 19-DEC-1996.
XX

```

PF 06-JUN-1996; 96WO-US0009306.
 XX
 PR 07-JUN-1995; 95US-00474497.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 PI Nyce JW, Metzger WJ;
 XX WPI; 1997-051871/05.
 XX
 DR
 XX
 XX Treatment of airway diseases such as asthma - by topically applying
 PT adenosine-free antisense oligo:nucleotide to airway epithelium of
 PT subject.
 XX
 XX Claim 5; Page 28; 71pp; English.
 XX
 CC A method for treating airway disease in a subject has been produced,
 CC which involves the topical administration of an essentially adenosine
 CC free antisense oligonucleotide (ON) to the airway epithelium of the
 CC subject. The present sequence is an antisense oligonucleotide HSICAM1A56
 CC specific for the human intercellular adhesion molecule-1 (ICAM-1). The
 CC method can be used to treat airway diseases such as cystic fibrosis,
 CC asthma, chronic obstructive pulmonary disease, bronchitis and other
 CC airway diseases characterised by an inflammatory response. By eliminating
 CC adenosine from the antisense ON, its liberation upon antisense
 CC degradation is prevented, thereby preventing adenosine- induced
 CC bronchoconstriction in patients with hyper-reactive airways
 XX
 SQ Sequence 23 BP; 0 A; 6 C; 8 G; 9 T; 0 U; 0 Other;
 Query Match 0.8%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1203 ACACAGAACCCAGCCGGGAGC 1225
 Db 23 ACACAAGAACCCAGCCGGGAGC 1
 RESULT 55
 AAX53943/C
 ID AAX53943 standard; DNA; 23 BP.
 AC AAX53943;
 XX
 XX 05-JUL-1999 (first entry)
 DT
 XX Intercellular adhesion molecule-1 (ICAM-1) antisense oligonucleotide.
 DE
 KW Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impeded respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 XX
 XX Synthetic.
 OS
 XX WO9913886-A1.
 PN
 XX
 XX 25-MAR-1999.
 PD
 XX
 XX 17-SEP-1998; 98WO-US019419.
 PF
 XX
 XX 17-SEP-1997; 97US-0059160P.
 PR
 XX 09-JUN-1998; 98US-00093972.
 XX
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX

PI Nyce JW;
 XX
 DR WPI; 1999-229400/19.
 XX
 PT New antisense oligonucleotides used in treatment of, e.g. pulmonary
 PT vasoconstriction.
 XX
 XX Disclosure; Page 47; 120pp; English.
 XX
 CC The specification describes antisense oligonucleotides (AAX52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene initiation
 CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-
 CC end and the juxta-section between coding and non-coding regions and all
 CC segments of RNAs encoding proteins associated with one or more diseases,
 CC conditions or mixtures. The antisense oligonucleotides may be derived
 CC from sequences AAX5272-74. These multiple target oligonucleotides
 CC (specifically AAX55180-271) can be used for the antisense treatment of
 CC diseases and conditions. Typical diseases and conditions are those
 CC associated with impaired respiration and inflammation, including lung
 CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
 CC acute asthma, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
 CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
 CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
 CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
 CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
 CC well as all types of cancers which may metastasize or have metastasized
 CC to the lungs, including breast and prostate cancer
 XX
 SQ Sequence 23 BP; 0 A; 9 C; 6 G; 8 T; 0 U; 0 Other;
 Query Match 0.8%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 939 GGGGAACCCAGAGCCAGGAGACAC 961
 Db 23 GGGGAACCCAGAGCCAGGAGACAC 1
 RESULT 56
 AAX53945/C
 ID AAX53945 standard; DNA; 23 BP.
 AC AAX53945;
 XX
 XX 05-JUL-1999 (first entry)
 DT
 XX Intercellular adhesion molecule-1 (ICAM-1) antisense oligonucleotide.
 DE
 KW Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impeded respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 XX
 XX Synthetic.
 OS
 XX WO9913886-A1.
 PN
 XX
 XX 25-MAR-1999.
 PD
 XX
 XX 17-SEP-1998; 98WO-US019419.
 PF
 XX
 XX 17-SEP-1997; 97US-0059160P.
 PR
 XX 09-JUN-1998; 98US-00093972.
 XX
 XX

```
PA (UYEC-) UNIV EAST CAROLINA.
XX
XX
PI Nyce JW;
XX
XX WPI; 1999-229400/19.
XX
XX New antisense oligonucleotides used in treatment of, e.g. pulmonary
PT vasoconstriction.
XX
XX
PS Disclosure; Page 47; 120pp; English.
XX
XX The specification describes antisense oligonucleotides (AA52869-X55271)
CC directed against at least 2 mRNAs selected from target genes, coding and
CC non-coding regions of RNAs corresponding to target genes, gene initiation
CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-
CC end and the juxta-section between coding and non-coding regions and all
CC segments of RNAs encoding proteins associated with one or more diseases,
CC conditions or mixtures. The antisense oligonucleotides may be derived
CC from sequences AA5272-74. These multiple target oligonucleotides
CC (specifically AA55180-271) can be used for the antisense treatment of
CC diseases and conditions. Typical diseases and conditions are those
CC associated with impaired respiration and inflammation, including lung
CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
CC acute asthma, allergies, asthma, impaired respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
CC well as all types of cancers which may metastasize or have metastasized
CC to the lungs, including breast and prostate cancer
XX
XX Sequence 23 BP; 0 A; 6 C; 8 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 23; DB 1; Length 23;
XX Best Local Similarity 100.0%; Pred. No. 2.2e+02;
XX Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1203 ACACAAGAACCCAGACCCGGGAGC 1225
DB 23 ACACAAGAACCCAGACCCGGGAGC 1
RESULT 57
AA33388/c
XX ID AAA33388 standard; DNA; 23 BP.
XX AC AAA33388;
XX
XX 28-JUL-2000 (first entry)
XX
XX Low adenosine antisense oligonucleotide SEQ ID NO:1077.
XX
XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
XX phosphorothioate; impaired respiration; inflammation; allergy;
XX allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
XX antiallergic; antiasthmatic; cyostatic; analgesic; impaired airway;
XX lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
XX respiratory distress syndrome; pain; cystic fibrosis; emphysema;
XX pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
XX cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
XX Homo sapiens.
XX
XX WO200009525-A2.
XX
XX 24-FEB-2000.
XX
XX 03-AUG-1999; 99WO-US017712.
XX
XX 03-AUG-1998; 98US-0095212P.
XX
XX (UYEC-) UNIV EAST CAROLINA.
PA
```

```
XX
XX
XX Nyce JW;
XX
XX WPI; 2000-205971/18.
XX
XX New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers.
XX
XX Claim 18; Page 400; 1343pp; English.
XX
XX The present invention describes a new composition comprising an antisense
CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antiasthmatic, cyostatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
CC impaired respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,
CC carcinomas, and cancers which may metastasize to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of the
CC ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
CC AAA33992) are specifically claimed ONs from the present invention. N.B.
CC Sequences given in the disclosure of the present invention do not match
CC up with their corresponding SEQ ID NO: sequences given in the sequence
XX listing
XX
XX Sequence 23 BP; 0 A; 6 C; 8 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 23; DB 1; Length 23;
XX Best Local Similarity 100.0%; Pred. No. 2.2e+02;
XX Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1203 ACACAAGAACCCAGACCCGGGAGC 1225
DB 23 ACACAAGAACCCAGACCCGGGAGC 1
RESULT 58
AA33386/c
XX ID AAA33386 standard; DNA; 23 BP.
XX AC AAA33386;
XX
XX 28-JUL-2000 (first entry)
XX
XX Low adenosine antisense oligonucleotide SEQ ID NO:1075.
XX
XX Human; adenosine receptor; low adenosine antisense oligonucleotide;
XX phosphorothioate; impaired respiration; inflammation; allergy;
XX allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
XX antiallergic; antiasthmatic; cyostatic; analgesic; impaired airway;
XX lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
XX respiratory distress syndrome; pain; cystic fibrosis; emphysema;
XX pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
XX cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
XX Homo sapiens.
XX
XX WO200009525-A2.
XX
XX 24-FEB-2000.
XX
```

```
XX PF 03-AUG-1999; 99WO-US017712.
XX PR 03-AUG-1998; 98US-0095212P.
XX PA (UYEC-) UNIV EAST CAROLINA.
XX PI Nyce JW;
XX DR WPI; 2000-205971/18.
XX PR New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers.
XX PS Claim 18; Page 399; 1343pp; English.
XX CC The present invention describes a new composition comprising an antisense
CC oligonucleotide (ON) with low adenine (up to 15%), which targets
CC nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antiasthmatic, cytostatic and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
CC impeded respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC carcinomas, and cancers which may metastasize to the lungs, including
CC breast and prostate cancer. The reduction of the adenine content of the
CC ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA32313 to AAA3512 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
CC AAA33992) are specifically claimed ONs from the present invention. N.B.
CC Sequences given in the disclosure of the present invention do not match
CC up with their corresponding SEQ ID NO: sequences given in the sequence
CC listing
XX SQ Sequence 23 BP; 0 A; 9 C; 6 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 939 GGGGAACCCAGAGCCAGGAGACAC 961
DB 23 GGGGAACCCAGAGCCAGGAGACAC 1
|||||

RESULT 59
AAF19508/C
ID AAF19508 standard; DNA; 23 BP.
AC AAF19508;
XX
XX 14-MAR-2001 (first entry)
XX Human ICAM-1 polynucleotide fragment #1075.
XX
XX Low adenine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory bronchodilator; antiinflammatory;
KW immunosuppressive; antiaesthetic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW
```

```
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
cancer; ss.
XX
XX Homo sapiens.
XX PN WO200062736-A2.
XX PD 26-OCT-2000.
XX PF 24-MAR-2000; 2000WO-US008020.
XX PR 06-APR-1999; 99US-0127958P.
XX PA (UYEC-) UNIV EAST CAROLINA.
XX PI (NYCE/) NYCE J W.
XX PI Nyce JW;
XX WPI; 2000-679539/66.
XX Low adenine (A) content antisense oligonucleotides which do not trigger
PT adenosine receptors during metabolism, useful e.g. for treating cancers
PT and respiratory obstructions.
XX Claim 14; Page 145; 1592pp; English.
XX The present invention describes low adenine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiaesthetic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and/or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
CC surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of
CC the present invention
XX SQ Sequence 23 BP; 0 A; 9 C; 6 G; 8 T; 0 U; 0 Other;

Query Match 0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 939 GGGGAACCCAGAGCCAGGAGACAC 961
DB 23 GGGGAACCCAGAGCCAGGAGACAC 1
|||||

RESULT 60
AAF19510/C
ID AAF19510 standard; DNA; 23 BP.
XX
XX AAF19510;
XX
```

DT 14-MAR-2001 (first entry)
XX Human ICAM-1 polynucleotide fragment #1077.
DE
XX
XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
KW respiratory obstruction; pulmonary vasoconstriction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW Cancer; ss.
XX
XX Homo sapiens.
XX WO200062736-A2.
XX 26-OCT-2000.
XX 24-MAR-2000; 2000WO-US008020.
XX 06-APR-1999; 99US-0127958P.
XX (UYEC-) UNIV EAST CAROLINA.
PA (NYCE/) NYCE J W.
XX
XX Nyce JW;
XX WPI; 2000-679539/66.
XX
XX Low adenosine (A) content antisense oligonucleotides which do not trigger
PT adenosine receptors during metabolism, useful e.g. for treating cancers
PT and respiratory obstructions.
XX
XX Claim 14; Page 145; 1592pp; English.
XX
XX The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
CC surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of
CC the present invention
XX
XX Sequence 23 BP; 0 A; 6 C; 8 G; 9 T; 0 U; 0 Other;

Query Match 0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1203 ACACAGAACCCAGACCCGGGAGC 1225
DB 23 ACACAGAACCCAGACCCGGGAGC 1
RESULT 61
ABZ95204/c
ID ABZ95204 standard; DNA; 23 BP.
XX
XX AC ABZ95204;
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM-1 antisense fragment no.1069.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
XX WO200285308-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
XX 24-APR-2001; 2001US-0286137P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 10446; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 23 BP; 0 A; 6 C; 8 G; 9 T; 0 U; 0 Other;

Query Match 0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1203 ACACAGAACCCAGACCCGGGAGC 1225
 ID ABZ95202/c
 XX ABZ95202 standard; DNA; 23 BP.
 AC ABZ95202;
 XX 17-OCT-2003 (first entry)
 DT Human ICAM-1 antisense fragment no.1067.
 XX Human; antisense; lung dysfunction; nasal airway dysfunction;
 XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX Homo sapiens.
 OS WO200285308-A2.
 XX 31-OCT-2002.
 XX 23-APR-2002; 2002WO-US013135.
 PF 24-APR-2001; 2001US-0286137P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-229219/22.
 DR Pharmacuetical composition for treating ailments associated with impaired
 XX respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX Disclosure; SEQ ID NO 10444; 872pp; English.

QY 939 GGGGAACCCAGACCCGGGAGC 961
 ID ABD19144/c
 XX ABD19144 standard; DNA; 23 BP.
 AC ABD19144;
 XX 29-JUL-2004 (first entry)
 DT Human ICAM-1 DNA fragment 1067.
 XX Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ds.
 XX Homo sapiens.
 OS WO200285309-A2.
 XX 31-OCT-2002.
 XX 23-APR-2002; 2002WO-US013143.
 PF 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR Pharmacuetical composition for treating asthma, has antisense
 XX oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 10444; 763pp; English.

RESULT 62
 ABD19144/c
 ID ABD19144 standard; DNA; 23 BP.
 XX ABD19144;
 AC ABD19144;
 XX 29-JUL-2004 (first entry)
 DT Human ICAM-1 DNA fragment 1067.
 XX Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ds.
 XX Homo sapiens.
 OS WO200285308-A2.
 XX 31-OCT-2002.
 XX 23-APR-2002; 2002WO-US013135.
 PF 24-APR-2001; 2001US-0286137P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-229219/22.
 DR Pharmacuetical composition for treating ailments associated with impaired
 XX respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX Disclosure; SEQ ID NO 10444; 872pp; English.

Claim 15; SEQ ID NO 10444; 763pp; English.
 This invention describes a novel composition (a) a first active agent,
 comprising oligonucleotides, effective for alleviating
 bronchoconstriction, respiratory tract inflammation, allergies and
 reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 surfactant depletion or hyposcretion, when administered to a mammal. The
 oligonucleotides are derived from a gene encoding or regulating
 expression of a target polypeptide associated with lung airway or lung
 dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 The invention also describes a kit, that comprises: (a) a delivery
 device, in separate containers, (b) the oligonucleotides, (c)
 instructions for adding a carrier and for use of the kit. The composition
 of the invention has antiallergic, antiinflammatory, antiasthmatic,
 analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 beta-adrenergic agonist. The composition is useful for preventing or
 treating a respiratory, lung or malignant disease. The administered
 composition comprises oligo and is administered to reduce the production
 or availability, or to increase the degradation of the target mRNA or to
 reduce the amount of target polypeptide present in the lungs. The
 pulmonary obstruction, and/or bronchoconstriction and/or lung
 inflammation, allergies and/or surfactant hypoproduction are associated
 with a disease or condition such as pulmonary vasoconstriction,
 inflammation, allergies, asthma, impeded respiration, respiratory
 distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

Sequence 23 BP; 0 A; 9 C; 6 G; 8 T; 0 U; 0 Other;
 Query Match 0.8%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 23 BP; 0 A; 9 C; 6 G; 8 T; 0 U; 0 Other;
 Query Match 0.8%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 939 GGGGACCCAGAGCAGACAC 961
 DB 23 GGGGACCCAGAGCAGACAC 1
 RESULT 64
 ABD19146/c
 ID ABD19146 standard; DNA; 23 BP.
 AC ABD19146;
 XX
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-1 DNA fragment 1069.
 XX
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ds.
 XX
 XX Homo sapiens.
 OS
 XX WO200285309-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIC-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shanabuddin S;
 XX
 XX WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 10446; 763pp; English.
 PS
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,

CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 23 BP; 0 A; 6 C; 8 G; 9 T; 0 U; 0 Other;
 Query Match 0.8%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1203 ACACAAGAACCCAGACCCGGGAGC 1225
 DB 23 ACACAAGAACCCAGACCCGGGAGC 1
 RESULT 65
 ADJ76669
 ID ADJ76669 standard; DNA; 23 BP.
 XX
 AC ADJ76669;
 XX
 DT 20-MAY-2004 (first entry)
 XX
 XX ICAM1 forward PCR primer SEQ ID NO:1921.
 DE
 XX bronchial asthma; chronic obstructive pulmonary disease;
 KW respiratory epithelial cell; interleukin-13; respiratory; antiasthmatic;
 KW gene therapy; marker; PCR; primer; ss.
 XX
 XX Homo sapiens.
 OS
 XX Synthetic.
 XX
 XX EP1394274-A2.
 PN
 XX 03-MAR-2004.
 PD
 XX 04-AUG-2003; 2003EP-00254857.
 PF
 XX 06-AUG-2002; 2002JP-00229312.
 PR 20-MAR-2003; 2003JP-00077212.
 XX
 XX (GENO-) GENOX RES INC.
 PA
 XX Ohtani N, Sugita Y, Yamaya M, Kubo H, Nagai H, Izuwara K;
 PI WPI; 2004-193155/19.
 DR
 XX Testing for bronchial asthma or chronic obstructive pulmonary disease by
 PT comparing the expression level of a marker gene in a biological sample
 PT from a subject with the expression level of the gene in a sample from a
 PT healthy subject.
 XX
 XX Example 11; SEQ ID NO 1921; 241pp; English.
 PS
 XX The present invention describes a method of testing for bronchial asthma
 CC or chronic obstructive pulmonary disease. The method comprises
 CC determining the expression level of a marker gene in a biological sample
 CC from a subject, comparing the expression level determined with the

expression level of the marker gene in a biological sample from a healthy subject, and judging whether the subject has bronchial asthma or chronic obstructive pulmonary disease. The marker gene comprises: (a) a group of genes (S1) whose expression levels increase when respiratory epithelial cells are stimulated with interleukin-13; or (b) a group of genes (S2) whose expression levels decrease when respiratory epithelial cells are stimulated with interleukin-13. Also described: (1) a reagent (I) for testing for bronchial asthma or chronic obstructive pulmonary disease; (2) a kit for screening for a candidate compound for a therapeutic agent to treat bronchial asthma or chronic obstructive pulmonary disease; (3) an animal model for bronchial asthma or chronic obstructive pulmonary disease; (4) an inducer that induces bronchial asthma in a mouse; (5) a method for producing an animal model for bronchial asthma or chronic obstructive pulmonary disease; (6) a therapeutic agent for bronchial asthma or chronic obstructive pulmonary disease, comprising the compound, a marker gene or an antisense nucleic acid corresponding to a portion of the marker gene, a ribozyme, a polynucleotide that suppresses the expression of the gene through an RNAi effect or an antibody recognising a protein encoded by a marker gene; and (7) a DNA chip for testing for bronchial asthma or a chronic obstructive pulmonary disease, on which a probe has been immobilised to assay a marker gene. (I) has respiratory and antiasthmatic activities, and can be used in gene therapy. The method is useful for testing for or screening for a therapeutic agent for bronchial asthma or chronic obstructive pulmonary disease. The present sequence is used in the exemplification of the present invention.

Sequence 23 BP; 5 A; 4 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 918 GCTGACGTGTCAGTATCTGG 940
Db 1 GCTGACGTGTCAGTATCTGG 23

RESULT 66

ADP45898/c
ID ADP45898 standard; DNA; 23 BP.

AC ADP45898;

26-AUG-2004 (first entry)

Extend primer 95 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.

breast cancer; cytostatic; gene therapy; human;
intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
CD54; cell surface glycoprotein P3.58; ICAM-4;
Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
ss; primer; PCR; SNP; single nucleotide polymorphism; probe.

Homo sapiens.

WO2004047623-A2.

10-JUN-2004.

25-NOV-2003; 2003WO-US037948.

25-NOV-2002; 2002US-0429136P.

24-JUL-2003; 2003US-0490234P.

(SEQU-) SEQUENOM INC.

Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;

WPI; 2004-441051/41.

Identifying a subject at risk of breast cancer by detecting the presence of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE regions which are associated with breast cancer in a nucleic acid sample

PT from a subject.

XX Example 4; Page 87; 289pp; English.

XX The invention relates to a novel method for identifying a subject at risk of breast cancer comprising detecting the presence or absence of one or more polymorphic variations associated with breast cancer in a nucleic acid sample from a subject. The method of the invention has cytostatic applications and may be useful for identifying a subject at risk of breast cancer, for early diagnosis, prevention and treatment of breast cancer, possibly via gene therapy, as well as to analyse and predict a response to a breast cancer treatment and in clinical drug trials. The current sequence is that of an Extend primer (also described as probe) of the invention which was used to genotype human intercellular adhesion molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor; BB2; CD54; cell surface glycoprotein P3.58) has been mapped to chromosome 19p13.3-p13.2, ICAM-4 (Landsteiner-Wiener blood group; LW) has been mapped to chromosome 19p13.2-cen and ICAM-5 (telencephalin) has been mapped to chromosome 19p13.2.

Sequence 23 BP; 3 A; 9 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 23; DB 1; Length 23;

Best Local Similarity 100.0%; Pred. No. 2.2e+02;

Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1113 GAGGGCCCGAGCTCTCTGAAGG 1135

Db 23 GAGGGCCCGAGCTCTCTGAAGG 1

RESULT 67

ADQ14963

ID ADQ14963 standard; DNA; 23 BP.

AC ADQ14963;

07-OCT-2004 (first entry)

CD54 probe seqid 87.

multifunctional oligomeric compound; RNA expression modulator;
double-stranded oligomeric compound; CD54; probe; ss.

Homo sapiens.

US2004137471-A1.

15-JUL-2004.

18-SEP-2003; 2003US-00664639.

18-SEP-2002; 2002US-0411780P.

(VICK/) VICKERS T.

(KOOS/) KOO S.

(BENN/) BENNETT C P.

(CROO/) CROOKE S T.

(DEAN/) DEAN N M.

(BAKE/) BAKER B F.

Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;

WPI; 2004-533354/51.

Identifying a multifunctional oligomeric compound to modulate expression of RNA comprises identifying an inhibiting antisense strand and inhibiting double-stranded oligomeric compound as multifunctional oligomeric compounds.

Example 2; SEQ ID NO 87; 55pp; English.

The invention describes a method of identifying a multifunctional

CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a probe used to detect DNA encoding c-rat to
 CC determine RNA levels following multifunctional oligomeric compound
 CC manipulation.

XX SQ Sequence 23 BP; 6 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 23; DB 1; Length 23;
 Best Local Similarity 100.0%; Pred. No. 2.2e+02;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 265 CTCCTGCTGGGAACACCGGAA 287
 |||||
 Db 1 CTCCTGCTGGGAACACCGGAA 23

RESULT 68
 AD194387/c
 ID AD194387 standard; DNA; 24 BP.
 XX
 AC AD194387;
 XX
 DT 04-NOV-2004 (first entry)
 XX
 DE Human ICAM-associated primer SEQ ID 1697.
 XX
 KW functional domain; nucleic acid cleavage assay; nuclease; polymerase;
 KW detection; microorganism; RNA genome; hepatitis C;
 KW human immunodeficiency virus; ss; primer.

OS Homo sapiens.
 XX WO200190337-A2.
 XX
 PN 29-NOV-2001.
 PD
 XX 24-MAY-2001; 2001WO-US017086.
 XX
 PF 24-MAY-2000; 2000US-00577304.
 XX
 PR 11-JAN-2001; 2001US-00758282.
 PR
 PR 24-MAY-2001; 2001US-00864426.
 PR
 PR 24-MAY-2001; 2001US-00864636.
 XX
 XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
 PA
 XX Allawi H, Bartholomay CT, Chehak L, Curtis ML, Eis PS, Hall JG;
 PI

PI Ip HS, Kaiser M, Kwiatkowski RW, Lukowiak AA, Lyamichev V, Ma W;
 PI Olson-Munoz MC, Olson SM, Schaefer JJ, Skrzypczynski Z, Takova TY;
 PI Vedvik KL, Lyamichev NE, Neri BP;
 XX WPI; 2002-083110/11.
 DR
 XX Composition comprising enzyme which comprises heterologous functional
 PT domain that provides altered functionality in nucleic acid cleavage
 PT assay, useful for cleaving nucleic acid, and detecting presence of RNA
 PT target.
 XX
 XX Claim 95; SEQ ID NO 1697; 1266pp; English.
 PS
 XX This invention describes a novel composition comprising an enzyme which
 CC contains a heterologous functional domain that provides altered
 CC functionality in a nucleic acid cleavage assay. The enzyme comprises a 5'
 CC nuclease, preferably a thermostable 5' nuclease, or a polymerase which is
 CC altered in sequence related to a naturally occurring sequence of a
 CC polymerase such that it exhibits reduced DNA synthetic activity from that
 CC of the naturally occurring polymerase. Preferably the polymerase is a
 CC thermostable polymerase from a Thermus species such as T. aquaticus, T.
 CC flavus, T. thermophilus, T. filiformis or T. scotoductus. The enzyme
 CC comprises a heterologous functional domain, an amino acid sequence that
 CC provides an improved substrate binding activity in the nucleic acid
 CC cleavage assay and an amino acid sequence that provides improved
 CC background specificity in the nucleic acid cleavage assay. The invasive
 CC cleavage structure comprises a RNA target nucleic acid (a cytochrome
 CC P450, or cytokine RNA). Cleavage of the invasive cleavage structure
 CC generates a non-target cleavage product, which is then detected by
 CC detecting fluorescence, mass or fluorescence energy transfer or by
 CC detecting radioactivity luminescence, phosphorescence, fluorescence
 CC polarisation or charge. The enzyme is useful for cleaving a nucleic acid
 CC which involves exposing a sample (a cell lysate) comprising substrate
 CC nucleic acid to the enzyme which produces at least one detectable
 CC cleavage product. The enzyme is employed for detecting target DNAs and
 CC RNAs comprising wild-type and mutant alleles of genes including genes
 CC from humans, other animal or plant that are or may be associated with
 CC disease or other conditions. In addition, the enzymes may be useful for
 CC detecting and identifying strains of microorganisms including bacteria,
 CC fungi, protozoa, ciliates and viruses, preferably detecting and
 CC identifying viruses having RNA genomes, such as hepatitis C and human
 CC immunodeficiency virus.

XX SQ Sequence 24 BP; 4 A; 5 C; 11 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 23; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1645 ACGCCTCCTGACCTATCCCGG 1667
 |||||
 Db 23 ACGCCTCCTGACCTATCCCGG 1

RESULT 69
 ABL57035
 ID ABL57035 standard; DNA; 25 BP.
 XX
 AC ABL57035;
 XX
 DT 22-JUL-2002 (first entry)
 XX
 DE ICAM-1 mutagenic primer.
 XX
 KW Intercellular adhesion molecule-1; ICAM-1; human; LFA-1;
 KW lymphocyte function-associated antigen-1; inflammation; antiinflammatory;
 KW tumour; metastasis; antitumour; primer; mutagenesis; ss.
 XX
 OS Synthetic.
 XX
 XX US6358510-B1.
 PN
 XX 19-MAR-2002.
 PD

XX PF 07-JUN-1995; 95US-00479763.
 XX PR 04-MAY-1987; 87US-00045963.
 XX PR 02-NOV-1987; 87US-00115798.
 XX PR 16-FEB-1988; 88US-00155943.
 XX PR 03-MAY-1988; 88US-00189915.
 XX PR 28-SEP-1988; 88US-00250446.
 XX PR 16-MAR-1989; 89US-00324481.
 XX PR 30-JUN-1989; 89US-00373882.
 XX PR 22-DEC-1989; 89US-00456647.
 XX PR 27-APR-1990; 90US-00515478.
 XX PR 25-JAN-1994; 94US-00186456.
 XX (DAND) DANA FARBER CANCER INST INC.
 XX PA Springer TA, Dustin ML, Rothlein R, Marlin SD;
 XX PI WPI; 2002-302950/34.
 XX DR Novel derivatives of intracellular adhesion molecule-1 (ICAM-1) with
 XX PT altered ability to bind lymphocyte function-associated antigen-1 (LFA-1).
 XX PT
 XX PS Example 32; Col 64; 72pp; English.
 XX
 XX The present sequence is that of a mutagenic primer used to generate a
 XX CC truncated functional derivative of human intercellular adhesion molecule-
 XX CC 1 (ICAM-1) lacking the cytoplasmic domains, but containing the
 XX CC transmembrane domain and the extracellular region possessing all 5
 XX CC immunoglobulin-like domains. The primer was used to transform the codon
 XX CC for amino acid Tyr-476 to a TAG stop codon. The mutant protein, designed
 XX CC Y476TAG, was produced in COS cells. Functional derivatives of ICAM-1 (see
 XX CC ABB76147), comprising a soluble fragment of ICAM-1 containing a specific
 XX CC amino acid substitution, are claimed. These have an altered ability to
 XX CC bind lymphocyte function-associated antigen-1 (LFA-1). The invention
 XX CC provides methods for using ICAM-1, its functional derivatives, and
 XX CC antibodies, for the treatment and diagnosis of inflammation,
 XX CC haematopoietic tumour cell metastasis, and ICAM-1-expressing tumours
 XX
 XX Sequence 25 BP; 6 A; 10 C; 4 G; 4 T; 0 U; 1 Other;
 XX
 XX Query Match 0.8%; Score 23; DB 1; Length 25;
 XX Best Local Similarity 92.0%; Pred. No. 2e+02;
 XX Matches 23; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX QY 1550 TCAGCAGTACCTCTATACCGCCA 1574
 XX Db ||||| :|||||
 XX 1 TCAGCAGTACCTCTAGMACCGCCA 25
 XX
 XX RESULT 70
 XX ACF05122/c
 XX ID ACF05122 standard; DNA; 24 BP.
 XX AC ACF05122;
 XX XX
 XX DT 06-NOV-2003 (first entry)
 XX XX
 XX DE Human genomic DNA primer Alu.
 XX XX
 XX KW Human; alphoid; immunodeficiency virus; HIV; anti-HIV; latency; PCR;
 XX KW primer; ss.
 XX OS Homo sapiens.
 XX XX
 XX PN WO2003054160-A2.
 XX XX
 XX PD 03-JUL-2003.
 XX XX
 XX PF 18-DEC-2002; 2002WO-US040698.
 XX XX
 XX PR 19-DEC-2001; 2001US-0341727P.
 XX XX

PA (REGC) UNIV CALIFORNIA.
 XX PI Verdin E, Jordan A;
 XX DR WPI; 2003-577369/54.
 XX
 XX Novel isolated cells that comprise transcription competent
 XX PT immunodeficiency virus e.g. HIV-1, or immunodeficiency virus-based
 XX PT retroviral vector integrated into its genome, useful for identifying
 XX PT latent HIV activators.
 XX XX
 XX Example 1; Page 33; 71pp; English.
 XX
 XX The present sequence is that of primer Alu (EVI255) for human genomic
 XX CC DNA. This primer was used with primer A (see ACC05121) in alphoid PCR
 XX CC amplifications that demonstrated preferential HIV integration in or near
 XX CC alphoid DNA in latently infected Jurkat cells. The invention provides
 XX CC isolated cells that harbour a latent immunodeficiency virus that is
 XX CC transcription competent, that can be reactivated, and that is an in vitro
 XX CC model for latent HIV infection in vivo. The cells are useful for
 XX CC investigating the nature of latency, and also in drug screening assays to
 XX CC identify agents that activate latent HIV. Such agents are useful for
 XX CC reducing the reservoir of latent HIV. Methods are provided of treating an
 XX CC immunodeficiency virus infection
 XX
 XX Sequence 24 BP; 4 A; 7 C; 9 G; 4 T; 0 U; 0 Other;
 XX
 XX Query Match 0.8%; Score 22.4; DB 1; Length 24;
 XX Best Local Similarity 95.8%; Pred. No. 2.4e+02;
 XX Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 XX QY 2844 CCTCAGCCTCCTGAGTAGCTGGGA 2867
 XX Db ||||| :|||||
 XX 24 CCTCAGCCTCCGAGTAGCTGGGA 1
 XX
 XX RESULT 71
 XX ACF35685/c
 XX ID ACF35685 standard; DNA; 24 BP.
 XX AC ACF35685;
 XX XX
 XX DT 13-OCT-2003 (first entry)
 XX XX
 XX DE Human TGNP promoter amplifying forward primer.
 XX XX
 XX KW Trans-Golgi network integral membrane protein; TGNP; chromosome 2p11.2;
 XX KW cytosolic; antiinflammatory; immunomodulator; neuroprotective; human;
 XX KW neutropic; gene therapy; PCR; primer; ss.
 XX XX
 XX OS Homo sapiens.
 XX XX
 XX PN WO2003050302-A2.
 XX XX
 XX PD 19-JUN-2003.
 XX XX
 XX PF 13-DEC-2002; 2002WO-GB005670.
 XX XX
 XX PR 13-DEC-2001; 2001GB-00029846.
 XX XX
 XX PA (EIRX-) EIRX THERAPEUTICS LTD.
 XX XX
 XX PI Hayes I, Cotter T, Murphy F, Seery L;
 XX XX
 XX DR WPI; 2003-532920/50.
 XX
 XX Detecting apoptosis in a cell, useful for treating cancer, an
 XX PT inflammatory disease, an autoimmune disease or a neurodegenerative
 XX PT disease, comprises detecting a decrease in TGNP activity or expression.
 XX XX
 XX Example 11; Page 80; 110pp; English.
 XX
 XX The invention relates to detecting apoptosis in a cell. The method

CC involves detecting a decrease in trans-Golgi network integral membrane
 CC protein (TGNP) activity or expression by detecting the decrease in TGNP
 CC polypeptide or its homologue, a nucleic acid encoding the polypeptide, a
 CC nucleic acid that hybridizes under stringent conditions to the
 CC aforementioned nucleic acid, or their complements. The method,
 CC polypeptides, nucleic acids and modulators are useful for treating
 CC cancer, an inflammatory disease, an autoimmune disease or a
 CC neurodegenerative disease. The present sequence represents a PCR primer
 CC for amplifying the human TGNP promoter
 XX
 SQ Sequence 24 BP; 6 A; 6 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 22.4; DB 1; Length 24;
 Best Local Similarity 95.8%; Pred. No. 2.4e+02;
 Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2763 CTCTGTCAACCCAGGCTGGAGTGCA 2786
 |||||
 Db 24 CTCTGTCAACCCAGGCTGGAGTGCA 1

RESULT 72
 AAT76144/c
 ID AAT76144 standard; DNA; 22 BP.
 XX
 AC AAT76144;
 XX
 DT 12-SEP-1997 (first entry)
 XX
 DE Human intercellular adhesion molecule-1 antisense oligonucleotide.
 XX
 KW Asthma; airway epithelium; adenosine free; cystic fibrosis;
 KW chronic obstructive pulmonary disease; bronchitis; ss.
 XX
 OS Synthetic.
 XX
 PN WO9640162-A1.
 XX
 PD 19-DEC-1996.
 XX
 PF 06-JUN-1996; 96WO-US009306.
 XX
 PR 07-JUN-1995; 95US-00474497.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 PI Nyce JW, Metzger WJ;
 XX
 DR WPI; 1997-051871/05.
 XX

PT Treatment of airway diseases such as asthma - by topically applying
 PT adenosine-free antisense oligonucleotide to airway epithelium of
 PT subject.
 XX
 PS Claim 5; Page 27; 71pp; English.
 XX
 CC A method for treating airway disease in a subject has been produced,
 CC which involves the topical administration of an essentially adenosine
 CC free antisense oligonucleotide (ON) to the airway epithelium of the
 CC subject. The present sequence is an antisense oligonucleotide HSTCAM1A51
 CC specific for the human intercellular adhesion molecule-1 (CAM-1). The
 CC method can be used to treat airway diseases such as cystic fibrosis,
 CC asthma, chronic obstructive pulmonary disease, bronchitis and other
 CC airway diseases characterised by an inflammatory response. By eliminating
 CC adenosine from the antisense ON, its liberation upon antisense
 CC degradation is prevented, thereby preventing adenosine-induced
 CC bronchoconstriction in patients with hyper-reactive airways
 XX
 SQ Sequence 22 BP; 0 A; 6 C; 14 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 3e+02;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 64 CCAGCAGCCCCCGCGCGCGC 85
 |||||
 Db 22 CCAGCAGCCCCCGCGCGCGC 1

RESULT 73
 AAV38622/c
 ID AAV38622 standard; DNA; 22 BP.
 XX
 AC AAV38622;
 XX
 DT 13-OCT-1998 (first entry)
 XX
 DE Human ICAM-1, E-selectin, VCAM-1 antisense oligonucleotide.

XX
 KW ICAM-1; intracellular adhesion molecule-1; E-selectin; VCAM-1;
 KW vascular cell adhesion molecule-1; antisense; inflammatory; disease;
 KW treatment; septic shock; psoriasis; wounds; burns; acne; arthritis;
 KW organ rejection; inhibition; expression; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9824797-A1.
 XX
 PD 11-JUN-1998.
 XX
 PF 02-DEC-1996; 96WO-US019194.
 XX
 PR 02-DEC-1996; 96WO-US019194.
 XX
 PA (DYAD-) DYAD PHARM CORP.
 XX
 PI Hoke GD, Bradley MO, Williams TJ, Lee C;
 XX
 DR WPI; 1998-333253/29.

XX
 PT Antisense oligonucleotides to ICAM-1, E-selectin or VCAM-1 - useful for
 PT treating diseases having an inflammatory component, e.g. psoriasis,
 PT wounds and septic shock.
 XX
 PS Claim 8; Page 40; 48pp; English.
 XX
 CC The sequence is that of an antisense oligonucleotide which is
 CC substantially complementary to at least a portion of the pre- or mature
 CC RNA transcript of human intracellular adhesion molecule (ICAM), E-
 CC selectin or vascular cell adhesion molecule (VCAM). It can be used to
 CC inhibit expression of these proteins. Inhibition of these proteins forms
 CC the basis for treatment of conditions and diseases that have an
 CC inflammatory component, e.g. acne, psoriasis, arthritis, organ rejection,
 CC wounds, burns, septic shock or inflammatory complications of septic shock
 XX
 SQ Sequence 22 BP; 6 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 3e+02;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CTGAGCTCCTCTGCTACTCAGA 37
 |||||
 Db 22 CTGAGCTCCTCTGCTACTCAGA 1

RESULT 74
 AAA33383/c
 ID AAA33383 standard; DNA; 22 BP.
 XX
 AC AAA33383;
 XX
 DT 28-JUL-2000 (first entry)
 XX
 DE Low adenosine antisense oligonucleotide SEQ ID NO:1072.

XX KW Human; adenosine receptor; low adenosine antisenense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cyostatic; analgesic; hypotensive; cytostatic;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX OS Homo sapiens.
 XX PN WO200009525-A2.
 XX PD 24-FEB-2000.
 XX PF 03-AUG-1999; 99WO-US017712.
 XX PR 03-AUG-1998; 98US-0095212P.
 XX PA (UYEC-) UNIV EAST CAROLINA.
 XX PI Nyce JW;
 XX PS WPI; 2000-205971/19.
 XX CC The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cyostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impaired respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukemias, lymphomas,
 CC carcinomas, and cancers which may metastasize to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
 CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
 CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
 CC AAA33992) are specifically claimed ONs from the present invention. N.B.
 CC Sequences given in the disclosure of the present invention do not match
 CC up with their corresponding SEQ ID NO: sequences given in the sequence
 CC listing
 XX SQ Sequence 22 BP; 0 A; 6 C; 14 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 3e+02;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 64 CCAGAGCCCCCGCCCGCCG 85
 Db 22 CCAGAGCCCCCGCCCGCCG 1
 RESULT 75
 AAF19505/c
 ID AAF19505 standard; DNA; 22 BP.

XX AAF19505;
 XX AC 14-MAR-2001 (first entry)
 XX DT Human ICAM-1 polynucleotide fragment #1072.
 XX DE Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX OS Homo sapiens.
 XX PN WO200062736-A2.
 XX PD 26-OCT-2000.
 XX PF 24-MAR-2000; 2000WO-US008020.
 XX PR 06-APR-1999; 99US-0127958P.
 XX PA (UYEC-) UNIV EAST CAROLINA.
 XX PI (NYCE/) NYCE J W.
 XX PS Nyce JW;
 XX WPI; 2000-679539/66.
 XX CC Low adenosine (A) content antisense oligonucleotides which do not trigger
 CC adenosine receptors during metabolism, useful e.g. for treating cancers
 CC and respiratory obstructions.
 CC Claim 14; Page 145; 1592pp; English.
 CC The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulin and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
 CC surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention
 XX SQ Sequence 22 BP; 0 A; 6 C; 14 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 64 CCCAGCAGCCCCCGCCGCGGC 85
DB 22 CCCAGCAGCCCCCGCCGCGGC 1

RESULT 76
AAI68676
ID AAI68676 standard; DNA; 22 BP.
XX AC AAI68676;
XX DT 14-JAN-2002 (first entry)
XX DE ICAM-1 triple helix associated PCR primer SEQ ID 78.
XX ICAM-1; triple helix; transcription inhibition; antipsoriatic;
KW intracellular adhesion molecule; dermatological; antiasthmatic;
KW antiinflammatory; immunosuppressive; gastrointestinal; psoriasis;
KW neurodermatitis; allergic asthma; Crohn's disease; autoimmune disease;
KW transplant rejection; psoralen; photo-ultra-violet therapy; PCR primer;
KW ss.
XX OS Unidentified.
XX PN WO200179487-A2.
XX PD 25-OCT-2001.
XX PF 18-APR-2001; 2001WO-DE001509.
XX PR 18-APR-2000; 2000DE-01019252.
XX PA (DEGI/) DEGITS K K.
XX PA (BESC/) BESCH R.
XX PI Degitz KK, Besch R;
XX WPI; 2002-017614/02.
XX Triple-helix forming polydeoxyribonucleotides, useful for treating
PT intracellular adhesion molecule-1 related diseases, e.g. psoriasis, are
PT directed against transcribed or promoter regions of the ICAM-1 gene.
XX Example 5; Page 24; 61pp; German.
XX This invention describes novel polydeoxyribonucleotides (A), for use as
CC triple-helix forming oligonucleotides, having at least 3 sequential
CC purine and/or pyrimidine bases, capable of inhibiting transcription of
CC ICAM-1. (A) has a sequence specific for the transcribed or promoter
CC regions of the ICAM-1 (intracellular adhesion molecule) gene. The
CC products of the invention have antipsoriatic, dermatological,
CC antiasthmatic, antiinflammatory, immunosuppressive and gastrointestinal
CC diseases, specifically psoriasis, neurodermatitis, allergic asthma,
CC Crohn's disease, autoimmune diseases and transplant rejection. Compared
CC with antisense oligonucleotides, (A) provide a longer-lasting effect
CC (they bind directly to the gene, so a compensatory increase in
CC transcription is not possible). (A) may be coupled to psoralen to provide
CC light-regulatable, sequence-specific downregulation of genes; this should
CC make photo-ultra-violet therapy more specific, with reduced side effects.
CC This sequence represents a PCR primer used in the amplification of the
CC ICAM-1 gene used to illustrate the method of the invention
XX SQ Sequence 22 BP; 3 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 488 CCAACCTCACCGTGGTGTGCT 509
DB 1 CCAACCTCACCGTGGTGTGCT 22

RESULT 77
AAI68674
ID AAI68674 standard; DNA; 22 BP.
XX AC AAI68674;
XX DT 14-JAN-2002 (first entry)
XX DE ICAM-1 triple helix associated PCR primer SEQ ID 76.
XX ICAM-1; triple helix; transcription inhibition; antipsoriatic;
KW intracellular adhesion molecule; dermatological; antiasthmatic;
KW antiinflammatory; immunosuppressive; gastrointestinal; psoriasis;
KW neurodermatitis; allergic asthma; Crohn's disease; autoimmune disease;
KW transplant rejection; psoralen; photo-ultra-violet therapy; PCR primer;
KW ss.
XX OS Unidentified.
XX PN WO200179487-A2.
XX PD 25-OCT-2001.
XX PF 18-APR-2001; 2001WO-DE001509.
XX PR 18-APR-2000; 2000DE-01019252.
XX PA (DEGI/) DEGITS K K.
XX PA (BESC/) BESCH R.
XX PI Degitz KK, Besch R;
XX WPI; 2002-017614/02.
XX Triple-helix forming polydeoxyribonucleotides, useful for treating
PT intracellular adhesion molecule-1 related diseases, e.g. psoriasis, are
PT directed against transcribed or promoter regions of the ICAM-1 gene.
XX Example 5; Page 23; 61pp; German.

XX This invention describes novel polydeoxyribonucleotides (A), for use as
CC triple-helix forming oligonucleotides, having at least 3 sequential
CC purine and/or pyrimidine bases, capable of inhibiting transcription of
CC ICAM-1. (A) has a sequence specific for the transcribed or promoter
CC regions of the ICAM-1 (intracellular adhesion molecule) gene. The
CC products of the invention have antipsoriatic, dermatological,
CC antiasthmatic, antiinflammatory, immunosuppressive and gastrointestinal
CC activity. (A) are used for treatment or prevention of ICAM-1-associated
CC diseases, specifically psoriasis, neurodermatitis, allergic asthma,
CC Crohn's disease, autoimmune diseases and transplant rejection. Compared
CC with antisense oligonucleotides, (A) provide a longer-lasting effect
CC (they bind directly to the gene, so a compensatory increase in
CC transcription is not possible). (A) may be coupled to psoralen to provide
CC light-regulatable, sequence-specific downregulation of genes; this should
CC make photo-ultra-violet therapy more specific, with reduced side effects.
CC This sequence represents a PCR primer used in the amplification of the
CC ICAM-1 gene used to illustrate the method of the invention
XX SQ Sequence 22 BP; 3 A; 11 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 406 GAACTGGCACCCCTCCCTCTT 427
DB 1 GAACTGGCACCCCTCCCTCTT 22

```
RESULT 78
ABZ95199/c
ID ABZ95199 standard; DNA; 22 BP.
XX
XX
AC ABZ95199;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM-1 antisense fragment no.1064.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiqunone.
XX
XX Disclosure; SEQ ID NO 10441; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiqunone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiqunone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 22 BP; 0 A; 6 C; 14 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 64 CCCAGCAGCCCCCGCCCGCCG 85
Db 22 CCCAGCAGCCCCCGCCCGCCG 1
```

```
CC prevent any unwanted effects due to it
XX
SQ Sequence 22 BP; 0 A; 6 C; 14 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 64 CCCAGCAGCCCCCGCCGCGC 85
Db 22 CCCAGCAGCCCCCGCCGCGC 1

RESULT 80
ADJ78611
ID ADJ78611 standard; cDNA; 22 BP.
XX
AC ADJ78611;
XX
DT 06-MAY-2004 (first entry)
XX
DE Chimeric ICAM-1 transgene identification primer, NS25.
XX
KW ss: ICAM-1; intracellular adhesion molecule-1; transgenic animal;
KW domain D1; domain D2; major group; human rhinovirus; HRV; primer.
XX
OS Synthetic.
XX
PN WO2004009810-A2.
XX
PD 29-JAN-2004.
XX
PF 17-JUL-2003; 2003WO-EP007939.
XX
PR 18-JUL-2002; 2002GB-00016729.
XX
PA (GLAX ) GLAXO GROUP LTD.
XX
PI Blair ED, Clarke NJ, Johnston SL, Rowlands DJ;
XX WPI; 2004-123396/12.
XX
PT New transgenic non-human animal whose genome comprises a polynucleotide
PT encoding human intracellular adhesion molecule-1 domains D1 and D2,
PT useful as a model for studying, or screening agents for treating human
PT rhinovirus infection.
XX
PS Example 3.3; Page 19; 42pp; English.
XX
CC This sequence is a primer which was used to determine the presence of a
CC transgene encoding chimeric human/mouse ICAM-1 (intracellular adhesion
CC molecule-1). The transgenic animals genome comprises a polynucleotide
CC encoding human intracellular adhesion molecule-1 (ICAM-1) domains D1 and
CC D2. The animal of the invention may be used in a method of screening test
CC agents for use in the treatment of a condition associated with or
CC exacerbated by major group human rhinovirus (HRV) infection by
CC administering a test agent to the transgenic non-human animal, and
CC determining whether the test agent substance prevents or delays the onset
CC of the condition or treats or alleviates the condition. The transgenic
CC non-human animal is useful as a model for studying human rhinovirus
CC infection, and for screening of test agent for treating such infections.
XX
SQ Sequence 22 BP; 8 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 352 GGGCAGTCAACAGCTAAACCT 373
Db 1 GGGCAGTCAACAGCTAAACCT 22

RESULT 81
ADL66997
ID ADL66997 standard; DNA; 22 BP.
XX
AC ADL66997;
XX
DT 03-JUN-2004 (first entry)
XX
DE Multiplex PCR primer #1.
XX
KW DNA polymerase; anti-DNAP antibody; reverse transcriptase;
KW anti-RT antibody; single strand binding protein; SSB; ss; primer.
XX
OS Synthetic.
XX
PN WO2004022770-A2.
XX
PD 18-MAR-2004.
XX
PF 05-SEP-2003; 2003WO-US027705.
XX
PR 05-SEP-2002; 2002US-0408609P.
PR 19-NOV-2002; 2002US-0427867P.
XX
PA (INVI-) INVITROGEN CORP.
XX
PI Park K;
XX
PN WPI; 2004-248479/23.
XX
PT New compositions comprising one or more anti-reverse transcriptase
PT antibodies, anti-DNA polymerases or single strand binding proteins,
PT useful for synthesizing nucleic acids.
XX
PS Example 4; Page 89; 201pp; English.
XX
CC The invention relates to a new composition which comprises at least one
CC anti-DNA polymerases (anti-DNAP) antibody and/or at least one anti-
CC reverse transcriptase (anti-RT) antibody, and at least one single strand
CC binding protein (SSB) or at least two different SSBs. The compositions
CC are useful for nucleic acid synthesis reactions or are generated during
CC nucleic acid synthesis reactions. The methods are useful for synthesising
CC one or more nucleic acid molecules. The compositions and methods are also
CC be used in amplifying nucleic acid molecules, in reverse transcription of
CC nucleic acid molecules and in coupled or uncoupled reverse
CC transcription/amplification. The present sequence is used in the
CC exemplification of the present invention.
XX
SQ Sequence 22 BP; 4 A; 3 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2775 GGCTGGAGTGCAGTGGTCAAT 2796
Db 1 GGCTGGAGTGCAGTGGTCAAT 22

RESULT 82
ADQ14962/c
ID ADQ14962 standard; DNA; 22 BP.
XX
AC ADQ14962;
XX
DT 07-OCT-2004 (first entry)
XX
DE CD54 reverse transcriptase PCR primer seqid 86.
XX
KW multifunctional oligomeric compound; RNA expression modulator;
KW double-stranded oligomeric compound; CD54; reverse transcriptase PCR;
KW RT-PCR; real-time PCR; primer; ss.
XX
```

OS Homo sapiens.
 XX US2004137471-A1.
 XX 15-JUL-2004.
 XX 18-SEP-2003; 2003US-00664639.
 XX 18-SEP-2002; 2002US-0411780P.
 XX (VICK/) VICKERS T.
 XX (KOOS/) KOO S.
 XX (BENN/) BENNETT C F.
 XX (CROO/) CROOKE S T.
 XX (DEAN/) DEAN N M.
 XX (BAKE/) BAKER B F.
 XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
 XX WPI; 2004-533354/51.
 XX Identifying a multifunctional oligomeric compound to modulate expression
 PT of RNA comprises identifying an inhibiting antisense strand and
 PT inhibiting double-stranded oligomeric compound as multifunctional
 PT oligomeric compounds.
 XX Example 2; SEQ ID NO 86; 55pp; English.
 XX The invention describes a method of identifying a multifunctional
 CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a reverse transcriptase PCR primer used to isolate
 CC DNA encoding c-rat to determine RNA levels following multifunctional
 CC oligomeric compound manipulation.
 XX Sequence 22 BP; 3 A; 6 C; 4 G; 9 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 22; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 3e+02;
 Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 302 GCAATGTGCAAGATAGGCA 323
 |||||
 Db 22 GCAATGTGCAAGATAGGCA 1
 |||||
 RESULT 83

ADQ14961
 ID ADQ14961 standard; DNA; 22 BP.
 XX
 AC ADQ14961;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE CD54 reverse transcriptase PCR primer seqid 85.
 XX
 KW multifunctional oligomeric compound; RNA expression modulator;
 KW double-stranded oligomeric compound; CD54; reverse transcriptase PCR;
 KW RT-PCR; real-time PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2004137471-A1.
 XX
 PD 15-JUL-2004.
 XX
 PF 18-SEP-2003; 2003US-00664639.
 XX
 PR 18-SEP-2002; 2002US-0411780P.
 XX
 XX (VICK/) VICKERS T.
 XX (KOOS/) KOO S.
 XX (BENN/) BENNETT C F.
 XX (CROO/) CROOKE S T.
 XX (DEAN/) DEAN N M.
 XX (BAKE/) BAKER B F.
 XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
 XX WPI; 2004-533354/51.
 XX Identifying a multifunctional oligomeric compound to modulate expression
 PT of RNA comprises identifying an inhibiting antisense strand and
 PT inhibiting double-stranded oligomeric compound as multifunctional
 PT oligomeric compounds.
 XX Example 2; SEQ ID NO 85; 55pp; English.
 XX The invention describes a method of identifying a multifunctional
 CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a reverse transcriptase PCR primer used to isolate
 CC DNA encoding c-rat to determine RNA levels following multifunctional
 CC oligomeric compound manipulation.


```
XX
SQ Sequence 22 BP; 7 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 234 CATAGAGCCCCGTTGCCTAAA 255
DB 1 CATAGAGCCCCGTTGCCTAAA 22

RESULT 84
ADP45859/c
ID ADP45859 standard; DNA; 23 BP.
XX
AC ADP45859;
XX
DT 26-AUG-2004 (first entry)
XX
DE Extend primer 51 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.
XX
KW breast cancer; cytostatic; gene therapy; human;
KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
KW CD54; cell surface glycoprotein P3.58; ICAM-4;
KW Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
KW ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
XX
OS Homo sapiens.
XX
PN WO2004047623-A2.
XX
PD 10-JUN-2004.
XX
PF 25-NOV-2003; 2003WO-US037948.
XX
PR 25-NOV-2002; 2002US-0429136P.
PR 24-JUL-2003; 2003US-0490234P.
XX
PA (SEQU-) SEQUENOM INC.
XX
PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX
PS WPI; 2004-441051/41.
XX
PT Identifying a subject at risk of breast cancer by detecting the presence
PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
PT regions which are associated with breast cancer in a nucleic acid sample
PT from a subject.
XX
PS Example 4; Page 83; 289pp; English.
XX
CC The invention relates to a novel method for identifying a subject at risk
CC of breast cancer comprising detecting the presence or absence of one or
CC more polymorphic variations associated with breast cancer in a nucleic
CC acid sample from a subject. The method of the invention has cytostatic
CC applications and may be useful for identifying a subject at risk of
CC breast cancer, for early diagnosis, prevention and treatment of breast
CC cancer, possibly via gene therapy, as well as to analyse and predict a
CC response to a breast cancer treatment and in clinical drug trials. The
CC current sequence is that of an extend primer (also described as probe) of
CC the invention which was used to genotype human intercellular adhesion
CC molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor; BB2
CC CD54; cell surface glycoprotein P3.58) has been mapped to chromosomal
CC position 19p13.3-p13.2, ICAM-4 (Landsteiner-Wiener blood group; LW) has
CC been mapped to chromosomal position 19p13.2-cen and ICAM-5
CC (telencephalin) has been mapped to chromosomal position 19p13.2.
XX
SQ Sequence 23 BP; 5 A; 4 C; 6 G; 8 T; 0 U; 0 Other;
Query Match 0.7%; Score 22; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2253 TCACATTCAAGGTCAACAGGTA 2274
DB 22 TCACATTCAAGGTCAACAGGTA 1

RESULT 85
AAH40163/c
ID AAH40163 standard; DNA; 25 BP.
XX
AC AAH40163;
XX
DT 14-AUG-2001 (first entry)
XX
DE SNP specific SNPE primer SEQ ID 2959.
XX
KW Single nucleotide polymorphism; SNP; single nucleotide primer extension;
KW SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
KW Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
KW acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
KW inflammation; forensic investigation; paternity analysis; primer; ss.
XX
OS Homo sapiens.
XX
PN WO200129262-A2.
XX
PD 26-APR-2001.
XX
PF 13-OCT-2000; 2000WO-US028436.
XX
PR 15-OCT-1999; 99US-0160096P.
XX
PA (ORCH-) ORCHID BIOSCIENCES INC.
XX
PI Picoult-Newburg L, Pohl M;
XX
PS WPI; 2001-290930/30.
XX
PT New genotyping oligonucleotide, useful for detecting the presence,
PT absence or identity of single polynucleotide polymorphism in a nucleic
PT acid sample.
XX
PS Claim 1; Page 65; 83pp; English.
XX
CC Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
CC primer extension (SNPE) primers, and the sequences of regions flanking
CC sites of single nucleotide polymorphisms SNPs. The present invention
CC includes kits for determining the presence or absence of a SNP, using the
CC oligonucleotides of the invention. The PCR primers are used to amplify a
CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.
CC The oligonucleotides are useful for genotyping a nucleic acid sample by
CC performing a single-nucleotide primer extension reaction. The
CC oligonucleotides are useful for determining the presence, absence or
CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to
CC assess by association analysis the genotype of an individual or group of
CC individuals, having a pathological phenotypic trait suspected of being
CC caused by one or more SNPs. Phenotypic traits include diseases e.g.
CC agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
CC traits also include symptoms of or susceptibility to multifactorial
CC disease of which a component is or may be genetic such as autoimmune
CC diseases, including, rheumatoid arthritis, multiple sclerosis,
CC inflammation, cancer, nervous system diseases and infection by pathogenic
CC microorganism. The method is also useful in forensic investigations and
CC paternity analysis. The present sequence represents a single nucleotide
CC primer extension (SNPE) primer specific for a human SNP containing DNA
CC sequence
XX
SQ Sequence 25 BP; 12 A; 12 C; 1 G; 0 T; 0 U; 0 Other;
Query Match 0.7%; Score 21.8; DB 1; Length 25;
```


PD 17-MAR-1994.
 XX 27-AUG-1993; 93WO-US008101.
 XX 02-SEP-1992; 92US-00939855.
 PR 21-JAN-1993; 93US-00007997.
 PR 17-MAY-1993; 93US-00063167.
 XX (ISIS-) ISIS PHARM INC.
 XX Bennet CF, Mirabelli CK;
 PI WPI; 1994-100869/12.
 DR Oligo:nucleotide modulation of cell adhesion - used in the treatment of
 PT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
 XX Claim 15; Page 48; 101pp; English.
 XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
 CC both the phosphodiester and phosphorothioate forms. The oligonucleotides
 CC are useful to treat diseases which are modulated by changes in
 CC intercellular adhesion molecules. This sequence corresponds to
 CC nucleotides 2190-3010 (sic) of the 3'- untranslated region of the human
 CC ICAM-1 coding sequence. (Updated on 25-MAR-2003 to correct PN field.)
 XX Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2176 ACCAGCTATTATTGAGTGTC 2196
 Db 21 ACCAGCTATTATTGAGTGTC 1
 RESULT 91
 AAT01741/c
 ID AAT01741 standard; DNA; 21 BP.
 AC AAT01741;
 XX 18-DEC-1995 (first entry)
 XX Peptide Nucleic acid oligomer targeting ICAM-1 3'-UTR.
 DE peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
 KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
 KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.
 XX Synthetic.
 XX Key Location/Qualifiers
 FH misc_feature 1..21
 FT /tag= a
 FT /note= "at least one (and preferably all) of the backbone
 FT subunits are composed of amide units, so that the
 FT oligomer consists of the nucleobases attached covalently
 FT to a polyamide backbone"
 XX WO9504749-A1.
 XX 16-FEB-1995.
 PD 05-AUG-1994; 94WO-US009026.
 XX 05-AUG-1993; 93US-00102650.
 XX (ISIS-) ISIS PHARM INC.
 PA Bennett CF, Mirabelli CK;
 PI

DR WPI; 1995-090842/12.
 XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes
 PT - are stable anti-sense cpds. of high affinity, partic. for treating
 PT inflammation, viral infection, cancer etc.
 XX Claim 2; Page 35; 57pp; English.
 XX New oligomers are claimed which (A) have at least one peptide nucleic
 CC acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
 CC coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
 CC or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated
 CC region, exon/intron junction region or 3'-untranslated region of VCAM-1.
 CC The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
 CC produce antisense-type gene regulation moieties. Hence they may be used
 CC therapeutically for modulating cellular adhesion and thus as
 CC antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
 CC AIDS agents and antiinflammatory agents. They may also be useful as
 CC diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
 CC affinity for complementary single stranded DNA. They are also able to
 CC form triple helices in which a first PNA strand binds with RNA or ssDNA
 CC and a second PNA strand binds with the resulting double helix or with the
 CC first PNA strand. The PNAs possess no significant charge and are water
 CC soluble, which facilitates cellular uptake. Further, since they contain
 CC amides of non-biological amino acids, they are biostable and resistant to
 CC enzymatic degradation by proteases. The present sequence targets human
 CC intercellular adhesion molecule-1 (ICAM-1) 3' untranslated region
 XX Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2176 ACCAGCTATTATTGAGTGTC 2196
 Db 21 ACCAGCTATTATTGAGTGTC 1
 RESULT 92
 AAT30213/c
 ID AAT30213 standard; DNA; 21 BP.
 XX AAT30213;
 XX 20-JAN-1997 (first entry)
 DT Antisense oligonucleotide ISIS 1572.
 XX Antisense oligonucleotide; human; intracellular adhesion molecule-1;
 DE ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
 KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; breguarin;
 KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
 KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
 KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
 KW ss.
 XX Synthetic.
 OS Key Location/Qualifiers
 XX modified_base 1..21
 FH /tag= a
 FT /note= "phosphorothioate backbone"
 XX WO9615780-A1.
 XX 30-MAY-1996.
 PD 22-NOV-1995; 95WO-US015536.
 XX 23-NOV-1994; 94US-00344155.
 PR (ISIS-) ISIS PHARM INC.
 PA

PA (TEXA) UNIV TEXAS SYSTEM.
 XX Bennett CF, Stepkowski SM;
 XX WPI; 1996-268321/27.
 XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
 PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
 PT rejection.
 XX
 XX Example 2; Page 17; 92pp; English.
 XX
 XX AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
 CC oligonucleotides of the invention. These sequences target regions of the
 CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
 CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
 CC targets the 3' untranslated region (nucleotides 2190-2210) of ICAM-1.
 CC ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
 CC molecules involved in the adherence of white blood cells to vascular
 CC endothelium. These sequences can be used in a composition for treating
 CC allograft rejection. The composition contains one of these sequences in
 CC combination with an immunosuppressive agent. The immunosuppressive agent
 CC used in the compositions is brequinar, rapamycin, anti-lymphocyte serum,
 CC a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The
 CC compositions can be used for treating or preventing allograft rejection,
 CC such as cardiac or renal allograft rejection. By using these
 CC compositions, allograft survival times are extended, and donor-specific
 CC transplant tolerance is induced
 XX
 SQ Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 2176 ACCAGCTATTATTGAGTGTC 2196
 DB |||||
 XX 21 ACCAGCTATTATTGAGTGTC 1
 XX
 RESULT 93
 AAT80604/C
 ID AAT80604 standard; RNA; 21 BP.
 XX AAT80604;
 XX
 XX 25-MAR-2003 (revised)
 DT 05-NOV-1997 (first entry)
 XX
 XX Antisense oligonucleotide for inhibiting mRNA activity.
 XX
 XX 5' cap; inhibition; mRNA activity; eukaryotic initiation factor 4E;
 KW eIF-4E; viral infection; ss.
 XX
 XX Synthetic.
 OS
 XX US5643780-A.
 PN
 XX 01-JUL-1997.
 PD
 XX 21-OCT-1994; 94US-00327363.
 PF
 XX 03-APR-1992; 92US-00847054.
 PR
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Baker BP;
 XX
 XX WPI; 1997-350245/32.
 DR
 XX Conjugates for inhibiting mRNA activity by altering 5' cap structure -
 PT comprising targetting oligo:nucleotide linked to amine or metal complex.

XX
 PS Example 7; Col 17; 19pp; English.
 XX
 CC A novel composition has been produced for inhibiting the activity of an
 CC mRNA molecule. The composition comprises: (a) a targetting portion which
 CC is an oligonucleotide or oligonucleotide analogue specifically
 CC hybridisable with the 5' end of the mRNA molecule; (b) a reactive portion
 CC which is an amine or metal complex that chemically modifies or cleaves
 CC the 5' cap structure of the mRNA molecule; and (c) a linker that connects
 CC the targetting and reactive portions so that, upon hybridisation of the
 CC targeting portion to the mRNA, the reactive portion can contact the 5'
 CC cap. The present sequence represents an antisense oligonucleotide for use
 CC in the inhibiting of mRNA activity. The composition can be used for
 CC masking the 5' cap to inhibit binding of eukaryotic initiation factor 4E
 CC (eIF-4E) to the mRNA or for inhibiting production of a protein encoded by
 CC the mRNA in a eukaryotic cell. This has possible therapeutic
 CC applications, e.g. for treating viral infections. (Updated on 25-MAR-2003
 CC to correct PF field.)
 XX
 SQ Sequence 21 BP; 6 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 17 TCAGCTCCTCTGCTACTCAGA 37
 DB |||||
 XX 21 TCAGCTCCTCTGCTACTCAGA 1
 XX
 RESULT 94
 AAT58076/C
 ID AAT58076 standard; DNA; 21 BP.
 XX AAT58076;
 XX
 XX 25-MAR-2003 (revised)
 DT 18-MAR-1997 (first entry)
 XX
 XX ICAM-1 antisense oligonucleotide #6.
 XX
 XX Antisense; pre-mRNA; mature mRNA; vascular defect; tissue defect;
 KW human intercellular adhesion molecule-1; ICAM-1; inflammation;
 KW adult respiratory distress syndrome; multiple organ failure; GM1594;
 KW septic shock; ss.
 XX
 XX Synthetic.
 OS
 XX US5580969-A.
 PN
 XX 03-DEC-1996.
 PD
 XX 12-OCT-1993; 93US-00136118.
 PF
 XX 24-JUL-1992; 92US-00918259.
 PR
 XX (USNA) US SEC OF NAVY.
 PA
 XX Lee C, Hoke GD, Bradley MO, Williams TJ;
 PI
 XX WPI; 1997-033603/03.
 DR
 XX Anti-sense oligo:nucleotide(s) for blocking ICAM-1 mRNA translation - for
 PT treating septic shock, adult respiratory distress syndrome etc.
 PT
 XX Claim 1; Col 21; 16pp; English.
 PS
 XX The sequences given in AAT58071-85 represent oligonucleotides which are
 CC antisense to sequences contained in the pre-mRNA or mature mRNA
 CC transcript of human intercellular adhesion molecule-1 (ICAM-1). These
 CC oligonucleotides may be used for treating septic shock and the
 CC manifestations of septic shock, e.g. inflammation, and vascular and
 CC tissue defects. They are also useful in the treatment of septic shock

CC associated diseases, e.g. adult respiratory distress syndrome, multiple organ failure etc. This sequence represents the oligonucleotide GM1594 which is complementary to bases 84-104 of the ICAM-1 molecule. This CC oligonucleotide inhibits hTNF-alpha-induced ICAM-1 expression by 81%. CC (Updated on 25-MAR-2003 to correct PF field.)

XX Sequence 21 BP; 5 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 18 GAGCTCCTCTGCTACTCAGAG 38
|||||

Db 21 GAGCTCCTCTGCTACTCAGAG 1
|||||

RESULT 95
AAT58080/c
ID AAT58080 standard; DNA; 21 BP.
XX AC AAT58080;
XX AC AAT58080;
XX 25-MAR-2003 (revised)
DT 18-MAR-1997 (first entry)
XX ICAM-1 antisense oligonucleotide #10.
XX Antisense; pre-mRNA; mature mRNA; vascular defect; tissue defect;
KW human intercellular adhesion molecule-1; ICAM-1; inflammation;
KW adult respiratory distress syndrome; multiple organ failure; GM1594;
KW septic shock; ss.
XX Synthetic.
XX OS US5580969-A.
XX PN 03-DEC-1996.
XX PD 12-OCT-1993; 93US-00136118.
PF 24-JUL-1992; 92US-00918259.
PR (USNA) US SEC OF NAVY.
XX Lee C, Hoke GD, Bradley MO, Williams TJ;
PI WPI; 1997-033603/03.
XX Anti-sense oligo:nucleotide(s) for blocking ICAM-1 mRNA translation - for treating septic shock, adult respiratory distress syndrome etc.
XX Claim 1; Col 21; 16pp; English.
XX The sequences given in AAT58071-85 represent oligonucleotides which are antisense to sequences contained in the pre-mRNA or mature mRNA transcript of human intercellular adhesion molecule-1 (ICAM-1). These oligonucleotides may be used for treating septic shock and the manifestations of septic shock, e.g. inflammation, and vascular and tissue defects. They are also useful in the treatment of septic shock associated diseases, e.g. adult respiratory distress syndrome, multiple organ failure etc. This sequence represents the oligonucleotide GM1595 which is complementary to bases 109-129 of the ICAM-1 mRNA molecule. This CC oligonucleotide inhibits hTNF-alpha-induced ICAM-1 expression by 80%. CC (Updated on 25-MAR-2003 to correct PF field.)

XX Sequence 21 BP; 11 A; 9 C; 0 G; 1 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
|||||

Db 21 TGTGTGTGTGTGTGTGTGTGT 1
|||||

RESULT 96
AAT58081/c
ID AAT58081 standard; DNA; 21 BP.
XX AC AAT58081;
XX 25-MAR-2003 (revised)
DT 18-MAR-1997 (first entry)
XX ICAM-1 antisense oligonucleotide #11.
XX Antisense; pre-mRNA; mature mRNA; vascular defect; tissue defect;
KW human intercellular adhesion molecule-1; ICAM-1; inflammation;
KW adult respiratory distress syndrome; multiple organ failure; GM1594;
KW septic shock; ss.
XX Synthetic.
XX OS US5580969-A.
XX PN 03-DEC-1996.
XX PD 12-OCT-1993; 93US-00136118.
PF 24-JUL-1992; 92US-00918259.
PR (USNA) US SEC OF NAVY.
XX Lee C, Hoke GD, Bradley MO, Williams TJ;
PI WPI; 1997-033603/03.
XX Anti-sense oligo:nucleotide(s) for blocking ICAM-1 mRNA translation - for treating septic shock, adult respiratory distress syndrome etc.
XX Claim 1; Col 23; 16pp; English.
XX The sequences given in AAT58071-85 represent oligonucleotides which are antisense to sequences contained in the pre-mRNA or mature mRNA transcript of human intercellular adhesion molecule-1 (ICAM-1). These oligonucleotides may be used for treating septic shock and the manifestations of septic shock, e.g. inflammation, and vascular and tissue defects. They are also useful in the treatment of septic shock associated diseases, e.g. adult respiratory distress syndrome, multiple organ failure etc. This sequence represents the oligonucleotide GM1595 which is complementary to bases 109-129 of the ICAM-1 mRNA molecule. This CC oligonucleotide inhibits hTNF-alpha-induced ICAM-1 expression by 80%. CC (Updated on 25-MAR-2003 to correct PF field.)

XX Sequence 21 BP; 5 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 43 AACCTCAGCTCGCTATGCT 63
|||||

Db 21 AACCTCAGCTCGCTATGCT 1
|||||

RESULT 97
AAT58079/c
ID AAT58079 standard; DNA; 21 BP.
XX AC AAT58079;
XX 25-MAR-2003 (revised)
DT 18-MAR-1997 (first entry)
XX ICAM-1 antisense oligonucleotide #9.
XX Antisense; pre-mRNA; mature mRNA; vascular defect; tissue defect;

CC degradation is prevented, thereby preventing adenosine- induced
 CC bronchoconstriction in patients with hyper-reactive airways
 XX
 SQ Sequence 21 BP; 0 A; 11 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1765 GGGACGCCGAGGACAGGGCA 1785

Db 21 GGGACGCCGAGGACAGGGCA 1

RESULT 100

AAV38621/c
 ID AAV38621 standard; DNA; 21 BP.

XX
 AC AAV38621;

DT 13-OCT-1998 (first entry)

DE Human ICAM-1, E-selectin, VCAM-1 antisense oligonucleotide.

XX ICAM-1; intracellular adhesion molecule-; E-selectin; VCAM-1;
 KW vascular cell adhesion molecule-1; antisense; inflammatory; disease;
 KW treatment; septic shock; psoriasis; wounds; burns; acne; arthritis;
 KW organ rejection; inhibition; expression; ss.

OS Synthetic.
 OS Homo sapiens.

XX
 PN WO9824797-A1.

XX
 PD 11-JUN-1998.

XX 02-DEC-1996; 96WO-US019194.

XX 02-DEC-1996; 96WO-US019194.

XX (DYAD-) DYAD PHARM CORP.

XX Hoke GD, Bradley MO, Williams TJ, Lee C;

XX WPI; 1998-333253/29.

XX Antisense oligonucleotides to ICAM-1, E-selectin or VCAM-1 - useful for
 PT treating diseases having an inflammatory component, e.g. psoriasis,
 PT wounds and septic shock.

XX Claim 8; Page 40; 48pp; English.

XX The sequence is that of an antisense oligonucleotide which is
 CC substantially complementary to at least a portion of the pre- or mature
 CC RNA transcript of human intracellular adhesion molecule (ICAM), E-
 CC selectin or vascular cell adhesion molecule (VCAM). It can be used to
 CC inhibit expression of these proteins. Inhibition of these proteins forms
 CC the basis for treatment of conditions and diseases that have an
 CC inflammatory component, e.g. acne, psoriasis, arthritis, organ rejection,
 CC wounds, burns, septic shock or inflammatory complications of septic shock
 XX

SQ Sequence 21 BP; 3 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1937 TGAGAGGGGAAGTGTGGGGG 1957

Db 21 TGAGAGGGGAAGTGTGGGGG 1

RESULT 101

AAV38612/c
 ID AAV38612 standard; DNA; 21 BP.

XX
 AC AAV38612;

DT 13-OCT-1998 (first entry)

DE Human ICAM-1, E-selectin, VCAM-1 antisense oligonucleotide.

XX ICAM-1; intracellular adhesion molecule-; E-selectin; VCAM-1;
 KW vascular cell adhesion molecule-1; antisense; inflammatory; disease;
 KW treatment; septic shock; psoriasis; wounds; burns; acne; arthritis;
 KW organ rejection; inhibition; expression; ss.

XX Synthetic.

OS Homo sapiens.

XX
 PN WO9824797-A1.

XX 11-JUN-1998.

XX 02-DEC-1996; 96WO-US019194.

XX 02-DEC-1996; 96WO-US019194.

XX (DYAD-) DYAD PHARM CORP.

XX Hoke GD, Bradley MO, Williams TJ, Lee C;

XX WPI; 1998-333253/29.

XX Antisense oligonucleotides to ICAM-1, E-selectin or VCAM-1 - useful for
 PT treating diseases having an inflammatory component, e.g. psoriasis,
 PT wounds and septic shock.

XX Claim 8; Page 40; 48pp; English.

XX The sequence is that of an antisense oligonucleotide which is
 CC substantially complementary to at least a portion of the pre- or mature
 CC RNA transcript of human intracellular adhesion molecule (ICAM), E-
 CC selectin or vascular cell adhesion molecule (VCAM). It can be used to
 CC inhibit expression of these proteins. Inhibition of these proteins forms
 CC the basis for treatment of conditions and diseases that have an
 CC inflammatory component, e.g. acne, psoriasis, arthritis, organ rejection,
 CC wounds, burns, septic shock or inflammatory complications of septic shock
 XX

SQ Sequence 21 BP; 5 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGAG 38

Db 21 GAGCTCCTCTGCTACTCAGAG 1

RESULT 102

AAV38614/c

ID AAV38614 standard; DNA; 21 BP.

XX
 AC AAV38614;

DT 13-OCT-1998 (first entry)

DE Human ICAM-1, E-selectin, VCAM-1 antisense oligonucleotide.

XX ICAM-1; intracellular adhesion molecule-; E-selectin; VCAM-1;
 KW vascular cell adhesion molecule-1; antisense; inflammatory; disease;
 KW treatment; septic shock; psoriasis; wounds; burns; acne; arthritis;
 KW organ rejection; inhibition; expression; ss.

XX Synthetic.


```

OS Homo sapiens.
XX WO9824797-A1.
XX 11-JUN-1998.
XX
XX 02-DEC-1996; 96WO-US019194.
XX
XX 02-DEC-1996; 96WO-US019194.
XX
XX (DYAD-) DYAD PHARM CORP.
XX
XX Hoke GD, Bradley MO, Williams TJ, Lee C;
XX WPI; 1998-333253/29.
XX
XX Antisense oligonucleotides to ICAM-1, E-selectin or VCAM-1 - useful for
XX treating diseases having an inflammatory component, e.g. psoriasis,
XX wounds and septic shock.
XX
XX Claim 8; Page 40; 48pp; English.
XX
XX The sequence is that of an antisense oligonucleotide which is
XX substantially complementary to at least a portion of the pre- or mature
XX RNA transcript of human intracellular adhesion molecule (ICAM), E-
XX selectin or vascular cell adhesion molecule (VCAM). It can be used to
XX inhibit expression of these proteins. Inhibition of these proteins forms
XX the basis for treatment of conditions and diseases that have an
XX inflammatory component, e.g. acne, psoriasis, arthritis, organ rejection,
XX wounds, burns, septic shock or inflammatory complications of septic shock
XX
XX Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 4e+02;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2053 CCCTCCATGACATGTGTAGC 2073
XX
XX Db 21 CCCTCCATGACATGTGTAGC 1
XX
XX RESULT 103
XX AAV38616/c
XX ID AAV38616 standard; DNA; 21 BP.
XX AC
XX AAV38616;
XX
XX 13-OCT-1998 (first entry)
XX
XX Human ICAM-1, E-selectin, VCAM-1 antisense oligonucleotide.
XX
XX ICAM-1; intracellular adhesion molecule-; E-selectin; VCAM-1;
XX vascular cell adhesion molecule-1; antisense; inflammatory; disease;
XX treatment; septic shock; psoriasis; wounds; burns; acne; arthritis;
XX organ rejection; inhibition; expression; ss.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX WO9824797-A1.
XX
XX 11-JUN-1998.
XX
XX 02-DEC-1996; 96WO-US019194.
XX
XX 02-DEC-1996; 96WO-US019194.
XX
XX (DYAD-) DYAD PHARM CORP.
XX
XX Hoke GD, Bradley MO, Williams TJ, Lee C;
XX WPI; 1998-333253/29.
XX
XX Antisense oligonucleotides to ICAM-1, E-selectin or VCAM-1 - useful for
XX treating diseases having an inflammatory component, e.g. psoriasis,
XX wounds and septic shock.
XX
XX Claim 8; Page 40; 48pp; English.
XX
XX The sequence is that of an antisense oligonucleotide which is
XX substantially complementary to at least a portion of the pre- or mature
XX RNA transcript of human intracellular adhesion molecule (ICAM), E-
XX selectin or vascular cell adhesion molecule (VCAM). It can be used to
XX inhibit expression of these proteins. Inhibition of these proteins forms
XX the basis for treatment of conditions and diseases that have an
XX inflammatory component, e.g. acne, psoriasis, arthritis, organ rejection,
XX wounds, burns, septic shock or inflammatory complications of septic shock
XX
XX Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 4e+02;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2053 CCCTCCATGACATGTGTAGC 2073
XX
XX Db 21 CCCTCCATGACATGTGTAGC 1
XX
XX RESULT 103
XX AAV38616/c
XX ID AAV38616 standard; DNA; 21 BP.
XX AC
XX AAV38616;
XX
XX 13-OCT-1998 (first entry)
XX
XX Human ICAM-1, E-selectin, VCAM-1 antisense oligonucleotide.
XX
XX ICAM-1; intracellular adhesion molecule-; E-selectin; VCAM-1;
XX vascular cell adhesion molecule-1; antisense; inflammatory; disease;
XX treatment; septic shock; psoriasis; wounds; burns; acne; arthritis;
XX organ rejection; inhibition; expression; ss.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX WO9824797-A1.
XX
XX 11-JUN-1998.
XX
XX 02-DEC-1996; 96WO-US019194.
XX
XX 02-DEC-1996; 96WO-US019194.
XX
XX (DYAD-) DYAD PHARM CORP.
XX
XX Hoke GD, Bradley MO, Williams TJ, Lee C;
XX WPI; 1998-333253/29.
XX

```

```

XX Antisense oligonucleotides to ICAM-1, E-selectin or VCAM-1 - useful for
XX treating diseases having an inflammatory component, e.g. psoriasis,
XX wounds and septic shock.
XX
XX Claim 8; Page 40; 48pp; English.
XX
XX The sequence is that of an antisense oligonucleotide which is
XX substantially complementary to at least a portion of the pre- or mature
XX RNA transcript of human intracellular adhesion molecule (ICAM), E-
XX selectin or vascular cell adhesion molecule (VCAM). It can be used to
XX inhibit expression of these proteins. Inhibition of these proteins forms
XX the basis for treatment of conditions and diseases that have an
XX inflammatory component, e.g. acne, psoriasis, arthritis, organ rejection,
XX wounds, burns, septic shock or inflammatory complications of septic shock
XX
XX Sequence 21 BP; 11 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 4e+02;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
XX
XX Db 21 TGTGTGTGTGTGTGTGTGTGT 1
XX
XX RESULT 104
XX AAV38615/c
XX ID AAV38615 standard; DNA; 21 BP.
XX AC
XX AAV38615;
XX
XX 13-OCT-1998 (first entry)
XX
XX Human ICAM-1, E-selectin, VCAM-1 antisense oligonucleotide.
XX
XX ICAM-1; intracellular adhesion molecule-; E-selectin; VCAM-1;
XX vascular cell adhesion molecule-1; antisense; inflammatory; disease;
XX treatment; septic shock; psoriasis; wounds; burns; acne; arthritis;
XX organ rejection; inhibition; expression; ss.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX WO9824797-A1.
XX
XX 11-JUN-1998.
XX
XX 02-DEC-1996; 96WO-US019194.
XX
XX 02-DEC-1996; 96WO-US019194.
XX
XX (DYAD-) DYAD PHARM CORP.
XX
XX Hoke GD, Bradley MO, Williams TJ, Lee C;
XX WPI; 1998-333253/29.
XX
XX Antisense oligonucleotides to ICAM-1, E-selectin or VCAM-1 - useful for
XX treating diseases having an inflammatory component, e.g. psoriasis,
XX wounds and septic shock.
XX
XX Claim 8; Page 40; 48pp; English.
XX
XX The sequence is that of an antisense oligonucleotide which is
XX substantially complementary to at least a portion of the pre- or mature
XX RNA transcript of human intracellular adhesion molecule (ICAM), E-
XX selectin or vascular cell adhesion molecule (VCAM). It can be used to
XX inhibit expression of these proteins. Inhibition of these proteins forms
XX the basis for treatment of conditions and diseases that have an
XX inflammatory component, e.g. acne, psoriasis, arthritis, organ rejection,
XX wounds, burns, septic shock or inflammatory complications of septic shock
XX

```

XX SQ Sequence 21 BP; 5 A; 1 C; 10 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2494 CCACCCACATACATTTCTGCC 2514
 |||||
 Db 21 CCACCCACATACATTTCTGCC 1
 |||||
 RESULT 105
 AAX53948/c
 ID AAX53948 standard; DNA; 21 BP.
 AC AAX53948;
 XX
 XX 05-JUL-1999 (first entry)
 DT
 DE Intercellular adhesion molecule-1 (ICAM-1) antisense oligonucleotide.
 XX
 XX Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impeded respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 XX
 XX Synthetic.
 OS
 XX WO9913886-A1.
 PN
 XX 25-MAR-1999.
 PD
 XX 17-SEP-1998; 98WO-US019419.
 PF
 XX 17-SEP-1997; 97US-0059160P.
 PR 09-JUN-1998; 98US-00093972.
 XX
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX Nyce JW;
 PI
 XX WPI; 1999-229400/19.
 DR
 XX New antisense oligonucleotides used in treatment of, e.g. pulmonary
 PT vasoconstriction.
 PT
 PS Disclosure; Page 47; 120pp; English.
 XX
 CC The specification describes antisense oligonucleotides (AAX52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene initiation
 CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-
 CC end and the juxta-section between coding and non-coding regions and all
 CC segments of RNAs encoding proteins associated with one or more diseases,
 CC conditions or mixtures. The antisense oligonucleotides may be derived
 CC from sequences AAX55272-74. These multiple target oligonucleotides
 CC (specifically AAX55180-271) can be used for the antisense treatment of
 CC diseases and conditions. Typical diseases and conditions are those
 CC associated with impaired respiration and inflammation, including lung
 CC diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
 CC acute asthma, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
 CC pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
 CC disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
 CC colon cancer, breast cancer, lung cancer, pancreatic cancer,
 CC hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as

CC well as all types of cancers which may metastasize or have metastasized
 CC to the lungs, including breast and prostate cancer
 XX
 SQ Sequence 21 BP; 0 A; 11 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1765 GGGAGCGCGGAGGACAGGGCA 1785
 |||||
 Db 21 GGGAGCGCGGAGGACAGGGCA 1
 |||||
 RESULT 106
 AAX00533/c
 ID AAX00533 standard; DNA; 21 BP.
 XX
 XX AAX00533;
 AC
 XX 30-MAR-1999 (first entry)
 DT
 DE Antisense oligonucleotide ISIS#1572 targeted to ICAM-1.
 XX
 XX Target; antisense; selective rank; inhibition; ranking; stability;
 KW interaction; intercellular adhesion molecule; ICAM; ss.
 KW
 XX Synthetic.
 OS
 XX Key Location/Qualifiers
 FH misc_feature 1..20
 FT /tag= a
 FT /note= "contains phosphorothioate internucleotide
 FT linkages"
 FT
 XX US5856103-A.
 PN
 XX 05-JAN-1999.
 PD
 XX 03-MAR-1997; 97US-00808474.
 PF
 XX 07-OCT-1994; 94US-00320507.
 PR (TEXA) UNIV TEXAS.
 XX
 XX Clark CL, Gray DM;
 PI
 XX WPI; 1999-105098/09.
 DR
 XX Selectively ranking nucleic acid molecules, for inhibitory efficiency -
 PT comprises determining the fraction a set of nearest-neighbour nucleic
 PT acid base pair types in a target sequence zone, substituting nearest-
 PT neighbour nucleic acid base pair fractions to determine the fractions and
 PT multiplying.
 PT
 XX Example 1; Col 21-22; 72pp; English.
 PS
 XX This oligonucleotide represents an antisense oligonucleotides (ASO)
 CC targeted to a region in the intercellular adhesion molecule (ICAM)-1 gene
 CC which is generated by a method of selectively ranking nucleic acid
 CC molecules for inhibitory efficiency. The method comprises: (a)
 CC determining the fraction of each of a set of 13 nearest-neighbour nucleic
 CC acid base pair types in a target sequence zone RNA:ASO-DNA hybrid nucleic
 CC acid sequence; (b) substituting nearest-neighbour nucleic acid base pair
 CC fractions into formulas to determine the fractions of each of a series of
 CC 13 nearest-neighbour nucleic acid base pair types to provide determined
 CC fractions; and (c) multiplying the fractions of the 13 nearest-neighbour
 CC nucleic acid base pair types by a stability ranking to the nucleic acid
 CC antisense sequence; where the results are ordered to produce a ranking
 CC of nucleic acid oligomer binding interactions to select sequence zones
 CC for antisense targeting
 XX

```
SQ Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2176 ACCAGCTATTATTGAGTGTC 2196
|||||
Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 107
AA18670/c
ID AAX18670 standard; DNA; 21 BP.
XX AAX18670;
XX
XX 10-MAY-1999 (first entry)
XX
XX Cellular adhesion protein ICM-1 antisense oligonucleotide GM1595.
XX
XX Cellular adhesion protein; proliferation; antisense oligonucleotide;
KW alimentary canal; transport; gastrointestinal mucosa; cancer;
KW Alzheimer's disease; beta-thalassemia; malaria; viral infection; HIV;
KW inflammation; ss.
XX
XX Synthetic.
XX
XX WO9901579-AL.
XX
XX 14-JAN-1999.
XX
XX 01-JUL-1998; 98WO-US013574.
XX
XX 01-JUL-1997; 97US-00886829.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Teng C, Hardee G;
XX
XX WPI; 1999-106077/09.
XX
XX Composition comprising nucleic acid and penetration enhancer - used
PT particularly for delivering therapeutic antisense oligonucleotides across
PT the gastrointestinal mucosa, provides high bioavailability.
XX
XX Example 2; Page 78; 115pp; English.
XX
XX A pharmaceutical composition has been developed which comprises a nucleic
CC acid and at least one penetration enhancer. The compositions are used:
CC (i) to treat or prevent any disease or disorder that can be treated with
CC the nucleic acid, e.g. cancer, Alzheimer's disease, beta-thalassemia,
CC malaria, viral infections (including human immune deficiency virus
CC (HIV)), inflammation, in human or animal medicine; (ii) to investigate
CC the role of a gene or gene product in non-human animals; and (iii) to
CC modulate gene expression in cells, tissues or organs. The compositions
CC provide bioavailability of at least 15, preferably 17-35,%. The
CC penetration enhancer improves: (i) transport of the nucleic acid across
CC the mucosa of the alimentary canal and into cells; and (ii) increases
CC stability of the nucleic acid. Oral administration avoids the
CC complications and expense of intravenous or other methods of
CC administration. AAX18669 to AAX18799 and AAX18801 represent antisense
CC oligonucleotides which can be used as the nucleic acid in the method of
CC the invention
XX
XX Sequence 21 BP; 5 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 AACCTCAGCCTCGCTATGGCT 63
|||||

Db 21 AACCTCAGCCTCGCTATGGCT 1

RESULT 108
AAX09079/c
ID AAX09079 standard; DNA; 21 BP.
XX AAX09079;
XX
XX 14-JUN-1999 (first entry)
XX
XX Tumour necrosis factor alpha antisense oligonucleotide.
XX
XX Tumour necrosis factor alpha; TNF-alpha; antisense oligonucleotide; ASO;
KW inhibition; expression; treatment; disease; disorder; ss.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX WO9901139-AL.
XX
XX 14-JAN-1999.
XX
XX 02-JUL-1998; 98WO-US013711.
XX
XX 03-JUL-1997; 97US-0051705P.
XX
XX (UYJE-) UNIV JEFFERSON THOMAS.
XX
XX Tu G, Israel Y;
XX
XX WPI; 1999-105767/09.
XX
XX Generation of antisense oligonucleotides - by specifically targeting a
PT GGGA motif found in mRNA sequences.
XX
XX Example 2; Page 37; 55pp; English.
XX
XX Antisense oligonucleotides (ASO) for inhibiting a tumour necrosis factor-
CC alpha (TNF-alpha) gene in an animal, preferably a human, comprise 12-50
CC nucleotides, 90% of which are complementary to a region of mRNA
CC containing a GGGA sequence motif. The ASO is used to inhibit expression
CC of a gene in an animal and for treating the animal when afflicted with a
CC disease or disorder characterised by the presence of an mRNA from a gene
CC containing a GGGA motif. The ASO are specifically targeted to a GGGA
CC sequence motif found in mRNA from a gene. A study of known ASO has shown
CC that at least half of the most efficacious ASO's contain one or more TCCC
CC motifs. This ASO comprises a TCCC motif followed by a cytosine residue
CC and corresponds to a region of the human ICM-1 3' untranslated region
XX
XX Sequence 21 BP; 3 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1937 TGAGAGGGGAACTGGTGGGG 1957
|||||
Db 21 TGAGAGGGGAACTGGTGGGG 1

RESULT 109
AAX23579/c
ID AAX23579 standard; DNA; 21 BP.
XX AAX23579;
XX
XX 18-JUN-1999 (first entry)
XX
XX Deletion sequence oligonucleotide 32.
KW Deletion sequence oligonucleotide; sensor array; eukaryotic pathogen;
KW probe; cellular adhesion modulator; cellular proliferation modulator;
```

KW human retrovirus; human immunodeficiency virus; non-human retrovirus;
 KW HIV; primer; ss.
 XX
 OS Synthetic.
 XX
 PN W09911820-A1.
 XX
 PD 11-MAR-1999.
 XX
 XX 01-SEP-1998; 98WO-US018084.
 XX
 PF 02-SEP-1997; 97US-00923771.
 XX
 PR (ISIS-) ISIS PHARM INC.
 XX
 PA Chen D; Srivatsa GS;
 XX
 PI WPI; 1999-205198/17.
 XX
 DR
 XX
 XX New compositions comprising sensor arrays made up of unique probe
 PT oligonucleotides - useful for characterizing a sample of target deletion
 PT oligonucleotides.
 PT
 XX
 PS Example 9; Page 100; 163pp; English.
 XX
 CC This invention describes a novel composition comprising a number of
 CC sensor arrays, where each array comprises a unique probe oligonucleotide,
 CC which is the reverse complement of part of a unique target
 CC oligonucleotide present in a mixture of target deletion sequence
 CC oligonucleotides. The compositions form a method for characterizing a
 CC sample of target deletion oligonucleotides which are labelled and
 CC hybridize with the probe oligonucleotides of the sensor arrays. Such
 CC oligonucleotides and their targets are represented in AAX23548-X23709.
 CC Oligonucleotides characterized by the method form pharmaceutical
 CC compositions that are useful for modulating cellular adhesion or
 CC proliferation, and being active against a eukaryotic pathogen, a human
 CC retrovirus, a human immunodeficiency virus (HIV), or a non-human
 CC retrovirus, including influenza virus, Epstein-Barr virus, Respiratory
 CC Syncytial Virus or cytomegalovirus (CMV). The compositions enable
 CC characterization of deletion sequence oligonucleotides having related,
 CC but different nucleobase sequences, and quantification of different
 CC species of deletion sequence ("target") oligonucleotides in a mixture.
 CC Also, if the specificity of the oligonucleotide's nucleobase sequence for
 CC its reverse complement is not modified, the method may be performed using
 CC oligodeoxynucleotides
 XX
 SQ Sequence 21 BP; 5 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 43 AACCTCAGCTCGCTATGGCT 63
 DB 21 AACCTCAGCTCGCTATGGCT 1
 RESULT 110
 AAA33391/c
 ID AAA33391 standard; DNA; 21 BP.
 XX
 AC AAA33391;
 XX
 DT 28-JUL-2000 (first entry)
 XX
 DE Low adenosine antisense oligonucleotide SEQ ID NO:1080.
 XX
 KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiasthmatic; cytosstatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;

KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 OS Homo sapiens.
 XX
 PN W0200009525-A2.
 XX
 PD 24-FEB-2000.
 XX
 XX 03-AUG-1999; 99WO-US017712.
 PF
 XX 03-AUG-1998; 98US-0095212P.
 PR (UYEC-) UNIV EAST CAROLINA.
 XX
 PA Nyce JW;
 XX
 PI WPI; 2000-205971/18.
 XX
 DR
 XX New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers.
 XX
 PS Claim 18; Page 400; 1343pp; English.
 XX
 CC The present invention describes a new composition comprising an antisense
 CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
 CC nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cytosstatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
 CC impaired respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of the
 CC ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
 CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
 CC from the previously named sequences. SEQ ID NO:11 to 1880 (AAA32323 to
 CC AAA33992) are specifically claimed ONs from the present invention. N.B.
 CC Sequences given in the disclosure of the present invention do not match
 CC up with their corresponding SEQ ID NO: sequences given in the sequence
 CC listing
 XX
 SQ Sequence 21 BP; 0 A; 11 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1765 GGGACGCCCGGAGGACAGGGCA 1785
 DB 21 GGGACGCCCGGAGGACAGGGCA 1
 RESULT 111
 AAZ49338/c
 ID AAZ49338 standard; DNA; 21 BP.
 XX
 AC AAZ49338;
 XX
 DT 14-MAR-2000 (first entry)
 XX
 DE ICAM-1 targetted antisense oligonucleotide GM1595.
 XX

KW Cellular adhesion; expression; modulation; antisense; non-parenteral;
 KW delivery; uptake; administration; emulsion; ulcerative colitis;
 KW Crohn's disease; inflammatory bowel disease; cellular proliferation; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9960012-A1.
 XX
 PD 25-NOV-1999.
 XX
 XX 20-MAY-1999; 99WO-US011394.
 XX
 PF 21-MAY-1998; 98US-00082624.
 XX
 PR (ISIS-) ISIS PHARM INC.
 XX
 PA Teng C, Cook PD, Tillman L, Hardee GE, Ecker DJ, Manoharan M;
 XX
 PI WPI; 2000-072428/06.
 XX
 DR New oligonucleotide compositions used for the non-parenteral delivery of
 PT e.g. antisense oligos, ribozymes, peptide nucleic acids, molecular
 PT decoys, external guide sequences or aptamers.
 XX
 PS Example 2 ; Page 120; 133pp; English.
 XX
 CC Sequences AAZ49336-Z49343 and AAZ49390 represent antisense
 CC oligonucleotides designed to modulate cellular adhesion. The invention
 CC relates to new compositions for the non-parenteral delivery of
 CC oligonucleotides comprising at least one oligonucleotide in an emulsion.
 CC Oligonucleotides delivered via the compositions of the invention can be
 CC used to modulate expression of a cellular adhesion protein, modulate a
 CC rate of cellular proliferation, or have biological activity against
 CC eukaryotic pathogens or retroviruses. They can be used for treating
 CC conditions including e.g., ulcerative colitis, Crohn's disease,
 CC inflammatory bowel disease or undue cellular proliferation. The
 CC compositions can enhance the local and systemic uptake and delivery of
 CC nucleic acids via non-parenteral routes of administration (e.g., via the
 CC alimentary canal, skin, eyes, pulmonary tract, urethra or vagina)
 XX
 SQ Sequence 21 BP; 5 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 43 AACCTCAGCTCGCTATGGCT 63
 Db 21 AACCTCAGCTCGCTATGGCT 1
 RESULT 112
 AAFL9513/C
 ID AAFL9513 standard; DNA; 21 BP.
 XX
 AC AAFL9513;
 XX
 XX 14-MAR-2001 (first entry)
 XX
 XX Human ICAM-1 polynucleotide fragment #1080.
 XX
 KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX

OS Homo sapiens.
 XX
 PN WO200062736-A2.
 XX
 PD 26-OCT-2000.
 XX
 XX 24-MAR-2000; 2000WO-US008020.
 XX
 PF 06-APR-1999; 99US-0127958P.
 XX
 PR (UYEC-) UNIV EAST CAROLINA.
 XX
 PA (NYCE/) NYCE J W.
 XX
 PI Nyce JW;
 XX
 XX WPI; 2000-679539/66.
 XX
 DR Low adenosine (A) content antisense oligonucleotides which do not trigger
 PT adenosine receptors during metabolism, useful e.g. for treating cancers
 PT and respiratory obstructions.
 XX
 PS Claim 14; Page 145; 1592pp; English.
 XX
 CC The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and/or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
 CC surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAFL8434 to AAFL21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention
 XX
 SQ Sequence 21 BP; 0 A; 11 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1765 GGGACGCGGAGGACAGGGCA 1785
 Db 21 GGGACGCGGAGGACAGGGCA 1
 RESULT 113
 AAZ48895/C
 ID AAZ48895 standard; DNA; 21 BP.
 XX
 AC AAZ48895;
 XX
 XX 29-MAR-2000 (first entry)
 XX
 XX Human ICAM-1 antisense inhibitor, ISIS #1572.

XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
KW ss.
XX Homo sapiens.
OS
XX WO9961462-A1.
PN
XX 02-DEC-1999.
PD
XX 26-MAY-1999; 99WO-US011548.
PF
XX 27-MAY-1998; 98US-00085759.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Bennett CF, Mirabelli CK, Baker BF;
PI WPI; 2000-072600/06.
DR
XX New antisense oligonucleotides, used for treating e.g. inflammatory
PT conditions, psoriasis, graft rejection, cancers, infections,
PT cardiovascular disorders or autoimmune disorders.
PT
XX Example 7; Page 65; 199pp; English.
PS
XX This sequence is an antisense oligonucleotide of the invention. The
CC antisense oligonucleotides are targeted to a nucleic acid encoding a
CC cellular adhesion molecule (CAM) and is capable of modulating the
CC expression of the CAM. They particularly inhibit intercellular adhesion
CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
CC oligonucleotides can be used to modulate CAM activity in mediating
CC cell-cell interactions and subsequent cellular and biological responses,
CC e.g. T cell activation, leukocyte transmigration and inflammation. The
CC antisense sequences can be used for modulating the synthesis of a CAM.
CC They can be used for treating an animal suspected of having or being
CC prone to a disease or condition associated with a CAM. Oligonucleotides
CC targeted to ICAM-1 can be used for treating an inflammatory disease or
CC condition e.g. inflammatory bowel disease such as Crohn's disease,
CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
CC can also be used for reducing corticosteroid use in a patient or for
CC reducing cyclosporine use in a patient. The oligonucleotides can also be
CC used for detection and diagnosis. They can also be used for treating e.g.
CC hyperproliferative disorders, tumours, diapedesis, graft versus host
CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
CC vulgaris, systemic lupus erythematosus, cardiovascular disorders, acute
CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
CC myocarditis, ischaemic heart disease or stroke
XX
SQ Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2176 ACCAGCTATTATTAGTGTC 2196
|||
Db 21 ACCAGCTATTATTAGTGTC 1
|||

AAF96034
ID AAF96034 standard; DNA; 21 BP.
XX
AC AAF96034;
XX
DT 18-NOV-2004 (revised)
XT 06-JUN-2001 (first entry)
XX
DE Human gene single nucleotide polymorphism #795.
XX
DE Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.
XX
OS Homo sapiens.
OS Unidentified.
XX
FH Key Location/Qualifiers
FT variation 11
FT /*tag= a
FT /standard_name= "Single nucleotide polymorphism"
XX
XX WO200118250-A2.
XX
XX 15-MAR-2001.
XX
XX 07-SEP-2000; 2000WO-US024503.
PF
XX 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
PR
XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
PI WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
XX Example; Page 104; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
CC
CC Revised record issued on 18-NOV-2004 : The variantion feature was
CC incorrectly given a capital V
XX
SQ Sequence 21 BP; 3 A; 7 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1452 GGTCAACCCGCGAGGTGACCGT 1472
|||||
Db 1 GGTCAACCCGCGAGGTGACCGT 21
|||||

```
RESULT 115
AAF96035
ID AAF96035 standard; DNA; 21 BP.
XX
XX
AC AAF96035;
XX
XX 18-NOV-2004 (revised)
DT 06-JUN-2001 (first entry)
XX
XX Human gene single nucleotide polymorphism #796.
XX
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
OS
OS Unidentified.
XX
XX Key Location/Qualifiers
FH variation 11
FT /*tag= a
FT /standard_name= "Single nucleotide polymorphism"
XX
XX WO200118250-A2.
XX
XX 15-MAR-2001.
XX
XX 07-SEP-2000; 2000WO-US024503.
XX
XX 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JU;
PI WPI; 2001-226749/23.
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
XX Example; Page 104; 242pp; English.
XX
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
XX
XX Revised record issued on 18-NOV-2004 : The variantion feature was
CC incorrectly given a captial V
XX
XX Sequence 21 BP; 4 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 214 GACCAGCCCAAGTTGTGGGC 234
Db 1 GACCAGCCCAAGTTGTGGGC 21
RESULT 116
AAF87790/c
ID AAF87790 standard; DNA; 21 BP.
XX
XX
AC AAF87790;
XX
XX 11-JUL-2001 (first entry)
DT
XX
XX Human intracellular adhesion molecule 1 (ICAM-1) S-ASO SEQ ID NO:17.
XX
XX Antisense DNA oligomer; ASO; identification; gene therapy; target;
KW Nearest-Neighbour Thermal Stability Program; thermal melting temperature;
KW phosphorothioate; disease treatment; DNA-RNA hybrid; human; ICAM-1;
KW intracellular adhesion molecule 1; ss.
XX
XX Homo sapiens.
OS
XX US6183966-B1.
XX
XX 06-FEB-2001.
XX
XX 22-JAN-1999; 99US-00235614.
XX
XX 07-OCT-1994; 94US-00320507.
PR 03-MAR-1997; 97US-00808474.
XX
XX (TEXA ) UNIV TEXAS SYSTEM.
XX
XX Gray DM, Clark CU;
PI WPI; 2001-280429/29.
XX
XX Identifying a nucleic acid having a sequence capable of targeting a gene
PT of interest, for identifying nucleic acids for gene therapy, comprises
PT using the Nearest-Neighbor Thermal Stability Program.
XX
XX Example 1; Col 27-28; 43pp; English.
XX
XX The present invention describes a method for the identification of a
CC nucleic acid having a sequence capable of targeting a gene of interest
CC comprises: (a) a first database having a list of stability values for
CC independent combinations of N(x); (b) a computing unit having a means for
CC inputting data comprising N(x); data list, defining a nucleic acid
CC sequence of interest to be targeted to provide a second database; and (c)
CC a program capable of processing the first and second database to N(x)
CC comparison, and a stability value of a nucleic acid sequence capable of
CC targeting the gene of interest. The method is useful for identifying a
CC nucleic acid having a sequence capable of targeting a gene of interest.
CC These nucleic acids are useful in gene therapy and disease treatment. The
CC method may be used to obtain thermodynamic parameters for 20 combinations
CC of nearest-neighbour base pairs of DNA:RNA hybrid sequences. The Nearest-
CC Neighbour Thermal Stability Program can process data for use in
CC calculating thermal melting temperatures for phosphorothioate DNA:RNA
CC hybrids. The program can be readily extended to predict the most stable
CC triplex-forming sequences, or antigene oligomers. The present sequence
CC represents an antisense DNA oligomer designated S-ASO targeted to the
CC human intracellular adhesion molecule 1 (ICAM-1), which is used in an
CC example from the present invention
XX
XX Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2176 ACCAGCTATTATTGAGTGTC 2196
Db 21 ACCAGCTATTATTGAGTGTC 1
RESULT 117
AB279519/c
```

ID ABZ79519 standard; DNA; 21 BP.
 XX AC ABZ79519;
 XX OS
 XX 10-MAY-2003 (first entry)
 DT XX
 DE ICAM-1 reverse primer # SEQ ID 24.
 XX
 XX AK155 receptor; cytokine receptor; inflammation; Crohn's disease;
 KW autoimmune disease; multiple sclerosis; rheumatoid arthritis; psoriasis;
 KW asthma; allergy; diabetes mellitus; Sjogren's syndrome;
 KW transplant rejection; angiogenesis; cancer; PCR; primer; ss.
 XX
 XX Unidentified.
 OS
 XX WO2003002717-A2.
 PN
 XX 09-JAN-2003.
 PD
 XX 27-JUN-2002; 2002WO-US020489.
 PF
 XX 28-JUN-2001; 2001US-0302176P.
 PR
 XX 03-JAN-2002; 2002US-0345690P.
 PR
 XX (SCHE) SCHERING CORP.
 XX (FINK/) FINKENSCHER H.
 PA
 PA Finkensch H, De Waal Malefyt R, Nagalakshmi ML, Moore K;
 PI
 XX WPI; 2003-278256/27.
 DR
 XX
 XX New cells recombinantly altered to express an exogenous AK155 cytokine
 PT receptor, useful for identifying agents for treating AK155-mediated
 PT diseases, e.g. inflammation, angiogenesis or cancer.
 XX
 XX Example 2; Page 51; 100pp; English.
 PS
 XX The present invention relates to a cell recombinantly altered to express
 CC an exogenous AK155 cytokine receptor comprising alpha and beta subunits.
 CC The cytokine receptor, when expressed in Ba/F3 cells, binds to AK155 and
 CC stimulates binding of STAT3 to interferon (IFN) gamma-activated
 CC sequences. The cell is useful in expressing AK155 cytokine receptor which
 CC may be used for identifying therapeutic agents useful for treating AK155-
 CC mediated conditions or diseases, such as inflammation (e.g. Crohn's
 CC disease), autoimmune diseases (e.g. multiple sclerosis, rheumatoid
 CC arthritis, psoriasis, asthma, allergies, diabetes mellitus, Sjogren's
 CC syndrome), transplant rejection, angiogenesis, and cancer. The current
 CC sequence represents an ICAM-1 reverse primer sequence
 XX
 XX Sequence 21 BP; 4 A; 5 C; 5 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 997 AACGTGATTCGACGAAGCCA 1017
 Db |||||
 21 AACGTGATTCGACGAAGCCA 1
 RESULT 118
 ADC38977/c
 ID ADC38977 standard; DNA; 21 BP.
 XX
 XX ADC38977;
 AC
 XX 18-DEC-2003 (first entry)
 DT
 XX Human ICAM-1 targeted primer #3.
 DE
 XX ss; primer; immunosuppressive; antisense therapy;
 KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
 KW extracellular adhesion molecule-1; ELAM-1;

KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
 XX
 XX Synthetic.
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FT misc_difference 1..21
 FT /tag= a
 FT /note= "internucleotide linkages are optionally
 XX phosphodiester bonds"
 PN WO2003032920-A2.
 XX
 XX 24-APR-2003.
 PD
 XX 16-OCT-2002; 2002WO-US033236.
 PF
 XX 18-OCT-2001; 2001US-00982262.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Bennett CF, Mirabelli CK;
 PI
 XX WPI; 2003-403142/38.
 DR
 XX Inhibiting corneal allograft rejection, by contacting an allograft with a
 PT formulation having an oligonucleotide targeted to intercellular
 PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
 PT molecule-1.
 XX
 XX Example 5; SEQ ID NO 3; 106pp; English.
 PS
 XX The invention relates to a method of inhibiting corneal allograft
 CC rejection, by contacting the allograft with a topical formulation
 CC comprising an antisense oligonucleotide targeted to intercellular
 CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
 CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
 CC useful for inhibiting corneal allograft rejection or for preserving a
 CC corneal explant ex vivo, where the explant is human. This sequence
 CC corresponds to one of the oligonucleotide of the invention.
 XX
 XX Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2176 ACCAGCTATTATTGAGTGTC 2196
 Db |||||
 21 ACCAGCTATTATTGAGTGTC 1
 RESULT 119
 AAD58981/c
 ID AAD58981 standard; DNA; 21 BP.
 XX
 XX AAD58981;
 AC
 XX 18-DEC-2003 (first entry)
 DT
 XX Intracellular adhesion molecule (ICAM-1) antisense oligo, GM1595.
 DE
 XX Inflammatory bowel disorder; ulcerative colitis; Crohn's disease;
 KW cellular proliferation; intracellular adhesion molecule; ICAM-1;
 KW antisense; ss.
 KW
 XX Unidentified.
 OS
 XX US2003040497-A1.
 PN
 XX 27-FEB-2003.
 PD
 XX 21-DEC-2001; 2001US-00029598.
 PF


```
XX 01-JUL-1997; 97US-00866829.
PR 01-JUL-1998; 98US-00108673.
PR 20-MAY-1999; 99US-00315298.
XX (TENG/) TENG C.
PA (COOK/) COOK P. D.
PA (TILL/) TILLMAN L.
PA (HARD/) HARDEE G. E.
PA (ECKE/) ECKER D. J.
PA (MANO/) MANOHARAN M.
XX Teng C, Cook PD, Tillman L, Hardee GE, Ecker DJ, Manoharan M;
PI WPI; 2003-596370/56.
XX
XX Formulation, useful for treating inflammatory bowel disorder, e.g.
PT ulcerative colitis or Crohn's disease, comprises oligonucleotide for
PT rectal delivery.
XX
XX Example 2; Page 33; 45pp; English.
XX The invention relates to formulations and methods which enhance the local
XX and systemic uptake and delivery of oligonucleotides and nucleic acids
XX via non-parenteral routes of administration. The formulation is used for
XX treating inflammatory bowel disorders, e.g. ulcerative colitis, Crohn's
XX disease or inflammatory bowel disease, in animals (e.g. human). It can
XX also be used for treating undue cellular proliferation. The present
XX sequence is an antisense oligonucleotide targetted to intracellular
XX adhesion molecule (ICAM-1) gene. This sequence is used to illustrate the
XX method of the invention
XX
XX Sequence 21 BP; 5 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 43 AACCTCAGCCTCGCTATGGCT 63
DB 21 AACCTCAGCCTCGCTATGGCT 1
|
RESULT 120
ADD56653/c
ID ADD56653 standard; DNA; 21 BP.
AC ADD56653;
XX 15-JAN-2004 (first entry)
DE Human gene expression analysis multiplex Start-PCR primer #173.
XX
XX Gene expression; multiplex standardised reverse transcriptase-PCR;
KW Start-PCR; high density oligonucleotide array; cDNA array;
KW small biological sample; fine needle aspirate biopsy;
KW laser captured microdissected material; human; primer; ss.
XX
XX Homo sapiens.
XX US2003186246-A1.
XX 02-OCT-2003.
XX 28-MAR-2002; 2002US-00109349.
XX 28-MAR-2002; 2002US-00109349.
XX (WILL/) WILLEY J C.
XX (CRAW/) CRAWFORD E L.
XX Willey JC, Crawford EL;
XX WPI; 2003-811730/76.
XX Direct comparison of numerical gene expression values between samples of
PT genes comprises using multiplex standardized reverse transcription-
XX polymerase chain reaction.
XX Example 1; SEQ ID NO 172; 59pp; English.
```

```
DR WPI; 2003-811730/76.
XX Direct comparison of numerical gene expression values between samples of
PT genes comprises using multiplex standardized reverse transcription-
PT polymerase chain reaction.
XX Example 1; SEQ ID NO 173; 59pp; English.
XX The present invention relates to a method for the direct comparison of
XX numerical gene expression values between samples of genes. The method
XX comprises amplifying cDNA in the presence of a competitive template
XX mixture and primer pairs for several genes and then amplifying aliquots
XX of the PCR products using a primer pair specific for each gene. The
XX method of amplification is by multiplex standardised reverse
XX transcriptase-polymerase chain reaction (Start-PCR). High density
XX oligonucleotide or cDNA arrays are used to measure PCR products following
XX quantitative Start-PCR. The method is useful for the assessment of gene
XX expression in small biological samples such as fine needle aspirate
XX biopsies, and laser captured microdissected materials. The method allows
XX for the standardised measurement of hundreds of genes from the same
XX sample, which in prior art, could only be assessed for one gene. The
XX present sequence represents a multiplex Start-PCR primer which can be
XX used in the method of the present invention.
XX
XX Sequence 21 BP; 4 A; 5 C; 5 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 997 AACGTGATTCTGACGAGCCCA 1017
DB 21 AACGTGATTCTGACGAGCCCA 1
|
RESULT 121
ADD56652
ID ADD56652 standard; DNA; 21 BP.
AC ADD56652;
XX 15-JAN-2004 (first entry)
DE Human gene expression analysis multiplex Start-PCR primer #172.
XX
XX Gene expression; multiplex standardised reverse transcriptase-PCR;
KW Start-PCR; high density oligonucleotide array; cDNA array;
KW small biological sample; fine needle aspirate biopsy;
KW laser captured microdissected material; human; primer; ss.
XX
XX Homo sapiens.
XX US2003186246-A1.
XX 02-OCT-2003.
XX 28-MAR-2002; 2002US-00109349.
XX 28-MAR-2002; 2002US-00109349.
XX (WILL/) WILLEY J C.
XX (CRAW/) CRAWFORD E L.
XX Willey JC, Crawford EL;
XX WPI; 2003-811730/76.
XX Direct comparison of numerical gene expression values between samples of
PT genes comprises using multiplex standardized reverse transcription-
XX polymerase chain reaction.
XX Example 1; SEQ ID NO 172; 59pp; English.
```

CC The present invention relates to a method for the direct comparison of
 CC numerical gene expression values between samples of genes. The method
 CC comprises amplifying cDNA in the presence of a competitive template
 CC mixture and primer pairs for several genes and then amplifying aliquots
 CC of the PCR products using a primer pair specific for each gene. The
 CC method of amplification is by multiplex standardised reverse
 CC transcriptase-polymerase chain reaction (Start-PCR). High density
 CC oligonucleotide or cDNA arrays are used to measure PCR products following
 CC quantitative Start-PCR. The method is useful for the assessment of gene
 CC expression in small biological samples such as fine needle aspirate
 CC biopsies, and laser captured microdissected materials. The method allows
 CC for the standardised measurement of hundreds of genes from the same
 CC sample, which in prior art, could only be assessed for one gene. The
 CC present sequence represents a multiplex Start-PCR primer which can be
 CC used in the method of the present invention.

XX Sequence 21 BP; 4 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 674 CCTACCAGCTCCAGACCTTTG 594
 DB 1 CCTACCAGCTCCAGACCTTTG 21
 |||||

RESULT 122

ADF70305/c
 ID ADF70305 standard; DNA; 21 BP.

XX ADF70305;

XX 12-FEB-2004 (first entry)

DE ICAM antisense oligonucleotide SeqID18.

XX expression modulation; hepatic system; sterol group; hepatotropic;
 KW gene therapy; hepatic disease; antisense therapy; ss; ICAM;
 KW intercellular adhesion molecule.

XX Unidentified.

XX WO2003072711-A2.

XX 04-SEP-2003.

XX 21-FEB-2003; 2003WO-US005066.

XX 22-FEB-2002; 2002US-00080979.

XX (ISIS-) ISIS PHARM INC.

XX Cook PD, Manoharan M, Bennett FC;

XX WPI; 2003-679947/64.

XX Modulating the expression of a nucleic acid in the hepatic system, useful
 PT for treating hepatic disorders, comprises administering to the mammal an
 PT oligonucleotide that hybridizes to the nucleic acid to modulate its
 PT expression.

XX Example 7; SEQ ID NO 18; 98pp; English.

XX This invention relates to a novel method of modulating the expression of
 CC a nucleic acid in the hepatic system of a mammal which comprises
 CC administering to the mammal an oligonucleotide that hybridizes to the
 CC nucleic acid to modulate the expression of the nucleic acid, where the
 CC oligonucleotide has two sterol groups that are covalently bonded. The
 CC invention may be useful for the development of a compound with
 CC hepatotropic activity whilst the genetic sequences of the invention may
 CC prove useful for gene therapy. The methods are useful for treating
 CC hepatic disease or disorder associated with a protein encoded by a gene.

CC Note: These oligonucleotides may have one or more of several
 CC modifications which are detailed in the specification, including having a
 CC phosphorothioate backbone or having ribonucleoside bases.

XX Sequence 21 BP; 4 A; 8 C; 5 G; 3 T; 1 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGCA 2120
 DB 21 TGACGGATGCCAGCTTGGCA 1
 |||||

RESULT 123

ADF70359/c
 ID ADF70359 standard; DNA; 21 BP.

XX ADF70359;

XX 12-FEB-2004 (first entry)

DE ICAM antisense oligonucleotide SeqID73.

XX expression modulation; hepatic system; sterol group; hepatotropic;
 KW gene therapy; hepatic disease; antisense therapy; ss; ICAM;
 KW intercellular adhesion molecule.

XX Unidentified.

XX WO2003072711-A2.

XX 04-SEP-2003.

XX 21-FEB-2003; 2003WO-US005066.

XX 22-FEB-2002; 2002US-00080979.

XX (ISIS-) ISIS PHARM INC.

XX Cook PD, Manoharan M, Bennett FC;

XX WPI; 2003-679947/64.

XX Modulating the expression of a nucleic acid in the hepatic system, useful
 PT for treating hepatic disorders, comprises administering to the mammal an
 PT oligonucleotide that hybridizes to the nucleic acid to modulate its
 PT expression.

XX Example 7; SEQ ID NO 73; 98pp; English.

XX This invention relates to a novel method of modulating the expression of
 CC a nucleic acid in the hepatic system of a mammal which comprises
 CC administering to the mammal an oligonucleotide that hybridizes to the
 CC nucleic acid to modulate the expression of the nucleic acid, where the
 CC oligonucleotide has two sterol groups that are covalently bonded. The
 CC invention may be useful for the development of a compound with
 CC hepatotropic activity whilst the genetic sequences of the invention may
 CC prove useful for gene therapy. The methods are useful for treating
 CC hepatic disease or disorder associated with a protein encoded by a gene.
 CC Note: These oligonucleotides may have one or more of several
 CC modifications which are detailed in the specification, including having a
 CC phosphorothioate backbone or having ribonucleoside bases.

XX Sequence 21 BP; 4 A; 8 C; 5 G; 3 T; 1 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGCA 2120
 |||||

Db 21 TGACGGATGCCAGCTGGGCA 1

RESULT 124
ABZ95207/c
ID ABZ95207 standard; DNA; 21 BP.
XX
AC ABZ95207;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM-1 antisense fragment no.1072.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW adenosine gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 10449; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 21 BP; 0 A; 11 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1765 GGGAGCGCCGAGGACAGGGCA 1785
|||||

Db 21 GGGAGCGCCGAGGACAGGGCA 1

RESULT 125
ABD19149/c
ID ABD19149 standard; DNA; 21 BP.
XX
AC ABD19149;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human ICAM-1 DNA fragment 1072.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ds.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 10449; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposcretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiasthmatic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of

CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 21 BP; 0 A; 11 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1765 GGGACCGCCGGACACAGGCA 1785
DB 21 GGGACCGCCGGACACAGGCA 1

RESULT 126

AD156732
ID AD156732 standard; DNA; 21 BP.

XX AC AD156732;

XX DT 15-APR-2004 (first entry)

XX DE Human ICAM-1 G496 allele PCR primer, SEQ ID 6.

XX KW Schizophrenia; intercellular adhesion molecule-1; ICAM-1; human; PCR;
XX primer; ss.

XX OS Homo sapiens.

XX PN WO2004009845-A2.

XX PD 29-JAN-2004.

XX PF 23-JUL-2003; 2003WO-EP008086.

XX PR 23-JUL-2002; 2002US-0397611P.

XX PA (MUEL/) MUELLER N.

XX PI Mueller N;

XX DR WPI; 2004-123407/12.

XX PT Screening for schizophrenia, useful for predicting clinical response to a
XX compound for treating schizophrenia comprising assaying nucleic acid for
XX a codon encoding arginine at amino acid position 241 of intercellular
XX adhesion molecule-1.

XX PS Disclosure; SEQ ID NO 6; 34pp; English.

XX CC The present invention relates to a method for screening for
XX schizophrenia. The method comprises assaying a DNA sample for the
XX presence of a codon encoding arginine at amino acid position 241 of the
XX intercellular adhesion molecule-1 (ICAM-1) protein or a protein sample
XX for the presence of the ICAM-1 protein having the 241A polymorphism,
XX where the presence of a codon encoding arginine at amino acid position
XX 241 of the ICAM-1 protein or of the polymorphism is indicative of a
XX schizophrenia. The method is useful for predicting clinical response to a
XX therapeutic compound in the treatment of ICAM-1 mediated schizophrenia.
XX The present sequence is a PCR primer, which was used in an example from
XX the invention.

XX SQ Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1403 GAGATCTTGAGGCACCTACC 1423
DB 1 GAGATCTTGAGGCACCTACC 21

RESULT 127

AD156734/c
ID AD156734 standard; DNA; 21 BP.

XX AC AD156734;

XX DT 15-APR-2004 (first entry)

XX DE Human ICAM-1 A496G allele SNAPshot primer, SEQ ID 8.

XX KW Schizophrenia; intercellular adhesion molecule-1; ICAM-1; human;
XX SNAPshot; primer; ss.

XX OS Homo sapiens.

XX PN WO2004009845-A2.

XX PD 29-JAN-2004.

XX PF 23-JUL-2003; 2003WO-EP008086.

XX PR 23-JUL-2002; 2002US-0397611P.

XX PA (MUEL/) MUELLER N.

XX PI Mueller N;

XX DR WPI; 2004-123407/12.

XX PT Screening for schizophrenia, useful for predicting clinical response to a
XX compound for treating schizophrenia comprising assaying nucleic acid for
XX a codon encoding arginine at amino acid position 241 of intercellular
XX adhesion molecule-1.

XX PS Disclosure; SEQ ID NO 8; 34pp; English.

XX CC The present invention relates to a method for screening for
XX schizophrenia. The method comprises assaying a DNA sample for the
XX presence of a codon encoding arginine at amino acid position 241 of the
XX intercellular adhesion molecule-1 (ICAM-1) protein or a protein sample
XX for the presence of the ICAM-1 protein having the 241A polymorphism,
XX where the presence of a codon encoding arginine at amino acid position
XX 241 of the ICAM-1 protein or of the polymorphism is indicative of a
XX schizophrenia. The method is useful for predicting clinical response to a
XX therapeutic compound in the treatment of ICAM-1 mediated schizophrenia.
XX The present sequence is a PCR primer, which was used in an example from
XX the invention.

XX SQ Sequence 21 BP; 6 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 AGGTGACCGTGAATGCTCT 1483
DB 21 AGGTGACCGTGAATGCTCT 1

RESULT 128

AD182247
ID AD182247 standard; DNA; 21 BP.

XX AC AD182247;

XX DT 22-APR-2004 (first entry)

XX DE RTQ PCR probe for Human ICAM.

XX KW Human; ss; PCR; embryonic stem cell; pluripotent stem cell;
XX abnormal cell growth; malignancy; differentiation; probe; RTQ-PCR;
XX realtime quantitative PCR.

```

XX OS Homo sapiens.
XX PN US2003224411-A1.
XX PD 04-DEC-2003.
XX PF 13-MAR-2003; 2003US-00388578.
XX PR 13-MAR-2003; 2003US-00388578.
XX PA (STAN/) STANTON L W.
XX PA (BRAN/) BRANDENBERGER R.
XX PA (GOLD/) GOLD J D.
XX PA (IRVI/) IRVING J M.
XX PA (MAND/) MANDALAM R.
XX PA (MOKM/) MOK M.
XX PA (SHEL/) SHELTON D.
XX PI Stanton LW, Brandenberger R, Gold JD, Irving JM, Mandalam R;
XX PI Mok M, Shelton D;
XX DR WPI; 2004-119701/12.
XX PT Assessing culture of undifferentiated primate pluripotent stem cells by
XX PT detecting expression of markers e.g., Zic family member 3, other than
XX PT human telomerase reverse transcriptase/octamer binding transcription
XX PT factor.
XX PS Example 4; SEQ ID NO 77; 106pp; English.
XX CC The invention relates to assessing a culture of undifferentiated primate
XX CC pluripotent stem cells (pPS, e.g. embryonic stem cells), involving
XX CC detecting expression of markers (MR1) e.g. Zic family member 3 (ZIC3), as
XX CC given in specification, other than human telomerase reverse transcriptase
XX CC (hTERT) or octamer binding transcription factor (Oct)3/4, or a marker
XX CC (MR2) such as crypto or podocalyxin-like protein and hTERT and/or Oct3/4
XX CC or second marker chosen from (MR2). Also included are maintaining (M2)
XX CC pPS cells in a pluripotent state (involves causing them to express one of
XX CC the following markers (MR3) at a higher level, FOXO1A, ZIC3, hypothetical
XX CC KRAB-zinc finger protein SZFI-1 or zinc finger protein of cerebellum
XX CC ZIC2, or any other marker (MR4) chosen from PHD protein Jade-1 (Jade-1),
XX CC kruppel-like zinc finger protein (ZNF300), etc., as given in the
XX CC specification), causing pPS cells to differentiate into a particular
XX CC tissue type by causing them to express one of the markers chosen from
XX CC (MR3) or (MR4) (or markers chosen from GATA binding protein 3 (GATA3),
XX CC core promoter element binding protein (COPEB), etc., as given in the
XX CC specification), maintaining pPS cells in a pluripotent state (involves
XX CC culturing pPS cells or their progeny in the presence of a normally
XX CC secreted protein that is encoded by a gene that down-regulated upon
XX CC differentiation of human embryonic stem (hES) cells, chosen from
XX CC Fibrillin 3 gene, LEFT B gene, ZIC3 gene, EPHA1 gene, etc., as given in
XX CC the specification), causing pPS cells to differentiate (involves
XX CC culturing pPS cells or their progeny in the presence of a normally
XX CC secreted protein that is encoded by a gene that up-regulated upon
XX CC differentiation of hES cells, chosen from P311 protein gene, Tax
XX CC interaction protein 1 gene, KIAA0853 protein gene, keratin 19 (KRT 19)
XX CC gene, etc., as given in the specification), causing an encoding sequence
XX CC to be preferentially expressed in undifferentiated pPS cells, causing an
XX CC encoding sequence to be preferentially expressed in differentiated cells,
XX CC sorting (M4) differentiated cells from less differentiated cells
XX CC (involves separating cells expressing a surface marker chosen from any
XX CC one of MR1 from cells not expressing the marker), causing pPS cells to
XX CC proliferate without differentiation, identifying genes that are up or
XX CC down regulated during differentiation of pPS cells, and a kit (I) for
XX CC assessing a culture of pPS cells by M1. The method (M1) is useful for
XX CC assessing culture of undifferentiated primate pluripotent stem cells and
XX CC for assessing the growth characteristics of a cell population. The cell
XX CC population has been obtained by culturing cells from human blastocyst or
XX CC from a human patient suspected of having a clinical condition related to
XX CC abnormal cell growth. The method further involves determining whether the
XX CC cell population is pluripotent from the marker expression and assessing

```

```

CC whether the patient has a malignancy from the marker expression. The
CC present sequence is an RTQ-PCR probe (realtime quantitative PCR) used to
CC assay the expression of a human mRNA in a pPS population.
XX SQ Sequence 21 BP; 2 A; 12 C; 3 G; 4 T; 0 U; 0 Other;
    Query Match      0.7%; Score 21; DB 1; Length 21;
    Best Local Similarity 100.0%; Pred. No. 4e+02;
    Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 414 ACCCTCCCTCTTGGCAGCC 434
    |||||
DB 1 ACCCTCCCTCTTGGCAGCC 21
    |||||
RESULT 129
ADI82246
ID ADI82246 standard; DNA; 21 BP.
XX AC ADI82246;
XX DT 22-APR-2004 (first entry)
XX DE RTQ PCR primer #1 for Human ICAM.
XX KW Human; ss; PCR; embryonic stem cell; pluripotent stem cell;
XX KW abnormal cell growth; malignancy; differentiation; primer; RTQ-PCR;
XX KW realtime quantitative PCR.
XX OS Homo sapiens.
XX PN US2003224411-A1.
XX PD 04-DEC-2003.
XX PF 13-MAR-2003; 2003US-00388578.
XX PR 13-MAR-2003; 2003US-00388578.
XX PA (STAN/) STANTON L W.
XX PA (BRAN/) BRANDENBERGER R.
XX PA (GOLD/) GOLD J D.
XX PA (IRVI/) IRVING J M.
XX PA (MAND/) MANDALAM R.
XX PA (MOKM/) MOK M.
XX PA (SHEL/) SHELTON D.
XX PI Stanton LW, Brandenberger R, Gold JD, Irving JM, Mandalam R;
XX PI Mok M, Shelton D;
XX DR WPI; 2004-119701/12.
XX PT Assessing culture of undifferentiated primate pluripotent stem cells by
XX PT detecting expression of markers e.g., Zic family member 3, other than
XX PT human telomerase reverse transcriptase/octamer binding transcription
XX PT factor.
XX PS Example 4; SEQ ID NO 76; 106pp; English.
XX CC The invention relates to assessing a culture of undifferentiated primate
XX CC pluripotent stem cells (pPS, e.g. embryonic stem cells), involving
XX CC detecting expression of markers (MR1) e.g. Zic family member 3 (ZIC3), as
XX CC given in specification, other than human telomerase reverse transcriptase
XX CC (hTERT) or octamer binding transcription factor (Oct)3/4, or a marker
XX CC (MR2) such as crypto or podocalyxin-like protein and hTERT and/or Oct3/4
XX CC or second marker chosen from (MR2). Also included are maintaining (M2)
XX CC pPS cells in a pluripotent state (involves causing them to express one of
XX CC the following markers (MR3) at a higher level, FOXO1A, ZIC3, hypothetical
XX CC KRAB-zinc finger protein SZFI-1 or zinc finger protein of cerebellum
XX CC ZIC2, or any other marker (MR4) chosen from PHD protein Jade-1 (Jade-1),
XX CC kruppel-like zinc finger protein (ZNF300), etc., as given in the
XX CC specification), causing pPS cells to differentiate into a particular
XX CC tissue type by causing them to express one of the markers chosen from
XX CC (MR3) or (MR4) (or markers chosen from GATA binding protein 3 (GATA3),
XX CC core promoter element binding protein (COPEB), etc., as given in the
XX CC specification), maintaining pPS cells in a pluripotent state (involves
XX CC culturing pPS cells or their progeny in the presence of a normally
XX CC secreted protein that is encoded by a gene that down-regulated upon
XX CC differentiation of human embryonic stem (hES) cells, chosen from
XX CC Fibrillin 3 gene, LEFT B gene, ZIC3 gene, EPHA1 gene, etc., as given in
XX CC the specification), causing pPS cells to differentiate (involves
XX CC culturing pPS cells or their progeny in the presence of a normally
XX CC secreted protein that is encoded by a gene that up-regulated upon
XX CC differentiation of hES cells, chosen from P311 protein gene, Tax
XX CC interaction protein 1 gene, KIAA0853 protein gene, keratin 19 (KRT 19)
XX CC gene, etc., as given in the specification), causing an encoding sequence
XX CC to be preferentially expressed in undifferentiated pPS cells, causing an
XX CC encoding sequence to be preferentially expressed in differentiated cells,
XX CC sorting (M4) differentiated cells from less differentiated cells
XX CC (involves separating cells expressing a surface marker chosen from any
XX CC one of MR1 from cells not expressing the marker), causing pPS cells to
XX CC proliferate without differentiation, identifying genes that are up or
XX CC down regulated during differentiation of pPS cells, and a kit (I) for
XX CC assessing a culture of pPS cells by M1. The method (M1) is useful for
XX CC assessing culture of undifferentiated primate pluripotent stem cells and
XX CC for assessing the growth characteristics of a cell population. The cell
XX CC population has been obtained by culturing cells from human blastocyst or
XX CC from a human patient suspected of having a clinical condition related to
XX CC abnormal cell growth. The method further involves determining whether the
XX CC cell population is pluripotent from the marker expression and assessing

```

tissue type by causing them to express one of the markers chosen from (MR3) or (MR4) (or markers chosen from GATA binding protein 3 (GATA3), core promoter element binding protein (COPEB), etc., as given in the specification), maintaining pPS cells in a pluripotent state (involves culturing pPS cells or their progeny in the presence of a normally secreted protein that is encoded by a gene that down-regulated upon differentiation of human embryonic stem (hES) cells, chosen from Fibrillin 3 gene, LEFT B gene, ZIC3 gene, EPHA1 gene, etc., as given in the specification), causing pPS cells to differentiate (involves culturing pPS cells or their progeny in the presence of a normally secreted protein that is encoded by a gene that up-regulated upon differentiation of hES cells, chosen from P311 protein gene, Tax interaction protein 1 gene, KIA0853 protein gene, keratin 19 (KRT 19) gene, etc., as given in the specification), causing an encoding sequence to be preferentially expressed in undifferentiated pPS cells, causing an encoding sequence to be preferentially expressed in differentiated cells, sorting (M4) differentiated cells from less differentiated cells (involves separating cells expressing a surface marker chosen from any one of MR1 from cells not expressing the marker), causing pPS cells to proliferate without differentiation, identifying genes that are up or down regulated during differentiation of pPS cells, and a kit (I) for assessing a culture of pPS cells by M1. The method (M1) is useful for assessing a culture of undifferentiated primate pluripotent stem cells and for assessing the growth characteristics of a cell population. The cell population has been obtained by culturing cells from human blastocyst or from a human patient suspected of having a clinical condition related to abnormal cell growth. The method further involves determining whether the cell population is pluripotent from the marker expression and assessing whether the patient has a malignancy from the marker expression. The present sequence is an RTQ-PCR primer (realtime quantitative PCR) used to assay the expression of a human mRNA in a pPS population.

Sequence 21 BP; 6 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 4e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 ACTCCAGACGGTGGAGCTG 411

DB 1 ACTCCAGACGGTGGAGCTG 21

RESULT 130

AD182248/c

ID AD182248 standard; DNA; 21 BP.

AC AD182248;

DT 22-APR-2004 (first entry)

DE RTQ PCR primer #2 for Human ICAM.

XX Human; ss; PCR; embryonic stem cell; pluripotent stem cell; abnormal cell growth; malignancy; differentiation; primer; RTQ-PCR; realtime quantitative PCR.

OS Homo sapiens.

PN US2003224411-A1.

PD 04-DEC-2003.

PF 13-MAR-2003; 2003US-00388578.

PR 13-MAR-2003; 2003US-00388578.

PA (STAN/) STANTON L W.

PA (BRAN/) BRANDENBERGER R.

PA (GOLD/) GOLD J D.

PA (IRVI/) IRVING J M.

PA (MAND/) MANDALAM R.

PA (MOKM/) MOK M.

PA (SHEL/) SHELTON D.

XX Stanton LW, Brandenberger R, Gold JD, Irving JM, Mandalam R;

PI Mok M, Shelton D;

XX WPI; 2004-119701/12.

DR Assessing culture of undifferentiated primate pluripotent stem cells by detecting expression of markers e.g., Zic family member 3, other than human telomerase reverse transcriptase/octamer binding transcription factor.

XX Example 4; SEQ ID NO 78; 106pp; English.

XX The invention relates to assessing a culture of undifferentiated primate pluripotent stem cells (pPS, e.g. embryonic stem cells), involving detecting expression of markers (MR1) e.g. Zic family member 3 (ZIC3), as given in specification, other than human telomerase reverse transcriptase (hTERT) or octamer binding transcription factor (Oct)3/4, or a marker (MR2) such as crypto or podocalyxin-like protein and hTERT and/or Oct3/4 or second marker chosen from (MR2). Also included are maintaining (M2) pPS cells in a pluripotent state (involves causing them to express one of the following markers (MR3) at a higher level, FOXO1A, ZIC3, hypothetical protein FLJ20582, Forkhead box H1 (FOXH1), Zinc finger protein, Healt2, K2AB-zinc finger protein SZF1-1 or zinc finger protein of cerebellum ZIC2, or any other marker (MR4) chosen from PHD protein Jade-1 (Jade-1), kruppel-like zinc finger protein (ZNF300), etc., as given in the specification), causing pPS cells to differentiate into a particular tissue type by causing them to express one of the markers chosen from (MR3) or (MR4) (or markers chosen from GATA binding protein 3 (GATA3), core promoter element binding protein (COPEB), etc., as given in the specification), maintaining pPS cells in a pluripotent state (involves culturing pPS cells or their progeny in the presence of a normally secreted protein that is encoded by a gene that down-regulated upon differentiation of human embryonic stem (hES) cells, chosen from Fibrillin 3 gene, LEFT B gene, ZIC3 gene, EPHA1 gene, etc., as given in the specification), causing pPS cells to differentiate (involves culturing pPS cells or their progeny in the presence of a normally secreted protein that is encoded by a gene that up-regulated upon differentiation of hES cells, chosen from P311 protein gene, Tax interaction protein 1 gene, KIA0853 protein gene, keratin 19 (KRT 19) gene, etc., as given in the specification), causing an encoding sequence to be preferentially expressed in undifferentiated pPS cells, causing an encoding sequence to be preferentially expressed in differentiated cells, sorting (M4) differentiated cells from less differentiated cells (involves separating cells expressing a surface marker chosen from any one of MR1 from cells not expressing the marker), causing pPS cells to proliferate without differentiation, identifying genes that are up or down regulated during differentiation of pPS cells, and a kit (I) for assessing a culture of pPS cells by M1. The method (M1) is useful for assessing a culture of undifferentiated primate pluripotent stem cells and for assessing the growth characteristics of a cell population. The cell population has been obtained by culturing cells from human blastocyst or from a human patient suspected of having a clinical condition related to abnormal cell growth. The method further involves determining whether the cell population is pluripotent from the marker expression and assessing whether the patient has a malignancy from the marker expression. The present sequence is an RTQ-PCR primer (realtime quantitative PCR) used to assay the expression of a human mRNA in a pPS population.

XX Sequence 21 BP; 3 A; 5 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 4e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 438 GGGCAAGAACCTTACCTACG 458

DB 21 GGGCAAGAACCTTACCTACG 1

RESULT 131

ADJ76671/c

ID XX ADJ76671 standard; DNA; 21 BP.
 AC XX ADJ76671;
 XX DT 20-MAY-2004 (first entry)
 XX DT ICAM1 probe SEQ ID NO:1923.
 DE XX bronchial asthma; chronic obstructive pulmonary disease;
 XX KW respiratory epithelial cell; interleukin-13; respiratory; antiasthmatic;
 KW KW gene therapy; marker; probe; ss.
 XX XX Homo sapiens.
 OS OS Synthetic.
 XX XX EP1394274-A2.
 XX XX 03-MAR-2004.
 XX XX 04-AUG-2003; 2003EP-00254857.
 XX XX 06-AUG-2002; 2002JP-00229312.
 PR PR 20-MAR-2003; 2003JP-00077212.
 XX XX (GENO-) GENOX RES INC.
 XX XX Ohtani N, Sugita Y, Yamaya M, Kubo H, Nagai H, Izuhara K;
 PI PI WPI; 2004-193155/19.
 DR XX Testing for bronchial asthma or chronic obstructive pulmonary disease by
 XX PT comparing the expression level of a marker gene in a biological sample
 PT PT from a subject with the expression level of the gene in a sample from a
 XX PT healthy subject.
 XX PS Example 11; SEQ ID NO 1923; 241pp; English.
 XX CC The present invention describes a method of testing for bronchial asthma
 CC or chronic obstructive pulmonary disease. The method comprises
 CC determining the expression level of a marker gene in a biological sample
 CC from a subject, comparing the expression level determined with the
 CC expression level of the marker gene in a biological sample from a healthy
 CC subject, and judging whether the subject has bronchial asthma or chronic
 CC obstructive pulmonary disease. The marker gene comprises: (a) a group of
 CC genes (S1) whose expression levels increase when respiratory epithelial
 CC cells are stimulated with interleukin-13; or (b) a group of genes (S2)
 CC whose expression levels decrease when respiratory epithelial cells are
 CC stimulated with interleukin-13. Also described: (1) a reagent (I) for
 CC testing for bronchial asthma or chronic obstructive pulmonary disease;
 CC (2) a kit for screening for a candidate compound for a therapeutic agent
 CC to treat bronchial asthma or chronic obstructive pulmonary disease; (3)
 CC an animal model for bronchial asthma or chronic obstructive pulmonary
 CC disease; (4) an inducer that induces bronchial asthma in a mouse; (5) a
 CC method for producing an animal model for bronchial asthma or chronic
 CC obstructive pulmonary disease; (6) a therapeutic agent for bronchial
 CC asthma or chronic obstructive pulmonary disease, comprising the compound,
 CC a marker gene or an antisense nucleic acid corresponding to a portion of
 CC the marker gene, a ribozyme, a polynucleotide that suppresses the
 CC expression of the gene through an RNAi effect or an antibody recognising
 CC a protein encoded by a marker gene; and (7) a DNA chip for testing for
 CC bronchial asthma or a chronic obstructive pulmonary disease, on which a
 CC probe has been immobilised to assay a marker gene. (I) has respiratory
 CC and antiasthmatic activities, and can be used in gene therapy. The method
 CC is useful for testing for or screening for a therapeutic agent for
 CC bronchial asthma or chronic obstructive pulmonary disease. The present
 CC sequence is used in the exemplification of the present invention.
 XX SQ Sequence 21 BP; 2 A; 6 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1009 ACGAAGCCAGAGGTCTCAGAA 1029
 DB 21 ACGAAGCCAGAGGTCTCAGAA 1
 RESULT 132
 ADM46454/C
 ID ADM46454 standard; DNA; 21 BP.
 XX AC ADM46454;
 XX DT 03-JUN-2004 (first entry)
 XX DE Antisense oligonucleotide targeting human ICAM-1 #3.
 XX KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
 KW KW vascular cell adhesion molecule; VCAM-1;
 KW KW endothelial leukocyte adhesion molecule; ELAM-1;
 KW KW inflammatory ophthalmological disorder; redness; inflammation;
 KW KW corneal explant; corneal allograft rejection.
 XX OS Homo sapiens.
 XX XX US2004033977-A1.
 XX XX 19-FEB-2004.
 XX XX 04-JUN-2003; 2003US-00454663.
 XX XX 14-AUG-1990; 90US-00567286.
 PR PR 02-SEP-1992; 92US-00939855.
 PR PR 21-JAN-1993; 93US-00007997.
 PR PR 10-FEB-1993; 93US-00969151.
 PR PR 17-MAY-1993; 93US-00063167.
 PR PR 12-MAY-1995; 95US-00440740.
 PR PR 03-AUG-1998; 98US-00128496.
 PR PR 12-SEP-2000; 2000US-00659288.
 PR PR 18-OCT-2001; 2001US-00982262.
 XX (BENN/) BENNETT C F.
 XX (MIRA/) MIRABELLI C.
 XX PI Bennett CF, Mirabelli C;
 XX WPI; 2004-180090/17.
 XX New antisense oligonucleotide, useful for diagnosing, as research
 PT reagents and for treating disease states, which respond to modulation of
 PT the synthesis or metabolism of cell adhesion molecules.
 XX Example 5; SEQ ID NO 3; 72pp; English.
 XX The invention relates to an antisense oligonucleotide targeting human
 CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as
 CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
 CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridises with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological

CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.

XX
 SQ Sequence 21 BP; 8 A; 4 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2176 ACCAGCTATTATTAGTGTC 2196
 |||||
 Db 21 ACCAGCTATTATTAGTGTC 1

RESULT 133

AD003877/c
 ID ADO03877 standard; DNA; 21 BP.

AC ADO03877;
 XX

DT 01-JUL-2004 (first entry)

XX Human ICAM-specific antisense oligonucleotide #3.

XX Antisense activity; down-regulation; antisense; ICAM; human; ss.

XX Homo sapiens.

XX US2004073376-A1.

XX 15-APR-2004.

PF 14-JAN-2002; 2002US-00050888.

XX 19-JAN-2001; 2001US-0262993P.

XX (UTAH) UNIV UTAH RES FOUND.

XX Gesteland RF, Atkins JF, Matveeva OV, Giddings MC;

XX WPI; 2004-364070/34.

XX Predicting antisense activity of an oligonucleotide for down-regulating
 PT expression of an RNA, comprises developing an artificial neural network,
 PT determining counts of mapped sequence motifs, and obtaining a output of
 PT activity.

PS Disclosure; SEQ ID NO 13; 25pp; English.

XX The present invention relates to the method for making an artificial
 CC neural network embodied on a computer-readable medium for predicting
 CC antisense activity of oligonucleotides for down-regulating expression of
 CC a selected RNA. The invention provides a five-fold reduction in the
 CC number of oligonucleotides to be screened in vivo to find effective
 CC targets. The present sequence is human ICAM-specific antisense
 CC oligonucleotide. This sequence is used in the invention.

XX Sequence 21 BP; 3 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1937 TGAGAGGGGAAGTGGTGGGG 1957
 |||||
 Db 21 TGAGAGGGGAAGTGGTGGGG 1

RESULT 134

ADQ16477/c
 ID ADQ16477 standard; DNA; 21 BP.

XX AC ADQ16477;

XX DT 09-SEP-2004 (first entry)

XX Oligonucleotide.

XX ss; antisense; hepatic tissue targeting; liver gene expression;
 KW improved biostability; altered biodistribution.

XX Synthetic.

XX US6753423-B1.

XX 22-JUN-2004.

XX 10-APR-2000; 2000US-00546596.

XX 12-SEP-1997; 97US-00928823.

XX (ISIS-) ISIS PHARM INC.

XX Cook PD, Manoharan M, Bennett CF;

XX WPI; 2004-466815/44.

XX Targeting an antisense oligonucleotide to hepatic tissues to modulate the
 PT expression of a gene in the liver involves conjugating the
 PT oligonucleotide to a cholesteryl moiety and administering the conjugate.

XX Disclosure; SEQ ID NO 26; 64pp; English.

XX The invention relates to a method of targeting an antisense
 CC oligonucleotide to hepatic tissues involving conjugating the
 CC oligonucleotide to a cholesteryl moiety and administering the conjugate.
 CC The method is useful for targeting an antisense oligonucleotide to
 CC hepatic tissues to modulate the expression of a gene in the liver. The
 CC oligonucleotide is useful in diagnostics, therapeutics, as research
 CC reagents and kits, in pharmaceutical composition and for treating
 CC diseases produced by undesired production of proteins. The method
 CC provides lipophilic oligonucleotide conjugates with improved biostability
 CC and altered biodistribution in mammals. The present sequence represents
 CC an oligonucleotide.

XX Sequence 21 BP; 4 A; 8 C; 5 G; 3 T; 1 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGCA 2120
 |||||
 Db 21 TGACGGATGCCAGCTTGGGCA 1

RESULT 135

ADQ16469/c

ID ADQ16469 standard; DNA; 21 BP.

XX AC ADQ16469;

XX DT 09-SEP-2004 (first entry)

XX Modified oligonucleotide used for NMR analysis #5.

XX ss; antisense; hepatic tissue targeting; liver gene expression;
 KW improved biostability; altered biodistribution; DNA-RNA hybrid.

XX Synthetic.

XX Key Location/Qualifiers


```

FT misc_rna 1 /*tag= a
FT FT
XX US6753423-B1.
XX
XX 22-JUN-2004.
XX
XX 10-APR-2000; 2000US-00546596.
XX PF
XX 12-SEP-1997; 97US-00928823.
XX
XX (ISIS-) ISIS PHARM INC.
XX PA
XX Cook PD, Manoharan M, Bennett CF;
XX PI
XX WPI; 2004-466815/44.
XX
XX Targeting an antisense oligonucleotide to hepatic tissues to modulate the
XX expression of a gene in the liver involves conjugating the
XX oligonucleotide to a cholesteryl moiety and administering the conjugate.
XX
XX Example 7; SEQ ID NO 18; 64pp; English.
XX
XX The invention relates to a method of targeting an antisense
XX oligonucleotide to hepatic tissues involving conjugating the
XX oligonucleotide to a cholesteryl moiety and administering the
XX conjugate.
XX The method is useful for targeting an antisense oligonucleotide to
XX hepatic tissues to modulate the expression of a gene in the liver. The
XX oligonucleotide is useful in diagnostics, therapeutics, as research
XX reagents and kits, in pharmaceutical composition and for treating
XX diseases produced by undesired production of proteins. The method
XX provides lipophilic oligonucleotide conjugates with improved biostability
XX and altered biodistribution in mammals. The present sequence represents a
XX modified oligonucleotide used for NMR analysis.
XX
XX Sequence 21 BP; 4 A; 8 C; 5 G; 3 T; 1 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGCA 2120
DB 21 TGACGGATGCCAGCTTGGGCA 1

RESULT 136
ADQ88550/c
ID ADQ88550 standard; DNA; 21 BP.
XX
XX ADQ88550;
XX
XX 07-OCT-2004 (first entry)
XX
XX Murine ICAM-1 antisense analogue DNA-RNA hybrid oligo, oligomer 69.
XX
XX Hepatic system; liver; transcription inhibition; DNA degradation;
XX therapy; phosphorothioate backbone; murine; ICAM; antisense;
XX DNA-RNA hybrid; ss.
XX
XX Mus sp.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..21
FT /*tag= c
FT /mod_base= OTHER
FT /note= "Phosphothioate backbone"
FT modified_base 1
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-O- (hexylamino-(cholesterol)) uridine
FT phosphoramidite"
FT

```

```

FT misc_rna 1 /*tag= a
FT FT
XX US2004142899-A1.
XX
XX 22-JUL-2004.
XX
XX 17-FEB-2004; 2004US-00780439.
XX PF
XX 11-JAN-1990; 90US-00463358.
XX 13-AUG-1990; 90US-00566977.
XX 24-OCT-1991; 91US-00782374.
XX 23-OCT-1992; 92WO-US009196.
XX 03-SEP-1993; 93US-00117363.
XX 05-JUN-1995; 95US-00464953.
XX 10-APR-2000; 2000US-00546596.
XX
XX (ISIS-) ISIS PHARM INC.
XX PA
XX Cook PD, Manoharan M, Bennett CF;
XX PI
XX WPI; 2004-561278/54.
XX
XX Use of a lipophilic antisense compound for modulating expression of a
XX nucleic acid in the liver and associated tissue and hepatic gene
XX expression.
XX
XX Example 7; SEQ ID NO 18; 48pp; English.
XX
XX The invention relates to compositions and methods for enhanced
XX biostability and altered biodistribution of oligonucleotides in mammals.
XX The invention also relates to a method for modulating expression of
XX nucleic acid in hepatic system of a mammal. The method is useful for
XX modulating the expression of a nucleic acid in the liver and associated
XX tissue, gene expression in cell, tissue or organs; for inhibiting
XX transfection and/or replication of particular genes; for inducing
XX degradation of regions of double stranded DNA in cells; for killing cells
XX or virus; in diagnostics, therapeutics and as research reagents and kits.
XX The present sequence is a murineintercellular adhesion molecule 1 (ICAM-
XX 1) gene targeted antisense analogue DNA-RNA hybrid oligonucleotide. This
XX sequence is used to illustrate the method of the invention.
XX
XX Sequence 21 BP; 4 A; 8 C; 5 G; 3 T; 1 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGCA 2120
DB 21 TGACGGATGCCAGCTTGGGCA 1

RESULT 137
ADQ88606/c
ID ADQ88606 standard; DNA; 21 BP.
XX
XX ADQ88606;
XX
XX 07-OCT-2004 (first entry)
XX
XX Oligomer 77 used to characterise functionalised oligonucleotides.
XX Hepatic system; liver; transcription inhibition; DNA degradation;
XX therapy; ss.
XX
XX Unidentified.
XX
XX US2004142899-A1.
XX
XX 22-JUL-2004.
XX

```

PF 17-FEB-2004; 2004US-00780439.
 XX
 PR 11-JAN-1990; 90US-00463358.
 PR 13-AUG-1990; 90US-00566977.
 PR 24-OCT-1991; 91US-00782374.
 PR 23-OCT-1992; 92WO-US0009196.
 PR 03-SEP-1993; 93US-00117363.
 PR 05-JUN-1995; 95US-00464953.
 PR 10-APR-2000; 2000US-00546596.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Cook PD, Manoharan M, Bennett CF;
 XX
 DR WPI; 2004-561278/54.
 XX
 XX
 PT Use of a lipophilic antisense compound for modulating expression of a
 PT nucleic acid in the liver and associated tissue and hepatic gene
 PT expression.
 XX
 PS Example 7; Page 22; 48pp; English.
 XX
 CC The invention relates to compositions and methods for enhanced
 CC bioscability and altered biodistribution of oligonucleotides in mammals.
 CC The invention also relates to a method for modulating expression of
 CC nucleic acid in hepatic system of a mammal. The method is useful for
 CC modulating the expression of a nucleic acid in the liver and associated
 CC tissue, gene expression in cell, tissue or organs; for inhibiting
 CC transcription and/or replication of particular genes; for inducing
 CC degradation of regions of double stranded DNA in cells; for killing cells
 CC or virus; in diagnostics, therapeutics and as research reagents and kits.
 CC The present sequence is an oligomer to characterise functionalised
 CC oligonucleotides. This sequence is used to illustrate the method of the
 CC invention.
 XX
 SQ Sequence 21 BP; 4 A; 8 C; 5 G; 3 T; 1 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTGGGCA 2120
 Db 21 TGACGGATGCCAGCTGGGCA 1
 RESULT 138
 ADQ82771
 ID ADQ82771 standard; DNA; 21 BP.
 AC ADQ82771;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 23.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiartherosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX

PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 DR WPI; 2004-580723/56.
 XX
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 23; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 4 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 161 AGTCATCTGCCCCGGGAG 181
 Db 1 AAGTCATCTGCCCCGGGAG 21
 RESULT 139
 ADQ82794
 ID ADQ82794 standard; DNA; 21 BP.
 XX
 AC ADQ82794;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 46.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiartherosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.

```
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX Homo sapiens.
OS
XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX
XX 16-JAN-2003; 2003US-0440579P.
XX
XX (UYPE-) UNIV PENNSYLVANIA.
XX
XX Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 46; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX
XX Sequence 21 BP; 6 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 442 AAGAACCTTACCTACGCTGC 462
|||
Db 1 AAGAACCTTACCTACGCTGC 21
|||

RESULT 140
ADQ82812
ID ADQ82812 standard; DNA; 21 BP.
XX
XX ADQ82812;
```

QY 1028 AAGGACCGAGGTGACAGTGA 1048
 |||||
 Db 1 AAGGACCGAGGTGACAGTGA 21

RESULT 141
 ADQ82814
 ID ADQ82814 standard; DNA; 21 BP.
 XX
 AC ADQ82814;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 66.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 DR WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 66; 71pp; English.

CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I

CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.

XX
 SQ Sequence 21 BP; 5 A; 2 C; 9 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02; 0; Gaps 0;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1072 AAGGTGACGCTGAATGGGTT 1092
 |||||
 Db 1 AAGGTGACGCTGAATGGGTT 21

RESULT 142
 ADQ82783
 ID ADQ82783 standard; DNA; 21 BP.
 XX
 AC ADQ82783;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 35.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 DR WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 35; 71pp; English.

CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I

CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 8 A; 5 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02; Mismatches 0; Gaps 0;
 Matches 21; Conservative 0; Indels 0; Indels 0; Gaps 0;
 QY 314 AAGATAGCCCAACCAATGTGCT 334
 |||||
 Db 1 AAGATAGCCCAACCAATGTGCT 21
 RESULT 143
 ADQ82790
 ID ADQ82790 standard; DNA; 21 BP.
 XX AC ADQ82790;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 42.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; Small interfering RNA; siRNA;
 KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 DR
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 42; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially

CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 5 A; 8 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02; Mismatches 0; Gaps 0;
 Matches 21; Conservative 0; Indels 0; Indels 0; Gaps 0;
 QY 368 AAACCTTCTCTCACCGTGACT 388
 |||||
 Db 1 AAACCTTCTCTCACCGTGACT 21
 RESULT 144
 ADQ82793
 ID ADQ82793 standard; DNA; 21 BP.
 XX AC ADQ82793;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 45.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; Small interfering RNA; siRNA;
 KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 DR

XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
XX cancer.

XX Disclosure; SEQ ID NO 45; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs)
XX comprising sense and antisense RNA strands forming a RNA duplex, where
XX the sense RNA strand comprises nucleotide sequence substantially
XX identical to a target sequence of 19-25 contiguous nucleotides in human
XX or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
XX (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
XX interactions. The siRNAs of the invention specifically target and cause
XX RNA-interference induced degradation of mRNA from ICAM-1 genes thus
XX leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
XX for inhibiting cell adhesion or cell adhesion-mediated pathologies such
XX as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
XX Alzheimer's disease, angiodenesis, asthma, atherosclerosis, toxic
XX corneal/limbic injury, type I diabetes, contact dermal hypersensitivity,
XX diabetes, Graves' disease, inflammatory bowel diseases, inflammatory lung
XX diseases, inflammatory sequelae of viral infections, inflammatory skin
XX disorders, allograft rejection, immune cell interactions such as T-cell
XX killing, mixed lymphocyte reaction, T-cell mediated B-cell
XX differentiation, meningitis, multiple sclerosis, multiple myeloma,
XX myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
XX retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
XX metastasis and uveitis. The siRNAs are also useful for treating an
XX angiogenic disease such as cancer, diabetic retinopathy age-related
XX macular degeneration, preferably age-related macular degeneration. The
XX siRNAs are also useful for treating complications arising from type I
XX diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
XX nephropathy and macrovascular disease. The macrovascular disease is
XX coronary artery disease, cerebrovascular disease or peripheral vascular
XX disease. The present oligonucleotide is a ICAM-1 target sequence from
XX which the siRNAs of the invention can be derived.

XX Sequence 21 BP; 3 A; 11 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 AACTGGCACCCCTCCCTCTT 427
|||||
DB 1 AACTGGCACCCCTCCCTCTT 21

RESULT 145
ADQ82828
ID ADQ82828 standard; DNA; 21 BP.
XX AC ADQ82828;
XX 21-OCT-2004 (first entry)
XX DE Human ICAM-1 oligonucleotide, SEQ ID 80.
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
XX Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
XX Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
XX Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
XX Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
XX Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
XX intracellular adhesion molecule-1; ICAM-1; RNA-interference;
XX cell adhesion; human; ss.
XX Homo sapiens.
XX WO2004065546-A2.

PD 05-AUG-2004.
XX 16-JAN-2004; 2004WO-US001166.
XX 16-JAN-2003; 2003US-0440579P.
XX (UYPE-) UNIV PENNSYLVANIA.
XX Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
XX cancer.

XX Example 1; SEQ ID NO 80; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs)
XX comprising sense and antisense RNA strands forming a RNA duplex, where
XX the sense RNA strand comprises nucleotide sequence substantially
XX identical to a target sequence of 19-25 contiguous nucleotides in human
XX or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
XX (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
XX interactions. The siRNAs of the invention specifically target and cause
XX RNA-interference induced degradation of mRNA from ICAM-1 genes thus
XX leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
XX for inhibiting cell adhesion or cell adhesion-mediated pathologies such
XX as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
XX Alzheimer's disease, angiodenesis, asthma, atherosclerosis, toxic
XX nephritis, immune-based nephritis, contact dermal hypersensitivity,
XX corneal/limbic injury, type I diabetes, complications arising from type I
XX diabetes, Graves' disease, inflammatory bowel diseases, inflammatory lung
XX diseases, inflammatory sequelae of viral infections, inflammatory skin
XX disorders, allograft rejection, immune cell interactions such as T-cell
XX killing, mixed lymphocyte reaction, T-cell mediated B-cell
XX differentiation, meningitis, multiple sclerosis, multiple myeloma,
XX myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
XX retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
XX metastasis and uveitis. The siRNAs are also useful for treating an
XX angiogenic disease such as cancer, diabetic retinopathy age-related
XX macular degeneration, preferably age-related macular degeneration. The
XX siRNAs are also useful for treating complications arising from type I
XX diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
XX nephropathy and macrovascular disease. The macrovascular disease is
XX coronary artery disease, cerebrovascular disease or peripheral vascular
XX disease. The present oligonucleotide is a ICAM-1 target sequence from
XX which the siRNAs of the invention can be derived.

XX Sequence 21 BP; 7 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1345 AAGTGTCTAAGGATGGCACT 1365
|||||
DB 1 AAGTGTCTAAGGATGGCACT 21

RESULT 146
ADQ82832
ID ADQ82832 standard; DNA; 21 BP.
XX AC ADQ82832;
XX 21-OCT-2004 (first entry)
XX DE Human ICAM-1 oligonucleotide, SEQ ID 84.
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
XX Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;

KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarrhythmic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; Small interfering RNA; siRNA;
KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.
OS
XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX
XX 16-JAN-2003; 2003US-0440579P.
XX
XX (UYPE-) UNIV PENNSYLVANIA.
XX
XX Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 84; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angioneurosis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX
XX Sequence 21 BP; 5 A; 5 C; 10 G; 1 T; 0 U; 0 Other;
SQ

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 46+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1445 AAGGGGAGGTCAACCCGAGG 1465
Db 1 AAGGGGAGGTCAACCCGAGG 21

RESULT 147

ADQ82840
ID ADQ82840 standard; DNA; 21 BP.
XX
AC ADQ82840;
XX
XX 21-OCT-2004 (first entry)
XX
XX Human ICAM-1 oligonucleotide, SEQ ID 92.
XX
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarrhythmic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; Small interfering RNA; siRNA;
KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.
OS
XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX
XX 16-JAN-2003; 2003US-0440579P.
XX
XX (UYPE-) UNIV PENNSYLVANIA.
XX
XX Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 92; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angioneurosis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX
XX Sequence 21 BP; 9 A; 7 C; 5 G; 0 T; 0 U; 0 Other;
SQ

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1601 AACAGGCCCAAAAGGACCC 1621
 |||||
 DB 1 AACAGGCCCAAAAGGACCC 21

RESULT 148
 ADQ82769
 ID ADQ82769 standard; DNA; 21 BP.
 XX AC ADQ82769;
 XX AC
 XX 21-OCT-2004 (first entry)
 XX DE Human ICAM-1 oligonucleotide, SEQ ID 21.
 XX KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX KW
 OS Homo sapiens.
 XX KW WO2004065546-A2.
 XX PN
 XX PD 05-AUG-2004.
 XX PF 16-JAN-2004; 2004WO-US001166.
 XX PR 16-JAN-2003; 2003US-0440579P.
 XX PA (UYPE-) UNIV PENNSYLVANIA.
 XX PI Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX PS Disclosure; SEQ ID NO 21; 71pp; English.
 XX CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, anglogenesis, asthma, atherosclerosis, toxic
 CC hepatitis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour

CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX SQ Sequence 21 BP; 5 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 159 AAAAGTCATCTGCCCCGGG 179
 |||||
 DB 1 AAAAGTCATCTGCCCCGGG 21

RESULT 149
 ADQ82776
 ID ADQ82776 standard; DNA; 21 BP.
 XX AC ADQ82776;
 XX AC
 XX 21-OCT-2004 (first entry)
 XX DE Human ICAM-1 oligonucleotide, SEQ ID 28.
 XX KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX KW
 OS Homo sapiens.
 XX KW WO2004065546-A2.
 XX PN
 XX PD 05-AUG-2004.
 XX PF 16-JAN-2004; 2004WO-US001166.
 XX PR 16-JAN-2003; 2003US-0440579P.
 XX PA (UYPE-) UNIV PENNSYLVANIA.
 XX PI Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX PS Disclosure; SEQ ID NO 28; 71pp; English.
 XX CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such

as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic nephritis, immune-based nephritis, contact dermal hypersensitivity, corneal/limbic injury, type I diabetes, complications arising from type I diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung diseases, inflammatory sequelae of viral infections, inflammatory skin disorders, allograft rejection, immune cell interactions such as T-cell killing, mixed lymphocyte reaction, T-cell mediated B-cell differentiation, meningitis, multiple sclerosis, multiple myeloma, myocarditis, pulmonary fibrosis, reperfusion injury, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour metastasis and uveitis. The siRNAs are also useful for treating an angiogenic disease such as cancer, diabetic retinopathy age-related macular degeneration, preferably age-related macular degeneration. The siRNAs are also useful for treating complications arising from type I diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy and macrovascular disease. The macrovascular disease is coronary artery disease, cerebrovascular disease or peripheral vascular disease. The present oligonucleotide is a ICAM-1 target sequence from which the siRNAs of the invention can be derived.

Sequence 21 BP; 3 A; 5 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 256 AAGGAGTTGCTCTGCTGGG 276
|||||
Db 1 AAGGAGTTGCTCTGCTGGG 21

RESULT 150
ADQ82800
ID ADQ82800 standard; DNA; 21 BP.
AC ADQ82800;
XX
XX 21-OCT-2004 (first entry)
XX Human ICAM-1 oligonucleotide, SEQ ID 52.
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.
XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX
XX 16-JAN-2003; 2003US-0440579P.
XX
XX (UYPE-) UNIV PENNSYLVANIA.
XX
XX Reich SU, Tolentino MJ;
XX WPI; 2004-580723/56.
XX
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 52; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs) comprising sense and antisense RNA strands forming a RNA duplex, where the sense RNA strand comprises nucleotide sequence substantially identical to a target sequence of 19-25 contiguous nucleotides in human or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix interactions. The siRNAs of the invention specifically target and cause RNA-interference induced degradation of mRNA from ICAM-1 genes thus leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful for inhibiting cell adhesion or cell adhesion-mediated pathologies such as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic nephritis, immune-based nephritis, contact dermal hypersensitivity, corneal/limbic injury, type I diabetes, complications arising from type I diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung diseases, inflammatory sequelae of viral infections, inflammatory skin disorders, allograft rejection, immune cell interactions such as T-cell killing, mixed lymphocyte reaction, T-cell mediated B-cell differentiation, meningitis, multiple sclerosis, multiple myeloma, myocarditis, pulmonary fibrosis, reperfusion injury, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour metastasis and uveitis. The siRNAs are also useful for treating an angiogenic disease such as cancer, diabetic retinopathy age-related macular degeneration, preferably age-related macular degeneration. The siRNAs are also useful for treating complications arising from type I diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy and macrovascular disease. The macrovascular disease is coronary artery disease, cerebrovascular disease or peripheral vascular disease. The present oligonucleotide is a ICAM-1 target sequence from which the siRNAs of the invention can be derived.

Sequence 21 BP; 5 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 604 AATTTCTCGTGGCGCACTGAA 624
|||||
Db 1 AATTTCTCGTGGCGCACTGAA 21

RESULT 151
ADQ82802
ID ADQ82802 standard; DNA; 21 BP.
XX
XX ADQ82802;
XX
XX 21-OCT-2004 (first entry)
XX Human ICAM-1 oligonucleotide, SEQ ID 54.
XX
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.
XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX
XX 16-JAN-2003; 2003US-0440579P.
XX
XX (UYPE-) UNIV PENNSYLVANIA.

```

XX PI Reich SJ, Tolentino MJ;
XX PN WPI; 2004-580723/56.
XX DR
XX PT Novel isolated small interfering RNA comprising sense RNA strand having
XX PF sequence identical to human intracellular adhesion molecule mRNA, and
XX PT antisense RNA strand, useful for treating angiogenic diseases such as
XX PT cancer.
XX PS Disclosure; SEQ ID NO 54; 71pp; English.
XX CC
XX CC The present invention relates to novel small interfering RNAs (siRNAs)
XX CC comprising sense and antisense RNA strands forming a RNA duplex, where
XX CC the sense RNA strand comprises nucleotide sequence substantially
XX CC identical to a target sequence of 19-25 contiguous nucleotides in human
XX CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
XX CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
XX CC interactions. The siRNAs of the invention specifically target and cause
XX CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
XX CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
XX CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
XX CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
XX CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
XX CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
XX CC corneal/limbic injury, type I diabetes, complications arising from type I
XX CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
XX CC diseases, inflammatory sequelae of viral infections, inflammatory skin
XX CC disorders, allograft rejection, immune cell interactions such as T-cell
XX CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
XX CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
XX CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
XX CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor
XX CC metastasis and uveitis. The siRNAs are also useful for treating an
XX CC angiogenic disease such as cancer, diabetic retinopathy age-related
XX CC macular degeneration, preferably age-related macular degeneration. The
XX CC siRNAs are also useful for treating complications arising from type I
XX CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
XX CC nephropathy and macrovascular disease. The macrovascular disease is
XX CC coronary artery disease, cerebrovascular disease or peripheral vascular
XX CC disease. The present oligonucleotide is a ICAM-1 target sequence from
XX CC which the siRNAs of the invention can be derived.
XX CC
XX CC Sequence 21 BP; 5 A; 2 C; 9 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 4e+02;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 641 AAGGGCTGGAGCTGTTTGAGA 661
DB 1 AAGGGCTGGAGCTGTTTGAGA 21
|||||
RESULT 152
ADQ82772
ID ADQ82772 standard; DNA; 21 BP.
XX AC ADQ82772;
XX
XX 21-OCT-2004 (first entry)
XX
XX Human ICAM-1 oligonucleotide, SEQ ID 24.
XX
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
XX Antiangiogenic; Antiasthmatic; Antiartherosclerotic; Dermatological;
XX Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
XX Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
XX Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
XX Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
XX intracellular adhesion molecule-1; ICAM-1; RNA-interference;
XX cell adhesion; human; ss.
XX

```

```

OS Homo sapiens.
XX
XX PN WO2004065546-A2.
XX
XX PD 05-AUG-2004.
XX
XX PF 16-JAN-2004; 2004WO-US001166.
XX
XX PR 16-JAN-2003; 2003US-0440579P.
XX
XX PA (UYPE-) UNIV PENNSYLVANIA.
XX
XX PI Reich SJ, Tolentino MJ;
XX DR WPI; 2004-580723/56.
XX
XX PT Novel isolated small interfering RNA comprising sense RNA strand having
XX PF sequence identical to human intracellular adhesion molecule mRNA, and
XX PT antisense RNA strand, useful for treating angiogenic diseases such as
XX PT cancer.
XX PS Disclosure; SEQ ID NO 24; 71pp; English.
XX
XX CC The present invention relates to novel small interfering RNAs (siRNAs)
XX CC comprising sense and antisense RNA strands forming a RNA duplex, where
XX CC the sense RNA strand comprises nucleotide sequence substantially
XX CC identical to a target sequence of 19-25 contiguous nucleotides in human
XX CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
XX CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
XX CC interactions. The siRNAs of the invention specifically target and cause
XX CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
XX CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
XX CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
XX CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
XX CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
XX CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
XX CC corneal/limbic injury, type I diabetes, complications arising from type I
XX CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
XX CC diseases, inflammatory sequelae of viral infections, inflammatory skin
XX CC disorders, allograft rejection, immune cell interactions such as T-cell
XX CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
XX CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
XX CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
XX CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor
XX CC metastasis and uveitis. The siRNAs are also useful for treating an
XX CC angiogenic disease such as cancer, diabetic retinopathy age-related
XX CC macular degeneration, preferably age-related macular degeneration. The
XX CC siRNAs are also useful for treating complications arising from type I
XX CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
XX CC nephropathy and macrovascular disease. The macrovascular disease is
XX CC coronary artery disease, cerebrovascular disease or peripheral vascular
XX CC disease. The present oligonucleotide is a ICAM-1 target sequence from
XX CC which the siRNAs of the invention can be derived.
XX CC
XX CC Sequence 21 BP; 6 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 21; DB 1; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 4e+02;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 223 AAGTTGTTGGCATAGAGACC 243
DB 1 AAGTTGTTGGCATAGAGACC 21
|||||
RESULT 153
ADQ82785
ID ADQ82785 standard; DNA; 21 BP.
XX AC ADQ82785;
XX
XX 21-OCT-2004 (first entry)
XX

```

DE Human ICAM-1 oligonucleotide, SEQ ID 37.
XX
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.
XX
XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX
XX 16-JAN-2003; 2003US-0440579P.
XX
XX (UYPE-) UNIV PENNSYLVANIA.
XX
XX Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 37; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angogenesis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX
XX Sequence 21 BP; 6 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
SQ

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 327 AATGTGCTATTCAAACTGCC 347
|||||||

Db 1 AATGTGCTATTCAAACTGCC 21
RESULT 154
ADQ82787
ID ADQ82787 standard; DNA; 21 BP.
XX
XX AC ADQ82787;
XX
XX DT 21-OCT-2004 (first entry)
XX
XX Human ICAM-1 oligonucleotide, SEQ ID 39.
XX
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.
XX
XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX
XX 16-JAN-2003; 2003US-0440579P.
XX
XX (UYPE-) UNIV PENNSYLVANIA.
XX
XX Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 39; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angogenesis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX
XX Sequence 21 BP; 6 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
SQ

CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 340 AACGGCCCTGATGGGAGTCA 360
 |||||
 DB 1 AACGGCCCTGATGGGAGTCA 21
 RESULT 155
 ADQ82795
 ID ADQ82795 standard; DNA; 21 BP.
 XX
 AC ADQ82795;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 47.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; Small interfering RNA; siRNA;
 KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 XX WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Example 1; SEQ ID NO 47; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angioneurosis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell

CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 5 A; 9 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 445 AACCTTACCCTACGCTGCCAG 465
 |||||
 DB 1 AACCTTACCCTACGCTGCCAG 21
 RESULT 156
 ADQ82809
 ID ADQ82809 standard; DNA; 21 BP.
 XX
 AC ADQ82809;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 61.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; Small interfering RNA; siRNA;
 KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 XX WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 61; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angioneurosis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell

CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 CC
 CC Sequence 21 BP; 8 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 943 AACACAGCCAGGACACTG 963
 |||||
 DB 1 AACACAGCCAGGACACTG 21

RESULT 157
 ADQ82830
 ID ADQ82830 standard; DNA; 21 BP.
 XX
 AC ADQ82830;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 82.
 XX

Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antidiabetic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2004065546-A2.
 XX
 XX 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 XX (UYPE-) UNIV PENNSYLVANIA.
 PA
 XX Reich SJ, Tolentino MJ;
 PI
 XX WPI; 2004-580723/56.
 DR
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT

PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 82; 71pp; English.
 XX

The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 CC
 CC Sequence 21 BP; 5 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1354 AAGGATGGCAGCTTCCCACTG 1374
 |||||
 DB 1 AAGGATGGCAGCTTCCCACTG 21

RESULT 158
 ADQ82835
 ID ADQ82835 standard; DNA; 21 BP.
 XX
 AC ADQ82835;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 87.
 XX

Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antidiabetic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO2004065546-A2.
 XX
 XX 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX

XX PR 16-JAN-2003; 2003US-0440579P.
XX PA (UYPE-) UNIV PENNSYLVANIA.
XX PI Reich SJ, Tolentino MJ;
XX DR WPI; 2004-580723/56.
XX PT Novel isolated small interfering RNA comprising sense RNA strand having
XX PT sequence identical to human intracellular adhesion molecule mRNA, and
XX PT antisense RNA strand, useful for treating angiogenic diseases such as
XX PT cancer.
XX PS Example 1; SEQ ID NO 87; 71pp; English.
XX CC The present invention relates to novel small interfering RNAs (siRNAs)
XX CC comprising sense and antisense RNA strands forming a RNA duplex, where
XX CC the sense RNA strand comprises nucleotide sequence substantially
XX CC identical to a target sequence of 19-25 contiguous nucleotides in human
XX CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
XX CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
XX CC interactions. The siRNAs of the invention specifically target and cause
XX CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
XX CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
XX CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
XX CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
XX CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
XX CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
XX CC corneal/limbic injury, type I diabetes, complications arising from type I
XX CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
XX CC diseases, inflammatory sequelae of viral infections, inflammatory skin
XX CC disorders, allograft rejection, immune cell interactions such as T-cell
XX CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
XX CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
XX CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
XX CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
XX CC metastasis and uveitis. The siRNAs are also useful for treating an
XX CC angiogenic disease such as cancer, diabetic retinopathy age-related
XX CC macular degeneration, preferably age-related macular degeneration. The
XX CC siRNAs are also useful for treating complications arising from type I
XX CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
XX CC nephropathy and macrovascular disease. The macrovascular disease is
XX CC coronary artery disease, cerebrovascular disease or peripheral vascular
XX CC disease. The present oligonucleotide is a ICAM-1 target sequence from
XX CC which the siRNAs of the invention can be derived.
XX SQ Sequence 21 BP; 8 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1567 AACCGCCAGCGGAAGATCAAG 1587
Db 1 AACCGCCAGCGGAAGATCAAG 21
RESULT 159
ADQ82805
ID ADQ82805 standard; DNA; 21 BP.
XX AC ADQ82805;
XX DT 21-OCT-2004 (first entry)
XX DE Human ICAM-1 oligonucleotide, SEQ ID 57.
XX KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
XX KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
XX KW Vulnerary; Antidiabetic; Antihypertoid; Gastrointestinal; Virucide;
XX KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
XX KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;

KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
XX cell adhesion; human; ss.
OS Homo sapiens.
XX WO2004065546-A2.
XX PN 05-AUG-2004.
XX PD 16-JAN-2004; 2004WO-US001166.
XX PF 16-JAN-2003; 2003US-0440579P.
XX PR (UYPE-) UNIV PENNSYLVANIA.
XX PA Reich SJ, Tolentino MJ;
XX PI WPI; 2004-580723/56.
XX DR Novel isolated small interfering RNA comprising sense RNA strand having
XX PT sequence identical to human intracellular adhesion molecule mRNA, and
XX PT antisense RNA strand, useful for treating angiogenic diseases such as
XX PT cancer.
XX PS Disclosure; SEQ ID NO 57; 71pp; English.
XX CC The present invention relates to novel small interfering RNAs (siRNAs)
XX CC comprising sense and antisense RNA strands forming a RNA duplex, where
XX CC the sense RNA strand comprises nucleotide sequence substantially
XX CC identical to a target sequence of 19-25 contiguous nucleotides in human
XX CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
XX CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
XX CC interactions. The siRNAs of the invention specifically target and cause
XX CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
XX CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
XX CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
XX CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
XX CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
XX CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
XX CC corneal/limbic injury, type I diabetes, complications arising from type I
XX CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
XX CC diseases, inflammatory sequelae of viral infections, inflammatory skin
XX CC disorders, allograft rejection, immune cell interactions such as T-cell
XX CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
XX CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
XX CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
XX CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
XX CC metastasis and uveitis. The siRNAs are also useful for treating an
XX CC angiogenic disease such as cancer, diabetic retinopathy age-related
XX CC macular degeneration, preferably age-related macular degeneration. The
XX CC siRNAs are also useful for treating complications arising from type I
XX CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
XX CC nephropathy and macrovascular disease. The macrovascular disease is
XX CC coronary artery disease, cerebrovascular disease or peripheral vascular
XX CC disease. The present oligonucleotide is a ICAM-1 target sequence from
XX CC which the siRNAs of the invention can be derived.
XX SQ Sequence 21 BP; 6 A; 9 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 835 AACCCACAGTCACCTATGCG 855
Db 1 AACCCACAGTCACCTATGCG 21
RESULT 160
ADQ82824
ID ADQ82824 standard; DNA; 21 BP.
XX XX

AC ADQ82824;
XX 21-OCT-2004 (first entry)
XX Human ICAM-1 oligonucleotide, SEQ ID 76.
DE
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.
OS
XX
XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX
XX 16-JAN-2003; 2003US-0440579P.
XX
XX (UYPE-) UNIV PENNSYLVANIA.
XX
XX Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 76; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX
XX Sequence 21 BP; 8 A; 7 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1290 AAATTCCGAGACTCCCAAT 1310
DB 1 AAATTCCGAGACTCCCAAT 21
RESULT 161
ADQ82755/C
ID ADQ82755 standard; RNA; 21 BP.
XX
XX ADQ82755;
XX 21-OCT-2004 (first entry)
XX
XX ICAM-1 siRNA antisense strand, SEQ ID 7.
XX
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; ds.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FT misc_feature 20..21
FT /*tag= a
FT /note= "2 deoxynucleotide overhang"
XX
XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX
XX 16-JAN-2003; 2003US-0440579P.
XX
XX (UYPE-) UNIV PENNSYLVANIA.
XX
XX Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 7; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.

CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is the antisense strand for one such
 CC ICAM-1 siRNA. The corresponding sense strand is given in ADQ82754.
 XX
 SQ Sequence 21 BP; 5 A; 7 C; 3 G; 2 T; 4 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 223 AAGTTGTTGGCATAGAGACC 243
 |||||
 Db 21 AAGTTGTTGGCATAGAGACC 1

RESULT 162
 ADQ82827
 ID ADQ82827 standard; DNA; 21 BP.

XX AC ADQ82827;
 XX DT 21-OCT-2004 (first entry)
 XX DE Human ICAM-1 oligonucleotide, SEQ ID 79.
 XX KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 XX KW Antiangiogenic; Antiasthmatic; Antiartherosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 XX OS Homo sapiens.
 XX PN WO2004065546-A2.
 XX PD 05-AUG-2004.
 XX PF 16-JAN-2004; 2004WO-US001166.
 XX PR 16-JAN-2003; 2003US-0440579P.
 XX PA (UYPE-) UNIV PENNSYLVANIA.
 XX PI Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 XX PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 XX cancer.
 XX PS Disclosure; SEQ ID NO 79; 71pp; English.
 XX

CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC cornel/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 6 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1327 AACCCATTGCCGAGCTCAAG 1347
 |||||
 Db 1 AACCCATTGCCGAGCTCAAG 21

RESULT 163
 ADQ82831
 ID ADQ82831 standard; DNA; 21 BP.

XX AC ADQ82831;
 XX DT 21-OCT-2004 (first entry)
 XX DE Human ICAM-1 oligonucleotide, SEQ ID 83.
 XX KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 XX KW Antiangiogenic; Antiasthmatic; Antiartherosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 XX OS Homo sapiens.
 XX PN WO2004065546-A2.
 XX PD 05-AUG-2004.
 XX PF 16-JAN-2004; 2004WO-US001166.
 XX PR 16-JAN-2003; 2003US-0440579P.
 XX PA (UYPE-) UNIV PENNSYLVANIA.
 XX PI Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 XX PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 XX cancer.
 XX

XX PS Disclosure; SEQ ID NO 83; 71pp; English.

XX CC The present invention relates to novel small interfering RNAs (siRNAs) comprising sense and antisense RNA strands forming a RNA duplex, where the sense RNA strand comprises nucleotide sequence substantially identical to a target sequence of 19-25 contiguous nucleotides in human or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix interactions. The siRNAs of the invention specifically target and cause RNA-interference induced degradation of mRNA from ICAM-1 genes thus leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful for inhibiting cell adhesion or cell adhesion-mediated pathologies such as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, angogenesis, asthma, atherosclerosis, toxic nephritis, immune-based nephritis, contact dermal hypersensitivity, corneal/limbic injury, type I diabetes, complications arising from type I diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung diseases, inflammatory sequelae of viral infections, inflammatory skin disorders, allograft rejection, immune cell interactions such as T-cell killing, mixed lymphocyte reaction, T-cell mediated B-cell differentiation, meningitis, multiple sclerosis, multiple myeloma, myocarditis, pulmonary fibrosis, septic arthritis, stroke, tumour retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour metastasis and uveitis. The siRNAs are also useful for treating an angiogenic disease such as cancer, diabetic retinopathy age-related macular degeneration, preferably age-related macular degeneration. The siRNAs are also useful for treating complications arising from type I diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy and macrovascular disease. The macrovascular disease is coronary artery disease, cerebrovascular disease or peripheral vascular disease. The present oligonucleotide is a ICAM-1 target sequence from which the siRNAs of the invention can be derived.

XX SQ Sequence 21 BP; 6 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1385 AATCAGTGACTGTCAGTCCGAG 1405
 |||||
 Db 1 AATCAGTGACTGTCAGTCCGAG 21

RESULT 164
 ADQ82836
 ID ADQ82836 standard; DNA; 21 BP.
 XX AC ADQ82836;
 XX DT 21-OCT-2004 (first entry)
 XX DE Human ICAM-1 oligonucleotide, SEQ ID 88.
 XX KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiartherosclerotic; Dermatological;
 KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX OS Homo sapiens.
 XX PN W02004065546-A2.
 XX XX
 XX PD 05-AUG-2004.
 XX XX
 XX PF 16-JAN-2004; 2004WO-US0001166.
 XX XX
 XX PR 16-JAN-2003; 2003US-0440579P.

XX PA (UYPE-) UNIV PENNSYLVANIA.

XX PI Reich SU, Tolentino MJ;

XX DR WPI; 2004-580723/56.

XX PT Novel isolated small interfering RNA comprising sense RNA strand having sequence identical to human intracellular adhesion molecule mRNA, and antisense RNA strand, useful for treating angiogenic diseases such as cancer.

XX PS Disclosure; SEQ ID NO 88; 71pp; English.

XX CC The present invention relates to novel small interfering RNAs (siRNAs) comprising sense and antisense RNA strands forming a RNA duplex, where the sense RNA strand comprises nucleotide sequence substantially identical to a target sequence of 19-25 contiguous nucleotides in human or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix interactions. The siRNAs of the invention specifically target and cause RNA-interference induced degradation of mRNA from ICAM-1 genes thus leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful for inhibiting cell adhesion or cell adhesion-mediated pathologies such as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, angogenesis, asthma, atherosclerosis, toxic nephritis, immune-based nephritis, contact dermal hypersensitivity, corneal/limbic injury, type I diabetes, complications arising from type I diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung diseases, inflammatory sequelae of viral infections, inflammatory skin disorders, allograft rejection, immune cell interactions such as T-cell killing, mixed lymphocyte reaction, T-cell mediated B-cell differentiation, meningitis, multiple sclerosis, multiple myeloma, myocarditis, pulmonary fibrosis, septic arthritis, stroke, tumour retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour metastasis and uveitis. The siRNAs are also useful for treating an angiogenic disease such as cancer, diabetic retinopathy age-related macular degeneration, preferably age-related macular degeneration. The siRNAs are also useful for treating complications arising from type I diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy and macrovascular disease. The macrovascular disease is coronary artery disease, cerebrovascular disease or peripheral vascular disease. The present oligonucleotide is a ICAM-1 target sequence from which the siRNAs of the invention can be derived.

XX SQ Sequence 21 BP; 12 A; 3 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1579 AAGATCAAGAAATACAGACTA 1599
 |||||
 Db 1 AAGATCAAGAAATACAGACTA 21

RESULT 165
 ADQ82773
 ID ADQ82773 standard; DNA; 21 BP.
 XX AC ABQ82773;
 XX DT 21-OCT-2004 (first entry)
 XX DE Human ICAM-1 oligonucleotide, SEQ ID 25.
 XX KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiartherosclerotic; Dermatological;
 KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;

KW cell adhesion; human; ss.
 XX Homo sapiens.
 OS WO2004065546-A2.
 PN 05-AUG-2004.
 XX 16-JAN-2004; 2004WO-US001166.
 XX 16-JAN-2003; 2003US-0440579P.
 PR (UYPE-) UNIV PENNSYLVANIA.
 PA Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 DR Novel isolated small interfering RNA comprising sense RNA strand having
 XX sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX Disclosure; SEQ ID NO 25; 71pp; English.
 PS The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, restenosis,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX Sequence 21 BP; 6 A; 5 C; 5 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 253 AAAAAGGAGTTCCTCGCCT 273
 DB 1 AAAAAGGAGTTCCTCGCCT 21
 RESULT 166
 ID ADQ82775
 XX ADQ82775 standard; DNA; 21 BP.
 AC ADQ82775;
 XX

DT 21-OCT-2004 (first entry)
 XX Human ICAM-1 oligonucleotide, SEQ ID 27.
 DE Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 XX Antiangiogenic; Antiasthmatic; Antithyroid; Gastrointestinal; Virucide;
 KW Vulnary; Antidiabetic; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Immunosuppressive; Antiarthritic; Anticardiac; Anticardiac;
 KW Respiratory; Vasotropic; Antiarthritic; Anticardiac; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 XX cell adhesion; human; ss.
 OS Homo sapiens.
 XX WO2004065546-A2.
 PN 05-AUG-2004.
 XX 16-JAN-2004; 2004WO-US001166.
 XX 16-JAN-2003; 2003US-0440579P.
 PR (UYPE-) UNIV PENNSYLVANIA.
 PA Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 DR Novel isolated small interfering RNA comprising sense RNA strand having
 XX sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX Disclosure; SEQ ID NO 27; 71pp; English.
 PS The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, restenosis,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX Sequence 21 BP; 4 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 255 AAAGGAGTTGCTCTGCTGG 275
Db 1 AAAGGAGTTGCTCTGCTGG 21

RESULT 167

ADQ82784

ID ADQ82784 standard; DNA; 21 BP.

XX AC ADQ82784;

XX DT 21-OCT-2004 (first entry)

XX DE Human ICAM-1 oligonucleotide, SEQ ID 36.

XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.

XX OS Homo sapiens.

XX PN WO2004065546-A2.

XX PD 05-AUG-2004.

XX PF 16-JAN-2004; 2004WO-US001166.

XX PR 16-JAN-2003; 2003US-0440579P.

XX PA (UYPE-) UNIV PENNSYLVANIA.

XX PI Reich SJ, Tolentino MJ;

XX DR WPI; 2004-580723/56.

XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.

XX Disclosure; SEQ ID NO 36; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angogenesis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic

CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.

XX SQ Sequence 21 BP; 8 A; 5 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 4e+02; 0; Indels 0; Gaps 0;

Matches 21; Conservative 0; Mismatches 0;

QY 323 AACCAATGCTATTCAAAC 343

Db 1 AACCAATGCTATTCAAAC 21

RESULT 168

ADQ82798

ID ADQ82798 standard; DNA; 21 BP.

XX AC ADQ82798;

XX DT 21-OCT-2004 (first entry)

XX DE Human ICAM-1 oligonucleotide, SEQ ID 50.

XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.

XX OS Homo sapiens.

XX PN WO2004065546-A2.

XX PD 05-AUG-2004.

XX PF 16-JAN-2004; 2004WO-US001166.

XX PR 16-JAN-2003; 2003US-0440579P.

XX PA (UYPE-) UNIV PENNSYLVANIA.

XX PI Reich SJ, Tolentino MJ;

XX DR WPI; 2004-580723/56.

XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.

XX Disclosure; SEQ ID NO 50; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angogenesis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung

CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC reinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 5 A; 4 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 529 AAACGGAGCCAGCTGTGGG 549
 |||||
 DB 1 AAACGGAGCCAGCTGTGGG 21

RESULT 169
 ADQ82796
 ID ADQ82796 standard; DNA; 21 BP.
 XX
 AC ADQ82796;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 48.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; Small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX WO2004065546-A2.
 XX
 XX 05-AUG-2004.
 XX
 XX 16-JAN-2004; 2004WO-US001166.
 XX
 XX 16-JAN-2003; 2003US-0440579P.
 XX
 XX (UYPE-) UNIV PENNSYLVANIA.
 XX
 XX Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 XX Disclosure; SEQ ID NO 48; 71pp; English.
 XX
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human

CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC reinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 3 A; 8 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 490 AACCTCACCGTGTGTGCTC 510
 |||||
 DB 1 AACCTCACCGTGTGTGCTC 21

RESULT 170
 ADQ82808
 ID ADQ82808 standard; DNA; 21 BP.
 XX
 AC ADQ82808;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 60.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; Small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX WO2004065546-A2.
 XX
 XX 05-AUG-2004.
 XX
 XX 16-JAN-2004; 2004WO-US001166.
 XX
 XX 16-JAN-2003; 2003US-0440579P.
 XX
 XX (UYPE-) UNIV PENNSYLVANIA.
 XX
 XX Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 XX

PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.

XX Disclosure; SEQ ID NO 60; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.

XX Sequence 21 BP; 8 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 AATACTGGGGAACACGAGCCA 953
 |||||
 Db 1 AATACTGGGGAACACGAGCCA 21

RESULT 171
 ADQ82823
 ID ADQ82823 standard; DNA; 21 BP.
 XX AC ADQ82823;
 XX 21-OCT-2004 (first entry)
 XX Human ICAM-1 oligonucleotide, SEQ ID 75.
 XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiatheriosclerotic; Dermatological;
 KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX Homo sapiens.
 OS
 XX WO2004065546-A2.
 PN
 XX 05-AUG-2004.

XX 16-JAN-2004; 2004WO-US001166.
 XX 16-JAN-2003; 2003US-0440579P.
 XX (UYPE-) UNIV PENNSYLVANIA.
 XX Reich SJ, Tolentino MJ;
 PI WPI; 2004-580723/56.
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.

XX Disclosure; SEQ ID NO 75; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.

XX Sequence 21 BP; 9 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1289 AAAATTCCAGCAGACTCCAA 1309
 |||||
 Db 1 AAAATTCCAGCAGACTCCAA 21

RESULT 172
 ADQ82753/c
 ID ADQ82753 standard; RNA; 21 BP.
 XX AC ADQ82753;
 XX 21-OCT-2004 (first entry)
 XX ICAM-1 siRNA antisense strand, SEQ ID 5.
 XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiatheriosclerotic; Dermatological;
 KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;

KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; ds.

XX Synthetic.

XX WO2004065546-A2.

XX 05-AUG-2004.

XX 16-JAN-2004; 2004WO-US001166.

XX 16-JAN-2003; 2003US-0440579P.

XX (UYPE-) UNIV PENNSYLVANIA.

XX Reich SJ, Tolentino MJ;

XX WPI; 2004-580723/56.

XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.

XX Disclosure; SEQ ID NO 5; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angioneurosis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is the antisense strand for one such
CC ICAM-1 siRNA. The corresponding sense strand is given in ADQ82752.

XX Sequence 21 BP; 5 A; 7 C; 3 G; 0 T; 6 U; 0 Other;

XX Query Match 0.7%; Score 21; DB 1; Length 21;

XX Best Local Similarity 100.0%; Pred. No. 48+02;

XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 223 AAGTTGTTGGCATAGACC 243

DB 21 AAGTTGTTGGCATAGACC 1

RESULT 173

ADQ82816

ID ADQ82816 standard; DNA; 21 BP.

XX ADQ82816;

XX 21-OCT-2004 (first entry)

XX Human ICAM-1 oligonucleotide, SEQ ID 68.

XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
XX Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
XX Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
XX Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.

XX Homo sapiens.

XX WO2004065546-A2.

XX 05-AUG-2004.

XX 16-JAN-2004; 2004WO-US001166.

XX 16-JAN-2003; 2003US-0440579P.

XX (UYPE-) UNIV PENNSYLVANIA.

XX Reich SJ, Tolentino MJ;

XX WPI; 2004-580723/56.

XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.

XX Disclosure; SEQ ID NO 68; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angioneurosis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.

XX Sequence 21 BP; 8 A; 8 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02; Indels 0; Gaps 0;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1132 AAGGCCACCCGAGGACAC 1152
 |||||
 DB 1 AAGGCCACCCGAGGACAC 21

RESULT 174
 ADQ82818
 ID ADQ82818 standard; DNA; 21 BP.
 XX
 AC ADQ82818;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 70.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 DR WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 70; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, anglogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastatis and uveitis. The siRNAs are also useful for treating an

CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 4 A; 7 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1176 AACCTGGAGGTGGCGGCCA 1196
 |||||
 DB 1 AACCTGGAGGTGGCGGCCA 21

RESULT 175
 ADQ82770
 ID ADQ82770 standard; DNA; 21 BP.
 XX
 AC ADQ82770;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 22.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 DR WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 22; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, anglogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastatis and uveitis. The siRNAs are also useful for treating an

CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, stroke, tumour
 CC myocarditis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 5 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 160 AAGTCACTCTGCCCCGGGA 180
 DB 1 AAGTCACTCTGCCCCGGGA 21
 RESULT 176
 ADQ82780
 ID ADQ82780 standard; DNA; 21 BP.
 XX
 AC ADQ82780;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 32.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 XX WPI; 2004-580723/56.
 XX
 DR Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 XX Disclosure; SEQ ID NO 32; 71pp; English.

CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, stroke, tumour
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 9 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 296 AACTGAGCAATGTGCAAGAG 316
 DB 1 AACTGAGCAATGTGCAAGAG 21
 RESULT 177
 ADQ82781
 ID ADQ82781 standard; DNA; 21 BP.
 XX
 AC ADQ82781;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 33.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.


```

PI Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX
XX
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 33; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angioedema, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX
XX Sequence 21 BP; 10 A; 3 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 304 AATGTGCAAGAGATAGCCAA 324
DB 1 AATGTGCAAGAGATAGCCAA 21
|||||
RESULTS 178
ADQ82819
ID ADQ82819 standard; DNA; 21 BP.
XX
XX ADQ82819;
AC
XX
XX 21-OCT-2004 (first entry)
XX
XX Human ICAM-1 oligonucleotide, SEQ ID 71.
XX
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipeptidic; Nephrotropic; small interfering RNA; siRNA;
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.

```

```

XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX
XX 16-JAN-2003; 2003US-0440579P.
XX
XX (UYPE-) UNIV PENNSYLVANIA.
XX
XX Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 71; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angioedema, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX
XX Sequence 21 BP; 7 A; 6 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1207 AAGAACCCAGACCCGGAGCTT 1227
DB 1 AAGAACCCAGACCCGGAGCTT 21
|||||
RESULTS 179
ADQ82834
ID ADQ82834 standard; DNA; 21 BP.
XX
XX ADQ82834;
AC
XX
XX 21-OCT-2004 (first entry)
XX
XX Human ICAM-1 oligonucleotide, SEQ ID 86.

```

XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarrhythmic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX Homo sapiens.
 OS
 XX WO2004065546-A2.
 PN
 XX 05-AUG-2004.
 XX
 XX 16-JAN-2004; 2004WO-US001166.
 XX
 XX 16-JAN-2003; 2003US-0440579P.
 PR
 XX (UYPE-) UNIV PENNSYLVANIA.
 PA
 XX Reich SJ, Tolentino MJ;
 PI
 XX WPI; 2004-580723/56.
 DR
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 PT
 XX Disclosure; SEQ ID NO 86; 71pp; English.
 PS
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, anglogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 XX Sequence 21 BP; 5 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1533 AATGGCACTGCAGGCTCAG 1553
 |||||
 1 AATGGCACTGCAGGCTCAG 1553

RESULT 180

ADQ82842
 ID ADQ82842 standard; DNA; 21 BP.
 XX
 AC ADQ82842;
 XX
 XX 21-OCT-2004 (first entry)
 DT
 XX Human ICAM-1 oligonucleotide, SEQ ID 94.
 DE
 XX
 XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarrhythmic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX Homo sapiens.
 OS
 XX WO2004065546-A2.
 PN
 XX 05-AUG-2004.
 XX
 XX 16-JAN-2004; 2004WO-US001166.
 PF
 XX 16-JAN-2003; 2003US-0440579P.
 PR
 XX (UYPE-) UNIV PENNSYLVANIA.
 PA
 XX Reich SJ, Tolentino MJ;
 PI
 XX WPI; 2004-580723/56.
 DR
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 PT
 XX Disclosure; SEQ ID NO 94; 71pp; English.
 PS
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, anglogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 XX Sequence 21 BP; 5 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1533 AATGGCACTGCAGGCTCAG 1553
 |||||
 1 AATGGCACTGCAGGCTCAG 1553

CC which the siRNAs of the invention can be derived.

XX Sequence 21 BP; 9 A; 7 C; 4 G; 1 T; 0 U; 0 Other;

SQ Sequence 21 BP; 9 A; 7 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1611 AAAGGACCCCATGAAC 1631

DB 1 AAAGGACCCCATGAAC 21

RESULT 181

ADQ82779

ID ADQ82779 standard; DNA; 21 BP.

XX

AC ADQ82779;

XX

DT 21-OCT-2004 (first entry)

XX

DE Human ICAM-1 oligonucleotide, SEQ ID 31.

XX

KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; Small interfering RNA; siRNA;
KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.

XX Homo sapiens.

OS

XX WO2004065546-A2.

PN

XX 05-AUG-2004.

PD

XX 16-JAN-2004; 2004WO-US001166.

PF

XX 16-JAN-2003; 2003US-0440579P.

PR

XX (UYPE-) UNIV PENNSYLVANIA.

PA

XX Reich SJ, Tolentino MJ;

PI

XX WPI; 2004-580723/56.

DR

XX Novel isolated small interfering RNA comprising sense RNA strand having
sequence identical to human intracellular adhesion molecule mRNA, and
antisense RNA strand, useful for treating angiogenic diseases such as
cancer.

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.

SQ Sequence 21 BP; 8 A; 2 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 4e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 286 AGGTCTATGACTGACCAAT 306

DB 1 AAGGTGTATGACTGACCAAT 21

RESULT 182

ADQ82789

ID ADQ82789 standard; DNA; 21 BP.

XX

AC ADQ82789;

XX

DT 21-OCT-2004 (first entry)

XX

DE Human ICAM-1 oligonucleotide, SEQ ID 41.

XX

KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; Small interfering RNA; siRNA;
KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.

XX Homo sapiens.

OS

XX WO2004065546-A2.

PN

XX 05-AUG-2004.

PD

XX 16-JAN-2004; 2004WO-US001166.

PF

XX 16-JAN-2003; 2003US-0440579P.

PR

XX (UYPE-) UNIV PENNSYLVANIA.

PA

XX Reich SJ, Tolentino MJ;

PI

XX WPI; 2004-580723/56.

DR

XX Novel isolated small interfering RNA comprising sense RNA strand having
sequence identical to human intracellular adhesion molecule mRNA, and
antisense RNA strand, useful for treating angiogenic diseases such as
cancer.

PT Disclosure; SEQ ID NO 41; 71pp; English.

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

PT

CC The present invention relates to novel small interfering RNAs (siRNAs)
comprising sense and antisense RNA strands forming a RNA duplex, where
the sense RNA strand comprises nucleotide sequence substantially
identical to a target sequence of 19-25 contiguous nucleotides in human
or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
(ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
interactions. The siRNAs of the invention specifically target and cause
RNA-interference induced degradation of mRNA from ICAM-1 genes thus
leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
for inhibiting cell adhesion or cell adhesion-mediated pathologies such
as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
Alzheimer's disease, angogenesis, asthma, atherosclerosis, toxic
nephritis, immune-based nephritis, contact dermal hypersensitivity,
corneal/limbic injury, type I diabetes, complications arising from type I
diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
diseases, inflammatory sequelae of viral infections, inflammatory skin
disorders, allograft rejection, immune cell interactions such as T-cell
killing, mixed lymphocyte reaction, T-cell mediated B-cell

CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.

XX
 SQ Sequence 21 BP; 6 A; 8 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 367 AAAACCTTCTCCACCGGTAC 387
 |||||
 Db 1 AAAACCTTCTCCACCGGTAC 21

RESULT 183
 ADQ82801
 ID ADQ82801 standard; DNA; 21 BP.
 AC ADQ82801;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 53.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antischismatic; Antiartherosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as

PT cancer.
 XX
 PS Disclosure; SEQ ID NO 53; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.

XX
 SQ Sequence 21 BP; 5 A; 8 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 623 AACTGGACCTGGCGGCCCAAG 643
 |||||
 Db 1 AACTGGACCTGGCGGCCCAAG 21

RESULT 184
 ADQ82803
 ID ADQ82803 standard; DNA; 21 BP.
 AC ADQ82803;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 55.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antischismatic; Antiartherosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX

PR 16-JAN-2003; 2003US-0440579P.
 XX (UYPE-) UNIV PENNSYLVANIA.
 XX Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 DR
 XX
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 XX Disclosure; SEQ ID NO 55; 71pp; English.
 PS
 XX
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 XX Sequence 21 BP; 5 A; 11 C; 3 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02; Indels 0; Gaps 0;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 661 AACACCTCGGCCCTACCAG 681
 |||||
 DB 1 AACACCTCGGCCCTACCAG 21
 |||||
 RESULT 185
 ADQ82810
 ID ADQ82810 standard; DNA; 21 BP.
 XX
 XX ADQ82810;
 AC
 XX
 XX 21-OCT-2004 (first entry)
 DT
 XX Human ICAM-1 oligonucleotide, SEQ ID 62.
 DE
 XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiartherosclerotic; Dermatological;
 KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;

KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; sg.
 XX
 XX Homo sapiens.
 OS
 XX WO2004065546-A2.
 PN
 XX 05-AUG-2004.
 PD
 XX 16-JAN-2004; 2004WO-US001166.
 PF
 XX 16-JAN-2003; 2003US-0440579P.
 PR
 XX (UYPE-) UNIV PENNSYLVANIA.
 PA
 XX Reich SJ, Tolentino MJ;
 PI WPI; 2004-580723/56.
 DR
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 XX Example 1; SEQ ID NO 62; 71pp; English.
 PS
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 XX Sequence 21 BP; 7 A; 5 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02; Indels 0; Gaps 0;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 997 AACGTGATTCTGACGAAGCCA 1017
 |||||
 DB 1 AACGTGATTCTGACGAAGCCA 21
 |||||
 RESULT 186
 ADQ82833
 ID ADQ82833 standard; DNA; 21 BP.
 XX
 XX ADQ82833;
 AC

XX 21-OCT-2004 (first entry)
 XX Human ICAM-1 oligonucleotide, SEQ ID 85.
 XX
 XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 XX Homo sapiens.
 XX WO2004065546-A2.
 XX
 XX 05-AUG-2004.
 XX
 XX 16-JAN-2004; 2004WO-US001166.
 XX
 XX 16-JAN-2003; 2003US-0440579P.
 XX
 XX (UYPE-) UNIV PENNSYLVANIA.
 XX
 XX Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 XX
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 XX Disclosure; SEQ ID NO 85; 71pp; English.
 XX
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 XX Sequence 21 BP; 3 A; 8 C; 4 G; 6 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1474 AATGTGCTCTCCCGCGGTAT 1494
 |||||
 Db 1 AATGTGCTCTCCCGCGGTAT 21
 |||||
 RESULT 187
 ADQ82806
 ID ADQ82806 standard; DNA; 21 BP.
 XX
 AC ADQ82806;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 XX Human ICAM-1 oligonucleotide, SEQ ID 58.
 XX
 XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 XX Homo sapiens.
 XX WO2004065546-A2.
 XX
 XX 05-AUG-2004.
 XX
 XX 16-JAN-2004; 2004WO-US001166.
 XX
 XX 16-JAN-2003; 2003US-0440579P.
 XX
 XX (UYPE-) UNIV PENNSYLVANIA.
 XX
 XX Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 XX
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 XX Example 1; SEQ ID NO 58; 71pp; English.
 XX
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX

CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 5 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 856 AACGACTCTCTCGCCCAAG 876
 Db 1 AACGACTCTCTCGCCCAAG 21
 RESULT 188
 ADQ82815
 ID ADQ82815 standard; DNA; 21 BP.
 XX
 AC ADQ82815;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 67.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antidiabetic; Antiarteriosclerotic; Dermatological;
 KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 XN WO2004065546-A2.
 PN
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 DR WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 67; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angioneurosis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I

CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 5 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1084 AATGGGGTTCAGCCAGCCA 1104
 Db 1 AATGGGGTTCAGCCAGCCA 21
 RESULT 189
 ADQ82817
 ID ADQ82817 standard; DNA; 21 BP.
 XX
 AC ADQ82817;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 69.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antidiabetic; Antiarteriosclerotic; Dermatological;
 KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 XN WO2004065546-A2.
 PN
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 DR WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 69; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially

identical to a target sequence of 19-25 contiguous nucleotides in human or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix interactions. The siRNAs of the invention specifically target and cause RNA-interference induced degradation of mRNA from ICAM-1 genes thus leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful for inhibiting cell adhesion or cell adhesion-mediated pathologies such as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic nephritis, immune-based nephritis, contact dermal hypersensitivity, corneal/limbic injury, type I diabetes, complications arising from type I diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung diseases, inflammatory sequelae of viral infections, inflammatory skin disorders, allograft rejection, immune cell interactions such as T-cell killing, mixed lymphocyte reaction, T-cell mediated B-cell differentiation, meningitis, multiple sclerosis, multiple myeloma, myocarditis, pulmonary fibrosis, reperfusion injury, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis and uveitis. The siRNAs are also useful for treating an angiogenic disease such as cancer, diabetic retinopathy age-related macular degeneration, preferably age-related macular degeneration. The siRNAs are also useful for treating complications arising from type I diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy and macrovascular disease. The macrovascular disease is coronary artery disease, cerebrovascular disease or peripheral vascular disease. The present oligonucleotide is a ICAM-1 target sequence from which the siRNAs of the invention can be derived.

Sequence 21 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 4e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1150 AACGGCGGAGCTTCCTGC 1170-

Db 1 AACGGCGGAGCTTCCTGC 21

RESULT 190

ADQ82825 ID ADQ82825 standard; DNA; 21 BP.

AC ADQ82825;

DT 21-OCT-2004 (first entry)

DE Human ICAM-1 oligonucleotide, SEQ ID 77.

XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.

XX Homo sapiens.

OS WO2004065546-A2.

XX 05-AUG-2004.

PF 16-JAN-2004; 2004WO-US001166.

XX 16-JAN-2003; 2003US-0440579P.

XX (UYPE-) UNIV PENNSYLVANIA.

XX Reich SJ, Tolentino MJ;

XX WPI; 2004-580723/56.

XX

Novel isolated small interfering RNA comprising sense RNA strand having sequence identical to human intracellular adhesion molecule mRNA, and antisense RNA strand, useful for treating angiogenic diseases such as cancer.

Disclosure; SEQ ID NO 77; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs) comprising sense and antisense RNA strands forming a RNA duplex, where the sense RNA strand comprises nucleotide sequence substantially identical to a target sequence of 19-25 contiguous nucleotides in human or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix interactions. The siRNAs of the invention specifically target and cause RNA-interference induced degradation of mRNA from ICAM-1 genes thus leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful for inhibiting cell adhesion or cell adhesion-mediated pathologies such as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic nephritis, immune-based nephritis, contact dermal hypersensitivity, corneal/limbic injury, type I diabetes, complications arising from type I diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung diseases, inflammatory sequelae of viral infections, inflammatory skin disorders, allograft rejection, immune cell interactions such as T-cell killing, mixed lymphocyte reaction, T-cell mediated B-cell differentiation, meningitis, multiple sclerosis, multiple myeloma, myocarditis, pulmonary fibrosis, reperfusion injury, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis and uveitis. The siRNAs are also useful for treating an angiogenic disease such as cancer, diabetic retinopathy age-related macular degeneration, preferably age-related macular degeneration. The siRNAs are also useful for treating complications arising from type I diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy and macrovascular disease. The macrovascular disease is coronary artery disease, cerebrovascular disease or peripheral vascular disease. The present oligonucleotide is a ICAM-1 target sequence from which the siRNAs of the invention can be derived.

Sequence 21 BP; 7 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 4e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1291 AATCCGAGCAGCTCCAATG 1311

Db 1 AATCCGAGCAGCTCCAATG 21

RESULT 191

ADQ82837 ID ADQ82837 standard; DNA; 21 BP.

XX ADQ82837;

AC 21-OCT-2004 (first entry)

DE Human ICAM-1 oligonucleotide, SEQ ID 89.

XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.

XX Homo sapiens.

XX WO2004065546-A2.

XX

PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 DR
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 XX Disclosure; SEQ ID NO 89; 71pp; English.
 PS
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 XX Sequence 21 BP; 12 A; 4 C; 3 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1585 AGAAATACAGACTACACAG 1605
 DB 1 AAGAAATACAGACTACACAG 21
 RESULT 192
 ADQ82838
 ID ADQ82838 standard; DNA; 21 BP.
 XX
 AC ADQ82838;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 90.
 XX
 DE Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;

KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cystostatic; Cardiac; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004065546-A2.
 PN
 XX 05-AUG-2004.
 PD
 XX 16-JAN-2004; 2004WO-US001166.
 PF
 XX 16-JAN-2003; 2003US-0440579P.
 PR
 XX (UYPE-) UNIV PENNSYLVANIA.
 PA
 XX Reich SJ, Tolentino MJ;
 PI WPI; 2004-580723/56.
 DR
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 XX Disclosure; SEQ ID NO 90; 71pp; English.
 PS
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 XX Sequence 21 BP; 10 A; 6 C; 3 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1588 AAATACAGACTACACAGGCC 1608
 DB 1 AAATACAGACTACACAGGCC 21
 RESULT 193

ADQ82841
ID ADQ82841 standard; DNA; 21 BP.
AC ADQ82841;
XX
XX
DT 21-OCT-2004 (first entry)
XX
DE Human ICAM-1 oligonucleotide, SEQ ID 93.
XX
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.
XX
XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX
XX 16-JAN-2003; 2003US-0440579P.
XX
XX (UYPE-) UNIV PENNSYLVANIA.
XX
XX Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 93; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, restenosis,
CC myocarditis, pulmonary fibrosis, reperfusion injury, stroke, tumour
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX
XX Sequence 21 BP; 10 A; 6 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1610 AAAAGGGAGCCCCCATGAAC 1630
DB 1 AAAAGGGAGCCCCCATGAAC 21
RESULT 194
ADQ82786
ID ADQ82786 standard; DNA; 21 BP.
XX
XX AC ADQ82786;
XX
XX DT 21-OCT-2004 (first entry)
XX
XX Human ICAM-1 oligonucleotide, SEQ ID 38.
XX
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.
XX
XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX
XX 16-JAN-2003; 2003US-0440579P.
XX
XX (UYPE-) UNIV PENNSYLVANIA.
XX
XX Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 38; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, restenosis,
CC myocarditis, pulmonary fibrosis, reperfusion injury, stroke, tumour
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX
XX Sequence 21 BP; 10 A; 6 C; 4 G; 1 T; 0 U; 0 Other;

XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 4 A; 4 C; 11 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 530 AACGGGAGCCAGCTGTGGGG 550
 Db 1 AACGGGAGCCAGCTGTGGGG 21
 |||||
 RESULT 197
 ADQ82820
 ID ADQ82820 standard; DNA; 21 BP.
 XX
 AC ADQ82820;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 72.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO2004045546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.

XX Reich SJ, Tolentino MJ;
 PI WPI; 2004-580723/56.
 XX
 DR Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 72; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 5 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1210 AACGAGACCCGGAGCTTCGT 1230
 Db 1 AACGAGACCCGGAGCTTCGT 21
 |||||
 RESULT 198
 ADQ82829
 ID ADQ82829 standard; DNA; 21 BP.
 XX
 AC ADQ82829;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 81.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX

OS Homo sapiens.
 XX WO2004065546-A2.
 PN 05-AUG-2004.
 PD 16-JAN-2004; 2004WO-US001166.
 PF 16-JAN-2003; 2003US-0440579P.
 PR (UYPE-) UNIV PENNSYLVANIA.
 XX Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 DR Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX Disclosure; SEQ ID NO 81; 71pp; English.
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angioedema, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermatitis hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel diseases, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1353 AAAGGATGGCATTCTCCCACT 1373
 Db 1 AAAGGATGGCATTCTCCCACT 21
 RESULT 199
 ID ADQ82839
 ID ADQ82839 standard; DNA; 21 BP.
 XX ADQ82839;
 AC ADQ82839;
 XX 21-OCT-2004 (first entry)
 DT
 XX

DE Human ICAM-1 oligonucleotide, SEQ ID 91.
 XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX Homo sapiens.
 OS WO2004065546-A2.
 PN 05-AUG-2004.
 PD 16-JAN-2004; 2004WO-US001166.
 PF 16-JAN-2003; 2003US-0440579P.
 PR (UYPE-) UNIV PENNSYLVANIA.
 XX Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 DR Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX Disclosure; SEQ ID NO 91; 71pp; English.
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angioedema, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermatitis hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel diseases, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX Sequence 21 BP; 9 A; 7 C; 3 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1589 AATACAGACTACACAGGCC 1609
 |||||||||||||||||||
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1589 AATACAGACTACACAGGCC 1609
 |||||||||||||||||||

Db 1 AATACAGACTACACAGGCC 21

RESULT 200

ADQ82768

ID ADQ82768 standard; DNA; 21 BP.

XX

AC ADQ82768;

XX

DT 21-OCT-2004 (first entry)

XX

DE Human ICAM-1 oligonucleotide, SEQ ID 20.

XX

KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;

KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;

KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;

KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;

KW Respiratory; Vasotropic; Antiarrhythmic; Antirheumatic; Cerebroprotective;

KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;

KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;

cell adhesion; human; ss.

XX

OS Homo sapiens.

XX

PN WO2004065546-A2.

XX

PD 05-AUG-2004.

XX

PF 16-JAN-2004; 2004WO-US001166.

XX

PR 16-JAN-2003; 2003US-0440579P.

XX

PA (UYPE-) UNIV PENNSYLVANIA.

XX

PI Reich SJ, Tolentino MJ;

XX

DR WPI; 2004-580723/56.

XX

PT Novel isolated small interfering RNA comprising sense RNA strand having

PT sequence identical to human intracellular adhesion molecule mRNA, and

PT antisense RNA strand, useful for treating angiogenic diseases such as

PT cancer.

XX

PS Example 1; SEQ ID NO 20; 71pp; English.

XX

CC The present invention relates to novel small interfering RNAs (siRNAs)

CC comprising sense and antisense RNA strands forming a RNA duplex, where

CC the sense RNA strand comprises nucleotide sequence substantially

CC identical to a target sequence of 19-25 contiguous nucleotides in human

CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence

CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix

CC interactions. The siRNAs of the invention specifically target and cause

CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus

CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful

CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such

CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,

CC Alzheimer's disease, angioneurosis, asthma, atherosclerosis, toxic

CC nephritis, immune-based nephritis, contact dermal hypersensitivity,

CC corneal/limbic injury, type I diabetes, complications arising from type I

CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung

CC diseases, inflammatory sequelae of viral infections, inflammatory skin

CC disorders, allograft rejection, immune cell interactions such as T-cell

CC killing, mixed lymphocyte reaction, T-cell mediated B-cell

CC differentiation, meningitis, multiple sclerosis, multiple myeloma,

CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,

CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour

CC metastasis and uveitis. The siRNAs are also useful for treating an

CC angiogenic disease such as cancer, diabetic retinopathy age-related

CC macular degeneration, preferably age-related macular degeneration. The

CC siRNAs are also useful for treating complications arising from type I

CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic

CC nephropathy and macrovascular disease. The macrovascular disease is

CC coronary artery disease, cerebrovascular disease or peripheral vascular

CC disease. The present oligonucleotide is a ICAM-1 target sequence from

CC which the siRNAs of the invention can be derived.

XX

Sequence 21 BP; 5 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 4e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 133 AATGCCAGACATCTGTGCC 153

Db 1 AATGCCAGACATCTGTGCC 21

RESULT 201

ADQ82777

ID ADQ82777 standard; DNA; 21 BP.

XX

AC ADQ82777;

XX

DT 21-OCT-2004 (first entry)

XX

DE Human ICAM-1 oligonucleotide, SEQ ID 29.

XX

KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;

KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;

KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;

KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;

KW Respiratory; Vasotropic; Antiarrhythmic; Antirheumatic; Cerebroprotective;

KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;

KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;

cell adhesion; human; ss.

XX

OS Homo sapiens.

XX

PN WO2004065546-A2.

XX

PD 05-AUG-2004.

XX

PF 16-JAN-2004; 2004WO-US001166.

XX

PR 16-JAN-2003; 2003US-0440579P.

XX

PA (UYPE-) UNIV PENNSYLVANIA.

XX

PI Reich SJ, Tolentino MJ;

XX

DR WPI; 2004-580723/56.

XX

PT Novel isolated small interfering RNA comprising sense RNA strand having

PT sequence identical to human intracellular adhesion molecule mRNA, and

PT antisense RNA strand, useful for treating angiogenic diseases such as

PT cancer.

XX

PS Example 1; SEQ ID NO 29; 71pp; English.

XX

CC The present invention relates to novel small interfering RNAs (siRNAs)

CC comprising sense and antisense RNA strands forming a RNA duplex, where

CC the sense RNA strand comprises nucleotide sequence substantially

CC identical to a target sequence of 19-25 contiguous nucleotides in human

CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence

CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix

CC interactions. The siRNAs of the invention specifically target and cause

CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus

CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful

CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such

CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,

CC Alzheimer's disease, angioneurosis, asthma, atherosclerosis, toxic

CC nephritis, immune-based nephritis, contact dermal hypersensitivity,

CC corneal/limbic injury, type I diabetes, complications arising from type I

CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung

CC diseases, inflammatory sequelae of viral infections, inflammatory skin

CC disorders, allograft rejection, immune cell interactions such as T-cell

CC killing, mixed lymphocyte reaction, T-cell mediated B-cell

CC differentiation, meningitis, multiple sclerosis, multiple myeloma,

CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,

CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour

CC metastasis and uveitis. The siRNAs are also useful for treating an

CC angiogenic disease such as cancer, diabetic retinopathy age-related

CC macular degeneration, preferably age-related macular degeneration. The

CC siRNAs are also useful for treating complications arising from type I

CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic

CC nephropathy and macrovascular disease. The macrovascular disease is

CC coronary artery disease, cerebrovascular disease or peripheral vascular

CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC antigenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 9 A; 3 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 277 AACACCGGAGGTGTATGAA 297
 Db 1 AACACCGGAGGTGTATGAA 21
 RESULT 202
 ADQ82778
 ID ADQ82778 standard; DNA; 21 BP.
 AC ADQ82778;
 XX
 XX 21-OCT-2004 (first entry)
 DT Human ICAM-1 oligonucleotide, SEQ ID 30.
 DE
 XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX Homo sapiens.
 OS
 XX WO2004065546-A2.
 PN
 XX 05-AUG-2004.
 PD
 XX 16-JAN-2004; 2004WO-US001166.
 PF
 XX 16-JAN-2003; 2003US-0440579P.
 PR
 XX (UYPE-) UNIV PENNSYLVANIA.
 PA
 XX Reich SJ, Tolentino MJ;
 PI WPI; 2004-580723/56.
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 XX Example 1; SEQ ID NO 30; 71pp; English.
 PS
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix

CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC antigenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 7 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 280 AACCGGAGGTGTATCACTG 300
 Db 1 AACCGGAGGTGTATCACTG 21
 RESULT 203
 ADQ82792
 ID ADQ82792 standard; DNA; 21 BP.
 XX ADQ82792;
 XX 21-OCT-2004 (first entry)
 DT Human ICAM-1 oligonucleotide, SEQ ID 44.
 DE
 XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX Homo sapiens.
 OS
 XX WO2004065546-A2.
 PN
 XX 05-AUG-2004.
 PD
 XX 16-JAN-2004; 2004WO-US001166.
 PF
 XX 16-JAN-2003; 2003US-0440579P.
 PR
 XX (UYPE-) UNIV PENNSYLVANIA.
 PA
 XX Reich SJ, Tolentino MJ;
 PI WPI; 2004-580723/56.
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.

PT antisense RNA strand, useful for treating angiogenic diseases such as
 XX cancer.
 XX
 PS Disclosure; SEQ ID NO 44; 71pp; English.
 XX
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 XX Sequence 21 BP; 5 A; 7 C; 7 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 398 AACGGTGAACCTGGACCCC 418
 DB 1 AACGGTGAACCTGGACCCC 21
 RESULT 204
 ADQ82807
 ID ADQ82807 standard; DNA; 21 BP.
 XX
 AC ADQ82807;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 59.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO2004065546-A2.
 PN
 XX
 XX 05-AUG-2004.
 PD
 XX
 XX 16-JAN-2004; 2004WO-US001166.

XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 DR WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 59; 71pp; English.
 XX
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 XX Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 874 AAGGCTCAGTCAGTGTGACC 894
 DB 1 AAGGCTCAGTCAGTGTGACC 21
 RESULT 205
 ADQ82821
 ID ADQ82821 standard; DNA; 21 BP.
 XX
 AC ADQ82821;
 XX
 XX 21-OCT-2004 (first entry)
 DT
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 73.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;

KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 XX cell adhesion; human; ss.

XX Homo sapiens.

OS WO2004065546-A2.

PN 05-AUG-2004.

XX 16-JAN-2004; 2004WO-US001166.

XX 16-JAN-2003; 2003US-0440579P.

XX (UYPE-) UNIV PENNSYLVANIA.

XX Reich SJ, Tolentino MJ;

XX WPI; 2004-580723/56.

XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.

XX Disclosure; SEQ ID NO 73; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.

XX Sequence 21 BP; 9 A; 4 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02; Indels 0; Gaps 0;
 Matches 21; Conservative 0; Mismatches 0;

QY 1272 AAACGTGACGTGCCAGAAAA 1292

DB 1 AAACGTGACGTGCCAGAAAA 21

RESULT 206

ADQ82774

ID ADQ82774 standard; DNA; 21 BP.

XX

AC ADQ82774;

XX 21-OCT-2004 (first entry)

XX Human ICAM-1 oligonucleotide, SEQ ID 26.

XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.

XX Homo sapiens.

XX WO2004065546-A2.

XX 05-AUG-2004.

XX 16-JAN-2004; 2004WO-US001166.

XX 16-JAN-2003; 2003US-0440579P.

XX (UYPE-) UNIV PENNSYLVANIA.

XX Reich SJ, Tolentino MJ;

XX WPI; 2004-580723/56.

XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.

XX Disclosure; SEQ ID NO 26; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.

XX Sequence 21 BP; 5 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 254 AAAAGGAGTTGCTCCTCCCTG 274
 |||||
 Db 1 AAAAGGAGTTGCTCCTCCCTG 21

RESULT 207
 ADQ82782

ID ADQ82782 standard; DNA; 21 BP.
 XX
 AC ADQ82782;
 XX

DT 21-OCT-2004 (first entry)
 XX

DE Human ICAM-1 oligonucleotide, SEQ ID 34.
 XX

KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antiporiatic; Nephrotropic; Small interfering RNA; siRNA;
 KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX

OS Homo sapiens.
 XX

PN WO2004065546-A2.
 XX

PD 05-AUG-2004.
 XX

PF 16-JAN-2004; 2004WO-US001166.
 XX

PR 16-JAN-2003; 2003US-0440579P.
 XX

PA (UYPE-) UNIV PENNSYLVANIA.
 XX

PI Reich SJ, Tolentino MJ;
 XX

DR WPI; 2004-580723/56.
 XX

Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX

PS Disclosure; SEQ ID NO 34; 71pp; English.
 XX

The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angioedema, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The

CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX

SQ Sequence 21 BP; 10 A; 4 C; 4 G; 3 T; 0 U; 0 Other;
 XX

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 311 AAGAAGATAGCCCAACCAATGT 331
 |||||
 Db 1 AAGAAGATAGCCCAACCAATGT 21

RESULT 208
 ADQ82788

ID ADQ82788 standard; DNA; 21 BP.
 XX

AC ADQ82788;
 XX

DT 21-OCT-2004 (first entry)
 XX

DE Human ICAM-1 oligonucleotide, SEQ ID 40.
 XX

KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antiporiatic; Nephrotropic; Small interfering RNA; siRNA;
 KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX

OS Homo sapiens.
 XX

PN WO2004065546-A2.
 XX

PD 05-AUG-2004.
 XX

PF 16-JAN-2004; 2004WO-US001166.
 XX

PR 16-JAN-2003; 2003US-0440579P.
 XX

PA (UYPE-) UNIV PENNSYLVANIA.
 XX

PI Reich SJ, Tolentino MJ;
 XX

DR WPI; 2004-580723/56.
 XX

Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX

PS Disclosure; SEQ ID NO 40; 71pp; English.
 XX

The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angioedema, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The

CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 8 A; 8 C; 1 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 360 AACAGCTAAACCTTCTCTCAC 380
 DB 1 AACAGCTAAACCTTCTCTCAC 21
 RESULT 209
 ADQ82804
 ID ADQ82804 standard; DNA; 21 BP.
 XX
 AC ADQ82804;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 56.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 XX (UYPE-) UNIV PENNSYLVANIA.
 PA
 PI Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 56; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where

CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, anglogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory skin
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 3 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 716 AACCTGTGACCCCGGGTCC 736
 DB 1 AACCTGTGACCCCGGGTCC 21
 RESULT 210
 ADQ82826
 ID ADQ82826 standard; DNA; 21 BP.
 XX
 AC ADQ82826;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 78.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 XX (UYPE-) UNIV PENNSYLVANIA.
 PA
 PI Reich SJ, Tolentino MJ;
 XX

DR WPI; 2004-580723/56.

XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.

XX Disclosure; SEQ ID NO 78; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs)
 XX comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.

XX Sequence 21 BP; 5 A; 3 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1308 AATGTCACGCTTGGGGAA 1328
 |||||
 DB 1 AATGTCACGCTTGGGGAA 21

RESULT 211
 ADQ82791
 ID ADQ82791 standard; DNA; 21 BP.
 XX AC ADQ82791;
 XX 21-OCT-2004 (first entry)
 XX Human ICAM-1 oligonucleotide, SEQ ID 43.

XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiaesthetic; Antiartherosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.

XX Homo sapiens.
 OS
 XX WO2004065546-A2.
 PN

XX 05-AUG-2004.

XX 16-JAN-2004; 2004WO-US001166.

XX 16-JAN-2003; 2003US-0440579P.

XX (UYPE-) UNIV PENNSYLVANIA.

XX Reich SJ, Tolentino MJ;
 PI WPI; 2004-580723/56.

XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.

XX Disclosure; SEQ ID NO 43; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.

XX Sequence 21 BP; 4 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 369 AACCTTCCTCACCGTGACTG 389
 |||||
 DB 1 AACCTTCCTCACCGTGACTG 21

RESULT 212
 ADQ82811
 ID ADQ82811 standard; DNA; 21 BP.
 XX AC ADQ82811;
 XX 21-OCT-2004 (first entry)
 XX Human ICAM-1 oligonucleotide, SEQ ID 63.

XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW

KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.
XX WO2004065546-A2.
XX 05-AUG-2004.
XX 16-JAN-2004; 2004WO-US001166.
XX 16-JAN-2003; 2003US-0440579P.
XX (UYPE-) UNIV PENNSYLVANIA.
XX Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 63; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX
SQ Sequence 21 BP; 7 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1012 AAGCCAGAGGTTCTCAGAGGG 1032
|||||
Db 1 AAGCCAGAGGTTCTCAGAGGG 21

RESULT 213
ADQ82813
ID ADQ82813 standard; DNA; 21 BP.
XX
AC ADQ82813;
XX
DT 21-OCT-2004 (first entry)
XX
DE Human ICAM-1 oligonucleotide, SEQ ID 65.
XX
KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnery; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.
XX WO2004065546-A2.
XX 05-AUG-2004.
XX 16-JAN-2004; 2004WO-US001166.
XX 16-JAN-2003; 2003US-0440579P.
XX (UYPE-) UNIV PENNSYLVANIA.
XX Reich SJ, Tolentino MJ;
XX WPI; 2004-580723/56.
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Example 1; SEQ ID NO 65; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX

SQ Sequence 21 BP; 6 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1048 AAGTGTGAGCCACCCCTAGA 1068
 |||||
 Db 1 AAGTGTGAGCCACCCCTAGA 21

RESULT 214
 ADQ82822
 ID ADQ82822 standard; DNA; 21 BP.
 XX
 AC ADQ82822;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 74.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antidiabetic; Antiartherosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 KW WO2004065546-A2.
 PN
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US0001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 XX
 DR Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Example 1; SEQ ID NO 74; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiodenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel diseases, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,

CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 21 BP; 8 A; 4 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1273 AACTGGACGTGGCCAGAAAT 1293
 |||||
 Db 1 AACTGGACGTGGCCAGAAAT 21

RESULT 215
 ADR44329/C
 ID ADR44329 standard; DNA; 21 BP.
 XX
 AC ADR44329;
 XX
 DT 04-NOV-2004 (first entry)
 XX
 DE Human ICAM-1 targeted antisense oligonucleotide, GMI595.
 XX
 KW Pouchitis; intercellular adhesion molecule-1; ICAM-1; ulcerative colitis;
 KW Crohn's disease; inflammatory bowel disease; cellular proliferation;
 KW antisense; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2004162259-A1.
 XX
 PD 19-AUG-2004.
 XX
 PF 12-FEB-2004; 2004US-00777838.
 XX
 PR 13-FEB-2003; 2003US-0447215P.
 PR 07-NOV-2003; 2003US-0518053P.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Wedel MK, Miner PB;
 XX WPI; 2004-603583/58.
 XX
 DR Treating pouchitis in a human in need comprises administering to the
 PT human a pharmaceutical composition comprising an oligonucleotide targeted
 PT to human ICAM-1 mRNA.
 XX
 PS Example 2; SEQ ID NO 3; 42pp; English.
 XX
 CC The invention relates to a method for treating pouchitis in a human which
 CC involves administering a pharmaceutical composition comprising an
 CC oligonucleotide targeted to human intercellular adhesion molecule-1 (ICAM
 CC -1) mRNA. The method is useful for treating pouchitis, ulcerative
 CC colitis, Crohn's disease, inflammatory bowel disease or undue cellular
 CC proliferation. The present sequence is an antisense oligonucleotide
 CC targeted to human ICAM-1. This sequence is used to illustrate the method
 CC of the invention.
 XX
 SQ Sequence 21 BP; 5 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 AACCTCAGCTCGCTATGGCT 63
 DB 21 AACCTCAGCTCGCTATGGCT 1
 RESULT 216
 ADR70558/c
 ID ADR70558 standard; DNA; 21 BP.
 AC ADR70558;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Reverse RTQ primer for human ICAM.
 XX
 KW Human; ss; PCR; telomerase reverse transcriptase; TERT; POU domain;
 KW class 5 transcription factor; POU5F1; Oct3; Oct4;
 KW teratocarcinoma-derived growth factor; Cripto; podocalyxin-like; PODXL;
 KW gastrin-releasing peptide receptor; GRPR; human embryonic stem cell; hES;
 KW primate pluripotent stem cell; cancer; gene expression; cell separation;
 KW differentiation; primer; RTQ PCR; real time quantitative PCR.
 XX
 OS Homo sapiens.
 XX
 PN US2004180347-A1.
 XX
 PD 16-SEP-2004.
 XX
 XX 13-MAR-2003; 2003US-00389431.
 PF
 XX 13-MAR-2003; 2003US-00389431.
 PR
 XX (STAN/) STANTON L W.
 PA (BRAN/) BRANDENBERGER R.
 PA (GOLD/) GOLD J D.
 PA (IRVI/) IRVING J M.
 PA (MAND/) MANDALAM R.
 PA (MOKN/) MOK M.
 XX
 PI Stanton LW, Brandenberger R, Gold JD, Irving JM, Mandalam R;
 PI Mok M;
 XX
 XX WPI; 2004-675599/66.
 DR
 XX Assessing culture of undifferentiated human embryonic stem cells or their
 PT progeny, by detecting Cripto, gastrin-releasing peptide (GRP) receptor
 PT and podocalyxin-like protein markers, and either hTERT and/or Oct3/4, or
 PT GRP receptor.
 XX
 PS Disclosure; SEQ ID NO 78; 57pp; English.
 CC
 CC The invention relates to assessing a culture of undifferentiated human
 CC embryonic stem (hES) cells (undifferentiated primate pluripotent stem
 CC cells) or their progeny, involves detecting or measuring a marker such as
 CC Cripto (teratocarcinoma-derived growth factor), gastrin-releasing peptide
 CC (GRP) receptor and podocalyxin-like protein, and either hTERT (telomerase
 CC reverse transcriptase) and/or Oct3/4 (also known as POU domain, class 5,
 CC transcription factor 1 (POU5F1), or GRP receptor. The method involves
 CC detecting or measuring at least two markers, and detecting or measuring
 CC hTERT and/or Oct3/4. The expression of the marker(s) is detected or
 CC measured at mRNA level by PCR amplification. The expression of the
 CC marker(s) is detected or measured at the protein level by antibody assay.
 CC The method involves quantifying the proportion of undifferentiated hES
 CC cells or differentiated cells in the culture from the marker expression.
 CC The level of the marker is determined to be at least 100-fold higher than
 CC the level of the marker in BJ fibroblasts or is determined to be no less
 CC than 100-fold lower than the level of the marker in hES cells, cultured
 CC on an extracellular matrix in medium conditioned with mouse embryonic
 CC fibroblasts and containing 4 ng/ml basic fibroblast growth factor. The
 CC method further involves modifying the culture conditions so as to cause
 CC the hES cells to increase expression of the marker detected or measured
 CC in the culture. The method is useful for assessing a culture of

CC undifferentiated hES cells or their progeny. The marker used in the above
 CC method is useful for characterising pluripotent stem cells and their
 CC differentiated progeny, for clinical diagnosis of cancer, for assessing
 CC and manipulating culture conditions, regulating gene expression, cell
 CC separation and purification, and to influence differentiation. The
 CC present sequence is a real time quantitative PCR primer used to assay
 CC mRNA expression in undifferentiated stem cells.
 XX
 SQ Sequence 21 BP; 3 A; 5 C; 7 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 438 GGGCAAGAACCTTACCCTACG 458
 DB 21 GGGCAAGAACCTTACCCTACG 1
 RESULT 217
 ADR70557
 ID ADR70557 standard; DNA; 21 BP.
 XX
 AC ADR70557;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE RTQ probe for human ICAM.
 XX
 KW Human; ss; PCR; telomerase reverse transcriptase; TERT; POU domain;
 KW class 5 transcription factor; POU5F1; Oct3; Oct4;
 KW teratocarcinoma-derived growth factor; Cripto; podocalyxin-like; PODXL;
 KW gastrin-releasing peptide receptor; GRPR; human embryonic stem cell; hES;
 KW primate pluripotent stem cell; cancer; gene expression; cell separation;
 KW differentiation; probe; RTQ PCR; real time quantitative PCR.
 XX
 OS Homo sapiens.
 XX
 PN US2004180347-A1.
 XX
 PD 16-SEP-2004.
 XX
 XX 13-MAR-2003; 2003US-00389431.
 PF
 XX 13-MAR-2003; 2003US-00389431.
 PR
 XX (STAN/) STANTON L W.
 PA (BRAN/) BRANDENBERGER R.
 PA (GOLD/) GOLD J D.
 PA (IRVI/) IRVING J M.
 PA (MAND/) MANDALAM R.
 PA (MOKN/) MOK M.
 XX
 PI Stanton LW, Brandenberger R, Gold JD, Irving JM, Mandalam R;
 PI Mok M;
 XX
 XX WPI; 2004-675599/66.
 DR
 XX Assessing culture of undifferentiated human embryonic stem cells or their
 PT progeny, by detecting Cripto, gastrin-releasing peptide (GRP) receptor
 PT and podocalyxin-like protein markers, and either hTERT and/or Oct3/4, or
 PT GRP receptor.
 XX
 PS Disclosure; SEQ ID NO 77; 57pp; English.
 CC
 CC The invention relates to assessing a culture of undifferentiated human
 CC embryonic stem (hES) cells (undifferentiated primate pluripotent stem
 CC cells) or their progeny, involves detecting or measuring a marker such as
 CC Cripto (teratocarcinoma-derived growth factor), gastrin-releasing peptide
 CC (GRP) receptor and podocalyxin-like protein, and either hTERT (telomerase
 CC reverse transcriptase) and/or Oct3/4 (also known as POU domain, class 5,
 CC transcription factor 1 (POU5F1), or GRP receptor. The method involves
 CC detecting or measuring at least two markers, and detecting or measuring
 CC hTERT and/or Oct3/4. The expression of the marker(s) is detected or
 CC measured at mRNA level by PCR amplification. The expression of the
 CC marker(s) is detected or measured at the protein level by antibody assay.
 CC The method involves quantifying the proportion of undifferentiated hES
 CC cells or differentiated cells in the culture from the marker expression.
 CC The level of the marker is determined to be at least 100-fold higher than
 CC the level of the marker in BJ fibroblasts or is determined to be no less
 CC than 100-fold lower than the level of the marker in hES cells, cultured
 CC on an extracellular matrix in medium conditioned with mouse embryonic
 CC fibroblasts and containing 4 ng/ml basic fibroblast growth factor. The
 CC method further involves modifying the culture conditions so as to cause
 CC the hES cells to increase expression of the marker detected or measured
 CC in the culture. The method is useful for assessing a culture of

CC hTERT and/or Oct3/4. The expression of the marker(s) is detected or
 CC measured at mRNA level by PCR amplification. The expression of the
 CC marker(s) is detected or measured at the protein level by antibody assay.
 CC The method involves quantifying the proportion of undifferentiated hES
 CC cells or differentiated cells in the culture from the marker expression.
 CC The level of the marker is determined to be at least 100-fold higher than
 CC the level of the marker in BJ fibroblasts or is determined to be no less
 CC than 100-fold lower than the level of the marker in hES cells, cultured
 CC on an extracellular matrix in medium conditioned with mouse embryonic
 CC fibroblasts and containing 4 ng/ml basic fibroblast growth factor. The
 CC method further involves modifying the culture conditions so as to cause
 CC the hES cells to increase expression of the marker detected or measured
 CC in the culture. The method is useful for assessing a culture of
 CC undifferentiated hES cells or their progeny. The marker used in the above
 CC method is useful for characterising pluripotent stem cells and their
 CC differentiated progeny, for clinical diagnosis of cancer, for assessing
 CC and manipulating culture conditions, regulating gene expression, cell
 CC separation and purification, and to influence differentiation. The
 CC present sequence is a real time quantitative PCR probe used to assay mRNA
 CC expression in undifferentiated stem cells.
 XX Sequence 21 BP; 2 A; 12 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 414 ACCCTCCCTCTTGGCAGCC 434

DB 1 ACCCTCCCTCTTGGCAGCC 21

RESULT 218

AD70556
 ID ADR70556 standard; DNR; 21 BP.

XX ADR70556;

XX 02-DEC-2004 (first entry)

DE Forward RTQ primer for human ICAM.

XX Human; ss; PCR; telomerase reverse transcriptase; TERT; POU domain;
 XX class 5 transcription factor; POU5f1; Oct3; Oct4;
 KW teratocarcinoma-derived growth factor; Cripto; podocalyxin-like; PODXL;
 KW gastrin-releasing peptide receptor; GRPR; human embryonic stem cell; hES;
 KW primate pluripotent stem cell; cancer; gene expression; cell separation;
 KW differentiation; primer; RTQ PCR; real time quantitative PCR.

XX Homo sapiens.

XX US2004180347-A1.

XX 16-SEP-2004.

XX 13-MAR-2003; 2003US-00389431.

XX 13-MAR-2003; 2003US-00389431.

XX (STAN/) STANTON L W.

PA (BRAN/) BRANDENBERGER R.

PA (GOLD/) GOLD J D.

PA (IRVI/) IRVING J M.

PA (MAND/) MANDALAM R.

PA (MOKM/) MOK M.

XX Stanton LW, Brandenberger R, Gold JD, Irving JM, Mandalam R;

PI Mok M;

XX WPI; 2004-675599/66.

XX Assessing culture of undifferentiated human embryonic stem cells or their
 PT progeny, by detecting Cripto, gastrin-releasing peptide (GRP) receptor

PT and podocalyxin-like protein markers, and either hTERT and/or Oct3/4, or
 PT GRP receptor.

PS Disclosure; SEQ ID NO 76; 57pp; English.

XX The invention relates to assessing a culture of undifferentiated human
 CC embryonic stem (hES) cells (undifferentiated primate pluripotent stem
 CC cells) or their progeny, involves detecting or measuring a marker such as
 CC Cripto (teratocarcinoma-derived growth factor), gastrin-releasing peptide
 CC (GRP) receptor and podocalyxin-like protein, and either hTERT (telomerase
 CC reverse transcriptase) and/or Oct3/4 (also known as POU domain, class 5,
 CC transcription factor 1 (POU5F1)), or GRP receptor. The method involves
 CC detecting or measuring at least two markers, and detecting or measuring
 CC hTERT and/or Oct3/4. The expression of the marker(s) is detected or
 CC measured at mRNA level by PCR amplification. The expression of the
 CC marker(s) is detected or measured at the protein level by antibody assay.
 CC The method involves quantifying the proportion of undifferentiated hES
 CC cells or differentiated cells in the culture from the marker expression.
 CC The level of the marker is determined to be at least 100-fold higher than
 CC the level of the marker in BJ fibroblasts or is determined to be no less
 CC than 100-fold lower than the level of the marker in hES cells, cultured
 CC on an extracellular matrix in medium conditioned with mouse embryonic
 CC fibroblasts and containing 4 ng/ml basic fibroblast growth factor. The
 CC method further involves modifying the culture conditions so as to cause
 CC the hES cells to increase expression of the marker detected or measured
 CC in the culture. The method is useful for assessing a culture of
 CC undifferentiated hES cells or their progeny. The marker used in the above
 CC method is useful for characterising pluripotent stem cells and their
 CC differentiated progeny, for clinical diagnosis of cancer, for assessing
 CC and manipulating culture conditions, regulating gene expression, cell
 CC separation and purification, and to influence differentiation. The
 CC present sequence is a real time quantitative PCR primer used to assay
 CC mRNA expression in undifferentiated stem cells.

XX Sequence 21 BP; 6 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 21; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 4e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 ACTCCAGAACGGGTGGAACGTG 411

DB 1 ACTCCAGAACGGGTGGAACGTG 21

RESULT 219

ADF70356/c

ID ADF70356 standard; DNA; 22 BP.

XX ADF70356;

XX 12-FEB-2004 (first entry)

XX ICAM antisense oligonucleotide SeqID70.

XX expression modulation; hepatic system; sterol group; hepatotropic;
 KW gene therapy; hepatic disease; antisense therapy; ss; ICAM;
 KW intercellular adhesion molecule.

XX Unidentified.

XX WO2003072711-A2.

XX 04-SEP-2003.

XX 21-FEB-2003; 2003WO-US005066.

XX 22-FEB-2002; 2002US-00080979.

XX (ISIS-) ISIS PHARM INC.

XX Cook PD, Manoharan M, Bennett FC;

DR WPI; 2003-679947/64.
 XX
 PT Modulating the expression of a nucleic acid in the hepatic system, useful
 PT for treating hepatic disorders, comprises administering to the mammal an
 PT oligonucleotide that hybridizes to the nucleic acid to modulate its
 PT expression.
 XX
 PS Example 7; SEQ ID NO 70; 98pp; English.
 XX
 CC This invention relates to a novel method of modulating the expression of
 CC a nucleic acid in the hepatic system of a mammal which comprises
 CC administering to the mammal an oligonucleotide that hybridizes to the
 CC nucleic acid to modulate the expression of the nucleic acid, where the
 CC oligonucleotide has two sterol groups that are covalently bonded. The
 CC invention may be useful for the development of a compound with
 CC hepatotropic activity whilst the genetic sequences of the invention may
 CC prove useful for gene therapy. The methods are useful for treating
 CC hepatic disease or disorder associated with a protein encoded by a gene.
 CC Note: These oligonucleotides may have one or more of several
 CC modifications which are detailed in the specification, including having a
 CC phosphorothioate backbone or having ribonucleoside bases.
 XX
 SQ Sequence 22 BP; 4 A; 8 C; 5 G; 3 T; 1 U; 1 Other;
 Query Match 0.7%; Score 21; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 3.8e+02; Indels 0; Gaps 0;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGCA 2120
 DB 21 TGACGGATGCCAGCTTGGGCA 1
 RESULT 220
 ADP45810/C
 ID ADP45810 standard; DNA; 22 BP.
 AC ADP45810;
 XX
 DT 26-AUG-2004 (first entry)
 XX
 DE Extend primer 2 used to genotype human ICAM-1/ICAM-4/ICAM-5 polymorphism.
 KW breast cancer; cytostatic; gene therapy; human;
 KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
 KW CD54; cell surface glycoprotein P3.58; ICAM-4;
 KW Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
 KW ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
 XX
 OS Homo sapiens.
 XX
 FN WO2004047623-A2.
 XX
 PD 10-JUN-2004.
 XX
 XX 25-NOV-2003; 2003WO-US037948.
 XX
 PR 25-NOV-2002; 2002US-0429136P.
 PR 24-JUL-2003; 2003US-0490234P.
 XX
 PA (SEQU-) SEQUENOM INC.
 XX
 XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
 PI WPI; 2004-441051/41.
 XX
 DR Identifying a subject at risk of breast cancer by detecting the presence
 PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
 PT regions which are associated with breast cancer in a nucleic acid sample
 PT from a subject.
 XX
 PS Example 4; Page 82; 289pp; English.
 XX

CC The invention relates to a novel method for identifying a subject at risk
 CC of breast cancer comprising detecting the presence or absence of one or
 CC more polymorphic variations associated with breast cancer in a nucleic
 CC acid sample from a subject. The method of the invention has cytostatic
 CC applications and may be useful for identifying a subject at risk of
 CC breast cancer, for early diagnosis, prevention and treatment of breast
 CC cancer, possibly via gene therapy, as well as to analyse and predict a
 CC response to a breast cancer treatment and in clinical drug trials. The
 CC current sequence is that of an Extend primer (also described as probe) of
 CC the invention which was used to genotype human intercellular adhesion
 CC molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor;BB2
 CC ;CD54;cell surface glycoprotein P3.58) has been mapped to chromosome
 CC position 19p13.3-p13.2, ICAM-4 (Landsteiner-Wiener blood group;LW) has
 CC been mapped to chromosome position 19p13.2-cen and ICAM-5
 CC (telencephalin) has been mapped to chromosome position 19p13.2.
 XX
 SQ Sequence 22 BP; 6 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 21; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 3.8e+02; Indels 0; Gaps 0;
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1463 AGGTGACCGTGAATGCTCT 1483
 DB 22 AGGTGACCGTGAATGCTCT 2
 RESULT 221
 AAQ73576
 ID AAQ73576 standard; DNA; 24 BP.
 AC AAQ73576;
 XX
 DT 25-MAR-2003 (revised)
 DT 25-JUN-1995 (first entry)
 XX
 DE Enhancer element er-6 conserved basepair sequence.
 XX
 KW Enhancer element; carcinoma; tumor; cancer; SLPI gene;
 KW secretory leukoprotease-inhibitor gene; cytokeratin gene-8; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT misc_difference 14 /tag= a
 FT /label= purine
 FT misc_difference 16 /tag= b
 FT /label= pyrimidine
 FT misc_difference 22 /tag= c
 FT /label= purine
 FT
 XX WO9421118-A1.
 XX
 PD 29-SEP-1994.
 XX
 PF 24-MAR-1994; 94WO-US003197.
 XX
 PR 24-MAR-1993; 93US-00035435.
 XX
 PA (UABR-) UAB RES FOUND.
 XX
 PI Garver RI, Sorscher EJ;
 XX
 DR WPI; 1994-316537/39.
 XX
 PT DNA construct for treating human carcinoma - includes a cancer-
 PT therapeutic gene under the control of a promoter and a gp. of enhancer
 PT sequences.
 XX
 PS Claim 1; Fig 6; 54pp; English.

XX This enhancer element is part of a DNA construct used for treating human
 CC carcinoma which contains a cancer therapeutic protein under the control
 CC of a promoter and 3 enhancer sequences in a specific 5'-3' order. This
 CC enhancer element is derived from the flanking region of the human
 CC epithelial cell cytokeratin-8 gene. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 24 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 3 Other;
 Query Match 0.7%; Score 21; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 3.5e+02;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2844 CCTCAGCCTCCTGAGTAGCTGGGA 2867
 DB 1 CCTCAGCCTCCTGAGTAGCTGGGA 24
 RESULT 222
 AAQ73577
 ID AAQ73577 standard; DNA; 24 BP.
 XX AAQ73577;
 AC
 XX
 DT 25-MAR-2003 (revised)
 DT 25-JUN-1995 (first entry)
 XX
 DE Enhancer element er-6 conserved basepair sequence.
 XX
 KW Enhancer element; carcinoma; tumor; cancer; SLPI gene;
 KW secretory leukoprotease-inhibitor gene; cytokeratin gene-8; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT misc_difference 14 /*tag= a
 FT /*label= purine
 FT
 FT misc_difference 16 /*tag= b
 FT /*label= pyrimidine
 FT misc_difference 22 /*tag= c
 FT /*label= purine
 FT
 FT
 PN WO9421118-Al.
 XX
 XX 29-SEP-1994.
 XX
 XX 24-MAR-1994; 94WO-US0003197.
 XX
 XX 24-MAR-1993; 93US-00035435.
 XX
 XX (UABR-) UAB-RES FOUND.
 XX
 XX Garver RI, Sorscher EJ;
 XX
 XX WPI; 1994-316537/39.
 XX
 XX DNA construct for treating human carcinoma - includes a cancer-
 PT therapeutic gene under the control of a promoter and a gp. of enhancer
 PT sequences.
 PT
 XX Claim 1; Fig 6; 54pp; English.
 XX
 XX This enhancer element is part of a DNA construct used for treating human
 CC carcinoma which contains a cancer therapeutic protein under the control
 CC of a promoter and 3 enhancer sequences in a specific 5'-3' order. This
 CC enhancer element is derived from the flanking region of the human
 CC epithelial cell secretory leukoprotease-inhibitor gene. (Updated on 25-
 CC MAR-2003 to correct PN field.)
 XX

SQ Sequence 24 BP; 3 A; 8 C; 6 G; 4 T; 0 U; 3 Other;
 Query Match 0.7%; Score 21; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 3.5e+02;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2844 CCTCAGCCTCCTGAGTAGCTGGGA 2867
 DB 1 CCTCAGCCTCCTGAGTAGCTGGGA 24
 RESULT 223
 AAQ33986
 ID AAQ33986 standard; DNA; 24 BP.
 XX AAQ33986;
 AC
 XX
 DT 25-MAR-2003 (revised)
 DT 02-FEB-1993 (first entry)
 XX
 DE Microsatellite sequence from clone TGLA382.
 XX
 KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.
 XX
 OS Bos taurus.
 XX
 PN WO9213102-Al.
 XX
 PD 06-AUG-1992.
 XX
 PF 15-JAN-1992; 92WO-US000340.
 XX
 PR 15-JAN-1991; 91US-00642342.
 XX
 XX (GENM-) GENMARK.
 XX
 XX Georges M, Massey JM;
 XX WPI; 1992-284684/34.
 XX
 XX Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.
 PT
 XX Table 7; Page 324; 517pp; English.
 XX
 CC The sequence is that of a bovine microsatellite sequence obtd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)₁₅ and a (TC)₁₅ oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T6)_n >9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved the determination of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20.8; DB 1; Length 24;
 Best Local Similarity 91.7%; Pred. No. 3.7e+02;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 DB 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 24

XX 12-NOV-1999; 99WO-US026931.
XX 16-NOV-1998; 98US-00193320.
XX (GENE-) GENELABS TECHNOLOGIES INC.
XX Dolganov G, Novikov A;
XX WPI; 2000-387825/33.
XX Measuring target polynucleotide sequences in biological samples by
PT contacting sequence-selective primer pairs, forming conjugates with
PT adaptor molecules, polymerizing target-identifier dimers and quantifying
PT them.
XX
XX Disclosure; Page 99; 103pp; English.
XX
XX A novel method for simultaneously determining the level of a number of
CC target polynucleotides in a sample has been disclosed. The method
CC involves forming double stranded copies of the target sequence in direct
CC proportion to the target levels in the original sample. The target
CC sequence is copied using primer pairs designed to flank a defined region
CC in the target sequence. The double stranded copies are then cleaved and
CC reacted with either first or second adaptor sequences. The first and
CC second conjugate mixtures are then allowed to form dimers with each other
CC through the target sequences. The adaptor sequences are then removed to
CC leave target sequence dimers. These dimers are then polymerised to form
CC dimer multimers. The relative abundances of target identifiers in the
CC multimer allow expression levels to be determined. This method is useful
CC for developing polynucleotide abundance level profiles for cells and
CC tissues under various conditions, stages of development and disease
CC states, particularly where the target polynucleotide is present at low
CC levels. The method may also be used in the discovery and evaluation of
CC candidate therapeutic agents and their effective dosage levels. In
CC addition to the method described above, the invention also includes the
CC polynucleotide and polypeptide of P2. P2 is thought to be a member of a
CC novel chemokine family, denoted CX5C and may be associated with immune
CC function. Compositions of the P2 polypeptide may be useful in the
CC treatment of asthma, allergic rhinitis (hay fever), urticaria (hives),
CC anaphylactic shock and conditions involving immune system
CC hypersensitivity. The P2 polynucleotide to treat conditions using gene
CC therapy. The human P2 gene has been localised to chromosome 5, within the
CC cytokine gene cluster at 5q31. The present sequence is the reverse primer
CC P2 for target sequence human P2 gene
XX
XX Sequence 24 BP; 4 A; 6 C; 9 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY .2764 TGTGTACCCAGCGTGTGAGTGCAG 2787
DB 1 TATGTCACCCAGCGTGTGAGTGCAG 24
RESULT 227
AAH46016
ID AAH46016 standard; DNA; 24 BP.
XX
XX AAH46016;
XX
XX 12-SEP-2001 (first entry)
XX
XX Synthetic oligonucleotide 16.
XX
XX Synthetic oligonucleotide; dinucleotide repeat; cytostatic; apoptosis;
XX cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
XX tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
XX lymphoma; ss.
XX
XX Synthetic.

XX WO200144465-A2.
XX 21-JUN-2001.
XX 12-DEC-2000; 2000WO-CA001467.
XX 13-DEC-1999; 99US-0170325P.
XX 29-AUG-2000; 2000US-0228925P.
XX (BION-) BIONICHE LIFE SCI INC.
XX Phillips NC, Filion MC;
XX WPI; 2001-398150/42.
XX
XX Composition comprising synthetic oligonucleotides which comprise multiple
PT repeats of dinucleotides such as GT, TG useful for treating cancer by
PT inducing cell cycle arrest, inhibiting proliferation, activating
PT caspases.
XX
XX Claim 6; Page 17; 77pp; English.
XX
XX The present sequence is that of a synthetic oligonucleotide useful to the
CC invention. The invention relates to a composition, comprising a 2 to 20
CC base 3'-OH, 5'-OH synthetic oligonucleotide which comprises multiple
CC repeats of dinucleotides such as GT, TG, etc., according to specific
CC formula and having cytostatic activity. The oligonucleotide compositions
CC are useful for inducing cell cycle arrest, inhibition of proliferation,
CC activation of caspases and induction of apoptosis or production of
CC cytokines such as interleukin (IL)-1-beta, IL-6, IL-10, IL-12 and tumour
CC necrosis factor (TNF)-alpha by immune system cells, in an animal having
CC cancer such as primary carcinoma, secondary carcinoma, primary sarcoma
CC and secondary sarcoma such as, leukemia, lymphoma, breast, prostate,
CC colorectal, ovarian or bone cancer. The compositions induce apoptosis
CC independent of Fas, p53/p21, p21/waf-1/CIP, p15(ink4B), p16(ink4), drug
CC resistance, caspase 3, transforming growth factor (TGF)-beta 1 receptor
CC and hormone dependence
XX
XX Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
DB 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 24
RESULT 228
AAI66532
ID AAI66532 standard; DNA; 24 BP.
XX
XX AAI66532;
XX
XX 11-DEC-2001 (first entry)
XX
XX Human pterin-molybdenum oxidoreductase 10 cDNA PCR primer #2.
DE
XX Human; pterin-molybdenum oxidoreductase 10; cancer; haemopathy;
XX immunological disease; HIV infection; inflammation; gene therapy;
XX PCR primer; ss.
XX
XX Homo sapiens.
XX
XX WO200172788-A1.
XX
XX 04-OCT-2001.
PD
XX 23-MAR-2001; 2001WO-CN000393.
PF
XX 24-MAR-2000; 2000CN-00115110.
PR


```

XX PD 02-SEP-2004.
XX PF
XX PF 25-FEB-2003; 2003US-00374307.
XX PR 25-FEB-2003; 2003US-00374307.
XX PA (LEPR/) LEPROUST E M.
XX PA (AMOR/) AMORESE D A.
XX PA (KRON/) KRONICK M N.
XX PI Leproust EM, Amorese DA, Kronick MN;
XX PS WPI; 2004-634540/61.
XX CC Detection of deposition unit misalignment of in situ polymeric array
XX CC synthesis device, by contacting test probe feature with different
XX CC distinguishably labeled targets, and evaluating binding of labeled
XX CC targets to test probe feature.
XX PS Example 2; Page 16; 36pp; English.
XX CC The invention relates to a method of detection of deposition unit
XX CC misalignment of an in situ polymeric array synthesis device which
XX CC comprises synthesising test probe feature(s) on substrate using in situ
XX CC polymeric array synthesis device, contacting test probe feature with at
XX CC least two different distinguishably labelled targets and evaluating
XX CC binding of labelled targets to test probe feature to detect any pulse jet
XX CC misalignment of polymeric array synthesis device. The method is useful
XX CC for detecting deposition unit misalignment e.g. printhead misalignment,
XX CC of an in situ polymeric, e.g. nucleic acid, array synthesis device. The
XX CC method is easy to use, cost effective. effective at detecting printhead
XX CC misalignments and may enable immediate detection and/or adjustments of
XX CC one or more printheads of an in situ nucleic acid array synthesis fluid
XX CC deposition device if misalignment is detected. The present sequence
XX CC represents an oligonucleotide synthesised on a microarray.
XX SQ Sequence 24 BP; 12 A; 12 C; 0 G; 0 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
Db 24 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 231
ADR48245
ID ADR48245 standard; DNA; 24 BP.
XX AC ADR48245;
XX DT 19-NOV-2004 (first entry)
XX DE Microarray synthesised oligonucleotide #9.
XX KW ss; deposition unit misalignment; polymeric array synthesis;
XX KW pulse jet misalignment; printhead misalignment; microarray.
XX OS Synthetic.
XX PN US2004170984-A1.
XX PD 02-SEP-2004.
XX PF 25-FEB-2003; 2003US-00374307.
XX PR 25-FEB-2003; 2003US-00374307.
XX PA (LEPR/) LEPROUST E M.
XX PA (AMOR/) AMORESE D A.

```

```

PA (KRON/) KRONICK M N.
XX Leproust EM, Amorese DA, Kronick MN;
XX DR WPI; 2004-634540/61.
XX PT Detection of deposition unit misalignment of in situ polymeric array
XX PT synthesis device, by contacting test probe feature with different
XX PT distinguishably labeled targets, and evaluating binding of labeled
XX PT targets to test probe feature.
XX PS Example 2; Page 16; 36pp; English.
XX CC The invention relates to a method of detection of deposition unit
XX CC misalignment of an in situ polymeric array synthesis device which
XX CC comprises synthesising test probe feature(s) on substrate using in situ
XX CC polymeric array synthesis device, contacting test probe feature with at
XX CC least two different distinguishably labelled targets and evaluating
XX CC binding of labelled targets to test probe feature to detect any pulse jet
XX CC misalignment of polymeric array synthesis device. The method is useful
XX CC for detecting deposition unit misalignment e.g. printhead misalignment,
XX CC of an in situ polymeric, e.g. nucleic acid, array synthesis device. The
XX CC method is easy to use, cost effective. effective at detecting printhead
XX CC misalignments and may enable immediate detection and/or adjustments of
XX CC one or more printheads of an in situ nucleic acid array synthesis fluid
XX CC deposition device if misalignment is detected. The present sequence
XX CC represents an oligonucleotide synthesised on a microarray.
XX SQ Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 3.7e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
Db 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 24

RESULT 232
AAQ33918
ID AAQ33918 standard; DNA; 25 BP.
XX AC AAQ33918;
XX DT 25-MAR-2003 (revised)
XX DT 02-FEB-1993 (first entry)
XX DE Microsatellite sequence from clone TGLA327.
XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
XX KW genetic mapping; traits; amplification; ss.
XX OS Bos taurus.
XX PN WO9213102-A1.
XX PD 06-AUG-1992.
XX PF 15-JAN-1992; 92WO-US000340.
XX PR 15-JAN-1991; 91US-00642342.
XX PA (GENM-) GENMARK.
XX PI Georges M, Massey JM;
XX DR WPI; 1992-284684/34.
XX PT Polymorphic bovine DNA markers - used in genetic identification, gene
XX PT mapping, and selective breeding.
XX PS Table 7; Page 297; 517pp; English.

```

XX The sequence is that of a bovine microsatellite sequence obt'd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T₆)_n > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved the determinism of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX Sequence 25 BP; 0 A; 0 C; 12 G; 13 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20.8; DB 1; Length 25;
 Best Local Similarity 91.7%; Pred. No. 3.5e+02;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db | | | | | | | | | | | | | | | | | | | |
 2 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 25

RESULT 233
 AAQ33642
 ID AAQ33642 standard; DNA; 25 BP.
 XX
 AC AAQ33642;
 XX
 DT 25-MAR-2003 (revised)
 DT 02-FEB-1993 (first entry)
 XX
 DE Microsatellite sequence from clone MTGT13B.
 XX
 KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.
 XX
 OS Bos taurus.
 XX
 PN WO9213102-A1.
 XX
 PD 06-AUG-1992.
 XX
 PF 15-JAN-1992; 92WO-US000340.
 XX
 PR 15-JAN-1991; 91US-00642342.
 XX
 PA (GENM-) GENMARK.
 XX
 PI Georges M, Massey JM;
 XX
 XX WPI; 1992-284684/34.
 XX
 PT Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.
 XX
 PS Table 7; Page 186; 517pp; English.
 XX
 CC The sequence is that of a bovine microsatellite sequence obt'd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T₆)_n > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the

CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved the determinism of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX Sequence 25 BP; 0 A; 0 C; 12 G; 13 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20.8; DB 1; Length 25;
 Best Local Similarity 91.7%; Pred. No. 3.5e+02;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db | | | | | | | | | | | | | | | | | | | |
 2 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 25

RESULT 234
 AAQ33962
 ID AAQ33962 standard; DNA; 25 BP.
 XX
 AC AAQ33962;
 XX
 DT 25-MAR-2003 (revised)
 DT 02-FEB-1993 (first entry)
 XX
 DE Microsatellite sequence from clone TGLA354.
 XX
 KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.
 XX
 OS Bos taurus.
 XX
 PN WO9213102-A1.
 XX
 PD 06-AUG-1992.
 XX
 PF 15-JAN-1992; 92WO-US000340.
 XX
 PR 15-JAN-1991; 91US-00642342.
 XX
 PA (GENM-) GENMARK.
 XX
 PI Georges M, Massey JM;
 XX
 XX WPI; 1992-284684/34.
 XX
 PT Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.
 XX
 PS Table 7; Page 315; 517pp; English.
 XX
 CC The sequence is that of a bovine microsatellite sequence obt'd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T₆)_n > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved the determinism of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX Sequence 25 BP; 0 A; 0 C; 12 G; 13 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20.8; DB 1; Length 25;
 Best Local Similarity 91.7%; Pred. No. 3.5e+02;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 DB 2 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 25

RESULT 235

AAQ33861
 ID AAQ33861 standard; DNA; 25 BP.

XX AC AAQ33861;

XX 25-MAR-2003 (revised)

DT 02-FEB-1993 (first entry)

XX Microsatellite sequence from clone TGLA264.

XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.

XX Bos taurus.

XX WO9213102-A1.

XX 06-AUG-1992.

PF 15-JAN-1992; 92WO-US000340.

XX 15-JAN-1991; 91US-00642342.

XX (GENM-) GENMARK.

XX Georges M, Massey JM;

XX WPI; 1992-284684/34.

XX Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.

XX Table 7; Page 274; 517pp; English.

XX The sequence is that of a bovine microsatellite sequence obt'd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (TC)n > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the correp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved the determinism of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)

XX Sequence 25 BP; 0 A; 0 C; 13 G; 12 T; 0 U; 0 Other;

Query Match 0.7%; Score 20.8; DB 1; Length 25;
 Best Local Similarity 91.7%; Pred. No. 3.5e+02;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 DB 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 24

RESULT 236

AAAT65734/c
 ID AAT65734 standard; DNA; 25 BP.

XX AC AAT65734;

XX 25-MAR-2003 (revised)

DT 17-JUN-1997 (first entry)

XX Repeat sequence from polymorphic marker clone Mfd32.

XX Polymorphism; repeat sequence; genetic marker; primer; amplification;
 KW PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
 KW linkage analysis; genetic disease; animal; plant; breeding; locus;
 KW hybridisation; chromosome; ds.

XX Homo sapiens.

XX US5582979-A.

XX 10-DEC-1996.

XX 04-APR-1994; 94US-00222177.

XX 21-APR-1989; 89US-00341562.

XX 05-SEP-1991; 91US-00754351.

XX (MARS-) MARSHFIELD CLINIC.

XX Weber JL;

XX WPI; 1997-042299/04.

XX Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
 PT using novel nucleic acid mols. as primers.

XX Disclosure; Col 9-10; 186pp; English.

XX The invention relates to the isolation of polymorphic repeat sequences
 CC having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
 CC markers. Primers based on these sequences can be used to detect these
 CC repeats, especially for use in e.g paternity or maternity testing, human
 CC genetic analysis such as linkage analysis of genetic disease, commercial
 CC animal or plant breeding or pedigree analysis. Clones containing the
 CC repeat sequences were isolated by hybridisation of chromosome-specific
 CC phage libraries with a synthetic poly(dC-dA). (dG-dT) probe. Over 100
 CC repeat blocks were isolated. The inserts from the clones were amplified
 CC by primers AAT65798-T66047. Those clones where the repeat sequence has
 CC been determined are shown in AAT65704-797. This repeat sequence is from
 CC the marker clone Mfd32 which contains the repeat sequence having the
 CC formula: (AC)12A. (Updated on 25-MAR-2003 to correct PF field.)

XX Sequence 25 BP; 13 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 20.8; DB 1; Length 25;
 Best Local Similarity 91.7%; Pred. No. 3.5e+02;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 DB 24 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 237

AAH38303
 ID AAH38303 standard; DNA; 25 BP.

XX AC AAH38303;

XX 14-AUG-2001 (first entry)

XX SNP specific SNPE primer SEQ ID 1099.

XX Single nucleotide polymorphism; SNP; single nucleotide primer extension;

XX PF 15-JAN-1992; 92WO-US000340.
 XX PR 15-JAN-1991; 91US-00642342.
 XX PA (GENM-) GENMARK.
 XX PI Georges M, Massey JM;
 XX PR WPI; 1992-284684/34.
 XX PT Polymorphic bovine DNA markers - used in genetic identification, gene
 XX mapping, and selective breeding.
 XX PS Table 7; Page 203; 517pp; English.
 XX CC The sequence is that of a bovine microsatellite sequence obt'd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T₆)_n > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX SQ Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20.8; DB 1; Length 26;
 Best Local Similarity 91.7%; Pred. No. 3.4e+02;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 24
 RESULT 240
 AAQ33704
 ID AAQ33704 standard; DNA; 26 BP.
 XX AC AAQ33704;
 XX DT 25-MAR-2003 (revised)
 XX DT 02-FEB-1993 (first entry)
 XX DE Microsatellite sequence from clone TGLA130.
 XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 XX KW genetic mapping; traits; amplification; ss.
 XX OS Bos taurus.
 XX PN WO9213102-A1.
 XX PD 06-AUG-1992.
 XX PF 15-JAN-1992; 92WO-US000340.
 XX PR 15-JAN-1991; 91US-00642342.
 XX PA (GENM-) GENMARK.
 XX PI Georges M, Massey JM;
 XX PR WPI; 1992-284684/34.
 XX PT Polymorphic bovine DNA markers - used in genetic identification, gene
 XX mapping, and selective breeding.
 XX PS Table 7; Page 203; 517pp; English.
 XX CC The sequence is that of a bovine microsatellite sequence obt'd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T₆)_n > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX SQ Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20.8; DB 1; Length 26;
 Best Local Similarity 91.7%; Pred. No. 3.4e+02;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 24
 RESULT 240
 AAQ33704
 ID AAQ33704 standard; DNA; 26 BP.
 XX AC AAQ33704;
 XX DT 25-MAR-2003 (revised)
 XX DT 02-FEB-1993 (first entry)
 XX DE Microsatellite sequence from clone TGLA130.
 XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 XX KW genetic mapping; traits; amplification; ss.
 XX OS Bos taurus.
 XX PN WO9213102-A1.
 XX PD 06-AUG-1992.
 XX PF 15-JAN-1992; 92WO-US000340.
 XX PR 15-JAN-1991; 91US-00642342.
 XX PA (GENM-) GENMARK.
 XX PI Georges M, Massey JM;
 XX PR WPI; 1992-284684/34.

XX PF Polymorphic bovine DNA markers - used in genetic identification, gene
 XX mapping, and selective breeding.
 XX PS Table 7; Page 211; 517pp; English.
 XX CC The sequence is that of a bovine microsatellite sequence obt'd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T₆)_n > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX SQ Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20.8; DB 1; Length 26;
 Best Local Similarity 91.7%; Pred. No. 3.4e+02;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 24
 RESULT 241
 AAQ33831
 ID AAQ33831 standard; DNA; 26 BP.
 XX AC AAQ33831;
 XX DT 25-MAR-2003 (revised)
 XX DT 02-FEB-1993 (first entry)
 XX DE Microsatellite sequence from clone TGLA231.
 XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 XX KW genetic mapping; traits; amplification; ss.
 XX OS Bos taurus.
 XX PN WO9213102-A1.
 XX PD 06-AUG-1992.
 XX PF 15-JAN-1992; 92WO-US000340.
 XX PR 15-JAN-1991; 91US-00642342.
 XX PA (GENM-) GENMARK.
 XX PI Georges M, Massey JM;
 XX PR WPI; 1992-284684/34.
 XX PT Polymorphic bovine DNA markers - used in genetic identification, gene
 XX mapping, and selective breeding.
 XX PS Table 7; Page 262; 517pp; English.
 XX CC The sequence is that of a bovine microsatellite sequence obt'd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of

CC microsatellites and MboI sites, the frequency of (T₆)_n >9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved in the determination of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20.8; DB 1; Length 26;
 Best Local Similarity 91.7%; Pred. No. 3.4e+02;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 2 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 25
 RESULT 242
 AAQ33837
 ID AAQ33837 standard; DNA; 26 BP.
 XX
 AC AAQ33837;
 XX
 DT 25-MAR-2003 (revised)
 DT 02-FEB-1993 (first entry)
 XX
 DE Microsatellite sequence from clone TGLA25.
 XX
 KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.
 XX
 OS Bos taurus.
 XX
 PN WO9213102-A1.
 XX
 PD 06-AUG-1992.
 XX
 PF 15-JAN-1992; 92WO-US000340.
 XX
 PR 15-JAN-1991; 91US-00642342.
 XX
 PA (GENM-) GENMARK.
 XX
 PI Georges M, Massey JM;
 XX
 DR WPI; 1992-284684/34.
 XX
 PT Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.
 XX
 PS Table 7; Page 264; 517pp; English.
 XX
 CC The sequence is that of a bovine microsatellite sequence obt'd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)₁₅ and a (TC)₁₅ oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T₆)_n >9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved in the determination of
 CC economically important traits esp. in cattle, to allow selective

CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 26 BP; 0 A; 0 C; 13 G; 13 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20.8; DB 1; Length 26;
 Best Local Similarity 91.7%; Pred. No. 3.4e+02;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 2 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 25
 RESULT 243
 AAQ47179
 ID AAQ47179 standard; DNA; 26 BP.
 XX
 AC AAQ47179;
 XX
 DT 25-MAR-2003 (revised)
 DT 25-JAN-1994 (first entry)
 XX
 DE MHC DR A intron binding oligomer GTcon.
 XX
 KW MHC; major histocompatibility complex; class II; control oligomers; DR A;
 KW transplantation; antigen; autoimmune disease; ss.
 XX
 OS Synthetic.
 XX
 PN WO9314769-A1.
 XX
 PD 05-AUG-1993.
 XX
 PF 29-JAN-1993; 93WO-US000797.
 XX
 PR 31-JAN-1992; 92US-00830427.
 PR 14-SEP-1992; 92US-00944868.
 XX
 PA (REGC) UNIV CALIFORNIA.
 XX
 PI Weiss TL, Garovoy MR, Hunt A, Huey B, Tam S;
 XX
 DR WPI; 1993-258367/32.
 XX
 PT Depletion of transplantation antigens in donor cells - using anti-sense
 PT or triplex-forming oligonucleotide(s), used for treating auto-immune
 PT disease and in transplants.
 XX
 PS Example; Page 22; 71pp; English.
 XX
 CC The sequences given in AAQ47176-77 represent triplex forming oligo-
 CC nucleotides which bind to the mRNA sequence of the MHC class II locus DR
 CC A structural gene at positions 851-876. The sequences given in AAQ47178-
 CC 80 represent control oligomers which contain base compositions similar to
 CC that around this DR A region but not containing the correct sequences. DR
 CC A is a transplantation antigen. Binding of this sequence to the DR A gene
 CC inhibits antigen production. This method may be used for treating
 CC individuals with autoimmune disease, characterised by dysfunctional
 CC expression of a transplantation antigen. It may also be used to produce
 CC cells which are more easily transplanted into a recipient. (Updated on 25
 CC -MAR-2003 to correct PN field.)
 XX
 SQ Sequence 26 BP; 0 A; 0 C; 14 G; 12 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20.8; DB 1; Length 26;
 Best Local Similarity 91.7%; Pred. No. 3.4e+02;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 2 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 25

XX	02-FEB-2001 (first entry)
DT	SNP flanking sequence #104 used in multiplexing PCR/SBE assay.
XX	
DE	SNP flanking sequence #104 used in multiplexing PCR/SBE assay.
XX	
KW	Oligonucleotide array; genotyping; single base extension reaction; SBE;
KW	polymorphic locus; single nucleotide polymorphism; ss.
XX	
OS	Unidentified.
XX	
FN	WO2000058516-A2.
XX	
PD	05-OCT-2000.
XX	
XX	27-MAR-2000; 2000WO-US008069.
XX	
PR	26-MAR-1999; 99US-0126473P.
PR	23-JUN-1999; 99US-0140359P.
XX	
PA	(WHED) WHITEHEAD INST BIOMEDICAL RES.
PA	(AFFY-) AFFYMETRIX INC.
XX	
PI	Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
PI	Ryder T, Sklar P;
XX	
DR	WPI; 2000-656171/63.
XX	
PT	Universal array of oligonucleotides tags attached to a solid substrate
PT	along with locus-specific tagged oligonucleotides useful in genotyping
PT	using single base extension reactions.
XX	
PS	Example 7; Page 59; 70pp; English.
XX	
CC	The present invention relates to an oligonucleotide array comprising
CC	oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC	array is useful for genotyping a nucleic acid sample at one or more loci
CC	via single base extension (SBE) reactions. A pair of primers is used to
CC	amplify a polymorphic locus in a sample e.g. a single nucleotide
CC	polymorphism (SNP). The present sequence is one such polymorphic locus
CC	used in the present invention. The amplified nucleic acid product is then
CC	used as a template in a SBE reaction with an extension primer. The SBE
CC	reaction products are used to form the oligonucleotide array. Note: This
CC	sequence includes a SNP represented by the degenerate codon in the
CC	sequence
XX	
SQ	Sequence 21 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 1 Other;
	Query Match 0.7%; Score 20.6; DB 1; Length 21;
	Best Local Similarity 95.2%; Pred. No. 4.4e+02;
	Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0
QY	1452 GGTACCCCGCGAGGTGACCGT 1472
	:
Db	1 GGTACCCCGCGAGGTGACCGT 21
RESULT 246	
AAC73472	
ID	AAC73472 standard; DNA; 21 BP.
XX	
AC	AAC73472;
XX	
DT	02-FEB-2001 (first entry)
XX	
DE	SNP flanking sequence #101 used in multiplexing PCR/SBE assay.
XX	
KW	Oligonucleotide array; genotyping; single base extension reaction; SBE;
KW	polymorphic locus; single nucleotide polymorphism; ss.
XX	
OS	Unidentified.
XX	
FN	WO2000058516-A2.
XX	

PD 05-OCT-2000.
XX
PF 27-MAR-2000; 2000WO-US008069.
XX
PR 26-MAR-1999; 99US-0126473P.
PR 23-JUN-1999; 99US-0140359P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY-) AFFYMETRIX INC.
XX
PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
PI Ryder T, Sklar P;
XX
DR WPI; 2000-656171/63.
XX
PT Universal array of oligonucleotides tags attached to a solid substrate
PT along with locus-specific tagged oligonucleotides useful in genotyping
PT using single base extension reactions.
XX
PS Example 7; Page 58; 70pp; English.
XX
CC The present invention relates to an oligonucleotide array comprising
CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC array is useful for genotyping a nucleic acid sample at one or more loci
CC via single base extension (SBE) reactions. A pair of primers is used to
CC amplify a polymorphic locus in a sample e.g. a single nucleotide
CC polymorphism (SNP). The present sequence is one such polymorphic locus
CC used in the present invention. The amplified nucleic acid product is then
CC used as a template in a SBE reaction with an extension primer. The SBE
CC reaction products are used to form the oligonucleotide array. Note: This
CC sequence includes a SNP represented by the degenerate codon in the
CC sequence
XX
SQ Sequence 21 BP; 1 A; 8 C; 5 G; 6 T; 0 U; 1 Other;
Query Match 0.7%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.4e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 768 TTCCCTGGACGGCTGTGCC 788
Db 1 TTCCCTGGACGGCTGTGCC 21
RESULT 247
AAC73476
ID AAC73476 standard; DNA; 21 BP.
XX
AC AAC73476;
XX
DT 02-FEB-2001 (first entry)
XX
DE SNP flanking sequence #102 used in multiplexing PCR/SBE assay.
XX
KW Oligonucleotide array; genotyping; single base extension reaction; SBE;
KW polymorphic locus; single nucleotide polymorphism; ss.
XX
OS Unidentified.
XX
PN WO200058516-A2.
XX
PD 05-OCT-2000.
XX
PF 27-MAR-2000; 2000WO-US008069.
XX
PR 26-MAR-1999; 99US-0126473P.
PR 23-JUN-1999; 99US-0140359P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY-) AFFYMETRIX INC.
XX
PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
PI Ryder T, Sklar P;

XX WPI; 2000-656171/63.
XX
PT Universal array of oligonucleotides tags attached to a solid substrate
PT along with locus-specific tagged oligonucleotides useful in genotyping
PT using single base extension reactions.
XX
PS Example 7; Page 58; 70pp; English.
XX
CC The present invention relates to an oligonucleotide array comprising
CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC array is useful for genotyping a nucleic acid sample at one or more loci
CC via single base extension (SBE) reactions. A pair of primers is used to
CC amplify a polymorphic locus in a sample e.g. a single nucleotide
CC polymorphism (SNP). The present sequence is one such polymorphic locus
CC used in the present invention. The amplified nucleic acid product is then
CC used as a template in a SBE reaction with an extension primer. The SBE
CC reaction products are used to form the oligonucleotide array. Note: This
CC sequence includes a SNP represented by the degenerate codon in the
CC sequence
XX
SQ Sequence 21 BP; 3 A; 8 C; 3 G; 6 T; 0 U; 1 Other;
Query Match 0.7%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.4e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 39 TTGCAACCTTCACCTCGCTAT 59
Db 1 TTGCAACCTTCACCTCGCTAT 21
RESULT 248
AAC73480
ID AAC73480 standard; DNA; 21 BP.
XX
AC AAC73480;
XX
DT 02-FEB-2001 (first entry)
XX
DE SNP flanking sequence #103 used in multiplexing PCR/SBE assay.
XX
KW Oligonucleotide array; genotyping; single base extension reaction; SBE;
KW polymorphic locus; single nucleotide polymorphism; ss.
XX
OS Unidentified.
XX
PN WO200058516-A2.
XX
PD 05-OCT-2000.
XX
PF 27-MAR-2000; 2000WO-US008069.
XX
PR 26-MAR-1999; 99US-0126473P.
PR 23-JUN-1999; 99US-0140359P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY-) AFFYMETRIX INC.
XX
PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
PI Ryder T, Sklar P;
XX
DR WPI; 2000-656171/63.
XX
PT Universal array of oligonucleotides tags attached to a solid substrate
PT along with locus-specific tagged oligonucleotides useful in genotyping
PT using single base extension reactions.
XX
PS Example 7; Page 58; 70pp; English.
XX
CC The present invention relates to an oligonucleotide array comprising
CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC array is useful for genotyping a nucleic acid sample at one or more loci
CC via single base extension (SBE) reactions. A pair of primers is used to
CC amplify a polymorphic locus in a sample e.g. a single nucleotide
CC polymorphism (SNP). The present sequence is one such polymorphic locus
CC used in the present invention. The amplified nucleic acid product is then
CC used as a template in a SBE reaction with an extension primer. The SBE
CC reaction products are used to form the oligonucleotide array. Note: This
CC sequence includes a SNP represented by the degenerate codon in the
CC sequence
XX
SQ Sequence 21 BP; 3 A; 8 C; 3 G; 6 T; 0 U; 1 Other;
Query Match 0.7%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 4.4e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 39 TTGCAACCTTCACCTCGCTAT 59
Db 1 TTGCAACCTTCACCTCGCTAT 21
RESULT 248
AAC73480
ID AAC73480 standard; DNA; 21 BP.
XX
AC AAC73480;
XX
DT 02-FEB-2001 (first entry)
XX
DE SNP flanking sequence #103 used in multiplexing PCR/SBE assay.
XX
KW Oligonucleotide array; genotyping; single base extension reaction; SBE;
KW polymorphic locus; single nucleotide polymorphism; ss.
XX
OS Unidentified.
XX
PN WO200058516-A2.
XX
PD 05-OCT-2000.
XX
PF 27-MAR-2000; 2000WO-US008069.
XX
PR 26-MAR-1999; 99US-0126473P.
PR 23-JUN-1999; 99US-0140359P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY-) AFFYMETRIX INC.
XX
PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
PI Ryder T, Sklar P;
XX
DR WPI; 2000-656171/63.
XX
PT Universal array of oligonucleotides tags attached to a solid substrate
PT along with locus-specific tagged oligonucleotides useful in genotyping
PT using single base extension reactions.
XX
PS Example 7; Page 58; 70pp; English.
XX
CC The present invention relates to an oligonucleotide array comprising
CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC array is useful for genotyping a nucleic acid sample at one or more loci

CC via single base extension (SBE) reactions. A pair of primers is used to
 CC amplify a polymorphic locus in a sample e.g. a single nucleotide
 CC polymorphism (SNP). The present sequence is one such polymorphic locus
 CC used in the present invention. The amplified nucleic acid product is then
 CC used as a template in a SBE reaction with an extension primer. The SBE
 CC reaction products are used to form the oligonucleotide array. Note: This
 CC sequence includes a SNP represented by the degenerate codon in the
 CC sequence

XX Sequence 21 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 1 Other;

Query Match 0.7%; Score 20.6; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 4.4e+02;
 Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 214 GACCAGCCCAAGTTGTTGGGC 234
 DB 1 GACCAGCCCAAGTTGTTGGGC 21

RESULT 249

ADD69512
 ID ADD69512 standard; DNA; 23 BP.

XX AC ADD69512;

XX 15-JAN-2004 (first entry)

DE 5' anchored (ISSR)-PCR primer - SEQ ID 5 alternative.

XX inter-simple sequence repeat; ISSR; SSR; PCR; primer; genotyping; plant;
 KW animal; Basmati rice; ss.

XX Synthetic.

XX WO2003085133-A2.

XX 16-OCT-2003.

XX 09-JAN-2003; 2003WO-IB000041.

XX 08-APR-2002; 2002IN-CH000260.

XX (DNAP-) CENT DNA FINGERPRINTING & DIAGNOSTICS.

XX Nagaraju JG;

XX WPI; 2003-804317/75.

XX New set of inter-simple sequence repeats (ISSR)-PCR primers for
 PT genotyping eukaryotes, useful for genotyping diverse genomes of plant and
 PT animal systems.

PS Claim 1; Page 17; 60pp; English.

XX The invention relates to a novel set of inter-simple sequence repeats
 CC (ISSR)-PCR primers for genotyping eukaryotes. The primers of the
 CC invention may be useful for genotyping diverse genomes of plant and
 CC animal systems, in particular for distinguishing Basmati rice varieties
 CC from non-Basmati rice varieties and traditional Basmati rice varieties
 CC from evolved Basmati rice varieties. The current sequence is that of the
 CC 5' anchored (ISSR)-PCR primer of the invention.

XX Sequence 23 BP; 0 A; 1 C; 9 G; 11 T; 0 U; 2 Other;

Query Match 0.7%; Score 20.6; DB 1; Length 23;
 Best Local Similarity 87.0%; Pred. No. 4.1e+02;
 Matches 20; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2727 CGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 DB 1 CRTRTGTGTGTGTGTGTGTGTGTGTGTGTGT 23

RESULT 250

AAQ33810
 ID AAQ33810 standard; DNA; 22 BP.

XX AAQ33810;

XX 25-MAR-2003 (revised)

XX 02-FEB-1993 (first entry)

XX Microsatellite sequence from clone TGLA214.

XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.

XX Bos taurus.

XX WO9213102-A1.

XX 06-AUG-1992.

XX 15-JAN-1992; 92WO-US000340.

XX 15-JAN-1991; 91US-00642342.

XX (GENM-) GENMARK.

XX Georges M, Massey JM;

XX WPI; 1992-284684/34.

XX Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.

XX Table 7; Page 253; 517pp; English.

XX The sequence is that of a bovine microsatellite sequence obtd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)₁₅ and a (TC)₁₅ oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (TC)₁₅ > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved the determinism of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)

XX Sequence 22 BP; 0 A; 0 C; 11 G; 11 T; 0 U; 0 Other;

Query Match 0.7%; Score 20.4; DB 1; Length 22;
 Best Local Similarity 95.5%; Pred. No. 4.5e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 DB 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 22

RESULT 251

AAQ83952/c
 ID AAQ83952 standard; DNA; 22 BP.

XX AAQ83952;

XX 25-MAR-2003 (revised)

XX 04-OCT-1995 (first entry)

DE Oligonucleotide clamp n, for producing comb-type brached polymer.
 XX HIV; pol; nef; oligonucleotide clamp; branched; macromolecule; ss.
 KW Synthetic.
 XX
 OS
 XX
 FH Key Location/Qualifiers
 FT modified_base 1 /*tag= a
 FT /note= "Modified with BrCH2(=O)CNH-"
 FT modified_base 8..9 /*tag= b
 FT /note= "C(pnp)A, pnp = a linkage or monomer containing a
 FT bromoacetyl amino functionality, and p = phosphodiester
 FT linkage"
 FT modified_base 14..15 /*tag= c
 FT /note= "C(pnp)A, pnp = a linkage or monomer containing a.
 FT bromoacetyl amino functionality, and p = phosphodiester
 FT linkage"
 FT modified_base 21..22 /*tag= d
 FT /note= "C(pnp)A, pnp = a linkage or monomer containing a
 FT bromoacetyl amino functionality, and p = phosphodiester
 FT linkage"
 XX WO9501365-A1.
 XX
 XX 12-JAN-1995.
 XX
 XX 05-JUL-1994; 94WO-US007557.
 XX
 XX 02-JUL-1993; 93US-00087386.
 XX
 XX (LYNX-) LYNX THERAPEUTICS INC.
 XX
 XX Gryaznov SM;
 XX
 XX WPI; 1995-060944/08.
 XX
 XX Synthesis of branched polymers and novel branched polymeric structures -
 PT used as molecular probes esp. for detecting poly-nucleotide(s).
 PT
 XX Example 8; Page 33; 52pp; English.
 XX
 CC The sequences given in AAQ83938, AAQ83952 and AAQ83940 are used in the
 CC construction of an oligonucleotide clamp. The clamp is a comb-type
 CC branched polymer which has 3' termini and was used to bind a target
 CC sequence comprising a segment of the HIV pol and nef genes in single
 CC stranded or double stranded forms. An oligonucleotide clamp is a compound
 CC capable of forming a covalently closed macromolecule or a stable circular
 CC complex after specifically binding to the target polynucleotide.
 CC Oligonucleotide clamps generally comprise one or more oligonucleotide
 CC moieties capable of specific binding to the target molecule and one or
 CC more pairs of binding moieties covalently linked to the oligonucleotide
 CC moieties. Upon annealing of the oligonucleotides moieties to the target
 CC polynucleotide, the binding moieties of a pair are brought into
 CC juxtaposition so that they form a stable covalent or non-covalent linkage
 CC or complex. The interaction of the binding moieties effectively clamps
 CC the specifically annealed oligonucleotide moieties to the target
 CC polynucleotide. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 XX Sequence 22 BP; 11 A; 11 C; 0 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20.4; DB 1; Length 22;
 Best Local Similarity 95.5%; Pred. No. 4.5e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GTCGTGTCGTGTCGTGTCGT 2749
 DB 22 GTCGTGTCGTGTCGTGTCGT 1

RESULT 252
 AAT45854/C
 ID AAT45854 standard; DNA; 22 BP.
 XX
 AC AAT45854;
 XX
 DT 11-FEB-1997 (first entry)
 XX
 DE ICAM antisense oligonucleotide with thiol modified backbone #2.
 XX
 KW Thiol; antisense; intracellular adhesion molecule; ICAM; 5' cap;
 KW inhibition; antisense technology; alkylthiol functionality;
 KW cellular transport; membrane transport; lipophilic; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 20..21 /*tag= a
 FT /note= "Linked via a thiol modified backbone"
 FT
 XX WO9506474-A1.
 XX
 XX 09-MAR-1995.
 XX
 XX 31-AUG-1994; 94WO-US010053.
 XX
 XX 03-SEP-1993; 93US-00116801.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Cook PD, Manoharan M;
 XX
 XX WPI; 1995-115256/15.
 XX
 XX Nucleoside and oligo:nucleoside analogues contg. alkyl-thiol gp. - useful
 PT for anti-sense applications e.g. modulating gene expression and detecting
 PT the presence or absence of RNA in a sample.
 XX
 XX Example 18; Page 28; 48pp; English.
 XX
 CC The sequences given in AAT45853-54 represent thiol-modified
 CC oligonucleotides. These sequences are antisense to sequences found in the
 CC intracellular adhesion molecule (ICAM) coding sequence. These
 CC oligonucleotides may be used to inhibit gene expression in vivo by
 CC hybridising to mRNA expressed in the cell. They are therefore useful in
 CC antisense technology. The modification of the backbone with an alkylthiol
 CC functionality improves cellular and membrane transport as it is
 CC lipophilic. This sequence is antisense to sequences in the 5' cap region
 CC of ICAM
 XX
 XX Sequence 22 BP; 7 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20.4; DB 1; Length 22;
 Best Local Similarity 95.5%; Pred. No. 4.5e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 16 CTGAGCTCTCTGCTACTCAGA 37
 DB 22 CTTAGCTCTCTGCTACTCAGA 1
 RESULT 253
 AAT65727/C
 ID AAT65727 standard; DNA; 22 BP.
 XX
 AC AAT65727;
 XX
 DT 25-MAR-2003 (revised)
 DT 17-JUN-1997 (first entry)
 XX
 DE Repeat sequence from polymorphic marker clone Mfd25.
 XX


```
XX PN US5852182-A.
XX PD 22-DEC-1998.
XX PF 02-JUN-1995; 95US-00458396.
XX PR 11-JAN-1990; 90US-00463358.
XX PR 13-AUG-1990; 90US-00566977.
XX PR 24-OCT-1991; 91US-00782374.
XX PR 23-OCT-1992; 92WO-US009196.
XX PR 03-SEP-1993; 93US-00116801.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Cook PD, Manoharan M;
XX DR WPI; 1999-080503/07.
XX PT Thiol-derivatised oligo:nucleoside(s) - are useful e.g. for inhibiting
XX FT transcription and/or replication of particular genes.
XX PS Example 18; Col 16; 16pp; English.
XX CC This sequence represents an example of a thiol-derivatised
XX CC oligonucleotide of the invention. The compounds of the invention comprise
XX CC a number of linked nucleosides, where each nucleoside comprises a
XX CC ribofuranosyl sugar portion and a base portion. At least one nucleoside
XX CC bears a group of formula -Rs-S-R1 at a 2'-O-position, 3'-O-position or 5'-
XX CC -O-position, where Rs = Ra, Ra-C(O)-Q-Ra or Ra-Q-Ra-Q-Ra; each Ra = a 1-
XX CC 10C alkyl; Q = NH, O or S; R1 = H, a thiol-protecting group, S-R2,
XX CC CH2C(O)-NH-R2, CH2-CH2-C(O)-R2, -CH2-CH2-NH-S(O)2-R2 or (maleimido)-R2;
XX CC and R2 = a steroid molecule, a reporter molecule, a lipophilic molecule,
XX CC a reporter enzyme, a peptide, a protein, a reporter group, an alkylator,
XX CC an intercalator, a cell receptor-binding molecule, a crown ether, a crown
XX CC amine, a porphyrin, a crosslinking agent, a peptide nucleic acid, or a
XX CC thiol attached to a polyethylene glycol. The thiol-derivatised
XX CC oligonucleosides can be used to inhibit transcription and/or replication
XX CC of particular genes, for inducing degradation of particular regions of
XX CC double-stranded DNA in cells of an organism, or for killing cells or
XX CC viruses
XX SQ Sequence 22 BP; 7 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 16 CTGAGCTCCTCTGCTACTCAGA 37
Db |||||||||||||||||||
22 CTTAGCTCCTCTGCTACTCAGA 1

RESULT 256
AAA95048/c
ID AAA95048 standard; DNA; 22 BP.
XX AC AAA95048;
XX DT 23-FEB-2001 (first entry)
XX DE Protein production prevention modified antisense oligonucleotide #2.
XX KW Protein production prevention; antisense oligonucleotide;
XX KW alkylthio group; ss.
XX OS Synthetic.
XX PH Key Location/Qualifiers
XX FT modified_base 20 /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "2'-O-thiol modified-2'-deoxyadenosine"

Query Match 0.7%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 16 CTGAGCTCCTCTGCTACTCAGA 37
Db |||||||||||||||||||
22 CTTAGCTCCTCTGCTACTCAGA 1

RESULT 257
AAD20067/c
ID AAD20067 standard; DNA; 22 BP.
XX AC AAD20067;
XX DT 03-JAN-2002 (first entry)
XX DE Antisense oligo for synthesis of oligonucleotides.
XX KW Thio-derivatised nucleoside; cellular membrane; diagnostic; therapeutic;
XX KW pharmaceutical; antisense; ss.
XX OS Unidentified.
XX PH Key Location/Qualifiers
XX FT modified_base 20 /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "2'-O-thiol modified-2'-deoxyadenosine"

US6265558-B1.
24-JUL-2001.
26-AUG-1999; 99US-00383856.
11-JAN-1990; 90US-00463358.
13-AUG-1990; 90US-00566977.
```

```
XX PN US6114513-A.
XX PD 05-SEP-2000.
XX PF 05-SEP-1997; 97US-00924326.
XX PR 11-JAN-1990; 90US-00463358.
XX PR 13-AUG-1990; 90US-00566977.
XX PR 24-OCT-1991; 91US-00782374.
XX PR 23-OCT-1992; 92WO-US009196.
XX PR 03-SEP-1993; 93US-00116801.
XX PR 02-JUN-1995; 95US-00458396.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Manoharan M, Cook PD;
XX DR WPI; 2000-586484/55.
XX PT Use of oligonucleosides containing thiol groups which hybridize to RNA
XX FT and have improved transport across cell membranes, in diagnosis or
XX FT treatment of viral infections and abnormal cell proliferation.
XX PS Example 18; Col 16; 18pp; English.
XX CC The present sequence is a modified antisense molecule which was used to
XX CC demonstrate the methods of the invention. These involve the use of
XX CC nucleosides, modified by alkylthio groups, as antisense strands which
XX CC bind to RNA to prevent translation. This can be used in the treatment of
XX CC diseases characterised by the undesired production of a protein. The
XX CC organisms treated may be prokaryotic or eukaryotic
XX SQ Sequence 22 BP; 7 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 16 CTGAGCTCCTCTGCTACTCAGA 37
Db |||||||||||||||||||
22 CTTAGCTCCTCTGCTACTCAGA 1

RESULT 257
AAD20067/c
ID AAD20067 standard; DNA; 22 BP.
XX AC AAD20067;
XX DT 03-JAN-2002 (first entry)
XX DE Antisense oligo for synthesis of oligonucleotides.
XX KW Thio-derivatised nucleoside; cellular membrane; diagnostic; therapeutic;
XX KW pharmaceutical; antisense; ss.
XX OS Unidentified.
XX PH Key Location/Qualifiers
XX FT modified_base 20 /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "2'-O-thiol modified-2'-deoxyadenosine"

US6265558-B1.
24-JUL-2001.
26-AUG-1999; 99US-00383856.
11-JAN-1990; 90US-00463358.
13-AUG-1990; 90US-00566977.
```



```

PF 28-JUN-2002; 2002US-00184372.
XX
PR 29-NOV-1999; 99US-00450209.
XX
PA (NEDE ) NEDERLANDSE ORG TOEGEPAST.
PI Bank RA, Van Der Slot AJ, Zuurmond A, Te Koppele JM;
XX
DR WPI; 2004-080749/08.
XX
XX
PT Obtaining a collagenous matrix with modified resistance against
PT proteolytic degradation, for treating a fibrotic condition, comprises
PT controlling the ratio of hydroxyallysine to allysine cross-links.
XX
XX Example 3; Page 12; 25pp; English.
XX
CC The invention relates to a method of obtaining a collagenous matrix which
CC comprises cross-linked collagen molecules, where the resistance of the
CC collagenous matrix against proteolytic degradation is controlled by
CC controlling the ratio of hydroxyallysine cross-links to allysine cross-
CC links in the collagenous matrix. The method is useful for obtaining a
CC collagenous matrix comprising cross-linked collagen molecules, where the
CC resistance of the collagenous matrix to proteolytic degradation, is
CC modulated. The method is useful for treating a fibrotic condition in a
CC mammal by administering to the mammal (preferably human) an effective
CC amount of a compound or composition which reduces the lysyl hydroxylation
CC level of collagen telopeptides and thereby results in a collagenous
CC matrix having a decreased ratio of hydroxyallysine cross-links to
CC allysine cross-links. The method comprises administration of compound or
CC composition that inhibits the activity or production of TLH encoded by a
CC PLOD2 gene but not the activity or production of lysyl oxidase. The
CC method is useful for treating fibrosis by inhibiting fibrotic processes,
CC in tissue engineering or drug delivery. The method provides collagen
CC cross-linked by hydroxyallysine cross-links which are more difficult to
CC degrade than collagen cross-linked by allysine. The present sequence
CC represents a PLOD2 PCR primer.
XX
SQ Sequence 22 BP; 10 A; 9 C; 2 G; 1 T; 0 U; 0 Other;
Query Match 0.7%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 4.5e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2727 CGTGTGTGTGTGTGTATGTG 2748
DB 22 CGTGTGTGTGTGTGTATGTG 1
RESULT 260
AAQ33663
ID AAQ33663 standard; DNA; 23 BP.
XX
AC AAQ33663;
XX
DT 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX
DE Microsatellite sequence from clone TGLA110.
XX
KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
XX
OS Bos taurus.
XX
PN WO9213102-A1.
XX
PD 06-AUG-1992.
XX
PF 15-JAN-1992; 92WO-US000340.
XX
PR 15-JAN-1991; 91US-00642342.
XX
PA (GENM-) GENMARK.
XX
XX
PI Georges M, Massey JM;
XX
DR WPI; 1992-284684/34.
XX
PT Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.
XX
PS Table 7; Page 12; 25pp; English.
XX
XX
CC The sequence is that of a bovine microsatellite sequence obtd. by
CC screening a library of bovine MboI DNA fragments of between 250 and 500
CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MboI sites, the frequency of (16)n > 9 microsatellites
CC in the bovine genome is estimated at >100, 000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPTIPRIM). The microsatellites may be
CC used to identify individuals, for parentage testing, and in the genetic
CC mapping of economic trait loci, or genes involved the determinism of
CC economically important traits esp. in cattle, to allow selective
CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SQ Sequence 23 BP; 0 A; 0 C; 11 G; 12 T; 0 U; 0 Other;
Query Match 0.7%; Score 20.4; DB 1; Length 23;
Best Local Similarity 95.5%; Pred. No. 4.3e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2728 GGTGTGTGTGTGTGTATGTGT 2749
DB 2 GGTGTGTGTGTGTGTGTGTGT 23
RESULT 261
AAQ33773
ID AAQ33773 standard; DNA; 23 BP.
XX
AC AAQ33773;
XX
DT 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX
DE Microsatellite sequence from clone TGLA176.
XX
KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
XX
OS Bos taurus.
XX
PN WO9213102-A1.
XX
PD 06-AUG-1992.
XX
PF 15-JAN-1992; 92WO-US000340.
XX
PR 15-JAN-1991; 91US-00642342.
XX
PA (GENM-) GENMARK.
XX
XX
PI Georges M, Massey JM;
XX
DR WPI; 1992-284684/34.
XX
PT Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.
XX
PS Table 7; Page 239; 517pp; English.
XX
XX

```

CC The sequence is that of a bovine microsatellite sequence obt'd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)₁₅ and a (TC)₁₅ oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T₆)_n > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved in the determination of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 CC XX

SQ Sequence 23 BP; 0 A; 0 C; 11 G; 12 T; 0 U; 0 Other;

Query Match 0.7%; Score 20.4; DB 1; Length 23;
 Best Local Similarity 95.5%; Pred. No. 4.3e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGT 2749

DB 2 GTGTGTGTGTGTGTGTGTGTGTGT 23

RESULT 262

AAQ33885
 ID AAQ33885 standard; DNA; 23 BP.

XX AAQ33885;

DT 25-MAR-2003 (revised)

DT 02-FEB-1993 (first entry)

XX Microsatellite sequence from clone TGLA304.

XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 XX genetic mapping; traits; amplification; ss.

XX Bos taurus.

XX WO9213102-A1.

PD 06-AUG-1992.

XX 15-JAN-1992; 92WO-US000340.

XX 15-JAN-1991; 91US-00642342.

XX (GENM-) GENMARK.

XX Georges M, Massey JM;

XX WPI; 1992-284684/34.

XX Polymorphic bovine DNA markers - used in genetic identification, gene
 XX mapping, and selective breeding.

XX Table 7; Page 283; 517pp; English.

XX The sequence is that of a bovine microsatellite sequence obt'd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)₁₅ and a (TC)₁₅ oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T₆)_n > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.

CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved in the determination of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 CC XX

SQ Sequence 23 BP; 0 A; 0 C; 11 G; 12 T; 0 U; 0 Other;

Query Match 0.7%; Score 20.4; DB 1; Length 23;
 Best Local Similarity 95.5%; Pred. No. 4.3e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGT 2749

DB 2 GTGTGTGTGTGTGTGTGTGTGTGT 23

RESULT 263

AAAT66105/c
 ID AAT66105 standard; DNA; 23 BP.

XX AAT66105;

XX 25-MAR-2003 (revised)

DT 18-JUN-1997 (first entry)

XX Repeat sequence found in the human chromosomal clone SW13.

XX Polymorphism; repeat sequence; genetic marker; primer; amplification;
 KW PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
 KW linkage analysis; genetic disease; animal; plant; breeding; locus;
 KW hybridisation; chromosome; ds.

XX Homo sapiens.

XX US5582979-A.

XX 10-DEC-1996.

XX 04-APR-1994; 94US-00222177.

XX 21-APR-1989; 89US-00341562.

PR 05-SEP-1991; 91US-00754351.

XX (MARS-) MARSHFIELD CLINIC.

XX Weber JL;

XX WPI; 1997-042299/04.

XX Detection of polymorphic genetic markers of the form (dC-dA)_n(dG-dT)_n -
 XX using novel nucleic acid mols. as primers.

XX Example 9; Col 61-62; 186pp; English.

XX The invention relates to the isolation of polymorphic repeat sequences
 CC having the sequence (dC-dA)_n(dG-dT)_n which can be used as genetic
 CC markers. Primers based on these sequences can be used to detect these
 CC repeats, especially for use in e.g paternity or maternity testing, human
 CC genetic analysis such as linkage analysis of genetic disease, commercial
 CC animal or plant breeding or pedigree analysis. The sequences AAT66084-
 CC T66107 represent repeat sequences of low informativeness found in
 CC specific human genes. This repeat sequence is found in the human
 CC chromosomal clone SW13. The sequence is amplified by primers AAT66106-7.
 CC (Updated on 25-MAR-2003 to correct PF field.)
 CC XX

SQ Sequence 23 BP; 12 A; 11 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 20.4; DB 1; Length 23;
 Best Local Similarity 95.5%; Pred. No. 4.3e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
 Db 22 GTGTGTGTGTGTGTGTGTGTGT 1

RESULT 264
 AAF60472/c
 ID AAF60472 standard; DNA; 23 BP.

XX AC AAF60472;
 XX DT 27-APR-2001 (first entry)
 XX DE Oligonucleotide clamp #17.
 XX KW Oligonucleotide clamp; ds.
 XX OS Unidentified.
 XX PN US6180777-B1.
 XX PD 30-JAN-2001.
 XX PF 03-JAN-1997; 97US-00787321.
 XX PR 12-JAN-1996; 96US-0009918P.
 XX PA (FARB) BAYER CORP.
 XX PI Horn T;
 XX DR WPI; 2001-201911/20.
 XX PT Synthesizing branched nucleic acids useful as diagnostic and molecular probes, involves combining first units having haloalkylamino groups and second units having thiol or phosphorothioate groups.
 XX PS Example 7; Col 19; 20pp; English.

XX CC The present invention relates to a method for synthesising a branched or multiply connected macromolecular structure, comprising oligonucleotide clamps (OC). The macromolecular structure is capable of specifically binding to a target molecule, and can therefore be used as probes. At least one OC comprises a target binding sequence that binds specifically and stably with the target molecule, and at least two OCs comprise signal generation moieties capable of generating a detectable signal in the presence of the target molecule. In addition the OCs are connected to one another by thioalkylamino, or thiophosphorylalkylamino bridges. The present sequence is an OC used in the present invention
 XX SQ Sequence 23 BP; 11 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 20.4; DB 1; Length 23;
 Best Local Similarity 95.5%; Pred. No. 4.3e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
 Db 23 GTGTGTGTGTGTGTGTGTGTGT 2

RESULT 265
 AAQ34158
 ID AAQ34158 standard; DNA; 24 BP.

XX AC AAQ34158;
 XX DT 25-MAR-2003 (revised)
 XX DT 02-FEB-1993 (first entry)
 XX DE Sequence of a microsatellite from clone TGLA80.
 XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;

KW genetic mapping; traits; amplification; ss.
 XX Bos taurus.

XX PN WO9213102-A1.
 XX PD 06-AUG-1992.
 XX PF 15-JAN-1992; 92WO-US000340.
 XX PR 15-JAN-1991; 91US-00642342.
 XX PA (GENM-) GENMARK.

XX PI Georges M, Massey JM;
 XX DR WPI; 1992-284684/34.

XX PT Polymorphic bovine DNA markers - used in genetic identification, gene mapping, and selective breeding.

XX PS Table 7; Page 394; 517pp; English.

XX CC The sequence is that of a bovine microsatellite sequence obt'd. by screening a library of bovine MboI DNA fragments of between 250 and 500 bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50 clones cross-hybridised. Assuming independent distribution of microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites in the bovine genome is estimated at >100, 000. The sequence information for ca. 230 such bovine microsatellites is summarised in the specification and indexed herein (see below). The sequences upstream and downstream of the microsatellite sequence were used to generate the required PCR primers for in vitro amplification of the corresp. microsatellite (using the program OPTIPRIM). The microsatellites may be used to identify individuals, for parentage testing, and in the genetic mapping of economic trait loci, or genes involved in the determination of economically important traits esp. in cattle, to allow selective breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN field.)

XX SQ Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

Query Match 0.7%; Score 20.4; DB 1; Length 24;
 Best Local Similarity 95.5%; Pred. No. 4.1e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
 Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 266

AAQ34024
 ID AAQ34024 standard; DNA; 24 BP.

XX AC AAQ34024;

XX DT 25-MAR-2003 (revised)
 XX DT 02-FEB-1993 (first entry)

XX DE Microsatellite sequence from clone TGLA423.

XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 XX genetic mapping; traits; amplification; ss.

XX OS Bos taurus.

XX PN WO9213102-A1.

XX PD 06-AUG-1992.

XX PF 15-JAN-1992; 92WO-US000340.

XX KW

PR 15-JAN-1991; 91US-00642342.
 XX (GENM-) GENMARK.
 XX
 PA Georges M, Massey JM;
 PI
 XX WPI; 1992-284684/34.
 XX
 DR Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.
 PT
 PS Table 7; Page 340; 517pp; English.
 XX
 CC The sequence is that of a bovine microsatellite sequence obt'd. by
 CC screening a library of bovine MbolI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MbolI sites, the frequency of (T6)n >9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved in the determinism of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 CC
 XX SQ Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20.4; DB 1; Length 24;
 Best Local Similarity 95.5%; Pred. No. 4.1e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 DB |||||
 2 GTGTGTGTGTGTGTGTGTGTGTGTGT 23
 RESULT 267
 AAQ33707
 ID AAQ33707 standard; DNA; 24 BP.
 XX
 AC AAQ33707;
 XX
 DT 25-MAR-2003 (revised)
 DT 02-FEB-1993 (first entry)
 XX
 DE Microsatellite sequence from clone TGLA131.
 XX
 KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW Genetic mapping; traits; amplification; ss.
 XX
 OS Bos taurus.
 XX
 PN WO9213102-A1.
 XX
 PD 06-AUG-1992.
 XX
 PF 15-JAN-1992; 92WO-US000340.
 XX
 PR 15-JAN-1991; 91US-00642342.
 XX
 PA (GENM-) GENMARK.
 XX
 PI Georges M, Massey JM;
 XX
 DR WPI; 1992-284684/34.
 XX
 PT Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.

XX
 PS Table 7; Page 213; 517pp; English.
 XX
 CC The sequence is that of a bovine microsatellite sequence obt'd. by
 CC screening a library of bovine MbolI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MbolI sites, the frequency of (T6)n >9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved in the determinism of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 CC
 XX SQ Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20.4; DB 1; Length 24;
 Best Local Similarity 95.5%; Pred. No. 4.1e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 DB |||||
 2 GTGTGTGTGTGTGTGTGTGTGTGTGT 23
 RESULT 268
 AAT66096/C
 ID AAT66096 standard; DNA; 24 BP.
 XX
 AC AAT66096;
 XX
 DT 25-MAR-2003 (revised)
 DT 18-JUN-1997 (first entry)
 XX
 DE Repeat sequence found in the human chromosomal clone JW42.
 XX
 KW Polymorphism; repeat sequence; genetic marker; primer; amplification;
 KW PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
 KW linkage analysis; genetic disease; animal; plant; breeding; locus;
 KW hybridisation; chromosome; ds.
 XX
 OS Homo sapiens.
 XX
 PN US5582979-A.
 XX
 PD 10-DEC-1996.
 XX
 PF 04-APR-1994; 94US-00222177.
 XX
 PR 21-APR-1989; 89US-00341562.
 PR 05-SEP-1991; 91US-00754351.
 XX
 PA (MARS-) MARSHFIELD CLINIC.
 XX
 PI Weber JL;
 XX
 DR WPI; 1997-042299/04.
 XX
 PT Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
 PT using novel nucleic acid mols. as primers.
 XX
 PS Example 9; Col 61-62; 186pp; English.
 XX
 CC The invention relates to the isolation of polymorphic repeat sequences
 CC having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
 CC markers. Primers based on these sequences can be used to detect these
 CC repeats, especially for use in e.g paternity or maternity testing, human

Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 271

ABL55369

ID ABL55369 standard; DNA; 24 BP.

XX

AC ABL55369;

XX

DT 23-JUL-2002 (first entry)

XX

DE Human leucine zipper protein 11.99 RT-PCR primer, SEQ ID NO:3.

XX

XX Human; leucine zipper protein 11.99; recombinant production; tumour;

KW cancer; embryonic development disorder; cytostatic; gene therapy;

KW reverse transcription-PCR; RT-PCR; primer; ss.

XX

OS Homo sapiens.

XX

PN CN1331194-A.

XX

PD 16-JAN-2002.

XX

PF 30-JUN-2000; 2000CN-00116898.

XX

PR 30-JUN-2000; 2000CN-00116898.

XX

XX (BODE-) BODE GENE DEV CO LTD SHANGHAI.

PA

PI Mao Y, Xie Y;

XX

XX WPI; 2002-292862/34.

DR

XX Polypeptide-human leucine zipper protein 11.99 and polynucleotide for

PT coding it.

PT

XX Example 2; Page 19 (disclosure); 35pp; Chinese.

PS

XX The invention relates to human leucine zipper protein 11.99 (AAM49285)

CC and to nucleic acids encoding it (ABL55368). The protein has a molecular

CC weight of 12 kD. The invention also relates to a method for the

CC recombinant production of the protein, an antagonist of the protein, and

CC the use of the protein, gene and antagonist in therapeutic applications.

CC Leucine zipper protein 11.99 can be used in the treatment of a variety of

CC diseases such as embryonic development disorders and tumours. Sequences

CC ABL55369-ABL55370 represent reverse transcription-PCR (RT-PCR) primers

CC used in an exemplification of the invention to isolate human leucine

CC zipper protein 11.99 cDNA

XX

Sequence 24 BP; 4 A; 5 C; 10 G; 5 T; 0 U; 0 Other;

SQ

Query Match 0.7%; Score 20.4; DB 1; Length 24;

Best Local Similarity 95.5%; Pred. No. 4.1e+02;

Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTGCAGTGGTG 2792

|||||

Db 1 CCCAGGCTGGAGTGCATGGTG 22

|||||

RESULT 272

ABS78584

ID ABS78584 standard; DNA; 24 BP.

XX

AC ABS78584;

XX

DT 13-DEC-2002 (first entry)

XX

XX Angiogenesis inhibitory oligonucleotide #1068.

DE

XX Angiogenesis inhibitor; ss; angiogenesis; solid tumour growth;

KW tumour metastasis; precancerous lesion; rheumatoid arthritis; psoriasis;

KW diabetic retinopathy; retinopathy of prematurity; macular degeneration;

KW corneal graft rejection; neovascular glaucoma; retrolental fibroplasia;

KW rubecosis; Osler-Webber Syndrome; myocardial angiogenesis;

KW plaque neovascularisation; telangiectasia; haemophilic joint;

KW angiofibroma; wound granulation; intestinal adhesion; atherosclerosis;

XX scleroderma; hypertrophic scar.

XX Synthetic.

XX OS

XX WO200253141-A2.

PN

XX 11-JUL-2002.

PD

XX 14-DEC-2001; 2001WO-US048458.

XX

PF 14-DEC-2000; 2000US-0255534P.

XX

PR (COLE-) COLEY PHARM GROUP INC.

XX

PA Bratzler RL;

XX

PI WPI; 2002-566690/60.

XX

DR Inhibiting angiogenesis in a subject, involves administering at least one

XX antiangiogenic nucleic acid molecule to the subject.

PT

XX Claim 2; Page 38; 276pp; English.

PS

XX The invention relates to inhibiting angiogenesis in a subject, comprising

CC administering at least one antiangiogenic nucleic acid molecule. Also

CC included is a kit comprising a first container housing the antiangiogenic

CC nucleic acids, and instructions for administering them to a subject

CC having a condition characterised by unwanted angiogenesis. The method is

CC useful for inhibiting angiogenesis associated with solid tumour growth,

CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,

CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,

CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,

CC rubecosis, Osler-Webber Syndrome, myocardial angiogenesis, plaque

CC neovascularisation, telangiectasia, haemophilic joints, angiofibroma,

CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and

CC hypertrophic scars. The present sequence is an antiangiogenic nucleic

CC acid of the invention

XX

Sequence 24 BP; 0 A; 0 C; 12 G; 12 T; 0 U; 0 Other;

SQ

Query Match 0.7%; Score 20.4; DB 1; Length 24;

Best Local Similarity 95.5%; Pred. No. 4.1e+02;

Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749

|||||

Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

|||||

RESULT 273

ABZ25854

ID ABZ25854 standard; DNA; 24 BP.

XX

AC ABZ25854;

XX

DT 28-MAR-2003 (first entry)

XX

XX Human basic transcription factor 2-9.9 RT-PCR primer, SEQ ID NO:3.

DE

XX Human; basic transcription factor 2-9.9; recombinant production;

KW gene therapy; tumour; cancer; diabetes; cytostatic;

KW reverse transcription-PCR; RT-PCR; primer; ss.

XX

OS Homo sapiens.

XX

PN CN1355208-A.

XX

PD 26-JUN-2002.

XX

Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 276
ADH93896
ID ADH93896 standard; DNA; 24 BP.
AC ADH93896;
XX
XX 22-APR-2004 (first entry)
DT
DE Human gene PCR primer #741.
XX
XX human, gene sequence; single nucleotide polymorphism; SNP;
KW disease diagnosis; ss; PCR; primer.
XX
XX Homo sapiens.
OS
XX JP2003174883-A.
PN
XX 24-JUN-2003.
PD
XX 11-DEC-2001; 2001JP-00377637.
PF
XX 11-DEC-2001; 2001JP-00377637.
PR
XX (KAGAKU GIJUTSU SHINKO JIGYODAN.
PA
XX WPI; 2003-819215/77.
DR
XX Polynucleotide for detecting single nucleotide polymorphisms existing in
PT human gene, contains isolated human gene having specified sequence.
PT
XX Claim 2; SEQ ID NO 1733; 529pp; Japanese.
PS
XX The invention comprises isolated human gene sequences and PCR primer
CC sequences which can be used to detect single nucleotide polymorphisms
CC (SNPs). The DNA sequences of the invention are useful for detecting SNPs
CC existing in human genes and for the diagnosis of human disease. The
CC present DNA sequence represents a human gene PCR primer of the invention.
XX
XX Sequence 24 BP; 1 A; 2 C; 9 G; 12 T; 0 U; 0 Other;
SQ

Query Match 0.7%; Score 20.4; DB 1; Length 24;
Best Local Similarity 95.5%; Pred. No. 4.1e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
DB 1 GTGTGTGTGTGTGTGTGTGT 22

RESULT 277
ADH81094/c
ID ADH81094 standard; DNA; 24 BP.
XX
XX ADH81094;
AC
XX 29-JUL-2004 (first entry)
DT
XX Sheep prion protein microsatellite locus primer #65.
DE
XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; PCR; primer; ss.
XX
XX Ovis aries.
OS
XX DE10236711-A1.
PN
XX 26-FEB-2004.
PD

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
DB 23 GTGTGTGTGTGTGTGTGTGT 2

RESULT 278
ADH81099/c
ID ADH81099 standard; DNA; 24 BP.
XX
XX ADH81099;
AC
XX 29-JUL-2004 (first entry)
DT
XX Sheep prion protein microsatellite locus primer #70.
DE
XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; PCR; primer; ss.
XX
XX Ovis aries.
OS
XX DE10236711-A1.
PN
XX 26-FEB-2004.
PD

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
DB 23 GTGTGTGTGTGTGTGTGTGT 2

RESULT 279
ADH81099/c
ID ADH81099 standard; DNA; 24 BP.
XX
XX ADH81099;
AC
XX 29-JUL-2004 (first entry)
DT
XX Sheep prion protein microsatellite locus primer #70.
DE
XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; PCR; primer; ss.
XX
XX Ovis aries.
OS
XX DE10236711-A1.
PN
XX 26-FEB-2004.
PD

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
DB 23 GTGTGTGTGTGTGTGTGTGT 2

RESULT 280
ADH81099/c
ID ADH81099 standard; DNA; 24 BP.
XX
XX ADH81099;
AC
XX 29-JUL-2004 (first entry)
DT
XX Sheep prion protein microsatellite locus primer #70.
DE
XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; PCR; primer; ss.
XX
XX Ovis aries.
OS
XX DE10236711-A1.
PN
XX 26-FEB-2004.
PD

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
DB 23 GTGTGTGTGTGTGTGTGTGT 2

RESULT 281
ADH81099/c
ID ADH81099 standard; DNA; 24 BP.
XX
XX ADH81099;
AC
XX 29-JUL-2004 (first entry)
DT
XX Sheep prion protein microsatellite locus primer #70.
DE
XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; PCR; primer; ss.
XX
XX Ovis aries.
OS
XX DE10236711-A1.
PN
XX 26-FEB-2004.
PD

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
DB 23 GTGTGTGTGTGTGTGTGTGT 2

RESULT 282
ADH81099/c
ID ADH81099 standard; DNA; 24 BP.
XX
XX ADH81099;
AC
XX 29-JUL-2004 (first entry)
DT
XX Sheep prion protein microsatellite locus primer #70.
DE
XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; PCR; primer; ss.
XX
XX Ovis aries.
OS
XX DE10236711-A1.
PN
XX 26-FEB-2004.
PD

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
DB 23 GTGTGTGTGTGTGTGTGTGT 2

RESULT 283
ADH81099/c
ID ADH81099 standard; DNA; 24 BP.
XX
XX ADH81099;
AC
XX 29-JUL-2004 (first entry)
DT
XX Sheep prion protein microsatellite locus primer #70.
DE
XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; PCR; primer; ss.
XX
XX Ovis aries.
OS
XX DE10236711-A1.
PN
XX 26-FEB-2004.
PD

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
DB 23 GTGTGTGTGTGTGTGTGTGT 2

RESULT 284
ADH81099/c
ID ADH81099 standard; DNA; 24 BP.
XX
XX ADH81099;
AC
XX 29-JUL-2004 (first entry)
DT
XX Sheep prion protein microsatellite locus primer #70.
DE
XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; PCR; primer; ss.
XX
XX Ovis aries.
OS
XX DE10236711-A1.
PN
XX 26-FEB-2004.
PD

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
DB 23 GTGTGTGTGTGTGTGTGTGT 2

RESULT 285
ADH81099/c
ID ADH81099 standard; DNA; 24 BP.
XX
XX ADH81099;
AC
XX 29-JUL-2004 (first entry)
DT
XX Sheep prion protein microsatellite locus primer #70.
DE
XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; PCR; primer; ss.
XX
XX Ovis aries.
OS
XX DE10236711-A1.
PN
XX 26-FEB-2004.
PD

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
DB 23 GTGTGTGTGTGTGTGTGTGT 2

RESULT 286
ADH81099/c
ID ADH81099 standard; DNA; 24 BP.
XX
XX ADH81099;
AC
XX 29-JUL-2004 (first entry)
DT
XX Sheep prion protein microsatellite locus primer #70.
DE
XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; PCR; primer; ss.
XX
XX Ovis aries.
OS
XX DE10236711-A1.
PN
XX 26-FEB-2004.
PD

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
DB 23 GTGTGTGTGTGTGTGTGTGT 2

RESULT 287
ADH81099/c
ID ADH81099 standard; DNA; 24 BP.
XX
XX ADH81099;
AC
XX 29-JUL-2004 (first entry)
DT
XX Sheep prion protein microsatellite locus primer #70.
DE
XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; PCR; primer; ss.
XX
XX Ovis aries.
OS
XX DE10236711-A1.
PN
XX 26-FEB-2004.
PD

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
DB 23 GTGTGTGTGTGTGTGTGTGT 2

RESULT 288
ADH81099/c
ID ADH81099 standard; DNA; 24 BP.
XX
XX ADH81099;
AC
XX 29-JUL-2004 (first entry)
DT
XX Sheep prion protein microsatellite locus primer #70.
DE
XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; PCR; primer; ss.
XX
XX Ovis aries.
OS
XX DE10236711-A1.
PN
XX 26-FEB-2004.
PD

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
DB 23 GTGTGTGTGTGTGTGTGTGT 2

RESULT 289
ADH81099/c
ID ADH81099 standard; DNA; 24 BP.
XX
XX ADH81099;
AC
XX 29-JUL-2004 (first entry)
DT
XX Sheep prion protein microsatellite locus primer #70.
DE
XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;<

XX Geldermann H, Preuss S, Han Y;
 XX WPI; 2004-215730/21.
 XX
 XX Typing genes that contain polymorphic microsatellite loci, useful for
 PT identifying predisposition to disease, by amplification and determining
 PT length of amplicons.
 XX
 XX Example 3; Page 30; 64pp; German.
 XX
 XX The invention describes a method of typing (M1) a gene (I) that has one
 CC or more polymorphic microsatellite loci (PML). The method comprises: PCR
 CC amplification of at least one DNA region of (I) that includes PML, using
 CC as template a DNA sample containing at least one segment of (I); and
 CC determining the length of the resulting amplicon(s). Also described are:
 XX a method of determining (M2) microsatellite markers (MM) for
 CC predisposition to a disease, associated with a gene that includes one or
 CC more PML; and prediagnosis (M3) of diseases associated with gene that
 CC include PML. The method is used to identify microsatellite markers, in a
 CC disease-related gene, that are associated with a predisposition to
 CC diseases and for prediagnosis of such diseases, especially prion diseases
 CC but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
 CC metabolic diseases; also to type genes that encode milk proteins,
 CC hormones or transcription factors. The method is simpler, quicker and
 CC particularly less expensive than known methods based on sequencing. This
 CC sequence represents a primer used to genotype a region of the sheep prion
 CC protein (PrP) comprising a polymorphic microsatellite locus.
 XX
 XX Sequence 24 BP; 12 A; 12 C; 0 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20.4; DB 1; Length 24;
 Best Local Similarity 95.5%; Pred. No. 4.1e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 23 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2
 RESULT 279
 AD081051/c
 ID AD081051 standard; DNA; 24 BP.
 XX AD081051;
 XX 29-JUL-2004 (first entry)
 DT Cow prion protein microsatellite locus primer #63.
 DE
 DE gene typing; polymorphic microsatellite loci; PML;
 KW disease predisposition; microsatellite marker; prion disease;
 KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
 KW milk protein; hormone; transcription factor; prion-blue-vector; cow;
 KW microsatellite; PCR; primer; ss.
 XX
 XX Bos taurus.
 XX
 XX DE10236711-A1.
 XX 26-FEB-2004.
 XX
 XX 09-AUG-2002; 2002DE-01036711.
 XX
 XX 09-AUG-2002; 2002DE-01036711.
 XX (UYHO-) UNIV HOHENHEIM.
 XX Geldermann H, Preuss S, Han Y;
 XX WPI; 2004-215730/21.
 XX
 XX Typing genes that contain polymorphic microsatellite loci, useful for

PT identifying predisposition to disease, by amplification and determining
 PT length of amplicons.
 XX
 XX Example 3; Page 27; 64pp; German.
 XX
 XX The invention describes a method of typing (M1) a gene (I) that has one
 CC or more polymorphic microsatellite loci (PML). The method comprises: PCR
 CC amplification of at least one DNA region of (I) that includes PML, using
 CC as template a DNA sample containing at least one segment of (I); and
 CC determining the length of the resulting amplicon(s). Also described are:
 XX a method of determining (M2) microsatellite markers (MM) for
 CC predisposition to a disease, associated with a gene that includes one or
 CC more PML; and prediagnosis (M3) of diseases associated with gene that
 CC include PML. The method is used to identify microsatellite markers, in a
 CC disease-related gene, that are associated with a predisposition to
 CC diseases and for prediagnosis of such diseases, especially prion diseases
 CC but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
 CC metabolic diseases; also to type genes that encode milk proteins,
 CC hormones or transcription factors. The method is simpler, quicker and
 CC particularly less expensive than known methods based on sequencing. This
 CC sequence represents a primer used to genotype a region of the cow prion
 CC protein (PrP) comprising a polymorphic microsatellite locus.
 XX
 XX Sequence 24 BP; 12 A; 12 C; 0 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20.4; DB 1; Length 24;
 Best Local Similarity 95.5%; Pred. No. 4.1e+02;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 23 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2
 RESULT 280
 ADRI6077/c
 ID ADRI6077 standard; DNA; 24 BP.
 XX ADRI6077;
 XX 21-OCT-2004 (first entry)
 DT Human PARP DNA 85-bp allelic fragment.
 DE
 DE Genetic testing; systemic lupus erythematosus; SLE;
 KW poly(ADP-riboseyl)polymerase; PARP; genetic counselling; human; de.
 XX
 XX Homo sapiens.
 XX
 XX US2004152075-A1.
 XX
 XX 05-AUG-2004.
 XX
 XX 18-JUL-2001; 2001US-00909317.
 XX
 XX 29-MAR-1999; 99US-00280181.
 XX
 XX (TSAO/) TSAO B P.
 XX (CANT/) CANTOR R M.
 XX (ROTT/) ROTTER J I.
 XX
 XX Tsao BP, Cantor RM, Rotter JI;
 XX WPI; 2004-561490/54.
 XX
 XX Genetic testing for systemic lupus erythematosus in human, by amplifying
 PT nucleic acids from tissue sample to obtain amplification products, and
 PT detecting presence or absence of dinucleotide repeat sequence in
 PT amplification products.
 XX
 XX Claim 1; SEQ ID NO 6; 17pp; English.
 XX
 XX The invention relates to a genetic testing method for diagnosing systemic

CC lupus erythematosus (SLE) in human. The method involves amplifying
CC nucleic acids from human tissue samples and detecting the presence or
CC absence of variant alleles of a gene encoding poly(ADP-ribosyl)polymerase
CC (PARP), which is a diagnostic of SLE or indication of a genetic
CC predisposition for developing SLE. The method is useful for genetic
CC testing for SLE in a human subject. It is useful in genetic counselling
CC to provide useful information to persons considering their reproductive
CC options. The present sequence is human PARP DNA 85-bp allelic fragment.
CC This sequence is used to illustrate the method of the invention.
XX
SQ Sequence 24 BP; 12 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular dystrophy, familial hypercholesterolaemia, polycystic kidney disease, osteogenesis imperfecta and acute intermittent porphyria. Phenotypic traits also include symptoms of or susceptibility to multifactorial disease of which a component is or may be genetic such as autoimmune diseases, including, rheumatoid arthritis, multiple sclerosis, inflammation, cancer, nervous system diseases and infection by pathogenic microorganism. The method is also useful in forensic investigations and paternity analysis. The present sequence represents a single nucleotide primer extension (SNPE) primer specific for a human SNP containing DNA sequence

```

Db      20 CAGTCGACGCTGAGCTCCTC 1
|||||
RESULT 283
AAQ22639/c
ID AAQ22639 standard; DNA; 20 BP.
XX
AC AAQ22639;
XX
DT 08-JUL-1992 (first entry)
XX
DE Antisense oligonucleotide #11 targetted to ICAM-1 CDS (889-908).
XX
KW Intercellular adhesion molecule-1; inhibitor; phosphorothioate bond;
KW triple helix; coding region; ss.
XX
OS Synthetic.
XX
PN WO9203139-A.
XX
PD 05-MAR-1992.
XX
PF 23-JUL-1991; 91WO-US005209.
XX
PR 14-AUG-1990; 90US-00567286.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Mirabelli CK, Mira;
XX
WPI; 1992-096579/12.
XX
PT New oligonucleotides hybridisable to cell adhesion modulators - for
PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
PT and diagnosis of intercellular adhesion dysfunction.
XX
PS Example 5; Page 41; 75pp; English.
XX
CC This antisense oligonucleotide was designed to hybridise 3' to the AUG
CC codon of human ICAM-1 mRNA. It was synthesised in the phosphorothioate
CC form as none of the phosphodiester form-antisense oligonucleotides which
CC were initially tested demonstrated inhibitory activity. Oligonucleotides
CC #5,9,10 and 12 also hybridise to the coding region (see AAQ22633, Q22637, 8
CC and AAQ22640, respectively). In common with oligonucleotide #11, they all
CC showed weak inhibitory activity on ICAM-1 expression
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGTGACC 894
|||||
Db      20 AGCCCTCAGTCAGTGTGACC 1

RESULT 284
AAQ22636/c
ID AAQ22636 standard; DNA; 20 BP.
XX
AC AAQ22636;
XX
DT 08-JUL-1992 (first entry)
XX
DE Antisense oligonucleotide #8 targetted to ICAM-1 AUG codon (72-91).
XX
KW Intercellular adhesion molecule-1; inhibitor; phosphorothioate bond;
KW triple helix; ss.
XX
OS Synthetic.
XX

PN WO9203139-A.
XX
PD 05-MAR-1992.
XX
PF 23-JUL-1991; 91WO-US005209.
XX
PR 14-AUG-1990; 90US-00567286.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Mirabelli CK, Mira;
XX
WPI; 1992-096579/12.
XX
PT New oligonucleotides hybridisable to cell adhesion modulators - for
PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
PT and diagnosis of intercellular adhesion dysfunction.
XX
PS Example 5; Page 46; 75pp; English.
XX

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCCGAGCAGCCCCCG 77
|||||
Db      20 ATGGCTCCCGAGCAGCCCCCG 1

RESULT 285
AAQ22652/c
ID AAQ22652 standard; DNA; 20 BP.
XX
AC AAQ22652;
XX
DT 08-JUL-1992 (first entry)
XX
DE Antisense oligonucleotide #24 targetted to ICAM-1 3'-UTR (1895-1914).
XX
KW Intercellular adhesion molecule-1; inhibitor; phosphorothioate bond;
KW triple helix; 3' untranslated region; ss.
XX
OS Synthetic.
XX
PN WO9203139-A.
XX
PD 05-MAR-1992.
XX
PF 23-JUL-1991; 91WO-US005209.
XX
PR 14-AUG-1990; 90US-00567286.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Mirabelli CK, Mira;
XX
WPI; 1992-096579/12.
XX
PT New oligonucleotides hybridisable to cell adhesion modulators - for
PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
PT and diagnosis of intercellular adhesion dysfunction.
XX
PS Example 5; Page 46; 75pp; English.
XX

```

```

XX CC Oligonucleotide #15 (see AAQ22643) was designed to hybridise to the 3'-
CC UTR of human ICAM-1 mRNA and was synthesised in the phosphorothioate
CC form. It exhibited the greatest antisense activity of 16 oligonucleotides
CC tested. Other phosphorothioate sequences were synthesised which hybridise
CC to 3'-UTR. Oligo #24 is one of these. See AAQ22650-1 and AAQ22653-4 for
CC the others
XX SQ Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900
DB 20 CAAGAGGAGGAGCAAGACT 1

RESULT 286
AAQ22643/c
ID AAQ22643 standard; DNA; 20 BP.
XX AC AAQ22643;
XX DT 08-JUL-1992 (first entry)
XX DE Antisense oligonucleotide #15 targetted to ICAM-1 3'-UTR (1952-1971).
XX KW Inter cellular adhesion molecule-1; inhibitor; phosphorothioate bond;
XX KW triple helix; 3' untranslated region; ss.
XX OS Synthetic.
XX PN WO9203139-A.
XX PD 05-MAR-1992.
XX PF 23-JUL-1991; 91WO-US005209.
XX PR 14-AUG-1990; 90US-00567286.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CF, Mirabelli CK, Mira;
XX DR WPI; 1992-096579/12.
XX PT New oligonucleotides hybridisable to cell adhesion modulators - for
XX PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
XX PT and diagnosis of intercellular adhesion dysfunction.
XX PS Example 5; Page 43; 75pp; English.
XX CC This antisense oligonucleotide was designed to hybridise to the 3'-UTR of
XX CC human ICAM-1 mRNA. It was synthesised in the phosphorothioate form as
XX CC none of the phosphodiester form-antisense oligonucleotides which were
XX CC initially tested demonstrated inhibitory activity. Oligonucleotide #15
XX CC was found to be the most active of 16 potentially inhibitory anti-sense
XX CC sequences. Its anti-sense activity was not shared by other
XX CC oligonucleotides which hybridise to 3'-untranslated sequences. See e.g.
XX CC AAQ22644
XX SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGAGAGTGGTGGGG 1957
DB 20 GAGAGGGAGAGTGGTGGGG 1

```

```

RESULT 287
AAQ22650/c
ID AAQ22650 standard; DNA; 20 BP.
XX AC AAQ22650;
XX DT 08-JUL-1992 (first entry)
XX DE Antisense oligonucleotide #22 targetted to ICAM-1 3'-UTR (2114-2133).
XX KW Inter cellular adhesion molecule-1; inhibitor; phosphorothioate bond;
XX KW triple helix; 3' untranslated region; ss.
XX OS Synthetic.
XX PN WO9203139-A.
XX PD 05-MAR-1992.
XX PF 23-JUL-1991; 91WO-US005209.
XX PR 14-AUG-1990; 90US-00567286.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CF, Mirabelli CK, Mira;
XX DR WPI; 1992-096579/12.
XX PT New oligonucleotides hybridisable to cell adhesion modulators - for
XX PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
XX PT and diagnosis of intercellular adhesion dysfunction.
XX PS Example 5; Page 45; 75pp; English.
XX CC Oligonucleotide #15 (see AAQ22643) was designed to hybridise to the 3'-
XX CC UTR of human ICAM-1 mRNA and was synthesised in the phosphorothioate
XX CC form. It exhibited the greatest antisense activity of 16 oligonucleotides
XX CC tested. Other phosphorothioate sequences were synthesised which hybridise
XX CC to 3'-UTR. Oligo #22 hybridises to the ICAM-1 mRNA at a position 143
XX CC bases 3' to the #15 target and was the most active of the series
XX CC (AAQ22650-4), having activity comparable to that of #15
XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 288
AAQ22641/c
ID AAQ22641 standard; DNA; 20 BP.
XX AC AAQ22641;
XX DT 08-JUL-1992 (first entry)
XX DE Antisense oligonucleotide #13 targetted to ICAM-1 stop codon.
XX KW Inter cellular adhesion molecule-1; inhibitor; phosphorothioate bond;
XX KW triple helix; termination codon; ss.
XX OS Synthetic.
XX PN WO9203139-A.
XX PD 05-MAR-1992.

```

```

XX
PF 23-JUL-1991; 91WO-US005209.
XX
PR 14-AUG-1990; 90US-00567286.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Mirabelli CK, Mira;
XX
DR WPI; 1992-096579/12.
XX
XX New oligonucleotides hybridisable to cell adhesion modulators - for
PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
PT and diagnosis of intercellular adhesion dysfunction.
XX
PS Example 5; Page 42; 75pp; English.
XX
XX This antisense oligonucleotide was designed to hybridise to the
CC termination codon of human ICAM-1 mRNA. It was synthesised in the
CC phosphorothioate form as none of the phosphodiester form-antisense
CC oligonucleotides which were initially tested demonstrated inhibitory
CC activity. Oligonucleotide #14 also hybridises to the termination codon
CC (see AAQ22642). Both oligonucleotides exhibited moderate inhibitory
CC activity on ICAM-1 expression
XX
SQ Sequence 20 BP; 2 A; 3 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCAGCGCTCCCTGA 1656
DB 20 CACAAGCCAGCGCTCCCTGA 1

RESULT 289
AAQ22635/c
ID AAQ22635 standard; DNA; 20 BP.
XX
AC AAQ22635;
XX
DT 08-JUL-1992 (first entry)
XX
DE Antisense oligonucleotide #7 targetted to ICAM-1 AUG codon (55-74).
XX
KW Intercellular adhesion molecule-1; inhibitor; phosphorothioate bond;
KW triple helix; ss.
XX
OS Synthetic.
XX
PN WO9203139-A.
XX
PD 05-MAR-1992.
XX
PF 23-JUL-1991; 91WO-US005209.
XX
PR 14-AUG-1990; 90US-00567286.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Mirabelli CK, Mira;
XX
DR WPI; 1992-096579/12.
XX
XX New oligonucleotides hybridisable to cell adhesion modulators - for
PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
PT and diagnosis of intercellular adhesion dysfunction.
XX
PS Example 5; Page 40; 75pp; English.
XX
XX This antisense oligonucleotide was designed to hybridise 5' to the AUG
CC codon of human ICAM-1 mRNA. It was synthesised in the phosphorothioate

```

```

CC form as none of the phosphodiester form-antisense oligonucleotides which
CC were initially tested demonstrated inhibitory activity. Oligonucleotides
CC #1 and 8 also hybridise in the AUG region (see AAQ22629 and AAQ22636,
CC respectively). All three oligos inhibit ICAM-1 expression, although #8 is
CC slightly less active than the other two
XX
SQ Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCACCTCAGCCTCGCTATG 60
DB 20 GCACCTCAGCCTCGCTATG 1

RESULT 290
AAQ22640/c
ID AAQ22640 standard; DNA; 20 BP.
XX
AC AAQ22640;
XX
DT 08-JUL-1992 (first entry)
XX
DE Antisense oligonucleotide #12 targetted to ICAM-1 CDS (1459-1468).
XX
KW Intercellular adhesion molecule-1; inhibitor; phosphorothioate bond;
KW triple helix; coding region; ss.
XX
OS Synthetic.
XX
PN WO9203139-A.
XX
PD 05-MAR-1992.
XX
PF 23-JUL-1991; 91WO-US005209.
XX
PR 14-AUG-1990; 90US-00567286.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Mirabelli CK, Mira;
XX
DR WPI; 1992-096579/12.
XX
XX New oligonucleotides hybridisable to cell adhesion modulators - for
PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
PT and diagnosis of intercellular adhesion dysfunction.
XX
PS Example 5; Page 42; 75pp; English.
XX
XX This antisense oligonucleotide was designed to hybridise to the coding
CC region of human ICAM-1 mRNA. It was synthesised in the phosphorothioate
CC form as none of the phosphodiester form-antisense oligonucleotides which
CC were initially tested demonstrated inhibitory activity. Oligonucleotides
CC #5,9,10 and 11 also hybridise to the coding region (see AAQ22633 and
CC AAQ22637-Q22639, respectively). In common with oligonucleotide #12, they
CC all showed weak inhibitory activity on ICAM-1 expression
XX
SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGAGGTCAACCCGCGAG 1464
DB 20 AAGGGAGGTCAACCCGCGAG 1

RESULT 291
AAQ22642/c

```

ID AAQ22642 standard; DNA; 20 BP.
 XX AC AAQ22642;
 XX DT 08-JUL-1992 (first entry)
 XX DE Antisense oligonucleotide #14 targetted to ICAM-1 stop codon.
 XX DE Inter cellular adhesion molecule-1; inhibitor; phosphorothioate bond;
 KW triple helix; termination codon; ss.
 XX OS Synthetic.
 XX PN WO9203139-A.
 XX PD 05-MAR-1992.
 XX PF 23-JUL-1991; 91WO-US005209.
 XX PR 14-AUG-1990; 90US-00567286.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Bennett CF, Mirabelli CK, Mira;
 XX DT WPI; 1992-096579/12.
 XX PT New oligonucleotides hybridisable to cell adhesion modulators - for
 PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
 PT and diagnosis of intercellular adhesion dysfunction.
 XX PS Example 5; Page 42; 75pp; English.
 XX CC This antisense oligonucleotide was designed to hybridise to the
 CC termination codon of human ICAM-1 mRNA. It was synthesised in the
 CC phosphorothioate form as none of the phosphodiester form-antisense
 CC oligonucleotides which were initially tested demonstrated inhibitory
 CC activity. Oligonucleotide #13 also hybridises to the termination codon
 CC (see AAQ22641). Both oligonucleotides exhibited moderate inhibitory
 CC activity on ICAM-1 expression
 XX SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1654 TGAACCTATCCCGGACAGG 1673
 DB 20 TGAACCTATCCCGGACAGG 1
 RESULT 292
 AAQ22638/c
 ID AAQ22638 standard; DNA; 20 BP.
 XX AC AAQ22638;
 XX DT 08-JUL-1992 (first entry)
 XX DE Antisense oligonucleotide #10 targetted to ICAM-1 CDS (351-370).
 XX DE Inter cellular adhesion molecule-1; inhibitor; phosphorothioate bond;
 KW triple helix; coding region; ss.
 XX OS Synthetic.
 XX PN WO9203139-A.
 XX PD 05-MAR-1992.
 XX PF 23-JUL-1991; 91WO-US005209.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Bennett CF, Mirabelli CK, Mira;
 XX DT WPI; 1992-096579/12.
 XX PT New oligonucleotides hybridisable to cell adhesion modulators - for
 PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
 PT and diagnosis of intercellular adhesion dysfunction.
 XX PS Example 5; Page 43; 75pp; English.
 XX CC This antisense oligonucleotide was designed to hybridise to the
 CC polyadenylation signal in the 3'-UTR of human ICAM-1 mRNA. It was
 CC synthesised in the phosphorothioate form as none of the phosphodiester
 CC form-antisense oligonucleotides which were initially tested demonstrated
 CC inhibitory activity. Oligonucleotide #16 failed to inhibit ICAM-1

PR 14-AUG-1990; 90US-00567286.
 XX (ISIS-) ISIS PHARM INC.
 XX PI Bennett CF, Mirabelli CK, Mira;
 XX DT WPI; 1992-096579/12.
 XX DE New oligonucleotides hybridisable to cell adhesion modulators - for
 XX treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
 XX PT and diagnosis of intercellular adhesion dysfunction.
 XX PS Example 5; Page 41; 75pp; English.
 XX CC This antisense oligonucleotide was designed to hybridise to the coding
 CC region of human ICAM-1 mRNA. It was synthesised in the phosphorothioate
 CC form as none of the phosphodiester form-antisense oligonucleotides which
 CC were initially tested demonstrated inhibitory activity. Oligonucleotides
 CC #5,9,11 and 12 also hybridise to the coding region (see AAQ22633,022637
 CC and AAQ22639-022640, respectively). In common with oligonucleotide #10,
 CC they all showed weak inhibitory activity
 XX SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 337 TCAAACTGCCCTGATGGCA 356
 DB 20 TCAAACTGCCCTGATGGCA 1
 RESULT 293
 AAQ22644/c
 ID AAQ22644 standard; DNA; 20 BP.
 XX AC AAQ22644;
 XX DT 08-JUL-1992 (first entry)
 XX DE Antisense oligonucleotide #16 targetted to ICAM-1 3'-UTR (2975-2994).
 XX DE Inter cellular adhesion molecule-1; inhibitor; phosphorothioate bond;
 KW triple helix; 3' untranslated region; ss.
 XX OS Synthetic.
 XX PN WO9203139-A.
 XX PD 05-MAR-1992.
 XX PF 23-JUL-1991; 91WO-US005209.
 XX PR 14-AUG-1990; 90US-00567286.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Bennett CF, Mirabelli CK, Mira;
 XX DT WPI; 1992-096579/12.
 XX PT New oligonucleotides hybridisable to cell adhesion modulators - for
 PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
 PT and diagnosis of intercellular adhesion dysfunction.
 XX PS Example 5; Page 43; 75pp; English.
 XX CC This antisense oligonucleotide was designed to hybridise to the
 CC polyadenylation signal in the 3'-UTR of human ICAM-1 mRNA. It was
 CC synthesised in the phosphorothioate form as none of the phosphodiester
 CC form-antisense oligonucleotides which were initially tested demonstrated
 CC inhibitory activity. Oligonucleotide #16 failed to inhibit ICAM-1

PI Bennett CF, Mirabelli CK, Mira;
XX WPI; 1992-096579/12.
XX
XX New oligonucleotides hybridisable to cell adhesion modulators - for
PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
PT and diagnosis of intercellular adhesion dysfunction.
XX
XX Example 5; Page 41; 75pp; English.
XX
XX This antisense oligonucleotide was designed to hybridise to the coding
CC region of human ICAM-1 mRNA. It was synthesised in the phosphorothioate
CC form as none of the phosphodiester form-antisense oligonucleotides which
CC were initially tested demonstrated inhibitory activity. Oligonucleotides
CC #5,10,11 and 12 also hybridise to the coding region (see AAQ22633 and
CC AAQ22638-Q22640, respectively). In common with oligonucleotide #9, they
CC all showed weak inhibitory activity
XX
XX Sequence 20 BP; 6 A; 7 C; 7 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 97 CTGGTCTGCTCGGGCTCT 116
Db 20 CTGGTCTGCTCGGGCTCT 1
RESULT 297
AAQ22654/c
ID AAQ22654 standard; DNA; 20 BP.
XX
AC AAQ22654;
XX
XX 08-JUL-1992 (first entry)
DT
XX
DE Antisense oligonucleotide #26 targetted to ICAM-1 3'-UTR (1976-1995).
XX
KW Intercellular adhesion molecule-1; inhibitor; phosphorothioate bond;
KW triple helix; 3' untranslated region; ss.
XX
OS Synthetic.
XX
XX WO9203139-A.
XX
XX 05-MAR-1992.
XX
XX 23-JUL-1991; 91WO-US005209.
XX
XX 14-AUG-1990; 90US-00567286.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Bennett CF, Mirabelli CK, Mira;
PI
XX WPI; 1992-096579/12.
XX
XX New oligonucleotides hybridisable to cell adhesion modulators - for
PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
PT and diagnosis of intercellular adhesion dysfunction.
XX
XX Example 5; Page 46; 75pp; English.
XX
XX Oligonucleotide #15 (see AAQ22643) was designed to hybridise to the 3'-
CC UTR of human ICAM-1 mRNA and was synthesised in the phosphorothioate
CC form. It exhibited the greatest antisense activity of 16 oligonucleotides
CC tested. Other phosphorothioate sequences were synthesised which hybridise
CC to 3'-UTR. Oligo #26 hybridises to the ICAM-1 mRNA at a position only 5
CC bases 3' to the #15 target and was the least active of the series
CC (AAQ22650-4)
XX
XX Sequence 20 BP; 2 A; 4 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1962 ATAGCCCCCACCATGAGGACA 1981
Db 20 ATAGCCCCCACCATGAGGACA 1
RESULT 298
AAQ22398/c
ID AAQ22398 standard; DNA; 20 BP.
XX
AC AAQ22398;
XX
XX 09-JUL-1992 (first entry)
DT
XX
XX DNA for modulating effects of cytomegalovirus infection.
XX
XX IE1; IE2; DNA polymerase; CMV; prophylactic; therapeutic;
KW antisense inhibition; gene expression; intron/exon boundary; ss.
XX
OS Cytomegalovirus.
XX
XX WO9203456-A.
XX
XX 05-MAR-1992.
XX
XX 14-AUG-1991; 91WO-U0005815.
XX
XX 16-AUG-1990; 90US-00568366.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Anderson KP, Draper KG;
PI
XX WPI; 1992-096819/12.
XX
XX Oligo-nucleotide(s) for modulating effects of cytomegalovirus infections
PT - which can be hybridised with portion of RNA or DNA derived from IE1,
PT IE2 or DNA genes of cytomegalovirus.
XX
XX Disclosure; Table 2; 44pp; English.
XX
XX The oligonucleotide was synthesised to be complementary to a random
CC region of human cytomegalovirus. This site is known to control mRNA
CC stability, processing and/or translational efficiency. The synthetic
CC oligomer can hybridise to the native DNA polymerase of cytomegalovirus
CC and modulate the activity of CMV. The oligomer can be used
CC prophylactically or therapeutically to reduce the severity of disease
CC caused by CMV. It specifically inhibits replication of CMV by antisense
CC inhibition of gene expression. See also AAQ22353-400
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCTCTGCTACTCAGA 37
Db 20 GAGCTCTCTGCTACTCAGA 1
RESULT 299
AAQ40559/c
ID AAQ40559 standard; DNA; 20 BP.
XX
AC AAQ40559;
XX
XX 25-MAR-2003 (revised)
DT
XX 12-AUG-1993 (first entry)

```

XX DE 2' functionalised oligomer 42.
XX
XX Linked; nucleoside; functionalised; 2'; steroid; reporter; protein;
KW non-aromatic; lipophilic; molecule; enzyme; peptide; metal chelator;
KW water soluble; vitamin; RNA cleaving complex; cholic acid; pyrene;
KW porphyrin; alkylator; hybrid; photo-nuclease; intercalator; agent;
KW aryl azide; photo-crosslinking; folic acid; heterocyclic base;
XX inter-strand; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 20
FT /tag= a
FT /notes="Functionalised at the 2' position with
FT phenanthroline via a thiol linker of the structure; 2'-O-
FT (CH2)3-NH-C(=O)-CH2-S-CH2-C(=O)-NH-"
XX
XX WO9307883-A1.
XX
XX 29-APR-1993.
XX
XX 23-OCT-1992; 92WO-US009196.
XX
XX 24-OCT-1991; 91US-00782374.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Manoharan M, Cook PD, Bennett CF;
XX WPI; 1993-152175/18.
XX
XX Linked nucleoside(s) in which at least one nucleoside is functionalised -
PT used as anti-sense diagnostic or therapeutic agents with enhanced
PT activity.
XX
XX Disclosure; Page 49; 73pp; English.
XX
XX The sequences given in AAQ40518-61 are oligonucleosides which comprise
CC linked nucleosides at least one of which is functionalised at its 2',
CC position by attachment of a molecule selected from a steroid molecule, a
CC reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme,
CC a peptide, a protein, a water soluble vitamin, an RNA cleaving complex, a
CC metal chelator, a porphyrin, an alkylator, a hybrid photo-
CC nuclease/intercalator and an aryl azide photo-crosslinking agent. The
CC oligonucleosides may also comprise a 2' functionalised nucleoside having
CC cholic acid, pyrene, or folic acid linked to the 2' position of the
CC nucleoside, a heterocyclic base functionalised nucleoside having cholic
CC acid or folic acid linked to the heterocyclic base of the nucleoside, a
CC 5' or 3' terminal nucleoside having cholic acid, pyrene or folic acid
CC linked to the 5' or 3' position of the nucleoside respectively, or an
CC inter-strand nucleoside having cholic acid, pyrene or folic acid linked
CC to an inter-nucleotide linkage linking the inter- strand nucleoside to an
CC adjacent nucleoside. (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 300
AAQ40557/C
ID AAQ40557 standard; DNA; 20 BP.
XX
XX AAQ40557;
XX

```

```

DT 25-MAR-2003 (revised)
DT 12-AUG-1993 (first entry)
XX
XX Cytidine based aminolinker functionalised oligomer 40.
XX
XX Linked; nucleoside; functionalised; 2'; steroid; reporter; protein;
KW non-aromatic; lipophilic; molecule; enzyme; peptide; metal chelator;
KW water soluble; vitamin; RNA cleaving complex; cholic acid; pyrene;
KW porphyrin; alkylator; hybrid; photo-nuclease; intercalator; agent;
KW aryl azide; photo-crosslinking; folic acid; heterocyclic base;
XX inter-strand; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 20
FT /tag= a
FT /notes="Functionalised to incorporate a propyl-N-
FT phthalimido functionality and a 2'-aminolinker"
XX
XX WO9307883-A1.
XX
XX 29-APR-1993.
XX
XX 23-OCT-1992; 92WO-US009196.
XX
XX 24-OCT-1991; 91US-00782374.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Manoharan M, Cook PD, Bennett CF;
XX WPI; 1993-152175/18.
XX
XX Linked nucleoside(s) in which at least one nucleoside is functionalised -
PT used as anti-sense diagnostic or therapeutic agents with enhanced
PT activity.
XX
XX Disclosure; Page 48; 73pp; English.
XX
XX The sequences given in AAQ40518-61 are oligonucleosides which comprise
CC linked nucleosides at least one of which is functionalised at its 2',
CC position by attachment of a molecule selected from a steroid molecule, a
CC reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme,
CC a peptide, a protein, a water soluble vitamin, an RNA cleaving complex, a
CC metal chelator, a porphyrin, an alkylator, a hybrid photo-
CC nuclease/intercalator and an aryl azide photo-crosslinking agent. The
CC oligonucleosides may also comprise a 2' functionalised nucleoside having
CC cholic acid, pyrene, or folic acid linked to the 2' position of the
CC nucleoside, a heterocyclic base functionalised nucleoside having cholic
CC acid or folic acid linked to the heterocyclic base of the nucleoside, a
CC 5' or 3' terminal nucleoside having cholic acid, pyrene or folic acid
CC linked to the 5' or 3' position of the nucleoside respectively, or an
CC inter-strand nucleoside having cholic acid, pyrene or folic acid linked
CC to an inter-nucleotide linkage linking the inter- strand nucleoside to an
CC adjacent nucleoside. (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 301
AAQ72765
ID AAQ72765 standard; mRNA; 20 BP.
XX
XX AAQ72765;
XX

```

XX	25-MAR-2003 (revised)	
DT	15-JUN-1995 (first entry)	
XX	ICAM-1 mRNA 5'end.	
XX	ICAM-1 mRNA; nascent mRNA capping inhibitor; steric interference;	
KW	chemical modification; disease treatment; gene expression; ss.	
XX	Synthetic.	
XX	W09422488-A1.	
PN	13-OCT-1994.	
PD	29-MAR-1994; 94WO-US003401.	
XX	01-APR-1993; 93US-00045268.	
XX	(ISIS-) ISIS PHARM INC.	
PA	Baker BF;	
XX	WPI; 1994-332834/41.	
DR	Oligo:nucleotide inhibiting capping of specific nascent mRNA - by steric	
XX	interference or chemical modification, are useful for treating diseases	
PT	and for regulating gene expression.	
PT	Example 2; Page 11; 29pp; English.	
XX	AAQ72765 describes the 5'end of ICAM-1 nascent mRNA, to which the	
CC	antisense oligonucleotides described in AAQ72766 and AAQ72767 are	
CC	complementary. These two complementary oligonucleotides are ICAM-1	
CC	nascent mRNA capping inhibitors, they work by preventing the binding of	
CC	the capping enzyme through steric interference, or chemical modification.	
CC	This inhibition interferes with ICAM-1's export from the nucleus, its	
CC	translation and its stability. The capping inhibitors can therefore be	
CC	used in the treatment of diseases and in the regulation of gene	
CC	expression in experimental systems. (Updated on 25-MAR-2003 to correct PN	
CC	field.)	
XX	Sequence 20 BP; 4 A; 7 C; 4 G; 0 T; 5 U; 0 Other;	
SQ	Query Match 0.7%; Score 20; DB 1; Length 20;	
	Best Local Similarity 75.0%; Pred. No. 5.4e+02;	
	Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0	
Qy	18 GAGCTCCTCTGCTACTCAGA 37	
	: : : : : :	
Db	1 GAGCUCUCUGCUACUCAGA 20	
	: : : : : :	
RESULT 302		
AAQ44518/c		
ID	AAQ44518 standard; DNA; 20 BP.	
XX	AC AAQ44518;	
XX	25-MAR-2003 (revised)	
DT	26-SEP-1994 (first entry)	
XX	Antisense oligonucleotide which targets human ICAM-1 AUG codon.	
DE	Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;	
XX	inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;	
KW	antisense oligonucleotide; therapy; ss.	
XX	Synthetic.	
OS	Key Key Location/Qualifiers	
XX	FT. misc_feature 1..20	
FT	/*tag= a	

PA (ISIS-) ISIS PHARM INC.
 XX Bennet CF, Mirabelli CK;
 XX WPI; 1994-100869/12.
 XX
 PT Oligo:nucleotide modulation of cell adhesion - used in the treatment of
 FT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
 XX
 PS Claim 15; Page 50; 101pp; English.
 XX
 CC Antisense oligonucleotides which target human ICAM-1 were synthesised in
 CC both the phosphodiester and phosphorothioate forms. The oligonucleotides
 CC are useful to treat diseases which are modulated by changes in
 CC intercellular adhesion molecules. This sequence corresponds to the region
 CC around the AUG codon (72-91) of the human ICAM-1 coding sequence.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 20 BP; 2 A; 5 C; 10 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 58 ATGGCTCCCGAGCAGCCCGG 77
 Db 20 ATGGCTCCCGAGCAGCCCGG 1
 RESULT 304
 AAQ44523/C
 ID AAQ44523 standard; DNA; 20 BP.
 XX
 AC AAQ44523;
 XX
 XX
 DT 25-MAR-2003 (revised)
 DT 26-SEP-1994 (first entry)
 XX
 XX Antisense oligonucleotide which targets human ICAM-1 3'-UTR.
 XX
 KW Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
 KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
 KW antisense oligonucleotide; therapy; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_feature 1..20
 FT /*tag= a
 FT /note= "in phosphorothioate form"
 FT
 XX
 PN W09405333-A1.
 XX
 PD 17-MAR-1994.
 XX
 PF 27-AUG-1993; 93WO-US008101.
 XX
 PR 02-SEP-1992; 92US-00939855.
 PR 21-JAN-1993; 93US-00007997.
 PR 17-MAY-1993; 93US-00063167.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Bennet CF, Mirabelli CK;
 XX WPI; 1994-100869/12.
 XX
 PT Oligo:nucleotide modulation of cell adhesion - used in the treatment of
 FT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
 XX
 PS Claim 15; Page 52; 101pp; English.
 XX
 CC Antisense oligonucleotides which target human ICAM-1 were synthesised in

CC both the phosphodiester and phosphorothioate forms. The oligonucleotides
 CC are useful to treat diseases which are modulated by changes in
 CC intercellular adhesion molecules. This sequence corresponds to
 CC nucleotides 2975-2994 of the 3'- untranslated region of the human ICAM-1
 CC coding sequence. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 2962 AGTTAATAAGCTTTCTCAA 2981
 Db 20 AGTTAATAAGCTTTCTCAA 1
 RESULT 305
 AAQ44520/C
 ID AAQ44520 standard; DNA; 20 BP.
 XX
 AC AAQ44520;
 XX
 XX
 DT 25-MAR-2003 (revised)
 DT 26-SEP-1994 (first entry)
 XX
 XX Antisense oligonucleotide which targets human ICAM-1 stop codon.
 XX
 KW Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
 KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
 KW antisense oligonucleotide; therapy; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_feature 1..20
 FT /*tag= a
 FT /note= "in phosphorothioate form"
 FT
 XX
 PN W09405333-A1.
 XX
 PD 17-MAR-1994.
 XX
 PF 27-AUG-1993; 93WO-US008101.
 XX
 PR 02-SEP-1992; 92US-00939855.
 PR 21-JAN-1993; 93US-00007997.
 PR 17-MAY-1993; 93US-00063167.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Bennet CF, Mirabelli CK;
 XX WPI; 1994-100869/12.
 XX
 PT Oligo:nucleotide modulation of cell adhesion - used in the treatment of
 FT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
 XX
 PS Claim 15; Page 51; 101pp; English.
 XX
 CC Antisense oligonucleotides which target human ICAM-1 were synthesised in
 CC both the phosphodiester and phosphorothioate forms. The oligonucleotides
 CC are useful to treat diseases which are modulated by changes in
 CC intercellular adhesion molecules. This sequence corresponds to the region
 CC around the termination codon (1651-1687, sic) of the human ICAM-1 coding
 CC sequence. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 20 BP; 2 A; 3 C; 10 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCAGCCTCCTCGA 1656
 |||||
 Db 20 CACAAGCCAGCCTCCTCGA 1

RESULT 306
 AAQ44582/c
 ID AAQ44582 standard; DNA; 20 BP.
 AC AAQ44582;
 XX
 XX
 DT 25-MAR-2003 (revised)
 FT 26-SEP-1994 (first entry)
 XX
 XX Antisense oligonucleotide which targets human ICAM-1 3'-UTR.
 XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
 KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
 KW antisense oligonucleotide; therapy; ss.
 XX
 XX Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_feature 1..20
 FT /*tag= a
 FT /note= "in phosphorothioate form"
 XX
 PN WO9405333-AL.
 XX
 PD 17-MAR-1994.
 XX
 XX 27-AUG-1993; 93WO-US008101.
 XX
 PR 02-SEP-1992; 92US-00939855.
 PR 21-JAN-1993; 93US-00007997.
 PR 17-MAY-1993; 93US-00063167.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Bennet CF, Mirabelli CK;
 XX WPI; 1994-100869/12.
 XX
 XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
 PT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
 XX
 XX Claim 15; Page 48; 101pp; English.
 XX
 CC Antisense oligonucleotides which target human ICAM-1 were synthesised in
 CC both the phosphodiester and phosphorothioate forms. Some of the
 CC oligonucleotides are useful to treat diseases which are modulated by
 CC changes in intercellular adhesion molecules. This sequence corresponds to
 CC nucleotides 2039-2058 of the 3'- untranslated region of the human ICAM-1
 CC coding sequence and is not one of the preferred antisense
 CC oligonucleotides. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 XX Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
 |||||
 Db 20 GAGGCCACAGACTTACAGA 1

RESULT 307
 AAQ44513/c
 ID AAQ44513 standard; DNA; 20 BP.
 AC AAQ44513;
 XX
 XX

DT 25-MAR-2003 (revised)
 DT 26-SEP-1994 (first entry)
 XX
 XX Antisense oligonucleotide which targets human ICAM-1 5'-UTR.
 XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
 KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
 KW antisense oligonucleotide; therapy; ss.
 XX
 XX Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_feature 1..20
 FT /*tag= a
 FT /note= "opt. in phosphorothioate form"
 XX
 PN WO9405333-AL.
 XX
 PD 17-MAR-1994.
 XX
 XX 27-AUG-1993; 93WO-US008101.
 XX
 PR 02-SEP-1992; 92US-00939855.
 PR 21-JAN-1993; 93US-00007997.
 PR 17-MAY-1993; 93US-00063167.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Bennet CF, Mirabelli CK;
 XX WPI; 1994-100869/12.
 XX
 XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
 PT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
 XX
 XX Claim 15; Page 48; 101pp; English.
 XX
 CC Antisense oligonucleotides which target human ICAM-1 were synthesised in
 CC both the phosphodiester and phosphorothioate forms. The oligonucleotides
 CC are useful to treat diseases which are modulated by changes in
 CC intercellular adhesion molecules. This sequence corresponds to
 CC nucleotides 32-49 of the 5'-untranslated region of the human ICAM-1
 CC coding sequence. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 XX Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
 |||||
 Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 308
 AAQ44521/c
 ID AAQ44521 standard; DNA; 20 BP.
 AC AAQ44521;
 XX
 XX 25-MAR-2003 (revised)
 DT 26-SEP-1994 (first entry)
 XX
 XX Antisense oligonucleotide which targets human ICAM-1 stop codon.
 XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
 KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
 KW antisense oligonucleotide; therapy; ss.
 XX
 XX Synthetic.
 XX
 FH Key Location/Qualifiers

FT misc_feature 1..20
FT /tag= a
FT /note= "in phosphorothioate form"

XX WO9405333-A1.

XX 17-MAR-1994.

XX 27-AUG-1993; 93WO-US008101.

XX 02-SEP-1992; 92US-00939855.

XX 21-JAN-1993; 93US-00007997.

XX 17-MAY-1993; 93US-00063167.

XX (ISIS-) ISIS PHARM INC.

XX Bennet CF, Mirabelli CK;

XX WPI; 1994-100869/12.

XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
PT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.

XX Claim 15; Page 51; 101pp; English.

XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
CC both the phosphodiester and phosphorothioate forms. The oligonucleotides
CC are useful to treat diseases which are modulated by changes in
CC intercellular adhesion molecules. This sequence corresponds to the region
CC around the termination codon (1668-1687) of the human ICAM-1 coding
CC sequence. (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673

DB 20 TGAACCTATCCCGGACAGG 1

RESULT 309

AAQ44583/c

ID AAQ44583 standard; DNA; 20 BP.

XX AAQ44583;

XX 25-MAR-2003 (revised)

XX 26-SEP-1994 (first entry)

XX Antisense oligonucleotide which targets human ICAM-1 3'-UTR.

XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
KW antisense oligonucleotide; therapy; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT misc_feature 1..20

FT /tag= a

FT /note= "in phosphorothioate form"

XX WO9405333-A1.

XX 17-MAR-1994.

XX 27-AUG-1993; 93WO-US008101.

XX 02-SEP-1992; 92US-00939855.

XX 21-JAN-1993; 93US-00007997.

PR 17-MAY-1993; 93US-00063167.

XX (ISIS-) ISIS PHARM INC.

XX Bennet CF, Mirabelli CK;

XX WPI; 1994-100869/12.

XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
PT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.

XX Example 5; Page 54; 101pp; English.

XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
CC both the phosphodiester and phosphorothioate forms. Some of the
CC oligonucleotides are useful to treat diseases which are modulated by
CC changes in intercellular adhesion molecules. This sequence corresponds to
CC nucleotides 1895-1914 of the 3'- untranslated region of the human ICAM-1
CC coding sequence and is not one of the preferred antisense
CC oligonucleotides. (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900

DB 20 CAAGAGGAGGAGCAAGACT 1

RESULT 310

AAQ44590/c

ID AAQ44590 standard; DNA; 20 BP.

XX AAQ44590;

XX 25-MAR-2003 (revised)

XX 26-SEP-1994 (first entry)

XX Antisense oligonucleotide which targets human ICAM-1 coding region.

XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
KW antisense oligonucleotide; therapy; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT misc_feature 1..20

FT /tag= a
FT /note= "in phosphorothioate form"

XX WO9405333-A1.

XX 17-MAR-1994.

XX 27-AUG-1993; 93WO-US008101.

XX 02-SEP-1992; 92US-00939855.

XX 21-JAN-1993; 93US-00007997.

XX 17-MAY-1993; 93US-00063167.

XX (ISIS-) ISIS PHARM INC.

XX Bennet CF, Mirabelli CK;

XX WPI; 1994-100869/12.

XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
PT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.

PS Example 5; Page 51; 101pp; English.

XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
CC both the phosphodiester and phosphorothioate forms. Some of the
CC oligonucleotides are useful to treat diseases which are modulated by
CC changes in intercellular adhesion molecules. This sequence corresponds to
CC nucleotides 1459-1468 of the coding region of the human ICAM-1 coding
CC sequence and is not one of the preferred antisense oligonucleotides.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX

SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGAGGTCACCCGCGAG 1464

DB 20 AAGGGAGGTCACCCGCGAG 1

RESULT 311

AAQ44585/c

ID AAQ44585 standard; DNA; 20 BP.

XX AAQ44585;

XX AC

XX 25-MAR-2003 (revised)

DT 26-SEP-1994 (first entry)

XX

XX Antisense oligonucleotide which targets human ICAM-1 3'-UTR.

XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
KW antisense oligonucleotide; therapy; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT misc_feature 1..20

FT /*tag= a

FT /note= "in phosphorothioate form"

XX WO9405333-A1.

XX 17-MAR-1994.

XX 27-AUG-1993; 93WO-US008101.

XX 02-SEP-1992; 92US-00939855.

XX 21-JAN-1993; 93US-00007997.

XX 17-MAY-1993; 93US-00063167.

XX (ISIS-) ISIS PHARM INC.

XX Bennet CF, Mirabelli CK;

XX WPI; 1994-100869/12.

XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of

XX e.g. psoriasis, inflammatory bowel disease or malignant melanoma.

XX Example 5; Page 54; 101pp; English.

XX Antisense oligonucleotides which target human ICAM-1 were synthesised in

CC both the phosphodiester and phosphorothioate forms. Some of the
CC oligonucleotides are useful to treat diseases which are modulated by
CC changes in intercellular adhesion molecules. This sequence corresponds to
CC nucleotides 1976-1995 of the 3'- untranslated region of the human ICAM-1
CC coding sequence and is not one of the preferred antisense
CC oligonucleotides. (Updated on 25-MAR-2003 to correct PN field.)
XX

SQ Sequence 20 BP; 2 A; 4 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCCACCATGAGGACA 1981

DB 20 ATAGCCCCCACCATGAGGACA 1

RESULT 312

AAQ44589/c

ID AAQ44589 standard; DNA; 20 BP.

XX AAQ44589;

XX AC

XX 25-MAR-2003 (revised)

DT 26-SEP-1994 (first entry)

XX

XX Antisense oligonucleotide which targets human ICAM-1 coding region.

XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
KW antisense oligonucleotide; therapy; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT misc_feature 1..20

FT /*tag= a

FT /note= "in phosphorothioate form"

XX WO9405333-A1.

XX 17-MAR-1994.

XX 27-AUG-1993; 93WO-US008101.

XX 02-SEP-1992; 92US-00939855.

XX 21-JAN-1993; 93US-00007997.

XX 17-MAY-1993; 93US-00063167.

XX (ISIS-) ISIS PHARM INC.

XX Bennet CF, Mirabelli CK;

XX WPI; 1994-100869/12.

XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
XX e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
XX Example 5; Page 50; 101pp; English.

XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
CC both the phosphodiester and phosphorothioate forms. Some of the
CC oligonucleotides are useful to treat diseases which are modulated by
CC changes in intercellular adhesion molecules. This sequence corresponds to
CC nucleotides 889-908 of the coding region of the human ICAM-1 coding
CC sequence and is not one of the preferred antisense oligonucleotides.
CC (Updated on 25-MAR-2003 to correct PN field.)
XX

SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGTGACC 894

DB 20 AGGCCTCAGTCAGTGTGACC 1

RESULT 313


```

AAQ44584/c
ID AAQ44584 standard; DNA; 20 BP.
XX
AC AAQ44584;
XX
DT 25-MAR-2003 (revised)
DT 26-SEP-1994 (first entry)
XX
XX Antisense oligonucleotide which targets human ICAM-1 3'-UTR.
XX
XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
KW antisense oligonucleotide; therapy; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_feature 1..20
FT /tag= a
FT /note= "in phosphorothioate form"
XX
XX WO9405333-A1.
XX
XX 17-MAR-1994.
XX
XX 27-AUG-1993; 93WO-US008101.
XX
XX 02-SEP-1992; 92US-00939855.
XX
XX 21-JAN-1993; 93US-00007997.
XX
XX 17-MAY-1993; 93US-00063167.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennet CF, Mirabelli CK;
XX
XX WPI; 1994-100869/12.
XX
XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
PT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
XX
XX Example 5; Page 54; 101pp; English.
XX
XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
CC both the phosphodiester and phosphorothioate forms. Some of the
CC oligonucleotides are useful to treat diseases which are modulated by
CC changes in intercellular adhesion molecules. This sequence corresponds to
CC nucleotides 1935-1954 of the 3'- untranslated region of the human ICAM-1
CC coding sequence and is not one of the preferred antisense
CC oligonucleotides. (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAGTCTAGCCTGATGAG 1940
| | | | | | | | | | | | | | | | | |
Db 20 TTAAGTCTAGCCTGATGAG 1

RESULT 314
AAQ44522/c
ID AAQ44522 standard; DNA; 20 BP.
XX
AC AAQ44522;
XX
XX 25-MAR-2003 (revised)
DT 26-SEP-1994 (first entry)
XX
XX Antisense oligonucleotide which targets human ICAM-1 3'-UTR.
XX
XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
KW antisense oligonucleotide; therapy; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_feature 1..20
FT /tag= a
FT /note= "in phosphorothioate form"
XX
XX WO9405333-A1.
XX

```

```

KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
KW antisense oligonucleotide; therapy; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_feature 1..20
FT /tag= a
FT /note= "in phosphorothioate form"
XX
XX WO9405333-A1.
XX
XX 17-MAR-1994.
XX
XX 27-AUG-1993; 93WO-US008101.
XX
XX 02-SEP-1992; 92US-00939855.
XX
XX 21-JAN-1993; 93US-00007997.
XX
XX 17-MAY-1993; 93US-00063167.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennet CF, Mirabelli CK;
XX
XX WPI; 1994-100869/12.
XX
XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
PT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
XX
XX Claim 15; Page 51; 101pp; English.
XX
XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
CC both the phosphodiester and phosphorothioate forms. The oligonucleotides
CC are useful to treat diseases which are modulated by changes in
CC intercellular adhesion molecules. This sequence corresponds to
CC nucleotides 1952-1971 of the 3'- untranslated region of the human ICAM-1
CC coding sequence. (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGGAAGTGTGTGGGG 1957
| | | | | | | | | | | | | | | | | |
Db 20 GAGAGGGGGAAGTGTGTGGGG 1

RESULT 315
AAQ44565/c
ID AAQ44565 standard; DNA; 20 BP.
XX
AC AAQ44565;
XX
XX 25-MAR-2003 (revised)
DT 26-SEP-1994 (first entry)
XX
XX Antisense oligonucleotide which targets human ICAM-1 5'-CAP site.
XX
XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
KW antisense oligonucleotide; therapy; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_feature 1..20
FT /tag= a
FT /note= "in phosphorothioate form"
XX
XX WO9405333-A1.
XX

```

```

PD 17-MAR-1994.
XX
XX 27-AUG-1993; 93WO-US008101.
XX
XX 02-SEP-1992; 92US-00939855.
XX 21-JAN-1993; 93US-00007997.
XX 17-MAY-1993; 93US-00063167.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennet CF, Mirabelli CK;
XX
XX WPI; 1994-100869/12.
XX
XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
XX e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
XX
XX Claim 50; Page 68; 101pp; English.
XX
XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
XX both the phosphodiester and phosphorothioate forms. Some of the
XX oligonucleotides are useful to treat diseases which are modulated by
XX changes in intercellular adhesion molecules. This sequence corresponds to
XX the coding region of the human ICAM-1 coding sequence. (Updated on 25-MAR-2003
XX to correct PN field.)
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCTCTGCTACTCAGA 37
DB 20 GAGCTCTCTGCTACTCAGA 1
RESULT 316
AAQ44588/c
ID AAQ44588 standard; DNA; 20 BP.
XX
XX AAQ44588;
XX
XX 25-MAR-2003 (revised)
XX 26-SEP-1994 (first entry)
XX
XX Antisense oligonucleotide which targets human ICAM-1 coding region.
XX
XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
XX inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
XX antisense oligonucleotide; therapy; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX misc_feature 1..20
XX /tag= a
XX /note= "in phosphorothioate form"
XX
XX WO9405333-A1.
XX
XX 17-MAR-1994.
XX
XX 27-AUG-1993; 93WO-US008101.
XX
XX 02-SEP-1992; 92US-00939855.
XX 21-JAN-1993; 93US-00007997.
XX 17-MAY-1993; 93US-00063167.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennet CF, Mirabelli CK;
XX
XX WPI; 1994-100869/12.
XX
XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
XX e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
XX
XX Claim 50; Page 68; 101pp; English.
XX
XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
XX both the phosphodiester and phosphorothioate forms. Some of the
XX oligonucleotides are useful to treat diseases which are modulated by
XX changes in intercellular adhesion molecules. This sequence corresponds to
XX the coding region of the human ICAM-1 coding sequence. (Updated on 25-MAR-2003
XX to correct PN field.)
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCTCTGCTACTCAGA 37
DB 20 GAGCTCTCTGCTACTCAGA 1
RESULT 317
AAQ44543/c
ID AAQ44543 standard; DNA; 20 BP.
XX
XX AAQ44543;
XX
XX 25-MAR-2003 (revised)
XX 26-SEP-1994 (first entry)
XX
XX Antisense oligonucleotide which targets human ICAM-1 3'-UTR.
XX
XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
XX inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
XX antisense oligonucleotide; therapy; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX misc_feature 1..20
XX /tag= a
XX /note= "in phosphorothioate form"
XX
XX WO9405333-A1.
XX
XX 17-MAR-1994.
XX
XX 27-AUG-1993; 93WO-US008101.
XX
XX 02-SEP-1992; 92US-00939855.
XX 21-JAN-1993; 93US-00007997.
XX 17-MAY-1993; 93US-00063167.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennet CF, Mirabelli CK;
XX
XX WPI; 1994-100869/12.
XX
XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
XX e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
XX
XX Claim 15; Page 68; 101pp; English.
XX
XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
XX both the phosphodiester and phosphorothioate forms. The oligonucleotides
XX are useful to treat diseases which are modulated by changes in
XX intercellular adhesion molecules. This sequence corresponds to

```

```

DR WPI; 1994-100869/12.
XX
XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
XX e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
XX
XX Example 5; Page 50; 101pp; English.
XX
XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
XX both the phosphodiester and phosphorothioate forms. Some of the
XX oligonucleotides are useful to treat diseases which are modulated by
XX changes in intercellular adhesion molecules. This sequence corresponds to
XX the coding region of the human ICAM-1 coding sequence and is not one of the preferred antisense oligonucleotides.
XX (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 337 TCAAACTGCCCTGATGGCA 356
DB 20 TCAAACTGCCCTGATGGCA 1
RESULT 317
AAQ44543/c
ID AAQ44543 standard; DNA; 20 BP.
XX
XX AAQ44543;
XX
XX 25-MAR-2003 (revised)
XX 26-SEP-1994 (first entry)
XX
XX Antisense oligonucleotide which targets human ICAM-1 3'-UTR.
XX
XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
XX inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
XX antisense oligonucleotide; therapy; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX misc_feature 1..20
XX /tag= a
XX /note= "in phosphorothioate form"
XX
XX WO9405333-A1.
XX
XX 17-MAR-1994.
XX
XX 27-AUG-1993; 93WO-US008101.
XX
XX 02-SEP-1992; 92US-00939855.
XX 21-JAN-1993; 93US-00007997.
XX 17-MAY-1993; 93US-00063167.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennet CF, Mirabelli CK;
XX
XX WPI; 1994-100869/12.
XX
XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
XX e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
XX
XX Claim 15; Page 68; 101pp; English.
XX
XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
XX both the phosphodiester and phosphorothioate forms. The oligonucleotides
XX are useful to treat diseases which are modulated by changes in
XX intercellular adhesion molecules. This sequence corresponds to

```

CC nucleotides 1959-1978 of the 3'- untranslated region of the human ICAM-1
CC coding sequence. (Updated on 25-MAR-2003 to correct PN field.)

```

SQ Sequence 20 BP; 3 A; 10 C; 1 G; 6 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy 1945 GAAGTGGTGGGGAGACATA 1964
 |||||
 Db 20 GAAGTGGTGGGGAGACATA 1

RESULT 318
AAQ44524/c
ID AAQ44524 standard; DNA; 20 BP.

AC	ARQ44524;
XX	
DT	25-MAR-2003 (revised)
DT	26-SEP-1994 (first entry)
XX	
DE	Antisense oligonucleotide which targets human ICAM-1 3'-UTR.

KW Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
KW antisense oligonucleotide; therapy; ss.

OS Synthetic.

FT	Key	Location/Qualifiers
FT	misc_feature	1..20
FT		/*tag= a
FT		/note= "in phosphorothioate form"

XX WO9405333-A1.
PN
XX
PD 17-MAR-1994.

XX	27-AUG-1993;	93WO-US008101.
PF		
XX		
PR	02-SEP-1992;	92US-00939855.
PR	21-JAN-1993;	93US-00007997.
PR	17-MAY-1993;	93US-00063167.

PA (ISIS-) ISIS PHARM INC.

PI Bennet CF. Mirabelli CK:

WPT: 1994-100869/12

XX
PT
PT
PT
PT
XX

Oligo:nucleotide modulation of cell adhesion - used in the treatment of e.g. psoriasis, inflammatory bowel disease or malignant melanoma.

PS Claim 15; Page 53; 101pp; English.

Antisense oligonucleotides which target human ICAM-1 were synthesised in both the phosphodiester and phosphorothioate forms. The oligonucleotides are useful to treat diseases which are modulated by changes in intercellular adhesion molecules. This sequence corresponds to nucleotides 2114-2133 of the 3'- untranslated region of the human ICAM-1 coding sequence. (Updated on 25-MAR-2003 to correct PN field.)

Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match	0.7%;	Score 20;	DB 1;	Length 20;
Best Local Similarity	100.0%;	Pred. No. 5.4e+02;		
Matches 20;	Conservative	0;	Mismatches 0;	Indels 0;
				Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 319
AAQ4587/C
ID AAQ44587 standard; DNA; 20 BP.
XX
XX
XX AC AAQ44587;
XX
XX 25-MAR-2003 (revised)
DT 26-SEP-1994 (first entry)
DT

Antisense oligonucleotide which targets human ICAM-1 coding region.

Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation; inflammation; psoriasis; malignant melanoma; inflammatory bowel disease; antisense oligonucleotide; therapy; ss.

XX OS Synthetic.

AA	key	Location/Qualifiers
FH	misc_feature	1..20
FT		/*tag= a
FT		/note= "in phosphorothioate form"
FT		

XX PN WO9405333-A1.

XX
17-MAR-1994

XX 27-AUG-1993: 93WO-US008101.

02-SEP-1992: 92US-00939855.

PR 21-JAN-1993; 93US-00007997;
PR 17-MAY-1993: 93US-00063167;

PA (ISIS-) ISIS PHARM INC.

PI Bennet CF. Mirabelli CK:

XX
DR WPI: 1994-100869/12.

PT Oligo:nucleotide modulation of cell adhesion - used in the treatment of
PT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.

PS Example 5: Page 50: 101pp: English:

Antisense oligonucleotides which target human ICAM-1 were synthesised in both the phosphodiester and phosphorothioate forms. Some of the oligonucleotides are useful to treat diseases which are modulated by changes in intercellular adhesion molecules. This sequence corresponds to nucleotides 111-130 of the coding region of the human ICAM-1 coding sequence and is not one of the preferred antisense oligonucleotides. (Updated on 25-MAR-2003 to correctPN field.)

Sequence 20 BP: 6 A: 7 C: 7 G: 0 T: 0 U: 0 Other: 0

Query Match	0.7%	Score 20;	DB 1;	Length 20;
Best Local Similarity	100.0%;	Pred. No. 5.4e+02;		
Matches 20. Conservative	0.	Mismatches 0.	Indels 0.	Gaps 0.

QY 97 CTGGTCCTGCTCGGGCTCT 116
|||||
pb 20 CTGGTCCTGCTCGGGCTCT 1

RESULT 320
AAQ45153/c
ID AAQ45153 standard; DNA; 20 BP.

XX	AAQ45153;	
AC		(revised)
XX		(first entry)
DT	25-MAR-2003	
DT	31-OCT-1994	

DE Oligonucleotide used in amine containing therapeutic.

KW Oligonucleotide; analogue; antisense; therapy; diagnosis; identification;
KW retention; therapeutic; amine; lipophile; ss.

XX Synthetic.

XX Key Location/Qualifiers
FH misc_feature 20
FT /tag= a
FT /note= "2'-aminopropoxy cytosine."

XX WO9406815-A1.

XX 31-MAR-1994.

XX 03-SEP-1993; 93WO-US008367.

XX 11-SEP-1992; 92US-00943516.

XX (ISIS-) ISIS PHARM INC.

XX Manoharan M, Cook PD;

XX WPI; 1994-118388/14.

XX Nucleotide and oligo-nucleotide (poly)amine analogues - used in anti-
PT sense therapy, diagnosis, and identification, amino gp. enhances cell
PT uptake and retention.

XX Example 4; Page 31; 93pp; English.

XX The sequence is used in the production of an amine analogue. The analogue
CC may be used in antisense therapy. The analogue may also have enhanced
CC cellular uptake, increased lipophilicity, cause greater cellular
CC retention and demonstrate increased distribution. (Updated on 25-MAR-2003
CC to correct PN field.)

XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCTCTGCTACTCAGA 37

DB 20 GAGCTCTCTGCTACTCAGA 1

RESULT 321

AAAT01762/c

ID AAAT01762 standard; DNA; 20 BP.

AC AAAT01762;

18-DEC-1995 (first entry)

Peptide nucleic acid oligomer targetting ICAM-1 3'-UTR.

peptide-nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.

XX Synthetic.

XX Key Location/Qualifiers

FH misc_feature 1. .20

FT /tag= a

FT /note= "at least one (and preferably all) of the backbone
FT subunits are composed of amide units, so that the
FT oligomer consists of the nucleobases attached covalently
FT to a polyamide backbone"

XX

PN WO9504749-A1.

XX 16-FEB-1995.

XX 05-AUG-1994; 94WO-US009026.

XX 05-AUG-1993; 93US-00102650.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK;

XX WPI; 1995-090842/12.

XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes
XX - are stable anti-sense cpds. of high affinity, partic. for treating
XX inflammation, viral infection, cancer etc.

XX Claim 2; Page 35; 57pp; English.

XX New oligomers are claimed which (A) have at least one peptide nucleic
XX acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
XX coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
XX or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated
XX region, exon/intron junction region or 3'-untranslated region of VCAM-1.
XX The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
XX produce antisense-type gene regulation moieties. Hence they may be used
XX therapeutically for modulating cellular adhesion and thus as
XX CC antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
XX AIDS agents and antiinflammatory agents. They may also be useful as
XX CC diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
XX CC affinity for complementary single stranded DNA. They are also able to
XX CC form triple helices in which a first PNA strand binds with RNA or ssDNA
XX CC and a second PNA strand binds with the resulting double helix or with the
XX CC first PNA strand. The PNAs possess no significant charge and are water
XX CC soluble, which facilitates cellular uptake. Further, since they contain
XX CC amides of non-biological amino acids, they are biostable and resistant to
XX CC enzymatic degradation by proteases. The present sequence targets human
XX CC intercellular adhesion molecule-1 (ICAM-1) 3' untranslated region

XX Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900

DB 20 CAAGAGGAGGAGCAAGACT 1

RESULT 322

AAAT01748/c

ID AAAT01748 standard; DNA; 20 BP.

XX AAAT01748;

18-DEC-1995 (first entry)

Peptide Nucleic acid oligomer targetting ICAM-1 coding region.

peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.

XX Synthetic.

XX Key Location/Qualifiers

FH misc_feature 1. .20

FT /tag= a

FT /note= "at least one (and preferably all) of the backbone
FT subunits are composed of amide units, so that the
FT oligomer consists of the nucleobases attached covalently
FT to a polyamide backbone"

XX

to a polyamide backbone"

FT XX WO9504749-A1.
 PN XX 16-FEB-1995.
 PD XX 05-AUG-1994; 94WO-US009026.
 PF XX 05-AUG-1993; 93US-00102650.
 PR XX (ISIS-) ISIS PHARM INC.
 PA Bennett CF, Mirabelli CK;
 PI WPI; 1995-090842/12.
 DR New peptide nucleic acid oligomers hybridising to adhesion molecule genes
 PT - are stable anti:sense cpds. of high affinity, partic. for treating
 PT inflammation, viral infection, cancer etc.
 PS Claim 2; Page 35; 57pp; English.
 XX
 CC New oligomers are claimed which (A) have at least one peptide nucleic
 CC acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
 CC coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
 CC or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated
 CC region, exon/intron junction region or 3'-untranslated region of VCAM-1.
 CC The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
 CC produce antisense-type gene regulation moieties. Hence they may be used
 CC therapeutically for modulating cellular adhesion and thus as
 CC antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
 CC AIDS agents and antiinflammatory agents. They may also be useful as
 CC diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
 CC affinity for complementary single stranded DNA. They are also able to
 CC form triple helices in which a first PNA strand binds with RNA or ssDNA
 CC and a second PNA strand binds with the resulting double helix or with the
 CC first PNA strand. The PNAs possess no significant charge and are water
 CC soluble, which facilitates cellular uptake. Further, since they contain
 CC amides of non-biological amino acids, they are biostable and resistant to
 CC enzymatic degradation by proteases. The present sequence targets human
 CC intercellular adhesion molecule-1 (ICAM-1) coding region
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e-02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 337 TCAAACTGCCCTGATGGCA 356
 DB 20 TCAAACTGCCCTGATGGCA 1
 RESULT 323
 AAT01760/C
 ID AAT01760 standard; DNA; 20 BP.
 AC AAT01760;
 XX
 XX 18-DEC-1995 (first entry)
 DE Peptide Nucleic acid oligomer targetting ICAM-1 3'-UTR.
 XX
 XX peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
 KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
 KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FT misc_feature 1..20
 FT /*tag= a
 FT /note= "at least one (and preferably all) of the backbone

FT XX WO9504749-A1.
 PN XX 16-FEB-1995.
 PD XX 05-AUG-1994; 94WO-US009026.
 PF XX 05-AUG-1993; 93US-00102650.
 PR XX (ISIS-) ISIS PHARM INC.
 PA Bennett CF, Mirabelli CK;
 PI WPI; 1995-090842/12.
 DR New peptide nucleic acid oligomers hybridising to adhesion molecule genes
 PT - are stable anti:sense cpds. of high affinity, partic. for treating
 PT inflammation, viral infection, cancer etc.
 PS Claim 2; Page 35; 57pp; English.
 XX
 CC New oligomers are claimed which (A) have at least one peptide nucleic
 CC acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
 CC coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
 CC or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated
 CC region, exon/intron junction region or 3'-untranslated region of VCAM-1.
 CC The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
 CC produce antisense-type gene regulation moieties. Hence they may be used
 CC therapeutically for modulating cellular adhesion and thus as
 CC antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
 CC AIDS agents and antiinflammatory agents. They may also be useful as
 CC diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
 CC affinity for complementary single stranded DNA. They are also able to
 CC form triple helices in which a first PNA strand binds with RNA or ssDNA
 CC and a second PNA strand binds with the resulting double helix or with the
 CC first PNA strand. The PNAs possess no significant charge and are water
 CC soluble, which facilitates cellular uptake. Further, since they contain
 CC amides of non-biological amino acids, they are biostable and resistant to
 CC enzymatic degradation by proteases. The present sequence targets human
 CC intercellular adhesion molecule-1 (ICAM-1) 3' untranslated region
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e-02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 DB 20 TGACGGATGCCAGCTTGGGC 1
 RESULT 324
 AAT01766/C
 ID AAT01766 standard; DNA; 20 BP.
 AC AAT01766;
 XX
 XX 18-DEC-1995 (first entry)
 DE Peptide nucleic acid oligomer targetting ICAM-1 5'-CAP.
 XX
 XX peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
 KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
 KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FT misc_feature 1..20

subunits are composed of amide units, so that the
 oligomer consists of the nucleobases attached covalently
 to a polyamide backbone"

```

FT FT      /*tag= a
FT FT /note= "at least one (and preferably all) of the backbone
FT FT subunits are composed of amide units, so that the
FT FT oligomer consists of the nucleobases attached covalently
FT FT to a polyamide backbone"
FT FT 20
FT FT misc_feature
FT FT /mod_base= cytosine-Lys
FT FT /tag= b
XX XX WO9504749-A1.
XX XX 16-FEB-1995.
XX XX 05-AUG-1994; 94WO-US009026.
XX XX 05-AUG-1993; 93US-00102650.
XX XX (ISIS-) ISIS PHARM INC.
XX XX Bennett CF, Mirabelli CK;
XX XX WPI; 1995-090842/12.
XX XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes
XX XX - are stable anti-sense cpds. of high affinity, partic. for treating
XX XX inflammation, viral infection, cancer etc.
XX XX Claim 2; Page 35; 57pp; English.
XX XX New oligomers are claimed which (A) have at least one peptide nucleic
XX XX acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
XX XX coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
XX XX or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated
XX XX region, exon/intron junction region or 3'-untranslated region of VCAM-1.
XX XX The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
XX XX produce antisense-type gene regulation moieties. Hence they may be used
XX XX therapeutically for modulating cellular adhesion and thus as
XX XX antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
XX XX AIDS agents and antiinflammatory agents. They may also be useful as
XX XX diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
XX XX affinity for complementary single stranded DNA. They are also able to
XX XX form triple helices in which a first PNA strand binds with RNA or ssDNA
XX XX and a second PNA strand binds with the resulting double helix or with the
XX XX first PNA strand. The PNAs possess no significant charge and are water
XX XX soluble, which facilitates cellular uptake. Further, since they contain
XX XX amides of non-biological amino acids, they are biostable and resistant to
XX XX enzymatic degradation by proteases. The present sequence targets human
XX XX intercellular adhesion molecule-1 (ICAM-1) 5' CAP region
XX XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
    |||||
DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 325
AAT01753/c
ID AAT01753 standard; DNA; 20 BP.
XX AAT01753;
XX AAT01753;
XX 18-DEC-1995 (first entry)
XX Peptide Nucleic acid oligomer targeting ICAM-1 3'-UTR.
XX peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.

```

```

XX XX Synthetic.
XX XX Key Location/Qualifiers
XX XX misc_feature 1..20
FT FT /tag= a
FT FT /note= "at least one (and preferably all) of the backbone
FT FT subunits are composed of amide units, so that the
FT FT oligomer consists of the nucleobases attached covalently
FT FT to a polyamide backbone"
XX XX WO9504749-A1.
XX XX 16-FEB-1995.
XX XX 05-AUG-1994; 94WO-US009026.
XX XX 05-AUG-1993; 93US-00102650.
XX XX (ISIS-) ISIS PHARM INC.
XX XX Bennett CF, Mirabelli CK;
XX XX WPI; 1995-090842/12.
XX XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes
XX XX - are stable anti-sense cpds. of high affinity, partic. for treating
XX XX inflammation, viral infection, cancer etc.
XX XX Claim 2; Page 35; 57pp; English.
XX XX New oligomers are claimed which (A) have at least one peptide nucleic
XX XX acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
XX XX coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
XX XX or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated
XX XX region, exon/intron junction region or 3'-untranslated region of VCAM-1.
XX XX The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
XX XX produce antisense-type gene regulation moieties. Hence they may be used
XX XX therapeutically for modulating cellular adhesion and thus as
XX XX antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
XX XX AIDS agents and antiinflammatory agents. They may also be useful as
XX XX diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
XX XX affinity for complementary single stranded DNA. They are also able to
XX XX form triple helices in which a first PNA strand binds with RNA or ssDNA
XX XX and a second PNA strand binds with the resulting double helix or with the
XX XX first PNA strand. The PNAs possess no significant charge and are water
XX XX soluble, which facilitates cellular uptake. Further, since they contain
XX XX amides of non-biological amino acids, they are biostable and resistant to
XX XX enzymatic degradation by proteases. The present sequence targets human
XX XX intercellular adhesion molecule-1 (ICAM-1) 3' untranslated region.
XX XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTCTGCGGG 1957
    |||||
DB 20 GAGAGGGGAAGTCTGCGGG 1

RESULT 326
AAT01749/c
ID AAT01749 standard; DNA; 20 BP.
XX AAT01749;
XX AAT01749;
XX 18-DEC-1995 (first entry)
XX Peptide Nucleic acid oligomer targeting ICAM-1 coding region.
XX peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
KW peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;

```

KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
 KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.

XX Synthetic.

XX Key Location/Qualifiers
 FH misc_feature 1..20
 FT /tag= a

FT /note= "at least one (and preferably all) of the backbone
 FT subunits are composed of amide units, so that the
 FT oligomer consists of the nucleobases attached covalently
 FT to a polyamide backbone"

XX WO9504749-A1.

XX 16-FEB-1995.

XX 05-AUG-1994; 94WO-US009026.

XX 05-AUG-1993; 93US-00102650.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK;

XX WPI; 1995-090842/12.

XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes
 PT - are stable anti:sense cpds. of high affinity, partic. for treating
 PT inflammation, viral infection, cancer etc.

XX Claim 2; Page 35; 57pp; English.

XX New oligomers are claimed which (A) have at least one peptide nucleic
 CC acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
 CC coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
 CC or ELAM-1, or hybridisable to AUG region, coding region, 5'-untranslated
 CC region, exon/intron junction region or 3'-untranslated region of VCAM-1.
 CC The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
 CC produce antisense-type gene regulation moieties. Hence they may be used
 CC therapeutically for modulating cellular adhesion and thus as
 CC antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
 CC AIDS agents and antiinflammatory agents. They may also be useful as
 CC diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
 CC affinity for complementary single stranded DNA. They are also able to
 CC form triple helices in which a first PNA strand binds with RNA or ssDNA
 CC and a second PNA strand binds with the resulting double helix or with the
 CC first PNA strand. The PNAs possess no significant charge and are water
 CC soluble, which facilitates cellular uptake. Further, since they contain
 CC amides of non-biological amino acids, they are biostable and resistant to
 CC enzymatic degradation by proteases. The present sequence targets human
 CC intercellular adhesion molecule-1 (ICAM-1) coding region

XX Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGTGACC 894

Db 20 AGGCCTCAGTCAGTGTGACC 1

RESULT 327

AAT01747/c

ID AAT01747 standard; DNA; 20 BP.

XX AAT01747;

XX 18-DEC-1995 (first entry)

DE Peptide Nucleic acid oligomer targeting ICAM-1 coding region.

XX peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
 KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
 KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.

XX Synthetic.

XX Key Location/Qualifiers
 FH misc_feature 1..20
 FT /tag= a

FT /note= "at least one (and preferably all) of the backbone
 FT subunits are composed of amide units, so that the
 FT oligomer consists of the nucleobases attached covalently
 FT to a polyamide backbone"

XX WO9504749-A1.

XX 16-FEB-1995.

XX 05-AUG-1994; 94WO-US009026.

XX 05-AUG-1993; 93US-00102650.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK;

XX WPI; 1995-090842/12.

XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes
 PT - are stable anti:sense cpds. of high affinity, partic. for treating
 PT inflammation, viral infection, cancer etc.

XX Claim 2; Page 35; 57pp; English.

XX New oligomers are claimed which (A) have at least one peptide nucleic
 CC acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
 CC coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
 CC or ELAM-1, or hybridisable to AUG region, coding region, 5'-untranslated
 CC region, exon/intron junction region or 3'-untranslated region of VCAM-1.
 CC The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
 CC produce antisense-type gene regulation moieties. Hence they may be used
 CC therapeutically for modulating cellular adhesion and thus as
 CC antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
 CC AIDS agents and antiinflammatory agents. They may also be useful as
 CC diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
 CC affinity for complementary single stranded DNA. They are also able to
 CC form triple helices in which a first PNA strand binds with RNA or ssDNA
 CC and a second PNA strand binds with the resulting double helix or with the
 CC first PNA strand. The PNAs possess no significant charge and are water
 CC soluble, which facilitates cellular uptake. Further, since they contain
 CC amides of non-biological amino acids, they are biostable and resistant to
 CC enzymatic degradation by proteases. The present sequence targets human
 CC intercellular adhesion molecule-1 (ICAM-1) coding region

XX Sequence 20 BP; 6 A; 7 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTCTCTCGGGGCTCT 116

Db 20 CTGGTCTCTCTCGGGGCTCT 1

RESULT 328

AAT01750/c

ID AAT01750 standard; DNA; 20 BP.

XX AAT01750;

XX 18-DEC-1995 (first entry)

```

XX DE Peptide Nucleic acid oligomer targetting ICAM-1 coding region.
XX DE
XX KW peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
XX KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
XX KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.
XX OS Synthetic.
XX OS
XX FH Key Location/Qualifiers
XX FT misc_feature 1..20
XX FT /tag= a
XX FT /note= "at least one (and preferably all) of the backbone
XX FT subunits are composed of amide units, so that the
XX FT oligomer consists of the nucleobases attached covalently
XX FT to a polyamide backbone"
XX PN WO9504749-A1.
XX XX
XX PD 16-FEB-1995.
XX XX
XX PF 05-AUG-1994; 94WO-US009026.
XX XX
XX PR 05-AUG-1993; 93US-00102650.
XX XX
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CF, Mirabelli CK;
XX PI WPI; 1995-090842/12.
XX DR
XX PT New peptide nucleic acid oligomers hybridising to adhesion molecule genes
XX PT - are stable anti:sense cpds. of high affinity, partic. for treating
XX PT inflammation, viral infection, cancer etc.
XX PS Claim 2; Page 35; 57pp; English.
XX XX
XX CC New oligomers are claimed which (A) have at least one peptide nucleic
XX CC acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
XX CC coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
XX CC or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated
XX CC region, exon/intron junction region or 3'-untranslated region of VCAM-1.
XX CC The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
XX CC produce antisense-type gene regulation moieties. Hence they may be used
XX CC therapeutically for modulating cellular adhesion and thus as
XX CC antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
XX CC AIDS agents and antiinflammatory agents. They may also be useful as
XX CC diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
XX CC affinity for complementary single stranded DNA. They are also able to
XX CC form triple helices in which a first PNA strand binds with RNA or ssDNA
XX CC and a second PNA strand binds with the resulting double helix or with the
XX CC first PNA strand. The PNAs possess no significant charge and are water
XX CC soluble, which facilitates cellular uptake. Further, since they contain
XX CC amides of non-biological amino acids, they are biostable and resistant to
XX CC enzymatic degradation by proteases. The present sequence targets human
XX CC intercellular adhesion molecule-1 (ICAM-1) coding region
XX SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGAGGTCACCCGGAG 1464
Db |||||||||||||||||||
20 AAGGGAGGTCACCCGGAG 1

RESULT 329
AAT01754/c
ID AAT01754 standard; DNA; 20 BP.
XX
AC AAT01754;

```

```

XX XX 18-DEC-1995 (first entry)
XX DE Peptide Nucleic acid oligomer targetting ICAM-1 3'-UTR.
XX DE
XX KW peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
XX KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
XX KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.
XX OS Synthetic.
XX OS
XX FH Key Location/Qualifiers
XX FT misc_feature 1..20
XX FT /tag= a
XX FT /note= "at least one (and preferably all) of the backbone
XX FT subunits are composed of amide units, so that the
XX FT oligomer consists of the nucleobases attached covalently
XX FT to a polyamide backbone"
XX PN WO9504749-A1.
XX XX
XX PD 16-FEB-1995.
XX XX
XX PF 05-AUG-1994; 94WO-US009026.
XX XX
XX PR 05-AUG-1993; 93US-00102650.
XX XX
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CF, Mirabelli CK;
XX PI WPI; 1995-090842/12.
XX DR
XX PT New peptide nucleic acid oligomers hybridising to adhesion molecule genes
XX PT - are stable anti:sense cpds. of high affinity, partic. for treating
XX PT inflammation, viral infection, cancer etc.
XX PS Claim 2; Page 35; 57pp; English.
XX XX
XX CC New oligomers are claimed which (A) have at least one peptide nucleic
XX CC acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
XX CC coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
XX CC or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated
XX CC region, exon/intron junction region or 3'-untranslated region of VCAM-1.
XX CC The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
XX CC produce antisense-type gene regulation moieties. Hence they may be used
XX CC therapeutically for modulating cellular adhesion and thus as
XX CC antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
XX CC AIDS agents and antiinflammatory agents. They may also be useful as
XX CC diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
XX CC affinity for complementary single stranded DNA. They are also able to
XX CC form triple helices in which a first PNA strand binds with RNA or ssDNA
XX CC and a second PNA strand binds with the resulting double helix or with the
XX CC first PNA strand. The PNAs possess no significant charge and are water
XX CC soluble, which facilitates cellular uptake. Further, since they contain
XX CC amides of non-biological amino acids, they are biostable and resistant to
XX CC enzymatic degradation by proteases. The present sequence targets human
XX CC intercellular adhesion molecule-1 (ICAM-1) 3' untranslated region
XX SQ Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAAGCTTCTCAA 2981
Db |||||||||||||||||||
20 AGTTAATAAAGCTTCTCAA 1

RESULT 330
AAT01763/c
ID AAT01763 standard; DNA; 20 BP.

```



```

XX AAT01763;
AC 18-DEC-1995 (first entry)
XX
XX
XX
XX Peptide nucleic acid oligomer targetting ICAM-1 3'-UTR.
DE
DE peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX misc_feature 1..20
XX /tag= a
XX /note= "at least one (and preferably all) of the backbone
XX subunits are composed of amide units, so that the
XX oligomer consists of the nucleobases attached covalently
XX to a polyamide backbone"
XX
XX WO9504749-A1.
XX
XX 16-FEB-1995.
XX
XX 05-AUG-1994; 94WO-US009026.
XX
XX 05-AUG-1993; 93US-00102650.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Mirabelli CK;
XX WPI; 1995-090842/12.
XX
XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes
XX - are stable anti-sense cpds. of high affinity, partic. for treating
XX inflammation, viral infection, cancer etc.
XX
XX Claim 2; Page 35; 57pp; English.
XX
XX New oligomers are claimed which (A) have at least one peptide nucleic
XX acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
XX coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
XX or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated
XX region, exon/intron junction region or 3'-untranslated region of VCAM-1.
XX The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
XX produce antisense-type gene regulation moieties. Hence they may be used
XX therapeutically for modulating cellular adhesion and thus as
XX antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
XX AIDS agents and antiinflammatory agents. They may also be useful as
XX diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
XX affinity for complementary single stranded DNA. They are also able to
XX form triple helices in which a first PNA strand binds with RNA or ssDNA
XX and a second PNA strand binds with the resulting double helix or with the
XX first PNA strand. The PNAs possess no significant charge and are water
XX soluble, which facilitates cellular uptake. Further, since they contain
XX amides of non-biological amino acids, they are biostable and resistant to
XX enzymatic degradation by proteases. The present sequence targets human
XX intercellular adhesion molecule-1 (ICAM-1) 3' untranslated region
XX
XX Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1921 TTAAAGTCTAGCCTGATGAG 1940
XX |||||
XX 20 TTAAAGTCTAGCCTGATGAG 1
XX
XX RESULT 331

```

```

AAT01746/c
ID AAT01746 standard; DNA; 20 BP.
XX
XX AAT01746;
XX
XX 18-DEC-1995 (first entry)
XX
XX Peptide Nucleic acid oligomer targetting ICAM-1 AUG.
DE
DE peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX misc_feature 1..20
XX /tag= a
XX /note= "at least one (and preferably all) of the backbone
XX subunits are composed of amide units, so that the
XX oligomer consists of the nucleobases attached covalently
XX to a polyamide backbone"
XX
XX WO9504749-A1.
XX
XX 16-FEB-1995.
XX
XX 05-AUG-1994; 94WO-US009026.
XX
XX 05-AUG-1993; 93US-00102650.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Mirabelli CK;
XX WPI; 1995-090842/12.
XX
XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes
XX - are stable anti-sense cpds. of high affinity, partic. for treating
XX inflammation, viral infection, cancer etc.
XX
XX Claim 2; Page 35; 57pp; English.
XX
XX New oligomers are claimed which (A) have at least one peptide nucleic
XX acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
XX coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
XX or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated
XX region, exon/intron junction region or 3'-untranslated region of VCAM-1.
XX The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
XX produce antisense-type gene regulation moieties. Hence they may be used
XX therapeutically for modulating cellular adhesion and thus as
XX antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
XX AIDS agents and antiinflammatory agents. They may also be useful as
XX diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
XX affinity for complementary single stranded DNA. They are also able to
XX form triple helices in which a first PNA strand binds with RNA or ssDNA
XX and a second PNA strand binds with the resulting double helix or with the
XX first PNA strand. The PNAs possess no significant charge and are water
XX soluble, which facilitates cellular uptake. Further, since they contain
XX amides of non-biological amino acids, they are biostable and resistant to
XX enzymatic degradation by proteases. The present sequence targets human
XX intercellular adhesion molecule-1 (ICAM-1) translation initiation codon
XX (AUG) region
XX
XX Sequence 20 BP; 2 A; 5 C; 10 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 58 ATGGGTCCGAGCAGCCCCG 77
XX |||||
XX 20 ATGGGTCCGAGCAGCCCCG 1
XX
XX RESULT 331

```


QY	7	CAGTCGACGCTGAGCTCCTC 26	Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Db	20	CAGTCGACGCTGAGCTCCTC 1	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
RESULT 334			
AAT01751/c			
ID	AAT01751	standard; DNA; 20 BP.	
XX			
AC	AAT01751;		
XX			
DT	18-DEC-1995	(first entry)	
XX			
DE	Peptide Nucleic acid oligomer targetting ICAM-1	termination region.	
XX			
KW	peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;		
KW	endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;		
KW	anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.		
XX			
OS	Synthetic.		
XX			
FH	Key	Location/Qualifiers	
FT	misc_feature	1..20	
FT		/tag= a	
FT		/note= "at least one (and preferably all) of the backbone	
FT		subunits are composed of amide units, so that the	
FT		oligomer consists of the nucleobases attached covalently	
FT		to a polyamide backbone"	
XX			
PN	WO9504749-A1.		
XX			
PD	16-FEB-1995.		
XX			
PF	05-AUG-1994;	94WO-US009026.	
XX			
PR	05-AUG-1993;	93US-00102650.	
XX			
PA	(ISIS-) ISIS PHARM INC.		
XX			
PI	Bennett CF, Mirabelli CK;		
XX			
DR	WPI; 1995-090842/12.		
XX			
PT	New peptide nucleic acid oligomers hybridising to adhesion molecule genes		
PT	- are stable anti-sense cpds. of high affinity, partic. for treating		
PT	inflammation, viral infection, cancer etc.		
XX			
PS	Claim 2; Page 35; 57pp; English.		
XX			
CC	New oligomers are claimed which (A) have at least one peptide nucleic		
CC	acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,		
CC	coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1		
CC	or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated		
CC	region, exon/intron junction region or 3'-untranslated region of VCAM-1.		
CC	The PNAs can be used to target RNA and single stranded DNA (ssDNA) to		
CC	produce antisense-type gene regulation moieties. Hence they may be used		
CC	therapeutically for modulating cellular adhesion and thus as		
CC	antimetastatic agents, anticancer agents, antirhinoviral agents, anti-		
CC	AIDS agents and antiinflammatory agents. They may also be useful as		
CC	diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high		
CC	affinity for complementary single stranded DNA. They are also able to		
CC	form triple helices in which a first PNA strand binds with RNA or ssDNA		
CC	and a second PNA strand binds with the resulting double helix or with the		
CC	first PNA strand. The PNAs possess no significant charge and are water		
CC	soluble, which facilitates cellular uptake. Further, since they contain		
CC	amides of non-biological amino acids, they are biostable and resistant to		
CC	enzymatic degradation by proteases. The present sequence targets human		
CC	intercellular adhesion molecule-1 (ICAM-1) translation termination region		
XX			
SQ	Sequence 20 BP; 2 A; 3 C; 10 G; 5 T; 0 U; 0 Other;		
Query Match	0.7%;	Score 20;	DB 1; Length 20;

SQ Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCCTGCTATG 60
|||||
Db 20 GCAACCTCAGCCCTGCTATG 1

RESULT 336

AAO1761/c
ID AAO1761 standard; DNA; 20 BP.

XX

AC AAO1761;

DT 18-DEC-1995 (first entry)

XX Peptide nucleic acid oligomer targeting ICAM-1 3'-UTR.

XX peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
XX endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
XX anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.

XX Synthetic.

Key Location/Qualifiers

FT misc_feature 1..20

FT /*tag= a

FT /note= "at least one (and preferably all) of the backbone
FT subunits are composed of amide units, so that the
FT oligomer consists of the nucleobases attached covalently
FT to a polyamide backbone"

XX WO9504749-A1.

PN 16-FEB-1995.

XX 05-AUG-1994; 94WO-US009026.

XX 05-AUG-1993; 93US-00102650.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK;

XX WPI; 1995-090842/12.

XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes
PT - are stable anti-sense cpds. of high affinity, partic. for treating
PT inflammation, viral infection, cancer etc.

PS Claim 2; Page 35; 57pp; English.

XX New oligomers are claimed which (A) have at least one peptide nucleic
CC acid (PNA) subunit and (B) have a sequence hybridisable to AUG region.
CC coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
CC or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated
CC region, exon/intron junction region or 3'-untranslated region of VCAM-1.
CC The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
CC produce antisense-type gene regulation moieties. Hence they may be used
CC therapeutically for modulating cellular adhesion and thus as
CC antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
CC AIDS agents and antiinflammatory agents. They may also be useful as
CC diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
CC affinity for complementary single stranded DNA. They are also able to
CC form triple helices in which a first PNA strand binds with RNA or ssDNA
CC and a second PNA strand binds with the resulting double helix or with the
CC first PNA strand. The PNAs possess no significant charge and are water
CC soluble, which facilitates cellular uptake. Further, since they contain
CC amides of non-biological amino acids, they are biostable and resistant to
CC enzymatic degradation by proteases. The present sequence targets human

CC intercellular adhesion molecule-1 (ICAM-1) 3' untranslated region

SQ Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
|||||
Db 20 GAGGCCACAGACTTACAGA 1

RESULT 337

AAO81115/c
ID AAO81115 standard; DNA; 20 BP.

XX

AC AAO81115;

XX 25-MAR-2003 (revised)

DT 28-SEP-1995 (first entry)

XX Peptide nucleic acid.

XX Peptide nucleic acid; gene therapy; transcription arrest; diagnosis;
XX prophylaxis; ss.

XX Synthetic.

Key Location/Qualifiers

FT modified_base 20

FT /*tag= a

FT /note= "covalently bound Lys-NH2 group"

XX WO9501370-A1.

XX 12-JAN-1995.

XX 28-JUN-1994; 94WO-US007319.

XX 02-JUL-1993; 93US-00088658.

XX (ISIS-) ISIS PHARM INC.

XX Buchardt O, Egholm M, Nielsen PE, Berg RH, Ecker DJ;

XX Mollegaard NE;

XX WPI; 1995-060949/08.

XX Use of oligonucleotide analogues, partic. peptide nucleic acids - for
PT binding to ssDNA, dsDNA or RNA for use in therapy, diagnosis and
PT prophylaxis.

PS Example 1; Page 28; 139pp; English.

XX AAO81115 is a peptide nucleic acid (PNA), which binds a target sequence.
CC The binding of the PNA prevents the transcription of the target sequence
CC by RNA polymerase. The ability of the PNA to arrest transcription makes
CC it useful in gene therapy, and in diagnostic and prophylactic methods.
CC (Updated on 25-MAR-2003 to correct PN field.)

SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 338

```

AAQ81119/c
ID  AAQ81119 standard; DNA; 20 BP.
XX
AC
AAQ81119;
XX
DT  25-MAR-2003 (revised)
DT  28-SEP-1995 (first entry)
XX
DE  Peptide nucleic acid.
XX
KW  Peptide nucleic acid; gene therapy; transcription arrest; diagnosis;
KW  prophylaxis; ss.
XX
OS  Synthetic.
XX
FH  Key
FT  modified_base      Location/Qualifiers
FT  20
FT  /*tag= a
FT  /*note= "amidated"
XX
PN  WO9501370-A1.
XX
XX
PD  12-JAN-1995.
XX
PF  28-JUN-1994;  94WO-US007319.
XX
PR  02-JUL-1993;  93US-00088658.
XX
PA  (ISIS-) ISIS PHARM INC.
XX
PI  Buchardt O, Egholm M, Nielsen PE, Berg RH, Ecker DJ;
PI  Mollegaard NE;
XX
XX  WPI; 1995-060949/08.
XX
PT  Use of oligonucleotide analogues, partic. peptide nucleic acids - for
PT  binding to ssDNA, dsDNA or RNA for use in therapy, diagnosis and
PT  prophylaxis.
XX
PS  Example 1; Page 28; 139pp; English.
XX
CC  AAQ81119 is a peptide nucleic acid (PNA), which binds a target sequence.
CC  The binding of the PNA prevents the transcription of the target sequence
CC  by RNA polymerase. The ability of the PNA to arrest transcription makes
CC  it useful in gene therapy, and in diagnostic and prophylactic methods.
XX  (Updated on 25-MAR-2003 to correct PN field.)
XX
SQ  Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  1938 GAGAGGGGAAGTGTGTGGGG 1957
Db  20 GAGAGGGGAAGTGTGTGGGG 1

RESULT 339
AAT11968/c
ID  AAT11968 standard; DNA; 20 BP.
XX
AC  AAT11968;
XX
XX
DT  25-MAR-2003 (revised)
DT  13-MAR-1996 (first entry)
XX
DE  Antisense oligonucleotide (ISIS 3224) complementary to human CMV.
XX
KW  antisense; cytomegalovirus; CMV; human; therapy; prophylaxis; diagnosis;
KW  intermediate early complex; IE1; IE2; DNA polymerase gene; ss.
XX
OS  Synthetic.

AAQ88741/c
ID  AAQ88741 standard; DNA; 20 BP.
XX
AC  AAQ88741;
XX
XX
DT  27-FEB-1996 (first entry)
XX
DE  Human ICAM modified antisense oligonucleotide.
XX
KW  antisense; analogue; non-terminal pyrimidine; phosphorothioate; backbone;
KW  treatment; HIV; human immunodeficiency virus; HSV; herpes simplex virus;
KW  cancer; integrin; cell adhesion receptor; infection; diagnosis;
KW  nuclease resistance; ss.
XX
OS  Homo sapiens.
XX
PN  EP653439-A2.
XX
PD  17-MAY-1995.
XX
PF  07-NOV-1994;  94EP-00117513.
XX
PR  12-NOV-1993;  93DE-04338704.
XX
PA  (FARH ) HOECHST AG.

XX  Key
XX  modified_base      Location/Qualifiers
XX  1..20
XX  /*tag= a
XX  /*note= "phosphorothioate backbone and modified by O-Me on
XX  the sugar moiety at the 2' position"
XX
PN  US5442049-A.
XX
XX
PD  15-AUG-1995.
XX
PF  25-JAN-1993;  93US-0009263.
XX
PR  19-NOV-1992;  92US-00927506.
XX
XX  (ISIS-) ISIS PHARM INC.
XX
XX  Baker B, Draper K, Anderson K;
XX  WPI; 1995-292538/38.
XX
XX  New oligo-nucleotide inhibits cytomegalovirus replication - by binding to
XX  a portion of cytomegalovirus RNA, for the diagnosis, prophylaxis and
XX  treatment of CMV diseases.
XX
XX  Example 5; Col 13-14; 66pp; English.
XX
XX  This is an antisense oligonucleotide (ON) tested for activity against
XX  cytomegalovirus (CMV). The ON targets a random sequence of the human CMV
XX  genome. Antisense ONs targeting CMV DNA or RNA coding for the IE1, IE2 or
XX  DNA polymerase proteins have been shown to be effective in therapy,
XX  prophylaxis and diagnosis of CMV infection. The ONs may be modified to
XX  reduce nuclease resistance and to increase their efficacy. Modifications
XX  include phosphorothioate backbones, alkyl and halogen-substituted sugar
XX  moieties at the 2' position. (Updated on 25-MAR-2003 to correct PF field.)
XX
XX  Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  18 GAGTCTCTCTGCTACTCAGA 37
Db  20 GAGTCTCTCTGCTACTCAGA 1

RESULT 340
AAQ88741/c
ID  AAQ88741 standard; DNA; 20 BP.
XX
AC  AAQ88741;
XX
XX
DT  27-FEB-1996 (first entry)
XX
DE  Human ICAM modified antisense oligonucleotide.
XX
KW  antisense; analogue; non-terminal pyrimidine; phosphorothioate; backbone;
KW  treatment; HIV; human immunodeficiency virus; HSV; herpes simplex virus;
KW  cancer; integrin; cell adhesion receptor; infection; diagnosis;
KW  nuclease resistance; ss.
XX
OS  Homo sapiens.
XX
PN  EP653439-A2.
XX
PD  17-MAY-1995.
XX
PF  07-NOV-1994;  94EP-00117513.
XX
PR  12-NOV-1993;  93DE-04338704.
XX
PA  (FARH ) HOECHST AG.

```

XX PI Peyman A, Uhlmann E, Mag M, Kretzschmar G, Helsing M, Winkler I;
 XX DR WPI; 1995-180677/24.
 XX DR
 XX PT New anti-sense oligo:nucleotide analogues - with modified non-terminal
 PT pyrimidine nucleotide units, useful for treating viral infections,
 PT cancer, etc.
 XX PT
 XX PS Claim 1; Page 31; 36pp; German.
 XX CC The antisense oligonucleotide (ON) shown is a derivative of an equivalent
 CC wild type Human ICAM ON, in which at least one, esp. 2-10, non-terminal
 CC pyrimidine nucleotide(s) is/are modified. The modification may be: (a)
 CC replacement of a phosphodiester linkage by: a phosphorothioate (PS), -
 CC dithioate, -aramidate, borano-, alkyl-, aralkyl-phosphate; 2,2,2-
 CC trichloro-1,1dimethyl-, alkyl- or aryl-, aralkyl-phosphate; 2,2,2-
 CC thioformacetal, methylhydroxylamine, oxime, methylenedimethylhydrazo,
 CC dimethylene sulphone or silyl linkage; (b) replacement of a sugar
 CC phosphate backbone by a 'morpholinonucleoside' oligomer; (c) replacement
 CC of beta-D-2-deoxyribose by another sugar or carbocyclic, open-chain or
 CC bicyclic sugar analogue; or (d) replacement of the natural nucleoside
 CC base by an analogue, e.g. 5-hydroxymethyl-uridine. The 5' and/or 3'
 CC terminus may also be modified with a lipophilic gp., eg. a farnesyl. The
 CC modifications increase nuclease resistance and thus improve stability and
 CC activity
 XX CC
 XX SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1938 GAGAGGGGAGTGTGGGG 1957
 Db 20 GAGAGGGGAGTGTGGGG 1
 RESULT 341
 AAQ88742/c
 ID AAQ88742 standard; DNA; 20 BP.
 XX AC AAQ88742;
 XX DT 27-FEB-1996 (first entry)
 XX DE Human ICAM modified antisense oligonucleotide.
 XX KW antisense; analogue; non-terminal pyrimidine; phosphorothioate; backbone;
 KW treatment; HIV; human immunodeficiency virus; HSV; herpes simplex virus;
 KW cancer; integrin; cell adhesion receptor; infection; diagnosis;
 KW nuclease resistance; ss.
 XX OS Homo sapiens.
 XX PN EP653439-A2.
 XX PD 17-MAY-1995.
 XX PF 07-NOV-1994; 94EP-00117513.
 XX PR 12-NOV-1993; 93DE-04338704.
 XX PA (FARH) HOECHST AG.
 XX PI Peyman A, Uhlmann E, Mag M, Kretzschmar G, Helsing M, Winkler I;
 XX DR WPI; 1995-180677/24.
 XX PT New anti-sense oligo:nucleotide analogues - with modified non-terminal
 PT pyrimidine nucleotide units, useful for treating viral infections,
 PT cancer, etc.
 XX PT

PS Claim 1; Page 32; 36pp; German.
 XX CC The antisense oligonucleotide (ON) shown is a derivative of an equivalent
 CC wild type Human ICAM ON, in which at least one, esp. 2-10, non-terminal
 CC pyrimidine nucleotide(s) is/are modified. The modification may be: (a)
 CC replacement of a phosphodiester linkage by: a phosphorothioate (PS), -
 CC dithioate, -aramidate, borano-, alkyl-, aralkyl-phosphate; 2,2,2-
 CC trichloro-1,1dimethyl-, alkyl- or aryl-, aralkyl-phosphate; 2,2,2-
 CC thioformacetal, methylhydroxylamine, oxime, methylenedimethylhydrazo,
 CC dimethylene sulphone or silyl linkage; (b) replacement of a sugar
 CC phosphate backbone by a 'morpholinonucleoside' oligomer; (c) replacement
 CC of beta-D-2-deoxyribose by another sugar or carbocyclic, open-chain or
 CC bicyclic sugar analogue; or (d) replacement of the natural nucleoside
 CC base by an analogue, e.g. 5-hydroxymethyl-uridine. The 5' and/or 3'
 CC terminus may also be modified with a lipophilic gp., eg. a farnesyl. The
 CC modifications increase nuclease resistance and thus improve stability and
 CC activity
 XX CC
 XX SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1940 GAGGGGAGTGTGGGGGAG 1959
 Db 20 GAGGGGAGTGTGGGGGAG 1
 RESULT 342
 AAT44449/c
 ID AAT44449 standard; DNA; 20 BP.
 XX AC AAT44449;
 XX DT 27-JAN-1997 (first entry)
 XX DE Antisense oligonucleotide against ICAM gene.
 XX KW 8-azapurine; modification; stronger complex; inhibition;
 KW intracellular adhesion molecule; ss.
 XX OS Synthetic.
 XX PN EP680969-A2.
 XX PD 08-NOV-1995.
 XX PF 26-APR-1995; 95EP-00106230.
 XX PR 02-MAY-1994; 94DE-04415370.
 XX PA (FARH) HOECHST AG.
 XX PI Seela F, Lampe S;
 XX DR WPI; 1995-375165/49.
 XX PT New oligo:nucleotide(s) contg. 8-aza-purine base - useful as therapeutic
 PT and diagnostic agents with more stable hybridisation to target nucleic
 PT acid.
 XX PS Disclosure; Page 44; 51pp; German.
 XX CC AAT44449-54 are antisense oligonucleotides which have at least one 8-
 CC azapurine base. The presence of an 8-azapurine base results in
 CC significantly stronger complexing when hybridising to target nucleic
 CC acids. The present sequence is against the intracellular adhesion
 CC molecule (ICAM) gene
 XX CC
 XX SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;

```
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 343
AAT44450/c
ID AAT44450 standard; DNA; 20 BP.
XX
AC AAT44450;
XX
DT 27-JAN-1997 (first entry)
XX
DE Antisense oligonucleotide against ICAM gene.
XX
KW 8-azapurine; modification; stronger complex; inhibition;
KW intracellular adhesion molecule; ss.
XX
OS Synthetic.
XX
PN EP680969-A2.
XX
PD 08-NOV-1995.
XX
PF 26-APR-1995; 9SEP-00106230.
XX
PR 02-MAY-1994; 94DE-04415370.
XX
PA (FARH ) HOECHST AG.
XX
PI Seela F, Lampe S;
XX
PI WPI; 1995-375165/49.
XX
PT New oligo:nucleotide(s) contg. 8-aza:purine base - useful as therapeutic
PT and diagnostic agents with more stable hybridisation to target nucleic
PT acid.
XX
PS Disclosure; Page 45; 51pp; German.
XX
CC AAT44425-54 are antisense oligonucleotides which have at least one 8-
CC azapurine base. The presence of an 8-azapurine base results in
CC significantly stronger complexing when hybridising to target nucleic
CC acids. The present sequence is against the intracellular adhesion
CC molecule (ICAM) gene
XX
SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGTGGGGG 1959
|||||
Db 20 GAGGGGAAGTGTGGGGG 1

RESULT 344
AAT44450/c
ID AAT44450 standard; DNA; 20 BP.
XX
AC AAT444250;
XX
DT 22-JUL-1997 (first entry)
XX
DE ICAM antisense component of capped oligonucleotide.
XX
KW Antisense therapy; guanosine; intercellular adhesion molecule; ICAM;
KW nuclease resistance; stability; ss.
XX

Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 345
AAT44251/c
ID AAT44251 standard; DNA; 20 BP.
XX
AC AAT44251;
XX
DT 22-JUL-1997 (first entry)
XX
DE ICAM antisense component of capped oligonucleotide.
XX
KW Antisense therapy; guanosine; intercellular adhesion molecule; ICAM;
KW nuclease resistance; stability; ss.
XX
OS Synthetic.
XX
PN DE19502912-A1.
XX
PD 01-AUG-1996.
XX
PF 31-JAN-1995; 95DE-01002912.
XX
PR 31-JAN-1995; 95DE-01002912.
XX
PA (FARH ) HOECHST AG.
XX
PI Peyman A, Uhlmann E;
XX
PI WPI; 1996-355223/36.
XX
PT Oligo:nucleotide(s) with series of G residues at at least one end have
PT increased stability against nuclease and cell penetration, - are partic.
PT increased stability against nuclease and cell penetration, - are partic.

OS Synthetic.
XX
PN DE19502912-A1.
XX
PD 01-AUG-1996.
XX
PF 31-JAN-1995; 95DE-01002912.
XX
PR 31-JAN-1995; 95DE-01002912.
XX
PA (FARH ) HOECHST AG.
XX
PI Peyman A, Uhlmann E;
XX
PI WPI; 1996-355223/36.
XX
PT Oligo:nucleotide(s) with series of G residues at at least one end have
PT increased stability against nuclease and cell penetration, - are partic.

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 346
AAT44251/c
ID AAT44251 standard; DNA; 20 BP.
XX
AC AAT44251;
XX
DT 22-JUL-1997 (first entry)
XX
DE ICAM antisense component of capped oligonucleotide.
XX
KW Antisense therapy; guanosine; intercellular adhesion molecule; ICAM;
KW nuclease resistance; stability; ss.
XX
OS Synthetic.
XX
PN DE19502912-A1.
XX
PD 01-AUG-1996.
XX
PF 31-JAN-1995; 95DE-01002912.
XX
PR 31-JAN-1995; 95DE-01002912.
XX
PA (FARH ) HOECHST AG.
XX
PI Peyman A, Uhlmann E;
XX
PI WPI; 1996-355223/36.
XX
PT Oligo:nucleotide(s) with series of G residues at at least one end have
PT increased stability against nuclease and cell penetration, - are partic.
```

PT anti-sense sequences for treating and diagnosing cancer, viral diseases
 PT etc.

XX Claim 3; Page 13; 15pp; German.

XX Ten- to 40-mer oligonucleotides which have a cap of 1-10 (esp. 4) G
 CC residues on at least one end are provided; if caps are present at both
 CC ends, they can be of the same or different lengths. A cap sequence
 CC increases nuclease resistance of the oligonucleotide and also increases
 CC cell penetration. The present sequence is that of a preferred
 CC oligonucleotide, directed against an intercellular adhesion molecule
 CC sequence, which can be capped for use in anticancer therapy

XX SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGTGGGGGAG 1959

Db 20 GAGGGGAAGTGTGGGGGAG 1

RESULT 346

AAX33922/c
 ID AAX33922 standard; DNA; 20 BP.

XX AC AAX33922;

XX DT 30-JUN-1999 (first entry)

XX DE ICAM expression inhibitor.

XX KW Gene expression inhibitor; probe; nucleic acid detection; growth factor;
 KW viral infection; therapy; HSV-1; cancer; restenosis; integrin;
 KW cell-cell adhesion receptor; ICAM; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN AU9648028-A.

XX PD 26-SEP-1996.

XX PF 12-MAR-1996; 96AU-00048028.

XX PR 13-MAR-1995; 95DE-01008923.

XX PR 24-NOV-1995; 95DE-01043865.

XX PA (FARH) HOECHST AG.

XX PI Peyman A, Uhlmann E, Breipohl G, Wallmeier H;

XX DR WPI; 1996-455932/46.

XX New phosphono-mono:ester oligo:nucleotide analogues - inhibitors of gene
 PT expression for treating viral infections, cancer, restenosis, etc.

XX PS Disclosure; Page 42; 129pp; English.

XX This sequence represents an inhibitor of ICAM, and is an example of an
 CC oligonucleotide analogue of the invention. The oligonucleotide analogues
 CC of the invention are used as inhibitors of gene expression (antisense
 CC oligonucleotides, ribozymes, sense oligonucleotides and triplex-forming
 CC oligonucleotides), as probes for the detection of nucleic acids, and as
 CC auxiliaries in molecular biology. As gene expression inhibitors they may
 CC be used for treating viral infections (especially where the virus is HSV-
 CC 1, HSV-2, an influenza virus, VSV, hepatitis B or papilloma virus),
 CC cancer, restenosis, and medical conditions mediated by integrins or cell-cell
 CC adhesion receptors, and medical conditions induced by growth factors
 CC (especially TNF-alpha)

XX

SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGGGGAAGTGTGGGGG 1957

Db 20 GAGGGGAAGTGTGGGGG 1

RESULT 347

AAX33923/c
 ID AAX33923 standard; DNA; 20 BP.

XX AC AAX33923;

XX DT 30-JUN-1999 (first entry)

XX DE ICAM expression inhibitor.

XX KW Gene expression inhibitor; probe; nucleic acid detection; growth factor;
 KW viral infection; therapy; HSV-1; cancer; restenosis; integrin;
 KW cell-cell adhesion receptor; ICAM; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN AU9648028-A.

XX PD 26-SEP-1996.

XX PF 12-MAR-1996; 96AU-00048028.

XX PR 13-MAR-1995; 95DE-01008923.

XX PR 24-NOV-1995; 95DE-01043865.

XX PA (FARH) HOECHST AG.

XX PI Peyman A, Uhlmann E, Breipohl G, Wallmeier H;

XX DR WPI; 1996-455932/46.

XX New phosphono-mono:ester oligo:nucleotide analogues - inhibitors of gene
 PT expression for treating viral infections, cancer, restenosis, etc.

XX PS Disclosure; Page 42; 129pp; English.

XX This sequence represents an inhibitor of ICAM, and is an example of an
 CC oligonucleotide analogue of the invention. The oligonucleotide analogues
 CC of the invention are used as inhibitors of gene expression (antisense
 CC oligonucleotides, ribozymes, sense oligonucleotides and triplex-forming
 CC oligonucleotides), as probes for the detection of nucleic acids, and as
 CC auxiliaries in molecular biology. As gene expression inhibitors they may
 CC be used for treating viral infections (especially where the virus is HSV-
 CC 1, HSV-2, an influenza virus, VSV, hepatitis B or papilloma virus),
 CC cancer, restenosis, and medical conditions mediated by integrins or cell-cell
 CC adhesion receptors, and medical conditions induced by growth factors
 CC (especially TNF-alpha)

XX SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGTGGGGGAG 1959

Db 20 GAGGGGAAGTGTGGGGGAG 1

RESULT 348

AAT30226/c


```

ID  AAT30226 standard; DNA; 20 BP.
XX  AAT30226;
AC  20-JAN-1997 (first entry)
XX  Antisense oligonucleotide ISIS 1938.
DE  Antisense oligonucleotide ISIS 1938.
XX  Antisense oligonucleotide; human; intracellular adhesion molecule-1;
XX  ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
KW  vascular cell adhesion molecule-1; VCAM-1; white blood cell; breguinar;
KW  vascular endothelium; allograft rejection; immunosuppression; rapamycin;
KW  anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
KW  renal allograft rejection; donor-specific transplant tolerance; LFA-1;
XX  ss.
XX  Synthetic.
XX  Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /note= "phosphorothioate backbone"
XX  WO9615780-A1.
XX  30-MAY-1996.
XX  22-NOV-1995; 95WO-US015536.
XX  23-NOV-1994; 94US-00344155.
XX  (ISIS-) ISIS PHARM INC.
PA (TEXA ) UNIV TEXAS SYSTEM.
XX  Bennett CF, Stepkowski SM;
XX  WPI; 1996-268321/27.
XX  Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
PT rejection.
XX  Example 5; Page 48; 92pp; English.
XX  AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
CC oligonucleotides of the invention. These sequences target regions of the
CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
CC targets the termination codon (nucleotides 1668-1687) of ICAM-1. ICAM-1,
CC ELAM-1, and VCAM-1 represent three of the five cell adhesion molecules
CC involved in the adherence of white blood cells to vascular endothelium.
CC These sequences can be used in a composition for treating allograft
CC rejection. The composition contains one of these sequences in combination
CC with an immunosuppressive agent. The immunosuppressive agent used in the
CC compositions is breguinar, rapamycin, anti-lymphocyte serum, a monoclonal
CC antibody against LFA-1 or an antisense oligonucleotide. The compositions
CC can be used for treating or preventing allograft rejection, such as
CC cardiac or renal allograft rejection. By using these compositions,
CC allograft survival times are extended, and donor-specific transplant
CC tolerance is induced
XX  Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1654 TGAACCTATCCCGGACAGG 1673
DB 20 TGAACCTATCCCGGACAGG 1

```

```

RESULT 349
AAT30227/c
ID  AAT30227 standard; DNA; 20 BP.
XX  AAT30227;
AC  20-JAN-1997 (first entry)
XX  Antisense oligonucleotide ISIS 1939.
DE  Antisense oligonucleotide ISIS 1939.
XX  Antisense oligonucleotide; human; intracellular adhesion molecule-1;
XX  ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
KW  vascular cell adhesion molecule-1; VCAM-1; white blood cell; breguinar;
KW  vascular endothelium; allograft rejection; immunosuppression; rapamycin;
KW  anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
KW  renal allograft rejection; donor-specific transplant tolerance; LFA-1;
XX  ss.
XX  Synthetic.
XX  Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /note= "phosphorothioate backbone"
XX  WO9615780-A1.
XX  30-MAY-1996.
XX  22-NOV-1995; 95WO-US015536.
XX  23-NOV-1994; 94US-00344155.
XX  (ISIS-) ISIS PHARM INC.
PA (TEXA ) UNIV TEXAS SYSTEM.
XX  Bennett CF, Stepkowski SM;
XX  WPI; 1996-268321/27.
XX  Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
PT rejection.
XX  Example 5; Page 49; 92pp; English.
XX  AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
CC oligonucleotides of the invention. These sequences target regions of the
CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
CC targets the 3' untranslated region (nucleotides 1952-1971) of ICAM-1.
CC ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
CC molecules involved in the adherence of white blood cells to vascular
CC endothelium. These sequences can be used in a composition for treating
CC allograft rejection. The composition contains one of these sequences in
CC combination with an immunosuppressive agent. The immunosuppressive agent
CC used in the compositions is breguinar, rapamycin, anti-lymphocyte serum,
CC a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The
CC compositions can be used for treating or preventing allograft rejection,
CC such as cardiac or renal allograft rejection. By using these
CC compositions, allograft survival times are extended, and donor-specific
CC transplant tolerance is induced
XX  Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAAGTGGTGGGG 1957
DB 20 GAGAGGGGAAGTGGTGGGG 1

```

RESULT 350
AAT30222/c
ID AAT30222 standard; DNA; 20 BP.
XX AC AAT30222;
XX DT 20-JAN-1997 (first entry)
XX DE Antisense oligonucleotide ISIS 1934.
XX KW Antisense oligonucleotide; human; intracellular adhesion molecule-1;
KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; breguinar;
KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
XX SS.
XX OS Synthetic.
XX PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /note= "phosphorothioate backbone"
XX PN WO9615780-A1.
XX PD 30-MAY-1996.
XX PF 22-NOV-1995; 95WO-US015536.
XX PR 23-NOV-1994; 94US-00344155.
XX XX (ISIS-) ISIS PHARM INC.
XX PA (TEXA) UNIV TEXAS SYSTEM.
XX PI Bennett CF, Stepkowski SM;
XX WPI; 1996-268321/27.
XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
PT rejection.
XX PS Example 5; Page 47; 92pp; English.
XX CC AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
CC oligonucleotides of the invention. These sequences target regions of the
CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
CC targets the a fragment of the coding region (nucleotides 351-370) of ICAM
CC -1. ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
CC molecules involved in the adherence of white blood cells to vascular
CC endothelium. These sequences can be used in a composition for treating
CC allograft rejection. The composition contains one of these sequences in
CC combination with an immunosuppressive agent. The immunosuppressive agent
CC used in the compositions is breguinar, rapamycin, anti-lymphocyte serum,
CC a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The
CC compositions can be used for treating or preventing allograft rejection,
CC such as cardiac or renal allograft rejection. By using these
CC compositions, allograft survival times are extended, and donor-specific
CC transplant tolerance is induced
XX SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 337 TCAAACTGCCCTGATGGCA 356

Db 20 TCAAACTGCCCTGATGGCA 1
RESULT 351
AAT30228/c
ID AAT30228 standard; DNA; 20 BP.
XX AC AAT30228;
XX DT 20-JAN-1997 (first entry)
XX DE Antisense oligonucleotide ISIS 1940.
XX KW Antisense oligonucleotide; human; intracellular adhesion molecule-1;
KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; breguinar;
KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
XX SS.
XX OS Synthetic.
XX PH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /note= "phosphorothioate backbone"
XX PN WO9615780-A1.
XX PD 30-MAY-1996.
XX PF 22-NOV-1995; 95WO-US015536.
XX PR 23-NOV-1994; 94US-00344155.
XX XX (ISIS-) ISIS PHARM INC.
XX PA (TEXA) UNIV TEXAS SYSTEM.
XX PI Bennett CF, Stepkowski SM;
XX WPI; 1996-268321/27.
XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
PT rejection.
XX PS Example 5; Page 49; 92pp; English.
XX CC AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
CC oligonucleotides of the invention. These sequences target regions of the
CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
CC targets the 3' untranslated region (nucleotides 2975-2994) of ICAM-1.
CC ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
CC molecules involved in the adherence of white blood cells to vascular
CC endothelium. These sequences can be used in a composition for treating
CC allograft rejection. The composition contains one of these sequences in
CC combination with an immunosuppressive agent. The immunosuppressive agent
CC used in the compositions is breguinar, rapamycin, anti-lymphocyte serum,
CC a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The
CC compositions can be used for treating or preventing allograft rejection,
CC such as cardiac or renal allograft rejection. By using these
CC compositions, allograft survival times are extended, and donor-specific
CC transplant tolerance is induced
XX SQ Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY      2962 AGTTAATAAAGCTTTCTCAA 2981
      |||||||
Db      20 AGTTAATAAAGCTTTCTCAA 1

RESULT 352
AAT30211/c
ID      AAT30211 standard; DNA; 20 BP.
AC      AAT30211;
XX
DT      20-JAN-1997 (first entry)
XX
DE      Antisense oligonucleotide ISIS 2302.
XX
KW      Antisense oligonucleotide; human; intracellular adhesion molecule-1;
KW      ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
KW      vascular cell adhesion molecule-1; VCAM-1; white blood cell; brequinar;
KW      vascular endothelium; allograft rejection; immunosuppression; rapamycin;
KW      anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
KW      renal allograft rejection; donor-specific transplant tolerance; LFA-1;
KW      ss.
XX
OS      Synthetic.
XX
FH      Key Location/Qualifiers
FT      modified_base 1..20
FT      /*tag= a
FT      /note= "phosphorothioate backbone"
XX
PN      WO9615780-A1.
XX
PD      30-MAY-1996.
XX
PF      22-NOV-1995; 95WO-US015536.
XX
PR      23-NOV-1994; 94US-00344155.
XX
PA      (ISIS-) ISIS PHARM INC.
PA      (TEXA ) UNIV TEXAS SYSTEM.
XX
PI      Bennett CF, Stepkowski SM;
XX
DR      WPI; 1996-268321/27.
XX
PT      Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
PT      ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
PT      rejection.
XX
PS      Claim 2; Page 51; 92pp; English.
XX
CC      AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
CC      oligonucleotides of the invention. These sequences target regions of the
CC      coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
CC      endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
CC      selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
CC      targets the 3' untranslated region (nucleotides 2039-2058) of ICAM-1.
CC      ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
CC      molecules involved in the adherence of white blood cells to vascular
CC      endothelium. These sequences can be used in a composition for treating
CC      allograft rejection. The composition contains one of these sequences in
CC      combination with an immunosuppressive agent. The immunosuppressive agent
CC      used in the compositions is brequinar, rapamycin, anti-lymphocyte serum,
CC      a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The
CC      compositions can be used for treating or preventing allograft rejection.
CC      such as cardiac or renal allograft rejection. By using these
CC      compositions, allograft survival times are extended, and donor-specific
CC      transplant tolerance is induced
XX
SQ      Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
      |||||||
Db      20 TGACGGATGCCAGCTTGGGC 1

RESULT 353
AAT30221/c
ID      AAT30221 standard; DNA; 20 BP.
AC      AAT30221;
XX
DT      20-JAN-1997 (first entry)
XX
DE      Antisense oligonucleotide ISIS 1933.
XX
KW      Antisense oligonucleotide; human; intracellular adhesion molecule-1;
KW      ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
KW      vascular cell adhesion molecule-1; VCAM-1; white blood cell; brequinar;
KW      vascular endothelium; allograft rejection; immunosuppression; rapamycin;
KW      anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
KW      renal allograft rejection; donor-specific transplant tolerance; LFA-1;
KW      ss.
XX
OS      Synthetic.
XX
FH      Key Location/Qualifiers
FT      modified_base 1..20
FT      /*tag= a
FT      /note= "phosphorothioate backbone"
XX
PN      WO9615780-A1.
XX
PD      30-MAY-1996.
XX
PF      22-NOV-1995; 95WO-US015536.
XX
PR      23-NOV-1994; 94US-00344155.
XX
PA      (ISIS-) ISIS PHARM INC.
PA      (TEXA ) UNIV TEXAS SYSTEM.
XX
PI      Bennett CF, Stepkowski SM;
XX
DR      WPI; 1996-268321/27.
XX
PT      Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
PT      ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
PT      rejection.
XX
PS      Example 5; Page 47; 92pp; English.
XX
CC      AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
CC      oligonucleotides of the invention. These sequences target regions of the
CC      coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
CC      endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
CC      selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
CC      targets the a fragment of the coding region (nucleotides 111-130) of ICAM
CC      -1. ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
CC      molecules involved in the adherence of white blood cells to vascular
CC      endothelium. These sequences can be used in a composition for treating
CC      allograft rejection. The composition contains one of these sequences in
CC      combination with an immunosuppressive agent. The immunosuppressive agent
CC      used in the compositions is brequinar, rapamycin, anti-lymphocyte serum,
CC      a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The
CC      compositions can be used for treating or preventing allograft rejection.
CC      such as cardiac or renal allograft rejection. By using these
CC      compositions, allograft survival times are extended, and donor-specific
CC      transplant tolerance is induced
XX
SQ      Sequence 20 BP; 6 A; 7 C; 7 G; 0 T; 0 U; 0 Other;

```

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTGCTCGGGGCTCT 116
 |||||
 DB 20 CTGGTCTGCTCGGGGCTCT 1

RESULT 354

AAT30225/C
 ID AAT30225 standard; DNA; 20 BP.

XX AC AAT30225;

XX DT 20-JAN-1997 (first entry)

XX DE Antisense oligonucleotide ISIS 1937.

XX KW Antisense oligonucleotide; human; intracellular adhesion molecule-1;
 KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
 KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; Breguinar;
 KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
 KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
 KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
 KW ss.

XX OS Synthetic.

XX FH Key Location/Qualifiers
 FT modified_base 1..20

FT /*tag= a
 FT /note= "phosphorothioate backbone"

XX PN WO9615780-A1.

XX XX 30-MAY-1996.

XX XX 22-NOV-1995; 95WO-US015536.

XX XX 23-NOV-1994; 94US-00344155.

XX XX (ISIS-) ISIS PHARM INC.

XX XX (TEXA) UNIV TEXAS SYSTEM.

XX PI Bennett CF, Stepkowski SM;

XX XX WPI; 1996-268321/27.

XX XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
 PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
 PT rejection.

XX XX Example 5; Page 48; 92pp; English.

XX CC AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
 CC oligonucleotides of the invention. These sequences target regions of the
 CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
 CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
 CC targets the termination codon (nucleotides 1651-1687) of ICAM-1. ICAM-1,
 CC ELAM-1, and VCAM-1 represent three of the five cell adhesion molecules
 CC involved in the adherence of white blood cells to vascular endothelium.
 CC These sequences can be used in a composition for treating allograft
 CC rejection. The composition contains one of these sequences in combination
 CC with an immunosuppressive agent. The immunosuppressive agent used in the
 CC compositions is Breguinar, rapamycin, anti-lymphocyte serum, a monoclonal
 CC antibody against LFA-1 or an antisense oligonucleotide. The compositions
 CC can be used for treating or preventing allograft rejection, such as
 CC cardiac or renal allograft rejection. By using these compositions,
 CC allograft survival times are extended, and donor-specific transplant
 CC tolerance is induced

XX SQ Sequence 20 BP; 2 A; 3 C; 10 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCAGCCTCCCTGA 1656
 |||||
 DB 20 CACAAGCCAGCCTCCCTGA 1

RESULT 355

AAT36668/C

ID AAT36668 standard; DNA; 20 BP.

XX AC AAT36668;

XX DT 21-JAN-1997 (first entry)

XX DE Antisense oligonucleotide ISIS 2304.

XX KW Antisense oligonucleotide; human; intracellular adhesion molecule-1;
 KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
 KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; Breguinar;
 KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
 KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
 KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
 KW ss.

XX OS Synthetic.

XX FH Key Location/Qualifiers
 FT modified_base 1..20

FT /*tag= a
 FT /note= "phosphorothioate backbone"

XX PN WO9615780-A1.

XX XX 30-MAY-1996.

XX XX 22-NOV-1995; 95WO-US015536.

XX XX 23-NOV-1994; 94US-00344155.

XX XX (ISIS-) ISIS PHARM INC.

XX XX (TEXA) UNIV TEXAS SYSTEM.

XX PI Bennett CF, Stepkowski SM;

XX XX WPI; 1996-268321/27.

XX XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
 PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
 PT rejection.

XX XX Example 5; Page 52; 92pp; English.

XX CC AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
 CC oligonucleotides of the invention. These sequences target regions of the
 CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
 CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
 CC targets the 3' untranslated region (nucleotides 1895-1914) of ICAM-1.
 CC ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
 CC molecules involved in the adherence of white blood cells to vascular
 CC endothelium. These sequences can be used in a composition for treating
 CC allograft rejection. The composition contains one of these sequences in
 CC combination with an immunosuppressive agent. The immunosuppressive agent
 CC used in the compositions is Breguinar, rapamycin, anti-lymphocyte serum,
 CC a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The
 CC compositions can be used for treating or preventing allograft rejection,
 CC such as cardiac or renal allograft rejection. By using these

CC compositions, allograft survival times are extended, and donor-specific
 CC transplant tolerance is induced

XX Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900
 |||||
 Db 20 CAAGAGGAGGAGCAAGACT 1

RESULT 356
 AAT36669/C
 ID AAT36669 standard; DNA; 20 BP.
 XX AC AAT36669;
 XX AC AAT36669;
 XX DT 21-JAN-1997 (first entry)
 XX DE Antisense oligonucleotide ISIS 2305.
 XX KW Antisense oligonucleotide; human; intracellular adhesion molecule-1;
 KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
 KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; breguarin;
 KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
 KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
 KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
 KW ss.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /note= "phosphorothioate backbone"

XX MO9615780-A1.
 XX 30-MAY-1996.
 XX 22-NOV-1995; 95WO-US015536.
 XX 23-NOV-1994; 94US-00344155.
 XX (ISIS-) ISIS PHARM INC.
 XX (TEXA) UNIV TEXAS SYSTEM.
 XX PI Bennett CF, Stepkowski SM;
 XX WPI; 1996-268321/27.
 XX DR
 XX PT Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
 PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
 PT rejection.
 XX PS Example 5; Page 52; 92pp; English.
 XX CC AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
 CC oligonucleotides of the invention. These sequences target regions of the
 CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
 CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
 CC targets the 3' untranslated region (nucleotides 1935-1954) of ICAM-1.
 CC ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
 CC molecules involved in the adherence of white blood cells to vascular
 CC endothelium. These sequences can be used in a composition for treating
 CC allograft rejection. The composition contains one of these sequences in
 CC combination with an immunosuppressive agent. The immunosuppressive agent
 CC used in the compositions is breguarin, rapamycin, anti-lymphocyte serum,
 CC a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The

CC compositions can be used for treating or preventing allograft rejection,
 CC such as cardiac or renal allograft rejection. By using these
 CC compositions, allograft survival times are extended, and donor-specific
 CC transplant tolerance is induced

XX Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAAGTCTAGCCTGATGAG 1940
 |||||
 Db 20 TTAAAGTCTAGCCTGATGAG 1

RESULT 357
 AAT36670/C
 ID AAT36670 standard; DNA; 20 BP.
 XX AC AAT36670;
 XX AC AAT36670;
 XX DT 21-JAN-1997 (first entry)
 XX DE Antisense oligonucleotide ISIS 2307.
 XX KW Antisense oligonucleotide; human; intracellular adhesion molecule-1;
 KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
 KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; breguarin;
 KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
 KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
 KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
 KW ss.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /note= "phosphorothioate backbone"

XX MO9615780-A1.
 XX 30-MAY-1996.
 XX 22-NOV-1995; 95WO-US015536.
 XX 23-NOV-1994; 94US-00344155.
 XX (ISIS-) ISIS PHARM INC.
 XX (TEXA) UNIV TEXAS SYSTEM.
 XX PI Bennett CF, Stepkowski SM;
 XX WPI; 1996-268321/27.
 XX DR
 XX PT Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
 PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
 PT rejection.
 XX PS Example 5; Page 52; 92pp; English.
 XX CC AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
 CC oligonucleotides of the invention. These sequences target regions of the
 CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
 CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
 CC targets the 3' untranslated region (nucleotides 1976-1995) of ICAM-1.
 CC ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
 CC molecules involved in the adherence of white blood cells to vascular
 CC endothelium. These sequences can be used in a composition for treating
 CC allograft rejection. The composition contains one of these sequences in
 CC combination with an immunosuppressive agent. The immunosuppressive agent

CC used in the compositions is brequinar, rapamycin, anti-lymphocyte serum,
 CC a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The
 CC compositions can be used for treating or preventing allograft rejection,
 CC such as cardiac or renal allograft rejection. By using these
 CC compositions, allograft survival times are extended, and donor-specific
 CC transplant tolerance is induced

XX Sequence 20 BP; 2 A; 4 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCCACCATGAGGACA 1981

Db 20 ATAGCCCCCACCATGAGGACA 1

RESULT 358

AAT36672/C

ID AAT36672 standard; DNA; 20 BP.

AC AAT36672;

DT 21-JAN-1997 (first entry)

XX Antisense oligonucleotide ISIS 3067.

DE Antisense oligonucleotide ISIS 3067.
 XX Antisense oligonucleotide; human; intracellular adhesion molecule-1;
 KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
 KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; brequinar;
 KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
 KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
 KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
 KW ss.

XX Synthetic.

OS Key Location/Qualifiers

FH modified_base 1..22
 FT /*tag= a
 FT /note= "phosphorothioate backbone"

XX WO9615780-A1.

XX 30-MAY-1996.

XX 22-NOV-1995; 95WO-US015536.

XX 23-NOV-1994; 94US-00344155.

XX (ISIS-) ISIS PHARM INC.

XX (TEXA) UNIV TEXAS SYSTEM.

XX Bennett CF, Stepkowski SM;

XX WPI; 1996-268321/27.

XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
 PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
 PT rejection.

XX Example 5; Page 71; 92pp; English.

XX AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
 CC oligonucleotides of the invention. These sequences target regions of the
 CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
 CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
 CC targets the 5' CAP region (nucleotides 32-51) of ICAM-1. ICAM-1, ELAM-1,
 CC and VCAM-1 represent three of the five cell adhesion molecules involved
 CC in the adherence of white blood cells to vascular endothelium. These
 CC sequences can be used in a composition for treating allograft rejection.

CC The composition contains one of these sequences in combination with an
 CC immunosuppressive agent. The immunosuppressive agent used in the
 CC compositions is brequinar, rapamycin, anti-lymphocyte serum, a monoclonal
 CC antibody against LFA-1 or an antisense oligonucleotide. The compositions
 CC can be used for treating or preventing allograft rejection, such as
 CC cardiac or renal allograft rejection. By using these compositions,
 CC allograft survival times are extended, and donor-specific transplant
 CC tolerance is induced

XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37

Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 359

AAT30215/C

ID AAT30215 standard; DNA; 20 BP.

XX AAT30215;

DT 20-JAN-1997 (first entry)

XX Antisense oligonucleotide ISIS 1559/1571.

DE Antisense oligonucleotide ISIS 1559/1571.
 XX Antisense oligonucleotide; human; intracellular adhesion molecule-1;
 KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
 KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; brequinar;
 KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
 KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
 KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
 KW ss.

XX Synthetic.

OS Key Location/Qualifiers

FH modified_base 1..20
 FT /*tag= a
 FT /note= "phosphorothioate or phosphodiester backbone"

XX WO9615780-A1.

XX 30-MAY-1996.

XX 22-NOV-1995; 95WO-US015536.

XX 23-NOV-1994; 94US-00344155.

XX (ISIS-) ISIS PHARM INC.

XX (TEXA) UNIV TEXAS SYSTEM.

XX Bennett CF, Stepkowski SM;

XX WPI; 1996-268321/27.

XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
 PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
 PT rejection.

XX Example 5; Page 45; 92pp; English.

XX AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
 CC oligonucleotides of the invention. These sequences target regions of the
 CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
 CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
 CC targets the 5' untranslated region (nucleotides 32-49) of ICAM-1. ICAM-1,
 CC ELAM-1, and VCAM-1 represent three of the five cell adhesion molecules

CC involved in the adherence of white blood cells to vascular endothelium.
 CC These sequences can be used in a composition for treating allograft
 CC rejection. The composition contains one of these sequences in combination
 CC with an immunosuppressive agent. The immunosuppressive agent used in the
 CC compositions is brequinar, rapamycin, anti-lymphocyte serum, a monoclonal
 CC antibody against LFA-1 or an antisense oligonucleotide. The compositions
 CC can be used for treating or preventing allograft rejection, such as
 CC cardiac or renal allograft rejection. By using these compositions,
 CC allograft survival times are extended, and donor-specific transplant
 CC tolerance is induced
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
 |||||
 Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 360
 AAT30224/c
 ID AAT30224 standard; DNA; 20 BP.
 XX
 AC AAT30224;
 XX
 DT 20-JAN-1997 (first entry)
 XX
 DE Antisense oligonucleotide ISIS 1936.

XX Antisense oligonucleotide; human; intracellular adhesion molecule-1;
 KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
 KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; brequinar;
 KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
 KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
 KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
 KW ss.

XX Synthetic.
 XX
 OS
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /note= "phosphorothioate backbone"

FT WO9615780-A1.
 XX
 PN 30-MAY-1996.
 XX
 PD 22-NOV-1995; 95WO-US015536.
 XX
 PF 23-NOV-1994; 94US-00344155.
 XX
 PR (ISIS-) ISIS PHARM INC.
 XX (TEXA) UNIV TEXAS SYSTEM.
 PA
 PA Bennett CF, Stepkowski SM;
 XX
 PI WPI; 1996-268321/27.
 XX
 DR
 XX

XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
 PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
 PT rejection.
 PT

XX Example 5; Page 48; 92pp; English.

XX AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
 CC oligonucleotides of the invention. These sequences target regions of the
 CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
 CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence

CC targets the a fragment of the coding region (nucleotides 1459-1468) of
 CC ICAM-1. ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell
 CC adhesion molecules involved in the adherence of white blood cells to
 CC vascular endothelium. These sequences can be used in a composition for
 CC treating allograft rejection. The composition contains one of these
 CC sequences in combination with an immunosuppressive agent. The
 CC immunosuppressive agent used in the compositions is brequinar, rapamycin,
 CC anti-lymphocyte serum, a monoclonal antibody against LFA-1 or an
 CC antisense oligonucleotide. The compositions can be used for treating or
 CC preventing allograft rejection, such as cardiac or renal allograft
 CC rejection. By using these compositions, allograft survival times are
 CC extended, and donor-specific transplant tolerance is induced
 XX
 SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGGAGGTCACCCGCGAG 1464
 |||||
 Db 20 AAGGGGAGGTCACCCGCGAG 1

RESULT 361
 AAT30219/c
 ID AAT30219 standard; DNA; 20 BP.
 XX
 AC AAT30219;
 XX
 DT 20-JAN-1997 (first entry)
 XX
 DE Antisense oligonucleotide ISIS 1931.

XX Antisense oligonucleotide; human; intracellular adhesion molecule-1;
 KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
 KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; brequinar;
 KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
 KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
 KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
 KW ss.

XX Synthetic.
 XX
 OS
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /note= "phosphorothioate backbone"

FT WO9615780-A1.
 XX
 PN 30-MAY-1996.
 XX
 PD 22-NOV-1995; 95WO-US015536.
 XX
 PF 23-NOV-1994; 94US-00344155.
 XX
 PR (ISIS-) ISIS PHARM INC.
 XX (TEXA) UNIV TEXAS SYSTEM.
 PA
 PA Bennett CF, Stepkowski SM;
 XX
 PI WPI; 1996-268321/27.
 XX

XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
 PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
 PT rejection.
 PT

XX Example 5; Page 46; 92pp; English.

XX AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
 CC oligonucleotides of the invention. These sequences target regions of the
 CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),

CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
 CC targets the AUG initiation codon (nucleotides 55-74) of ICAM-1. ICAM-1,
 CC ELAM-1, and VCAM-1 represent three of the five cell adhesion molecules
 CC involved in the adherence of white blood cells to vascular endothelium.
 CC These sequences can be used in a composition for treating allograft
 CC rejection. The composition contains one of these sequences in combination
 CC with an immunosuppressive agent. The immunosuppressive agent used in the
 CC compositions is brequinar, rapamycin, anti-lymphocyte serum, a monoclonal
 CC antibody against LFA-1 or an antisense oligonucleotide. The compositions
 CC can be used for treating or preventing allograft rejection, such as
 CC cardiac or renal allograft rejection. By using these compositions,
 CC allograft survival times are extended, and donor-specific transplant
 CC tolerance is induced
 CC
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCTCGCTATG 60
 |||||
 Db 20 GCAACCTCAGCCTCGCTATG 1

RESULT 362

AAT33100/c
 ID AAT33100 standard; DNA; 20 BP.

XX AAT33100;

DT 21-JAN-1997 (first entry)

DE Antisense oligonucleotide ISIS 3581.

XX Antisense oligonucleotide; human; intracellular adhesion molecule-1;
 KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
 KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; brequinar;
 KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
 KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
 KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
 ss.

XX Synthetic.

Key Location/Qualifiers
 modified_base 1..20
 /tag= a
 /note= "phosphorothioate backbone"

PN WO9615780-A1.

XX 30-MAY-1996.

PD 22-NOV-1995; 95WO-US015536.

PF 23-NOV-1994; 94US-00344155.

PR (ISIS-) ISIS PHARM INC.

PA (TEXA) UNIV TEXAS SYSTEM.

XX Bennett CF, Stepkowski SM;

PI WPI; 1996-268321/27.

XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
 PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
 PT rejection.

XX Example 5; Page 71; 92pp; English.

PS AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense

CC oligonucleotides of the invention. These sequences target regions of the
 CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
 CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
 CC targets the 3' untranslated region (nucleotides 1959-1978) of ICAM-1.
 CC ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
 CC molecules involved in the adherence of white blood cells to vascular
 CC endothelium. These sequences can be used in a composition for treating
 CC allograft rejection. The composition contains one of these sequences in
 CC combination with an immunosuppressive agent. The immunosuppressive agent
 CC used in the compositions is brequinar, rapamycin, anti-lymphocyte serum,
 CC a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The
 CC compositions can be used for treating or preventing allograft rejection.
 CC such as cardiac or renal allograft rejection. By using these
 CC compositions, allograft survival times are extended, and donor-specific
 CC transplant tolerance is induced
 CC
 XX

SQ Sequence 20 BP; 3 A; 10 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGGTGGGGAGACATA 1964
 |||||
 Db 20 GAAGTGGTGGGGAGACATA 1

RESULT 363

AAT30223/c

ID AAT30223 standard; DNA; 20 BP.

XX AAT30223;

DT 20-JAN-1997 (first entry)

DE Antisense oligonucleotide ISIS 1935.

XX Antisense oligonucleotide; human; intracellular adhesion molecule-1;
 KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
 KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; brequinar;
 KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
 KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
 KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
 ss.

XX Synthetic.

Key Location/Qualifiers
 modified_base 1..20
 /tag= a
 /note= "phosphorothioate backbone"

PN WO9615780-A1.

XX 30-MAY-1996.

PD 22-NOV-1995; 95WO-US015536.

PF 23-NOV-1994; 94US-00344155.

PR (ISIS-) ISIS PHARM INC.

PA (TEXA) UNIV TEXAS SYSTEM.

XX Bennett CF, Stepkowski SM;

PI WPI; 1996-268321/27.

XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
 PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
 PT rejection.

PS Example 5; Page 47; 92pp; English.


```

XX AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
CC oligonucleotides of the invention. These sequences target regions of the
CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
CC targets the a fragment of the coding region (nucleotides 889-908) of ICAM
CC -1. ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
CC molecules involved in the adherence of white blood cells to vascular
CC endothelium. These sequences can be used in a composition for treating
CC allograft rejection. The composition contains one of these sequences in
CC combination with an immunosuppressive agent. The immunosuppressive agent
CC used in the compositions is brequinar, rapamycin, anti-lymphocyte serum,
CC a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The
CC compositions can be used for treating or preventing allograft rejection,
CC such as cardiac or renal allograft rejection. By using these
CC compositions, allograft survival times are extended, and donor-specific
CC transplant tolerance is induced
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGACC 894
DB 20 AGGCCTCAGTCAGTGACC 1

RESULT 364
AAT30220/c
ID AAT30220 standard; DNA; 20 BP.
XX
AC AAT30220;
DT
DT 20-JAN-1997 (first entry)
XX
DE Antisense oligonucleotide ISIS 1932.
XX
KW Antisense oligonucleotide; human; intracellular adhesion molecule-1;
KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; brequinar;
KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
KW ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /note= "phosphorothioate backbone"
XX
XX WO9615780-A1.
XX
XX 30-MAY-1996.
XX
XX 22-NOV-1995; 95WO-US015536.
XX
XX 23-NOV-1994; 94US-00344155.
XX
XX (ISIS-) ISIS PHARM INC.
XX (TEXA ) UNIV TEXAS SYSTEM.
XX
XX Bennett CF, Stepkowski SM;
XX
XX WPI; 1996-268321/27.
XX
XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
PT rejection.

```

```

XX Example 5; Page 46; 92pp; English.
XX
XX AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
CC oligonucleotides of the invention. These sequences target regions of the
CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
CC targets the AUG initiation codon (nucleotides 72-91) of ICAM-1. ICAM-1,
CC ELAM-1, and VCAM-1 represent three of the five cell adhesion molecules
CC involved in the adherence of white blood cells to vascular endothelium.
CC These sequences can be used in a composition for treating allograft
CC rejection. The composition contains one of these sequences in combination
CC with an immunosuppressive agent. The immunosuppressive agent used in the
CC compositions is brequinar, rapamycin, anti-lymphocyte serum, a monoclonal
CC antibody against LFA-1 or an antisense oligonucleotide. The compositions
CC can be used for treating or preventing allograft rejection, such as
CC cardiac or renal allograft rejection. By using these compositions,
CC allograft survival times are extended, and donor-specific transplant
CC tolerance is induced
XX
SQ Sequence 20 BP; 2 A; 5 C; 10 G; 3 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCGAGCAGCCCCG 77
DB 20 ATGGCTCCGAGCAGCCCCG 1

RESULT 365
AAT36667/c
ID AAT36667 standard; DNA; 20 BP.
XX
AC AAT36667;
DT
DT 21-JAN-1997 (first entry)
XX
DE Antisense oligonucleotide ISIS 2303.
XX
KW Antisense oligonucleotide; human; intracellular adhesion molecule-1;
KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; brequinar;
KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
KW ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /note= "phosphorothioate backbone"
XX
XX WO9615780-A1.
XX
XX 30-MAY-1996.
XX
XX 22-NOV-1995; 95WO-US015536.
XX
XX 23-NOV-1994; 94US-00344155.
XX
XX (ISIS-) ISIS PHARM INC.
XX (TEXA ) UNIV TEXAS SYSTEM.
XX
XX Bennett CF, Stepkowski SM;
XX
XX WPI; 1996-268321/27.
XX
XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
PT rejection.

```

PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
 XX rejection.

PS Example 5; Page 51; 92pp; English.

XX
 CC AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
 CC oligonucleotides of the invention. These sequences target regions of the
 CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
 CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
 CC targets the 3' untranslated region (nucleotides 2039-2058) of ICAM-1.
 CC ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
 CC molecules involved in the adherence of white blood cells to vascular
 CC endothelium. These sequences can be used in a composition for treating
 CC allograft rejection. The composition contains one of these sequences in
 CC combination with an immunosuppressive agent. The immunosuppressive agent
 CC used in the compositions is brequinar, rapamycin, anti-lymphocyte serum,
 CC a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The
 CC compositions can be used for treating or preventing allograft rejection,
 CC such as cardiac or renal allograft rejection. By using these
 CC compositions, allograft survival times are extended, and donor-specific
 CC transplant tolerance is induced

XX SQ Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044

Db 20 GAGGCCACAGACTTACAGA 1

RESULT 366

AAX24204/c

ID AAX24204 standard; DNA; 20 BP.

AC AAX24204;

XX 01-JUL-1999 (first entry)

XX Phosphonomonoester oligonucleotide analogue 21.

XX Phosphonomonoester analogue; inhibitor; antisense; cancer; restenosis;
 KW ribozyme; diagnostic agent; detection; treatment; disease; virus;
 KW integrin; cell-cell adhesion receptor; TNF-alpha; ss.

XX Synthetic.

XX DE19508923-A1.

XX 19-SEP-1996.

XX 13-MAR-1995; 95DE-01008923.

XX 13-MAR-1995; 95DE-01008923.

XX (FARH) HOECHST AG.

XX Anuschirwan P, Uhlmann E, Breipohl G, Wallmeier H;

XX WPI; 1996-425893/43.

XX New oligo:nucleotide analogues contg. phospho:mono:ester bridges - for
 PT therapeutic inhibition of gene expression, e.g. in cancer or viral
 PT infection, with good specificity and in vivo stability.

XX Disclosure; Page 23; 36pp; German.

XX This invention describes novel phosphonomonoester oligonucleotide
 CC analogues which act as inhibitors of gene expression (as sense/antisense,
 CC ribozyme or triplex-forming molecules), useful as diagnostic agents (i.e.

CC probes for detecting nucleic acid) or for treatment of diseases caused by
 CC viruses, influenced by integrins or cell-cell adhesion receptors, induced
 CC by factors such as TNF-alpha, or cancer or restenosis. The products of
 CC the invention satisfy the requirements of good in-vivo stability; ability
 CC to cross cellular and nuclear membranes, and specific binding to target
 CC nucleic acid better than known oligonucleotides

XX SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957

Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 367

AAX24205/c

ID AAX24205 standard; DNA; 20 BP.

XX AAX24205;

XX 01-JUL-1999 (first entry)

XX Phosphonomonoester oligonucleotide analogue 22.

XX Phosphonomonoester analogue; inhibitor; antisense; cancer; restenosis;
 KW ribozyme; diagnostic agent; detection; treatment; disease; virus;
 KW integrin; cell-cell adhesion receptor; TNF-alpha; ss.

XX Synthetic.

XX DE19508923-A1.

XX 19-SEP-1996.

XX 13-MAR-1995; 95DE-01008923.

XX 13-MAR-1995; 95DE-01008923.

XX (FARH) HOECHST AG.

XX Anuschirwan P, Uhlmann E, Breipohl G, Wallmeier H;

XX WPI; 1996-425893/43.

XX New oligo:nucleotide analogues contg. phospho:mono:ester bridges - for
 PT therapeutic inhibition of gene expression, e.g. in cancer or viral
 PT infection, with good specificity and in vivo stability.

XX Disclosure; Page 23; 36pp; German.

XX This invention describes novel phosphonomonoester oligonucleotide
 CC analogues which act as inhibitors of gene expression (as sense/antisense,
 CC ribozyme or triplex-forming molecules), useful as diagnostic agents (i.e.
 CC probes for detecting nucleic acid) or for treatment of diseases caused by
 CC viruses, influenced by integrins or cell-cell adhesion receptors, induced
 CC by factors such as TNF-alpha, or cancer or restenosis. The products of
 CC the invention satisfy the requirements of good in-vivo stability; ability
 CC to cross cellular and nuclear membranes, and specific binding to target
 CC nucleic acid better than known oligonucleotides

XX SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGAG 1959

Db 20 GAGGGGAAGTGGTGGGGAG 1

```
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

DT 13-MAR-1997 (first entry)
 XX
 DE ISIS-2302, ICAM-1 inhibitor.
 XX
 KW RNA transcription inhibitor; hepatitis C virus; HCV; inflammation; AIDS;
 KW phosphorothioate oligonucleotide; primer; nuclease; RNaseH; therapy;
 XX thermodynamic stability; cytomegalovirus infection; cancer; ss.
 XX
 OS Synthetic.
 XX
 PN US5576302-A.
 XX
 PD 19-NOV-1996.
 XX
 XX 06-JUN-1995; 95US-00468447.
 XX
 PR 15-OCT-1991; 91US-00777670.
 PR 16-OCT-1991; 91US-00777007.
 PR 03-MAY-1993; 93US-00058023.
 PR 29-AUG-1994; 94US-00297703.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Cook PD, Hoke G;
 PI
 XX WPI; 1997-011289/01.
 DR
 XX New oligo:nucleotide(s) for inhibiting transcription of hepatitis C virus
 PT RNA - contain diastereomerically pure phosphorothioate links for
 PT formation of more stable complexes with target nucleic acid.
 XX
 XX Example 11; Col 19; 18pp; English.
 XX
 CC AAT51073-T51079 represent inhibitors of the invention. This sequence
 CC specifically inhibits the intercellular adhesion molecule (ICAM-1). 75-
 CC 100 % of the nucleotides in these sequences are preferably joined by
 CC either Sp or Rp phosphorothioate 3' to 5' links. To create these
 CC sequences, 2'-deoxyribonucleoside-5'-O-(1-thiophosphate) (dNTPalphas) is
 CC prepared as a racemic mixture, and the pure Sp and Rp diastereomers are
 CC isolated (such as by reverse-phase HPLC on ODS Hypersil). The chiral
 CC products are then used to make these sequences enzymatically in the
 CC presence of a template, primer, and nuclease. Alternatively these
 CC sequences can be chemically synthesized. Oligonucleotides with chirally
 CC pure intersugar links form heteroduplexes with target RNA or DNA of
 CC greater thermodynamic stability (compared with racemic mixtures), and
 CC elicit RNaseH activity. Chirally pure oligonucleotides also have a better
 CC resistance to nuclease digestion. As these sequences inhibit HCV RNA
 CC transcription, they can be used as therapeutic, diagnostic, and research
 CC agents. More generally, chirally pure phosphorothioate oligonucleotides
 CC can be used as therapeutic agents in the same way as racemic (or non-
 CC sulphur substituted) compounds, such as to treat AIDS, inflammation,
 CC cytomegalovirus infection, and various cancers. (Updated on 25-MAR-2003
 CC to correct PF field.)
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1
 RESULT 371
 AAV47978/c
 ID AAV47978 standard; DNA; 20 BP.
 AC
 XX AAV47978;
 XX
 XX 19-OCT-1998 (first entry)
 XX

DE Human B7-2 targetted oligonucleotide 2302.
 XX
 KW ss: human; B7; T cell; inflammation; autoimmune disease; cell activation;
 KW cell proliferation.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9829124-A1.
 XX
 PD 09-JUL-1998.
 XX
 XX 16-DEC-1997; 97WO-US023270.
 XX
 XX 31-DEC-1996; 96US-00777266.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Bennett CF, Vickers TA;
 PI
 XX WPI; 1998-387783/33.
 DR
 XX New oligo:nucleotide(s) that modulate expression of B7 proteins - used
 PT for, e.g. controlling activation and proliferation of T cells,
 PT particularly for treatment, diagnosis and prevention of inflammation.
 XX
 XX Example 7; Page 67; 120pp; English.
 XX
 CC The oligonucleotides which specifically hybridise to B7 modulate its
 CC expression (and thus T cell activation and proliferation). This is
 CC particularly useful for treatment and prevention of inflammation and
 CC autoimmune diseases, e.g. asthma, (juvenile) diabetes, myasthenia gravis,
 CC Grave's disease, rheumatoid arthritis, allograft rejection, psoriasis,
 CC (systemic) lupus erythematosus, multiple sclerosis, contact dermatitis,
 CC rinitis, allergy, cancer and metastases. The oligonucleotides may also
 CC be used to manipulate T cell activation ex vivo; to determine or detect
 CC B7 protein expression; for diagnosis; as assay and purification reagents,
 CC and to study physiological roles of B7 proteins
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1
 RESULT 372
 AAV06893/c
 ID AAV06893 standard; DNA; 20 BP.
 XX
 XX AAV06893;
 AC
 XX
 XX 03-JUL-1998 (first entry)
 DT
 XX Modified oligonucleotide 3067 which targets ICAM-1 mRNA transcript.
 DE
 XX Modified oligonucleotide; antisense inhibition; protein translation;
 KW 5' capped region; human intercellular adhesion molecule-1; ICAM-1;
 KW ribosome assembly; mRNA transcript; peptide-nucleic acid; PNA;
 KW E-selectin; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH misc_feature 1..20 a
 FT /*tag= a
 FT /note= "Phosphorothioate internucleotide linkages"
 XX
 XX

FT misc_feature 1. .19
 FT /*tag= a
 FT /note= "2'-methoxyethoxy nucleotides, all cytosine
 FT residues are 5-methylcytosine residues"
 XX
 PN WO9745437-A1.
 XX
 PD 04-DEC-1997.
 XX
 XX 29-APR-1997; 97WO-US007132.
 XX
 XX 24-MAY-1996; 96US-00653653.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Baker B, Bennett CF, Anderson KP, Condon TP;
 PI WPI; 1998-032572/03.
 XX
 XX Inhibiting translation of capped target mRNA - by contact with
 PT oligo:nucleotide having modified 2'-position, oligo:nucleoside or peptide
 PT -nucleic acid which is specifically hybridisable with a 5' cap region of
 PT the target mRNA.
 XX
 XX Disclosure; Page 17; 57pp; English.
 XX
 XX This sequence represents a 2'-methoxy modified oligonucleotide. The
 CC invention relates to a method for inhibiting the translation of a capped
 CC target mRNA, which comprises contacting the capped target mRNA with an
 CC oligomer which: (1) is 8-25 bases in length; (2) is an oligonucleotide
 CC having a modified 2'-position, an oligonucleoside, or a peptide-nucleic
 CC acid; and (3) is specifically hybridisable with a 5' cap region of the
 CC target mRNA which includes at least one of the first 20 nucleotides at
 CC the 5' terminus of the target mRNA. The oligomer interferes with ribosome
 CC assembly on the mRNA. The method is particularly useful for inhibiting
 CC the translation of capped target mRNA encoding human ICAM-1, human E-
 CC selectin or a cytomegalovirus protein (preferably an IE1 or IE2 gene
 CC product). Elevated ICAM-1 levels are associated with rheumatoid
 CC arthritis, ulcerative colitis, Crohn's disease, psoriasis and renal
 CC transplant rejection. E-selectin (also known as endothelial leukocyte
 CC adhesion molecule-1, or ELAM-1) is involved in the adherence of white
 CC blood cells to vasculature endothelium and subsequent migration out of
 CC the vasculature. Antisense drugs targeted to cytomegalovirus IE2 mRNA may
 CC be effective against CMV retinitis in AIDS patients
 XX
 XX Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 33 TCAGAGTTGCAACCTCAGCC 52
 Db 20 TCAGAGTTGCAACCTCAGCC 1
 AAV16212/C
 ID AAV16212 standard; cDNA; 20 BP.
 AC
 AC AAV16212;
 XX
 XX 02-JUN-1998 (first entry)
 DT
 XX Antisense molecule active against intercellular adhesion molecule-1.
 DE Inducible; cytokine; overexpression; cellular adhesion molecule;
 KW intracellular adhesion molecule-1; ICAM-1; antisense molecule;
 KW lipid mixture; Alzheimer's disease; multiple sclerosis; viral hepatitis;
 KW cholangitis; cardiac allograft rejection; ss.
 XX
 OS Synthetic.
 XX

PN WO9746671-A1.
 XX
 PD 11-DEC-1997.
 XX
 XX 22-MAY-1997; 97WO-CA000347.
 PF
 XX 30-MAY-1996; 96US-00657753.
 PR
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA
 XX Klimuk SK, Semple SC, Scherrer P, Hope MJ;
 PI WPI; 1998-042180/04.
 DR
 XX
 XX Composition for treatment of conditions associated with overexpression of
 PT ICAM-1 - used to treat e.g. Alzheimer's disease, glomerulonephritis,
 PT rheumatoid arthritis etc.
 PT
 XX Disclosure; Page 61; 81pp; English.
 PS
 XX Oligonucleotides AAV16212-13 represent antisense oligonucleotides of the
 CC invention. Pathological conditions associated with the overexpression of
 CC cellular adhesion molecules, such as intracellular adhesion molecule-1
 CC (ICAM-1), can be treated with a novel pharmaceutical composition which
 CC contains the present sequence. The composition comprises an effective
 CC amount of an ICAM-1 antisense molecule encapsulated in a lipid mixture,
 CC the lipid mixture comprising at least two members selected from
 CC phospholipids, sterols and cationic lipids. The composition is used in a
 CC method to treat pathological conditions associated with overexpression of
 CC ICAM-1, such as Alzheimer's disease, multiple sclerosis, viral hepatitis,
 CC cholangitis, cardiac allograft rejection, etc
 XX
 XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TCACGGATGCCAGCTTGGGC 2119
 Db 20 TCACGGATGCCAGCTTGGGC 1
 RESULT 376
 AAX17885/C
 ID AAX17885 standard; DNA; 20 BP.
 XX
 AC AAX17885;
 XX
 XX 11-MAY-1999 (first entry)
 DT
 XX Anti-CMV oligonucleotide #3224.
 DE
 XX Antisense; oligonucleotide; immediate early; DNA polymerase; CMV;
 KW cytomegalovirus; inhibition; replication; sugar modification;
 KW phosphorothioate; infection; retinitis; ss.
 XX
 OS Synthetic.
 OS Human herpesvirus 5.
 XX
 XX Key Location/Qualifiers
 FH modified_base 1. .20
 FT /*tag= a
 FT /note= "contains phosphorothioate internucleotide
 FT linkages and 2'-O-Methyl substituted sugars"
 FT
 XX WO9845314-A1.
 PN
 XX 15-OCT-1998.
 PD
 XX 07-APR-1998; 98WO-US006895.
 PF
 XX 09-APR-1997; 97US-00838715.
 PR

XX PA (ISIS-) ISIS PHARM INC.
XX PI Draper KG, Kisner DL, Anderson KP, Chapman S;
XX DR WPI; 1998-568330/48.
XX PT New antisense oligonucleotides that target cytomegalovirus nucleic acid -
PT particularly including 2-methoxyethoxy sugar modifications, especially
PT for treating viral retinitis, with long-lasting retention in the retina.
XX WPI; 1998-568330/48.
XX PS Disclosure; Page 24; 99pp; English.
XX CC Antisense oligonucleotides (AA17861-X17924) are targeted to a nucleic
CC acid (AA17925-X17948) encoding IE (immediate early) 1 or 2, or DNA
CC polymerase of cytomegalovirus (CMV) and are able to inhibit CMV
CC replication. Optionally the oligonucleotides include at least one 2'-(2-
CC methoxyethoxy) sugar modification or phosphorothioate internucleotide
CC linkages. The oligonucleotides are used to inhibit CMV infections (by in
CC vivo or in vitro contact with cells, tissues or body fluids), especially
CC to treat or prevent CMV infections, particularly retinitis
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
DB 20 GAGCTCCTCTGCTACTCAGA 1
RESULT 377
AAZ11594/c
ID AAZ11594 standard; DNA; 20 BP.
XX
AC AAZ11594;
XX
XX 16-NOV-1999 (first entry)
XX Fully modified phosphorothioate oligo seq ID No: 8.
XX Phosphorus-linked oligomer; deprotection; protic acid; ether solvent;
KW hybridization probe; amplification primer; forensic; paleontology;
KW antisense agent; ss.
XX Synthetic.
XX WO9943694-A1.
XX
XX 02-SEP-1999.
XX 26-FEB-1999; 99WO-US004213.
XX 26-FEB-1998; 98US-00032972.
XX (ISIS-) ISIS PHARM INC.
XX Krotz AH, Ravikumar VT;
XX WPI; 1999-540559/45.
XX Use of aromatic solvents during deprotection of 5'-hydroxy groups in
PT solid phase synthesis of oligonucleotides.
XX Example 10; Page 30; 42pp; English.
XX The invention provides improved methods for synthesis of phosphorus-
CC linked oligomers. The method comprises deprotecting a 5'-hydroxy using a
CC protic acid in an aromatic, alkylaromatic, haloaromatic, halo-
CC alkylaromatic or aromatic ether solvent. The phosphorus-linked oligomers
CC particularly oligonucleotides, are useful as diagnostic or research

CC reagents, e.g. hybridization probes or amplification primers, useful in
CC forensics, paleontology, evolutionary studies, for screening expression
CC libraries, sequencing etc., or as therapeutic (antisense) agents for
CC inhibiting expression of genes or activity of transcription factors. The
CC aromatic solvents are less expensive to use than hazardous halogenated
CC alkanes since they do not require large investments in recycling
CC equipment to meet environmental standards for disposal. They are thus
CC better suited for large scale operations. Sequences AAZ11587-594
CC represent phosphorothioate oligomers synthesized using the new method of
XX the invention
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1
RESULT 378
AAZ11588/c
ID AAZ11588 standard; DNA; 20 BP.
XX
AC AAZ11588;
XX
XX 16-NOV-1999 (first entry)
XX Fully modified phosphorothioate oligo seq ID No: 2.
XX Phosphorus-linked oligomer; deprotection; protic acid; ether solvent;
KW hybridization probe; amplification primer; forensic; paleontology;
KW antisense agent; ss.
XX Synthetic.
XX WO9943694-A1.
XX
XX 02-SEP-1999.
XX 26-FEB-1999; 99WO-US004213.
XX 26-FEB-1998; 98US-00032972.
XX (ISIS-) ISIS PHARM INC.
XX Krotz AH, Ravikumar VT;
XX WPI; 1999-540559/45.
XX Use of aromatic solvents during deprotection of 5'-hydroxy groups in
PT solid phase synthesis of oligonucleotides.
XX Example 4; Page 27; 42pp; English.
XX The invention provides improved methods for synthesis of phosphorus-
CC linked oligomers. The method comprises deprotecting a 5'-hydroxy using a
CC protic acid in an aromatic, alkylaromatic, haloaromatic, halo-
CC alkylaromatic or aromatic ether solvent. The phosphorus-linked oligomers
CC particularly oligonucleotides, are useful as diagnostic or research
CC reagents, e.g. hybridization probes or amplification primers, useful in
CC forensics, paleontology, evolutionary studies, for screening expression
CC libraries, sequencing etc., or as therapeutic (antisense) agents for
CC inhibiting expression of genes or activity of transcription factors. The
CC aromatic solvents are less expensive to use than hazardous halogenated
CC alkanes since they do not require large investments in recycling
CC equipment to meet environmental standards for disposal. They are thus
CC better suited for large scale operations. Sequences AAZ11587-594
CC represent phosphorothioate oligomers synthesized using the new method of
XX the invention
XX

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 379

AAZ11593/c

ID AAZ11593 standard; DNA; 20 BP.

XX

AC AAZ11593;

XX

DT 16-NOV-1999 (first entry)

XX

DE Fully modified phosphorothioate oligo seq ID No: 7.

XX

KW Phosphorus-linked oligomer; deprotection; protic acid; ether solvent;
KW hybridization probe; amplification primer; forensic; paleontology;
KW antisense agent; ss.

XX

OS Synthetic.

XX

PN WO9943694-A1.

XX

PD 02-SEP-1999.

XX

PF 26-FEB-1999; 99WO-US004213.

XX

PR 26-FEB-1998; 98US-00032972.

XX

PA (ISIS-) ISIS PHARM INC.

XX

PI Krotz AH, Ravikumar VT;

XX

DR WPI; 1999-540559/45.

XX

PT Use of aromatic solvents during deprotection of 5'-hydroxy groups in
PT solid phase synthesis of oligonucleotides.

XX

PS Example 9; Page 29; 42pp; English.

XX

CC The invention provides improved methods for synthesis of phosphorus-linked oligomers. The method comprises deprotecting a 5'-hydroxy using a protic acid in an aromatic, alkylaromatic, haloaromatic, haloaromatic, alkyaromatic or aromatic ether solvent. The phosphorus-linked oligomers particularly oligonucleotides, are useful as diagnostic or research reagents, e.g. hybridization probes or amplification primers, useful in forensics, paleontology, evolutionary studies, for screening expression libraries, sequencing etc., or as therapeutic (antisense) agents for inhibiting expression of genes or activity of transcription factors. The aromatic solvents are less expensive to use than hazardous halogenated alkanes since they do not require large investments in recycling equipment to meet environmental standards for disposal. They are thus better suited for large scale operations. Sequences AAZ11587-594 represent phosphorothioate oligomers synthesized using the new method of the invention

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 380

AAV99422/c

ID AAV99422 standard; DNA; 20 BP.

XX

AC AAV99422;

XX

DT 22-MAR-1999 (first entry)

XX

DE Antisense oligonucleotide directed against human ICAM-1.

XX

KW Antisense oligonucleotide; human intracellular adhesion molecule-1;
KW ICAM-1; phosphorothioate; phosphodiester; lipid-encapsulation; tumour;
KW aberrant gene expression; treatment; inflammation; infection; ss.

XX

OS Synthetic.

OS Homo sapiens.

XX

FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a

FT /note= "phosphorothioate or phosphodiester bonds"

XX

PN WO9851278-A2.

XX

PD 19-NOV-1998.

XX

PF 14-MAY-1998; 98WO-CA000485.

XX

PR 14-MAY-1997; 97US-00856374.

XX

PA (INEX-) INEX PHARM CORP.

XX

PI Semple SC, Klimuk SK, Harasym T, Hope MJ, Ansell SM, Cullis P;

PI Scherrer P, Debeyer D;

XX

DR WPI; 1999-045179/04.

XX

CC Composition containing lipid-encapsulated therapeutic agent - useful, e.g. for delivering antisense molecules or ribozymes or treating diseases associated with aberrant gene expression.

XX

PS Example 4; Page 51; 98pp; English.

XX

CC The present sequence represents an antisense oligonucleotide directed against human intracellular adhesion molecule-1 (ICAM-1). The oligonucleotide can have either phosphorothioate or phosphodiester bonds. The oligonucleotide is lipid-encapsulated using the method of the invention. A composition comprising lipid-encapsulated particles of a therapeutic agent, e.g. antisense oligonucleotides, is prepared by mixing at least 2 lipids with buffered aqueous solution of charged therapeutic agent to form an intermediate mixture of lipid-encapsulated particles, and changing the pH of the mixture to neutralise at least some of the external surface charges on the particles. One lipid has a (de)protonatable group with Ka such that the lipid is charged at a first pH but neutral at a second pH (particularly near physiological pH) and the buffer maintains this lipid in the charged form (i.e. cationic when the therapeutic agent is anionic in the buffer, or vice versa). The second lipid prevents particle aggregation during formation of the lipid-therapeutic agent particles. The composition is used to introduce therapeutic agents into cells, in vivo or in vitro, particularly to treat or prevent diseases associated with aberrant gene expression in mammals, specifically tumours, inflammation or infection

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1


```

RESULT 381
AAV4295/c
ID AAV4295 standard; DNA; 20 BP.
XX
XX
AC AAX33397;
XX
XX
DT 29-JUN-1999 (first entry)
XX
XX
DE Phosphorothioate 20-mer oligonucleotide #2.
XX
XX
KW Phosphorothioate; sulphurised oligonucleotide; ss.
XX
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /*note= "phosphorothioate linkages"
XX
XX
PN W09919340-A1.
XX
XX
PD 22-APR-1999.
XX
XX
PF 13-OCT-1998; 98WO-US021502.
XX
XX
PR 15-OCT-1997; 97US-00950779.
XX
XX
(ISTS-) ISIS PHARM INC.
XX
XX
PI Cole DL, Ravikumar VT, Cheruvallath ZS;
XX
XX
DR WPI; 1999-287949/24.
XX
XX
Preparation of Phosphorothioate oligonucleotides applicable throughout
nucleic acid chemistry.
XX
XX
Example 3; Page 8; 17pp; English.
XX
XX
The present invention describes a method for preparing phosphorothioate
oligonucleotides by phosphorylating the 5'-hydroxyl of a nucleic acid
moiety in an acetonitrile containing solvent mixture to form a phosphite
intermediate (II) and oxidizing (II) with an acetyl disulfide in an
acetonitrile containing solvent mixture to effect conversion of the
intermediate to phosphorothioate (II). The present sequence represents a
phosphorothioate oligonucleotide from an example of the present
invention. The method can be used to sulphurise oligonucleotides of 8-50
nucleotides. The method is widely applicable throughout nucleic acid
chemistry. The process allows formation of phosphorothioate linkages in
the oligonucleotides or derivatives, without the need for complex solvent
mixtures and repeated washing or solvent changes. The process uses a
simplified solvent system and produces oligonucleotides having
phosphorothioate groups with efficiency and improved yields
XX
XX
Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 382
AAV4295/c
ID AAV4295 standard; DNA; 20 BP.
XX
XX
AC AAV4295;
XX
XX
DT 29-MAR-1999 (first entry)
XX
XX
DE ICAM-1 antisense oligonucleotide primer #3.
XX
XX
KW ICAM-1; intercellular adhesion molecule-1; antisense; primer; prevention;
perfusion injury; transplantation; pre-operative treatment; donor; organ;
ss.
XX
XX
OS Synthetic.
XX
XX
PN DE19745666-A1.
XX
XX
PD 14-JAN-1999.
XX
XX
PF 17-OCT-1997; 97DE-01045666.
XX
XX
PR 07-JUL-1997; 97DE-01028923.
XX
XX
(DELB-) DELBRUECK CENT MOLEKULARE MEDIZIN MAX.
XX
XX
Haller H;
XX
XX
WPI; 1999-082662/08.
XX
XX
Use of antisense oligonucleotide against ICAM-1 - for preventing
perfusion injury during transplantation of e.g. kidney, heart, lung or
pancreas.
XX
XX
Claim 4; Page 2; 4pp; German.
XX
XX
AAV4293-V74297 are antisense oligonucleotide primers used against the
intercellular adhesion molecule ICAM-1 for preventing perfusion injury
during transplantation. The oligonucleotides are used for pre-operative
treatment of the transplant donor or for pre-treatment of the donor organ
CC (preferably kidney, heart, lung or pancreas) before transplantation
XX
XX
Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 383
AAV74294/c
ID AAV74294 standard; DNA; 20 BP.
XX
XX
AC AAV74294;
XX
XX
DT 29-MAR-1999 (first entry)
XX
XX
DE ICAM-1 antisense oligonucleotide primer #2.
XX
XX
KW ICAM-1; intercellular adhesion molecule-1; antisense; primer; prevention;
perfusion injury; transplantation; pre-operative treatment; donor; organ;
ss.
XX
XX
OS Synthetic.
XX
XX
PN DE19745666-A1.
XX
XX
PD 14-JAN-1999.
XX
XX
PF 17-OCT-1997; 97DE-01045666.
XX
XX
PR 07-JUL-1997; 97DE-01028923.
XX
XX
(DELB-) DELBRUECK CENT MOLEKULARE MEDIZIN MAX.
XX
XX
Haller H;
XX
XX

```

DR WPI; 1999-082662/08.
 XX Use of antisense oligonucleotide against ICAM-1 - for preventing
 PT perfusion injury during transplantation of e.g. kidney, heart, lung or
 PT pancreas.
 XX
 PS Claim 4; Page 2; 4pp; German.
 XX
 CC AAV74293-V74297 are antisense oligonucleotide primers used against the
 CC intercellular adhesion molecule ICAM-1 for preventing perfusion injury
 CC during transplantation. The oligonucleotides are used for pre-operative
 CC treatment of the transplant donor or for pre-treatment of the donor organ
 CC (preferably kidney, heart, lung or pancreas) before transplantation
 XX
 XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
 |||||
 DB 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 384
 AAV74296/c
 ID AAV74296 standard; DNA; 20 BP.
 XX
 AC AAV74296;
 XX
 DT 29-MAR-1999 (first entry)
 XX
 DE ICAM-1 antisense oligonucleotide primer #4.
 XX
 KW ICAM-1; intercellular adhesion molecule-1; antisense; primer; prevention;
 KW perfusion injury; transplantation; pre-operative treatment; donor; organ;
 KW ss.
 XX Synthetic.
 XX DE19745666-AL.
 PN 14-JAN-1999.
 PD 17-OCT-1997; 97DE-01045666.
 PF 07-JUL-1997; 97DE-01028923.
 PR (DELB-) DELBRUECK CENT MOLEKULARE MEDIZIN MAX.
 XX Haller H;
 PI
 DR WPI; 1999-082662/08.
 XX
 PT Use of antisense oligonucleotide against ICAM-1 - for preventing
 PT perfusion injury during transplantation of e.g. kidney, heart, lung or
 PT pancreas.
 XX
 PS Claim 4; Page 2; 4pp; German.
 XX
 CC AAV74293-V74297 are antisense oligonucleotide primers used against the
 CC intercellular adhesion molecule ICAM-1 for preventing perfusion injury
 CC during transplantation. The oligonucleotides are used for pre-operative
 CC treatment of the transplant donor or for pre-treatment of the donor organ
 CC (preferably kidney, heart, lung or pancreas) before transplantation
 XX
 XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
 |||||
 DB 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 384
 AAV74296/c
 ID AAV74296 standard; DNA; 20 BP.
 XX
 AC AAV74296;
 XX
 DT 29-MAR-1999 (first entry)
 XX
 DE ICAM-1 antisense oligonucleotide primer #4.
 XX
 KW ICAM-1; intercellular adhesion molecule-1; antisense; primer; prevention;
 KW perfusion injury; transplantation; pre-operative treatment; donor; organ;
 KW ss.
 XX Synthetic.
 XX DE19745666-AL.
 PN 14-JAN-1999.
 PD 17-OCT-1997; 97DE-01045666.
 PF 07-JUL-1997; 97DE-01028923.
 PR (DELB-) DELBRUECK CENT MOLEKULARE MEDIZIN MAX.
 XX Haller H;
 PI
 DR WPI; 1999-082662/08.
 XX
 PT Use of antisense oligonucleotide against ICAM-1 - for preventing
 PT perfusion injury during transplantation of e.g. kidney, heart, lung or
 PT pancreas.
 XX
 PS Claim 4; Page 2; 4pp; German.
 XX
 CC AAV74293-V74297 are antisense oligonucleotide primers used against the
 CC intercellular adhesion molecule ICAM-1 for preventing perfusion injury
 CC during transplantation. The oligonucleotides are used for pre-operative
 CC treatment of the transplant donor or for pre-treatment of the donor organ
 CC (preferably kidney, heart, lung or pancreas) before transplantation
 XX
 XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 SQ

QY 18 GAGCTCCTCTGCTACTCAGA 37
 |||||
 DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 385
 AAX99983/c
 ID AAX99983 standard; DNA; 20 BP.
 XX
 AC AAX99983;
 XX
 DT 19-OCT-1999 (first entry)
 XX
 DE Phosphorothioate oligonucleotide #2.
 XX
 KW Phosphorothioate oligonucleotide; benzyl(thio)phosphite residue; primer;
 KW benzyl(thio)phosphoramidite; probe production; linker; adapter;
 KW gene fragment; ss.
 XX Synthetic.
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /note= "phosphorothioate backbone"
 FT
 XX WO9940101-A1.
 XX 12-AUG-1999.
 XX 09-FEB-1999; 99WO-US002474.
 XX 10-FEB-1998; 98US-00021277.
 XX (ISIS-) ISIS PHARM INC.
 XX Capaldi DC, Ravikumar VT;
 XX WPI; 1999-508484/42.
 XX
 PT Oligonucleotide synthesis using substituted benzyl phosphoramidite for
 PT reaction with synthon having free 5'-hydroxy.
 XX
 PS Example 11; Page 46; 72pp; English.
 XX
 CC This sequence represents a phosphorothioate oligonucleotide synthesised
 CC using the method of the invention. The method is for the preparation of
 CC oligonucleotides containing a substituted benzyl(thio)phosphite residue
 CC comprises reacting an (oligo)nucleotide with a 3' substituted
 CC benzyl(thio)phosphoramidite with an (oligo)nucleotide having a free 5'-
 CC hydroxy, with one of the reactants, optionally immobilised on a solid
 CC phase. The method is used to prepare oligonucleotides, or analogues, for
 CC use as probes, primers, linkers, adapters or gene fragments, for
 CC diagnostic or therapeutic use, or as research reagents. The specified
 CC substituted benzyl group can be eliminated without release of toxic
 CC acrylonitrile (contrast conventional 2-cyanoethoxy protecting groups)
 XX
 XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TCACGGATCCAGCTTGGGC 2119
 |||||
 DB 20 TCACGGATCCAGCTTGGGC 1

RESULT 386
 AAX00534/c
 ID AAX00534 standard; DNA; 20 BP.
 XX
 AC AAX00534;

```

XX 30-MAR-1999 (first entry)
DT
DE Antisense oligonucleotide ISIS#1940 targeted to ICAM-1.
DE
XX Target; antisense; selective rank; inhibition; ranking; stability;
KW interaction; intercellular adhesion molecule; ICAM; ss.
XX
XX Synthetic.
OS
XX Key Location/Qualifiers
FH misc_feature 1..20
FT /*tag= a
FT /note= "contains phosphorothioate internucleotide
FT linkages"
FT
XX US5856103-A.
PN
XX 05-JAN-1999.
PD
XX 03-MAR-1997; 97US-00808474.
PF
XX 07-OCT-1994; 94US-00320507.
PR
XX (TEXA ) UNIV TEXAS.
PA
XX Clark CL, Gray DM;
PI
XX WPI; 1999-105098/09.
PS
XX
XX Selectively ranking nucleic acid molecules, for inhibitory efficiency -
CC comprises determining the fraction a set of nearest-neighbour nucleic
CC acid base pair types in a target sequence zone, substituting nearest-
CC neighbour nucleic acid base pair fractions to determine the fractions and
CC multiplying.
XX
XX Example 1; Col 21-22; 72pp; English.
XX
XX This oligonucleotide represents an antisense oligonucleotides (ASO)
CC targeted to a region in the intercellular adhesion molecule (ICAM)-1 gene
CC which is generated by a method of selectively ranking nucleic acid
CC molecules for inhibitory efficiency. The method comprises: (a)
CC determining the fraction of each of a set of 13 nearest-neighbour nucleic
CC acid base pair types in a target sequence zone RNA:ASO-DNA hybrid nucleic
CC acid sequence; (b) substituting nearest-neighbour nucleic acid base pair
CC fractions into formulas to determine the fractions of each of a series of
CC 13 nearest-neighbour nucleic acid base pair types to provide determined
CC fractions; and (c) multiplying the fractions of the 13 nearest-neighbour
CC nucleic acid base pair types by a stability ranking to the nucleic acid
CC antisense sequence; where the results are ordered to produce a ranking.
CC The process is used to rank nucleic acid sequences based on the stability
CC of nucleic acid oligomer binding interactions to select sequence zones
CC for antisense targeting
XX
XX Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATTAAGCTTTCTCAA 2981
Db |||||||||||||||||||
20 AGTTAATTAAGCTTTCTCAA 1

RESULT 387
AAX00532/c
ID AAX00532 standard; DNA; 20 BP.
XX
AC AAX00532;
XX
XX 30-MAR-1999 (first entry)
DT
DE Antisense oligonucleotide ISIS#1938 targeted to ICAM-1.
DE
KW Target; antisense; selective rank; inhibition; ranking; stability;
XX interaction; intercellular adhesion molecule; ICAM; ss.
XX

```

```

DE Antisense oligonucleotide ISIS#2302 targeted to ICAM-1.
XX
XX Target; antisense; selective rank; inhibition; ranking; stability;
KW interaction; intercellular adhesion molecule; ICAM; ss.
XX
XX Synthetic.
OS
XX Key Location/Qualifiers
FH misc_feature 1..20
FT /*tag= a
FT /note= "contains phosphorothioate internucleotide
FT linkages"
FT
XX US5856103-A.
PN
XX 05-JAN-1999.
PD
XX 03-MAR-1997; 97US-00808474.
PF
XX 07-OCT-1994; 94US-00320507.
PR
XX (TEXA ) UNIV TEXAS.
PA
XX Clark CL, Gray DM;
PI
XX WPI; 1999-105098/09.
PS
XX
XX Selectively ranking nucleic acid molecules, for inhibitory efficiency -
CC comprises determining the fraction a set of nearest-neighbour nucleic
CC acid base pair types in a target sequence zone, substituting nearest-
CC neighbour nucleic acid base pair fractions to determine the fractions and
CC multiplying.
XX
XX Example 1; Col 21-22; 72pp; English.
XX
XX This oligonucleotide represents an antisense oligonucleotides (ASO)
CC targeted to a region in the intercellular adhesion molecule (ICAM)-1 gene
CC which is generated by a method of selectively ranking nucleic acid
CC molecules for inhibitory efficiency. The method comprises: (a)
CC determining the fraction of each of a set of 13 nearest-neighbour nucleic
CC acid base pair types in a target sequence zone RNA:ASO-DNA hybrid nucleic
CC acid sequence; (b) substituting nearest-neighbour nucleic acid base pair
CC fractions into formulas to determine the fractions of each of a series of
CC 13 nearest-neighbour nucleic acid base pair types to provide determined
CC fractions; and (c) multiplying the fractions of the 13 nearest-neighbour
CC nucleic acid base pair types by a stability ranking to the nucleic acid
CC antisense sequence; where the results are ordered to produce a ranking.
CC The process is used to rank nucleic acid sequences based on the stability
CC of nucleic acid oligomer binding interactions to select sequence zones
CC for antisense targeting
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TCACCGATGCCAGCTTGGGC 2119
Db |||||||||||||||||||
20 TCACCGATGCCAGCTTGGGC 1

RESULT 388
AAX00530/c
ID AAX00530 standard; DNA; 20 BP.
XX
AC AAX00530;
XX
XX 30-MAR-1999 (first entry)
DT
DE Antisense oligonucleotide ISIS#1938 targeted to ICAM-1.
DE
KW Target; antisense; selective rank; inhibition; ranking; stability;
XX interaction; intercellular adhesion molecule; ICAM; ss.
XX

```

KW interaction; intercellular adhesion molecule; ICAM; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT misc_feature 1..20

FT /tag= a

FT /note= "contains phosphorothioate internucleotide linkages"

XX US5856103-A.

PN 05-JAN-1999.

XX 03-MAR-1997;

XX 07-OCT-1994; 94US-00320507.

XX (TEXA) UNIV TEXAS.

XX Clark CL, Gray DM;

XX WPI; 1999-105098/09.

XX Selectively ranking nucleic acid molecules, for inhibitory efficiency - comprises determining the fraction a set of nearest-neighbour nucleic acid base pair types in a target sequence zone, substituting nearest-neighbour nucleic acid base pair fractions to determine the fractions and multiplying.

XX Example 1; Col 21-22; 72pp; English.

XX This oligonucleotide represents an antisense oligonucleotides (ASO) targeted to a region in the intercellular adhesion molecule (ICAM)-1 gene which is generated by a method of selectively ranking nucleic acid molecules for inhibitory efficiency. The method comprises: (a) determining the fraction of each of a set of 13 nearest-neighbour nucleic acid base pair types in a target sequence zone RNA:ASO-DNA hybrid nucleic acid sequence; (b) substituting nearest-neighbour nucleic acid base pair fractions into formulas to determine the fractions of each of a series of 13 nearest-neighbour nucleic acid base pair types to provide determined fractions; and (c) multiplying the fractions of the 13 nearest-neighbour nucleic acid base pair types by a stability ranking to the nucleic acid antisense sequence; where the results are ordered to produce a ranking. The process is used to rank nucleic acid sequences based on the stability of nucleic acid oligomer binding interactions to select sequence zones for antisense targeting

XX Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1654 TGAACCTATCCCGGACAGG 1673

Db 20 TGAACCTATCCCGGACAGG 1

RESULT 389

AAX00529/c

ID AAX00529 standard; DNA; 20 BP.

XX AAX00529;

XX 30-MAR-1999 (first entry)

XX Antisense oligonucleotide ISIS#1934 targeted to ICAM-1.

XX Target; antisense; selective rank; inhibition; ranking; stability;

XX interaction; intercellular adhesion molecule; ICAM; ss.

XX Synthetic.

XX

FH

FT

FT

FT

FT

XX

PN

XX

XX

PD

XX

PF

XX

XX

PR

XX

XX

PA

XX

PI

XX

DR

XX

XX

PT

PT

PT

PT

PT

PT

XX

XX

PS

XX

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

Key Location/Qualifiers

FT misc_feature 1..20

FT /tag= a

FT /note= "contains phosphorothioate internucleotide linkages"

XX US5856103-A.

XX 05-JAN-1999.

XX 03-MAR-1997;

XX 07-OCT-1994; 94US-00320507.

XX (TEXA) UNIV TEXAS.

XX Clark CL, Gray DM;

XX WPI; 1999-105098/09.

XX Selectively ranking nucleic acid molecules, for inhibitory efficiency - comprises determining the fraction a set of nearest-neighbour nucleic acid base pair types in a target sequence zone, substituting nearest-neighbour nucleic acid base pair fractions to determine the fractions and multiplying.

XX Example 1; Col 21-22; 72pp; English.

XX This oligonucleotide represents an antisense oligonucleotides (ASO) targeted to a region in the intercellular adhesion molecule (ICAM)-1 gene which is generated by a method of selectively ranking nucleic acid molecules for inhibitory efficiency. The method comprises: (a) determining the fraction of each of a set of 13 nearest-neighbour nucleic acid base pair types in a target sequence zone RNA:ASO-DNA hybrid nucleic acid sequence; (b) substituting nearest-neighbour nucleic acid base pair fractions into formulas to determine the fractions of each of a series of 13 nearest-neighbour nucleic acid base pair types to provide determined fractions; and (c) multiplying the fractions of the 13 nearest-neighbour nucleic acid base pair types by a stability ranking to the nucleic acid antisense sequence; where the results are ordered to produce a ranking. The process is used to rank nucleic acid sequences based on the stability of nucleic acid oligomer binding interactions to select sequence zones for antisense targeting

XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 337 TCAAACTGCCCTGATGGCA 356

Db 20 TCAAACTGCCCTGATGGCA 1

RESULT 390

AAX00531/c

ID AAX00531 standard; DNA; 20 BP.

XX AAX00531;

XX 30-MAR-1999 (first entry)

XX Antisense oligonucleotide ISIS#1939 targeted to ICAM-1.

XX Target; antisense; selective rank; inhibition; ranking; stability;

XX interaction; intercellular adhesion molecule; ICAM; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT misc_feature 1..20

FT /*tag= a
 FT /note= "Contains phosphorothioate internucleotide
 FT linkages"

PN US5856103-A.

PD 05-JAN-1999.

XX 03-MAR-1997; 97US-00808474.

XX 07-OCT-1994; 94US-00320507.

XX (TEXA) UNIV TEXAS.

XX Clark CL, Gray DM;

PI WPI; 1999-105098/09.

XX Selectively ranking nucleic acid molecules, for inhibitory efficiency -
 PT comprises determining the fraction a set of nearest-neighbour nucleic
 PT acid base pair types in a target sequence zone, substituting nearest-
 PT neighbour nucleic acid base pair fractions to determine the fractions and
 PT multiplying.

XX Example 1; Col 21-22; 72pp; English.

CC This oligonucleotide represents an antisense oligonucleotides (ASO)
 CC targeted to a region in the intercellular adhesion molecule (ICAM)-1 gene
 CC which is generated by a method of selectively ranking nucleic acid
 CC molecules for inhibitory efficiency. The method comprises: (a)
 CC determining the fraction of each of a set of 13 nearest-neighbour nucleic
 CC acid base pair types in a target sequence zone RNA:ASO-DNA hybrid nucleic
 CC acid sequence; (b) substituting nearest-neighbour nucleic acid base pair
 CC fractions into formulas to determine the fractions of each of a series of
 CC 13 nearest-neighbour nucleic acid base pair types to provide determined
 CC fractions; and (c) multiplying the fractions of the 13 nearest-neighbour
 CC nucleic acid base pair types by a stability ranking to the nucleic acid
 CC antisense sequence; where the results are ordered to produce a ranking.
 CC The process is used to rank nucleic acid sequences based on the stability
 CC of nucleic acid oligomer binding interactions to select sequence zones
 CC for antisense targeting

XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGG 1957

DB |||||
 20 GAGAGGGGAAGTGTGGGG 1

RESULT 391

AAAX18669/C

ID AAX18669 standard; DNA; 20 BP.

XX AAX18669;

XX 10-MAY-1999 (first entry)

DE Cellular adhesion protein ICAM-1 antisense oligonucleotide ISIS 2302.

XX Cellular adhesion protein; proliferation; antisense oligonucleotide;
 KW alimentary canal; transport; gastrointestinal mucosa; cancer;
 KW Alzheimer's disease; beta-thalassemia; malaria; viral infection; HIV;
 KW inflammation; ss.

XX Synthetic.

XX WO9901579-A1.

XX 14-JAN-1999.

XX 01-JUL-1998; 98WO-US013574.

XX 01-JUL-1997; 97US-00886829.

XX (ISIS-) ISIS PHARM INC.

XX Teng C, Hardee G;

XX WPI; 1999-106077/09.

XX Composition comprising nucleic acid and penetration enhancer - used
 PT particularly for delivering therapeutic antisense oligonucleotides across
 PT the gastrointestinal mucosa, provides high bioavailability.

XX Example 2; Page 77; 115pp; English.

XX A pharmaceutical composition has been developed which comprises a nucleic
 CC acid and at least one penetration enhancer. The compositions are used:
 CC (i) to treat or prevent any disease or disorder that can be treated with
 CC the nucleic acid, e.g. cancer, Alzheimer's disease, beta-thalassemia,
 CC malaria, viral infections (including human immune deficiency virus
 CC (HIV)), inflammation, in human or animal medicine; (ii) to investigate
 CC the role of a gene or gene product in non-human animals; and (iii) to
 CC modulate gene expression in cells, tissues or organs. The compositions
 CC provide bioavailability of at least 15, preferably 17-35%. The
 CC penetration enhancer improves: (i) transport of the nucleic acid across
 CC the mucosa of the alimentary canal and into cells; and (ii) increases
 CC stability of the nucleic acid. Oral administration avoids the
 CC complications and expense of intravenous or other methods of
 CC administration. AAX18669 to AAX18799 and AAX18801 represent antisense
 CC oligonucleotides which can be used as the nucleic acid in the method of
 CC the invention

XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119

DB |||||
 20 TGACGGATGCCAGCTTGGGC 1

RESULT 392

AAV72648/C

ID AAV72648 standard; DNA; 20 BP.

XX AAV72648;

XX 11-FEB-1999 (first entry)

XX Human ICAM-1 antisense oligonucleotide.

XX Mouse; protein kinase C-alpha; PKC-alpha; antisense oligonucleotide;
 KW phosphorothioate; enhanced bioavailability; oral delivery; diagnosis;
 KW heteroatomic backbone modification; 2'-modified sugar; tumour;
 KW autoimmune disease; inflammation; graft vs. host disease; ss.

XX Synthetic.

XX Homo sapiens.

XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /note= "phosphorothioate linkages"

XX WO9849348-A1.

XX 05-NOV-1998.

XX 30-APR-1998; 98WO-US008798.

```

XX 30-APR-1997; 97US-00847151.
XX (ISIS-) ISIS PHARM INC.
XX Dean NM, Bennett CF, Monia BP, Draper K, Anderson KP, Baker BF;
XX Ecker DJ;
XX WPI; 1999-009446/01.
XX
XX Modified antisense oligonucleotide with increased bioavailability after
XX oral delivery - has heteroatomic backbone modification or 2'-modified
XX sugar, useful for diagnosis and therapy, e.g. of tumours.
XX
XX Example 6; Page 27; 54pp; English.
XX
XX The present invention describes oligonucleotides having: (a) at least one
XX heteroatomic backbone modification or at least one 2'-sugar modification;
XX and (b) during or after administration to the alimentary canal, greater
XX bioavailability than the corresponding phosphorothioate
XX oligodeoxynucleotide. Also described are compositions containing the
XX oligonucleotides having at least one 2'-alkoxyalkoxy sugar modification
XX and at least one 5-methylcytidine (5MeC) residue. The oligonucleotides
XX are antisense oligonucleotides for modulating expression of target genes
XX for diagnostic or therapeutic purposes, e.g. in cases of tumours,
XX autoimmune disease and inflammation, including graft vs. host disease.
XX The specified modifications increase bioavailability from the digestive
XX tract, eliminating the need for intravenous or other routes of
XX administration. The present sequence represents an antisense
XX oligonucleotide which is used in example to examine the effect of 2'MOE
XX modifications with 5-methylcytidine modifications on in vivo
XX bioavailability
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2100 TGACGGATGCCAGCTGGGC 2119
DB |||||
20 TGACGGATGCCAGCTGGGC 1
XX
RESULT 393
AAV72641/c
ID AAV72641 standard; DNA; 20 BP.
XX
AC AAV72641;
XX
DT 11-FEB-1999 (first entry)
XX
DE Rat intercellular adhesion molecule 1 oligonucleotide.
XX
KW Rat; intercellular adhesion molecule 1; antisense oligonucleotide;
XX phosphorothioate; enhanced bioavailability; oral delivery; diagnosis;
XX heteroatomic backbone modification; 2'-modified sugar; tumour;
XX autoimmune disease; inflammation; graft vs. host disease; ss.
XX
OS Synthetic.
OS Rattus sp.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /note= "phosphorothioate linkages"
XX
PN WO9849348-A1.
XX
PD 05-NOV-1998.
XX
PF 30-APR-1998; 98WO-US008798.
XX

```

```

PR 30-APR-1997; 97US-00847151.
XX (ISIS-) ISIS PHARM INC.
XX Dean NM, Bennett CF, Monia BP, Draper K, Anderson KP, Baker BF;
XX Ecker DJ;
XX WPI; 1999-009446/01.
XX
XX Modified antisense oligonucleotide with increased bioavailability after
XX oral delivery - has heteroatomic backbone modification or 2'-modified
XX sugar, useful for diagnosis and therapy, e.g. of tumours.
XX
XX Example 1; Page 37; 54pp; English.
XX
XX The present invention describes oligonucleotides having: (a) at least one
XX heteroatomic backbone modification or at least one 2'-sugar modification;
XX and (b) during or after administration to the alimentary canal, greater
XX bioavailability than the corresponding phosphorothioate
XX oligodeoxynucleotide. Also described are compositions containing the
XX oligonucleotides having at least one 2'-alkoxyalkoxy sugar modification
XX and at least one 5-methylcytidine (5MeC) residue. The oligonucleotides
XX are antisense oligonucleotides for modulating expression of target genes
XX for diagnostic or therapeutic purposes, e.g. in cases of tumours,
XX autoimmune disease and inflammation, including graft vs. host disease.
XX The specified modifications increase bioavailability from the digestive
XX tract, eliminating the need for intravenous or other routes of
XX administration. The present sequence represents an antisense
XX oligonucleotide which is used in example to examine the effect of 2'
XX modifications on bioavailability after gastrointestinal administration in
XX mice
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 18 GAGCTCCTCTGCTACTCAGA 37
DB |||||
20 GAGCTCCTCTGCTACTCAGA 1
XX
RESULT 394
AAX09078/c
ID AAX09078 standard; DNA; 20 BP.
XX
AC AAX09078;
XX
DT 14-JUN-1999 (first entry)
XX
DE Tumour necrosis factor alpha antisense oligonucleotide.
XX
KW Tumour necrosis factor alpha; TNF-alpha; antisense oligonucleotide; ASO;
XX inhibition; expression; treatment; disease; disorder; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9901139-A1.
XX
PD 14-JAN-1999.
XX
PF 02-JUL-1998; 98WO-US013711.
XX
PR 03-JUL-1997; 97US-0051705P.
XX (UYJE-) UNIV JEFFERSON THOMAS.
XX Tu G, Israel Y;
XX WPI; 1999-105767/09.
XX

```

PT Generation of antisense oligonucleotides - by specifically targeting a
PT GGGA motif found in mRNA sequences.

XX Example 2; Page 37; 55pp; English.

XX Antisense oligonucleotides (ASO) for inhibiting a tumour necrosis factor-
CC alpha (TNF-alpha) gene in an animal, preferably a human, comprise 12-50
CC nucleotides, 90% of which are complementary to a region of mRNA
CC containing a GGGA sequence motif. The ASO is used to inhibit expression
CC of a gene in an animal and for treating the animal when afflicted with a
CC disease or disorder characterised by the presence of an mRNA from a gene
CC containing a GGGA motif. The ASO are specifically targeted to a GGGA
CC sequence motif found in mRNA from a gene. A study of known ASO has shown
CC that at least half of the most efficacious ASO's contain one or more TCCC
CC motifs. This ASO comprises a TCCC motif followed by a cytosine residue
CC and corresponds to a region of the human ICAM-1 3' untranslated region

XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
DB 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 395
AAAX23578/c
ID AAAX23578 standard; DNA; 20 BP.
XX
AC AAX23578;
XX
DT 18-JUN-1999 (first entry)
XX
DE Deletion sequence oligonucleotide 31.
XX
KW Deletion sequence oligonucleotide; sensor array; eukaryotic pathogen;
KW probe; cellular adhesion modulator; cellular proliferation modulator;
KW human retrovirus; human immunodeficiency virus; non-human retrovirus;
KW HIV; primer; ss.
XX
OS Synthetic.
XX
PN WO9911820-Al.
XX
PD 11-MAR-1999.
XX
PF 01-SEP-1998; 98WO-US018084.
XX
PR 02-SEP-1997; 97US-00923771.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Chen D, Srivatsa GS;
XX
DR WPI; 1999-205198/17.
XX
XX New compositions comprising sensor arrays made up of unique probe
PT oligonucleotides - useful for characterizing a sample of target deletion
PT oligonucleotides.

XX Example 9; Page 100; 163pp; English.

XX This invention describes a novel composition comprising a number of
CC sensor arrays, where each array comprises a unique probe oligonucleotide,
CC which is the reverse complement of part of a unique target
CC oligonucleotide present in a mixture of target deletion sequence
CC oligonucleotides. The compositions form a method for characterizing a
CC sample of target deletion oligonucleotides which are labelled and
CC hybridize with the probe oligonucleotides of the sensor arrays. Such
CC oligonucleotides and their targets are represented in AAX23548-X23709.

CC Oligonucleotides characterized by the method form pharmaceutical
CC compositions that are useful for modulating cellular adhesion or
CC proliferation, and being active against a eukaryotic pathogen, a human
CC retrovirus, a human immunodeficiency virus (HIV), or a non-human
CC retrovirus, including influenza virus, Epstein-Barr virus, Respiratory
CC Syncytial virus or cytomegalovirus (CMV). The compositions enable
CC characterization of deletion sequence oligonucleotides having related,
CC but different nucleobase sequences, and quantification of different
CC species of deletion sequence ("target") oligonucleotides in a mixture.
CC Also, if the specificity of the oligonucleotide's nucleobase sequence for
CC its reverse complement is not modified, the method may be performed using
CC oligodeoxynucleotides

XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TCACGGATGCCAGCTTGGGC 2119
|||||
DB 20 TCACGGATGCCAGCTTGGGC 1

RESULT 396
AAC62737/c
ID AAC62737 standard; DNA; 20 BP.
XX
AC AAC62737;
XX
DT 05-FEB-2001 (first entry)
XX
DE Phosphorothioate oligonucleotide ISIS-2302.
XX
KW Phosphorothioate; lipid; liposome; drug deliver; ss.
XX
OS Unidentified.
XX
PN WO200059474-Al.
XX
PD 12-OCT-2000.
XX
PF 06-APR-2000; 2000WO-US009473.
XX
PR 06-APR-1999; 99US-00287175.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Leamon CP;
XX
DR WPI; 2000-679320/66.
XX
PT New pro-cationic lipid compounds useful as components of liposomes used
PT as vehicles for delivering pharmaceutical agents into cells.
XX
PS Disclosure; Page 31; 65pp; English.

XX The present oligonucleotide is given in a specification disclosing a new
CC lipid compound and its salts, solvates and hydrates. The compound
CC comprises a hydrophobic tail part covalently linked to a hydrophilic head
CC part. A region proximal to the hydrophobic tail part has a net positive
CC charge at physiological pH and a region distal to the hydrophobic tail
CC part has a net negative charge at physiological pH. A disulphide bond
CC connects the regions. The lipid compound is useful for the construction
CC of liposomes used as vehicles for delivering pharmaceutical agents into
CC cells. The lipids and liposomes are fusogenic with membranes and deliver
CC pharmaceutical agents to tissues or cells without inherent aggregation,
CC which reduces toxicity

XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTGGGC 2119
 |||||
 Db 20 TGACGGATGCCAGCTGGGC 1

RESULT 397
 AAZ58232/c
 ID AAZ58232 standard; DNA; 20 BP.
 XX
 AC AAZ58232;
 XX
 DT 23-MAY-2000 (first entry)
 XX
 DE ICAM-1 targeted PS/PO oligonucleotide 15537.
 XX
 KW 2'-Modified oligonucleotide; phosphorothioate linkage;
 KW nuclease resistance; ICAM-1; human; antisense; antiinflammatory;
 KW inflammation; therapy; ss.
 XX
 OS Synthetic.
 XX

Key Location/Qualifiers
 1. .20
 FT modified_base /tag= u
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages"
 FT modified_base 1
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-thymidine"
 FT modified_base 2
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-5-methylcytidine"
 FT modified_base 3
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-thymidine"
 FT modified_base 4
 FT /tag= d
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-guanosine"
 FT modified_base 5
 FT /tag= e
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-adenosine"
 FT modified_base 6
 FT /tag= f
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-guanosine"
 FT modified_base 7
 FT /tag= g
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-thymidine"
 FT modified_base 8
 FT /tag= h
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-adenosine"
 FT modified_base 9
 FT /tag= i
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-guanosine"
 FT modified_base 10
 FT /tag= j
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-5-methylcytidine"
 FT modified_base 11
 FT /tag= k
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-adenosine"
 FT modified_base 12

FT /tag= l
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-guanosine"
 FT modified_base 13
 FT /tag= m
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-adenosine"
 FT modified_base 14
 FT /tag= n
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-guanosine"
 FT modified_base 15
 FT /tag= o
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-guanosine"
 FT modified_base 16
 FT /tag= p
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-adenosine"
 FT modified_base 17
 FT /tag= q
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-guanosine"
 FT modified_base 18
 FT /tag= r
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-5-methylcytidine"
 FT modified_base 19
 FT /tag= s
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-thymidine"
 FT modified_base 20
 FT /tag= t
 FT /mod_base= OTHER
 FT /note= "2'-O-CH2-CH2-O-CH3-cytidine"
 FT XX
 PN W0200003720-A1.
 XX
 PD 27-JAN-2000.
 XX
 PF 07-JUL-1999; 99WO-US015347.
 XX
 PR 14-JUL-1998; 98US-00115025.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Manoharan M;
 XX
 DR WPI; 2000-182334/16.
 XX
 PT Oligonucleotides containing segments of alternate phosphate and
 PT phosphorothioate internucleoside linkages, used in treating, e.g.
 PT inflammatory disorders.
 XX
 PS Example 3; Page 53; 77pp; English.
 XX
 CC The present sequence is that of oligonucleotide 15537. The
 CC oligonucleotide consists of 2'-modified nucleosides connected by
 CC phosphorothioate linkages. It is capable of modulating the activity of
 CC human ICAM-1, and hence may be useful as an antiinflammatory agent. The
 CC presence of phosphorothioate linkages provides resistance to nucleases.
 CC The invention relates to novel oligonucleotides that mimic and/or
 CC modulate the activity of wild-type nucleic acids. The oligonucleotides
 CC generally contain at least 1 region of 2'-modified nucleosides connected
 CC by alternating phosphodiester and phosphorothioate linkages (see also
 CC AAZ58227). They are antisense to a DNA or RNA segment and modulate the
 CC production and activity of a particular protein which may be undesired
 CC and lead to a disease
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;


```
Matches 20; Conservative 0; Mismatches 0; Indels 0; Caps 0;

Qy 18 GAGCTGCTGCTACTCAGA 37
Db |||||
20 GAGCTGCTGCTACTCAGA 1

RESULT 398
AAZ58229/c
ID AAZ58229 standard; DNA; 20 BP.
XX AC
XX AAZ58229;
XX DT
XX 23-MAY-2000 (first entry)
XX ICAM-1 targeted PS/PO oligonucleotide 25303.
XX
KW 2'-Modified oligonucleotide; phosphorothioate linkage;
KW nuclease resistance; ICAM-1; human; antisense; antiinflammatory;
KW inflammation; therapy; ss.
XX Synthetic.
XX Key
FH Location/Qualifiers
FT modified_base 1..2
FT /tag= n
FT /note= "phosphorothioate linkage"
FT modified_base 2..3
FT /tag= o
FT /note= "phosphorothioate linkage"
FT modified_base 2
FT /tag= a
FT /mod_base= OTHER
FT /note= "5-methylcytidine"
FT modified_base 3..4
FT /tag= p
FT /note= "phosphorothioate linkage"
FT modified_base 3
FT /tag= b
FT /mod_base= OTHER
FT /note= "5-methylcytidine"
FT modified_base 4..5
FT /tag= g
FT /note= "phosphorothioate linkage"
FT modified_base 4
FT /tag= c
FT /mod_base= OTHER
FT /note= "5-methylcytidine"
FT modified_base 5..6
FT /tag= r
FT /note= "phosphorothioate linkage"
FT modified_base 6..7
FT /tag= s
FT /note= "phosphorothioate linkage"
FT modified_base 7..8
FT /tag= t
FT /note= "phosphorothioate linkage"
FT modified_base 8..9
FT /tag= u
FT /note= "phosphorothioate linkage"
FT modified_base 8
FT /tag= d
FT /mod_base= OTHER
FT /note= "5-methylcytidine"
FT modified_base 9..10
FT /tag= v
FT /note= "phosphorothioate linkage"
FT modified_base 10..11
FT /tag= w
FT /note= "phosphorothioate linkage"
FT modified_base 11..12
FT /tag= x
FT /note= "phosphorothioate linkage"
```

```
12 modified_base /tag= e
FT /mod_base= OTHER
FT /note= "5-methylcytidine"
13..14 modified_base
FT /tag= y
FT /note= "phosphorothioate linkage"
13 modified_base
FT /tag= f
FT /mod_base= OTHER
FT /note= "2'-O-CH2-CH2-O-CH3-adenosine"
14 modified_base
FT /tag= g
FT /mod_base= OTHER
FT /note= "2'-O-CH2-CH2-O-CH3-thymidine"
15..16 modified_base
FT /tag= z
FT /note= "phosphorothioate linkage"
15 modified_base
FT /tag= h
FT /mod_base= OTHER
FT /note= "2'-O-CH2-CH2-O-CH3-5-methylcytidine"
16 modified_base
FT /tag= i
FT /mod_base= OTHER
FT /note= "2'-O-CH2-CH2-O-CH3-5-methylcytidine"
17..18 modified_base
FT /tag= aa
FT /note= "phosphorothioate linkage"
17 modified_base
FT /tag= j
FT /mod_base= OTHER
FT /note= "2'-O-CH2-CH2-O-CH3-guanosine"
18 modified_base
FT /tag= k
FT /mod_base= OTHER
FT /note= "2'-O-CH2-CH2-O-CH3-thymidine"
19..20 modified_base
FT /tag= ab
FT /note= "phosphorothioate linkage"
19 modified_base
FT /tag= l
FT /mod_base= OTHER
FT /note= "2'-O-CH2-CH2-O-CH3-5-methylcytidine"
20 modified_base
FT /tag= m
FT /mod_base= OTHER
FT /note= "2'-O-CH2-CH2-O-CH3-adenosine"

WO200003720-A1.
27-JAN-2000.
XX
XX 07-JUL-1999; 99WO-US015347.
XX
XX 14-JUL-1998; 98US-00115025.
XX
XX (ISIS-) ISIS PHARM INC.
XX Manoharan M;
XX WPI; 2000-182334/16.
XX
XX Oligonucleotides containing segments of alternate phosphate and
XX phosphorothioate internucleoside linkages, used in treating, e.g.
XX inflammatory disorders.
XX
XX Example 1; Page 50; 77pp; English.
XX
XX The present sequence is that of nuclease resistant oligonucleotide 25303.
XX The oligonucleotide consists of 2'-modified nucleosides connected by
XX phosphodiester and regions of phosphorothioate linkages. The
XX oligonucleotide is capable of modulating the activity of human ICAM-1 and
```

CC can be used as an antiinflammatory agent. The present sequence is an
 CC example of novel oligonucleotides of the invention that mimic and/or
 CC modulate the activity of wild-type nucleic acids. The oligonucleotides
 CC are antisense to a DNA or RNA segment and modulate the production and
 CC activity of a particular protein which may be undesired and lead to a
 CC disease

XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119

Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 399

AAZ58227/c

ID AAZ58227 standard; DNA; 20 BP.

AC AAZ58227;

XX 23-MAY-2000 (first entry)

DE ICAM-1 targeted PS/PO oligonucleotide 18268.

XX 2'-Modified oligonucleotide; phosphorothioate linkage;
 KW nuclease resistance; ICAM-1; human; antisense; antiinflammatory;
 KW inflammation; therapy; ss.

XX Synthetic.

PH Key Location/Qualifiers

FT modified_base	1..2	/tag= u	/note= "phosphorothioate linkage"
FT modified_base	1	/tag= a	/mod_base= OTHER
FT modified_base	2	/note= "2'-O-CH2-CH2-O-CH3-thymidine"	
FT modified_base	3..4	/tag= b	/mod_base= OTHER
FT modified_base	3	/note= "2'-O-CH2-CH2-O-CH3-5-methylcytidine"	
FT modified_base	4	/tag= v	/note= "phosphorothioate linkage"
FT modified_base	5	/tag= c	/mod_base= OTHER
FT modified_base	6	/note= "2'-O-CH2-CH2-O-CH3-thymidine"	
FT modified_base	7	/tag= d	/mod_base= OTHER
FT modified_base	8	/note= "2'-O-CH2-CH2-O-CH3-guanosine"	
FT modified_base	9	/tag= w	/note= "phosphorothioate linkage"
FT modified_base	10	/tag= e	/mod_base= OTHER
FT modified_base	11	/note= "2'-O-CH2-CH2-O-CH3-adenosine"	
FT modified_base	12	/tag= f	/mod_base= OTHER
FT modified_base	13	/note= "2'-O-CH2-CH2-O-CH3-guanosine"	
FT modified_base	14	/tag= x	/note= "phosphorothioate linkage"
FT modified_base	15	/tag= g	

FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-thymidine"
FT	/tag= h
FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-adenosine"
FT	/tag= .10
FT	/note= "phosphorothioate linkage"
FT	/tag= i
FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-guanosine"
FT	/tag= j
FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-5-methylcytidine"
FT	/tag= z
FT	/note= "phosphorothioate linkage"
FT	/tag= k
FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-adenosine"
FT	/tag= l
FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-guanosine"
FT	/tag= aa
FT	/note= "phosphorothioate linkage"
FT	/tag= m
FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-adenosine"
FT	/tag= n
FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-guanosine"
FT	/tag= ab
FT	/note= "phosphorothioate linkage"
FT	/tag= o
FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-guanosine"
FT	/tag= p
FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-adenosine"
FT	/tag= ac
FT	/note= "phosphorothioate linkage"
FT	/tag= q
FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-guanosine"
FT	/tag= r
FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-5-methylcytidine"
FT	/tag= ad
FT	/note= "phosphorothioate linkage"
FT	/tag= s
FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-thymidine"
FT	/tag= t
FT	/mod_base= OTHER
FT	/note= "2'-O-CH2-CH2-O-CH3-cytidine"
XX	

```

PN WO200003720-A1.
XX
PD
XX
XX
PF
XX
PR 07-JUL-1999; 99WO-US015347.
XX
PR 14-JUL-1998; 98US-00115025.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Manoharan M;
PI
XX
XX WPI; 2000-182334/16.
DR
XX
XX
PT Oligonucleotides containing segments of alternate phosphate and
PT phosphorothioate internucleoside linkages, used in treating, e.g.
PT inflammatory disorders.
XX
XX
PS Example 1; Page 50; 77pp; English.
XX
CC The present sequence is that of nuclease resistant oligonucleotide 18268.
CC The oligonucleotide consists of 2'-modified nucleosides connected by
CC alternating phosphodiester and phosphorothioate linkages. The
CC oligonucleotide is capable of modulating the activity of human ICAM-1 and
CC can be used as an antiinflammatory agent. The present sequence is an
CC example of novel oligonucleotides of the invention that mimic and/or
CC modulate the activity of wild-type nucleic acids. The oligonucleotides
CC are antisense to a DNA or RNA segment and modulate the production and
CC activity of a particular protein which may be undesired and lead to a
CC disease
XX
XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 400
AAZ58230/C.
ID AAZ58230 standard; DNA; 20 BP.
XX
XX AC
XX AAZ58230;
XX
XX 23-MAY-2000 (first entry)
XX
XX ICAM-1 targeted PS/PO oligonucleotide 16952.
DE
XX
XX 2'-Modified oligonucleotide; phosphorothioate linkage;
KW nuclease resistance; ICAM-1; human; antisense; antiinflammatory;
KW inflammation; therapy; ss.
XX
XX Synthetic.
OS
XX
XX
FH Key Location/Qualifiers
FT modified_base 1 /*tag= a
FT /*mod_base= OTHER
FT /*note= "2'-O-CH2-CH2-O-CH3-thymidine"
FT modified_base 2 /*tag= b
FT /*mod_base= OTHER
FT /*note= "2'-O-CH2-CH2-O-CH3-5-methylcytidine"
FT modified_base 3 /*tag= c
FT /*mod_base= OTHER
FT /*note= "2'-O-CH2-CH2-O-CH3-thymidine"
FT modified_base 4 /*tag= d

/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-guanosine"
5
/*tag= e
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-adenosine"
6
/*tag= f
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-guanosine"
7
/*tag= g
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-thymidine"
8
/*tag= h
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-adenosine"
9
/*tag= i
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-guanosine"
10
/*tag= j
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-5-methylcytidine"
11
/*tag= k
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-adenosine"
12
/*tag= l
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-guanosine"
13
/*tag= m
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-adenosine"
14
/*tag= n
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-guanosine"
15
/*tag= o
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-guanosine"
16
/*tag= p
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-adenosine"
17
/*tag= q
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-guanosine"
18
/*tag= r
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-5-methylcytidine"
19
/*tag= s
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-thymidine"
20
/*tag= t
/mod_base= OTHER
/*note= "2'-O-CH2-CH2-O-CH3-cytidine"

WO200003720-A1.
XX
XX 27-JAN-2000.
XX
XX 07-JUL-1999; 99WO-US015347.
XX

```

```

PR 14-JUL-1998; 98US-00115025.
XX (ISIS-) ISIS PHARM INC.
XX Manoharan M;
XX WPI; 2000-182334/16.
XX Oligonucleotides containing segments of alternate phosphate and
PT phosphorothioate internucleoside linkages, used in treating, e.g.
PT inflammatory disorders.
XX Example 3; Page 53; 77pp; English.
XX The present sequence is that of oligonucleotide 16952. The
CC oligonucleotide consists of 2'-modified nucleosides connected by
CC phosphodiester linkages. It is capable of modulating the activity of
CC human ICAM-1. Such oligonucleotides have potential use as
CC anti-inflammatory agents. The invention relates to novel oligonucleotides
CC that mimic and/or modulate the activity of wild-type nucleic acids. The
CC oligonucleotides generally contain at least 1 region of 2'-modified
CC nucleosides connected by alternating phosphodiester and phosphorothioate
CC linkages (see also AA258227). They are antisense to a DNA or RNA segment
CC and modulate the production and activity of a particular protein which
CC may be undesired and lead to a disease
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCTCTGCTACTCAGA 37
DB 20 GAGCTCTCTGCTACTCAGA 1
RESULT 401
AA257446/c
ID AA257446 standard; DNA; 20 BP.
XX AA257446;
XX 10-APR-2000 (first entry)
XX Phosphorothioate oligonucleotide SEQ ID NO:5.
XX Phosphorothioate; antisense oligonucleotide; triester oligonucleotide;
KW bioreversible phosphate blocking group; therapeutic; diagnosis; ss.
XX Synthetic.
XX Key Location/Qualifiers
FT modified_base 1..18
FT /*tag= a
FT /note= "phosphorothioate linkages"
XX WO9964434-A1.
XX 16-DEC-1999.
XX 10-JUN-1999; 99WO-US013141.
XX 11-JUN-1998; 98US-00095822.
XX (ISIS-) ISIS PHARM INC.
XX Manoharan M, Guzaev A;
XX WPI; 2000-116518/10.
XX Oligonucleotide bioreversible phosphate esters used as, e.g. research
PT agents.

```

```

XX Example 5; Page 35; 61pp; English.
XX The present invention describes oligonucleotides containing bioreversible
XX phosphate ester groups and their mimetics. The oligonucleotides are of
XX value in therapeutics, diagnostics, and as research reagents. The
XX compound from the present invention may be used in control of hereditary,
XX metabolic, and/or cellular processes in any organism utilizing DNA-RNA
XX transcription and/or RNA-protein translation. These organisms include
XX prokaryotic and eukaryotic unicellular and multicellular organisms;
XX including bacteria, yeasts, protozoa, algae, and all plants and higher
XX animal forms, including warm blooded animals, particularly humans; also
XX organelle sub-cellular translation and transcription processes. The new
XX synthetic process provides pro-oligonucleotides, i.e., oligonucleotides
XX blocked at phosphate groups by bioreversible groups which can be cleaved
XX by intracellular and intercellular enzymes to generate an active
XX oligonucleotide, as for prodrugs and drugs. By careful selection of
XX protecting groups, deprotection of nucleobases and partial deprotection
XX of phosphate linkages can be achieved in the reaction sequence. Suggested
XX specific groups include S-pivaloylmercaptosethyl (SPME) and
XX cyanoethylcarbonyl (CEOC) groups. Spacer molecules include diglycolyl
XX (COCH22OCH22CO) and its analogue with a catechol biresidue replacing the
XX oxygen atom (1,2-phenylenedioxy-diacetic acid). The present sequence
XX represents a phosphorothioate oligonucleotide used in the exemplification
XX of the present invention
XX
XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGGAAGTGGTGGGG 1957
DB 20 GAGAGGGGGAAGTGGTGGGG 1
RESULT 402
AA96410/c
ID AAA96410 standard; DNA; 20 BP.
XX AAA96410;
XX 08-FEB-2001 (first entry)
XX Primer used to amplify a sara43/44 polymorphic microsatellite repeat.
XX Autoimmune disease; polymorphic microsatellite repeat; PMR; CD28 gene;
KW ICOS gene; CTLA4 gene; costimulatory receptor gene locus; CGRL; lupus;
KW insulin-dependent diabetes mellitus; IDDM; Addison's disease; leprosy;
KW Graves disease; autoimmune hypothyroidism; myasthenia gravis; thymoma;
KW thyroiditis; postpartum thyroiditis; rheumatoid arthritis;
KW Hashimoto's disease; coeliac disease; PCR primer; ss.
XX Homo sapiens.
XX WO200056856-A2.
XX 28-SEP-2000.
XX 24-MAR-2000; 2000WO-US007938.
XX 25-MAR-1999; 99US-0126215P.
XX (GEMY ) GENETICS INST INC.
XX Ling V, Wu P, Gray GS;
XX WPI; 2000-628257/60.
XX Determining predisposition of humans to develop autoimmune disease
PT involves detecting polymorphic microsatellite repeat sequence within
PT human costimulatory receptor gene locus.

```

XX PS Claim 18; Page 154; 160pp; English.

XX CC PCR primers AAA96409-10 were used to amplify polymorphic microsatellite repeat (PMR) sequences from the human costimulatory receptor gene locus (hCGR). The primers are used in the method of the invention. The CC CC specification describes a method for determining the predisposition of a human subject to develop autoimmune disease. The method comprises CC CC detecting a PMR sequence in the CD28, ICOS gene or CTLA4 gene of the CC CC length among individuals and can be amplified to generate products that CC CC differ in size. These products can then be detected by rapid and CC CC convenient high resolution processes. The method is useful for CC CC determining the predisposition of insulin-dependent diabetes mellitus (IDDM), Addison's disease, Graves disease, autoimmune hypothyroidism, CC CC myasthenia gravis, thymoma, lupus, thyroiditis, postpartum thyroiditis, CC CC rheumatoid arthritis, Hashimoto's disease, coeliac disease and leprosy. CC CC PMR sequences within hCGR are useful as markers in a variety of assays CC CC and in the field of forensic medicine, disease diagnosis and human genome CC CC mapping

XX SQ Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTCAGTGG 2790

Db 20 CCCAGGCTGGAGTCAGTGG 1

RESULT 403

AAZ90212/c

ID AAZ90212 standard; DNA; 20 BP.

XX AC AAZ90212;

XX DT 22-MAY-2000 (first entry)

XX DE Phosphorothioate human ICAM-1 antisense oligonucleotide, SEQ ID NO:1.

XX KW Phosphorothioate; chiral; nuclease resistant; Sp enantiomer; Rp; diagnosis; prophylaxis; therapy; antisense; human; ICAM-1; inflammatory disorder; ss.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /tag= a

FT /note= "Phosphorothioate linkages"

FT modified_base 1..2

FT /tag= b

FT /note= "Optionally the phosphorothioate linkage is the Sp enantiomer"

FT modified_base 2..19

FT /tag= c

FT /note= "Optionally the phosphorothioate linkage is the Rp enantiomer"

FT modified_base 19..20

FT /tag= d

FT /note= "Optionally the phosphorothioate linkage is the Sp enantiomer"

XX WO200004034-A2.

XX PD 27-JAN-2000.

XX PF 14-JUL-1999; 99WO-US015960.

XX PR 14-JUL-1998; 98US-00115027.

PA (ISIS-) ISIS PHARM INC.

XX PI Cook PD, Manoharan M;

XX DR WPI; 2000-182393/16.

XX PT Oligonucleotides having chiral R- and S- phosphorothioate internucleoside linkage regions, used as, e.g. antisense agents in therapy and diagnostics.

XX PS Example 32; Page 76; 116pp; English.

XX CC The invention relates to oligonucleotides having chiral R- and S- phosphorothioate internucleoside linkage regions, and their chiral intermediates. The oligonucleotides of the invention are particularly CC CC phosphorothioate nucleotides wherein the 5' and 3' terminal internucleoside linkages are chirally Sp and the internal internucleoside linkages are Rp. The oligonucleotides of the invention have increased CC CC stability relative to phosphodiester nucleotides as they are not CC CC recognised by extracellular and intracellular nucleases. The CC CC phosphorothioate nucleotides are of value as therapeutic, prophylactic and diagnostic agents, optionally as kits, for clinical disorders, and as CC CC research tools (e.g., for mutagenesis, or for forensic investigation). CC CC Oligonucleotides targetted against ICAM-1, VCAM-1, and ELAM-1 may be used in the treatment of inflammatory disorders such as psoriasis, lichen CC CC planus, contact dermatitis, and drug eruption. Those targetted against protein kinase C may be used to inhibit cell proliferation, tumorigenesis CC CC and metastasis. The oligonucleotides may also be of value in antiviral CC CC and antifungal applications e.g., for the treatment of HIV infection and Lyme disease. Sequences AAZ90212-290217 are oligonucleotides used in an CC CC exemplification of the present invention. They are respectively targetted CC CC against genes encoding human ICAM-1, human H-ras, human protein kinase alpha (PKC alpha), human C-ras, hepatitis C virus and murine ICAM-1

XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 404

AAA40808/c

ID AAA40808 standard; DNA; 20 BP.

XX AC AAA40808;

XX DT 16-AUG-2000 (first entry)

XX DE Human TNFalpha antisense oligonucleotide ISIS# 13393.

XX KW Antisense oligonucleotide; phosphorothioate; TNFalpha; cytokine; inhibit; tumour necrosis factor alpha; inflammatory bowel disease; diabetes; CC CC rheumatoid arthritis; infectious disease; multiple sclerosis; hepatitis; CC CC pancreatitis; atopic dermatitis; allograft rejection; autoimmune disease; CC CC inflammatory disease; ss.

XX OS Synthetic.

XX WO2000020645-A1.

XX PD 13-APR-2000.

XX PF 05-OCT-1999; 99WO-US023205.

XX PR 05-OCT-1998; 98US-00166186.

XX PR 18-MAY-1999; 99US-00313932.

XX PA (ISIS-) ISIS PHARM INC.

XX Baker BF, Bennett CF, Butler MM, Shanahan WJ;
 XX WPI; 2000-303808/26.
 XX
 XX Oligonucleotide for treating diseases associated with human tumor
 PT necrosis factor-alpha (TNF-alpha) such as, diabetes and rheumatoid
 PT arthritis, comprises nucleotide sequence complementary to intron of
 PT nucleic acid encoding TNF-alpha.
 XX
 XX Example 6; Page 56; 283pp; English.
 XX
 CC This sequence represents an antisense oligonucleotide sequence which
 CC targets a region of the human tumor necrosis factor alpha (TNFalpha)
 CC nucleotide sequence. TNFalpha is an important cytokine that plays a role
 CC in host defence. It is produced mainly in macrophages and monocytes in
 CC response to infection, invasion, injury or inflammation. Overexpression
 CC of TNFalpha can result in disease states, particularly in infectious,
 CC inflammatory and autoimmune diseases. The invention relates to antisense
 CC oligonucleotides, such as that represented by the present sequence which
 CC are capable of modulating the TNFalpha gene expression. The
 CC oligonucleotides optionally have a phosphorothioate backbone, and may
 CC also optionally contain at least one 2'-O-methoxyethyl modification. The
 CC oligonucleotides are useful for modulating the expression of human
 CC TNFalpha in cells and tissues, reducing a human cell inflammatory
 CC response, reducing the blood glucose level in a human and treating a
 CC human having a disease or condition associated with TNFalpha. Examples of
 CC diseases associated with TNFalpha include diabetes, inflammatory bowel
 CC disease, multiple sclerosis, pancreatitis, rheumatoid arthritis,
 CC infectious disease, hepatitis, atopic dermatitis or allograft rejection.
 CC The antisense oligonucleotides are also useful for modulating the
 CC function of a selected nucleic acid sequence in adipose tissue
 XX
 XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 18 GAGCTCTCTGCTACTCAGA 37
 |||||
 DB 20 GAGCTCTCTGCTACTCAGA 1
 RESULT 405
 AAA40800/c
 ID AAA40800 standard; DNA; 20 BP.
 XX
 AC AAA40800;
 XX
 DT 16-AUG-2000 (first entry)
 XX
 DE Control antisense oligonucleotide.
 XX
 KW Antisense oligonucleotide; phosphorothioate; TNFalpha; cytokine; inhibit;
 KW tumour necrosis factor alpha; inflammatory bowel disease; diabetes;
 KW rheumatoid arthritis; infectious disease; multiple sclerosis; hepatitis;
 KW pancreatitis; atopic dermatitis; allograft rejection; autoimmune disease;
 KW inflammatory disease; ss.
 XX
 OS Synthetic.
 XX
 XX WO200020645-A1.
 PN 13-APR-2000.
 PD
 XX 05-OCT-1999; 99WO-US023205.
 PF
 XX 05-OCT-1998; 98US-00166186.
 PR
 PR 18-MAY-1999; 99US-00313932.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX

PI Baker BF, Bennett CF, Butler MM, Shanahan WJ;
 XX WPI; 2000-303808/26.
 XX
 XX Oligonucleotide for treating diseases associated with human tumor
 PT necrosis factor-alpha (TNF-alpha) such as, diabetes and rheumatoid
 PT arthritis, comprises nucleotide sequence complementary to intron of
 PT nucleic acid encoding TNF-alpha.
 XX
 XX Example 2; Page 40; 283pp; English.
 XX
 CC Tumour necrosis factor alpha (TNFalpha) is an important cytokine that
 CC plays a role in host defence. It is produced mainly in macrophages and
 CC monocytes in response to infection, invasion, injury or inflammation.
 CC Overexpression of TNFalpha can result in disease states, particularly in
 CC infectious, inflammatory and autoimmune diseases. The invention relates
 CC to antisense oligonucleotides which are capable of modulating the
 CC TNFalpha gene expression. The present sequence represents a control
 CC antisense oligonucleotide used in an example of the invention. The
 CC oligonucleotides optionally have a phosphorothioate backbone, and may
 CC also optionally contain at least one 2'-O-methoxyethyl modification. The
 CC oligonucleotides are useful for modulating the expression of human
 CC TNFalpha in cells and tissues, reducing a human cell inflammatory
 CC response, reducing the blood glucose level in a human and treating a
 CC human having a disease or condition associated with TNFalpha. Examples of
 CC diseases associated with TNFalpha include diabetes, inflammatory bowel
 CC disease, multiple sclerosis, pancreatitis, rheumatoid arthritis,
 CC infectious disease, hepatitis, atopic dermatitis or allograft rejection.
 CC The antisense oligonucleotides are also useful for modulating the
 CC function of a selected nucleic acid sequence in adipose tissue
 XX
 XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 |||||
 DB 20 TGACGGATGCCAGCTTGGGC 1
 RESULT 406
 AAZ95215/c
 ID AAZ95215 standard; DNA; 20 BP.
 XX
 AC AAZ95215;
 XX
 DT 05-JUN-2000 (first entry)
 XX
 DE 2'-modified oligonucleotide #2 targetting human ICAM-1.
 XX
 KW 2'-modified oligonucleotide; increase binding affinity; diagnostic;
 KW therapeutic; hepatitis C infection; ICAM-1; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20 /tag= a
 FT /mod_base= OTHER
 FT /note= "All phosphorothioate internucleoside linkages, C
 FT is 5-methyl C"
 FT modified_base 13..20 /tag= b
 FT /mod_base= OTHER
 FT /note= "A, T and G are 2-O-(trans-2-methoxycyclohexyl)
 FT nucleosides"
 XX
 PN WO200006590-A1.
 XX
 XX 10-FEB-2000.
 PD
 XX

PF 21-JUL-1999; 99WO-US016541.
 XX
 PR 27-JUL-1998; 98US-00123108.
 XX
 PA (ISIS-) ISIS PHARM INC.
 PI Manoharan M, Mohan V, Boswell H;
 XX WPI; 2000-183089/16.
 DR
 XX New nucleosides and oligonucleotides have increased binding affinity or
 PT nucleases resistance useful e.g. for treating hepatitis C.
 PT
 PS Example 15; Page 36; 59pp; English.
 XX
 CC This sequence represents an antisense 2'-modified oligonucleotide,
 CC targetting human ICAM-1. The invention relates to 2'-modified
 CC oligonucleotide compounds comprising at least one 2'-O-modified ribosyl
 CC nucleoside. The modified oligonucleotides have increased binding affinity
 CC for target RNA and/or nuclease resistance and can be used in diagnostics,
 CC therapeutics and as research agents e.g. for antisense oligonucleotide
 CC therapy of hepatitis C viral infections
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTGGGC 2119
 DB 20 TGACGGATGCCAGCTGGGC 1
 RESULT 407
 AAZ95212/c
 ID AAZ95212 standard; DNA; 20 BP.
 XX
 AC AAZ95212;
 XX
 DT 05-JUN-2000 (first entry)
 XX
 DE 2'-modified oligonucleotide targetting human ICAM-1.
 XX
 KW 2'-modified oligonucleotide; increase binding affinity; diagnostic;
 KW therapeutic; hepatitis C infection; ICAM-1; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /note= "Optionally all phosphorothioate internucleoside
 FT linkages 'A', 'T', and 'G' are 2'-O-(trans-2-methoxycyclohexyl)
 FT nucleosides and 'C' is 5-methyl-'C"
 XX
 PN WO200006590-A1.
 XX
 PD 10-FEB-2000.
 XX
 PF 21-JUL-1999; 99WO-US016541.
 XX
 PR 27-JUL-1998; 98US-00123108.
 XX
 PA (ISIS-) ISIS PHARM INC.
 PI Manoharan M, Mohan V, Boswell H;
 XX WPI; 2000-183089/16.
 DR
 XX New nucleosides and oligonucleotides have increased binding affinity or
 PT nucleases resistance useful e.g. for treating hepatitis C.
 PT

XX Example 15; Page 36; 59pp; English.
 PS
 XX
 CC This sequence represents an antisense 2'-modified oligonucleotide,
 CC targetting human ICAM-1. The invention relates to 2'-modified
 CC oligonucleotide compounds comprising at least one 2'-O-modified ribosyl
 CC nucleoside. The modified oligonucleotides have increased binding affinity
 CC for target RNA and/or nuclease resistance and can be used in diagnostics,
 CC therapeutics and as research agents e.g. for antisense oligonucleotide
 CC therapy of hepatitis C viral infections
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 18 GAGCTCCTCTGCTACTCAGA 37
 DB 20 GAGCTCCTCTGCTACTCAGA 1
 RESULT 408
 AAA58396/c
 ID AAA58396 standard; DNA; 20 BP.
 XX
 AC AAA58396;
 XX
 DT 17-JAN-2001 (first entry)
 XX
 DE Synthetic 3'-P-O-allyl amidite derived oligonucleotide # 6.
 XX
 KW 3'-P-O-allyl amidite derived oligonucleotide; oligonucleotide synthesis;
 KW ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /note= "All are phosphorothioate deoxynucleotides"
 XX
 PN WO200027859-A1.
 XX
 PD 18-MAY-2000.
 XX
 PF 29-OCT-1999; 99WO-US025476.
 XX
 PR 06-NOV-1998; 98US-00187995.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA Manoharan M;
 PI WPI; 2000-387403/33.
 DR
 XX Method of preparing oligomeric compounds containing a phosphodiester or
 PT phosphorothioate linkage uses a mixture of ammonium hydroxide and a thiol
 PT in the deblocking step.
 XX
 PS Example 1; Page 27; 40pp; English.
 XX
 CC The present sequence is a synthetic 3'-P-O-allyl amidite derived
 CC oligonucleotide. This sequence was synthesised using the method of the
 CC present invention by which oligomeric compounds which have a
 CC phosphodiester or phosphorothioate backbone can be prepared. The method
 CC involves using either ammonium hydroxide and a thiol compound during a
 CC deblocking step of all or selected internucleoside linkages, or a
 CC mercapto compound in an aqueous amine followed by ammonium hydroxide
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;

```

XX
KW Oligomeric compound; 2'-O-modified ribosyl nucleoside;
KW human intracellular adhesion molecule 1; ICAM-1; 3' endo geometry;
KW nuclease resistance; phosphorothioate; phosphodiester; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /note= "2'-O-[2-(2-N,N-dimethylaminoethyl)oxyethyl]-5-
FT methyl nucleosides"
FT misc_feature 1..20
FT /*tag= b
FT /note= "nucleosides linked by phosphorothioate linkages
FT or phosphodiester linkages"
FT modified_base 2
FT /*tag= c
FT /note= "5-methyl-C"
FT modified_base 10
FT /*tag= c
FT /note= "5-methyl-C"
FT modified_base 18
FT /*tag= c
FT /note= "5-methyl-C"
XX
XX WO200008044-A1.
XX
XX 17-FEB-2000.
XX
XX 06-AUG-1999; 99WO-US017895.
XX
XX 07-AUG-1998; 98US-00130566.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Manoharan M, Cook PD;
XX
XX WPI; 2000-205668/18.
XX
XX Novel 2'-O-aminoethyloxyethyl modified nucleosides and oligonucleotides
XX used in diagnostic, therapeutic and research reagents.
XX
XX Disclosure; Page 43; 60pp; English.
XX
XX The present sequence represents an oligomeric compound containing 2'-O-
XX modified ribosyl nucleosides. The oligomeric compound is directed to
XX human intracellular adhesion molecule (ICAM)-1. The 2'-O-modified
XX nucleosides include ring structures that position the sugar moiety of the
XX nucleosides preferentially in 3' endo geometries. The modified oligomeric
XX compounds have increased binding affinity and increased nuclease
XX resistance. The oligomeric compounds can be used in diagnostic,
XX therapeutic and research reagents
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 18 GAGCTCCTCTGCTACTCAGA 37
XX ||||||||||||||||
XX Db 20 GAGCTCCTCTGCTACTCAGA 1
XX
XX RESULT 411
XX AAZ61389/C
XX ID AAZ61389 standard; DNA; 20 BP.
XX
XX AC AAZ61387;
XX
XX 19-JUN-2000 (first entry)
XX
XX 2'-O-modified ribosyl oligonucleotide directed against ICAM-1.
XX

```

```

XX
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2100 TGACGGATGCCAGCTTGGGC 2119
XX ||||||||||||||||
XX Db 20 TGACGGATGCCAGCTTGGGC 1
XX
XX RESULT 409
XX AAZ59000/C
XX ID AAZ59000 standard; DNA; 20 BP.
XX
XX AC AAZ59000;
XX
XX 12-MAY-2000 (first entry)
XX
XX Sequence of a phosphorothioate oligonucleotide.
XX
XX Linker arm; solid-phase oligonucleotide synthesis; ss.
XX
XX Synthetic.
XX
XX WO200001711-A1.
XX
XX 13-JAN-2000.
XX
XX 30-JUN-1999; 99WO-CA000600.
XX
XX 02-JUL-1998; 98CA-02242649.
XX
XX 02-JUL-1998; 98US-0091683P.
XX
XX (UYTE-) UNIV TECHNOLOGIES INT INC.
XX
XX Pon RT, Yu S;
XX
XX WPI; 2000-170995/15.
XX
XX Resuable linker arm for solid-phase oligonucleotide synthesis, is
XX attached through hydroxy group.
XX
XX Example 4; Page 35; 91pp; English.
XX
XX The invention provides a reusable linker arm for solid-phase
XX oligonucleotide synthesis. The linker arm has the formula (nt) n'-Z-O-T-
XX Support; where n' = 0 or 1; Z = linker; T = organic radical and nt =
XX nucleoside. The use of a hydroxy-functionalized support provides a linker
XX arm that can be regenerated and used repeatedly. Unlike known reusable
XX arms (WO 9723496) preparation of the present reusable linker arm does not
XX require a two-stage derivatization of the support and they have better
XX resistance against partial cleavage during regeneration. The present
XX sequence represents a phosphorothioate oligonucleotide synthesised during
XX the course of the invention
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2100 TGACGGATGCCAGCTTGGGC 2119
XX ||||||||||||||||
XX Db 20 TGACGGATGCCAGCTTGGGC 1
XX
XX RESULT 410
XX AAZ61387/C
XX ID AAZ61387 standard; DNA; 20 BP.
XX
XX AC AAZ61387;
XX
XX 19-JUN-2000 (first entry)
XX
XX 2'-O-modified ribosyl oligonucleotide directed against ICAM-1.
XX

```


DE 2'-O-modified ribosyl oligonucleotide directed against ICAM-1.
XX
KW Oligomeric compound; 2'-O-modified ribosyl nucleoside;
KW human intracellular adhesion molecule 1; ICAM-1; 3' endo geometry;
KW nuclease resistance; phosphorothioate; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT misc_feature 1..20
FT /tag= a
FT /note= "nucleosides linked by phosphorothioate linkages
FT or phosphodiester linkages"
FT modified_base 2
FT /tag= b
FT /note= "5-methyl-C"
FT modified_base 3
FT /tag= c
FT /note= "5-methyl-C"
FT modified_base 4
FT /tag= d
FT /note= "5-methyl-C"
FT modified_base 8
FT /tag= e
FT /note= "5-methyl-C"
FT modified_base 12
FT /tag= f
FT /note= "5-methyl-C"
FT modified_base 13..20
FT /tag= g
FT /note= "2'-O-[2-(2-N,N-dimethylaminoethyl)oxyethyl]-5-
FT methyl nucleosides"
FT modified_base 15
FT /tag= h
FT /note= "5-methyl-C"
FT modified_base 16
FT /tag= i
FT /note= "5-methyl-C"
FT modified_base 20
FT /tag= j
FT /note= "5-methyl-C"
XX WO200008044-A1.
XX
XX 17-FEB-2000.
XX
XX 06-AUG-1999; 99WO-US017895.
XX
XX 07-AUG-1998; 98US-00130566.
XX
XX (ISIS-) ISIS PHARM INC.
XX Manoharan M, Cook PD;
XX WPI; 2000-205668/18.
XX
XX Novel 2'-O-aminoethyloxyethyl modified nucleosides and oligonucleotides
XX used in diagnostic, therapeutic and research reagents.
XX
XX Disclosure; Page 43; 60pp; English.
XX
XX The present sequence represents an oligomeric compound containing 2'-O-
XX modified ribosyl nucleosides. The oligomeric compound is directed to
XX human intracellular adhesion molecule (ICAM)-1. The 2'-O-modified
XX nucleosides include ring structures that position the sugar moiety of the
XX nucleosides preferentially in 3' endo geometries. The modified oligomeric
XX compounds have increased binding affinity and increased nuclease
XX resistance. The oligomeric compounds can be used in diagnostic,
XX therapeutic and research reagents
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;
QY 2100 TGACGGATCCAGCTTGGGC 2119
Db 20 TGACGGATCCAGCTTGGGC 1
RESULT 412
AAZ48638/c
ID AAZ48638 standard; DNA; 20 BP.
XX
AC AAZ48638;
XX
DT 07-MAR-2000 (first entry)
XX
DE ICAM-1 antisense inhibitor, ISIS-1939.
XX
KW Antisense inhibitor; oligonucleotide delivery agent; erythema multiforme;
KW expression modulator; cellular adhesion protein; malignant melanoma;
KW cellular proliferation modification; toxic epidermal necrolysis;
KW psoriasis; lichen planus; carcinoma; Paget's disease; Kaposi's sarcoma;
KW pulmonary fibrosis; Lyme disease; infection; therapy; ICAM-1; ss.
XX
OS Synthetic.
XX
XX WO9960167-A1.
XX
XX 25-NOV-1999.
XX
XX 20-MAY-1999; 99WO-US011142.
XX
XX 21-MAY-1998; 98US-00082336.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Mehta R, Hardee GE, Cook PD, Ecker DJ, Tsai YJ, Templin MV;
XX WPI; 2000-062467/05.
XX
XX New oligonucleotide compositions for topical delivery, used for the
XX delivery of bioactive agents for, e.g. modulating expression of a
XX cellular adhesion protein.
XX
XX Example 1; Page 47; 94pp; English.
XX
XX This sequence represents an antisense inhibitor of ICAM-1. The invention
XX relates to a pharmaceutical composition comprises an oligonucleotide (ON)
XX admixed with a topical delivery agent. The compositions can be used for
XX the delivery of a ribozyme, an external guide sequence, an antisense ON,
XX an antisense peptide nucleic acid, an aptamer or a molecular decoy. The
XX ONs can be used to modulate expression of a cellular adhesion protein or
XX modulate a rate of cellular proliferation. The compositions can also be
XX used to treat psoriasis. They can also be used to treat e.g. lichen
XX planus, toxic epidermal necrolysis, erythema multiforme, basal cell
XX carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease,
XX Kaposi's sarcoma, pulmonary fibrosis, Lyme disease and viral, fungal and
XX bacterial infections of the skin. They can be used to treat humans and
XX primates, avians including chickens and turkeys, domestic household,
XX sport or farm animals including rats, mice, rabbits and guinea pigs,
XX fish, reptiles and zoo animals. The compositions and methods may also be
XX used to examine the function of various proteins and genes in vitro in
XX cultured or preserved dermal tissues and in animals
XX
XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;
QY 1938 GAGAGGGGAAGTGGTGGGG 1957
Db 20 GAGAGGGGAAGTGGTGGGG 1

```

RESULT 413
AAZ48637/c
ID AAZ48637 standard; DNA; 20 BP.
XX
XX AAZ48637;
AC
XX 07-MAR-2000 (first entry)
DT
XX
XX ICAM-1 antisense inhibitor, ISIS-2302.
DE
XX
XX Antisense inhibitor; oligonucleotide delivery agent; erythema multiforme;
KW expression modulator; cellular adhesion protein; malignant melanoma;
KW cellular proliferation modification; toxic epidermal necrolysis;
KW psoriasis; lichen planus; carcinoma; Paget's disease; Kaposi's sarcoma;
KW pulmonary fibrosis; Lyme disease; infection; therapy; ICAM-1; ss.
XX
XX Synthetic.
OS
XX WO9960167-A1.
PN
XX
XX 25-NOV-1999.
PD
XX
XX 20-MAY-1999; 99WO-US011142.
PF
XX
XX 21-MAY-1998; 98US-00082336.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Mehta R, Hardee GE, Cook PD, Ecker DJ, Teai YJ, Templin MV;
PI WPI; 2000-062467/05.
XX
XX
XX New oligonucleotide compositions for topical delivery, used for the
PT delivery of bioactive agents for, e.g. modulating expression of a
PT cellular adhesion protein.
XX
XX Claim 60; Page 47; 94pp; English.
XX
XX This sequence represents an antisense inhibitor of ICAM-1. The invention
CC relates to a pharmaceutical composition comprises an oligonucleotide (ON)
CC admixed with a topical delivery agent. The compositions can be used for
CC the delivery of a ribozyme, an external guide sequence, an antisense ON,
CC an antisense peptide nucleic acid, an aptamer or a molecular decoy. The
CC ONs can be used to modulate expression of a cellular adhesion protein or
CC modulate a rate of cellular proliferation. The compositions can also be
CC used to treat psoriasis. They can also be used to treat e.g. lichen
CC planus, toxic epidermal necrolysis, erythema multiforme, basal cell
CC carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease,
CC Kaposi's sarcoma, pulmonary fibrosis, Lyme disease and viral, fungal and
CC bacterial infections of the skin. They can be used to treat humans and
CC primates, avians including chickens and turkeys, domestic household,
CC sport or farm animals including rats, mice, rabbits and guinea pigs,
CC fish, reptiles and zoo animals. The compositions and methods may also be
CC used to examine the function of various proteins and genes in vitro in
CC cultured or preserved dermal tissues and in animals
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1
|||||
|||||
RESULT 414
AAAI4454/c
ID AAAI4454 standard; DNA; 20 BP.
XX

```

```

AC AAAI4454;
XX
XX 21-AUG-2000 (first entry)
XX
XX ICAM-1 targeting oligonucleotide.
DE
XX
XX Targeting oligonucleotide; ICAM-1; ribonuclease activity;
KW zinc finger peptide; homodimer; single-stranded RNA cleavage;
KW pyrimidine selective; male-associated ZFY protein; human; ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /*note= "2'-MOE nucleotides"
FT modified_base 1
FT /*tag= b
FT /*note= "Joined to zinc finger peptide via ON-linker"
XX
XX WO200020622-A1.
XX
XX 13-APR-2000.
XX
XX 06-OCT-1999; 99WO-US023273.
XX
XX 06-OCT-1998; 98US-0103309P.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Lima WF, Crooke ST, Manoharan M;
XX WPI; 2000-303795/26.
XX
XX Use of zinc finger peptides for cleaving nucleic acids, particularly
PT single stranded RNA, useful in diagnostic, therapeutic and research
PT applications.
XX
XX Example 17; Page 19; 38pp; English.
XX
XX The invention relates to a novel method of cleaving single-stranded RNAs
CC using a zinc finger peptide, such as that derived from the human male-
CC associated ZFY protein (AAI90588). Dimerisation of these peptides is
CC essential for ribonuclease activity; zinc finger peptides tend to
CC homodimerise when the concentration of zinc is reduced. The homodimerised
CC zinc finger peptides specifically cleave pyrimidines in single-stranded
CC RNAs, preferentially cleaving 5'-pyrimidine-A-3'. The peptides do not
CC cleave single-stranded DNA, double-stranded RNA and DNA or 2'-methoxy
CC modified sequences. In one embodiment of the invention, a nucleic acid of
CC preselected sequence is cleaved using a zinc finger protein which is
CC tethered to a nucleotide sequence selected to specifically hybridise to a
CC portion of the preselected nucleic acid. The use of such a targeting
CC moiety enables the preparation of zinc finger peptides with activity
CC against particular RNA sequence (e.g., an mRNA important in disease). The
CC zinc finger peptides can be used to cleave nucleic acids, particularly
CC single stranded RNA. They are useful as therapeutics, diagnostics and
CC research reagents. The destruction or disablement of RNA can be a useful
CC event in interfering with disease states. The ability to cleave single
CC stranded RNA, especially with respect to other nucleic acids and
CC selectively with respect to cleavage site makes these molecules useful
CC for research where such selective cleavage can readily be used to
CC advantage. Similarly, diagnosis of disease may be had through use of zinc
CC finger peptides to cleave RNA in a predictable fashion. The activity of
CC the zinc finger peptides are zinc concentration dependent. Since the zinc
CC concentration directly affects dimerisation and concomitant cleavage,
CC control (especially automated control) of zinc ion concentration can be
CC used to control the cleavage reactions. The tethering to a specificity
CC enhancing moiety can lead to highly specific cleavage of nucleic acids,
CC specific not only as to the site of cleavage, occurring at pyrimidines
CC and Pyr-A, but also as to molecular identity. Sequences AAAI4452-AAI4455
CC represent oligonucleotides used in exemplifications as targeting
CC moieties for the human male-associated ZFY protein zinc finger peptide
CC (AAI90588). The present sequence represents an ICAM-1 targeting

```

```
CC oligonucleotide which is tethered to the peptide
XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
   |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 415
AAAI2077/c
ID AAAI2077 standard; DNA; 20 BP.
XX
AC AAAI2077;
XX
DT 07-AUG-2000 (first entry)
XX
DE Human ICAM-1 antisense oligonucleotide AUGC.
XX
KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
KW antitussive gene therapy; inflammatory disease; virus infection;
KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
XX
OS Homo sapiens.
XX
PN WO200018907-A2.
XX
PD 06-APR-2000.
XX
PF 21-SEP-1999; 99WO-EP006972.
XX
PR 25-SEP-1998; 98DE-01044111.
PR 04-DEC-1998; 98DE-01056138.
PR 08-JUN-1999; 99DE-01026110.
XX
PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
XX
PI Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
XX WPI; 2000-293146/25.
XX
PT Novel antisense nucleic acids targeted to specific sequences within the
XX ICAM-1 gene, useful for treating inflammation and metastasis.
XX
PS Claim 1; Page 23; 28pp; German.
XX
CC This invention describes novel antisense nucleic acids (I) targeted
CC against a specific nucleic acid sequence within human ICAM-1. The
CC products of the invention have cytostatic, anti-inflammatory,
CC dermatological, antiviral, antirheumatic, antiarthritic,
CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
CC can be used for antisense therapy; gene therapy. The antisense nucleic
CC acids or vectors are used to inhibit or eliminate acute or chronic
CC inflammatory diseases of humans, virus infection, metastasis,
CC inflammation of the skin, mobilization of hematopoietic stem cells,
CC coughs and all biological processes under the influence of ICAM-1,
CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
CC rejection, graft-versus-host reaction after bone marrow transplantation,
CC psoriasis, asthma and neurodermatitis. In particular, the antisense
CC nucleic acids are used to treat acute or chronic inflammation of gum
CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
CC expression. The antisense nucleic acids or vectors can be used to
CC suppress immune reactions against gene therapy using viral or non-viral
CC vectors in mammals. The antisense nucleic acids may also be used in kits
CC to diagnose ICAM-1 associated disturbances. AAAI2063-AI2092 and AAAI2099
```

```
CC represent the antisense oligonucleotides described in the method of the
CC invention
XX
SQ Sequence 20 BP; 5 A; 4 C; 9 G; 2 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 45 CCTCAGCCTCGCTATGGCTC 64
   |||||
Db 20 CCTCAGCCTCGCTATGGCTC 1

RESULT 416
AAAI2081/c
ID AAAI2081 standard; DNA; 20 BP.
XX
AC AAAI2081;
XX
DT 07-AUG-2000 (first entry)
XX
DE Human ICAM-1 antisense oligonucleotide 650D.
XX
KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
KW antitussive gene therapy; inflammatory disease; virus infection;
KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
XX
OS Homo sapiens.
XX
PN WO200018907-A2.
XX
PD 06-APR-2000.
XX
PF 21-SEP-1999; 99WO-EP006972.
XX
PR 25-SEP-1998; 98DE-01044111.
PR 04-DEC-1998; 98DE-01056138.
PR 08-JUN-1999; 99DE-01026110.
XX
PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
XX
PI Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
XX WPI; 2000-293146/25.
XX
PT Novel antisense nucleic acids targeted to specific sequences within the
XX ICAM-1 gene, useful for treating inflammation and metastasis.
XX
PS Claim 1; Page 24; 28pp; German.
XX
CC This invention describes novel antisense nucleic acids (I) targeted
CC against a specific nucleic acid sequence within human ICAM-1. The
CC products of the invention have cytostatic, anti-inflammatory,
CC dermatological, antiviral, antirheumatic, antiarthritic,
CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
CC can be used for antisense therapy; gene therapy. The antisense nucleic
CC acids or vectors are used to inhibit or eliminate acute or chronic
CC inflammatory diseases of humans, virus infection, metastasis,
CC inflammation of the skin, mobilization of hematopoietic stem cells,
CC coughs and all biological processes under the influence of ICAM-1,
CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
CC rejection, graft-versus-host reaction after bone marrow transplantation,
CC psoriasis, asthma and neurodermatitis. In particular, the antisense
CC nucleic acids are used to treat acute or chronic inflammation of gum
CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
CC expression. The antisense nucleic acids or vectors can be used to
CC suppress immune reactions against gene therapy using viral or non-viral
CC vectors in mammals. The antisense nucleic acids may also be used in kits
```

CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention

XX Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 584 GGAGAGATCACCATGGAGCC 603

Db 20 GGAGAGATCACCATGGAGCC 1

RESULT 417

AAA12063/C

ID AAA12063 standard; DNA; 20 BP.

XX AC AAA12063;

XX DT 07-AUG-2000 (first entry)

XX DE Human ICAM-1 antisense oligonucleotide 1630A.

XX Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.

XX OS Homo sapiens.

XX PN WO200018907-A2.

XX PD 06-APR-2000.

XX PF 21-SEP-1999; 99WO-EP006972.

XX PR 25-SEP-1998; 98DE-01044111.

XX PR 04-DEC-1998; 98DE-01056138.

XX PR 08-JUN-1999; 99DE-01026110.

XX PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.

XX PI Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;

XX DR WPI; 2000-293146/25.

XX Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.

XX PS Claim 1; Page 20; 28pp; German.

XX This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral

CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention

XX Sequence 20 BP; 0 A; 3 C; 10 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1630 CCGAACACACAGCCACGCC 1649

Db 20 CCGAACACACAGCCACGCC 1

RESULT 418

AAA12078/C

ID AAA12078 standard; DNA; 20 BP.

XX AC AAA12078;

XX DT 07-AUG-2000 (first entry)

XX DE Human ICAM-1 antisense oligonucleotide 650A.

XX Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.

XX OS Homo sapiens.

XX PN WO200018907-A2.

XX PD 06-APR-2000.

XX PF 21-SEP-1999; 99WO-EP006972.

XX PR 25-SEP-1998; 98DE-01044111.

XX PR 04-DEC-1998; 98DE-01056138.

XX PR 08-JUN-1999; 99DE-01026110.

XX PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.

XX PI Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;

XX DR WPI; 2000-293146/25.

XX Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.

XX PS Claim 1; Page 23; 28pp; German.

XX This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to

CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 596 ATGGAGCCCAATTCTCGTGC 615
 Db 20 ATGGAGCCCAATTCTCGTGC 1
 RESULT 419
 AAA12088/C
 ID AAA12088 standard; DNA; 20 BP.
 XX
 AC AAA12088;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 1380A.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 XX 21-SEP-1999; 99WO-EP006972.
 XX
 XX 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 PI Patzel V, Kronenwett R, Steidl U, Haas R, Szakiel G;
 XX
 DR WPI; 2000-293146/25.
 XX
 PT Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 PS Claim 1; Page 25; 28pp; German.
 XX
 CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene

CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1376 CCATCGGGGAATCAGTGACT 1395
 Db 20 CCATCGGGGAATCAGTGACT 1
 RESULT 420
 AAA12073/C
 ID AAA12073 standard; DNA; 20 BP.
 XX
 AC AAA12073;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 1630N.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 XX 21-SEP-1999; 99WO-EP006972.
 XX
 XX 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 PI Patzel V, Kronenwett R, Steidl U, Haas R, Szakiel G;
 XX
 DR WPI; 2000-293146/25.
 XX
 PT Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 PS Claim 1; Page 22; 28pp; German.
 XX
 CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum

CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 2 A; 3 C; 9 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1638 ACAAGCCACGCTCCCTGAA 1657
 Db 20 ACAAGCCACGCTCCCTGAA 1
 RESULT 421
 AAA12076/c
 ID AAA12076 standard; DNA; 20 BP.
 XX
 AC AAA12076;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide AUGB.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-EP006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 PI Patzel V, Kronenwett R, Steidl U, Haas R, Szakiel G;
 XX
 DR WPI; 2000-293146/25.
 XX
 PT Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 PS Claim 1; Page 23; 28pp; German.
 XX
 CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense

CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 47 TCAGCCTCGCTATGGCTCCC 66
 Db 20 TCAGCCTCGCTATGGCTCCC 1
 RESULT 422
 AAA12092/c
 ID AAA12092 standard; DNA; 20 BP.
 XX
 AC AAA12092;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 1840b.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-EP006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 PI Patzel V, Kronenwett R, Steidl U, Haas R, Szakiel G;
 XX
 DR WPI; 2000-293146/25.
 XX
 PT Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 PS Claim 1; Page 26; 28pp; German.
 XX
 CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,

CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1841 CACTAGGCCACGCATCTGAT 1860
 Db 20 CACTAGGCCACGCATCTGAT 1
 RESULT 423
 AAA12064/C
 ID AAA12064 standard; DNA; 20 BP.
 XX
 AC AAA12064;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 1630B.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-BF006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 PI Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
 XX
 DR WPI; 2000-293146/25.
 XX
 PT Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 PS Claim 1; Page 20; 28pp; German.
 XX
 CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological process under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ

CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 1 A; 3 C; 6 G; 10 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1624 ATGAACCGAACACACACAGC 1643
 Db 20 ATGAACCGAACACACAGC 1
 RESULT 424
 AAA12075/C
 ID AAA12075 standard; DNA; 20 BP.
 XX
 AC AAA12075;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide AUGA.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-BF006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 PI Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
 XX
 DR WPI; 2000-293146/25.
 XX
 PT Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 PS Claim 1; Page 22; 28pp; German.
 XX
 CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological process under the influence of ICAM-1,
 CC

CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 CC
 SQ Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 49 AGCCTCGCTATGCTCCAG 68
 |||||
 Db 20 AGCCTCGCTATGCTCCAG 1
 |||||
 RESULT 425
 AAA12079/c
 ID AAA12079 standard; DNA; 20 BP.
 AC AAA12079;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 650B.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-EP006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 PI Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
 XX
 DR WPI; 2000-293146/25.
 XX
 PT Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 PS Claim 1; Page 23; 28pp; German.
 XX
 CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,

CC coughs and all biological process under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 CC
 SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 589 GATCACCATGGAGCCCAATTT 608
 |||||
 Db 20 GATCACCATGGAGCCCAATTT 1
 |||||
 RESULT 426
 AAA12084/c
 ID AAA12084 standard; DNA; 20 BP.
 AC AAA12084;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 650G.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-EP006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 PI Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
 XX
 DR WPI; 2000-293146/25.
 XX
 PT Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 PS Claim 1; Page 24; 28pp; German.
 XX
 CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,

CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 597 TGGAGCCAAATTTCTCGTGC 616
 Db 20 TGGAGCCAAATTTCTCGTGC 1
 RESULT 427
 AAA12065/c
 ID AAA12065 standard; DNA; 20 BP.
 AC AAA12065;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 1630C.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-EP006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 PI Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
 XX
 XX WPI; 2000-293146/25.
 XX
 PT Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 PS Claim 1; Page 21; 28pp; German.
 XX
 CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic

CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 1 A; 5 C; 7 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1613 AAGGGACCCCATGAACCG 1632
 Db 20 AAGGGACCCCATGAACCG 1
 RESULT 428
 AAA12072/c
 ID AAA12072 standard; DNA; 20 BP.
 AC AAA12072;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 1630L.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-EP006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 PI Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
 XX
 XX WPI; 2000-293146/25.
 XX
 PT Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 PS Claim 1; Page 22; 28pp; German.
 XX
 CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic

CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 2 A; 3 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1636 ACACAGCCACGCTCCCTG 1655
 |||||
 Db 20 ACACAGCCACGCTCCCTG 1

RESULT 429
 AAA12086/C
 ID AAA12086 standard; DNA; 20 BP.
 XX
 AC AAA12086;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 1200A.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-EP006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 PI Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
 PI WPI; 2000-293146/25.
 XX
 DR Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 PS Claim 1; Page 24; 28pp; German.
 XX
 CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and

CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 0 A; 6 C; 6 G; 8 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1205 ACAAGAACCCAGACCCCGGAG 1224
 |||||
 Db 20 ACAAGAACCCAGACCCCGGAG 1

RESULT 430
 AAA12090/C
 ID AAA12090 standard; DNA; 20 BP.
 XX
 AC AAA12090;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 1380C.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-EP006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 PI Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
 PI WPI; 2000-293146/25.
 XX
 DR Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 PS Claim 1; Page 25; 28pp; German.
 XX
 CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,

CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1.
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-Al2092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1377 CATCGGGAATCAGTGACTG 1396
 Db 20 CATCGGGAATCAGTGACTG 1

RESULT 431
 AAA12068/C
 ID AAA12068 standard; DNA; 20 BP.
 XX
 AC AAA12068;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 1630H.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.

XX Homo sapiens.
 OS
 XX WO200018907-A2.
 PN
 XX 06-APR-2000.
 PD
 XX 21-SEP-1999; 99WO-EP006972.
 PF
 XX 25-SEP-1998; 98DE-01044111.
 PR
 XX 04-DEC-1998; 98DE-01056138.
 PR
 XX 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 XX Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
 PI
 XX WPI; 2000-293146/25.
 DR
 XX Novel antisense nucleic acids targeted to specific sequences within the
 XX ICAM-1 gene, useful for treating inflammation and metastasis.
 PT
 XX Claim 1; Page 21; 28pp; German.
 PS
 XX This invention describes novel antisense nucleic acids (I) targeted
 XX against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,

CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1.
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-Al2092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 1 A; 3 C; 9 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1632 GAACACACAAAGCCGCCTC 1651
 Db 20 GAACACACAAAGCCGCCTC 1

RESULT 432
 AAA12071/C
 ID AAA12071 standard; DNA; 20 BP.
 XX
 AC AAA12071;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 1630K.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.

XX Homo sapiens.
 OS
 XX WO200018907-A2.
 PN
 XX 06-APR-2000.
 PD
 XX 21-SEP-1999; 99WO-EP006972.
 PF
 XX 25-SEP-1998; 98DE-01044111.
 PR
 XX 04-DEC-1998; 98DE-01056138.
 PR
 XX 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 XX Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
 PI
 XX WPI; 2000-293146/25.
 DR
 XX Novel antisense nucleic acids targeted to specific sequences within the
 XX ICAM-1 gene, useful for treating inflammation and metastasis.
 PT
 XX Claim 1; Page 22; 28pp; German.
 PS
 XX This invention describes novel antisense nucleic acids (I) targeted
 XX against a specific nucleic acid sequence within human ICAM-1. The

CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC acids or vectors are used for antiseptic therapy; gene therapy. The antisense nucleic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX SQ Sequence 20 BP; 2 A; 2 C; 11 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1635 CACACAGCCACGCTCCCT 1654
 DB 20 CACACAGCCACGCTCCCT 1
 RESULT 433
 AAA12082/c
 ID AAA12082 standard; DNA; 20 BP.
 XX AAA12082;
 AC
 XX 07-AUG-2000 (first entry)
 DT
 XX Human ICAM-1 antisense oligonucleotide 650E.
 DE
 XX Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antithratic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 OS
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-EP006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 XX (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 PA
 XX Patzel V, Kronenwett R, Steidl U, Haas R, Sczakiel G;
 PI WPI; 2000-293146/25.
 DR
 XX Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 PT
 XX Claim 1; Page 24; 28pp; German.
 PS
 XX This invention describes novel antisense nucleic acids (I) targeted

CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC acids or vectors are used for antiseptic therapy; gene therapy. The antisense nucleic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 593 ACCATGGAGCCCAATTTCTCG 612
 DB 20 ACCATGGAGCCCAATTTCTCG 1
 RESULT 434
 AAA12089/c
 ID AAA12089 standard; DNA; 20 BP.
 XX AAA12089;
 AC
 XX 07-AUG-2000 (first entry)
 DT
 XX Human ICAM-1 antisense oligonucleotide 1380B.
 DE
 XX Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antithratic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 OS
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-EP006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 XX (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 PA
 XX Patzel V, Kronenwett R, Steidl U, Haas R, Sczakiel G;
 PI WPI; 2000-293146/25.
 DR
 XX Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 PT
 XX Claim 1; Page 25; 28pp; German.
 PS
 XX

CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-AL2092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1370 CACTGCCCATCGGGGAATCA 1389
 |||||
 DB 20 CACTGCCCATCGGGGAATCA 1

RESULT 435
 AAA12067/C
 ID AAA12067 standard; DNA; 20 BP.
 XX
 AC AAA12067;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 1630E.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-EP006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 XX Patzel V, Kronenwett R, Steidl U, Haas R, Sczakiel G;
 PI WPI; 2000-293146/25.
 XX
 DR Novel antisense nucleic acids targeted to specific sequences within the
 XX ICAM-1 gene, useful for treating inflammation and metastasis.
 PT Claim 1; Page 21; 28pp; German.
 PS

XX
 CC This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-AL2092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 0 A; 3 C; 8 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1628 AACCGAACACACAGCCAGC 1647
 |||||
 DB 20 AACCGAACACACAGCCAGC 1
 RESULT 436
 AAA12074/C
 ID AAA12074 standard; DNA; 20 BP.
 XX
 AC AAA12074;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 1630P.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-EP006972.
 XX
 PR 25-SEP-1998; 98DE-01044111.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX
 PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 XX Patzel V, Kronenwett R, Steidl U, Haas R, Sczakiel G;
 PI WPI; 2000-293146/25.
 XX
 DR Novel antisense nucleic acids targeted to specific sequences within the
 XX ICAM-1 gene, useful for treating inflammation and metastasis.
 PT
 XX

PS Claim 1; Page 22; 28pp; German.

XX This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention

XX Sequence 20 BP; 1 A; 4 C; 8 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Mismatches 0;

QY 1616 GGACCCCATGAACCGAAC 1635
 |||||
 DB 20 GGACCCCATGAACCGAAC 1

RESULT 437

AAA12080/c

ID AAA12080 standard; DNA; 20 BP.

AC AAA12080;

XX 07-AUG-2000 (first entry)

XX Human ICAM-1 antisense oligonucleotide 650C.

XX Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.

XX Homo sapiens.

XX WO200018907-A2.

XX 06-APR-2000.

XX 21-SEP-1999; 99WO-EP006972.

XX 25-SEP-1998; 98DE-01044111.

PR 04-DEC-1998; 98DE-01056138.

PR 08-JUN-1999; 99DE-01026110.

XX (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.

XX Patzel V, Kronenwett R, Steidl U, Haas R, Sczakiel G;

XX WPI; 2000-293146/25.

XX Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.

XX PS

Claim 1; Page 23; 28pp; German.

XX This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC inflammation of the skin, mobilization of hematopoietic stem cells,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention

XX Sequence 20 BP; 3 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Mismatches 0;

QY 579 GGTGAGGAGATCACCATG 598
 |||||
 DB 20 GGTGAGGAGATCACCATG 1

RESULT 438

AAA12083/c

ID AAA12083 standard; DNA; 20 BP.

AC AAA12083;

XX 07-AUG-2000 (first entry)

XX Human ICAM-1 antisense oligonucleotide 650F.

XX Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.

XX Homo sapiens.

XX WO200018907-A2.

XX 06-APR-2000.

XX 21-SEP-1999; 99WO-EP006972.

XX 25-SEP-1998; 98DE-01044111.

PR 04-DEC-1998; 98DE-01056138.

PR 08-JUN-1999; 99DE-01026110.

XX (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.

XX Patzel V, Kronenwett R, Steidl U, Haas R, Sczakiel G;

XX WPI; 2000-293146/25.

XX Novel antisense nucleic acids targeted to specific sequences within the

PT ICAM-1 gene, useful for treating inflammation and metastasis.

PS Claim 1; Page 24; 28pp; German.

XX
XX This invention describes novel antisense nucleic acids (I) targeted
CC against a specific nucleic acid sequence within human ICAM-1. The
CC products of the invention have cytostatic, anti-inflammatory,
CC dermatological, antiviral, antirheumatic, antiarthritic,
CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
CC can be used for antisense therapy; gene therapy. The antisense nucleic
CC acids or vectors are used to inhibit or eliminate acute or chronic
CC inflammatory diseases of humans, virus infection, metastasis,
CC inflammation of the skin, mobilization of hematopoietic stem cells,
CC coughs and all biological processes under the influence of ICAM-1,
CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
CC rejection, graft-versus-host reaction after bone marrow transplantation,
CC psoriasis, asthma and neurodermatitis. In particular, the antisense
CC nucleic acids are used to treat acute or chronic inflammation of gum
CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
CC expression. The antisense nucleic acids or vectors can be used to
CC suppress immune reactions against gene therapy using viral or non-viral
CC vectors in mammals. The antisense nucleic acids may also be used in kits
CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
CC represent the antisense oligonucleotides described in the method of the
CC invention

XX SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 595 CATGGAGCCCAATTCGTG 614
Db 20 CATGGAGCCCAATTCGTG 1

RESULT 439

AAA12085/c

ID AAA12085 standard; DNA; 20 BP.

AC AAA12085;

DT 07-AUG-2000 (first entry)

DE Human ICAM-1 antisense oligonucleotide 650H.

XX Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
KW antitussive gene therapy; inflammatory disease; virus infection;
KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
KW graft-versus-host reaction; neurodermatitis; gum disease; ss.

XX Homo sapiens.

OS

XX WO200018907-A2.

PN

XX 06-APR-2000.

PD

XX 21-SEP-1999; 99WO-EP006972.

PF

XX 25-SEP-1998; 98DE-01044111.

PR

XX 04-DEC-1998; 98DE-01056138.

PR

XX 08-JUN-1999; 99DE-01026110.

PR

XX (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.

PA

XX Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;

PI

XX WPI; 2000-293146/25.

XX

PT Novel antisense nucleic acids targeted to specific sequences within the
PT ICAM-1 gene, useful for treating inflammation and metastasis.

PS Claim 1; Page 24; 28pp; German.

XX
XX This invention describes novel antisense nucleic acids (I) targeted
CC against a specific nucleic acid sequence within human ICAM-1. The
CC products of the invention have cytostatic, anti-inflammatory,
CC dermatological, antiviral, antirheumatic, antiarthritic,
CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
CC can be used for antisense therapy; gene therapy. The antisense nucleic
CC acids or vectors are used to inhibit or eliminate acute or chronic
CC inflammatory diseases of humans, virus infection, metastasis,
CC inflammation of the skin, mobilization of hematopoietic stem cells,
CC coughs and all biological processes under the influence of ICAM-1,
CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
CC rejection, graft-versus-host reaction after bone marrow transplantation,
CC psoriasis, asthma and neurodermatitis. In particular, the antisense
CC nucleic acids are used to treat acute or chronic inflammation of gum
CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
CC expression. The antisense nucleic acids or vectors can be used to
CC suppress immune reactions against gene therapy using viral or non-viral
CC vectors in mammals. The antisense nucleic acids may also be used in kits
CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
CC represent the antisense oligonucleotides described in the method of the
CC invention

XX SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 601 GCCAATTCCTCGTGGCGCAC 620
Db 20 GCCAATTCCTCGTGGCGCAC 1

RESULT 440

AAA12091/c

ID AAA12091 standard; DNA; 20 BP.

AC AAA12091;

DT 07-AUG-2000 (first entry)

DE Human ICAM-1 antisense oligonucleotide 1840A.

XX Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
KW antitussive gene therapy; inflammatory disease; virus infection;
KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
KW graft-versus-host reaction; neurodermatitis; gum disease; ss.

XX Homo sapiens.

OS

XX WO200018907-A2.

PN

XX 06-APR-2000.

PD

XX 21-SEP-1999; 99WO-EP006972.

PF

XX 25-SEP-1998; 98DE-01044111.

PR

XX 04-DEC-1998; 98DE-01056138.

PR

XX 08-JUN-1999; 99DE-01026110.

PR

XX (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.

PA

XX Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;

PI

XX WPI; 2000-293146/25.

XX

```

XX Novel antisense nucleic acids targeted to specific sequences within the
PT ICAM-1 gene, useful for treating inflammation and metastasis.
XX
XX Claim 1; Page 25; 28pp; German.
XX
XX This invention describes novel antisense nucleic acids (I) targeted
CC against a specific nucleic acid sequence within human ICAM-1. The
CC products of the invention have cytostatic, anti-inflammatory,
CC dermatological, antiviral, antirheumatic, antiarthritic,
CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
CC can be used for antisense therapy; gene therapy. The antisense nucleic
CC acids or vectors are used to inhibit or eliminate acute or chronic
CC inflammatory diseases of humans, virus infection, metastasis,
CC coughs and all biological process under the influence of ICAM-1,
CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
CC rejection, graft-versus-host reaction after bone marrow transplantation,
CC psoriasis, asthma and neurodermatitis. In particular, the antisense
CC nucleic acids are used to treat acute or chronic inflammation of gum
CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
CC expression. The antisense nucleic acids or vectors can be used to
CC suppress immune reactions against gene therapy using viral or non-viral
CC vectors in mammals. The antisense nucleic acids may also be used in kits
CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
CC represent the antisense oligonucleotides described in the method of the
CC invention
XX
XX Sequence 20 BP; 2 A; 3 C; 7 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1937 AAAACACTAGGCCAGCATC 1856
DB 20 AAAACACTAGGCCAGCATC 1
|||||
RESULT 441
AAA12069/C
ID AAA12069 standard; DNA; 20 BP.
AC AAA12069;
XX
XX 07-AUG-2000 (first entry)
DT
XX
DE Human ICAM-1 antisense oligonucleotide 1630I.
XX
KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
KW antitussive gene therapy; inflammatory disease; virus infection;
KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
XX
XX Homo sapiens.
OS
XX WO200018907-A2.
PN
XX 06-APR-2000.
PD
XX 21-SEP-1999; 99WO-EP006972.
PF
XX 25-SEP-1998; 98DE-01044111.
PR 04-DEC-1998; 98DE-01056138.
PR 08-JUN-1999; 99DE-01026110.
XX
XX (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
PA
XX Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
XX

```

```

DR WPI; 2000-293146/25.
XX
XX Novel antisense nucleic acids targeted to specific sequences within the
PT ICAM-1 gene, useful for treating inflammation and metastasis.
XX
XX Claim 1; Page 21; 28pp; German.
XX
XX This invention describes novel antisense nucleic acids (I) targeted
CC against a specific nucleic acid sequence within human ICAM-1. The
CC products of the invention have cytostatic, anti-inflammatory,
CC dermatological, antiviral, antirheumatic, antiarthritic,
CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
CC can be used for antisense therapy; gene therapy. The antisense nucleic
CC acids or vectors are used to inhibit or eliminate acute or chronic
CC inflammatory diseases of humans, virus infection, metastasis,
CC inflammation of the skin, mobilization of hematopoietic stem cells,
CC coughs and all biological process under the influence of ICAM-1,
CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
CC rejection, graft-versus-host reaction after bone marrow transplantation,
CC psoriasis, asthma and neurodermatitis. In particular, the antisense
CC nucleic acids are used to treat acute or chronic inflammation of gum
CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
CC expression. The antisense nucleic acids or vectors can be used to
CC suppress immune reactions against gene therapy using viral or non-viral
CC vectors in mammals. The antisense nucleic acids may also be used in kits
CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
CC represent the antisense oligonucleotides described in the method of the
CC invention
XX
XX Sequence 20 BP; 1 A; 2 C; 10 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1633 AACACACAAGCCAGCCTCC 1652
DB 20 AACACACAAGCCAGCCTCC 1
|||||
RESULT 442
AAA12099/C
ID AAA12099 standard; DNA; 20 BP.
AC AAA12099;
XX
XX 07-AUG-2000 (first entry)
DT
XX
DE Human ICAM-1 antisense control oligonucleotide.
XX
KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
KW antitussive gene therapy; inflammatory disease; virus infection;
KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
XX
XX Homo sapiens.
OS
XX WO200018907-A2.
PN
XX 06-APR-2000.
PD
XX 21-SEP-1999; 99WO-EP006972.
PF
XX 25-SEP-1998; 98DE-01044111.
PR 04-DEC-1998; 98DE-01056138.
PR 08-JUN-1999; 99DE-01026110.
XX
XX (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
PA
XX Patzel V, Kronenwett R, Steidl U, Haas R, Szczakiel G;
XX

```



```

XX DR WPI; 2000-293146/25.
XX
XX Novel antisense nucleic acids targeted to specific sequences within the
PT ICAM-1 gene, useful for treating inflammation and metastasis.
XX
XX Disclosure; Page 27; 28pp; German.
XX
XX This invention describes novel antisense nucleic acids (I) targeted
CC against a specific nucleic acid sequence within human ICAM-1. The
CC products of the invention have cytostatic, anti-inflammatory,
CC dermatological, antiviral, antirheumatic, antiarthritic,
CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
CC can be used for antisense therapy; gene therapy. The antisense nucleic
CC acids or vectors are used to inhibit or eliminate acute or chronic
CC inflammatory diseases of humans, virus infection, metastasis,
CC inflammation of the skin, mobilization of hematopoietic stem cells,
CC coughs and all biological process under the influence of ICAM-1,
CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
CC rejection, graft-versus-host reaction after bone marrow transplantation,
CC psoriasis, asthma and neurodermatitis. In particular, the antisense
CC nucleic acids are used to treat acute or chronic inflammation of gum
CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
CC expression. The antisense nucleic acids or vectors can be used to
CC suppress immune reactions against gene therapy using viral or non-viral
CC vectors in mammals. The antisense nucleic acids may also be used in kits
CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
CC represent the antisense oligonucleotides described in the method of the
CC invention
XX
XX Sequence 20 BP; 6 A; 4 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1350 TCTAAGGATGGCATTTC 1369
DB 20 TCTAAGGATGGCATTTC 1
RESULT 443
AA12087/C
ID AAA12087 standard; DNA; 20 BP.
XX
AC AAA12087;
XX
XX 07-AUG-2000 (first entry)
XX
XX Human ICAM-1 antisense oligonucleotide 1200B.
XX
XX Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
KW antitussive gene therapy; inflammatory disease; virus infection;
KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
XX
XX Homo sapiens.
XX
XX WO200018907-A2.
XX
XX 06-APR-2000.
XX
XX 21-SEP-1999; 99WO-EP006972.
XX
XX 25-SEP-1998; 98DE-0104111.
XX 04-DEC-1998; 98DE-01056138.
XX 08-JUN-1999; 99DE-01026110.
XX (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
XX

```

```

PI Patzel V, Kronenwett R, Steidl U, Haas R, Sczakiel G;
XX
XX WPI; 2000-293146/25.
XX
XX Novel antisense nucleic acids targeted to specific sequences within the
PT ICAM-1 gene, useful for treating inflammation and metastasis.
XX
XX Claim 1; Page 25; 28pp; German.
XX
XX This invention describes novel antisense nucleic acids (I) targeted
CC against a specific nucleic acid sequence within human ICAM-1. The
CC products of the invention have cytostatic, anti-inflammatory,
CC dermatological, antiviral, antirheumatic, antiarthritic,
CC immunosuppressive, antipsoriatic, antiasthmatic, antitussive activity and
CC can be used for antisense therapy; gene therapy. The antisense nucleic
CC acids or vectors are used to inhibit or eliminate acute or chronic
CC inflammatory diseases of humans, virus infection, metastasis,
CC inflammation of the skin, mobilization of hematopoietic stem cells,
CC coughs and all biological process under the influence of ICAM-1,
CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
CC rejection, graft-versus-host reaction after bone marrow transplantation,
CC psoriasis, asthma and neurodermatitis. In particular, the antisense
CC nucleic acids are used to treat acute or chronic inflammation of gum
CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
CC expression. The antisense nucleic acids or vectors can be used to
CC suppress immune reactions against gene therapy using viral or non-viral
CC vectors in mammals. The antisense nucleic acids may also be used in kits
CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
CC represent the antisense oligonucleotides described in the method of the
CC invention
XX
XX Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1209 GAACCGACCCGGAGCTTC 1228
DB 20 GAACCGACCCGGAGCTTC 1
RESULT 444
AA12066/C
ID AAA12066 standard; DNA; 20 BP.
XX
AC AAA12066;
XX
XX 07-AUG-2000 (first entry)
XX
XX Human ICAM-1 antisense oligonucleotide 1630D.
XX
XX Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
KW antiarthritic; immunosuppressive; antipsoriatic; antiasthmatic;
KW antitussive gene therapy; inflammatory disease; virus infection;
KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
XX
XX Homo sapiens.
XX
XX WO200018907-A2.
XX
XX 06-APR-2000.
XX
XX 21-SEP-1999; 99WO-EP006972.
XX
XX 25-SEP-1998; 98DE-0104111.
XX 04-DEC-1998; 98DE-01056138.
XX 08-JUN-1999; 99DE-01026110.
XX (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
XX

```

XX PI Patzel V, Kronenwett R, Steidl U, Haas R, Sczakiel G;
 XX DR WPI; 2000-293146/25.
 XX
 XX
 XX Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 XX Claim 1; Page 21; 28pp; German.
 XX
 XX This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antiproliferative, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 1 A; 5 C; 7 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1615 GGGACCCCGATGAACCGAA 1634
 Db 20 GGGACCCCGATGAACCGAA 1
 |||||
 RESULT 445
 AAA12070/c
 ID AAA12070 standard; DNA; 20 BP.
 XX
 AC AAA12070;
 XX
 DT 07-AUG-2000 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide 1630J.
 XX
 KW Antisense; primer; ICAM-1; human; adhesion molecule; cytostatic;
 KW anti-inflammatory; dermatological; antiviral; antirheumatic; asthma;
 KW antiarthritic; immunosuppressive; antiproliferative; antiasthmatic;
 KW antitussive gene therapy; inflammatory disease; virus infection;
 KW metastasis; hematopoietic stem mobilization; ulcerative colitis;
 KW rheumatoid arthritis; lupus erythematosus; organ rejection; psoriasis;
 KW graft-versus-host reaction; neurodermatitis; gum disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN W0200018907-A2.
 XX
 PD 06-APR-2000.
 XX
 PF 21-SEP-1999; 99WO-EP006972.
 XX
 PR 25-SEP-1998; 98DE-0104411.
 PR 04-DEC-1998; 98DE-01056138.
 PR 08-JUN-1999; 99DE-01026110.
 XX

PA (DEKE-) DEUT KREBSFORSCHUNGSZENTRUM.
 XX
 PI Patzel V, Kronenwett R, Steidl U, Haas R, Sczakiel G;
 XX
 XX WPI; 2000-293146/25.
 XX
 XX Novel antisense nucleic acids targeted to specific sequences within the
 PT ICAM-1 gene, useful for treating inflammation and metastasis.
 XX
 XX Claim 1; Page 21; 28pp; German.
 XX
 XX This invention describes novel antisense nucleic acids (I) targeted
 CC against a specific nucleic acid sequence within human ICAM-1. The
 CC products of the invention have cytostatic, anti-inflammatory,
 CC dermatological, antiviral, antirheumatic, antiarthritic,
 CC immunosuppressive, antiproliferative, antiasthmatic, antitussive activity and
 CC can be used for antisense therapy; gene therapy. The antisense nucleic
 CC acids or vectors are used to inhibit or eliminate acute or chronic
 CC inflammatory diseases of humans, virus infection, metastasis,
 CC coughs and all biological processes under the influence of ICAM-1,
 CC ulcerative colitis, rheumatoid arthritis, lupus erythematosus, organ
 CC rejection, graft-versus-host reaction after bone marrow transplantation,
 CC psoriasis, asthma and neurodermatitis. In particular, the antisense
 CC nucleic acids are used to treat acute or chronic inflammation of gum
 CC disease. The antisense nucleic acids regulate or suppress ICAM-1 gene
 CC expression. The antisense nucleic acids or vectors can be used to
 CC suppress immune reactions against gene therapy using viral or non-viral
 CC vectors in mammals. The antisense nucleic acids may also be used in kits
 CC to diagnose ICAM-1 associated disturbances. AAA12063-A12092 and AAA12099
 CC represent the antisense oligonucleotides described in the method of the
 CC invention
 XX
 SQ Sequence 20 BP; 1 A; 2 C; 11 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1634 ACACACAGCCAGCGCTCCC 1653
 Db 20 ACACACAGCCAGCGCTCCC 1
 |||||
 RESULT 446
 AAZ40363/c
 ID AAZ40363 standard; DNA; 20 BP.
 XX
 AC AAZ40363;
 XX
 DT 02-MAR-2000 (first entry)
 XX
 DE Antisense inhibitor of ICAM-1, ISIS-2302.
 XX
 KW Antisense oligonucleotide; inhibitor; pulmonary delivery composition;
 KW gene expression modulation; asthma; lung cancer; pulmonary fibrosis;
 KW rhinovirus; tuberculosis; bronchitis; pneumonia; pulmonary disorder;
 KW viral disease; obstructive lung disorder; pulmonary embolism; emphysema;
 KW anaphylaxis; chronic obstructive pulmonary disease; COPD; bronchiectasis;
 KW chronic bronchitis; cystic fibrosis; therapy; ICAM-1; ss.
 XX
 OS Synthetic.
 XX
 PN W09960010-A1.
 XX
 PD 25-NOV-1999.
 XX
 PF 20-MAY-1999; 99WO-US011214.
 XX
 PR 21-MAY-1998; 98US-00083585.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX

PI Bennett CF, Ecker DJ, Cook PD;
 XX WPI; 2000-062437/05.
 XX
 XX Composition for pulmonary delivery useful for treating and diagnosing
 PT pulmonary diseases such as asthma, tuberculosis, etc.
 PT
 XX Claim 54; Page 33; 85pp; English.
 XX
 CC This sequence represents an antisense inhibitor of ICAM-1. The invention
 CC relates to a pharmaceutical composition (C) for pulmonary delivery of an
 CC oligonucleotide, comprising at least one oligonucleotide or its
 CC bioequivalent. (C) can be used to investigate the role of a gene or gene
 CC product in an animal other than human. (C) is also useful in a method of
 CC modulating the expression of a gene in an animal. (C) is useful in
 CC treating or diagnosing asthma, lung cancer, pulmonary fibrosis,
 CC rhinovirus, tuberculosis, bronchitis, pneumonia. The oligonucleotides are
 CC useful in determining the nature, function and potential relationships to
 CC body or disease status in animal of various genetic components of the
 CC body. (C) is useful for therapeutic, palliative or prophylactic treatment
 CC or to prevent the onset or recurrence of the diseases associated with
 CC pulmonary disorders. (C) is also useful in the treatment of diseases
 CC caused by viruses (such as respiratory syncytial virus, Hemophilus
 CC influenza, parainfluenza, etc.), obstructive lung disorders (such as
 CC pulmonary embolism or anaphylaxis), chronic obstructive pulmonary disease
 CC (COPD), emphysema, chronic bronchitis, bronchiectasis and cystic
 CC fibrosis. (C) administered through pulmonary delivery overcomes the
 CC complication and expenses associated with other routes of administration.
 CC Modified or substituted oligonucleotides have enhanced cellular uptake,
 CC target binding and increased stability in the presence of nucleases.
 CC Pulmonary administration of phosphodiester oligonucleotides lowers the
 CC level of nuclease activity in lung tissue to afford phosphodiester
 CC oligonucleotides longer lifetimes in lung tissue
 XX
 XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1
 RESULT 447
 AAZ47918/c
 ID AAZ47918 standard; DNA; 20 BP.
 XX
 XX AAZ47918;
 XX
 XX 10-MAR-2000 (first entry)
 XX
 XX ICAM-1 phosphorothioate antisense oligonucleotide ISIS 15839.
 XX
 XX Phosphorothioate; antisense oligonucleotide; ICAM-1; pulmonary delivery;
 KW asthma; lung cancer; pulmonary fibrosis; cytostatic; antiasthmatic;
 KW antiviral; rhinovirus; tuberculosis; bronchitis; pneumonia; anaphylaxis;
 KW respiratory syncytial virus; parainfluenza; obstructive lung disorder;
 KW pulmonary embolism; chronic obstructive pulmonary disease; COPD;
 KW emphysema; chronic bronchitis; bronchiectasis; cystic fibrosis; ss.
 XX Synthetic.
 OS
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= a
 FT /note= "phosphorothioate linkages"
 FT
 XX WO9960166-A1.
 PN
 XX 25-NOV-1999.
 PD
 XX

PF 20-MAY-1999; 99WO-US011141.
 XX
 PR 21-MAY-1998; 98US-00083586.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Ecker DJ, Cook PD;
 XX
 XX WPI; 2000-062466/05.
 XX
 XX New pharmaceutical composition useful for pulmonary delivery of
 PT oligonucleotide for treating asthma, lung cancer and pulmonary fibrosis.
 PT
 XX Claim 62; Page 34; 90pp; English.
 XX
 CC The present invention describes a pharmaceutical composition for
 CC pulmonary delivery of an oligonucleotide comprising at least one
 CC oligonucleotide where the sugar moiety of at least one nucleoside unit of
 CC the oligonucleotide is not a 2'-deoxyribofuranosyl sugar moiety or at
 CC least one internucleotide linkage within the oligonucleotide is not a
 CC phosphodiester or a phosphothioate linkage. The composition is useful for
 CC treating an animal having or suspected of having a disease or a disorder
 CC that is treatable with one or more nucleic acids e.g. asthma, a cancer of
 CC the lung, pulmonary fibrosis, rhinovirus, tuberculosis, bronchitis or
 CC pneumonia and other lung disorders e.g. respiratory syncytial virus, H.
 CC influenza, parainfluenza, obstructive lung disorders e.g. pulmonary
 CC embolism or anaphylaxis, chronic obstructive pulmonary disease (COPD),
 CC emphysema, chronic bronchitis, bronchiectasis and cystic fibrosis. The
 CC oligonucleotides are also useful for determining the nature, function and
 CC potential relationships to body or disease states in animals or various
 CC genetic components of the body. Pulmonary administration of an antisense
 CC oligonucleotide bypasses the complications and expense associated with
 CC intravenous and other routes of administration providing enhanced
 CC delivery of the oligonucleotides. The modified oligonucleotides have
 CC enhanced cellular uptake, enhanced binding to target and increased
 CC stability in the presence of nucleases. The present sequence represents
 CC an antisense oligonucleotide used in the exemplification of the present
 CC invention
 XX
 XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1
 RESULT 448
 AAA14945/c
 ID AAA14945 standard; DNA; 20 BP.
 XX
 XX AAA14945;
 XX
 XX 08-AUG-2000 (first entry)
 XX
 XX PCR primer SR1 used to amplify the repeated DNA sequences Alu.
 DE
 XX Chromosomal labelling; chromosomal band; IRS-PCR; Alu; LINE; karyotype;
 KW interspersed repeat sequence-polymerase chain reaction; probe;
 KW chromosomal rearrangement; PCR primer; ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200022164-A1.
 PN
 XX 20-APR-2000.
 PD
 XX
 XX 15-OCT-1999; 99WO-FR002517.
 PF
 XX 15-OCT-1998; 98FR-00012957.
 PR

```

XX PA (GEST ) GENSET.
XX PI Cherif D;
XX XX
XX DR WPI; 2000-318009/27.
XX XX
XX PT Probes for chromosomal labeling, useful for diagnostic determination of
XX PT karyotype, are prepared by amplification using primers specific for
XX PT repeated DNA sequences.
XX XX
XX PS Claim 6; Page 14; 39pp; French.
XX XX
XX CC PCR primers AAA14945-47 were used to amplify DNA containing the repeated
XX CC DNA sequences Alu. The amplified fragment was used as a probe of the
XX CC invention. The specification describes probes which are used for
XX CC chromosomal labelling. The probes consist of a set of DNA segments
XX CC represented at higher level in certain chromosomal bands and produced by
XX CC IRS-PCR (interspersed repeat sequence-polymerase chain reaction) using
XX CC primers specific for the repeated DNA sequences Alu and LINE. The probes
XX CC are used for studying karyotypes, including those associated with
XX CC chromosomal rearrangements, particularly in multicolour fluorescent in
XX CC situ hybridisation
XX XX
XX SQ Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
XX XX
XX XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX XX
QY 2771 CCCAGGCTGGAGTGCAGTGG 2790
Db 20 CCCAGGCTGGAGTGCAGTGG 1
XX XX
XX XX RESULT 449
XX XX AAA10247/c
XX XX ID AAA10247 standard; DNA; 20 BP.
XX AC AAA10247;
XX XX
XX DT 03-JUL-2000 (first entry)
XX XX
XX DE 2-aminoadenosine-containing oligonucleotide #24682, SEQ ID NO:3.
XX XX
XX KW 2-aminoadenosine; oligonucleotide; hybridisation; antisense therapy;
XX KW diagnosis; ss.
XX OS Synthetic.
XX XX
XX FH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= a
XX FT /note= "Phosphorothioate linkages"
XX FT modified_base 2
XX FT /*tag= b
XX FT /mod_base= m5c
XX FT modified_base 3
XX FT /*tag= c
XX FT /mod_base= m5c
XX FT modified_base 4
XX FT /*tag= d
XX FT /mod_base= m5c
XX FT modified_base 5
XX FT /*tag= e
XX FT /mod_base= OTHER
XX FT /note= "OTHER = 2-aminoadenosine"
XX FT modified_base 6
XX FT /*tag= f
XX FT /mod_base= OTHER
XX FT /note= "OTHER = 2-aminoadenosine"
XX FT modified_base 8
XX FT /*tag= g
XX FT

```

```

FT FT /mod_base= m5c
FT FT 12
FT FT /*tag= h
FT FT /mod_base= m5c
FT FT 13
FT FT /*tag= i
FT FT /mod_base= OTHER
FT FT 15
FT FT /note= "OTHER = 2-aminoadenosine"
FT FT /*tag= j
FT FT /mod_base= m5c
FT FT 16
FT FT /*tag= k
FT FT /mod_base= m5c
FT FT 19
FT FT /*tag= l
FT FT /mod_base= m5c
FT FT 20
FT FT /*tag= m
FT FT /mod_base= OTHER
FT FT /note= "OTHER = 2-aminoadenosine"
XX XX
XX PN WO200012563-A1.
XX XX
XX PD 09-MAR-2000.
XX XX
XX PF 31-AUG-1999; 99WO-US019907.
XX XX
XX PR 01-SEP-1998; 98US-00144883.
XX XX
XX PA (ISIS-) ISIS PHARM INC.
XX XX
XX PI Ross BS, Manoharan M;
XX XX
XX DR WPI; 2000-246728/21.
XX XX
XX PT Preparation of an oligonucleotide incorporating 2-aminoadenosine, with
XX PT stronger hybridization to its target sequence and useful in diagnosis and
XX PT therapy.
XX XX
XX PS Example 23; Page 42; 48pp; English.
XX XX
XX CC The invention relates to a novel method for the preparation of
XX CC oligonucleotides incorporating 2-aminoadenosine. A halogenated adenosine
XX CC is incorporated into an oligonucleotide using standard synthesis methods,
XX CC which is then reacted with an amine to produce 2-aminoadenosine. The
XX CC incorporation of 2-aminoadenosine and similar moieties into
XX CC oligonucleotides in place of adenosine provides an additional site for
XX CC hydrogen bonding to uridine or thymidine. This modification has been
XX CC shown to increase the binding affinity of oligonucleotides to their
XX CC target RNA sequences and, to a lesser extent, DNA sequences.
XX CC Oligonucleotides incorporating 2-aminoadenosine are useful as probes and
XX CC primers (e.g., for diagnostic use), linkers, adapters, and as antisense
XX CC therapeutics. Oligonucleotides incorporating 2-aminoadenosine exhibit
XX CC stronger hybridisation with their target sequences. Sequences AAA10245-
XX CC AAA10252 represent 2-aminoadenosine-containing oligonucleotides
XX CC synthesised in an exemplification of the present invention
XX XX
XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
XX XX
XX XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX XX
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
XX XX
XX XX RESULT 450
XX XX AA298648/c
XX XX ID AA298648 standard; DNA; 20 BP.
XX XX

```

```

AC AAZ98648;
XX
XX
DT
XX
XX
DE
XX
DE
XX
KW Antisense oligonucleotide; phosphorothioate; inflammatory disease;
KW ICAM-1; tumour; gene therapy; aberrant gene expression; treatment;
KW infectious disease; ss.
XX
XX
OS Mus sp.
XX
XX
PH Key Location/Qualifiers
FT misc_feature 1..20
FT /*tag= a
FT FT note= "Optionally phosphorothioate internucleotide
FT FT linkages"
XX
XX
PN CA2271582-A1.
XX
XX
PD 14-NOV-1999.
XX
XX
PF 13-MAY-1999; 99CA-02271582.
XX
XX
PR 14-MAY-1998; 98US-00078955.
XX
XX
PA (KLIM/) KLIMUK S K.
PA (HARA/) HARASYM T.
PA (HOPE/) HOPE M J.
PA (ANSE/) ANSELL S M.
PA (CULL/) CULLIS P R.
PA (MOKW/) MOK W K.
PA (SCHE/) SCHERRER P.
PA (SEMP/) SEMPLE S C.
XX
XX
PI Klimuk SK, Harasym T, Hope MJ, Ansell SM, Cullis PR, Mok WWK;
PI Scherrer P, Semple SC;
XX
XX
XX WPI; 2000-225058/20.
XX
XX
DR A method for delivering antisense oligonucleotides to cells using lipid
PT capsules comprising steric barrier lipids.
PT
XX
XX Example 4; Page 55; 99pp; English.
XX
XX This sequence represents an antisense oligonucleotide sequence which has
CC human intracellular adhesion molecule-1 (ICAM-1) as its target gene. The
CC oligonucleotide is used in a method for delivering lipid encapsulated
CC therapeutic agents (i.e. antisense oligonucleotides) to mammals. The lipid
CC capsule comprises steric barrier lipids that prevent particle aggregation
CC during lipid nucleic acid formation. The method may be used for the
CC delivery of therapeutic agents to mammalian cells. It is especially
CC suitable for delivering nucleic acid molecules, and in particular
CC antisense molecules which may be administered to down regulate the
CC expression of aberrant genes. The aberrant gene may be ICAM-1, c-myc, c-
CC myb, ras, raf, erb-B-2, PKC-alpha, IGF-1R, EGFR, VEGF and/or VEGF-R-1. The
CC method may be used for the treatment of tumours, inflammatory diseases
CC and/or infectious diseases
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1
RESULT 451
AAZ48119/c
ID AAZ48119 standard; DNA; 20 BP.

```

```

XX AAZ48119;
XX
XX 14-MAR-2000 (first entry)
XX
XX ICAM-1 targeting antisense oligonucleotide ISIS-2302 SEQ ID NO:1.
XX
XX Antisense oligonucleotide; phosphorothioate; inhibition; liposome;
KW long-circulating liposome; anticancer; anti-inflammatory; tumour;
KW inflammation; autoimmune disease; cytostatic; immunosuppressive;
KW gene therapy; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT FT note= "phosphorothioate linkages"
XX
XX WO959547-A1.
XX
XX 25-NOV-1999.
XX
XX 20-MAY-1999; 99WO-US011267.
XX
XX 21-MAY-1998; 98US-00082365.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Mehta R, Hardee GE, Leamon C;
XX
XX WPI; 2000-072399/06.
XX
XX New liposome compositions having long plasma half-lives, used for
PT delivering compounds for treating e.g. tumors, inflammation or autoimmune
PT diseases.
XX
XX Disclosure; Page 33; 91pp; English.
XX
XX The present invention describes a liposome (I) which has a plasma half-
CC life of at least 5 hours and comprises at most 10 mol % of a
CC phosphatidylglycerol (PG) compound that has a fatty acid portion of 10 to
CC 20 carbon atoms. The liposomes can be used to encapsulate a bioactive
CC agent, e.g. an anticancer agent, an anti-inflammatory agent, an
CC oligonucleotide (such as a hemimer, molecular decoy or an aptamer) or an
CC antisense compound (such as a ribozyme, an external guide sequence, a
CC compound comprising at most synthetic moiety which has nuclease activity,
CC an antisense peptide nucleic acid, an antisense nucleotide and/or
CC comprising a sequence that hybridises to a nucleotide sequence present in
CC a viral gene, ras gene or a gene encoding a cellular adhesion molecule).
CC Such liposomes can be used for: (1) preventing cancer or reducing the
CC rate of growth of a tumour or cancer in a mammal; (2) preventing or
CC reducing the severity of inflammation in a mammal (especially a human);
CC (3) modulating expression of a gene by contacting cells, tissues, organs
CC or organisms expressing the gene with the liposome; or (4) preventing,
CC reducing the rate of progression of or reducing the severity of symptoms
CC resulting from an autoimmune disease in a mammal. The liposomes have long
CC circulating half-life in mammalian plasma. AAZ48119 to AAZ48130 represent
CC antisense oligonucleotide sequences used in the exemplification of the
XX present invention
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1
RESULT 452
AAZ48119/c
ID AAZ48119 standard; DNA; 20 BP.

```

AAZ49336/c
ID AAZ49336 standard; DNA; 20 BP.

XX AC AAZ49336;
XX

XX 14-MAR-2000 (first entry)

XX DE ICAM-1 targetted phosphorothioate oligonucleotide ISIS 2302.

XX KW ICAM-1; cellular adhesion; expression; modulation; antisense;
KW non-parenteral; delivery; uptake; administration; emulsion;
KW ulcerative colitis; Crohn's disease; inflammatory bowel disease;
KW cellular proliferation; ss.

XX OS Synthetic.
OS Homo sapiens.

XX XX

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate linkages"

XX XX

XX PN WO9960012-A1.

XX XX

XX PD 25-NOV-1999.

XX XX

XX PF 20-MAY-1999; 99WO-US011394.

XX XX

XX PR 21-MAY-1998; 98US-00082624.

XX XX

XX PA (ISIS-) ISIS PHARM INC.

XX XX

XX PI Teng C, Cook PD, Tillman L, Hardee GE, Ecker DJ, Manoharan M;

XX XX

XX DR WPI; 2000-072428/06.

XX XX

XX PT New oligonucleotide compositions used for the non-parenteral delivery of
PT e.g. antisense oligos, ribozymes, peptide nucleic acids, molecular
PT decoys, external guide sequences or aptamers.

XX XX

XX PS Claim 80; Page 37; 133pp; English.

XX XX

XX CC Sequences AAZ49336-Z49343 and AAZ49390 represent antisense
CC oligonucleotides designed to modulate cellular adhesion. The invention
CC relates to new compositions for the non-parenteral delivery of
CC oligonucleotides comprising at least one oligonucleotide in an emulsion.
CC Oligonucleotides delivered via the compositions of the invention can be
CC used to modulate expression of a cellular adhesion protein, modulate a
CC rate of cellular proliferation, or have biological activity against
CC eukaryotic pathogens or retroviruses. They can be used for treating
CC conditions including e.g., ulcerative colitis, Crohn's disease,
CC inflammatory bowel disease or undue cellular proliferation. The
CC compositions can enhance the local and systemic uptake and delivery of
CC nucleic acids via non-parenteral routes of administration (e.g., via the
CC alimentary canal, skin, eyes, pulmonary tract, urethra or vagina)

XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTGGGC 2119

|||||

Db 20 TGACGGATGCCAGCTGGGC 1

RESULT 453

AAZ49390/c

ID AAZ49390 standard; DNA; 20 BP.

XX XX

XX AC AAZ49390;

XX

XX DT

XX XX

XX DE

XX XX

XX 14-MAR-2000 (first entry)

XX XX

XX DE ICAM-1 targetted phosphorothioate oligonucleotide ISIS 15839.

XX KW ICAM-1; cellular adhesion; expression; modulation; antisense;

XX KW non-parenteral; delivery; uptake; administration; emulsion;

XX KW ulcerative colitis; Crohn's disease; inflammatory bowel disease;

XX KW cellular proliferation; ss.

XX XX

XX OS Synthetic.

XX OS Homo sapiens.

XX XX

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate linkages"

FT 2

FT /*tag= b

FT /mod_base= m5c

FT 3

FT /*tag= c

FT /mod_base= m5c

FT 4

FT /*tag= d

FT /mod_base= m5c

FT 8

FT /*tag= e

FT /mod_base= m5c

FT 12

FT /*tag= f

FT /mod_base= m5c

FT 13..20

FT /*tag= g

FT /mod_base= OTHER

FT /note= "2'-methoxyethoxy oligonucleotides"

FT 15

FT /*tag= h

FT /mod_base= m5c

FT 16

FT /*tag= i

FT /mod_base= m5c

FT 19

FT /*tag= j

FT /mod_base= m5c

XX

XX WO9960012-A1.

XX XX

XX PD 25-NOV-1999.

XX XX

XX PF 20-MAY-1999; 99WO-US011394.

XX XX

XX PR 21-MAY-1998; 98US-00082624.

XX XX

XX PA (ISIS-) ISIS PHARM INC.

XX XX

XX PI Teng C, Cook PD, Tillman L, Hardee GE, Ecker DJ, Manoharan M;

XX XX

XX DR WPI; 2000-072428/06.

XX XX

XX PT New oligonucleotide compositions used for the non-parenteral delivery of

XX PT e.g. antisense oligos, ribozymes, peptide nucleic acids, molecular

XX PT decoys, external guide sequences or aptamers.

XX XX

XX Claim 80; Page 37; 133pp; English.

XX XX

XX CC Sequences AAZ49336-Z49343 and AAZ49390 represent antisense

XX CC oligonucleotides designed to modulate cellular adhesion. The invention

XX CC relates to new compositions for the non-parenteral delivery of

XX CC oligonucleotides comprising at least one oligonucleotide in an emulsion.

XX CC Oligonucleotides delivered via the compositions of the invention can be

XX CC used to modulate expression of a cellular adhesion protein, modulate a

CC rate of cellular proliferation, or have biological activity against
CC eukaryotic pathogens or retroviruses. They can be used for treating
CC conditions including e.g., ulcerative colitis, Crohn's disease,
CC inflammatory bowel disease or undue cellular proliferation. The
CC compositions can enhance the local and systemic uptake and delivery of
CC nucleic acids via non-parenteral routes of administration (e.g., via the
CC alimentary canal, skin, eyes, pulmonary tract, urethra or vagina)
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGC 2119
DB 20 TGACGGATGCCAGCTTGGC 1
RESULT 454
AAZ49337/C
ID AAZ49337 standard; DNA; 20 BP.
XX AAZ49337;
XX 14-MAR-2000 (first entry)
XX ICAM-1 targetted phosphorothioate oligonucleotide ISIS 1939.
XX ICAM-1; cellular adhesion; expression; modulation; antisense;
KW non-parenteral; delivery; uptake; administration; emulsion;
KW ulcerative colitis; Crohn's disease; inflammatory bowel disease;
KW cellular proliferation; ss.
XX Synthetic.
OS Homo sapiens.
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages"
XX WO960012-A1.
XX 25-NOV-1999.
XX 20-MAY-1999; 99WO-US011394.
XX 21-MAY-1998; 98US-00082624.
XX (ISIS-) ISIS PHARM INC.
XX Teng C, Cook PD, Tillman L, Hardee GE, Ecker DJ, Manoharan M;
XX WPI; 2000-072428/06.
XX New oligonucleotide compositions used for the non-parenteral delivery of
PT e.g. antisense oligos, ribozymes, peptide nucleic acids, molecular
PT decoys, external guide sequences or aptamers.
XX Claim 80; Page 37; 133pp; English.
XX Sequences AAZ49336-Z49343 and AAZ49390 represent antisense
CC oligonucleotides designed to modulate cellular adhesion. The invention
CC relates to new compositions for the non-parenteral delivery of
CC oligonucleotides comprising at least one oligonucleotide in an emulsion.
CC Oligonucleotides delivered via the compositions of the invention can be
CC used to modulate expression of a cellular adhesion protein, modulate a
CC rate of cellular proliferation, or have biological activity against
CC eukaryotic pathogens or retroviruses. They can be used for treating
CC conditions including e.g., ulcerative colitis, Crohn's disease,
CC inflammatory bowel disease or undue cellular proliferation. The

CC compositions can enhance the local and systemic uptake and delivery of
CC nucleic acids via non-parenteral routes of administration (e.g., via the
CC alimentary canal, skin, eyes, pulmonary tract, urethra or vagina)
XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAAGTGGTGGGG 1957
DB 20 GAGAGGGGAAGTGGTGGGG 1
RESULT 455
AAA93139
ID AAA93139 standard; DNA; 20 BP.
XX AAA93139;
XX 12-JAN-2001 (first entry)
XX Clone vc68_1 secreted protein coding sequence probe SEQ ID NO: 70.
XX Human secreted protein; cytokine; cell proliferation;
KW nutritional supplement; immune modulation; autoimmune disorder;
KW haematopoiesis regulation; tissue growth; haemostasis; inflammation;
KW probe; ss.
XX Homo sapiens.
XX WO200049134-A1.
XX 24-AUG-2000.
XX 18-FEB-2000; 2000WO-US004340.
XX 19-FEB-1999; 99US-0120680P.
XX 23-APR-1999; 99US-00298733.
XX 17-AUG-1999; 99US-0149639P.
XX 23-SEP-1999; 99US-0155686P.
XX 01-OCT-1999; 99US-0157247P.
XX 29-NOV-1999; 99US-0167822P.
XX 29-NOV-1999; 99US-0167823P.
XX 15-FEB-2000; 2000US-0182711P.
XX (ALPH-) ALPHAGENE INC.
XX Valenzuela D, Yuan O, Hoffman H, Hall J, Rapiejko P;
XX WPI; 2000-549267/50.
XX New secreted proteins and polynucleotides encoding them, which are
PT derived from Homosapiens, useful for therapy, diagnosis, and research, as
PT well as nutritional sources or supplements.
XX Disclosure; Page 292; 309pp; English.
XX The present invention is concerned with a number of secreted proteins and
CC their coding sequences isolated from various human cDNA libraries. The
CC probes shown in the specification (AAA93132-A93156) can be used to obtain
CC the cloned sequences from bacterial cells. The proteins and coding
CC sequences can be used in the isolation of similar genes and proteins, in
CC the elucidation of their function in vivo, and to treat a number of
CC conditions. It is possible that they may have uses as nutritional
CC supplements, as cytokine or cell proliferation factors, in immune
CC modulation, where they may be used to treat immune and autoimmune
CC diseases, as haematopoiesis regulators (treating myeloid or lymphoid cell
CC deficiencies), in the promotion of tissue growth, they may have chemokine
CC or chemotactic activity, haemostatic or thrombolytic activity, or anti-
CC inflammatory activity

SQ Sequence 20 BP; 4 A; 9 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2828 TCAAGTATCTCCACCTC 2847
| | | | | | | | | | | | | | | | | | | | | |
Db 1 TCAAGTATCTCCACCTC 20

RESULT 456
AAA06838/c
ID AAA06838 standard; DNA; 20 BP.

XX AC AAA06838;

DT 19-JUN-2000 (first entry)

XX ICAM-1 antisense dimethylaminoxyethyl (DMAOE) oligo, SEQ ID NO:18.

XX Antisense; ICAM-1; dimethylaminoxyethyl; DMAOE; modified nucleoside;
KW phosphorothioate; 2'-deoxy-erythro-pentofuranosyl sugar moiety;
KW nuclease resistant; hybridisation; binding affinity; ss.

XX Homo sapiens.
OS Synthetic.

XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a

FT /note= "These nucleotides are 2'-O-substituted with 2'-O-
FT DMAOE, optionally phosphorothioate linkages"

XX WO200008042-A1.

XX 17-FEB-2000.

XX 09-AUG-1999; 99WO-US017988.

XX 07-AUG-1998; 98US-00130973.

XX (ISIS-) ISIS PHARM INC.

XX Manoharan M, Cook PD, Prakash TP, Kawasaki AM;

XX WPI; 2000-224020/19.

XX Aminoxy-modified nucleosides and oligonucleotides useful in diagnostic,
PT therapeutic and research reagents and for modulating the expression of
PT protein in organisms.

PS Example 84; Page 109; 195pp; English.

XX The invention relates to aminoxy-modified nucleosides and
CC oligonucleotides and to oligonucleotides that elicit RNase H for cleavage
CC in a complementary nucleic acid strand. It also relates to
CC oligonucleotides wherein at least some of the nucleotides are
CC functionalised to be nuclease resistant, at least some of the nucleotides
CC include a substituent that potentiates hybridisation of the
CC oligonucleotide to a complementary strand, and at least some of the
CC nucleotides include a 2'-deoxy-erythro-pentofuranosyl sugar moiety. The
CC inclusion of one or more aminoxy moieties in such oligonucleotides
CC provides for improved binding of such oligonucleotides to a complementary
CC strand. The oligonucleotides of the invention are used as diagnostic,
CC therapeutic or research reagents, and can be used to modulate gene
CC expression in organisms. The oligonucleotides containing the modified
CC nucleosides have increased nuclease resistance and increased binding
CC affinity to a complementary strand. The present sequence represents a
CC uniformly modified dimethylaminoxyethyl (DMAOE) antisense
CC oligonucleotide, targeted against the ICAM-1 gene, which was used in
XX exemplifications of the present invention

SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 457
AAZ99779/c

ID AAZ99779 standard; DNA; 20 BP.

XX AC AAZ99779;

DT 12-JUL-2000 (first entry)

XX Nucleotide sequence of an antisense polyanide oligonucleotide.

XX Antisense polyanide nucleic acid; peptide nucleic acid; PNA;
KW RNase L activator; RNA cleavage; antisense PNA; tumour growth;
KW respiratory syncytial virus infection; viral infection;
KW human immunodeficiency virus; HIV; autosomal dominant disease;
KW chronic myelogenous leukemia; Crohns disease; inflammatory condition; ss.
XX Synthetic.

XX WO200014219-A2.

XX 16-MAR-2000.

XX 02-SEP-1999; 99WO-US020159.

XX 04-SEP-1998; 98US-0099173P.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
XX (UYLE-) RIJCSUNIV LEIDEN.

XX Torrence PF, Van Boom JH, Verheijen JC, Van Der Marel GA;

XX WPI; 2000-256971/22.

XX Cleaving a specific RNA comprising hybridizing the RNA with a chimeric
PT molecule consisting of antisense polyamide nucleic acid (pna) and RNase L
PT activator moieties, useful for treating e.g. cancer and inflammatory
PT diseases.

PS Disclosure; Page 12; 41pp; English.

XX The present sequence represents an antisense polyamide nucleic acid
CC (peptide nucleic acid (PNA)), which is covalently linked to a RNase L
CC activator moiety. The oligonucleotide is used in the method of the
CC invention. The specification describes a method of cleaving a specific
CC RNA, optionally contained within a cell. The method comprises hybridising
CC the RNA with a chimeric molecule of antisense PNA and RNase L activator
CC moieties, and reacting the resulting complex with RNase L. The chimeric
CC molecule is useful for treating Respiratory Syncytial Virus infection,
CC inhibiting tumour growth, treating viral infection (e.g. human
CC immunodeficiency virus (HIV)), autosomal dominant diseases caused by a
CC mutant gene, chronic myelogenous leukemias, and Crohns disease and other
CC inflammatory conditions. It is also useful for sequence-specific
CC inhibition of a targeted mRNA in order to effectively knock out the
CC associated gene as an aid to elucidating the function of the encoded
CC protein

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 458
AA14472/c
ID AA14472 standard; DNA; 20 BP.

XX AA14472;
AC AA14472;
DT 21-AUG-2000 (first entry)
XX Synthetic oligonucleotide #2.
DE
XX Solid phase DNA synthesis; phosphoramidate nucleoside; acetoneitrile;
KW water content; synthetic oligonucleotide; ss.
XX
XX Synthetic.

XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /note= "Phosphorothioate linkages"
XX

PN WO200020431-A1.
XX
XX 13-APR-2000.
XX
XX 01-OCT-1999; 99WO-US022892.
XX
XX 06-OCT-1998; 98US-00167165.
XX

PA (ISIS-) ISIS PHARM INC.
XX
XX Scozzari A;
XX
XX WPI; 2000-303729/26.
XX

PT Coupling of a phosphoramidite nucleoside to a solid support-bound
PT nucleoside, useful for the synthesis of oligonucleotides for use in
PT diagnostic, research or therapeutic applications.
XX
XX Example 5; Page 18; 30pp; English.

CC The invention relates to the use of acetonitrile having a water content
CC of 30-1250 ppm in the linking of a phosphoramidite nucleoside (PMN) to a
CC solid support-bound nucleoside, and to the use of this process in the
CC synthesis of oligonucleotides. The method is used for the coupling of a
CC phosphoramidite nucleoside to a solid support-bound nucleoside,
CC particularly in the large-scale synthesis of oligonucleotides using the
CC phosphoramidite method. The oligonucleotides can be used in diagnostic,
CC research and therapeutic applications, e.g., as probes, primers, linkers,
CC adaptors and antisense oligonucleotides. The use of acetonitrile having a
CC water content of 30-1250 ppm as compared to conventional methods using
CC lower water content acetonitrile (at most 30 ppm) provides more
CC economical synthesis without reduced efficiency of oligonucleotide
CC synthesis. Sequences AA14471-A14474 represent oligonucleotides
CC synthesised using the process of the invention
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 459
AA248918/c

ID AA248918 standard; DNA; 20 BP.
XX
AC AA248918;
XX
DT 29-MAR-2000 (first entry)
XX
DE Human ICAM-1 antisense inhibitor, ISIS #2305.

XX
KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
KW ss.

XX Homo sapiens.
XX
XX WO9961462-A1.
XX
XX 02-DEC-1999.

XX 26-MAY-1999; 99WO-US011548.
XX
XX 27-MAY-1998; 98US-00085759.
XX
XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK, Baker BF;
XX
XX WPI; 2000-072600/06.
XX

PT New antisense oligonucleotides, used for treating e.g. inflammatory
PT conditions, psoriasis, graft rejection, cancers, infections,
PT cardiovascular disorders or autoimmune disorders.
XX

PS Example 10; Page 178; 199pp; English.

CC This sequence is an antisense oligonucleotide of the invention. The
CC antisense oligonucleotides are targeted to a nucleic acid encoding a
CC cellular adhesion molecule (CAM) and is capable of modulating the
CC expression of the CAM. They particularly inhibit intercellular adhesion
CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
CC oligonucleotides can be used to modulate CAM activity in mediating
CC cell:cell interactions and subsequent cellular and biological responses,
CC e.g. T cell activation, leukocyte transmigration and inflammation. The
CC antisense sequences can be used for modulating the synthesis of a CAM.
CC They can be used for treating an animal suspected of having or being
CC prone to a disease or condition associated with a CAM. Oligonucleotides
CC targeted to ICAM-1 can be used for treating an inflammatory disease or
CC condition e.g. inflammatory bowel disease such as Crohn's disease,
CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
CC can also be used for reducing corticosteroid use in a patient or for
CC reducing cyclosporine use in a patient. The oligonucleotides can also be
CC used for detection and diagnosis. They can also be used for treating e.g.
CC hyperproliferative disorders, tumours, diapedesis, graft versus host
CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
CC myocarditis, ischaemic heart disease or stroke

XX Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAGTCTAGCCTGATGAG 1940
 DB 20 TTAAGTCTAGCCTGATGAG 1

RESULT 460
 AAZ48910/C
 ID AAZ48910 standard; DNA; 20 BP.

XX
 AC AAZ48910;
 XX
 DT 29-MAR-2000 (first entry)
 XX
 DE Human ICAM-1 antisense inhibitor, ISIS #1940.

XX
 KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.

XX
 OS Homo sapiens.

XX
 PN W09961462-A1.

XX
 PD 02-DEC-1999.

XX
 PF 26-MAY-1999; 99WO-US011548.

XX
 PR 27-MAY-1998; 98US-00085759.

XX
 PA (ISIS-) ISIS PHARM INC.

XX
 PI Bennett CF, Mirabelli CK, Baker BF;

XX
 DR WPI; 2000-072600/06.

XX
 PT New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.

XX
 PS Example 10; Page 176; 199pp; English.

XX
 CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,

CC
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 CC
 CC Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;
 CC
 CC Query Match 0.7%; Score 20; DB 1; Length 20;
 CC Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 CC Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 CC QY 2962 AGTTAATAAGCTTCTCAA 2981
 CC DB 20 AGTTAATAAGCTTCTCAA 1

RESULT 461
 AAZ48917/C
 ID AAZ48917 standard; DNA; 20 BP.

XX
 AC AAZ48917;
 XX
 DT 29-MAR-2000 (first entry)
 XX
 DE Human ICAM-1 antisense inhibitor, ISIS #2304.

XX
 KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.

XX
 OS Homo sapiens.

XX
 PN W09961462-A1.

XX
 PD 02-DEC-1999.

XX
 PF 26-MAY-1999; 99WO-US011548.

XX
 PR 27-MAY-1998; 98US-00085759.

XX
 PA (ISIS-) ISIS PHARM INC.

XX
 PI Bennett CF, Mirabelli CK, Baker BF;

XX
 DR WPI; 2000-072600/06.

XX
 PT New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.

XX
 PS Example 10; Page 178; 199pp; English.

XX
 CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences

CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1881 CAAGAGGAGGAGCAAGACT 1900
 |||||
 DB 20 CAAGAGGAGGAGCAAGACT 1

RESULT 462
 AAZ48916/c
 ID AAZ48916 standard; DNA; 20 BP.
 XX AAZ48916;
 AC
 DT 29-MAR-2000 (first entry)
 XX Human ICAM-1 antisense inhibitor, ISIS #2303.
 DE
 KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX Homo sapiens.
 OS
 XX
 PN WO9961462-A1.
 XX
 PD 02-DEC-1999.
 XX
 PF 26-MAY-1999; 99WO-US011548.
 XX
 PR 27-MAY-1998; 98US-00085759.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK, Baker BF;
 XX
 DR WPI; 2000-072600/06.
 XX
 PT New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX
 FS Example 10; Page 178; 199pp; English.

CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The

CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2025 GAGGCCACAGACTTACAGA 2044
 |||||
 DB 20 GAGGCCACAGACTTACAGA 1

RESULT 463
 AAZ48907/c
 ID AAZ48907 standard; DNA; 20 BP.
 XX AAZ48907;
 DT 29-MAR-2000 (first entry)
 XX Human ICAM-1 antisense inhibitor, ISIS #1937.
 DE
 KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX Homo sapiens.
 OS
 XX
 PN WO9961462-A1.
 XX
 PD 02-DEC-1999.
 XX
 PF 26-MAY-1999; 99WO-US011548.
 XX
 PR 27-MAY-1998; 98US-00085759.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK, Baker BF;
 XX
 DR WPI; 2000-072600/06.
 XX
 PT New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX
 FS Example 10; Page 176; 199pp; English.
 XX
 CC This sequence is an antisense oligonucleotide of the invention. The

CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell-cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 20 BP; 2 A; 3 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1637 CACAAGCCAGCCTCCCTGA 1656
 DB 20 CACAAGCCAGCCTCCCTGA 1

RESULT 464
 AAZ48884/c
 ID AAZ48884 standard; DNA; 20 BP.
 XX AAZ48884;
 AC
 XX
 DT 29-MAR-2000 (first entry)
 XX
 DE Human ICAM-1 antisense inhibitor, ISIS #16863.

XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.

XX Homo sapiens.
 OS
 XX WO9961462-A1.
 PN
 XX
 PD 02-DEC-1999.
 XX
 XX 26-MAY-1999; 99WO-US011548.
 PF
 XX
 XX 27-MAY-1998; 98US-00085759.
 PR
 XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK, Baker BF;
 PI
 XX WPI; 2000-072600/06.
 DR

XX
 PT
 PT
 XX
 PS
 XX

New antisense oligonucleotides, used for treating e.g. inflammatory conditions, psoriasis, graft rejection, cancers, infections, cardiovascular disorders or autoimmune disorders.

Claim 5; Page 193; 199pp; English.

XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell-cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 20 BP; 7 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1497 GATTGTCAATCATCATCTGTGG 1516
 DB 20 GATTGTCAATCATCATCTGTGG 1

RESULT 465
 AAZ48892/c
 ID AAZ48892 standard; DNA; 20 BP.
 XX AAZ48892;
 AC
 XX
 DT 29-MAR-2000 (first entry)
 XX
 DE Human ICAM-1 antisense inhibitor, ISIS #2302.

XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.

XX Homo sapiens.
 OS
 XX WO9961462-A1.
 PN
 XX 02-DEC-1999.
 PD
 XX 26-MAY-1999; 99WO-US011548.
 PF

```
XX PR 27-MAY-1998; 98US-00085759.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CF, Mirabelli CK, Baker BF;
XX DR WPI; 2000-072600/06.
XX
XX New antisense oligonucleotides, used for treating e.g. inflammatory
PT conditions, psoriasis, graft rejection, cancers, infections,
PT cardiovascular disorders or autoimmune disorders.
XX
XX Claim 5; Page 177; 199pp; English.
XX
XX This sequence is an antisense oligonucleotide of the invention. The
CC antisense oligonucleotides are targeted to a nucleic acid encoding a
CC cellular adhesion molecule (CAM) and is capable of modulating the
CC expression of the CAM. They particularly inhibit intercellular adhesion
CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
CC oligonucleotides can be used to modulate CAM activity in mediating
CC cell:cell interactions and subsequent cellular and biological responses,
CC e.g. T cell activation, leukocyte transmigration and inflammation. The
CC antisense sequences can be used for modulating the synthesis of a CAM.
CC They can be used for treating an animal suspected of having or being
CC prone to a disease or condition associated with a CAM. Oligonucleotides
CC targeted to ICAM-1 can be used for treating an inflammatory disease or
CC condition e.g. inflammatory bowel disease such as Crohn's disease,
CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
CC can also be used for reducing corticosteroid use in a patient or for
CC reducing cyclosporine use in a patient. The oligonucleotides can also be
CC used for detection and diagnosis. They can also be used for treating e.g.
CC hyperproliferative disorders, tumours, diapedesis, graft versus host
CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
CC myocarditis, ischaemic heart disease or stroke
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGTTGGGC 2119
DB 20 TGACGGATGCCAGTTGGGC 1
RESULT 466
AAZ48902/C
ID AAZ48902 standard; DNA; 20 BP.
XX AAZ48902;
XX
XX 29-MAR-2000 (first entry)
XX
XX Human ICAM-1 antisense inhibitor, ISIS #1932.
XX
XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
KW ss.
```

```
XX OS Homo sapiens.
XX PN WO9961462-A1.
XX PD 02-DEC-1999.
XX PF 26-MAY-1999; 99WO-US011548.
XX PR 27-MAY-1998; 98US-00085759.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Bennett CF, Mirabelli CK, Baker BF;
XX DR WPI; 2000-072600/06.
XX
XX New antisense oligonucleotides, used for treating e.g. inflammatory
PT conditions, psoriasis, graft rejection, cancers, infections,
PT cardiovascular disorders or autoimmune disorders.
XX
XX Example 10; Page 174; 199pp; English.
XX
XX This sequence is an antisense oligonucleotide of the invention. The
CC antisense oligonucleotides are targeted to a nucleic acid encoding a
CC cellular adhesion molecule (CAM) and is capable of modulating the
CC expression of the CAM. They particularly inhibit intercellular adhesion
CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
CC oligonucleotides can be used to modulate CAM activity in mediating
CC cell:cell interactions and subsequent cellular and biological responses,
CC e.g. T cell activation, leukocyte transmigration and inflammation. The
CC antisense sequences can be used for modulating the synthesis of a CAM.
CC They can be used for treating an animal suspected of having or being
CC prone to a disease or condition associated with a CAM. Oligonucleotides
CC targeted to ICAM-1 can be used for treating an inflammatory disease or
CC condition e.g. inflammatory bowel disease such as Crohn's disease,
CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
CC can also be used for reducing corticosteroid use in a patient or for
CC reducing cyclosporine use in a patient. The oligonucleotides can also be
CC used for detection and diagnosis. They can also be used for treating e.g.
CC hyperproliferative disorders, tumours, diapedesis, graft versus host
CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
CC myocarditis, ischaemic heart disease or stroke
XX
XX Sequence 20 BP; 2 A; 5 C; 10 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 58 ATGGCTCCCGAGCAGCCCCCG 77
DB 20 ATGGCTCCCGAGCAGCCCCCG 1
RESULT 467
AAZ48906/C
ID AAZ48906 standard; DNA; 20 BP.
XX AAZ48906;
XX
XX 29-MAR-2000 (first entry)
XX
XX Human ICAM-1 antisense inhibitor, ISIS #1936.
XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
```

KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.

XX Homo sapiens.

XX WO9961462-A1.

XX 02-DEC-1999.

XX 26-MAY-1999; 99WO-US011548.

XX 27-MAY-1998; 98US-00085759.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK, Baker BF;

XX WPI; 2000-072600/06.

XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.

XX Example 10; Page 175; 199pp; English.

CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease.
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke

XX Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGGAGGTACCCCGGAG 1464

|||||
 20 AAGGGGAGGTACCCCGGAG 1

RESULT 468

AAZ48909/C

ID AAZ48909 standard; DNA; 20 BP.

XX

AC AAZ48909;

DT 29-MAR-2000 (first entry)

DE Human ICAM-1 antisense inhibitor, ISIS #1939.

XX

KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.

XX Homo sapiens.

XX WO9961462-A1.

XX 02-DEC-1999.

XX 26-MAY-1999; 99WO-US011548.

XX 27-MAY-1998; 98US-00085759.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK, Baker BF;

XX WPI; 2000-072600/06.

XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.

XX Example 10; Page 176; 199pp; English.

CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke

XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
 DB 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 469
 AAZ48903/c
 ID AAZ48903 standard; DNA; 20 BP.
 XX AAZ48903;
 AC AAZ48903;
 DT 29-MAR-2000 (first entry)
 DE Human ICAM-1 antisense inhibitor, ISIS #1933.
 XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX Homo sapiens.
 OS WO9961462-A1.
 PN 02-DEC-1999.
 PD 26-MAY-1999; 99WO-US011548.
 PF 27-MAY-1998; 98US-00085759.
 PR (ISIS-) ISIS PHARM INC.
 PA Bennett CF, Mirabelli CK, Baker BF;
 PI WPI; 2000-072600/06.
 DR New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX Example 10; Page 175; 199pp; English.

This sequence is an antisense oligonucleotide of the invention. The
 antisense oligonucleotides are targeted to a nucleic acid encoding a
 cellular adhesion molecule (CAM) and is capable of modulating the
 expression of the CAM. They particularly inhibit intercellular adhesion
 molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 oligonucleotides can be used to modulate CAM activity in mediating
 cell-cell interactions and subsequent cellular and biological responses,
 e.g. T cell activation, leukocyte transmigration and inflammation. The
 antisense sequences can be used for modulating the synthesis of a CAM.
 They can be used for treating an animal suspected of having or being
 prone to a disease or condition associated with a CAM. Oligonucleotides
 targeted to ICAM-1 can be used for treating an inflammatory disease or
 condition e.g. inflammatory bowel disease such as Crohn's disease,
 colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 pemphonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 can also be used for reducing corticosteroid use in a patient or for
 reducing cyclosporine use in a patient. The oligonucleotides can also be
 used for detection and diagnosis. They can also be used for treating e.g.
 hyperproliferative disorders, tumours, diapedesis, graft versus host
 disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute

CC myocarditis, ischaemic heart disease or stroke
 XX Sequence 20 BP; 6 A; 7 C; 7 G; 0 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTCTCTCGGGGCTCT 116
 DB 20 CTGGTCTCTCTCGGGGCTCT 1

RESULT 470
 AAZ48887/c
 ID AAZ48887 standard; DNA; 20 BP.
 XX AAZ48887;
 AC AAZ48887;
 DT 29-MAR-2000 (first entry)
 DE Human ICAM-1 antisense inhibitor, ISIS #16867.
 XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX Homo sapiens.
 OS WO9961462-A1.
 PN 02-DEC-1999.
 PD 26-MAY-1999; 99WO-US011548.
 PF 27-MAY-1998; 98US-00085759.
 PR (ISIS-) ISIS PHARM INC.
 PA Bennett CF, Mirabelli CK, Baker BF;
 PI WPI; 2000-072600/06.
 DR New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX Claim 5; Page 93; 199pp; English.

This sequence is an antisense oligonucleotide of the invention. The
 antisense oligonucleotides are targeted to a nucleic acid encoding a
 cellular adhesion molecule (CAM) and is capable of modulating the
 expression of the CAM. They particularly inhibit intercellular adhesion
 molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 oligonucleotides can be used to modulate CAM activity in mediating
 cell-cell interactions and subsequent cellular and biological responses,
 e.g. T cell activation, leukocyte transmigration and inflammation. The
 antisense sequences can be used for modulating the synthesis of a CAM.
 They can be used for treating an animal suspected of having or being
 prone to a disease or condition associated with a CAM. Oligonucleotides
 targeted to ICAM-1 can be used for treating an inflammatory disease or
 condition e.g. inflammatory bowel disease such as Crohn's disease,
 colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 pemphonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 can also be used for reducing corticosteroid use in a patient or for

CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 20 BP; 2 A; 4 C; 4 G; 10 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1587 GAAATACAGACTACAACAGG 1606
 |||||
 Db 20 GAAATACAGACTACAACAGG 1

RESULT 471
 AAZ48901/C
 ID AAZ48901 standard; DNA; 20 BP.

XX AAZ48901;

XX 29-MAR-2000 (first entry)

XX Human ICAM-1 antisense inhibitor, ISIS #1931.

XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.

XX Homo sapiens.

XX WO9961462-A1.

XX 02-DEC-1999.

XX 26-MAY-1999; 99WO-US011548.

XX 27-MAY-1998; 98US-00085759.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK, Baker BF;

XX WPI; 2000-072600/06.

XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.

XX Example 10; Page 174; 199pp; English.

XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.

CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease.
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCTCGCTATG 60
 |||||
 Db 20 GCAACCTCAGCCTCGCTATG 1

RESULT 472
 AAZ48905/C

XX AAZ48905 standard; DNA; 20 BP.

XX AAZ48905;

XX 29-MAR-2000 (first entry)

XX Human ICAM-1 antisense inhibitor, ISIS #1935.

XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.

XX Homo sapiens.

XX WO9961462-A1.

XX 02-DEC-1999.

XX 26-MAY-1999; 99WO-US011548.

XX 27-MAY-1998; 98US-00085759.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK, Baker BF;

XX WPI; 2000-072600/06.

XX New antisense oligonucleotides, used for treating e.g. inflammatory.
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.

XX Example 10; Page 175; 199pp; English.

XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a

CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell-cell interactions and subsequent cellular and biological responses.
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke

SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGACC 894

|||||

DB 20 AGGCCTCAGTCAGTGACC 1

RESULT 473

AAZ48921/c

ID AAZ48921 standard; DNA; 20 BP.

AC AAZ48921;

XX 29-MAR-2000 (first entry)

DE Human ICAM-1 antisense inhibitor, ISIS #3581.

XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.

XX Homo sapiens.

OS WO9961462-A1.

PN 02-DEC-1999.

PD 26-MAY-1999; 99WO-US011548.

PF 27-MAY-1998; 98US-00085759.

XX (ISIS-) ISIS PHARM INC.

PA Bennett CF, Mirabelli CK, Baker BP;

XX WPI; 2000-072600/06.

XX

PT New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 CC cardiovascular disorders or autoimmune disorders.

XX Example 10; Page 191; 199pp; English.

XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell-cell interactions and subsequent cellular and biological responses.
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke

XX Sequence 20 BP; 3 A; 10 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGGTGGGGGAGACATA 1964

|||||

DB 20 GAAGTGGTGGGGGAGACATA 1

RESULT 474

AAZ4897/c

ID AAZ4897 standard; DNA; 20 BP.

AC AAZ4897;

XX 29-MAR-2000 (first entry)

DE Human ICAM-1 antisense inhibitor, ISIS #1559.

XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.

XX Homo sapiens.

OS WO9961462-A1.

PN 02-DEC-1999.

PD 26-MAY-1999; 99WO-US011548.

XX

KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO9961462-A1.
 PN
 XX
 XX 02-DEC-1999.
 PD
 XX
 XX 26-MAY-1999; 99WO-US011548.
 PF
 XX
 XX 27-MAY-1998; 98US-00085759.
 PR
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX
 XX Bennett CF, Mirabelli CK, Baker BF;
 PI
 XX
 XX WPI; 2000-072600/06.
 DR
 XX
 XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 PT
 XX
 XX Example 10; Page 178; 199pp; English.
 PS
 XX
 XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell-cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 XX Sequence 20 BP; 2 A; 4 C; 7 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1962 ATAGCCCCCACCATGAGGACA 1981
 |||||
 DB 20 ATAGCCCCCACCATGAGGACA 1
 RESULT 477
 AAZ48908/c
 ID AAZ48908 standard; DNA; 20 BP.
 XX

AC AAZ48908;
 XX
 DT 29-MAR-2000 (first entry)
 XX
 DE Human ICAM-1 antisense inhibitor, ISIS #1938.
 XX
 KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO9961462-A1.
 PN
 XX
 XX 02-DEC-1999.
 PD
 XX
 XX 26-MAY-1999; 99WO-US011548.
 PF
 XX
 XX 27-MAY-1998; 98US-00085759.
 PR
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX
 XX Bennett CF, Mirabelli CK, Baker BF;
 PI
 XX
 XX WPI; 2000-072600/06.
 DR
 XX
 XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 PT
 XX
 XX Example 10; Page 176; 199pp; English.
 PS
 XX
 XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell-cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 XX Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1654 TGAACCTATCCCGGACAGG 1673

Db 20 TGAACCTATCCCGGACAGG 1

RESULT 478
AAZ48875/c
ID AAZ48875 standard; DNA; 20 BP.
XX AAZ48875;
XX
XX 29-MAR-2000 (first entry)
XX
XX Human ICAM-1 antisense inhibitor, ISIS #3067.
XX
XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
KW ss.
XX Homo sapiens.
XX
XX WO9961462-A1.
XX
XX 02-DEC-1999.
XX
XX 26-MAY-1999; 99WO-US011548.
XX
XX 27-MAY-1998; 98US-00085759.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Mirabelli CK, Baker BP;
XX
XX WPI; 2000-072606/06.
XX
XX New antisense oligonucleotides, used for treating e.g. inflammatory
PT conditions, psoriasis, graft rejection, cancers, infections,
PT cardiovascular disorders or autoimmune disorders.
XX
XX Claim 5; Page 191; 199pp; English.
XX
XX This sequence is an antisense oligonucleotide of the invention. The
CC antisense oligonucleotides are targeted to a nucleic acid encoding a
CC cellular adhesion molecule (CAM) and is capable of modulating the
CC expression of the CAM. They particularly inhibit intercellular adhesion
CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
CC oligonucleotides can be used to modulate CAM activity in mediating
CC cell-cell interactions and subsequent cellular and biological responses,
CC e.g. T cell activation, leukocyte transmigration and inflammation. The
CC antisense sequences can be used for modulating the synthesis of a CAM.
CC They can be used for treating an animal suspected of having or being
CC prone to a disease or condition associated with a CAM. Oligonucleotides
CC targeted to ICAM-1 can be used for treating an inflammatory disease or
CC condition e.g. inflammatory bowel disease such as Crohn's disease,
CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
CC can also be used for reducing corticosteroid use in a patient or for
CC reducing cyclosporine use in a patient. The oligonucleotides can also be
CC used for detection and diagnosis. They can also be used for treating e.g.
CC hyperproliferative disorders, tumours, diapedesis, graft versus host
CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
CC myocarditis, ischaemic heart disease or stroke

XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 479
AAZ57157/c
ID AAZ57157 standard; DNA; 20 BP.
XX
XX AAZ57157;
XX
XX 03-APR-2000 (first entry)
XX ICAM targeting phosphorothioate oligonucleotide #1.
XX
XX Phosphorothioate; activator; oligonucleotide synthesis; phosphoramidite;
KW phosphitylating reagent; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /note= "phosphorothioate linkages"
XX
XX WO9962922-A1.
XX
XX 09-DEC-1999.
XX
XX 02-JUN-1999; 99WO-US012251.
XX
XX 02-JUN-1998; 98US-0087757P.
XX 23-OCT-1998; 98US-00177953.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Sanghvi Y, Manoharan M, Ravikumar VT;
XX WPI; 2000-097311/08.
XX
XX Preparation of nucleoside phosphoramidites and oligonucleotides.
XX
XX Example 42; Page 93; 153pp; English.
XX
XX The present invention describes nucleoside phosphoramidites and
CC oligonucleotides (ON's) prepared using pyridinium, imidazolium or
CC benzimidazolium salts as activators. The preparation of a phosphitylated
CC compound comprises reacting a compound having a hydroxyl group with a
CC phosphitylating reagent in the presence of a pyridinium salt in a
CC solvent. The phosphoramidites are useful as building blocks for synthesis
CC of oligonucleotides, which are potentially useful in therapeutic and
CC diagnostic applications. The activators can be produced in situ by mixing
CC pyridine and an acid, producing benefits in large scale synthesis.
CC Compared with conventional activators, e.g. 1H tetrazole, the pyridinium
CC salts, and materials necessary for their generation in situ, are non-
CC explosive and easier to store, and also cheaper and have higher
CC solubility in organic solvents. Final purity of the phosphitylated
CC material results from use of a less acidic reaction medium when
CC pyridinium salts are used. The present sequence represents a
CC phosphorothioate 20-mer oligonucleotide, the synthesis of which is
CC described in an example from the present invention
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;

```
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTGTGCTACTCAGA 37
DB 18 GAGCTCCTGTGCTACTCAGA 1
20 GAGCTCCTGTGCTACTCAGA 1

RESULT 480
AAZ57150/c
ID AAZ57150 standard; DNA; 20 BP.
XX
AC AAZ57150;
XX
DT 03-APR-2000 (first entry)
XX
DE Phosphorothioate 20-mer oligonucleotide #2.
XX
KW Phosphorothioate; activator; oligonucleotide synthesis; phosphoramidite;
KW phosphitylating reagent; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /note= "phosphorothioate linkages"
XX
PN WO9962922-A1.
XX
PD 09-DEC-1999.
XX
PF 02-JUN-1999; 99WO-US012251.
XX
PR 02-JUN-1998; 98US-0087757P.
PR 23-OCT-1998; 98US-00177953.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Sanghvi Y, Manoharan M, Ravikumar VT;
XX
PS WPI; 2000-097311/08.
XX
PT Preparation of nucleoside phosphoramidites and oligonucleotides.
XX
PS Example 19; Page 81; 153pp; English.
XX
CC The present invention describes nucleoside phosphoramidites and
CC oligonucleotides (ON's) prepared using pyridinium, imidazolium or
CC benzimidazolium salts as activators. The preparation of a phosphitylated
CC compound comprises reacting a compound having a hydroxyl group with a
CC phosphitylating reagent in the presence of a pyridinium salt in a
CC solvent. The phosphoramidites are useful as building blocks for synthesis
CC of oligonucleotides, which are potentially useful in therapeutic and
CC diagnostic applications. The activators can be produced in situ by mixing
CC pyridine and an acid, producing benefits in large scale synthesis.
CC Compared with conventional activators, e.g. 1H tetrazole, the pyridinium
CC salts, and materials necessary for their generation in situ, are non-
CC explosive and easier to store, and also cheaper and have higher
CC solubility in organic solvents. Final purity of the phosphitylated
CC material results from use of a less acidic reaction medium when
CC pyridinium salts are used. The present sequence represents a
CC phosphorothioate 20-mer oligonucleotide, the synthesis of which is
CC described in an example from the present invention
XX
SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
DB 20 TGACGGATGCCAGCTTGGC 1
20 TGACGGATGCCAGCTTGGC 1
```

```
RESULT 481
AAA50200/c
ID AAA50200 standard; DNA; 20 BP.
XX
AC AAA50200;
XX
DT 07-NOV-2000 (first entry)
XX
DE 2'-Methoxyethoxy-modified phosphodiester oligonucleotide.
XX
KW Phosphodiester oligonucleotide; H-phosphonate chemistry; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /note= "2'-methoxyethoxy modified nucleosides"
XX
PN WO200047593-A1.
XX
PD 17-AUG-2000.
XX
PF 11-FEB-2000; 2000WO-US003543.
XX
PR 12-FEB-1999; 99US-00250075.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Manoharan M, Maier MA;
XX
PS WPI; 2000-558188/51.
XX
PT Preparation of mixed backbone oligomeric compounds useful as e.g. primers
PT for diagnostic tests, involves oxidation of H-phosphonate internucleoside
PT linkages to phosphodiester internucleoside linkages.
XX
PS Example 6; Page 34; 49pp; English.
XX
CC The present sequence is that of a phosphodiester oligonucleotide
CC containing T, C, A and G nucleobases, each having a 2'-methoxyethoxy
CC group on its 5' ribosyl sugar moiety, and prepared using 5'-O-DMT-2'-MOE-
CC 5-methylcytidine-3'-succinyl controlled pore glass as the solid support.
CC It is an example of an oligomeric compound produced according to the
CC methods of the invention. The invention provides compounds and methods
CC for the preparation of mixed backbone oligomeric, or chimeric, compounds
CC having phosphodiester internucleoside linkages in addition to
CC phosphorothioate and/or phosphoramidate internucleoside linkages. The
CC methods also include incorporation of boranophosphate internucleoside
CC linkages. The methods utilize H-phosphonate intermediates that are
CC coupled together forming contiguous regions of 1 or more H-phosphonate
CC internucleoside linkages. Each contiguous region is subsequently oxidized
CC to phosphodiester, phosphorothioate, phosphoramidate or boranophosphate
CC internucleoside linkages prior to further elongation. Mixed backbone
CC oligomeric compounds are prepared in this manner by oxidizing adjacent
CC regions with different reagents. Oligomeric compounds of the invention
CC are prepared using novel oxidation steps that oxidize a region of 1 or
CC more H-phosphonate internucleoside linkages without degrading existing
CC linkages that have been previously oxidized. The oligonucleotides
CC obtained are useful as primers in PCR, probes, linkers, gene fragments
CC and for other diagnostic tests on e.g. biological tissue, fluid, cells
CC etc., as research reagents, and as antiviral agents
XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTGTGCTACTCAGA 37
18 GAGCTCCTGTGCTACTCAGA 37
|||||
```

Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 482
AAA94747/C
ID AAA94747 standard; DNA; 20 BP.
XX AC AAA94747;
XX 19-JAN-2001 (first entry)
XX XX Oligonucleotide #1.
XX VP22; gene therapy; tumour; psoriasis; eczema; skin cancer; ss.
XX Unidentified.
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "All bases are phosphorothioate deoxynucleotides.
FT Optionally labelled at 3' end with fluorescein or at 5'
FT end with biotin"
XX WO200053722-A2.
XX 14-SEP-2000.
XX 10-MAR-2000; 2000WO-GB000897.
XX 10-MAR-1999; 99GB-00005444.
XX 24-DEC-1999; 99GB-00030499.
XX (PHOG-) PHOGEN LTD.
XX O'hare PFJ, Normand NM;
XX WPI; 2000-594314/56.
XX Aggregated composition suitable for phototherapy or prophylaxis of
FT psoriasis, eczema or skin cancer and for delivering nucleic acids and
FT proteins into cells, comprises transport protein VP22 and an
FT oligonucleotide.
XX Example 1; Page 11; 28pp; English.
XX The present invention relates to an aggregated composition comprising a
CC polypeptide having the transport function of herpesviral transport
CC protein VP22. The aggregates can be useful for delivery of
CC oligonucleotides and proteins into cells. The present sequence is one
CC such oligonucleotide which may be delivered into cells using the method
CC of the present invention. The aggregated composition is useful for
CC preparing a medicament for therapy or prophylaxis of a disease and for
CC delivering molecules to cells in vitro. The aggregates are delivered to
CC target cells such as tumour cells in vivo and are useful for treating
CC psoriasis, eczema or skin cancer
XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAGTGGTGGGG 1957
Db 20 GAGAGGGGAGTGGTGGGG 1
RESULT 483
AAA94540/C
ID AAA94540 standard; DNA; 20 BP.
XX

AC AAA94540;
XX 10-JAN-2001 (first entry)
XX Example biologically active oligonucleotide #2.
XX Oligonucleotide; non-parenteral; multi-particulate; phosphorothioate; ss.
XX Synthetic.
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate internucleotide linkage"
XX WO200050050-A1.
XX 31-AUG-2000.
XX 23-FEB-2000; 2000WO-US004662.
XX 23-FEB-1999; 99US-00256515.
XX (ISIS-) ISIS PHARM INC.
XX Hardee GE, Tillman LG, Mehta RC, Teng C;
XX WPI; 2000-572032/53.
XX Non-parenteral multi-particulate formulations comprise biologically
PT active substances bound to carrier particles for delivery across mucosal
PT membranes.
XX Claim 4; Page 8; 38pp; English.
XX The present invention relates to non-parenteral multi-particulate
CC formulations for transporting agents (for example therapeutic) across
CC mucosal membranes. The formulations comprise carrier particles bound with
CC a biologically active agent and a penetration enhancer. The formulations
CC associate with buccal, nasal, pulmonary, gastrointestinal and vaginal
CC mucosal membranes to transport the biologically active agents to the
CC lymph system, blood system or epithelial tissue of the subject. The
CC formulation is administered orally which is preferred by patients. The
CC present sequence is an example oligonucleotide that may be used in the
CC formulation
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 484
AAA71631/C
ID AAA71631 standard; DNA; 20 BP.
XX AC AAA71631;
XX 14-DEC-2000 (first entry)
XX Phosphorothioate 20-mer primer DNA #1.
XX Phosphorothioate; primer; oligomer synthesis; antisense therapy; ss.
XX Synthetic.
XX Key Location/Qualifiers

```

FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate linkage"
PN EP1028124-A2.
XX 16-AUG-2000.
XX
XX 06-SEP-1999; 99BP-00307066.
XX
XX 04-FEB-1999; 99US-0118564P.
PR 09-APR-1999; 99US-00288679.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX Ravikumar VT, Manoharan M, Capaldi DC, Krotz A, Cole DL;
PI Guzaev A;
XX
XX WPI; 2000-500332/45.
XX
XX Novel method for the production of oligomers with reduced exocyclic
PT adducts comprises treatment with deprotecting and cleaving reagents.
PT
XX Example 3; Page 17; 33pp; English.
XX
XX This invention describes a novel synthetic method (M) comprising: (a)
CC providing a sample comprising a number of oligomers of formula (i); (b)
CC contacting the sample with a deprotecting agent to remove Rt groups from
CC the oligomers; and (c) reacting the oligomer with a cleaving reagent. The
CC method is used to produce oligomeric compounds for use in antisense and
CC oligonucleotide therapies. The method enables the synthesis of oligomers
CC with a reduction in the number acrylonitrile groups attached.
CC Acrylonitrile has been demonstrated to be a potent carcinogen in rats.
CC This sequence represents a phosphorothioate 20-mer primer which is used
CC in the method of the invention
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 485
AAA99217/c
ID AAA99217 standard; DNA; 20 BP.
XX
XX AAA99217;
AC
XX 23-JAN-2001 (first entry)
DT
XX
XX ICAM-1 target phosphorothioate antisense oligonucleotide SEQ ID NO:1.
DE
XX Phosphorothioate; antisense oligonucleotide; target; purification;
KW dimethoxytrityl group removal; synthesis; deprotection; ss.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /note= "phosphorothioate linkages"
XX
XX WO200055170-A1.
PN
XX 21-SEP-2000.
PD
XX 17-MAR-2000; 2000WO-US007003.
PF

XX 17-MAR-1999; 99US-00271220.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Krotz AH, Mcelroy B, Scozzari AN;
PI
XX WPI; 2000-647063/62.
DR
XX
XX Improving deprotection of acid labile 5'-hydroxy protecting group-
PT containing oligonucleotides for large scale synthesis of
PT oligonucleotides, involves determining the half life of protecting groups
PT in acid solution.
XX
XX Example 1; Page 14; 25pp; English.
XX
XX The present invention describes a method for improving deprotection of an
CC acid labile 5'-hydroxy protecting group-containing oligonucleotides (I).
CC The method involves determining the half life for (I) in an acid solution
CC capable of removing the 5'-hydroxy protecting group from oligonucleotide,
CC and reacting (I) in acid solution for approximately 5-20 half lives. The
CC method is useful for synthesizing and purifying oligonucleotides in large
CC scale. The method allows the user to determine an optical reaction time
CC for removal of the 5'-hydroxy protecting group so that a fine balance
CC between detritylation and depurination is maintained. The present
CC sequence represents a phosphorothioate antisense oligonucleotide targeted
CC to ICAM-1, which is used in an example from the present invention
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 486
AAC73477
ID AAC73477 standard; DNA; 20 BP.
XX
XX AAC73477;
AC
XX 02-FEB-2001 (first entry)
DT
XX
XX Forward primer #102 used in multiplexing PCR/SBE assay.
DE
XX Oligonucleotide array; genotyping; single base extension reaction; SBE;
KW PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
XX
XX Unidentified.
OS
XX WO200058516-A2.
PN
XX 05-OCT-2000.
PD
XX
XX 27-MAR-2000; 2000WO-US008069.
PF
XX 26-MAR-1999; 99US-0126473P.
PR 23-JUN-1999; 99US-0140359P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY-) AFFYMETRIX INC.
XX
XX Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
PI Ryder T, Sklar P;
XX
XX WPI; 2000-656171/63.
DR
XX Universal array of oligonucleotides tags attached to a solid substrate
PT along with locus-specific tagged oligonucleotides useful in genotyping

```

PT using single base extension reactions.

XX PS Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
XX Mismatches 0; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX Example 7; Page 58; 70pp; English.
XX The present invention relates to an oligonucleotide array comprising
XX oligonucleotide tags fixed to a solid substrate. The oligonucleotide
XX array is useful for genotyping a nucleic acid sample at one or more loci
XX via single base extension (SBE) reactions. A pair of primers is used to
XX amplify a polymorphic locus in a sample e.g. a single nucleotide
XX polymorphism (SNP). The present sequence is one of the primers used in
XX the method of the present invention to amplify a polymorphic sample. The
XX amplified nucleic acid product is then used as a template in a SBE
XX reaction with an extension primer. The SBE reaction products are used to
XX form the oligonucleotide array

SQ Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 27 TGCTACTCAGATTGCAACC 46
Db 1 TGCTACTCAGATTGCAACC 20

RESULT 487

AAF32820/C
ID AAF32820 standard; DNA; 20 BP.

XX AAF32820;

AC 23-MAR-2001 (first entry)

XX ICAM-1 antisense oligonucleotide SEQ ID NO: 17.

XX Human; mouse; B7-1; B7-2; antisense; PCR primer; inflammation;
XX autoimmune disorder; phosphorothioate backbone; ss.

XX Unidentified.

XX WO200074687-A1.

XX 14-DEC-2000.

XX 25-MAY-2000; 2000WO-US014471.

XX 04-JUN-1999; 99US-00326186.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Vickers TA, Karras JG;

XX WPI; 2001-049991/06.

XX Novel compound for diagnosing, preventing and treating immune disorders,
XX comprising an oligonucleotide that specifically hybridizes with a nucleic
XX acid sequence encoding B7 protein.

XX Example 1; Page 123; 162pp; English.

XX The present invention provides sequences of antisense oligonucleotides
XX targeted at the murine and human B7-1 and B7-2 coding and mRNA sequences.
XX The antisense sequences have phosphorothioate backbones and some
XX nucleotides are 2'-methoxyethoxy residues. The sequences can be used in
XX the treatment of inflammatory and autoimmune disorders, including asthma,
XX juvenile diabetes mellitus, myasthenia gravis, Graves' disease,
XX rheumatoid arthritis, allograft rejection, inflammatory bowel disease,
XX multiple sclerosis, psoriasis, systemic lupus erythematosus, contact
XX dermatitis, rhinitis, allergies and cancer

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 488

ABA04587/C

ID ABA04587 standard; DNA; 20 BP.

XX ABA04587;

XX 15-FEB-2002 (first entry)

XX Oligonucleotide #7.

XX Analytical support; genomic sequencing; mutation detection;
XX pharmaceutical development; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT modified_base 1

FT /*tag= a

FT /mod_base= OTHER

FT /notes= "OTHER = Fl(CH2)6-PO-thymine, where Fl is flavine
and PO is a phosphate group"

XX FR2805348-A1.

XX 24-AUG-2001.

XX 23-FEB-2000; 2000FR-00002236.

XX 23-FEB-2000; 2000FR-00002236.

XX (COMS) COMMISSARIAT ENERGIE ATOMIQUE.

XX Cuzin M, Peltie P, Fontecave M, Decout JL, Dueymes C;

XX WPI; 2001-628265/73.

XX Support for hybridization analysis of nucleic acids for sequencing
XX techniques, comprises an array of oligonucleotides having a label where
XX the fluorescence changes follow hybridization.

XX Example 8; Page 18; 33pp; French.

XX The present invention relates to an analytical support, to which a number
XX of oligonucleotides are fixed. The oligonucleotides are labelled with a
XX fluorescent compound, the fluorescence of which varies when the
XX oligonucleotide hybridises to its complement. The analytical support is
XX useful in hybridisation testing for identification of specific nucleic
XX acids, such as genomic sequencing, detecting mutations or pharmaceutical
XX development. The present oligonucleotide was used to illustrate the
XX invention

XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957

Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 489

AAF56197/C

ID AAF56197 standard; DNA; 20 BP.
XX AC AAF56197;
XX DT 19-APR-2001 (first entry)
XX DE Human ICAM-1 phosphorothioate antisense oligodeoxynucleotide.
XX KW Human; ICAM-1; phosphorothioate; lipid-encapsulated therapeutic agent;
XX KW antisense therapy; gene therapy; antisense oligonucleotide; ss.
XX OS Homo sapiens.
XX PN WO200105374-A1.
XX PD 25-JAN-2001.
XX PF 14-JUL-2000; 2000WO-CA000843.
XX PR 15-JUL-1999; 99US-0143978P.
XX PA (INEX-) INEX PHARM CORP.
XX PI Maurer N, Wong KF, Cullis PR;
XX DR WPI; 2001-159464/16.
XX PT Preparation of lipid-encapsulated therapeutic agents, particularly
PT encapsulated nucleic acid particles, useful in antisense therapy or gene
PT therapy.
XX Example 5; Page 15; 57pp; English.
XX The present sequence was used in an example to describe a novel method
CC for preparing lipid-encapsulated therapeutic agents from oppositely
CC charged lipid and therapeutic agents. The encapsulated particles are
CC useful in antisense therapy and gene therapy
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1
RESULT 490
ID AAF23804/c standard; DNA; 20 BP.
XX AC AAF23804;
XX DT 22-MAR-2001 (first entry)
XX Oligo #4 used to produce ligand-conjugated oligomeric compounds.
DE Ligand-conjugated oligomeric compound; aryl propionic acid;
KW nucleic acid delivery; ss.
XX Synthetic.
XX WO200076554-A1.
XX 21-DEC-2000.
XX 15-JUN-2000; 2000WO-US016534.
XX 15-JUN-1999; 99US-00334130.
XX (ISIS-) ISIS PHARM INC.

XX Manoharan M;
PI WPI; 2001-032292/04.
XX New conjugates of oligomeric compounds e.g. oligonucleotides and aryl
PT propionic acids e.g. ibuprofen are used for transmembrane delivery of
PT nucleic acid and oligonucleotides to cells for therapeutic and diagnostic
PT purposes.
XX Example 28; Page 81; 149pp; English.
XX The present sequence was used to produce an oligomeric compound
CC conjugated to an aryl propionic acid that interacts with a protein. The
CC compound is used for transmembrane delivery of nucleic acids to a wide
CC range of cells for diagnostic and therapeutic purposes. It allows more
CC efficient cellular uptake of oligonucleotides and nucleic acids than
CC prior art processes
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
DB 20 GAGCTCCTCTGCTACTCAGA 1
RESULT 491
ID AAF60943/c standard; DNA; 20 BP.
XX AC AAF60943;
XX DT 15-MAY-2001 (first entry)
XX DE Anti-ICAM-1 oligonucleotide SEQ ID 52.
XX Transport; membrane; cytostatic; virucide; vasotropic; dermatological;
KW antipsoriatic; antiasthmatic; gene therapy; tumor cell; antisense;
KW tumor therapy; drug; ss.
XX Unidentified.
XX DE19935302-A1.
XX 08-FEB-2001.
XX 28-JUL-1999; 99DE-01035302.
XX 28-JUL-1999; 99DE-01035302.
XX (AVET) AVENTIS PHARMA DEUT GMBH.
XX Uhlmann E, Greiner B, Unger E, Gothe G, Schwerdel M;
PI WPI; 2001-203679/21.
XX New substituted aryl conjugates of parent molecules, especially
PT oligonucleotides, having improved transmembrane and intracellular
PT transport properties, useful as medicaments or diagnostic agents.
XX Disclosure; Page 8; 28pp; German.
XX This invention describes a novel conjugate (I) which consists of (A) a
CC molecule to be transported and (B) at least one aryl residue of formula -
CC Ar-(X-C(Y)-R₁)-n (II). Ar = group containing at least one aromatic ring;
CC X = O or N (sic); Y = O, S or NH-R₂ (sic); R₁ = optionally substituted
CC 1-23C alkyl (optionally containing double and/or triple bonds); R₂ =
CC optionally substituted 1-18C alkyl (optionally containing double and/or
CC triple bonds); n = integer of 1 or more. (A) is bonded to (B) directly or

XX PI Uhlmann E, Greiner B, Unger E, Gothe G, Schwerdel M;
 XX DR WPI; 2001-203679/21.
 XX
 XX New substituted aryl conjugates of parent molecules, especially
 PT oligonucleotides, having improved transmembrane and intracellular
 PT transport properties, useful as medicaments or diagnostic agents.
 XX
 XX Disclosure; Page 8; 28pp; German.
 XX
 XX This invention describes a novel conjugate (I) which consists of (A) a
 CC molecule to be transported and (B) at least one aryl residue of formula -
 CC Ar-(X-C(Y)-R₁)_n (II); Ar = group containing at least one aromatic ring;
 CC X = O or N (sic); Y = O, S or NH-R₂ (sic); R₁ = optionally substituted
 CC 1-23C alkyl (optionally containing double and/or triple bonds); R₂ =
 CC optionally substituted 1-18C alkyl (optionally containing double and/or
 CC triple bonds); n = integer of 1 or more. (A) is bonded to (B) directly or
 CC via a chemical group, provided that the chemical group is other than CH₂
 CC -S if the bond is via a phosphodiester linkage of (A). The invention also
 CC describes (i) the preparation of a conjugate (I') of (A') a molecule to
 CC be transported and (B') at least one aryl residue (not restricted to
 CC (II)), by preparing (A') containing a reactive function at the position
 CC at which (B') is to be bonded, preparing (B') and reacting (A') and (B');
 CC and (ii) the use of aryl groups (II) (optionally bonded via a chemical
 CC group) for transporting (A) across biological membranes. The products of
 CC the invention have cytostatic, virucide, vasotropic, dermatological,
 CC antipneumatic and antiasthmatic activity and can be used for gene
 CC therapy. Conjugation of (A) with (B) is useful for transporting (A)
 CC across biological membranes or into eukaryotic or prokaryotic cells
 CC (specifically bacterial, yeast or mammalian cells, including human cells,
 CC particularly tumor cells). Medicaments, diagnostic agents and test kits
 CC containing (I) are also claimed. Typically (I) are antisense
 CC oligonucleotide derivatives for tumor therapy; oligonucleotide drugs for
 CC treating viral infections or diseases associated with integrins or cell-
 CC cell interactions (e.g. restenosis, vitiligo, psoriasis or asthma); or
 CC labeled oligonucleotides for in vivo diagnostic use, e.g. by in situ
 CC hybridization. Conjugation with (B) markedly improves the cellular uptake
 CC of (A), e.g. in tumor cells. (B) include fluorescein derivative residues,
 CC in which case the conjugates (I) are fluorescently labeled, allowing
 CC microscopic monitoring of cellular uptake etc. The cellular uptake of (I)
 CC is superior to that obtained using other conjugated groups related to
 CC (II); e.g. oligonucleotides conjugated with fluorescein diacetate (within
 CC the scope of (B)) have superior uptake to corresponding fluorescein
 CC conjugates
 XX
 XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1938 GAGAGGGGAAGTGGTGGGG 1957
 DB 20 GAGAGGGGAAGTGGTGGGG 1
 RESULT 494
 AAF75800/c
 ID AAF75800 standard; DNA; 20 BP.
 AC AAF75800;
 XX
 XX 16-MAY-2001 (first entry)
 DT
 DE 3' untranslated region of human ICAM-1, INX-2302.
 XX
 XX Human; ICAM; cytostatic; immunostimulant; cytokine secretion stimulant;
 KW neoplasia; ds.
 XX
 XX Homo sapiens.
 OS
 XX WO200115726-A2.
 PN

XX PD 08-MAR-2001.
 XX PF 28-AUG-2000; 2000WO-CA001013.
 XX PR 27-AUG-1999; 99US-0151211P.
 PR 13-JAN-2000; 2000US-0176406P.
 XX (INEX-) INEX PHARM CORP.
 XX
 XX Semple SC, Harasym TO, Klimuk SK, Kojic LD, Bramson JL, Mui B;
 PI Hope MJ;
 XX WPI; 2001-226663/23.
 XX
 XX New vaccine composition comprising a nucleic acid polymer encapsulated in
 PT a cationic lipid particle useful for stimulating cytokine secretion and
 PT inducing immune response in a mammal.
 XX
 XX Disclosure; Page 16; 94pp; English.
 XX
 XX The present invention relates to a composition for stimulating cytokine
 CC secretion in a mammal comprising an oligonucleotide encapsulated in a
 CC lipid particle comprising a cationic lipid. The present sequence is one
 CC such oligonucleotide, which can be used in the composition of the present
 CC invention. The composition is useful for stimulating cytokine secretion
 CC and inducing immune response in a mammal. The composition may also be
 CC used for treating neoplasia
 XX
 XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 DB 20 TGACGGATGCCAGCTTGGGC 1
 RESULT 495
 AAD13419/c
 ID AAD13419 standard; DNA; 20 BP.
 XX AAD13419;
 AC AAD13419;
 XX
 XX 06-NOV-2001 (first entry)
 DT
 XX
 XX Human ICAM-1 targeted antisense oligonucleotide ISIS #2302.
 DE
 XX Human; ICAM-1; antisense; phosphorothioate backbone; allergic dermatitis;
 KW cytostatic; virucide; antibacterial; psoriasis; inflammatory disorder;
 KW osteopathic; antiallergic; fungicide; anti-HIV; therapy; Paget's disease;
 KW toxic epidermal necrolysis; carcinoma; malignant melanoma; skin cancer;
 KW Acquired Immune Deficiency Disorder; ss.
 XX
 XX Homo sapiens.
 OS
 XX Synthetic.
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; 5' and 3' terminal
 FT internucleoside linkages are Sp and internal inter
 FT nucleoside linkages are Rp"
 XX
 XX WO200140515-A1.
 PN
 XX 07-JUN-2001.
 PD
 XX 10-NOV-2000; 2000WO-US030971.
 PF
 XX

PR 12-NOV-1999; 99US-00438989.
 XX (ISIS-) ISIS PHARM INC.
 PA Sanghvi YS, Manoharan M;
 PI
 XX WPI; 2001-502400/55.
 DR
 XX New oligonucleotide compounds, useful as nuclease resistant gapped
 PT oligonucleotides for e.g. therapeutics, comprise e.g. internal region of
 PT chiral phosphorothioate linked 2'-deoxynucleosides and two external
 PT regions imparting nuclease resistance.
 XX
 XX Example 31; Page 75; 129pp; English.
 PS
 XX The invention relates to oligomeric compound comprising a plurality of
 CC covalently-bound nucleosides. The oligomeric compound has an internal
 CC region of Rp chiral phosphorothioate linked 2'-deoxynucleosides and two
 CC external regions flanking the internal region. The external regions
 CC impart nuclease resistance to the oligomeric compound. The oligomeric
 CC compounds are nuclease resistant gapped oligonucleotides (i.e. gapmers)
 CC useful for therapeutics, diagnostics and as research reagents. They mimic
 CC and/or modulate the activity of wild type DNA and RNA. They are useful
 CC for treating diseases in unicellular prokaryotic, eukaryotic or
 CC multicellular eukaryotic organisms. These include organisms that utilise
 CC DNA-RNA transcription or RNA-protein translation as part of their
 CC hereditary, metabolic or cellular control. Therapeutic or diagnostic
 CC oligomeric compounds are useful for treating bacteria, yeast, protozoa,
 CC algae, all plants and all higher animal forms, including warm-blooded
 CC animals and organelles such as mitochondria and chloroplasts. The
 CC oligomeric compound is also useful for treating psoriasis, inflammatory
 CC disorders of the skin (e.g. lichen planus, toxic epidermal necrolysis,
 CC erythema multiforme), allergic contact dermatitis, skin cancer including
 CC benign tumours (warts and moles), and malignant tumours such as basalcell
 CC carcinoma, squamous cell carcinoma, malignant melanoma, Paget's disease,
 CC Kaposi's sarcoma; infectious diseases of the skin caused by viral,
 CC bacterial or fungal agents; AIDS, atherosclerosis and for determining the
 CC nature, function and potential relationship of various genetic components
 CC of the body to disease or body states in animals. The present sequence is
 CC a phosphorothioate antisense oligonucleotide targetted to human ICAM-1
 CC DNA
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGC 2119
 Db |||||
 20 TGACGGATGCCAGCTTGGC 1
 RESULT 496
 AAF31596/c
 ID AAF31596 standard; DNA; 20 BP.
 AC AAF31596;
 XX
 DT 10-APR-2001 (first entry)
 DE Oligonucleotide targeted to human ICAM-1.
 XX
 KW Oligonucleotide; 2-aminoadenosine; 5-substituted uridine; cytidine;
 KW phosphorothioate; disease; immune; ss.
 XX
 OS Synthetic.
 XX
 PN WO200102608-A1.
 XX
 PD 11-JAN-2001.
 XX
 PF 05-JUL-2000; 2000WO-US018415.
 XX
 PR 06-JUL-1999; 99US-00348106.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Manoharan M, Cook PD;
 XX
 DR WPI; 2001-168359/17.
 XX
 XX New oligonucleotides comprising 2-aminoadenosine and 5-substituted
 PT uridine or cytidine nucleoside units with a phosphorothioate linkage
 PT useful for treating a disease or conditions associated with gene
 PT expression.
 XX
 PS Claim 8; Page 32; 47pp; English.
 XX
 XX The present invention relates to oligonucleotides with at least one 2-
 CC aminoadenosine nucleoside unit, at least one phosphorothioate
 CC internucleoside linkage, and at least one 5-substituted uridine or
 CC cytidine nucleoside unit. The oligonucleotides are useful in inhibiting
 CC expression of a gene and in treating a disease or condition associated
 CC with the expression of a gene in an animal by reducing immune
 CC stimulation. The oligonucleotides may also be used as probes, primers,
 CC linkers, adapters, gene fragments, research reagents, and in the
 CC preparation of biological molecules
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGC 2119
 Db |||||
 20 TGACGGATGCCAGCTTGGC 1
 RESULT 497
 AAF31599/c
 ID AAF31599 standard; DNA; 20 BP.
 XX
 AC AAF31599;
 XX
 DT 10-APR-2001 (first entry)
 DE Oligonucleotide targeted to human ICAM-1.
 XX
 KW Oligonucleotide; 2-aminoadenosine; 5-substituted uridine; cytidine;
 KW phosphorothioate; disease; immune; ss.
 XX
 OS Synthetic.
 XX
 PN WO200102608-A1.
 XX
 PD 11-JAN-2001.
 XX
 PF 05-JUL-2000; 2000WO-US018415.
 XX
 PR 06-JUL-1999; 99US-00348106.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Manoharan M, Cook PD;
 XX
 DR WPI; 2001-168359/17.
 XX
 XX New oligonucleotides comprising 2-aminoadenosine and 5-substituted
 PT uridine or cytidine nucleoside units with a phosphorothioate linkage
 PT useful for treating a disease or conditions associated with gene
 PT expression.
 XX
 PS Example 22; Page 33; 47pp; English.
 XX
 XX

XX 06-JUL-1999; 99US-00348106.
 XX (ISIS-) ISIS PHARM INC.
 PA Manoharan M, Cook PD;
 PI
 XX WPI; 2001-168359/17.
 DR
 XX New oligonucleotides comprising 2-aminoadenosine and 5-substituted
 PT uridine or cytidine nucleoside units with a phosphorothioate linkage
 PT useful for treating a disease or conditions associated with gene
 PT expression.
 XX
 PS Claim 8; Page 32; 47pp; English.
 XX
 XX The present invention relates to oligonucleotides with at least one 2-
 CC aminoadenosine nucleoside unit, at least one phosphorothioate
 CC internucleoside linkage, and at least one 5-substituted uridine or
 CC cytidine nucleoside unit. The oligonucleotides are useful in inhibiting
 CC expression of a gene and in treating a disease or condition associated
 CC with the expression of a gene in an animal by reducing immune
 CC stimulation. The oligonucleotides may also be used as probes, primers,
 CC linkers, adapters, gene fragments, research reagents, and in the
 CC preparation of biological molecules
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGC 2119
 Db |||||
 20 TGACGGATGCCAGCTTGGC 1
 RESULT 497
 AAF31599/c
 ID AAF31599 standard; DNA; 20 BP.
 XX
 AC AAF31599;
 XX
 DT 10-APR-2001 (first entry)
 DE Oligonucleotide targeted to human ICAM-1.
 XX
 KW Oligonucleotide; 2-aminoadenosine; 5-substituted uridine; cytidine;
 KW phosphorothioate; disease; immune; ss.
 XX
 OS Synthetic.
 XX
 PN WO200102608-A1.
 XX
 PD 11-JAN-2001.
 XX
 PF 05-JUL-2000; 2000WO-US018415.
 XX
 PR 06-JUL-1999; 99US-00348106.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Manoharan M, Cook PD;
 XX
 DR WPI; 2001-168359/17.
 XX
 XX New oligonucleotides comprising 2-aminoadenosine and 5-substituted
 PT uridine or cytidine nucleoside units with a phosphorothioate linkage
 PT useful for treating a disease or conditions associated with gene
 PT expression.
 XX
 PS Example 22; Page 33; 47pp; English.
 XX
 XX

CC The present invention relates to oligonucleotides with at least one 2'-
 CC aminoadenosine nucleoside unit, at least one phosphorothioate
 CC internucleoside linkage, and at least one 5-substituted uridine or
 CC cytidine nucleoside unit. The oligonucleotides are useful in inhibiting
 CC expression of a gene and in treating a disease or condition associated
 CC with the expression of a gene in an animal by reducing immune
 CC stimulation. The oligonucleotides may also be used as probes, primers,
 CC linkers, adapters, gene fragments, research reagents, and in the
 CC preparation of biological molecules
 CC
 CC Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
 |||||
 Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 498
 AAS11376/c
 ID AAS11376 standard; DNA; 20 BP.
 XX
 AC AAS11376;
 XX
 DT 24-OCT-2001 (first entry)
 XX
 DE Phosphorothioate oligonucleotide ISIS 2302.
 XX
 KW ISIS 2302; oligonucleotide; phosphorothioate modification;
 KW complement activation; inflammation; immune disease; autoimmune disease;
 KW myasthenia gravis; systemic lupus erythematosus; ischaemia; reperfusion;
 KW transplant rejection; organ failure; adult respiratory distress syndrome;
 KW ARDS; Alzheimer's disease; neurodegenerative disorder; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /label= OTHER
 FT /note= "Phosphorothioate backbone"
 XX
 PN US6232296-B1.
 XX
 PD 15-MAY-2001.
 XX
 PF 30-SEP-1999; 99US-00409816.
 XX
 PR 30-SEP-1999; 99US-00409816.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Henry S;
 XX
 XX WPI; 2001-335084/35.
 XX
 XX Modulating complement activation in a cell, tissue or a bodily fluid,
 PT useful for treating diseases associated with complement activation,
 PT comprises administering oligonucleotide containing phosphorothioate
 PT modifications.
 XX
 XX Disclosure; Col 29; 22pp; English.
 PS
 CC The sequence represents an oligonucleotide which is modified with a
 CC phosphorothioate backbone. The oligonucleotide is an example of an
 CC oligonucleotide of the invention which can modulate complement activation
 CC in a cell, tissue or bodily fluid by being administered in two
 CC independent concentrations, one which initiates complement activation and
 CC a second concentration which inhibits complement activation. The method
 CC of is useful for modulating complement activation and thus useful

CC therapeutically for the treatment of abnormal and/or undesirable
 CC conditions which can arise as a result of complement activation, such as
 CC inflammation, immune diseases or autoimmune diseases (e.g. myasthenia
 CC gravis, systemic lupus erythematosus, ischaemia-reperfusion states,
 CC transplant rejection, organ failure, adult respiratory distress syndrome,
 CC ARDS, Alzheimer's disease and other neurodegenerative disorders). The
 CC oligonucleotides are useful as diagnostic and research reagents, and in
 CC gene therapy. The oligonucleotides possess modifications that provide
 CC improved characteristics such as compound stability and cellular uptake,
 CC which makes it suitable for therapeutic and prophylactic purposes
 CC
 CC Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
 |||||
 Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 499
 AAF77810/c
 ID AAF77810 standard; DNA; 20 BP.
 XX
 AC AAF77810;
 XX
 DT 29-MAY-2001 (first entry)
 XX
 DE ICAM-1 antisense oligodeoxynucleotide ISIS#2302.
 XX
 KW ICAM-2; antisense gene therapy; intercellular adhesion molecule;
 KW Crohn's disease; cancer; ss.
 XX
 OS Unidentified.
 XX
 PN WO200113914-A1.
 XX
 PD 01-MAR-2001.
 XX
 PF 22-AUG-2000; 2000WO-US022957.
 XX
 PR 24-AUG-1999; 99US-00379718.
 XX
 PA (UYVI-) UNIV VIRGINIA COMMONWEALTH.
 XX
 PI Farrell NP;
 XX
 XX WPI; 2001-257588/26.
 DR
 XX Delivering antisense oligodeoxynucleotide to cells for treating cancers,
 PT involves forming a complex comprising the oligodeoxynucleotide and a
 PT polynuclear platinum compound, and providing the complex to the cells.
 XX
 PS Disclosure; Page 23; 52pp; English.
 XX
 XX The present invention relates to a method for delivering an antisense
 CC oligodeoxynucleotide to cells. The method comprises forming a complex
 CC comprising the antisense oligonucleotide and a polynuclear platinum
 CC compound, and providing the complex to the cells. The present sequence is
 CC an antisense oligonucleotide for intercellular adhesion molecule (ICAM-
 CC 1), which may be used in the present invention. ICAM-1 is involved in
 CC Crohn's disease. The complex of the present invention is useful for
 CC treating Crohn's disease and any other disease amenable to the treatment
 CC by antisense oligonucleotides e.g. cancer
 CC
 CC Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 500
 AAF92894
 ID AAF92894 standard; DNA; 20 BP.
 XX AC AAF92894;
 XX 17-MAY-2001 (first entry)
 DT Human ABC1 transcription factor binding site #55.
 XX High density lipoprotein-cholesterol; HDL-C; cardiovascular; ABC1; ds.
 KW Homo sapiens.
 OS
 XX WO200115676-A2.
 PN 08-MAR-2001.
 PD 01-SEP-2000; 2000WO-IB001492.
 PF 01-SEP-1999; 99US-0151977P.
 PR 15-MAR-2000; 2000US-00526193.
 PR 23-JUN-2000; 2000US-0213958P.
 XX (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON GENETICS INC.
 XX Hayden MR, Brooks-Wilson AR, Pimstone SN, Clee SM;
 PI WPI; 2001-244356/25.
 DR Treating a lower than normal high density lipoprotein-cholesterol (HDL-C)
 XX level, a higher than normal triglyceride level, or a cardiovascular
 PT disease, by administering a compound that modulates LXR- or RXR-mediated
 PT transcriptional activity.
 XX Disclosure; Fig 3; 317pp; English.
 XX The present invention relates to a method for treating a patient
 CC diagnosed as having a lower than normal high density lipoprotein-
 CC cholesterol (HDL-C) level, a higher than normal triglyceride level, or a
 CC cardiovascular disease, involving administering a compound that modulates
 CC LXR- or RXR-mediated transcriptional activity or ABC1 expression or
 CC activity. The LXR gene product may be used in an assay to identify
 CC compounds useful for the treatment of a disease or condition selected a
 CC lower than normal HDL cholesterol level, a higher than normal
 CC triglyceride level, and a cardiovascular disease
 XX Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2825 GGCTCAAGTGATCCTCCAC 2844
 Db 1 GGCTCAAGTGATCCTCCAC 20

RESULT 501
 AAS11587/C
 ID AAS11587 standard; DNA; 20 BP.
 XX AAS11587;
 AC AAS11587;
 XX 24-OCT-2001 (first entry)
 DT Fully modified phosphorothioate oligonucleotide #1.
 XX

XX Oligonucleotide; AIDS; arteriosclerosis; Antiarteriosclerotic; anti-HIV;
 KW acquired immunodeficiency syndrome; antisense; ss.
 XX Synthetic.
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= a
 FT /label= OTHER
 FT /note= "Other= Phosphorothioate backbone and each residue
 FT is phosphoroamidated"
 XX WO200149701-A1.
 PN 12-JUL-2001.
 XX 29-DEC-2000; 2000WO-US035612.
 XX 05-JAN-2000; 2000US-00477878.
 XX (ISIS-) ISIS PHARM INC.
 XX Capaldi DC, Ravikumar V, Cole DL;
 PI WPI; 2001-514406/56.
 DR Preparation of oligomeric compounds, useful for inhibiting specific gene
 XX expression, comprises reaction between two tetrahydrofuran derivatives.
 PT Example 5; Page 38; 62pp; English.
 XX The invention relates to preparation of oligomeric compounds (e.g.
 CC synthetic oligonucleotides) comprising the reaction between two
 CC tetrahydrofuran derivatives. Oligonucleotides prepared by the method of
 CC the invention (e.g. those which are complementary to the mRNA of a target
 CC gene i.e. antisense molecules) can be used in diagnostics, therapeutics
 CC and as research reagents and kits. They can be used for treating diseases
 CC associated with a specific protein e.g. by specifically hybridising with
 CC a strand of nucleic acid coding for the undesirable proteins and can be
 CC used on unicellular prokaryotic and eukaryotic organisms and
 CC multicellular eukaryotic organisms. The oligomeric compounds can be used
 CC to treat e.g. AIDS (acquired immunodeficiency syndrome), in conjunction
 CC with AZT, or arteriosclerosis. The present sequence is a modified
 CC oligonucleotide prepared by the method of the invention
 XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 502
 AAF28597/C
 ID AAF28597 standard; DNA; 20 BP.
 XX AAF28597;
 AC AAF28597;
 XX 03-APR-2001 (first entry)
 DT Phosphorothioate oligonucleotide ISIS-2302.
 XX Phosphorothioate; oligonucleotide purification;
 KW oligonucleotide separation; displacement chromatography; ss.
 XX Unidentified.
 OS
 XX WO200100642-A1.
 PN

XX 04-JAN-2001.
PD
XX 28-JUN-2000; 2000WO-US017750.
PF
XX 29-JUN-1999; 99US-00343006.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Shukla AA, Deshmukh RR, Cramer SM, Moore JA;
PI WPI; 2001-122992/13.
XX
XX Purification and separation of oligonucleotides from an industrial
PT mixture, involving displacement chromatography on an anion-exchange
PT column using low molecular weight, high affinity anionic-displacers.
PT
XX Example 1; Page 15; 38pp; English.
PS
XX The present invention relates to a method for purification and separation
CC of oligonucleotides by displacement chromatography on an anion-exchange
CC column using high affinity, low molecular weight anionic displacers of
CC less than 10000 Da. The present sequence is an oligonucleotide used to
CC exemplify the method of the present invention. This oligonucleotide has a
CC phosphorothioate backbone
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1
RESULT 503
AAF89460/C
ID AAF89460 standard; DNA; 20 BP.
XX
XX AAF89460;
AC
XX 14-AUG-2001 (first entry)
DT
XX Human ICAM-1 antisense oligonucleotide.
DE
XX Antisense therapy; oligonucleotide detection; probe;
KW oligonucleotide quantitation; ss.
KW
XX Homo sapiens.
OS
XX WO200134845-A1.
PN
XX 17-MAY-2001.
PD
XX 10-NOV-2000; 2000WO-US031042.
PF
XX 12-NOV-1999; 99US-0165184P.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Baker BF, Yu Z, Leeds JM;
PI WPI; 2001-329098/34.
XX
XX Detecting or quantifying oligonucleotides in bodily fluid or extract for
PT therapeutic, pharmacokinetic purposes, by contacting with complementary
PT probes and enzymes recognizing specific nucleic acid structures.
PT
XX Example 1; Page 28; 56pp; English.
PS
XX The present invention describes a method of detecting and quantitating an

CC oligonucleotide in a bodily fluid, involving contacting the fluid with a
CC probe complementary to the oligonucleotide to form a hybrid, contacting
CC the hybrid with an enzyme, labelling the hybrid and detecting the label.
CC This is especially useful to determine oligonucleotide concentrations in
CC antisense therapy, and to study nucleic acid pharmacokinetic properties.
CC The present sequence is an antisense sequence used in the exemplification
CC of the invention
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1
RESULT 504
AAS09545/C
ID AAS09545 standard; DNA; 20 BP.
XX
XX AAS09545;
AC
XX 24-OCT-2001 (first entry)
DT
XX FITC-labeled ICAM oligonucleotide.
DE
XX FITC; ICAM; oligonucleotide; ss; fluorescein isothiocyanate; VP22; BH3;
KW apoptosis; hyper-proliferating cell; cancer; tumour; eczema;
KW cell-cycle progression regulator; genital warts; restenosis; skin cancer;
KW psoriasis; scar tissue; intracellular-adhesion molecule.
XX
XX Homo sapiens.
OS
XX Synthetic.
XX
XX Key misc_feature 1 Location/Qualifiers
FT /*tag= a
FT /note= "C is labeled with FITC"
XX
XX WO200147960-A1.
PN
XX 05-JUL-2001.
PD
XX 21-DEC-2000; 2000WO-GB004965.
PF
XX 24-DEC-1999; 99GB-00030519.
PR
XX (PHOG-) PHOGEN LTD.
PA
XX O'hare PFJ, Normand NM, Brewis ND, Phelan A;
PI WPI; 2001-418224/44.
XX
XX Inhibiting cancer cell proliferation by exposing cells to a composition
PT of fusion proteins comprising VP22 polypeptides coupled to cell cycle
PT progression regulators, and further exposing cells to cell death
PT stimulators.
PT
XX Disclosure; Page 14; 23pp; English.
PS
XX The sequence represents an FITC (fluorescein isothiocyanate) labeled
CC oligonucleotide complementary to part of the mRNA encoding the
CC intracellular-adhesion molecule ICAM. The oligonucleotide is included in
CC a composition comprising a fusion protein of herpes virus VP22 protein
CC 159-301 (having the transport function) and a cell-cycle progression
CC regulator (or its DNA) e.g. BH3 or apoptotic proteins. The composition is
CC used to reduce the proliferation of cells. The method of making the VP22
CC containing compositions is used for reducing proliferation of hyper-
CC proliferating cells e.g., cancer cells, for manufacturing a medicament to
CC reduce or treat cell proliferation e.g., cancer cell proliferation. The

CC method is also used for reducing or treating cell proliferation, in
 CC tumour cells present in tumour cell mass, non-malignant cells e.g.,
 CC benign tumour cells such as genital warts, smooth muscle cells present in
 CC restenosis, proliferating skin cells e.g., skin cancer, psoriasis or
 CC eczema skin cells, or proliferating cells of scar tissue

SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1938 GAGAGGGGAAGTGTGGGG 1957
 Db 20 GAGAGGGGAAGTGTGGGG 1

RESULT 505
 AAH46458/c
 ID AAH46458 standard; DNA; 20 BP.
 XX AC AAH46458;
 XX
 DT 14-SEP-2001 (first entry)
 XX
 DE Oligonucleotide #7.
 XX
 KW Phosphorothioate; anti-viral therapy; stereochemical pathway;
 KW DNA-RNA hybrid; ss.
 XX
 OS Synthetic.

Key Location/Qualifiers
 modified_base 1..20
 /tag= a
 /mod_base= OTHER
 /note= "All bases are phosphorothioate"
 modified_base 12
 /tag= b
 /mod_base= OTHER
 /note= "Modified with 2'-methoxyethyl"
 misc_RNA 14..18
 /tag= c
 /label= RNA

US6242591-B1.
 05-JUN-2001.
 11-JAN-2000; 2000US-00481486.
 15-OCT-1997; 97US-00950779.
 (ISIS-) ISIS PHARM INC.
 Cole DL, Ravikumar VT, Cheruvallath ZS;
 WPI; 2001-407218/43.

Preparing sulfurized 2' substituted phosphorothioate oligonucleotides
 useful in biological research, comprises phosphorylating the 5'-hydroxyl
 of a nucleic acid having a nucleoside with a 2' modification.

Example 10; Col 7; 7pp; English.

The present invention relates to a method for preparing phosphorothioate
 oligonucleotides having at least one nucleoside with a 2' modification.
 The method comprises phosphorylating the 5'-hydroxyl of a nucleic acid
 group having at least one nucleoside with a 2' modification in an
 acetonitrile. The present sequence was used to illustrate the method of
 the present invention. The method is useful for synthesising sulphurised
 2' substituted phosphorothioate oligonucleotides, which may be used in
 molecular biological research, in applications such as anti-viral

CC therapy, and for determining the stereochemical pathways of certain
 CC enzymes which recognise nucleic acids
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 1 T; 2 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 506
 AAH46464/c
 ID AAH46464 standard; DNA; 20 BP.
 XX
 AC AAH46464;
 XX
 DT 14-SEP-2001 (first entry)
 XX
 DE Oligonucleotide #12.

Phosphorothioate; anti-viral therapy; stereochemical pathway; ss.
 Synthetic.

Key Location/Qualifiers
 modified_base 1..20
 /tag= a
 /mod_base= OTHER
 /note= "All bases are phosphorothioate"
 modified_base 12
 /tag= b
 /mod_base= OTHER
 /note= "Modified with 2'-O-methoxyethyl"

US6242591-B1.
 05-JUN-2001.
 11-JAN-2000; 2000US-00481486.
 15-OCT-1997; 97US-00950779.
 (ISIS-) ISIS PHARM INC.
 Cole DL, Ravikumar VT, Cheruvallath ZS;
 WPI; 2001-407218/43.

Preparing sulfurized 2' substituted phosphorothioate oligonucleotides
 useful in biological research, comprises phosphorylating the 5'-hydroxyl
 of a nucleic acid having a nucleoside with a 2' modification.

Example 21; Col 10; 7pp; English.

The present invention relates to a method for preparing phosphorothioate
 oligonucleotides having at least one nucleoside with a 2' modification.
 The method comprises phosphorylating the 5'-hydroxyl of a nucleic acid
 group having at least one nucleoside with a 2' modification in an
 acetonitrile. The present sequence was used to illustrate the method of
 the present invention. The method is useful for synthesising sulphurised
 2' substituted phosphorothioate oligonucleotides, which may be used in
 molecular biological research, in applications such as anti-viral
 CC therapy, and for determining the stereochemical pathways of certain
 CC enzymes which recognise nucleic acids

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;


```
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 507
AAH46452/c
ID AAH46452 standard; DNA; 20 BP.
XX
XX AAH46452;
AC
XX 14-SEP-2001 (first entry)
DT
XX Oligonucleotide #2.
DE
XX Phosphorothioate; anti-viral therapy; stereochemical pathway; ss.
KW
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "optionally phosphorothioate backbone"
DE
XX Oligonucleotide #2.
DE
XX Phosphorothioate; anti-viral therapy; stereochemical pathway; ss.
KW
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "All bases are phosphorothioate"
DE
XX US6242591-B1.
DE
XX 05-JUN-2001.
DE
XX 11-JAN-2000; 2000US-00481486.
PF
XX 15-OCT-1997; 97US-00950779.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Cole DL, Ravikumar VT, Cheruvallath ZS;
PI WPI; 2001-407218/43.
DR
XX
XX Preparing sulfurized 2' substituted phosphorothioate oligonucleotides
PT useful in biological research, comprises phosphorylating the 5'-hydroxyl
PT of a nucleic acid having a nucleoside with a 2' modification.
XX
XX Example 4; Col 5; 7pp; English.
XX
XX The present invention relates to a method for preparing phosphorothioate
CC oligonucleotides having at least one nucleoside with a 2' modification.
CC The method comprises phosphorylating the 5'-hydroxyl of a nucleic acid
CC group having at least one nucleoside with a 2' modification in an
CC acetonitrile. The present sequence was used to illustrate the method of
CC the present invention. The method is useful for synthesising sulphurised
CC 2' substituted phosphorothioate oligonucleotides, which may be used in
CC molecular biological research, in applications such as anti-viral
CC therapy, and for determining the stereochemical pathways of certain
CC enzymes which recognise nucleic acids
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 508
AAH25746/c
ID AAH25746 standard; RNA; 20 BP.
XX
```

```
AC AAH25746;
XX
XX 14-AUG-2001 (first entry)
DT
XX Human type II RNase H substrate oligonucleotide #12.
DE
XX Human; RNase H type II; RNase H1 cleavage substrate; antisense therapy;
KW gene therapy; primer; phosphorothioate backbone; ss.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "optionally phosphorothioate backbone"
DE
XX modified_base 2..4
FT /tag= b
FT /mod_base= OTHER
FT /note= "optionally 5-methyl-C"
DE
XX modified_base 8
FT /tag= c
FT /mod_base= OTHER
FT /note= "optionally 5-methyl-C"
DE
XX modified_base 12
FT /tag= d
FT /mod_base= OTHER
FT /note= "optionally 5-methyl-C"
DE
XX modified_base 15..16
FT /tag= e
FT /mod_base= OTHER
FT /note= "optionally 5-methyl-C"
DE
XX modified_base 19
FT /tag= f
FT /mod_base= OTHER
FT /note= "optionally 5-methyl-C"
XX
XX WO200123613-A1.
PN
XX 05-APR-2001.
PD
XX
XX 29-SEP-2000; 2000WO-US026729.
PF
XX 30-SEP-1999; 99US-00409926.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Crooke ST, Lima WF, Wu H, Manoharan M;
XX WPI; 2001-343164/36.
DR
XX Chimeric oligonucleotides that can serve as substrates for human RNase
PT H1, useful for enhancing the effectiveness of antisense gene therapies.
XX
XX Example; Page 135; 178pp; English.
XX
XX The present invention provides a number of DNA-RNA oligonucleotides which
CC can act as substrates for human RNase H1 (a type II RNase). The sequence
CC consists of two portions, one of which is capable of supporting cleavage
CC of a complementary target RNA and the other of which is incapable of
CC supporting such cleavage. These can be used to enhance the effectiveness
CC of antisense therapies. The present sequence is an RNase H substrate used
CC in the exemplification of the invention
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
```

```

RESULT 509
AAC88206/c
ID AAC88206 standard; DNA; 20 BP.
XX
AC AAC88206;
XX
DT 01-MAR-2001 (first entry)
XX
DE Modified phosphorothioate 20-mer SEQ ID NO: 2.
XX
KW Phosphorothioate oligomer; diagnosis; therapy; disease; AIDS;
XX
OS atherosclerosis; ss.
XX
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone"
XX
PN WO200068241-A1.
XX
PD 16-NOV-2000.
XX
XX 05-MAY-2000; 2000WO-US012447.
XX
PR 06-MAY-1999; 99US-00306278.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Ravikumar VT, Capaldi DC, Cole DT;
XX
DR WPI; 2001-049743/06.
XX
XX Preparation of oligonucleotides useful in diagnostics using
XX phosphoramidite compositions.
XX
PS Example 6; Page 43; 75pp; English.
XX
CC The present invention provides novel compositions comprising
CC phosphoramidite compounds which can be used to synthesise modified
CC oligonucleotides. These modified oligonucleotides have phosphorothioate
CC backbones. They can be used to produce probes, primers, linkers, adaptors
CC and gene fragments and in disease diagnosis and therapy, for example in
CC the treatment of AIDS and atherosclerosis
XX
SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 510
AAD20914/c
ID AAD20914 standard; DNA; 20 BP.
XX
AC AAD20914;
XX
DT 15-JAN-2002 (first entry)
XX
DE Phosphorothioate oligo #1 used as an antisense therapeutic reagent.
XX
KW Phosphorothioate backbone; purification; contaminant; amino reagent;
XX a-basic site; antisense therapeutic reagent; ss.
XX

OS Unidentified.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
XX
PN WO200155160-A1.
XX
PD 02-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US002951.
XX
PR 31-JAN-2000; 2000US-00495398.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Krotz AH, Ravikumar VT;
XX
XX WPI; 2001-648159/74.
XX
XX Purification of oligonucleotides, useful as therapeutic and diagnostic
XX agents, by treatment with amine reagents that convert a-basic impurities
XX to removable imines.
XX
XX Example 8; Page 57; 84pp; English.
XX
CC The present invention relates to a method for purification of an
CC oligonucleotide from a mixture containing at least one contaminant by
CC treating the mixture with an amino reagent that forms an imine bond to
CC amino reagent and separating the oligonucleotide from the imine-bonded
CC amino reagent. The method is especially used to purify oligonucleotide
CC from sequences containing a-basic sites. Oligonucleotide are useful as
CC antisense therapeutic reagents for specific inhibition of gene
CC expression, also as diagnostic probes and research reagents. The method
CC is suitable for large scale (many kg) production and purification of
CC oligonucleotide. The present sequence is phosphorothioate oligonucleotide
XX used in the exemplification of the invention
XX
SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 511
AAH49228/c
ID AAH49228 standard; DNA; 20 BP.
XX
AC AAH49228;
XX
DT 26-NOV-2001 (first entry)
XX
DE Anti-ICAM oligonucleotide XXI.
XX
KW Polyamide-oligonucleotide derivative; anticancer; antiproliferative;
XX antiviral; hepatotropic; vasotropic; antisense inhibition; ribozyme;
XX integrin; cell-cell adhesion; cancer; restenosis; stability; PNA;
XX peptide nucleic acid; ss.
XX
XX Synthetic.
XX
XX EP1113021-A2.
XX
PD 04-JUL-2001.
XX
XX 08-MAR-1995; 2001EP-00104012.

```

XX 14-MAR-1994; 94DE-04408528.
 PR 08-MAR-1995; 95EP-00103332.
 XX
 XX (AVET) AVENTIS PHARMA DEUT GMBH.
 XX Uhlmann E, Breipohl G;
 XX WPI; 2001-591267/67.
 DR
 XX New DNA-peptide nucleic acid chimeras, useful e.g. as antisense agents
 PT for treating e.g. cancer, also as diagnostic probes and primers.
 PT
 XX Disclosure; Page 24; 54pp; German.
 PS
 XX This invention describes novel polyamide-oligonucleotide derivatives (I)
 CC and their physiologically acceptable salts of formula F(DNA)-Li) q(PNA-
 CC Li) x(DNA-Li) s(PNA) t) xP' where q, r, s, t = 0 or 1, with the sum of
 CC two or more adjacent letters at least 2; x = 1-20; DNA = nucleic acid
 CC (such as DNA or RNA or their known derivatives); Li = covalent linkage
 CC between DNA and PNA, i.e. a bond or a residue containing at least one
 CC atom of carbon, nitrogen, oxygen or sulfur; PNA = polyamide structure
 CC containing at least one nucleobase different from thymine; and F, F' =
 CC end groups and/or are connected through a covalent bond. The products of
 CC the invention have anticancer, antiproliferative, antiviral, hepatotropic
 CC and vasotropic activity and can be used for the inhibition of gene
 CC expression by antisense, ribozyme, sense, or triple-helix methods, or by
 CC binding to proteins (aptamers). (I) are used for treating diseases caused
 CC by viruses (human immune deficiency, herpes simplex, influenza, vesicular
 CC stomatitis, hepatitis B or papilloma), or mediated by integrins or cell-
 CC cell adhesion reactions, for treating cancer, or for inhibiting
 CC restenosis, particularly as antisense reagents. They are also useful in
 CC heterogeneous or homogeneous assays, as primers or probes, particularly
 CC where the target is amplified before being detected by hybridization, for
 CC diagnosis of genetic, malignant or pathogen-related diseases. (I) retain
 CC the increased affinity for complementary strands and better stability in
 CC serum, associated with conventional peptide nucleic acids (PNA), but lack
 CC the disadvantages, i.e. have improved cellular uptake, do not aggregate
 CC in aqueous solution, and have reduced affinity for purification
 CC materials, reduced cytotoxicity, better sequence specificity. They are
 CC more active than either DNA or PNA oligomers. When used as probes, (I)
 CC show different responses to base-pair mismatches in the DNA and PNA
 CC segments, allowing better discrimination between pathogenic and non-
 CC pathogenic conditions such as the transition from proto-oncogene to
 CC oncogene, also, when used as primers, with the PNA segment at the 5'-end,
 CC they produce amplicons resistant to 5'-exonuclease, allowing this enzyme
 CC to be used to eliminate RNA or DNA primers. The DNA component allows
 CC additional reactions not possible with PNA alone, e.g. 3'-tailing and (I)
 CC may be incorporated into a gene. AAH49208-AAH49264 represent
 CC oligonucleotides used to illustrate the method of the invention
 XX
 XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1938 GAGAGGGGAAGTGGTGGGG 1957
 |||||
 Db 20 GAGAGGGGAAGTGGTGGGG 1
 RESULT 512
 AAH49229/c
 ID AAH49229 standard; DNA; 20 BP.
 XX
 XX AAH49229;
 AC
 XX 26-NOV-2001 (first entry)
 DT
 XX Anti-ICAM oligonucleotide XXII.
 DE
 XX Polyamide-oligonucleotide derivative; anticancer; antiproliferative;

KW antiviral; hepatotropic; vasotropic; antisense inhibition; ribozyme;
 KW integrin; cell-cell adhesion; cancer; restenosis; stability; PNA;
 KW peptide nucleic acid; ss.
 XX Synthetic.
 XX EP1113021-A2.
 XX
 XX 04-JUL-2001.
 PD
 XX 08-MAR-1995; 2001EP-00104012.
 PF
 XX 14-MAR-1994; 94DE-04408528.
 PR
 XX 08-MAR-1995; 95EP-00103332.
 XX
 XX (AVET) AVENTIS PHARMA DEUT GMBH.
 PA Uhlmann E, Breipohl G;
 PI WPI; 2001-591267/67.
 XX
 XX New DNA-peptide nucleic acid chimeras, useful e.g. as antisense agents
 PT for treating e.g. cancer, also as diagnostic probes and primers.
 PT
 XX Disclosure; Page 24; 54pp; German.
 PS
 XX This invention describes novel polyamide-oligonucleotide derivatives (I)
 CC and their physiologically acceptable salts of formula F(DNA)-Li) q(PNA-
 CC Li) x(DNA-Li) s(PNA) t) xP' where q, r, s, t = 0 or 1, with the sum of
 CC two or more adjacent letters at least 2; x = 1-20; DNA = nucleic acid
 CC (such as DNA or RNA or their known derivatives); Li = covalent linkage
 CC between DNA and PNA, i.e. a bond or a residue containing at least one
 CC atom of carbon, nitrogen, oxygen or sulfur; PNA = polyamide structure
 CC containing at least one nucleobase different from thymine; and F, F' =
 CC end groups and/or are connected through a covalent bond. The products of
 CC the invention have anticancer, antiproliferative, antiviral, hepatotropic
 CC and vasotropic activity and can be used for the inhibition of gene
 CC expression by antisense, ribozyme, sense, or triple-helix methods, or by
 CC binding to proteins (aptamers). (I) are used for treating diseases caused
 CC by viruses (human immune deficiency, herpes simplex, influenza, vesicular
 CC stomatitis, hepatitis B or papilloma), or mediated by integrins or cell-
 CC cell adhesion reactions, for treating cancer, or for inhibiting
 CC restenosis, particularly as antisense reagents. They are also useful in
 CC heterogeneous or homogeneous assays, as primers or probes, particularly
 CC where the target is amplified before being detected by hybridization, for
 CC diagnosis of genetic, malignant or pathogen-related diseases. (I) retain
 CC the increased affinity for complementary strands and better stability in
 CC serum, associated with conventional peptide nucleic acids (PNA), but lack
 CC the disadvantages, i.e. have improved cellular uptake, do not aggregate
 CC in aqueous solution, and have reduced affinity for purification
 CC materials, reduced cytotoxicity, better sequence specificity. They are
 CC more active than either DNA or PNA oligomers. When used as probes, (I)
 CC show different responses to base-pair mismatches in the DNA and PNA
 CC segments, allowing better discrimination between pathogenic and non-
 CC pathogenic conditions such as the transition from proto-oncogene to
 CC oncogene, also, when used as primers, with the PNA segment at the 5'-end,
 CC they produce amplicons resistant to 5'-exonuclease, allowing this enzyme
 CC to be used to eliminate RNA or DNA primers. The DNA component allows
 CC additional reactions not possible with PNA alone, e.g. 3'-tailing and (I)
 CC may be incorporated into a gene. AAH49208-AAH49264 represent
 CC oligonucleotides used to illustrate the method of the invention
 XX
 XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1940 GAGGGGAAGTGGTGGGGG 1959
 |||||
 Db 20 GAGGGGAAGTGGTGGGGG 1

```
RESULT 513
AAF87785/c
ID AAF87785 standard; DNA; 20 BP.
XX AC
XX AAF87785;
XX
XX
DT 11-JUL-2001 (first entry)
XX
DE DNA 20-mer ASO (antisense DNA oligomer) SEQ ID NO:12.
XX
XX Antisense DNA oligomer; ASO; identification; gene therapy; target;
XX Nearest-Neighbour Thermal Stability Program; thermal melting temperature;
XX phosphorothioate; disease treatment; DNA:RNA hybrid; ss.
XX
XX Synthetic.
XX
XX US6183966-B1.
XX
XX 06-FEB-2001.
XX
XX 22-JAN-1999; 99US-00235614.
XX
XX 07-OCT-1994; 94US-00320507.
XX 03-MAR-1997; 97US-00808474.
XX
XX (TEXA ) UNIV TEXAS SYSTEM.
XX
XX Gray DM, Clark CL;
XX WPI; 2001-280429/29.
XX
XX Identifying a nucleic acid having a sequence capable of targeting a gene
XX of interest, for identifying nucleic acids for gene therapy, comprises
XX using the Nearest-Neighbor Thermal Stability Program.
XX
XX Example 1; Col 21-22; 43pp; English.
XX
XX The present invention describes a method for the identification of a
XX nucleic acid having a sequence capable of targeting a gene of interest
XX comprises: (a) a first database having a list of stability values for
XX independent combinations of N(x); (b) a computing unit having a means for
XX inputting data comprising N(x); data list, defining a nucleic acid
XX sequence of interest to be targeted to provide a second database; and (c)
XX a program capable of processing the first and second database to N(x)
XX comparison, and a stability value of a nucleic acid sequence capable of
XX targeting the gene of interest. The method is useful for identifying a
XX nucleic acid having a sequence capable of targeting a gene of interest.
XX These nucleic acids are useful in gene therapy and disease treatment. The
XX method may be used to obtain thermodynamic parameters for 20 combinations
XX of nearest-neighbour base pairs of DNA:RNA hybrid sequences. The Nearest-
XX Neighbour Thermal Stability Program can process data for use in
XX calculating thermal melting temperatures for phosphorothioate DNA:RNA
XX hybrids. The program can be readily extended to predict the most stable
XX triplex-forming sequences, or antigene oligomers. The present sequence
XX represents a DNA 20-mer ASO (antisense DNA oligomer) sequence which is
XX used in the exemplification of the present invention
XX
XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1938 GAGAGGGGAAGTGGGGG 1957
XX |||||||
XX 20 GAGAGGGGAAGTGGGGG 1
XX
XX
RESULT 514
AAF87786/c
ID AAF87786 standard; DNA; 20 BP.
XX
XX AAF87786;
XX
XX
XX
DT 11-JUL-2001 (first entry)
XX
DE Human intracellular adhesion molecule 1 (ICAM-1) S-ASO SEQ ID NO:13.
XX
XX Antisense DNA oligomer; ASO; identification; gene therapy; target;
XX Nearest-Neighbour Thermal Stability Program; thermal melting temperature;
XX phosphorothioate; disease treatment; DNA:RNA hybrid; human; ICAM-1;
XX intracellular adhesion molecule 1; ss.
XX
XX Homo sapiens.
XX
XX US6183966-B1.
XX
XX 06-FEB-2001.
XX
XX 22-JAN-1999; 99US-00235614.
XX
XX 07-OCT-1994; 94US-00320507.
XX 03-MAR-1997; 97US-00808474.
XX
XX (TEXA ) UNIV TEXAS SYSTEM.
XX
XX Gray DM, Clark CL;
XX WPI; 2001-280429/29.
XX
XX Identifying a nucleic acid having a sequence capable of targeting a gene
XX of interest, for identifying nucleic acids for gene therapy, comprises
XX using the Nearest-Neighbor Thermal Stability Program.
XX
XX Example 1; Col 25-26; 43pp; English.
XX
XX The present invention describes a method for the identification of a
XX nucleic acid having a sequence capable of targeting a gene of interest
XX comprises: (a) a first database having a list of stability values for
XX independent combinations of N(x); (b) a computing unit having a means for
XX inputting data comprising N(x); data list, defining a nucleic acid
XX sequence of interest to be targeted to provide a second database; and (c)
XX a program capable of processing the first and second database to N(x)
XX comparison, and a stability value of a nucleic acid sequence capable of
XX targeting the gene of interest. The method is useful for identifying a
XX nucleic acid having a sequence capable of targeting a gene of interest.
XX These nucleic acids are useful in gene therapy and disease treatment. The
XX method may be used to obtain thermodynamic parameters for 20 combinations
XX of nearest-neighbour base pairs of DNA:RNA hybrid sequences. The Nearest-
XX Neighbour Thermal Stability Program can process data for use in
XX calculating thermal melting temperatures for phosphorothioate DNA:RNA
XX hybrids. The program can be readily extended to predict the most stable
XX triplex-forming sequences, or antigene oligomers. The present sequence
XX represents an antisense DNA oligomer designated S-ASO targeted to the
XX human intracellular adhesion molecule 1 (ICAM-1), which is used in an
XX example from the present invention
XX
XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 337 TCAAACTGCCCTGATGGCA 356
XX |||||||
XX 20 TCAAACTGCCCTGATGGCA 1
XX
XX
RESULT 515
AAF87788/c
ID AAF87788 standard; DNA; 20 BP.
XX
XX AAF87788;
XX
XX
XX
DT 11-JUL-2001 (first entry)
XX
DE human intracellular adhesion molecule 1 (ICAM-1), which is used in an
XX example from the present invention
XX
XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 337 TCAAACTGCCCTGATGGCA 356
XX |||||||
XX 20 TCAAACTGCCCTGATGGCA 1
XX
XX
RESULT 515
AAF87788/c
ID AAF87788 standard; DNA; 20 BP.
XX
XX AAF87788;
XX
XX
XX
DT 11-JUL-2001 (first entry)
XX
```

```

DE Human intracellular adhesion molecule 1 (ICAM-1) S-ASO SEQ ID NO:15.
XX
XX Antisense DNA oligomer; ASO; identification; gene therapy; target;
KW Nearest-Neighbour Thermal Stability Program; thermal melting temperature;
KW phosphorothioate; disease treatment; DNA:RNA hybrid; human; ICAM-1;
XX intracellular adhesion molecule 1; ss.
XX
XX Homo sapiens.
OS
XX
XX US6183966-B1.
PN
XX
XX 06-FEB-2001.
PD
XX
XX 22-JAN-1999; 99US-00235614.
PF
XX
XX 07-OCT-1994; 94US-00320507.
PR
XX 03-MAR-1997; 97US-00808474.
PR
XX
XX (TEXA ) UNIV TEXAS SYSTEM.
PA
XX
XX Gray DM, Clark CL;
PI
XX
XX WPI; 2001-280429/29.
DR
XX
XX Identifying a nucleic acid having a sequence capable of targeting a gene
PT of interest, for identifying nucleic acids for gene therapy, comprises
PT using the Nearest-Neighbor Thermal Stability Program.
XX
XX Example 1; Col 25-26; 43pp; English.
PS
XX
XX The present invention describes a method for the identification of a
CC nucleic acid having a sequence capable of targeting a gene of interest
CC comprises: (a) a first database having a list of stability values for
CC independent combinations of N(x); (b) a computing unit having a means for
CC inputting data comprising N(x); data list, defining a nucleic acid
CC sequence of interest to be targeted to provide a second database; and (c)
CC a program capable of processing the first and second database to N(x)
CC comparison, and a stability value of a nucleic acid sequence capable of
CC targeting the gene of interest. The method is useful for identifying a
CC nucleic acid having a sequence capable of targeting a gene of interest.
CC These nucleic acids are useful in gene therapy and disease treatment. The
CC method may be used to obtain thermodynamic parameters for 20 combinations
CC of nearest-neighbour base pairs of DNA:RNA hybrid sequences. The Nearest-
CC Neighbour Thermal Stability Program can process data for use in
CC calculating thermal melting temperatures for phosphorothioate DNA:RNA
CC hybrids. The program can be readily extended to predict the most stable
CC triplex-forming sequences, or antigenic oligomers. The present sequence
CC represents an antisense DNA oligomer designated S-ASO targeted to the
CC human intracellular adhesion molecule 1 (ICAM-1), which is used in an
CC example from the present invention
XX
XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAAGTGGTGGGG 1957
DB 20 GACAGGGGAAGTGGTGGGG 1
RESULT 516
AAF87791/c
ID AAF87791 standard; DNA; 20 BP.
XX
XX AAF87791;
AC
XX 11-JUL-2001 (first entry)
DT
XX Human intracellular adhesion molecule 1 (ICAM-1) S-ASO SEQ ID NO:18.
DE
XX Antisense DNA oligomer; ASO; identification; gene therapy; target;
KW intracellular adhesion molecule 1; ss.

```

```

KW Nearest-Neighbour Thermal Stability Program; thermal melting temperature;
KW phosphorothioate; disease treatment; DNA:RNA hybrid; human; ICAM-1;
XX intracellular adhesion molecule 1; ss.
XX
XX Homo sapiens.
OS
XX
XX US6183966-B1.
PN
XX
XX 06-FEB-2001.
PD
XX
XX 22-JAN-1999; 99US-00235614.
PF
XX
XX 07-OCT-1994; 94US-00320507.
PR
XX 03-MAR-1997; 97US-00808474.
PR
XX
XX (TEXA ) UNIV TEXAS SYSTEM.
PA
XX
XX Gray DM, Clark CL;
PI
XX
XX WPI; 2001-280429/29.
DR
XX
XX Identifying a nucleic acid having a sequence capable of targeting a gene
PT of interest, for identifying nucleic acids for gene therapy, comprises
PT using the Nearest-Neighbor Thermal Stability Program.
XX
XX Example 1; Col 27-28; 43pp; English.
PS
XX
XX The present invention describes a method for the identification of a
CC nucleic acid having a sequence capable of targeting a gene of interest
CC comprises: (a) a first database having a list of stability values for
CC independent combinations of N(x); (b) a computing unit having a means for
CC inputting data comprising N(x); data list, defining a nucleic acid
CC sequence of interest to be targeted to provide a second database; and (c)
CC a program capable of processing the first and second database to N(x)
CC comparison, and a stability value of a nucleic acid sequence capable of
CC targeting the gene of interest. The method is useful for identifying a
CC nucleic acid having a sequence capable of targeting a gene of interest.
CC These nucleic acids are useful in gene therapy and disease treatment. The
CC method may be used to obtain thermodynamic parameters for 20 combinations
CC of nearest-neighbour base pairs of DNA:RNA hybrid sequences. The Nearest-
CC Neighbour Thermal Stability Program can process data for use in
CC calculating thermal melting temperatures for phosphorothioate DNA:RNA
CC hybrids. The program can be readily extended to predict the most stable
CC triplex-forming sequences, or antigenic oligomers. The present sequence
CC represents an antisense DNA oligomer designated S-ASO targeted to the
CC human intracellular adhesion molecule 1 (ICAM-1), which is used in an
CC example from the present invention
XX
XX Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2962 AGTTAATAAAGCTTCTCAA 2981
DB 20 AGTTAATAAAGCTTCTCAA 1
RESULT 517
AAF87789/c
ID AAF87789 standard; DNA; 20 BP.
XX
XX AAF87789;
AC
XX 11-JUL-2001 (first entry)
DT
XX Human intracellular adhesion molecule 1 (ICAM-1) S-ASO SEQ ID NO:16.
DE
XX Antisense DNA oligomer; ASO; identification; gene therapy; target;
KW Nearest-Neighbour Thermal Stability Program; thermal melting temperature;
KW phosphorothioate; disease treatment; DNA:RNA hybrid; human; ICAM-1;
XX intracellular adhesion molecule 1; ss.

```

```

XX OS Homo sapiens.
XX PN US6183966-B1.
XX PD 06-FEB-2001.
XX PF 22-JAN-1999; 99US-00235614.
XX PP 07-OCT-1994; 94US-00320507.
XX PR 03-MAR-1997; 97US-00808474.
XX PA (TEXA ) UNIV TEXAS SYSTEM.
XX PI Gray DM, Clark CL;
XX DR WPI; 2001-280429/29.
XX PT Identifying a nucleic acid having a sequence capable of targeting a gene
XX of interest, for identifying nucleic acids for gene therapy, comprises
XX using the Nearest-Neighbor Thermal Stability Program.
XX PS Example 1; Col 25-26; 43pp; English.
XX CC The present invention describes a method for the identification of a
XX nucleic acid having a sequence capable of targeting a gene of interest
XX comprises: (a) a first database having a list of stability values for
XX independent combinations of N(x); (b) a computing unit having a means for
XX inputting data comprising N(x); data list, defining a nucleic acid
XX sequence of interest to be targeted to provide a second database; and (c)
XX a program capable of processing the first and second database to N(x)
XX comparison, and a stability value of a nucleic acid sequence capable of
XX targeting the gene of interest. The method is useful for identifying a
XX nucleic acid having a sequence capable of targeting a gene of interest.
XX These nucleic acids are useful in gene therapy and disease treatment. The
XX method may be used to obtain thermodynamic parameters for 20 combinations
XX of nearest-neighbour base pairs of DNA:RNA hybrid sequences. The Nearest-
XX Neighbour Thermal Stability Program can process data for use in
XX calculating thermal melting temperatures for phosphorothioate DNA:RNA
XX hybrids. The program can be readily extended to predict the most stable
XX triplex-forming sequences, or antigene oligomers. The present sequence
XX represents an antisense DNA oligomer designated S-ASO targeted to the
XX human intracellular adhesion molecule 1 (ICAM-1), which is used in an
XX example from the present invention
XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGTTGGC 2119
DB 20 TGACGGATGCCAGTTGGC 1

RESULT 518
AAF87787/c
ID AAF87787 standard; DNA; 20 BP.
AC AAF87787;
XX 11-JUL-2001 (first entry)
XX Human intracellular adhesion molecule 1 (ICAM-1) S-ASO SEQ ID NO:14.
XX Antisense DNA oligomer; ASO; identification; gene therapy; target;
XX Nearest-Neighbor Thermal Stability Program; thermal melting temperature;
XX phosphorothioate; disease treatment; DNA:RNA hybrid; human; ICAM-1;
XX intracellular adhesion molecule 1; ss.
XX Homo sapiens.
XX OS
XX FT

```

```

PN US6183966-B1.
XX 06-FEB-2001.
XX 22-JAN-1999; 99US-00235614.
XX 07-OCT-1994; 94US-00320507.
XX 03-MAR-1997; 97US-00808474.
XX (TEXA ) UNIV TEXAS SYSTEM.
XX Gray DM, Clark CL;
XX WPI; 2001-280429/29.
XX Identifying a nucleic acid having a sequence capable of targeting a gene
XX of interest, for identifying nucleic acids for gene therapy, comprises
XX using the Nearest-Neighbor Thermal Stability Program.
XX PS Example 1; Col 25-26; 43pp; English.
XX CC The present invention describes a method for the identification of a
XX nucleic acid having a sequence capable of targeting a gene of interest
XX comprises: (a) a first database having a list of stability values for
XX independent combinations of N(x); (b) a computing unit having a means for
XX inputting data comprising N(x); data list, defining a nucleic acid
XX sequence of interest to be targeted to provide a second database; and (c)
XX a program capable of processing the first and second database to N(x)
XX comparison, and a stability value of a nucleic acid sequence capable of
XX targeting the gene of interest. The method is useful for identifying a
XX nucleic acid having a sequence capable of targeting a gene of interest.
XX These nucleic acids are useful in gene therapy and disease treatment. The
XX method may be used to obtain thermodynamic parameters for 20 combinations
XX of nearest-neighbour base pairs of DNA:RNA hybrid sequences. The Nearest-
XX Neighbour Thermal Stability Program can process data for use in
XX calculating thermal melting temperatures for phosphorothioate DNA:RNA
XX hybrids. The program can be readily extended to predict the most stable
XX triplex-forming sequences, or antigene oligomers. The present sequence
XX represents an antisense DNA oligomer designated S-ASO targeted to the
XX human intracellular adhesion molecule 1 (ICAM-1), which is used in an
XX example from the present invention
XX SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
DB 20 TGAACCTATCCCGGACAGG 1

RESULT 519
ABK12804/c
ID ABK12804 standard; DNA; 20 BP.
XX ABK12804;
XX 19-JUN-2002 (first entry)
XX Oligonucleotide ISIS 2302.
XX VP22; viral protein 22; ss; cytostatic; antipsoriatic; dermatological;
XX disaggregating agent; Aluminium phthalocyanine; cell proliferation;
XX apoptosis; psoriasis; eczema; skin cancer; restenosis; scarring;
XX ISIS2302.
XX Synthetic.
XX Key Location/Qualifiers
XX modified_base 1 /*tag= a
XX FT

```

FT /label= OTHER
 FT /note= "G is covalently linked to a Bodipy 630/650 moiety"
 XX
 PN WO200220060-A1.
 XX
 PD 14-MAR-2002.
 XX
 XX
 XX 10-SEP-2001; 2001WO-GB004057.
 PF
 XX 08-SEP-2000; 2000GB-00022101.
 PR
 XX (PHOG-) PHOGEN LTD.
 PA
 XX O'hare PFJ, Brewis ND, Normand NM, Sunassee KR;
 PI WPI; 2002-304326/34.
 XX
 XX Use of aggregates comprising VP22 protein/polypeptide with the transport
 PT function of VP22 and oligonucleotides/polynucleotides with disaggregating
 PT agent, useful for treating or preventing cell proliferation.
 PT
 XX Example 6; Page 21; 31pp; English.
 PS
 XX The invention relates to the use of aggregates comprising VP22 (viral
 CC protein 22) protein (or a polypeptide with the transport function of
 CC VP22), and oligonucleotides or polynucleotides with a disaggregating
 CC agent e.g. Aluminium phthalocyanine (AT) (simultaneously or sequentially)
 CC to treat target cells by delivering molecules to the cells and/or
 CC preventing cell proliferation and/or killing cells. Also included are a
 CC method of treating target cells to deliver molecules to the cells and/or
 CC prevent their proliferation and/or kill them comprising: (a) exposing the
 CC cells to the aggregate composition cited above; and (b) exposing the
 CC cells to the disaggregating agent cited above; which can promote
 CC disaggregation of the aggregate composition in cells, where steps (a) and
 CC (b) are carried out simultaneously or sequentially. a product comprising
 CC the aggregate composition and the disaggregating agent, as combined
 CC preparation for administration of these components, either sequentially
 CC or together, a pharmaceutical comprising the aggregate composition and
 CC the disaggregating agent, in combination with a pharmaceutical excipient
 CC and a cell preparation obtainable by treating the target cells in vitro
 CC as cited in the method above. The aggregate composition and
 CC disaggregating agent are useful in the manufacture of a medicament for
 CC treating diseases or target cells, and/or preventing cell proliferation
 CC and/or killing cells. These compositions, product or pharmaceutical are
 CC useful in therapy, particularly for manufacturing medicaments for use in
 CC therapy, or as a medicament for delivering molecules to cells to prevent
 CC cell proliferation or kill cells. In particular, these may be used for
 CC treating psoriasis, eczema, skin cancer, restenosis and scarring. The
 CC present sequence is an oligonucleotide used to demonstrate the method of
 CC the invention
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTGGGC 2119
 Db |||||
 20 TGACGGATGCCAGCTGGGC 1
 RESULT 520
 ABK12803/c
 ID ABK12803 standard; DNA; 20 BP.
 XX
 AC ABK12803;
 XX
 XX 18-JUN-2002 (first entry)
 DT
 XX Intracellular-adhesion molecule, ICAM, oligonucleotide.
 DE
 XX

KW VP22; viral protein 22; ss; cytostatic; antipsoriatic; dermatological;
 KW disaggregating agent; Aluminium phthalocyanine; cell proliferation;
 KW apoptosis; psoriasis; eczema; skin cancer; restenosis; scarring;
 KW intracellular-adhesion molecule; ICAM.
 XX
 OS Unidentified.
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= a
 FT /label= OTHER
 FT FT
 FT /note= "Phosphorothioate backbone"
 FT modified_base 1
 FT /*tag= b
 FT /label= OTHER
 FT FT
 FT /note= "C is covalently linked to a fluorescein moiety"
 FT
 XX WO200220060-A1.
 XX
 XX 14-MAR-2002.
 PD
 XX 10-SEP-2001; 2001WO-GB004057.
 PF
 XX 08-SEP-2000; 2000GB-00022101.
 PR
 XX (PHOG-) PHOGEN LTD.
 PA
 XX O'hare PFJ, Brewis ND, Normand NM, Sunassee KR;
 PI WPI; 2002-304326/34.
 XX
 XX Use of aggregates comprising VP22 protein/polypeptide with the transport
 PT function of VP22 and oligonucleotides/polynucleotides with disaggregating
 PT agent, useful for treating or preventing cell proliferation.
 PT
 XX Example 1; Page 17; 31pp; English.
 PS
 XX The invention relates to the use of aggregates comprising VP22 (viral
 CC protein 22) protein (or a polypeptide with the transport function of
 CC VP22), and oligonucleotides or polynucleotides with a disaggregating
 CC agent e.g. Aluminium phthalocyanine (AT) (simultaneously or sequentially)
 CC to treat target cells by delivering molecules to the cells and/or
 CC preventing cell proliferation and/or killing cells. Also included are a
 CC method of treating target cells to deliver molecules to the cells and/or
 CC prevent their proliferation and/or kill them comprising: (a) exposing the
 CC cells to the aggregate composition cited above; and (b) exposing the
 CC cells to the disaggregating agent cited above; which can promote
 CC disaggregation of the aggregate composition in cells, where steps (a) and
 CC (b) are carried out simultaneously or sequentially. a product comprising
 CC the aggregate composition and the disaggregating agent, as combined
 CC preparation for administration of these components, either sequentially
 CC or together, a pharmaceutical comprising the aggregate composition and
 CC the disaggregating agent, in combination with a pharmaceutical excipient
 CC and a cell preparation obtainable by treating the target cells in vitro
 CC as cited in the method above. The aggregate composition and
 CC disaggregating agent are useful in the manufacture of a medicament for
 CC treating diseases or target cells, and/or preventing cell proliferation
 CC and/or killing cells. These compositions, product or pharmaceutical are
 CC useful in therapy, particularly for manufacturing medicaments for use in
 CC therapy, or as a medicament for delivering molecules to cells to prevent
 CC cell proliferation or kill cells. In particular, these may be used for
 CC treating psoriasis, eczema, skin cancer, restenosis and scarring. The
 CC present sequence is an oligonucleotide encoding an intracellular-adhesion
 CC molecule, ICAM, which can form aggregates and is used to demonstrate the
 CC method of the invention
 XX
 SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1938 GAGAGGGGAAGTGGTGGGG 1957

```

Db      20 GAGAGGGGAAGTGTGGGG 1
|||||
RESULT 521
ABL01636/c
ID      ABL01636 standard; DNA; 20 BP.
XX
AC      ABL01636;
XX
DT      15-MAR-2002 (first entry)
XX
DE      ICAM-1 targeted antisense peptide nucleic acid SEQ ID NO: 42.
XX
KW      Peptide nucleic acid; PNA; cytostatic; virucide; dermatological;
KW      antiasthmatic; overexpression; viral infection; vitiligo; antisense;
KW      pigmentation disorder; asthma; polyamide backbone; ss.
XX
OS      Unidentified.
XX
FH      Key Location/Qualifiers
FT      modified_base 1..20 /*tag= a
FT      /*note= "This sequence is a peptide nucleic acid, i.e. it
FT      contains a polyamide backbone instead of a deoxyribose
FT      backbone"
FT      modified_base 1 /*tag= b
FT      /*mod_base= OTHER
FT      /*note= "linked to one of the peptides shown in ABB04517
FT      and ABB04518 to form a PNA-peptide conjugate"
XX
PN      WO200179216-A2.
XX
PD      25-OCT-2001.
XX
PF      07-APR-2001; 2001WO-EP004030.
XX
PR      18-APR-2000; 2000DE-01019135.
XX
PA      (AVET ) AVENTIS PHARMA DEUT GMBH.
XX
PI      Uhlmann E, Breipohl G, Will DW;
XX      WPI; 2002-075055/10.
XX
DR      New peptide nucleic acid derivatives, useful e.g. for tumor treatment and
PT      diagnosis, contain terminal, deprotonizable phosphoryl groups for e.g.
PT      improved solubility.
XX
PS      Disclosure; Page 22; 93pp; German.
XX
CC      The present invention relates to peptide nucleic acid (PNA) derivatives
CC      having at the C-, and optionally N-, terminus one or more phosphoryl
CC      groups, at least one of which contains one or more deprotonisable groups,
CC      preferably hydroxy or mercapto. These PNAs are useful in the treatment of
CC      tumours or any disease associated with (over)expression of particular
CC      genes, including viral infections, vitiligo or other pigmentation
CC      disorders, and asthma. The present sequence is a peptide nucleic acid
CC      described in the exemplification of the invention
XX
SQ      Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1938 GAGAGGGGAAGTGTGGGG 1957
|||||
Db      20 GAGAGGGGAAGTGTGGGG 1
|||||
RESULT 522

```

```

ABL01637/c
ID      ABL01637 standard; DNA; 20 BP.
XX
AC      ABL01637;
XX
DT      15-MAR-2002 (first entry)
XX
DE      ICAM-1 targeted antisense peptide nucleic acid SEQ ID NO: 43.
XX
KW      Peptide nucleic acid; PNA; cytostatic; virucide; dermatological;
KW      antiasthmatic; overexpression; viral infection; vitiligo; antisense;
KW      pigmentation disorder; asthma; polyamide backbone; ss.
XX
OS      Unidentified.
XX
FH      Key Location/Qualifiers
FT      modified_base 1..20 /*tag= a
FT      /*note= "This sequence is a peptide nucleic acid, i.e. it
FT      contains a polyamide backbone instead of a deoxyribose
FT      backbone"
FT      modified_base 1 /*tag= b
FT      /*mod_base= OTHER
FT      /*note= "linked to one of the peptides shown in ABB04517
FT      and ABB04518 to form a PNA-peptide conjugate"
XX
PN      WO200179216-A2.
XX
PD      25-OCT-2001.
XX
PF      07-APR-2001; 2001WO-EP004030.
XX
PR      18-APR-2000; 2000DE-01019135.
XX
PA      (AVET ) AVENTIS PHARMA DEUT GMBH.
XX
PI      Uhlmann E, Breipohl G, Will DW;
XX      WPI; 2002-075055/10.
XX
DR      New peptide nucleic acid derivatives, useful e.g. for tumor treatment and
PT      diagnosis, contain terminal, deprotonizable phosphoryl groups for e.g.
PT      improved solubility.
XX
PS      Disclosure; Page 22; 93pp; German.
XX
CC      The present invention relates to peptide nucleic acid (PNA) derivatives
CC      having at the C-, and optionally N-, terminus one or more phosphoryl
CC      groups, at least one of which contains one or more deprotonisable groups,
CC      preferably hydroxy or mercapto. These PNAs are useful in the treatment of
CC      tumours or any disease associated with (over)expression of particular
CC      genes, including viral infections, vitiligo or other pigmentation
CC      disorders, and asthma. The present sequence is a peptide nucleic acid
CC      described in the exemplification of the invention
XX
SQ      Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1940 GAGGGGAAGTGTGGGGGAG 1959
|||||
Db      20 GAGGGGAAGTGTGGGGGAG 1
|||||
RESULT 523
ABL01635/c
ID      ABL01635 standard; DNA; 20 BP.
XX
AC      ABL01635;
XX

```


DT 15-MAR-2002 (first entry)
 XX ICAM-1 targeted antisense peptide nucleic acid SEQ ID NO: 41.
 DE Peptide nucleic acid; PNA; cytostatic; virucide; dermatological;
 XX antiasthmatic; overexpression; viral infection; vitiligo; antisense;
 KW pigmentation disorder; asthma; polyamide backbone; ss.
 KW Unidentified.
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= a
 FT /notes= "This sequence is a peptide nucleic acid, i.e. it
 FT contains a polyamide backbone instead of a deoxyribose
 FT backbone"
 FT modified_base 1
 FT /tag= b
 FT /mod_base= OTHER
 FT /notes= "linked to one of the peptides shown in ABB04517
 FT and ABB04518 to form a PNA-peptide conjugate"
 XX
 XX WO200179216-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 07-APR-2001; 2001WO-EP004030.
 XX
 XX 18-APR-2000; 2000DE-01019135.
 XX
 XX (AVET) AVENTIS PHARMA DEUT GMBH.
 XX
 XX Uhlmann E, Breipohl G, Will DW;
 XX
 XX WPI; 2002-075055/10.
 DR
 XX New peptide nucleic acid derivatives, useful e.g. for tumor treatment and
 XX diagnosis, contain terminal, deprotonizable phosphoryl groups for e.g.
 PT improved solubility.
 PT
 XX Disclosure; Page 22; 93pp; German.
 XX
 XX The present invention relates to peptide nucleic acid (PNA) derivatives
 CC having at the C-, and optionally N-, terminus one or more phosphoryl
 CC groups, at least one of which contains one or more deprotonisable groups,
 CC preferably hydroxy or mercapto. These PNAs are useful in the treatment of
 CC tumours or any disease associated with (over)expression of particular
 CC genes, including viral infections, vitiligo or other pigmentation
 CC disorders, and asthma. The present sequence is a peptide nucleic acid
 CC described in the exemplification of the invention
 XX
 XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1
 RESULT 524
 ID ABK87928/c
 XX ABK87928 standard; DNA; 20 BP.
 XX
 XX ABK87928;
 XX
 XX 07-OCT-2002 (first entry)
 DT Antisense oligonucleotide, INX-2302, directed against ICAM-1 mRNA.
 DE Antisense oligonucleotide, INX-2302, directed against ICAM-1 mRNA.
 XX INX-2302; ss; antisense; cytostatic; ICAM-1; multimeric aggregates;
 KW

KW toxicity; therapeutic; cancer; quadruplex; cisplatin; hepatocarcinoma.
 XX Unidentified.
 OS
 XX WO200236767-A2.
 XX
 XX 10-MAY-2002.
 XX
 XX 31-OCT-2001; 2001WO-CA001540.
 XX
 XX 02-NOV-2000; 2000US-0245176P.
 XX
 XX (INEX-) INEX PHARM CORP.
 XX
 XX Madden TD, Webb MS;
 XX
 XX WPI; 2002-557427/59.
 XX
 XX Reducing in vivo toxicity of therapeutic oligonucleotide which forms
 PT multimeric aggregates, by treating oligonucleotide such that is converted
 PT to monomeric form, or formation of multimeric aggregates is prevented.
 XX
 XX Example 3; Page 17; 39pp; English.
 PS
 XX The invention discloses a method for reducing the in vivo toxicity of a
 CC therapeutic oligonucleotide which tends to form multimeric aggregates.
 CC The method comprises heat treating the therapeutic oligonucleotide, in
 CC multimeric aggregate form, in order to convert all of the therapeutic
 CC oligonucleotide to a monomeric form or to prevent the formation of
 CC multimeric aggregates. One example of oligonucleotides which undergo
 CC multimerisation are those which include a sequence of four G bases. Such
 CC oligonucleotides aggregate into a quadruplex. The method is useful for
 CC reducing the in vivo toxicity of a therapeutic oligonucleotide which
 CC tends to form multimeric aggregates and for preparing a therapeutic
 CC oligonucleotide composition which is useful for administering to a mammal
 CC in need of therapy. The therapeutic composition, in combination with
 CC cisplatin, is useful for treating disorders, particularly cancer of the
 CC head and neck, upper gastro-intestinal cancers, such as hepatocarcinoma,
 CC cancers of the lower or upper oesophagus and metastatic breast cancer.
 CC The method reduces the toxicity of the therapeutic oligonucleotides
 CC (stemming from interactions with blood proteins, complement activation
 CC and inhibition of coagulation) and thus allows the use of higher and more
 CC efficacious doses. Thus, the monomeric oligonucleotides increase the
 CC margin of safety. The sequence presented is the antisense
 CC oligonucleotide, INX-2302, which is directed against ICAM-1 mRNA
 XX
 XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1
 RESULT 525
 ID ABA97491/c
 XX ABA97491 standard; DNA; 20 BP.
 XX
 XX ABA97491;
 XX
 XX 16-APR-2002 (first entry)
 DT ICAM-1 targeted antisense peptide nucleic acid SEQ ID NO: 37.
 DE
 XX Peptide nucleic acid; PNA; polyamide backbone; phosphoryl radical;
 KW cytostatic; virucide; dermatological; antiasthmatic; cancer; antisense;
 XX viral infection; vitiligo; pigmentation disorder; asthma; ss.
 XX Unidentified.
 OS Synthetic.

XX WO200179249-A2.
 XX 25-OCT-2001.
 XX 07-APR-2001; 2001WO-EP004027.
 XX 18-APR-2000; 2000DE-01019136.
 XX (AVET) AVENTIS PHARMA DEUT GMBH.
 XX Uhlmann E, Breipohl G, Will DW;
 XX WPI; 2002-089643/12.
 XX New peptide nucleic acid derivatives, useful e.g. for treating tumors and
 PT diagnosis, have N-terminal phosphoryl residue for improving e.g.
 PT solubility in water.
 XX Disclosure; Page 87; 96pp; German.
 XX The present invention relates to peptide nucleic acid (PNA) derivatives.
 CC These can be used in the treatment of cancer, viral infections, vitiligo
 CC or other pigmentation disorders, and asthma. The present sequence is an
 CC oligonucleotide fragment of a PNA described in the exemplification of the
 CC invention
 XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1938 GAGAGGGGAAGTGGTGGGG 1957
 DB 20 GAGAGGGGAAGTGGTGGGG 1
 RESULT 526
 ABA97490/c
 ID ABA97490 standard; DNA; 20 BP.
 XX ABA97490;
 XX 16-APR-2002 (first entry)
 XX ICAM-1 targeted antisense peptide nucleic acid SEQ ID NO: 36.
 XX Peptide nucleic acid; PNA; polyamide backbone; phosphoryl radical;
 KW cytostatic; virucide; dermatological; antiasthmatic; cancer; antisense;
 KW viral infection; vitiligo; pigmentation disorder; asthma; ss.
 XX Unidentified.
 OS Synthetic.
 XX WO200179249-A2.
 XX 25-OCT-2001.
 XX 07-APR-2001; 2001WO-EP004027.
 XX 18-APR-2000; 2000DE-01019136.
 XX (AVET) AVENTIS PHARMA DEUT GMBH.
 XX Uhlmann E, Breipohl G, Will DW;
 XX WPI; 2002-089643/12.
 XX New peptide nucleic acid derivatives, useful e.g. for treating tumors and
 PT diagnosis, have N-terminal phosphoryl residue for improving e.g.
 PT solubility in water.
 XX Unidentified.
 OS Synthetic.
 XX WO200179249-A2.
 XX 25-OCT-2001.
 XX 07-APR-2001; 2001WO-EP004027.
 XX 18-APR-2000; 2000DE-01019136.
 XX (AVET) AVENTIS PHARMA DEUT GMBH.
 XX Uhlmann E, Breipohl G, Will DW;
 XX WPI; 2002-089643/12.
 XX New peptide nucleic acid derivatives, useful e.g. for treating tumors and
 PT diagnosis, have N-terminal phosphoryl residue for improving e.g.
 PT solubility in water.

PS Disclosure; Page 87; 96pp; German.
 XX The present invention relates to peptide nucleic acid (PNA) derivatives.
 CC These can be used in the treatment of cancer, viral infections, vitiligo
 CC or other pigmentation disorders, and asthma. The present sequence is an
 CC oligonucleotide fragment of a PNA described in the exemplification of the
 CC invention
 XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 DB 20 TGACGGATGCCAGCTTGGGC 1
 RESULT 527
 ABA97492/c
 ID ABA97492 standard; DNA; 20 BP.
 XX ABA97492;
 XX 16-APR-2002 (first entry)
 XX ICAM-1 targeted antisense peptide nucleic acid SEQ ID NO: 38.
 XX Peptide nucleic acid; PNA; polyamide backbone; phosphoryl radical;
 KW cytostatic; virucide; dermatological; antiasthmatic; cancer; antisense;
 KW viral infection; vitiligo; pigmentation disorder; asthma; ss.
 XX Unidentified.
 OS Synthetic.
 XX WO200179249-A2.
 XX 25-OCT-2001.
 XX 07-APR-2001; 2001WO-EP004027.
 XX 18-APR-2000; 2000DE-01019136.
 XX (AVET) AVENTIS PHARMA DEUT GMBH.
 XX Uhlmann E, Breipohl G, Will DW;
 XX WPI; 2002-089643/12.
 XX New peptide nucleic acid derivatives, useful e.g. for treating tumors and
 PT diagnosis, have N-terminal phosphoryl residue for improving e.g.
 PT solubility in water.
 XX Unidentified.
 OS Synthetic.
 XX WO200179249-A2.
 XX 25-OCT-2001.
 XX 07-APR-2001; 2001WO-EP004027.
 XX 18-APR-2000; 2000DE-01019136.
 XX (AVET) AVENTIS PHARMA DEUT GMBH.
 XX Uhlmann E, Breipohl G, Will DW;
 XX WPI; 2002-089643/12.
 XX New peptide nucleic acid derivatives, useful e.g. for treating tumors and
 PT diagnosis, have N-terminal phosphoryl residue for improving e.g.
 PT solubility in water.
 XX Unidentified.
 OS Synthetic.
 XX WO200179249-A2.
 XX 25-OCT-2001.
 XX 07-APR-2001; 2001WO-EP004027.
 XX 18-APR-2000; 2000DE-01019136.
 XX (AVET) AVENTIS PHARMA DEUT GMBH.
 XX Uhlmann E, Breipohl G, Will DW;
 XX WPI; 2002-089643/12.
 XX New peptide nucleic acid derivatives, useful e.g. for treating tumors and
 PT diagnosis, have N-terminal phosphoryl residue for improving e.g.
 PT solubility in water.
 XX Unidentified.
 OS Synthetic.
 XX WO200179249-A2.
 XX 25-OCT-2001.
 XX 07-APR-2001; 2001WO-EP004027.
 XX 18-APR-2000; 2000DE-01019136.
 XX (AVET) AVENTIS PHARMA DEUT GMBH.
 XX Uhlmann E, Breipohl G, Will DW;
 XX WPI; 2002-089643/12.
 XX New peptide nucleic acid derivatives, useful e.g. for treating tumors and
 PT diagnosis, have N-terminal phosphoryl residue for improving e.g.
 PT solubility in water.
 XX Unidentified.
 OS Synthetic.
 XX WO200179249-A2.
 XX 25-OCT-2001.
 XX 07-APR-2001; 2001WO-EP004027.
 XX 18-APR-2000; 2000DE-01019136.
 XX (AVET) AVENTIS PHARMA DEUT GMBH.
 XX Uhlmann E, Breipohl G, Will DW;
 XX WPI; 2002-089643/12.
 XX New peptide nucleic acid derivatives, useful e.g. for treating tumors and
 PT diagnosis, have N-terminal phosphoryl residue for improving e.g.
 PT solubility in water.

QY 1940 GAGGGGAAGTGGTGGGGAG 1959
 DB 20 GAGGGGAAGTGGTGGGGAG 1
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1940 GAGGGGAAGTGGTGGGGAG 1959
 DB 20 GAGGGGAAGTGGTGGGGAG 1

RESULT 528
 ABA91946/C
 ID ABA91946 standard; DNA; 20 BP.
 XX
 AC ABA91946;
 XX
 DT 23-MAY-2002 (first entry)
 XX
 DE ICAM-1 targeted 2'-O-(2-methyl-thioethyl) modified oligonucleotide.
 XX
 KW ICAM-1; human; intercellular adhesion molecule 1;
 KW 2'-O-alkyl oligonucleotide; hybridisation; diagnosis; therapy; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1 /tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)thymidine"
 FT modified_base 2 /tag= b
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)5-methylcytidine"
 FT modified_base 3 /tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)thymidine"
 FT modified_base 4 /tag= d
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
 FT modified_base 5 /tag= e
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)adenosine"
 FT modified_base 6 /tag= f
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
 FT modified_base 7 /tag= g
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)thymidine"
 FT modified_base 8 /tag= h
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)adenosine"
 FT modified_base 9 /tag= i
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
 FT modified_base 10 /tag= j
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)5-methylcytidine"
 FT modified_base 11 /tag= k
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)adenosine"
 FT modified_base 12 /tag= l
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
 FT modified_base 13 /tag= m
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)adenosine"
 FT modified_base 14 /tag= n
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
 FT modified_base 15

FT /tag= o
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
 FT modified_base 16 /tag= p
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)adenosine"
 FT modified_base 17 /tag= q
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
 FT modified_base 18 /tag= r
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)5-methylcytidine"
 FT modified_base 19 /tag= s
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)thymidine"
 FT modified_base 20 /tag= t
 FT /mod_base= OTHER
 FT /note= "2'-O-(2-methyl-thioethyl)cytidine"
 PN US6277982-B1.
 XX 21-AUG-2001.
 XX 20-AUG-1999; 99US-00378665.
 XX 20-AUG-1999; 99US-00378665.
 XX (ISIS-) ISIS PHARM INC.
 XX Fraser AS, Manoharan M, Cook PD, Jung ME, Kawasaki AM;
 XX WPI; 2002-235143/29.
 XX Alkylation of alcohols, amines, or thiols, useful for preparing
 FT nucleosides that are precursors for preparation of oligomeric compounds
 FT beneficial as therapeutics, involves use of cyclic sulfate intermediates.
 XX Example 15; Col 34; 45pp; English.
 XX The present sequence is that of a human intercellular adhesion molecule 1
 CC targeted oligonucleotide containing a phosphodiester backbone and 2'-O-(2-
 CC -methyl-thioethyl) modifications. This was compared with an
 CC oligonucleotide with a phosphorothioate backbone (see ABA91945) and with
 CC an oligonucleotide with only partial 2'-O-alkylation (see ABA91948), for
 CC targeted reduction of ICAM-1 levels in HUVEC cells. The invention
 CC provides methods for the alkylation of alcohols, amines, thiols and their
 CC derivatives by cyclic sulfate intermediates. Methods for the alkylation
 CC of the 2', 3' or 5'-hydroxy position of nucleosides and their analogues
 CC with cyclic sulfates to form the 2', 3' or 5'-O-alkyl sulfate modified
 CC compounds are disclosed. Displacement of the 2', 3' or 5'-O-sulfate with
 CC a nucleophile provides 2', 3' or 5'-O-modified nucleosides and their
 CC analogues. The methods are especially useful for the preparation of 2'-O-
 CC alkyl nucleotides, nucleosides and nucleoside surrogates that are
 CC precursors for the preparation of oligomeric compounds useful as
 CC therapeutics, diagnostics and research reagents. 2'-O-modification
 CC generally increases hybridisation, while use of a phosphorothioate
 CC internucleoside linkage improves nuclease resistance
 XX
 XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 18 GAGCTCCTCTGCTACTCAGA 37
 |||||
 Db 20 GAGCTCCTCTGCTACTCAGA 1

```
RESULT 529
ABA91945/c
ID ABA91945 standard; DNA; 20 BP.
XX AC ABA91945;
XX 23-MAY-2002 (first entry)
XX ICAM-1 targeted 2'-O-(2-methyl-thioethyl) modified oligonucleotide.
XX ICAM-1; human; intercellular adhesion molecule 1;
KW 2'-O-alkyl oligonucleotide; hybridisation; diagnosis; therapy; ss.
XX Synthetic.
XX
XX Key Location/Qualifiers
PH modified_base 1. .19
FT /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate linkage"
FT modified_base 1
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)thymidine"
FT modified_base 2
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)5-methylcytidine"
FT modified_base 3
FT /tag= d
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)thymidine"
FT modified_base 4
FT /tag= e
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
FT modified_base 5
FT /tag= f
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)adenosine"
FT modified_base 6
FT /tag= g
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
FT modified_base 7
FT /tag= h
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)thymidine"
FT modified_base 8
FT /tag= i
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)adenosine"
FT modified_base 9
FT /tag= j
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
FT modified_base 10
FT /tag= k
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)5-methylcytidine"
FT modified_base 11
FT /tag= l
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)adenosine"
FT modified_base 12
FT /tag= m
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
FT modified_base 13
FT /tag= n
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)adenosine"
```

```
FT modified_base 14
FT /tag= o
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
FT modified_base 15
FT /tag= p
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
FT modified_base 16
FT /tag= q
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)adenosine"
FT modified_base 17
FT /tag= r
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)guanosine"
FT modified_base 18
FT /tag= s
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)5-methylcytidine"
FT modified_base 19
FT /tag= t
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)thymidine"
FT modified_base 20
FT /tag= u
FT /mod_base= OTHER
FT /note= "2'-O-(2-methyl-thioethyl)cytidine"
XX US6277982-B1.
XX
XX 21-AUG-2001.
XX
XX 20-AUG-1999; 99US-00378665.
XX 20-AUG-1999; 99US-00378665.
XX (ISIS-) ISIS PHARM INC.
XX
XX Fraser AS, Manoharan M, Cook PD, Jung ME, Kawasaki AM;
XX WPI; 2002-235143/29.
XX
XX Alkylation of alcohols, amines, or thiols, useful for preparing
XX nucleosides that are precursors for preparation of oligomeric compounds
XX beneficial as therapeutics, involves use of cyclic sulfate intermediates.
XX
XX Example 15; Col 34; 45pp; English.
XX
XX The present sequence is that of a human intercellular adhesion molecule 1
XX targeted oligonucleotide containing a phosphorothioate backbone and 2'-O-
XX (2-methyl-thioethyl) modifications. This was compared with an
XX oligonucleotide with a phosphodiester backbone (see ABA91946) and with an
XX oligonucleotide with only partial 2'-O-alkylation (see ABA91948), for
XX targeted reduction of ICAM-1 levels in HUVEC cells. The invention
XX provides methods for the alkylation of alcohols, amines, thiols and their
XX derivatives by cyclic sulfate intermediates. Methods for the alkylation
XX of the 2', 3' or 5'-hydroxy position of nucleosides and their analogues
XX with cyclic sulfates to form the 2', 3' or 5'-O-alkyl sulfate modified
XX compounds are disclosed. Displacement of the 2', 3' or 5'-O-sulfate with
XX a nucleophile provides 2', 3' or 5'-O-modified nucleosides and their
XX analogues. The methods are especially useful for the preparation of 2'-O-
XX alkyl nucleotides, nucleosides and nucleoside surrogates that are
XX precursors for the preparation of oligomeric compounds useful as
XX therapeutics, diagnostics and research reagents. 2'-O-modification
XX generally increases hybridisation, while use of a phosphorothioate
XX internucleoside linkage improves nuclease resistance
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      18 GAGCTCCTGCTACTCAGA 37
Db      |||||
        20 GAGCTCCTGCTACTCAGA 1

RESULT 530
ABA91948/c
ID      ABA91948 standard; DNA; 20 BP.
XX
XX      ABA91948;
XX
XX      23-MAY-2002 (first entry)
XX
XX      ICAM-1 targeted 2'-O-(2-methyl-thioethyl) modified oligonucleotide.
XX
XX      ICAM-1; human; intercellular adhesion molecule 1;
KW      2'-O-alkyl oligonucleotide; hybridisation; diagnosis; therapy; ss.
XX
XX      Synthetic.
OS
XX
XX      Key
FH      Location/Qualifiers
FT      modified_base 1..19
FT      /tag= a
FT      /mod_base= OTHER
FT      /note= "phosphorothioate linkage"
FT      modified_base 2
FT      /tag= b
FT      /mod_base= m5c
FT      modified_base 3
FT      /tag= c
FT      /mod_base= m5c
FT      modified_base 4
FT      /tag= d
FT      /mod_base= m5c
FT      modified_base 8
FT      /tag= e
FT      /mod_base= m5c
FT      modified_base 12
FT      /tag= f
FT      /mod_base= m5c
FT      modified_base 13
FT      /tag= g
FT      /mod_base= OTHER
FT      /note= "2'-O-(2-methyl-thioethyl)adenosine"
FT      modified_base 14
FT      /tag= h
FT      /mod_base= OTHER
FT      /note= "2'-O-(2-methyl-thioethyl)thymidine"
FT      modified_base 15
FT      /tag= i
FT      /mod_base= OTHER
FT      /note= "2'-O-(2-methyl-thioethyl)-5-methylcytidine"
FT      modified_base 16
FT      /tag= j
FT      /mod_base= OTHER
FT      /note= "2'-O-(2-methyl-thioethyl)-5-methylcytidine"
FT      modified_base 17
FT      /tag= k
FT      /mod_base= OTHER
FT      /note= "2'-O-(2-methyl-thioethyl)guanosine"
FT      modified_base 18
FT      /tag= l
FT      /mod_base= OTHER
FT      /note= "2'-O-(2-methyl-thioethyl)thymidine"
FT      modified_base 19
FT      /tag= m
FT      /mod_base= OTHER
FT      /note= "2'-O-(2-methyl-thioethyl)5-methyl-cytidine"
FT      modified_base 20
FT      /tag= n
FT      /mod_base= OTHER
FT      /note= "2'-O-(2-methyl-thioethyl)adenosine"

```

```

XX      US6277982-B1.
XX      21-AUG-2001.
XX
XX      20-AUG-1999; 99US-00378665.
XX
XX      20-AUG-1999; 99US-00378665.
XX      (ISIS-) ISIS PHARM INC.
XX
XX      Fraser AS, Manoharan M, Cook PD, Jung ME, Kawasaki AM;
XX      WPI; 2002-235143/29.
XX
XX      Alkylation of alcohols, amines, or thiols, useful for preparing
XX      nucleosides that are precursors for preparation of oligomeric compounds
XX      beneficial as therapeutics, involves use of cyclic sulfate intermediates.
XX
XX      Example 15; Col 34; 45pp; English.
XX
XX      The present sequence is that of a human intercellular adhesion molecule 1
XX      targeted oligonucleotide containing a phosphorothioate backbone and some
XX      2'-O-(2-methyl-thioethyl) modifications. This was compared with an
XX      oligonucleotide with a phosphodiester backbone (see ABA91946) and with an
XX      oligonucleotide with complete 2'-O-alkylation (see ABA91945), for
XX      targeted reduction of ICAM-1 levels in HUVEC cells. The invention
XX      provides methods for the alkylation of alcohols, amines, thiols and their
XX      derivatives by cyclic sulfate intermediates. Methods for the alkylation
XX      of the 2', 3' or 5'-hydroxy position of nucleosides and their analogues
XX      with cyclic sulfates to form the 2', 3' or 5'-O-alkyl sulfate modified
XX      compounds are disclosed. Displacement of the 2', 3' or 5'-O-sulfate with
XX      a nucleophile provides 2', 3' or 5'-O-modified nucleosides and their
XX      analogues. The methods are especially useful for the preparation of 2'-O-
XX      alkyl nucleotides, nucleosides and nucleoside surrogates that are
XX      precursors for the preparation of oligomeric compounds useful as
XX      therapeutics, diagnostics and research reagents. 2'-O-modification
XX      generally increases hybridisation, while use of a phosphorothioate
XX      internucleoside linkage improves nuclease resistance
XX
XX      Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX      Query Match 0.7%; Score 20; DB 1; Length 20;
XX      Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY      2100 TGACGGATGCCAGCTTGGGC 2119
        |||||
Db      20 TGACGGATGCCAGCTTGGGC 1

RESULT 531
ABV73951/c
ID      ABV73951 standard; DNA; 20 BP.
XX
XX      ABV73951;
XX
XX      13-JAN-2003 (first entry)
XX
XX      Methylated antisense oligonucleotide 5155.
XX
XX      Immunostimulant; infection; allergy; asthma; cancer; anaemia;
KW      thrombocytopaenia; neutropaenia; antimicrobial; antiasthmatic;
KW      cytostatic; antianaemic; antiallergic; haemostatic; antisense;
XX      phosphorothioate; ss.
XX
XX      Synthetic.
XX
XX      Key
FH      Location/Qualifiers
FT      modified_base 1..20
FT      /tag= a
FT      /mod_base= OTHER
FT      /note= "phosphorothioate linkage"

```

```

FT modified_base 2 /*tag= b
FT /*mod_base= m5c
FT modified_base 3 /*tag= c
FT /*mod_base= m5c
FT modified_base 4 /*tag= d
FT /*mod_base= m5c
FT modified_base 8 /*tag= e
FT /*mod_base= m5c
FT modified_base 12 /*tag= f
FT /*mod_base= m5c
FT modified_base 15 /*tag= g
FT /*mod_base= m5c
FT modified_base 16 /*tag= h
FT /*mod_base= m5c
FT modified_base 19 /*tag= i
FT /*mod_base= m5c
XX
XX WO200269369-A2.
XX
XX 06-SEP-2002.
XX
XX 10-DEC-2001; 2001WO-IB002888.
XX
XX 08-DEC-2000; 2000US-0254341P.
XX
XX (COLE-) COLEY PHARM GROUP LTD.
XX
XX Schetter C, Vollmer J;
XX
XX WPI; 2002-723213/78.
XX
XX New compositions comprising CpG-like immunostimulatory nucleic acids,
XX useful for treating or preventing infectious diseases, cancer, allergy,
XX asthma, immunodeficiency, anemia, thrombocytopenia or neutropenia.
XX
XX Example 1; Page 89; 148pp; English.
XX
XX The present sequence is that of methylated oligonucleotide (ODN) 5155, a
XX methylated version of antisense ODN 5116 (see ABV73947), which was used
XX in an example of the invention in which methylated CpG-like ODNs were
XX compared with unmethylated ODNs for their immunostimulant activity. ODN
XX 5116 exhibited significant stimulatory capability on human B cells. ODN
XX 5155 also induced stimulation, although to a lesser extent. Methylated
XX CpG, CpI and ZpY ODNs of the invention (see ABV73935-37) are useful for
XX inducing an immune response in a subject, including humans, for the
XX treatment or prevention of an infectious disease, cancer, allergy or
XX asthma, for enhancing or stimulating bone marrow proliferation in an
XX immunodeficiency, particularly in a subject undergoing chemotherapy, for
XX enhancing erythropoiesis in anaemia, for enhancing thrombopoiesis in
XX thrombocytopenia, for enhancing neutrophil proliferation in
XX neutropenia, and for inducing cytokine (e.g. interleukin (IL)-1 beta, IL
XX -2, IL-6, IL-12, IL-18, TNF, interferon-alpha or interferon-gamma)
XX production (all claimed)
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2100 TGACGGATGCCAGCTTGGGC 2119
XX ||||||||||||||||
XX Db 20 TGACGGATGCCAGCTTGGGC 1

```

```

RESULT 532
ABV73947/c
ID ABV73947 standard; DNA; 20 BP.
XX
XX AC ABV73947;
XX
XX DT 13-JAN-2003 (first entry)
XX
XX DE Antisense oligonucleotide 5116.
XX
XX KW Immunostimulant; infection; allergy; asthma; cancer; anaemia;
XX thrombocytopenia; neutropenia; antimicrobial; antitasthmatic;
XX cytostatic; antianaemic; antiallergic; haemostatic; antisense;
XX phosphorothioate; ss.
XX
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /*mod_base= OTHER
XX /*note= "phosphorothioate linkage"
XX
XX PN WO200269369-A2.
XX
XX 06-SEP-2002.
XX
XX 10-DEC-2001; 2001WO-IB002888.
XX
XX 08-DEC-2000; 2000US-0254341P.
XX
XX (COLE-) COLEY PHARM GROUP LTD.
XX
XX Schetter C, Vollmer J;
XX
XX WPI; 2002-723213/78.
XX
XX New compositions comprising CpG-like immunostimulatory nucleic acids,
XX useful for treating or preventing infectious diseases, cancer, allergy,
XX asthma, immunodeficiency, anemia, thrombocytopenia or neutropenia.
XX
XX Example 1; Page 89; 148pp; English.
XX
XX The present sequence is that of antisense oligonucleotide (ODN) 5116
XX (2302 ISIS), which was used in an example of the invention in which
XX methylated CpG-like oligonucleotides were compared with unmethylated ODNs
XX for their immunostimulant activity. ODN 5116 exhibited significant
XX stimulatory capability on human B cells, and its corresponding methylated
XX form, ODN 5155 (see ABV73951) also induced stimulation, although to a
XX lesser extent. Methylated CpG, CpI and ZpY ODNs of the invention (see
XX ABV73935-37) are useful for inducing an immune response in a subject,
XX including humans, for the treatment or prevention of an infectious
XX disease, cancer, allergy or asthma, for enhancing or stimulating bone
XX marrow proliferation in an immunodeficiency, particularly in a subject
XX undergoing chemotherapy, for enhancing erythropoiesis in anaemia, for
XX enhancing thrombopoiesis in thrombocytopenia, for enhancing neutrophil
XX proliferation in neutropenia, and for inducing cytokine (e.g.
XX interleukin (IL)-1 beta, IL-2, IL-5, IL-6, IL-12, IL-18, TNF, interferon-alpha
XX or interferon-gamma) production (all claimed)
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2100 TGACGGATGCCAGCTTGGGC 2119
XX ||||||||||||||||
XX Db 20 TGACGGATGCCAGCTTGGGC 1

```

```

RESULT 533
ABL90980/c

```

ID ABL90980 standard; DNA; 20 BP.
 XX
 AC ABL90980;
 XX
 DT 27-MAY-2002 (first entry)
 XX
 DE ICAM-1 mediated inflammatory disease treatment oligonucleotide.
 XX
 KW Human; PKC antisense oligonucleotide; protein kinase C; PKC; PKC-alpha;
 KW PKC-beta type I; PKC-beta type II; PKC-gamma; PKC-delta; PKC-epsilon;
 KW PKC-zeta; PKC-eta; PKC expression modulation; ss;
 KW hyperproliferative condition; tumour; glioblastoma; bladder cancer;
 KW breast cancer; colon cancer; lung cancer; inflammatory condition;
 KW psoriasis; phosphorothioate backbone.
 XX
 OS Unidentified.
 XX
 PN US6339066-B1.
 XX
 PD 15-JAN-2002.
 XX
 PF 31-MAR-1997; 97US-00829637.
 XX
 PR 11-JAN-1990; 90US-00463358.
 PR 13-AUG-1990; 90US-00566977.
 PR 11-JAN-1991; 91WO-US000243.
 PR 15-OCT-1991; 91US-00777760.
 PR 16-OCT-1991; 91US-00777707.
 PR 16-MAR-1992; 92US-00852852.
 PR 05-MAY-1993; 93US-00058023.
 PR 09-JUL-1993; 93US-00089996.
 PR 28-AUG-1994; 94US-00297703.
 PR 07-JUN-1995; 95US-00481066.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Dean NM, Cook PD, Hoke G;
 XX
 DR WPI; 2002-215022/27.
 XX
 PT New antisense oligonucleotide having nucleoside units which specifically
 PT binds mRNA encoding human protein kinase C isoform, useful for treating
 PT hyperproliferative and inflammatory diseases e.g. psoriasis, tumor and
 PT cancer.
 XX
 XX Example 19; Col 25; 77pp; English.
 XX
 PS The invention comprises antisense oligonucleotides designed to bind mRNA
 CC encoding a human protein kinase C (PKC) isoform (i.e. PKC-alpha, PKC-beta
 CC type I, PKC-beta type II, PKC-gamma, PKC-delta, PKC-epsilon, PKC-zeta,
 CC and PKC-eta). The antisense oligonucleotides of the invention are useful
 CC for modulating the expression of the PKC isoforms. The antisense
 CC oligonucleotides are useful for treating hyperproliferative conditions
 CC (e.g. tumour, glioblastoma, bladder cancer, breast cancer, colon cancer
 CC and lung cancer), and inflammatory conditions (e.g. psoriasis). The
 CC antisense oligonucleotides of the invention are also useful for detection
 CC and diagnosis of PKC expression. The present sequence represents a human
 CC PKC antisense oligonucleotide of the invention. NOTE: The present
 CC sequence contains a phosphorothioate backbone
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 DB 20 TGACGGATGCCAGCTTGGGC 1
 XX
 RESULT 534
 ABL46182/c

ID ABL46182 standard; DNA; 20 BP.
 XX
 AC ABL46182;
 XX
 DT 26-APR-2002 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide ISIS 2302 SEQ ID NO:149.
 XX
 KW Nucleic acid accessible hybridisation site; detection; hybridisation;
 KW characterisation; identification; nucleic acid structure; diagnosis;
 KW PCR primer; probe; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN WO2001198537-A2.
 XX
 PD 27-DEC-2001.
 XX
 PF 15-JUN-2001; 2001WO-US019401.
 XX
 PR 17-JUN-2000; 2000US-0212308P.
 PR 15-JUN-2001; 2001US-00212308.
 XX
 PA (THIR-) THIRD WAVE TECHNOLOGIES INC.
 XX
 PI Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;
 DR WPI; 2002-049698/06.
 XX
 PT Identifying oligonucleotides hybridizing to nucleic acids containing
 PT secondary structure, useful in clinical diagnosis, comprises identifying
 PT primers that interact with the target to form an extension product under
 PT amplification conditions.
 XX
 XX Example 17; Page 382; 409pp; English.
 XX
 CC The present invention describes a method for identifying oligonucleotides
 CC with desired hybridisation properties to nucleic acid targets containing
 CC secondary structure. The method comprises amplifying a target nucleic
 CC acid having at least one accessible and one inaccessible site. Primers
 CC that form an extension product are identified as the oligonucleotides
 CC which can interact with the folded target nucleic acid. Oligonucleotides
 CC from the present invention can be used in novel detection methods for
 CC clinical diagnostic purposes, including the detection and identification
 CC of pathogenic organisms (e.g. HIV). The method allows the ability to
 CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent
 CC sequences used in the exemplification of the present invention
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 DB 20 TGACGGATGCCAGCTTGGGC 1
 XX
 RESULT 535
 ABL46180/c
 ID ABL46180 standard; DNA; 20 BP.
 XX
 AC ABL46180;
 XX
 DT 26-APR-2002 (first entry)
 XX
 DE Human ICAM-1 antisense oligonucleotide ISIS 1571 SEQ ID NO:147.
 XX
 KW Nucleic acid accessible hybridisation site; detection; hybridisation;
 KW characterisation; identification; nucleic acid structure; diagnosis;
 KW PCR primer; probe; ss.

```
XX OS Homo sapiens.
XX OS Synthetic.
XX PN WO200198537-A2.
XX XX 27-DEC-2001.
XX XX
XX XX 15-JUN-2001; 2001WO-US019401.
XX XX 17-JUN-2000; 2000US-0212308P.
XX XX 15-JUN-2001; 2001US-00212308.
XX XX
XX XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX XX
XX XX Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;
XX XX WPI; 2002-049698/06.
XX XX
XX XX Identifying oligonucleotides hybridizing to nucleic acids containing
XX XX secondary structure, useful in clinical diagnosis, comprises identifying
XX XX primers that interact with the target to form an extension product under
XX XX amplification conditions.
XX XX
XX XX Example 17; Page 382; 409pp; English.
XX XX
XX XX The present invention describes a method for identifying oligonucleotides
XX XX with desired hybridisation properties to nucleic acid targets containing
XX XX secondary structure. The method comprises amplifying a target nucleic
XX XX acid having at least one accessible and one inaccessible site. Primers
XX XX that form an extension product are identified as the oligonucleotides
XX XX which can interact with the folded target nucleic acid. Oligonucleotides
XX XX from the present invention can be used in novel detection methods for
XX XX clinical diagnostic purposes, including in novel detection and identification
XX XX of pathogenic organisms (e.g. HIV). The method allows the ability to
XX XX rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent
XX XX sequences used in the exemplification of the present invention
XX XX
XX XX Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
XX XX
XX XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX XX
XX QY 7 CAGTCGACGCTGAGCTCCTC 26
XX DB 20 CAGTCGACGCTGAGCTCCTC 1
XX
XX RESULT 536
XX ABL46181/c
XX ID ABL46181 standard; DNA; 20 BP.
XX XX
XX AC ABL46181;
XX XX
XX DT 26-APR-2002 (first entry)
XX XX
XX DE Human ICAM-1 antisense oligonucleotide ISIS 1934 SEQ ID NO:148.
XX XX
XX KW Nucleic acid accessible hybridisation site; detection; hybridisation;
XX KW characterisation; identification; nucleic acid structure; diagnosis;
XX KW PCR primer; probe; ss.
XX XX
XX OS Homo sapiens.
XX OS Synthetic.
XX XX
XX PN WO200198537-A2.
XX XX
XX PD 27-DEC-2001.
XX XX
XX PF 15-JUN-2001; 2001WO-US019401.
XX XX
XX PR 17-JUN-2000; 2000US-0212308P.
XX PR
XX XX
```

```
PR 15-JUN-2001; 2001US-00212308.
XX XX
XX PA (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX XX
XX PI Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;
XX XX WPI; 2002-049698/06.
XX XX
XX DR Identifying oligonucleotides hybridizing to nucleic acids containing
XX XX secondary structure, useful in clinical diagnosis, comprises identifying
XX XX primers that interact with the target to form an extension product under
XX XX amplification conditions.
XX XX
XX PS Example 17; Page 382; 409pp; English.
XX XX
XX CC The present invention describes a method for identifying oligonucleotides
XX CC with desired hybridisation properties to nucleic acid targets containing
XX CC secondary structure. The method comprises amplifying a target nucleic
XX CC acid having at least one accessible and one inaccessible site. Primers
XX CC that form an extension product are identified as the oligonucleotides
XX CC which can interact with the folded target nucleic acid. Oligonucleotides
XX CC from the present invention can be used in novel detection methods for
XX CC clinical diagnostic purposes, including in novel detection and identification
XX CC of pathogenic organisms (e.g. HIV). The method allows the ability to
XX CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent
XX CC sequences used in the exemplification of the present invention
XX CC
XX SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
XX XX
XX XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX XX
XX QY 337 TCAAACTGCCCTGATGGCA 356
XX DB 20 TCAAACTGCCCTGATGGCA 1
XX
XX RESULT 537
XX ABL46178/c
XX ID ABL46178 standard; DNA; 20 BP.
XX XX
XX AC ABL46178;
XX XX
XX DT 26-APR-2002 (first entry)
XX XX
XX DE Human ICAM-1 antisense oligonucleotide ISIS 1939 SEQ ID NO:145.
XX XX
XX KW Nucleic acid accessible hybridisation site; detection; hybridisation;
XX KW characterisation; identification; nucleic acid structure; diagnosis;
XX KW PCR primer; probe; ss.
XX XX
XX OS Homo sapiens.
XX OS Synthetic.
XX XX
XX PN WO200198537-A2.
XX XX
XX PD 27-DEC-2001.
XX XX
XX PF 15-JUN-2001; 2001WO-US019401.
XX XX
XX PR 17-JUN-2000; 2000US-0212308P.
XX PR
XX PR 15-JUN-2001; 2001US-00212308.
XX XX
XX XX (THIR-) THIRD WAVE TECHNOLOGIES INC.
XX XX
XX PI Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;
XX XX WPI; 2002-049698/06.
XX XX
XX DR Identifying oligonucleotides hybridizing to nucleic acids containing
XX DR secondary structure, useful in clinical diagnosis, comprises identifying
XX DR primers that interact with the target to form an extension product under
XX DR amplification conditions.
XX XX
```


PT amplification conditions.

XX Example 17; Page 382; 409pp; English.

XX

CC The present invention describes a method for identifying oligonucleotides with desired hybridisation properties to nucleic acid targets containing secondary structure. The method comprises amplifying a target nucleic acid having at least one accessible and one inaccessible site. Primers that form an extension product are identified as the oligonucleotides which can interact with the folded target nucleic acid. Oligonucleotides from the present invention can be used in novel detection methods for clinical diagnostic purposes, including the detection and identification of pathogenic organisms (e.g. HIV). The method allows the ability to rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent sequences used in the exemplification of the present invention

XX

SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
- 20 GAGAGGGGAAGTGGTGGGG 1

Db

RESULT 538
ABL57312/c
ID ABL57312 standard; DNA; 20 BP.
XX
AC ABL57312;
XX
DT 09-AUG-2002 (first entry)
XX
DE Phosphorothioate antisense oligonucleotide.
XX
KW Oligonucleotide; synthesis; antisense; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20 /tag= a
FT /notes= "Phosphorothioate linkage"
FT
FT
XX WO200220541-A2.
XX
XX 14-MAR-2002.
XX
XX 05-SEP-2001; 2001WO-CA001244.
XX
XX 05-SEP-2000; 2000US-0229532P.
XX
XX (UYTE-) UNIV TECHNOLOGIES INT INC.
XX
XX Pon RT, Sanghvi Y, Yu S;
XX
XX WPI; 2002-443885/47.
XX
XX Preparation of molecules of interest on solid support material e.g.
PT oligonucleotides such as backbone modified oligonucleotides and labeled
PT oligonucleotides, involves reacting specific materials.
XX
XX Example 3; Page 26; 63pp; English.
XX
XX The present sequence is a phosphorothioate antisense 20-mer oligonucleotide of mixed base composition that was produced in tandem synthesis on glycerol-derivatised controlled pore glass beads. The invention relates to a process for producing multiple molecules of interest, especially oligonucleotides, on a solid support. The process is used to produce 2, 3, 4 or more molecules of interest (the same or different from one another) on a single support material. It is useful

CC for preparing backbone-modified oligonucleotides such as phosphorothioate, phosphorodithioate and methyl phosphonate analogues useful as oligotherapeutic agents, labeled oligonucleotides, sugar-modified oligonucleotides and oligonucleotide derivatives such as oligonucleotide-peptide conjugates. In an example from the invention, the present oligonucleotide was prepared in tandem using a reusable support. With a column containing 12.4 mg of support, used 5 times, product yield was 77,000 A260 units/g support, compared with 10,900 A260 units/g in a control column used once. In another example, levulinic acid was used as a temporary capping group during synthesis of this oligonucleotide

XX

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
- 20 TGACGGATGCCAGCTTGGGC 1

Db

RESULT 539
ABK86103/c
ID ABK86103 standard; DNA; 20 BP.
XX
AC ABK86103;
XX
DT 23-AUG-2002 (first entry)
XX
DE Human ICAM-1 oligonucleotide phosphorothioate 2'-O-MOE gapmer.
XX
KW ICAM-1; peptide linked oligomeric compound; ss; human;
KW phosphorothioate 2'-O-MOE gapmer oligonucleotide.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..19 /tag= a
FT /note= "2'-O-MOE nucleotides"
FT modified_base 20 /tag= b
FT /label= m5C
FT /note= "5-methyl cytidine"
FT
XX WO200220544-A1.
XX
XX 14-MAR-2002.
XX
XX 07-SEP-2001; 2001WO-US028083.
XX
XX 08-SEP-2000; 2000US-00658517.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Manoharan M, Guzaev AP;
XX
XX WPI; 2002-489670/52.
XX
XX Preparing peptide linked oligomeric compound useful for diagnostics, therapeutics and as research reagents and kits by employing equimolar amounts functionalized oligomeric compounds and peptide reagents.
XX
XX Example 13; Page 70; 124pp; English.
XX
XX This invention relates to a novel method for preparing peptide linked oligomeric compounds by deprotecting the hydroxyl groups of a compound derivatising support medium, reacting deprotected hydroxyl groups with a nucleoside to form a compound from which a capped compound is formed, oxidized and cleaved to form an oligomeric compound having a reactive sulfur moiety. The reactive sulphur moiety is reacted with peptide with functional group reactive with sulfur moiety, to form a peptide linked

CC oligomeric compound. The method of the invention is useful for preparing
 CC an oligomeric compound. The oligomeric compounds can be used in
 CC diagnostics, therapeutics and as research reagents and kits. They can
 CC also be used in pharmaceutical compositions by including a suitable
 CC diluent or carrier. The oligomeric compounds of the invention can further
 CC be used for treating organisms having a disease characterised by the
 CC undesired production of a protein. This method is suitable for large
 CC scale synthesis of oligomeric compounds, the methods provide improved
 CC synthetic schemes which avoid the problem of prior art. The synthetic
 CC methods employed equimolar amounts of functionalised oligomeric compounds
 CC and peptide reagents which has successfully resulted in large scale
 CC synthesis. This scaled up synthesis is significantly larger than any
 CC synthesis method described previously. The methods are highly economical.
 CC The present sequence represents a human ICAM-1 oligomeric
 CC phosphorothioate 2'-O-MOE gapmer oligonucleotide used in an example of
 CC the method of the invention

XX SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCTCTGCTACTCAGA 37
 Db 20 GAGCTCTCTGCTACTCAGA 1
 |||||

RESULT 540
 ABK90764/c
 ID ABK90764 standard; DNA; 20 BP.

XX AC ABK90764;
 XX DT 05-NOV-2002 (first entry)

XX DE Oligomeric compound synthesis method associated polynucleotide #6.

XX KW Oligomeric synthesis method; diagnostic; therapeutic; antisense agent;
 XX KW antiviral agent; competitive inhibitor; ss.

XX OS Synthetic.

XX PN US2002055623-A1.

XX PD 09-MAY-2002.

XX PF 11-DEC-2001; 2001US-00016465.

XX PR 08-JUL-1998; 98US-00111678.

XX PR 08-JUL-1999; 99US-00349659.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Chervallath ZS, Ravikumar VT, Cole DL;

XX PI WPI; 2002-589134/63.

XX PT New oligomeric compounds containing e.g. phosphite, phosphodiester and
 PT phosphorothioate linkages, useful as oligonucleotides or analogs in
 PT diagnostics, therapeutics and as research agents.

XX PS Example 14; Page 20; 33pp; English.

XX CC The invention describes oligomeric compounds containing a moiety. The
 CC oligomeric compounds are useful e.g. as oligonucleotides or
 CC oligonucleotide analogues in diagnostics, therapeutics and as research
 CC agents. Oligonucleotides and their analogues have been used in molecular
 CC biology as probes, primers, linkers, adapters and gene fragments. They
 CC may also be useful as antisense agents for various disease states, e.g.
 CC antiviral agents, or as competitive inhibitors of transcription factors
 CC to modulate their action. Oligonucleotides and their analogues have also
 CC been used as direct and indirect regulators of protein, in diagnostic

CC hybridisation techniques, and as primers in PCR reactions. This sequence
 CC represents a synthetic polynucleotide created using the oligomeric
 CC compounds synthesis method described in the invention
 XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1
 |||||

RESULT 541
 ABK90760/c

ID ABK90760 standard; DNA; 20 BP.

XX AC ABK90760;

XX DT 05-NOV-2002 (first entry)

XX DE Oligomeric compound synthesis method associated polynucleotide #2.

XX KW Oligomeric synthesis method; diagnostic; therapeutic; antisense agent;
 XX KW antiviral agent; competitive inhibitor; ss.

XX OS Synthetic.

XX PN US2002055623-A1.

XX PD 09-MAY-2002.

XX PF 11-DEC-2001; 2001US-00016465.

XX PR 08-JUL-1998; 98US-00111678.

XX PR 08-JUL-1999; 99US-00349659.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Chervallath ZS, Ravikumar VT, Cole DL;

XX PI WPI; 2002-589134/63.

XX PT New oligomeric compounds containing e.g. phosphite, phosphodiester and
 PT phosphorothioate linkages, useful as oligonucleotides or analogs in
 PT diagnostics, therapeutics and as research agents.

XX PS Example 10; Page 19; 33pp; English.

XX CC The invention describes oligomeric compounds containing a moiety. The
 CC oligomeric compounds are useful e.g. as oligonucleotides or
 CC oligonucleotide analogues in diagnostics, therapeutics and as research
 CC agents. Oligonucleotides and their analogues have been used in molecular
 CC biology as probes, primers, linkers, adapters and gene fragments. They
 CC may also be useful as antisense agents for various disease states, e.g.
 CC antiviral agents, or as competitive inhibitors of transcription factors
 CC to modulate their action. Oligonucleotides and their analogues have also
 CC been used as direct and indirect regulators of protein, in diagnostic
 CC hybridisation techniques, and as primers in PCR reactions. This sequence
 CC represents a synthetic polynucleotide created using the oligomeric
 CC compounds synthesis method described in the invention

XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1
 |||||

```
RESULT 542
ABK15435/c
ID ABK15435 standard; DNA; 20 BP.
AC ABK15435;
XX
XX
XX 21-MAY-2002 (first entry)
XX
XX Human ICAM-1 antisense oligonucleotide ISIS #18268.
XX
XX Antisense oligonucleotide; antipruritic; antipruritic; antiinflammatory;
KW dermatological; antipruritic; cytostatic; antibacterial; virucide;
KW fungicide; inhibitor; psoriasis; inflammatory disorder; skin; ss;
KW lichen planus; toxic epidermal necrolysis; erythema multiform; ICAM-1;
XX skin cancer; infectious disorder; intercellular adhesion molecule 1.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Alternating phosphodiester/phosphorothioate
FT linkages"
FT modified_base 2..20
FT /*tag= b
FT /mod_base= OTHER
FT modified_base 2
FT /*tag= c
FT /mod_base= m5c
FT /note= "5-methyl-C"
FT modified_base 10
FT /*tag= d
FT /mod_base= m5c
FT /note= "5-methyl-C"
FT modified_base 18
FT /*tag= e
FT /mod_base= m5c
FT /note= "5-methyl-C"
FT modified_base 20
FT /*tag= f
FT /mod_base= OTHER
FT /note= "Optionally 5-methyl-C"
XX
XX US6326358-B1.
XX
XX 04-DEC-2001.
XX
XX 07-JUL-1999; 99US-00349007.
XX
XX 14-JUL-1998; 98US-00115025.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Manoharan M;
XX
XX WPI; 2002-194575/25.
XX
XX New 2'-modified oligonucleotides having alternating internucleoside
PT linkages, useful for inhibiting the production or activity of a protein
PT and treating e.g. psoriasis.
XX
XX Example 1; Col 25-26; 28pp; English.
XX
XX The invention relates to novel oligonucleotides containing at least one
CC region of 2'-modified nucleosides connected by alternating phosphodiester
CC and phosphorothioate linkages. The oligonucleotides are used for
CC inhibiting the production or activity of a protein in an organism. The
CC oligonucleotides can be used in diagnostics, therapeutics and as research
CC reagents and kits, for treating e.g. psoriasis and inflammatory disorders
CC
```

```
CC of the skin (such as lichen planus, toxic epidermal necrolysis, erythema
CC multiform), skin cancer, and infectious disorders of the skin (bacterial,
CC viral or fungal). The compounds are resistant to nuclease degradation,
CC and have increased binding affinity relative to phosphorothioate
CC oligomers. The staggered phosphorothioate/phosphodiester linkages will
CC also modulate the protein binding to plasma proteins. The present
CC sequence represents one of 13 antisense oligonucleotides of the invention
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 18 GAGCTCCTCTGCTACTCAGA 37
XX |||||
XX Db 20 GAGCTCCTCTGCTACTCAGA 1
XX
XX RESULT 543
XX ABK15447/c
XX ID ABK15447 standard; DNA; 20 BP.
XX
XX AC ABK15447;
XX
XX DT 21-MAY-2002 (first entry)
XX
XX DE Human ICAM-1 antisense oligonucleotide ISIS #18268.
XX
XX KW Antisense oligonucleotide; antipruritic; antiinflammatory;
KW dermatological; antipruritic; cytostatic; antibacterial; virucide;
KW fungicide; inhibitor; psoriasis; inflammatory disorder; skin; ss;
KW lichen planus; toxic epidermal necrolysis; erythema multiform; ICAM-1;
KW skin cancer; infectious disorder; intercellular adhesion molecule 1.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Alternating phosphodiester/phosphorothioate
FT linkages; 2'-methoxyethoxy (2' MOE) nucleotides"
FT modified_base 2
FT /*tag= c
FT /mod_base= m5c
FT /note= "5-methyl-C"
FT modified_base 10
FT /*tag= d
FT /mod_base= m5c
FT /note= "5-methyl-C"
FT modified_base 18
FT /*tag= e
FT /mod_base= m5c
FT /note= "5-methyl-C"
XX
XX US6326358-B1.
XX
XX 04-DEC-2001.
XX
XX 07-JUL-1999; 99US-00349007.
XX
XX 14-JUL-1998; 98US-00115025.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Manoharan M;
XX
XX WPI; 2002-194575/25.
XX
XX New 2'-modified oligonucleotides having alternating internucleoside
PT linkages, useful for inhibiting the production or activity of a protein
PT and treating e.g. psoriasis.
XX
XX Example 1; Col 25-26; 28pp; English.
XX
XX The invention relates to novel oligonucleotides containing at least one
CC region of 2'-modified nucleosides connected by alternating phosphodiester
CC and phosphorothioate linkages. The oligonucleotides are used for
CC inhibiting the production or activity of a protein in an organism. The
CC oligonucleotides can be used in diagnostics, therapeutics and as research
CC reagents and kits, for treating e.g. psoriasis and inflammatory disorders
CC
```

XX Example 3; Col 29; 28pp; English.
XX
CC The invention relates to novel oligonucleotides containing at least one
CC and phosphorothioate linkages. The oligonucleotides are used for
CC inhibiting the production or activity of a protein in an organism. The
CC oligonucleotides can be used in diagnostics, therapeutics and as research
CC reagents and kits, for treating e.g. psoriasis and inflammatory disorders
CC of the skin (such as lichen planus, toxic epidermal necrolysis, erythema
CC multiform), skin cancer, and infectious disorders of the skin (bacterial,
CC viral or fungal). The compounds are resistant to nuclease degradation,
CC and have increased binding affinity relative to phosphorothioate
CC oligomers. The staggered phosphorothioate/phosphodiester linkages will
CC also modulate the protein binding to plasma proteins. The present
CC sequence represents one of 13 antisense oligonucleotides of the invention
XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCTCTGCTACTCAGA 37
Db 20 GAGCTCTCTGCTACTCAGA 1

RESULT 544
ABK15441/c
ID ABK15441 standard; DNA; 20 BP.
XX
AC ABK15441;
XX
DT 21-MAY-2002 (first entry)
XX
DE Human ICAM-1 antisense oligonucleotide ISIS #11158.
XX
KW Antisense oligonucleotide; antipsoriatic; antiinflammatory;
KW dermatological; antipruritic; cytostatic; antibacterial; virucide;
KW fungicide; inhibitor; psoriasis; inflammatory disorder; skin; ss;
KW lichen planus; toxic epidermal necrolysis; erythema multiform; ICAM-1;
KW skin cancer; infectious disorder; intercellular adhesion molecule 1.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethoxy (2' MOE) nucleotides"
XX
PN US6326358-B1.
XX
XX
PD 04-DEC-2001.
XX
XX
PF 07-JUL-1999; 99US-00349007.
XX
XX
PR 14-JUL-1998; 98US-00115025.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Manoharan M;
XX
XX WPI; 2002-194575/25.
XX
XX New 2'-modified oligonucleotides having alternating internucleoside
PT linkages, useful for inhibiting the production or activity of a protein
PT and treating e.g. psoriasis.
XX
XX Example 2; Col 33; 28pp; English.
XX
CC The invention relates to novel oligonucleotides containing at least one

CC region of 2'-modified nucleosides connected by alternating phosphodiester
CC and phosphorothioate linkages. The oligonucleotides are used for
CC inhibiting the production or activity of a protein in an organism. The
CC oligonucleotides can be used in diagnostics, therapeutics and as research
CC reagents and kits, for treating e.g. psoriasis and inflammatory disorders
CC of the skin (such as lichen planus, toxic epidermal necrolysis, erythema
CC multiform), skin cancer, and infectious disorders of the skin (bacterial,
CC viral or fungal). The compounds are resistant to nuclease degradation,
CC and have increased binding affinity relative to phosphorothioate
CC oligomers. The staggered phosphorothioate/phosphodiester linkages will
CC also modulate the protein binding to plasma proteins. The present
CC sequence represents one of 13 antisense oligonucleotides of the invention
XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCTCTGCTACTCAGA 37
Db 20 GAGCTCTCTGCTACTCAGA 1

RESULT 545
ABK15437/c
ID ABK15437 standard; DNA; 20 BP.
XX
AC ABK15437;
XX
DT 21-MAY-2002 (first entry)
XX
DE Human ICAM-1 antisense oligonucleotide #3.
XX
KW Antisense oligonucleotide; antipsoriatic; antiinflammatory;
KW dermatological; antipruritic; cytostatic; antibacterial; virucide;
KW fungicide; inhibitor; psoriasis; inflammatory disorder; skin; ss;
KW lichen planus; toxic epidermal necrolysis; erythema multiform; ICAM-1;
KW skin cancer; infectious disorder; intercellular adhesion molecule 1.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Alternating phosphodiester/phosphorothioate
FT linkages"
FT modified_base 2
FT /*tag= b
FT /mod_base= m5c
FT /note= "5-methyl-C"
FT modified_base 3
FT /*tag= c
FT /mod_base= m5c
FT /note= "5-methyl-C"
FT modified_base 4
FT /*tag= d
FT /mod_base= m5c
FT /note= "5-methyl-C"
FT modified_base 8
FT /*tag= e
FT /mod_base= m5c
FT /note= "5-methyl-C"
FT modified_base 12
FT /*tag= f
FT /mod_base= m5c
FT /note= "5-methyl-C"
FT modified_base 13..20
FT /*tag= j
FT /mod_base= OTHER
FT /note= "2'-methoxyethoxy (2' MOE) nucleotides"
FT modified_base 15

```

FT      /*tag= g
FT      /mod_base= m5c
FT      /note= "5-methyl-C"
FT      16
FT      modified_base
FT      /*tag= h
FT      /mod_base= m5c
FT      /note= "5-methyl-C"
FT      19
FT      modified_base
FT      /*tag= i
FT      /mod_base= m5c
FT      /note= "5-methyl-C"
FT      20
XX      US6326358-B1.
XX      04-DEC-2001.
XX      07-JUL-1999; 99US-00349007.
XX      14-JUL-1998; 98US-00115025.
XX      (ISIS-) ISIS PHARM INC.
XX      Manoharan M;
XX      WPI; 2002-194575/25.
XX      New 2'-modified oligonucleotides having alternating internucleoside
XX      linkages, useful for inhibiting the production or activity of a protein
XX      and treating e.g. psoriasis.
XX      Example 1; Col 25-26; 28pp; English.
XX      The invention relates to novel oligonucleotides containing at least one
XX      region of 2'-modified nucleosides connected by alternating phosphodiester
XX      and phosphorothioate linkages. The oligonucleotides are used for
XX      inhibiting the production or activity of a protein in an organism. The
XX      oligonucleotides can be used in diagnostics, therapeutics and as research
XX      reagents and kits, for treating e.g. psoriasis and inflammatory disorders
XX      of the skin (such as lichen planus, toxic epidermal necrolysis, erythema
XX      multiform, skin cancer, and infectious disorders of the skin (bacterial,
XX      viral or fungal). The compounds are resistant to nuclease degradation,
XX      and have increased binding affinity relative to phosphorothioate
XX      oligomers. The staggered phosphorothioate/phosphodiester linkages will
XX      also modulate the protein binding to plasma proteins. The present
XX      sequence represents one of 13 antisense oligonucleotides of the invention
XX      SQ      Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
          |||||
          20 TGACGGATGCCAGCTTGGGC 1
Db

RESULT 546
ABK15438/c
ID      ABK15438 standard; DNA; 20 BP.
XX      ABK15438;
XX      21-MAY-2002 (first entry)
XX      Human ICAM-1 antisense oligonucleotide ISIS #11910.
XX      Antisense oligonucleotide; antipsoriatic; antiinflammatory;
XX      dermatological; antipruritic; cytostatic; antibacterial; virucide;
XX      fungicide; inhibitor; psoriasis; inflammatory disorder; skin; ss;
XX      lichen planus; toxic epidermal necrolysis; erythema multiform; ICAM-1;
XX      skin cancer; infectious disorder; intercellular adhesion molecule 1.
XX      Synthetic.
XX      Key      Location/Qualifiers
FH      modified_base 1..20
FT      /tag= a
FT      /mod_base= OTHER
FT      /note= "2'-methoxyethoxy (2' MOE) nucleotides"
FT      modified_base 2
FT      /tag= b
FT      /mod_base= m5c

```

OS Synthetic.

XX US6326358-B1.

XX 04-DEC-2001.

XX 07-JUL-1999; 99US-00349007.

XX 14-JUL-1998; 98US-00115025.

XX (ISIS-) ISIS PHARM INC.

XX Manoharan M;

XX WPI; 2002-194575/25.

XX New 2'-modified oligonucleotides having alternating internucleoside linkages, useful for inhibiting the production or activity of a protein and treating e.g. psoriasis.

XX Example 2; Col 31; 28pp; English.

XX The invention relates to novel oligonucleotides containing at least one region of 2'-modified nucleosides connected by alternating phosphodiester and phosphorothioate linkages. The oligonucleotides are used for inhibiting the production or activity of a protein in an organism. The oligonucleotides can be used in diagnostics, therapeutics and as research reagents and kits, for treating e.g. psoriasis and inflammatory disorders of the skin (such as lichen planus, toxic epidermal necrolysis, erythema multiform), skin cancer, and infectious disorders of the skin (bacterial, viral or fungal). The compounds are resistant to nuclease degradation, and have increased binding affinity relative to phosphorothioate oligomers. The staggered phosphorothioate/phosphodiester linkages will also modulate the protein binding to plasma proteins. The present sequence represents one of 13 antisense oligonucleotides of the invention

SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20; Best Local Similarity 100.0%; Pred. No. 5.4e+02; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||

Db 20 GAGCTCCTCTGCTACTCAGA 1
|||||

RESULT 547
ABK15443/c
ID ABK15443 standard; DNA; 20 BP.
XX ABK15443;
XX 21-MAY-2002 (first entry)
XX Human ICAM-1 antisense oligonucleotide, ISIS #16952.
XX Antisense oligonucleotide; antipsoriatic; antiinflammatory; dermatological; antipruritic; cytostatic; antibacterial; virucide; fungicide; inhibitor; psoriasis; inflammatory disorder; skin; ss; lichen planus; toxic epidermal necrolysis; erythema multiform; ICAM-1; skin cancer; infectious disorder; intercellular adhesion molecule 1.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethoxy (2' MOE) nucleotides"
FT modified_base 2
FT /tag= b
FT /mod_base= m5c

FT modified_base /note= "5-methyl-C"
 10
 FT OS /*tag= c
 FT FT /mod_base= m5c
 FT modified_base /note= "5-methyl-C"
 18
 FT FT /*tag= d
 FT FT /mod_base= m5c
 FT modified_base /note= "5-methyl-C"
 20
 FT FT /*tag= e
 FT FT /mod_base= m5c
 FT FT /note= "5-methyl-C"

XX US6326358-B1.

PN 04-DEC-2001.

XX 07-JUL-1999; 99US-00349007.

XX 14-JUL-1998; 98US-00115025.

XX (ISIS-) ISIS PHARM INC.

PI Manoharan M;

XX WPI; 2002-194575/25.

PT New 2'-modified oligonucleotides having alternating internucleoside linkages, useful for inhibiting the production or activity of a protein and treating e.g. psoriasis.

XX Example 3; Col 28; 28pp; English.

CC The invention relates to novel oligonucleotides containing at least one region of 2'-modified nucleosides connected by alternating phosphodiester and phosphorothioate linkages. The oligonucleotides are used for inhibiting the production or activity of a protein in an organism. The oligonucleotides can be used in diagnostics, therapeutics and as research reagents and kits, for treating e.g. psoriasis and inflammatory disorders of the skin (such as lichen planus, toxic epidermal necrolysis, erythema multiform), skin cancer, and infectious disorders of the skin (bacterial, viral or fungal). The compounds are resistant to nuclease degradation, and have increased binding affinity relative to phosphorothioate oligomers. The staggered phosphorothioate/phosphodiester linkages will also modulate the protein binding to plasma proteins. The present CC sequence represents one of 13 antisense oligonucleotides of the invention

XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
 |||||
 Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 548

ABK15439/C

ID ABK15439 standard; DNA; 20 BP.

XX

AC ABK15439;

XX

DT 21-MAY-2002 (first entry)

XX Human ICAM-1 antisense oligonucleotide ISIS #3067.

XX Antisense oligonucleotide; antipsoriatic; antiinflammatory;
 KW dermatological; antipruritic; cytostatic; antibacterial; virucide;
 KW fungicide; inhibitor; psoriasis; inflammatory disorder; skin; ss;
 KW lichen planus; toxic epidermal necrolysis; erythema multiform; ICAM-1;

KW skin cancer; infectious disorder; intercellular adhesion molecule 1.
 XX Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20 /*tag= a
 FT FT /mod_base= OTHER
 FT FT /note= "Phosphorothioate linkages"

XX US6326358-B1.

PN 04-DEC-2001.

XX 07-JUL-1999; 99US-00349007.

XX 14-JUL-1998; 98US-00115025.

XX (ISIS-) ISIS PHARM INC.

XX Manoharan M;

XX WPI; 2002-194575/25.

PT New 2'-modified oligonucleotides having alternating internucleoside linkages, useful for inhibiting the production or activity of a protein and treating e.g. psoriasis.

XX Example 2; Col 31; 28pp; English.

CC The invention relates to novel oligonucleotides containing at least one region of 2'-modified nucleosides connected by alternating phosphodiester and phosphorothioate linkages. The oligonucleotides are used for inhibiting the production or activity of a protein in an organism. The oligonucleotides can be used in diagnostics, therapeutics and as research reagents and kits, for treating e.g. psoriasis and inflammatory disorders of the skin (such as lichen planus, toxic epidermal necrolysis, erythema multiform), skin cancer, and infectious disorders of the skin (bacterial, viral or fungal). The compounds are resistant to nuclease degradation, and have increased binding affinity relative to phosphorothioate oligomers. The staggered phosphorothioate/phosphodiester linkages will also modulate the protein binding to plasma proteins. The present CC sequence represents one of 13 antisense oligonucleotides of the invention

XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
 |||||
 Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 549

ABK15445/C

ID ABK15445 standard; DNA; 20 BP.

XX

AC ABK15445;

XX

DT 21-MAY-2002 (first entry)

XX Human ICAM-1 antisense oligonucleotide, ISIS #15537.

XX Antisense oligonucleotide; antipsoriatic; antiinflammatory;
 KW dermatological; antipruritic; cytostatic; antibacterial; virucide;
 KW fungicide; inhibitor; psoriasis; inflammatory disorder; skin; ss;
 KW lichen planus; toxic epidermal necrolysis; erythema multiform; ICAM-1;
 KW skin cancer; infectious disorder; intercellular adhesion molecule 1.
 XX Synthetic.
 XX

```

FH Key Location/Qualifiers
FT modified_base 1..20
FT FT /tag= a
FT DE /mod_base= OTHER
FT FT /note= "2'-methoxyethoxy (2' MOE) nucleotides;
FT modified_base 2
FT FT /tag= b
FT FT /mod_base= m5C
FT FT /note= "5-methyl-C"
FT modified_base 10
FT FT /tag= c
FT FT /mod_base= m5C
FT FT /note= "5-methyl-C"
FT modified_base 18
FT FT /tag= d
FT FT /mod_base= m5C
FT FT /note= "5-methyl-C"
FT modified_base 20
FT FT /tag= e
FT FT /mod_base= m5C
FT FT /note= "5-methyl-C"
FT US6326358-B1.
FT PN 04-DEC-2001.
FT PD
FT XX 07-JUL-1999; 99US-00349007.
FT PF
FT XX 14-JUL-1998; 98US-00115025.
FT PR
FT XX (ISIS-) ISIS PHARM INC.
FT PA
FT PI Manoharan M;
FT XX WPI; 2002-194575/25.
FT DR
FT XX New 2'-modified oligonucleotides having alternating internucleoside
FT linkages, useful for inhibiting the production or activity of a protein
FT and treating e.g. psoriasis.
FT XX Example 3; Col 28; 28pp; English.
FT PS
FT CC The invention relates to novel oligonucleotides containing at least one
FT region of 2'-modified nucleosides connected by alternating phosphodiester
FT and phosphorothioate linkages. The oligonucleotides are used for
FT inhibiting the production or activity of a protein in an organism. The
FT oligonucleotides can be used in diagnostics, therapeutics and as research
FT reagents and kits, for treating e.g. psoriasis and inflammatory disorders
FT of the skin (such as lichen planus, toxic epidermal necrolysis, erythema
FT multiform), skin cancer, and infectious disorders of the skin (bacterial,
FT viral or fungal). The compounds are resistant to nuclease degradation,
FT and have increased binding affinity relative to phosphorothioate
FT oligomers. The staggered phosphorothioate/phosphodiester linkages will
FT also modulate the protein binding to plasma proteins. The present
FT sequence represents one of 13 antisense oligonucleotides of the invention
FT XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
RESULT 550
ABK15442/c
ID ABK15442 standard; DNA; 20 BP.
XX
AC ABK15442;

XX 21-MAY-2002 (first entry)
XX Human ICAM-1 antisense oligonucleotide ISIS #18268.
XX Antisense oligonucleotide; antipsoriatic; antiinflammatory;
XX dermatological; antipruritic; cytostatic; antibacterial; virucide;
XX fungicide; inhibitor; psoriasis; inflammatory disorder; skin; ss;
XX lichen planus; toxic epidermal necrolysis; erythema multiform; ICAM-1;
XX skin cancer; infectious disorder; intercellular adhesion molecule 1.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT FT /tag= a
FT FT /mod_base= OTHER
FT FT /note= "Alternating phosphodiester/phosphorothioate
FT linkages"
FT modified_base 1..20
FT FT /tag= a
FT FT /mod_base= OTHER
FT FT /note= "Alternating 2'-methoxyethoxy (2' MOE) -/ 2'-deoxy-
FT nucleotides"
FT US6326358-B1.
FT PN 04-DEC-2001.
FT PD
FT XX 07-JUL-1999; 99US-00349007.
FT PF
FT XX 14-JUL-1998; 98US-00115025.
FT PR
FT XX (ISIS-) ISIS PHARM INC.
FT PA
FT PI Manoharan M;
FT XX WPI; 2002-194575/25.
FT DR
FT XX New 2'-modified oligonucleotides having alternating internucleoside
FT linkages, useful for inhibiting the production or activity of a protein
FT and treating e.g. psoriasis.
FT XX Example 2; Col 33; 28pp; English.
FT PS
FT CC The invention relates to novel oligonucleotides containing at least one
FT region of 2'-modified nucleosides connected by alternating phosphodiester
FT and phosphorothioate linkages. The oligonucleotides are used for
FT inhibiting the production or activity of a protein in an organism. The
FT oligonucleotides can be used in diagnostics, therapeutics and as research
FT reagents and kits, for treating e.g. psoriasis and inflammatory disorders
FT of the skin (such as lichen planus, toxic epidermal necrolysis, erythema
FT multiform), skin cancer, and infectious disorders of the skin (bacterial,
FT viral or fungal). The compounds are resistant to nuclease degradation,
FT and have increased binding affinity relative to phosphorothioate
FT oligomers. The staggered phosphorothioate/phosphodiester linkages will
FT also modulate the protein binding to plasma proteins. The present
FT sequence represents one of 13 antisense oligonucleotides of the invention
FT XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
RESULT 551
ABK15440/c
ID ABK15440 standard; DNA; 20 BP.

```

XX AC ABK15440;
XX XX
DT 21-MAY-2002 (first entry)
XX XX
DE Human ICAM-1 antisense oligonucleotide ISIS #11159.
XX XX
KW Antisense oligonucleotide; antipsoriatic; antiinflammatory;
KW dermatological; antipruritic; cytostatic; antibacterial; virucide;
KW fungicide; inhibitor; psoriasis; inflammatory disorder; skin; ss;
KW lichen planus; toxic epidermal necrolysis; erythema multiform; ICAM-1;
KW skin cancer; infectious disorder; intercellular adhesion molecule 1.
XX XX
OS Synthetic.
XX XX
FH Key Location/Qualifiers
FT modified_base 1..20 /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethoxy (2' MOE) nucleotides;
FT phosphorothioate linkages"
XX XX
PN US6326358-B1.
XX XX
PD 04-DEC-2001.
XX XX
PF 07-JUL-1999; 99US-00349007.
XX XX
PR 14-JUL-1998; 98US-00115025..
XX XX
PA (ISIS-) ISIS PHARM INC.
XX XX
PI Manoharan M;
XX XX
DR WPI; 2002-194575/25.
XX XX
PT New 2'-modified oligonucleotides having alternating internucleoside
PT linkages, useful for inhibiting the production or activity of a protein
PT and treating e.g. psoriasis.
XX XX
PS Example 2; Col 33; 28pp; English.
XX XX
CC The invention relates to novel oligonucleotides containing at least one
CC region of 2'-modified nucleosides connected by alternating phosphodiester
CC and phosphorothioate linkages. The oligonucleotides are used for
CC inhibiting the production or activity of a protein in an organism. The
CC oligonucleotides can be used in diagnostics, therapeutics and as research
CC reagents and kits, for treating e.g. psoriasis and inflammatory disorders
CC of the skin (such as lichen planus, toxic epidermal necrolysis, erythema
CC multiform), skin cancer, and infectious disorders of the skin (bacterial,
CC viral or fungal). The compounds are resistant to nuclease degradation,
CC and have increased binding affinity relative to phosphorothioate
CC oligomers. The staggered phosphorothioate/phosphodiester linkages will
CC also modulate the protein binding to plasma proteins. The present
CC sequence represents one of 13 antisense oligonucleotides of the invention
XX XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
Db |||||||||||||||||||
20 GAGCTCCTCTGCTACTCAGA 1
RESULT 552
AAL46755/c
ID AAL46755 standard; DNA; 20 BP.
XX AC AAL46755;
XX XX

DT 08-AUG-2002 (first entry)
XX XX
DE ICAM antisense oligonucleotide #1.
XX XX
KW Modified antisense oligonucleotide; antisense; HIV; cancer; infection;
KW cytostatic; virucide; anti-HIV; hepatotropic; antiinflammatory;
KW phosphorothioate backbone; integrin; cell-cell adhesion receptor; ss.
XX XX
OS Unidentified.
FH Key Location/Qualifiers
FT modified_base 1..13 /tag= a
FT /mod_base= OTHER
FT /note= "optionally phosphorothioate backbone"
FT modified_base 6..8 /tag= b
FT /mod_base= OTHER
FT /note= "optionally phosphorothioate backbone"
FT modified_base 11..13 /tag= c
FT /mod_base= OTHER
FT /note= "optionally phosphorothioate backbone"
FT modified_base 16..19 /tag= d
FT /mod_base= OTHER
FT /note= "optionally phosphorothioate backbone"
XX XX
PN EP1182206-A2.
XX XX
PD 27-FEB-2002.
XX XX
PF 07-NOV-1994; 2001EP-00124078.
XX XX
PR 12-NOV-1993; 93DE-04338704.
PR 07-NOV-1994; 94EP-00117513.
XX XX
PA (PARH) HOECHST AG.
XX XX
PI Peymann A, Uhlmann E, Mag M, Kretschmar G, Helsberg M, Winkler I;
XX XX
DR WPI; 2002-353922/39.
XX XX
CC New nuclease-resistant oligonucleotides having modified non-terminal
CC pyrimidine nucleoside(s), useful e.g. for treating cancer or viral
CC diseases or as diagnostic reagents.
XX XX
PS Disclosure; Page 12; 19pp; German.
XX XX
CC The present invention relates to oligonucleotides having at least one non
CC -terminal pyrimidine nucleoside modified and additionally having the 5'-
CC and/or 3'-terminal modified. These can be used in the treatment of viral
CC infections, such as HIV, HSV-1, HSV-2, influenza virus, VSV, hepatitis B
CC and papilloma viruses, cancer and diseases involving integrins and cell-
CC cell adhesion receptors. The present sequence is an antisense
CC oligonucleotide of the invention
XX XX
SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGGAAGTGGTGGGG 1957
Db |||||||||||||||||||
20 GAGAGGGGGAAGTGGTGGGG 1
RESULT 553
AAL46756/c
ID AAL46756 standard; DNA; 20 BP.
XX AC AAL46756;
XX XX


```
XX 08-AUG-2002 (first entry)
DT
XX ICAM antisense oligonucleotide #2.
DE
XX Modified antisense oligonucleotide; antisense; HIV; cancer; infection;
KW cytostatic; virucide; anti-HIV; hepatotropic; antiinflammatory;
KW phosphorothioate backbone; integrin; cell-cell adhesion receptor; ss.
XX Unidentified.
XX
XX Key Location/Qualifiers
FH modified_base 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "optionally phosphorothioate backbone"
FT modified_base 9
FT /*tag= b
FT /mod_base= OTHER
FT /note= "optionally phosphorothioate backbone"
FT modified_base 13
FT /*tag= c
FT /mod_base= OTHER
FT /note= "optionally phosphorothioate backbone"
FT modified_base 16..19
FT /*tag= d
FT /mod_base= OTHER
FT /note= "optionally phosphorothioate backbone"
XX
XX BP1182206-A2.
XX
XX 27-FEB-2002.
XX
XX 07-NOV-1994; 2001EP-00124078.
XX
XX 12-NOV-1993; 93DE-04338704.
XX
XX 07-NOV-1994; 94EP-00117513.
XX
XX (FARH ) HOECHST AG.
XX
XX Peymann A, Uhlmann E, Mag M, Kretschmar G, Helsberg M, Winkler I;
XX WPI; 2002-353922/39.
XX
XX New nuclease-resistant oligonucleotides having modified non-terminal
XX pyrimidine nucleoside(s), useful e.g. for treating cancer or viral
XX diseases or as diagnostic reagents.
XX
XX Disclosure; Page 13; 19pp; German.
XX
XX The present invention relates to oligonucleotides having at least one non
XX -terminal pyrimidine nucleoside modified and additionally having the 5'-
XX and/or 3'-terminal modified. These can be used in the treatment of viral
XX infections, such as HIV, HSV-1, HSV-2, influenza virus, VSV, hepatitis B
XX and papilloma viruses, cancer and diseases involving integrins and cell-
XX cell adhesion receptors. The present sequence is an antisense
XX oligonucleotide of the invention
XX
XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1940 GAGGGGAAGTGTGGGGGAG 1959
XX |||||
XX 20 GAGGGGAAGTGTGGGGGAG 1
XX
XX RESULT 554
XX ABA00065/c
XX ID ABA00065 standard; DNA; 20 BP.
XX
```

```
AC ABA00065;
XX
XX 25-OCT-2002 (first entry)
DT
XX Antisense oligonucleotide ISIS 2302.
DE
XX Antisense; ss.
KW
XX Synthetic.
OS
XX WO200259137-A1.
XX
XX 01-AUG-2002.
PD
XX
XX 23-OCT-2001; 2001WO-US049702.
PF
XX
XX 03-NOV-2000; 2000US-00705587.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Yu Z, Baker BF, Wu J;
XX WPI; 2002-599758/64.
XX
XX Detecting or quantitating oligonucleotides in a bodily fluid or extract
XX useful for studying pharmacokinetic properties of oligonucleotides in
XX humans comprises contacting the fluid or extract with a single-strand
XX specific nuclease.
XX
XX Disclosure; Page 5; 48pp; English.
XX
XX The sequences given in ABA00064-67 are antisense oligonucleotides which
XX were detected using the method of the invention for detecting or
XX quantitating an oligonucleotide in a bodily fluid or extract. The method
XX comprises contacting the fluid or extract with a probe complementary to
XX the oligonucleotide, and with a single-strand specific nuclease under
XX conditions in which the probe which is not hybridized to the
XX oligonucleotide is degraded. The method is useful for detecting,
XX localizing and quantifying administered oligonucleotides in bodily fluids
XX and extracts taken from patients undergoing antisense oligonucleotide
XX therapy. The method is also useful for studying the pharmacokinetic
XX properties of oligonucleotides in animal models and in humans. The method
XX is highly sensitive through providing an increased detection of small
XX molecules when compared to traditional slab-gel electrophoresis
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 2100 TCACGGATGCCAGCTTGGGC 2119
XX |||||
XX 20 TCACGGATGCCAGCTTGGGC 1
XX
XX RESULT 555
XX ABK91305/c
XX ID ABK91305 standard; DNA; 20 BP.
XX
XX ABK91305;
AC
XX
XX 05-NOV-2002 (first entry)
DT
XX
XX Oligonucleotide, ISIS 15839, used to inhibit complement activation.
XX
XX Complement activation; inhibitor; complement mediated immune response;
XX complement mediated inflammatory effect; myasthenia gravis; angioedema;
XX immune complex excess syndrome; systemic lupus erythematosus; ISIS 15839;
XX ischaemia-reperfusion state; hyper-acute transplant rejection; ss;
XX organ failure; adult respiratory distress syndrome; Alzheimer's disease;
XX neurodegenerative disorders.
XX
```

```

OS Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2' methoxyethoxy (2'MOE) nucleotides;
FT phosphorothioate backbone"
XX
XX US2002082227-A1.
XX
XX 27-JUN-2002.
XX
XX 27-FEB-2001; 2001US-00794824.
XX
XX 30-SEP-1999; 99US-00409816.
XX
XX (HENS/) HENRY S.
XX
XX Henry S;
XX
XX WPI; 2002-626556/67.
XX
XX Inhibiting complement activation in a human cell, tissue or bodily fluid,
XX useful for treating abnormal and/or undesirable conditions arising from
XX complement activation, comprises administering modified oligonucleotides.
XX
XX Claim 8; Page 20; 35pp; English.
XX
XX The invention relates to a method for inhibiting complement activation in
XX a human cell, tissue or bodily fluid comprising administering an
XX oligonucleotide to the cell, tissue or bodily fluid. Also described is a
XX composition comprising an oligonucleotide and a complement activation
XX inhibitory molecule, where the oligonucleotide comprises one or more
XX phosphorothioate modifications and one or more 2'-methoxyethoxy
XX modifications. The method is useful for the inhibition and/or modulation
XX of the complement mediated immune response, and for treating abnormal
XX and/or undesirable conditions which can arise as a result of complement
XX activation or complement mediated inflammatory effects, such as
XX myasthenia gravis, immune complex excess syndromes such as systemic lupus
XX erythematosus, ischaemia-reperfusion states, angioedema, hyper-acute
XX rejection of transplants, organ failure conditions such as adult
XX respiratory distress syndrome, Alzheimer's disease, and related
XX neurodegenerative disorders. The present sequence represents an
XX oligonucleotide used in the method of the invention
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 556
ABK91301/c
ID ABK91301 standard; DNA; 20 BP.
XX
XX AC ABK91301;
XX
XX DT 05-NOV-2002 (first entry)
XX
XX Oligonucleotide, ISIS 2302, used to inhibit complement activation.
XX
XX Complement activation; inhibitor; complement mediated immune response;
XX complement mediated inflammatory effect; myasthenia gravis; angioedema;
XX immune complex excess syndrome; systemic lupus erythematosus; ISIS 2302;
XX ischaemia-reperfusion state; hyper-acute transplant rejection; ss;
XX organ failure; adult respiratory distress syndrome; Alzheimer's disease;
XX neurodegenerative disorders.

```

```

XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate nucleotides"
XX
XX US2002082227-A1.
XX
XX 27-JUN-2002.
XX
XX 27-FEB-2001; 2001US-00794824.
XX
XX 30-SEP-1999; 99US-00409816.
XX
XX (HENS/) HENRY S.
XX
XX Henry S;
XX
XX WPI; 2002-626556/67.
XX
XX Inhibiting complement activation in a human cell, tissue or bodily fluid,
XX useful for treating abnormal and/or undesirable conditions arising from
XX complement activation, comprises administering modified oligonucleotides.
XX
XX Claim 9; Page 20; 35pp; English.
XX
XX The invention relates to a method for inhibiting complement activation in
XX a human cell, tissue or bodily fluid comprising administering an
XX oligonucleotide to the cell, tissue or bodily fluid. Also described is a
XX composition comprising an oligonucleotide and a complement activation
XX inhibitory molecule, where the oligonucleotide comprises one or more
XX phosphorothioate modifications and one or more 2'-methoxyethoxy
XX modifications. The method is useful for the inhibition and/or modulation
XX of the complement mediated immune response, and for treating abnormal
XX and/or undesirable conditions which can arise as a result of complement
XX activation or complement mediated inflammatory effects, such as
XX myasthenia gravis, immune complex excess syndromes such as systemic lupus
XX erythematosus, ischaemia-reperfusion states, angioedema, hyper-acute
XX rejection of transplants, organ failure conditions such as adult
XX respiratory distress syndrome, Alzheimer's disease, and related
XX neurodegenerative disorders. The present sequence represents an
XX oligonucleotide used in the method of the invention
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 557
ABK91307/c
ID ABK91307 standard; DNA; 20 BP.
XX
XX AC ABK91307;
XX
XX DT 05-NOV-2002 (first entry)
XX
XX Oligonucleotide, ISIS 14725, used to inhibit complement activation.
XX
XX Complement activation; inhibitor; complement mediated immune response;
XX complement mediated inflammatory effect; myasthenia gravis; angioedema;
XX immune complex excess syndrome; systemic lupus erythematosus; ISIS 14725;
XX ischaemia-reperfusion state; hyper-acute transplant rejection; ss;
XX organ failure; adult respiratory distress syndrome; Alzheimer's disease;
XX neurodegenerative disorders.

```

```
XX OS Synthetic.
XX FH Key
XX FT modified_base Location/Qualifiers
XX FT 1. .20
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "2' methoxyethoxy (2'MOE) nucleotides; mixed
XX FT backbone"
XX PN US2002082227-A1.
XX PD 27-JUN-2002.
XX PF 27-FEB-2001; 2001US-00794824.
XX PR 30-SEP-1999; 99US-00409816.
XX PA (HENR/) HENRY S.
XX PI Henry S;
XX DR WPI; 2002-626556/67.
XX PT Inhibiting complement activation in a human cell, tissue or bodily fluid,
XX PT useful for treating abnormal and/or undesirable conditions arising from
XX PT complement activation, comprises administering modified oligonucleotides.
XX PS Claim 8; Page 20; 35pp; English.
XX CC The invention relates to a method for inhibiting complement activation in
XX CC a human cell, tissue or bodily fluid comprising administering an
XX CC oligonucleotide to the cell, tissue or bodily fluid. Also described is a
XX CC composition comprising an oligonucleotide and a complement activation
XX CC inhibitory molecule, where the oligonucleotide comprises one or more
XX CC phosphorothioate modifications and one or more 2'-methoxyethoxy
XX CC modifications. The method is useful for the inhibition and/or modulation
XX CC of the complement mediated immune response, and for treating abnormal
XX CC and/or undesirable conditions which can arise as a result of complement
XX CC activation or complement mediated inflammatory effects, such as
XX CC myasthenia gravis, immune complex excess syndromes such as systemic lupus
XX CC erythematosus, ischaemia-reperfusion states, angioedema, hyper-acute
XX CC rejection of transplants, organ failure conditions such as adult
XX CC respiratory distress syndrome, Alzheimer's disease, and related
XX CC neurodegenerative disorders. The present sequence represents an
XX CC oligonucleotide used in the method of the invention
XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 558
AAD22784/c
ID AAD22784 standard; DNA; 20 BP.
XX AAD22784;
XX 26-FEB-2002 (first entry)
XX Human ICAM-1 antisense oligonucleotide, PS-2302.
XX Treatment; tumour; lipid-therapeutic agent particle; sphingomyelin;
XX distearylphosphatidylcholine; palmitoylcholine; phosphatidylcholine; DSPC;
KW POPC; 1,2-dioleoyl-sn-3-phosphoethanolamine; cholesterol; SM; DOPE;
KW inflammation; intracellular adhesion molecule-1; human;
KW infectious disease; phosphorothioate backbone; ss.
```

```
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key
XX FT modified_base Location/Qualifiers
XX FT 1. .20
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "phosphorothioate backbone"
XX PN US6287591-B1.
XX PD 11-SEP-2001.
XX PF 14-MAY-1998; 98US-00078954.
XX PR 14-MAY-1997; 97US-00856374.
XX PA (INEX-) INEX PHARM CORP.
XX PI Semple SC, Klimuk SK, Harasym T, Hope MJ, Ansell SM, Cullis P;
XX PI Scherrer P, Debeyer D;
XX DR WPI; 2002-024658/03.
XX PT Composition useful for treatment of e.g. tumors comprises particles
XX PT comprising lipid portion and a charged therapeutic agent.
XX PS Example 4; Col 15-16; 48pp; English.
XX CC The invention relates to a composition useful for treatment of e.g.
XX CC tumours. The composition comprises lipid-therapeutic agent particles
XX CC comprising a lipid portion and a charged therapeutic agent which is
XX CC encapsulated in the lipid portion. The lipid portion comprises a first
XX CC lipid component selected from lipids containing a protonatable or
XX CC deprotonatable (preferably protonatable) group that has a pKa such that
XX CC the lipid is in charged form at a first pH and in neutral form at a
XX CC second pH. The pKa of lipid component is from 4-11. The first lipid
XX CC component is further selected such that the charged form is cationic when
XX CC the therapeutic agent is anionic and vice versa; the second lipid
XX CC component is selected from lipids that prevent particle aggregation
XX CC during lipid-therapeutic agent particles formation and which exchange out
XX CC the lipid particle at a rate greater than PKC-Cerc20; third lipid
XX CC component is a neutral lipid selected from distearylphosphatidylcholine
XX CC (DSPC), palmitoylcholine (DOPE) or SM (sphingomyelin) and a fourth lipid
XX CC component which is cholesterol. Compositions of the invention are used
XX CC for treatment or prevention of a disease caused by aberrant expression of
XX CC a gene preferably ICAM-1 (intracellular adhesion molecule-1), C-myc, C-
XX CC myb, ras, raf, erb-B-2, PKC-alpha (phosphokinase C-alpha), IGF-1R
XX CC (insulin growth factor 1-receptor), bcl-2, EGFR (epidermal growth factor
XX CC receptor), VEGF and VEGF-R-1 (vascular endothelial growth factor receptor
XX CC 1) in a mammal or by inflammations such as tumour or an infectious
XX CC disease. The present sequence is an antisense oligonucleotide targeted
XX CC to human ICAM-1 gene
XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 559
AAD22890/c
ID AAD22890 standard; DNA; 20 BP.
XX AAD22890;
XX 26-FEB-2002 (first entry)
XX Human ICAM-1 antisense oligonucleotide, PS-2302.
XX Treatment; tumour; lipid-therapeutic agent particle; sphingomyelin;
XX distearylphosphatidylcholine; palmitoylcholine; phosphatidylcholine; DSPC;
KW POPC; 1,2-dioleoyl-sn-3-phosphoethanolamine; cholesterol; SM; DOPE;
KW inflammation; intracellular adhesion molecule-1; human;
KW infectious disease; phosphorothioate backbone; ss.
```

DT 26-FEB-2002 (first entry)
XX Human ICAM-1 antisense oligonucleotide, PO-2302.
XX
XX Treatment; tumour; lipid-therapeutic agent particle; sphingomyelin;
KW distearoylphosphatidylcholine; palmitoyl-oleoyl phosphatidylcholine; DSPC;
KW POPC; 1,2-dioleoyl-sn-3-phosphoethanolamine; cholesterol; SM; DOPE;
KW inflammation; intracellular adhesion molecule-1; human;
KW infectious disease; ss.
XX Homo sapiens.
XX
XX US6287591-B1.
PN XX
XX 11-SEP-2001.
PD XX
XX 14-MAY-1998; 98US-00078954.
PF XX
XX 14-MAY-1997; 97US-00856374.
PR XX
XX (INEX-) INEX PHARM CORP.
PA XX
XX Semple SC, Klimuk SK, Harasym T, Hope MJ, Ansell SM, Cullis P;
PI Scherrer P, Debeyer D;
PI
XX WPI; 2002-024658/03.
DR XX
XX Composition useful for treatment of e.g. tumors comprises particles
PT comprising lipid portion and a charged therapeutic agent.
PT
XX Example 5; Col 15-16; 48pp; English.
PS
XX The invention relates to a composition useful for treatment of e.g.
CC tumours. The composition comprises lipid-therapeutic agent particles
CC comprising a lipid portion and a charged therapeutic agent which is
CC encapsulated in the lipid portion. The lipid portion comprises a first
CC lipid component selected from lipids containing a protonatable or
CC deprotonatable (preferably protonatable) group that has a pKa such that
CC the lipid is in charged form at a first pH and in neutral form at a
CC second pH. The pKa of lipid component is from 4-11. The first lipid
CC component is further selected such that the charged form is cationic when
CC the therapeutic agent is anionic and vice versa; the second lipid
CC component is selected from lipids that prevent particle aggregation
CC during lipid-therapeutic agent particles formation and which exchange out
CC the lipid particle at a rate greater than PEG-CerC20; third lipid
CC component is a neutral lipid selected from distearoylphosphatidylcholine
CC (DSPC), palmitoyl-oleoyl phosphatidylcholine (POPC), 1,2-dioleoyl-sn-3-
CC phosphoethanolamine (DOPE) or SM (sphingomyelin) and a fourth lipid
CC component which is cholesterol. Compositions of the invention are used
CC for treatment or prevention of a disease caused by aberrant expression of
CC a gene preferably ICAM-1 (intracellular adhesion molecule-1), C-myc, c-
CC myb, ras, raf, erb-B-2, PKC-alpha (phosphokinase C-alpha), IGF-1R
CC (insulin growth factor 1-receptor), bcl-2, EGFR (epidermal growth factor
CC receptor), VEGF and VEGF-R-1 (vascular endothelial growth factor receptor
CC 1) in a mammal or by inflammations such as tumour or an infectious
CC disease. The present sequence is an antisense oligonucleotide targeted
CC to human ICAM-1 gene
XX
SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 560
ACC49158/c
ID ACC49158 standard; DNA; 20 BP.
XX

AC ACC49158;
XX 19-JUN-2003 (first entry)
XX
XX ICAM-1 inhibitory antisense oligonucleotide SEQ ID NO:1.
DE
XX Inhibition; antisense oligonucleotide; phosphorothioate; bioadhesive;
KW enhanced mucosal drug absorption; antiulcer; antiinflammatory; cancer;
KW antirheumatic; antiarthritic; cytostatic; ulcerative colitis; tumour;
KW rheumatoid arthritis; Crohn's disease; inflammatory bowel disease;
KW cellular proliferation; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages"
XX
XX WO2003018134-A2.
PN
XX 06-MAR-2003.
PD
XX 22-AUG-2002; 2002WO-US026925.
PF
XX 22-AUG-2001; 2001US-00935316.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Teng C, Weinbach SP, Tillman LG, Geary RS, Hardee GE;
PI WPI; 2003-342432/32.
XX
XX Oral pharmaceutical formulation for delivering bioactive macromolecule
PT to mucosal surface, contains drug, bioadhesive compound, and penetration
PT enhancer.
XX
XX Disclosure; Page 28; 62pp; English.
XX
XX The present invention describes an oral pharmaceutical formulation (I)
CC for delivering a bioactive macromolecule to a mucosal surface. (I)
CC comprises a first population of carrier particles comprising drug and a
CC bioadhesive compound; and a second population of carrier particles
CC comprising a penetration enhancer. Also described is a method for
CC enhancing the mucosal absorption of the bioactive macromolecule in a
CC mammal (preferably a human) by mucosally administering (I). (I) has
CC antiulcer, antiinflammatory, antirheumatic, antiarthritic and cytostatic
CC activities. (I) can be used for delivering a bioactive macromolecule to
CC a mucosal surface. It is used for the oral delivery of a drug to an
CC animal encompassing a human as well as other mammals, reptiles, fish,
CC amphibians and birds. It is used to deliver drugs including peptides,
CC proteins, monoclonal antibodies their fragments, nucleic acids (DNA and
CC RNA), oligonucleotides, antisense oligonucleotides, and small molecules.
CC It can be used to examine the function of various proteins and genes in
CC an animal, including those that are essential to animal development. It
CC can be used for the treatment of animals that are known or suspected to
CC suffer from any disease treatable with the inventive composition, e.g.
CC ulcerative colitis, rheumatoid arthritis, Crohn's disease, inflammatory
CC bowel disease, or undue cellular proliferation (cancers and tumours). The
CC present sequence represents an exemplary oligonucleotide from the present
CC invention, which can be used to inhibit ICAM-1
XX
SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 560
ACC49158/c
ID ACC49158 standard; DNA; 20 BP.
XX

RESULT 561
ACC49159/C
ID ACC49159 standard; DNA; 20 BP.
XX
AC ACC49159;
XX
DT 19-JUN-2003 (first entry)
DE ICAM-1 inhibitory antisense oligonucleotide SEQ ID NO:2.
XX
KW Inhibition; antisense oligonucleotide; phosphorothioate; bioadhesive;
KW enhanced mucosal drug absorption; antiulcer; antiinflammatory; cancer;
KW antirheumatic; antiarthritic; cytostatic; ulcerative colitis; tumour;
KW rheumatoid arthritis; Crohn's disease; inflammatory bowel disease;
KW cellular proliferation; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages"
XX
PN WO2003018134-A2.
XX
XX
PD 06-MAR-2003.
XX
PF 22-AUG-2002; 2002WO-US026925.
XX
PR 22-AUG-2001; 2001US-0093316.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Teng C, Weinbach SP, Tillman LG, Geary RS, Hardee GE;
XX
DR WPI; 2003-342432/32.
XX
PT Oral pharmaceutical formulation for delivering bioactive macromolecule
PT to mucosal surface, contains drug, bioadhesive compound, and penetration
PT enhancer.
XX
PS Disclosure; Page 28; 62pp; English.
XX
CC The present invention describes an oral pharmaceutical formulation (I)
CC for delivering a bioactive macromolecule to a mucosal surface. (I)
CC comprises a first population of carrier particles comprising drug and a
CC bioadhesive compound; and a second population of carrier particles
CC comprising a penetration enhancer. Also described is a method for
CC enhancing the mucosal absorption of the bioactive macromolecule in a
CC mammal (preferably a human) by mucosally administering (I). (I) has
CC antiulcer, antiinflammatory, antirheumatic, antiarthritic and cytostatic
CC activities. (I) can be used for delivering a bioactive macromolecule to
CC a mucosal surface. It is used for the oral delivery of a drug to an
CC animal encompassing a human as well as other mammals, reptiles, fish,
CC amphibians and birds. It is used to deliver drugs including peptides,
CC proteins, monoclonal antibodies their fragments, nucleic acids (DNA and
CC RNA), oligonucleotides, antisense oligonucleotides, and small molecules.
CC It can be used to examine the function of various proteins and genes in
CC an animal, including those that are essential to animal development. It
CC can be used for the treatment of animals that are known or suspected to
CC suffer from any disease treatable with the inventive composition, e.g.
CC ulcerative colitis, rheumatoid arthritis, Crohn's disease, inflammatory
CC bowel disease, or undue cellular proliferation (cancers and tumours). The
CC present sequence represents an exemplary oligonucleotide from the present
CC invention, which can be used to inhibit ICAM-1
XX
SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
DB 20 GAGAGGGGAAGTGGTGGGG 1
XX
RESULT 562
ABZ77539/C
ID ABZ77539 standard; DNA; 20 BP.
XX
AC ABZ77539;
XX
DT 03-JUN-2003 (first entry)
DE Nucleotide sequence of a probe for flavin reductase.
XX
KW Probe; enzyme cofactor marker; enzyme; flavin; flavin reductase; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1
FT /*tag= a
FT /note= "-p-C6flavin attached"
XX
PN FR2827304-A1.
XX
XX
PD 17-JAN-2003.
XX
PF 16-JUL-2001; 2001FR-00009460.
XX
PR 16-JUL-2001; 2001FR-00009460.
XX
PA (COMS) COMMISSARIAT ENERGIE ATOMIQUE.
PA (UYFO-) UNIV FOURIER JOSEPH.
XX
PI Decout JL, Fontecave M, Dueymes C;
XX
DR WPI; 2003-270376/27.
XX
PT Analyzing DNA or RNA targets, useful for determining nucleic acid in a
PT biological sample, comprises using probes marked by a cofactor for an
PT enzyme.
XX
PS Example 1; Page 15; 36pp; French.
XX
CC The specification describes a method of analysing DNA or RNA targets. The
CC method comprises contacting the targets with oligonucleotide probes
CC attached to an enzyme cofactor marker which is recognized less by the
CC enzyme when it is on a free oligonucleotide than when it is on a
CC hybridized oligonucleotide. The method is useful for analysing DNA or RNA
CC targets. The invention is used to determine the amount of a target
CC nucleic acid in a biological sample and the level of complementarity
CC between the probe and the target nucleic acid. The present sequence
CC represents an oligonucleotide probe attached to flavin, an enzyme
CC cofactor marker for flavin reductase. The probe, together with its
CC complement ABZ77540, was used to study the activity of flavin reductase
XX
SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAAGTGGTGGGG 1957
DB 20 GAGAGGGGAAGTGGTGGGG 1
XX
RESULT 563
ABZ79518
ID ABZ79518 standard; DNA; 20 BP.
XX

AC ABZ79518;
 XX 10-MAY-2003 (first entry)
 XX ICAM-1 forward primer # SEQ ID 23.
 DE
 XX AK155 receptor; cytokine receptor; inflammation; Crohn's disease;
 KW autoimmune disease; multiple sclerosis; rheumatoid arthritis; psoriasis;
 KW asthma; allergy; diabetes mellitus; Sjogren's syndrome;
 KW transplant rejection; angiogenesis; cancer; PCR; primer; ss.
 XX Unidentified.
 OS
 XX WO2003002717-A2.
 PN
 XX 09-JAN-2003.
 PD
 XX 27-JUN-2002; 2002WO-US020489.
 PF
 XX 28-JUN-2001; 2001US-0302176P.
 PR
 XX 03-JAN-2002; 2002US-0345690P.
 PR
 XX (SCHE) SCHERING CORP.
 PA (FINK/) FINKENSCHER H.
 PA Finkenschner H, De Waal Malefyt R, Nagalakshmi ML, Moore K;
 PI WPI; 2003-278256/27.
 DR
 XX New cells recombinantly altered to express an exogenous AK155 cytokine
 PT receptor, useful for identifying agents for treating AK155-mediated
 PT diseases, e.g. inflammation, angiogenesis or cancer.
 PT
 XX Example 2; Page 51; 100pp; English.
 PS
 XX The present invention relates to a cell recombinantly altered to express
 CC an exogenous AK155 cytokine receptor comprising alpha and beta subunits.
 CC The cytokine receptor, when expressed in Ba/F3 cells, binds to AK155 and
 CC stimulates binding of STAT3 to interferon (IFN) gamma-activated
 CC sequences. The cell is useful in expressing AK155 cytokine receptor which
 CC may be used for identifying therapeutic agents useful for treating AK155-
 CC mediated conditions or diseases, such as inflammation (e.g. Crohn's
 CC disease), autoimmune diseases (e.g. multiple sclerosis, rheumatoid
 CC arthritis, psoriasis, asthma, allergies, diabetes mellitus, Sjogren's
 CC syndrome), transplant rejection, angiogenesis, and cancer. The current
 CC sequence represents an ICAM-1 forward primer sequence
 XX Sequence 20 BP; 7 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 950 GCCAGGAGACACTGCAGACA 969
 Db 1 GCCAGGAGACACTGCAGACA 20
 RESULT 564
 ACC59002/c
 ID ACC59002 standard; DNA; 20 BP.
 AC
 XX ACC59002;
 AC
 XX 01-JUL-2003 (first entry)
 DT Human ICAM-1 antisense oligonucleotide.
 DE Human; antisense; transcobalamin receptor; intrinsic factor receptor;
 KW cytostatic; antiviral; anti-HIV; hepatotropic; antiinflammatory; ICAM-1;
 KW virucide; tuberculostatic; protozoacide; cancer; viral disease; ss.
 XX Homo sapiens.
 OS

XX WO2003025139-A2.
 PN
 XX 27-MAR-2003.
 PD
 XX 17-SEP-2002; 2002WO-US029571.
 PF
 XX 17-SEP-2001; 2001US-0322821P.
 PR
 XX 13-SEP-2002; 2002US-0410627P.
 PR
 XX (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
 PA Collins DA, Callstrom M, Prendergast FG;
 XX WPI; 2003-430085/40.
 PI
 XX Compound useful for treating e.g. cancer comprises optionally stabilized
 PT nucleic acid, aptamer, antisense sequence, or antisense mimic conjugated
 PT to a ligand for the transcobalamin receptor or intrinsic factor receptor.
 PT
 XX Disclosure; Page 87; 156pp; English.
 PS
 XX The invention relates to a novel compound comprising an optionally
 CC stabilised nucleic acid or its analogue encoding a peptide, protein or
 CC other biological modifier, aptamer, antisense sequence, or antisense
 CC mimic conjugated directly or through a linker to a ligand for the
 CC transcobalamin receptor or intrinsic factor receptor. A compound of the
 CC invention has cytostatic, antiviral, anti-HIV, hepatotropic,
 CC antiinflammatory, virucide, tuberculostatic, and protozoacide activity.
 CC The compounds may be useful in the manufacture of a medicament for the
 CC delivery of material that affects gene translation or gene transcription
 CC and modulates a biological process, in medical therapy. A compound is
 CC also useful for treating cancer, viral diseases such as infection caused
 CC by HIV, hepatitis (hepatitis B, hepatitis C and hepatitis D), herpes, TB,
 CC Epstein-Barr virus, malaria, influenza virus, Para influenza virus, mumps
 CC virus, adenoviruses, reoviruses, respiratory syncytial virus,
 CC rhinoviruses, polioviruses, coxsackie-viruses, echoviruses,
 CC enteroviruses, gastroenteritis viruses, rubella viruses, rubella virus,
 CC mollusum contagiosum virus, human parvovirus B19, cytomegalovirus, human
 CC papillomavirus, varicella zoster, arenaviruses or filoviruses. The
 CC present sequence is used in the exemplification of the invention
 XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1
 RESULT 565
 ACD27443/c
 ID ACD27443 standard; DNA; 20 BP.
 XX
 AC ACD27443;
 AC
 XX 16-SEP-2003 (first entry)
 DT Human ICAM-1 targeted oligonucleotide ISIS 16952.
 DE Human; ICAM-1; ss; ISIS 16952; psoriasis; nuclease resistant;
 KW DNA activity modulator; RNA activity modulator.
 XX Homo sapiens.
 OS
 XX Synthetic.
 XX Key Location/Qualifiers
 PH modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER

FT /note= "OTHER= All nucleotides 2'methoxyethoxy (2'MOE).
 FT All cytosines are 5-methyl cytosine"
 PN
 XX US2002165181-A1.
 XX
 PD 07-NOV-2002.
 XX
 XX 27-SEP-2001; 2001US-00965551.
 PF
 XX 14-JUL-1998; 98US-00115025.
 XX 07-JUL-1999; 99US-00349007.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Manoharan M;
 XX
 PI WPI; 2003-521523/49.
 DR
 XX New compounds used for modulating activity of protein for e.g. treating
 XX bacteria, yeast, protozoa and algae organisms, comprise covalently bound
 XX 2'-modified nucleosides.
 XX
 XX Example 3; Page 16; 29pp; English.
 PS
 XX The invention relates to compounds comprising covalently bound 2'-
 XX modified nucleosides. The compounds of the invention are useful for
 XX treating an organism, particularly bacteria, yeast, protozoa, algae and
 XX warm-blooded animals, having a disease caused by undesirable production
 XX of a protein, for assaying a nucleic acid, in diagnostics and
 XX therapeutics and as research reagents and kits. The compounds are
 XX particularly used for treating psoriasis. The compounds are resistant to
 XX nuclease degradation and modulating the activity of DNA or RNA. The
 XX present sequence represents the human ICAM-1 targeted oligonucleotide
 XX ISIS 16952
 XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 18 GAGCTCCTCTGCTACTCAGA 37
 Db 20 GAGCTCCTCTGCTACTCAGA 1
 RESULT 566
 ACD27441/c
 ID ACD27441 standard; DNA; 20 BP.
 XX
 AC ACD27441;
 XX
 DT 16-SEP-2003 (first entry)
 XX
 DE Human ICAM-1 targeted oligonucleotide ISIS 11158.
 XX
 KW Human; ICAM-1; ss; ISIS 11158; psoriasis; nuclease resistant;
 KW DNA activity modulator; RNA activity modulator.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= All nucleotides 2'methoxyethoxy (2'MOE)"
 FT
 XX US2002165181-A1.
 PN
 XX 07-NOV-2002.
 PD
 XX 27-SEP-2001; 2001US-00965551.
 PF

XX 14-JUL-1998; 98US-00115025.
 PR 07-JUL-1999; 99US-00349007.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Manoharan M;
 XX
 PI WPI; 2003-521523/49.
 DR
 XX New compounds used for modulating activity of protein for e.g. treating
 XX bacteria, yeast, protozoa and algae organisms, comprise covalently bound
 XX 2'-modified nucleosides.
 XX
 XX Example 2; Page 16; 29pp; English.
 PS
 XX The invention relates to compounds comprising covalently bound 2'-
 XX modified nucleosides. The compounds of the invention are useful for
 XX treating an organism, particularly bacteria, yeast, protozoa, algae and
 XX warm-blooded animals, having a disease caused by undesirable production
 XX of a protein, for assaying a nucleic acid, in diagnostics and
 XX therapeutics and as research reagents and kits. The compounds are
 XX particularly used for treating psoriasis. The compounds are resistant to
 XX nuclease degradation and modulating the activity of DNA or RNA. The
 XX present sequence represents the human ICAM-1 targeted oligonucleotide
 XX ISIS 11158
 XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 18 GAGCTCCTCTGCTACTCAGA 37
 Db 20 GAGCTCCTCTGCTACTCAGA 1
 RESULT 567
 ACD27445/c
 ID ACD27445 standard; DNA; 20 BP.
 XX
 AC ACD27445;
 XX
 DT 16-SEP-2003 (first entry)
 XX
 DE Human ICAM-1 targeted oligonucleotide ISIS 15537.
 XX
 KW Human; ICAM-1; ss; ISIS 15537; psoriasis; nuclease resistant;
 KW DNA activity modulator; RNA activity modulator.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone. All nucleotides
 FT 2'methoxyethoxy (2'MOE). All cytosines are 5-methyl
 FT cytosine"
 XX
 XX US2002165181-A1.
 PN
 XX 07-NOV-2002.
 PD
 XX 27-SEP-2001; 2001US-00965551.
 PF
 XX 14-JUL-1998; 98US-00115025.
 PR 07-JUL-1999; 99US-00349007.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX

PI Manoharan M;
 XX WPI; 2003-521523/49.
 XX
 XX New compounds used for modulating activity of protein for e.g. treating
 PT bacteria, yeast, protozoa and algae organisms, comprise covalently bound
 PT 2'-modified nucleosides.
 FT
 XX
 PS Example 3; Page 16; 29pp; English.
 XX
 CC The invention relates to compounds comprising covalently bound 2'-
 CC modified nucleosides. The compounds of the invention are useful for
 CC treating an organism, particularly bacteria, yeast, protozoa, algae and
 CC warm-blooded animals, having a disease caused by undesirable production
 CC of a protein, for assaying a nucleic acid, in diagnostics and
 CC therapeutics and as research reagents and kits. The compounds are
 CC particularly used for treating psoriasis. The compounds are resistant to
 CC nuclease degradation and modulating the activity of DNA or RNA. The
 CC present sequence represents the human ICAM-1 targeted oligonucleotide
 CC ISIS 15537
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 18 GAGCTCCTCTGCTACTCAGA 37
 DB 20 GAGCTCCTCTGCTACTCAGA 1
 ACCT27437/C
 ID ACCT27437 standard; DNA; 20 BP.
 XX
 AC ACCT27437;
 DT 16-SEP-2003 (first entry)
 XX
 XX Human ICAM-1 targeted oligonucleotide ISIS 25303.
 DE Human; ICAM-1; ss; ISIS 25303; psoriasis; nuclease resistant;
 KW DNA activity modulator; RNA activity modulator.
 XX Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= All cytosines are 5-methyl cytosine"
 FT modified_base 1..12
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone"
 FT modified_base 13..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'Methoxyethoxy nucleotides"
 FT modified_base 13..14
 FT /tag= d
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone"
 FT modified_base 15..16
 FT /tag= e
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone"
 FT modified_base 17..18
 FT /tag= f
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone"

FT modified_base 19..20
 FT /tag= g
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone"
 XX
 FN US2002165181-A1.
 XX
 PD 07-NOV-2002.
 XX
 XX 27-SEP-2001; 2001US-00965551.
 XX
 PR 14-JUL-1998; 98US-00115025.
 PR 07-JUL-1999; 99US-00349007.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Manoharan M;
 XX
 XX WPI; 2003-521523/49.
 XX
 XX New compounds used for modulating activity of protein for e.g. treating
 PT bacteria, yeast, protozoa and algae organisms, comprise covalently bound
 PT 2'-modified nucleosides.
 FT
 XX
 PS Example 1; Page 15; 29pp; English.
 XX
 CC The invention relates to compounds comprising covalently bound 2'-
 CC modified nucleosides. The compounds of the invention are useful for
 CC treating an organism, particularly bacteria, yeast, protozoa, algae and
 CC warm-blooded animals, having a disease caused by undesirable production
 CC of a protein, for assaying a nucleic acid, in diagnostics and
 CC therapeutics and as research reagents and kits. The compounds are
 CC particularly used for treating psoriasis. The compounds are resistant to
 CC nuclease degradation and modulating the activity of DNA or RNA. The
 CC present sequence represents the human ICAM-1 targeted oligonucleotide
 CC ISIS 25303
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 DB 20 TGACGGATGCCAGCTTGGGC 1
 ACCT27440/C
 ID ACCT27440 standard; DNA; 20 BP.
 XX
 AC ACCT27440;
 DT 16-SEP-2003 (first entry)
 XX
 XX Human ICAM-1 targeted oligonucleotide ISIS 11159.
 DE Human; ICAM-1; ss; ISIS 11159; psoriasis; nuclease resistant;
 KW DNA activity modulator; RNA activity modulator.
 XX Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone. All nucleotides
 FT 2'methoxyethoxy (2'MOE)"
 XX
 FN US2002165181-A1.
 XX


```

DR WPI; 2003-521523/49.
XX
XX New compounds used for modulating activity of protein for e.g. treating
PT bacteria, yeast, protozoa and algae organisms, comprise covalently bound
PT 2'-modified nucleosides.
XX
XX Example 3; Page 16; 29pp; English.
XX
XX The invention relates to compounds comprising covalently bound 2'-
CC modified nucleosides. The compounds of the invention are useful for
CC treating an organism, particularly bacteria, yeast, protozoa, algae and
CC warm-blooded animals, having a disease caused by undesirable production
CC of a protein, for assaying a nucleic acid, in diagnostics and
CC therapeutics and as research reagents and kits. The compounds are
CC particularly used for treating psoriasis. The compounds are resistant to
CC nuclease degradation and modulating the activity of DNA or RNA. The
CC present sequence represents the human ICAM-1 targeted oligonucleotide
CC ISIS 18268
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 572
ACD27435/c
XX ID ACD27435 standard; DNA; 20 BP.
XX
XX ACD27435;
XX
XX 16-SEP-2003 (first entry)
XX
XX Human ICAM-1 targeted oligonucleotide ISIS 182685.
XX
XX Human; ICAM-1; ss; ISIS 182685; psoriasis; nuclease resistant;
KW DNA activity modulator; RNA activity modulator.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 2..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= 2'Methoxyethoxy nucleotide. All cytosines
FT are 5-methyl cytosine"
FT modified_base 2..3
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone"
FT modified_base 4..5
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone"
FT modified_base 6..7
FT /*tag= d
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone"
FT modified_base 8..9
FT /*tag= e
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone"
FT modified_base 10..11
FT /*tag= f
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone"
FT modified_base 12..13

```

```

FT /*tag= g
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone"
FT modified_base 14..15
FT /*tag= h
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone"
FT modified_base 16..17
FT /*tag= i
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone"
FT modified_base 18..19
FT /*tag= j
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone"
XX
XX US2002165181-A1.
XX
XX 07-NOV-2002.
XX
XX 27-SEP-2001; 2001US-00965551.
XX
XX 14-JUL-1998; 98US-00115025.
XX 07-JUL-1999; 99US-00349007.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Manoharan M;
XX
XX WPI; 2003-521523/49.
XX
XX New compounds used for modulating activity of protein for e.g. treating
PT bacteria, yeast, protozoa and algae organisms, comprise covalently bound
PT 2'-modified nucleosides.
XX
XX Example 1; Page 15; 29pp; English.
XX
XX The invention relates to compounds comprising covalently bound 2'-
CC modified nucleosides. The compounds of the invention are useful for
CC treating an organism, particularly bacteria, yeast, protozoa, algae and
CC warm-blooded animals, having a disease caused by undesirable production
CC of a protein, for assaying a nucleic acid, in diagnostics and
CC therapeutics and as research reagents and kits. The compounds are
CC particularly used for treating psoriasis. The compounds are resistant to
CC nuclease degradation and modulating the activity of DNA or RNA. The
CC present sequence represents the human ICAM-1 targeted oligonucleotide
CC ISIS 182685
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 573
ACD27439/c
XX ID ACD27439 standard; DNA; 20 BP.
XX
XX ACD27439;
XX
XX 16-SEP-2003 (first entry)
XX
XX Human ICAM-1 targeted oligonucleotide ISIS 11910.
XX
XX Human; ICAM-1; ss; ISIS 11910; psoriasis; nuclease resistant;
KW DNA activity modulator; RNA activity modulator.
XX
XX Homo sapiens.
OS

```

```

OS Synthetic.
XX US2002165181-A1.
XX 07-NOV-2002.
XX 27-SEP-2001; 2001US-00965551.
XX 14-JUL-1998; 98US-00115025.
XX 07-JUL-1999; 99US-00349007.
XX (ISIS-) ISIS PHARM INC.
XX Manoharan M;
XX WPI; 2003-521523/49.
XX New compounds used for modulating activity of protein for e.g. treating
XX bacteria, yeast, protozoa and algae organisms, comprise covalently bound
XX 2'-modified nucleosides.
XX Example 2; Page 16; 29pp; English.
XX The invention relates to compounds comprising covalently bound 2'-
XX modified nucleosides. The compounds of the invention are useful for
XX treating an organism, particularly bacteria, yeast, protozoa, algae and
XX warm-blooded animals, having a disease caused by undesirable production
XX of a protein, for assaying a nucleic acid, in diagnostics and
XX therapeutics and as research reagents and kits. The compounds are
XX particularly used for treating psoriasis. The compounds are resistant to
XX nuclease degradation and modulating the activity of DNA or RNA. The
XX present sequence represents the human ICAM-1 targeted oligonucleotide
XX ISIS 11910
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 574
ACD27438/c
ID ACD27438 standard; DNA; 20 BP.
XX ACD27438;
AC ACD27438;
XX 16-SEP-2003 (first entry)
DT 16-SEP-2003 (first entry)
XX Human ICAM-1 targeted oligonucleotide ISIS 3067.
DE Human; ICAM-1; ss; ISIS 3067; psoriasis; nuclease resistant;
XX DNA activity modulator; RNA activity modulator.
KW Homo sapiens.
XX Synthetic.
OS Key Location/Qualifiers
XX modified_base 1..20
XX /tag= a
XX /mod_base= OTHER
XX /note= "OTHER= phosphorothioate backbone"
XX US2002165181-A1.
XX 07-NOV-2002.
XX 27-SEP-2001; 2001US-00965551.
XX

```

```

PR 14-JUL-1998; 98US-00115025.
PR 07-JUL-1999; 99US-00349007.
XX (ISIS-) ISIS PHARM INC.
XX Manoharan M;
XX WPI; 2003-521523/49.
XX New compounds used for modulating activity of protein for e.g. treating
XX bacteria, yeast, protozoa and algae organisms, comprise covalently bound
XX 2'-modified nucleosides.
XX Example 2; Page 16; 29pp; English.
XX The invention relates to compounds comprising covalently bound 2'-
XX modified nucleosides. The compounds of the invention are useful for
XX treating an organism, particularly bacteria, yeast, protozoa, algae and
XX warm-blooded animals, having a disease caused by undesirable production
XX of a protein, for assaying a nucleic acid, in diagnostics and
XX therapeutics and as research reagents and kits. The compounds are
XX particularly used for treating psoriasis. The compounds are resistant to
XX nuclease degradation and modulating the activity of DNA or RNA. The
XX present sequence represents the human ICAM-1 targeted oligonucleotide
XX ISIS 3067
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 575
ACD67194/c
ID ACD67194 standard; DNA; 20 BP.
XX ACD67194;
AC ACD67194;
XX 17-SEP-2003 (first entry)
DT 17-SEP-2003 (first entry)
XX Derivatized oligonucleotide oligomer 53.
DE ICAM-1; intracellular cell adhesion molecule-1; antisense; ss;
XX improved transfer; improved uptake; steroid/reporter molecule; porphyrin;
XX non-aromatic lipophilic molecule; reporter enzyme; metal chelator;
XX water/lipid soluble vitamin; RNA cleaving complex; alkylator;
XX hybrid photo-nuclease/intercalator; aryl azide photo-crosslinking agent.
XX Synthetic.
XX US2002177150-A1.
XX 28-NOV-2002.
XX 11-FEB-2002; 2002US-00073718.
XX 23-OCT-1992; 92WO-US009196.
XX 15-DEC-1998; 98US-00211882.
XX 07-AUG-2000; 2000US-00633659.
XX (ISIS-) ISIS PHARM INC.
XX Manoharan M, Cook PD, Bennett CF;
XX WPI; 2003-521529/49.
XX New derivatized oligonucleotide, useful for effecting cellular uptake,
XX comprises several linked nucleosides bearing a substituent such as
PT

```

PT steroid/reporter molecule, reporter enzyme or peptide.

PS Example 19; Page 16; 23pp; English.

XX The invention relates to a derivatised oligonucleotide comprising several
XX linked nucleosides having a functionalised nucleoside bearing a
CC substituent such as steroid/reporter molecule, non-aromatic lipophilic
CC molecule, reporter enzyme, peptide, protein, water/lipid soluble vitamin,
CC RNA cleaving complex, metal chelator, porphyrin, alkylator, hybrid photo-
CC nuclease/intercalator or aryl azide photo-crosslinking agent. The
CC oligonucleotide is useful for effecting cellular uptake of the
CC oligonucleotide by contacting an organism with the oligonucleotide. The
CC oligonucleotide is useful in research and diagnostic methods, for
CC assaying bodily states in animals, especially disease states, or for
CC treatment of diseases through modulation of the activity of DNA or RNA.
CC The oligonucleotide has improved transfer across cellular membranes and
CC uptake properties. The effect of conjugation of an oligonucleotide with
CC folic acid was determined by the inhibition of intercellular cell
CC adhesion molecule-1 (ICAM-1). The present sequence represents a
CC derivatised oligonucleotide oligomer

XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37

Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 576

ACD67192/c

ID ACD67192 standard; DNA; 20 BP.

XX ACD67192;

XX 17-SEP-2003 (first entry)

XX Derivatised oligonucleotide oligomer 51.

XX ICAM-1; intracellular cell adhesion molecule-1; antisense; ss;
KW improved transfer; improved uptake; steroid/reporter molecule; porphyrin;
KW non-aromatic lipophilic molecule; reporter enzyme; metal chelator;
KW water/lipid soluble vitamin; RNA cleaving complex; alkylator;
KW hybrid photo-nuclease/intercalator; aryl azide photo-crosslinking agent.

XX Synthetic.

XX US2002177150-A1.

XX 28-NOV-2002.

XX 11-FEB-2002; 2002US-00073718.

XX 23-OCT-1992; 92WO-US009196.

PR 15-DEC-1998; 98US-00211882.

PR 07-AUG-2000; 2000US-00633659.

XX (ISIS-) ISIS PHARM INC.

XX Manoharan M, Cook PD, Bennett CF;

XX WPI; 2003-521529/49.

XX New derivatised oligonucleotide, useful for effecting cellular uptake,
PT comprises several linked nucleosides bearing a substituent such as
PT steroid/reporter molecule, reporter enzyme or peptide.

XX Example 19; Page 16; 23pp; English.

XX The invention relates to a derivatised oligonucleotide comprising several

CC linked nucleosides having a functionalised nucleoside bearing a
CC substituent such as steroid/reporter molecule, non-aromatic lipophilic
CC molecule, reporter enzyme, peptide, protein, water/lipid soluble vitamin,
CC RNA cleaving complex, metal chelator, porphyrin, alkylator, hybrid photo-
CC nuclease/intercalator or aryl azide photo-crosslinking agent. The
CC oligonucleotide is useful for effecting cellular uptake of the
CC oligonucleotide by contacting an organism with the oligonucleotide. The
CC oligonucleotide is useful in research and diagnostic methods, for
CC assaying bodily states in animals, especially disease states, or for
CC treatment of diseases through modulation of the activity of DNA or RNA.
CC The oligonucleotide has improved transfer across cellular membranes and
CC uptake properties. The effect of conjugation of an oligonucleotide with
CC folic acid was determined by the inhibition of intercellular cell
CC adhesion molecule-1 (ICAM-1). The present sequence represents a
CC derivatised oligonucleotide oligomer

SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37

Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 577

ACC58504/c

ID ACC58504 standard; DNA; 20 BP.

XX ACC58504;

XX 26-AUG-2003 (first entry)

XX Oligonucleotide ODN #12 (PS-8997).

XX Lipid nucleic acid; LNA; intracellular adhesion molecule 1; human;
KW mucosal; vaccine; immunostimulant; ss.

XX Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /tag= a

FT /mod_base= OTHER

FT /note= "OTHER= optional phosphorothioate nucleotides"

XX WO2003039595-A2.

XX 15-MAY-2003.

XX 07-NOV-2002; 2002WO-CA001717.

XX 07-NOV-2001; 2001US-0337522P.

PR 10-MAY-2002; 2002US-0379343P.

XX (INEX-) INEX PHARM CORP.

XX Semple S, Klimuk S, Yuan Z;

XX WPI; 2003-493235/46.

XX Improved mucosal adjuvant useful in the preparation of vaccine for
PT stimulating an immune response comprises a lipid-nucleic acid formulation
PT containing a nucleic acid component encapsulated by a lipid.

XX Disclosure; Page 20; 71pp; English.

XX The present sequence is that of oligodeoxynucleotide ODN #12 (PS-8997)
CC for human intracellular adhesion molecule 1. This is an example of an ODN
CC that can be used in lipid-nucleic acid (LNA) formulations of the
CC invention comprising a lipid component and a nucleic acid component. The

CC invention is based on the discovery that such LNA formulations associated
CC with a target antigen stimulate enhanced mucosal immune responses,
CC especially IgA production, directed to that target antigen in vivo as
CC compared to the target antigen alone or mixed with free or unencapsulated
CC forms of the ODN. Claimed improved mucosal vaccines comprise an LNA
CC formulation with at least one antigen, the LNA formulation comprising a
CC lipid component that encapsulates the nucleic acid component, with the
CC lipid and nucleic acid components acting synergistically to stimulate
CC antigen-specific IgG production in a mammal
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 578
ACC58503/c
ID ACC58503 standard; DNA; 20 BP.
XX
AC ACC58503;
XX
DT 26-AUG-2003 (first entry)
XX
DE Oligonucleotide ODN #11 (PS-2302).
XX
KW Lipid nucleic acid; LNA; intracellular adhesion molecule 1; human;
KW mucosal; vaccine; immunostimulant; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
XX
PN WO2003039595-A2.
XX
PD 15-MAY-2003.
XX
XX 07-NOV-2002; 2002WO-CA001717.
XX
PF 07-NOV-2001; 2001US-0337522P.
PR 10-MAY-2002; 2002US-0379343P.
XX
XX (INEX-) INEX PHARM CORP.
XX
XX Sample S, Klimuk S, Yuan Z;
XX
XX WPI; 2003-493235/46.
XX
XX Improved mucosal adjuvant useful in the preparation of vaccine for
XX stimulating an immune response comprises a lipid-nucleic acid formulation
XX containing a nucleic acid component encapsulated by a lipid.
XX
XX Disclosure; Page 20; 71pp; English.
XX
XX The present sequence is that of oligodeoxynucleotide ODN #11 (PS-2302)
CC for human intracellular adhesion molecule 1. This is an example of an ODN
CC that can be used in lipid-nucleic acid (LNA) formulations of the
CC invention comprising a lipid component and a nucleic acid component. The
CC invention is based on the discovery that such LNA formulations associated
CC with a target antigen stimulate enhanced mucosal immune responses,
CC especially IgA production, directed to that target antigen in vivo as
CC compared to the target antigen alone or mixed with free or unencapsulated
CC forms of the ODN. Claimed improved mucosal vaccines comprise an LNA
CC formulation with at least one antigen, the LNA formulation comprising a

CC lipid component that encapsulates the nucleic acid component, with the
CC lipid and nucleic acid components acting synergistically to stimulate
CC antigen-specific IgG production in a mammal
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 579
ACD27755/c
ID ACD27755 standard; DNA; 20 BP.
XX
XX ACD27755;
XX
DT 18-SEP-2003 (first entry)
XX
DE Peptide linked oligomeric compound associated oligonucleotide #4.
XX
KW Peptide linked oligomeric compound; diagnostic; therapeutic;
KW research reagent; protein production inhibitor;
KW phosphorothioate 2'-O-MOE gapmer; ss; human.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 5' methyl"
XX
PN US2002156235-A1.
XX
PD 24-OCT-2002.
XX
XX 07-SEP-2001; 2001US-00949474.
XX
XX 08-SEP-2000; 2000US-00658517.
XX
XX (MANO/) MANOHARAN M.
XX (GUZA/) GUZAEV A P.
XX
XX Manoharan M, Guzaev AP;
XX
XX WPI; 2003-521518/49.
XX
XX Preparation of peptide linked oligomeric compounds useful in diagnostics
XX involves reacting deprotected hydroxyl group with nucleoside having a
XX protected hydroxyl group and an activated phosphorus containing
XX substituent group.
XX
XX Example 14; Page 22; 45pp; English.
XX
XX The invention describes preparation of a peptide linked oligomeric
XX compound (I) involving reacting a deprotected hydroxyl group with a
XX nucleoside having a protected hydroxyl group and activated phosphorus
XX containing substituent group. (I) is useful in the preparation of peptide
XX linked oligomeric compounds useful in diagnostics, therapeutics and as
XX research reagents. They are useful in the treatment of diseases
XX characterised by the undesired production of a protein in organisms such
XX as bacteria, yeast, protozoa, algae, plants and animals including warm-
XX blooded animals. The method is applicable to a large-scale synthesis of
XX peptide-linked oligomeric compounds; is cost-effective and efficient. The
XX method reduces the cost of preparation of (I). The process provides (I)
XX without the problems of aggregation associated with electrostatic
XX interactions. The process provides (I) with an increase in efficiency and

CC provides an improved synthetic scheme avoiding the problems encountered
 CC during synthesis of cationic peptides e.g. problems generated by use of
 CC excess peptide reagents used. This sequence represents an oligonucleotide
 CC phosphorothioate 2'-O-MOE gapper based on human ICAM-1 used in the
 CC preparation of a peptide linker oligomeric compound

XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02; Indels 0; Gaps 0;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCTCTGCTACTCAGA 37

|||||

20 GAGCTCTCTGCTACTCAGA 1

RESULT 580

ACC85089

ID ACC85089 standard; DNA; 20 BP.

XX

AC ACC85089;

XX

DT 13-OCT-2003 (first entry)

XX

DE Human ICAM-1 cDNA amplifying sense primer.

XX

KW Bactericidal permeability increasing protein; antibacterial; lipoxin;

KW immunosuppressive; antimicrobial; BPI; ICAM-1; PCR; primer; ss.

XX

OS Homo sapiens.

XX

PN WO2003051350-A1.

XX

PD 26-JUN-2003.

XX

PF 18-DEC-2002; 2002WO-US040620.

XX

PR 18-DEC-2001; 2001US-0342138P.

XX

PR 18-DEC-2002; 2002US-00323591.

XX

PA (BGHM) BRIGHAM & WOMENS HOSPITAL.

XX

PI Serhan CN, Colgan SP;

XX

WPI; 2003-598092/56.

XX

PT Stimulating bactericidal permeability increasing protein in subject's
 PT tissue for inhibiting or preventing infection or invasion by bacteria in
 PT a subject, by administering lipoxin or lipoxin analog.

XX

PS Example; Page 78; 161pp; English.

XX

CC The invention relates to stimulating bactericidal permeability increasing
 CC protein (BPI) in a subject's tissue. The method involves administering a
 CC therapeutically effective amount of lipoxin or a lipoxin analogue, such
 CC that the subject's tissue expresses increased levels of BPI to treat
 CC infection. The method is useful for stimulating BPI in a subject's
 CC tissue, preferably mucosal cells e.g. oral epithelial cells or intestinal
 CC cells, and thus for inhibiting or preventing infection or invasion by
 CC bacteria in a subject. The method is useful for treating sepsis and
 CC infectious diseases. Sequences ACC85089-90 represent PCR primers for
 CC amplifying the human ICAM-1 cDNA, used in a transcriptional analysis of
 CC human BPI

XX

SQ Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.7%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 CACAGTCACCTATGCAACG 859

|||||

Db 1 CACAGTCACCTATGCAACG 20

RESULT 581

ADA24219/c

ID ADA24219 standard; DNA; 20 BP.

XX

AC ADA24219;

XX

DT 20-NOV-2003 (first entry)

XX

DE Human ICAM-1 antisense oligonucleotide SEQ ID NO:2.

XX

KW therapeutic oligonucleotide; double-stranded RNA; dsRNA; mobile protein;
 KW cytostatic; immunosuppressive; virucide; anti-HIV; antibacterial;
 KW cardiant; hyperproliferation; cancer; haematological; metastatic;
 KW autoimmune disease; infection; endocrine; neural; cardiovascular;
 KW pulmonary; reproductive system disorder; endocytosis; metabolic process;
 KW murine; intracellular adhesion molecule 1; ICAM-1;
 KW antisense oligonucleotide; phosphorothioate; ss.

XX

OS Synthetic.

OS Homo sapiens.

XX

FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "phosphorothioate backbone"

XX

PN WO2003069306-A2.

XX

PD 21-AUG-2003.

XX

PF 13-FEB-2003; 2003WO-US004323.

XX

PR 13-FEB-2002; 2002US-0356053P.

XX

PA (MEDB-) MEDBRIDGE INC.

XX

PI Xie D;

XX

WPI; 2003-646491/61.

XX

PT Treating diseases with oligonucleotides or interfering RNA, useful e.g.
 PT for cancer or autoimmune diseases, covalently coupled to mobile proteins,
 PT in vivo or in vitro.

XX

PS Claim 128; Page 11; 42pp; English.

XX

CC The present invention describes a method for treating a disease by
 CC administering: (a) a therapeutic oligonucleotide (TON) or double-stranded
 CC RNA (dsRNA) that includes a reactive group (RG) that can react with a
 CC mobile protein (MP) to form a covalent conjugate of TON/dsRNA and MP; or
 CC (b) TON or dsRNA already conjugated to MP through a covalent bond. Also
 CC described: (1) TON of 15-30 bases that includes (i) a part that binds to
 CC target RNA or DNA and (ii) RG; (2) TON of 15-30 bases that includes a
 CC part that binds to target RNA or DNA and is conjugated to MP through a
 CC covalent link; (3) dsRNA that includes RG; and (4) dsRNA that is
 CC conjugated to MP through a covalent link. TON have cytostatic,
 CC immunosuppressive, virucide, anti-HIV, antibacterial and cardiant
 CC activities. The method is used to treat, or prevent, hyperproliferation
 CC (particularly cancers, solid or haematological, including prevention of
 CC metastatic spread); autoimmune diseases; viral or bacterial infections;
 CC endocrine, neural, cardiovascular, pulmonary or reproductive system
 CC disorders. Also where TON or dsRNA are labelled, they can be used for
 CC diagnosis and monitoring of therapy. When linked to a mobile protein,
 CC TON/dsRNA have better cell entry (via endocytosis or other parts of the
 CC mobile protein metabolic process) and longer therapeutic life, increased
 CC from hours to weeks (the result of increased resistance to nuclease),
 CC without loss of affinity for the target. In many cases immune response to
 CC TON/dsRNA is also reduced, as is non-specific binding to endogenous
 CC proteins. The present sequence represents a human intracellular adhesion

CC molecule 1 (ICAM-1) antisense oligonucleotide, which is a specifically
CC claimed TON from the present invention.
XX
SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 582
ACD05028/c
ID ACD05028 standard; DNA; 20 BP.
XX
AC ACD05028;
XX
DT 05-AUG-2003 (first entry)
XX
DE Tumour necrosis factor alpha antisense oligonucleotide #40.
XX
KW Tumour necrosis factor alpha; TNF-alpha; antiinflammatory; antirheumatic;
KW antiarthritic; antidiabetic; dermatological; hepatotropic; antiasthmatic;
KW inflammatory disorder; inflammatory bowel disease; Crohn's disease;
KW colitis; rheumatoid arthritis; diabetes; pancreatitis;
KW multiple sclerosis; atopic dermatitis; asthma; hepatitis;
KW antisense technology; ss.
XX
OS Synthetic.
XX
PN US2003022848-A1.
XX
PD 30-JAN-2003.
XX
PF 02-APR-2001; 2001US-00824322.
XX
PR 05-OCT-1998; 98US-00166186.
XX
PR 18-MAY-1999; 99US-00313932.
XX
PA (BAKE/) BAKER B F.
PA (BENN/) BENNETT C F.
PA (BUTL/) BUTLER M M.
PA (SHAN/) SHANAHAN W R.
XX
PI Baker BF, Bennett CF, Butler MM, Shanahan WR;
XX WPI; 2003-447433/42.
XX
PT Treating inflammatory disorders such as inflammatory bowel disease,
PT Crohn's disease or rheumatoid arthritis, in a subject, by administering
PT oligonucleotide which inhibits expression of human tumor necrosis factor
PT alpha.
XX
PS Example 2; Page 13; 142pp; English.
XX
XX The invention describes a method of treating an inflammatory disorder in
XX an individual, comprising administering to the individual an
XX oligonucleotide upto 30 nucleotides in length complementary to a nucleic
XX acid molecule encoding human tumor necrosis factor (TNF)-alpha. The
XX method is useful for treating an inflammatory disorder such as
XX inflammatory bowel disease, Crohn's disease, colitis or rheumatoid
XX arthritis, in an individual. The method is also useful for treating
XX diabetes, pancreatitis, multiple sclerosis, atopic dermatitis, asthma,
XX and hepatitis in an individual. This sequence represents an antisense
XX oligonucleotide used to modulate expression of tumour necrosis factor
XX alpha (TNF-alpha)
SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 583
ACD05036/c
ID ACD05036 standard; DNA; 20 BP.
XX
AC ACD05036;
XX
DT 05-AUG-2003 (first entry)
XX
DE Tumour necrosis factor alpha related oligonucleotide #1.
XX
KW Tumour necrosis factor alpha; TNF-alpha; antiinflammatory; antirheumatic;
KW antiarthritic; antidiabetic; dermatological; hepatotropic; antiasthmatic;
KW inflammatory disorder; inflammatory bowel disease; Crohn's disease;
KW colitis; rheumatoid arthritis; diabetes; pancreatitis;
KW multiple sclerosis; atopic dermatitis; asthma; hepatitis;
KW antisense technology; ss.
XX
OS Synthetic.
XX
PN US2003022848-A1.
XX
PD 30-JAN-2003.
XX
PF 02-APR-2001; 2001US-00824322.
XX
PR 05-OCT-1998; 98US-00166186.
PR 18-MAY-1999; 99US-00313932.
XX
PA (BAKE/) BAKER B F.
PA (BENN/) BENNETT C F.
PA (BUTL/) BUTLER M M.
PA (SHAN/) SHANAHAN W R.
XX
PI Baker BF, Bennett CF, Butler MM, Shanahan WR;
XX WPI; 2003-447433/42.
XX
PT Treating inflammatory disorders such as inflammatory bowel disease,
PT Crohn's disease or rheumatoid arthritis, in a subject, by administering
PT oligonucleotide which inhibits expression of human tumor necrosis factor
PT alpha.
XX
PS Example 5; Page 16; 142pp; English.
XX
XX The invention describes a method of treating an inflammatory disorder in
XX an individual, comprising administering to the individual an
XX oligonucleotide upto 30 nucleotides in length complementary to a nucleic
XX acid molecule encoding human tumor necrosis factor (TNF)-alpha. The
XX method is useful for treating an inflammatory disorder such as
XX inflammatory bowel disease, Crohn's disease, colitis or rheumatoid
XX arthritis, in an individual. The method is also useful for treating
XX diabetes, pancreatitis, multiple sclerosis, atopic dermatitis, asthma,
XX and hepatitis in an individual. This sequence represents an
XX oligonucleotide associated with the method of modulating tumour necrosis
XX factor alpha (TNF-alpha) using antisense technology
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 584
ADC24654/c
ID ADC24654 standard; DNA; 20 BP.
XX
AC ADC24654;
XX
DT 18-DEC-2003 (first entry)
XX
DE Antisense DNA #2 that can be conjugated to the carriers of invention.
XX
KW cobalamin-bound detectable; radioimaging; infectious disease;
KW cardiovascular disorder; antibiotic; antiviral agent; ss.
XX
OS Synthetic.
XX
PN W02003026674-A1.
XX
PD 03-APR-2003.
XX
PF 30-SEP-2002; 2002WO-US031038.
XX
PR 28-SEP-2001; 2001US-0326183P.
XX
PA (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
XX
PI Collins DA;
XX
DR WPI; 2003-393314/37.
XX
PT Composition useful for the treatment of e.g. infectious disease,
PT comprises a cobalamin-bound detectable or therapeutic agent in
PT combination with a cobalamin transport protein.
XX
PS Example 4; SEQ ID NO 2; 97pp; English.
XX
CC The present invention relates to a cobalamin-bound detectable or
CC therapeutic agent in combination with a cobalamin transport protein. In
CC the manufacture of a medicament to increase the uptake of detectable
CC agent useful in radioimaging or therapeutic agent for treatment of a
CC disorder associated with abnormal cellular proliferation, an infectious
CC disease and cardiovascular disorder; as an antibiotic or antiviral agent;
CC for transcription of a factor. The method increases efficiency of
CC vitamin B12 or vitamin B12 conjugated materials. The presents sequence
CC represents an antisense nucleotide that can be conjugated to the carriers
CC described in the present invention.
XX
SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1
RESULT 585
ADC38983/c
ID ADC38983 standard; DNA; 20 BP.
XX
AC ADC38983;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human ICAM-1 targeted primer #9.
XX
KW ss; primer; immunosuppressive; antisense therapy;
KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
KW extracellular adhesion molecule-1; ELAM-1;
KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.

XX
OS Synthetic.
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT misc_difference 1..20
FT /*tag= a
FT /*note= "all internucleotide linkages are phosphodiester
bonds"
XX
PN W02003032920-A2.
XX
PD 24-APR-2003.
XX
PF 16-OCT-2002; 2002WO-US033236.
XX
PR 18-OCT-2001; 2001US-00982262.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Mirabelli CK;
XX
DR WPI; 2003-403142/38.
XX
PT Inhibiting corneal allograft rejection, by contacting an allograft with a
PT formulation having an oligonucleotide targeted to intercellular adhesion
PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
PT molecule-1.
XX
PS Example 5; SEQ ID NO 9; 106pp; English.
XX
CC The invention relates to a method of inhibiting corneal allograft
CC rejection, by contacting the allograft with a topical formulation
CC comprising an antisense oligonucleotide targeted to intercellular
CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
CC useful for inhibiting corneal allograft rejection or for preserving a
CC corneal explant ex vivo, where the explant is human. This sequence
CC corresponds to one of the oligonucleotide of the invention.
XX
SQ Sequence 20 BP; 6 A; 7 C; 7 G; 0 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 97 CTGGTCCTGCTCGGGCTCT 116
DB 20 CTGGTCCTGCTCGGGCTCT 1
RESULT 586
ADC38989/c
ID ADC38989 standard; DNA; 20 BP.
XX
AC ADC38989;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human ICAM-1 targeted primer #15.
XX
KW ss; primer; immunosuppressive; antisense therapy;
KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
KW extracellular adhesion molecule-1; ELAM-1;
KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
XX
OS Synthetic.
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT misc_difference 1..20
FT /*tag= a
FT /*note= "all internucleotide linkages are phosphodiester
bonds"


```

FT modified_base 1..20
FT bonds"
FT /tag= b
FT /mod_base= OTHER
FT /note= "OTHER = all A, C and U are 2'-fluoro bases or 2'-
FT O-methyl"
XX WO2003032920-A2.
XX
XX
XX 24-APR-2003.
XX
XX 16-OCT-2002; 2002WO-US033236.
XX
XX 18-OCT-2001; 2001US-00982262.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Mirabelli CK;
XX WPI; 2003-403142/38.
XX
XX Inhibiting corneal allograft rejection, by contacting an allograft with a
XX formulation having an oligonucleotide targeted to intercellular adhesion
XX molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
XX molecule-1.
XX
XX Example 5; SEQ ID NO 15; 106pp; English.
XX
XX The invention relates to a method of inhibiting corneal allograft
XX rejection, by contacting the allograft with a topical formulation
XX comprising an antisense oligonucleotide targeted to intercellular
XX adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
XX or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
XX useful for inhibiting corneal allograft rejection or for preserving a
XX corneal explant ex vivo, where the explant is human. This sequence
XX corresponds to one of the oligonucleotide of the invention.
XX
XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1938 GAGAGGGGAAGTGGTGGGG 1957
DB 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 587
ADC38990/c
ID ADC38990 standard; DNA; 20 BP.
XX
XX ADC38990;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human ICAM-1 targeted primer #16.
XX
XX ss; primer; immunosuppressive; antisense therapy;
XX corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
XX extracellular adhesion molecule-1; ELAM-1;
XX vascular cell adhesion molecule-1; VCAM-1; corneal explant.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX misc_difference 1..20
XX /tag= a
XX /note= "all internucleotide linkages are phosphodiester
XX bonds"
XX
XX WO2003032920-A2.
XX
XX
XX
XX Key Location/Qualifiers
XX misc_difference 1..20
XX /tag= a
XX /note= "all internucleotide linkages are phosphodiester
XX bonds"
XX
XX WO2003032920-A2.

```

```

XX 24-APR-2003.
XX
XX 16-OCT-2002; 2002WO-US033236.
XX
XX 18-OCT-2001; 2001US-00982262.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Mirabelli CK;
XX WPI; 2003-403142/38.
XX
XX Inhibiting corneal allograft rejection, by contacting an allograft with a
XX formulation having an oligonucleotide targeted to intercellular adhesion
XX molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
XX molecule-1.
XX
XX Example 5; SEQ ID NO 16; 106pp; English.
XX
XX The invention relates to a method of inhibiting corneal allograft
XX rejection, by contacting the allograft with a topical formulation
XX comprising an antisense oligonucleotide targeted to intercellular
XX adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
XX or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
XX useful for inhibiting corneal allograft rejection or for preserving a
XX corneal explant ex vivo, where the explant is human. This sequence
XX corresponds to one of the oligonucleotide of the invention.
XX
XX Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2962 AGTTAATAAAGCTTCTCTCAA 2981
DB 20 AGTTAATAAAGCTTCTCTCAA 1

RESULT 588
ADC39059/c
ID ADC39059 standard; DNA; 20 BP.
XX
XX ADC39059;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human ICAM-1 targeted primer #29.
XX
XX ss; primer; immunosuppressive; antisense therapy;
XX corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
XX extracellular adhesion molecule-1; ELAM-1;
XX vascular cell adhesion molecule-1; VCAM-1; corneal explant.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX misc_difference 1..20
XX /tag= a
XX /note= "all internucleotide linkages are phosphodiester
XX linkages"
XX
XX WO2003032920-A2.
XX
XX 24-APR-2003.
XX
XX 16-OCT-2002; 2002WO-US033236.
XX
XX 18-OCT-2001; 2001US-00982262.
XX
XX (ISIS-) ISIS PHARM INC.

```

XX Bennett CF, Mirabelli CK;
XX WPI; 2003-403142/38.
XX
XX Inhibiting corneal allograft rejection, by contacting an allograft with a
PT formulation having an oligonucleotide targeted to intercellular adhesion
PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
PT molecule-1.
XX
XX Example 5; SEQ ID NO 85; 106pp; English.
XX
XX The invention relates to a method of inhibiting corneal allograft
CC rejection, by contacting the allograft with a topical formulation
CC comprising an antisense oligonucleotide targeted to intercellular
CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
CC useful for inhibiting corneal allograft rejection or for preserving a
CC corneal explant ex vivo, where the explant is human. This sequence
CC corresponds to one of the oligonucleotide of the invention.
XX
XX Sequence 20 BP; 3 A; 10 C; 1 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1945 GAAGTGTGGGGGAGACATA 1964
|||||
Db 20 GAAGTGTGGGGGAGACATA 1
RESULT 589
ADC38996/c
ID ADC38996 standard; DNA; 20 BP.
XX
AC ADC38996;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human ICAM-1 targeted primer #22.
XX
XX ss; primer; immunosuppressive; antisense therapy;
KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
KW extracellular adhesion molecule-1; ELAM-1;
KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX Key Location/Qualifiers
FH misc_difference 1..16
FT /tag= a
FT /note= "all internucleotide linkages are phosphodiester
bonds"
XX
PN WO2003032920-A2.
XX
PD 24-APR-2003.
XX
PF 16-OCT-2002; 2002WO-US033236.
XX
PR 18-OCT-2001; 2001US-00982262.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Mirabelli CK;
XX
DR WPI; 2003-403142/38.
XX
XX Inhibiting corneal allograft rejection, by contacting an allograft with a
PT formulation having an oligonucleotide targeted to intercellular adhesion
PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
PT molecule-1.

PT molecule-1.
XX
XX Example 5; SEQ ID NO 22; 106pp; English.
XX
XX The invention relates to a method of inhibiting corneal allograft
CC rejection, by contacting the allograft with a topical formulation
CC comprising an antisense oligonucleotide targeted to intercellular
CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
CC useful for inhibiting corneal allograft rejection or for preserving a
CC corneal explant ex vivo, where the explant is human. This sequence
CC corresponds to one of the oligonucleotide of the invention.
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 590
ADC38981/c
ID ADC38981 standard; DNA; 20 BP.
XX
AC ADC38981;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human ICAM-1 targeted primer #7.
XX
XX ss; primer; immunosuppressive; antisense therapy;
KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
KW extracellular adhesion molecule-1; ELAM-1;
KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX Key Location/Qualifiers
FH misc_difference 1..20
FT /tag= a
FT /note= "all internucleotide linkages are phosphodiester
bonds"
XX
PN WO2003032920-A2.
XX
PD 24-APR-2003.
XX
PF 16-OCT-2002; 2002WO-US033236.
XX
PR 18-OCT-2001; 2001US-00982262.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Mirabelli CK;
XX
DR WPI; 2003-403142/38.
XX
XX Inhibiting corneal allograft rejection, by contacting an allograft with a
PT formulation having an oligonucleotide targeted to intercellular adhesion
PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
PT molecule-1.
XX
XX Example 5; SEQ ID NO 7; 106pp; English.
XX
XX The invention relates to a method of inhibiting corneal allograft
CC rejection, by contacting the allograft with a topical formulation
CC comprising an antisense oligonucleotide targeted to intercellular
CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
CC

CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
CC useful for inhibiting corneal allograft rejection or for preserving a
CC corneal explant ex vivo, where the explant is human. This sequence
CC corresponds to one of the oligonucleotide of the invention.
XX
SQ Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCTCGCTATG 60
DB 20 GCAACCTCAGCCTCGCTATG 1

RESULT 591
ADC38988/C
ID ADC38988 standard; DNA; 20 BP.
XX
AC ADC38988;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human ICAM-1 targeted primer #14.
XX
KW ss; primer; immunosuppressive; antisense therapy;
KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
KW extracellular adhesion molecule-1; ELAM-1;
KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
XX
OS Synthetic.
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT misc_difference 1..20
FT /*tag= a
FT /note= "all internucleotide linkages are phosphodiester
FT bonds"
XX
PN WO2003032920-A2.
XX
PD 24-APR-2003.
XX
PF 16-OCT-2002; 2002WO-US033236.
XX
PR 18-OCT-2001; 2001US-00982262.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Mirabelli CK;
XX
PS WPI; 2003-403142/38.
XX
DR Inhibiting corneal allograft rejection, by contacting an allograft with a
PT formulation having an oligonucleotide targeted to intercellular adhesion
PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
PT molecule-1.
XX
PS Example 5; SEQ ID NO 14; 106pp; English.
XX
CC The invention relates to a method of inhibiting corneal allograft
CC rejection, by contacting the allograft with a topical formulation
CC comprising an antisense oligonucleotide targeted to intercellular
CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
CC useful for inhibiting corneal allograft rejection or for preserving a
CC corneal explant ex vivo, where the explant is human. This sequence
CC corresponds to one of the oligonucleotide of the invention.
XX
SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
DB 20 TGAACCTATCCCGGACAGG 1

RESULT 592
ADC38999/C
ID ADC38999 standard; DNA; 20 BP.
XX
AC ADC38999;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human ICAM-1 targeted primer #25.
XX
KW ss; primer; immunosuppressive; antisense therapy;
KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
KW extracellular adhesion molecule-1; ELAM-1;
KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
XX
OS Synthetic.
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT misc_difference 1..20
FT /*tag= a
FT /note= "all internucleotide linkages are phosphodiester
FT bonds"
XX
PN WO2003032920-A2.
XX
PD 24-APR-2003.
XX
PF 16-OCT-2002; 2002WO-US033236.
XX
PR 18-OCT-2001; 2001US-00982262.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Mirabelli CK;
XX
PS WPI; 2003-403142/38.
XX
DR Inhibiting corneal allograft rejection, by contacting an allograft with a
PT formulation having an oligonucleotide targeted to intercellular adhesion
PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
PT molecule-1.
XX
PS Example 5; SEQ ID NO 25; 106pp; English.
XX
CC The invention relates to a method of inhibiting corneal allograft
CC rejection, by contacting the allograft with a topical formulation
CC comprising an antisense oligonucleotide targeted to intercellular
CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
CC useful for inhibiting corneal allograft rejection or for preserving a
CC corneal explant ex vivo, where the explant is human. This sequence
CC corresponds to one of the oligonucleotide of the invention.
XX
SQ Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAGTCTAGCCTGATGAG 1940
DB 20 TTAAGTCTAGCCTGATGAG 1

```

RESULT 593
ADC39058/c
ID   ADC39058 standard; DNA; 20 BP.
XX
AC   ADC39058;
XX
DT   18-DEC-2003 (first entry)
XX
DE   Human ICAM-1 targeted primer #28.
XX
KW   ss; primer; immunosuppressive; antisense therapy;
KW   corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
KW   extracellular adhesion molecule-1; ELAM-1;
KW   vascular cell adhesion molecule-1; VCAM-1; corneal explant.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
FH   Key Location/Qualifiers
FT   misc_difference 1..20
FT   /tag= a
FT   /note= "internucleotide linkages are optionally
FT   phosphodiester bonds"
FT   modified_base 1..20
FT   /tag= b
FT   /mod_base= OTHER
FT   /note= "OTHER = all 2'-O-methyl"
XX
PN   WO2003032920-A2.
XX
PD   24-APR-2003.
XX
PF   16-OCT-2002; 2002WO-US033236.
XX
PR   18-OCT-2001; 2001US-00982262.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF, Mirabelli CK;
XX
WPI; 2003-403142/38.
XX
PT   Inhibiting corneal allograft rejection, by contacting an allograft with a
PT   formulation having an oligonucleotide targeted to intercellular adhesion
PT   molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
PT   molecule-1.
XX
PS   Example 5; SEQ ID NO 84; 106pp; English.
XX
CC   The invention relates to a method of inhibiting corneal allograft
CC   rejection, by contacting the allograft with a topical formulation
CC   comprising an antisense oligonucleotide targeted to intercellular
CC   adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
CC   or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
CC   useful for inhibiting corneal allograft rejection or for preserving a
CC   corneal explant ex vivo, where the explant is human. This sequence
CC   corresponds to one of the oligonucleotide of the invention.
XX
SQ   Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   18 GAGCTCCTCTGCTACTCAGA 37
DB   |||||||||||||||||||
      20 GAGCTCCTCTGCTACTCAGA 1

RESULT 594
ADC38976/c
ID   ADC38976 standard; DNA; 20 BP.
XX

```

```

AC   ADC38976;
XX
DT   18-DEC-2003 (first entry)
XX
DE   Human ICAM-1 targeted primer #2.
XX
KW   ss; primer; immunosuppressive; antisense therapy;
KW   corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
KW   extracellular adhesion molecule-1; ELAM-1;
KW   vascular cell adhesion molecule-1; VCAM-1; corneal explant.
XX
OS   Synthetic.
OS   Homo sapiens.
XX
FH   Key Location/Qualifiers
FT   misc_difference 1..20
FT   /tag= a
FT   /note= "internucleotide linkages are optionally
FT   phosphodiester bonds"
XX
PN   WO2003032920-A2.
XX
PD   24-APR-2003.
XX
PF   16-OCT-2002; 2002WO-US033236.
XX
PR   18-OCT-2001; 2001US-00982262.
XX
PA   (ISIS-) ISIS PHARM INC.
XX
PI   Bennett CF, Mirabelli CK;
XX
WPI; 2003-403142/38.
XX
PT   Inhibiting corneal allograft rejection, by contacting an allograft with a
PT   formulation having an oligonucleotide targeted to intercellular adhesion
PT   molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
PT   molecule-1.
XX
PS   Example 5; SEQ ID NO 2; 106pp; English.
XX
CC   The invention relates to a method of inhibiting corneal allograft
CC   rejection, by contacting the allograft with a topical formulation
CC   comprising an antisense oligonucleotide targeted to intercellular
CC   adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
CC   or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
CC   useful for inhibiting corneal allograft rejection or for preserving a
CC   corneal explant ex vivo, where the explant is human. This sequence
CC   corresponds to one of the oligonucleotide of the invention.
XX
SQ   Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   7 CAGTCGACGCTGAGCTCCTC 26
DB   |||||||||||||||||||
      20 CAGTCGACGCTGAGCTCCTC 1

RESULT 595
ADC38982/c
ID   ADC38982 standard; DNA; 20 BP.
XX
AC   ADC38982;
XX
DT   18-DEC-2003 (first entry)
XX
DE   Human ICAM-1 targeted primer #8.
XX
KW   ss; primer; immunosuppressive; antisense therapy;
KW   corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;

```

KW extracellular adhesion molecule-1; ELAM-1;
 KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.

XX Synthetic.
 OS Homo sapiens.

XX Key Location/Qualifiers
 FH misc_difference 1..20

FT /*tag= a
 FT /note= "all internucleotide linkages are phosphodiester bonds"

XX WO2003032920-A2.

XX 24-APR-2003.

XX 16-OCT-2002; 2002WO-US033236.

XX 18-OCT-2001; 2001US-00982262.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK;

XX WPI; 2003-403142/38.

XX Inhibiting corneal allograft rejection, by contacting an allograft with a formulation having an oligonucleotide targeted to intercellular adhesion molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion molecule-1.

XX Example 5; SEQ ID NO 8; 106pp; English.

XX The invention relates to a method of inhibiting corneal allograft rejection, by contacting the allograft with a topical formulation comprising an antisense oligonucleotide targeted to intercellular adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1) or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is useful for inhibiting corneal allograft rejection or for preserving a corneal explant ex vivo, where the explant is human. This sequence corresponds to one of the oligonucleotide of the invention.

XX Sequence 20 BP; 2 A; 5 C; 10 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCCGAGCAGCCCGG 77
 |||||
 DB 20 ATGGCTCCCGAGCAGCCCGG 1

RESULT 596

ADC38984/C

ID ADC38984 standard; DNA; 20 BP.

AC ADC38984;

DT 18-DEC-2003 (first entry)

DE Human ICAM-1 targeted primer #10.

XX ss; primer; immunosuppressive; antisense therapy;
 KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
 KW extracellular adhesion molecule-1; ELAM-1;
 KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.

OS Synthetic.
 OS Homo sapiens.

XX Key Location/Qualifiers
 FH misc_difference 1..20

FT /*tag= a
 FT /note= "all internucleotide linkages are phosphodiester bonds"

XX WO2003032920-A2.

XX 24-APR-2003.

XX 16-OCT-2002; 2002WO-US033236.

XX 18-OCT-2001; 2001US-00982262.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK;

XX WPI; 2003-403142/38.

XX Inhibiting corneal allograft rejection, by contacting an allograft with a formulation having an oligonucleotide targeted to intercellular adhesion molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion molecule-1.

XX Example 5; SEQ ID NO 10; 106pp; English.

XX The invention relates to a method of inhibiting corneal allograft rejection, by contacting the allograft with a topical formulation comprising an antisense oligonucleotide targeted to intercellular adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1) or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is useful for inhibiting corneal allograft rejection or for preserving a corneal explant ex vivo, where the explant is human. This sequence corresponds to one of the oligonucleotide of the invention.

XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
 |||||
 DB 20 TCAAACTGCCCTGATGGCA 1

RESULT 597

ADC38997/c

ID ADC38997 standard; DNA; 20 BP.

AC ADC38997;

DT 18-DEC-2003 (first entry)

DE Human ICAM-1 targeted primer #23.

XX ss; primer; immunosuppressive; antisense therapy;
 KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
 KW extracellular adhesion molecule-1; ELAM-1;
 KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.

OS Synthetic.

OS Homo sapiens.

XX Key Location/Qualifiers
 FH misc_difference 1..20

FT /*tag= a
 FT /note= "all internucleotide linkages are phosphodiester bonds"

XX WO2003032920-A2.

XX 24-APR-2003.

PF 16-OCT-2002; 2002WO-US033236.
 XX
 PR 18-OCT-2001; 2001US-00982262.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK;
 XX
 DR WPI; 2003-403142/38.
 XX
 XX Inhibiting corneal allograft rejection, by contacting an allograft with a
 PT formulation having an oligonucleotide targeted to intercellular adhesion
 PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
 PT molecule-1.
 XX
 XX Example 5; SEQ ID NO 23; 106pp; English.
 XX
 CC The invention relates to a method of inhibiting corneal allograft
 CC rejection, by contacting the allograft with a topical formulation
 CC comprising an antisense oligonucleotide targeted to intercellular
 CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
 CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
 CC useful for inhibiting corneal allograft rejection or for preserving a
 CC corneal explant ex vivo, where the explant is human. This sequence
 CC corresponds to one of the oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2025 GAGGCCACAGACTTACAGA 2044
 DB 20 GAGGCCACAGACTTACAGA 1
 RESULT 598
 ADC38985/c
 ID ADC38985 standard; DNA; 20 BP.
 XX
 AC ADC38985;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human ICAM-1 targeted primer #11.
 XX
 KW ss; primer; immunosuppressive; antisense therapy;
 KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
 KW extracellular adhesion molecule-1; ELAM-1;
 KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT misc_difference 1..20
 FT /*tag= a
 FT /note= "all internucleotide linkages are phosphodiester
 FT bonds"
 XX
 PN WO2003032920-A2.
 XX
 PD 24-APR-2003.
 XX
 PF 16-OCT-2002; 2002WO-US033236.
 XX
 PR 18-OCT-2001; 2001US-00982262.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK;
 XX
 DR WPI; 2003-403142/38.
 XX
 XX Inhibiting corneal allograft rejection, by contacting an allograft with a
 PT formulation having an oligonucleotide targeted to intercellular adhesion
 PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
 PT molecule-1.
 XX
 XX Example 5; SEQ ID NO 23; 106pp; English.
 XX
 CC The invention relates to a method of inhibiting corneal allograft
 CC rejection, by contacting the allograft with a topical formulation
 CC comprising an antisense oligonucleotide targeted to intercellular
 CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
 CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
 CC useful for inhibiting corneal allograft rejection or for preserving a
 CC corneal explant ex vivo, where the explant is human. This sequence
 CC corresponds to one of the oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

DR WPI; 2003-403142/38.
 XX
 XX Inhibiting corneal allograft rejection, by contacting an allograft with a
 PT formulation having an oligonucleotide targeted to intercellular adhesion
 PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
 PT molecule-1.
 XX
 XX Example 5; SEQ ID NO 11; 106pp; English.
 XX
 CC The invention relates to a method of inhibiting corneal allograft
 CC rejection, by contacting the allograft with a topical formulation
 CC comprising an antisense oligonucleotide targeted to intercellular
 CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
 CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
 CC useful for inhibiting corneal allograft rejection or for preserving a
 CC corneal explant ex vivo, where the explant is human. This sequence
 CC corresponds to one of the oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 875 AGGCCTCAGTCAGTGTGACC 894
 DB 20 AGGCCTCAGTCAGTGTGACC 1
 RESULT 599
 ADC38986/c
 ID ADC38986 standard; DNA; 20 BP.
 XX
 AC ADC38986;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human ICAM-1 targeted primer #12.
 XX
 KW ss; primer; immunosuppressive; antisense therapy;
 KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
 KW extracellular adhesion molecule-1; ELAM-1;
 KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT misc_difference 1..20
 FT /*tag= a
 FT /note= "all internucleotide linkages are phosphodiester
 FT bonds"
 XX
 PN WO2003032920-A2.
 XX
 PD 24-APR-2003.
 XX
 PF 16-OCT-2002; 2002WO-US033236.
 XX
 PR 18-OCT-2001; 2001US-00982262.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK;
 XX
 DR WPI; 2003-403142/38.
 XX
 XX Inhibiting corneal allograft rejection, by contacting an allograft with a
 PT formulation having an oligonucleotide targeted to intercellular adhesion
 PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
 PT molecule-1.
 XX
 XX Example 5; SEQ ID NO 12; 106pp; English.

XX The invention relates to a method of inhibiting corneal allograft
 CC rejection, by contacting the allograft with a topical formulation
 CC comprising an antisense oligonucleotide targeted to intercellular
 CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
 CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
 CC useful for inhibiting corneal allograft rejection or for preserving a
 CC corneal explant ex vivo, where the explant is human. This sequence
 CC corresponds to one of the oligonucleotide of the invention.
 XX SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1445 AAGGGGAGGTCACCCGCGAG 1464
 |||||
 Db 20 AAGGGGAGGTCACCCGCGAG 1
 RESULT 600
 ADC38998/c
 ID ADC38998 standard; DNA; 20 BP.
 XX
 AC ADC38998;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human ICAM-1 targeted primer #24.
 DE
 XX
 KW ss; primer; immunosuppressive; antisense therapy;
 KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
 KW extracellular adhesion molecule-1; ELAM-1;
 KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
 XX
 OS Synthetic.
 OS Homo sapiens.
 OS
 XX
 FH Key Location/Qualifiers
 FT misc_difference 1..20 /*tag= a
 FT /note= "all internucleotide linkages are phosphodiester
 FT bonds"
 XX
 XX WO2003032920-A2.
 PN
 XX
 PD 24-APR-2003.
 XX
 XX 16-OCT-2002; 2002WO-US033236.
 XX
 PR 18-OCT-2001; 2001US-00982262.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK;
 XX
 XX WPI; 2003-403142/38.
 DR
 XX
 XX Inhibiting corneal allograft rejection, by contacting an allograft with a
 PT formulation having an oligonucleotide targeted to intercellular adhesion
 PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
 PT molecule-1.
 XX
 XX Example 5; SEQ ID NO 24; 106pp; English.
 PS
 CC The invention relates to a method of inhibiting corneal allograft
 CC rejection, by contacting the allograft with a topical formulation
 CC comprising an antisense oligonucleotide targeted to intercellular
 CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
 CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
 CC useful for inhibiting corneal allograft rejection or for preserving a
 CC corneal explant ex vivo, where the explant is human. This sequence

CC corresponds to one of the oligonucleotide of the invention.
 XX SQ Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1881 CAAGAGGAGGAGCAAGACT 1900
 |||||
 Db 20 CAAGAGGAGGAGCAAGACT 1
 RESULT 601
 ADC38987/c
 ID ADC38987 standard; DNA; 20 BP.
 XX
 AC ADC38987;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human ICAM-1 targeted primer #13.
 DE
 XX
 KW ss; primer; immunosuppressive; antisense therapy;
 KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
 KW extracellular adhesion molecule-1; ELAM-1;
 KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
 XX
 OS Synthetic.
 OS Homo sapiens.
 OS
 XX
 FH Key Location/Qualifiers
 FT misc_difference 1..20 /*tag= a
 FT /note= "all internucleotide linkages are phosphodiester
 FT bonds"
 XX
 XX WO2003032920-A2.
 PN
 XX
 PD 24-APR-2003.
 XX
 XX 16-OCT-2002; 2002WO-US033236.
 XX
 PR 18-OCT-2001; 2001US-00982262.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 PI Bennett CF, Mirabelli CK;
 XX
 XX WPI; 2003-403142/38.
 DR
 XX
 XX Inhibiting corneal allograft rejection, by contacting an allograft with a
 PT formulation having an oligonucleotide targeted to intercellular adhesion
 PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
 PT molecule-1.
 XX
 XX Example 5; SEQ ID NO 13; 106pp; English.
 PS
 CC The invention relates to a method of inhibiting corneal allograft
 CC rejection, by contacting the allograft with a topical formulation
 CC comprising an antisense oligonucleotide targeted to intercellular
 CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
 CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
 CC useful for inhibiting corneal allograft rejection or for preserving a
 CC corneal explant ex vivo, where the explant is human. This sequence
 CC corresponds to one of the oligonucleotide of the invention.
 XX SQ Sequence 20 BP; 2 A; 3 C; 10 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCACGCTCCCTGA 1656
 Db 20 CACAAGCCACGCTCCCTGA 1

RESULT 602
 ADC39000/c
 ID ADC39000 standard; DNA; 20 BP.
 XX AC ADC39000;
 XX DT 18-DEC-2003 (first entry)
 XX DE Human ICAM-1 targeted primer #26.
 XX KW ss; primer: immunosuppressive; antisense therapy;
 KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
 KW extracellular adhesion molecule-1; ELAM-1;
 KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
 XX OS Synthetic.
 OS Homo sapiens.
 XX FH Key Location/Qualifiers
 FT misc_difference 1..20
 FT /*tag= a
 FT /note= "all internucleotide linkages are phosphodiester
 bonds"
 XX WO2003032920-A2.
 XX 24-APR-2003.
 XX 16-OCT-2002; 2002WO-US033236.
 XX 18-OCT-2001; 2001US-00982262.
 XX (ISIS-) ISIS PHARM INC.
 XX Bennett CF, Mirabelli CK;
 XX WPI; 2003-403142/38.
 XX Inhibiting corneal allograft rejection, by contacting an allograft with a
 PT formulation having an oligonucleotide targeted to intercellular adhesion
 PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
 PT molecule-1.
 XX Example 5; SEQ ID NO 26; 106pp; English.
 XX The invention relates to a method of inhibiting corneal allograft
 CC rejection, by contacting the allograft with a topical formulation
 CC comprising an antisense oligonucleotide targeted to intercellular
 CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
 CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
 CC useful for inhibiting corneal allograft rejection or for preserving a
 CC corneal explant ex vivo, where the explant is human. This sequence
 CC corresponds to one of the oligonucleotide of the invention.
 XX SQ Sequence 20 BP; 2 A; 4 C; 7 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1662 ATAGCCCCACCATGAGGACA 1981
 Db 20 ATAGCCCCACCATGAGGACA 1

RESULT 603
 AAD58980/c
 ID AAD58980 standard; DNA; 20 BP.

XX AAD58980;
 XX 18-DEC-2003 (first entry)
 XX Human ICAM-1 antisense oligo, ISIS 1939.
 XX Inflammatory bowel disorder; ulcerative colitis; Crohn's disease;
 KW cellular proliferation; intracellular adhesion molecule; ICAM-1;
 KW phosphorothioate backbone; antisense; human; ss.
 XX OS Homo sapiens.
 OS Synthetic.
 XX FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone"
 XX US2003040497-A1.
 XX 27-FEB-2003.
 XX 21-DEC-2001; 2001US-00029598.
 XX 01-JUL-1997; 97US-00886829.
 XX 01-JUL-1998; 98US-00108673.
 XX 20-MAY-1999; 99US-00315298.
 XX (TENG/) TENG C.
 PA (COOK/) COOK P D.
 PA (TILL/) TILLMAN L.
 PA (HARD/) HARDEE G E.
 PA (ECKE/) ECKER D J.
 PA (MANO/) MANOHARAN M.
 XX Teng C, Cook PD, Tillman L, Hardee GE, Ecker DJ, Manoharan M;
 XX WPI; 2003-596370/56.
 XX Formulation, useful for treating inflammatory bowel disorder, e.g.
 PT ulcerative colitis or Crohn's disease, comprises oligonucleotide for
 PT rectal delivery.
 XX Example 2; Page 7; 45pp; English.
 XX The invention relates to formulations and methods which enhance the local
 CC and systemic uptake and delivery of oligonucleotides and nucleic acids
 CC via non-parenteral routes of administration. The formulation is used for
 CC treating inflammatory bowel disorders, e.g. ulcerative colitis, Crohn's
 CC disease or inflammatory bowel disease, in animals (e.g. human). It can
 CC also be used for treating undue cellular proliferation. The present
 CC sequence is an antisense oligonucleotide targeted to human intracellular
 CC adhesion molecule (ICAM-1) gene. This sequence is used to illustrate the
 CC method of the invention
 XX SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1938 GAGAGGGGAAAGTGGTGGGG 1957
 Db 20 GAGAGGGGAAAGTGGTGGGG 1

RESULT 604
 AAD59033/c
 ID AAD59033 standard; DNA; 20 BP.
 XX AAD59033;
 XX AAD59033;

XX 18-DEC-2003 (first entry)
XX Antisense oligonucleotide #1.
XX Inflammatory bowel disorder; ulcerative colitis; Crohn's disease;
KW cellular proliferation; phosphorothioate backbone; antisense; ss.
XX Unidentified.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT modified_base 2..4
FT /note= "Phosphorothioate backbone"
FT /tag= c
FT /mod_base= m5c
FT modified_base 8
FT /tag= d
FT /mod_base= m5c
FT modified_base 12
FT /tag= e
FT /mod_base= m5c
FT modified_base 13..20
FT /tag= b
FT /mod_base= OTHER
FT modified_base 15..16
FT /tag= f
FT /mod_base= m5c
FT modified_base 19
FT /tag= g
FT /mod_base= m5c
XX US2003040497-A1.
XX 27-FEB-2003.
XX
XX 21-DEC-2001; 2001US-00029598.
XX 01-JUL-1997; 97US-00886829.
XX 01-JUL-1998; 98US-00108673.
XX 20-MAY-1999; 99US-00315298.
XX (TENG/) TENG C.
XX (COOK/) COOK P D.
XX (TILL/) TILLMAN L.
XX (HARD/) HARDEE G E.
XX (ECKE/) ECKER D J.
XX (MANO/) MANOHARAN M.
XX
XX Teng C, Cook PD, Tillman L, Hardee GE, Ecker DJ, Manoharan M;
PI WPI; 2003-596370/56.
XX
XX Formulation, useful for treating inflammatory bowel disorder, e.g.
PT ulcerative colitis or Crohn's disease, comprises oligonucleotide for
PT rectal delivery.
XX
XX Disclosure; Page 42; 45pp; English.
XX
XX The invention relates to formulations and methods which enhance the local
CC and systemic uptake and delivery of oligonucleotides and nucleic acids
CC via non-parenteral routes of administration. The formulation is used for
CC treating inflammatory bowel disorders, e.g. ulcerative colitis, Crohn's
CC disease or inflammatory bowel disease, in animals (e.g. human). It can
CC also be used for treating undue cellular proliferation. The present
CC sequence is an antisense oligonucleotide used to illustrate the method of
CC the invention
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGATGCCAGCTTGGGC 2119
DB 20 TGACGATGCCAGCTTGGGC 1

RESULT 605
AAD58979/c
ID AAD58979 standard; DNA; 20 BP.
XX
AC AAD58979;
XX 18-DEC-2003 (first entry)
XX Human ICAM-1 antisense oligo, ISIS 2302.
XX
XX Inflammatory bowel disorder; ulcerative colitis; Crohn's disease;
KW cellular proliferation; intracellular adhesion molecule; ICAM-1;
KW phosphorothioate backbone; antisense; human; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; Optionally all
FT cytidines are 5-methyl cytidines"
FT modified_base 13..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
XX US2003040497-A1.
XX 27-FEB-2003.
XX
XX 21-DEC-2001; 2001US-00029598.
XX 01-JUL-1997; 97US-00886829.
XX 01-JUL-1998; 98US-00108673.
XX 20-MAY-1999; 99US-00315298.
XX (TENG/) TENG C.
XX (COOK/) COOK P D.
XX (TILL/) TILLMAN L.
XX (HARD/) HARDEE G E.
XX (ECKE/) ECKER D J.
XX (MANO/) MANOHARAN M.
XX
XX Teng C, Cook PD, Tillman L, Hardee GE, Ecker DJ, Manoharan M;
PI WPI; 2003-596370/56.
XX
XX Formulation, useful for treating inflammatory bowel disorder, e.g.
PT ulcerative colitis or Crohn's disease, comprises oligonucleotide for
PT rectal delivery.
XX
XX Claim 12; Page 7; 45pp; English.
XX
XX The invention relates to formulations and methods which enhance the local
CC and systemic uptake and delivery of oligonucleotides and nucleic acids
CC via non-parenteral routes of administration. The formulation is used for
CC treating inflammatory bowel disorders, e.g. ulcerative colitis, Crohn's
CC disease or inflammatory bowel disease, in animals (e.g. human). It can
CC also be used for treating undue cellular proliferation. The present
CC sequence is an antisense oligonucleotide targetted to human intracellular
CC adhesion molecule (ICAM-1) gene. This sequence is used to illustrate the
CC method of the invention

XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 |||||
 Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 606
 ADD82033/c
 ID ADD82093 standard; DNA; 20 BP.
 XX
 AC ADD82093;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Phosphorothioate monoester modified antisense oligonucleotide #1.
 XX
 KW Phosphorothioate monoester; antisense; ss; RNase H ; nuclease resistance;
 KW antisense gene therapy.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 12 /*tag= a
 FT /mod_base= OTHER
 FT /note= "A is covalently linked to a Phosphorothioate
 FT monoester at the 2' position"
 XX
 PN US2003190626-A1.
 XX
 PD 09-OCT-2003.
 XX
 PF 09-APR-2002; 2002US-00119432.
 XX
 PR 09-APR-2002; 2002US-00119432.
 XX
 PA (RAVI/) RAVIKUMAR V.
 XX
 PI Ravikumar V;
 XX
 DR WPI; 2003-864173/80.
 XX
 PT New phosphorothioate monoester modified oligomers useful for treating
 PT organism having a disease caused by undesired production of protein.
 XX
 PS Example 1; SEQ ID NO 1; 22pp; English.
 XX
 CC The invention relates to phosphorothioate monoester modified antisense
 CC oligomers (of formula detailed in the specification). Also included is
 CC modifying in vitro a nucleic acid involving contacting a test solution
 CC containing RNase H and the nucleic acid with the phosphorothioate
 CC monoester modified antisense oligomer. The phosphorothioate monoester
 CC modified antisense oligomer is used for treating an organism having a
 CC disease caused by undesired production of protein, for modifying in vitro
 CC a nucleic acid, for diagnostic and research purposes, for modulating the
 CC expression of protein in organisms, for the diagnosis, detection and
 CC treatment of other conditions responsive to oligonucleotide therapeutics,
 CC for identification or quantification of an RNA or DNA or for modulating
 CC the activity of an RNA or DNA molecule. The compound enhances the
 CC hybridization and RNase H activation in the organism compared to
 CC oligomeric compounds without the modification. The compound has increased
 CC nuclease resistance and binding affinity to a complementary strand of
 CC nucleic acid. The compound has maximum therapeutic effect and minimum
 CC side effects. The compound enhances the efficiency of antisense
 CC inhibition of gene expression. The present sequence is a phosphorothioate
 CC monoester modified antisense oligomer of the invention.
 XX

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 |||||
 Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 607
 ADE27755/c
 ID ADE27755 standard; DNA; 20 BP.
 XX
 AC ADE27755;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE ICAM-1 targeted oligonucleotide SEQ ID 17.
 XX
 KW ss; ICAM-1; intracellular adhesion molecule-1;
 KW inflammatory skin disorder; antisense; psoriasis; contact dermatitis;
 KW atopic dermatitis; seborrheic dermatitis; nummular dermatitis;
 KW generalised exfoliative dermatitis; eczema;
 KW critical costimulatory molecule.
 XX
 OS Synthetic.
 XX
 PN US2003176374-A1.
 XX
 PD 18-SEP-2003.
 XX
 PF 09-MAY-2001; 2001US-00851871.
 XX
 PR 31-DEC-1996; 96US-00777266.
 PR 04-JUN-1999; 99US-00326186.
 PR 25-MAY-2000; 2000WO-US014471.
 XX
 PA (BENN/) BENNETT C F.
 PA (VICK/) VICKERS T A.
 PA (KARR/) KARRAS J G.
 XX
 PI Bennett CF, Vickers TA, Karras JG;
 XX
 DR WPI; 2003-863863/80.
 XX
 PT Treating an inflammatory skin disorder such as psoriasis comprises
 PT topically applying an antisense compound targeted to the nucleic acid
 PT encoding human B7 protein.
 XX
 PS Example 1; SEQ ID NO 17; 8pp; English.
 XX
 CC The invention relates to a method of treating an inflammatory skin
 CC disorder in an individual by topically applying an antisense compound
 CC targeted to a nucleic acid molecule encoding a human B7 protein. The
 CC invention is for treating an inflammatory skin disorder in individual.
 CC The skin disorder is psoriasis, contact dermatitis, atopic dermatitis,
 CC seborrheic dermatitis, nummular dermatitis, generalised exfoliative
 CC dermatitis or eczema. The invention effectively modulates critical
 CC costimulatory molecules such as the B7 protein. The present sequence
 CC represents an ICAM-1 targeted oligonucleotide.
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 |||||
 Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 608
ADE99241/c
ID ADE99241 standard; DNA; 20 BP.
XX AC ADE99241;
XX AC ADE99241;
DT 12-FEB-2004 (first entry)
XX DE Modified oligomeric compound #1.
XX DE Oligomeric compound; hepatitis C virus; 2'-O-modification;
KW Oligomeric compound; hepatitis C virus; 2'-O-modification;
KW nuclease resistance; hepatotropic; virucide; antiinflammatory; ss.
XX OS Synthetic.
XX US6600032-B1.
XX 29-JUL-2003.
XX 06-AUG-1999; 99US-00370625.
XX 07-AUG-1998; 98US-00130566.
XX (ISIS-) ISIS PHARM INC.
PI Manoharan M, Cook PD;
XX WPI; 2003-895259/82.
XX New oligomeric compound having at least one nucleoside useful for
PT therapeutic and investigative purposes e.g. for treating hepatitis C
PT virus infection.
XX Disclosure; SEQ ID NO 1; 26pp; English.
PS The invention relates to oligomeric compounds having at least one
CC nucleoside. The compounds are useful for therapeutic and investigative
CC purposes and for treating hepatitis C virus infection. The compounds
CC having 2'-O-modifications increases their affinity and nuclease
CC resistance. This sequence represents an oligomeric compound of the
CC invention.
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTGCTACTCAGA 37
DB 20 GAGCTCCTGCTACTCAGA 1
RESULT 609
ADE99244/c
ID ADE99244 standard; DNA; 20 BP.
XX AC ADE99244;
XX AC ADE99244;
DT 12-FEB-2004 (first entry)
XX DE Modified oligomeric compound #4.
XX DE Oligomeric compound; hepatitis C virus; 2'-O-modification;
KW Oligomeric compound; hepatitis C virus; 2'-O-modification;
KW nuclease resistance; hepatotropic; virucide; antiinflammatory; ss.
XX OS Synthetic.
XX US6600032-B1.
XX 29-JUL-2003.
XX

PF 06-AUG-1999; 99US-00370625.
XX 07-AUG-1998; 98US-00130566.
XX (ISIS-) ISIS PHARM INC.
XX Manoharan M, Cook PD;
XX WPI; 2003-895259/82.
XX New oligomeric compound having at least one nucleoside useful for
PT therapeutic and investigative purposes e.g. for treating hepatitis C
PT virus infection.
XX Disclosure; SEQ ID NO 4; 26pp; English.
XX The invention relates to oligomeric compounds having at least one
CC nucleoside. The compounds are useful for therapeutic and investigative
CC purposes and for treating hepatitis C virus infection. The compounds
CC having 2'-O-modifications increases their affinity and nuclease
CC resistance. This sequence represents an oligomeric compound of the
CC invention.
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGATGCCAGCTTGGGC 2119
DB 20 TGACGATGCCAGCTTGGGC 1
RESULT 610
ADE99242/c
ID ADE99242 standard; DNA; 20 BP.
XX AC ADE99242;
XX 12-FEB-2004 (first entry)
XX Modified oligomeric compound #2.
XX Oligomeric compound; hepatitis C virus; 2'-O-modification;
KW nuclease resistance; hepatotropic; virucide; antiinflammatory; ss.
XX Synthetic.
XX US6600032-B1.
XX 29-JUL-2003.
XX 06-AUG-1999; 99US-00370625.
XX 07-AUG-1998; 98US-00130566.
XX (ISIS-) ISIS PHARM INC.
XX Manoharan M, Cook PD;
XX WPI; 2003-895259/82.
XX New oligomeric compound having at least one nucleoside useful for
PT therapeutic and investigative purposes e.g. for treating hepatitis C
PT virus infection.
XX Disclosure; SEQ ID NO 2; 26pp; English.
XX The invention relates to oligomeric compounds having at least one
CC nucleoside. The compounds are useful for therapeutic and investigative
CC purposes and for treating hepatitis C virus infection. The compounds
CC having 2'-O-modifications increases their affinity and nuclease

CC resistance. This sequence represents an oligomeric compound of the invention.

XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 611

ADF82816/c

ID ADF82816 standard; DNA; 20 BP.

XX AC ADF82816;

XX DT 26-FEB-2004 (first entry)

XX DE Immunostimulant ODN11, component of lipid-nucleic acid vaccine.

XX KW Immunostimulant; vaccine; lipid-nucleic acid; phosphorothioate; human;

XX KW intracellular adhesion molecule-1; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= phosphorothioate nucleotides"

XX PN WO2003094829-A2.

XX PD 20-NOV-2003.

XX PF 12-MAY-2003; 2003WO-CA000680.

XX PR 10-MAY-2002; 2002US-0379343P.

XX PR 07-NOV-2002; 2002US-00290545.

XX PR 12-MAR-2003; 2003US-0454298P.

XX PA (INEX-) INEX PHARM CORP.

XX PI Sample S, Chikh G, Hope MJ, Tam YK;

XX DR WPI; 2003-903935/82.

XX PT New pathogen vaccine having a lipid-nucleic acid formulation in

FT combination with at least one microbial antigen, useful for stimulating

PT enhanced responses against bacterial, viral and parasitic infections.

XX PS Disclosure; SEQ ID NO 11; 138pp; English.

XX CC The present sequence is that of ODN11 (PS-2302) for human intracellular

CC adhesion molecule-1. This is an immunostimulatory oligonucleotide that

CC can be used in lipid-nucleic acid (LNA) vaccines of the invention.

CC Claimed vaccines comprise an LNA formulation in combination with at least

CC one microbial antigen, such as hepatitis B virus surface antigen. The

CC lipid component of the LNA comprises at least one cationic lipid. The

CC oligonucleotide component of the LNA preferably comprises at least one

CC CpG dinucleotide, a methylated cytosine and a phosphorothioate backbone.

CC The vaccine is capable of stimulating Th1 type humoral and cellular

CC immune responses. An enhanced humoral response is demonstrated by a

CC strong early peak of interferon-gamma production observed within hours of

CC vaccine followed by a second stronger peak of interferon-gamma production

CC observed several days later, correlated with antibody isotype switching.

XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 612

ADF82817/c

ID ADF82817 standard; DNA; 20 BP.

XX AC ADF82817;

XX DT 26-FEB-2004 (first entry)

XX DE Immunostimulant ODN12, component of lipid-nucleic acid vaccine.

XX KW Immunostimulant; vaccine; lipid-nucleic acid; phosphorothioate; human;

XX KW intracellular adhesion molecule-1; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= phosphorothioate nucleotides"

XX PN WO2003094829-A2.

XX PD 20-NOV-2003.

XX PF 12-MAY-2003; 2003WO-CA000680.

XX PR 10-MAY-2002; 2002US-0379343P.

XX PR 07-NOV-2002; 2002US-00290545.

XX PR 12-MAR-2003; 2003US-0454298P.

XX PA (INEX-) INEX PHARM CORP.

XX PI Sample S, Chikh G, Hope MJ, Tam YK;

XX DR WPI; 2003-903935/82.

XX PT New pathogen vaccine having a lipid-nucleic acid formulation in

FT combination with at least one microbial antigen, useful for stimulating

PT enhanced responses against bacterial, viral and parasitic infections.

XX PS Disclosure; SEQ ID NO 12; 138pp; English.

XX CC The present sequence is that of ODN12 (PS-8997) for human intracellular

CC adhesion molecule-1. This is an immunostimulatory oligonucleotide that

CC can be used in lipid-nucleic acid (LNA) vaccines of the invention.

CC Claimed vaccines comprise an LNA formulation in combination with at least

CC one microbial antigen, such as hepatitis B virus surface antigen. The

CC lipid component of the LNA comprises at least one cationic lipid. The

CC oligonucleotide component of the LNA preferably comprises at least one

CC CpG dinucleotide, a methylated cytosine and a phosphorothioate backbone.

CC The vaccine is capable of stimulating Th1 type humoral and cellular

CC immune responses. An enhanced humoral response is demonstrated by a

CC strong early peak of interferon-gamma production observed within hours of

CC vaccine followed by a second stronger peak of interferon-gamma production

CC observed several days later, correlated with antibody isotype switching.

XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 613
ADG42098
ID ADG42098 standard; DNA; 20 BP.
XX
AC ADG42098;
XX
XX 26-FEB-2004 (first entry)
XX Human ICAM-1 RT-PCR primer #1.
DE
XX Human; ss; PCR; CAP37; cationic antimicrobial protein 37;
KW ophthalmological; antibacterial; antiinflammatory; ocular condition;
KW bactericidal; bacteriostatic; contact lens; corneal transplant;
KW bacterial keratitis; Pseudomonas aeruginosa; Staphylococcus aureus;
KW bacterial conjunctivitis; endophthalmitis; blebitis; corneal ulcer;
KW eye wound; bacterial infection; disinfectant; primer;
KW pro-inflammatory cytokines; RT-PCR; reverse transcriptase PCR; ICAM-1;
KW VCAM-1; PECAM-1; E-selectin; Beta actin.
XX
OS Homo sapiens.
XX US2003206938-A1.
FN
XX 06-NOV-2003.
PD
XX 25-APR-2003; 2003US-00423311.
XX
XX 03-MAY-2002; 2002US-0378295P.
PR
XX (PERE/) PEREIRA H A.
PA (CHOD/) CHODOSH J.
PA (CALL/) CALLEGAN M C.
XX
XX Pereira HA, Chodosh J, Callegan MC;
PI WPI; 2003-901038/82.
XX
XX Use of cationic antimicrobial protein of Mr 57 kDa (CAP37), a CAP37
PT peptide, or a CAP37 peptide monocyte derivative for treating
PT bacterial keratitis, bacterial conjunctivitis, endophthalmitis, or
PT blebitis.
XX
XX Disclosure; SEQ ID NO 11; 31pp; English.
PS
XX The invention relates to treating an ocular condition in an eye of a
CC mammal comprising administering a cationic antimicrobial protein of Mw 57
CC kDa (CAP37), a CAP37 peptide, or a CAP37 peptide monocyte derivative
CC to the eye of the mammal. Also included are a bactericidal or
CC bacteriostatic contact lens (comprising a contact lens, and a coating
CC comprising a CAP37, a CAP37 peptide, or a monocyte derivative of a
CC CAP37 peptide disposed upon a surface of the contact lens), and a method
CC of storing a mammalian corneal transplant comprising providing a medium
CC comprising a bactericidal or bacteriostatic quantity of a CAP37, a CAP37
CC peptide, or a CAP37 peptide monocyte derivative and disposing the
CC mammalian corneal transplant in the medium. The method is useful for
CC treating an ocular condition is bacterial keratitis caused by Pseudomonas
CC aeruginosa or Staphylococcus aureus, bacterial conjunctivitis,
CC endophthalmitis, or blebitis. The method is particularly useful for
CC treating corneal ulcer or wound in an eye of a mammal, or for inhibiting
CC bacterial infection or contamination of or by a contact lens. CAP37 and
CC CAP37 peptides may also be used as a disinfectant for cleaning or
CC sterilisation of contact lenses, and as a storage solution for preventing
CC contact lenses from becoming contaminated with bacteria while in storage
CC cases. An experiment was performed to determine whether CAP37 induced
CC ICAM-1, VCAM-1, PECAM-1, E-selectin (and control Beta actin) mRNA. The
CC present sequence is a reverse transcriptase (RT)-PCR primer used in the
CC above assay.

XX
SQ . Sequence 20 BP; 5 A; 9 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 150 GTCCCCCTCAAAAGTCATCC 169
Db 1 GTCCCCCTCAAAAGTCATCC 20
RESULT 614
AAD64776/c
ID AAD64776 standard; DNA; 20 BP.
XX
AC AAD64776;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human ICAM-1 specific oligonucleotide, INX-2032.
XX
KW Human; immunostimulatory; cytokine secretion; tumour associated antigen;
KW hepatitis B antigen; ICAM-1; ss.
XX
OS Homo sapiens.
XX US2003104044-A1.
FN
XX 05-JUN-2003.
PD
XX 01-MAR-2002; 2002US-00086477.
XX
PR 14-MAY-1997; 97US-00856374.
PR 14-MAY-1998; 98US-00078954.
PR 27-AUG-1999; 99US-0151211P.
PR 13-JAN-2000; 2000US-0176406P.
PR 28-AUG-2000; 2000US-00649527.
PR 01-MAR-2001; 2001US-0273293P.
XX
XX (SEMP/) SEMPL S C.
PA (HARA/) HARASYM T O.
PA (KLIM/) KLIMUK S K.
PA (KOJI/) KOJIC L D.
PA (BRAM/) BRAMSON J L.
PA (MUIB/) MUI B.
PA (HOPE/) HOPE M J.
XX
XX Sample SC, Harasym TO, Klimuk SK, Kojic LD, Bramson JL, Mui B;
PI Hope MJ;
XX
XX WPI; 2003-874615/81.
DR
XX Immunostimulatory composition for stimulating cytokine secretion and for
PT inducing immune response to target antigen in mammal, comprises nucleic
PT acid polymer encapsulated in lipid particle comprising cationic lipid.
XX
XX Example; SEQ ID NO 1; Opp; English.
PS
XX The invention relates to an immunostimulatory composition which comprises
CC a nucleic acid polymer encapsulated in a lipid particle comprising a
CC cationic lipid. The invention is useful for stimulating cytokine
CC secretion in a mammal and for inducing an immune response to a target
CC antigen such as hepatitis B antigen or tumour associated antigen. The
CC present sequence is human ICAM-1 specific oligonucleotide. This sequence
CC is used in the exemplification of the invention
XX
XX . Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2100 TGACGGATGCCAGCTTGGC 2119
 Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 615

AAD50285/c

ID AAD50285 standard; DNA; 20 BP.

XX AC

XX AD50285;

XX DT 24-MAR-2003 (first entry)

XX DE Cholesterol-/Dialkylglycerol-conjugated oligonucleotide.

XX KW Therapy; research reagent; diagnostic; phosphorothioate backbone; ss.

XX KW Unidentified.

XX OS

XX FH Key

XX modified_base

XX Location/Qualifiers

XX 1..20

XX /*tag= a

XX /mod_base= OTHER

XX /note= "Phosphorothioate backbone"

XX modified_base

XX 1

XX /*tag= b

XX /mod_base= OTHER

XX /note= "Optionally linked to cholesterol or

XX Dialkylglycerol"

XX

PN WO200279216-A1.

XX

XX 10-OCT-2002.

XX

XX 29-MAR-2002; 2002WO-US010178.

XX PF

XX 30-MAR-2001; 2001US-00823031.

XX PR

XX (ISIS-) ISIS PHARM INC.

XX PA

XX Manoharan M, Guzaev A;

XX PI

XX WPI; 2003-103258/09.

XX DR

XX New method for preparing an oligonucleotide useful e.g. in therapeutics

XX PT comprises treating derivatized solid support with acidic reagent to

XX PT deblock acid labile hydroxyl protecting group and reacting with

XX PT phosphoramidite and conjugate group.

XX

XX Example 29; Page 67; 111pp; English.

XX PS

XX The invention relates to a method for preparing an oligonucleotide by

XX CC treating derivatised solid support with acidic reagent to deblock acid

XX CC labile hydroxyl protecting group and reacting with phosphoramidite and

XX CC conjugate group. The method is useful for preparing compounds containing

XX CC phosphorus functionalities and oligomeric compounds containing monomeric

XX CC subunits joined by functionalities such as phosphate, phosphodiester,

XX CC phosphorothioate and/or phosphorodithioate residue; in diagnostics,

XX CC therapeutics and as research reagents and kits; for treating organisms

XX CC having a disease characterised by the undesired production of a protein.

XX CC The present sequence is an oligonucleotide used to illustrate the method

XX CC of the invention

XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.7%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2100 TGACGGATGCCAGCTTGGC 2119

Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 616

ABZ98387/c

ID ABZ98387 standard; DNA; 20 BP.

XX AC

XX ABZ98387;

XX DT 17-OCT-2003 (first entry)

XX DE Human ICAM oligonucleotide sequence.

XX

XX Human; antisense; lung dysfunction; nasal airway dysfunction;

XX KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

XX KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

XX KW lung inflammation; respiratory disease; ds.

XX

OS Homo sapiens.

XX

XX WO200285308-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013135.

XX

PR 24-APR-2001; 2001US-0286137P.

XX

XX (EPIG-) EPIGENESIS PHARM INC.

XX PA

NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX

XX WPI; 2003-229219/22.

XX

XX Pharmaceutical composition for treating ailments associated with impaired

XX PT respiration, has oligo(s) antisense to specific gene(s) or its

XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

XX PT ubiquinone.

XX

XX Disclosure; SEQ ID NO 13629; 872pp; English.

XX PS

XX The invention relates to a novel pharmaceutical composition, which has a

XX CC first active agent comprising an oligonucleotide antisense to the

XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

XX CC junctions of genes encoding a polypeptide associated with lung and/or

XX CC nasal airway dysfunction and a second active agent comprising an

XX CC antiinflammatory steroid and ubiquinone. A composition of the invention

XX CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

XX CC immunosuppressive, and cytostatic activity. The composition may have a

XX CC use in antisense gene therapy. The composition is useful for treating or

XX CC preventing a respiratory, lung or malignant disease or condition, also

XX CC for enhancing the prophylactic or therapeutic respiratory effect of an

XX CC antiinflammatory steroid in a subject, for reducing or depleting levels

XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or

XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

XX CC lung inflammation, lung allergies, or a respiratory disease or condition.

XX CC Note: The sequence data for this patent is not represented in the printed

XX CC specification, but was obtained in electronic format directly from WIPO

XX CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 20 BP; 4 A; 4 C; 3 G; 9 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.7%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1981 ATACAACTGGGAATACTGA 2000

Db 20 ATACAACTGGGAATACTGA 1

```
RESULT 617
ABZ98418/c
ID ABZ98418 standard; DNA; 20 BP.
XX
AC ABZ98418;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; bronchodilation; lung allergy;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13660; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 5 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1671 AGGGCCTCTTCCTCGGCCTT 1690
|||||
Db 20 AGGGCCTCTTCCTCGGCCTT 1
```

```
RESULT 618
ABZ98430/c
ID ABZ98430 standard; DNA; 20 BP.
XX
AC ABZ98430;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; bronchodilation; lung allergy;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13672; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1551 CAGCAGCGTACCTCTATACC 1570
|||||
Db 20 CAGCAGCGTACCTCTATACC 1
```

RESULT 619
ABZ98448/c
ID ABZ98448 standard; DNA; 20 BP.
XX
AC ABZ98448;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13690; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1371 ACTGCCCATCGGGGATCAG 1390
DB 20 ACTGCCCATCGGGGATCAG 1

RESULT 620
ABZ98470/c
ID ABZ98470 standard; DNA; 20 BP.
XX
AC ABZ98470;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13712; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 6 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1151 ACGGGCGGAGCTTCCTGCG 1170
DB 20 ACGGGCGGAGCTTCCTGCG 1

RESULT 621
ABZ98474/c
ID ABZ98474 standard; DNA; 20 BP.
XX
XX
AC ABZ98474;
XX
XX
DT 17-OCT-2003 (first entry)
XX
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX
FN WO200285308-A2.
XX
XX
PD 31-OCT-2002.
XX
XX
PF 23-APR-2002; 2002WO-US013135.
XX
XX
PR 24-APR-2001; 2001US-0286137P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX
DR WPI; 2003-229219/22.
XX
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX
PS Disclosure; SEQ ID NO 13716; 872pp; English.
XX
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1111 CCAGGCGCCAGCTCTGCT 1130
|||||
Db 20 CCAGGCGCCAGCTCTGCT 1

RESULT 622
ABZ98494/c
ID ABZ98494 standard; DNA; 20 BP.
XX
XX
AC ABZ98494;
XX
XX
DT 17-OCT-2003 (first entry)
XX
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX
FN WO200285308-A2.
XX
XX
PD 31-OCT-2002.
XX
XX
PF 23-APR-2002; 2002WO-US013135.
XX
XX
PR 24-APR-2001; 2001US-0286137P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX
DR WPI; 2003-229219/22.
XX
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX
PS Disclosure; SEQ ID NO 13736; 872pp; English.
XX
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 911 CCAGCGGCTGACGTGTGCA 930
|||||
Db 20 CCAGCGGCTGACGTGTGCA 1

RESULT 623
ABZ98503/c
ID ABZ98503 standard; DNA; 20 BP.
XX
AC ABZ98503;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13745; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 821 GGGACAGAGGTTGAACCCC 840
DB 20 GGGACAGAGGTTGAACCCC 1

RESULT 624
ABZ98509/c
ID ABZ98509 standard; DNA; 20 BP.
XX
AC ABZ98509;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13751; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 8 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 761 TGGTCTGTTCCCTGGACGGG 780
DB 20 TGGTCTGTTCCCTGGACGGG 1

RESULT 625
ABZ98518/C
ID ABZ98518 standard; DNA; 20 BP.
XX
AC ABZ98518;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13760; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 2 C; 12 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 671 CCCCTACGCTCCAGACC 690
|||||
DB 20 CCCCTACGCTCCAGACC 1

RESULT 626
ABZ98552/C
ID ABZ98552 standard; DNA; 20 BP.
XX
AC ABZ98552;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13794; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 331 TGCTATTCAACTGCCCTGA 350
|||||
DB 20 TGCTATTCAACTGCCCTGA 1

RESULT 627
ABZ98558/c
ID ABZ98558 standard; DNA; 20 BP.
XX
XX
AC ABZ98558;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13800; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 271 CCTGGGAACACCGGAAGT 290
DB 20 CCTGGGAACACCGGAAGT 1

RESULT 628
ABZ98384/c
ID ABZ98384 standard; DNA; 20 BP.
XX
XX
AC ABZ98384;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13626; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2011 CTATTGGGTATGCTAGGCC 2030
DB 20 CTATTGGGTATGCTAGGCC 1

RESULT 629
 ABZ98408/c
 ID ABZ98408 standard; DNA; 20 BP.
 XX AC ABZ98408;
 XX DT 17-OCT-2003 (first entry)
 XX DE Human ICAM oligonucleotide sequence.
 XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX OS Homo sapiens.
 XX PN WO200285308-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013135.
 XX PR 24-APR-2001; 2001US-0286137P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-229219/22.
 XX PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX PS Disclosure; SEQ ID NO 13650; 872pp; English.
 XX CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1771 CCGAGGACAGGGCATTGTC 1790
 |||||
 20 CCGAGGACAGGGCATTGTC 1

RESULT 630
 ABZ98428/c
 ID ABZ98428 standard; DNA; 20 BP.
 XX AC ABZ98428;
 XX DT 17-OCT-2003 (first entry)
 XX DE Human ICAM oligonucleotide sequence.
 XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX OS Homo sapiens.
 XX PN WO200285308-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013135.
 XX PR 24-APR-2001; 2001US-0286137P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-229219/22.
 XX PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX PS Disclosure; SEQ ID NO 13670; 872pp; English.
 XX CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 20 BP; 1 A; 6 C; 4 G; 9 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1571 GCCAGCGGAAGATCAAGAAA 1590
 |||||
 20 GCCAGCGGAAGATCAAGAAA 1

RESULT 631
ABZ98455/c
ID ABZ98455 standard; DNA; 20 BP.
XX
AC ABZ98455;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13697; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1301 AGACTCAATGTCAGGCT 1320
|||||
DB 20 AGACTCAATGTCAGGCT 1

RESULT 632
ABZ98461/c
ID ABZ98461 standard; DNA; 20 BP.
XX
AC ABZ98461;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13703; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1241 GCCCGGACTGACGAGG 1260
|||||
DB 20 GCCCGGACTGACGAGG 1

```
RESULT 633
ABZ98484/c
ID ABZ98484 standard; DNA; 20 BP.
XX
XX
AC ABZ98484;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
FN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13726; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1011 GAAGCCAGAGGTTCTCAGAAG 1030
DB 20 GAAGCCAGAGGTTCTCAGAAG 1
```

```
RESULT 634
ABZ98485/c
ID ABZ98485 standard; DNA; 20 BP.
XX
XX
AC ABZ98485;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
FN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13727; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1001 TGATTCTGACGAGCGACAG 1020
DB 20 TGATTCTGACGAGCGACAG 1
```

RESULT 635
 ABZ98486/c
 ID ABZ98486 standard; DNA; 20 BP.
 XX
 AC ABZ98486;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human ICAM oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-229219/22.
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 PS Disclosure; SEQ ID NO 13728; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 991 GCGCCCAACGTGATTCTGAC 1010
 DB 20 GCGCCCAACGTGATTCTGAC 1

RESULT 636
 ABZ98500/c
 ID ABZ98500 standard; DNA; 20 BP.
 XX
 AC ABZ98500;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human ICAM oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-229219/22.
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 PS Disclosure; SEQ ID NO 13742; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 851 ATGGCAACGACTCTCTCG 870
 DB 20 ATGGCAACGACTCTCTCG 1

RESULT 637
ABZ98506/c
ID ABZ98506 standard; DNA; 20 BP.
XX
AC ABZ98506;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13748; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 791 TCTCGAGGCCAGGTCCAC 810
|||||
Db 20 TCTCGAGGCCAGGTCCAC 1

RESULT 638
ABZ98526/c
ID ABZ98526 standard; DNA; 20 BP.
XX
AC ABZ98526;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13768; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 591 TCACCATGGAGCAATTCT 610
|||||
Db 20 TCACCATGGAGCAATTCT 1

RESULT 639

ABZ98529/c
ID ABZ98529 standard; DNA; 20 BP.

XX
AC ABZ98529;

XX
DT 17-OCT-2003 (first entry)

XX
DE Human ICAM oligonucleotide sequence.

XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;

XX
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

XX
KW antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy;

XX
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

XX
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

XX
KW lung inflammation; respiratory disease; ds.

XX
OS Homo sapiens.

XX
PN WO200285308-A2.

XX
PD 31-OCT-2002.

XX
PF 23-APR-2002; 2002WO-US013135.

XX
PR 24-APR-2001; 2001US-0286137P.

XX
PA (EPIG-) EPIGENESIS PHARM INC.

XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX
PI Miller S, Tang L, Shahabuddin S;

XX
DR WPI; 2003-229219/22.

XX
PT Pharmaceutical composition for treating ailments associated with impaired

PT respiration, has oligo(s) antisense to specific gene(s) or its

PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

PT ubiquinone.

XX
PS Disclosure; SEQ ID NO 13771; 872pp; English.

XX
CC The invention relates to a novel pharmaceutical composition, which has a

CC first active agent comprising an oligonucleotide antisense to the

CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an

CC antiinflammatory steroid and ubiquinone. A composition of the invention

CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

CC immunosuppressive, and cytostatic activity. The composition may have a

CC use in antisense gene therapy. The composition is useful for treating or

CC preventing a respiratory, lung or malignant disease or condition, also

CC for enhancing the prophylactic or therapeutic respiratory effect of an

CC antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

CC receptor, producing bronchodilation, increasing levels of ubiquinone or

CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

CC lung inflammation, lung allergies, or a respiratory disease or condition.

CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX
QY 561 GGTCACGACACCGTCTGG 580

XXXXXXXXXXXXXXXXXXXX

XX
DB 20 GGTCACGACACCGTCTGG 1

RESULT 640

ABZ98536/c
ID ABZ98536 standard; DNA; 20 BP.

XX
AC ABZ98536;

XX
DT 17-OCT-2003 (first entry)

XX
DE Human ICAM oligonucleotide sequence.

XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;

XX
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

XX
KW antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy;

XX
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

XX
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

XX
KW lung inflammation; respiratory disease; ds.

XX
OS Homo sapiens.

XX
PN WO200285308-A2.

XX
PD 31-OCT-2002.

XX
PF 23-APR-2002; 2002WO-US013135.

XX
PR 24-APR-2001; 2001US-0286137P.

XX
PA (EPIG-) EPIGENESIS PHARM INC.

XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX
PI Miller S, Tang L, Shahabuddin S;

XX
DR WPI; 2003-229219/22.

XX
PT Pharmaceutical composition for treating ailments associated with impaired

PT respiration, has oligo(s) antisense to specific gene(s) or its

PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

PT ubiquinone.

XX
PS Disclosure; SEQ ID NO 13778; 872pp; English.

XX
CC The invention relates to a novel pharmaceutical composition, which has a

CC first active agent comprising an oligonucleotide antisense to the

CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an

CC antiinflammatory steroid and ubiquinone. A composition of the invention

CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

CC immunosuppressive, and cytostatic activity. The composition may have a

CC use in antisense gene therapy. The composition is useful for treating or

CC preventing a respiratory, lung or malignant disease or condition, also

CC for enhancing the prophylactic or therapeutic respiratory effect of an

CC antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

CC receptor, producing bronchodilation, increasing levels of ubiquinone or

CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

CC lung inflammation, lung allergies, or a respiratory disease or condition.

CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX
QY 491 ACCTCACCGTGTGCTGCTC 510

XXXXXXXXXXXXXXXXXXXX

XX
DB 20 ACCTCACCGTGTGCTGCTC 1

RESULT 641
ABZ98542/C
ID ABZ98542 standard; DNA; 20 BP.
XX
XX AC ABZ98542;
XX
XX 17-OCT-2003 (first entry)
XX
XX DE Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX OS Homo sapiens.
XX
XX PN WO200285308-A2.
XX
XX PD 31-OCT-2002.
XX
XX PF 23-APR-2002; 2002WO-US013135.
XX
XX PR 24-APR-2001; 2001US-0286137P.
XX
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmacutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX PS Disclosure; SEQ ID NO 13784; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 431 AGCCAGTGGGCAAGAACCTT 450
|||||
Db 20 AGCCAGTGGGCAAGAACCTT 1

RESULT 642
ABZ98549/C
ID ABZ98549 standard; DNA; 20 BP.
XX
XX AC ABZ98549;
XX
XX 17-OCT-2003 (first entry)
XX
XX DE Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX OS Homo sapiens.
XX
XX PN WO200285308-A2.
XX
XX PD 31-OCT-2002.
XX
XX PF 23-APR-2002; 2002WO-US013135.
XX
XX PR 24-APR-2001; 2001US-0286137P.
XX
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmacutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX PS Disclosure; SEQ ID NO 13791; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 4 A; 1 C; 8 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 361 ACAGCTAAACCTTCTCTCAC 380
|||||
Db 20 ACAGCTAAACCTTCTCTCAC 1

RESULT 643

ABZ98555/c

ID ABZ98555 standard; DNA; 20 BP.

XX AC ABZ98555;

XX DT 17-OCT-2003 (first entry)

XX DE Human ICAM oligonucleotide sequence.

XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;

XX KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

XX KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;

XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

XX KW lung inflammation; respiratory disease; ds.

XX OS Homo sapiens.

XX PN WO200285308-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.

XX PR 24-APR-2001; 2001US-0286137P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX PI Miller S, Tang L, Shahabuddin S;

XX XX WPI; 2003-229219/22.

XX PT Pharmaceutical composition for treating ailments associated with impaired

XX PT respiration, has oligo(s) antisense to specific gene(s) or its

XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

XX PT ubiquinone.

XX PS Disclosure; SEQ ID NO 13797; 872pp; English.

XX CC The invention relates to a novel pharmaceutical composition, which has a

XX CC first active agent comprising an oligonucleotide antisense to the

XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

XX CC junctions of genes encoding a polypeptide associated with lung and/or

XX CC nasal airway dysfunction and a second active agent comprising an

XX CC antiinflammatory steroid and ubiquinone. A composition of the invention

XX CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

XX CC immunosuppressive, and cytotatic activity. The composition may have a

XX CC use in antisense gene therapy. The composition is useful for treating or

XX CC preventing a respiratory, lung or malignant disease or condition, also

XX CC for enhancing the prophylactic or therapeutic respiratory effect of an

XX CC antiinflammatory steroid in a subject, for reducing or depleting levels

XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or

XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

XX CC lung inflammation, lung allergies, or a respiratory disease or condition.

XX CC Note: The sequence data for this patent is not represented in the printed

XX CC specification, but was obtained in electronic format directly from WIPO

XX CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 20 BP; 3 A; 6 C; 2 G; 9 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 20; DB 1; Length 20;

XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;

XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX QY 301 AGCAATGTGCAAGAGATAG 320

XX DB 20 AGCAATGTGCAAGAGATAG 1

RESULT 644

ABZ98566/c

ID ABZ98566 standard; DNA; 20 BP.

XX AC ABZ98566;

XX DT 17-OCT-2003 (first entry)

XX DE Human ICAM oligonucleotide sequence.

XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;

XX KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

XX KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;

XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

XX KW lung inflammation; respiratory disease; ds.

XX OS Homo sapiens.

XX PN WO200285308-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.

XX PR 24-APR-2001; 2001US-0286137P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX PI Miller S, Tang L, Shahabuddin S;

XX XX WPI; 2003-229219/22.

XX PT Pharmaceutical composition for treating ailments associated with impaired

XX PT respiration, has oligo(s) antisense to specific gene(s) or its

XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

XX PT ubiquinone.

XX PS Disclosure; SEQ ID NO 13808; 872pp; English.

XX CC The invention relates to a novel pharmaceutical composition, which has a

XX CC first active agent comprising an oligonucleotide antisense to the

XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

XX CC junctions of genes encoding a polypeptide associated with lung and/or

XX CC nasal airway dysfunction and a second active agent comprising an

XX CC antiinflammatory steroid and ubiquinone. A composition of the invention

XX CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

XX CC immunosuppressive, and cytotatic activity. The composition may have a

XX CC use in antisense gene therapy. The composition is useful for treating or

XX CC preventing a respiratory, lung or malignant disease or condition, also

XX CC for enhancing the prophylactic or therapeutic respiratory effect of an

XX CC antiinflammatory steroid in a subject, for reducing or depleting levels

XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or

XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

XX CC lung inflammation, lung allergies, or a respiratory disease or condition.

XX CC Note: The sequence data for this patent is not represented in the printed

XX CC specification, but was obtained in electronic format directly from WIPO

XX CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 20; DB 1; Length 20;

XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;

XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX QY 191 TGGTGACATGCAGCACTCC 210

XX DB 20 TGGTGACATGCAGCACTCC 1

```
RESULT 645
ID ABZ98585/c
XX ABZ98585 standard; DNA; 20 BP.
XX AC ABZ98585;
XX 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
XX KW antinflammatory steroid; ubiquinone; antinflammatory; antiallergic;
XX KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX KW Pharmaceutical composition for treating ailments associated with impaired
XX PT respiration, has oligo(s) antisense to specific gene(s) or its
XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13827; 872pp; English.
XX KW The invention relates to a novel pharmaceutical composition, which has a
XX CC first active agent comprising an oligonucleotide antisense to the
XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX CC junctions of genes encoding a polypeptide associated with lung and/or
XX CC nasal airway dysfunction and a second active agent comprising an
XX CC antinflammatory steroid and ubiquinone. A composition of the invention
XX CC has antinflammatory, antiallergic, antiasthmatic, hypotensive,
XX CC immunosuppressive, and cytostatic activity. The composition may have a
XX CC use in antisense gene therapy. The composition is useful for treating or
XX CC preventing a respiratory, lung or malignant disease or condition, also
XX CC for enhancing the prophylactic or therapeutic respiratory effect of an
XX CC antinflammatory steroid in a subject, for reducing or depleting levels
XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or
XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX CC lung inflammation, lung allergies, or a respiratory disease or condition.
XX CC Note: The sequence data for this patent is not represented in the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 2 A; 7 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 GCGCCCGAGTCGAGCTGAG 20
|||||
DB 20 GCGCCCGAGTCGAGCTGAG 1

RESULT 646
ID ABZ99055
XX ABZ99055 standard; DNA; 20 BP.
XX AC ABZ99055;
XX 17-OCT-2003 (first entry)
XX DE Human PDE4C oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
XX KW antinflammatory steroid; ubiquinone; antinflammatory; antiallergic;
XX KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX KW Pharmaceutical composition for treating ailments associated with impaired
XX PT respiration, has oligo(s) antisense to specific gene(s) or its
XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX PT ubiquinone.
XX PS Disclosure; SEQ ID NO 14297; 872pp; English.
XX KW The invention relates to a novel pharmaceutical composition, which has a
XX CC first active agent comprising an oligonucleotide antisense to the
XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX CC junctions of genes encoding a polypeptide associated with lung and/or
XX CC nasal airway dysfunction and a second active agent comprising an
XX CC antinflammatory steroid and ubiquinone. A composition of the invention
XX CC has antinflammatory, antiallergic, antiasthmatic, hypotensive,
XX CC immunosuppressive, and cytostatic activity. The composition may have a
XX CC use in antisense gene therapy. The composition is useful for treating or
XX CC preventing a respiratory, lung or malignant disease or condition, also
XX CC for enhancing the prophylactic or therapeutic respiratory effect of an
XX CC antinflammatory steroid in a subject, for reducing or depleting levels
XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or
XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX CC lung inflammation, lung allergies, or a respiratory disease or condition.
XX CC Note: The sequence data for this patent is not represented in the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2771 CCCAGCTGAGTCGAGTCG 2790
|||||
DB 1 CCCAGCTGAGTCGAGTCG 20
```


RESULT 649
ABZ98410/C
ID ABZ98410 standard; DNA; 20 BP.
XX
AC ABZ98410;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13652; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1751 CACCTACCGCCCTGGAGC 1770
|||||
DB 20 CACCTACCGCCCTGGAGC 1

RESULT 650
ABZ98417/C
ID ABZ98417 standard; DNA; 20 BP.
XX
AC ABZ98417;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13659; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1681 CCTCGGCCTTCCCATATGG 1700
|||||
DB 20 CCTCGGCCTTCCCATATGG 1

RESULT 651
ABZ98422/C
ID ABZ98422 standard; DNA; 20 BP.
XX
XX
AC ABZ98422;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13664; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytosolic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 1 A; 3 C; 9 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1631 CGAACACACAGCCAGCCCT 1650
|||||
Db 20 CGAACACACAGCCAGCCCT 1

RESULT 652
ABZ98460/C
ID ABZ98460 standard; DNA; 20 BP.
XX
XX
AC ABZ98460;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13702; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytosolic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 3 A; 10 C; 3 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1251 GGACGAGAGGATGTCGG 1270
|||||
Db 20 GGACGAGAGGATGTCGG 1

RESULT 653
 ABZ98464/C
 ID ABZ98464 standard; DNA; 20 BP.
 XX
 AC ABZ98464;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human ICAM oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 24-APR-2001; 2001US-0286137P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 PI
 XX WPI; 2003-229219/22.
 XX
 XX Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 XX Disclosure; SEQ ID NO 13706; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1211 ACCAGACCCGGAGCTTCGT 1230
 |||||
 Db 20 ACCAGACCCGGAGCTTCGT 1

RESULT 654
 ABZ98467/C
 ID ABZ98467 standard; DNA; 20 BP.
 XX
 AC ABZ98467;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human ICAM oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 24-APR-2001; 2001US-0286137P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 PI
 XX WPI; 2003-229219/22.
 XX
 XX Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 XX Disclosure; SEQ ID NO 13709; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 20 BP; 4 A; 9 C; 5 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1181 TGGAGTGGCCGCCAGCTT 1200
 |||||
 Db 20 TGGAGTGGCCGCCAGCTT 1

RESULT 655

ABZ98469/c

ID ABZ98469 standard; DNA; 20 BP.

XX AC ABZ98469;

XX DT 17-OCT-2003 (first entry)

XX DE Human ICAM oligonucleotide sequence.

XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;

XX KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

XX KW antiasthmatic; hypotensive; immunosuppressive; cytosstatic; gene therapy;

XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

XX KW lung inflammation; respiratory disease; ds.

XX OS Homo sapiens.

XX PN WO200285308-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.

XX PR 24-APR-2001; 2001US-0286137P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX PI Miller S, Tang L, Shahabuddin S;

XX XX WPI; 2003-229219/22.

XX PT Pharmaceutical composition for treating ailments associated with impaired

XX PT respiration, has oligo(s) antisense to specific gene(s) or its

XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

XX PT ubiquinone.

XX PS Disclosure; SEQ ID NO 13711; 872pp; English.

XX CC The invention relates to a novel pharmaceutical composition, which has a

XX CC first active agent comprising an oligonucleotide antisense to the

XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

XX CC junctions of genes encoding a polypeptide associated with lung and/or

XX CC nasal airway dysfunction and a second active agent comprising an

XX CC antiinflammatory steroid and ubiquinone. A composition of the invention

XX CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

XX CC immunosuppressive, and cytostatic activity. The composition may have a

XX CC use in antisense gene therapy. The composition is useful for treating or

XX CC preventing a respiratory, lung or malignant disease or condition, also

XX CC for enhancing the prophylactic or therapeutic respiratory effect of an

XX CC antiinflammatory steroid in a subject, for reducing or depleting levels

XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or

XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

XX CC lung inflammation, lung allergies, or a respiratory disease or condition.

XX CC Note: The sequence data for this patent is not represented in the printed

XX CC specification, but was obtained in electronic format directly from WIPO

XX CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 20 BP; 6 A; 2 C; 10 G; 2 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.7%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1161 CTCTCTCTCTCTGCAACCC 1180

DB 20 CTCTCTCTCTCTGCAACCC 1

RESULT 656

ABZ98475/c

ID ABZ98475 standard; DNA; 20 BP.

XX AC ABZ98475;

XX DT 17-OCT-2003 (first entry)

XX DE Human ICAM oligonucleotide sequence.

XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;

XX KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

XX KW antiasthmatic; hypotensive; immunosuppressive; cytosstatic; gene therapy;

XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

XX KW lung inflammation; respiratory disease; ds.

XX OS Homo sapiens.

XX PN WO200285308-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.

XX PR 24-APR-2001; 2001US-0286137P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX PI Miller S, Tang L, Shahabuddin S;

XX XX WPI; 2003-229219/22.

XX PT Pharmaceutical composition for treating ailments associated with impaired

XX PT respiration, has oligo(s) antisense to specific gene(s) or its

XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

XX PT ubiquinone.

XX PS Disclosure; SEQ ID NO 13717; 872pp; English.

XX CC The invention relates to a novel pharmaceutical composition, which has a

XX CC first active agent comprising an oligonucleotide antisense to the

XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

XX CC junctions of genes encoding a polypeptide associated with lung and/or

XX CC nasal airway dysfunction and a second active agent comprising an

XX CC antiinflammatory steroid and ubiquinone. A composition of the invention

XX CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

XX CC immunosuppressive, and cytostatic activity. The composition may have a

XX CC use in antisense gene therapy. The composition is useful for treating or

XX CC preventing a respiratory, lung or malignant disease or condition, also

XX CC for enhancing the prophylactic or therapeutic respiratory effect of an

XX CC antiinflammatory steroid in a subject, for reducing or depleting levels

XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or

XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

XX CC lung inflammation, lung allergies, or a respiratory disease or condition.

XX CC Note: The sequence data for this patent is not represented in the printed

XX CC specification, but was obtained in electronic format directly from WIPO

XX CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 20 BP; 1 A; 8 C; 9 G; 2 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.7%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1101 GCCACTGGGCGGAGGGCCC 1120

DB 20 GCCACTGGGCGGAGGGCCC 1

RESULT 657
ABZ98476/C
ID ABZ98476 standard; DNA; 20 BP.
XX
XX
AC ABZ98476;
XX
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13718; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1091 TTCAGCCCGCCACTGGC 1110
|||||
Db 20 TTCAGCCCGCCACTGGC 1

RESULT 658
ABZ98481/C
ID ABZ98481 standard; DNA; 20 BP.
XX
XX
AC ABZ98481;
XX
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13723; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GACAGTGAAGTGTGAGGCC 1060
|||||
Db 20 GACAGTGAAGTGTGAGGCC 1

RESULT 659
ABZ98483/C
ID ABZ98483 standard; DNA; 20 BP.
XX
AC ABZ98483;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13725; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1021 GTCTCAGAGGACCGAGGT 1040
|||
DB 20 GTCTCAGAGGACCGAGGT 1

RESULT 660
ABZ98489/C
ID ABZ98489 standard; DNA; 20 BP.
XX
AC ABZ98489;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13731; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 961 CTCGACAGAGTGACCATCTA 980
|||
DB 20 CTCGACAGAGTGACCATCTA 1

RESULT 661
ABZ98495/c
ID ABZ98495 standard; DNA; 20 BP.
XX
AC ABZ98495;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13737; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 901 GACGAGGGCACCCAGCGGCT 920
|||
DB 20 GACGAGGGCACCCAGCGGCT 1

RESULT 662
ABZ98496/c
ID ABZ98496 standard; DNA; 20 BP.
XX
AC ABZ98496;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13738; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 0 A; 9 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 891 GACCGCAGAGCAGCGGCA 910
|||
DB 20 GACCGCAGAGCAGCGGCA 1

RESULT 663
 ABZ98519/c
 ID ABZ98519 standard; DNA; 20 BP.
 XX
 AC ABZ98519;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human ICAM oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-229219/22.
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 PS Disclosure; SEQ ID NO 13761; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 2 A; 2 C; 11 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 661 AACACCTCGGCCCTACCA 680
 |||||
 20 AACACCTCGGCCCTACCA 1
 Db

RESULT 664
 ABZ98547/c
 ID ABZ98547 standard; DNA; 20 BP.
 XX
 AC ABZ98547;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human ICAM oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-229219/22.
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 PS Disclosure; SEQ ID NO 13789; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 381 CGTGTAAGTCCAGAAC 400
 |||||
 20 CGTGTAAGTCCAGAAC 1
 Db

```
RESULT 665
ABZ98561/C
ID ABZ98561 standard; DNA; 20 BP.
XX
AC ABZ98561;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WIPI; 2003-229219/22.
XX
DR
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13803; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 241 ACCCGTTGCTAAAGA 260
DB 20 ACCCGTTGCTAAAGA 1
```

```
RESULT 666
ABZ98563/C
ID ABZ98563 standard; DNA; 20 BP.
XX
AC ABZ98563;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WIPI; 2003-229219/22.
XX
DR
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13805; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 221 CCAAGTTGTCGATAG 240
DB 20 CCAAGTTGTCGATAG 1
```

RESULT 667
ABZ98568/c
ID ABZ98568 standard; DNA; 20 BP.
XX
XX
AC ABZ98568;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13810; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytotatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 9 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 171 GCCCGGGGAGGCTCGTGC 190
|||||
DB 20 GCCCGGGGAGGCTCGTGC 1

RESULT 668
ABZ98574/c
ID ABZ98574 standard; DNA; 20 BP.
XX
XX
AC ABZ98574;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13816; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytotatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 111 GGCTCTGTTCCAGGACCTG 130
|||||
DB 20 GGCTCTGTTCCAGGACCTG 1

RESULT 669
ABZ98581/c
ID ABZ98581 standard; DNA; 20 BP.
XX AC
XX ABZ98581;
DT 17-OCT-2003 (first entry)
XX DE
XX Human ICAM oligonucleotide sequence.
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS
XX Homo sapiens.
XX WO200285308-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
XX 24-APR-2001; 2001US-0286137P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Disclosure; SEQ ID NO 13823; 872pp; English.
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACTCAGCCTCGCTATG 60
|||||
DB 20 GCAACTCAGCCTCGCTATG 1

RESULT 670
ABZ98582/c
ID ABZ98582 standard; DNA; 20 BP.
XX AC
XX ABZ98582;
DT 17-OCT-2003 (first entry)
XX DE
XX Human ICAM oligonucleotide sequence.
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS
XX Homo sapiens.
XX WO200285308-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
XX 24-APR-2001; 2001US-0286137P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Disclosure; SEQ ID NO 13824; 872pp; English.
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 31 ACTCAGATTGCAACCTCAG 50
|||||
DB 20 ACTCAGATTGCAACCTCAG 1

RESULT 671
ABZ98411/c
ID ABZ98411 standard; DNA; 20 BP.
XX
AC ABZ98411;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13653; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1741 CATGAGCTACACCTACCGG 1760
DB 20 CATGAGCTACACCTACCGG 1

RESULT 672
ABZ98492/c
ID ABZ98492 standard; DNA; 20 BP.
XX
AC ABZ98492;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13734; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 931 GTAATCTGGGACACGAG 950
DB 20 GTAATCTGGGACACGAG 1

RESULT 673
ABZ98493/c
ID ABZ98493 standard; DNA; 20 BP.
XX
AC ABZ98493;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13735; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 921 GACGTGTGACGTAATCTGG 940
|||||
Db 20 GACGTGTGACGTAATCTGG 1

RESULT 674
ABZ98498/c
ID ABZ98498 standard; DNA; 20 BP.
XX
AC ABZ98498;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13740; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 871 GCCAGGCCTCAGTCAGTGT 890
|||||
Db 20 GCCAGGCCTCAGTCAGTGT 1

RESULT 675
ABZ98531/c
ID ABZ98531 standard; DNA; 20 BP.

XX AC ABZ98531;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.

XX OS Homo sapiens.

XX PN WO200285308-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.

XX PR 24-APR-2001; 2001US-0286137P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-229219/22.

XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX PS Disclosure; SEQ ID NO 13773; 872pp; English.

XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 20 BP; 3 A; 10 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 541 GCTGTGGGGGAGCCCGCTGA 560
Db 20 GCTGTGGGGGAGCCCGCTGA 1

RESULT 676

ABZ98533/c
ID ABZ98533 standard; DNA; 20 BP.

XX AC ABZ98533;

XX DT 17-OCT-2003 (first entry)

XX DE Human ICAM oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.

XX OS Homo sapiens.

XX PN WO200285308-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.

XX PR 24-APR-2001; 2001US-0286137P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-229219/22.

XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX PS Disclosure; SEQ ID NO 13775; 872pp; English.

XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 20 BP; 1 A; 8 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 521 AGGAGCTGAACGGGAGCCA 540
Db 20 AGGAGCTGAACGGGAGCCA 1

RESULT 677
ABZ98560/c
ID ABZ98560 standard; DNA; 20 BP.
XX AC ABZ98560;
XX
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13802; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 251 CTAAGAGGAGTGTCTCTG 270
|||||
Db 20 CTAAGAGGAGTGTCTCTG 1

RESULT 678
ABZ98562/c
ID ABZ98562 standard; DNA; 20 BP.
XX AC ABZ98562;
XX
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13804; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 231 GGGCATAGACCCCGTTGC 250
|||||
Db 20 GGGCATAGACCCCGTTGC 1

RESULT 679

ABZ98567/c
ID ABZ98567 standard; DNA; 20 BP.

XX
AC ABZ98567;

XX
DT 17-OCT-2003 (first entry)

XX
DE Human ICAM oligonucleotide sequence.

XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosstatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX
OS Homo sapiens.

XX
PN WO200285308-A2.

XX
PD 31-OCT-2002.

XX
PF 23-APR-2002; 2002WO-US013135.

XX
PR 24-APR-2001; 2001US-0286137P.

XX
PA (EPIG-) EPIGENESIS PHARM INC.

XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;

XX
DR WPI; 2003-229219/22.

XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX
PS Disclosure; SEQ ID NO 13809; 872pp; English.

XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytosstatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_sequences

XX
SQ Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 181 GGCTCCGTCGTGGTGCATG 200

DB 20 GGCTCCGTCGTGGTGCATG 1

RESULT 680

ABZ98570/c
ID ABZ98570 standard; DNA; 20 BP.

XX
AC ABZ98570;

XX
DT 17-OCT-2003 (first entry)

XX
DE Human ICAM oligonucleotide sequence.

XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosstatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX
OS Homo sapiens.

XX
PN WO200285308-A2.

XX
PD 31-OCT-2002.

XX
PF 23-APR-2002; 2002WO-US013135.

XX
PR 24-APR-2001; 2001US-0286137P.

XX
PA (EPIG-) EPIGENESIS PHARM INC.

XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;

XX
DR WPI; 2003-229219/22.

XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX
PS Disclosure; SEQ ID NO 13812; 872pp; English.

XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytosstatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_sequences

XX
SQ Sequence 20 BP; 5 A; 1 C; 9 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 151 TCCCTCTCAAAAGTCATCT 170

DB 20 TCCCTCTCAAAAGTCATCT 1

RESULT 681
 ABZ98434/C
 ID ABZ98434 standard; DNA; 20 BP.
 XX
 AC ABZ98434;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human ICAM oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-229219/22.
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 PS Disclosure; SEQ ID NO 13676; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1511 CTGTGTAGCAGCGCAGTC 1530
 Db 20 CTGTGTAGCAGCGCAGTC 1

RESULT 682
 ABZ98447/C
 ID ABZ98447 standard; DNA; 20 BP.
 XX
 AC ABZ98447;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human ICAM oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-229219/22.
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 PS Disclosure; SEQ ID NO 13689; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1381 GGGGAATCAGTCACTGTAC 1400
 Db 20 GGGGAATCAGTCACTGTAC 1

RESULT 683
ABZ98472/c
ID ABZ98472 standard; DNA; 20 BP.
XX AC ABZ98472;
XX AC ABZ98472;
DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX KW Pharmacutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13714; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 0 A; 6 C; 7 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1131 GAAGGGCCACCCAGAGGACA 1150
Db 20 GAAGGGCCACCCAGAGGACA 1

RESULT 684
ABZ98501/c
ID ABZ98501 standard; DNA; 20 BP.
XX AC ABZ98501;
XX AC ABZ98501;
DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX KW Pharmacutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13743; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 841 ACAGTCACCTATGGCAACGA 860
Db 20 ACAGTCACCTATGGCAACGA 1

RESULT 685
ABZ98505/c
ID ABZ98505 standard; DNA; 20 BP.
XX AC
XX ABZ98505;
XX AC
XX 17-OCT-2003 (first entry)
DT
XX DE
XX Human ICAM oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX OS
XX Homo sapiens.
XX PN WO200285308-A2.
XX 31-OCT-2002.
XX PD
XX 23-APR-2002; 2002WO-US013135.
XX PF
XX 24-APR-2001; 2001US-0286137P.
XX PR
XX (SPIG-) EPIGENESIS PHARM INC.

XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX Disclosure; SEQ ID NO 13747; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 801 CCAGGTCCACTGGCACTGG 820
DB 20 CCAGGTCCACTGGCACTGG 1

RESULT 686
ABZ98523/c
ID ABZ98523 standard; DNA; 20 BP.
XX AC
XX ABZ98523;
XX AC
XX 17-OCT-2003 (first entry)
DT
XX DE
XX Human ICAM oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX OS
XX Homo sapiens.
XX PN WO200285308-A2.
XX 31-OCT-2002.
XX PD
XX 23-APR-2002; 2002WO-US013135.
XX PF
XX 24-APR-2001; 2001US-0286137P.
XX PR
XX (EPIG-) EPIGENESIS PHARM INC.

XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX Disclosure; SEQ ID NO 13765; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 621 TGAACCTGGACCTGGCGCCCC 640
DB 20 TGAACCTGGACCTGGCGCCCC 1

RESULT 687

ABZ98556/c
ID ABZ98556 standard; DNA; 20 BP.

XX

XX

AC ABZ98556;

XX

XX

DT 17-OCT-2003 (first entry)

XX

XX

DE Human ICAM oligonucleotide sequence.

XX

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;

KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

KW lung inflammation; respiratory disease; ds.

XX

OS Homo sapiens.

XX

XX

PN WO200285308-A2.

XX

XX

PD 31-OCT-2002.

XX

XX

PF 23-APR-2002; 2002WO-US013135.

XX

XX

PR 24-APR-2001; 2001US-0286137P.

XX

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

XX

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX

XX

DR WPI; 2003-229219/22.

XX

XX

PT Pharmaceutical composition for treating ailments associated with impaired

PT respiration, has oligo(s) antisense to specific gene(s) or its

PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

PT ubiquinone.

XX

XX

PS Disclosure; SEQ ID NO 13798; 872pp; English.

XX

XX

CC The invention relates to a novel pharmaceutical composition, which has a

CC first active agent comprising an oligonucleotide antisense to the

CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an

CC antiinflammatory steroid and ubiquinone. A composition of the invention

CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

CC immunosuppressive, and cytostatic activity. The composition may have a

CC use in antisense gene therapy. The composition is useful for treating or

CC preventing a respiratory, lung or malignant disease or condition, also

CC for enhancing the prophylactic or therapeutic respiratory effect of an

CC antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

CC receptor, producing bronchodilation, increasing levels of ubiquinone or

CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

CC lung inflammation, lung allergies, or a respiratory disease or condition.

CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_sequences

XX

XX

SQ Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 291 GTATGAAGTGGCAATGTC 310

DB 20 GTATGAAGTGGCAATGTC 1

RESULT 688

ABZ98379/c
ID ABZ98379 standard; DNA; 20 BP.

XX

XX

AC ABZ98379;

XX

XX

DT 17-OCT-2003 (first entry)

XX

XX

DE Human ICAM oligonucleotide sequence.

XX

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;

KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

KW lung inflammation; respiratory disease; ds.

XX

OS Homo sapiens.

XX

XX

PN WO200285308-A2.

XX

XX

PD 31-OCT-2002.

XX

XX

PF 23-APR-2002; 2002WO-US013135.

XX

XX

PR 24-APR-2001; 2001US-0286137P.

XX

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

XX

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX

XX

DR WPI; 2003-229219/22.

XX

XX

PT Pharmaceutical composition for treating ailments associated with impaired

PT respiration, has oligo(s) antisense to specific gene(s) or its

PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

PT ubiquinone.

XX

XX

PS Disclosure; SEQ ID NO 13621; 872pp; English.

XX

XX

CC The invention relates to a novel pharmaceutical composition, which has a

CC first active agent comprising an oligonucleotide antisense to the

CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

CC junctions of genes encoding a polypeptide associated with lung and/or

CC nasal airway dysfunction and a second active agent comprising an

CC antiinflammatory steroid and ubiquinone. A composition of the invention

CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

CC immunosuppressive, and cytostatic activity. The composition may have a

CC use in antisense gene therapy. The composition is useful for treating or

CC preventing a respiratory, lung or malignant disease or condition, also

CC for enhancing the prophylactic or therapeutic respiratory effect of an

CC antiinflammatory steroid in a subject, for reducing or depleting levels

CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

CC receptor, producing bronchodilation, increasing levels of ubiquinone or

CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

CC lung inflammation, lung allergies, or a respiratory disease or condition.

CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at ftp.wipo.int/pub/published_sequences

XX

XX

SQ Sequence 20 BP; 5 A; 4 C; 3 G; 8 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2060 TAGACATGTGTAGCATCAAA 2079

DB 20 TAGACATGTGTAGCATCAAA 1

RESULT 689
 ABZ98394/C
 ID ABZ98394 standard; DNA; 20 BP.
 XX
 AC ABZ98394;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human ICAM oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-229219/22.
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 PS Disclosure; SEQ ID NO 13636; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 8 A; 5 C; 1 G; 6 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1911 TTGATGATGTTAAAGTCTA 1930
 |||||
 DB 20 TTGATGATGTTAAAGTCTA 1

RESULT 690
 ABZ98412/C
 ID ABZ98412 standard; DNA; 20 BP.
 XX
 AC ABZ98412;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human ICAM oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-229219/22.
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 PS Disclosure; SEQ ID NO 13654; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1731 AGACATATGCCATGCAGCTA 1750
 |||||
 DB 20 AGACATATGCCATGCAGCTA 1

```
RESULT 691
ABZ98413/c
ID ABZ98413 standard; DNA; 20 BP.
XX
XX
AC ABZ98413;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13655; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytosatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 3 A; 6 C; 3 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1721 ACAGAGTGGAGACATATGC 1740
Db 20 ACAGAGTGGAGACATATGC 1

RESULT 692
ABZ98431/c
ID ABZ98431 standard; DNA; 20 BP.
XX
XX
AC ABZ98431;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13673; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytosatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1541 CTGCAGGCTTCAGCAGGTAC 1560
Db 20 CTGCAGGCTTCAGCAGGTAC 1
```

RESULT 693
ABZ98437/C
ID ABZ98437 standard; DNA; 20 BP.
XX
AC ABZ98437;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WI PI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13679; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1481 TCTCCCCCGGTATGAGATT 1500
|||||
Db 20 TCTCCCCCGGTATGAGATT 1

RESULT 694
ABZ98446/C
ID ABZ98446 standard; DNA; 20 BP.
XX
AC ABZ98446;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WI PI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13688; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1391 TGACTGTCTCAGATCTT 1410
|||||
Db 20 TGACTGTCTCAGATCTT 1

RESULT 695

ABZ98456/c

ID ABZ98456 standard; DNA; 20 BP.

XX

AC ABZ98456;

XX

DT 17-OCT-2003 (first entry)

XX

DE Human ICAM oligonucleotide sequence.

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

OS Homo sapiens.

XX

PN WO200285308-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013135.

XX

PR 24-APR-2001; 2001US-0286137P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX

DR WPI; 2003-229219/22.

XX

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX

PS Disclosure; SEQ ID NO 13698; 872pp; English.

XX

CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytosolic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine or
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 20 BP; 4 A; 2 C; 7 G; 7 T; 0 U; 0 Other;

XX

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1291 AATCCAGAGACTCAAT 1310

DB

20 AATCCAGAGACTCAAT 1

RESULT 696

ABZ98462/c

ID ABZ98462 standard; DNA; 20 BP.

XX

AC ABZ98462;

XX

DT 17-OCT-2003 (first entry)

XX

DE Human ICAM oligonucleotide sequence.

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

OS Homo sapiens.

XX

PN WO200285308-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013135.

XX

PR 24-APR-2001; 2001US-0286137P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX

DR WPI; 2003-229219/22.

XX

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX

PS Disclosure; SEQ ID NO 13704; 872pp; English.

XX

CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytosolic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine or
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

XX

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1231 GTCTGTATGGCCCCGACT 1250

DB

20 GTCTGTATGGCCCCGACT 1

RESULT 697
ABZ98482/c
ID ABZ98482 standard; DNA; 20 BP.
XX AC
XX ABZ98482;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIC-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX Pharmacutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Disclosure; SEQ ID NO 13724; 872pp; English.
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX Sequence 20 BP; 2 A; 9 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1031 GGACCGAGGTGACAGTGAAG 1050
Db 20 GGACCGAGGTGACAGTGAAG 1

RESULT 698
ABZ98512/c
ID ABZ98512 standard; DNA; 20 BP.
XX AC
XX ABZ98512;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIC-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX Pharmacutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Disclosure; SEQ ID NO 13754; 872pp; English.
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 731 GGGTCTTAGAGGTGGACACG 750
Db 20 GGGTCTTAGAGGTGGACACG 1

RESULT 699

ABZ98530/c

ID ABZ98530 standard; DNA; 20 BP.

XX

AC ABZ98530;

XX

DT 17-OCT-2003 (first entry)

XX

DE Human ICAM oligonucleotide sequence.

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;

KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

KW lung inflammation; respiratory disease; ds.

XX

OS Homo sapiens.

XX

PN WO200285308-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013135.

XX

PR 24-APR-2001; 2001US-0286137P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX

DR WPI; 2003-229219/22.

XX

Pharmaceutical composition for treating ailments associated with impaired respiration, has oligo(s) antisense to specific gene(s) or its corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or ubiquinone.

XX

PS Disclosure; SEQ ID NO 13772; 872pp; English.

XX

The invention relates to a novel pharmaceutical composition, which has a first active agent comprising an oligonucleotide antisense to the initiation codon, coding region, 5' or 3' end genomic flanking regions, 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of junctions of genes encoding a polypeptide associated with lung and/or nasal airway dysfunction and a second active agent comprising an antiinflammatory steroid and ubiquinone. A composition of the invention has antiinflammatory, antiallergic, antiasthmatic, hypotensive, immunosuppressive, and cytostatic activity. The composition may have a use in antisense gene therapy. The composition is useful for treating or preventing a respiratory, lung or malignant disease or condition, also for enhancing the prophylactic or therapeutic respiratory effect of an antiinflammatory steroid in a subject, for reducing or depleting levels of, or reducing sensitivity to adenosine, reducing levels of adenosine receptor, producing bronchodilation, increasing levels of ubiquinone or lung surfactant in a subject's tissue, or treating bronchoconstriction, lung inflammation, lung allergies, or a respiratory disease or condition. Note: The sequence data for this patent is not represented in the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

XX

Sequence 20 BP; 2 A; 6 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

SQ

QY

551 AGCCCGCTGAGTCAAGACC 570

DB

20 AGCCCGCTGAGTCAAGACC 1

RESULT 700

ABZ98575/c

ID ABZ98575 standard; DNA; 20 BP.

XX

AC ABZ98575;

XX

DT 17-OCT-2003 (first entry)

XX

DE Human ICAM oligonucleotide sequence.

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;

KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

KW lung inflammation; respiratory disease; ds.

XX

OS Homo sapiens.

XX

PN WO200285308-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013135.

XX

PR 24-APR-2001; 2001US-0286137P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX

DR WPI; 2003-229219/22.

XX

Pharmaceutical composition for treating ailments associated with impaired respiration, has oligo(s) antisense to specific gene(s) or its corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or ubiquinone.

XX

PS Disclosure; SEQ ID NO 13817; 872pp; English.

XX

The invention relates to a novel pharmaceutical composition, which has a first active agent comprising an oligonucleotide antisense to the initiation codon, coding region, 5' or 3' end genomic flanking regions, 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of junctions of genes encoding a polypeptide associated with lung and/or nasal airway dysfunction and a second active agent comprising an antiinflammatory steroid and ubiquinone. A composition of the invention has antiinflammatory, antiallergic, antiasthmatic, hypotensive, immunosuppressive, and cytostatic activity. The composition may have a use in antisense gene therapy. The composition is useful for treating or preventing a respiratory, lung or malignant disease or condition, also for enhancing the prophylactic or therapeutic respiratory effect of an antiinflammatory steroid in a subject, for reducing or depleting levels of, or reducing sensitivity to adenosine, reducing levels of adenosine receptor, producing bronchodilation, increasing levels of ubiquinone or lung surfactant in a subject's tissue, or treating bronchoconstriction, lung inflammation, lung allergies, or a respiratory disease or condition. Note: The sequence data for this patent is not represented in the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences

SQ

Sequence 20 BP; 7 A; 6 C; 7 G; 0 T; 0 U; 0 Other;

Query Match

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY

101 TCCTGCTCGGGCTCTGTTTC 120

DB

20 TCCTGCTCGGGCTCTGTTTC 1

RESULT 701
ABZ98583/C
ID ABZ98583 standard; DNA; 20 BP.
XX AC ABZ98583;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antitense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antitense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antitense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13825; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antitense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antitense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 7 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 CTCCTCTGCTACTCAGATT 40
|||||
Db 20 CTCCTCTGCTACTCAGATT 1

RESULT 702
ABZ98388/C
ID ABZ98388 standard; DNA; 20 BP.
XX AC ABZ98388;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antitense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antitense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antitense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13630; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antitense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antitense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1971 CCATGAGGACATACACTGG 1990
|||||
Db 20 CCATGAGGACATACACTGG 1

RESULT 703
ABZ98424/c
ID ABZ98424 standard; DNA; 20 BP.
XX
XX
AC ABZ98424;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
DE
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13666; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 1 A; 4 C; 6 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1611 AAAAGGAGCCCATGTAAC 1630
|||||
DB 20 AAAAGGAGCCCATGTAAC 1

RESULT 704
ABZ98425/c
ID ABZ98425 standard; DNA; 20 BP.
XX
XX
AC ABZ98425;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
DE
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13667; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 0 A; 5 C; 6 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1601 AACAGGCCCAAAAGGGACC 1620
|||||
DB 20 AACAGGCCCAAAAGGGACC 1

RESULT 707

ABZ98507/C

ID ABZ98507 standard; DNA; 20 BP.

XX AC ABZ98507;

XX DT 17-OCT-2003 (first entry)

XX DE Human ICAM oligonucleotide sequence.

XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;

XX KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

XX KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

XX KW lung inflammation; respiratory disease; ds.

XX OS Homo sapiens.

XX PN WO200285308-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.

XX PR 24-APR-2001; 2001US-0286137P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX PI Miller S, Tang L, Shahabuddin S;

XX DR WPI; 2003-229219/22.

XX PT Pharmaceutical composition for treating ailments associated with impaired

XX PT respiration, has oligo(s) antisense to specific gene(s) or its

XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

XX PT ubiquinone.

XX PS Disclosure; SEQ ID NO 13749; 872pp; English.

XX CC The invention relates to a novel pharmaceutical composition, which has a

XX CC first active agent comprising an oligonucleotide antisense to the

XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

XX CC junctions of genes encoding a polypeptide associated with lung and/or

XX CC nasal airway dysfunction and a second active agent comprising an

XX CC antiinflammatory steroid and ubiquinone. A composition of the invention

XX CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

XX CC immunosuppressive, and cytostatic activity. The composition may have a

XX CC use in antisense gene therapy. The composition is useful for treating or

XX CC preventing a respiratory, lung or malignant disease or condition, also

XX CC for enhancing the prophylactic or therapeutic respiratory effect of an

XX CC antiinflammatory steroid in a subject, for reducing or depleting levels

XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or

XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

XX CC lung inflammation, lung allergies, or a respiratory disease or condition.

XX CC Note: The sequence data for this patent is not represented in the printed

XX CC specification, but was obtained in electronic format directly from WIPO

XX CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 20 BP; 5 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.7%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 781 CTGTTCCAGTCTCGAGGC 800

DB 20 CTGTTCCAGTCTCGAGGC 1

RESULT 708

ABZ98377/C

ID ABZ98377 standard; DNA; 20 BP.

XX AC ABZ98377;

XX DT 17-OCT-2003 (first entry)

XX DE Human ICAM oligonucleotide sequence.

XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;

XX KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;

XX KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;

XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;

XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;

XX KW lung inflammation; respiratory disease; ds.

XX OS Homo sapiens.

XX PN WO200285308-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.

XX PR 24-APR-2001; 2001US-0286137P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX PI Miller S, Tang L, Shahabuddin S;

XX DR WPI; 2003-229219/22.

XX PT Pharmaceutical composition for treating ailments associated with impaired

XX PT respiration, has oligo(s) antisense to specific gene(s) or its

XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or

XX PT ubiquinone.

XX PS Disclosure; SEQ ID NO 13619; 872pp; English.

XX CC The invention relates to a novel pharmaceutical composition, which has a

XX CC first active agent comprising an oligonucleotide antisense to the

XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of

XX CC junctions of genes encoding a polypeptide associated with lung and/or

XX CC nasal airway dysfunction and a second active agent comprising an

XX CC antiinflammatory steroid and ubiquinone. A composition of the invention

XX CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,

XX CC immunosuppressive, and cytostatic activity. The composition may have a

XX CC use in antisense gene therapy. The composition is useful for treating or

XX CC preventing a respiratory, lung or malignant disease or condition, also

XX CC for enhancing the prophylactic or therapeutic respiratory effect of an

XX CC antiinflammatory steroid in a subject, for reducing or depleting levels

XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or

XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,

XX CC lung inflammation, lung allergies, or a respiratory disease or condition.

XX CC Note: The sequence data for this patent is not represented in the printed

XX CC specification, but was obtained in electronic format directly from WIPO

XX CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 20 BP; 2 A; 2 C; 9 G; 7 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.7%; Score 20; DB 1; Length 20;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2080 ACACAAGGCCACACTTCC 2099

DB 20 ACACAAGGCCACACTTCC 1

RESULT 709
ABZ98390/c
ID ABZ98390 standard; DNA; 20 BP.
XX
AC ABZ98390;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13632; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1951 GTGGGGGAGACATAGCCCCA 1970
Db 20 GTGGGGGAGACATAGCCCCA 1

RESULT 710
ABZ98393/c
ID ABZ98393 standard; DNA; 20 BP.
XX
AC ABZ98393;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13635; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1921 TTAAAGTCTAGCCTGATGAG 1940
Db 20 TTAAAGTCTAGCCTGATGAG 1

RESULT 711
ABZ98404/c
ID ABZ98404 standard; DNA; 20 BP.
XX AC ABZ98404;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX KW Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13646; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytotatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 6 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1811 TTGGGGCCATGCTACCTGC 1830
DB 20 TTGGGGCCATGCTACCTGC 1

RESULT 712
ABZ98415/c
ID ABZ98415 standard; DNA; 20 BP.
XX AC ABZ98415;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX KW Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13657; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytotatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1701 TGGCAGTGGTGCCACTGA 1720
DB 20 TGGCAGTGGTGCCACTGA 1

RESULT 713
ABZ98432/C
ID ABZ98432 standard; DNA; 20 BP.
XX
AC ABZ98432;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
FN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13674; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1531 ATAATGGGCACTGCGCCT 1550
|||||
DB 20 ATAATGGGCACTGCGCCT 1

RESULT 714
ABZ98449/C
ID ABZ98449 standard; DNA; 20 BP.
XX
AC ABZ98449;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
FN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13691; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 2 C; 10 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1361 GCACCTTCCCACTGCCCATC 1380
|||||
DB 20 GCACCTTCCCACTGCCCATC 1

RESULT 715
ABZ98465/c
ID ABZ98465 standard; DNA; 20 BP.
XX
AC ABZ98465;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13707; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 1 A; 3 C; 7 G; 9 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1201 ATACACAGAACGACGACCG 1220
|||||
20 ATACACAGAACGACGACCG 1
Db

RESULT 716
ABZ98466/c
ID ABZ98466 standard; DNA; 20 BP.
XX
AC ABZ98466;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13708; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1191 CGCCAGCTTATACACAGA 1210
|||||
20 CGCCAGCTTATACACAGA 1
Db

RESULT 717
ABZ98477/C
ID ABZ98477 standard; DNA; 20 BP.
XX
AC ABZ98477;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13719; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1081 CTGAATGGGGTTCCAGCCCA 1100
|||||
Db 20 CTGAATGGGGTTCCAGCCCA 1

RESULT 718
ABZ98508/C
ID ABZ98508 standard; DNA; 20 BP.
XX
AC ABZ98508;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13750; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 771 CCTGGACGGGCTGTCCCG 790
|||||
Db 20 CCTGGACGGGCTGTCCCG 1

RESULT 719

ABZ98517/C
ID ABZ98517 standard; DNA; 20 BP.
XX
AC ABZ98517;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13759; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 681 GCTCCAGACCTTTGCTCTGC 700

DB 20 GCTCCAGACCTTTGCTCTGC 1

RESULT 720

ABZ98554/C.
ID ABZ98554 standard; DNA; 20 BP.
XX
AC ABZ98554;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13796; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 4 C; 4 G; 10 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 311 AAGAAGATAGCCCAACCAATG 330

DB 20 AAGAAGATAGCCCAACCAATG 1

```
RESULT 721
ABZ98569/C
ID ABZ98569 standard; DNA; 20 BP.
XX
XX
AC ABZ98569;
XX
XX 17-OCT-2003 (first entry)
DT
XX
XX Human ICAM oligonucleotide sequence.
DE
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX
XX WO200285308-A2.
FN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002WO-US013135.
PF
XX
XX 24-APR-2001; 2001US-0286137P.
PR
XX
XX (EPIC-) EPIGENESIS PHARM INC.
PA
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13811; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 161 AAGTCATCTGCCCCGGGA 180
DB 20 AAGTCATCTGCCCCGGGA 1
```

```
RESULT 722
ABZ98584/C
ID ABZ98584 standard; DNA; 20 BP.
XX
XX
AC ABZ98584;
XX
XX 17-OCT-2003 (first entry)
DT
XX
XX Human ICAM oligonucleotide sequence.
DE
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX
XX WO200285308-A2.
FN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002WO-US013135.
PF
XX
XX 24-APR-2001; 2001US-0286137P.
PR
XX
XX (EPIC-) EPIGENESIS PHARM INC.
PA
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13826; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 11 CGACGCTGAGCTCCTCTGCT 30
DB 20 CGACGCTGAGCTCCTCTGCT 1
```

RESULT 723

ABZ98380/c
ID ABZ98380 standard; DNA; 20 BP.
XX
XX AC ABZ98380;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13622; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2050 TGGCCCTCCATAGACATGTG 2069

Db 20 TGGCCCTCCATAGACATGTG 1

RESULT 724

ABZ98382/c
ID ABZ98382 standard; DNA; 20 BP.
XX
XX AC ABZ98382;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13624; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 2 A; 4 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2030 CCACAGACTTACAGAGAAG 2049

Db 20 CCACAGACTTACAGAGAAG 1

RESULT 725
ABZ98400/c
ID ABZ98400 standard; DNA; 20 BP.
XX AC ABZ98400;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX DE
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX
XX PT Pharmacological composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13642; 872pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1851 CGCATCTGATCTGTAGTCAC 1870
|||||
DB 20 CGCATCTGATCTGTAGTCAC 1

RESULT 726
ABZ98427/c
ID ABZ98427 standard; DNA; 20 BP.
XX AC ABZ98427;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX DE
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX
XX PT Pharmacological composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13669; 872pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 3 A; 3 C; 4 G; 10 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1581 GATCAAGAAATACAGACTAC 1600
|||||
DB 20 GATCAAGAAATACAGACTAC 1

RESULT 727
ABZ98468/c
ID ABZ98468 standard; DNA; 20 BP.
XX
XX
AC ABZ98468;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13710; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1171 TCTGCAACCTGGAGGTGGC 1190
|||||
DB 20 TCTGCAACCTGGAGGTGGC 1

RESULT 728
ABZ98491/c
ID ABZ98491 standard; DNA; 20 BP.
XX
XX
AC ABZ98491;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13733; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 0 A; 7 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 941 GGAACCCAGAGCCAGGAGACA 960
|||||
DB 20 GGAACCCAGAGCCAGGAGACA 1

```
RESULT 729
ABZ98527/c
ID ABZ98527 standard; DNA; 20 BP.
XX
XX
AC ABZ98527;
XX
XX
DT 17-OCT-2003 (first entry)
XX
XX
DE Human ICAM oligonucleotide sequence.
XX
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX
OS Homo sapiens.
XX
XX
PN WO200285308-A2.
XX
XX
PD 31-OCT-2002.
XX
XX
PF 23-APR-2002; 2002WO-US013135.
XX
XX
PR 24-APR-2001; 2001US-0286137P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX
DR WPI; 2003-229219/22.
XX
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX
PS Disclosure; SEQ ID NO 13769; 872pp; English.
XX
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 581 TGAGGAGAGATCACCATGGA 600
|||||
DB 20 TGAGGAGAGATCACCATGGA 1
```

```
RESULT 730
ABZ98535/c
ID ABZ98535 standard; DNA; 20 BP.
XX
XX
AC ABZ98535;
XX
XX
DT 17-OCT-2003 (first entry)
XX
XX
DE Human ICAM oligonucleotide sequence.
XX
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX
OS Homo sapiens.
XX
XX
PN WO200285308-A2.
XX
XX
PD 31-OCT-2002.
XX
XX
PF 23-APR-2002; 2002WO-US013135.
XX
XX
PR 24-APR-2001; 2001US-0286137P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX
DR WPI; 2003-229219/22.
XX
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX
PS Disclosure; SEQ ID NO 13777; 872pp; English.
XX
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX
SQ Sequence 20 BP; 4 A; 10 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 501 GGTGCTGCTCCGTGGGGAGA 520
|||||
DB 20 GGTGCTGCTCCGTGGGGAGA 1
```

RESULT 731
ABZ98544/C
ID ABZ98544 standard; DNA; 20 BP.
XX
AC ABZ98544;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13786; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 4 C; 11 G; 1 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e-02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 411 GGACACCCCTCCCTCTGGC 430
DB 20 GGACACCCCTCCCTCTGGC 1

RESULT 732
ABZ98565/C
ID ABZ98565 standard; DNA; 20 BP.
XX
AC ABZ98565;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13807; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 4 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e-02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 201 CAGCACCTCTCTGACCAGC 220
DB 20 CAGCACCTCTCTGACCAGC 1

RESULT 733	
ABZ98386/c	
ID	ABZ98386 standard; DNA; 20 BP.
XX	
AC	ABZ98386;
XX	
DT	17-OCT-2003 (first entry)
XX	
DE	Human ICAM oligonucleotide sequence.
XX	
KW	Human; antisense; lung dysfunction; nasal airway dysfunction;
KW	antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW	antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW	antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW	adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW	lung inflammation; respiratory disease; ds.
XX	
OS	Homo sapiens.
XX	
PN	WO200285308-A2.
XX	
PD	31-OCT-2002.
XX	
PF	23-APR-2002; 2002WO-US013135.
XX	
PR	24-APR-2001; 2001US-0286137P.
XX	
PA	(EPIG-) EPIGENESIS PHARM INC.
XX	
PI	Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI	Miller S, Tang L, Shahabuddin S;
XX	
DR	WPI; 2003-229219/22.
XX	
PT	Pharmaceutical composition for treating ailments associated with impaired
PT	respiration, has oligo(s) antisense to specific gene(s) or its
PT	corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT	ubiquinone.
XX	
PS	Disclosure; SEQ ID NO 13628; 872pp; English.
XX	
CC	The invention relates to a novel pharmaceutical composition, which has a
CC	first active agent comprising an oligonucleotide antisense to the
CC	initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC	5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC	junctions of genes encoding a polypeptide associated with lung and/or
CC	nasal airway dysfunction and a second active agent comprising an
CC	antiinflammatory steroid and ubiquinone. A composition of the invention
CC	has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC	immunosuppressive, and cytostatic activity. The composition may have a
CC	use in antisense gene therapy. The composition is useful for treating or
CC	preventing a respiratory, lung or malignant disease or condition, also
CC	for enhancing the prophylactic or therapeutic respiratory effect of an
CC	antiinflammatory steroid in a subject, for reducing or depleting levels
CC	of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC	receptor, producing bronchodilation, increasing levels of ubiquinone or
CC	lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC	lung inflammation, lung allergies, or a respiratory disease or condition.
CC	Note: The sequence data for this patent is not represented in the printed
CC	specification, but was obtained in electronic format directly from WIPO
CC	at ftp.wipo.int/pub/published_pct_sequences
XX	
SQ	Sequence 20 BP; 5 A; 4 C; 4 G; 7 T; 0 U; 0 Other;
	Query Match 0.7%; Score 20; DB 1; Length 20;
	Best Local Similarity 100.0%; Pred. No. 5 4e+02;
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0
Qy	1991 GAAATACTGAACCTTGCTGC 2010
Db	20 GAAATACTGAACCTTGCTGC 1

RESULT 734
ABZ98395/C
ID ABZ98395 standard; DNA; 20 BP.
XX AC ABZ98395;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antinflammatory steroid; ubiquinone; nasal airway dysfunction;
KW antiasthmatic; hypotensive; immunosuppressive; antiinflammatory; antiallergic;
KW antisenese gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyece JW, Li Y, Sandrasagra A, Katz B, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX ubiquinone.
PS Disclosure; SEQ ID NO 13637; 872pp; English.
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive, has a
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

Sequence 20 BP; 5 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1901 CAAGACATGATTGGTGGATG 1920
Db 20 CAAGACATGATTGGTGGATG 1

RESULT 735

ABZ98398/c

ID ABZ98398 standard; DNA; 20 BP.

XX

AC ABZ98398;

XX

DT 17-OCT-2003 (first entry)

XX

DE Human ICAM oligonucleotide sequence.

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX

OS Homo sapiens.

XX

PN WO200285308-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013135.

XX

PR 24-APR-2001; 2001US-0286137P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX

DR WPI; 2003-229219/22.

XX

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX

PS Disclosure; SEQ ID NO 13640; 872pp; English.

XX

CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 20 BP; 2 A; 6 C; 3 G; 9 T; 0 U; 0 Other;

XX

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1871 ATGACTAAGCCAGAGGAAG 1890

|||

20 ATGACTAAGCCAGAGGAAG 1

Db

RESULT 736

ABZ98401/c

ID ABZ98401 standard; DNA; 20 BP.

XX

AC ABZ98401;

XX

DT 17-OCT-2003 (first entry)

XX

DE Human ICAM oligonucleotide sequence.

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX

OS Homo sapiens.

XX

PN WO200285308-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013135.

XX

PR 24-APR-2001; 2001US-0286137P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX

DR WPI; 2003-229219/22.

XX

PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX

PS Disclosure; SEQ ID NO 13643; 872pp; English.

XX

CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX

SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

XX

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1841 CACTAGGCCACGATCTGAT 1860

|||

20 CACTAGGCCACGATCTGAT 1

Db

RESULT 737
ABZ98438/C
ID ABZ98438 standard; DNA; 20 BP.
XX
AC ABZ98438;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13680; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1471 GTCAATGTGCTCTCCCCCG 1490
|||||
Db 20 GTCAATGTGCTCTCCCCCG 1

RESULT 738
ABZ98441/C
ID ABZ98441 standard; DNA; 20 BP.
XX
AC ABZ98441;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13683; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1441 ACTCAAGGGGAGGTCAACCG 1460
|||||
Db 20 ACTCAAGGGGAGGTCAACCG 1

RESULT 739
ABZ98442/c
ID ABZ98442 standard; DNA; 20 BP.
XX
XX
AC ABZ98442;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13684; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1431 GGCCAGGAGCACTCAAGGG 1450
DB 20 GGCCAGGAGCACTCAAGGG 1

RESULT 740
ABZ98453/c
ID ABZ98453 standard; DNA; 20 BP.
XX
XX
AC ABZ98453;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13695; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1321 TGGGGGAACCCATTGCCCGA 1340
DB 20 TGGGGGAACCCATTGCCCGA 1

RESULT 741
AB298457/c
ID AB298457 standard; DNA; 20 BP.
XX AC AB298457;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13699; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1281 GTGCCAGAAAAATTCACG 1300
DB 20 GTGCCAGAAAAATTCACG 1

RESULT 742
AB298458/c
ID AB298458 standard; DNA; 20 BP.
XX AC AB298458;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13700; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1271 GAACTGGACGTGGCCAGAA 1290
DB 20 GAACTGGACGTGGCCAGAA 1

RESULT 743
ABZ98497/C
ID ABZ98497 standard; DNA; 20 BP.
XX
AC ABZ98497;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13739; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 881 CAGTCAGTGTGACCGCAGAG 900
DB 20 CAGTCAGTGTGACCGCAGAG 1

RESULT 744
ABZ98521/C
ID ABZ98521 standard; DNA; 20 BP.
XX
AC ABZ98521;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13763; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 9 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 641 AAGGCTGAGCTGTTTGAG 660
DB 20 AAGGCTGAGCTGTTTGAG 1

RESULT 745
ABZ98534/c
ID ABZ98534 standard; DNA; 20 BP.
XX
XX
AC ABZ98534;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13776; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 10 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 511 CGTGGGAGAGAGCTGAA 530
|||||
DB 20 CGTGGGAGAGAGCTGAA 1

RESULT 746
ABZ98559/c
ID ABZ98559 standard; DNA; 20 BP.
XX
XX
AC ABZ98559;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13801; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 261 GTTGCTCTGCTGGGACA 280
|||||
DB 20 GTTGCTCTGCTGGGACA 1

RESULT 747
ABZ98378/c
ID ABZ98378 standard; DNA; 20 BP.
XX
AC ABZ98378;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13620; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 3 C; 5 G; 10 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2070 TAGCATCAAAACACAAAGGC 2089
|||||
DB 20 TAGCATCAAAACACAAAGGC 1

RESULT 748
ABZ98381/c
ID ABZ98381 standard; DNA; 20 BP.
XX
AC ABZ98381;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13623; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2040 ACAGAGAAGTGGCCCTCCA 2059
|||||
DB 20 ACAGAGAAGTGGCCCTCCA 1

RESULT 749
ABZ98406/C
ID ABZ98406 standard; DNA; 20 BP.
XX
AC ABZ98406;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
FN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13648; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 3 C; 6 G; 8 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1791 CTCAGTCAGATACACAGCA 1810
|||||
DB 20 CTCAGTCAGATACACAGCA 1

RESULT 750
ABZ98444/C
ID ABZ98444 standard; DNA; 20 BP.
XX
AC ABZ98444;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
FN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13686; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1411 GAGGGCACCCTACTCTCTGCG 1430
|||||
DB 20 GAGGGCACCCTACTCTCTGCG 1

RESULT 751
ABZ98454/c
ID ABZ98454 standard; DNA; 20 BP.
XX
XX AC ABZ98454;
XX
XX DT 17-OCT-2003 (first entry)
XX
XX DE Human ICAM oligonucleotide sequence.
XX
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX OS Homo sapiens.
XX
XX PN WO200285308-A2.
XX
XX PD 31-OCT-2002.
XX
XX PF 23-APR-2002; 2002WO-US013135.
XX
XX PR 24-APR-2001; 2001US-0286137P.
XX
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX PS Disclosure; SEQ ID NO 13696; 872pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytotatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1311 GTCCAGGCTTGGGGGAACC 1330
|||||
Db 20 GTCCAGGCTTGGGGGAACC 1

RESULT 752
ABZ98471/c
ID ABZ98471 standard; DNA; 20 BP.
XX
XX AC ABZ98471;
XX
XX DT 17-OCT-2003 (first entry)
XX
XX DE Human ICAM oligonucleotide sequence.
XX
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX OS Homo sapiens.
XX
XX PN WO200285308-A2.
XX
XX PD 31-OCT-2002.
XX
XX PF 23-APR-2002; 2002WO-US013135.
XX
XX PR 24-APR-2001; 2001US-0286137P.
XX
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX PS Disclosure; SEQ ID NO 13713; 872pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytotatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 20 BP; 0 A; 8 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1141 CCAGGAGCAACGGCGCAG 1160
|||||
Db 20 CCAGGAGCAACGGCGCAG 1

RESULT 753
ABZ98541/c
ID ABZ98541 standard; DNA; 20 BP.
XX AC ABZ98541;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX DE Human; antitense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antitense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antitense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13783; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antitense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antitense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 441 CAAGAACCTTACCCCTAGCT 460
Db 20 CAAGAACCTTACCCCTAGCT 1

RESULT 754
ABZ98548/c
ID ABZ98548 standard; DNA; 20 BP.
XX AC ABZ98548;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX DE Human; antitense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antitense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antitense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13790; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antitense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antitense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 371 CCTTCTCACCCTGCTAGCT 390
Db 20 CCTTCTCACCCTGCTAGCT 1

RESULT 755
ABZ98553/C
ID ABZ98553 standard; DNA; 20 BP.
XX
XX
AC ABZ98553;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13795; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 2 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e-02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 321 CCAACCAATGCTATTCAA 340
DB 20 CCAACCAATGCTATTCAA 1

RESULT 756
ABZ98573/C
ID ABZ98573 standard; DNA; 20 BP.
XX
XX
AC ABZ98573;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13815; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e-02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 121 CCAGGACCTGGCAATGCCCA 140
DB 20 CCAGGACCTGGCAATGCCCA 1

RESULT 757
 ABZ98409/c
 ID ABZ98409 standard; DNA; 20 BP.
 XX AC
 XX ABZ98409;
 XX DT 17-OCT-2003 (first entry)
 XX DE Human ICAM oligonucleotide sequence.
 XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX OS Homo sapiens.
 XX PN WO200285308-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013135.
 XX PR 24-APR-2001; 2001US-0286137P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-229219/22.
 XX PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX PS Disclosure; SEQ ID NO 13651; 872pp; English.
 XX CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1761 CCTGGACCGCGAGACA 1780
 |||||
 Db 20 CCTGGACCGCGAGACA 1

RESULT 758
 ABZ98445/c
 ID ABZ98445 standard; DNA; 20 BP.
 XX AC
 XX ABZ98445;
 XX DT 17-OCT-2003 (first entry)
 XX DE Human ICAM oligonucleotide sequence.
 XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX OS Homo sapiens.
 XX PN WO200285308-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013135.
 XX PR 24-APR-2001; 2001US-0286137P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-229219/22.
 XX PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX PS Disclosure; SEQ ID NO 13687; 872pp; English.
 XX CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1401 TCGAGATCTTGAGGCACCT 1420
 |||||
 Db 20 TCGAGATCTTGAGGCACCT 1

RESULT 759
ABZ98450/c
ID ABZ98450 standard; DNA; 20 BP.
XX AC ABZ98450;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13692; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1351 CTAAGGATGGCACTTTCCC 1370
DB 20 CTAAGGATGGCACTTTCCC 1

RESULT 760
ABZ98516/c
ID ABZ98516 standard; DNA; 20 BP.
XX AC ABZ98516;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13758; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 691 TTGTCTCTCCGCGACTCC 710
DB 20 TTGTCTCTCCGCGACTCC 1

RESULT 761
ABZ98522/c
ID ABZ98522 standard; DNA; 20 BP.
XX AC ABZ98522;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13764; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 631 CTGCGGCCCAAGGGCTGGA 650
|||||
Db 20 CTGCGGCCCAAGGGCTGGA 1

RESULT 762
ABZ98537/c
ID ABZ98537 standard; DNA; 20 BP.
XX AC ABZ98537;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13779; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 2 A; 4 C; 11 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 481 CCCCAGGCGCAACCTCACCGT 500
|||||
Db 20 CCCCAGGCGCAACCTCACCGT 1

```
RESULT 763
ABZ98539/c
ID ABZ98539 standard; DNA; 20 BP.
XX
XX
AC ABZ98539;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
XX respiration, has oligo(s) antisense to specific gene(s) or its
XX corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX ubiquinone.
XX
XX Disclosure; SEQ ID NO 13781; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
XX first active agent comprising an oligonucleotide antisense to the
XX initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX junctions of genes encoding a polypeptide associated with lung and/or
XX nasal airway dysfunction and a second active agent comprising an
XX antiinflammatory steroid and ubiquinone. A composition of the invention
XX has antiallergic, antiasthmatic, immunosuppressive, hypotensive,
XX use in antisense gene therapy. The composition is useful for treating or
XX preventing a respiratory, lung or malignant disease or condition, also
XX for enhancing the prophylactic or therapeutic respiratory effect of an
XX antiinflammatory steroid in a subject, for reducing or depleting levels
XX of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX receptor, producing bronchodilation, increasing levels of ubiquinone or
XX lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX lung inflammation, lung allergies, or a respiratory disease or condition.
XX Note: The sequence data for this patent is not represented in the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 2 A; 12 C; 3 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 461 GCCAGGTGGAGGTGGGCA 480
DB 20 GCCAGGTGGAGGTGGGCA 1

RESULT 764
ABZ98550/c
ID ABZ98550 standard; DNA; 20 BP.
XX
XX
AC ABZ98550;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
XX respiration, has oligo(s) antisense to specific gene(s) or its
XX corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX ubiquinone.
XX
XX Disclosure; SEQ ID NO 13792; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
XX first active agent comprising an oligonucleotide antisense to the
XX initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX junctions of genes encoding a polypeptide associated with lung and/or
XX nasal airway dysfunction and a second active agent comprising an
XX antiinflammatory steroid and ubiquinone. A composition of the invention
XX has antiallergic, antiasthmatic, immunosuppressive, hypotensive,
XX use in antisense gene therapy. The composition is useful for treating or
XX preventing a respiratory, lung or malignant disease or condition, also
XX for enhancing the prophylactic or therapeutic respiratory effect of an
XX antiinflammatory steroid in a subject, for reducing or depleting levels
XX of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX receptor, producing bronchodilation, increasing levels of ubiquinone or
XX lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX lung inflammation, lung allergies, or a respiratory disease or condition.
XX Note: The sequence data for this patent is not represented in the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 3 A; 5 C; 4 G; 8 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 351 TGGGCGAGTCACAGCTAAAA 370
DB 20 TGGGCGAGTCACAGCTAAAA 1
```


RESULT 767
ABZ98392/c
ID ABZ98392 standard; DNA; 20 BP.
XX
AC ABZ98392;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13634; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 10 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1931 GCCTGATGAGGGGGAAGTG 1950
|||||
DB 20 GCCTGATGAGGGGGAAGTG 1

RESULT 768
ABZ98397/c
ID ABZ98397 standard; DNA; 20 BP.
XX
AC ABZ98397;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13639; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1881 CAAGAGGAAGGAGCAAGACT 1900
|||||
DB 20 CAAGAGGAAGGAGCAAGACT 1

RESULT 769
ABZ98416/c
ID ABZ98416 standard; DNA; 20 BP.
XX
AC ABZ98416;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
FN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13658; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1691 CCATATTGGTGCAGTGGT 1710
|||
Db 20 CCATATTGGTGCAGTGGT 1

RESULT 770
ABZ98429/c
ID ABZ98429 standard; DNA; 20 BP.
XX
AC ABZ98429;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
FN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13671; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1561 CTCCTATACCGCCAGCGGAA 1580
|||
Db 20 CTCCTATACCGCCAGCGGAA 1

```
RESULT 771
ABZ98433/c
ID ABZ98433 standard; DNA; 20 BP.
XX
XX
AC ABZ98433;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13675; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1521 AGCCGAGTCATAATGGCA 1540
DB 20 AGCCGAGTCATAATGGCA 1
1221 GGAGCTTCGTGCTGTATG 1240
DB 20 GGAGCTTCGTGCTGTATG 1
```

```
RESULT 772
ABZ98463/c
ID ABZ98463 standard; DNA; 20 BP.
XX
XX
AC ABZ98463;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytosolic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13705; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 7 A; 7 C; 4 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1221 GGAGCTTCGTGCTGTATG 1240
DB 20 GGAGCTTCGTGCTGTATG 1
```

RESULT 773
ABZ98488/c
ID ABZ98488 standard; DNA; 20 BP.
XX AC ABZ98488;
XX
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmacutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13730; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 971 TGACCATCTACAGCTTTCG 990
|||
Db 20 TGACCATCTACAGCTTTCG 1

RESULT 774
ABZ98504/c
ID ABZ98504 standard; DNA; 20 BP.
XX AC ABZ98504;
XX
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmacutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13746; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 811 CTGGCACTGGGGACACAG 830
|||
Db 20 CTGGCACTGGGGACACAG 1

RESULT 775
ABZ98524/c
ID ABZ98524 standard; DNA; 20 BP.
XX
XX
AC ABZ98524;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalán J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13766; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 611 CGTGGCGCACTGAACCTGGAC 630
DB 20 CGTGGCGCACTGAACCTGGAC 1

RESULT 776
ABZ98525/c
ID ABZ98525 standard; DNA; 20 BP.
XX
XX
AC ABZ98525;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalán J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13767; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 601 GCCAATTTCTCGTGGCGCAC 620
DB 20 GCCAATTTCTCGTGGCGCAC 1

```

RESULT 777
ABZ98540/C
ID ABZ98540 standard; DNA; 20 BP.
XX
AC ABZ98540;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
FN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13782; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 451 ACCCTACGCTGCAGGTGGA 470
DB 20 ACCCTACGCTGCAGGTGGA 1

```

```

RESULT 778
ABZ98551/C
ID ABZ98551 standard; DNA; 20 BP.
XX
AC ABZ98551;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
FN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13793; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 341 ACTGCCCTGATGGCAGTCA 360
DB 20 ACTGCCCTGATGGCAGTCA 1

```

RESULT 779
ABZ98576/c
ID ABZ98576 standard; DNA; 20 BP.
XX
AC ABZ98576;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
NYce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13818; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 6 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 91 GCACCTCGTCTGCTCG 110
DB 20 GCACCTCGTCTGCTCG 1

RESULT 780
ABZ98577/c
ID ABZ98577 standard; DNA; 20 BP.
XX
AC ABZ98577;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
NYce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13819; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 6 C; 10 G; 1 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 81 CGCGCTGCGCGCACTCTGG 100
DB 20 CGCGCTGCGCGCACTCTGG 1

RESULT 781
ABZ98580/c
ID ABZ98580 standard; DNA; 20 BP.
XX AC
XX ABZ98580;
DT 17-OCT-2003 (first entry)
XX DE
XX Human ICAM oligonucleotide sequence.
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS
XX Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIC-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13822; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 51 CCTCGCTATGGCTCCAGCA 70
DB 20 CCTCGCTATGGCTCCAGCA 1

RESULT 782
ABZ98385/c
ID ABZ98385 standard; DNA; 20 BP.
XX AC
XX ABZ98385;
DT 17-OCT-2003 (first entry)
XX DE
XX Human ICAM oligonucleotide sequence.
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS
XX Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIC-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13627; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 7 A; 5 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2001 AACTTGCTGCTATGGGTA 2020
DB 20 AACTTGCTGCTATGGGTA 1

RESULT 783
ABZ98389/c
ID ABZ98389 standard; DNA; 20 BP.
XX
XX
AC ABZ98389;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13631; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 4 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1961 CATAGCCCCCATTGAGGAC 1980
|||||
DB 20 CATAGCCCCCATTGAGGAC 1

RESULT 784
ABZ98402/c
ID ABZ98402 standard; DNA; 20 BP.
XX
XX
AC ABZ98402;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13644; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 2 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1831 ACACCTAAACACTAGGCCA 1850
|||||
DB 20 ACACCTAAACACTAGGCCA 1

RESULT 785
ABZ98403/C
ID ABZ98403 standard; DNA; 20 BP.
XX
XX
AC ABZ98403;
XX
XX 17-OCT-2003 (first entry)
DT
XX
XX Human ICAM oligonucleotide sequence.
DE
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX
XX WO200285308-A2.
FN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002WO-US013135.
PF
XX
XX 24-APR-2001; 2001US-0286137P.
PR
XX
XX (EPIC-) EPIGENESIS PHARM INC.
PA
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX
XX WPI; 2003-229219/22.
DR
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiqunone.
XX
XX Disclosure; SEQ ID NO 13645; 872pp; English.
PS
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiqunone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiqunone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 4 A; 3 C; 6 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1821 TGGTACCTGCACACCTAAAA 1840
|||||
DB 20 TGGTACCTGCACACCTAAAA 1

RESULT 786
ABZ98419/C
ID ABZ98419 standard; DNA; 20 BP.
XX
XX
AC ABZ98419;
XX
XX 17-OCT-2003 (first entry)
DT
XX
XX Human ICAM oligonucleotide sequence.
DE
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX
XX WO200285308-A2.
FN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002WO-US013135.
PF
XX
XX 24-APR-2001; 2001US-0286137P.
PR
XX
XX (EPIC-) EPIGENESIS PHARM INC.
PA
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX
XX WPI; 2003-229219/22.
DR
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiqunone.
XX
XX Disclosure; SEQ ID NO 13661; 872pp; English.
PS
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiqunone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiqunone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1661 ATCCCGGGACAGGGCTCTT 1680
|||||
DB 20 ATCCCGGGACAGGGCTCTT 1

RESULT 787
ABZ98423/c
ID ABZ98423 standard; DNA; 20 BP.
XX
XX
AC ABZ98423;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antinflammatory steroid; ubiquinone; antinflammatory; antiallergic;
KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPITG-) EPIGENESIS PHARM INC.
XX
NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13665; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antinflammatory steroid and ubiquinone. A composition of the invention
CC has antinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 1 A; 2 C; 8 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1621 CCCATGAACCGGACACACA 1640
DB 20 CCCATGAACCGGACACACA 1

RESULT 788
ABZ98426/c
ID ABZ98426 standard; DNA; 20 BP.
XX
XX
AC ABZ98426;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antinflammatory steroid; ubiquinone; antinflammatory; antiallergic;
KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPITG-) EPIGENESIS PHARM INC.
XX
NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13668; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antinflammatory steroid and ubiquinone. A composition of the invention
CC has antinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 3 C; 7 G; 8 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1591 TACAGACTACACAGGCCCA 1610
DB 20 TACAGACTACACAGGCCCA 1

RESULT 789
ABZ98435/C
ID ABZ98435 standard; DNA; 20 BP.
XX AC ABZ98435;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIC-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX DR
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13677; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1501 GTCATCATCACTGTGGTAGC 1520
DB 20 GTCATCATCACTGTGGTAGC 1

RESULT 790
ABZ98459/C
ID ABZ98459 standard; DNA; 20 BP.
XX AC ABZ98459;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIC-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX DR
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13701; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1261 GATTGTCCGGAACTGGAC 1280
DB 20 GATTGTCCGGAACTGGAC 1

RESULT 791
ABZ98479/c
ID ABZ98479 standard; DNA; 20 BP.

XX AC ABZ98479;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.

XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
XX KW antinflammatory steroid; ubiquinone; antinflammatory; antiallergic;
XX KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX KW lung inflammation; respiratory disease; db.

XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPITG-) EPIGENESIS PHARM INC.

XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-229219/22.

XX PT Pharmaceutical composition for treating ailments associated with impaired
XX PT respiration, has oligo(s) antisense to specific gene(s) or its
XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX PT ubiquinone.

XX PS Disclosure; SEQ ID NO 13721; 872pp; English.

XX CC The invention relates to a novel pharmaceutical composition, which has a
XX CC first active agent comprising an oligonucleotide antisense to the
XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX CC junctions of genes encoding a polypeptide associated with lung and/or
XX CC nasal airway dysfunction and a second active agent comprising an
XX CC antinflammatory steroid and ubiquinone. A composition of the invention
XX CC has antinflammatory, antiallergic, antisthmatic, hypotensive,
XX CC immunosuppressive, and cytostatic activity. The composition may have a
XX CC use in antisense gene therapy. The composition is useful for treating or
XX CC preventing a respiratory, lung or malignant disease or condition, also
XX CC for enhancing the prophylactic or therapeutic respiratory effect of an
XX CC antinflammatory steroid in a subject, for reducing or depleting levels
XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or
XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX CC lung inflammation, lung allergies, or a respiratory disease or condition.
XX CC Note: The sequence data for this patent is not represented in the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e-02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1061 ACCCTAGAGCCCAAGTGAGC 1080
DB 20 ACCCTAGAGCCCAAGTGAGC 1

RESULT 792
ABZ98513/c

ID ABZ98513 standard; DNA; 20 BP.

XX AC ABZ98513;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.

XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
XX KW antinflammatory steroid; ubiquinone; antinflammatory; antiallergic;
XX KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX KW lung inflammation; respiratory disease; db.

XX OS Homo sapiens.
XX PN WO200285308-A2.
XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPITG-) EPIGENESIS PHARM INC.

XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-229219/22.

XX PT Pharmaceutical composition for treating ailments associated with impaired
XX PT respiration, has oligo(s) antisense to specific gene(s) or its
XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX PT ubiquinone.

XX PS Disclosure; SEQ ID NO 13755; 872pp; English.

XX CC The invention relates to a novel pharmaceutical composition, which has a
XX CC first active agent comprising an oligonucleotide antisense to the
XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX CC junctions of genes encoding a polypeptide associated with lung and/or
XX CC nasal airway dysfunction and a second active agent comprising an
XX CC antinflammatory steroid and ubiquinone. A composition of the invention
XX CC has antinflammatory, antiallergic, antisthmatic, hypotensive,
XX CC immunosuppressive, and cytostatic activity. The composition may have a
XX CC use in antisense gene therapy. The composition is useful for treating or
XX CC preventing a respiratory, lung or malignant disease or condition, also
XX CC for enhancing the prophylactic or therapeutic respiratory effect of an
XX CC antinflammatory steroid in a subject, for reducing or depleting levels
XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or
XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX CC lung inflammation, lung allergies, or a respiratory disease or condition.
XX CC Note: The sequence data for this patent is not represented in the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e-02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 GTCAGCCCCCGGTCTCTAGA 740
DB 20 GTCAGCCCCCGGTCTCTAGA 1

RESULT 793
ABZ98528/C
ID ABZ98528 standard; DNA; 20 BP.
XX AC ABZ98528;
XX 17-OCT-2003 (first entry)
XX Human ICAM oligonucleotide sequence.
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
XX 24-APR-2001; 2001US-0286137P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX Pharmacutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Disclosure; SEQ ID NO 13770; 872pp; English.
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX Sequence 20 BP; 3 A; 10 C; 2 G; 5 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 571 ACGTGCTGCTGAGGAGAGA 590
Db 20 ACGGTGCTGCTGAGGAGAGA 1

RESULT 794
ABZ98538/C
ID ABZ98538 standard; DNA; 20 BP.
XX AC ABZ98538;
XX 17-OCT-2003 (first entry)
XX Human ICAM oligonucleotide sequence.
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX PN WO200285308-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013135.
XX 24-APR-2001; 2001US-0286137P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-229219/22.
XX Pharmacutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX Disclosure; SEQ ID NO 13780; 872pp; English.
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX Sequence 20 BP; 1 A; 10 C; 7 G; 2 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 471 GGGTGGGGCACCCTGGGCCA 490
Db 20 GGGTGGGGCACCCTGGGCCA 1

RESULT 795
ABZ98571/c
ID ABZ98571 standard; DNA; 20 BP.
XX
XX
AC ABZ98571;
DT 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13813; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytotatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 141 GACATCTGTCTCCCTCAA 160
|||||
DB 20 GACATCTGTCTCCCTCAA 1

RESULT 796
ABZ98579/c
ID ABZ98579 standard; DNA; 20 BP.
XX
XX
AC ABZ98579;
DT 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13821; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytotatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 1 A; 5 C; 12 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 61 GCTCCAGCAGCCCCCGGCC 80
|||||
DB 20 GCTCCAGCAGCCCCCGGCC 1


```
RESULT 797
ABZ98405/C
ID ABZ98405 standard; DNA; 20 BP.
XX
AC ABZ98405;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13647; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pt_sequences
XX
SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1801 TACAACAGCATTTGGGGCCA 1820
DB 20 TACAACAGCATTTGGGGCCA 1
```

```
RESULT 798
ABZ98407/C
ID ABZ98407 standard; DNA; 20 BP.
XX
AC ABZ98407;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13649; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pt_sequences
XX
SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1781 GGGCATTGTCCTCAGTCAGA 1800
DB 20 GGGCATTGTCCTCAGTCAGA 1
```

RESULT 799
ABZ98414/c
ID ABZ98414 standard; DNA; 20 BP.
XX
XX AC ABZ98414;
XX
XX DT 17-OCT-2003 (first entry)
XX
XX DE Human ICAM oligonucleotide sequence.
XX
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX OS Homo sapiens.
XX
XX PN WO200285308-A2.
XX
XX PD 31-OCT-2002.
XX
XX PF 23-APR-2002; 2002WO-US013135.
XX
XX PR 24-APR-2001; 2001US-0286137P.
XX
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX DR WPI; 2003-229219/22.
XX
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX PS Disclosure; SEQ ID NO 13656; 872pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 20 BP; 2 A; 6 C; 5 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1711 GCCACACTGAACAGAGTGA 1730
|||||
20 GCCACACTGAACAGAGTGA 1
Db

RESULT 800
ABZ98420/c
ID ABZ98420 standard; DNA; 20 BP.
XX
XX AC ABZ98420;
XX
XX DT 17-OCT-2003 (first entry)
XX
XX DE Human ICAM oligonucleotide sequence.
XX
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX OS Homo sapiens.
XX
XX PN WO200285308-A2.
XX
XX PD 31-OCT-2002.
XX
XX PF 23-APR-2002; 2002WO-US013135.
XX
XX PR 24-APR-2001; 2001US-0286137P.
XX
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX DR WPI; 2003-229219/22.
XX
XX PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX PS Disclosure; SEQ ID NO 13662; 872pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 20 BP; 3 A; 4 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1651 CCTGAACTATCCCGGAC 1670
|||||
20 CCTGAACTATCCCGGAC 1
Db

RESULT 803
ABZ98514/c
ID ABZ98514 standard; DNA; 20 BP.
XX
AC ABZ98514;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13756; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 2 C; 11 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 711 CCCACAACTGTGAGCCCC 730
DB 20 CCCACAACTGTGAGCCCC 1

RESULT 804
ABZ98515/c
ID ABZ98515 standard; DNA; 20 BP.
XX
AC ABZ98515;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13757; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 2 C; 10 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 701 CAGCGACTCCCCCACTT 720
DB 20 CAGCGACTCCCCCACTT 1

```
RESULT 805
ABZ98520/c
ID ABZ98520 standard; DNA; 20 BP.
XX
XX AC ABZ98520;
XX
XX DT 17-OCT-2003 (first entry)
XX
XX DE Human ICAM oligonucleotide sequence.
XX
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.
XX
XX OS Homo sapiens.
XX
XX PN WO200285308-A2.
XX
XX PD 31-OCT-2002.
XX
XX PF 23-APR-2002; 2002WO-US013135.
XX
XX PR 24-APR-2001; 2001US-0286137P.
XX
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX
XX DR WPI; 2003-229219/22.
XX
XX PT Pharmaceutical composition for treating ailments associated with impaired
XX respiration, has oligo(s) antisense to specific gene(s) or its
XX corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX ubiquinone.
XX
XX PS Disclosure; SEQ ID NO 13762; 872pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition, which has a
XX first active agent comprising an oligonucleotide antisense to the
XX initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX junctions of genes encoding a polypeptide associated with lung and/or
XX nasal airway dysfunction and a second active agent comprising an
XX antiinflammatory steroid and ubiquinone. A composition of the invention
XX has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX immunosuppressive, and cytostatic activity. The composition may have a
XX use in antisense gene therapy. The composition is useful for treating or
XX preventing a respiratory, lung or malignant disease or condition, also
XX for enhancing the prophylactic or therapeutic respiratory effect of an
XX antiinflammatory steroid in a subject, for reducing or depleting levels
XX of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX receptor, producing bronchodilation, increasing levels of ubiquinone or
XX lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX lung inflammation, lung allergies, or a respiratory disease or condition.
XX Note: The sequence data for this patent is not represented in the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 651 GCTGTTTGAACACCTCGG 670
XX |||||||||||||||
XX Db 20 GCTGTTTGAACACCTCGG 1
```

```
RESULT 806
ABZ98532/c
ID ABZ98532 standard; DNA; 20 BP.
XX
XX AC ABZ98532;
XX
XX DT 17-OCT-2003 (first entry)
XX
XX DE Human ICAM oligonucleotide sequence.
XX
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
XX antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX lung inflammation; respiratory disease; ds.
XX
XX OS Homo sapiens.
XX
XX PN WO200285308-A2.
XX
XX PD 31-OCT-2002.
XX
XX PF 23-APR-2002; 2002WO-US013135.
XX
XX PR 24-APR-2001; 2001US-0286137P.
XX
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX
XX DR WPI; 2003-229219/22.
XX
XX PT Pharmaceutical composition for treating ailments associated with impaired
XX respiration, has oligo(s) antisense to specific gene(s) or its
XX corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX ubiquinone.
XX
XX PS Disclosure; SEQ ID NO 13774; 872pp; English.
XX
XX CC The invention relates to a novel pharmaceutical composition, which has a
XX first active agent comprising an oligonucleotide antisense to the
XX initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX junctions of genes encoding a polypeptide associated with lung and/or
XX nasal airway dysfunction and a second active agent comprising an
XX antiinflammatory steroid and ubiquinone. A composition of the invention
XX has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX immunosuppressive, and cytostatic activity. The composition may have a
XX use in antisense gene therapy. The composition is useful for treating or
XX preventing a respiratory, lung or malignant disease or condition, also
XX for enhancing the prophylactic or therapeutic respiratory effect of an
XX antiinflammatory steroid in a subject, for reducing or depleting levels
XX of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX receptor, producing bronchodilation, increasing levels of ubiquinone or
XX lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX lung inflammation, lung allergies, or a respiratory disease or condition.
XX Note: The sequence data for this patent is not represented in the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
XX SQ Sequence 20 BP; 2 A; 11 C; 4 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 531 ACGGAGCCAGCTGTGGGGG 550
XX |||||||||||||||
XX Db 20 ACGGAGCCAGCTGTGGGGG 1
```

RESULT 807
ABZ98545/c
ID ABZ98545 standard; DNA; 20 BP.

XX AC ABZ98545;
XX

DT 17-OCT-2003 (first entry)

XX Human ICAM oligonucleotide sequence.

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX Homo sapiens.

XX WO200285308-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-229219/22.

XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX Disclosure; SEQ ID NO 13787; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 401 GGGTGGAACGGCACCCCTC 420

DB 20 GGGTGGAACGGCACCCCTC 1

RESULT 808
ABZ98546/c

ID ABZ98546 standard; DNA; 20 BP.

XX AC ABZ98546;

XX 17-OCT-2003 (first entry)

XX Human ICAM oligonucleotide sequence.

XX

KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX Homo sapiens.

XX WO200285308-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-229219/22.

XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX Disclosure; SEQ ID NO 13788; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 ACTCCAGACGGGTGGACT 410

DB 20 ACTCCAGACGGGTGGACT 1

```
RESULT 809
ABZ98557/c
ID ABZ98557 standard; DNA; 20 BP.
XX AC ABZ98557;
XX AC ABZ98557;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
XX KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX XX WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
XX PT respiration, has oligo(s) antisense to specific gene(s) or its
XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13799; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
XX CC first active agent comprising an oligonucleotide antisense to the
XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX CC junctions of genes encoding a polypeptide associated with lung and/or
XX CC nasal airway dysfunction and a second active agent comprising an
XX CC antiinflammatory steroid and ubiquinone. A composition of the invention
XX CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX CC immunosuppressive, and cytostatic activity. The composition may have a
XX CC use in antisense gene therapy. The composition is useful for treating or
XX CC preventing a respiratory, lung or malignant disease or condition, also
XX CC for enhancing the prophylactic or therapeutic respiratory effect of an
XX CC antiinflammatory steroid in a subject, for reducing or depleting levels
XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or
XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX CC lung inflammation, lung allergies, or a respiratory disease or condition.
XX CC Note: The sequence data for this patent is not represented in the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 281 ACCGGAAGGTGTATGAAC TG 300
Db 20 ACCGGAAGGTGTATGAAC TG 1
RESULT 810
ABZ98572/c
ID ABZ98572 standard; DNA; 20 BP.
XX AC ABZ98572;
XX AC ABZ98572;
XX DT 17-OCT-2003 (first entry)
XX DE Human ICAM oligonucleotide sequence.
XX KW Human; antisense; lung dysfunction; nasal airway dysfunction;
XX KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
XX KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
XX KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
XX KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
XX KW lung inflammation; respiratory disease; ds.
XX OS Homo sapiens.
XX XX WO200285308-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013135.
XX PR 24-APR-2001; 2001US-0286137P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-229219/22.
XX PT Pharmaceutical composition for treating ailments associated with impaired
XX PT respiration, has oligo(s) antisense to specific gene(s) or its
XX PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX PT ubiquinone.
XX PS Disclosure; SEQ ID NO 13814; 872pp; English.
XX CC The invention relates to a novel pharmaceutical composition, which has a
XX CC first active agent comprising an oligonucleotide antisense to the
XX CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
XX CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
XX CC junctions of genes encoding a polypeptide associated with lung and/or
XX CC nasal airway dysfunction and a second active agent comprising an
XX CC antiinflammatory steroid and ubiquinone. A composition of the invention
XX CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
XX CC immunosuppressive, and cytostatic activity. The composition may have a
XX CC use in antisense gene therapy. The composition is useful for treating or
XX CC preventing a respiratory, lung or malignant disease or condition, also
XX CC for enhancing the prophylactic or therapeutic respiratory effect of an
XX CC antiinflammatory steroid in a subject, for reducing or depleting levels
XX CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
XX CC receptor, producing bronchodilation, increasing levels of ubiquinone or
XX CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
XX CC lung inflammation, lung allergies, or a respiratory disease or condition.
XX CC Note: The sequence data for this patent is not represented in the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 131 GCAATGCCAGACATCTGTG 150
Db 20 GCAATGCCAGACATCTGTG 1
```

RESULT 811
ABZ98578/c
ID ABZ98578 standard; DNA; 20 BP.
XX
AC ABZ98578;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN W0200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13820; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytotatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 1 A; 6 C; 13 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 71 GCCCGCGCGCGCGCGCGCGCG 90
|||
DB 20 GCCCGCGCGCGCGCGCGCGCG 1

RESULT 812
ABZ98421/c
ID ABZ98421 standard; DNA; 20 BP.
XX
AC ABZ98421;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytotatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN W0200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13663; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytotatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 3 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1641 AGCCAGCGCTCCTGAACT 1660
|||
DB 20 AGCCAGCGCTCCTGAACT 1

RESULT 813
ABZ98436/c
ID ABZ98436 standard; DNA; 20 BP.
XX AC
XX ABZ98436;
XX AC
DT 17-OCT-2003 (first entry)
XX DE
XX Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13678; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 7 A; 4 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1491 GTATGAGATTGTCATCATCA 1510
|||||
DB 20 GTATGAGATTGTCATCATCA 1

RESULT 814
ABZ98451/c
ID ABZ98451 standard; DNA; 20 BP.
XX AC
XX ABZ98451;
XX AC
DT 17-OCT-2003 (first entry)
XX DE
XX Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13693; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1341 GCTCAAGTGTCTAAAGGATG 1360
|||||
DB 20 GCTCAAGTGTCTAAAGGATG 1

RESULT 815
ABZ98452/c
ID ABZ98452 standard; DNA; 20 BP.
XX
XX
AC ABZ98452;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13694; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1331 CATTGCCCGAGCTCAAGTGT 1350
DB 20 CATTGCCCGAGCTCAAGTGT 1

RESULT 816
ABZ98478/c
ID ABZ98478 standard; DNA; 20 BP.
XX
XX
AC ABZ98478;
XX
XX 17-OCT-2003 (first entry)
XX
XX Human ICAM oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13720; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1071 CAAGGTGACGCTGAATGGG 1090
DB 20 CAAGGTGACGCTGAATGGG 1

```
RESULT 817
ABZ98480/C
ID ABZ98480 standard; DNA; 20 BP.
XX
AC ABZ98480;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
Disclosure; SEQ ID NO 13722; 872pp; English.
XX
The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1051 TGTGAGGCCACCCCTAGAGC 1070
DB 20 TGTGAGGCCACCCCTAGAGC 1
```

```
RESULT 818
ABZ98487/C
ID ABZ98487 standard; DNA; 20 BP.
XX
AC ABZ98487;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
Disclosure; SEQ ID NO 13729; 872pp; English.
XX
The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 981 CAGCTTTCCGGCGCCCAAGC 1000
DB 20 CAGCTTTCCGGCGCCCAAGC 1
```

RESULT 819
ABZ98499/c
ID ABZ98499 standard; DNA; 20 BP.
XX
AC ABZ98499;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13741; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 4 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 861 CTCCTTCTCGGCCAAGCCT 880
DB 20 CTCCTTCTCGGCCAAGCCT 1

RESULT 820
ABZ98510/c
ID ABZ98510 standard; DNA; 20 BP.
XX
AC ABZ98510;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13752; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 751 CAGGGGACCGTGTCTGTTC 770
DB 20 CAGGGGACCGTGTCTGTTC 1

RESULT 821
ABZ98511/c
ID ABZ98511 standard; DNA; 20 BP.
XX AC
XX ABZ98511;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13753; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 1 A; 10 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 GGTGGACACGCGGGGACCG 760
|||||
Db 20 GGTGGACACGCGGGGACCG 1

RESULT 822
ABZ98543/c
ID ABZ98543 standard; DNA; 20 BP.
XX AC
XX ABZ98543;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13785; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 421 CCCTCTTGGCAGCCAGTGGG 440
|||||
Db 20 CCCTCTTGGCAGCCAGTGGG 1

RESULT 823
 ABZ75966/c
 ID ABZ75966 standard; DNA; 20 BP.
 XX
 XX
 AC ABZ75966;
 XX
 DT 29-MAY-2003 (first entry)
 XX
 DE ICAM-1 gene targeting 2'-deoxyoligonucleotide ISIS 2302.
 XX
 XX ICAM-1; desulphurization; antioxidant; intercellular adhesion molecule-1;
 KW ss.
 XX Synthetic.
 OS Homo sapiens.
 OS
 XX
 PN W02003005822-A1.
 XX
 PD 23-JAN-2003.
 XX
 PF 11-JUL-2002; 2002WO-US022038.
 XX
 PR 11-JUL-2001; 2001US-00902953.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Krotz AH, Mehta R;
 XX
 DR WPI; 2003-229426/22.
 XX
 PF 11-JUL-2002; 2002WO-US022038.
 XX
 PR 11-JUL-2001; 2001US-00902953.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Krotz AH, Mehta R;
 XX
 DR WPI; 2003-229426/22.
 XX
 PT Preventing desulfurization of oligonucleotide comprising phosphorothioate
 PT linkages in bi-phasic/multi-phasic formulation, by adding to formulation
 PT an antioxidant that partitions into aqueous phase of the formulation.
 XX
 PS Disclosure; Page 11; 51pp; English.
 XX
 CC The invention relates to preventing desulphurization of an
 CC oligonucleotide or its bioequivalent comprising one or more
 CC phosphorothioate linkages in a bi-phasic or multi-phasic formulation. The
 CC method involves including in the formulation an antioxidant which
 CC partitions into the aqueous phase of the formulation. The method is
 CC useful for increasing the stability of oligonucleotide comprising
 CC phosphorothioate linkages. The present sequence represents a 2'-
 CC deoxyoligonucleotide having a phosphorothioate backbone and is targeted
 CC to the 3' UTR (untranslated region) of ICAM-1 (intercellular adhesion
 CC molecule-1)
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 Qy 2100 TGACGGATGCCAGCTGGGC 2119
 Db 20 TGACGGATGCCAGCTGGGC 1
 XX
 RESULT 824
 ABZ75967/c
 ID ABZ75967 standard; DNA; 20 BP.
 XX
 XX
 AC ABZ75967;
 XX
 DT 29-MAY-2003 (first entry)
 XX
 DE ICAM-1 gene targeting 2'-deoxyoligonucleotide ISIS 1939.
 XX
 XX ICAM-1; desulphurization; antioxidant; intercellular adhesion molecule-1;
 KW ss.
 XX Synthetic.

OS Homo sapiens.
 XX
 PN W02003005822-A1.
 XX
 PD 23-JAN-2003.
 XX
 PF 11-JUL-2002; 2002WO-US022038.
 XX
 PR 11-JUL-2001; 2001US-00902953.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Krotz AH, Mehta R;
 XX
 DR WPI; 2003-229426/22.
 XX
 PT Preventing desulfurization of oligonucleotide comprising phosphorothioate
 PT linkages in bi-phasic/multi-phasic formulation, by adding to formulation
 PT an antioxidant that partitions into aqueous phase of the formulation.
 XX
 PS Disclosure; Page 12; 51pp; English.
 XX
 CC The invention relates to preventing desulphurization of an
 CC oligonucleotide or its bioequivalent comprising one or more
 CC phosphorothioate linkages in a bi-phasic or multi-phasic formulation. The
 CC method involves including in the formulation an antioxidant which
 CC partitions into the aqueous phase of the formulation. The method is
 CC useful for increasing the stability of oligonucleotide comprising
 CC phosphorothioate linkages. The present sequence represents a 2'-
 CC deoxyoligonucleotide having a phosphorothioate backbone and is targeted
 CC to the 3' UTR (untranslated region) of ICAM-1 (intercellular adhesion
 CC molecule-1)
 XX
 SQ Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 Qy 1938 GAGAGGGGAAGTGGTGGGG 1957
 Db 20 GAGAGGGGAAGTGGTGGGG 1
 XX
 RESULT 825
 ACC49170/c
 ID ACC49170 standard; DNA; 20 BP.
 XX
 AC ACC49170;
 XX
 DT 19-JUN-2003 (first entry)
 XX
 DE ICAM-1 inhibitory antisense oligonucleotide SEQ ID NO:2.
 XX
 KW Inhibition; phosphorothioate; delayed release oral formulation;
 KW enhanced gastrointestinal absorption; ulcerative colitis;
 KW rheumatoid arthritis; Crohn's disease; inflammatory bowel disease;
 KW abnormal cellular proliferation; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /notes= "phosphorothioate linkages"
 XX
 PN W02003017940-A2.
 XX
 PD 06-MAR-2003.
 XX
 PR 22-AUG-2002; 2002WO-US026924.
 XX
 XX

```
PR 22-AUG-2001; 2001US-00944493.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Weinbach SP, Tillman LG, Geary RS, Hardee GE;
XX
XX WPI; 2003-354422/33.
XX
XX Pulsed release oral formulation providing enhanced gastrointestinal
PT absorption, comprises first particles containing drug and penetration
PT enhancer and second particles containing delayed release penetration
PT enhancer.
XX
XX Disclosure; Page 28; 59pp; English.
XX
XX The present invention describes a delayed release oral formulation (A),
CC giving enhanced gastrointestinal (GI) absorption of a drug (I). (A)
CC comprises a first set of particles containing (I) and a penetration
CC enhancer (II) and a second set of particles containing (II) in a delayed
CC release coating or matrix (III). (A) is used for enhancing the absorption
CC of (I) in mammals, especially humans. Typical disorders to be treated
CC include ulcerative colitis, rheumatoid arthritis, Crohn's disease,
CC inflammatory bowel disease and abnormal cellular proliferation. When the
CC particles release (I) and (II) at a first location in the GI tract
CC (generally the intestines), (II) is rapidly absorbed (during a first
CC release pulse) and is often present in insufficient amount to promote
CC absorption of the entire dose of (I). This problem is solved by providing
CC further (II) in delayed release form in the particles, so that absorption
CC of (I) is completed in a second pulse. The present sequence represents an
CC exemplary oligonucleotide from the present invention which inhibits ICAM-
CC 1
XX
XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAAGTGTGGGG 1957
DB 20 GAGAGGGGAAGTGTGGGG 1
RESULT 826
ACC49169/C
ID ACC49169 standard; DNA; 20 BP.
XX
XX ACC49169;
XX
XX 19-JUN-2003 (first entry)
XX
XX ICAM-1 inhibitory antisense oligonucleotide SEQ ID NO:1.
XX
XX Inhibition; phosphorothioate; delayed release oral formulation;
XX enhanced gastrointestinal absorption; ulcerative colitis;
XX rheumatoid arthritis; Crohn's disease; inflammatory bowel disease;
XX abnormal cellular proliferation; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1..20 /*tag= a
FT /*mod_base= OTHER
FT /*note= "phosphorothioate linkages"
XX
XX WO2003017940-A2.
XX
XX 06-MAR-2003.
XX
XX 22-AUG-2002; 2002WO-US026924.
XX
XX 22-AUG-2001; 2001US-00944493.
PR
```

```
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Weinbach SP, Tillman LG, Geary RS, Hardee GE;
XX
XX WPI; 2003-354422/33.
XX
XX Pulsed release oral formulation providing enhanced gastrointestinal
PT absorption, comprises first particles containing drug and penetration
PT enhancer and second particles containing delayed release penetration
PT enhancer.
XX
XX Disclosure; Page 28; 59pp; English.
XX
XX The present invention describes a delayed release oral formulation (A),
CC giving enhanced gastrointestinal (GI) absorption of a drug (I). (A)
CC comprises a first set of particles containing (I) and a penetration
CC enhancer (II) and a second set of particles containing (II) in a delayed
CC release coating or matrix (III). (A) is used for enhancing the absorption
CC of (I) in mammals, especially humans. Typical disorders to be treated
CC include ulcerative colitis, rheumatoid arthritis, Crohn's disease,
CC inflammatory bowel disease and abnormal cellular proliferation. When the
CC particles release (I) and (II) at a first location in the GI tract
CC (generally the intestines), (II) is rapidly absorbed (during a first
CC release pulse) and is often present in insufficient amount to promote
CC absorption of the entire dose of (I). This problem is solved by providing
CC further (II) in delayed release form in the particles, so that absorption
CC of (I) is completed in a second pulse. The present sequence represents an
CC exemplary oligonucleotide from the present invention which inhibits ICAM-
CC 1
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
DB 20 TGACGGATGCCAGCTTGGGC 1
RESULT 827
ABX13929/C
ID ABX13929 standard; DNA; 20 BP.
XX
XX ABX13929;
XX
XX 03-MAR-2003 (first entry)
XX
XX Oligonucleotide with site specific chiral phosphorothioate linkage #1.
XX
XX Site specific phosphorothioate linkage; nuclease resistant;
XX protein production modulation; protein activity modulation;
XX protein kinase C modulation; ICAM-1 modulation; VCAM-1 modulation;
XX PECAM-1 modulation; ELAM-1 modulation; H-ras modulation;
XX K-ras modulation; AP-1 modulation; Jun N-terminal kinase modulation;
XX matrix metalloproteinase modulation; psoriasis; inflammatory disorder;
XX infectious disease; skin; skin cancer; Paget's disease; Kaposi's sarcoma;
XX squamous cell carcinoma; AIDS; atherosclerosis;
XX acquired immunodeficiency syndrome; ISIS no 2302; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1 /*tag= a
FT /*note= "Optionally chiral Sp internucleoside linkage"
FT modified_base 2..19 /*tag= b
FT /*note= "Optionally chiral Rp internucleoside linkage"
FT modified_base 20 /*tag= c
FT
```

FT XX /note= "Optionally chiral Sp internucleoside linkage"

PN XX US6440943-B1.

XX XX 27-AUG-2002.

PD XX 14-JUL-1999; 99US-00352058.

XX XX 14-JUL-1998; 98US-00115027.

PF XX (ISIS-) ISIS PHARM INC.

PR XX Cook PD, Manoharan M;

XX XX WPI; 2003-138122/13.

DR XX Nuclease resistant phosphorothioate oligomeric compound useful for

XX XX treating diseases such as psoriasis, skin cancer, or inflammatory

PT disorders of the skin, comprises a number of covalently-bound

FT nucleosides.

XX XX Example 32; Col 43-44; 43pp; English.

PS XX This invention describes a nuclease resistant phosphorothioate oligomeric

XX XX compound (I) comprising a number of covalently-bound nucleosides. (I) is

CC useful for modulating the production or activity of a protein in an

CC organism, by contacting the organism with (I), where the protein is

CC protein kinase C, ICAM-1, VCAM-1, PECAM-1, ELAM-1, H-ras, K-ras, AP-1, a

CC Jun N-terminal kinase or a matrix metalloproteinase. (I) is useful for

CC treating an organism having a disease characterised by the undesired

CC production of a protein, by contacting the organism with (I), where the

CC disease is psoriasis, an inflammatory disorder of the skin, an infectious

CC disease of the skin, or skin cancer e.g. Paget's disease, Kaposi's

CC sarcoma or squamous cell carcinoma. (I) is useful for therapeutic,

CC diagnostic and a research agents, and for for assaying a nucleic acid by

CC contacting a solution suspected to contained the nucleic acid with (I).

CC (I) is also useful for treating AIDS or atherosclerosis. This sequence

CC represents a nuclease resistant oligonucleotide having site specific

CC chiral phosphorothioate internucleoside linkages

XX XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGTTGGC 2119

DB 20 TGACGGATGCCAGTTGGC 1

RESULT 828

ABD31411/c

ID ABD31411 standard; DNA; 20 BP.

AC ABD31411;

XX 29-JUL-2004 (first entry)

DT Human ICAM-derived oligonucleotide SEQ ID 13622.

DE Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;

KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;

KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS Human ICAM-derived oligonucleotide SEQ ID 13706.

XX WO200285309-A2.

PN

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

PP 24-APR-2001; 2001US-0286036P.

PR (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

DR Pharmaceutical composition for treating asthma, has antisense

XX oligonucleotide containing less percentage of adenosine, targeted to

PT nucleic acids associated with lung airway or lung dysfunction, and

PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13622; 763pp; English.

PS This invention describes a novel composition (a) a first active agent,

XX comprising oligonucleotides, effective for alleviating

CC bronchoconstriction, respiratory tract inflammation, allergies and

CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,

CC surfactant depletion or hyposecretion, when administered to a mammal. The

CC oligonucleotides are derived from a gene encoding or regulating

CC expression of a target polypeptide associated with lung airway or lung

CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.

CC The invention also describes a kit, that comprises: (a) a delivery

CC device, in separate containers, (b) the oligonucleotides, (c)

CC instructions for adding a carrier and for use of the kit. The composition

CC of the invention has antiallergic, antiinflammatory, antiasthmatic, is a

CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

CC beta-adrenergic agonist. The composition is useful for preventing or

CC treating a respiratory, lung or malignant disease. The administered

CC composition comprises oligo and is administered to reduce the production

CC or availability, or to increase the degradation of the target mRNA or to

CC reduce the amount of target polypeptide present in the lungs. The

CC pulmonary obstruction, and/or bronchoconstriction and/or lung

CC inflammation, allergies and/or surfactant hypoproduction are associated

CC with a disease or condition such as pulmonary vasoconstriction,

CC inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary

CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

CC transplantation rejection, pulmonary infections, bronchitis or cancer.

CC The reduced adenosine content of the anti-sense oligos corresponding to

CC thymidines present in the target RNA serves to prevent the breakdown of

CC the oligonucleotides into products that free adenosine into the system

CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to

CC prevent any unwanted effects due to it

XX Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2050 TGGCCCTCCATGACATGTG 2069

DB 20 TGGCCCTCCATGACATGTG 1

RESULT 829

ABD31495/c

ID ABD31495 standard; DNA; 20 BP.

XX ABD31495;

XX AC ABD31495;

XX 29-JUL-2004 (first entry)

DT Human ICAM-derived oligonucleotide SEQ ID 13706.

XX

DE

KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13706; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1211 ACCAGACCCGGGAGCTTCGT 1230

Db 20 ACCAGACCCGGGAGCTTCGT 1

RESULT 830

ABD31516/C

ID ABD31516 standard; DNA; 20 BP.

XX ABD31516;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13727.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13727; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system

CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1001 TGATTTCTGACGACCCAGAG 1020
 |||||
 Db 20 TGATTTCTGACGACCCAGAG 1
 |||||
 RESULT 831
 ID ABD31531/c
 ID ABD31531 standard; DNA; 20 BP.
 XX
 AC ABD31531;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13742.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13742; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production

CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 XX prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 851 ATGGCAACGACTCCTCTCG 870
 |||||
 Db 20 ATGGCAACGACTCCTCTCG 1
 |||||
 RESULT 832
 ID ABD31551/c
 ID ABD31551 standard; DNA; 20 BP.
 XX
 AC ABD31551;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13762.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13762; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production

surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antilasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

Sequence 20 BP: 5 A, 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Qy 651 GCTGTTTGAGAACACCTCGG 670
|||
Dy 20 GCTGTTTGAGAACACCTCGG 1

RESULT 833
ABD31568/c
ID ABD31568 standard: DNA: 20 BP.

ABD31568;
29-JUL-2004 (first entry)

Human ICAM-derived oligonucleotide SEQ ID 13779.

Human; antiseize; bronchoconstriction; allergy; hyposcretion; pain; respiratory tract inflammation; adenosine sensitivity; lung; cancer; surfactant depletion; antiallergic; antiinflammatory; antiaesthetic; analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis; beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction; respiratory distress syndrome; allergic rhinitis; pulmonary hypertension; emphysema; chronic obstructive pulmonary disease; cancer; bronchitis; pulmonary transplantation rejection; ss; primer.

Homo sapiens.

WO200285309-A2

31-OCT-2002.

23-APR-2002: 2002WO-US013143.

24-APR-2001: 2001US-0286036P.

(EPIG-) EPIGENESIS PHARM INC.

XX NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shanabuddin S;
XX WPI: 2003-093058/08.
DR

Pharmaceutical composition for treating asthma, has antisense oligonucleotide containing less percentage of adenosine, targeted to nucleic acids associated with lung airway or lung dysfunction, and bronchodilating agent.

Claim 15; SEQ ID NO 13779; 763pp; English.

This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

Sequence 20 BP: 2 A: 4 C: 11 G: 3 T: 0 U: 0 Other:

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches	20;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
---------	-----	--------------	----	------------	----	--------	----	------	----

481 CCCCGGCCAACCTCACCGT 500

QY
pB

RESIT.T 834

RESULI 634
ABD31570/C

ABD31570/C
ID ABD31570 standard; DNA; 20 BP.

AC ABD31570:

XX 29-JUL-2004 (first entry)

Human ICAM-derived oligonucleotide SEO ID 13781.

Human; antiseize; bronchoconstriction; allergy; hyposecretion; pain;
respiratory tract inflammation; adenosine sensitivity; lung; cancer;
surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
beta-adrenergic agonists; respiratory disease; pulmonary vasoconstriction;
respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
pulmonary transplantation rejection. ss: primer.

44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523
 524
 525
 526
 527
 528
 529
 530
 531
 532
 533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547
 548
 549
 550
 551
 552
 553
 554
 555
 556
 557
 558
 559
 560
 561
 562

XX PN WO200285309-A2.

 \mathbb{Y}

PD 31-OCT-2002.
 XX
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13781; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 2 A; 12 C; 3 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 461 GCCAGGTGGAGGTGGGCA 480
 DB 20 GCCAGGTGGAGGTGGGCA 1
 RESULT 835
 ABD31596/C
 ID ABD31596 standard; DNA; 20 BP.
 XX
 XX ABD31596;
 AC
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13807.
 XX
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 XX
 XX WO200285309-A2.
 DN
 XX
 XX 31-OCT-2002.
 PD
 XX
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 DR
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13807; 763pp; English.
 PS
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 3 A; 4 C; 9 G; 4 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 201 CAGCACCTCTGTGACCAGC 220
 DB 20 CAGCACCTCTGTGACCAGC 1

CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1741 CATGCAGCTACACTACCGG 1760

Db 20 CATGCAGCTACACTACCGG 1

RESULT 838

ABD31463/c

ID ABD31463 standard; DNA; 20 BP.

XX ABD31463;

AC ABD31463;

XX 29-JUL-2004 (first entry)

DT 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13674.

DE Human ICAM-derived oligonucleotide SEQ ID 13674.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;

KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS Homo sapiens.

XX WO200285309-A2.

PN 31-OCT-2002.

PD 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

PA Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to

PT nucleic acids associated with lung airway or lung dysfunction, and

PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13674; 763bp; English.

PS This invention describes a novel composition (a) a first active agent,

XX comprising oligonucleotides, effective for alleviating

CC bronchoconstriction, respiratory tract inflammation, allergies and

CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,

CC surfactant depletion or hyposecretion, when administered to a mammal. The

CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.

CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1531 ATAATGGCAGCTGCGGCT 1550

Db 20 ATAATGGCAGCTGCGGCT 1

RESULT 839

ABD31477/c

ID ABD31477 standard; DNA; 20 BP.

XX ABD31477;

AC ABD31477;

XX 29-JUL-2004 (first entry)

DT 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13688.

DE Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;

KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS WO200285309-A2.

PN 31-OCT-2002.

PD 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

PA Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13688; 763bp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1391 TGACTGTCACTCGAGATCTT 1410
Db ||||||||||||||||||
20 TGACTGTCACTCGAGATCTT 1
RESULT 840
ABD31525/c
ID ABD31525 standard; DNA; 20 BP.
XX
XX ABD31525;
XX
XX 29-JUL-2004 (first entry)
XX Human ICAM-derived oligonucleotide SEQ ID 13736.
DE
DE Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
OS
XX WO200285309-A2.
PN
XX 31-OCT-2002.

XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13736; 763bp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 911 CCCAGCGGCTGACGTGCA 930
Db ||||||||||||||||||
20 CCCAGCGGCTGACGTGCA 1
RESULT 841
ABD31536/c
ID ABD31536 standard; DNA; 20 BP.
XX
XX ABD31536;
XX
XX 29-JUL-2004 (first entry)
XX Human ICAM-derived oligonucleotide SEQ ID 13747.
DE
DE Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;

KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.

OS Homo sapiens.

PN WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13747; 763pp; English.

CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 801 CCAGGTCACCTGGCACTGG 820
 |||||
 Db 20 CCAGGTCACCTGGCACTGG 1

RESULT 842

ABD31545/c

ID ABD31545 standard; DNA; 20 BP.

XX ABD31545;

AC ABD31545;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13756.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;

XX surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;

XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

XX pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13756; 763pp; English.

CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX SQ Sequence 20 BP; 3 A; 2 C; 11 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 711 CCACAACTGTCAGCCCC 730
DB 20 CCACAACTGTCAGCCCC 1
RESULT 843
ABD31555/c
ID ABD31555 standard; DNA; 20 BP.
AC ABD31555;
XX
DT 29-JUL-2004 (first entry)
XX Human ICAM-derived oligonucleotide SEQ ID 13766.
DE Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; anti-asthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX Homo sapiens.
OS
XX WO200285309-A2.
PN
XX 31-OCT-2002.
PD
XX 23-APR-2002; 2002WO-US013143.
PF
XX 24-APR-2001; 2001US-0286036P.
PR
XX (EPIG-) EPIGENESIS PHARM INC.
PA
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
DR
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX Claim 15; SEQ ID NO 13766; 763pp; English.
PS
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, anti-asthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The

CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 611 CQTGCGCACTGCACTGGAC 630
DB 20 CQTGCGCACTGCACTGGAC 1
RESULT 844
ABD31566/c
ID ABD31566 standard; DNA; 20 BP.
XX
AC ABD31566;
XX
DT 29-JUL-2004 (first entry)
XX Human ICAM-derived oligonucleotide SEQ ID 13777.
DE Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; anti-asthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX Homo sapiens.
OS
XX WO200285309-A2.
PN
XX 31-OCT-2002.
PD
XX 23-APR-2002; 2002WO-US013143.
PF
XX 24-APR-2001; 2001US-0286036P.
PR
XX (EPIG-) EPIGENESIS PHARM INC.
PA
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
DR
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX Claim 15; SEQ ID NO 13777; 763pp; English.
PS
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, anti-asthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The

expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

Sequence 20 BP; 4 A; 10 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 501 GGTCGCTCCGCGGGGAGA 520
|||||
DB 20 GGTCGCTCCGCGGGGAGA 1

RESULT 845

ABD31574/C
ID ABD31574 standard; DNA; 20 BP.

AC ABD31574;

DT 29-JUL-2004 (first entry)

Human ICAM-derived oligonucleotide SEQ ID 13785.

Human; antisense; bronchoconstriction; allergy; hyposecretion; pain; respiratory tract inflammation; adenosine sensitivity; lung; cancer; surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic; analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis; beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction; respiratory distress syndrome; allergic rhinitis; pulmonary hypertension; emphysema; chronic obstructive pulmonary disease; cancer; bronchitis; pulmonary transplantation rejection; ss; primer.

Homo sapiens.

WO200285309-A2.

31-OCT-2002.

23-APR-2002; 2002WO-US013143.

24-APR-2001; 2001US-0286036P.

(EPIG-) EPIGENESIS PHARM INC.

Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D; Miller S, Tang L, Shahabuddin S;

WPI; 2003-093058/08.

Pharmaceutical composition for treating asthma, has antisense

oligonucleotide containing less percentage of adenosine, targeted to nucleic acids associated with lung airway or lung dysfunction, and bronchodilating agent.

Claim 15; SEQ ID NO 13785; 763pp; English.

This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 421 CCCTCTTGGCAGCCAGTGGG 440
|||||
DB 20 CCCTCTTGGCAGCCAGTGGG 1

RESULT 846

ABD31581/C

ID ABD31581 standard; DNA; 20 BP.

AC ABD31581;

DT 29-JUL-2004 (first entry)

Human ICAM-derived oligonucleotide SEQ ID 13792.

Human; antisense; bronchoconstriction; allergy; hyposecretion; pain; respiratory tract inflammation; adenosine sensitivity; lung; cancer; surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic; analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis; beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction; respiratory distress syndrome; allergic rhinitis; pulmonary hypertension; emphysema; chronic obstructive pulmonary disease; cancer; bronchitis; pulmonary transplantation rejection; ss; primer.

Homo sapiens.

WO200285309-A2.

31-OCT-2002.

```
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
XX (EPIC-) EPIGENESIS PHARM INC.
PA
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13792; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyosecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 3 A; 5 C; 4 G; 8 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 351 TGGGCAGTCAACAGCTAAAA 370
DB 20 TGGGCAGTCAACAGCTAAAA 1
| | | | | | | | | | | | | | | |
RESULT 847
ABD31594/c
ID ABD31594 standard; DNA; 20 BP.
XX
XX ABD31594;
AC
XX
XX 29-JUL-2004 (first entry)
DT
XX
XX Human ICAM-derived oligonucleotide SEQ ID 13805.
DE
XX
XX Human; antisense; bronchoconstriction; allergy; hyosecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
```

ABD31603/c
 ID ABD31603 standard; DNA; 20 BP.
 XX
 AC ABD31603;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13814.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13814; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 131 GCAATGCCAGACATCTGTG 150
 Db 20 GCAATGCCAGACATCTGTG 1
 RESULT 849
 ABD31613/c
 ID ABD31613 standard; DNA; 20 BP.
 XX
 AC ABD31613;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13824.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13824; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 31 ACTCAGAGTTGCAACCTCAG 50
 Db 20 ACTCAGAGTTGCAACCTCAG 1
 |||||
 RESULT 850
 ID ABD31616/c
 AC ABD31616;
 XX
 XX 29-JUL-2004 (first entry)
 DT
 XX Human ICAM-derived oligonucleotide SEQ ID 13827.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 XX Homo sapiens.
 OS
 XX WO200285309-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 PI
 XX WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13827; 763pp; English.
 PS
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung

CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GCGCCCCAGTCGACGCTGAG 20
 Db 20 GCGCCCCAGTCGACGCTGAG 1
 |||||
 RESULT 851
 ID ABD31417/c
 AC ABD31417 standard; DNA; 20 BP.
 XX
 XX ABD31417;
 XX
 XX 29-JUL-2004 (first entry)
 DT
 XX Human ICAM-derived oligonucleotide SEQ ID 13628.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 XX Homo sapiens.
 OS
 XX WO200285309-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 PI
 XX WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to

PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13628; 763pp; English.

PS This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC transplantation rejection, chronic obstructive pulmonary disease, pulmonary
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 5 A; 4 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1991 GAAATGCTGAACTTCTGTC 2010

DB 20 GAAATGCTGAACTTCTGTC 1

RESULT 852

ID ABD31423/C

XX ABD31423 standard; DNA; 20 BP.

AC ABD31423;

DT 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13634.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX

PR

XX

PA

XX

PI

XX

PI

XX

DR

XX

PT

XX

PT

XX

PT

XX

PS

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

CC

XX

24-APR-2001; 2001US-0286036P.

(EPIC-) EPICGENESIS PHARM INC.

Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

Miller S, Tang L, Shahabuddin S;

WPI; 2003-093058/08.

Pharmaceutical composition for treating asthma, has antisense

oligonucleotide containing less percentage of adenosine, targeted to

nucleic acids associated with lung airway or lung dysfunction, and

bronchodilating agent.

Claim 15; SEQ ID NO 13634; 763pp; English.

This invention describes a novel composition (a) a first active agent,

comprising oligonucleotides, effective for alleviating

bronchoconstriction, respiratory tract inflammation, allergies and

reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,

surfactant depletion or hyposecretion, when administered to a mammal. The

oligonucleotides are derived from a gene encoding or regulating

expression of a target polypeptide associated with lung airway or lung

dysfunction or cancer and can be anti-sense to the corresponding mRNA.

The invention also describes a kit, that comprises: (a) a delivery

device, in separate containers, (b) the oligonucleotides, (c)

instructions for adding a carrier and for use of the kit. The composition

of the invention has anti-allergic, anti-inflammatory, antiasthmatic,

analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

beta-adrenergic agonist. The composition is useful for preventing or

treating a respiratory, lung or malignant disease. The administered

composition comprises oligo and is administered to reduce the production

or availability, or to increase the degradation of the target mRNA or to

reduce the amount of target polypeptide present in the lungs. The

pulmonary obstruction, and/or bronchoconstriction and/or lung

inflammation, allergies and/or surfactant hypoproduction are associated

with a disease or condition such as pulmonary vasoconstriction,

inflammation, allergies, asthma, impeded respiration, respiratory

distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary

hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

transplantation rejection, chronic obstructive pulmonary disease, cancer.

The reduced adenosine content of the anti-sense oligos corresponding to

thymidines present in the target RNA serves to prevent the breakdown of

the oligonucleotides into products that free adenosine into the system

e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to

prevent any unwanted effects due to it

Sequence 20 BP; 3 A; 10 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1931 GCCTGATGAGAGGGGAGTG 1950

DB 20 GCCTGATGAGAGGGGAGTG 1

RESULT 853

ID ABD31428/C

XX ABD31428 standard; DNA; 20 BP.

AC ABD31428;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13639.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

respiratory tract inflammation; adenosine sensitivity; lung; cancer;

surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisen
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13639; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyosecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1881 CAAGAGGAGGACCAAGACT 1900
 Db |||||
 20 CAAGAGGAGGACCAAGACT 1
 RESULT 854
 ABD31464/c

ID ABD31464 standard; DNA; 20 BP.
 XX
 AC ABD31464;
 XX
 XX 29-JUL-2004 (first entry)
 XX
 XX Human ICAM-derived oligonucleotide SEQ ID 13675.
 DE
 XX
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 XX Homo sapiens.
 OS
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisen
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13675; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyosecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1521 AGCGGAGTCATATGGGCA 1540
 |||||
 DB 20 AGCGGAGTCATATGGGCA 1

RESULT 855

ABD31465/C
 ID ABD31465 standard; DNA; 20 BP.

XX ABD31465;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13676.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13676; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated

CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

SQ Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1511 CTGTGTAGCAGCGCAGTC 1530

|||||
 DB 20 CTGTGTAGCAGCGCAGTC 1

RESULT 856

ABD31490/C

ID ABD31490 standard; DNA; 20 BP.

XX ABD31490;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13701.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13701; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.

CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1261 GATTGTCGGGAACCTGGAC 1280
 DB 20 GATTGTCGGGAACCTGGAC 1
 |||||
 RESULT 857
 ID ABD31502/c
 ID ABD31502 standard; DNA; 20 BP.
 XX AC ABD31502;
 XX DT 29-JUL-2004 (first entry)
 XX DE Human ICAM-derived oligonucleotide SEQ ID 13713.
 XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX OS Homo sapiens.
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIC-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and

PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13713; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 0 A; 8 C; 6 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1141 CCAGAGGACACGGCGCGCAG 1160
 DB 20 CCAGAGGACACGGCGCGCAG 1
 |||||
 RESULT 858
 ID ABD31514/c
 ID ABD31514 standard; DNA; 20 BP.
 XX AC ABD31514;
 XX DT 29-JUL-2004 (first entry)
 XX DE Human ICAM-derived oligonucleotide SEQ ID 13725.
 XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX OS Homo sapiens.
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX

XX ABD31540;
AC XX 29-JUL-2004 (first entry)
DT XX Human ICAM-derived oligonucleotide SEQ ID 13751.
DE XX
DE XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
XX WO200285309-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
XX 24-APR-2001; 2001US-0286036P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13751; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 6 A; 8 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 761 TGGTCTGTTCCTGGACGGG 780
DB 20 TGGTCTGTTCCTGGACGGG 1

RESULT 861
ABD31547/c
ID ABD31547 standard; DNA; 20 BP.
XX ABD31547;
XX 29-JUL-2004 (first entry)
XX
XX Human ICAM-derived oligonucleotide SEQ ID 13758.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
XX WO200285309-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
XX 24-APR-2001; 2001US-0286036P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13758; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies and/or surfactant hypoproduction are associated

CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 691 TTGTCTCTGCGCAGGCTCC 710
 DB 20 TTGTCTCTGCGCAGGCTCC 1
 RESULT 862
 ABD31553/c
 ID ABD31553 standard; DNA; 20 BP.
 XX
 AC ABD31553;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13764.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cycostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PS Claim 15; SEQ ID NO 13764; 763pp; English.
 CC
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery

CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cycostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 631 CTGCGCCCCAGGGCTGGA 650
 DB 20 CTGCGCCCCAGGGCTGGA 1
 RESULT 863
 ABD31556/c
 ID ABD31556 standard; DNA; 20 BP.
 XX
 AC ABD31556;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13767.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cycostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX PS Claim 15; SEQ ID NO 13767; 763pp; English.

XX CC This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating

XX CC bronchoconstriction, respiratory tract inflammation, allergies and

XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The

XX CC oligonucleotides are derived from a gene encoding or regulating

XX CC expression of a target polypeptide associated with lung airway or lung

XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.

XX CC The invention also describes a kit, that comprises: (a) a delivery

XX CC device, in separate containers, (b) the oligonucleotides, (c)

XX CC instructions for adding a carrier and for use of the kit. The composition

XX CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,

XX CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

XX CC beta-adrenergic agonist. The composition is useful for preventing or

XX CC treating a respiratory, lung or malignant disease. The administered

XX CC composition comprises oligo and is administered to reduce the production

XX CC or availability, or to increase the degradation of the target mRNA or to

XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung

XX CC inflammation, allergies and/or surfactant hypoproduction are associated

XX CC with a disease or condition such as pulmonary vasoconstriction,

XX CC distress syndrome, asthma, impeded respiration, respiratory

XX CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

XX CC transplantation rejection, pulmonary infections, bronchitis or cancer.

XX CC The reduced adenosine content of the anti-sense oligos corresponding to

XX CC thymidines present in the target RNA serves to prevent the breakdown of

XX CC the oligonucleotides into products that free adenosine into the system

XX CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to

XX CC prevent any unwanted effects due to it

XX SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred.No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 601 GCCAATTCTCGTGGCGCAC 620
 |||||
 DB 20 GCCAATTCTCGTGGCGCAC 1

RESULT 864
 ABD31563/c
 ID ABD31563 standard; DNA; 20 BP.

AC ABD31563;

XX DT 29-JUL-2004 (first entry)

XX DE Human ICAM-derived oligonucleotide SEQ ID 13774.

XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 pulmonary transplantation rejection; ss; primer.

XX OS Homo sapiens.

XX PN W0200285309-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013143.

XX PR 24-APR-2001; 2001US-0286036P.

XX PA (EP1G-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 Miller S, Tang L, Shahabuddin S;
 WPI; 2003-093058/08.

XX DR

XX PT Pharmaceutical composition for treating asthma, has antisense
 oligonucleotide containing less percentage of adenosine, targeted to
 nucleic acids associated with lung airway or lung dysfunction, and
 bronchodilating agent.

XX PS Claim 15; SEQ ID NO 13774; 763pp; English.

XX CC This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating

XX CC bronchoconstriction, respiratory tract inflammation, allergies and

XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The

XX CC oligonucleotides are derived from a gene encoding or regulating

XX CC expression of a target polypeptide associated with lung airway or lung

XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.

XX CC The invention also describes a kit, that comprises: (a) a delivery

XX CC device, in separate containers, (b) the oligonucleotides, (c)

XX CC instructions for adding a carrier and for use of the kit. The composition

XX CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,

XX CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

XX CC beta-adrenergic agonist. The composition is useful for preventing or

XX CC treating a respiratory, lung or malignant disease. The administered

XX CC composition comprises oligo and is administered to reduce the production

XX CC or availability, or to increase the degradation of the target mRNA or to

XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung

XX CC inflammation, allergies and/or surfactant hypoproduction are associated

XX CC with a disease or condition such as pulmonary vasoconstriction,

XX CC distress syndrome, asthma, impeded respiration, respiratory

XX CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

XX CC transplantation rejection, pulmonary infections, bronchitis or cancer.

XX CC The reduced adenosine content of the anti-sense oligos corresponding to

XX CC thymidines present in the target RNA serves to prevent the breakdown of

XX CC the oligonucleotides into products that free adenosine into the system

XX CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to

XX CC prevent any unwanted effects due to it

XX SQ Sequence 20 BP; 2 A; 11 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred.No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 531 ACGGAGCCAGCTGTGGGG 550
 |||||
 DB 20 ACGGAGCCAGCTGTGGGG 1

RESULT 865
 ABD31437/c
 ID ABD31437 standard; DNA; 20 BP.

XX AC ABD31437;

XX DT 29-JUL-2004 (first entry)

XX DE Human ICAM-derived oligonucleotide SEQ ID 13648.

XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 XX WO200285309-A2.
 XX 31-OCT-2002.
 XX 23-APR-2002; 2002WO-US013143.
 XX 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13648; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 3 A; 3 C; 6 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1791 CTCAGTCAGATACACGCA 1810
 |||||
 Db 20 CTCAGTCAGATACACGCA 1
 RESULT 866
 ABO31443/C
 ID ABO31443 standard; DNA; 20 BP.
 XX

AC ABO31443;
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13654.
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 XX WO200285309-A2.
 XX 31-OCT-2002.
 XX 23-APR-2002; 2002WO-US013143.
 XX 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13654; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 4 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0

QY 1731 AGACATATGCGCAGCTA 1750
|||||
20 AGACATATGCGCAGCTA 1

Db

RESULT 867
ABD31447/c
ID ABD31447 standard; DNA; 20 BP.
XX
AC ABD31447;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human ICAM-derived oligonucleotide SEQ ID 13658.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13658; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has antiallergic, antiinflammatory, antiasthmatic, is a
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc. tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX

SQ Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1691 CCATATTCGTGGCAGTGGT 1710

Db 20 CCATATTCGTGGCAGTGGT 1

RESULT 868

ABD31453/c

ID ABD31453 standard; DNA; 20 BP.

XX

AC ABD31453;

XX

DT 29-JUL-2004 (first entry)

XX

XX Human ICAM-derived oligonucleotide SEQ ID 13664.

XX

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;

XX surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;

XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

XX pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX

XX WO200285309-A2.

XX

XX 31-OCT-2002.

XX

XX 23-APR-2002; 2002WO-US013143.

XX

XX 24-APR-2001; 2001US-0286036P.

XX

XX (EPIG-) EPIGENESIS PHARM INC.

XX

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX

XX Pharmaceutical composition for treating asthma, has antisense

XX oligonucleotide containing less percentage of adenosine, targeted to

XX nucleic acids associated with lung airway or lung dysfunction, and

XX bronchodilating agent.

XX

XX Claim 15; SEQ ID NO 13664; 763pp; English.

XX

XX This invention describes a novel composition (a) a first active agent,

XX comprising oligonucleotides, effective for alleviating

XX bronchoconstriction, respiratory tract inflammation, allergies and

XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,

XX surfactant depletion or hyposecretion, when administered to a mammal. The

XX oligonucleotides are derived from a gene encoding or regulating

XX expression of a target polypeptide associated with lung airway or lung

XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.

XX The invention also describes a kit, that comprises: (a) a delivery

XX device, in separate containers, (b) the oligonucleotides, (c)

XX instructions for adding a carrier and for use of the kit. The composition

XX of the invention has antiallergic, antiinflammatory, antiasthmatic, is a

XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

XX beta-adrenergic agonist. The composition is useful for preventing or

XX treating a respiratory, lung or malignant disease. The administered

XX composition comprises oligo and is administered to reduce the production

CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 1 A; 3 C; 9 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1631 CGAACACACAGCCAGCGCT 1650

DB 20 CGAACACACAGCCAGCGCT 1

RESULT 869

ID ABD31478/c
 ID ABD31478 standard; DNA; 20 BP.

AC ABD31478;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13689.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 PI WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to

PT nucleic acids associated with lung airway or lung dysfunction, and

PT bronchodilating agent.

PS Claim 15; SEQ ID NO 13689; 763bp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1381 GGGGAATCAGTCACTGTCAC 1400

DB 20 GGGGAATCAGTCACTGTCAC 1

RESULT 870

ABD31482/c

ID ABD31482 standard; DNA; 20 BP.

AC ABD31482;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13693.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.


```
PA (EPiG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13693; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX transplantation rejection, pulmonary infections, bronchitis or cancer.
XX The reduced adenosine content of the anti-sense oligos corresponding to
XX thymidines present in the target RNA serves to prevent the breakdown of
XX the oligonucleotides into products that free adenosine into the system
XX e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1341 GCTCAAGTGCTAAAGATG 1360
Db 20 GCTCAAGTGCTAAAGATG 1

RESULT 871
ABD31485/c
XX ID ABD31485 standard; DNA; 20 BP.
XX AC ABD31485;
XX
XX 29-JUL-2004 (first entry)
XX
XX Human ICAM-derived oligonucleotide SEQ ID 13696.
XX
XX Human; antisense: bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX
```

```
KW pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
XX
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPiG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13696; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX transplantation rejection, pulmonary infections, bronchitis or cancer.
XX The reduced adenosine content of the anti-sense oligos corresponding to
XX thymidines present in the target RNA serves to prevent the breakdown of
XX the oligonucleotides into products that free adenosine into the system
XX e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1311 GTGCCAGGCTTGGGGAAACC 1330
Db 20 GTGCCAGGCTTGGGGAAACC 1

RESULT 872
ABD31501/c
XX ID ABD31501 standard; DNA; 20 BP.
XX AC ABD31501;
```


CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
 CC
 CC Query Match 0.7%; Score 20; DB 1; Length 20;
 CC Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 CC Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 QY 921 GACGTGTCAGTAATACTGG 940
 Db 20 GACGTGTCAGTAATACTGG 1
 ||||||||||||||||||
 RESULT 874
 ABD31559/c
 ID ABD31559 standard; DNA; 20 BP.
 XX
 AC ABD31559;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13770.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PS Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 Claim 15; SEQ ID NO 13770; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition

CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 3 A; 10 C; 2 G; 5 T; 0 U; 0 Other;
 CC
 CC Query Match 0.7%; Score 20; DB 1; Length 20;
 CC Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 CC Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 QY 571 ACGGTGCTGGTGAGGAGAGA 590
 Db 20 ACGGTGCTGGTGAGGAGAGA 1
 ||||||||||||||||||
 RESULT 875
 ABD31590/c
 ID ABD31590 standard; DNA; 20 BP.
 XX
 AC ABD31590;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13801.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PS Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 Claim 15; SEQ ID NO 13801; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 261 GTTGCTCCTGCGGGAACA 280
 Db |||||
 20 GTTGCTCCTGCGGGAACA 1
 XX
 RESULT 876
 ABD31593/C
 ID ABD31593 standard; DNA; 20 BP.
 XX
 AC ABD31593;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13804.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 PN
 XX
 PD 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA

XX NYCE JW, Li Y, Sandraesgra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13804; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 231 GGGCATAGAGACCCGTTGC 250
 Db |||||
 20 GGGCATAGAGACCCGTTGC 1
 XX
 RESULT 877
 ABD31597/C
 ID ABD31597 standard; DNA; 20 BP.
 XX
 AC ABD31597;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13808.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

```
XX OS Homo sapiens.
XX PN WO200285309-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013143.
XX PR 24-APR-2001; 2001US-0286036P.
XX PA (EPIC-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-093058/08.
XX PT Pharmaceutical composition for treating asthma, has antisense
XX PT oligonucleotide containing less percentage of adenosine, targeted to
XX PT nucleic acids associated with lung airway or lung dysfunction, and
XX PT bronchodilating agent.
XX PS Claim 15; SEQ ID NO 13808; 763pp; English.
XX CC This invention describes a novel composition (a) a first active agent,
XX CC comprising oligonucleotides, effective for alleviating
XX CC bronchoconstriction, respiratory tract inflammation, allergies and
XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX CC surfactant depletion or hyposecretion, when administered to a mammal. The
XX CC oligonucleotides are derived from a gene encoding or regulating
XX CC expression of a target polypeptide associated with lung airway or lung
XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX CC The invention also describes a kit, that comprises: (a) a delivery
XX CC device, in separate containers, (b) the oligonucleotides, (c)
XX CC instructions for adding a carrier and for use of the kit. The composition
XX CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX CC beta-adrenergic agonist. The composition is useful for preventing or
XX CC treating a respiratory, lung or malignant disease. The administered
XX CC composition comprises oligo and is administered to reduce the production
XX CC or availability, or to increase the degradation of the target mRNA or to
XX CC reduce the amount of target polypeptide present in the lungs. The
XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung
XX CC inflammation, allergies and/or surfactant hypoproduction are associated
XX CC with a disease or condition such as pulmonary vasoconstriction,
XX CC inflammation, allergies, asthma, impeded respiration, respiratory
XX CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX CC transplantation rejection, pulmonary infections, bronchitis or cancer.
XX CC The reduced adenosine content of the anti-sense oligos corresponding to
XX CC thymidines present in the target RNA serves to prevent the breakdown of
XX CC the oligonucleotides into products that free adenosine into the system
XX CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX CC prevent any unwanted effects due to it
XX SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 191 TGGTGACATGCACGACCTCC 210
Db |||||
20 TGGTGACATGCACGACCTCC 1
RESULT 878
ABD31614/C
ID ABD31614 standard; DNA; 20 BP.
XX
AC ABD31614;
XX
```

```
DT 29-JUL-2004 (first entry)
XX Human ICAM-derived oligonucleotide SEQ ID 13825.
XX DE
XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX KW pulmonary transplantation rejection; ss; primer.
XX OS Homo sapiens.
XX XX WO200285309-A2.
XX PD 31-OCT-2002.
XX PF 23-APR-2002; 2002WO-US013143.
XX PR 24-APR-2001; 2001US-0286036P.
XX PA (EPIC-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
XX PI Miller S, Tang L, Shahabuddin S;
XX DR WPI; 2003-093058/08.
XX PT Pharmaceutical composition for treating asthma, has antisense
XX PT oligonucleotide containing less percentage of adenosine, targeted to
XX PT nucleic acids associated with lung airway or lung dysfunction, and
XX PT bronchodilating agent.
XX PS Claim 15; SEQ ID NO 13825; 763pp; English.
XX CC This invention describes a novel composition (a) a first active agent,
XX CC comprising oligonucleotides, effective for alleviating
XX CC bronchoconstriction, respiratory tract inflammation, allergies and
XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX CC surfactant depletion or hyposecretion, when administered to a mammal. The
XX CC oligonucleotides are derived from a gene encoding or regulating
XX CC expression of a target polypeptide associated with lung airway or lung
XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX CC The invention also describes a kit, that comprises: (a) a delivery
XX CC device, in separate containers, (b) the oligonucleotides, (c)
XX CC instructions for adding a carrier and for use of the kit. The composition
XX CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX CC beta-adrenergic agonist. The composition is useful for preventing or
XX CC treating a respiratory, lung or malignant disease. The administered
XX CC composition comprises oligo and is administered to reduce the production
XX CC or availability, or to increase the degradation of the target mRNA or to
XX CC reduce the amount of target polypeptide present in the lungs. The
XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung
XX CC inflammation, allergies and/or surfactant hypoproduction are associated
XX CC with a disease or condition such as pulmonary vasoconstriction,
XX CC inflammation, allergies, asthma, impeded respiration, respiratory
XX CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX CC transplantation rejection, pulmonary infections, bronchitis or cancer.
XX CC The reduced adenosine content of the anti-sense oligos corresponding to
XX CC thymidines present in the target RNA serves to prevent the breakdown of
XX CC the oligonucleotides into products that free adenosine into the system
XX CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX CC prevent any unwanted effects due to it
XX SQ Sequence 20 BP; 7 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 21 CTCCTCTGCTACTCAGAGTT 40
 DB 20 CTCCTCTGCTACTCAGAGTT 1

RESULT 879
 ABD31409/c
 ID ABD31409 standard; DNA; 20 BP.
 AC ABD31409;
 XX
 XX 29-JUL-2004 (first entry)
 DE Human ICAM-derived oligonucleotide SEQ ID 13620.
 XX
 XX Human; antiseize; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiasthmatic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antiseize
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13620; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 2 A; 3 C; 5 G; 10 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2070 TAGCATCAAAACACAAAGGC 2089
 DB 20 TAGCATCAAAACACAAAGGC 1
 RESULT 880
 ABD31415/c
 ID ABD31415 standard; DNA; 20 BP.
 XX
 XX ABD31415;
 AC
 XX
 XX 29-JUL-2004 (first entry)
 DT
 XX
 XX Human ICAM-derived oligonucleotide SEQ ID 13626.
 DE
 XX
 XX Human; antiseize; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiasthmatic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antiseize
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13626; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 SQ Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2011 CTATTGGGTATGCTGAGGCC 2030
 DB 20 CTATTGGGTATGCTGAGGCC 1
 |||||
 RESULT 881
 ABD31432/C
 ID ABD31432 standard; DNA; 20 BP.
 XX ABD31432;
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13643.
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS WO200285309-A2.
 PN 31-OCT-2002.
 XX 23-APR-2002; 2002WO-US013143.
 XX 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 PI WPI; 2003-093058/08.
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13643; 763pp; English.

CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1841 CACTAGGCCACGCATCTGAT 1860
 DB 20 CACTAGGCCACGCATCTGAT 1
 |||||
 RESULT 882
 ABD31457/C
 ID ABD31457 standard; DNA; 20 BP.
 XX ABD31457;
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13668.
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS WO200285309-A2.
 PN 31-OCT-2002.
 XX 23-APR-2002; 2002WO-US013143.
 XX 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR
 XX
 XX
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX
 PS Claim 15; SEQ ID NO 13668; 763pp; English.
 CC
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 2 A; 3 C; 7 G; 8 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1591 TACAGACTACACAGGCCCA 1610
 DB 20 TACAGACTACACAGGCCCA 1
 RESULT 883
 ABD31462/c
 ID ABD31462 standard; DNA; 20 BP.
 XX
 AC ABD31462;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13673.
 XX
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX

OS Homo sapiens.
 XX
 PN W0200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 PI
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 DR
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13673; 763pp; English.
 CC
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1541 CTGACGGCTCTCAGCAGGTAC 1560
 DB 20 CTGACGGCTCTCAGCAGGTAC 1
 RESULT 884
 ABD31467/c
 ID ABD31467 standard; DNA; 20 BP.
 XX
 AC ABD31467;
 XX
 DT 29-JUL-2004 (first entry)
 XX

XX DE Human ICAM-derived oligonucleotide SEQ ID 13678.
 XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX KW Homo sapiens.
 OS XX
 XX DE WO200285309-A2.
 XX PN
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX XX
 XX PR 24-APR-2001; 2001US-0286036P.
 XX XX
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX XX
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX XX
 XX DR WPI; 2003-093058/08.
 XX XX
 XX PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX XX
 XX PS Claim 15; SEQ ID NO 13678; 763pp; English.
 XX XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX XX
 XX SQ Sequence 20 BP; 7 A; 4 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1491 GATGAGATTGTCATCATCA 1510
 Db |||||
 20 GATGAGATTGTCATCATCA 1
 RESULT 885
 ABD31475/c
 ID ABD31475 standard; DNA; 20 BP.
 XX ABD31475;
 XX 29-JUL-2004 (first entry)
 XX XX
 XX DE Human ICAM-derived oligonucleotide SEQ ID 13686.
 XX XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX XX
 OS Homo sapiens.
 XX XX
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX XX
 XX PF 23-APR-2002; 2002WO-US013143.
 XX XX
 XX PR 24-APR-2001; 2001US-0286036P.
 XX XX
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX XX
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 DR WPI; 2003-093058/08.
 XX XX
 XX PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX XX
 XX PS Claim 15; SEQ ID NO 13686; 763pp; English.
 XX XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX XX
 XX SQ Sequence 20 BP; 7 A; 4 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1411 GAGGGACCTACCTCTGTCG 1430
 |||||
 DB 20 GAGGGACCTACCTCTGTCG 1

RESULT 886
 ABD31481/c
 ID ABD31481 standard; DNA; 20 BP.
 XX
 AC ABD31481;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13692.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.

XX WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13692; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1351 CTAAGGATGGCACTTTCCC 1370
 |||||
 DB 20 CTAAGGATGGCACTTTCCC 1

RESULT 887
 ABD31487/c
 ID ABD31487 standard; DNA; 20 BP.
 XX
 AC ABD31487;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13698.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.
 XX WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13698; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,

CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 4 A; 2 C; 7 G; 7 T; 0 U; 0 Other;
 CC
 CC Query Match 0.7%; Score 20; DB 1; Length 20;
 CC Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 CC Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 CC QY 1291 AATCCAGCAGACTCCAAAT 1310
 CC Db 20 AATCCAGCAGACTCCAAAT 1
 CC
 CC RESULT 888
 CC ABD31494/C
 CC ID ABD31494 standard; DNA; 20 BP.
 CC AC ABD31494;
 CC XX
 CC DT 29-JUL-2004 (first entry)
 CC XX
 CC DE Human ICAM-derived oligonucleotide SEQ ID 13705.
 CC XX
 CC KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 CC KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 CC KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 CC KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 CC KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 CC KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 CC KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 CC KW pulmonary transplantation rejection; ss; primer.
 CC XX
 CC OS Homo sapiens.
 CC XX
 CC PN WO200285309-A2.
 CC XX
 CC PD 31-OCT-2002.
 CC XX
 CC PF 23-APR-2002; 2002WO-US013143.
 CC XX
 CC PR 24-APR-2001; 2001US-0286036P.
 CC XX
 CC PA (SPIG-) EPIGENESIS PHARM INC.
 CC XX
 CC PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13705; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 7 A; 7 C; 4 G; 2 T; 0 U; 0 Other;
 CC
 CC Query Match 0.7%; Score 20; DB 1; Length 20;
 CC Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 CC Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 CC QY 1221 GGAGCTTCGTGTCCTGATG 1240
 CC Db 20 GGAGCTTCGTGTCCTGATG 1
 CC
 CC RESULT 889
 CC ABD31506/C
 CC ID ABD31506 standard; DNA; 20 BP.
 CC XX
 CC AC ABD31506;
 CC XX
 CC DT 29-JUL-2004 (first entry)
 CC XX
 CC DE Human ICAM-derived oligonucleotide SEQ ID 13717.
 CC XX
 CC KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 CC KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 CC KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 CC KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 CC KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 CC KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 CC KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 CC KW pulmonary transplantation rejection; ss; primer.
 CC XX
 CC OS Homo sapiens.

XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 XX PI Miller S, Tang L, Shahabuddin S;
 XX DR WPI; 2003-093058/08.
 XX PT Pharmaceutical composition for treating asthma, has antisense
 XX PT oligonucleotide containing less percentage of adenosine, targeted to
 XX PT nucleic acids associated with lung airway or lung dysfunction, and
 XX PT bronchodilating agent.
 XX PS Claim 15; SEQ ID NO 13717; 763pp; English.
 XX CC This invention describes a novel composition (a) a first active agent,
 XX CC comprising oligonucleotides, effective for alleviating
 XX CC bronchoconstriction, respiratory tract inflammation, allergies and
 XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 XX CC surfactant depletion or hyposecretion, when administered to a mammal. The
 XX CC oligonucleotides are derived from a gene encoding or regulating
 XX CC expression of a target polypeptide associated with lung airway or lung
 XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 XX CC The invention also describes a kit, that comprises: (a) a delivery
 XX CC device, in separate containers, (b) the oligonucleotides, (c)
 XX CC instructions for adding a carrier and for use of the kit. The composition
 XX CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 XX CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 XX CC beta-adrenergic agonist. The composition is useful for preventing or
 XX CC treating a respiratory, lung or malignant disease. The administered
 XX CC composition comprises oligo and is administered to reduce the production
 XX CC or availability, or to increase the degradation of the target mRNA or to
 XX CC reduce the amount of target polypeptide present in the lungs. The
 XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 XX CC inflammation, allergies and/or surfactant hypoproduction are associated
 XX CC with a disease or condition such as pulmonary vasoconstriction,
 XX CC inflammation, allergies, asthma, impeded respiration, respiratory
 XX CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 XX CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 XX CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 XX CC The reduced adenosine content of the anti-sense oligos corresponding to
 XX CC thymidines present in the target RNA serves to prevent the breakdown of
 XX CC the oligonucleotides into products that free adenosine into the system
 XX CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 XX CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 1 A; 8 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 1101 GCCACTGGCCCGAGGCC 1120
 Db 20 GCCACTGGCCCGAGGCC 1
 RESULT 890
 ABD31538/c
 ID ABD31538 standard; DNA; 20 BP.
 AC ABD31538;
 XX AC ABD31538;
 XX DT 29-JUL-2004 (first entry)
 XX

DE XX Human ICAM-derived oligonucleotide SEQ ID 13749.
 KW XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW XX pulmonary transplantation rejection; sb; primer.
 XX OS Homo sapiens.
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 XX PI Miller S, Tang L, Shahabuddin S;
 XX DR WPI; 2003-093058/08.
 XX PT Pharmaceutical composition for treating asthma, has antisense
 XX PT oligonucleotide containing less percentage of adenosine, targeted to
 XX PT nucleic acids associated with lung airway or lung dysfunction, and
 XX PT bronchodilating agent.
 XX PS Claim 15; SEQ ID NO 13749; 763pp; English.
 XX CC This invention describes a novel composition (a) a first active agent,
 XX CC comprising oligonucleotides, effective for alleviating
 XX CC bronchoconstriction, respiratory tract inflammation, allergies and
 XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 XX CC surfactant depletion or hyposecretion, when administered to a mammal. The
 XX CC oligonucleotides are derived from a gene encoding or regulating
 XX CC expression of a target polypeptide associated with lung airway or lung
 XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 XX CC The invention also describes a kit, that comprises: (a) a delivery
 XX CC device, in separate containers, (b) the oligonucleotides, (c)
 XX CC instructions for adding a carrier and for use of the kit. The composition
 XX CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 XX CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 XX CC beta-adrenergic agonist. The composition is useful for preventing or
 XX CC treating a respiratory, lung or malignant disease. The administered
 XX CC composition comprises oligo and is administered to reduce the production
 XX CC or availability, or to increase the degradation of the target mRNA or to
 XX CC reduce the amount of target polypeptide present in the lungs. The
 XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 XX CC inflammation, allergies and/or surfactant hypoproduction are associated
 XX CC with a disease or condition such as pulmonary vasoconstriction,
 XX CC inflammation, allergies, asthma, impeded respiration, respiratory
 XX CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 XX CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 XX CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 XX CC The reduced adenosine content of the anti-sense oligos corresponding to
 XX CC thymidines present in the target RNA serves to prevent the breakdown of
 XX CC the oligonucleotides into products that free adenosine into the system
 XX CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 XX CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 5 A; 6 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 781 CTGTTCCAGTCTCGGAGGC 800

CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 251 CTAAAGAGGAGTTGCTCCCTG 270
 DB 20 CTAAAGAGGAGTTGCTCCCTG 1
 RESULT 892
 ABD31592/c
 ID ABD31592 standard; DNA; 20 BP.
 XX
 AC ABD31592;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13803.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13802; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to

DB 20 CTGTTCCCACTCTCGGAGGC 1
 RESULT 891
 ABD31591/c
 ID ABD31591 standard; DNA; 20 BP.
 XX
 AC ABD31591;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13802.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13802; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to

CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypotension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 241 ACCCGTTCCTAAAGGA 260
 DB 20 ACCCGTTCCTAAAGGA 1

RESULT 893
 ABD31602/C

ID ABD31602 standard; DNA; 20 BP.

XX ABD31602;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13813.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13813; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating

CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypotension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 141 GACATCTGTGTCCTCAAA 160

DB 20 GACATCTGTGTCCTCAAA 1

RESULT 894

ABD31435/C

ID ABD31435 standard; DNA; 20 BP.

XX ABD31435;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13646.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX DR WPI; 2003-093058/08.

XX PT Pharmaceutical composition for treating asthma, has antisense

XX PT oligonucleotide containing less percentage of adenosine, targeted to

XX PT nucleic acids associated with lung airway or lung dysfunction, and

XX PT bronchodilating agent.

XX PS Claim 15; SEQ ID NO 13646; 763pp; English.

XX CC This invention describes a novel composition (a) a first active agent,

XX CC comprising oligonucleotides, effective for alleviating

XX CC bronchoconstriction, respiratory tract inflammation, allergies and

XX CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,

XX CC surfactant depletion or hyposecretion, when administered to a mammal. The

XX CC oligonucleotides are derived from a gene encoding or regulating

XX CC expression of a target polypeptide associated with lung airway or lung

XX CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.

XX CC The invention also describes a kit, that comprises: (a) a delivery

XX CC device, in separate containers, (b) the oligonucleotides, (c)

XX CC instructions for adding a carrier and for use of the kit. The composition

XX CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,

XX CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

XX CC beta-adrenergic agonist. The composition is useful for preventing or

XX CC treating a respiratory, lung or malignant disease. The administered

XX CC composition comprises oligo and is administered to reduce the production

XX CC or availability, or to increase the degradation of the target mRNA or to

XX CC reduce the amount of target polypeptide present in the lungs. The

XX CC pulmonary obstruction, and/or bronchoconstriction and/or lung

XX CC inflammation, allergies and/or surfactant hypoproduction are associated

XX CC with a disease or condition such as pulmonary vasoconstriction,

XX CC inflammation, allergies, asthma, impeded respiration, respiratory

XX CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary

XX CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

XX CC transplantation rejection, pulmonary infections, bronchitis or cancer.

XX CC The reduced adenosine content of the anti-sense oligos corresponding to

XX CC thymidines present in the target RNA serves to prevent the breakdown of

XX CC the oligonucleotides into products that free adenosine into the system

XX CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to

XX CC prevent any unwanted effects due to it

XX SQ Sequence 20 BP; 6 A; 7 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1811 TTGTGGGGCCATGTACTCTGC 1830

Db 20 TTGTGGGGCCATGTACTCTGC 1

RESULT 895

ID ABD31452/c

AC ABD31452 standard; DNA; 20 BP.

XX ABD31452;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13663.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;

XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

XX pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

PN WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense

XX oligonucleotide containing less percentage of adenosine, targeted to

XX nucleic acids associated with lung airway or lung dysfunction, and

XX bronchodilating agent.

XX Claim 15; SEQ ID NO 13663; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,

XX comprising oligonucleotides, effective for alleviating

XX bronchoconstriction, respiratory tract inflammation, allergies and

XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,

XX surfactant depletion or hyposecretion, when administered to a mammal. The

XX oligonucleotides are derived from a gene encoding or regulating

XX expression of a target polypeptide associated with lung airway or lung

XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.

XX The invention also describes a kit, that comprises: (a) a delivery

XX device, in separate containers, (b) the oligonucleotides, (c)

XX instructions for adding a carrier and for use of the kit. The composition

XX of the invention has anti-allergic, anti-inflammatory, antiasthmatic,

XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

XX beta-adrenergic agonist. The composition is useful for preventing or

XX treating a respiratory, lung or malignant disease. The administered

XX composition comprises oligo and is administered to reduce the production

XX or availability, or to increase the degradation of the target mRNA or to

XX reduce the amount of target polypeptide present in the lungs. The

XX pulmonary obstruction, and/or bronchoconstriction and/or lung

XX inflammation, allergies and/or surfactant hypoproduction are associated

XX with a disease or condition such as pulmonary vasoconstriction,

XX inflammation, allergies, asthma, impeded respiration, respiratory

XX distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary

XX hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

XX transplantation rejection, pulmonary infections, bronchitis or cancer.

XX The reduced adenosine content of the anti-sense oligos corresponding to

XX thymidines present in the target RNA serves to prevent the breakdown of

XX the oligonucleotides into products that free adenosine into the system

XX e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to

XX prevent any unwanted effects due to it

XX SQ Sequence 20 BP; 3 A; 3 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1641 AGCCAGCGCTCCCTGAACCT 1660

Db 20 AGCCAGCGCTCCCTGAACCT 1

RESULT 896

ID ABD31474/c

XX ABD31474 standard; DNA; 20 BP.

XX ABD31474;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13685.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cycostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13685; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic, is a
 CC analgesic, hypotensive, immunosuppressive and cycostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC the oligonucleotides into the target RNA serves to prevent the breakdown of
 CC e.g., lung, brain, kidney, etc. tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1421 ACCTCTGTCGGCCAGGAGC 1440
 ||||||||||||||||||

Db 20 ACCTCTGTCGGCCAGGAGC 1
 RESULT 897
 ABD31476/c
 ID ABD31476 standard; DNA; 20 BP.
 XX
 AC ABD31476;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13687.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cycostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13687; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic, is a
 CC analgesic, hypotensive, immunosuppressive and cycostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC the oligonucleotides into the target RNA serves to prevent the breakdown of
 CC thymidines present in the target RNA serves to prevent the breakdown of

CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1401 TCGAGATCTTGAGGGCACCT 1420
DB 20 TCGAGATCTTGAGGGCACCT 1
RESULT 898
ABD31488/C
ID ABD31488 standard; DNA; 20 BP.
XX
AC ABD31488;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human ICAM-derived oligonucleotide SEQ ID 13699.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 13699; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposcretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered

CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1281 GTGGCCAGAAAATTCACG 1300
DB 20 GTGGCCAGAAAATTCACG 1
RESULT 899
ABD31491/C
ID ABD31491 standard; DNA; 20 BP.
XX
AC ABD31491;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human ICAM-derived oligonucleotide SEQ ID 13702.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 13702; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposcretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered

CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 XX Sequence 20 BP; 3 A; 10 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1251 GGACGAGAGGGATTGTCGG 1270

DB 20 GGACGAGAGGGATTGTCGG 1

RESULT 900

ABD31515/C

ID ABD31515 standard; DNA; 20 BP.

XX ABD31515;

XX 29-JUL-2004 (first entry)

XX Human ICM-derived oligonucleotide SEQ ID 13726.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;

XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

XX pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIC-) EPICGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasegra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX

DR WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to

PT nucleic acids associated with lung airway or lung dysfunction, and

PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13726; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,

CC comprising oligonucleotides, effective for alleviating

CC bronchoconstriction, respiratory tract inflammation, allergies and

CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,

CC surfactant depletion or hyposecretion, when administered to a mammal. The

CC oligonucleotides are derived from a gene encoding or regulating

CC expression of a target polypeptide associated with lung airway or lung

CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.

CC The invention also describes a kit, that comprises: (a) a delivery

CC device, in separate containers, (b) the oligonucleotides, (c)

CC instructions for adding a carrier and for use of the kit. The composition

CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic, is a

CC beta-adrenergic agonist. The composition is useful for preventing or

CC treating a respiratory, lung or malignant disease. The administered

CC composition comprises oligo and is administered to reduce the production

CC or availability, or to increase the degradation of the target mRNA or to

CC reduce the amount of target polypeptide present in the lungs. The

CC pulmonary obstruction, and/or bronchoconstriction and/or lung

CC inflammation, allergies and/or surfactant hypoproduction are associated

CC with a disease or condition such as pulmonary vasoconstriction,

CC inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary

CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

CC transplantation rejection, pulmonary infections, bronchitis or cancer.

CC The reduced adenosine content of the anti-sense oligos corresponding to

CC thymidines present in the target RNA serves to prevent the breakdown of

CC the oligonucleotides into products that free adenosine into the system

CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to

CC prevent any unwanted effects due to it

XX Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAAGCCAGAGGTTCTCAGAAG 1030

DB 20 GAAGCCAGAGGTTCTCAGAAG 1

RESULT 901

ABD31520/C

ID ABD31520 standard; DNA; 20 BP.

XX ABD31520;

XX 29-JUL-2004 (first entry)

XX Human ICM-derived oligonucleotide SEQ ID 13731.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;

XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

XX pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13731; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 961 CTGCAGACAGTGACCATCTA 980
 Db ||||||||||||||||
 20 CTGCAGACAGTGACCATCTA 1
 RESULT 902
 ABD31532/c
 ID ABD31532 standard; DNA; 20 BP.
 AC ABD31532;
 XX ABD31532;
 XX 29-JUL-2004 (first entry)
 DT Human ICAM-derived oligonucleotide SEQ ID 13743.
 XX

KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS WO200285309-A2.
 PN 31-OCT-2002.
 PD 23-APR-2002; 2002WO-US013143.
 PF 24-APR-2001; 2001US-0286036P.
 PR (EPIG-) EPIGENESIS PHARM INC.
 XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13743; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 841 ACAGTCACCTATGGCAACGA 860
 Db ||||||||||||||||
 20 ACAGTCACCTATGGCAACGA 1

CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 1 A; 10 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 741 GGTGGACACGCGGACCG 760
 Db 20 GGTGGACACGCGGACCG 1
 RESULT 904
 ABD31542/c
 ID ABD31542 standard; DNA; 20 BP.
 XX
 AC ABD31542;
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13753.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13753; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system

CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 1 A; 10 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 741 GGTGGACACGCGGACCG 760
 Db 20 GGTGGACACGCGGACCG 1
 RESULT 904
 ABD31558/c
 ID ABD31558 standard; DNA; 20 BP.
 XX
 AC ABD31558;
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13769.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13769; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system

CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 XX Sequence 20 BP; 3 A; 7 C; 7 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 581 TGAGGAGAGATCACCATTGGA 600
 Db 20 TGAGGAGAGATCACCATTGGA 1
 RESULT 905
 ABD31608/c
 ID ABD31608 standard; DNA; 20 BP.
 AC ABD31608;
 XX
 DT 29-JUL-2004 (first entry)
 DE Human ICAM-derived oligonucleotide SEQ ID 13819.
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 FT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13819; 763bp; English.
 PS
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,

CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer.
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 XX Sequence 20 BP; 3 A; 6 C; 10 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 81 CGCGTGTCCCGCACTCTCTGG 100
 Db 20 CGCGTGTCCCGCACTCTCTGG 1
 RESULT 906
 ABD31408/c
 ID ABD31408 standard; DNA; 20 BP.
 AC ABD31408;
 XX
 DT 29-JUL-2004 (first entry)
 DE Human ICAM-derived oligonucleotide SEQ ID 13619.
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX

XX Pharmacutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13619; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyosecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 2 A; 2 C; 9 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2080 ACACAAAGGCCCACTTCC 2099
 |||||
 DB 20 ACACAAAGGCCCACTTCC 1

RESULT 907
 ABD31433/C
 ID ABD31433 standard; DNA; 20 BP.
 AC ABD31433;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13644.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyosecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.
 OS
 XX
 XX WO200285309-A2.
 PN
 XX

PD 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIC-) EPIGENESIS PHARM INC.
 PA
 XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 PI
 XX WPI; 2003-093058/08.
 DR
 XX Pharmacutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13644; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyosecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 2 A; 2 C; 7 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1831 ACACCTAAACACTAGGCCA 1850
 |||||
 DB 20 ACACCTAAACACTAGGCCA 1

RESULT 908
 ABD31434/C
 ID ABD31434 standard; DNA; 20 BP.
 XX
 AC ABD31434;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13645.
 XX
 XX Human; antisense; bronchoconstriction; allergy; hyosecretion; pain;

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cyostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS
 XX WO200285309-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13645; 763pp; English.
 PS
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic, is a
 CC analgesic, hypotensive, immunosuppressive and cyostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 4 A; 3 C; 6 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1921 TGGTACTCGACACCTTAAA 1840
 |||||
 Db 20 TGGTACTCGACACCTTAAA 1

RESULT 909
 ABD311440/c
 ID ABD31440 standard; DNA; 20 BP.
 XX
 AC ABD31440;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 XX Human ICAM-derived oligonucleotide SEQ ID 13651.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cyostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS
 XX WO200285309-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13651; 763pp; English.
 PS
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic, is a
 CC analgesic, hypotensive, immunosuppressive and cyostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 4 A; 3 C; 6 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1921 TGGTACTCGACACCTTAAA 1840
 |||||
 Db 20 TGGTACTCGACACCTTAAA 1

CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1761 CCTGGGACCCGGAGGACA 1780
 |||||
 DB 20 CCTGGGACCCGGAGGACA 1
 RESULT 910
 ABD31446/c
 ID ABD31446 standard; DNA; 20 BP.
 AC ABD31446;
 XX
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13657.
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13657; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to

CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1701 TGGCAGTGGTGCCACACTGA 1720
 |||||
 DB 20 TGGCAGTGGTGCCACACTGA 1
 RESULT 911
 ABD31455/c
 ID ABD31455 standard; DNA; 20 BP.
 XX
 AC ABD31455;
 XX
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13666.
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13666; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to

CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cyostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc. tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 1 A; 4 C; 6 G; 9 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1611 AAAAGGACCCCATGAAC 1630
 Db | | | | | | | | | | | | | | | | | | | |
 20 AAAAGGACCCCATGAAC 1
 RESULT 912
 ABD31489/c
 ID ABD31489 standard; DNA; 20 BP.
 AC ABD31489;
 XX
 XX 29-JUL-2004 (first entry)
 DT Human ICAM-derived oligonucleotide SEQ ID 13700.
 DE
 XX Human; antisease; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cyostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 PD 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR
 XX

PT Pharmaceutical composition for treating asthma, has antisease
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13700; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cyostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc. tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1271 GAAACTGGACGTGGCCAGAA 1290
 Db | | | | | | | | | | | | | | | | | | | |
 20 GAAACTGGACGTGGCCAGAA 1
 RESULT 913
 ABD31526/c
 ID ABD31526 standard; DNA; 20 BP.
 AC ABD31526;
 XX
 XX 29-JUL-2004 (first entry)
 DT Human ICAM-derived oligonucleotide SEQ ID 13737.
 DE
 XX Human; antisease; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cyostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 PD 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13737; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 901 GACGAGGCGCACCCAGCGGCT 920
 DB |||||
 20 GACGAGGCGCACCCAGCGGCT 1
 RESULT 914
 ABD31535/c
 ID ABD31535 standard; DNA; 20 BP.
 XX
 XX ABD31535;
 XX
 XX 29-JUL-2004 (first entry)
 XX
 XX Human ICAM-derived oligonucleotide SEQ ID 13746.
 XX
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW

KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 XX OS
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13746; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 811 CTGGCACTGGGGGACACAG 830
 DB |||||
 20 CTGGCACTGGGGGACACAG 1

RESULT 915
ABD31589/c
ID ABD31589 standard; DNA; 20 BP.
XX
XX
XX ABD31589;
AC
XX 29-JUL-2004 (first entry)
DT
XX
XX Human ICAM-derived oligonucleotide SEQ ID 13800.
DE
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
OS
XX WO200285309-A2.
PN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002WO-US013143.
PF
XX
XX 24-APR-2001; 2001US-0286036P.
PR
XX
XX (EPIG-) EPIGENESIS PHARM INC.
PA
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13800; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytosstatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
CC prevent any unwanted effects due to it

XX
SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. NO. 5.4e-02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 271 CCTGGGACACCGGAAGGT 290
DB 20 CCTGGGACACCGGAAGGT 1
RESULT 916
ABD31609/c
ID ABD31609 standard; DNA; 20 BP.
XX
XX ABD31609;
AC
XX 29-JUL-2004 (first entry)
DT
XX
XX Human ICAM-derived oligonucleotide SEQ ID 13820.
DE
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
OS
XX WO200285309-A2.
PN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002WO-US013143.
PF
XX
XX 24-APR-2001; 2001US-0286036P.
PR
XX
XX (EPIG-) EPIGENESIS PHARM INC.
PA
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
PI
XX
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13820; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytosstatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
CC prevent any unwanted effects due to it

CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction.
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 1 A; 6 C; 13 G; 0 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 71 GCCCGCGCGCGCTGCC 90
 |||||
 Db 20 GCCCGCGCGCGCTGCC 1

RESULT 917
 ABD31419/c
 ID ABD31419 standard; DNA; 20 BP.

AC ABD31419;
 XX
 DT 29-JUL-2004 (first entry)
 XX

DE Human ICAM-derived oligonucleotide SEQ ID 13630.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cystostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS WO200285309-A2.

PN 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.

DR Claim 15; SEQ ID NO 13630; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating

CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX

SQ Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1971 CCATGAGGACATCAACTGG 1990
 |||||
 Db 20 CCATGAGGACATCAACTGG 1

RESULT 918

ABD31425/c

ID ABD31425 standard; DNA; 20 BP.

XX ABD31425;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13636.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cystostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13636; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 8 A; 5 C; 1 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1911 TTGATCGATGTTAAAGTCTA 1930
XX |||||
XX DB 20 TTGATCGATGTTAAAGTCTA 1
XX
XX RESULT 919
XX ABD31427/C
XX ID ABD31427 standard; DNA; 20 BP.
XX AC ABD31427;
XX
XX DT 29-JUL-2004 (first entry)
XX
XX DE Human ICAM-derived oligonucleotide SEQ ID 13638.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX
XX OS Homo sapiens.
XX
XX PN WO200285309-A2.
XX
XX PD 31-OCT-2002.
XX

PF 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIC-) EPIGENESIS PHARM INC.
XX
XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13638; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory
XX distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX transplantation rejection, pulmonary infections, bronchitis or cancer.
XX The reduced adenosine content of the anti-sense oligos corresponding to
XX thymidines present in the target RNA serves to prevent the breakdown of
XX the oligonucleotides into products that free adenosine into the system
XX e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 2 A; 5 C; 4 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1891 GAGCAGACTCAAGACATGA 1910
XX |||||
XX DB 20 GAGCAGACTCAAGACATGA 1
XX
XX RESULT 920
XX ABD31456/C
XX ID ABD31456 standard; DNA; 20 BP.
XX AC ABD31456;
XX
XX DT 29-JUL-2004 (first entry)
XX
XX DE Human ICAM-derived oligonucleotide SEQ ID 13667.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis; beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction; respiratory distress syndrome; allergic rhinitis; pulmonary hypertension; emphysema; chronic obstructive pulmonary disease; cancer; bronchitis; pulmonary transplantation rejection; ss; primer.

Homo sapiens.

WO200285309-A2.

31-OCT-2002.

23-APR-2002; 2002WO-US013143.

24-APR-2001; 2001US-0286036P.

(EPIG-) EPIGENESIS PHARM INC.

Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D; Miller S, Tang L, Shahabuddin S; WPI; 2003-093058/08.

Pharmaceutical composition for treating asthma, has antisense oligonucleotide containing less percentage of adenosine, targeted to nucleic acids associated with lung airway or lung dysfunction, and bronchodilating agent.

Claim 15; SEQ ID NO 13667; 763pp; English.

This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

Sequence 20 BP; 0 A; 5 C; 6 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1601 AACAGGCCCAAAAGGACC 1620

20 AACAGGCCCAAAAGGACC 1

RESULT 921

ABD31479/c

ID ABD31479 standard; DNA; 20 BP.

XX ABD31479;

AC ABD31479;

XX 29-JUL-2004 (first entry)

DT

XX Human ICAM-derived oligonucleotide SEQ ID 13690.

DE

XX

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain; respiratory tract inflammation; adenosine sensitivity; lung; cancer; surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic; analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis; beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction; respiratory distress syndrome; allergic rhinitis; pulmonary hypertension; emphysema; chronic obstructive pulmonary disease; cancer; bronchitis; pulmonary transplantation rejection; ss; primer.

XX

OS Homo sapiens.

XX

XX WO200285309-A2.

PN

XX

PD 31-OCT-2002.

XX

XX 23-APR-2002; 2002WO-US013143.

PF

XX

XX 24-APR-2001; 2001US-0286036P.

PR

XX

XX (EPIG-) EPIGENESIS PHARM INC.

PA

XX

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D; Miller S, Tang L, Shahabuddin S; WPI; 2003-093058/08.

PI

XX

XX Pharmaceutical composition for treating asthma, has antisense oligonucleotide containing less percentage of adenosine, targeted to nucleic acids associated with lung airway or lung dysfunction, and bronchodilating agent.

PT

XX

XX Claim 15; SEQ ID NO 13690; 763pp; English.

PS

XX

XX This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

XX

```
SQ  Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY  1371 ACTGCCCATCGGGGAATCAG 1390
Db    |||||
      20 ACTGCCCATCGGGGAATCAG 1

RESULT 922
ABD31517/C
ID  ABD31517 standard; DNA; 20 BP.
AC  ABD31517;
XX
DT  29-JUL-2004 (first entry)
XX
DE  Human ICAM-derived oligonucleotide SEQ ID 13728.
XX
KW  Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW  respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW  surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW  analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW  beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW  respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW  emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW  pulmonary transplantation rejection; ss; primer.
XX
OS  Homo sapiens.
XX
PN  WO200285309-A2.
XX
PD  31-OCT-2002.
XX
PF  23-APR-2002; 2002WO-US013143.
XX
PR  24-APR-2001; 2001US-0286036P.
XX
PA  (EPIG-) EPIGENESIS PHARM INC.
XX
PI  Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI  Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-093058/08.
XX
Pharmaceutical composition for treating asthma, has antisense
PT  oligonucleotide containing less percentage of adenosine, targeted to
PT  nucleic acids associated with lung airway or lung dysfunction, and
PT  bronchodilating agent.
XX
PS  Claim 15; SEQ ID NO 13728; 763pp; English.
XX
CC  This invention describes a novel composition (a) a first active agent,
CC  comprising oligonucleotides, effective for alleviating
CC  bronchoconstriction, respiratory tract inflammation, allergies and
CC  reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC  surfactant depletion or hyposecretion, when administered to a mammal. The
CC  oligonucleotides are derived from a gene encoding or regulating
CC  expression of a target polypeptide associated with lung airway or lung
CC  dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC  The invention also describes a kit, that comprises: (a) a delivery
CC  device, in separate containers, (b) the oligonucleotides, (c)
CC  instructions for adding a carrier and for use of the kit. The composition
CC  of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC  analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC  beta-adrenergic agonist. The composition is useful for preventing or
CC  treating a respiratory, lung or malignant disease. The administered
CC  composition comprises oligo and is administered to reduce the production
CC  or availability, or to increase the degradation of the target mRNA or to
CC  reduce the amount of target polypeptide present in the lungs. The
CC  pulmonary obstruction, and/or bronchoconstriction and/or lung
```


CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC SQ Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;
 CC
 CC Query Match 0.7%; Score 20; DB 1; Length 20;
 CC Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 CC Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 CC QY 731 GGGTCTCTAGAGTGGACACG 750
 CC |
 CC Db 20 GGGTCTCTAGAGTGGACACG 1
 CC
 CC RESULT 924
 CC ABD31548/c
 CC ID ABD31548 standard; DNA; 20 BP.
 CC AC ABD31548;
 CC XX
 CC XX 29-JUL-2004 (first entry)
 CC DE Human ICAM-derived oligonucleotide SEQ ID 13759.
 CC KW Human: antisense; bronchoconstriction; allergy; hyposecretion; pain;
 CC KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 CC KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 CC KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 CC KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 CC KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 CC KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 CC KW pulmonary transplantation rejection; ss; primer.
 CC XX
 CC OS Homo sapiens.
 CC XX
 CC PN WO200285309-A2.
 CC XX
 CC PD 31-OCT-2002.
 CC PF 23-APR-2002; 2002WO-US013143.
 CC
 CC PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 CC PI Miller S, Tang L, Shahabuddin S;
 CC XX
 CC DR WPI; 2003-093058/08.
 CC
 CC XX Pharmaceutical composition for treating asthma, has antisense
 CC PT oligonucleotide containing less percentage of adenosine, targeted to

PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13759; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC SQ Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 CC
 CC Query Match 0.7%; Score 20; DB 1; Length 20;
 CC Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 CC Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 CC QY 681 GCTCCAGACCTTTGCTCTGC 700
 CC |
 CC Db 20 GCTCCAGACCTTTGCTCTGC 1
 CC
 CC RESULT 925
 CC ABD31552/c
 CC ID ABD31552 standard; DNA; 20 BP.
 CC XX ABD31552;
 CC AC
 CC XX 29-JUL-2004 (first entry)
 CC DE Human ICAM-derived oligonucleotide SEQ ID 13763.
 CC KW Human: antisense; bronchoconstriction; allergy; hyposecretion; pain;
 CC KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 CC KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 CC KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 CC KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 CC KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 CC KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 CC KW pulmonary transplantation rejection; ss; primer.
 CC XX
 CC OS Homo sapiens.
 CC XX
 CC PN WO200285309-A2.
 CC XX
 CC PD 31-OCT-2002.
 CC XX
 CC PF 23-APR-2002; 2002WO-US013143.

XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 XX PI Miller S, Tang L, Shahabuddin S;
 XX DR WPI; 2003-093058/08.
 XX PT Pharmaceutical composition for treating asthma, has antisense
 XX PT oligonucleotide containing less percentage of adenosine, targeted to
 XX PT nucleic acids associated with lung airway or lung dysfunction, and
 XX PT bronchodilating agent.
 XX PS Claim 15; SEQ ID NO 13763; 763pp; English.
 XX CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 5 A; 9 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 641 AAGGGCTGGAGCTGTTGAG 660
 Db 20 AAGGGCTGGAGCTGTTGAG 1
 |||||
 RESULT 926
 ABD31560/c
 ID ABD31560 standard; DNA; 20 BP.
 XX AC ABD31560;
 XX DT 29-JUL-2004 (first entry)
 XX DE Human ICAM-derived oligonucleotide SEQ ID 13771.
 XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX OS Homo sapiens.
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 XX PI Miller S, Tang L, Shahabuddin S;
 XX DR WPI; 2003-093058/08.
 XX PT Pharmaceutical composition for treating asthma, has antisense
 XX PT oligonucleotide containing less percentage of adenosine, targeted to
 XX PT nucleic acids associated with lung airway or lung dysfunction, and
 XX PT bronchodilating agent.
 XX PS Claim 15; SEQ ID NO 13771; 763pp; English.
 XX CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 561 GGTCACGACACGGTGTGG 580
 Db 20 GGTCACGACACGGTGTGG 1
 |||||
 RESULT 927
 ABD31573/c

CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
 CC
 CC Query Match 0.7%; Score 20; DB 1; Length 20;
 CC Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 CC Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 CC QY 391 ACTCCAGACGGGTGGAAC 410
 CC Db 20 ACTCCAGACGGGTGGAAC 1
 CC
 CC RESULT 929
 CC ABD31605/c
 CC ID ABD31605 standard; DNA; 20 BP.
 CC XX ABD31605;
 CC XX 29-JUL-2004 (first entry)
 CC XX Human ICAM-derived oligonucleotide SEQ ID 13816.
 CC XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 CC respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 CC surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 CC analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 CC beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 CC respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 CC emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 CC pulmonary transplantation rejection; ss; primer.
 CC XX Homo sapiens.
 CC OS
 CC PN WO200285309-A2.
 CC XX 31-OCT-2002.
 CC XX 23-APR-2002; 2002WO-US013143.
 CC XX 24-APR-2001; 2001US-0286036P.
 CC XX (EPIG-) EPIGENESIS PHARM INC.
 CC XX
 CC PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 CC PI Miller S, Tang L, Shahabuddin S;
 CC XX WPI; 2003-093058/08.
 CC XX
 CC PT Pharmaceutical composition for treating asthma, has antisense
 CC oligonucleotide containing less percentage of adenosine, targeted to
 CC nucleic acids associated with lung airway or lung dysfunction, and
 CC bronchodilating agent.
 CC
 CC Claim 15; SEQ ID NO 13816; 763pp; English.
 CC
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.

CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers; (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 5 A; 6 C; 7 G; 2 T; 0 U; 0 Other;
 CC
 CC Query Match 0.7%; Score 20; DB 1; Length 20;
 CC Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 CC Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 CC
 CC QY 111 GGCTCTGTTCCCGAGGACCTG 130
 CC Db 20 GGCTCTGTTCCCGAGGACCTG 1
 CC
 CC RESULT 930
 CC ABD31606/c
 CC ID ABD31606 standard; DNA; 20 BP.
 CC XX ABD31606;
 CC XX 29-JUL-2004 (first entry)
 CC XX Human ICAM-derived oligonucleotide SEQ ID 13817.
 CC XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 CC respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 CC surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 CC analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 CC beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 CC respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 CC emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 CC pulmonary transplantation rejection; ss; primer.
 CC XX Homo sapiens.
 CC OS
 CC PN WO200285309-A2.
 CC XX 31-OCT-2002.
 CC XX 23-APR-2002; 2002WO-US013143.
 CC XX 24-APR-2001; 2001US-0286036P.
 CC XX (EPIG-) EPIGENESIS PHARM INC.
 CC XX
 CC PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 CC PI Miller S, Tang L, Shahabuddin S;
 CC XX WPI; 2003-093058/08.
 CC XX
 CC PT Pharmaceutical composition for treating asthma, has antisense
 CC oligonucleotide containing less percentage of adenosine, targeted to
 CC nucleic acids associated with lung airway or lung dysfunction, and

PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13817; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 7 A; 6 C; 7 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 101 TCTGCTCGGGCTCTGTTTC 120
 Db |||||
 20 TCTGCTCGGGCTCTGTTTC 1
 RESULT 931
 ABD31424/c
 ID ABD31424 standard; DNA; 20 BP.
 AC ABD31424;
 XX
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13635.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX

PR 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13635; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1921 TTAAAGTCTAGCCTGATGAG 1940
 Db |||||
 20 TTAAAGTCTAGCCTGATGAG 1
 RESULT 932
 ABD31459/c
 ID ABD31459 standard; DNA; 20 BP.
 XX ABD31459;
 AC ABD31459;
 XX
 XX 29-JUL-2004 (first entry)
 DT
 XX Human ICAM-derived oligonucleotide SEQ ID 13670.
 DE
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 DR
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13670; 763pp; English.
 PS
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 1 A; 6 C; 4 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1571 GCCAGCGGAGATCAGAAA 1590
 Db 20 GCCAGCGGAGATCAGAAA 1
 |||||
 RESULT 933
 ABD31484/C
 ID ABD31484 standard; DNA; 20 BP.

XX ABD31484;
 AC 29-JUL-2004 (first entry)
 DT
 XX Human ICAM-derived oligonucleotide SEQ ID 13695.
 DE
 XX
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 XX Homo sapiens.
 OS
 XX WO200285309-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPTG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 DR
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13695; 763pp; English.
 PS
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1321 TGGGGGAACCATGCGCGA 1340
DB 20 TGGGGGAACCATGCGCGA 1

RESULT 934
ABD31492/C
ID ABD31492 standard; DNA; 20 BP.
XX ABD31492;
XX 29-JUL-2004 (first entry)
XX Human ICAM-derived oligonucleotide SEQ ID 13703.
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX Homo sapiens.
XX OS
XX WO200285309-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
XX 24-APR-2001; 2001US-0286036P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX Claim 15; SEQ ID NO 13703; 763pp; English.
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has antiallergic, antiinflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytosstatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,

CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1241 GCCCCGACTGGACGAGAGG 1260
DB 20 GCCCCGACTGGACGAGAGG 1

RESULT 935
ABD31496/C
ID ABD31496 standard; DNA; 20 BP.
XX ABD31496;
XX AC
XX 29-JUL-2004 (first entry)
XX Human ICAM-derived oligonucleotide SEQ ID 13707.
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX Homo sapiens.
XX OS
XX WO200285309-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
XX 24-APR-2001; 2001US-0286036P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX Claim 15; SEQ ID NO 13707; 763pp; English.
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has antiallergic, antiinflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytosstatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,

CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 1 A; 3 C; 7 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1201 ATACACAGAACGACGACCG 1220
 Db 20 ATACACAGAACGACGACCG 1
 |||||
 RESULT 936
 ABD31505/c
 ID ABD31505 standard; DNA; 20 BP.
 AC ABD31505;
 XX
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13716.
 DE
 DE Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EP1G-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX
 PS Claim 15; SEQ ID NO 13716; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1111 CCGAGGGCCGCTCTGCT 1130
 Db 20 CCGAGGGCCGCTCTGCT 1
 |||||
 RESULT 937
 ABD31508/c
 ID ABD31508 standard; DNA; 20 BP.
 XX
 AC ABD31508;
 XX
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13719.
 XX
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX

XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13719; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1081 CTGAATGGGTTTCAGCCCA 1100
 Db 20 CTGAATGGGTTTCAGCCCA 1
 RESULT 938
 ABD31519/c
 ID ABD31519 standard; DNA; 20 BP.
 XX
 XX ABD31519;
 XX
 XX 29-JUL-2004 (first entry)
 XX
 XX Human ICAM-derived oligonucleotide SEQ ID 13730.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS
 PN WO200285309-A2.
 XX
 XX 31-OCT-2002.
 PD
 XX
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 DR
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13730; 763pp; English.
 PS
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 971 TGACCATCTACAGCTTTCG 990
 Db 20 TGACCATCTACAGCTTTCG 1
 RESULT 939
 ABD31521/c
 ID ABD31521 standard; DNA; 20 BP.
 XX

AC ABD31521;
 XX DT 29-JUL-2004 (first entry)
 XX DE Human ICAM-derived oligonucleotide SEQ ID 13732.
 XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX OS Homo sapiens.
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX PS Claim 15; SEQ ID NO 13732; 763pp; English.
 XX CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 1 A; 6 C; 6 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 951 CCAGGAGACACTGCAGACAG 970
 DB 20 CCAGGAGACACTGCAGACAG 1
 RESULT 940
 ABD31549/C
 ID ABD31549 standard; DNA; 20 BP.
 XX AC ABD31549;
 XX DT 29-JUL-2004 (first entry)
 XX DE Human ICAM-derived oligonucleotide SEQ ID 13760.
 XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX OS Homo sapiens.
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX PS Claim 15; SEQ ID NO 13760; 763pp; English.
 XX CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic, is a
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 SQ Sequence 20 BP; 2 A; 2 C; 12 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 671 CCCCTTACCAGTCCAGACC 690
 |||||
 DB 20 CCCCTTACCAGTCCAGACC 1

RESULT 941

ABD31550/c
 ID ABD31550 standard; DNA; 20 BP.

AC ABD31550;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13761.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13761; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)

CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 SQ Sequence 20 BP; 2 A; 2 C; 11 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 661 AACACCTCGGCCCTACCA 680

DB 20 AACACCTCGGCCCTACCA 1
 |||||

RESULT 942

ABD31567/c

ID ABD31567 standard; DNA; 20 BP.

XX ABD31567;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13778.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

PS Claim 15; SEQ ID NO 13778; 763pp; English.

XX This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

XX Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 491 ACCTCACCGTGGTGTCTC 510
|||||

Db 20 ACCTCACCGTGGTGTCTC 1

RESULT 943
ABD31569/c

XX ABD31569 standard; DNA; 20 BP.

AC ABD31569;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13780.

DE Human; antisense; bronchoconstriction; allergy; hyposecretion; pain; respiratory tract inflammation; adenosine sensitivity; lung; cancer; surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic; analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis; beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction; respiratory distress syndrome; allergic rhinitis; pulmonary hypertension; emphysema; chronic obstructive pulmonary disease; cancer; bronchitis; pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS WO200285309-A2.

PN 31-OCT-2002.

PD 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

PA (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.

DR Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13780; 763pp; English.

PS This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

XX Sequence 20 BP; 1 A; 10 C; 7 G; 2 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 471 GGGTGGGGCACCCCGGCCA 490
|||||

Db 20 GGGTGGGGCACCCCGGCCA 1

RESULT 944
ABD31575/c

XX ABD31575 standard; DNA; 20 BP.

AC ABD31575;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13786.

DE Human; antisense; bronchoconstriction; allergy; hyposecretion; pain; respiratory tract inflammation; adenosine sensitivity; lung; cancer; surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic; analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis; beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction; respiratory distress syndrome; allergic rhinitis; pulmonary hypertension; emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

KW pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13786; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyosecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it

XX Sequence 20 BP; 4 A; 4 C; 11 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 411 GGCACCCCTCCCTCTGGC 430

Db 20 GGCACCCCTCCCTCTGGC 1

RESULT 945

ABD31598/c

ID ABD31598 standard; DNA; 20 BP.

XX

AC ABD31598;

XX

DT

XX

DE

XX

XX

KW

KW

KW

KW

KW

KW

KW

KW

XX

OS

XX

XX

PN

XX

XX

PD

XX

XX

PF

XX

XX

PR

XX

XX

XX

PA

XX

XX

PI

XX

PI

XX

XX

DR

XX

XX

PT

XX

PT

XX

PT

XX

PT

XX

XX

PS

XX

PS

XX

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

XX

29-JUL-2004 (first entry)

Human ICAM-derived oligonucleotide SEQ ID 13809.

Human; antisense; bronchoconstriction; allergy; hyosecretion; pain;
respiratory tract inflammation; adenosine sensitivity; lung; cancer;
surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

Pharmaceutical composition for treating asthma, has antisense
oligonucleotide containing less percentage of adenosine, targeted to
nucleic acids associated with lung airway or lung dysfunction, and
bronchodilating agent.

XX Claim 15; SEQ ID NO 13809; 763pp; English.

This invention describes a novel composition (a) a first active agent,
comprising oligonucleotides, effective for alleviating
bronchoconstriction, respiratory tract inflammation, allergies and
reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
surfactant depletion or hyosecretion, when administered to a mammal. The
oligonucleotides are derived from a gene encoding or regulating
expression of a target polypeptide associated with lung airway or lung
dysfunction or cancer and can be anti-sense to the corresponding mRNA.
The invention also describes a kit, that comprises: (a) a delivery
device, in separate containers, (b) the oligonucleotides, (c)
instructions for adding a carrier and for use of the kit. The composition
of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
beta-adrenergic agonist. The composition is useful for preventing or
treating a respiratory, lung or malignant disease. The administered
composition comprises oligo and is administered to reduce the production
or availability, or to increase the degradation of the target mRNA or to
reduce the amount of target polypeptide present in the lungs. The
pulmonary obstruction, and/or bronchoconstriction and/or lung
inflammation, allergies and/or surfactant hypoproduction are associated
with a disease or condition such as pulmonary vasoconstriction,
inflammation, allergies, asthma, impeded respiration, respiratory
distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
transplantation rejection, pulmonary infections, bronchitis or cancer.
The reduced adenosine content of the anti-sense oligos corresponding to
thymidines present in the target RNA serves to prevent the breakdown of
the oligonucleotides into products that free adenosine into the system
e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
prevent any unwanted effects due to it

XX Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 181 GGTCCTCGTGTGTGACATG 200
 Db 20 GGTCCTCGTGTGTGACATG 1

RESULT 946
 ABD31600/c
 ID ABD31600 standard; DNA; 20 BP.
 XX
 AC ABD31600;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13811.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13811; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic, is a
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary

CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX
 SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. NO. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 161 AAGTCATCTCTGCCCGGGA 180
 Db 20 AAGTCATCTCTGCCCGGGA 1

RESULT 947
 ABD31412/c
 ID ABD31412 standard; DNA; 20 BP.
 XX
 AC ABD31412;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13623.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13623; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition

CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytosstatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC hyperextension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2040 ACAGAGAGTGGCCCTCCA 2059

DB 20 ACAGAGAGTGGCCCTCCA 1
 |||||

RESULT 948

ABD31420/c

ID ABD31420 standard; DNA; 20 BP.

XX ABD31420;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13631.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13631; 763pp; English.

PA (EPIG-) EPIGENESIS PHARM INC.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytosstatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 2 A; 4 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1961 CATAGCCCCCAGGAGGAC 1980

DB 20 CATAGCCCCCAGGAGGAC 1
 |||||

RESULT 949

ABD31439/c

ID ABD31439 standard; DNA; 20 BP.

XX ABD31439;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13650.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13650; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1771 CCGAGGACAGGGCATTGTC 1790
 DB 20 CCGAGGACAGGGCATTGTC 1
 RESULT 950
 ABD31445/c
 ID ABD31445 standard; DNA; 20 BP.
 XX
 AC ABD31445;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13656.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.
 OS WO200285309-A2.
 PN 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13656; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 2 A; 6 C; 5 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1711 GCCACACTGACAGACTGGA 1730
 DB 20 GCCACACTGACAGACTGGA 1
 RESULT 951
 ABD31480/c
 ID ABD31480 standard; DNA; 20 BP.
 XX
 AC ABD31480;
 XX

29-JUL-2004 (first entry)
Human ICAM-derived oligonucleotide SEQ ID 13691.

Human; antisense; bronchoconstriction; allergy; hyposecretion; pain; respiratory tract inflammation; adenosine sensitivity; lung; cancer; surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic; analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis; beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction; respiratory distress syndrome; allergic rhinitis; pulmonary hypertension; emphysema; chronic obstructive pulmonary disease; cancer; bronchitis; pulmonary transplantation rejection; ss; primer.

Homo sapiens.

WO200285309-A2.

31-OCT-2002.

23-APR-2002; 2002WO-US013143.

24-APR-2001; 2001US-0286036P.

(EPIG-) EPIGENESIS PHARM INC.

Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D; Miller S, Tang L, Shahabuddin S;

WPI; 2003-093058/08.

Pharmaceutical composition for treating asthma, has antisense oligonucleotide containing less percentage of adenosine, targeted to nucleic acids associated with lung airway or lung dysfunction, and bronchodilating agent.

Claim 15; SEQ ID NO 13691; 763pp; English.

This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

Sequence 20 BP; 5 A; 2 C; 10 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1361 GCACCTTCCCACTGCCCATC 1380
Db |||||
20 GCACCTTCCCACTGCCCATC 1

RESULT 952
ABD31513/c
ID ABD31513 standard; DNA; 20 BP.

XX
AC ABD31513;

XX
DT 29-JUL-2004 (first entry)

XX
DE Human ICAM-derived oligonucleotide SEQ ID 13724.

XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain; respiratory tract inflammation; adenosine sensitivity; lung; cancer; surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic; analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis; beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction; respiratory distress syndrome; allergic rhinitis; pulmonary hypertension; emphysema; chronic obstructive pulmonary disease; cancer; bronchitis; pulmonary transplantation rejection; ss; primer.

XX
OS Homo sapiens.

XX
PN WO200285309-A2.

XX
PD 31-OCT-2002.

XX
PF 23-APR-2002; 2002WO-US013143.

XX
PR 24-APR-2001; 2001US-0286036P.

XX
PA (EPIG-) EPIGENESIS PHARM INC.

XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D; Miller S, Tang L, Shahabuddin S;

XX
WPI; 2003-093058/08.

XX
PT Pharmaceutical composition for treating asthma, has antisense oligonucleotide containing less percentage of adenosine, targeted to nucleic acids associated with lung airway or lung dysfunction, and bronchodilating agent.

XX
PS Claim 15; SEQ ID NO 13724; 763pp; English.

XX
CC This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to reduce the amount of target polypeptide present in the lungs. The pulmonary obstruction, and/or bronchoconstriction and/or lung inflammation, allergies and/or surfactant hypoproduction are associated with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 2 A; 9 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1031 GGACCGAGGTGACAGTGAAG 1050
 |||||
 DB 20 GGACCGAGGTGACAGTGAAG 1

RESULT 953
 ABD31530/C
 ID ABD31530 standard; DNA; 20 BP.

XX ABD31530;
 XX
 DT 29-JUL-2004 (first entry)
 XX

DE Human ICAM-derived oligonucleotide SEQ ID 13741.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

PS Claim 15; SEQ ID NO 13741; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,

CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, cystic fibrosis, allergic rhinitis, pulmonary
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer.
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX

SQ Sequence 20 BP; 5 A; 4 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 861 CTCCTTCTCGCCAAAGGCT 880
 |||||
 DB 20 CTCCTTCTCGCCAAAGGCT 1

RESULT 954

ABD31541/C

ID ABD31541 standard; DNA; 20 BP.

XX ABD31541;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13752.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

PS Claim 15; SEQ ID NO 13752; 763pp; English.

CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hyperextension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it

SQ Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 751 CAGGGGACCGTGGTCTGTTTC 770
 |||||
 DB 20 CAGGGGACCGTGGTCTGTTTC 1

RESULT 955
 ABD31565/c
 ID ABD31565 standard; DNA; 20 BP.

XX ABD31565;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13776.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX W0200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX

PI NYCE JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13776; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hyperextension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 2 A; 10 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 511 CGTGGGGAGAGGAGCTGAA 530
 |||||
 DB 20 CGTGGGGAGAGGAGCTGAA 1

RESULT 956

ABD31580/c

ID ABD31580 standard; DNA; 20 BP.

XX ABD31580;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13791.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

```

OS Homo sapiens.
XX WO200285309-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
XX 24-APR-2001; 2001US-0286036P.
XX (EPIC-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13791; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyosecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory
XX distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX transplantation rejection, pulmonary infections, bronchitis or cancer.
XX The reduced adenosine content of the anti-sense oligos corresponding to
XX thymidines present in the target RNA serves to prevent the breakdown of
XX the oligonucleotides into products that free adenosine into the system
XX e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 4 A; 1 C; 8 G; 7 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 361 ACAGCTAAACCTTCCTCAC 380
Db 20 ACAGCTAAACCTTCCTCAC 1
|||||
RESULT 957
ABD31610/C
ID ABD31610 standard; DNA; 20 BP.
XX
XX ABD31610;
XX
XX 29-JUL-2004 (first entry)

```

```

XX Human ICAM-derived oligonucleotide SEQ ID 13821.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
XX
XX WO200285309-A2.
XX 31-OCT-2002.
XX 23-APR-2002; 2002WO-US013143.
XX 24-APR-2001; 2001US-0286036P.
XX (EPIC-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13821; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyosecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory
XX distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX transplantation rejection, pulmonary infections, bronchitis or cancer.
XX The reduced adenosine content of the anti-sense oligos corresponding to
XX thymidines present in the target RNA serves to prevent the breakdown of
XX the oligonucleotides into products that free adenosine into the system
XX e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 1 A; 5 C; 12 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

Qy 61 GCTCCACAGACCCCGGCC 80
 Db 20 GCTCCACAGACCCCGGCC 1

RESULT 958
 ID ABD31413/C
 AC ABD31413 standard; DNA; 20 BP.
 XX ABD31413;
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13624.
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13624; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.

CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX
 SQ Sequence 20 BP; 2 A; 4 C; 5 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2030 CCACAGACTTACAGAGAAG 2049
 Db 20 CCACAGACTTACAGAGAAG 1

RESULT 959
 ID ABD31438/C
 AC ABD31438 standard; DNA; 20 BP.
 XX ABD31438;
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13649.
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13649; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.

PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13655; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1721 ACAGAGTGGAGACATATGC 1740
 Db |||||
 20 ACAGAGTGGAGACATATGC 1
 RESULT 962
 ABD311448/c
 ID ABD311448 standard; DNA; 20 BP.
 XX
 AC ABD311448;
 XX
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13659.
 XX
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 XX Homo sapiens.

XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13659; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1681 CCTCGGCGCTTCCCATATGG 1700
 Db |||||
 20 CCTCGGCGCTTCCCATATGG 1
 RESULT 963
 ABD311458/c
 ID ABD311458 standard; DNA; 20 BP.
 XX
 AC ABD311458;
 XX
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13659.
 XX
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 XX Homo sapiens.

DE XX Human ICAM-derived oligonucleotide SEQ ID 13669.

XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;

KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

KW pulmonary transplantation rejection; ss; primer.

XX OS Homo sapiens.

XX PN WO200285309-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013143.

XX PR 24-APR-2001; 2001US-0286036P.

XX PA (EPiG-) EPIGENESIS PHARM INC.

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX PT Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to

PT nucleic acids associated with lung airway or lung dysfunction, and

PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13669; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,

CC comprising oligonucleotides, effective for alleviating

CC bronchoconstriction, respiratory tract inflammation, allergies and

CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,

CC surfactant depletion or hyposecretion, when administered to a mammal. The

CC oligonucleotides are derived from a gene encoding or regulating

CC expression of a target polypeptide associated with lung airway or lung

CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.

CC The invention also describes a kit, that comprises: (a) a delivery

CC device, in separate containers, (b) the oligonucleotides, (c)

CC instructions for adding a carrier and for use of the kit. The composition

CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,

CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

CC beta-adrenergic agonist. The composition is useful for preventing or

CC treating a respiratory, lung or malignant disease. The administered

CC composition comprises oligo and is administered to reduce the production

CC or availability, or to increase the degradation of the target mRNA or to

CC reduce the amount of target polypeptide present in the lungs. The

CC pulmonary obstruction, and/or bronchoconstriction and/or lung

CC inflammation, allergies and/or surfactant hypoproduction are associated

CC with a disease or condition such as pulmonary vasoconstriction,

CC inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary

CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

CC transplantation rejection, pulmonary infections, bronchitis or cancer.

CC The reduced adenosine content of the anti-sense oligos corresponding to

CC thymidines present in the target RNA serves to prevent the breakdown of

CC the oligonucleotides into products that free adenosine into the system

CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to

CC prevent any unwanted effects due to it

XX SQ Sequence 20 BP; 3 A; 3 C; 4 G; 10 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e-02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1581 GATCAAGAAATACAGACTAC 1600

Db 20 GATCAAGAAATACAGACTAC 1

RESULT 964

ABD31472/c

ID ABD31472 standard; DNA; 20 BP.

XX ABD31472;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13683.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;

KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

KW pulmonary transplantation rejection; ss; primer.

XX OS Homo sapiens.

XX PN WO200285309-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013143.

XX PR 24-APR-2001; 2001US-0286036P.

XX PA (EPiG-) EPIGENESIS PHARM INC.

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX PT Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to

PT nucleic acids associated with lung airway or lung dysfunction, and

PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13683; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,

CC comprising oligonucleotides, effective for alleviating

CC bronchoconstriction, respiratory tract inflammation, allergies and

CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,

CC surfactant depletion or hyposecretion, when administered to a mammal. The

CC oligonucleotides are derived from a gene encoding or regulating

CC expression of a target polypeptide associated with lung airway or lung

CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.

CC The invention also describes a kit, that comprises: (a) a delivery

CC device, in separate containers, (b) the oligonucleotides, (c)

CC instructions for adding a carrier and for use of the kit. The composition

CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,

CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

CC beta-adrenergic agonist. The composition is useful for preventing or

CC treating a respiratory, lung or malignant disease. The administered

CC composition comprises oligo and is administered to reduce the production

CC or availability, or to increase the degradation of the target mRNA or to

CC reduce the amount of target polypeptide present in the lungs. The

CC pulmonary obstruction, and/or bronchoconstriction and/or lung

CC inflammation, allergies and/or surfactant hypoproduction are associated

CC with a disease or condition such as pulmonary vasoconstriction,

CC inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary

CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

CC transplantation rejection, pulmonary infections, bronchitis or cancer.

CC The reduced adenosine content of the anti-sense oligos corresponding to

CC thymidines present in the target RNA serves to prevent the breakdown of

CC the oligonucleotides into products that free adenosine into the system

CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to

CC prevent any unwanted effects due to it

CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1441 ACTCAGGGGAGGTCAACCG 1460

DB 20 ACTCAAGGGGAGGTCAACCG 1

RESULT 965

ABD31493/C

ID ABD31493 standard; DNA; 20 BP.

XX AC ABD31493;

XX DT 29-JUL-2004 (first entry)

XX DE Human ICAM-derived oligonucleotide SEQ ID 13704.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13704; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or

CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1231 GTCCTGTATGCCCCCGACT 1250

DB 20 GTCCTGTATGCCCCCGACT 1

RESULT 966

ABD31497/C

ID ABD31497 standard; DNA; 20 BP.

XX AC ABD31497;

XX DT 29-JUL-2004 (first entry)

XX DE Human ICAM-derived oligonucleotide SEQ ID 13708.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13708; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating

CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1191 CGGCCAGCTTATACACAAGA 1210

DB 20 CGGCCAGCTTATACACAAGA 1

RESULT 967

ABD31503/c
 ID ABD31503 standard; DNA; 20 BP.

AC ABD31503;

XX

XX

DT 29-JUL-2004 (first entry)

XX

XX

XX

KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS

XX

PN WO200285309-A2.

XX

PD 31-OCT-2002.

XX

PF 23-APR-2002; 2002WO-US013143.

XX

PR 24-APR-2001; 2001US-0286036P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX

DR

XX

PT

PT

PT

PT

XX

PS

CC

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

WPI; 2003-093058/08.

Pharmaceutical composition for treating asthma, has antisense
 oligonucleotide containing less percentage of adenosine, targeted to
 nucleic acids associated with lung airway or lung dysfunction, and
 bronchodilating agent.

Claim 15; SEQ ID NO 13714; 763pp; English.

This invention describes a novel composition (a) a first active agent,
 comprising oligonucleotides, effective for alleviating
 bronchoconstriction, respiratory tract inflammation, allergies and
 reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 surfactant depletion or hyposecretion, when administered to a mammal. The
 oligonucleotides are derived from a gene encoding or regulating
 expression of a target polypeptide associated with lung airway or lung
 dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 The invention also describes a kit, that comprises: (a) a delivery
 device, in separate containers, (b) the oligonucleotides, (c)
 instructions for adding a carrier and for use of the kit. The composition
 of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 beta-adrenergic agonist. The composition is useful for preventing or
 treating a respiratory, lung or malignant disease. The administered
 composition comprises oligo and is administered to reduce the production
 or availability, or to increase the degradation of the target mRNA or to
 reduce the amount of target polypeptide present in the lungs. The
 pulmonary obstruction, and/or bronchoconstriction and/or lung
 inflammation, allergies and/or surfactant hypoproduction are associated
 with a disease or condition such as pulmonary vasoconstriction,
 inflammation, allergies, asthma, impeded respiration, respiratory
 distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 transplantation rejection, pulmonary infections, bronchitis or cancer.
 The reduced adenosine content of the anti-sense oligos corresponding to
 thymidines present in the target RNA serves to prevent the breakdown of
 the oligonucleotides into products that free adenosine into the system
 e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 prevent any unwanted effects due to it

Sequence 20 BP; 0 A; 6 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1131 GAAGGCCACCCAGAGGACA 1150

DB 20 GAAGGCCACCCAGAGGACA 1

RESULT 968

ABD31595/c

ID ABD31595 standard; DNA; 20 BP.

XX

AC ABD31595;

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

PN W0200285309-A2.
 XX 31-OCT-2002.
 PD 23-APR-2002; 2002WO-US013143.
 PF 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13806; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyosecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 211 TGTGACGAGCCCAAGTTGTT 230
 Db ||||||||||||||||
 20 TGTGACGAGCCCAAGTTGTT 1
 RESULT 969
 ABD31418/C
 ID ABD31418 standard; DNA; 20 BP.
 XX ABD31418;
 AC ABD31418;
 XX 29-JUL-2004 (first entry)
 DT Human ICAM-derived oligonucleotide SEQ ID 13629.
 XX

XX Human; antisense; bronchoconstriction; allergy; hyosecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS W0200285309-A2.
 PN 31-OCT-2002.
 PD 23-APR-2002; 2002WO-US013143.
 PF 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13629; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyosecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX Sequence 20 BP; 4 A; 4 C; 3 G; 9 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1981 ATACAACTCGGAATACTCA 2000
 ||||||||||||||||

Db 20 ATACAACTGGGAATACTGA 1
 RESULT 970
 ID ABD31450/c
 XX ABD31450 standard; DNA; 20 BP.
 AC ABD31450;
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13661.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 PI WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13661; 763pp; English.
 CC
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of

CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred.No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1661 ATCCCGGACAGGGCCTCTT 1680
 Db 20 ATCCCGGACAGGGCCTCTT 1
 RESULT 971
 ID ABD31468/c
 XX ABD31468 standard; DNA; 20 BP.
 AC ABD31468;
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13679.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 PI WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13679; 763pp; English.
 CC
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to

CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 XX Sequence 20 BP; 6 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1481 TCTCCCGGATGAGATT 1500
 DB 20 TCTCCCGGATGAGATT 1

RESULT 972

ABD31499/c
 ID ABD31499 standard; DNA; 20 BP.

AC ABD31499;

XX 29-JUL-2004 (first entry)

DE Human ICAM-derived oligonucleotide SEQ ID 13710.

KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.

XX WO200285309-A2.

PN 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13710; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and

CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 XX Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1171 TCTGCAACCTGGAGGTGGC 1190

DB 20 TCTGCAACCTGGAGGTGGC 1

RESULT 973

ABD31528/c
 ID ABD31528 standard; DNA; 20 BP.

XX ABD31528;

XX 29-JUL-2004 (first entry)

DE Human ICAM-derived oligonucleotide SEQ ID 13739.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

DR WPI; 2003-093058/08.

XX
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.

XX
XX Claim 15; SEQ ID NO 13739; 763pp; English.

XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
CC prevent any unwanted effects due to it

XX
XX Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 881 CAGTCAGTGTGACCGCAGAG 900
|||||
Db 20 CAGTCAGTGTGACCGCAGAG 1

RESULT 974
ABD31546/c
ID ABD31546 standard; DNA; 20 BP.

XX
XX ABD31546;

XX
XX 29-JUL-2004 (first entry)

XX
XX Human ICAM-derived oligonucleotide SEQ ID 13757.

XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.

XX
XX Homo sapiens.

OS
XX WO200285309-A2.

PN

XX
PD 31-OCT-2002.

XX
XX 23-APR-2002; 2002WO-US013143.

XX
XX 24-APR-2001; 2001US-0286036P.

XX
XX (EPG-) EPIGENESIS PHARM INC.

XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-093058/08.

XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.

XX
XX Claim 15; SEQ ID NO 13757; 763pp; English.

XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
CC prevent any unwanted effects due to it

XX
XX Sequence 20 BP; 3 A; 2 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 701 CAGCGACTCCCCCACAACCTT 720
|||||
Db 20 CAGCGACTCCCCCACAACCTT 1

RESULT 975
ABD31554/c
ID ABD31554 standard; DNA; 20 BP.

XX
XX ABD31554;

XX
XX 29-JUL-2004 (first entry)

XX
XX Human ICAM-derived oligonucleotide SEQ ID 13765.

XX

KW Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosolic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 XX Homo sapiens.
 XX
 XX WO200285309-A2.
 PN
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 DR
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

PS Claim 15; SEQ ID NO 13765; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposcretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytosolic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 621 TGAACCTGGACCTGGGCCCC 640

DB 20 TGAACCTGGACCTGGGCCCC 1

RESULT 976

ID ABD31572/c

XX ABD31572 standard; DNA; 20 BP.

XX AC ABD31572;

XX DT 29-JUL-2004 (first entry)

XX XX

DE Human ICAM-derived oligonucleotide SEQ ID 13783.

XX

XX Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosolic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO200285309-A2.
 PN
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 DR
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

PS Claim 15; SEQ ID NO 13783; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposcretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytosolic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system

CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 441 CAAGAACCTTACCTAGCT 460
 Db 20 CAAGAACCTTACCTAGCT 1
 RESULT 977
 ABD31578/c
 ID ABD31578 standard; DNA; 20 BP.
 AC ABD31578;
 XX
 XX 29-JUL-2004 (first entry)
 DE Human ICAM-derived oligonucleotide SEQ ID 13789.
 DE
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 OS
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13789; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production

CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer,
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 381 CGGTACTCGACTCCAGAAC 400
 Db 20 CGGTACTCGACTCCAGAAC 1
 RESULT 978
 ABD31582/c
 ID ABD31582 standard; DNA; 20 BP.
 AC ABD31582;
 XX
 XX 29-JUL-2004 (first entry)
 DE Human ICAM-derived oligonucleotide SEQ ID 13793.
 DE
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 OS
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13793; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production

CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 341 ACTGCCCTGATGGCAGTCA 360
 DB 20 ACTGCCCTGATGGCAGTCA 1

RESULT 979

ABD31585/c
 ID ABD31585 standard; DNA; 20 BP.

XX AC ABD31585;

XX DT 29-JUL-2004 (first entry)

XX DE Human ICAM-derived oligonucleotide SEQ ID 13796.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX OS Homo sapiens.

XX PN WO200285309-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013143.

XX PR 24-APR-2001; 2001US-0286036P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Li Y, Sandrasgra A, Katz E, Pabalan J, Aguilar D;

XX PI Miller S, Tang L, Shahabuddin S;

XX DR WPI; 2003-093058/08.

XX PT Pharmaceutical composition for treating asthma, has antisense
 CC oligonucleotide containing less percentage of adenosine, targeted to
 CC nucleic acids associated with lung airway or lung dysfunction, and
 CC bronchodilating agent.

XX Claim 15; SEQ ID NO 13796; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 2 A; 4 C; 4 G; 10 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 311 AAGAAGATAGCCCAACCAATG 330
 DB 20 AAGAAGATAGCCCAACCAATG 1

RESULT 980

ABD31601/c

ID ABD31601 standard; DNA; 20 BP.

XX AC ABD31601;

XX DT 29-JUL-2004 (first entry)

XX DE Human ICAM-derived oligonucleotide SEQ ID 13812.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX OS Homo sapiens.

XX PN WO200285309-A2.

PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13812; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 5 A; 1 C; 9 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 151 TCCCTCCCTCAAAAGTCATCCT 170
 Db 20 TCCCTCCCTCAAAAGTCATCCT 1
 RESULT 981
 ABD31612/c
 ID ABD31612 standard; DNA; 20 BP.
 XX
 AC ABD31612;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13823.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13823; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 41 GCAACTCAGCTCGCTATG 60
 Db 20 GCAACTCAGCTCGCTATG 1

RESULT 982
 ABD31416/C
 ID ABD31416 standard; DNA; 20 BP.
 XX
 AC ABD31416;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13627.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 DE WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13627; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer, and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC of the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to

CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 7 A; 5 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2001 AACTTGCTGCTATTGGGTA 2020
 Db 20 AACTTGCTGCTATTGGGTA 1
 RESULT 983
 ABD31436/C
 ID ABD31436 standard; DNA; 20 BP.
 XX
 AC ABD31436;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13647.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 DE WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13647; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer, and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC of the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to

Pharmaceutical composition for treating asthma, has antisense oligonucleotide containing less percentage of adenosine, targeted to nucleic acids associated with lung airway or lung dysfunction, and bronchodilating agent.

Claim 15; SEQ ID NO 13709; 763pp; English.

This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to pulmonary obstruction, and/or surfactant hypoproduction and/or lung inflammation, allergies and/or bronchoconstriction and/or lung with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

Sequence 20 BP; 4 A; 9 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1181 TGGAGGTGGCGCGCCAGCTT 1200
DB 20 TGGAGGTGGCGCGCCAGCTT 1

RESULT 986
ABD31504/c
ID ABD31504 standard; DNA; 20 BP.

XX ABD31504;
AC
XX
XX 29-JUL-2004 (first entry)
XX Human ICAM-derived oligonucleotide SEQ ID 13715.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
respiratory tract inflammation; adenosine sensitivity; lung; cancer;
surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
pulmonary transplantation rejection; ss; primer.
XX Homo sapiens.
OS
XX
XX WO200285309-A2.
PN
XX
XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (BPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense oligonucleotide containing less percentage of adenosine, targeted to nucleic acids associated with lung airway or lung dysfunction, and bronchodilating agent.

XX Claim 15; SEQ ID NO 13715; 763pp; English.

This invention describes a novel composition (a) a first active agent, comprising oligonucleotides, effective for alleviating bronchoconstriction, respiratory tract inflammation, allergies and reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors, surfactant depletion or hyposecretion, when administered to a mammal. The oligonucleotides are derived from a gene encoding or regulating expression of a target polypeptide associated with lung airway or lung dysfunction or cancer and can be anti-sense to the corresponding mRNA. The invention also describes a kit, that comprises: (a) a delivery device, in separate containers, (b) the oligonucleotides, (c) instructions for adding a carrier and for use of the kit. The composition of the invention has anti-allergic, anti-inflammatory, antiasthmatic, analgesic, hypotensive, immunosuppressive and cytostatic activity, is a beta-adrenergic agonist. The composition is useful for preventing or treating a respiratory, lung or malignant disease. The administered composition comprises oligo and is administered to reduce the production or availability, or to increase the degradation of the target mRNA or to pulmonary obstruction, and/or surfactant hypoproduction and/or lung inflammation, allergies and/or bronchoconstriction and/or lung with a disease or condition such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, respiratory distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary transplantation rejection, pulmonary infections, bronchitis or cancer. The reduced adenosine content of the anti-sense oligos corresponding to thymidines present in the target RNA serves to prevent the breakdown of the oligonucleotides into products that free adenosine into the system e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to prevent any unwanted effects due to it

Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 AGCTCCTGCTGAGGCCACC 1140
DB 20 AGCTCCTGCTGAGGCCACC 1

RESULT 987
ABD31511/c
ID ABD31511 standard; DNA; 20 BP.

XX ABD31511;
AC
XX
XX 29-JUL-2004 (first entry)
XX Human ICAM-derived oligonucleotide SEQ ID 13722.
DE
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX

KW surfactant depletion; anti-allergic; anti-inflammatory; anti-asthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX
OS Homo sapiens.
XX
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13722; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, anti-asthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1051 TGTGAGGCCACCCCTAGAGC 1070
|||||
Db 20 TGTGAGGCCACCCCTAGAGC 1

RESULT 988
ABD31518/c
ID ABD31518 standard; DNA; 20 BP.
XX
AC ABD31518;
XX
DT 29-JUL-2004 (first entry)
XX
XX Human ICAM-derived oligonucleotide SEQ ID 13729.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; anti-asthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
XX
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13729; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, anti-asthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX

XX SQ Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 981 CAGCTTTCCGCGCCCAACG 1000
 |||||
 20 CAGCTTTCCGCGCCCAACG 1
 Db
 RESULT 989
 ID ABD31534/c
 AC ABD31534 standard; DNA; 20 BP.
 AC ABD31534;
 XX
 DT 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13745.
 DE
 DE Human; antiseize; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 OS
 XX WO200285309-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antiseize
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13745; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The

CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 821 GGGACCAGAGGTTGAACCCC 840
 |||||
 20 GGGACCAGAGGTTGAACCCC 1
 Db
 RESULT 990
 ID ABD31544/c
 AC ABD31544 standard; DNA; 20 BP.
 XX
 AC ABD31544;
 XX
 DT 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13755.
 DE
 DE Human; antiseize; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 OS
 XX WO200285309-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antiseize
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13755; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The

CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 GTCAGCCCCCGGTCCTAGA 740
 DB 20 GTCAGCCCCCGGTCCTAGA 1

RESULT 991
 ABD31557/c

ID ABD31557 standard; DNA; 20 BP.

XX ABD31557;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13768.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 XX bronchodilating agent.

XX Claim 15; SEQ ID NO 13768; 763pp; English.

CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAAATTTCT 610

DB 20 TCACCATGGAGCCAAATTTCT 1

RESULT 992

ABD31564/c

ID ABD31564 standard; DNA; 20 BP.

XX ABD31564;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13775.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPiG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13775; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytoskeletal activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 1 A; 8 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 521 AGGAGCTGAACCGGAGCCA 540
 |||||
 Db 20 AGGAGCTGAACCGGAGCCA 1
 RESULT 993
 ID ABD31571/C
 XX ABD31571 standard; DNA; 20 BP.
 AC ABD31571;
 XX
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13782.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

KW analgesic; hypotensive; immunosuppressive; cytoskeletal; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX Homo sapiens.
 OS
 XX WO200285309-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPiG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13782; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytoskeletal activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 451 ACCCTACGCTGCCAGTGGA 470
 |||||
 Db 20 ACCCTACGCTGCCAGTGGA 1
 RESULT 994

ABD31410/C
ID ABD31410 standard; DNA; 20 BP.
XX
AC ABD31410;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human ICAM-derived oligonucleotide SEQ ID 13621.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13621; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytosstatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory
XX distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX transplantation rejection, pulmonary infections, bronchitis or cancer.
XX The reduced adenosine content of the anti-sense oligos corresponding to
XX thymidines present in the target RNA serves to prevent the breakdown of
XX the oligonucleotides into products that free adenosine into the system
XX e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX prevent any unwanted effects due to it

SQ Sequence 20 BP; 5 A; 4 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2060 TAGACATGTGTAGCATCAAA 2079
DB 20 TAGACATGTGTAGCATCAAA 1
RESULT 995
ABD31454/C
ID ABD31454 standard; DNA; 20 BP.
XX
AC ABD31454;
XX
XX 29-JUL-2004 (first entry)
XX
XX Human ICAM-derived oligonucleotide SEQ ID 13665.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
XX surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
XX analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
XX beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
XX respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
XX emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
XX pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
XX
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13665; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
XX analgesic, hypotensive, immunosuppressive and cytosstatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory
XX distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
XX hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
XX transplantation rejection, pulmonary infections, bronchitis or cancer.
XX The reduced adenosine content of the anti-sense oligos corresponding to
XX thymidines present in the target RNA serves to prevent the breakdown of
XX the oligonucleotides into products that free adenosine into the system
XX e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
XX prevent any unwanted effects due to it

CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 XX Sequence 20 BP; 1 A; 2 C; 8 G; 9 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1621 CCCATGAACCGACACACA 1640
 DB 20 CCCATGAACCGACACACA 1
 |||||
 RESULT 996
 ABD31466/c
 ID ABD31466 standard; DNA; 20 BP.
 AC ABD31466;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13677.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13677; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung

CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 XX Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1501 GTCATCATCATCTGTGGTAGC 1520
 DB 20 GTCATCATCATCTGTGGTAGC 1
 |||||
 RESULT 997
 ABD31469/c
 ID ABD31469 standard; DNA; 20 BP.
 AC ABD31469;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13680.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to

PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13680; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 XX comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1471 GTCAATGTGCTCTCCCGG 1490

DB 20 GTCAATGTGCTCTCCCGG 1

RESULT 998

ID ABD31473/c

XX ABD31473 standard; DNA; 20 BP.

AC ABD31473;

XX 29-JUL-2004 (first entry)

DT Human ICAM-derived oligonucleotide SEQ ID 13684.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;

KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX

XX

XX

XX

XX

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

PI WPI; 2003-093058/08.

DR Pharmaceutical composition for treating asthma, has antisense

XX oligonucleotide containing less percentage of adenosine, targeted to

PT nucleic acids associated with lung airway or lung dysfunction, and

PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13684; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,

XX comprising oligonucleotides, effective for alleviating

CC bronchoconstriction, respiratory tract inflammation, allergies and

CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,

CC surfactant depletion or hyposecretion, when administered to a mammal. The

CC oligonucleotides are derived from a gene encoding or regulating

CC expression of a target polypeptide associated with lung airway or lung

CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.

CC The invention also describes a kit, that comprises: (a) a delivery

CC device, in separate containers, (b) the oligonucleotides, (c)

CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,

CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

CC beta-adrenergic agonist. The composition is useful for preventing or

CC treating a respiratory, lung or malignant disease. The administered

CC composition comprises oligo and is administered to reduce the production

CC or availability, or to increase the degradation of the target mRNA or to

CC reduce the amount of target polypeptide present in the lungs. The

CC pulmonary obstruction, and/or bronchoconstriction and/or lung

CC inflammation, allergies and/or surfactant hypoproduction are associated

CC with a disease or condition such as pulmonary vasoconstriction,

CC inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary

CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

CC transplantation rejection, pulmonary infections, bronchitis or cancer.

CC The reduced adenosine content of the anti-sense oligos corresponding to

CC thymidines present in the target RNA serves to prevent the breakdown of

CC the oligonucleotides into products that free adenosine into the system

CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to

CC prevent any unwanted effects due to it

XX Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1431 GGCCAGGAGCACTCAAGGGG 1450

DB 20 GGCCAGGAGCACTCAAGGGG 1

RESULT 999

ID ABD31527/c

XX ABD31527 standard; DNA; 20 BP.

AC ABD31527;

XX 29-JUL-2004 (first entry)

DT Human ICAM-derived oligonucleotide SEQ ID 13738.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;

KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX

KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

DR WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

PS Claim 15; SEQ ID NO 13738; 763pp; English.

CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 0 A; 9 C; 5 G; 6 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 891 GACCGCAGAGGACGAGGCA 910

|||||

Db 20 GACCGCAGAGGACGAGGCA 1

RESULT 1000

ABD31529/c

ID ABD31529 standard; DNA; 20 BP.

XX ABD31529;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13740.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

DR WPI; 2003-093058/08.

PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

PS Claim 15; SEQ ID NO 13740; 763pp; English.

CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 871 GCCAAGGCTCAGTCAGTGT 890
 Db 20 GCCAAGGCTCAGTCAGTGT 1

RESULT 1001
 ID ABD31537/c
 XX ABD31537 standard; DNA; 20 BP.
 AC ABD31537;
 XX
 DT 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13748.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13748; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated

CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 791 TCTCGAGGCCCGAGTCCAC 810
 Db 20 TCTCGAGGCCCGAGTCCAC 1

RESULT 1002
 ID ABD31561/c
 XX ABD31561 standard; DNA; 20 BP.
 AC ABD31561;
 XX
 DT 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13772.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13772; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated

CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytosstatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 XX Sequence 20 BP; 2 A; 6 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 551 AGCCCGCTGAGTCAAGACC 570
 DB 20 AGCCCGCTGAGTCAAGACC 1

RESULT 1003
 ABD31584/c

ID ABD31584 standard; DNA; 20 BP.

AC ABD31584;

XX 29-JUL-2004 (first entry)

DE Human ICAM-derived oligonucleotide SEQ ID 13795.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS WO200285309-A2.

PN 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and

PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13795; 763bp; English.

CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic, (c)
 CC analgesic, hypotensive, immunosuppressive and cytosstatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 XX Sequence 20 BP; 5 A; 2 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 321 CCAACCAATGTGCTATTCAA 340
 DB 20 CCAACCAATGTGCTATTCAA 1

RESULT 1004

ABD31587/c

ID ABD31587 standard; DNA; 20 BP.

XX ABD31587;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13798.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

PR 24-APR-2001; 2001US-0286036P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
DR
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13798; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 291 GTATGAAGCTGAGCAATGTC 310
Db |||||
20 GTATGAAGCTGAGCAATGTC 1

RESULT 1005
ABD31588/c
ID ABD31588 standard; DNA; 20 BP.
XX
AC ABD31588;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human ICAM-derived oligonucleotide SEQ ID 13799.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
DR
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13799; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 281 ACCGGAAGCTGTATGAATG 300
Db |||||
20 ACCGGAAGCTGTATGAATG 1

RESULT 1006
ABD31611/c
ID ABD31611 standard; DNA; 20 BP.

XX AC ABD31611;
 XX DT 29-JUL-2004 (first entry)
 XX DE Human ICAM-derived oligonucleotide SEQ ID 13822.
 XX KW Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cyrostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX OS Homo sapiens.
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX PS Claim 15; SEQ ID NO 13822; 763pp; English.
 XX CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposcretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic, (c)
 CC analgesic, hypotensive, immunosuppressive and cyrostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 51 CCTCGCTATGGCTCCGACGA 70
 DB 20 CCTCGCTATGGCTCCGACGA 1
 RESULT 1007
 ABD31421/c
 ID ABD31421 standard; DNA; 20 BP.
 XX AC ABD31421;
 XX DT 29-JUL-2004 (first entry)
 XX DE Human ICAM-derived oligonucleotide SEQ ID 13632.
 XX KW Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cyrostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX OS Homo sapiens.
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX PS Claim 15; SEQ ID NO 13632; 763pp; English.
 XX CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposcretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic, (c)
 CC analgesic, hypotensive, immunosuppressive and cyrostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,

CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1951 GTGGGGGACATAGCCCCA 1970
 DB 20 GTGGGGGACATAGCCCCA 1
 RESULT 1008
 ABD31422/c
 ID ABD31422 standard; DNA; 20 BP.
 AC ABD31422;
 XX
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13633.
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytotatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX WO200285309-A2.
 XX 31-OCT-2002.
 XX 23-APR-2002; 2002WO-US013143.
 XX 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13633; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery

CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic, is a
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 2 A; 13 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1941 AGGGGAAGTGTGGGGGAGA 1960
 DB 20 AGGGGAAGTGTGGGGGAGA 1
 RESULT 1009
 ABD31429/c
 ID ABD31429 standard; DNA; 20 BP.
 AC ABD31429;
 XX
 XX 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13640.
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytotatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX WO200285309-A2.
 XX 31-OCT-2002.
 XX 23-APR-2002; 2002WO-US013143.
 XX 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX PS Claim 15; SEQ ID NO 13640; 763pp; English.

XX CC This invention describes a novel composition (a) a first active agent,

CC comprising oligonucleotides, effective for alleviating

CC bronchoconstriction, respiratory tract inflammation, allergies and

CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,

CC surfactant depletion or hyposecretion, when administered to a mammal. The

CC oligonucleotides are derived from a gene encoding or regulating

CC expression of a target polypeptide associated with lung airway or lung

CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.

CC The invention also describes a kit, that comprises: (a) a delivery

CC device, in separate containers, (b) the oligonucleotides, (c)

CC instructions for adding a carrier and for use of the kit. The composition

CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,

CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

CC beta-adrenergic agonist. The composition is useful for preventing or

CC treating a respiratory, lung or malignant disease. The administered

CC composition comprises oligo and is administered to reduce the production

CC or availability, or to increase the degradation of the target mRNA or to

CC reduce the amount of target polypeptide present in the lungs. The

CC pulmonary obstruction, and/or bronchoconstriction and/or lung

CC inflammation, allergies and/or surfactant hypoproduction are associated

CC with a disease or condition such as pulmonary vasoconstriction,

CC inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary

CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

CC transplantation rejection, pulmonary infections, bronchitis or cancer.

CC The reduced adenosine content of the anti-sense oligos corresponding to

CC thymidines present in the target RNA serves to prevent the breakdown of

CC the oligonucleotides into products that free adenosine into the system

CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to

CC prevent any unwanted effects due to it

XX SQ Sequence 20 BP; 2 A; 6 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1871 ATGACTAAGCCAGAGGAAG 1890

DB 20 ATGACTAAGCCAGAGGAAG 1

RESULT 1010

ABD31431/c

ID ABD31431 standard; DNA; 20 BP.

XX AC ABD31431; .

XX DT 29-JUL-2004 (first entry)

DE Human ICAM-derived oligonucleotide SEQ ID 13642.

XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;

KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

KW pulmonary transplantation rejection; ss; primer.

XX OS Homo sapiens.

XX PN WO200285309-A2.

XX PD 31-OCT-2002.

XX PF 23-APR-2002; 2002WO-US013143.

XX PR 24-APR-2001; 2001US-0286036P.

XX PA (EPIC-) EPICGENESIS PHARM INC.

XX PI Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shanabuddin S;

XX DR WPI; 2003-093058/08.

XX PT Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to

PT nucleic acids associated with lung airway or lung dysfunction, and

PT bronchodilating agent.

XX PS Claim 15; SEQ ID NO 13642; 763pp; English.

XX CC This invention describes a novel composition (a) a first active agent,

CC comprising oligonucleotides, effective for alleviating

CC bronchoconstriction, respiratory tract inflammation, allergies and

CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,

CC surfactant depletion or hyposecretion, when administered to a mammal. The

CC oligonucleotides are derived from a gene encoding or regulating

CC expression of a target polypeptide associated with lung airway or lung

CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.

CC The invention also describes a kit, that comprises: (a) a delivery

CC device, in separate containers, (b) the oligonucleotides, (c)

CC instructions for adding a carrier and for use of the kit. The composition

CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,

CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

CC beta-adrenergic agonist. The composition is useful for preventing or

CC treating a respiratory, lung or malignant disease. The administered

CC composition comprises oligo and is administered to reduce the production

CC or availability, or to increase the degradation of the target mRNA or to

CC reduce the amount of target polypeptide present in the lungs. The

CC pulmonary obstruction, and/or bronchoconstriction and/or lung

CC inflammation, allergies and/or surfactant hypoproduction are associated

CC with a disease or condition such as pulmonary vasoconstriction,

CC inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary

CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

CC transplantation rejection, pulmonary infections, bronchitis or cancer.

CC The reduced adenosine content of the anti-sense oligos corresponding to

CC thymidines present in the target RNA serves to prevent the breakdown of

CC the oligonucleotides into products that free adenosine into the system

CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to

CC prevent any unwanted effects due to it

XX SQ Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1851 CGCATCTGATCTGTAGTCAC 1870

DB 20 CGCATCTGATCTGTAGTCAC 1

RESULT 1011

ABD31449/c

ID ABD31449 standard; DNA; 20 BP.

XX AC ABD31449;

XX DT 29-JUL-2004 (first entry)

DE Human ICAM-derived oligonucleotide SEQ ID 13660.

XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;

KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;

KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;

KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;

KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;

KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX Homo sapiens.
OS
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
PR
XX (EPIG-) EPIGENESIS PHARM INC.
PA
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-093058/08.
DR
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13660; 763pp; English.
PS
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 6 A; 5 C; 8 G; 1 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 1671 AGGGCCTCTTCCCTCGGCTT 1690
|||||
Db 20 AGGGCCTCTTCCCTCGGCTT 1
RESULT 1012
ABD31460/c
ID ABD31460 standard; DNA; 20 BP.
XX

AC ABD31460;
XX
XX 29-JUL-2004 (first entry)
XX
XX Human ICAM-derived oligonucleotide SEQ ID 13671.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
OS
XX WO200285309-A2.
PN
XX
XX 31-OCT-2002.
PD
XX
XX 23-APR-2002; 2002WO-US013143.
PF
XX
XX 24-APR-2001; 2001US-0286036P.
PR
XX
XX (EPIG-) EPIGENESIS PHARM INC.
PA
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-093058/08.
DR
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13671; 763pp; English.
PS
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic, is a
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1561 CTCCTATAACCCGAGCGGAA 1580
DB 20 CTCCTATAACCCGAGCGGAA 1

RESULT 1013
ABD31461/c
ID ABD31461 standard; DNA; 20 BP.
AC ABD31461;
XX
XX
DT 29-JUL-2004 (first entry)
XX
DE Human ICAM-derived oligonucleotide SEQ ID 13672.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
XX
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13672; 763pp; English..
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has antiallergic, antiinflammatory, antiasthmatic, is a
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1551 CAGCAGTACCTCTATAACC 1570
DB 20 CAGCAGTACCTCTATAACC 1

RESULT 1014
ABD31500/c
ID ABD31500 standard; DNA; 20 BP.
XX
XX ABD31500;
AC
XX
XX 29-JUL-2004 (first entry)
DT
XX
XX Human ICAM-derived oligonucleotide SEQ ID 13711.
DE
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
XX Homo sapiens.
XX
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
XX Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
XX oligonucleotide containing less percentage of adenosine, targeted to
XX nucleic acids associated with lung airway or lung dysfunction, and
XX bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13711; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
XX bronchoconstriction, respiratory tract inflammation, allergies and
XX reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
XX surfactant depletion or hyposecretion, when administered to a mammal. The
XX oligonucleotides are derived from a gene encoding or regulating
XX expression of a target polypeptide associated with lung airway or lung
XX dysfunction or cancer and can be anti-sense to the corresponding mRNA.
XX The invention also describes a kit, that comprises: (a) a delivery
XX device, in separate containers, (b) the oligonucleotides, (c)
XX instructions for adding a carrier and for use of the kit. The composition
XX of the invention has antiallergic, antiinflammatory, antiasthmatic, is a
XX analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
XX beta-adrenergic agonist. The composition is useful for preventing or
XX treating a respiratory, lung or malignant disease. The administered
XX composition comprises oligo and is administered to reduce the production
XX or availability, or to increase the degradation of the target mRNA or to
XX reduce the amount of target polypeptide present in the lungs. The
XX pulmonary obstruction, and/or bronchoconstriction and/or lung
XX inflammation, allergies and/or surfactant hypoproduction are associated
XX with a disease or condition such as pulmonary vasoconstriction,
XX inflammation, allergies, asthma, impeded respiration, respiratory

CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 SQ Sequence 20 BP; 6 A; 2 C; 10 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1161 CTTCTCTGCTGCTGCAACCC 1180
 Db 20 CTTCTCTGCTGCTGCAACCC 1
 RESULT 1015
 ABD31507/c
 ID ABD31507 standard; DNA; 20 BP.
 AC ABD31507;
 XX
 DT 29-JUL-2004 (first entry)
 XX Human ICAM-derived oligonucleotide SEQ ID 13718.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX

PS Claim 15; SEQ ID NO 13718; 763pp; English.
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer,
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 SQ Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1091 TTCCAGCCCGCAGCCACTGGGC 1110
 Db 20 TTCCAGCCCGCAGCCACTGGGC 1
 RESULT 1016
 ABD31510/c
 ID ABD31510 standard; DNA; 20 BP.
 XX ABD31510;
 AC ABD31510;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 XX Human ICAM-derived oligonucleotide SEQ ID 13721.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX

PA (EPIG-) EPIGENESIS PHARM INC.
XX Nvce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13721; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyosecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1061 ACCCTAGAGCCAGGTGACG 1080
DB 20 ACCCTAGAGCCAGGTGACG 1
RESULT 1017
ABD31512/c
ID ABD31512 standard; DNA; 20 BP.
XX ABD31512;
XX
XX 29-JUL-2004 (first entry)
XX Human ICAM-derived oligonucleotide SEQ ID 13723.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;

KW pulmonary transplantation rejection; ss; primer.
XX Homo sapiens.
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nvce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX WPI; 2003-093058/08.
XX
XX Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
XX Claim 15; SEQ ID NO 13723; 763pp; English.
XX
XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyosecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
XX Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1041 GACAGTGAAGTGTGAGGCC 1060
DB 20 GACAGTGAAGTGTGAGGCC 1
RESULT 1018
ABD31522/c
ID ABD31522 standard; DNA; 20 BP.
XX ABD31522;
AC

XX 29-JUL-2004 (first entry)

DT Human ICAM-derived oligonucleotide SEQ ID 13733.

DE

XX Human; antitense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cyostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13733; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cyostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 0 A; 7 C; 5 G; 8 T; 0 U; 0 Other;

SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 941 GGAACCCAGAGCCAGGAGACA 960

DB 20 GGAACCCAGAGCCAGGAGACA 1

RESULT 1019

ABD31579/c

ID ABD31579 standard; DNA; 20 BP.

XX

AC ABD31579;

XX

DT 29-JUL-2004 (first entry)

XX

DE Human ICAM-derived oligonucleotide SEQ ID 13790.

XX

XX Human; antitense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cyostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13790; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cyostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

SQ Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 371 CCTTCTCCTACCGTACTGG 390
 |||||
 Db 20 CCTTCTCCTACCGTACTGG 1

RESULT 1020
 ABD31599/c
 ID ABD31599 standard; DNA; 20 BP.

XX ABD31599;

AC ABD31599;

DT 29-JUL-2004 (first entry)

DE Human ICAM-derived oligonucleotide SEQ ID 13810.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13810; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition

CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

SQ Sequence 20 BP; 2 A; 9 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 171 GCCCGGGGAGGCTCCGTGC 190

Db 20 GCCCGGGGAGGCTCCGTGC 1

RESULT 1021

ABD31604/c

ID ABD31604 standard; DNA; 20 BP.

XX ABD31604;

AC ABD31604;

DT 29-JUL-2004 (first entry)

DE Human ICAM-derived oligonucleotide SEQ ID 13815.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13815; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hyperinflation, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX

XX SQ Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0

QY 121 CCAGGACCTGGCAATGCCCA 140
|||
DB 20 CCAGGACCTGGCAATGCCCA 1

RESULT 1022
ABD31607/c

ID ABD31607 standard; DNA; 20 BP.
AC ABD31607;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human ICAM-derived oligonucleotide SEQ ID 13818.
XX
KW Human; antiseize; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
XX WO200285309-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX 24-APR-2001; 2001US-0286036P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX PA

XX	Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI	Miller S, Tang L, Shahabuddin S;
XX	WPI; 2003-093058/08.
DR	
XX	
XX	Pharmaceutical composition for treating asthma, has antisense
PT	oligonucleotide containing less percentage of adenosine, targeted to
PT	nucleic acids associated with lung airway or lung dysfunction, and
PT	bronchodilating agent.
XX	
XX	Claim 15; SEQ ID NO 13818; 763pp; English.
XX	This invention describes a novel composition (a) a first active agent,
CC	comprising oligonucleotides, effective for alleviating
CC	bronchoconstriction, respiratory tract inflammation, allergies and
CC	reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC	surfactant depletion or hyposecretion, when administered to a mammal. The
CC	oligonucleotides are derived from a gene encoding or regulating
CC	expression of a target polypeptide associated with lung airway or lung
CC	dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC	The invention also describes a kit, that comprises: (a) a delivery
CC	device, in separate containers, (b) the oligonucleotides, (c)
CC	instructions for adding a carrier and for use of the kit. The composition
CC	of the invention has anti-allergic, anti-inflammatory, antialsthmatic,
CC	analgesic, hypnotensive, immunosuppressive and cytostatic activity, is a
CC	beta-adrenergic agonist. The composition is useful for preventing or
CC	treating a respiratory, lung or malignant disease. The administered
CC	composition comprises oligo and is administered to reduce the production
CC	or availability, or to increase the degradation of the target mRNA or to
CC	reduce the amount of target polypeptide present in the lungs. The
CC	pulmonary obstruction, and/or bronchoconstriction and/or lung
CC	inflammation, allergies and/or surfactant hypoproduction are associated
CC	with a disease or condition such as pulmonary vasoconstriction,
CC	inflammation, allergies, asthma, impeded respiration, respiratory
CC	distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC	hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC	transplantation rejection, pulmonary infections, bronchitis or cancer.
CC	The reduced adenosine content of the anti-sense oligos corresponding to
CC	thymidines present in the target RNA serves to prevent the breakdown of
CC	the oligonucleotides into products that free adenosine into the system
CC	e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC	prevent any unwanted effects due to it
XX	
SQ	Sequence 20 BP; 5 A; 6 C; 8 G; 1 T; 0 U; 0 Other;
	Query Match 0.7%; Score 20; DB 1; Length 20;
	Best Local Similarity 100.0%; Pred. No. 5.4e+02;
	Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0
Qy	91 GCATCTCGTGCCTGCTCGG 110
Dd	20 GCATCTCGTGCCTGCTCGG 1
RESULT 1023	
ABD32086	
ID	ABD32086 standard; DNA; 20 BP.
XX	
AC	ABD32086;
XX	
DT	29-JUL-2004 (first entry)
XX	
DE	Human PDB4C-derived oligonucleotide SEQ ID 14297.
XX	
Kw	Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
Kw	respiratory tract inflammation; adenosine sensitivity; lung; cancer;
Kw	surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
Kw	analgesic; hypnotensive; immunosuppressive; cytostatic; cystic fibrosis;
Kw	beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
Kw	respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
Kw	emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
Kw	pulmonary transplantation rejection; ss; primer.

XX OS Homo sapiens.
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 XX PI Miller S, Tang L, Shahabuddin S;
 XX DR WPI; 2003-093058/08.
 XX PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX PS Claim 15; SEQ ID NO 14297; 763pp; English.
 XX CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2771 CCCAGGCTGGAGTGCAGTGG 2790
 Db 1 |||||
 RESULT 1024
 ABD31430/C
 ID ABD31430 standard; DNA; 20 BP.
 XX
 AC ABD31430;
 XX

DT 29-JUL-2004 (first entry)
 XX DE Human ICAM-derived oligonucleotide SEQ ID 13641.
 XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX OS Homo sapiens.
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 XX PI Miller S, Tang L, Shahabuddin S;
 XX DR WPI; 2003-093058/08.
 XX PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX PS Claim 15; SEQ ID NO 13641; 763pp; English.
 XX CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1861 CTGTAGTCACATGACTAAGC 1880
 DB 20 CTGTAGTCACATGACTAAGC 1
 RESULT 1025
 ABD31451/C
 ID ABD31451 standard; DNA; 20 BP.
 AC ABD31451;
 XX
 XX 29-JUL-2004 (first entry)
 DE Human ICAM-derived oligonucleotide SEQ ID 13662.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13662; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 3 A; 4 C; 9 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1651 CCTGAACCTATCCCGGAC 1670
 DB 20 CCTGAACCTATCCCGGAC 1
 RESULT 1026
 ABD31486/C
 ID ABD31486 standard; DNA; 20 BP.
 XX
 AC ABD31486;
 XX
 XX 29-JUL-2004 (first entry)
 DT
 XX
 DE Human ICAM-derived oligonucleotide SEQ ID 13697.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13697; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary

CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hyperextension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1301 AGACTCCAAATGTGCAGGCT 1320
 |||||
 DB 20 AGACTCCAAATGTGCAGGCT 1

RESULT 1027
 ABD31509/c
 ID ABD31509 standard; DNA; 20 BP.

XX
 AC ABD31509;
 XX
 DT 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13720.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense

PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13720; 763pp; English.

XX

CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, respiratory
 CC hyperextension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 SQ Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1071 CAAGGTGACGCTGAATGGGG 1090
 |||||
 DB 20 CAAGGTGACGCTGAATGGGG 1

RESULT 1028

ABD31533/c

ID ABD31533 standard; DNA; 20 BP.

XX ABD31533;

XX 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13744.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX DR
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 .PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13744; 763pp; English.
 PS
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 831 GTTGAACCCACAGTCACCT 850
 Db ||||||||||||||||||
 20 GTTGAACCCACAGTCACCT 1
 RESULT 1029
 ABD31539/C
 ID ABD31539 standard; DNA; 20 BP.
 XX
 AC ABD31539;
 XX
 XX 29-JUL-2004 (first entry)
 DT
 XX Human ICAM-derived oligonucleotide SEQ ID 13750.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 DR
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13750; 763pp; English.
 PS
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 771 CCTGGACGGGCTGTCCCG 790
 Db ||||||||||||||||||
 20 CCTGGACGGGCTGTCCCG 1
 RESULT 1030
 ABD31576/C
 ID ABD31576 standard; DNA; 20 BP.
 XX
 AC ABD31576;
 XX
 XX 29-JUL-2004 (first entry)
 DT

XX DE Human ICAM-derived oligonucleotide SEQ ID 13787.
 XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX OS Homo sapiens.
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13787; 763pp; English.
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytosstatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, respiratory
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 401 GGGTGGAACTGGCACCCTC 420
 DB |||||
 20 GGGTGGAACTGGCACCCTC 1
 RESULT 1031
 ABD31583/c
 ID ABD31583 standard; DNA; 20 BP.
 XX AC ABD31583;
 XX DT 29-JUL-2004 (first entry)
 XX DE Human ICAM-derived oligonucleotide SEQ ID 13794.
 XX KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytosstatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX OS Homo sapiens.
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX Claim 15; SEQ ID NO 13794; 763pp; English.
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytosstatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 331 TGCTATTCAAACTGCCTGA 350
 |||||
 Db 20 TGCTATTCAAACTGCCTGA 1

RESULT 1032
 ABD31586/c
 ID ABD31586 standard; DNA; 20 BP.

XX ABD31586;

AC ABD31586;

DT 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13797.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

PN 31-OCT-2002.

PD 23-APR-2002; 2002WO-US013143.

PF 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

DR WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13797; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 SQ Sequence 20 BP; 3 A; 6 C; 2 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 301 AGCAATGTGCAAGAGATAG 320
 |||||
 Db 20 AGCAATGTGCAAGAGATAG 1

RESULT 1033

ABD31615/c

ID ABD31615 standard; DNA; 20 BP.

XX ABD31615;

AC 29-JUL-2004 (first entry)

XX Human ICAM-derived oligonucleotide SEQ ID 13826.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

PN 31-OCT-2002.

PD 23-APR-2002; 2002WO-US013143.

PF 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

DR WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13826; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,

CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 CGACGCTGAGCTCTCTGCT 30
 Db 20 CGACGCTGAGCTCTCTGCT 1

RESULT 1034
 ADE90158/c
 ID ADE90158 standard; DNA; 20 BP.

AC ADE90158;

XX 12-FEB-2004 (first entry)

DT Human ICAM-1 antisense oligonucleotide.

DE ss; lipid-encapsulated therapeutic agent particle;
 KW aberrant gene expression; intercellular adhesion molecule; ICAM-1; c-myc;
 KW c-myc; ras; raf; erb-B-2; protein kinase C; PKC-alpha;
 KW insulin-like growth factor; IGF-IR; epidermal growth factor receptor;
 KW EGFR; vascular endothelial growth factor; VEGF; VEGF-R-1; tumour;
 KW inflammation; infection; antisense; human.

XX Homo sapiens.

XX US2003129221-A1.

XX 10-JUL-2003.

XX 29-JUN-2001; 2001US-00895480.

XX 14-MAY-1997; 97US-00856374.

XX 14-MAY-1998; 98US-00078954.

XX (SEMP/) SAMPLE S C.

PA (KLIM/) KLIMUK S K.

PA (HARA/) HARASYM T.

PA (HOPE/) HOPE M J.

PA (ANSE/) ANSELL S M.
 PA (CULL/) CULLIS P.
 PA (SCHE/) SCHERRER P.
 PA (DEBE/) DEBEYER D.
 XX
 PI Sample SC, Klimuk SK, Harasym T, Hope MJ, Ansell SM, Cullis P;
 PI Scherrer P, Debeyer D;
 PI WPI; 2004-031296/03.

XX Preparation of a composition comprising lipid-encapsulated therapeutic
 PT agent particles, useful for introducing a nucleic acid into a cell and
 PT for treating diseases characterized by aberrant gene expression.

XX Example 4; SEQ ID NO 2; 52pp; English.

XX The invention relates to a method of preparation of a composition
 CC comprising lipid-encapsulated therapeutic agent particles. The
 CC composition is useful for introducing a nucleic acid into a cell and for
 CC treating diseases characterized by aberrant gene expression (especially
 CC intercellular adhesion molecule (ICAM)-1, c-myc, c-myc, ras, raf erb-B-2,
 CC protein kinase C (PKC)-alpha, insulin-like growth factor (IGF)-IR,
 CC epidermal growth factor receptor (EGFR), vascular endothelial growth
 CC factor (VEGF) or VEGF-R-1), e.g. tumours, inflammation or infection. The
 CC present sequence represents an antisense oligonucleotide.

XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
 Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 1035

ADE39677/c

ID ADE39677 standard; DNA; 20 BP.

XX ADE39677;

XX 12-FEB-2004 (first entry)

XX Oligonucleotide ODN 12 (PS-8997) SEQ ID NO:12.

XX cancer; vaccine; lipid-nucleic acid; LNA; tumour-associated antigen;
 KW Th-1 based immune response; cytostatic; gene therapy;
 KW tumour growth inhibition; tumour; human; ss.

XX Synthetic.

XX Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "optionally phosphorothioate linkages"

XX WO2003094828-A2.

XX 20-NOV-2003.

XX 12-MAY-2003; 2003WO-CA000679.

XX 10-MAY-2002; 2002US-0379343P.

XX 07-NOV-2002; 2002US-00290545.

XX 04-APR-2003; 2003US-0460646P.

XX (INEX-) INEX PHARM CORP.

XX Tam YK, Semple S, Klimuk S, Chikh G;

XX DR WPI; 2004-011992/01.

XX PT New cancer vaccine having a lipid-nucleic acid formulation in combination

XX PT with at least one tumor-associated antigen, useful for stimulating

XX PT enhanced responses against tumor-associated antigens and for inhibiting

XX PT tumor growth.

XX PS Example 9; SEQ ID NO 12; 119pp; English.

XX CC The present invention describes a cancer vaccine (I), which comprises a

XX CC lipid-nucleic acid (LNA) formulation in combination with at least one

XX CC tumour-associated antigen that is mixed with or associated with the LNA

XX CC formulation comprising a lipid component having at least one cationic

XX CC oligonucleotide, where the vaccine is capable of stimulating a Th-1 based

XX CC immune response in vivo to the at least one tumour-associated antigen.

XX CC (I) has cytostatic activity, and can be used in vaccines, and in gene

XX CC therapy. The methods and compositions of the present invention can be

XX CC used for stimulating enhanced responses against tumour-associated

XX CC antigens and for inhibiting tumour growth. The present sequence

XX CC represents an oligonucleotide which is used in the exemplification of the

XX CC present invention.

XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119

DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 1036

AD39676/c

ID ADE39676 standard; DNA; 20 BP.

XX AC ADE39676;

XX DT 12-FEB-2004 (first entry)

XX DE Oligonucleotide ODN 11 (PS-2302) SEQ ID NO:11.

XX KW cancer; vaccine; lipid-nucleic acid; LNA; tumour-associated antigen;

XX KW Th-1 based immune response; cytostatic; gene therapy;

XX KW tumour growth inhibition; tumour; human; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Optionally phosphorothioate linkages"

XX KW WO2003094828-A2.

XX PN 20-NOV-2003.

XX PD 12-MAY-2003; 2003WO-CA000679.

XX PF 10-MAY-2002; 2002US-0379343P.

XX PR 07-NOV-2002; 2002US-00290545.

XX PR 04-APR-2003; 2003US-0460646P.

XX XX (INEX-) INEX PHARM CORP.

XX PA Tam YK, Semple S, Klimuk S, Chikh G;

XX PI WPI; 2004-011992/01.

XX PT New cancer vaccine having a lipid-nucleic acid formulation in combination

XX PT with at least one tumor-associated antigen, useful for stimulating

XX PT enhanced responses against tumor-associated antigens and for inhibiting

XX PT tumor growth.

XX PS Example 9; SEQ ID NO 11; 119pp; English.

XX CC The present invention describes a cancer vaccine (I), which comprises a

XX CC lipid-nucleic acid (LNA) formulation in combination with at least one

XX CC tumour-associated antigen that is mixed with or associated with the LNA

XX CC formulation comprising a lipid component having at least one cationic

XX CC oligonucleotide, where the vaccine is capable of stimulating a Th-1 based

XX CC immune response in vivo to the at least one tumour-associated antigen.

XX CC (I) has cytostatic activity, and can be used in vaccines, and in gene

XX CC therapy. The methods and compositions of the present invention can be

XX CC used for stimulating enhanced responses against tumour-associated

XX CC antigens and for inhibiting tumour growth. The present sequence

XX CC represents an oligonucleotide which is used in the exemplification of the

XX CC present invention.

XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119

DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 1037

ADF42913/c

ID ADF42913 standard; DNA; 20 BP.

XX AC ADF42913;

XX DT 11-MAR-2004 (first entry)

XX DE Methylated immunostimulatory oligonucleotide ODN 12 SEQ ID NO:12.

XX KW lipid-methylated nucleic acid formulation; immune response;

XX KW lipid-nucleic acid; vaccine; immunostimulant; cytostatic;

XX KW antiinflammatory; antiarthritic; gene therapy; cancer; inflammation;

XX KW arthritis; immunodeficiency disorder;

XX KW methylated immunostimulatory oligonucleotide; ss.

XX OS Synthetic.

XX XX WO2003094963-A2.

XX XX 20-NOV-2003.

XX PF 12-MAY-2003; 2003WO-CA000678.

XX PR 10-MAY-2002; 2002US-0379343P.

XX PR 07-NOV-2002; 2002US-00290545.

XX PR 04-APR-2003; 2003US-0460646P.

XX XX (INEX-) INEX PHARM CORP.

XX XX Tam YK, Semple S, Klimuk S, Chikh G;

XX XX WPI; 2004-142698/14.

XX PT Lipid-methylated nucleic acid formulation for stimulating an immune

XX PT response in an animal comprises a lipid component and a nucleic acid

XX PT component comprising a methylated nucleic acid sequence.

XX PS Disclosure; SEQ ID NO 12; 102pp; English.

XX XX

CC The present invention describes a lipid-methylated nucleic acid
 CC formulation for stimulating an immune response in an animal, comprising a
 CC lipid component and a nucleic acid component which is a methylated
 CC nucleic acid sequence. Also described: (1) an adjuvant comprising a lipid
 CC -nucleic acid (LNA) formulation; (2) a vaccine comprising the LNA
 CC formulation in combination with at least one target antigen; (3)
 CC stimulating an enhanced host immune response to antigenic stimulation,
 CC host dendritic cells in vivo, comprising contacting at least one
 CC dendritic cell with the lipid-methylated nucleic acid formulation to a
 CC host; and (5) simultaneously delivering antigenic and adjuvant immune
 CC stimulation to antigen presenting cells, comprising the administration of
 CC the LNA formulation associated with a target antigen. The lipid-
 CC methylation nucleic acid formulation has immunostimulant, cytostatic,
 CC antiinflammatory and antiarthritic activities, and can be used in
 CC vaccines, and in gene therapy. The formulation and methods are useful in
 CC stimulating a host's immune response to antigenic stimulation, or in
 CC activating and/or expanding dendritic cell populations in response to
 CC antigenic stimulation. They may be used for treating cancer,
 CC inflammation, arthritis or immunodeficiency disorders. The present
 CC sequence represents a methylated immunostimulatory oligonucleotide given
 CC in the exemplification of the present invention.

XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
 |||||
 DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 1038
 ADF42912/c
 ID ADF42912 standard; DNA; 20 BP.
 XX
 AC ADF42912;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Methylated immunostimulatory oligonucleotide ODN 11 SEQ ID NO:11.
 XX
 KW lipid-methylated nucleic acid formulation; immune response;
 KW lipid-nucleic acid; vaccine; immunostimulant; cytostatic;
 KW antiinflammatory; antiarthritic; gene therapy; cancer; inflammation;
 KW arthritis; immunodeficiency disorder;
 KW methylated immunostimulatory oligonucleotide; ss.
 XX
 OS Synthetic.
 XX
 PN WO2003094963-A2.
 XX
 PD 20-NOV-2003.
 XX
 PF 12-MAY-2003; 2003WO-CA000678.
 XX
 PR 10-MAY-2002; 2002US-0379343P.
 PR 07-NOV-2002; 2002US-0029054S.
 PR 04-APR-2003; 2003US-0460646P.
 XX
 PA (INEX-) INEX PHARM CORP.
 XX
 PI Tam YK, Semple S, Klimuk S, Chikh G;
 XX
 DR WPI; 2004-142698/14.
 XX
 PT Lipid-methylated nucleic acid formulation for stimulating an immune
 PT response in an animal comprises a lipid component and a nucleic acid
 PT component comprising a methylated nucleic acid sequence.
 XX
 PS Disclosure; SEQ ID NO 11; 102pp; English.

XX The present invention describes a lipid-methylated nucleic acid
 CC formulation for stimulating an immune response in an animal, comprising a
 CC lipid component and a nucleic acid component which is a methylated
 CC nucleic acid sequence. Also described: (1) an adjuvant comprising a lipid
 CC -nucleic acid (LNA) formulation; (2) a vaccine comprising the LNA
 CC formulation in combination with at least one target antigen; (3)
 CC stimulating an enhanced host immune response to antigenic stimulation,
 CC host dendritic cells in vivo, comprising contacting at least one
 CC dendritic cell with the lipid-methylated nucleic acid formulation to a
 CC host; and (5) simultaneously delivering antigenic and adjuvant immune
 CC stimulation to antigen presenting cells, comprising the administration of
 CC the LNA formulation associated with a target antigen. The lipid-
 CC methylation nucleic acid formulation has immunostimulant, cytostatic,
 CC antiinflammatory and antiarthritic activities, and can be used in
 CC vaccines, and in gene therapy. The formulation and methods are useful in
 CC stimulating a host's immune response to antigenic stimulation, or in
 CC activating and/or expanding dendritic cell populations in response to
 CC antigenic stimulation. They may be used for treating cancer,
 CC inflammation, arthritis or immunodeficiency disorders. The present
 CC sequence represents a methylated immunostimulatory oligonucleotide given
 CC in the exemplification of the present invention.

XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
 |||||
 DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 1039
 ADI56727
 ID ADI56727 standard; DNA; 20 BP.
 XX
 AC ADI56727;
 XX
 DT 15-APR-2004 (first entry)
 XX
 DE Human ICAM-1 A241 allele PCR primer, SEQ ID 1.
 XX
 KW Schizophrenia; intercellular adhesion molecule-1; ICAM-1; human; PCR;
 KW primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004009845-A2.
 XX
 PD 29-JAN-2004.
 XX
 PF 23-JUL-2003; 2003WO-EP008086.
 XX
 PR 23-JUL-2002; 2002US-0397611P.
 XX
 PA (MUEL/) MUELLER N.
 XX
 PI Mueller N;
 XX
 DR WPI; 2004-123407/12.
 XX
 PT Screening for schizophrenia, useful for predicting clinical response to a
 PT compound for treating schizophrenia comprising assaying nucleic acid for
 PT a codon encoding arginine at amino acid position 241 of intercellular
 PT adhesion molecule-1.
 XX
 PS Claim 4; SEQ ID NO 1; 34pp; English.
 XX
 CC The present invention relates to a method for screening for
 CC schizophrenia. The method comprises assaying a DNA sample for the

CC presence of a codon encoding arginine at amino acid position 241 of the
 CC intercellular adhesion molecule-1 (ICAM-1) protein or a protein sample
 CC for the presence of the ICAM-1 protein having the 241A polymorphism,
 CC where the presence of a codon encoding arginine at amino acid position
 CC 241 of the ICAM-1 protein or of the polymorphism is indicative of a
 CC schizophrenia. The method is useful for predicting clinical response to a
 CC therapeutic compound in the treatment of ICAM-1 mediated schizophrenia.
 CC The present sequence is a PCR primer, which was used in an example from
 CC the invention.

XX Sequence 20 BP; 5 A; 9 C; 2 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 706 ACTCCGCCCACTTGTTCAG 725
 Db 1 ACTCCGCCCACTTGTTCAG 20

RESULT 1040
 ADI33382/c
 ID ADI33382 standard; DNA; 20 BP.
 XX
 AC ADI33382;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE Labelled ISIS 2302 antisense DNA oligonucleotide SeqID 2.
 XX
 KW antisense; body fluid; methoxyethyl modification;
 KW antisense oligonucleotide therapy; pharmacokinetic; ss.
 XX
 OS Synthetic.
 XX
 PN US2004005618-A1.
 XX
 PD 08-JAN-2004.
 XX
 PF 27-MAY-2003; 2003US-00445996.
 XX
 PR 03-NOV-2000; 2000US-00705587.
 XX
 PA (YUZZ/) YU Z.
 PA (BAKE/) BAKER B F.
 PA (WUHH/) WU H.
 XX
 PI Yu Z, Baker BF, Wu H;
 XX
 DR WPI; 2004-081716/08.
 XX
 PT Detecting antisense oligonucleotide in body fluid comprises forming
 PT hybrids comprising oligonucleotide and probe complementary to
 PT oligonucleotide and comprising detectable marker, degrading unhybridized
 PT probe by nuclease.
 XX
 PS Disclosure; SEQ ID NO 2; 20pp; English.
 XX
 CC This invention relates to a novel method for detecting and quantitating
 CC antisense oligonucleotides in a body fluid or extract. Specifically, it
 CC comprises contacting the sample with a detectable, complementary probe to
 CC form hybrid moieties that can bind to a solid support in order to
 CC separate and identify the oligos of interest. The present invention
 CC describes this method as useful for detecting antisense oligonucleotides
 CC (20-30 nucleobases in length) in a bodily fluid such as plasma using a
 CC probe that comprises at least one phosphorothioate linkage and a 2' MOE
 CC (methoxyethyl) modification of at least one sugar moiety. The method can
 CC be used to detect, localise and quantify administered oligonucleotides in
 CC bodily fluids and extracts taken from patients undergoing antisense
 CC oligonucleotide therapy and for studying the pharmacokinetic properties
 CC of such oligos in animal models and in humans. The method is highly
 CC sensitive (in the picomolar range) and provides improvements in detection

CC level sensitivity over the prior art that describe detection of modified
 CC oligonucleotides only in the nanogram range. This oligonucleotide
 CC sequence is an ISIS antisense oligo of the invention.

XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 1041
 ADI29042/c
 ID ADI29042 standard; DNA; 20 BP.
 XX
 AC ADI29042;
 XX
 DT 22-APR-2004 (first entry)
 XX
 DE Oligonucleotide #2, used in phosphorus deprotection method.
 XX
 KW Deprotection; phosphorothioate; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /notes= "Optional phosphorothioate backbone"
 XX
 PN WO2004009612-A1.
 XX
 PD 29-JAN-2004.
 XX
 PF 17-JUL-2003; 2003WO-US022211.
 XX
 PR 24-JUL-2002; 2002US-00201799.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Ravikumar V;
 XX
 DR WPI; 2004-169187/16.
 XX
 PT Deprotection of phosphorus-protected oligonucleotide useful for the
 PT preparation of pharmaceutical compound involves contacting the phosphorus
 PT -protected oligonucleotide with non-malodorous deprotecting agent.
 XX
 PS Example 6; Page 38; 59pp; English.
 XX
 CC The present invention relates to a method for deprotection of phosphorus-
 CC protected oligonucleotides. The method involves contacting the phosphorus
 CC -protected oligonucleotide with non-malodorous deprotecting agent to
 CC remove the phosphorus protecting group (which is optionally substituted
 CC alkyl). The method is useful for the preparation of phosphorus protected
 CC oligonucleotides, which is useful for the preparation of pharmaceutical
 CC compound. The present sequence is an oligonucleotide, used to illustrate
 CC the method of the invention.

XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1

DE Oligonucleotide associated to ICAM #17.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS WO2004011613-A2.
 PN 05-FEB-2004.
 PD 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 XX (EPIC-) EPIGENESIS PHARM INC.
 PF Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 PR WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1099; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1921 TTTAAAGTCTAGCCTGATGAG 1940
 DB 20 TTTAAAGTCTAGCCTGATGAG 1
 RESULT 1045
 ADJ60261/c
 ID ADJ60261 standard; DNA; 20 BP.
 XX AC ADJ60261;
 XX 06-MAY-2004 (first entry)
 DT Oligonucleotide associated to ICAM #35.
 DE interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW ss.

KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS WO2004011613-A2.
 PN 05-FEB-2004.
 PD 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 XX (EPIC-) EPIGENESIS PHARM INC.
 PF Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 PR WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1117; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1741 CATGCAGCTACACCTACCGG 1760
 DB 20 CATGCAGCTACACCTACCGG 1
 RESULT 1046
 ADJ60286/c
 ID ADJ60286 standard; DNA; 20 BP.
 XX AC ADJ60286;
 XX 06-MAY-2004 (first entry)
 DT Oligonucleotide associated to ICAM #60.
 DE interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 OS Homo sapiens.
 XX

PN WO2004011613-A2.
 XX 05-FEB-2004.
 XX 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1142; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 7 A; 4 C; 3 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1491 GTATGAGATTGTCATCATCA 1510
 Db 20 GTATGAGATTGTCATCATCA 1
 RESULT 1047
 ADJ60288/C
 ID ADJ60288 standard; DNA; 20 BP.
 XX AC ADJ60288;
 XX 06-MAY-2004 (first entry)
 DE Oligonucleotide associated to ICAM #62.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS WO2004011613-A2.
 PN 05-FEB-2004.
 XX 25-JUL-2003; 2003WO-US023509.
 XX 05-FEB-2004.
 XX 25-JUL-2003; 2003WO-US023509.

XX 29-JUL-2002; 2002US-0399076P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1144; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1471 GTGAATGTGCTCTCCCCCG 1490
 Db 20 GTGAATGTGCTCTCCCCCG 1
 RESULT 1048
 ADJ60292/C
 ID ADJ60292 standard; DNA; 20 BP.
 XX AC ADJ60292;
 XX 06-MAY-2004 (first entry)
 DE Oligonucleotide associated to ICAM #66.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS WO2004011613-A2.
 PN 05-FEB-2004.
 XX 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 XX (EPIG-) EPIGENESIS PHARM INC.

PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX DR WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1148; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1431 GGCCAGGAGCCTCAAGGGG 1450
 Db 20 GGCCAGGAGCCTCAAGGGG 1
 RESULT 1049
 ADJ60301/c
 ID ADJ60301 standard; DNA; 20 BP.
 AC ADJ60301;
 XX
 XX 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #75.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX DR WPI; 2004-203534/19.
 XX

PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1157; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1341 GCTCAAGTGTCTAAAGGATG 1360
 Db 20 GCTCAAGTGTCTAAAGGATG 1
 RESULT 1050
 ADJ60304/c
 ID ADJ60304 standard; DNA; 20 BP.
 XX
 AC ADJ60304;
 XX
 XX 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #78.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX DR WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX

PS Claim 2; SEQ ID NO 1160; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.,

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.

XX SQ Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1311 GTGCCAGGCTTGGGGGAACC 1330

DB 20 GTGCCAGGCTTGGGGGAACC 1

RESULT 1051

ADJ60336/c

ID ADJ60336 standard; DNA; 20 BP.

XX AC ADJ60336;

XX 06-MAY-2004 (first entry)

XX Oligonucleotide associated to ICAM #110.

KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

KW airway inflammation; allergy; asthma; impeded respiration;

KW cystic fibrosis; acute respiratory distress syndrome;

KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX ss.

XX Homo sapiens.

XX WO2004011613-A2.

XX 05-FEB-2004.

XX 25-JUL-2003; 2003WO-US023509.

XX 29-JUL-2002; 2002US-0399076P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1192; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.,

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.

XX SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 991 GCGCCCAACGTGATTCTGAC 1010

DB 20 GCGCCCAACGTGATTCTGAC 1

RESULT 1052

ADJ60354/c

ID ADJ60354 standard; DNA; 20 BP.

XX AC ADJ60354;

XX 06-MAY-2004 (first entry)

XX Oligonucleotide associated to ICAM #128.

KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

KW airway inflammation; allergy; asthma; impeded respiration;

KW cystic fibrosis; acute respiratory distress syndrome;

KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX ss.

XX Homo sapiens.

XX WO2004011613-A2.

XX 05-FEB-2004.

XX 25-JUL-2003; 2003WO-US023509.

XX 29-JUL-2002; 2002US-0399076P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1210; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.,

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 811 CTGGCACTGGGGACCAGAG 830
 Db 20 CTGGCACTGGGGACCAGAG 1

RESULT 1053
 ADJ60357/c
 ID ADJ60357 standard; DNA; 20 BP.

XX AC ADJ60357;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #131.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 28-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1213; 85pp; English.

XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

SQ Sequence 20 BP; 5 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 781 CTGTTCCCACTCTCGGAGGC 800
 Db 20 CTGTTCCCACTCTCGGAGGC 1

RESULT 1054
 ADJ60380/c

ID ADJ60380 standard; DNA; 20 BP.

XX AC ADJ60380;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #154.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1236; 85pp; English.

XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

SQ Sequence 20 BP; 2 A; 6 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 551 AGCCGCTGAGGTACGACC 570
DB 20 AGCCGCTGAGGTACGACC 1

RESULT 1055
ADJ60416/c
ID ADJ60416 standard; DNA; 20 BP.

XX AC ADJ60416;

XX XX 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #190.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.

XX OS Homo sapiens.

XX XX WO2004011613-A2.

XX PN 05-FEB-2004.

XX PD 25-JUL-2003; 2003WO-US023509.

XX PF 29-JUL-2002; 2002US-0399076P.

XX PR (EPIG-) EPIGENESIS PHARM INC.

XX PA Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX PI WPI; 2004-203534/19.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1272; 85pp; English.

XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.,
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 191 TGGTGACATGCAGCACCTCC 210
DB 20 TGGTGACATGCAGCACCTCC 1

RESULT 1056
ADJ60424/c

ID ADJ60424 standard; DNA; 20 BP.

XX AC ADJ60424;

XX XX 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #198.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.

XX OS Homo sapiens.

XX XX WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX PI Shahabuddin S, Lu H, Cong H;

XX PI WPI; 2004-203534/19.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1280; 85pp; English.

XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.,
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 5 A; 6 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 111 GGCTCTGTTCACGAGACCTG 130
DB 20 GGCTCTGTTCACGAGACCTG 1

```

RESULT 1057
ADJ60435/c
ID   ADJ60435 standard; DNA; 20 BP.
XX
XX
AC   ADJ60435;
XX
XX
DT   06-MAY-2004 (first entry)
XX
XX
DE   Oligonucleotide associated to ICAM #209.
XX
XX
KW   interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW   airway inflammation; allergy; asthma; impeded respiration;
KW   cystic fibrosis; acute respiratory distress syndrome;
KW   pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW   ss.
XX
XX
OS   Homo sapiens.
XX
XX
PN   WO2004011613-A2.
XX
XX
PD   05-FEB-2004.
XX
XX
PF   25-JUL-2003; 2003WO-US023509.
XX
XX
PR   29-JUL-2002; 2002US-0399076P.
XX
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI   Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI   Shahabuddin S, Lu H, Cong H;
XX
XX
DR   WPI; 2004-203534/19.
XX
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codons and introns of respiratory disease-relevant genes e.g.,
PT   CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT   disease e.g., asthma.
XX
XX
PS   Claim 2; SEQ ID NO 1291; 85pp; English.
XX
XX
CC   The present invention relates to an oligonucleotide anti-sense to e.g.,
CC   initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC   end of nucleic acid target comprising gene(s) chosen from e.g.
CC   interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC   oligonucleotide and optionally surfactant operatively linked to the
CC   oligonucleotide. The method is useful for preventing or treating a
CC   respiratory or lung disease, which involves administering to the airways
CC   of a subject an effective amount of an inhibitor. The oligonucleotide is
CC   useful for production of a medicament for the prevention and/or treatment
CC   of a respiratory or lung disease. The respiratory or lung disease is
CC   chosen from airway inflammation, allergy(ies), asthma, impeded
CC   respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC   (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC   (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC   obstruction. The present sequence represents an oligonucleotide of the
CC   invention.
XX
XX
SQ   Sequence 20 BP; 2 A; 7 C; 8 G; 3 T; 0 U; 0 Other;
      Query Match      0.7%; Score 20; DB 1; Length 20;
      Best Local Similarity 100.0%; Pred. No. 5.4e+02;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   1 GCGCCCCAGTCGACGCTGAG 20
      |||||||
      20 GCGCCCCAGTCGACGCTGAG 1

Db

RESULT 1058
ADJ60231/c
ID   ADJ60231 standard; DNA; 20 BP.
XX
XX
AC   ADJ60231;

```

```

XX
DT   06-MAY-2004 (first entry)
XX
XX
DE   Oligonucleotide associated to ICAM #5.
XX
XX
KW   interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW   airway inflammation; allergy; asthma; impeded respiration;
KW   cystic fibrosis; acute respiratory distress syndrome;
KW   pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW   ss.
XX
XX
OS   Homo sapiens.
XX
XX
PN   WO2004011613-A2.
XX
XX
PD   05-FEB-2004.
XX
XX
PF   25-JUL-2003; 2003WO-US023509.
XX
XX
PR   29-JUL-2002; 2002US-0399076P.
XX
XX
PA   (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI   Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI   Shahabuddin S, Lu H, Cong H;
XX
XX
DR   WPI; 2004-203534/19.
XX
XX
PT   Novel single or multiple target oligonucleotide anti-sense to e.g.
PT   initiation codons and introns of respiratory disease-relevant genes e.g.,
PT   CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT   disease e.g., asthma.
XX
XX
PS   Claim 2; SEQ ID NO 1087; 85pp; English.
XX
XX
CC   The present invention relates to an oligonucleotide anti-sense to e.g.,
CC   initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC   end of nucleic acid target comprising gene(s) chosen from e.g.
CC   interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC   oligonucleotide and optionally surfactant operatively linked to the
CC   oligonucleotide. The method is useful for preventing or treating a
CC   respiratory or lung disease, which involves administering to the airways
CC   of a subject an effective amount of an inhibitor. The oligonucleotide is
CC   useful for production of a medicament for the prevention and/or treatment
CC   of a respiratory or lung disease. The respiratory or lung disease is
CC   chosen from airway inflammation, allergy(ies), asthma, impeded
CC   respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC   (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC   (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC   obstruction. The present sequence represents an oligonucleotide of the
CC   invention.
XX
XX
SQ   Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;
      Query Match      0.7%; Score 20; DB 1; Length 20;
      Best Local Similarity 100.0%; Pred. No. 5.4e+02;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY   2040 ACAGAGAAGTGGCCCTCCA 2059
      |||||||
      20 ACAGAGAAGTGGCCCTCCA 1

Db

RESULT 1059
ADJ60244/c
ID   ADJ60244 standard; DNA; 20 BP.
XX
XX
AC   ADJ60244;
XX
XX
DT   06-MAY-2004 (first entry)
XX
XX
DE   Oligonucleotide associated to ICAM #18.
XX

```


XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.,

XX initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1135; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;

SQ

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1561 CTCTATAACCGCCGAGGAA 1580

DB 20 CTCTATAACCGCCGAGGAA 1

RESULT 1064

ADJ60311/c

ID ADJ60311 standard; DNA; 20 BP.

XX AC ADJ60311;

XX 06-MAY-2004 (first entry)

XX Oligonucleotide associated to ICAM #85.

XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;

XX airway inflammation; allergy; asthma; impeded respiration;

XX cystic fibrosis; acute respiratory distress syndrome;

XX pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX ss.

XX Homo sapiens.

XX WO2004011613-A2.

XX 05-FEB-2004.

XX 25-JUL-2003; 2003WO-US023509.

XX 29-JUL-2002; 2002US-0399076P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1167; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;

SQ

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1241 GCCCCGACTGGACGAGG 1260

DB 20 GCCCCGACTGGACGAGG 1

RESULT 1065

ADJ60314/c

ID ADJ60314 standard; DNA; 20 BP.

XX AC ADJ60314;

XX 06-MAY-2004 (first entry)

XX Oligonucleotide associated to ICAM #88.

XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;

XX airway inflammation; allergy; asthma; impeded respiration;

XX cystic fibrosis; acute respiratory distress syndrome;

XX pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX ss.

XX Homo sapiens.

XX WO2004011613-A2.

XX 05-FEB-2004.

XX 25-JUL-2003; 2003WO-US023509.

XX 29-JUL-2002; 2002US-0399076P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1170; 85pp; English.

XX

CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from allergy inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1211 ACCAGACCCGGAGCTTCGT 1230
 Db 20 ACCAGACCCGGAGCTTCGT 1
 RESULT 1066
 ADJ60320/c
 ID ADJ60320 standard; DNA; 20 BP.
 AC ADJ60320;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 DE Oligonucleotide associated to ICAM #94.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX
 PS Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1176; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC chosen from allergy inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from allergy inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 6 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1151 ACGGGCGCAGCTTCCTGCG 1170
 Db 20 ACGGGCGCAGCTTCCTGCG 1
 RESULT 1067
 ADJ60324/c
 ID ADJ60324 standard; DNA; 20 BP.
 AC ADJ60324;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 DE Oligonucleotide associated to ICAM #98.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX
 PS Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1180; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1111 CCGAGGCCCGAGCTCTGCT 1130
 ID ADJ60326 standard; DNA; 20 BP.
 XX AC ADJ60326;
 XX DT 06-MAY-2004 (first entry)
 XX DE Oligonucleotide associated to ICAM #100.
 XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX OS Homo sapiens.
 XX PN WO2004011613-A2.
 XX PD 05-FEB-2004.
 XX PF 25-JUL-2003; 2003WO-US023509.
 XX PR 29-JUL-2002; 2002US-0399076P.
 XX PA (EPIC-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX PS Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1182; 85pp; English.
 XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.
 XX SQ Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1091 TTCAGCCCCCAGCTGGGC 1110
 ID ADJ60341 standard; DNA; 20 BP.
 XX AC ADJ60341;
 XX DT 06-MAY-2004 (first entry)
 XX DE Oligonucleotide associated to ICAM #115.
 XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX OS Homo sapiens.
 XX PN WO2004011613-A2.
 XX PD 05-FEB-2004.
 XX PF 25-JUL-2003; 2003WO-US023509.
 XX PR 29-JUL-2002; 2002US-0399076P.
 XX PA (EPIC-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX PS Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1197; 85pp; English.
 XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 0 A; 7 C; 5 G; 8 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;


```
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 941 GGAACCCAGCCAGGAGACA 960
   |||||
   20 GGAACCCAGCCAGGAGACA 1
Db

RESULT 1070
ADJ60345/c
ID ADJ60345 standard; DNA; 20 BP.
XX AC ADJ60345;
XX DT 06-MAY-2004 (first entry)
XX DE Oligonucleotide associated to ICAM #119.
XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX KW airway inflammation; allergy; asthma; impeded respiration;
XX KW cystic fibrosis; acute respiratory distress syndrome;
XX KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX ss.
XX OS Homo sapiens.
XX PN WO2004011613-A2.
XX PD 05-FEB-2004.
XX PF 25-JUL-2003; 2003WO-US023509.
XX PR 29-JUL-2002; 2002US-0399076P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX PI Shahabuddin S, Lu H, Cong H;
XX DR WPI; 2004-203534/19.
XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
XX PT initiation codons and introns of respiratory disease-relevant genes e.g.,
XX PT CCRI, RANTES, MCP4, useful for prophylaxis or treating respiratory
XX PT disease e.g., asthma.
XX PS Claim 2; SEQ ID NO 1201; 85pp; English.
XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
XX CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
XX CC end of nucleic acid target comprising gene(s) chosen from e.g.
XX CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
XX CC oligonucleotide and optionally surfactant operatively linked to the
XX CC oligonucleotide. The method is useful for preventing or treating a
XX CC respiratory or lung disease, which involves administering to the airways
XX CC of a subject an effective amount of an inhibitor. The oligonucleotide is
XX CC useful for production of a medicament for the prevention and/or treatment
XX CC of a respiratory or lung disease. The respiratory or lung disease is
XX CC chosen from airway inflammation, allergy(ies), asthma, impeded
XX CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
XX CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
XX CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
XX CC obstruction. The present sequence represents an oligonucleotide of the
XX CC invention.
XX SQ Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 901 GACGAGGGCACCAGCGGCT 920
   |||||
   20 GACGAGGGCACCAGCGGCT 1
Db

RESULT 1070
ADJ60345/c
ID ADJ60345 standard; DNA; 20 BP.
XX AC ADJ60345;
XX DT 06-MAY-2004 (first entry)
XX DE Oligonucleotide associated to ICAM #119.
XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX KW airway inflammation; allergy; asthma; impeded respiration;
XX KW cystic fibrosis; acute respiratory distress syndrome;
XX KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX ss.
XX OS Homo sapiens.
XX PN WO2004011613-A2.
XX PD 05-FEB-2004.
XX PF 25-JUL-2003; 2003WO-US023509.
XX PR 29-JUL-2002; 2002US-0399076P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX PI Shahabuddin S, Lu H, Cong H;
XX DR WPI; 2004-203534/19.
XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
XX PT initiation codons and introns of respiratory disease-relevant genes e.g.,
XX PT CCRI, RANTES, MCP4, useful for prophylaxis or treating respiratory
XX PT disease e.g., asthma.
XX PS Claim 2; SEQ ID NO 1201; 85pp; English.
XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
XX CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
XX CC end of nucleic acid target comprising gene(s) chosen from e.g.
XX CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
XX CC oligonucleotide and optionally surfactant operatively linked to the
XX CC oligonucleotide. The method is useful for preventing or treating a
XX CC respiratory or lung disease, which involves administering to the airways
XX CC of a subject an effective amount of an inhibitor. The oligonucleotide is
XX CC useful for production of a medicament for the prevention and/or treatment
XX CC of a respiratory or lung disease. The respiratory or lung disease is
XX CC chosen from airway inflammation, allergy(ies), asthma, impeded
XX CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
XX CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
XX CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
XX CC obstruction. The present sequence represents an oligonucleotide of the
XX CC invention.
XX SQ Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 901 GACGAGGGCACCAGCGGCT 920
   |||||
   20 GACGAGGGCACCAGCGGCT 1
Db

RESULT 1071
ADJ60362/c
ID ADJ60362 standard; DNA; 20 BP.
XX AC ADJ60362;
XX DT 06-MAY-2004 (first entry)
XX DE Oligonucleotide associated to ICAM #136.
XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX KW airway inflammation; allergy; asthma; impeded respiration;
XX KW cystic fibrosis; acute respiratory distress syndrome;
XX KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX ss.
XX OS Homo sapiens.
XX PN WO2004011613-A2.
XX PD 05-FEB-2004.
XX PF 25-JUL-2003; 2003WO-US023509.
XX PR 29-JUL-2002; 2002US-0399076P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX PI Shahabuddin S, Lu H, Cong H;
XX DR WPI; 2004-203534/19.
XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
XX PT initiation codons and introns of respiratory disease-relevant genes e.g.,
XX PT CCRI, RANTES, MCP4, useful for prophylaxis or treating respiratory
XX PT disease e.g., asthma.
XX PS Claim 2; SEQ ID NO 1218; 85pp; English.
XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
XX CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
XX CC end of nucleic acid target comprising gene(s) chosen from e.g.
XX CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
XX CC oligonucleotide and optionally surfactant operatively linked to the
XX CC oligonucleotide. The method is useful for preventing or treating a
XX CC respiratory or lung disease, which involves administering to the airways
XX CC of a subject an effective amount of an inhibitor. The oligonucleotide is
XX CC useful for production of a medicament for the prevention and/or treatment
XX CC of a respiratory or lung disease. The respiratory or lung disease is
XX CC chosen from airway inflammation, allergy(ies), asthma, impeded
XX CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
XX CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
XX CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
XX CC obstruction. The present sequence represents an oligonucleotide of the
XX CC invention.
XX SQ Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 731 GGGTCCTAGAGGTGGACAG 750
   |||||
   20 GGGTCCTAGAGGTGGACAG 1
Db

RESULT 1072
ADJ60379/c
```

ID ADJ60379 standard; DNA; 20 BP.
 XX AC ADJ60379;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #153.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 XX ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PP 05-FEB-2004.
 XX
 PR 25-JUL-2003; 2003WO-US023509.
 XX
 PX 29-JUL-2002; 2002US-0399076P.
 XX
 PY (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1235; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 561 GGTCAGACACCGTGTCTGG 580
 DB 20 GGTCAGACACCGTGTCTGG 1
 RESULT 1073
 ID ADJ60432/c
 XX ADJ60432 standard; DNA; 20 BP.
 XX
 AC ADJ60432;
 XX
 DT 06-MAY-2004 (first entry)

XX
 DE Oligonucleotide associated to ICAM #206.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 XX ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PP 29-JUL-2002; 2002US-0399076P.
 XX
 PX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1288; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 31 ACTCAGAGTTGCAACCTCAG 50
 DB 20 ACTCAGAGTTGCAACCTCAG 1
 RESULT 1074
 ID ADJ60277/c
 XX ADJ60277 standard; DNA; 20 BP.
 XX
 AC ADJ60277;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #51.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;

KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 PN WO2004011613-A2.
 XX
 XX
 XX 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 XX
 XX 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1133; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 3 C; 4 G; 10 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1581 GATCAAGAAATACAGACTAC 1600
 Db 20 GATCAAGAAATACAGACTAC 1
 RESULT 1075
 ADJ60321/C
 ID ADJ60321 standard; DNA; 20 BP.
 XX
 XX
 AC ADJ60321;
 XX
 XX 06-MAY-2004 (first entry)
 XX
 XX Oligonucleotide associated to ICAM #95.
 DE
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.

XX
 PN WO2004011613-A2.
 XX
 XX 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 XX
 XX 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1177; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 0 A; 8 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1141 CCAGAGGACACGGGCGCAG 1160
 Db 20 CCAGAGGACACGGGCGCAG 1
 RESULT 1076
 ADJ60347/C
 ID ADJ60347 standard; DNA; 20 BP.
 XX
 XX
 AC ADJ60347;
 XX
 XX 06-MAY-2004 (first entry)
 XX
 XX Oligonucleotide associated to ICAM #121.
 DE
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 XX
 XX 05-FEB-2004.
 XX

PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1203; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 881 CAGTCAGTGTGACCGCAGAG 900
 Db 20 CAGTCAGTGTGACCGCAGAG 1
 RESULT 1077
 ADJ60359/c
 ID ADJ60359 standard; DNA; 20 BP.
 XX
 AC ADJ60359;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #133.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.

XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1215; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 6 A; 8 C; 5 G; 1 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 761 TGGTCTGTTCCTCGACGGG 780
 Db 20 TGGTCTGTTCCTCGACGGG 1
 RESULT 1078
 ADJ60361/c
 ID ADJ60361 standard; DNA; 20 BP.
 XX
 AC ADJ60361;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #135.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1217; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 1 A; 10 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 741 GGTGGACACCGAGGGACCG 760
DB 20 GGTGGACACCGAGGGACCG 1
RESULT 1079
ADJ60370/c
ID ADJ60370 standard; DNA; 20 BP.
XX
AC ADJ60370;
XX
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #144.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.

XX
PS Claim 2; SEQ ID NO 1226; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 651 GCTGTTTGAGAACACCTCGG 670
DB 20 GCTGTTTGAGAACACCTCGG 1
RESULT 1080
ADJ60392/c
ID ADJ60392 standard; DNA; 20 BP.
XX
AC ADJ60392;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #166.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1248; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 431 AGCCAGTGGCGAAGACCTT 450
 DB 20 AGCCAGTGGCGAAGACCTT 1

RESULT 1081

ADJ60402/C
 ID ADJ60402 standard; DNA; 20 BP.

XX AC ADJ60402;

DT 06-MAY-2004 (first entry)

DE Oligonucleotide associated to ICAM #176.

KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX Homo sapiens.

XX WO2004011613-A2.

XX 05-FEB-2004.

XX 25-JUL-2003; 2003WO-US023509.

XX 29-JUL-2002; 2002US-0399076P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1258; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 331 TGCTATTCAAACTGCCCTCA 350
 DB 20 TGCTATTCAAACTGCCCTCA 1

RESULT 1082

ADJ60406/C

ID ADJ60406 standard; DNA; 20 BP.

XX AC ADJ60406;

DT 06-MAY-2004 (first entry)

DE Oligonucleotide associated to ICAM #180.

KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX Homo sapiens.

XX WO2004011613-A2.

XX 05-FEB-2004.

XX 25-JUL-2003; 2003WO-US023509.

XX 29-JUL-2002; 2002US-0399076P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1262; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 291 GTATGAAGTGGCAATGTGC 310
DB 20 GTATGAAGTGGCAATGTGC 1
RESULT 1083
ADJ60408/c
ID ADJ60408 standard; DNA; 20 BP.
XX
AC ADJ60408;
XX
XX 06-MAY-2004 (first entry)
XX
XX Oligonucleotide associated to ICAM #182.
DE
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
PI WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1264; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX

SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 271 CCTGGGACACCGGAGGT 290
DB 20 CCTGGGACACCGGAGGT 1
RESULT 1084
ADJ60260/c
ID ADJ60260 standard; DNA; 20 BP.
XX
AC ADJ60260;
XX
XX 06-MAY-2004 (first entry)
XX
XX Oligonucleotide associated to ICAM #34.
DE
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
PI WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1116; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX

Qy 1751 CACCTACCGCCCTGGGACG 1770
 Db 20 CACCTACCGCCCTGGGACG 1

RESULT 1085
 ADJ60271/c
 ID ADJ60271 standard; DNA; 20 BP.
 XX AC ADJ60271;
 XX AC ADJ60271;
 DT 06-MAY-2004 (first entry)
 DE Oligonucleotide associated to ICAM #45.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW SS.
 XX Homo sapiens.
 OS Homo sapiens.
 PN WO2004011613-A2.
 XX 05-FEB-2004.
 XX 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 XX (EPIC-) EPIGENESIS PHARM INC.
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1127; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 3 A; 3 C; 10 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1641 AGCCAGCCCTCCCTGACCT 1660
 Db 20 AGCCAGCCCTCCCTGACCT 1

RESULT 1087
 ADJ60306/c
 ID ADJ60306 standard; DNA; 20 BP.
 XX

RESULT 1086
 ADJ60284/c
 ID ADJ60284 standard; DNA; 20 BP.
 XX AC ADJ60284;
 XX AC ADJ60284;
 DT 06-MAY-2004 (first entry)
 DE Oligonucleotide associated to ICAM #58.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW SS.
 XX Homo sapiens.
 OS Homo sapiens.
 PN WO2004011613-A2.
 XX 05-FEB-2004.
 XX 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 XX (EPIC-) EPIGENESIS PHARM INC.
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1140; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1511 CTGTGTAGCAGCCGAGTC 1530
 Db 20 CTGTGTAGCAGCCGAGTC 1

RESULT 1087
 ADJ60306/c
 ID ADJ60306 standard; DNA; 20 BP.
 XX

AC ADJ60306;
 XX 06-MAY-2004 (first entry)
 DT
 XX
 XX
 DE Oligonucleotide associated to ICAM #80.
 DE
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX 05-FEB-2004.
 PD
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCRI, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 PT
 XX Claim 2; SEQ ID NO 1162; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 4 A; 2 C; 7 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1291 AATTCCGAGCAGACTCCAAT 1310
 Db 20 AATTCCGAGCAGACTCCAAT 1
 RESULT 1088
 ADJ60307/c
 ID ADJ60307 standard; DNA; 20 BP.
 XX
 AC ADJ60307;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX Oligonucleotide associated to ICAM #81.
 DE

XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX 05-FEB-2004.
 PD
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCRI, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 PT
 XX Claim 2; SEQ ID NO 1163; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1281 GTGGCCAGAAAATTCACGC 1300
 Db 20 GTGGCCAGAAAATTCACGC 1
 RESULT 1089
 ADJ60312/c
 ID ADJ60312 standard; DNA; 20 BP.
 XX
 AC ADJ60312;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX Oligonucleotide associated to ICAM #86.
 DE
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW

KW ss.
 XX Homo sapiens.
 OS
 XX
 PN W02004011613-A2.
 XX
 XX 05-FEB-2004.
 PD
 XX
 PF 25-JUL-2003; 2003WO-US0233509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPiG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1168; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1231 GTCTGTATGCCCCCGACT 1250
 Db 20 GTCTGTATGCCCCCGACT 1
 RESULT 1090
 ADJ60316/c
 ID ADJ60316 standard; DNA; 20 BP.
 XX
 AC ADJ60316;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX
 DE Oligonucleotide associated to ICAM #90.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 OS
 XX W02004011613-A2.
 PN

XX
 PD
 XX
 PF 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US0233509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPiG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1172; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1191 CGCCGAGCTTATACACAGA 1210
 Db 20 CGCCGAGCTTATACACAGA 1
 RESULT 1091
 ADJ60356/c
 ID ADJ60356 standard; DNA; 20 BP.
 XX
 AC ADJ60356;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX
 DE Oligonucleotide associated to ICAM #130.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 OS
 XX W02004011613-A2.
 PN
 PD
 XX
 XX 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US0233509.
 XX

PR 29-JUL-2002; 2002US-0399076P.
XX (EPIG-) EPIGENESIS PHARM INC.
PA
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
DR
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.,
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1212; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.,
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 791 TCTCGGAGGCCAGGTCCAC 810
Db 20 TCTCGGAGGCCAGGTCCAC 1
RESULT 1092
ADJ60369/c
ID ADJ60369 standard; DNA; 20 BP.
XX
XX AC ADJ60369;
XX
XX 06-MAY-2004 (first entry)
XX
XX DE Oligonucleotide associated to ICAM #143.
XX
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
XX 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX PF
XX PD 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX PF
XX PR 29-JUL-2002; 2002US-0399076P.
XX
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX WPI; 2004-203534/19.
XX
XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.

PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.,
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1225; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.,
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 2 A; 2 C; 11 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 661 AACACCTCGGCCCTACCA 680
Db 20 AACACCTCGGCCCTACCA 1
RESULT 1093
ADJ60388/c
ID ADJ60388 standard; DNA; 20 BP.
XX
XX AC ADJ60388;
XX
XX 06-MAY-2004 (first entry)
XX
XX DE Oligonucleotide associated to ICAM #162.
XX
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
XX 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX PF
XX PR 29-JUL-2002; 2002US-0399076P.
XX
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1244; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 10 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 471 GGGTGGGGACCCCGGCCA 490
 Db 20 GGGTGGGGACCCCGGCCA 1
 RESULT 1094
 ADJ60227/c
 ID ADJ60227 standard; DNA; 20 BP.
 XX
 AC ADJ60227;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #1.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1083; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 2 C; 9 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2080 ACACAAAGGCCACACTTC 2099
 Db 20 ACACAAAGGCCACACTTC 1
 RESULT 1095
 ADJ60235/c
 ID ADJ60235 standard; DNA; 20 BP.
 XX
 AC ADJ60235;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #9.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1091; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 7 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2001 AACTTGCTGCTATTGGGTA 2020
 DB 20 AACTTGCTGCTATTGGGTA 1

RESULT 1096
 ADJ60247/C
 ID ADJ60247 standard; DNA; 20 BP.

XX AC ADJ60247;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #21.

XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1103; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX

SQ Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900
 DB 20 CAAGAGGAGGAGCAAGACT 1

RESULT 1097
 ADJ60303/C

ID ADJ60303 standard; DNA; 20 BP.

XX AC ADJ60303;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #77.

XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1159; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1321 TGGGGGAACCATGCGCGA 1340
 Db 20 TGGGGGAACCATGCGCGA 1

RESULT 1098
 ADJ60360/C
 ID ADJ60360 standard; DNA; 20 BP.

XX AC ADJ60360;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #134.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX OS Homo sapiens.

XX PN W02004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1216; 85pp; English.

XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 751 CAGGGGACCGTGTCTGTTC 770
 Db 20 CAGGGGACCGTGTCTGTTC 1

RESULT 1099
 ADJ60364/C
 ID ADJ60364 standard; DNA; 20 BP.

XX AC ADJ60364;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #138.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX OS Homo sapiens.

XX PN W02004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1220; 85pp; English.

XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 3 A; 2 C; 11 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 CCCACAACTGTGTGAGCCCC 730

```

Db      20 CCCACAACTGTGTCAGCCCC 1
|||||
RESULT 1100
ADJ60374/c
ID ADJ60374 standard; DNA; 20 BP.
XX
AC ADJ60374;
XX
XX 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #148.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCRI, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1230; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      611 CGTCCGCACTGAACGGAC 630
      |||||||
Db      20 CGTCCGCACTGAACGGAC 1

RESULT 1101

```

```

ADJ60385/c
ID ADJ60385 standard; DNA; 20 BP.
XX
AC ADJ60385;
XX
XX 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #159.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCRI, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1241; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 4 A; 10 C; 4 G; 2 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      501 GGTGCTGCTCCGTGGGAGA 520
      |||||||
Db      20 GGTGCTGCTCCGTGGGAGA 1

RESULT 1102
ADJ60387/c
ID ADJ60387 standard; DNA; 20 BP.
XX
AC ADJ60387;
XX

```

DT 06-MAY-2004 (first entry)
 XX Oligonucleotide associated to ICAM #161.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 XX
 XX WO2004011613-A2.
 XX
 XX 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 XX
 XX 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codons and introns of respiratory disease-relevant genes e.g.,
 XX CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 XX disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1243; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 XX initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 XX end of nucleic acid target comprising gene(s) chosen from e.g.
 XX interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 XX oligonucleotide and optionally surfactant operatively linked to the
 XX oligonucleotide. The method is useful for preventing or treating a
 XX respiratory or lung disease, which involves administering to the airways
 XX of a subject an effective amount of an inhibitor. The oligonucleotide is
 XX useful for production of a medicament for the prevention and/or treatment
 XX of a respiratory or lung disease. The respiratory or lung disease is
 XX chosen from airway inflammation, allergy(ies), asthma, impeded
 XX respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 XX (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 XX (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 XX obstruction. The present sequence represents an oligonucleotide of the
 XX invention.
 XX
 XX Sequence 20 BP; 2 A; 4 C; 11 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 481 CCCGGGCGCAACCTCACCGT 500
 DB 20 CCCGGGCGCAACCTCACCGT 1
 XX
 RESULT 1103
 ADJ60411/c
 ID ADJ60411 standard; DNA; 20 BP.
 XX
 XX ADJ60411;
 AC
 XX
 XX 06-MAY-2004 (first entry)
 DT Oligonucleotide associated to ICAM #185.
 XX
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 XX
 XX WO2004011613-A2.
 XX
 XX 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 XX
 XX 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codons and introns of respiratory disease-relevant genes e.g.,
 XX CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 XX disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1267; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 XX initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 XX end of nucleic acid target comprising gene(s) chosen from e.g.
 XX interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 XX oligonucleotide and optionally surfactant operatively linked to the
 XX oligonucleotide. The method is useful for preventing or treating a
 XX respiratory or lung disease, which involves administering to the airways
 XX of a subject an effective amount of an inhibitor. The oligonucleotide is
 XX useful for production of a medicament for the prevention and/or treatment
 XX of a respiratory or lung disease. The respiratory or lung disease is
 XX chosen from airway inflammation, allergy(ies), asthma, impeded
 XX respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 XX (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 XX (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 XX obstruction. The present sequence represents an oligonucleotide of the
 XX invention.
 XX
 XX Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 241 ACCCGTTCGCTAAAAGGA 260
 DB 20 ACCCGTTCGCTAAAAGGA 1
 XX
 RESULT 1104
 ADJ60428/c
 ID ADJ60428 standard; DNA; 20 BP.
 XX
 XX ADJ60428;
 AC
 XX
 XX 06-MAY-2004 (first entry)
 DT Oligonucleotide associated to ICAM #202.
 XX
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

OS Homo sapiens.
 XX WO2004011613-A2.
 PN
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1284; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 1 A; 6 C; 13 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 71 GCCCCCGCGCGCGTGC 90
 Db 20 GCCCCCGCGCGCGTGC 1
 RESULT 1105
 ADJ60234/c
 ID ADJ60234 standard; DNA; 20 BP.
 XX
 XX ADJ60234;
 AC
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX
 XX Oligonucleotide associated to ICAM #8.
 DE
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX 05-FEB-2004.
 PD

XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1090; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2011 CTATTGGGTATCTGAGGCC 2030
 Db 20 CTATTGGGTATCTGAGGCC 1
 RESULT 1106
 ADJ60248/c
 ID ADJ60248 standard; DNA; 20 BP.
 XX
 XX ADJ60248;
 AC
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX
 XX Oligonucleotide associated to ICAM #22.
 DE
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX 05-FEB-2004.
 PD
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX

PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-203534/19.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1104; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 6 C; 3 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 1871 ATGACTAAGCCAGAGGAG 1890
 Db 20 ATGACTAAGCCAGAGGAG 1
 |||||
 RESULT 1107
 ADJ60294/c
 ID ADJ60294 standard; DNA; 20 BP.
 XX
 AC ADJ60294;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #68.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-203534/19.

DR WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1150; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 1411 GAGGCGACCTACCTCTGTCG 1430
 Db 20 GAGGCGACCTACCTCTGTCG 1
 |||||
 RESULT 1108
 ADJ60309/c
 ID ADJ60309 standard; DNA; 20 BP.
 XX
 AC ADJ60309;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #83.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.
 PS Claim 2; SEQ ID NO 1165; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1261 GATTGTCGGGAACTGGAC 1280
 Db 20 GATTGTCGGGAACTGGAC 1
 RESULT 1109
 ADJ60333/c
 ID ADJ60333 standard; DNA; 20 BP.
 AC ADJ60333;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 DE Oligonucleotide associated to ICAM #107.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX 05-FEB-2004.
 PD
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1189; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1021 GTCTCAGAGGACCGAGGT 1040
 Db 20 GTCTCAGAGGACCGAGGT 1
 RESULT 1110
 ADJ60337/c
 ID ADJ60337 standard; DNA; 20 BP.
 XX
 AC ADJ60337;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 DE Oligonucleotide associated to ICAM #111.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX 05-FEB-2004.
 PD
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1193; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 981 CAGCTTTCGCGCCCAACG 1000

Db 20 CAGCTTTCGCGCCCAACG 1

RESULT 1111

ADJ60338/C

ID ADJ60338 standard; DNA; 20 BP.

XX AC ADJ60338;

XX 06-MAY-2004 (first entry)

XX Oligonucleotide associated to ICAM #112.

XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX Homo sapiens.

XX WO2004011613-A2.

XX 05-FEB-2004.

XX 25-JUL-2003; 2003WO-US023509.

XX 29-JUL-2002; 2002US-0399076P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

XX initiation codons and introns of respiratory disease-relevant genes e.g.,

XX CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

XX disease e.g., asthma.

XX Claim 2; SEQ ID NO 1194; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 971 TGACCATCTACAGCTTTCG 990

Db 20 TGACCATCTACAGCTTTCG 1

RESULT 1112

ADJ60343/C

ID ADJ60343 standard; DNA; 20 BP.

XX AC ADJ60343;

XX 06-MAY-2004 (first entry)

XX Oligonucleotide associated to ICAM #117.

XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX Homo sapiens.

XX WO2004011613-A2.

XX 05-FEB-2004.

XX 25-JUL-2003; 2003WO-US023509.

XX 29-JUL-2002; 2002US-0399076P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

XX initiation codons and introns of respiratory disease-relevant genes e.g.,

XX CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

XX disease e.g., asthma.

XX Claim 2; SEQ ID NO 1199; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

[illegible]

DE Oligonucleotide associated to ICAM #155.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PN 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
PI WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1237; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 10 C; 5 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 541 GCTGTGGGGGAGCCCGCTGA 560
DB 20 GCTGTGGGGGAGCCCGCTGA 1

RESULT 1118
ADJ60389/C
ID ADJ60389 standard; DNA; 20 BP.
XX
AC ADJ60389;
XX
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #163.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW

KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PN 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
PI WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1245; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 2 A; 12 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 461 GCCAGGTGGAGGTGGGCA 480
DB 20 GCCAGGTGGAGGTGGGCA 1

RESULT 1119
ADJ60405/C
ID ADJ60405 standard; DNA; 20 BP.
XX
AC ADJ60405;
XX
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #179.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX

PN WO2004011613-A2.
 XX
 PD
 XX
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1261; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 3 A; 6 C; 2 G; 9 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 301 AGCAATGTGCAAGAGATAG 320
 Db 20 AGCAATGTGCAAGAGATAG 1
 RESULT 1120
 ADJ60420/c
 ID ADJ60420 standard; DNA; 20 BP.
 XX
 XX ADJ60420;
 XX
 XX 06-MAY-2004 (first entry)
 XX
 XX Oligonucleotide associated to ICAM #194.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 XX
 XX WO2004011613-A2.
 XX
 XX 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 XX
 XX 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.

XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1276; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 5 A; 1 C; 9 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 151 TCCCTCTCAAAAGTCATCCT 170
 Db 20 TCCCTCTCAAAAGTCATCCT 1
 RESULT 1121
 ADJ60229/c
 ID ADJ60229 standard; DNA; 20 BP.
 XX
 XX ADJ60229;
 XX
 XX 06-MAY-2004 (first entry)
 XX
 XX Oligonucleotide associated to ICAM #3.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 XX
 XX WO2004011613-A2.
 XX
 XX 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 XX
 XX 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.

PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR
 XX
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX
 PS Claim 2; SEQ ID NO 1085; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2060 TAGACATGTGTAGCATCAA 2079
 DB 20 TAGACATGTGTAGCATCAA 1
 RESULT 1122
 ADJ60239/C
 ID ADJ60239 standard; DNA; 20 BP.
 XX
 AC ADJ60239;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #13.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 XX ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR
 XX

PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX
 PS Claim 2; SEQ ID NO 1095; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 4 C; 8 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1961 CATAGCCCCCACCATGAGGAC 1980
 DB 20 CATAGCCCCCACCATGAGGAC 1
 RESULT 1123
 ADJ60241/C
 ID ADJ60241 standard; DNA; 20 BP.
 XX
 AC ADJ60241;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #15.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 XX ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX

PS Claim 2; SEQ ID NO 1097; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.,

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from asthma, allergic rhinitis (AR), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 2 A; 13 C; 0 G; 5 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1941 AGGGGAAGTGGTGGGGGAGA 1360

DB 20 AGGGGAAGTGGTGGGGGAGA 1

RESULT 1124

ADJ60245/C

ID ADJ60245 standard; DNA; 20 BP.

XX AC ADJ60245;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #19.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

XX KW airway inflammation; allergy; asthma; impeded respiration;

XX KW cystic fibrosis; acute respiratory distress syndrome;

XX KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX ss.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1101; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.,

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from asthma, allergic rhinitis (AR), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 2 A; 13 C; 0 G; 5 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1941 AGGGGAAGTGGTGGGGGAGA 1360

DB 20 AGGGGAAGTGGTGGGGGAGA 1

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from asthma, allergic rhinitis (AR), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 5 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1901 CAAGACATGATGATGATG 1920

DB 20 CAAGACATGATGATGATG 1

RESULT 1125

ADJ60249/C

ID ADJ60249 standard; DNA; 20 BP.

XX AC ADJ60249;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #23.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

XX KW airway inflammation; allergy; asthma; impeded respiration;

XX KW cystic fibrosis; acute respiratory distress syndrome;

XX KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX ss.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1105; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.,

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1861 CTGTAGTCACATGACTAAGC 1880
Db 20 CTGTAGTCACATGACTAAGC 1
RESULT 1126
ADJ60250/c
ID ADJ60250 standard; DNA; 20 BP.
XX
AC ADJ60250;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #24.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-203534/19.
XX
PS Claim 2; SEQ ID NO 1106; 85pp; English.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1106; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1851 CGCATCTGATCTGTAGTCAC 1870
Db 20 CGCATCTGATCTGTAGTCAC 1
RESULT 1127
ADJ60264/c
ID ADJ60264 standard; DNA; 20 BP.
XX
AC ADJ60264;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #38.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-203534/19.
XX
PS Claim 2; SEQ ID NO 1120; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 2 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1711 GCCACACTGAACAGAGTGGG 1730
 ID ADJ60268 standard; DNA; 20 BP.
 AC ADJ60268;
 XX
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #42.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX
 PF 25-JUL-2003; 2003WO-US0233509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1124; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 6 A; 5 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1671 AGGCCTCTTCTCGGCCTT 1690
 Db 20 AGGCCTCTTCTCGGCCTT 1

RESULT 1129
 ADJ60305/c
 ID ADJ60305 standard; DNA; 20 BP.
 AC ADJ60305;
 XX
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #79.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX
 PF 25-JUL-2003; 2003WO-US0233509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1161; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1301 AGACTCCAATGTGCCAGGCT 1320
 Db 20 AGACTCCAATGTGCCAGGCT 1

RESULT 1130
 ADJ60332/c
 ID ADJ60332 standard; DNA; 20 BP.
 XX
 AC ADJ60332;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #106.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1188; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 9 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1031 GGACCGAGGTGACAGTGAAG 1050
 Db 20 GGACCGAGGTGACAGTGAAG 1
 RESULT 1131
 ADJ60334/c
 ID ADJ60334 standard; DNA; 20 BP.
 XX
 AC ADJ60334;

XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #108.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1190; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1011 GAAGCCAGAGGTCTCAGAAG 1030
 Db 20 GAAGCCAGAGGTCTCAGAAG 1
 RESULT 1132
 ADJ60342/c
 ID ADJ60342 standard; DNA; 20 BP.
 XX
 AC ADJ60342;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #116.

KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX
 XX 05-FEB-2004.
 PD
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 XX
 XX 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 PT
 XX Claim 2; SEQ ID NO 1198; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 931 GTAATACCTGGGACACAG 950
 Db 20 GTAATACCTGGGACACAG 1
 RESULT 1133
 ADJ60382/c
 ID ADJ60382 standard; DNA; 20 BP.
 XX
 XX ADJ60382;
 AC
 XX 06-MAY-2004 (first entry)
 DT
 XX Oligonucleotide associated to ICAM #156.
 DE
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX
 XX 05-FEB-2004.
 PD
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 XX
 XX 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 PT
 XX Claim 2; SEQ ID NO 1238; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 11 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 531 ACGGAGCCAGCTGTGGGG 550
 Db 20 ACGGAGCCAGCTGTGGGG 1
 RESULT 1134
 ADJ60383/c
 ID ADJ60383 standard; DNA; 20 BP.
 XX
 XX ADJ60383;
 AC
 XX 06-MAY-2004 (first entry)
 DT
 XX Oligonucleotide associated to ICAM #157.
 DE
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 XX

```
PD 05-FEB-2004.
XX
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX
DR WPI; 2004-203534/19.
XX
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX
PS Claim 2; SEQ ID NO 1239; 85pp; English.
XX
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
XX
SQ Sequence 20 BP; 1 A; 8 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 521 AGGAGCTGAACGGGAGCCA 540
DB 20 AGGAGCTGAACGGGAGCCA 1
RESULT 1135
ADJ60228/C
ID ADJ60228 standard; DNA; 20 BP.
XX
XX
AC ADJ60228;
XX
XX
DT 06-MAY-2004 (first entry)
XX
XX
DE Oligonucleotide associated to ICAM #2.
XX
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
XX
OS Homo sapiens.
XX
XX
PN WO2004011613-A2.
XX
XX
PD 05-FEB-2004.
XX
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX
DR WPI; 2004-203534/19.
XX
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX
PS Claim 2; SEQ ID NO 1239; 85pp; English.
XX
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
XX
SQ Sequence 20 BP; 1 A; 8 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 521 AGGAGCTGAACGGGAGCCA 540
DB 20 AGGAGCTGAACGGGAGCCA 1
RESULT 1135
ADJ60228/C
ID ADJ60228 standard; DNA; 20 BP.
XX
XX
AC ADJ60228;
XX
XX
DT 06-MAY-2004 (first entry)
XX
XX
DE Oligonucleotide associated to ICAM #2.
XX
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
XX
OS Homo sapiens.
XX
XX
PN WO2004011613-A2.
XX
XX
PD 05-FEB-2004.
XX
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX
DR WPI; 2004-203534/19.
XX
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX
PS Claim 2; SEQ ID NO 1084; 85pp; English.
XX
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
XX
SQ Sequence 20 BP; 2 A; 3 C; 5 G; 10 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2070 TAGCATCAAAACACAAAGGC 2089
DB 20 TAGCATCAAAACACAAAGGC 1
RESULT 1136
ADJ60237/C
ID ADJ60237 standard; DNA; 20 BP.
XX
XX
AC ADJ60237;
XX
XX
DT 06-MAY-2004 (first entry)
XX
XX
DE Oligonucleotide associated to ICAM #11.
XX
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
XX
OS Homo sapiens.
XX
XX
PN WO2004011613-A2.
XX
XX
PD 05-FEB-2004.
XX
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
```

XX WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.,
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1093; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 4 A; 4 C; 3 G; 9 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1981 ATCAACTGGGAATCTGA 2000
 Db |||||
 20 ATCAACTGGGAATCTGA 1
 RESULT 1137
 ADJ60252/c
 ID ADJ60252 standard; DNA; 20 BP.
 XX AC ADJ60252;
 XX 06-MAY-2004 (first entry)
 XX Oligonucleotide associated to ICAM #26.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS WO2004011613-A2.
 PN 05-FEB-2004.
 PD 25-JUL-2003; 2003WO-US023509.
 PF 29-JUL-2002; 2002US-0399076P.
 PR (EPIG-) EPIGENESIS PHARM INC.
 PA Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.,
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 PS Claim 2; SEQ ID NO 1108; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 2 A; 2 C; 7 G; 9 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1831 ACACCTAAACACTAGGCCA 1850
 Db |||||
 20 ACACCTAAACACTAGGCCA 1
 RESULT 1138
 ADJ60282/c
 ID ADJ60282 standard; DNA; 20 BP.
 XX AC ADJ60282;
 XX 06-MAY-2004 (first entry)
 XX Oligonucleotide associated to ICAM #56.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS WO2004011613-A2.
 PN 05-FEB-2004.
 PD 25-JUL-2003; 2003WO-US023509.
 PF 29-JUL-2002; 2002US-0399076P.
 PR (EPIG-) EPIGENESIS PHARM INC.
 PA Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.,
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1138; 85pp; English.

CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1531 ATAAATGGGCACTGCAGGCCT 1550
 |||||
 Db 20 ATAAATGGGCACTGCAGGCCT 1
 RESULT 1139
 ADJ60300/c
 ID ADJ60300 standard; DNA; 20 BP.
 XX
 AC ADJ60300;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #74.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-203534/19.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1156; 85pp; English.
 PS
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is

CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1351 CTAAGGATGGCACTTTCC 1370
 |||||
 Db 20 CTAAGGATGGCACTTTCC 1
 RESULT 1140
 ADJ60302/c
 ID ADJ60302 standard; DNA; 20 BP.
 XX
 AC ADJ60302;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #76.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-203534/19.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1158; 85pp; English.
 PS
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.

SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1331 CATTGCCGAGCTCAAGTGT 1350
DB 20 CATTGCCGAGCTCAAGTGT 1

RESULT 1141
ADJ60319/C
ID ADJ60319 standard; DNA; 20 BP.
XX AC ADJ60319;
XX AC ADJ60319;
XX AC ADJ60319;
DT 06-MAY-2004 (first entry)
DE Oligonucleotide associated to ICAM #93.
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX Homo sapiens.
XX WO2004011613-A2.
XX 05-FEB-2004.
XX 25-JUL-2003; 2003WO-US023509.
XX 29-JUL-2002; 2002US-0399076P.
XX (EPIG-) EPIGENESIS PHARM INC.
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
PI WPI; 2004-203534/19.
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX Claim 2; SEQ ID NO 1175; 85pp; English.
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.
XX SQ Sequence 20 BP; 6 A; 2 C; 10 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1161 CTTCTCTGCTCTGCAACCC 1180
DB 20 CTTCTCTGCTCTGCAACCC 1

RESULT 1142
ADJ60340/C
ID ADJ60340 standard; DNA; 20 BP.
XX AC ADJ60340;
XX AC ADJ60340;
DT 06-MAY-2004 (first entry)
DE Oligonucleotide associated to ICAM #114.
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX Homo sapiens.
XX WO2004011613-A2.
XX 05-FEB-2004.
XX 25-JUL-2003; 2003WO-US023509.
XX 29-JUL-2002; 2002US-0399076P.
XX (EPIG-) EPIGENESIS PHARM INC.
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
PI WPI; 2004-203534/19.
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX Claim 2; SEQ ID NO 1196; 85pp; English.
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.

SQ Sequence 20 BP; 1 A; 6 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02; Indels 0; Gaps 0; Mismatches 0; Conservative 0; Matches 20;

QY 951 CCAGGAGACTCGACAG 970
|||||
20 CCAGGAGACTCGACAG 1

Db

RESULT 1143
ADJ60353/c
ID ADJ60353 standard; DNA; 20 BP.
XX
AC ADJ60353;
XX
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #127.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
XX WO2004011613-A2.
PN
PD 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
PF
XX
XX 29-JUL-2002; 2002US-0399076P.
PR
XX
XX (EPIG-) EPIGENESIS PHARM INC.
PA
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
DR
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1209; 85pp; English.
PS
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 821 GGGACCAGAGTTGAACCCC 840
|||||

Db

RESULT 1145
ADJ60412/c

Db 20 GGGACCAGAGTTGAACCCC 1

RESULT 1144
ADJ60375/c
ID ADJ60375 standard; DNA; 20 BP.
XX
XX ADJ60375;
XX
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #149.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
XX WO2004011613-A2.
PN
PD 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
PF
XX
XX 29-JUL-2002; 2002US-0399076P.
PR
XX
XX (EPIG-) EPIGENESIS PHARM INC.
PA
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
DR
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1231; 85pp; English.
PS
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 601 GCCAATTTCTCGTGGCGCAC 620
|||||

Db 20 GCCAATTTCTCGTGGCGCAC 1

RESULT 1145
ADJ60412/c

ID ADJ60412 standard; DNA; 20 BP.
 AC ADJ60412;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #186.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1268; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 231 GGGCATAGACCCCGTGC 250
 DB 20 GGGCATAGACCCCGTGC 1
 XX
 RESULT 1146
 ADJ60421/c
 ID ADJ60421 standard; DNA; 20 BP.
 XX
 AC ADJ60421;
 XX
 DT 06-MAY-2004 (first entry)
 XX

XX
 DE Oligonucleotide associated to ICAM #195.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1277; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 141 GACATCTGTGTCCTCCCTCAA 160
 DB 20 GACATCTGTGTCCTCCCTCAA 1
 XX
 RESULT 1147
 ADJ60422/c
 ID ADJ60422 standard; DNA; 20 BP.
 XX
 AC ADJ60422;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #196.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW

PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR
 XX 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1132; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 3 C; 7 G; 8 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1591 TACAGACTACACAGGCCCA 1610
 Db
 |||||
 20 TACAGACTACACAGGCCCA 1
 RESULT 1150
 ADJ60278/c
 ID ADJ60278 standard; DNA; 20 BP.
 XX
 AC ADJ60278;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 XX Oligonucleotide associated to ICAM #52.
 DE
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 OS
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 XX
 XX 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR

XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1134; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 6 C; 4 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1571 GCCAGCGGAAGATCAAGAAA 1590
 Db
 |||||
 20 GCCAGCGGAAGATCAAGAAA 1
 RESULT 1151
 ADJ60285/c
 ID ADJ60285 standard; DNA; 20 BP.
 XX
 AC ADJ60285;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 XX Oligonucleotide associated to ICAM #59.
 DE
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 OS
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 XX
 XX 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.,
PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
XX disease e.g., asthma.
XX Claim 2; SEQ ID NO 1141; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 1501 GTCATCATCATCTGCTGGTAGC 1520
DB 20 GTCATCATCATCTGCTGGTAGC 1
RESULT 1152
ADJ60295/c
ID ADJ60295 standard; DNA; 20 BP.
XX
AC ADJ60295;
XX
XX 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #69.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1151; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 1401 TCGAGATCTTGAGGGCACCT 1420
DB 20 TCGAGATCTTGAGGGCACCT 1
RESULT 1153
ADJ60310/c
ID ADJ60310 standard; DNA; 20 BP.
XX
AC ADJ60310;
XX
XX 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #84.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1166; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 3 A; 10 C; 3 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1251 GGACGAGAGGATGTCGG 1270
 DB 20 GGACGAGAGGATGTCGG 1

RESULT 1154
 ADJ60313/C
 ID ADJ60313 standard; DNA; 20 BP.
 XX
 AC ADJ60313;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #87.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1169; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 7 A; 7 C; 4 G; 2 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1221 GGAGCTTCGTCTCTGTATG 1240
 DB 20 GGAGCTTCGTCTCTGTATG 1

RESULT 1155
 ADJ60315/C
 ID ADJ60315 standard; DNA; 20 BP.
 XX
 AC ADJ60315;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #89.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1171; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

QY 911 CCCAGCGGCTGACGTGTGCA 930
ID ADJ60346/c
DB 20 CCCAGCGGCTGACGTGTGCA 1

RESULT 1158
ADJ60346/c
ID ADJ60346 standard; DNA; 20 BP.

XX AC ADJ60346;
XX XX
XX DT 06-MAY-2004 (first entry)
XX DE Oligonucleotide associated to ICAM #120.
XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX OS Homo sapiens.
XX PN WO2004011613-A2.
XX PD 05-FEB-2004.
XX PF 25-JUL-2003; 2003WO-US023509.
XX PR 29-JUL-2002; 2002US-0399076P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX PI Shahabuddin S, Lu H, Cong H;
XX DR WPI; 2004-203534/19.
XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX PS Claim 2; SEQ ID NO 1202; 85pp; English.
XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 0 A; 9 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 891 GACCGCAGAGGACGAGGCA 910
DB 20 GACCGCAGAGGACGAGGCA 1

RESULT 1159
ADJ60395/c
ID ADJ60395 standard; DNA; 20 BP.
XX AC ADJ60395;
XX XX
XX DT 06-MAY-2004 (first entry)
XX DE Oligonucleotide associated to ICAM #169.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX OS Homo sapiens.
XX PN WO2004011613-A2.
XX PD 05-FEB-2004.
XX PF 25-JUL-2003; 2003WO-US023509.
XX PR 29-JUL-2002; 2002US-0399076P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX PI Shahabuddin S, Lu H, Cong H;
XX DR WPI; 2004-203534/19.
XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX PS Claim 2; SEQ ID NO 1251; 85pp; English.
XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 401 GGGTGAAGTGGCACCCTC 420
DB 20 GGGTGAAGTGGCACCCTC 1

RESULT 1160
ADJ60417/c
ID ADJ60417 standard; DNA; 20 BP.
XX

AC ADJ60417;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #191.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 XX
 PF 29-JUL-2002; 2002US-0399076P.
 XX
 PR (EPIG-) EPIGENESIS PHARM INC.
 XX
 PA Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCRL1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1273; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 181 GGCTCCGTCGTCGTGACATG 200
 Db 20 GGCTCCGTCGTCGTGACATG 1
 RESULT 1161
 ADJ60242/c
 ID ADJ60242 standard; DNA; 20 BP.
 XX
 AC ADJ60242;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #16.

XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 XX
 PF 29-JUL-2002; 2002US-0399076P.
 XX
 PR (EPIG-) EPIGENESIS PHARM INC.
 XX
 PA Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCRL1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1098; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 10 C; 2 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1931 GCCTGATGAGCGGGAAGTG 1950
 Db 20 GCCTGATGAGCGGGAAGTG 1
 RESULT 1162
 ADJ60246/c
 ID ADJ60246 standard; DNA; 20 BP.
 XX
 AC ADJ60246;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #20.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

KW ss.
 XX Homo sapiens.
 OS
 XX
 PN W02004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 XX
 PF 29-JUL-2002; 2002US-0399076P.
 XX
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1102; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 5 C; 4 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1891 GAGCAGACTCAAGACATGA 1910
 Db 20 GAGCAGACTCAAGACATGA 1
 RESULT 1163
 ADJ60253/c
 ID ADJ60253 standard; DNA; 20 BP.
 XX
 AC ADJ60253;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX
 DE Oligonucleotide associated to ICAM #27.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 OS Homo sapiens.
 XX
 PN W02004011613-A2.

XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1109; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 3 C; 6 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1821 TGGTACCTGCACACCTAATA 1840
 Db 20 TGGTACCTGCACACCTAATA 1
 RESULT 1164
 ADJ60255/c
 ID ADJ60255 standard; DNA; 20 BP.
 XX
 AC ADJ60255;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX
 DE Oligonucleotide associated to ICAM #29.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 OS Homo sapiens.
 XX
 PN W02004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.

```

PR 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1111; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1801 TACAACAGCATTGGGGCCA 1820
DB 20 TACAACAGCATTGGGGCCA 1

RESULT 1165
ADJ60257/c
ID ADJ60257 standard; DNA; 20 BP.
XX
XX ADJ60257;
XX
XX 06-MAY-2004 (first entry)
XX
XX Oligonucleotide associated to ICAM #31.
DE
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX airway inflammation; allergy; asthma; impeded respiration;
XX cystic fibrosis; acute respiratory distress syndrome;
XX pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX ss.
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
XX 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.

```

```

PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1113; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1781 GGGCATTGTCCTCAGTCAGA 1800
DB 20 GGGCATTGTCCTCAGTCAGA 1

RESULT 1166
ADJ60280/c
ID ADJ60280 standard; DNA; 20 BP.
XX
XX ADJ60280;
XX
XX 06-MAY-2004 (first entry)
XX
XX Oligonucleotide associated to ICAM #54.
XX
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX airway inflammation; allergy; asthma; impeded respiration;
XX cystic fibrosis; acute respiratory distress syndrome;
XX pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX ss.
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
XX 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.

```

PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.

PS Claim 2; SEQ ID NO 1136; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1551 CAGCAGTACTCTATTAACC 1570

DB 20 CAGCAGTACTCTATTAACC 1

RESULT 1167

ADJ60281/c

ID ADJ60281 standard; DNA; 20 BP.

XX AC ADJ60281;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #55.

XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX OS Homo sapiens.

XX PN W02004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1137; 85pp; English.

XX

CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1541 CTCAGGCGCTCAGCAGTAC 1560

DB 20 CTCAGGCGCTCAGCAGTAC 1

RESULT 1168

ADJ60291/c

ID ADJ60291 standard; DNA; 20 BP.

XX AC ADJ60291;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #65.

XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX OS Homo sapiens.

XX PN W02004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1147; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1441 ACTCAAGGGGAGGTCAACCG 1460
DB 20 ACTCAAGGGGAGGTCAACCG 1

RESULT 1169
ADJ60329/C
ID ADJ60329 standard; DNA; 20 BP.

XX AC ADJ60329;

DT 06-MAY-2004 (first entry)

XX Oligonucleotide associated to ICAM #103.

KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.

XX Homo sapiens.

XX WO2004011613-A2.

XX 05-FEB-2004.

XX 25-JUL-2003; 2003WO-US023509.

XX 29-JUL-2002; 2002US-0399076P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1185; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX

SQ Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1061 ACCCTAGAGCCCAAGGTGACG 1080
DB 20 ACCCTAGAGCCCAAGGTGACG 1

RESULT 1170
ADJ60351/C

ID ADJ60351 standard; DNA; 20 BP.

XX AC ADJ60351;

DT 06-MAY-2004 (first entry)

XX Oligonucleotide associated to ICAM #125.

KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.

XX Homo sapiens.

XX WO2004011613-A2.

XX 05-FEB-2004.

XX 25-JUL-2003; 2003WO-US023509.

XX 29-JUL-2002; 2002US-0399076P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1207; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.

XX Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 841 ACAGTCACCTATGCGACAGA 860
|||||

Db 20 ACAGTCACCTATGCGACAGA 1

RESULT 1171

ADJ60358/c

ID ADJ60358 standard; DNA; 20 BP.

XX AC

XX ADJ60358;

XX XX

DT 06-MAY-2004 (first entry)

XX XX

DE Oligonucleotide associated to ICAM #132.

XX XX

KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

KW airway inflammation; allergy; asthma; impeded respiration;

KW cystic fibrosis; acute respiratory distress syndrome;

KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX ss.

XX XX

OS Homo sapiens.

XX XX

PN WO2004011613-A2.

XX XX

PD 05-FEB-2004.

XX XX

PF 25-JUL-2003; 2003WO-US023509.

XX XX

PR 29-JUL-2002; 2002US-0399076P.

XX XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX XX

PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

PT Shahabuddin S, Lu H, Cong H;

XX XX

XX WPI; 2004-203534/19.

XX XX

PT Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX XX

PS Claim 2; SEQ ID NO 1214; 85pp; English.

XX XX

CC The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

XX invention.

XX Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 771 CCTGGACGGGCTGTTCACG 790
|||||

Db 20 CCTGGACGGGCTGTTCACG 1

RESULT 1172

ADJ60398/c

ID ADJ60398 standard; DNA; 20 BP.

XX AC

XX ADJ60398;

XX XX

DT 06-MAY-2004 (first entry)

XX XX

DE Oligonucleotide associated to ICAM #172.

XX XX

KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

KW airway inflammation; allergy; asthma; impeded respiration;

KW cystic fibrosis; acute respiratory distress syndrome;

KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX ss.

XX XX

OS Homo sapiens.

XX XX

PN WO2004011613-A2.

XX XX

PD 05-FEB-2004.

XX XX

PF 25-JUL-2003; 2003WO-US023509.

XX XX

PR 29-JUL-2002; 2002US-0399076P.

XX XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX XX

PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

PT Shahabuddin S, Lu H, Cong H;

XX XX

XX WPI; 2004-203534/19.

XX XX

PT Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX XX

PS Claim 2; SEQ ID NO 1254; 85pp; English.

XX XX

CC The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

XX invention.

XX Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 371 CCTTCTCACCCTGTACTGG 390


```

Db      20 CCTTCTCACCAGTGACTGG 1
|||||
RESULT 1173
ADJ60400/c
ID      ADJ60400 standard; DNA; 20 BP.
AC      ADJ60400;
XX
XX
XX      06-MAY-2004 (first entry)
XX
DE      Oligonucleotide associated to ICAM #174.
XX
KW      interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW      airway inflammation; allergy; asthma; impeded respiration;
KW      cystic fibrosis; acute respiratory distress syndrome;
KW      pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW      ss.
XX
XX      Homo sapiens.
XX
XX      WO2004011613-A2.
XX
XX      05-FEB-2004.
XX
XX      25-JUL-2003; 2003WO-US023509.
XX
XX      29-JUL-2002; 2002US-0399076P.
XX
XX      (EPIG-) EPIGENESIS PHARM INC.
XX
XX      Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX      Shahabuddin S, Lu H, Cong H;
XX      WPI; 2004-203534/19.
XX
XX      Novel single or multiple target oligonucleotide anti-sense to e.g.
XX      initiation codons and introns of respiratory disease-relevant genes e.g.,
XX      CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
XX      disease e.g., asthma.
XX
XX      Claim 2; SEQ ID NO 1256; 85pp; English.
XX
XX      The present invention relates to an oligonucleotide anti-sense to e.g.;
XX      initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
XX      end of nucleic acid target comprising gene(s) chosen from e.g.
XX      interleukin (IL)-4 receptor, IL-5 receptor or salts of the
XX      oligonucleotide and optionally surfactant operatively linked to the
XX      oligonucleotide. The method is useful for preventing or treating a
XX      respiratory or lung disease, which involves administering to the airways
XX      of a subject an effective amount of an inhibitor. The oligonucleotide is
XX      useful for production of a medicament for the prevention and/or treatment
XX      of a respiratory or lung disease. The respiratory or lung disease is
XX      chosen from airway inflammation, allergy(ies), asthma, impeded
XX      respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
XX      (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
XX      (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
XX      obstruction. The present sequence represents an oligonucleotide of the
XX      invention.
XX
XX      Sequence 20 BP; 3 A; 5 C; 4 G; 8 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      351 TGGGCACTCAACAGCTAAAA 370
|||||
Db      20 TGGGCACTCAACAGCTAAAA 1
|||||
RESULT 1174

```

```

ADJ60427/c
ID      ADJ60427 standard; DNA; 20 BP.
XX
XX      ADJ60427;
XX
XX
XX      06-MAY-2004 (first entry)
XX
DE      Oligonucleotide associated to ICAM #201.
XX
XX      interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX      airway inflammation; allergy; asthma; impeded respiration;
XX      cystic fibrosis; acute respiratory distress syndrome;
XX      pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX      ss.
XX
XX      Homo sapiens.
XX
XX      WO2004011613-A2.
XX
XX      05-FEB-2004.
XX
XX      25-JUL-2003; 2003WO-US023509.
XX
XX      29-JUL-2002; 2002US-0399076P.
XX
XX      (EPIG-) EPIGENESIS PHARM INC.
XX
XX      Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX      Shahabuddin S, Lu H, Cong H;
XX      WPI; 2004-203534/19.
XX
XX      Novel single or multiple target oligonucleotide anti-sense to e.g.
XX      initiation codons and introns of respiratory disease-relevant genes e.g.,
XX      CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
XX      disease e.g., asthma.
XX
XX      Claim 2; SEQ ID NO 1283; 85pp; English.
XX
XX      The present invention relates to an oligonucleotide anti-sense to e.g.;
XX      initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
XX      end of nucleic acid target comprising gene(s) chosen from e.g.
XX      interleukin (IL)-4 receptor, IL-5 receptor or salts of the
XX      oligonucleotide and optionally surfactant operatively linked to the
XX      oligonucleotide. The method is useful for preventing or treating a
XX      respiratory or lung disease, which involves administering to the airways
XX      of a subject an effective amount of an inhibitor. The oligonucleotide is
XX      useful for production of a medicament for the prevention and/or treatment
XX      of a respiratory or lung disease. The respiratory or lung disease is
XX      chosen from airway inflammation, allergy(ies), asthma, impeded
XX      respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
XX      (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
XX      (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
XX      obstruction. The present sequence represents an oligonucleotide of the
XX      invention.
XX
XX      Sequence 20 BP; 3 A; 6 C; 10 G; 1 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      81 CGCGCTGCCCGCACTCTGG 100
|||||
Db      20 CGCGCTGCCCGCACTCTGG 1
|||||
RESULT 1175
ADJ60430/c
ID      ADJ60430 standard; DNA; 20 BP.
XX
XX      ADJ60430;
XX

```

DT 06-MAY-2004 (first entry)
 DE Oligonucleotide associated to ICAM #204.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1286; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 51 CCTCGCTATGCTCCAGCA 70
 DB 20 CCTCGCTATGCTCCAGCA 1
 RESULT 1176
 ADJ60431/C
 ID ADJ60431 standard; DNA; 20 BP.
 XX
 AC ADJ60431;
 XX
 XX 06-MAY-2004 (first entry)
 DT Oligonucleotide associated to ICAM #205.
 DE
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW

KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1287; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 41 GCAACCTCAGCCTCGCTATG 60
 DB 20 GCAACCTCAGCCTCGCTATG 1
 RESULT 1177
 ADJ60254/C
 ID ADJ60254 standard; DNA; 20 BP.
 XX
 AC ADJ60254;
 XX
 XX 06-MAY-2004 (first entry)
 DT Oligonucleotide associated to ICAM #28.
 DE
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX

OS Homo sapiens.
 XX WO2004011613-A2.
 XX PD 05-FEB-2004.
 XX 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1110; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 6 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1811 TTTGGGGCCCATGCTACTGC 1830
 Db 20 TTTGGGGCCCATGCTACTGC 1
 RESULT 1178
 ADJ60262/c
 ID ADJ60262 standard; DNA; 20 BP.
 XX AC ADJ60262;
 XX 06-MAY-2004 (first entry)
 XX Oligonucleotide associated to ICAM #36.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 SS.
 XX Homo sapiens.
 OS WO2004011613-A2.
 XX PD 05-FEB-2004.

XX 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1118; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 4 A; 4 C; 5 G; 7 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1731 AGACATATGCCATGCAGCTA 1750
 Db 20 AGACATATGCCATGCAGCTA 1
 RESULT 1179
 ADJ60269/c
 ID ADJ60269 standard; DNA; 20 BP.
 XX AC ADJ60269;
 XX 06-MAY-2004 (first entry)
 XX Oligonucleotide associated to ICAM #43.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 SS.
 XX Homo sapiens.
 OS WO2004011613-A2.
 XX PD 05-FEB-2004.
 XX 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.

PA (EPIC-) EPIGENESIS PHARM INC.
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1125; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1661 ATCCCGGACAGGGCCTCTT 1680
 DB 20 ATCCCGGACAGGGCCTCTT 1
 RESULT 1180
 ADJ60275/c
 ID ADJ60275 standard; DNA; 20 BP.
 AC ADJ60275;
 XX 06-MAY-2004 (first entry)
 DE Oligonucleotide associated to ICAM #49.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 XX WO2004011613-A2.
 PN 05-FEB-2004.
 PD 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 PR (EPIC-) EPIGENESIS PHARM INC.
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1125; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1661 ATCCCGGACAGGGCCTCTT 1680
 DB 20 ATCCCGGACAGGGCCTCTT 1
 RESULT 1180
 ADJ60275/c
 ID ADJ60275 standard; DNA; 20 BP.
 AC ADJ60275;
 XX 06-MAY-2004 (first entry)
 DE Oligonucleotide associated to ICAM #49.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 XX WO2004011613-A2.
 PN 05-FEB-2004.
 PD 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 PR (EPIC-) EPIGENESIS PHARM INC.
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1125; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1661 ATCCCGGACAGGGCCTCTT 1680
 DB 20 ATCCCGGACAGGGCCTCTT 1

DR WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1131; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 0 A; 5 C; 6 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1601 AACAGGCCCAAAAGGGACC 1620
 DB 20 AACAGGCCCAAAAGGGACC 1
 RESULT 1181
 ADJ60296/c
 ID ADJ60296 standard; DNA; 20 BP.
 XX ADJ60296;
 XX 06-MAY-2004 (first entry)
 DE Oligonucleotide associated to ICAM #70.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 XX WO2004011613-A2.
 PN 05-FEB-2004.
 PD 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 PR (EPIC-) EPIGENESIS PHARM INC.
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1131; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 0 A; 5 C; 6 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1601 AACAGGCCCAAAAGGGACC 1620
 DB 20 AACAGGCCCAAAAGGGACC 1

PT disease e.g., asthma.

PS Claim 2; SEQ ID NO 1152; 85pp; English.

XX

CC The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.

XX

SQ Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1391 TGACTGTCACTCGAGATCTT 1410

DB 20 TGACTGTCACTCGAGATCTT 1

RESULT 1182

ADJ60308/c

ID ADJ60308 standard; DNA; 20 BP.

XX

AC ADJ60308;

XX

DT 06-MAY-2004 (first entry)

XX

DE Oligonucleotide associated to ICAM #82.

XX

KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

KW airway inflammation; allergy; asthma; impeded respiration;

KW cystic fibrosis; acute respiratory distress syndrome;

KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

KW ss.

XX

OS Homo sapiens.

XX

PN WO2004011613-A2.

XX

PD 05-FEB-2004.

XX

PF 25-JUL-2003; 2003WO-US023509.

XX

PR 29-JUL-2002; 2002US-0399076P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX

DR WPI; 2004-203534/19.

XX

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX

PS Claim 2; SEQ ID NO 1164; 85pp; English.

XX

CC The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.

XX

SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1271 GAAACTGGACGTGGCCAGAA 1290

DB 20 GAAACTGGACGTGGCCAGAA 1

RESULT 1183

ADJ60372/c

ID ADJ60372 standard; DNA; 20 BP.

XX

AC ADJ60372;

XX

DT 06-MAY-2004 (first entry)

XX

DE Oligonucleotide associated to ICAM #146.

XX

KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

KW airway inflammation; allergy; asthma; impeded respiration;

KW cystic fibrosis; acute respiratory distress syndrome;

KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

KW ss.

XX

OS Homo sapiens.

XX

PN WO2004011613-A2.

XX

PD 05-FEB-2004.

XX

PF 25-JUL-2003; 2003WO-US023509.

XX

PR 29-JUL-2002; 2002US-0399076P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX

DR WPI; 2004-203534/19.

XX

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX

PS Claim 2; SEQ ID NO 1228; 85pp; English.

XX

CC The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 631 CTGGGCCCCAAGGCTGGA 650
 ID ADJ60373 standard; DNA; 20 BP.
 Db 20 CTGGGCCCCAAGGCTGGA 1

RESULT 1184
 ADJ60373/c
 ID ADJ60373 standard; DNA; 20 BP.

XX AC ADJ60373;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #147.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

XX KW airway inflammation; allergy; asthma; impeded respiration;

XX KW cystic fibrosis; acute respiratory distress syndrome;

XX KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX SS.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.

XX PT initiation codons and introns of respiratory disease-relevant genes e.g.,

XX PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

XX PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1229; 85pp; English.

XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,

XX CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

XX CC end of nucleic acid target comprising gene(s) chosen from e.g.

XX CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

XX CC oligonucleotide and optionally surfactant operatively linked to the

XX CC oligonucleotide. The method is useful for preventing or treating a

XX CC respiratory or lung disease, which involves administering to the airways

XX CC of a subject an effective amount of an inhibitor. The oligonucleotide is

XX CC useful for production of a medicament for the prevention and/or treatment

XX CC of a respiratory or lung disease. The respiratory or lung disease is

XX CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX

SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 621 TGAACCTGGACCTGCGCCCC 640

Db 20 TGAACCTGGACCTGCGCCCC 1

RESULT 1185
 ADJ60386/c
 ID ADJ60386 standard; DNA; 20 BP.

XX AC ADJ60386;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #160.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

XX KW airway inflammation; allergy; asthma; impeded respiration;

XX KW cystic fibrosis; acute respiratory distress syndrome;

XX KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX SS.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.

XX PT initiation codons and introns of respiratory disease-relevant genes e.g.,

XX PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

XX PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1242; 85pp; English.

XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,

XX CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

XX CC end of nucleic acid target comprising gene(s) chosen from e.g.

XX CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

XX CC oligonucleotide and optionally surfactant operatively linked to the

XX CC oligonucleotide. The method is useful for preventing or treating a

XX CC respiratory or lung disease, which involves administering to the airways

XX CC of a subject an effective amount of an inhibitor. The oligonucleotide is

XX CC useful for production of a medicament for the prevention and/or treatment

XX CC of a respiratory or lung disease. The respiratory or lung disease is

XX CC chosen from airway inflammation, allergy(ies), asthma, impeded

XX CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

XX CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

XX CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

XX CC obstruction. The present sequence represents an oligonucleotide of the

XX CC invention.

XX SQ Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 491 ACCTCACCGTGGTGTGCTC 510
DB 20 ACCTCACCGTGGTGTGCTC 1

RESULT 1186
ADJ60399/C
ID ADJ60399 standard; DNA; 20 BP.

XX AC ADJ60399;
XX AC
DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #173.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.

XX OS Homo sapiens.

XX PN W02004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPiG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1255; 85pp; English.

XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 4 A; 1 C; 8 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 361 ACAGCTAAACCTTCTCTAC 380
DB 20 ACAGCTAAACCTTCTCTAC 1

RESULT 1187
ADJ60423/C
ID ADJ60423 standard; DNA; 20 BP.

XX AC ADJ60423;

XX AC
DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #197.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.

XX OS Homo sapiens.

XX PN W02004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPiG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1279; 85pp; English.

XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 121 CCAGGACCTGGCAATGCCCA 140
DB 20 CCAGGACCTGGCAATGCCCA 1

```

XX AC ADJ60426;
XX ID ADJ60426 standard; DNA; 20 BP.
XX AC ADJ60426;
XX AC ADJ60426;
XX 06-MAY-2004 (first entry)
XX Oligonucleotide associated to ICAM #200.
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX airway inflammation; allergy; asthma; impeded respiration;
XX cystic fibrosis; acute respiratory distress syndrome;
XX pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX ss.
XX Homo sapiens.
XX WO2004011613-A2.
XX 05-FEB-2004.
XX 25-JUL-2003; 2003WO-US023509.
XX 29-JUL-2002; 2002US-0399076P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
XX initiation codons and introns of respiratory disease-relevant genes e.g.,
XX CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
XX disease e.g., asthma.
XX Claim 2; SEQ ID NO 1282; 85pp; English.
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
XX initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
XX end of nucleic acid target comprising gene(s) chosen from e.g.
XX interleukin (IL)-4 receptor, IL-5 receptor or salts of the
XX oligonucleotide and optionally surfactant operatively linked to the
XX oligonucleotide. The method is useful for preventing or treating a
XX respiratory or lung disease, which involves administering to the airways
XX of a subject an effective amount of an inhibitor. The oligonucleotide is
XX useful for production of a medicament for the prevention and/or treatment
XX of a respiratory or lung disease. The respiratory or lung disease is
XX chosen from airway inflammation, allergy(ies), asthma, impeded
XX respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
XX (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
XX (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
XX obstruction. The present sequence represents an oligonucleotide of the
XX invention.
XX Sequence 20 BP; 5 A; 6 C; 8 G; 1 T; 0 U; 0 Other;
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 91 GCACCTCTGCTCTGCTCGG 110
XX |||||||||||||||
XX 20 GCACCTCTGCTCTGCTCGG 1
XX
XX RESULT 1189
XX ADJ60267/c
XX ID ADJ60267 standard; DNA; 20 BP.

```

```

XX AC ADJ60267;
XX 06-MAY-2004 (first entry)
XX Oligonucleotide associated to ICAM #41.
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX airway inflammation; allergy; asthma; impeded respiration;
XX cystic fibrosis; acute respiratory distress syndrome;
XX pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX ss.
XX Homo sapiens.
XX WO2004011613-A2.
XX 05-FEB-2004.
XX 25-JUL-2003; 2003WO-US023509.
XX 29-JUL-2002; 2002US-0399076P.
XX (EPIG-) EPIGENESIS PHARM INC.
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
XX initiation codons and introns of respiratory disease-relevant genes e.g.,
XX CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
XX disease e.g., asthma.
XX Claim 2; SEQ ID NO 1123; 85pp; English.
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
XX initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
XX end of nucleic acid target comprising gene(s) chosen from e.g.
XX interleukin (IL)-4 receptor, IL-5 receptor or salts of the
XX oligonucleotide and optionally surfactant operatively linked to the
XX oligonucleotide. The method is useful for preventing or treating a
XX respiratory or lung disease, which involves administering to the airways
XX of a subject an effective amount of an inhibitor. The oligonucleotide is
XX useful for production of a medicament for the prevention and/or treatment
XX of a respiratory or lung disease. The respiratory or lung disease is
XX chosen from airway inflammation, allergy(ies), asthma, impeded
XX respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
XX (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
XX (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
XX obstruction. The present sequence represents an oligonucleotide of the
XX invention.
XX Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1681 CCTCGGCTTCCCATATTGG 1700
XX |||||||||||||||
XX 20 CCTCGGCTTCCCATATTGG 1
XX
XX RESULT 1190
XX ADJ60273/c
XX ID ADJ60273 standard; DNA; 20 BP.
XX AC ADJ60273;
XX 06-MAY-2004 (first entry)

```


DE Oligonucleotide associated to ICAM #47.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PN 29-JUL-2002; 2002US-0399076P.
 XX
 PD (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 DR
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1129; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 2 C; 8 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1621 CCCATGAACCGAACACACA 1640
 DB 20 CCCATGAACCGAACACACA 1
 RESULT 1191
 ADJ60274/C
 ID ADJ60274 standard; DNA; 20 BP.
 XX
 AC ADJ60274;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX Oligonucleotide associated to ICAM #48.
 DE
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW

KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PN 29-JUL-2002; 2002US-0399076P.
 XX
 PD (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 DR
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1130; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 4 C; 6 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1611 AAAAGGGACCCCATGAAC 1630
 DB 20 AAAAGGGACCCCATGAAC 1
 RESULT 1192
 ADJ60298/C
 ID ADJ60298 standard; DNA; 20 BP.
 XX
 AC ADJ60298;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX Oligonucleotide associated to ICAM #72.
 DE
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 OS Homo sapiens.
 XX

PN WO2004011613-A2.
 XX 05-FEB-2004.
 XX 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 PR (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1154; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1371 ACTGCCCATCGGGGAATCAG 1390
 Db 20 ACTGCCCATCGGGGAATCAG 1
 RESULT 1193
 ADJ60317/C
 ID ADJ60317 standard; DNA; 20 BP.
 XX AC ADJ60317;
 XX 06-MAY-2004 (first entry)
 XX Oligonucleotide associated to ICAM #91.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS WO2004011613-A2.
 PN 05-FEB-2004.
 XX 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 PR (EPIG-) EPIGENESIS PHARM INC.

XX 29-JUL-2002; 2002US-0399076P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1173; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 4 A; 9 C; 5 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1181 TGGAGGTGGCGGCCAGCTT 1200
 Db 20 TGGAGGTGGCGGCCAGCTT 1
 RESULT 1194
 ADJ60328/C
 ID ADJ60328 standard; DNA; 20 BP.
 XX AC ADJ60328;
 XX 06-MAY-2004 (first entry)
 XX Oligonucleotide associated to ICAM #102.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS WO2004011613-A2.
 PN 05-FEB-2004.
 XX 25-JUL-2003; 2003WO-US023509.
 XX 29-JUL-2002; 2002US-0399076P.
 PR (EPIG-) EPIGENESIS PHARM INC.

```

PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX DR WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.,
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1184; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1071 CAAGGTGACCTGAATGGGG 1090
DB 20 CAAGGTGACCTGAATGGGG 1
RESULT 1195
ADJ60330/c
ID ADJ60330 standard; DNA; 20 BP.
XX AC ADJ60330;
XX
XX 06-MAY-2004 (first entry)
XX
XX Oligonucleotide associated to ICAM #104.
XX
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX airway inflammation; allergy; asthma; impeded respiration;
XX cystic fibrosis; acute respiratory distress syndrome;
XX pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX ss.
XX
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
XX 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.,
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1184; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1071 CAAGGTGACCTGAATGGGG 1090
DB 20 CAAGGTGACCTGAATGGGG 1
RESULT 1196
ADJ60339/c
ID ADJ60339 standard; DNA; 20 BP.
XX AC ADJ60339;
XX
XX 06-MAY-2004 (first entry)
XX
XX Oligonucleotide associated to ICAM #113.
XX
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX airway inflammation; allergy; asthma; impeded respiration;
XX cystic fibrosis; acute respiratory distress syndrome;
XX pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX ss.
XX
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
XX 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.,
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1186; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1051 TGTGAGGCCACCTAGAGC 1070
DB 20 TGTGAGGCCACCTAGAGC 1
RESULT 1196
ADJ60339/c
ID ADJ60339 standard; DNA; 20 BP.
XX AC ADJ60339;
XX
XX 06-MAY-2004 (first entry)
XX
XX Oligonucleotide associated to ICAM #113.
XX
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX airway inflammation; allergy; asthma; impeded respiration;
XX cystic fibrosis; acute respiratory distress syndrome;
XX pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX ss.
XX
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
XX 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.,
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1186; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1051 TGTGAGGCCACCTAGAGC 1070
DB 20 TGTGAGGCCACCTAGAGC 1

```

PS Claim 2; SEQ ID NO 1195; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.,

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

QQ Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 961 CTGCAGACGTGACCACTCA 980

DB 20 CTGCAGACGTGACCACTCA 1

RESULT 1197

ADJ60348/c

ID ADJ60348 standard; DNA; 20 BP.

XX AC ADJ60348;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #122.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

XX KW airway inflammation; allergy; asthma; impeded respiration;

XX KW cystic fibrosis; acute respiratory distress syndrome;

XX KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX KW ss.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1204; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

QQ Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 871 GCCAAGGCCTCAGTCAGTGT 890

DB 20 GCCAAGGCCTCAGTCAGTGT 1

RESULT 1198

ADJ60384/c

ID ADJ60384 standard; DNA; 20 BP.

XX AC ADJ60384;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #158.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

XX KW airway inflammation; allergy; asthma; impeded respiration;

XX KW cystic fibrosis; acute respiratory distress syndrome;

XX KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX KW ss.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1240; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 2 A; 10 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 511 CGTGGGAGAGGAGTGA 530
 Db 20 CGTGGGAGAGGAGTGA 1
 |||||

RESULT 1199
 ADJ60391/c
 ID ADJ60391 standard; DNA; 20 BP.
 XX AC
 XX ADJ60391;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #165.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1247; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 441 CAAGAACCTTACCCTACGCT 460
 Db 20 CAAGAACCTTACCCTACGCT 1
 |||||

RESULT 1200
 ADJ60396/c
 ID ADJ60396 standard; DNA; 20 BP.
 XX AC
 XX ADJ60396;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #170.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1252; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 ACTCCAGACGGGTGGAAC 410
 ID ADJ60401 standard; DNA; 20 BP.
 XX AC ADJ60401;
 XX AC ADJ60401;
 DT 06-MAY-2004 (first entry)
 XX DE Oligonucleotide associated to ICAM #175.
 XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX OS Homo sapiens.
 XX PN WO2004011613-A2.
 XX PD 05-FEB-2004.
 XX PF 25-JUL-2003; 2003WO-US023509.
 XX PR 29-JUL-2002; 2002US-0399076P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 DR WPI; 2004-203534/19.
 XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX PS Claim 2; SEQ ID NO 1257; 85pp; English.
 XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 341 ACTGCCCTGATGGCAGTCA 360
 ID ADJ60413 standard; DNA; 20 BP.
 XX AC ADJ60413;
 XX AC ADJ60413;
 DT 06-MAY-2004 (first entry)
 XX DE Oligonucleotide associated to ICAM #187.
 XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX OS Homo sapiens.
 XX PN WO2004011613-A2.
 XX PD 05-FEB-2004.
 XX PF 25-JUL-2003; 2003WO-US023509.
 XX PR 29-JUL-2002; 2002US-0399076P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 DR WPI; 2004-203534/19.
 XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX PS Claim 2; SEQ ID NO 1269; 85pp; English.
 XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 221 CCAAGTTGTTGGCATAGAG 240
 ID ADJ60413 standard; DNA; 20 BP.
 XX AC ADJ60413;
 XX AC ADJ60413;
 DT 06-MAY-2004 (first entry)
 XX DE Oligonucleotide associated to ICAM #187.
 XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX OS Homo sapiens.
 XX PN WO2004011613-A2.
 XX PD 05-FEB-2004.
 XX PF 25-JUL-2003; 2003WO-US023509.
 XX PR 29-JUL-2002; 2002US-0399076P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 DR WPI; 2004-203534/19.
 XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX PS Claim 2; SEQ ID NO 1269; 85pp; English.
 XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
RESULT 1203
ADJ60425/c
ID ADJ60425 standard; DNA; 20 BP.
XX
XX AC ADJ60425;
XX
XX 06-MAY-2004 (first entry)
XX
XX Oligonucleotide associated to ICAM #199.
XX
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX airway inflammation; allergy; asthma; impeded respiration;
XX cystic fibrosis; acute respiratory distress syndrome;
XX pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX ss.
XX
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
XX 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
XX initiation codons and introns of respiratory disease-relevant genes e.g.,
XX CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
XX disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1281; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
XX initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
XX end of nucleic acid target comprising gene(s) chosen from e.g.
XX interleukin (IL)-4 receptor, IL-5 receptor or salts of the
XX oligonucleotide and optionally surfactant operatively linked to the
XX oligonucleotide. The method is useful for preventing or treating a
XX respiratory or lung disease, which involves administering to the airways
XX of a subject an effective amount of an inhibitor. The oligonucleotide is
XX useful for production of a medicament for the prevention and/or treatment
XX of a respiratory or lung disease. The respiratory or lung disease is
XX chosen from airway inflammation, allergy(ies), asthma, impeded
XX respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
XX (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
XX (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
XX obstruction. The present sequence represents an oligonucleotide of the
XX invention.
XX
XX Sequence 20 BP; 7 A; 6 C; 7 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 101 TCCTGCTCGGGGCTCTGTTTC 120
Db 20 TCCTGCTCGGGGCTCTGTTTC 1

RESULT 1204
ADJ60434/c
ID ADJ60434 standard; DNA; 20 BP.
XX
XX AC ADJ60434;
XX
```

```
XX
XX 06-MAY-2004 (first entry)
XX
XX Oligonucleotide associated to ICAM #208.
XX
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
XX airway inflammation; allergy; asthma; impeded respiration;
XX cystic fibrosis; acute respiratory distress syndrome;
XX pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX ss.
XX
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
XX 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
XX Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
XX initiation codons and introns of respiratory disease-relevant genes e.g.,
XX CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
XX disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1290; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
XX initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
XX end of nucleic acid target comprising gene(s) chosen from e.g.
XX interleukin (IL)-4 receptor, IL-5 receptor or salts of the
XX oligonucleotide and optionally surfactant operatively linked to the
XX oligonucleotide. The method is useful for preventing or treating a
XX respiratory or lung disease, which involves administering to the airways
XX of a subject an effective amount of an inhibitor. The oligonucleotide is
XX useful for production of a medicament for the prevention and/or treatment
XX of a respiratory or lung disease. The respiratory or lung disease is
XX chosen from airway inflammation, allergy(ies), asthma, impeded
XX respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
XX (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
XX (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
XX obstruction. The present sequence represents an oligonucleotide of the
XX invention.
XX
XX Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 CGACGCTGAGCTCCTCTGCT 30
Db 20 CGACGCTGAGCTCCTCTGCT 1

RESULT 1205
ADJ60236/c
ID ADJ60236 standard; DNA; 20 BP.
XX
XX AC ADJ60236;
XX
XX 06-MAY-2004 (first entry)
XX
XX Oligonucleotide associated to ICAM #10.
XX
```

KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1092; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 1991 GAAATACCTGAACTGTGTC 2010
 Db ||||||||||||||||
 20 GAAATACCTGAACTGTGTC 1
 RESULT 1206
 ADJ60259/c
 ID ADJ60259 standard; DNA; 20 BP.
 XX
 AC ADJ60259;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #33.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.

XX Homo sapiens.
 OS
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1115; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 1761 CCCTGGGACGCCGGAGGACA 1780
 Db ||||||||||||||||
 20 CCCTGGGACGCCGGAGGACA 1
 RESULT 1207
 ADJ60287/c
 ID ADJ60287 standard; DNA; 20 BP.
 XX
 AC ADJ60287;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #61.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS
 PN WO2004011613-A2.
 XX

PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPiG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1143; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 6 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1481 TCTCCCCCGGTATGAGATT 1500
Db 20 TCTCCCCCGGTATGAGATT 1

RESULT 1208
ADJ60293/C
ID ADJ60293 standard; DNA; 20 BP.
XX
AC ADJ60293;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #67.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.

XX
PA (EPiG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1149; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1421 ACCTCTGTGGGCCAGGAGC 1440
Db 20 ACCTCTGTGGGCCAGGAGC 1

RESULT 1209
ADJ60325/C
ID ADJ60325 standard; DNA; 20 BP.
XX
AC ADJ60325;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #99.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPiG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1181; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 1 A; 8 C; 9 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1101 GCCACTGGCCCGAGGAGGCC 1120
 Db |||||
 20 GCCACTGGCCCGAGGAGGCC 1
 RESULT 1210
 ADJ60365/c
 ID ADJ60365 standard; DNA; 20 BP.
 XX AC ADJ60365;
 XX 06-MAY-2004 (first entry)
 XX Oligonucleotide associated to ICAM #139.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS WO2004011613-A2.
 PN 05-FEB-2004.
 PD 25-JUL-2003; 2003WO-US023509.
 PF 29-JUL-2002; 2002US-0399076P.
 PR (EPIG-) EPIGENESIS PHARM INC.
 PA Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1221; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 3 A; 2 C; 10 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 701 CAGCGACTCCCCCACAACCTT 720
 Db |||||
 20 CAGCGACTCCCCCACAACCTT 1
 RESULT 1211
 ADJ60367/c
 ID ADJ60367 standard; DNA; 20 BP.
 XX AC ADJ60367;
 XX 06-MAY-2004 (first entry)
 XX Oligonucleotide associated to ICAM #141.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS WO2004011613-A2.
 PN 05-FEB-2004.
 PD 25-JUL-2003; 2003WO-US023509.
 PF 29-JUL-2002; 2002US-0399076P.
 PR (EPIG-) EPIGENESIS PHARM INC.
 PA Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1223; 85pp; English.
 XX

CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 681 GCTCCAGACCTTGTCTGTC 700
 Db 20 GCTCCAGACCTTGTCTGTC 1
 RESULT 1212
 ADJ60394/c
 ID ADJ60394 standard; DNA; 20 BP.
 AC ADJ60394;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX
 DE Oligonucleotide associated to ICAM #168.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1250; 85pp; English.
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 11 G; 1 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 411 GGCACCCCTCCCTCTTGGC 430
 Db 20 GGCACCCCTCCCTCTTGGC 1
 RESULT 1213
 ADJ60397/c
 ID ADJ60397 standard; DNA; 20 BP.
 AC ADJ60397;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX
 DE Oligonucleotide associated to ICAM #171.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1253; 85pp; English.
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 381 CGTGACTGACTCCAGAAC 400
DB 20 CGTGACTGACTCCAGAAC 1

RESULT 1214
ADJ60414/c
ID ADJ60414 standard; DNA; 20 BP.
XX AC ADJ60414;
XX DT 06-MAY-2004 (first entry)
XX DE Oligonucleotide associated to ICAM #188.
XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX SS.
XX OS Homo sapiens.
XX PN WO2004011613-A2.
XX PD 05-FEB-2004.
XX PF 25-JUL-2003; 2003WO-US023509.
XX PR 29-JUL-2002; 2002US-0399076P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX PS Novel single or multiple target oligonucleotide anti-sense to e.g.
XX PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
XX CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
XX disease e.g., asthma.
XX Claim 2; SEQ ID NO 1270; 85pp; English.
XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.
XX SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 211 TGTGACGACGCCCAAGTTGTT 230
DB 20 TGTGACGACGCCCAAGTTGTT 1

RESULT 1215
ADJ60419/c
ID ADJ60419 standard; DNA; 20 BP.
XX AC ADJ60419;
XX DT 06-MAY-2004 (first entry)
XX DE Oligonucleotide associated to ICAM #193.
XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX SS.
XX OS Homo sapiens.
XX PN WO2004011613-A2.
XX PD 05-FEB-2004.
XX PF 25-JUL-2003; 2003WO-US023509.
XX PR 29-JUL-2002; 2002US-0399076P.
XX PA (EPIG-) EPIGENESIS PHARM INC.
XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX PS Novel single or multiple target oligonucleotide anti-sense to e.g.
XX PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
XX CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
XX disease e.g., asthma.
XX Claim 2; SEQ ID NO 1275; 85pp; English.
XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
XX invention.
XX SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 161 AAGTCATCTGCCCCGGGA 180
|||||
20 AAGTCATCTGCCCCGGGA 1

Db

RESULT 1216
ADJ60238/c
ID ADJ60238 standard; DNA; 20 BP.
AC
XX ADJ60238;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #12.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
FN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1094; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1971 CCATGAGGACATCAACTGG 1990
|||||

Db 20 CCATGAGGACATCAACTGG 1

RESULT 1217
ADJ60240/c
ID ADJ60240 standard; DNA; 20 BP.
XX
AC ADJ60240;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #14.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
FN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1096; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1951 GTGGGGGAGACATAGCCCCA 1970
|||||

Db 20 GTGGGGGAGACATAGCCCCA 1

RESULT 1218
ADJ60251/c

ID ADJ60251 standard; DNA; 20 BP.
 XX AC ADJ60251;
 XX
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #25.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX
 PN W02004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1107; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome,
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1841 CACTAGGCCACGATCTGAT 1860
 DB 20 CACTAGGCCACGATCTGAT 1
 RESULT 1219
 ADJ60256/c
 ID ADJ60256 standard; DNA; 20 BP.
 XX
 XX AC ADJ60256;
 XX
 DT 06-MAY-2004 (first entry)

XX
 DE
 XX
 KW Oligonucleotide associated to ICAM #30.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX
 PN W02004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1112; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome,
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 3 A; 3 C; 6 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1791 CTCAGTCAGATCAACAGCA 1810
 DB 20 CTCAGTCAGATCAACAGCA 1
 RESULT 1220
 ADJ60265/c
 ID ADJ60265 standard; DNA; 20 BP.
 XX
 XX AC ADJ60265;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #39.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;

KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 XX
 PD 05-FEB-2004.
 XX
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1121; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1701 TGGCAGTGGTGCCACACTGA 1720
 DB 20 TGGCAGTGGTGCCACACTGA 1
 RESULT 1221
 ADJ60349/c
 ID ADJ60349 standard; DNA; 20 BP.
 XX
 AC ADJ60349;
 XX
 XX
 DT 06-MAY-2004 (first entry)
 XX
 XX Oligonucleotide associated to ICAM #123.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.

XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1205; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 861 CTCCTTCTCGGCACAGGCCT 880
 DB 20 CTCCTTCTCGGCACAGGCCT 1
 RESULT 1222
 ADJ60368/c
 ID ADJ60368 standard; DNA; 20 BP.
 XX
 AC ADJ60368;
 XX
 XX
 DT 06-MAY-2004 (first entry)
 XX
 XX Oligonucleotide associated to ICAM #142.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.

```

PF 25-JUL-2003; 2003WO-US023509.
XX
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
XX
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX
PS Claim 2; SEQ ID NO 1224; 85pp; English.
XX
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 2 A; 2 C; 12 G; 4 T; 0 U; 0 Other;
      Query Match      0.7%; Score 20; DB 1; Length 20;
      Best Local Similarity 100.0%; Pred. No. 5.4e+02;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 671 CCCCTACCAGTCCAGACC 690
Db 20 CCCCTACCAGTCCAGACC 1
      |||||
      |||||

RESULT 1223
ADJ60378/c
ID ADJ60378 standard; DNA; 20 BP.
XX
XX
AC ADJ60378;
XX
XX
DT 06-MAY-2004 (first entry)
DE Oligonucleotide associated to ICAM #152.
XX
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
XX
OS Homo sapiens.
XX
XX
PN WO2004011613-A2.
XX
XX
PD 05-FEB-2004.
XX
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
XX
PD 05-FEB-2004.
XX
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
XX
XX

```

```

XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
XX
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX
PS Claim 2; SEQ ID NO 1234; 85pp; English.
XX
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 10 C; 2 G; 5 T; 0 U; 0 Other;
      Query Match      0.7%; Score 20; DB 1; Length 20;
      Best Local Similarity 100.0%; Pred. No. 5.4e+02;
      Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 571 ACGGTCTGCTGAGAGAGA 590
Db 20 ACGGTCTGCTGAGAGAGA 1
      |||||
      |||||

RESULT 1224
ADJ60410/c
ID ADJ60410 standard; DNA; 20 BP.
XX
XX
AC ADJ60410;
XX
XX
DT 06-MAY-2004 (first entry)
DE Oligonucleotide associated to ICAM #184.
XX
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
XX
OS Homo sapiens.
XX
XX
PN WO2004011613-A2.
XX
XX
PD 05-FEB-2004.
XX
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
XX
XX

```


XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 CC CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1266; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 251 CTAAAGAGGAGTTCCTCG 270
 DB 20 CTAAAGAGGAGTTCCTCG 1
 RESULT 1225
 ADJ60418/C
 ID ADJ60418 standard; DNA; 20 BP.
 XX
 AC ADJ60418;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #192.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 1274; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 9 C; 8 G; 1 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 171 GCCCGGGGAGGCTCGTGC 190
 DB 20 GCCCGGGGAGGCTCGTGC 1
 RESULT 1226
 ADJ60433/C
 ID ADJ60433 standard; DNA; 20 BP.
 XX
 AC ADJ60433;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #207.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1289; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 7 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 CTCCTCTGCTACTCAGAGTT 40
 Db 20 CTCCTCTGCTACTCAGAGTT 1

RESULT 1227
 ADJ60297/c
 ID ADJ60297 standard; DNA; 20 BP.
 XX
 AC ADJ60297;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #71.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1153; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1381 GGGGAATCAGTCTCTC 1400
 Db 20 GGGGAATCAGTCTCTC 1

RESULT 1228
 ADJ60299/c
 ID ADJ60299 standard; DNA; 20 BP.
 XX
 AC ADJ60299;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #73.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-203534/19.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1155; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (CPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX

SQ Sequence 20 BP; 5 A; 2 C; 10 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1361 GCATTTCACATGCCCATC 1380
| | | | | | | | | | | | | |
DB 20 GCATTTCACACTGCCCATC 1

RESULT 1229
ADJ60318/c
ID ADJ60318 standard; DNA; 20 BP.
XX
XX
AC ADJ60318;
XX
DT DT
XX 06-MAY-2004 (first entry)
XX Oligonucleotide associated to ICAM #92.
DE DE
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
XX Homo sapiens.
OS
XX WO2004011613-A2.
PN
XX
PD PD
XX 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX 29-JUL-2002; 2002US-0399076P.
PR
XX (BPIG-) EPIGENESIS PHARM INC.
PA
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
PI
XX WPI; 2004-203534/19.
DR
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCRL, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 1174; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
XX initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
XX end of nucleic acid target comprising gene(s) chosen from e.g.
XX interleukin (IL)-4 receptor, IL-5 receptor or salts of the
XX oligonucleotide and optionally surfactant operatively linked to the
XX oligonucleotide. The method is useful for preventing or treating a
XX respiratory or lung disease, which involves administering to the airways
XX of a subject an effective amount of an inhibitor. The oligonucleotide is
XX useful for production of a medicament for the prevention and/or treatment
XX of a respiratory or lung disease. The respiratory or lung disease is
XX chosen from airway inflammation, allergy(ies), asthma, impeded
XX respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
XX (CPD), allergic rhinitis (AR), acute respiratory distress syndrome
XX (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
XX obstruction. The present sequence represents an oligonucleotide of the
XX invention.
XX

SQL	Sequence	20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;	
	Query Match	0.7%; Score 20; DB 1; Length 20;	
	Best Local Similarity	100.0%; Pred. No. 5.4e+02;	
	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	1171	TCTGCAACCTGGAGGTGGC 1190	
DB	20	TCTGCAACCTGGAGGTGGC 1	
	RESULT 1230		
	ADJ60322/c		
ID	ADJ60322	standard; DNA; 20 BP.	
XX	AC	ADJ60322;	
XX	DT	06-MAY-2004 (first entry)	
XX	DE	Oligonucleotide associated to ICAM #96.	
XX	KW	interleukin; IL-4 receptor; IL-5 receptor; lung disease;	
XX	KW	airway inflammation; allergy; asthma; impeded respiration;	
XX	KW	cystic fibrosis; acute respiratory distress syndrome;	
XX	KW	pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;	
XX	SS	ss.	
OS	Homo sapiens.		
XX	XX	WO2004011613-A2.	
XX	XX	05-FEB-2004.	
XX	XX	25-JUL-2003; 2003WO-US023509.	
PF	XX	29-JUL-2002; 2002US-0399076P.	
PR	XX	(EPIG-) EPIGENESIS PHARM INC.	
XX	PA	Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;	
PI	PI	Shahabuddin S, Lu H, Cong H;	
XX	XX	WPI; 2004-203534/19.	
DR	XX	Novel single or multiple target oligonucleotide anti-sense to e.g.	
XX	XX	initiation codons and introns of respiratory disease-relevant genes e.g.,	
PT	PT	CRL1, RANTES, MCP4, useful for prophylaxis or treating respiratory	
PT	PT	disease e.g., asthma.	
XX	XX	Claim 2; SEQ ID NO 1178; 85pp; English.	
PS	XX	The present invention relates to an oligonucleotide anti-sense to e.g.,	
CC	CC	initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-	
CC	CC	end of nucleic acid target comprising gene(s) chosen from e.g.	
CC	CC	interleukin (IL)-4 receptor, IL-5 receptor or salts of the	
CC	CC	oligonucleotide and optionally surfactant operatively linked to the	
CC	CC	oligonucleotide. The method is useful for preventing or treating a	
CC	CC	respiratory or lung disease, which involves administering to the airways	
CC	CC	of a subject an effective amount of an inhibitor. The oligonucleotide is	
CC	CC	useful for production of a medicament for the prevention and/or treatment	
CC	CC	of a respiratory or lung disease. The respiratory or lung disease is	
CC	CC	chosen from airway inflammation, allergy(ies), asthma, impeded	
CC	CC	respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases	
CC	CC	(COPD), allergic rhinitis (AR), acute respiratory distress syndrome	
CC	CC	(ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway	
CC	CC	obstruction. The present sequence represents an oligonucleotide of the	
CC	CC	invention.	
XX	XX	Sequence 20 BP; 0 A; 6 C; 7 G; 7 T; 0 U; 0 Other;	
	Query Match	0.7%; Score 20; DB 1; Length 20;	
	Best Local Similarity	100.0%; Pred. No. 5.4e+02;	
	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	

QY 1131 GAAGGCCACCCGAGGACA 1150
 ID ADJ60323/c
 DB 20 GAAGGCCACCCGAGGACA 1

RESULT 1231
 ADJ60323/c
 ID ADJ60323 standard; DNA; 20 BP.
 XX AC ADJ60323;
 XX AC ADJ60323;
 DT 06-MAY-2004 (first entry)
 DE Oligonucleotide associated to ICAM #97.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS Homo sapiens.
 XX WO2004011613-A2.
 PN 05-FEB-2004.
 XX 25-JUL-2003; 2003WO-US023509.
 PF 29-JUL-2002; 2002US-0399076P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1179; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1121 AGCTCTGCTGAGGCCACC 1140
 DB 20 AGCTCTGCTGAGGCCACC 1

RESULT 1232
 ADJ60335/c
 ID ADJ60335 standard; DNA; 20 BP.
 XX AC ADJ60335;
 XX AC ADJ60335;
 DT 06-MAY-2004 (first entry)
 DE Oligonucleotide associated to ICAM #109.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS Homo sapiens.
 XX WO2004011613-A2.
 PN 05-FEB-2004.
 XX 25-JUL-2003; 2003WO-US023509.
 PF 29-JUL-2002; 2002US-0399076P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1191; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1001 TGATTCGACGAGCCAGAG 1020
 DB 20 TGATTCGACGAGCCAGAG 1

RESULT 1233
 ADJ60350/c
 ID ADJ60350 standard; DNA; 20 BP.
 XX

AC ADJ60350;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to ICAM #124.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasegura A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 PT
 XX Claim 2; SEQ ID NO 1206; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering or treating a
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 851 ATGGCAACGACTCCTTCTCG 870
 Db 20 ATGGCAACGACTCCTTCTCG 1
 RESULT 1234
 ADJ60377/c
 ID ADJ60377 standard; DNA; 20 BP.
 XX
 AC ADJ60377;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX Oligonucleotide associated to ICAM #151.
 DE

XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasegura A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 PT
 XX Claim 2; SEQ ID NO 1233; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering or treating a
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 581 TGAGGAGAGATCACCATGGA 600
 Db 20 TGAGGAGAGATCACCATGGA 1
 RESULT 1235
 ADJ60409/c
 ID ADJ60409 standard; DNA; 20 BP.
 XX
 AC ADJ60409;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX Oligonucleotide associated to ICAM #183.
 DE
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW

KW ss.
 XX Homo sapiens.
 OS
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US0233509.
 XX
 PF 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1265; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 261 GTTGCTCCTCGTGGGAACA 280
 Db 20 GTTGCTCCTCGTGGGAACA 1
 RESULT 1236
 ADJ60415/C
 ID ADJ60415 standard; DNA; 20 BP.
 XX
 AC ADJ60415;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX
 DE Oligonucleotide associated to ICAM #189.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.

XX
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US0233509.
 XX
 PF 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1271; 85pp; English.
 XX
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 4 C; 9 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 201 CAGCACCTCTGTGACCAGC 220
 Db 20 CAGCACCTCTGTGACCAGC 1
 RESULT 1237
 ADJ60263/C
 ID ADJ60263 standard; DNA; 20 BP.
 XX
 AC ADJ60263;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX
 DE Oligonucleotide associated to ICAM #37.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US0233509.
 XX

```
PR 29-JUL-2002; 2002US-0399076P.
XX (EPIG-) EPIGENESIS PHARM INC.
PA
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1119; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 6 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1721 ACAGAGTGGAGACATATGC 1740
Db 20 ACAGAGTGGAGACATATGC 1

RESULT 1238
ADJ60270/c
ID ADJ60270 standard; DNA; 20 BP.
XX
AC ADJ60270;
XX
XX 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #44.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1126; 85pp; English.
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 4 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1651 CCCTGAACCTATCCCGGAC 1670
Db 20 CCCTGAACCTATCCCGGAC 1

RESULT 1239
ADJ60283/c
ID ADJ60283 standard; DNA; 20 BP.
XX
AC ADJ60283;
XX
XX 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #57.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
```

PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1139; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1521 AGCGCGAGTCATTAATGGCA 1540
 Db 20 AGCGCGAGTCATTAATGGCA 1
 RESULT 1240
 ADJ60327/c
 ID ADJ60327 standard; DNA; 20 BP.
 AC ADJ60327;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX
 DE Oligonucleotide associated to ICAM #101.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX 05-FEB-2004.
 PD
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1183; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1081 CTGAATGGGTTCCAGCCCA 1100
 Db 20 CTGAATGGGTTCCAGCCCA 1
 RESULT 1241
 ADJ60371/c
 ID ADJ60371 standard; DNA; 20 BP.
 XX
 AC ADJ60371;
 XX
 XX 06-MAY-2004 (first entry)
 DT
 XX
 DE Oligonucleotide associated to ICAM #145.
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX 05-FEB-2004.
 PD
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 XX Claim 2; SEQ ID NO 1227; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 9 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 641 AAGGGCTGGAGCTGTTGAG 660
 DB 20 AAGGGCTGGAGCTGTTGAG 1

RESULT 1242
 ADJ60376/c
 ID ADJ60376 standard; DNA; 20 BP.

XX AC ADJ60376;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #150.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW SS.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT Initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1232; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX

SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCAATTCT 610
 DB 20 TCACCATGGAGCAATTCT 1

RESULT 1243
 ADJ60390/c

ID ADJ60390 standard; DNA; 20 BP.

XX AC ADJ60390;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to ICAM #164.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

KW airway inflammation; allergy; asthma; impeded respiration;

KW cystic fibrosis; acute respiratory distress syndrome;

KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

KW SS.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT Initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX Claim 2; SEQ ID NO 1246; 85pp; English.

XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.

XX Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;

SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 451 ACCCTACGCTGCCAGGTGGA 470

Db 20 ACCCTACGCTGCCAGGTGGA 1

RESULT 1244

ADJ60393/c

ID ADJ60393 standard; DNA; 20 BP.

XX

AC ADJ60393;

DT 06-MAY-2004 (first entry)

XX Oligonucleotide associated to ICAM #167.

XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.

XX Homo sapiens.

OS

PN WO2004011613-A2.

XX

PD 05-FEB-2004.

XX

PF 25-JUL-2003; 2003WO-US023509.

XX

PR 29-JUL-2002; 2002US-0399076P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX

DR WPI; 2004-203534/19.

XX

PT Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX

PS Claim 2; SEQ ID NO 1249; 85pp; English.

XX

CC The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 421 CCCTCTTGGCAGCCAGTGGG 440

Db 20 CCCTCTTGGCAGCCAGTGGG 1

RESULT 1245

ADJ60403/c

ID ADJ60403 standard; DNA; 20 BP.

XX

AC ADJ60403;

XX

DT 06-MAY-2004 (first entry)

XX Oligonucleotide associated to ICAM #177.

XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;

KW airway inflammation; allergy; asthma; impeded respiration;

KW cystic fibrosis; acute respiratory distress syndrome;

KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

KW ss.

XX Homo sapiens.

OS

PN WO2004011613-A2.

XX

PD 05-FEB-2004.

XX

PF 25-JUL-2003; 2003WO-US023509.

XX

PR 29-JUL-2002; 2002US-0399076P.

XX

PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX

DR WPI; 2004-203534/19.

XX

PT Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codons and introns of respiratory disease-relevant genes e.g.,

PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.

XX

PS Claim 2; SEQ ID NO 1259; 85pp; English.

XX

CC The present invention relates to an oligonucleotide anti-sense to e.g.,

CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

CC end of nucleic acid target comprising gene(s) chosen from e.g.

CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

CC oligonucleotide and optionally surfactant operatively linked to the

CC oligonucleotide. The method is useful for preventing or treating a

CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 5 A; 2 C; 6 G; 7 T; 0 U; 0 Other;

SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 321 CCAACCAATGTGCTATTCAA 340

```

Db      20  CCAACCAATGCTATTCAA 1
|||||
RESULT 1246
ADJ60404/c
ID  ADJ60404 standard; DNA; 20 BP.
XX
AC  ADJ60404;
XX
XX  06-MAY-2004 (first entry)
XX
DE  Oligonucleotide associated to ICAM #178.
XX
KW  interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW  airway inflammation; allergy; asthma; impeded respiration;
KW  cystic fibrosis; acute respiratory distress syndrome;
KW  pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW  ss.
XX
OS  Homo sapiens.
XX
PN  WO2004011613-A2.
XX
PD  05-FEB-2004.
XX
PF  25-JUL-2003; 2003WO-US023509.
XX
PR  29-JUL-2002; 2002US-0399076P.
XX
PA  (EPIG-) EPIGENESIS PHARM INC.
XX
PI  Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI  Shahabuddin S, Lu H, Cong H;
XX  WPI; 2004-203534/19.
XX
PT  Novel single or multiple target oligonucleotide anti-sense to e.g.
PT  initiation codons and introns of respiratory disease-relevant genes e.g.,
PT  CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT  disease e.g., asthma.
XX
PS  Claim 2; SEQ ID NO 1260; 85pp; English.
XX
CC  The present invention relates to an oligonucleotide anti-sense to e.g.,
CC  initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC  end of nucleic acid target comprising gene(s) chosen from e.g.
CC  interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC  oligonucleotide and optionally surfactant operatively linked to the
CC  oligonucleotide. The method is useful for preventing or treating a
CC  respiratory or lung disease, which involves administering to the airways
CC  of a subject an effective amount of an inhibitor. The oligonucleotide is
CC  useful for production of a medicament for the prevention and/or treatment
CC  of a respiratory or lung disease. The respiratory or lung disease is
CC  chosen from airway inflammation, allergy(ies), asthma, impeded
CC  respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC  (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC  (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC  obstruction. The present sequence represents an oligonucleotide of the
CC  invention.
XX
SQ  Sequence 20 BP; 2 A; 4 C; 4 G; 10 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      311  AAGAAGATGCCCAACCAATG 330
      |||||
Db      20  AAGAAGATGCCCAACCAATG 1
|||||
RESULT 1247

```

```

ADJ60407/c
ID  ADJ60407 standard; DNA; 20 BP.
XX
AC  ADJ60407;
XX
XX  06-MAY-2004 (first entry)
XX
DE  Oligonucleotide associated to ICAM #181.
XX
KW  interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW  airway inflammation; allergy; asthma; impeded respiration;
KW  cystic fibrosis; acute respiratory distress syndrome;
KW  pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW  ss.
XX
OS  Homo sapiens.
XX
PN  WO2004011613-A2.
XX
PD  05-FEB-2004.
XX
PF  25-JUL-2003; 2003WO-US023509.
XX
PR  29-JUL-2002; 2002US-0399076P.
XX
PA  (EPIG-) EPIGENESIS PHARM INC.
XX
PI  Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI  Shahabuddin S, Lu H, Cong H;
XX  WPI; 2004-203534/19.
XX
PT  Novel single or multiple target oligonucleotide anti-sense to e.g.
PT  initiation codons and introns of respiratory disease-relevant genes e.g.,
PT  CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT  disease e.g., asthma.
XX
PS  Claim 2; SEQ ID NO 1263; 85pp; English.
XX
CC  The present invention relates to an oligonucleotide anti-sense to e.g.,
CC  initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC  end of nucleic acid target comprising gene(s) chosen from e.g.
CC  interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC  oligonucleotide and optionally surfactant operatively linked to the
CC  oligonucleotide. The method is useful for preventing or treating a
CC  respiratory or lung disease, which involves administering to the airways
CC  of a subject an effective amount of an inhibitor. The oligonucleotide is
CC  useful for production of a medicament for the prevention and/or treatment
CC  of a respiratory or lung disease. The respiratory or lung disease is
CC  chosen from airway inflammation, allergy(ies), asthma, impeded
CC  respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC  (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC  (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC  obstruction. The present sequence represents an oligonucleotide of the
CC  invention.
XX
SQ  Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      281  ACCGGAAGGTGTATGAACGTG 300
      |||||
Db      20  ACCGGAAGGTGTATGAACGTG 1
      |||||
RESULT 1248
ADJ60429/c
ID  ADJ60429 standard; DNA; 20 BP.
XX
AC  ADJ60429;
XX

```

DT 06-MAY-2004 (first entry)
 XX Oligonucleotide associated to ICAM #203.
 DE
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX 05-FEB-2004.
 PD
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 PT
 XX Claim 2; SEQ ID NO 1285; 85pp; English.
 PS
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 1 A; 5 C; 12 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 61 GCTCCAGCAGCCCCCGGCC 80
 Db 20 GCTCCAGCAGCCCCCGGCC 1
 RESULT 1249
 ADJ77768/c
 ID ADJ77768 standard; DNA; 20 BP.
 XX
 AC ADJ77768;
 XX
 DT 06-MAY-2004 (first entry)
 DE Modified antisense oligonucleotide #4.
 XX
 XX 2'-O-aminoethylthioethyl-modified ribosyl nucleoside;
 KW

KW antisense oligonucleotide; ss.
 XX Synthetic.
 OS
 XX US6673912-B1.
 PN
 XX 06-JAN-2004.
 PD
 XX 11-APR-2002; 2002US-00121135.
 PF
 XX 07-AUG-1998; 98US-00130566.
 PR
 XX 06-AUG-1999; 99US-00370625.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Manoharan M, Cook PD;
 PI
 XX WPI; 2004-106293/11.
 DR
 XX New 2'-O-aminoethylthioethyl-modified ribosyl nucleosides useful as
 PT monomer for the synthesis of modified anti-sense oligonucleotides.
 PT
 XX Disclosure; SEQ ID NO 4; 26pp; English.
 PS
 XX The invention relates to 2'-O-aminoethylthioethyl-modified ribosyl
 CC nucleosides. The modified ribosyl nucleosides are used as monomers for
 CC the synthesis of modified antisense oligonucleotides, which are useful in
 CC diagnosis and therapeutics (e.g. in gene therapy, for treating organisms
 CC having a disease associated by the undesired production of proteins) and
 CC as research reagents. The oligonucleotides obtained from the monomers
 CC show enhanced hybrid binding affinity towards targeted DNA or RNA and
 CC resistance towards nucleases. This sequence represents a modified
 CC antisense oligonucleotide of the invention.
 CC
 XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db 20 TGACGGATGCCAGCTTGGGC 1
 RESULT 1250
 ADJ77765/c
 ID ADJ77765 standard; DNA; 20 BP.
 XX
 AC ADJ77765;
 XX
 DT 06-MAY-2004 (first entry)
 DE Modified antisense oligonucleotide #1.
 XX
 XX 2'-O-aminoethylthioethyl-modified ribosyl nucleoside;
 KW antisense oligonucleotide; ss.
 KW Synthetic.
 OS
 XX US6673912-B1.
 PN
 XX 06-JAN-2004.
 PD
 XX 11-APR-2002; 2002US-00121135.
 PF
 XX 07-AUG-1998; 98US-00130566.
 PR
 XX 06-AUG-1999; 99US-00370625.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Manoharan M, Cook PD;
 PI
 XX

DR WPI; 2004-106293/11.
XX New 2'-O-aminoethylthioethyl-modified ribosyl nucleosides useful as
PT monomer for the synthesis of modified anti-sense oligonucleotides.
XX
XX PS Disclosure; SEQ ID NO 1; 26pp; English.
XX
XX CC The invention relates to 2'-O-aminoethylthioethyl-modified ribosyl
CC nucleosides. The modified ribosyl nucleosides are used as monomers for
CC the synthesis of modified antisense oligonucleotides, which are useful in
CC diagnosis and therapeutics (e.g. in gene therapy, for treating organisms
CC having a disease associated by the undesired production of proteins) and
CC as research reagents. The oligonucleotides obtained from the monomers
CC show enhanced hybrid binding affinity towards targeted DNA or RNA and
CC resistance towards nucleases. This sequence represents a modified
CC antisense oligonucleotide of the invention.
XX
XX SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
XX
XX RESULT 1251
ADJ77766/c
ID ADJ77766 standard; DNA; 20 BP.
XX
XX AC ADJ77766;
XX
XX DT 06-MAY-2004 (first entry)
XX
XX DE Modified antisense oligonucleotide #2.
XX
XX KW 2'-O-aminoethylthioethyl-modified ribosyl nucleoside;
KW antisense oligonucleotide; ss.
XX
XX OS Synthetic.
XX
XX PN US6673912-B1.
XX
XX PD 06-JAN-2004.
XX
XX PF 11-APR-2002; 2002US-00121135.
XX
XX PR 07-AUG-1998; 98US-00130566.
XX
XX PR 06-AUG-1999; 99US-00370625.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX PI Manoharan M, Cook PD;
XX
XX WPI; 2004-106293/11.
XX
XX New 2'-O-aminoethylthioethyl-modified ribosyl nucleosides useful as
PT monomer for the synthesis of modified anti-sense oligonucleotides.
XX
XX PS Disclosure; SEQ ID NO 2; 26pp; English.
XX
XX CC The invention relates to 2'-O-aminoethylthioethyl-modified ribosyl
CC nucleosides. The modified ribosyl nucleosides are used as monomers for
CC the synthesis of modified antisense oligonucleotides, which are useful in
CC diagnosis and therapeutics (e.g. in gene therapy, for treating organisms
CC having a disease associated by the undesired production of proteins) and
CC as research reagents. The oligonucleotides obtained from the monomers
CC show enhanced hybrid binding affinity towards targeted DNA or RNA and
CC resistance towards nucleases. This sequence represents a modified
CC antisense oligonucleotide of the invention.
XX

SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
XX
XX RESULT 1252
ADJ54197/c
ID ADJ54197 standard; DNA; 20 BP.
XX
XX AC ADJ54197;
XX
XX DT 06-MAY-2004 (first entry)
XX
XX DE Human B7-2 DNA control oligonucleotide #1.
XX
XX KW Airway hyperresponsiveness; pulmonary inflammation;
KW antisense oligonucleotide; human; B7 protein; B7-2; asthma;
KW antiasthmatic; antiinflammatory; ss.
XX
XX OS Homo sapiens.
XX
XX PN US2004023917-A1.
XX
XX PD 05-FEB-2004.
XX
XX PF 23-MAY-2003; 2003US-00444206.
XX
XX PR 31-DEC-1996; 96US-00777266.
PR 04-JUN-1999; 99US-00326186.
PR 25-MAY-2000; 2000WO-US014471.
PR 09-MAY-2001; 2001US-00851871.
XX
XX (BENN/) BENNETT C F.
PA (VICK/) VICKERS T A.
PA (KARR/) KARRAS J G.
XX
XX PI Bennett CF, Vickers TA, Karras JG;
XX
XX WPI; 2004-132608/13.
XX
XX Treating airway hyperresponsiveness or pulmonary inflammation comprises
PT administering an antisense compound targeted to a nucleic acid molecule
PT encoding a human B7 protein to the individual.
XX
XX Example 7; SEQ ID NO 17; 182pp; English.
XX
XX The invention relates to a method for treating airway hyperresponsiveness
CC or pulmonary inflammation in an individual comprising administering an
CC antisense compound targeted to a nucleic acid molecule encoding a human
CC B7 protein. The invention also relates to a method of inhibiting
CC expression of a nucleic acid molecule encoding B7-1 or B7-2. The
CC antisense compound is an antisense oligonucleotide which has a modified
CC sugar moiety and nucleobase. The human B7 protein is human B7-1 or B7-2
CC protein or both. The compound is useful for treating airway
CC hyperresponsiveness or pulmonary inflammation, which is associated with
CC asthma, by inhibiting expression of human B7 protein. This sequence
CC represents a control oligonucleotide used in the scope of the invention.
XX
XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 1253
ADK69872/c
ID ADK69872 standard; DNA; 20 BP.
XX
AC ADK69872;
XX
DT 06-MAY-2004 (first entry)
XX
DE Sulphurised oligonucleotide #2.
XX
KW Phosphorothioate backbone; sulphurised oligonucleotide; ss.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
XX
PN US2003212267-A1.
XX
PD 13-NOV-2003.
XX
PF 12-DEC-2002; 2002US-00181200.
XX
PR 11-JAN-2000; 2000US-00481486.
PR 10-JAN-2001; 2001WO-US000715.
XX
PA (COLE/) COLE D L.
PA (RAVI/) RAVIKUMAR V T.
PA (CHER/) CHERUVALLATH Z S.
XX
PI Cole DL, Ravikumar VT, Cheruvallath ZS;
XX
DR WPI; 2004-069376/07.
XX
PT Preparation of phosphorothioate oligonucleotides involves oxidizing
PT phosphite intermediate with acetyl disulfide in acetonitrile for time to
PT effect conversion of phosphite intermediate to phosphorothioate.
XX
PS Example 4; SEQ ID NO 2; 8pp; English.
XX
CC The invention relates to phosphorothioate oligonucleotides having
CC nucleoside with 240 modification are prepared by phosphorylating 5'-
CC hydroxyl of a nucleic acid moiety having a nucleoside with 2',
CC modification in an acetonitrile containing solvent mixture to form a
CC phosphite intermediate; and oxidising the phosphite intermediate with an
CC acetyl disulfide in an acetonitrile for a time to effect conversion of
CC the phosphite intermediate to phosphorothioate. The invented method
CC achieves high yields and greater efficiency. The present sequence is
CC sulphurised oligonucleotide used in the exemplification of the invention.
XX
SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 1254
ADK69878/c
ID ADK69878 standard; DNA; 20 BP.
XX
AC ADK69878;
XX
DT 06-MAY-2004 (first entry)

XX
DE Sulphurised oligonucleotide #8 (RNA-DNA hybrid).
XX
KW Phosphorothioate backbone; sulphurised oligonucleotide; RNA-DNA hybrid;
KW ss.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
XX
FT misc_RNA 13..20
FT /*tag= b
FT /label= RNA
FT /note= "2'-methoxyethyl residues"
XX
PN US2003212267-A1.
XX
PD 13-NOV-2003.
XX
PF 12-DEC-2002; 2002US-00181200.
XX
PR 11-JAN-2000; 2000US-00481486.
PR 10-JAN-2001; 2001WO-US000715.
XX
PA (COLE/) COLE D L.
PA (RAVI/) RAVIKUMAR V T.
PA (CHER/) CHERUVALLATH Z S.
XX
PI Cole DL, Ravikumar VT, Cheruvallath ZS;
XX
DR WPI; 2004-069376/07.
XX
PT Preparation of phosphorothioate oligonucleotides involves oxidizing
PT phosphite intermediate with acetyl disulfide in acetonitrile for time to
PT effect conversion of phosphite intermediate to phosphorothioate.
XX
PS Example 10; SEQ ID NO 8; 8pp; English.
XX
CC The invention relates to phosphorothioate oligonucleotides having
CC nucleoside with 240 modification are prepared by phosphorylating 5'-
CC hydroxyl of a nucleic acid moiety having a nucleoside with 2',
CC modification in an acetonitrile containing solvent mixture to form a
CC phosphite intermediate; and oxidising the phosphite intermediate with an
CC acetyl disulfide in an acetonitrile for a time to effect conversion of
CC the phosphite intermediate to phosphorothioate. The invented method
CC achieves high yields and greater efficiency. The present sequence is
CC sulphurised oligonucleotide used in the exemplification of the invention.
XX
SQ Sequence 20 BP; 4 A; 8 C; 5 G; 1 T; 2 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 1255
ADK69879/c
ID ADK69879 standard; DNA; 20 BP.
XX
AC ADK69879;
XX
DT 06-MAY-2004 (first entry)
XX
DE Sulphurised oligonucleotide #9 (RNA-DNA hybrid).
XX
KW Phosphorothioate backbone; sulphurised oligonucleotide; RNA-DNA hybrid;

```

KW ss.
XX Unidentified.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT
FT misc_RNA
FT 13..20
FT /tag= b
FT /label= RNA
FT /note= "2'-methoxyethyl residues"
XX
XX US2003212267-A1.
XX
XX 13-NOV-2003.
XX
XX 12-DEC-2002; 2002US-00181200.
XX
XX 11-JAN-2000; 2000US-00481486.
XX 10-JAN-2001; 2001WO-US000715.
XX
XX (COLE/) COLE D L.
XX (RAVI/) RAVIKUMAR V T.
XX (CHER/) CHERUVALLATH Z S.
XX
XX Cole DL, Ravikumar VT, Cheruvallath ZS;
XX WPI; 2004-069376/07.
XX
XX Preparation of phosphorothioate oligonucleotides involves oxidizing
XX phosphite intermediate with acetyl disulfide in acetonitrile for time to
XX effect conversion of phosphite intermediate to phosphorothioate.
XX
XX Example 11; SEQ ID NO 9; 8pp; English.
XX
XX The invention relates to phosphorothioate oligonucleotides having
XX nucleoside with 240 modification are prepared by phosphorylating 5'-
XX hydroxyl of a nucleic acid moiety having a nucleoside with 2'
XX modification in an acetonitrile containing solvent mixture to form a
XX phosphite intermediate; and oxidising the phosphite intermediate with an
XX acetyl disulfide in an acetonitrile for a time to effect conversion of
XX the phosphite intermediate to phosphorothioate. The invented method
XX achieves high yields and greater efficiency. The present sequence is
XX sulphurised oligonucleotide used in the exemplification of the invention.
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 1 T; 2 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2100 TGACGGATGCCAGCTTGGGC 2119
XX
XX Db
XX
XX RESULT 1256
XX ADX69884/c
XX ID ADX69884 standard; DNA; 20 BP.
XX
XX AC ADX69884;
XX
XX 06-MAY-2004 (first entry)
XX
XX Sulphurised oligonucleotide #14.
XX
XX Phosphorothioate backbone; sulphurised oligonucleotide; ss.
XX
XX Unidentified.
XX
XX Key Location/Qualifiers

```

```

FT modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT
FT modified_base 13..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyl residues"
XX
XX US2003212267-A1.
XX
XX 13-NOV-2003.
XX
XX 12-DEC-2002; 2002US-00181200.
XX
XX 11-JAN-2000; 2000US-00481486.
XX 10-JAN-2001; 2001WO-US000715.
XX
XX (COLE/) COLE D L.
XX (RAVI/) RAVIKUMAR V T.
XX (CHER/) CHERUVALLATH Z S.
XX
XX Cole DL, Ravikumar VT, Cheruvallath ZS;
XX WPI; 2004-069376/07.
XX
XX Preparation of phosphorothioate oligonucleotides involves oxidizing
XX phosphite intermediate with acetyl disulfide in acetonitrile for time to
XX effect conversion of phosphite intermediate to phosphorothioate.
XX
XX Example 21; SEQ ID NO 14; 8pp; English.
XX
XX The invention relates to phosphorothioate oligonucleotides having
XX nucleoside with 240 modification are prepared by phosphorylating 5'-
XX hydroxyl of a nucleic acid moiety having a nucleoside with 2'
XX modification in an acetonitrile containing solvent mixture to form a
XX phosphite intermediate; and oxidising the phosphite intermediate with an
XX acetyl disulfide in an acetonitrile for a time to effect conversion of
XX the phosphite intermediate to phosphorothioate. The invented method
XX achieves high yields and greater efficiency. The present sequence is
XX sulphurised oligonucleotide used in the exemplification of the invention.
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2100 TGACGGATGCCAGCTTGGGC 2119
XX
XX Db
XX
XX RESULT 1257
XX ADJ65128/c
XX ID ADJ65128 standard; DNA; 20 BP.
XX
XX AC ADJ65128;
XX
XX 20-MAY-2004 (first entry)
XX
XX Antisense oligonucleotide #5.
XX
XX Complement activation; 2' sugar modification;
XX complement activation inhibition; phosphorothioate modification;
XX 2'-methoxyethoxy modification; antisense oligonucleotide; Factor H;
XX inflammation; immune response; compound stability; antiinflammatory; ss.
XX
XX Synthetic.
XX
XX US2004038925-A1.
XX
XX 26-FEB-2004.

```

```

XX PF 07-AUG-2003; 2003US-00636452.
XX PR
XX PR 30-SEP-1999; 99US-00409816.
XX PR 27-FEB-2001; 2001US-00794824.
XX PR
XX PR (HENR/) HENRY S.
XX PA
XX PI Henry S;
XX PI WPI; 2004-213947/20.
XX DR
XX DR
XX PT Inhibition of complement activation in human cell, tissue or bodily
XX PT fluid, comprises contacting the cell, tissue or bodily fluid with
XX PT oligonucleotide comprising 2' sugar modification(s), preferably 2'-
XX PT methoxyethoxy modification.
XX PT
XX PS Example 10; SEQ ID NO 5; 35pp; English.
XX CC The invention relates to a method of inhibiting complement activation in
XX CC a human cell, tissue or bodily fluid, comprising contacting the cell,
XX CC tissue or bodily fluid with an oligonucleotide comprising at least one 2'
XX CC sugar modification. The invention also relates to a composition
XX CC comprising an oligonucleotide and a complement activation inhibitory
XX CC molecule, where the oligonucleotide comprises at least one
XX CC phosphorothioate modification and at least one 2'-methoxyethoxy
XX CC phosphorothioate modification and at least one 2'-methoxyethoxy
XX CC modification. The oligonucleotide has at least one modified
XX CC internucleotide linkage, which is a phosphorothioate. The oligonucleotide
XX CC is an antisense oligonucleotide. The complement activation inhibitory
XX CC molecule is Factor H. The 2' sugar modification is 2'-methoxyethoxy
XX CC modification. The method is useful for inhibiting complement activation
XX CC (such as inflammation) in a human cell, tissue or bodily fluid, in the
XX CC result of complement activation. The method inhibits and/or modulates
XX CC treatment of abnormal and/or undesirable conditions which can arise as a
XX CC result of complement activation. The method inhibits and/or modulates
XX CC complement mediated immune responses using modified oligonucleotides that
XX CC might incorporate modifications of characteristics such as compound
XX CC stability and cellular uptake. This sequence represents an antisense
XX CC oligonucleotide of the invention.
XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db |||||
20 TGACGGATGCCAGCTTGGGC 1

RESULT 1258
ADJ65130/c
ID ADJ65130 standard; DNA; 20 BP.
AC ADJ65130;
XX
XX 20-MAY-2004 (first entry)
XX DE
XX DE Antisense oligonucleotide #7.
XX KW Complement activation; 2' sugar modification;
XX KW complement activation inhibition; phosphorothioate modification;
XX KW 2'-methoxyethoxy modification; antisense oligonucleotide; Factor H;
XX KW inflammation; immune response; compound stability; antiinflammatory; ss.
XX OS Synthetic.
XX OS
XX PN US2004038925-A1.
XX PN
XX PD 26-FEB-2004.
XX PD
XX PF 07-AUG-2003; 2003US-00636452.
XX PR

```

```

PR 30-SEP-1999; 99US-00409816.
PR 27-FEB-2001; 2001US-00794824.
PR (HENR/) HENRY S.
PR Henry S;
PR WPI; 2004-213947/20.
PR
PR Inhibition of complement activation in human cell, tissue or bodily
PR fluid, comprises contacting the cell, tissue or bodily fluid with
PR oligonucleotide comprising 2' sugar modification(s), preferably 2'-
PR methoxyethoxy modification.
PR
PR PS Example 10; SEQ ID NO 7; 35pp; English.
PR CC The invention relates to a method of inhibiting complement activation in
PR CC a human cell, tissue or bodily fluid, comprising contacting the cell,
PR CC tissue or bodily fluid with an oligonucleotide comprising at least one 2'
PR CC sugar modification. The invention also relates to a composition
PR CC comprising an oligonucleotide and a complement activation inhibitory
PR CC molecule, where the oligonucleotide comprises at least one
PR CC phosphorothioate modification and at least one 2'-methoxyethoxy
PR CC phosphorothioate modification and at least one 2'-methoxyethoxy
PR CC modification. The oligonucleotide has at least one modified
PR CC internucleotide linkage, which is a phosphorothioate. The oligonucleotide
PR CC is an antisense oligonucleotide. The complement activation inhibitory
PR CC molecule is Factor H. The 2' sugar modification is 2'-methoxyethoxy
PR CC modification. The method is useful for inhibiting complement activation
PR CC (such as inflammation) in a human cell, tissue or bodily fluid, in the
PR CC result of complement activation. The method inhibits and/or modulates
PR CC complement mediated immune responses using modified oligonucleotides that
PR CC might incorporate modifications of characteristics such as compound
PR CC stability and cellular uptake. This sequence represents an antisense
PR CC oligonucleotide of the invention.
PR SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db |||||
20 TGACGGATGCCAGCTTGGGC 1

RESULT 1259
ADJ46467/c
ID ADJ46467 standard; DNA; 20 BP.
AC ADJ46467;
XX
XX 03-JUN-2004 (first entry)
XX DE
XX DE Antisense oligonucleotide targeting human ICAM-1 #16.
XX KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
XX KW vascular cell adhesion molecule; VCAM-1;
XX KW endothelial leukocyte adhesion molecule; ELAM-1;
XX KW inflammatory ophthalmological disorder; redness; inflammation;
XX KW corneal explant; corneal allograft rejection.
XX OS Homo sapiens.
XX OS
XX PN US2004033977-A1.
XX PN
XX PD 19-FEB-2004.
XX PD
XX PF 04-JUN-2003; 2003US-00454663.
XX PF
XX PR 14-AUG-1990; 90US-00567286.
XX PR 02-SEP-1992; 92US-00939855.
XX PR

```


PR 21-JAN-1993; 93US-00007997.
 PR 10-FEB-1993; 93US-00969151.
 PR 17-MAY-1993; 93US-00063167.
 PR 12-MAY-1995; 95US-00404740.
 PR 03-AUG-1998; 98US-00128496.
 PR 12-SEP-2000; 2000US-00659288.
 PR 18-OCT-2001; 2001US-00982262.
 XX
 PA (BENN/) BENNETT C F.
 PA (MIRA/) MIRABELLI C.
 XX
 PI Bennett CF, Mirabelli C;
 XX
 DR WPI; 2004-180090/17.
 XX
 PT New antisense oligonucleotide, useful for diagnosing, as research
 PT reagents and for treating disease states, which respond to modulation of
 PT the synthesis or metabolism of cell adhesion molecules.
 XX
 PS Example 5; SEQ ID NO 16; 72pp; English.
 XX
 CC The invention relates to an antisense oligonucleotide targeting human
 CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as
 CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
 CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridises with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.
 XX
 SQ Sequence 20 BP; 7 A; 2 C; 3 G; 8 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2962 AGTTAATAAAGCTTCTCAA 2981
 |||||
 DB 20 AGTTAATAAAGCTTCTCAA 1
 RESULT 1260
 ADM46465/C
 ID ADM46465 standard; DNA; 20 BP.
 XX
 AC ADM46465;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE Antisense oligonucleotide targeting human ICAM-1 #14.
 XX
 KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
 KW vascular cell adhesion molecule; VCAM-1;
 KW endothelial leukocyte adhesion molecule; ELAM-1;

KW inflammatory ophthalmological disorder; redness; inflammation;
 KW corneal explant; corneal allograft rejection.
 XX
 OS Homo sapiens.
 XX
 PN US2004033977-A1.
 XX
 PD 19-FEB-2004.
 XX
 XX 04-JUN-2003; 2003US-00454663.
 XX
 PR 14-AUG-1990; 90US-00567286.
 PR 02-SEP-1992; 92US-00939855.
 PR 21-JAN-1993; 93US-00007997.
 PR 10-FEB-1993; 93US-00969151.
 PR 17-MAY-1995; 95US-00404740.
 PR 12-MAY-1998; 98US-00128496.
 PR 03-AUG-1998; 98US-00128496.
 PR 12-SEP-2000; 2000US-00659288.
 PR 18-OCT-2001; 2001US-00982262.
 XX
 PA (BENN/) BENNETT C F.
 PA (MIRA/) MIRABELLI C.
 XX
 PI Bennett CF, Mirabelli C;
 XX
 DR WPI; 2004-180090/17.
 XX
 PT New antisense oligonucleotide, useful for diagnosing, as research
 PT reagents and for treating disease states, which respond to modulation of
 PT the synthesis or metabolism of cell adhesion molecules.
 XX
 PS Example 5; SEQ ID NO 14; 72pp; English.
 XX
 CC The invention relates to an antisense oligonucleotide targeting human
 CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as
 CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
 CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridises with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1654 TGAACCTATCCGGGACAGG 1673
 |||||
 DB 20 TGAACCTATCCGGGACAGG 1

CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.

XX Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGGAGGTCAACCGCGAG 1464

Db 20 AAGGGGAGGTCAACCGCGAG 1

RESULT 1263

ADM46453/c
 ID ADM46453 standard; DNA; 20 BP.

AC ADM46453;

XX 03-JUN-2004 (first entry)

DE Antisense oligonucleotide targeting human ICAM-1 #2.

XX Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
 KW vascular cell adhesion molecule; VCAM-1;
 KW endothelial leukocyte adhesion molecule; ELAM-1;
 KW inflammatory ophthalmological disorder; redness; inflammation;
 KW corneal explant; corneal allograft rejection.

XX Homo sapiens.

XX US2004033977-A1.

XX 19-FEB-2004.

XX 04-JUN-2003; 2003US-00454663.

XX 14-AUG-1990; 90US-00567286.

PR 02-SEP-1992; 92US-00939855.

PR 21-JAN-1993; 93US-00007997.

PR 10-FEB-1993; 93US-00969151.

PR 17-MAY-1993; 93US-00063167.

PR 12-MAY-1995; 95US-00440740.

PR 03-AUG-1998; 98US-00128496.

PR 12-SEP-2000; 2000US-00659288.

PR 18-OCT-2001; 2001US-00982262.

XX (BEN)/ BENNETT C F.

XX (MIRA)/ MIRABELLI C.

XX Bennett CF, Mirabelli C;

XX WI; 2004-180090/17.

XX New antisense oligonucleotide, useful for diagnosing, as research
 PT reagents and for treating disease states, which respond to modulation of
 PT the synthesis or metabolism of cell adhesion molecules.

XX Example 5; SEQ ID NO 2; 72pp; English.

CC The invention relates to an antisense oligonucleotide targeting human
 CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as
 CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
 CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridises with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.

XX Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGTCCCTC 26

Db 20 CAGTCGACGCTGAGTCCCTC 1

RESULT 1264

ADM46459/c

ID ADM46459 standard; DNA; 20 BP.

XX ADM46459;

XX 03-JUN-2004 (first entry)

XX Antisense oligonucleotide targeting human ICAM-1 #8.

XX Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
 KW vascular cell adhesion molecule; VCAM-1;
 KW endothelial leukocyte adhesion molecule; ELAM-1;
 KW inflammatory ophthalmological disorder; redness; inflammation;
 KW corneal explant; corneal allograft rejection.

XX Homo sapiens.

XX US2004033977-A1.

XX 19-FEB-2004.

XX 04-JUN-2003; 2003US-00454663.

XX 14-AUG-1990; 90US-00567286.

PR 02-SEP-1992; 92US-00939855.

PR 21-JAN-1993; 93US-00007997.

PR 10-FEB-1993; 93US-00969151.

PR 17-MAY-1993; 93US-00063167.

PR 12-MAY-1995; 95US-00440740.

PR 03-AUG-1998; 98US-00128496.

PR 12-SEP-2000; 2000US-00659288.

PR 18-OCT-2001; 2001US-00982262.

PA (BENN/) BENNETT C F.
 PA (MIRA/) MIRABELLI C.
 XX
 PI Bennett CF, Mirabelli C;
 XX
 DR WPI; 2004-180090/17.
 XX
 PT New antisense oligonucleotide, useful for diagnosing, as research
 PT reagents and for treating disease states, which respond to modulation of
 PT the synthesis or metabolism of cell adhesion molecules.
 XX
 XX Example 5; SEQ ID NO 8; 72pp; English.
 XX
 CC The invention relates to an antisense oligonucleotide targeting human
 CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as
 CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
 CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridises with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.
 XX
 XX Sequence 20 BP; 2 A; 5 C; 10 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 58 ATGGCTCCACGAGCCCCCG 77
 DB 20 ATGGCTCCACGAGCCCCCG 1
 RESULT 1265
 ADM46466/c
 ID ADM46466 standard; DNA; 20 BP.
 XX
 AC ADM46466;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 XX Antisense oligonucleotide targeting human ICAM-1 #15.
 XX
 KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
 KW vascular cell adhesion molecule; VCAM-1;
 KW endothelial leukocyte adhesion molecule; ELAM-1;
 KW inflammatory ophthalmological disorder; redness; inflammation;
 KW corneal explant; corneal allograft rejection.
 XX
 OS Homo sapiens.
 XX
 XX US2004033977-A1.
 PN
 XX 19-FEB-2004.

XX
 XX 04-JUN-2003; 2003US-00454663.
 XX
 PR 14-AUG-1990; 90US-00567286.
 PR 02-SEP-1992; 92US-00939855.
 PR 21-JAN-1993; 93US-00007997.
 PR 10-FEB-1993; 93US-00969151.
 PR 17-MAY-1993; 93US-00063167.
 PR 12-MAY-1995; 95US-00440740.
 PR 03-AUG-1998; 98US-00128496.
 PR 12-SEP-2000; 2000US-00659288.
 PR 18-OCT-2001; 2001US-00982262.
 XX
 XX (BENN/) BENNETT C F.
 XX (MIRA/) MIRABELLI C.
 XX
 PI Bennett CF, Mirabelli C;
 XX
 DR WPI; 2004-180090/17.
 XX
 PT New antisense oligonucleotide, useful for diagnosing, as research
 PT reagents and for treating disease states, which respond to modulation of
 PT the synthesis or metabolism of cell adhesion molecules.
 XX
 XX Example 5; SEQ ID NO 15; 72pp; English.
 XX
 CC The invention relates to an antisense oligonucleotide targeting human
 CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as
 CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
 CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridises with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.
 XX
 XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 1938 GAGAGGGGAAGTGGTGGGG 1957
 DB 20 GAGAGGGGAAGTGGTGGGG 1
 RESULT 1266
 ADM46462/c
 ID ADM46462 standard; DNA; 20 BP.
 XX
 AC ADM46462;
 XX
 XX 03-JUN-2004 (first entry)
 DT
 XX

DE	Antisense oligonucleotide targeting human ICAM-1 #11.		
XX	Antisense; ss; human; intercellular adhesion molecule; ICAM-1;		
KW	vascular cell adhesion molecule; VCAM-1;		
KW	endothelial leukocyte adhesion molecule; ELAM-1;		
KW	inflammatory ophthalmological disorder; redness; inflammation;		
KW	corneal explant; corneal allograft rejection.		
XX	Homo sapiens.		
XX	US2004033977-A1.		
XX	19-FEB-2004.		
XX	04-JUN-2003; 2003US-00454663.		
XX	14-AUG-1990; 90US-00567286.		
PR	02-SEP-1992; 92US-00939855.		
PR	21-JAN-1993; 93US-00007997.		
PR	10-FEB-1993; 93US-00969151.		
PR	17-MAY-1993; 93US-00063167.		
PR	12-MAY-1995; 95US-00440740.		
PR	03-AUG-1998; 98US-00128496.		
PR	12-SEP-2000; 2000US-00659288.		
PR	18-OCT-2001; 2001US-00982262.		
XX	(BENN/) BENNETT C F.		
PA	(MIRA/) MIRABELLI C.		
XX	Bennett CF, Mirabelli C;		
XX	WPI; 2004-180090/17.		
XX	New antisense oligonucleotide, useful for diagnosing, as research		
PT	reagents and for treating disease states, which respond to modulation of		
PT	the synthesis or metabolism of cell adhesion molecules.		
PS	Example 5; SEQ ID NO 11; 72pp; English.		
XX	The invention relates to an antisense oligonucleotide targeting human		
CC	intercellular adhesion molecule (ICAM-1) having a sequence appearing as		
CC	ADM46473. In the oligonucleotide, at least one adenosine nucleotide is		
CC	replaced with a thymidine, cytidine or guanosine nucleotide, at least one		
CC	thymidine nucleotide is replaced with an adenosine, cytidine or guanosine		
CC	nucleotide, at least one guanosine nucleotide is replaced with an		
CC	adenosine, thymidine or cytidine nucleotide or at least one cytidine		
CC	nucleotide. The oligonucleotide is one of 88 disclosed antisense		
CC	oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-		
CC	1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are		
CC	an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA		
CC	(where the compound specifically hybridises with the human ICAM-1 mRNA		
CC	and inhibits the expression of human ICAM-1 mRNA), and a double stranded		
CC	RNA compound having the RNA equivalent sequence of ADM46473. The		
CC	oligonucleotide is useful for modulating the activity of the RNA and DNA		
CC	and the modulation of the synthesis and metabolism of specific cell		
CC	adhesion molecules. It is also useful for the diagnosis, as research		
CC	reagents and for treating disease states, which respond to modulation of		
CC	the synthesis or metabolism of cell adhesion molecules. The		
CC	oligonucleotide is suitable for treating inflammatory ophthalmological		
CC	disorders including redness and inflammation caused by allergens and		
CC	allergic reactions. The oligonucleotides can also be used to preserve		
CC	corneal explants ex vivo and to prevent corneal allograft rejections. The		
CC	specific hybridisation exhibited by the oligonucleotides may be used for		
CC	assays, purifications or cellular product preparations. The present		
CC	sequence is an antisense oligonucleotide targeting ICAM-1.		
XX	Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;		
SQ			
Query Match	0.7%; Score 20; DB 1; Length 20;		
Best Local Similarity	100.0%; Pred. No. 5.4e+02;		
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
QY	875 AGGCCTCAGTCAGTGTGACC 894		
Db	20 AGGCCTCAGTCAGTGTGACC 1		
RESULT 1267			
ADM46473/c			
ID	ADM46473 standard; DNA; 20 BP.		
AC	XX		
AD	ADM46473;		
XX	XX		
DT	03-JUN-2004 (first entry)		
XX	XX		
DE	Antisense oligonucleotide targeting human ICAM-1 #22.		
XX	Antisense; ss; human; intercellular adhesion molecule; ICAM-1;		
KW	vascular cell adhesion molecule; VCAM-1;		
KW	endothelial leukocyte adhesion molecule; ELAM-1;		
KW	inflammatory ophthalmological disorder; redness; inflammation;		
KW	corneal explant; corneal allograft rejection.		
XX	Homo sapiens.		
XX	US2004033977-A1.		
XX	19-FEB-2004.		
XX	04-JUN-2003; 2003US-00454663.		
XX	14-AUG-1990; 90US-00567286.		
PR	02-SEP-1992; 92US-00939855.		
PR	21-JAN-1993; 93US-00007997.		
PR	10-FEB-1993; 93US-00969151.		
PR	17-MAY-1993; 93US-00063167.		
PR	12-MAY-1995; 95US-00440740.		
PR	03-AUG-1998; 98US-00128496.		
PR	12-SEP-2000; 2000US-00659288.		
PR	18-OCT-2001; 2001US-00982262.		
XX	(BENN/) BENNETT C F.		
PA	(MIRA/) MIRABELLI C.		
XX	Bennett CF, Mirabelli C;		
XX	WPI; 2004-180090/17.		
XX	New antisense oligonucleotide, useful for diagnosing, as research		
PT	reagents and for treating disease states, which respond to modulation of		
PT	the synthesis or metabolism of cell adhesion molecules.		
PS	Claim 1; SEQ ID NO 22; 72pp; English.		
XX	The invention relates to an antisense oligonucleotide targeting human		
CC	intercellular adhesion molecule (ICAM-1) having a sequence appearing as		
CC	ADM46473. In the oligonucleotide, at least one adenosine nucleotide is		
CC	replaced with a thymidine, cytidine or guanosine nucleotide, at least one		
CC	thymidine nucleotide is replaced with an adenosine, cytidine or guanosine		
CC	nucleotide, at least one guanosine nucleotide is replaced with an		
CC	adenosine, thymidine or cytidine nucleotide or at least one cytidine		
CC	nucleotide. The oligonucleotide is one of 88 disclosed antisense		
CC	oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-		
CC	1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are		
CC	an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA		
CC	(where the compound specifically hybridises with the human ICAM-1 mRNA		
CC	and inhibits the expression of human ICAM-1 mRNA), and a double stranded		
CC	RNA compound having the RNA equivalent sequence of ADM46473. The		
CC	oligonucleotide is useful for modulating the activity of the RNA and DNA		
CC	and the modulation of the synthesis and metabolism of specific cell		
CC	adhesion molecules. It is also useful for the diagnosis, as research		
CC	reagents and for treating disease states, which respond to modulation of		
CC	the synthesis or metabolism of cell adhesion molecules. The		
CC	oligonucleotide is suitable for treating inflammatory ophthalmological		
CC	disorders including redness and inflammation caused by allergens and		
CC	allergic reactions. The oligonucleotides can also be used to preserve		
CC	corneal explants ex vivo and to prevent corneal allograft rejections. The		
CC	specific hybridisation exhibited by the oligonucleotides may be used for		
CC	assays, purifications or cellular product preparations. The present		
CC	sequence is an antisense oligonucleotide targeting ICAM-1.		

CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisations exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
 |||||
 Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 1268
 ADM46474/c
 ID ADM46474 standard; DNA; 20 BP.
 XX
 AC ADM46474;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE Antisense oligonucleotide targeting human ICAM-1 #23.
 XX
 KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
 KW vascular cell adhesion molecule; VCAM-1;
 KW endothelial leukocyte adhesion molecule; ELAM-1;
 KW inflammatory ophthalmological disorder; redness; inflammation;
 KW corneal explant; corneal allograft rejection.

XX Homo sapiens.

XX US2004033977-A1.

XX 19-FEB-2004.

XX 04-JUN-2003; 2003US-00454663.

XX 14-AUG-1990; 90US-00567286.

XX 02-SEP-1992; 92US-00939855.

XX 21-JAN-1993; 93US-00007997.

XX 10-FEB-1993; 93US-00969151.

XX 17-MAY-1993; 93US-00063167.

XX 12-MAY-1995; 95US-00440740.

XX 03-AUG-1998; 98US-00128496.

XX 12-SEP-2000; 2000US-00659288.

XX 18-OCT-2001; 2001US-00982262.

XX (BENNETT C F.

XX (MIRA/) MIRABELLI C.

XX Bennett CF, Mirabelli C;

XX WPI; 2004-180090/17.

XX New antisense oligonucleotide, useful for diagnosing, as research

XX reagents and for treating disease states, which respond to modulation of

XX the synthesis or metabolism of cell adhesion molecules.

XX Example 5; SEQ ID NO 23; 72pp; English.

XX The invention relates to an antisense oligonucleotide targeting human

XX intercellular adhesion molecule (ICAM-1) having a sequence appearing as

XX ADM46473. In the oligonucleotide, at least one adenosine nucleotide is

XX replaced with a thymidine, cytidine or guanosine nucleotide, at least one

CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridises with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisations exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.

XX Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044

Db 20 GAGGCCACAGACTTACAGA 1

RESULT 1269

ADM46477/c

ID ADM46477 standard; DNA; 20 BP.

XX ADM46477;

XX 03-JUN-2004 (first entry)

XX Antisense oligonucleotide targeting human ICAM-1 #26.

XX Antisense; ss; human; intercellular adhesion molecule; ICAM-1;

XX vascular cell adhesion molecule; VCAM-1;

XX endothelial leukocyte adhesion molecule; ELAM-1;

XX inflammatory ophthalmological disorder; redness; inflammation;

XX corneal explant; corneal allograft rejection.

XX Homo sapiens.

XX US2004033977-A1.

XX 19-FEB-2004.

XX 04-JUN-2003; 2003US-00454663.

XX 14-AUG-1990; 90US-00567286.

XX 02-SEP-1992; 92US-00939855.

XX 21-JAN-1993; 93US-00007997.

XX 10-FEB-1993; 93US-00969151.

XX 17-MAY-1993; 93US-00063167.

XX 12-MAY-1995; 95US-00440740.

XX 03-AUG-1998; 98US-00128496.

XX 12-SEP-2000; 2000US-00659288.

XX 18-OCT-2001; 2001US-00982262.

XX (BENNETT C F.

XX (MIRA/) MIRABELLI C.

XX Bennett CF, Mirabelli C;

XX WPI; 2004-180090/17.

XX New antisense oligonucleotide, useful for diagnosing, as research

PT reagents and for treating disease states, which respond to modulation of
 PT the synthesis or metabolism of cell adhesion molecules.

XX Example 5; SEQ ID NO 26; 72bp; English.

XX The invention relates to an antisense oligonucleotide targeting human
 CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as
 CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
 CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridizes with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.

XX Sequence 20 BP; 2 A; 4 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCCACCATGAGGACA 1981

DB 20 ATAGCCCCCACCATGAGGACA 1

RESULT 1270

ID ADM46458/c

AC ADM46458 standard; DNA; 20 BP.

XX

XX 03-JUN-2004 (first entry)

XX Antisense oligonucleotide targeting human ICAM-1 #7.

DE Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
 KW vascular cell adhesion molecule; VCAM-1;
 KW endothelial leukocyte adhesion molecule; ELAM-1;
 KW inflammatory ophthalmological disorder; redness; inflammation;
 KW corneal explant; corneal allograft rejection.

XX Homo sapiens.

XX US2004033977-A1.

XX 19-FEB-2004.

XX 04-JUN-2003; 2003US-00454663.

XX 14-AUG-1990; 90US-00567286.

PR 02-SEP-1992; 92US-00939855.

PR 21-JAN-1993; 93US-00007997.

PR 10-FEB-1993; 93US-00969151.

PR 17-MAY-1993; 93US-00063167.

PR 12-MAY-1995; 95US-00440740.
 PR 03-AUG-1998; 98US-00128496.
 PR 12-SEP-2000; 2000US-00659288.
 PR 18-OCT-2001; 2001US-00982262.

XX (BENN/) BENNETT C F.
 PA (MIRA/) MIRABELLI C.

XX Bennett CF, Mirabelli C;

XX WPI; 2004-180090/17.

XX New antisense oligonucleotide, useful for diagnosing, as research
 PT reagents and for treating disease states, which respond to modulation of
 PT the synthesis or metabolism of cell adhesion molecules.

XX Example 5; SEQ ID NO 7; 72bp; English.

XX The invention relates to an antisense oligonucleotide targeting human
 CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as
 CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
 CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridizes with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.

XX Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCTCGCTATG 60

DB 20 GCAACCTCAGCCTCGCTATG 1

RESULT 1271

ID ADM46476/c

AC ADM46476 standard; DNA; 20 BP.

XX

XX 03-JUN-2004 (first entry)

XX Antisense oligonucleotide targeting human ICAM-1 #25.

XX Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
 KW vascular cell adhesion molecule; VCAM-1;
 KW endothelial leukocyte adhesion molecule; ELAM-1;
 KW inflammatory ophthalmological disorder; redness; inflammation;
 KW corneal explant; corneal allograft rejection.

```

OS Homo sapiens.
XX US2004033977-A1.
XX 19-FEB-2004.
XX
XX 04-JUN-2003; 2003US-00454663.
XX
XX 14-AUG-1990; 90US-00567286.
XX 02-SEP-1992; 92US-00939855.
XX 21-JAN-1993; 93US-00007997.
XX 10-FEB-1993; 93US-00969151.
XX 17-MAY-1993; 93US-00063167.
XX 12-MAY-1995; 95US-00440740.
XX 03-AUG-1998; 98US-00128496.
XX 12-SEP-2000; 2000US-00659288.
XX 18-OCT-2001; 2001US-00982262.
XX
XX (BENNETT) BENNETT C F.
XX (MIRA) MIRABELLI C.
XX
XX Bennett CF, Mirabelli C;
XX WPI; 2004-180090/17.
XX
XX New antisense oligonucleotide, useful for diagnosing, as research
XX reagents and for treating disease states, which respond to modulation of
XX the synthesis or metabolism of cell adhesion molecules.
XX
XX Example 5; SEQ ID NO 25; 72pp; English.
XX
XX The invention relates to an antisense oligonucleotide targeting human
XX intercellular adhesion molecule (ICAM-1) having a sequence appearing as
XX ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
XX replaced with a thymidine, cytidine or guanosine nucleotide, at least one
XX thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
XX nucleotide, at least one guanosine nucleotide is replaced with an
XX adenosine, thymidine or cytidine nucleotide or at least one cytidine
XX nucleotide is replaced with an adenosine, cytidine or guanosine
XX nucleotide. The oligonucleotide is one of 88 disclosed antisense
XX oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
XX 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
XX an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
XX and inhibits the expression of human ICAM-1 mRNA, and a double stranded
XX RNA compound having the RNA equivalent sequence of ADM46473. The
XX oligonucleotide is useful for modulating the activity of the RNA and DNA
XX adhesion molecules. It is also useful for the diagnosis, as research
XX reagents and for treating disease states, which respond to modulation of
XX the synthesis or metabolism of cell adhesion molecules. The
XX oligonucleotide is suitable for treating inflammatory ophthalmological
XX disorders including redness and inflammation caused by allergens and
XX allergic reactions. The oligonucleotides can also be used to preserve
XX corneal explants ex vivo and to prevent corneal allograft rejections. The
XX specific hybridisation exhibited by the oligonucleotides may be used for
XX assays, purifications or cellular product preparations. The present
XX sequence is an antisense oligonucleotide targeting ICAM-1.
XX
XX Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1921 TTAAGTCTAGCCTGATGAG 1940
XX |||||
XX Db 20 TTAAGTCTAGCCTGATGAG 1
XX
XX RESULT 1272
XX ADM46461/c
XX ID ADM46461 standard; DNA; 20 BP.

```

```

XX AC ADM46461;
XX DT 03-JUN-2004 (first entry)
XX DE Antisense oligonucleotide targeting human ICAM-1 #10.
XX
XX KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
XX KW vascular cell adhesion molecule; VCAM-1;
XX KW endothelial leukocyte adhesion molecule; ELAM-1;
XX KW inflammatory ophthalmological disorder; redness; inflammation;
XX KW corneal explant; corneal allograft rejection.
XX
XX OS Homo sapiens.
XX
XX PN US2004033977-A1.
XX
XX PD 19-FEB-2004.
XX
XX PF 04-JUN-2003; 2003US-00454663.
XX
XX PR 14-AUG-1990; 90US-00567286.
XX PR 02-SEP-1992; 92US-00939855.
XX PR 21-JAN-1993; 93US-00007997.
XX PR 10-FEB-1993; 93US-00969151.
XX PR 17-MAY-1993; 93US-00063167.
XX PR 12-MAY-1995; 95US-00440740.
XX PR 03-AUG-1998; 98US-00128496.
XX PR 12-SEP-2000; 2000US-00659288.
XX PR 18-OCT-2001; 2001US-00982262.
XX
XX (BENNETT) BENNETT C F.
XX (MIRA) MIRABELLI C.
XX
XX Bennett CF, Mirabelli C;
XX WPI; 2004-180090/17.
XX
XX New antisense oligonucleotide, useful for diagnosing, as research
XX reagents and for treating disease states, which respond to modulation of
XX the synthesis or metabolism of cell adhesion molecules.
XX
XX Example 5; SEQ ID NO 10; 72pp; English.
XX
XX The invention relates to an antisense oligonucleotide targeting human
XX intercellular adhesion molecule (ICAM-1) having a sequence appearing as
XX ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
XX replaced with a thymidine, cytidine or guanosine nucleotide, at least one
XX thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
XX nucleotide, at least one guanosine nucleotide is replaced with an
XX adenosine, thymidine or cytidine nucleotide or at least one cytidine
XX nucleotide is replaced with an adenosine, cytidine or guanosine
XX nucleotide. The oligonucleotide is one of 88 disclosed antisense
XX oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
XX 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
XX an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
XX and inhibits the expression of human ICAM-1 mRNA, and a double stranded
XX RNA compound having the RNA equivalent sequence of ADM46473. The
XX oligonucleotide is useful for modulating the activity of the RNA and DNA
XX adhesion molecules. It is also useful for the diagnosis, as research
XX reagents and for treating disease states, which respond to modulation of
XX the synthesis or metabolism of cell adhesion molecules. The
XX oligonucleotide is suitable for treating inflammatory ophthalmological
XX disorders including redness and inflammation caused by allergens and
XX allergic reactions. The oligonucleotides can also be used to preserve
XX corneal explants ex vivo and to prevent corneal allograft rejections. The
XX specific hybridisation exhibited by the oligonucleotides may be used for
XX assays, purifications or cellular product preparations. The present
XX sequence is an antisense oligonucleotide targeting ICAM-1.
XX
XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
XX
XX

```


Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
|||||
Db 20 TCAAACTGCCCTGATGGCA 1

RESULT 1273
ADM46460/C
ID ADM46460 standard; DNA; 20 BP.

XX AC ADM46460;

XX DT 03-JUN-2004 (first entry)

XX DE Antisense oligonucleotide targeting human ICAM-1 #9.

XX KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
KW vascular cell adhesion molecule; VCAM-1;
KW endothelial leukocyte adhesion molecule; ELAM-1;
KW inflammatory ophthalmological disorder; redness; inflammation;
KW corneal explant; corneal allograft rejection.

XX OS Homo sapiens.

XX XX US2004033977-A1.

XX PN 19-FEB-2004.

XX PD 04-JUN-2003; 2003US-00454663.

XX PF 14-AUG-1990; 90US-00567286.

XX PR 02-SEP-1992; 92US-00939855.

XX PR 21-JAN-1993; 93US-00007997.

XX PR 10-FEB-1993; 93US-00969151.

XX PR 17-MAY-1993; 93US-00063167.

XX PR 12-MAY-1995; 95US-00440740.

XX PR 03-AUG-1998; 98US-00128496.

XX PR 12-SEP-2000; 2000US-00659288.

XX PR 18-OCT-2001; 2001US-00982262.

XX PA (BENK/) BENNETT C F.
XX (MIRA/) MIRABELLI C.

XX PI Bennett CF, Mirabelli C;

XX DR WPI; 2004-180090/17.

XX XX New antisense oligonucleotide, useful for diagnosing, as research

PT reagents and for treating disease states, which respond to modulation of

PT the synthesis or metabolism of cell adhesion molecules.

XX Example 5; SEQ ID NO 9; 72pp; English.

XX CC The invention relates to an antisense oligonucleotide targeting human

CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as

CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is

CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one

CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine

CC nucleotide, at least one guanosine nucleotide or at least one cytidine

CC and the modulation of the synthesis and metabolism of specific cell

CC adhesion molecules. It is also useful for the diagnosis, as research

CC reagents and for treating disease states, which respond to modulation of

CC the synthesis or metabolism of cell adhesion molecules. The

CC oligonucleotide is suitable for treating inflammatory ophthalmological

CC disorders including redness and inflammation caused by allergens and

CC allergic reactions. The oligonucleotides can also be used to preserve

CC corneal explants ex vivo and to prevent corneal allograft rejections. The

CC specific hybridisation exhibited by the oligonucleotides may be used for

CC assays, purifications or cellular product preparations. The present

CC sequence is an antisense oligonucleotide targeting ICAM-1.

XX XX Sequence 20 BP; 6 A; 7 C; 7 G; 0 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 20; DB 1; Length 20;

XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;

XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTCTCGGGGCTCT 116

Db 20 CTGGTCTCTCGGGGCTCT 1

RESULT 1274

ADM46464/C

ID ADM46464 standard; DNA; 20 BP.

XX AC ADM46464;

XX DT 03-JUN-2004 (first entry)

XX DE Antisense oligonucleotide targeting human ICAM-1 #13.

XX KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;

XX KW vascular cell adhesion molecule; VCAM-1;

XX KW endothelial leukocyte adhesion molecule; ELAM-1;

XX KW inflammatory ophthalmological disorder; redness; inflammation;

XX KW corneal explant; corneal allograft rejection.

XX OS Homo sapiens.

XX XX US2004033977-A1.

XX PN 19-FEB-2004.

XX PD 04-JUN-2003; 2003US-00454663.

XX PF 14-AUG-1990; 90US-00567286.

XX PR 02-SEP-1992; 92US-00939855.

XX PR 21-JAN-1993; 93US-00007997.

XX PR 10-FEB-1993; 93US-00969151.

XX PR 17-MAY-1993; 93US-00063167.

XX PR 12-MAY-1995; 95US-00440740.

XX PR 03-AUG-1998; 98US-00128496.

XX PR 12-SEP-2000; 2000US-00659288.

XX PR 18-OCT-2001; 2001US-00982262.

XX XX (BENK/) BENNETT C F.

XX (MIRA/) MIRABELLI C.

XX PI Bennett CF, Mirabelli C;

XX DR WPI; 2004-180090/17.

XX XX New antisense oligonucleotide, useful for diagnosing, as research

PT reagents and for treating disease states, which respond to modulation of

PT the synthesis or metabolism of cell adhesion molecules.

XX Example 5; SEQ ID NO 13; 72pp; English.

XX CC The invention relates to an antisense oligonucleotide targeting human

CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as

CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is

CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one

CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine

CC nucleotide, at least one guanosine nucleotide or at least one cytidine

CC nucleotide is replaced with an adenosine, cytidine or guanosine

CC nucleotide. The oligonucleotide is one of 88 disclosed antisense

CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-

CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are

CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA

CC (where the compound specifically hybridises with the human ICAM-1 mRNA

CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded

CC RNA compound having the RNA equivalent sequence of ADM46473. The

CC oligonucleotide is useful for modulating the activity of the RNA and DNA

CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridises with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.

XX SQ Sequence 20 BP; 2 A; 3 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCAGCCTCCCTGA 1656

DB 20 CACAAGCCAGCCTCCCTGA 1

RESULT 1275

ADM46535/c

ID ADM46535 standard; DNA; 20 BP.

AC ADM46535;

XX 03-JUN-2004 (first entry)

DE Antisense oligonucleotide targeting human ICAM-1 #30.

KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;

KW vascular cell adhesion molecule; VCAM-1;

KW endothelial leukocyte adhesion molecule; ELAM-1;

KW inflammatory ophthalmological disorder; redness; inflammation;

KW corneal explant; corneal allograft rejection.

XX Homo sapiens.

XX US2004033977-A1.

XX 19-FEB-2004.

XX 04-JUN-2003; 2003US-00454663.

XX 14-AUG-1990; 90US-00567286.

PR 02-SEP-1992; 92US-00939855.

PR 21-JAN-1993; 93US-00007997.

PR 10-FEB-1993; 93US-00969151.

PR 17-MAY-1993; 93US-00063167.

PR 12-MAY-1995; 95US-00440740.

PR 03-AUG-1998; 98US-00128496.

PR 12-SEP-2000; 2000US-00659288.

PR 18-OCT-2001; 2001US-00982262.

PA (BENN/) BENNETT C F.

PA (MIRA/) MIRABELLI C;

XX

PI Bennett CF, Mirabelli C;

XX WPI; 2004-180090/17.

XX New antisense oligonucleotide, useful for diagnosing, as research

PT reagents and for treating disease states, which respond to modulation of

PT the synthesis or metabolism of cell adhesion molecules.

XX Example 5; SEQ ID NO 84; 72pp; English.

XX The invention relates to an antisense oligonucleotide targeting human
 CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as
 CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
 CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridises with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.

XX SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37

DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 1276

ADM46536/c

ID ADM46536 standard; DNA; 20 BP.

XX ADM46536;

XX 03-JUN-2004 (first entry)

XX Antisense oligonucleotide targeting human ICAM-1 #31.

KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;

KW vascular cell adhesion molecule; VCAM-1;

KW endothelial leukocyte adhesion molecule; ELAM-1;

KW inflammatory ophthalmological disorder; redness; inflammation;

KW corneal explant; corneal allograft rejection.

XX Homo sapiens.

XX US2004033977-A1.

XX 19-FEB-2004.

XX 04-JUN-2003; 2003US-00454663.

PR 14-AUG-1990; 90US-00567286.
 PR 02-SEP-1992; 92US-00939855.
 PR 21-JAN-1993; 93US-00007997.
 PR 10-FEB-1993; 93US-00969151.
 PR 17-MAY-1993; 93US-00063167.
 PR 12-MAY-1995; 95US-0040740.
 PR 03-AUG-1998; 98US-00128496.
 PR 12-SEP-2000; 2000US-00659288.
 PR 18-OCT-2001; 2001US-00982262.
 XX (BENNETT/) BENNETT C F.
 PA (MIRA/) MIRABELLI C.
 XX
 XX Bennett CF, Mirabelli C;
 PI
 XX WPI; 2004-180090/17.
 DR
 XX
 XX New antisense oligonucleotide, useful for diagnosing, as research
 PT reagents and for treating disease states, which respond to modulation of
 PT the synthesis or metabolism of cell adhesion molecules.
 XX
 XX Example 5; SEQ ID NO 85; 72pp; English.
 XX
 CC The invention relates to an antisense oligonucleotide targeting human
 CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as
 CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
 CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridises with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisations exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.
 XX
 XX Sequence 20 BP; 3 A; 10 C; 1 G; 6 T; 0 U; 0 Other;
 SQ

XX Homo sapiens.
 OS
 XX US2004073376-A1.
 PN
 XX 15-APR-2004.
 XX
 XX 14-JAN-2002; 2002US-00050888.
 PF
 XX 19-JAN-2001; 2001US-0262993P.
 PR
 XX (UTAH) UNIV UTAH RES FOUND.
 XX
 XX Gesteland RF, Atkins JF, Matveeva OV, Giddings MC;
 PI
 XX WPI; 2004-364070/34.
 DR
 XX
 XX Predicting antisense activity of an oligonucleotide for down-regulating
 PT expression of an RNA, comprises developing an artificial neural network,
 PT determining counts of mapped sequence motifs, and obtaining a output of
 PT activity.
 XX
 XX Disclosure; SEQ ID NO 7; 25pp; English.
 PS
 XX The present invention relates to the method for making an artificial
 CC neural network embodied on a computer-readable medium for predicting
 CC antisense activity of oligonucleotides for down-regulating expression of
 CC a selected RNA. The invention provides a five-fold reduction in the
 CC number of oligonucleotides to be screened in vivo to find effective
 CC targets. The present sequence is human ICAM-specific antisense
 CC oligonucleotide. This sequence is used in the invention.
 CC
 XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGG 1957
 Db 20 GAGAGGGGAAGTGTGGGG 1

RESULT 1278
 ADM15363/C
 ID ADM15363 standard; DNA; 20 BP.
 XX
 XX ADM15363;
 XX
 XX 01-JUL-2004 (first entry)
 DT
 XX
 XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1550.
 DE
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW immunomodulatory; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 KW
 XX Homo sapiens.
 OS
 OS Synthetic.
 XX
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5

FT FT /*tag= a
FT FT /mod_base= OTHER
FT FT /note= "2'-O-methoxyethyls"
FT FT 16..20
FT FT /*tag= c
FT FT /mod_base= OTHER
FT FT /note= "2'-O-methoxyethyls"
XX XX
XX WO2004028458-A2.
XX XX
XX 08-APR-2004.
XX XX
XX 25-SEP-2003; 2003WO-US030374.
XX XX
XX 25-SEP-2002; 2002US-0413549P.
XX XX
XX (PHAA) PHARMACIA CORP.
XX XX
XX Gierse JK;
XX WPI; 2004-305094/28.
XX XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX XX
XX Claim 4; SEQ ID NO 1550; 132pp; English.
XX XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nontropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX XX
XX Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2845 CTCAGCCTCTGAGTAGCTG 2864
DB 20 CTCAGCCTCTGAGTAGCTG 1
RESULT 1279
ADM15356/c
ID ADM15356 standard; DNA; 20 BP.
XX
AC ADM15356;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1543.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;

KW neuroprotective; nontropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
OS Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT modified_base 16..20
FT /note= "2'-O-methoxyethyls"
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX (PHAA) PHARMACIA CORP.
XX Gierse JK;
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX XX
XX Claim 4; SEQ ID NO 1543; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nontropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX XX
XX Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2846 TCAGCCTCTGAGTAGCTGG 2865
DB 20 TCAGCCTCTGAGTAGCTGG 1

RESULT 1280	
ADM15266/c	
ID ADM15266 standard; DNA; 20 BP.	
XX	
XX	
AC AC	ADM15266;
XX	
DT DT	01-JUL-2004 (first entry)
XX	
DE	Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1453.
XX	
KW	chimeric; antisense oligonucleotide; phosphorothioate; human;
KW	microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW	microsomal prostaglandin E2 synthase inhibitor; cytotstatic; antiidiabetic;
KW	immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW	neuroprotective; nootropic; antiarthritic; vasotropic; ophthalomological;
KW	immunomodulatory; cardiovascular; gene therapy; inflammation;
KW	Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW	reperfusion injury; ophthalmic disorder; immunological disorder;
KW	cardiovascular disorder; neurological disorder; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
PH	Key
FT	Location/Qualifiers
FT	modified_base 1..20
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note= "phosphorothioate linkages and all cytidine
FT	residues are 5-methylcytidines"
FT	modified_base 1..5
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "2'-O-methoxyethyls"
FT	modified_base 16..20
FT	/*tag= c
FT	/mod_base= OTHER
FT	/note= "2'-O-methoxyethyls"
XX	
PN	WO2004028458-A2.
XX	
PD	08-APR-2004.
XX	
PP	25-SEP-2003; 2003WO-US030374.
PP	
PP	25-SEP-2002; 2002US-0413549P.
XX	
PA	(PHAA) PHARMACIA CORP.
XX	
PI	Gierse JK;
XX	
DR	WPI; 2004-305094/28.
XX	
PT	New antisense compound, having a sequence targeted to a nucleic acid
PT	encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT	inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT	ischemia.
XX	
XX	Claim 4; SEQ ID NO 1453; 132pp; English.
XX	
CC	The present sequence represents a chimeric antisense oligonucleotide
CC	targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC	human mPGES-1 gene is located on chromosome 9, more specifically to
CC	9q34.3. The present invention also describes: (1) antisense compounds,
CC	having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC	mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC	inhibits its expression; (2) a method of inhibiting the expression of
CC	mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC	having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC	antisense oligonucleotides and antisense compounds have cytotstatic,
CC	antiidiabetic, immunomodulator, cardiant, neuroprotective,
CC	antiinflammatory, neuroprotective nootropic, antiarthritic, vasotropic,
CC	

PT ischemia.

PS Claim 4; SEQ ID NO 1144; 132pp; English.

XX

CC The present sequence represents a chimeric antisense oligonucleotide

CC targeted to human microsomal prostaglandin E2 synthase (MPGES-1). The

CC human MPGES-1 gene is located on chromosome 9, more specifically to

CC 9q34.3. The present invention also describes: (1) antisense compounds,

CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding

CC MPGES-1, which specifically hybridize with the nucleic acid MPGES-1 and

CC inhibits its expression; (2) a method of inhibiting the expression of

CC MPGES-1 in cells or tissues; and (3) a method of treating an animal

CC having a disease or condition associated with MPGES-1. MPGES-1 chimeric

CC antisense oligonucleotides and antisense compounds have cytostatic,

CC antidiabetic, immunomodulatory, cardiant, neuroprotective,

CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,

CC ophthalmological, immunomodulatory and cardiovascular activities, and can

CC be used as MPGES-1 inhibitors and in gene therapy. The antisense compound

CC can be used for preparing a composition for treating a disease or

CC condition associated with MPGES-1 e.g., inflammation, Alzheimer's

CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or

CC ophthalmic, immunological, cardiovascular or neurological disorder.

XX

SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2848 AGCCTCTGAGTAGCTGGGA 2867

DB 20 AGCCTCTGAGTAGCTGGGA 1

RESULT 1282

ADM15081/c

ID ADM15081 standard; DNA; 20 BP.

XX

AC ADM15081;

XX

XX 01-JUL-2004 (first entry)

XX

DE Human MPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1268.

XX

KW chimeric; antisense oligonucleotide; phosphorothioate; human;

KW microsomal prostaglandin E2 synthase; MPGES-1; MPGES-1 inhibitor;

KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;

KW immunomodulatory; cardiant; neuroprotective; antiinflammatory;

KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;

KW immunomodulatory; cardiovascular; gene therapy; inflammation;

KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;

KW reperfusion injury; ophthalmic disorder; immunological disorder;

KW cardiovascular disorder; neurological disorder; ss.

XX

OS Homo sapiens.

OS Synthetic.

XX

PH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "phosphorothioate linkages and all cytidine

FT residues are 5-methylcytidines"

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

XX

PN WO2004028458-A2.

XX

PD 08-APR-2004.

XX

PF 25-SEP-2003; 2003WO-US030374.

XX

PR 25-SEP-2002; 2002US-0413549P.

XX

PA (PHAA) PHARMACIA CORP.

XX

PI Gierse JK;

XX

DR WPI; 2004-305094/28.

XX

PT New antisense compound, having a sequence targeted to a nucleic acid

PT encoding MPGES-1, useful for preparing a composition for treating e.g.,

PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or

PT ischemia.

XX

PS Claim 4; SEQ ID NO 1268; 132pp; English.

XX

CC The present sequence represents a chimeric antisense oligonucleotide

CC targeted to human microsomal prostaglandin E2 synthase (MPGES-1). The

CC human MPGES-1 gene is located on chromosome 9, more specifically to

CC 9q34.3. The present invention also describes: (1) antisense compounds,

CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding

CC MPGES-1, which specifically hybridize with the nucleic acid MPGES-1 and

CC inhibits its expression; (2) a method of inhibiting the expression of

CC MPGES-1 in cells or tissues; and (3) a method of treating an animal

CC having a disease or condition associated with MPGES-1. MPGES-1 chimeric

CC antisense oligonucleotides and antisense compounds have cytostatic,

CC antidiabetic, immunomodulatory, cardiant, neuroprotective,

CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,

CC ophthalmological, immunomodulatory and cardiovascular activities, and can

CC be used as MPGES-1 inhibitors and in gene therapy. The antisense compound

CC can be used for preparing a composition for treating a disease or

CC condition associated with MPGES-1 e.g., inflammation, Alzheimer's

CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or

CC ophthalmic, immunological, cardiovascular or neurological disorder.

XX

SQ Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2847 CAGCCTCTGAGTAGCTGGG 2866

DB 20 CAGCCTCTGAGTAGCTGGG 1

RESULT 1283

ADO58939/c

ID ADO58939 standard; DNA; 20 BP.

XX

AC ADO58939;

XX

XX 15-JUL-2004 (first entry)

XX

DE Human ICAM-1 specific oligonucleotide #2.

XX

KW Renal uptake enhancement; therapy; human;

KW intracellular adhesion molecule-1; ICAM-1; infection; ss.

XX

OS Homo sapiens.

XX

PH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "All bases are 2'-O-[2-N,N-dimethyl aminoethyl] 1

FT oxyethyl]-5-methylated"

FT modified_base 2

FT /*tag= b

FT /mod_base= m5c
 FT 10
 FT /*tag= c
 FT /mod_base= m5c
 FT 18
 FT /*tag= d
 FT /mod_base= m5c

US2004009938-A1.

XX 15-JAN-2004.

XX 06-FEB-2003; 2003US-00359328.

XX 07-AUG-1998; 98US-00130566.

PR 06-AUG-1999; 99US-00370625.

XX (MANO/) MANOHARAN M.

PA (COOK/) COOK P D.

PI Manoharan M, Cook PD;

XX WPI; 2004-201317/19.

XX Enhancing renal uptake of an oligomeric compound in the diagnostic and
 PT therapeutic applications involves incorporating at least one modified
 PT ribosyl nucleoside into the oligomeric compound.

XX Example 19; SEQ ID NO 2; 21pp; English.

XX The invention relates to 2'-O-modified ribosyl nucleosides and methods of
 CC enhancing renal uptake of an oligomeric compound. The method is useful
 CC for enhancing renal uptake of an oligomeric compound. The sequences of
 CC the invention are useful in diagnostics, therapeutics and as research
 CC reagents; and for treating infection caused by organisms (e.g. bacteria,
 CC yeast, protozoa and algae) in plants and higher animals. The present
 CC sequence is an oligonucleotide targeted to human intracellular adhesion
 CC molecule-1 (ICAM-1) DNA. This sequence is used to illustrate the method
 CC of the invention.

XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37

Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 1284

ADO58938/c

ID ADO58938 standard; DNA; 20 BP.

XX ADO58938;

XX 15-JUL-2004 (first entry)

XX Human ICAM-1 specific oligonucleotide #1.

XX Renal uptake enhancement; therapy; human;
 KW intracellular adhesion molecule-1; phosphorothioate backbone; ICAM-1;
 KW infection; ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone in which all bases are

FT modified_base
 FT 2
 FT /*tag= b
 FT /mod_base= m5c

FT modified_base
 FT 10
 FT /*tag= c
 FT /mod_base= m5c

FT modified_base
 FT 18
 FT /*tag= d
 FT /mod_base= m5c

US2004009938-A1.

XX 15-JAN-2004.

XX 06-FEB-2003; 2003US-00359328.

XX 07-AUG-1998; 98US-00130566.

PR 06-AUG-1999; 99US-00370625.

XX (MANO/) MANOHARAN M.

PA (COOK/) COOK P D.

PI Manoharan M, Cook PD;

XX WPI; 2004-201317/19.

XX Enhancing renal uptake of an oligomeric compound in the diagnostic and
 PT therapeutic applications involves incorporating at least one modified
 PT ribosyl nucleoside into the oligomeric compound.

XX Example 19; SEQ ID NO 1; 21pp; English.

XX The invention relates to 2'-O-modified ribosyl nucleosides and methods of
 CC enhancing renal uptake of an oligomeric compound. The method is useful
 CC for enhancing renal uptake of an oligomeric compound. The sequences of
 CC the invention are useful in diagnostics, therapeutics and as research
 CC reagents; and for treating infection caused by organisms (e.g. bacteria,
 CC yeast, protozoa and algae) in plants and higher animals. The present
 CC sequence is an oligonucleotide targeted to human intracellular adhesion
 CC molecule-1 (ICAM-1) DNA. This sequence is used to illustrate the method
 CC of the invention.

XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37

Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 1285

ADO58941/c

ID ADO58941 standard; DNA; 20 BP.

XX ADO58941;

XX 15-JUL-2004 (first entry)

XX Human ICAM-1 specific oligonucleotide #3.

XX Renal uptake enhancement; therapy; human;
 KW intracellular adhesion molecule-1; phosphorothioate backbone; ICAM-1;
 KW infection; ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

```

FT modified_base 1. .20
FT /mod_base= a
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone. Residues 2, 3, 4, 8,
FT 12, 15, 16 and 19 are 5-methylcytosine (m5c)"
FT modified_base 13. .20
FT /mod_base= b
FT /mod_base= OTHER
FT /note= "All bases are 2'-O-(2-N,N-dimethyl aminoethyl)
FT oxyethyl]-5-methylated"
XX US2004009938-A1.
XX
XX 15-JAN-2004.
XX
XX 06-FEB-2003; 2003US-00359328.
XX
XX 07-AUG-1998; 98US-00130566.
XX 06-AUG-1999; 99US-00370625.
XX
XX (MANO/) MANOHARAN M.
XX (COOK/) COOK P D.
XX
XX Manoharan M, Cook PD;
XX
XX WPI; 2004-201317/19.
XX
XX Enhancing renal uptake of an oligomeric compound in the diagnostic and
XX therapeutic applications involves incorporating at least one modified
XX ribosyl nucleoside into the oligomeric compound.
XX
XX Example 19; SEQ ID NO 4; 21pp; English.
XX
XX The invention relates to 2'-O-modified ribosyl nucleosides and methods of
XX enhancing renal uptake of an oligomeric compound. The method is useful
XX for enhancing renal uptake of an oligomeric compound. The sequences of
XX the invention are useful in diagnostics, therapeutics and as research
XX reagents, and for treating infection caused by organisms (e.g. bacteria,
XX yeast, protozoa and algae) in plants and higher animals. The present
XX sequence is an oligonucleotide targeted to human intracellular adhesion
XX molecule-1 (ICAM-1) DNA. This sequence is used to illustrate the method
XX of the invention.
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 2100 TGACGGATGCCAGCTGGGC 2119
XX |||||||||||||||||||
XX 20 TGACGGATGCCAGCTGGGC 1
XX
XX RESULT 1286
XX ADO45720/c
XX ID ADO45720 standard; DNA; 20 BP.
XX
XX ADO45720;
XX
XX 15-JUL-2004 (first entry)
XX
XX Human oligonucleotide #1086.
XX
XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
XX CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
XX tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
XX lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
XX asthma; lung allergy; inflammation; inflammatory disease;
XX airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
XX chronic obstructive pulmonary disease; COPD; allergic rhinitis;
XX acute respiratory distress syndrome; pulmonary hypertension;
XX lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

```

```

XX OS Homo sapiens.
XX
XX PN US2004049022-A1.
XX
XX PD 11-MAR-2004.
XX
XX 25-JUL-2003; 2003US-00627930.
XX
XX 23-APR-2002; 2002WO-US013135.
XX 23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
XX (SAND/) SANDRASAGRA A.
XX (TANG/) TANG L.
XX (AGUI/) AGUILAR D.
XX (MILL/) MILLER S.
XX (SHAH/) SHAHABUDDIN S.
XX (LUHH/) LU H.
XX (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
XX Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
XX asthma.
XX
XX Claim 2; SEQ ID NO 1087; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
XX codon, coding region, 5' or 3' intron-exon junction, intron or region
XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
XX also relates to a method of screening a candidate compound that binds to
XX one or more nucleic acid target(s) or expressed product(s), for the
XX prevention and/or treatment of a respiratory or lung disease. The
XX oligonucleotides are useful for reducing or inhibiting expression of a
XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
XX useful for preventing or treating a respiratory or lung disease. The
XX respiratory or lung disease is associated with hyper-responsiveness to
XX and/or increased levels of, adenosine and/or levels of adenosine A
XX receptor(s), and/or asthma and/or lung allergies associated with
XX inflammation or an inflammatory disease. The respiratory or lung disease
XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
XX hypertension, lung inflammation, bronchitis, airway obstruction or
XX bronchoconstriction. This sequence represents an oligonucleotide of the
XX invention.
XX
XX Sequence 20 BP; 2 A; 5 C; 6 G; 7 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 2040 ACAGAGAAGTGGCCCTCCA 2059
XX |||||||||||||||||||
XX 20 ACAGAGAAGTGGCCCTCCA 1
XX
XX RESULT 1287
XX ADO45752/c
XX ID ADO45752 standard; DNA; 20 BP.
XX
XX

```


AC ADO45752;
XX
XX 15-JUL-2004 (first entry)
XX DE Human oligonucleotide #1118.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS Homo sapiens.
XX
XX US2004049022-A1.
XX
XX 11-MAR-2004.
XX
XX 25-JUL-2003; 2003US-00627930.
XX
XX 23-APR-2002; 2002WO-US013135.
XX 23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
XX (SAND/) SANDRASAGRA A.
XX (TANG/) TANG L.
XX (AGUI/) AGUILAR D.
XX (MILL/) MILLER S.
XX (SHAH/) SHAHABUDDIN S.
XX (LUHH/) LU H.
XX (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
XX Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
XX asthma.
XX
XX Claim 2; SEQ ID NO 1119; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
XX codon, coding region, 5' or 3' intron-exon junction, intron or region
XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
XX also relates to a method of screening a candidate compound that binds to
XX one or more nucleic acid target(s) or expressed product(s), for the
XX prevention and/or treatment of a respiratory or lung disease. The
XX oligonucleotides are useful for reducing or inhibiting expression of a
XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
XX useful for preventing or treating a respiratory or lung disease. The
XX respiratory or lung disease is associated with hyper-responsiveness to
XX and/or increased levels of, adenosine and/or levels of adenosine A
XX receptor(s), and/or asthma and/or lung allergies associated with
XX inflammation or an inflammatory disease. The respiratory or lung disease
XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
XX hypertension, lung inflammation, bronchitis, airway obstruction or
XX bronchoconstriction. This sequence represents an oligonucleotide of the
XX invention.

SQ Sequence 20 BP; 3 A; 6 C; 3 G; 8 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1721 ACAGAGTGGAGACATATGC 1740
DB 20 ACAGAGTGGAGACATATGC 1
RESULT 1288
ADO45772/C
ID ADO45772 standard; DNA; 20 BP.
XX
XX ADO45772;
XX
XX 15-JUL-2004 (first entry)
XX Human oligonucleotide #1138.
XX
XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
XX Homo sapiens.
XX
XX US2004049022-A1.
XX
XX 11-MAR-2004.
XX
XX 25-JUL-2003; 2003US-00627930.
XX
XX 23-APR-2002; 2002WO-US013135.
XX 23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
XX (SAND/) SANDRASAGRA A.
XX (TANG/) TANG L.
XX (AGUI/) AGUILAR D.
XX (MILL/) MILLER S.
XX (SHAH/) SHAHABUDDIN S.
XX (LUHH/) LU H.
XX (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
XX Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
XX asthma.
XX
XX Claim 2; SEQ ID NO 1139; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
XX codon, coding region, 5' or 3' intron-exon junction, intron or region
XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
XX also relates to a method of screening a candidate compound that binds to
XX one or more nucleic acid target(s) or expressed product(s), for the
XX prevention and/or treatment of a respiratory or lung disease. The
XX oligonucleotides are useful for reducing or inhibiting expression of a
XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
XX useful for preventing or treating a respiratory or lung disease. The
XX respiratory or lung disease is associated with hyper-responsiveness to
XX and/or increased levels of, adenosine and/or levels of adenosine A
XX receptor(s), and/or asthma and/or lung allergies associated with
XX inflammation or an inflammatory disease. The respiratory or lung disease
XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
XX hypertension, lung inflammation, bronchitis, airway obstruction or
XX bronchoconstriction. This sequence represents an oligonucleotide of the
XX invention.

PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCRI,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1178; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 0 A; 6 C; 7 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1131 GAAGGCCACCCAGAGGACA 1150
 Db 20 GAAGGCCACCCAGAGGACA 1
 |||||
 RESULT 1291
 ADO45825/c
 ID ADO45825 standard; DNA; 20 BP.
 XX
 XX ADO45825;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1191.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCRI; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;

KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCRI,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1192; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 991 GCGCCCAACGTCGATTCGAC 1010
 Db 20 GCGCCCAACGTCGATTCGAC 1
 |||||
 RESULT 1292
 ADO45835/c

ID AC AD045835 standard; DNA; 20 BP.
 XX AC AD045835;
 XX XX
 DT 15-JUL-2004 (first entry)
 DE Human oligonucleotide #1201.
 XX XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX OS Homo sapiens.
 XX XX
 XX US2004049022-A1.
 XX 11-MAR-2004.
 XX XX
 XX 25-JUL-2003; 2003US-00627930.
 XX XX
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX XX
 XX Claim 2; SEQ ID NO 1202; 174pp; English.
 XX XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease. The
 XX respiratory or lung disease is associated with hyper-responsiveness to
 XX and/or increased levels of, adenosine and/or levels of adenosine A
 XX receptor(s), and/or asthma and/or lung allergies associated with
 XX inflammation or an inflammatory disease. The respiratory or lung disease
 XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
 XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
 XX hypertension, lung inflammation, bronchitis, airway obstruction or
 XX bronchoconstriction. This sequence represents an oligonucleotide of the

CC invention.
 XX XX
 SQ Sequence 20 BP; 0 A; 9 C; 5 G; 6 T; 0 U; 0 Other;
 XX XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX XX
 QY 891 GACCGCAGAGGACGAGGGCA 910
 DB 20 GACCGCAGAGGACGAGGGCA 1
 XX XX
 RESULT 1293
 AD045854/c
 ID AD045854 standard; DNA; 20 BP.
 XX XX
 XX AC AD045854;
 XX XX
 XX 15-JUL-2004 (first entry)
 XX XX
 XX Human oligonucleotide #1220.
 XX XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX OS Homo sapiens.
 XX XX
 XX US2004049022-A1.
 XX 11-MAR-2004.
 XX XX
 XX 25-JUL-2003; 2003US-00627930.
 XX XX
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX XX
 XX Claim 2; SEQ ID NO 1221; 174pp; English.
 XX XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease. The
 XX respiratory or lung disease is associated with hyper-responsiveness to
 XX and/or increased levels of, adenosine and/or levels of adenosine A
 XX receptor(s), and/or asthma and/or lung allergies associated with
 XX inflammation or an inflammatory disease. The respiratory or lung disease
 XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
 XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
 XX hypertension, lung inflammation, bronchitis, airway obstruction or
 XX bronchoconstriction. This sequence represents an oligonucleotide of the

CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

SQ Sequence 20 BP; 3 A; 2 C; 10 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 701 CAGCGACTCCCCACAACTT 720
 Db ||||| ||||| ||||| ||||| |||||
 20 CAGCGACTCCCCACAACTT 1

RESULT 1294
 ADO45859/c
 ID ADO45859 standard; DNA; 20 BP.
 AC ADO45859;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1225.
 XX

KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR
 XX

PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1226; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 651 GCTGTTTGAGAACACCTCGG 670
 Db ||||| ||||| ||||| ||||| |||||
 20 GCTGTTTGAGAACACCTCGG 1

RESULT 1295
 ADO45875/c
 ID ADO45875 standard; DNA; 20 BP.
 XX ADO45875;
 AC
 XX 15-JUL-2004 (first entry)
 DT
 XX Human oligonucleotide #1241.
 DE
 XX
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR
 XX

XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX NYCE JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI: 2004-293804/27.
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX Claim 2; SEQ ID NO 1242; 174pp; English.
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 491 ACTCACCCTGGTGGTGGTCTC 510
DB ||||||||||||||||||||
20 ACCTCACCCTGGTGGTGGTCTC 1
RESULT 1296
AD045881/c
ID AD045881 standard; DNA; 20 BP.
XX AD045881;
AC
XX 15-JUL-2004 (first entry)
DT
XX Human oligonucleotide #1247.
DE
XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;

KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX Homo sapiens.
XX US2004049022-A1.
XX 11-MAR-2004.
XX 25-JUL-2003; 2003US-00627930.
XX 23-APR-2002; 2002WO-US013135.
XX 23-APR-2002; 2002WO-US013143.
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX NYCE JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI: 2004-293804/27.
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX Claim 2; SEQ ID NO 1248; 174pp; English.
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 431 AGCCAGTGGGCAAGACCTT 450
DB ||||||||||||||||||||
20 AGCCAGTGGGCAAGACCTT 1

RESULT 1297
 AD045883/c
 ID ADO45883 standard; DNA; 20 BP.
 XX
 AC ADO45883;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1249.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1250; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC

CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 11 G; 1 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 411 GGCACCCCTCCCTCTTGGC 430
 Db 20 GGCACCCCTCCCTCTTGGC 1
 RESULT 1298
 AD045736/c
 ID ADO45736 standard; DNA; 20 BP.
 XX
 AC ADO45736;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1102.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1103; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC

CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900

DB 20 CAAGAGGAGGAGCAAGACT 1

RESULT 1299

ADO45753/c

ID ADO45753 standard; DNA; 20 BP.

XX ADO45753;

DT 15-JUL-2004 (first entry)

DE Human oligonucleotide #1119.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

OS US2004049022-A1.

PN 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

PR 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX

DR WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1120; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 2 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1711 GCCACACTGACAGAGTGGA 1730

DB 20 GCCACACTGACAGAGTGGA 1

RESULT 1300

ADO45757/c

ID ADO45757 standard; DNA; 20 BP.

XX ADO45757;

XX 15-JUL-2004 (first entry)

DT Human oligonucleotide #1123.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

OS US2004049022-A1.

PN 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 1391 TGACTGTCACGAGATCTT 1410
 Db 20 TGACTGTCACGAGATCTT 1
 RESULT 1303
 ID ADO45789/c
 ID ADO45789 standard; DNA; 20 BP.
 XX
 AC ADO45789;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1155.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 WPI; 2004-293804/27.
 XX
 Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1,
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 Claim 2; SEQ ID NO 1152; 174pp; English.
 XX
 The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 7 A; 4 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 1391 TGACTGTCACGAGATCTT 1410
 Db 20 TGACTGTCACGAGATCTT 1
 RESULT 1303
 ID ADO45789/c
 ID ADO45789 standard; DNA; 20 BP.
 XX
 AC ADO45789;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1155.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; COPD; allergic rhinitis;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 WPI; 2004-293804/27.
 XX
 Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1,
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 Claim 2; SEQ ID NO 1152; 174pp; English.
 XX
 The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,

CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1351 CTAAGGATGGCACTTTCCC 1370
 |||||
 Db 20 CTAAGGATGGCACTTTCCC 1

RESULT 1304
 ADO45801/c
 ID ADO45801 standard; DNA; 20 BP.

XX
 AC ADO45801;

XX
 DT 15-JUL-2004 (first entry)

XX
 DE Human oligonucleotide #1167.

XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; COPD; allergic rhinitis;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX
 OS Homo sapiens.

XX
 PN US2004049022-A1.

XX
 PD 11-MAR-2004.

XX
 PF 25-JUL-2003; 2003US-00627930.

XX
 PR 23-APR-2002; 2002WO-US013135.

XX
 PR 23-APR-2002; 2002WO-US013143.

XX
 PA (NYCE/) NYCE J W.

XX
 PA (SAND/) SANDRASAGRA A.

XX
 PA (TANG/) TANG L.

XX
 PA (AGUI/) AGUILAR D.

XX
 PA (MILL/) MILLER S.

XX
 PA (SHAH/) SHAHABUDDIN S.

XX
 PA (LUHH/) LU H.

XX
 PA (CONG/) CONG H.

XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.

XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX
 PS Claim 2; SEQ ID NO 1168; 174pp; English.

XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1231 GTCCTGTATGCCCGCGACT 1250
 |||||
 Db 20 GTCCTGTATGCCCGCGACT 1

RESULT 1305
 ADO45836/c
 ID ADO45836 standard; DNA; 20 BP.

XX
 AC ADO45836;

XX
 DT 15-JUL-2004 (first entry)

XX
 DE Human oligonucleotide #1202.

XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; COPD; allergic rhinitis;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX
 OS Homo sapiens.

XX
 PN US2004049022-A1.

XX
 PD 11-MAR-2004.

PF 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1203; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC triptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred.No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 881 CAGTCAGTGTGACCGCAGAG 900
 Db 20 CAGTCAGTGTGACCGCAGAG 1
 RESULT 1306
 ADO45845/c
 ID ADO45845 standard; DNA; 20 BP.
 AC ADO45845;
 XX
 XX 15-JUL-2004 (first entry)
 XX Human oligonucleotide #1211.
 DE Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 XX

KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX US2004049022-A1.
 PN 11-MAR-2004.
 PD 25-JUL-2003; 2003US-00627930.
 PF 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1212; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred.No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 791 TCTCGAGGCCCGCAGGTCCAC 810

Db 20 TCTCGAGGCCAGGCTCCAC 1
|||||
RESULT 1307
ADO45861/c
ID ADO45861 standard; DNA; 20 BP.
XX
AC ADO45861;
XX
XX 15-JUL-2004 (first entry)
DT
XX
DE Human oligonucleotide #1227.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS Homo sapiens.
XX
XX US2004049022-A1.
PN
XX 11-MAR-2004.
PD
XX 25-JUL-2003; 2003US-00627930.
PF
XX 23-APR-2002; 2002WO-US013135.
PR
XX 23-APR-2002; 2002WO-US013143.
PR
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 1228; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with

CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 2 A; 8 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 631 CTGCGGCCCAAGGCTGGA 650
Db 20 CTGCGGCCCAAGGCTGGA 1
|||||
RESULT 1308
ADO45864/c
ID ADO45864 standard; DNA; 20 BP.
XX
AC ADO45864;
XX
XX 15-JUL-2004 (first entry)
DT
XX
DE Human oligonucleotide #1230.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS Homo sapiens.
XX
XX US2004049022-A1.
PN
XX 11-MAR-2004.
PD
XX 25-JUL-2003; 2003US-00627930.
PF
XX 23-APR-2002; 2002WO-US013135.
PR
XX 23-APR-2002; 2002WO-US013143.
PR
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 1231; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region

CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the

XX SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 601 GCCAAATTCGTCGCGCCAC 620
 DB |||||||||||||||||||
 20 GCCAAATTCGTCGCGCCAC 1

RESULT 1309
 ADO45866/c
 ID ADO45866 standard; DNA; 20 BP.

XX AC ADO45866;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 XX Human oligonucleotide #1232.
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX (NYCE//) NYCE J W.

XX (SAND//) SANDRASAGRA A.

XX (TANG//) TANG L.

XX (AGUI//) AGUILAR D.

XX (MILL//) MILLER S.

XX (SHAH//) SHAHABUDDIN S.

XX (LUHH//) LU H.

XX NYCE JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1233; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the

XX SQ Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 581 TCAGGAGAGATCACCATGGA 600
 DB |||||||||||||||||||
 20 TCAGGAGAGATCACCATGGA 1

RESULT 1310

ADO45891/c

ID ADO45891 standard; DNA; 20 BP.

XX ADO45891;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1257.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX

```

PD 11-MAR-2004.
XX
XX
XX 25-JUL-2003; 2003US-00627930.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 1258; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 331 TGCATTTCAAACGCGCTCA 350
DB 20 TGCATTTCAAACGCGCTCA 1
RESULT 1311
AD045907/c
ID AD045907 standard; DNA; 20 BP.
XX
XX ADO45907;
XX
XX 15-JUL-2004 (first entry)
XX
XX Human oligonucleotide #1273.

```

```

XX
XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
XX CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
XX tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
XX lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
XX asthma; lung allergy; inflammation; inflammatory disease;
XX airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
XX chronic obstructive pulmonary disease; COPD; allergic rhinitis;
XX acute respiratory distress syndrome; pulmonary hypertension;
XX lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
XX Homo sapiens.
XX
XX US2004049022-A1.
XX
XX 11-MAR-2004.
XX
XX 25-JUL-2003; 2003US-00627930.
XX
XX 23-APR-2002; 2002WO-US013135.
XX 23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
XX (SAND/) SANDRASAGRA A.
XX (TANG/) TANG L.
XX (AGUI/) AGUILAR D.
XX (MILL/) MILLER S.
XX (SHAH/) SHAHABUDDIN S.
XX (LUHH/) LU H.
XX (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 1258; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 331 TGCATTTCAAACGCGCTCA 350
DB 20 TGCATTTCAAACGCGCTCA 1
RESULT 1311
AD045907/c
ID AD045907 standard; DNA; 20 BP.
XX
XX ADO45907;
XX
XX 15-JUL-2004 (first entry)
XX
XX Human oligonucleotide #1273.

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 171 GCCCGGGGAGGCTCCGTCG 190
 Db 20 GCCCGGGGAGGCTCCGTCG 1

RESULT 1312
 ADO45725/c
 ID ADO45725 standard; DNA; 20 BP.
 XX AC ADO45725;
 XX DT 15-JUL-2004 (first entry)
 XX DE Human oligonucleotide #1091.
 XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX OS Homo sapiens.
 XX PN US2004049022-A1.
 XX PD 11-MAR-2004.
 XX XX 25-JUL-2003; 2003US-00627930.
 XX PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX NYce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1,
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g. asthma.
 PS Claim 2; SEQ ID NO 1092; 174pp; English.
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to

CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.
 XX SQ Sequence 20 BP; 5 A; 4 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1991 GAAATGACTGAAACTTCTGTCG 2010
 Db 20 GAAATGACTGAAACTTCTGTCG 1

RESULT 1313
 ADO45726/c
 ID ADO45726 standard; DNA; 20 BP.
 XX AC ADO45726;
 XX DT 15-JUL-2004 (first entry)
 XX DE Human oligonucleotide #1092.
 XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX OS Homo sapiens.
 XX PN US2004049022-A1.
 XX PD 11-MAR-2004.
 XX XX 25-JUL-2003; 2003US-00627930.
 XX PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX NYce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g. asthma.
 PS Claim 2; SEQ ID NO 1093; 174pp; English.
 XX

CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 4 A; 4 C; 3 G; 9 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1981 ATACAACTGGGAATACTGA 2000
 Db |||||
 20 ATACAACTGGGAATACTGA 1
 RESULT 1314
 ADO45728/C
 ID ADO45728 standard; DNA; 20 BP.
 XX
 AC ADO45728;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1094.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1095; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 4 C; 8 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1961 CATAGCCCCCACCATGAGGAC 1980
 Db |||||
 20 CATAGCCCCCACCATGAGGAC 1
 RESULT 1315
 ADO45737/C
 ID ADO45737 standard; DNA; 20 BP.
 XX
 AC ADO45737;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1103.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX

PN US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1104; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 2 A; 6 C; 3 G; 9 T; 0 U; 0 Other;
 XX Query Match 0.7%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1871 ATGACTAAGCCAGAGAGAG 1890
 DB 20 ATGACTAAGCCAGAGAGAG 1
 RESULT 1316
 ADO45776/c
 ID ADO45776 standard; DNA; 20 BP.
 XX ADO45776;
 XX ADO45776;
 XX 15-JUL-2004 (first entry)

Human oligonucleotide #1142.
 Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 asthma; lung allergy; inflammation; inflammatory disease;
 airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 acute respiratory distress syndrome; pulmonary hypertension;
 lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 Homo sapiens.
 US2004049022-A1.
 11-MAR-2004.
 25-JUL-2003; 2003US-00627930.
 23-APR-2002; 2002WO-US013135.
 23-APR-2002; 2002WO-US013143.
 (NYCE/) NYCE J W.
 (SAND/) SANDRASAGRA A.
 (TANG/) TANG L.
 (AGUI/) AGUILAR D.
 (MILL/) MILLER S.
 (SHAH/) SHAHABUDDIN S.
 (LUHH/) LU H.
 (CONG/) CONG H.
 Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 Shahabuddin S, Lu H, Cong H;
 WPI; 2004-293804/27.
 Novel single or multiple target oligonucleotide anti-sense to e.g.
 initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 asthma.
 Claim 2; SEQ ID NO 1143; 174pp; English.
 The invention relates to oligonucleotides anti-sense to an initiation
 codon, coding region, 5' or 3' intron-exon junction, intron or region
 with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 also relates to a method of screening a candidate compound that binds to
 one or more nucleic acid target(s) or expressed product(s), for the
 prevention and/or treatment of a respiratory or lung disease. The
 oligonucleotides are useful for reducing or inhibiting expression of a
 gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 useful for preventing or treating a respiratory or lung disease. The
 respiratory or lung disease is associated with hyper-responsiveness to
 and/or increased levels of, adenosine and/or levels of adenosine A
 receptor(s), and/or asthma and/or lung allergies associated with
 inflammation or an inflammatory disease. The respiratory or lung disease
 is chosen from allergic rhinitis, acute respiratory distress syndrome, pulmonary
 cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 hypertension, lung inflammation, bronchitis, airway obstruction or
 bronchoconstriction. This sequence represents an oligonucleotide of the
 invention.
 Sequence 20 BP; 6 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;

PS Claim 2; SEQ ID NO 1214; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 771 CCTGGACGGCTGTCCAG 790
 Db ||||||||||||||||

20 CCTGGACGGCTGTCCAG 1

RESULT 1319
 ADO45867/c

ID ADO45867 standard; DNA; 20 BP.

XX ADO45867;

AC ADO45867;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1233.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

OS Homo sapiens.

XX US2004049022-A1.

PN 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

PR 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX - WPI; 2004-293804/27.

DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1234; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 3 A; 10 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 571 ACGGTCTGGTGAGAGAGA 590
 Db ||||||||||||||||

20 ACGGTCTGGTGAGAGAGA 1

RESULT 1320
 ADO45877/c

ID ADO45877 standard; DNA; 20 BP.

XX ADO45877;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1243.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

OS Homo sapiens.
XX US2004049022-A1.
XX 11-MAR-2004.
XX 25-JUL-2003; 2003US-00627930.
XX 23-APR-2002; 2002WO-US013135.
XX 23-APR-2002; 2002WO-US013143.
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1,
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX Claim 2; SEQ ID NO 1244; 174pp; English.
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
XX invention.
XX Sequence 20 BP; 1 A; 10 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 471 GGGTGGGGCACCCGGGCCA 490
|||
Db 20 GGGTGGGGCACCCGGGCCA 1
RESULT 1321
ADO45902/c
ID ADO45902 standard; DNA; 20 BP.
XX
AC ADO45902;

XX
DT
XX
DE
XX
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1, RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX Homo sapiens.
OS US2004049022-A1.
XX 11-MAR-2004.
XX 25-JUL-2003; 2003US-00627930.
XX 23-APR-2002; 2002WO-US013135.
XX 23-APR-2002; 2002WO-US013143.
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1,
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX Claim 2; SEQ ID NO 1269; 174pp; English.
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
XX invention.
XX Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 221 CCAAGTTGTTGGCATAG 240
 |||||
 Db 20 CCAAGTTGTTGGCATAG 1

RESULT 1322
 ADO45923/C
 ID ADO45923 standard; DNA; 20 BP.

XX AC ADO45923;
 XX
 DT 15-JUL-2004 (first entry)
 DE Human oligonucleotide #1289.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.
 XX US2004049022-A1.
 XX
 PD 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

PS Claim 2; SEQ ID NO 1290; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,

CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

SQ Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 11 CGACGCTGAGCTCTCTGCT 30
 |||||
 Db 20 CGACGCTGAGCTCTCTGCT 1

RESULT 1323
 ADO45740/C
 ID ADO45740 standard; DNA; 20 BP.

XX ADO45740;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1106.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.

PT asthma.
 XX Claim 2; SEQ ID NO 1107; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from an inflammatory disease, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1841 CACTAGGCCACGATCTGAT 1860
 Db |||||
 20 CACTAGGCCACGATCTGAT 1
 RESULT 1324
 ADO45741/c
 ID ADO45741 standard; DNA; 20 BP.
 AC ADO45741;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1107.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 PR
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1108; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from an inflammatory disease, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 2 C; 7 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1831 ACACCTAAACACTAGGCCA 1850
 Db |||||
 20 ACACCTAAACACTAGGCCA 1
 RESULT 1325
 ADO45755/c
 ID ADO45755 standard; DNA; 20 BP.
 XX
 AC ADO45755;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1121.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW acute respiratory distress syndrome; pulmonary hypertension;

KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 OS US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 PF 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1,
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1122; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1691 CCCATATTGGTCGAGTGGT 1710
 |||||
 Db 20 CCCATATTGGTCGAGTGGT 1
 RESULT 1326
 ADO45762/c
 ID ADO45762 standard; DNA; 20 BP.

XX ADO45762;
 XX 15-JUL-2004 (first entry)
 DT Human oligonucleotide #1128.
 XX
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 OS US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 PF 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1129; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.


```

XX
SQ Sequence 20 BP; 1 A; 2 C; 8 G; 9 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1621 CCATGAACCGAACACACA 1640
Db 20 CCATGAACCGAACACACA 1

RESULT 1327
ADO45792/C
ID ADO45792 standard; DNA; 20 BP.
XX
AC ADO45792;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human oligonucleotide #1158.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS Homo sapiens.
XX
PN US2004049022-A1.
XX
PD 11-MAR-2004.
XX
PF 25-JUL-2003; 2003US-00627930.
XX
PR 23-APR-2002; 2002WO-US013135.
PR 23-APR-2002; 2002WO-US013143.
PA (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
PS WPI; 2004-293804/27.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
PS Claim 2; SEQ ID NO 1159; 174pp; English.
XX
CC The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The

```

```

CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1321 TGGGGGAACCCATTGCCCGA 1340
Db 20 TGGGGGAACCCATTGCCCGA 1

RESULT 1328
ADO45808/C
ID ADO45808 standard; DNA; 20 BP.
XX
AC ADO45808;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human oligonucleotide #1174.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS Homo sapiens.
XX
PN US2004049022-A1.
XX
PD 11-MAR-2004.
XX
PF 25-JUL-2003; 2003US-00627930.
XX
PR 23-APR-2002; 2002WO-US013135.
PR 23-APR-2002; 2002WO-US013143.
PA (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
PS WPI; 2004-293804/27.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.

```

PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.

PS Claim 2; SEQ ID NO 1175; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 6 A; 2 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1161 CTCTCTCTGCTGCAACCC 1180
DB 20 CTCTCTCTGCTGCAACCC 1

RESULT 1329
ADO45826/c

ID ADO45826 standard; DNA; 20 BP.

XX ADO45826;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1192.

KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; impeded respiration;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX

(NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.

XX Claim 2; SEQ ID NO 1193; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 981 CAGCTTTCCGGCGCCCAACG 1000
DB 20 CAGCTTTCCGGCGCCCAACG 1

RESULT 1330

ADO45827/c

ID ADO45827 standard; DNA; 20 BP.

XX ADO45827;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1193.

KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;

KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1194; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or the
 CC invention.
 XX
 SQ Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 971 TGACCTCTACAGCTTCCG 990
 |||||
 Db 20 TGACCTCTACAGCTTCCG 1
 |||||
 RESULT 1331

AD045842/c
 ID AD045842 standard; DNA; 20 BP.
 XX
 AC AD045842;
 XX
 XX 15-JUL-2004 (first entry)
 DT
 XX
 XX Human oligonucleotide #1208.
 DE
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease; CF;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 PN
 XX
 XX 11-MAR-2004.
 PD
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1209; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or the
 CC invention.
 XX
 SQ Sequence 20 BP; 6 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 971 TGACCTCTACAGCTTCCG 990
 |||||
 Db 20 TGACCTCTACAGCTTCCG 1
 |||||
 RESULT 1331

CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

SQ Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other; 0;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 821 GGGACACAGAGTTGAACCCC 840
 |||||
 Db 20 GGGACACAGAGTTGAACCCC 1

RESULT 1332
 ADO45862/c
 ID ADO45862 standard; DNA; 20 BP.

XX ADO45862;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1228.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

XX (SAND/) SANDRASAGRA A.

XX (TANG/) TANG L.

XX (AGUI/) AGUILAR D.

XX (MILL/) MILLER S.

XX (SHAH/) SHAHABUDDIN S.

XX (LUHH/) LU H.

XX (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

XX Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1229; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to

CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 3 A; 10 C; 2 G; 5 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 20; DB 1; Length 20;

XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;

XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 571 ACGGTCTCGTGAGGAGAGA 590

Db 20 ACGGTCTCGTGAGGAGAGA 1

RESULT 1333

ADO45870/c

ID ADO45870 standard; DNA; 20 BP.

XX ADO45870;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1236.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

XX (SAND/) SANDRASAGRA A.

XX (TANG/) TANG L.

XX (AGUI/) AGUILAR D.

XX (MILL/) MILLER S.

XX (SHAH/) SHAHABUDDIN S.

XX (LUHH/) LU H.

XX (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

XX Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-293804/27.

KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1257; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease
 XX inflammation and/or asthma and/or lung allergies associated with
 XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
 XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
 XX hypertension, lung inflammation, bronchitis, airway obstruction or
 XX bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.
 XX
 XX Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 341 ACTGCCCTGATGGCAGTCA 360
 DB 20 ACTGCCCTGATGGCAGTCA 1

RESULT 1336
 ADO45917/c
 ID ADO45917 standard; DNA; 20 BP.
 XX
 XX ADO45917;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 XX Human oligonucleotide #1283.
 XX
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease; CF;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1284; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease. The
 XX respiratory or lung disease is associated with hyper-responsiveness to
 XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
 XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
 XX hypertension, lung inflammation, bronchitis, airway obstruction or
 XX bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.

CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 SQ Sequence 20 BP; 1 A; 6 C; 13 G; 0 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 71 GCCCCGGCGCGCTGCC 90
 Db 20 GCCCCGGCGCGCTGCC 1
 RESULT 1337
 ADO45716/C
 ID ADO45716 standard; DNA; 20 BP.
 XX AC ADO45716;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1082.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 FN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1083; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,

CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 2 C; 9 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2080 ACACAAAGGCCACACTTCC 2099
 Db 20 ACACAAAGGCCACACTTCC 1
 RESULT 1338
 ADO45734/C
 ID ADO45734 standard; DNA; 20 BP.
 XX AC ADO45734;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1100.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 FN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-293804/27.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.

XX PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,

XX PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.

XX PT asthma.

XX PS Claim 2; SEQ ID NO 1101; 174pp; English.

XX CC The invention relates to oligonucleotides anti-sense to an initiation

CC codon, coding region, 5' or 3' intron-exon junction, intron or region

CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target

CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)

CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,

CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention

CC also relates to a method of screening a candidate compound that binds to

CC one or more nucleic acid target(s) or expressed product(s), for the

CC prevention and/or treatment of a respiratory or lung disease. The

CC oligonucleotides are useful for reducing or inhibiting expression of a

CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,

CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,

CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are

CC useful for preventing or treating a respiratory or lung disease. The

CC respiratory or lung disease is associated with hyper-responsiveness to

CC and/or increased levels of, adenosine and/or levels of adenosine A

CC receptor(s), and/or asthma and/or lung allergies associated with

CC inflammation or an inflammatory disease. The respiratory or lung disease

CC is chosen from airway inflammation, allergy, asthma, impeded respiration,

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),

CC allergic rhinitis, acute respiratory distress syndrome, pulmonary

CC hypertension, lung inflammation, bronchitis, airway obstruction or

CC bronchoconstriction. This sequence represents an oligonucleotide of the

XX CC invention.

XX SQ Sequence 20 BP; 5 A; 6 C; 2 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1901 CAGACATGATGATGATG 1920

DB 20 CAGACATGATGATGATG 1

RESULT 1339

ADO45744/c

ID ADO45744 standard; DNA; 20 BP.

XX AC ADO45744;

XX DT 15-JUL-2004 (first entry)

XX DE Human oligonucleotide #1110.

XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;

KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;

KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;

KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;

KW asthma; lung allergy; inflammation; inflammatory disease;

KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;

KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;

KW acute respiratory distress syndrome; pulmonary hypertension;

KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

OS Homo sapiens.

XX US2004049022-A1.

XX PD 11-MAR-2004.

XX PF 25-JUL-2003; 2003US-00627930.

XX PR 23-APR-2002; 2002WO-US013135.

XX PR 23-APR-2002; 2002WO-US013143.

XX NYCE/ NYCE J W.

PA (SAND//) SANDRASAGRA A.

PA (TANG//) TANG L.

PA (AGUI//) AGUILAR D.

PA (MILL//) MILLER S.

PA (SHAH//) SHAHABUDDIN S.

PA (LUH//) LU H.

PA (CONG//) CONG H.

XX NYCE JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,

PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.

PT asthma.

XX PS Claim 2; SEQ ID NO 1111; 174pp; English.

XX CC The invention relates to oligonucleotides anti-sense to an initiation

CC codon, coding region, 5' or 3' intron-exon junction, intron or region

CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target

CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)

CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,

CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention

CC also relates to a method of screening a candidate compound that binds to

CC one or more nucleic acid target(s) or expressed product(s), for the

CC prevention and/or treatment of a respiratory or lung disease. The

CC oligonucleotides are useful for reducing or inhibiting expression of a

CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,

CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,

CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are

CC useful for preventing or treating a respiratory or lung disease. The

CC respiratory or lung disease is associated with hyper-responsiveness to

CC and/or increased levels of, adenosine and/or levels of adenosine A

CC receptor(s), and/or asthma and/or lung allergies associated with

CC inflammation or an inflammatory disease. The respiratory or lung disease

CC is chosen from airway inflammation, allergy, asthma, impeded respiration,

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),

CC allergic rhinitis, acute respiratory distress syndrome, pulmonary

CC hypertension, lung inflammation, bronchitis, airway obstruction or

CC bronchoconstriction. This sequence represents an oligonucleotide of the

XX CC invention.

XX SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1801 TACAACAGCATTTGGGGCCA 1820

DB 20 TACAACAGCATTTGGGGCCA 1

RESULT 1340

ADO45818/c

ID ADO45818 standard; DNA; 20 BP.

XX AC ADO45818;

XX DT 15-JUL-2004 (first entry)

XX DE Human oligonucleotide #1184.

XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;

KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;

KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1185; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e-02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1061 ACCCTAGAGCCCAAGGTGACG 1080
 |||||

Db 20 ACCCTAGAGCCCAAGGTGACG 1
 RESULT 1341
 ADO45820/c
 ID ADO45820 standard; DNA; 20 BP.
 XX
 AC ADO45820;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 XX Human oligonucleotide #1186.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1187; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC invention.

CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GACAGTGAAGTGAGGCC 1060

Db 20 GACAGTGAAGTGAGGCC 1

RESULT 1342

ADO45841/c

ID ADO45841 standard; DNA; 20 BP.

XX ADO45841;

DT 15-JUL-2004 (first entry)

DE Human oligonucleotide #1207.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

XX (SAND/) SANDRASAGRA A.

XX (TANG/) TANG L.

XX (AGUI/) AGUILAR D.

XX (MILL/) MILLER S.

XX (SHAH/) SHAHABUDDIN S.

XX (LUHH/) LU H.

XX (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

XX Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,

PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.

PT asthma.

XX Claim 2; SEQ ID NO 1208; 174pp; English.

PS The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target

CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 831 GTTGAACCCACAGTCACCT 850

Db 20 GTTGAACCCACAGTCACCT 1

RESULT 1343

ADO45856/c

ID ADO45856 standard; DNA; 20 BP.

XX ADO45856;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1222.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;

CC CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;

KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;

KW acute respiratory distress syndrome; pulmonary hypertension;

KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

XX (SAND/) SANDRASAGRA A.

XX (TANG/) TANG L.

XX (AGUI/) AGUILAR D.

XX (MILL/) MILLER S.

XX (SHAH/) SHAHABUDDIN S.

XX (LUHH/) LU H.

XX (CONG/) CONG H.

PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRL,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1223; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCRL, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 681 GCTCCAGACCTTTGCTCTGC 700
 Db |||||
 20 GCTCCAGACCTTTGCTCTGC 1
 RESULT 1344
 ADO45886/c
 ID ADO45886 standard; DNA; 20 BP.
 XX ADO45886;
 AC ADO45886;
 XX
 XX 15-JUL-2004 (first entry)
 DT Human oligonucleotide #1252.
 DE
 XX Human; 88; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 OS
 XX US2004049022-A1.
 PN
 XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRL,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1253; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCRL, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 381 CGTGACTGCGACTCCAGAAC 400
 Db |||||
 20 CGTGACTGCGACTCCAGAAC 1
 RESULT 1345
 ADO45920/c
 ID ADO45920 standard; DNA; 20 BP.
 XX ADO45920;
 AC ADO45920;
 XX
 XX 15-JUL-2004 (first entry)
 DT Human oligonucleotide #1286.
 DE
 XX

Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5; CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a; tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease; lung disease; hyper-responsiveness; adenosine; adenosine A receptor; asthma; lung allergy; inflammation; inflammatory disease; airway inflammation; allergy; impeded respiration; cystic fibrosis; CF; chronic obstructive pulmonary disease; COPD; allergic rhinitis; acute respiratory distress syndrome; pulmonary hypertension; lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

OS Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

PR 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S; Shahabuddin S, Lu H, Cong H; WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g. PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1, PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g. PT asthma.

XX Claim 2; SEQ ID NO 1287; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation CC codon, coding region, 5' or 3' intron-exon junction, intron or region CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention CC also relates to a method of screening a candidate compound that binds to CC one or more nucleic acid target(s) or expressed product(s), for the CC prevention and/or treatment of a respiratory or lung disease. The CC oligonucleotides are useful for reducing or inhibiting expression of a CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor, CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are CC useful for preventing or treating a respiratory or lung disease. The CC respiratory or lung disease is associated with hyper-responsiveness to CC and/or increased levels of, adenosine and/or levels of adenosine A CC receptor(s), and/or asthma and/or lung allergies associated with CC inflammation or an inflammatory disease. The respiratory or lung disease CC is chosen from airway inflammation, allergy, asthma, impeded respiration, CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), CC allergic rhinitis, acute respiratory distress syndrome, pulmonary CC hypertension, lung inflammation, bronchitis, airway obstruction or CC bronchoconstriction. This sequence represents an oligonucleotide of the CC invention.

XX Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e-02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCTCGCTATG 60
 Db |||||
 20 GCAACCTCAGCCTCGCTATG 1

RESULT 1346
 ADO45924/C
 ID ADO45924 standard; DNA; 20 BP.
 AC ADO45924;
 XX
 XX 15-JUL-2004 (first entry)
 DT Human oligonucleotide #1290.
 DE
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5; CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a; tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease; lung disease; hyper-responsiveness; adenosine; adenosine A receptor; asthma; lung allergy; inflammation; inflammatory disease; airway inflammation; allergy; impeded respiration; cystic fibrosis; CF; chronic obstructive pulmonary disease; COPD; allergic rhinitis; acute respiratory distress syndrome; pulmonary hypertension; lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

PR 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S; Shahabuddin S, Lu H, Cong H; WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g. PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1, PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g. PT asthma.

XX Claim 2; SEQ ID NO 1291; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation CC codon, coding region, 5' or 3' intron-exon junction, intron or region CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention CC also relates to a method of screening a candidate compound that binds to CC one or more nucleic acid target(s) or expressed product(s), for the CC prevention and/or treatment of a respiratory or lung disease. The CC oligonucleotides are useful for reducing or inhibiting expression of a CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor, CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are CC useful for preventing or treating a respiratory or lung disease. The CC respiratory or lung disease is associated with hyper-responsiveness to CC and/or increased levels of, adenosine and/or levels of adenosine A

CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 2 A; 7 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GCGCCCCAGTCGACGCTGAG 20
 Db 20 GCGCCCCAGTCGACGCTGAG 1

RESULT 1347
 ADO45747/c
 ID ADO45747 standard; DNA; 20 BP.
 XX
 AC ADO45747;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1113.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1114; 174pp; English.
 PS
 XX The invention relates to oligonucleotides anti-sense to an initiation

CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1771 CCGGAGGACAGGGCATTGTC 1790
 Db 20 CCGGAGGACAGGGCATTGTC 1

RESULT 1348
 ADO45770/c
 ID ADO45770 standard; DNA; 20 BP.
 XX
 AC ADO45770;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1136.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.

PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1137; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1541 CTGCAGGCTCAGCAGGTAC 1560
 Db |||||
 20 CTGCAGGCTCAGCAGGTAC 1
 RESULT 1349
 ADO45787/C
 ID ADO45787 standard; DNA; 20 BP.
 XX
 AC ADO45787;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1153.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 OS Homo sapiens.
 XX
 PN US2004049022-A1.

XX 11-MAR-2004.
 XX PD
 XX PF
 XX PR 25-JUL-2003; 2003US-00627930.
 XX PR 23-APR-2002; 2002WO-US013135.
 XX PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1154; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1371 ACTGCCCATCGGGGATCAG 1390
 Db |||||
 20 ACTGCCCATCGGGGATCAG 1
 RESULT 1350
 ADO45795/C
 ID ADO45795 standard; DNA; 20 BP.
 XX
 AC ADO45795;
 XX
 DT 15-JUL-2004 (first entry)
 XX

DE Human oligonucleotide #1161.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;

KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;

KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;

KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;

KW asthma; lung allergy; inflammation; inflammatory disease;

KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;

KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;

KW acute respiratory distress syndrome; pulmonary hypertension;

KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

PN 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

PR 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,

PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.

PT asthma.

XX Claim 2; SEQ ID NO 1162; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation

CC codon, coding region, 5' or 3' intron-exon junction, intron or region

CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target

CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)

CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,

CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention

CC also relates to a method of screening a candidate compound that binds to

CC one or more nucleic acid target(s) or expressed product(s), for the

CC prevention and/or treatment of a respiratory or lung disease. The

CC oligonucleotides are useful for reducing or inhibiting expression of a

CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,

CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,

CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are

CC useful for preventing or treating a respiratory or lung disease. The

CC and/or increased levels of, adenosine and/or levels of adenosine A

CC receptor(s), and/or asthma and/or lung allergies associated with

CC inflammation or an inflammatory disease. The respiratory or lung disease

CC is chosen from airway inflammation, allergy, asthma, impeded respiration,

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),

CC allergic rhinitis, acute respiratory distress syndrome, pulmonary

CC hypertension, lung inflammation, bronchitis, airway obstruction or

CC bronchoconstriction. This sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 4 A; 2 C; 7 G; 7 T; 0 U; 0 Other;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1291 AATTCGACGAGCTCCCAAT 1310

Db 20 AATTCGACGAGCTCCCAAT 1

RESULT 1351

AD045799/c

ID ADO45799 standard; DNA; 20 BP.

XX ADO45799;

AC XX

DT 15-JUL-2004 (first entry)

XX XX

DE Human oligonucleotide #1165.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;

KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;

KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;

KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;

KW asthma; lung allergy; inflammation; inflammatory disease;

KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;

KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;

KW acute respiratory distress syndrome; pulmonary hypertension;

KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

OS US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

PR 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,

PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.

PT asthma.

XX Claim 2; SEQ ID NO 1166; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation

CC codon, coding region, 5' or 3' intron-exon junction, intron or region

CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target

CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)

CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,

CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention

CC also relates to a method of screening a candidate compound that binds to

CC one or more nucleic acid target(s) or expressed product(s), for the

CC prevention and/or treatment of a respiratory or lung disease. The

CC oligonucleotides are useful for reducing or inhibiting expression of a

CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,

CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,

CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are

CC useful for preventing or treating a respiratory or lung disease. The

CC and/or increased levels of, adenosine and/or levels of adenosine A

CC receptor(s), and/or asthma and/or lung allergies associated with

CC inflammation or an inflammatory disease. The respiratory or lung disease

CC is chosen from airway inflammation, allergy, asthma, impeded respiration,

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),

CC allergic rhinitis, acute respiratory distress syndrome, pulmonary

CC hypertension, lung inflammation, bronchitis, airway obstruction or

CC bronchoconstriction. This sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 4 A; 2 C; 7 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 10 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1251 GGACGAGAGGATGTCGG 1270
 DB 20 GGACGAGAGGATGTCGG 1
 RESULT 1352
 ADO45813/c
 ID ADO45813 standard; DNA; 20 BP.
 XX
 AC ADO45813;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1179.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1180; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1111 CCGAGGGCCAGCTCTGCT 1130
 DB 20 CCGAGGGCCAGCTCTGCT 1
 RESULT 1353
 ADO45822/c
 ID ADO45822 standard; DNA; 20 BP.
 XX
 AC ADO45822;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1188.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRI,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1189; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1021 GTCTCAGAGGGACCGAGGT 1040
 ||||||||||||||||||
 Db 20 GTCTCAGAGGGACCGAGGT 1
 RESULT 1354
 AD045833/c
 ID AD045833 standard; DNA; 20 BP.
 AC
 AC AD045833;
 XX
 XX 15-JUL-2004 (first entry)
 XX Human oligonucleotide #1199.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCRI; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 OS

XX US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US0131135.
 XX 23-APR-2002; 2002WO-US0131143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRI,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1200; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 911 CCCAGCGGTGACGTGCA 930
 ||||||||||||||||||
 Db 20 CCCAGCGGTGACGTGCA 1
 RESULT 1355
 AD045838/c
 ID AD045838 standard; DNA; 20 BP.
 XX
 XX AD045838;
 XX

DT 15-JUL-2004 (first entry)
 XX Human oligonucleotide #1204.
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX Claim 2; SEQ ID NO 1205; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease. The
 XX respiratory or lung disease is associated with hyper-responsiveness to
 XX and/or increased levels of, adenosine and/or levels of adenosine A
 XX receptor(s), and/or asthma and/or lung allergies associated with
 XX inflammation or an inflammatory disease. The respiratory or lung disease
 XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
 XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
 XX hypertension, lung inflammation, bronchitis, airway obstruction or
 XX bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.

Sequence 20 BP; 5 A; 4 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 861 CTCCTTCTCGGCCAAGGCCT 880
 Db 20 CTCCTTCTCGGCCAAGGCCT 1
 RESULT 1356
 ADO45840/c
 ID ADO45840 standard; DNA; 20 BP.
 XX
 XX ADO45840;
 XX
 XX 15-JUL-2004 (first entry)
 XX Human oligonucleotide #1206.
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX OS
 XX US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX Claim 2; SEQ ID NO 1207; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease. The
 XX respiratory or lung disease is associated with hyper-responsiveness to
 XX and/or increased levels of, adenosine and/or levels of adenosine A
 XX receptor(s), and/or asthma and/or lung allergies associated with
 XX inflammation or an inflammatory disease. The respiratory or lung disease
 XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
 XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
 XX hypertension, lung inflammation, bronchitis, airway obstruction or
 XX bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.

CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 841 ACAGTCACCTATGGCAACGA 860
 DB 20 ACAGTCACCTATGGCAACGA 1

RESULT 1357
 ADO45844/c

ID ADO45844 standard; DNA; 20 BP.

XX AC ADO45844;

XX DT 15-JUL-2004 (first entry)

XX DE Human oligonucleotide #1210.

XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX OS Homo sapiens.

XX PN US2004049022-A1.

XX PD 11-MAR-2004.

XX PF 25-JUL-2003; 2003US-00627930.

XX PR 23-APR-2002; 2002WO-US013135.

XX PR 23-APR-2002; 2002WO-US013143.

XX PA (NYCE/) NYCE J W.

XX PA (SAND/) SANDRASAGRA A.

XX PA (AGUI/) AGUILAR D.

XX PA (MILL/) MILLER S.

XX PA (SHAH/) SHAHABUDDIN S.

XX PA (LUHH/) LU H.

XX PA (CONG/) CONG H.

XX PI NYCE JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1211; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 801 CCAGGTCCACCTGGCACTGG 820
 DB 20 CCAGGTCCACCTGGCACTGG 1

RESULT 1358
 ADO45846/c

ID ADO45846 standard; DNA; 20 BP.

XX AC ADO45846;

XX DT 15-JUL-2004 (first entry)

XX DE Human oligonucleotide #1212.

XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX OS Homo sapiens.

XX PN US2004049022-A1.

XX PD 11-MAR-2004.

XX PF 25-JUL-2003; 2003US-00627930.

XX PR 23-APR-2002; 2002WO-US013135.

XX PR 23-APR-2002; 2002WO-US013143.

XX PA (NYCE/) NYCE J W.

XX PA (SAND/) SANDRASAGRA A.

XX PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1213; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC chronic obstructive pulmonary disease, COPD, allergic rhinitis;
 CC acute respiratory distress syndrome; pulmonary hypertension;
 CC lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 781 CTGTTCCAGTCTCGGAGGC 800
 Db ||||||||||||||||||
 20 CTGTTCCAGTCTCGGAGGC 1
 RESULT 1359
 ADO45850/c
 ID ADO45850 standard; DNA; 20 BP.
 AC ADO45850;
 XX
 DT 15-JUL-2004 (first entry)
 XX Human oligonucleotide #1216.
 DE
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.
 OS US2004049022-A1.
 PN 11-MAR-2004.
 XX
 PD 25-JUL-2003; 2003US-00627930.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 23-APR-2002; 2002WO-US013143.
 PR
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1217; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 10 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 741 GTGTGACACGCGAGGACCG 760
 Db ||||||||||||||||||
 20 GTGTGACACGCGAGGACCG 1
 RESULT 1360
 ADO45888/c
 ID ADO45888 standard; DNA; 20 BP.
 XX

AC ADO45888;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1254.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 PD
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 PR
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1255; 174pp; English.
 PS
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

SQ Sequence 20 BP; 4 A; 1 C; 8 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 361 ACAGCTAAACCTTCCTCAC 380
 DB 20 ACAGCTAAACCTTCCTCAC 1
 RESULT 1361
 ADO45898/c
 ID ADO45898 standard; DNA; 20 BP.
 XX
 AC ADO45898;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 XX Human oligonucleotide #1264.
 DE
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease; cystic fibrosis; CF;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 PR
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1265; 174pp; English.
 PS
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 261 GTTGCTCTGCTGGGAACA 280
 Db |||||
 20 GTTGCTCTGCTGGGAACA 1
 RESULT 1362
 ADO45918/c
 ID ADO45918 standard; DNA; 20 BP.
 XX
 AC ADO45918;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1284.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,

PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1285; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 5 C; 12 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 61 GTTCCAGCAGCCCCCGGCC 80
 Db |||||
 20 GTTCCAGCAGCCCCCGGCC 1
 RESULT 1363
 ADO45717/c
 ID ADO45717 standard; DNA; 20 BP.
 XX
 AC ADO45717;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1083.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1084; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 2 A; 3 C; 5 G; 10 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2070 TAGCATCAAAACACAAAGGC 2089
 Db ||||||||||||||||
 20 TAGCATCAAAACACAAAGGC 1
 RESULT 1364
 ADO45723/c
 ID ADO45723 standard; DNA; 20 BP.
 XX
 XX ADO45723;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 XX Human oligonucleotide #1089.
 XX
 XX Human; ss: interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;

KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1090; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2011 CTATTGGGTATGCTGAGGCC 2030
 Db ||||||||||||||||
 20 CTATTGGGTATGCTGAGGCC 1
 RESULT 1365
 ADO45731/c

XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX NYCE JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI: 2004-293804/27.
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX Claim 2; SEQ ID NO 1116; 174pp; English.
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
XX invention.
XX Sequence 20 BP; 2 A; 6 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1751 CACCTACCGCCCTGGAGC 1770
DB 20 CACCTACCGCCCTGGAGC 1
RESULT 1369
ADO45758/c
ID ADO45758 standard; DNA; 20 BP.
XX ADO45758;
XX 15-JUL-2004 (first entry)
XX Human oligonucleotide #1124.
XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;

KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
OS Homo sapiens.
XX US2004049022-A1.
XX 11-MAR-2004.
XX 25-JUL-2003; 2003US-00627930.
XX 23-APR-2002; 2002WO-US013135.
XX 23-APR-2002; 2002WO-US013143.
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX NYCE JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI: 2004-293804/27.
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX Claim 2; SEQ ID NO 1125; 174pp; English.
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
XX invention.
XX Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1661 ATCCCGGGACAGGGCCTCTT 1680
DB 20 ATCCCGGGACAGGGCCTCTT 1

RESULT 1370
 ADO45773/c
 ID ADO45773 standard; DNA; 20 BP.
 XX
 AC ADO45773;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1139.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1140; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary

CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1511 CTGTGGTAGCAGCGCAGTC 1530
 Db 20 CTGTGGTAGCAGCGCAGTC 1
 RESULT 1371
 ADO45774/c
 ID ADO45774 standard; DNA; 20 BP.
 XX
 AC ADO45774;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 XX Human oligonucleotide #1140.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1141; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary

CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1501 GTCATCATCACTGTGGTAGC 1520

DB 20 GTCATCATCACTGTGGTAGC 1

RESULT 1372

ADO45777/c

ID ADO45777 standard; DNA; 20 BP.

AC ADO45777;

DT 15-JUL-2004 (first entry)

DE Human oligonucleotide #1143.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUILAR/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX

DR WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1144; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1471 GTGAATGTCTCTCCCCCG 1490

DB 20 GTGAATGTCTCTCCCCCG 1

RESULT 1373

ADO45814/c

ID ADO45814 standard; DNA; 20 BP.

XX ADO45814;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1180.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX

```

PR 23-APR-2002; 2002WO-US0113135.
PR 23-APR-2002; 2002WO-US0113143.
XX
PA (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRL,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 1181; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC inflammation, and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
XX invention.
XX
XX Sequence 20 BP; 1 A; 8 C; 9 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1101 GCCACTGGGCCCGAGGCC 1120
XX |||||
XX 20 GCCACTGGGCCCGAGGCC 1
XX
RESULT 1374
AD045821/c
ID AD045821 standard; DNA; 20 BP.
XX
XX AD045821;
XX
XX 15-JUL-2004 (first entry)
XX
XX Human oligonucleotide #1187.
XX
XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
XX CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
XX tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
XX

```

```

KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
XX Homo sapiens.
XX
XX US2004049022-A1.
XX
XX 11-MAR-2004.
XX
XX 25-JUL-2003; 2003US-00627930.
XX
XX 23-APR-2002; 2002WO-US0113135.
XX 23-APR-2002; 2002WO-US0113143.
XX
XX (NYCE/) NYCE J W.
XX (SAND/) SANDRASAGRA A.
XX (TANG/) TANG L.
XX (AGUI/) AGUILAR D.
XX (MILL/) MILLER S.
XX (SHAH/) SHAHABUDDIN S.
XX (LUHH/) LU H.
XX (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRL,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 1188; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
XX invention.
XX
XX Sequence 20 BP; 2 A; 9 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1031 GGACCGAGGTGACAGTGAAG 1050
XX |||||
XX 20 GGACCGAGGTGACAGTGAAG 1
XX

```

RESULT 1375
 ADO45839/c
 ID ADO45839 standard; DNA; 20 BP.
 XX
 AC ADO45839;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 XX Best Local Similarity 100.0%; Pred.No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX Human oligonucleotide #1205.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX
 XX Claim 2; SEQ ID NO 1206; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease. The
 XX respiratory or lung disease is associated with hyper-responsiveness to
 XX and/or increased levels of, adenosine and/or levels of adenosine A
 XX receptor(s), and/or asthma and/or lung allergies associated with
 XX inflammation or an inflammatory disease. The respiratory or lung disease
 XX is chosen from airway inflammation, allergy, asthma, impeded respiration,

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred.No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 851 ATGGCAACGACTCTCTCTCG 870
 Db 20 ATGGCAACGACTCTCTCTCG 1
 RESULT 1376
 ADO45896/c
 ID ADO45896 standard; DNA; 20 BP.
 XX
 AC ADO45896;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 XX Human oligonucleotide #1262.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX
 XX Claim 2; SEQ ID NO 1263; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)

CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 281 ACCGGAAGGTGTATGAACGTG 300
 Db |||||
 20 ACCGGAAGGTGTATGAACGTG 1
 RESULT 1377
 ADO46429
 ID ADO46429 standard; DNA; 20 BP.
 XX
 AC ADO46429;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1795.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1796; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2771 CCCAGGCTGGAGTGCAGTGG 2790
 Db |||||
 1 CCCAGGCTGGAGTGCAGTGG 20
 RESULT 1378
 ADO45719/C
 ID ADO45719 standard; DNA; 20 BP.
 XX
 AC ADO45719;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1085.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.

PF 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1086; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC triptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2050 TGGCCCTCCATAGCATGTG 2069
 Db |||||
 20 TGGCCCTCCATAGCATGTG 1
 RESULT 1379
 AD045721/c
 ID AD045721 standard; DNA; 20 BP.
 XX
 AC AD045721;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1087.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;

KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease; CF;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CP;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1088; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 4 C; 5 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2030 CCACAGACTTACAGAGAAG 2049

Db 20 CCACAGACTTACAGAGAG 1
 RESULT 1380
 ID ADO45738/c
 ID ADO45738 standard; DNA; 20 BP.
 XX ADO45738;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1104.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 CC CR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 XX
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 PS Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1105; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with

CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1861 CTGTAGTCACATGACTTAAGC 1880
 Db 20 CTGTAGTCACATGACTTAAGC 1
 RESULT 1381
 ID ADO45760/c
 ID ADO45760 standard; DNA; 20 BP.
 XX ADO45760;
 AC ADO45760;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1126.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 CC CR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 XX
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 PS Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1127; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region

CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 3 C; 10 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1641 AGCCAGCGCTCCTGACCT 1660
 DB |||||
 20 AGCCAGCGCTCCTGACCT 1
 RESULT 1382
 ADO45784/C
 ID ADO45784 standard; DNA; 20 BP.
 AC ADO45784;
 XX
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1150.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; COPD; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.

XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 DR WPI; 2004-293804/27.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1151; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1401 TCGAGATCTTGAGGCACCT 1420
 DB |||||
 20 TCGAGATCTTGAGGCACCT 1
 RESULT 1383
 ADO45786/C
 ID ADO45786 standard; DNA; 20 BP.
 XX ADO45786;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1152.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; COPD; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX

QY 1201 ATACAGAAGAACGAGCCG 1220
 DB 20 ATACAGAAGAACGAGCCG 1
 RESULT 1385
 ADO45872/c
 ID ADO45872 standard; DNA; 20 BP.
 XX
 AC ADO45872;
 XX
 DT 15-JUL-2004 (first entry)
 DE
 DE Human oligonucleotide #1238.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; COPD; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1239; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to

CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 8 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 521 AGGAGCTGAACCGGAGCCCA 540
 DB 20 AGGAGCTGAACCGGAGCCCA 1
 RESULT 1386
 ADO45912/c
 ID ADO45912 standard; DNA; 20 BP.
 XX
 AC ADO45912;
 XX
 DT 15-JUL-2004 (first entry)
 DE
 DE Human oligonucleotide #1278.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; COPD; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1279; 174pp; English.
 XX
 XX

CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 121 CCAGGACCTGGCAATGCCCA 140
 DB 20 CCAGGACCTGGCAATGCCCA 1
 RESULT 1387
 ADO45921/c
 ID ADO45921 standard; DNA; 20 BP.
 XX
 AC ADO45921;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1287.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX
 XX (SAND/) SANDRASAGRA A.
 XX
 XX (TANG/) TANG L.
 XX
 XX (AGUI/) AGUILAR D.
 XX
 XX (MILL/) MILLER S.
 XX
 XX (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1288; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 31 ACTCAGAGTTGCAACCTCAG 50
 DB 20 ACTCAGAGTTGCAACCTCAG 1
 RESULT 1398
 ADO45718/c
 ID ADO45718 standard; DNA; 20 BP.
 XX
 AC ADO45718;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1084.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX

PN US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1085; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from asthma, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 5 A; 4 C; 3 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e-02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2060 TAGACATGTGTAGCATCAA 2079
 |||||
 Db 20 TAGACATGTGTAGCATCAA 1
 RESULT 1389
 ADO45743/C
 ID ADO45743 standard; DNA; 20 BP.
 XX
 AC ADO45743;
 XX
 DT 15-JUL-2004 (first entry)

Human oligonucleotide #1109.
 Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 asthma; lung allergy; inflammation; inflammatory disease;
 airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 acute respiratory distress syndrome; pulmonary hypertension;
 lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 Homo sapiens.
 US2004049022-A1.
 11-MAR-2004.
 25-JUL-2003; 2003US-00627930.
 23-APR-2002; 2002WO-US013135.
 23-APR-2002; 2002WO-US013143.
 (NYCE/) NYCE J W.
 (SAND/) SANDRASAGRA A.
 (TANG/) TANG L.
 (AGUI/) AGUILAR D.
 (MILL/) MILLER S.
 (SHAH/) SHAHABUDDIN S.
 (LUHH/) LU H.
 (CONG/) CONG H.
 Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 Shahabuddin S, Lu H, Cong H;
 WPI; 2004-293804/27.
 Novel single or multiple target oligonucleotide anti-sense to e.g.
 initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 asthma.
 Claim 2; SEQ ID NO 1110; 174pp; English.
 The invention relates to oligonucleotides anti-sense to an initiation
 codon, coding region, 5' or 3' intron-exon junction, intron or region
 with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 also relates to a method of screening a candidate compound that binds to
 one or more nucleic acid target(s) or expressed product(s), for the
 prevention and/or treatment of a respiratory or lung disease. The
 oligonucleotides are useful for reducing or inhibiting expression of a
 gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 useful for preventing or treating a respiratory or lung disease. The
 respiratory or lung disease is associated with hyper-responsiveness to
 and/or increased levels of, adenosine and/or levels of adenosine A
 receptor(s), and/or asthma and/or lung allergies associated with
 inflammation or an inflammatory disease. The respiratory or lung disease
 is chosen from asthma, allergy, asthma, impeded respiration,
 cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 allergic rhinitis, acute respiratory distress syndrome, pulmonary
 hypertension, lung inflammation, bronchitis, airway obstruction or
 bronchoconstriction. This sequence represents an oligonucleotide of the
 invention.
 Sequence 20 BP; 6 A; 7 C; 5 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02; Mismatches 0; Conservative 0; Indels 0; Gaps 0;

QY 1811 TTTGGGGCCATGCTACTGC 1830
 |||||
 Db 20 TTTGGGGCCATGCTACTGC 1

RESULT 1390
 ADO45759/c
 ID ADO45759 standard; DNA; 20 BP.
 AC ADO45759;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1125.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1126; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are

CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.
 XX
 SQ Sequence 20 BP; 3 A; 4 C; 9 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1651 CCCTGAACCTATCCCGGAC 1670
 |||||
 Db 20 CCCTGAACCTATCCCGGAC 1

RESULT 1391
 ADO45828/c
 ID ADO45828 standard; DNA; 20 BP.
 XX
 AC ADO45828;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1194.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX

PS Claim 2; SEQ ID NO 1195; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation

CC codon, coding region, 5' or 3' intron-exon junction, intron or region

CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target

CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)

CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,

CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention

CC also relates to a method of screening a candidate compound that binds to

CC one or more nucleic acid target(s) or expressed product(s), for the

CC prevention and/or treatment of a respiratory or lung disease. The

CC oligonucleotides are useful for reducing or inhibiting expression of a

CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,

CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,

CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are

CC useful for preventing or treating a respiratory or lung disease. The

CC and/or increased levels of, adenosine and/or levels of adenosine A

CC receptor(s), and/or asthma and/or lung allergies associated with

CC inflammation or an inflammatory disease. The respiratory or lung disease

CC is chosen from airway inflammation, allergy, asthma, impaired respiration,

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),

CC allergic rhinitis, acute respiratory distress syndrome, pulmonary

CC hypertension, lung inflammation, bronchitis, airway obstruction or

CC bronchoconstriction. This sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 4 A; 4 C; 6 G; 6 T; 0 U; 0 Other;

SQ

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 961 CTCGACAGGTGACCATCTA 980

DB 20 CTCGACAGGTGACCATCTA 1

RESULT 1392

ADO45831/c

ID ADO45831 standard; DNA; 20 BP.

XX

AC ADO45831;

XX

15-JUL-2004 (first entry)

XX

Human oligonucleotide #1197.

XX

Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;

KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;

KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;

KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;

KW asthma; lung allergy; inflammation; inflammatory disease;

KW airway inflammation; allergy; impaired respiration; cystic fibrosis; CF;

KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;

KW acute respiratory distress syndrome; pulmonary hypertension;

KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

OS Homo sapiens.

XX

US2004049022-A1.

XX

11-MAR-2004.

XX

25-JUL-2003; 2003US-00627930.

XX

23-APR-2002; 2002WO-US013135.

PR

23-APR-2002; 2002WO-US013143.

XX

(NYCE/J) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

XX (CONG/) CONG H.

PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

XX Shahabuddin S, Lu H, Cong H;

PI WPI; 2004-293804/27.

DR

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,

PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.

PT asthma.

XX Claim 2; SEQ ID NO 1198; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation

CC codon, coding region, 5' or 3' intron-exon junction, intron or region

CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target

CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)

CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,

CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention

CC also relates to a method of screening a candidate compound that binds to

CC one or more nucleic acid target(s) or expressed product(s), for the

CC prevention and/or treatment of a respiratory or lung disease. The

CC oligonucleotides are useful for reducing or inhibiting expression of a

CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,

CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,

CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are

CC useful for preventing or treating a respiratory or lung disease. The

CC respiratory or lung disease is associated with hyper-responsiveness to

CC and/or increased levels of, adenosine and/or levels of adenosine A

CC receptor(s), and/or asthma and/or lung allergies associated with

CC inflammation or an inflammatory disease. The respiratory or lung disease

CC is chosen from airway inflammation, allergy, asthma, impaired respiration,

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),

CC allergic rhinitis, acute respiratory distress syndrome, pulmonary

CC hypertension, lung inflammation, bronchitis, airway obstruction or

CC bronchoconstriction. This sequence represents an oligonucleotide of the

CC invention.

XX

SQ Sequence 20 BP; 3 A; 7 C; 3 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 931 GTAATACTGGGAACCCAGAG 950

DB 20 GTAATACTGGGAACCCAGAG 1

RESULT 1393

ADO45855/c

ID ADO45855 standard; DNA; 20 BP.

XX

AC ADO45855;

XX

15-JUL-2004 (first entry)

XX

Human oligonucleotide #1221.

XX

Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;

KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;

KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;

KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;

KW asthma; lung allergy; inflammation; inflammatory disease;

KW airway inflammation; allergy; impaired respiration; cystic fibrosis; CF;

KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;

KW acute respiratory distress syndrome; pulmonary hypertension;

KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX

OS Homo sapiens.
 XX US2004049022-A1.
 PN XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCRI,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1222; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5,4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 691 TTGTGCTCTCCAGCGACTCC 710
 |||||||||
 Db 20 TTGTGCTCTCCAGCGACTCC 1
 RESULT 1394
 ADO45880/c
 ID ADO45880 standard; DNA; 20 BP.
 XX
 AC ADO45880;

XX 15-JUL-2004 (first entry)
 DT
 XX Human oligonucleotide #1246.
 DE
 XX
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 PN
 XX 11-MAR-2004.
 PD
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCRI,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1247; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 441 CAAGAACCTTACCTAGGCT 460
 DB 20 CAAGAACCTTACCTAGGCT 1

RESULT 1395
 ADO45882/C
 ID ADO45882 standard; DNA; 20 BP.

XX AC ADO45882;

XX DT 15-JUL-2004 (first entry)

XX DE Human oligonucleotide #1248.

XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX OS Homo sapiens.

XX XX US2004049022-A1.

XX XX 11-MAR-2004.

XX PF 25-JUL-2003; 2003US-00627930.

XX XX 23-APR-2002; 2002WO-US013135.

XX PR 23-APR-2002; 2002WO-US013143.

XX XX (NYCE/) NYCE J W.

XX PA (SAND/) SANDRASAGRA A.

XX PA (TANG/) TANG L.

XX PA (AGUI/) AGUILAR D.

XX PA (MILL/) MILLER S.

XX PA (SHAH/) SHAHABUDDIN S.

XX PA (LUHH/) LU H.

XX PA (CONG/) CONG H.

XX PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX XX WPI; 2004-293804/27.

XX DR Novel single or multiple target oligonucleotide anti-sense to e.g.

XX PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,

XX PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.

XX PT asthma.

XX PS Claim 2; SEQ ID NO 1249; 174pp; English.

XX CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,

CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the

XX SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 421 CCCTCTTGGCAGCCAGTGGG 440

DB 20 CCCTCTTGGCAGCCAGTGGG 1

RESULT 1396

ADO45903/C

ID ADO45903 standard; DNA; 20 BP.

XX AC ADO45903;

XX XX

XX DT 15-JUL-2004 (first entry)

XX DE Human oligonucleotide #1269.

XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX OS Homo sapiens.

XX XX US2004049022-A1.

XX XX 11-MAR-2004.

XX XX 25-JUL-2003; 2003US-00627930.

XX XX 23-APR-2002; 2002WO-US013135.

XX PR 23-APR-2002; 2002WO-US013143.

XX XX (NYCE/) NYCE J W.

XX PA (SAND/) SANDRASAGRA A.

XX PA (TANG/) TANG L.

XX PA (AGUI/) AGUILAR D.

XX PA (MILL/) MILLER S.

XX PA (SHAH/) SHAHABUDDIN S.

XX PA (LUHH/) LU H.

XX PA (CONG/) CONG H.

XX PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX XX WPI; 2004-293804/27.

XX DR Novel single or multiple target oligonucleotide anti-sense to e.g.

XX PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,

XX PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.

PT asthma.
XX
PS Claim 2; SEQ ID NO 1270; 174pp; English.
XX
CC The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 211 TGTGACGACGCCAAGTTGTT 230
DB |||||
20 TGTGACGACGCCAAGTTGTT 1

RESULT 1397
ADO45915/C
ID ADO45915 standard; DNA; 20 BP.
XX
AC ADO45915;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human oligonucleotide #1281.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS Homo sapiens.
XX
XX US2004049022-A1.
XX
XX 11-MAR-2004.
XX
XX 25-JUL-2003; 2003US-00627930.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
DR
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
PS Claim 2; SEQ ID NO 1282; 174pp; English.
XX
CC The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 5 A; 6 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 91 GCACCTCGTGGTCTGCTCGG 110
DB |||||
20 GCACCTCGTGGTCTGCTCGG 1

RESULT 1398
ADO45732/C
ID ADO45732 standard; DNA; 20 BP.
XX
AC ADO45732;
XX
XX 15-JUL-2004 (first entry)
XX
XX Human oligonucleotide #1098.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW acute respiratory distress syndrome; pulmonary hypertension;

KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRI,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1099; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 6 A; 5 C; 3 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1921 TTAAGTCTAGCCTGATGAG 1940
 Db |||||
 20 TTAAGTCTAGCCTGATGAG 1
 RESULT 1399
 ADO45751/c
 ID ADO45751 standard; DNA; 20 BP.

XX ADO45751;
 XX 15-JUL-2004 (first entry)
 DT Human oligonucleotide #1117.
 XX
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRI,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1118; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX
SQ Sequence 20 BP; 4 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1731 AGACATATGCCATGCGAGCTA 1750
DB 20 AGACATATGCCATGCGAGCTA 1

RESULT 1400
ADO45756/c
ID ADO45756 standard; DNA; 20 BP.

XX
AC ADO45756;

XX
DT 15-JUL-2004 (first entry)

XX
DE Human oligonucleotide #1122.

XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX
OS Homo sapiens.

XX
PN US2004049022-A1.

XX
PD 11-MAR-2004.

XX
PF 25-JUL-2003; 2003US-00627930.

XX
PR 23-APR-2002; 2002WO-US013135.

XX
PR 23-APR-2002; 2002WO-US013143.

XX
PA (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX
PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;

XX
WPI; 2004-293804/27.

XX
Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.

XX
FS Claim 2; SEQ ID NO 1123; 174pp; English.

XX
CC The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The

CC
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.

XX
SQ Sequence 20 BP; 6 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1681 CCTCGGCGCTTCCCATATTGG 1700
DB 20 CCTCGGCGCTTCCCATATTGG 1

RESULT 1401
ADO45771/c
ID ADO45771 standard; DNA; 20 BP.

XX
AC ADO45771;

XX
DT 15-JUL-2004 (first entry)

XX
DE Human oligonucleotide #1137.

XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX
OS Homo sapiens.

XX
PN US2004049022-A1.

XX
PD 11-MAR-2004.

XX
PF 25-JUL-2003; 2003US-00627930.

XX
PR 23-APR-2002; 2002WO-US013135.

XX
PR 23-APR-2002; 2002WO-US013143.

XX
PA (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX
PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;

XX
WPI; 2004-293804/27.

XX
Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1138; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1531 ATATGGGCACTGCAGGCT 1550
 |||||
 Db 20 ATATGGGCACTGCAGGCT 1

RESULT 1402

ADO45793/c

ID ADO45793 standard; DNA; 20 BP.

XX ADO45793;

DT 15-JUL-2004 (first entry)

DE Human oligonucleotide #1159.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

OS US2004049022-A1.

PN 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

PR 23-APR-2002; 2002WO-US013143.

XX

PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX MPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1160; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 3 A; 9 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1311 GTGCCAGGCTTGGGGGAACC 1330
 |||||
 Db 20 GTGCCAGGCTTGGGGGAACC 1

RESULT 1403

ADO45807/c

ID ADO45807 standard; DNA; 20 BP.

XX ADO45807;

DT 15-JUL-2004 (first entry)

XX Human oligonucleotide #1173.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;

KW Chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 XX Homo sapiens.
 OS
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRL,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1174; 174pp; English.
 PS
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1171 TCTGCACCTCGAGGTGGC 1190
 |||||
 Db 20 TCTGCACCTCGAGGTGGC 1
 RESULT 1404

AD045810/c
 ID AD045810 standard; DNA; 20 BP.
 XX
 AC AD045810;
 XX
 XX 15-JUL-2004 (first entry)
 DT
 XX
 DE Human oligonucleotide #1176.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 PN
 XX
 XX 11-MAR-2004.
 PD
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRL,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1177; 174pp; English.
 PS
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1171 TCTGCACCTCGAGGTGGC 1190
 |||||
 Db 20 TCTGCACCTCGAGGTGGC 1
 RESULT 1404

CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 0 A; 8 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1141 CCAGAGGACAAACGGCGCAG 1160
 Db 20 CCAGAGGACAAACGGCGCAG 1
 RESULT 1405
 ADO45815/c
 ID ADO45815 standard; DNA; 20 BP.
 XX
 AC ADO45815;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1181.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1182; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to

CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 5 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1091 TTCCAGCCCGACCTGGGC 1110
 Db 20 TTCCAGCCCGACCTGGGC 1
 RESULT 1406
 ADO45819/c
 ID ADO45819 standard; DNA; 20 BP.
 XX
 AC ADO45819;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 XX Human oligonucleotide #1185.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.


```

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
PS Claim 2; SEQ ID NO 1196; 174pp; English.
XX
CC The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1051 TGTGAGGCCACCTAGAGC 1070
Db 20 TGTGAGGCCACCTAGAGC 1
RESULT 1407
AD045829/c
ID AD045829 standard; DNA; 20 BP.
XX
AC AD045829;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human oligonucleotide #1195.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS Homo sapiens.
XX
PN US2004049022-A1.
XX
PD 11-MAR-2004.
XX
FF 25-JUL-2003; 2003US-00627930.
XX
XX 23-APR-2002; 2002WO-US013135.

```

```

PR 23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
PS Claim 2; SEQ ID NO 1196; 174pp; English.
XX
CC The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 1 A; 6 C; 6 G; 7 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 951 CCAGAGACACATGCAGACAG 970
Db 20 CCAGAGACACATGCAGACAG 1
RESULT 1408
AD045848/c
ID AD045848 standard; DNA; 20 BP.
XX
AC AD045848;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human oligonucleotide #1214.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;

```

KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX
 XX Claim 2; SEQ ID NO 1215; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease. The
 XX respiratory or lung disease is associated with hyper-responsiveness to
 XX and/or increased levels of, adenosine and/or levels of adenosine A
 XX receptor(s), and/or asthma and/or lung allergies associated with
 XX inflammation, lung inflammation, bronchitis, asthma, impeded respiration,
 XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
 XX hypertension, lung inflammation, bronchitis, airway obstruction or
 XX bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.
 XX
 XX Sequence 20 BP; 6 A; 8 C; 5 G; 1 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 761 TGGTCTGTTCCCTGGACGGG 780
 DB 20 TGGTCTGTTCCCTGGACGGG 1

RESULT 1409
 ADO45852/c
 ID ADO45852 standard; DNA; 20 BP.
 XX
 XX ADO45852;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 XX Human oligonucleotide #1218.
 XX
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 XX CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 XX tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 XX lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 XX asthma; lung allergy; inflammation; inflammatory disease;
 XX airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 XX chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 XX acute respiratory distress syndrome; pulmonary hypertension;
 XX lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 XX Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX
 XX Claim 2; SEQ ID NO 1219; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease. The
 XX respiratory or lung disease is associated with hyper-responsiveness to
 XX and/or increased levels of, adenosine and/or levels of adenosine A
 XX receptor(s), and/or asthma and/or lung allergies associated with
 XX inflammation or an inflammatory disease. The respiratory or lung disease
 XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
 XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),

CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 GTGAGCCCCCGGCTCCTAGA 740
 DB 20 GTGAGCCCCCGGCTCCTAGA 1

RESULT 1410
 ADO45869/C
 ID ADO45869 standard; DNA; 20 BP.
 XX
 AC ADO45869;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1235.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1,
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1236; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,

CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 2 A; 6 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 551 AGCCCGCTGAGTCAAGACC 570
 DB 20 AGCCCGCTGAGTCAAGACC 1

RESULT 1411
 ADO45873/C
 ID ADO45873 standard; DNA; 20 BP.
 XX
 AC ADO45873;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1239.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1240; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 2 A; 10 C; 2 G; 6 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 511 CGTGGGAGAGAGGCTGAA 530
 Db ||||||||||||||||||
 20 CGTGGGAGAGAGGCTGAA 1
 RESULT 1412
 ADO45892/C
 ID ADO45892 standard; DNA; 20 BP.
 XX ADO45892;
 AC
 XX 15-JUL-2004 (first entry)
 DT
 XX Human oligonucleotide #1258.
 DE
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 OS
 XX US2004049022-A1.
 PN
 XX 11-MAR-2004.
 PD
 XX 25-JUL-2003; 2003US-00627930.
 PF

XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1259; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 5 A; 2 C; 6 G; 7 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 321 CCAACCAATGCTATTCAA 340
 Db ||||||||||||||||||
 20 CCAACCAATGCTATTCAA 1
 RESULT 1413
 ADO45909/C
 ID ADO45909 standard; DNA; 20 BP.
 XX ADO45909;
 AC
 XX 15-JUL-2004 (first entry)
 DT
 XX Human oligonucleotide #1275.
 DE
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;

KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX (NYCE) NYCE J W, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1276; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 5 A; 1 C; 9 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e-02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 151 TCCCGCTCAAAAGTCATCCT 170
 |||||||||

Db 20 TCCCGCTCAAAAGTCATCCT 1
 RESULT 1414
 ID ADO45730/c
 ID ADO45730 standard; DNA; 20 BP.
 XX
 AC ADO45730;
 XX
 XX 15-JUL-2004 (first entry)
 DT
 XX
 DE Human oligonucleotide #1096.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 PN
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1097; 174pp; English.
 PS
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

SQ Sequence 20 BP; 2 A; 13 C; 0 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1941 AGGGGAAGTGGTGGGGAGA 1960
 ID ADO45733 standard; DNA; 20 BP.
 DB 20 AGGGGAAGTGGTGGGGAGA 1

RESULT 1415
 ADO45733/c
 ID ADO45733 standard; DNA; 20 BP.

XX ADO45733;

DT 15-JUL-2004 (first entry)

DE Human oligonucleotide #1099.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

XX (SAND/) SANDRASAGRA A.

XX (TANG/) TANG L.

XX (AGUI/) AGUILAR D.

XX (MILL/) MILLER S.

XX (SHAH/) SHAHABUDDIN S.

XX (LUHH/) LU H.

XX (CONG/) CONG H.

PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1100; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target

CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

SQ Sequence 20 BP; 8 A; 5 C; 1 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1911 TTGATGGATGTTAAAGTCTA 1930

DB 20 TTGATGGATGTTAAAGTCTA 1

RESULT 1416

ADO45768/c

ID ADO45768 standard; DNA; 20 BP.

XX

AC ADO45768;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1134.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

XX (SAND/) SANDRASAGRA A.

XX (TANG/) TANG L.

XX (AGUI/) AGUILAR D.

XX (MILL/) MILLER S.

XX (SHAH/) SHAHABUDDIN S.

XX (LUHH/) LU H.

XX (CONG/) CONG H.

PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRL,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1135; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 3 A; 4 C; 7 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1561 CTCTATAACCGCCGCGGAA 1580
 Db ||||||||||||||||||
 20 CTCTATAACCGCCGCGGAA 1
 RESULT 1417
 ADO45832/c
 ID ADO45832 standard; DNA; 20 BP.
 XX ADO45832;
 AC ADO45832;
 XX 15-JUL-2004 (first entry)
 DT Human oligonucleotide #1198.
 DE
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 OS
 XX US2004049022-A1.
 PN
 XX 11-MAR-2004.
 PD

XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-293804/27.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCRL,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1199; 174pp; English.
 PS The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 921 GACGTGTGCAGTAATACTGG 940
 Db ||||||||||||||||||
 20 GACGTGTGCAGTAATACTGG 1
 RESULT 1418
 ADO45834/c
 ID ADO45834 standard; DNA; 20 BP.
 XX ADO45834;
 AC ADO45834;
 XX 15-JUL-2004 (first entry)
 DT Human oligonucleotide #1200.
 DE
 XX

Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5; CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a; tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease; lung disease; hyper-responsiveness; adenosine; adenosine A receptor; asthma; lung allergy; inflammation; inflammatory disease; airway inflammation; allergy; impeded respiration; cystic fibrosis; CF; chronic obstructive pulmonary disease; COPD; allergic rhinitis; acute respiratory distress syndrome; pulmonary hypertension; lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

OS Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

PR 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S; Shahabuddin S, Lu H, Cong H; WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1, initiation codon, intron of respiratory disease-relevant gene e.g. CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g. asthma.

XX Claim 2; SEQ ID NO 1201; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation codon, coding region, 5' or 3' intron-exon junction, intron or region with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention also relates to a method of screening a candidate compound that binds to one or more nucleic acid target(s) or expressed product(s), for the prevention and/or treatment of a respiratory or lung disease. The oligonucleotides are useful for reducing or inhibiting expression of a gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention also relates to a method of screening a candidate compound that binds to one or more nucleic acid target(s) or expressed product(s), for the prevention and/or treatment of a respiratory or lung disease. The oligonucleotides are useful for reducing or inhibiting expression of a gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The oligonucleotides are useful for preventing or treating a respiratory or lung disease. The respiratory or lung disease is associated with hyper-responsiveness to and/or increased levels of, adenosine and/or levels of adenosine A receptor(s), and/or asthma and/or lung allergies associated with inflammation or an inflammatory disease. The respiratory or lung disease is chosen from airway inflammation, allergy, asthma, impeded respiration, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), allergic rhinitis, acute respiratory distress syndrome, pulmonary hypertension, lung inflammation, bronchitis, airway obstruction or bronchoconstriction. This sequence represents an oligonucleotide of the invention.

XX Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 901 GACGAGGGCACCAGCGGCT 920
 |||||
 Db 20 GACGAGGGCACCAGCGGCT 1
 |||||
 RESULT 1419
 ADO45837/C
 ID ADO45837 standard; DNA; 20 BP.
 XX
 AC ADO45837;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1203.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5; CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a; tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease; lung disease; hyper-responsiveness; adenosine; adenosine A receptor; asthma; lung allergy; inflammation; inflammatory disease; airway inflammation; allergy; impeded respiration; cystic fibrosis; CF; chronic obstructive pulmonary disease; COPD; allergic rhinitis; acute respiratory distress syndrome; pulmonary hypertension; lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

OS Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

PR 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S; Shahabuddin S, Lu H, Cong H; WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1, initiation codon, intron of respiratory disease-relevant gene e.g. CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g. asthma.

XX Claim 2; SEQ ID NO 1204; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation codon, coding region, 5' or 3' intron-exon junction, intron or region with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention also relates to a method of screening a candidate compound that binds to one or more nucleic acid target(s) or expressed product(s), for the prevention and/or treatment of a respiratory or lung disease. The oligonucleotides are useful for reducing or inhibiting expression of a gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The oligonucleotides are useful for preventing or treating a respiratory or lung disease. The respiratory or lung disease is associated with hyper-responsiveness to and/or increased levels of, adenosine and/or levels of adenosine A

CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 871 GCCAAGGCTCAGTCAGTGT 890
 Db 20 GCCAAGGCTCAGTCAGTGT 1
 RESULT 1420
 ADO45843/c
 ID ADO45843 standard; DNA; 20 BP.
 XX
 AC ADO45843;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1209.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1210; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation

CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 9 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 811 CTGGCACTGGGGACCCAGAG 830
 Db 20 CTGGCACTGGGGACCCAGAG 1
 RESULT 1421
 ADO45849/c
 ID ADO45849 standard; DNA; 20 BP.
 XX
 AC ADO45849;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1215.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.

PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1216; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC triptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, triptase a,
 CC triptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 751 CAGGGGACCGTGTCTTTC 770
 Db |||||
 20 CAGGGGACCGTGTCTTTC 1
 RESULT 1422
 ADO45858/C
 ID ADO45858 standard; DNA; 20 BP.
 XX
 AC ADO45858;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1224.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; triptase a;
 KW triptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 OS
 XX
 PN US2004049022-A1.

XX 11-MAR-2004.
 PD
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1225; 174pp; English.
 PS The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC triptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, triptase a,
 CC triptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 2 A; 2 C; 11 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 661 AACACCTCGGCCCTTACCA 680
 Db |||||
 20 AACACCTCGGCCCTTACCA 1
 RESULT 1423
 ADO45893/C
 ID ADO45893 standard; DNA; 20 BP.
 XX
 AC ADO45893;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 PN US2004049022-A1.

DE Human oligonucleotide #1259.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

OS US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

PR 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1260; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 311 AAGAAGATAGCCCAACCAATG 330
 |||||
 Db 20 AAGAAGATAGCCCAACCAATG 1

RESULT 1424
 ADO45905/C
 ID ADO45905 standard; DNA; 20 BP.

XX ADO45905;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1271.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

OS US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

PR 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1272; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;

CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 4 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 AC ADO45906;
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1272.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 XX
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S,
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1273; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 181 GGCTCGCTCGTGACATG 200
 DB 20 GGCTCGCTCGTGACATG 1
 XX
 RESULT 1426
 ADO45908/C
 ID ADO45908 standard; DNA; 20 BP.
 XX ADO45908;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1274.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 XX
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1275; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 161 AAGTCATCTCTGCCCCGGGA 180
 |||||
 Db 20 AAGTCATCTCTGCCCCGGGA 1
 |||||
 RESULT 1427
 ADO45913/c
 ID ADO45913 standard; DNA; 20 BP.
 AC
 AC ADO45913;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1279.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.

XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1280; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 111 GGCTCTGTTCAGGACCTG 130
 |||||
 Db 20 GGCTCTGTTCAGGACCTG 1
 |||||
 RESULT 1428
 ADO45746/c
 ID ADO45746 standard; DNA; 20 BP.
 XX
 AC ADO45746;
 XX

DT 15-JUL-2004 (first entry)
 XX Human oligonucleotide #1112.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1,
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX
 XX Claim 2; SEQ ID NO 1113; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease. The
 XX respiratory or lung disease is associated with hyper-responsiveness to
 XX and/or increased levels of, adenosine and/or levels of adenosine A
 XX receptor(s), and/or asthma and/or lung allergies associated with
 XX inflammation or an inflammatory disease. The respiratory or lung disease
 XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
 XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
 XX hypertension, lung inflammation, bronchitis, airway obstruction or
 XX bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.

Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1781 GGGCATTGTCTCAGTCAGA 1800
 Db 20 GGGCATTGTCTCAGTCAGA 1
 RESULT 1429
 ADO45748/c
 ID ADO45748 standard; DNA; 20 BP.
 XX
 XX ADO45748;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 XX Human oligonucleotide #1114.
 XX
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX
 XX Claim 2; SEQ ID NO 1115; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease. The
 XX respiratory or lung disease is associated with hyper-responsiveness to
 XX and/or increased levels of, adenosine and/or levels of adenosine A
 XX receptor(s), and/or asthma and/or lung allergies associated with
 XX inflammation or an inflammatory disease. The respiratory or lung disease
 XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
 XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
 XX hypertension, lung inflammation, bronchitis, airway obstruction or
 XX bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.

CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1761 CCTGGGACCGCGAGACA 1780
 Db 20 CCTGGGACCGCGAGACA 1

RESULT 1430
 ADO45750/c

ID ADO45750 standard; DNA; 20 BP.

XX AC ADO45750;

XX DT 15-JUL-2004 (first entry)

XX XX Human oligonucleotide #1116.

XX XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX OS Homo sapiens.

XX XX US2004049022-A1.

XX XX 11-MAR-2004.

XX XX 25-JUL-2003; 2003US-00627930.

XX XX 23-APR-2002; 2002WO-US013135.

XX XX 23-APR-2002; 2002WO-US013143.

XX XX (NYCE/) NYCE J W.

XX XX (SAND/) SANDRASAGRA A.

XX XX (AGUI/) AGUILAR D.

XX XX (MILL/) MILLER S.

XX XX (SHAH/) SHAHABUDDIN S.

XX XX (LUHH/) LU H.

XX XX (CONG/) CONG H.

XX XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;

XX XX WPI; 2004-293804/27.

XX XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1117; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 3 A; 4 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1741 CATGCAGCTACACCTACCGG 1760
 Db 20 CATGCAGCTACACCTACCGG 1

RESULT 1431
 ADO45763/c

ID ADO45763 standard; DNA; 20 BP.

XX AC ADO45763;

XX XX 15-JUL-2004 (first entry)

XX XX Human oligonucleotide #1129.

XX XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX OS Homo sapiens.

XX XX US2004049022-A1.

XX XX 11-MAR-2004.

XX XX 25-JUL-2003; 2003US-00627930.

XX XX 23-APR-2002; 2002WO-US013135.

XX XX 23-APR-2002; 2002WO-US013143.

XX XX (NYCE/) NYCE J W.

XX XX (SAND/) SANDRASAGRA A.

XX XX (TANG/) TANG L.

PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1130; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 4 C; 6 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1611 AAAAGGACCCCATGAAC 1630
 |||||
 Db 20 AAAAGGACCCCATGAAC 1
 RESULT 1432
 ADO45780/c
 ID ADO45780 standard; DNA; 20 BP.
 XX
 AC ADO45780;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1146.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX
 OS Homo sapiens.
 XX US2004049022-A1.
 PN
 XX 11-MAR-2004.
 PD
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 DR WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1147; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1441 ACTCAAGGGGAGGTCAACCG 1460
 |||||
 Db 20 ACTCAAGGGGAGGTCAACCG 1
 RESULT 1433
 ADO45782/c
 ID ADO45782 standard; DNA; 20 BP.
 XX

AC ADO45782;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1148.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW trypsinase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1149; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC trypsinase a, trypsinase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC trypsinase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1421 ACCTCTGTCTGGGCGCAGGAGC 1440
 DB 20 ACCTCTGTCTGGGCGCAGGAGC 1
 RESULT 1434
 ADO45783/C
 ID ADO45783 standard; DNA; 20 BP.
 XX ADO45783;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1149.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW trypsinase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1150; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC trypsinase a, trypsinase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC trypsinase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hyperextension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 4 A; 6 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1411 GAGGGACCTACCTCTGTGC 1430
 Db |||||||
 20 GAGGGACCTACCTCTGTGC 1

RESULT 1435
 ADO45788/c
 ID ADO45788 standard; DNA; 20 BP.

XX AC ADO45788;
 XX DT 15-JUL-2004 (first entry)
 XX DE Human oligonucleotide #1154.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX OS Homo sapiens.
 XX XX US2004049022-A1.
 XX PD 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.
 XX XX 23-APR-2002; 2002WO-US013135.
 XX PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 XX PA (SAND/) SANDRASAGRA A.
 XX PA (TANG/) TANG L.
 XX PA (AGUI/) AGUILAR D.
 XX PA (MILL/) MILLER S.
 XX PA (SHAH/) SHAHABUDDIN S.
 XX PA (LUHH/) LU H.
 XX PA (CONG/) CONG H.

XX NYce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-233804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,

PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1155; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 5 A; 2 C; 10 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1361 GCACCTTCCCACTGCCCATC 1380
 Db |||||||
 20 GCACCTTCCCACTGCCCATC 1

RESULT 1436
 ADO45791/c
 ID ADO45791 standard; DNA; 20 BP.

XX AC ADO45791;
 XX DT 15-JUL-2004 (first entry)
 XX DE Human oligonucleotide #1157.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX OS Homo sapiens.
 XX XX US2004049022-A1.
 XX PD 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.
 XX XX 23-APR-2002; 2002WO-US013135.
 XX PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1158; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1331 CATTGCCGAGCTCAAGTGT 1350
 Db ||||||||||||||||
 20 CATTGCCGAGCTCAAGTGT 1
 RESULT 1437
 ADO45802/c
 ID ADO45802 standard; DNA; 20 BP.
 XX
 AC ADO45802;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1168.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;

KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX US2004049022-A1.
 XX 11-MAR-2004.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1169; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 7 A; 7 C; 4 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1221 GGAGCTTCGTGTCCTGTATG 1240
 Db ||||||||||||||||
 20 GGAGCTTCGTGTCCTGTATG 1
 RESULT 1438
 ADO45805/c

ID AD045805 standard; DNA; 20 BP.
 AC AD045805;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1171.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 PN
 XX
 XX 11-MAR-2004.
 PD
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 PR
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-293804/27.
 DR
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1172; 174pp; English.
 PS
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the

CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 1191 CGGCCAGCTTATACACAAGA 1210
 Db 20 CGGCCAGCTTATACACAAGA 1
 XX
 RESULT 1439
 ADO45853/c
 ID ADO45853 standard; DNA; 20 BP.
 XX
 XX ADO45853;
 XX
 XX 15-JUL-2004 (first entry)
 DT
 XX
 XX Human oligonucleotide #1219.
 DE
 XX
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 PN
 XX
 XX 11-MAR-2004.
 PD
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 PR
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-293804/27.
 DR
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1220; 174pp; English.
 PS
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the

CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 3 A; 2 C; 11 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 CCCACAACTTGTGAGCCCC 730
 Db 20 CCCACAACTTGTGAGCCCC 1

RESULT 1440
 ADO45857/c
 ID ADO45857 standard; DNA; 20 BP.
 AC ADO45857;
 XX
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1223.
 XX

Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX

(NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX

Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 XX

PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX Claim 2; SEQ ID NO 1224; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 2 A; 2 C; 12 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 671 CCCCTTACGAGCTCCAGACC 690
 Db 20 CCCCTTACGAGCTCCAGACC 1

RESULT 1441
 ADO45868/c
 ID ADO45868 standard; DNA; 20 BP.
 XX
 AC ADO45868;
 XX
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1234.
 XX

Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX

XX PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX DR WPI; 2004-293804/27.
 XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX PS Claim 2; SEQ ID NO 1235; 174pp; English.
 XX CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 561 GGTACACGACACCGTGTGG 580
 Db ||||||||||||||||||
 20 GGTACACGACACCGTGTGG 1
 RESULT 1442
 ADO45878/c
 ID ADO45878 standard; DNA; 20 BP.
 XX AC ADO45878;
 XX DT 15-JUL-2004 (first entry)
 XX DE Human oligonucleotide #1244.
 XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;

KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 OS Homo sapiens.
 XX US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX PS Claim 2; SEQ ID NO 1245; 174pp; English.
 XX CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 2 A; 12 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 461 GCCAGGTGGAGGTGGGCA 480
 Db ||||||||||||||||||
 20 GCCAGGTGGAGGTGGGCA 1

RESULT 1443
AD045897/c
ID AD045897 standard; DNA; 20 BP.
XX
XX
AC AD045897;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human oligonucleotide #1263.
XX
XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS Homo sapiens.
XX
XX US2004049022-A1.
XX
XX 11-MAR-2004.
XX
XX 25-JUL-2003; 2003US-00627930.
XX
XX 23-APR-2002; 2002WO-US013135.
PR
XX 23-APR-2002; 2002WO-US013143.
PR
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H. H.
PA (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 1264; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC

CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 271 CCTGGGAACACACCGGAAGGT 290
DB 20 CCTGGGAACACACCGGAAGGT 1
XX
RESULT 1444
AD045910/c
ID AD045910 standard; DNA; 20 BP.
XX
XX AC AD045910;
XX
XX 15-JUL-2004 (first entry)
XX
XX Human oligonucleotide #1276.
XX
XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS Homo sapiens.
XX
XX US2004049022-A1.
XX
XX 11-MAR-2004.
XX
XX 25-JUL-2003; 2003US-00627930.
XX
XX 23-APR-2002; 2002WO-US013135.
PR
XX 23-APR-2002; 2002WO-US013143.
PR
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H. H.
PA (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 1277; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC

CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 5 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 141 GACATCTGTGTCCTCCCTCAA 160
 |||||
 Db 20 GACATCTGTGTCCTCCCTCAA 1

RESULT 1445
 ADO45919/c
 ID ADO45919 standard; DNA; 20 BP.

XX AC ADO45919;

XX DT 15-JUL-2004 (first entry)

XX DE Human oligonucleotide #1285.

XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 CCRL1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX OS Homo sapiens.

XX PN US2004049022-A1.

XX PD 11-MAR-2004.

XX XX 25-JUL-2003; 2003US-00627930.

XX PR 23-APR-2002; 2002WO-US013135.

XX PR 23-APR-2002; 2002WO-US013143.

XX XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX NYce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;

XX XX

DR WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.

XX PS Claim 2; SEQ ID NO 1286; 174pp; English.

XX CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 51 CCTCGCTATGGCTCCAGCA 70
 |||||
 Db 20 CCTCGCTATGGCTCCAGCA 1

RESULT 1446

ADO45922/c

ID ADO45922 standard; DNA; 20 BP.

XX AC ADO45922;

XX DT 15-JUL-2004 (first entry)

XX DE Human oligonucleotide #1288.

XX KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 CCRL1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX OS Homo sapiens.

XX PN US2004049022-A1.

XX PD 11-MAR-2004.

XX XX 25-JUL-2003; 2003US-00627930.


```

PR 23-APR-2002; 2002WO-US013135.
PR 23-APR-2002; 2002WO-US013143.
XX
PA (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1,
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 1289; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
XX invention.
XX
XX Sequence 20 BP; 7 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 21 CTCCTCTGCTACTCAGAGTT 40
Db |||||
20 CTCCTCTGCTACTCAGAGTT 1
RESULT 1447
AD045727/c
ID ADO45727 standard; DNA; 20 BP.
XX
XX ADO45727;
XX
XX 15-JUL-2004 (first entry)
XX
XX Human oligonucleotide #1093.
XX
XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
XX CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
XX tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
XX

```

lung disease; hyper-responsiveness; adenosine; adenosine A receptor; asthma; lung allergy; inflammation; inflammatory disease; cystic fibrosis; CF; airway inflammation; allergy; impeded respiration; cystic fibrosis; CF; chronic obstructive pulmonary disease; COPD; allergic rhinitis; acute respiratory distress syndrome; pulmonary hypertension; lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

Homo sapiens.

US2004049022-A1.

11-MAR-2004.

25-JUL-2003; 2003US-00627930.

23-APR-2002; 2002WO-US013135.

23-APR-2002; 2002WO-US013143.

(NYCE/) NYCE J W.

(SAND/) SANDRASAGRA A.

(TANG/) TANG L.

(AGUI/) AGUILAR D.

(MILL/) MILLER S.

(SHAH/) SHAHABUDDIN S.

(LUHH/) LU H.

(CONG/) CONG H.

Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S; Shahabuddin S, Lu H, Cong H; WPI; 2004-293804/27.

Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1, initiation codon, intron of respiratory disease-relevant gene e.g. CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g. asthma.

Claim 2; SEQ ID NO 1094; 174pp; English.

The invention relates to oligonucleotides anti-sense to an initiation codon, coding region, 5' or 3' intron-exon junction, intron or region with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention also relates to a method of screening a candidate compound that binds to one or more nucleic acid target(s) or expressed product(s), for the prevention and/or treatment of a respiratory or lung disease. The oligonucleotides are useful for reducing or inhibiting expression of a gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are useful for preventing or treating a respiratory or lung disease. The respiratory or lung disease is associated with hyper-responsiveness to and/or increased levels of, adenosine and/or levels of adenosine A receptor(s), and/or asthma and/or lung allergies associated with inflammation or an inflammatory disease. The respiratory or lung disease is chosen from airway inflammation, allergy, asthma, impeded respiration, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), allergic rhinitis, acute respiratory distress syndrome, pulmonary hypertension, lung inflammation, bronchitis, airway obstruction or bronchoconstriction. This sequence represents an oligonucleotide of the invention.

Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20; Best Local Similarity 100.0%; Pred. No. 5.4e+02; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1971 CCATGAGGACATACAACTGG 1990
|||||
20 CCATGAGGACATACAACTGG 1

CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 6 C; 4 G; 9 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1571 GCCAGCGGAGATCAAGAAA 1590
 Db 20 GCCAGCGGAGATCAAGAAA 1
 RESULT 1450
 ADO45775/c
 ID ADO45775 standard; DNA; 20 BP.
 XX
 AC ADO45775;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1141.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1142; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 7 A; 4 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1491 GTATGAGATTGTCATCATCA 1510
 Db 20 GTATGAGATTGTCATCATCA 1
 RESULT 1451
 ADO45794/c
 ID ADO45794 standard; DNA; 20 BP.
 XX
 AC ADO45794;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1160.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX 11-MAR-2004.
 XX

PF 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1161; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.
 XX
 XX Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 1301-AGACTCCAAATGTCAGGCT 1320
 DB 20 AGACTCCAAATGTCAGGCT 1
 XX
 XX RESULT 1452
 AD045798/c
 ID AD045798 standard; DNA; 20 BP.
 XX
 XX ADO45798;
 AC
 XX
 XX 15-JUL-2004 (first entry)
 DT
 XX Human oligonucleotide #1164.
 DE
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 XX

KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1165; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.
 XX
 XX Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX

QY 1261 GATTGTCCGGAAACTGGAC 1280

Db 20 GATTGTCGGGAACCTGGAC 1
|||||
RESULT 1453
ADO45800/c
ID ADO45800 standard; DNA; 20 BP.
AC ADO45800;
XX
XX 15-JUL-2004 (first entry)
XX
XX Human oligonucleotide #1166.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS Homo sapiens.
XX
XX US2004049022-A1.
XX
XX 11-MAR-2004.
XX
XX 25-JUL-2003; 2003US-00627930.
XX
XX 23-APR-2002; 2002WO-US013135.
XX 23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
XX (SAND/) SANDRASAGRA A.
XX (TANG/) TANG L.
XX (AGUI/) AGUILAR D.
XX (MILL/) MILLER S.
XX (SHAH/) SHAHABUDDIN S.
XX (LUHH/) LU H.
XX (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
XX Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
XX PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
XX PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
XX PT asthma.
XX
XX Claim 2; SEQ ID NO 1167; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
XX codon, coding region, 5' or 3' intron-exon junction, intron or region
XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
XX also relates to a method of screening a candidate compound that binds to
XX one or more nucleic acid target(s) or expressed product(s), for the
XX prevention and/or treatment of a respiratory or lung disease. The
XX oligonucleotides are useful for reducing or inhibiting expression of a
XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
XX useful for preventing or treating a respiratory or lung disease. The
XX respiratory or lung disease is associated with hyper-responsiveness to
XX and/or increased levels of, adenosine and/or levels of adenosine A
XX receptor(s), and/or asthma and/or lung allergies associated with

CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 1 A; 8 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1241 GCCCCGACTGGACGAGAGG 1260
Db 20 GCCCCGACTGGACGAGAGG 1
|||||
RESULT 1454
ADO45803/c
ID ADO45803 standard; DNA; 20 BP.
XX
XX ADO45803;
XX
XX 15-JUL-2004 (first entry)
XX Human oligonucleotide #1169.
XX
XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
XX Homo sapiens.
XX
XX US2004049022-A1.
XX
XX 11-MAR-2004.
XX
XX 25-JUL-2003; 2003US-00627930.
XX
XX 23-APR-2002; 2002WO-US013135.
XX 23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
XX (SAND/) SANDRASAGRA A.
XX (TANG/) TANG L.
XX (AGUI/) AGUILAR D.
XX (MILL/) MILLER S.
XX (SHAH/) SHAHABUDDIN S.
XX (LUHH/) LU H.
XX (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
XX Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
XX PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
XX PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
XX PT asthma.
XX
XX Claim 2; SEQ ID NO 1170; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
XX codon, coding region, 5' or 3' intron-exon junction, intron or region

CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1211 ACCAGACCCGGGAGCTTCGT 1230
 DB 20 ACCAGACCCGGGAGCTTCGT 1
 RESULT 1455
 ADO45817/c
 ID ADO45817 standard; DNA; 20 BP.
 XX
 XX ADO45817;
 XX
 XX 15-JUL-2004 (first entry)
 DT Human oligonucleotide #1183.
 XX
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; COPD; allergic rhinitis;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 XX Homo sapiens.
 OS
 XX US2004049022-A1.
 PN
 XX 11-MAR-2004.
 PD
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.

XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1184; 174pp; English.
 PS
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1071 CAAGGTGACGCTGAATGGGG 1090
 DB 20 CAAGGTGACGCTGAATGGGG 1
 RESULT 1456
 ADO45824/c
 ID ADO45824 standard; DNA; 20 BP.
 XX
 XX ADO45824;
 XX
 XX 15-JUL-2004 (first entry)
 DT Human oligonucleotide #1190.
 XX
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; COPD; allergic rhinitis;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 XX Homo sapiens.
 OS
 XX US2004049022-A1.
 PN
 XX

PD 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,

PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.

PT asthma.

XX Claim 2; SEQ ID NO 1191; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation

CC codon, coding region, 5' or 3' intron-exon junction, intron or region

CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target

CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)

CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,

CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention

CC also relates to a method of screening a candidate compound that binds to

CC one or more nucleic acid target(s) or expressed product(s), for the

CC prevention and/or treatment of a respiratory or lung disease. The

CC oligonucleotides are useful for reducing or inhibiting expression of a

CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,

CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,

CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are

CC useful for preventing or treating a respiratory or lung disease. The

CC respiratory or lung disease is associated with hyper-responsiveness to

CC and/or increased levels of, adenosine and/or levels of adenosine A

CC receptor(s), and/or asthma and/or lung allergies associated with

CC inflammation or an inflammatory disease. The respiratory or lung disease

CC is chosen from an inflammatory disease, allergy, asthma, impeded respiration,

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),

CC allergic rhinitis, acute respiratory distress syndrome, pulmonary

CC hypertension, lung inflammation, bronchitis, airway obstruction or

CC bronchoconstriction. This sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 20; DB 1; Length 20;

XX Best Local Similarity 100.0%; Pred. No. 5.4e-02;

XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1001 TGATTTCTGACGAGCCAGAG 1020

DB 20 TGATTTCTGACGAGCCAGAG 1

RESULT 1457

ID ADO45904/c

XX ADO45904 standard; DNA; 20 BP.

AC ADO45904;

XX 15-JUL-2004 (first entry)

DT Human oligonucleotide #1270.

XX

DE

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;

KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;

KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;

KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;

KW asthma; lung allergy; inflammation; inflammatory disease;

KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;

KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;

KW acute respiratory distress syndrome; pulmonary hypertension;

KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

OS Homo sapiens.

XX US2004049022-A1.

PN 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

PA (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,

PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.

PT asthma.

XX Claim 2; SEQ ID NO 1271; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation

CC codon, coding region, 5' or 3' intron-exon junction, intron or region

CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target

CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)

CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,

CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention

CC also relates to a method of screening a candidate compound that binds to

CC one or more nucleic acid target(s) or expressed product(s), for the

CC prevention and/or treatment of a respiratory or lung disease. The

CC oligonucleotides are useful for reducing or inhibiting expression of a

CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,

CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,

CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are

CC useful for preventing or treating a respiratory or lung disease. The

CC respiratory or lung disease is associated with hyper-responsiveness to

CC and/or increased levels of, adenosine and/or levels of adenosine A

CC receptor(s), and/or asthma and/or lung allergies associated with

CC inflammation or an inflammatory disease. The respiratory or lung disease

CC is chosen from an inflammatory disease, allergy, asthma, impeded respiration,

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),

CC allergic rhinitis, acute respiratory distress syndrome, pulmonary

CC hypertension, lung inflammation, bronchitis, airway obstruction or

CC bronchoconstriction. This sequence represents an oligonucleotide of the

CC invention.

XX Sequence 20 BP; 3 A; 4 C; 9 G; 4 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 20; DB 1; Length 20;

XX Best Local Similarity 100.0%; Pred. No. 5.4e-02;

XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 201 CAGCACCTCTGTGACGAGC 220
 Db 20 CAGCACCTCTGTGACGAGC 1

RESULT 1458
 ADO45911/c
 ID ADO45911 standard; DNA; 20 BP.
 XX
 AC ADO45911;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1277.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE//) NYCE J W.
 PA (SAND//) SANDRASAGRA A.
 PA (TANG//) TANG L.
 PA (AGUI//) AGUILAR D.
 PA (MILL//) MILLER S.
 PA (SHAH//) SHAHABUDDIN S.
 PA (LUHH//) LU H.
 PA (CONG//) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1,
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1278; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to

CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 131 GCAATGCCGACATCTGTG 150
 Db 20 GCAATGCCGACATCTGTG 1

RESULT 1459
 ADO45739/c
 ID ADO45739 standard; DNA; 20 BP.
 XX
 AC ADO45739;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1105.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE//) NYCE J W.
 PA (SAND//) SANDRASAGRA A.
 PA (TANG//) TANG L.
 PA (AGUI//) AGUILAR D.
 PA (MILL//) MILLER S.
 PA (SHAH//) SHAHABUDDIN S.
 PA (LUHH//) LU H.
 PA (CONG//) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1,
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1106; 174pp; English.
 XX

CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1851 CGCATCTGATCTCTAGTCTAC 1870
 DB ||||||||||||||||||
 20 CGCATCTGATCTCTAGTCTAC 1
 RESULT 1460
 AD045761/c
 ID AD045761 standard; DNA; 20 BP.
 XX AC AD045761;
 XX 15-JUL-2004 (first entry)
 XX Human oligonucleotide #1127.
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 CC CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 CC tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 CC lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 CC asthma; lung allergy; inflammation; inflammatory disease;
 CC airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 CC chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 CC acute respiratory distress syndrome; pulmonary hypertension;
 CC lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 OS US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1128; 174pp; English.
 PS The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 1 A; 3 C; 9 G; 7 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1631 CGAACACACAGCCAGCGCT 1650
 DB ||||||||||||||||||
 20 CGAACACACAGCCAGCGCT 1
 RESULT 1461
 AD045809/c
 ID AD045809 standard; DNA; 20 BP.
 XX AC AD045809;
 XX 15-JUL-2004 (first entry)
 XX Human oligonucleotide #1175.
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 CC CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 CC tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 CC lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 CC asthma; lung allergy; inflammation; inflammatory disease;
 CC airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 CC chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 CC acute respiratory distress syndrome; pulmonary hypertension;
 CC lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 OS

PN US2004049022-A1.
 PD 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE//) NYCE J W.
 PA (SAND//) SANDRASAGRA A.
 PA (TANG//) TANG L.
 PA (AGUI//) AGUILAR D.
 PA (MILL//) MILLER S.
 PA (SHAH//) SHAHABUDDIN S.
 PA (LUHH//) LU H.
 PA (CONG//) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1176; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 6 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1151 ACGGGCGAGCTCTCTCTGC 1170
 |||||
 DB 20 ACGGGCGAGCTCTCTCTGC 1
 RESULT 1462
 ID ADO45830/c
 AC ADO45830 standard; DNA; 20 BP.
 XX
 AC ADO45830;
 XX
 DT 15-JUL-2004 (first entry)

XX Human oligonucleotide #1196.
 DE
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 OS US2004049022-A1.
 PN 11-MAR-2004.
 PD 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE//) NYCE J W.
 PA (SAND//) SANDRASAGRA A.
 PA (TANG//) TANG L.
 PA (AGUI//) AGUILAR D.
 PA (MILL//) MILLER S.
 PA (SHAH//) SHAHABUDDIN S.
 PA (LUHH//) LU H.
 PA (CONG//) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1197; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 0 A; 7 C; 5 G; 8 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02; Mismatches 0; Conservative 0; Indels 0; Gaps 0;

QY 941 GGAAACAGAGCCAGGAGACA 960
 ID ADO45884 standard; DNA; 20 BP.
 AC ADO45884;
 XX
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1250.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5; CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a; tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease; lung disease; hyper-responsiveness; adenosine; adenosine A receptor; asthma; lung allergy; inflammation; inflammatory disease; airway inflammation; allergy; impeded respiration; cystic fibrosis; CF; chronic obstructive pulmonary disease; COPD; allergic rhinitis; acute respiratory distress syndrome; pulmonary hypertension; lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1, initiation codon, intron of respiratory disease-relevant gene e.g. CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g. asthma.
 XX
 XX Claim 2; SEQ ID NO 1251; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation codon, coding region, 5' or 3' intron-exon junction, intron or region with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention also relates to a method of screening a candidate compound that binds to one or more nucleic acid target(s) or expressed product(s), for the prevention and/or treatment of a respiratory or lung disease. The oligonucleotides are useful for reducing or inhibiting expression of a gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are

CC useful for preventing or treating a respiratory or lung disease. The respiratory or lung disease is associated with hyper-responsiveness to and/or increased levels of, adenosine and/or levels of adenosine A receptor(s), and/or asthma and/or lung allergies associated with inflammation or an inflammatory disease. The respiratory or lung disease is chosen from airway inflammation, allergy, asthma, impeded respiration, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), allergic rhinitis, acute respiratory distress syndrome, pulmonary hypertension, lung inflammation, bronchitis, airway obstruction or bronchoconstriction. This sequence represents an oligonucleotide of the

XX
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02; Mismatches 0; Gaps 0;
 Matches 20; Conservative 0; Indels 0; Gaps 0;

QY 401 GGGTGGAACTGGCACCCTC 420
 Db 20 GGGTGGAACTGGCACCCTC 1
 RESULT 1464
 ADO45895/c
 ID ADO45895 standard; DNA; 20 BP.
 XX ADO45895;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1261.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5; CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a; tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease; lung disease; hyper-responsiveness; adenosine; adenosine A receptor; asthma; lung allergy; inflammation; inflammatory disease; airway inflammation; allergy; impeded respiration; cystic fibrosis; CF; chronic obstructive pulmonary disease; COPD; allergic rhinitis; acute respiratory distress syndrome; pulmonary hypertension; lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g. CCR1, initiation codon, intron of respiratory disease-relevant gene e.g. CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g. asthma.
 XX
 XX Claim 2; SEQ ID NO 1251; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation codon, coding region, 5' or 3' intron-exon junction, intron or region with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention also relates to a method of screening a candidate compound that binds to one or more nucleic acid target(s) or expressed product(s), for the prevention and/or treatment of a respiratory or lung disease. The oligonucleotides are useful for reducing or inhibiting expression of a gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are

PS Claim 2; SEQ ID NO 1262; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation codon, coding region, 5' or 3' intron-exon junction, intron or region with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention also relates to a method of screening a candidate compound that binds to one or more nucleic acid target(s) or expressed product(s), for the prevention and/or treatment of a respiratory or lung disease. The oligonucleotides are useful for reducing or inhibiting expression of a gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are useful for preventing or treating a respiratory or lung disease. The respiratory or lung disease is associated with hyper-responsiveness to and/or increased levels of, adenosine and/or levels of adenosine A receptor(s), and/or asthma and/or lung allergies associated with inflammation or an inflammatory disease. The respiratory or lung disease is chosen from airway inflammation, allergy, asthma, impeded respiration, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), allergic rhinitis, acute respiratory distress syndrome, pulmonary hypertension, lung inflammation, bronchitis, airway obstruction or bronchoconstriction. This sequence represents an oligonucleotide of the invention.

XX Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 291 GTATGACTGAGCAATGTC 310
DB |||||

RESULT 1465
ADO45899/c
ID ADO45899 standard; DNA; 20 BP.

XX ADO45899;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1265.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5; CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a; tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease; lung disease; hyper-responsiveness; adenosine; adenosine A receptor; asthma; lung allergy; inflammation; inflammatory disease; airway inflammation; allergy; impeded respiration; cystic fibrosis; CF; chronic obstructive pulmonary disease; COPD; allergic rhinitis; acute respiratory distress syndrome; pulmonary hypertension; lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

OS Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

PR 23-APR-2002; 2002WO-US013143.

XX (NYCE/J) NYCE J W.

PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.

PA (AGUI/) AGUILAR D.

PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.

PA (LUHH/) LU H.

XX (CONG/) CONG H.

PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

DR WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g. PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1, PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g. asthma.

XX Claim 2; SEQ ID NO 1266; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation codon, coding region, 5' or 3' intron-exon junction, intron or region with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention also relates to a method of screening a candidate compound that binds to one or more nucleic acid target(s) or expressed product(s), for the prevention and/or treatment of a respiratory or lung disease. The oligonucleotides are useful for reducing or inhibiting expression of a gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are useful for preventing or treating a respiratory or lung disease. The respiratory or lung disease is associated with hyper-responsiveness to and/or increased levels of, adenosine and/or levels of adenosine A receptor(s), and/or asthma and/or lung allergies associated with inflammation or an inflammatory disease. The respiratory or lung disease is chosen from airway inflammation, allergy, asthma, impeded respiration, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), allergic rhinitis, acute respiratory distress syndrome, pulmonary hypertension, lung inflammation, bronchitis, airway obstruction or bronchoconstriction. This sequence represents an oligonucleotide of the invention.

XX Sequence 20 BP; 5 A; 5 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 251 CTAAAAAGGAGTTGCTCCTG 270
DB |||||

RESULT 1466
ADO45900/c
ID ADO45900 standard; DNA; 20 BP.

XX ADO45900;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1266.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5; CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a; tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease; lung disease; hyper-responsiveness; adenosine; adenosine A receptor; asthma; lung allergy; inflammation; inflammatory disease; airway inflammation; allergy; impeded respiration; cystic fibrosis; CF; chronic obstructive pulmonary disease; COPD; allergic rhinitis; acute respiratory distress syndrome; COPD; allergic rhinitis; lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

OS Homo sapiens.
XX US2004049022-A1.
PN XX
XX 11-MAR-2004.
XX
XX 25-JUL-2003; 2003US-00627930.
PF
XX 23-APR-2002; 2002WO-US013135.
PR 23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 1267; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 3 A; 4 C; 6 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 241 ACCCGGTGCTAAAGGA 260
Db 20 ACCCGGTGCTAAAGGA 1
RESULT 1467
AD045901/c
ID AD045901 standard; DNA; 20 BP.
XX
AC AD045901;

15-JUL-2004 (first entry)
Human oligonucleotide #1267.
Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
asthma; lung allergy; inflammation; inflammatory disease;
airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
chronic obstructive pulmonary disease; COPD; allergic rhinitis;
acute respiratory distress syndrome; pulmonary hypertension;
lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
Homo sapiens.
US2004049022-A1.
11-MAR-2004.
25-JUL-2003; 2003US-00627930.
23-APR-2002; 2002WO-US013135.
23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 1268; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 231 GGGCATAGAGACCCCGTTC 250
 DB 20 GGGCATAGAGACCCCGTTC 1

RESULT 1468
 ADO45914/c
 ID ADO45914 standard; DNA; 20 BP.
 AC ADO45914;
 XX
 XX
 DT 15-JUL-2004 (first entry)
 XX
 XX Human oligonucleotide #1280.
 DE
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX
 XX Claim 2; SEQ ID NO 1281; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,

CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 useful for preventing or treating a respiratory or lung disease. The
 respiratory or lung disease is associated with hyper-responsiveness to
 and/or increased levels of, adenosine and/or levels of adenosine A
 receptor(s), and/or asthma and/or lung allergies associated with
 inflammation or an inflammatory disease. The respiratory or lung disease
 is chosen from airway inflammation, allergy, asthma, impeded respiration,
 cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 allergic rhinitis, acute respiratory distress syndrome, pulmonary
 hypertension, lung inflammation, bronchitis, airway obstruction or
 bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 7 A; 6 C; 7 G; 0 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 101 TCCTGCTCGGGGCTCTGTTTC 120
 DB 20 TCCTGCTCGGGGCTCTGTTTC 1

RESULT 1469
 ADO45724/c
 ID ADO45724 standard; DNA; 20 BP.
 AC ADO45724;
 XX
 XX
 DT 15-JUL-2004 (first entry)
 XX
 XX Human oligonucleotide #1090.
 DE
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.

PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1091; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 7 A; 5 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2001 AACTTGCTGCTATTGGGTA 2020
 Db |||||
 20 AACTTGCTGCTATTGGGTA 1
 RESULT 1470
 ADO45754/c
 ID ADO45754 standard; DNA; 20 BP.
 AC ADO45754;
 XX
 XX 15-JUL-2004 (first entry)
 DT
 XX Human oligonucleotide #1120.
 DE
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 PN
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.

PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1121; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1701 TGGCAGTGGTGGCAGACTGA 1720
 Db |||||
 20 TGGCAGTGGTGGCAGACTGA 1
 RESULT 1471
 ADO45765/c
 ID ADO45765 standard; DNA; 20 BP.
 XX
 AC ADO45765;
 XX
 XX 15-JUL-2004 (first entry)
 DT
 XX Human oligonucleotide #1131.
 DE
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW acute respiratory distress syndrome; pulmonary hypertension;

KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX NYCE JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1132; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.
 XX Sequence 20 BP; 2 A; 3 C; 7 G; 8 T; 0 U; 0 Other;
 SQ
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1591 TACAGACTACACAGGCCCA 1610
 Db |||||
 20 TACAGACTACACAGGCCCA 1
 RESULT 1472
 ADO45766/c
 ID ADO45766 standard; DNA; 20 BP.

XX ADO45766;
 XX 15-JUL-2004 (first entry)
 XX Human oligonucleotide #1132.
 XX Human; ES; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX US2004049022-A1.
 XX 11-MAR-2004.
 XX 25-JUL-2003; 2003US-00627930.
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX NYCE JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1133; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.

XX Sequence 20 BP; 3 A; 3 C; 4 G; 10 T; 0 U; 0 Other;
SQ Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1581 GATCAGAAATACAGACTAC 1600
|||||
DB 20 GATCAGAAATACAGACTAC 1

RESULT 1473
ADO45816/c
ID ADO45816 standard; DNA; 20 BP.
XX ADO45816;
AC
XX
DT 15-JUL-2004 (first entry)
XX
DE Human oligonucleotide #1182.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX Homo sapiens.
OS
XX
PN US2004049022-A1.
XX
PD 11-MAR-2004.
XX
PF 25-JUL-2003; 2003US-00627930.
XX
PR 23-APR-2002; 2002WO-US013135.
PR 23-APR-2002; 2002WO-US013143.
XX
PA (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX
PS Claim 2; SEQ ID NO 1183; 174pp; English.
XX
CC The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The

CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1081 CTGAATGGGGTTCCAGCCCA 1100
|||||
DB 20 CTGAATGGGGTTCCAGCCCA 1

RESULT 1474
ADO45823/c
ID ADO45823 standard; DNA; 20 BP.
XX ADO45823;
AC
XX
DT 15-JUL-2004 (first entry)
XX
DE Human oligonucleotide #1189.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX Homo sapiens.
OS
XX
PN US2004049022-A1.
XX
PD 11-MAR-2004.
XX
PF 25-JUL-2003; 2003US-00627930.
XX
PR 23-APR-2002; 2002WO-US013135.
PR 23-APR-2002; 2002WO-US013143.
XX
PA (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.

PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.

PS Claim 2; SEQ ID NO 1190; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAAGCCAGAGGTTCTCAGAAG 1030
DB 20 GAAGCCAGAGGTTCTCAGAAG 1

RESULT 1475

ADO45860/c

ID ADO45860 standard; DNA; 20 BP.

XX ADO45860;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1226.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

PA (NYCE/) NYCE J W.
PA (SAND/) SANDRAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.

XX NYce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.

XX Claim 2; SEQ ID NO 1227; 174pp; English.

XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 5 A; 9 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 641 AGGGCTGGAGCTGTTTGAG 660
DB 20 AAGGGCTGGAGCTGTTTGAG 1

RESULT 1476

ADO45871/c

ID ADO45871 standard; DNA; 20 BP.

XX ADO45871;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1237.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;

KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1238; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 2 A; 11 C; 4 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 531 ACGGGAGCCAGCTGTGGGG 550
 |||||
 Db 20 ACGGGAGCCAGCTGTGGGG 1
 RESULT 1477

AD045879/C
 ID ADO45879 standard; DNA; 20 BP.
 XX
 AC ADO45879;
 XX
 XX 15-JUL-2004 (first entry)
 DT
 XX
 XX Human oligonucleotide #1245.
 DE
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung-allergy; inflammation; inflammatory disease; CF;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 XX Homo sapiens.
 OS
 XX US2004049022-A1.
 PN
 XX
 XX 11-MAR-2004.
 PD
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1246; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 451 ACCCTACGCTGCCAGGTGGA 470
 Db 20 ACCCTACGCTGCCAGGTGGA 1
 RESULT 1478
 ADO45885/c
 ID ADO45885 standard; DNA; 20 BP.
 XX
 AC ADO45885;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1251.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 asthma; lung allergy; inflammation; inflammatory disease;
 airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 acute respiratory distress syndrome; pulmonary hypertension;
 lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1252; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to

CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 391 ACTCCAGAACGGGTGGA 410
 Db 20 ACTCCAGAACGGGTGGA 1
 RESULT 1479
 ADO45887/c
 ID ADO45887 standard; DNA; 20 BP.
 XX
 AC ADO45887;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1253.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 asthma; lung allergy; inflammation; inflammatory disease;
 airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 acute respiratory distress syndrome; pulmonary hypertension;
 lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.

asthma, lung allergy; inflammation; inflammatory disease; CF;
 airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 acute respiratory distress syndrome; pulmonary hypertension;
 lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 Homo sapiens.
 US2004049022-A1.
 11-MAR-2004.
 25-JUL-2003; 2003US-00627930.
 23-APR-2002; 2002WO-US013135.
 23-APR-2002; 2002WO-US013143.
 (NYCE/) NYCE J W.
 (SAND/) SANDRASAGRA A.
 (TANG/) TANG L.
 (AGUI/) AGUILAR D.
 (MILL/) MILLER S.
 (SHAH/) SHAHABUDDIN S.
 (LUHH/) LU H.
 (CONG/) CONG H.
 Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 Shahabuddin S, Lu H, Cong H;
 WPI; 2004-293804/27.
 Novel single or multiple target oligonucleotide anti-sense to e.g.
 initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 asthma.
 Claim 2; SEQ ID NO 1283; 174pp; English.
 The invention relates to oligonucleotides anti-sense to an initiation
 codon, coding region, 5' or 3' intron-exon junction, intron or region
 with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 also relates to a method of screening a candidate compound that binds to
 one or more nucleic acid target(s) or expressed product(s), for the
 prevention and/or treatment of a respiratory or lung disease. The
 oligonucleotides are useful for reducing or inhibiting expression of a
 gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 useful for preventing or treating a respiratory or lung disease. The
 respiratory or lung disease is associated with hyper-responsiveness to
 and/or increased levels of, adenosine and/or levels of adenosine A
 receptor(s), and/or asthma and/or lung allergies associated with
 inflammation or an inflammatory disease. The respiratory or lung disease
 is chosen from airway inflammation, allergy, asthma, impeded respiration,
 cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 allergic rhinitis, acute respiratory distress syndrome, pulmonary
 hypertension, lung inflammation, bronchitis, airway obstruction or
 bronchoconstriction. This sequence represents an oligonucleotide of the
 invention.
 Sequence 20 BP; 3 A; 6 C; 10 G; 1 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 81 CGGCTGCCGCACTCTCTGG 100
 |||||
 Db 20 CGGCTGCCGCACTCTCTGG 1

RESULT 1482
 ADO45729/c
 ID ADO45729 standard; DNA; 20 BP.
 XX ADO45729;
 XX
 XX 15-JUL-2004 (first entry)
 XX
 XX Human oligonucleotide #1095.
 XX
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX
 XX Claim 2; SEQ ID NO 1096; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease. The
 XX respiratory or lung disease is associated with hyper-responsiveness to
 XX and/or increased levels of, adenosine and/or levels of adenosine A
 XX receptor(s), and/or asthma and/or lung allergies associated with
 XX inflammation or an inflammatory disease. The respiratory or lung disease
 XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
 XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
 XX hypertension, lung inflammation, bronchitis, airway obstruction or
 XX bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.
 XX Sequence 20 BP; 3 A; 6 C; 10 G; 1 T; 0 U; 0 Other;
 XX Query Match 0.7%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX QY 81 CGGCTGCCGCACTCTCTGG 100
 XX |||||
 XX Db 20 CGGCTGCCGCACTCTCTGG 1

CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1951 GTGGGGGAGACATAGCCCCA 1970
 DB 20 GTGGGGGAGACATAGCCCCA 1

RESULT 1483
 ADO45764/c
 ID ADO45764 standard; DNA; 20 BP.
 AC ADO45764;
 XX

15-JUL-2004 (first entry)
 XX Human oligonucleotide #1130.
 XX

Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX

US2004049022-A1.
 XX 11-MAR-2004.
 XX

25-JUL-2003; 2003US-00627930.
 XX
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE// NYCE J W.
 PA (SAND// SANDRASAGRA A.
 PA (TANG// TANG L.
 PA (AGUI// AGUILAR D.
 PA (MILL// MILLER S.
 PA (SHAH// SHAHABUDDIN S.
 PA (LUHH// LU H.
 PA (CONG// CONG H.
 XX

Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX

WPI; 2004-293804/27.
 XX

Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX

Claim 2; SEQ ID NO 1131; 174pp; English.
 PS

The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC

CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX Sequence 20 BP; 0 A; 5 C; 6 G; 9 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1601 AACAGGCCCAAAAGGACC 1620
 DB 20 AACAGGCCCAAAAGGACC 1

RESULT 1484
 ADO45769/c
 ID ADO45769 standard; DNA; 20 BP.
 XX ADO45769;
 XX

15-JUL-2004 (first entry)
 XX Human oligonucleotide #1135.
 XX

Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX

US2004049022-A1.
 XX 11-MAR-2004.
 XX

25-JUL-2003; 2003US-00627930.
 XX
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX (NYCE// NYCE J W.
 PA (SAND// SANDRASAGRA A.
 PA (TANG// TANG L.
 PA (AGUI// AGUILAR D.
 PA (MILL// MILLER S.
 PA (SHAH// SHAHABUDDIN S.
 PA (LUHH// LU H.
 PA (CONG// CONG H.
 XX

Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX

XX WPI; 2004-293804/27.
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
PS Claim 2; SEQ ID NO 1136; 174bp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1551 CAGCAGCTACTCTATAACC 1570
DB 20 CAGCAGCTACTCTATAACC 1
RESULT 1485
ADO45790/c
ID ADO45790 standard; DNA; 20 BP.
XX
AC ADO45790;
XX
DT - 15-JUL-2004 (first entry)
XX
DE Human oligonucleotide #1156.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
OS Homo sapiens.
XX
XX US2004049022-A1.
PN
XX
PD 11-MAR-2004.
XX
XX 25-JUL-2003; 2003US-00627930.

XX
PR 23-APR-2002; 2002WO-US013135.
PR 23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H. H.
PA (CONG/) CONG H.
XX
XX NYCE JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
PS Claim 2; SEQ ID NO 1157; 174bp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1341 GCTCAAGTCTCTAAAGGATG 1360
DB 20 GCTCAAGTCTCTAAAGGATG 1
RESULT 1486
ADO45796/c
ID ADO45796 standard; DNA; 20 BP.
XX
AC ADO45796;
XX
XX 15-JUL-2004 (first entry)
DT
XX
DE Human oligonucleotide #1162.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;

KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX NYCE JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1163; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred.No. 5.4e-02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1281 GTGGCCAGAAAATTCGCCAGC 1300
 ||||||||||||||||||

Db 20 GTGGCCAGAAAATTCGCCAGC 1
 RESULT 1487
 ADO45812/C
 ID ADO45812 standard; DNA; 20 BP.
 XX
 AC ADO45812;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1178.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX NYCE JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1179; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease

CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 AGCTCTGCTGAAGCCACC 1140
 DB 20 AGCTCTGCTGAAGCCACC 1

RESULT 1488
 ADO45851/c
 ID ADO45851 standard; DNA; 20 BP.
 XX
 AC ADO45851;
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1217.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 1218; 174pp; English.
 PS
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target

CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX SQ Sequence 20 BP; 3 A; 9 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 731 GGGTCTAGAGTGGACAG 750
 DB 20 GGGTCTAGAGTGGACAG 1

RESULT 1489
 ADO45863/c
 ID ADO45863 standard; DNA; 20 BP.
 XX
 AC ADO45863;
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1229.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 PN US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX

PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRI,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1230; 174pp; English.
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC triptase a, triptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, triptase a,
 CC triptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 561 GGTCACGACACGGTCTGG 580
 Db |||||
 20 GGTCACGACACGGTCTGG 1
 RESULT 1490
 ADO45865/c
 ID ADO45865 standard; DNA; 20 BP.
 XX ADO45865;
 AC
 XX 15-JUL-2004 (first entry)
 DT Human oligonucleotide #1231.
 DE
 XX Human; 88; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCRI; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; triptase a;
 KW triptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 OS
 XX US2004049022-A1.
 PN
 XX 11-MAR-2004.
 PD

XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 PR
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUH/) LU H.
 PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCRI,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX Claim 2; SEQ ID NO 1232; 174pp; English.
 PS The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC triptase a, triptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCRI, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, triptase a,
 CC triptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 591 TCACCATGGAGCCAAATTTCT 610
 Db |||||
 20 TCACCATGGAGCCAAATTTCT 1
 RESULT 1491
 ADO45876/c
 ID ADO45876 standard; DNA; 20 BP.
 XX ADO45876;
 AC
 XX 15-JUL-2004 (first entry)
 DT Human oligonucleotide #1242.
 DE
 XX

KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 OS Homo sapiens.
 XX
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX
 XX Claim 2; SEQ ID NO 1243; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease. The
 XX and/or increased levels of, adenosine and/or levels of adenosine A
 XX receptor(s), and/or asthma and/or lung allergies associated with
 XX inflammation or an inflammatory disease. The respiratory or lung disease
 XX is chosen from airway inflammation, allergy, asthma, impeded respiration,
 XX cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 XX allergic rhinitis, acute respiratory distress syndrome, pulmonary
 XX hypertension, lung inflammation, bronchitis, airway obstruction or
 XX bronchoconstriction. This sequence represents an oligonucleotide of the
 XX invention.
 XX
 XX SQ Sequence 20 BP; 2 A; 4 C; 11 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 20; DB 1; Length 20;
 XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 481 CCCCGGCGCCCACTCACCGT 500
 Db 20 CCCCGGCGCCCACTCACCGT 1
 RESULT 1492
 ADO45889/c
 ID ADO45889 standard; DNA; 20 BP.
 XX
 XX ADO45889;
 XX
 XX 15-JUL-2004 (first entry)
 XX Human oligonucleotide #1255.
 XX
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 XX (SAND/) SANDRASAGRA A.
 XX (TANG/) TANG L.
 XX (AGUI/) AGUILAR D.
 XX (MILL/) MILLER S.
 XX (SHAH/) SHAHABUDDIN S.
 XX (LUHH/) LU H.
 XX (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 XX Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 XX RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 XX asthma.
 XX
 XX Claim 2; SEQ ID NO 1256; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 XX codon, coding region, 5' or 3' intron-exon junction, intron or region
 XX with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 XX chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 XX -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 XX tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 XX also relates to a method of screening a candidate compound that binds to
 XX one or more nucleic acid target(s) or expressed product(s), for the
 XX prevention and/or treatment of a respiratory or lung disease. The
 XX oligonucleotides are useful for reducing or inhibiting expression of a
 XX gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 XX tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 XX useful for preventing or treating a respiratory or lung disease. The
 XX respiratory or lung disease is associated with hyper-responsiveness to
 XX and/or increased levels of, adenosine and/or levels of adenosine A

CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 3 A; 5 C; 4 G; 8 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 351 TGGGCAGTCAACAGCTAAAA 370
 |||||
 DB 20 TGGGCAGTCAACAGCTAAAA 1

RESULT 1493
 ADP87907/c
 ID ADP87907 standard; DNA; 20 BP.
 XX
 AC ADP87907;
 XX
 DT 26-AUG-2004 (first entry)
 XX
 DE 2',5'-oligoadenylic acid analog related oligonucleotide #34.
 XX
 KW Cytostatic; virucide; 2'; 5'-oligoadenylic acid analog; antitumour;
 KW antiviral; cancer; ss.
 XX
 OS Synthetic.

XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= d
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone"
 FT modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2',4'-oxyethylene linkage in the sugar residues"
 FT modified_base 16..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2',4'-oxyethylene linkage in the sugar residues"
 FT modified_base 20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "A-hydroxyethyl phosphate"

XX
 PN WO2004046161-A1.
 XX
 PD 03-JUN-2004.
 XX
 PF 19-NOV-2003; 2003WO-JP014748.
 XX
 PR 19-NOV-2002; 2002JP-00334731.
 XX
 PA (SANY) SANKYO CO LTD.
 XX
 PI Koizumi M, Morita K;
 XX
 DR WPI; 2004-460494/43.
 XX
 PT Stable 2',5'-oligoadenylic acid analogs containing natural and modified
 PT nucleic acid units as well as unusual phosphate groups with excellent
 PT activity particularly antitumor, applicable in cancer or antiviral
 PT therapy.

XX
 PS Disclosure; Page 105-106; 220pp; Japanese.

XX
 CC The present invention relates to novel 2',5'-oligoadenylic acid analogs
 CC and their pharmacologically- acceptable salts. The analogs are stable
 CC with superior antitumour and antiviral activity and so are useful in
 CC cancer or antiviral therapy e.g. as antisease drugs. The present sequence
 CC was used to illustrate the invention.

XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
 |||||
 DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 1494
 ADP87902/c
 ID ADP87902 standard; DNA; 20 BP.
 XX
 AC ADP87902;
 XX
 DT 26-AUG-2004 (first entry)
 XX
 DE 2',5'-oligoadenylic acid analog related oligonucleotide #29.
 XX
 KW Cytostatic; virucide; 2'; 5'-oligoadenylic acid analog; antitumour;
 KW antiviral; cancer; ss.
 XX
 OS Synthetic.

XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2',4'-oxyethylene linkage in the sugar residues"
 FT modified_base 20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "A-hydroxyethyl phosphate"

XX
 PN WO2004046161-A1.
 XX
 PD 03-JUN-2004.
 XX
 PF 19-NOV-2003; 2003WO-JP014748.
 XX
 PR 19-NOV-2002; 2002JP-00334731.
 XX
 PA (SANY) SANKYO CO LTD.
 XX
 PI Koizumi M, Morita K;
 XX
 DR WPI; 2004-460494/43.
 XX
 PT Stable 2',5'-oligoadenylic acid analogs containing natural and modified
 PT nucleic acid units as well as unusual phosphate groups with excellent
 PT activity particularly antitumor, applicable in cancer or antiviral
 PT therapy.

XX
 PS Disclosure; Page 105; 220pp; Japanese.

XX
 CC The present invention relates to novel 2',5'-oligoadenylic acid analogs
 CC and their pharmacologically- acceptable salts. The analogs are stable
 CC with superior antitumour and antiviral activity and so are useful in
 CC cancer or antiviral therapy e.g. as antisease drugs. The present sequence
 CC was used to illustrate the invention.

XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;

PT Isolating fully thioated, single stranded antisense oligonucleotides from
PT a biological solution, useful in drug discovery, comprises contacting the
PT solution with an immobilized metal ion adsorption chromatography resin.

PS Example 1; Page 15; 28pp; English.

XX The invention relates to a method of isolating fully thioated single

CC stranded antisense oligonucleotides from a biological solution. The

CC method comprises contacting the biological solution with an immobilised

CC metal ion adsorption chromatography (IMAC) resin to adsorb antisense

CC oligonucleotides to the resin; and contacting the resin with an eluent

CC under conditions that provide desorption of the antisense

CC oligonucleotides from the resin, where the fully thioated antisense

CC oligonucleotides are separated from incorrectly thioated antisense

CC oligonucleotides in the solution. The invention also relates to antisense

CC oligonucleotides isolated using the method of the invention, and a kit

CC for purification of fully thioated single stranded antisense

CC oligonucleotides according to the method of the invention. The metal ion

CC used in the method is preferably Fe³⁺ or Zr²⁺, which are able to interact

CC with a backbone phosphorothioate group of a nucleic acid. The method

CC permits antisense oligonucleotides to be isolated from incorrectly

CC synthesised and/or non-fully thioated oligonucleotides to provide a

CC substantially pure preparation of the desired fully-thioate

CC oligonucleotides. The oligonucleotides isolated using the method may be

CC used therapeutically or other applications (e.g., drug discovery).

CC Compared to prior art methods, the method of the invention has improved

CC selectivity, reduces the need for organic solvents and/or high pressures,

CC and is easier to scale up and is hence more cost-effective. The present

CC sequence represents an antisense oligonucleotide used in the examples to

CC demonstrate the method of the invention. Three different forms of the

CC oligonucleotide were used: a fully phosphorothioated version, an

CC unmodified phosphodiester version, and a predominantly phosphorothioate

CC version in which two bonds (positions 10 and 15) are phosphodiester.

XX

SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119

DB ||||||||||||||||||

20 TGACGGATGCCAGCTTGGGC 1

RESULT 1497

ADP08716

ID ADP08716 standard; DNA; 20 BP.

XX

AC ADP08716;

XX

26-AUG-2004 (first entry)

XX

Extend primer 53 used to genotype human glycoprotein VI polymorphism.

XX

breat cancer; cytostatic; gene therapy; human; platelet glycoprotein VI;

KW GP6; GPIV; GPVI; chromosome 19q13.4; ss; PCR; primer; SNP;

KW single nucleotide polymorphism.

XX

Homo sapiens.

OS

WO2004047767-A2.

PN

10-JUN-2004.

XX

25-NOV-2003; 2003WO-US037966.

PF

25-NOV-2002; 2002US-0429136P.

XX

24-JUL-2003; 2003US-0490234P.

PR

(SEQU-) SEQUENOM INC.

PA

Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;

PI

WPI; 2004-441082/41.

XX

Identifying a subject at risk of breast cancer by detecting the presence

PT or absence of one or more nucleotide polymorphic variations, useful for

PT diagnosing, preventing and/or treating breast cancer.

XX

XX Example 3; Page 83; 286pp; English.

XX The invention relates to a novel method for identifying a subject at risk

CC of breast cancer which comprises detecting the presence or absence of one

CC or more polymorphic variations associated with breast cancer in a nucleic

CC acid sample from a subject. The method of the invention has cytostatic

CC applications and may be useful for identifying a risk of breast cancer,

CC as well as therapeutic and prophylactic treatments that specifically

CC target breast cancer, such as gene therapy. The current sequence is that

CC of an extend primer of the invention which was used to genotype single

CC nucleotide polymorphisms within human glycoprotein VI (platelet) (GP6;

CC GPIV;GPVI) DNA which is located at chromosomal position 19q13.4.

XX

SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2846 TCAGCCTCCTGAGTAGCTGG 2865

DB ||||||||||||||||||

1 TCAGCCTCCTGAGTAGCTGG 20

RESULT 1498

ADP45836

ID ADP45836 standard; DNA; 20 BP.

XX

AC ADP45836;

XX

26-AUG-2004 (first entry)

XX

Extend primer 28 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.

XX

breat cancer; cytostatic; gene therapy; human;

KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;

KW CD54; cell surface glycoprotein P3.58; ICAM-4;

KW Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;

KW ss; primer; PCR; SNP; single nucleotide polymorphism; probe.

XX

Homo sapiens.

OS

WO2004047623-A2.

PN

10-JUN-2004.

XX

25-NOV-2003; 2003WO-US037948.

PF

25-NOV-2002; 2002US-0429136P.

XX

24-JUL-2003; 2003US-0490234P.

PR

(SEQU-) SEQUENOM INC.

PA

Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;

PI

WPI; 2004-441051/41.

XX

Identifying a subject at risk of breast cancer by detecting the presence

PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE

PT regions which are associated with breast cancer in a nucleic acid sample

PT from a subject.

XX

XX Example 4; Page 83; 289pp; English.

XX The invention relates to a novel method for identifying a subject at risk

CC of breast cancer comprising detecting the presence or absence of one or

CC more polymorphic variations associated with breast cancer in a nucleic

CC acid sample from a subject. The method of the invention has cytostatic

CC applications and may be useful for identifying a subject at risk of

CC breast cancer, for early diagnosis, prevention and treatment of breast

CC cancer, possibly via gene therapy, as well as to analyse and predict a
 CC response to a breast cancer treatment and in clinical drug trials. The
 CC current sequence is that of an Extend primer (also described as probe) of
 CC the invention which was used to genotype human intercellular adhesion
 CC molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor; BB2
 CC CD54; cell surface glycoprotein P3.58) has been mapped to chromosomal
 CC position 19p13.3-p13.2, ICAM-4 (Landsteiner-Wiener blood group; LW) has
 CC been mapped to chromosomal position 19p13.2-cen and ICAM-5
 CC (telencephalin) has been mapped to chromosomal position 19p13.2.

XX SQ Sequence 20 BP; 3 A; 5 C; 4 G; 8 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2805 ACTGCAGCTCTGACCTTTTG 2824

Db 1 ACTGCAGCTCTGACCTTTTG 20

RESULT 1499

ADQ16468/C

ID ADQ16468 standard; DNA; 20 BP.

XX AC ADQ16468;

XX DT 09-SEP-2004 (first entry)

XX DE Modified oligonucleotide used for NMR analysis #4.

XX KW ss; antisense; hepatic tissue targeting; liver gene expression;
 XX KW improved biostability; altered biodistribution; DNA-RNA hybrid.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "OTHER = phosphorothioate backbone. Optionally

FT absent"

FT misc_RNA 1

FT /*tag= a

XX US6753423-B1.

XX PD 22-JUN-2004.

XX PF 10-APR-2000; 2000US-00546596.

XX PR 12-SEP-1997; 97US-00928823.

XX XX (ISIS-) ISIS PHARM INC.

XX PI Cook PD, Manoharan M, Bennett CF;

XX DR WPI; 2004-466815/44.

XX XX Targeting an antisense oligonucleotide to hepatic tissues to modulate the

FT expression of a gene in the liver involves conjugating the

FT oligonucleotide to a cholesteryl moiety and administering the conjugate.

XX Example 7; SEQ ID NO 17; 64pp; English.

XX CC The invention relates to a method of targeting an antisense

CC oligonucleotide to hepatic tissues involving conjugating the

CC oligonucleotide to a cholesteryl moiety and administering the conjugate.

CC The method is useful for targeting an antisense oligonucleotide to

CC hepatic tissues to modulate the expression of a gene in the liver. The

CC oligonucleotide is useful in diagnostics, therapeutics, as research

CC reagents and kits, in pharmaceutical composition and for treating

CC diseases produced by undesired production of proteins. The method

CC provides lipophilic oligonucleotide conjugates with improved biostability
 CC and altered biodistribution in mammals. The present sequence represents a
 CC modified oligonucleotide used for NMR analysis.

XX SQ Sequence 20 BP; 5 A; 4 C; 7 G; 3 T; 1 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37

Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 1500

ADQ75054/C

ID ADQ75054 standard; DNA; 20 BP.

XX AC ADQ75054;

XX DT 23-SEP-2004 (first entry)

XX DE Ligand conjugated oligomeric compound associated oligo seqid 4.

XX KW virucide; oligonucleotide binder; protein binder; serum binder;

XX KW vascular protein binder; cellular protein binder; oligomeric compound;

XX KW arylpropionic acid; ibuprofen; suprofen; fenbufen; ketoprofen;

XX KW (S)-(-)-pranoprofen; carprofen; integrin; diagnostic;

XX KW Epstein-Barr virus infection; EBV infection; pharmacokinetic property;

XX KW urinary excretion; serum half life; ss; ISIS 32361-1; ISIS 32362-1;

XX KW ISIS 29782-1.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT modified_base 1..19

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= Phosphodiester backbone with 2'-O-

FT methoxyethyl (MOE) nucleotides, or phosphorothioate

FT modified_base 2

FT /*tag= b

FT /mod_base= OTHER

FT /note= "OTHER= 5-methyl cytidine"

FT modified_base 10

FT /*tag= c

FT /mod_base= OTHER

FT /note= "OTHER= 5-methyl cytidine"

FT modified_base 18

FT /*tag= d

FT /mod_base= OTHER

FT /note= "OTHER= 5-methyl cytidine"

FT modified_base 20

FT /*tag= e

FT /mod_base= OTHER

FT /note= "OTHER= 3'-O-palmityl-aminoethyl-cytidine, 3'-O-

FT fluorenyl-aminoethyl-cytidine, 2'-O-PEG2000-

FT aminopropylcytidine, 2'-O-biotinylaminopropylcytidine or

FT 2'-O-pyrenylpropylcarbonylaminopropylcytidine"

XX US6762169-B1.

XX PD 13-JUL-2004.

XX PF 15-JUN-2000; 2000US-00594387.

XX PR 15-JUN-1999; 99US-00334130.

XX XX (ISIS-) ISIS PHARM INC.

XX PI Manoharan M;

XX DR WPI; 2004-532495/51.
 XX PT New oligomeric compound conjugated to an arylpropionic acid optionally
 PT interacting with a plasma protein useful for increasing the concentration
 PT of an oligonucleotide in serum.
 XX PS Example 28; SEQ ID NO 4; 42pp; English.
 XX CC The invention describes an oligomeric compound conjugated to an
 CC arylpropionic acid that optionally interacts with a plasma protein. The
 CC arylpropionic acid is ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(-)-
 CC pranoprofen, or carprofen (preferably ibuprofen). Also described is a
 CC method for increasing the concentration of an oligonucleotide in serum or
 CC promoting cellular uptake of an oligonucleotide in a cell involving:
 CC selecting an arylpropionic acid that is known to bind to a plasma protein
 CC or cell surface integrin; conjugating the arylpropionic acid to the
 CC oligonucleotide to form a conjugated oligonucleotide; and adding the
 CC conjugated oligonucleotide to the serum or exposing the cell to the
 CC conjugated oligonucleotide. The compound is also useful in diagnostic
 CC applications as well as therapeutic applications and for the treatment of
 CC latent Epstein-Barr virus (EBV) infection. The ligand-conjugated
 CC oligomeric compounds increase the concentration of an oligonucleotide in
 CC serum; increase the capacity of serum for an oligonucleotide; increase
 CC the binding of an oligonucleotide to a portion of the vascular system;
 CC promote cellular uptake of an oligonucleotide in cells; bind to protein
 CC molecules and possess enhanced pharmacokinetic properties. The ligand
 CC conjugated oligomeric compounds are capable of interacting with a protein
 CC or are conjugated to drug moieties. The oligomeric compounds can be
 CC prepared having covalently attached ligands that bind reversibly to at
 CC least one serum, vascular or cellular proteins. This reversible binding
 CC is expected to decrease urinary excretion, increase serum half life and
 CC greatly increase the distribution of oligomeric compounds thus
 CC conjugated. The compounds enhance the efficiency of oligonucleotide
 CC inhibition of gene expression. This sequence represents an
 CC oligonucleotide used in the creation of ligand conjugated oligomeric
 CC compounds of the invention.
 XX SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 18 GAGCTCCTCTGCTACTCAGA 37
 Db 20 GAGCTCCTCTGCTACTCAGA 1
 RESULT 1501
 ADQ76194/c
 ID ADQ76194 standard; DNA; 20 BP.
 XX AC ADQ76194;
 XX DT 23-SEP-2004 (first entry)
 XX DE Chemokine modulation-related human ICAM-1 RT-PCR primer SeqID28.
 XX KW chemokine activity; chemokine level; NF-HEV; antiinflammatory;
 KW gene therapy; inflammatory disorder; PCR; primer; ss; RT-PCR;
 KW reverse transcription PCR; human; ICAM-1.
 XX OS Homo sapiens.
 XX PN WO2004056868-A2.
 XX PD 08-JUL-2004.
 XX PF 18-DEC-2003; 2003WO-IB006477.
 XX PR 19-DEC-2002; 2002US-0435827P.
 XX

PA (ENDO-) ENDOCUBE SAS.
 PA (CNRS) CNRS CENT NAT RECH SCI.
 PA (UYOS-) UNIV OSLO.
 PA (GIRA/) GIRARD J.
 XX PI Aguilar L, Erard M, Haraldsen G, Baekkevold E, Veuger M;
 PI Brandtzaeg P;
 XX DR WPI; 2004-500287/47.
 XX PT Modulating the level or activity of a chemokine for preparing a
 PT composition for treating inflammatory disorder by modulating in an
 PT endothelial cell the level or activity of the NF-HEV polypeptide.
 XX PS Example 16; SEQ ID NO 28; 164pp; English.
 XX CC This invention relates to a novel method of modulating the level or
 CC activity of a chemokine which comprises modulating in an endothelial cell
 CC the level or activity of the NF-HEV polypeptide. The invention may be
 CC useful for the production of compounds with an antiinflammatory activity
 CC whilst the disclosed sequences may be used for gene therapy. The method
 CC is useful in modulating the level or activity of a chemokine for
 CC preparing a composition for treating inflammatory disorder. The present
 CC sequence is that of an RT-PCR primer which was used for amplification of
 CC a region of the human ICAM-1 gene in the exemplification of the
 CC invention.
 XX SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 279 CAACCGGAGGTTGTATGAAC 298
 Db 20 CAACCGGAGGTTGTATGAAC 1
 RESULT 1502
 ADQ29110/c
 ID ADQ29110 standard; DNA; 20 BP.
 XX AC ADQ29110;
 XX DT 07-OCT-2004 (first entry)
 XX DE Human ICAM-1 antisense oligonucleotide seqid 41.
 XX KW antimicrobial; antidiabetic; antirheumatic; antiarthritic;
 KW gastrointestinal; antiinflammatory; neuroprotective; dermatological;
 KW virucide; hepatotropic; human; TNF-alpha; tumour necrosis factor alpha;
 KW survivin; TNF-alpha associated disease; infection; diabetes;
 KW rheumatoid arthritis; Crohn's disease; pancreatitis; multiple sclerosis;
 KW atopic dermatitis; hepatitis; antisense oligonucleotide;
 KW antisense technology; ss; intracellular cell adhesion molecule-1; ICAM-1.
 XX OS Homo sapiens.
 XX PN US2004142346-A1.
 XX PD 22-JUL-2004.
 XX PF 29-AUG-2003; 2003US-00652795.
 XX PR 05-OCT-1998; 98US-00166186.
 PR 18-MAY-1999; 99US-00313932.
 PR 02-APR-2001; 2001US-00824322.
 XX (BAKE/) BAKER B F.
 PA (BENN/) BENNETT C F.
 PA (BUTL/) BUTLER M M.
 PA (SHAN/) SHANAHAN W R.
 XX

```

PI Baker BF, Bennett CF, Butler MM, Shanahan WR;
XX WPI; 2004-552557/53.
XX
XX New double stranded RNA compound inhibiting expression of human TNF-alpha
XX PT and survivin, useful for diagnosing, preventing or treating infection,
XX PT diabetes, arthritis, multiple sclerosis and hepatitis.
XX
XX Example 2; SEQ ID NO 41; 156pp; English.
XX
XX The invention describes a double stranded RNA compound 8-80 nucleobases
XX in length targeted to a nucleic acid molecule encoding human TNF-alpha,
XX where the compound specifically hybridises with the nucleic acid molecule
XX encoding TNF-alpha and inhibits the expression of survivin. Also
XX described is a double stranded RNA compound having a fully defined
XX sequence of 20 bp (SEQ ID NO: 432) as given in the specification. Also
XX disclosed are TNF-alpha polypeptides, host cells, vectors and antibodies
XX used in the methods of the invention. The methods and compositions of the
XX present invention are useful for the diagnosis, prevention and/or
XX treatment of diseases or conditions associated with aberrant expression
XX or activity of TNF-alpha, such as infection, diabetes, rheumatoid
XX arthritis, Crohn's disease, pancreatitis, multiple sclerosis, atopic
XX dermatitis and hepatitis. This sequence represents a human intracellular
XX adhesion molecule-1 (ICAM-1) antisense oligonucleotide used as a control
XX to test human tumour necrosis factor antisense oligonucleotides.
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTGGGC 2119
DB 20 TGACGGATGCCAGCTGGGC 1

RESULT 1503
ADQ29118/c
ID ADQ29118 standard; DNA; 20 BP.
XX
XX AC ADQ29118;
XX
XX 07-OCT-2004 (first entry)
XX
XX Human ICAM-1 antisense oligonucleotide seqid 49.
XX
XX antimicrobial; antidiabetic; antirheumatic; antiarthritic;
XX gastrointestinal; antiinflammatory; neuroprotective; dermatological;
XX virucide; hepatotropic; human; TNF-alpha; tumour necrosis factor alpha;
XX survivin; TNF-alpha associated disorder; infection; diabetes;
XX rheumatoid arthritis; Crohn's disease; pancreatitis; multiple sclerosis;
XX atopic dermatitis; hepatitis; antisense oligonucleotide;
XX antisense technology; ss; intracellular adhesion molecule-1; ICAM-1.
XX
XX Homo sapiens.
XX
XX US2004142346-A1.
XX
XX 22-JUL-2004.
XX
XX 29-AUG-2003; 2003US-00652795.
XX
XX 05-OCT-1998; 98US-00166186.
XX
XX 18-MAY-1999; 99US-00313932.
XX
XX 02-APR-2001; 2001US-00824322.
XX
XX (BAKE/) BAKER B F.
XX
XX (BENN/) BENNETT C F.
XX
XX (BUTL/) BUTLER M M.
XX
XX (SHAN/) SHANAHAN W R.
XX
PI Baker BF, Bennett CF, Butler MM, Shanahan WR;

WPI; 2004-552557/53.
New double stranded RNA compound inhibiting expression of human TNF-alpha
and survivin, useful for diagnosing, preventing or treating infection,
diabetes, arthritis, multiple sclerosis and hepatitis.
Example 5; SEQ ID NO 49; 156pp; English.
The invention describes a double stranded RNA compound 8-80 nucleobases
in length targeted to a nucleic acid molecule encoding human TNF-alpha,
where the compound specifically hybridises with the nucleic acid molecule
encoding TNF-alpha and inhibits the expression of survivin. Also
described is a double stranded RNA compound having a fully defined
sequence of 20 bp (SEQ ID NO: 432) as given in the specification. Also
disclosed are TNF-alpha polypeptides, host cells, vectors and antibodies
used in the methods of the invention. The methods and compositions of the
present invention are useful for the diagnosis, prevention and/or
treatment of diseases or conditions associated with aberrant expression
or activity of TNF-alpha, such as infection, diabetes, rheumatoid
arthritis, Crohn's disease, pancreatitis, multiple sclerosis, atopic
dermatitis and hepatitis. This sequence represents a human intracellular
adhesion molecule-1 (ICAM-1) antisense oligonucleotide used as a control
to test human tumour necrosis factor antisense oligonucleotides.
Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 1504
ADQ88549/c
ID ADQ88549 standard; DNA; 20 BP.
XX
XX AC ADQ88549;
XX
XX 07-OCT-2004 (first entry)
XX
XX Murine ICAM-1 antisense analogue DNA-RNA hybrid oligo, oligomer 62.
XX
XX Hepatic system; liver; transcription inhibition; DNA degradation;
XX therapy; murine; intercellular adhesion molecule 1; ICAM-1; antisense;
XX DNA-RNA hybrid; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1
XX /*tag= b
XX /mod_base= OTHER
XX /note= "Optionally 2'-O-hexylamino (dinitrophenyl)
XX uridine phosphoramidite or 2'-O- [hexylamino-
XX (cholesterol)] uridine phosphoramidite or 2'-O-
XX [hexylamino-(fluorescein)] amidite"
XX
XX misc_RNA 1
XX /*tag= a
XX /label= RNA
XX
XX modified_base 2..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2'-O-methyl substitutes"
XX
XX US2004142899-A1.
XX
XX 22-JUL-2004.
XX
XX 17-FEB-2004; 2004US-00780439.

```

```

XX PR 11-JAN-1990; 90US-00463358.
XX PR 13-AUG-1990; 90US-00566977.
XX PR 24-OCT-1991; 91US-00782374.
XX PR 23-OCT-1992; 92WO-US0009196.
XX PR 03-SEP-1993; 93US-00117363.
XX PR 05-JUN-1995; 95US-00464953.
XX PR 10-APR-2000; 2000US-00545596.
XX PA (ISIS-) ISIS PHARM INC.
XX XX
XX PI Cook PD, Manoharan M, Bennett CF;
XX XX
XX WPI; 2004-561278/54.
XX XX
XX PT Use of a lipophilic antisense compound for modulating expression of a
XX PT nucleic acid in the liver and associated tissue and hepatic gene
XX PT expression.
XX XX
XX PS Example 7; SEQ ID NO 17; 48pp; English.
XX XX
XX CC The invention relates to compositions and methods for enhanced
XX CC biostability and altered biodistribution of oligonucleotides in mammals.
XX CC The invention also relates to a method for modulating expression of
XX CC nucleic acid in hepatic system of a mammal. The method is useful for
XX CC modulating the expression of a nucleic acid in the liver and associated
XX CC tissue, gene expression in cell, tissue or organs; for inhibiting
XX CC transcription and/or replication of particular genes; for inducing
XX CC degradation of regions of double stranded DNA in cells; for killing cells
XX CC or virus; in diagnostics, therapeutics and as research reagents and kits.
XX CC The present sequence is a murine intercellular adhesion molecule 1 (ICAM-
XX CC 1) gene targeted antisense analogue DNA-RNA hybrid oligonucleotide. This
XX CC sequence is used to illustrate the method of the invention.
XX XX
XX SQ Sequence 20 BP; 5 A; 4 C; 7 G; 3 T; 1 U; 0 Other;
XX XX
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 1505
ADQ14892/c
ID ADQ14892 standard; DNA; 20 BP.
XX AC ADQ14892;
XX DT
XX DT 07-OCT-2004 (first entry)
XX XX
XX DE CD54 RNase H dependent antisense oligonucleotide seqid 16.
XX XX
XX KW multifunctional oligomeric compound; RNA expression modulator;
XX KW double-stranded oligomeric compound;
XX KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
XX KW antisense technology; ss; ISIS number 121740.
XX XX
XX OS Homo sapiens.
XX XX
XX FH Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= b
XX /*mod_base= OTHER
XX /*note= "OTHER= Phosphorothioate backbone"
XX modified_base 1..5
XX /*tag= a
XX /*mod_base= OTHER
XX /*note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX modified_base 15..20
XX /*tag= c

```

```

FT FT
XX XX /mod_base= OTHER
XX PN /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX XX US2004137471-A1.
XX PD 15-JUL-2004.
XX XX
XX PF 18-SEP-2003; 2003US-00664639.
XX XX
XX PR 18-SEP-2002; 2002US-0411780P.
XX XX
XX PA (VICK/) VICKERS T.
XX PA (KOOS/) KOO S.
XX PA (BENN/) BENNETT C F.
XX PA (CROO/) CROOKE S T.
XX PA (DEAN/) DEAN N M.
XX PA (BAKE/) BAKER B F.
XX XX
XX PI Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX XX
XX DR WPI; 2004-53354/51.
XX XX
XX PT Identifying a multifunctional oligomeric compound to modulate expression
XX PT of RNA comprises identifying an inhibiting antisense strand and
XX PT inhibiting double-stranded oligomeric compound as multifunctional
XX PT oligomeric compounds.
XX XX
XX PS Example 1; SEQ ID NO 16; 55pp; English.
XX XX
XX CC The invention describes a method of identifying a multifunctional
XX CC oligomeric compound to modulate expression of RNA. The method comprises:
XX CC contacting a target RNA with one or more double-stranded oligomeric
XX CC compounds hybridisable to one or more target regions of the RNA and
XX CC identifying double-stranded oligomeric compounds which inhibit target RNA
XX CC levels by at least 50%; contacting the target RNA with an antisense
XX CC strand of the modulating double-stranded oligomeric compound and
XX CC determining whether the antisense strand inhibits target RNA levels by at
XX CC least 50%; and identifying the inhibiting antisense strand and the
XX CC inhibiting double-stranded oligomeric compound as multifunctional
XX CC oligomeric compounds. Also described are: a multifunctional oligomeric
XX CC compound identified as above; a method for optimising target region
XX CC selection for modulation of RNA expression; a method of modulating RNA
XX CC expression; methods of optimising modulation of RNA; a method of
XX CC selecting a target region of a gene; a method of selecting an optimised
XX CC single-stranded oligomeric compound; a method of selecting an optimised
XX CC double-stranded oligomeric compound; a method of selecting a single-
XX CC stranded oligomeric compound; a method of identifying one or more optimised double
XX CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
XX CC in length, targeted to a target RNA, where the oligomeric compound
XX CC specifically hybridises the target RNA and the oligomeric compound
XX CC inhibits RNA levels by at least 50% in both single-stranded and double-
XX CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
XX CC targeted to a target RNA, where the oligomeric compound has a least 80%
XX CC sequence homology to the complement of the target RNA and where the
XX CC oligomeric compound inhibits RNA levels by at least 60% in both single-
XX CC stranded and double-stranded forms. The method is useful for identifying
XX CC a multifunctional oligomeric compound to modulate expression of RNA. This
XX CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
XX CC used to modulate RNA expression.
XX XX
XX SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1501 GTCATCATCAGTGTGAGC 1520
Db 20 GTCATCATCAGTGTGAGC 1

RESULT 1506

```

ADQ14896/c
ID ADQ14896 standard; DNA; 20 BP.
XX
AC
XX
ADQ14896;
XX
DT 07-OCT-2004 (first entry)
XX
DE CD54 RNase H dependent antisense oligonucleotide seqid 20.
XX
KW multifunctional oligomeric compound; RNA expression modulator;
KW double-stranded oligomeric compound;
KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
KW antisense technology; ss; ISIS number 121744.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
US2004137471-A1.
XX
XX
XX 15-JUL-2004.
XX
XX 18-SEP-2003; 2003US-00664639.
XX
XX 18-SEP-2002; 2002US-0411780P.
XX
XX (VICK/) VICKERS T.
XX (KOOS/) KOO S.
XX (BENN/) BENNETT C F.
XX (CROO/) CROOKE S T.
XX (DEAN/) DEAN N M.
XX (BAKE/) BAKER B F.
XX
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX
XX WPI; 2004-533354/51.
XX
XX Identifying a multifunctional oligomeric compound to modulate expression
PT of RNA comprises identifying an inhibiting antisense strand and
PT inhibiting double-stranded oligomeric compound as multifunctional
PT oligomeric compounds.
XX
XX Example 1; SEQ ID NO 20; 55pp; English.
XX
XX The invention describes a method of identifying a multifunctional
CC oligomeric compound to modulate expression of RNA. The method comprises:
CC contacting a target RNA with one or more double-stranded oligomeric
CC compounds hybridisable to one or more target regions of the RNA and
CC identifying double-stranded oligomeric compounds which inhibit target RNA
CC levels by at least 50%; contacting the target RNA with an antisense
CC strand of the modulating double-stranded oligomeric compound and
CC determining whether the antisense strand inhibits target RNA levels by at
CC least 50%; and identifying the inhibiting antisense strand and the
CC inhibiting double-stranded oligomeric compound as multifunctional
CC oligomeric compounds. Also described are: a multifunctional oligomeric
CC compound identified as above; a method for optimising target region
CC selection for modulation of RNA expression; a method of modulating RNA
CC expression; methods of optimising modulation of RNA; a method of
CC selecting a target region of a gene; a method of selecting an optimised
CC single-stranded oligomeric compound; a method of selecting an optimised
CC double-stranded oligomeric compound; a method of selecting a single-

CC stranded oligomeric compound; a method of selecting a double-stranded
CC oligomeric compound; a method of identifying one or more optimised double
CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-
CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
CC used to modulate RNA expression.
XX
SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1666 GGGACAGGGCCTCTTCCTCG 1685
Db 20 GGGACAGGGCCTCTTCCTCG 1

RESULT 1507
ADQ14913/c
ID ADQ14913 standard; DNA; 20 BP.
XX
AC ADQ14913;
XX
DT 07-OCT-2004 (first entry)
XX
DE CD54 RNase H dependent antisense oligonucleotide seqid 37.
XX
KW multifunctional oligomeric compound; RNA expression modulator;
KW double-stranded oligomeric compound;
KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
KW antisense technology; ss; ISIS number 121761.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
US2004137471-A1.
XX
XX 15-JUL-2004.
XX
XX 18-SEP-2003; 2003US-00664639.
XX
XX 18-SEP-2002; 2002US-0411780P.
XX
XX (VICK/) VICKERS T.
XX (KOOS/) KOO S.
XX (BENN/) BENNETT C F.
XX (CROO/) CROOKE S T.
XX (DEAN/) DEAN N M.
XX (BAKE/) BAKER B F.
XX
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX
XX WPI; 2004-533354/51.

XX
DR WPI; 2004-533354/51.
XX
XX Identifying a multifunctional oligomeric compound to modulate expression
PT of RNA comprises identifying an inhibiting antisense strand and
PT inhibiting double-stranded oligomeric compound as multifunctional
PT oligomeric compounds.
XX
XX Example 1; SEQ ID NO 37; 55pp; English.
XX
XX The invention describes a method of identifying a multifunctional
CC oligomeric compound to modulate expression of RNA. The method comprises:
CC contacting a target RNA with one or more double-stranded oligomeric
CC compounds hybridisable to one or more target regions of the RNA and
CC identifying double-stranded oligomeric compounds which inhibit target RNA
CC levels by at least 50%; contacting the target RNA with an antisense
CC strand of the modulating double-stranded oligomeric compound and
CC determining whether the antisense strand inhibits target RNA levels by at
CC least 50%; and identifying the inhibiting antisense strand and the
CC inhibiting double-stranded oligomeric compound as multifunctional
CC oligomeric compounds. Also described are: a multifunctional oligomeric
CC compound identified as above; a method for optimising target region
CC selection for modulation of RNA expression; a method of modulating RNA
CC expression; methods of optimising modulation of RNA; a method of
CC selecting a target region of a gene; a method of selecting an optimised
CC single-stranded oligomeric compound; a method of selecting an optimised
CC double-stranded oligomeric compound; a method of selecting a single-
CC stranded oligomeric compound; a method of selecting a double-stranded
CC oligomeric compound; a method of identifying one or more optimised double
CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-
CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
XX used to modulate RNA expression.
SQ Sequence 20 BP; 4 A; 3 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2831 AGTGATCCTCCACCTCAGC 2850
Db |||||||||||||||||||
20 AGTGATCCTCCACCTCAGC 1

RESULT 1508
ADQ14897/C
ID ADQ14897 standard; DNA; 20 BP.
XX
AC ADQ14897;
XX
XX 07-OCT-2004 (first entry)
XX
DE CD54 RNase H dependent antisense oligonucleotide seqid 21.
XX
XX multifunctional oligomeric compound; RNA expression modulator;
KW double-stranded oligomeric compound;
KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
KW antisense technology; ss; ISIS number 121745.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b

FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone"
FT 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX US2004137471-A1.
XX
XX 15-JUL-2004.
XX
XX 18-SEP-2003; 2003US-00664639.
XX
XX 18-SEP-2002; 2002US-0411780P.
XX
XX (VICK/) VICKERS T.
XX (KOOS/) KOO S.
XX (BENN/) BENNETT C F.
XX (CROO/) CROOKE S T.
XX (DEAN/) DEAN N M.
XX (BAKE/) BAKER B F.
XX
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
PI WPI; 2004-533354/51.
XX
XX Identifying a multifunctional oligomeric compound to modulate expression
PT of RNA comprises identifying an inhibiting antisense strand and
PT inhibiting double-stranded oligomeric compound as multifunctional
PT oligomeric compounds.
XX
XX Example 1; SEQ ID NO 21; 55pp; English.
XX
XX The invention describes a method of identifying a multifunctional
CC oligomeric compound to modulate expression of RNA. The method comprises:
CC contacting a target RNA with one or more double-stranded oligomeric
CC compounds hybridisable to one or more target regions of the RNA and
CC identifying double-stranded oligomeric compounds which inhibit target RNA
CC levels by at least 50%; contacting the target RNA with an antisense
CC strand of the modulating double-stranded oligomeric compound and
CC determining whether the antisense strand inhibits target RNA levels by at
CC least 50%; and identifying the inhibiting antisense strand and the
CC inhibiting double-stranded oligomeric compound as multifunctional
CC oligomeric compounds. Also described are: a multifunctional oligomeric
CC compound identified as above; a method for optimising target region
CC selection for modulation of RNA expression; a method of modulating RNA
CC expression; methods of optimising modulation of RNA; a method of
CC selecting a target region of a gene; a method of selecting an optimised
CC single-stranded oligomeric compound; a method of selecting an optimised
CC double-stranded oligomeric compound; a method of selecting a single-
CC stranded oligomeric compound; a method of selecting a double-stranded
CC oligomeric compound; a method of identifying one or more optimised double
CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-
CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
XX used to modulate RNA expression.
SQ Sequence 20 BP; 2 A; 6 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 100.0%; Pred. No. 5.4e+02;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1711 GCCACACTGAACAGAGTGGG 1730
 |||||
 Db 20 GCCACACTGAACAGAGTGGG 1

RESULT 1509
 ADQ14903/C
 ID ADQ14903 standard; DNA; 20 BP.
 XX
 AC ADQ14903;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE CD54 RNase H dependent antisense oligonucleotide seqid 27.
 XX
 KW multifunctional oligomeric compound; RNA expression modulator;
 KW double-stranded oligomeric compound;
 KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
 KW antisense technology; ss; ISIS number 121751.
 XX
 OS Homo sapiens.
 XX

Key Location/Qualifiers
 modified_base 1..20
 /tag= b
 /mod_base= OTHER
 /note= "OTHER= Phosphorothioate backbone"
 modified_base 1..5
 /tag= a
 /mod_base= OTHER
 /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 modified_base 15..20
 /tag= c
 /mod_base= OTHER
 /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 US2004137471-A1.
 15-JUL-2004.
 18-SEP-2003; 2003US-00664639.
 18-SEP-2002; 2002US-0411780P.

(WICK/) VICKERS T.
 (KOO/) KOO S.
 (BENN/) BENNETT C F.
 (CROO/) CROOKE S T.
 (DEAN/) DEAN N M.
 (BAKE/) BAKER B F.

Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
 WPI; 2004-533354/51.
 Identifying a multifunctional oligomeric compound to modulate expression
 of RNA comprises identifying an inhibiting antisense strand and
 inhibiting double-stranded oligomeric compound as multifunctional
 oligomeric compounds.
 Example 1; SEQ ID NO 27; 55pp; English.
 The invention describes a method of identifying a multifunctional
 oligomeric compound to modulate expression of RNA. The method comprises:
 contacting a target RNA with one or more double-stranded oligomeric
 compounds hybridisable to one or more target regions of the RNA and
 identifying double-stranded oligomeric compounds which inhibit target RNA
 levels by at least 50%; contacting the target RNA with an antisense
 strand of the modulating double-stranded oligomeric compound and
 determining whether the antisense strand inhibits target RNA levels by at
 least 50%; and identifying the inhibiting antisense strand and the

CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting a single-
 CC double-stranded oligomeric compound; a method of selecting a double-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.
 XX
 SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2056 TCCATAGACATGTGTAGCAT 2075
 |||||
 Db 20 TCCATAGACATGTGTAGCAT 1

RESULT 1510
 ADQ14909/C
 ID ADQ14909 standard; DNA; 20 BP.
 XX
 AC ADQ14909;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE CD54 RNase H dependent antisense oligonucleotide seqid 33.
 XX
 KW multifunctional oligomeric compound; RNA expression modulator;
 KW double-stranded oligomeric compound;
 KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
 KW antisense technology; ss; ISIS number 121757.
 XX
 OS Homo sapiens.
 XX

Key Location/Qualifiers
 modified_base 1..20
 /tag= b
 /mod_base= OTHER
 /note= "OTHER= Phosphorothioate backbone"
 modified_base 1..5
 /tag= a
 /mod_base= OTHER
 /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 modified_base 15..20
 /tag= c
 /mod_base= OTHER
 /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 US2004137471-A1.
 15-JUL-2004.
 18-SEP-2003; 2003US-00664639.
 18-SEP-2002; 2002US-0411780P.

PA (VICK/) VICKERS T.
 PA (KOOS/) KOO S.
 PA (BENN/) BENNETT C F.
 PA (CROO/) CROOKE S T.
 PA (DEAN/) DEAN N M.
 PA (BAKE/) BAKER B F.
 XX
 PI Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
 XX
 XX WPI; 2004-533354/51.
 DR
 XX Identifying a multifunctional oligomeric compound to modulate expression
 PT of RNA comprises identifying an inhibiting antisense strand and
 PT inhibiting double-stranded oligomeric compound as multifunctional
 PT oligomeric compounds.
 XX
 XX Example 1; SEQ ID NO 33; 55pp; English.
 PS
 XX The invention describes a method of identifying a multifunctional
 CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting a single-
 CC double-stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 5 G; 6 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2417 TCACAGGTTTCAGAGATTACC 2436
 |||||
 DB 20 TCACAGGTTTCAGAGATTACC 1
 RESULT 1511
 ADQ14881/C
 ID ADQ14881 standard; DNA; 20 BP.
 AC ADQ14881;
 XX
 XX 07-OCT-2004 (first entry)
 DT
 XX CD54 RNase H dependent antisense oligonucleotide seqid 5.
 DE
 XX multifunctional oligomeric compound; RNA expression modulator;
 KW double-stranded oligomeric compound;
 KW

KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
 KW antisense technology; ss; ISIS number 121729.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= Phosphorothioate backbone"
 FT
 FT modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 15..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 FT
 FT
 XX US2004137471-A1.
 PN
 XX 15-JUL-2004.
 PD
 XX 18-SEP-2003; 2003US-00664639.
 PF
 XX 18-SEP-2002; 2002US-0411780P.
 PR
 XX (VICK/) VICKERS T.
 XX (KOOS/) KOO S.
 XX (BENN/) BENNETT C F.
 XX (CROO/) CROOKE S T.
 XX (DEAN/) DEAN N M.
 XX (BAKE/) BAKER B F.
 XX
 PI Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
 XX
 XX WPI; 2004-533354/51.
 DR
 XX Identifying a multifunctional oligomeric compound to modulate expression
 PT of RNA comprises identifying an inhibiting antisense strand and
 PT inhibiting double-stranded oligomeric compound as multifunctional
 PT oligomeric compounds.
 XX
 XX Example 1; SEQ ID NO 5; 55pp; English.
 PS
 XX The invention describes a method of identifying a multifunctional
 CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting a single-
 CC double-stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying

CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;
 SQ

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 422 CCTCTTGCGAGCCAGTGGGC 441
 DB 20 CCTCTTGCGAGCCAGTGGGC 1

RESULT 1512
 ADQ14889/c
 ID ADQ14889 standard; DNA; 20 BP.
 XX
 AC ADQ14889;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE CD54 RNase H dependent antisense oligonucleotide seqid 13.
 XX
 KW multifunctional oligomeric compound; RNA expression modulator;
 KW double-stranded oligomeric compound;
 KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
 KW antisense technology; ss; ISIS number 121737.
 XX
 OS Homo sapiens.

XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= Phosphorothioate backbone"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 15..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 PN US2004137471-A1.
 XX
 XX 15-JUL-2004.
 XX
 XX 18-SEP-2003; 2003US-00664639.
 XX
 XX 18-SEP-2002; 2002US-0411780P.
 PR
 XX (VICK/) VICKERS T.
 PA (KOOS/) KOO S.
 PA (BENN/) BENNETT C F.
 PA (CROO/) CROOKE S T.
 PA (DEAN/) DEAN N M.
 PA (BAKE/) BAKER B F.
 XX
 XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
 PI WPI; 2004-533354/51.
 XX
 DR Identifying a multifunctional oligomeric compound to modulate expression
 XX of RNA comprises identifying an inhibiting antisense strand and
 PT inhibiting double-stranded oligomeric compound as multifunctional
 PT oligomeric compounds.
 XX
 XX Example 1; SEQ ID NO 13; 55pp; English.
 PS The invention describes a method of identifying a multifunctional
 XX

CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX
 SQ Sequence 20 BP; 7 A; 7 C; 4 G; 2 T; 0 U; 0 Other;
 XX

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1221 GGAGCTTCGTGCTCTGATG 1240
 DB 20 GGAGCTTCGTGCTCTGATG 1

RESULT 1513
 ADQ14911/c
 ID ADQ14911 standard; DNA; 20 BP.
 XX
 AC ADQ14911;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE CD54 RNase H dependent antisense oligonucleotide seqid 35.
 XX
 KW multifunctional oligomeric compound; RNA expression modulator;
 KW double-stranded oligomeric compound;
 KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
 KW antisense technology; ss; ISIS number 121759.
 XX
 OS Homo sapiens.

XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= Phosphorothioate backbone"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 15..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 XX

PN US2004137471-A1.
XX 15-JUL-2004.
XX 18-SEP-2003; 2003US-00664639.
XX 18-SEP-2002; 2002US-0411780P.
XX (VICK/) VICKERS T.
PA (KOOS/) KOO S.
PA (BENN/) BENNETT C F.
PA (CROO/) CROOKE S T.
PA (DEAN/) DEAN N M.
PA (BAKE/) BAKER B F.
XX
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
PI WPI; 2004-533354/51.
XX
XX Identifying a multifunctional oligomeric compound to modulate expression
PT of RNA comprises identifying an inhibiting antisense strand and
PT inhibiting double-stranded oligomeric compound as multifunctional
PT oligomeric compounds.
XX
XX Example 1; SEQ ID NO 35; 55pp; English.
XX
XX The invention describes a method of identifying a multifunctional
CC oligomeric compound to modulate expression of RNA. The method comprises:
CC contacting a target RNA with one or more double-stranded oligomeric
CC compounds hybridisable to one or more target regions of the RNA and
CC identifying double-stranded oligomeric compounds which inhibit target RNA
CC levels by at least 50%; contacting the target RNA with an antisense
CC strand of the modulating double-stranded oligomeric compound and
CC determining whether the antisense strand inhibits target RNA levels by at
CC least 50%; and identifying the inhibiting antisense strand and the
CC inhibiting double-stranded oligomeric compound as multifunctional
CC oligomeric compounds. Also described are: a multifunctional oligomeric
CC compound identified as above; a method for optimising target region
CC selection for modulation of RNA expression; a method of modulating RNA
CC expression; methods of optimising modulation of RNA; a method of
CC selecting a target region of a gene; a method of selecting an optimised
CC single-stranded oligomeric compound; a method of selecting a single-
CC double-stranded oligomeric compound; a method of selecting a double-stranded
CC oligomeric compound; a method of identifying one or more optimised double-
CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-
CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
CC used to modulate RNA expression.
XX
XX Sequence 20 BP; 6 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2619 TTGCACTATTGCAGCTCCAG 2638
|||||
DB 20 TTGCACTATTGCAGCTCCAG 1
RESULT 1514
ADQ14899/C
ID ADQ14899 standard; DNA; 20 BP.
XX

AC ADQ14899;
XX 07-OCT-2004 (first entry)
XX
XX CD54 RNase H dependent antisense oligonucleotide seqid 23.
XX multifunctional oligomeric compound; RNA expression modulator;
KW double-stranded oligomeric compound;
KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
XX antisense technology; ss; ISIS number 121747.
OS Homo sapiens.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX US2004137471-A1.
XX 15-JUL-2004.
XX 18-SEP-2003; 2003US-00664639.
XX 18-SEP-2002; 2002US-0411780P.
XX (VICK/) VICKERS T.
PA (KOOS/) KOO S.
PA (BENN/) BENNETT C F.
PA (CROO/) CROOKE S T.
PA (DEAN/) DEAN N M.
PA (BAKE/) BAKER B F.
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX WPI; 2004-533354/51.
XX Identifying a multifunctional oligomeric compound to modulate expression
PT of RNA comprises identifying an inhibiting antisense strand and
PT inhibiting double-stranded oligomeric compound as multifunctional
PT oligomeric compounds.
XX
XX Example 1; SEQ ID NO 23; 55pp; English.
XX
XX The invention describes a method of identifying a multifunctional
CC oligomeric compound to modulate expression of RNA. The method comprises:
CC contacting a target RNA with one or more double-stranded oligomeric
CC compounds hybridisable to one or more target regions of the RNA and
CC identifying double-stranded oligomeric compounds which inhibit target RNA
CC levels by at least 50%; contacting the target RNA with an antisense
CC strand of the modulating double-stranded oligomeric compound and
CC determining whether the antisense strand inhibits target RNA levels by at
CC least 50%; and identifying the inhibiting antisense strand and the
CC inhibiting double-stranded oligomeric compound as multifunctional
CC oligomeric compounds. Also described are: a multifunctional oligomeric
CC compound identified as above; a method for optimising target region
CC selection for modulation of RNA expression; a method of modulating RNA
CC expression; methods of optimising modulation of RNA; a method of
CC selecting a target region of a gene; a method of selecting an optimised
CC single-stranded oligomeric compound; a method of selecting a single-
CC double-stranded oligomeric compound; a method of selecting a double-stranded
CC oligomeric compound; a method of identifying one or more optimised double-
CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases

CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1818 CCATGGTACCTGCACACCTA 1837
 DB 20 CCATGGTACCTGCACACCTA 1

RESULT 1515
 ADQ14891/c
 ID ADQ14891 standard; DNA; 20 BP.

XX AC ADQ14891;

XX 07-OCT-2004 (first entry)

XX CD54 RNase H dependent antisense oligonucleotide seqid 15.

XX multifunctional oligomeric compound; RNA expression modulator;

XX double-stranded oligomeric compound;

XX CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;

XX antisense technology; ss; ISIS number 121739.

XX Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= Phosphorothioate backbone"

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

FT modified_base 15..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

XX US2004137471-A1.

XX 15-JUL-2004.

XX 18-SEP-2003; 2003US-00664639.

XX 18-SEP-2002; 2002US-0411780P.

XX (VICK/) VICKERS T.

XX (KOOS/) KOO S.

XX (BENN/) BENNETT C F.

XX (CROO/) CROOKE S T.

XX (DEAN/) DEAN N M.

XX (BAKE/) BAKER B F.

XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;

XX WPI; 2004-533354/51.

PT Identifying a multifunctional oligomeric compound to modulate expression
 PT of RNA comprises identifying an inhibiting antisense strand and
 PT inhibiting double-stranded oligomeric compound as multifunctional
 PT oligomeric compounds.

XX Example 1; SEQ ID NO 15; 55pp; English.

XX The invention describes a method of identifying a multifunctional
 CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC oligomeric compound; a method of identifying one or more optimised double
 CC oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX Sequence 20 BP; 3 A; 7 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1421 ACCTCTGTGGCCAGGAGC 1440

DB 20 ACCTCTGTGGCCAGGAGC 1

RESULT 1516

ADQ14900/c

ID ADQ14900 standard; DNA; 20 BP.

XX AC ADQ14900;

XX 07-OCT-2004 (first entry)

XX CD54 RNase H dependent antisense oligonucleotide seqid 24.

XX multifunctional oligomeric compound; RNA expression modulator;

XX double-stranded oligomeric compound;

XX CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;

XX antisense technology; ss; ISIS number 121748.

XX Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "OTHER= Phosphorothioate backbone"

FT modified_base 1..5

```
FT FT /*tag= a
FT FT /mod_base= OTHER
FT FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT FT modified_base 15..20
FT FT /*tag= c
FT FT /mod_base= OTHER
FT FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX XX
XX XX US2004137471-A1.
XX XX
XX XX 15-JUL-2004.
XX XX
XX XX 18-SEP-2003; 2003US-00664639.
XX XX
XX XX 18-SEP-2002; 2002US-0411780P.
XX XX
XX XX (VICK/) VICKERS T.
XX XX (KOOS/) KOO S.
XX XX (BENN/) BENNETT C F.
XX XX (CROO/) CROOKE S T.
XX XX (DEAN/) DEAN N M.
XX XX (BAKE/) BAKER B F.
XX XX
XX XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX XX WPI; 2004-533354/51.
XX XX
XX XX Identifying a multifunctional oligomeric compound to modulate expression
XX XX of RNA comprises identifying an inhibiting antisense strand and
XX XX inhibiting double-stranded oligomeric compound as multifunctional
XX XX oligomeric compounds.
XX XX
XX XX Example 1; SEQ ID NO 24; 55pp; English.
XX XX
XX XX The invention describes a method of identifying a multifunctional
XX XX oligomeric compound to modulate expression of RNA. The method comprises:
XX XX contacting a target RNA with one or more double-stranded oligomeric
XX XX compounds hybridisable to one or more target regions of the RNA and
XX XX identifying double-stranded oligomeric compounds which inhibit target RNA
XX XX levels by at least 50%; contacting the target RNA with an antisense
XX XX strand of the modulating double-stranded oligomeric compound and
XX XX determining whether the antisense strand inhibits target RNA levels by at
XX XX least 50%; and identifying the inhibiting antisense strand and the
XX XX inhibiting double-stranded oligomeric compound as multifunctional
XX XX oligomeric compounds. Also described are: a multifunctional oligomeric
XX XX compound identified as above; a method for optimising target region
XX XX selection for modulation of RNA expression; a method of modulating RNA
XX XX expression; methods of optimising modulation of RNA; a method of
XX XX selecting a target region of a gene; a method of selecting an optimised
XX XX single-stranded oligomeric compound; a method of selecting an optimised
XX XX double-stranded oligomeric compound; a method of selecting a single-
XX XX stranded oligomeric compound; a method of selecting a double-stranded
XX XX oligomeric compound; a method of identifying one or more optimised double
XX XX -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
XX XX in length, targeted to a target RNA, where the oligomeric compound
XX XX specifically hybridises the target RNA and the oligomeric compound
XX XX inhibits RNA levels by at least 50% in both single-stranded and double-
XX XX stranded forms; and an oligomeric compound, 8-80 nucleobases in length
XX XX targeted to a target RNA, where the oligomeric compound has a least 80%
XX XX sequence homology to the complement of the target RNA and where the
XX XX oligomeric compound inhibits RNA levels by at least 60% in both single-
XX XX stranded and double-stranded forms. The method is useful for identifying
XX XX a multifunctional oligomeric compound to modulate expression of RNA. This
XX XX sequence represents a CD54 RNase H dependent oligonucleotide that can be
XX XX used to modulate RNA expression.
XX XX
XX XX Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;
XX XX
XX XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Db 20 AAGTCTAGCCTGATGAGG 1
|||||
RESULT 1517
ADQ14908/c
ID ADQ14908 standard; DNA; 20 BP.
XX
XX AC ADQ14908;
XX
XX DT 07-OCT-2004 (first entry)
XX
XX DE CD54 RNase H dependent antisense oligonucleotide seqid 32.
XX
XX KW multifunctional oligomeric compound; RNA expression modulator;
XX double-stranded oligomeric compound;
XX KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
XX antisense technology; ss; ISIS number 121756.
XX
XX OS Homo sapiens.
XX
XX FH Key Location/Qualifiers
XX modified_base 1..20
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "OTHER= Phosphorothioate backbone"
XX
XX FT modified_base 1..5
XX FT /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX FT modified_base 15..20
XX FT /*tag= c
XX FT /mod_base= OTHER
XX FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX US2004137471-A1.
XX
XX PN 15-JUL-2004.
XX
XX PD
XX
XX PF 18-SEP-2003; 2003US-00664639.
XX
XX PR 18-SEP-2002; 2002US-0411780P.
XX
XX XX (VICK/) VICKERS T.
XX XX (KOOS/) KOO S.
XX XX (BENN/) BENNETT C F.
XX XX (CROO/) CROOKE S T.
XX XX (DEAN/) DEAN N M.
XX XX (BAKE/) BAKER B F.
XX
XX XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX XX WPI; 2004-533354/51.
XX
XX XX Identifying a multifunctional oligomeric compound to modulate expression
XX XX of RNA comprises identifying an inhibiting antisense strand and
XX XX inhibiting double-stranded oligomeric compound as multifunctional
XX XX oligomeric compounds.
XX XX
XX XX Example 1; SEQ ID NO 32; 55pp; English.
XX XX
XX XX The invention describes a method of identifying a multifunctional
XX XX oligomeric compound to modulate expression of RNA. The method comprises:
XX XX contacting a target RNA with one or more double-stranded oligomeric
XX XX compounds hybridisable to one or more target regions of the RNA and
XX XX identifying double-stranded oligomeric compounds which inhibit target RNA
XX XX levels by at least 50%; contacting the target RNA with an antisense
XX XX strand of the modulating double-stranded oligomeric compound and
XX XX determining whether the antisense strand inhibits target RNA levels by at
XX XX least 50%; and identifying the inhibiting antisense strand and the
XX XX inhibiting double-stranded oligomeric compound as multifunctional
XX XX oligomeric compounds. Also described are: a multifunctional oligomeric
XX XX compound identified as above; a method for optimising target region
XX XX selection for modulation of RNA expression; a method of modulating RNA
XX XX expression; methods of optimising modulation of RNA; a method of
XX XX selecting a target region of a gene; a method of selecting an optimised
XX XX single-stranded oligomeric compound; a method of selecting an optimised
XX XX double-stranded oligomeric compound; a method of selecting a single-
XX XX stranded oligomeric compound; a method of selecting a double-stranded
XX XX oligomeric compound; a method of identifying one or more optimised double
XX XX -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
XX XX in length, targeted to a target RNA, where the oligomeric compound
XX XX specifically hybridises the target RNA and the oligomeric compound
XX XX inhibits RNA levels by at least 50% in both single-stranded and double-
XX XX stranded forms; and an oligomeric compound, 8-80 nucleobases in length
XX XX targeted to a target RNA, where the oligomeric compound has a least 80%
XX XX sequence homology to the complement of the target RNA and where the
XX XX oligomeric compound inhibits RNA levels by at least 60% in both single-
XX XX stranded and double-stranded forms. The method is useful for identifying
XX XX a multifunctional oligomeric compound to modulate expression of RNA. This
XX XX sequence represents a CD54 RNase H dependent oligonucleotide that can be
XX XX used to modulate RNA expression.
XX XX
XX XX Sequence 20 BP; 4 A; 7 C; 3 G; 6 T; 0 U; 0 Other;
```

CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX Sequence 20 BP; 6 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2341 CATTGGCCACCTGCCCTTC 2360

Db 20 CATTGGCCACCTGCCCTTC 1

RESULT 1518

ADQ14912/c

ID ADQ14912 standard; DNA; 20 BP.

AC ADQ14912;

XX 07-OCT-2004 (first entry)

XX CD54 RNase H dependent antisense oligonucleotide seqid 36.

XX multifunctional oligomeric compound; RNA expression modulator;

XX double-stranded oligomeric compound;

XX CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;

XX antisense technology; ss; ISIS number 121760.

XX Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "OTHER= Phosphorothioate backbone"

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

FT modified_base 15..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

XX US2004137471-A1.

XX 15-JUL-2004.

XX 18-SEP-2003; 2003US-00664639.

XX 18-SEP-2002; 2002US-0411780P.

XX (VICK/) VICKERS T.

PA (KOOS/) KOO S.

PA (BENN/) BENNETT C F.

(CROO/) CROOKE S T.

PA (DEAN/) DEAN N M.

PA (BAKE/) BAKER B F.

XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;

XX WPI; 2004-533354/51.

XX Identifying a multifunctional oligomeric compound to modulate expression
 of RNA comprises identifying an inhibiting antisense strand and
 PT inhibiting double-stranded oligomeric compound as multifunctional
 PT oligomeric compounds.

XX Example 1; SEQ ID NO 36; 55pp; English.

XX The invention describes a method of identifying a multifunctional
 CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX Sequence 20 BP; 10 A; 8 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2731 TGTGTGTGTGTATGTGTA 2750

Db 20 TGTGTGTGTGTATGTGTA 1

RESULT 1519

ADQ14882/c

ID ADQ14882 standard; DNA; 20 BP.

XX AC ADQ14882;

XX 07-OCT-2004 (first entry)

XX CD54 RNase H dependent antisense oligonucleotide seqid 6.

XX multifunctional oligomeric compound; RNA expression modulator;

XX double-stranded oligomeric compound;

XX CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;

XX antisense technology; ss; ISIS number 121730.

OS Homo sapiens.
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX US2004137471-A1.
XX 15-JUL-2004.
XX 18-SEP-2003; 2003US-00664639.
XX 18-SEP-2002; 2002US-0411780P.
XX (VICK/) VICKERS T.
XX (KOOS/) KOO S.
XX (BENN/) BENNETT C F.
XX (CROO/) CROOKE S T.
XX (DEAN/) DEAN N M.
XX (BAKE/) BAKER B F.
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX WPI; 2004-533354/51.
XX Identifying a multifunctional oligomeric compound to modulate expression
PT of RNA comprises identifying an inhibiting antisense strand and
PT inhibiting double-stranded oligomeric compound as multifunctional
PT oligomeric compounds.
XX Example 1; SEQ ID NO 6; 55pp; English.
XX The invention describes a method of identifying a multifunctional
CC oligomeric compound to modulate expression of RNA. The method comprises:
CC contacting a target RNA with one or more double-stranded oligomeric
CC compounds hybridisable to one or more target regions of the RNA and
CC identifying double-stranded oligomeric compounds which inhibit target RNA
CC levels by at least 50%; contacting the target RNA with an antisense
CC strand of the modulating double-stranded oligomeric compound and
CC determining whether the antisense strand inhibits target RNA levels by at
CC least 50%; and identifying the inhibiting antisense strand and the
CC inhibiting double-stranded oligomeric compound as multifunctional
CC oligomeric compounds. Also described are: a multifunctional oligomeric
CC compound identified as above; a method for optimising target region
CC selection for modulation of RNA expression; a method of modulating RNA
CC expression; methods of optimising modulation of RNA; a method of
CC selecting a target region of a gene; a method of selecting an optimised
CC single-stranded oligomeric compound; a method of selecting a single-
CC stranded oligomeric compound; a method of selecting a double-stranded
CC oligomeric compound; a method of identifying one or more optimised double
CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-
CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
CC used to modulate RNA expression.

XX SQ Sequence 20 BP; 3 A; 10 C; 2 G; 5 T; 0 U; 0 Other;
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. NO. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 571 ACGTGCTGCTGGTGGAGAGAGA 590
DB 20 ACGTGCTGCTGGTGGAGAGAGA 1
RESULT 1520
ADQ14883/c
ID ADQ14883 standard; DNA; 20 BP.
XX AC ADQ14883;
XX DT 07-OCT-2004 (first entry)
XX DE CD54 RNase H dependent antisense oligonucleotide seqid 7.
XX KW multifunctional oligomeric compound; RNA expression modulator;
XX KW double-stranded oligomeric compound;
XX KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
XX KW antisense technology; ss; ISIS number 121731.
XX OS Homo sapiens.
XX FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX US2004137471-A1.
XX 15-JUL-2004.
XX 18-SEP-2003; 2003US-00664639.
XX 18-SEP-2002; 2002US-0411780P.
XX (VICK/) VICKERS T.
XX (KOOS/) KOO S.
XX (BENN/) BENNETT C F.
XX (CROO/) CROOKE S T.
XX (DEAN/) DEAN N M.
XX (BAKE/) BAKER B F.
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX WPI; 2004-533354/51.
XX Identifying a multifunctional oligomeric compound to modulate expression
PT of RNA comprises identifying an inhibiting antisense strand and
PT inhibiting double-stranded oligomeric compound as multifunctional
PT oligomeric compounds.
XX Example 1; SEQ ID NO 7; 55pp; English.
XX The invention describes a method of identifying a multifunctional
CC oligomeric compound to modulate expression of RNA. The method comprises:
CC contacting a target RNA with one or more double-stranded oligomeric
CC compounds hybridisable to one or more target regions of the RNA and
CC identifying double-stranded oligomeric compounds which inhibit target RNA
CC levels by at least 50%; contacting the target RNA with an antisense
CC strand of the modulating double-stranded oligomeric compound and
CC determining whether the antisense strand inhibits target RNA levels by at
CC least 50%; and identifying the inhibiting antisense strand and the
CC inhibiting double-stranded oligomeric compound as multifunctional
CC oligomeric compounds. Also described are: a multifunctional oligomeric
CC compound identified as above; a method for optimising target region
CC selection for modulation of RNA expression; a method of modulating RNA
CC expression; methods of optimising modulation of RNA; a method of
CC selecting a target region of a gene; a method of selecting an optimised
CC single-stranded oligomeric compound; a method of selecting a single-
CC stranded oligomeric compound; a method of selecting a double-stranded
CC oligomeric compound; a method of identifying one or more optimised double
CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-
CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
CC used to modulate RNA expression.

CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX
 SQ Sequence 20 BP; 5 A; 2 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. NO. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 674 CCTACCAGCTCCAGACCTTT 693
 DB 20 CCTACCAGCTCCAGACCTTT 1

RESULT 1521

ID ADQ14893/C
 ADQ14893 standard; DNA; 20 BP.

AC ADQ14893;

DT 07-OCT-2004 (first entry)

DE CD54 RNase H dependent antisense oligonucleotide seqid 17.

XX multifunctional oligomeric compound; RNA expression modulator;

KW double-stranded oligomeric compound;

KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;

KW antisense technology; ss; ISIS number 121741.

XX Homo sapiens.

OS

FT Key Location/Qualifiers

FT modified_base 1..20

FT /tag= b

FT /mod_base= OTHER

FT /note= "OTHER= Phosphorothioate backbone"

FT modified_base 1..5

FT /tag= a

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

FT modified_base 15..20

FT /tag= c

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

PN US2004137471-A1.

XX

PD 15-JUL-2004.

XX 18-SEP-2003; 2003US-00664639.
 XX 18-SEP-2002; 2002US-0411780P.

XX (VICK/) VICKERS T.
 XX (KOOS/) KOO S.
 XX (BENN/) BENNETT C F.
 XX (CROO/) CROOKE S T.
 XX (DEAN/) DEAN N M.
 XX (BAKE/) BAKER B F.

XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
 WIPI; 2004-533354/51.

XX Identifying a multifunctional oligomeric compound to modulate expression
 of RNA comprises identifying an inhibiting antisense strand and
 PT inhibiting double-stranded oligomeric compound as multifunctional
 PT oligomeric compounds.

XX Example 1; SEQ ID NO 17; 55pp; English.

XX The invention describes a method of identifying a multifunctional
 CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX Sequence 20 BP; 1 A; 2 C; 7 G; 10 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. NO. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1622 CCATGAACCGAACACACAA 1641

DB 20 CCATGAACCGAACACACAA 1

RESULT 1522

ADQ14894/C

ID ADQ14894 standard; DNA; 20 BP.

XX ADQ14894;

XX

DT 07-OCT-2004 (first entry)

XX CD54 RNase H dependent antisense oligonucleotide seqid 18.
DE
XX multifunctional oligomeric compound; RNA expression modulator;
XX double-stranded oligomeric compound;
KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
KW antisense technology; ss; ISIS number 121742.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN US2004137471-A1.
XX
XX 15-JUL-2004.
XX
XX 18-SEP-2003; 2003US-00664639.
XX
XX 18-SEP-2002; 2002US-0411780P.
XX
XX (VICK/) VICKERS T.
XX (KOOS/) KOO S.
XX (BENN/) BENNETT C F.
XX (CROO/) CROOKE S T.
XX (DEAN/) DEAN N M.
XX (BAKE/) BAKER B F.
XX
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
PI WPI; 2004-533354/51.
XX
XX Identifying a multifunctional oligomeric compound to modulate expression
of RNA comprises identifying an inhibiting antisense strand and
PT inhibiting double-stranded oligomeric compound as multifunctional
PT oligomeric compounds.
XX
XX Example 1; SEQ ID NO 18; 55pp; English.
XX
XX The invention describes a method of identifying a multifunctional
CC oligomeric compound to modulate expression of RNA. The method comprises:
CC contacting a target RNA with one or more double-stranded oligomeric
CC compounds hybridisable to one or more target regions of the RNA and
CC identifying double-stranded oligomeric compounds which inhibit target RNA
CC levels by at least 50%; contacting the target RNA with an antisense
CC strand of the modulating double-stranded oligomeric compound and
CC determining whether the antisense strand inhibits target RNA levels by at
CC least 50%; and identifying the inhibiting antisense strand and the
CC inhibiting double-stranded oligomeric compound as multifunctional
CC oligomeric compounds. Also described are: a multifunctional oligomeric
CC compound identified as above; a method for optimising target region
CC selection for modulation of RNA expression; a method of modulating RNA
CC expression; methods of optimising modulation of RNA; a method of
CC selecting a target region of a gene; a method of selecting an optimised
CC single-stranded oligomeric compound; a method of selecting a single-
CC double-stranded oligomeric compound; a method of selecting a double-stranded
CC oligomeric compound; a method of identifying one or more optimised double
CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-

CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
CC used to modulate RNA expression.
XX
XX Sequence 20 BP; 1 A; 2 C; 10 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1633 AACACACAGCCAGCCCTCC 1652
Db 20 AACACACAGCCAGCCCTCC 1
|||||||
RESULT 1523
ADQ14879/c
ID ADQ14879 standard; DNA; 20 BP.
XX
XX AC ADQ14879;
XX
XX 07-OCT-2004 (first entry)
XX
XX CD54 RNase H dependent antisense oligonucleotide seqid 3.
XX
XX multifunctional oligomeric compound; RNA expression modulator;
KW double-stranded oligomeric compound;
KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
KW antisense technology; ss; ISIS number 121727.
XX
XX Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX US2004137471-A1.
XX
XX 15-JUL-2004.
XX
XX 18-SEP-2003; 2003US-00664639.
XX
XX 18-SEP-2002; 2002US-0411780P.
XX
XX (VICK/) VICKERS T.
XX (KOOS/) KOO S.
XX (BENN/) BENNETT C F.
XX (CROO/) CROOKE S T.
XX (DEAN/) DEAN N M.
XX (BAKE/) BAKER B F.
XX
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
PI WPI; 2004-533354/51.
XX
XX Identifying a multifunctional oligomeric compound to modulate expression
of RNA comprises identifying an inhibiting antisense strand and
PT inhibiting double-stranded oligomeric compound as multifunctional
PT oligomeric compounds.
XX
XX Example 1; SEQ ID NO 18; 55pp; English.
XX
XX The invention describes a method of identifying a multifunctional
CC oligomeric compound to modulate expression of RNA. The method comprises:
CC contacting a target RNA with one or more double-stranded oligomeric
CC compounds hybridisable to one or more target regions of the RNA and
CC identifying double-stranded oligomeric compounds which inhibit target RNA
CC levels by at least 50%; contacting the target RNA with an antisense
CC strand of the modulating double-stranded oligomeric compound and
CC determining whether the antisense strand inhibits target RNA levels by at
CC least 50%; and identifying the inhibiting antisense strand and the
CC inhibiting double-stranded oligomeric compound as multifunctional
CC oligomeric compounds. Also described are: a multifunctional oligomeric
CC compound identified as above; a method for optimising target region
CC selection for modulation of RNA expression; a method of modulating RNA
CC expression; methods of optimising modulation of RNA; a method of
CC selecting a target region of a gene; a method of selecting an optimised
CC single-stranded oligomeric compound; a method of selecting a single-
CC double-stranded oligomeric compound; a method of selecting a double-stranded
CC oligomeric compound; a method of identifying one or more optimised double
CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-

```

PT oligomeric compounds.
XX
XX Example 1; SEQ ID NO 3; 55pp; English.
XX
CC The invention describes a method of identifying a multifunctional
CC oligomeric compound to modulate expression of RNA. The method comprises:
CC contacting a target RNA with one or more double-stranded oligomeric
CC compounds hybridisable to one or more target regions of the RNA and
CC identifying double-stranded oligomeric compounds which inhibit target RNA
CC levels by at least 50%; contacting the target RNA with an antisense
CC strand of the modulating double-stranded oligomeric compound and
CC determining whether the antisense strand inhibits target RNA levels by at
CC least 50%; and identifying the inhibiting antisense strand and the
CC inhibiting double-stranded oligomeric compound as multifunctional
CC oligomeric compounds. Also described are: a multifunctional oligomeric
CC compound identified as above; a method for optimising target region
CC selection for modulation of RNA expression; a method of modulating RNA
CC expression; methods of optimising modulation of RNA; a method of
CC selecting a target region of a gene; a method of selecting an optimised
CC single-stranded oligomeric compound; a method of selecting an optimised
CC double-stranded oligomeric compound; a method of selecting a single-
CC stranded oligomeric compound; a method of selecting a double-stranded
CC oligomeric compound; a method of identifying one or more optimised double
CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-
CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
CC used to modulate RNA expression.
XX
XX Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 256 AAGAGTGTCTCTGCTGG 275
DB 20 AAGAGTGTCTCTGCTGG 1
RESULT 1524
ADQ14902/c
ID ADQ14902 standard; DNA; 20 BP.
XX
XX ADQ14902;
XX
XX 07-OCT-2004 (first entry)
XX
XX CD54 RNase H dependent antisense oligonucleotide seqid 26.
XX multifunctional oligomeric compound; RNA expression modulator;
XX double-stranded oligomeric compound;
XX CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
XX antisense technology; ss; ISIS number 121750.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT

```

```

FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX US2004137471-A1.
XX
XX 15-JUL-2004.
XX
XX 18-SEP-2003; 2003US-00664639.
XX
XX 18-SEP-2002; 2002US-0411780P.
XX (VICK// VICKERS T.
XX (KOOS// KOO S.
XX (BENN// BENNETT C F.
XX (CROO// CROOKE S T.
XX (DEAN// DEAN N M.
XX (BAKE// BAKER B F.
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX WPI; 2004-533354/51.
XX
XX Identifying a multifunctional oligomeric compound to modulate expression
XX of RNA comprises identifying an inhibiting antisense strand and
XX inhibiting double-stranded oligomeric compound as multifunctional
XX oligomeric compounds.
XX
XX Example 1; SEQ ID NO 26; 55pp; English.
XX
XX The invention describes a method of identifying a multifunctional
XX oligomeric compound to modulate expression of RNA. The method comprises:
XX contacting a target RNA with one or more double-stranded oligomeric
XX compounds hybridisable to one or more target regions of the RNA and
XX identifying double-stranded oligomeric compounds which inhibit target RNA
XX levels by at least 50%; contacting the target RNA with an antisense
XX strand of the modulating double-stranded oligomeric compound and
XX determining whether the antisense strand inhibits target RNA levels by at
XX least 50%; and identifying the inhibiting antisense strand and the
XX inhibiting double-stranded oligomeric compound as multifunctional
XX oligomeric compounds. Also described are: a multifunctional oligomeric
XX compound identified as above; a method for optimising target region
XX selection for modulation of RNA expression; a method of modulating RNA
XX expression; methods of optimising modulation of RNA; a method of
XX selecting a target region of a gene; a method of selecting an optimised
XX double-stranded oligomeric compound; a method of selecting a single-
XX stranded oligomeric compound; a method of selecting a double-stranded
XX oligomeric compound; an oligomeric compound, 8-80 nucleobases
XX in length, targeted to a target RNA, where the oligomeric compound
XX specifically hybridises the target RNA and the oligomeric compound
XX inhibits RNA levels by at least 50% in both single-stranded and double-
XX stranded forms; and an oligomeric compound, 8-80 nucleobases in length
XX targeted to a target RNA, where the oligomeric compound has a least 80%
XX sequence homology to the complement of the target RNA and where the
XX oligomeric compound inhibits RNA levels by at least 60% in both single-
XX stranded and double-stranded forms. The method is useful for identifying
XX a multifunctional oligomeric compound to modulate expression of RNA. This
XX sequence represents a CD54 RNase H dependent oligonucleotide that can be
XX used to modulate RNA expression.
XX
XX Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2012 TATTGGGTATGCTGAGGCC 2031
DB 20 TATTGGGTATGCTGAGGCC 1

```



```

CC single-stranded oligomeric compound; a method of selecting an optimised
CC double-stranded oligomeric compound; a method of selecting a single-
CC stranded oligomeric compound; a method of identifying one or more optimised double
CC oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-
CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
CC used to modulate RNA expression.
XX
XX Sequence 20 BP; 2 A; 2 C; 9 G; 7 T; 0 U; 0 Other;
SQ
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2871 TAGGCTCACACACACACACC 2890
DB 20 TAGGCTCACACACACACC 1
RESULT 1526
ADQ14914/c
ID ADQ14914 standard; DNA; 20 BP.
AC ADQ14914;
DT 07-OCT-2004 (first entry)
DE CD54 RNase H dependent antisense oligonucleotide seqid 38.
XX multifunctional oligomeric compound; RNA expression modulator;
KW double-stranded oligomeric compound;
KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
KW antisense technology; ss; ISIS number 121762.
XX
XX Homo sapiens.
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
PN US2004137471-A1.
XX
XX 15-JUL-2004.
XX
XX 18-SEP-2003; 2003US-00664639.
XX
XX 18-SEP-2002; 2002US-0411780P.
XX
XX (VICK/) VICKERS T.
XX (KOOS/) KOO S.
XX (BENN/) BENNETT C F.
XX (CROO/) CROOKE S T.
XX (DEAN/) DEAN N M.
XX (BAKE/) BAKER B F.
XX
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX WPI; 2004-533354/51.
XX
XX Identifying a multifunctional oligomeric compound to modulate expression
XX of RNA comprises identifying an inhibiting antisense strand and
XX inhibiting double-stranded oligomeric compound as multifunctional
XX oligomeric compounds.
XX
XX Example 1; SEQ ID NO 38; 55pp; English.
XX
XX The invention describes a method of identifying a multifunctional
XX oligomeric compound to modulate expression of RNA. The method comprises:
XX contacting a target RNA with one or more double-stranded oligomeric
XX compounds hybridisable to one or more target regions of the RNA and
XX identifying double-stranded oligomeric compounds which inhibit target RNA
XX levels by at least 50%; contacting the target RNA with an antisense
XX strand of the modulating double-stranded oligomeric compound and
XX determining whether the antisense strand inhibits target RNA levels by at
XX least 50%; and identifying the inhibiting antisense strand and the
XX inhibiting double-stranded oligomeric compound as multifunctional
XX oligomeric compounds. Also described are: a multifunctional oligomeric
XX compound identified as above; a method for optimising target region
XX selection for modulation of RNA expression; a method of modulating RNA
XX expression; methods of optimising modulation of RNA; a method of
XX selecting a target region of a gene; a method of selecting an optimised

```

```

CC single-stranded oligomeric compound; a method of selecting an optimised
CC double-stranded oligomeric compound; a method of selecting a single-
CC stranded oligomeric compound; a method of identifying one or more optimised double
CC oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-
CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
CC used to modulate RNA expression.
XX
XX Sequence 20 BP; 2 A; 2 C; 9 G; 7 T; 0 U; 0 Other;
SQ
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2871 TAGGCTCACACACACACACC 2890
DB 20 TAGGCTCACACACACACC 1
RESULT 1526
ADQ14888/c
ID ADQ14888 standard; DNA; 20 BP.
XX
XX ADQ14888;
XX
XX 07-OCT-2004 (first entry)
XX
XX CD54 RNase H dependent antisense oligonucleotide seqid 12.
XX multifunctional oligomeric compound; RNA expression modulator;
KW double-stranded oligomeric compound;
KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
KW antisense technology; ss; ISIS number 121736.
XX
XX Homo sapiens.
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX US2004137471-A1.
XX
XX 15-JUL-2004.
XX
XX 18-SEP-2003; 2003US-00664639.
XX
XX 18-SEP-2002; 2002US-0411780P.
XX
XX (VICK/) VICKERS T.
XX (KOOS/) KOO S.
XX (BENN/) BENNETT C F.
XX (CROO/) CROOKE S T.
XX (DEAN/) DEAN N M.
XX (BAKE/) BAKER B F.
XX
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX WPI; 2004-533354/51.
XX
XX Identifying a multifunctional oligomeric compound to modulate expression
XX of RNA comprises identifying an inhibiting antisense strand and
XX inhibiting double-stranded oligomeric compound as multifunctional
XX oligomeric compounds.
XX
XX Example 1; SEQ ID NO 38; 55pp; English.
XX
XX The invention describes a method of identifying a multifunctional
XX oligomeric compound to modulate expression of RNA. The method comprises:
XX contacting a target RNA with one or more double-stranded oligomeric
XX compounds hybridisable to one or more target regions of the RNA and
XX identifying double-stranded oligomeric compounds which inhibit target RNA
XX levels by at least 50%; contacting the target RNA with an antisense
XX strand of the modulating double-stranded oligomeric compound and
XX determining whether the antisense strand inhibits target RNA levels by at
XX least 50%; and identifying the inhibiting antisense strand and the
XX inhibiting double-stranded oligomeric compound as multifunctional
XX oligomeric compounds. Also described are: a multifunctional oligomeric
XX compound identified as above; a method for optimising target region
XX selection for modulation of RNA expression; a method of modulating RNA
XX expression; methods of optimising modulation of RNA; a method of
XX selecting a target region of a gene; a method of selecting an optimised

```

```

XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
PI WPI; 2004-533354/51.
DR Identifying a multifunctional oligomeric compound to modulate expression
XX of RNA comprises identifying an inhibiting antisense strand and
PT inhibiting double-stranded oligomeric compound as multifunctional
PT oligomeric compounds.
XX
XX Example 1; SEQ ID NO 12; 55pp; English.
XX
XX The invention describes a method of identifying a multifunctional
CC oligomeric compound to modulate expression of RNA. The method comprises:
CC contacting a target RNA with one or more double-stranded oligomeric
CC compounds hybridisable to one or more target regions of the RNA and
CC identifying double-stranded oligomeric compounds which inhibit target RNA
CC levels by at least 50%; contacting the target RNA with an antisense
CC strand of the modulating double-stranded oligomeric compound and
CC determining whether the antisense strand inhibits target RNA levels by at
CC least 50%; and identifying the inhibiting antisense strand and the
CC inhibiting double-stranded oligomeric compound as multifunctional
CC oligomeric compounds. Also described are: a multifunctional oligomeric
CC compound identified as above; a method for optimising target region
CC selection for modulation of RNA expression; a method of modulating RNA
CC expression; methods of optimising modulation of RNA; a method of
CC selecting a target region of a gene; a method of selecting an optimised
CC single-stranded oligomeric compound; a method of selecting an optimised
CC double-stranded oligomeric compound; a method of selecting a single-
CC stranded oligomeric compound; a method of selecting a double-stranded
CC oligomeric compound; a method of identifying one or more optimised double
CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-
CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
CC used to modulate RNA expression.
XX
XX Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1121 AGCTCTGCTGAAGGCCACC 1140
DB 20 AGCTCTGCTGAAGGCCACC 1
RESULT 1527
ADQ14890/c
ID ADQ14890 standard; DNA; 20 BP.
AC ADQ14890;
XX
XX 07-OCT-2004 (first entry)
XX
XX CD54 RNase H dependent antisense oligonucleotide seqid 14.
XX
XX multifunctional oligomeric compound; RNA expression modulator;
XX double-stranded oligomeric compound;
XX CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
XX antisense technology; ss; ISIS number 121738.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH

```

```

modified_base 1..20
FT FT /*tag= b
FT FT /mod_base= OTHER
FT FT /note= "OTHER= Phosphorothioate backbone"
modified_base 1..5
FT FT /*tag= a
FT FT /mod_base= OTHER
FT FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
modified_base 15..20
FT FT /*tag= c
FT FT /mod_base= OTHER
FT FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX

```

US2004137471-A1.

15-JUL-2004.

18-SEP-2003; 2003US-00664639.

18-SEP-2002; 2002US-0411780P.

(VICK/) VICKERS T.

(KOOS/) KOO S.

(BENN/) BENNETT C F.

(CROO/) CROOKE S T.

(DEAN/) DEAN N M.

(BAKE/) BAKER B F.

Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;

WPI; 2004-533354/51.

Identifying a multifunctional oligomeric compound to modulate expression of RNA comprises identifying an inhibiting antisense strand and inhibiting double-stranded oligomeric compound as multifunctional oligomeric compounds.

Example 1; SEQ ID NO 14; 55pp; English.

The invention describes a method of identifying a multifunctional oligomeric compound to modulate expression of RNA. The method comprises: contacting a target RNA with one or more double-stranded oligomeric compounds hybridisable to one or more target regions of the RNA and identifying double-stranded oligomeric compounds which inhibit target RNA levels by at least 50%; contacting the target RNA with an antisense strand of the modulating double-stranded oligomeric compound and determining whether the antisense strand inhibits target RNA levels by at least 50%; and identifying the inhibiting antisense strand and the inhibiting double-stranded oligomeric compound as multifunctional oligomeric compounds. Also described are: a multifunctional oligomeric compound identified as above; a method for optimising target region selection for modulation of RNA expression; a method of modulating RNA expression; methods of optimising modulation of RNA; a method of selecting a target region of a gene; a method of selecting an optimised single-stranded oligomeric compound; a method of selecting an optimised double-stranded oligomeric compound; a method of selecting a single-stranded oligomeric compound; a method of selecting a double-stranded oligomeric compound; an oligomeric compound, 8-80 nucleobases in length, targeted to a target RNA, where the oligomeric compound specifically hybridises the target RNA and the oligomeric compound inhibits RNA levels by at least 50% in both single-stranded and double-stranded forms; and an oligomeric compound, 8-80 nucleobases in length targeted to a target RNA, where the oligomeric compound has a least 80% sequence homology to the complement of the target RNA and where the oligomeric compound inhibits RNA levels by at least 60% in both single-stranded and double-stranded forms. The method is useful for identifying a multifunctional oligomeric compound to modulate expression of RNA. This sequence represents a CD54 RNase H dependent oligonucleotide that can be used to modulate RNA expression.

Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1341 GCTCAAGTGCTAAAGGATG 1360
 |||||
 Db 20 GCTCAAGTGCTAAAGGATG 1

RESULT 1528
 ADQ14904/c
 ID ADQ14904 standard; DNA; 20 BP.
 XX ADQ14904;
 XX
 DT 07-OCT-2004 (first entry)
 XX
 DE CD54 RNase H dependent antisense oligonucleotide seqid 28.
 XX
 KW multifunctional oligomeric compound; RNA expression modulator;
 KW double-stranded oligomeric compound;
 KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
 KW antisense technology; ss; ISIS number 121752.
 XX
 OS Homo sapiens.
 XX

Key Location/Qualifiers
 modified_base 1..20
 /tag= b
 /mod_base= OTHER
 /note= "OTHER= Phosphorothioate backbone"
 modified_base 1..5
 /tag= a
 /mod_base= OTHER
 /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 modified_base 15..20
 /tag= c
 /mod_base= OTHER
 /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 US2004137471-A1.
 15-JUL-2004.
 18-SEP-2003; 2003US-00664639.
 18-SEP-2002; 2002US-0411780P.
 (VICK/) VICKERS T.
 (KOOS/) KOO S.
 (BENN/) BENNETT C. F.
 (CROO/) CROOKE S. T.
 (DEAN/) DEAN N. M.
 (BAKE/) BAKER B. F.
 Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
 WPI; 2004-533354/51.
 Identifying a multifunctional oligomeric compound to modulate expression
 of RNA comprises identifying an inhibiting antisense strand and
 inhibiting double-stranded oligomeric compound as multifunctional
 oligomeric compounds.
 Example 1; SEQ ID NO 28; 55pp; English.
 The invention describes a method of identifying a multifunctional
 oligomeric compound to modulate expression of RNA. The method comprises:
 contacting a target RNA with one or more double-stranded oligomeric
 compounds hybridisable to one or more target regions of the RNA and
 identifying double-stranded oligomeric compounds which inhibit target RNA
 levels by at least 50%; contacting the target RNA with an antisense
 strand of the modulating double-stranded oligomeric compound and

CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
 |||||
 Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 1529
 ADQ14906/c

ID ADQ14906 standard; DNA; 20 BP.

XX ADQ14906;

XX 07-OCT-2004 (first entry)

XX CD54 RNase H dependent antisense oligonucleotide seqid 30.

XX multifunctional oligomeric compound; RNA expression modulator;
 KW double-stranded oligomeric compound;
 KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
 KW antisense technology; ss; ISIS number 121754.

XX Homo sapiens.

Key Location/Qualifiers

modified_base 1..20
 /tag= b
 /mod_base= OTHER
 /note= "OTHER= Phosphorothioate backbone"
 modified_base 1..5
 /tag= a
 /mod_base= OTHER
 /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 modified_base 15..20
 /tag= c
 /mod_base= OTHER
 /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

US2004137471-A1.

15-JUL-2004.

18-SEP-2003; 2003US-00664639.

```

PR 18-SEP-2002; 2002US-0411780P.
XX (VICK/) VICKERS T.
PA (KOOS/) KOO S.
PA (BENN/) BENNETT C F.
PA (CROO/) CROOKE S T.
PA (DEAN/) DEAN N M.
PA (BAKE/) BAKER B F.
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX WPI; 2004-533354/51.
XX Identifying a multifunctional oligomeric compound to modulate expression
PT of RNA comprises identifying an inhibiting antisense strand and
PT inhibiting double-stranded oligomeric compound as multifunctional
PT oligomeric compounds.
XX Example 1; SEQ ID NO 30; 55pp; English.
XX The invention describes a method of identifying a multifunctional
CC oligomeric compound to modulate expression of RNA. The method comprises:
CC contacting a target RNA with one or more double-stranded oligomeric
CC compounds hybridisable to one or more target regions of the RNA and
CC identifying double-stranded oligomeric compounds which inhibit target RNA
CC levels by at least 50%; contacting the target RNA with an antisense
CC strand of the modulating double-stranded oligomeric compound and
CC determining whether the antisense strand inhibits target RNA levels by at
CC least 50%; and identifying the inhibiting antisense strand and the
CC inhibiting double-stranded oligomeric compound as multifunctional
CC oligomeric compounds. Also described are: a method of selecting an optimised
CC compound identified as above; a method for optimising target region
CC selection for modulation of RNA expression; a method of modulating RNA
CC expression; methods of optimising modulation of RNA; a method of
CC selecting a target region of a gene; a method of selecting an optimised
CC single-stranded oligomeric compound; a method of selecting a single-
CC double-stranded oligomeric compound; a method of selecting a double-
CC stranded oligomeric compound; a method of identifying one or more optimised double
CC stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-
CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
CC used to modulate RNA expression.
XX Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2221 GGTCCTCGGCTCAGGAGC 2240
DB 20 GGTCCTCGGCTCAGGAGC 1
RESULT 1530
ADQ14907/c
ID ADQ14907 standard; DNA; 20 BP.
XX AC ADQ14907;
XX AC ADQ14907;
XX DT 07-OCT-2004 (first entry)
XX DE CD54 RNase H dependent antisense oligonucleotide seqid 31.
XX

```

multifunctional oligomeric compound; RNA expression modulator;
double-stranded oligomeric compound;
CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
antisense technology; ss; ISIS number 121755.

Homo sapiens.

Key Location/Qualifiers
modified_base 1..20
/tag= b
/mod_base= OTHER
/note= "OTHER= Phosphorothioate backbone"
modified_base 1..5
/tag= a
/mod_base= OTHER
/note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
modified_base 15..20
/tag= c
/mod_base= OTHER
/note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
US2004137471-A1.
15-JUL-2004.
18-SEP-2003; 2003US-00664639.
18-SEP-2002; 2002US-0411780P.
(VICK/) VICKERS T.
(KOOS/) KOO S.
(BENN/) BENNETT C F.
(CROO/) CROOKE S T.
(DEAN/) DEAN N M.
(BAKE/) BAKER B F.
Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
WPI; 2004-533354/51.
Identifying a multifunctional oligomeric compound to modulate expression
of RNA comprises identifying an inhibiting antisense strand and
inhibiting double-stranded oligomeric compound as multifunctional
oligomeric compounds.
Example 1; SEQ ID NO 31; 55pp; English.
The invention describes a method of identifying a multifunctional
oligomeric compound to modulate expression of RNA. The method comprises:
contacting a target RNA with one or more double-stranded oligomeric
compounds hybridisable to one or more target regions of the RNA and
identifying double-stranded oligomeric compounds which inhibit target RNA
levels by at least 50%; contacting the target RNA with an antisense
strand of the modulating double-stranded oligomeric compound and
determining whether the antisense strand inhibits target RNA levels by at
least 50%; and identifying the inhibiting antisense strand and the
inhibiting double-stranded oligomeric compound as multifunctional
oligomeric compounds. Also described are: a method of selecting an optimised
compound identified as above; a method for optimising target region
selection for modulation of RNA expression; a method of modulating RNA
expression; methods of optimising modulation of RNA; a method of
selecting a target region of a gene; a method of selecting an optimised
single-stranded oligomeric compound; a method of selecting a single-
double-stranded oligomeric compound; a method of selecting a double-
stranded oligomeric compound; a method of identifying one or more optimised double
stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
in length, targeted to a target RNA, where the oligomeric compound
specifically hybridises the target RNA and the oligomeric compound
inhibits RNA levels by at least 50% in both single-stranded and double-
stranded forms; and an oligomeric compound, 8-80 nucleobases in length
targeted to a target RNA, where the oligomeric compound has a least 80%
sequence homology to the complement of the target RNA and where the
oligomeric compound inhibits RNA levels by at least 60% in both single-
stranded and double-stranded forms. The method is useful for identifying
a multifunctional oligomeric compound to modulate expression of RNA. This
sequence represents a CD54 RNase H dependent oligonucleotide that can be
used to modulate RNA expression.

CC oligomeric compound inhibits RNA levels by at least 60% in both single-stranded and double-stranded forms. The method is useful for identifying CC a multifunctional oligomeric compound to modulate expression of RNA. This CC sequence represents a CD54 RNase H dependent oligonucleotide that can be CC used to modulate RNA expression.

SQ Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2291 ACACCTGACGAGAGTGCCTG 2310
 |||||
 Db 20 ACACCTGACGAGAGTGCCTG 1

RESULT 1531
 ADQ14910/c

ID ADQ14910 standard; DNA; 20 BP.

XX AC ADQ14910;

XX 07-OCT-2004 (first entry)

DE CD54 RNase H dependent antisense oligonucleotide seqid 34.

XX multifunctional oligomeric compound; RNA expression modulator;
 double-stranded oligomeric compound;
 CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
 antisense technology; ss; ISIS number 121758.

OS Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..20
 /tag= b
 /mod_base= OTHER

FT modified_base 1..5
 /tag= a
 /mod_base= OTHER

FT modified_base 15..20
 /tag= c
 /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

US2004137471-A1.

15-JUL-2004.

18-SEP-2003; 2003US-00664639.

18-SEP-2002; 2002US-0411780P.

(VICK/) VICKERS T.
 (KOOS/) KOO S.
 (BENN/) BENNETT C F.
 (CROO/) CROOKE S T.
 (DEAN/) DEAN N M.
 (BAKE/) BAKER B F.

Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
 WPI; 2004-533354/51.

Identifying a multifunctional oligomeric compound to modulate expression of RNA comprises identifying an inhibiting antisense strand and inhibiting double-stranded oligomeric compound as multifunctional oligomeric compounds.

Example 1; SEQ ID NO 34; 55bp; English.

XX The invention describes a method of identifying a multifunctional oligomeric compound to modulate expression of RNA. The method comprises: contacting a target RNA with one or more double-stranded oligomeric compounds hybridisable to one or more target regions of the RNA and identifying double-stranded oligomeric compounds which inhibit target RNA levels by at least 50%; contacting the target RNA with an antisense strand of the modulating double-stranded oligomeric compound and determining whether the antisense strand inhibits target RNA levels by at least 50%; and identifying the inhibiting antisense strand and the inhibiting double-stranded oligomeric compound as multifunctional oligomeric compounds. Also described are: a multifunctional oligomeric compound identified as above; a method for optimising target region selection for modulation of RNA expression; a method of modulating RNA expression; methods of optimising modulation of RNA; a method of selecting a target region of a gene; a method of selecting an optimised single-stranded oligomeric compound; a method of selecting a single-stranded oligomeric compound; a method of selecting a single-stranded oligomeric compound; a method of selecting a double-stranded oligomeric compound; an oligomeric compound, 8-80 nucleobases in length, targeted to a target RNA, where the oligomeric compound specifically hybridises the target RNA and the oligomeric compound inhibits RNA levels by at least 50% in both single-stranded and double-stranded forms; and an oligomeric compound, 8-80 nucleobases in length targeted to a target RNA, where the oligomeric compound has a least 80% sequence homology to the complement of the target RNA and where the oligomeric compound inhibits RNA levels by at least 60% in both single-stranded and double-stranded forms. The method is useful for identifying a multifunctional oligomeric compound to modulate expression of RNA. This sequence represents a CD54 RNase H dependent oligonucleotide that can be used to modulate RNA expression.

SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2531 CTCACGCGTCATGCTGGAC 2550
 |||||
 Db 20 CTCACGCGTCATGCTGGAC 1

RESULT 1532
 ADQ14915/c

ID ADQ14915 standard; DNA; 20 BP.

XX AC ADQ14915;

XX 07-OCT-2004 (first entry)

DE CD54 RNase H dependent antisense oligonucleotide seqid 39.

XX multifunctional oligomeric compound; RNA expression modulator;
 double-stranded oligomeric compound;
 CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
 antisense technology; ss; ISIS number 121763.

OS Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..20
 /tag= b
 /mod_base= OTHER

FT modified_base 1..5
 /tag= a
 /mod_base= OTHER

FT modified_base 15..20
 /tag= c
 /mod_base= OTHER

```
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
PN US2004137471-A1.
XX
XX 15-JUL-2004.
XX
XX 18-SEP-2003; 2003US-00664639.
XX
XX 18-SEP-2002; 2002US-0411780P.
XX
XX (VICK/) VICKERS T.
XX (KOOS/) KOO S.
XX (BENN/) BENNETT C F.
XX (CROO/) CROOKE S T.
XX (DEAN/) DEAN N M.
XX (BAKE/) BAKER B F.
XX
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX
XX WPI; 2004-533354/51.
XX
XX Identifying a multifunctional oligomeric compound to modulate expression
XX of RNA comprises identifying an inhibiting antisense strand and
XX inhibiting double-stranded oligomeric compound as multifunctional
XX oligomeric compounds.
XX
XX Example 1; SEQ ID NO 39; 55pp; English.
XX
XX The invention describes a method of identifying a multifunctional
XX oligomeric compound to modulate expression of RNA. The method comprises:
XX contacting a target RNA with one or more double-stranded oligomeric
XX compounds hybridisable to one or more target regions of the RNA and
XX identifying double-stranded oligomeric compounds which inhibit target RNA
XX levels by at least 50%; contacting the target RNA with an antisense
XX strand of the modulating double-stranded oligomeric compound and
XX determining whether the antisense strand inhibits target RNA levels by at
XX least 50%; and identifying the inhibiting antisense strand and the
XX inhibiting double-stranded oligomeric compound as multifunctional
XX oligomeric compounds. Also described are: a multifunctional oligomeric
XX compound identified as above; a method for optimising target region
XX selection for modulation of RNA expression; a method of modulating RNA
XX expression; methods of optimising modulation of RNA; a method of
XX selecting a target region of a gene; a method of selecting an optimised
XX single-stranded oligomeric compound; a method of selecting an optimised
XX double-stranded oligomeric compound; a method of selecting a single-
XX stranded oligomeric compound; a method of selecting a double-stranded
XX oligomeric compound; a method of identifying one or more optimised double
XX -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
XX in length, targeted to a target RNA, where the oligomeric compound
XX specifically hybridises the target RNA and the oligomeric compound
XX inhibits RNA levels by at least 50% in both single-stranded and double-
XX stranded forms; and an oligomeric compound, 8-80 nucleobases in length
XX targeted to a target RNA, where the oligomeric compound has a least 80%
XX sequence homology to the complement of the target RNA and where the
XX oligomeric compound inhibits RNA levels by at least 60% in both single-
XX stranded and double-stranded forms. The method is useful for identifying
XX a multifunctional oligomeric compound to modulate expression of RNA. This
XX sequence represents a CD54 RNase H dependent oligonucleotide that can be
XX used to modulate RNA expression.
XX
XX Sequence 20 BP; 8 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2944 CCAGACTTCCTTGTTGTAG 2963
XX | | | | | | | | | | | | | | | | | | | |
XX Db 20 CCAGACTTCCTTGTTGTAG 1
XX
XX RESULT 1533
XX ADQ14880/c
```

```
ID ADQ14880 standard; DNA; 20 BP.
XX
XX ADQ14880;
XX
XX 07-OCT-2004 (first entry)
XX
XX CD54 RNase H dependent antisense oligonucleotide seqid 4.
XX
XX multifunctional oligomeric compound; RNA expression modulator;
XX double-stranded oligomeric compound;
XX CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
XX antisense technology; ss; ISIS number 121728.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= b
XX /mod_base= OTHER
XX /note= "OTHER= Phosphorothioate backbone"
XX
XX modified_base 1..5
XX /*tag= a
XX /mod_base= OTHER
XX
XX modified_base 15..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX US2004137471-A1.
XX
XX 15-JUL-2004.
XX
XX 18-SEP-2003; 2003US-00664639.
XX
XX 18-SEP-2002; 2002US-0411780P.
XX
XX (VICK/) VICKERS T.
XX (KOOS/) KOO S.
XX (BENN/) BENNETT C F.
XX (CROO/) CROOKE S T.
XX (DEAN/) DEAN N M.
XX (BAKE/) BAKER B F.
XX
XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX
XX WPI; 2004-533354/51.
XX
XX Identifying a multifunctional oligomeric compound to modulate expression
XX of RNA comprises identifying an inhibiting antisense strand and
XX inhibiting double-stranded oligomeric compound as multifunctional
XX oligomeric compounds.
XX
XX Example 1; SEQ ID NO 4; 55pp; English.
XX
XX The invention describes a method of identifying a multifunctional
XX oligomeric compound to modulate expression of RNA. The method comprises:
XX contacting a target RNA with one or more double-stranded oligomeric
XX compounds hybridisable to one or more target regions of the RNA and
XX identifying double-stranded oligomeric compounds which inhibit target RNA
XX levels by at least 50%; contacting the target RNA with an antisense
XX strand of the modulating double-stranded oligomeric compound and
XX determining whether the antisense strand inhibits target RNA levels by at
XX least 50%; and identifying the inhibiting antisense strand and the
XX inhibiting double-stranded oligomeric compound as multifunctional
XX oligomeric compounds. Also described are: a multifunctional oligomeric
XX compound identified as above; a method for optimising target region
XX selection for modulation of RNA expression; a method of modulating RNA
XX expression; methods of optimising modulation of RNA; a method of
XX selecting a target region of a gene; a method of selecting an optimised
XX single-stranded oligomeric compound; a method of selecting an optimised
XX double-stranded oligomeric compound; a method of selecting a single-
XX stranded oligomeric compound; a method of selecting a double-stranded
XX oligomeric compound; a method of identifying one or more optimised double
XX -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
XX in length, targeted to a target RNA, where the oligomeric compound
XX specifically hybridises the target RNA and the oligomeric compound
XX inhibits RNA levels by at least 50% in both single-stranded and double-
XX stranded forms; and an oligomeric compound, 8-80 nucleobases in length
XX targeted to a target RNA, where the oligomeric compound has a least 80%
XX sequence homology to the complement of the target RNA and where the
XX oligomeric compound inhibits RNA levels by at least 60% in both single-
XX stranded and double-stranded forms. The method is useful for identifying
XX a multifunctional oligomeric compound to modulate expression of RNA. This
XX sequence represents a CD54 RNase H dependent oligonucleotide that can be
XX used to modulate RNA expression.
XX
XX Sequence 20 BP; 8 A; 4 C; 5 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 20; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 2944 CCAGACTTCCTTGTTGTAG 2963
XX | | | | | | | | | | | | | | | | | | | |
XX Db 20 CCAGACTTCCTTGTTGTAG 1
XX
XX RESULT 1533
XX ADQ14880/c
```

CC oligomeric compound; a method of identifying one or more optimised double
CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-
CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
CC used to modulate RNA expression.
XX
SQ Sequence 20 BP; 5 A; 2 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 321 CCAACCAATGCTGCTATTCAA 340
DB 20 CCAACCAATGCTGCTATTCAA 1

RESULT 1534
ADQ14885/c
ID ADQ14885 standard; DNA; 20 BP.
XX
AC ADQ14885;
XX
DT 07-OCT-2004 (first entry)
XX
DE CD54 RNase H dependent antisense oligonucleotide seqid 9.
XX
KW multifunctional oligomeric compound; RNA expression modulator;
KW double-stranded oligomeric compound;
KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
KW antisense technology; ss; ISIS number 121733.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
FN US2004137471-A1.
XX
PD 15-JUL-2004.
XX
PF 18-SEP-2003; 2003US-00664639.
XX
PR 18-SEP-2002; 2002US-0411780P.
XX
PA (VICK/) VICKERS T.
PA (KOOS/) KOO S.
PA (BENN/) BENNETT C. F.
PA (CROO/) CROOKE S. T.
PA (DEAN/) DEAN N. M.
PA (BAKE/) BAKER B. F.
XX
PI Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX

DR WPI; 2004-533354/51.
XX
PT Identifying a multifunctional oligomeric compound to modulate expression
of RNA comprises identifying an inhibiting antisense strand and
inhibiting double-stranded oligomeric compound as multifunctional
oligomeric compounds.
XX
PS Example 1; SEQ ID NO 9; 55pp; English.
XX
CC The invention describes a method of identifying a multifunctional
oligomeric compound to modulate expression of RNA. The method comprises:
contacting a target RNA with one or more double-stranded oligomeric
compounds hybridisable to one or more target regions of the RNA and
identifying double-stranded oligomeric compounds which inhibit target RNA
levels by at least 50%; contacting the target RNA with an antisense
strand of the modulating double-stranded oligomeric compound and
determining whether the antisense strand inhibits target RNA levels by at
least 50%; and identifying the inhibiting antisense strand and the
inhibiting double-stranded oligomeric compound as multifunctional
oligomeric compounds. Also described are: a multifunctional oligomeric
compound identified as above; a method for optimising target region
selection for modulation of RNA expression; a method of modulating RNA
expression; methods of optimising modulation of RNA; a method of
selecting a target region of a gene; a method of selecting an optimised
single-stranded oligomeric compound; a method of selecting a single-
double-stranded oligomeric compound; a method of selecting a double-stranded
oligomeric compound; a method of identifying one or more optimised double
-stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
in length, targeted to a target RNA, where the oligomeric compound
specifically hybridises the target RNA and the oligomeric compound
inhibits RNA levels by at least 50% in both single-stranded and double-
stranded forms; and an oligomeric compound, 8-80 nucleobases in length
targeted to a target RNA, where the oligomeric compound has a least 80%
sequence homology to the complement of the target RNA and where the
oligomeric compound inhibits RNA levels by at least 60% in both single-
stranded and double-stranded forms. The method is useful for identifying
a multifunctional oligomeric compound to modulate expression of RNA. This
sequence represents a CD54 RNase H dependent oligonucleotide that can be
used to modulate RNA expression.
XX
SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 801 CCAGGTCCACCTGGCACTGG 820
DB 20 CCAGGTCCACCTGGCACTGG 1

RESULT 1535
ADQ14898/c
ID ADQ14898 standard; DNA; 20 BP.
XX
AC ADQ14898;
XX
DT 07-OCT-2004 (first entry)
XX
DE CD54 RNase H dependent antisense oligonucleotide seqid 22.
XX
KW multifunctional oligomeric compound; RNA expression modulator;
KW double-stranded oligomeric compound;
KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
KW antisense technology; ss; ISIS number 121746.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
XX

CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 8 AGTCGACGCTGAGCTCTCT 27

DB 20 AGTCGACGCTGAGCTCTCT 1

RESULT 1537

ADQ14884/c

ID ADQ14884 standard; DNA; 20 BP.

AC ADQ14884;

XX 07-OCT-2004 (first entry)

XX CD54 RNase H dependent antisense oligonucleotide seqid 8.

XX multifunctional oligomeric compound; RNA expression modulator;

KW double-stranded oligomeric compound;

KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;

KW antisense technology; ss; ISIS number 121732.

XX Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "OTHER= Phosphorothioate backbone"

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

FT modified_base 15..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

XX US2004137471-A1.

PN 15-JUL-2004.

XX 18-SEP-2003; 2003US-00664639.

XX 18-SEP-2002; 2002US-0411780P.

XX (WICK/) VICKERS T.

PA (KOOS/) KOO S.
 PA (BENN/) BENNETT C F.
 PA (CROO/) CROOKE S T.
 PA (DEAN/) DEAN N M.
 PA (BAKE/) BAKER B F.

XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;

PI WPI; 2004-53354/51.

XX Identifying a multifunctional oligomeric compound to modulate expression
 of RNA comprises identifying an inhibiting antisense strand and
 PT inhibiting double-stranded oligomeric compound as multifunctional
 PT oligomeric compounds.

XX Example 1; SEQ ID NO 8; 55pp; English.

XX The invention describes a method of identifying a multifunctional
 CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 732 GGTCTTAGAGTGGACACG 751

DB 20 GGTCTTAGAGTGGACACG 1

RESULT 1538

ADQ14886/c

ID ADQ14886 standard; DNA; 20 BP.

XX ADQ14886;

XX 07-OCT-2004 (first entry)

XX CD54 RNase H dependent antisense oligonucleotide seqid 10.

XX multifunctional oligomeric compound; RNA expression modulator;

KW double-stranded oligomeric compound;

KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;

KW antisense technology; ss; ISIS number 121734.
 XX Homo sapiens.
 XX Key Location/Qualifiers
 XX modified_base 1..20
 XX /*tag= b
 XX /mod_base= OTHER
 FT /note= "OTHER= Phosphorothioate backbone"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 15..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 XX
 PN US2004137471-A1.
 XX
 XX 15-JUL-2004.
 XX
 XX 18-SEP-2003; 2003US-00664639.
 XX
 XX 18-SEP-2002; 2002US-0411780P.
 XX
 XX (VICK/) VICKERS T.
 XX (KOOS/) KOO S.
 XX (BENN/) BENNETT C F.
 XX (CROO/) CROOKE S T.
 XX (DEAN/) DEAN N M.
 XX (BAKE/) BAKER B F.
 XX
 XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
 PI WPI; 2004-533354/51.
 XX
 XX Identifying a multifunctional oligomeric compound to modulate expression
 PT of RNA comprises identifying an inhibiting antisense strand and
 PT inhibiting double-stranded oligomeric compound as multifunctional
 PT oligomeric compounds.
 XX
 XX Example 1; SEQ ID NO 10; 55pp; English.
 XX
 XX The invention describes a method of identifying a multifunctional
 CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This

CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 XX used to modulate RNA expression.
 XX SQ Sequence 20 BP; 5 A; 7 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 921 GACGTGTGCAGTAATACTGG 940
 Db 20 GACGTGTGCAGTAATACTGG 1
 RESULT 1539
 ADQ14895/c
 ID ADQ14895 standard; DNA; 20 BP.
 XX
 XX ADQ14895;
 XX
 XX 07-OCT-2004 (first entry)
 XX
 XX CD54 RNase H dependent antisense oligonucleotide seqid 19.
 XX
 XX multifunctional oligomeric compound; RNA expression modulator;
 KW double-stranded oligomeric compound;
 KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;
 KW antisense technology; ss; ISIS number 121743.
 XX
 XX Homo sapiens.
 XX
 XX Key Location/Qualifiers
 XX modified_base 1..20
 XX /*tag= b
 XX /mod_base= OTHER
 FT /note= "OTHER= Phosphorothioate backbone"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 15..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 XX
 XX US2004137471-A1.
 XX
 XX 15-JUL-2004.
 XX
 XX 18-SEP-2003; 2003US-00664639.
 XX
 XX 18-SEP-2002; 2002US-0411780P.
 XX
 XX (VICK/) VICKERS T.
 XX (KOOS/) KOO S.
 XX (BENN/) BENNETT C F.
 XX (CROO/) CROOKE S T.
 XX (DEAN/) DEAN N M.
 XX (BAKE/) BAKER B F.
 XX
 XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
 PI WPI; 2004-533354/51.
 XX
 XX Identifying a multifunctional oligomeric compound to modulate expression
 PT of RNA comprises identifying an inhibiting antisense strand and
 PT inhibiting double-stranded oligomeric compound as multifunctional
 PT oligomeric compounds.
 XX
 XX Example 1; SEQ ID NO 19; 55pp; English.
 XX
 XX The invention describes a method of identifying a multifunctional
 CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This

CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCGGGACAGG 1673
 Db 20 TGAACCTATCCGGGACAGG 1

RESULT 1540

ADQ14901/c

ID ADQ14901 standard; DNA; 20 BP.

XX ADQ14901;

XX 07-OCT-2004 (first entry)

XX CD54 RNase H dependent antisense oligonucleotide seqid 25.

XX multifunctional oligomeric compound; RNA expression modulator;

KW double-stranded oligomeric compound;

KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;

KW antisense technology; ss; ISIS number 121749.

XX Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "OTHER= Phosphorothioate backbone"

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

FT modified_base 15..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

XX US2004137471-A1.

XX 15-JUL-2004.
 XX 18-SEP-2003; 2003US-00664639.
 XX 18-SEP-2002; 2002US-0411780P.

XX (VICK/) VICKERS T.
 XX (KOOS/) KOO S.
 XX (BENN/) BENNETT C F.
 XX (CROO/) CROOKE S T.
 XX (DEAN/) DEAN N M.
 XX (BAKE/) BAKER B F.

XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
 XX WPI; 2004-533354/51.

XX Identifying a multifunctional oligomeric compound to modulate expression
 PT of RNA comprises identifying an inhibiting antisense strand and
 PT inhibiting double-stranded oligomeric compound as multifunctional
 PT oligomeric compounds.

XX Example 1; SEQ ID NO 25; 55pp; English.

XX The invention describes a method of identifying a multifunctional
 CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1971 CCATGAGGACATACAACCTGG 1990
 Db 20 CCATGAGGACATACAACCTGG 1

RESULT 1541

ID ADQ14905/c

XX ADQ14905 standard; DNA; 20 BP.

XX ADQ14905;

XX 07-OCT-2004 (first entry)

XX CD54 RNase H dependent antisense oligonucleotide seqid 29.

XX multifunctional oligomeric compound; RNA expression modulator;

XX double-stranded oligomeric compound;

KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;

KW antisense technology; ss; ISIS number 121753.

XX Homo sapiens.

XX

PH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "OTHER= Phosphorothioate backbone"

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

FT modified_base 15..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

XX

PN US2004137471-A1.

XX

XX 15-JUL-2004.

XX

XX 18-SEP-2003; 2003US-00664639.

XX

XX 18-SEP-2002; 2002US-0411780P.

XX

PA (VICK/) VICKERS T.

PA (KOOS/) KOO S.

PA (BENN/) BENNETT C F.

PA (CROO/) CROOKE S T.

PA (DEAN/) DEAN N M.

PA (BAKE/) BAKER B F.

XX

XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;

PI WPI; 2004-533354/51.

XX

XX Identifying a multifunctional oligomeric compound to modulate expression of RNA comprises identifying an inhibiting antisense strand and inhibiting double-stranded oligomeric compound as multifunctional oligomeric compounds.

XX

XX Example 1; SEQ ID NO 29; 55pp; English.

XX

CC The invention describes a method of identifying a multifunctional oligomeric compound to modulate expression of RNA. The method comprises: contacting a target RNA with one or more double-stranded oligomeric compounds hybridisable to one or more target regions of the RNA and identifying double-stranded oligomeric compounds which inhibit target RNA levels by at least 50%; contacting the target RNA with an antisense strand of the modulating double-stranded oligomeric compound and determining whether the antisense strand inhibits target RNA levels by at least 50%; and identifying the inhibiting antisense strand and the inhibiting double-stranded oligomeric compound as multifunctional oligomeric compounds. Also described are: a multifunctional oligomeric compound identified as above; a method for optimising target region selection for modulation of RNA expression; a method of modulating RNA expression; methods of optimising modulation of RNA; a method of selecting a target region of a gene; a method of selecting an optimised single-stranded oligomeric compound; a method of selecting a single-stranded oligomeric compound; a method of selecting a double-stranded oligomeric compound; a method of identifying one or more optimised double-stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases in length, targeted to a target RNA, where the oligomeric compound

CC specifically hybridises the target RNA and the oligomeric compound inhibits RNA levels by at least 50% in both single-stranded and double-stranded forms; and an oligomeric compound, 8-80 nucleobases in length targeted to a target RNA, where the oligomeric compound has a least 80% sequence homology to the complement of the target RNA and where the oligomeric compound inhibits RNA levels by at least 60% in both single-stranded and double-stranded forms. The method is useful for identifying a multifunctional oligomeric compound to modulate expression of RNA. This sequence represents a CD54 RNase H dependent oligonucleotide that can be used to modulate RNA expression.

XX

XX Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

XX

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2103 CGGATGCCAGCTGGGCACT 2122

DB 20 CGGATGCCAGCTGGGCACT 1

RESULT 1542

ADQ14916/C

ID ADQ14916 standard; DNA; 20 BP.

XX

XX ADQ14916;

XX AC

XX 07-OCT-2004 (first entry)

XX

XX CD54 RNase H dependent antisense oligonucleotide seqid 40.

XX

KW multifunctional oligomeric compound; RNA expression modulator;

KW double-stranded oligomeric compound;

KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;

XX antisense technology; ss; ISIS number 121764.

XX Homo sapiens.

XX

PH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "OTHER= Phosphorothioate backbone"

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

FT modified_base 15..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

XX

XX US2004137471-A1.

XX

XX 15-JUL-2004.

XX

XX 18-SEP-2003; 2003US-00664639.

XX

XX 18-SEP-2002; 2002US-0411780P.

XX

PA (VICK/) VICKERS T.

PA (KOOS/) KOO S.

PA (BENN/) BENNETT C F.

PA (CROO/) CROOKE S T.

PA (DEAN/) DEAN N M.

PA (BAKE/) BAKER B F.

XX

XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;

PI WPI; 2004-533354/51.

XX

XX Identifying a multifunctional oligomeric compound to modulate expression

PT of RNA comprises identifying an inhibiting antisense strand and
 PT inhibiting double-stranded oligomeric compound as multifunctional
 PT oligomeric compounds.

XX Example 1; SEQ ID NO 40; 55pp; English.

XX The invention describes a method of identifying a multifunctional
 CC oligomeric compound to modulate expression of RNA. The method comprises:
 CC contacting a target RNA with one or more double-stranded oligomeric
 CC compounds hybridisable to one or more target regions of the RNA and
 CC identifying double-stranded oligomeric compounds which inhibit target RNA
 CC levels by at least 50%; contacting the target RNA with an antisense
 CC strand of the modulating double-stranded oligomeric compound and
 CC determining whether the antisense strand inhibits target RNA levels by at
 CC least 50%; and identifying the inhibiting antisense strand and the
 CC inhibiting double-stranded oligomeric compound as multifunctional
 CC oligomeric compounds. Also described are: a multifunctional oligomeric
 CC compound identified as above; a method for optimising target region
 CC selection for modulation of RNA expression; a method of modulating RNA
 CC expression; methods of optimising modulation of RNA; a method of
 CC selecting a target region of a gene; a method of selecting an optimised
 CC single-stranded oligomeric compound; a method of selecting an optimised
 CC double-stranded oligomeric compound; a method of selecting a single-
 CC stranded oligomeric compound; a method of selecting a double-stranded
 CC oligomeric compound; a method of identifying one or more optimised double
 CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
 CC in length, targeted to a target RNA, where the oligomeric compound
 CC specifically hybridises the target RNA and the oligomeric compound
 CC inhibits RNA levels by at least 50% in both single-stranded and double-
 CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
 CC targeted to a target RNA, where the oligomeric compound has a least 80%
 CC sequence homology to the complement of the target RNA and where the
 CC oligomeric compound inhibits RNA levels by at least 60% in both single-
 CC stranded and double-stranded forms. The method is useful for identifying
 CC a multifunctional oligomeric compound to modulate expression of RNA. This
 CC sequence represents a CD54 RNase H dependent oligonucleotide that can be
 CC used to modulate RNA expression.

XX SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 5.4e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2104 GGATGCCAGCTTGGGCACTG 2123
 DB 20 GGATGCCAGCTTGGGCACTG 1
 |||||

RESULT 1543

ADQ14878/c

ID ADQ14878 standard; DNA; 20 BP.

XX

AC ADQ14878;

DT

XX 07-OCT-2004 (first entry)

DE

XX CD54 RNase H dependent antisense oligonucleotide seqid 2.

XX

KW multifunctional oligomeric compound; RNA expression modulator;

KW

KW double-stranded oligomeric compound;

KW

KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;

XX

XX antisense technology; ss; ISIS number 121726.

OS

XX Homo sapiens.

XX

XX Key Location/Qualifiers

FT

FT modified_base 1..20

FT

FT /tag= b

FT

FT /mod_base= OTHER

FT

FT /note= "OTHER= Phosphorothioate backbone"

FT

FT modified_base 1..5

FT

FT /tag= a

FT

FT

FT

FT

FT

FT

FT

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

XX

/mod_base= OTHER
 /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 modified_base 15..20
 /tag= c

/mod_base= OTHER
 /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 US2004137471-A1.

15-JUL-2004.

18-SEP-2003; 2003US-00664639.

18-SEP-2002; 2002US-0411780P.

(VICK/) VICKERS T.

(KOOS/) KOO S.

(BENN/) BENNETT C F.

(CROO/) CROOKE S T.

(DEAN/) DEAN N M.

(BAKE/) BAKER B F.

Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;

WPI; 2004-533354/51.

Identifying a multifunctional oligomeric compound to modulate expression

of RNA comprises identifying an inhibiting antisense strand and

inhibiting double-stranded oligomeric compound as multifunctional

oligomeric compounds.

Example 1; SEQ ID NO 2; 55pp; English.

The invention describes a method of identifying a multifunctional

oligomeric compound to modulate expression of RNA. The method comprises:

contacting a target RNA with one or more double-stranded oligomeric

compounds hybridisable to one or more target regions of the RNA and

identifying double-stranded oligomeric compounds which inhibit target RNA

levels by at least 50%; contacting the target RNA with an antisense

strand of the modulating double-stranded oligomeric compound and

determining whether the antisense strand inhibits target RNA levels by at

least 50%; and identifying the inhibiting antisense strand and the

inhibiting double-stranded oligomeric compound as multifunctional

oligomeric compounds. Also described are: a multifunctional oligomeric

compound identified as above; a method for optimising target region

selection for modulation of RNA expression; a method of modulating RNA

expression; methods of optimising modulation of RNA; a method of

selecting a target region of a gene; a method of selecting an optimised

single-stranded oligomeric compound; a method of selecting an optimised

double-stranded oligomeric compound; a method of selecting a single-

stranded oligomeric compound; a method of selecting a double-stranded

oligomeric compound; a method of identifying one or more optimised double

-stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases

in length, targeted to a target RNA, where the oligomeric compound

specifically hybridises the target RNA and the oligomeric compound

inhibits RNA levels by at least 50% in both single-stranded and double-

stranded forms; and an oligomeric compound, 8-80 nucleobases in length

targeted to a target RNA, where the oligomeric compound has a least 80%

sequence homology to the complement of the target RNA and where the

oligomeric compound inhibits RNA levels by at least 60% in both single-

stranded and double-stranded forms. The method is useful for identifying

a multifunctional oligomeric compound to modulate expression of RNA. This

sequence represents a CD54 RNase H dependent oligonucleotide that can be

used to modulate RNA expression.

Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5.4e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 33 TCAGAGTTGCACCTCAGCC 52

|||||

Db 20 TCAGAGTTGCAACCTCAGCC 1

RESULT 1544

ID ADQ14887/c

ADQ14887 standard; DNA; 20 BP.

XX

AC ADQ14887;

XX

XX 07-OCT-2004 (first entry)

XX

XX CD54 RNase H dependent antisense oligonucleotide seqid 11.

XX

XX multifunctional oligomeric compound; RNA expression modulator;

KW double-stranded oligomeric compound;

KW CD54 RNase H dependent oligonucleotide; antisense oligonucleotide;

KW antisense technology; ss; ISIS number 121735.

XX

OS Homo sapiens.

XX

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "OTHER= Phosphorothioate backbone"

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

FT modified_base 15..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

XX

XX US2004137471-A1.

XX

XX 15-JUL-2004.

XX

XX 18-SEP-2003; 2003US-00664639.

XX

XX 18-SEP-2002; 2002US-0411780P.

XX

XX (VICK/) VICKERS T.

PA (KOOS/) KOO S.

PA (BENN/) BENNETT C F.

PA (CROO/) CROOKE S T.

PA (DEAN/) DEAN N M.

PA (BAKE/) BAKER B F.

XX

XX Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;

XX WPI; 2004-533354/51.

XX

XX Identifying a multifunctional oligomeric compound to modulate expression

XX of RNA comprises identifying an inhibiting antisense strand and

XX inhibiting double-stranded oligomeric compound as multifunctional

XX oligomeric compounds.

XX

XX Example 1; SEQ ID NO 11; 55pp; English.

XX

XX The invention describes a method of identifying a multifunctional

XX oligomeric compound to modulate expression of RNA. The method comprises:

XX contacting a target RNA with one or more double-stranded oligomeric

XX compounds hybridisable to one or more target regions of the RNA and

XX identifying double-stranded oligomeric compounds which inhibit target RNA

XX levels by at least 50%; contacting the target RNA with an antisense

XX strand of the modulating double-stranded oligomeric compound and

XX determining whether the antisense strand inhibits target RNA levels by at

XX least 50%; and identifying the inhibiting antisense strand and the

XX inhibiting double-stranded oligomeric compound as multifunctional

XX oligomeric compounds. Also described are: a multifunctional oligomeric

XX compound identified as above; a method for optimising target region

XX selection for modulation of RNA expression; a method of modulating RNA

CC expression; methods of optimising modulation of RNA; a method of

CC selecting a target region of a gene; a method of selecting an optimised

CC single-stranded oligomeric compound; a method of selecting an optimised

CC double-stranded oligomeric compound; a method of selecting a single-

CC stranded oligomeric compound; a method of selecting a double-stranded

CC oligomeric compound; a method of identifying one or more optimised double

CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases

CC in length, targeted to a target RNA, where the oligomeric compound

CC specifically hybridises the target RNA and the oligomeric compound

CC inhibits RNA levels by at least 50% in both single-stranded and double-

CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length

CC targeted to a target RNA, where the oligomeric compound has a least 80%

CC sequence homology to the complement of the target RNA and where the

CC oligomeric compound inhibits RNA levels by at least 60% in both single-

CC stranded and double-stranded forms. The method is useful for identifying

CC a multifunctional oligomeric compound to modulate expression of RNA. This

CC sequence represents a CD54 RNase H dependent oligonucleotide that can be

CC used to modulate RNA expression.

XX

XX Query Match 0.7%; Score 20; DB 1; Length 20;

XX Best Local Similarity 100.0%; Pred. No. 5.4e+02;

XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1002 GATTCTGACGAGCCAGAGG 1021

DB 20 GATTCTGACGAGCCAGAGG 1

RESULT 1545

ADQ2634/c

ID ADR02634 standard; DNA; 20 BP.

XX

XX ADR02634;

XX

XX 21-OCT-2004 (first entry)

XX

XX Antisense oligonucleotide targeting human TNFalpha ISIS13393.

XX

XX Human; tumour necrosis factor alpha; TNFalpha; ss;

KW antisense gene therapy; inflammatory disorder; phosphorothioate linkage;

KW methylene(methylimino) intersugar linkage; infection; autoimmune disease;

KW diabetes; rheumatoid arthritis; Crohn's disease; pancreatitis;

KW multiple sclerosis; atopic dermatitis; inflammatory bowel disease;

KW colitis; hepatitis.

XX

XX Homo sapiens.

XX

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate linkages"

XX

XX US2004152652-A1.

XX

XX 05-AUG-2004.

XX

XX 26-AUG-2003; 2003US-00647918.

XX

XX 05-OCT-1998; 98US-00166186.

PR 18-MAY-1999; 99US-00313932.

PR 02-APR-2001; 2001US-00824322.

XX

XX (BAKE/) BAKER B F.

PA (BENN/) BENNETT C F.

PA (BUTL/) BUTLER M M.

PA (SHAN/) SHANAHAN W R.

XX

XX Baker BF, Bennett CF, Butler MM, Shanahan WR;

XX WPI; 2004-580193/56.

DR

XX Treating inflammatory disorders, such as diabetes, rheumatoid arthritis
PT and multiple sclerosis, using antisense oligonucleotides targeted to
PT nucleic acids encoding human tumor necrosis factor-alpha (TNF-alpha).
XX
XX Example 5; SEQ ID NO 49; 145pp; English.
XX
XX The invention relates to treating an inflammatory disorder in an
CC individual comprising administering an oligonucleotide (an antisense
CC oligonucleotide) up to 30 nucleotides in length complementary to a
CC nucleic acid molecule encoding human tumor necrosis factor-alpha (TNF-
CC alpha). The oligonucleotide useful in treating an inflammatory disorder
CC inhibits the expression of the human tumor necrosis factor-alpha, and
CC comprises at least an 8 nucleobase portion of any of 50 20-21 base pair
CC sequences, given in the specification. The antisense oligonucleotide is
CC administered orally, topically or parenterally. The oligonucleotide
CC comprises at least one modified intersugar linkage. The intersugar
CC linkage is a phosphorothioate linkage. The oligonucleotide further
CC comprises at least one 2'-O-methoxyethyl modification and at least one 5-
CC methyl cytidine, where every 2'-O-methoxyethyl modified cytidine residue
CC is a 5-methyl cytidine, and where every cytidine residue is a 5-methyl
CC cytidine. The modified intersugar linkage is a methylene(methylimino)
CC intersugar linkage. The methods and compositions of the present invention
CC are useful for the diagnosis, prevention and/or treatment of diseases or
CC conditions associated with aberrant expression or activity of the TNF-
CC alpha, such as inflammatory, infectious and autoimmune diseases,
CC including diabetes, rheumatoid arthritis, Crohn's disease, pancreatitis,
CC multiple sclerosis, atopic dermatitis, inflammatory bowel disease,
CC colitis and hepatitis. The present sequence is an antisense
CC oligonucleotide targeting the human TNFalpha gene.
XX
XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCTCTGCTACTCAGA 37
DB 20 GAGCTCTCTGCTACTCAGA 1
|||||
RESULT 1546
ID R02626/c
AD R02626 standard; DNA; 20 BP.
XX
AC ADR02626;
XX
XX 21-OCT-2004 (first entry)
XX
DE Control antisense oligonucleotide (human ICAM-1) #1.
XX
XX Human; tumor necrosis factor alpha; TNFalpha; ss;
KW antisense gene therapy; inflammatory disorder; phosphorothioate linkage;
KW methylene(methylimino) intersugar linkage; infection; autoimmune disease;
KW diabetes; rheumatoid arthritis; Crohn's disease; pancreatitis;
KW multiple sclerosis; atopic dermatitis; inflammatory bowel disease;
KW colitis; hepatitis.
XX
XX Homo sapiens.
XX
XX US2004152652-A1.
XX
XX 05-AUG-2004.
XX
XX 26-AUG-2003; 2003US-00647918.
XX
XX 05-OCT-1998; 98US-00166186.
XX 18-MAY-1999; 99US-00313932.
XX 02-APR-2001; 2001US-00824322.
XX
XX (BAKE/) BAKER B F.
PA (BENN/) BENNETT C F.

PA (BUTL/) BUTLER M M.
PA (SHAN/) SHANAHAN W R.
XX Baker BF, Bennett CF, Butler MM, Shanahan WR;
XX WPI; 2004-580193/56.
XX
XX Treating inflammatory disorders, such as diabetes, rheumatoid arthritis
PT and multiple sclerosis, using antisense oligonucleotides targeted to
PT nucleic acids encoding human tumor necrosis factor-alpha (TNF-alpha).
XX
XX Example 2; SEQ ID NO 41; 145pp; English.
XX
XX The invention relates to treating an inflammatory disorder in an
CC individual comprising administering an oligonucleotide (an antisense
CC oligonucleotide) up to 30 nucleotides in length complementary to a
CC nucleic acid molecule encoding human tumor necrosis factor-alpha (TNF-
CC alpha). The oligonucleotide useful in treating an inflammatory disorder
CC inhibits the expression of the human tumor necrosis factor-alpha, and
CC comprises at least an 8 nucleobase portion of any of 50 20-21 base pair
CC sequences, given in the specification. The antisense oligonucleotide is
CC administered orally, topically or parenterally. The oligonucleotide
CC comprises at least one modified intersugar linkage. The intersugar
CC linkage is a phosphorothioate linkage. The oligonucleotide further
CC comprises at least one 2'-O-methoxyethyl modification and at least one 5-
CC methyl cytidine, where every 2'-O-methoxyethyl modified cytidine residue
CC is a 5-methyl cytidine, and where every cytidine residue is a 5-methyl
CC cytidine. The modified intersugar linkage is a methylene(methylimino)
CC intersugar linkage. The methods and compositions of the present invention
CC are useful for the diagnosis, prevention and/or treatment of diseases or
CC conditions associated with aberrant expression or activity of the TNF-
CC alpha, such as inflammatory, infectious and autoimmune diseases,
CC including diabetes, rheumatoid arthritis, Crohn's disease, pancreatitis,
CC multiple sclerosis, atopic dermatitis, inflammatory bowel disease,
CC colitis and hepatitis. The present sequence is a control antisense
CC oligonucleotide used in the exemplification of the invention.
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTGGGC 2119
DB 20 TGACGGATGCCAGCTGGGC 1
|||||
RESULT 1547
ADR44328/c
ID ADR44328 standard; DNA; 20 BP.
XX
AC ADR44328;
XX
XX 04-NOV-2004 (first entry)
XX
DE Human ICAM-1 targeted antisense oligonucleotide, ISIS 1939.
XX
XX Pouchitis; intercellular adhesion molecule-1; ICAM-1; ulcerative colitis;
KW Crohn's disease; inflammatory bowel disease; cellular proliferation;
KW antisense; human; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
XX
XX US2004162259-A1.
XX

```

PD 19-AUG-2004.
XX
PF 12-FEB-2004; 2004US-00777838.
XX
PR 13-FEB-2003; 2003US-0447215P.
XX
PR 07-NOV-2003; 2003US-0518053P.
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX Wedel MK, Miner PB;
XX WPI; 2004-603583/58.
XX
XX Treating pouchitis in a human in need comprises administering to the
PT human a pharmaceutical composition comprising an oligonucleotide targeted
PT to human ICAM-1 mRNA.
XX
XX Example 2; SEQ ID NO 2; 42pp; English.
XX
XX The invention relates to a method for treating pouchitis in a human which
CC involves administering a pharmaceutical composition comprising an
CC oligonucleotide targeted to human intercellular adhesion molecule-1 (ICAM
CC -1) mRNA. The method is useful for treating pouchitis, ulcerative
CC colitis, Crohn's disease, inflammatory bowel disease or undue cellular
CC proliferation. The present sequence is an antisense oligonucleotide
CC targeted to human ICAM-1. This sequence is used to illustrate the method
CC of the invention.
XX
XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAGTGGTGGGG 1957
DB 20 GAGAGGGGAGTGGTGGGG 1
RESULT 1548
ADR44327/C
ID ADR44327 standard; DNA; 20 BP.
XX
AC ADR44327;
XX
XX 04-NOV-2004 (first entry)
XX
DE Human ICAM-1 targeted antisense oligonucleotide, ISIS 15839.
XX
XX Pouchitis; intercellular adhesion molecule-1; ICAM-1; ulcerative colitis;
KW Crohn's disease; inflammatory bowel disease; cellular proliferation;
KW antisense; human; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20 /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone, optionally all
FT cytosines are 5-methyl cytosine bases"
FT modified_base 13..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "Optionally 2'-methoxyethoxy bases"
XX
XX US2004162259-A1.
XX
XX 19-AUG-2004.
XX
XX 12-FEB-2004; 2004US-00777838.
XX
XX
PR 13-FEB-2003; 2003US-0447215P.
XX
PR 07-NOV-2003; 2003US-0518053P.
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX Wedel MK, Miner PB;
XX WPI; 2004-603583/58.
XX
XX Treating pouchitis in a human in need comprises administering to the
PT human a pharmaceutical composition comprising an oligonucleotide targeted
PT to human ICAM-1 mRNA.
XX
XX Example 2; SEQ ID NO 2; 42pp; English.
XX
XX The invention relates to a method for treating pouchitis in a human which
CC involves administering a pharmaceutical composition comprising an
CC oligonucleotide targeted to human intercellular adhesion molecule-1 (ICAM
CC -1) mRNA. The method is useful for treating pouchitis, ulcerative
CC colitis, Crohn's disease, inflammatory bowel disease or undue cellular
CC proliferation. The present sequence is an antisense oligonucleotide
CC targeted to human ICAM-1. This sequence is used to illustrate the method
CC of the invention.
XX
XX Sequence 20 BP; 2 A; 14 C; 0 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAGTGGTGGGG 1957
DB 20 GAGAGGGGAGTGGTGGGG 1
RESULT 1548
ADR44327/C
ID ADR44327 standard; DNA; 20 BP.
XX
AC ADR44327;
XX
XX 04-NOV-2004 (first entry)
XX
DE Human ICAM-1 targeted antisense oligonucleotide, ISIS 15839.
XX
XX Pouchitis; intercellular adhesion molecule-1; ICAM-1; ulcerative colitis;
KW Crohn's disease; inflammatory bowel disease; cellular proliferation;
KW antisense; human; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20 /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone, optionally all
FT cytosines are 5-methyl cytosine bases"
FT modified_base 13..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "Optionally 2'-methoxyethoxy bases"
XX
XX US2004162259-A1.
XX
XX 19-AUG-2004.
XX
XX 12-FEB-2004; 2004US-00777838.
XX
XX
PR 13-FEB-2003; 2003US-0447215P.
XX
PR 07-NOV-2003; 2003US-0518053P.
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX Wedel MK, Miner PB;
XX WPI; 2004-603583/58.
XX
XX Treating pouchitis in a human in need comprises administering to the
PT human a pharmaceutical composition comprising an oligonucleotide targeted
PT to human ICAM-1 mRNA.
XX
XX Claim 4; SEQ ID NO 1; 42pp; English.
XX
XX The invention relates to a method for treating pouchitis in a human which
CC involves administering a pharmaceutical composition comprising an
CC oligonucleotide targeted to human intercellular adhesion molecule-1 (ICAM
CC -1) mRNA. The method is useful for treating pouchitis, ulcerative
CC colitis, Crohn's disease, inflammatory bowel disease or undue cellular
CC proliferation. The present sequence is an antisense oligonucleotide
CC targeted to human ICAM-1. This sequence is used to illustrate the method
CC of the invention.
XX
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATCCAGCTTGGGC 2119
DB 20 TGACGGATCCAGCTTGGGC 1
RESULT 1549
AAQ85816/C
ID AAQ85816 standard; DNA; 21 BP.
XX
XX AAQ85816;
XX
XX 25-MAR-2003 (revised)
XX 07-NOV-1995 (first entry)
XX
DE Anti-ICAM 2'-O-alkylamino-containing oligomer #69.
XX
XX Alkylamino group; ribofuranosyl sugar; antisense therapy; virus; HIV;
KW herpes; papilloma; antiviral; ss.
XX
XX Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..21 /tag= b
FT /note= "contains phosphorothioate linkages between
FT nucleosides"
FT modified_base 1 /tag= a
FT /mod_base= OTHER
FT /note= "2'-O-[hexyl-N-(3-oxycarbonyl-cholesterlyl)amino]-
FT uridine or may be 5'-O-dimethoxytrityl-2'-O-[hexyl-N-(5-
FT thiocarbonyl-3,6-dipivoyl fluorescein)amino]uridine"
XX
XX WO9506659-A1.
XX
XX 09-MAR-1995.
XX
XX 02-SEP-1994; 94WO-US010131.
XX
XX 03-SEP-1993; 93US-00117363.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX

```


CC applications, e.g. for treating viral infections. (Updated on 25-MAR-2003
 XX to correct PF field.)

SQ Sequence 21 BP; 5 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37

Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 1552

AAV27991/c
 ID AAV27991 standard; DNA; 21 BP.

XX AC AAV27991;

XX DT 25-SEP-1998 (first entry)

XX DE Ataxia telangiectasia exon 17 primer 2.

XX KW ss; PCR; primer; amplification; ataxia telangiectasia; diagnosis; human;
 radiation; breast cancer.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN WO9822621-A1.

XX PD 28-MAY-1998.

XX PF 17-NOV-1997; 97WO-US020953.

XX PR 20-NOV-1996; 96US-00753147.

XX PA (VIRG-) VIRGINIA MASON RES CENT.

XX PI Concannon P;

XX DR WPI; 1998-312503/27.

XX PT Method of detecting ataxia telangiectasia - comprises use of primers
 based on intron-exon boundaries, useful for diagnosing disease in
 heterozygotes.

XX PS Claim 6; Page 6; 47pp; English.

XX CC The primers AAV27964-V28086 are used to amplify ataxia telangiectasia
 (ATM) exons and their adjacent splice junction sites. These can be used
 as a method of detecting a mutation in the ATM gene by comparing the PCR
 products of amplification from a sample from a patient suspected of
 having an ATM mutation with a sample from a non-mutated ATM patient. This
 method is especially useful for diagnosing ataxia telangiectasia in
 heterozygotes and can be used to locate the positions of the mutation.
 The diagnosis of ataxia telangiectasia in patients needing therapeutic
 radiation will prevent fatal radiation burns and the development of
 breast cancer which can occur

SQ Sequence 21 BP; 3 A; 10 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGAGTGCAGTGG 2790

Db 21 CCCAGGCTGAGTGCAGTGG 2

RESULT 1553

ADF70304/c
 ID ADF70304 standard; DNA; 21 BP.

XX AC ADF70304;

XX DT 12-FEB-2004 (first entry)

XX DE ICAM antisense oligonucleotide SeqID17.

XX KW expression modulation; hepatic system; sterol group; hepatotropic;
 gene therapy; hepatic disease; antisense therapy; ss; ICAM;
 intercellular adhesion molecule.

XX OS Unidentified.

XX PN WO2003072711-A2.

XX PD 04-SEP-2003.

XX PF 21-FEB-2003; 2003WO-US005066.

XX PR 22-FEB-2002; 2002US-00080979.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Cook PD, Manoharan M, Bennett FC;

XX DR WPI; 2003-679947/64.

XX PT Modulating the expression of a nucleic acid in the hepatic system, useful
 for treating hepatic disorders, comprises administering to the mammal an
 oligonucleotide that hybridizes to the nucleic acid to modulate its
 expression.

XX PS Example 7; SEQ ID NO 17; 98pp; English.

XX CC This invention relates to a novel method of modulating the expression of
 a nucleic acid in the hepatic system of a mammal which comprises
 administering to the mammal an oligonucleotide that hybridizes to the
 nucleic acid to modulate the expression of the nucleic acid, where the
 oligonucleotide has two sterol groups that are covalently bonded. The
 invention may be useful for the development of a compound with
 hepatotropic activity whilst the genetic sequences of the invention may
 prove useful for gene therapy. The methods are useful for treating
 hepatic disease or disorder associated with a protein encoded by a gene.
 Note: These oligonucleotides may have one or more of several
 modifications which are detailed in the specification, including having a
 phosphorothioate backbone or having ribonucleoside bases.

XX SQ Sequence 21 BP; 5 A; 4 C; 7 G; 3 T; 1 U; 1 Other;

Query Match 0.7%; Score 20; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 5.2e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37

Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 1554

AAQ22655/c
 ID AAQ22655 standard; DNA; 22 BP.

XX AC AAQ22655;

XX DT 08-JUL-1992 (first entry)

XX DE Antisense oligonucleotide #27 targetted to ICAM-1 5'-CAP (32-51).

XX KW Intercellular adhesion molecule-1; inhibitor; phosphorothioate bond;
 triple helix; mRNA capping; transcription initiation; ss.

OS Synthetic.
 XX WO9203139-A.
 PN PD 05-MAR-1992.
 XX 23-JUL-1991; 91WO-US005209.
 XX 14-AUG-1990; 90US-00567286.
 PR (ISIS-) ISIS PHARM INC.
 XX PA Bennett CF, Mirabelli CK, Mira;
 XX WPI; 1992-096579/12.
 XX New oligonucleotides hybridisable to cell adhesion modulators - for
 PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
 PT and diagnosis of intercellular adhesion dysfunction.
 XX Example 5; Page 47; 75pp; English.
 XX This antisense oligonucleotide was designed to hybridise to the 5' cap
 CC region of human ICAM-1 mRNA. It was synthesised in the phosphorothioate
 CC form as none of the phosphodiester form-antisense oligonucleotides which
 CC were initially tested demonstrated inhibitory activity. Oligonucleotide
 CC #27 was approximately as active in IL-1-beta-stimulated cells as the
 CC oligonucleotide which binds to the AUG codon (see AAQ22629)
 XX
 SQ Sequence 22 BP; 6 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 4.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 18 GAGCTCCTCTGCTACTCAGA 37
 DB |||||
 20 GAGCTCCTCTGCTACTCAGA 1
 RESULT 1555
 AAQ44586/c
 ID AAQ44586 standard; DNA; 22 BP.
 XX
 AC AAQ44586;
 XX
 DT 25-MAR-2003 (revised)
 DT 26-SEP-1994 (first entry)
 DE Antisense oligonucleotide which targets human ICAM-1 5'-cap.
 XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
 KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
 KW antisense oligonucleotide; therapy; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_feature 1..22
 FT /*tag= a
 FT /note= "in phosphorothioate form; G and C added as spacer
 FT to 3"
 FT
 PN WO9405333-A1.
 XX
 PD 17-MAR-1994.
 XX 27-AUG-1993; 93WO-US008101.
 XX 02-SEP-1992; 92US-00939855.
 PR 21-JAN-1993; 93US-00007997.
 PR 17-MAY-1993; 93US-00063167.
 XX

PA (ISIS-) ISIS PHARM INC.
 XX Bennet CF, Mirabelli CK;
 XX WPI; 1994-100869/12.
 XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
 PT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
 PT Example 5; Page 54; 101pp; English.
 XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
 CC both the phosphodiester and phosphorothioate forms. Some of the
 CC oligonucleotides are useful to treat diseases which are modulated by
 CC changes in intercellular adhesion molecules. This sequence corresponds to
 CC nucleotides 32-51 of the 5'-cap region of the human ICAM-1 coding
 CC sequence and is not one of the preferred antisense oligonucleotides.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 22 BP; 6 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 4.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 18 GAGCTCCTCTGCTACTCAGA 37
 DB |||||
 20 GAGCTCCTCTGCTACTCAGA 1
 RESULT 1556
 AAT01767/c
 ID AAT01767 standard; DNA; 22 BP.
 XX
 AC AAT01767;
 XX
 DT 19-DEC-1995 (first entry)
 XX
 DE Peptide nucleic acid oligomer targeting ICAM-1 5'-CAP.
 XX
 KW peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
 KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
 KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_feature 1..22
 FT /*tag= a
 FT /note= "at least one (and preferably all) of the backbone
 FT subunits are composed of amide units, so that the
 FT oligomer consists of the nucleobases attached covalently
 FT to a polyamide backbone"
 FT
 PN WO9504749-A1.
 XX
 PD 16-FEB-1995.
 XX 05-AUG-1994; 94WO-US009026.
 XX 05-AUG-1993; 93US-00102650.
 XX (ISIS-) ISIS PHARM INC.
 XX Bennett CF, Mirabelli CK;
 XX WPI; 1995-090842/12.
 XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes
 PT - are stable anti-sense cpds. of high affinity, partic. for treating
 PT inflammation, viral infection, cancer etc.
 XX Claim 2; Page 35; 57pp; English.
 PS

XX New oligomers are claimed which (A) have at least one peptide nucleic
 CC acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
 CC coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
 CC or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated
 CC region, exon/intron junction region or 3'-untranslated region of VCAM-1.
 CC The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
 CC produce antisense-type gene regulation moieties. Hence they may be used
 CC therapeutically for modulating cellular adhesion and thus as
 CC antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
 CC AIDS agents and antiinflammatory agents. They may also be useful as
 CC diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
 CC affinity for complementary single stranded DNA. They are also able to
 CC form triple helices in which a first PNA strand binds with RNA or ssDNA
 CC and a second PNA strand binds with the resulting double helix or with the
 CC first PNA strand. The PNAs possess no significant charge and are water
 CC soluble, which facilitates cellular uptake. Further, since they contain
 CC amides of non-biological amino acids, they are biostable and resistant to
 CC enzymatic degradation by proteases. The present sequence targets human
 CC intercellular adhesion molecule-1 (ICAM-1) 5' CAP region
 XX
 SQ Sequence 22 BP; 6 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 4.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
 |||||
 Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 1557
 AAT01765/c
 ID AAT01765 standard; DNA; 22 BP.
 AC AAT01765;
 XX
 XX 18-DEC-1995 (first entry)
 XX
 DE Peptide nucleic acid oligomer targeting ICAM-1 5'-CAP;
 XX
 KW peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
 KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
 KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT misc_feature 1..22
 FT /*tag= a
 FT /note= "at least one (and preferably all) of the backbone
 FT subunits are composed of amide units, so that the
 FT oligomer consists of the nucleobases attached covalently
 FT to a polyamide backbone"
 XX
 PN WO9504749-A1.
 XX
 PD 16-FEB-1995.
 XX
 XX 05-AUG-1994; 94WO-US0009026.
 XX
 PR 05-AUG-1993; 93US-00102650.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK;
 XX
 XX WPI; 1995-090842/12.
 DR
 XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes
 FT - are stable anti-sense cpds. of high affinity, partic. for treating
 PT inflammation, viral infection, cancer etc.

XX Claim 2; Page 35; 57pp; English.
 XX
 CC New oligomers are claimed which (A) have at least one peptide nucleic
 CC acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
 CC coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
 CC or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated
 CC region, exon/intron junction region or 3'-untranslated region of VCAM-1.
 CC The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
 CC produce antisense-type gene regulation moieties. Hence they may be used
 CC therapeutically for modulating cellular adhesion and thus as
 CC antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
 CC AIDS agents and antiinflammatory agents. They may also be useful as
 CC diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
 CC affinity for complementary single stranded DNA. They are also able to
 CC form triple helices in which a first PNA strand binds with RNA or ssDNA
 CC and a second PNA strand binds with the resulting double helix or with the
 CC first PNA strand. The PNAs possess no significant charge and are water
 CC soluble, which facilitates cellular uptake. Further, since they contain
 CC amides of non-biological amino acids, they are biostable and resistant to
 CC enzymatic degradation by proteases. The present sequence targets human
 CC intercellular adhesion molecule-1 (ICAM-1) 5' CAP region
 XX
 SQ Sequence 22 BP; 6 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 22;
 Best Local Similarity 100.0%; Pred. No. 4.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
 |||||
 Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 1558
 AAT36671/c
 ID AAT36671 standard; DNA; 22 BP.
 AC AAT36671;
 XX
 XX 21-JAN-1997 (first entry)
 XX
 DE Antisense oligonucleotide ISIS 3064.
 XX
 KW Antisense oligonucleotide; human; intracellular adhesion molecule-1;
 KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
 KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; breguarin;
 KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
 KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
 KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
 KW ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..22
 FT /*tag= a
 FT /note= "phosphorothioate backbone"
 XX
 PN WO9615780-A1.
 XX
 PD 30-MAY-1996.
 XX
 XX 22-NOV-1995; 95WO-US015536.
 XX
 PR 23-NOV-1994; 94US-00344155.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PA (TEXA) UNIV TEXAS SYSTEM.
 XX
 XX Bennett CF, Stepkowski SM;
 PI
 XX WPI; 1996-268321/27.
 DR

XX Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
PT rejection.
XX
XX Example 5; Page 53; 92pp; English.
XX
XX AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
CC oligonucleotides of the invention. These sequences target regions of the
CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
CC targets the 5' CAP region (nucleotides 32-51) of ICAM-1. ICAM-1, ELAM-1,
CC and VCAM-1 represent three of the five cell adhesion molecules involved
CC in the adherence of white blood cells to vascular endothelium. These
CC sequences can be used in a composition for treating allograft rejection.
CC The composition contains one of these sequences in combination with an
CC immunosuppressive agent. The immunosuppressive agent used in the
CC compositions is brequinar, rapamycin, anti-lymphocyte serum, a monoclonal
CC antibody against LFA-1 or an antisense oligonucleotide. The compositions
CC can be used for treating or preventing allograft rejection, such as
CC cardiac or renal allograft rejection. By using these compositions,
CC allograft survival times are extended, and donor-specific transplant
CC tolerance is induced
XX
XX Sequence 22 BP; 6 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 1559
AAZ48920/C
ID AAZ48920 standard; DNA; 22 BP.
XX
XX AAZ48920;
AC
XX
XX 29-MAR-2000 (first entry)
XX
XX Human ICAM-1 antisense inhibitor, ISIS #3064.
XX
XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
KW ss.
XX
XX Homo sapiens.
XX
XX WO9961462-A1.
XX
XX 02-DEC-1999.
XX
XX 26-MAY-1999; 99WO-US011548.
XX
XX 27-MAY-1998; 98US-00085759.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Mirabelli CK, Baker BF;
XX
XX WPI; 2000-072600/06.
XX
XX New antisense oligonucleotides, used for treating e.g. inflammatory

PT conditions, psoriasis, graft rejection, cancers, infections,
PT cardiovascular disorders or autoimmune disorders.
XX
XX Example 10; Page 179; 199pp; English.
XX
XX This sequence is an antisense oligonucleotide of the invention. The
CC antisense oligonucleotides are targeted to a nucleic acid encoding a
CC cellular adhesion molecule (CAM) and is capable of modulating the
CC expression of the CAM. They particularly inhibit intercellular adhesion
CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
CC oligonucleotides can be used to modulate CAM activity in mediating
CC cell-cell interactions and subsequent cellular and biological responses,
CC e.g. T cell activation, leukocyte transmigration and inflammation. The
CC antisense sequences can be used for modulating the synthesis of a CAM.
CC They can be used for treating an animal suspected of having or being
CC prone to a disease or condition associated with a CAM. Oligonucleotides
CC targeted to ICAM-1 can be used for treating an inflammatory disease or
CC condition e.g. inflammatory bowel disease such as Crohn's disease,
CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
CC can also be used for reducing corticosteroid use in a patient or for
CC reducing cyclosporine use in a patient. The oligonucleotides can also be
CC used for detection and diagnosis. They can also be used for treating e.g.
CC hyperproliferative disorders, tumours, diapedesis, graft versus host
CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
CC myocarditis, ischaemic heart disease or stroke
XX
XX Sequence 22 BP; 6 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 1560
ADC39001/C
ID ADC39001 standard; DNA; 22 BP.
XX
XX ADC39001;
AC
XX
XX 18-DEC-2003 (first entry)
XX
XX Human ICAM-1 targeted primer #27.
DE
XX ss; primer; immunosuppressive; antisense therapy;
KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
KW extracellular adhesion molecule-1; ELAM-1;
KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX
XX Key Location/Qualifiers
FT misc_difference 1..22
FT /*tag= a
FT /note= "all internucleotide linkages are phosphodiester
FT bonds"
XX
XX WO2003032920-A2.
XX
XX 24-APR-2003.
XX
XX 16-OCT-2002; 2002WO-US033236.

```

XX 18-OCT-2001; 2001US-00982262.
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Mirabelli CK;
XX
XX WPI; 2003-403142/38.
XX
XX Inhibiting corneal allograft rejection, by contacting an allograft with a
XX formulation having an oligonucleotide targeted to intercellular adhesion
XX molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
XX molecule-1.
XX
XX Example 5; SEQ ID NO 27; 106pp; English.
XX
XX The invention relates to a method of inhibiting corneal allograft
XX rejection, by contacting the allograft with a topical formulation
XX comprising an antisense oligonucleotide targeted to intercellular
XX adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
XX or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
XX useful for inhibiting corneal allograft rejection or for preserving a
XX corneal explant ex vivo, where the explant is human. This sequence
XX corresponds to one of the oligonucleotide of the invention.
XX
XX Sequence 22 BP; 6 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
RESULT 1561
ADM46478/c
ID ADM46478 standard; DNA; 22 BP.
AC
AC ADM46478;
XX
XX 03-JUN-2004 (first entry)
XX
XX Antisense oligonucleotide targeting human ICAM-1 #27.
XX
XX Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
XX vascular cell adhesion molecule; VCAM-1;
XX endothelial leukocyte adhesion molecule; ELAM-1;
XX inflammatory ophthalmological disorder; redness; inflammation;
XX corneal explant; corneal allograft rejection.
XX
XX Homo sapiens.
XX
XX US2004033977-A1.
XX
XX 19-FEB-2004.
XX
XX 04-JUN-2003; 2003US-00454663.
XX
XX 14-AUG-1990; 90US-00567286.
XX 02-SEP-1992; 92US-00939855.
XX 21-JAN-1993; 93US-00007997.
XX 10-FEB-1993; 93US-00969151.
XX 17-MAY-1993; 93US-00063167.
XX 12-MAY-1995; 95US-00440740.
XX 03-AUG-1998; 98US-00128496.
XX 12-SEP-2000; 2000US-00659288.
XX 18-OCT-2001; 2001US-00982262.
XX (BENNETT) BENNETT C F.
XX (MIRA/) MIRABELLI C.
XX

```

```

PI Bennett CF, Mirabelli C;
XX
XX WPI; 2004-180090/17.
XX
XX New antisense oligonucleotide, useful for diagnosing, as research
XX reagents and for treating disease states, which respond to modulation of
XX the synthesis or metabolism of cell adhesion molecules.
XX
XX Example 5; SEQ ID NO 27; 72pp; English.
XX
XX The invention relates to an antisense oligonucleotide targeting human
XX intercellular adhesion molecule (ICAM-1) having a sequence appearing as
XX ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
XX replaced with a thymidine, cytidine or guanosine nucleotide, at least one
XX thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
XX nucleotide, at least one guanosine nucleotide is replaced with an
XX adenosine, thymidine or cytidine nucleotide or at least one cytidine
XX nucleotide is replaced with an adenosine, cytidine or guanosine
XX nucleotide. The oligonucleotide is one of 88 disclosed antisense
XX oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
XX 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
XX an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
XX (where the compound specifically hybridises with the human ICAM-1 mRNA
XX and inhibits the expression of human ICAM-1 mRNA), and a double stranded
XX RNA compound having the RNA equivalent sequence of ADM46473. The
XX oligonucleotide is useful for modulating the activity of the RNA and DNA
XX and the modulation of the synthesis and metabolism of specific cell
XX adhesion molecules. It is also useful for the diagnosis, as research
XX reagents and for treating disease states, which respond to modulation of
XX the synthesis or metabolism of cell adhesion molecules. The
XX oligonucleotide is suitable for treating inflammatory ophthalmological
XX disorders including redness and inflammation caused by allergens and
XX allergic reactions. The oligonucleotides can also be used to preserve
XX corneal explants ex vivo and to prevent corneal allograft rejections. The
XX specific hybridisation exhibited by the oligonucleotides may be used for
XX assays, purifications or cellular product preparations. The present
XX sequence is an antisense oligonucleotide targeting ICAM-1.
XX
XX Sequence 22 BP; 6 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
RESULT 1562
AAT58185/c
ID AAT58185 standard; DNA; 24 BP.
XX
XX AAT58185;
XX
XX 22-JUL-1997 (first entry)
XX
XX 5'-Guanosine-capped anti-ICAM antisense oligonucleotide 21.
XX
XX Antisense therapy; intercellular adhesion molecule; ICAM;
XX cell adhesion receptor; integrin; 3'-cap; 5'-cap; nuclease resistance;
XX stability; ss.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX misc_feature 1..4
XX /tag= a
XX /function= "cap"
XX /note= "All 4 nucleotides are linked via P=S bonds"
XX /tag= b
XX misc_feature 5..24
XX /tag= b
XX /label= anti-ICAM_oligonucleotide
XX

```


PT infection, with good specificity and in vivo stability.

XX PS Disclosure; Page 21; 36pp; German.

XX CC This invention describes novel phosphonomonoester oligonucleotide analogues which act as inhibitors of gene expression (as sense/antisense, ribozyme or triplex-forming molecules), useful as diagnostic agents (i.e. probes for detecting nucleic acid) or for treatment of diseases caused by viruses, influenced by integrins or cell-cell adhesion receptors, induced by factors such as TNF-alpha, or cancer or restenosis. The products of the invention satisfy the requirements of good in-vivo stability; ability to cross cellular and nuclear membranes, and specific binding to target nucleic acid better than known oligonucleotides

XX SQ Sequence 24 BP; 2 A; 14 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGG 1957

DB 24 GAGAGGGGAAGTGTGGGG 5

RESULT 1565

AAAX24168/c

ID AAAX24168 standard; DNA; 24 BP.

XX AC AAAX24168;

XX DT 01-JUL-1999 (first entry)

XX DE ICAM directed phosphonomonoester oligonucleotide analogue 2.

XX KW Phosphonomonoester analogue; inhibitor; antisense; cancer; restenosis;
ribozyme; diagnostic agent; detection; treatment; disease; virus;
integrin; cell-cell adhesion receptor; TNF-alpha; ICAM; ss.

XX OS Synthetic.

XX PN DE19508923-A1.

XX PD 19-SEP-1996.

XX PF 13-MAR-1995; 95DE-01008923.

XX PR 13-MAR-1995; 95DE-01008923.

XX PA (FARH) HOECHST AG.

XX PI Anuschirwan P, Uhlmann E, Breipohl G, Wallmeier H;

XX DR WPI; 1996-425893/43.

XX PT New oligo:nucleotide analogues contg. phospho:mono:ester bridges - for
therapeutic inhibition of gene expression, e.g. in cancer or viral
infection, with good specificity and in vivo stability.

XX PS Disclosure; Page 21; 36pp; German.

XX CC This invention describes novel phosphonomonoester oligonucleotide analogues which act as inhibitors of gene expression (as sense/antisense, ribozyme or triplex-forming molecules), useful as diagnostic agents (i.e. probes for detecting nucleic acid) or for treatment of diseases caused by viruses, influenced by integrins or cell-cell adhesion receptors, induced by factors such as TNF-alpha, or cancer or restenosis. The products of the invention satisfy the requirements of good in-vivo stability; ability to cross cellular and nuclear membranes, and specific binding to target nucleic acid better than known oligonucleotides

XX SQ Sequence 24 BP; 2 A; 14 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGG 1957

DB 20 GAGAGGGGAAGTGTGGGG 1

RESULT 1566

AA89463/c

ID AA89463 standard; DNA; 25 BP.

XX AC AA89463;

XX DT 14-AUG-2001 (first entry)

XX DE Human ICAM-1 modified antisense oligonucleotide.

XX KW Antisense therapy; oligonucleotide detection; probe;
oligonucleotide quantitation; ss.

XX OS Homo sapiens.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT misc_RNA 21..25

FT /*tag= a

FT modified_base 21..25

FT /*tag= b

FT /mod_base= OTHER

FT /note= "modified by digoxigenin"

XX WO200134845-A1.

XX PD 17-MAY-2001.

XX PF 10-NOV-2000; 2000WO-US031042.

XX PR 12-NOV-1999; 99US-0165184P.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Baker BF, Yu Z, Leeds JM;

XX DR WPI; 2001-329098/34.

XX PT Detecting or quantifying oligonucleotides in bodily fluid or extract for
therapeutic, pharmacokinetic purposes, by contacting with complementary
probes and enzymes recognizing specific nucleic acid structures.

XX PS Disclosure; Fig 1; 56pp; English.

XX CC The present invention describes a method of detecting and quantitating an
oligonucleotide in a bodily fluid, involving contacting the fluid with a
probe complementary to the oligonucleotide to form a hybrid, contacting
the hybrid with an enzyme, labeling the hybrid and detecting the label.
This is especially useful to determine oligonucleotide concentrations in
antisense therapy, and to study nucleic acid pharmacokinetic properties.
The present sequence is an antisense sequence used in the exemplification
of the invention

XX SQ Sequence 25 BP; 4 A; 8 C; 5 G; 3 T; 5 U; 0 Other;

Query Match 0.7%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACCGATCCAGCTTGGGC 2119

DB 20 TGACCGATCCAGCTTGGGC 1

RESULT 1567
 AAF89464
 ID AAF89464 standard; DNA; 25 BP.
 XX
 AC AAF89464;
 XX
 DT 14-AUG-2001 (first entry)
 XX
 DE Human ICM-1 antisense oligonucleotide complementary probe #2.
 XX
 KW Antisense therapy; oligonucleotide detection; probe;
 KW oligonucleotide quantitation; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200134845-A1.
 XX
 PD 17-MAY-2001.
 XX
 PF 10-NOV-2000; 2000WO-US031042.
 XX
 PR 12-NOV-1999; 99US-0165184P.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Baker BF, Yu Z, Leeds JM;
 XX
 DR WPI; 2001-329098/34.
 XX
 PT Detecting or quantifying oligonucleotides in bodily fluid or extract for
 PT therapeutic, pharmacokinetic purposes, by contacting with complementary
 PT probes and enzymes recognizing specific nucleic acid structures.
 XX
 PS Disclosure; Fig 1; 56pp; English.
 XX
 CC The present invention describes a method of detecting and quantitating an
 CC oligonucleotide in a bodily fluid, involving contacting the fluid with a
 CC probe complementary to the oligonucleotide to form a hybrid, contacting
 CC the hybrid with an enzyme, labeling the hybrid and detecting the label.
 CC This is especially useful to determine oligonucleotide concentrations in
 CC antisense therapy, and to study nucleic acid pharmacokinetic properties.
 CC The present sequence is an oligonucleotide probe complementary to an
 CC antisense sequence used in the exemplification of the invention
 XX
 SQ Sequence 25 BP; 8 A; 5 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.7%; Score 20; DB 1; Length 25;
 Best Local Similarity 100.0%; Pred. No. 4.3e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 DB 6 TGACGGATGCCAGCTTGGGC 25
 RESULT 1568
 ADD69447
 ID ADD69447 standard; DNA; 23 BP.
 XX
 AC ADD69447;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE 5' anchored (ISSR)-PCR primer - SEQ ID 5.
 XX
 KW inter-simple sequence repeat; ISSR; SSR; PCR; primer; genotyping; plant;
 KW animal; Basmati rice; ss.
 XX
 OS Synthetic.
 XX
 PN WO2003085133-A2.
 XX
 PD 16-OCT-2003.
 XX
 XX 09-JAN-2003; 2003WO-IB0000041.
 XX
 PR 08-APR-2002; 2002IN-CH0000260.
 XX
 PA (DNAF-) CENT DNA FINGERPRINTING & DIAGNOSTICS.
 XX
 PI Nagaraju JG;
 XX
 DR WPI; 2003-804317/75.
 XX
 PT New set of inter-simple sequence repeats (ISSR)-PCR primers for
 PT genotyping eukaryotes, useful for genotyping diverse genomes of plant and
 PT animal systems.
 XX
 PS Claim 1; SEQ ID NO 5; 60pp; English.
 XX
 CC The invention relates to a novel set of inter-simple sequence repeats
 CC (ISSR)-PCR primers for genotyping eukaryotes. The primers of the
 CC invention may be useful for genotyping diverse genomes of plant and
 CC animal systems, in particular for distinguishing Basmati rice varieties
 CC from non-Basmati rice varieties and traditional Basmati rice varieties
 CC from evolved Basmati rice varieties. The current sequence is that of the
 CC 5' anchored (ISSR)-PCR primer of the invention.
 XX
 SQ Sequence 23 BP; 1 A; 1 C; 10 G; 11 T; 0 U; 0 Other;
 Query Match 0.7%; Score 19.8; DB 1; Length 23;
 Best Local Similarity 91.3%; Pred. No. 5e+02;
 Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2727 CCGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 DB 1 CCGTGTGTGTGTGTGTGTGTGTGTGTGTGT 23
 RESULT 1569
 AAZ27796/C
 ID AAZ27796 standard; DNA; 24 BP.
 XX
 AC AAZ27796;
 XX
 DT 23-DEC-1999 (first entry)
 XX
 DE PCR primer for human DNA marker clone G212.
 XX
 KW Tandem repeat sequence; DNA isolation; intermediate tandem repeat;
 KW ITR sequence; pentanucleotide tandem repeat; stutter artifact;
 KW DNA typing; DNA profiling; linkage analysis; criminal justice;
 KW paternity testing; animal lineage analysis; microsatellite loci;
 KW polymorphism detection; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9940194-A1.
 XX
 PD 12-AUG-1999.
 XX
 PF 04-FEB-1999; 99WO-US002345.
 XX
 PR 04-FEB-1998; 98US-00018584.
 XX
 PA (PROM-) PROMEGA CORP.
 XX
 PI Schumm JW, Bacher JW;
 XX
 DR WPI; 1999-590696/50.
 XX
 PT Isolating DNA containing intermediate tandem repeat sequences, useful in
 PT DNA profiling.
 XX
 PS Claim 30; Page 21; 111pp; English.

Db 24 CGTGTGTGTGTGTGCGTGTGT 2

RESULT 1572
AAC73488
ID AAC73488 standard; DNA; 21 BP.
XX
AC AAC73488;
XX
DT 02-FEB-2001 (first entry)
XX
XX SNP flanking sequence #105 used in multiplexing PCR/SBE assay.
DE
KW Oligonucleotide array; genotyping; single base extension reaction; SBE;
KW polymorphic locus; single nucleotide polymorphism; ss.
XX
OS Unidentified.
XX
PN WO200058516-A2.
XX
PD 05-OCT-2000.
XX
PF 27-MAR-2000; 2000WO-US008069.
XX
PR 26-MAR-1999; 99US-0126473P.
PR 23-JUN-1999; 99US-0140359P.
XX
PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY-) AFFYMETRIX INC.
XX
PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
PI Ryder T, Sklar P;
XX
XX WPI; 2000-656171/63.
XX
XX Universal array of oligonucleotides tags attached to a solid substrate
PT along with locus-specific tagged oligonucleotides useful in genotyping
PT using single base extension reactions.
XX
PS Example 7; Page 59; 70pp; English.
XX
CC The present invention relates to an oligonucleotide array comprising
CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC array is useful for genotyping a nucleic acid sample at one or more loci
CC via single base extension (SBE) reactions. A pair of primers is used to
CC amplify a polymorphic locus in a sample e.g. a single nucleotide
CC polymorphism (SNP). The present sequence is one such polymorphic locus
CC used in the present invention. The amplified nucleic acid product is then
CC used as a template in a SBE reaction with an extension primer. The SBE
CC reaction products are used to form the oligonucleotide array. Note: This
CC sequence includes a SNP represented by the degenerate codon in the
CC sequence
XX
SQ Sequence 21 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 1 Other;

Query Match 0.7%; Score 19.6; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1238 ATGGCCCCCGACTGGACGAG 1257
|||||:|||||
2 ATGGCCCCCGACTGGACGAG 21

Db 2 ATGGCCCCCGACTGGACGAG 21

RESULT 1573
AAQ33891
ID AAQ33891 standard; DNA; 21 BP.
XX
AC AAQ33891;
XX
XX 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX

DE Microsatellite sequence from clone TGLA307.
XX
KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
XX
OS Bos taurus.
XX
PN WO9213102-A1.
XX
PD 06-AUG-1992.
XX
PF 15-JAN-1992; 92WO-US000340.
XX
PR 15-JAN-1991; 91US-00642342.
XX
PA (GENM-) GENMARK.
XX
PI Georges M, Massey JW;
XX
XX WPI; 1992-284684/34.
XX
PT Polymorphic bovine DNA markers - used in genetic identification, gene
PT mapping, and selective breeding.
XX
PS Table 7; Page 286; 517pp; English.
XX
CC The sequence is that of a bovine microsatellite sequence obtd. by
CC screening a library of bovine MboI DNA fragments of between 250 and 500
CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC in the bovine genome is estimated at >100, 000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPTIPRIM). The microsatellites may be
CC used to identify individuals, for parentage testing, and in the genetic
CC mapping of economic trait loci, or genes involved the determination of
CC economically important traits esp. in cattle, to allow selective
CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX
SQ Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;

Query Match 0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 6e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
|||||:|||||
1 TGTGTGTGTGTGTGTGTGTGT 21

Db 1 TGTGTGTGTGTGTGTGTGTGT 21

RESULT 1574
AAQ34015
ID AAQ34015 standard; DNA; 21 BP.
XX
AC AAQ34015;
XX
XX 25-MAR-2003 (revised)
DT 02-FEB-1993 (first entry)
XX
DE Microsatellite sequence from clone TGLA419.
XX
KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
KW genetic mapping; traits; amplification; ss.
XX
OS Bos taurus.
XX
PN WO9213102-A1.
XX
PD 06-AUG-1992.

AAH46013
ID AAH46013 standard; DNA; 21 BP.
XX
AC AAH46013;
XX
DT 12-SEP-2001 (first entry)
XX
DE Synthetic oligonucleotide 13.
XX
KW Synthetic oligonucleotide; dinucleotide repeat; cytostatic; apoptosis;
KW cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
KW tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
KW lymphoma; ss.
XX
OS Synthetic.
XX
PN WO200144465-A2.
XX
PD 21-JUN-2001.
XX
PF 12-DEC-2000; 2000WO-CA001467.
XX
PR 13-DEC-1999; 98US-0170325P.
XX
PR 29-AUG-2000; 2000US-0228925P.
XX
PA (BION-) BIONICHE LIFE SCI INC.
XX
PI Phillips NC, Filion MC;
XX
DR WPI; 2001-398150/42.
XX
PT Composition comprising synthetic oligonucleotides which comprise multiple
PT repeats of dinucleotides such as GT, TG useful for treating cancer by
PT inducing cell cycle arrest, inhibiting proliferation, activating
PT caspases.
XX
PS Example 4; Page 17; 77pp; English.
XX
CC The present sequence is that of a synthetic oligonucleotide useful to the
CC invention. The invention relates to a composition, comprising a 2 to 20
CC base 3'-OH, 5'-OH synthetic oligonucleotide which comprises multiple
CC repeats of dinucleotides such as GT, TG, etc., according to specific
CC formula and having cytostatic activity. The oligonucleotide compositions
CC are useful for inducing cell cycle arrest, inhibition of proliferation,
CC activation of caspases and induction of apoptosis or production of
CC cytokines such as interleukin (IL)-1-beta, IL-6, IL-10, IL-12 and tumour
CC necrosis factor (TNF)-alpha by immune system cells, in an animal having
CC cancer such as primary carcinoma, secondary carcinoma, primary sarcoma
CC and secondary sarcoma such as, leukemia, lymphoma, breast, prostate,
CC colorectal, ovarian or bone cancer. The compositions induce apoptosis
CC independent of Fas, p53/p21, p21/waf-1/CIP, pl5(ink4B), pl6(ink4), drug
CC resistance, caspase 3, transforming growth factor (TGF)-beta 1 receptor
CC and hormone dependence
XX
SQ Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;
Query Match 0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 6e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2729 TGTGTCGTGTCGTATGTCGT 2749
DB 1 TGTGTCGTGTCGTGTCGT 21
RESULT 1590
AAH46014
ID AAH46014 standard; DNA; 21 BP.
XX
AC AAH46014;
XX
DT 12-SEP-2001 (first entry)
XX


```

XX PD 11-JUL-2002.
XX PF 14-DEC-2001; 2001WO-US048458.
XX PR 14-DEC-2000; 2000US-0255534P.
XX PA (COLE-) COLEY PHARM GROUP INC.
XX PI Bratzler RL;
XX PR WPI; 2002-566690/60.
XX PS
XX PT Inhibiting angiogenesis in a subject, involves administering at least one
XX PT antiangiogenic nucleic acid molecule to the subject.
XX PS Claim 2; Page 35; 276pp; English.
XX CC The invention relates to inhibiting angiogenesis in a subject, comprising
XX CC administering at least one antiangiogenic nucleic acid molecule. Also
XX CC included is a kit comprising a first container housing the antiangiogenic
XX CC nucleic acids, and instructions for administering them to a subject
XX CC having a condition characterised by unwanted angiogenesis. The method is
XX CC useful for inhibiting angiogenesis associated with solid tumour growth,
XX CC tumour metastasis, precancerous lesion, rheumatoid arthritis, psoriasis,
XX CC diabetic retinopathy, retinopathy of prematurity, macular degeneration,
XX CC corneal graft rejection, neovascular glaucoma, retrolental fibroplasia,
XX CC rubeosis, Osler-Weber Syndrome, myocardial angiogenesis, plaque
XX CC neovascularisation, telangiectasia, haemophilic joints, angiofibroma,
XX CC wound granulation, intestinal adhesions, atherosclerosis, scleroderma and
XX CC hypertrophic scars. The present sequence is an antiangiogenic nucleic
XX CC acid of the invention
XX SQ
XX
XX SQ Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 19.4; DB 1; Length 21;
XX Best Local Similarity 95.2%; Pred. No. 6e+02;
XX Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
XX DB 1 TGTGTGTGTGTGTGTGTGTGT 21
XX
XX RESULT 1584
XX ADH47846/c
XX ID ADH47846 standard; DNA; 21 BP.
XX AC ADH47846;
XX
XX DT 25-MAR-2004 (first entry)
XX
XX DE NOV14 probe, SEQ ID 259.
XX
XX Antidiabetic; anorectic; cardiac; hypotensive; antiarteriosclerotic;
XX anorectic; virucide; antibacterial; fungicide; protozoacide; nootropic;
XX neuroprotective; antiparkinsonian; anticonvulsant; osteopathic;
XX antiarthritic; antiinflammatory; dermatological; antiasthmatic;
XX antilipaeamic; Gene therapy; human; metabolic disorder; diabetes; obesity;
XX viral infection; bacterial infection; fungal infection;
XX helminthic infection; protozoal infection; anorexia; cancer;
XX cardiovascular disease; neurodegenerative disorder; Alzheimer's disease;
XX Parkinson's disease; epilepsy; immune disorder; haematopoietic disorder;
XX inflammatory skin disorder; asthma; dyslipidaemia; NOV14; probe; ss.
XX
XX OS Homo sapiens.
XX
XX PN W0200268647-A2.
XX
XX PD 06-SEP-2002.
XX
XX PF 16-JAN-2002; 2002WO-US001311.
XX

```

```

PR 16-JAN-2001; 2001US-0261376P.
PR 18-JAN-2001; 2001US-0262454P.
PR 18-JAN-2001; 2001US-0262587P.
PR 31-JAN-2001; 2001US-0265530P.
PR 31-JAN-2001; 2001US-0268595P.
PR 28-FEB-2001; 2001US-0272409P.
PR 16-FEB-2001; 2001US-0276777P.
PR 17-MAY-2001; 2001US-0291672P.
PR 27-SEP-2001; 2001US-0325306P.
PR 18-OCT-2001; 2001US-0330336P.
PR 09-NOV-2001; 2001US-0345202P.
XX
XX (CURA-) CURAGEN CORP.
XX
XX Padigaru M, Alsobrook JP, Colman SD, Spytek KA, Boldog F;
XX Vernet CAM, Li L, Shenoy S, Casman S, Guo X, Edinger S;
XX Macdougall J, Malyankar U, Patturajan M, Shinketa RA, Pena C;
XX Tchernev V, Zernusen BD, Millett I, Miller C, Iepley DM, Smithson G;
XX Baumgartner J, Herrmann J, Peyman JA, Gorman L, Mezes P, Kekuda R;
XX Taupier RJ, Gerlach V, Grosse WM, Liu X, Ellerman K, Rothenberg M;
XX Stone DJ, Burgess CE;
XX WPI; 2002-698671/75.
XX
XX New isolated NOVX polypeptides and polynucleotides, useful for
XX preventing, diagnosing or treating NOVX-associated disorders e.g.
XX osteoarthritis, obesity, atherosclerosis, cancer, Parkinson's disease,
XX asthma, or infections.
XX
XX Example 3; Page 346; 380pp; English.
XX
XX The present invention relates to novel proteins (I) referred to as NOVX,
XX where X is any number from 1 to 18, and their coding sequences (II). The
XX proteins and their coding sequences are useful in the manufacture of a
XX medicament for treating a syndrome associated with a human disease,
XX preferably a NOVX-associated disorder such as metabolic disorders,
XX diabetes, obesity, infectious diseases (viral, bacterial, fungal,
XX helminthic, and protozoal), anorexia, cancer, cardiovascular diseases
XX (hypertension, atherosclerosis), neurodegenerative disorders, Alzheimer's
XX disease, Parkinson's disease, epilepsy, immune disorders
XX (osteoarthritis), haematopoietic disorders, inflammatory skin disorders,
XX asthma, and various dyslipidaemias. The present sequence is a probe for a
XX NOVX sequence. This sequence has a TET modification at the 5' end and a
XX TAMRA modification at the 3' end.
XX
XX SQ Sequence 21 BP; 3 A; 11 C; 3 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 19.4; DB 1; Length 21;
XX Best Local Similarity 95.2%; Pred. No. 6e+02;
XX Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 2774 AGGCTGGAGTGCAGTGTGCA 2794
XX DB 21 AGGCTGGAGGCGAGTGTGCA 1
XX
XX RESULT 1585
XX ACR64055/c
XX ID ACR64055 standard; DNA; 21 BP.
XX
XX AC ACR64055;
XX
XX DT 13-OCT-2003 (first entry)
XX
XX DE IFNARI forward PCR primer #31.
XX
XX Human; detection; computer-readable storage medium; polymorphic site;
XX signal carrying data; data processing system; multiple sclerosis;
XX PCR primer; ss.
XX
XX OS Homo sapiens.
XX
XX Synthetic.
XX

```


PN WO2003014319-A2.
 XX
 PD 20-FEB-2003.
 XX
 PF 07-AUG-2002; 2002WO-US025268.
 PR 07-AUG-2001; 2001US-0310741P.
 PR 24-SEP-2001; 2001US-0324790P.
 XX
 PA (DNAS-) DNA SCI INC.
 XX
 PI Jones HB, Xu H, White R, Rienhoff HY, Jin W, Natsoulis G;
 XX
 DR WPI; 2003-268196/26.
 XX
 PT New polynucleotide, useful for detecting loci associated with multiple
 PT sclerosis.
 XX
 PS Disclosure; Page 10; 93pp; English.
 XX
 CC The present invention describes an isolated polynucleotide (PN)
 CC comprising: (a) a sequence comprising at least 15 contiguous nucleotides
 CC of a sequence comprising variant sequences (A) from Table 4 given in the
 CC specification; or (b) a sequence that is complementary to (A). Also
 CC described: (1) an array of (PN)s comprising two or more of the isolated
 CC (PN)s; (2) detecting a (PN) in an individual; (3) a computer-readable
 CC storage medium, where each record has a field identifying a base
 CC occupying a (PN) site and a location of the polymorphic site; and (4) a
 CC signal carrying data for access by an application program having executed
 CC on a data processing system. The (PN) can be used for detecting loci
 CC associated with multiple sclerosis. ACF64025 to ACF64424 represent
 CC sequences used in the exemplification of the present invention
 XX
 SQ Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 6e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2776 GCTGGAGTGCAGTGGTGCAT 2796
 Db 21 GCTAGAGTGCAGTGGTGCAT 1
 RESULT 1586
 ACH03241
 ID ACH03241 standard; DNA; 21 BP.
 XX
 AC ACH03241;
 XX
 DT 25-SEP-2003 (first entry)
 XX
 DE Immunostimulatory nucleic acid #876.
 XX
 KW Immunostimulatory; antiinflammatory; dermatological; antipsoriatic;
 KW antiulcer; gene therapy; vaccine; non-allergic inflammatory disease;
 KW psoriasis; eczema; allergic contact dermatitis; latex dermatitis;
 KW inflammatory bowel disease; ulcerative colitis; Crohn's disease; ss.
 XX
 OS Synthetic.
 XX
 XX US2003050268-A1.
 PN
 PD 13-MAR-2003.
 XX
 PF 29-MAR-2002; 2002US-00112653.
 XX
 PR 29-MAR-2001; 2001US-0279642P.
 XX
 PA (KRIE/) KRIEG A M.
 PA (BERG/) BERG D J.
 XX
 PI Krieg AM, Berg DJ;

XX WPI; 2003-521815/49.
 XX
 PT Treating non-allergic inflammatory diseases, such as psoriasis, eczema,
 PT allergic contact dermatitis, latex dermatitis or inflammatory bowel
 PT disease by administering an immunostimulatory nucleic acid.
 XX
 PS Disclosure; Page 32; 229pp; English.
 XX
 CC The invention describes a method of treating non-allergic inflammatory
 CC disease comprising administering to a subject having or at risk of
 CC developing a non-allergic inflammatory disease an immunostimulatory
 CC nucleic acid for prevention or treatment of the disease. The method is
 CC useful for treating non-allergic inflammatory diseases, such as
 CC psoriasis, eczema, allergic contact dermatitis, latex dermatitis or
 CC inflammatory bowel disease e.g., ulcerative colitis or Crohn's disease.
 CC This sequence represents an immunostimulatory nucleic acid
 XX
 SQ Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 6e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
 Db 1 TGTGTGTGTGTGTGTGTGTGT 21
 RESULT 1587
 ADB37204
 ID ADB37204 standard; DNA; 21 BP.
 XX
 AC ADB37204;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Immunostimulatory nucleic acid #818.
 XX
 KW ds; allergy; asthma; poly-G nucleic acid; aerosol formulation;
 KW hypo-responsive subject; immunostimulatory.
 XX
 OS Synthetic.
 XX
 XX US2003087848-A1.
 PN
 PD 08-MAY-2003.
 XX
 PF 02-FEB-2001; 2001US-00776479.
 XX
 PR 03-FEB-2000; 2000US-0179991P.
 XX
 PA (BRAT/) BRATZLER R L.
 PA (PETE/) PETERSEN D M.
 PA (FOUR/) FOURON Y.
 XX
 PI Bratzler RL, Petersen DM, Fouron Y;
 XX
 DR WPI; 2003-657977/62.
 XX
 PT Treating and/or preventing allergy or asthma using an immunostimulatory
 PT nucleic acid alone or in combination with an asthma/allergy medicament.
 XX
 PS Disclosure; Page 17; 221pp; English.
 XX
 CC The invention relates to a method of treating or preventing allergy or
 CC asthma which comprises administering to a subject a poly-G nucleic acid
 CC in an aerosol formulation. The methods and compositions of the present
 CC invention are useful for diagnosing and/or treating asthma and allergy
 CC especially in a hypo-responsive subject. The present sequence represents
 CC an immunostimulatory nucleic acid of the invention.
 XX
 SQ Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;

Query Match 0.6%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 6e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
 |||||
 Db 1 TGTGTGTGTGTGTGTGTGT 21

RESULT 1588
 ADH59619
 ID ADH59619 standard; DNA; 21 BP.
 XX AC
 XX ADH59619;
 XX 25-MAR-2004 (first entry)
 XX Non-nucleotide probe of the invention #23.
 XX non-nucleotide probe; Bacterial Artificial Chromosome clone; BAC; ss;
 KW probe.
 XX Synthetic.
 XX WO2003027328-A2.
 XX 03-APR-2003.
 XX 24-SEP-2002; 2002WO-US030573.
 XX 24-SEP-2001; 2001US-0324499P.
 XX (BOST-) BOSTON PROBES INC
 PA (DAKO-) DAKOCYTOMATION DENMARK AS.
 XX Kirtsen NV, Hyldig-Nielsen JJ, Williams BF;
 XX WPI; 2003-421160/39.
 XX Non-nucleotide probe for suppressing binding of detectable nucleic acid
 PT probes to undesired sequences, has aggregate nucleobase sequence
 PT homologous to randomly distributed repeat sequence of genomic nucleic
 PT acid.
 XX Claim 10; SEQ ID NO 25; 103pp; English.

The present sequence represents a non-nucleotide probe. The probe is
 CC useful for suppressing the binding of one or more detectable nucleic acid
 CC probes, that are greater than 100 base pairs and that have been derived
 CC from genomic nucleic acid, to one or more undesired sequences in an assay
 CC for determining target genomic nucleic acid of a sample. The method
 CC comprises contacting the sample with the mixture of probes (preferably
 CC comprising 5-50 probes), contacting the sample with the one or more
 CC detectable nucleic acid probes, and determining the target genomic
 CC nucleic acid of the sample by determining the hybridization of the one
 CC more detectable nucleic acid probes to the target genomic nucleic acid of
 CC the sample. The genomic nucleic acid is contained in a fixed tissue or a
 CC cell, and the sample is metaphase spreads, interphase nucleic or nucleic
 CC found in paraffin embedded tissue material or frozen tissue sections. The
 CC probe is also useful in comparing a sample of genomic nucleic acid with
 CC that of a control sample using a genomic nucleic acid reference array.
 CC The method comprises treating a sample of genomic nucleic acid and
 CC control genomic nucleic acid, which are differentially labelled, the
 CC array or both the sample and control genomic nucleic acid and the array
 CC with the mixture of the probe under suitable hybridization conditions,
 CC contacting the array with treated mixture of sample and control genomic
 CC nucleic acid under suitable hybridization conditions, and comparing the
 CC intensities of the signals from the differential labels of the array to
 CC that caused by hybridization of the probes to genomic nucleic acid, thus
 CC determining one or more variations in copy numbers of sequences in the
 CC sample as compared with the relative copy numbers of substantially
 CC identical sequences in the control. The hybridization of the genomic

array is determined using an intercalating dye or a detectable antibody,
 CC or its fragment, that is specific for a nucleic acid/nucleic acid hybrid.
 CC The sample of genomic nucleic acid to be tested and the reference of
 CC nucleic acid are labelled with detectable moiety such that hybridization
 CC of the genomic array is determined by determining the presence, absence,
 CC amount or location of the detectable label on the one or more genomic
 CC arrays. The genomic array comprises nucleic acid that is prepared from
 CC Bacterial Artificial Chromosome (BAC) clones. The present sequence
 CC represents a non-nucleotide probe of the invention.

XX Sequence 21 BP; 3 A; 6 C; 8 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 6e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2766 TGTACCCAGGCTGGAGTGCA 2786
 |||||
 Db 1 TGTGCCCCAGGCTGGAGTGCA 21

RESULT 1589
 ADP68377/C
 ID ADP68377 standard; DNA; 21 BP.
 XX AC
 XX ADP68377;
 XX 12-AUG-2004 (first entry)
 XX DNA probe used to detect human NOV14 DNA (Ag210) SeqID 261.
 XX human; probe; ss; NOVX; Alzheimer's disease; Huntington's; inflammatory;
 KW Crohn's disease; rheumatoid arthritis; immunological; endocrine;
 KW pigmentation; haematopoietic; psychotic; autoimmune; muscular;
 KW osteoporosis; angina pectoris; hypotension; anxiety; alopecia; bulimia;
 KW cancer; manic depression; viricide; antibacterial; analgesic;
 KW neuroprotective; nootropic; cerebroprotective; anticonvulsant;
 KW dermatological; osteopathic; antiarthritic; antiinflammatory; cytostatic;
 KW hypotensive; cardiant; hypertensive; antitumor; antiallergic;
 KW antianginal; immunosuppressive; antidepressant; neurodegenerative.
 XX Homo sapiens.
 OS
 XX WO200281510-A2.
 XX 17-OCT-2002.
 XX 18-JAN-2002; 2002WO-US001467.
 XX 18-JAN-2001; 2001US-0262454P.
 XX 23-JAN-2001; 2001US-0263605P.
 XX 25-JAN-2001; 2001US-0264159P.
 XX 31-JAN-2001; 2001US-0265517P.
 XX 07-FEB-2001; 2001US-0267057P.
 XX 15-FEB-2001; 2001US-0269098P.
 XX 27-FEB-2001; 2001US-0271855P.
 XX 02-MAR-2001; 2001US-0272920P.
 XX 18-APR-2001; 2001US-0284549P.
 XX 20-APR-2001; 2001US-0285040P.
 XX 24-APR-2001; 2001US-0286287P.
 XX 05-JUL-2001; 2001US-0303229P.
 XX (CURA-) CURAGEN CORP.
 XX Anderson D, Burgess CE, Casman SJ, Colman S, Edinger S;
 XX Ellerman K, Gerlach V, Gunther E, Kekuda R, Macdougall JR;
 PI Mehrahan F, Patturajan M, Rothenberg M, Shimkets RA, Smithson G;
 PI Spytek KA, Stone DJ, Vernet CAM, Zerhusen BD;
 XX WPI; 2003-058497/05.
 XX New NOVX polypeptides useful for treating cancers, blood disorders,
 PT asthma, psoriasis, vascular disorders, hypertension, viral, bacterial or

PT parasitic infections, allergy, renal disorders and skin disorders.
 XX
 PS Example 3; SEQ ID NO 261; 415pp; English.

XX
 CC This invention relates to novel nucleic acid molecules encoding NOVX
 CC polypeptides selected from NOV1 to NOV11 inclusive, as well as variants
 CC thereof. Specifically, it refers to vectors, host cells, antibodies,
 CC agonists, antagonists and recombinant methods for producing proteins,
 CC including GPCRs, secretory proteins and dual specificity phosphatases.
 CC The present invention describes these proteins as useful for the
 CC development of compositions that can be used to treat neurodegenerative
 CC diseases such as Alzheimer's and Huntington's, inflammatory conditions
 CC including Crohn's disease and rheumatoid arthritis, as well as
 CC immunological, endocrine, pigmentation, haematopoietic, psychotic,
 CC autoimmune and muscular disorders. Accordingly, it refers to various
 CC conditions including osteoporosis, angina pectoris, hypotension, anxiety,
 CC alopecia, bulimia, cancer and manic depression. As such, they exhibit
 CC various activities including vulnery, virucide, antibacterial,
 CC analgesic, neuroprotective, nootropic, cerebroprotective, anticonvulsant,
 CC dermatological, osteopathic, antiarthritic, antiinflammatory, cytostatic,
 CC hypotensive, cardiant, hypertensive, antiulcer, antiallergic,
 CC antianigmal, immunosuppressive and antidepressant. This oligonucleotide
 CC is a 5' TET/ 3' TAMRA labelled DNA probe used to detect human NOVX DNA in
 CC an exemplification of the invention.

XX
 SQ Sequence 21 BP; 3 A; 11 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 6e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 AGGCTGGAGTGCAGTGTGCA 2794

DB 21 AGGCTGGAGGCGAGTGTGCA 1

RESULT 1590
 ADL25728/c

ID ADL25728 standard; DNA; 21 BP.

XX ADL25728;

XX 20-MAY-2004 (first entry)

XX Human NOVX gene, probe #29.

DE ss; probe; Cytostatic; Neuroprotective; Immunosuppressive; Gene therapy;
 KW Vaccine; human; neurodegenerative disorder; autoimmune disorder; cancer.

XX Homo sapiens.

XX US2004005557-A1.

XX 08-JAN-2004.

XX 16-JAN-2002; 2002US-00051874.

XX 16-JAN-2001; 2001US-0261376P.

PR 18-JAN-2001; 2001US-0262454P.

PR 18-JAN-2001; 2001US-0262587P.

PR 31-JAN-2001; 2001US-0265530P.

PR 14-FEB-2001; 2001US-0268595P.

PR 28-FEB-2001; 2001US-0272409P.

PR 16-MAR-2001; 2001US-0276777P.

PR 17-MAY-2001; 2001US-0291672P.

PR 27-SEP-2001; 2001US-0325306P.

PR 18-OCT-2001; 2001US-0330336P.

PR 09-NOV-2001; 2001US-0345202P.

XX (PADI/) PADIGARU M.

PA (ALSO/) ALSOBROOK J P.

PA (COLM/) COLMAN S D.

PA (SPYT/) SPYTEK K A.

PA (BOLD/) BOLDOG F L.
 PA (VERN/) VERNET C A M.
 PA (LILL/) LI L.
 PA (SHEN/) SHENOY S G.
 PA (CASH/) CASMAN S J.
 PA (GUOX/) GUO X.
 PA (EDIN/) EDINGER S R.
 PA (MACD/) MACDOUGALL J R.
 PA (MALY/) MALLYANKAR U M.
 PA (PATT/) PATTURAJAN M.
 PA (SHIM/) SHIMKETS R A.
 PA (PENA/) PENA C E A.
 PA (TCH/) TCHERNEV V T.
 PA (ZERR/) ZERRHUSEN B D.
 PA (MILL/) MILLET I.
 PA (MILL/) MILLER C E.
 PA (LEPL/) LEPLEY D M.
 PA (SMIT/) SMITHSON G.
 PA (BAUM/) BAUMGARTNER J C.
 PA (HERR/) HERRMANN J L.
 PA (PEYM/) PEYMAN J A.
 PA (GORM/) GORMAN L.
 PA (MEZE/) MEZES P D.
 PA (KEKU/) KEKUDA R.
 PA (TAUP/) TAUPIER R J.
 PA (GERL/) GERLACH V.
 PA (GROS/) GROSSE W M.
 PA (LIUX/) LIU X.
 PA (ELLE/) ELLERMAN K.
 PA (ROTH/) ROTHENBERG M.
 PA (STON/) STONE D J.
 PA (BURG/) BURGESS C E.

XX
 PI Padigaru M, Alsobrook JP, Colman SD, Spytek KA, Boldog FL;
 PI Vernet CAM, Li L, Shenoy SG, Casman SJ, Guo X, Edinger SR;
 PI Macdougall JR, Malyankar UM, Patturajan M, Shimkets RA, Pena CE;
 PI Tchernev VT, Zerrhusen BD, Millet I, Miller CE, Lepley DM;
 PI Smithson G, Baumgartner JC, Herrmann JL, Peyman JA, Gorman L;
 PI Mezes PD, Kekuda R, Taupier RJ, Gerlach V, Grosse WM, Liu X;
 PI Ellerman K, Rothenberg M, Stone DJ, Burgess CE;
 XX WPI; 2004-081706/08.

XX New NOVX polypeptide, useful for preparing a composition for treating or
 PT preventing a NOVX-associated disorder, e.g., neurodegenerative or
 PT autoimmune disorders or cancer.

XX Example 3; Page 263; 282pp; English.

XX The invention relates to novel human NOVX nucleic acids and polypeptides.
 CC The polypeptide, nucleic acid or antibody is useful for preparing a
 CC composition for treating or preventing a NOVX-associated disorder, e.g.,
 CC neurodegenerative or autoimmune disorders or cancer. The present sequence
 CC represents a probe used to isolate human NOVX genes of the invention.

XX Sequence 21 BP; 3 A; 11 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 19.4; DB 1; Length 21;
 Best Local Similarity 95.2%; Pred. No. 6e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 AGGCTGGAGTGCAGTGTGCA 2794

DB 21 AGGCTGGAGGCGAGTGTGCA 1

RESULT 1591

AAQ33675

ID AAQ33675 standard; DNA; 22 BP.

XX AAQ33675;

XX 25-MAR-2003 (revised)

XX WPI; 1992-284684/34.
 XX Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.
 XX Table 7; Page 363; 517pp; English.
 XX The sequence is that of a bovine microsatellite sequence obtd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
 CC in the bovine genome is estimated at >100,000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved in the determination of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX Sequence 22 BP; 0 A; 0 C; 11 G; 11 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 19.4; DB 1; Length 22;
 Best Local Similarity 95.2%; Pred. No. 5.7e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
 DB 1 TGTGTGTGTGTGTGTGTGTGT 21
 RESULT 1594
 AAQ33991
 ID AAQ33991 standard; DNA; 22 BP.
 XX AAQ33991;
 XX 25-MAR-2003 (revised)
 DT 02-FEB-1993 (first entry)
 XX Microsatellite sequence from clone TGLA39.
 XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.
 XX Bos taurus.
 OS WO9213102-A1.
 PN 06-AUG-1992.
 PD 15-JAN-1992; 92WO-US000340.
 PF 15-JAN-1991; 91US-00642342.
 PR (GENM-) GENMARK.
 PA Georges M, Massey JM;
 PI WPI; 1992-284684/34.
 DR Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.
 XX Table 7; Page 327; 517pp; English.
 XX The sequence is that of a bovine microsatellite sequence obtd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500

CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
 CC in the bovine genome is estimated at >100,000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved in the determination of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX Sequence 22 BP; 0 A; 0 C; 11 G; 11 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 19.4; DB 1; Length 22;
 Best Local Similarity 95.2%; Pred. No. 5.7e+02;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
 DB 1 TGTGTGTGTGTGTGTGTGTGT 21
 RESULT 1595
 AA164448
 ID AA164448 standard; DNA; 22 BP.
 XX AA164448;
 XX 23-NOV-2001 (first entry)
 DT SSR motif #8.
 DE Simple Sequence Repeat; SSR; clover; microsatellite; genome mapping;
 KW trait mapping; marker-assisted selection; gene selection; legume;
 KW DNA profiling; breeding; ds.
 XX Unidentified.
 OS NZ509194-A.
 PN 25-MAY-2001.
 PD 03-JAN-2001; 2001NZ-00509194.
 PF 24-DEC-1999; 99AU-00004907.
 PR 28-MAR-2000; 2000AU-00006520.
 XX (AGRI-) AGRIC VICTORIA SERVICES PTY LTD.
 PA Koelliker R, Forster JW;
 XX WPI; 2001-431058/46.
 DR Novel simple sequence repeats in clover species useful for selection of
 PT genes in legume breeding, for profiling legume species varieties and for
 PT testing the purity of legume seed batches.
 XX Claim 6; Page 35; 52pp; English.
 PS The present invention relates to Simple Sequence Repeats (SSRs) from
 CC clover species. SSRs, also called microsatellites, are based on a 1-7
 CC nucleotide core element which is tandemly repeated. The SSR array is
 CC embedded in complex flanking DNA. SSRs are ideal markers for genome
 CC mapping, trait mapping and marker-assisted selection. The SSRs may be
 CC used in methods for selecting genes in clover/ legume breeding. The SSRs
 CC are also useful for DNA profiling of clover varieties and for testing the
 CC purity of legume seed batches. The present sequence is a SSR motif, which
 CC was used in the present invention
 XX

SQ Sequence 22 BP; 0 A; 0 C; 11 G; 11 T; 0 U; 0 Other;

Query Match 0.6%; Score 19.4; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 5.7e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
DB 1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 21

RESULT 1596

AD081143/c
ID AD081143 standard; DNA; 22 BP.

XX AC AD081143;

DT 29-JUL-2004 (first entry)

XX Prion protein polymorphic microsatellite marker consensus sequence #21.

XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; ds.

XX Synthetic.

XX DB10236711-Al.

XX 26-FEB-2004.

XX 09-AUG-2002; 2002DE-01036711.

XX 09-AUG-2002; 2002DE-01036711.

XX (UYHO-) UNIV HOHENHEIM.

XX Geldermann H, Preuss S, Han Y;

XX WPI; 2004-215730/21.

XX Typing genes that contain polymorphic microsatellite loci, useful for
PT identifying predisposition to disease, by amplification and determining
PT length of amplicons.

XX Claim 9; Page 50; 64pp; German.

XX The invention describes a method of typing (M1) a gene (I) that has one
CC or more polymorphic microsatellite loci (PML). The method comprises: PCR
CC amplification of at least one DNA region of (I) that includes PML, using
CC as template a DNA sample containing at least one segment of (I); and
CC determining the length of the resulting amplicon(s). Also described are:
CC a method of determining (M2) microsatellite markers (MM) for
CC predisposition to a disease, associated with a gene that includes one or
CC more PML; and prediagnosis (M3) of diseases associated with gene that
CC include PML. The method is used to identify microsatellite markers, in a
CC disease-related gene, that are associated with a predisposition to
CC diseases and for prediagnosis of such diseases, especially prion diseases
CC but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
CC metabolic diseases; also to type genes that encode milk proteins,
CC hormones or transcription factors. The method is simpler, quicker and
CC particularly less expensive than known methods based on sequencing. This
CC sequence represents a prion protein polymorphic microsatellite marker
CC consensus sequence.

XX Sequence 22 BP; 11 A; 11 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 19.4; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 5.7e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
DB 22 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2

RESULT 1597

AD081098/c

ID AD081098 standard; DNA; 22 BP.

XX AC AD081098;

XX 29-JUL-2004 (first entry)

XX Sheep prion protein microsatellite locus primer #69.

XX gene typing; polymorphic microsatellite loci; PML;
KW disease predisposition; microsatellite marker; prion disease;
KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
KW microsatellite; PCR; primer; ss.

XX Ovis aries.

XX DE10236711-Al.

XX 26-FEB-2004.

XX 09-AUG-2002; 2002DE-01036711.

XX 09-AUG-2002; 2002DE-01036711.

XX (UYHO-) UNIV HOHENHEIM.

XX Geldermann H, Preuss S, Han Y;

XX WPI; 2004-215730/21.

XX Typing genes that contain polymorphic microsatellite loci, useful for
PT identifying predisposition to disease, by amplification and determining
PT length of amplicons.

XX Example 3; Page 30; 64pp; German.

XX The invention describes a method of typing (M1) a gene (I) that has one
CC or more polymorphic microsatellite loci (PML). The method comprises: PCR
CC amplification of at least one DNA region of (I) that includes PML, using
CC as template a DNA sample containing at least one segment of (I); and
CC determining the length of the resulting amplicon(s). Also described are:
CC a method of determining (M2) microsatellite markers (MM) for
CC predisposition to a disease, associated with a gene that includes one or
CC more PML; and prediagnosis (M3) of diseases associated with gene that
CC include PML. The method is used to identify microsatellite markers, in a
CC disease-related gene, that are associated with a predisposition to
CC diseases and for prediagnosis of such diseases, especially prion diseases
CC but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
CC metabolic diseases; also to type genes that encode milk proteins,
CC hormones or transcription factors. The method is simpler, quicker and
CC particularly less expensive than known methods based on sequencing. This
CC sequence represents a primer used to genotype a region of the sheep prion
CC protein (PrP) comprising a polymorphic microsatellite locus.

XX Sequence 22 BP; 11 A; 11 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 19.4; DB 1; Length 22;
Best Local Similarity 95.2%; Pred. No. 5.7e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
DB 22 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2

RESULT 1598

AAH39074/C	
ID	AAH39074 standard; DNA; 24 BP.
XX	
AC	AAH39074;
XX	
DT	14-AUG-2001 (first entry)
XX	
XX	SNP specific lower PCR primer SEQ ID 1870.
XX	
XX	single nucleotide polymorphism; SNP; single nucleotide primer extension;
KW	SNPE; genotyping; agammaglobulinemia; diabetes insipidus; cancer;
KW	Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
KW	polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
KW	acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
KW	inflammation; forensic investigation; paternity analysis; PCR primer; ss.
XX	
OS	Homo sapiens.
DE	
PN	WO200129262-A2.
XX	
PD	26-APR-2001.
XX	
PF	13-OCT-2000; 2000WO-US028436.
XX	
PR	15-OCT-1999; 99US-0160096P.
XX	
PA	(ORCH-) ORCHID BIOSCIENCES INC.
PI	Picoult-Newburg L, Pohl M;
XX	
XX	WPI; 2001-290930/30.
XX	
PT	New genotyping oligonucleotide, useful for detecting the presence,
PT	absence or identity of single polynucleotide polymorphism in a nucleic
PT	acid sample.
XX	
PS	Claim 1; Page 59; 83pp; English.
XX	
CC	Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
CC	primer extension (SNPE) primers, and the sequences of regions flanking
CC	sites of single nucleotide polymorphisms SNPs. The present invention
CC	includes kits for determining the presence or absence of a SNP, using the
CC	oligonucleotides of the invention. The PCR primers are used to amplify a
CC	SNP flanking sequence, the SNPE primer is used as a genotyping primer.
CC	The oligonucleotides are useful for genotyping a nucleic acid sample by
CC	performing a single-nucleotide primer extension reaction. The
CC	oligonucleotides are useful for determining the presence, absence or
CC	identity of a SNP and for genotyping nucleic acid samples, for e.g. to
CC	assess by association analysis the genotype of an individual or group of
CC	individuals, having a pathological phenotypic trait suspected of being
CC	caused by one or more SNPs. Phenotypic traits include diseases e.g.
CC	agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC	dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
CC	osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
CC	traits also include symptoms of or susceptibility to multifactorial
CC	disease of which a component is or may be genetic such as autoimmune
CC	diseases, including, rheumatoid arthritis, multiple sclerosis,
CC	inflammation, cancer, nervous system diseases and infection by pathogenic
CC	microorganism. The method is also useful in forensic investigations and
CC	paternity analysis. The present sequence represents a PCR primer specific
CC	for a human SNP containing DNA sequence
XX	
SQ	Sequence 24 BP; 12 A; 11 C; 0 G; 1 T; 0 U; 0 Other;
	Query Match 0.6%; Score 19.4; DB 1; Length 24;
	Best Local Similarity 95.2%; Pred. No. 5.3e+02;
	Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0
QY	2729 TGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
DB	21 TGTGTGTGTGTGTGTGTGTGTGTGTGT 1

DE Human mPer3-10.01 PCR primer 1 SEQ ID NO:3.

XX Human, mPer3-10.01; vegetative nervous dysfunction; psychic disease;
KW endocrinopathy; growth development disturbance disease; tumour;
KW PCR primer; ss.

XX Homo sapiens.

XX CN1345805-A.

XX 24-APR-2002.

XX 26-SEP-2000; 2000CN-00125425.

XX 26-SEP-2000; 2000CN-00125425.

XX (SHAN-) SHANGHAI BLOWINDOW GENE DEV INC.

XX Mao Y, Xie Y;

XX WPI; 2002-539321/58.

XX Novel polypeptide-human mPer 3-10.01 and polynucleotide for encoding the
PT polypeptide.

XX Example 2; Page 17 (Disclosure); 33pp; Chinese.

XX The present invention describes human mPer3-10.01 (I). Also described is
CC a method for producing (I) using DNA recombination technology. (I) can be
CC used in the treatment of several diseases, such as vegetative nervous
CC dysfunction, psychic disease, endocrinopathy, growth development
CC disturbance disease and tumours. The present sequence represents a PCR
CC primer for (I), which is used in an example from the present invention

XX Sequence 24 BP; 4 A; 8 C; 6 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 19.2; DB 1; Length 24;

Best Local Similarity 87.5%; Pred. No. 5.5e+02;

Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCTGTCACCCAGGCTGGA 2781

DB 1 TCTCACTCTGTCTGCCAAGGCTGGA 24

RESULT 1606

AAI66326

ID AAI66326 standard; DNA; 24 BP.

AC AAI66326;

XX 23-JAN-2002 (first entry)

DE Human thyroglobuline 9 coding sequence PCR primer #2.

XX Human; thyroglobuline 9; thyroïdal disease; cancer; haemopathy;

KW development disorder; HIV infection; immunological disease; inflammation;

KW gene therapy; PCR primer; ss.

XX Homo sapiens.

XX WO200175025-A2.

XX 11-OCT-2001.

XX 19-MAR-2001; 2001WO-CN000374.

XX 22-MAR-2000; 2000CN-00115018.

XX (BIOW-) BLOWINDOW GENE DEV INC SHANGHAI.

XX Mao Y, Xie Y;

XX

DR WPI; 2002-025847/03.

XX Human thyroglobulin 9 and encoded polynucleotide, used in diagnosis and
PT treatment of malignant tumors, hemopathy, human immunodeficiency virus
PT infection, immunological diseases and inflammation.

XX Example 2; Page 12; 32pp; Chinese.

XX The present invention provides the protein and coding sequences of human
CC thyroglobuline 9. The sequences can be used in the treatment of thyroïdal
CC diseases, cancer, haemopathy, developmental diseases, HIV infection,
CC immunological diseases and inflammation. The present sequence is a PCR
CC primer for the coding sequence of the invention

XX Sequence 24 BP; 5 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 19.2; DB 1; Length 24;

Best Local Similarity 87.5%; Pred. No. 5.5e+02;

Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2752 ACAAGCTCTCGCTCTGTCTGTCACCCAG 2775

DB 1 ACAGGCTCTCACTCTGTCTGTCACCCAG 24

RESULT 1607

ABZ221100/c

ID ABZ221100 standard; DNA; 24 BP.

XX AC ABZ221100;

XX 25-MAR-2003 (first entry)

XX Zinc finger protein 54.67 PCR primer #2.

XX Zinc finger protein 54.67; tumour; inflammation; immunological disease;
KW haemopathy; HIV infection; cytostatic; anti-HIV; PCR; primer; ss.

XX Unidentified.

XX CN1352015-A.

XX 05-JUN-2002.

XX 06-NOV-2000; 2000CN-00127270.

XX 06-NOV-2000; 2000CN-00127270.

XX (BODE-) BODE GENE DEV CO LTD.

XX Mao Y, Xie Y;

XX WPI; 2002-699446/76.

XX New zinc finger protein 54.67 polypeptide for treating malignant tumors,
PT inflammations, immunological diseases, hemopathy and human
PT immunodeficiency virus infection.

XX Example 2; Page 16 (Disclosure); 34pp; Chinese.

XX The present invention relates to zinc finger protein 54.67 (ABB98889).
CC The zinc finger protein can be used for treating various diseases, such
CC as malignant tumors, inflammations, immunological diseases, haemopathy
CC and HIV-infection. The present sequence is a PCR primer, which was used
CC in an example from the invention

XX Sequence 24 BP; 4 A; 7 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 19.2; DB 1; Length 24;

Best Local Similarity 87.5%; Pred. No. 5.5e+02;

Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2849 GCCTCTGAGTAGCTGGGACCATA 2872

XX Mao Y, Xie Y;
 XX WPI; 2002-106613/14.
 XX New histidyl-tRNA synthetase-like protein 13.2 polypeptide for treating
 XX tumor and disease associated with metabolic disturbance of protein.
 XX Disclosure; Page 12; 36pp; Chinese.
 XX The sequence represents a PCR primer used in the invention. The invention
 XX relates to a novel isolated polypeptide of histidyl-tRNA synthetase-like.
 XX The protein has cytosolic activity, and may have a use in gene therapy.
 XX The polypeptide and nucleic acid encoding it are used in treatment of
 XX tumour and disease associated with metabolic disturbance of protein
 XX Sequence 24 BP; 7 A; 9 C; 3 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 5.5e+02;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2750 AGACAGCTCTCGTCTGTACCC 2773
 DB 1 AGACAAAGTCTCACTGTACCC 24

RESULT 1611
 ABQ75907
 ID ABQ75907 standard; DNA; 24 BP.
 XX
 AC ABQ75907;
 XX
 XX
 DT 17-OCT-2002 (first entry)
 XX
 XX Human L1 factor ORF2 relative protein 10.78 related primer 2.
 DE
 XX Human; L1 factor ORF2 relative protein 10.78; protein metabolic disorder;
 KW embryo development malformation; tumour; PCR; primer; ss.
 XX Homo sapiens.
 OS
 XX CN1339478-A.
 XX
 XX 13-MAR-2002.
 XX
 XX 21-AUG-2000; 2000CN-00119675.
 XX
 XX 21-AUG-2000; 2000CN-00119675.
 XX
 XX (BODE-) BODE GENE DEV CO LTD SHANGHAI.
 PA
 XX Mao Y, Xie Y;
 PI
 XX WPI; 2002-464065/50.
 XX
 XX New human L1 factor open reading frame 2 relative protein 10.78 and
 PT encoding polynucleotide, useful for treating embryo development
 PT malformation, tumor and protein metabolic disease.
 XX
 XX Example 3; Page 19 (disclosure); 34pp; Chinese.
 PS
 XX The invention relates to a human L1 factor open reading frame (ORF) 2
 XX relative protein 10.78, encoding polynucleotide, and a DNA recombination
 CC process to produce the polypeptide. The polypeptide is useful in treating
 CC embryo development malformation, tumour and protein metabolic disorder.
 CC The current sequence represents a human L1 factor ORF2 relative protein
 CC 10.78 related PCR primer sequence
 XX
 XX Sequence 24 BP; 6 A; 9 C; 4 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 5.5e+02;

Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2752 ACAAGCTCTCGTCTGTACCCAG 2775
 DB 1 ACAGGATCTCACTGTGTACCCAG 24

RESULT 1612
 ABA01638
 ID ABA01638 standard; DNA; 24 BP.
 XX
 AC ABA01638;
 XX
 DT 05-FEB-2002 (first entry)
 XX
 XX Human tyrosinase 12 PCR primer 2 SEQ ID NO:4.
 DE
 XX Human; tyrosinase 12; cytostatic; virucidal; immunomodulatory;
 KW antiinflammatory; haemostatic; diagnosis; malignancy; haemopathy;
 KW human immunodeficiency virus; HIV infection; immunological disease;
 KW inflammation; tumour; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200175117-A1.
 XX
 XX 11-OCT-2001.
 XX
 XX 19-MAR-2001; 2001WO-CN000353.
 PF
 XX 22-MAR-2000; 2000CN-00115034.
 XX
 XX (BIOW-) BIOWINDOW GENE DEV INC SHANGHAI.
 PA
 XX Mao Y, Xie Y;
 PI
 XX WPI; 2002-025864/03.
 XX
 XX Human tyrosinase 12 and encoded polynucleotide, applicable in diagnosis
 PT and treatment of malignancy, hemopathy, human immunodeficiency virus
 PT infection, immunological diseases and inflammation.
 XX
 XX Example 2; Page 11; 33pp; Chinese.
 PS
 XX The present invention describes human tyrosinase 12 (I). (I) and the
 CC polynucleotide encoding it (II) have cytostatic, virucidal,
 CC immunomodulatory, antiinflammatory and haemostatic activities. (I) and
 CC (II) can be used in the diagnosis and treatment of malignancy, malignant
 CC tumour, haemopathy, human immunodeficiency virus (HIV) infection,
 CC immunological diseases and various inflammations. The present sequence
 CC represents a PCR primer for human tyrosinase 12, which is used in an
 CC example from the present invention
 XX
 XX Sequence 24 BP; 4 A; 8 C; 6 G; 6 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 19.2; DB 1; Length 24;
 Best Local Similarity 87.5%; Pred. No. 5.5e+02;
 Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2752 ACAAGCTCTCGTCTGTACCCAG 2775
 DB 1 ACAGGATCTGTGTGTACCCAG 24

RESULT 1613
 ABZ57678
 ID ABZ57678 standard; DNA; 24 BP.
 XX
 AC ABZ57678;
 XX
 XX 10-APR-2003 (first entry)
 DT
 XX Human zinc finger protein 9.46 RT-PCR primer, SEQ ID NO:3.
 DE

KW ICAM-R; autoimmunity; inflammation; arthritis; glomerulonephritis;
 KW transplant rejection; ss.

XX Synthetic.

XX WO9314776-A1.

XX 05-AUG-1993.

XX 26-JAN-1993; 93WO-US000787.

XX 27-JAN-1992; 92US-00827689.

XX 26-MAY-1992; 92US-00889724.

XX 03-JUN-1992; 92US-00894061.

XX 22-JAN-1993; 93US-00009266.

XX (ICOS-) ICOS CORP.

XX Gallatin WM, Vazeux R;

XX WPI; 1993-258372/32.

XX DNA encoding new human inter-cellular adhesion molecule polypeptide (ICAM-R) - useful for treating immune and inflammatory diseases, tumours and viral infection e.g. HIV.

XX Example 4; Page 19; 126pp; English.

XX ICAM-R polypeptides can be used in the modulation of immune cell activation/proliferation and for the treatment of conditions resulting from responses of the non-specific and specific immune response in a mammal. A clone containing immunoglobulin like domains of ICAM-1 was used to generate the probe for screening of cDNA libraries. (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 19 BP; 5 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 7.3e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCCAATTC 609

DB 19 TCACCATGGAGCCCAATTC 1

RESULT 1616

AAQ97342

ID AAQ97342 standard; cDNA; 19 BP.

XX AAQ97342;

XX 19-JAN-1996 (first entry)

XX Probe used for identifying ICAM-1 G241 allele.

XX Inflammatory bowel disease; IBD; ICAM-1; ulcerative colitis;

XX Crohn's disease; intracellular adhesion molecule; screening;

XX identification; R241; ss.

XX Synthetic.

XX WO9521941-A1.

XX 17-AUG-1995.

XX 06-FEB-1995; 95WO-US001434.

XX 11-FEB-1994; 94US-00196003.

XX (CEDA-) CEDARS SINAI MEDICAL CENT.

XX Beaudet AL, Rotter JT, Targan SR, Yang H, Vora D;

XX

XX WPI; 1995-293137/38.

XX Screening for inflammatory bowel disease, prof. ulcerative colitis - by assaying a subject's nucleic acid for the presence of the R241 allele of the ICAM-1 gene.

XX Example 2b; Page 34; 59pp; English.

XX A method for screening for inflammatory bowel disease (IBD) comprises assaying nucleic acid from a subject for the presence or absence of the R241 allele of the ICAM-1 gene, where the presence is indicative of IBD. The method is useful for screening for the disease. The IBD is Crohn's disease or ulcerative colitis. Two probes (AAQ97342, AAQ97343) were used to identify the G241 and R241 allele of the ICAM-1 gene respectively

XX Sequence 19 BP; 1 A; 7 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 7.3e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 769 TCCTCGACGGGCTGTTC 787

DB 1 TCCTCGACGGGCTGTTC 19

RESULT 1617

AAQ88743/C

ID AAQ88743 standard; DNA; 19 BP.

XX AAQ88743;

XX 27-FEB-1996 (first entry)

XX Human ICAM modified antisense oligonucleotide.

XX antisense; analogue; non-terminal pyrimidine; phosphorothioate; backbone; treatment; HIV; human immunodeficiency virus; HSV; herpes simplex virus; cancer; integrin; cell adhesion receptor; infection; diagnosis; nucleic acid resistance; ss.

XX Homo sapiens.

XX EP653439-A2.

XX 17-MAY-1995.

XX 07-NOV-1994; 94EP-00117513.

XX 12-NOV-1993; 93DE-04338704.

XX (FARH) HOECHST AG.

XX Peyman A, Uhlmann E, Mag M, Kretzschmar G, Helsing M, Winkler I;

XX WPI; 1995-180677/24.

XX New anti-sense oligonucleotide analogues - with modified non-terminal pyrimidine nucleotide units, useful for treating viral infections, cancer, etc.

XX Claim 1; Page 32; 36pp; German.

XX The antisense oligonucleotide (ON) shown is a derivative of an equivalent wild type Human ICAM ON, in which at least one, esp. 2-10, non-terminal pyrimidine nucleotide(s) is/are modified. The modification may be: (a) replacement of a phosphodiester linkage by a phosphorothioate (PS), - dithioate, -aramidate; borano-, alkyl-, aralkyl-phosphate; 2,2,2-trichloro-1,1dimethyl-, alkyl- or aryl- phosphate linkage; or (3'-thio)formacetal, methylhydroxylamine, oxime, methylenedimethylidrazo, dimethylene sulphone or silyl linkage; (b) replacement of a sugar phosphate backbone by a 'morpholinonucleoside' oligomer; (c) replacement

CC of beta-D-2-deoxyribose by another sugar or carbocyclic, open-chain or
 CC bicyclic sugar analogue; or (c) replacement of the natural nucleoside
 CC base by an analogue, e.g. 5-hydroxymethyl-uridine. The 5' and/or 3'
 CC terminus may also be modified with a lipophilic gp., eg. a farnesyl. The
 CC modifications increase nuclease resistance and thus improve stability and
 CC activity

XX Sequence 19 BP; 4 A; 4 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 7.3e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCGAGC 69

DB 19 CCTCGCTATGGCTCCGAGC 1

RESULT 1618

AAT44451/c

ID AAT44451 standard; DNA; 19 BP.

XX

AC AAT44451;

XX

XX 27-JAN-1997 (first entry)

XX

DE Antisense oligonucleotide against ICAM gene.

XX

XX 8-azapurine; modification; stronger complex; inhibition;

KW intracellular adhesion molecule; ss.

XX

XX Synthetic.

OS

XX

PN EP680969-A2.

XX

XX 08-NOV-1995.

PD

XX 26-APR-1995; 95BP-00106230.

PF

XX 02-MAY-1994; 94DE-04415370.

PR

XX (FARH) HOECHST AG.

XX

XX Seela F, Lampe S;

PI

XX WPI; 1995-375165/49.

XX

XX New oligo:nucleotide(s) contg. 8-aza:purine base - useful as therapeutic

PT and diagnostic agents with more stable hybridisation to target nucleic

PT acid.

XX

XX Disclosure; Page 45; 51pp; German.

PS

XX AAT44425-54 are antisense oligonucleotides which have at least one 8-

CC azapurine base. The presence of an 8-azapurine base results in

CC significantly stronger complexing when hybridising to target nucleic

CC acids. The present sequence is against the intracellular adhesion

CC molecule (ICAM) gene

XX Sequence 19 BP; 4 A; 4 C; 9 G; 2 T; 0 U; 0 Other;

SQ

Query Match 0.6%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 7.3e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCGAGC 69

DB 19 CCTCGCTATGGCTCCGAGC 1

RESULT 1619

AAT444252/c

ID AAT444252 standard; DNA; 19 BP.

XX AAT44252;

XX 22-JUL-1997 (first entry)

DT

DE ICAM antisense component of capped oligonucleotide.

XX

XX Antisense therapy; guanosine; intercellular adhesion molecule; ICAM;

KW nuclease resistance; stability; ss.

XX

OS Synthetic.

XX

PN DE19502912-A1.

XX

PD 01-AUG-1996.

XX

XX 31-JAN-1995; 95DE-01002912.

PF

XX 31-JAN-1995; 95DE-01002912.

PR

XX (FARH) HOECHST AG.

XX

XX Peyman A, Uhlmann E;

PI

XX WPI; 1996-355223/36.

XX

XX Claim 3; Page 13; 15pp; German.

PS

XX Ten- to 40-mer oligonucleotides which have a cap of 1-10 (esp. 4) G

CC residues on at least one end are provided; if caps are present at both

CC ends, they can be of the same or different lengths. A cap sequence

CC increases nuclease resistance of the oligonucleotide and also increases

CC cell penetration. The present sequence is that of a preferred

CC oligonucleotide, directed against an intercellular adhesion molecule

CC sequence, which can be capped for use in anticancer therapy

XX

SQ Sequence 19 BP; 4 A; 4 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 7.3e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCGAGC 69

DB 19 CCTCGCTATGGCTCCGAGC 1

RESULT 1620

AAX33924/c

ID AAX33924 standard; DNA; 19 BP.

XX

AC AAX33924;

XX

XX 30-JUN-1999 (first entry)

DT

XX ICAM expression inhibitor.

XX

XX Gene expression inhibitor; probe; nucleic acid detection; growth factor;

KW viral infection; therapy; HSV-1; cancer; restenosis; integrin;

XX cell-cell adhesion receptor; ICAM; ss.

XX

OS Synthetic.

OS Homo sapiens.

XX

PN AU9648028-A.

XX

PD 26-SEP-1996.

XX

PF 12-MAR-1996; 96AU-00048028.
 XX
 PR 13-MAR-1995; 95DE-01008923.
 PR 24-NOV-1995; 95DE-01043865.
 XX (FARH) HOECHST AG.
 XX
 PI Peyman A, Uhlmann E, Breipohl G, Wallmeier H;
 XX WPI; 1996-455932/46.
 XX
 DR New phosphono-mono:ester oligo:nucleotide analogues - inhibitors of gene
 PT expression for treating viral infections, cancer, restenosis, etc.
 PT
 XX Disclosure; Page 42; 129pp; English.
 XX
 CC This sequence represents an inhibitor of ICAM, and is an example of an
 CC oligonucleotide analogue of the invention. The oligonucleotide analogues
 CC of the invention are used as inhibitors of gene expression (antisense
 CC oligonucleotides, ribozymes, sense oligonucleotides and triplex-forming
 CC oligonucleotides), as probes for the detection of nucleic acids, and as
 CC auxiliaries in molecular biology. As gene expression inhibitors they may
 CC be used for treating viral infections (especially where the virus is HSV-
 CC 1, HSV-2, an influenza virus, VSV, hepatitis B or papilloma virus),
 CC cancer, restenosis, medical conditions mediated by integrins or cell-cell
 CC adhesion receptors, and medical conditions induced by growth factors
 CC (especially TNF-alpha)
 XX
 SQ Sequence 19 BP; 4 A; 4 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 51 CCTCGCTATGCTCCCGC 69
 DB 19 CCTCGCTATGCTCCCGC 1
 RESULT 1621
 AAX24206/C
 ID AAX24206 standard; DNA; 19 BP.
 AC
 AC AAX24206;
 XX
 XX 01-JUL-1999 (first entry)
 DT
 DE Phosphonomonoester oligonucleotide analogue 23.
 XX
 XX Phosphonomonoester analogue; inhibitor; antisense; cancer; restenosis;
 KW ribozyme; diagnostic agent; detection; treatment; disease; virus;
 KW integrin; cell-cell adhesion receptor; TNF-alpha; ss.
 XX
 OS Synthetic.
 XX
 XX DE19508923-A1.
 PN
 XX 19-SEP-1996.
 PD
 XX
 XX 13-MAR-1995; 95DE-01008923.
 PF
 XX
 XX 13-MAR-1995; 95DE-01008923.
 PR
 XX (FARH) HOECHST AG.
 PA
 XX
 XX Anuschirwan P, Uhlmann E, Breipohl G, Wallmeier H;
 PI WPI; 1996-425893/43.
 DR
 XX
 XX New oligo:nucleotide analogues contg. phospho-mono:ester bridges - for
 PT therapeutic inhibition of gene expression, e.g. in cancer or viral
 PT infection, with good specificity and in vivo stability.
 XX
 XX

PS Disclosure; Page 23; 36pp; German.
 XX
 CC This invention describes novel phosphonomonoester oligonucleotide
 CC analogues which act as inhibitors of gene expression (as sense/antisense,
 CC ribozyme or triplex-forming molecules), useful as diagnostic agents (i.e.
 CC probes for detecting nucleic acid) or for treatment of diseases caused by
 CC viruses, influenced by integrins or cell-cell adhesion receptors, induced
 CC by factors such as TNF-alpha, or cancer or restenosis. The products of
 CC the invention satisfy the requirements of good in-vivo stability; ability
 CC to cross cellular and nuclear membranes, and specific binding to target
 CC nucleic acid better than known oligonucleotides
 XX
 SQ Sequence 19 BP; 4 A; 4 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 51 CCTCGCTATGCTCCCGC 69
 DB 19 CCTCGCTATGCTCCCGC 1
 RESULT 1622
 AAT80607/C
 ID AAT80607 standard; RNA; 19 BP.
 XX
 AC AAT80607;
 XX
 XX 25-MAR-2003 (revised)
 DT 05-NOV-1997 (first entry)
 XX
 XX Oligonucleotide ISIS-3251 for use in inhibiting mRNA activity.
 DE
 XX 5' cap; inhibition; mRNA activity; eukaryotic initiation factor 4E;
 KW eIF-4E; viral infection; ss.
 XX
 OS Synthetic.
 XX
 XX US5643780-A.
 PN
 XX 01-JUL-1997.
 PD
 XX 21-OCT-1994; 94US-00327363.
 PF
 XX 03-APR-1992; 92US-00847054.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Baker BF;
 PI
 XX WPI; 1997-350245/32.
 DR
 XX
 XX Conjugates for inhibiting mRNA activity by altering 5' cap structure -
 PT comprising targetting oligo:nucleotide linked to amine or metal complex.
 PT
 XX Example 8; Col 17; 19pp; English.
 PS
 XX A novel composition has been produced for inhibiting the activity of an
 CC mRNA molecule. The composition comprises: (a) a targetting portion which
 CC is an oligonucleotide or oligonucleotide analogue specifically
 CC hybridisable with the 5' end of the mRNA molecule; (b) a reactive portion
 CC which is an amine or metal complex that chemically modifies or cleaves
 CC the 5' cap structure of the mRNA molecule; and (c) a linker that connects
 CC the targetting and reactive portions so that, upon hybridisation of the
 CC targetting portion to the mRNA, the reactive portion can contact the 5'
 CC cap. The present sequence represents an oligonucleotide ISIS-3251 for
 CC tethering triethylene tetramine to the 3' terminus of an oligonucleotide
 CC via a modified uridine tether, for use in the inhibiting of mRNA
 CC activity. The composition can be used for masking the 5' cap to inhibit
 CC binding of eukaryotic initiation factor 4E (eIF-4E) to the mRNA or for
 CC inhibiting production of a protein encoded by the mRNA in a eukaryotic
 CC cell. This has possible therapeutic applications, e.g. for treating viral

CC infections. (Updated on 25-MAR-2003 to correct PF field.)
 XX
 SQ Sequence 19 BP; 5 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 20 GCTCCTCTGCTACTACAG 38
 |||||
 Db 19 GCTCCTCTGCTACTACAG 1

RESULT 1623
 AAT76145/c
 ID AAT76145 standard; DNA; 19 BP.

XX AC AAT76145;

XX DT 12-SEP-1997 (first entry)

XX DE Human intercellular adhesion molecule-1 antisense oligonucleotide.

XX KW Asthma; airway epithelium; adenosine free; cystic fibrosis;
 chronic obstructive pulmonary disease; bronchitis; ss.

XX OS Synthetic.

XX PN WO9640162-A1.

XX PD 19-DEC-1996.

XX PF 06-JUN-1996; 96WO-US009306.

XX PR 07-JUN-1995; 95US-00474497.

XX PA (UYEC-) UNIV EAST CAROLINA.

XX PI Nyce JW, Metzger WJ;

XX PS WPI; 1997-051871/05.

XX PT Treatment of airway diseases such as asthma - by topically applying
 adenosine-free antisense oligo:nucleotide to airway epithelium of
 subject.

XX PS Claim 5; Page 27; 71pp; English.

CC A method for treating airway disease in a subject has been produced,
 which involves the topical administration of an essentially adenosine
 free antisense oligonucleotide (ON) to the airway epithelium of the
 subject. The present sequence is an antisense oligonucleotide HSICAM1A52
 specific for the human intercellular adhesion molecule-1 (CAM-1). The
 method can be used to treat airway diseases such as cystic fibrosis,
 asthma, chronic obstructive pulmonary disease, bronchitis and other
 airway diseases characterised by an inflammatory response. By eliminating
 adenosine from the antisense ON, its liberation upon antisense
 degradation is prevented, thereby preventing adenosine-induced
 bronchoconstriction in patients with hyper-reactive airways

SQ Sequence 19 BP; 0 A; 7 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 475 GGGGCACCCCGGCCAAC 493
 |||||
 Db 19 GGGGCACCCCGGCCAAC 1

RESULT 1624
 AAV54842/c

ID AAV54842 standard; DNA; 19 BP.
 XX AC AAV54842;

XX DT 25-MAR-2003 (revised)

XX DT 18-NOV-1998 (first entry)

XX DE Probe Icam 1-3 used to isolate lambda clone pVZ147 encoding ICAM-R.

XX KW Human; ICAM-R; intercellular adhesion molecule; adhesion; treatment;
 inflammatory condition; asthma; tumour growth; metastasis;
 viral infection; probe; ss.

XX OS Synthetic.

XX OS Homo sapiens.

XX PN US5811517-A.

XX PD 22-SEP-1998.

XX PF 07-JUN-1995; 95US-00483389.

XX PR 27-JAN-1992; 92US-00827689.

XX PR 26-MAY-1992; 92US-00889724.

XX PR 05-JUN-1992; 92US-00894061.

XX PR 22-JAN-1993; 93US-00009266.

XX PR 26-JAN-1993; 93WO-US000787.

XX PR 05-AUG-1993; 93US-00102852.

XX PR 05-AUG-1994; 94US-00286754.

XX PA (ICOS-) ICOS CORP.

XX PI Vazeux R, Gallatin WM;

XX DR WPI; 1998-530940/45.

XX PT DNA encoding mutant ICAM-R poly:peptide(s) - useful for diagnosis and
 treatment of cell adhesion based disease conditions e.g. inflammation or
 asthma.

XX PS Example 4; Col 14; 111pp; English.

XX CC Probes AAV54837-42 were used to isolate lambda clone pVZ147 encoding
 human ICAM-R (intercellular adhesion molecule-R). ICAMs are polypeptides
 that are expressed on blood vessel endothelial cell surfaces and are
 involved in the adhesion events in various conditions. ICAM-R variants
 (see AAW71264-69) can be used to treat or monitor inflammatory conditions
 involving specific or nonspecific immune responses, asthma, tumour growth
 and/or metastasis and viral infections. The ICAM variants are produced
 recombinantly, from expression libraries of mutated sequences, and the
 ones that are claimed are the ones that have been found to be especially
 involved in adhesion events. They can also be used to raise antibodies,
 also for use as therapeutic or diagnostic agents. (Updated on 25-MAR-2003
 to correct PR field.)

SQ Sequence 19 BP; 5 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 591 TCACCATGGAGCCAAATTC 609
 |||||
 Db 19 TCACCATGGAGCCAAATTC 1

RESULT 1625

AAV28151/c

ID AAV28151 standard; DNA; 19 BP.

XX AC AAV28151;

XX DT 08-OCT-1998 (first entry)

XX Deletion derivative of oligonucleotide ISIS 2302.
 DE Purification; oligonucleotide; matrix; affinity unit;
 XX affinity purification; ss.
 KW Synthetic.
 XX

XX WO9827425-A1.
 PN 25-JUN-1998.
 PD 18-DEC-1997; 97WO-US023284.
 PF 19-DEC-1996; 96US-00769951.
 PR (ISIS-) ISIS PHARM INC.
 PA Chen D, Srivateja GS, Cole DL;
 PI WPI; 1998-362922/31.
 XX

XX Matrix for selective separation of oligo:nucleotide - useful for, e.g.
 XX large scale purification of anti-sense agents from their deletion
 PT derivatives formed during synthesis.
 PT
 XX Example 1; Page 35; 183pp; English.
 PS AAV28150-54 represent deletion derivatives of target oligonucleotide ISIS
 XX 2302 (AAV28149). The oligonucleotides were used to demonstrate the method
 CC of the invention, where the goal was to purify oligonucleotide ISIS 2302.
 CC The specification describes a matrix that comprises a support and an
 CC affinity unit that specifically and reversibly binds a target
 CC oligonucleotide, and comprises a sequence of bases having the reverse
 CC complement of a hybridising portion of the target oligonucleotide. The
 CC matrix is used for affinity purification of synthetic oligonucleotides,
 CC specifically antisense agents, for treatment of hyperproliferative
 CC diseases, for treating a non-pathogen, non-hyperproliferative disease,
 CC e.g. Alzheimer's, for modulating expression of cell surface proteins, and
 CC to inhibit a eukaryotic pathogen, retrovirus or other viruses
 XX Sequence 19 BP; 4 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTGGG 2118
 |||||
 Db 19 TGACGGATGCCAGCTGGG 1

RESULT 1626
 AAV56364/c
 ID AAV56364 standard; DNA; 19 BP.
 XX
 AC AAV56364;
 XX

DT 20-NOV-1998 (first entry)
 XX

DE Human ICAM-R cDNA probe Icam 1-3'.
 XX

KW Intercellular adhesion molecule; ICAM-R; human; modulator; 14.3.3 family;
 KW HSI-beta; tubulin; inhibitor; stimulator; effector; immune response;
 KW inflammation; disorder; T cell activation; macrophage; Crohn's disease;
 KW adult respiratory distress syndrome; stroke; multiple sclerosis; asthma;
 KW rheumatoid arthritis; tumour growth; human immune deficiency virus;
 KW infection; diabetes; graft vs. host disease; passive immunisation; probe;
 KW ss.

XX Synthetic.
 OS Homo sapiens.
 XX

PN US5773218-A.
 XX 30-JUN-1998.
 PD 07-JUN-1995; 95US-00482882.
 PF 27-JAN-1992; 92US-00827689.
 XX 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 05-AUG-1994; 94US-00286754.
 XX (ICOS-) ICOS CORP.
 PA Gallatin WM, Vazeux R;
 XX WPI; 1998-386989/33.
 DR

XX Identifying compounds that modulate interaction of intracellular adhesion
 PT molecule R - with ligands HSI-beta and tubulin using two-hybrid assay,
 PT useful for treating inflammation, T cell activation etc.
 XX Example 4; Col 101-102; 108pp; English.
 PS

XX AAV56349-V56366 are primers and probes used in the isolation of a novel
 CC human intercellular adhesion molecule, ICAM-R. This sequence is used in a
 CC method which investigates modulators of the interaction between ICAM-R
 CC and the 14.3.3 family member HSI-beta and tubulin. An anti-ICAM-R
 CC antibody optionally coupled to toxin or radionuclide, or an ICAM-R
 CC peptide, can block, inhibit or stimulate ligand/receptor interactions
 CC involving ICAM-R, particularly its effector functions involved in
 CC (non)specific immune responses. ICAM-R related agents may be used to
 CC treat or monitor inflammation, disorders involving T cell activation or
 CC macrophages, e.g. adult respiratory distress syndrome, stroke, Crohn's
 CC disease, multiple sclerosis, rheumatoid arthritis, asthma, tumour growth,
 CC human immune deficiency virus infection, diabetes, graft vs. host disease
 CC and many others. Antibodies may also be used for passive immunisation,
 CC for purifying, detecting or quantifying ICAM-R and for identifying ICAM-R
 CC expressing cells
 XX

SQ Sequence 19 BP; 5 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAAATTC 609
 |||||
 Db 19 TCACCATGGAGCCAAATTC 1

RESULT 1627
 AAV69141/c
 ID AAV69141 standard; DNA; 19 BP.
 XX
 AC AAV69141;
 XX

DT 17-FEB-1999 (first entry)
 XX

DE ICAM-R cDNA screening probe Icam 1-3.
 XX

KW Intercellular adhesion molecule polypeptide; ICAM-R; humanised; ICR 1.1;
 KW ICR 8.1; monoclonal antibody; therapeutic; inflammatory; asthma; tumour;
 KW graft-versus-host disease; viral infection; toxin; radionuclide; probe;
 KW neovascularisation site; ss.

XX Synthetic.
 OS Homo sapiens.
 XX

XX US5837822-A.
 XX

PD 17-NOV-1998.
 XX
 PF 07-JUN-1995; 95US-00487113.
 XX
 PR 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 28-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 XX
 PA (ICOS-) ICOS CORP.
 XX
 PI Vazeux R, Gallatin WM;
 XX WPI; 1999-023535/02.
 DR
 XX Humanised antibodies specific for intercellular adhesion molecule
 PT polypeptide - useful for therapeutic or diagnostic purposes.
 XX
 PS Example 4; Col 14; 116pp; English.
 XX
 CC Probes AAV69136 to AAV69141 are used in the course of the invention for
 CC screening for a cDNA encoding human intercellular adhesion molecule
 CC polypeptide (ICAM-R). The invention relates to humanised ICR 1.1 and ICR
 CC 8.1 antibodies targeted to the ICAM-R polypeptide. Antibodies specific
 CC for ICAM-R are potentially useful as therapeutic compounds, for treating
 CC e.g. immune-mediated inflammatory conditions (e.g. graft-versus-host
 CC disease), asthma, tumours or viral infections. Monoclonal antibodies
 CC specific for ICAM-R, or their conjugates formed with e.g. toxins or
 CC radionuclides are useful for therapeutically targeting or detecting
 CC neovascularisation sites
 XX
 SQ Sequence 19 BP; 5 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 591 TCACCATGGAGCCCAATTC 609
 Db 19 TCACCATGGAGCCCAATTC 1
 RESULT 1628
 AAX21854/c
 ID AAX21854 standard; DNA; 19 BP.
 XX
 AC AAX21854;
 XX
 DT 14-MAY-1999 (first entry)
 XX
 DE Primer for ICAM immunoglobulin-like loop motif.
 XX
 KW ICAM; immunoglobulin-like loop; intercellular adhesion molecule receptor;
 KW alpha d/CD18; antibody; immunisation; inflammatory response; asthma;
 KW tumour growth; viral infection; therapy; primer; ss.
 XX
 OS Synthetic.
 XX
 PN US5880268-A.
 XX
 PD 09-MAR-1999.
 XX
 PF 07-JUN-1995; 95US-00483932.
 XX
 PR 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 05-AUG-1994; 94US-00286754.
 XX

XX
 PA (ICOS-) ICOS CORP.
 XX
 PI Vazeux R, Gallatin WM;
 XX WPI; 1999-204041/17.
 DR
 XX New intercellular adhesion molecule receptor (ICAM-R) specific antibodies
 PT - useful for modulating ligand/receptor binding and biological activities
 PT involving ICAM-R, especially those of the specific and non-specific
 PT immune systems.
 XX
 PS Example 4; Col 14; 108pp; English.
 XX
 CC This sequence is a primer for an ICAM immunoglobulin-like loop domain.
 CC The invention relates to antibodies (Ab) which bind specifically to the
 CC intercellular adhesion molecule receptor (ICAM-R), inhibiting the
 CC interaction between ICAM-R and alpha d/CD18. Abs with specific ICAM-R
 CC binding are useful in compositions for immunisation, and for purifying
 CC ICAM-R polypeptides and identifying cells expressing ICAM-R on their cell
 CC surface, modulating ligand/receptor binding and biological activities
 CC involving ICAM-R, especially inflammatory responses of the specific
 CC immune system, the non-specific immune system, monitoring and treating
 CC asthma, tumour growth, and/or metastasis, and viral infection (e.g. HIV
 CC infection). In particular diseases involving an essential T cell
 CC activation (e.g. asthma, psoriasis, diabetes, graft vs. host disease,
 CC tissue transplant rejection, and multiple sclerosis) may be treated with
 CC anti-ICAM-R antibodies. The Abs specifically bind to and identify ICAM-R
 CC and disrupt ICAM-R to cell adhesion molecule, especially alpha d/CD18
 CC binding
 XX
 SQ Sequence 19 BP; 5 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 591 TCACCATGGAGCCCAATTC 609
 Db 19 TCACCATGGAGCCCAATTC 1
 RESULT 1629
 AAA33384/c
 ID AAA33384 standard; DNA; 19 BP.
 XX
 AC AAA33384;
 XX
 DT 28-JUL-2000 (first entry)
 XX
 DE Low adenosine antisense oligonucleotide SEQ ID NO:1073.
 XX
 KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; anti-inflammatory;
 KW antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200009525-A2.
 XX
 PD 24-FEB-2000.
 XX
 PF 03-AUG-1999; 99WO-US017712.
 XX
 PR 03-AUG-1998; 98US-0095212P.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX

PI	Nyce JW;
XX	
DR	WPI; 2000-205971/18.
XX	
XX	New antisense oligonucleotides useful for treating e.g. pulmonary
PT	vasoconstriction, inflammation, allergies, asthma, hypertension,
PT	bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT	cancers.
XX	
XX	Claim 18; Page 399; 1343pp; English.
PS	
CC	The present invention describes a new composition comprising an antisense
CC	oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC	nucleic acids involved in bronchoconstriction, allergies, and/or
CC	inflammation. The ON can have antiinflammatory, antiallergic,
CC	antisthmatic, cytostatic and analgesic activities. The compositions are
CC	useful for the treatment of diseases associated with inflammation,
CC	impaired airways, including lung disease and diseases whose secondary
CC	effects afflict the lungs of a subject. They can be used for treating
CC	e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
CC	impaired respiration, respiratory distress syndrome, pain, cystic
CC	fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC	pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC	carcinomas, and cancers which may metastasise to the lungs, including
CC	breast and prostate cancer. The reduction of the adenosine content of the
CC	ONs reduces side effects. The A-containing ONs break down with the
CC	release of deoxyadenosine which activates adenosine receptors causing
CC	bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
CC	nucleotide sequences given in the sequence listing from the present
CC	invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
CC	sequences are also called SEQ ID NO:1 to 185, but the sequences differ
CC	from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to
CC	AAA33992) are specifically claimed ONs from the present invention. N.B.
CC	Sequences given in the disclosure of the present invention do not match
CC	up with their corresponding SEQ ID NO: sequences given in the sequence
CC	listing
XX	
SQ	Sequence 19 BP; 0 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
	Query Match 0.6%; Score 19; DB 1; Length 19;
	Best Local Similarity 100.0%; Pred. No. 7.3e+02;
	Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	475 GGGGCACCCCGGCCCAACC 493
Db	19 GGGGCACCCCGGCCCAACC 1
RESULT 1630	
ID	AAZ24278/C
XX	AZ24278 standard; DNA; 19 BP.
AC	AAZ24278;
XX	
DT	16-FEB-2000 (first entry)
XX	
DE	Human ICAM oligonucleotide probe Icam1-3.
XX	
KW	ICAM-R; human; intercellular adhesion molecule; phosphorylation;
KW	protein kinase C; modulator; probe; ss.
XX	
OS	Synthetic.
OS	Homo sapiens.
XX	
PN	US5989843-A.
XX	
PD	23-NOV-1999.
XX	
PX	27-SEP-1996; 96US-00720420.
PF	
PR	27-JAN-1992; 92US-00827689.
PR	26-MAY-1992; 92US-00899724.
PR	05-JUN-1992; 92US-00894061.

PR	22-JAN-1993; 93US-00009266.
PR	26-JAN-1993; 93WO-US000787.
PR	05-AUG-1993; 93US-00102852.
XX	07-JUN-1995; 95US-00487113.
XX	(ICOS-) ICOS CORP.
PA	Gallatin WM, Vazeux R;
XX	
PI	WPI; 2000-022778/02.
DR	
XX	
XX	Identifying modulators of protein kinase C phosphorylation of human
PT	intercellular adhesion molecule polypeptide.
XX	
PS	Example 4; Col 117-118; 122pp; English.
XX	
CC	This invention describes a novel method for identifying a compound that
CC	modulates phosphorylation of human intercellular adhesion molecule
CC	polypeptide (ICAM-R) by protein kinase C isoform. The method comprises:
CC	(a) exposing a purified peptide consisting of the cytoplasmic domain of
CC	ICAM-R to protein kinase C isoform and labeled adenosine triphosphate in
CC	the presence and absence of a test compound; (b) measuring labeled
CC	phosphate transferred to the peptide; and (c) identifying a test compound
CC	that affects transfer of the labeled phosphate as a modulator compound.
CC	The method is useful for identifying compounds that modulate the
CC	phosphorylation of human intercellular adhesion molecule polypeptide
CC	which might form the basis for the development of therapeutic and
CC	diagnostic agents. This sequence represents a probe used in the method of
CC	the invention
XX	
SQ	Sequence 19 BP; 5 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
	Query Match 0.6%; Score 19; DB 1; Length 19;
	Best Local Similarity 100.0%; Pred. No. 7.3e+02;
	Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	591 TCACCATGGAGCCAATTTC 609
Db	19 TCACCATGGAGCCAATTTC 1
RESULT 1631	
ID	AAZ27847/C
XX	AZ27847 standard; DNA; 19 BP.
AC	AAZ27847;
XX	
DT	12-SEP-2000 (first entry)
XX	
DE	ICAM-1 3' non-coding region antisense oligonucleotide ISIS 1939.
XX	
KW	Oligomeric conjugate; oligonucleotide transfer; antisense; ICAM-1;
KW	intercellular adhesion molecule-1; inflammation; antiinflammatory;
KW	autoimmune disease; cancer; antitumour; infection; graft rejection;
KW	allergy; therapy; ss.
XX	
OS	Synthetic.
XX	
FH	Key Location/Qualifiers
FT	modified_base 1..19
FT	/tag= a
FT	/note= "phosphorothioate linkage"
XX	
PN	WO200032764-A1.
XX	
PD	08-JUN-2000.
XX	
PF	22-NOV-1999; 99WO-EP008980.
XX	
PR	02-DEC-1998; 98EP-00403015.
XX	
PA	(IDMI-) IDM IMMUNO-DESIGNED MOLECULES.
XX	

PI Midoux P, Pichon C, Bello-Roufaie M, Monsigny M;
 XX WPI; 2000-431102/37.
 XX
 PT New positively charged oligomeric conjugate, useful for delivering e.g.
 PT oligonucleotides to cytosol and cell nuclei, contains a controlled number
 PT of positively charged amino groups.
 XX
 XX Disclosure; Page 21; 64pp; English.
 XX
 CC ISIS 1939 is an antisense phosphorothioate oligonucleotide that is
 CC targeted to the 3' non-coding region of intercellular adhesion molecule-1
 CC (ICAM-1) mRNA. It was used to demonstrate the ability of novel oligomeric
 CC conjugates to transfer biological molecules, such as oligonucleotides,
 CC into cells. These novel oligomeric conjugates contain an oligomer with a
 CC polymerization degree (PD) of 5-50, preferably 10-40, and more preferably
 CC 20, formed from monomeric components having free NH₂ in a number equal
 CC to or higher than 50% of the PD. An example of is histidylated polylysine
 CC (see AA95255 and AA95256). The oligomeric conjugate induces a membrane
 CC destabilization at acidic pH allowing the transfer of biological
 CC molecules to the cytoplasm or cell nucleus in vitro, in vivo or ex vivo.
 CC Suitable biological molecules are antisense, triplex-forming and ribozyme
 CC molecules, RNA decoys, and antigenic peptides, e.g. for the treatment of
 CC cancer, inflammatory or immunological diseases such as graft rejection,
 CC allergy or autoimmunity, or infectious diseases (claimed). Larger DNA is
 CC not transferred. Tumour necrosis factor-induced ICAM-1 expression was
 CC inhibited by ISIS 1939 in the presence of 20 uM histidylated oligolysines
 XX
 XX Sequence 19 BP; 2 A; 13 C; 0 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1939 AGAGGGGAAGTGTGGGG 1957
 Db |||||||||
 19 AGAGGGGAAGTGTGGGG 1
 RESULT 1632
 AAA97106/c
 ID AAA97106 standard; DNA; 19 BP.
 XX
 AC AAA97106;
 XX
 DT 19-DEC-2000 (first entry)
 XX
 DE PCR primer Icam 1-3 used in ICAM-R DNA isolation.
 XX
 KW Anti-human immunodeficiency virus; HIV; cytostatic; ICAM-R; ARDS; stroke;
 KW intercellular adhesion molecule; immunoglobulin heavy chain; septicemia;
 KW inflammatory conditions; glomerulonephritis; arthritis; dermatosis;
 KW haemodialysis; leukapheresis; ulcerative colitis; Crohn's disease;
 KW necrotising enterocolitis; atherosclerosis; psoriasis; asthma;
 KW transplant rejection; diabetes; tumour; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX US6100383-A.
 XX
 PD 08-AUG-2000.
 XX
 PF 07-JUN-1995; 95US-00475680.
 XX
 XX 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 28-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 05-AUG-1994; 94US-00286754.
 XX
 PA (ICOS-) ICOS CORP.

XX
 PI Gallatin WM, Vazeux R;
 DR WPI; 2000-542449/49.
 XX
 XX Hybrid fusion proteins comprising intercellular adhesion molecule or its
 PT variants useful, for treating inflammatory conditions, Crohn's disease,
 PT atherosclerosis and diabetes.
 XX
 XX Example 4; Col 14; 109pp; English.
 PS
 XX This invention relates to a hybrid fusion protein comprising an
 CC intercellular adhesion molecule (ICAM-R) amino acid fragment at its amino
 CC terminus and a constant domain of an immunoglobulin heavy chain at its
 CC carboxy terminus. ICAM-R polypeptides are useful for treating and
 CC monitoring inflammatory conditions such as adult respiratory distress
 CC syndrome, multiple organ injury syndrome secondary to septicemia or
 CC trauma, reperfusion injury of tissue, acute glomerulonephritis, reactive
 CC arthritis, dermatosis, stroke, thermal injury, haemodialysis,
 CC leukapheresis, ulcerative colitis, Crohn's disease, necrotising
 CC enterocolitis, granulocyte transfusion associated syndrome,
 CC atherosclerosis and cytokine induced toxicity. ICAM-R polypeptides are
 CC also useful for treating conditions resulting from a response of the
 CC specific immune system in a mammal e.g. psoriasis, organ/tissue
 CC transplant rejection and autoimmune diseases including Raynaud's
 CC syndrome, autoimmune thyroiditis, multiple sclerosis, rheumatoid
 CC arthritis, diabetes and lupus erythematosus. ICAM-R products and ICAM-R
 CC related products are also useful in monitoring and treating asthma,
 CC tumour growth and/or metastasis, and viral infection (e.g. HIV
 CC infection). Sequences AAA97090 and AAB13036 represent the human ICAM-R
 CC DNA and protein sequences. Sequences AAA97091-A97112 represent ICAM-R DNA
 CC fragments, PCR primers and probes, all used in the identification of the
 CC ICAM-R DNA sequence. AAA97113-A97123 and AAA97129-A97152 represent
 CC primers used in the production of humanised anti-ICAM-R antibody ICR-8.1,
 CC and fragments of the humanised antibody. Sequences AAA97124-A97128,
 CC AAA97132, AAA97144 represent ICR-8.1 sequences. Sequences AAA97153-A97176
 CC excluding AAA97155-A97156 represent primers used in the production of
 CC humanised anti-ICAM-R antibody ICR-1.1, and fragments of the humanised
 CC antibody. Sequences AAA97155-A97156 and AAB13047-B13048 represent murine
 CC ICR-1.1 sequences. DNA and peptide sequences used in the production of
 CC the chimeric protein of the invention include AAA97177-A97188 and
 CC AAB13050-B13051
 XX
 XX Sequence 19 BP; 5 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 591 TCACCATGGAGCCAAATTC 609
 Db |||||||||
 19 TCACCATGGAGCCAAATTC 1
 RESULT 1633
 AA08252/c
 ID AA08252 standard; DNA; 19 BP.
 XX
 AC AA08252;
 XX
 XX 28-JUN-2000 (first entry)
 DT
 XX Human ICAM oligonucleotide probe SEQ ID NO:22.
 DE
 XX Human; ICAM-R; chromosome 19; intracellular adhesion molecule receptor;
 KW CAM; ICAM-1; ICAM-2; humanised; antibody; mutagenic; PCR primer; probe;
 KW chimeric; vulnary; nephropathic; antiarthritic; cerebroprotective;
 KW antitumor; antiarteriosclerotic; immunosuppressive; antidiabetic;
 KW neuroprotective; antithyroid; dermatological; antiasthmatic; cytostatic;
 KW antiviral; antiinflammatory; anti-HIV; vasoregic; antipsoriatic;
 KW immunomodulator; cell adhesion mediator; antirheumatic;
 KW inflammatory condition; immunisation; immune response; ss.
 XX

OS Homo sapiens.
 XX US6040176-A;
 XX 21-MAR-2000.
 PD
 XX 12-SEP-1996; 96US-00714017.
 XX 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 05-AUG-1994; 94US-00286754.
 XX
 PA (ICOS-) ICOS CORP.
 XX
 PI Gallatin WM, Vazeux R;
 XX WPI; 2000-270138/23.
 DR
 XX Novel monoclonal antibody directed against ICAM-R proteins useful for
 PT treating acute glomerulonephritis, ulcerative colitis, psoriasis,
 PT rheumatoid arthritis, diabetes, multiple sclerosis, asthma and viral
 PT infection.
 XX
 XX Example 4; Col 14; 117pp; English.
 PS
 XX The present invention describes a monoclonal antibody (MAB) (I), produced
 CC by the hybridoma cell line 81K2F (ATCC HB 11692). Also described are: (I)
 CC a hybridoma cell line 81K2F; and (2) a MAB (II), that competes with (I)
 CC for binding to ICAM-R (intracellular adhesion molecule receptor) (III).
 CC (II) mimics the activity of natural binding proteins through which
 CC intercellular and intracellular activities of (III) are modulated. (II)
 CC is also used for modulating the immune responses. (I) is used for
 CC immunisation as well as for purifying (III). They are also useful in
 CC modulating the ligand/receptor binding biological activity involving
 CC (III) especially those effector functions of (III) involved in specific
 CC and non-specific immune system responses. Inflammatory conditions which
 CC may be treated or monitored with related products of (III) include
 CC conditions resulting from a response of the non-specific immune system in
 CC a mammal e.g. adult respiratory distress syndrome, multiple organ injury
 CC syndrome secondary to septicemia or trauma, reperfusion injury of tissue,
 CC acute glomerulonephritis, reactive arthritis, stroke, ulcerative colitis
 CC and atherosclerosis, and conditions resulting from a response of the
 CC specific immune system in a mammal, e.g. psoriasis, organ/tissue.
 CC transplantation rejection, autoimmune diseases such as autoimmune
 CC thyroiditis, multiple sclerosis, rheumatoid arthritis, diabetes and lupus
 CC erythematosus. AAA08236 to AAA08334, and AAY82435 to AAY82451 represent
 CC sequences used in the exemplification of the present invention
 XX
 SQ Sequence 19 BP; 5 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 591 TCACCATGGAGCCCAATTC 609
 DB 19 TCACCATGGAGCCCAATTC 1
 RESULT 1634
 AAF19506/c
 ID AAF19506 standard; DNA; 19 BP.
 XX
 AC AAF19506;
 XX
 DT 14-MAR-2001 (first entry)
 XX Human ICAM-1 polynucleotide fragment #1073.
 DE
 XX

KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary vasoconstriction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX Homo sapiens.
 OS WO200062736-A2.
 XX 26-OCT-2000.
 PD
 XX 24-MAR-2000; 2000WO-US008020.
 PF
 XX 06-APR-1999; 99US-0127958P.
 PR
 XX (UYEC-) UNIV EAST CAROLINA.
 PA (NYCE/) NYCE J W.
 XX
 PI Nyce JW;
 XX WPI; 2000-679539/66.
 DR
 XX Low adenosine (A) content antisense oligonucleotides which do not trigger
 PT adenosine receptors during metabolism, useful e.g. for treating cancers
 PT and respiratory obstructions.
 XX
 XX Claim 14; Page 145; 1592pp; English.
 PS
 XX The present invention describes low adenosine (A) content antisense
 CC oligonucleotides and compositions (I) comprising them. In the antisense
 CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
 CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
 CC immunosuppressive, antiasthmatic, hypotensive and cytostatic activities.
 CC The antisense oligonucleotides and (I) can be used to down-regulate the
 CC expression and or activity of target polypeptides associated with
 CC lung/respiratory disorders and malignancies, such as stimulating and
 CC activating peptide factors and transmitters, transcription factors,
 CC immunoglobulins and antibodies, antibody receptors, cytokines and
 CC chemokines, endogenously produced specific and non-specific enzymes,
 CC binding proteins, adhesion molecules and their receptors, cytokine and
 CC chemokine receptors, adenosine receptors, bradykinin receptors, central
 CC nervous system (CNS) and peripheral nervous and non-nervous system
 CC receptors, CNS and peripheral nervous and non-nervous system peptide
 CC transmitters, defensins, growth factors, vasoactive peptides and
 CC receptors, binding proteins and malignancy associated proteins. The
 CC antisense oligonucleotides may be used in this way to treat disorders
 CC including respiratory obstruction (especially pulmonary obstruction
 CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
 CC surfactant hypoproduction which are associated with a disease or
 CC condition selected from pulmonary vasoconstriction, inflammation,
 CC allergies, asthma, impeded respiration, respiratory distress syndrome
 CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
 CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
 CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
 CC fragments and antisense oligonucleotides used in the exemplification of
 CC the present invention
 XX
 SQ Sequence 19 BP; 0 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 475 GGGGCACCCCGGCCCAACC 493
 DB 19 GGGGCACCCCGGCCCAACC 1

```

RESULT 1635
AAC73490/c
ID AAC73490 standard; DNA; 19 BP.
XX AC AAC73490;
XX DT 02-FEB-2001 (first entry)
XX DE Reverse primer #105 used in multiplexing PCR/SBE assay.
XX KW Oligonucleotide array; genotyping; single base extension reaction; SBE;
XX KW PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
XX OS Unidentified.
XX PN WO200058516-A2.
XX PD 05-OCT-2000.
XX PF 27-MAR-2000; 2000WO-US008069.
XX PR 26-MAR-1999; 99US-0126473P.
XX PR 23-JUN-1999; 99US-0140359P.
XX PA (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
XX PA (AFFY-) AFFYMETRIX INC.
XX PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
XX PI Ryder T, Sklar P;
XX DR WPI; 2000-656171/63.
XX XX
XX PF 27-MAR-2000; 2000WO-US008069.
XX PR 26-MAR-1999; 99US-0126473P.
XX PR 23-JUN-1999; 99US-0140359P.
XX PA (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
XX PA (AFFY-) AFFYMETRIX INC.
XX PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
XX PI Ryder T, Sklar P;
XX DR WPI; 2000-656171/63.
XX XX
XX PT Universal array of oligonucleotides tags attached to a solid substrate
XX PT along with locus-specific tagged oligonucleotides useful in genotyping
XX PT using single base extension reactions.
XX PS Example 7; Page 59; 70pp; English.
XX CC The present invention relates to an oligonucleotide array comprising
XX CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
XX CC array is useful for genotyping a nucleic acid sample at one or more loci
XX CC via single base extension (SBE) reactions. A pair of primers is used to
XX CC amplify a polymorphic locus in a sample e.g. a single nucleotide
XX CC polymorphism (SNP). The present sequence is one of the primers used in
XX CC the method of the present invention to amplify a polymorphic sample. The
XX CC amplified nucleic acid product is then used as a template in a SBE
XX CC reaction with an extension primer. The SBE reaction products are used to
XX CC form the oligonucleotide array
XX SQ Sequence 19 BP; 4 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1249 CTGACGAGAGGATTGTC 1267
DB 19 CTGACGAGAGGATTGTC 1

RESULT 1636
AAC73482/c
ID AAC73482 standard; DNA; 19 BP.
XX AC AAC73482;
XX DT 02-FEB-2001 (first entry)
XX DE Reverse primer #103 used in multiplexing PCR/SBE assay.
XX KW Oligonucleotide array; genotyping; single base extension reaction; SBE;
XX OS Unidentified.
XX PN WO200058516-A2.
XX PD 05-OCT-2000.
XX PF 27-MAR-2000; 2000WO-US008069.
XX PR 26-MAR-1999; 99US-0126473P.
XX PR 23-JUN-1999; 99US-0140359P.
XX PA (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
XX PA (AFFY-) AFFYMETRIX INC.
XX PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
XX PI Ryder T, Sklar P;
XX DR WPI; 2000-656171/63.
XX XX
XX PT Universal array of oligonucleotides tags attached to a solid substrate
XX PT along with locus-specific tagged oligonucleotides useful in genotyping
XX PT using single base extension reactions.
XX PS Example 7; Page 59; 70pp; English.
XX CC The present invention relates to an oligonucleotide array comprising
XX CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
XX CC array is useful for genotyping a nucleic acid sample at one or more loci
XX CC via single base extension (SBE) reactions. A pair of primers is used to
XX CC amplify a polymorphic locus in a sample e.g. a single nucleotide
XX CC polymorphism (SNP). The present sequence is one of the primers used in
XX CC the method of the present invention to amplify a polymorphic sample. The
XX CC amplified nucleic acid product is then used as a template in a SBE
XX CC reaction with an extension primer. The SBE reaction products are used to
XX CC form the oligonucleotide array
XX SQ Sequence 19 BP; 4 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 226 TTGTTGGGCATAGACCC 244
DB 19 TTGTTGGGCATAGACCC 1

RESULT 1637
AAF60946/c
ID AAF60946 standard; DNA; 19 BP.
XX AC AAF60946;
XX DT 15-MAY-2001 (first entry)
XX DE Anti-ICAM-1 oligonucleotide SEQ ID 55.
XX KW Transport; membrane; cytostatic; virucide; vasotropic; dermatological;
XX KW antipsoriatic; antiasthmatic; gene therapy; tumor cell; antisense;
XX KW tumor therapy; drug; ss.
XX OS Unidentified.
XX PN DE19935302-A1.
XX PD 08-FEB-2001.
XX PF 28-JUL-1999; 99DE-01035302.
XX PR 28-JUL-1999; 99DE-01035302.
XX XX

```

PA (AVET) AVENTIS PHARMA DEUT GMBH.
 XX Uhlmann E, Greiner B, Unger E, Gothe G, Schwerdel M;
 XX WPI; 2001-203679/21.
 DR
 XX New substituted aryl conjugates of parent molecules, especially
 PT oligonucleotides, having improved transmembrane and intracellular
 PT transport properties, useful as medicaments or diagnostic agents.
 XX
 XX Disclosure; Page 8; 28pp; German.
 PS
 XX This invention describes a novel conjugate (I) which consists of (A) a
 CC molecule to be transported and (B) at least one aryl residue of formula -
 CC Ar-(X-C(V)-R.1) n (II). Ar = group containing at least one aromatic ring;
 CC X = O or N (sic); Y = O, S or NH-R.2 (sic); R.1 = optionally substituted
 CC 1-23C alkyl (optionally containing double and/or triple bonds); R.2 =
 CC optionally substituted 1-18C alkyl (optionally containing double and/or
 CC triple bonds); n = integer of 1 or more. (A) is bonded to (B) directly or
 CC via a chemical group, provided that the chemical group is other than CH.2
 CC -S if the bond is via a phosphodiester linkage of (A). The invention also
 CC describes (i) the preparation of a conjugate (I') of (A') a molecule to
 CC be transported and (B') at least one aryl residue (not restricted to
 CC (II)), by preparing (A') containing a reactive function at the position
 CC at which (B') is to be bonded, preparing (B') and reacting (A') and (B');
 CC and (ii) the use of aryl groups (II) (optionally bonded via a chemical
 CC group) for transporting (A) across biological membranes. The products of
 CC the invention have cytostatic, virucide, vasotropic, dermatological,
 CC antipariatic and antiasthmatic activity and can be used for gene
 CC therapy. Conjugation of (A) with (B) is useful for transporting (A)
 CC across biological membranes or into eukaryotic or prokaryotic cells
 CC (specifically bacterial, yeast or mammalian cells, including human cells,
 CC particularly tumor cells). Medicaments, diagnostic agents and test kits
 CC containing (I) are also claimed. Typically (I) are antisense
 CC oligonucleotide derivatives for tumor therapy; oligonucleotide drugs for
 CC treating viral infections or diseases associated with integrins or cell-
 CC cell interactions (e.g. restenosis, vitiligo, psoriasis or asthma); or
 CC labeled oligonucleotides for in vivo diagnostic use, e.g. by in situ
 CC hybridization. Conjugation with (B) markedly improves the cellular uptake
 CC of (A), e.g. in tumor cells. (B) include fluorescent derivative residues,
 CC in which case the conjugates (I) are fluorescently labeled, allowing
 CC microscopic monitoring of cellular uptake etc. The cellular uptake of (I)
 CC is superior to that obtained using other conjugated groups related to
 CC (II); e.g. oligonucleotides conjugated with fluorescein diacetate (within
 CC the scope of (B)) have superior uptake to corresponding fluorescein
 CC conjugates
 XX
 SQ Sequence 19 BP; 4 A; 4 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02; Indels 0; Gaps 0;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 51 CCTCGCTATGCTCCAGC 69
 |||||
 Db 19 CCTCGCTATGCTCCAGC 1
 RESULT 1638
 AAH37310/C
 ID AAH37310 standard; DNA; 19 BP.
 XX
 AC AAH37310;
 XX
 XX 14-AUG-2001 (first entry)
 DT
 XX SNP specific lower PCR primer SEQ ID 106.
 DE
 XX Single nucleotide polymorphism; SNP; single nucleotide primer extension;
 KW SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
 KW Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
 KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
 KW acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
 KW
 OS Homo sapiens.

inflammation; forensic investigation; paternity analysis; PCR primer; ss.
 Homo sapiens.
 WO200129262-A2.
 26-APR-2001.
 13-OCT-2000; 2000WO-US028436.
 15-OCT-1999; 99US-0160096P.
 (ORCH-) ORCHID BIOSCIENCES INC.
 Picoult-Newburg L, Pohl M;
 WPI; 2001-290930/30.
 New genotyping oligonucleotide, useful for detecting the presence,
 PT absence or identity of single polynucleotide polymorphism in a nucleic
 PT acid sample.
 XX
 Claim 1; Page 50; 83pp; English.
 PS
 XX Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
 CC primer extension (SNPE) primers, and the sequences of regions flanking
 CC sites of single nucleotide polymorphisms SNPs. The present invention
 CC includes kits for determining the presence or absence of a SNP, using the
 CC oligonucleotides of the invention. The PCR primers are used to amplify a
 CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.
 CC The oligonucleotides are useful for genotyping a nucleic acid sample by
 CC performing a single-nucleotide primer extension reaction. The
 CC oligonucleotides are useful for determining the presence, absence or
 CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to
 CC assess by association analysis the genotype of an individual or group of
 CC individuals, having a pathological phenotypic trait suspected of being
 CC caused by one or more SNPs. Phenotypic traits include diseases e.g.
 CC agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
 CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
 CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
 CC traits also include symptoms of or susceptibility to multifactorial
 CC disease of which a component is or may be genetic such as autoimmune
 CC diseases, including, rheumatoid arthritis, multiple sclerosis,
 CC inflammation, cancer, nervous system diseases and infection by pathogenic
 CC microorganism. The method is also useful in forensic investigations and
 CC paternity analysis. The present sequence represents a PCR primer specific
 CC for a human SNP containing DNA sequence
 XX
 SQ Sequence 19 BP; 4 A; 9 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02; Indels 0; Gaps 0;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2773 CAGGCTGGAGTGCAGTGGT 2791
 |||||
 Db 19 CAGGCTGGAGTGCAGTGGT 1
 RESULT 1639
 AAC91943/C
 ID AAC91943 standard; DNA; 19 BP.
 XX
 AC AAC91943;
 XX
 XX 19-MAR-2001 (first entry)
 DT
 XX Human ICAM-R probe Icam 1-3.
 DE
 XX Human; ICAM-R; intercellular adhesion molecule polypeptide;
 KW leukointegrin; Mac-1; gpi5095; probe; ss.
 XX
 OS Homo sapiens.


```

XX PN US6153395-A.
XX PD 28-NOV-2000.
XX PF 26-AUG-1994; 94US-00296749.
XX PR 27-JAN-1992; 92US-00827689.
XX PR 26-MAY-1992; 92US-00889724.
XX PR 05-JUN-1992; 92US-00894061.
XX PR 22-JAN-1993; 93US-00009266.
XX PR 26-JAN-1993; 93WO-US000787.
XX PR 05-AUG-1993; 93US-00102852.
XX PA (ICOS-) ICOS CORP.
XX PI Vazeux R, Gallatin WM;
XX WPI; 2001-060087/07.
XX PT Identifying inhibitors of human intercellular adhesion molecule binding
XX PT to Mac-1 or Gp15095 comprise determining a reduction in the label bound
XX PT in the presence of the test compound.
XX PS Example 4; Col 12; 82pp; English.
XX CC The present invention relates to a method for identifying compounds that
XX CC inhibit the binding of human intercellular adhesion molecule polypeptide
XX CC (ICAM-R) to the leukointegrins Mac-1 or Gp15095. The method comprises
XX CC determining the effect of a test compound on the amount of labelled ICAM-
XX CC R, or labelled Mac-1 or Gp15095 bound. The present sequence is a probe
XX CC for human ICAM-R (see AAC91927)
XX SQ Sequence 19 BP; 5 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 591 TCACCATGGAGCAATTC 609
Db 19 TCACCATGGAGCAATTC 1
RESULT 1640
AAH49230/c
ID AAH49230 standard; DNA; 19 BP.
AC AAH49230;
XX 26-NOV-2001 (first entry)
XX Anti-ICAM oligonucleotide XXIII.
XX Polyamide-oligonucleotide derivative; anticancer; antiproliferative;
XX antiviral; hepatotropic; vasotropic; antisense inhibition; ribozyme;
XX integrin; cell-cell adhesion; cancer; restenosis; stability; PNA;
XX peptide nucleic acid; ss.
XX Synthetic.
XX EP1113021-A2.
XX 04-JUL-2001.
XX 08-MAR-1995; 2001EP-00104012.
XX 14-MAR-1994; 94DE-04408528.
XX 08-MAR-1995; 95EP-00103332.
XX (AVET ) AVENTIS PHARMA DEUT GMBH.
XX Uhlmann E, Breipohl G;

```

```

XX WPI; 2001-591267/67.
XX New DNA-peptide nucleic acid chimeras, useful e.g. as antisense agents
XX for treating e.g. cancer, also as diagnostic probes and primers.
XX Disclosure; Page 25; 54pp; German.
XX This invention describes novel polyamide-oligonucleotide derivatives (I)
XX and their physiologically acceptable salts of formula F(DNA)-Li-q(PNA-
XX Li) r(DNA-Li) s(PNA) t xF' where q, r, s, t = 0 or 1, with the sum of
XX two or more adjacent letters at least 2; x = 1-20; DNA = nucleic acid
XX (such as DNA or RNA or their known derivatives); Li = covalent linkage
XX between DNA and PNA, i.e. a bond or a residue containing at least one
XX atom of carbon, nitrogen, oxygen or sulfur; PNA = polyamide structure
XX containing at least one nucleobase different from thymine; and F, F' =
XX end groups and/or are connected through a covalent bond. The products of
XX the invention have anticancer, antiproliferative, antiviral, hepatotropic
XX and vasotropic activity and can be used for the inhibition of gene
XX expression by antisense, ribozyme, sense, or triple-helix methods, or by
XX binding to proteins (aptamers). (I) are used for treating diseases caused
XX by viruses (human immune deficiency, herpes simplex, influenza, vesicular
XX stomatitis, hepatitis B or papilloma), or mediated by integrins or cell-
XX cell adhesion reactions, for treating cancer, or for inhibiting
XX restenosis, particularly as antisense reagents. They are also useful in
XX heterogeneous or homogeneous assays, as primers or probes, particularly
XX where the target is amplified before being detected by hybridization, for
XX diagnosis of genetic, malignant or pathogen-related diseases. (I) retain
XX the increased affinity for complementary strands and better stability in
XX serum, associated with conventional peptide nucleic acids (PNA), but lack
XX the disadvantages, i.e. have improved cellular uptake, do not aggregate
XX in aqueous solution, and have reduced affinity for purification
XX materials, reduced cytotoxicity, better sequence specificity. They are
XX more active than either DNA or PNA oligomers. When used as probes, (I)
XX show different responses to base-pair mismatches in the DNA and PNA
XX segments, allowing better discrimination between pathogenic and non-
XX pathogenic conditions such as the transition from proto-oncogene to
XX oncogene, also, when used as primers, with the PNA segment at the 5'-end,
XX they produce amplicons resistant to 5'-exonuclease, allowing this enzyme
XX to be used to eliminate RNA or DNA primers. The DNA component allows
XX additional reactions not possible with PNA alone, e.g. 3'-tailing and (I)
XX may be incorporated into a gene. AAH49208-AAH49264 represent
XX oligonucleotides used to illustrate the method of the invention
XX SQ Sequence 19 BP; 4 A; 4 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 51 CCTCGCTATGGCTCCAGC 69
Db 19 CCTCGCTATGGCTCCAGC 1
RESULT 1641
ABL01638/c
ID ABL01638 standard; DNA; 19 BP.
XX ABL01638;
XX 15-MAR-2002 (first entry)
XX ICAM-1 targeted antisense peptide nucleic acid SEQ ID NO: 44.
XX Peptide nucleic acid; PNA; cytostatic; virucide; dermatological;
XX antiasthmatic; overexpression; viral infection; vitiligo; antisense;
XX pigmentation disorder; asthma; polyamide backbone; ss.
XX Unidentified.
XX Key Location/Qualifiers
XX modified_base 1..19

```

PT /*tag= a
 FT /note= "This sequence is a peptide nucleic acid, i.e. it
 FT contains a polyamide backbone instead of a deoxyribose
 FT backbone"
 FT 1
 FT /mod_base= OTHER
 FT /note= "linked to one of the peptides shown in ABB04517
 FT and ABB04518 to form a PNA-peptide conjugate"
 FT 1
 PN WO200179216-A2.
 XX 25-OCT-2001.
 PD 07-APR-2001; 2001WO-EP004030.
 XX 18-APR-2000; 2000DE-01019135.
 XX (AVET) AVENTIS PHARMA DEUT GMBH.
 PA Uhlmann E, Breipohl G, Will DW;
 PI WPI; 2002-075055/10.
 DR New peptide nucleic acid derivatives, useful e.g. for tumor treatment and
 PT diagnosis, contain terminal, deprotonizable phosphoryl groups for e.g.
 PT improved solubility.
 PT
 XX Disclosure; Page 22; 93pp; German.
 PS
 XX The present invention relates to peptide nucleic acid (PNA) derivatives
 CC having at the C- and optionally N-, terminus one or more phosphoryl
 CC groups, at least one of which contains one or more deprotonisable groups,
 CC preferably hydroxy or mercapto. These PNAs are useful in the treatment of
 CC tumours or any disease associated with (over)expression of particular
 CC genes, including viral infections, vitiligo or other pigmentation
 CC disorders, and asthma. The present sequence is a peptide nucleic acid
 CC described in the exemplification of the invention
 XX
 SQ Sequence 19 BP; 4 A; 4 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 51 CCTCGCTATGGCTCCGAGC 69
 DB 19 CCTCGCTATGGCTCCGAGC 1
 RESULT 1642
 ABK09295/C
 ID ABK09295 standard; DNA; 19 BP.
 XX
 AC ABK09295;
 XX
 DT 30-DEC-2002 (first entry)
 XX
 DE Intercellular adhesion molecule, ICAM-R PCR probe Icam1-3.
 XX
 KW Human; intercellular adhesion molecule; ICAM; antiinflammatory; stroke;
 KW antibacterial; vulnery; vasotropic; nephrotropic; antiarthritis;
 KW cerebroprotective; dermatological; antileuk; immunosuppressive; tumour;
 KW antipsoriatic; antiarteriosclerotic; neuroprotective; antithyroid; asthma;
 KW virucide; antineumatic; antidiabetic; antiasthmatic; cytostatic; trauma;
 KW hybridoma cell line; ATCC HB 12190; inflammation; septicaemia; trauma;
 KW adult respiratory distress syndrome; multiple organ injury syndrome;
 KW tissue reperfusion injury; acute glomerulonephritis; arthritis; vaccine;
 KW dermatosis; thermal injury; haemodialysis; PCR primer; psoriasis;
 KW Crohn's disease; ulcerative colitis; multiple sclerosis; infection; ss.
 OS Homo sapiens.
 XX

PN US2001029293-A1.
 XX 11-OCT-2001.
 PD 03-JAN-2001; 2001US-00753436.
 PF
 XX 27-JAN-1992; 92US-00827699.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 07-JUN-1995; 95US-00487113.
 PR 24-AUG-1999; 99US-00382289.
 XX (ICOS-) ICOS CORP.
 XX Gallatin WM, Vazeux R;
 PI WPI; 2002-009992/01.
 DR
 XX Novel hybridoma cell line useful for producing monoclonal antibody for
 PT treating inflammatory conditions, immune system disorders and infectious
 PT diseases, is deposited under specified ATCC accession number.
 PT
 XX Page 8; Example 4; 126pp; English.
 PS
 XX The invention relates to a novel hybridoma cell line (I) ATCC HB 12190.
 CC (I) is useful for producing an intercellular adhesion molecule (ICAM)
 CC monoclonal antibody (II). (II) is useful for treating inflammatory
 CC conditions including adult respiratory distress syndrome, multiple organ
 CC injury syndrome secondary to septicemia or trauma, tissue reperfusion
 CC injury, acute glomerulonephritis, reactive arthritis, dermatosis with
 CC acute inflammatory components, stroke, thermal injury, haemodialysis,
 CC leukophereis, ulcerative colitis, Crohn's disease, necrotising
 CC enterocolitis, granulocyte transfusion associated syndrome, diabetes,
 CC atherosclerosis, cytokine-induced toxicity, psoriasis, organ/tissue
 CC transplant rejection, autoimmune diseases including Raynaud's syndrome,
 CC autoimmune thyroiditis, multiple sclerosis, rheumatoid arthritis, lupus
 CC erythematosus, asthma, tumour growth and/or metastasis, viral infection,
 CC tissue transplant rejection, graft versus host disease and multiple
 CC sclerosis. (II) is also useful for immunisation, for purifying ICAM-R
 CC polypeptides and for identifying cells that display the polypeptides on
 CC their surfaces. AAS09279-AAS09380 represent ICAM coding sequences, PCR
 CC primers and related sequences of the invention
 XX
 SQ Sequence 19 BP; 5 A; 3 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 591 TCACCATGGAGGCAATTC 609
 DB 19 TCACCATGGAGGCAATTC 1
 RESULT 1643
 ABA97493/C
 ID ABA97493 standard; DNA; 19 BP.
 XX
 AC ABA97493;
 XX
 DT 16-APR-2002 (first entry)
 XX
 DE ICAM-1 targeted antisense peptide nucleic acid SEQ ID NO: 39.
 KW Peptide nucleic acid; PNA; polyamide backbone; phosphoryl radical;
 KW cytostatic; virucide; dermatological; antiasthmatic; cancer; antisense;
 KW viral infection; vitiligo; pigmentation disorder; asthma; ss.
 XX Unidentified.
 OS Synthetic.

XX WO200179249-A2.
 XX
 XX 25-OCT-2001.
 XX
 XX 07-APR-2001; 2001WO-EP004027.
 XX
 XX 18-APR-2000; 2000DE-01019136.
 XX
 XX (AVET) AVENTIS PHARMA DEUT GMBH.
 XX
 XX Uhlmann E, Breipohl G, Will DW;
 XX
 XX WPI; 2002-089643/12.
 XX
 XX New peptide nucleic acid derivatives, useful e.g. for treating tumors and
 PT diagnosis, have N-terminal phosphoryl residue for improving e.g.
 PT solubility in water.
 PT
 XX Disclosure; Page 88; 96pp; German.
 XX
 XX The present invention relates to peptide nucleic acid (PNA) derivatives.
 CC These can be used in the treatment of cancer, viral infections, vitiligo
 CC or other pigmentation disorders, and asthma. The present sequence is an
 CC oligonucleotide fragment of a PNA described in the exemplification of the
 CC invention
 CC
 XX Sequence 19 BP; 4 A; 4 C; 9 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 51 CCTCGCTATGGCTCCAGC 69
 DB 19 CCTCGCTATGGCTCCAGC 1
 RESULT 1644
 AAL46757/c
 ID AAL46757 standard; DNA; 19 BP.
 XX
 XX AAL46757;
 XX
 DT 08-AUG-2002 (first entry)
 XX
 DE ICAM antisense oligonucleotide #3.
 XX
 XX Modified antisense oligonucleotide; antisense; HIV; cancer; infection;
 KW cytostatic; virucide; anti-HIV; hepatotropic; antiinflammatory;
 KW phosphorothioate backbone; integrin; cell-cell adhesion receptor; ss.
 XX
 OS Unidentified.
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..2
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "optionally phosphorothioate backbone"
 FT modified_base 9
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "optionally phosphorothioate backbone"
 FT modified_base 11..12
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "optionally phosphorothioate backbone"
 FT modified_base 14..15
 FT /tag= d
 FT /mod_base= OTHER
 FT /note= "optionally phosphorothioate backbone"
 FT modified_base 17..18
 FT /tag= e

ET
 FT
 XX /mod_base= OTHER
 PN /note= "optionally phosphorothioate backbone"
 XX
 XX EP1182206-A2.
 XX
 XX 27-FEB-2002.
 XX
 XX 07-NOV-1994; 2001EP-00124078.
 XX
 XX 12-NOV-1993; 93DE-04338704.
 PR 07-NOV-1994; 94EP-00117513.
 XX
 XX (FARH) HOECHST AG.
 XX
 XX Peymann A, Uhlmann E, Mag M, Kretschmar G, Helsberg M, Winkler I;
 PI WPI; 2002-353922/39.
 XX
 XX New nuclease-resistant oligonucleotides having modified non-terminal
 PT pyrimidine nucleoside(s), useful e.g. for treating cancer or viral
 PT diseases or as diagnostic reagents.
 PT
 XX Disclosure; Page 13; 19pp; German.
 XX
 XX The present invention relates to oligonucleotides having at least one non
 CC -terminal pyrimidine nucleoside modified and additionally having the 5'-
 CC and/or 3'-terminal modified. These can be used in the treatment of viral
 CC infections, such as HIV, HSV-1, HSV-2, Influenza virus, VSV, hepatitis B
 CC and papilloma viruses, cancer and diseases involving integrins and cell-
 CC cell adhesion receptors. The present sequence is an antisense
 CC oligonucleotide of the invention
 XX
 XX Sequence 19 BP; 4 A; 4 C; 9 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 OY 51 CCTCGCTATGGCTCCAGC 69
 DB 19 CCTCGCTATGGCTCCAGC 1
 RESULT 1645
 AAD52577/c
 ID AAD52577 standard; DNA; 19 BP.
 XX
 XX AAD52577;
 XX
 DT 14-MAY-2003 (first entry)
 XX
 DE Intercellular adhesion molecule-1 (ICAM-1) antisense oligonucleotide.
 XX
 XX Antisense; infection; inflammation; research reagent; phosphorothioate;
 KW tumour; intercellular adhesion molecule-1; ICAM-1; ss.
 XX
 OS Unidentified.
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..19
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone"
 XX
 XX WO200292616-A1.
 XX
 XX 21-NOV-2002.
 XX
 XX 13-MAY-2002; 2002WO-US015166.
 XX
 XX 11-MAY-2001; 2001US-0290436P.
 XX
 XX (ORAS-) ORASENSE LTD.

XX Bibby DC, Raoof AB, Gudipati M, Reingold SW;
 XX WPI; 2003-129260/12.
 XX Composition useful for the treatment of e.g. tumor comprises an antisense
 XX compound and a permeation enhancer.
 XX Example 4; Page 44; 46pp; English.
 XX The invention relates to a composition which comprises an antisense
 XX compound, a permeation enhancer and optionally a vehicle. The invention
 XX is useful for treating a condition that can be treated by modulating the
 XX expression of a protein e.g. to prevent or delay infection, inflammation
 XX and tumour formation; and also used in diagnostics, kits and as research
 XX reagents. The present sequence is an antisense oligonucleotide targeted
 XX to intercellular adhesion molecule-1 (ICAM-1). This oligo is used in the
 XX exemplification of the invention
 XX Sequence 19 BP; 2 A; 13 C; 0 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1938 GAGAGGGGGAAGTGGTGGG 1956
 DB 19 GAGAGGGGGAAGTGGTGGG 1
 RESULT 1646
 ACD67155/c
 ID ACD67155 standard; DNA; 19 BP.
 AC ACD67155;
 XX 17-SEP-2003 (first entry)
 DT Derivatized oligonucleotide oligomer 4.
 DE ICAM-1; intracellular cell adhesion molecule-1; antisense; ss;
 KW improved transfer; improved uptake; steroid/reporter molecule; porphyrin;
 KW non-aromatic lipophilic molecule; reporter enzyme; metal chelator;
 KW water/lipid soluble vitamin; RNA cleaving complex; alkylator;
 KW hybrid photo-nuclease/intercalator; aryl azide photo-crosslinking agent.
 XX Synthetic.
 OS US2002177150-A1.
 XX 28-NOV-2002.
 PD 11-FEB-2002; 2002US-00073718.
 PF 23-OCT-1992; 92WO-US009196.
 PR 15-DEC-1998; 98US-00211882.
 PR 07-AUG-2000; 2000US-00633659.
 XX (ISIS-) ISIS PHARM INC.
 PA Manoharan M, Cook PD, Bennett CF;
 PI WPI; 2003-521529/49.
 XX New derivatized oligonucleotide, useful for effecting cellular uptake,
 XX comprises several linked nucleosides bearing a substituent such as
 XX steroid/reporter molecule, reporter enzyme or peptide.
 XX Example 4; Page 7; 23pp; English.
 PS The invention relates to a derivatized oligonucleotide comprising several
 XX linked nucleosides having a functionalised nucleoside bearing a
 XX substituent such as steroid/reporter molecule, non-aromatic lipophilic

CC molecule, reporter enzyme, peptide, protein, water/lipid soluble vitamin,
 CC RNA cleaving complex, metal chelator, porphyrin, alkylator, hybrid photo-
 CC nuclease/intercalator or aryl azide photo-crosslinking agent. The
 CC oligonucleotide is useful for effecting cellular uptake of the
 CC oligonucleotide by contacting an organism with the oligonucleotide. The
 CC oligonucleotide is useful in research and diagnostic methods, for
 CC assaying bodily states in animals, especially disease states, or for
 CC treatment of diseases through modulation of the activity of DNA or RNA.
 CC The oligonucleotide has improved transfer across cellular membranes and
 CC uptake properties. The effect of conjugation of an oligonucleotide with
 CC folic acid was determined by the inhibition of intercellular cell
 CC adhesion molecule-1 (ICAM-1). The present sequence represents a
 CC derivatized oligonucleotide oligomer
 XX Sequence 19 BP; 4 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 49 AGCCTGCTATGGCTCCCA 67
 DB 19 AGCCTGCTATGGCTCCCA 1
 RESULT 1647
 ACC85090/c
 ID ACC85090 standard; DNA; 19 BP.
 XX ACC85090;
 XX 13-OCT-2003 (first entry)
 DT Human ICAM-1 cDNA amplifying antisense primer.
 DE Bactericidal permeability increasing protein; antibacterial; lipoxin;
 KW immunosuppressive; antimicrobial; BPI; ICAM-1; PCR; primer; ss.
 XX Homo sapiens.
 OS WO2003051350-A1.
 PN 26-JUN-2003.
 PD 18-DEC-2002; 2002WO-US040620.
 PF 18-DEC-2001; 2001US-0342138P.
 PR 18-DEC-2002; 2002US-00323591.
 XX (BGHM) BRIGHAM & WOMENS HOSPITAL.
 PA Serhan CN, Colgan SP;
 PI WPI; 2003-598092/56.
 DR Stimulating bactericidal permeability increasing protein in subject's
 XX tissue for inhibiting or preventing infection or invasion by bacteria in
 XX a subject, by administering lipoxin or lipoxin analog.
 PS Example; Page 78; 161pp; English.
 XX The invention relates to stimulating bactericidal permeability increasing
 XX protein (BPI) in a subject's tissue. The method involves administering a
 XX therapeutically effective amount of lipoxin or a lipoxin analogue, such
 XX that the subject's tissue expresses increased levels of BPI to treat
 XX infection. The method is useful for stimulating BPI in a subject's
 XX tissue, preferably mucosal cells e.g. oral epithelial cells or intestinal
 XX cells, and thus for inhibiting or preventing infection or invasion by
 XX bacteria in a subject. The method is useful for treating sepsis and
 XX infectious diseases. Sequences ACC85089-90 represent PCR primers for
 XX amplifying the human ICAM-1 cDNA, used in a transcriptional analysis of
 XX human BPI

CC presence and absence of test compound, detecting the label bound to the
CC immobilised binding partner and identifying a modulating compound as a
CC test compound that affects the label bound in the presence of the test
CC compound in comparison to the label bound in the absence of the test
CC compound) and identification of a compound that modulates phosphorylation
CC of ICAM-R by protein kinase C isoform (involving: exposing ICAM-R peptide
CC comprising amino acids 482-518 of ABG25651 to protein kinase C isoform
CC and labelled phosphate in the presence and absence of a test compound,
CC measuring labelled phosphate transferred to the ICAM-R peptide and
CC identifying a test compound that affects transfer of the labelled
CC phosphate as a modulator compound). The hybridoma cell line ATCC HB 12190
CC is useful in the production of monoclonal antibodies useful for
CC identifying compounds and for the treatment of conditions resulting from
CC a response of the nonspecific immune system in a mammal (e.g. adult
CC respiratory distress syndrome, multiple organ injury syndrome secondary
CC to septicemia, multiple organ injury syndrome secondary to trauma,
CC reperfusion injury of tissue, acute glomerulonephritis, reactive
CC arthritis, dermatosis with acute inflammatory components, stroke, thermal
CC injury, haemodialysis, leukapheresis, ulcerative colitis, Crohn's
CC disease, necrotising enterocolitis, granulocyte transfusion associated
CC syndrome, atherosclerosis and cytokine-induced toxicity) and conditions
CC resulting from a response of the specific immune system in a mammal (e.g.
CC psoriasis, organ/tissue transplant rejection and autoimmune diseases
CC including Raynaud's syndrome, autoimmune thyroiditis, experimental
CC autoimmune encephalomyelitis (EAE), multiple sclerosis, rheumatoid
CC arthritis, diabetes or lupus erythematosus), asthma, tumour growth and/or
CC metastasis and viral infection (e.g. HIV infection). The monoclonal
CC antibodies are readily available using immunogens comprising cells
CC naturally expressing intercellular adhesion molecule polypeptide (ICAM-R)
CC or its variants and display ligand/receptor binding biological activities
CC and/or immunological properties specific to ICAM-R. The present sequence
CC is a primer or probe used in the isolation of nucleic acids encoding
CC human ICAM-R.

XX
SQ Sequence 19 BP; 5 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAAATTC 609
DB 19 TCACCATGGAGCCAAATTC 1

RESULT 1650
ABZ95200/C

ID ABZ95200 standard; DNA; 19 BP.

XX
AC ABZ95200;

XX
DT 17-OCT-2003 (first entry)

XX
DE Human ICAM-1 antisense fragment no.1065.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.

XX
OS Homo sapiens.

XX
PN WO200285308-A2.

XX
PD 31-OCT-2002.

XX
PF 23-APR-2002; 2002WO-US013135.

XX
PR 24-APR-2001; 2001US-0286137P.

XX
PA (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

XX Miller S, Tang L, Shahabuddin S;

DR WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.

XX
XX Disclosure; SEQ ID NO 10442; 872pp; English.

XX The invention relates to a novel pharmacological composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine or
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX
SQ Sequence 19 BP; 0 A; 7 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 475 GGGGCACCCCGGGCCACC 493
DB 19 GGGGCACCCCGGGCCACC 1

RESULT 1651

ADL25033

ID ADL25033 standard; DNA; 19 BP.

XX
AC ADL25033;

XX
DT 20-MAY-2004 (first entry)

XX
DE Intestinal epithelium/peyer's patch M cell-associated PCR primer #178.

XX Intestinal epithelium cell development; peyer's patch M cell development;
KW inflammatory bowel disease; glutenenteropathy; infectious disease;
KW autoimmune disease; haemolytic anaemia; rheumatoid arthritis; dermatitis;
KW Grave's disease; multiple sclerosis; allergy; asthma; diabetic mellitus;
KW immune system disorder; hypersensitivity; anaphylaxis;
KW blood group incompatibility; ss; human; PCR; primer.

XX
OS Homo sapiens.

XX
PN WO200280852-A2.

XX
PD 17-OCT-2002.

XX
PF 04-APR-2002; 2002WO-US010873.

XX
PR 04-APR-2001; 2001US-0281416P.

XX
PA (DIGI-) DIGITAL GENE TECHNOLOGIES INC.

XX PT Brayden DJ, Byrne D, O'mahony DJ, Evans CF, Mah SP, Lo DD;
 XX DR WPI; 2003-075470/07.
 XX XX
 XX Novel isolated or purified polypeptide encoded by genes associated with
 PT intestinal epithelium or M cell development, differentiation or function,
 PT useful for treating autoimmune diseases and infectious diseases.
 XX XX
 XX PS Disclosure; SEQ ID NO 543; 152pp; English.
 XX XX
 CC The invention comprises DNA sequences which are associated with
 CC intestinal epithelium and peyer's patch M cells. The DNA sequences of the
 CC invention are useful for assessing, modifying, modulating or regulating
 CC intestinal epithelium or M cell development. The DNA sequences of the
 CC invention are also useful in the treatment of: inflammatory bowel
 CC disease, glutenenteropathy, rheumatoid arthritis, dermatitis, Grave's
 CC (e.g. haemolytic anaemia, infectious diseases, autoimmune diseases
 CC disease, multiple sclerosis, rheumatoid arthritis, dermatitis, Grave's
 CC diseases or disorders of the immune system, hypersensitivity,
 CC anaphylaxis, and blood group incompatibility. The present DNA sequence
 CC represents a PCR primer that was used to amplify an intestinal
 CC epithelium/peyer's patch M cell-associated DNA sequence of the invention.
 XX XX
 XX Sequence 19 BP; 3 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2766 TGTACCCAGCTGGAGTG 2784
 Db 1 TGTACCCAGCTGGAGTG 19
 |||||
 RESULT 1652
 ABD19142/c
 ID ABD19142 standard; DNA; 19 BP.
 XX AC ABD19142;
 XX XX
 XX 29-JUL-2004 (first entry)
 XX DE Human ICAM-1 DNA fragment 1065.
 XX XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ds.
 XX XX
 XX Homo sapiens.
 XX XX
 XX WO200285309-A2.
 XX XX
 XX 31-OCT-2002.
 XX XX
 XX 23-APR-2002; 2002WO-US013143.
 XX XX
 XX 24-APR-2001; 2001US-0286036P.
 XX XX
 XX (EPIC-) EPIGENESIS PHARM INC.
 XX XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 XX Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to

PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX PS Claim 15; SEQ ID NO 10442; 763pp; English.
 XX XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impaired respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX XX
 XX Sequence 19 BP; 0 A; 7 C; 9 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 475 GGGGCACCCCGGCCAAC 493
 Db 19 GGGGCACCCCGGCCAAC 1
 |||||
 RESULT 1653
 ADJ65124/c
 ID ADJ65124 standard; DNA; 19 BP.
 XX AC ADJ65124;
 XX XX
 XX 20-MAY-2004 (first entry)
 XX XX
 XX Antisense oligonucleotide #1.
 XX XX
 KW Complement activation; 2' sugar modification;
 KW Complement activation inhibition; phosphorothioate modification;
 KW 2'-methoxyethoxy modification; antisense oligonucleotide; Factor H;
 KW inflammation; immune response; compound stability; antiinflammatory; ss.
 XX XX
 XX Synthetic.
 XX XX
 XX US2004038925-A1.
 XX XX
 XX 26-FEB-2004.
 XX XX
 XX 07-AUG-2003; 2003US-00636452.
 XX XX
 XX 30-SEP-1999; 99US-00409816.
 XX 27-FEB-2001; 2001US-00794824.
 XX XX

PA (HENR/) HENRY S.
 XX Henry S;
 XX WPI; 2004-213947/20.
 XX Inhibition of complement activation in human cell, tissue or bodily
 PT fluid, comprises contacting the cell, tissue or bodily fluid with
 PT oligonucleotide comprising 2' sugar modification(s), preferably 2'-
 PT methoxyethoxy modification.
 XX
 XX Disclosure; SEQ ID NO 1; 35pp; English.
 XX
 CC The invention relates to a method of inhibiting complement activation in
 CC a human cell, tissue or bodily fluid, comprising contacting the cell,
 CC tissue or bodily fluid with an oligonucleotide comprising at least one 2'
 CC sugar modification. The invention also relates to a composition
 CC comprising an oligonucleotide and a complement activation inhibitory
 CC molecule, where the oligonucleotide comprises at least one
 CC phosphorothioate modification and at least one 2'-methoxyethoxy
 CC modification. The oligonucleotide has at least one modified
 CC internucleotide linkage, which is a phosphorothioate. The oligonucleotide
 CC is an antisense oligonucleotide. The complement activation inhibitory
 CC molecule is Factor H. The 2' sugar modification is 2'-methoxyethoxy
 CC modification. The method is useful for inhibiting complement activation
 CC (such as inflammation) in a human cell, tissue or bodily fluid, in the
 CC treatment of abnormal and/or undesirable conditions which can arise as a
 CC result of complement activation. The method inhibits and/or modulates
 CC complement mediated immune responses using modified oligonucleotides that
 CC might incorporate modifications of characteristics such as compound
 CC stability and cellular uptake. This sequence represents an antisense
 CC oligonucleotide of the invention.
 XX
 XX Sequence 19 BP; 4 A; 8 C; 4 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTGGG 2118
 DB 19 TGACGGATGCCAGCTGGG 1
 |||||
 RESULT 1654
 ADO22992
 ID ADO22992 standard; DNA; 19 BP.
 XX
 AC ADO22992;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human CD54 gene antisense oligonucleotide.
 XX
 KW Human; ss; SDO; short double stranded oligonucleotide; cleavage site;
 KW viral infection; malignant tumour; genetic disease; metabolic disease;
 KW gene chip; protein chip; microarray; gene drug; Dermogene; Lungene;
 KW Hepatogene; Leukogene; Lymphogene; Prostagene; Breastogene;
 KW Braintumogene; Skin-whitogene; short interfering RNA; siRNA; cancer;
 KW RNA interference; antisense.
 XX
 OS Homo sapiens.
 XX
 XX US2004072769-A1.
 XX
 XX 15-APR-2004.
 XX
 XX 16-SEP-2002; 2002US-00016490.
 XX
 XX 16-SEP-2002; 2002US-00016490.
 XX
 XX (YINJ/) YIN J Q.

PI Yin JQ;
 XX WPI; 2004-355427/33.
 XX
 PT Designing and selecting short double-stranded oligonucleotides for
 PT treating viral infections, cancer and genetic or metabolic diseases,
 PT comprises using gene chip and protein chip microarrays to identify
 PT specific DNA sequences.
 XX
 XX Example 3; Page 22; 58pp; English.
 XX
 CC The invention relates to screening, identifying or predicting, and
 CC assembling 19-25 nt double-stranded oligonucleotides (termed short double
 CC stranded oligonucleotides, SDO) as active pharmaceutical compositions
 CC for the treatment of viral infections, malignant tumours, and genetic and
 CC metabolic diseases, comprising screening and identifying a specific DNA
 CC sequence in an abnormal gene encoding a protein with gene chip and
 CC protein chip microarrays. The above method comprises screening the
 CC disease-causing genes, over-expressing in cells and/or tissues, with the
 CC gene chip and protein chip microarrays, identifying a specific DNA
 CC sequence within the abnormal gene encoding a protein or playing other
 CC biological roles with the assistance of computer and specific software,
 CC predicting efficacious 19-25 nt double-stranded oligonucleotides with a
 CC 5'-AU(T)CCG-3' or 5'-U(T)CCG-3' special pattern complementary to at
 CC least a portion of an RNA molecule and making sure that selected sequence
 CC is not localised within the stem-loop of target mRNA with any related
 CC software. Also included are pharmaceutical compositions of gene drugs
 CC (such as Dermogene, Lungene, Hepatogene, Leukogene, Lymphogene,
 CC Prostagene, Breastogene, Braintumogene and Skin-whitogene including but
 CC being not limited to part or all of the following components: single or a
 CC group of specific 19-25 nt dsRNA, 19-25 nt ssRNA-cDNA, 19-25 nt dsRNA
 CC and/or single-stranded RNA and/or DNA with the special pattern, 5'-
 CC CGCAT(U)-3' or its derivatives, one or more nucleic acid condensation
 CC agents (or none), one or more pharmaceutical carriers, one or more
 CC specific cell-targeting proteins and other active agents and additional
 CC materials) and a simplified method for predicting and selecting a
 CC specific and efficacious small double-stranded oligonucleotides (SDSO),
 CC antisense oligonucleotide molecules or short interfering RNA (siRNA)
 CC (comprising identifying a special pattern that can be localised in any
 CC position of an oligonucleotide sequence evaluating the specificity of a
 CC selected sequence). The short interfering RNA (siRNA) are targeted
 CC against genes involved in viral infection, malignant tumours, genetic and
 CC metabolic diseases. The methods are useful for designing and selecting
 CC short double-stranded oligonucleotides as a gene drug that can
 CC specifically inactivate a group of corresponding genes. The composition
 CC may be used for treating diseases or disorders associated with abnormal
 CC expression of genes in cells or tissues of humans or animals, such as
 CC viral infections, cancer, or genetic or metabolic diseases. The present
 CC sequence is a previously identified efficacious antisense
 CC oligonucleotide.
 XX
 SQ Sequence 19 BP; 4 A; 0 C; 12 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1937 TCAGAGGGGAACTGGTGGG 1955
 DB 1 TCAGAGGGGAACTGGTGGG 19
 |||||
 RESULT 1655
 ADP46421
 ID ADP46421 standard; RNA; 19 BP.
 XX
 AC ADP46421;
 XX
 XX 26-AUG-2004 (first entry)
 XX
 XX siRNA 3 targeted to human intercellular adhesion molecule ICAM-3.
 DE breast cancer; cytostatic; gene therapy; human;
 XX

KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
 KW CD54; cell surface glycoprotein P3.58; chromosome 19p13.3-p13.2; siRNA;
 XX small interfering RNA; ss.
 OS Homo sapiens.
 PN WO2004047623-A2.
 XX 10-JUN-2004.
 XX 25-NOV-2003; 2003WO-US037948.
 XX 25-NOV-2002; 2002US-0429136P.
 PR 24-JUL-2003; 2003US-0490234P.
 XX (SEQU-) SEQUENOM INC.
 PA PA
 XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
 XX WPI; 2004-441051/41.
 DR Identifying a subject at risk of breast cancer by detecting the presence
 XX of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
 XX regions which are associated with breast cancer in a nucleic acid sample
 XX from a subject.
 PS Claim 42; Page 136; 289pp; English.
 XX The invention relates to a novel method for identifying a subject at risk
 CC of breast cancer comprising detecting the presence or absence of one or
 CC more polymorphic variations associated with breast cancer in a nucleic
 CC acid sample from a subject. The method of the invention has cytostatic
 CC applications and may be useful for identifying a subject at risk of
 CC breast cancer, for early diagnosis, prevention and treatment of breast
 CC cancer, possibly via gene therapy, as well as to analyse and predict a
 CC response to a breast cancer treatment and in clinical drug trials. The
 CC current sequence is that of an siRNA (small interfering RNA) targeted to
 CC human intercellular adhesion molecule ICAM-1 of the invention. ICAM-1
 CC (human rhinovirus receptor;BB2;CD54;cell surface glycoprotein P3.58) has
 CC been mapped to chromosomal position 19p13.3-p13.2.
 XX Sequence 19 BP; 6 A; 5 C; 4 G; 0 T; 4 U; 0 Other;
 SQ Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 78.9%; Pred. No. 7.3e+02;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 OY 589 GATCACCATGGAGCCCAATT 607
 DB 1 GAUCACCAUGGAGCCCAUU 19
 ||:||||:|||||||:
 ||:||||:|||||||:
 RESULT 1656
 ADP46419
 ID ADP46419 standard; RNA; 19 BP.
 XX ADP46419;
 AC ADP46419;
 XX 26-AUG-2004 (first entry)
 DT siRNA 1 targeted to human intercellular adhesion molecule ICAM-1.
 DE breast cancer; cytostatic; gene therapy; human;
 XX intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
 KW CD54; cell surface glycoprotein P3.58; chromosome 19p13.3-p13.2; siRNA;
 KW small interfering RNA; ss.
 XX Homo sapiens.
 OS WO2004047623-A2.
 PN 10-JUN-2004.
 XX 25-NOV-2003; 2003WO-US037948.
 XX 25-NOV-2002; 2002US-0429136P.
 PR 24-JUL-2003; 2003US-0490234P.
 XX (SEQU-) SEQUENOM INC.
 PA PA
 XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
 XX WPI; 2004-441051/41.

PF 25-NOV-2003; 2003WO-US037948.
 XX 25-NOV-2002; 2002US-0429136P.
 PR 24-JUL-2003; 2003US-0490234P.
 XX (SEQU-) SEQUENOM INC.
 XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
 XX WPI; 2004-441051/41.
 DR Identifying a subject at risk of breast cancer by detecting the presence
 XX of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
 XX regions which are associated with breast cancer in a nucleic acid sample
 XX from a subject.
 PS Claim 42; Page 136; 289pp; English.
 XX The invention relates to a novel method for identifying a subject at risk
 CC of breast cancer comprising detecting the presence or absence of one or
 CC more polymorphic variations associated with breast cancer in a nucleic
 CC acid sample from a subject. The method of the invention has cytostatic
 CC applications and may be useful for identifying a subject at risk of
 CC breast cancer, for early diagnosis, prevention and treatment of breast
 CC cancer, possibly via gene therapy, as well as to analyse and predict a
 CC response to a breast cancer treatment and in clinical drug trials. The
 CC current sequence is that of an siRNA (small interfering RNA) targeted to
 CC human intercellular adhesion molecule ICAM-1 of the invention. ICAM-1
 CC (human rhinovirus receptor;BB2;CD54;cell surface glycoprotein P3.58) has
 CC been mapped to chromosomal position 19p13.3-p13.2.
 XX Sequence 19 BP; 7 A; 3 C; 6 G; 0 T; 3 U; 0 Other;
 SQ Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 7.3e+02;
 Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 OY 278 ACAACCGGAGGTGTATGA 296
 DB 1 ACAACCGGAGGUGUAUGA 19
 ||:|||||||:
 ||:|||||||:
 RESULT 1657
 ADP46420
 ID ADP46420 standard; RNA; 19 BP.
 XX ADP46420;
 AC ADP46420;
 XX 26-AUG-2004 (first entry)
 DT siRNA 2 targeted to human intercellular adhesion molecule ICAM-2.
 DE breast cancer; cytostatic; gene therapy; human;
 XX intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
 KW CD54; cell surface glycoprotein P3.58; chromosome 19p13.3-p13.2; siRNA;
 KW small interfering RNA; ss.
 XX Homo sapiens.
 OS WO2004047623-A2.
 PN 10-JUN-2004.
 XX 25-NOV-2003; 2003WO-US037948.
 XX 25-NOV-2002; 2002US-0429136P.
 PR 24-JUL-2003; 2003US-0490234P.
 XX (SEQU-) SEQUENOM INC.
 PA PA
 XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
 XX WPI; 2004-441051/41.

XX Identifying a subject at risk of breast cancer by detecting the presence
PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
PT regions which are associated with breast cancer in a nucleic acid sample
PT from a subject.
XX
XX Claim 42; Page 136; 289pp; English.
XX
XX The invention relates to a novel method for identifying a subject at risk
CC of breast cancer comprising detecting the presence or absence of one or
CC more polymorphic variations associated with breast cancer in a nucleic
CC acid sample from a subject. The method of the invention has cytostatic
CC applications and may be useful for identifying a subject at risk of
CC breast cancer, for early diagnosis, prevention and treatment of breast
CC cancer, possibly via gene therapy, as well as to analyse and predict a
CC response to a breast cancer treatment and in clinical drug trials. The
CC current sequence is that of an siRNA (small interfering RNA) targeted to
CC human intercellular adhesion molecule ICAM-1 of the invention. ICAM-1
CC (human rhinovirus receptor;BB2;CD54;cell surface glycoprotein P3.58) has
CC been mapped to chromosomal position 19p13.3-p13.2.
XX
XX Sequence 19' BP; 5 A; 6 C; 3 G; 0 T; 5 U; 0 Other;
SQ
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 7.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 320 GCCAACCAATGCTGCTATTC 338
DB 1 GCCAACCAAGUCGUAUUC 19
RESULT 1658
ADP46422
ID ADP46422 standard; RNA; 19 BP.
XX
AC ADP46422;
XX
DT 26-AUG-2004 (first entry)
XX
DE siRNA 4 targeted to human intercellular adhesion molecule ICAM-4.
XX
XX breast cancer; cytostatic; gene therapy; human;
KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
KW CD54; cell surface glycoprotein P3.58; chromosome 19p13.3-p13.2; siRNA;
KW small interfering RNA; ss.
XX
XX Homo sapiens.
XX
XX WO2004047623-A2.
XX
XX 10-JUN-2004.
XX
XX 25-NOV-2003; 2003WO-US037948.
XX
XX 25-NOV-2002; 2002US-0429136P.
XX
XX 24-JUL-2003; 2003US-0490234P.
XX
XX (SEQU-) SEQUENOM INC.
XX
XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
PI WPI; 2004-441051/41.
XX
XX Identifying a subject at risk of breast cancer by detecting the presence
PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
PT regions which are associated with breast cancer in a nucleic acid sample
PT from a subject.
XX
XX Claim 42; Page 136; 289pp; English.
XX
XX The invention relates to a novel method for identifying a subject at risk
CC of breast cancer comprising detecting the presence or absence of one or

CC more polymorphic variations associated with breast cancer in a nucleic
CC acid sample from a subject. The method of the invention has cytostatic
CC applications and may be useful for identifying a subject at risk of
CC breast cancer, for early diagnosis, prevention and treatment of breast
CC cancer, possibly via gene therapy, as well as to analyse and predict a
CC response to a breast cancer treatment and in clinical drug trials. The
CC current sequence is that of an siRNA (small interfering RNA) targeted to
CC human intercellular adhesion molecule ICAM-1 of the invention. ICAM-1
CC (human rhinovirus receptor;BB2;CD54;cell surface glycoprotein P3.58) has
CC been mapped to chromosomal position 19p13.3-p13.2.
XX
XX Sequence 19 BP; 4 A; 5 C; 4 G; 0 T; 6 U; 0 Other;
SQ
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 7.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
QY 1394 CTGTACTCTGAGATCTTGA 1412
DB 1 CUGUCACUCGAGAUUCUGA 19
RESULT 1659
ADP45848/C
ID ADP45848 standard; DNA; 19 BP.
XX
AC ADP45848;
XX
DT 26-AUG-2004 (first entry)
XX
DE Extend primer 40 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.
XX
XX breast cancer; cytostatic; gene therapy; human;
KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
KW CD54; cell surface glycoprotein P3.58; ICAM-4;
KW Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
KW ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
XX
XX Homo sapiens.
XX
XX WO2004047623-A2.
XX
XX 10-JUN-2004.
XX
XX 25-NOV-2003; 2003WO-US037948.
XX
XX 25-NOV-2002; 2002US-0429136P.
XX
XX 24-JUL-2003; 2003US-0490234P.
XX
XX (SEQU-) SEQUENOM INC.
XX
XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
PI WPI; 2004-441051/41.
XX
XX Identifying a subject at risk of breast cancer by detecting the presence
PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
PT regions which are associated with breast cancer in a nucleic acid sample
PT from a subject.
XX
XX Example 4; Page 83; 289pp; English.
XX
XX The invention relates to a novel method for identifying a subject at risk
CC of breast cancer comprising detecting the presence or absence of one or
CC more polymorphic variations associated with breast cancer in a nucleic
CC acid sample from a subject. The method of the invention has cytostatic
CC applications and may be useful for identifying a subject at risk of
CC breast cancer, for early diagnosis, prevention and treatment of breast
CC cancer, possibly via gene therapy, as well as to analyse and predict a
CC response to a breast cancer treatment and in clinical drug trials. The
CC current sequence is that of an Extend primer (also described as probe) of
CC the invention which was used to genotype human intercellular adhesion
CC molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor;BB2

CC : CD54; cell surface glycoprotein P3 58) has been mapped to chromosomal
 CC position 19p13.3-p13.2, ICAM-4 (Landsteiner-Wiener blood group; LW) has
 CC been mapped to chromosomal position 19p13.2-cen and ICAM-5
 CC (telencephalin) has been mapped to chromosomal position 19p13.2.
 SQ Sequence 19 BP; 4 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02; Indels 0; Gaps 0;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2826 GCTCAAGTGCATCTCCAC 2844
 |||||
 Db 19 GCTCAAGTGCATCTCCAC 1
 RESULT 1660
 ADQ82757
 ID ADQ82757 standard; DNA; 19 BP.
 XX AC ADQ82757;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 9.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 DR WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 9; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, anglogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung

CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 19 BP; 5 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02; Indels 0; Gaps 0;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 282 CCGAAGGTGTATGAAC TG 300
 |||||
 Db 1 CCGAAGGTGTATGAAC TG 19
 RESULT 1661
 ADQ82764
 ID ADQ82764 standard; DNA; 19 BP.
 XX AC ADQ82764;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 16.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 DR WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 16; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, anglogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung

CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC cornel/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, stroke, tumor
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 19 BP; 2 A; 4 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 532 CGGAGCCAGCTGTGGGG 550
 DB 1 CGGAGCCAGCTGTGGGG 19

RESULT 1662

ID ADQ82758
 XX ADQ82758 standard; DNA; 19 BP.
 AC ADQ82758;
 XX
 XX 21-OCT-2004 (first entry)
 XX Human ICAM-1 oligonucleotide, SEQ ID 10.

XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 XX Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 XX Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 XX Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 XX Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 XX Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 XX intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 XX cell adhesion; human; ss.

XX Homo sapiens.

OS WO2004065546-A2.

PN 05-AUG-2004.

PD 16-JAN-2004; 2004WO-US001166.

PF 16-JAN-2003; 2003US-0440579P.

PR (UYPE-) UNIV PENNSYLVANIA.

PA Reich SJ, Tolentino MJ;

PI WPI; 2004-580723/56.

DR
 XX

PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.

XX Disclosure; SEQ ID NO 10; 71pp; English.

XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC cornel/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, stroke, tumor
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.

XX Sequence 19 BP; 7 A; 3 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 7.3e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 298 CTGAGCAATGTGCAAGAG 316

DB 1 CTGAGCAATGTGCAAGAG 19

RESULT 1663

ADQ82763

ID ADQ82763 standard; DNA; 19 BP.

AC ADQ82763;

XX 21-OCT-2004 (first entry)

XX Human ICAM-1 oligonucleotide, SEQ ID 15.

XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 XX Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 XX Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 XX Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 XX Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 XX Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 XX intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 XX cell adhesion; human; ss.

OS Homo sapiens.

XX WO2004065546-A2.

PN 05-AUG-2004.

XX 16-JAN-2004; 2004WO-US001166.
 PF Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 XX Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 PR Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 XX cell adhesion; human; ss.
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX Disclosure; SEQ ID NO 15; 71pp; English.
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angioneurosis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel diseases, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, stroke, tumor
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX Sequence 19 BP; 1 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 492 CCTCACCGGTGCTGCTC 510
 Db 1 CCTCACCGGTGCTGCTC 19
 RESULT 1664
 ID ADQ82751
 XX ADQ82751 standard; DNA; 19 BP.
 AC ADQ82751;
 XX 21-OCT-2004 (first entry)
 DT Human ICAM-1 oligonucleotide, SEQ ID 3.
 DE Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 XX Antiangiogenic; Antiaesthetic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;

KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 XX cell adhesion; human; ss.
 OS Homo sapiens.
 XX WO2004065546-A2.
 PN 05-AUG-2004.
 PD 16-JAN-2004; 2004WO-US001166.
 XX 16-JAN-2003; 2003US-0440579P.
 PR (UYPE-) UNIV PENNSYLVANIA.
 XX Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX Disclosure; SEQ ID NO 3; 71pp; English.
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angioneurosis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel diseases, inflammatory skin
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, stroke, tumor
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX Sequence 19 BP; 4 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 225 GTTGTGGCATAGAGACC 243
 Db 1 GTTGTGGCATAGAGACC 19
 RESULT 1665
 ADQ82766

ID ADQ82766 standard; DNA; 19 BP.
XX AC ADQ82766;
XX DT 21-OCT-2004 (first entry)
XX DE Human ICAM-1 oligonucleotide, SEQ ID 18.
XX
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.
XX
XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX PF
XX 16-JAN-2003; 2003US-0440579P.
XX PR
XX (UYPE-) UNIV PENNSYLVANIA.
XX PA
XX Reich SJ, Tolentino MJ;
XX PI
XX WPI; 2004-580723/56.
XX DR
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 18; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX
XX Sequence 19 BP; 3 A; 8 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.3e-02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 625 CTGGACCTGGGCCCCAAG 643
DB 1 CTGGACCTGGGCCCCAAG 19

RESULT 1666
ADQ82760
ID ADQ82760 standard; DNA; 19 BP.
XX AC ADQ82760;
XX DT 21-OCT-2004 (first entry)
XX DE Human ICAM-1 oligonucleotide, SEQ ID 12.
XX
XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.
XX
XX Homo sapiens.
XX WO2004065546-A2.
XX
XX 05-AUG-2004.
XX
XX 16-JAN-2004; 2004WO-US001166.
XX PF
XX 16-JAN-2003; 2003US-0440579P.
XX PR
XX (UYPE-) UNIV PENNSYLVANIA.
XX PA
XX Reich SJ, Tolentino MJ;
XX PI
XX WPI; 2004-580723/56.
XX DR
XX Novel isolated small interfering RNA comprising sense RNA strand having
PT sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as
PT cancer.
XX
XX Disclosure; SEQ ID NO 12; 71pp; English.
XX
XX The present invention relates to novel small interfering RNAs (siRNAs)
CC comprising sense and antisense RNA strands forming a RNA duplex, where
CC the sense RNA strand comprises nucleotide sequence substantially
CC identical to a target sequence of 19-25 contiguous nucleotides in human
CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
CC interactions. The siRNAs of the invention specifically target and cause
CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
CC corneal/limbic injury, type I diabetes, complications arising from type I
CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
CC diseases, inflammatory sequelae of viral infections, inflammatory skin
CC disorders, allograft rejection, immune cell interactions such as T-cell
CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
CC metastasis and uveitis. The siRNAs are also useful for treating an
CC angiogenic disease such as cancer, diabetic retinopathy age-related
CC macular degeneration, preferably age-related macular degeneration. The
CC siRNAs are also useful for treating complications arising from type I
CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
CC nephropathy and macrovascular disease. The macrovascular disease is
CC coronary artery disease, cerebrovascular disease or peripheral vascular
CC disease. The present oligonucleotide is a ICAM-1 target sequence from
CC which the siRNAs of the invention can be derived.
XX
XX Sequence 19 BP; 3 A; 8 C; 6 G; 2 T; 0 U; 0 Other;

CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 19 BP; 2 A; 8 C; 3 G; 6 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 371 CCTTCTCACCCTGTTACTG 389
 DB 1 CCTTCTCACCCTGTTACTG 19
 RESULT 1667
 ADQ82762
 ID ADQ82762 standard; DNA; 19 BP.
 AC ADQ82762;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 14.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 DR WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 14; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,

CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from
 CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 19 BP; 3 A; 9 C; 3 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 447 CCTTACCTACGCTGCCAG 465
 DB 1 CCTTACCTACGCTGCCAG 19
 RESULT 1668
 ADQ82761
 ID ADQ82761 standard; DNA; 19 BP.
 XX
 AC ADQ82761;
 XX
 DT 21-OCT-2004 (first entry)
 XX
 DE Human ICAM-1 oligonucleotide, SEQ ID 13.
 XX
 KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX
 DR WPI; 2004-580723/56.
 XX
 PT Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 13; 71pp; English.
 XX

CC The present invention relates to novel small interfering RNAs (siRNAs) comprising sense and antisense RNA strands forming a RNA duplex, where the sense RNA strand comprises nucleotide sequence substantially identical to a target sequence of 19-25 contiguous nucleotides in human or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix interactions. The siRNAs of the invention specifically target and cause RNA-interference induced degradation of mRNA from ICAM-1 genes thus leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful for inhibiting cell adhesion or cell adhesion-mediated pathologies such as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic nephritis, immune-based nephritis, contact dermal hypersensitivity, corneal/limbic injury, type I diabetes, complications arising from type I diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung diseases, inflammatory sequelae of viral infections, inflammatory skin disorders, allograft rejection, immune cell interactions such as T-cell killing, mixed lymphocyte reaction, T-cell mediated B-cell differentiation, meningitis, multiple sclerosis, multiple myeloma, myocarditis, pulmonary fibrosis, reperfusion injury, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour metastasis and uveitis. The siRNAs are also useful for treating an angiogenic disease such as cancer, diabetic retinopathy age-related macular degeneration, preferably age-related macular degeneration. The siRNAs are also useful for treating complications arising from type I diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy and macrovascular disease. The macrovascular disease is coronary artery disease, cerebrovascular disease or peripheral vascular disease. The present oligonucleotide is a ICAM-1 target sequence from which the siRNAs of the invention can be derived.

XX
SQ Sequence 19 BP; 3 A; 7 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 400 CGGGTGGAACTGGCACCCC 418
|||||

Db 1 CGGGTGGAACTGGCACCCC 19

RESULT 1669

ADQ82756

ID ADQ82756 standard; DNA; 19 BP.

XX

AC ADQ82756;

XX

DT 21-OCT-2004 (first entry)

XX

DE Human ICAM-1 oligonucleotide, SEQ ID 8.

XX

KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiaesthetic; Antiartherosclerotic; Dermatological;
KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.

XX Homo sapiens.

XX

PN WO2004065546-A2.

XX

PD 05-AUG-2004.

XX

PF 16-JAN-2004; 2004WO-US001166.

XX

PR 16-JAN-2003; 2003US-0440579P.

XX

PA (TYPE-) UNIV PENNSYLVANIA.

XX

PI Reich SJ, Tolentino MJ;

XX

DR WPI; 2004-580723/56.

XX

PT Novel isolated small interfering RNA comprising sense RNA strand having sequence identical to human intracellular adhesion molecule mRNA, and
PT antisense RNA strand, useful for treating angiogenic diseases such as cancer.

XX

PS Disclosure; SEQ ID NO 8; 71pp; English.

XX

CC The present invention relates to novel small interfering RNAs (siRNAs) comprising sense and antisense RNA strands forming a RNA duplex, where the sense RNA strand comprises nucleotide sequence substantially identical to a target sequence of 19-25 contiguous nucleotides in human or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix interactions. The siRNAs of the invention specifically target and cause RNA-interference induced degradation of mRNA from ICAM-1 genes thus leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful for inhibiting cell adhesion or cell adhesion-mediated pathologies such as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic nephritis, immune-based nephritis, contact dermal hypersensitivity, corneal/limbic injury, type I diabetes, complications arising from type I diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung diseases, inflammatory sequelae of viral infections, inflammatory skin disorders, allograft rejection, immune cell interactions such as T-cell killing, mixed lymphocyte reaction, T-cell mediated B-cell differentiation, meningitis, multiple sclerosis, multiple myeloma, myocarditis, pulmonary fibrosis, reperfusion injury, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour metastasis and uveitis. The siRNAs are also useful for treating an angiogenic disease such as cancer, diabetic retinopathy age-related macular degeneration, preferably age-related macular degeneration. The siRNAs are also useful for treating complications arising from type I diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy and macrovascular disease. The macrovascular disease is coronary artery disease, cerebrovascular disease or peripheral vascular disease. The present oligonucleotide is a ICAM-1 target sequence from which the siRNAs of the invention can be derived.

XX Sequence 19 BP; 1 A; 5 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 7.3e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 258 GGAGTTGCTCCTGCTGGG 276
|||||

Db 1 GGAGTTGCTCCTGCTGGG 19

RESULT 1670

ADQ82759

ID ADQ82759 standard; DNA; 19 BP.

XX

AC ADQ82759;

XX

DT 21-OCT-2004 (first entry)

XX

DE Human ICAM-1 oligonucleotide, SEQ ID 11.

XX

KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
KW Antiangiogenic; Antiaesthetic; Antiartherosclerotic; Dermatological;
KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
KW Intracellular adhesion molecule-1; ICAM-1; RNA-interference;
KW cell adhesion; human; ss.

XX Homo sapiens.

OS


```
XX PN WO2004065546-A2.
XX PD 05-AUG-2004.
XX PF 16-JAN-2004; 2004WO-US001166.
XX PR 16-JAN-2003; 2003US-0440579P.
XX PA (UYPE-) UNIV PENNSYLVANIA.
XX PI Reich SJ, Tolentino MJ;
XX PN WPI; 2004-580723/56.
XX DR
XX PT Novel isolated small interfering RNA comprising sense RNA strand having
XX PF sequence identical to human intracellular adhesion molecule mRNA, and
XX PT antisense RNA strand, useful for treating angiogenic diseases such as
XX PT cancer.
XX PS Disclosure; SEQ ID NO 11; 71pp; English.
XX CC
XX CC The present invention relates to novel small interfering RNAs (siRNAs)
XX CC comprising sense and antisense RNA strands forming a RNA duplex, where
XX CC the sense RNA strand comprises nucleotide sequence substantially
XX CC identical to a target sequence of 19-25 contiguous nucleotides in human
XX CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
XX CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
XX CC interactions. The siRNAs of the invention specifically target and cause
XX CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
XX CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
XX CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
XX CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
XX CC Alzheimer's disease, angogenesis, asthma, atherosclerosis, toxic
XX CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
XX CC corneal/limbic injury, type I diabetes, complications arising from type I
XX CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory skin
XX CC diseases, inflammatory sequelae of viral infections, inflammatory lung
XX CC disorders, allograft rejection, immune cell interactions such as T-cell
XX CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
XX CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
XX CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
XX CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
XX CC metastasis and uveitis. The siRNAs are also useful for treating an
XX CC angiogenic disease such as cancer, diabetic retinopathy age-related
XX CC macular degeneration, preferably age-related macular degeneration. The
XX CC siRNAs are also useful for treating complications arising from type I
XX CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
XX CC nephropathy and macrovascular disease. The macrovascular disease is
XX CC coronary artery disease, cerebrovascular disease or peripheral vascular
XX CC disease. The present oligonucleotide is a ICAM-1 target sequence from
XX CC which the siRNAs of the invention can be derived.
XX SQ Sequence 19 BP; 4 A; 6 C; 3 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 7.3e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 329 TGTGCTATTCAAACTGCC 347
XX Db 1 TGTGCTATTCAAACTGCC 19
XX
XX RESULT 1671
XX ADQ82765
XX ID ADQ82765 standard; DNA; 19 BP.
XX AC ADQ82765;
XX XX
XX XX 21-OCT-2004 (first entry)
XX XX Human ICAM-1 oligonucleotide, SEQ ID 17.
XX DE
```

```
XX KW Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
XX KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
XX KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
XX KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
XX KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
XX KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
XX KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
XX KW cell adhesion; human; ss.
XX OS Homo sapiens.
XX PI WO2004065546-A2.
XX PN
XX XX 05-AUG-2004.
XX PD
XX PF 16-JAN-2004; 2004WO-US001166.
XX PR 16-JAN-2003; 2003US-0440579P.
XX PA (UYPE-) UNIV PENNSYLVANIA.
XX PI Reich SJ, Tolentino MJ;
XX XX WPI; 2004-580723/56.
XX DR
XX PT Novel isolated small interfering RNA comprising sense RNA strand having
XX PF sequence identical to human intracellular adhesion molecule mRNA, and
XX PT antisense RNA strand, useful for treating angiogenic diseases such as
XX PT cancer.
XX PS Disclosure; SEQ ID NO 17; 71pp; English.
XX CC
XX CC The present invention relates to novel small interfering RNAs (siRNAs)
XX CC comprising sense and antisense RNA strands forming a RNA duplex, where
XX CC the sense RNA strand comprises nucleotide sequence substantially
XX CC identical to a target sequence of 19-25 contiguous nucleotides in human
XX CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
XX CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
XX CC interactions. The siRNAs of the invention specifically target and cause
XX CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
XX CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
XX CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
XX CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
XX CC Alzheimer's disease, angogenesis, asthma, atherosclerosis, toxic
XX CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
XX CC corneal/limbic injury, type I diabetes, complications arising from type I
XX CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory skin
XX CC diseases, inflammatory sequelae of viral infections, inflammatory lung
XX CC disorders, allograft rejection, immune cell interactions such as T-cell
XX CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
XX CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
XX CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
XX CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
XX CC metastasis and uveitis. The siRNAs are also useful for treating an
XX CC angiogenic disease such as cancer, diabetic retinopathy age-related
XX CC macular degeneration, preferably age-related macular degeneration. The
XX CC siRNAs are also useful for treating complications arising from type I
XX CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
XX CC nephropathy and macrovascular disease. The macrovascular disease is
XX CC coronary artery disease, cerebrovascular disease or peripheral vascular
XX CC disease. The present oligonucleotide is a ICAM-1 target sequence from
XX CC which the siRNAs of the invention can be derived.
XX SQ Sequence 19 BP; 3 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 19; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 7.3e+02;
XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 606 TTTCTCGTCCGCACTGAA 624
XX Db 1 TTTCTCGTCCGCACTGAA 19
XX
XX RESULT 1671
XX ADQ82765
XX ID ADQ82765 standard; DNA; 19 BP.
XX AC ADQ82765;
XX XX
XX XX 21-OCT-2004 (first entry)
XX XX Human ICAM-1 oligonucleotide, SEQ ID 17.
XX DE
```

CC which the siRNAs of the invention can be derived.
 XX
 SQ Sequence 19 BP; 3 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 7.3e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 876 GGCTCAGTCAGTGTGACC 894
 DB 1 GGCTCAGTCAGTGTGACC 19
 RESULT 1673
 AAQ85815/c
 ID AAQ85815 standard; DNA; 20 BP.
 XX AAQ85815;
 AC AAQ85815;
 XX 25-MAR-2003 (revised)
 DT 07-NOV-1995 (first entry)
 XX
 DE Anti-ICAM 2'-O-alkylamino-containing oligomer #62.
 XX
 KW Alkylamino group; ribofuranosyl sugar; antisense therapy; virus; HIV;
 KW herpes; papilloma; antiviral; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1 /*tag= a
 FT /*mod_base= OTHER
 FT /*note= "5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(2,4-dinitrophenyl)amino uridine"
 FT modified_base 2..20 /*tag= c
 FT /*note= "nucleotides contain 2'-O-methyl substitutions"
 FT modified_base 20 /*tag= b
 FT /*note= "may contain non-nucleoside 6C amino linker"
 XX
 PN WO9506659-A1.
 XX
 PD 09-MAR-1995.
 XX
 PF 02-SEP-1994; 94WO-US010131.
 XX
 PR 03-SEP-1993; 93US-00117363.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Cook PD, Manoharan M, Guinosso CJ;
 XX WPI; 1995-115397/15.
 DR
 PT New amine-derivatised nucleoside(s) and oligo:nucleoside(s) - useful as
 PT diagnostics, therapeutics and research reagents, partic. in anti-sense
 PT therapy.
 XX
 PS Example 42; Page 55; 117pp; English.
 XX
 CC Oligomers AAQ85813-5 are analogues of an antisense sequence to the inter-
 CC cellular adhesion molecule (ICAM). The oligomers are generated to contain
 CC a 2'-O-alkylamino-modified nucleoside at various positions and may
 CC include phosphorothioate linkages between the nucleosides. The modified
 CC nucleosides may increase the half-life of the oligomers in cell extract
 CC assays for the inhibition of specific genes. The modified oligomer is an
 CC example of a compound (see AAQ85799-Q85839 for other examples) e.g. a
 CC nucleoside or oligonucleoside, which contains a ribofuranosyl sugar
 CC portion and a base portion, such that at least one of the nucleoside
 CC contains at a 2'-O-, 3'-O- or 5'-O-position, a substitution (see AAQ85799
 CC for details of the substitutions). The compounds are useful in

RESULT 1672
 ADQ82767
 ID ADQ82767 standard; DNA; 19 BP.
 XX
 AC ADQ82767;
 XX 21-OCT-2004 (first entry)
 DT
 XX Human ICAM-1 oligonucleotide, SEQ ID 19.
 DE
 XX
 KW Anti-HIV; Neotropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnerary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004065546-A2.
 XX
 PD 05-AUG-2004.
 XX
 PF 16-JAN-2004; 2004WO-US001166.
 XX
 PR 16-JAN-2003; 2003US-0440579P.
 XX
 PA (UYPE-) UNIV PENNSYLVANIA.
 XX
 PI Reich SJ, Tolentino MJ;
 XX WPI; 2004-580723/56.
 DR
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 PS Disclosure; SEQ ID NO 19; 71pp; English.
 XX
 CC The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angiogenesis, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, multiple myeloma,
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumour
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is a ICAM-1 target sequence from

CC diagnostics, therapeutics and as research reagents particularly in
CC antisense therapy for killing cells and viruses such as HIV, herpes or
CC papilloma viruses. (Updated on 25-MAR-2003 to correct FN field.)
XX
SQ Sequence 20 BP; 5 A; 4 C; 7 G; 3 T; 0 U; 1 Other;
Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 19; Conservative 0;
QY 18 GAGCTCTCTGCTACTCAG 36
DB 20 GAGCTCTCTGCTACTCAG 2
RESULT 1674
AAZ07267/c
ID AAZ07267 standard; DNA; 20 BP.
XX
AC AAZ07267;
XX
DT 22-OCT-1999 (first entry)
XX
DE Human telomerase RNA gene (hTR) specific primer hTR10F.
XX
KW Telomerase RNA; TR; promoter; cytotoxin; cancer; neoplasia; hTR;
KW gene therapy; thymidine kinase gene; anticancer therapy; human;
KW PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9938964-A2.
XX
PD 05-AUG-1999.
XX
PF 29-JAN-1999; 99WO-GB000308.
XX
PR 29-JAN-1998; 98GB-00001902.
XX
PA (CANC-) CANCER RES CAMPAIGN TECHNOLOGY.
XX
PI Keith WN;
XX
DR WPI; 1999-479183/40.
XX
PT Mouse and human telomerase RNA gene promoters, useful for tumor specific
PT gene therapy.
XX
PS Disclosure; Fig 6; 109pp; English.
XX
CC The invention relates to promoter regions from mouse and human telomerase
CC RNA (TR) component genes. The TR gene promoter can be linked to a
CC heterologous gene, especially a gene encoding a cytotoxin, for therapy of
CC cancer, especially neoplasias. The telomerase is necessary for the
CC unrestricted proliferative capacity of many human cancers. Mutation or
CC dysregulation of the telomerase repression pathway may cause reactivation
CC or upregulation of telomerase expression in cancer. Substances,
CC identified in the methods, can be used to block transcription from the TR
CC gene promoter through interaction of the 5' regulatory sequences. These
CC substances, e.g. antisense oligonucleotides, transcription factors,
CC peptide nucleic acids and factors that disrupt signal transduction, are
CC useful for cancer therapy. In particular, gene therapy vectors
CC (especially pG162-codAupp) comprising the promoter and a viral thymidine
CC kinase gene can be used to convert a prodrug, e.g. gancyclovir, so that
CC neoplasia can be controlled or treated. Direct down-regulation of
CC telomerase RNA gene through manipulation of transcription factors may be
CC effective anticancer therapy and the cloning of the hTR gene promoter
CC allows the analysis of therapeutic molecules which modulate hTR promoter
CC activity. Sequences AAZ07623-80 represents PCR primers for amplifying
CC human TR gene (hTR) promoter sequence
XX
SQ Sequence 20 BP; 6 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 19; Conservative 0;
QY 2845 CTCAGCTCTCTGAGTAGCT 2863
DB 19 CTCAGCTCTCTGAGTAGCT 1
RESULT 1675
AAZ37713/c
ID AAZ37713 standard; DNA; 20 BP.
XX
AC AAZ37713;
XX
DT 07-JAN-2000 (first entry)
XX
DE Human mdm2 phosphorothioate oligodeoxynucleotide #243.
XX
KW Human mdm2 gene; proliferation; tumour; phosphorothioate; p53; cancer;
KW antisense; modulation; oligonucleotide; expression; inhibition;
KW hyperproliferation; blood cancer; brain cancer; breast cancer;
KW lung cancer; soft tissue cancer; psoriasis; fibrosis; atherosclerosis;
KW restenosis; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9949065-A1.
XX
PD 30-SEP-1999.
XX
PF 26-MAR-1999; 99WO-US006702.
XX
PR 26-MAR-1998; 98US-00048810.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowse LM;
XX
DR WPI; 1999-610754/52.
XX
PT New antisense compounds used to treat eg. hyperproliferative conditions.
XX
PS Example 9; Page 54; 157pp; English.
XX
CC AAZ37473-Z37738 represent human mdm2 phosphorothioate oligonucleotides.
CC AAZ37471, AAZ37472, AAZ37739, AAZ37740 and AAZ37741 are used in the
CC exemplification of the present invention. The present invention describes
CC novel nucleotide antisense compounds, targeted to the 5' untranslated,
CC translation termination codon, or 3' untranslated region of a nucleic
CC acid encoding human mdm2, that modulates expression of human mdm2. The
CC oligonucleotides mediate their effect by antisense inhibition of
CC hyperproliferative gene expression. The antisense compound is used to
CC treat an animal having a disease or condition associated with mdm2,
CC particularly a hyperproliferative condition, more particularly cancer,
CC especially of the blood, brain, breast, lung or soft tissue, or
CC psoriasis, fibrosis, atherosclerosis or restenosis
XX
SQ Sequence 20 BP; 3 A; 10 C; 4 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 19; Conservative 0;
QY 2772 CCAGGCTGGAGTGCAGTGG 2790
DB 20 CCAGGCTGGAGTGCAGTGG 2
RESULT 1676
AAZ21805/c

ID AA221805 standard; DNA; 20 BP.
 XX
 AC AA221805;
 XX
 DT 01-DEC-1999 (first entry)
 XX
 DE Exemplary oligonucleotide primer X80250 (For).
 XX
 KW neoplasia; mutant; target nucleotide; hybridization; lung cancer; ss;
 KW neck cancer; head cancer; saliva test; chemotherapy; early detection;
 KW primer; PCR; amplification.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9946408-A1.
 XX
 PD 16-SEP-1999.
 XX
 PF 10-MAR-1999; 99WO-US005220.
 XX
 PR 10-MAR-1998; 98US-00038637.
 XX
 PA (UJJO) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
 XX
 PI Sidransky D;
 XX
 DR WPI; 1999-551428/46.
 XX
 PT Detection of cancers comprises assaying for a genetic mutation associated
 PT with cancer.
 XX
 PS Disclosure; Page 29; 99pp; English.
 XX
 CC This is an exemplary oligonucleotide primer, for use in the detection of
 CC neoplastic related gene mutations. There are over 40 known proto-
 CC oncogenes and suppressor genes to date, which control growth,
 CC development, and cell differentiation. Regulation of these genes can,
 CC under certain circumstances, be altered and normal cells can assume
 CC neoplastic growth characteristics. The invention provides a method for
 CC detecting a neoplastic disorder of the head and neck or lung in a
 CC subject. The detection of a target mutant nucleotide sequence in the
 CC saliva is indicative of a neoplastic disorder of the head, neck or lung.
 CC This allows early detection and therefore treatment of the preneoplasia
 CC or cancer, and can also be used to monitor high risk patients undergoing
 CC chemoprevention or chemotherapy
 XX
 SQ Sequence 20 BP; 4 A; 10 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 7e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2774 AGGCTGGAGTGCAGTGGTG 2792
 Db |||||
 20 AGGCTGGAGTGCAGTGGTG 2
 RESULT 1677
 AAF31817/c
 ID AAF31817 standard; DNA; 20 BP.
 XX
 AC AAF31817;
 XX
 DT 10-APR-2001 (first entry)
 XX
 DE Human RANK antisense oligonucleotide, SEQ ID NO: 75.
 XX
 KW Human; cytostatic; antiinflammatory; antisense oligonucleotide; cancer;
 KW receptor activator of NF-kappaB; RANK; infection; inflammation; ss.
 XX
 OS Homo sapiens.
 XX

PN US6171860-B1.
 XX
 PD 09-JAN-2001.
 XX
 PF 05-NOV-1999; 99US-00435296.
 XX
 PR 05-NOV-1999; 99US-00435296.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Baker BF, Cowseert LM;
 XX
 DR WPI; 2001-136876/14.
 XX
 PT Novel antisense compounds capable of modulating expression of human
 PT receptor activator of NF-kappaB useful for diagnosis, prophylaxis and
 PT treatment of diseases associated with expression of RANK.
 XX
 PS Claim 14; Col 43; 40pp; English.
 XX
 CC The present sequence is one of a number of antisense compounds of 8 to 30
 CC nucleobases in length that have been designed to target a 5'untranslated
 CC region, start codon, coding region or 3'untranslated region of the human
 CC receptor activator of NF-kappaB (RANK). The antisense compounds
 CC specifically hybridise with and inhibit the expression of RANK. The
 CC antisense oligonucleotides are useful for inhibiting the expression of
 CC human RANK in human cells or tissues. They can be utilised for
 CC diagnostics, therapeutics for the treatment of diseases associated with
 CC the expression of RANK, prophylaxis e.g. to prevent or delay infection,
 CC inflammation or tumour formation, and as research reagent. The antisense
 CC compounds are safely and effectively administered to humans
 XX
 SQ Sequence 20 BP; 4 A; 2 C; 8 G; 6 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 7e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2830 AAGTGATCTCCACCTCA 2848
 Db |||||
 20 AAGTGATCTCCACCTCA 2
 RESULT 1678
 AAF80867/c
 ID AAF80867 standard; DNA; 20 BP.
 XX
 AC AAF80867;
 XX
 DT 02-MAY-2001 (first entry)
 XX
 DE Human mdm2 phosphorothioate oligonucleotide #241.
 XX
 KW Antisense; mdm2; hyperproliferation; cancer; psoriasis; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6184212-B1.
 XX
 PD 06-FEB-2001.
 XX
 PF 26-MAR-1999; 99US-00280805.
 XX
 PR 26-MAR-1998; 98US-00048810.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowseert LM;
 XX
 DR WPI; 2001-190948/19.
 XX
 PT Novel antisense compound 8-30 nucleobases in length targeted to a nucleic
 PT acid molecule encoding human mdm-2 useful for modulating the expression

PT of human mdm-2 and reducing hyperproliferation of human cells.

XX Example 9; Col 31; 77pp; English.

XX The present invention relates to an antisense compound 8-30 nucleobases in length targeted to nucleobases 1-308 of the 5' untranslated region, CC 1776-1806 of the translation termination codon region or 1818-2370 of the CC 3' untranslated region of a nucleic acid molecule encoding human mdm-2. CC The invention is useful for reducing hyperproliferation of human cells, CC modulating the expression of mdm2 in human cells or tissues or in vitro. CC The hyperproliferative disorder includes cancer or psoriasis

XX Sequence 20 BP; 3 A; 10 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 7e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTGG 2790

DB 20 CCAGGCTGGAGTGCAGTGG 2

RESULT 1679

AAS29482/c

ID AAS29482 standard; DNA; 20 BP.

XX AAS29482;

XX 21-NOV-2001 (first entry)

XX Human mdm2 antisense oligonucleotide 31620.

XX Human; mdm2; hyperproliferative disorder; cancer; psoriasis;

KW atherosclerosis; tumour; cytostatic; anti psoriatic;

KW anti arteriosclerotic; vasotropic; antisense; phosphorothioate; ss.

XX Homo sapiens.

XX Key

FT modified_base 1..20

FT Location/Qualifiers

FT /tag= a

FT /mod_base= OTHER

FT /note= "OTHER= All phosphorothioate linkages,

FT additionally bases 1-6 and bases 15-20 are 2'-O-

FT methoxyethyl bases, and bases 7-14 are deoxynucleotides"

XX US2001016575-A1.

XX 23-AUG-2001.

XX 02-JAN-2001; 2001US-00752983.

XX 26-MAR-1998; 98US-00048810.

XX 26-MAR-1999; 99US-00280805.

XX (MIRA/) MIRAGLIA L J.

XX (NERO/) NERO P.

XX (GRAH/) GRAHAM M J.

XX (MONI/) MONIA B P.

XX (COWS/) COWSERT L M.

XX Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowsert LM;

XX WPI; 2001-535565/59.

XX An antisense compound, useful for treating e.g. cancer, comprises

PT nucleobases targeted a region (e.g. translation termination codon region)

PT of a nucleic acid encoding human mdm2.

XX Example 9; Page 18; 81pp; English.

XX The present invention relates to antisense compounds, 8-30 nucleobases in

CC length targeted to the 5' untranslated region, translation termination CC codon region, 3' untranslated region, coding region or translation start CC site of a nucleic acid encoding human mdm2, where the antisense compound CC modulates the expression of human mdm2. The antisense oligonucleotides of CC the invention are useful for encoding human mdm2 and for inhibiting the CC expression of human mdm2. They may be used for treating an animal having CC a disease or condition associated with amplification of mdm2 gene or CC overexpression of mdm2 e.g. a hyperproliferative disorder such as cancer CC (blood, brain, breast, lung, or a soft tissue cancer) and psoriasis, CC fibrosis, atherosclerosis or restenosis, tumours, colorectal carcinoma CC and chronic myelogenous leukemia. The antisense compound may be CC administered with a chemotherapeutic agent to overcome drug resistance. CC The antisense compound reduces hyperproliferation of human cells. The CC method, which involves the use of the antisense compound, is also useful CC for detecting the role of mdm2 expression in various cell functions and CC physiological processes and useful in both clinical research and CC diagnostic tools. AAS2942-AAS29507 represent the human mdm2 antisense CC oligonucleotides of the present invention

XX Sequence 20 BP; 3 A; 10 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 7e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTGG 2790

DB 20 CCAGGCTGGAGTGCAGTGG 2

RESULT 1680

AAK98932

ID AAK98932 standard; DNA; 20 BP.

XX AAK98932;

XX 24-MAY-2002 (first entry)

XX Human Beta-globin 5' MAR antisense primer BMR1.

DE Expression vector; beta-globin nuclear matrix attachment region; MAR;

KW SV40 virus; gastrin; tumour growth factor beta soluble receptor II;

KW TGF-beta SRII; TGF-beta-overexpressed disease; human; PCR; primer; ss.

XX Homo sapiens.

XX WO200214525-A2.

XX 21-FEB-2002.

XX 27-JUL-2001; 2001WO-KR001285.

XX 29-JUL-2000; 2000KR-00043996.

XX (MOGA-) MOGAM BIOTECHNOLOGY RES INST.

XX (PANG-) PAN-GEN BIOTECH LAB INC.

XX Kim J, Kim J, Oh S, Yoon J, Baek K, Chung S, Park D, Yoon Y;

XX WPI; 2002-269202/31.

XX New expression vectors for use in animal cells (e.g. pMS, pSG and pMSG

PT vectors), useful for producing recombinant proteins in various animal

PT cells, and recombinant protein having a unique structure and function.

XX Example 1; Page 77; 85pp; English.

XX The invention relates to new expression vectors for animal cells

CC comprising a beta-globin nuclear matrix attachment region (MAR) sequence

CC or its complementary sequence at 5'-terminal end of a promoter and/or a

CC SV40 virus poly-A signal and transcription termination site of gastrin

CC gene. The expression vectors are useful for producing recombinant

CC proteins in various animals cells and recombinant protein having a unique

CC structure and function. The vectors, which have increased expression
 CC efficiency and levels for foreign genes, are useful for expressing
 CC foreign proteins used in an animal cell system, e.g. tumour growth factor
 CC beta soluble receptor II (TGF-beta SR11), which can be used for treatment
 CC of TGF-beta-overexpressed disease. This polynucleotide sequence
 CC represents a PCR primer of human Beta-globin 5' MAR of the invention
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 7e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2850 CCTCTCAGTAGCTGGGAC 2868
 |||||
 Db 1 CCTCTCAGTAGCTGGGAC 19

RESULT 1681
 ACC99628
 ID ACC99628 standard; DNA; 20 BP.
 XX
 AC ACC99628;
 XX
 DT 02-SEP-2003 (first entry)
 XX
 DE Telenc/ICA PCR primer SEQ ID NO:9.
 XX
 KW Multiplex real-time quantitative PCR; PCR primer; copy number;
 KW Alzheimer's disease; ss.
 XX
 OS Synthetic.
 XX
 XX WO2003048377-A2.
 XX
 PD 12-JUN-2003.
 XX
 PF 02-DEC-2002; 2002WO-US038806.
 XX
 PR 30-NOV-2001; 2001US-0336095P.
 PR 19-JUL-2002; 2002US-0397475P.
 XX
 XX (UYRP) UNIV ROCHESTER.
 PA (THER) THERIANOS S.
 XX
 XX Zhu M, Coleman P;
 PI
 XX WPI; 2003-532841/50.
 DR

XX Determining the relative copy number of a group of target nucleic acid
 PT molecules present in a sample by performing a first or second PCR in a
 PT PCR mixture and quantifying the number of copies of the second target
 PT nucleic acid product.
 XX
 XX Example 1; Fig 8; 118pp; English.
 XX

XX The present invention describes a multiplex real-time quantitative PCR
 CC method for determining the relative copy number of a group of target
 CC nucleic acid molecules present in a sample. The method comprises: (1)
 CC performing a first PCR in a PCR mixture; (2) performing a second PCR in a
 CC PCR mixture; and (3) quantifying the number of copies of the second
 CC target nucleic acid product present in the sample containing the target
 CC nucleic acid molecule. Also described: (1) quantifying the copy number of
 CC a group of target nucleic acids in a sample; and (2) determining whether
 CC a subject is at risk of acquiring Alzheimer's disease. The method is
 CC useful for determining the relative copy number of a group of target
 CC nucleic acid molecules present in a sample for determining whether a
 CC subject is at risk of acquiring Alzheimer's disease. ACC99620 to ACC99730
 CC represent PCR primer used in the exemplification of the present invention
 XX

SQ Sequence 20 BP; 4 A; 4 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 7e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 596 ATGGAGCCAAATTTCTCGTG 614
 |||||
 Db 1 ATGGAGCCAAATTTCTCGTG 19

RESULT 1682
 ADD21678/c
 ID ADD21678 standard; DNA; 20 BP.
 XX
 AC ADD21678;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Human mdm2 antisense oligonucleotide #241.
 XX

KW antisense oligonucleotide; human; mdm2; hyperproliferation;
 KW hyperproliferative disorder; cancer; psoriasis; fibrosis;
 KW atherosclerosis; restenosis; apoptosis modulation; p21; ss;
 KW 2'-methoxyethoxy-residue; phosphorothioate backbone.
 XX

OS Homo sapiens.

XX WO2003048315-A2.

XX 12-JUN-2003.

XX 02-DEC-2002; 2002WO-US038281.

XX 04-DEC-2001; 2001US-00005344.

XX (ISIS-) ISIS PHARM INC.

XX Miraglia LJ, Nero PS, Graham MJ, Monia BP, Koller E, Chiang MY;
 PI Manoharan M;
 PI

XX WPI; 2003-577263/54.
 XX

XX Novel antisense compound targeted to 5' untranslated region, coding
 PT region, or intron:exon junction of nucleic acid molecule encoding mdm2,
 PT useful for treating e.g. cancer, psoriasis or restenosis by inhibiting
 PT mdm2 expression.
 XX

XX Claim 4; SEQ ID NO 243; 289pp; English.

XX The invention comprises antisense oligonucleotides which are targeted to
 CC the human mdm2 gene. The antisense oligonucleotides of the invention are
 CC useful for reducing hyperproliferation of human cells. The antisense
 CC oligonucleotides are also useful for treating: hyperproliferative
 CC disorders (e.g. cancer), psoriasis, fibrosis, atherosclerosis, or
 CC restenosis. The antisense oligonucleotides are also useful for modulating
 CC apoptosis, and for increasing expression of p21. The present DNA sequence
 CC represents a human mdm2 gene antisense oligonucleotide of the invention.
 CC The present sequence contains 2'-methoxyethoxy-residues and has a
 CC phosphorothioate backbone.
 XX

SQ Sequence 20 BP; 3 A; 10 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 7e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTGG 2790
 |||||
 Db 20 CCAGGCTGGAGTGCAGTGG 2

RESULT 1683
 ABZ98002
 ID ABZ98002 standard; DNA; 20 BP.
 XX

AC ABZ98002;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human RANTES oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 XX WO200285308-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX
 XX 24-APR-2001; 2001US-0286137P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-229219/22.
 XX
 XX Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 XX Disclosure; SEQ ID NO 13244; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 XX Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 7a+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2766 TGTCCACCAGGCTGGAGTG 2784
 |||
 Db 2 TGTCCACCAGGCTGGAGTG 20
 RESULT 1684
 ABD31033
 ID ABD31033 standard; DNA; 20 BP.
 XX

AC ABD31033;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human RANTES-derived oligonucleotide SEQ ID 13244.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 XX Homo sapiens.
 OS
 XX WO200285309-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13244; 763pp; English.
 PS
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic, is a
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 7e+02; Mismatches 0; Gaps 0; Indels 0; Gaps 0;

QY 2766 TGTCAACCCAGGCTGGAGTG 2784
|||||

Db 2 TGTCAACCCAGGCTGGAGTG 20
|||||

RESULT 1685
ADJ59867
ID ADJ59867 standard; DNA; 20 BP.
XX
XX
AC ADJ59867;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to RANTES #116.
XX
XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
XX Homo sapiens.
XX
XX WO2004011613-A2.
XX
XX 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 723; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC Initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
XX invention.
XX
XX Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7e+02; Mismatches 0; Gaps 0; Indels 0; Gaps 0;

QY 2766 TGTCAACCCAGGCTGGAGTG 2784
|||||

Db 2 TGTCAACCCAGGCTGGAGTG 20
RESULT 1686
ADM15261/C
ID ADM15261 standard; DNA; 20 BP.
XX
XX ADM15261;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1448.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nontropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /*note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /*note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /*note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
XX Claim 4; SEQ ID NO 1448; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,

CC antiinflammatory, neuroprotective, neurotropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX Sequence 20 BP; 4 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 19; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 7e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCTGAGTAGC 2862
 Db 19 CCTCAGCCTCTGAGTAGC 1

RESULT 1687
 ADM15012/c
 ID ADM15012 standard; DNA; 20 BP.
 XX AC
 XX ADM15012;
 DT 01-JUL-2004 (first entry)
 XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1199.
 DE chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microosomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microosomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; neurotropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX Homo sapiens.
 OS Synthetic.

Key Location/Qualifiers
 modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX
 PN WO2004028458-A2.
 XX
 PD 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 PF
 XX 25-SEP-2002; 2002US-0413549P.
 XX
 XX (PHAA) PHARMACIA CORP.
 PA
 XX Gierse JK;
 PI
 XX WPI; 2004-305094/28.
 DR
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,

PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 XX Claim 4; SEQ ID NO 1199; 132pp; English.
 XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microosomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, neurotropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 19; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 7e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2849 GCCTCCTGAGTAGCTGGGA 2867
 Db 20 GCCTCCTGAGTAGCTGGGA 2

RESULT 1688
 ADO45357
 ID ADO45357 standard; DNA; 20 BP.
 XX AC
 XX ADO45357;
 DT 15-JUL-2004 (first entry)
 XX Human oligonucleotide #723.
 DE Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 OS
 XX US2004049022-A1.
 PN
 XX 11-MAR-2004.
 PD
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.

PA (CONG/) CONG H.
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX Claim 2; SEQ ID NO 723; 174pp; English.
 PS
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 XX Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 19; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 7e-02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2766 TGTACCCAGGCTGGAGTG 2784
 DB |||||
 2 TGTACCCAGGCTGGAGTG 20
 RESULT 1689
 AAQ45143/C
 ID AAQ45143 standard; DNA; 21 BP.
 AC AAQ45143;
 XX
 XX 25-MAR-2003 (revised)
 DT 31-OCT-1994 (first entry)
 XX
 XX Oligonucleotide used in amine containing therapeutic.
 DE
 XX Oligonucleotide; analogue; antisense; therapy; diagnosis; identification;
 KW retention; therapeutic; amine; lipophile; ss.
 XX
 OS Synthetic.
 XX
 XX WO9406815-A1.
 PN 31-MAR-1994.
 PD
 XX 03-SEP-1993; 93WO-US008367.
 PF 11-SEP-1992; 92US-00943516.
 PR

XX (ISIS-) ISIS PHARM INC.
 PA Manoharan M, Cook PD;
 PI WPI; 1994-118388/14.
 XX
 XX Nucleotide and oligo-nucleotide (poly)amine analogues - used in anti-
 PT sense therapy, diagnosis, and identification, amino gp. enhances cell
 PT uptake and retention.
 XX
 XX Disclosure; Page 23; 93pp; English.
 PS
 XX The sequence is used in the production of an amine analogue. The analogue
 CC can be used in antisense therapy. The analogue may also have enhanced
 CC cellular uptake, increased lipophilicity, cause greater cellular
 CC retention and demonstrate increased distribution. (Updated on 25-MAR-2003
 CC to correct PN field.)
 XX
 XX Sequence 21 BP; 4 A; 5 C; 9 G; 2 T; 1 U; 0 Other;
 SQ
 Query Match 0.6%; Score 19; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 6.6e-02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 49 AGCTCGCTATGGCTCCCA 67
 DB |||||
 19 AGCTCGCTATGGCTCCCA 1
 RESULT 1690
 ADQ82752
 ID ADQ82752 standard; RNA; 21 BP.
 XX
 XX ADQ82752;
 AC
 XX 21-OCT-2004 (first entry)
 DT
 XX
 XX ICAM-1 siRNA sense strand, SEQ ID 4.
 DE
 XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnerrary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; ds.
 XX
 OS Synthetic.
 XX
 XX WO2004065546-A2.
 PN
 XX 05-AUG-2004.
 PD
 XX 16-JAN-2004; 2004WO-US001166.
 PF
 XX 16-JAN-2003; 2003US-0440579P.
 PR
 XX (UYPE-) UNIV PENNSYLVANIA.
 PA
 XX Reich SJ, Tolentino MJ;
 PI WPI; 2004-580723/56.
 DR
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 XX Disclosure; SEQ ID NO 4; 71pp; English.
 PS
 XX The present invention relates to novel small interfering RNAs (siRNAs)

CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angioedema, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, stroke, tumor
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is the sense strand for one such
 CC ICAM-1 siRNA. The corresponding anti-sense strand is given in ADQ82753.
 XX
 SQ Sequence 21 BP; 4 A; 3 C; 7 G; 0 T; 7 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 21;
 Best Local Similarity 73.7%; Pred. No. 6.6e+02;
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 225 GTGTGGGCATAGAGACC 243
 Db 1 GUUGUUGGGCAUAGAGACC 19
 ||:::|||||:|||||

RESULT 1691
 ADQ82754
 ID ADQ82754 standard; RNA; 21 BP.
 XX AC ADQ82754;
 XX
 XX 21-OCT-2004 (first entry)
 XX
 XX ICAM-1 siRNA sense strand, SEQ ID 6.
 XX
 XX Anti-HIV; Nootropic; Antiallergic; Ophthalmological; Neuroprotective;
 KW Antiangiogenic; Antiasthmatic; Antiarteriosclerotic; Dermatological;
 KW Vulnary; Antidiabetic; Antithyroid; Gastrointestinal; Virucide;
 KW Immunosuppressive; Antibacterial; Cytostatic; Cardiant; Antiinflammatory;
 KW Respiratory; Vasotropic; Antiarthritic; Antirheumatic; Cerebroprotective;
 KW Antipsoriatic; Nephrotropic; small interfering RNA; siRNA;
 KW intracellular adhesion molecule-1; ICAM-1; RNA-interference;
 KW cell adhesion; ds.
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FH misc_feature 20..21
 FT /*tag= a
 FT /note= "2 deoxynucleotide overhang"
 XX
 XX W02004065546-A2.
 XX
 XX 05-AUG-2004.
 XX
 XX 16-JAN-2004; 2004WO-US001166.
 XX

PR 16-JAN-2003; 2003US-0440579P.
 XX (UYPE-) UNIV PENNSYLVANIA.
 PA
 XX Reich SU, Tolentino MJ;
 PI
 XX WPI; 2004-580723/56.
 DR
 XX Novel isolated small interfering RNA comprising sense RNA strand having
 PT sequence identical to human intracellular adhesion molecule mRNA, and
 PT antisense RNA strand, useful for treating angiogenic diseases such as
 PT cancer.
 XX
 XX Disclosure; SEQ ID NO 6; 71pp; English.
 PS
 XX The present invention relates to novel small interfering RNAs (siRNAs)
 CC comprising sense and antisense RNA strands forming a RNA duplex, where
 CC the sense RNA strand comprises nucleotide sequence substantially
 CC identical to a target sequence of 19-25 contiguous nucleotides in human
 CC or mouse intracellular adhesion molecule-1 (ICAM-1) nucleotide sequence
 CC (ADQ82749 and ADQ82750). ICAMs mediate cell-cell and cell-matrix
 CC interactions. The siRNAs of the invention specifically target and cause
 CC RNA-interference induced degradation of mRNA from ICAM-1 genes thus
 CC leading to inhibition of ICAM-1 mRNA expression. The siRNAs are useful
 CC for inhibiting cell adhesion or cell adhesion-mediated pathologies such
 CC as AIDS-related dementia, allergic conjunctivitis, allergic rhinitis,
 CC Alzheimer's disease, angioedema, asthma, atherosclerosis, toxic
 CC nephritis, immune-based nephritis, contact dermal hypersensitivity,
 CC corneal/limbic injury, type I diabetes, complications arising from type I
 CC diabetes, Graves' disease, inflammatory bowel disease, inflammatory lung
 CC diseases, inflammatory sequelae of viral infections, inflammatory skin
 CC disorders, allograft rejection, immune cell interactions such as T-cell
 CC killing, mixed lymphocyte reaction, T-cell mediated B-cell
 CC differentiation, meningitis, multiple sclerosis, stroke, tumor
 CC myocarditis, pulmonary fibrosis, reperfusion injury, restenosis,
 CC retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor
 CC metastasis and uveitis. The siRNAs are also useful for treating an
 CC angiogenic disease such as cancer, diabetic retinopathy age-related
 CC macular degeneration, preferably age-related macular degeneration. The
 CC siRNAs are also useful for treating complications arising from type I
 CC diabetes such as diabetic retinopathy, diabetic neuropathy, diabetic
 CC nephropathy and macrovascular disease. The macrovascular disease is
 CC coronary artery disease, cerebrovascular disease or peripheral vascular
 CC disease. The present oligonucleotide is the sense strand for one such
 CC ICAM-1 siRNA. The corresponding anti-sense strand is given in ADQ82755.
 XX
 SQ Sequence 21 BP; 4 A; 3 C; 7 G; 2 T; 5 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 21;
 Best Local Similarity 73.7%; Pred. No. 6.6e+02;
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 225 GTGTGGGCATAGAGACC 243
 Db 1 GUUGUUGGGCAUAGAGACC 19
 ||:::|||||:|||||

RESULT 1692
 AAT58190/c
 ID AAT58190 standard; DNA; 22 BP.
 XX AC AAT58190;
 XX
 XX 22-JUL-1997 (first entry)
 XX
 XX 5'-Guanosine-capped anti-ICAM antisense oligonucleotide 23.
 XX
 XX Antisense therapy; intercellular adhesion molecule; ICAM;
 KW cell adhesion receptor; integrin; 3'-cap; 5'-cap; nuclease resistance;
 KW stability; ss.
 XX
 OS Synthetic.

PS Example 1; SEQ ID NO 38; 98pp; Japanese.

XX

CC The invention relates to a DNA methylation inducer (I) containing double-stranded (ds)RNA that targets the region which contains CpG or CpNG (N is A, T, C or G) on DNA in mammalian cell, or expression vector (VI) having DNA that codes dsRNA that targets the region which contains CpG or CpNG on DNA in mammalian cell. (I) is useful in the DNA methylation process, which involves introducing (I) in a mammalian cell, where the mammalian cell is obtained from human. (I) is useful as gene expression inhibitor or cell growth inhibitor. A gene expression inhibitor (II) is useful for suppressing gene expression, where the gene is a disease related gene relevant to a disease, and the expression of the gene causes the disease. The gene is erbB2 and the disease is the tumour. (I) is useful for controlling various biological activities in a mammal by controlling the transcription level of the respective gene by methylating the respective DNA. (I) or (II) enables specific methylation of the CpG island-containing domain on a gene promoter of the target gene, where the methylation of a promoter suppresses the expression of the target gene. (I) induces sequence specific DNA methylation in a plant, and controls the expression of the specific gene at the transcription level. (I) enables DNA methylation in the promoter region of a gene, where the methylation changes the structure of the DNA, enabling suppression of the gene expression at the transcription level (DNA to mRNA). This sequence corresponds to an E-cadherin gene PCR primer used in the method to silence gene expression in cells.

XX

SQ Sequence 22 BP; 4 A; 6 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 19; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTGG 2790
|||||
Db 1 CCAGGCTGGAGTGCAGTGG 19

RESULT 1695
ADT00206/c

ID ADT00206 standard; DNA; 22 BP.

XX

AC ADT00206;

XX

DT 16-DEC-2004 (first entry)

XX

DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID194.

XX

KW tyrosine kinase; cancer; anti-cancer agent; signalling molecule;

KW tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;

KW GUCY2F; MCK4; kinase domain; cytostatic; tyrosine kinase inhibitor;

KW guanylate cyclase stimulator; ss.

XX

OS Homo sapiens.

XX

PN WO2004082458-A2.

XX

PD 30-SEP-2004.

XX

PF 18-FEB-2004; 2004WO-US0004452.

XX

PR 21-FEB-2003; 2003US-0448537P.

PR 29-MAY-2003; 2003US-0473895P.

XX

PA (UYJO) UNIV JOHNS HOPKINS.

XX

PI Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;

XX

DR WPI; 2004-718702/70.

XX

PT Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCK4) and associated methods for diagnosing cancer and screening for anti-cancer agents.

XX

PS Disclosure; SEQ ID NO 194; 363pp; English.

XX

CC This invention relates to a novel activated mutant protein tyrosine kinases and associated methods for diagnosing cancer and screening for anti-cancer agents. Protein kinases are signalling molecules involved in tumorigenesis. Mutational analysis of the human tyrosine kinase gene family identified somatic alteration sin 1 in 5 colorectal cancers, with the majority of mutations occurring in the NTRK3, FES, GUCY2F and MCK4/MLK4 genes. Most were identified in the kinase domain. The invention may be useful for the production of compounds with a cytostatic activity acting as protein tyrosine kinase inhibitors or guanylate cyclase stimulators. The invention may be useful for developing methods for detecting mutations involved in cancer or screening for anti-cancer agents. The present sequence is that of a human-derived oligonucleotide which is related to the invention.

XX

SQ Sequence 22 BP; 11 A; 10 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 6.7e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGTGT 2749
|||||
Db 22 GTGTGTGTGTGTGTGTGT 1

RESULT 1696
AAH79355/c

ID AAH79355 standard; DNA; 23 BP.

XX

AC AAH79355;

XX

DT 04-DEC-2001 (first entry)

XX

DE Human Charcot-Leyden crystal 4 CLC4 coding sequence PCR primer #7.

XX

KW Human; Charcot-Leyden crystal 4; CLC4; PCR primer; ss.

XX

OS Homo sapiens.

XX

PN CN1302876-A.

XX

PD 11-JUL-2001.

XX

PF 28-OCT-1999; 99CN-00119883.

XX

PR 28-OCT-1999; 99CN-00119883.

XX

PA (UYFU-) UNIV FUDAN.

XX

PI Yu L, Zhao Y, Zhang H;

XX

DR WPI; 2001-558262/63.

XX

PT Human charcot-leiden crystal 4, its nucleic acid sequence, its preparation method and its application.

XX

PS Example 1; Page 11(Disclosure); 27pp; Chinese.

XX

CC The present invention provides the protein and coding sequences of human Charcot-Leyden crystal 4 (CLC4). The present sequence is a PCR primer for the coding sequence of the invention

XX

SQ Sequence 23 BP; 7 A; 6 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.8; DB 1; Length 23;
Best Local Similarity 90.9%; Pred. No. 6.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2756 GCTCTCGTCTGTCTCACCAGGC 2777
|||||
Db 22 GTTCTTGTCTGTCTCACCAGGC 1

[illegible]

```

Db          2 ATCATGTTCACTGCAGCCTTG 23
          ||||| ||||| ||||| ||||| |||||
RESULT 1699
AAQ34170
ID AAQ34170 standard; DNA; 20 BP.
XX AC AAQ34170;
XX DT 25-MAR-2003 (revised)
XX DT 02-FEB-1993 (first entry)
XX DE Sequence of a microsatellite from clone TGLA86.
XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
XX KW genetic mapping; traits; amplification; ss.
XX OS Bos taurus.
XX PN WO9213102-A1.
XX PD 06-AUG-1992.
XX PF 15-JAN-1992; 92WO-US000340.
XX PR 15-JAN-1991; 91US-00642342.
XX PA (GENM-) GENMARK.
XX PI Georges M, Massey JM;
XX DR WPI; 1992-284684/34.
XX PT Polymorphic bovine DNA markers - used in genetic identification, gene
XX PT mapping, and selective breeding.
XX PS Table 7; Page 397; 517pp; English.
XX CC The sequence is that of a bovine microsatellite sequence obtd. by
CC screening a library of bovine MboI DNA fragments of between 250 and 500
CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
CC clones cross-hybridised. Assuming independent distribution of
CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
CC in the bovine genome is estimated at >100,000. The sequence information
CC for ca. 230 such bovine microsatellites is summarised in the
CC specification and indexed herein (see below). The sequences upstream and
CC downstream of the microsatellite sequence were used to generate the
CC required PCR primers for in vitro amplification of the corresp.
CC microsatellite (using the program OPTIPRIM). The microsatellites may be
CC used to identify individuals, for parentage testing, and in the genetic
CC mapping of economic trait loci, or genes involved the determinism of
CC economically important traits esp. in cattle, to allow selective
CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
CC field.)
XX SQ Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;
      Query Match 0.6%; Score 18.4; DB 1; Length 20;
      Best Local Similarity 95.0%; Pred. No. 8.1e+02;
      Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
      ||||| ||||| ||||| ||||| |||||
Db 1 TGTGTGTGTGTGTGTGTGTG 20

RESULT 1701
AAQ33672
ID AAQ33672 standard; DNA; 20 BP.
XX AC AAQ33672;
XX DT 25-MAR-2003 (revised)
XX DT 02-FEB-1993 (first entry)
XX DE Microsatellite sequence from clone TGLA116.
XX KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
XX KW genetic mapping; traits; amplification; ss.
XX OS Bos taurus.
XX

```

PN WO9213102-A1.
 XX
 PD 06-AUG-1992.
 XX
 PF 15-JAN-1992; 92WO-US000340.
 XX
 PR 15-JAN-1991; 91US-00642342.
 XX
 XX (GENM-) GENMARK.
 XX
 PA Georges M, Massey JM;
 PI
 XX WPI; 1992-284684/34.
 DR
 XX
 XX Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.
 PT
 XX Table 7; Page 198; 517pp; English.
 PS
 XX The sequence is that of a bovine microsatellite sequence obtd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (TG)n >9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved the determinism of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding, for example this microsatellite is a marker for the Weaver
 CC condition and the GFL trait of enhanced milk prodn. in Brown Swiss
 CC cattle. See also AAQ33501-34442. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GTGTGTGTGTGTGTGTGTGT 2747
 Db |||||
 1 GTGTGTGTGTGTGTGTGTGT 20
 RESULT 1702
 AAT10907/C
 ID AAT10907 standard; DNA; 20 BP.
 AC
 AC AAT10907;
 XX
 XX 06-SEP-1996 (first entry)
 DT
 XX Human cytochrome P4501A2 (CYP1A2) gene 5' UTR fragment PCR primer.
 DE
 XX Cytochrome P450; detection; diagnosis; polymorphism; substitution;
 KW metabolism; respiration; polymerase chain reaction; ss.
 XX
 OS Synthetic.
 XX
 XX WO9601328-A1.
 PN
 XX 18-JAN-1996.
 PD
 XX 06-JUL-1995; 95WO-JF001352.
 PF
 XX 06-JUL-1994; 94JP-00154571.
 PR
 XX (SAKA) OTSUKA PHARM CO LTD.
 PA

PA (KIMS/) KIM S.
 PA (SHIN/) SHIN K.
 XX (SHIN/) SHIN J.
 PI Fukui T, Katsuragi K, Kinoshita M;
 XX WPI; 1996-087678/09.
 DR
 XX
 XX Detection of human cytochrome p4501A2 gene polymorphism - useful in gene
 PT diagnosis of metabolic activity polymorphism.
 XX
 XX Example 3; Page 13; 23pp; Japanese.
 PS
 XX AAT10907-T10910 are PCR primers used for the amplification of a 5'
 CC untranslated fragment of the the human cytochrome P4501A2 gene including
 CC base -1569. They are used in a method for detecting cytochrome P4501A2
 CC gene polymorphism, in partic. for detecting a base substitution at
 CC position -1569 and may be used with primers for the detection of a T to G
 CC base substitution at position 2064 and a C to A substitution at position
 CC 2640. The method is easy, convenient and has a high degree of sensitivity
 CC and accuracy. Polymorphisms in the P4501A2 gene can lead to a
 CC modification of metabolism which may be beneficial or deleterious
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2849 GCCTCCTGAGTAGCTGGGAC 2868
 Db |||||
 20 GCCTCCTGAGTAGCTGGGAC 1
 RESULT 1703
 AAT93829
 ID AAT93829 standard; DNA; 20 BP.
 AC
 AC AAT93829;
 XX
 XX 25-MAR-2003 (revised)
 DT 24-FEB-1998 (first entry)
 XX
 XX Antitumoural phosphodiester oligonucleotide 19 with cytotoxic activity.
 DE
 XX Phosphodiester; selective binding; cell viability; growth;
 KW tumoural cell line; cytotoxic activity; tumour cell; lymphoma;
 KW lymphoblastic tumour; ss.
 XX
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= a
 FT /note= "phosphodiester oligonucleotide"
 XX
 XX WO9720924-A1.
 PN
 XX 12-JUN-1997.
 PD
 XX 04-DEC-1996; 96WO-EP005388.
 PF
 XX 04-DEC-1995; 95IT-MI002539.
 PR (SAIC-) SAICOM SRL.
 PA
 XX Scaggiante B, Quadrifoglio F;
 PI
 XX WPI; 1997-319771/29.
 DR
 XX New phospho:di:esteric oligo:nucleotide(s) - which exert a specific and
 PT selective cytotoxic effect on tumour cells, for treating both solid and
 PT liquid tumours.

XX Claim 11; Page 4; 38pp; English.

PS The present phosphodiesteric oligonucleotide is based on the generic

CC formula, in the 3'-5' or 5'-3' direction: (Gata')a''-(Gbrb')b''-

CC (Gctc')c''-(Gdtd')d''-(Gete')e''-(Gftf')f''-(Ggtg')g''-N', where: N and

CC N' = T or G, equal or different from each other; x = 0-8, equal or

CC different from each other; a, b, c, d, e, f, and g = 0-10, equal or

CC different from each other; a', b', c', d', e', f', and g' = 0-30, equal

CC or different from each other; a'', b'', c'', d'', e'', f'', and g'' = 1-

CC 16, equal or different from each other; Oligonucleotides of this generic

CC sequence (see also AAT93811-27) are believed to selectively bind and

CC of tumoural cell line. They have specific and selective cytotoxic

CC activity against tumour cells, and can be used for treating tumours of

CC the liquid type, in particular of lymphoblastic origin, and of solid

CC type, in particular lymphomas. The present oligonucleotide is known, but

CC no biological activity has been reported until the reported cytotoxic

CC antitumour activity. (Updated on 25-MAR-2003 to correct PR field.)

XX Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;

SQ

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGT 2747

DB 1 GTGTGTGTGTGTGTGTGTGT 20

RESULT 1704

AAV06824

ID AAV06824 standard; DNA; 20 BP.

XX AAV06824;

XX 01-JUL-1998 (first entry)

XX Oligonucleotide which binds retroviral nucleocapsid protein.

DE Retroviral nucleocapsid protein; NC; high affinity; viral replication;

XX gene therapy; retroviral infection; HIV; transduced cell; ss.

XX Synthetic.

XX WO9744064-A2.

XX 27-NOV-1997.

XX 19-MAY-1997; 97WO-US008936.

XX 20-MAY-1996; 96US-0017128P.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX Rein A, Casas-Finet J, Fisher R, Fivash M, Henderson LE;

XX WPI; 1998-018230/02.

XX Oligo:nucleotide which binds to retroviral nucleocapsid protein with high

PT affinity - used in targeted molecules, transduced cells and gene therapy

PT vectors for treatment of retroviral infections such as those caused by

PT HIV.

XX Claim 7; Page 56; 70pp; English.

XX This sequence represents an oligonucleotide which binds to a retroviral

CC nucleocapsid (NC) protein with high affinity. The invention relates to a

CC targeted molecule which binds to a retroviral nucleocapsid protein with

CC high affinity and comprises the oligonucleotide and a fusion partner.

CC Retroviral nucleocapsid proteins, such as NC and the Gag precursors, bind

CC to specific nucleic acid sequences with high affinity. This binding is

CC dependent upon the zinc fingers of the NC protein and has a strong

CC hydrophobic component. The specific nucleic acid sequences which bind NC

CC are useful as molecular decoys for retroviral NC proteins, for making

CC fusion proteins which inactivate retroviral NC proteins, in screening

CC assays for detecting molecules which inactivate retroviral NC proteins. In

CC nucleic acid binding, and for purification of retroviral NC proteins. In

CC particular, the targeted molecules, the transduced cells and gene therapy

CC vectors based on the oligonucleotides can be used for treatment and

CC prevention of retroviral infections such as those caused by HIV

XX Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;

SQ

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGTG 2748

DB 1 TGTGTGTGTGTGTGTGTGTGTG 20

RESULT 1705

AAZ37712/c

ID AAZ37712 standard; DNA; 20 BP.

XX AAZ37712;

XX 07-JAN-2000 (first entry)

XX Human mdm2 phosphorothioate oligodeoxynucleotide #242.

XX Human mdm2 gene; proliferation; tumour; phosphorothioate; p53; cancer;

XX antisense; modulation; oligonucleotide; expression; inhibition;

XX hyperproliferation; blood cancer; brain cancer; breast cancer;

XX lung cancer; soft tissue cancer; psoriasis; fibrosis; atherosclerosis;

XX restenosis; ss.

XX Synthetic.

XX Homo sapiens.

XX WO9949065-A1.

XX 30-SEP-1999.

XX 26-MAR-1999; 99WO-US006702.

XX 26-MAR-1998; 98US-00048810.

XX (ISIS-) ISIS PHARM INC.

XX Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowse LM;

XX WPI; 1999-610754/52.

XX New antisense compounds used to treat eg. hyperproliferative conditions.

XX Example 9; Page 54; 157pp; English.

XX AAZ37473-237738 represent human mdm2 phosphorothioate oligonucleotides.

CC AAZ37471, AAZ37472, AAZ37739, AAZ37740 and AAZ37741 are used in the

CC exemplification of the present invention. The present invention describes

CC novel nucleotide antisense compounds, targeted to the 5' untranslated,

CC translation termination codon, or 3' untranslated region of a nucleic

CC acid encoding human mdm2, that modulates expression of human mdm2. The

CC oligonucleotides mediate their effect by antisense inhibition of

CC hyperproliferative gene expression. The antisense compound is used to

CC treat an animal having a disease or condition associated with mdm2,

CC particularly a hyperproliferative condition, more particularly cancer,

CC especially of the blood, brain, breast, lung or soft tissue, or

CC psoriasis, fibrosis, atherosclerosis or restenosis

XX Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2765 CTGTCACCCAGGCTGGAGTG 2784
 ||||| ||||| ||||| ||||| |||||
 Db 20 CTGTCACCCAGGCTGGAGTG 1

RESULT 1706
 AAA39091
 ID AAA39091 standard; DNA; 20 BP.
 XX
 AC AAA39091;
 XX
 DT 30-AUG-2000 (first entry)
 XX
 DE 20-mer oligonucleotide sequence.
 DE
 KW Displacement chromatography; purification; separation; ss.
 XX
 OS Unidentified.
 OS
 XX W0200023798-A1.
 PN
 XX 27-APR-2000.
 PD
 XX
 XX 20-OCT-1999; 99WO-GB003463.
 PF
 XX 20-OCT-1998; 98GB-00022963.
 PR
 XX (MARS/) MARSDEN J C.
 PA
 PA (AGNE/) AGNER E.
 XX
 XX Agner E;
 PI
 XX
 DR WPI; 2000-339759/29.
 XX

Displacement chromatography for purification of peptide samples by non-homogeneous application of sample components to chromatography bed.

Example 2; Page 22; 37pp; English.

The present invention describes a method (I) for sample displacement chromatography separation. The method comprises applying a multicomponent sample to one end of a chromatography bed, distributing the sample along the bed by passing non-eluting mobile solvent phase over the bed, and recovering a desired component of the sample from at least a portion of the bed. The sample components are applied in a non-homogeneous manner to enhance concentration of at least one component with relatively low and/or high affinity for the stationary phase material, respectively, during an earlier and later part of the sample application. The method is useful for chromatographic separation of samples. The method permits recovery of sample components at significantly higher concentrations and generally makes more efficient use of the stationary phase material. The method allows ten-fold greater loading than comparable gradient elution separation, it involves minimal use of costly HPLC solvents and fraction analysis, avoids the use of displacer solution during actual separation and operating costs are lower. The present sequence represents a 20-mer oligonucleotide which is used in an example from the present invention for the purification of an oligonucleotide by sample displacement chromatography

Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
 ||||| ||||| ||||| ||||| |||||
 Db 1 TGTGTGTGTGTGTGTGTGTG 20

RESULT 1707
 AAA11944
 ID AAA11944 standard; DNA; 20 BP.
 XX
 AC AAA11944;
 XX
 DT 16-AUG-2000 (first entry)
 XX
 DE Human MDMX antisense oligonucleotide #31066.

XX MDMX; human; antisense; inhibitor; anticarcinogen; antiinflammatory;
 KW antiinfectious; modulation; treatment; disease; diagnosis; primer; ss.
 XX
 OS Homo sapiens.

XX US6046320-A.

XX 04-APR-2000.

XX 09-APR-1999; 99US-00289267.

XX 09-APR-1999; 99US-00289267.

XX (ISIS-) ISIS PHARM INC.

XX Monia BP, Cowsert LM;

XX WPI; 2000-282710/24.

New antisense oligonucleotides targeting nucleic acids encoding human MDMX useful for inhibiting MDMX expression and for treating diseases associated with MDMX expression e.g. tumor formation, inflammation.

Example 15; Col 97-98; 51pp; English.

This invention describes a novel antisense compound (I), 8-30 nucleobases in length, targeted to a nucleic acid encoding a human MDMX. (I) specifically hybridizes with and inhibits the expression of human MDMX. The products of the invention have anticarcinogen, antiinflammatory and antinfectious activity. Synthesized chimeric oligonucleotides targeted to human MDMX, 20 nucleotides in length, composed of a central gap region consisting of ten 2'-deoxynucleotides flanked on both sides by 5-nucleotide wings were tested for antisense inhibition of MDMX expression. Results of real-time quantitative polymerase chain reaction (PCR) showed 71 out of the 159, 20 base pair sequences, all fully defined in the specification, demonstrated at least 30% inhibition of MDMX expression. The antisense oligonucleotides are useful for effective and specific modulation, particularly inhibition of MDMX expression, and may be used in treating humans or animals suspected of having or being prone to a disease or condition associated with expression of MDMX. The antisense oligonucleotides may also be used as research reagents or kits, and as diagnostics, e.g. to elucidate the function of a particular gene or to distinguish between functions of various members of a biological pathway, and as prophylaxis, e.g. to prevent or delay infection, inflammation or tumor formation. AAA11781-A11945 represent antisense oligonucleotides described in the method of the invention

Sequence 20 BP; 2 A; 8 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTCCACCCAGGCTG 2779
 ||||| ||||| ||||| ||||| |||||
 Db 1 TCGCGCTGTCCACCCAGGCTG 20

RESULT 1708
 AAS13762
 ID AAS13762 standard; DNA; 20 BP.
 XX

CC The invention is useful for reducing hyperproliferation of human cells,
 CC modulating the expression of mdm2 in human cells or tissues or in vitro.
 CC The hyperproliferative disorder includes cancer or psoriasis

XX SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2765 CTGTCACCCAGGCTGGAGTG 2784

Db 20 CTGTACCCAGGCTGGAGTG 1

RESULT 1713

AAF62932/c

ID AAF62932 standard; DNA; 20 BP.

AC AAF62932;

XX 08-MAY-2001 (first entry)

DT Human PEPCCK-cytosolic antisense oligonucleotide ISIS 108106.

DE Human; antiinflammatory; cytostatic; antisense gene therapy;

KW phosphoenol pyruvate carboxykinase-cytosolic; PEPCCK-cytosolic; infection;

KW inflammation; tumour formation; phosphorothioate; ss.

XX Homo sapiens.

OS US6187545-B1.

PN 13-FEB-2001.

XX 21-JAN-2000; 2000US-00488671.

XX 21-JAN-2000; 2000US-00488671.

XX (ISIS-) ISIS PHARM INC.

PI McKay R, Butler MM, Wyatt J, Cowser LM;

XX WPI; 2001-190979/19.

DR Antisense compound capable of modulating the expression of phosphoenol
 PT pyruvate carboxykinase-cytosolic, useful for preventing or delaying
 PT infection, inflammation or tumor formation.

XX Claim 1; Col 43; 64pp; English.

XX The present sequence is one of a number of antisense compounds of up to
 CC 30 nucleobases in length that are capable of inhibiting the expression of
 CC phosphoenol pyruvate carboxykinase-cytosolic (PEPCCK-cytosolic). The
 CC antisense compounds are useful for inhibiting the expression of PEPCCK-
 CC cytosolic in cells or tissues. They are commonly used as research
 CC reagents and in diagnostics, e.g. to elucidate the function of particular
 CC genes. They are also useful for distinguishing between functions of
 CC various members of a biological pathway and for research use. The
 CC antisense compounds are also useful prophylactically, e.g. to prevent or
 CC delay infection, inflammation or tumour formation. The present sequence
 CC is a chimeric phosphorothioate oligonucleotide with 2'-MOE wings and a
 CC deoxy gap

XX SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGT 2747

Db 20 GTGTGTGTGTGTGTGTGTGT 1

RESULT 1714

AAF28355/c

ID AAF28355 standard; DNA; 20 BP.

XX AAF28355;

XX 02-APR-2001 (first entry)

DT DNA oligomer #5.

DE Deoxynucleic S-Methylthiouracil; DNmt; antisense therapy;

XX cardiovascular disease; inflammatory disease; neurocellular disease;

KW antiviral therapy; human immunodeficiency virus; human-cytomegalovirus;

KW influenza; herpes; infection; ss.

XX Unidentified.

OS US6169176-B1.

PN 02-JAN-2001.

XX 28-SEP-1999; 99US-00407675.

XX 02-JUL-1998; 98US-0091481P.

PR 11-DEC-1998; 98US-0111800P.

PR 02-JUL-1999; 99US-00347443.

XX (REGC) UNIV CALIFORNIA.

XX Dev AP, Bruce TC;

PI WPI; 2001-122276/13.

XX Preparing novel deoxynucleic alkyl thiourea oligonucleotide for use in

PT antisense therapy, by synthesizing oligonucleotides comprising backbone

PT of alkyl or alkoxy thiourea linkages in solution or on solid phase.

XX Example 7; Fig 16; 48pp; English.

XX The present sequence was used to demonstrate the ability of deoxynucleic

CC S-Methylthiouracil (DNmt) compounds to form triplexes with DNA oligomers. An

CC increase in the C content of the oligos resulted in a large decrease in

CC binding. This experiment was performed as an example of a method for

CC preparing oligonucleotides comprising a backbone of alkyl or alkoxy

CC thiourea linkages. The method is useful for preparing oligonucleotides

CC for use in antisense or antigenic therapy, to inhibit production of

CC proteins associated with genetic diseases, cardiovascular, inflammatory

CC and neurocellular diseases, and for antiviral therapy, e.g. to treat

CC human immunodeficiency virus, human-cytomegalovirus, influenza and herpes

CC infections. The compounds are also useful as diagnostic reagents to

CC detect the presence or absence of the target DNA or RNA sequences to

CC which they specifically bind and by antagonising the normal biological

CC activity of a target protein, they can be used in the manipulation of

CC tissue e.g. tissue differentiation, both in vivo and in ex vivo tissue

CC cultures. The method provides an efficient and rapid solid-phase method

CC for the synthesis of thiourea and S-methylthiouracil

XX SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGTG 2748

Db 20 TGTGTGTGTGTGTGTGTGTGTG 1

RESULT 1715

AAH48201

ID AAH48201 standard; DNA; 20 BP.

PS Claim 6; Page 35; 52pp; English.

XX The present invention relates to Simple Sequence Repeats (SSRs) from

CC clover species. SSRs, also called microsatellites, are based on a 1-7

CC nucleotide core element which is tandemly repeated. The SSR array is

CC embedded in complex flanking DNA. SSRs are ideal markers for genome

CC mapping, trait mapping and marker-assisted selection. The SSRs may be

CC used in methods for selecting genes in clover/ legume breeding. The SSRs

CC are also useful for DNA profiling of clover varieties and for testing the

CC purity of legume seed batches. The present sequence is a SSR motif, which

CC was used in the present invention

XX

SQ Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGT 2747

DB 1 GTGTGTGTGTGTGTGTGT 20

RESULT 1718

AAS29481/c

ID AAS29481 standard; DNA; 20 BP.

XX AAS29481;

XX

XX 21-NOV-2001 (first entry)

XX

XX Human mdm2 antisense oligonucleotide 31781.

XX

XX Human; mdm2; hyperproliferative disorder; cancer; psoriasis;

KW atherosclerosis; tumour; cytostatic; anti psoriatic;

KW anti arteriosclerotic; vasotropic; antisense; phosphorothioate; ss.

XX

XX Homo sapiens.

XX

FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= All phosphorothioate linkages,

FT additionally bases 1-6 and bases 15-20 are 2'-O-

FT methoxyethyl bases, and bases 7-14 are deoxynucleotides"

XX

XX US2001016575-A1.

XX

XX 23-AUG-2001.

XX

XX 02-JAN-2001; 2001US-00752983.

XX

XX 26-MAR-1998; 98US-00048810.

XX 26-MAR-1999; 99US-00280805.

XX

XX (MIRA/) MIRAGLIA L J.

XX (NERO/) NERO P.

XX (GRAH/) GRAHAM M J.

XX (MONI/) MONIA B P.

XX (COWS/) COWSERT L M.

XX

XX Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowsert LM;

XX WPI; 2001-535565/59.

XX

XX An antisense compound, useful for treating e.g. cancer, comprises

PT nucleobases targeted a region (e.g. translation termination codon region)

PT of a nucleic acid encoding human mdm2.

XX

XX Example 9; Page 18; 81pp; English.

XX

XX The present invention relates to antisense compounds, 8-30 nucleobases in

CC length targeted to the 5' untranslated region, translation termination

CC codon region, 3' untranslated region, coding region or translation start

CC site of a nucleic acid encoding human mdm2, where the antisense compound

CC modulates the expression of human mdm2. The antisense oligonucleotides of

CC the invention are useful for encoding human mdm2 and for inhibiting the

CC expression of human mdm2. They may be used for treating an animal having

CC a disease or condition associated with amplification of mdm2 gene or

CC overexpression of mdm2 e.g. a hyperproliferative disorder such as cancer

CC (blood, brain, breast, lung, or a soft tissue cancer) and psoriasis,

CC fibrosis, atherosclerosis or restenosis, tumours, colorectal carcinoma

CC and chronic myelogenous leukemia. The antisense compound may be

CC administered with a chemotherapeutic agent to overcome drug resistance.

CC The antisense compound reduces hyperproliferation of human cells. The

CC method, which involves the use of the antisense compound, is also useful

CC for detecting the role of mdm2 expression in various cell functions and

CC physiological processes and useful in both clinical research and

CC diagnostic tools. AAS2942-AAS29507 represent the human mdm2 antisense

CC oligonucleotides of the present invention

XX

SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2765 CTGTCACCCAGGCTGGAGTG 2784

DB 20 CTGTTACCCAGGCTGGAGTG 1

RESULT 1719

ABS67840/c

ID ABS67840 standard; DNA; 20 BP.

XX ABS67840;

XX

XX 29-NOV-2002 (first entry)

XX

XX Human casein kinase 2-alpha prime antisense oligonucleotide #1.

XX

XX Human; casein kinase 2-alpha prime; diabetes mellitus;

KW hyperproliferative disorder; breast cancer; prostate cancer;

KW liver cancer; infection; inflammation; tumour formation; cytostatic;

KW antidiabetic; antiinflammatory; antimicrobial; phosphorothioate;

KW antisense therapy; ss.

XX

XX Homo sapiens.

XX

XX WO200262951-A2.

XX

XX 15-AUG-2002.

XX

XX 01-FEB-2002; 2002WO-US002772.

XX

XX 08-FEB-2001; 2001US-00780173.

XX

XX (ISIS-) ISIS PHARM INC.

XX

XX McKay R, Freier SM, Wyatt JR;

XX WPI; 2002-627539/67.

XX

XX New antisense oligonucleotides targeted to nucleic acid encoding casein

PT kinase 2-alpha prime, useful for diagnosing and/or treating a disease or

PT condition associated with expression of casein kinase 2-alpha prime.

XX

XX Claim 3; Page 94; 129pp; English.

XX

XX The present invention relates to antisense oligonucleotides and methods

CC for modulating the expression of human or mouse casein kinase 2-alpha

CC prime. The antisense oligonucleotides are useful for inhibiting the

CC expression of casein kinase 2-alpha prime, and for treating diseases or

CC conditions associated with aberrant expression of casein kinase 2-alpha

CC prime. Such diseases include diabetes mellitus, and hyperproliferative disorders (particularly cancers e.g. breast cancer, prostate cancer, or liver cancer). The antisense compounds are also useful for diagnostics, CC therapeutics, prophylaxis, e.g. to prevent or delay infection, CC inflammation or tumour formation, as research reagents and kits, and in CC distinguishing between functions of various members of a biological CC pathway. ABS67840-ABS67917 represent human or mouse casein kinase 2-alpha CC prime antisense oligonucleotides which comprise a phosphorothioate CC backbone

XX
SQ Sequence 20 BP; 3 A; 10 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGTG 2792
DB 20 CAGGCTGGAGTGCAGTGGCG 1

RESULT 1720

AAL45125
ID AAL45125 standard; DNA; 20 BP.

XX AC

XX AAL45125;

XX DT

XX 24-MAY-2002 (first entry)

XX DE

XX Oligonucleotide synthesis method related DNA #4.

XX KW

XX Oligonucleotide synthesis; polynucleotide array; protecting group; oxidation; ss.

XX OS

XX Synthetic.

XX EP1176151-A1.

XX PD

XX 30-JAN-2002.

XX PF

XX 27-JUL-2001; 2001EP-00118360.

XX PR

XX 28-JUL-2000; 2000US-00627249.

XX PA

XX (AGIL-) AGILENT TECHNOLOGIES INC.

XX PI

XX Dellinger DJ, Perbost MGM, Betley JR, Caruthers M;

XX DR

XX WPI; 2002-156732/21.

XX PT

XX Synthesis of polynucleotide useful during fabrication of an array involves coupling nucleoside phosphoramidite and a solid-supported nucleoside and treating the product with an oxidation/deprotection composition.

XX PS

XX Example 1; Page 15; 36pp; English.

XX CC

XX The present invention relates to a method for the synthesis of a polynucleotide which involves coupling a second nucleoside to a first nucleoside through a phosphite linkage, where the second nucleoside has a non-carbonate protecting group protecting a hydroxyl, and exposing the product to a composition which concurrently oxidizes the phosphite formed to a phosphate and deprotects the protected hydroxyl of the second nucleoside. The method is useful for synthesizing the polynucleotides, for carrying out either 3' to 5' or 5' to 3' synthesis and for fabricating an addressable array of polynucleotides on a substrate. The present sequence is an oligonucleotide produced to demonstrate the method of the invention

XX SQ

Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.6%; Score 18.4; DB 1; Length 20;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
DB 1 TGTGTGTGTGTGTGTGTGTG 20

RESULT 1721

ABA96307/C

ID ABA96307 standard; DNA; 20 BP.

XX AC

XX ABA96307;

XX DT

XX 18-MAR-2002 (first entry)

XX DE

XX Oligonucleotide SEQ ID NO 2.

XX KW

XX Immobilisation; Diels-Alder reaction; ss.

XX OS

XX Synthetic.

XX FH

XX Key Location/Qualifiers

XX modified_base 1

XX FT /tag= a

XX FT /mod_base= OTHER

XX FT /note= "5' fluorescein label"

XX PN

XX WO200184234-A1.

XX PD

XX 08-NOV-2001.

XX PF

XX 01-MAY-2001; 2001WO-US013956.

XX PR

XX 01-MAY-2000; 2000US-0201561P.

XX PR

XX 30-JAN-2001; 2001US-0265020P.

XX PA

XX (PROL-) PROLIGO LLC.

XX PI

XX Pieken W, Wolter A, Sebesta DP, Leuck M, Latham-Timmons HA;

XX PI

XX Pilon J, Husar GW;

XX DR

XX WPI; 2002-114155/15.

XX PT

XX New method for immobilizing a molecule on a support comprises reacting a derivatized molecule with a derivatized support via a cycloaddition reaction, shows high selectivity and efficiency.

XX PS

XX Example 6; Page 31; 86pp; English.

XX CC

XX The invention relates to a method for immobilising a molecule on a support comprising reacting a derivatised molecule with a derivatised support capable of reacting with the molecule via a cycloaddition reaction. The method is used for immobilising molecules on a support using cycloaddition reactions such as the Diels-Alder reaction. The method shows better chemoselectivity, functional groups do not need to be protected and it is highly efficient for immobilising molecules compared to other methods. The present sequence is that of an oligonucleotide, useful to the invention

XX SQ

Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match

Best Local Similarity 0.6%; Score 18.4; DB 1; Length 20;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTG 2748

DB 20 TGTGTGTGTGTGTGTGTGTG 1

RESULT 1722

ABA96306

ID ABA96306 standard; DNA; 20 BP.


```
XX ABA96306;
AC
XX
AC 18-MAR-2002 (first entry)
DT
XX
DE Oligonucleotide SEQ ID NO 1.
XX
DE Immobilisation; Diels-Alder reaction; ss.
XX
XX Synthetic.
XX
XX WO200184234-A1.
XX
XX 08-NOV-2001.
XX
XX 01-MAY-2001; 2001WO-US013956.
XX
XX 01-MAY-2000; 2000US-0201561P.
XX
XX 30-JAN-2001; 2001US-0265020P.
XX
XX (PROL-) PROLIGO LLC.
XX
XX Pieken W, Wolter A, Sebesta DP, Leuck M, Latham-Timmons HA;
PI Pilon J, Husar GW;
XX
XX WPI; 2002-114155/15.
XX
XX New method for immobilizing a molecule on a support comprises reacting a
PT derivatized molecule with a derivatized support via a cycloaddition
PT reaction, shows high selectivity and efficiency.
XX
XX Example 6; Page 31; 86pp; English.
XX
XX The invention relates to a method for immobilising a molecule on a
CC support comparing reacting a derivatised molecule with a derivatised
CC support capable of reacting with the molecule via a cycloaddition
CC reaction. The method is used for immobilising molecules on a support
CC using cycloaddition reactions such as the Diels-Alder reaction. The
CC method shows better chemoselectivity, functional groups do not need to be
CC protected and it is highly efficient for immobilising molecules compared
CC to other methods. The present sequence is that of an oligonucleotide,
XX useful to the invention
XX
XX Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2729 TGTGTGTGTGTGTGTGTGTGTG 2748
Db 1 TGTGTGTGTGTGTGTGTGTG 20
RESULT 1723
ABK68939
ID ABK68939 standard; DNA; 20 BP.
XX
XX ABK68939;
XX
XX 02-JUL-2002 (first entry)
XX
XX Human phosphorylase kinase beta antisense oligonucleotide #52.
XX
XX Human; phosphorylase kinase beta; metabolic disorder; diabetes;
KW infection; inflammation; tumour formation; antidiabetic;
KW antiinflammatory; cytostatic; phosphorothioate; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT
```

```
FT
FT /mod base= OTHER
FT /note= "OTHER= Phosphorothioate internucleotide linkages,
FT optionally bases 1-5 and 16-20 are 2'-methoxyethoxy (2'-
FT MOE) bases, where the 2'-MOE cytidines are also
FT 5'-methylcytidines"
XX
XX WO200222637-A1.
XX
XX 21-MAR-2002.
XX
XX 12-SEP-2001; 2001WO-US028586.
XX
XX 14-SEP-2000; 2000US-00662250.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
PI
XX WPI; 2002-351873/38.
XX
XX Novel antisense oligonucleotide which inhibits expression of
PT phosphorylase kinase beta, useful for treating metabolic disorder e.g.
PT diabetes, prevent or delay infection, inflammation or tumor formation.
XX
XX Claim 3; Page 83; 132pp; English.
XX
XX The present invention relates to antisense compounds and methods for
CC modulating the expression of human phosphorylase kinase beta. The
CC antisense compounds, particularly antisense oligonucleotides, target and
CC inhibit the expression of human phosphorylase kinase beta. The antisense
CC compounds are useful for inhibiting the expression of human phosphorylase
CC kinase beta in human cells or tissues and for treating an animal,
CC particularly a human suspected of having or being prone to a disease or
CC condition associated with expression of phosphorylase kinase beta such as
CC a metabolic disorder e.g. diabetes. The compounds are useful for
CC diagnostics, therapeutics and as research reagent, e.g. prophylactically
CC to prevent or delay infection, inflammation or tumour formation. The
CC antisense compounds are useful in the preparation of a pharmaceutical
CC formulation. They are highly specific, have an enhanced affinity for the
CC nucleic acid target, and are safely and effectively administered to
CC humans. ABK6888-ABK6895 represent human phosphorylase kinase beta
CC antisense oligonucleotides which comprise a phosphorothioate backbone
XX
XX Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2764 TCTGTCACCAGGCTGGAGT 2783
Db 1 TCTGTCACCAGGCTGGTGT 20
RESULT 1724
ACC55324/c
ID ACC55324 standard; DNA; 20 BP.
XX
XX ACC55324;
XX
XX 27-JUN-2003 (first entry)
XX
XX Human ADAMTS13 STS marker GL4-1 5' PCR primer.
XX
XX Human; thrombotic thrombocytopenic purpura; TTP; disintegrin;
KW metalloproteinase; thrombospondin 1-like domains 13; ADAMTS13;
KW thrombolytic; haemostatic; PCR; primer; RT-PCR; 5' RACE; 3' RACE; ss.
XX
XX Homo sapiens.
XX
XX WO2003016492-A2.
XX
XX 27-FEB-2003.
```


CC each other. The invention also provides methods to detect analytes in a
 CC solution through measurement of the heat of binding or reaction generated
 CC from the interaction of the analytes with binding or reaction partners.
 CC Detection devices are provided that consist of spatially addressable
 CC arrays of thermistors, which are useful in the multiparallel thermal
 CC analysis of samples. The methods and devices are particularly in the
 CC analysis of nucleic acids, especially DNA/DNA, DNA/RNA, DNA/LNA (linear
 CC nucleic acid), DNA/siRNA (short interfering RNA) and DNA/PNA (peptide
 CC nucleic acid). The binding between the analyte and its binding partner
 CC comprises part of an enzymatic amplification reaction, especially PCR or
 CC primer extension reaction. The detection device provides a real time,
 CC digital profile of the binding or reaction between the analyte and its
 CC binding or reaction partner. An example from the invention, using the
 CC present oligonucleotide, showed that the thermal detection technique is
 CC able to distinguish between perfectly matched and mismatched DNA
 CC sequences
 CC
 XX Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
 Db 1 TGTGTGTGTGTGTGTGTG 20
 RESULT 1727
 ADD26665
 ID ADD26665 standard; DNA; 20 BP.
 XX
 AC ADD26665;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Polynucleotide (dsDNA) used in treatment of SLE.
 XX
 KW Systemic lupus erythematosus; SLE; impaired renal function;
 KW LJP 394 conjugate; dermatological; immunosuppressive; antiinflammatory;
 KW ds.
 XX
 OS Unidentified.
 XX
 PN US2003114405-A1.
 XX
 PD 19-JUN-2003.
 XX
 PF 13-AUG-2002; 2002US-00219238.
 XX
 PR 13-AUG-2001; 2001US-0311858P.
 PR 22-AUG-2001; 2001US-0314281P.
 XX
 PA (LINN/) LINNIK M D.
 PA (HEPB/) HEPBURN B.
 XX
 PI Linnik MD, Hepburn B;
 XX
 DR WPI; 2003-810915/76.
 XX
 XX Treating systemic lupus erythematosus comprises selecting an individual
 PT having significantly impaired renal function and administering conjugate
 PT having non-immunogenic valency platform molecule and double stranded DNA
 PT epitopes.
 XX
 PS Claim 3; Page 18; 22pp; English.
 XX
 CC The present invention relates to a method of treating systemic lupus
 CC erythematosus (SLE) in an individual. The method comprises selecting an
 CC individual having SLE, significantly impaired renal function, and
 CC antibodies with high affinity to a polynucleotide epitope by
 CC administering a conjugate comprising non-immunogenic valency platform
 CC molecules and two or more double stranded DNA (dsDNA) epitopes that are

CC polynucleotides. Also disclosed is a kit comprising the conjugate, LJP
 CC 394. The conjugate is administered in an amount effective to reduce
 CC incidence of renal flares in the individual. A medication chosen from
 CC corticosteroids and cyclophosphamide is also administered to the
 CC individual. The conjugate is administered in an amount effective to
 CC reduce the amount of a corticosteroid or cyclophosphamide administered to
 CC the individual. The present sequence represents a polynucleotide (dsDNA)
 CC used in the treatment of SLE.
 XX
 SQ Sequence 20 BP; 0 A; 0 C; 10 G; 10 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GTGTGTGTGTGTGTGTGTG 2747
 Db 1 GTGTGTGTGTGTGTGTGTG 20
 RESULT 1728
 ADD21677/c
 ID ADD21677 standard; DNA; 20 BP.
 XX
 AC ADD21677;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Human mdm2 antisense oligonucleotide #240.
 XX
 KW antisense oligonucleotide; human; mdm2; hyperproliferation;
 KW hyperproliferative disorder; cancer; psoriasis; fibrosis;
 KW atherosclerosis; restenosis; apoptosis modulation; p21; ss;
 KW 2'-methoxyethoxy-residue; phosphorothioate backbone.
 XX
 OS Homo sapiens.
 XX
 PN WO2003048315-A2.
 XX
 PD 12-JUN-2003.
 XX
 PF 02-DEC-2002; 2002WO-US038281.
 XX
 PR 04-DEC-2001; 2001US-00005344.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Miraglia LJ, Nero PS, Graham MJ, Monia BP, Kollier E, Chiang MY;
 PI Manohatan M;
 XX
 DR WPI; 2003-577263/54.
 XX
 PT Novel antisense compound targeted to 5' untranslated region, coding
 PT region, or intron:exon junction of nucleic acid molecule encoding mdm2,
 PT useful for treating e.g. cancer, psoriasis or restenosis by inhibiting
 PT mdm2 expression.
 XX
 PS Example 9; SEQ ID NO 242; 289pp; English.
 XX
 CC The invention comprises antisense oligonucleotides which are targeted to
 CC the human mdm2 gene. The antisense oligonucleotides of the invention are
 CC useful for reducing hyperproliferation of human cells. The antisense
 CC oligonucleotides are also useful for treating: hyperproliferative
 CC disorders (e.g. cancer), psoriasis, fibrosis, atherosclerosis, or
 CC restenosis. The antisense oligonucleotides are also useful for modulating
 CC apoptosis, and for increasing expression of p21. The present DNA sequence
 CC represents a human mdm2 gene antisense oligonucleotide of the invention.
 CC The present sequence contains 2'-methoxyethoxy-residues and has a
 CC phosphorothioate backbone.
 XX
 SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02; Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2765 CTGTACCCAGCGTGGAGTG 2784
 |||||
 Db 20 CTGTACCCAGCGTGGAGTG 1

RESULT 1729
 ADG42099/c
 ID ADG42099 standard; DNA; 20 BP.
 XX AC ADG42099;
 XX DT 26-FEB-2004 (first entry)
 XX DE Human ICAM-1 RT-PCR primer #2.
 XX Human; ss; PCR; CAP37; cationic antimicrobial protein 37;
 KW ophthalmological; antibacterial; antiinflammatory; ocular condition;
 KW bacterial keratitis; bacteriostatic; contact lens; corneal transplant;
 KW bacterial keratitis; Pseudomonas aeruginosa; Staphylococcus aureus;
 KW bacterial conjunctivitis; endophthalmitis; blebitis; corneal ulcer;
 KW eye wound; bacterial infection; disinfectant; primer;
 KW pro-inflammatory cytokines; RT-PCR; reverse transcriptase PCR; ICAM-1;
 KW VCAM-1; PECAM-1; E-selectin; Beta actin.
 XX Homo sapiens.
 OS US2003206938-A1.
 PN US2003206938-A1.
 XX 06-NOV-2003.
 XX 25-APR-2003; 2003US-00423311.
 XX 03-MAY-2002; 2002US-0378295P.
 XX (PERE/) PEREIRA H A.
 PA (CHOD/) CHODOSH J.
 PA (CALL/) CALLEGAN M C.
 XX Pereira HA, Chodosh J, Callegan MC;
 PI WPI; 2003-901038/82.
 XX Use of cationic antimicrobial protein of Mr 57 kDa (CAP37), a CAP37
 PT peptide, or a CAP37 peptide monocyte derivative for treating
 PT bacterial keratitis, bacterial conjunctivitis, endophthalmitis, or
 PT blebitis.
 XX Disclosure; SEQ ID NO 12; 31pp; English.

The invention relates to treating an ocular condition in an eye of a
 CC mammal comprising administering a cationic antimicrobial protein of Mw 57
 CC kDa (CAP37), a CAP37 peptide, or a CAP37 peptide monocyte derivative
 CC to the eye of the mammal. Also included are a bactericidal or
 CC bacteriostatic contact lens (comprising a contact lens, and a coating
 CC comprising a CAP37, a CAP37 peptide, or a monocyte derivative of a
 CC CAP37 peptide disposed upon a surface of the contact lens) and a method
 CC of storing a mammalian corneal transplant comprising providing a medium
 CC comprising a bactericidal or bacteriostatic quantity of a CAP37, a CAP37
 CC peptide, or a CAP37 peptide monocyte derivative and disposing the
 CC mammalian corneal transplant in the medium. The method is useful for
 CC treating an ocular condition is bacterial keratitis caused by Pseudomonas
 CC aeruginosa or Staphylococcus aureus, bacterial conjunctivitis,
 CC endophthalmitis, or blebitis. The method is particularly useful for
 CC treating corneal ulcer or wound in an eye of a mammal, or for inhibiting
 CC bacterial infection or contamination of or by a contact lens. CAP37 and
 CC CAP37 peptides may also be used as a disinfectant for cleaning or
 CC sterilization of contact lenses, and as a storage solution for preventing
 CC contact lenses from becoming contaminated with bacteria while in storage
 CC cases. An experiment was performed to determine whether CAP37 induced
 CC ICAM-1, VCAM-1, PECAM-1, E-selectin (and control Beta actin) mRNA. The

CC present sequence is a reverse transcriptase (RT)-PCR primer used in the
 CC above assay.
 XX Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1073 AGGTGACGCTGAATGGGTT 1092
 |||||
 Db 20 ACGTGACGCTGAATGGGTT 1

RESULT 1730
 ABZ98011
 ID ABZ98011 standard; DNA; 20 BP.
 XX AC ABZ98011;
 XX DT 17-OCT-2003 (first entry)
 XX DE Human RANTES oligonucleotide sequence.
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX Homo sapiens.
 OS WO200285308-A2.
 PN WO200285308-A2.
 XX 31-OCT-2002.
 XX 23-APR-2002; 2002WO-US013135.
 XX 24-APR-2001; 2001US-0286137P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-229219/22.
 DR Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiqunone.
 XX Disclosure; SEQ ID NO 13253; 872pp; English.

The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiqunone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive, or
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiqunone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;
SQ Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCAACCCAGGCT 2778
|||||
Db 1 CTCGCTCTGTGCGCCAGGCT 20

RESULT 1731
ABZ98014
ID ABZ98014 standard; DNA; 20 BP.
XX
AC ABZ98014;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human RANTES oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13256; 872pp; English.
XX

CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX Sequence 20 BP; 3 A; 4 C; 10 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 AGGCTGGAGTGCAGTGGTGC 2793
|||||
Db 1 AGGCTGGAGTGCAGTGGCGC 20

RESULT 1732
ABZ98012
ID ABZ98012 standard; DNA; 20 BP.
XX
AC ABZ98012;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human RANTES oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13254; 872pp; English.
XX

CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2764 TCTGTACCCAGGCTGGAGT 2783
||||| |||||||
Db 1 TCTGTGCCAGGCTGGAGT 20
RESULT 1733
ABZ97908
ID ABZ97908 standard; DNA; 20 BP.
XX
AC ABZ97908;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human RANTES oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WQ200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiqunone.
XX
PS Disclosure; SEQ ID NO 13150; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiqunone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiqunone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2845 CTCAGCCTCCTGAGTAGCTG 2864
||||| |||||||
Db 1 CTCAGCCTCCGAGTAGCTG 20
RESULT 1734
ABZ98003
ID ABZ98003 standard; DNA; 20 BP.
XX
AC ABZ98003;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human RANTES oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WQ200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiqunone.
XX
PS Disclosure; SEQ ID NO 13245; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiqunone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of ubiqunone or
CC receptor, producing bronchodilation, increasing levels of ubiqunone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2770 ACCAGGCTGGAGTGCAGTG 2789
| | | | | | | | | | | | | | | | | | | |
Db 1 ACCAGGCTGGAGTGAAGTG 20
| | | | | | | | | | | | | | | | | | | |

RESULT 1735
ABZ98013
ID ABZ98013 standard; DNA; 20 BP.
XX
XX
AC ABZ98013;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human RANTES oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiaesthetic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
OS
WQ200285308-A2.
PN
XX
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13255; 872pp; English.
XX
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiaesthetic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTCGAGT 2788
| | | | | | | | | | | | | | | | | | | | |
Db 1 CGCCCGAGCTGGAGTCGAGT 20

RESULT 1736
ABZ99088
ID ABZ99088 standard; DNA; 20 BP.
XX
AC ABZ99088;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human PBE4C oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
WO200283308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (SPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmacutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 14330; 872pp; English.
XX

The invention relates to a novel pharmaceutical composition, which has a
first active agent comprising an oligonucleotide antisense to the
initiation codon, coding region, 5' or 3' end genomic flanking regions,
5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
junctions of genes encoding a polypeptide associated with lung and/or
nasal airway dysfunction and a second active agent comprising an
antiinflammatory steroid and ubiquinone. A composition of the invention
has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
immunosuppressive, and cytostatic activity. The composition may have a
use in antisense gene therapy. The composition is useful for treating or
preventing a respiratory, lung or malignant disease or condition, also
for enhancing the prophylactic or therapeutic respiratory effect of an
antiinflammatory steroid in a subject, for reducing or depleting levels
of, or reducing sensitivity to adenosine, reducing levels of adenosine
receptor, producing bronchodilation, increasing levels of ubiquinone or
lung surfactant in a subject's tissue, or treating bronchoconstriction,
lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 3 C; 9 G; 4 T; 0 U; 0 Other;
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2774 AGGCTGGAGTGACGTGTC 2793
|||||
Db 1 AGGCTGGAGTGACGTGTC 20
RESULT 1737
ABZ98439/c
ID ABZ98439 standard; DNA; 20 BP.
XX
AC ABZ98439;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13681; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1461 CGAGGTGACCGTGAATGTC 1480
|||||
Db 20 CGAGGTGACCGTGAATGTC 1
RESULT 1738
ABZ98440/c
ID ABZ98440 standard; DNA; 20 BP.
XX
AC ABZ98440;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human ICAM oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 13682; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed

CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pt_sequences
XX
SQ Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1451 AGTTCACCCGCGAGGTGACC 1470
DB 20 AGTTCACCCGCGAGGTGACC 1
RESULT 1739
ACA88946/c
ID ACA88946 standard; DNA; 20 BP.
XX
AC ACA88946;
XX
DT 08-JUL-2003 (first entry)
XX
DE Selection and amplification of genetic markers PCR related primer #57.
XX
KW Genetic marker selection; multiplex PCR amplification;
KW prenatal diagnostic testing; foetal sex determination;
KW genetic identification; DNA profiling; DNA fingerprinting;
KW forensic analysis; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2003031646-A1.
XX
PD 17-APR-2003.
XX
PF 14-OCT-2002; 2002WO-AU001388.
XX
PR 12-OCT-2001; 2001AU-00008234.
XX
PS 12-OCT-2001; 2001AU-00008235.
XX
PA (UYQU) UNIV QUEENSLAND.
XX
PI Findlay I, Matthews PL, Mulcahy BK;
XX
DR WPI; 2003-391725/36.
XX
PS Selecting genetic markers as targets for nucleic acid sequence
PT amplification, useful for improving genetic testing, e.g. fetal sex
PT determination, comprises selecting each of the genetic markers according
PT to a heterozygosity index.
XX
PS Claim 36; Page 40; 64pp; English.
XX
CC The invention describes a method of selecting genetic markers as targets
CC for nucleic acid sequence amplification comprising selecting each of the
CC genetic markers according to a heterozygosity index of 0.5 or greater.
CC Selecting and amplification of genetic markers are useful as targets for
CC nucleic acid sequence amplification, for genetic testing or facilitating
CC multiplex PCR amplification from limiting amounts of target nucleic acid.
CC The methods are also useful for improving genetic diagnostic and
CC screening methods, such as prenatal diagnostic testing, foetal sex
CC determination or genetic identification, e.g. DNA profiling or DNA
CC fingerprinting. The nucleic acid sequence amplification is also useful in
CC forensic analysis of degraded, old, ancient and difficult samples that
CC are difficult to amplify and identify. This sequence represents a PCR
CC primer used in the selection and amplification of genetic markers
XX
SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2762 GCTCTGTACCCAGGCTGGA 2781
DB 20 GCTCTGTACCTAGGCTGGA 1
RESULT 1740
ABD30939
ID ABD30939 standard; DNA; 20 BP.
XX
AC ABD30939;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human RANTES-derived oligonucleotide SEQ ID 13150.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PS (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PS Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 13150; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impaired respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.

CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2845 CTGAGCTCTGAGTAGCTG 2864

Db 1 CTCAGCTCCGAGTAGCTG 20

RESULT 1741

ABD31043

ID ABD31043 standard; DNA; 20 BP.

XX ABD31043;

XX 29-JUL-2004 (first entry)

XX Human RANTES-derived oligonucleotide SEQ ID 13254.

XX Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13254; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposcretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

SQ Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2764 TCTGTCACTCCAGCTGGAGT 2783

Db 1 TCTGTCCGCTGGAGT 20

RESULT 1742

ABD31044

ID ABD31044 standard; DNA; 20 BP.

XX ABD31044;

XX 29-JUL-2004 (first entry)

XX Human RANTES-derived oligonucleotide SEQ ID 13255.

XX Human; antisense; bronchoconstriction; allergy; hyposcretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

OS WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13255; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,

CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTGCAGT 2788
 Db 1 CGCCAGGCTGGAGTGCAGT 20
 |||||

RESULT 1743
 ABD31045
 ID ABD31045 standard; DNA; 20 BP.
 XX
 AC ABD31045;
 XX
 XX 29-JUL-2004 (first entry)
 XX Human RANTES-derived oligonucleotide SEQ ID 13256.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.
 OS
 XX WO20028309-A2.
 XX
 XX 31-OCT-2002.
 PD
 XX
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13256; 763pp; English.
 PS
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 3 A; 4 C; 10 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 AGGCTGGAGTGCAGTGGTGC 2793
 Db 1 AGGCTGGAGTGCAGTGGTGC 20
 |||||

RESULT 1744
 ABD31042
 ID ABD31042 standard; DNA; 20 BP.
 XX
 AC ABD31042;
 XX
 XX 29-JUL-2004 (first entry)
 XX Human RANTES-derived oligonucleotide SEQ ID 13253.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.

XX WO200285309-A2.
 PN 31-OCT-2002.
 PD 23-APR-2002; 2002WO-US013143.
 PP 24-APR-2001; 2001US-0286036P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13253; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2759 CTCGCTCTGTCCACCCAGGCT 2778
 Db 1 CTCGCTCTGTCCACCCAGGCT 20
 RESULT 1745
 ABD31034
 ID ABD31034 standard; DNA; 20 BP.
 XX
 AC ABD31034;
 XX
 DT 29-JUL-2004 (first entry)
 XX

DE Human RANTES-derived oligonucleotide SEQ ID 13245.
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 XX respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX 31-OCT-2002.
 XX 23-APR-2002; 2002WO-US013143.
 PP 24-APR-2001; 2001US-0286036P.
 XX
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13245; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2770 ACCCAGGCTGGAGTGCAGTG 2789

```
Db      1  ||||| ||||| ||||| ||||| |||||
1  ACCCAGGCTGGAGTGAAGT 20

RESULT 1746
ABD31471/c
ABD31471 standard; DNA; 20 BP.
XX
AC  ABD31471;
XX
DT  29-JUL-2004 (first entry)
XX
DE  Human ICAM-derived oligonucleotide SEQ ID 13682.
XX
KW  Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW  respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW  surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW  analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW  beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW  respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW  emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW  pulmonary transplantation rejection; ss; primer.
XX
OS  Homo sapiens.
XX
PN  WO200285309-A2.
XX
PD  31-OCT-2002.
XX
PF  23-APR-2002; 2002WO-US013143.
XX
PR  24-APR-2001; 2001US-0286036P.
XX
PA  (EPIG-) EPIGENESIS PHARM INC.
XX
PI  Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI  Miller S, Tang L, Shahabuddin S;
XX
DR  WPI; 2003-093058/08.
XX
PT  Pharmaceutical composition for treating asthma, has antisense
PT  oligonucleotide containing less percentage of adenosine, targeted to
PT  nucleic acids associated with lung airway or lung dysfunction, and
PT  bronchodilating agent.
XX
PS  Claim 15; SEQ ID NO 13682; 763pp; English.
XX
CC  This invention describes a novel composition (a) a first active agent,
CC  comprising oligonucleotides, effective for alleviating
CC  bronchoconstriction, respiratory tract inflammation, allergies and
CC  reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC  surfactant depletion or hyposecretion, when administered to a mammal. The
CC  oligonucleotides are derived from a gene encoding or regulating
CC  expression of a target polypeptide associated with lung airway or lung
CC  dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC  The invention also describes a kit, that comprises: (a) a delivery
CC  device, in separate containers, (b) the oligonucleotides, (c)
CC  instructions for adding a carrier and for use of the kit. The composition
CC  of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC  analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC  beta-adrenergic agonist. The composition is useful for preventing or
CC  treating a respiratory, lung or malignant disease. The administered
CC  composition comprises oligo and is administered to reduce the production
CC  or availability, or to increase the degradation of the target mRNA or to
CC  reduce the amount of target polypeptide present in the lungs. The
CC  pulmonary obstruction, and/or bronchoconstriction and/or lung
CC  inflammation, allergies and/or surfactant hypoproduction are associated
CC  with a disease or condition such as pulmonary vasoconstriction,
CC  inflammation, allergies, asthma, impeded respiration, respiratory
CC  distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC  hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC  transplantation rejection, pulmonary infections, bronchitis or cancer.
CC  The reduced adenosine content of the anti-sense oligos corresponding to
```

```
CC  thymidines present in the target RNA serves to prevent the breakdown of
CC  the oligonucleotides into products that free adenosine into the system
CC  e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC  prevent any unwanted effects due to it
XX
SQ  Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;
XX
Query Match      0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
OY  1451 AGGTCACCGCGAGGTGACC 1470
    ||||| ||||| ||||| |||||
DB  20 AGGTCACCGCGAGGTGACC 1
XX
RESULT 1747
ABD31470/c
ID  ABD31470 standard; DNA; 20 BP.
XX
AC  ABD31470;
XX
DT  29-JUL-2004 (first entry)
XX
DE  Human ICAM-derived oligonucleotide SEQ ID 13681.
XX
KW  Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW  respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW  surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KW  analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW  beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW  respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW  emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW  pulmonary transplantation rejection; ss; primer.
XX
OS  Homo sapiens.
XX
PN  WO200285309-A2.
XX
PD  31-OCT-2002.
XX
PF  23-APR-2002; 2002WO-US013143.
XX
PR  24-APR-2001; 2001US-0286036P.
XX
PA  (EPIG-) EPIGENESIS PHARM INC.
XX
PI  Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI  Miller S, Tang L, Shahabuddin S;
XX
DR  WPI; 2003-093058/08.
XX
PT  Pharmaceutical composition for treating asthma, has antisense
PT  oligonucleotide containing less percentage of adenosine, targeted to
PT  nucleic acids associated with lung airway or lung dysfunction, and
PT  bronchodilating agent.
XX
PS  Claim 15; SEQ ID NO 13681; 763pp; English.
XX
CC  This invention describes a novel composition (a) a first active agent,
CC  comprising oligonucleotides, effective for alleviating
CC  bronchoconstriction, respiratory tract inflammation, allergies and
CC  reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC  surfactant depletion or hyposecretion, when administered to a mammal. The
CC  oligonucleotides are derived from a gene encoding or regulating
CC  expression of a target polypeptide associated with lung airway or lung
CC  dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC  The invention also describes a kit, that comprises: (a) a delivery
CC  device, in separate containers, (b) the oligonucleotides, (c)
CC  instructions for adding a carrier and for use of the kit. The composition
CC  of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC  analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC  beta-adrenergic agonist. The composition is useful for preventing or
CC  treating a respiratory, lung or malignant disease. The administered
CC  composition comprises oligo and is administered to reduce the production
CC  or availability, or to increase the degradation of the target mRNA or to
CC  reduce the amount of target polypeptide present in the lungs. The
CC  pulmonary obstruction, and/or bronchoconstriction and/or lung
CC  inflammation, allergies and/or surfactant hypoproduction are associated
CC  with a disease or condition such as pulmonary vasoconstriction,
CC  inflammation, allergies, asthma, impeded respiration, respiratory
CC  distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC  hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC  transplantation rejection, pulmonary infections, bronchitis or cancer.
CC  The reduced adenosine content of the anti-sense oligos corresponding to
```

CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypotension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1461 CGAGGTGACCGTGAATGTC 1480
 DB 20 CAAGGTGACCGTGAATGTC 1

RESULT 1748

ABD32119
 ID ABD32119 standard; DNA; 20 BP.

XX
 AC ABD32119;

XX
 DT 29-JUL-2004 (first entry)

XX
 DE Human PDE4C-derived oligonucleotide SEQ ID 14330.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 14330; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating

CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypotension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 4 A; 3 C; 9 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 AGCGTGAGTCAGTGTGTC 2793
 DB 1 AGCGTGAGTCAGTGTGTC 20

RESULT 1749

AD156729

ID AD156729 standard; DNA; 20 BP.

XX
 AC AD156729;

XX 15-APR-2004 (first entry)

XX Human ICAM-1 G241A allele SNAPshot primer, SEQ ID 3.

XX Schizophrenia; intercellular adhesion molecule-1; ICAM-1; human;
 KW SNAPshot; primer; ss.

XX Homo sapiens.

XX WO2004009845-A2.

XX 29-JAN-2004.

XX 23-JUL-2003; 2003WO-EP008086.

XX 23-JUL-2002; 2002US-0397611P.

XX (MUEL/) MUELLER N.

XX Mueller N;

XX WPI; 2004-123407/12.

XX Screening for schizophrenia, useful for predicting clinical response to a
 PT compound for treating schizophrenia comprising assaying nucleic acid for
 PT a codon encoding arginine at amino acid position 241 of intercellular
 PT adhesion molecule-1.

XX PS Claim 5; SEQ ID NO 3; 34pp; English.

XX CC The present invention relates to a method for screening for

XX CC schizophrenia. The method comprises assaying a DNA sample for the

XX CC presence of a codon encoding arginine at amino acid position 241 of the

XX CC intercellular adhesion molecule-1 (ICAM-1) protein or a protein sample

XX CC for the presence of the ICAM-1 protein having the 241A polymorphism,

XX CC where the presence of a codon encoding arginine at amino acid position

XX CC 241 of the ICAM-1 protein or of the polymorphism is indicative of a

XX CC schizophrenia. The method is useful for predicting clinical response to a

XX CC therapeutic compound in the treatment of ICAM-1 mediated schizophrenia.

XX CC The present sequence is a PCR primer, which was used in an example from

XX CC the invention.

XX SQ Sequence 20 BP; 1 A; 7 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 758 CCGTGTCTGTTCCTCCGAC 777

Db 1 CCGTGTCTGTTCCTCCGAC 20

RESULT 1750

ADJ59878

ID ADJ59878 standard; DNA; 20 BP.

XX AC ADJ59878;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to RANTES #127.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

XX KW airway inflammation; allergy; asthma; impeded respiration;

XX KW cystic fibrosis; acute respiratory distress syndrome;

XX KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX KW ss.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.

XX PT initiation codons and introns of respiratory disease-relevant genes e.g.,

XX PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

XX PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 734; 85pp; English.

XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,

XX CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

XX CC end of nucleic acid target comprising gene(s) chosen from e.g.

XX CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

XX CC oligonucleotide and optionally surfactant operatively linked to the

XX CC oligonucleotide. The method is useful for preventing or treating a

XX CC respiratory or lung disease, which involves administering to the airways

CC of a subject an effective amount of an inhibitor. The oligonucleotide is

CC useful for production of a medicament for the prevention and/or treatment

CC of a respiratory or lung disease. The respiratory or lung disease is

CC chosen from airway inflammation, allergy(ies), asthma, impeded

CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome

CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway

CC obstruction. The present sequence represents an oligonucleotide of the

XX CC invention.

SQ Sequence 20 BP; 3 A; 6 G; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTGCACT 2788

Db 1 CGCCCAAGGCTGGAGTGCACT 20

RESULT 1751

ADJ59868

ID ADJ59868 standard; DNA; 20 BP.

XX AC ADJ59868;

XX DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to RANTES #117.

XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;

XX KW airway inflammation; allergy; asthma; impeded respiration;

XX KW cystic fibrosis; acute respiratory distress syndrome;

XX KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

XX KW ss.

XX OS Homo sapiens.

XX PN WO2004011613-A2.

XX PD 05-FEB-2004.

XX PF 25-JUL-2003; 2003WO-US023509.

XX PR 29-JUL-2002; 2002US-0399076P.

XX PA (EPIG-) EPIGENESIS PHARM INC.

XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;

XX PI Shahabuddin S, Lu H, Cong H;

XX DR WPI; 2004-203534/19.

XX PT Novel single or multiple target oligonucleotide anti-sense to e.g.

XX PT initiation codons and introns of respiratory disease-relevant genes e.g.,

XX PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

XX PT disease e.g., asthma.

XX PS Claim 2; SEQ ID NO 724; 85pp; English.

XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,

XX CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-

XX CC end of nucleic acid target comprising gene(s) chosen from e.g.

XX CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the

XX CC oligonucleotide and optionally surfactant operatively linked to the

XX CC oligonucleotide. The method is useful for preventing or treating a

XX CC respiratory or lung disease, which involves administering to the airways

XX CC of a subject an effective amount of an inhibitor. The oligonucleotide is

XX CC useful for production of a medicament for the prevention and/or treatment

XX CC of a respiratory or lung disease. The respiratory or lung disease is

XX CC chosen from airway inflammation, allergy(ies), asthma, impeded

XX CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases

CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2770 ACCAGCTGGAGTGGAGT 2789
 DB 1 ACCAGCTGGAGTGGAGT 20
 RESULT 1752
 ADJ59877
 ID ADJ59877 standard; DNA; 20 BP.
 XX AC
 XX AC ADJ59877;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to RANTES #126.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 733; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

SQ Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2764 TGTGTCACCCAGCTGGAGT 2783
 DB 1 TGTGTCGCCCAGCTGGAGT 20
 RESULT 1753
 ADJ59879
 ID ADJ59879 standard; DNA; 20 BP.
 XX AC
 XX AC ADJ59879;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to RANTES #128.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX
 PT Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 735; 85pp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

SQ Sequence 20 BP; 3 A; 4 C; 10 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 AGGCTGAGTGCAGTGGTGC 2793
 Db 1 AGGCTGAGTGCAGTGGCGC 20

RESULT 1754
 ADJ60289/c
 ID ADJ60289 standard; DNA; 20 BP.
 XX AC ADJ60289;
 XX AC
 XX 06-MAY-2004 (first entry)
 DT
 DE Oligonucleotide associated to ICAM #63.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1145; 85pp; English.
 PS The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC respiratory or lung disease, which involves administering or treating a
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 4 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1461 CGAGGTGACCGTAATGTGC 1480
 Db 20 CAAGGTGACCGTAATGTGC 1

RESULT 1755
 ADJ60973
 ID ADJ60973 standard; DNA; 20 BP.
 XX AC ADJ60973;
 XX AC
 XX 06-MAY-2004 (first entry)
 DT
 DE Oligonucleotide associated to PDE4C #39.
 XX interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 PD 05-FEB-2004.
 XX
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 1829; 85pp; English.
 PS The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC respiratory or lung disease, which involves administering or treating a
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 4 A; 3 C; 9 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 AGGCTGAGTGCAGTGGTGC 2793
 Db 1 AGGCTGAGTGCAGTGGTGC 20

RESULT 1756
 ADJ60290/c
 ID ADJ60290 standard; DNA; 20 BP.
 XX

AC ADJ60290;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to ICAM #64.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 1146; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
XX initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
XX end of nucleic acid target comprising gene(s) chosen from e.g.
XX interleukin (IL)-4 receptor, IL-5 receptor or salts of the
XX oligonucleotide and optionally surfactant operatively linked to the
XX respiratory or lung disease, which involves administering to the airways
XX of a subject an effective amount of an inhibitor. The oligonucleotide is
XX useful for production of a medicament for the prevention and/or treatment
XX of a respiratory or lung disease. The respiratory or lung disease is
XX chosen from airway inflammation, allergy(ies), asthma, impeded
XX respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
XX (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
XX (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
XX obstruction. The present sequence represents an oligonucleotide of the
XX invention.
XX
SQ Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1451 AGGTACCCCGAGGTGACC 1470
DB 20 AGGTACCCCGAGGTGACC 1

RESULT 1757
ADJ59773
ID ADJ59773 standard; DNA; 20 BP.
XX
AC ADJ59773;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to RANTES #22.

XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
KW ss.
XX
OS Homo sapiens.
XX
PN WO2004011613-A2.
XX
PD 05-FEB-2004.
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-203534/19.
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
PS Claim 2; SEQ ID NO 629; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
XX initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
XX end of nucleic acid target comprising gene(s) chosen from e.g.
XX interleukin (IL)-4 receptor, IL-5 receptor or salts of the
XX oligonucleotide and optionally surfactant operatively linked to the
XX respiratory or lung disease, which involves administering to the airways
XX of a subject an effective amount of an inhibitor. The oligonucleotide is
XX useful for production of a medicament for the prevention and/or treatment
XX of a respiratory or lung disease. The respiratory or lung disease is
XX chosen from airway inflammation, allergy(ies), asthma, impeded
XX respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
XX (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
XX (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
XX obstruction. The present sequence represents an oligonucleotide of the
XX invention.
XX
SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTG 2864
DB 1 CTCAGCCTCCTGAGTAGCTG 20

RESULT 1758
ADJ59876
ID ADJ59876 standard; DNA; 20 BP.
XX
AC ADJ59876;
XX
DT 06-MAY-2004 (first entry)
XX
DE Oligonucleotide associated to RANTES #125.
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;

KW ss.
XX Homo sapiens.
OS WO2004011613-A2.
PN 05-FEB-2004.
XX
XX 25-JUL-2003; 2003WO-US023509.
XX
XX 29-JUL-2002; 2002US-0399076P.
XX
XX (EPIG-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
PI
XX WPI; 2004-203534/19.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX Claim 2; SEQ ID NO 732; 85pp; English.
XX
XX The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2759 CTCGCTCTGTCCACCCAGGCT 2778
DB 1 CTCGCTCTGTCTGCCACCGCT 20
RESULT 1759
ADJ96297
ID ADJ96297 standard; DNA; 20 BP.
XX
AC ADJ96297;
XX
XX 06-MAY-2004 (first entry)
XX
XX Human breast cancer-1 associated antisense oligonucleotide #15.
XX
XX Breast cancer-1; diagnosis; hyperproliferative disorder; cancer;
KW antisense therapy; antisense; ss.
XX
XX Synthetic.
OS Unidentified.
XX
XX US2004014051-A1.
PN
PD 22-JAN-2004.

XX 18-JUL-2002; 2002US-00199676.
PF
XX 18-JUL-2002; 2002US-00199676.
PR
XX (ISIS-) ISIS PHARM INC.
XX
XX Brown-Driver VL, Dobie KW;
PI
XX WPI; 2004-121557/12.
DR
XX
XX New antisense oligonucleotide compounds, useful for diagnosing,
PT preventing and/or treating conditions with aberrant activity of breast
PT cancer-1, such as breast, ovary, prostate and/or peritoneum cancers.
PT
XX Disclosure; SEQ ID NO 38; 175pp; English.
PS
XX The present invention is directed to novel antisense compounds targeted
XX to breast cancer-1 proteins and their encoding nucleic acids. The
CC invention is useful for the diagnosis, prevention and/or treatment of
CC diseases and conditions associated with aberrant expression and activity
CC of breast cancer-1 such as a hyperproliferative disorder in particular
CC breast, ovary, prostate and peritoneum cancers. The invention is also
CC used in antisense therapy. The present sequence is human breast cancer-1
CC associated antisense oligonucleotide. Note: This sequence given in the
CC sequence listing differs from that given in example 15 of the
CC specification.
XX
XX Sequence 20 BP; 2 A; 7 C; 7 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2763 CTCGTCTACCCAGGCTGGAG 2782
DB 1 CTCGTCTGCCACCGCTGGAG 20
RESULT 1760
ADJ96333/c
ID ADJ96333 standard; DNA; 20 BP.
XX
AC ADJ96333;
XX
XX 06-MAY-2004 (first entry)
XX
XX Human breast cancer-1 associated antisense oligonucleotide #51.
XX
XX Breast cancer-1; diagnosis; hyperproliferative disorder; cancer;
KW antisense therapy; antisense; ss.
XX
XX Synthetic.
OS Unidentified.
XX
XX US2004014051-A1.
PN
PD 22-JAN-2004.
XX
XX 18-JUL-2002; 2002US-00199676.
XX
XX 18-JUL-2002; 2002US-00199676.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX Brown-Driver VL, Dobie KW;
PI
XX WPI; 2004-121557/12.
DR
XX
XX New antisense oligonucleotide compounds, useful for diagnosing,
PT preventing and/or treating conditions with aberrant activity of breast
PT cancer-1, such as breast, ovary, prostate and/or peritoneum cancers.
PT
XX

PS Disclosure; SEQ ID NO 74; 175pp; English.
 XX
 CC The present invention is directed to novel antisense compounds targetted
 CC to breast cancer-1 proteins and their encoding nucleic acids. The
 CC invention is useful for the diagnosis, prevention and/or treatment of
 CC diseases and conditions associated with aberrant expression and activity
 CC of breast cancer-1 such as a hyperproliferative disorder in particular
 CC breast, ovary, prostate and peritoneum cancers. The invention is also
 CC used in antisense therapy. The present sequence is human breast cancer-1
 CC associated antisense oligonucleotide. Note: This sequence given in the
 CC sequence listing differs from that given in example 15 of the
 CC specification.
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2763 CTCTGTACCCAGGCTGGAG 2782
 Db 20 CTCTGTCCGCCAGGCTGGAG 1
 RESULT 1761
 ADJ96393
 ID ADJ96393 standard; DNA; 20 BP.
 AC
 AC ADJ96393;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Human breast cancer-1 antisense oligonucleotide #197042.
 XX
 KW Breast cancer-1; diagnosis; hyperproliferative disorder; cancer;
 KW antisense therapy; human; antisense; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone where all cytidines are
 FT 5'- methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'- methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'- methoxyethyl (2'-MOE) nucleotides"
 XX
 PN US2004014051-A1.
 PD 22-JAN-2004.
 XX
 PF 18-JUL-2002; 2002US-00199676.
 XX
 PR 18-JUL-2002; 2002US-00199676.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Brown-Driver VL, Dobie KW;
 XX
 DR WPI; 2004-121557/12.
 XX
 PT New antisense oligonucleotide compounds, useful for diagnosing,
 PT preventing and/or treating conditions with aberrant activity of breast
 PT cancer-1, such as breast, ovary, prostate and/or peritoneum cancers.
 XX

PS Example 15; Page 31; 175pp; English.
 XX
 CC The present invention is directed to novel antisense compounds targetted
 CC to breast cancer-1 proteins and their encoding nucleic acids. The
 CC invention is useful for the diagnosis, prevention and/or treatment of
 CC diseases and conditions associated with aberrant expression and activity
 CC of breast cancer-1 such as a hyperproliferative disorder in particular
 CC breast, ovary, prostate and peritoneum cancers. The invention is also
 CC used in antisense therapy. The present sequence is human breast cancer-1
 CC associated antisense oligonucleotide. Note: This sequence given in example 15 of the
 CC specification differs from that given in the sequence listing.
 XX
 SQ Sequence 20 BP; 2 A; 7 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2763 CTCTGTACCCAGGCTGGAG 2782
 Db 1 CTCTGTCCGCCAGGCTGGAG 20
 RESULT 1762
 ADJ96457/c
 ID ADJ96457 standard; DNA; 20 BP.
 XX
 AC ADJ96457;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Human breast cancer-1 target oligonucleotide #42.
 XX
 KW Breast cancer-1; diagnosis; hyperproliferative disorder; cancer;
 KW antisense therapy; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2004014051-A1.
 PD 22-JAN-2004.
 XX
 PF 18-JUL-2002; 2002US-00199676.
 XX
 PR 18-JUL-2002; 2002US-00199676.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Brown-Driver VL, Dobie KW;
 XX
 DR WPI; 2004-121557/12.
 XX
 PT New antisense oligonucleotide compounds, useful for diagnosing,
 PT preventing and/or treating conditions with aberrant activity of breast
 PT cancer-1, such as breast, ovary, prostate and/or peritoneum cancers.
 XX
 Example 15; Page 32; 175pp; English.
 XX
 CC The present invention is directed to novel antisense compounds targetted
 CC to breast cancer-1 proteins and their encoding nucleic acids. The
 CC invention is useful for the diagnosis, prevention and/or treatment of
 CC diseases and conditions associated with aberrant expression and activity
 CC of breast cancer-1 such as a hyperproliferative disorder in particular
 CC breast, ovary, prostate and peritoneum cancers. The invention is also
 CC used in antisense therapy. The present sequence is human breast cancer-1
 CC target oligonucleotide.
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2763 CTCTGTACCCAGGCTGGAG 2782
 Db 1 CTCTGTCCGCCAGGCTGGAG 20
 RESULT 1762
 ADJ96457/c
 ID ADJ96457 standard; DNA; 20 BP.
 XX
 AC ADJ96457;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Human breast cancer-1 target oligonucleotide #42.
 XX
 KW Breast cancer-1; diagnosis; hyperproliferative disorder; cancer;
 KW antisense therapy; human; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2004014051-A1.
 PD 22-JAN-2004.
 XX
 PF 18-JUL-2002; 2002US-00199676.
 XX
 PR 18-JUL-2002; 2002US-00199676.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Brown-Driver VL, Dobie KW;
 XX
 DR WPI; 2004-121557/12.
 XX
 PT New antisense oligonucleotide compounds, useful for diagnosing,
 PT preventing and/or treating conditions with aberrant activity of breast
 PT cancer-1, such as breast, ovary, prostate and/or peritoneum cancers.
 XX
 Example 15; Page 32; 175pp; English.
 XX
 CC The present invention is directed to novel antisense compounds targetted
 CC to breast cancer-1 proteins and their encoding nucleic acids. The
 CC invention is useful for the diagnosis, prevention and/or treatment of
 CC diseases and conditions associated with aberrant expression and activity
 CC of breast cancer-1 such as a hyperproliferative disorder in particular
 CC breast, ovary, prostate and peritoneum cancers. The invention is also
 CC used in antisense therapy. The present sequence is human breast cancer-1
 CC target oligonucleotide.
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2763 CTCTGTCACCCAGGCTGGAG 2782
 ||||| ||||| ||||| |||||
 Db 20 CTCTGTCGCCAGGCTGGAG 1

RESULT 1763
 ADM13954/c
 ID ADM13954 standard; DNA; 20 BP.
 XX
 AC ADM13954;
 XX
 XX 01-JUL-2004 (first entry)
 XX
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:141.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.

Key Location/Qualifiers
 modified_base 1..20
 /tag= b
 /mod_base= OTHER
 /note= "phosphorothioate linkages and all cytidine residues are 5-methylcytidines"
 modified_base 1..5
 /tag= a
 /mod_base= OTHER
 /note= "2'-O-methoxyethyls"
 modified_base 16..20
 /tag= c
 /mod_base= OTHER
 /note= "2'-O-methoxyethyls"
 WO2004028458-A2.
 08-APR-2004.
 25-SEP-2003; 2003WO-US030374.
 25-SEP-2002; 2002US-0413549P.
 (PHAA) PHARMACIA CORP.
 Gierse JK;
 WPI; 2004-305094/28.
 New antisense compound, having a sequence targeted to a nucleic acid encoding mPGES-1, useful for preparing a composition for treating e.g., inflammation, Alzheimer's disease, arthritis, diabetes, cancer or ischemia.
 Claim 4; SEQ ID NO 141; 132pp; English.

The present sequence represents a chimeric antisense oligonucleotide targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The human mPGES-1 gene is located on chromosome 9, more specifically to 9q34.3. The present invention also describes: (1) antisense compounds, having a sequence comprising 8-30 bp targeted to a nucleic acid encoding mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and inhibits its expression; (2) a method of inhibiting the expression of mPGES-1 in cells or tissues; and (3) a method of treating an animal having a disease or condition associated with mPGES-1. mPGES-1 chimeric

CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e-02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
 ||||| ||||| ||||| |||||
 Db 20 TGTGTGTGTGTGTGTGTGTG 1

RESULT 1764
 ADM14466/c
 ID ADM14466 standard; DNA; 20 BP.
 XX
 AC ADM14466;
 XX
 XX 01-JUL-2004 (first entry)
 XX
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:653.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.

Key Location/Qualifiers
 modified_base 1..20
 /tag= b
 /mod_base= OTHER
 /note= "phosphorothioate linkages and all cytidine residues are 5-methylcytidines"
 modified_base 1..5
 /tag= a
 /mod_base= OTHER
 /note= "2'-O-methoxyethyls"
 modified_base 16..20
 /tag= c
 /mod_base= OTHER
 /note= "2'-O-methoxyethyls"
 WO2004028458-A2.
 08-APR-2004.
 25-SEP-2003; 2003WO-US030374.
 25-SEP-2002; 2002US-0413549P.
 (PHAA) PHARMACIA CORP.
 Gierse JK;
 WPI; 2004-305094/28.

PT New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 XX
 XX
 PS Claim 4; SEQ ID NO 653; 132pp; English.
 XX
 XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GTGTGTGTGTGTGTGTGTGT 2747
 Db 20 GTGTGTGTGTGTGTGTGTGT 1
 RESULT 1765
 ADM14546/c
 ID ADM14546 standard; DNA; 20 BP.
 XX
 AC ADM14546;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:733.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 modified_base 1..20
 FT FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 modified_base 1..5
 FT FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 modified_base 16..20
 FT FT /*tag= c
 FT /mod_base= OTHER
 FT

FT
 XX
 PN /note= "2'-O-methoxyethyls"
 WO2004028458-A2.
 XX
 PD 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 PF
 XX 25-SEP-2002; 2002US-0413549P.
 PR
 PA (PHAA) PHARMACIA CORP.
 XX
 XX Gierse JK;
 PI
 DR WPI; 2004-305094/28.
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 PT
 PS Claim 4; SEQ ID NO 733; 132pp; English.
 XX
 XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 9 A; 9 C; 2 G; 0 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2723 TCCGCTGTGTGTGTGTGTGTG 2742
 Db 20 TCCGCTGTGTGTGTGTGTGTG 1
 RESULT 1766
 ADM13955/c
 ID ADM13955 standard; DNA; 20 BP.
 XX
 AC ADM13955;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:142.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX

XX SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GTGTGTGTGTGTGTGTGTGT 2747
 Db 20 GTGTGTGTGTGTGTGTGTGT 1
 RESULT 1768
 ADM14113/c
 ID ADM14113 standard; DNA; 20 BP.
 XX AC ADM14413;
 XX DT 01-JUL-2004 (first entry)
 XX DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:600.
 XX KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX PN WO2004028458-A2.
 XX PD 08-APR-2004.
 XX PF 25-SEP-2003; 2003WO-US030374.
 XX PR 25-SEP-2002; 2002US-0413549P.
 XX PA (PHAA) PHARMACIA CORP.
 XX PI Gierse JK;
 XX PI WPI; 2004-305094/28.
 XX DR New antisense compound, having a sequence targeted to a nucleic acid
 XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
 XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 XX ischemia.
 XX PS Claim 4; SEQ ID NO 600; 132pp; English.
 XX CC The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The

CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTGTGT 2748
 Db 20 TGTGTGTGTGTGTGTGTGTGT 1
 RESULT 1769
 ADM14566/c
 ID ADM14566 standard; DNA; 20 BP.
 XX AC ADM14566;
 XX DT 01-JUL-2004 (first entry)
 XX DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:753.
 XX KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX PN WO2004028458-A2.
 XX PD 08-APR-2004.
 XX PF 25-SEP-2003; 2003WO-US030374.
 XX PR 25-SEP-2002; 2002US-0413549P.


```

XX PA (PHAA ) PHARMACIA CORP.
XX PI Gierse JK;
XX XX
XX DR WPI; 2004-305094/28.
XX PT New antisense compound, having a sequence targeted to a nucleic acid
XX PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX PT ischemia.
XX PS Claim 4; SEQ ID NO 753; 132pp; English.
XX CC
XX CC The present sequence represents a chimeric antisense oligonucleotide
XX CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX CC human mPGES-1 gene is located on chromosome 9, more specifically to
XX CC 9q34.3. The present invention also describes: (1) antisense compounds,
XX CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX CC inhibits its expression; (2) a method of inhibiting the expression of
XX CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX CC antisense oligonucleotides and antisense compounds have cytostatic,
XX CC antiinflammatory, neuroprotective, cardiant, neuroprotective,
XX CC antidiabetic, immunomodulatory and cardiovascular activities, and can
XX CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX CC can be used for preparing a composition for treating a disease or
XX CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX SQ Sequence 20 BP; 4 A; 4 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2839 TCCACCTCAGCTCTCTGAG 2858
DB 20 TCCCGGCTCAGCTCTCTGAG 1
|||||
|||||

RESULT 1770
ADM14345/c
ID ADM14345 standard; DNA; 20 BP.
XX AC
XX AC ADM14345;
XX DT 01-JUL-2004 (first entry)
XX XX
XX DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:532.
XX KW chimeric; antisense oligonucleotide; phosphorothioate; human;
XX KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
XX KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX KW neuroprotective; nototropic; antiarthritic; vasotropic; ophthalmological;
XX KW immunomodulatory; cardiovascular; gene therapy; inflammation;
XX KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX KW reperfusion injury; ophthalmic disorder; immunological disorder;
XX KW cardiovascular disorder; neurological disorder; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH
XX FT Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /tag= b
XX FT /mod_base= OTHER
XX FT /note= "phosphorothioate linkages and all cytidine
XX FT residues are 5-methylcytidines"

```

```

FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX WO2004028458-A2.
XX PN
XX XX
XX PD 08-APR-2004.
XX XX
XX PF 25-SEP-2003; 2003WO-US030374.
XX PR
XX PR 25-SEP-2002; 2002US-0413549P.
XX PA (PHAA ) PHARMACIA CORP.
XX PI Gierse JK;
XX WPI; 2004-305094/28.
XX PT New antisense compound, having a sequence targeted to a nucleic acid
XX PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX PT ischemia.
XX PS Claim 4; SEQ ID NO 532; 132pp; English.
XX CC
XX CC The present sequence represents a chimeric antisense oligonucleotide
XX CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX CC human mPGES-1 gene is located on chromosome 9, more specifically to
XX CC 9q34.3. The present invention also describes: (1) antisense compounds,
XX CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX CC inhibits its expression; (2) a method of inhibiting the expression of
XX CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX CC antisense oligonucleotides and antisense compounds have cytostatic,
XX CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
XX CC antiinflammatory, neuroprotective, nototropic, antiarthritic, vasotropic,
XX CC ophthalmological, immunomodulatory and cardiovascular activities, and can
XX CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GGTGTGTGTGTGTGTGTGTGT 2747
DB 20 GGTGTGTGTGTGTGTGTGTGT 1
|||||
|||||

RESULT 1771
ADM14426/c
ID ADM14426 standard; DNA; 20 BP.
XX AC
XX AC ADM14426;
XX XX
XX DT 01-JUL-2004 (first entry)
XX DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:613.
XX KW chimeric; antisense oligonucleotide; phosphorothioate; human;
XX KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;

```


CC antiinflammatory, neuroprotective, neurotropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX Sequence 20 BP; 4 A; 3 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2838 CTCACCTCAGCTCTCTGA 2857
 Db 20 CTCACCTCAGCTCTCTGA 1

RESULT 1773
 ADM13951/c
 ID ADM13951 standard; DNA; 20 BP.
 XX
 AC ADM13951;

XX 01-JUL-2004 (first entry)
 XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:138.

XX chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; neurotropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

XX Homo sapiens.
 OS Synthetic.

XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"

XX W02004028458-A2.

XX 08-APR-2004.

XX 25-SEP-2003; 2003WO-US030374.

XX 25-SEP-2002; 2002US-0413549P.

XX (PHAA) PHARMACIA CORP.

XX Gierse JK;

XX WPI; 2004-305094/28.

XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,

PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.

XX Claim 4; SEQ ID NO 138; 132pp; English.

XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, neurotropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.

XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GGTGTGTGTGTGTGTGTGTGT 2747
 Db 20 GGTGTGTGTGTGTGTGTGTGT 1

RESULT 1774

ADM14130/c
 ID ADM14130 standard; DNA; 20 BP.

XX ADM14130;

XX 01-JUL-2004 (first entry)

XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:317.

XX chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; neurotropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

XX Homo sapiens.
 OS Synthetic.

XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"

DT 01-JUL-2004 (first entry)
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:586.
DE
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulator; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT
FT
PN WO2004028458-A2.
XX
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
XX Claim 4; SEQ ID NO 586; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytosolic,
CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 9 A; 10 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2727 CGTGTGTGTGTGTGTATG 2746
DB 20 CGTGTGTGTGTGTGTGTG 1
RESULT 1777
ADM15236/c
ID ADM15236 standard; DNA; 20 BP.
XX
XX ADM15236;
XX
XX 01-JUL-2004 (first entry)
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1423.
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT
FT
PN WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
XX Claim 4; SEQ ID NO 1423; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytosolic,
CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 9 A; 10 C; 1 G; 0 T; 0 U; 0 Other;

CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, neurotropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 10 A; 8 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGT 2747

Db 20 GTGTGTGTGTGTGTGTGTGT 1

RESULT 1778

ADM13989/C

ID ADM13989 standard; DNA; 20 BP.

XX AC ADM13989;

XX XX 01-JUL-2004 (first entry)

XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:176.

XX chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; neurotropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "phosphorothioate linkages and all cytidine

FT residues are 5-methylcytidines"

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

XX WO2004028458-A2.

XX 08-APR-2004.

XX 25-SEP-2003; 2003WO-US030374.

XX 25-SEP-2002; 2002US-0413549P.

XX (PHAA) PHARMACIA CORP.

XX Gierse JK;

XX WPI; 2004-305094/28.

XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.

PS Claim 4; SEQ ID NO 176; 132pp; English.

XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, neurotropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX

SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGT 2747

Db 20 GTGTGTGTGTGTGTGTGTGT 1

RESULT 1779

ADM14297/C

ID ADM14297 standard; DNA; 20 BP.

XX AC ADM14297;

XX XX 01-JUL-2004 (first entry)

XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:484.

XX chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; neurotropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "phosphorothioate linkages and all cytidine

FT residues are 5-methylcytidines"

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX
 XX WO2004028458-A2.
 XX
 XX 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 XX
 XX 25-SEP-2002; 2002US-0413549P.
 XX
 XX (PHAA) PHARMACIA CORP.
 XX
 XX Gierse JK;
 XX
 XX WPI; 2004-305094/28.
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 XX
 XX Claim 4; SEQ ID NO 484; 132pp; English.
 XX
 CC The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
 |||||
 Db 20 TGTGTGTGTGTGTGTGTG 1
 RESULT 1780
 ADM14346/c
 ID ADM14346 standard; DNA; 20 BP.
 XX
 XX ADM14346;
 XX
 XX 01-JUL-2004 (first entry)
 DT
 XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:533.
 DE
 XX chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;

KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 XX Homo sapiens.
 XX Synthetic.
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX
 XX WO2004028458-A2.
 XX
 XX 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 XX
 XX 25-SEP-2002; 2002US-0413549P.
 XX
 XX (PHAA) PHARMACIA CORP.
 XX
 XX Gierse JK;
 XX
 XX WPI; 2004-305094/28.
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 XX
 XX Claim 4; SEQ ID NO 533; 132pp; English.
 XX
 CC The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GGTGTGTGTGTGTGTGTGTG 2747
 |||||
 Db 20 GGTGTGTGTGTGTGTGTG 1

RESULT 1781	
ADM14695/c	
ID	ADM14695 standard; DNA; 20 BP.
XX	
XX	ADM14695;
XX	
XX	01-JUL-2004 (first entry)
DT	
XX	
XX	Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:882.
XX	
KW	chimeric; antisense oligonucleotide; phosphorothioate; human;
KW	microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW	microsomal prostaglandin E2 synthase inhibitor; cycostatic; antiadipatic;
KW	immunomodulatory; cardiant; neuroprotective; antiinflammatory;
KW	neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW	immunomodulatory; cardiovascular; gene therapy; inflammation;
KW	Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW	reperfusion injury; ophthalmic disorder; immunological disorder;
KW	cardiovascular disorder; neurological disorder; ss.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
XX	Key
XX	Location/Qualifiers
FT	modified_base 1..20
FT	/*tag= b
FT	/mod_base= OTHER
FT	/note= "phosphorothioate linkages and all cytidine
FT	residues are 5-methylcytidines"
FT	modified_base 1..5
FT	/*tag= a
FT	/mod_base= OTHER
FT	/note= "2'-O-methoxyethyls"
FT	modified_base 16..20
FT	/*tag= c
FT	/mod_base= OTHER
FT	/note= "2'-O-methoxyethyls"
XX	
XX	WO2004028458-A2.
PN	
XX	
XX	08-APR-2004.
PD	
XX	
XX	25-SEP-2003; 2003WO-US030374.
PP	
XX	
XX	25-SEP-2002; 2002US-0413549P.
PR	
XX	(PHAA) PHARMACIA CORP.
PA	
XX	
XX	Gierae JK;
PI	
XX	
XX	WPI; 2004-305094/28.
DR	
XX	
XX	New antisense compound, having a sequence targeted to a nucleic acid
XX	encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT	inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT	ischemia.
PT	
XX	
XX	Claim 4; SEQ ID NO 882; 132pp; English.
PS	
XX	
XX	The present sequence represents a chimeric antisense oligonucleotide
XX	targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC	human mPGES-1 gene is located on chromosome 9, more specifically to
CC	9q34.3. The present invention also describes: (1) antisense compounds,
CC	having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC	mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC	inhibits its expression; (2) a method of inhibiting the expression of
CC	mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC	having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC	antisense oligonucleotides and antisense compounds have cytostatic,
CC	antidiabetic, immunomodulator, cardiant, neuroprotective,
CC	antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC	ophthalmological, immunomodulatory and cardiovascular activities, and can


```

PT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding MPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 140; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (MPGES-1). The
XX human MPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX MPGES-1, which specifically hybridise with the nucleic acid MPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX MPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with MPGES-1. MPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulatory, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as MPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with MPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
XX
Query Match 0.68; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.08; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2729 TGTGTGTGTGTGTGTGTGTG 2748
      |||||
Db 20 TGTGTGTGTGTGTGTGTG 1

RESULT 1785
ADM14344/c
ID ADM14344 standard; DNA; 20 BP.
XX
XX ADM14344;
XX
XX 01-JUL-2004 (first entry)
XX

```

```

DE Human MPGES-1 chimeric antisense oligonucleotide SEQ ID NO:531.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; MPGES-1; MPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
XX immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= b
XX /mod_base= OTHER
XX /note= "phosphorothioate linkages and all cytidine
XX residues are 5-methylcytidines"
XX modified_base 1..5
XX /*tag= a
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyls"
XX modified_base 16..20
XX /*tag= c
XX /mod_base= OTHER
XX /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding MPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 531; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (MPGES-1). The
XX human MPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX MPGES-1, which specifically hybridise with the nucleic acid MPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX MPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with MPGES-1. MPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX antidiabetic, immunomodulatory, cardiant, neuroprotective,
XX antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as MPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with MPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 9 A; 9 C; 2 G; 0 T; 0 U; 0 Other;
XX
Query Match 0.68; Score 18.4; DB 1; Length 20;

```

Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2724 CC CGGTGTGTGTGTGTGTGTGT 2743
||| ||||| ||||| |||||
Db 20 CC GTGTGTGTGTGTGTGTGT 1

RESULT 1786
ADM15498/c
ID ADM15498 standard; DNA; 20 BP.
XX
AC ADM15498;
XX
XX Sequence 20 BP; 10 A; 8 C; 0 G; 2 T; 0 U; 0 Other;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1685.
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 1685; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and

CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytosolic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 8 C; 0 G; 2 T; 0 U; 0 Other;
XX

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGTG 2748
||| ||||| ||||| |||||
Db 20 TGTGTGTGTGTGTGTGTGTG 1

RESULT 1787
ADM14129/c
ID ADM14129 standard; DNA; 20 BP.
XX
AC ADM14129;
XX
XX 01-JUL-2004 (first entry)
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:316.
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX
XX (PHAA) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 1685; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and

```

XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 316; 132bp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX anti-diabetic, immunomodulatory, cardiant, neuroprotective,
XX anti-inflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2728 GGTGTGTGTGTGTGTGTGT 2747
DB 20 GGTGTGTGTGTGTGTGTGT 1
RESULT 1788
ADMI14134/c
ID ADMI14134 standard; DNA; 20 BP.
AC ADMI14134;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:321.
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
XX immunomodulatory; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT

```

```

FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX ischemia.
XX
XX Claim 4; SEQ ID NO 321; 132bp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX human mPGES-1 gene is located on chromosome 9, more specifically to
XX 9q34.3. The present invention also describes: (1) antisense compounds,
XX having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX inhibits its expression; (2) a method of inhibiting the expression of
XX mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX antisense oligonucleotides and antisense compounds have cytostatic,
XX anti-diabetic, immunomodulatory, cardiant, neuroprotective,
XX anti-inflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX ophthalmological, immunomodulatory and cardiovascular activities, and can
XX be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX can be used for preparing a composition for treating a disease or
XX condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2728 GGTGTGTGTGTGTGTGTGT 2747
DB 20 GGTGTGTGTGTGTGTGTGT 1
RESULT 1789
ADMI14296/c
ID ADMI14296 standard; DNA; 20 BP.
XX
XX ADMI14296;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:483.
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
XX immunomodulatory; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX

```

KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

OS Homo sapiens.
 OS Synthetic.

XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /*note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /*note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /*note= "2'-O-methoxyethyls"

XX WO2004028458-A2.

XX 08-APR-2004.

XX 25-SEP-2003; 2003WO-US030374.

XX 25-SEP-2002; 2002US-0413549P.

XX (PHAA) PHARMACIA CORP.

XX Gierse JK;

XX WPI; 2004-305094/28.

XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.

XX Claim 4; SEQ ID NO 483; 132pp; English.

XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.

SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTG 2748

Db 20 TGTGTGTGTGTGTGTG 1

RESULT 1790

ADM14298/c
 ID ADM14298 standard; DNA; 20 BP.
 XX
 AC ADM14298;
 XX
 XX 01-JUL-2004 (first entry)
 XX
 XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:485.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /*note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /*note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /*note= "2'-O-methoxyethyls"
 XX
 XX WO2004028458-A2.
 XX
 XX 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 XX
 XX 25-SEP-2002; 2002US-0413549P.
 XX (PHAA) PHARMACIA CORP.
 XX
 XX Gierse JK;
 XX
 XX WPI; 2004-305094/28.
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 XX
 XX Claim 4; SEQ ID NO 485; 132pp; English.
 XX
 XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.

The present sequence represents a chimeric antisense oligonucleotide targeted to human microsomal prostaglandin E2 synthase (MPGES-1). The human MPGES-1 gene is located on chromosome 9, more specifically to 9q34.3. The present invention also describes: (1) antisense compounds, having a sequence comprising 8-30 bp targeted to a nucleic acid encoding MPGES-1, which specifically hybridise with the nucleic acid MPGES-1 and inhibits its expression; (2) a method of inhibiting the expression of MPGES-1 in cells or tissues; and (3) a method of treating an animal having a disease or condition associated with MPGES-1. MPGES-1 chimeric antisense oligonucleotides and antisense compounds have cytostatic, anti-diabetic, immunomodulator, cardiant, neuroprotective, anti-inflammatory, neuroprotective, nootropic, antiarthritic, vasotropic, ophthalmological, immunomodulatory and cardiovascular activities, and can be used as MPGES-1 inhibitors and in gene therapy. The antisense compound can be used for preparing a composition for treating a disease or condition associated with MPGES-1 e.g., inflammation, Alzheimer's disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or ophthalmic, immunological, cardiovascular or neurological disorder.

Sequence 20 BP; 10 A; 8 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2730 GTGTGTGTGTGTGTGTGTGT 2749
 ||||| ||||| ||||| |||||
 DB 20 GTGTGTGTGTGTGTGTGTGT 1

RESULT 1792
 ADM14131/c
 ID ADM14131 standard; DNA; 20 BP.
 AC ADM14131;
 XX
 XX 01-JUL-2004 (first entry)
 XX Human MPGES-1 chimeric antisense oligonucleotide SEQ ID NO:318.
 DE
 XX chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; MPGES-1; MPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; anti-diabetic;
 KW immunomodulator; cardiant; neuroprotective; anti-inflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /*mod_base= OTHER
 FT /*note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /*mod_base= OTHER
 FT /*note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /*mod_base= OTHER
 FT /*note= "2'-O-methoxyethyls"
 XX
 XX WO2004028458-A2.
 XX
 PD 08-APR-2004.
 XX

```

PF 25-SEP-2003; 2003WO-US030374.
XX
PR 25-SEP-2002; 2002US-0413549P.
XX
PA (PHAA ) PHARMACIA CORP.
XX
PI Gierse JK;
XX
DR WPI; 2004-305094/28.
XX
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
XX Claim 4; SEQ ID NO 318; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
Db |||||
RESULT 1793
ID ADM15408/C
XX ADM15408 standard; DNA; 20 BP.
XX
XX ADM15408;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1595.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
OS Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= b

```

```

FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
XX Claim 4; SEQ ID NO 1595; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 9 A; 8 C; 1 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2727 CGTGTGTGTGTGTGTGTGTG 2746
Db |||||
RESULT 1794
ID ADM14133/C
XX ADM14133 standard; DNA; 20 BP.
XX
XX ADM14133;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:320.
XX

```


CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, neurotropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 9 A; 8 C; 2 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2722 ATCCGCGTGTGTGTGTGT 2741
 Db 20 ATCCGCGTGTGTGTGTGT 1
 ||||| ||||| ||||| ||||| |||||

RESULT 1796
 ADM15478/C
 ID ADM15478 standard; DNA; 20 BP.
 XX
 AC ADM15478;
 XX
 XX 01-JUL-2004 (first entry)
 DT
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1665.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; neurotropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 15..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT
 FT WO2004028458-A2.
 XX
 XX 08-APR-2004.
 PD
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 XX
 XX 25-SEP-2002; 2002US-0413549P.
 XX
 XX (PHAA) PHARMACIA CORP.
 PA
 XX Gierse JK;
 PI
 XX WPI; 2004-305094/28.
 DR

XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 XX
 PS Claim 4; SEQ ID NO 1665; 132pp; English.
 XX
 CC The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, neurotropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 10 A; 8 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GGTGTGTGTGTGTGTGTGT 2747
 Db 20 GGTGTGTGTGTGTGTGTGT 1
 ||||| ||||| ||||| ||||| |||||

RESULT 1797
 ADM14295/C
 ID ADM14295 standard; DNA; 20 BP.
 XX
 AC ADM14295;
 XX
 XX 01-JUL-2004 (first entry)
 DT
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:482.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; neurotropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT

FT FT /mod_base= OTHER
 XX XX /note= "2'-O-methoxyethyls"
 PN WO2004028458-A2.
 XX
 XX 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 PF
 XX 25-SEP-2002; 2002US-0413549P.
 XX
 XX (PHAA) PHARMACIA CORP.
 PA
 XX Gierse JK;
 XX WPI; 2004-305094/28.
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 PT
 XX Claim 4; SEQ ID NO 482; 132pp; English.
 PS
 XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
 Db 20 TGTGTGTGTGTGTGTGTG 1
 RESULT 1798
 ADM13952/c
 ID ADM13952 standard; DNA; 20 BP.
 XX
 AC ADM13952;
 XX
 XX 01-JUL-2004 (first entry)
 DT
 XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:139.
 DE
 XX chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

XX Homo sapiens.
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /*tag= "2'-O-methoxyethyls"
 XX WO2004028458-A2.
 PN
 XX 08-APR-2004.
 PD
 XX 25-SEP-2003; 2003WO-US030374.
 PF
 XX 25-SEP-2002; 2002US-0413549P.
 PR
 XX (PHAA) PHARMACIA CORP.
 PA
 XX Gierse JK;
 XX WPI; 2004-305094/28.
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 PT
 XX Claim 4; SEQ ID NO 139; 132pp; English.
 PS
 XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
 Db 20 TGTGTGTGTGTGTGTGTG 1
 RESULT 1799
 ADM13988/c
 ID ADM13988 standard; DNA; 20 BP.

XX ADM13988;
 AC
 XX
 DT 01-JUL-2004 (first entry)
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:175.
 XX
 DE chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /*tag= "2'-O-methoxyethyls"
 FT /note= "2'-O-methoxyethyls"
 XX
 WO2004028458-A2.
 XX
 XX
 PD 08-APR-2004.
 XX
 PF 25-SEP-2003; 2003WO-US030374.
 XX
 PR 25-SEP-2002; 2002US-0413549P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Gierse JK;
 XX
 DR WPI; 2004-305094/28.
 XX
 PT New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 XX
 PS Claim 4; SEQ ID NO 175; 132pp; English.
 XX
 CC The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytosstatic,
 CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
 CC antiinflammatory, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or

CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GGTGTGTGTGTGTGTATGT 2747
 Db 20 GGTGTGTGTGTGTGTGTGT 1
 RESULT 1800
 ADM14427/c
 ID ADM14427 standard; DNA; 20 BP.
 XX
 AC ADM14427;
 XX
 XX 01-JUL-2004 (first entry)
 DT Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:614.
 XX
 DE chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosstatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /*tag= "2'-O-methoxyethyls"
 FT /note= "2'-O-methoxyethyls"
 XX
 WO2004028458-A2.
 XX
 XX
 PD 08-APR-2004.
 XX
 PF 25-SEP-2003; 2003WO-US030374.
 XX
 PR 25-SEP-2002; 2002US-0413549P.
 XX
 PA (PHAA) PHARMACIA CORP.
 XX
 PI Gierse JK;
 XX
 DR WPI; 2004-305094/28.
 XX
 PT New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 XX
 PS Claim 4; SEQ ID NO 614; 132pp; English.
 XX
 CC The present sequence represents a chimeric antisense oligonucleotide

CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC anti-diabetic, immunomodulatory, cardiant, neuroprotective,
 CC anti-inflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.

XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGT 2747
 Db |||||
 20 GTGTGTGTGTGTGTGTGTGT 1

RESULT 1801
 ADM14814/c
 ID ADM14814 standard; DNA; 20 BP.
 XX
 AC ADM14814;
 XX
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1001.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; anti-diabetic;
 KW immunomodulatory; cardiant; neuroprotective; anti-inflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT
 XX WO2004028458-A2.
 PN
 XX
 XX
 PD 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 PF
 XX

PR 25-SEP-2002; 2002US-0413549P.
 XX (PHAA) PHARMACIA CORP.
 PA
 XX
 XX Gierse JK;
 PI
 XX
 XX WPI; 2004-305094/28.
 DR
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 XX
 PS Claim 4; SEQ ID NO 1001; 132pp; English.
 XX
 XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC anti-diabetic, immunomodulatory, cardiant, neuroprotective,
 CC anti-inflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.

XX Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2841 CCACCTCAGCCTCTGAGTA 2860
 Db |||||
 20 CCGCCTCAGCCTCTGAGTA 1

RESULT 1802
 ADO45368
 ID ADO45368 standard; DNA; 20 BP.
 XX
 AC ADO45368;
 XX
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #734.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 OS
 XX US2004049022-A1.
 PN
 XX
 XX 11-MAR-2004.
 PD
 XX
 XX 25-JUL-2003; 2003US-00627930.
 PF
 XX

PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRI,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 734; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2769 CACCCAGGCTGGAGTCAGT 2788
 DB 1 CGCCCGAGGCTGGAGTCAGT 20
 RESULT 1803
 ADO45263
 ID ADO45263 standard; DNA; 20 BP.
 XX
 AC ADO45263;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #629.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;

KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX US2004049022-A1.
 XX 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCRI,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 629; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 3 A; 8 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2845 CTCAGCCTCCTGAGTAGCTG 2864
 DB 1 CTCAGCCTCCTGAGTAGCTG 20

RESULT 1804
ADO45779/c

ID ADO45779 standard; DNA; 20 BP.

XX ADO45779;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #1145.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
CCRL1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

XX (SAND/) SANDRASAGRA A.

XX (TANG/) TANG L.

XX (AGUI/) AGUILAR D.

XX (MILL/) MILLER S.

XX (SHAH/) SHAHABUDDIN S.

XX (LUHH/) LU H.

XX (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX Claim 2; SEQ ID NO 1146; 174pp; English.
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,

CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.

XX SQ Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;

XX Query Match 0.6%; Score 18.4; DB 1; Length 20;

XX Best Local Similarity 95.0%; Pred. No. 8.1e+02;

XX Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1451 AGGTCACCCGCGAGGTGACC 1470

Db 20 AGGTCACCCGCGAGGTGACC 1

RESULT 1805

ADO45369

ID ADO45369 standard; DNA; 20 BP.

XX ADO45369;

XX 15-JUL-2004 (first entry)

XX Human oligonucleotide #735.

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
CCRL1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

XX Homo sapiens.

XX US2004049022-A1.

XX 11-MAR-2004.

XX 25-JUL-2003; 2003US-00627930.

XX 23-APR-2002; 2002WO-US013135.

XX 23-APR-2002; 2002WO-US013143.

XX (NYCE/) NYCE J W.

XX (SAND/) SANDRASAGRA A.

XX (TANG/) TANG L.

XX (AGUI/) AGUILAR D.

XX (MILL/) MILLER S.

XX (SHAH/) SHAHABUDDIN S.

XX (LUHH/) LU H.

XX (CONG/) CONG H.

XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;

PI Shahabuddin S, Lu H, Cong H;

XX WPI; 2004-293804/27.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX Claim 2; SEQ ID NO 735; 174pp; English.
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)

-5 receptor, CCRI, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention also relates to a method of screening a candidate compound that binds to one or more nucleic acid target(s) or expressed product(s), for the prevention and/or treatment of a respiratory or lung disease. The oligonucleotides are useful for reducing or inhibiting expression of a gene or mRNA encoding Interleukin-4 receptor, Interleukin-5 receptor, CCRI, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are useful for preventing or treating a respiratory or lung disease. The respiratory or lung disease is associated with hyper-responsiveness to and/or increased levels of, adenosine and/or levels of adenosine A receptor(s), and/or asthma and/or lung allergies associated with inflammation or an inflammatory disease. The respiratory or lung disease is chosen from airway inflammation, allergy, asthma, impeded respiration, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), allergic rhinitis, acute respiratory distress syndrome, pulmonary hypertension, lung inflammation, bronchitis, airway obstruction or bronchoconstriction. This sequence represents an oligonucleotide of the invention.

Sequence 20 BP: 3 A; 4 C; 10 G; 3 T; 0 U; 0 Other;
xx
xx

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2774 AGGCTGGAGTGCAGTGGTGC 2793
Db 1 AGGCTGGAGTGCAGTGGCGC 20

RESULT 1806
ADO45778/C
ID ADO45778 standard; DNA; 20 BP.
XX
XX ADO45778;
AC
XX
XX
15-JUL-2004 (first entry)
DT
DE Human oligonucleotide #1144.
XX

PI	Shahabuddin S, Lu H, Cong H;
XX	
DR	WPI; 2004-293804/27.
XX	
PT	Novel single or multiple target oligonucleotide anti-sense to e.g.
PT	initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT	RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT	asthma.
XX	
PS	Claim 2; SEQ ID NO 1145; 174pb; English.

Query Match	0.6%	Score 18.4	DB 1	Length 20
Best Local Similarity	95.0%	Pred. No. 8.1e+02		
Matches 19	Conservative 0	Mismatches 1	Indels 0	Gaps 0

Qy 1461 CGAGGTGACCGTGAATGTGC 1480
Db 20 CAAGGTGACCGTGAATGTGC 1

RESULT 1807	
ADO45366	
ADO45366 standard; DNA; 20 BP.	
XX	
XX	
AC	
AC	ADO45366;
XX	
DT	15-JUL-2004 (first entry)
XX	
DE	Human oligonucleotide #732.
XX	
XX	Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW	CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW	tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW	lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW	asthma; lung allergy; inflammation; inflammatory disease;
KW	airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW	chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW	acute respiratory distress syndrome; pulmonary hypertension;
KW	lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX	
OS	Homo sapiens.
XX	
PN	US2004049022-A1.
XX	
PD	11-MAR-2004.

PF 25-JUL-2003; 2003US-00627930.
 XX
 PR 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 PA (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 732; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2759 CTCGCTCTGTCACCCAGGCT 2778
 DB 1 CTCGCTCTGTCACCCAGGCT 20
 RESULT 1808
 ID ADO46462
 AC ADO46462 standard; DNA; 20 BP.
 AC ADO46462;
 XX
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #1828.
 XX
 XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;

KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 XX
 XX US2004049022-A1.
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.
 XX
 PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-293804/27.
 DR
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 PS Claim 2; SEQ ID NO 1829; 174pp; English.
 XX
 CC The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 3 C; 9 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 AGCGTGCAGTCAGTGGTGC 2793


```

Db      1 AGGCTGGAGTGCAGTGATGC 20
|||||
RESULT 1809
ADO45358
ID      ADO45358 standard; DNA; 20 BP.
XX
AC      ADO45358;
XX
DT      15-JUL-2004 (first entry)
XX
DE      Human oligonucleotide #724.
XX
KW      Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW      CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW      tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW      lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW      asthma; lung allergy; inflammation; inflammatory disease;
KW      airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW      chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW      acute respiratory distress syndrome; pulmonary hypertension;
KW      lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS      Homo sapiens.
XX
PN      US2004049022-A1.
XX
PD      11-MAR-2004.
XX
PF      25-JUL-2003; 2003US-00627930.
XX
PR      23-APR-2002; 2002WO-US013135.
PR      23-APR-2002; 2002WO-US013143.
XX
PA      (NYCE/) NYCE J W.
PA      (SAND/) SANDRASAGRA A.
PA      (TANG/) TANG L.
PA      (AGUI/) AGUILAR D.
PA      (MILL/) MILLER S.
PA      (SHAH/) SHAHABUDDIN S.
PA      (LUHH/) LU H.
PA      (CONG/) CONG H.
XX
PI      Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI      Shahabuddin S, Lu H, Cong H;
XX
WPI; 2004-293804/27.
XX
PT      Novel single or multiple target oligonucleotide anti-sense to e.g.
PT      initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT      RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT      asthma.
XX
PS      Claim 2; SEQ ID NO 724; 174pp; English.
XX
CC      The invention relates to oligonucleotides anti-sense to an initiation
CC      codon, coding region, 5' or 3' intron-exon junction, intron or region
CC      with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC      chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC      -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC      tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC      also relates to a method of screening a candidate compound that binds to
CC      one or more nucleic acid target(s) or expressed product(s), for the
CC      prevention and/or treatment of a respiratory or lung disease. The
CC      oligonucleotides are useful for reducing or inhibiting expression of a
CC      gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC      CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC      tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC      useful for preventing or treating a respiratory or lung disease. The
CC      respiratory or lung disease is associated with hyper-responsiveness to
CC      and/or increased levels of, adenosine and/or levels of adenosine A
CC      receptor(s), and/or asthma and/or lung allergies associated with

```

```

CC      inflammation or an inflammatory disease. The respiratory or lung disease
CC      is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC      cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC      allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC      hypertension, lung inflammation, bronchitis, airway obstruction or
CC      bronchoconstriction. This sequence represents an oligonucleotide of the
CC      invention.
XX
SQ      Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
Query Match      0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY      2770 ACCCAGGCTGGAGTGCAGTG 2789
DB      1 ACCCAGGCTGGAGTGAAGTG 20
|||||
RESULT 1810
ADO45367
ID      ADO45367 standard; DNA; 20 BP.
XX
AC      ADO45367;
XX
DT      15-JUL-2004 (first entry)
XX
DE      Human oligonucleotide #733.
XX
KW      Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW      CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW      tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW      lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW      asthma; lung allergy; inflammation; inflammatory disease;
KW      airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW      chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW      acute respiratory distress syndrome; pulmonary hypertension;
KW      lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
XX
OS      Homo sapiens.
XX
PN      US2004049022-A1.
XX
PD      11-MAR-2004.
XX
PF      25-JUL-2003; 2003US-00627930.
XX
PR      23-APR-2002; 2002WO-US013135.
PR      23-APR-2002; 2002WO-US013143.
XX
PA      (NYCE/) NYCE J W.
PA      (SAND/) SANDRASAGRA A.
PA      (TANG/) TANG L.
PA      (AGUI/) AGUILAR D.
PA      (MILL/) MILLER S.
PA      (SHAH/) SHAHABUDDIN S.
PA      (LUHH/) LU H.
PA      (CONG/) CONG H.
XX
PI      Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI      Shahabuddin S, Lu H, Cong H;
XX
WPI; 2004-293804/27.
XX
PT      Novel single or multiple target oligonucleotide anti-sense to e.g.
PT      initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT      RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT      asthma.
XX
PS      Claim 2; SEQ ID NO 733; 174pp; English.
XX
CC      The invention relates to oligonucleotides anti-sense to an initiation
CC      codon, coding region, 5' or 3' intron-exon junction, intron or region

```

CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

SQ Sequence 20 BP; 2 A; 6 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2764 TCTGTACCCAGCTGGAGT 2783
 DB 1 TCTGTGCCCCAGCTGGAGT 20
 ||||| ||||| ||||| ||||| |||||

RESULT 1811
 ADO81052/c
 ID ADO81052 standard; DNA; 20 BP.

XX ADO81052;
 XX
 XX 29-JUL-2004 (first entry)
 XX Cow prion protein microsatellite locus primer #64.
 XX gene typing; polymorphic microsatellite loci; PML;
 KW disease predisposition; microsatellite marker; prion disease;
 KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
 KW milk protein; hormone; transcription factor; pT7-blue-vector; cow;
 KW microsatellite; PCR; primer; ss.
 XX
 XX Bos taurus.
 XX DE10236711-Al.
 XX 26-FEB-2004.
 XX 09-AUG-2002; 2002DE-01036711.
 XX 09-AUG-2002; 2002DE-01036711.
 XX (UYHO-) UNIV HOHENHEIM.
 XX Geldermann H, Preuss S, Han Y;
 XX WPI; 2004-215730/21.

XX Typing genes that contain polymorphic microsatellite loci, useful for
 PT identifying predisposition to disease, by amplification and determining
 PT length of amplicons.
 XX Example 3; Page 27; 64pp; German.
 XX The invention describes a method of typing (M1) a gene (I) that has one

CC or more polymorphic microsatellite loci (PML). The method comprises: PCR
 CC amplification of at least one DNA region of (I) that includes PML, using
 CC as template a DNA sample containing at least one segment of (I); and
 CC determining the length of the resulting amplicon(s). Also described are:
 CC a method of determining (M2) microsatellite markers (MM) for
 CC predisposition to a disease, associated with a gene that includes one or
 CC more PML; and prediagnosis (M3) of diseases associated with gene that
 CC include PML. The method is used to identify microsatellite markers, in a
 CC disease-related gene, that are associated with a predisposition to
 CC diseases and for prediagnosis of such diseases, especially prion diseases
 CC but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
 CC metabolic diseases; also to type genes that encode milk proteins,
 CC hormones or transcription factors. The method is simpler, quicker and
 CC particularly less expensive than known methods based on sequencing. This
 CC sequence represents a primer used to genotype a region of the cow prion
 CC protein (PrP) comprising a polymorphic microsatellite locus.

SQ Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGTG 2748
 DB 20 TGTGTGTGTGTGTGTGTGTGTG 1
 ||||| ||||| ||||| ||||| |||||

RESULT 1812
 ADO81097/c
 ID ADO81097 standard; DNA; 20 BP.

XX ADO81097;
 XX
 XX 29-JUL-2004 (first entry)
 XX Sheep prion protein microsatellite locus primer #68.
 XX gene typing; polymorphic microsatellite loci; PML;
 KW disease predisposition; microsatellite marker; prion disease;
 KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
 KW milk protein; hormone; transcription factor; pT7-blue-vector; sheep;
 KW microsatellite; PCR; primer; ss.
 XX
 XX Ovis aries.
 XX DE10236711-Al.
 XX 26-FEB-2004.
 XX 09-AUG-2002; 2002DE-01036711.
 XX 09-AUG-2002; 2002DE-01036711.
 XX (UYHO-) UNIV HOHENHEIM.
 XX Geldermann H, Preuss S, Han Y;
 XX WPI; 2004-215730/21.

XX Typing genes that contain polymorphic microsatellite loci, useful for
 PT identifying predisposition to disease, by amplification and determining
 PT length of amplicons.

XX Example 3; Page 30; 64pp; German.

XX The invention describes a method of typing (M1) a gene (I) that has one
 CC or more polymorphic microsatellite loci (PML). The method comprises: PCR
 CC amplification of at least one DNA region of (I) that includes PML, using
 CC as template a DNA sample containing at least one segment of (I); and
 CC determining the length of the resulting amplicon(s). Also described are:
 CC a method of determining (M2) microsatellite markers (MM) for
 CC predisposition to a disease, associated with a gene that includes one or

CC more PML; and prediagnosis (M3) of diseases associated with gene that
 CC include PML. The method is used to identify microsatellite markers, in a
 CC disease-related gene, that are associated with a predisposition to
 CC diseases and for prediagnosis of such diseases, especially prion diseases
 CC but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
 CC metabolic diseases; also to type genes that encode milk proteins,
 CC hormones or transcription factors. The method is simpler, quicker and
 CC particularly less expensive than known methods based on sequencing. This
 CC sequence represents a primer used to genotype a region of the sheep prion
 CC protein (PrP) comprising a polymorphic microsatellite locus.

XX Sequence 20 BP; 10 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTG 2748

Db 20 TGTGTGTGTGTGTGTGTG 1

RESULT 1813

AD052210

ID AD052210 standard; DNA; 20 BP.

XX AC AD052210;

XX DT 12-AUG-2004 (first entry)

XX DE Human inhibitor of apoptosis-like antisense oligonucleotide seqid 84.

XX KW cytostatic; gene therapy; inhibitors of apoptosis-like; IAP-like;

XX KW IAP-like modulator; IAP-like associated disorder;

XX KW hyperproliferative disorder; human; antisense oligonucleotide;

XX KW antisense technology; ss.

XX OS Homo sapiens.

XX FH Key

FT modified_base 1..20

FT /tag= b

FT /mod_base= OTHER

FT /note= "OTHER= Phosphorothioate backbone. All cytidines

FT are 5-methylcytidines"

FT modified_base 1..5

FT /tag= a

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

FT modified_base 15..20

FT /tag= c

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

XX US2004102395-A1.

XX PN

XX PD 27-MAY-2004.

XX PF 22-NOV-2002; 2002US-00303325.

XX PR 22-NOV-2002; 2002US-00303325.

XX XX (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Dobie KW;

XX XX WPI; 2004-399725/37.

XX XX New compound targeted to a nucleic acid molecule encoding inhibitors of

XX PT apoptosis (IAP)-like and inhibits expression of IAP-like, useful for

XX PT modulating the expression of IAP-like or for treating, e.g.

XX PT hyperproliferative disorder.

XX XX

PS Example 14; SEQ ID NO 84; 58pp; English.

XX CC The invention describes a compound 8-80 nucleobases in length targeted to
 CC a nucleic acid molecule encoding inhibitors of apoptosis (IAP)-like,
 CC where the compound specifically hybridizes with the nucleic acid molecule
 CC encoding IAP-like comprising 16000 bp (SEQ ID NO. 4) and inhibits the
 CC expression of IAP-like. Also described are: inhibiting the expression of
 CC IAP-like in cells or tissues; screening for a modulator of IAP-like; a
 CC diagnostic method for identifying a disease state comprising identifying
 CC the presence of IAP-like in a sample using at least one of the primers
 CC selected from 2 sequences comprising SEQ ID NO. 5 or 6, or the probe
 CC comprising SEQ ID NO. 7; a kit or assay device comprising the compound;
 CC and treating an animal having a disease or condition associated with IAP-
 CC like. The compound is useful for modulating the expression of IAP-like.
 CC It is also useful for diagnosing or treating diseases associated with
 CC expression of IAP-like, e.g. a hyperproliferative disorder. This sequence
 CC represents a human inhibitor of apoptosis (IAP)-like antisense
 CC oligonucleotide.

XX SQ Sequence 20 BP; 1 A; 9 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 20;

Best Local Similarity 95.0%; Pred. No. 8.1e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCAACCCAGGC 2777

Db 1 TCTCGCTCTGTCAACCCGGGC 20

RESULT 1814

AD052274/c

ID AD052274 standard; DNA; 20 BP.

XX AC AD052274;

XX DT 12-AUG-2004 (first entry)

XX DE Human inhibitor of apoptosis-like antisense oligonucleotide seqid 150.

XX KW cytostatic; gene therapy; inhibitors of apoptosis-like; IAP-like;

XX KW IAP-like modulator; IAP-like associated disorder;

XX KW hyperproliferative disorder; human; antisense oligonucleotide;

XX KW antisense technology; ss.

XX OS Homo sapiens.

XX FH Key

FT modified_base 1..20

FT /tag= b

FT /mod_base= OTHER

FT /note= "OTHER= Phosphorothioate backbone. All cytidines

FT are 5-methylcytidines"

FT modified_base 1..5

FT /tag= a

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

FT modified_base 15..20

FT /tag= c

FT /mod_base= OTHER

FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"

XX US2004102395-A1.

XX PN

XX PD 27-MAY-2004.

XX PF 22-NOV-2002; 2002US-00303325.

XX PR 22-NOV-2002; 2002US-00303325.

XX XX (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Dobie KW;

XX XX WPI; 2004-399725/37.

XX XX New compound targeted to a nucleic acid molecule encoding inhibitors of

XX PT apoptosis (IAP)-like and inhibits expression of IAP-like, useful for

XX PT modulating the expression of IAP-like or for treating, e.g.

XX PT hyperproliferative disorder.

XX XX

XX WPI; 2004-399725/37.
 XX
 XX New compound targeted to a nucleic acid molecule encoding inhibitors of
 PT apoptosis (IAP)-like and inhibits expression of IAP-like, useful for
 PT modulating the expression of IAP-like or for treating, e.g.
 PT hyperproliferative disorder.
 XX
 XX Example 14; SEQ ID NO 148; 58pp; English.
 XX
 XX The invention describes a compound 8-80 nucleobases in length targeted to
 CC a nucleic acid molecule encoding inhibitors of apoptosis (IAP)-like,
 CC where the compound specifically hybridises with the nucleic acid molecule
 CC encoding IAP-like comprising 16000 bp (SEQ ID NO. 4) and inhibits the
 CC expression of IAP-like. Also described are: inhibiting the expression of
 CC IAP-like in cells or tissues; screening for a modulator of IAP-like; a
 CC diagnostic method for identifying a disease state comprising identifying
 CC the presence of IAP-like in a sample using at least one of the primers
 CC selected from 2 sequences comprising SEQ ID NO. 5 or 6, or the probe
 CC comprising SEQ ID NO. 7; a kit or assay device comprising the compound;
 CC and treating an animal having a disease or condition associated with IAP-
 CC like. The compound is useful for modulating the expression of IAP-like.
 CC It is also useful for diagnosing or treating diseases associated with
 CC expression of IAP-like, e.g. a hyperproliferative disorder. This sequence
 CC represents a human inhibitor of apoptosis (IAP)-like antisense
 CC oligonucleotide.
 XX
 XX Sequence 20 BP; 5 A; 5 C; 9 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 2758 TCTCGCTCTGTCTACCCAGGC 2777
 Db |||||
 20 TCTCGCTCTGTCTACCCAGGC 1
 XX
 RESULT 1815
 ADP45826
 ID ADP45826 standard; DNA; 20 BP.
 XX
 AC ADP45826;
 XX
 DT 26-AUG-2004 (first entry)
 XX
 DE Extend primer 18 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.
 XX
 KW breast cancer; cytostatic; gene therapy; human;
 KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
 KW CD54; cell surface glycoprotein P3.58; ICAM-4;
 KW Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
 KW ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
 XX
 OS Homo sapiens.
 XX
 PN WO2004047623-A2.
 XX
 PD 10-JUN-2004.
 XX
 PF 25-NOV-2003; 2003WO-US037948.
 XX
 PR 25-NOV-2002; 2002US-0429136P.
 PR 24-JUL-2003; 2003US-0490234P.
 XX
 PA (SEQU-) SEQUENOM INC.
 XX
 PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
 XX WPI; 2004-441051/41.
 XX
 XX Identifying a subject at risk of breast cancer by detecting the presence
 PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
 PT regions which are associated with breast cancer in a nucleic acid sample
 from a subject.
 XX

PT regions which are associated with breast cancer in a nucleic acid sample
 PT from a subject.
 XX
 XX Example 4; Page 83; 289pp; English.
 XX
 XX The invention relates to a novel method for identifying a subject at risk
 CC of breast cancer comprising detecting the presence or absence of one or
 CC more polymorphic variations associated with breast cancer in a nucleic
 CC acid sample from a subject. The method of the invention has cytostatic
 CC applications and may be useful for identifying a subject at risk of
 CC breast cancer for early diagnosis, prevention and treatment of breast
 CC cancer, possibly via gene therapy, as well as to analyse and predict a
 CC response to a breast cancer treatment and in clinical drug trials. The
 CC current sequence is that of an Extend primer (also described as probe) of
 CC the invention which was used to genotype human intercellular adhesion
 CC molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor; BB2
 CC ;CD54;cell surface glycoprotein P3.58) has been mapped to chromosomal
 CC position 19p13.3-p13.2, ICAM-4 (Landsteiner-Wiener blood group; LW) has
 CC been mapped to chromosomal position 19p13.2-cen and ICAM-5
 CC (telencephalin) has been mapped to chromosomal position 19p13.2.
 XX
 XX Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 8.1e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 XX
 QY 2762 GCTCTGTCTACCCAGGCTGGA 2781
 Db |||||
 1 GCTTTGTCTACCCAGGCTGGA 20
 XX
 RESULT 1816
 ADP45838
 ID ADP45838 standard; DNA; 20 BP.
 XX
 AC ADP45838;
 XX
 DT 26-AUG-2004 (first entry)
 XX
 DE Extend primer 30 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.
 XX
 KW breast cancer; cytostatic; gene therapy; human;
 KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
 KW CD54; cell surface glycoprotein P3.58; ICAM-4;
 KW Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
 KW ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
 XX
 OS Homo sapiens.
 XX
 PN WO2004047623-A2.
 XX
 PD 10-JUN-2004.
 XX
 PF 25-NOV-2003; 2003WO-US037948.
 XX
 PR 25-NOV-2002; 2002US-0429136P.
 PR 24-JUL-2003; 2003US-0490234P.
 XX
 PA (SEQU-) SEQUENOM INC.
 XX
 PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
 XX WPI; 2004-441051/41.
 XX
 XX Identifying a subject at risk of breast cancer by detecting the presence
 PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
 PT regions which are associated with breast cancer in a nucleic acid sample
 from a subject.
 XX
 XX Example 4; Page 83; 289pp; English.
 XX
 XX The invention relates to a novel method for identifying a subject at risk

RESULT 1819
ADT01088/c
ID ADT01088 standard; DNA; 20 BP.
XX
AC ADT01088;
XX
DT 16-DEC-2004 (first entry)
XX
DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID1076.
XX
KW tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
KW tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
KW GUCY2F; MCKK; MLK4; kinase domain; cytosolic; tyrosine kinase inhibitor;
KW guanylate cyclase stimulator; ss.
XX
OS Homo sapiens.
XX
PN WO2004082458-A2.
XX
PD 30-SEP-2004.
XX
PF 18-FEB-2004; 2004WO-US004452.
XX
PW tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
KW tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
KW GUCY2F; MCKK; MLK4; kinase domain; cytosolic; tyrosine kinase inhibitor;
KW guanylate cyclase stimulator; ss.
XX
OS Homo sapiens.
XX
PN WO2004082458-A2.
XX
PD 30-SEP-2004.
XX
PF 18-FEB-2004; 2004WO-US004452.
XX
PR 21-FEB-2003; 2003US-0448537P.
PR 29-MAY-2003; 2003US-0473895P.
XX
PA (UWJO) UNIV JOHNS HOPKINS.
XX
PI Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;
XX WPI; 2004-718702/70.
XX
PT Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCKK) and
PT associated methods for diagnosing cancer and screening for anti-cancer
PT agents.
XX
PS Disclosure; SEQ ID NO 1076; 363pp; English.
XX
CC This invention relates to a novel activated mutant protein tyrosine
CC kinases and associated methods for diagnosing cancer and screening for
CC anti-cancer agents. Protein kinases are signalling molecules involved in
CC tumorigenesis. Mutational analysis of the human tyrosine kinase gene
CC family identified somatic alteration sin 1 in 5 colorectal cancers, with
CC the majority of mutations occurring in the NTRK3, FES, GUCY2F and
CC MCKK/MLK4 genes. Most were identified in the kinase domain. The invention
CC may be useful for the production of compounds with a cytosolic activity
CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
CC stimulators. The invention may be useful for developing methods for
CC detecting mutations involved in cancer or screening for anti-cancer
CC agents. The present sequence is that of a human-derived oligonucleotide
CC which is related to the invention.
XX
SQ Sequence 20 BP; 5 A; 3 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2759 CTCGCTCTGTACCCAGGCT 2778
DB 20 CTCACCTCTGTACCCAGGCT 1
RESULT 1820
ADT00235/c
ID ADT00235 standard; DNA; 20 BP.
XX
AC ADT00235;
XX
DT 16-DEC-2004 (first entry)
XX
DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID223.
XX

KW tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
KW tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
KW GUCY2F; MCKK; MLK4; kinase domain; cytosolic; tyrosine kinase inhibitor;
KW guanylate cyclase stimulator; ss.
XX
OS Homo sapiens.
XX
PN WO2004082458-A2.
XX
PD 30-SEP-2004.
XX
PF 18-FEB-2004; 2004WO-US004452.
XX
PR 21-FEB-2003; 2003US-0448537P.
PR 29-MAY-2003; 2003US-0473895P.
XX
PA (UWJO) UNIV JOHNS HOPKINS.
XX
PI Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;
XX WPI; 2004-718702/70.
XX
PT Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCKK) and
PT associated methods for diagnosing cancer and screening for anti-cancer
PT agents.
XX
PS Disclosure; SEQ ID NO 223; 363pp; English.
XX
CC This invention relates to a novel activated mutant protein tyrosine
CC kinases and associated methods for diagnosing cancer and screening for
CC anti-cancer agents. Protein kinases are signalling molecules involved in
CC tumorigenesis. Mutational analysis of the human tyrosine kinase gene
CC family identified somatic alteration sin 1 in 5 colorectal cancers, with
CC the majority of mutations occurring in the NTRK3, FES, GUCY2F and
CC MCKK/MLK4 genes. Most were identified in the kinase domain. The invention
CC may be useful for the production of compounds with a cytosolic activity
CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
CC stimulators. The invention may be useful for developing methods for
CC detecting mutations involved in cancer or screening for anti-cancer
CC agents. The present sequence is that of a human-derived oligonucleotide
CC which is related to the invention.
XX
SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 8.1e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2763 CTCGTGTACCCAGGCTGGAG 2782
DB 20 CTCGTGTACCCAGGATGGAG 1
RESULT 1821
ABN88973
ID ABN88973 standard; DNA; 21 BP.
XX
AC ABN88973;
XX
DT 22-AUG-2002 (first entry)
XX
DE Phosphorothioate 21mer oligonucleotide SEQ ID NO:2.
XX
KW Phosphorothioate; oligonucleotide synthesis; phosphoramidite; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..21 /tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages"
XX

PN WO20020543-A2.
 XX
 PD 14-MAR-2002.
 XX
 PF 06-SEP-2001; 2001WO-GB003973.
 XX
 PR 07-SEP-2000; 2000US-0230685P.
 XX
 PA (AVEC-) AVECIA BIOTECHNOLOGY INC.
 PA (AVEC-) AVECIA LTD.
 XX
 XX Sinha N;
 XX
 XX WPI; 2002-479457/51.
 DR
 XX
 XX Novel phosphoramidite compound, useful for the synthesis of
 PT oligonucleotides, comprising nucleoside moieties linked by one or more
 PT internucleoside phosphorus atoms.
 XX
 XX Example 4; Page 28; 67pp; English.
 PS
 XX The present invention describes a phosphoramidite compound (I) comprising
 CC two or more nucleoside moieties linked by one or more internucleoside
 CC phosphorus atoms, where the internucleoside phosphorus atoms are
 CC phosphorus (III) atoms. Also described: (1) preparing a trivalent
 CC phosphorus multimer or its stereoisomer (I); (2) a trivalent phosphorus
 CC multimer derivatised solid support (II); and (3) preparing (II). (I) or
 CC (II) can be used for the synthesis of oligonucleotides. The present
 CC sequence represents a phosphorothioate 21mer oligonucleotide which is
 CC synthesised in an example from the present invention
 XX
 XX Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;
 SQ
 CC The present invention describes a phosphoramidite compound (I) comprising
 CC two or more nucleoside moieties linked by one or more internucleoside
 CC phosphorus atoms, where the internucleoside phosphorus atoms are
 CC phosphorus (III) atoms. Also described: (1) preparing a trivalent
 CC phosphorus multimer or its stereoisomer (I); (2) a trivalent phosphorus
 CC multimer derivatised solid support (II); and (3) preparing (II). (I) or
 CC (II) can be used for the synthesis of oligonucleotides. The present
 CC sequence represents a phosphorothioate 21mer oligonucleotide which is
 CC synthesised in an example from the present invention
 XX
 XX Sequence 21 BP; 0 A; 0 C; 10 G; 11 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 18.4; DB 1; Length 21;
 Best Local Similarity 95.0%; Pred. No. 7.7e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2728 GTGTGTGTGTGTGTGTGT 2747
 DB 1 GTGTGTGTGTGTGTGTGT 20
 RESULT 1822
 ABN88972/C
 ID ABN88972 standard; DNA; 21 BP.
 XX
 AC ABN88972;
 XX
 XX 22-AUG-2002 (first entry)
 DT
 XX Phosphorothioate 21mer oligonucleotide SEQ ID NO:1.
 DE
 KW Phosphorothioate; oligonucleotide synthesis; phosphoramidite; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..21
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages"
 XX
 PN WO20020543-A2.
 XX
 XX 14-MAR-2002.
 PD
 XX
 XX 06-SEP-2001; 2001WO-GB003973.
 XX
 XX 07-SEP-2000; 2000US-0230685P.
 XX
 XX (AVEC-) AVECIA BIOTECHNOLOGY INC.
 XX (AVEC-) AVECIA LTD.

PI Sinha N;
 XX
 DR WPI; 2002-479457/51.
 XX
 XX Novel phosphoramidite compound, useful for the synthesis of
 PT oligonucleotides, comprising nucleoside moieties linked by one or more
 PT internucleoside phosphorus atoms.
 XX
 XX Example 4; Page 28; 67pp; English.
 PS
 XX The present invention describes a phosphoramidite compound (I) comprising
 CC two or more nucleoside moieties linked by one or more internucleoside
 CC phosphorus atoms, where the internucleoside phosphorus atoms are
 CC phosphorus (III) atoms. Also described: (1) preparing a trivalent
 CC phosphorus multimer or its stereoisomer (I); (2) a trivalent phosphorus
 CC multimer derivatised solid support (II); and (3) preparing (II). (I) or
 CC (II) can be used for the synthesis of oligonucleotides. The present
 CC sequence represents a phosphorothioate 21mer oligonucleotide which is
 CC synthesised in an example from the present invention
 XX
 XX Sequence 21 BP; 10 A; 10 C; 0 G; 1 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 18.4; DB 1; Length 21;
 Best Local Similarity 95.0%; Pred. No. 7.7e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 OY 2728 GTGTGTGTGTGTGTGTGT 2747
 DB 20 GTGTGTGTGTGTGTGTGT 1
 RESULT 1823
 AAD31456
 ID AAD31456 standard; DNA; 22 BP.
 XX
 AC AAD31456;
 XX
 XX 31-MAY-2002 (first entry)
 DT
 XX Human chromosome 17 92Kb gene fragment amplifying PCR primer, Wt3F.
 DE
 KW Human; Van Buchem's disease; genomic deletion; craniofacial hypertosis;
 KW autosomal recessive disorder; chromosome 17; chromosome 17q21;
 KW bone dysplasia; 92Kb gene fragment; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200210455-A2.
 XX
 XX 07-FEB-2002.
 PD
 XX 30-JUL-2001; 2001WO-US023968.
 PF
 XX 28-JUL-2000; 2000US-0221855P.
 PR
 XX 06-JUL-2001; 2001US-030386P.
 XX
 XX (CELL-) CELLTECH R & D INC.
 PA (STRA/) STRAHLING HAMPTON K.
 XX
 XX Brunkow ME, Proll S, Paepers B;
 PI WPI; 2002-227089/28.
 XX
 DR
 XX Methods for identifying subjects who are afflicted with or carriers of
 PT diseases associated with genomic deletion(s), e.g. Van Buchem's disease,
 PT by determining the presence of a deletion in the 92 kb region of human
 PT chromosome 17 at 17q21.
 XX
 XX Example 3; Page 26; 109pp; English.
 PS
 XX The present invention relates to methods for distinguishing between
 CC individuals homozygous for and therefore afflicted with Van Buchem's
 CC disease, individuals heterozygous for and therefore carriers of Van

CC Buchem's disease and individuals who are not afflicted with Van Buchem's
CC disease comprise identifying a large genomic deletion in chromosome 17 at
CC 17q21. The method is useful for identifying individuals who are afflicted
CC with or carriers of diseases associated with one or more genomic
CC deletion, particularly Van Buchem's disease, which is a rare autosomal
CC recessive disorder that results in a bone dysplasia referred to a
CC craniofacial hypertosis. The present sequence is a PCR primer used to
CC amplify 92Kb gene fragment in human chromosome 17 at 17q21
XX
XX Sequence 22 BP; 4 A; 3 C; 10 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 22;
Best Local Similarity 95.0%; Pred. NO. 7.e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2773 CAGCGTGGAGTGCAGTGGTG 2792
|||||
Db 1 CAGCGTGGAGTGCAGTGGTG 20

RESULT 1824

AAH39005
ID AAH39005 standard; DNA; 23 BP.

XX AC AAH39005;

XX 14-AUG-2001 (first entry)

XX SNP specific upper PCR primer SEQ ID 1801.

XX Single nucleotide polymorphism; SNP; single nucleotide primer extension;
KW SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
KW Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
KW acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
KW inflammation; forensic investigation; paternity analysis; PCR primer; ss.

XX Homo sapiens.

XX WO200129262-A2.

XX 26-APR-2001.

XX 13-OCT-2000; 2000WO-US028436.

XX 15-OCT-1999; 99US-0160096P.

XX (ORCH-) ORCHID BIOSCIENCES INC.

XX Picoult-Newburg L, Pohl M;

XX WPI; 2001-290930/30.

XX New genotyping oligonucleotide, useful for detecting the presence,
PT absence or identity of single polynucleotide polymorphism in a nucleic
PT acid sample.

XX Claim 1; Page 59; 83pp; English.

XX Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
CC primer extension (SNPE) primers, and the sequences of regions flanking
CC sites of single nucleotide polymorphisms SNPs. The present invention
CC includes kits for determining the presence or absence of a SNP, using the
CC oligonucleotides of the invention. The PCR primers are used to amplify a
CC SNP flanking sequence, the SNPs primer is used as a genotyping primer.
CC The oligonucleotides are useful for genotyping a nucleic acid sample by
CC performing a single-nucleotide primer extension reaction. The
CC oligonucleotides are useful for determining the presence, absence or
CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to
CC assess by association analysis the genotype of an individual or group of
CC individuals, having a pathological phenotypic trait suspected of being
CC caused by one or more SNPs. Phenotypic traits include diseases e.g.
CC agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular

CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
CC traits also include symptoms of or susceptibility to multifactorial
CC disease of which a component is or may be genetic such as autoimmune
CC diseases, including, rheumatoid arthritis, multiple sclerosis,
CC inflammation, cancer, nervous system diseases and infection by pathogenic
CC microorganism. The method is also useful in forensic investigations and
CC paternity analysis. The present sequence represents a PCR primer specific
CC for a human SNP containing DNA sequence

XX Sequence 23 BP; 0 A; 0 C; 10 G; 13 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 23;

Best Local Similarity 95.0%; Pred. NO. 7.e+02;

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
|||||
Db 4 TGTGTGTGTGTGTGTGTGTG 23

RESULT 1825

ADC79601

ID ADC79601 standard; DNA; 23 BP.

XX AC ADC79601;

XX 01-JAN-2004 (first entry)

XX Human p53 forward RT-PCR primer.

XX cytoplasmic; cancer; chemotherapy; carcinomas; tumour; RT-PCR; ss;

XX primer; primer.

XX Homo sapiens.

XX WO2003035894-A2.

XX 01-MAY-2003.

XX 28-OCT-2002; 2002WO-US034397.

XX 26-OCT-2001; 2001US-0330669P.

XX 04-APR-2002; 2002US-0369945P.

XX (IMMU-) IMMUNIVEST CORP.

XX O'hara SM, Zweitzig D, Foulk B;

XX WPI; 2003-482052/45.

XX Extracting intact cytoplasmic biomolecules e.g. proteins, nucleic acids
PT from cells, by treating sample comprising cells containing target cells
PT with permeabilizing agents to release biomolecules and recovering them.

XX Example 10; Page 59; 119pp; English.

XX The invention relates to a novel method for extracting intact cytoplasmic
CC biomolecules from cells. The method of the invention is useful for
CC extracting or acquiring cytoplasmic biomolecules such as proteins or
CC nucleic acids which include cytoplasmic RNA, nuclear and mitochondrial
CC RNA, nuclear and mitochondrial DNA, cytoplasmic mRNA, or their
CC combinations from cells. The method is useful in cancer screening,
CC selecting and monitoring for chemotherapy treatment or cancer recurrence.
CC This type of cell analysis is useful in cancer diagnostics. The method is
CC useful in profiling cells isolated from tissues or body fluids and serves
CC as an adjunct to clinical diagnosis of diverse carcinomas including early
CC stage detection and classification of circulating tumour cells. The
CC present sequence is used in the exemplification of the invention.

XX Sequence 23 BP; 3 A; 9 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 23;

Best Local Similarity 95.0%; Pred. No. 7e+02; Mismatches 0; Indels 1; Gaps 0;

QY 2844 CCTCAGCCTCCTGAGTAGCT 2863
 ID ADE44542 standard; DNA; 23 BP.
 XX |||||
 Db 4 CCTCAGCCTCCGGAGTAGCT 23

RESULT 1826
 ADE44542
 ID ADE44542 standard; DNA; 23 BP.
 XX |||||
 AC ADE44542;
 XX
 XX 29-JAN-2004 (first entry)
 DT
 DE Primer #1 to amplify the p53 gene for cancer-detection method.
 XX
 XX ss: primer; diagnosis: cancer; epithelial cell; immunomagnetic particle;
 KW prostate cancer; breast cancer; colon cancer apudoma; choristoma;
 KW branchioma; malignant carcinoid syndrome; carcinoid heart disease;
 XX carcinoma.
 XX Homo sapiens.
 OS
 XX W02003035895-A2.
 PN
 XX
 XX 01-MAY-2003.
 PD
 XX 28-OCT-2002; 2002WO-US034570.
 XX
 XX 26-OCT-2001; 2001US-0330669P.
 PR
 PR 04-APR-2002; 2002US-0369945P.
 XX
 XX (IMMU-) IMMUNIVEST CORP.
 PA
 XX
 XX O'hara SM, Zweitzig D, Foulk B;
 PI
 XX WPI; 2003-421425/39.
 DR
 XX
 XX Diagnosing severity of disease in a test subject, by mixing the sample
 PT comprising cancer cells with immunomagnetic particles and separating cell
 PT fraction to diagnose enriched fraction for the presence of cancer cells.
 XX
 XX Example 10; Page 59; 105pp; English.
 PS
 XX The invention relates to a method of diagnosing the severity of a disease
 CC in a test subject, by obtaining a sample having a mixed cell population
 CC suspected of containing cancer cells of epithelial origin, mixing the
 CC sample with immunomagnetic particles which bind specifically to the
 CC cancer cells, subjecting the mixture to produce a separated cell
 CC fraction, and assaying the enriched fraction for the presence of the
 CC cancer cells. The method is useful for diagnosing the severity of a
 CC disease in a test subject. The test subject is for assessment of a
 CC presence of circulating cancer cells. The test subject response to cancer
 CC eradication procedures and is assessed by the presence of circulating
 CC cancer cells. The test subject has been diagnosed with a cancer selected
 CC from prostate cancer, breast cancer, colon cancer apudoma, choristoma,
 CC branchioma, malignant carcinoid syndrome, carcinoid heart disease, and
 CC carcinoma e.g. Walker, basal cell, basosquamous, Brown-Pearce, ductal,
 CC Ehrlich tumor, Krebs 2, merkel cells, mucinous, and non-small cell lung.
 CC This sequence represents a primer used to amplify a specific gene cDNA
 CC sequence in the method of the invention.
 XX
 XX Sequence 23 BP; 3 A; 9 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 18.4; DB 1; Length 23;
 Best Local Similarity 95.0%; Pred. No. 7e+02; Mismatches 0; Indels 1; Gaps 0;
 Matches 19; Conservative 0;

QY 2844 CCTCAGCCTCCTGAGTAGCT 2863
 ID ADE44542 standard; DNA; 23 BP.
 XX |||||
 Db 4 CCTCAGCCTCCGGAGTAGCT 23

RESULT 1827
 AAQ25869/c
 ID AAQ25869 standard; DNA; 19 BP.
 XX
 XX AAQ25869;
 AC
 XX 25-MAR-2003 (revised)
 DT 04-JAN-1993 (first entry)
 XX
 XX 3' Alu primer.
 DE
 XX PCR; sequence conservation; DNA synthesis; amplification; ss.
 KW
 XX Synthetic.
 OS
 XX W09210566-A1.
 PN
 XX 25-JUN-1992.
 PD
 XX 21-NOV-1991; 91WO-US008739.
 PF
 XX 13-DEC-1990; 90US-00627945.
 XX
 XX (TEXA) UNIV TEXAS SYSTEM.
 PA
 XX Siciliano MJ, Liu P;
 PI
 XX WPI; 1992-234623/28.
 DR
 XX Chromosome-specific DNA probes free of species-specific repeat DNA - used
 PT for identification and banding of human chromosomes.
 PT
 XX Claim 65; Page 63; 73pp; English.
 PS
 XX The sequences given in AAQ25868-9 are nucleotide primers which are
 CC characterised by binding to a 5' and a 3' Alu terminus, respectively.
 CC These Alu primers were based on a current revision of consensus sequence
 CC of Alu repeats. This revision is based on nucleotide sequences of 50
 CC different, cloned and sequenced human Alu segments. Two regions on the
 CC sequence showed a high degree of conservation and these were used as
 CC candidate regions for the primer locations. In order to minimize the
 CC incorporation of Alu sequence itself in the inter-Alu-PCR, the 5' primer
 CC was designed to recognise a specific region and to direct DNA synthesis
 CC off the 5' end and away from the middle of the Alu segment to which it is
 CC bound. The converse is true for the 3' primer. Amplification using these
 CC two primers yields products ranging from a few hundred to several
 CC thousand base pairs. The primer design maximizes both the number of Alu
 CC segments recruited and the number of inter-Alu unique sequences
 CC amplified. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 XX Sequence 19 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 2 Other;

Query Match 0.6%; Score 18.2; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 8.9e+02;
 Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTCAGTGCT 2791
 ID AAQ48683 standard; cDNA; 19 BP.
 XX
 XX AAQ48683;
 AC
 XX 25-MAR-2003 (revised)
 DT 25-FEB-1994 (first entry)
 XX
 XX Human Alu segment consensus sequence PCR primer Alu-2.

RESULT 1828
 AAQ48683/c
 ID AAQ48683 standard; cDNA; 19 BP.
 XX
 XX AAQ48683;
 AC
 XX 25-MAR-2003 (revised)
 DT 25-FEB-1994 (first entry)
 XX
 XX Human Alu segment consensus sequence PCR primer Alu-2.

XX Abnormality; polymerase chain reaction; amplification; ss.
 XX Synthetic.
 OS
 XX WO9317104-A1.
 PN
 XX 02-SEP-1993.
 PD
 XX 19-FEB-1993; 93WO-US001545.
 XX
 XX 20-FEB-1992; 92US-00839255.
 XX
 XX (MASI) MASSACHUSETTS INST TECHNOLOGY.
 PA
 XX Brook JD, Housman DE;
 PI
 XX WPI; 1993-288410/36.
 DR
 XX DNA sequence of myotonic dystrophy gene - used to produce probes and
 PT identify CHR 19 abnormality and protein kinase responsible.
 PT
 XX Example; Page 32; 64pp; English.
 PS
 XX

CC The sequence is that of a PCR primer Alu-2 which specifically recognises
 CC human consensus sequences located at the 5' and 3' ends of Alu segments.
 CC It was used with 2F5 template to amplify human unique sequences. (Updated
 CC on 25-MAR-2003 to correct PN field.)
 CC

XX SQ Sequence 19 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 2 Other;

Query Match 0.6%; Score 18.2; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 8.9e+02;
 Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2773 CAGGCTGGAGTGCAGTGGT 2791

Db 19 CAGGCTGGAGTGCARTGGY 1

RESULT 1829

AAQ85677/c
 ID AAQ85677 standard; DNA; 19 BP.

XX AC AAQ85677;

XX 25-MAR-2003 (revised)

DT 04-OCT-1995 (first entry)

XX PCR primer alu 2 for inter-Alu region of Wilson's disease gene.

DE Wilson's disease; chromosome 13; Alu; PCR primer; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT misc_difference 1..19

FT /tag= a

FT /note= "Std IUPAC codes used"

XX WO9506714-A1.

XX 09-MAR-1995.

XX 01-SEP-1994; 94WO-US009851.

XX 01-SEP-1993; 93US-00118441.

XX (UYCO) UNIV COLUMBIA NEW YORK.

PA (GEHO) GEN HOSPITAL CORP.

XX Gilliam TC, Tanzi RE;

XX

DR WPI; 1995-115430/15.

XX Isolated Wilson's disease nucleic acid mol. - also probes, vectors, etc.,
 PT useful for diagnosis and gene therapy of Wilson's disease.
 XX
 XX Example; Page 30; 175pp; English.

XX

CC In order to physically map and clone the region of the Wilson's disease
 CC (WD) gene, a 4.3kb insert from the WD flanking marker D13S31 (probe
 CC PCR1324) was used to screen a large insert, CEPH II YAC sublibrary. A
 CC higher resolution YAC map was constructed using inter-Alu PCR product
 CC from 4 large YAC clones to screen the 1431 colony CEPH I YAC sublibrary.
 CC A total of 16 mid-size YACs were identified. The pattern of mid-size YACs
 CC detected by each large YAC clone was used to order the smaller YAC clones
 CC relative to one another. Inter-Alu PCR "fingerprinting" of YAC clones
 CC further assisted the ordering process. The data for this are not given in
 CC the publication. (Updated on 25-MAR-2003 to correct PN field.)
 XX

XX SQ Sequence 19 BP; 3 A; 8 C; 3 G; 3 T; 0 U; 2 Other;

Query Match 0.6%; Score 18.2; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 8.9e+02;

Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 2773 CAGGCTGGAGTGCAGTGGT 2791

Db 19 CAGGCTGGAGTGCARTGGY 1

RESULT 1830

AAQ22629/c

ID AAQ22629 standard; DNA; 18 BP.

XX AC AAQ22629;

XX 08-JUL-1992 (first entry)

XX Antisense oligonucleotide #1 targeted to ICAM-1 AUG codon (64-81).

XX Intercellular adhesion molecule-1; inhibitor; phosphorothioate bond;
 XX triple helix; ss.

XX Synthetic.

XX WO9203139-A.

XX 05-MAR-1992.

XX 23-JUL-1991; 91WO-US005209.

XX 14-AUG-1990; 90US-00567286.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK, Mira;

XX WPI; 1992-096579/12.

XX New oligonucleotides hybridisable to cell adhesion modulators - for
 PT treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
 PT and diagnosis of intercellular adhesion dysfunction.

XX Example 5; Page 38; 75pp; English.

XX This antisense oligonucleotide was designed to hybridise to the AUG codon
 CC of human ICAM-1 mRNA. The same sequence was synthesised in phosphodiester
 CC and phosphorothioate forms. The oligonucleotides were tested for
 CC inhibition of ICAM-1 expression on the surface of interleukin-1-beta-
 CC stimulated cells in two different cell lines. The phosphodiester
 CC oligonucleotide did not inhibit ICAM-1 expression. The phosphorothioate
 CC (P=S) form was the most active of 5 different P=S anti-sense
 CC oligonucleotides which were tested (see AAQ22630-4). The effect of
 CC oligonucleotide length on antisense activity was tested using truncated

CC versions of the phosphorothioate form of oligonucleotide #1. In general,
 CC antisense activity decreased as the length of the oligonucleotides
 CC decreased
 XX
 SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 50 GCCTCGCTATGGCTCCCA 67
 Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1831
 AAQ22633/c
 ID AAQ22633 standard; DNA; 18 BP.
 XX
 AC AAQ22633;
 XX
 DT 08-JUL-1992 (first entry)
 XX
 DE Antisense oligonucleotide #5 targetted to ICAM-1 coding region.
 XX
 KW Intercellular adhesion molecule-1; inhibitor; phosphorothioate bond;
 KW triple helix; ss.
 XX
 OS Synthetic.
 XX
 PN WO9203139-A.
 XX
 PD 05-MAR-1992.
 XX
 PF 23-JUL-1991; 91WO-US005209.
 XX
 PR 14-AUG-1990; 90US-00567286.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK, Mira;
 XX
 DR WPI; 1992-096579/12.
 XX
 CC New oligonucleotides hybridisable to cell adhesion modulators - for
 CC treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
 PT
 PT and diagnosis of intercellular adhesion dysfunction.
 XX
 PS Example 5; Page 39; 75pp; English.
 XX
 CC This antisense oligonucleotide was designed to hybridise to the coding
 CC region of human ICAM-1 mRNA. The same sequence was synthesised in
 CC phosphodiester and phosphorothioate forms. The oligonucleotides were
 CC tested for inhibition of ICAM-1 expression on the surface of interleukin-
 CC 1-beta-stimulated cells in two different cell lines. The phosphodiester
 CC oligonucleotide did not inhibit ICAM-1 expression, but the
 CC phosphorothioate (P=S) form did. See AAQ22629-Q22632
 XX
 SQ Sequence 18 BP; 5 A; 2 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1364 CTTTCCCACTGCCCATCG 1381
 Db 18 CTTTCCCACTGCCCATCG 1

RESULT 1832
 AAQ22632/c
 ID AAQ22632 standard; DNA; 18 BP.
 XX

AC AAQ22632;
 XX
 DT 08-JUL-1992 (first entry)
 XX
 DE Antisense oligonucleotide #4 targetted to ICAM-1 3'-UTR (2849-2866).
 XX
 KW Intercellular adhesion molecule-1; inhibitor; phosphorothioate bond;
 KW triple helix; ss.
 XX
 OS Synthetic.
 XX
 PN WO9203139-A.
 XX
 PD 05-MAR-1992.
 XX
 PF 23-JUL-1991; 91WO-US005209.
 XX
 PR 14-AUG-1990; 90US-00567286.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK, Mira;
 XX
 DR WPI; 1992-096579/12.
 XX
 CC New oligonucleotides hybridisable to cell adhesion modulators - for
 CC treatment and diagnosis of e.g. allograft rejection, cancer, AIDS etc.
 PT
 PT and diagnosis of intercellular adhesion dysfunction.
 XX
 PS Example 5; Page 39; 75pp; English.
 XX
 CC This antisense oligonucleotide was designed to hybridise to the 3'-UTR of
 CC human ICAM-1 mRNA. The same sequence was synthesised in phosphodiester
 CC and phosphorothioate forms. The oligonucleotides were tested for
 CC inhibition of ICAM-1 expression on the surface of interleukin-1-beta-
 CC stimulated cells in two different cell lines. The phosphodiester
 CC oligonucleotide did not inhibit ICAM-1 expression, but the
 CC phosphorothioate (P=S) form did. See AAQ22629-Q22631 and AAQ22633
 XX
 SQ Sequence 18 BP; 4 A; 1 C; 11 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2836 TCCTCCCACTCAGCCTC 2853
 Db 18 TCCTCCCACTCAGCCTC 1

RESULT 1833
 AAQ47006
 ID AAQ47006 standard; DNA; 18 BP.
 XX
 AC AAQ47006;
 XX
 DT 25-MAR-2003 (revised)
 DT 25-JAN-1994 (first entry)
 XX
 DE Probe (Icam 1-5) for cellular adhesion molecules.
 XX
 KW ICAM-R; autoimmunity; inflammation; arthritis; glomerulonephritis;
 KW transplant rejection; ss.
 XX
 OS Synthetic.
 XX
 PN WO9314776-A1.
 XX
 PD 05-AUG-1993.
 XX
 PF 26-JAN-1993; 93WO-US000787.
 XX
 PR 27-JAN-1992; 92US-00827689.

```

PR 26-MAY-1992; 92US-00889724.
PR 05-JUN-1992; 92US-00894061.
PR 22-JAN-1993; 93US-00009266.
XX (ICOS-) ICOS CORP.
XX Gallatin WM, Vazeux R;
XX WPI; 1993-258372/32.
XX DNA encoding new human inter-cellular adhesion molecule polypeptide (ICAM
PT -R) - useful for treating immune and inflammatory diseases, tumours and
PT viral infection e.g. HIV.
XX Example 4; Page 19; 126pp; English.
XX ICAM-R polypeptides can be used in the modulation of immune cell
CC activation/proliferation and for the treatment of conditions resulting
CC from responses of the non-specific and specific immune response in a
CC mammal. A clone containing immunoglobulin like domains of ICAM-1 was used
CC to generate the probe for screening of cDNA libraries. (Updated on 25-MAR
CC -2003 to correct PN field.)
XX Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 440 GCAAGAACCTTACCTAC 457
Db 1 GCAAGAACCTTACCTAC 18
RESULT 1834
AAQ40531/C
ID AAQ40531 standard; DNA; 18 BP.
XX AAQ40531;
XX 25-MAR-2003 (revised)
DT 12-AUG-1993 (first entry)
XX 2' protected-amine functionalised oligomer 14.
XX Linked; nucleoside; functionalised; 2'; steroid; reporter; protein;
KW non-aromatic; lipophilic; molecule; enzyme; peptide; metal chelator;
KW water soluble; vitamin; RNA cleaving complex; cholic acid; pyrene;
KW porphyrin; alkylator; hybrid; photo-nuclease; intercalator; agent;
KW aryl azide; photo-crosslinking; folic acid; heterocyclic base;
KW inter-strand; ss.
XX Synthetic.
OS
XX Key Location/Qualifiers
FH modified_base 1..2
FT /tag= a
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 2..3
FT /tag= b
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 3..4
FT /tag= c
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 4..5
FT /tag= d
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 5..6
FT /tag= f
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT /tag= e
FT /note= "Nucleotide functionalised to incorporate a pentyl
FT -N-phthalimido functionality"
FT modified_base 6..7
FT /tag= g
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 7..8
FT /tag= h
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 8..9
FT /tag= i
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 9..10
FT /tag= k
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 9
FT /tag= j
FT /note= "Nucleotide functionalised to incorporate a pentyl
FT -N-phthalimido functionality"
FT modified_base 10..11
FT /tag= l
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 11..12
FT /tag= n
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 11
FT /tag= m
FT /note= "Nucleotide functionalised to incorporate a pentyl
FT -N-phthalimido functionality"
FT modified_base 12..13
FT /tag= o
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 13..14
FT /tag= p
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 14..15
FT /tag= q
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 15..16
FT /tag= s
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 15
FT /tag= r
FT /note= "Nucleotide functionalised to incorporate a pentyl
FT -N-phthalimido functionality"
FT modified_base 16..17
FT /tag= t
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 17..18
FT /tag= u
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 18..19
FT /tag= v
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT modified_base 19..20
FT /tag= w
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"

```

```

FT XX linkage"
PN XX WO9307883-A1.
XX XX
PD XX
PP XX
PF XX 23-OCT-1992; 92WO-US009196.
PX XX
PR XX 24-OCT-1991; 91US-00782374.
XX XX
PA XX (ISIS-) ISIS PHARM INC.
XX XX
PI XX Manoharan M, Cook PD, Bennett CF;
XX XX WPI; 1993-152175/18.
DR XX
XX XX
XX XX Linked nucleoside(s) in which at least one nucleoside is functionalised -
PT PT used as anti-sense diagnostic or therapeutic agents with enhanced
PT PT activity.
XX XX
PS PS Disclosure; Page 25; 73pp; English.
XX XX
XX XX The sequences given in AAQ40518-61 are oligonucleosides which comprise
CC CC linked nucleosides at least one of which is functionalised at its 2',
CC CC position by attachment of a molecule selected from a steroid molecule, a
CC CC reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme, a
CC CC peptide, a protein, a water soluble vitamin, an RNA cleaving complex, a
CC CC metal chelator, a porphyrin, an alkylator, a hybrid photo-
CC CC nuclease/intercalator and an aryl azide photo-crosslinking agent. The
CC CC oligonucleosides may also comprise a 2' functionalised nucleoside having
CC CC cholic acid, pyrene, or folic acid linked to the 2' position of the
CC CC nucleoside, a heterocyclic base functionalised nucleoside having cholic
CC CC acid or folic acid linked to the heterocyclic base of the nucleoside, a
CC CC 5' or 3' terminal nucleoside having cholic acid, pyrene or folic acid
CC CC linked to the 5' or 3' position of the nucleoside respectively, or an
CC CC inter-strand nucleoside having cholic acid, pyrene or folic acid linked
CC CC to an inter-nucleotide linkage linking the inter- strand nucleoside to an
CC CC adjacent nucleoside. (Updated on 25-MAR-2003 to correct PN field.)
XX XX
XX XX Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1835
AAQ40530/c
ID AAQ40530 standard; DNA; 18 BP.
XX XX
AC AAQ40530;
XX XX
XX XX 25-MAR-2003 (revised)
DT 12-AUG-1993 (first entry)
XX XX
XX XX 2' protected-amine functionalised oligomer 13.
XX XX
XX XX Linked; nucleoside; functionalised; 2'; steroid; reporter; protein;
KW KW non-aromatic; lipophilic; molecule; enzyme; peptide; metal chelator;
KW KW water soluble; vitamin; RNA cleaving complex; cholic acid; pyrene;
KW KW porphyrin; alkylator; hybrid; photo-nuclease; intercalator; agent;
KW KW aryl azide; photo-crosslinking; folic acid; heterocyclic base;
KW KW inter-strand; ss.
XX XX
XX XX Synthetic.
XX XX
XX XX Key Location/Qualifiers
FH modified_base 1..2 /*tag= a
FT FT

```

```

FT PT /note= "Phosphorothioate inter-nucleotide backbone
PT linkage"
FT 2..3 /*tag= b
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 3..4 /*tag= c
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 4..5 /*tag= d
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 5..6 /*tag= e
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 6..7 /*tag= f
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 7..8 /*tag= g
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 8..9 /*tag= h
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 9..10 /*tag= i
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 10..11 /*tag= j
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 11..12 /*tag= k
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 12..13 /*tag= l
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 13..14 /*tag= m
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 14..15 /*tag= n
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 15..16 /*tag= o
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 15
FT /*tag= o
FT /note= "Nucleotide functionalised to incorporate a pentyl
FT -N-phthalimido functionality"
FT 16..17 /*tag= q
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 17..18 /*tag= r
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
FT 18..19 /*tag= s
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"

```

```

FT modified_base linkage"
FT 19..20 /*tag= t
FT /note= "Phosphorothioate inter-nucleotide backbone
FT linkage"
XX W09307883-A1.
XX
XX 29-APR-1993.
XX
XX 23-OCT-1992; 92WO-US009196.
XX
XX 24-OCT-1991; 91US-00782374.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Manoharan M, Cook PD, Bennett CF;
XX WPI; 1993-152175/18.
XX
XX Linked nucleoside(s) in which at least one nucleoside is functionalised -
XX used as anti-sense diagnostic or therapeutic agents with enhanced
XX activity.
XX
XX Disclosure; Page 25; 73pp; English.
XX
XX The sequences given in AAQ40518-61 are oligonucleosides which comprise
XX linked nucleosides at least one of which is functionalised at its 2'
XX position by attachment of a molecule selected from a steroid molecule, a
XX reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme,
XX a peptide, a protein, a water soluble vitamin, an RNA cleaving complex, a
XX metal chelator, a porphyrin, an alkylator, a hybrid photo-
XX nuclease/intercalator and an aryl azide photo-crosslinking agent. The
XX oligonucleosides may also comprise a 2' functionalised nucleoside having
XX cholic acid, pyrene, or folic acid linked to the 2' position of the
XX nucleoside, a heterocyclic base functionalised nucleoside having cholic
XX acid or folic acid linked to the heterocyclic base of the nucleoside, a
XX 5' or 3' terminal nucleoside having cholic acid, pyrene or folic acid
XX linked to the 5' or 3' position of the nucleoside respectively, or an
XX inter-strand nucleoside having cholic acid, pyrene or folic acid linked
XX to an inter-nucleotide linkage linking the inter- strand nucleoside to an
XX adjacent nucleoside. (updated on 25-MAR-2003 to correct PN field.)
XX
XX SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1
RESULT 1836
AAQ40521/c
ID AAQ40521 standard; DNA; 18 BP.
XX
XX AAQ40521;
XX
XX 25-MAR-2003 (revised)
XX 12-AUG-1993 (first entry)
XX
XX Cholic acid labelled functionalised oligomer 4.
XX
XX Linked; nucleoside; functionalised; 2'; steroid; reporter; protein;
XX non-aromatic; lipophilic; molecule; enzyme; peptide; metal chelator;
XX water soluble; vitamin; RNA cleaving complex; cholic acid; pyrene;
XX porphyrin; alkylator; hybrid; photo-nuclease; intercalator; agent;
XX aryl azide; photo-crosslinking; folic acid; heterocyclic base;
XX inter-strand; ss.
XX
XX Synthetic.

```

XX	Key	Location/Qualifiers
PH	modified_base	1..2
FT		/*tag= a
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	2..3
FT		/*tag= b
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	3..4
FT		/*tag= c
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	4..5
FT		/*tag= d
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	5..6
FT		/*tag= e
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	6..7
FT		/*tag= f
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	7..8
FT		/*tag= g
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	8..9
FT		/*tag= h
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	9..10
FT		/*tag= i
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	10..11
FT		/*tag= j
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	11..12
FT		/*tag= k
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	12..13
FT		/*tag= l
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	13..14
FT		/*tag= m
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	14..15
FT		/*tag= n
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	15..16
FT		/*tag= o
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	16..17
FT		/*tag= p
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	17..18
FT		/*tag= q
FT		/note= "Phosphorothioate inter-nucleotide backbone
FT		linkage"
FT	modified_base	18
FT		/*tag= r
FT		/note= "Nucleotide functionalised to include a cholic

FT acid linked to the 5' position of the nucleoside"

XX WO9307883-A1.

XX 29-APR-1993.

XX 23-OCT-1992; 92WO-US009196.

XX 24-OCT-1991; 91US-00782374.

XX (ISIS-) ISIS PHARM INC.

XX Manoharan M, Cook PD, Bennett CF;

XX WPI; 1993-152175/18.

XX Linked nucleoside(s) in which at least one nucleoside is functionalised -
PT used as anti-sense diagnostic or therapeutic agents with enhanced
PT activity.

XX Disclosure; Page 21; 73pp; English.

XX The sequences given in AAQ40518-61 are oligonucleosides which comprise
CC linked nucleosides at least one of which is functionalised at its 2',
CC position by attachment of a molecule selected from a steroid molecule, a
CC reporter molecule, a non-aromatic lipophilic molecule, a reporter enzyme,
CC a peptide, a protein, a water soluble vitamin, an RNA cleaving complex, a
CC metal chelator, a porphyrin, an alkylator, a hybrid photo-
CC nuclease/intercalator and an aryl azide photo-crosslinking agent. The
CC oligonucleosides may also comprise a 2' functionalised nucleoside having
CC cholic acid, pyrene, or folic acid linked to the 2' position of the
CC nucleoside, a heterocyclic base functionalised nucleoside having cholic
CC acid or folic acid linked to the heterocyclic base of the nucleoside, a
CC 5' or 3' terminal nucleoside having cholic acid, pyrene or folic acid
CC linked to the 5' or 3' position of the nucleoside respectively, or an
CC inter-strand nucleoside having cholic acid, pyrene or folic acid linked
CC to an inter-nucleotide linkage linking the inter- strand nucleoside to an
CC adjacent nucleoside. (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 9.9e+02; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1837

AAQ41487/c

ID AAQ41487 standard; DNA; 18 BP.

XX AAQ41487;

XX 25-MAR-2003 (revised)

DT 24-AUG-1993 (first entry)

XX Target region for the ICAM-I proto-oncogene.

XX Chiral oligonucleotide; antisense therapy; sugar linkage; Rp; Sp;
KW intercellular adhesion molecule-1; ss.

XX Synthetic.

XX WO9308296-A1.

XX 29-APR-1993.

XX 14-OCT-1992; 92WO-US008797.

XX 15-OCT-1991; 91US-00777670.

PR 16-OCT-1991; 91US-00777007.

XX (ISIS-) ISIS PHARM INC.

XX Hoke GD, Cook PD;

XX WPI; 1993-152487/18.

XX Synthesis of new oligo:nucleotide(s) with chiral inter-sugar links - by
PT nucleophilic substitution or polymerase catalysed primer extension,
PT useful in anti-sense therapy for controlling protein expression.

XX Disclosure; Page 91; 114pp; English.

XX The invention describes oligonucleotides with chiral inter-sugar links
CC (Sp or Rp). Various therapeutic areas can be targeted with these
CC antisense oligomers to inhibit RNA translation in vivo. For example, the
CC sequence shown is a target region of the ICAM-I proto- oncogene. An
CC antisense oligomer to this target sequence may be used to diagnose and
CC treat diseases caused by the proto oncogene. See also AAQ41482-91.
CC (Updated on 25-MAR-2003 to correct PN field.)

XX Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 9.9e+02; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1838

AAQ62001/c

ID AAQ62001 standard; DNA; 18 BP.

XX AAQ62001;

XX 25-MAR-2003 (revised)

DT 04-NOV-1994 (first entry)

XX Guanine quartet containing oligomer, #12.

XX Inhibition; replication; herpes simplex virus; HSV; HIV; retard;

XX human cytomegalovirus; influenza virus; inflammation; telomere length;
KW neurological disorders; phospholipase A2 activity; hyperproliferation;
KW malignancy; cardiovascular disease; snake bite; malignancy; aging; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT misc_feature 1..18

FT /*tag= a

FT /note= "Phosphorothionate intersugar linkages"

XX WO9408053-A1.

XX 14-APR-1994.

XX 29-SEP-1993; 93WO-US009297.

XX 29-SEP-1992; 92US-00954185.

XX (ISIS-) ISIS PHARM INC.

XX Hanecak RC, Anderson KP, Bennett CF, Chiang M, Brown-Driver VL;

XX Ecker DJ, Vickers TA, Wyatt JR, Imbach JL;

XX WPI; 1994-135613/16.

XX New modified oligo-nucleotide contg guanine quartet - inhibits activity
PT of viruses, e.g. HIV, and phospholipase A2 and modulates telomere length

PT	of chromosomes.
XX	
PS	Disclosure; Page 108; 144pp; English.
XX	
CC	The sequences given in AAQ61990-2001 are oligonucleotides which contain
CC	G4 or G3 stretches and which may be used for inhibiting replication of
CC	herpes simplex virus (HSV), activity of HIV, human cytomegalovirus or
CC	influenza virus, or for treating inflammatory and neurological disorders
CC	caused by phospholipase A2 activity in cases of hyper- proliferation,
CC	maligancy, cardiovascular disease and snake bite. Oligonucleotides such
CC	as these, may be used for inhibiting division of malignant cells by
CC	modulating telomere length, which may also retard aging. (Updated on 25-
CC	MAR-2003 to correct PN field.)
XX	
XX	
SQ	Sequence 18 BP; 4 A; 1 C; 11 G; 2 T; 0 U; 0 Other;
	Query Match 0.6%; Score 18; DB 1; Length 18;
	Best Local Similarity 100.0%; Pred. No. 9.9e+02;
	Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	2836 TCCTCCACCTCAGCCTC 2853
Db	18 TCCTCCACCTCAGCCTC 1
RESULT 1839	
AAQ44512/c	
ID	AAQ44512 standard; DNA; 18 BP.
XX	
AC	AAQ44512;
XX	
DT	25-MAR-2003 (revised)
DT	26-SEP-1994 (first entry)
XX	
DE	Antisense oligonucleotide which targets human ICAM-1 AUG codon.
XX	
KW	Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
KW	inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
KW	antisense oligonucleotide; therapy; ss.
XX	
OS	Synthetic.
XX	
FH	Key Location/Qualifiers
FT	misc_feature 1..18
FT	/*tag= a
FT	/note= "pref. in phosphorothioate form; the
FT	phosphodiester form of this oligonucleotide did not
FT	inhibit ICAM-1 expression while the phosphorothioate form
FT	gave 90% inhibition at 1microm"
XX	
PN	WO9405333-A1.
XX	
PD	17-MAR-1994.
XX	
PF	27-AUG-1993; 93WO-US008101.
XX	
PR	02-SEP-1992; 92US-00939855.
PR	21-JAN-1993; 93US-00007997.
PR	17-MAY-1993; 93US-00063167.
XX	
PA	(ISIS-) ISIS PHARM INC.
PI	Bennet CF, Mirabelli CK;
XX	
XX	WFI; 1994-100869/12.
DR	
XX	
PT	Oligo:nucleotide modulation of cell adhesion - used in the treatment of
PT	e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
XX	
PS	Claim 15; Page 48; 101pp; English.
XX	
CC	Antisense oligonucleotides which target human ICAM-1 were synthesised in
CC	both the phosphodiester and phosphorothioate forms. The oligonucleotides


```

Db      18 TCCTCCACCTGAGCTC 1
|||||
RESULT 1841
AAQ44516/c
ID AAQ44516 standard; DNA; 18 BP.
XX
AC AAQ44516;
XX
XX 25-MAR-2003 (revised)
DT 26-SEP-1994 (first entry)
XX
DE Antisense oligonucleotide which targets human ICAM-1 coding region.
XX
KW Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
KW antisense oligonucleotide; therapy; ss.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH misc_feature 1..18
FT /*tag= a
FT /note= "opt. in phosphorothioate form"
XX
XX WO9405333-A1.
XX
XX 17-MAR-1994.
XX
XX 27-AUG-1993; 93WO-US008101.
XX
XX 02-SEP-1992; 92US-00939855.
PR 21-JAN-1993; 93US-00007997.
PR 17-MAY-1993; 93US-00063167.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennet CF, Mirabelli CK;
PI WPI; 1994-100869/12.
XX
XX 27-AUG-1993; 93WO-US008101.
XX
XX 02-SEP-1992; 92US-00939855.
PR 21-JAN-1993; 93US-00007997.
PR 17-MAY-1993; 93US-00063167.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennet CF, Mirabelli CK;
PI WPI; 1994-100869/12.
XX
XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
PT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
XX
XX Claim 15; Page 49; 101pp; English.
XX
XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
CC both the phosphodiester and phosphorothioate forms. The oligonucleotides
CC are useful to treat diseases which are modulated by changes in
CC intercellular adhesion molecules. This sequence corresponds to
CC nucleotides 1378-1395 of the coding region of the human ICAM-1 coding
CC sequence. (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 18 BP; 5 A; 2 C; 9 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCATCG 1381
|||||
Db 18 CTTTCCCACTGCCATCG 1

RESULT 1842
AAQ44566
ID AAQ44566 standard; DNA; 18 BP.
XX
XX AAQ44566;
XX
XX 25-MAR-2003 (revised)
DT 26-SEP-1994 (first entry)
XX
XX WO9406815-A1.

```

```

XX Oligonucleotide complementary to anti-ICAM-1 oligonucleotide.
DE
XX
XX Human intercellular adhesion molecule; ICAM-1; cell adhesion; modulation;
KW inflammation; psoriasis; malignant melanoma; inflammatory bowel disease;
KW antisense oligonucleotide; therapy; ss.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
FH misc_feature 1..18
FT /*tag= a
FT /note= "in phosphorothioate form"
XX
XX WO9405333-A1.
XX
XX 17-MAR-1994.
XX
XX 27-AUG-1993; 93WO-US008101.
XX
XX 02-SEP-1992; 92US-00939855.
PR 21-JAN-1993; 93US-00007997.
PR 17-MAY-1993; 93US-00063167.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennet CF, Mirabelli CK;
PI WPI; 1994-100869/12.
XX
XX Oligo:nucleotide modulation of cell adhesion - used in the treatment of
PT e.g. psoriasis, inflammatory bowel disease or malignant melanoma.
XX
XX Example 1; Page 67; 101pp; English.
XX
XX Antisense oligonucleotides which target human ICAM-1 were synthesised in
CC both the phosphodiester and phosphorothioate forms. The oligonucleotides
CC are useful to treat diseases which are modulated by changes in
CC intercellular adhesion molecules. The sequence AAQ44512 corresponds to
CC the region around the AUG codon (84-81) of the human ICAM-1 coding
CC sequence; sequence AAQ44566 is complementary to this antisense
CC oligonucleotide and was used to show that the inhibition of ICAM-1
CC expression by the phosphorothioate form of AAQ44512 was due to antisense
CC effects. (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 18 BP; 2 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGCTGCCA 67
|||||
Db 1 GCCTCGCTATGCTGCCA 18

RESULT 1843
AAQ45149/c
ID AAQ45149 standard; DNA; 18 BP.
XX
XX AAQ45149;
XX
XX 25-MAR-2003 (revised)
DT 31-OCT-1994 (first entry)
XX
XX Oligonucleotide used in amine containing therapeutic.
XX
XX Oligonucleotide; analogue; antisense; therapy; diagnosis; identification;
KW retention; therapeutic; amine; lipophile; ss.
XX
XX Synthetic.
XX
XX WO9406815-A1.

```

PN	WO9506659-A1.
XX	
PD	09-MAR-1995.
XX	
PF	02-SEP-1994; 94WO-US010131.
XX	
PR	03-SEP-1993; 93US-00117363.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	
PI	Cook PD, Manoharan M, Guinasso CJ;
XX	
DR	WPI; 1995-115397/15.
XX	
PT	New amine-derivatised nucleoside(s) and oligo:nucleoside(s) - useful as
PT	diagnostics, therapeutics and research reagents, partic. in anti-sense
PT	therapy.
XX	
PS	Example 1; Page 16; 117pp; English.
XX	
CC	The sequence of a oligonucleotide sequence with a nucleotide
CC	incorporating an alkylamino functional group e.g. pentyl-N- phthalimido
CC	function. This oligonucleotide is an antisense sequence targeted to the
CC	inter-cellular adhesion molecule (ICAM). This is an example of a compound
CC	(see AAQ85799-Q85839 for other examples) e.g. a nucleoside or
CC	oligonucleoside, which contains a ribofuranosyl sugar portion and a base
CC	portion, such that at least one of the nucleoside contains a substitution
CC	at a 2'-O-, 3'-O- or 5'-O-position. (See AAQ85799 for details of the
CC	substitutions). The compounds are useful in diagnostics, therapeutics and
CC	as research reagents particularly in antisense therapy for killing cells
CC	and viruses such as HIV, herpes or papilloma viruses. (Updated on 25-MAR-
CC	2003 to correct PN field.)
XX	
SQ	Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
	Query Match 0.6%; Score 18; DB 1; Length 18;
	Best Local Similarity 100.0%; Pred. NO. 9.9e+02;
	Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	50 GCCTCGCTATGGCTCCCA 67
DB	18 GCCTCGCTATGGCTCCCA 1
RESULT 1845	
AAQ86986/C	ID AAQ86986 standard; DNA; 18 BP.
XX	
AC	AAQ86986;
XX	
DT	05-JAN-1996 (first entry)
XX	
DE	S-oligonucleotide alpha for antisense therapy.
XX	
KW	S-oligonucleotide alpha; antisense therapy; ICAM-1;
KW	nuclear localisation signal peptide; ss.
XX	
OS	Synthetic.
XX	
PN	JP07099976-A.
XX	
PD	18-APR-1995.
XX	
PP	30-SEP-1993; 93JP-00244753.
XX	
PR	30-SEP-1993; 93JP-00244753.
XX	
PA	(TAKE) TAKEDA CHEM IND LTD.
XX	
DR	WPI; 1995-182069/24.
XX	
PT	Oligo:nucleotide attached to nuclear localisation signal peptide - is
PT	readily taken into cell nuclei and can be used for anti-sense therapy.

XX Example 1; Page 8; 11pp; Japanese.

PS

CC AAQ86986 and AAQ86987 are S-oligonucleotides antisense to the ICAM-1 DNA, they were covalently linked to the nuclear localisation signal peptide AAR84191, and incubated with the human cell line A549. Treatment with the modified antisense oligonucleotides showed significant inhibition of ICAM-1 expression compared to untreated A549 cells

XX

SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||

Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1846
AAT01739/c

ID AAT01739 standard; DNA; 18 BP.

AC AAT01739;

XX

DT 17-DEC-1995 (first entry)

XX

XX Peptide Nucleic acid oligomer targeting ICAM-1 AUG.

DE

XX peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.

KW

XX Synthetic.

OS

XX Key Location/Qualifiers

FT misc_feature 1..18

FT /note= "at least one (and preferably all) of the backbone subunits are composed of amide units, so that the oligomer consists of the nucleobases attached covalently to a polyamide backbone"

FT

FT

FT

FT

FT

FT

PN WO9504749-A1.

XX

XX 16-FEB-1995.

XX

XX 05-AUG-1994; 94WO-US009026.

XX

XX 05-AUG-1993; 93US-00102650.

XX

XX (ISIS-) ISIS PHARM INC.

PA

XX Bennett CF, Mirabelli CK;

PI

XX WPI; 1995-090842/12.

DR

XX

XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes - are stable anti:sense cpds. of high affinity, partic. for treating inflammation, viral infection, cancer etc.

PT

PT

XX

PS Claim 2; Page 35; 57pp; English.

XX

XX New oligomers are claimed which (A) have at least one peptide nucleic acid (PNA) subunit and (B) have a sequence hybridisable to AUG region, coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1 or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated region, exon/intron junction region or 3'-untranslated region of VCAM-1. The PNAs can be used to target RNA and single stranded DNA (ssDNA) to produce antisense-type gene regulation moieties. Hence they may be used therapeutically for modulating cellular adhesion and thus as antimetastatic agents, anticancer agents, antirhinoviral agents, anti-

CC AIDS agents and antiinflammatory agents. They may also be useful as diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high affinity for complementary single stranded DNA. They are also able to form triple helices in which a first PNA strand binds with RNA or ssDNA and a second PNA strand binds with the resulting double helix or with the first PNA strand. The PNAs possess no significant charge and are water soluble, which facilitates cellular uptake. Further, since they contain amides of non-biological amino acids, they are biostable and resistant to enzymatic degradation by proteases. The present sequence targets human intercellular adhesion molecule-1 (ICAM-1) translation initiation codon (AUG) region

CC

XX

SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||

Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1847
AAT01743/c

ID AAT01743 standard; DNA; 18 BP.

XX

AC AAT01743;

XX

DT 18-DEC-1995 (first entry)

XX

XX Peptide Nucleic acid oligomer targeting ICAM-1 coding region.

DE

XX peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.

KW

XX Synthetic.

OS

XX Key Location/Qualifiers

FT misc_feature 1..18

FT /note= "at least one (and preferably all) of the backbone subunits are composed of amide units, so that the oligomer consists of the nucleobases attached covalently to a polyamide backbone"

FT

FT

FT

FT

FT

PN WO9504749-A1.

XX

XX 16-FEB-1995.

XX

XX 05-AUG-1994; 94WO-US009026.

XX

XX 05-AUG-1993; 93US-00102650.

XX

XX (ISIS-) ISIS PHARM INC.

PA

XX Bennett CF, Mirabelli CK;

PI

XX WPI; 1995-090842/12.

DR

XX

XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes - are stable anti:sense cpds. of high affinity, partic. for treating inflammation, viral infection, cancer etc.

PT

PT

XX

PS Claim 2; Page 35; 57pp; English.

XX

XX New oligomers are claimed which (A) have at least one peptide nucleic acid (PNA) subunit and (B) have a sequence hybridisable to AUG region, coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1 or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated region, exon/intron junction region or 3'-untranslated region of VCAM-1. The PNAs can be used to target RNA and single stranded DNA (ssDNA) to produce antisense-type gene regulation moieties. Hence they may be used therapeutically for modulating cellular adhesion and thus as antimetastatic agents, anticancer agents, antirhinoviral agents, anti-

CC produce antisense-type gene regulation moieties. Hence they may be used
 CC therapeutically for modulating cellular adhesion and thus as
 CC antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
 CC AIDS agents and antiinflammatory agents. They may also be useful as
 CC diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
 CC affinity for complementary single stranded DNA. They are also able to
 CC form triple helices in which a first PNA strand binds with RNA or ssDNA
 CC and a second PNA strand binds with the resulting double helix or with the
 CC first PNA strand. The PNAs possess no significant charge and are water
 CC soluble, which facilitates cellular uptake. Further, since they contain
 CC amides of non-biological amino acids, they are biostable and resistant to
 CC enzymatic degradation by proteases. The present sequence targets human
 CC intercellular adhesion molecule-1 (ICAM-1) coding region
 XX
 SQ Sequence 18 BP; 5 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCCATCG 1381
 |||||
 Db 18 CTTTCCCACTGCCCATCG 1

RESULT 1848
 AAT01742/c
 ID AAT01742 standard; DNA; 18 BP.

AC AAT01742;

XX 18-DEC-1995 (first entry)

XX Peptide Nucleic acid oligomer targeting ICAM-1 3'-UTR.

XX peptide nucleic acid; PNA; intercellular adhesion molecule; ICAM-1;
 KW endothelial leukocyte; ELAM-1; vascular; VCAM-1; antiinflammatory;
 KW anticancer; antimetastatic; anti-AIDS; anti-rhinoviral; ss.

XX Synthetic.

PH Key Location/Qualifiers
 FT misc_feature 1..18

FT /*tag= a
 FT /note= "at least one (and preferably all) of the backbone
 FT subunits are composed of amide units, so that the
 FT oligomer consists of the nucleobases attached covalently
 FT to a polyamide backbone"

XX WO9504749-A1.

XX 16-FEB-1995.

XX 05-AUG-1994; 94WO-US0009026.

XX 05-AUG-1993; 93US-00102650.

PA (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK;

XX WPI; 1995-090842/12.

XX New peptide nucleic acid oligomers hybridising to adhesion molecule genes
 PT - are stable anti-sense cpds. of high affinity, partic. for treating
 PT inflammation, viral infection, cancer etc.

XX Claim 2; Page 35; 57pp; English.

XX New oligomers are claimed which (A) have at least one peptide nucleic
 CC acid (PNA) subunit and (B) have a sequence hybridisable to AUG region,
 CC coding region, 5'-untranslated region or 3'-untranslated region of ICAM-1
 CC or ELAM-1, or hybridisable to AUG region, coding region, 5'- untranslated

CC region, exon/intron junction region or 3'-untranslated region of VCAM-1.
 CC The PNAs can be used to target RNA and single stranded DNA (ssDNA) to
 CC produce antisense-type gene regulation moieties. Hence they may be used
 CC therapeutically for modulating cellular adhesion and thus as
 CC antimetastatic agents, anticancer agents, antirhinoviral agents, anti-
 CC AIDS agents and antiinflammatory agents. They may also be useful as
 CC diagnostics, e.g. as probes for specific mRNAs. PNA oligomers have high
 CC affinity for complementary single stranded DNA. They are also able to
 CC form triple helices in which a first PNA strand binds with RNA or ssDNA
 CC and a second PNA strand binds with the resulting double helix or with the
 CC first PNA strand. The PNAs possess no significant charge and are water
 CC soluble, which facilitates cellular uptake. Further, since they contain
 CC amides of non-biological amino acids, they are biostable and resistant to
 CC enzymatic degradation by proteases. The present sequence targets human
 CC intercellular adhesion molecule-1 (ICAM-1) 3' untranslated region
 XX

SQ Sequence 18 BP; 4 A; 1 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCCACTCAGCCTC 2853
 |||||
 Db 18 TCCTCCCACTCAGCCTC 1

RESULT 1849
 AAQ97339/c
 ID AAQ97339 standard; cDNA; 18 BP.

XX AAQ97339;

XX 19-JAN-1996 (first entry)

XX Primer used for amplifying ICAM-1 gene fragment.

XX Inflammatory bowel disease; IBD; ICAM-1; ulcerative colitis;
 KW Crohn's disease; intracellular adhesion molecule; screening;
 KW identification; R241; ss.

XX Synthetic.

XX WO9521941-A1.

XX 17-AUG-1995.

XX 06-FEB-1995; 95WO-US001434.

XX 11-FEB-1994; 94US-00196003.

XX (CEDA-) CEDARS SINAI MEDICAL CENT.

XX Beaudet AL, Rotter JI, Targan SR, Yang H, Vora D;

XX WPI; 1995-293137/38.

XX Screening for inflammatory bowel disease, pref. ulcerative colitis - by
 PT assaying a subject's nucleic acid for the presence of the R241 allele of
 PT the ICAM-1 gene.

XX Example 2a; Page 34; 59pp; English.

XX A method for screening for inflammatory bowel disease (IBD) comprises
 CC assaying nucleic acid from a subject for the presence or absence of the
 CC R241 allele of the ICAM-1 gene, where the presence is indicative of IBD.
 CC The method is useful for screening for the disease. The IBD is Crohn's
 CC disease or ulcerative colitis. Two primers (AAQ97338, AAQ97339) were used
 CC to amplify a fragment of the ICAM-1 gene

XX Sequence 18 BP; 3 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;

```

Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 844 GTCACCTATGGCAACGAC 861
Db |||||
18 GTCACCTATGGCAACGAC 1

RESULT 1850
AAT33112
ID AAT33112 standard; DNA; 18 BP.
XX
AC AAT33112;
XX
DT 21-JAN-1997 (first entry)
XX
DE Antisense oligonucleotide #21.
XX
KW Antisense oligonucleotide; human; intracellular adhesion molecule-1;
KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; brequinar;
KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
KW ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..18
FT /*tag= a
FT /note= "phosphodiester backbone"
XX
PN WO9615780-A1.
XX
PD 30-MAY-1996.
XX
PF 22-NOV-1995; 95WO-US015536.
XX
PR 23-NOV-1994; 94US-00344155.
XX
PA (ISIS-) ISIS PHARM INC.
PA (TEXA ) UNIV TEXAS SYSTEM.
XX
PI Bennett CF, Stepkowski SM;
XX
PI WPI; 1996-268321/27.
XX
DR
XX
PT Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
PT rejection.
XX
PS Disclosure; Page 70; 92pp; English.
XX
CC AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
CC oligonucleotides of the invention. These sequences target regions of the
CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). ICAM-1,
CC and VCAM-1 represent three of the five cell adhesion molecules involved
CC in the adherence of white blood cells to vascular endothelium. These
CC sequences can be used in a composition for treating allograft rejection.
CC The composition contains one of these sequences in combination with an
CC immunosuppressive agent. The immunosuppressive agent used in the
CC compositions is brequinar, rapamycin, anti-lymphocyte serum, a monoclonal
CC antibody against LFA-1 or an antisense oligonucleotide. The compositions
CC can be used for treating or preventing allograft rejection, such as
CC cardiac or renal allograft rejection. By using these compositions,
CC allograft survival times are extended, and donor-specific transplant
CC tolerance is induced
XX
SQ Sequence 18 BP; 2 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db |||||
1 GCCTCGCTATGGCTCCCA 18

RESULT 1851
AAT30212/C
ID AAT30212 standard; DNA; 18 BP.
XX
AC AAT30212;
XX
DT 20-JAN-1997 (first entry)
XX
DE Antisense oligonucleotide ISIS 1558.
XX
KW Antisense oligonucleotide; human; intracellular adhesion molecule-1;
KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; brequinar;
KW vascular endothelium; allograft rejection; immunosuppression; rapamycin;
KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
KW ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..18
FT /*tag= a
FT /note= "phosphodiester backbone"
XX
PN WO9615780-A1.
XX
PD 30-MAY-1996.
XX
PF 22-NOV-1995; 95WO-US015536.
XX
PR 23-NOV-1994; 94US-00344155.
XX
PA (ISIS-) ISIS PHARM INC.
PA (TEXA ) UNIV TEXAS SYSTEM.
XX
PI Bennett CF, Stepkowski SM;
XX
PI WPI; 1996-268321/27.
XX
DR
XX
PT Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
PT rejection.
XX
PS Example 2; Page 17; 92pp; English.
XX
CC AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
CC oligonucleotides of the invention. These sequences target regions of the
CC coding sequences for human intercellular adhesion molecule-1 (ICAM-1),
CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
CC targets the AUG translation initiation codon (nucleotides 64-80) of ICAM-
CC 1. ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
CC molecules involved in the adherence of white blood cells to vascular
CC endothelium. These sequences can be used in a composition for treating
CC allograft rejection. The composition contains one of these sequences in
CC combination with an immunosuppressive agent. The immunosuppressive agent
CC used in the compositions is brequinar, rapamycin, anti-lymphocyte serum,
CC a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The
CC compositions can be used for treating or preventing allograft rejection,
CC such as cardiac or renal allograft rejection. By using these
CC compositions, allograft survival times are extended, and donor-specific
CC transplant tolerance is induced
XX
SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1852
AAT30217/c
ID AAT30217 standard; DNA; 18 BP.
XX
AC AAT30217;
XX
DT 20-JAN-1997 (first entry)
XX
DE Antisense oligonucleotide ISIS 1565/1574.
XX
KW Antisense oligonucleotide; human; intracellular adhesion molecule-1;
KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; breguarin;
KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
KW ss.
XX Synthetic.
XX
Key Location/Qualifiers
FH modified_base 1..18
FT /*tag= a
FT /note= "phosphorothioate or phosphodiester backbone"
XX
PN WO9615780-A1.
XX
PD 30-MAY-1996.
XX
PF 22-NOV-1995; 95WO-US015536.
XX
PR 23-NOV-1994; 94US-00344155.
XX
PA (ISIS-) ISIS PHARM INC.
XX (TEXA ) UNIV TEXAS SYSTEM.
XX
PI Bennett CF, Stepkowski SM;
XX WPI; 1996-268321/27.
XX
PT Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
PT rejection.
XX
PS Example 5; Page 4521; 92pp; English.
XX
CC AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
CC oligonucleotides of the invention. These sequences target regions of the
CC coding sequences for human intracellular adhesion molecule-1 (ICAM-1),
CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
CC targets the coding region (nucleotides 1378-1395) of ICAM-1. ICAM-1, ELAM-
CC -1, and VCAM-1 represent three of the five cell adhesion molecules
CC involved in the adherence of white blood cells to vascular endothelium.
CC These sequences can be used in a composition for treating allograft
CC rejection. The composition contains one of these sequences in combination
CC with an immunosuppressive agent. The immunosuppressive agent used in the
CC compositions is breguarin, rapamycin, anti-lymphocyte serum, a monoclonal
CC antibody against LFA-1 or an antisense oligonucleotide. The compositions
CC can be used for treating or preventing allograft rejection, such as
CC cardiac or renal allograft rejection. By using these compositions,
CC allograft survival times are extended, and donor-specific transplant
CC tolerance is induced
XX
SQ Sequence 18 BP; 5 A; 2 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 9.9e-02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCCATCG 1381
Db 18 CTTTCCCACTGCCCATCG 1

RESULT 1853
AAT30216/c
ID AAT30216 standard; DNA; 18 BP.
XX
AC AAT30216;
XX
DT 20-JAN-1997 (first entry)
XX
DE Antisense oligonucleotide ISIS 1564/1573.
XX
KW Antisense oligonucleotide; human; intracellular adhesion molecule-1;
KW ICAM-1; endothelial leukocyte adhesion molecule-1; ELAM-1; E-selectin;
KW vascular cell adhesion molecule-1; VCAM-1; white blood cell; breguarin;
KW anti-lymphocyte serum; monoclonal antibody; cardiac allograft; therapy;
KW renal allograft rejection; donor-specific transplant tolerance; LFA-1;
KW ss.
XX Synthetic.
XX
Key Location/Qualifiers
FH modified_base 1..18
FT /*tag= a
FT /note= "phosphorothioate or phosphodiester backbone"
XX
PN WO9615780-A1.
XX
PD 30-MAY-1996.
XX
PF 22-NOV-1995; 95WO-US015536.
XX
PR 23-NOV-1994; 94US-00344155.
XX
PA (ISIS-) ISIS PHARM INC.
XX (TEXA ) UNIV TEXAS SYSTEM.
XX
PI Bennett CF, Stepkowski SM;
XX WPI; 1996-268321/27.
XX
PT Oligo:nucleotide targetted to a nucleic acid sequence encoding ICAM-1,
PT ELAM-1 or VCAM-1 - useful for treating or preventing allo:graft
PT rejection.
XX
PS Example 5; Page 45; 92pp; English.
XX
CC AAT30211-T30233, AAT33058-T33112 and AAT36667-T36684 represent antisense
CC oligonucleotides of the invention. These sequences target regions of the
CC coding sequences for human intracellular adhesion molecule-1 (ICAM-1),
CC endothelial leukocyte adhesion molecule-1 (ELAM-1, also known as E-
CC selectin), or vascular cell adhesion molecule-1 (VCAM-1). This sequence
CC targets the 3' untranslated region (nucleotides 2849-2866) of ICAM-1.
CC ICAM-1, ELAM-1, and VCAM-1 represent three of the five cell adhesion
CC molecules involved in the adherence of white blood cells to vascular
CC endothelium. These sequences can be used in a composition for treating
CC allograft rejection. The composition contains one of these sequences in
CC combination with an immunosuppressive agent. The immunosuppressive agent
CC used in the compositions is breguarin, rapamycin, anti-lymphocyte serum,
CC a monoclonal antibody against LFA-1 or an antisense oligonucleotide. The
CC compositions can be used for treating or preventing allograft rejection,
CC such as cardiac or renal allograft rejection. By using these
CC compositions, allograft survival times are extended, and donor-specific
CC transplant tolerance is induced
XX
SQ Sequence 18 BP; 4 A; 1 C; 11' G; 2 T; 0 U; 0 Other;

```

```
Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2836 TCCTCCACCTCAGCCTC 2853
    18 TCCTCCACCTCAGCCTC 1
Db

RESULT 1854
AAT33484/c
ID AAT33484 standard; DNA; 18 BP.
XX
AC AAT33484;
XX
DT 18-FEB-1997 (first entry)
XX
DE Oligomeric compound with 2'-O-substituted pyrimidine nucleoside.
XX
KW Oligomer; pyrimidine; inhibition; gene expression; gene therapy;
KW research; diagnostic reagent; diagnosis; protein kinase C; PKC; ss.
XX
OS Synthetic.
XX
PN W09627606-A1.
XX
PD 12-SEP-1996.
XX
PF 06-MAR-1996; 96WO-US003174.
XX
PR 06-MAR-1995; 95US-00398901.
PR 07-JUN-1995; 95US-00475467.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Cook PD, Sanghvi YS, Sprankle KG, Ross BS, Griffey RH;
PI Springer RH;
XX
DR WPI; 1996-425375/42.
XX
New 2'-O-substituted pyrimidine monomeric nucleoside sub-unit(s) - used
PT for the prepn. of oligomeric cpds. which can be used for gene therapy or
PT as research or diagnostic reagents.
XX
PS Procedure 2; Page 65; 97pp; English.
XX
Oligomeric compounds containing 2'-O-substituted pyrimidine nucleoside
CC subunits can be used for inhibiting specific gene expression in gene
CC therapy and as research and diagnostic reagents. The oligomeric compounds
CC exhibit high binding affinity to nucleic acids and high nuclease
CC resistance. This sequence is a deoxyphosphodiester 15 mer
CC oligoribonucleotide which was used in hybridisation stability studies.
CC Modifications to the sequence included 2'-O-methyl, 2'-O-propyl, 2'-O-
CC pentyl substitutions on the sugar molecule as well as having a
CC phosphorothioate backbone. The melting temperatures for each of these
CC modified oligoribonucleotides was 55.3, 80.9, 78.3 and 54.2 degrees
CC Celsius respectively
XX
SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 50 GCCTCGCTATGGCTCCCA 67
    18 GCCTCGCTATGGCTCCCA 1
Db

RESULT 1855
AAT58085/c
ID AAT58085 standard; DNA; 18 BP.
XX
AC AAT58085;
XX
DT 25-MAR-2003 (revised)
DT 18-MAR-1997 (first entry)
XX
DE ICAM-1 antisense oligonucleotide #15.
XX
KW Antisense; pre-mRNA; mature mRNA; vascular defect; tissue defect;
KW human intercellular adhesion molecule-1; ICAM-1; inflammation;
KW adult respiratory distress syndrome; multiple organ failure; GM1594;
KW septic shock; ss.
XX
OS Synthetic.
XX
PN US5580969-A.
XX
PD 03-DEC-1996.
XX
PF 12-OCT-1993; 93US-00136118.
XX
PR 24-JUL-1992; 92US-00918259.
XX
PA (USNA ) US SEC OF NAVY.
XX
PI Lee C, Hoke GD, Bradley MO, Williams TJ;
XX
DR WPI; 1997-033603/03.
XX
Anti-sense oligo:nucleotide(s) for blocking ICAM-1 mRNA translation - for
PT treating septic shock, adult respiratory distress syndrome etc.
XX
Claim 1; Col 25; 16pp; English.
XX
The sequences given in AAT58071-85 represent oligonucleotides which are
CC antisense to sequences contained in the pre-mRNA or mature mRNA
CC transcript of human intercellular adhesion molecule-1 (ICAM-1). These
CC oligonucleotides may be used for treating septic shock and the
CC manifestations of septic shock, e.g. inflammation, and vascular and
CC tissue defects. They are also useful in the treatment of septic shock
CC associated diseases, e.g. adult respiratory distress syndrome, multiple
CC organ failure etc. (Updated on 25-MAR-2003 to correct PF field.)
XX
SQ Sequence 18 BP; 3 A; 5 C; 4 G; 6 T; 0 U; 0 Other;

Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2038 TTACAGACAGAGTGGCCC 2055
    18 TTACAGACAGAGTGGCCC 1
Db

RESULT 1856
AAT91274/c
ID AAT91274 standard; DNA; 18 BP.
XX
AC AAT91274;
XX
DT 27-APR-1998 (first entry)
XX
DE ICAM-1 codon 241-specific PCR primer.
XX
KW Intracellular adhesion molecule-1; ICAM-1; human; Crohn's disease;
KW ulcerative colitis; inflammatory bowel disease; diagnosis; PCR; primer;
KW ss.
XX
OS Synthetic.
XX
PN Homo sapiens.
XX
PN W09739148-A1.
XX
```


PA (ICOS-) ICOS CORP.
 XX Gallatin WM, Vazeux R;
 PI XX
 XX WPI; 1998-386989/33.
 DR XX
 XX Identifying compounds that modulate interaction of intracellular adhesion
 PT molecule R - with ligands Hs1-beta and tubulin using two-hybrid assay,
 PT useful for treating inflammation, T cell activation etc.
 XX
 XX Example 4; Col 101-102; 108pp; English.
 PS XX
 XX AAV56349-V56366 are primers and probes used in the isolation of a novel
 CC human intercellular adhesion molecule, ICAM-R. This sequence is used in a
 CC method which investigates modulators of the interaction between ICAM-R
 CC and the 14.3.3 family member Hs1-beta and tubulin. An anti-ICAM-R
 CC antibody optionally coupled to toxin or radionuclide, or an ICAM-R
 CC peptide, can block, inhibit or stimulate ligand/receptor interactions
 CC involving ICAM-R, particularly its effector functions involved in
 CC (non)specific immune responses. ICAM-R related agents may be used to
 CC treat or monitor inflammation, disorders involving T cell activation or
 CC macrophages, e.g. adult respiratory distress syndrome, stroke, Crohn's
 CC disease, multiple sclerosis, rheumatoid arthritis, asthma, tumour growth,
 CC human immune deficiency virus infection, diabetes, graft vs. host disease
 CC and many others. Antibodies may also be used for passive immunisation.
 CC for purifying, detecting or quantifying ICAM-R and for identifying ICAM-R
 CC expressing cells
 XX
 SQ Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 440 GCAAGAACCTTACCTAC 457
 Db 1 GCAAGAACCTTACCTAC 18
 RESULT 1859
 AAV38620/C
 ID AAV38620 standard; DNA; 18 BP.
 XX
 AC AAV38620;
 XX
 XX 13-OCT-1998 (first entry)
 XX Human ICAM-1, E-selectin, VCAM-1 antisense oligonucleotide.
 XX ICAM-1; intracellular adhesion molecule-; E-selectin; VCAM-1;
 KW vascular cell adhesion molecule-1; antisense; inflammatory; disease;
 KW treatment; septic shock; psoriasis; wounds; burns; acne; arthritis;
 KW organ rejection; inhibition; expression; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9824797-A1.
 XX
 XX 11-JUN-1998.
 XX
 XX 02-DEC-1996; 96WO-US019194.
 PF
 XX 02-DEC-1996; 96WO-US019194.
 PR
 XX (DYAD-) DYAD PHARM CORP.
 PA
 XX Hoke GD, Bradley MO, Williams TJ, Lee C;
 PI WPI; 1998-333253/29.
 DR
 XX Antisense oligonucleotides to ICAM-1, E-selectin or VCAM-1 - useful for
 PT treating diseases having an inflammatory component, e.g. psoriasis,

PT wounds and septic shock.
 XX Claim 8; Page 40; 48pp; English.
 XX
 CC The sequence is that of an antisense oligonucleotide which is
 CC substantially complementary to at least a portion of the pre- or mature
 CC RNA transcript of human intracellular adhesion molecule (ICAM), E-
 CC selectin or vascular cell adhesion molecule (VCAM). It can be used to
 CC inhibit expression of these proteins. Inhibition of these proteins forms
 CC the basis for treatment of conditions and diseases that have an
 CC inflammatory component, e.g. acne, psoriasis, arthritis, organ rejection,
 CC wounds, burns, septic shock or inflammatory complications of septic shock
 XX
 SQ Sequence 18 BP; 3 A; 5 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2038 TTACAGAGAGAGTGGCCC 2055
 Db 18 TTACAGAGAGAGTGGCCC 1
 RESULT 1860
 AAV06904/C
 ID AAV06904 standard; DNA; 18 BP.
 XX
 AC AAV06904;
 XX
 XX 03-JUL-1998 (first entry)
 DT
 XX Modified oligonucleotide 14290 which targets ICAM-1 mRNA transcript.
 DE
 XX Modified oligonucleotide; antisense inhibition; protein translation;
 KW 5' capped region; human intercellular adhesion molecule-1; ICAM-1;
 KW ribosome assembly; mRNA transcript; peptide-nucleic acid; PNA;
 KW E-selectin; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH misc_feature 1..18
 FT /tag= a
 FT /note= "Alternating methylene (methylimino) backbone"
 FT misc_feature 1..17
 FT /tag= b
 FT /note= "All cytosine residues are 5-methylcytosine
 FT residues"
 XX
 PN WO9745437-A1.
 XX
 XX 04-DEC-1997.
 XX
 XX 29-APR-1997; 97WO-US007132.
 PP
 XX 24-MAY-1996; 96US-00653653.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Baker B, Bennett CF, Anderson KP, Condon TP;
 PI WPI; 1998-032572/03.
 DR
 XX Inhibiting translation of capped target mRNA - by contact with
 PT oligo:nucleotide having modified 2'-position, oligo:nucleoside or peptide
 PT -nucleic acid which is specifically hybridisable with a 5' cap region of
 PT the target mRNA.
 XX
 XX Disclosure; Page 17; 57pp; English.
 PS
 XX The present sequence represents a modified oligonucleotide. The invention

CC relates to a method for inhibiting the translation of a capped target
 CC mRNA, which comprises contacting the capped target mRNA with an oligomer
 CC which: (1) is 8-25 bases in length; (2) is an oligonucleotide having a
 CC modified 2'-position, an oligonucleoside, or a peptide-nucleic acid; and
 CC (3) is specifically hybridisable with a 5' cap region of the target mRNA
 CC which includes at least one of the first 20 nucleotides at the 5'
 CC terminus of the target mRNA. The oligomer interferes with ribosome
 CC assembly on the mRNA. The method is particularly useful for inhibiting
 CC the translation of capped target mRNA encoding human ICAM-1, human E-
 CC selectin or a cytomegalovirus protein (preferably an IE1 or IE2 gene
 CC product). Elevated ICAM-1 levels are associated with rheumatoid
 CC arthritis, ulcerative colitis, Crohn's disease, psoriasis and renal
 CC transplant rejection. E-selectin (also known as endothelial leukocyte
 CC adhesion molecule-1, or ELAM-1) is involved in the adherence of white
 CC blood cells to vasculature endothelium and subsequent migration out of
 CC the vasculature. Antisense drugs targeted to cytomegalovirus IE2 mRNA may
 CC be effective against CMV retinitis in AIDS patients
 XX
 SQ Sequence 18 BP; 5 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCTCTGCTACTCA 35
 DB 18 GAGCTCTCTGCTACTCA 1

RESULT 1861
 AAV06894/c
 ID AAV06894 standard; DNA; 18 BP.

XX AAV06894;

DT 03-JUL-1998 (first entry)

DE Peptide-nucleic acid ISIS 10535 which targets ICAM-1 mRNA transcript.
 KW Modified oligonucleotide; antisense inhibition; protein translation;
 KW 5' capped region; human intercellular adhesion molecule-1; ICAM-1;
 KW ribosome assembly; mRNA transcript; peptide-nucleic acid; PNA;
 KW E-selectin; ss.

OS Synthetic.

OS Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1 /*tag= a

FT /*note= "Arg-Arg-Arg-Thymine"

FT modified_base 18

FT /*tag= b

FT /*note= "Cytosine-Lys".

XX W09745437-AL.

XX 04-DEC-1997.

XX 29-APR-1997; 97WO-US007132.

XX 24-MAY-1996; 96US-00653653.

XX (ISIS-) ISIS PHARM INC.

XX Baker B, Bennett CF, Anderson KP, Condon TP;

XX WPI; 1998-032572/03.

XX Inhibiting translation of capped target mRNA - by contact with

PT oligo:nucleotide having modified 2'-position, oligo:nucleoside or peptide

PT -nucleic acid which is specifically hybridisable with a 5' cap region of

PT the target mRNA.

XX Disclosure; Page 41; 57pp; English.

XX This sequence represents a peptide-nucleic acid (PNA). The invention
 CC relates to a method for inhibiting the translation of a capped target
 CC mRNA, which comprises contacting the capped target mRNA with an oligomer
 CC which: (1) is 8-25 bases in length; (2) is an oligonucleotide having a
 CC modified 2'-position, an oligonucleoside, or a peptide-nucleic acid; and
 CC (3) is specifically hybridisable with a 5' cap region of the target mRNA
 CC which includes at least one of the first 20 nucleotides at the 5'
 CC terminus of the target mRNA. The oligomer interferes with ribosome
 CC assembly on the mRNA. The method is particularly useful for inhibiting
 CC the translation of capped target mRNA encoding human ICAM-1, human E-
 CC selectin or a cytomegalovirus protein (preferably an IE1 or IE2 gene
 CC product). Elevated ICAM-1 levels are associated with rheumatoid
 CC arthritis, ulcerative colitis, Crohn's disease, psoriasis and renal
 CC transplant rejection. E-selectin (also known as endothelial leukocyte
 CC adhesion molecule-1, or ELAM-1) is involved in the adherence of white
 CC blood cells to vasculature endothelium and subsequent migration out of
 CC the vasculature. Antisense drugs targeted to cytomegalovirus IE2 mRNA may
 CC be effective against CMV retinitis in AIDS patients
 XX
 SQ Sequence 18 BP; 5 A; 3 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCTCCTCTGCTACTCAGA 37
 DB 18 GCTCCTCTGCTACTCAGA 1

RESULT 1862

AAV73853/c

ID AAV73853 standard; DNA; 18 BP.

XX AAV73853;

DT 17-OCT-2003 (revised)

DT 25-FEB-1999 (first entry)

XX ICAM-1 DNA target region for antisense inhibition.

DE Antisense; inhibition; chiral phosphate linkage; reporter gene; drug;
 KW RNase H activity; nuclease resistance; hybridisation; diagnostic;
 KW cellular absorption; transport; enzymatic interaction; ss.

XX unidentified.

XX US5852188-A.

XX 22-DEC-1998.

XX 19-APR-1996; 96US-00635009.

XX 11-JAN-1990; 90US-00463358.

XX 13-AUG-1990; 90US-00566977.

XX 11-JAN-1991; 91WO-US000243.

XX (ISIS-) ISIS PHARM INC.

XX Cook PD;

XX WPI; 1999-080505/07.

XX New oligo-nucleotide(s) for e.g. testing anti-sense activity - comprise
 PT non-naturally occurring nucleoside unit and chiral phosphate linkages.
 PT Disclosure; Col 12; 18pp; English.

XX This sequence is used as a target sequence for a novel method to test for

CC antisense activity using an oligonucleotide comprising nucleoside units

CC linked via phosphate linkages in which at least one of the nucleoside
 CC units is a non-naturally occurring nucleoside unit and at least two of
 CC the nucleoside units are linked via chiral phosphate linkages. The
 CC oligonucleotides can be used to test for antisense activity using
 CC reporter genes in assays and to test antisense activity against selected
 CC cellular target mRNA's in cultured cells. Some of the oligonucleotides
 CC are useful for to elicit RNase H activity as a termination event or to
 CC increase nuclease resistance. The oligonucleotides are expected to
 CC exhibit one or more properties such as hybridisation with target RNA's
 CC and DNA's, cellular absorption, transport, or to improve enzymatic
 CC interaction without diminishing existing properties giving improved,
 CC drugs, diagnostics and research agents. (Updated on 17-OCT-2003 to
 CC standardise OS field)
 XX
 SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1863
 AAV74297/c
 ID AAV74297 standard; DNA; 18 BP.
 XX
 AC AAV74297;
 XX
 DT 29-MAR-1999 (first entry)
 XX
 XX ICAM-1 antisense oligonucleotide primer #5.
 XX
 KW ICAM-1; intercellular adhesion molecule-1; antisense; primer; prevention;
 KW perfusion injury; transplantation; pre-operative treatment; donor; organ;
 KW ss.
 XX
 OS Synthetic.
 XX
 PN DE19745666-A1.
 XX
 XX 14-JAN-1999.
 XX
 PF 17-OCT-1997; 97DE-01045666.
 XX
 PR 07-JUL-1997; 97DE-01028923.
 XX
 PA (DELB-) DELBRUECK CENT MOLEKULARE MEDIZIN MAX.
 XX
 PI Haller H;
 XX
 DR WPI; 1999-082662/08.
 XX
 XX Use of antisense oligonucleotide against ICAM-1 - for preventing
 PT perfusion injury during transplantation of e.g. kidney, heart, lung or
 PT pancreas.
 PT
 XX
 XX Claim 4; Page 2; 4pp; German.
 PS
 XX
 CC AAV74293-V74297 are antisense oligonucleotide primers used against the
 CC intercellular adhesion molecule ICAM-1 for preventing perfusion injury
 CC during transplantation. The oligonucleotides are used for pre-operative
 CC treatment of the transplant donor or for pre-treatment of the donor organ
 CC (preferably kidney, heart, lung or pancreas) before transplantation
 XX
 XX Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1864
 AAV69140
 ID AAV69140 standard; DNA; 18 BP.
 XX
 AC AAV69140;
 XX
 DT 17-FEB-1999 (first entry)
 XX
 DE ICAM-R cDNA screening probe Icam 1-5.
 XX
 KW Intercellular adhesion molecule polypeptide; ICAM-R; humanised; ICR 1.1;
 KW ICR 8.1; monoclonal antibody; therapeutic; inflammatory; asthma; tumour;
 KW graft-versus-host disease; viral infection; toxin; radionuclide; probe;
 KW neovascularisation site; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN US5837822-A.
 XX
 PD 17-NOV-1998.
 XX
 PF 07-JUN-1995; 95US-00487113.
 XX
 PR 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 XX
 PA (ICOS-) ICOS CORP.
 XX
 PI Vazeux R, Gallatin WM;
 XX
 DR WPI; 1999-023535/02.
 XX
 PT Humanised antibodies specific for intercellular adhesion molecule
 PT polypeptide - useful for therapeutic or diagnostic purposes.
 XX
 PS Example 4; Col 14; 116pp; English.
 XX
 CC Probes AAV69136 to AAV69141 are used in the course of the invention for
 CC screening for a cDNA encoding human intercellular adhesion molecule
 CC polypeptide (ICAM-R). The invention relates to humanised ICR 1.1 and ICR
 CC 8.1 antibodies targeted to the ICAM-R polypeptide. Antibodies specific
 CC for ICAM's are potentially useful as therapeutic compounds, for treating
 CC e.g. immune-mediated inflammatory conditions (e.g. graft-versus-host
 CC disease), asthma, tumours or viral infections. Monoclonal antibodies
 CC specific for ICAM-R, or their conjugates formed with e.g. toxins or
 CC radionuclides are useful for therapeutically targeting or detecting
 CC neovascularisation sites
 XX
 SQ Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGACCTTACCCTAC 457
 DB 1 GCAAGACCTTACCCTAC 18

RESULT 1865
 AAX21853
 ID AAX21853 standard; DNA; 18 BP.
 XX

AC AAX21853;
 XX 14-MAY-1999 (first entry)
 XX
 XX Primer for ICAM immunoglobulin-like loop motif.
 XX
 KW ICAM; immunoglobulin-like loop; intercellular adhesion molecule receptor;
 KW alpha d/CD18; antibody; immunisation; inflammatory response; asthma;
 KW tumour growth; viral infection; therapy; primer; ss.
 XX
 XX Synthetic.
 XX
 PN US5880268-A.
 XX
 XX 09-MAR-1999.
 XX
 XX 07-JUN-1995; 95US-00483932.
 XX
 XX 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 05-AUG-1994; 94US-00286754.
 XX
 XX (ICOS-) ICOS CORP.
 PA
 XX Vazeux R, Gallatin WM;
 PI
 XX WPI; 1999-204041/17.
 XX
 XX New intercellular adhesion molecule receptor (ICAM-R) specific antibodies
 PT - useful for modulating ligand/receptor binding and biological activities
 PT involving ICAM-R, especially those of the specific and non-specific
 PT immune systems.
 XX
 XX Example 4; Col 14; 108pp; English.
 XX
 XX This sequence is a primer for an ICAM immunoglobulin-like loop domain.
 CC The invention relates to antibodies (Ab) which bind specifically to the
 CC intercellular adhesion molecule receptor (ICAM-R), inhibiting the
 CC interaction between ICAM-R and alpha d/CD18. Abs with specific ICAM-R
 CC binding are useful in compositions for immunisation, and for purifying
 CC ICAM-R polypeptides and identifying cells expressing ICAM-R on their cell
 CC surface, modulating ligand/receptor binding and biological activities
 CC involving ICAM-R, especially inflammatory responses of the specific
 CC immune system, the non-specific immune system, monitoring and treating
 CC asthma, tumour growth, and/or metastasis, and viral infection (e.g. HIV
 CC infection). In particular diseases involving an essential T cell
 CC activation (e.g. asthma, psoriasis, diabetes, graft vs. host disease,
 CC tissue transplant rejection, and multiple sclerosis) may be treated with
 CC anti-ICAM-R antibodies. The Abs specifically bind to and identify ICAM-R
 CC and disrupt ICAM-R to cell adhesion molecule, especially alpha d/CD18
 CC binding
 XX
 XX Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 440 GCAAGAACCTTACCCCTAC 457
 DB 1 GCAAGAACCTTACCCCTAC 18
 RESULT 1866
 AA224277
 ID AA224277 standard; DNA; 18 BP.
 XX
 AC AA224277;
 XX

DT 16-FEB-2000 (first entry)
 XX
 XX Human ICAM oligonucleotide probe Icam1-5.
 XX
 KW ICAM-R; human; intercellular adhesion molecule; phosphorylation;
 KW protein kinase C; modulator; probe; ss.
 XX
 XX Synthetic.
 OS
 XX Homo sapiens.
 XX
 PN US5989843-A.
 XX
 XX 23-NOV-1999.
 XX
 XX 27-SEP-1996; 96US-00720420.
 XX
 XX 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-00009266.
 PR 26-JAN-1993; 93WO-US000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 07-JUN-1995; 95US-00487113.
 XX
 XX (ICOS-) ICOS CORP.
 PA
 XX Gallatin WM, Vazeux R;
 PI
 XX WPI; 2000-022778/02.
 XX
 XX Identifying modulators of protein kinase C phosphorylation of human
 PT intercellular adhesion molecule polypeptide.
 PT
 XX Example 4; Col 117-118; 122pp; English.
 XX
 XX This invention describes a novel method for identifying a compound that
 CC modulates phosphorylation of human intercellular adhesion molecule
 CC polypeptide (ICAM-R) by protein kinase C isoform. The method comprises:
 CC (a) exposing a purified peptide consisting of the cytoplasmic domain of
 CC ICAM-R to protein kinase C isoform and labeled adenosine triphosphate in
 CC the presence and absence of a test compound; (b) measuring labeled
 CC phosphate transferred to the peptide; and (c) identifying a test compound
 CC that affects transfer of the labeled phosphate as a modulator compound.
 CC The method is useful for identifying compounds that modulate the
 CC phosphorylation of human intercellular adhesion molecule polypeptide
 CC which might form the basis for the development of therapeutic and
 CC diagnostic agents. This sequence represents a probe used in the method of
 CC the invention
 XX
 XX Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 440 GCAAGAACCTTACCCCTAC 457
 DB 1 GCAAGAACCTTACCCCTAC 18
 RESULT 1867
 AAA97105
 ID AAA97105 standard; DNA; 18 BP.
 XX
 AC AAA97105;
 XX
 XX 19-DEC-2000 (first entry)
 XX
 XX PCR primer Icam 1-5 used in ICAM-R DNA isolation.
 XX
 XX Anti-human immunodeficiency virus; HIV; cytostatic; ICAM-R; ARDS; stroke;
 KW intercellular adhesion molecule; immunoglobulin heavy chain; septicemia;
 KW inflammatory conditions; glomerulonephritis; arthritis; dermatosis;

KW haemodialysis; leukapheresis; ulcerative colitis; Crohn's disease;
 KW necrotising enterocolitis; atherosclerosis; psoriasis, asthma;
 KW transplant rejection; diabetes; tumour; PCR primer; ss.

XX Homo sapiens.

OS US6100383-A.

XX PD 08-AUG-2000.

XX PF 07-JUN-1995; 95US-00475680.

XX PR 27-JAN-1992; 92US-00827689.

XX PR 26-MAY-1992; 92US-00889724.

XX PR 05-JUN-1992; 92US-00894061.

XX PR 22-JAN-1993; 93US-00009266.

XX PR 26-JAN-1993; 93US-0000787.

XX PR 05-AUG-1993; 93US-00102852.

XX PR 05-AUG-1994; 94US-00286754.

XX PA (ICOS-) ICOS CORP.

XX PI Gallatin WM, Vazeux R;

XX PR WPI; 2000-542449/49.

XX PS Hybrid fusion proteins comprising intercellular adhesion molecule or its

XX PT variants useful, for treating inflammatory conditions, Crohn's disease,
 XX PT atherosclerosis and diabetes.

XX PS Example 4; Col 14; 109pp; English.

XX CC This invention relates to a hybrid fusion protein comprising an
 CC intercellular adhesion molecule (ICAM-R) amino acid fragment at its amino
 CC terminus and a constant domain of an immunoglobulin heavy chain at its
 CC carboxy terminus. ICAM-R polypeptides are useful for treating and
 CC monitoring inflammatory conditions such as adult respiratory distress
 CC syndrome, multiple organ injury syndrome secondary to septicemia or
 CC trauma, reperfusion injury of tissue, acute glomerulonephritis, reactive
 CC arthritis, dermatosis, stroke, thermal injury, haemodialysis,
 CC leukapheresis, ulcerative colitis, Crohn's disease, necrotising
 CC enterocolitis, granulocyte transfusion associated syndrome,
 CC atherosclerosis and cytokine induced toxicity. ICAM-R polypeptides are
 CC also useful for treating conditions resulting from a response of the
 CC specific immune system in a mammal e.g. psoriasis, organ/tissue
 CC transplant rejection and autoimmune diseases including Raynaud's
 CC arthritis, diabetes and lupus erythematosus. ICAM-R products and ICAM-R
 CC related products are also useful in monitoring and treating asthma,
 CC tumour growth and/or metastasis, and viral infection (e.g. HIV
 CC infection). Sequences AAA97090 and AAB13036 represent the human ICAM-R
 CC DNA and protein sequences. Sequences AAA97091-A97112 represent ICAM-R DNA
 CC fragments, PCR primers and probes, all used in the identification of the
 CC ICAM-R DNA sequence. AAA97113-A97123 and AAA97129-A97152 represent
 CC primers used in the production of humanised anti-ICAM-R antibody ICR-8.1,
 CC and fragments of the humanised antibody. Sequences AAA97124-A97128,
 CC AAA97132, AAA97144 represent ICR-8.1 sequences. Sequences AAA97153-A97176
 CC excluding AAA97155-A97156 represent primers used in the production of
 CC humanised anti-ICAM-R antibody ICR-1.1, and fragments of the humanised
 CC antibody. Sequences AAA97155-A97156 and AAB13047-B13048 represent murine
 CC ICR-1.1 sequences. DNA and peptide sequences used in the production of
 CC the chimeric protein of the invention include AAA97177-A97188 and
 CC AAB13050-B13051

XX SQ Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCCTAC 457

Db 1 GCAAGAACCTTACCCCTAC 18

RESULT 1868
 AAA07354/c
 ID AAA07354 standard; DNA; 18 BP.
 XX AC AAA07354;
 XX AC AAA07354;
 XX DT 30-JUN-2000 (first entry)
 XX DE Human ICAM-1 antisense inhibitor Oligomer 2.

XX KW Human; ICAM-1; intercellular adhesion molecule-1; haloacetyl linker;
 KW antisense oligonucleotide; oligomeric compound preparation; primer;
 KW pendant group; heterobifunctional phosphoramidite building block;
 KW oligonucleotide analogue production; probe; ss.

XX OS Homo sapiens.

XX FH Key Location/Qualifiers
 XX modified_base 2

XX FT /*tag= a

XX FT /note= "incorporates N2- (3-N-chloroacetyl-propylamine)

XX FT functional group"

XX FT modified_base 12

XX FT /*tag= b

XX FT /note= "incorporates N2- (3-N-chloroacetyl-propylamine)

XX FT functional group"

XX PN WO200014098-A1.

XX PD 16-MAR-2000.

XX PF 27-AUG-1999; 99WO-US019828.

XX PR 07-SEP-1998; 98US-00149156.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Manoharan M;

XX WPI; 2000-256929/22.

XX PT Preparation of oligomeric compounds with pendant groups conjugated to

XX PT them via haloacetyl linkers, utilizing heterobifunctional phosphoramidite

XX PT building blocks.

XX PS Example 14; Page 50; 65pp; English.

XX CC This sequence represents an antisense oligonucleotide targeted against
 CC human ICAM-1 (Intercellular Adhesion Molecule-1). The invention relates
 CC to methods for the preparation of oligomeric compounds with pendant
 CC groups conjugated to them via haloacetyl linkers, utilizing
 CC heterobifunctional phosphoramidite building blocks. The methods may be
 CC used for producing oligonucleotide analogues for use as probes, primers,
 CC linkers, adapters and/or gene fragments

XX SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 9.9e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1869

AAA07353/c

ID AAA07353 standard; DNA; 18 BP.

XX AC AAA07353;

XX DT 30-JUN-2000 (first entry)

XX XX Human ICAM-1 antisense inhibitor Oligomer 1.

DE XX

XX KW Human; ICAM-1; intercellular adhesion molecule-1; haloacetyl linker;

DE XX antisense oligonucleotide; oligomeric compound preparation; primer;

XX KW pendant group; heterobifunctional phosphoramidite building block;

XX KW oligonucleotide analogue production; probe; ss.

XX OS Homo sapiens.

XX XX

XX FH Key Location/Qualifiers

DE XX modified_base 2

FT FT /*tag= a

FT FT /note= "incorporates N2- (3-N-chloroacetyl-propylamine)

FT FT functional group"

XX WO200014098-A1.

XX XX

XX PD 16-MAR-2000.

XX XX

XX PF 27-AUG-1999; 99WO-US019828.

XX XX

XX PR 07-SEP-1998; 98US-00149156.

XX XX

XX PA (ISIS-) ISIS PHARM INC.

XX PI Manoharan M;

XX XX

XX DR WPI; 2000-256929/22.

XX XX

XX PT Preparation of oligomeric compounds with pendant groups conjugated to

XX PT them via haloacetyl linkers, utilizing heterobifunctional phosphoramidite

XX PT building blocks.

XX XX

XX PS Example 14; Page 50; 65pp; English.

XX XX

XX CC This sequence represents an antisense oligonucleotide targeted against

XX CC human ICAM-1 (intercellular Adhesion Molecule-1). The invention relates

XX CC to methods for the preparation of oligomeric compounds with pendant

XX CC groups conjugated to them via haloacetyl linkers, utilising

XX CC heterobifunctional phosphoramidite building blocks. The methods may be

XX CC used for producing oligonucleotide analogues for use as probes, primers,

XX CC linkers, adapters and/or gene fragments

XX XX

XX SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 9.9e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1870

AA08251

ID AAA08251 standard; DNA; 18 BP.

XX AC

XX AC AAA08251;

XX DT 28-JUN-2000 (first entry)

XX XX

DE XX Human ICAM oligonucleotide probe SEQ ID NO:21.

XX XX

XX KW Human; ICAM-R; chromosome 19; intracellular adhesion molecule receptor;

XX KW CAM; ICAM-1; ICAM-2; humanised; antibody; mutagenic; PCR primer; probe;

XX KW chimeric; vulnaray; nephropathic; antiarthritic; cerebroprotective;

XX KW antitumor; antiarteriosclerotic; immunosuppressive; antidiabetic;

XX KW neuroprotective; antithyroid; dermatological; antiasthmatic; cytostatic;

XX KW antiviral; antiinflammatory; anti-HIV; vasotropic; antipsoriatic;

XX KW immunomodulator; cell adhesion mediator; antirheumatic;

XX KW inflammatory condition; immunisation; immune response; ss.

XX OS Homo sapiens.

XX XX

XX PN US6040176-A.

XX PD 21-MAR-2000.

XX XX

XX PF 12-SEP-1996; 96US-00714017.

XX XX

XX PR 27-JAN-1992; 92US-00827689.

XX PR 26-MAY-1992; 92US-00889724.

XX PR 05-JUN-1992; 92US-00894061.

XX PR 22-JAN-1993; 93US-00009266.

XX PR 26-JAN-1993; 93WO-US000787.

XX PR 05-AUG-1993; 93US-00102852.

XX PR 05-AUG-1994; 94US-00286754.

XX XX

XX PA (ICOS-) ICOS CORP.

XX XX

XX PI Gallatin WM, Vazeux R;

XX XX

XX DR WPI; 2000-270138/23.

XX XX

XX PT Novel monoclonal antibody directed against ICAM-R proteins useful for

XX PT treating acute glomerulonephritis, ulcerative colitis, psoriasis,

XX PT rheumatoid arthritis, diabetes, multiple sclerosis, asthma and viral

XX PT infection.

XX XX

XX XX Example 4; Col 14; 117pp; English.

XX XX

XX CC The present invention describes a monoclonal antibody (Mab) (I), produced

XX CC by the hybridoma cell line 81K2F (ATCC HB 11692). Also described are: (i)

XX CC a hybridoma cell line 81K2F; and (2) a Mab (II), that competes with (I)

XX CC for binding to ICAM-R (intracellular adhesion molecule receptor) (III).

XX CC (II) mimics the activity of natural binding proteins through which

XX CC intercellular and intracellular activities of (III) are modulated. (II)

XX CC is also used for modulating the immune responses. (I) is used for

XX CC immunisation as well as for purifying (III). They are also useful in

XX CC modulating the ligand/receptor binding biological activity involving

XX CC (III) especially those effector functions of (III) involved in specific

XX CC and non-specific immune system responses. Inflammatory conditions which

XX CC may be treated or monitored with related products of (III) include

XX CC conditions resulting from a response of the non-specific immune system in

XX CC a mammal e.g. adult respiratory distress syndrome, multiple organ injury

XX CC syndrome secondary to septicemia or trauma, reperfusion injury of tissue,

XX CC acute glomerulonephritis, reactive arthritis, stroke, ulcerative colitis

XX CC and atherosclerosis, and conditions resulting from a response of the

XX CC specific immune system in a mammal, e.g. psoriasis, organ/tissue

XX CC transplantation rejection, autoimmune diseases such as autoimmune

XX CC thyroiditis, multiple sclerosis, rheumatoid arthritis, diabetes and lupus

XX CC erythematosus. AAA08236 to AAA08334, and AAA82435 to AAA82451 represent

XX CC sequences used in the exemplification of the present invention

XX XX

XX SQ Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 9.9e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCCTAC 457

DB 1 GCAAGAACCTTACCCCTAC 18

RESULT 1871

AAZ48879/c

ID AAZ48879 standard; DNA; 18 BP.

XX AC

XX AC AAZ48879;

XX XX

XX DT 29-MAR-2000 (first entry)

XX DE Human ICAM-1 antisense inhibitor, ISIS #16857.
 XX DE
 XX DE Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX OS Homo sapiens.
 XX OS
 XX PN WO9961462-A1.
 XX PN
 XX PD 02-DEC-1999.
 XX PD
 XX PF 26-MAY-1999; 99WO-US011548.
 XX PF
 XX PR 27-MAY-1998; 98US-00085759.
 XX PR
 XX PA (ISIS-) ISIS PHARM INC.
 XX PA
 XX PI Bennett CF, Mirabelli CK, Baker BF;
 XX PI
 XX DR WPI; 2000-072600/06.
 XX DR
 XX CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell-cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX Sequence 18 BP; 4 A; 4 C; 5 G; 5 T; 0 U; 0 Other;
 XX

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 1337 CCGAGCTCAAGTCTTAA 1354
 |||||
 18 CCGAGCTCAAGTCTTAA 1

RESULT 1872
 AAZ48880/c
 ID AAZ48880 standard; DNA; 18 BP.
 XX AC AAZ48880;
 XX DT 29-MAR-2000 (first entry)
 XX DE Human ICAM-1 antisense inhibitor, ISIS #16858.
 XX DE
 KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX OS Homo sapiens.
 XX OS
 XX PN WO9961462-A1.
 XX PN
 XX PD 02-DEC-1999.
 XX PD
 XX PF 26-MAY-1999; 99WO-US011548.
 XX PF
 XX PR 27-MAY-1998; 98US-00085759.
 XX PR
 XX PA (ISIS-) ISIS PHARM INC.
 XX PA
 XX PI Bennett CF, Mirabelli CK, Baker BF;
 XX PI
 XX DR WPI; 2000-072600/06.
 XX DR
 XX CC New antisense oligonucleotides, used for treating e.g. inflammatory
 CC conditions, psoriasis, graft rejection, cancers, infections,
 CC cardiovascular disorders or autoimmune disorders.
 XX Claim 5; Page 192; 199pp; English.
 XX
 CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell-cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX Sequence 18 BP; 4 A; 7 C; 3 G; 4 T; 0 U; 0 Other;
 XX

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1380 CGGGGAATCAGTGACTGT 1397
 |||||
 Db 18 CGGGGAATCAGTGACTGT 1

RESULT 1873
 AA248899/c
 ID AA248899 standard; DNA; 18 BP.
 XX
 AC AA248899;
 XX
 DT 29-MAR-2000 (first entry)
 XX
 DE Human ICAM-1 antisense inhibitor, ISIS #1565.
 XX
 KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9961462-A1.
 XX
 PD 02-DEC-1999.
 XX
 PF 26-MAY-1999; 99WO-US011548.
 XX
 PR 27-MAY-1998; 98US-00085759.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK, Baker BF;
 XX
 DR WPI; 2000-072600/06.
 XX
 PT New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX
 PS Example 10; Page 174; 199pp; English.
 XX
 CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell-cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune

CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 18 BP; 5 A; 2 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCCATCG 1381
 |||||
 Db 18 CTTTCCCACTGCCCATCG 1

RESULT 1874
 AA248878/c
 ID AA248878 standard; DNA; 18 BP.
 XX
 AC AA248878;
 XX
 DT 29-MAR-2000 (first entry)
 XX
 DE Human ICAM-1 antisense inhibitor, ISIS #16855.
 XX
 KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9961462-A1.
 XX
 PD 02-DEC-1999.
 XX
 PF 26-MAY-1999; 99WO-US011548.
 XX
 PR 27-MAY-1998; 98US-00085759.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK, Baker BF;
 XX
 DR WPI; 2000-072600/06.
 XX
 PT New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX
 PS Claim 5; Page 192; 199pp; English.
 XX
 CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell-cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,

CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 18 BP; 3 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1296 CCAGCAGACTCCCAATGTG 1313
 Db 18 CCAGCAGACTCCCAATGTG 1
 RESULT 1875
 AAZ48962/C
 ID AAZ48962 standard; DNA; 18 BP.
 XX
 AC AAZ48962;
 XX
 XX 29-MAR-2000 (first entry)
 DT
 XX
 DE Human ICAM-1 antisense inhibitor, ISIS #16856.
 XX
 KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO9961462-A1.
 PN
 XX
 PD 02-DEC-1999.
 XX
 XX 26-MAY-1999; 99WO-US011548.
 PF
 XX
 XX 27-MAY-1998; 98US-00085759.
 PR
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK, Baker BF;
 XX
 XX WPI; 2000-072600/06.
 DR
 XX
 XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense

CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell-cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 18 BP; 2 A; 6 C; 6 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1324 GCGAACCCCATGCCCGAG 1341
 Db 18 GCGAACCCCATGCCCGAG 1
 RESULT 1876
 AAZ48894
 ID AAZ48894 standard; DNA; 18 BP.
 XX
 AC AAZ48894;
 XX
 DT 29-MAR-2000 (first entry)
 DE
 XX Human ICAM-1 antisense inhibitor.
 KW
 KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX WO9961462-A1.
 PN
 XX
 PD 02-DEC-1999.
 XX
 XX 26-MAY-1999; 99WO-US011548.
 PF
 XX
 XX 27-MAY-1998; 98US-00085759.
 PR
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 XX Bennett CF, Mirabelli CK, Baker BF;
 PI
 XX
 XX WPI; 2000-072600/06.
 DR
 XX
 XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX

Example 7; Page 64; 199pp; English.

PS This sequence is an antisense oligonucleotide of the invention. The
 XX antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 18 BP; 2 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 9.9e+02; Indels 0; Gaps 0;
 Matches 18; Conservative 0; Mismatches 0;

QY 50 GCCTCGCTATGCTCCCA 67
 |||||
 Db 1 GCCTCGCTATGCTCCCA 18

RESULT 1877

AAZ48876/c

ID AAZ48876 standard; DNA; 18 BP.

AC AAZ48876;

XX 29-MAR-2000 (first entry)

DT Human ICAM-1 antisense inhibitor, ISIS #16851.

DE Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 XX vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 XX ss.

OS Homo sapiens.

XX WO9961462-A1.

PN 02-DEC-1999.

XX 26-MAY-1999; 99WO-US011548.

XX 27-MAY-1998; 98US-00085759.

XX (ISIS-) ISIS PHARM INC.

PI Bennett CF, Mirabelli CK, Baker BF;

XX WPI; 2000-072600/06.

XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.

XX Claim 5; Page 191; 199pp; English.

CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 18 BP; 3 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 9.9e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1192 GGCCAGCTTATACACAAG 1209

Db 18 GGCCAGCTTATACACAAG 1

RESULT 1878

AAZ48885/c

ID AAZ48885 standard; DNA; 18 BP.

XX AAZ48885;

XX 29-MAR-2000 (first entry)

DE Human ICAM-1 antisense inhibitor, ISIS #16865.

XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 XX ss.

XX Homo sapiens.

XX WO9961462-A1.

PD 02-DEC-1999.
 XX
 PF 26-MAY-1999; 99WO-US011548.
 XX
 PR 27-MAY-1998; 98US-00085759.
 XX
 PA (ISIS-) ISIS PHARM INC.
 PI Bennett CF, Mirabelli CK, Baker BF;
 XX WPI; 2000-072600/06.
 XX
 XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX
 XX Claim 5; Page 193; 199pp; English.
 XX
 CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 XX Sequence 18 BP; 3 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1542 TGCAGGCTCAGCACGTA 1559
 |||||
 DB 18 TGCAGGCTCAGCACGTA 1
 RESULT 1879
 AAZ48889/C
 ID AAZ48889 standard; DNA; 18 BP.
 XX
 AC AAZ48889;
 XX
 XX 29-MAR-2000 (first entry)
 DT
 XX Human ICAM-1 antisense inhibitor, ISIS #16869.
 XX
 XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX Homo sapiens.
 XX WO9961462-A1.
 XX 02-DEC-1999.
 XX 26-MAY-1999; 99WO-US011548.
 XX 27-MAY-1998; 98US-00085759.
 XX (ISIS-) ISIS PHARM INC.
 XX Bennett CF, Mirabelli CK, Baker BF;
 XX WPI; 2000-072600/06.
 XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX
 XX Claim 5; Page 93; 199pp; English.
 XX
 CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 XX Sequence 18 BP; 3 A; 3 C; 5 G; 7 T; 0 U; 0 Other;
 XX
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1791 CTCAGTCAGATACACAG 1808
 |||||
 DB 18 CTCAGTCAGATACACAG 1
 RESULT 1880
 AAZ48963/C
 ID AAZ48963 standard; DNA; 18 BP.
 XX
 AC AAZ48963;
 XX
 XX 29-MAR-2000 (first entry)
 DT
 XX

DE Human ICAM-1 antisense inhibitor, ISIS #16862.

XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.

XX Homo sapiens.

XX WO9961462-A1.

XX 02-DEC-1999.

XX 26-MAY-1999; 99WO-US011548.

XX 27-MAY-1998; 98US-00085759.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK, Baker BF;

XX WPI; 2000-072600/06.

XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.

XX Example 27; Page 92; 199pp; English.

XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell-cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC pemphigus vulgaris, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke

XX Sequence 18 BP; 5 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e-02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1487 CCCGGTATGAGATTGTCA 1504
 |||||
 DB 18 CCCGGTATGAGATTGTCA 1

RESULT 1881
 AAZ48883/C
 ID AAZ48883 standard; DNA; 18 BP.
 XX
 AC AAZ48883;
 XX
 XX 29-MAR-2000 (first entry)
 DT
 XX Human ICAM-1 antisense inhibitor, ISIS #16861.
 DE
 XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.

XX Homo sapiens.

XX WO9961462-A1.

XX 02-DEC-1999.

XX 26-MAY-1999; 99WO-US011548.

XX 27-MAY-1998; 98US-00085759.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Mirabelli CK, Baker BF;

XX WPI; 2000-072600/06.

XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.

XX Claim 5; Page 193; 199pp; English.

XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell-cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC pemphigus vulgaris, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke

XX Sequence 18 BP; 1 A; 8 C; 3 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;

CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 18 BP; 4 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1412 AGGGCACCTACTCTGTC 1429
 |||||
 Db 18 AGGGCACCTACTCTGTC 1
 RESULT 1884
 AAZ48881/C
 ID AAZ48881 standard; DNA; 18 BP.
 AC AAZ48881;
 XX
 XX 29-MAR-2000 (first entry)
 DT Human ICAM-1 antisense inhibitor, ISIS #16859.
 DE
 XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 SS
 XX Homo sapiens.
 OS
 XX WO9961462-A1.
 PN
 XX 02-DEC-1999.
 PD
 XX 26-MAY-1999; 99WO-US011548.
 PF
 XX 27-MAY-1998; 98US-00085759.
 PR (ISIS-) ISIS PHARM INC.
 PA
 XX Bennett CF, Mirabelli CK, Baker BF;
 PI
 XX WPI; 2000-072600/06.
 DR
 XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX
 PS Claim 5; Page 192; 199pp; English.
 XX
 CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating

CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 18 BP; 5 A; 5 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1390 GTGACTGTCACTCGAGAT 1407
 |||||
 Db 18 GTGACTGTCACTCGAGAT 1
 RESULT 1885
 AAZ48888/C
 ID AAZ48888 standard; DNA; 18 BP.
 AC AAZ48888;
 XX
 XX 29-MAR-2000 (first entry)
 DT Human ICAM-1 antisense inhibitor, ISIS #16868.
 DE
 XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 SS
 XX Homo sapiens.
 OS
 XX WO9961462-A1.
 PN
 XX 02-DEC-1999.
 PD
 XX 26-MAY-1999; 99WO-US011548.
 PF
 XX 27-MAY-1998; 98US-00085759.
 PR (ISIS-) ISIS PHARM INC.
 PA
 XX Bennett CF, Mirabelli CK, Baker BF;
 PI
 XX WPI; 2000-072600/06.
 DR
 XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX
 PS Claim 5; Page 93; 199pp; English.

XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX Sequence 18 BP; 3 A; 4 C; 7 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1743 TGCAGCTACACCTACCGG 1760
 |||||
 DB 18 TGCAGCTACACCTACCGG 1
 RESULT 1886
 AAZ48886/C
 ID AAZ48886 standard; DNA; 18 BP.
 AC AAZ48886;
 XX
 XX 29-MAR-2000 (first entry)
 DT Human ICAM-1 antisense inhibitor, ISIS #16866.
 DE
 XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO9961462-A1.
 FN
 XX 02-DEC-1999.
 PD
 XX 26-MAY-1999; 99WO-US011548.
 PF
 XX 27-MAY-1998; 98US-00085759.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Bennett CF, Mirabelli CK, Baker BP;
 PI

XX WPI; 2000-072600/06.
 DR New antisense oligonucleotides, used for treating e.g. inflammatory
 XX conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 PT
 XX Claim 5; Page 93; 199pp; English.
 PS
 XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX Sequence 18 BP; 4 A; 2 C; 8 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1556 CGTACTCTATTAACGCC 1573
 |||||
 DB 18 CGTACTCTATTAACGCC 1
 RESULT 1887
 AAZ48893/C
 ID AAZ48893 standard; DNA; 18 BP.
 XX
 XX AAZ48893;
 XX 29-MAR-2000 (first entry)
 DT Human ICAM-1 antisense inhibitor, ISIS #1558.
 DE
 XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO9961462-A1.
 FN
 XX 02-DEC-1999.
 PD

XX PF 26-MAY-1999; 99WO-US011548.
 XX PR 27-MAY-1998; 98US-00085759.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Bennett CF, Mirabelli CK, Baker BF;
 XX WPI; 2000-072600/06.
 XX
 XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX
 XX Example 7; Page 64; 199pp; English.
 XX
 CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 50 GCCTCGCTATGGCTCCCA 67
 DB 18 GCCTCGCTATGGCTCCCA 1
 RESULT 1888
 AAZ48877/C
 ID AAZ48877 standard; DNA; 18 BP.
 XX AAZ48877;
 XX
 XX 29-MAR-2000 (first entry)
 XX
 XX Human ICAM-1 antisense inhibitor, ISIS #16853.
 DE
 XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW

KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 ss.
 XX Homo sapiens.
 XX WO9961462-A1.
 XX 02-DEC-1999.
 XX 26-MAY-1999; 99WO-US011548.
 XX 27-MAY-1998; 98US-00085759.
 XX (ISIS-) ISIS PHARM INC.
 XX Bennett CF, Mirabelli CK, Baker BF;
 XX WPI; 2000-072600/06.
 XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX
 XX Claim 5; Page 191; 199pp; English.
 XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 18 BP; 3 A; 9 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1254 CGAGAGGGATTGTCGGG 1271
 DB 18 CGAGAGGGATTGTCGGG 1
 RESULT 1889
 AAZ48890/C
 ID AAZ48890 standard; DNA; 18 BP.
 XX AAZ48890;
 XX 29-MAR-2000 (first entry)
 XX Human ICAM-1 antisense inhibitor, ISIS #16870.

XX Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX Homo sapiens.
 XX WO9961462-A1.
 XX 02-DEC-1999.
 XX 26-MAY-1999; 99WO-US011548.
 XX 27-MAY-1998; 98US-00085759.
 XX (ISIS-) ISIS PHARM INC.
 XX Bennett CF, Mirabelli CK, Baker BF;
 XX WPI; 2000-072600/06.
 XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX Claim 5; Page 93; 199pp; English.
 XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX Sequence 18 BP; 4 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1844 TAGGCCACGCATCTGATC 1861
 Db |||||
 18 TAGGCCACGCATCTGATC 1

RESULT 1890

AAZ4898/c
 ID AAZ4898 standard; DNA; 18 BP.
 AC AAZ4898;
 XX 29-MAR-2000 (first entry)
 DT Human ICAM-1 antisense inhibitor, ISIS #1564.
 DE Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX Homo sapiens.
 OS WO9961462-A1.
 PN 02-DEC-1999.
 PD 26-MAY-1999; 99WO-US011548.
 PF 27-MAY-1998; 98US-00085759.
 PR (ISIS-) ISIS PHARM INC.
 XX Bennett CF, Mirabelli CK, Baker BF;
 PI WPI; 2000-072600/06.
 XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX Example 10; Page 174; 199pp; English.
 XX This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be
 CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX Sequence 18 BP; 4 A; 1 C; 11 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 100.0%; Pred. No. 9.9e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2836 TCCTCCACCTCAGCCTC 2853
 |||||
 Db 18 TCCTCCACCTCAGCCTC 1

RESULT 1891
 AAC73474/C
 ID AAC73474 standard; DNA; 18 BP.
 AC AAC73474;
 XX
 XX
 DT 02-FEB-2001 (first entry)
 XX
 DE Reverse primer #101 used in multiplexing PCR/SBE assay.
 XX
 KW Oligonucleotide array; genotyping; single base extension reaction; SBE;
 KW PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
 XX
 OS Unidentified.
 XX
 PN WO200058516-A2.
 XX
 PD 05-OCT-2000.
 XX
 XX 27-MAR-2000; 2000WO-US008069.
 XX
 PF 26-MAR-1999; 99US-0126473P.
 XX
 PR 23-JUN-1999; 99US-0140359P.
 XX
 XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
 PA (AFFY-) AFFYMETRIX INC.
 XX
 PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
 PI Ryder T, Sklar P;
 XX
 DR WPI; 2000-656171/63.
 XX
 XX 27-MAR-2000; 2000WO-US008069.
 XX
 PF 26-MAR-1999; 99US-0126473P.
 XX
 PR 23-JUN-1999; 99US-0140359P.
 XX
 XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
 PA (AFFY-) AFFYMETRIX INC.
 XX
 PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
 PI Ryder T, Sklar P;
 XX
 DR WPI; 2000-656171/63.
 XX
 XX Universal array of oligonucleotides tags attached to a solid substrate
 PT along with locus-specific tagged oligonucleotides useful in genotyping
 PT using single base extension reactions.
 XX
 XX Example 7; Page 58; 70pp; English.
 XX
 CC The present invention relates to an oligonucleotide array comprising
 CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
 CC array is useful for genotyping a nucleic acid sample at one or more loci
 CC via single base extension (SBE) reactions. A pair of primers is used to
 CC amplify a polymorphic locus in a sample e.g. a single nucleotide
 CC polymorphism (SNP). The present sequence is one of the primers used in
 CC the method of the present invention to amplify a polymorphic sample. The
 CC amplified nucleic acid product is then used as a template in a SBE
 CC reaction with an extension primer. The SBE reaction products are used to
 CC form the oligonucleotide array
 XX
 SQ Sequence 18 BP; 5 A; 6 C; 5 G; 2 T; 0 U; 0 Other;
 XX
 XX Query Match 0.6%; Score 18; DB 1; Length 18;
 CC Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 CC Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 782 TGTTCCTCAGTCTCGAGG 799
 |||||
 Db 18 TGTTCCTCAGTCTCGAGG 1

RESULT 1892
 AAC73481
 ID AAC73481 standard; DNA; 18 BP.
 AC AAC73481;
 XX
 XX

DT 02-FEB-2001 (first entry)
 XX
 DE Forward primer #103 used in multiplexing PCR/SBE assay.
 XX
 KW Oligonucleotide array; genotyping; single base extension reaction; SBE;
 KW PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
 XX
 OS Unidentified.
 XX
 PN WO200058516-A2.
 XX
 PD 05-OCT-2000.
 XX
 XX 27-MAR-2000; 2000WO-US008069.
 XX
 PF 26-MAR-1999; 99US-0126473P.
 XX
 PR 23-JUN-1999; 99US-0140359P.
 XX
 XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
 PA (AFFY-) AFFYMETRIX INC.
 XX
 PI Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
 PI Ryder T, Sklar P;
 XX
 DR WPI; 2000-656171/63.
 XX
 XX Universal array of oligonucleotides tags attached to a solid substrate
 PT along with locus-specific tagged oligonucleotides useful in genotyping
 PT using single base extension reactions.
 XX
 XX Example 7; Page 58; 70pp; English.
 XX
 CC The present invention relates to an oligonucleotide array comprising
 CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
 CC array is useful for genotyping a nucleic acid sample at one or more loci
 CC via single base extension (SBE) reactions. A pair of primers is used to
 CC amplify a polymorphic locus in a sample e.g. a single nucleotide
 CC polymorphism (SNP). The present sequence is one of the primers used in
 CC the method of the present invention to amplify a polymorphic sample. The
 CC amplified nucleic acid product is then used as a template in a SBE
 CC reaction with an extension primer. The SBE reaction products are used to
 CC form the oligonucleotide array
 XX
 SQ Sequence 18 BP; 3 A; 9 C; 3 G; 3 T; 0 U; 0 Other;
 XX
 XX Query Match 0.6%; Score 18; DB 1; Length 18;
 CC Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 CC Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 204 CACCTCCTGTGACGACC 221
 |||||
 Db 1 CACCTCCTGTGACGACC 18

RESULT 1893
 AAC73473
 ID AAC73473 standard; DNA; 18 BP.
 AC AAC73473;
 XX
 XX 02-FEB-2001 (first entry)
 XX
 DE Forward primer #101 used in multiplexing PCR/SBE assay.
 XX
 KW Oligonucleotide array; genotyping; single base extension reaction; SBE;
 KW PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
 XX
 OS Unidentified.
 XX
 PN WO200058516-A2.
 XX
 PD 05-OCT-2000.
 XX

```

PF 27-MAR-2000; 2000WO-US008069.
XX
XX
PR 26-MAR-1999; 99US-0126473P.
PR 23-JUN-1999; 99US-0140359P.
XX
XX (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY-) AFFYMETRIX INC.
XX
XX Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
PI Ryder T, Sklar P;
XX WPI; 2000-656171/63.
XX
XX Universal array of oligonucleotides tags attached to a solid substrate
PT along with locus-specific tagged oligonucleotides useful in genotyping
PT using single base extension reactions.
XX
XX Example 7; Page 58; 70pp; English.
XX
XX The present invention relates to an oligonucleotide array comprising
CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC array is useful for genotyping a nucleic acid sample at one or more loci
CC via single base extension (SBE) reactions. A pair of primers is used to
CC amplify a polymorphic locus in a sample e.g. a single nucleotide
CC polymorphism (SNP). The present invention is one of the primers used in
CC the method of the present invention to amplify a polymorphic sample. The
CC amplified nucleic acid product is then used as a template in a SBE
CC reaction with an extension primer. The SBE reaction products are used to
CC form the oligonucleotide array
XX
XX Sequence 18 BP; 1 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 759 CGTGGTCTGTCCCTGGA 776
Db 1 CGTGGTCTGTCCCTGGA 18
RESULT 1894
AAC73486/c
ID AAC73486 standard; DNA; 18 BP.
XX
XX AAC73486;
XX
XX 02-FEB-2001 (first entry)
XX
XX Reverse primer #104 used in multiplexing PCR/SBE assay.
XX
XX Oligonucleotide array; genotyping; single base extension reaction; SBE;
KW PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
XX
XX Unidentified.
XX
XX WO200058516-A2.
XX
XX 05-OCT-2000.
XX
XX 27-MAR-2000; 2000WO-US008069.
XX
XX 26-MAR-1999; 99US-0126473P.
PR 23-JUN-1999; 99US-0140359P.
XX
XX (WHEED ) WHITEHEAD INST BIOMEDICAL RES.
PA (AFFY-) AFFYMETRIX INC.
XX
XX Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
PI Ryder T, Sklar P;
XX WPI; 2000-656171/63.
XX
XX Universal array of oligonucleotides tags attached to a solid substrate
PT along with locus-specific tagged oligonucleotides useful in genotyping
PT using single base extension reactions.
XX
XX Example 7; Page 59; 70pp; English.
XX
XX The present invention relates to an oligonucleotide array comprising
CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
CC array is useful for genotyping a nucleic acid sample at one or more loci
CC via single base extension (SBE) reactions. A pair of primers is used to
CC amplify a polymorphic locus in a sample e.g. a single nucleotide
CC polymorphism (SNP). The present invention is one of the primers used in
CC the method of the present invention to amplify a polymorphic sample. The
CC amplified nucleic acid product is then used as a template in a SBE
CC reaction with an extension primer. The SBE reaction products are used to
CC form the oligonucleotide array
XX
XX Sequence 18 BP; 5 A; 7 C; 3 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1464 GGTGACCGTGAATGTGCT 1481
Db 18 GGTGACCGTGAATGTGCT 1
RESULT 1895
AAC91942
ID AAC91942 standard; DNA; 18 BP.
XX
XX AAC91942;
XX
XX 19-MAR-2001 (first entry)
XX
XX Human ICAM-R probe Icam 1-5.
XX
XX Human; ICAM-R; intercellular adhesion molecule polypeptide;
KW leukointegrin; Mac-1; gp15095; probe; ss.
XX
XX Homo sapiens.
XX
XX US6153395-A.
XX
XX 28-NOV-2000.
XX
XX 26-AUG-1994; 94US-00296749.
XX
XX 27-JAN-1992; 92US-00827689.
PR 26-MAY-1992; 92US-00889724.
PR 05-JUN-1992; 92US-00894061.
PR 22-JAN-1993; 93US-00009266.
PR 26-JAN-1993; 93WO-US000787.
PR 05-AUG-1993; 93US-00102852.
XX
XX (ICOS-) ICOS CORP.
XX
XX Vazeux R, Gallatin WM;
PI WPI; 2001-060087/07.
XX
XX Identifying inhibitors of human intercellular adhesion molecule binding
PT to Mac-1 or Gp15095 comprise determining a reduction in the label bound
PT in the presence of the test compound.
XX
XX Example 4; Col 12; 82pp; English.
XX
XX The present invention relates to a method for identifying compounds that
CC inhibit the binding of human intercellular adhesion molecule polypeptide
CC (ICAM-R) to the leukointegrins Mac-1 or gp15095. The method comprises
CC determining the effect of a test compound on the amount of labelled ICAM-
CC R, or labelled Mac-1 or Gp15095 bound. The present sequence is a probe

```

CC for human ICAM-R (see AAC91927)

SQ Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCTAC 457

DB 1 GCAAGAACCTTACCCTAC 18

RESULT 1896

ABK09294

ID ABK09294 standard; DNA; 18 BP.

XX

AC ABK09294;

XX

DT 30-DEC-2002 (first entry)

XX

DE Intercellular adhesion molecule, ICAM-R PCR probe Icaml-5.

XX

KW Human; intercellular adhesion molecule; ICAM; antiinflammatory; stroke;
KW antibacterial; vulnary; vasotropic; nephrotropic; antiarthritic;
KW cerebroprotective; dermatological; antitumor; immunosuppressive; tumor;
KW antiproliferative; antitumor; neuroprotective; antithyroid;
KW virucide; antirheumatic; antidiabetic; antiasthmatic; cytostatic; asthma;
KW hybridoma cell line; ATCC HB 12190; inflammation; septicemia; trauma;
KW adult respiratory distress syndrome; multiple organ injury syndrome;
KW tissue reperfusion injury; acute glomerulonephritis; arthritis; vaccine;
KW dermatosis; thermal injury; haemodialysis; psoriasis;
KW Crohn's disease; ulcerative colitis; multiple sclerosis; infection; ss.

XX

OS Homo sapiens.

XX

PN US2001029293-A1.

XX

PD 11-OCT-2001.

XX

PF 03-JAN-2001; 2001US-00753436.

XX

PR 27-JAN-1992; 92US-00827689.

PR

PR 26-MAY-1992; 92US-00889724.

PR

PR 05-JUN-1992; 92US-00894061.

PR

PR 22-JAN-1993; 93US-00009266.

PR

PR 26-JAN-1993; 93WO-US000787.

PR

PR 05-AUG-1993; 93US-00102852.

PR

PR 07-JUN-1995; 95US-00487113.

PR

PR 24-AUG-1999; 99US-00382289.

XX

XX (ICOS-) ICOS CORP.

PA

XX Gallatin WM, Vazeux R;

XX

XX WPI; 2002-009992/01.

XX

XX Novel hybridoma cell line useful for producing monoclonal antibody for

PT

PT treating inflammatory conditions, immune system disorders and infectious

PT

PT diseases, is deposited under specified ATCC accession number.

XX

XX Page 8; Example 4; 126pp; English.

XX

CC The invention relates to a novel hybridoma cell line (I) ATCC HB 12190.

CC

CC (I) is useful for producing an intercellular adhesion molecule (ICAM)

CC transplant rejection, autoimmune diseases including Raynaud's syndrome,
CC autoimmune thyroiditis, multiple sclerosis, rheumatoid arthritis, lupus
CC erythematous, asthma, tumour growth and/or metastasis, viral infection,
CC tissue transplant rejection, graft versus host disease and multiple
CC sclerosis. (II) is also useful for immunisation, for purifying ICAM-R
CC polypeptides and for identifying cells that display the polypeptides on
CC their surfaces. AAS09279-AAS09380 represent ICAM coding sequences, PCR
CC primers and related sequences of the invention

SQ Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCTAC 457

DB 1 GCAAGAACCTTACCCTAC 18

RESULT 1897

ABL46179/C

ID ABL46179 standard; DNA; 18 BP.

XX

AC ABL46179;

XX

DT 26-APR-2002 (first entry)

XX

DE Human ICAM-1 antisense oligonucleotide ISIS 1570 SEQ ID NO:146.

XX

KW Nucleic acid accessible hybridisation site; detection; hybridisation;
KW characterisation; identification; nucleic acid structure; diagnosis;
KW PCR primer; probe; ss.

XX

OS Homo sapiens.

OS

XX Synthetic.

XX

PN WO200198537-A2.

XX

PD 27-DEC-2001.

XX

PF 15-JUN-2001; 2001WO-US019401.

XX

PR 17-JUN-2000; 2000US-0212308P.

PR

PR 15-JUN-2001; 2001US-00212308.

XX

XX (THIR-) THIRD WAVE TECHNOLOGIES INC.

PA

XX Lyamichev V, Allawi H, Dong F, Neri BP, Vener IT;

XX

XX WPI; 2002-049698/06.

XX

PT Identifying oligonucleotides hybridizing to nucleic acids containing

PT

PT secondary structure, useful in clinical diagnosis, comprises identifying

PT

PT primers that interact with the target to form an extension product under

PT

PT amplification conditions.

XX

PS Example 17; Page 382; 409pp; English.

XX

CC The present invention describes a method for identifying oligonucleotides

CC

CC with desired hybridisation properties to nucleic acid targets containing

CC

CC secondary structure. The method comprises amplifying a target nucleic

CC

CC acid having at least one accessible and one inaccessible site. Primers

CC

CC that form an extension product are identified as the oligonucleotides

CC

CC which can interact with the folded target nucleic acid. Oligonucleotides

CC

CC from the present invention can be used in novel detection methods for

CC

CC clinical diagnostic purposes, including the detection and identification

CC

CC of pathogenic organisms (e.g. HIV). The method allows the ability to

CC

CC rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent

CC

CC sequences used in the exemplification of the present invention

XX

SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

CC folic acid was determined by the inhibition of intercellular cell
 CC adhesion molecule-I (ICAM-I). The present sequence represents a
 CC derivatised oligonucleotide oligomer

XX Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1900
 ACD67198/c
 ID ACD67198 standard; DNA; 18 BP.
 XX AC ACD67198;

XX 17-SEP-2003 (first entry)

XX ICAM-1 specific antisense oligonucleotide.

XX Human; ss; ICAM-1; intracellular cell adhesion molecule-1; antisense;
 KW improved transfer; improved uptake; steroid/reporter molecule; porphyrin;
 KW non-aromatic lipophilic molecule; reporter enzyme; metal chelator;
 KW water/lipid soluble vitamin; RNA cleaving complex; alkylator;
 KW hybrid photo-nuclease/intercalator; aryl azide photo-crosslinking agent.

XX Homo sapiens.

XX US2002177150-A1.

XX 28-NOV-2002.

XX 11-FEB-2002; 2002US-00073718.

XX 23-OCT-1992; 92WO-US0009196.

XX 15-DEC-1998; 98US-00211882.

XX 07-AUG-2000; 2000US-00633659.

XX (ISIS-) ISIS PHARM INC.

XX Manoharan M, Cook PD, Bennett CF;

XX WPI; 2003-521529/49.

XX New derivatized oligonucleotide, useful for effecting cellular uptake,
 PT comprises several linked nucleosides bearing a substituent such as
 PT steroid/reporter molecule, reporter enzyme or peptide.

XX Example 32; Page 19; 23pp; English.

XX The invention relates to a derivatised oligonucleotide comprising several
 CC linked nucleosides having a functionalised nucleoside bearing a
 CC substituent such as steroid/reporter molecule, non-aromatic lipophilic
 CC molecule, reporter enzyme, peptide, protein, water/lipid soluble vitamin,
 CC RNA cleaving complex, metal chelator, porphyrin, alkylator, hybrid photo-
 CC nuclease/intercalator or aryl azide photo-crosslinking agent. The
 CC oligonucleotide is useful for effecting cellular uptake of the
 CC oligonucleotide by contacting an organism with the oligonucleotide. The
 CC oligonucleotide is useful in research and diagnostic methods, for
 CC assaying bodily states in animals, especially disease states, or for
 CC treatment of diseases through modulation of the activity of DNA or RNA.
 CC The oligonucleotide has improved transfer across cellular membranes and
 CC uptake properties. The effect of conjugation of an oligonucleotide with
 CC folic acid was determined by the inhibition of intercellular cell
 CC adhesion molecule-I (ICAM-I). The present sequence represents the ICAM-1
 CC specific antisense oligonucleotide

XX Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1901
 ACD67163/c
 ID ACD67163 standard; DNA; 18 BP.
 XX AC ACD67163;

XX 17-SEP-2003 (first entry)

XX Derivatised oligonucleotide oligomer 16.

XX ICAM-1; intracellular cell adhesion molecule-1; antisense; ss;
 KW improved transfer; improved uptake; steroid/reporter molecule; porphyrin;
 KW non-aromatic lipophilic molecule; reporter enzyme; metal chelator;
 KW water/lipid soluble vitamin; RNA cleaving complex; alkylator;
 KW hybrid photo-nuclease/intercalator; aryl azide photo-crosslinking agent.

XX Synthetic.

XX US2002177150-A1.

XX 28-NOV-2002.

XX 11-FEB-2002; 2002US-00073718.

XX 23-OCT-1992; 92WO-US0009196.

XX 15-DEC-1998; 98US-00211882.

XX 07-AUG-2000; 2000US-00633659.

XX (ISIS-) ISIS PHARM INC.

XX Manoharan M, Cook PD, Bennett CF;

XX WPI; 2003-521529/49.

XX New derivatized oligonucleotide, useful for effecting cellular uptake,
 PT comprises several linked nucleosides bearing a substituent such as
 PT steroid/reporter molecule, reporter enzyme or peptide.

XX Example 7; Page 8; 23pp; English.

XX The invention relates to a derivatised oligonucleotide comprising several
 CC linked nucleosides having a functionalised nucleoside bearing a
 CC substituent such as steroid/reporter molecule, non-aromatic lipophilic
 CC molecule, reporter enzyme, peptide, protein, water/lipid soluble vitamin,
 CC RNA cleaving complex, metal chelator, porphyrin, alkylator, hybrid photo-
 CC nuclease/intercalator or aryl azide photo-crosslinking agent. The
 CC oligonucleotide is useful for effecting cellular uptake of the
 CC oligonucleotide by contacting an organism with the oligonucleotide. The
 CC oligonucleotide is useful in research and diagnostic methods, for
 CC assaying bodily states in animals, especially disease states, or for
 CC treatment of diseases through modulation of the activity of DNA or RNA.
 CC The oligonucleotide has improved transfer across cellular membranes and
 CC uptake properties. The effect of conjugation of an oligonucleotide with
 CC folic acid was determined by the inhibition of intercellular cell
 CC adhesion molecule-I (ICAM-I). The present sequence represents a
 CC derivatised oligonucleotide oligomer

XX Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1902
 ADC38978/c
 ID ADC38978 standard; DNA; 18 BP.
 XX
 AC ADC38978;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human ICAM-1 targeted primer #4.
 XX
 KW ss; primer; immunosuppressive; antisense therapy;
 KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
 KW extracellular adhesion molecule-1; ELAM-1;
 KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT misc_difference 1..18
 FT /*tag= a
 FT /note= "internucleotide linkages are optionally
 FT phosphodiester bonds"
 FT modified_base 1..18
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER = all A, C and U are 2'-fluoro bases"
 XX
 PN WO2003032920-A2.
 XX
 PD 24-APR-2003.
 XX
 PF 16-OCT-2002; 2002WO-US033236.
 XX
 PR 18-OCT-2001; 2001US-00982262.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK;
 XX
 DR WPI; 2003-403142/38.
 XX
 PT Inhibiting corneal allograft rejection, by contacting an allograft with a
 PT formulation having an oligonucleotide targeted to intercellular adhesion
 PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
 PT molecule-1.
 XX
 PS Example 5; SEQ ID NO 4; 106pp; English.
 XX
 CC The invention relates to a method of inhibiting corneal allograft
 CC rejection, by contacting the allograft with a topical formulation
 CC comprising an antisense oligonucleotide targeted to intercellular
 CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
 CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
 CC useful for inhibiting corneal allograft rejection or for preserving a
 CC corneal explant ex vivo, where the explant is human. This sequence
 CC corresponds to one of the oligonucleotide of the invention.
 XX
 SQ Sequence 18 BP; 4 A; 1 C; 11 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCACCTCAGCCTC 2853
 Db 18 TCCTCCACCTCAGCCTC 1

RESULT 1903
 ADC38975/c
 ID ADC38975 standard; DNA; 18 BP.

XX
 AC ADC38975;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human ICAM-1 targeted primer #1.
 XX
 KW ss; primer; immunosuppressive; antisense therapy;
 KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
 KW extracellular adhesion molecule-1; ELAM-1;
 KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT misc_difference 1..18
 FT /*tag= a
 FT /note= "internucleotide linkages are optionally
 FT phosphodiester bonds"
 FT modified_base 1..18
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER = all A, C and U are 2'-fluoro bases"
 XX
 PN WO2003032920-A2.
 XX
 PD 24-APR-2003.
 XX
 PF 16-OCT-2002; 2002WO-US033236.
 XX
 PR 18-OCT-2001; 2001US-00982262.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Mirabelli CK;
 XX
 DR WPI; 2003-403142/38.
 XX
 PT Inhibiting corneal allograft rejection, by contacting an allograft with a
 PT formulation having an oligonucleotide targeted to intercellular adhesion
 PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
 PT molecule-1.
 XX
 PS Example 5; SEQ ID NO 1; 106pp; English.
 XX
 CC The invention relates to a method of inhibiting corneal allograft
 CC rejection, by contacting the allograft with a topical formulation
 CC comprising an antisense oligonucleotide targeted to intercellular
 CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
 CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
 CC useful for inhibiting corneal allograft rejection or for preserving a
 CC corneal explant ex vivo, where the explant is human. This sequence
 CC corresponds to one of the oligonucleotide of the invention.
 XX
 SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 XX
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1904
 ADC38979/c
 ID ADC38979 standard; DNA; 18 BP.
 XX
 AC ADC38979;
 XX
 DT 18-DEC-2003 (first entry)

XX DE Human ICAM-1 targeted primer #5.
 XX XX
 KW ss; primer; immunosuppressive; antisense therapy;
 KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
 KW extracellular adhesion molecule-1; ELAM-1;
 KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
 XX XX
 OS Synthetic.
 OS Homo sapiens.
 XX XX
 FH Key Location/Qualifiers
 FT misc_difference 1..18
 FT /tag= a
 FT /note= "internucleotide linkages are optionally
 FT phosphodiester bonds"
 XX XX
 PN WO2003032920-A2.
 XX XX
 PD 24-APR-2003.
 XX XX
 PF 16-OCT-2002; 2002WO-US033236.
 XX XX
 PR 18-OCT-2001; 2001US-00982262.
 XX XX
 PA (ISIS-) ISIS PHARM INC.
 XX XX
 PI Bennett CF, Mirabelli CK;
 XX WPI; 2003-403142/38.
 XX XX
 PT Inhibiting corneal allograft rejection, by contacting an allograft with a
 PT formulation having an oligonucleotide targeted to intercellular adhesion
 PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
 PT molecule-1.
 XX XX
 PS Example 5; SEQ ID NO 5; 106pp; English.
 XX XX
 CC The invention relates to a method of inhibiting corneal allograft
 CC rejection, by contacting the allograft with a topical formulation
 CC comprising an antisense oligonucleotide targeted to intercellular
 CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
 CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
 CC useful for inhibiting corneal allograft rejection or for preserving a
 CC corneal explant ex vivo, where the explant is human. This sequence
 CC corresponds to one of the oligonucleotide of the invention.
 XX XX
 SQ Sequence 18 BP; 5 A; 2 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX XX
 QY 1364 CTTTCCCACTGCCCATCG 1381
 Db 18 CTTTCCCACTGCCCATCG 1
 RESULT 1905
 ADC39055
 ID ADC39055 standard; DNA; 18 BP.
 XX AC
 XX ADC39055;
 XX DT 18-DEC-2003 (first entry)
 XX DE Human adhesion molecule gene targeted primer #21.
 XX XX
 KW ss; primer; immunosuppressive; antisense therapy;
 KW corneal allograft rejection; intercellular adhesion molecule-1; ICAM-1;
 KW extracellular adhesion molecule-1; ELAM-1;
 KW vascular cell adhesion molecule-1; VCAM-1; corneal explant.
 XX XX

OS Synthetic.
 OS Homo sapiens.
 XX XX
 PN WO2003032920-A2.
 XX XX
 PD 24-APR-2003.
 XX XX
 PF 16-OCT-2002; 2002WO-US033236.
 XX XX
 PR 18-OCT-2001; 2001US-00982262.
 XX XX
 PA (ISIS-) ISIS PHARM INC.
 XX XX
 PI Bennett CF, Mirabelli CK;
 XX WPI; 2003-403142/38.
 XX XX
 PT Inhibiting corneal allograft rejection, by contacting an allograft with a
 PT formulation having an oligonucleotide targeted to intercellular adhesion
 PT molecule-1, extracellular adhesion molecule-1 or vascular cell adhesion
 PT molecule-1.
 XX XX
 PS Disclosure; SEQ ID NO 81; 106pp; English.
 XX XX
 CC The invention relates to a method of inhibiting corneal allograft
 CC rejection, by contacting the allograft with a topical formulation
 CC comprising an antisense oligonucleotide targeted to intercellular
 CC adhesion molecule-1 (ICAM-1), extracellular adhesion molecule-1 (ELAM-1)
 CC or vascular cell adhesion molecule-1 (VCAM-1). The oligonucleotide is
 CC useful for inhibiting corneal allograft rejection or for preserving a
 CC corneal explant ex vivo, where the explant is human. This sequence
 CC corresponds to one of the oligonucleotide of the invention.
 XX XX
 SQ Sequence 18 BP; 2 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX XX
 QY 50 GCCTCGCTATGGCTCCCA 67
 Db 1 GCCTCGCTATGGCTCCCA 18
 RESULT 1906
 ADF70292/C
 ID ADF70292 standard; DNA; 18 BP.
 XX AC
 XX ADF70292;
 XX DT 12-FEB-2004 (first entry)
 XX DE ICAM antisense oligonucleotide SeqID5.
 XX XX
 KW expression modulation; hepatic system; sterol group; hepatotropic;
 KW gene therapy; hepatic disease; antisense therapy; ss; ICAM;
 KW intercellular adhesion molecule.
 XX XX
 OS Unidentified.
 XX XX
 PN WO2003072711-A2.
 XX XX
 PD 04-SEP-2003.
 XX XX
 PF 21-FEB-2003; 2003WO-US005066.
 XX XX
 PR 22-FEB-2002; 2002US-00080979.
 XX XX
 PA (ISIS-) ISIS PHARM INC.
 XX XX
 PI Cook PD, Manoharan M, Bennett FC;
 XX WPI; 2003-679947/64.
 XX XX

XX Modulating the expression of a nucleic acid in the hepatic system, useful
PT for treating hepatic disorders, comprises administering to the mammal an
PT oligonucleotide that hybridizes to the nucleic acid to modulate its
PT expression.
XX Example 7; SEQ ID NO 5; 98pp; English.
XX This invention relates to a novel method of modulating the expression of
CC a nucleic acid in the hepatic system of a mammal which comprises
CC administering to the mammal an oligonucleotide that hybridizes to the
CC nucleic acid to modulate the expression of the nucleic acid, where the
CC oligonucleotide has two sterol groups that are covalently bonded. The
CC invention may be useful for the development of a compound with
CC hepatotropic activity whilst the genetic sequences of the invention may
CC prove useful for gene therapy. The methods are useful for treating
CC hepatic disease or disorder associated with a protein encoded by a gene.
CC Note: These oligonucleotides may have one or more of several
CC modifications which are detailed in the specification, including having a
CC phosphorothioate backbone or having ribonucleoside bases.
XX
XX
SQ Sequence 18 BP; 4 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1
RESULT 1907
ADF70291/c
ID ADF70291 standard; DNA; 18 BP.
XX
AC ADF70291;
XX
XX 12-FEB-2004 (first entry)
XX
DE ICAM antisense oligonucleotide SeqID4.
XX
KW expression modulation; hepatic system; sterol group; hepatotropic;
KW gene therapy; hepatic disease; antisense therapy; ss; ICAM;
KW intercellular adhesion molecule.
XX
OS Unidentified.
XX
PN WO2003072711-A2.
XX
XX 04-SEP-2003.
XX
XX 21-FEB-2003; 2003WO-US005066.
XX
XX 22-FEB-2002; 2002US-00080979.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Manoharan M, Bennett FC;
XX WPI; 2003-679947/64.
XX
XX 04-SEP-2003.
XX
XX 21-FEB-2003; 2003WO-US005066.
XX
XX 22-FEB-2002; 2002US-00080979.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Manoharan M, Bennett FC;
XX WPI; 2003-679947/64.
XX
XX Modulating the expression of a nucleic acid in the hepatic system, useful
PT for treating hepatic disorders, comprises administering to the mammal an
PT oligonucleotide that hybridizes to the nucleic acid to modulate its
PT expression.
XX Example 1; SEQ ID NO 4; 98pp; English.
XX This invention relates to a novel method of modulating the expression of
CC a nucleic acid in the hepatic system of a mammal which comprises
CC administering to the mammal an oligonucleotide that hybridizes to the
CC nucleic acid to modulate the expression of the nucleic acid, where the

CC oligonucleotide has two sterol groups that are covalently bonded. The
CC invention may be useful for the development of a compound with
CC hepatotropic activity whilst the genetic sequences of the invention may
CC prove useful for gene therapy. The methods are useful for treating
CC hepatic disease or disorder associated with a protein encoded by a gene.
CC Note: These oligonucleotides may have one or more of several
CC modifications which are detailed in the specification, including having a
CC phosphorothioate backbone or having ribonucleoside bases.
XX
XX
SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1
RESULT 1908
ADF70352/c
ID ADF70352 standard; DNA; 18 BP.
XX
AC ADF70352;
XX
XX 12-FEB-2004 (first entry)
XX
DE ICAM antisense oligonucleotide SeqID66.
XX
KW expression modulation; hepatic system; sterol group; hepatotropic;
KW gene therapy; hepatic disease; antisense therapy; ss; ICAM;
KW intercellular adhesion molecule.
XX
OS Unidentified.
XX
PN WO2003072711-A2.
XX
XX 04-SEP-2003.
XX
XX 21-FEB-2003; 2003WO-US005066.
XX
XX 22-FEB-2002; 2002US-00080979.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Manoharan M, Bennett FC;
XX WPI; 2003-679947/64.
XX
XX Modulating the expression of a nucleic acid in the hepatic system, useful
PT for treating hepatic disorders, comprises administering to the mammal an
PT oligonucleotide that hybridizes to the nucleic acid to modulate its
PT expression.
XX Example 1; SEQ ID NO 66; 98pp; English.
XX This invention relates to a novel method of modulating the expression of
CC a nucleic acid in the hepatic system of a mammal which comprises
CC administering to the mammal an oligonucleotide that hybridizes to the
CC nucleic acid to modulate the expression of the nucleic acid, where the
CC oligonucleotide has two sterol groups that are covalently bonded. The
CC invention may be useful for the development of a compound with
CC hepatotropic activity whilst the genetic sequences of the invention may
CC prove useful for gene therapy. The methods are useful for treating
CC hepatic disease or disorder associated with a protein encoded by a gene.
CC Note: These oligonucleotides may have one or more of several
CC modifications which are detailed in the specification, including having a
CC phosphorothioate backbone or having ribonucleoside bases.
XX
XX
SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 18; DB 1; Length 18;
Query Match 0.6%; Score 18; DB 1; Length 18;

XX WO2002101045-A2.
 PN
 XX
 PD
 XX
 PF 19-DEC-2002.
 XX
 XX 13-JUN-2002; 2002WO-EP006520.
 XX
 PR 13-JUN-2001; 2001US-0297835P.
 PR 22-JAN-2002; 2002US-0351238P.
 PR 23-JAN-2002; 2002US-0352914P.
 PR 12-FEB-2002; 2002US-0357161P.
 PR 15-MAY-2002; 2002US-0381086P.
 PR 16-MAY-2002; 2002US-0381739P.
 XX
 PA (NOVS) NOVARTIS AG.
 PA (IRMI-) IRM LLC.
 XX
 XX Patapoutian A, Song C, Ganju P, Peier A, McIntyre P, Bevan S;
 XX
 XX WPI; 2003-156962/15.
 XX
 XX New isolated TRPV3, TRPV4 or TRPM8 vanilloid receptor nucleic acid
 PT molecule and polypeptides, useful for the diagnosis and treatment of
 PT disorders such as pain, inflammation, skin diseases and cancer.
 XX
 XX Example 1; SEQ ID NO 46; 197pp; English.
 PS
 XX
 XX This invention relates to novel vanilloid receptor (VR) related nucleic
 CC acids and encoded proteins thereof. Specifically, it refers to certain
 CC members of the VR family that are involved in pain perception, in
 CC particular, TRPV3 (previously known as VR3, VRX, VR4 & TRPV7), TRPV4
 CC (previously known as VRL3 & OTRPC4) and TRPM8 (previously known as TRPX).
 CC Furthermore, this invention includes trkA+ pain specific genes expressed
 CC in the sensory neurons of the dorsal root ganglia. Accordingly, such
 CC compositions can be useful for the diagnosis, treatment and prevention of
 CC pain, inflammation, skin disorders and cancer, and so exhibit analgesic,
 CC antiinflammatory, dermatological and cytostatic activities. This
 CC oligonucleotide sequence is a PCR primer used to amplify the murine TRPV3
 CC DNA of the invention.
 XX
 XX Sequence 18 BP; 4 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e-02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2766 TGTACCCAGGCTGGAGT 2783
 Db 18 TGTACCCAGGCTGGAGT 1
 RESULT 1912
 ADG25671
 ID ADG25671 standard; DNA; 18 BP.
 XX
 AC ADG25671;
 XX
 XX 26-FEB-2004 (first entry)
 DT
 XX
 XX Human ICAM-1 probe Icam 1-5.
 XX
 XX Human; intercellular adhesion molecule; ICAM-R; hybridoma cell line;
 KW ATCC HB 12190; monoclonal antibody; CD11b; nonspecific immune system;
 KW adult respiratory distress syndrome; multiple organ injury syndrome;
 KW septicemia; trauma; reperfusion injury; acute glomerulonephritis;
 KW reactive arthritis; dermatosis with acute inflammatory component; stroke;
 KW thermal injury; haemodialysis; leukapheresis; ulcerative colitis;
 KW Crohn's disease; necrotising enterocolitis;
 KW granulocyte transfusion associated syndrome; atherosclerosis;
 KW cytokine-induced toxicity; specific immune system; psoriasis;
 KW organ transplant rejection; autoimmune disease; Raynaud's syndrome;
 KW autoimmune thyroiditis; experimental autoimmune encephalomyelitis; EAE;
 KW multiple sclerosis; rheumatoid arthritis; diabetes; lupus erythematosus;
 KW

KW asthma; tumour growth; metastasis; viral infection; HIV infection;
 KW immunogen; ss; primer; probe.
 XX
 OS Homo sapiens.
 XX
 XX US2003199423-A1.
 PN
 XX 23-OCT-2003.
 XX
 XX 05-JUN-2002; 2002US-00163942.
 XX
 PR 27-JAN-1992; 92US-00827689.
 PR 26-MAY-1992; 92US-00889724.
 PR 05-JUN-1992; 92US-00894061.
 PR 22-JAN-1993; 93US-0009266.
 PR 26-JAN-1993; 93WO-US0000787.
 PR 05-AUG-1993; 93US-00102852.
 PR 07-JUN-1995; 95US-00487113.
 PR 24-AUG-1999; 99US-00382289.
 PR 03-JAN-2001; 2001US-00753436.
 XX
 XX (GALL/) GALLATIN W M.
 PA (VAZE/) VAZEUX R.
 PA
 XX
 XX Gallatin WM, Vazeux R;
 PI
 XX
 XX WPI; 2003-900201/82.
 DR
 XX
 XX Hybridoma cell line for production of monoclonal antibodies useful for
 PT treating e.g. asthma and arthritis.
 PT
 XX
 XX Example 4; SEQ ID NO 21; 127pp; English.
 PS
 XX
 XX The invention relates to a hybridoma cell line ATCC HB 12190 producing a
 CC monoclonal antibody against human intercellular adhesion molecule
 CC polypeptide (ICAM-R). Also included are a monoclonal antibody produced by
 CC the hybridoma cell line, identification of a compound that modulates the
 CC interaction of binding partners intercellular adhesion molecule
 CC polypeptide (ICAM-R) and CD11b (involving: immobilising ICAM-R or CD11b,
 CC detectably labelling the non-immobilised binding partner, contacting the
 CC immobilised binding partner with the labelled binding partner in the
 CC presence and absence of test compound, detecting the label bound to the
 CC immobilised binding partner and identifying a modulating compound as a
 CC test compound that affects the label bound in the presence of the test
 CC compound in comparison to the label bound in the absence of the test
 CC compound) and identification of a compound that modulates phosphorylation
 CC of ICAM-R by protein kinase C isoform (involving: exposing ICAM-R peptide
 CC comprising amino acids 482-518 of ADG25651 to protein kinase C isoform
 CC and labelled phosphate in the presence and absence of a test compound,
 CC measuring labelled phosphate transferred to the ICAM-R peptide and
 CC identifying a test compound that affects transfer of the labelled
 CC phosphate as a modulator compound). The hybridoma cell line ATCC HB 12190
 CC is useful in the production of monoclonal antibodies useful for
 CC identifying compounds and for the treatment of conditions resulting from
 CC a response of the nonspecific immune system in a mammal (e.g. adult
 CC respiratory distress syndrome, multiple organ injury syndrome secondary
 CC to septicemia, multiple organ injury syndrome secondary to trauma,
 CC reperfusion injury of tissue, acute glomerulonephritis, reactive
 CC arthritis, dermatosis with acute inflammatory components, stroke, thermal
 CC injury, haemodialysis, leukapheresis, ulcerative colitis, Crohn's
 CC disease, necrotising enterocolitis, granulocyte transfusion associated
 CC syndrome, atherosclerosis and cytokine-induced toxicity) and conditions
 CC resulting from a response of the specific immune system in a mammal (e.g.
 CC psoriasis, organ/tissue transplant rejection and autoimmune diseases
 CC including Raynaud's syndrome, autoimmune thyroiditis, experimental
 CC autoimmune encephalomyelitis (EAE), multiple sclerosis, rheumatoid
 CC arthritis, diabetes or lupus erythematosus), asthma, tumour growth and/or
 CC metastasis and viral infection (e.g. HIV infection). The monoclonal
 CC antibodies are readily available using immunogens comprising cells
 CC naturally expressing intercellular adhesion molecule polypeptide (ICAM-R)
 CC or its variants and display ligand/receptor binding biological activities
 CC and/or immunological properties specific to ICAM-R. The present sequence
 CC is a primer or probe used in the isolation of nucleic acids encoding

```

CC human ICAM-R.
XX
SQ Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 U; 0 Other;
    Query Match      0.6%; Score 18; DB 1; Length 18;
    Best Local Similarity 100.0%; Pred. No. 9.9e+02;
    Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 440 GCAAGAACCTTACCTAC 457
Db 1 GCAAGAACCTTACCTAC 18

RESULT 1913
ADM46452/c
ID ADM46452 standard; DNA; 18 BP.
XX
AC ADM46452;
XX
XX
DT 03-JUN-2004 (first entry)
XX
DE Antisense oligonucleotide targeting human ICAM-1 #1.
XX
KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
KW vascular cell adhesion molecule; VCAM-1;
KW endothelial leukocyte adhesion molecule; ELAM-1;
KW inflammatory ophthalmological disorder; redness; inflammation;
KW corneal explant; corneal allograft rejection.
XX
OS Homo sapiens.
XX
XX US2004033977-A1.
XX
XX 19-FEB-2004.
XX
XX 04-JUN-2003; 2003US-00454663.
XX
PR 14-AUG-1990; 90US-00567286.
PR 02-SEP-1992; 92US-00939855.
PR 21-JAN-1993; 93US-00007997.
PR 10-FEB-1993; 93US-00969151.
PR 17-MAY-1993; 93US-00063167.
PR 12-MAY-1995; 95US-00440740.
PR 03-AUG-1998; 98US-00128496.
PR 12-SEP-2000; 2000US-00659288.
PR 18-OCT-2001; 2001US-00982262.
XX
PA (BENN/) BENNETT C F.
PA (MIRA/) MIRABELLI C.
XX
XX Bennett CF, Mirabelli C;
XX
XX WPI; 2004-180090/17.
XX
XX New antisense oligonucleotide, useful for diagnosing, as research
XX reagents and for treating disease states, which respond to modulation of
XX the synthesis or metabolism of cell adhesion molecules.
XX
XX Example 5; SEQ ID NO 1; 72pp; English.
XX
XX The invention relates to an antisense oligonucleotide targeting human
XX intercellular adhesion molecule (ICAM-1) having a sequence appearing as
XX ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
XX replaced with a thymidine, cytidine or guanosine nucleotide, at least one
XX thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
XX nucleotide, at least one guanosine nucleotide is replaced with an
XX adenosine, thymidine or cytidine nucleotide or at least one cytidine
XX nucleotide is replaced with an adenosine, cytidine or guanosine
XX nucleotide. The oligonucleotide is one of 88 disclosed antisense
XX oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
XX 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
XX an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
XX (where the compound specifically hybridizes with the human ICAM-1 mRNA

```

```

CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
CC RNA compound having the RNA equivalent sequence of ADM46473. The
CC oligonucleotide is useful for modulating the activity of the RNA and DNA
CC and the modulation of the synthesis and metabolism of specific cell
CC adhesion molecules. It is also useful for the diagnosis, as research
CC reagents and for treating disease states, which respond to modulation of
CC the synthesis or metabolism of cell adhesion molecules. The
CC oligonucleotide is suitable for treating inflammatory ophthalmological
CC disorders including redness and inflammation caused by allergens and
CC allergic reactions. The oligonucleotides can also be used to preserve
CC corneal explants ex vivo and to prevent corneal allograft rejections. The
CC specific hybridisation exhibited by the oligonucleotides may be used for
CC assays, purifications or cellular product preparations. The present
CC sequence is an antisense oligonucleotide targeting ICAM-1.
XX
SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
    Query Match      0.6%; Score 18; DB 1; Length 18;
    Best Local Similarity 100.0%; Pred. No. 9.9e+02;
    Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 50 GCCTCGCTATGGCTCCA 67
Db 18 GCCTCGCTATGGCTCCA 1

RESULT 1914
ADM46455/c
ID ADM46455 standard; DNA; 18 BP.
XX
AC ADM46455;
XX
XX 03-JUN-2004 (first entry)
XX
DE Antisense oligonucleotide targeting human ICAM-1 #4.
XX
KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
KW vascular cell adhesion molecule; VCAM-1;
KW endothelial leukocyte adhesion molecule; ELAM-1;
KW inflammatory ophthalmological disorder; redness; inflammation;
KW corneal explant; corneal allograft rejection.
XX
OS Homo sapiens.
XX
XX US2004033977-A1.
XX
XX 19-FEB-2004.
XX
XX 04-JUN-2003; 2003US-00454663.
XX
XX 14-AUG-1990; 90US-00567286.
XX 02-SEP-1992; 92US-00939855.
XX 21-JAN-1993; 93US-00007997.
XX 10-FEB-1993; 93US-00969151.
XX 17-MAY-1993; 93US-00063167.
XX 12-MAY-1995; 95US-00440740.
XX 03-AUG-1998; 98US-00128496.
XX 12-SEP-2000; 2000US-00659288.
XX 18-OCT-2001; 2001US-00982262.
XX
XX (BENN/) BENNETT C F.
XX (MIRA/) MIRABELLI C.
XX
XX Bennett CF, Mirabelli C;
XX
XX WPI; 2004-180090/17.
XX
XX New antisense oligonucleotide, useful for diagnosing, as research
XX reagents and for treating disease states, which respond to modulation of
XX the synthesis or metabolism of cell adhesion molecules.
XX
XX Example 5; SEQ ID NO 4; 72pp; English.
XX
XX

```

CC The invention relates to an antisense oligonucleotide targeting human
 CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as
 CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
 CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridizes with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.
 XX
 SQ Sequence 18 BP; 4 A; 1 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02; Mismatches 0; Gaps 0;
 Matches 18; Conservative 0; Indels 0;

QY 2836 TCCTCCACCTCAGCCTC 2853
 |||||
 Db 18 TCCTCCACCTCAGCCTC 1

RESULT 1915
 ADM46456/c
 ID ADM46456 standard; DNA; 18 BP.
 XX
 AC ADM46456;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE Antisense oligonucleotide targeting human ICAM-1 #5.
 XX
 KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
 KW vascular cell adhesion molecule; VCAM-1;
 KW endothelial leukocyte adhesion molecule; ELAM-1;
 KW inflammatory ophthalmological disorder; redness; inflammation;
 KW corneal explant; corneal allograft rejection.

XX Homo sapiens.
 XX US2004033977-A1.
 XX 19-FEB-2004.
 XX
 PF 04-JUN-2003; 2003US-00454663.
 XX
 FR 14-AUG-1990; 90US-00567286.
 FR 02-SEP-1992; 92US-009339855.
 PR 21-JAN-1993; 93US-00007997.
 PR 10-FEB-1993; 93US-00969151.
 PR 17-MAY-1993; 93US-00063167.
 PR 12-MAY-1995; 95US-00440740.
 PR 03-AUG-1998; 98US-00128496.
 PR 12-SEP-2000; 2000US-00659288.
 PR 18-OCT-2001; 2001US-00982262.

PA (BENN/) BENNETT C F.
 PA (MIRA/) MIRABELLI C.
 PI Bennett CF, Mirabelli C;
 XX WPI; 2004-180090/17.
 DR
 XX
 PT New antisense oligonucleotide, useful for diagnosing, as research
 PT reagents and for treating disease states, which respond to modulation of
 PT the synthesis or metabolism of cell adhesion molecules.
 XX
 PS Example 5; SEQ ID NO 5; 72pp; English.

CC The invention relates to an antisense oligonucleotide targeting human
 CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as
 CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
 CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridizes with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.
 XX
 SQ Sequence 18 BP; 5 A; 2 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02; Mismatches 0; Gaps 0;
 Matches 18; Conservative 0; Indels 0;

QY 1364 CTTTCCCACTGCCCATCG 1381
 |||||
 Db 18 CTTTCCCACTGCCCATCG 1

RESULT 1916
 ADM46532
 ID ADM46532 standard; DNA; 18 BP.
 XX
 AC ADM46532;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE Antisense oligonucleotide targeting human ICAM-1 #28.
 XX
 KW Antisense; ss; human; intercellular adhesion molecule; ICAM-1;
 KW vascular cell adhesion molecule; VCAM-1;
 KW endothelial leukocyte adhesion molecule; ELAM-1;
 KW inflammatory ophthalmological disorder; redness; inflammation;
 KW corneal explant; corneal allograft rejection.
 XX Homo sapiens.
 XX US2004033977-A1.
 XX 19-FEB-2004.

XX 04-JUN-2003; 2003US-00454663.
 XX 14-AUG-1990; 90US-00567286.
 XX 02-SEP-1992; 92US-00931955.
 XX 21-JAN-1993; 93US-00007997.
 XX 10-FEB-1993; 93US-00969151.
 XX 17-MAY-1993; 93US-00631167.
 XX 12-MAY-1995; 95US-00440740.
 XX 03-AUG-1998; 98US-00128496.
 XX 12-SEP-2000; 2000US-00659288.
 XX 18-OCT-2001; 2001US-00982262.
 XX (BEN)/ BENNETT C F.
 XX (MIRA)/ MIRABELLI C.
 XX Bennett CF, Mirabelli C;
 XX WPI; 2004-180090/17.
 XX New antisense oligonucleotide, useful for diagnosing, as research
 PT reagents and for treating disease states, which respond to modulation of
 PT the synthesis or metabolism of cell adhesion molecules.
 XX
 XX Example 1; SEQ ID NO 81; 72pp; English.
 XX
 XX The invention relates to an antisense oligonucleotide targeting human
 CC intercellular adhesion molecule (ICAM-1) having a sequence appearing as
 CC ADM46473. In the oligonucleotide, at least one adenosine nucleotide is
 CC replaced with a thymidine, cytidine or guanosine nucleotide, at least one
 CC thymidine nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide, at least one guanosine nucleotide is replaced with an
 CC adenosine, thymidine or cytidine nucleotide or at least one cytidine
 CC nucleotide is replaced with an adenosine, cytidine or guanosine
 CC nucleotide. The oligonucleotide is one of 88 disclosed antisense
 CC oligonucleotides targeting ICAM-1, vascular cell adhesion molecule (VCAM-
 CC 1) or endothelial leukocyte adhesion molecule (ELAM-1). Also included are
 CC an RNA compound 8-80 nucleobases in length targeted to human ICAM-1 mRNA
 CC (where the compound specifically hybridizes with the human ICAM-1 mRNA
 CC and inhibits the expression of human ICAM-1 mRNA), and a double stranded
 CC RNA compound having the RNA equivalent sequence of ADM46473. The
 CC oligonucleotide is useful for modulating the activity of the RNA and DNA
 CC and the modulation of the synthesis and metabolism of specific cell
 CC adhesion molecules. It is also useful for the diagnosis, as research
 CC reagents and for treating disease states, which respond to modulation of
 CC the synthesis or metabolism of cell adhesion molecules. The
 CC oligonucleotide is suitable for treating inflammatory ophthalmological
 CC disorders including redness and inflammation caused by allergens and
 CC allergic reactions. The oligonucleotides can also be used to preserve
 CC corneal explants ex vivo and to prevent corneal allograft rejections. The
 CC specific hybridisation exhibited by the oligonucleotides may be used for
 CC assays, purifications or cellular product preparations. The present
 CC sequence is an antisense oligonucleotide targeting ICAM-1.
 XX
 XX Sequence 18 BP; 2 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 50 GCCTCGCTATGGCTCCCA 67
 DB 1 GCCTCGCTATGGCTCCCA 18
 RESULT 1917
 ADO25281/c
 ID ADO25281 standard; DNA; 18 BP.
 XX
 AC ADO25281;
 XX
 XX 12-AUG-2004 (first entry)
 DT
 XX

DE ICAM-1 specific antisense phosphorothioate oligonucleotide.
 XX conjugated oligomeric compound; gene silencing;
 KW gene expression modulation; ss; antisense oligonucleotide;
 KW phosphorothioate; ICAM-1.
 XX Unidentified.
 XX WO2004044141-A2.
 XX 27-MAY-2004.
 XX
 XX 04-NOV-2003; 2003WO-US035088.
 XX 05-NOV-2002; 2002US-0423760P.
 XX 09-JUL-2003; 2003US-00616241.
 XX (ISIS-) ISIS PHARM INC.
 XX Manoharan M, Baker B, Eldrup A, Bhat B, Griffey RH, Swayze EE;
 XX Crooke SA;
 XX WPI; 2004-411712/38.
 XX
 XX Novel oligomer compound comprises first region capable of hybridizing to
 PT second region and conjugate moiety, useful for treating or preventing
 PT disease or disorder associated with target nucleic acid.
 XX
 XX Example 14; SEQ ID NO 23; 116pp; English.
 XX
 XX The invention comprises a conjugated oligomeric compound that is capable
 CC of hybridizing to a target nucleic acid, the conjugated oligomeric
 CC compound contains two regions, where the first region is capable of
 CC hybridizing with the second region. The conjugated oligomeric compound of
 CC the invention is useful for modulating the expression of a target nucleic
 CC acid in a cell, or for treating or preventing a disease/disorder
 CC associated with a target nucleic acid. The present DNA sequence
 CC represents an ICAM-1 specific antisense phosphorothioate oligonucleotide.
 XX
 XX Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 50 GCCTCGCTATGGCTCCCA 67
 DB 18 GCCTCGCTATGGCTCCCA 1
 RESULT 1918
 ADP45890/c
 ID ADP45890 standard; DNA; 18 BP.
 XX
 AC ADP45890;
 XX
 XX 26-AUG-2004 (first entry)
 DT
 XX Extend primer 82 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.
 XX
 XX breast cancer; cytostatic; gene therapy; human;
 KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
 KW CD54; cell surface glycoprotein P3.58; ICAM-4;
 KW Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
 KW ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
 XX Homo sapiens.
 XX OS
 XX WO2004047623-A2.
 XX
 XX 10-JUN-2004.
 XX
 XX 25-NOV-2003; 2003WO-US037948.
 XX

```

XX 25-NOV-2002; 2002US-0429136P.
PR 24-JUL-2003; 2003US-0490234P.
XX (SEQU-) SEQUENOM INC.
PA
PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX WPI; 2004-441051/41.
XX
XX Identifying a subject at risk of breast cancer by detecting the presence
PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
PT regions which are associated with breast cancer in a nucleic acid sample
PT from a subject.
XX
XX Example 4; Page 84; 289pp; English.
XX
XX The invention relates to a novel method for identifying a subject at risk
XX of breast cancer comprising detecting the presence or absence of one or
XX more polymorphic variations associated with breast cancer in a nucleic
XX acid sample from a subject. The method of the invention has cytostatic
XX applications and may be useful for identifying a subject at risk of
XX breast cancer, for early diagnosis, prevention and treatment of breast
XX cancer, possibly via gene therapy, as well as to analyse and predict a
XX response to a breast cancer treatment and in clinical drug trials. The
XX current sequence is that of an Extend primer (also described as probe) of
XX the invention which was used to genotype human intercellular adhesion
XX molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor;BB2
XX ;CD54;cell surface glycoprotein P3.58) has been mapped to chromosomal
XX position 19p13.3-p13.2, ICAM-4 (Landsteiner-Wiener blood group;LW) has
XX been mapped to chromosomal position 19p13.2-cen and ICAM-5
XX (telencephalin) has been mapped to chromosomal position 19p13.2.
XX
XX Sequence 18 BP; 2 A; 3 C; 6 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2029 CCCACAGACTTACAGAAG 2046
Db 18 CCCACAGACTTACAGAAG 1

RESULT 1919
ADP45866/c
ID ADP45866 standard; DNA; 18 BP.
XX
XX ADP45866;
XX
XX 26-AUG-2004 (first entry)
XX
XX Extend primer 58 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.
XX
XX breast cancer; cytostatic; gene therapy; human;
XX intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
XX CD54; cell surface glycoprotein P3.58; ICAM-4;
XX Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
XX ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
XX
XX Homo sapiens.
XX
XX WO2004047623-A2.
XX
XX 10-JUN-2004.
XX
XX 25-NOV-2003; 2003WO-US037948.
XX
XX 25-NOV-2002; 2002US-0429136P.
XX
XX 24-JUL-2003; 2003US-0490234P.
XX
XX (SEQU-) SEQUENOM INC.
XX
XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX WPI; 2004-441051/41.
XX
XX Identifying a subject at risk of breast cancer by detecting the presence
PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
PA

```

```

PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX WPI; 2004-441051/41.
XX
XX Identifying a subject at risk of breast cancer by detecting the presence
PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
PT regions which are associated with breast cancer in a nucleic acid sample
PT from a subject.
XX
XX Example 4; Page 84; 289pp; English.
XX
XX The invention relates to a novel method for identifying a subject at risk
XX of breast cancer comprising detecting the presence or absence of one or
XX more polymorphic variations associated with breast cancer in a nucleic
XX acid sample from a subject. The method of the invention has cytostatic
XX applications and may be useful for identifying a subject at risk of
XX breast cancer, for early diagnosis, prevention and treatment of breast
XX cancer, possibly via gene therapy, as well as to analyse and predict a
XX response to a breast cancer treatment and in clinical drug trials. The
XX current sequence is that of an Extend primer (also described as probe) of
XX the invention which was used to genotype human intercellular adhesion
XX molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor;BB2
XX ;CD54;cell surface glycoprotein P3.58) has been mapped to chromosomal
XX position 19p13.3-p13.2, ICAM-4 (Landsteiner-Wiener blood group;LW) has
XX been mapped to chromosomal position 19p13.2-cen and ICAM-5
XX (telencephalin) has been mapped to chromosomal position 19p13.2.
XX
XX Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 779 GGCTGTTCACAGTCTCGG 796
Db 18 GGCTGTTCACAGTCTCGG 1

RESULT 1920
ADP45865/c
ID ADP45865 standard; DNA; 18 BP.
XX
XX ADP45865;
XX
XX 26-AUG-2004 (first entry)
XX
XX Extend primer 57 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.
XX
XX breast cancer; cytostatic; gene therapy; human;
XX intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
XX CD54; cell surface glycoprotein P3.58; ICAM-4;
XX Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
XX ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
XX
XX Homo sapiens.
XX
XX WO2004047623-A2.
XX
XX 10-JUN-2004.
XX
XX 25-NOV-2003; 2003WO-US037948.
XX
XX 25-NOV-2002; 2002US-0429136P.
XX
XX 24-JUL-2003; 2003US-0490234P.
XX
XX (SEQU-) SEQUENOM INC.
XX
XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX WPI; 2004-441051/41.
XX
XX Identifying a subject at risk of breast cancer by detecting the presence
PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
PT

```

PT regions which are associated with breast cancer in a nucleic acid sample
 PT from a subject.

PS Example 4; Page 84; 289pp; English.

XX
 CC The invention relates to a novel method for identifying a subject at risk
 CC of breast cancer comprising detecting the presence or absence of one or
 CC more polymorphic variations associated with breast cancer in a nucleic
 CC acid sample from a subject. The method of the invention has cytostatic
 CC applications and may be useful for identifying a subject at risk of
 CC breast cancer, for early diagnosis, prevention and treatment of breast
 CC cancer, possibly via gene therapy, as well as to analyse and predict a
 CC response to a breast cancer treatment and in clinical trials. The
 CC current sequence is that of an Extend primer (also described as probe) of
 CC the invention which was used to genotype human intercellular adhesion
 CC molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor; BB2
 CC ;CD54; cell surface glycoprotein P3.58) has been mapped to chromosomal
 CC position 19p13.3-p13.2, ICAM-4 (Landsteiner-Wiener blood group; LW) has
 CC been mapped to chromosomal position 19p13.2-cen and ICAM-5
 CC (telencephalin) has been mapped to chromosomal position 19p13.2.

XX Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 779 GGCTGTTCACAGTCTCG 796

Db 18 GGCTGTTCACAGTCTCG 1

RESULT 1921

ADQ16466/c

ID ADQ16466 standard; DNA; 18 BP.

XX AC ADQ16466;

XX 09-SEP-2004 (first entry)

XX Modified oligonucleotide used for NMR analysis #2.

XX ss; antisense; hepatic tissue targeting; liver gene expression;
 KW improved biostability; altered biodistribution; DNA-RNA hybrid.

XX Synthetic.

Key	Location/Qualifiers
modified_base	1..18
	/*tag= b
	/mod_base= OTHER
	/note= "OTHER = phosphorothioate backbone. Optionally
	absent"
misc_RNA	1
	/*tag= a
modified_base	18
	/*tag= c
	/mod_base= OTHER
	/note= "OTHER = Non-nucleoside 6-carbon amino linker.
	Optionally absent"

US6753423-B1.

22-JUN-2004.

10-APR-2000; 2000US-00546596.

12-SEP-1997; 97US-00928823.

(ISIS-) ISIS PHARM INC.

Cook PD, Manoharan M, Bennett CF;

XX

DR WPI; 2004-466815/44.

XX Targeting an antisense oligonucleotide to hepatic tissues to modulate the
 PT expression of a gene in the liver involves conjugating the
 PT oligonucleotide to a cholesteryl moiety and administering the conjugate.

XX Example 7; SEQ ID NO 15; 64pp; English.

XX The invention relates to a method of targeting an antisense
 CC oligonucleotide to hepatic tissues involving conjugating the
 CC oligonucleotide to a cholesteryl moiety and administering the conjugate.
 CC The method is useful for targeting an antisense oligonucleotide to
 CC hepatic tissues to modulate the expression of a gene in the liver. The
 CC oligonucleotide is useful in diagnostics, therapeutics, as research
 CC reagents and kits, in pharmaceutical composition and for treating
 CC diseases produced by undesired production of proteins. The method
 CC provides lipophilic oligonucleotide conjugates with improved biostability
 CC and altered biodistribution in mammals. The present sequence represents a
 CC modified oligonucleotide used for NMR analysis.

XX Sequence 18 BP; 4 A; 4 C; 8 G; 1 T; 1 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1922

ADQ16456/c

ID ADQ16456 standard; DNA; 18 BP.

XX AC ADQ16456;

XX 09-SEP-2004 (first entry)

XX Modified oligonucleotide used for NMR analysis #1.

XX ss; antisense; hepatic tissue targeting; liver gene expression;
 KW improved biostability; altered biodistribution; DNA-RNA hybrid.

XX Synthetic.

Key	Location/Qualifiers
modified_base	1..18
	/*tag= b
	/mod_base= OTHER
	/note= "OTHER = phosphorothioate backbone"
misc_RNA	1
	/*tag= a
misc_RNA	10
	/*tag= c
modified_base	18
	/*tag= d
	/mod_base= OTHER
	/note= "OTHER = Non-nucleoside 6-carbon amino linker.
	Optionally absent"

US6753423-B1.

22-JUN-2004.

10-APR-2000; 2000US-00546596.

12-SEP-1997; 97US-00928823.

(ISIS-) ISIS PHARM INC.

Cook PD, Manoharan M, Bennett CF;

XX


```

DR WPI; 2004-466815/44.
XX Targeting an antisense oligonucleotide to hepatic tissues to modulate the
PT expression of a gene in the liver involves conjugating the
PT oligonucleotide to a cholesterol moiety and administering the conjugate.
XX
XX Example 7; SEQ ID NO 5; 64pp; English.
XX
CC The invention relates to a method of targeting an antisense
CC oligonucleotide to hepatic tissues involving conjugating the
CC oligonucleotide to a cholesterol moiety and administering the conjugate.
CC The method is useful for targeting an antisense oligonucleotide to
CC hepatic tissues to modulate the expression of a gene in the liver. The
CC oligonucleotide is useful in diagnostics, therapeutics, as research
CC reagents and kits, in pharmaceutical composition and for treating
CC diseases produced by undesired production of proteins. The method
CC provides lipophilic oligonucleotide conjugates with improved biostability
CC and altered biodistribution in mammals. The present sequence represents a
CC modified oligonucleotide used for NMR analysis.
XX
SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1923
ADQ16455/c
ID ADQ16455 standard; DNA; 18 BP.
XX
AC ADQ16455;
XX
XX 09-SEP-2004 (first entry)
XX
DE 2'-protected-amine linking group oligonucleotide #4.
XX
KW ss; antisense; hepatic tissue targeting; liver gene expression;
KW improved biostability; altered biodistribution.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..18
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER =modified to incorporate pentyl-N-
FT phthalimido. Optionally absent"
FT modified_base 11
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER =modified to incorporate pentyl-N-
FT phthalimido. Optionally absent"
FT modified_base 15
FT /*tag= d
FT /mod_base= OTHER
FT /note= "OTHER =modified to incorporate pentyl-N-
FT phthalimido. Optionally absent"
XX
XX US6753423-B1.
XX
XX 22-JUN-2004.
XX
XX 10-APR-2000; 2000US-00546596.
XX
XX

```

```

PR 12-SEP-1997; 97US-00928823.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Manoharan M, Bennett CF;
XX
XX WPI; 2004-466815/44.
XX
PT Targeting an antisense oligonucleotide to hepatic tissues to modulate the
PT expression of a gene in the liver involves conjugating the
PT oligonucleotide to a cholesterol moiety and administering the conjugate.
XX
XX Example 1; SEQ ID NO 4; 64pp; English.
XX
CC The invention relates to a method of targeting an antisense
CC oligonucleotide to hepatic tissues involving conjugating the
CC oligonucleotide to a cholesterol moiety and administering the conjugate.
CC The method is useful for targeting an antisense oligonucleotide to
CC hepatic tissues to modulate the expression of a gene in the liver. The
CC oligonucleotide is useful in diagnostics, therapeutics, as research
CC reagents and kits, in pharmaceutical composition and for treating
CC diseases produced by undesired production of proteins. The method
CC provides lipophilic oligonucleotide conjugates with improved biostability
CC and altered biodistribution in mammals. The present sequence represents a
CC 2'-protected-amine linking group oligonucleotide.
XX
SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1924
ADQ16467/c
ID ADQ16467 standard; DNA; 18 BP.
XX
AC ADQ16467;
XX
XX 09-SEP-2004 (first entry)
XX
DE Modified oligonucleotide used for NMR analysis #3.
XX
KW ss; antisense; hepatic tissue targeting; liver gene expression;
KW improved biostability; altered biodistribution; DNA-RNA hybrid.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..18
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER = phosphorothioate backbone. Optionally
FT absent"
FT misc_RNA 10
FT /*tag= b
XX
XX US6753423-B1.
XX
XX 22-JUN-2004.
XX
XX 10-APR-2000; 2000US-00546596.
XX
XX 12-SEP-1997; 97US-00928823.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Manoharan M, Bennett CF;
XX
XX

```

DR WPI; 2004-466815/44.
 XX Targeting an antisense oligonucleotide to hepatic tissues to modulate the
 PT expression of a gene in the liver involves conjugating the
 PT oligonucleotide to a cholesteryl moiety and administering the conjugate.
 XX
 PS Example 7; SEQ ID NO 16; 64pp; English.
 XX
 CC The invention relates to a method of targeting an antisense
 CC oligonucleotide to hepatic tissues involving conjugating the
 CC oligonucleotide to a cholesteryl moiety and administering the conjugate.
 CC The method is useful for targeting an antisense oligonucleotide to
 CC hepatic tissues to modulate the expression of a gene in the liver. The
 CC oligonucleotide is useful in diagnostics, therapeutics, as research
 CC reagents and kits, in pharmaceutical composition and for treating
 CC diseases produced by undesired production of proteins. The method
 CC provides lipophilic oligonucleotide conjugates with improved biostability
 CC and altered biodistribution in mammals. The present sequence represents a
 CC modified oligonucleotide used for NMR analysis.
 XX
 SQ Sequence 18 BP; 4 A; 4 C; 8 G; 1 T; 1 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 50 GCCTCGCTATGGCTCCCA 67
 |||||
 DB 18 GCCTCGCTATGGCTCCCA 1
 RESULT 1925
 ADQ88547/c
 ID ADQ88547 standard; DNA; 18 BP.
 XX
 AC ADQ88547;
 XX
 XX 07-OCT-2004 (first entry)
 XX
 DE Murine ICAM-1 antisense analogue DNA-RNA hybrid oligo, oligomer 57.
 XX
 KW Hepatic system; liver; transcription inhibition; DNA degradation;
 KW therapy; phosphorothioate backbone; murine; antisense; DNA-RNA hybrid;
 KW intercellular adhesion molecule 1; ICAM-1; ss.
 XX
 OS Mus sp.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..18
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "Phosphothioate backbone"
 FT modified_base 1
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-O-hexylamino (dinitrophenyl) uridine
 FT phosphoramidite"
 FT misc_RNA 1
 FT /*tag= a
 FT /label= RNA
 XX
 XX US2004142899-A1.
 XX
 PD 22-JUL-2004.
 XX
 XX 17-FEB-2004; 2004US-00780439.
 XX
 PR 11-JAN-1990; 90US-00463358.
 PR 13-AUG-1990; 90US-00566977.
 PR 24-OCT-1991; 91US-00782374.
 PR 23-OCT-1992; 92WO-US009196.
 PR 05-SEP-1993; 93US-00117363.
 PR 03-SEP-1993; 93US-00117363.

PR (05-JUN-1995; 95US-00464953.
 PR 10-APR-2000; 2000US-00546596.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Cook PD, Manoharan M, Bennett CF;
 XX
 XX WPI; 2004-561278/54.
 DR
 XX
 PT Use of a lipophilic antisense compound for modulating expression of a
 PT nucleic acid in the liver and associated tissue and hepatic gene
 PT expression.
 XX
 PS Example 7; SEQ ID NO 15; 48pp; English.
 XX
 CC The invention relates to compositions and methods for enhanced
 CC biostability and altered biodistribution of oligonucleotides in mammals.
 CC The invention also relates to a method for modulating expression of
 CC nucleic acid in hepatic system of a mammal. The method is useful for
 CC modulating the expression of a nucleic acid in the liver and associated
 CC tissue, gene expression in cell, tissue or organs; for inhibiting
 CC transcription and/or replication of particular genes; for inducing
 CC degradation of regions of double stranded DNA in cells; for killing cells
 CC or virus; in diagnostics, therapeutics and as research reagents and kits.
 CC The present sequence is a murine intercellular adhesion molecule 1 (ICAM-
 CC 1) gene targeted antisense analogue DNA-RNA hybrid oligonucleotide. This
 CC sequence is used to illustrate the method of the invention.
 XX
 SQ Sequence 18 BP; 4 A; 4 C; 8 G; 1 T; 1 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 9.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 50 GCCTCGCTATGGCTCCCA 67
 |||||
 DB 18 GCCTCGCTATGGCTCCCA 1
 RESULT 1926
 ADQ88596/c
 ID ADQ88596 standard; RNA; 18 BP.
 XX
 AC ADQ88596;
 XX
 XX 07-OCT-2004 (first entry)
 XX
 DE Murine ICAM-1 targeted antisense oligo, oligomer 60.
 XX
 KW Hepatic system; liver; transcription inhibition; DNA degradation;
 KW therapy; phosphorothioate backbone; murine;
 KW intercellular adhesion molecule 1; ICAM-1; antisense; ss.
 XX
 OS Mus sp.
 OS Synthetic.
 XX
 XX US2004142899-A1.
 XX
 PD 22-JUL-2004.
 XX
 XX 17-FEB-2004; 2004US-00780439.
 XX
 PR 11-JAN-1990; 90US-00463358.
 PR 13-AUG-1990; 90US-00566977.
 PR 24-OCT-1991; 91US-00782374.
 PR 23-OCT-1992; 92WO-US009196.
 PR 05-SEP-1993; 93US-00117363.
 PR 03-SEP-1993; 93US-00117363.
 PR 10-APR-2000; 2000US-00546596.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Cook PD, Manoharan M, Bennett CF;
 PI

XX DR WPI; 2004-561278/54.

XX PT Use of a lipophilic antisense compound for modulating expression of a

XX PI nucleic acid in the liver and associated tissue and hepatic gene

XX PT expression.

XX PS Example 7; SEQ ID NO 5; 48pp; English.

XX CC The invention relates to compositions and methods for enhanced

CC biostability and altered biodistribution of oligonucleotides in mammals.

CC The invention also relates to a method for modulating expression of

CC nucleic acid in hepatic system of a mammal. The method is useful for

CC modulating the expression of a nucleic acid in the liver and associated

CC tissue, gene expression in cell, tissue or organs; for inhibiting

CC transcription and/or replication of particular genes; for inducing

CC degradation of regions of double stranded DNA in cells; for killing cells

CC or virus; in diagnostics, therapeutics and as research reagents and kits.

CC The present sequence is an antisense oligonucleotide targeted to murine

CC intercellular adhesion molecule 1 (ICAM-1) gene. This sequence is used to

CC illustrate the method of the invention.

XX CC

XX SQ Sequence 18 BP; 4 A; 4 C; 8 G; 0 T; 2 U; 0 Other;

Query Match. 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 9.9e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1927

ADQ88604/c

ID ADQ88604 standard; DNA; 18 BP.

XX AC ADQ88604;

XX DT 07-OCT-2004 (first entry)

XX DE Murine ICAM-1 antisense analogue DNA-RNA hybrid oligo, oligomer 59.

XX KW Hepatic system; liver; transcription inhibition; DNA degradation;

XX KW therapy; murine; intercellular adhesion molecule 1; ICAM-1; antisense;

XX KW DNA-RNA hybrid; ss.

XX OS Mus sp.

XX FH Key Location/Qualifiers

FT modified_base 1 /*tag= b

FT /mod_base= OTHER

FT /note= "Optionally 2'-O-hexylamino (dinitrophenyl)

FT uridine phosphoramidite or 2'-O- [hexylamino-

FT (cholesterol)] uridine phosphoramidite or 2'-O-

FT [hexylamino-(fluorescein)] amidite"

FT misc_RNA 1

FT /*tag= a

FT /label= RNA

XX US2004142899-A1.

XX PD 22-JUL-2004.

XX XX 17-FEB-2004; 2004US-00780439.

XX PR 11-JAN-1990; 90US-00463358.

XX PR 13-AUG-1990; 90US-00566977.

XX PR 24-OCT-1991; 91US-00782374.

XX PR 23-OCT-1992; 92WO-US0009196.

XX PR 03-SEP-1993; 93US-00117363.

XX PR 05-JUN-1995; 95US-00464953.

PR 10-APR-2000; 2000US-00546596.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Cook PD, Manoharan M, Bennett CF;

XX XX WPI; 2004-561278/54.

XX PT Use of a lipophilic antisense compound for modulating expression of a

XX PI nucleic acid in the liver and associated tissue and hepatic gene

XX PT expression.

XX PS Example 7; Page 21; 48pp; English.

XX CC The invention relates to compositions and methods for enhanced

CC biostability and altered biodistribution of oligonucleotides in mammals.

CC The invention also relates to a method for modulating expression of

CC nucleic acid in hepatic system of a mammal. The method is useful for

CC modulating the expression of a nucleic acid in the liver and associated

CC tissue, gene expression in cell, tissue or organs; for inhibiting

CC transcription and/or replication of particular genes; for inducing

CC degradation of regions of double stranded DNA in cells; for killing cells

CC or virus; in diagnostics, therapeutics and as research reagents and kits.

CC The present sequence is a murine intercellular adhesion molecule 1 (ICAM-

CC 1) gene targeted antisense analogue DNA-RNA hybrid oligonucleotide. This

CC sequence is used to illustrate the method of the invention.

XX CC

XX SQ Sequence 18 BP; 4 A; 4 C; 8 G; 1 T; 1 U; 0 Other;

Query Match. 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 9.9e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1928

ADQ88548/c

ID ADQ88548 standard; DNA; 18 BP.

XX AC ADQ88548;

XX DT 07-OCT-2004 (first entry)

XX DE Murine ICAM-1 antisense analogue DNA-RNA hybrid oligo, oligomer 61.

XX KW Hepatic system; liver; transcription inhibition; DNA degradation;

XX KW therapy; murine; intercellular adhesion molecule 1; ICAM-1; antisense;

XX KW DNA-RNA hybrid; ss.

XX OS Mus sp.

XX FH Key Location/Qualifiers

FT modified_base 1 /*tag= a

FT /mod_base= OTHER

FT /note= "Optionally 2'-O-hexylamino (dinitrophenyl)

FT uridine phosphoramidite or 2'-O- [hexylamino-

FT (cholesterol)] uridine phosphoramidite or 2'-O-

FT [hexylamino-(fluorescein)] amidite"

FT misc_RNA 10

FT /*tag= b

FT /label= RNA

XX US2004142899-A1.

XX PD 22-JUL-2004.

XX XX 17-FEB-2004; 2004US-00780439.

XX PR 11-JAN-1990; 90US-00463358.

```

PR 13-AUG-1990; 90US-00566977.
PR 24-OCT-1991; 91US-00782374.
PR 23-OCT-1992; 92WO-US009196.
PR 03-SEP-1993; 93US-00117363.
PR 05-JUN-1995; 95US-00464953.
PR 10-APR-2000; 2000US-00546596.
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Manoharan M, Bennett CF;
XX
XX WPI; 2004-561278/54.
XX
XX Use of a lipophilic antisense compound for modulating expression of a
XX nucleic acid in the liver and associated tissue and hepatic gene
XX expression.
XX
XX Example 7; SEQ ID NO 16; 48pp; English.
XX
XX The invention relates to compositions and methods for enhanced
XX biostability and altered biodistribution of oligonucleotides in mammals.
XX The invention also relates to a method for modulating expression of
XX nucleic acid in hepatic system of a mammal. The method is useful for
XX modulating the expression of a nucleic acid in the liver and associated
XX tissue, gene expression in cell, tissue or organs; for inhibiting
XX transcription and/or replication of particular genes; for inducing
XX degradation of regions of double stranded DNA in cells; for killing cells
XX or virus; in diagnostics, therapeutics and as research reagents and kits.
XX The present sequence is a murineintercellular adhesion molecule 1 (ICAM-
XX 1) gene targeted antisense analogue DNA-RNA hybrid oligonucleotide. This
XX sequence is used to illustrate the method of the invention.
XX
XX Sequence 18 BP; 4 A; 4 C; 8 G; 1 T; 1 U; 0 Other;
XX
XX Query Match 0.6%; Score 18; DB 1; Length 18;
XX Best Local Similarity 100.0%; Pred.No. 9.9e+02; Indels 0; Gaps 0;
XX Matches 18; Conservative 0; Mismatches 0;
XX
XX QY 50 GCCTCGCTATGGCTCCCA 67
XX |||||
XX Db 18 GCCTCGCTATGGCTCCCA 1
XX
XX RESULT 1929
XX ADQ88537/c
XX ID ADQ88537 standard; DNA; 18 BP.
XX
XX AC ADQ88537;
XX
XX DT 07-OCT-2004 (first entry)
XX
XX DE Murine ICAM-1 targeted antisense oligo, oligomer 15.
XX
XX KW Hepatic system; liver; transcription inhibition; DNA degradation;
XX therapy; phosphorothioate backbone; murine; antisense;
XX intercellular adhesion molecule 1; ICAM-1; ss.
XX
XX OS Mus sp.
XX OS Synthetic.
XX
XX FH Key Location/Qualifiers
XX modified_base 1..18
XX /*tag= a
XX /mod_base= OTHER
XX /note= "Phosphorothioate backbone"
XX
XX modified_base 5
XX /*tag= b
XX /mod_base= OTHER
XX /note= "Optionally linked to pentyl-N-phthalimido group"
XX
XX modified_base 9
XX /*tag= c
XX /mod_base= OTHER
XX /note= "Optionally linked to pentyl-N-phthalimido group"
XX
XX FT

```

```

FT modified_base 11
FT /*tag= d
FT /mod_base= OTHER
FT /note= "Optionally linked to pentyl-N-phthalimido group"
FT
FT modified_base 15
FT /*tag= e
FT /mod_base= OTHER
FT /note= "Linked to pentyl-N-phthalimido group"
XX
XX US2004142899-A1.
XX
XX 22-JUL-2004.
XX
XX 17-FEB-2004; 2004US-00780439.
XX
XX 11-JAN-1990; 90US-00463358.
XX 13-AUG-1990; 90US-00566977.
XX 24-OCT-1991; 91US-00782374.
XX 23-OCT-1992; 92WO-US009196.
XX 03-SEP-1993; 93US-00117363.
XX 05-JUN-1995; 95US-00464953.
XX 10-APR-2000; 2000US-00546596.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Manoharan M, Bennett CF;
XX
XX WPI; 2004-561278/54.
XX
XX Use of a lipophilic antisense compound for modulating expression of a
XX nucleic acid in the liver and associated tissue and hepatic gene
XX expression.
XX
XX Example 1; SEQ ID NO 4; 48pp; English.
XX
XX The invention relates to compositions and methods for enhanced
XX biostability and altered biodistribution of oligonucleotides in mammals.
XX The invention also relates to a method for modulating expression of
XX nucleic acid in hepatic system of a mammal. The method is useful for
XX modulating the expression of a nucleic acid in the liver and associated
XX tissue, gene expression in cell, tissue or organs; for inhibiting
XX transcription and/or replication of particular genes; for inducing
XX degradation of regions of double stranded DNA in cells; for killing cells
XX or virus; in diagnostics, therapeutics and as research reagents and kits.
XX The present sequence is an antisense oligonucleotide targeted to murine
XX intercellular adhesion molecule 1 (ICAM-1) gene. This sequence is used to
XX illustrate the method of the invention.
XX
XX Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 18; DB 1; Length 18;
XX Best Local Similarity 100.0%; Pred.No. 9.9e+02; Indels 0; Gaps 0;
XX Matches 18; Conservative 0; Mismatches 0;
XX
XX QY 50 GCCTCGCTATGGCTCCCA 67
XX |||||
XX Db 18 GCCTCGCTATGGCTCCCA 1
XX
XX RESULT 1930
XX ADS41455/c
XX ID ADS41455 standard; DNA; 18 BP.
XX
XX AC ADS41455;
XX
XX DT 16-DEC-2004 (first entry)
XX
XX DE Human autoimmune disease-related PCR primer - SEQ ID 6669.
XX
XX KW single nucleotide polymorphism detection; SNP detection;
XX rheumatoid arthritis; type 1 diabetes; multiple sclerosis;
XX systemic lupus erythematosus; inflammatory bowel disease; psoriasis;
XX thyroiditis; celiac disease; pernicious anaemia; asthma; vitiligo;
XX

```

KW glomerulonephritis; Grave's disease; myocarditis; Sjogren's disease;
KM primary systemic vasculitis; PCR; primer; ss.
XX Homo sapiens.
XX WO2004083403-A2.
XX 30-SEP-2004.
XX 18-MAR-2004; 2004WO-US008461.
XX 18-MAR-2003; 2003US-0455444P.
PR 25-APR-2003; 2003US-0465241P.
XX (APPL-) APPLERA CORP.
XX Cargill M, Begovich AB, Alexander HC;
XX WPI; 2004-728480/71.
XX New isolated nucleic acid molecule comprises at least 8 contiguous
PT nucleotides where one of the nucleotides is a single nucleotide
PT polymorphism (SNP), useful for diagnosing or treating autoimmune
PT diseases, e.g. rheumatoid arthritis.
XX Claim 21; SEQ ID NO 6669; 123pp; English.
XX The invention comprises amino acid and coding sequences containing
CC genetic polymorphisms associated with an altered risk of developing an
CC autoimmune disease (e.g. rheumatoid arthritis). The invention further
CC comprises a method of identifying an individual that has an altered risk
CC of developing an autoimmune disease, comprising detecting a single
CC nucleotide polymorphism (SNP) in a nucleic acid of the invention. The DNA
CC and protein sequences of the invention are useful for diagnosing and
CC treating autoimmune diseases, such as: rheumatoid arthritis, type 1
CC diabetes, multiple sclerosis, systemic lupus erythematosus, inflammatory
CC bowel diseases, psoriasis, thyroiditis, celiac disease, pernicious
CC anaemia, asthma, vitiligo, glomerulonephritis, Grave's disease, the
CC myocarditis, Sjogren's disease, or primary systemic vasculitis. The
CC present DNA sequence represents a human autoimmune disease-related PCR
CC primer of the invention. NOTE: The present sequence is not shown in the
CC specification, but has been retrieved from the WIPO website.
XX
SQ Sequence 18 BP; 4 A; 8 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 9.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1462 GAGGTGACCGTGAATGTG 1479
Db |||||
18 GAGGTGACCGTGAATGTG 1
RESULT 1931
AAQ45144/C
ID AAQ45144 standard; DNA; 19 BP.
XX
AC AAQ45144;
XX
XX 25-MAR-2003 (revised)
DT 31-OCT-1994 (first entry)
XX
XX Oligonucleotide used in amine containing therapeutic.
DE
XX Oligonucleotide; analogue; antisense; therapy; diagnosis; identification;
XX retention; therapeutic; amine; lipophile; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH misc_feature 19
FT /*tag= a

FT
XX /note= "Abasic, aldehydic species."
PN WO9406815-A1.
XX
XX 31-MAR-1994.
XX
XX 03-SEP-1993; 93WO-US008367.
XX
XX 11-SEP-1992; 92US-00943516.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Manoharan M, Cook PD;
XX
XX WPI; 1994-118388/14.
XX
XX Nucleotide and oligo-nucleotide (poly)amine analogues - used in anti-
PT sense therapy, diagnosis, and identification, amino gp. enhances cell
PT uptake and retention.
XX
XX Disclosure; Page 23; 93pp; English.
XX
XX The sequence is used in the production of an amine analogue. The analogue
CC may be used in antisense therapy. The analogue may also have enhanced
CC cellular uptake, increased lipophilicity, cause greater cellular
CC retention and demonstrate increased distribution. (Updated on 25-MAR-2003
CC to correct PN field.)
XX
SQ Sequence 19 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 1 Other;
Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGCTCCCA 67
Db |||||
18 GCCTCGCTATGCTCCCA 1
RESULT 1932
AAV28149/C
ID AAV28149 standard; DNA; 19 BP.
XX
XX AAV28149;
XX
XX 08-OCT-1998 (first entry)
DT
XX
XX Oligonucleotide ISIS 2302.
XX
XX Purification; oligonucleotide; matrix; affinity unit;
XX affinity purification; ss.
XX
XX Synthetic.
XX
XX WO9827425-A1.
XX
XX 25-JUN-1998.
XX
XX 18-DEC-1997; 97WO-US023284.
PF
XX
XX 19-DEC-1996; 96US-00769951.
PR
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX Chen D, Srivatsa GS, Cole DL;
PI
XX WPI; 1998-362922/31.
DR
XX Matrix for selective separation of oligo-nucleotide - useful for, e.g.
PT large scale purification of anti-sense agents from their deletion
PT derivatives formed during synthesis.
XX
XX Example 1; Page 34; 183pp; English.
PS

XX The present sequence represents target oligonucleotide ISIS 2302. The
 CC method of the invention was used to purify this oligonucleotide. The
 CC specification describes a matrix that comprises a support and an affinity
 CC unit that specifically and reversibly binds a target oligonucleotide, and
 CC comprises a sequence of bases having the reverse complement of a
 CC hybridising portion of the target oligonucleotide. The matrix is used for
 CC affinity purification of synthetic oligonucleotides, specifically
 CC antisense agents, for treatment of hyperproliferative diseases, for
 CC treating a non-pathogen, non-hyperproliferative disease, e.g.
 CC Alzheimer's, for modulating expression of cell surface proteins, and to
 CC inhibit a eukaryotic pathogen, retrovirus or other viruses
 XX

SQ Sequence 19 BP; 4 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 9.4e+02; Mismatches 0; Gaps 0;
 Matches 18; Conservative 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTGG 2117
 |||||
 Db 19 TGACGGATGCCAGCTGG 2

RESULT 1933
 AAA06847/c
 ID AAA06847 standard; DNA; 19 BP.
 XX
 AC AAA06847;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE ICAM-1 antisense dimethylaminoxyethyl (DMAOE) oligo, SEQ ID NO:21.
 XX
 KW Antisense; ICAM-1; dimethylaminoxyethyl; DMAOE; modified nucleoside;
 KW phosphorothioate; 2'-deoxy-erythro-pentofuranosyl sugar moiety;
 KW nuclease resistant; hybridisation; binding affinity; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX

Key Location/Qualifiers
 modified_base 1..19
 FT /*tag= a
 FT /note= "These nucleotides are 2'-O-substituted with 2'-O-
 FT DMAOE, phosphorothioate linkages"
 XX
 PN WO200008042-A1.
 XX
 PD 17-FEB-2000.
 XX
 PF 09-AUG-1999; 99WO-US017988.
 XX
 PR 07-AUG-1998; 98US-00130973.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Manoharan M, Cook PD, Prakash TP, Kawasaki AM;
 XX
 DR WPI; 2000-224020/19.
 XX
 PT Aminoxy-modified nucleosides and oligonucleotides useful in diagnostic,
 PT therapeutic and research reagents and for modulating the expression of
 PT protein in organisms.
 XX
 PS Example 101; Page 193; 195pp; English.
 XX

The invention relates to aminoxy-modified nucleosides and
 CC oligonucleotides and to oligonucleotides that elicit RNase H for cleavage
 CC in a complementary nucleic acid strand. It also relates to
 CC oligonucleotides wherein at least some of the nucleotides are
 CC functionalised to be nuclease resistant, at least some of the nucleotides
 CC include a substituent that potentiates hybridisation of the

CC oligonucleotide to a complementary strand, and at least some of the
 CC nucleotides include a 2'-deoxy-erythro-pentofuranosyl sugar moiety. The
 CC inclusion of one or more aminoxy moieties in such oligonucleotides
 CC provides for improved binding of such oligonucleotides to a complementary
 CC strand. The oligonucleotides of the invention are used as diagnostic,
 CC therapeutic or research reagents, and can be used to modulate gene
 CC expression in organisms. The oligonucleotides containing the modified
 CC nucleosides have increased nuclease resistance and increased binding
 CC affinity to a complementary strand. The present sequence represents a
 CC uniformly modified dimethylaminoxyethyl (DMAOE) antisense
 CC oligonucleotide, targeted against the ICAM-1 gene, which was used in an
 CC exemplification of the present invention
 XX

SQ Sequence 19 BP; 5 A; 3 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 9.4e+02; Mismatches 0; Gaps 0;
 Matches 18; Conservative 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCA 35
 |||||
 Db 19 GAGCTCCTCTGCTACTCA 2

RESULT 1934
 AAS01233
 ID AAS01233 standard; cDNA; 19 BP.
 XX
 AC AAS01233;
 XX
 DT 04-JUL-2001 (first entry)
 XX
 DE Forward PCR primer, used in expression analysis of POLY5.
 XX
 KW Human secreted protein; therapeutic; diagnostic; human; cancer;
 KW PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200119856-A2.
 XX
 PD 22-MAR-2001.
 XX
 PF 13-SEP-2000; 2000WO-US025106.
 XX
 PR 13-SEP-1999; 99US-0153629P.
 PR 16-SEP-1999; 99US-0154520P.
 PR 20-SEP-1999; 99US-0154762P.
 PR 13-OCT-1999; 99US-0159231P.
 PR 12-SEP-2000; 2000US-00659634.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Shimkets RA, Fernandes E, Herrmann JL, Liu X, Yang M, Boldog FL;
 XX
 DR WPI; 2001-244781/25.
 XX
 PT New POLYX polypeptide useful for treating or preventing a POLYX
 PT associated disorder, e.g. cancer.
 XX
 PS Example 5; Page 111; 152pp; English.
 XX

The sequence represents the Forward PCR primer, used in expression
 CC analysis of human secreted protein, POLY5. POLYX nucleic acids,
 CC polypeptides and antibodies to POLYX can be used for treating or
 CC preventing a POLYX associated disorder in a subject, preferably a human.
 CC These can be used in the manufacture of a medicament for treating a
 CC syndrome associated with a human disease selected from a POLYX-associated
 CC disorder, where the therapeutic is a POLYX polypeptide, a POLYX
 CC nucleotide or a POLYX antibody. They may also be used to screen for a
 CC modulator of activity, or latency, or predisposition to a POLYX-
 CC associated disorder, e.g. cancer
 XX

SQ Sequence 19 BP; 4 A; 4 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTG 2789

Db 2 CCAGGCTGGAGTGCAGTG 19

RESULT 1935

ADF70310/c

ID ADF70310 standard; DNA; 19 BP.

XX AC

XX ADF70310;

XX XX

DT 12-FEB-2004 (first entry)

XX XX

DE ICAM antisense oligonucleotide SeqID23.

XX XX

KW expression modulation; hepatic system; sterol group; hepatotropic;
KW gene therapy; hepatic disease; antisense therapy; ss; ICAM;
KW intercellular adhesion molecule.

XX XX

OS Unidentified.

XX XX

PN WO2003072711-A2.

XX XX

PD 04-SEP-2003.

XX XX

PF 21-FEB-2003; 2003WO-US005066.

XX XX

PR 22-FEB-2002; 2002US-00080979.

XX XX

PA (ISIS-) ISIS PHARM INC.

XX XX

PI Cook PD, Manoharan M, Bennett FC;

XX XX

DR WPI; 2003-679947/64.

XX XX

PT Modulating the expression of a nucleic acid in the hepatic system, useful
PT for treating hepatic disorders, comprises administering to the mammal an
PT oligonucleotide that hybridizes to the nucleic acid to modulate its
PT expression.

XX XX

PS Example 7; SEQ ID NO 23; 98pp; English.

XX XX

CC This invention relates to a novel method of modulating the expression of
CC a nucleic acid in the hepatic system of a mammal which comprises
CC administering to the mammal an oligonucleotide that hybridizes to the
CC nucleic acid to modulate the expression of the nucleic acid, where the
CC oligonucleotide has two sterol groups that are covalently bonded. The
CC invention may be useful for the development of a compound with
CC hepatotropic activity whilst the genetic sequences of the invention may
CC prove useful for gene therapy. The methods are useful for treating
CC hepatic disease or disorder associated with a protein encoded by a gene.
CC Note: These oligonucleotides may have one or more of several
CC modifications which are detailed in the specification, including having a
CC phosphorothioate backbone or having ribonucleoside bases.

SQ Sequence 19 BP; 4 A; 4 C; 8 G; 1 T; 2 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

Db 19 GCCTCGCTATGGCTCCCA 2

RESULT 1936

ADF70302/c

ID ADF70302 standard; DNA; 19 BP.

XX AC

XX ADF70302;

XX XX

DT 12-FEB-2004 (first entry)

XX XX

DE ICAM antisense oligonucleotide SeqID15.

XX XX

KW expression modulation; hepatic system; sterol group; hepatotropic;
KW gene therapy; hepatic disease; antisense therapy; ss; ICAM;
KW intercellular adhesion molecule.

XX XX

OS Unidentified.

XX XX

PN WO2003072711-A2.

XX XX

PD 04-SEP-2003.

XX XX

PF 21-FEB-2003; 2003WO-US005066.

XX XX

PR 22-FEB-2002; 2002US-00080979.

XX XX

PA (ISIS-) ISIS PHARM INC.

XX XX

PI Cook PD, Manoharan M, Bennett FC;

XX XX

DR WPI; 2003-679947/64.

XX XX

PT Modulating the expression of a nucleic acid in the hepatic system, useful
PT for treating hepatic disorders, comprises administering to the mammal an
PT oligonucleotide that hybridizes to the nucleic acid to modulate its
PT expression.

XX XX

PS Example 7; SEQ ID NO 15; 98pp; English.

XX XX

CC This invention relates to a novel method of modulating the expression of
CC a nucleic acid in the hepatic system of a mammal which comprises
CC administering to the mammal an oligonucleotide that hybridizes to the
CC nucleic acid to modulate the expression of the nucleic acid, where the
CC oligonucleotide has two sterol groups that are covalently bonded. The
CC invention may be useful for the development of a compound with
CC hepatotropic activity whilst the genetic sequences of the invention may
CC prove useful for gene therapy. The methods are useful for treating
CC hepatic disease or disorder associated with a protein encoded by a gene.
CC Note: These oligonucleotides may have one or more of several
CC modifications which are detailed in the specification, including having a
CC phosphorothioate backbone or having ribonucleoside bases.

SQ Sequence 19 BP; 4 A; 4 C; 8 G; 1 T; 1 U; 1 Other;

Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1937

ADF70355/c

ID ADF70355 standard; DNA; 19 BP.

XX XX

AC ADF70355;

XX XX

DT 12-FEB-2004 (first entry)

XX XX

DE ICAM antisense oligonucleotide SeqID69.

XX XX

KW expression modulation; hepatic system; sterol group; hepatotropic;
KW gene therapy; hepatic disease; antisense therapy; ss; ICAM;
KW intercellular adhesion molecule.

XX OS Unidentified.
 XX PN W02003072711-A2.
 XX XX
 XX PD 04-SEP-2003.
 XX XX
 XX PF 21-FEB-2003; 2003WO-US005066.
 XX PR 22-FEB-2002; 2002US-00080979.
 XX XX
 XX PA (ISIS-) ISIS PHARM INC.
 XX XX
 XX PI Cook PD, Manoharan M, Bennett FC;
 XX XX
 XX DR WPI; 2003-679947/64.
 XX XX
 XX PT Modulating the expression of a nucleic acid in the hepatic system, useful
 PT for treating hepatic disorders, comprises administering to the mammal an
 PT oligonucleotide that hybridizes to the nucleic acid to modulate its
 PT expression.
 XX XX
 XX PS Example 7; SEQ ID NO 69; 98pp; English.
 XX XX
 XX CC This invention relates to a novel method of modulating the expression of
 CC a nucleic acid in the hepatic system of a mammal which comprises
 CC administering to the mammal an oligonucleotide that hybridizes to the
 CC nucleic acid to modulate the expression of the nucleic acid, where the
 CC oligonucleotide has two sterol groups that are covalently bonded. The
 CC invention may be useful for the development of a compound with
 CC hepatotropic activity whilst the genetic sequences of the invention may
 CC prove useful for gene therapy. The methods are useful for treating
 CC hepatic disease or disorder associated with a protein encoded by a gene.
 CC Note: These oligonucleotides may have one or more of several
 CC modifications which are detailed in the specification, including having a
 CC phosphorothioate backbone or having ribonucleoside bases.
 XX XX
 XX SQ Sequence 19 BP; 4 A; 4 C; 8 G; 0 T; 2 U; 1 Other;
 Query Match 0.6%; Score 18; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 9.4e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 50 GCCTCGCTATGGCTCCCA 67
 Db 18 GCCTCGCTATGGCTCCCA 1
 RESULT 1938
 ID ACA58212/c
 XX ACA58212 standard; DNA; 19 BP.
 XX AC ACA58212;
 XX XX
 XX DT 09-JUN-2003 (first entry)
 XX XX
 XX DE Human familial bipolar affective disorder chromosome marker #160.
 XX KW Human; genotype determination; familial bipolar affective disorder;
 KW chromosomal region linked; locus associated with resistance; D4S402;
 KW D4S424; D4S431; D4S404; D11S394; D11S29; chromosome marker; primer; ss.
 XX XX
 XX OS Homo sapiens.
 XX XX
 XX PN US2002192655-A1.
 XX XX
 XX PD 19-DEC-2002.
 XX XX
 XX PF 13-JUN-2001; 2001US-00881012.
 XX XX
 XX PR 29-MAR-1996; 96US-0014334P.
 XX PR 20-OCT-1997; 97US-0062924P.
 XX PR 19-OCT-1998; 98US-00175158.

XX (GINN/) GINN E I.
 PA (EGEL/) EGELAND J A.
 PA (PAUL/) PAUL S M.
 XX XX
 XX PI Ginn EI, Egeland JA, Paul SM;
 XX DR WPI; 2003-352708/33.
 XX XX
 XX PT Determining a genotype associated with increased or decreased resistance
 PT to familial bipolar affective disorder in a family comprises determining
 PT the genotype of e.g., chromosomal regions D4S402 and D4S424.
 XX XX
 XX PS Disclosure; Page 11; 79pp; English.
 XX XX
 XX CC The present invention relates to a method of determining a genotype
 CC associated with increased or decreased resistance to familial bipolar
 CC affective disorder. The method comprises determining the genotype with at
 CC least one marker of at least one chromosomal region linked to a locus
 CC associated with resistance to bipolar affective disorder, where the
 CC chromosomal regions are included of and localised between D4S402 and
 CC D4S424, D4S431 and D4S404, or D11S394 and D11S29. The invention also
 CC discloses a kit for determining a genotype associated with increased or
 CC decreased resistance to familial bipolar affective disorder, where the
 CC kit comprises markers for two or more of the chromosomal regions cited.
 CC The method and kit are useful for determining a genotype associated with
 CC increased or decreased resistance to familial bipolar affective disorder
 CC in a family affected by bipolar affective disorder, for determining the
 CC contribution of these chromosomal regions to bipolar affective disorder
 CC in an affective family member, and for assessing an increased or
 CC decreased risk of developing bipolar illness for a tested individual from
 CC an affected family. ACA58053-ACA58292 represent primers used in the
 CC present invention
 XX XX
 XX SQ Sequence 19 BP; 4 A; 7 C; 5 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 18; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 9.4e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2767 GTCACCCAGGCTGGAGTG 2784
 Db 19 GTCACCCAGGCTGGAGTG 2
 RESULT 1939
 ADH89039
 ID ADH89039 standard; DNA; 19 BP.
 XX XX
 XX AC ADH89039;
 XX XX
 XX DT 22-APR-2004 (first entry)
 XX XX
 XX DE Human POLYX PCR primer #9.
 XX KW Human; POLYX; PCR; ss; POLYX-associated disorder; cytostatic;
 KW immunostimulant; primer.
 XX XX
 XX OS Homo sapiens.
 XX XX
 XX PN US2003198958-A1.
 XX XX
 XX PD 23-OCT-2003.
 XX XX
 XX PF 13-MAR-2002; 2002US-00098871.
 XX XX
 XX PR 13-SEP-1999; 99US-0153629P.
 XX PR 16-SEP-1999; 99US-0154520P.
 XX PR 20-SEP-1999; 99US-0154762P.
 XX PR 13-OCT-1999; 99US-0159231P.
 XX PR 12-SEP-2000; 2000US-00659634.
 XX PR 19-MAR-2001; 2001US-0276960P.
 XX XX

PA (SHIM/) SHIMKETS R. A.
PA (FERN/) FERNANDES E.
PA (HERR/) HERRMANN J L.
PA (LIUX/) LIU X.
PA (YANG/) YANG M.
PA (BOLD/) BOLDOG F L.
PA (SMIT/) SMITHSON G.
PA (RAST/) RASTELLI L.
XX
XX Shimkets RA, Fernandes E, Herrmann JL, Liu X, Yang M, Boldog FL,
PI Smithson G, Rastelli L;
XX WPI; 2004-041344/04.
XX
XX Example 5; SEQ ID NO 37; 93pp; English.
XX
XX The invention relates to human POLYX polypeptides and the polynucleotides
CC encoding them. The invention also relates to an antibody that
CC immunospecifically binds to a POLYX polypeptide, a method of determining
CC the presence or amount of a POLYX polynucleotide in a sample involving
CC contacting the sample with a probe that binds to the polynucleotide and
CC determining the presence or amount of the probe bound to the DNA, a
CC method of identifying an agent that modulates the expression or activity
CC of a POLYX polypeptide involving providing a cell expressing the
CC polypeptide, contacting the cell with the agent and determining whether
CC the agent modulates expression or activity of the polypeptide where an
CC alteration in expression or activity of the polypeptide indicates a
CC modulation, and a method of modulating the activity of a polypeptide
CC involving contacting a cell sample expressing the polypeptide with a
CC compound that binds to the polypeptide in an amount sufficient to
CC modulate the activity. The POLYX polynucleotides are useful for
CC determining the presence of or predisposition to a disease associated
CC with altered levels of POLYX DNA or protein in a first mammalian subject,
CC involving measuring the level of expression of DNA or the amount of
CC protein in a sample from the first mammalian subject and comparing the
CC amount of DNA or protein in a sample from a second mammalian subject
CC known not to have or not be predisposed to the disease, where an
CC alteration in the expression level of DNA or protein in the first subject
CC as compared to the control sample indicates the presence of a
CC predisposition to the disease. The sequences of the invention are useful
CC for treating or preventing a POLYX-associated disorder which involves
CC administering POLYX DNA. A therapeutic such as a POLYX DNA, protein or
CC antibody is useful in the manufacture of a medicament for treating a
CC syndrome associated with a human disease. This sequence represents a PCR
CC primer used to amplify a human POLYX polynucleotide of the invention.
XX
XX Sequence 19 BP; 4 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2772 CCAGGCTGGAGTGCAGTG 2789
DB 2 CCAGGCTGGAGTGCAGTG 19
XX
RESULT 1940
ADQ16474/c
ID ADQ16474 standard; DNA; 19 BP.
XX
XX ADQ16474;
AC
XX
DT 09-SEP-2004 (first entry)
XX
XX Modified oligonucleotide used for NMR analysis #9.
XX
XX ss; antisense; hepatic tissue targeting; liver gene expression;
KW improved biostability; altered biodistribution; DNA-RNA hybrid.
XX
XX Synthetic.
OS
XX
XX Key Location/Qualifiers
FH

FT misc_rna 1..2
FT /*tag= b
FT modified_base 1
FT /*tag= a
FT /*mod_base= OTHER
FT /*note= "OTHER = fluorescein"
XX
XX US6753423-B1.
XX
XX 22-JUN-2004.
XX
XX 10-APR-2000; 2000US-00546596.
XX
XX 12-SEP-1997; 97US-00928823.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Manoharan M, Bennett CF;
XX WPI; 2004-466815/44.
XX
XX Targeting an antisense oligonucleotide to hepatic tissues to modulate the
PT expression of a gene in the liver involves conjugating the
PT oligonucleotide to a cholesteryl moiety and administering the conjugate.
XX
XX Example 7; SEQ ID NO 23; 64pp; English.
XX
XX The invention relates to a method of targeting an antisense
CC oligonucleotide to hepatic tissues involving conjugating the
CC oligonucleotide to a cholesteryl moiety and administering the conjugate.
CC The method is useful for targeting an antisense oligonucleotide to
CC hepatic tissues to modulate the expression of a gene in the liver. The
CC oligonucleotide is useful in diagnostics, therapeutics, as research
CC reagents and kits, in pharmaceutical composition and for treating
CC diseases produced by undesired production of proteins. The method
CC provides lipophilic oligonucleotide conjugates with improved biostability
CC and altered biodistribution in mammals. The present sequence represents a
CC modified oligonucleotide used for NMR analysis.
XX
XX Sequence 19 BP; 4 A; 4 C; 8 G; 1 T; 2 U; 0 Other;
XX
Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 9.4e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
DB 19 GCCTCGCTATGGCTCCCA 2
XX
RESULT 1941
ADQ88555/c
ID ADQ88555 standard; DNA; 19 BP.
XX
XX ADQ88555;
AC
XX
DT 07-OCT-2004 (first entry)
XX
XX Murine ICAM-1 antisense analogue DNA-RNA hybrid oligo, oligomer 74.
DE
XX Hepatic system; liver; transcription inhibition; DNA degradation;
KW therapy; phosphorothioate backbone; murine;
KW intercellular adhesion molecule 1; ICAM-1; antisense; DNA-RNA hybrid; ss.
XX
XX Mus sp.
OS
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1..19
FT /*tag= c
FT /*mod_base= OTHER
FT /*note= "Phosphothioate backbone"
FT misc_rna 1..2
FT

PT propionic acids e.g. ibuprofen are used for transmembrane delivery of
 PT nucleic acid and oligonucleotides to cells for therapeutic and diagnostic
 PT purposes.

XX Example 27; Page 78; 149pp; English.

XX The present sequence was used to produce an oligomeric compound
 CC conjugated to an aryl propionic acid that interacts with a protein. The
 CC compound is used for transmembrane delivery of nucleic acids to a wide
 CC range of cells for diagnostic and therapeutic purposes. It allows more
 CC efficient cellular uptake of oligonucleotides and nucleic acids than
 CC prior art processes

XX Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 8.9e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCTCCTCTGCTACTACAGA'37
 Db 18 GCTCCTCTGCTACTACAGA 1

RESULT 1944

AAD52338
 ID AAD52338 standard; DNA; 20 BP.

XX AAD52338;

XX 02-MAY-2003 (first entry)

XX Human IFNGR2 antisense oligonucleotide, ISIS #142816.

XX Antisense; interferon gamma receptor 2; autoimmune disorder; cancer;
 KW autoimmune thyroiditis; autoimmune insulinitis; multiple sclerosis;
 KW diabetes; autoimmune arthritis; Crohn's disease; apoptosis; IFNGR2;
 KW gene therapy; prophylaxis; human; phosphorothioate; ss.

XX Homo sapiens.
 OS Synthetic.

XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= a

FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"

FT modified_base 1..5

FT /tag= b

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl nucleotides"

FT modified_base 16..20

FT /tag= c

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl nucleotides"

XX WO200288163-A1.

XX 07-NOV-2002.

XX 16-APR-2002; 2002WO-US012007.

XX 26-APR-2001; 2001US-00843377.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Watt AT;

XX WPI; 2003-156688/15.

XX New antisense oligonucleotides for modulating Interferon gamma receptor

PT 2, particularly useful for treating autoimmune disorders (e.g. multiple

PT sclerosis or Crohn's disease), cancers or diseases caused by aberrant
 PT apoptosis.

XX Example 15; Page 86; 127pp; English.

XX The invention relates to antisense compounds, composition and methods for
 CC modulating the expression of human interferon gamma receptor 2 (IFNGR2).
 CC The compositions comprise antisense compounds targetted to nucleic acids
 CC encoding IFNGR2. Antisense compounds of the invention are useful for
 CC treating diseases or conditions associated with IFNGR2, e.g. autoimmune
 CC disorder (e.g. autoimmune thyroiditis, diabetes, multiple sclerosis,
 CC autoimmune arthritis, autoimmune insulinitis or Crohn's disease), cancer,
 CC or a disease/disorder caused by aberrant apoptosis. They are also useful
 CC for diagnostics, therapeutics, prophylaxis or as research reagents or
 CC kits. The invention is useful in gene therapy. The present sequence is an
 CC antisense oligonucleotide targetted to human IFNGR2 DNA

XX Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 8.9e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2762 GCTCTGTACCCAGGCTG 2779

Db 1 GCTCTGTACCCAGGCTG 18

RESULT 1945

AAL61524
 ID AAL61524 standard; DNA; 20 BP.

XX AAL61524;

XX 22-SEP-2003 (first entry)

XX Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130449.

XX Human; inhibitor-kappa B-R; I-kappaBR; IKBR; I-kappa-B-related; NFKBIL2;
 KW ikappab r; antisense; immune response; infection; inflammation; therapy;
 KW tumour; prophylaxis; phosphorothioate; ss.

XX Homo sapiens.
 OS Synthetic.

XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"

FT modified_base 1..5

FT /tag= b

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified_base 16..20

FT /tag= c

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX WO2003042360-A2.

XX 22-MAY-2003.

XX 05-NOV-2002; 2002WO-US035597.

XX 13-NOV-2001; 2001US-00993731.

XX (ISIS-) ISIS PHARM INC.

XX Monia BP, Watt AT;

XX WPI; 2003-468635/44.

XX New antisense oligonucleotides targeted to nucleic acids encoding
PT inhibitor-kappa B-R, useful for diagnosing or treating diseases
PT associated with expression of inhibitor-kappa B-R, e.g., a heightened
PT immune response or infection.
XX
XX Claim 3; Page 74; 108pp; English.
XX
CC The invention relates to antisense compounds targetted to a nucleic acid
CC molecule encoding human inhibitor-kappa B-R (also known as I-kappaBR,
CC IKBR, I-kappa-B-related, ikappab r, nuclear factor of kappa light
CC polypeptides gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
CC inhibit its expression. Antisense compounds of the invention are useful
CC for treating diseases or conditions associated with the expression of
CC inhibitor-kappa B-R such as a heightened immune response involving
CC increased cytokine expression, or a result of infection (e.g. bacterial,
CC viral or parasitic). They are useful for diagnostics, therapeutics,
CC prophylaxis e.g. to prevent or delay infection, inflammation or tumour
CC formation, as research reagents and kits and in distinguishing between
CC functions of various members of a biological pathway. They are also
CC useful in antisense therapy. The present sequence is an oligonucleotide
CC targetted to human inhibitor-kappa B-R DNA
XX
XX Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 18; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 8.9e+02;
XX Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2773 CAGCTGGAGTGCAGTGG 2790
DB 1 CAGCTGGAGTGCAGTGG 18
|||||
RESULT 1946
ADD69468
ID ADD69468 standard; DNA; 20 BP.
XX
AC ADD69468;
XX
XX 15-JAN-2004 (first entry)
XX
XX 3' anchored (ISSR)-PCR primer - SEQ ID 26.
DE inter-simple sequence repeat; ISSR; SSR; PCR; primer; genotyping; plant;
XX animal; Basmati rice; ss.
XX
XX Synthetic.
XX
XX WO2003085133-A2.
XX
XX 16-OCT-2003.
XX
XX 09-JAN-2003; 2003WO-IB000041.
XX
XX 08-APR-2002; 2002IN-CH000260.
XX
XX (DNAP-) CENT DNA FINGERPRINTING & DIAGNOSTICS.
XX
XX Nagaraju JG;
XX
XX WPI; 2003-804317/75.
XX
XX New set of inter-simple sequence repeats (ISSR)-PCR primers for
PT genotyping eukaryotes, useful for genotyping diverse genomes of plant and
PT animal systems.
XX
XX Claim 1; SEQ ID NO 26; 60pp; English.
XX
XX The invention relates to a novel set of inter-simple sequence repeats
CC (ISSR)-PCR primers for genotyping eukaryotes. The primers of the
CC invention may be useful for genotyping diverse genomes of plant and
CC animal systems, in particular for distinguishing Basmati rice varieties

CC from non-Basmati rice varieties and traditional Basmati rice varieties
CC evolved Basmati rice varieties. The current sequence is that of the
CC 3' anchored (ISSR)-PCR primer of the invention.
XX
XX Sequence 20 BP; 1 A; 2 C; 8 G; 9 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 18; DB 1; Length 20;
XX Best Local Similarity 100.0%; Pred. No. 8.9e+02;
XX Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 2728 GTCGTGCTGCTGCTGAT 2745
DB 1 GTCGTGCTGCTGCTGAT 18
|||||
RESULT 1947
ADH77439
ID ADH77439 standard; DNA; 20 BP.
XX
AC ADH77439;
XX
XX 22-APR-2004 (first entry)
XX
XX Human PTPN12 antisense oligonucleotide seq id 80.
DE
XX
XX cytostatic; PTPN12 Inhibitor; PTPN12;
KW protein tyrosine phosphatase, non-receptor type 12;
KW hyperproliferative disorder; colon cancer; metabolic disorder;
KW antisense technology; antisense oligonucleotide; human; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone. All cytidine
FT residues are 5-methoxycytidine"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-methoxyethyl (2'-MOE) nucleotides"
XX
XX US2003232434-A1.
XX
XX 18-DEC-2003.
XX
XX 17-JUN-2002; 2002US-00172911.
XX
XX 17-JUN-2002; 2002US-00172911.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cowbert LM, Dobie KW;
XX
XX WPI; 2004-061282/06.
XX
XX New antisense oligonucleotides targeted to a nucleic acid encoding
PT protein tyrosine phosphatase, non-receptor type 12 (PTPN12) useful for
PT treating a disease associated with PTPN12, e.g. colon cancer.
XX
XX Example 15; SEQ ID NO 80; 117pp; English.
XX
XX The invention describes a compound 8-80 nucleobases in length targeted
CC to, and which specifically hybridizes with a nucleic acid molecule
CC encoding PTPN12 (protein tyrosine phosphatase, non-receptor type 12), and
CC inhibits the expression of PTPN12. The compound, composition and methods
CC are useful for treating a disease or condition associated with PTPN12,
CC such as a hyperproliferative disorder, e.g. colon cancer, or a metabolic

CC disorder. They are also useful in research and diagnostics for modulating
 CC the expression of PTPN12. This sequence represents a human protein
 CC tyrosine phosphatase, non-receptor type 12 (PTPN12) antisense
 CC oligonucleotide.

XX
 SQ Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 8.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTGCAGT 2788
 |||||
 Db 3 CCCAGGCTGGAGTGCAGT 20

RESULT 1948
 ADM15442/c

ID ADM15442 standard; DNA; 20 BP.

XX
 AC ADM15442;

XX
 DT 01-JUL-2004 (first entry)

XX
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1629.

XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

XX
 OS Homo sapiens.

OS
 OS Synthetic.

XX
 FH Key Location/Qualifiers

FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"

FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"

FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"

XX
 WO2004028458-A2.

XX
 XX

PD 08-APR-2004.

XX
 XX

PF 25-SEP-2003; 2003WO-US030374.

XX
 PR 25-SEP-2002; 2002US-0413549P.

XX
 PA (PHAA) PHARMACIA CORP.

XX
 XX

PI Gierse JK;

XX
 XX

DR WPI; 2004-305094/28.

XX
 XX

PT New antisense compound, having a sequence targeted to a nucleic acid
 FT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 FT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 FT ischemia.

XX
 PT

PS Claim 4; SEQ ID NO 1629; 132pp; English.

XX
 CC The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.

XX
 SQ Sequence 20 BP; 6 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 8.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2850 CCTCTCTAGTAGCTGGGA 2867
 |||||
 Db 20 CCTCTCTAGTAGCTGGGA 3

RESULT 1949
 ADQ75052/c

ID ADQ75052 standard; DNA; 20 BP.

XX
 AC ADQ75052;

XX
 DT 23-SEP-2004 (first entry)

XX
 DE Ligand conjugated oligomeric compound associated oligo seqid 2.

XX
 KW virucide; oligonucleotide binder; protein binder; serum binder;
 KW vascular protein binder; cellular protein binder; oligomeric compound;
 KW arylpropionic acid; ibuprofen; suprofen; fenbufen; ketoprofen;
 KW (S)-(-)-pranoprofen; carprofen; integrin; diagnostic;
 KW Epstein-Barr virus infection; EBV infection; pharmacokinetic property;
 KW urinary excretion; serum half life; ss; DNA-RNA hybrid; ISIS 27700-1;
 KW ISIS 27701-1.

XX
 OS Synthetic.

XX
 FH Key Location/Qualifiers

FT modified_base 1..19
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-(2-methoxyethyl) residues"

FT modified_base 3
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-(2'-methoxyethyl)-5-methylcytidine"

FT modified_base 6..10
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-(2'-methoxyethyl)-5-methylcytidine"

FT modified_base 14..15
 FT /*tag= d
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-(2'-methoxyethyl)-5-methylcytidine"

FT modified_base 17..18
 FT /*tag= e
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-(2'-methoxyethyl)-5-methylcytidine"

XX
 FT

FT misc_RNA 20
 FT /*tag= f
 FT /label= RNA
 PN US6762169-B1.
 XX 13-JUL-2004.
 PD 15-JUN-2000; 2000US-00594387.
 PF 15-JUN-1999; 99US-00334130.
 PR (ISIS-) ISIS PHARM INC.
 PA Manoharan M;
 PI WPI; 2004-532495/51.
 DR New oligomeric compound conjugated to an arylpropionic acid optionally
 XX of an oligonucleotide in serum.
 PS Example 26; SEQ ID NO 2; 42pp; English.
 XX The invention describes an oligomeric compound conjugated to an
 CC arylpropionic acid that optionally interacts with a plasma protein. The
 CC arylpropionic acid is ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(-)-
 CC pranoprofen, or carprofen (preferably ibuprofen). Also described is a
 CC method for increasing the concentration of an oligonucleotide in serum or
 CC promoting cellular uptake of an oligonucleotide in a cell involving:
 CC selecting an arylpropionic acid that is known to bind to a plasma protein
 CC or cell surface integrin; conjugating the arylpropionic acid to the
 CC oligonucleotide to form a conjugated oligonucleotide; and adding the
 CC conjugated oligonucleotide to the serum or exposing the cell to the
 CC conjugated oligonucleotide. The compound is also useful in diagnostic
 CC applications as well as therapeutic applications and for the treatment of
 CC latent Epstein-Barr virus (EBV) infection. The ligand-conjugated
 CC oligomeric compounds increase the concentration of an oligonucleotide in
 CC serum; increase the capacity of serum for an oligonucleotide; increase
 CC the binding of an oligonucleotide to a portion of the vascular system;
 CC promote cellular uptake of an oligonucleotide in cells; bind to protein
 CC molecules and possess enhanced pharmacokinetic properties. The ligand
 CC conjugated oligomeric compounds are capable of interacting with a protein
 CC or are conjugated to drug moieties. The oligomeric compounds can be
 CC prepared having covalently attached ligands that bind reversibly to at
 CC least one serum, vascular or cellular proteins. This reversible binding
 CC is expected to decrease urinary excretion, increase serum half life and
 CC greatly increase the distribution of oligomeric compounds thus
 CC conjugated. The compounds enhance the efficiency of oligonucleotide
 CC inhibition of gene expression. This sequence represents an
 CC oligonucleotide used in the creation of ligand conjugated oligomeric
 CC compounds of the invention.
 XX SQ Sequence 20 BP; 5 A; 4 C; 7 G; 3 T; 1 U; 0 Other;
 Query Match 0.68; Score 18; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 8.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 20 GCTCCTCTGCTACTCAGA 37
 Db 18 GCTCCTCTGCTACTCAGA 1
 RESULT 1950
 ADQ75053/c
 ID ADQ75053 standard; DNA; 20 BP.
 XX AC ADQ75053;
 XX 23-SEP-2004 (first entry)
 XX DT
 XX DE Ligand conjugated oligomeric compound associated oligo seqid 3.

XX virucide; oligonucleotide binder; protein binder; serum binder;
 KW vascular protein binder; cellular protein binder; oligomeric compound;
 KW arylpropionic acid; ibuprofen, suprofen, fenbufen, ketoprofen;
 KW (S)-(-)-pranoprofen; carprofen, integrin; diagnostic;
 KW Epstein-Barr virus infection; EBV infection; pharmacokinetic property;
 KW urinary excretion; serum half life; 88; ISIS 25152-1; ISIS 25153-1;
 KW ISIS 25154-1; ISIS 25155-1; ISIS 11158.
 XX Synthetic.
 OS
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..19
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= Phosphodiester backbone with 2'-O-
 FT methoxyethyl (MOE) nucleotides"
 FT modified_base 1
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= Optionally Hexanolamine phosphodiester"
 XX
 XX US6762169-B1.
 PN 13-JUL-2004.
 PD 15-JUN-2000; 2000US-00594387.
 PF 15-JUN-1999; 99US-00334130.
 PR (ISIS-) ISIS PHARM INC.
 PA Manoharan M;
 PI WPI; 2004-532495/51.
 DR New oligomeric compound conjugated to an arylpropionic acid optionally
 XX interacting with a plasma protein useful for increasing the concentration
 XX of an oligonucleotide in serum.
 PS Example 27; SEQ ID NO 3; 42pp; English.
 XX The invention describes an oligomeric compound conjugated to an
 CC arylpropionic acid that optionally interacts with a plasma protein. The
 CC arylpropionic acid is ibuprofen, suprofen, fenbufen, ketoprofen, (S)-(-)-
 CC pranoprofen, or carprofen (preferably ibuprofen). Also described is a
 CC method for increasing the concentration of an oligonucleotide in serum or
 CC promoting cellular uptake of an oligonucleotide in a cell involving:
 CC selecting an arylpropionic acid that is known to bind to a plasma protein
 CC or cell surface integrin; conjugating the arylpropionic acid to the
 CC oligonucleotide to form a conjugated oligonucleotide; and adding the
 CC conjugated oligonucleotide to the serum or exposing the cell to the
 CC conjugated oligonucleotide. The compound is also useful in diagnostic
 CC applications as well as therapeutic applications and for the treatment of
 CC latent Epstein-Barr virus (EBV) infection. The ligand-conjugated
 CC oligomeric compounds increase the concentration of an oligonucleotide in
 CC serum; increase the capacity of serum for an oligonucleotide; increase
 CC the binding of an oligonucleotide to a portion of the vascular system;
 CC promote cellular uptake of an oligonucleotide in cells; bind to protein
 CC molecules and possess enhanced pharmacokinetic properties. The ligand
 CC conjugated oligomeric compounds are capable of interacting with a protein
 CC or are conjugated to drug moieties. The oligomeric compounds can be
 CC prepared having covalently attached ligands that bind reversibly to at
 CC least one serum, vascular or cellular proteins. This reversible binding
 CC is expected to decrease urinary excretion, increase serum half life and
 CC greatly increase the distribution of oligomeric compounds thus
 CC conjugated. The compounds enhance the efficiency of oligonucleotide
 CC inhibition of gene expression. This sequence represents an
 CC oligonucleotide used in the creation of ligand conjugated oligomeric
 CC compounds of the invention.
 XX SQ Sequence 20 BP; 5 A; 4 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 18; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 8.9e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCTCCTCTGCTACTCAGA 37
 ID |||||:|||||:|||||:
 Db 18 GCTCCTCTGCTACTCAGA 1

RESULT 1951
 ABX93650/c
 ID ABX93650 standard; DNA; 19 BP.
 XX
 AC ABX93650;
 XX
 DT 10-JUN-2003 (first entry)
 XX
 XX Human Alu-specific 3' PCR primer Alu-N2.

XX Human; ss; PCR; primer; Alu repeat sequence; artificial chromosome;
 KW genome chip; genetic disease; pre-labour diagnosis; tumour typing;
 KW radioactive ray damage; environmental damage.
 XX

OS Homo sapiens.
 XX WO2003014384-A1.
 PN
 XX 20-FEB-2003.

XX 27-JUL-2001; 2001WO-CN001208.
 PF
 XX 27-JUL-2001; 2001WO-CN001208.
 PR
 XX (UYHK-) UNIV HONG KONG.

PA Guan X;
 XX WPI; 2003-268207/26.

DR
 XX
 PT Eliminating genomic repeat sequences, useful for preparing genome chips
 PT from artificial chromosomes for use in diagnosis of e.g. genetic
 PT diseases.

XX Claim 5; Page 8; 18pp; Chinese.
 XX The invention relates to DNA Amplification by polymerase chain reaction
 CC (PCR), comprising an artificial chromosome or a large DNA fragment of 50-
 CC 5000 base pairs in length as a template and an Alu-specific primer, in
 CC which the primer binds specifically to the 5'-terminus of an Alu sequence
 CC and extends from 3' to 5' of the Alu sequence, or specifically to the 3'-
 CC terminus of an Alu sequence and extends from 5' to 3' of the Alu
 CC sequence. Also included is a method for preparing genome chips,
 CC comprising: (a) obtaining a polynucleotide product by performing the PCR
 CC amplification; and (b) spotting the polynucleotide product onto the chip
 CC substrate to form the gene chip. The method is used for eliminating a
 CC repeat sequence in a genome, which is useful for preparing genome chips
 CC from artificial chromosomes for use in diagnosis of genetic diseases, pre
 CC -labour diagnosis by screening genetic diseases in pregnant women, tumour
 CC typing, diagnosis and prognosis tests, and studying the damaging effects
 CC of radioactive rays and other environmental factors on humans. The method
 CC allows genome chips to be produced with elimination of Alu repeat
 CC sequences and enhanced accuracy by effectively reducing non-specific
 CC background signals during hybridisation. The present sequence is an Alu
 CC sequence-specific PCR primer for performing the method of the invention
 XX

SQ Sequence 19 BP; 3 A; 7 C; 3 G; 3 T; 0 U; 3 Other;
 Query Match 0.6%; Score 17.8; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 9.9e+02;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2773 CAGGCTGGAGTGCAGTGGT 2791
 ID |||||:|||||:|||||:
 Db 19 CAGGCTGGAGTGCAGTGGT 1

RESULT 1953
 AAN95063
 ID AAN95063 standard; DNA; 21 BP.
 XX
 AC AAN95063;
 XX

Db 19 CAGGCTGGAGTGCARTGGY 1

RESULT 1952
 ABX95026/c
 ID ABX95026 standard; DNA; 19 BP.
 XX
 AC ABX95026;
 XX

DT 06-JUN-2003 (first entry)
 XX
 XX Human Alu specific PCR primer Alu-N2.
 XX

XX Human; ss; PCR; primer; Alu; repeat sequence; fluorescence-labelling;
 KW genome chip; pre-labour diagnosis; tumour typing; radioactive ray damage;
 KW FISH; fluorescence in-situ hybridisation.
 XX

OS Homo sapiens.

XX WO2003014385-Al.

XX 20-FEB-2003.

XX 27-JUL-2001; 2001WO-CN001209.

XX 27-JUL-2001; 2001WO-CN001209.

XX (UYHK-) UNIV HONG KONG.

XX Guan X;

XX WPI; 2003-248303/24.

XX Novel method for eliminating repeat sequence in genome, applicable in
 PT preparing FISH (fluorescence in-situ hybridization) probes from
 PT artificial chromosome for use in diagnosis of e.g. genetic diseases.
 XX

XX Claim 5; Page 8; 18pp; Chinese.

XX The invention relates to a method of amplification by polymerase chain
 CC reaction (PCR) is by using an artificial chromosome or a large DNA
 CC fragment of 50-5000 base pairs in length as template and an Alu-specific
 CC primer. Also included is a method for preparing a fluorescence-labelling
 CC probe comprising obtaining a polynucleotide product by performing the PCR
 CC amplification and fluorescence-labelling the polynucleotide product to
 CC give the probe. The method is useful for eliminating a repeat sequence in
 CC a genome, which is applicable in preparing genome chips from artificial
 CC chromosome for use in diagnosis of genetic diseases, pre-labour diagnosis
 CC by screening genetic diseases in pregnant women, tumour typing, diagnosis
 CC and prognosis tests and studying damages of radioactive rays and other
 CC environmental factors on humans. With this method, FISH (fluorescence in-
 CC site hybridisation) probes can be produced with elimination of the Alu
 CC repeat sequence and enhanced accuracy by effectively reducing non-
 CC specific background signal during hybridisation. The present sequence
 CC represents the human Alu specific PCR primer Alu-N2
 XX

SQ Sequence 19 BP; 3 A; 7 C; 3 G; 3 T; 0 U; 3 Other;

Query Match 0.6%; Score 17.8; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 9.9e+02;
 Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGT 2791

Db 19 CAGGCTGGAGTGCARTGGY 1

RESULT 1953
 AAN95063
 ID AAN95063 standard; DNA; 21 BP.
 XX
 AC AAN95063;
 XX

DT 22-MAR-1991 (first entry)
 XX
 DE 3' - 5' DNA sequence encoding variant C-myc protein (Pro to Ser).
 XX
 KW C-myc gene; variant myc protein; ss.
 XX
 OS Unidentified.
 XX
 FH Key Location/Qualifiers
 FT CDS complement(7..21)
 FT /*tag= a
 FT
 XX
 PN JP01039999-A.
 XX
 PD 10-FEB-1989.
 XX
 XX 06-AUG-1987; 87JP-00197197.
 PF
 XX 06-AUG-1987; 87JP-00197197.
 PR
 XX (MITK) MITSUI TOATSU CHEM INC.
 PA
 XX WPI; 1989-089714/12.
 DR P-PSDB; AAP95654.
 DR
 XX MYC protein for antibody prepn. - is stabilised by converting
 PT aminoacid(s) (s) of MYC protein to other aminoacid to produce variant type
 PT MYC protein.
 PT
 XX Disclosure; Fig 5(2); 18pp; Japanese.
 PS
 XX It encodes a variant C-myc protein stabilised by converting at least one
 CC amino acid of the normal C-myc sequence to another amino acid, while not
 CC affecting the properties of the myc protein. The codon changed is the
 CC second codon (bases 4-6) (see also AAN91365-n91371)
 CC
 XX Sequence 21 BP; 4 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 8.9e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 24 CTCTGCTACTCAGAGTTGCAA 44
 Db 1 CGCTGCTACTCGAGTTGCAA 21
 RESULT 1954
 AAQ33789
 ID AAQ33789 standard; DNA; 21 BP.
 XX
 AC AAQ33789;
 XX
 DT 25-MAR-2003 (revised)
 DT 02-FEB-1993 (first entry)
 XX
 DE Microsatellite sequence from clone TGLA2.
 XX
 KW PCR; selection; primers; OPTIPRM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.
 XX
 XX Bos taurus.
 OS
 PN WO9213102-A1.
 XX
 PD 06-AUG-1992.
 XX
 PF 15-JAN-1992; 92WO-US000340.
 XX
 PR 15-JAN-1991; 91US-00642342.
 XX
 XX (GENM-) GENMARK.
 XX

PI Georges M, Massey JM;
 XX
 DR WPI; 1992-284684/34.
 XX
 PT Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.
 XX
 PS Table 7; Page 245; 517pp; English.
 XX
 CC The sequence is that of a bovine microsatellite sequence obtd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved the determinism of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 23-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 21 BP; 0 A; 1 C; 10 G; 10 T; 0 U; 0 Other;
 Query Match 0.6%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 8.9e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 2729 TGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 1 TGTGTGTGTGTGTGTGTGTGTGT 21
 RESULT 1955
 AAZ27760
 ID AAZ27760 standard; DNA; 21 BP.
 XX
 AC AAZ27760;
 XX
 DT 23-DEC-1999 (first entry)
 DT
 DE PCR primer for human DNA marker clone C240.
 XX
 KW Tandem repeat sequence; DNA isolation; intermediate tandem repeat;
 KW ITR sequence; pentanucleotide tandem repeat; stutter artifact;
 KW DNA typing; DNA profiling; linkage analysis; criminal justice;
 KW paternity testing; animal lineage analysis; microsatellite loci;
 KW polymorphism detection; PCR primer; ss.
 OS
 XX Synthetic.
 OS Homo sapiens.
 OS
 PN WO9940194-A1.
 XX
 PD 12-AUG-1999.
 XX
 PF 04-FEB-1999; 99WO-US002345.
 XX
 PR 04-FEB-1998; 98US-00018584.
 XX
 PA (PROM-) PROMEGA CORP.
 XX
 PI Schumm JW, Bacher JW;
 XX WPI; 1999-590696/50.
 XX
 XX Isolating DNA containing intermediate tandem repeat sequences, useful in
 PT DNA profiling.
 XX

PS Claim 30; Page 20; 111pp; English.

XX This sequence is a PCR primer for a human DNA marker clone used in the method of the invention. The method is for isolating a fragment of DNA containing an intermediate tandem repeat (ITR) sequence using hybridization selection, and comprises: (a) providing several DNA fragments, at least one of which contains an ITR sequence, a region of the DNA fragment which contains at least one repeat unit consisting of a sequence of five, six or seven bases repeated in tandem at least two times; (b) providing a stationary support having at least one oligonucleotide associated with it, where the oligonucleotide includes a sequence of nucleotides which is complementary to a portion of the ITR sequence; and (c) combining the DNA fragments with the support under conditions where the DNA fragments including the DNA fragment containing the ITR sequence hybridize to the support. The method is particularly used to isolate DNA containing pentanucleotide tandem repeat sequences as well as to detect target ITR DNA sequences having a low incidence of stutter artifacts (no more than 2.4%). The method is useful in DNA profiling for linkage analysis, criminal justice, paternity testing and other forensic and medical uses. DNA typing is also useful for confirming the lineage of horses, dogs and other prize animals. The invention overcomes problems related to the use of microsatellite loci in DNA profiling. The method can detect polymorphisms with a low incidence of stutter artifacts, which has previously been a problem in interpreting allelic content of loci. The development of markers based on larger repeat units, enables easier separation of the fragments on electrophoretic gels. This allows the simultaneous analysis of more loci

XX Sequence 21 BP; 3 A; 10 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 8.9e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2837 CCTCCCACTTCAGCTCCCTGA 2857
 ||||| ||||| ||||| ||||| |||||
 Db 1 CCTCCCATTCAGCTCCCTGA 21

RESULT 1956
 ABS97829/c

ID ABS97829 standard; DNA; 21 BP.

XX ABS97829;

XX 23-DEC-2002 (first entry)

XX Human NADPH quinone oxidoreductase 2 (NQO2) polymorphic sequence #37.

XX Human; de; cytochrome P450 A1; CYP450A1; UGT2B4; MDR1;
 cytochrome P450 A2; CYP450A2; cytochrome P450 02E; CYP45002E1; LTF;
 adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
 aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
 glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
 HNMT; kallikrein 2; KUK2; nicotinamide-N-methyl transferase; NNMT;
 NADPH quinone oxidoreductase 2; NQO2; sulfoxyltransferase thermolabile; STM;
 UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; UPA;
 multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 multidrug resistance associated protein 3; cancer; prostate;
 acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
 altered drug metabolism; cardiovascular function; colorectal tumour;
 central nervous system; pulmonary; immunological; SNP;
 single nucleotide polymorphism.

XX Homo sapiens.

XX WO200257410-A2.

XX 25-JUL-2002.

PP 28-NOV-2001; 2001WO-US044838.

XX 28-NOV-2000; 2000US-00724389.

XX (DNAS-) DNA SCI LAB INC.

XX Guida M, Hall J;

PI WPI; 2002-698522/75.

XX Isolated nucleic acid molecules having polymorphisms in known human genes e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers for locating, identifying and characterizing the genes responsible for disorder-related traits.

XX Example 16; Page 130; 714pp; English.

XX This invention relates to the sequence of an isolated nucleic acid molecule comprising at least one base variation from that of a known human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2), cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADRB1), aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl transferase (HNMT), kallikrein 2) KUK2, nicotinamide -N-methyl sulfoxyltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4 (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl transferase (UGT2B15), urokinase receptor (UPA), multidrug resistance 1 (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3 (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence. The polymorphisms in the human genes cited in the invention are useful as genetic linkage markers for locating and characterizing the genes that are responsible for specific traits within the genome and eventually identifying the genes responsible for a variety of disorder-related traits as a result of their e.g., overexpression, constitutive expression, mutation or underexpression, which may be used in diagnosing and/or treating the disorders. The nucleic acid molecules comprising the polymorphic sequences contained in CYP450A1, CYP450A2, CYP4502E1, ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR, MDR1 and/or MDR3 are useful for screening individuals for altered drug metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2, AHR, MDR1 and/or MDR3 may also be used to screen individuals for susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are used to screen for altered cardiovascular function, in COX2 for altered susceptibility to colorectal tumours, in DBI or CHMR1 for altered central nervous system function, in FLAP and HNMT for altered pulmonary, immunological or haematological function, in KUK2 for altered serine protease activity in the prostate, in LTF for altered immunological or haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and peripheral nervous system function. The present sequence represents a polymorphic DNA sequence of the invention

XX Sequence 21 BP; 11 A; 9 C; 0 G; 1 T; 0 U; 0 Other;

QY 2729 TCTGTGTGTGTGTGTGTGTGTGTGT 2749
 ||||| ||||| ||||| ||||| |||||
 Db 21 TATGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 1957
 ABS97831/c

ID ABS97831 standard; DNA; 21 BP.

XX ABS97831;

XX 23-DEC-2002 (first entry)

Query Match 0.6%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 8.9e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

XX	Human NADPH quinone oxidoreductase 2 (NQO2) polymorphic sequence #39.
DE	
XX	Human; ds; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;
KW	cytochrome P450 A2; CYP450A2; cytochrome P450 O2E; CYP450O2E1; LTF;
KW	adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
KW	aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
KW	cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
KW	epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
KW	glutathione-S-transferase 12; GSTI2; histamine-N-methyl transferase;
KW	HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
KW	NADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermolabile; STM;
KW	UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
KW	UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
KW	multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
KW	multidrug resistance associated protein 3; cancer; prostate;
KW	acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
KW	altered drug metabolism; cardiovascular function; colorectal tumour;
KW	central nervous system; pulmonary; immunological; SNP;
KW	single nucleotide polymorphism.
XX	
XX	Homo sapiens.
XX	
PN	WO200257410-A2.
XX	
XX	25-JUL-2002.
PD	
XX	28-NOV-2001; 2001WO-US044838.
XX	
PF	28-NOV-2000; 2000US-00724389.
PR	
XX	(DNAS-) DNA SCI LAB INC.
PA	
XX	Guida M, Hall J;
PI	
XX	WPI; 2002-698522/75.
DR	
XX	Isolated nucleic acid molecules having polymorphisms in known human genes
PT	e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
PT	for locating, identifying and characterizing the genes responsible for
PT	disorder-related traits.

CC	used to screen for altered cardiovascular function, in COX2 for altered
CC	susceptibility to colorectal tumours, in PBI or CHMR1 for altered central
CC	nervous system function, in FLAP and HNMT for altered pulmonary,
CC	immunologic or haematological function, in KLK2 for altered serine
CC	protease activity in the prostate, in LTF for altered immunological or
CC	haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
CC	peripheral nervous system function. The present sequence represents a
CC	polymorphic DNA sequence of the invention
XX	
SQ	Sequence 21 BP; 11 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
Query Match	0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity	90.5%; Pred. No. 8.9e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0	
QY	2729 TGTGTTGGTGTGTATGCT 2749
Db	21 TGTATGTTGGTGTGTGCT 1
RESULT 1958	
ADB17019/c	
ID	ADB17019 standard; DNA; 21 BP.
XX	AC ADB17019;
XX	
DT	20-NOV-2003 (first entry)
XX	
DE	Degenerate PCR primer 419PC used to isolate propionin P1.
XX	
KW	PCR; primer; 419PC; ss; propionicin T1; operon; bacteriocin;
KW	ABC transporter; antibacterial; food processing; preservative; additive.
OS	Propionibacterium thoenii.
XX	
FH	Key Location/Qualifiers
FT	misc_binding 1..21
FT	/tag= a
FT	/bound moiety= "Propionicin T1"
FT	/note= "Binds to {seqid:10} at nucleotides 633-653"
XX	
PN	US2003096365-A1.
XX	
PD	22-MAY-2003.
XX	
PF	24-SEP-2002; 2002US-00252819.
XX	
PR	24-SEP-2001; 2001US-0324046P.
XX	
PA	(PAYE/) FAYE T.
PA	(HOLO/) HOLO H.
PA	(LANG/) LANGSRUD T.
PA	(NESI/) NES I.
XX	
PI	Faye T, Holo H, Langsrud T, Nes I;
XX	
DR	WPI; 2003-597336/56.
XX	
PT	New isolated propionicin T1 polypeptide and nucleic acid, useful for
PT	diagnosing and treating anaerobic bacterial infections, and/or for food
PT	manufacturing and processing as a preservative.
XX	
PS	Example; Page 8; 29pp; English.
XX	
CC	This invention relates to a characterisation of the propionin T1
CC	operon isolated from Propionibacterium thoenii. The operon contains two
CC	genes, namely the novel bacteriocin called propionicin T1 and an ABC
CC	transporter, which represents a putative immunity factor that increases
CC	resistance to the bacteriocin. Bacteriocins are antibacterial peptides
CC	that are useful for diagnosing and treating anaerobic bacterial
CC	infections caused by pathogenic bacteria, and can therefore also be
CC	useful during food processing and as a preservative, particularly for
CC	protecting fermented foods. Furthermore, purified and concentrated

CC bacteriocins can be used directly as food additives. In addition, the ABC
 CC transporter can also serve as a coregulated marker for expression of this
 CC genetic operon. This oligonucleotide sequence is a PCR primer known as
 CC 419PC that is bacteriocin specific and is used in an exemplification of
 CC the invention.

XX
 SQ Sequence 21 BP; 1 A; 5 C; 5 G; 10 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 8.9e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1610 AAAAGGGACCCCATGAAC 1630
 Db 21 AAAAGGGACCCCATGAAC 1

RESULT 1959
 ACA54779
 ID ACA54779 standard; DNA; 21 BP.

AC AC
 XX ACAS4779;

XX
 DT 05-JUN-2003 (first entry)

XX
 DE Human NF-kappaB associated polynucleotide PCR primer #36.

XX Human; nuclear factor-kappaB; NF-kappaB; immune disorder; cancer;
 KW inflammatory disorder; apoptosis; hepatic disorder; Hodgkin's lymphoma;
 KW haematopoietic tumour; hyper-IGM syndrome; viral infection; asthma;
 KW hypohidrotic ectodermal dysplasia; human immunodeficiency virus; HIV;
 KW X-linked anhidrotic ectodermal dysplasia; al incontinentia pigmenti;
 KW influenza; rheumatoid arthritis; inflammatory bowel disease; colitis;
 KW atherosclerosis; cachexia; euthyroid sick syndrome; stroke; EAB;
 KW experimental allergic encephalomyelitis; autoimmune disorder; wound;
 KW hyper immune activity; acute phase response; hypercongenital condition;
 KW birth defect; necrotic lesion; organ transplant rejection; pancreas;
 KW signal transduction; hyperproliferative disorder; diabetes mellitus;
 KW vitamin B12 malabsorption; neurological disorder; Huntington's chorea;
 KW Turner's syndrome; bacterial infection; cardiovascular disorder;
 KW infertility; psoriasis; haemolytic anaemia; antiinflammatory; anti-HIV;
 KW cytostatic; hepatotropic; virucide; antirheumatic; antiarthritic;
 KW antiasthmatic; immunomodulator; antidiabetic; antiallergic;
 KW neuroprotective; immunosuppressive; vulnery; antibacterial;
 KW antiinfertility; antianaemic; antipsoriatic; cerebroprotective; cardiant;
 KW antiarteriosclerotic; PCR; primer; ss.

OS Homo sapiens.

XX WO200286076-A2.

XX
 PD 31-OCT-2002.

XX
 XX 19-APR-2002; 2002WO-US012636.

XX
 PF 19-APR-2001; 2001US-0284962P.

XX
 PR 28-APR-2001; 2001US-0286645P.

XX
 PR 09-JAN-2002; 2002US-0346986P.

XX (BRIM) BRISTOL-MYERS SQUIBB CO.

XX Carman J, Feder J, Nadler S;

XX
 PI WPI; 2003-093119/08.

XX Novel NF-kappaB-associated polypeptides and polynucleotides useful for

XX diagnosing, treating and preventing cancer, hepatic disorders, aberrant

XX apoptosis, viral infections, autoimmune disorders, asthma and stroke.

XX Example 3; Page 341; 608pp; English.

XX The present invention relates to the isolation of human nuclear factor-

CC kappaB (NF-kappaB) associated polypeptides and polynucleotides. The NF-

CC kappaB associated polypeptide and polynucleotide sequences are useful for
 CC preventing, treating or ameliorating various disorders including immune
 CC disorders, inflammatory disorders, cancers, disorders relating to
 CC aberrant apoptosis, hepatic disorders, Hodgkin's lymphoma,
 CC haematopoietic tumours, hyper-IGM syndromes, hypohidrotic ectodermal
 CC dysplasia, X-linked anhidrotic ectodermal dysplasia, immunodeficiency, al
 CC incontinentia pigmenti, viral infections (e.g. those caused by human
 CC immunodeficiency virus (HIV), human T-cell lymphotropic virus (HTLV),
 CC hepatitis B, hepatitis C, Epstein Barr virus (EBV), influenza),
 CC rheumatoid arthritis, inflammatory bowel disease, colitis, asthma,
 CC atherosclerosis, cachexia, euthyroid sick syndrome, stroke, experimental
 CC allergic encephalomyelitis (EAE), autoimmune disorders, disorders related
 CC to hyper immune activity, disorders related to aberrant acute phase
 CC responses, hypercongenital conditions, birth defects, necrotic lesions,
 CC wounds, organ transplant rejection, disorders related to aberrant signal
 CC transduction, hyperproliferative disorders, diseases of the pancreas
 CC (e.g. diabetes mellitus, vitamin B12 malabsorption), neurological
 CC disorders (e.g. Huntington's chorea), Turner's syndrome, bacterial
 CC infections, cardiovascular disorders, infertility, psoriasis and
 CC haemolytic anaemia. The present sequence represents a PCR primer used in
 XX the examples of the present invention

SQ Sequence 21 BP; 4 A; 2 C; 9 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.8; DB 1; Length 21;

Best Local Similarity 90.5%; Pred. No. 8.9e+02;

Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2778 TGGAGTGCAAGTGGTGCAATCA 2798
 Db 1 TGGAGTGCAAGTGGTGATCA 21

RESULT 1960

ABV75846/c

ID ABV75846 standard; DNA; 21 BP.

AC ABV75846;

XX 05-FEB-2003 (first entry)

DE Human NF-kappaB RANK receptor reverse PCR primer.

XX RANK; receptor; osteoprotegerin; OPG; human; autoimmune disease;
 KW rheumatoid arthritis; diabetes; osteoarthritis; psoriasis;
 KW inflammatory bowel disease; transplant rejection; allergy;
 KW immunosuppressive; antirheumatic; antidiabetic;
 KW antipsoriatic; immunosuppressive; antiallergic; antiinflammatory;
 KW osteopathic; antiulcer; monocyte; NF-kappaB; PCR; primer; ss.

XX Homo sapiens.

XX WO200276507-A2.

XX 03-OCT-2002.

XX 06-FEB-2002; 2002WO-US001238.

XX 23-MAR-2001; 2001US-0278215P.

XX (GETH) GENENTECH INC.

XX Grewal I;

XX WPI; 2003-058352/05.

XX Stimulating mammalian monocytes by exposing to an OPG ligand polypeptide,
 PT useful for treating immune related disorders such as autoimmune disease,
 PT rheumatoid arthritis, diabetes, osteoarthritis, psoriasis, and allergy.

XX Example 12; Page 74; 111pp; English.

XX The present sequence is that of a reverse PCR primer for the human

CC receptor activator of NF-kappaB, RANK. A RANK primer/probe set (see also
 CC ABV75845 and ABV75847) was used in FACS assays conducted to examine the
 CC expression of osteoprotegerin ligand (OPGL) and RANK in various cells and
 CC tissues. The results showed that OPGL was able to stimulate RANK mRNA
 CC expression in monocytes in a dose-dependent manner. The invention
 CC provides methods of using OPGL or agonist RANK antibodies to activate
 CC monocytes to secrete chemokines or cytokines. Also provided are methods
 CC of using OPGL to treat conditions or diseases in mammals associated with,
 CC or resulting from lack of, or decreased, chemokine or cytokine secretion
 CC by monocytes. An antagonist comprising an anti-OPGL antibody, an anti-OPG
 CC receptor antibody, an anti-RANK receptor antibody, an OPG receptor
 CC immunoadhesin or a RANK receptor immunoadhesin is used in a claimed
 CC method of treating an immune-related condition, especially an autoimmune
 CC disease, rheumatoid arthritis, insulin dependent diabetes,
 CC osteoarthritis, inflammatory bowel disease (especially ulcerative colitis
 CC or Crohn's disease), psoriasis, transplant rejection or allergy
 XX
 SQ Sequence 21 BP; 5 A; 1 C; 11 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.8; DB 1; Length 21;
 Best Local Similarity 90.5%; Pred. No. 8.9e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2834 GATCCTCCGACCTCAGCTCC 2854

Db 21 GATCCTCCGACCTCAGCTTC 1

RESULT 1961

AAQ33716
 ID AAQ33716 standard; DNA; 22 BP.
 XX
 AC AAQ33716;
 XX
 DT 25-MAR-2003 (revised)
 DT 02-FEB-1993 (first entry)
 XX
 DE Microsatellite sequence from clone TGLA135.
 XX
 KW PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.
 XX
 OS Bos taurus.
 XX
 PN W09213102-A1.
 XX
 PD 06-AUG-1992.
 XX
 PF 15-JAN-1992; 92WO-US000340.
 XX
 PR 15-JAN-1991; 91US-00642342.
 XX
 PA (GENM-) GENMARK.
 XX
 PI Georges M, Massey JM;
 XX
 DR WPI; 1992-284684/34.
 XX
 PT Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.
 XX
 PS Table 7; Page 216; 517pp; English.

CC The sequence is that of a bovine microsatellite sequence obtd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)₁₅ and a (TC)₁₅ oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (TC)_n > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.

CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved in the determination of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX
 SQ Sequence 22 BP; 1 A; 0 C; 11 G; 10 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.8; DB 1; Length 22;
 Best Local Similarity 90.5%; Pred. No. 8.5e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2729 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749

Db 1 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 21

RESULT 1962

AAT71942/c
 ID AAT71942 standard; DNA; 22 BP.

XX
 AC AAT71942;
 XX
 DT 18-AUG-1997 (first entry)
 XX
 DE Primer detects marker 950-8 in HH region of chromosome 6p2.1.

XX
 KW Primer; polymerase chain reaction; amplify; hereditary haemochromatosis;
 KW HH; mutation; HH-associated allele; base-pair polymorphism; HHP-1;
 KW HHP-19; HHP-29; microsatellite repeat allele; Genetic marker;
 KW interferon treatment; hepatitis C infection; ss.
 XX
 OS Synthetic.
 XX
 PN W09635803-A1.
 XX
 PD 14-NOV-1996.
 XX
 PF 08-MAY-1996; 96WO-US006583.
 XX
 PR 08-MAY-1995; 95US-00436074.
 PR 15-NOV-1995; 95US-00559302.
 PR 09-FEB-1996; 96US-00599252.
 XX
 PA (MERC-) MERCATOR GENETICS INC.

XX
 PI Drayna DT, Feder JN, Gnirke A, Kimmel BE, Thomas WJ, Wolff RK;
 XX
 DR WPI; 1996-518691/51.

XX
 PT Diagnosing and genotyping of hereditary haemochromatosis (HH) - using
 PT primers to detect specific polymorphisms of the HH gene on chromosome
 PT 6p2.1 or novel microsatellite markers.

XX
 PS Claim 14; Page 15; 67pp; English.

CC The sequences given in AAT71901-72 represent a series of primer pairs
 CC which were used to determine the presence or absence of the common
 CC hereditary haemochromatosis (HH) gene mutation in an individual. The
 CC method comprises assessing genomic DNA from an individual for the
 CC presence or absence of the HH-associated allele of the base-pair
 CC polymorphism HHP-1, HHP-19 or HHP-29, and/or at least one non-optimal
 CC marker comprising the following microsatellite repeat alleles of group A
 CC and optionally of group B: Group A: 19D9(205), 18B4(235), 1A2(239),
 CC 1B4(271), 24E2(245), 2B8(206), 3321-1(197), 4073-1(182), 4440-1(180),
 CC 4440-2(139), 731-1(177), 5091-1(148), 3216-1(221), 4072-2(148), 950-
 CC 1(142), 950-2(164), 950-3(165), 950-4(128), 950-5(180), 950-6(151), 950-
 CC 8(165), 63-1(128), 63-2(169), 63-3(169), 65-1(206), 65-2(81), 373-8(151),
 CC 373-29(109), 68-1(167), 241-6(105), 241-29(113) Group B: D6S464(206),
 CC D6S306(238), D6S258(199), D6S265(122), D6S105(124) and D6S1001(180);
 CC where the number in brackets indicates the number of nucleotides between
 CC and including the flanking primers and the absence of the genotype

CC indicates the likelihood of the presence of the HH mutation. Knowledge of
 CC the new genetic markers allows the definition of genotypes characteristic
 CC of heterozygous carriers and homozygotes having a HH mutation in their
 CC genomic DNA. The potential for HH in an individual interferes with the
 CC effectiveness of interferon treatment for hepatitis C infection. By
 CC diagnosing this potential, the responsiveness of interferon treatment may
 CC be evaluated

XX SQ Sequence 22 BP; 6 A; 4 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.8; DB 1; Length 22;
 Best Local Similarity 90.5%; Pred. No. 8.5e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCTCCAGGCTG 2779
 ||| ||||| ||||| |||||
 Db 21 CTCACCTCTGTCTCCAGGCTG 1

RESULT 1963

AAI72014/c
 ID AAT72014 standard; DNA; 22 BP.

XX AC

XX AAT72014;

DT 18-AUG-1997 (first entry)

XX DE Primer detects marker 950-8 in HH region of chromosome 6p2.1.

XX KW Primer; polymerase chain reaction; amplify; hereditary haemochromatosis;
 KW HH; mutation; HH-associated allele; base-pair polymorphism; HHP-1;
 KW HHP-19; HHP-29; microsatellite repeat allele; Genetic marker;
 KW interferon treatment; hepatitis C infection; ss.

XX OS Synthetic.

XX PN WO9635802-A1.

XX PD 14-NOV-1996.

XX PF 06-MAY-1996; 96WO-US006352.

XX PR 08-MAY-1995; 95US-00436074.

XX PR 15-NOV-1995; 95US-0059302.

XX PR 09-FEB-1996; 96US-00599252.

XX PA (MERC-) MERCATOR GENETICS INC.

XX PI Drayna DT, Feder JN, Gnirke A, Kimmel BE, Thomas WJ, Wolff RK;

XX DR WPI; 1996-518690/51.

XX PT Determn. of the common hereditary haemochromatosis gene mutation - using
 PT primers based on novel microsatellite repeat flanking sequences or on
 PT base-pair polymorphisms HHP-1, HHP-19 or HHP-29.

XX PS Claim 14; Page 15; 67pp; English.

XX CC The sequences given in AAT71973-2044 represent a series of primer pairs
 CC which were used to determine the presence or absence of the common
 CC hereditary haemochromatosis (HH) gene mutation in an individual. The
 CC method comprises assessing genomic DNA from an individual for the
 CC presence or absence of the HH-associated allele of the base-pair
 CC polymorphism HHP-1, HHP-19 or HHP-29, and/or at least one non-optional
 CC marker comprising the following microsatellite repeat alleles of group A
 CC and optionally of group B: Group A: 19D9(205), 18B4(235), 1A2(239),
 CC 1E4(271), 24E2(245), 2B8(206), 3321-1(197), 4073-1(182), 4440-1(180),
 CC 4440-2(139), 731-1(177), 5091-1(148), 3216-1(221), 4072-2(148), 950-
 CC 1(142), 950-2(164), 950-3(165), 950-4(128), 950-5(180), 950-6(151), 950-
 CC 8(165), 63-1(128), 63-2(169), 63-3(169), 65-1(206), 65-2(81), 373-8(151),
 CC 373-29(109), 68-1(167), 241-6(105), 241-29(113) Group B: D6S464(206),
 CC D6S306(238), D6S258(199), D6S265(122), D6S105(124) and D6S1001(180);
 CC where the number in brackets indicates the number of nucleotides between

CC and including the flanking primers and the absence of the genotype
 CC indicates the likelihood of the presence of the HH mutation. Knowledge of
 CC the new genetic markers allows the definition of genotypes characteristic
 CC of heterozygous carriers and homozygotes having a HH mutation in their
 CC genomic DNA. The potential for HH in an individual interferes with the
 CC effectiveness of interferon treatment for hepatitis C infection. By
 CC diagnosing this potential, the responsiveness of interferon treatment may
 CC be evaluated

XX SQ Sequence 22 BP; 6 A; 4 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.8; DB 1; Length 22;
 Best Local Similarity 90.5%; Pred. No. 8.5e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCTCCAGGCTG 2779
 ||| ||||| ||||| |||||
 Db 21 CTCACCTCTGTCTCCAGGCTG 1

RESULT 1964

AAI64456/c

ID AAI64456 standard; DNA; 22 BP.

XX AC AAI64456;

XX DT 23-NOV-2001 (first entry)

XX DE SSR motif #16.

XX KW Simple Sequence Repeat; SSR; clover; microsatellite; genome mapping;
 KW trait mapping; marker-assisted selection; gene selection; legume;
 KW DNA profiling; breeding; ds.

XX OS Unidentified.

XX PN NZ509194-A.

XX PD 25-MAY-2001.

XX PF 03-JAN-2001; 2001NZ-00509194.

XX PR 24-DEC-1999; 99AU-00004907.

XX PR 28-MAR-2000; 2000AU-00006520.

XX PA (AGRI-) AGRIC VICTORIA SERVICES PTY LTD.

XX PI Koelliker R, Forster JW;

XX DR WPI; 2001-431058/46.

XX PT Novel simple sequence repeats in clover species useful for selection of
 PT genes in legume breeding, for profiling legume species varieties and for
 PT testing the purity of legume seed batches.

XX PS Claim 6; Page 35; 52pp; English.

XX CC The present invention relates to Simple Sequence Repeats (SSRs) from
 CC clover species. SSRs, also called microsatellites, are based on a 1-7
 CC nucleotide core element which is tandemly repeated. The SSR array is
 CC embedded in complex flanking DNA. SSRs are ideal markers for genome
 CC mapping, trait mapping and marker-assisted selection. The SSRs may be
 CC used in methods for selecting genes in clover/ legume breeding. The SSRs
 CC are also useful for DNA profiling of clover varieties and for testing the
 CC purity of legume seed batches. The present sequence is a SSR motif, which
 CC was used in the present invention

XX SQ Sequence 22 BP; 10 A; 12 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.8; DB 1; Length 22;
 Best Local Similarity 90.5%; Pred. No. 8.5e+02;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2749
 Db 22 TGTGTGTGTGTGTGTGTGT 2

RESULT 1965
 ABQ93654/c
 ID ABQ93654 standard; DNA; 22 BP.
 XX AC ABQ93654;
 XX 16-OCT-2002 (first entry)
 XX Human DISC1/DISC2 PCR primer disc41 r2.
 XX Human; Disrupted In Schizophrenia 1; DISC1; neuroleptic; gene therapy;
 KW neuropsychiatric disorder; schizoaffective disorder; bipolar disorder;
 KW unipolar affective disorder; adolescent conduct disorder; schizophrenia;
 KW PCR; primer; ss.
 XX Homo sapiens.
 XX WO200258637-A2.
 XX 01-AUG-2002.
 XX 23-JAN-2002; 2002WO-US002186.
 XX 24-JAN-2001; 2001US-00770107.
 XX (MILL-) MILLENIUM PHARM INC.
 XX Meyer JM, Barrington-Martin R, Parker A, Barnes GT;
 XX WPI; 2002-590791/63.
 XX New human Disrupted-In-Schizophrenia (DISC) 1 and DISC2 genes containing
 PT single nucleotide polymorphisms, useful for preventing or treating
 PT neuropsychiatric disorders e.g. schizophrenia.
 XX Claim 17; Fig 4; 169pp; English.
 XX The invention relates to a novel Disrupted-In-Schizophrenia (DISC) 1
 CC allelic variant polynucleotide. The polypeptides of the invention have
 CC neuroleptic activity. The polynucleotides may have a use in gene therapy.
 CC DISC1 or DISC2 nucleic acid molecules are useful for diagnosing or
 CC treating a subject having a disease or disorder associated with specific
 CC DISC1 or DISC2 alleles and/or aberrant DISC1 expression or activity e.g.
 CC neuropsychiatric disorder such as schizoaffective, bipolar, unipolar
 CC affective or adolescent conduct disorder or schizophrenia. Similarly, the
 CC compound that inhibits DISC1 protein activity may be used in the method
 CC for treating such neuropsychiatric disorders. The sequences shown in
 CC ABQ93575-ABQ93658 represent the PCR primers used in the invention to
 CC amplify the sequences of DISC2 and DISC2
 XX

QY 2784 GCAGTGTGCAATCATGTTTC 2804
 Db 21 GCAGTGTGCAATCATAGCTC 1

RESULT 1966
 AAQ33728
 ID AAQ33728 standard; DNA; 19 BP.
 XX AC AAQ33728;
 XX 25-MAR-2003 (revised)

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
 Db 1 TGTGTGTGTGTGTGTGTGT 19

RESULT 1967
 AAQ97343
 ID AAQ97343 standard; cDNA; 19 BP.
 XX AC AAQ97343;
 XX 19-JAN-1996 (first entry)
 XX Probe used for identifying ICAM-1 R241 allele.
 XX Inflammatory bowel disease; IBD; ICAM-1; ulcerative colitis;
 KW Crohn's disease; intracellular adhesion molecule; screening;
 KW identification; R241; ss.
 XX Synthetic.
 XX WO9521941-A1.

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
 Db 1 TGTGTGTGTGTGTGTGTGT 19

RESULT 1967
 AAQ97343
 ID AAQ97343 standard; cDNA; 19 BP.
 XX AC AAQ97343;
 XX 19-JAN-1996 (first entry)
 XX Probe used for identifying ICAM-1 R241 allele.
 XX Inflammatory bowel disease; IBD; ICAM-1; ulcerative colitis;
 KW Crohn's disease; intracellular adhesion molecule; screening;
 KW identification; R241; ss.
 XX Synthetic.
 XX WO9521941-A1.

DT 02-FEB-1993 (first entry)
 XX Microsatellite sequence from clone TGLA147.
 DE PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.
 XX Bos taurus.
 XX WO9213102-A1.
 XX 06-AUG-1992.
 XX 15-JAN-1992; 92WO-US000340.
 XX 15-JAN-1991; 91US-00642342.
 XX (GENM-) GENMARK.
 XX Georges M, Massey JM;
 XX WPI; 1992-284684/34.
 XX Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.
 XX Table 7; Page 221; 517pp; English.
 XX The sequence is that of a bovine microsatellite sequence obtd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved the determinism of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX Sequence 19 BP; 0 A; 0 C; 9 G; 10 T; 0 U; 0 Other;
 SX Query Match 0.8%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 1.1e+03;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTGT 2747
 Db 1 TGTGTGTGTGTGTGTGTGT 19

XX 17-AUG-1995.
PD 06-FEB-1995; 95WO-US001434.
XX 11-FEB-1994; 94US-00196003.
XX (CEDA-) CEDARS SINAI MEDICAL CENT.
XX Beaudet AL, Rotter JI, Targan SR, Yang H, Vora D;
XX WPI; 1995-293137/38.
XX Screening for inflammatory bowel disease, pref. ulcerative colitis - by
PT assaying a subject's nucleic acid for the presence of the R241 allele of
PT the ICAM-1 gene.
XX Example 2b; Page 34; 59pp; English.
XX A method for screening for inflammatory bowel disease (IBD) comprises
CC assaying nucleic acid from a subject for the presence or absence of the
CC R241 allele of the ICAM-1 gene, where the presence is indicative of IBD.
CC The method is useful for screening for the disease. The IBD is Crohn's
CC disease or ulcerative colitis. Two probes (AAQ97342, AAQ97343) were used
CC to identify the G241 and R241 allele of the ICAM-1 gene respectively
XX
XX Sequence 19 BP; 2 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 769 TCCTGACGGGCTGTCC 787
Db 1 TCCTGACAGGCTGTCC 19

RESULT 1968
AAT30412
ID AAT30412 standard; DNA; 19 BP.
AC
AC AAT30412;
XX
XX 28-JAN-1997 (first entry)
XX
XX Compound simple sequence repeat primer (GT)7.5(AT)2.
DE
XX
XX Detection; polymorphism; perfect compound simple sequence repeat;
KW adaptor directed primer; genome; genetic; fingerprinting;
KW amplified fragment length polymorphism assay; microsatellite region;
KW genetic trait marking; germplasm comparisons; compound; ss.
XX
XX Synthetic.
OS
XX WO9617082-A2.
XX
XX 06-JUN-1996.
PD
XX 21-NOV-1995; 95WO-US015150.
PF
XX 28-NOV-1994; 94US-00346456.
XX
XX (DUPO) DU PONT DE NEMOURS & CO E. I.
PA
XX Morgante M, Vogel JM;
XX WPI; 1996-277795/28.
XX
XX Modified amplified fragment length polymorphism assay - for detection of
PT polymorphism esp. in micro:satellite regions.
XX
XX Example 2; Page 84; 173pp; English..
XX

CC Detecting polymorphisms between 2 nucleic acid samples, esp. in
CC microsatellite regions, comprises digesting the nucleic acid to generate
CC fragments, ligating adaptor segments to their ends, amplifying them using
CC primer directed amplification and comparing the prods. to detect
CC differences. The primers used in the amplification comprise a primer
CC consisting of a perfect cpd. simple sequence repeat (SSR), and an adaptor
CC directed primer, comprising a sequence complementary to an adaptor
CC segment. The present sequence is an example of a compound SSR primer. The
CC method represents a modified amplified fragment length polymorphism
CC assay, which is partic. useful for genome fingerprinting, i.e. for
CC genetic trait marking and germplasm comparisons
XX
XX Sequence 19 BP; 2 A; 0 C; 7 G; 10 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2729 TGTGTGTGTGTGTGTATGT 2747
Db 1 TGTGTGTGTGTGTATAT 19

RESULT 1969
AAT66093/c
ID AAT66093 standard; DNA; 19 BP.
XX
XX AAT66093;
XX
XX 25-MAR-2003 (revised)
DT 18-JUN-1997 (first entry)
XX
XX Repeat sequence found in the haemoglobin gamma G gene.
DE
XX
XX Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW linkage analysis; genetic disease; animal; plant; breeding; locus;
KW hybridisation; chromosome; ds.
XX
XX Homo sapiens.
OS
XX US5582979-A.
PN
XX 10-DEC-1996.
PD
XX 04-APR-1994; 94US-00222177.
PF
XX 21-APR-1989; 89US-00341562.
PR
XX 05-SEP-1991; 91US-00754351.
XX
XX (MARS-) MARSHFIELD CLINIC.
PA
XX
XX Weber JL;
PI
XX WPI; 1997-042299/04.
XX
XX Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT using novel nucleic acid mols. as primers.
XX
XX Example 9; Col 59-60; 186pp; English.
XX
XX The invention relates to the isolation of polymorphic repeat sequences
CC having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
CC markers. Primers based on these sequences can be used to detect these
CC repeats, especially for use in e.g paternity or maternity testing, human
CC genetic analysis such as linkage analysis of genetic disease, commercial
CC animal or plant breeding or pedigree analysis. The sequences AAT66084-
CC T66107 represent repeat sequences of low informativeness found in
CC specific human genes. This repeat sequence is found in the haemoglobin
CC gamma G gene located at chromosomal position 1p15.5. The sequence is
CC amplified by primers AAT66094-5. (Updated on 25-MAR-2003 to correct PF
XX field.)
XX

SQ Sequence 19 BP; 10 A; 9 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2729 TGTGTGTGTGTGTATGT 2747
| | | | | | | | | | | | | | | | | | | | |
Db 19 TGTGTGTGTGTGTGTGT 1

RESULT 1970

AA191272
ID AAT91272 standard; DNA; 19 BP.

XX AAT91272;

XX 27-APR-1998 (first entry)

XX ICAM-1 Arg-241 allele-specific probe.

XX Intracellular adhesion molecule-1; ICAM-1; human; Crohn's disease;
XX ulcerative colitis; inflammatory bowel disease; diagnosis; probe; ss.

XX Synthetic.

OS Homo sapiens.

XX WO9739148-A1.

XX 23-OCT-1997.

XX 11-APR-1997; 97WO-US006064.

XX 12-APR-1996; 96US-00630672.

XX 15-AUG-1996; 96US-00689873.

XX (CEDA-) CEDARS SINAI MEDICAL CENT.

XX Targan SR, Vasiliaskas EA, Plevy SE, Yang H, Rotter JI;

XX WPI; 1997-526481/48.

XX Diagnosis of clinical sub-types of Crohn's disease - by detection of an
PT Arg 241 allele at an ICAM-1 locus to indicate disease with features of
PT ulcerative colitis.

XX Claim 5; Page 43; 56pp; English.

XX This oligonucleotide comprises an intracellular adhesion molecule-1 (ICAM
CC -1) Arg241 allele-specific probe that can be used in a claimed method of
CC diagnosing a clinical subtype of Crohn's disease (CD) that has features
CC of ulcerative colitis. A nucleic acid that includes nucleotide 721 of the
CC human ICAM-1 coding sequence (see AA191271) is isolated from a patient
CC sample. The nucleic acid is then contacted with the Arg241 allele-
CC specific probe, and the presence of a specific hybrid is determined. The
CC probe will form a hybrid with a nucleic acid that has adenine at
CC nucleotide 721 but not with a nucleic acid that has guanine at this
CC position. The invention is based on the discovery that the frequency of
CC the Arg-241 ICAM-1 allele is significantly higher in the perinuclear anti
CC -neutrophil antibody (pANCA)-positive subtype of CD than in CANCA-
CC positive or ANCA-negative subtypes. Seven 7-mer Arg241 allele-specific
CC oligonucleotide probes are also claimed

SQ Sequence 19 BP; 2 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 769 TCCTGGACGGGTGTTC 787
| | | | | | | | | | | | | | | | | | | | |
Db 1 TCCTGGACGGGTGTTC 19

RESULT 1971

AAV57826/c

ID AAV57826 standard; DNA; 19 BP.

XX AAV57826;

XX 18-NOV-1998 (first entry)

XX Human chromosome 18 PCR primer F for D18S378.

XX Manic-depressive illness; susceptibility; genotype; diagnosis;
XX chromosomal marker; polymorphic marker; chromosome 18; human;
XX myo-inositol monophosphatase protein; IMP-18p; PCR primer; ss.

XX Synthetic.

OS Homo sapiens.

XX WO9818963-A1.

XX 07-MAY-1998.

XX 28-OCT-1997; 97WO-US019381.

XX 28-OCT-1996; 96US-0029278P.

XX (USSH) US DEPT HEALTH & HUMAN SERVICES.

XX Detera-Wadleigh SD, Gershon ES, Badner JA, Goldin LR;

XX Berrettini WH, Yoshikawa T, Sanders AR, Esterling LE;

XX WPI; 1998-272247/24.

XX New isolated IMP-18p myo-inositol monophosphatase - used to develop
PT products for determining susceptibility to manic depressive illness and
PT as targets for preventive and therapeutic treatments.

XX Disclosure; Page 3; 118pp; English.

XX A method has been developed for determining a genotype associated with
CC increased susceptibility to manic-depressive (MD) illness. The method
CC comprises determining the genotype of an affected individual with at
CC least one polymorphic marker localised within the chromosomal region
CC defined by and including markers D18S843 and D18S869 and determining the
CC genotype associated with increased susceptibility to MD disorder. The
CC method can be used for determining susceptibility to MD illness including
CC bipolar disorder, genetic counselling of individuals from families
CC affected with MD illness, and aid in the differential diagnosis of MD
CC illness from other psychiatric pathologies. Products from the present
CC invention can also be used to obtain modulators of IMP-18p myo- inositol
CC monophosphatase protein activity and as targets for preventive and
CC therapeutic treatments. The present sequence represents a PCR primer from
CC Table 1 in the present invention (see AAV57798 to AAV57877)

SQ Sequence 19 BP; 6 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2760 TCGCTCTGTGTCACCCAGGCT 2778
| | | | | | | | | | | | | | | | | | | | |
Db 19 TTGCTCTGTGTCACCCAGGCT 1

RESULT 1972

AAZ89471/c

ID AAZ89471 standard; DNA; 19 BP.

XX AAZ89471;

XX 16-JUN-2000 (first entry)

XX

DE SSA primer 3 for amplifying A. thaliana and Z. mays DNA.
 XX Simple sequence repeat; SSR; single site amplification; SSA; disease;
 KW primer; ss.
 XX Arabidopsis thaliana.
 OS Zea mays.
 XX US6054300-A.
 PN 25-APR-2000.
 XX 21-AUG-1997; 97US-00915609.
 XX 21-AUG-1997; 97US-00915609.
 PR (USDA) US SEC OF AGRIC.
 PA Mckendree WL;
 XX WPI; 2000-328353/28.
 XX Obtaining unknown DNA sequence flanking a single known sequence for use
 CC as PCR templates, involves single site amplification with polymerase
 CC having strand displacement capability.
 CC Example 1; Col 9-10; lpp; English.
 CC This invention describes a novel method for obtaining DNA of unknown
 CC sequence flanking a single site of known sequence involves single site
 CC amplification of circular DNA template flanking a target DNA of known
 CC sequence using a polymerase having strand displacement capability. The
 CC method is used for obtaining a particular target DNA sequence that can be
 CC useful as templates that contain entire simple sequence repeat (SSR)
 CC alleles for amplification (SSA) procedures e.g. PCR or can be employed as
 CC molecular markers, e.g. in distinguishing between species, strains or
 CC varieties within species or identifying the presence of a disease
 CC condition. It also provides a marker for use in areas such as import and
 CC export regulation, variety and ecotype identification, marker
 CC development, forensic DNA fingerprinting, etc. The method can also be
 CC used to generate a linear DNA molecule containing two target sequences
 CC from one sequence within a single stranded DNA template and flanking
 CC regions for these target sequences. It can also be used for e.g. for
 CC cloning cDNA or genomic DNA which flanks any known short target sequence.
 CC The present method can also be used to obtain entire coding regions of
 CC genes based upon a known nucleic acid sequence or by using a degenerate
 CC nucleic acid sequence derived from amino acid sequence back translation
 CC using a polymerase having strand displacement capability which can
 CC synthesize up to 10 kb fragments. This is especially useful for obtaining
 CC plant genes which are usually less than 10 kb in length. The method
 CC allows accelerated development of high resolution DNA markers that may be
 CC used for fingerprinting, mapping etc., using small amounts of tissue
 CC (less than 1 mug). It also allows the production of a PCR template with
 CC knowledge of only one region of target DNA sequence, the size of which is
 CC regulated only by the primer design. The present method also eliminates
 CC genomic DNA library preparation and screening which are the most time
 CC consuming steps, typically requiring no less than three months, with
 CC total time for target DNA development being between 4-6 months. AAZ89469-
 CC 289474 represent primers used to illustrate the method of the invention
 XX Sequence 19 BP; 9 A; 10 C; 0 G; 0 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 1.1e+03;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GTGTGTGTGTGTGTGTATG 2746
 Db 19 GTGTGTGTGTGTGTGTG 1
 RESULT 1973
 AAZ89472

ID AAZ89472 standard; DNA; 19 BP.
 XX AAZ89472;
 AC 16-JUN-2000 (first entry)
 DT SSA primer 4 for amplifying A. thaliana and Z. mays DNA.
 XX Simple sequence repeat; SSR; single site amplification; SSA; disease;
 DE primer; ss.
 XX Arabidopsis thaliana.
 OS Zea mays.
 XX US6054300-A.
 PN 25-APR-2000.
 XX 21-AUG-1997; 97US-00915609.
 XX 21-AUG-1997; 97US-00915609.
 PR (USDA) US SEC OF AGRIC.
 PA Mckendree WL;
 XX WPI; 2000-328353/28.
 XX Obtaining unknown DNA sequence flanking a single known sequence for use
 CC as PCR templates, involves single site amplification with polymerase
 CC having strand displacement capability.
 CC Example 1; Col 9-10; lpp; English.
 CC This invention describes a novel method for obtaining DNA of unknown
 CC sequence flanking a single site of known sequence involves single site
 CC amplification of circular DNA template flanking a target DNA of known
 CC sequence using a polymerase having strand displacement capability. The
 CC method is used for obtaining a particular target DNA sequence that can be
 CC useful as templates that contain entire simple sequence repeat (SSR)
 CC alleles for amplification (SSA) procedures e.g. PCR or can be employed as
 CC molecular markers, e.g. in distinguishing between species, strains or
 CC varieties within species or identifying the presence of a disease
 CC condition. It also provides a marker for use in areas such as import and
 CC export regulation, variety and ecotype identification, marker
 CC development, forensic DNA fingerprinting, etc. The method can also be
 CC used to generate a linear DNA molecule containing two target sequences
 CC from one sequence within a single stranded DNA template and flanking
 CC regions for these target sequences. It can also be used for e.g. for
 CC cloning cDNA or genomic DNA which flanks any known short target sequence.
 CC The present method can also be used to obtain entire coding regions of
 CC genes based upon a known nucleic acid sequence or by using a degenerate
 CC nucleic acid sequence derived from amino acid sequence back translation
 CC using a polymerase having strand displacement capability which can
 CC synthesize up to 10 kb fragments. This is especially useful for obtaining
 CC plant genes which are usually less than 10 kb in length. The method
 CC allows accelerated development of high resolution DNA markers that may be
 CC used for fingerprinting, mapping etc., using small amounts of tissue
 CC (less than 1 mug). It also allows the production of a PCR template with
 CC knowledge of only one region of target DNA sequence, the size of which is
 CC regulated only by the primer design. The present method also eliminates
 CC genomic DNA library preparation and screening which are the most time
 CC consuming steps, typically requiring no less than three months, with
 CC total time for target DNA development being between 4-6 months. AAZ89469-
 CC 289474 represent primers used to illustrate the method of the invention
 XX Sequence 19 BP; 0 A; 0 C; 10 G; 9 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 1.1e+03;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GTGTGTGTGTGTGTATG 2746

DR WPI; 2002-144136/19.

XX Arraying genome clones.

XX Claim 4; Page 50; 528pp; Japanese.

CC The present invention describes a method of arraying genome clones. The method comprises: (a) clones of the genomic libraries contained in multiwell plates numbered for discrimination are mixed in each of the multiwell plates; (b) a primer designed based on the chromosome marker sequence is added to the mixture to carry out an amplification reaction; (c) a signal corresponding to the marker is detected from the resultant amplified product to specify the discrimination Nos. of the multiwell plates containing the clones having said marker sequence; (d) the order of the markers is changed so that the same discrimination Nos. succeed to the maximum in the specified discrimination Nos. to array the multiwell plates; (e) the clones in the multiwell plates of the specified discrimination Nos. are mixed respectively in each wells of longitudinal and lateral directions; (f) the mixed clones are cultured and the resultant cultures are amplified by using the above primer; (g) signals are detected from the amplified products; (h) the clones in the multiwell plates are specified from the detected result; and (i) the clones are reconstituted as the positions on the chromosome and arrayed. The microarray is useful for gene analysis. ABL42957 to ABL45322 represent PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634 represent PCR primers for human chromosome 21q22.1, which are specifically claimed for use in the present invention

XX Sequence 19 BP; 4 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.4; DB 1; Length 19;

Best Local Similarity 94.7%; Pred. No. 1.1e+03;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2770 ACCCAGCTGGAGTGAGT 2788

Db 19 ACCCAGCTGGAGTGAGT 1

RESULT 1979

AD69517 ADD69517 standard; DNA; 19 BP.

AC ADD69517;

DT 15-JAN-2004 (first entry)

XX ISSR-related PCR primer 4.

XX inter-simple sequence repeat; ISSR; SSR; PCR; primer; genotyping; plant; animal; Basmati rice; ss.

XX Unidentified.

XX WO2003085133-A2.

XX 16-OCT-2003.

XX 09-JAN-2003; 2003WO-IB000041.

XX 08-APR-2002; 2002IN-CH000260.

XX (DNAP-) CENT DNA FINGERPRINTING & DIAGNOSTICS.

XX Nagataju JG;

XX WPI; 2003-804317/75.

XX New set of inter-simple sequence repeats (ISSR)-PCR primers for genotyping eukaryotes, useful for genotyping diverse genomes of plant and animal systems.

XX Disclosure; Page 19; 60pp; English.

XX

CC The invention relates to a novel set of inter-simple sequence repeats (ISSR)-PCR primers for genotyping eukaryotes. The primers of the invention may be useful for genotyping diverse genomes of plant and animal systems, in particular for distinguishing Basmati rice varieties from non-Basmati rice varieties and traditional Basmati rice varieties from evolved Basmati rice varieties. The current sequence is that of the ISSR-related PCR primer of the invention.

XX Sequence 19 BP; 0 A; 0 C; 9 G; 10 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.4; DB 1; Length 19;

Best Local Similarity 94.7%; Pred. No. 1.1e+03;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2747

Db 1 TGTGTGTGTGTGTGTGTGT 19

RESULT 1980

ADF36100

ID ADF36100 standard; RNA; 19 BP.

XX ADF36100;

XX 12-FEB-2004 (first entry)

XX Human VSGFRI short interfering nucleic acid (siNA) SEQ ID NO:389.

XX double-stranded short interfering nucleic acid;

XX short interfering nucleic acid; siNA; downregulation;

XX vascular endothelial growth factor receptor; VEGFR; antiangiogenic;

XX cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;

XX nephrotropic; gynaecological; angiogenesis-associated condition; cancer;

XX diabetic retinopathy; macular degeneration; neovascular glaucoma;

XX arthritis; psoriasis; endometriosis; angiofibroma;

XX polycystic kidney disease; ss.

XX Synthetic.

XX Homo sapiens.

XX WO2003070910-A2.

XX 28-AUG-2003.

XX 20-FEB-2003; 2003WO-US005022.

XX 20-FEB-2002; 2002US-0358580P.

XX 11-MAR-2002; 2002US-0363124P.

XX 29-MAY-2002; 2002WO-US017674.

XX 06-JUN-2002; 2002US-0386782P.

XX 03-JUL-2002; 2002US-0393796P.

XX 29-JUL-2002; 2002US-0399348P.

XX 29-AUG-2002; 2002US-0406784P.

XX 05-SEP-2002; 2002US-0408378P.

XX 09-SEP-2002; 2002US-0409293P.

XX 04-NOV-2002; 2002US-00287949.

XX 27-NOV-2002; 2002US-00306747.

XX 15-JAN-2003; 2003US-0440129P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswiggen J, Beigelman L, Pavco P;

XX WPI; 2003-679876/64.

XX New double-stranded interfering nucleic acid, useful e.g. for treatment and diagnosis of cancer, downregulates the vascular endothelial growth factor receptor gene.

XX Example 3; SEQ ID NO 389; 207pp; English.

XX

PT Selecting genetic markers as targets for nucleic acid sequence

CC genetic engineering, pharmacogenomics, studying gene function and gene
 CC mapping (e.g. of single-nucleotide polymorphisms). The present sequence
 CC represents the upper strand of cyclin D1 targeted double stranded siNA
 CC which is identical to the cyclin D1 transcript target sequence.
 XX
 SQ Sequence 19 BP; 10 A; 9 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.6%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 1.1e+03;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTGT 2747
 DB 19 TGTGTGTGTGTGTGTGTGT 1
 RESULT 1985
 ADH71084
 ID ADH71084 standard; DNA; 19 BP.
 AC ADH71084;
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Human Vbeta microsatellite primer #27.
 XX
 KW human; T-cell associated disease; Vbeta; autoimmune disease;
 KW degenerative nervous system disease; graft versus host disease;
 KW hypersensitivity disease; infectious disease; neoplastic disease;
 KW Addison's disease; atrophic gastritis;
 KW degenerative nervous system disease; multiple sclerosis;
 KW Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
 KW allergy; type II hypersensitivity; Goodpasture's syndrome;
 KW type IV hypersensitivity; leprosy; infectious disease; viral infection;
 KW HIV; fungal infection; Candida; parasitic infection; schistosoma;
 KW filaria; bacterial infection; Mycobacterium; neoplastic disease;
 KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
 KW breast cancer; ss; primer; microsatellite.
 XX
 OS Homo sapiens.
 XX
 PN US2002150891-A1.
 XX
 PD 17-OCT-2002.
 XX
 PF 05-MAR-1999; 99US-00263959.
 XX
 PR 19-SEP-1994; 94US-00309335.
 PR 19-SEP-1995; 95US-00531241.
 XX
 PA (HOOD/) HOOD L E.
 PA (ROWE/) ROWEN L.
 XX
 PI Hood LE, Rowen L;
 XX
 DR WPI; 2004-059052/06.
 XX
 XX
 PT Kit for diagnosing and treating T-cell associated diseases e.g.
 PT autoimmune, degenerative nervous system and infectious disease, comprises
 PT nucleic acid primers specifically priming and allowing amplification of a
 PT Vbeta gene.
 XX
 PS Disclosure; SEQ ID NO 1278; 164pp; English.
 XX
 CC The invention relates to a kit for diagnosing and treating T-cell
 CC associated diseases which comprises a panel of nucleic acid primers
 CC specifically priming and allowing amplification of each Vbeta gene,
 CC VbetarRNA or cDNA. The kit is useful for diagnosing organ transplant
 CC rejection and diagnosing and treating T-cell associated diseases
 CC including autoimmune diseases, degenerative nervous system diseases,
 CC graft versus host disease, hypersensitivity diseases, infectious diseases
 CC and neoplastic diseases. Autoimmune diseases include Addison's disease,
 CC atrophic gastritis. Degenerative nervous system diseases include multiple

CC sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
 CC I hypersensitivities such as contact with allergens that lead to
 CC allergies, Type II hypersensitivities such as those present in
 CC Goodpasture's syndrome and Type IV hypersensitivities such as those
 CC manifested in leprosy. Infectious diseases include viral infections
 CC caused by viruses such as HIV, fungal infections such as those caused by
 CC the yeast genus Candida, parasitic infections such as those caused by
 CC schistosomes, filaria and bacterial infections such as those caused by
 CC Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
 CC such as leukaemias, lymphomas and cancers such as cancer of the brain,
 CC breast. The present sequence represents a Vbeta microsatellite primer.
 XX
 SQ Sequence 19 BP; 3 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 1.1e+03;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2846 TCAGCCTCCTGAGTAGCTG 2864
 DB 1 TCAGCCTCCTGAGTAGCTG 19
 RESULT 1986
 ADP09402
 ID ADP09402 standard; DNA; 19 BP.
 XX
 AC ADP09402;
 XX
 DT 26-AUG-2004 (first entry)
 XX
 DE Extend primer 24 used to genotype human LOC338749 polymorphism.
 XX
 KW breast cancer; cytostatic; gene therapy; human; LOC338749;
 KW chromosome 11p15.3; ss; PCR; primer; SNP; single nucleotide polymorphism.
 XX
 OS Homo sapiens.
 XX
 PN WO2004047767-A2.
 XX
 PD 10-JUN-2004.
 XX
 PF 25-NOV-2003; 2003WO-US037966.
 XX
 PR 25-NOV-2002; 2002US-0429136P.
 PR 24-JUL-2003; 2003US-0490234P.
 XX
 PA (SEQU-) SEQUENOM INC.
 XX
 PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
 XX
 DR WPI; 2004-441082/41.
 XX
 PT Identifying a subject at risk of breast cancer by detecting the presence
 PT or absence of one or more nucleotide polymorphic variations, useful for
 PT diagnosing, preventing and/or treating breast cancer.
 XX
 XX
 PS Example 6; Page 110; 286pp; English.
 XX
 CC The invention relates to a novel method for identifying a subject at risk
 CC of breast cancer which comprises detecting the presence or absence of one
 CC or more polymorphic variations associated with breast cancer in a nucleic
 CC acid sample from a subject. The method of the invention has cytostatic
 CC applications and may be useful for identifying a risk of breast cancer,
 CC as well as therapeutic and prophylactic treatments that specifically
 CC target breast cancer, such as gene therapy. The current sequence is that
 CC of a Extend primer of the invention which was used to genotype single
 CC nucleotide polymorphisms within human LOC338749 DNA which is located at
 CC chromosomal position 11p15.3.
 XX
 SQ Sequence 19 BP; 3 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 17.4; DB 1; Length 19;

```

Best Local Similarity 94.7%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2763 CTCTGTCAACCCAGGCTGGA 2781
Db 1 CTCTGTCAACCCAGGCTGGA 19

RESULT 1987
ADP45856/c
ID ADP45856 standard; DNA; 19 BP.
XX
AC ADP45856;
XX
DT 26-AUG-2004 (first entry)
XX
DE Extend primer 48 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.
XX
KW breast cancer; cytostatic; gene therapy; human;
KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
KW CD54; cell surface glycoprotein P3.58; ICAM-4;
KW Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
KW ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
XX
OS Homo sapiens.
XX
PN WO2004047623-A2.
XX
PD 10-JUN-2004.
XX
PF 25-NOV-2003; 2003WO-US037948.
XX
PR 25-NOV-2002; 2002US-0429136P.
XX
PR 24-JUL-2003; 2003US-0490234P.
XX
PA (SEQU-) SEQUENOM INC.
XX
PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX WPI; 2004-441051/41.
XX
PT Identifying a subject at risk of breast cancer by detecting the presence
PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
PT regions which are associated with breast cancer in a nucleic acid sample
PT from a subject.
XX
PS Example 4; Page 83; 289pp; English.
XX
CC The invention relates to a novel method for identifying a subject at risk
CC of breast cancer comprising detecting the presence or absence of one or
CC more polymorphic variations associated with breast cancer in a nucleic
CC acid sample from a subject. The method of the invention has cytostatic
CC applications and may be useful for identifying a subject at risk of
CC breast cancer, for early diagnosis, prevention and treatment of breast
CC cancer, possibly via gene therapy, as well as to analyse and predict a
CC response to a breast cancer treatment and in clinical drug trials. The
CC current sequence is that of an Extend primer (also described as probe) of
CC the invention which was used to genotype human intercellular adhesion
CC molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor;BB2
CC ;CD54;cell surface glycoprotein P3.58) has been mapped to chromosomal
CC position 19p13.3-p13.2, ICAM-4 (Landsteiner-Wiener blood group;LW) has
CC been mapped to chromosomal position 19p13.2-cen and ICAM-5
CC (telencephalin) has been mapped to chromosomal position 19p13.2.
XX
SQ Sequence 19 BP; 3 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2919 CAGAGACGGGGTCTCGCAA 2937
Db 19 CAGAGACGGGGTCTCGCAA 1

RESULT 1989
ADR80916
ID ADR80916 standard; DNA; 19 BP.
XX

```

```

RESULT 1988
ADP45855/c
ID ADP45855 standard; DNA; 19 BP.
XX
AC ADP45855;
XX
DT 26-AUG-2004 (first entry)
XX
DE Extend primer 47 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.
XX
KW breast cancer; cytostatic; gene therapy; human;
KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
KW CD54; cell surface glycoprotein P3.58; ICAM-4;
KW Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
KW ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
XX
OS Homo sapiens.
XX
PN WO2004047623-A2.
XX
PD 10-JUN-2004.
XX
PF 25-NOV-2003; 2003WO-US037948.
XX
PR 25-NOV-2002; 2002US-0429136P.
XX
PR 24-JUL-2003; 2003US-0490234P.
XX
PA (SEQU-) SEQUENOM INC.
XX
PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX WPI; 2004-441051/41.
XX
PT Identifying a subject at risk of breast cancer by detecting the presence
PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
PT regions which are associated with breast cancer in a nucleic acid sample
PT from a subject.
XX
PS Example 4; Page 83; 289pp; English.
XX
CC The invention relates to a novel method for identifying a subject at risk
CC of breast cancer comprising detecting the presence or absence of one or
CC more polymorphic variations associated with breast cancer in a nucleic
CC acid sample from a subject. The method of the invention has cytostatic
CC applications and may be useful for identifying a subject at risk of
CC breast cancer, for early diagnosis, prevention and treatment of breast
CC cancer, possibly via gene therapy, as well as to analyse and predict a
CC response to a breast cancer treatment and in clinical drug trials. The
CC current sequence is that of an Extend primer (also described as probe) of
CC the invention which was used to genotype human intercellular adhesion
CC molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor;BB2
CC ;CD54;cell surface glycoprotein P3.58) has been mapped to chromosomal
CC position 19p13.3-p13.2, ICAM-4 (Landsteiner-Wiener blood group;LW) has
CC been mapped to chromosomal position 19p13.2-cen and ICAM-5
CC (telencephalin) has been mapped to chromosomal position 19p13.2.
XX
SQ Sequence 19 BP; 3 A; 7 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2919 CAGAGACGGGGTCTCGCAA 2937
Db 19 CAGAGACGGGGTCTCGCAA 1

RESULT 1989
ADR80916
ID ADR80916 standard; DNA; 19 BP.
XX

```



```
AC ADR80916;
XX
XX
XX 16-DEC-2004 (first entry)
XX
XX Human glucose-6-phosphatase oligonucleotide seqid 5415.
XX
XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytotatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; glucose-6-phosphatase; ss.
XX
OS Homo sapiens.
XX
XX WO2004080406-A2.
XX
XX 23-SEP-2004.
XX
XX 08-MAR-2004; 2004WO-US0007070.
XX
XX 07-MAR-2003; 2003US-0452682P.
XX 12-MAR-2003; 2003US-0454265P.
XX 13-MAR-2003; 2003US-0454962P.
XX 14-APR-2003; 2003US-0455050P.
XX 17-APR-2003; 2003US-0462894P.
XX 25-APR-2003; 2003US-0463772P.
XX 28-APR-2003; 2003US-0465665P.
XX 29-APR-2003; 2003US-0465802P.
XX 03-MAY-2003; 2003US-0469612P.
XX 08-AUG-2003; 2003US-0493986P.
XX 11-AUG-2003; 2003US-0494597P.
XX 26-SEP-2003; 2003US-0506341P.
XX 09-OCT-2003; 2003US-0510246P.
XX 10-OCT-2003; 2003US-0510318P.
XX 07-NOV-2003; 2003US-0518453P.
XX
XX (ALNY-) ALNYLAM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
XX disease, diabetes, cancer or neurological disease, comprises sense
XX sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 5415; 378pp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
XX sense sequence and an antisense sequence, where the sense sequences have
XX one or more asymmetrical 2'-O alkyl modifications, the antisense
XX sequences have one or more asymmetrical phosphorothioate modifications
XX and the antisense sequence targets a human gene sequence. Also described
XX are: a pharmaceutical preparation comprising (I); reducing (MI) apoB-100
XX levels or glucose-6-phosphatase levels in a subject; producing (I);
XX stabilising (I), involves selecting a sequence with activity and
XX introducing one or more asymmetrical modification in the sequence, where
XX the modification decreases nuclease sensitivity while not decreasing its
XX activity; a kit comprising (I) and instructions for its use; and a device
XX that can be dispense or administer a composition comprising (I). (I) is
XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (MI)
XX is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
XX The subject is suffering from a disorder characterised by elevated or
XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX disorder is chosen from the HDL/LDL cholesterol imbalance,
XX dyslipidemias, hypercholesterolaemia, statin-resistant
XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to
```

```
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a human glucose-6-phosphatase antisense oligonucleotide that
CC can be used to control glucose-6-phosphatase gene expression.
XX
XX Sequence 19 BP; 4 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2765 TGTCAACCCAGGCTGGAGTG 2784
DB 1 TATCAACCCAGGCTGGAGTG 19
RESULT 1990
ADR80886
ID ADR80886 standard; DNA; 19 BP.
XX
XX ADR80886;
XX
XX 16-DEC-2004 (first entry)
XX
XX Human glucose-6-phosphatase oligonucleotide seqid 5385.
XX
XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytotatic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; glucose-6-phosphatase; ss.
XX
XX Homo sapiens.
XX
XX WO2004080406-A2.
XX
XX 23-SEP-2004.
XX
XX 08-MAR-2004; 2004WO-US0007070.
XX
XX 07-MAR-2003; 2003US-0452682P.
XX 12-MAR-2003; 2003US-0454265P.
XX 13-MAR-2003; 2003US-0454962P.
XX 14-APR-2003; 2003US-0455050P.
XX 17-APR-2003; 2003US-0462894P.
XX 25-APR-2003; 2003US-0463772P.
XX 28-APR-2003; 2003US-0465665P.
XX 29-APR-2003; 2003US-0465802P.
XX 03-MAY-2003; 2003US-0469612P.
XX 08-AUG-2003; 2003US-0493986P.
XX 11-AUG-2003; 2003US-0494597P.
XX 26-SEP-2003; 2003US-0506341P.
XX 09-OCT-2003; 2003US-0510246P.
XX 10-OCT-2003; 2003US-0510318P.
XX 07-NOV-2003; 2003US-0518453P.
XX
XX (ALNY-) ALNYLAM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
XX disease, diabetes, cancer or neurological disease, comprises sense
XX sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 5415; 378pp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
XX sense sequence and an antisense sequence, where the sense sequences have
XX one or more asymmetrical 2'-O alkyl modifications, the antisense
XX sequences have one or more asymmetrical phosphorothioate modifications
XX and the antisense sequence targets a human gene sequence. Also described
XX are: a pharmaceutical preparation comprising (I); reducing (MI) apoB-100
XX levels or glucose-6-phosphatase levels in a subject; producing (I);
XX stabilising (I), involves selecting a sequence with activity and
XX introducing one or more asymmetrical modification in the sequence, where
XX the modification decreases nuclease sensitivity while not decreasing its
XX activity; a kit comprising (I) and instructions for its use; and a device
XX that can be dispense or administer a composition comprising (I). (I) is
XX useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (MI)
XX is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
XX The subject is suffering from a disorder characterised by elevated or
XX otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX disorder is chosen from the HDL/LDL cholesterol imbalance,
XX dyslipidemias, hypercholesterolaemia, statin-resistant
XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to
```

Example 5; SEQ ID NO 5385; 378pp; English.

The invention describes a RNA interference (iRNA) agent (I) comprising a sense sequence and an antisense sequence, where the sense sequences have one or more asymmetrical 2'-O alkyl modifications, the antisense sequences have one or more asymmetrical phosphorothioate modifications and the antisense sequence targets a human gene sequence. Also described are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100 levels or glucose-6-phosphatase levels in a subject; producing (I); stabilising (I), involves selecting a sequence with activity and introducing one or more asymmetrical modification in the sequence, where the modification decreases nuclease sensitivity while not decreasing its activity; a kit comprising (I) and instruction for its use; and a device that can be dispense or administer a composition comprising (I). (I) is useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1) is useful for reducing apoB-100 levels or glucose-6-phosphatase levels. The subject is suffering from a disorder characterised by elevated or otherwise unwanted expression of apoB-100, elevated or otherwise unwanted levels of cholesterol, and/or dysregulation of lipid metabolism. The disorder is chosen from the HDL/LDL cholesterol imbalance, dyslipidaemias, hypercholesterolaemia, statin-resistant disease (CHD) and atherosclerosis. (I) is administered to a subject to inhibit hepatic glucose production or for treating glucose-metabolism-related disorder e.g. diabetes or type-2 diabetes. (I) is useful for treating the diseases as mentioned above, cancer (e.g. breast, colon or lung cancer), neurological disease (e.g., Huntington disease or spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence represents a human glucose-6-phosphatase antisense oligonucleotide that can be used to control glucose-6-phosphatase gene expression.

SEQ Sequence 19 BP; 3 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCTCAGTAGCT 2863

DB 1 CTCAGCCTCTCAGTAGCT 19

RESULT 1991

AD81681

ID AD81681 standard; DNA; 19 BP.

AC AD81681;

XX 16-DEC-2004 (first entry)

DE Hepatitis C virus (HCV) oligonucleotide seqid 6180.

XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
KW cytosolic; anticonvulsant; nootropic; muscula; anti-HIV;
KW RNA interference; iRNA; antisense technology; lipid metabolism;
KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.

OS Hepatitis C virus.

XX WO2004080406-A2.

XX 23-SEP-2004.

XX 08-MAR-2004; 2004WO-US007070.

XX 07-MAR-2003; 2003US-0452682P.

PR 12-MAR-2003; 2003US-0454265P.

PR 13-MAR-2003; 2003US-0454962P.

PR 13-MAR-2003; 2003US-0455050P.

PR 14-APR-2003; 2003US-0462894P.

PR 17-APR-2003; 2003US-0463772P.

PR 25-APR-2003; 2003US-0465665P.

PR 25-APR-2003; 2003US-0465802P.

PR 09-MAY-2003; 2003US-0469612P.

PR 08-AUG-2003; 2003US-0493986P.

PR 11-AUG-2003; 2003US-0494597P.

PR 26-SEP-2003; 2003US-0506341P.

PR 09-OCT-2003; 2003US-0510246P.

PR 10-OCT-2003; 2003US-0510318P.

PR 07-NOV-2003; 2003US-0518453P.

XX (ALNY-) ALNYLAM PHARM.

PA Manoharan M, Bumcrot D;

XX WPI; 2004-677362/66.

XX Interference RNA agent useful for treating dyslipidemias, coronary artery disease, diabetes, cancer or neurological disease, comprises sense sequence and antisense sequence which has specific modifications.

PS Example 5; SEQ ID NO 6180; 378pp; English.

CC The invention describes a RNA interference (iRNA) agent (I) comprising a sense sequence and an antisense sequence, where the sense sequences have one or more asymmetrical 2'-O alkyl modifications, the antisense sequences have one or more asymmetrical phosphorothioate modifications and the antisense sequence targets a human gene sequence. Also described are a pharmaceutical preparation comprising (I); reducing (M1) apoB-100 levels or glucose-6-phosphatase levels in a subject; producing (I); stabilising (I), involves selecting a sequence with activity and introducing one or more asymmetrical modification in the sequence, where the modification decreases nuclease sensitivity while not decreasing its activity; a kit comprising (I) and instruction for its use; and a device that can be dispense or administer a composition comprising (I). (I) is useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1) is useful for reducing apoB-100 levels or glucose-6-phosphatase levels. The subject is suffering from a disorder characterised by elevated or otherwise unwanted expression of apoB-100, elevated or otherwise unwanted levels of cholesterol, and/or dysregulation of lipid metabolism. The disorder is chosen from the HDL/LDL cholesterol imbalance, dyslipidaemias, hypercholesterolaemia, statin-resistant disease (CHD) and atherosclerosis. (I) is administered to a subject to inhibit hepatic glucose production or for treating glucose-metabolism-related disorder e.g. diabetes or type-2 diabetes. (I) is useful for treating the diseases as mentioned above, cancer (e.g. breast, colon or lung cancer), neurological disease (e.g., Huntington disease or spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence represents a human glucose-6-phosphatase antisense oligonucleotide that can be used to control HCV gene expression.

CC Sequence 19 BP; 0 A; 0 C; 2 G; 17 T; 0 U; 0 Other;
Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2900 TGATTTTTTTTTTTTTTTT 2918

DB 1 TGGTTTTTTTTTTTTTTT 19

RESULT 1992

AAT30427/C

ID AAT30427 standard; DNA; 20 BP.

XX AAT30427;

XX 28-JAN-1997 (first entry)

```

DE XX Compound simple sequence repeat primer (CA)4.5(TA)7.5.
KW XX Detection; polymorphism; perfect compound simple sequence repeat;
KW XX adaptor directed primer; genome; genetic; fingerprinting;
KW XX amplified fragment length polymorphism assay; microsatellite region;
KW XX genetic trait marking; germplasm comparisons; compound; ss.
XX XX
OS XX Synthetic.
XX XX
XX XX WO9617082-A2.
XX XX
XX XX 06-JUN-1996.
XX XX
XX XX 21-NOV-1995; 95WO-US015150.
XX XX
XX XX 28-NOV-1994; 94US-00346456.
XX XX
XX XX (DUPO ) DU PONT DE NEMOURS & CO E I.
XX XX
XX XX Morgante M, Vogel JM;
XX XX
XX XX WPI; 1996-277795/28.
XX XX
XX XX Modified amplified fragment length polymorphism assay - for detection of
XX XX polymorphism esp. in micro: satellite regions.
XX XX
XX XX Disclosure; Fig 1c; 173pp; English.
XX XX
XX XX Detecting polymorphisms between 2 nucleic acid samples, esp. in
XX XX microsatellite regions, comprises digesting the nucleic acid to generate
XX XX fragments, ligating adaptor segments to their ends, amplifying them using
XX XX primer directed amplification and comparing the prods. to detect
XX XX differences. The primers used in the amplification comprise a primer
XX XX consisting of a perfect cpd. simple sequence repeat (SSR), and an adaptor
XX XX directed primer, comprising a sequence complementary to an adaptor
XX XX segment. The present sequence is an example of a compound SSR primer. The
XX XX method represents a modified amplified fragment length polymorphism
XX XX assay, which is partic. useful for genome fingerprinting, i.e. for
XX XX genetic trait marking and germplasm comparisons
XX XX
XX XX Sequence 20 BP; 10 A; 7 C; 0 G; 3 T; 0 U; 0 Other;
XX XX
XX XX Query Match 0.6%; Score 17.4; DB 1; Length 20;
XX XX Best Local Similarity 94.7%; Pred. No. 1e+03;
XX XX Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX XX
Qy 2729 TGTGTGTGTGTGTGTGTGT 2747
Db 20 TGTGTGTGTGTGTGTAT 2

RESULT 1993
AAZ98503/C
ID AAZ98503 standard; DNA; 20 BP.
XX XX
XX XX AAZ98503;
XX XX
XX XX 19-JUN-2000 (first entry)
XX XX
XX XX H. discus derived sequence #21.
XX XX
XX XX Satellite sequence; DNA fragmentation; microsatellite DNA; DNA marker;
XX XX Haliotis discus; ss.
XX XX
XX XX Haliotis discus.
XX XX
XX XX WO200011156-A1.
XX XX
XX XX 02-MAR-2000.
XX XX
XX XX 01-JUL-1999; 99WO-JP003551.
XX XX
XX XX 18-AUG-1998; 98JP-00232153.
XX XX

(NORQ ) JAPAN MIN AGRIC FORESTRY & FISHERIES.
Takahashi H, Sekino M;
WPI; 2000-224692/19.
XX XX
XX XX Isolation of satellite sequences from genomic DNA for use as DNA markers
XX XX comprises isolating a library with high homogeneity by DNA fragmentation.
XX XX Example 5; Page 14; 35pp; Japanese.
XX XX
XX XX The invention provides a novel method for isolation of satellite
XX XX sequences from genomic DNA that comprises fragmentation of the DNA by a
XX XX method which is not dependent on base sequences, then selection of the
XX XX satellite sequences from the obtained genomic library of high
XX XX homogeneity. The method is useful for the isolation of microsatellite DNA
XX XX sequences which can be used as DNA markers. The new method markedly
XX XX improves the efficiency of isolation of satellite sequences in comparison
XX XX to prior art methods which are reliant on base sequences. Sequences
XX XX AAZ98483-514 represent sequences from Haliotis discus, used in the method
XX XX of the invention
XX XX
XX XX Sequence 20 BP; 11 A; 9 C; 0 G; 0 T; 0 U; 0 Other;
XX XX
XX XX Query Match 0.6%; Score 17.4; DB 1; Length 20;
XX XX Best Local Similarity 94.7%; Pred. No. 1e+03;
XX XX Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX XX
Qy 2731 TGTGTGTGTGTGTGTGTGT 2749
Db 20 TGTGTGTGTGTGTGTGTGT 2

RESULT 1994
AAF31814/C
ID AAF31814 standard; DNA; 20 BP.
XX XX
XX XX AAF31814;
XX XX
XX XX 10-APR-2001 (first entry)
XX XX
XX XX Human RANK antisense oligonucleotide, SEQ ID NO: 72.
XX XX
XX XX Human; cytostatic; antiinflammatory; antisense oligonucleotide; cancer;
XX XX receptor activator of NF-kappaB; RANK; infection; inflammation; ss.
XX XX
XX XX Homo sapiens.
XX XX
XX XX US6171860-B1.
XX XX
XX XX 09-JAN-2001.
XX XX
XX XX 05-NOV-1999; 99US-00435296.
XX XX
XX XX 05-NOV-1999; 99US-00435296.
XX XX
XX XX (ISIS-) ISIS PHARM INC.
XX XX
XX XX Baker BF, Cowser LM;
XX XX
XX XX WPI; 2001-136876/14.
XX XX
XX XX Novel antisense compounds capable of modulating expression of human
XX XX receptor activator of NF-kappaB useful for diagnosis, prophylaxis and
XX XX treatment of diseases associated with expression of RANK.
XX XX
XX XX Claim 14; Col 43; 40pp; English.
XX XX
XX XX The present sequence is one of a number of antisense compounds of 8 to 30
XX XX nucleobases in length that have been designed to target a 5'untranslated
XX XX region, start codon, coding region or 3'untranslated region of the human
XX XX receptor activator of NF-kappaB (RANK). The antisense compounds

```

CC specifically hybridise with and inhibit the expression of RANK. The
CC antisense oligonucleotides are useful for inhibiting the expression of
CC human RANK in human cells or tissues. They can be utilised for
CC diagnostics, therapeutics for the treatment of diseases associated with
CC the expression of RANK, prophylaxis e.g. to prevent or delay infection,
CC inflammation or tumour formation, and as research reagent. The antisense
CC compounds are safely and effectively administered to humans
XX
SQ Sequence 20 BP; 4 A; 10 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1e+03; Mismatches 0; Gaps 0;

Matches 18; Conservative 0; Indels 1; Indels 0; Gaps 0;

Qy 2775 GGCTGGAGTGCAGTGGTGC 2793

Db 20 GGCTAGAGTGCAGTGGTGC 2

RESULT 1995

AAD12408/c

ID AAD12408 standard; DNA; 20 BP.

XX AAD12408;

XX 25-SEP-2001 (first entry)

XX Human caspase 8 mRNA antisense compound ISIS 107686.

XX Caspase 8; infection; inflammation; tumour; research reagent; cytostatic;
XX gene therapy; antisense; human; phosphorothioate; ss.

XX Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone"

FT modified_base 1..5

FT /*tag= b

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified_base 2

FT /*tag= d

FT /mod_base= m5c

FT modified_base 4

FT /*tag= e

FT /mod_base= m5c

FT modified_base 5

FT /*tag= f

FT /mod_base= m5c

FT modified_base 7

FT /*tag= g

FT /mod_base= m5c

FT modified_base 10

FT /*tag= h

FT /mod_base= m5c

FT modified_base 12

FT /*tag= i

FT /mod_base= m5c

FT modified_base 14

FT /*tag= j

FT /mod_base= m5c

FT modified_base 15

FT /*tag= k

FT /mod_base= m5c

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified_base 18

FT /*tag= 1

FT /mod_base= m5c

FT modified_base 19

FT /*tag= m

FT /mod_base= m5c

XX US6258600-B1.

XX 10-JUL-2001.

XX 19-JAN-2000; 2000US-00487445.

XX 19-JAN-2000; 2000US-00487445.

XX (ISIS-) ISIS PHARM INC.

XX Zhang H, Cowsett LM;

XX WPI; 2001-432165/46.

XX New antisense compounds capable of modulating expression of caspase 8 for

XX the diagnoses, prophylaxis and treatment of diseases associated with

XX expression of caspase 8, e.g. inflammation and tumor formation.

XX Example 15; Col 45-46; 56pp; English.

XX The invention relates to antisense compounds which inhibit the expression

XX of human caspase 8. The antisense compound is useful for diagnosing and

XX treating diseases associated with the expression of caspase 8 and for

XX prophylaxis e.g. to prevent or delay infection, inflammation or tumour

XX formation, and as a research reagent. The present sequence is an

XX antisense compound targeted to human caspase 8 mRNA

XX Sequence 20 BP; 4 A; 10 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.4; DB 1; Length 20;

Best Local Similarity 94.7%; Pred. No. 1e+03;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2774 AGGCTGGAGTGCAGTGGTGC 2792

Db 20 AGGCTGGAGTGCAGTGGCG 2

RESULT 1996

ABA99517

ID ABA99517 standard; DNA; 20 BP.

XX ABA99517;

XX 17-MAY-2002 (first entry)

XX Human tumour-associated antigen B345 probe SEQ ID NO 14.

XX Tumour-associated antigen; human; B345; cytostatic; cell communication;

XX cell interaction; signal transduction; metastasis; cancer; colon;

XX immunotherapy; carcinoma; lung; diagnosis; probe; ss.

XX Homo sapiens.

XX WO200204508-A1.

XX 17-JAN-2002.

XX 05-JUL-2001; 2001WO-BF007705.

XX 07-JUL-2000; 2000DE-01033080.

XX 19-APR-2001; 2001DE-01019294.

XX (BOEH) BOEHRINGER INGELHEIM INT GMBH.

XX Schweifer N, Scherl-Mostageer M, Sommergruber W, Abseher R;

XX

DR WPI; 2002-171704/22.
 XX
 PT New tumor-associated antigen B345, useful for diagnosis and immunotherapy
 PT of tumors, also related nucleic acid and antibodies.
 XX
 PS Example 6; Page 90; 102pp; German.
 XX
 CC This invention describes a novel tumour-associated antigen, designated
 CC B345 which has cytostatic activity. B345 is involved in communication,
 CC interaction and/or signal transduction with extracellular components and
 CC ligands, especially in the metastatic potential of cancers, particularly
 CC of the colon. B345 or its immunogenic fragments, also the DNA that
 CC encodes it, are useful for immunotherapy of cancer, particularly
 CC carcinoma of lung or colon. Antibodies raised against B345 are useful for
 CC treatment and diagnosis of cancers that are associated with B345
 CC expression, including their use for targeted delivery of cytotoxic or
 CC radioactive agents. Probes derived from B345 can be used to detect tumour
 CC -specific mutations in the B345 sequence, and can be used to screen for
 CC B345 specific modulators. This sequence represents a probe used in the
 CC isolation of the human B345 tumour-associated antigen described in the
 CC invention
 XX
 SQ Sequence 20 BP; 4 A; 10 C; 1 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 17.4; DB 1; Length 20;
 Best Local Similarity 94.7%; Pred. No. 1e+03; Mismatches 0; Indels 0; Gaps 0;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2835 ATCTCCCACTCAGCCTC 2853
 |||||
 DB 2 ATCTCCCACTCAGCCTC 20
 RESULT 1997
 ADD25037/c
 ID ADD25037 standard; DNA; 20 BP.
 XX
 AC ADD25037;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Human caspase-8 antisense oligonucleotide ISIS 107686.
 XX
 KW Caspase-8; cytostatic; immunosuppressant; anti-HIV; ss;
 KW antisense gene therapy; apoptosis; hyperproliferative disorder;
 KW haematopoietic disorder; autoimmune disorder; viral infection; AIDS;
 KW neurological disorder; Alzheimer's disease; Parkinson's disease;
 KW amyotrophic lateral sclerosis; retinitis pigmentosa; blood cell disorder;
 KW cancer; human.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone and all cytidines are 5
 -methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl residues"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl residues"
 XX
 PN US2003083296-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 12-JUL-2002; 2002US-00181177.
 XX

PR 19-JAN-2000; 2000US-00487445.
 PR 11-JAN-2001; 2001WO-US000955.
 XX
 PA (ZHAN/) ZHANG H.
 PA (CONS/) COWSERT L M.
 XX
 PI Zhang H, Cowsert LM;
 XX
 XX WPI; 2003-810793/76.
 DR
 XX
 PT New compounds, particularly antisense oligonucleotides targeted to a
 PT nucleic acid encoding caspase 8, useful for treating a disease/condition
 PT associated with caspase 8, such as hyperproliferative or autoimmune
 PT disorders.
 PT
 PS Example 15; SEQ ID NO 94; 59pp; English.
 XX
 CC The invention relates to a compound 8-30 nucleobases in length targeted
 CC to, and which specifically hybridises with a nucleic acid molecule
 CC encoding caspase 8 (a protein involved in apoptosis), and inhibits the
 CC expression of caspase 8, i.e. an antisense oligonucleotide. Also included
 CC are a compound 8-30 nucleobases in length that specifically hybridises
 CC with at least an 8-nucleobase portion of an active site on a nucleic acid
 CC molecule encoding caspase 8, a composition comprising the compound and a
 CC carrier or diluent, inhibiting the expression of caspase 8 in cells or
 CC tissues (by contacting the cells or tissues with the compound so that
 CC expression of caspase 8 is inhibited) and treating an animal having a
 CC disease or condition associated with caspase 8 by administering to the
 CC animal a therapeutic or prophylactic amount of the compound so that
 CC expression of caspase 8 is inhibited. The compound, composition and
 CC methods are useful for treating a disease or condition associated with
 CC caspase 8, such as hyperproliferative, hematopoietic or autoimmune
 CC disorder, viral infection such as AIDS, neurological disorders (e.g.
 CC Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis,
 CC retinitis pigmentosa), blood cell disorders and cancer. They are also
 CC useful in research and diagnostics for modulating the expression of
 CC interleukin 8. The present sequence is a caspase-8 targeting antisense
 CC oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 4 A; 10 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 17.4; DB 1; Length 20;
 Best Local Similarity 94.7%; Pred. No. 1e+03; Mismatches 0; Indels 0; Gaps 0;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2774 AGGCTGGAGTCAGTCAGTCGTG 2792
 |||||
 DB 20 AGGCTGGAGTCAGTCAGTCGCG 2
 RESULT 1998
 ABZ84919/c
 ID ABZ84919 standard; DNA; 20 BP.
 XX
 AC ABZ84919;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; anti-allergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX

PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Claim 15; SEQ ID NO 161; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2840 CCCACCTCAGCCTCCTGAG 2858
Db 19 CCCATCTCAGCCTCCTGAG 1

RESULT 1999
ABZ97909
ID ABZ97909 standard; DNA; 20 BP.
XX
AC ABZ97909;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human RANTES oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN W0200285308-A2.
XX
PD 31-OCT-2002.
XX

PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 13151; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2850 CCTCCTGACTGCTGGGAC 2868
Db 1 CCTCCGAGTAGCTGGGAC 19

RESULT 2000
ABD30940
ID ABD30940 standard; DNA; 20 BP.
XX
AC ABD30940;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human RANTES-derived oligonucleotide SEQ ID 13151.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW anaesthetic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN W0200285309-A2.
XX

PD 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 XX
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 XX
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13151; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 17.4; DB 1; Length 20;
 Best Local Similarity 94.7%; Pred. No. 1e+03;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2850 CCTCTGAGTAGCTGGAC 2868
 ||||| ||||| ||||| ||||| |||||
 Db 1 CCTCCGAGTAGCTGGAC 19
 RESULT 2001
 ABD21149/c
 ID ABD21149 standard; DNA; 20 BP.
 XX
 AC ABD21149;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 XX Human transglutaminase-derived oligo SEQ ID 161.
 XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;

KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 161; 763pp; English.
 PS
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 XX Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 17.4; DB 1; Length 20;
 Best Local Similarity 94.7%; Pred. No. 1e+03;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2840 CCCACTGAGCTCTCTGAG 2858
 ||||| ||||| ||||| ||||| |||||
 Db 19 CCCATCTCAGCTCTCTGAG 1

```

RESULT 2002
ADJ59774
ID ADJ59774 standard; DNA; 20 BP.
XX
XX
AC ADJ59774;
XX
XX
DT 06-MAY-2004 (first entry)
XX
XX
DE Oligonucleotide associated to RANTES #23.
XX
XX
KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
KW airway inflammation; allergy; asthma; impeded respiration;
KW cystic fibrosis; acute respiratory distress syndrome;
KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
XX
XX
OS Homo sapiens.
XX
XX
PN WO2004011613-A2.
XX
XX
PD 05-FEB-2004.
XX
XX
PF 25-JUL-2003; 2003WO-US023509.
XX
XX
PR 29-JUL-2002; 2002US-0399076P.
XX
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
XX
PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX
DR WPI; 2004-203534/19.
XX
XX
PT Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codons and introns of respiratory disease-relevant genes e.g.,
PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
PT disease e.g., asthma.
XX
XX
PS Claim 2; SEQ ID NO 630; 85pp; English.
XX
XX
CC The present invention relates to an oligonucleotide anti-sense to e.g.,
CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
CC end of nucleic acid target comprising gene(s) chosen from e.g.
CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
CC oligonucleotide and optionally surfactant operatively linked to the
CC oligonucleotide. The method is useful for preventing or treating a
CC respiratory or lung disease, which involves administering to the airways
CC of a subject an effective amount of an inhibitor. The oligonucleotide is
CC useful for production of a medicament for the prevention and/or treatment
CC of a respiratory or lung disease. The respiratory or lung disease is
CC chosen from airway inflammation, allergy(ies), asthma, impeded
CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
CC obstruction. The present sequence represents an oligonucleotide of the
XX
XX
SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;

Query Match          0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2850 CCTCTGAGTAGCTGGAC 2868
    |||||
DB 1 CCTCCCGAGTAGCTGGAC 19

RESULT 2003
ADM15156/c
ID ADM15156 standard; DNA; 20 BP.
XX

```

```

AC ADM15156;
XX
XX
DT 01-JUL-2004 (first entry)
XX
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1343.
XX
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX
XX
OS Homo sapiens.
XX
XX
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
XX
WO2004028458-A2.
XX
XX
PD 08-APR-2004.
XX
XX
PF 25-SEP-2003; 2003WO-US030374.
XX
XX
PR 25-SEP-2002; 2002US-0413549P.
XX
XX
PA (PHAA ) PHARMACIA CORP.
XX
XX
PI Gierse JK;
XX
XX
DR WPI; 2004-305094/28.
XX
XX
PS New antisense compound, having a sequence targeted to a nucleic acid
PS encoding mPGES-1, useful for preparing a composition for treating e.g.,
PS inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PS ischemia.
XX
XX
PS Claim 4; SEQ ID NO 1343; 132pp; English.
XX
XX
CC The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC anti-diabetic, immunomodulatory, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.

```



```

XX SQ Sequence 20 BP; 11 A; 7 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
Db 20 TGTATGTGTGTGTGTGTGT 2

RESULT 2004
ADM14911/c
ID ADM14911 standard; DNA; 20 BP.
XX AC ADM14911;
XX DT 01-JUL-2004 (first entry)
XX DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1098.
XX KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 1..20 /*tag= b
XX FT /*mod_base= OTHER
XX FT /*note= "phosphorothioate linkages and all cytidine
XX FT residues are 5-methylcytidines"
XX FT modified_base 1..5 /*tag= a
XX FT /*mod_base= OTHER
XX FT /*note= "2'-O-methoxyethyls"
XX FT modified_base 16..20 /*tag= c
XX FT /*mod_base= OTHER
XX FT /*note= "2'-O-methoxyethyls"
XX PN WO2004028458-A2.
XX PD 08-APR-2004.
XX PF 25-SEP-2003; 2003WO-US030374.
XX PR 25-SEP-2002; 2002US-0413549P.
XX (PHAA ) PHARMACIA CORP.
XX PA Gierse JK;
XX PI WPI; 2004-305094/28.
XX DR
XX PT New antisense compound, having a sequence targeted to a nucleic acid
XX PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX PT ischemia.
XX PS Claim 4; SEQ ID NO 1098; 132pp; English.
XX CC The present sequence represents a chimeric antisense oligonucleotide
XX CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The

```

```

CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytosolic,
CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX SQ Sequence 20 BP; 8 A; 8 C; 2 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2722 ATCCGGTGTGTGTGTGTGTG 2740
Db 19 ATCCGGTGTGTGTGTGTGTG 1

RESULT 2005
ADM14675/c
ID ADM14675 standard; DNA; 20 BP.
XX AC ADM14675;
XX DT 01-JUL-2004 (first entry)
XX DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:862.
XX KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW immunomodulatory; cardiovascular; gene therapy; inflammation;
KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW reperfusion injury; ophthalmic disorder; immunological disorder;
KW cardiovascular disorder; neurological disorder; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 1..20 /*tag= b
XX FT /*mod_base= OTHER
XX FT /*note= "phosphorothioate linkages and all cytidine
XX FT residues are 5-methylcytidines"
XX FT modified_base 1..5 /*tag= a
XX FT /*mod_base= OTHER
XX FT /*note= "2'-O-methoxyethyls"
XX FT modified_base 16..20 /*tag= c
XX FT /*mod_base= OTHER
XX FT /*note= "2'-O-methoxyethyls"
XX PN WO2004028458-A2.
XX PD 08-APR-2004.
XX PF 25-SEP-2003; 2003WO-US030374.
XX PR 25-SEP-2002; 2002US-0413549P.

```

XX	(PHAA) PHARMACIA CORP.
XX	Gierse JK;
XX	WPI; 2004-305094/28.
XX	New antisense compound, having a sequence targeted to a nucleic acid
XX	encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX	inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX	ischemia.
XX	Claim 4; SEQ ID NO 862; 132pp; English.
XX	The present sequence represents a chimeric antisense oligonucleotide
XX	targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX	human mPGES-1 gene is located on chromosome 9, more specifically to
XX	9q34.3. The present invention also describes: (1) antisense compounds,
XX	having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX	mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX	inhibits its expression; (2) a method of inhibiting the expression of
XX	mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX	having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX	antisense oligonucleotides and antisense compounds have cytostatic,
XX	antidiabetic, immunomodulatory, cardiant, neuroprotective,
XX	antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX	CC ophthalmological, immunomodulatory and cardiovascular activities, and can
XX	be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX	can be used for preparing a composition for treating a disease or
XX	condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX	disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX	CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX	Sequence 20 BP; 5 A; 3 C; 11 G; 1 T; 0 U; 0 Other;
QY	2838 CTCCTACCTCAGCTCTCTG 2856
DB	19 CTCCTACCTCAGCTCTCTG 1
RESULT 2006	
ADM15440/C	
ID	ADM15440 standard; DNA; 20 BP.
XX	ADM15440;
AC	
DT	01-JUL-2004 (first entry)
XX	Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1627.
DE	chimeric; antisense oligonucleotide; phosphorothioate; human;
XX	microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW	microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
KW	immunomodulator; cardiant; neuroprotective; antiinflammatory;
KW	neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KW	immunomodulatory; cardiovascular; gene therapy; inflammation;
KW	Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KW	reperfusion injury; ophthalmic disorder; immunological disorder;
KW	cardiovascular disorder; neurological disorder; sg.
XX	
OS	Homo sapiens.
OS	Synthetic.
XX	
XX	Key
FT	modified_base 1..20
FT	Location/Qualifiers
FT	1..20
FT	/mod_base= OTHER
FT	/note= "phosphorothioate linkages and all cytidine
FT	residues are 5-methylcytidines"

```

modified_base 1. 5
/*tag= a
/mod_base= OTHER
modified_base 16. 20
/*tag= C
/mod_base= OTHER
/note= "2'-O-methoxyethyls"
W02004028458-A2.
08-APR-2004.
25-SEP-2003; 2003WO-US030374.
25-SEP-2002; 2002US-0413549P.
(PHAA ) PHARMACIA CORP.
Gierse JK;
WPI; 2004-305094/28.
New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
Claim 4; SEQ ID NO 1627; 132pp; English.
The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX Sequence 20 BP; 10 A; 8 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 0.68; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0
Qy 2731 TGTGTGTGTGTGTGTGTGT 2749
Db 20 TGTGTGTGTGTGTGTGTGT 2
RESULT 2007
ADM14780/C
ID ADM14780 standard; DNA; 20 BP.
XX
XX ADM14780;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:967.
DE
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;

```


CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 9 A; 7 C; 2 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 17.4; DB 1; Length 20;
 Best Local Similarity 94.7%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2727 CGTGTGTGTGTGTGTAT 2745
 |||||
 Db 19 CGTGTGTGTGTGTGTAT 1
 RESULT 2009
 ADM15318/C
 ID ADM15318 standard; DNA; 20 BP.
 XX
 AC ADM15318;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1505.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT
 FT
 XX WO2004028458-A2.
 XX
 XX
 PD 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 XX
 XX 25-SEP-2002; 2002US-0413549P.
 PR
 XX (PHAA) PHARMACIA CORP.
 PA
 XX Gierse JK;
 XX
 XX WPI; 2004-305094/28.
 DR
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,

PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 XX
 PS Claim 4; SEQ ID NO 1505; 132pp; English.
 XX
 CC The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 CC
 XX Sequence 20 BP; 10 A; 8 C; 0 G; 2 T; 0 U; 0 Other;
 SQ
 Query Match 0.6%; Score 17.4; DB 1; Length 20;
 Best Local Similarity 94.7%; Pred. No. 1e+03; 1; Indels 0; Gaps 0;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2728 GTGTGTGTGTGTGTGTATG 2746
 |||||
 Db 19 GTGTGTGTGTGTGTGTATG 1
 RESULT 2010
 ADO45264
 ID ADO45264 standard; DNA; 20 BP.
 XX
 AC ADO45264;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #630.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX
 OS Homo sapiens.
 XX
 XX US2004049022-A1.
 PN
 XX
 PD 11-MAR-2004.
 XX
 XX 25-JUL-2003; 2003US-00627930..
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143..
 PR
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.

PA (CONG/) CONG H.
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
XX WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT Initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
XX Claim 2; SEQ ID NO 630; 174pp; English.
XX
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
XX Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 1e+03;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2850 CCTCTGAGTAGTGGGAC 2868
Db 1 CCTCCCGAGTAGTGGGAC 19
RESULT 2011
AAF85976
ID AAF85976 standard; DNA; 21 BP.
XX
XX AAF85976;
XX
XX 20-JUN-2001 (first entry)
XX
XX CA repeat fluorogenic probe.
XX
XX Probe; Fluorescein; tetramethyl rhodamine; copy number; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 1
FT /tag= a
FT /mod_base= OTHER
FT /note= "5' end attached to 6-carboxy fluorescein"
FT modified_base 21
FT /tag= b
FT /mod_base= OTHER
FT /note= "3' end attached to TAMRA"

XX US6180349-B1.
XX 30-JAN-2001.
XX
XX 18-MAY-1999; 99US-00314246.
XX
XX 18-MAY-1999; 99US-00314246.
XX (REGC) UNIV CALIFORNIA.
XX
XX Ginzinger DG, Godfrey TE, Jensen RH, Gray JW;
XX WPI; 2001-225787/23.
XX
XX Measuring copy number of a polynucleotide locus in sample useful as
PT diagnostic and prognostic tool, comprises quantifying amount of test
PT locus and reference loci in test and control subject.
XX
XX Claim 25; Col 33; 27pp; English.
XX
XX The present invention relates to measuring the copy number of a locus by
CC amplifying and comparing test and reference loci. The invention is useful
CC as diagnostic and prognostic tools and in correlating abnormal copy
CC number values for specific loci with disease and effectiveness of
CC different treatment options. The present sequence is a CA repeat
CC fluorogenic probe used in the invention
XX
XX Sequence 21 BP; 0 A; 0 C; 10 G; 9 T; 0 U; 2 Other;
SQ
Query Match 0.6%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2728 GTGTGTGTGTGTGTGTGTG 2746
Db 2 GTGTGTGTGTGTGTGTGTG 20
RESULT 2012
AAH91527/C
ID AAH91527 standard; DNA; 21 BP.
XX
XX AAH91527;
XX
XX 09-OCT-2001 (first entry)
XX
XX Human inflammatory bowel disease associated polymorphic site #602.
XX
XX Human; inflammatory bowel disease; Crohn's disease; ulcerative colitis;
KW single nucleotide polymorphism; SNP; chromosome 19p13; paternity test;
KW chromosome 5q31-33; forensic test; gene therapy; ds.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH misc_feature 13
FT /tag= a
FT /note= "SNP, optionally T or C at this position"
XX
XX WO200142511-A2.
XX
XX 14-JUN-2001.
XX
XX 11-DEC-2000; 2000WO-US033632.
XX
XX 10-DEC-1999; 99US-0170257P.
XX 10-APR-2000; 2000US-0196046P.
XX
XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA (ELLI-) ELLIPSIS BIOTHERAPEUTICS CORP.
XX
XX Daly M, Hudson TJ, Lander ES, Rioux J, Siminovitch K;

XX WPI; 2001-367874/38.
 XX Testing for the presence of polymorphisms associated with inflammatory
 PT bowel disease, using a hybridization assay.
 XX Claim 1; Page 64; 463pp; English.
 XX The present invention describes a method for detecting the presence of
 CC polymorphisms associated with inflammatory bowel diseases such as
 CC ulcerative colitis and Crohn's disease. The methods can be used to detect
 CC the presence of genetic polymorphisms associated with inflammatory bowel
 CC disease and correlating their occurrence with disease states. They may be
 CC used in this way for phenotypic correlations, forensics, paternity
 CC testing, medicine and genetic analysis. The present sequence is a
 CC polymorphic site described in the exemplification of the invention
 XX
 SQ Sequence 21 BP; 4 A; 4 C; 10 G; 2 T; 0 U; 1 Other;
 Query Match 0.6%; Score 17.4; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 9.8e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2832 GTGATCTCCCACTCAGCC 2851
 DB 20 GTGATCCNCCCTCCTCAGCC 1
 RESULT 2013
 ABL44374
 ID ABL44374 standard; DNA; 21 BP.
 AC ABL44374;
 XX 11-APR-2002 (first entry)
 DE Human chromosome 1p36-35 PCR primer SEQ ID NO:1418.
 KW Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
 KW PCR primer; ss.
 OS Homo sapiens.
 XX JP2001321190-A.
 PN 20-NOV-2001.
 PD 12-MAR-2001; 2001JP-00068285.
 XX 10-MAR-2000; 2000JP-00066716.
 XX (RIKA) RIKAGAKU KENKYUSHO.
 PA (GENO-) GENOTEX YG.
 XX WPI; 2002-144136/19.
 XX Arraying genome clones.
 PT Claim 4; Page 32; 528pp; Japanese.
 XX The present invention describes a method of arraying genome clones. The
 CC method comprises: (a) clones of the genomic libraries contained in
 CC multiwell plates numbered for discrimination are mixed in each of the
 CC multiwell plates; (b) a primer designed based on the chromosome marker
 CC sequence is added to the mixture to carry out an amplification reaction;
 CC (c) a signal corresponding to the marker is detected from the resultant
 CC amplified product to specify the discrimination Nos. of the multiwell
 CC plates containing the clones having said marker sequence; (d) the order
 CC of the markers is changed so that the same discrimination Nos. succeed to
 CC the maximum in the specified discrimination Nos. to array the multiwell
 CC plates; (e) the clones in the multiwell plates of the specified
 CC discrimination Nos. are mixed respectively in each wells of longitudinal
 CC and lateral directions; (f) the mixed clones are cultured and the

CC resultant cultures are amplified by using the above primer; (g) signals
 CC are detected from the amplified products; (h) the clones in the multiwell
 CC plates are specified from the detected result; and (i) the clones are
 CC reconstituted as the positions on the chromosome and arrayed. The
 CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
 CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
 CC represent PCR primers for human chromosome 21q22.1, which are
 CC specifically claimed for use in the present invention
 XX
 SQ Sequence 21 BP; 0 A; 2 C; 9 G; 10 T; 0 U; 0 Other;
 Query Match 0.6%; Score 17.4; DB 1; Length 21;
 Best Local Similarity 94.7%; Pred. No. 9.8e+02;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTGT 2747
 DB 1 TGTGTGTGTGTGTGTGTGT 19
 RESULT 2014
 AAQ76248/c
 ID AAQ76248 standard; DNA; 19 BP.
 XX AAQ76248;
 AC AAQ76248;
 XX 25-MAR-2003 (revised)
 DT 10-AUG-1995 (first entry)
 DE Generic primer from Alu-2 primer set.
 XX
 KW Primer; PCR; amplification; primer set; probe; Alu sequence; Alu repeat;
 KW Alu consensus sequence; chromosome; breakpoint; rearrangement;
 KW chronic myelogenous leukemia; Philadelphia chromosome; translocation; ss.
 XX Synthetic.
 OS WO9428178-A1.
 XX 08-DEC-1994.
 PD 01-JUN-1994; 94WO-US0006194.
 PF 01-JUN-1993; 93US-00070517.
 PR (TEXA) UNIV TEXAS SYSTEM.
 PA Siciliano MJ, Liu P;
 PI WPI; 1995-022844/03.
 DR DNA probe specific for Human chromosome region 9q34 - allows detection of
 PT bcr/abl rearrangement in interphase nuclei.
 PS Disclosure; Page 12; 81pp; English.
 XX The generic sequence of a primer set designated Alu-2. The primer set was
 CC based on bases 240-58 of the 3' end of a 300 bp Alu segment. The primers
 CC of the set have an identical sequence to the Alu consensus sequence. Thus
 CC priming with the Alu-1 set directs synthesis towards the 3' end (i.e.
 CC away from the middle) of the Alu segment. Since the primer set is
 CC designed to bind close to the edge of an Alu segment, amplification with
 CC these primers will reduce the amount of Alu segment sequence and increase
 CC the amount of specific chromosomal DNA present required for probe
 CC production. The primer set is useful in the production of chromosomal
 CC specific probes e.g for the detection of chromosomal breakpoints and
 CC rearrangements such as a probe to detect chronic myelogenous leukemia
 CC characterised by the Philadelphia chromosome, arising from a reciprocal
 CC translocation t(9;22) (q34;q11). (Updated on 25-MAR-2003 to correct PN
 CC field.)
 XX Sequence 19 BP; 3 A; 9 C; 2 G; 3 T; 0 U; 2 Other;

Query Match 0.6%; Score 17.2; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.1e+03;
 Matches 16; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2774 AGGCTGGAGTGCAGTGGT 2791
 |||||
 Db 18 AGGCTGGAGTGCARTGGY 1

RESULT 2015
 AAQ85814/c
 ID AAQ85814 standard; DNA; 18 BP.
 XX
 AC AAQ85814;
 XX
 XX 25-MAR-2003 (revised)
 DT 07-NOV-1995 (first entry)
 XX
 XX Anti-ICAM 2'-O-alkylamino-containing oligomer #61.
 DE
 XX Alkylamino group; ribofuranosyl sugar; antisense therapy; virus; HIV;
 KW herpes; papilloma; antiviral; ss.
 KW
 XX Synthetic.
 OS
 XX Key Location/Qualifiers
 FH modified_base 10
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "5'-O-(dimethoxytrityl)-2'-O-(hexyl-N-(2,4-dinitrophenyl)amino uridine"
 FT
 FT
 XX WO9506659-A1.
 XX
 XX 09-MAR-1995.
 XX
 XX 02-SEP-1994; 94WO-US010131.
 XX
 XX 03-SEP-1993; 93US-00117363.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Cook PD, Manoharan M, Guinosso CJ;
 PI
 XX WPI; 1995-115397/15.
 DR
 XX New amine-derivatised nucleoside(s) and oligo:nucleoside(s) - useful as
 PT diagnostics, therapeutics and research reagents, partic. in anti-sense
 PT therapy.
 XX
 XX Example 42; Page 55; 117pp; English.
 PS
 XX Oligomers AAQ85813-5 are analogues of an antisense sequence to the inter-
 CC cellular adhesion molecule (ICAM). The oligomers are generated to contain
 CC a 2'-O-alkylamino-modified nucleoside at various positions and may
 CC include phosphorothioate linkages between the nucleosides. The modified
 CC nucleosides may increase the half-life of the oligomers in cell extract
 CC assays for the inhibition of specific genes. The modified oligomer is an
 CC example of a compound (see AAQ85799-Q85839 for other examples) e.g. a
 CC nucleoside or oligonucleoside, which contains a ribofuranosyl sugar
 CC portion and a base portion, such that at least one of the nucleoside
 CC contains at a 2'-O-, 3'-O- or 5'-O-position, a substitution (see AAQ85799
 CC for details of the substitutions). The compounds are useful in
 CC diagnostics, therapeutics and as research reagents particularly in
 CC antisense therapy for killing cells and viruses such as HIV, herpes or
 CC papilloma viruses. (Updated on 25-MAR-2003 to correct PN field.)
 XX
 XX Sequence 18 BP; 4 A; 4 C; 8 G; 1 T; 0 U; 1 Other;

Query Match 0.6%; Score 17; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGCTCCCA 67
 |||||
 Db 18 GCCTCGCTATGCTCCCA 1

RESULT 2016
 AAQ85813/c
 ID AAQ85813 standard; DNA; 18 BP.
 XX
 AC AAQ85813;
 XX
 XX 25-MAR-2003 (revised)
 DT 07-NOV-1995 (first entry)
 XX
 XX Anti-ICAM 2'-O-alkylamino-containing oligomer #57.
 DE
 XX Alkylamino group; ribofuranosyl sugar; antisense therapy; virus; HIV;
 KW herpes; papilloma; antiviral; ss.
 KW
 XX Synthetic.
 OS
 XX Key Location/Qualifiers
 FH misc_feature 1..18
 FT /note= "optionally may contain phosphorothioate linkages
 FT between nucleosides"
 FT modified_base 1
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "5'-O-(dimethoxytrityl)-2'-O-(hexyl-N-(2,4-dinitrophenyl)amino uridine"
 FT 10
 FT modified_base 10
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Optionally may be 5'-O-(dimethoxytrityl)-2'-O-(hexyl-N-(2,4-dinitrophenyl)amino uridine"
 FT 18
 FT modified_base 18
 FT /*tag= c
 FT /note= "may contain non-nucleoside 6C amino linker"
 FT
 XX WO9506659-A1.
 XX
 XX 09-MAR-1995.
 XX
 XX 02-SEP-1994; 94WO-US010131.
 PF
 XX 03-SEP-1993; 93US-00117363.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Cook PD, Manoharan M, Guinosso CJ;
 PI
 XX WPI; 1995-115397/15.
 DR
 XX New amine-derivatised nucleoside(s) and oligo:nucleoside(s) - useful as
 PT diagnostics, therapeutics and research reagents, partic. in anti-sense
 PT therapy.
 XX
 XX Example 42; Page 55; 117pp; English.
 PS
 XX Oligomers AAQ85813-5 are analogues of an antisense sequence to the inter-
 CC cellular adhesion molecule (ICAM). The oligomers are generated to contain
 CC a 2'-O-alkylamino-modified nucleoside at various positions and may
 CC include phosphorothioate linkages between the nucleosides. The modified
 CC nucleosides may increase the half-life of the oligomers in cell extract
 CC assays for the inhibition of specific genes. The modified oligomer is an
 CC example of a compound (see AAQ85799-Q85839 for other examples) e.g. a
 CC nucleoside or oligonucleoside, which contains a ribofuranosyl sugar
 CC portion and a base portion, such that at least one of the nucleoside
 CC contains at a 2'-O-, 3'-O- or 5'-O-position, a substitution (see AAQ85799
 CC for details of the substitutions). The compounds are useful in
 CC diagnostics, therapeutics and as research reagents particularly in
 CC antisense therapy for killing cells and viruses such as HIV, herpes or
 CC papilloma viruses. (Updated on 25-MAR-2003 to correct PN field.)
 CC

XX SQ Sequence 18 BP; 4 A; 4 C; 8 G; 1 T; 0 U; 1 Other;
 Query Match 0.6%; Score 17; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGCTCC 66
 |||||
 DB 18 GCCTCGCTATGCTCC 2

RESULT 2017
 AAZ4882/c
 ID AAZ4882 standard; DNA; 18 BP.
 AC AAZ4882;
 XX
 DT 29-MAR-2000 (first entry)
 XX
 DE Human ICAM-1 antisense inhibitor, ISIS #16860.
 XX
 KW Antisense inhibitor; human; ICAM-1; intercellular adhesion molecule-1;
 KW vascular cell adhesion molecule-1; hyperproliferative disorder; VCAM-1;
 KW endothelial leukocyte adhesion molecule-1; ELAM-1; skin condition;
 KW cancer; viral infection; tumour; diapedesis; graft versus host disease;
 KW arthritis; infection; autoimmune disorder; multiple sclerosis; stroke;
 KW juvenile diabetes mellitus; arthritis; myasthenia gravis; therapy;
 KW pemphigus vulgaris; systemic lupus erythematosus; acute myocarditis;
 KW cardiovascular disorder; dilated cardiomyopathy; ischaemic heart disease;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO961462-A1.
 XX
 XX 02-DEC-1999.
 XX
 XX 26-MAY-1999; 99WO-US011548.
 XX
 XX 27-MAY-1998; 98US-00085759.
 XX
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Bennett CF, Mirabelli CK, Baker BF;
 XX
 XX WPI; 2000-072600/06.
 XX
 XX New antisense oligonucleotides, used for treating e.g. inflammatory
 PT conditions, psoriasis, graft rejection, cancers, infections,
 PT cardiovascular disorders or autoimmune disorders.
 XX
 XX Claim 5; Page 193; 199pp; English.
 XX
 CC This sequence is an antisense oligonucleotide of the invention. The
 CC antisense oligonucleotides are targeted to a nucleic acid encoding a
 CC cellular adhesion molecule (CAM) and is capable of modulating the
 CC expression of the CAM. They particularly inhibit intercellular adhesion
 CC molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), or
 CC endothelial leukocyte adhesion molecule-1 (ELAM-1). The antisense
 CC oligonucleotides can be used to modulate CAM activity in mediating
 CC cell:cell interactions and subsequent cellular and biological responses,
 CC e.g. T cell activation, leukocyte transmigration and inflammation. The
 CC antisense sequences can be used for modulating the synthesis of a CAM.
 CC They can be used for treating an animal suspected of having or being
 CC prone to a disease or condition associated with a CAM. Oligonucleotides
 CC targeted to ICAM-1 can be used for treating an inflammatory disease or
 CC condition e.g. inflammatory bowel disease such as Crohn's disease,
 CC colitis or ulcerative colitis, a condition of the skin, e.g. psoriasis or
 CC cytotoxic dermatitis, rheumatoid arthritis, allograft rejection, cancer,
 CC pneumonia, multiple sclerosis or a viral infection. The ICAM-1 sequences
 CC can also be used for reducing corticosteroid use in a patient or for
 CC reducing cyclosporine use in a patient. The oligonucleotides can also be

CC used for detection and diagnosis. They can also be used for treating e.g.
 CC hyperproliferative disorders, tumours, diapedesis, graft versus host
 CC disease, arthritis, infections, autoimmune disorders, e.g. autoimmune
 CC thyroid disorders, autoimmune forms of arthritis, multiple sclerosis,
 CC some forms of juvenile diabetes mellitus, myasthenia gravis, pemphigus
 CC vulgaris, systemic lupus erythematosus, cardiovascular disorders,
 CC myocardial ischaemia/reperfusion injury, dilated cardiomyopathy, acute
 CC myocarditis, ischaemic heart disease or stroke
 XX
 SQ Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 17; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1412 AGGCGACCTACCTCTGT 1428
 |||||
 DB 18 AGGCGACCTACCTCTGT 2

RESULT 2018
 ADO56979
 ID ADO56979 standard; DNA; 18 BP.
 XX
 AC ADO56979;
 XX
 DT 12-AUG-2004 (first entry)
 XX
 DE Human CARX/FPGT proximal SNP probe #45.
 XX
 KW gene therapy; human; ss; melanoma;
 KW melanoma associated polymorphic variation; SNP;
 KW single nucleotide polymorphism; CARX; FPGT;
 KW cardiac ankyrin repeat kinase; fucose-1-phosphate guanylyltransferase;
 KW probe.
 XX
 XX Homo sapiens.
 XX
 XX WO2004044164-A2.
 XX
 XX 27-MAY-2004.
 XX
 XX 06-NOV-2003; 2003WO-US035879.
 XX
 XX 06-NOV-2002; 2002US-0424475P.
 XX
 XX 23-JUL-2003; 2003US-0489703P.
 XX
 XX (SEQU-) SEQUENOM INC.
 XX
 XX Roth RB, Nelson MR, Braun A, Kammerer SM;
 XX
 XX WPI; 2004-411721/38.
 XX
 XX Identifying a subject at risk of melanoma, useful for treating melanoma,
 PT comprises detecting the presence or absence of one or more polymorphic
 PT variations associated with melanoma in a nucleic acid sample from a
 PT subject.
 XX
 XX Example 7; Page 121; 295pp; English.
 XX
 CC The invention relates to a method of identifying a subject at risk of
 CC melanoma comprising detecting the presence or absence of one or more
 CC polymorphic variations associated with melanoma in a nucleic acid sample
 CC from a subject. Preventing melanoma in a subject comprises detecting the
 CC presence or absence of one or more polymorphic variations associated with
 CC melanoma in a nucleic acid sample from a subject; and administering a
 CC melanoma preventative to a subject in need thereof based upon the
 CC presence or absence of the one or more polymorphic variations in the
 CC nucleic acid sample. The preventative reduces ultraviolet (UV) light
 CC exposure to the subject. The methods, nucleic acids, proteins, and
 CC compositions are useful for treating melanoma. The present sequence
 CC represents a human cardiac ankyrin repeat kinase/fucose-1-phosphate
 CC guanylyltransferase, CARX/FPGT, proximal probe.

XX SQ Sequence 18 BP; 3 A; 2 C; 9 G; 3 T; 0 U; 1 Other;

Query Match 0.6%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2774 AGGCTGGAGTGCAGTGG 2790
|||||
Db 1 AGGCTGGAGTGCAGTGG 17

RESULT 2019

ADSA41454/C
ID ADS41454 standard; DNA; 18 BP.
XX
AC ADS41454;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human autoimmune disease-related PCR primer - SEQ ID 6668.

XX single nucleotide polymorphism detection; SNP detection;
KW rheumatoid arthritis; type 1 diabetes; multiple sclerosis;
KW systemic lupus erythematosus; inflammatory bowel disease; psoriasis;
KW thyroiditis; celiac disease; pernicious anaemia; asthma; vitiligo;
KW glomerulonephritis; Grave's disease; myocarditis; Sjogren's disease;
KW primary systemic vasculitis; PCR; primer; ss.
XX
OS Homo sapiens.

XX
XX WO2004083403-A2.
PN
XX 30-SEP-2004.
PD

XX 18-MAR-2004; 2004WO-US008461.
XX
XX 18-MAR-2003; 2003US-0455444P.
PR
XX 25-APR-2003; 2003US-0465241P.
PR

XX (APPL-) APPLERA CORP.

XX Cargill M, Begovich AB, Alexander HC;
XX
XX WPI; 2004-728480/71.
DR

XX New isolated nucleic acid molecule comprises at least 8 contiguous
PT nucleotides where one of the nucleotides is a single nucleotide
PT polymorphism (SNP), useful for diagnosing or treating autoimmune
PT diseases, e.g. rheumatoid arthritis.
XX

PS Claim 21; SEQ ID NO 6668; 123pp; English.

XX The invention comprises amino acid and coding sequences containing
CC genetic polymorphisms associated with an altered risk of developing an
CC autoimmune disease (e.g. rheumatoid arthritis). The invention further
CC comprises a method of identifying an individual that has an altered risk
CC of developing an autoimmune disease, comprising detecting a single
CC nucleotide polymorphism (SNP) in a nucleic acid of the invention. The DNA
CC and protein sequences of the invention are useful for diagnosing and
CC treating autoimmune diseases, such as: rheumatoid arthritis, type 1
CC diabetes, multiple sclerosis, systemic lupus erythematosus, inflammatory
CC bowel diseases, psoriasis, thyroiditis, celiac disease, pernicious
CC anaemia, asthma, vitiligo, glomerulonephritis, Grave's disease,
CC myocarditis, Sjogren's disease, or primary systemic vasculitis. The
CC present DNA sequence represents a human autoimmune disease-related PCR
CC primer of the invention. NOTE: The present sequence is not shown in the
CC specification, but has been retrieved from the WIPO website.

XX SQ Sequence 18 BP; 4 A; 7 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;

Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1463 AGGTGACCGTGAATGTG 1479
|||||
Db 17 AGGTGACCGTGAATGTG 1

RESULT 2020

AAQ85821/c
ID AAQ85821 standard; DNA; 19 BP.

XX
AC AAQ85821;
XX

DT 25-MAR-2003 (revised)

DT 07-NOV-1995 (first entry)

XX

XX Anti-ICAM 2'-O-alkylamino-containing oligomer #74.

XX Alkylamino group; ribofuranosyl sugar; antisense therapy; virus; HIV;
KW herpes; papilloma; antiviral; ss.

XX Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..19

FT /tag= C

FT /note= "contains phosphorothioate linkages between
nucleosides"

FT modified_base 1

FT /tag= a

FT /note= "5'-O-dimethoxytrityl-2'-O-[hexyl-N-(5-

thiocarbonyl-3,6-dipivoly] fluorescein] amino] uridine"

FT modified_base 2

FT /tag= b

FT /mod_base= OTHER
FT /note= "2'-O-[hexyl-N-(3-oxycarbonyl-cholesteroyl) amino] -
uridine"

XX WO9506659-A1.

XX 09-MAR-1995.

XX 02-SEP-1994; 94WO-US010131.

XX 03-SEP-1993; 93US-00117363.

XX (ISIS-) ISIS PHARM INC.

XX Cook PD, Manoharan M, Guinosso CU;
XX

XX WPI; 1995-115397/15.

XX New amine-derivatised nucleoside(s) and oligo:nucleoside(s) - useful as
PT diagnostics, therapeutics and research reagents, partic. in anti-sense
PT therapy.

PS Example 43-44; Page 56; 117pp; English.

XX Oligomers AAQ85816-21 are generated to contain a 2'-O-alkylamino-modified
CC nucleoside containing either a cholesterol or fluorescein functional
CC group. This sequence is an analogue of an antisense sequence to the inter
CC cellular adhesion molecule (ICAM). The modified nucleosides may increase
CC the half-life of the oligomers in cell extract assays for the inhibition
CC of specific genes. The modified oligomer is an example of a compound (see
CC AAQ85799-Q85839 for other examples) e.g. a nucleoside or oligonucleoside,
CC which contains a ribofuranosyl sugar portion and a base portion, such
CC that at least one of the nucleoside contains at a 2'-O-, 3'-O- or 5'-O-
CC position, a substitution (see AAQ85799 for details of the substitutions).
CC The compounds are useful in diagnostics, therapeutics and as research
CC reagents particularly in antisense therapy for killing cells and viruses
CC such as HIV, herpes or papilloma viruses. (Updated on 25-MAR-2003 to
CC correct PN field.)

XX

SQ Sequence 19 BP; 4 A; 4 C; 8 G; 1 T; 0 U; 2 Other;
 Query Match 0.6%; Score 17; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 50 GCCTCGCTATGGCTCC 66
 Db 19 GCCTCGCTATGGCTCC 3

RESULT 2021
 AAT63215/c
 ID AAT63215 standard; DNA; 19 BP.
 XX
 AC AAT63215;
 XX
 DT 17-JUN-1997 (first entry)
 XX
 DE Primer Alu 3' used in Inter-Alu PCR for PAC isolation.
 XX
 KW S182 gene; familial Alzheimer's disease; diagnosis; transgenic animal;
 KW polymerase chain reaction; PCR; primer; artificial chromosome; PAC; ss.
 KW
 OS Synthetic.
 XX
 PN WO9703999-A1.
 XX
 PD 06-FEB-1997.
 XX
 PF 26-JUN-1996; 96WO-US011065.
 XX
 PR 18-JUL-1995; 95US-0001500P.
 PR 02-AUG-1995; 95US-0001800P.
 XX
 PA (UNIW) UNIV WASHINGTON SCHOOL MED.
 PA (UYSF-) UNIV SOUTH FLORIDA.
 XX
 PI Goate AM, Hardy JA;
 XX
 DR WPI; 1997-132571/12.
 XX
 PT New mutants of the S182 gene associated with familial Alzheimer's disease
 PT - and related protein and transgenic animals, useful as models for
 PT screening and assessing potential drugs.
 XX
 PS Example 2; Page 11; 26pp; English.
 XX
 CC Inter-Alu PCR was performed on YACs 905C2 and 763B11. Unpurified YAC DNA
 CC was amplified with generate primers Alu 5' (AAT63214) and Alu 3'
 CC (AAT63215). Genetic linkage strategies have placed a gene causing early
 CC onset Alzheimer's disease (AD) on the long arm of chromosome 14 between
 CC D14S289 and D14S61. The gene, S182 (see also AAT63207), was localised to
 CC a 100 kb region between D14S77 and D14S668E (see also AAT63216-22). A
 CC number of novel mutations in the S182 gene have been identified in
 CC families multiply affected by early onset AD
 XX
 SQ Sequence 19 BP; 3 A; 6 C; 2 G; 3 T; 0 U; 5 Other;
 Query Match 0.6%; Score 17; DB 1; Length 19;
 Best Local Similarity 73.7%; Pred. No. 1.2e+03;
 Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Qy 2779 GGAGTGCAGTGGTCAATC 2797
 Db 19 GGAGTGCAGTGGVRYATC 1

RESULT 2022
 AAH39033/c
 ID AAH39033 standard; DNA; 19 BP.
 XX
 AC AAH39033;

XX
 DT 14-AUG-2001 (first entry)
 XX
 DE SNP specific upper PCR primer SEQ ID 1829.
 XX
 KW Single nucleotide polymorphism; SNP; single nucleotide primer extension;
 KW SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
 KW Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
 KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
 KW acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
 KW inflammation; forensic investigation; paternity analysis; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200129262-A2.
 XX
 PD 26-APR-2001.
 XX
 PF 13-OCT-2000; 2000WO-US028436.
 XX
 PR 15-OCT-1999; 99US-0160096P.
 XX
 PA (ORCH-) ORCHID BIOSCIENCES INC.
 XX
 PI Picoult-Newburg L, Pohl M;
 XX
 DR WPI; 2001-290930/30.
 XX
 PT New genotyping oligonucleotide, useful for detecting the presence,
 PT absence or identity of single polynucleotide polymorphism in a nucleic
 PT acid sample.
 XX
 PS Claim 1; Page 59; 83pp; English.
 XX
 CC Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
 CC primer extension (SNPE) primers, and the sequences of regions flanking
 CC sites of single nucleotide polymorphisms SNPs. The present invention
 CC includes kits for determining the presence or absence of a SNP, using the
 CC oligonucleotides of the invention. The PCR primers are used to amplify a
 CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.
 CC The oligonucleotides are useful for genotyping a nucleic acid sample by
 CC performing a single-nucleotide primer extension reaction. The
 CC oligonucleotides are useful for determining the presence, absence or
 CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to
 CC assess by association analysis the genotype of an individual or group of
 CC individuals, having a pathological phenotypic trait suspected of being
 CC caused by one or more SNPs. Phenotypic traits include diseases e.g.
 CC agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
 CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
 CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
 CC traits also include symptoms of or susceptibility to multifactorial
 CC disease of which a component is or may be genetic such as autoimmune
 CC diseases, including, rheumatoid arthritis, multiple sclerosis,
 CC inflammation, cancer, nervous system diseases and infection by pathogenic
 CC microorganism. The method is also useful in forensic investigations and
 CC paternity analysis. The present sequence represents a PCR primer specific
 CC for a human SNP containing DNA sequence
 XX
 SQ Sequence 19 BP; 4 A; 10 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 17; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2776 GCTGGAGTGCAGTGGTG 2792
 Db 19 GCTGGAGTGCAGTGGTG 3

RESULT 2023
 ABZ75622/c
 ID ABZ75622 standard; DNA; 19 BP.
 XX

AC ABZ75622;
 XX
 DT 15-MAY-2003 (first entry)
 XX
 DE STR marker 21-32S specific PCR primer 32S forward.
 XX
 KW Aneuploidy; chromosome; multiplex assay; polymerase chain reaction; PCR;
 KW short tandem repeat; STR; turner syndrome; cystic fibrosis; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200268685-A2.
 XX
 PD 06-SEP-2002.
 XX
 PF 26-FEB-2002; 2002WO-GR000839.
 XX
 PR 26-FEB-2001; 2001GB-00004690.
 XX
 PA (CYTO-) CYTOGENETIC DNA SERVICES LTD.
 XX
 PI Levett LJ, Liddle S;
 XX
 DR WPI; 2002-707013/76.
 XX
 PT Detecting aneuploidy of a chromosome in a fetus by using a multiplex
 PT polymerase chain reaction assay comprising chromosome-specific short
 PT tandem repeat markers.
 XX
 PS Example 1; Page 16; 30pp; English.
 XX
 CC The invention relates to detecting aneuploidy of a chromosome and
 CC involves using a multiplex polymerase chain reaction assay having
 CC chromosome-specific short tandem repeat (STR) markers. The STR marker 21-
 CC 32S (informal designation) is useful as a marker for the diagnosis of
 CC aneuploidy of a chromosome, particularly trisomy 21, 13, 18 or X, or
 CC Turner Syndrome. The STR marker Y-40S (informal designation) is useful as
 CC a marker for the diagnosis of the sex of an individual. Marker CF508 is
 CC useful for detecting the presence or absence of a genetic disease,
 CC particularly cystic fibrosis. Sequences ABZ75621-22 represent PCR primers
 CC specific for the STR marker 21-32S
 XX
 SQ Sequence 19 BP; 4 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 0.6%; Score 17; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 2766 TGTCACCCAGGCTGGAG 2782
 |||||
 Db 17 TGTCACCCAGGCTGGAG 1
 XX
 RESULT 2024
 ADP09291/c
 ID ADP09291 standard; DNA; 19 BP.
 XX
 AC ADP09291;
 XX
 DT 26-AUG-2004 (first entry)
 XX
 DE Extend primer 86 used to genotype human chromogranin B polymorphism.
 XX
 KW breast cancer; cytostatic; gene therapy; human; chromogranin B; CHGB;
 KW secretogranin 1; SCG1; chromosome 20pter-p12; ss; PCR; primer; SNP;
 KW single nucleotide polymorphism.
 XX
 OS Homo sapiens.
 XX
 PN WO2004047767-A2.
 XX
 PD 10-JUN-2004.
 XX

PF 25-NOV-2003; 2003WO-US037966.
 XX
 PR 25-NOV-2002; 2002US-0429136P.
 PR 24-JUL-2003; 2003US-0490234P.
 XX
 PA (SEQU-) SEQUENOM INC.
 XX
 PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
 XX
 DR WPI; 2004-441082/41.
 XX
 PT Identifying a subject at risk of breast cancer by detecting the presence
 PT of absence of one or more nucleotide polymorphic variations, useful for
 PT diagnosing, preventing and/or treating breast cancer.
 XX
 PS Example 5; Page 103; 286pp; English.
 XX
 CC The invention relates to a novel method for identifying a subject at risk
 CC of breast cancer which comprises detecting the presence or absence of one
 CC or more polymorphic variations associated with breast cancer in a nucleic
 CC acid sample from a subject. The method of the invention has cytostatic
 CC applications and may be useful for identifying a risk of breast cancer,
 CC as well as therapeutic and prophylactic treatments that specifically
 CC target breast cancer, such as gene therapy. The current sequence is that
 CC of an extend primer of the invention which was used to genotype single
 CC nucleotide polymorphisms within human chromogranin B (CHGB; secretogranin
 CC 1; SCG1) DNA which is located at chromosomal position 20pter-p12.
 XX
 SQ Sequence 19 BP; 3 A; 9 C; 3 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.6%; Score 17; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.2e+03;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 2774 AGGCTGGAGTGCAGTGG 2790
 |||||
 Db 19 AGGCTGGAGTGCAGTGG 3
 XX
 RESULT 2025
 AAQ45156/c
 ID AAQ45156 standard; DNA; 20 BP.
 XX
 AC AAQ45156;
 XX
 DT 25-MAR-2003 (revised)
 DT 31-OCT-1994 (first entry)
 XX
 DE Oligonucleotide used in amine containing therapeutic.
 XX
 KW Oligonucleotide; analogue; antisense; therapy; diagnosis; identification;
 KW retention; therapeutic; amine; lipophile; ss.
 XX
 OS Synthetic.
 XX
 PN WO9406815-A1.
 XX
 PD 31-MAR-1994.
 XX
 PF 03-SEP-1993; 93WO-US008367.
 XX
 PR 11-SEP-1992; 92US-00943516.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Manoharan M, Cook PD;
 XX
 DR WPI; 1994-118388/14.
 XX
 PT Nucleotide and oligo-nucleotide (poly)amine analogues - used in anti-
 PT sense therapy, diagnosis, and identification, amino gp. enhances cell
 PT uptake and retention.
 XX

PS Example 7; Page 47; 93pp; English.

XX The sequence is used in the production of an amine analogue. The analogue
CC may be used in antisense therapy. The analogue may also have enhanced
CC cellular uptake, increased lipophilicity, cause greater cellular
CC retention and demonstrate increased distribution. (Updated on 25-MAR-2003
CC to correct FN field.)

XX SQ Sequence 20 BP; 4 A; 4 C; 8 G; 3 T; 1 U; 0 Other;

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGTATGGCTCCCA 67
DB 17 CCTCGTATGGCTCCCA 1

RESULT 2026

ABX10634/C

ID ABX10634 standard; DNA; 20 BP.

XX AC ABX10634;

XX DT 15-APR-2003 (first entry)

XX DE Synthetic phosphorothioate oligonucleotide #6.

XX KW ss; oligomeric compound; phosphite; phosphodiester; phosphorothioate;
XX KW phosphorodithioate; diagnostic; therapeutic; gene therapy.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= phosphorothioate backbone"

XX US6399756-B1.

XX PN 04-JUN-2002.

XX PD 08-JUL-1999; 99US-00349659.

XX PF 08-JUL-1998; 98US-00111678.

XX PR (ISIS-) ISIS PHARM INC.

XX PA Cheruvallath ZS, Ravikumar VT, Cole DL;

XX PI WPI; 2002-730487/79.

XX DR Method for preparation of oligomeric compounds, useful for modulating RNA
XX PT or DNA which code for a protein, in diagnostics and therapeutics and as
XX PT research reagents.

XX PS Example 14; Col 33; 31pp; English.

XX CC The invention discloses a method for preparation of oligomeric compounds
XX CC having phosphite, phosphodiester, phosphorothioate, phosphorodithioate or
XX CC other linkages. The method is useful for preparing oligomeric compounds
XX CC which are used to modulate RNA or DNA which code for a protein. They can
XX CC be used in diagnostics, therapeutics (e.g. gene therapy) and as research
XX CC reagents. The sequence presented is the phosphorothioate oligonucleotide
XX CC #6, which was synthesised in an example of the invention

XX SQ Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTG 2116

DB 20 TGACGGATGCCAGCTTG 4

RESULT 2027

ADA20965/C

ID ADA20965 standard; DNA; 20 BP.

XX AC ADA20965;

XX DT 20-NOV-2003 (first entry)

XX DE Mouse BAX chimeric phosphorothioate oligonucleotide SEQ ID NO:138.

XX KW BCL2-associated X; BAX; neurotropic; neuroprotective; antiparkinsonian;
XX KW anticonvulsant; ophthalmological; antidiabetic; virucide;
XX KW antisense therapy; BAX antagonist; BAX inhibitor;
XX KW familial amyotrophic lateral sclerosis; Alzheimer's disease;
XX KW Parkinson's disease; Hodgkin's disease; cartilage-hair hyperplasia;
XX KW diabetes-associated ocular disorder; scrapie infection;
XX KW aberrant apoptosis; mouse; phosphorothioate; ss.

XX OS Synthetic.

XX OS Mus musculus.

XX FH Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "phosphorothioate linkages, and all cytidine
FT residues are 5-methylcytidines"

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

XX WO2003008543-A2.

XX PN 30-JAN-2003.

XX PD 13-JUL-2002; 2002WO-US022417.

XX PF 17-JUL-2001; 2001US-00908147.

XX PR (ISIS-) ISIS PHARM INC.

XX PA Zhang H, Watt AT;

XX PI WPI; 2003-239321/23.

XX DR New antisense compounds, useful for modulating the expression of BCL2-
XX PT associated X (BAX) protein or for treating a disease or condition
XX PT associated with BAX protein, e.g. Parkinson's disease, Hodgkin's disease
XX PT or Alzheimer's disease.

XX PS Claim 3; Page 94; 139pp; English.

XX CC The present invention describes a compound (I) 8-50 nucleobases in length
XX CC targeted to a nucleic acid molecule encoding BCL2-associated X (BAX)
XX CC protein, where the compound specifically hybridises with the nucleic acid
XX CC molecule encoding BAX protein and inhibits the expression of BAX protein.
XX CC The compound specifically hybridises with at least 8-nucleobase portion
XX CC of an active site on a nucleic acid molecule encoding BAX protein. Also
XX CC described: (1) a composition comprising (I) and a pharmaceutical carrier
XX CC or diluent; (2) inhibiting the expression of BAX protein in cells or
XX CC tissues comprising contacting the cells or tissues with (1); and (3)
XX CC treating an animal having a disease or condition associated with BAX

CC protein comprising administering to the animal (I) so that expression of
 CC BAX protein is inhibited. (I) has neurotropic, neuroprotective,
 CC antiparkinsonian, anticonvulsant, ophthalmological, antidiabetic and
 CC virucide activities, and can be used in antisense therapy, and as a BAX
 CC antagonist. The antisense compounds (I) are useful for modulating the
 CC expression of BAX protein, and for treating a disease or condition
 CC associated with BAX protein, e.g. familial amyotrophic lateral
 CC sclerosis, Alzheimer's disease, Parkinson's disease, Hodgkin's disease,
 CC cartilage-hair hyperplasia, diabetes-associated ocular disorders or
 CC scrapie infection, or a condition that arises from aberrant apoptosis.
 CC The compounds are useful as research reagents and in diagnostics. The
 CC present sequence represents a mouse BAX chimeric phosphorothioate
 CC oligonucleotide, which is used in an example from the present invention.
 XX
 SQ Sequence 20 BP; 5 A; 5 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+03;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 963 GCAGACAGTGACCATCT 979
 DB 18 GCAGACAGTGACCATCT 2
 |||||

RESULT 2028

ABZ99108
 ID ABZ99108 standard; DNA; 20 BP.

XX
 AC ABZ99108;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human PDB4C oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.

OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX

31-OCT-2002.

23-APR-2002; 2002WO-US013135.

24-APR-2001; 2001US-0286137P.

(EPIG-) EPIGENESIS PHARM INC.

NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.

XX Disclosure; SEQ ID NO 14350; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention

CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences

XX Sequence 20 BP; 4 A; 12 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+03;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2838 CTCACACCTCAGCCTCC 2854
 DB 1 CTCACACCTCAGCCTCC 17
 |||||

RESULT 2029

ABD32139
 ID ABD32139 standard; DNA; 20 BP.

XX
 AC ABD32139;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human PDE4C-derived oligonucleotide SEQ ID 14350.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.

XX WO200285309-A2.

31-OCT-2002.

23-APR-2002; 2002WO-US013143.

24-APR-2001; 2001US-0286036P.

(EPIG-) EPIGENESIS PHARM INC.

NYce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX

WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 14350; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The

CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hyperinflation, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX
 SQ Sequence 20 BP; 4 A; 12 C; 1 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+03;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2838 CTCCTCAGCTCAGCTCC 2854
 DB 1 CTCCTCAGCTCAGCTCC 17

RESULT 2030
 ADJ60993
 ID ADJ60993 standard; DNA; 20 BP.
 XX
 AC ADJ60993;
 DT 06-MAY-2004 (first entry)
 DE Oligonucleotide associated to PDB4C #59.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS
 XX WO2004011613-A2.
 PN
 XX 05-FEB-2004.
 PD
 XX 25-JUL-2003; 2003WO-US023509.
 PF
 XX 29-JUL-2002; 2002US-0399076P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT Initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory

PT disease e.g., asthma.
 XX
 PS Claim 2; SEQ ID NO 1849; 85bp; English.
 XX
 CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 4 A; 12 C; 1 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+03;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2838 CTCCTCAGCTCAGCTCC 2854
 DB 1 CTCCTCAGCTCAGCTCC 17

RESULT 2031
 ADM15422/c
 ID ADM15422 standard; DNA; 20 BP.
 XX
 AC ADM15422;
 DT 01-JUL-2004 (first entry)
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1609.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX
 XX WO2004028458-A2.
 PN
 XX 08-APR-2004.
 PD

[illegible]

XX Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
 KW CCR1; CCR3; Botaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
 KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
 KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
 KW asthma; lung allergy; inflammation; inflammatory disease;
 KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
 KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
 KW acute respiratory distress syndrome; pulmonary hypertension;
 KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
 XX Homo sapiens.
 OS
 XX
 XX US2004049022-A1.
 PN
 XX
 XX 11-MAR-2004.
 PD
 XX
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX
 PF
 XX 23-APR-2002; 2002WO-US013135.
 XX
 PR 23-APR-2002; 2002WO-US013143.
 XX
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUH/) LU H.
 PA (CONG/) CONG H.
 XX
 XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI
 XX
 DR WPI; 2004-293804/27.
 XX
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
 PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
 PT asthma.
 XX
 XX
 PS Claim 2; SEQ ID NO 1849; 174pp; English.
 XX
 XX The invention relates to oligonucleotides anti-sense to an initiation
 CC codon, coding region, 5' or 3' intron-exon junction, intron or region
 CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
 CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
 CC -5 receptor, CCR1, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
 CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
 CC also relates to a method of screening a candidate compound that binds to
 CC one or more nucleic acid target(s) or expressed product(s), for the
 CC prevention and/or treatment of a respiratory or lung disease. The
 CC oligonucleotides are useful for reducing or inhibiting expression of a
 CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
 CC CCR1, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
 CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
 CC useful for preventing or treating a respiratory or lung disease. The
 CC respiratory or lung disease is associated with hyper-responsiveness to
 CC and/or increased levels of, adenosine and/or levels of adenosine A
 CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hyperinflation, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.
 XX
 SQ Sequence 20 BP; 4 A; 12 C; 1 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 17; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.1e+03;
 Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2838 CTCCACCTCAGCCTCC 2854
 Db 1 CTCCACCTCAGCCTCC 17
 RESULT 2034
 ADO40832/c
 ID ADO40832 standard; DNA; 20 BP.
 XX
 AC ADO40832;
 XX
 DT 12-AUG-2004 (first entry)
 XX
 DE Human CRLR gene 5' flanking region PCR primer #2.
 XX
 KW human; ss; primer; calcitonin receptor-like receptor; CRLR; hypertension;
 KW glucocorticoid administration; tumour; vasodilation; angiogenesis;
 KW gene therapy; PCR.
 XX
 OS Homo sapiens.
 XX WO2004044581-A2.
 PN
 XX 27-MAY-2004.
 PD
 XX
 XX 13-NOV-2003; 2003WO-GB004930.
 PF
 XX 13-NOV-2002; 2002GB-00026497.
 PR
 XX (ISIS-) ISIS INNOVATION LTD.
 PA
 XX Mackenzie I, Rees CMP, Nikitenko LL, Bicknell R, Smith DM;
 PI WPI; 2004-411760/38.
 XX
 XX Use of calcitonin receptor-like receptor (CRLR) genes for determining if
 PT a test compound can regulate expression of CRLR gene, for screening a
 PT test compound to counteract hypertension in glucocorticoid administration
 PT or for tumor therapy.
 XX
 XX Example 4; Page 24; 43pp; English.
 PS
 XX The invention relates to the use of the calcitonin receptor-like receptor
 CC (CRLR) gene for determining whether a test compound can regulate
 CC expression of CRLR gene, screening a test compound for ability to
 CC counteract hypertension in the course of glucocorticoid administration to
 CC a patient, diagnosing a lesion as a tumour, reducing the hypertensive
 CC side effect of a glucocorticoid administration regime in a patient, or
 CC for tumour therapy. The agents, e.g. adrenomedullin, CGRP or functional
 CC analogues of the peptides are useful in manufacture of a preparation for
 CC reducing the hypertensive side effect of a glucocorticoid administration
 CC regime. The compound that up-regulates CRLR gene expression or the up-
 CC regulator of CRLR gene promoter activity is also useful in the
 CC manufacture of a preparation for reducing the hypertensive side-effect of
 CC a glucocorticoid administration regime or for treating a condition where
 CC it is desired to promote vasodilation and/or angiogenesis. The compound
 CC that down-regulates CRLR expression in microvascular endothelial cells
 CC under hypoxic conditions is useful in the manufacture of a medicament for
 CC use in tumour therapy, e.g. a patient identified as having a tumour
 CC exhibiting elevated CRLR or elevated corresponding mRNA. It is also
 CC useful in the manufacture of a combined preparation for simultaneous,
 CC sequential or combined administration of the compound with an
 CC adrenomedullin binding inhibitor for tumour therapy. Glucocorticoid, or
 CC an analogue is useful in the manufacture of a preparation for up-
 CC regulating the CRLR gene promoter in micro vascular endothelial cells or
 CC for up-regulating a glucocorticoid responsive promoter derived from a
 CC CRLR gene in a vector administered for gene therapy. The compound
 CC identifiable or identified as an up-regulator of CRLR gene promoter
 CC activity is useful in the manufacture of a product for use in up-
 CC regulating a glucocorticoid responsive promoter derived from a CRLR gene
 CC in a vector administered for gene therapy. The present sequence
 CC represents a human calcitonin receptor-like receptor, CRLR, gene 5'


```

CC flanking region PCR primer.
XX Sequence 20 BP; 8 A; 10 C; 1 G; 1 T; 0 U; 0 Other;
SQ

Query Match      0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTG 2742
Db 17 GCGTGTGTGTGTGTGTG 1

RESULT 2035
AAQ53171
ID AAQ53171 standard; DNA; 20 BP.
XX AC AAQ53171;
XX 25-MAR-2003 (revised)
DT 09-JUN-1994 (first entry)
XX Familial dysautonomia detection D9S58 primer.
XX Probe; human chromosome 9; FD; gene; screening; ss.
XX Synthetic.
XX WO9324657-A2.
XX 09-DEC-1993.
XX 25-MAY-1993; 93WO-US004946.
XX 29-MAY-1992; 92US-00890719.
XX 16-APR-1993; 93US-00049678.
XX (GEO ) GEN HOSPITAL CORP.
XX Blumenfeld A, Gusella JF, Breakfield XO;
XX WPI; 1993-405845/50.
XX Detection of a gene associated with familial dysautonomia - by analysing
XX human chromosome 9 for DNA polymorphism linked to the gene.
XX Disclosure; Page 25; 50pp; English.
XX The sequence is that of a primer specific for the D9S58 marker
XX polymorphism which may be used in the detection of a gene associated with
XX familial dysautonomia (FD). It may be used in a test kit for screening of
XX fetuses and individuals at risk through their family. (Updated on 25-MAR
XX -2003 to correct PN field.)
XX Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;
SQ

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2853 CCTGAGTAGCTGGGACCAT 2872
Db 1 CCTGAGTAGCTGGGACTATA 20

RESULT 2036
AAQ63001/C
ID AAQ63001 standard; DNA; 20 BP.
XX AC AAQ63001;
XX 25-MAR-2003 (revised)
DT 17-NOV-1994 (first entry)

```

```

XX Hypertension/ACE linkage analysis primer 1.
DE
XX Primer; polymerase chain reaction; PCR; amplify; angiotensinogen; AGT;
XX predisposition; hypertension; human; 5' region; exon;
XX single stranded conformation polymorphism; SSCP; essential hypertension;
XX pregnancy-induced hypertension; ss.
XX Synthetic.
XX OS
XX WO9408048-A1.
XX PN
XX 14-APR-1994.
XX PD
XX 29-SEP-1993; 93WO-US009136.
XX PF
XX 30-SEP-1992; 92US-00952442.
XX PR
XX (UTAH ) UNIV UTAH RES FOUND.
XX PA (INRM ) INSERM INST NAT SANTE & RECH MED.
XX PA
XX Lalouel J, Jeunemaitre X, Lifton RP, Soubrier F, Kotelevtsev Y;
XX Corvol P;
XX PI
XX WPI; 1994-135608/16.
XX DR
XX Use of angiotensinogen gene variants - for determining a predisposition
XX to hypertension, partic essential hypertension or pregnancy-induced
XX hypertension.
XX Example 3; Page 23; 73pp; English.
XX The sequences given in AAQ63001-02 are primers which were used to compare
XX linkage between a predisposition to hypertension with the angiotensin-
XX converting enzyme (ACE) gene. These primers map to the 5' region or the
XX exons of the AGT gene. The amplified products are analysed by single
XX stranded conformation polymorphisms (SSCP) to identify any differences
XX which were then sequenced and compared to the normal gene. These primers
XX can especially be used to determine a predisposition to essential
XX hypertension or pregnancy-induced hypertension. (Updated on 25-MAR-2003
XX to correct PN field.)
XX CC
XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTGCACT 2788
Db 20 CTCGGAGGCTGGAGTGCACT 1

RESULT 2037
AAQ95370/C
ID AAQ95370 standard; DNA; 20 BP.
XX AC AAQ95370;
XX 08-FEB-1996 (first entry)
XX DT
XX Primer B (Group 2, Set A) for marker ATP5B, chromosome 12.
XX DE
XX primer; polymerase chain reaction; PCR; linkage study; locus;
XX microsatellite marker sequence; automated genotyping; allele;
XX polymorphism; detection; Homo sapiens; ss.
XX OS
XX Synthetic.
XX OS
XX WO9515400-A1.
XX PN
XX 08-JUN-1995.
XX PD
XX

```

```

PF 05-DEC-1994; 94WO-US013945.
XX
XX
PR 03-DEC-1993; 93US-00160837.
XX
XX
PA (UVJO ) UNIV JOHNS HOPKINS.
XX
XX
PI Levitt RC;
XX
XX
DR WPI; 1995-215278/28.
XX
XX
XX Kit for automated genotyping contg. pairs of PCR primers - designed to
PT amplify polymorphic nucleotide repeat sequences, arranged in sets each
PT with a characteristic fluorescence label, useful e.g. in detection of
PT disease related genetic rearrangement.
XX
XX
PS Claim 4; Fig 7B-2; 104pp; English.
XX
XX
CC The method aims to provide a collection of highly reproducible
CC microsatellite marker sequences (MMS) at approx. 10-50 cM intervals
CC throughout the human genome which can be detectably labelled. The MMS are
CC polymorphic, simple sequence repeats and can be used in automated
CC genotyping, esp. fluorescence-based. The primers correspond to the unique
CC DNA sequence surrounding each marker, and PCR is used to detect each
CC polymorphism. When the MMS show considerable polymorphism (ie. a
CC difference in the number of repeats) between individuals, the markers can
CC be particularly informative. The MMS can be ideal for linkage studies.
CC Kits comprise at least 4 groups, of at least 3 sets, each comprising
CC labelled primers for PCR amplification of the DNA. Group 2 primer pairs
CC are shown in AAQ95369-416. The published size range of the ATRSB allele
CC is 337-343 bp, and the degree of heterozygosity in the population is
CC about 60%
XX
XX
SQ Sequence 20 BP; 5 A; 1 C; 9 G; 5 T; 0 U; 0 Other;
Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2827 CTCAGTGATCTCCACCT 2846
DB ||||| ||||| ||||| |||||
20 CTCAGTTATCCACCCACCT 1
RESULT 2038
AAV23982/c
ID AAV23982 standard; DNA; 20 BP.
XX
XX
AC AAV23982;
XX
XX
DT 04-AUG-1998 (first entry)
XX
XX
DE Primer for human growth hormone fragment.
XX
XX
KW PCR primer; AGT; angiotensinogen; molecular variant detection;
KW essential hypertension predisposition; plasma AGT; G-6A mutation;
KW pregnancy induced hypertension; growth hormone; ss.
XX
XX
OS Synthetic.
XX
XX
OS Homo sapiens.
XX
XX
FN US5763168-A.
XX
XX
PD 09-JUN-1998.
XX
XX
PF 07-OCT-1994; 94US-00319545.
XX
XX
PR 30-SEP-1992; 92US-00952442.
XX
XX
PA (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
PA (UTAH ) UNIV UTAH RES FOUND.
XX
XX
PI Kotelevtsev Y, Lalouel J, Lifton RP, Corvol P, Jeunemaitre X;
Soubrier F;

```

```

XX WPI; 1998-347304/30.
XX
XX
PT Determination of pre-disposition to hypertension - by detecting mutation
PT G-6A in the angiotensin gene.
XX
XX
PS Example 3; Col 13; 26pp; English.
XX
XX
CC This sequence represents a PCR primer for human growth hormone, that can
CC be used in the method of the invention. The method is for the
CC determination of the predisposition of a human to essential hypertension
CC or pregnancy induced hypertension and comprises, analysing the DNA
CC sequence of the angiotensinogen (AGT) gene for the G-6A mutation, where
CC the presence of the mutation is indicative of a predisposition to
CC essential or pregnancy induced hypertension. The method is useful for the
CC molecular identification of hypertension. The mutation in the AGT gene at
CC position -6 leads to increased plasma AGT concentrations, giving the
CC physiological symptoms for this disease. The mutation (G to A) can be
CC screened for using sequencing methods or hybridisation with a mutation
CC specific primer. Previous disposition to the condition relied on
CC inheritance analysis (ratios, calculations, etc.) between
CC parents/siblings to determine linkage. With the method, a specific
CC diagnosis can be made
XX
XX
SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2769 CACCCAGGCTGGAGTGCAGT 2788
DB ||||| ||||| ||||| |||||
20 CTCGAGGCTGGAGTGCAGT 1
RESULT 2039
AAV85805/c
ID AAV85805 standard; DNA; 20 BP.
XX
XX
AC AAV85805;
XX
XX
DT 10-FEB-1999 (first entry)
XX
XX
DE LRP5 exon primer 58-11 1r.
XX
XX
KW LRP5; LDL-receptor related protein; LRP-3; IDDM; diagnosis; endocytosis;
KW insulin dependent diabetes mellitus; autoimmune disease;
KW glomerulonephritis; inflammation; viral infection; osteoporosis;
KW hypercholesterolemia; Alzheimer's disease; low density lipoprotein;
KW PCR primer; ss.
XX
XX
OS Synthetic.
XX
XX
OS Homo sapiens.
XX
XX
FN WO9846743-A1.
XX
XX
PD 22-OCT-1998.
XX
XX
PF 15-APR-1998; 98WO-GB001102.
XX
XX
PR 15-APR-1997; 97US-0043553P.
PR 05-JUN-1997; 97US-0048740P.
XX
XX
PA (WELL ) WELLCOME TRUST LTD.
PA (MERI ) MERCK & CO INC.
XX
XX
PI Todd JA, Hess JW, Caskey CT, Cox RD, Gerhold D, Hammond H;
PI Hey P, Kawaguchi Y, Merriman TR, Metzker ML, Nakagawa Y;
PI Phillips MS, Twells RCJ;
XX
XX
DR WPI; 1998-594573/50.
XX
XX
PT New isolated LDL-receptor related protein - used to develop products for

```

PT treating, e.g. elevated triglyceride levels, diabetes, autoimmune
PT disorders, inflammation or Alzheimer's disease.

XX Claim 12; Page 106; 200pp; English.

XX The present invention describes LRP5 (low density lipoprotein (LDL)
CC receptor related protein, previously designated LRP-3). AAV85587 to
CC AAV85922 represent exon primers used for obtaining LRP5 cDNA. Nucleic
CC acid molecules (NAMS) encoding LRP5 can be used for determining if an
CC individual is susceptible to insulin dependent diabetes mellitus (IDDM).
CC The NAMS or proteins can be used for reducing triglyceride levels in the
CC serum of an individual. Therapies that affect LRP5 may also be useful in
CC the treatment of autoimmune diseases such as glomerulonephritis, diseases
CC and disorders involving disruption of endocytosis and/or antigen
CC presentation, cytokine clearance and/or inflammation, viral infection,
CC pathogenic bacterial toxin contamination, elevation of free fatty acids
CC or hypercholesterolemia, type 2 diabetes, osteoporosis, Alzheimer's
CC disease and cardiovascular disease. Products from the present invention
CC can also be used for detection, diagnosis and drug screening

XX Sequence 20 BP; 6 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2828 TCAAGTGATCTCTCCACCTC 2847

Db 20 TCAAGTGATCTCTCTGCCTC 1

RESULT 2040

AAV8583/c

ID AAV85883 standard; DNA; 20 BP.

XX

AC AAV85883;

XX

DT 10-FEB-1999 (first entry)

XX

DE LRP5 SNP primer 58-11 lr.

XX

LRP5; LDL-receptor related protein; LRP-3; IDDM; diagnosis; endocytosis;
KW insulin dependent diabetes mellitus; autoimmune disease;
KW glomerulonephritis; inflammation; viral infection; osteoporosis;
KW hypercholesterolemia; Alzheimer's disease; low density lipoprotein;
KW PCR primer; ss.

XX

OS Synthetic.

OS

OS Homo sapiens.

XX

PN W09846743-A1.

XX

PD 22-OCT-1998.

XX

PF 15-APR-1998; 98WO-GB001102.

XX

PR 15-APR-1997; 97US-0043553P.

XX

PR 05-JUN-1997; 97US-0048740P.

XX

(WELL) WELLCOME TRUST LTD.

PA

PA (MERI) MERCK & CO INC.

XX

PI Todd JA, Hess JW, Caskey CT, Cox RD, Gerhold D, Hammond H;

PI

PI Hey P, Kawaguchi Y, Merriman TR, Metzker ML, Nakagawa Y;

PI

PI Phillips MS, Twells RCJ;

XX

DR WPI; 1998-594573/50.

XX

New isolated LDL-receptor related protein - used to develop products for
PT treating, e.g. elevated triglyceride levels, diabetes, autoimmune
PT disorders, inflammation or Alzheimer's disease.

XX

XX Claim 12; Page 111; 200pp; English.

PS

XX The present invention describes LRP5 (low density lipoprotein (LDL)
CC receptor related protein, previously designated LRP-3). AAV85823 to
CC AAV85900 represent SNP primers used for obtaining LRP5 cDNA. Nucleic acid
CC molecules (NAMS) encoding LRP5 can be used for determining if an
CC individual is susceptible to insulin dependent diabetes mellitus (IDDM).
CC The NAMS or proteins can be used for reducing triglyceride levels in the
CC serum of an individual. Therapies that affect LRP5 may also be useful in
CC the treatment of autoimmune diseases such as glomerulonephritis, diseases
CC and disorders involving disruption of endocytosis and/or antigen
CC presentation, cytokine clearance and/or inflammation, viral infection,
CC pathogenic bacterial toxin contamination, elevation of free fatty acids
CC or hypercholesterolemia, type 2 diabetes, osteoporosis, Alzheimer's
CC disease and cardiovascular disease. Products from the present invention
CC can also be used for detection, diagnosis and drug screening

XX Sequence 20 BP; 6 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2828 TCAAGTGATCTCTCCACCTC 2847

Db 20 TCAAGTGATCTCTCTGCCTC 1

RESULT 2041

AAZ37734/c

ID AAZ37734 standard; DNA; 20 BP.

XX

AC AAZ37734;

XX

XX 07-JAN-2000 (first entry)

XX

DT Human mdm2 phosphorothioate oligodeoxynucleotide #264.

DE

Human mdm2 gene; proliferation; tumour; phosphorothioate; p53; cancer;
KW antisenese; modulation; oligonucleotide; expression; inhibition;
KW hyperproliferation; blood cancer; brain cancer; breast cancer;
KW lung cancer; soft tissue cancer; psoriasis; fibrosis; atherosclerosis;
KW restenosis; ss.

XX

OS Synthetic.

OS

OS Homo sapiens.

XX

PN W09949065-A1.

XX

PN 30-SEP-1999.

XX

PF 26-MAR-1999; 99WO-US006702.

XX

PR 26-MAR-1998; 98US-00048810.

XX

(ISIS-) ISIS PHARM INC.

XX

PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowse LM;

XX

XX WPI; 1999-610754/52.

XX

New antisenese compounds used to treat eg. hyperproliferative conditions.

XX

XX Claim 4; Page 55; 157pp; English.

XX

AAZ37473-237738 represent human mdm2 phosphorothioate oligonucleotides.
CC AAZ37471, AAZ37472, AAZ37739, AAZ37740 and AAZ37741 are used in the
CC exemplification of the present invention. The present invention describes
CC novel nucleotide antisenese compounds, targeted to the 5' untranslated,
CC translation termination codon, or 3' untranslated region of a nucleic
CC acid encoding human mdm2, that modulates expression of human mdm2. The
CC oligonucleotides mediate their effect by antisense inhibition of
CC hyperproliferative gene expression. The antisense compound is used to
CC treat an animal having a disease or condition associated with mdm2,

CC particularly a hyperproliferative condition, more particularly cancer,
 CC especially of the blood, brain, breast, lung or soft tissue, or
 CC psoriasis, fibrosis, atherosclerosis or restenosis

SQ Sequence 20 BP; 4 A; 4 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 1.2e+03;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2833 TGATCCTCCACCTCAGCCT 2852

DB 20 TGATCCGCCACCTCGGCCT 1

RESULT 2042

AAZ37711/C

ID AAZ37711 standard; DNA; 20 BP.

AC AAZ37711;

XX 07-JAN-2000 (first entry)

XX Human mdm2 phosphorothioate oligodeoxynucleotide #241.

XX Human mdm2 gene; proliferation; tumour; phosphorothioate; p53; cancer;
 KW antisense; modulation; oligonucleotide; expression; inhibition;
 KW hyperproliferation; blood cancer; brain cancer; breast cancer;
 KW lung cancer; soft tissue cancer; psoriasis; fibrosis; atherosclerosis;
 KW restenosis; ss.

XX Synthetic.

OS Homo sapiens.

PN WO9949065-A1.

XX 30-SEP-1999.

XX 26-MAR-1999; 99WO-US006702.

XX 26-MAR-1998; 98US-00048810.

XX (ISIS-) ISIS PHARM INC.

XX Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowsett LM;

XX WPI; 1999-610754/52.

XX New antisense compounds used to treat eg. hyperproliferative conditions.

XX Example 9; Page 54; 157pp; English.

XX AAZ37473-237738 represent human mdm2 phosphorothioate oligonucleotides.
 CC AAZ37471, AAZ37472, AAZ37739, AAZ37740 and AAZ37741 are used in the
 CC exemplification of the present invention. The present invention describes
 CC novel nucleotide antisense compounds, targeted to the 5' untranslated,
 CC translation termination codon, or 3' untranslated region of a nucleic
 CC acid encoding human mdm2, that modulates expression of human mdm2. The
 CC oligonucleotides mediate their effect by antisense inhibition of
 CC hyperproliferative gene expression. The antisense compound is used to
 CC treat an animal having a disease or condition associated with mdm2,
 CC particularly a hyperproliferative condition, more particularly cancer,
 CC especially of the blood, brain, breast, lung or soft tissue, or
 CC psoriasis, fibrosis, atherosclerosis or restenosis

SQ Sequence 20 BP; 7 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 1.2e+03;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TCGTCTGTGTCACCCAGGCTG 2779

||||||| |||||||

DB 20 TTGCTCTGTATTACCCAGGCTG 1

RESULT 2043

AAZ21785/C

ID AAZ21785 standard; DNA; 20 BP.

AC AAZ21785;

XX 01-DEC-1999 (first entry)

XX Exemplary oligonucleotide primer D9S758 (For).

XX neoplasia; mutant; target nucleotide; hybridization; lung cancer; ss;
 KW neck cancer; head cancer; saliva test; chemotherapy; early detection;
 KW primer; PCR; amplification.

XX Synthetic.

OS Homo sapiens.

XX WO9946408-A1.

XX 16-SEP-1999.

XX 10-MAR-1999; 99WO-US005220.

XX 10-MAR-1998; 98US-00038637.

XX (UYJO) UNIV JOHNS HOPKINS SCHOOL MEDICINE.

XX Sidransky D;

XX WPI; 1999-551428/46.

XX Detection of cancers comprises assaying for a genetic mutation associated
 with cancer.

XX Disclosure; Page 28; 99pp; English.

XX This is an exemplary oligonucleotide primer, for use in the detection of
 CC neoplastic related gene mutations. There are over 40 known proto-
 CC oncogenes and suppressor genes to date, which control growth,
 CC development, and cell differentiation. Regulation of these genes can,
 CC under certain circumstances, be altered and normal cells can assume
 CC neoplastic growth characteristics. The invention provides a method for
 CC detecting a neoplastic disorder of the head and neck or lung in a
 CC subject. The detection of a target mutant nucleotide sequence in the
 CC saliva is indicative of a neoplastic disorder of the head, neck or lung.
 CC This allows early detection and therefore treatment of the preneoplasia
 CC or cancer, and can also be used to monitor high risk patients undergoing
 CC chemoprevention or chemotherapy

SQ Sequence 20 BP; 7 A; 4 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 1.2e+03;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTGCTCTGTGTCACCCAGGCT 2778

DB 20 CTGCTTTGTGTCACCCAGGCT 1

RESULT 2044

AAZ21793/C

ID AAZ21793 standard; DNA; 20 BP.

AC AAZ21793;

XX 01-DEC-1999 (first entry)

XX Exemplary oligonucleotide primer L17835 (For).

XX

KW neoplasia; mutant; target nucleotide; hybridization; lung cancer; ss;
 KW neck cancer; head cancer; saliva test; chemotherapy; early detection;
 KW primer; PCR; amplification.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN W09946408-A1.
 XX
 PD 16-SEP-1999.
 XX
 PF 10-MAR-1999; 99WO-US005220.
 XX
 PR 10-MAR-1998; 98US-00038637.
 XX
 PA (UYJO) UNIV JOHNS HOPKINS SCHOOL MEDICINE.
 XX
 PI Sidransky D;
 XX
 XX WPI; 1999-551428/46.
 DR
 XX
 PT Detection of cancers comprises assaying for a genetic mutation associated
 with cancer.
 XX
 PS Disclosure; Page 28; 99pp; English.
 XX
 CC This is an exemplary oligonucleotide primer, for use in the detection of
 CC neoplastic related gene mutations. There are over 40 known proto-
 CC oncogenes and suppressor genes to date, which control growth,
 CC development, and cell differentiation. Regulation of these genes can,
 CC under certain circumstances, be altered and normal cells can assume
 CC neoplastic growth characteristics. The invention provides a method for
 CC detecting a neoplastic disorder of the head and neck or lung in a
 CC subject. The detection of a target mutant nucleotide sequence in the
 CC saliva is indicative of a neoplastic disorder of the head, neck or lung.
 CC This allows early detection and therefore treatment of the preneoplasia
 CC or cancer, and can also be used to monitor high risk patients undergoing
 CC chemoprevention or chemotherapy
 XX
 SQ Sequence 20 BP; 5 A; 8 C; 2 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2776 GCTGGAGTGCAGTGGTGCAA 2795
 Db 20 GCTGGAGTATAGTGGTGCAA 1
 RESULT 2045
 AAZ18580/c
 ID AAZ18580 standard; DNA; 20 BP.
 XX
 AC AAZ18580;
 XX
 XX
 DT 19-OCT-1999 (first entry)
 DE
 DE Primer for ASTH1 polymorphic microsatellite marker.
 XX
 KW ASTH1; asthma; human; chromosome 11p; ASTH1I; ASTH1J; genetic locus; ss;
 KW therapeutic; immunogen; polymorphism; PCR primer; microsatellite marker.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN W09937809-A1.
 XX
 PD 29-JUL-1999.
 XX
 PF 21-JAN-1998; 98WO-US001260.
 XX
 PR 21-JAN-1998; 98WO-US001260.

XX
 PA (AXYS-) AXYS PHARM INC.
 XX
 PI Brooks-Wilson AR, Buckler A, Cardon L, Carey AH, Galvin M;
 PI Miller A, North M;
 XX
 XX WPI; 1999-479058/40.
 DR
 XX
 PT Mammalian asthma related genes, useful for diagnosis of a predisposition
 to development of asthma.
 PT
 XX
 PS Disclosure; Page 50; 195pp; English.
 XX
 CC The invention identifies a genetic locus ASTH1, associated with asthma,
 CC mapped to human chromosome 11p. ASTH1I and ASTH1J are genes present
 CC within the locus, located close to each other on human chromosome 11p,
 CC and have similar patterns of expression, and common sequence motifs. The
 CC ASTH1 genes and fragments, encoded protein, genomic regulatory regions
 CC and anti-ASTH1 antibodies are useful in the identification of individuals
 CC predisposed to development of asthma, and for the modulation of gene
 CC activity in vivo for prophylactic and therapeutic purposes. The ASTH1
 CC protein is useful as an immunogen to raise specific antibodies, in drug
 CC screening for compositions that mimic or modulate ASTH1 activity or
 CC expression, including altered forms of ASTH1 protein, and as a
 CC therapeutic. Sequences AAZ18510-218631 represent PCR primers for
 CC polymorphic microsatellite markers in the ASTH1 region
 CC
 SQ Sequence 20 BP; 6 A; 3 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2759 CTCGCTCTCTCACCCAGGCT 2778
 Db 20 CTCACCTCTCTCTCCAGGCT 1
 RESULT 2046
 AAA96399/c
 ID AAA96399 standard; DNA; 20 BP.
 XX
 AC AAA96399;
 XX
 DT 08-FEB-2001 (first entry)
 DE
 DE Primer used to amplify a sara31/32 polymorphic microsatellite repeat.
 XX
 KW Autoimmune disease; polymorphic microsatellite repeat; PMR; CD28 gene;
 KW ICOS gene; CTLA4 gene; costimulatory receptor gene locus; CGRL; lupus;
 KW insulin-dependent diabetes mellitus; IDDM; Addison's disease; leprosy;
 KW Graves disease; autoimmune hypothyroidism; myasthenia gravis; thymoma;
 KW thyroiditis; postpartum thyroiditis; rheumatoid arthritis;
 KW Hashimoto's disease; coeliac disease; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN W0200056856-A2.
 XX
 PD 28-SEP-2000.
 XX
 PF 24-MAR-2000; 2000WO-US007938.
 XX
 PR 25-MAR-1999; 99US-0126215P.
 XX
 XX (GEMY) GENETICS INST INC.
 XX
 PI Ling V, Wu P, Gray GS;
 XX
 XX WPI; 2000-628257/60.
 DR
 XX
 PT Determining predisposition of humans to develop autoimmune disease
 involves detecting polymorphic microsatellite repeat sequence within

CC dysautonomia comprising analyzing human chromosome 9. The method comprises analyzing human chromosome 9 for the presence of a polymorphism

2769 CACCCAGGCTGGAGTGCAGT 2788

```
Db      20  CTCGAGGCTGGAGTGCACT 1
|||||
RESULT 2049
AAZ38449/C
ID  AAZ38449 standard; DNA; 20 BP.
XX
XX
AC  AAZ38449;
XX
XX  22-FEB-2000 (first entry)
XX
XX  Human growth hormone (hGH)-A1819 PCR primer #1.
DE
XX
XX  Angiotensinogen; hypertension; pathogenesis; exon; allele; mutation;
KW  variant; susceptibility; predisposition; essential; pregnancy-induced;
KW  detection; diagnosis; management; ACE; angiotensin-converting enzyme;
KW  linkage; analysis; growth hormone; hGH; PCR; primer; ss.
XX
XX  Synthetic.
OS
XX  Homo sapiens.
OS
XX  US998145-A.
PN
XX  07-DEC-1999.
XX
XX  08-JUN-1998; 98US-00092988.
XX
XX  30-SEP-1992; 92US-00952442.
PR
XX  07-OCT-1994; 94US-00319545.
XX
XX  (UTAH ) UNIV UTAH RES FOUND.
PA
XX  (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
XX
XX  Lalouel J, Jeunemaitre X, Soubrier F, Kotelevtsev Y, Corvol P;
PI  Lifton RP;
XX
XX  WPI; 2000-052541/04.
XX
XX  Analyzing the DNA sequence of the angiotensinogen (AGT) gene for the
PT  mutation A-20C is useful for determining a predisposition to
PT  hypertension.
XX
XX  Example 3; Col 13; 25pp; English.
XX
XX  This sequence represents hGH-A1819 PCR primer #1, used with primer #2.
CC  (AAZ38450) to amplify a portion of the human growth hormone (hGH) gene
CC  for linkage analysis with the angiotensin-converting enzyme (ACE) gene.
CC  Genetic studies revealed that the genes encoding two key enzymes in the
CC  angiotensin II synthetic pathway, renin and ACE, were not associated with
CC  human hypertension; however, the angiotensinogen (AGT) gene was involved
CC  in the pathogenesis of essential hypertension. Sequence variations in the
CC  AGT gene can be identified via amplification of gene fragments via PCR,
CC  using primers AAZ38431-Z38448, and subsequent sequence analysis.
CC  Molecular variants of the AGT gene contribute to an individual's
CC  susceptibility to the development of hypertension. Analysis of the AGT
CC  gene can be used to identify individuals with a genetic predisposition to
CC  develop essential hypertension or pregnancy-induced hypertension.
CC  Detection of a predisposition would then allow specific management of
CC  hypertension in these subjects e.g., by dietary sodium restriction, by
CC  monitoring blood pressure and treating with conventional drugs, by
CC  administration of renin inhibitors or by administration of drugs to
CC  inhibit synthesis of AGT
XX
XX  Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2769  CACCGAGGCTGGAGTGCACT 2788
|||||
ID  20  CTCGAGGCTGGAGTGCACT 1

RESULT 2051
AAZ11941/C
ID  AAZ11941 standard; DNA; 20 BP.
XX
XX
AC  AAZ11943;
XX
XX  16-AUG-2000 (first entry)
XX
XX  Human MDMX antisense oligonucleotide #31223.
DE
XX
XX  MDMX; human; antisense; inhibitor; anticarcinogen; antiinflammatory;
KW  antiinfectious; modulation; treatment; disease; diagnosis; primer; ss.
XX
XX  Homo sapiens.
OS
XX  US6046320-A.
PN
XX  04-APR-2000.
XX
XX  09-APR-1999; 99US-00289267.
XX
XX  09-APR-1999; 99US-00289267.
XX
XX  (ISIS-) ISIS PHARM INC.
XX
XX  Monia BP, Cowseert LM;
PI
XX  WPI; 2000-282710/24.
XX
XX  New antisense oligonucleotides targeting nucleic acids encoding human
PT  MDMX useful for inhibiting MDMX expression and for treating diseases
PT  associated with MDMX expression e.g. tumor formation, inflammation.
XX
XX  Example 15; Col 97-98; 51pp; English.
XX
XX  This invention describes a novel antisense compound (I), 8-30 nucleobases
CC  in length, targeted to a nucleic acid encoding a human MDMX. (I)
CC  specifically hybridizes with and inhibits the expression of human MDMX.
CC  The products of the invention have anticarcinogen, antiinflammatory and
CC  antiinfectious activity. Synthesized chimeric oligonucleotides targeted
CC  to human MDMX, 20 nucleotides in length, composed of a central gap region
CC  consisting of ten 2'-deoxynucleotides flanked on both sides by 5-
CC  nucleotide wings were tested for antisense inhibition of MDMX expression.
CC  Results of real-time quantitative polymerase chain reaction (PCR) showed
CC  71 out of the 159, 20 base pair sequences, all fully defined in the
CC  specification, demonstrated at least 30% inhibition of MDMX expression.
CC  The antisense oligonucleotides are useful for effective and specific
CC  modulation, particularly inhibition of MDMX expression, and may be used
CC  in treating humans or animals suspected of having or being prone to a
CC  disease or condition associated with expression of MDMX. The antisense
CC  oligonucleotides may also be used as research reagents or kits, and as
CC  diagnostics, e.g. to elucidate the function of a particular gene or to
CC  distinguish between functions of various members of a biological pathway,
CC  and as prophylaxis, e.g. to prevent or delay infection, inflammation or
CC  tumor formation. AAZ11781-A11945 represent antisense oligonucleotides
CC  described in the method of the invention
XX
XX  Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2776  GCTGGAGTGCAGTGGTGCAA 2795
|||||
Db      1  GCTGGAGTGCAGTGGTGCAA 20
|||||

RESULT 2051
AAZ11941/C
ID  AAZ11941 standard; DNA; 20 BP.
```

XX AC AA11941;
 XX 16-AUG-2000 (first entry)
 XX DE Human MDMX antisense oligonucleotide #31222.
 XX MDMX; human; antisense; inhibitor; anticarcinogen; antiinflammatory;
 KW antiinfectious; modulation; treatment; disease; diagnosis; primer; ss.
 XX OS Homo sapiens.
 XX PN US6046320-A.
 XX PD 04-APR-2000.
 XX PF 09-APR-1999; 99US-00289267.
 XX PR 09-APR-1999; 99US-00289267.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Monia BP, Cowser LM;
 XX DR WPI; 2000-282710/24.
 XX PT New antisense oligonucleotides targeting nucleic acids encoding human
 PT MDMX useful for inhibiting MDMX expression and for treating diseases
 PT associated with MDMX expression e.g. tumor formation, inflammation.
 XX PS Example 15; Col 97-98; 51pp; English.
 XX CC This invention describes a nucleic acid encoding (I), 8-30 nucleobases
 CC in length, targeted to a nucleic acid encoding a human MDMX. (I)
 CC specifically hybridizes with and inhibits the expression of human MDMX.
 CC The products of the invention have anticarcinogen, antiinflammatory and
 CC antiinfectious activity. Synthesized chimeric oligonucleotides targeted
 CC to human MDMX, 20 nucleotides in length, composed of a central gap region
 CC consisting of ten 2'-deoxynucleotides flanked on both sides by 5-
 CC nucleotide wings were tested for antisense inhibition of MDMX expression.
 CC Results of real-time quantitative polymerase chain reaction (PCR) showed
 CC 71 out of the 159, 20 base pair sequences, all fully defined in the
 CC specification, demonstrated at least 30% inhibition of MDMX expression.
 CC The antisense oligonucleotides are useful for effective and specific
 CC modulation, particularly inhibition of MDMX expression, and may be used
 CC in treating humans or animals suspected of having or being prone to a
 CC disease or condition associated with expression of MDMX. The antisense
 CC oligonucleotides may also be used as research reagents or kits, and as
 CC diagnostics, e.g. to elucidate the function of a particular gene or to
 CC distinguish between functions of various members of a biological pathway,
 CC and as prophylaxis, e.g. to prevent or delay infection, inflammation or
 CC tumor formation. AA11781-11945 represent antisense oligonucleotides
 CC described in the method of the invention
 XX SQ Sequence 20 BP; 6 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2764 TCTGTACCCAGGCTGAAGT 2783
 Db 20 TCTGTCTCCAGGCTGAAGT 1
 RESULT 2052
 AAA80487/c
 ID AAA80487 standard; DNA; 20 BP.
 AC AAA80487;
 XX XX
 XX 22-NOV-2000 (first entry)
 XX

DE ASTH1 polymorphic microsatellite marker CA39_2 primer, SEQ ID NO:230.
 XX ASTH1 locus; ASTH1I; ASTH1J; human; chromosome 11p; asthma;
 KW bronchial hyperreactivity; ets family; transcription factor;
 KW splice variant; genetic predisposition; polymorphism; antibody;
 KW drug screening; prophylaxis; therapy; diagnosis;
 KW polymorphic microsatellite marker flanking sequence;
 XX batched analysis of genotypes; BAGs; PCR primer; ss.
 XX OS Homo sapiens.
 XX PN US6087485-A.
 XX PD 11-JUL-2000.
 XX PF 21-JAN-1998; 98US-00009913.
 XX PR 21-JAN-1997; 97US-0035663P.
 XX PR 01-JUL-1997; 97US-0051432P.
 XX PA (AXYS-) AXYS PHARM INC.
 XX PI Galvin M, Miller A, North M, Cardon L, Buckler A;
 PI Brooks-Wilson AR, Carey AH;
 XX DR WPI; 2000-505109/45.
 XX PT New nucleic acids other than naturally occurring chromosomes encoding
 PT ASTH1 protein, for e.g. screening compositions that modulate expression
 PT or function of ASTH1 proteins or as diagnostics for genetic
 PT predisposition to asthma.
 XX PS Example; Col 31-32; 131pp; English.
 XX CC The invention relates to the ASTH1 locus on the short arm of human
 CC chromosome (11p). This locus comprises the ASTH1I and ASTH1J genes, which
 CC are associated with a genetic predisposition to asthma and bronchial
 CC hyperreactivity. The ASTH1I and ASTH1J genes are oriented in opposite
 CC directions with the ASTH1 locus, and have similar patterns of expression
 CC and common sequence motifs. They are both expressed in trachea, lung and
 CC several other tissues. ASTH1I and ASTH1J are novel members of the ets
 CC family of transcription factors, which have been implicated in the
 CC activation of a variety of genes including the TCRA gene and cytokine
 CC genes known to be important in the aetiology of asthma. Both ASTH1I and
 CC ASTH1J mRNAs are alternatively spliced. Alternative splicing of
 CC transcripts has no effect on the open reading frame of ASTH1J, as the
 CC exons involved are all 5' to the start codon in exon b. In contrast,
 CC alternative splicing of ASTH1I transcripts results in 3 different ASTH1I
 CC isoforms. The invention also encompasses mouse asth1j protein. The ASTH1
 CC nucleic acids are useful as diagnostics to identify a hereditary
 CC predisposition to asthma, as probes for identifying ASTH1 related genes,
 CC for identifying expression of the gene in a biological specimen, and for
 CC generating genetically modified non-human animals or site specific gene
 CC modifications in cell lines. The encoded ASTH1 proteins are useful as
 CC immunogens to raise specific antibodies; in drug screening for
 CC compositions that mimic or modulate activity or expression of ASTH1I
 CC and/or ASTH1J (including altered forms of these proteins); and as a
 CC therapeutic. The ASTH1I genes or fragments thereof, encoded proteins,
 CC ASTH1I genomic regulatory regions, and anti-ASTH1I and anti-ASTH1J
 CC antibodies are useful in the identification of individuals predisposed to
 CC development of asthma, and for modulation of gene activity in vivo for
 CC prophylactic and therapeutic purposes. The intact ASTH1I or ASTH1J
 CC proteins or active fragments thereof may be used to modulate or reduce
 CC bronchial hyperreactivity. Sequences AAA80417-AAA80538 represent sequences
 CC flanking polymorphic microsatellite markers in the ASTH1 region, which
 CC were also used as PCR primers for amplification of the markers for
 CC batched analysis of genotypes (BAGs)
 XX SQ Sequence 20 BP; 6 A; 3 C; 9 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTGGCTCTGTCCACCGGCT 2778
 DB 20 CTCACTCTGTCTCCAGGCT 1

RESULT 2053
 AAF92856/c
 ID AAF92856 standard; DNA; 20 BP.
 XX
 AC AAF92856;
 XX
 DT 17-MAY-2001 (first entry)
 XX
 DE Human ABC1 transcription factor binding site #18.
 XX
 KW High density lipoprotein-cholesterol; HDL-C; cardiovascular; ABC1; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200115676-A2.
 XX
 PD 08-MAR-2001.
 XX
 PF 01-SEP-2000; 2000WO-IB001492.
 XX
 PR 01-SEP-1999; 99US-0151977P.
 PR 15-MAR-2000; 2000US-00526193.
 PR 23-JUN-2000; 2000US-0213958P.
 XX
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 PA (XENO-) XENON GENETICS INC.
 XX
 PI Hayden MR, Brooks-Wilson AR, Pimstone SN, Clee SM;
 XX
 XX WPI; 2001-244356/25.
 XX
 PT Treating a lower than normal high density lipoprotein-cholesterol (HDL-C)
 PT level, a higher than normal triglyceride level, or a cardiovascular
 PT disease, by administering a compound that modulates LXR- or RXR-mediated
 PT transcriptional activity.
 XX
 PS Disclosure; Fig 3; 317pp; English.
 XX
 CC The present invention relates to a method for treating a patient
 CC diagnosed as having a lower than normal high density lipoprotein-
 CC cholesterol (HDL-C) level, a higher than normal triglyceride level, or a
 CC cardiovascular disease, involving administering a compound that modulates
 CC LXR- or RXR-mediated transcriptional activity or ABC1 expression or
 CC activity. The LXR gene product may be used in an assay to identify
 CC compounds useful for the treatment of a disease or condition selected a
 CC lower than normal HDL cholesterol level, a higher than normal
 CC triglyceride level, and a cardiovascular disease
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2782 GTGCAGTGGTGCAATCATGG 2801
 DB 20 GTGCAGTGGTGCAATCATGG 1

RESULT 2054
 AAF80888/c
 ID AAF80888 standard; DNA; 20 BP.
 XX
 AC AAF80888;
 XX
 DT 02-MAY-2001 (first entry)
 XX
 XX

DE Human mdm2 phosphorothioate oligonucleotide #262.
 XX
 KW Antisense; mdm2; hyperproliferation; cancer; psoriasis; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6184212-B1.
 XX
 PD 06-FEB-2001.
 XX
 PF 26-MAR-1999; 99US-00280805.
 XX
 PR 26-MAR-1998; 98US-00048810.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowse LM;
 XX
 XX WPI; 2001-190948/19.
 XX
 PT Novel antisense compound 8-30 nucleobases in length targeted to a nucleic
 PT acid molecule encoding human mdm-2 useful for modulating the expression
 PT of human mdm-2 and reducing hyperproliferation of human cells.
 XX
 PS Example 9; Col 33; 77pp; English.
 XX
 CC The present invention relates to an antisense compound 8-30 nucleobases
 CC in length targeted to nucleobases 1-308 of the 5' untranslated region,
 CC 1776-1806 of the translation termination codon region or 1818-2370 of the
 CC 3' untranslated region of a nucleic acid molecule encoding human mdm-2.
 CC The invention is useful for reducing hyperproliferation of human cells,
 CC modulating the expression of mdm2 in human cells or tissues or in vitro.
 CC The hyperproliferative disorder includes cancer or psoriasis
 XX
 SQ Sequence 20 BP; 4 A; 4 C; 10 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2833 TGATCTCCACCTCAGCT 2852
 DB 20 TGATCGCCACCTCGGCT 1

RESULT 2055
 AAF80865/c
 ID AAF80865 standard; DNA; 20 BP.
 XX
 AC AAF80865;
 XX
 DT 02-MAY-2001 (first entry)
 XX
 DE Human mdm2 phosphorothioate oligonucleotide #239.
 XX
 KW Antisense; mdm2; hyperproliferation; cancer; psoriasis; ss.
 XX
 OS Homo sapiens.
 XX
 PN US6184212-B1.
 XX
 PD 06-FEB-2001.
 XX
 PF 26-MAR-1999; 99US-00280805.
 XX
 PR 26-MAR-1998; 98US-00048810.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowse LM;
 XX
 XX WPI; 2001-190948/19.
 XX

PT Novel antisense compound 8-30 nucleobases in length targeted to a nucleic
 PT acid molecule encoding human mdm-2 useful for modulating the expression
 PT of human mdm-2 and reducing hyperproliferation of human cells.

XX Example 9; Col 31; 77pp; English.

XX
 CC The present invention relates to an antisense compound 8-30 nucleobases
 CC in length targeted to nucleobases 1-308 of the 5' untranslated region,
 CC 1776-1806 of the translation termination codon region or 1818-2370 of the
 CC 3' untranslated region of a nucleic acid molecule encoding human mdm-2.
 CC The invention is useful for reducing hyperproliferation of human cells,
 CC modulating the expression of mdm2 in human cells or tissues or in vitro.
 CC The hyperproliferative disorder includes cancer or psoriasis

XX Sequence 20 BP; 7 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. NO. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTCCACCCAGGCTG 2779

DB 20 TTGCTCTGTACCAGGCTG 1

RESULT 2056

AAS09243
 ID AAS09243 standard; DNA; 20 BP.

XX AAS09243;

XX 24-OCT-2001 (first entry)

XX PCR primer #1 for marker D9S58 associated with familial dysautonomia.

XX Human; familial dysautonomia; chromosome 9q31-q33; Riley-Day syndrome;
 KW FD; developmental loss of neuron; nervous system; DNA marker D9S58;
 KW PCR primer; ss.

XX Homo sapiens.

XX US6262250-B1.

XX 17-JUL-2001.

XX 07-DEC-1999; 99US-00455683.

XX 29-MAY-1992; 92US-00890719.

PR 16-APR-1993; 93US-00049678.

XX 07-JUN-1995; 95US-00480655.

XX (GEO) GEN HOSPITAL CORP.

XX Blumenfeld A, Gusella JF, Breakfield XO, Slaugenhaut P;

XX WPI; 2001-450493/48.

XX Kit for detecting presence of polymorphisms linked to gene associated
 PT with familial dysautonomia (FD), comprises specific primers which detect
 PT polymorphisms, D9S309 and D9S310 identified in candidate region for FD
 PT gene.

XX Disclosure; Col 10; 28pp; English.

XX The present sequence for PCR primer #1 is used with PCR primer #2
 CC (AAS09244) to amplify DNA marker D9S58. Various oligonucleotide sequences
 CC (AAS09239-AAS09272) are described in an invention relating to the
 CC detection of polymorphisms associated with familial dysautonomia (FD).
 CC The FD gene has been mapped to chromosome 9q31-q33 by linkage with 10 DNA
 CC markers in 26 FD families. A kit to detect the presence of polymorphisms
 CC linked to a gene associated with FD, the Riley-Day syndrome (an autosomal
 CC recessive disorder characterised by developmental loss of neurons from
 CC sensory and autonomic nervous system) in an individual, comprises a

CC nucleic acid primer of at least 15 contiguous nucleotides and at least
 CC one other reagent. The kits are useful for diagnosing familial
 CC dysautonomia and the test can be used prenatally to screen a foetus, or
 CC presymptomatically to screen a subject at risk in affected FD families

XX Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. NO. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2853 CCTGAGTAGCTGGGACCATTA 2872

DB 1 CCTGAGTAGCCGGGACTATA 20

RESULT 2057

AAH39717
 ID AAH39717 standard; DNA; 20 BP.

XX AAH39717;

XX 14-AUG-2001 (first entry)

XX SNP specific upper PCR primer SEQ ID 2513.

XX Single nucleotide polymorphism; SNP; single nucleotide primer extension;
 KW SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
 KW Leach-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
 KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
 KW acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
 KW inflammation; forensic investigation; paternity analysis; PCR primer; ss.

XX Homo sapiens.

XX WO200129262-A2.

XX 26-APR-2001.

XX 13-OCT-2000; 2000WO-US028436.

XX 15-OCT-1999; 99US-0160096P.

XX (ORCH-) ORCHID BIOSCIENCES INC.

XX Picoult-Newburg L, Pohl M;

XX WPI; 2001-2909330/30.

XX New genotyping oligonucleotide, useful for detecting the presence,
 PT absence or identity of single polynucleotide polymorphism in a nucleic
 PT acid sample.

XX Claim 1; Page 62; 83pp; English.

XX Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
 CC primer extension (SNPE) primers, and the sequences of regions flanking
 CC sites of single nucleotide polymorphisms SNPs. The present invention
 CC includes kits for determining the presence or absence of a SNP, using the
 CC oligonucleotides of the invention. The PCR primers are used to amplify a
 CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.
 CC The oligonucleotides are useful for genotyping a nucleic acid sample by
 CC performing a single-nucleotide primer extension reaction. The
 CC oligonucleotides are useful for determining the presence, absence or
 CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to
 CC assess by association analysis the genotype of an individual or group of
 CC individuals, having a pathological phenotypic trait suspected of being
 CC caused by one or more SNPs. Phenotypic traits include diseases e.g.
 CC agammaglobulinaemia, diabetes insipidus, Leach-Nyhan syndrome, muscular
 CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
 CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
 CC traits also include symptoms of or susceptibility to multifactorial
 CC disease of which a component is or may be genetic such as autoimmune

CC diseases, including, rheumatoid arthritis, multiple sclerosis,
 CC inflammation, cancer, nervous system diseases and infection by pathogenic
 CC microorganism. The method is also useful in forensic investigations and
 CC paternity analysis. The present sequence represents a PCR primer specific
 CC for a human SNP containing DNA sequence

XX
 SQ Sequence 20 BP; 5 A; 9 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 1.2e+03;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2828 TCAAGTGATCCTCCACCTC 2847

Db 1 TCAAGGATCCTCACACCTC 20

RESULT 2058

AAC67119/c

ID AAC67119 standard; DNA; 20 BP.

XX AAC67119;

XX 03-APR-2001 (first entry)

DT

XX Human growth hormone gene PCR primer #1.

DE

XX Angiotensinogen; AGT; variant; human; hypertension; M235T mutation;

KW predisposition; PCR primer; ss.

XX Homo sapiens.

OS

XX US6165727-A.

XX 26-DEC-2000.

XX 29-OCT-1999; 99US-00429034.

XX 30-SEP-1992; 92US-00952442.

PR 07-OCT-1994; 94US-00319545.

PR 08-JUN-1998; 98US-00092988.

XX (UTAH) UNIV UTAH RES FOUND.

PA (INRM) INSERM INST NAT SANTE & RECH MEDICALE.

XX Lalouel J, Lifton RP, Soubrier F, Kotelevtsev Y, Corvol P;

PI Jeunemaitre X;

XX WPI; 2001-101691/11.

XX Determining predisposition of a human to hypertension, involves analyzing

PT DNA sequence of angiotensinogen for a mutation which is in linkage

PT disequilibrium with specific mutation.

XX Example 3; Col 12; 26pp; English.

XX The present invention describes a method for determining the

CC predisposition of an individual to hypertension, involving analysing the

CC angiotensinogen (AGT) alleles they possess. Individuals with a M235T

CC mutation in the angiotensinogen gene are at an increased risk of

CC hypertension

XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

SQ

Query Match 0.6%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 1.2e+03;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTGCAGT 2788

Db 20 CTCGAGGCTGGAGTGCAGT 1

RESULT 2059

AAS29480/c

ID AAS29480 standard; DNA; 20 BP.

XX AAS29480;

XX 21-NOV-2001 (first entry)

XX Human mdm2 antisense oligonucleotide 31467.

DE

XX Human; mdm2; hyperproliferative disorder; cancer; psoriasis;

KW atherosclerosis; tumour; cytostatic; anti psoriatic;

KW anti arteriosclerotic; vasotropic; antisense; phosphorothioate; ss.

XX Homo sapiens.

OS

XX Key

modified_base 1..20

FT Location/Qualifiers

FT /*tag= a

FT /mod_base= OTHER

FT /note= "OTHER= All phosphorothioate linkages,

FT additionally bases 1-6 and bases 15-20 are 2'-O-

FT methoxyethyl bases, and bases 7-14 are deoxynucleotides"

XX US2001016575-A1.

XX 23-AUG-2001.

XX 02-JAN-2001; 2001US-00752983.

XX 26-MAR-1998; 98US-00048810.

PR 26-MAR-1999; 99US-00280805.

XX (MIRA/) MIRAGLIA L J.

PA (NERO/) NERO P.

PA (GRAH/) GRAHAM M J.

PA (MONI/) MONIA B P.

PA (COWS/) COWSERT L M.

XX Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowsert LM;

XX WPI; 2001-535565/59.

XX An antisense compound, useful for treating e.g. cancer, comprises

PT nucleobases targeted a region (e.g. translation termination codon region)

PT of a nucleic acid encoding human mdm2.

XX Example 9; Page 18; 81pp; English.

XX The present invention relates to antisense compounds, 8-30 nucleobases in

CC length targeted to the 5' untranslated region, translation termination

CC codon region, 3' untranslated region, coding region or translation start

CC site of a nucleic acid encoding human mdm2, where the antisense compound

CC modulates the expression of human mdm2. The antisense oligonucleotides of

CC the invention are useful for encoding human mdm2 and for inhibiting the

CC expression of human mdm2. They may be used for treating an animal having

CC a disease or condition associated with amplification of mdm2 gene or

CC overexpression of mdm2 e.g. a hyperproliferative disorder such as cancer

CC (blood, brain, breast, lung, or a soft tissue cancer) and psoriasis,

CC fibrosis, atherosclerosis or restenosis, tumours, colorectal carcinoma

CC and chronic myelogenous leukemia. The antisense compound may be

CC administered with a chemotherapeutic agent to overcome drug resistance.

CC The antisense compound reduces hyperproliferation of human cells. The

CC method, which involves the use of the antisense compound, is also useful

CC for detecting the role of mdm2 expression in various cell functions and

CC physiological processes and useful in both clinical research and

CC diagnostic tools. AAS29242-AAS29507 represent the human mdm2 antisense

CC oligonucleotides of the present invention

XX Sequence 20 BP; 7 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

SQ

Query Match

Best Local Similarity

0.6%; Score 16.8; DB 1; Length 20;

90.0%; Pred. No. 1.2e+03;

CC diagnostic tools. AAS29242-AAS29507 represent the human mdm2 antisense
CC oligonucleotides of the present invention
XX
SQ Sequence 20 BP; 4 A; 4 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2833 TGATCCTCCACCTCAGCCT 2852
|||||
DB 20 TGATCGCCACCTCGCCT 1
|||||

RESULT 2061
ABL44512/c
ID ABL44512 standard; DNA; 20 BP.
XX
XX ABL44512;
AC
XX
XX 11-APR-2002 (first entry)
XX
XX Human chromosome 1p36-35 PCR primer SEQ ID NO:1556.
DE
XX
XX Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW PCR primer; ss.
XX
XX Homo sapiens.
OS
XX
XX JP2001321190-A.
FN
XX
XX 20-NOV-2001.
PD
XX
XX 12-MAR-2001; 2001JP-00068285.
PF
XX
XX 10-MAR-2000; 2000JP-00066716.
PR
XX
XX (RIKA) RIKAGAKU KENKYUSHO.
PA (GENO-) GENOTEX YG.
PA
XX
XX WPI; 2002-144136/19.
DR
XX
XX Arraying genome clones.
FT
XX
XX Claim 4; Page 35; 528pp; Japanese.
PS
XX
XX The present invention describes a method of arraying genome clones. The
CC method comprises: (a) clones of the genomic libraries contained in
CC multiwell plates numbered for discrimination are mixed in each of the
CC multiwell plates; (b) a primer designed based on the chromosome marker
CC sequence is added to the mixture to carry out an amplification reaction;
CC (c) a signal corresponding to the marker is detected from the resultant
CC amplified product to specify the discrimination Nos. of the multiwell
CC plates containing the clones having said marker sequence; (d) the order
CC of the markers is changed so that the same discrimination Nos. succeed to
CC the maximum in the specified discrimination Nos. to array the multiwell
CC plates; (e) the clones in the multiwell plates of the specified
CC discrimination Nos. are mixed respectively in each wells of longitudinal
CC and lateral directions; (f) the mixed clones are cultured and the
CC resultant cultures are amplified by using the above primer; (g) signals
CC are detected from the amplified products; (h) the clones in the multiwell
CC plates are specified from the detected result; and (i) the clones are
CC reconstituted as the positions on the chromosome and arrayed. The
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention
XX
XX Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX

```
QY      2845 CTCAGCCTCTGAGTAGCTG 2864
Db      |||||
        20 CTCAGCCTCCCAAGTAGCTG 1

RESULT 2062
ABL45275/C
ID      ABL45275 standard; DNA; 20 BP.
XX
AC      ABL45275;
XX
XX      11-APR-2002 (first entry)
XX
DE      Human chromosome 1p36-35 PCR primer SEQ ID NO:2319.
XX
KW      Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW      PCR primer; ss.
XX
OS      Homo sapiens.
XX
PN      JP2001321190-A.
XX
PD      20-NOV-2001.
XX
PF      12-MAR-2001; 2001JP-00068285.
XX
PR      10-MAR-2000; 2000JP-00066716.
XX
XX      (RIKA ) RIKAGAKU KENKYUSHO.
PA      (GENO-) GENOTEX YG.
XX
DR      WPI; 2002-144136/19.
XX
PT      Arraying genome clones.
XX
PS      Claim 4; Page 50; 528pp; Japanese.
XX
CC      The present invention describes a method of arraying genome clones. The
CC      method comprises: (a) clones of the genomic libraries contained in
CC      multiwell plates numbered for discrimination are mixed in each of the
CC      multiwell plates; (b) a primer designed based on the chromosome marker
CC      sequence is added to the mixture to carry out an amplification reaction;
CC      (c) a signal corresponding to the marker is detected from the resultant
CC      amplified product to specify the discrimination Nos. of the multiwell
CC      plates containing the clones having said marker sequence; (d) the order
CC      of the markers is changed so that the same discrimination Nos. succeed to
CC      the maximum in the specified discrimination Nos. to array the multiwell
CC      plates; (e) the clones in the multiwell plates of the specified
CC      discrimination Nos. are mixed respectively in each wells of longitudinal
CC      and lateral directions; (f) the mixed clones are cultured and the
CC      resultant cultures are amplified by using the above primer; (g) signals
CC      are detected from the amplified products; (h) the clones in the multiwell
CC      plates are specified from the detected result; and (i) the clones are
CC      reconstituted as the positions on the chromosome and arrayed. The
CC      microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC      PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC      represent PCR primers for human chromosome 21q22.1, which are
CC      specifically claimed for use in the present invention
XX
SQ      Sequence 20 BP; 4 A; 2 C; 9 G; 5 T; 0 U; 0 Other;

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2830 AAGTGATCTCTCCCACTCTCAG 2849
Db      |||||
        20 ACGTAATCTCTCCCACTCTCAG 1

RESULT 2063
ABL44316
```

```
ID      ABL44316 standard; DNA; 20 BP.
XX
AC      ABL44316;
XX
XX      11-APR-2002 (first entry)
XX
DE      Human chromosome 1p36-35 PCR primer SEQ ID NO:1360.
XX
KW      Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW      PCR primer; ss.
XX
OS      Homo sapiens.
XX
PN      JP2001321190-A.
XX
PD      20-NOV-2001.
XX
PF      12-MAR-2001; 2001JP-00068285.
XX
PR      10-MAR-2000; 2000JP-00066716.
XX
XX      (RIKA ) RIKAGAKU KENKYUSHO.
PA      (GENO-) GENOTEX YG.
XX
DR      WPI; 2002-144136/19.
XX
PT      Arraying genome clones.
XX
PS      Claim 4; Page 31; 528pp; Japanese.
XX
CC      The present invention describes a method of arraying genome clones. The
CC      method comprises: (a) clones of the genomic libraries contained in
CC      multiwell plates numbered for discrimination are mixed in each of the
CC      multiwell plates; (b) a primer designed based on the chromosome marker
CC      sequence is added to the mixture to carry out an amplification reaction;
CC      (c) a signal corresponding to the marker is detected from the resultant
CC      amplified product to specify the discrimination Nos. of the multiwell
CC      plates containing the clones having said marker sequence; (d) the order
CC      of the markers is changed so that the same discrimination Nos. succeed to
CC      the maximum in the specified discrimination Nos. to array the multiwell
CC      plates; (e) the clones in the multiwell plates of the specified
CC      discrimination Nos. are mixed respectively in each wells of longitudinal
CC      and lateral directions; (f) the mixed clones are cultured and the
CC      resultant cultures are amplified by using the above primer; (g) signals
CC      are detected from the amplified products; (h) the clones in the multiwell
CC      plates are specified from the detected result; and (i) the clones are
CC      reconstituted as the positions on the chromosome and arrayed. The
CC      microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC      PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC      represent PCR primers for human chromosome 21q22.1, which are
CC      specifically claimed for use in the present invention
XX
SQ      Sequence 20 BP; 4 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2759 CTCGCTCTGTCCACCCAGGCT 2778
Db      |||||
        1 CTCACCTCAGTCACCCAGGCT 20

RESULT 2064
ABL44473
ID      ABL44473 standard; DNA; 20 BP.
XX
AC      ABL44473;
XX
XX      11-APR-2002 (first entry)
XX
DE      Human chromosome 1p36-35 PCR primer SEQ ID NO:1517.
XX
```

KW Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
 KW PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX JP2001321190-A.
 PN
 XX 20-NOV-2001.
 PD
 XX
 XX 12-MAR-2001; 2001JP-00068285.
 XX
 XX 10-MAR-2000; 2000JP-00066716.
 PR
 XX (RIKA) RIKAGAKU KENKYUSHO.
 PA (GENO-) GENOTEX YG.
 XX
 XX WPI; 2002-144136/19.
 DR
 XX
 XX Arraying genome clones.
 PT
 XX Claim 4; Page 34; 528pp; Japanese.
 PS
 XX
 CC The present invention describes a method of arraying genome clones. The
 CC method comprises: (a) clones of the genomic libraries contained in
 CC multiwell plates numbered for discrimination are mixed in each of the
 CC multiwell plates; (b) a primer designed based on the chromosome marker
 CC sequence is added to the mixture to carry out an amplification reaction;
 CC (c) a signal corresponding to the marker is detected from the resultant
 CC amplified product to specify the discrimination Nos. of the multiwell
 CC plates containing the clones having said marker sequence; (d) the order
 CC of the markers is changed so that the same discrimination Nos. succeed to
 CC the maximum in the specified discrimination Nos. to array the multiwell
 CC plates; (e) the clones in the multiwell plates of the specified
 CC discrimination Nos. are mixed respectively in each wells of longitudinal
 CC and lateral directions; (f) the mixed clones are cultured and the
 CC resultant cultures are amplified by using the above primer; (g) signals
 CC are detected from the amplified products; (h) the clones in the multiwell
 CC plates are specified from the detected result; and (i) the clones are
 CC reconstituted as the positions on the chromosome and arrayed. The
 CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
 CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
 CC represent PCR primers for human chromosome 21q22.1, which are
 CC specifically claimed for use in the present invention
 XX
 SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.68; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2775 GGCTGGAGTGCAGTGGTGA 2794
 DB 1 GGCTGGAGTGCAGTGGTGA 20
 RESULT 2065
 ABS97833/C
 ID ABS97833 standard; DNA; 20 BP.
 XX
 AC ABS97833;
 XX
 XX 23-DEC-2002 (first entry)
 DT
 XX Human NADPH quinone oxidoreductase 2 (NQO2) polymorphic sequence #41.
 DE
 XX Human; db; cytochrome P450 A1; CYP450A1; UGT2B4; MDR1;
 KW cytochrome P450 A2; CYP450A2; cytochrome P450 02E; CYP45002E1; LTF;
 KW adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR1I2;
 KW aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 KW cyclooxgenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 KW epoxide hydroxylase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
 KW glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
 KW HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;

KW NADPH quinone oxidoreductase 2; NQO2; sulfotransferase thermolabile; STM;
 KW UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 KW UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
 KW multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 KW multidrug resistance associated protein 3; cancer; prostate;
 KW acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR4; CHMR5;
 KW altered drug metabolism; cardiovascular function; colorectal tumour;
 KW central nervous system; pulmonary; immunological; SNP;
 KW single nucleotide polymorphism.
 XX Homo sapiens.
 OS
 XX WO200257410-A2.
 PN
 XX 25-JUL-2002.
 XX
 XX 28-NOV-2001; 2001WO-US044838.
 XX
 XX 28-NOV-2000; 2000US-00724389.
 PR
 XX (DNAS-) DNA SCI LAB INC.
 PA
 XX Guida M, Hall J;
 PI
 XX WPI; 2002-698522/75.
 DR
 XX Isolated nucleic acid molecules having polymorphisms in known human genes
 XX e.g. cytochrome p450 and cathepsin S useful as genetic linkage markers
 XX for locating, identifying and characterizing the genes responsible for
 XX disorder-related traits.
 XX
 XX Example 16; Page 131; 714pp; English.
 PS
 XX This invention relates to the sequence of an isolated nucleic acid
 XX molecule comprising at least one base variation from that of a known
 XX human cytochrome P450 A1 (CYP450A1), cytochrome P450 A2 (CYP450A2),
 XX cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADRB1),
 XX aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
 XX (ARNT), cathepsin S (CTSS), cyclooxgenase 2 (COX2), diazepam binding
 XX inhibitor (DBI), epoxide hydroxylase 2 (EPHX2), 5-lipoxygenase activating
 XX protein (FLAP), glutathione-S-transferase 12 (GST12), histamine-N-methyl
 XX transferase (HNMT), kallikrein 2 (KLK2), nicotinamide-N-methyl
 XX sulfotransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
 XX (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
 XX transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance protein 3
 XX (MDR1), lactotransferrin (LTF), multidrug resistance associated protein 3
 XX (MRP3), orphan nuclear receptor (NR1I2), or acetylcholine muscarinic
 XX receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or CHMR5) sequence.
 XX The polymorphisms in the human genes cited in the invention are useful as
 XX genetic linkage markers for locating and characterising the genes that
 XX are responsible for specific traits within the genome and eventually
 XX identifying the genes responsible for a variety of disorder-related
 XX traits as a result of their e.g., overexpression, constitutive
 XX expression, mutation or underexpression, which may be used in diagnosing
 XX and/or treating the disorders. The nucleic acid molecules comprising the
 XX polymorphic sequences contained in CYP450A1, CYP450A2, CYP45002E1,
 XX ARNT, EPHX2, GST12, NNMT, NQO2, NR1I2, STM, UGT2B4, UGT2B7, UGT2B15, AHR,
 XX MDR1 and/or MDR3 are useful for screening individuals for altered drug
 XX metabolism. The polymorphic sequences contained in CYP450A1, CYP450A2,
 XX AHR, MDR1 and/or MDR3 may also be used to screen individuals for
 XX susceptibility to cancer. Polymorphic sequences in ADRB1 or CHMR2 are
 XX used to screen for altered cardiovascular function, in COX2 for altered
 XX susceptibility to colorectal tumours, in DBI or CHMR1 for altered central
 XX nervous system function, in FLAP and HNMT for altered pulmonary,
 XX immunological or haematological function, in KLK2 for altered serine
 XX protease activity in the prostate, in LTF for altered immunological or
 XX haematological function, in CHMR3, CHMR4 or CHMR5 for altered central and
 XX peripheral nervous system function. The present sequence represents a
 XX polymorphic DNA sequence of the invention
 XX
 SQ Sequence 20 BP; 10 A; 9 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2728 GTGTGTTGTGTGTATGT 2747
DB 20 GTATGTGTGTGTGTGTGT 1

RESULT 2066
ABK11979
ID ABK11979 standard; DNA; 20 BP.
XX AC
XX ABK11979;
XX
DT 05-JUN-2002 (first entry)
XX
DE Human D9S58 genetic marker PCR Primer #1.
XX
KW Human; linkage; familial dysautonomia; FD; D9S58; neuronal loss;
KW chromosome 9q31-q33; prenatal diagnosis; Riley-Day syndrome; ss; PCR;
KW primer.
XX
OS Homo sapiens.
XX
FN US2002025528-A1.
XX
PD 28-FEB-2002.
XX
PF 17-JUL-2001; 2001US-00907190.
XX
PR 29-MAY-1992; 92US-00890719.
PR 16-APR-1993; 93US-00049678.
PR 07-JUN-1995; 95US-00480655.
PR 07-DEC-1999; 99US-00455683.
XX
PA (BLUM/) BLUMENFELD A.
PA (GUSE/) GUSELLA J F.
PA (BREA/) BREAKFIELD X O.
PA (SLAU/) SLAUGENHAUPT S.
XX
PI Blumenfeld A, Gusella JF, Breakfield XO, Slaugenhaupt S;
XX WPI; 2002-267528/31.
XX
PT Detecting a polymorphism linked to a gene associated with familial
FT dysautonomia, involves analyzing human chromosome 9 for the presence of
PT the polymorphism.
XX
PS Disclosure; Page 6; 17pp; English.

This invention relates to a novel method for detecting a polymorphism linked to a gene associated with familial dysautonomia (FD). Familial dysautonomia is an autosomal recessive disorder characterised by the developmental loss of neurons from the sensory and autonomic nervous system. The method of the invention comprises analysing human chromosome 9 and detecting the presence of a polymorphism located between the genetic markers D9S53 and D9S105 inclusive, and linked to the gene associated with familial dysautonomia. The invention also includes nucleotide sequences for detecting a polymorphism associated with familial dysautonomia. Using the method of the invention it was possible to show that the gene for PD is located on human chromosome 9q31-q33. The method and sequences of the invention are useful for the diagnosis of familial dysautonomia and for the identification of carriers of the disease gene, such information will facilitate prenatal diagnosis and help reduce the number of new cases of FD. The present sequences represent an oligonucleotide primer that can be used to screen for the D9S58 genetic marker on chromosome 9, this primer was used to map the location of the familial dysotonomia gene

Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;

CC genomic DNA (from human blood samples and Raji (ATCC CCL-86) cells) were
 CC plotted as normalised, subtracted spectra and as data points in dot
 CC plots. The multiplex PCR system provides increased sample throughput and
 CC potential cost savings

XX
 SQ Sequence 20 BP; 3 A; 10 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2833 TGATCTCTCCACCTCAGCCT 2852
 ||||| ||| ||||| |||||
 Db 1 TGATCCACCGCCTCAGCCT 20

RESULT 2068
 AB280432
 ID AB280432 standard; DNA; 20 BP.
 XX AC AB280432;
 XX DT 28-MAY-2003 (first entry)
 XX Human protein PP10122 PCR primer #2.
 DE Human; cancer; cancer suppression; cancer inhibitor; PCR primer; ss.
 KW Homo sapiens.
 OS CN1368509-A.
 PN 11-SEP-2002.
 PD 08-FEB-2001; 201CN-00105310.
 PP 08-FEB-2001; 201CN-00105310.
 PR (SHAN-) SHANGHAI INST ONCOLOGY.
 PA Gu J;
 PI WPI; 2003-112778/11.
 DR Human protein that suppresses cancer cell growth and its coding sequence.
 XX Example 2; Page 10 (Disclosure); 36pp; Chinese.
 PS AB280408 to AB280418 encode the human proteins ABP96551 to ABP96561 which
 CC have cancer inhibiting functions. Also described is a method for
 CC preparing the proteins using recombination techniques. The human proteins
 CC from the present invention, and nucleotide sequences encoding them, can
 CC be used for treating diseases such as cancer. The present sequence
 CC represents a PCR primer for a human cancer inhibiting function related
 CC protein from the present invention

XX
 SQ Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2916 TTTACGAGACGGGCTCTGC 2935
 ||||| ||||| ||||| |||||
 Db 1 TTTAAGAGACGGGCTCTGC 20

RESULT 2069
 ADA20964/C
 ID ADA20964 standard; DNA; 20 BP.
 XX AC ADA20964;
 XX

DT 20-NOV-2003 (first entry)
 XX Mouse BAX chimeric phosphorothioate oligonucleotide SEQ ID NO:137.
 DE BCL2-associated X; BAX; nootropic; neuroprotective; antiparkinsonian;
 XX anticonvulsant; ophthalmological; antidiabetic; virucide;
 KW antitense therapy; BAX antagonist; BAX inhibitor;
 KW familial amyotrophic lateral sclerosis; Alzheimer's disease;
 KW Parkinson's disease; Hodgkin's disease; cartilage-hair hyperplasia;
 KW diabetes-associated ocular disorder; scrapie infection;
 KW aberrant apoptosis; mouse; phosphorothioate; ss.
 XX Synthetic.
 OS Mus musculus.
 OS

PH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages, and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT

XX WO2003008543-A2.
 XX 30-JAN-2003.
 XX 13-JUL-2002; 2002WO-US022417.
 XX 17-JUL-2001; 2001US-00908147.
 XX (ISIS-) ISIS PHARM INC.
 XX Zhang H, Watt AT;
 XX WPI; 2003-239321/23.
 XX New antisense compounds, useful for modulating the expression of BCL2-
 PT associated X (BAX) protein or for treating a disease or condition
 PT associated with BAX protein, e.g. Parkinson's disease, Hodgkin's disease
 PT or Alzheimer's disease.
 PT Claim 3; Page 94; 139pp; English.
 XX The present invention describes a compound (I) 8-50 nucleobases in length
 CC targeted to a nucleic acid molecule encoding BCL2-associated X (BAX)
 CC protein, where the compound specifically hybridises with the nucleic acid
 CC molecule encoding BAX protein and inhibits the expression of BAX protein.
 CC The compound specifically hybridises with at least 8-nucleobase portion
 CC of an active site on a nucleic acid molecule encoding BAX protein. Also
 CC described: (1) a composition comprising (I) and a pharmaceutical carrier
 CC or diluent; (2) inhibiting the expression of BAX protein in cells or
 CC tissues comprising contacting the cells or tissues with (I); and (3)
 CC treating an animal having a disease or condition associated with BAX
 CC protein comprising administering to the animal (I) so that expression of
 CC BAX protein is inhibited. (I) has nootropic, neuroprotective,
 CC antiparkinsonian, anticonvulsant, ophthalmological, antidiabetic and
 CC virucide activities, and can be used in antisense therapy, and as a BAX
 CC antagonist. The antisense compounds (I) are useful for modulating the
 CC expression of BAX protein, and for treating a disease or condition
 CC associated with BAX protein, e.g. familial amyotrophic lateral
 CC sclerosis, Alzheimer's disease, Parkinson's disease, Hodgkin's disease,
 CC cartilage-hair hyperplasia, diabetes-associated ocular disorders or
 CC scrapie infection, or a condition that arises from aberrant apoptosis.
 CC The compounds are useful as research reagents and in diagnostics. The
 CC present sequence represents a mouse BAX chimeric phosphorothioate

CC oligonucleotide, which is used in an example from the present invention.
XX
SQ Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 958 ACATGCGACAGTGCACAT 977
Db 20 ACATGGCAGACAGTGCACAT 1
||| ||||| ||||| |||||
||| ||||| ||||| |||||

RESULT 2070
AAL62710
ID AAL62710 standard; DNA; 20 BP.
XX
AC AAL62710;
XX
DT 06-OCT-2003 (first entry)
XX
DE Human CD36 antigen-like 1 (CD36L1) antisense oligo, ISIS 199377.
XX
KW Human; CD36 antigen-like 1; CD36L1; scavenger receptor class B type 1;
KW CLA-1; SRB1; SR-BI; cardiovascular; metabolic disorder; atherosclerosis;
KW lipid metabolism; gene therapy; phosphorothioate backbone; antisense; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone; All cytidines are 5-
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'methoxyethyl nucleotides"
XX
PN WO2003052062-A2.
XX
XX
PD 26-JUN-2003.
XX
XX
PF 09-DEC-2002; 2002WO-US039183.
XX
XX
PR 18-DEC-2001; 2001US-00024396.
XX
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX
PI Dobie KW;
XX
XX
DR WPI; 2003-533006/50.
XX
XX
PT New compound, having a sequence targeted to a nucleic acid encoding
PT CD36L1, useful for preparing a composition for treating
PT hyperproliferative or autoimmune disorders.
XX
XX
PS Example 15; Page 82; 122pp; English.
XX
XX
CC The invention relates to antisense compounds, compositions and methods
CC for modulating the expression of class B scavenger receptor, CD36 antigen
CC -like 1 (CD36L1). CD36L1 is also known as scavenger receptor class B type
CC 1 (SRB1), CLA-1 and mouse homologue, SR-BI. The antisense compound is
CC useful for preparing a composition for treating metabolic or
CC cardiovascular disorder, e.g. altered lipid metabolism or
CC atherosclerosis. It is also used in gene therapy. The present sequence is
CC an antisense oligonucleotide targetted to human CD36L1 DNA. This sequence

CC is used to illustrate the method of the invention
XX
SQ Sequence 20 BP; 1 A; 9 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2759 CTCGCTCTGTCTACCCAGGCT 2778
Db 1 CTCCTCTCTGTGCCAGGCT 20
||| ||||| ||||| |||||
||| ||||| ||||| |||||

RESULT 2071
ADB81564/c
ID ADB81564 standard; DNA; 20 BP.
XX
AC ADB81564;
XX
DT 04-DEC-2003 (first entry)
XX
DE Antisense oligo (SeqID 81) used to inhibit human EIF2C1 DNA.
XX
KW antisense; ss; human; eukaryotic translation initiation factor 2C 1;
KW EIF2C1; Co-eIF2C; eIF2C; Golgi ER protein 95kDa; GERP95; Q99;
KW gene therapy; hyperproliferative disorder;
KW familial hypercholesterolaemia; cancer; polycystic kidney disease;
KW cystic fibrosis; progeria syndrome; cytostatic; antilipaeamic.
XX
OS Homo sapiens.
XX
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate backbone, where 1-5 and
FT 16-20 are 2' methoxyethyl nucleotides. All cytidines are
FT 5-methylcytidines"
XX
PN WO2003040321-A2.
XX
XX
PD 15-MAY-2003.
XX
XX
PF 04-NOV-2002; 2002WO-US035324.
XX
XX
PR 08-NOV-2001; 2001US-00007078.
XX
XX
PA (ISIS-) ISIS PHARM INC.
XX
XX
PI Ward DT, Watt AT;
XX
XX
DR WPI; 2003-449448/42.
XX
XX
PT New compound, having a sequence targeted to a nucleic acid encoding human
PT collapsin response mediator protein 2, useful for preparing a composition
PT for treating hypercholesterolemia or hyperproliferative disorder, e.g.,
PT cancer.
XX
XX
PS Claim 3; Page 77; 120pp; English.
XX
XX
CC This invention relates to novel antisense oligonucleotides that modulate
CC the expression of human eukaryotic translation initiation factor 2C 1
CC (EIF2C1). EIF2C1 is located on chromosome 1p34-35, and is also known as
CC Co-eIF2C, eIF2C, Golgi ER protein 95kDa, GERP95 and Q99. It is an
CC intracellular membrane associated protein thought to be involved in
CC cellular differentiation, such that altered expression of EIF2C1 can
CC affect cell growth, morphology and tumorigenicity. Accordingly,
CC antisense oligonucleotides that inhibit the expression of EIF2C1 in cells
CC or tissues can be used in gene therapy to treat various conditions
CC including hyperproliferative disorders, familial hypercholesterolaemia
CC and cancer, as well as polycystic kidney disease, cystic fibrosis and
CC progeria syndrome. As such, the oligos of the present invention can be
CC described as having cytostatic and antilipaeamic activities. This

CC oligonucleotide sequence is an antisense oligo used to inhibit expression
CC of the human eukaryotic translation initiation factor 2C 1 (EIF2C1) DNA
CC of the invention.

XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2768 TCACCCAGGCTGGAGTGCAG 2787

Db 20 TCGTCCAGGCTGGAGTGCAG 1

RESULT 2072

ADC65799

ID ADC65799 standard; DNA; 20 BP.

XX AC

XX ADC65799;

XX 18-DEC-2003 (first entry)

DE Human TGF-beta receptor II targeted antisense oligonucleotide #76.

XX human; antisense oligonucleotide;

KW transforming growth factor beta receptor II; TGF-beta receptor II;

KW hyperproliferative disorder; breast cancer; autoimmune disorder;

KW rheumatoid arthritis; 2'-O-methoxyethyl gapmer;

KW phosphorothioate backbone; ss.

XX OS

XX Homo sapiens.

XX WO2003000656-A2.

XX 03-JAN-2003.

XX 19-JUN-2002; 2002WO-US019665.

XX 21-JUN-2001; 2001US-00888361.

PA (ISIS-) ISIS PHARM INC.

XX Murray SF, Wyatt JR;

XX WPI; 2003-175279/17.

XX New compound having a sequence targeted to a nucleic acid encoding
PT Transforming growth factor beta-receptor II, useful for preparing a
PT composition for treating hyperproliferative disorder e.g., lung, liver,
PT colon or gastric cancer.

XX Example 15; SEQ ID NO 95; 141pp; English.

XX The invention comprises antisense oligonucleotides that are targeted to
CC the nucleic acid encoding transforming growth factor beta (TGF-beta)
CC receptor II. The antisense oligonucleotides of the invention are useful
CC for treating: hyperproliferative disorders (e.g. breast cancer), or an
CC autoimmune disorder (e.g. rheumatoid arthritis). The present DNA sequence
CC represents a 2'-O-methoxyethyl gapmer oligonucleotide with a
CC phosphorothioate backbone that is targeted to human TGF-beta receptor II.

XX Sequence 20 BP; 5 A; 9 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2843 ACCTCAGCCTCCTCAGTAGC 2862

Db 1 ACCTCAGCCTCCTCAGTAGC 20

RESULT 2073

ADD21699/c

ID ADD21699 standard; DNA; 20 BP.

XX AC

XX ADD21699;

DT 15-JAN-2004 (first entry)

DE Human mdm2 antisense oligonucleotide #262.

XX antisense oligonucleotide; human; mdm2; hyperproliferation;

KW hyperproliferative disorder; cancer; psoriasis; fibrosis;

KW atherosclerosis; restenosis; apoptosis modulation; p21; ss;

KW 2'-methoxyethoxy-residue; phosphorothioate backbone.

XX OS

XX Homo sapiens.

XX WO2003048315-A2.

XX 12-JUN-2003.

XX 02-DEC-2002; 2002WO-US038281.

XX 04-DEC-2001; 2001US-00005344.

XX (ISIS-) ISIS PHARM INC.

XX Miraglia LJ, Nero PS, Graham MJ, Monia BP, Koller E, Chiang MY;

XX Manoharan M;

XX WPI; 2003-577263/54.

XX Novel antisense compound targeted to 5' untranslated region, coding
PT region, or intron:exon junction of nucleic acid molecule encoding mdm2,
PT useful for treating e.g. cancer, psoriasis or restenosis by inhibiting
PT mdm2 expression.

XX Claim 4; SEQ ID NO 264; 289pp; English.

XX The invention comprises antisense oligonucleotides which are targeted to
CC the human mdm2 gene. The antisense oligonucleotides of the invention are
CC useful for reducing hyperproliferation of human cells. The antisense
CC oligonucleotides are also useful for treating: hyperproliferative
CC disorders (e.g. cancer), psoriasis, fibrosis, atherosclerosis, or
CC restenosis. The antisense oligonucleotides are also useful for modulating
CC apoptosis, and for increasing expression of p21. The present DNA sequence
CC represents a human mdm2 gene antisense oligonucleotide of the invention.
CC The present sequence contains 2'-methoxyethoxy-residues and has a
CC phosphorothioate backbone.

XX Sequence 20 BP; 4 A; 4 C; 10 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2833 TGATCCTCCACCTCAGCCT 2852

Db 20 TGATCCTCCACCTCAGCCT 1

RESULT 2074

ADD21676/c

ID ADD21676 standard; DNA; 20 BP.

XX AC

XX ADD21676;

DT 15-JAN-2004 (first entry)

DE Human mdm2 antisense oligonucleotide #239.

XX antisense oligonucleotide; human; mdm2; hyperproliferation;

KW hyperproliferative disorder; cancer; psoriasis; fibrosis;

KW atherosclerosis; restenosis; apoptosis modulation; p21; ss;
 KW 2'-methoxyethoxy-residue; phosphorothioate backbone.

XX Homo sapiens.

XX WO2003048315-A2.

XX 12-JUN-2003.

XX 02-DEC-2002; 2002WO-US038281.

XX 04-DEC-2001; 2001US-00005344.

XX (ISIS-) ISIS PHARM INC.

XX Miraglia LJ, Nero PS, Graham MJ, Monia BP, Koller E, Chiang MY,
 PI Manoharan M;

XX WPI; 2003-577263/54.

XX Novel antisense compound targeted to 5' untranslated region, coding
 PT region, or intron:exon junction of nucleic acid molecule encoding mdm2,
 PT useful for treating e.g. cancer, psoriasis or restenosis by inhibiting
 PT mdm2 expression.

XX Claim 4; SEQ ID NO 241; 289pp; English.

XX The invention comprises antisense oligonucleotides which are targeted to
 CC the human mdm2 gene. The antisense oligonucleotides of the invention are
 CC useful for reducing hyperproliferation of human cells. The antisense
 CC oligonucleotides are also useful for treating: hyperproliferative
 CC disorders (e.g. cancer), psoriasis, fibrosis, atherosclerosis, or
 CC restenosis. The antisense oligonucleotides are also useful for modulating
 CC apoptosis, and for increasing expression of p21. The present DNA sequence
 CC represents a human mdm2 gene antisense oligonucleotide of the invention.
 CC The present sequence contains 2'-methoxyethoxy-residues and has a
 CC phosphorothioate backbone.

XX Sequence 20 BP; 7 A; 5 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 1.2e+03;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTACCCAGGCTG 2779

DB 20 TTGCTCTGTACCCAGGCTG 1

RESULT 2075

XX AAL55978
 ID AAL55978 standard; DNA; 20 BP.

XX AAL55978;

XX 11-MAR-2004 (first entry)

XX Human ribonucleotide reductase M2 subunit intron/exon junction #3.

XX Human; ribonucleotide reductase M2 subunit; cell proliferation; RRM2;
 KW gene therapy; cytostatic; cancer; gene; ds.

XX Homo sapiens.

XX WO2003085090-A2.

XX 16-OCT-2003.

XX 25-MAR-2003; 2003WO-US009301.

XX 29-MAR-2002; 2002US-0368685P.

XX (YENY/) YEN Y.

XX Yen Y;
 PI

DR WPI; 2003-853837/79.

XX New nucleic acid comprising a human ribonucleoside reductase M2 subunit
 PT promoter or genomic sequence, useful for diagnosing or treating cell
 PT proliferative disorders and in identifying compounds for treating such
 PT disorders.

XX Example 1; Page 18; Opp; English.

XX The present invention provides the gene of the human ribonucleotide
 CC reductase M2 subunit (RRM2). The sequence can be used in the diagnosis,
 CC prevention and treatment of a cell proliferation-associated disorder
 CC (e.g. cancer), and in identifying therapeutic compounds for treating such
 CC a disorder. The present sequence is a gene/fragment of the invention

XX Sequence 20 BP; 1 A; 13 C; 5 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 1.2e+03;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 62 CTCCTCAGCAGCCCGCGCCC 81

DB 1 CTCCTCAGCAGCCCGCGCCC 20

RESULT 2076

XX ABZ98001

ID ABZ98001 standard; DNA; 20 BP.

XX ABZ98001;

XX 17-OCT-2003 (first entry)

XX Human RANTES oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; anti-allergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.

XX Homo sapiens.

XX WO200285308-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013135.

XX 24-APR-2001; 2001US-0286137P.

XX (EPIC-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.

XX Disclosure; SEQ ID NO 13243; 872pp; English.

XX The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive, and
 CC immunosuppressive, and cytosstatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TCGTCTGTGTCACCCAGGCTG 2779
 |||||
 Db 1 TCACCTTTGTCACCCAGGCTG 20

RESULT 2077
 ABZ92716
 ID ABZ92716 standard; DNA; 20 BP.
 XX
 AC ABZ92716;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytosstatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasegra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-229219/22.
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 PS Disclosure; SEQ ID NO 7959; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive, and
 CC immunosuppressive, and cytosstatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2849 GCCTCTGTGAGTAGCTGGAC 2868
 |||||
 Db 1 GCCTCCCAAGTAGCTGGAC 20

RESULT 2078
 ABZ97900
 ID ABZ97900 standard; DNA; 20 BP.
 XX
 AC ABZ97900;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human RANTES oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytosstatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO200285308-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013135.
 XX
 PR 24-APR-2001; 2001US-0286137P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasegra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-229219/22.
 XX
 PT Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.
 XX
 PS Disclosure; SEQ ID NO 13142; 872pp; English.
 XX
 CC The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the
 CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC disease, gluten enteropathy, infectious diseases, autoimmune diseases
 CC (e.g. haemolytic anemia, rheumatoid arthritis, dermatitis, Grave's
 CC disease, multiple sclerosis, allergy, asthma and diabetic mellitus),
 CC diseases or disorders of the immune system, hypersensitivity,
 CC anaphylaxis, and blood group incompatibility. The present DNA sequence
 CC represents a PCR primer that was used to amplify an intestinal
 CC epithelium/peyer's patch M cell-associated DNA sequence of the invention.
 XX
 SQ Sequence 20 BP; 5 A; 9 C; 2 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2829 CAAGTGATCTCCCACTCA 2848
 ||||| ||||| ||||| |||||
 DB 1 CAAGCGATTCTCCCACTCA 20
 ||||| ||||| ||||| |||||
 RESULT 2081
 ABD26083/C
 ID ABD26083 standard; DNA; 20 BP.
 XX
 AC ABD26083;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE AA463249-derived oligonucleotide SEQ ID 5095.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 5095; 763pp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition

CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2846 TCAGCCTCTGAGTAGCTGG 2865
 ||||| ||||| ||||| |||||
 DB 20 TCAGCCTCTGAGTAGCTGG 1
 ||||| ||||| ||||| |||||
 RESULT 2082
 ABD30931
 ID ABD30931 standard; DNA; 20 BP.
 XX
 AC ABD30931;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human RANTES-derived oligonucleotide SEQ ID 13142.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 PF 23-APR-2002; 2002WO-US013143.
 XX
 PR 24-APR-2001; 2001US-0286036P.
 XX
 PA (EPIG-) EPIGENESIS PHARM INC.
 XX
 PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13142; 763pp; English.

XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCTGAGTAGCTG 2864
 |||||
 Db 1 CTTAGCCTCCGAGTAGCTG 20

RESULT 2083
 ABD31032
 ID ABD31032 standard; DNA; 20 BP.
 XX
 AC ABD31032;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE Human RANTES-derived oligonucleotide SEQ ID 13243.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shanabuddin S;
 XX WPI; 2003-093058/08.
 DR
 XX Pharmacological composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 PS Claim 15; SEQ ID NO 13243; 763bp; English.
 XX
 CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 CC
 CC Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TGCCTCTGTACCCAGGCTG 2779
 |||||
 Db 1 TCACCTTGTACCCAGGCTG 20

RESULT 2084
 ABD28946
 ID ABD28946 standard; DNA; 20 BP.
 XX
 AC ABD28946;
 XX
 DT 29-JUL-2004 (first entry)
 XX
 DE N58473-derived oligonucleotide SEQ ID 7958.
 XX
 KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.
 XX

XX OS Homo sapiens.
 XX PN WO200285309-A2.
 XX PD 31-OCT-2002.
 XX PF 23-APR-2002; 2002WO-US013143.
 XX PR 24-APR-2001; 2001US-0286036P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyece JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 XX PI Miller S, Tang L, Shahabuddin S;
 XX DR WPI; 2003-093058/08.
 XX PT Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX PS Claim 15; SEQ ID NO 7958; 763pp; English.
 XX CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX SQ Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2849 GCCTCTGAGTAGCTGGGAC 2868
 ||||| ||||| ||||| ||||| |||||
 Db 1 GCCTCCCAAGTAGCTGGGAC 20
 RESULT 2085
 ID ADH71020/c
 ID ADH71020 standard; DNA; 20 BP.
 XX AC ADH71020;
 XX

DT 25-MAR-2004 (first entry)
 XX DE Cosmid C215 repeat region PCR primer #1.
 XX KW human; T-cell associated disease; Vbeta; autoimmune disease;
 KW degenerative nervous system disease; graft versus host disease;
 KW hypersensitivity disease; infectious disease; neoplastic disease;
 KW Addison's disease; atrophic gastritis;
 KW degenerative nervous system disease; multiple sclerosis;
 KW Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
 KW allergy; type II hypersensitivity; Goodpasture's syndrome;
 KW type IV hypersensitivity; leprosy; infectious disease; viral infection;
 KW HIV; fungal infection; Candida; parasitic infection; schistosoma;
 KW filaria; bacterial infection; Mycobacterium; neoplastic disease;
 KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
 KW breast cancer; ss; PCR; primer.
 XX OS Homo sapiens.
 XX PN US2002150891-A1.
 XX PD 17-OCT-2002.
 XX PF 05-MAR-1999; 99US-00263959.
 XX PR 19-SEP-1994; 94US-00309335.
 XX PR 19-SEP-1995; 95US-00531241.
 XX PA (HOOD/) HOOD L E.
 XX PA (KOWE/) KOWEN L.
 XX PI Hood LE, Rowen L;
 XX DR WPI; 2004-059052/06.
 XX PT Kit for diagnosing and treating T-cell associated diseases e.g.
 PT autoimmune, degenerative nervous system and infectious disease, comprises
 PT nucleic acid primers specifically priming and allowing amplification of a
 PT Vbeta gene.
 XX PS Example 6; SEQ ID NO 1214; 164pp; English.
 XX CC The invention relates to a kit for diagnosing and treating T-cell
 CC associated diseases which comprises a panel of nucleic acid primers
 CC specifically priming and allowing amplification of each Vbeta gene,
 CC VbetarNA or cDNA. The kit is useful for diagnosing organ transplant
 CC rejection and diagnosing and treating T-cell associated diseases
 CC including autoimmune diseases, degenerative nervous system diseases,
 CC graft versus host disease, hypersensitivity diseases, infectious diseases
 CC and neoplastic diseases. Autoimmune diseases include Addison's disease,
 CC atrophic gastritis. Degenerative nervous system diseases include multiple
 CC sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
 CC I hypersensitivities such as contact with allergens that lead to
 CC allergies, Type II hypersensitivities such as those present in
 CC Goodpasture's syndrome and Type IV hypersensitivities such as those
 CC manifested in leprosy. Infectious diseases include viral infections
 CC caused by viruses such as HIV, fungal infections such as those caused by
 CC the yeast genus Candida, parasitic infections such as those caused by
 CC schistosomes, filaria and bacterial infections such as those caused by
 CC Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
 CC such as leukaemias, lymphomas and cancers such as cancer of the brain,
 CC breast. The present sequence represents a cosmid C215 repeat region PCR
 CC primer.
 XX SQ Sequence 20 BP; 7 A; 4 C; 8 G; 1 T; 0 U; 0 Other;
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2758 TCTCGCTCTGTGACCCAGGC 2777
 ||||| ||||| ||||| ||||| |||||
 Db 20 TCTTGTCTGTCTCCAGGC 1

RESULT 2086
 ADJ53542
 ID ADJ53542 standard; DNA; 20 BP.
 XX
 AC ADJ53542;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Human PPP3CB DNA antisense oligonucleotide #65.
 XX
 KW Human; PPP3CB; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine; autoimmune disorder;
 KW Alzheimer's disease; immunosuppressive; neurotropic; neuroprotective.
 XX
 OS Homo sapiens.
 XX
 PN US2004023382-A1.
 XX
 PD 05-FEB-2004.
 XX
 PF 31-JUL-2002; 2002US-00210723.
 XX
 PR 31-JUL-2002; 2002US-00210723.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Dean NM, Bennett CF, Dobie KW;
 XX WPI; 2004-142663/14.
 XX
 PT New compounds, particularly antisense oligonucleotides targeted to a
 PT nucleic acid encoding PPP3CB, useful for treating an autoimmune disorder,
 PT or Alzheimer's disease.
 XX
 PS Example 15; SEQ ID NO 78; 91pp; English.
 XX
 CC The invention relates to an antisense oligonucleotide targeted to a
 CC nucleic acid encoding the human PPP3CB polypeptide and inhibits
 CC expression of the PPP3CB polypeptide. The antisense oligonucleotide
 CC comprises at least one modified internucleoside linkage, i.e. a
 CC phosphorothioate linkage, at least one modified sugar moiety, preferably
 CC a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
 CC comprising a 5-methylcytosine. The antisense oligonucleotides are useful
 CC for inhibiting expression of the PPP3CB polypeptide and in preparation of
 CC a composition for treating autoimmune disorders or Alzheimer's disease.
 CC This sequence represents an antisense oligonucleotide of the invention.
 XX
 SQ Sequence 20 BP; 4 A; 9 C; 3 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2844 CCTCAGCCTCCTCAGTAGCT 2863
 Db 1 CCTCAGCCTCCCAAGTAGCT 20
 XX
 RESULT 2087
 ADJ53600/C
 ID ADJ53600 standard; DNA; 20 BP.
 XX
 AC ADJ53600;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Human PPP3CB DNA antisense oligonucleotide target region #51.
 XX
 KW Human; PPP3CB; ss; antisense oligonucleotide; phosphorothioate linkage;
 KW 2'-O-methoxyethyl sugar moiety; 5-methylcytosine; autoimmune disorder;
 KW Alzheimer's disease; immunosuppressive; neurotropic; neuroprotective.

XX
 OS Homo sapiens.
 XX
 PN US2004023382-A1.
 XX
 PD 05-FEB-2004.
 XX
 PF 31-JUL-2002; 2002US-00210723.
 XX
 PR 31-JUL-2002; 2002US-00210723.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Dean NM, Bennett CF, Dobie KW;
 XX WPI; 2004-142663/14.
 XX
 PT New compounds, particularly antisense oligonucleotides targeted to a
 PT nucleic acid encoding PPP3CB, useful for treating an autoimmune disorder,
 PT or Alzheimer's disease.
 XX
 PS Example 15; SEQ ID NO 136; 91pp; English.
 XX
 CC The invention relates to an antisense oligonucleotide targeted to a
 CC nucleic acid encoding the human PPP3CB polypeptide and inhibits
 CC expression of the PPP3CB polypeptide. The antisense oligonucleotide
 CC comprises at least one modified internucleoside linkage, i.e. a
 CC phosphorothioate linkage, at least one modified sugar moiety, preferably
 CC a 2'-O-methoxyethyl sugar moiety, or at least one modified nucleobase
 CC comprising a 5-methylcytosine. The antisense oligonucleotides are useful
 CC for inhibiting expression of the PPP3CB polypeptide and in preparation of
 CC a composition for treating autoimmune disorders or Alzheimer's disease.
 CC This sequence represents an antisense oligonucleotide target region of
 CC the invention.
 XX
 SQ Sequence 20 BP; 4 A; 3 C; 9 G; 4 T; 0 U; 0 Other;
 XX
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 QY 2844 CCTCAGCCTCCTCAGTAGCT 2863
 Db 20 CCTCAGCCTCCCAAGTAGCT 1
 XX
 RESULT 2088
 ADJ59866
 ID ADJ59866 standard; DNA; 20 BP.
 XX
 AC ADJ59866;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Oligonucleotide associated to RANTES #115.
 XX
 KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004011613-A2.
 XX
 PD 05-FEB-2004.
 XX
 PF 25-JUL-2003; 2003WO-US023509.
 XX
 PR 29-JUL-2002; 2002US-0399076P.
 XX
 PA (EPIC-) EPIGENESIS PHARM INC.

XX NYCE JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.
 XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 722; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2760 TCGCTCTGTCACCCAGGCTG 2779
 DB 1 TCACCTTTGTCACCCAGGCTG 20
 RESULT 2089
 ADJ59765
 ID ADJ59765 standard; DNA; 20 BP.
 AC ADJ59765;
 XX 06-MAY-2004 (first entry)
 DT Oligonucleotide associated to RANTES #14.
 DE interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX Homo sapiens.
 OS WO2004011613-A2.
 PN 05-FEB-2004.
 PD 25-JUL-2003; 2003WO-US023509.
 PP 29-JUL-2002; 2002US-0399076P.
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA NYCE JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 XX WPI; 2004-203534/19.

XX Novel single or multiple target oligonucleotide anti-sense to e.g.
 PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX Claim 2; SEQ ID NO 621; 85pp; English.
 XX The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.,
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC oligonucleotide. The method is useful for preventing or treating a
 CC respiratory or lung disease, which involves administering to the airways
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2845 CTCAGCCTCCTGAGTAGCTG 2864
 DB 1 CTTAGCCTCCGAGTAGCTG 20
 RESULT 2090
 ADK70840
 ID ADK70840 standard; DNA; 20 BP.
 XX ADK70840;
 AC ADK70840;
 XX 06-MAY-2004 (first entry)
 DT 5' mRNA DNA preparation method related tag DNA sequence #8.
 DE DNA preparation; 5' mRNA; linker synthesis; primer synthesis;
 KW gene regulation; gene expression; ss; tag.
 KW Unidentified.
 OS WO2003106672-A2.
 PN 24-DEC-2003.
 PD 12-JUN-2003; 2003WO-JP007514.
 PP 12-JUN-2002; 2002JP-00171851.
 PR 12-AUG-2002; 2002JP-00235294.
 XX (RIKE) RIKEN KK.
 PA (DNAP-) DNAPFORM KK.
 PI Hayaahizaki Y, Carninci P, Harbers MT;
 XX WPI; 2004-082194/08.
 XX Preparing DNA fragment corresponding to nucleotide sequence of 5' end
 PT region of mRNA, by preparing nucleic acid corresponding to nucleotide
 PT sequence of 5' end of mRNA, cleaving nucleic acid with restriction
 PT enzyme.
 XX Example 5; SEQ ID NO 40; 121pp; English.
 PS

XX The invention comprises a method for preparing a DNA fragment
 CC corresponding to a nucleotide sequence of a 5' end of an mRNA. The method
 CC is useful for synthesizing a nucleotide sequence to be used as a linker
 CC or primer and selectively collecting multiple nucleic acid fragments
 CC containing information on the nucleotide sequences at the 5' end of
 CC multiple mRNA in a sample. The method is also useful for identifying
 CC regions in the genome, which are required for gene regulation and gene
 CC expression. The present DNA sequence was used in an example of the
 CC invention.
 XX
 SQ Sequence 20 BP; 0 A; 1 C; 10 G; 9 T; 0 U; 0 Other;
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2728 GTGTGTGTGTGTGTGTGTGT 2747
 |||||
 Db 1 GTGTGTGTGTGTGTGTGTGT 20
 RESULT 2091
 ADL61592/c
 ID ADL61592 standard; DNA; 20 BP.
 XX
 AC ADL61592;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE Human protein tyrosine kinase biomarker-related RT-PCR primer SEQ ID 516.
 XX
 KW predictor set; protein tyrosine kinase biomarker; cytostatic;
 KW antiangiogenic; vasotropic; vulnerable; pharmacogenomic; drug sensitivity;
 KW breast cancer; hypervascular disease; angiogenesis; wound healing scar;
 KW human; ss; RT-PCR; PCR; primer.
 XX
 OS Homo sapiens.
 XX
 FN WO2004020583-A2.
 XX
 PD 11-MAR-2004.
 XX
 PF 26-AUG-2003; 2003WO-US026491.
 XX
 PR 27-AUG-2002; 2002US-0406385P.
 XX
 PA (BRIM) BRISTOL-MYERS SQUIBB CO.
 XX
 PI Huang F, Han X, Reeves KA, Amler L, Fairchild CR, Lee FY;
 PI Shaw P;
 XX
 DR WPI; 2004-239171/22.
 XX
 XX New predictor sets with a plurality of polynucleotides and/or
 PT polypeptides whose expression pattern predicts cell response to a
 PT compound that modulates protein tyrosine kinase activity, useful in
 PT treating breast cancer.
 XX
 PS Disclosure; SEQ ID NO 516; 649pp; English.
 XX
 CC The invention relates to a novel predictor set comprising a plurality of
 CC polynucleotides and/or polypeptides whose expression pattern is
 CC predictive of the response of cells to treatment with a compound that
 CC modulates protein tyrosine kinase activity or members of the protein
 CC tyrosine kinase pathway. The molecules of the invention demonstrate
 CC cytostatic, antiangiogenic, vasotropic and vulnerary activities and may
 CC be useful in the field of pharmacogenomics, in particular for determining
 CC drug sensitivity and in treating breast cancer, hypervascular diseases,
 CC angiogenesis and scars in wound healing. The current sequence is that of
 CC a human protein tyrosine kinase biomarker-related RT-PCR primer of the
 CC invention.

SQ Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2845 CTCAGCCTCCTGAGTAGCTG 2864
 |||||
 Db 20 CTCAGCCTCCCAAGTAGCTG 1
 RESULT 2092
 ADJ10322
 ID ADJ10322 standard; DNA; 20 BP.
 XX
 AC ADJ10322;
 XX
 DT 17-JUN-2004 (first entry)
 XX
 DE Phosphorothioate antisense DNA oligo to modulate human GGPS1 SeqID 71.
 XX
 KW antisense; ss; human; geranylgeranyl diphosphate synthase 1; GGPS1;
 KW geranylgeranyl pyrophosphate synthetase; GGPPS; ggppase;
 KW geranyltransferase; embryonic development; cell differentiation;
 KW apoptosis; 2' MOE wing; phosphorothioate backbone; developmental;
 KW hyperproliferative disorder; cancer; cytostatic.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20 /tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= phosphorothioate backbone"
 FT modified_base 1..5 /tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
 FT cytidine nucleobases are 5-methylcytidine."
 FT modified_base 16..20 /tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
 FT cytidine nucleobases are 5-methylcytidine."
 XX
 PN US2004005570-A1.
 XX
 XX 08-JAN-2004.
 XX
 XX 02-JUL-2002; 2002US-00189268.
 PF
 XX 02-JUL-2002; 2002US-00189268.
 PR
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Dean NM, Bennett CF, Dobie KW;
 PI
 XX WPI; 2004-201146/19.
 DR
 XX
 XX New antisense oligonucleotides for modulating geranylgeranyl diphosphate
 PT synthase 1 expression, useful for diagnosing, preventing or treating
 PT conditions associated with the protein, e.g. cancer.
 PT
 PS Example 15; SEQ ID NO 71; 76pp; English.
 XX
 CC This invention relates to a novel antisense compounds that modulate the
 CC expression of human geranylgeranyl diphosphate synthase 1 (also known as
 CC GGPS1, geranylgeranyl pyrophosphate synthetase, GGPPS, ggppase and
 CC geranyltransferase) and located on chromosome 1p43. Specifically, it
 CC refers to compositions useful for inhibiting the expression of GGPS1,
 CC which normally participates in embryonic development, cell
 CC differentiation and stimulates apoptosis via caspase-3 activation. The

CC present invention describes antisense oligonucleotides that comprise at
 CC least one modified sugar moiety, a 2'-O-methoxyethyl (2' MOE) and at
 CC least one modified nucleobase, a 5-methylcytosine. Accordingly, these
 CC compounds are useful for treating a disease or condition associated with
 CC GSPS1 such as a developmental or hyperproliferative disorder (e.g.
 CC cancer) that arise as a result of aberrant apoptosis. As such, these
 CC compositions exhibit cytostatic activity and are useful for diagnostics,
 CC prophylaxis, research reagents and various kits. This oligonucleotide
 CC sequence is a phosphorothioate antisense DNA oligo used to modulate human
 CC geranylgeranyl diphosphate synthase 1 expression in an exemplification of
 CC the invention.

XX Sequence 20 BP; 2 A; 5 C; 8 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2766 TGTCCACCGAGCTGGAGTGC 2785
 ||| |||||
 Db 1 TGTTCGCCAGGCTGGAGTGC 20

RESULT 2093

ADM15179/c

ID ADM15179 standard; DNA; 20 BP.

XX

AC ADM15179;

XX

DT 01-JUL-2004 (first entry)

XX

DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1366.

XX

KW chimeric; antisense oligonucleotide; phosphorothioate; human;

KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;

KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;

KW immunomodulator; cardiant; neuroprotective; antiinflammatory;

KW neuroprotective; cardiant; neuroprotective; antiinflammatory;

KW immunomodulatory; cardiovascular; gene therapy; inflammation;

KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;

KW reperfusion injury; ophthalmic disorder; immunological disorder;

KW cardiovascular disorder; neurological disorder; ss.

XX

OS Homo sapiens.

OS Synthetic.

XX

FH Key Location/Qualifiers

FT modified_base 1. .20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "phosphorothioate linkages and all cytidine

FT residues are 5-methylcytidines"

FT

FT modified_base 1. .5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

FT

FT modified_base 16. .20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

FT

XX WO2004028458-A2.

XX

XX 08-APR-2004.

XX

XX 25-SEP-2003; 2003WO-US030374.

XX

XX 25-SEP-2002; 2002US-0413549P.

XX

XX (PHAA) PHARMACIA CORP.

XX

XX Gierse JK;

XX

XX

DR WPI; 2004-305094/28.

XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.

XX Claim 4; SEQ ID NO 1366; 132pp; English.

XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytosolic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.

XX Sequence 20 BP; 11 A; 7 C; 0 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 1.2e+03;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2730 GTGTGTGTGTGTGTGTGTGT 2749

||| |||||
 Db 20 GTATGTGTGTGTGTGTGTGT 1

RESULT 2094

ADM14491/c

ID ADM14491 standard; DNA; 20 BP.

XX

AC ADM14491;

XX

DT 01-JUL-2004 (first entry)

XX

DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:678.

XX

KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

XX Homo sapiens.

OS Synthetic.

OS

FH Key Location/Qualifiers

FT modified_base 1. .20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "phosphorothioate linkages and all cytidine

FT residues are 5-methylcytidines"

FT

FT modified_base 1. .5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

FT

FT modified_base 16. .20

```

FT FT      /*tag= c
FT FT      /mod_base= OTHER
XX XX      /note= "2'-O-methoxyethyls"
XX PN      WO2004028458-A2.
XX PD      08-APR-2004.
XX XX
XX XX      25-SEP-2003; 2003WO-US030374.
XX PF
XX XX      25-SEP-2002; 2002US-0413549P.
XX PR
XX XX      (PHAA ) PHARMACIA CORP.
XX PA
XX XX      Gierse JK;
XX PI
XX XX      WPI; 2004-305094/28.
XX DR
XX XX      New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX XX      Claim 4; SEQ ID NO 678; 132pp; English.
XX PS
XX CC      The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulatory, cardiant, neuroprotective, vasotropic,
CC antiinflammatory, neuroprotective, nontropic, antiarthritic, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX XX      Sequence 20 BP; 5 A; 3 C; 10 G; 2 T; 0 U; 0 Other;
XX SQ
XX Query Match      0.6%; Score 16.8; DB 1; Length 20;
XX Best Local Similarity 90.0%; Pred. No. 1.2e+03;
XX Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY      2834 GATCCTCCACCTAGCCTC 2853
XX      ||||| ||||| |||||
XX DB      20 GATTCTCCGCTCAGCCTC 1
XX
XX RESULT 2095
XX ADM15004/c
XX ID      ADM15004 standard; DNA; 20 BP.
XX XX
XX AC      ADM15004;
XX XX
XX DT      01-JUL-2004 (first entry)
XX XX
XX DE      Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1191.
XX XX
XX KW      chimeric; antisense oligonucleotide; phosphorothioate; human;
XX KW      microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX KW      microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
XX KW      immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX KW      neuroprotective; nontropic; antiarthritic; vasotropic; ophthalmological;
XX KW      immunomodulatory; cardiovascular; gene therapy; inflammation;
XX KW      Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX KW      reperfusion injury; ophthalmic disorder; immunological disorder;

```

```

KW XX      cardiovascular disorder; neurological disorder; ss.
OS XX      Homo sapiens.
OS OS      Synthetic.
XX XX
XX FH      Key
XX FT      Location/Qualifiers
XX FT      modified_base 1..20
XX FT      /*tag= b
XX FT      /mod_base= OTHER
XX FT      /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
XX FT      modified_base 1..5
XX FT      /*tag= a
XX FT      /mod_base= OTHER
XX FT      modified_base 16..20
XX FT      /*tag= c
XX FT      /mod_base= OTHER
XX FT      /note= "2'-O-methoxyethyls"
XX XX
XX PN      WO2004028458-A2.
XX PD      08-APR-2004.
XX XX
XX XX      25-SEP-2003; 2003WO-US030374.
XX PF
XX XX      25-SEP-2002; 2002US-0413549P.
XX PR
XX XX      (PHAA ) PHARMACIA CORP.
XX PA
XX XX      Gierse JK;
XX PI
XX XX      WPI; 2004-305094/28.
XX DR
XX XX      New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX XX      Claim 4; SEQ ID NO 1191; 132pp; English.
XX PS
XX CC      The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
CC antidiabetic, immunomodulatory, cardiant, neuroprotective, vasotropic,
CC antiinflammatory, neuroprotective, nontropic, antiarthritic, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX XX      Sequence 20 BP; 11 A; 9 C; 0 G; 0 T; 0 U; 0 Other;
XX SQ
XX Query Match      0.6%; Score 16.8; DB 1; Length 20;
XX Best Local Similarity 90.0%; Pred. No. 1.2e+03;
XX Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY      2726 GCGTGTGTGTGTGTGTAT 2745
XX      ||||| ||||| |||||
XX DB      20 GTGTGTGTGTGTGTGTAT 1
XX
XX RESULT 2096
XX ADM14650/c

```

ID XX ADM14650 standard; DNA; 20 BP.
 AC XX ADM14650;
 DT XX 01-JUL-2004 (first entry)
 DE XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:837.
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nontropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX OS Homo sapiens.
 OS Synthetic.
 XX XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX WO2004028458-A2.
 XX XX
 PD 08-APR-2004.
 XX XX
 PF 25-SEP-2003; 2003WO-US030374.
 XX XX
 PR 25-SEP-2002; 2002US-0413549P.
 XX (PHAA) PHARMACIA CORP.
 PA Gierse JK;
 XX WPI; 2004-305094/28.
 DR
 XX New antisense compound, having a sequence targeted to a nucleic acid
 encoding mPGES-1, useful for preparing a composition for treating e.g.,
 inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 ischemia.
 PT
 XX Claim 4; SEQ ID NO 837; 132pp; English.
 PS
 CC The present sequence represents a chimeric antisense oligonucleotide
 targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 human mPGES-1 gene is located on chromosome 9, more specifically to
 9q34.3. The present invention also describes: (1) antisense compounds,
 having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 inhibits its expression; (2) a method of inhibiting the expression of
 mPGES-1 in cells or tissues; and (3) a method of treating an animal
 having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 antisense oligonucleotides and antisense compounds have cytostatic,
 antidiabetic, immunomodulator, cardiant, neuroprotective,
 antiinflammatory, neuroprotective, nontropic, antiarthritic, vasotropic,
 ophthalmological, immunomodulatory and cardiovascular activities, and can
 be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 can be used for preparing a composition for treating a disease or
 condition associated with mPGES-1 e.g., inflammation, Alzheimer's

CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2772 CCAGGCTGGAGTCAGTGGT 2791
 Db 20 CCAAGCTGGAGTGAAGTGGT 1
 ||| ||||| ||||| |||||
 RESULT 2097
 ADM14763/c
 ID ADM14763 standard; DNA; 20 BP.
 XX AC ADM14763;
 XX XX
 DT 01-JUL-2004 (first entry)
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:950.
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nontropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX OS Homo sapiens.
 OS Synthetic.
 XX XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX WO2004028458-A2.
 XX XX
 PD 08-APR-2004.
 XX XX
 PF 25-SEP-2003; 2003WO-US030374.
 XX XX
 PR 25-SEP-2002; 2002US-0413549P.
 XX (PHAA) PHARMACIA CORP.
 PA Gierse JK;
 XX WPI; 2004-305094/28.
 DR
 XX New antisense compound, having a sequence targeted to a nucleic acid
 encoding mPGES-1, useful for preparing a composition for treating e.g.,
 inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 ischemia.
 PT
 XX Claim 4; SEQ ID NO 950; 132pp; English.
 PS
 CC

CC The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC anti-diabetic, immunomodulatory, cardiant, neuroprotective,
 CC anti-inflammatory, neuroprotective, neurotropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX

SQ Sequence 20 BP; 3 A; 8 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2771 CCCAGCTGCAGTGCAGTGG 2790

DB ||||| ||||| ||||| ||||| |||||
 20 CCCAAGCTGGAGTGAAGTGG 1

RESULT 2098

ID ADM14410/C

AC ADM14410 standard; DNA; 20 BP.

XX

01-JUL-2004 (first entry)

Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:597.

chimeric; antisense oligonucleotide; phosphorothioate; human;
 microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 microsomal prostaglandin E2 synthase inhibitor; cytostatic; anti-diabetic;
 immunomodulator; cardiant; neuroprotective; anti-inflammatory;
 neuroprotective; neurotropic; antiarthritic; vasotropic; ophthalmological;
 immunomodulatory; cardiovascular; gene therapy; inflammation;
 Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 reperfusion injury; ophthalmic disorder; immunological disorder;
 cardiovascular disorder; neurological disorder; ss.

OS Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "phosphorothioate linkages and all cytidine
 residues are 5-methylcytidines"

FT modified_base 1..5

FT /*tag= a

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

FT modified_base 16..20

FT /*tag= c

FT /mod_base= OTHER

FT /note= "2'-O-methoxyethyls"

XX WO2004028458-A2.

XX

PD 08-APR-2004.

XX

PF 25-SEP-2003; 2003WO-US030374.

XX 25-SEP-2002; 2002US-0413549P.

PR (PHAA) PHARMACIA CORP.

XX Gierse JK;

XX WPI; 2004-305094/28.

XX New antisense compound, having a sequence targeted to a nucleic acid
 FT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.

XX Claim 4; SEQ ID NO 597; 132pp; English.

XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC anti-diabetic, immunomodulatory, cardiant, neuroprotective,
 CC anti-inflammatory, neuroprotective, neurotropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX

SQ Sequence 20 BP; 5 A; 2 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2835 ATCTCTCCACCTCAGCTCC 2854

DB ||||| ||||| ||||| ||||| |||||
 20 ATTCTCCGCTCAGCTCC 1

RESULT 2099

ID ADM14694/C

AC ADM14694 standard; DNA; 20 BP.

XX

AC ADM14694;

XX 01-JUL-2004 (first entry)

XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:881.

chimeric; antisense oligonucleotide; phosphorothioate; human;
 microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 microsomal prostaglandin E2 synthase inhibitor; cytostatic; anti-diabetic;
 immunomodulator; cardiant; neuroprotective; anti-inflammatory;
 neuroprotective; neurotropic; antiarthritic; vasotropic; ophthalmological;
 immunomodulatory; cardiovascular; gene therapy; inflammation;
 Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 reperfusion injury; ophthalmic disorder; immunological disorder;
 cardiovascular disorder; neurological disorder; ss.

OS Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified_base 1..20

FT /*tag= b

FT /mod_base= OTHER

FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1. .5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16. .20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX WO2004028458-A2.
 PN 08-APR-2004.
 XX 25-SEP-2003; 2003WO-US030374.
 XX 25-SEP-2002; 2002US-0413549P.
 XX (PHAA) PHARMACIA CORP.
 PA Gierse JK;
 PI WPI; 2004-305094/28.
 DR New antisense compound, having a sequence targeted to a nucleic acid
 XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
 FT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 FT ischemia.
 XX Claim 4; SEQ ID NO 881; 132pp; English.
 PS The present sequence represents a chimeric antisense oligonucleotide
 XX targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2776 GCTGGAGTCAGTGGTCAAA 2795
 Db 20 GCTGGAGTCAGTGGTCAAA 1
 RESULT 2100
 ID ADM14328/c
 ID ADM14328 standard; DNA; 20 BP.
 XX ADM14328;
 AC ADM14328;
 XX 01-JUL-2004 (first entry)
 DT Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:515.
 DE chimeric; antisense oligonucleotide; phosphorothioate; human;
 XX

KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytotstatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX Key Location/Qualifiers
 FH modified_base 1. .20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 FT residues are 5-methylcytidines"
 FT modified_base 1. .5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16. .20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX WO2004028458-A2.
 PN 08-APR-2004.
 XX 25-SEP-2003; 2003WO-US030374.
 XX 25-SEP-2002; 2002US-0413549P.
 XX (PHAA) PHARMACIA CORP.
 PA Gierse JK;
 PI WPI; 2004-305094/28.
 DR New antisense compound, having a sequence targeted to a nucleic acid
 XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
 FT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 FT ischemia.
 XX Claim 4; SEQ ID NO 515; 132pp; English.
 PS The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX Sequence 20 BP; 6 A; 2 C; 11 G; 1 T; 0 U; 0 Other;
 SQ Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2836 TCTTCCACCTCAGCCCTCT 2855
 Db 20 TTCTCCCGCTCAGCCCTCT 1

RESULT 2101
 ADM14595/c
 ID ADM14595 standard; DNA; 20 BP.
 XX
 AC ADM14595;

XX 01-JUL-2004 (first entry)
 XX
 DE Human MPGES-1 chimeric antisense oligonucleotide SEQ ID NO:782.

XX chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsome prostaglandin E2 synthase; MPGES-1; MPGES-1 inhibitor;
 KW microsome prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nontropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

XX Homo sapiens.
 OS Synthetic.

XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT
 FT WO2004028458-A2.
 XX
 PN 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 XX
 XX 25-SEP-2002; 2002US-0413549P.
 XX
 XX (PHAA) PHARMACIA CORP.
 XX
 XX Gierse JK;
 XX
 XX WPI; 2004-305094/28.
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding MPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.

XX Claim 4; SEQ ID NO 782; 132pp; English.

XX The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsome prostaglandin E2 synthase (MPGES-1). The
 CC human MPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC MPGES-1, which specifically hybridise with the nucleic acid MPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC MPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with MPGES-1. MPGES-1 chimeric

CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nontropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as MPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with MPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.

XX Sequence 20 BP; 5 A; 7 C; 2 G; 6 T; 0 U; 0 Other;
 SQ

Query Match 0.6%; Score 16.8; DB 1; Length 20;
 Best Local Similarity 90.0%; Pred. No. 1.2e+03;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2778 TGGAGTCGACGTGTCGAATC 2797
 Db 20 TGGAGTCGAAGTGTACATC 1
 ||||| ||||| ||||| ||||| |||||

RESULT 2102
 ADM14881/c
 ID ADM14881 standard; DNA; 20 BP.
 XX
 AC ADM14881;

XX 01-JUL-2004 (first entry)
 XX
 DE Human MPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1068.

XX chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsome prostaglandin E2 synthase; MPGES-1; MPGES-1 inhibitor;
 KW microsome prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nontropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.

XX Homo sapiens.
 OS Synthetic.

XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT
 FT WO2004028458-A2.
 XX
 PN 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 XX
 XX 25-SEP-2002; 2002US-0413549P.
 XX
 XX (PHAA) PHARMACIA CORP.
 XX
 XX Gierse JK;
 XX
 XX WPI; 2004-305094/28.

PT New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
PS Claim 4; SEQ ID NO 1068; 132pp; English.
XX
CC The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to the
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulator, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 5 A; 7 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2777 CTGGAGTGCAGTGGTGAAT 2796
||||| ||||| ||||| |||||
DB 20 CTGGAGTGAAGTGTACAAT 1
RESULT 2103
ADO45356
ID ADO45356 standard; DNA; 20 BP.
XX
AC ADO45356;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human oligonucleotide #722.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Botaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
OS Homo sapiens.
XX
FN US2004049022-A1.
XX
PD 11-MAR-2004.
XX
PP 25-JUL-2003; 2003US-00627930.
XX
PR 23-APR-2002; 2002WO-US013135.
PR 23-APR-2002; 2002WO-US013143.
XX
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.

PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX
PI Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S;
PI Shahabuddin S, Lu H, Cong H;
XX
DR WPI; 2004-293804/27.
XX
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
PT initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX
PS Claim 2; SEQ ID NO 722; 174pp; English.
XX
CC The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Botaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX
SQ Sequence 20 BP; 3 A; 7 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2760 TCGCTCTGTCAACCCAGGCTG 2779
||||| ||||| ||||| |||||
DB 1 TCACCTTTGTCAACCCAGGCTG 20
RESULT 2104
ADO45255
ID ADO45255 standard; DNA; 20 BP.
XX
AC ADO45255;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human oligonucleotide #621.
XX
KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5;
KW CCR1; CCR3; Botaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a;
KW tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease;
KW lung disease; hyper-responsiveness; adenosine; adenosine A receptor;
KW asthma; lung allergy; inflammation; inflammatory disease;
KW airway inflammation; allergy; impeded respiration; cystic fibrosis; CF;
KW chronic obstructive pulmonary disease; COPD; allergic rhinitis;
KW acute respiratory distress syndrome; pulmonary hypertension;
KW lung inflammation; bronchitis; airway obstruction; bronchoconstriction.
OS Homo sapiens.

XX US2004049022-A1.
PN 11-MAR-2004.
XX 25-JUL-2003; 2003US-00627930.
XX 23-APR-2002; 2002WO-US013135.
PR 23-APR-2002; 2002WO-US013143.
XX (NYCE/) NYCE J W.
PA (SAND/) SANDRASAGRA A.
PA (TANG/) TANG L.
PA (AGUI/) AGUILAR D.
PA (MILL/) MILLER S.
PA (SHAH/) SHAHABUDDIN S.
PA (LUHH/) LU H.
PA (CONG/) CONG H.
XX Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S,
PI Shahabuddin S, Lu H, Cong H;
XX WPI; 2004-293804/27.
XX Novel single or multiple target oligonucleotide anti-sense to e.g.
XX initiation codon, intron of respiratory disease-relevant gene e.g. CCR1,
PT RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g.
PT asthma.
XX Claim 2; SEQ ID NO 621; 174pp; English.
XX The invention relates to oligonucleotides anti-sense to an initiation
CC codon, coding region, 5' or 3' intron-exon junction, intron or region
CC with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target
CC chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)
CC -5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM,
CC tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention
CC also relates to a method of screening a candidate compound that binds to
CC one or more nucleic acid target(s) or expressed product(s), for the
CC prevention and/or treatment of a respiratory or lung disease. The
CC oligonucleotides are useful for reducing or inhibiting expression of a
CC gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor,
CC CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a,
CC tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are
CC useful for preventing or treating a respiratory or lung disease. The
CC respiratory or lung disease is associated with hyper-responsiveness to
CC and/or increased levels of, adenosine and/or levels of adenosine A
CC receptor(s), and/or asthma and/or lung allergies associated with
CC inflammation or an inflammatory disease. The respiratory or lung disease
CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
CC hypertension, lung inflammation, bronchitis, airway obstruction or
CC bronchoconstriction. This sequence represents an oligonucleotide of the
CC invention.
XX Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
SQ Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2845 CTCAGCTCTCGTAGTAGCTG 2864
|| ||||| |||||
Db 1 CTTAGCTCTCGTAGTAGCTG 20
RESULT 2105
ADN06744/c
ID ADN06744 standard; DNA; 20 BP.
XX AC ADN06744;
XX

DT 15-JUL-2004 (first entry)
XX Human FLAP related microsatellite marker SEQ ID NO:394.
DE
XX Leukotriene synthesis inhibitor; myocardial infarction;
KW acute coronary syndrome; antiatherosclerotic; cardiant; antianginal;
KW leukotriene biosynthesis inhibitor; leukotriene receptor antagonist;
KW 5-lipoxygenase activating protein; FLAP; human; chromosome 13;
KW chromosome 13q12; polymorphism; 5-lipoxygenase gene promoter;
KW 5-LO gene promoter; diabetes; hypertension; hypercholesterolemia;
KW obesity; inflammatory marker; low density lipoprotein; cholesterol;
KW high density lipoprotein; angina; atherosclerosis; microsatellite marker;
KW ss.
XX Homo sapiens.
OS Synthetic.
XX WO2004035741-A2.
PN
XX 29-APR-2004.
PD
XX 16-OCT-2003; 2003WO-US032556.
PF
XX 17-OCT-2002; 2002US-0419433P.
PR
XX 21-FEB-2003; 2003US-0449331P.
PR
XX (DECO-) DECODE GENETICS EHP.
PA
XX Helgadottir A, Gurney MB, Guicher JR;
PI WPI; 2004-357211/33.
XX Use of leukotriene synthesis inhibitor for manufacture of a medicament
PT for treatment for myocardial infarction or susceptibility to myocardial
PT infarction in individual.
XX Disclosure; SEQ ID NO 394; 306pp; English.
PS The present invention describes using a leukotriene synthesis inhibitor
XX (I) for the manufacture of a medicament for the treatment of myocardial
CC infarction or susceptibility to myocardial infarction in an individual.
CC Also described is a method (M1) for the treatment of acute coronary
CC syndrome (ACS) in an individual comprising administering (I). (I) has
CC antiatherosclerotic, cardiant and antianginal activities, and can be used
CC as a leukotriene biosynthesis inhibitor, and a leukotriene receptor
CC antagonist. (I) can be used for the manufacture of a medicament for the
CC treatment of myocardial infarction or susceptibility to myocardial
CC infarction in an individual who has at least one risk factor chosen from
CC an at-risk haplotype for myocardial infarction, an at-risk haplotype in a
CC the 5-lipoxygenase activating protein (FLAP) gene, a polymorphism in a
CC FLAP nucleic acid and an at-risk polymorphism in the 5-lipoxygenase (5-
CC LO) gene promoter; in an individual who has at least one risk factor
CC chosen from diabetes, hypertension, hypercholesterolemia, elevated
CC lp(a), obesity, past or current smoker; in an individual having elevated
CC inflammatory marker chosen from C-reactive protein (CRP), serum amyloid
CC A, fibrinogen, leukotriene, leukotriene metabolite, interleukin-6, tissue
CC necrosis factor-alpha, soluble vascular cell adhesion molecule (sVCAM),
CC soluble intervascular adhesion molecule (sICAM), E-selectin, matrix
CC metalloprotease type-1, matrix metalloprotease type-2, matrix
CC metalloprotease type-3 and matrix metalloprotease type-9; in an
CC individual having increased low density lipoprotein (LDL) cholesterol
CC and/or decreased high density lipoprotein (HDL) cholesterol; in an
CC individual having increased leukotriene synthesis; in an individual
CC having previous myocardial infarction or acute coronary syndrome (ACS)
CC event, stable angina; or in an individual who has atherosclerosis or who
CC requires treatment to restore blood flow in arteries. (M1) is useful for
CC treating an individual suffering from acute coronary syndrome chosen from
CC unstable angina, non-ST-elevation myocardial infarction (NSTEMI) and ST-
CC elevation myocardial infarction (STEMI). The human FLAP gene is located
CC on chromosome 13, more specifically to 13q12. The present sequence
CC represents a microsatellite marker used in the exemplification of the
CC present invention.
XX

[illegible]

```
RESULT 2115
AAZ27767/c
ID AAZ27767 standard; DNA; 21 BP.
XX
AC AAZ27767;
XX
DT 23-DEC-1999 (first entry)
XX
DE PCR primer for human DNA marker clone G022.
XX
KW Tandem repeat sequence; DNA isolation; intermediate tandem repeat;
KW ITR sequence; pentanucleotide tandem repeat; stutter artifact;
KW DNA typing; DNA profiling; linkage analysis; criminal justice;
KW paternity testing; animal lineage analysis; microsatellite loci;
KW polymorphism detection; PCR primer; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9940194-A1.
XX
PD 12-AUG-1999.
XX
PF 04-FEB-1999; 99WO-US002345.
XX
PR 04-FEB-1998; 98US-00018584.
XX
PA (PROM-) PROMEGA CORP.
XX
PI Schumm JW, Bacher JW;
XX
DR WPI; 1999-590696/50.
XX
KW Isolating DNA containing intermediate tandem repeat sequences, useful in
PT DNA profiling.
XX
PS Claim 30; Page 20; 11pp; English.
XX
CC This sequence is a PCR primer for a human DNA marker clone used in the
CC method of the invention. The method is for isolating a fragment of DNA
CC containing an intermediate tandem repeat (ITR) sequence using
CC hybridization selection, and comprises: (a) providing several DNA
CC fragments, at least one of which contains an ITR sequence, a region of
CC the DNA fragment which contains at least one repeat unit consisting of a
CC sequence of five, six or seven bases repeated in tandem at least two
CC times; (b) providing a stationary support having at least one
CC oligonucleotide associated with it, where the oligonucleotide includes a
CC sequence of nucleotides which is complementary to a portion of the ITR
CC sequence; and (c) combining the DNA fragments with the support under
CC conditions where the DNA fragments including the DNA fragment containing
CC the ITR sequence hybridize to the support. The method is particularly
CC used to isolate DNA containing pentanucleotide tandem repeat sequences as
CC well as to detect target ITR DNA sequences having a low incidence of
CC stutter artifacts (no more than 2.4%). The method is useful in DNA
CC profiling for linkage analysis, criminal justice, paternity testing and
CC other forensic and medical uses. DNA typing is also useful for confirming
CC the lineage of horses, dogs and other prize animals. The invention
CC overcomes problems related to the use of microsatellite loci in DNA
CC profiling. The method can detect polymorphisms with a low incidence of
CC stutter artifacts, which has previously been a problem in interpreting
CC allelic content of loci. The development of markers based on larger
CC repeat units, enables easier separation of the fragments on
CC electrophoretic gels. This allows the simultaneous analysis of more loci
XX
SQ Sequence 21 BP; 7 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2760 TCGCTCTGTGTCACCAAGGCTG 2779
| ||||| ||||| |||||
Db 1766 GGACGCGGAGGACAGGCA 1785
| ||||| ||||| |||||
QY 1766 GGACGCGGAGGACAGGCA 1785
| ||||| ||||| |||||
Db 21 GGACGCTGGAGGAGGCA 2
| ||||| ||||| |||||
QY 2117
RESULT 2116
ADD13897/c
ID ADD13897 standard; DNA; 21 BP.
XX
AC ADD13897;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human vH PCR primer vH3-11.
XX
KW library; transfection; humanized monoclonal antibody; antigen;
KW T cell receptor; primer; ss; PCR; vH.
XX
OS Homo sapiens.
XX
PN EP1298207-A1.
XX
PD 02-APR-2003.
XX
PF 01-OCT-2001; 2001EP-00123596.
XX
PR 01-OCT-2001; 2001EP-00123596.
XX
PA (DEKR-) DEUT KREBSFORSCHUNGSZENTRUM.
XX
PI Breilting F, Moldenhauer G, Poustka A, Kuehlwein T;
XX
DR WPI; 2003-383833/37.
XX
KW Preparing library of protein-producing eukaryotic cells, useful for
PT producing humanized high-affinity antibodies, comprises introducing
PT specific recombination signals into chromosomal gene loci and integrating
PT a variety of DNA sequences.
XX
PS Example 5; Fig 14C; 75pp; German.
XX
CC This invention describes a novel method of preparing a library of protein
CC producing eukaryotic cells comprising (a) introducing specific
CC recombination signals into one or two chromosomal gene loci, (b)
CC expanding at least one of the modified cells, (c) transfecting many
CC different DNA sequences, each flanked by recombination signals, into the
CC expanded cells and (d) integrating the DNA sequences into the gene loci
CC on the basis of the recombination signals and the appropriate
CC recombinase. The resulting cells express different proteins, each from an
CC integrated DNA sequence and the proteins are bound to the cell surface.
CC The method is particularly used to produce libraries of humanized
CC monoclonal antibodies, for selection of those with affinity for
CC particular antigens and useful for diagnostic or therapeutic use.
CC Libraries of T cell receptors may also be prepared. The method produces
CC libraries of high diversity; provides easy, quick and automatable
CC selection from a large number of proteins, allows relatively simple
CC alteration of the expressed gene (e.g. fusion to other protein-coding
CC sequences), is suitable for large scale protein production and allows
CC simple verification and characterization of selected cell lines. The
CC method does not require incorporation of a resistance marker. This
CC sequence represents a PCR primer used to amplify the genes of the
CC invention.
XX
SQ Sequence 21 BP; 1 A; 12 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 1.1e+03;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1766 GGACGCGGAGGACAGGCA 1785
| ||||| ||||| |||||
Db 21 GGACGCTGGAGGAGGCA 2
| ||||| ||||| |||||
QY 2117
```



```
AD011941/c
ID  AD011941 standard; DNA; 21 BP.
AC
XX
AC  AD011941;
XX
DT  15-JUL-2004 (first entry)
XX
XX  Single multiplex PCR primer #1313.
DE
XX  ss; primer; simultaneous amplification;
KW  single multiplex polymerase chain reaction; multifactorial disease;
KW  genetic alteration; pharmacogenetic reaction; genotyping; polymorphism;
KW  gene expression profiling.
XX
XX  Synthetic.
OS
XX
XX  WO2004033649-A2.
PN
XX
XX  22-APR-2004.
PD
XX
XX  07-OCT-2003; 2003WO-US031874.
PF
XX
XX  07-OCT-2002; 2002US-0417009P.
PR
XX
XX  (UYNE-) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PA
XX
XX  Li H, Li J;
PI
XX
XX  WPI; 2004-340914/31.
DR
XX
XX  Designing primers for simultaneous amplification of target DNA fragments
PT  in a single multiplex polymerase chain reaction, for high throughput
PT  multiplex DNA sequence amplification, comprises aligning two primers.
XX
XX  Disclosure; Page 39; 120pb; English.
PS
XX
XX  The invention relates to a method of designing primers for simultaneous
CC  amplification of target DNA fragments in a single multiplex polymerase
CC  chain reaction by aligning a first primer and a second primer. The method
CC  comprises: (a) aligning a first primer and a second primer; and (b)
CC  selecting the first primer where the first primer at its 3' end does not
CC  contain four or more bases that are perfectly matching to the 3' end
CC  sequence of the first primer or a second primer, the first primer at its
CC  3' end does not contain seven or more bases that are perfectly matching
CC  except one mismatch to the 3' end sequence of the first primer or the
CC  second primer, the first primer at its 3' end does not contain six or
CC  more bases that are perfectly matching to a sequence anywhere of the
CC  first primer or the second primer, and the first primer at its 3' end
CC  does not contain eleven or more bases that are perfectly matching except
CC  one mismatch to a sequence anywhere of the first primer or the second
CC  primer. The method is useful for designing primers for simultaneous
CC  amplification of target DNA fragments in a single multiplex polymerase
CC  chain reaction. It is also useful in the identification of multiple genes
CC  related to multifactorial diseases, the genome-scale detection of genetic
CC  alterations, the studies in pharmacogenetic reactions, the genotyping
CC  genetic polymorphisms in a large population, the gene expression
CC  profiling in various samples and high throughput genotyping technologies.
CC  This sequence corresponds to an example of a primer of the invention.
XX
XX  Sequence 21 BP; 4 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
SQ
XX
XX  Query Match 0.6%; Score 16.8; DB 1; Length 21;
XX  Best Local Similarity 90.0%; Pred. No. 1.1e+03;
XX  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  2848 AGCTCTCTGAGTAGCTGGGA 2867
DB  20 AGCTCTCCAGTAGCTGGGA 1
    ||||| ||||| ||||| |||||
    ||||| ||||| ||||| |||||

RESULT 2118
ADP08707
ID  ADP08707 standard; DNA; 21 BP.
```

```
XX
AC  ADP08707;
XX
XX  26-AUG-2004 (first entry)
DT
XX
XX  Extend primer 44 used to genotype human glycoprotein VI polymorphism.
DE
XX  breast cancer; cytostatic; gene therapy; human; platelet glycoprotein VI;
KW  GP6; GPIV; GPVI; chromosome 19q13.4; ss; PCR; primer; SNP;
KW  single nucleotide polymorphism.
XX
XX  Homo sapiens.
OS
XX
XX  WO2004047767-A2.
PN
XX
XX  10-JUN-2004.
PD
XX
XX  25-NOV-2003; 2003WO-US037966.
PF
XX
XX  25-NOV-2002; 2002US-0429136P.
PR
XX  24-JUL-2003; 2003US-0490234P.
PR
XX
XX  (SEQU-) SEQUENOM INC.
PA
XX
XX  Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX  WPI; 2004-441082/41.
DR
XX
XX  Identifying a subject at risk of breast cancer by detecting the presence
PT  or absence of one or more nucleotide polymorphic variations, useful for
PT  diagnosing, preventing and/or treating breast cancer.
XX
XX  Example 3; Page 82; 286pp; English.
PS
XX
XX  The invention relates to a novel method for identifying a subject at risk
CC  of breast cancer which comprises detecting the presence or absence of one
CC  or more polymorphic variations associated with breast cancer in a nucleic
CC  acid sample from a subject. The method of the invention has cytostatic
CC  applications and may be useful for identifying a risk of breast cancer,
CC  as well as therapeutic and prophylactic treatments that specifically
CC  target breast cancer, such as gene therapy. The current sequence is that
CC  of an Extend primer of the invention which was used to genotype single
CC  nucleotide polymorphisms within human glycoprotein VI (platelet) (GP6;
CC  GPIV;GPVI) DNA which is located at chromosomal position 19q13.4.
XX
XX  Sequence 21 BP; 3 A; 13 C; 1 G; 4 T; 0 U; 0 Other;
SQ
XX
XX  Query Match 0.6%; Score 16.8; DB 1; Length 21;
XX  Best Local Similarity 90.0%; Pred. No. 1.1e+03;
XX  Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  2835 ATCTCTCCAGCTCAGCTCC 2854
DB  2 ATCTCTCCAGCTCAGCTCC 21
    ||||| ||||| ||||| |||||
    ||||| ||||| ||||| |||||

RESULT 2119
AAV83938/c
ID  AAV83938 standard; DNA; 19 BP.
XX
XX  AAV83938;
AC
XX
XX  03-MAR-1999 (first entry)
DT
XX
XX  PCR primer used to produce a YAC probe.
DE
XX  Yeast artificial chromosome; YAC; probe; eukaryotic chromosome;
KW  neocentromere; replication; extra-chromosomal element; segregation;
KW  cell division; artificial chromosome; gene therapy;
KW  human artificial chromosome; transgenic; PCR primer; ss.
XX
XX  Synthetic.
OS
XX
```


XX PS Table 7; Page 219; 517pp; English.

CC The sequence is that of a bovine microsatellite sequence obtd. by

CC screening a library of bovine MboI DNA fragments of between 250 and 500

CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50

CC clones cross-hybridised. Assuming independent distribution of

CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites

CC in the bovine genome is estimated at >100, 000. The sequence information

CC for ca. 230 such bovine microsatellites is summarised in the

CC specification and indexed herein (see below). The sequences upstream and

CC downstream of the microsatellite sequence were used to generate the

CC required PCR primers for in vitro amplification of the corresp.

CC microsatellite (using the program OPTIPRIM). The microsatellites may be

CC used to identify individuals, for parentage testing, and in the genetic

CC mapping of economic trait loci, or genes involved the determinism of

CC economically important traits esp. in cattle, to allow selective

CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN

CC field.)

XX SQ Sequence 18 BP; 0 A; 0 C; 9 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 18;

Best Local Similarity 94.4%; Pred. No. 1.4e+03;

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGT 2743

DB 1 GTGTGTGTGTGTGTGTGT 18

RESULT 2122

AAQ33950

ID AAQ33950 standard; DNA; 18 BP.

XX AC AAQ33950;

XX 25-MAR-2003 (revised)

DT 02-FEB-1993 (first entry)

XX DE Microsatellite sequence from clone TGLA346.

XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;

KW genetic mapping; traits; amplification; ss.

XX OS Bos taurus.

XX WO9213102-A1.

XX 06-AUG-1992.

XX 15-JAN-1992; 92WO-US000340.

XX 15-JAN-1991; 91US-00642342.

XX (GENM-) GENMARK.

XX Georges M, Massey JM;

XX WPI; 1992-284684/34.

XX Polymorphic bovine DNA markers - used in genetic identification, gene

PT mapping, and selective breeding.

XX Table 7; Page 310; 517pp; English.

CC The sequence is that of a bovine microsatellite sequence obtd. by

CC screening a library of bovine MboI DNA fragments of between 250 and 500

CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50

CC clones cross-hybridised. Assuming independent distribution of

CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites

CC in the bovine genome is estimated at >100, 000. The sequence information

CC for ca. 230 such bovine microsatellites is summarised in the

CC specification and indexed herein (see below). The sequences upstream and

CC downstream of the microsatellite sequence were used to generate the

CC required PCR primers for in vitro amplification of the corresp.

CC microsatellite (using the program OPTIPRIM). The microsatellites may be

CC used to identify individuals, for parentage testing, and in the genetic

CC mapping of economic trait loci, or genes involved the determinism of

CC economically important traits esp. in cattle, to allow selective

CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN

CC field.)

XX SQ Sequence 18 BP; 0 A; 0 C; 9 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 18;

Best Local Similarity 94.4%; Pred. No. 1.4e+03;

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTATG 2746

DB 1 TGTGTGTGTGTGTGTGTG 18

RESULT 2123

AAQ33997

ID AAQ33997 standard; DNA; 18 BP.

XX AC AAQ33997;

XX 25-MAR-2003 (revised)

DT 02-FEB-1993 (first entry)

XX DE Microsatellite sequence from clone TGLA4.

XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;

KW genetic mapping; traits; amplification; ss.

XX OS Bos taurus.

XX WO9213102-A1.

XX 06-AUG-1992.

XX 15-JAN-1992; 92WO-US000340.

XX 15-JAN-1991; 91US-00642342.

XX (GENM-) GENMARK.

XX Georges M, Massey JM;

XX WPI; 1992-284684/34.

XX Polymorphic bovine DNA markers - used in genetic identification, gene

PT mapping, and selective breeding.

XX Table 7; Page 329; 517pp; English.

CC The sequence is that of a bovine microsatellite sequence obtd. by

CC screening a library of bovine MboI DNA fragments of between 250 and 500

CC bp with an (AC)15 and a (TC)15 oligonucleotide probe. One out of 50

CC clones cross-hybridised. Assuming independent distribution of

CC microsatellites and MboI sites, the frequency of (T6)n >9 microsatellites

CC in the bovine genome is estimated at >100, 000. The sequence information

CC for ca. 230 such bovine microsatellites is summarised in the

CC specification and indexed herein (see below). The sequences upstream and

CC downstream of the microsatellite sequence were used to generate the

CC required PCR primers for in vitro amplification of the corresp.

CC microsatellite (using the program OPTIPRIM). The microsatellites may be

CC used to identify individuals, for parentage testing, and in the genetic

CC mapping of economic trait loci, or genes involved the determinism of

CC economically important traits esp. in cattle, to allow selective

CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN

CC field.)

FT modified_base 11. .1

Query Match	Score	DB 1;	Length 18;
0.5%	Score 16.4;	DB 1;	Length 18;

Query Match	0.5%;	Score 16.4;	DB 1;	Length 18;
Best Local Similarity	94.4%;	Pred. No. 1.4e+03;		

```

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGTCCCA 67
Db 18 GCCTCGCTACGGTCCCA 1

RESULT 2125
AAQ46589
ID AAQ46589 standard; DNA; 18 BP.
XX
XX AAQ46589;
XX
XX 25-MAR-2003 (revised)
DT 10-MAR-2003 (revised)
DT 23-DEC-1993 (first entry)
XX
XX Simple sequence repeat (GT)9.
XX
XX Microsatellite; simple sequence repeat; SSR; polymorphism; variation;
KW genetic marker; human genome; mapping; ligation reaction; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH repeat_region 1..18
FT /*tag= a
FT /*note= "SSR"
FT 1..2
FT /*tag= b
FT /*rpt_type= TANDEM
XX
XX EP552545-A1.
XX
XX 28-JUL-1993.
XX
XX 09-DEC-1992; 92EP-00311242.
XX
XX 17-JAN-1992; 92US-00826930.
XX
XX (PION-) PIONEER HI-BRED INT INC.
XX
XX Grant D;
XX
XX WPI; 1993-236281/30.
XX
XX Detecting genetic variation between organisms - by detecting
PT polymorphisms in simple sequence repeats in DNA of organisms.
XX
XX Disclosure; Page 5; 8pp; English.
XX
XX A (CA)9 simple sequence repeat is used to illustrate the novel method for
CC detecting SSR polymorphisms without the need for direct sequencing or gel
CC electrophoresis. The length of a particular repeat region (i.e. number of
CC repeats) can be highly polymorphic; the sequences flanking the repeat
CC region, however, are conserved. Detection of a SSR of a specific length
CC is achieved by successful ligation of two oligonucleotides, one being
CC exactly complementary to the repeat region and one of its conserved
CC flanking sequences (i.e. comprising the sequence (GT)9) and the other
CC being complementary to the other conserved flanking sequence. (Updated on
CC 10-MAR-2003 to add missing OS field.) (Updated on 25-MAR-2003 to correct
CC PN field.)
XX
XX Sequence 18 BP; 0 A; 0 C; 9 G; 9 T; 0 U; 0 Other;
SQ

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 GCCTGTGTGTGTGTGTGT 2743
Db 1 GTGTGTGTGTGTGTGTGT 18

RESULT 2126
AAQ46588/c
ID AAQ46588 standard; DNA; 18 BP.
XX
XX AAQ46588;
XX
XX 25-MAR-2003 (revised)
DT 10-MAR-2003 (revised)
DT 23-DEC-1993 (first entry)
XX
XX Simple sequence repeat (CA)9.
XX
XX Microsatellite; simple sequence repeat; SSR; polymorphism; variation;
KW genetic marker; human genome; mapping; ligation reaction; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH repeat_region 1..18
FT /*tag= a
FT /*note= "SSR"
FT 1..2
FT /*tag= b
FT /*rpt_type= TANDEM
XX
XX EP552545-A1.
XX
XX 28-JUL-1993.
XX
XX 09-DEC-1992; 92EP-00311242.
XX
XX 17-JAN-1992; 92US-00826930.
XX
XX (PION-) PIONEER HI-BRED INT INC.
XX
XX Grant D;
XX
XX WPI; 1993-236281/30.
XX
XX Detecting genetic variation between organisms - by detecting
PT polymorphisms in simple sequence repeats in DNA of organisms.
XX
XX Disclosure; Page 5; 8pp; English.
XX
XX This (CA)9 simple sequence repeat is used to illustrate the novel method
CC for detecting SSR polymorphisms without the need for direct sequencing or
CC gel electrophoresis. The length of a particular repeat region (i.e.
CC number of repeats) can be highly polymorphic; the sequences flanking the
CC repeat region, however, are conserved. Detection of a SSR of a specific
CC length is achieved by successful ligation of two oligonucleotides, one
CC being exactly complementary to the repeat region and one of its conserved
CC flanking sequences and the other being complementary to the other
CC conserved flanking sequence. (Updated on 10-MAR-2003 to add missing OS
CC field.) (Updated on 25-MAR-2003 to correct PN field.)
XX
XX Sequence 18 BP; 9 A; 9 C; 0 G; 0 T; 0 U; 0 Other;
SQ

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTG 2746
Db 18 TGTGTGTGTGTGTGTGTG 1

RESULT 2127
AAQ45853/c
ID AAT45853 standard; DNA; 18 BP.
XX
XX AC AAT45853;
XX

```

```

DT 11-FEB-1997 (first entry)
XX ICAM antisense oligonucleotide with thiol modified backbone.
DE Thiol; antisense; intracellular adhesion molecule; ICAM; inhibition;
XX antisense technology; alkylthiol functionality; cellular transport;
XX membrane transport; lipophilic; ss.
OS Synthetic.
XX
XX Key Location/Qualifiers
PH modified_base 5_6
FT /*tag= a
FT /note= "Linked via a thiol modified backbone"
XX
XX WO9506474-A1.
XX
XX 09-MAR-1995.
XX
XX 31-AUG-1994; 94WO-US010053.
XX
XX 03-SEP-1993; 93US-00116801.
XX
XX (ISIS-) ISIS PHARM INC.
XX Cook PD, Manoharan M;
XX WPI; 1995-115256/15.
XX
XX Nucleoside and oligo:nucleoside analogues contg. alkyl-thiol gp. - useful
PT for antisense applications e.g. modulating gene expression and detecting
PT the presence or absence of RNA in a sample.
XX
XX Example 18; Page 28; 48pp; English.
XX
XX The sequences given in AAT45853-54 represent thiol-modified
CC oligonucleotides. These sequences are antisense to sequences found in the
CC intracellular adhesion molecule (ICAM) coding sequence. These
CC oligonucleotides may be used to inhibit gene expression in vivo by
CC hybridising to mRNA expressed in the cell. They are therefore useful in
CC antisense technology. The modification of the backbone with an alkylthiol
CC functionality improves cellular and membrane transport as it is
CC lipophilic
XX
XX Sequence 18 BP; 4 A; 5 C; 7 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GGCTCGCTATGGCTCCCA 1

RESULT 2128
AA33894/c
ID AAX33894 standard; DNA; 18 BP.
XX
XX AAX33894;
XX
XX 30-JUN-1999 (first entry)
XX
XX ICAM inhibiting antisense oligonucleotide.
DE
XX ICAM inhibitor; intracellular adhesion molecule; replication inhibitor;
KW gene expression inhibitor; transcription inhibitor; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
PH modified_base 1..18
FT /*tag= b

```

```

FT modified_base 5
FT /notes= "phosphorothioate backbone"
FT /*tag= a
FT /note= "thiol-modified nucleoside"
XX
XX US5578718-A.
XX
XX 26-NOV-1996.
XX
XX 03-SEP-1993; 93US-00116801.
XX
XX 11-JAN-1990; 90US-00463358.
XX
XX 13-AUG-1990; 90US-00566977.
XX
XX 24-OCT-1991; 91US-00782374.
XX
XX 23-OCT-1992; 92WO-US009196.
XX
XX 22-APR-1994; 94US-00211882.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Manoharan M, Cook PD;
XX WPI; 1997-020468/02.
XX
XX New nucleoside(s) contg. alkyl:thiol functionalities - and opt. also
PT incorporating steroids, reporter molecules, peptides or proteins attached
PT through the alkylthio gp.
XX
XX Example 18; Col 16; 14pp; English.
XX
XX This sequence represents an antisense oligonucleotide inhibitor of
CC intracellular adhesion molecules (ICAM). The invention relates to a
CC nucleoside that comprises a ribofuranosyl sugar portion and a base
CC portion, and bears at a 2'-O-, 3'-O- or 5'-O-position a substitution of
CC formula -Rs-S-R1, where Rs = Ra, Ra-C(O)-Q-Ra, or Ra-O-Ra-Q-Ra; each Ra =
CC 1-10C alkyl, each Q = NH, O or S; R1 = H, a thiol protecting group, or a
CC group S-R2, CH2C(O)NR2, CH2CH=CHC(O)R2, CH2CH2NHSO2-R2 or (maleimido)-R2
CC ; and R2 = a steroid molecule, a reporter molecule, a lipophilic
CC molecule, a peptide, a protein, an alkylator, an intercalator, a crown
CC ether, a crown amine, a porphyrin, a peptide nucleic acid, a thiol
CC attached to a poly(ethylene glycol), or a crosslinking agent. The
CC nucleosides may be incorporated into oligonucleosides or
CC oligonucleotides. They are capable of modulating the activity of DNA or
CC RNA and may be used e.g. to inhibit the expression of particular genes in
CC cells of an organism, to inhibit transcription and/or replication of
CC particular genes, to induce degradation of particular regions of double
CC stranded DNA in cells of an organism, or for killing cells or viruses.
CC The compounds include an alkylthiol chemical functionality. They exhibit
CC improved transfer across cellular membranes
XX
XX Sequence 18 BP; 4 A; 5 C; 7 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GGCTCGCTATGGCTCCCA 1

RESULT 2129
AAV21968/c
ID AAV21968 standard; DNA; 18 BP.
XX
XX AAV21968;
XX
XX 14-JUL-1998 (first entry)
XX
XX Nuclease resistant antisense oligo NBT 141 targeted against (AC) 9.
XX
XX Nuclease resistant; bacterial infection; antibiotic; target;
KW veterinary medicine; treatment; human; industrial process;
KW bacterial control; ss.

```

```

XX OS Synthetic.
XX PN W09803533-A1.
XX XX
XX PD 29-JAN-1998.
XX XX
XX PF 23-JUL-1997; 97WO-US012961.
XX XX
XX PR 24-JUL-1996; 96US-00685575.
XX XX
XX PA (OLIG-) OLIGOS ETC & OLIGOS THERAPEUTICS INC.
XX XX
XX PI Arrow A, Dale RMK, Thompson TL;
XX XX
XX DR WPI; 1998-120687/11.
XX XX
XX XX Treating bacterial infections in humans or animals with
XX PT oligo:nucleotide(s) - resistant to nuclease and targetted to bacterial
XX PT nucleic acid or proteins, also conjugates of these oligo:nucleotide(s)
XX PT with antibiotics.
XX XX
XX PS Claim 49; Page 87; 163pp; English.
XX XX
XX CC This antisense oligonucleotide is nuclease resistant and can be used in
XX CC the treatment of animals, including humans, having a bacterial infection.
XX CC The treatment comprises administration of such nuclease resistant
XX CC oligonucleotides, targeted to a nucleic acid or protein of the bacterium,
XX CC and formulated with a carrier. A compound comprising this nuclease
XX CC resistant oligonucleotide can be covalently linked to an antibiotic. The
XX CC method is used to treat infections by a wide variety of Gram-positive and
XX CC Gram-negative, or acid-fast, bacteria, in human and veterinary medicine.
XX CC The methods are particularly used in immuno-compromised individuals (e.g.
XX CC patients with acquired immunodeficiency syndrome or those receiving
XX CC chemotherapy or radiation therapy), optionally in combination with, or
XX CC fused to, antiviral or other antimicrobial oligonucleotides. Apart from
XX CC therapeutic use, the oligonucleotides can be used to control bacteria in
XX CC laboratory cultures, foods, beverages and industrial processes. The
XX CC oligonucleotides are specific for bacteria, without affecting metabolism
XX CC in mammalian cells. They may also activate RNase H and have a general,
XX CC non-specific immune-stimulating effect. The oligonucleotides can be
XX CC administered orally, intranasally, rectally, topically or by injection,
XX CC optionally coupled to an agent (e.g. carbohydrate or polyamine) that
XX CC enhances cellular uptake
XX XX
XX SQ Sequence 18 BP; 9 A; 9 C; 0 G; 0 T; 0 U; 0 Other;
Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2726 GCGTGTGTGTGTGTGTGT 2743
Db 18 GTGTGTGTGTGTGTGTGT 1
RESULT 2130
AAV08923/C
ID AAV08923 standard; DNA; 18 BP.
XX XX
XX AC AAV08923;
XX XX
XX DT 26-FEB-1999 (first entry)
XX XX
XX DE Antisense thiol-derivatised oligonucleotide #1.
XX XX
XX KW Thiol-derivatised oligonucleotide; transcription inhibitor;
XX KW replication inhibitor; double-stranded DNA degradation inducer; ss.
XX XX
XX OS Synthetic.
XX XX
XX FH Key Location/Qualifiers
XX FT modified_base 5

```

```

FT FT
XX XX /*tag= a
XX PN /note= "2'-O-thiol modified 2'-deoxyadenosine"
XX XX
XX PD US95852182-A.
XX XX
XX PF 22-DEC-1998.
XX XX
XX PF 02-JUN-1995; 95US-00458396.
XX XX
XX PR 11-JAN-1990; 90US-00463358.
XX PR 13-AUG-1990; 90US-00566977.
XX PR 24-OCT-1991; 91US-00782374.
XX PR 23-OCT-1992; 92WO-US009196.
XX PR 03-SEP-1993; 93US-00116801.
XX XX
XX PA (ISIS-) ISIS PHARM INC.
XX XX
XX PI Cook PD, Manoharan M;
XX XX
XX DR WPI; 1999-080503/07.
XX XX
XX PT Thiol-derivatised oligo:nucleotide(s) - are useful e.g. for inhibiting
XX PT transcription and/or replication of particular genes.
XX XX
XX PS Example 18; Col 16; 16pp; English.
XX XX
XX CC This sequence represents an example of a thiol-derivatised
XX CC oligonucleotide of the invention. The compounds of the invention comprise
XX CC a number of linked nucleosides, where each nucleoside comprises a
XX CC ribofuranosyl sugar portion and a base portion. At least one nucleoside
XX CC bears a group of formula -R8-S-R1 at a 2'-O-position, 3'-O-position or 5'-
XX CC -O-position, where R8 = R9, R9 = C(O)-Q-R10 or R9 = C(O)-Q-R10; each R10 = a 1-
XX CC 10C alkyl; Q = NH, O or S; R1 = H, a thiol-protecting group, S-R2,
XX CC CH2C(O)-NH-R2, CH2-CH2-C(O)-R2, -CH2-CH2-NH-S(O)2-R2 or (maleimido)-R2;
XX CC and R2 = a steroid molecule, a reporter molecule, a lipophilic molecule,
XX CC a reporter enzyme, a peptide, a protein, a reporter group, an alkylator,
XX CC an intercalator, a cell receptor-binding molecule, a crown ether, a crown
XX CC amine, a porphyrin, a crosslinking agent, a peptide nucleic acid, or a
XX CC thiol attached to a polyethylene glycol. The thiol-derivatised
XX CC oligonucleotides can be used to inhibit transcription and/or replication
XX CC of particular genes, for inducing degradation of particular regions of
XX CC double-stranded DNA in cells of an organism, or for killing cells or
XX CC viruses
XX XX
XX SQ Sequence 18 BP; 4 A; 5 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GGCTCGCTATGGCTCCCA 1
RESULT 2131
AAW76437
ID AAW76437 standard; DNA; 18 BP.
XX XX
XX AC AAW76437;
XX XX
XX DT 05-AUG-1999 (first entry)
XX XX
XX DE Sequencing reagent array oligonucleotide primer #28.
XX XX
XX KW Sequencing reagent array; primer; capture moiety; hybridisation;
XX KW detection; mutation; diagnosis; infectious disease; genetic disease; ss.
XX XX
XX OS Synthetic.
XX XX
XX PN W09927137-A1.
XX XX
XX PD 03-JUN-1999.

```

XX PF 20-NOV-1998; 98WO-US024966.
 XX XX 21-NOV-1997; 97US-00976427.
 XX XX (ORCH-) ORCHID BIOCOMPUTER INC.
 XX PA Head SR, Goelet P, Karn J, Boyce-Jacino M;
 XX PI WPI; 1999-357855/30.
 XX DR Reagent for nucleic acid sequencing by primer extension, used to detect
 XX PT mutations and to diagnose infectious or genetic diseases.
 XX XX Example 7; Page 27; 47pp; English.
 XX XX The present invention describes a sequencing reagent (I) comprising: (a)
 XX CC a capture group (CG) that can form a stable complex with a region of a
 XX CC template nucleic acid (II); (b) spacer region (SR); and (c) sequence-
 XX CC specific hybridisation region (SSHR) of 4-8 bases able to hybridise to a
 XX CC complementary sequence on (II). Also described are: (1) array comprising
 XX CC an orderly arrangement of many (I), immobilized on a solid support; and
 XX CC (2) method of sequencing (II) using a combinatorial array of (I). Arrays
 XX CC of (I) are used for sequencing nucleic acids by a primer extension
 XX CC method, e.g. to scan for mutations (particularly single-nucleotide
 XX CC polymorphisms) and for diagnosis of infectious and genetic diseases.
 XX CC Arrays of (I) allow sequencing of templates without any prior knowledge
 XX CC of the wild-type or expected sequence. By separating the capture and
 XX CC specific hybridisation functions, it becomes possible to use smaller
 XX CC primers, simplifying array analysis, reducing costs and allowing
 XX CC thousands of hybridisation reactions to be done simultaneously.
 XX CC Particularly, 4 times fewer primers are required, compared with standard
 XX CC methods, i.e. since primer extension increases the effective length of
 XX CC the primer by 1 base, an array of n-mers will be as effective as an array
 XX CC of n+1-mers in usual methods. The method may be applied to single- or
 XX CC double-stranded DNA. AAX76410 to AAX76440 represent sequencing reagent
 XX CC array oligonucleotide primers used in an example from the present
 XX CC invention
 XX XX Sequence 18 BP; 0 A; 0 C; 9 G; 9 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTG 2746
 Db 1 TGTGTGTGTGTGTGTGTG 18
 RESULT 2132
 AAA95047/c
 ID AAA95047 standard; DNA; 18 BP.
 AC AAA95047;
 XX 23-FEB-2001 (first entry)
 DT Protein production prevention modified antisense oligonucleotide #1.
 XX Protein production prevention; antisense oligonucleotide;
 KW alkythio group; ss.
 XX Synthetic.
 OS Key Location/Qualifiers
 FH modified_base 1. .18
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone"
 FT modified_base 5
 FT /*tag= b
 FT /mod_base= OTHER
 FT

FT XX US6114513-A.
 PN 05-SEP-2000.
 PD 05-SEP-1997; 97US-00924326.
 XX 11-JAN-1990; 90US-00463358.
 PR 13-AUG-1990; 90US-00566977.
 PR 24-OCT-1991; 91US-00782374.
 PR 23-OCT-1992; 92WO-US009196.
 PR 03-SEP-1993; 93US-00116801.
 PR 02-JUN-1995; 95US-00458396.
 XX (ISIS-) ISIS PHARM INC.
 PA Manoharan M, Cook PD;
 XX WPI; 2000-586484/55.
 DR Use of oligonucleosides containing thiol groups which hybridize to RNA
 XX PT and have improved transport across cell membranes, in diagnosis or
 XX PT treatment of viral infections and abnormal cell proliferation.
 XX Example 18; Col 16; 18pp; English.
 PS The present sequence is a modified antisense molecule which was used to
 CC demonstrate the methods of the invention. These involve the use of
 CC nucleosides, modified by alkythio groups, as antisense strands which
 CC bind to RNA to prevent translation. This can be used in the treatment of
 CC diseases characterised by the undesired production of a protein. The
 CC organisms treated may be prokaryotic or eukaryotic
 XX CC Sequence 18 BP; 4 A; 5 C; 7 G; 2 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 50 GCCTCGCTATGGCTCCCA 67
 Db 18 GCCTCGCTATGGCTCCCA 1
 RESULT 2133
 AAS13765
 ID AAS13765 standard; DNA; 18 BP.
 XX AAS13765;
 AC 08-MAY-2002 (first entry)
 DT Simple sequence repeat, SSR, #37.
 XX Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
 KW cereal profiling; grass profiling; seed batch purity testing.
 XX Lolium multiflorum.
 OS NZ509193-A.
 PN 25-MAY-2001.
 PD 03-JAN-2001; 2001NZ-00509193.
 XX 24-DEC-1999; 99AU-00004906.
 PR 04-MAY-2000; 2000AU-00007310.
 XX (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
 PA (UYSC-) UNIV SOUTHERN CROSS.
 PA (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
 PA (UYAD-) UNIV ADELAIDE.

/note= "2'-O-thiol modified-2'-deoxyadenosine"

PA (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
 XX Forster JW, Jones ES;
 PI WPI; 2001-512563/56.
 XX
 XX New simple sequence repeats having 2 or more tandemly repeated nucleotide
 PT core elements isolated from ryegrass and fescue, useful for selecting of
 PT genes in grass or cereal breeding or profiling grass or cereal species
 PT varieties.
 XX
 XX Example 1; Fig 6; 72pp; English.
 PS
 XX The invention relates to a substantially purified or isolated nucleic
 CC acid (I) from ryegrass or fescue species including a simple sequence
 CC repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
 CC 2-6 nucleotides in length. Also included are a nucleic acid primer
 CC suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
 CC library of ryegrass or fescue genomic DNA enriched for SSRs and
 CC identifying clones in the library containing SSRs, a library of ryegrass
 CC or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
 CC a gene in grass or cereal breeding by identifying an SSR that is closely
 CC associated with the gene such that the SSR and the gene are
 CC preferentially co-inherited, and selecting for the SSR in the breeding, a
 CC method for DNA profiling grass or cereal species varieties by assessing
 CC variation between SSR varieties and testing the purity of grass or cereal
 CC seed batches by assessing variation within seed batch of an SSR. The SSRs
 CC may be used in the selection of genes in grass or cereal breeding, for
 CC profiling grass or cereal species varieties, for testing the purity of
 CC grass or cereal seed batches, and for DNA profiling to establish the
 CC distinct identity, uniformity and/or stability of a cultivar. The present
 CC sequence is a ryegrass or fescue SSR
 XX
 SQ Sequence 18 BP; 0 A; 0 C; 9 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2726 GCGTGTGTGTGTGTGTGT 2743
 | | | | | | | | | | | | | | | | | |
 Db 1 GTGTGTGTGTGTGTGTGT 18
 RESULT 2134
 AAS13732/c
 ID AAS13732 standard; DNA; 18 BP.
 AC AAS13732;
 XX
 XX 08-MAY-2002 (first entry)
 DT
 XX Simple sequence repeat, SSR, #29.
 DE
 XX Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
 KW cereal profiling; grass profiling; seed batch purity testing.
 KW
 XX Poae.
 OS
 XX NZ509193-A.
 PN
 XX 25-MAY-2001.
 PD
 XX 03-JAN-2001; 2001NZ-00509193.
 PF
 XX 24-DEC-1999; 99AU-00004906.
 PR
 PR 04-MAY-2000; 2000AU-00007310.
 XX
 XX (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
 PA (UYSC-) UNIV SOUTHERN CROSS.
 PA (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
 PA (UYAD-) UNIV ADELAIDE.
 PA (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
 XX

XX Forster JW, Jones ES;
 PI WPI; 2001-512563/56.
 XX
 XX New simple sequence repeats having 2 or more tandemly repeated nucleotide
 PT core elements isolated from ryegrass and fescue, useful for selecting of
 PT genes in grass or cereal breeding or profiling grass or cereal species
 PT varieties.
 XX
 XX Claim 6; Page 51; 72pp; English.
 PS
 XX The invention relates to a substantially purified or isolated nucleic
 CC acid (I) from ryegrass or fescue species including a simple sequence
 CC repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
 CC 2-6 nucleotides in length. Also included are a nucleic acid primer
 CC suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
 CC library of ryegrass or fescue genomic DNA enriched for SSRs and
 CC identifying clones in the library containing SSRs, a library of ryegrass
 CC or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
 CC a gene in grass or cereal breeding by identifying an SSR that is closely
 CC associated with the gene such that the SSR and the gene are
 CC preferentially co-inherited, and selecting for the SSR in the breeding, a
 CC method for DNA profiling grass or cereal species varieties by assessing
 CC variation between SSR varieties and testing the purity of grass or cereal
 CC seed batches by assessing variation within seed batch of an SSR. The SSRs
 CC may be used in the selection of genes in grass or cereal breeding, for
 CC profiling grass or cereal species varieties, for testing the purity of
 CC grass or cereal seed batches, and for DNA profiling to establish the
 CC distinct identity, uniformity and/or stability of a cultivar. The present
 CC sequence is a ryegrass or fescue SSR
 XX
 SQ Sequence 18 BP; 9 A; 9 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTATG 2746
 | | | | | | | | | | | | | | | | | |
 Db 18 TGTGTGTGTGTGTGTGTG 1
 RESULT 2135
 AAS13723/c
 ID AAS13723 standard; DNA; 18 BP.
 AC AAS13723;
 XX
 XX 08-MAY-2002 (first entry)
 DT
 XX Simple sequence repeat, SSR, #20.
 DE
 XX Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
 KW cereal profiling; grass profiling; seed batch purity testing.
 KW
 XX Poae.
 OS
 XX NZ509193-A.
 PN
 XX 25-MAY-2001.
 PD
 XX 03-JAN-2001; 2001NZ-00509193.
 PF
 XX 24-DEC-1999; 99AU-00004906.
 PR
 PR 04-MAY-2000; 2000AU-00007310.
 XX
 XX (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
 PA (UYSC-) UNIV SOUTHERN CROSS.
 PA (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
 PA (UYAD-) UNIV ADELAIDE.
 PA (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
 XX

PI Forster JW, Jones ES;
 XX WPI; 2001-512563/56.
 XX
 XX New simple sequence repeats having 2 or more tandemly repeated nucleotide
 PT core elements isolated from ryegrass and fescue, useful for selecting of
 PT genes in grass or cereal breeding or profiling grass or cereal species
 PT varieties.
 XX
 XX Claim 6; Page 51; 72pp; English.
 XX
 XX The invention relates to a substantially purified or isolated nucleic
 CC acid (I) from ryegrass or fescue species including a simple sequence
 CC repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
 CC 2-6 nucleotides in length. Also included are a nucleic acid primer
 CC suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
 CC library of ryegrass or fescue genomic DNA enriched for SSRs and
 CC identifying clones in the library containing SSRs, a library of ryegrass
 CC or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
 CC a gene in grass or cereal breeding by identifying an SSR that is closely
 CC associated with the gene such that the SSR and the gene are
 CC preferentially co-inherited, and selecting for the SSR in the breeding, a
 CC method for DNA profiling grass or cereal species varieties by assessing
 CC variation between SSR varieties and testing the purity of grass or cereal
 CC seed batches by assessing variation within seed batch of an SSR. The SSRs
 CC may be used in the selection of genes in grass or cereal breeding, for
 CC profiling grass or cereal species varieties, for testing the purity of
 CC grass or cereal seed batches, and for DNA profiling to establish the
 CC distinct identity, uniformity and/or stability of a cultivar. The present
 CC sequence is a ryegrass or fescue SSR
 XX
 SQ Sequence 18 BP; 9 A; 9 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2726 GCGTGTGTGTGTGTGTGT 2743
 Db 18 GTGTGTGTGTGTGTGTGT 1
 RESULT 2136
 AAS13729
 ID AAS13729 standard; DNA; 18 BP.
 XX
 AC AAS13729;
 XX
 DT 08-MAY-2002 (first entry)
 XX
 DE Simple sequence repeat, SSR, #26.
 XX
 KW Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
 KW cereal profiling; grass profiling; seed batch purity testing.
 XX
 OS Poae.
 XX
 XX NZ509193-A.
 XX
 PD 25-MAY-2001.
 XX
 PF 03-JAN-2001; 2001NZ-00509193.
 XX
 PR 24-DEC-1999; 99AU-00004906.
 PR 04-MAY-2000; 2000AU-00007310.
 XX
 XX (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.
 PA (UYSC-) UNIV SOUTHERN CROSS.
 PA (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.
 PA (UYAD-) UNIV ADELAIDE.
 PA (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.
 XX
 PI Forster JW, Jones ES;

XX WPI; 2001-512563/56.
 XX
 XX New simple sequence repeats having 2 or more tandemly repeated nucleotide
 PT core elements isolated from ryegrass and fescue, useful for selecting of
 PT genes in grass or cereal breeding or profiling grass or cereal species
 PT varieties.
 XX
 XX Claim 6; Page 51; 72pp; English.
 XX
 XX The invention relates to a substantially purified or isolated nucleic
 CC acid (I) from ryegrass or fescue species including a simple sequence
 CC repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
 CC 2-6 nucleotides in length. Also included are a nucleic acid primer
 CC suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
 CC library of ryegrass or fescue genomic DNA enriched for SSRs and
 CC identifying clones in the library containing SSRs, a library of ryegrass
 CC or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for
 CC a gene in grass or cereal breeding by identifying an SSR that is closely
 CC associated with the gene such that the SSR and the gene are
 CC preferentially co-inherited, and selecting for the SSR in the breeding, a
 CC method for DNA profiling grass or cereal species varieties by assessing
 CC variation between SSR varieties and testing the purity of grass or cereal
 CC seed batches by assessing variation within seed batch of an SSR. The SSRs
 CC may be used in the selection of genes in grass or cereal breeding, for
 CC profiling grass or cereal species varieties, for testing the purity of
 CC grass or cereal seed batches, and for DNA profiling to establish the
 CC distinct identity, uniformity and/or stability of a cultivar. The present
 CC sequence is a ryegrass or fescue SSR
 XX
 SQ Sequence 18 BP; 0 A; 0 C; 9 G; 9 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2726 GCGTGTGTGTGTGTGTGT 2743
 Db 1 GTGTGTGTGTGTGTGTGT 18
 RESULT 2137
 AAH46012
 ID AAH46012 standard; DNA; 18 BP.
 XX
 AC AAH46012;
 XX
 DT 12-SEP-2001 (first entry)
 XX
 DE Synthetic oligonucleotide 12.
 XX
 KW Synthetic oligonucleotide; dinucleotide repeat; cytosstatic; apoptosis;
 KW cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
 KW tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
 XX lymphoma; ss.
 XX
 OS Synthetic.
 XX
 XX WO200144465-A2.
 XX
 PD 21-JUN-2001.
 XX
 PF 12-DEC-2000; 2000WO-CA001467.
 XX
 PR 13-DEC-1999; 99US-0170325P.
 PR 29-AUG-2000; 2000US-0228925P.
 XX
 XX (BION-) BIONICHE LIFE SCI INC.
 XX
 XX Phillips NC, Fillion MC;
 XX WPI; 2001-398150/42.
 XX

PT Composition comprising synthetic oligonucleotides which comprise multiple
 PT repeats of dinucleotides such as GT, TG useful for treating cancer by
 PT inducing cell cycle arrest, inhibiting proliferation, activating
 PT caspases.

XX Claim 5; Page 17; 77pp; English.

XX
 CC The present sequence is that of a synthetic oligonucleotide useful to the
 CC invention. The invention relates to a composition, comprising a 2 to 20
 CC base 3'-OH, 5'-OH synthetic oligonucleotide which comprises multiple
 CC repeats of dinucleotides such as GT, TG, etc., according to specific
 CC formula and having cytostatic activity. The oligonucleotide compositions
 CC are useful for inducing cell cycle arrest, inhibition of proliferation,
 CC activation of caspases and induction of apoptosis or production of
 CC cytokines such as interleukin (IL)-1-beta, IL-6, IL-10, IL-12 and tumour
 CC necrosis factor (TNF)-alpha by immune system cells, in an animal having
 CC cancer such as primary carcinoma, secondary carcinoma, primary sarcoma
 CC and secondary sarcoma such as, leukemia, lymphoma, breast, prostate,
 CC colorectal, ovarian or bone cancer. The compositions induce apoptosis
 CC independent of Fas, p53/p21, p21/waf-1/CIP, p15(ink4B), p16(ink4), drug
 CC resistance, caspase 3, transforming growth factor (TGF)-beta 1 receptor
 CC and hormone dependence

XX Sequence 18 BP; 0 A; 0 C; 9 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGT 2743

Db 1 GTGTGTGTGTGTGTGT 18

RESULT 2138

AAH46011

ID AAH46011 standard; DNA; 18 BP.

XX AC AAH46011;

XX DT 12-SEP-2001 (first entry)

XX DE Synthetic oligonucleotide 11.

XX KW Synthetic oligonucleotide; dinucleotide repeat; cytostatic; apoptosis;
 KW cell cycle arrest; cell proliferation; caspase; cytokine; interleukin;
 KW tumour necrosis factor; TNF; cancer; carcinoma; sarcoma; leukemia;
 KW lymphoma; ss.

XX OS Synthetic.

XX PN WO200144465-A2.

XX PD 21-JUN-2001.

XX PF 12-DEC-2000; 2000WO-CA001467.

XX PR 13-DEC-1999; 99US-0170325P.

XX PR 29-AUG-2000; 2000US-0228925P.

XX PA (BION-) BIONICHE LIFE SCI INC.

XX PI Phillips NC, Filion MC;

XX DR WPI; 2001-398150/42.

XX
 PT Composition comprising synthetic oligonucleotides which comprise multiple
 PT repeats of dinucleotides such as GT, TG useful for treating cancer by
 PT inducing cell cycle arrest, inhibiting proliferation, activating
 PT caspases.

XX Claim 5; Page 17; 77pp; English.

CC The present sequence is that of a synthetic oligonucleotide useful to the
 CC invention. The invention relates to a composition, comprising a 2 to 20
 CC base 3'-OH, 5'-OH synthetic oligonucleotide which comprises multiple
 CC repeats of dinucleotides such as GT, TG, etc., according to specific
 CC formula and having cytostatic activity. The oligonucleotide compositions
 CC are useful for inducing cell cycle arrest, inhibition of proliferation,
 CC activation of caspases and induction of apoptosis or production of
 CC cytokines such as interleukin (IL)-1-beta, IL-6, IL-10, IL-12 and tumour
 CC necrosis factor (TNF)-alpha by immune system cells, in an animal having
 CC cancer such as primary carcinoma, secondary carcinoma, primary sarcoma
 CC and secondary sarcoma such as, leukemia, lymphoma, breast, prostate,
 CC colorectal, ovarian or bone cancer. The compositions induce apoptosis
 CC independent of Fas, p53/p21, p21/waf-1/CIP, p15(ink4B), p16(ink4), drug
 CC resistance, caspase 3, transforming growth factor (TGF)-beta 1 receptor
 CC and hormone dependence

XX Sequence 18 BP; 0 A; 0 C; 9 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATG 2746

Db 1 TGTGTGTGTGTGTGTG 18

RESULT 2139

AAH38730/C

ID AAH38730 standard; DNA; 18 BP.

XX AC AAH38730;

XX DT 14-AUG-2001 (first entry)

XX DE SNP specific lower PCR primer SEQ ID 1526.

XX KW Single nucleotide polymorphism; SNP; single nucleotide primer extension;
 KW SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
 KW Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
 KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
 KW acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
 KW inflammation; forensic investigation; paternity analysis; PCR primer; ss.

XX OS Homo sapiens.

XX PN WO200129262-A2.

XX PD 26-APR-2001.

XX PF 13-OCT-2000; 2000WO-US028436.

XX PR 15-OCT-1999; 99US-0160096P.

XX PA (ORCH-) ORCHID BIOSCIENCES INC.

XX PI Picoult-Newburg L, Pohl M;

XX DR WPI; 2001-290930/30.

XX
 PT New genotyping oligonucleotide, useful for detecting the presence,
 PT absence or identity of single polynucleotide polymorphism in a nucleic
 PT acid sample.

XX Claim 1; Page 57; 83pp; English.

XX
 CC Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
 CC primer extension (SNPE) primers, and the sequences of regions flanking
 CC sites of single nucleotide polymorphisms SNPs. The present invention
 CC includes kits for determining the presence or absence of a SNP, using the
 CC oligonucleotides of the invention. The PCR primers are used to amplify a
 CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.
 CC The oligonucleotides are useful for genotyping a nucleic acid sample by

CC performing a single-nucleotide primer extension reaction. The
 CC oligonucleotides are useful for determining the presence, absence or
 CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to
 CC assess by association analysis the genotype of an individual or group of
 CC individuals, having a pathological phenotypic trait suspected of being
 CC caused by one or more SNPs. Phenotypic traits include diseases e.g.
 CC agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
 CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
 CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
 CC traits also include symptoms of or susceptibility to multifactorial
 CC disease of which a component is or may be genetic such as autoimmune
 CC diseases, including, rheumatoid arthritis, multiple sclerosis,
 CC inflammation, cancer, nervous system diseases and infection by pathogenic
 CC microorganism. The method is also useful in forensic investigations and
 CC paternity analysis. The present sequence represents a PCR primer specific
 CC for a human SNP containing DNA sequence

XX SQ Sequence 18 BP; 3 A; 9 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2776 GCTGAGTGCAGTGTGC 2793

Db 18 GCTGAGTGCAGTGTGC 1

RESULT 2140

AAD20066/C

ID AAD20066 standard; DNA; 18 BP.

XX AC AAD20066;

XX DT 03-JAN-2002 (first entry)

XX DE Phosphorothioate antisense oligo for synthesis of oligonucleotides.

XX KW Thio-derivatised nucleoside; cellular membrane; diagnostic; therapeutic;

XX KW pharmaceutical; antisense; phosphorothioate backbone; ss.

XX OS Unidentified.

XX FH Key Location/Qualifiers

FT modified_base 1..18

FT /*tag= a

FT /mod_base= OTHER

FT /note= "Phosphorothioate backbone"

FT modified_base 5

FT /*tag= b

FT /mod_base= OTHER

FT /note= "2'-O-thiol modified-2'-deoxyadenosine"

XX US6265558-B1.

XX PD 24-JUL-2001.

XX PF 26-AUG-1999; 99US-00383856.

XX PR 11-JAN-1990; 90US-00463358.

XX PR 13-AUG-1990; 90US-00566977.

XX PR 24-OCT-1991; 91US-00782374.

XX PR 23-OCT-1992; 92WO-US009196.

XX PR 03-SEP-1993; 93US-00116801.

XX PR 22-APR-1994; 94US-00211882.

XX PR 02-JUN-1995; 95US-00458396.

XX PR 05-SEP-1997; 97US-00924326.

XX PR 26-AUG-1999; 99US-00383856.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Cook PD, Manoharan M;

XX XX

DR WPI; 2001-624246/72.

XX Oligonucleotides and oligonucleosides useful in diagnostics comprise
 PT several linked nucleosides containing alkylthio chemical functionality.

XX Example 18; Col 16; 17pp; English.

XX The invention relates to oligonucleotides and oligonucleosides comprising
 CC several linked nucleosides having alkylthio chemical functionality. Thio-
 CC derivatised nucleosides and oligonucleosides have improved transfer
 CC across cellular membranes, provide improvements in research and
 CC diagnostic methods and materials for assaying disease states in animals,
 CC provide therapeutic and research materials having improved transfer and
 CC uptake properties for the treatment of diseases through modulation of the
 CC activity of RNA and DNA. The oligonucleotides and nucleosides are used in
 CC diagnostics, therapeutics and as research reagents and kits; in
 CC pharmaceutical compositions; for treating organisms having a disease
 CC characterised by the undesired production of a protein. The present
 CC sequence is antisense phosphorothioate oligo for synthesis of
 CC oligonucleotides

XX SQ Sequence 18 BP; 4 A; 5 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 18;

Best Local Similarity 94.4%; Pred. No. 1.4e+03;

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCTCGCTATGCTCCCA 67

Db 18 GCTCGCTATGCTCCCA 1

RESULT 2141

AAI64454/C

ID AAI64454 standard; DNA; 18 BP.

XX AC AAI64454;

XX DT 23-NOV-2001 (first entry)

XX DE SSR motif #14.

XX KW Simple Sequence Repeat; SSR; clover; microsatellite; genome mapping;

XX KW trait mapping; marker-assisted selection; gene selection; legume;

XX KW DNA profiling; breeding; ds.

XX OS Unidentified.

XX PN NZ509194-A.

XX PD 25-MAY-2001.

XX PF 03-JAN-2001; 2001NZ-00509194.

XX PR 24-DEC-1999; 99AU-00004907.

XX PR 28-MAR-2000; 2000AU-00006520.

XX PA (AGRI-) AGRIC VICTORIA SERVICES PTY LTD.

XX PI Koelliker R, Forster JW;

XX WPI; 2001-431058/46.

XX Novel simple sequence repeats in clover species useful for selection of

PT genes in legume breeding, for profiling legume species varieties and for

PT testing the purity of legume seed batches.

XX Claim 6; Page 35; 52pp; English.

XX The present invention relates to Simple Sequence Repeats (SSRs) from

CC clover species. SSRs, also called microsatellites, are based on a 1-7

CC nucleotide core element which is tandemly repeated. The SSR array is

CC embedded in complex flanking DNA. SSRs are ideal markers for genome

CC mapping, trait mapping and marker-assisted selection. The SSRs may be used in methods for selecting genes in clover/legume breeding. The SSRs are also useful for DNA profiling of clover varieties and for testing the purity of legume seed batches. The present sequence is a SSR motif, which was used in the present invention

SQ Sequence 18 BP; 9 A; 9 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTATG 2746
|||||
Db 18 TGTGTGTGTGTGTG 1

RESULT 2142
ABL43992/C
ID ABL43992 standard; DNA; 18 BP.
XX ABL43992;
AC ABL43992;
XX
DT 11-APR-2002 (first entry)
XX
DE Human chromosome 1p36-35 PCR primer SEQ ID NO:1036.

XX Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
KW PCR primer; ss.

XX Homo sapiens.

XX JP2001321190-A.

XX 20-NOV-2001.

XX 12-MAR-2001; 2001JP-00068285.

XX 10-MAR-2000; 2000JP-00066716.

XX (RIKA) RIKAGAKU KENKYUSHO.

PA (GENO-) GENOTEX YG.

DR WPI; 2002-144136/19.

XX Arraying genome clones.

PS Claim 4; Page 25; 528pp; Japanese.

XX The present invention describes a method of arraying genome clones. The method comprises: (a) clones of the genomic libraries contained in multiwell plates numbered for discrimination are mixed in each of the multiwell plates; (b) a primer designed based on the chromosome marker sequence is added to the mixture to carry out an amplification reaction; (c) a signal corresponding to the marker is detected from the resultant amplified product to specify the discrimination Nos. of the multiwell plates containing the clones having said marker sequence; (d) the order of the markers is changed so that the same discrimination Nos. succeed to the maximum in the specified discrimination Nos. to array the multiwell plates; (e) the clones in the multiwell plates of the specified discrimination Nos. are mixed respectively in each wells of longitudinal and lateral directions; (f) the mixed clones are cultured and the resultant cultures are amplified by using the above primer; (g) signals are detected from the amplified products; (h) the clones in the multiwell plates are specified from the detected result; and (i) the clones are reconstituted as the positions on the chromosome and arrayed. The microarray is useful for gene analysis. ABL42957 to ABL45322 represent PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634 represent PCR primers for human chromosome 21q22.1, which are specifically claimed for use in the present invention

XX Sequence 18 BP; 2 A; 5 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2862 CTGGACCATAGGCTCAC 2879
|||||
Db 18 CTGGACCATAGGCTCAC 1

RESULT 2143
ACD67190/C
ID ACD67190 standard; DNA; 18 BP.

XX ACD67190;

XX 17-SEP-2003 (first entry)

XX Derivatized oligonucleotide oligomer 49.

XX ICMW-1; intracellular cell adhesion molecule-1; antisense; ss;
KW improved transfer; improved uptake; steroid/reporter molecule; porphyrin;
KW non-aromatic lipophilic molecule; reporter enzyme; metal chelator;
KW water/lipid soluble vitamin; RNA cleaving complex; alkylator;
KW hybrid photo-nuclease/intercalator; aryl azide photo-crosslinking agent.

XX Synthetic.

XX US2002177150-A1.

XX 28-NOV-2002.

XX 11-FEB-2002; 2002US-00073718.

XX 23-OCT-1992; 92WO-US009196.

PR 15-DEC-1998; 98US-00211882.

PR 07-AUG-2000; 2000US-00633659.

XX (ISIS-) ISIS PHARM INC.

XX Manoharan M, Cook PD, Bennett CF;

XX WPI; 2003-521529/49.

PT New derivatized oligonucleotide, useful for effecting cellular uptake,

PT comprises several linked nucleosides bearing a substituent such as

PT steroid/reporter molecule, reporter enzyme or peptide.

XX Example 14; Page 14; 23pp; English.

XX The invention relates to a derivatized oligonucleotide comprising several linked nucleosides having a functionalised nucleoside bearing a substituent such as steroid/reporter molecule, non-aromatic lipophilic molecule, reporter enzyme, peptide, protein, water/lipid soluble vitamin, RNA cleaving complex, metal chelator, porphyrin, alkylator, hybrid photo-nuclease/intercalator or aryl azide photo-crosslinking agent. The oligonucleotide is useful for effecting cellular uptake of the oligonucleotide by contacting an organism with the oligonucleotide. The oligonucleotide is useful in research and diagnostic methods, for assaying bodily states in animals, especially disease states, or for treatment of diseases through modulation of the activity of DNA or RNA. The oligonucleotide has improved transfer across cellular membranes and uptake properties. The effect of conjugation of an oligonucleotide with folic acid was determined by the inhibition of intercellular cell adhesion molecule-1 (ICAM-1). The present sequence represents a derivatized oligonucleotide oligomer

XX Sequence 18 BP; 3 A; 4 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

```

Db      18 GCCTCGCTACGGCTCCCA 1
RESULT 2144
ACD67197/c
ID ACD67197 standard; DNA; 18 BP.
XX
AC ACD67197;
XX
DT 17-SEP-2003 (first entry)
XX
DE Derivatized oligonucleotide oligomer 55 #2.
XX
KW ICAM-1; intracellular cell adhesion molecule-1; antisense; ss;
KW improved transfer; improved uptake; steroid/reporter molecule; porphyrin;
KW non-aromatic lipophilic molecule; reporter enzyme; metal chelator;
KW water/lipid soluble vitamin; RNA cleaving complex; alkylator;
KW hybrid photo-nuclease/intercalator; aryl azide photo-crosslinking agent.
XX
OS Synthetic.
XX
PN US2002177150-A1.
XX
PD 28-NOV-2002.
XX
PF 11-FEB-2002; 2002US-00073718.
XX
PR 23-OCT-1992; 92WO-US009196.
XX
PR 15-DEC-1998; 98US-00211882.
XX
PR 07-AUG-2000; 2000US-00633659.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Manoharan M, Cook PD, Bennett CF;
XX
DR WPI; 2003-521529/49.
XX
XX
XX New derivatized oligonucleotide, useful for effecting cellular uptake,
XX comprises several linked nucleosides bearing a substituent such as
XX steroid/reporter molecule, reporter enzyme or peptide.
XX
XX Example 31; Page 19; 23pp; English.
XX
XX The invention relates to a derivatized oligonucleotide comprising several
XX linked nucleosides having a functionalized nucleoside bearing a
XX substituent such as steroid/reporter molecule, non-aromatic lipophilic
XX molecule, reporter enzyme, peptide, protein, water/lipid soluble vitamin,
XX RNA cleaving complex, metal chelator, porphyrin, alkylator, hybrid photo-
XX nuclease/intercalator or aryl azide photo-crosslinking agent. The
XX oligonucleotide is useful for effecting cellular uptake of the
XX oligonucleotide by contacting an organism with the oligonucleotide. The
XX oligonucleotide is useful in research and diagnostic methods, for
XX assaying bodily states in animals, especially disease states, or for
XX treatment of diseases through modulation of the activity of DNA or RNA.
XX The oligonucleotide has improved transfer across cellular membranes and
XX uptake properties. The effect of conjugation of an oligonucleotide with
XX folic acid was determined by the inhibition of intercellular cell
XX adhesion molecule-1 (ICAM-1). The present sequence represents a
XX derivatized oligonucleotide oligomer
XX
XX Sequence 18 BP; 3 A; 4 C; 9 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
Db      18 GCCTCGCTACGGCTCCCA 1
RESULT 2145
ADH71082/c
ID ADH71082 standard; DNA; 18 BP.
XX
AC ADH71082;
XX
DT 25-MAR-2004 (first entry)
XX
DE Human Vbeta microsatellite primer #25.
XX
KW human; T-cell associated disease; Vbeta; autoimmune disease;
KW degenerative nervous system disease; graft versus host disease;
KW hypersensitivity disease; infectious disease; neoplastic disease;
KW Addison's disease; atrophic gastritis;
KW degenerative nervous system disease; multiple sclerosis;
KW Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
KW allergy; type II hypersensitivity; Goodpasture's syndrome;
KW type IV hypersensitivity; leprosy; infectious disease; viral infection;
KW HIV; fungal infection; Candida; parasitic infection; schistosoma;
KW filaria; bacterial infection; Mycobacterium; neoplastic disease;
KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
KW breast cancer; ss; primer; microsatellite.
XX
XX Homo sapiens.
XX
OS US2002150891-A1.
XX
PN 17-OCT-2002.
XX
PD 05-MAR-1999; 99US-00263959.
XX
PF 19-SEP-1994; 94US-00309335.
XX
PR 19-SEP-1995; 95US-00531241.
XX
XX (HOOD/) HOOD L E.
XX
PA (ROWE/) ROWEN L.
XX
XX Hood LE, Rowen L;
XX
XX WPI; 2004-059052/06.
XX
XX Kit for diagnosing and treating T-cell associated diseases e.g.
XX autoimmune, degenerative nervous system and infectious disease, comprises
XX nucleic acid primers specifically priming and allowing amplification of a
XX Vbeta gene.
XX
XX Disclosure; SEQ ID NO 1276; 164pp; English.
XX
XX The invention relates to a kit for diagnosing and treating T-cell
XX associated diseases which comprises a panel of nucleic acid primers
XX specifically priming and allowing amplification of each Vbeta gene,
XX VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
XX rejection and diagnosing and treating T-cell associated diseases
XX including autoimmune diseases, degenerative nervous system diseases,
XX graft versus host disease, hypersensitivity diseases, infectious diseases
XX and neoplastic diseases. Autoimmune diseases include Addison's disease,
XX atrophic gastritis. Degenerative nervous system diseases include multiple
XX sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
XX I hypersensitivities such as contact with allergens that lead to
XX allergies, Type II hypersensitivities such as those present in
XX Goodpasture's syndrome and Type IV hypersensitivities such as those
XX manifested in leprosy. Infectious diseases include viral infections
XX caused by viruses such as HIV, fungal infections such as those caused by
XX the yeast genus Candida, parasitic infections such as those caused by
XX schistosomes, filaria and bacterial infections such as those caused by
XX Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
XX such as leukemias, lymphomas and cancers such as cancer of the brain,
XX breast. The present sequence represents a Vbeta microsatellite primer.
XX
XX Sequence 18 BP; 3 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.4e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 2769 CACCCAGGCTGGAGTGCA 2786
 |||||
 Db 18 CATCCAGGCTGGAGTGCA 1

RESULT 2146
 ADH76736/c
 ID ADH76736 standard; DNA; 18 BP.
 XX
 AC ADH76736;
 XX
 XX 22-APR-2004 (first entry)
 XX
 DE MCHR1 genomic sequence analysis primer #45.
 XX
 KW melanin-concentrating hormone receptor 1; MCHR1; anorectic; gene therapy;
 KW obesity; primer; ss.
 XX
 OS Unidentified.
 XX
 PN WO2003104489-A2.
 XX
 PD 18-DEC-2003.
 XX
 XX 05-JUN-2003; 2003WO-EP005917.
 PF
 XX 05-JUN-2002; 2002EP-00012569.
 PR
 XX (UYPH-) UNIV PHILIPPS MARBURG.
 PA
 XX Platzer M, Platzer C, Gudermann T, Hebebrand J, Hinney A;
 PI Reichwald K;
 PI
 XX WPI; 2004-062377/06.
 DR
 XX
 XX New diagnostic composition, useful for diagnosing obesity related to the
 PT presence of a molecular variant of the MCHR1 gene or a susceptibility to
 PT the disorder.
 XX
 XX Example 2; Page 43; 76pp; English.
 PS
 XX The invention relates to a novel diagnostic polynucleotide composition.
 CC The polynucleotide composition comprises: a sequence encoding a
 CC polypeptide with defined sequences given in the specification; a sequence
 CC capable of hybridizing to a melanin-concentrating hormone receptor 1
 CC (MCHR1) gene; a polynucleotide encoding an MCHR1 polypeptide; or a
 CC sequence comprising one or more of the nucleotide exchanges (SNP's) given
 CC in the specification and at least 8 bases of surrounding sequence of the
 CC MCHR1 gene. The composition has anorectic activity. The polynucleotide
 CC composition may be used in gene therapy to treat the disorders of the
 CC invention. The composition is useful for diagnosing obesity related to
 CC the presence of a molecular variant of the MCHR1 gene or a susceptibility
 CC to the disorder. The MCHR1 protein or polynucleotide is useful for
 CC preparing a medicament for treating or preventing obesity related to the
 CC presence of a molecular variant of the MCHR1 gene. This polynucleotide
 CC represents an MCHR1 primer of the invention.
 XX
 XX Sequence 18 BP; 5 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
 SQ

Query Match 0.5%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCAACCAGG 2776
 |||||
 Db 18 CTCGTCTGTCAACCAGG 1

RESULT 2147
 AD081096/c
 ID AD081096 standard; DNA; 18 BP.
 XX

AC AD081096;
 XX
 XX 29-JUL-2004 (first entry)
 XX
 DE Sheep prion protein microsatellite locus primer #67.
 XX
 KW gene typing; polymorphic microsatellite loci; PML;
 KW disease predisposition; microsatellite marker; prion disease;
 KW cystic fibrosis; malignant hyperthermia syndrome; metabolic disease;
 KW milk protein; hormone; transfection factor; pT7-blue-vector; sheep;
 KW microsatellite; PCR; primer; ss.
 XX
 OS Ovis aries.
 XX
 PN DE10236711-A1.
 XX
 XX 26-FEB-2004.
 PD
 XX 09-AUG-2002; 2002DE-01036711.
 PF
 XX 09-AUG-2002; 2002DE-01036711.
 PR
 XX (UYHO-) UNIV HOHENHEIM.
 XX
 XX Geldermann H, Preuss S, Han Y;
 XX WPI; 2004-215730/21.
 DR
 XX Typing genes that contain polymorphic microsatellite loci, useful for
 PT identifying predisposition to disease, by amplification and determining
 PT length of amplicons.
 XX
 XX Example 3; Page 30; 64pp; German.
 PS
 XX The invention describes a method of typing (M1) a gene (I) that has one
 CC or more polymorphic microsatellite loci (PML). The method comprises: PCR
 CC amplification of at least one DNA region of (I) that includes PML, using
 CC as template a DNA sample containing at least one segment of (I); and
 CC determining the length of the resulting amplicon(s). Also described are:
 CC a method of determining (M2) microsatellite markers (MM) for
 CC predisposition to a disease, associated with a gene that includes one or
 CC more PML; and prediagnosis (M3) of diseases associated with gene that
 CC include PML. The method is used to identify microsatellite markers, in a
 CC disease-related gene, that are associated with a predisposition to
 CC diseases and for prediagnosis of such diseases, especially prion diseases
 CC but also cystic fibrosis, malignant hyperthermia syndrome in pigs and
 CC metabolic diseases; also to type genes that encode milk proteins,
 CC hormones or transcription factors. The method is simpler, quicker and
 CC particularly less expensive than known methods based on sequencing. This
 CC sequence represents a primer used to genotype a region of the sheep prion
 CC protein (PrP) comprising a polymorphic microsatellite locus.
 XX
 XX Sequence 18 BP; 9 A; 9 C; 0 G; 0 T; 0 U; 0 Other;
 SQ

Query Match 0.5%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATG 2746
 |||||
 Db 18 TGTGTGTGTGTGTGTG 1

RESULT 2148
 ADL25097
 ID ADL25097 standard; DNA; 19 BP.
 XX
 AC ADL25097;
 XX
 XX 20-MAY-2004 (first entry)
 DT
 XX Intestinal epithelium/peyer's patch M cell-associated PCR primer #242.
 XX

KW intestinal epithelium cell development; peyer's patch M cell development;
 KW inflammatory bowel disease; glutenenteropathy; infectious disease;
 KW autoimmune disease; haemolytic anaemia; rheumatoid arthritis; dermatitis;
 KW Grave's disease; multiple sclerosis; allergy; asthma; diabetic mellitus;
 KW immune system disorder; hypersensitivity; anaphylaxis;
 KW blood group incompatibility; ss; human; PCR; primer.

OS Homo sapiens.

XX WO200208052-A2.

XX 17-OCT-2002.

PF 04-APR-2002; 2002WO-US010873.

XX 04-APR-2001; 2001US-0281416P.

PA (DIGI-) DIGITAL GENE TECHNOLOGIES INC.

PI Brayden DJ, Byrne D, O'mahony DJ, Evans CF, Mah SP, Lo DD;

XX WPI; 2003-075470/07.

XX Novel isolated or purified polypeptide encoded by genes associated with
 PT intestinal epithelium or M cell development, differentiation or function,
 PT useful for treating autoimmune diseases and infectious diseases.

XX Disclosure; SEQ ID NO 607; 152pp; English.

XX The invention comprises DNA sequences which are associated with
 CC intestinal epithelium and peyer's patch M cells. The DNA sequences of the
 CC invention are useful for assessing, modifying, modulating or regulating
 CC intestinal epithelium or M cell development. The DNA sequences of the
 CC invention are also useful in the treatment of: inflammatory bowel
 CC disease, glutenenteropathy, infectious diseases, autoimmune diseases
 CC (e.g. haemolytic anaemia, rheumatoid arthritis, dermatitis, Grave's
 CC disease, multiple sclerosis, allergy, asthma and diabetic mellitus),
 CC diseases or disorders of the immune system, hypersensitivity,
 CC anaphylaxis, and blood group incompatibility. The present DNA sequence
 CC represents a PCR primer that was used to amplify an intestinal
 CC epithelium/peyer's patch M cell-associated DNA sequence of the invention.

XX Sequence 19 BP; 4 A; 4 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 19;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2773 CAGGCTGAGTGCAGTGG 2790

Db 1 CAGGCTGAGTGCAGTGG 18

RESULT 2149

ADP26951/c

ID ADP26951 standard; DNA; 19 BP.

XX ADP26951;

XX 26-AUG-2004 (first entry)

XX Human P-cadherin PCR primer SEQ ID NO:52.

XX hair growth modulator; P-cadherin modulator; endocrine; depilatory;
 KW gene therapy; antisense therapy; hair growth; alopecia; baldness;
 KW unwanted hair growth; hirsutism;
 KW hypotrichosis associated with juvenile macular dystrophy; HJMD; human;
 KW P-cadherin; PCR; primer; ss.

XX Homo sapiens.

OS Synthetic.

XX EP1428893-A2.

PN

XX 16-JUN-2004.

XX 10-OCT-2003; 2003EP-00256411.

XX 15-OCT-2002; 2002US-0418163P.

XX (SPRE/) SPRECHER E.

XX (BERG/) BERGMAN R.

XX Sprecher E, Bergman R;

XX WPI; 2004-469945/45.

XX Identifying a hair growth modulator for treating alopecia and unwanted
 PT hair growth such as hirsutism, comprises identifying a P-cadherin
 PT modulator and testing whether the P-cadherin modulator is functional as a
 PT hair growth modulator.

XX Example; SEQ ID NO 52; 121pp; English.

XX The present invention describes a method (M1) for identifying a hair
 CC growth modulator. (M1) comprises identifying a P-cadherin modulator, and
 CC testing whether the P-cadherin modulator is functional as a hair growth
 CC modulator. Also described: (i) a hair growth modulator (I) identified by
 CC (M1); and (2) a composition (II) for modulating hair growth, comprising,
 CC as an active ingredient, a P-cadherin modulator functional as a hair
 CC growth modulator. (I) and (II) have endocrine and depilatory activities,
 CC and can be used as hair growth modulators, P-cadherin function
 CC modulators, and in gene and antisense therapy. (M1) is useful for
 CC identifying a hair growth modulator. (I) is useful in a method of medical
 CC treatment. (I) or (II) is useful for modulating hair growth for non-
 CC therapeutic cosmetic purposes which involves administering to a subject,
 CC (I) or (II). (I) can be used in the manufacture of a medicament for the
 CC therapeutic modulation of hair growth. (I) or (II) is useful for treating
 CC alopecia (baldness) and unwanted hair growth such as hirsutism. (I) or
 CC (II) comprising P-cadherin inducer is useful for correction of hair loss
 CC in congenital hypotrichosis associated with juvenile macular dystrophy
 CC (HJMD) and other alopecia patients. The present sequence represents a PCR
 CC primer human P-cadherin, which is used in an example from the present
 CC invention.

XX Sequence 19 BP; 5 A; 3 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 19;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCCACCAG 2775

Db 18 TCTCACTCTGTCCACCAG 1

RESULT 2150

ADR80887

ID ADR80887 standard; DNA; 19 BP.

XX ADR80887;

XX 16-DEC-2004 (first entry)

XX Human glucose-6-phosphatase oligonucleotide seqid 5386.

XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cyostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; glucose-6-phosphatase; ss.

XX

OS Homo sapiens.
 XX WO2004080406-A2.
 XX 23-SEP-2004.
 PD 08-MAR-2004; 2004WO-US007070.
 PF 07-MAR-2003; 2003US-0452682P.
 XX 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 14-MAR-2003; 2003US-0455050P.
 PR 15-MAR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX (ALNY-) ALNYLAM PHARM.
 PA Manoharan M, Bumcrot D;
 XX WPI; 2004-677362/66.
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX Example 5; SEQ ID NO 5386; 378pp; English.
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are a pharmaceutical preparation comprising (I); reducing (MI) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (MI)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human glucose-6-phosphatase antisense oligonucleotide that
 CC can be used to control glucose-6-phosphatase gene expression.
 XX
 SQ Sequence 19 BP; 3 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
 Query Match 0.58; Score 16.4; DB 1; Length 19;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2845 CTCAGCCTCTCAGTAGC 2862
 ||||| ||||| ||||| |||||

Db 2 CTCAGCCTCTCAGTAGC 19

RESULT 2151
 ADR80945
 ID ADR80945 standard; DNA; 19 BP.
 XX ADR80945;
 AC ADR80945;
 XX 16-DEC-2004 (first entry)
 DT Human glucose-6-phosphatase oligonucleotide segid 5444.
 DE
 XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytotstatic; anticonvulsant; nootropic; muscular; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; glucose-6-phosphatase; ss.
 XX Homo sapiens.
 OS
 XX WO2004080406-A2.
 PN
 XX 23-SEP-2004.
 PD
 XX 08-MAR-2004; 2004WO-US007070.
 PF
 XX 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX (ALNY-) ALNYLAM PHARM.
 PA Manoharan M, Bumcrot D;
 XX WPI; 2004-677362/66.
 XX Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX Example 5; SEQ ID NO 5444; 378pp; English.
 XX The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are a pharmaceutical preparation comprising (I); reducing (MI) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (MI)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human glucose-6-phosphatase antisense oligonucleotide that
 CC can be used to control glucose-6-phosphatase gene expression.
 XX

CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apob-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human glucose-6-phosphatase antisense oligonucleotide that
 CC can be used to control glucose-6-phosphatase gene expression.

XX
 SQ Sequence 19 BP; 3 A; 3 C; 10 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 19;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2773 CAGGCTGGAGTGGAGTGG 2790
 |||||
 Db 1 CAGGCTGGAGTGGAGTGG 18

RESULT 2152

ADT00298/c

ID ADT00298 standard; DNA; 19 BP.

XX

AC ADT00298;

XX

DT 16-DEC-2004 (first entry)

XX

DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID286.

XX

KW tyrosine kinase; cancer; anti-cancer agent; signalling molecule;

KW tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;

KW GUCY2F; MCKK; MLK4; kinase domain; cytostatic; tyrosine kinase inhibitor;

KW guanylate cyclase stimulator; ss.

XX

OS Homo sapiens.

XX

PN WO2004082458-A2.

XX

PD 30-SEP-2004.

XX

PF 18-FEB-2004; 2004WO-US004452.

XX

PR 21-FEB-2003; 2003US-0448537P.

XX

PR 29-MAY-2003; 2003US-0473895P.

XX

PA (UWJO) UNIV JOHNS HOPKINS.

XX

PI Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;

XX

DR WPI; 2004-718702/70.

XX

PT Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCKK) and
 PT associated methods for diagnosing cancer and screening for anti-cancer
 PT agents.

XX

PS Disclosure; SEQ ID NO 286; 363pp; English.

XX

CC This invention relates to a novel activated mutant protein tyrosine
 CC kinases and associated methods for diagnosing cancer and screening for
 CC anti-cancer agents. Protein kinases are signalling molecules involved in
 CC tumorigenesis. Mutational analysis of the human tyrosine kinase gene
 CC family identified somatic alteration sin 1 in 5 colorectal cancers, with
 CC the majority of mutations occurring in the NTRK3, FES, GUCY2F and
 CC MCKK/MLK4 genes. Most were identified in the kinase domain. The invention
 CC may be useful for the production of compounds with a cytostatic activity
 CC acting as protein tyrosine kinase inhibitors or guanylate cyclase

CC stimulators. The invention may be useful for developing methods for
 CC detecting mutations involved in cancer or screening for anti-cancer
 CC agents. The present sequence is that of a human-derived oligonucleotide
 CC which is related to the invention.

XX
 SQ Sequence 19 BP; 5 A; 8 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 19;
 Best Local Similarity 94.4%; Pred. No. 1.4e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2780 GAGTGCAGTGGTGCATC 2797
 |||||
 Db 19 GAGTGCAGTGGTGCATC 2

RESULT 2153

AAQ49455

ID AAQ49455 standard; DNA; 20 BP.

XX

AC AAQ49455;

XX

DT 06-MAY-1994 (first entry)

XX

DE Primer for detecting polymorphisms among highly related plant species.

XX

KW Detection; polymorphism; genetic fingerprinting; primer; ss.

XX

OS Synthetic.

XX

PN JF05244995-A.

XX

PD 24-SEP-1993.

XX

PF 24-SEP-1991; 91JP-00243122.

XX

PR 24-SEP-1991; 91JP-00243122.

XX

PA (KYOW) KYOWA HAKKO KOGYO KK.

XX

DR WPI; 1993-338949/43.

XX

PT Primer - for detecting polymorphism in DNA among highly interrelated rice
 PT plants or plants of family Brassicaceae.

XX

PS Disclosure; Page 5; 6pp; Japanese.

XX

CC The PCR primers (See also AAQ49449-54, AAQ49456) are used to detect
 CC polymorphisms among highly interrelated rice plants or among plants of
 CC family Brassicaceae. They can also be used for genetic fingerprinting of
 CC plants, allowing detection of polymorphism within one or the same species
 CC of plant

XX

SQ Sequence 20 BP; 0 A; 2 C; 9 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 20;

Best Local Similarity 94.4%; Pred. No. 1.3e+03;

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2729 TGTGTGTGTGTGTATG 2746
 |||||
 Db 1 TGTGTGTGTGTGTGTG 18

RESULT 2154

AAQ93404/c

ID AAQ93404 standard; DNA; 20 BP.

XX

AC AAQ93404;

XX

DT 20-DEC-1995 (first entry)

XX

DE Equine clone 595-1 5' proximal antisense strand SNP detection oligo.

```

XX Invariant; proximal; distal; single nucleotide polymorphism; SNP; equine;
KW human; primer; template-dependent extension; identification;
KW polymorphic allele; horse; identity; genotype; ancestry; parentage;
KW prediposition; genetic disease; linkage; ss.
XX
OS Equus caballus.
XX
PN WO9512607-A1.
XX
PD 11-MAY-1995.
XX
PF 02-NOV-1994; 94WO-US012632.
XX
PR 03-NOV-1993; 93US-00145145.
PR 23-MAR-1994; 94US-00216538.
XX
PA (MOLE-) MOLECULAR TOOL INC.
XX
PI Goelet P, Knapp MR;
XX
DR WPI; 1995-193812/25.
XX
Nucleic acid mols. for identifying single nucleotide polymorphism sites -
PT and related methods, useful for genotyping human or horse genome(s) for
PT analysis of pre-disposition to genetic traits, etc.
XX
PS Claim 6; Page 49; 129pp; English.
XX
CC The sequences given in AAQ93370-441 represent oligomers which are capable
CC of hybridising to an invariant proximal or distal sequence of a single
CC nucleotide polymorphism (SNP) site in equine DNA. These oligomers act as
CC primers, where template-dependent extension of the primer by a single
CC nucleotide base can be used to identify the polymorphic allele. These
CC sequences may be used to in the analysis of 18 SNP's from 5 different
CC horses. The analysis of SNP's is useful in determining identity, ancestry
CC or prediposition to genetic diseases. The method may also be used to
CC determine the linkage between two genetic traits
XX
SQ Sequence 20 BP; 11 A; 7 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2731 TGTGTGTGTGTGTATGTG 2748
Db 20 TGTGTGTGTGTGTATTTG 3

RESULT 2155
AAQ93403
ID AAQ93403 standard; DNA; 20 BP.
XX
AC AAQ93403;
XX
DT 20-DEC-1995 (first entry)
XX
DE Equine clone 595-1 3' distal sense strand SNP detection oligo.
XX
KW Invariant; proximal; distal; single nucleotide polymorphism; SNP; equine;
KW human; primer; template-dependent extension; identification;
KW polymorphic allele; horse; identity; genotype; ancestry; parentage;
KW prediposition; genetic disease; linkage; ss.
XX
OS Equus caballus.
XX
PN WO9512607-A1.
XX
PD 11-MAY-1995.
XX
PF 02-NOV-1994; 94WO-US012632.
XX

```

```

PR 03-NOV-1993; 93US-00145145.
PR 23-MAR-1994; 94US-00216538.
XX
PA (MOLE-) MOLECULAR TOOL INC.
XX
PI Goelet P, Knapp MR;
XX
DR WPI; 1995-193812/25.
XX
Nucleic acid mols. for identifying single nucleotide polymorphism sites -
PT and related methods, useful for genotyping human or horse genome(s) for
PT analysis of pre-disposition to genetic traits, etc.
XX
PS Claim 6; Page 49; 129pp; English.
XX
CC The sequences given in AAQ93370-441 represent oligomers which are capable
CC of hybridising to an invariant proximal or distal sequence of a single
CC nucleotide polymorphism (SNP) site in equine DNA. These oligomers act as
CC primers, where template-dependent extension of the primer by a single
CC nucleotide base can be used to identify the polymorphic allele. These
CC sequences may be used to in the analysis of 18 SNP's from 5 different
CC horses. The analysis of SNP's is useful in determining identity, ancestry
CC or prediposition to genetic diseases. The method may also be used to
CC determine the linkage between two genetic traits
XX
SQ Sequence 20 BP; 1 A; 1 C; 7 G; 11 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2731 TGTGTGTGTGTGTATGTG 2748
Db 1 TGTGTGTGTGTGTATTTG 18

RESULT 2156
AAQ66046/C
ID AAT66046 standard; DNA; 20 BP.
XX
AC AAT66046;
XX
DT 25-MAR-2003 (revised)
DT 18-JUN-1997 (first entry)
XX
DE Primer #1 to amplify repeat sequence marker Mfd125.
XX
KW Polymorphism; repeat sequence; genetic marker; primer; amplification;
KW PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
KW linkage analysis; genetic disease; animal; plant; breeding; locus;
KW hybridisation; chromosome; ds.
XX
OS Synthetic.
XX
PN US5582979-A.
XX
PD 10-DEC-1996.
XX
PF 04-APR-1994; 94US-00222177.
XX
PR 21-APR-1989; 89US-00341562.
PR 05-SEP-1991; 91US-00754351.
XX
PA (MARS-) MARSHFIELD CLINIC.
XX
PI Weber JL;
XX
DR WPI; 1997-0422299/04.
XX
PT Detection of polymorphic genetic markers of the form (dC-dA)n(dG-dT)n -
PT using novel nucleic acid mols. as primers.
XX
PS Claim 7; Col 13-14; 186pp; English.

```

XX The invention relates to the isolation of polymorphic repeat sequences
 CC having the sequence (dC-dA)n.(dG-dT)n which can be used as genetic
 CC markers. Primers based on these sequences can be used to detect these
 CC repeats, especially for use in e.g. paternity or maternity testing, human
 CC genetic analysis such as linkage analysis of genetic disease, commercial
 CC animal or plant breeding or pedigree analysis. Clones containing the
 CC repeat sequences were isolated by hybridisation of chromosome-specific
 CC phage libraries with a synthetic poly(dC-dA).(dG-dT) probe. Over 100
 CC repeat blocks were isolated. The primers AAT65798-T66047 were used to PCR
 CC amplify the inserts from the isolated clones containing the repeat
 CC sequences. The primers AAT66046-7 were used to amplify the repeat
 CC sequence marker clone Mdi25 (AAT65796). (Updated on 25-MAR-2003 to
 CC correct PF field.)
 XX
 SQ Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2916 TTTTCAGAGACGGGTCTC 2933
 Db 19 TTTTCAGAGACGGGTCTC 2
 RESULT 2157
 AAZ37726/C
 ID AAZ37726 standard; DNA; 20 BP.
 AC AAZ37726;
 XX
 XX 07-JAN-2000 (first entry)
 XX
 DE Human mdm2 phosphorothioate oligodeoxynucleotide #256.
 KW Human mdm2 gene; proliferation; tumour; phosphorothioate; p53; cancer;
 KW antisense; modulation; oligonucleotide; expression; inhibition;
 KW hyperproliferation; blood cancer; brain cancer; breast cancer;
 KW lung cancer; soft tissue cancer; psoriasis; fibrosis; atherosclerosis;
 KW restenosis; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9949065-A1.
 XX
 XX 30-SEP-1999.
 PD
 PF 26-MAR-1999; 99WO-US006702.
 XX
 PR 26-MAR-1998; 98US-00048810.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowser LT;
 XX
 DR WPI; 1999-610754/52.
 XX
 XX New antisense compounds used to treat eg. hyperproliferative conditions.
 PT
 XX Example 9; Page 55; 157pp; English.
 PS
 CC AAZ37473-237738 represent human mdm2 phosphorothioate oligonucleotides.
 CC AAZ37471, AAZ37472, AAZ37739, AAZ37740 and AAZ37741 are used in the
 CC exemplification of the present invention. The present invention describes
 CC novel nucleotide antisense compounds, targeted to the 5' untranslated,
 CC translation termination codon, or 3' untranslated region of a nucleic
 CC acid encoding human mdm2, that modulates expression of human mdm2. The
 CC oligonucleotides mediate their effect by antisense inhibition of
 CC hyperproliferative gene expression. The antisense compound is used to
 CC treat an animal having a disease or condition associated with mdm2,
 CC particularly a hyperproliferative condition, more particularly cancer,

CC especially of the blood, brain, breast, lung or soft tissue, or
 CC psoriasis, fibrosis, atherosclerosis or restenosis
 XX
 SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2882 CACCACACCTGGCAAAATT 2899
 Db 18 CACCACACCTGGCTAATT 1
 RESULT 2158
 AAX04029
 ID AAX04029 standard; DNA; 20 BP.
 XX
 AC AAX04029;
 XX
 XX 09-APR-1999 (first entry)
 XX
 DE Equine allele polymorphic site of clone 595-1 3'-distal sequence #1.
 XX
 KW Polymorphic site; equine allele; detection; identification; identity;
 KW ancestry; genetic disease; cancer; asthma; blindness; haemophilia;
 KW sickle-cell anaemia; ss.
 XX
 OS Equus caballus.
 XX
 PN WO9859066-A1.
 XX
 XX 30-DEC-1998.
 XX
 XX 24-JUN-1998; 98WO-US013042.
 PF
 XX 25-JUN-1997; 97US-00881845.
 PR
 XX (MOLE-) MOLECULAR TOOL INC.
 PA
 XX McIntosh T, Head S, Goelet P, Boyce-Jacino MT;
 PI
 XX WPI; 1999-081288/07.
 XX
 DR
 XX
 PT Detecting single nucleotide polymorphisms - by hybridisation with
 PT interrogation primer and extending this with non-extendible nucleotide or
 PT analogue which is then identified.
 XX
 PS Disclosure; Page 7; 57pp; English.
 XX
 CC A method has been developed for the detection of one or more single
 CC polymorphisms in the same sample. The method comprises: (a) hybridising
 CC at least one distinguishable interrogation oligonucleotide primer (IP) to
 CC one or more target nucleic acids (TNA), each IP being specific for a
 CC unique region in TNA with the 3'-end of IP immediately adjacent to a
 CC specific and unique target nucleotide (nt); (b) extending IP with a
 CC template-dependent polymerase in presence of at least one non-extendible
 CC nt (or analogue); and (c) determining, for each IP, the identity of the
 CC non-extendible nt or analogue incorporated, i.e. the complement of the
 CC target nt, so identifying each target nt. The method is used to identify
 CC a trait (specifically a genetic disease or condition) in nucleic acid
 CC from an animal, plant, bacterium, fungus, yeast, virus, viroid or other
 CC heritable agent. Applications include determining identity (Genetic
 CC fingerprinting); ancestry; predisposition to genetic diseases or
 CC conditions (e.g. cancer, asthma, blindness); presence or absence of
 CC desirable trait; diagnosis of disease (e.g. haemophilia or sickle-cell
 CC anaemia) and to relate polymorphisms to particular traits. AAX03996 to
 CC AAX04067 represent the invariant 5'-proximal and 3'-distal sequences of
 CC polymorphic sites of corresponding equine alleles
 XX
 SQ Sequence 20 BP; 1 A; 1 C; 7 G; 11 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;

Best Local Similarity 94.4%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2731 TGTGTGTGTGTGTGTGTG 2748
| | | | | | | | | | | | | | | | |
Db 1 TGTGTGTGTGTGTATTG 18

RESULT 2159
AA04030/c
ID AAX04030 standard; DNA; 20 BP.
XX
AC AAX04030;
XX
XX 09-APR-1999 (first entry)
DE Equine allele polymorphic site of clone 595-1 5'-proximal sequence #2.
XX
XX Polymorphic site; equine allele; detection; identification; identity;
KW ancestry; genetic disease; cancer; asthma; blindness; haemophilia;
KW sickle-cell anaemia; ss.
XX
OS Equus caballus.
XX
XX WO9859066-A1.
XX
XX 30-DEC-1998.
XX
XX 24-JUN-1998; 98WO-US013042.
XX
XX 25-JUN-1997; 97US-00881845.
XX
XX (MOLE-) MOLECULAR TOOL INC.
XX
XX McIntosh T, Head S, Goelet P, Boyce-Jacino MT;
PI WPI; 1999-081288/07.
XX
XX Detecting single nucleotide polymorphisms - by hybridisation with
PT interrogation primer and extending this with non-extendible nucleotide or
PT analogue which is then identified.
XX
XX Disclosure; Page 7; 57pp; English.
XX
XX A method has been developed for the detection of one or more single
CC polymorphisms in the same sample. The method comprises: (a) hybridising
CC at least one distinguishable interrogation oligonucleotide primer (IP) to
CC one or more target nucleic acids (TNA), each IP being specific for a
CC unique region in TNA with the 3'-end of IP immediately adjacent to a
CC specific and unique target nucleotide (nt); (b) extending IP with a
CC template-dependent polymerase in presence of at least one non-extendible
CC nt (or analogue); and (c) determining, for each IP, the identity of the
CC target nt, so identifying each target nt. The method is used to identify
CC a trait (specifically a genetic disease or condition) in nucleic acid
CC from an animal, plant, bacterium, fungus, yeast, virus, viroid or other
CC heritable agent. Applications include determining identity (genetic
CC fingerprinting); ancestry; predisposition to genetic diseases or
CC conditions (e.g. cancer, asthma, blindness); presence or absence of
CC desirable trait; diagnosis of disease (e.g. haemophilia or sickle-cell
CC anaemia) and to relate polymorphisms to particular traits. AAX03996 to
CC AAX04067 represent the invariant 5'-proximal and 3'-distal sequences of
CC polymorphic sites of corresponding equine alleles
XX
SQ Sequence 20 BP; 11 A; 7 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2731 TGTGTGTGTGTGTGTGTG 2748
| | | | | | | | | | | | | | | | |
Db 20 TGTGTGTGTGTGTATTG 3

RESULT 2160
AAA96372/c
ID AAA96372 standard; DNA; 20 BP.
XX
AC AAA96372;
XX
XX 08-FEB-2001 (first entry)
DE Primer used to amplify a sara3/4 polymorphic microsatellite repeat.
XX
XX Autoimmune disease; polymorphic microsatellite repeat; PMR; CD28 gene;
KW ICOS gene; CTLA4 gene; costimulatory receptor gene locus; CGRL; lupus;
KW insulin-dependent diabetes mellitus; IDDM; Addison's disease; leprosy;
KW Graves disease; autoimmune hypothyroidism; myasthenia gravis; thymoma;
KW thyroiditis; postpartum thyroiditis; rheumatoid arthritis;
KW Hashimoto's disease; coeliac disease; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200056856-A2.
XX
PD 28-SEP-2000.
XX
PF 24-MAR-2000; 2000WO-US007938.
XX
PR 25-MAR-1999; 99US-0126215P.
XX
XX (GEMY) GENETICS INST INC.
XX
XX Ling V, Wu P, Gray GS;
PI WPI; 2000-628257/60.
XX
XX Determining predisposition of humans to develop autoimmune disease
PT involves detecting polymorphic microsatellite repeat sequence within
PT human costimulatory receptor gene locus.
XX
PS Claim 18; Page 147; 160pp; English.
XX
XX PCR primers AAA96371-72 were used to amplify polymorphic microsatellite
CC repeat (PMR) sequences from the human costimulatory receptor gene locus
CC (hCGRL). The primers are used in the method of the invention. The
CC specification describes a method for determining the predisposition of a
CC human subject to develop autoimmune disease. The method comprises
CC detecting a PMR sequence in the CD28, ICOS gene or CTLA4 gene of the
CC human costimulatory receptor gene locus (hCGRL). PMR sequences vary in
CC length among individuals and can be amplified to generate products that
CC differ in size. These products can then be detected by rapid and
CC convenient high resolution processes. The method is useful for
CC determining the predisposition of insulin-dependent diabetes mellitus
CC (IDDM), Addison's disease, Graves disease, autoimmune hypothyroidism,
CC myasthenia gravis, thymoma, lupus, thyroiditis, postpartum thyroiditis,
CC rheumatoid arthritis, Hashimoto's disease, coeliac disease and leprosy.
CC PMR sequences within hCGRL are useful as markers in a variety of assays
CC and in the field of forensic medicine, disease diagnosis and human genome
CC mapping
XX
SQ Sequence 20 BP; 2 A; 7 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTGCA 2786
| | | | | | | | | | | | | | | | |
Db 20 CGCCAGGCTGGAGTGCA 3

RESULT 2161
AAZ98499/c
ID AAZ98499 standard; DNA; 20 BP.

```
XX AC AA298499;
XX DT 19-JUN-2000 (first entry)
XX DE H. discus derived sequence #17.
XX KW Satellite sequence; DNA fragmentation; microsatellite DNA; DNA marker;
XX KW Haliotis discus; ss.
XX OS Haliotis discus.
XX PN WO200011156-A1.
XX PD 02-MAR-2000.
XX PF 01-JUL-1999; 99WO-JP003551.
XX PR 18-AUG-1998; 98JP-00232153.
XX PA (NORQ) JAPAN MIN AGRIC FORESTRY & FISHERIES.
XX PI Takahashi H, Sekino M;
XX DR WPI; 2000-224692/19.
XX PT Isolation of satellite sequences from genomic DNA for use as DNA markers
XX PT comprises isolating a library with high homogeneity by DNA fragmentation.
XX PS Example 5; Page 14; 35pp; Japanese.
XX CC The invention provides a novel method for isolation of satellite
XX CC sequences from genomic DNA that comprises fragmentation of the DNA by a
XX CC method which is not dependent on base sequences, then selection of the
XX CC satellite sequences from the obtained genomic library of high
XX CC homogeneity. The method is useful for the isolation of microsatellite DNA
XX CC sequences which can be used as DNA markers. The new method markedly
XX CC improves the efficiency of isolation of satellite sequences in comparison
XX CC to prior art methods which are reliant on base sequences. Sequences
XX CC AA298483-514 represent sequences from Haliotis discus, used in the method
XX CC of the invention
XX SQ Sequence 20 BP; 6 A; 10 C; 4 G; 0 T; 0 U; 0 Other;
Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 2725 CGCGTGTGTGTGTGTGTG 2742
Db 18 CGCGGTGTGTGTGTGTG 1
RESULT 2162
AAF80880/c
ID AAF80880 standard; DNA; 20 BP.
AC AAF80880;
XX 02-MAY-2001 (first entry)
XX Human mdm2 phosphorothioate oligonucleotide #254.
DE Antisense; mdm2; hyperproliferation; cancer; psoriasis; ss.
XX Homo sapiens.
XX US6184212-B1.
XX 06-FEB-2001.
XX 26-MAR-1999; 99US-00280805.
XX PF
XX
```

```
PR 26-MAR-1998; 98US-00048810.
XX (ISIS-) ISIS PHARM INC.
XX PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowseert LM;
XX DR WPI; 2001-190948/19.
XX Novel antisense compound 8-30 nucleobases in length targeted to a nucleic
XX PT acid molecule encoding human mdm-2 useful for modulating the expression
XX PT of human mdm-2 and reducing hyperproliferation of human cells.
XX PS Example 9; Col 33; 77pp; English.
XX CC The present invention relates to an antisense compound 8-30 nucleobases
XX CC in length targeted to nucleobases 1-308 of the 5' untranslated region,
XX CC 1776-1806 of the translation termination codon region or 1818-2370 of the
XX CC 3' untranslated region of a nucleic acid molecule encoding human mdm-2.
XX CC The invention is useful for reducing hyperproliferation of human cells,
XX CC modulating the expression of mdm2 in human cells or tissues or in vitro.
XX CC The hyperproliferative disorder includes cancer or psoriasis
XX SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy 2882 CACCACACCTGGCAATT 2899
Db 18 CACCACACCTGGCTAATT 1
RESULT 2163
AAH20695/c
ID AAH20695 standard; DNA; 20 BP.
AC AAH20695;
XX 13-AUG-2001 (first entry)
XX Human telomeric repeat binding factor 2 oligonucleotide 111423.
DE Antisense; phosphorothioate; human; telomeric repeat binding factor 2;
XX inhibitor; premature aging; hyperproliferative disorder; cancer;
XX cytostatic; ss.
XX Homo sapiens.
XX Key Location/Qualifiers
XX modified_base 1..20
XX /tag= b
XX /mod_base= OTHER
XX /note= "phosphorothioate backbone"
XX modified_base 1..3
XX /tag= a
XX /mod_base= OTHER
XX /note= "2-O-methoxyethyl"
XX modified_base 13..20
XX /tag= c
XX /mod_base= OTHER
XX /note= "2-O-methoxyethyl"
XX WO200143752-A1.
XX 21-JUN-2001.
XX 14-DEC-2000; 2000WO-US033954.
XX 17-DEC-1999; 99US-00467642.
XX (ISIS-) ISIS PHARM INC.
XX
```

PI Monia BP, Cowsert LM;
 XX WPI; 2001-398071/42.
 XX Antisense compounds targeted to nucleic acid encoding telomeric repeat
 PT binding factor 2 useful for treating conditions such as premature aging
 PT and diseases such as cancer.
 XX Claim 3; Page 81; 108pp; English.
 XX This invention describes a novel antisense compound (I) 8-30 nucleobases
 CC in length targeted to a polynucleotide encoding human telomeric repeat
 CC binding factor 2 (II) which specifically hybridizes with, and inhibits
 CC the expression of (II). (I) is useful for treating a human having a
 CC disease or condition associated with (II) such as premature aging or a
 CC hyperproliferative disorder especially cancer, by inhibiting the
 CC expression of (II) in human cells or tissues. (I) is useful for
 CC diagnostics, therapeutics, prophylaxis and as research reagents and kits.
 CC The products of the invention have cytostatic activity. This sequence
 CC represents an antisense oligonucleotide used to illustrate the method of
 CC the invention
 XX SQ Sequence 20 BP; 4 A; 11 C; 3 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2775 GGCTGGAGTGCAGTGGTG 2792
 |||||
 DB 20 GGCTGGAGTGCAGTGGCG 3
 RESULT 2164
 AAS29495/c
 ID AAS29495 standard; DNA; 20 BP.
 XX AAS29495;
 AC AAS29495;
 XX 21-NOV-2001 (first entry)
 DE Human mdm2 antisense oligonucleotide 31470.
 XX Human; mdm2; hyperproliferative disorder; cancer; psoriasis;
 KW atherosclerosis; tumour; cytostatic; anti psoriatic;
 KW anti arteriosclerotic; vasotropic; antisense; phosphorothioate; ss.
 XX Homo sapiens.
 OS
 PH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= All phosphorothioate linkages,
 FT additionally bases 1-6 and bases 15-20 are 2'-O-
 FT methoxyethyl bases, and bases 7-14 are deoxynucleotides"
 XX
 PN US2001016575-A1.
 XX
 XX 23-AUG-2001.
 XX
 XX 02-JAN-2001; 2001US-00752983.
 XX
 XX 26-MAR-1998; 98US-00048810.
 XX 26-MAR-1999; 99US-00280805.
 XX
 XX (MIRA/) MIRAGLIA L J.
 XX (NERO/) NERO P.
 XX (GRAH/) GRAHAM M J.
 XX (MONI/) MONIA B P.
 XX (COWS/) COWSERT L M.
 XX
 PI Miraglia LJ, Nero P, Graham MJ, Monia BP, Cowsert LM;

XX WPI; 2001-535565/59.
 XX An antisense compound, useful for treating e.g. cancer, comprises
 PT nucleobases targeted a region (e.g. translation termination codon region)
 PT of a nucleic acid encoding human mdm2.
 XX
 XX Example 9; Page 18; 81pp; English.
 PS
 XX The present invention relates to antisense compounds, 8-30 nucleobases in
 CC length targeted to the 5' untranslated region, translation termination
 CC codon region, 3' untranslated region, coding region or translation start
 CC site of a nucleic acid encoding human mdm2, where the antisense compound
 CC modulates the expression of human mdm2. The antisense oligonucleotides of
 CC the invention are useful for encoding human mdm2 and for inhibiting the
 CC expression of human mdm2. They may be used for treating an animal having
 CC a disease or condition associated with amplification of mdm2 gene or
 CC overexpression of mdm2 e.g. a hyperproliferative disorder such as cancer
 CC (blood, brain, breast, lung, or a soft tissue cancer) and psoriasis,
 CC fibrosis, atherosclerosis or restenosis, tumours, colorectal carcinoma
 CC and chronic myelogenous leukemia. The antisense compound may be
 CC administered with a chemotherapeutic agent to overcome drug resistance.
 CC The antisense compound reduces hyperproliferation of human cells. The
 CC method, which involves the use of the antisense compound, is also useful
 CC for detecting the role of mdm2 expression in various cell functions and
 CC physiological processes and useful in both clinical research and
 CC diagnostic tools. AAS29242-AAS29507 represent the human mdm2 antisense
 CC oligonucleotides of the present invention
 XX SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2882 CACCACACCTGGCAAAATT 2899
 |||||
 DB 18 CACCACACCTGGCTAATT 1
 RESULT 2165
 ABX80012/c
 ID ABX80012 standard; cDNA; 20 BP.
 XX ABX80012;
 AC ABX80012;
 XX 17-APR-2003 (first entry)
 DT
 DE EST polymorphic DNA repeat polynucleotide #337.
 XX
 XX EST; expressed sequence tag; ss; polymorphic repeat; tandem repeat;
 KW polymorphic marker prediction of ubiquitous simple sequences; POMPOUS;
 KW Rep-X; human; genetic disease; drug-treatment; Machado-Joseph;
 KW Haw River syndrome; Huntington's disease; fragile-X syndrome;
 KW Friedrich's ataxia; myotonic dystrophy; hyperandrogenaemia;
 KW spinal atrophy; bulbar atrophy; spinocerebellar ataxia.
 XX
 OS Homo sapiens.
 XX
 XX US6472154-B1.
 XX
 XX 29-OCT-2002.
 XX
 XX 31-DEC-1999; 99US-00475947.
 XX 31-DEC-1999; 99US-00475947.
 XX
 XX (TEXA) UNIV TEXAS SYSTEM.
 XX
 XX Garner HR, Wren JD, Minna JD, Fondon JW;
 XX WPI; 2003-208818/20.
 XX

PT treating or preventing inflammation, cancer, psoriasis or diabetes.
 PS Example 15; Page 90; 135pp; English.
 XX
 CC The present invention describes a compound (I) comprising 8-50
 CC nucleobases which is targeted to a 5' untranslated region (UTR), coding,
 CC 3' UTR or intron region of a nucleic acid molecule encoding phospholipase
 CC A2, group IIA (synovial), where the compound specifically hybridises with
 CC and inhibits the expression of phospholipase A2, group IIA (synovial).
 CC Also described: (1) a composition comprising the compound and a carrier
 CC or diluent; (2) a method of inhibiting the expression of phospholipase
 CC A2, group IIA in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with phospholipase A2, group IIA
 CC (synovial). (I) has antiinflammatory, antidiabetic, cytostatic and
 CC anaporiatic activities, and can be used in vaccines and in gene
 CC therapy. The compound (I) can be used for preparing a composition for
 CC treating or preventing inflammation, cancer, psoriasis or diabetes. The
 CC present sequence represents a mouse phospholipase A2 group IIA (synovial)
 CC chimeric phosphorothioate antisense oligonucleotide, which is used in an
 CC example from the present invention
 XX
 SQ Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1060 CACCTAGAGCCAGGTG 1077
 |||||
 Db 20 CACCTAGAGCCAGGTG 3
 RESULT 2168
 AAL61525
 ID AAL61525 standard; DNA; 20 BP.
 XX
 AC AAL61525;
 XX
 DT 22-SEP-2003 (first entry)
 XX
 DE Human inhibitor-kappa B-R antisense oligonucleotide, ISIS #130450.
 XX
 KW Human; inhibitor-kappa B-R; I-kappaB; IKK β ; I-kappa-B-related; NFKBIL2;
 KW ikappaB γ ; antisense; immune response; infection; inflammation; therapy;
 KW tumour; prophylaxis; phosphorothioate; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 PN WO2003042360-A2.
 XX
 PD 22-MAY-2003.
 XX
 PF 05-NOV-2002; 2002WO-US035597.
 XX
 PR 13-NOV-2001; 2001US-00993731.
 XX
 PA (ISIS-) ISIS PHARM INC.

XX
 PI Monia BP, Watt AT;
 XX
 DR WPI; 2003-468635/44.
 XX
 PT New antisense oligonucleotides targeted to nucleic acids encoding
 PT inhibitor-kappa B-R, useful for diagnosing or treating diseases
 PT associated with expression of inhibitor-kappa B-R, e.g., a heightened
 PT immune response or infection.
 XX
 PS Claim 3; Page 74; 108pp; English.
 XX
 CC The invention relates to antisense compounds targetted to a nucleic acid
 CC molecule encoding human inhibitor-kappa B-R (also known as I-kappaB β ,
 CC IKK β , I-kappa-B-related, ikappaB β , nuclear factor of kappa light
 CC polypeptide gene enhancer in B-cells inhibitor-like 2 and NFKBIL2) to
 CC inhibit its expression. Antisense compounds of the invention are useful
 CC for treating diseases or conditions associated with the expression of
 CC inhibitor-kappa B-R such as a heightened immune response involving
 CC increased cytokine expression, or a result of infection (e.g. bacterial,
 CC viral or parasitic). They are useful for diagnostics, therapeutics,
 CC prophylaxis e.g. to prevent or delay infection, inflammation or tumour
 CC formation, as research reagents and kits and in distinguishing between
 CC functions of various members of a biological pathway. They are also
 CC useful in antisense therapy. The present sequence is an oligonucleotide
 CC targetted to human inhibitor-kappa B-R DNA
 XX
 SQ Sequence 20 BP; 4 A; 3 C; 9 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2773 CAGGCTGGAGTGCAGTGG 2790
 |||||
 Db 2 CAGGTTGGAGTGCAGTGG 19
 RESULT 2169
 ADC89591/c
 ID ADC89591 standard; DNA; 20 BP.
 XX
 AC ADC89591;
 XX
 DT 01-JAN-2004 (first entry)
 XX
 DE Human COREST antisense oligonucleotide #ISIS 165031.
 XX
 KW Cytostatic; antisense therapy; co-repressor;
 KW RE1 silencing transcription factor; COREST; antisense oligonucleotide;
 KW developmental; hyperproliferative; disorder; neuronal cancer; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone"
 FT /note= "all cytidines are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls (2'-MOE) wing"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls (2'-MOE) wing"
 XX
 PN WO2003011890-A1.
 XX
 PD 13-FEB-2003.
 XX

PF 31-JUL-2002; 2002WO-US024370.
 XX
 PR 01-AUG-2001; 2001US-00920671.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Bennett CF, Freier SM;
 XX
 XX WPI; 2003-256431/25.
 DR
 XX
 XX New antisense oligonucleotide compounds, useful for the diagnosis,
 PT prevention and/or treatment of conditions with aberrant expression or
 PT activity of CoREST, such as developmental and/or hyperproliferative
 PT disorders.
 XX
 XX Claim 3; SEQ ID NO 82; 145pp; English.
 PS
 XX
 CC The invention relates to a new antisense compound comprising 8-50
 CC nucleobases in length targeted to a nucleic acid molecule encoding a co-
 CC repressor for RE1 silencing transcription factor (CoREST), where the
 CC compound specifically hybridizes with and inhibits the expression of
 CC CoREST. The CoREST antisense oligonucleotide has any of 72 specifically
 CC claimed sequences of 20 bp, given in the specification. The methods and
 CC compositions of the present invention are useful for the diagnosis,
 CC prevention and/or treatment of diseases or conditions associated with
 CC aberrant expression or activity of CoREST, such as a developmental
 CC disorder and/or a hyperproliferative condition like neuronal cancer. The
 CC current sequence represents an antisense oligonucleotide for the
 CC inhibition of human CoREST mRNA levels. Nucleotides of the invention have
 CC 2-MOE wings and a deoxy gap.
 XX
 XX Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2850 CCTCCTGAGTAGCTGGGA 2867
 Db 20 CCTCCCGAGTAGCTGGGA 3
 RESULT 2170
 ADD21691/c
 ID ADD21691 standard; DNA; 20 BP.
 XX
 AC ADD21691;
 XX
 XX 15-JAN-2004 (first entry)
 DT
 DE Human mdm2 antisense oligonucleotide #254.
 DE
 KW antisense oligonucleotide; human; mdm2; hyperproliferation;
 KW hyperproliferative disorder; cancer; psoriasis; fibrosis;
 KW atherosclerosis; restenosis; apoptosis modulation; p21; ss;
 KW 2'-methoxyethoxy-residue; phosphorothioate backbone.
 XX
 OS Homo sapiens.
 XX
 XX WO2003048315-A2.
 PN
 XX 12-JUN-2003.
 PD
 XX 02-DEC-2002; 2002WO-US038281.
 PF
 XX 04-DEC-2001; 2001US-00005344.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Miraglia LJ, Nero PS, Graham MJ, Monia BP, Koller E, Chiang MY;
 PI Manoharan M;
 XX
 XX WPI; 2003-577263/54.
 DR

XX Novel antisense compound targeted to 5' untranslated region, coding
 PT region, or intron:exon junction of nucleic acid molecule encoding mdm2,
 PT useful for treating e.g. cancer, psoriasis or restenosis by inhibiting
 PT mdm2 expression.
 XX
 PS Claim 4; SEQ ID NO 256; 289pp; English.
 XX
 CC The invention comprises antisense oligonucleotides which are targeted to
 CC the human mdm2 gene. The antisense oligonucleotides of the invention are
 CC useful for reducing hyperproliferation of human cells. The antisense
 CC oligonucleotides are also useful for treating: hyperproliferative
 CC disorders (e.g. cancer), psoriasis, fibrosis, atherosclerosis, or
 CC restenosis. The antisense oligonucleotides are also useful for modulating
 CC apoptosis, and for increasing expression of p21. The present DNA sequence
 CC represents a human mdm2 gene antisense oligonucleotide of the invention.
 CC The present sequence contains 2'-methoxyethoxy-residues and has a
 CC phosphorothioate backbone.
 XX
 XX Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;
 SQ
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2882 CACCACACCTGGCAAAATT 2899
 Db 18 CACCACACCTGGCTAATT 1
 RESULT 2171
 ABZ97901
 ID ABZ97901 standard; DNA; 20 BP.
 XX
 AC ABZ97901;
 XX
 DT 17-OCT-2003 (first entry)
 DE
 DE Human RANTES oligonucleotide sequence.
 XX
 KW Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ublquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.
 XX
 OS Homo sapiens.
 XX
 XX WO200285308-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013135.
 PF
 XX 24-APR-2001; 2001US-0286137P.
 PR
 XX (EPIC-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-229219/22.
 DR
 XX Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ublquinone.
 XX
 XX Disclosure; SEQ ID NO 13143; 872pp; English.
 PS
 XX The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the

CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2850 CCTCCTGAGTAGCTGGGA 2867
 |||||
 Db 1 CCTCCCGAGTAGCTGGGA 18

RESULT 2172
 ABZ97918
 ID ABZ97918 standard; DNA; 20 BP.
 AC ABZ97918;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human RANTES oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.

OS Homo sapiens.
 XX
 XX WO200285308-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013135.
 PF
 XX 24-APR-2001; 2001US-0286137P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.

XX Disclosure; SEQ ID NO 13160; 872pp; English.
 XX
 XX The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the

CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences
 XX
 SQ Sequence 20 BP; 6 A; 9 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2827 CTCAGTGTATCTCCAC 2844
 |||||
 Db 3 CTCAGTGTATCACCAC 20

RESULT 2173
 ABZ88525
 ID ABZ88525 standard; DNA; 20 BP.
 AC ABZ88525;
 XX
 DT 17-OCT-2003 (first entry)
 XX
 DE Human oligonucleotide sequence.

XX Human; antisense; lung dysfunction; nasal airway dysfunction;
 KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
 KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
 KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
 KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
 KW lung inflammation; respiratory disease; ds.

OS Homo sapiens.
 XX
 XX WO200285308-A2.
 PN
 XX 31-OCT-2002.
 PD
 XX 23-APR-2002; 2002WO-US013135.
 PF
 XX 24-APR-2001; 2001US-0286137P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 XX WPI; 2003-229219/22.

XX Pharmaceutical composition for treating ailments associated with impaired
 PT respiration, has oligo(s) antisense to specific gene(s) or its
 PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
 PT ubiquinone.

XX Disclosure; SEQ ID NO 3767; 872pp; English.
 XX
 XX The invention relates to a novel pharmaceutical composition, which has a
 CC first active agent comprising an oligonucleotide antisense to the

CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
 CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
 CC junctions of genes encoding a polypeptide associated with lung and/or
 CC nasal airway dysfunction and a second active agent comprising an
 CC antiinflammatory steroid and ubiquinone. A composition of the invention
 CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
 CC immunosuppressive, and cytostatic activity. The composition may have a
 CC use in antisense gene therapy. The composition is useful for treating or
 CC preventing a respiratory, lung or malignant disease or condition, also
 CC for enhancing the prophylactic or therapeutic respiratory effect of an
 CC antiinflammatory steroid in a subject, for reducing or depleting levels
 CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
 CC receptor, producing bronchodilation, increasing levels of ubiquinone or
 CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
 CC lung inflammation, lung allergies, or a respiratory disease or condition.
 CC Note: The sequence data for this patent is not represented in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequences

SQ Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1647 GCCTCCTGACCTATCC 1664

Db 2 GCCTCTGACCTATCC 19

RESULT 2174

ABD30949
 ID ABD30949 standard; DNA; 20 BP.

AC ABD30949;

XX 29-JUL-2004 (first entry)

XX Human RANTES-derived oligonucleotide SEQ ID 13160.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;

XX WPI; 2003-093058/08.

XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.

XX Claim 15; SEQ ID NO 13160; 763pp; English.

XX

CC This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyposecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hyperinflation, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc., tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 20 BP; 6 A; 9 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 20;

Best Local Similarity 94.4%; Pred. No. 1.3e+03;

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2827 CTCAGTGATCCTCCAC 2844

Db 3 CTCAGTGATCACCAC 20

RESULT 2175

ABD30932

ID ABD30932 standard; DNA; 20 BP.

XX ABD30932;

XX 29-JUL-2004 (first entry)

XX Human RANTES-derived oligonucleotide SEQ ID 13143.

XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

XX Homo sapiens.

XX WO200285309-A2.

XX 31-OCT-2002.

XX 23-APR-2002; 2002WO-US013143.

XX 24-APR-2001; 2001US-0286036P.

XX (EPIG-) EPIGENESIS PHARM INC.

XX

PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 13143; 763pp; English.
 XX
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyosecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2850 CCTCCTGAGTAGCTGGGA 2867
 Db 1 CCTCCCGAGTAGCTGGGA 18
 RESULT 2176
 ID ABD24755
 AC ABD24755 standard; DNA; 20 BP.
 XX
 XX
 XX 29-JUL-2004 (first entry)
 XX
 XX A112689-derived oligonucleotide SEQ ID 3767.
 DE
 XX Human; antisense; bronchoconstriction; allergy; hyosecretion; pain;
 KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
 KW surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
 KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
 KW beta-adrenergic agonist; respiratory disease; cytostatic; pulmonary
 KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
 KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
 KW pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.
 XX
 PN WO200285309-A2.
 XX
 PD 31-OCT-2002.
 XX
 XX 23-APR-2002; 2002WO-US013143.
 PF
 XX 24-APR-2001; 2001US-0286036P.
 PR
 XX (EPIG-) EPIGENESIS PHARM INC.
 PA
 XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
 PI Miller S, Tang L, Shahabuddin S;
 XX
 DR WPI; 2003-093058/08.
 XX
 XX Pharmaceutical composition for treating asthma, has antisense
 PT oligonucleotide containing less percentage of adenosine, targeted to
 PT nucleic acids associated with lung airway or lung dysfunction, and
 PT bronchodilating agent.
 XX
 XX Claim 15; SEQ ID NO 3767; 763pp; English.
 PS
 XX This invention describes a novel composition (a) a first active agent,
 CC comprising oligonucleotides, effective for alleviating
 CC bronchoconstriction, respiratory tract inflammation, allergies and
 CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
 CC surfactant depletion or hyosecretion, when administered to a mammal. The
 CC oligonucleotides are derived from a gene encoding or regulating
 CC expression of a target polypeptide associated with lung airway or lung
 CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
 CC The invention also describes a kit, that comprises: (a) a delivery
 CC device, in separate containers, (b) the oligonucleotides, (c)
 CC instructions for adding a carrier and for use of the kit. The composition
 CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
 CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
 CC beta-adrenergic agonist. The composition is useful for preventing or
 CC treating a respiratory, lung or malignant disease. The administered
 CC composition comprises oligo and is administered to reduce the production
 CC or availability, or to increase the degradation of the target mRNA or to
 CC reduce the amount of target polypeptide present in the lungs. The
 CC pulmonary obstruction, and/or bronchoconstriction and/or lung
 CC inflammation, allergies and/or surfactant hypoproduction are associated
 CC with a disease or condition such as pulmonary vasoconstriction,
 CC inflammation, allergies, asthma, impeded respiration, respiratory
 CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
 CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
 CC transplantation rejection, pulmonary infections, bronchitis or cancer.
 CC The reduced adenosine content of the anti-sense oligos corresponding to
 CC thymidines present in the target RNA serves to prevent the breakdown of
 CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it
 XX
 SQ Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1647 GCCTCCCTGAGCTATCC 1664
 Db 2 GCCTCTCTGAACCTATCC 19
 RESULT 2177
 ADJ59766
 ID ADJ59766 standard; DNA; 20 BP.
 XX
 AC ADJ59766;
 XX
 DT 06-MAY-2004 (first entry)

XX DE Oligonucleotide associated to RANTES #15.
 XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;
 KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX KW Homo sapiens.
 OS W02004011613-A2.
 XX PN 05-FEB-2004.
 PD 25-JUL-2003; 2003WO-US023509.
 XX PF 29-JUL-2002; 2002US-0399076P.
 XX PR (EPIG-) EPIGENESIS PHARM INC.
 XX PA Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 XX PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX PS Claim 2; SEQ ID NO 622; 85pp; English.
 XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC respiratory or lung disease, which involves administering or treating a
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2850 CCTCTGAGTAGCTGGGA 2867
 DB 1 CCTCCCGAGTAGCTGGGA 18
 RESULT 2178
 ADJ59783
 ID ADJ59783 standard; DNA; 20 BP.
 XX AC ADJ59783;
 XX DT 06-MAY-2004 (first entry)
 XX DE Oligonucleotide associated to RANTES #32.
 XX KW interleukin; IL-4 receptor; IL-5 receptor; lung disease;
 KW airway inflammation; allergy; asthma; impeded respiration;

KW cystic fibrosis; acute respiratory distress syndrome;
 KW pulmonary hypertension; lung inflammation; bronchitis; oligonucleotide;
 KW ss.
 XX KW Homo sapiens.
 OS W02004011613-A2.
 XX PN 05-FEB-2004.
 XX PF 25-JUL-2003; 2003WO-US023509.
 XX PR 29-JUL-2002; 2002US-0399076P.
 XX PA (EPIG-) EPIGENESIS PHARM INC.
 XX PI Nyce JW, Tang L, Sandrasagra A, Aguilar D, Miller S;
 PI Shahabuddin S, Lu H, Cong H;
 PI WPI; 2004-203534/19.
 XX DR Novel single or multiple target oligonucleotide anti-sense to e.g.
 XX PT initiation codons and introns of respiratory disease-relevant genes e.g.,
 PT CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory
 PT disease e.g., asthma.
 XX PS Claim 2; SEQ ID NO 639; 85pp; English.
 XX CC The present invention relates to an oligonucleotide anti-sense to e.g.,
 CC initiation codon, coding region with 2-10 nucleotides of 5'-end and 3'-
 CC end of nucleic acid target comprising gene(s) chosen from e.g.
 CC interleukin (IL)-4 receptor, IL-5 receptor or salts of the
 CC oligonucleotide and optionally surfactant operatively linked to the
 CC respiratory or lung disease, which involves administering or treating a
 CC of a subject an effective amount of an inhibitor. The oligonucleotide is
 CC useful for production of a medicament for the prevention and/or treatment
 CC of a respiratory or lung disease. The respiratory or lung disease is
 CC chosen from airway inflammation, allergy(ies), asthma, impeded
 CC respiration, cystic fibrosis (CF), chronic obstructive pulmonary diseases
 CC (COPD), allergic rhinitis (AR), acute respiratory distress syndrome
 CC (ARDS), pulmonary hypertension, lung inflammation, bronchitis, airway
 CC obstruction. The present sequence represents an oligonucleotide of the
 CC invention.
 XX SQ Sequence 20 BP; 6 A; 9 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2827 CTCAGTGTATCTCCAC 2844
 DB 3 CTCAGTGTATCTCCAC 20
 RESULT 2179
 ADM15187/c
 ID ADM15187 standard; DNA; 20 BP.
 XX AC ADM15187;
 XX DT 01-JUL-2004 (first entry)
 XX DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1374.
 XX KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;

KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX
 PN WO2004028458-A2.
 XX
 XX 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 XX
 XX 25-SEP-2002; 2002US-0413549P.
 XX (PHAA) PHARMACIA CORP.
 XX
 XX Gierse JK;
 XX
 XX WPI; 2004-305094/28.
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 PT
 XX
 PS Claim 4; SEQ ID NO 1374; 132pp; English.
 XX
 XX The present sequence represents a chimeric antisense oligonucleotide
 targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 12 A; 8 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2728 GTGTGTGTGTGTGTGTAT 2745
 Db 19 GTGTGTGTGTGTGTGT 2
 RESULT 2180

ADM15454/c
 ID ADM15454 standard; DNA; 20 BP.
 XX
 AC ADM15454;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1641.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytotstatic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX
 PN WO2004028458-A2.
 XX
 XX 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 XX
 XX 25-SEP-2002; 2002US-0413549P.
 XX (PHAA) PHARMACIA CORP.
 XX
 XX Gierse JK;
 XX
 XX WPI; 2004-305094/28.
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 PT
 XX
 PS Claim 4; SEQ ID NO 1641; 132pp; English.
 XX
 XX The present sequence represents a chimeric antisense oligonucleotide
 targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 12 A; 8 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 2728 GTGTGTGTGTGTGTAT 2745
 Db 19 GTGTGTGTGTGTGT 2
 RESULT 2180

CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 10 A; 8 C; 0 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2732 GTGCTGTGTGTGTGTGT 2749
 Db 20 GTGCTGTGTGTGTGTGT 3
 RESULT 2181
 ADM14984/c
 ID ADM14984 standard; DNA; 20 BP.
 XX AC
 XX ADM14984;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1171.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nontropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX WO2004028458-A2.
 XX
 XX 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 XX
 XX 25-SEP-2002; 2002US-0413549P.
 XX
 XX (PHAA) PHARMACIA CORP.
 XX
 XX Gierse JK;
 XX
 XX WPI; 2004-305094/28.
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 XX encoding mPGES-1, useful for preparing a composition for treating e.g.,
 XX inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 XX ischaemia.
 XX
 PS Claim 4; SEQ ID NO 1171; 132pp; English.

XX
 CC The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nontropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 8 A; 8 C; 2 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2722 ATCCGCTGTGTGTGTGTGT 2739
 Db 18 ATCCGCTGTGTGTGTGTGT 1
 RESULT 2182
 ADM15240/c
 ID ADM15240 standard; DNA; 20 BP.
 XX AC
 XX ADM15240;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1427.
 XX
 KW chimeric; antisense oligonucleotide; phosphorothioate; human;
 KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
 KW microsomal prostaglandin E2 synthase inhibitor; cytosolic; antidiabetic;
 KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nontropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 XX WO2004028458-A2.
 XX
 XX 08-APR-2004.


```

PF 25-SEP-2003; 2003WO-US030374.
XX
PR 25-SEP-2002; 2002US-0413549P.
XX
PA (PHAA ) PHARMACIA CORP.
PI
PI Gierse JK;
XX
DR WPI; 2004-305094/28.
XX
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
XX Claim 4; SEQ ID NO 1427; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 11 A; 8 C; 1 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 16.4; DB 1; Length 20;
XX Best Local Similarity 94.4%; Pred. No. 1.3e+03;
XX Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2728 GTGTGTGTGTGTGTGTAT 2745
DB |||||||||||||||
20 GTGTGTGTGTGTGTGT 3

RESULT 2183
ID ADM15410/C
XX ADM15410 standard; DNA; 20 BP.
XX
XX ADM15410;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1597.
XX
XX chimeric; antisense oligonucleotide; phosphorothioate; human;
XX microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
XX immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX immunomodulatory; cardiovascular; gene therapy; inflammation;
XX Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX reperfusion injury; ophthalmic disorder; immunological disorder;
XX cardiovascular disorder; neurological disorder; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= b
FT

```

```

FT
FT
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
XX WO2004028458-A2.
XX
XX 08-APR-2004.
XX
XX 25-SEP-2003; 2003WO-US030374.
XX
XX 25-SEP-2002; 2002US-0413549P.
XX (PHAA ) PHARMACIA CORP.
XX
XX Gierse JK;
XX
XX WPI; 2004-305094/28.
XX
XX New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
XX Claim 4; SEQ ID NO 1597; 132pp; English.
XX
XX The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
CC human mPGES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
CC inhibits its expression; (2) a method of inhibiting the expression of
CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytostatic,
CC antidiabetic, immunomodulatory, cardiant, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory and cardiovascular activities, and can
CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
XX Sequence 20 BP; 10 A; 7 C; 0 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.5%; Score 16.4; DB 1; Length 20;
XX Best Local Similarity 94.4%; Pred. No. 1.3e+03;
XX Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
QY 2728 GTGTGTGTGTGTGTAT 2745
DB |||||||||||||||
18 GTGTATGTGTGTGTAT 1

RESULT 2184
ID ADO45256
XX ADO45256 standard; DNA; 20 BP.
XX
XX ADO45256;
XX
XX 15-JUL-2004 (first entry)
XX
XX Human oligonucleotide #622.
XX

```

Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5; CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a; tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease; lung disease; hyper-responsiveness; adenosine; adenosine A receptor; asthma; lung allergy; inflammation; inflammatory disease; airway inflammation; allergy; impeded respiration; cystic fibrosis; CF; chronic obstructive pulmonary disease; COPD; allergic rhinitis; acute respiratory distress syndrome; pulmonary hypertension; lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

Homo sapiens.

US2004049022-A1.

11-MAR-2004.

25-JUL-2003; 2003US-00627930.

23-APR-2002; 2002WO-US013135.

23-APR-2002; 2002WO-US013143.

(NYCE/) NYCE J W.

(SAND/) SANDRASAGRA A.

(TANG/) TANG L.

(AGUI/) AGUILAR D.

(MILL/) MILLER S.

(SHAH/) SHAHABUDDIN S.

(LUHH/) LU H.

(CONG/) CONG H.

Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S; Shahabuddin S, Lu H, Cong H;

WPI; 2004-293804/27.

Novel single or multiple target oligonucleotide anti-sense to e.g. initiation codon, intron of respiratory disease-relevant gene e.g. CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g. asthma.

Claim 2; SEQ ID NO 622; 174pp; English.

The invention relates to oligonucleotides anti-sense to an initiation codon, coding region, 5' or 3' intron-exon junction, intron or region with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention also relates to a method of screening a candidate compound that binds to one or more nucleic acid target(s) or expressed product(s), for the prevention and/or treatment of a respiratory or lung disease. The oligonucleotides are useful for reducing or inhibiting expression of a gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are useful for preventing or treating a respiratory or lung disease. The respiratory or lung disease is associated with hyper-responsiveness to respiratory or lung disease of, adenosine and/or levels of adenosine A receptor(s), and/or asthma and/or lung allergies associated with inflammation or an inflammatory disease. The respiratory or lung disease is chosen from airway inflammation, allergy, asthma, impeded respiration, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), allergic rhinitis, acute respiratory distress syndrome, pulmonary hypertension, lung inflammation, bronchitis, airway obstruction or bronchoconstriction. This sequence represents an oligonucleotide of the invention.

Sequence 20 BP; 3 A; 6 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2850 CCTCTGAGTAGCTGGGA 2867
 ||||| ||||| ||||| |||||
 Db 1 CCTCCCAGTAGCTGGGA 18

RESULT 2185
 ADO45273
 ID ADO45273 standard; DNA; 20 BP.
 XX
 AC ADO45273;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human oligonucleotide #639.
 XX
 KW Human; ss; interleukin-4 receptor; IL-4; interleukin-5 receptor; IL-5; CCR1; CCR3; Eotaxin-1; RANTES; MCP4; CD23; ICAM; VCAM; tryptase a; tryptase b; PDE4 A; PDE4 B; PDE4 C; PDE4 D; respiratory disease; lung disease; hyper-responsiveness; adenosine; adenosine A receptor; asthma; lung allergy; inflammation; inflammatory disease; airway inflammation; allergy; impeded respiration; cystic fibrosis; CF; chronic obstructive pulmonary disease; COPD; allergic rhinitis; acute respiratory distress syndrome; pulmonary hypertension; lung inflammation; bronchitis; airway obstruction; bronchoconstriction.

OS Homo sapiens.
 XX
 XX US2004049022-A1.
 PN
 XX 11-MAR-2004.
 PD
 XX 25-JUL-2003; 2003US-00627930.
 XX
 XX 23-APR-2002; 2002WO-US013135.
 PR
 XX 23-APR-2002; 2002WO-US013143.
 PR
 XX (NYCE/) NYCE J W.
 PA (SAND/) SANDRASAGRA A.
 PA (TANG/) TANG L.
 PA (AGUI/) AGUILAR D.
 PA (MILL/) MILLER S.
 PA (SHAH/) SHAHABUDDIN S.
 PA (LUHH/) LU H.
 PA (CONG/) CONG H.

Nyce JW, Sandrasagra A, Tang L, Aguilar D, Miller S; Shahabuddin S, Lu H, Cong H;

WPI; 2004-293804/27.

Novel single or multiple target oligonucleotide anti-sense to e.g. initiation codon, intron of respiratory disease-relevant gene e.g. CCR1, RANTES, MCP4, useful for prophylaxis or treating respiratory disease e.g. asthma.

Claim 2; SEQ ID NO 639; 174pp; English.

The invention relates to oligonucleotides anti-sense to an initiation codon, coding region, 5' or 3' intron-exon junction, intron or region with 2-10 nucleotides of the 5'-end or 3'-end of a nucleic acid target chosen from a gene encoding interleukin (IL)-4 receptor, interleukin (IL)-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C or PDE4 D. The invention also relates to a method of screening a candidate compound that binds to one or more nucleic acid target(s) or expressed product(s), for the prevention and/or treatment of a respiratory or lung disease. The oligonucleotides are useful for reducing or inhibiting expression of a gene or mRNA encoding interleukin-4 receptor, interleukin-5 receptor, CCR1, CCR3, Eotaxin-1, RANTES, MCP4, CD23, ICAM, VCAM, tryptase a, tryptase b, PDE4 A, PDE4 B, PDE4 C, or PDE4 D. The oligonucleotides are useful for preventing or treating a respiratory or lung disease. The respiratory or lung disease is associated with hyper-responsiveness to respiratory or lung disease of, adenosine and/or levels of adenosine A receptor(s), and/or asthma and/or lung allergies associated with inflammation or an inflammatory disease. The respiratory or lung disease is chosen from airway inflammation, allergy, asthma, impeded respiration, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), allergic rhinitis, acute respiratory distress syndrome, pulmonary hypertension, lung inflammation, bronchitis, airway obstruction or bronchoconstriction. This sequence represents an oligonucleotide of the invention.

CC receptor(s), and/or asthma and/or lung allergies associated with
 CC inflammation or an inflammatory disease. The respiratory or lung disease
 CC is chosen from airway inflammation, allergy, asthma, impeded respiration,
 CC cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD),
 CC allergic rhinitis, acute respiratory distress syndrome, pulmonary
 CC hypertension, lung inflammation, bronchitis, airway obstruction or
 CC bronchoconstriction. This sequence represents an oligonucleotide of the
 CC invention.

XX
 SQ Sequence 20 BP; 6 A; 9 C; 2 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2827 CTCAGTGTATCTCCAC 2844
 Db 3 CTCAGTGTATCTCCAC 20
 |||||

RESULT 2186
 ADN06467/c
 ID ADN06467 standard; DNA; 20 BP.
 XX
 AC ADN06467;
 XX
 DT 15-JUL-2004 (first entry)
 XX
 DE Human FLAP related microsatellite marker SEQ ID NO:115.
 XX
 KW leukotriene synthesis inhibitor; myocardial infarction;
 KW acute coronary syndrome; atherosclerotic; cardiac; antiangiinal;
 KW leukotriene biosynthesis inhibitor; leukotriene receptor antagonist;
 KW 5-lipoxygenase activating protein; FLAP; human; chromosome 13;
 KW chromosome 13q12; polymorphism; 5-lipoxygenase gene promoter;
 KW 5-LO gene promoter; diabetes; hypertension; hypercholesterolemia;
 KW obesity; inflammatory marker; low density lipoprotein; cholesterol;
 KW high density lipoprotein; angina; atherosclerosis; microsatellite marker;
 KW ss.

XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 PN W02004035741-A2.
 XX
 PD 29-APR-2004.
 XX
 XX 16-OCT-2003; 2003WO-US032556.
 PF
 XX 17-OCT-2002; 2002US-0419433P.
 PR
 XX 21-FEB-2003; 2003US-0449331P.
 XX
 PA (DECO-) DECODE GENETICS EHF.
 XX
 XX Helgadottir A, Gurney ME, Gulcher JR;
 PI
 XX WPI; 2004-357211/33.
 DR
 XX
 XX Use of leukotriene synthesis inhibitor for manufacture of a medicament
 FT for treatment for myocardial infarction or susceptibility to myocardial
 FT infarction in individual.
 XX
 XX Disclosure; SEQ ID NO 115; 306pp; English.

XX
 CC The present invention describes using a leukotriene synthesis inhibitor
 CC (I) for the manufacture of a medicament for the treatment of myocardial
 CC infarction or susceptibility to myocardial infarction in an individual.
 CC Also described is a method (M1) for the treatment of acute coronary
 CC syndrome (ACS) in an individual comprising administering (I). (I) has
 CC antiatherosclerotic, cardiant and antiangiinal activities, and can be used
 CC as a leukotriene biosynthesis inhibitor, and a leukotriene receptor
 CC antagonist. (I) can be used for the manufacture of a medicament for the
 CC treatment of myocardial infarction or susceptibility to myocardial

CC infarction in an individual who has at least one risk factor chosen from
 CC an at-risk haplotype for myocardial infarction, an at-risk haplotype in
 CC the 5-lipoxygenase activating protein (FLAP) gene, a polymorphism in a
 CC FLAP nucleic acid and an at-risk polymorphism in the 5-lipoxygenase (5-
 CC LO) gene promoter; in an individual who has at least one risk factor
 CC chosen from diabetes, hypertension, hypercholesterolemia, elevated
 CC lip(a), obesity, past or current smoker; in an individual having elevated
 CC inflammatory marker chosen from C-reactive protein (CRP), serum amyloid
 CC A, fibrinogen, leukotriene, leukotriene metabolite, interleukin-6, tissue
 CC necrosis factor-alpha, soluble vascular cell adhesion molecule (sVCAM),
 CC soluble intervascular adhesion molecule (sICAM), E-selectin, matrix
 CC metalloproteinase type-1, matrix metalloproteinase type-2, matrix
 CC metalloproteinase type-3 and matrix metalloproteinase type-9; in an
 CC individual having increased low density lipoprotein (LDL) cholesterol
 CC and/or decreased high density lipoprotein (HDL) cholesterol; in an
 CC individual having increased leukotriene synthesis; in an individual
 CC having previous myocardial infarction or acute coronary syndrome (ACS)
 CC event, stable angina; or in an individual who has atherosclerosis or who
 CC requires treatment to restore blood flow in arteries. (M1) is useful for
 CC treating an individual suffering from acute coronary syndrome chosen from
 CC unstable angina, non-ST-elevation myocardial infarction (NSTEMI) and ST-
 CC elevation myocardial infarction (STEMI). The human FLAP gene is located
 CC on chromosome 13, more specifically to 13q12. The present sequence
 CC represents a microsatellite marker used in the exemplification of the
 CC present invention.

XX
 SQ Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2832 GTGATCTCTCCACCTCAG 2849
 Db 20 GTGATCTCTCCACCTCAG 3
 |||||

RESULT 2187
 ADP31860/c
 ID ADP31860 standard; DNA; 20 BP.
 XX
 AC ADP31860;
 XX
 DT 26-AUG-2004 (first entry)
 XX
 DE Oestrogen-responsive finger protein antisense oligo seqid 159.
 XX
 KW cytostatic; antisense therapy; oestrogen-responsive finger protein;
 KW oestrogen-responsive finger protein associated disorder;
 KW hyperproliferative disorder; diagnostic; prophylaxis; human;
 KW antisense oligonucleotide; antisense technology; ss.

XX
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= Phosphorothioate backbone. All cytidines
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 15..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 XX US2004110159-A1.
 PN
 XX 10-JUN-2004.
 PD
 XX

```

PF 10-DEC-2002; 2002US-00317277.
XX
PR 10-DEC-2002; 2002US-00317277.
XX
XX (ISIS-) ISIS PHARM INC.
XX
FI Dobie KW;
XX
DR WPI; 2004-440347/41.
XX
XX New antisense oligonucleotides for modulating estrogen-responsive finger
PT protein expression, useful for diagnosing, preventing or treating
PT hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 160; 65pp; English.
XX
XX The invention describes a compound 8-80 nucleobases in length targeted to
CC a nucleic acid molecule encoding estrogen-responsive finger protein. The
CC compound specifically hybridises with the nucleic acid molecule encoding
CC estrogen-responsive finger protein (which comprises a sequence of 24295
CC bp fully defined in the specification) and inhibits the expression of
CC estrogen-responsive finger protein. Also described are: a method of
CC inhibiting the expression of estrogen-responsive finger protein in cells
CC or tissues; a method of screening for a modulator of estrogen-responsive
CC finger protein; a diagnostic method for identifying a disease state; a
CC kit or assay device comprising the above compound; and a method of
CC treating an animal having a disease or condition associated with estrogen
CC -responsive finger protein. The antisense oligonucleotide is useful for
CC inhibiting the expression of estrogen-responsive finger protein in cells
CC or tissues to prevent or treat diseases associated with aberrant
CC estrogen-responsive finger protein expression, such as
CC hyperproliferative disorders. In addition, the compound is used for
CC diagnostics, prophylaxis, or as research reagents or kits. This sequence
CC represents a human estrogen-responsive finger protein antisense
CC oligonucleotide.
XX
SQ Sequence 20 BP; 2 A; 6 C; 6 G; 6 T; 0 U; 0 Other;
Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGAAGGCCACCCACAG 1146
Db 20 CTGAAGGCTACCCACAG 3

RESULT 2189
ADP31785
ID ADP31785 standard; DNA; 20 BP.
XX
AC ADP31785;
XX
DT 26-AUG-2004 (first entry)
XX
DE Estrogen-responsive finger protein antisense oligo seqid 84.
XX
XX cytotstatic; antisense therapy; estrogen-responsive finger protein;
KW estrogen-responsive finger protein associated disorder;
KW hyperproliferative disorder; diagnostic; prophylaxis; human;
KW antisense oligonucleotide; antisense technology; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= Phosphorothioate backbone. All cytidines
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT

```

```

FT modified_base 15..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX
XX US2004110159-A1.
XX
XX 10-JUN-2004.
XX
XX 10-DEC-2002; 2002US-00317277.
XX
XX 10-DEC-2002; 2002US-00317277.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Dobie KW;
XX
XX WPI; 2004-440347/41.
XX
XX New antisense oligonucleotides for modulating estrogen-responsive finger
PT protein expression, useful for diagnosing, preventing or treating
PT hyperproliferative disorders.
XX
XX Example 15; SEQ ID NO 85; 65pp; English.
XX
XX The invention describes a compound 8-80 nucleobases in length targeted to
CC a nucleic acid molecule encoding estrogen-responsive finger protein. The
CC compound specifically hybridises with the nucleic acid molecule encoding
CC estrogen-responsive finger protein (which comprises a sequence of 24295
CC bp fully defined in the specification) and inhibits the expression of
CC estrogen-responsive finger protein. Also described are: a method of
CC inhibiting the expression of estrogen-responsive finger protein in cells
CC or tissues; a method of screening for a modulator of estrogen-responsive
CC finger protein; a diagnostic method for identifying a disease state; a
CC kit or assay device comprising the above compound; and a method of
CC treating an animal having a disease or condition associated with estrogen
CC -responsive finger protein. The antisense oligonucleotide is useful for
CC inhibiting the expression of estrogen-responsive finger protein in cells
CC or tissues to prevent or treat diseases associated with aberrant
CC estrogen-responsive finger protein expression, such as
CC hyperproliferative disorders. In addition, the compound is used for
CC diagnostics, prophylaxis, or as research reagents or kits. This sequence
CC represents a human oestrogen-responsive finger protein antisense
CC oligonucleotide.
XX
SQ Sequence 20 BP; 6 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGAAGGCCACCCACAG 1146
Db 1 CTGAAGGCTACCCACAG 18

RESULT 2189
ADQ14953/c
ID ADQ14953 standard; DNA; 20 BP.
XX
AC ADQ14953;
XX
DT 07-OCT-2004 (first entry)
XX
XX CoRest intron targeting allele specific oligonucleotide.
XX
XX multifunctional oligomeric compound; RNA expression modulator;
KW double-stranded oligomeric compound; allele specific oligonucleotide;
KW ASO; ss; CoRest.
XX
XX Homo sapiens.
XX

```

```
PN US2004137471-A1.
XX
PD 15-JUL-2004.
XX
PF 18-SEP-2003; 2003US-00664639.
XX
PR 18-SEP-2002; 2002US-0411780P.
XX
PA (VICK/) VICKERS T.
PA (KOOS/) KOO S.
PA (BENN/) BENNETT C F.
PA (CROO/) CROOKE S T.
PA (DEAN/) DEAN N M.
PA (BAKE/) BAKER B F.
XX
PI Vickers T, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF;
XX
DR WPI; 2004-533354/51.
XX
PT Identifying a multifunctional oligomeric compound to modulate expression
PT of RNA comprises identifying an inhibiting antisense strand and
PT inhibiting double-stranded oligomeric compound as multifunctional
PT oligomeric compounds.
XX
PS Example 1; SEQ ID NO 77; 55pp; English.
XX
CC The invention describes a method of identifying a multifunctional
CC oligomeric compound to modulate expression of RNA. The method comprises:
CC contacting a target RNA with one or more double-stranded oligomeric
CC compounds hybridisable to one or more target regions of the RNA and
CC identifying double-stranded oligomeric compounds which inhibit target RNA
CC levels by at least 50%; contacting the target RNA with an antisense
CC strand of the modulating double-stranded oligomeric compound and
CC determining whether the antisense strand inhibits target RNA levels by at
CC least 50%; and identifying the inhibiting antisense strand and the
CC inhibiting double-stranded oligomeric compound as multifunctional
CC oligomeric compounds. Also described are: a multifunctional oligomeric
CC compound identified as above; a method for optimising target region
CC selection for modulation of RNA expression; a method of modulating RNA
CC expression; methods of optimising modulation of RNA; a method of
CC selecting a target region of a gene; a method of selecting an optimised
CC single-stranded oligomeric compound; a method of selecting an optimised
CC double-stranded oligomeric compound; a method of selecting a single-
CC stranded oligomeric compound; a method of selecting a double-stranded
CC oligomeric compound; a method of identifying one or more optimised double
CC -stranded oligomeric compounds; an oligomeric compound, 8-80 nucleobases
CC in length, targeted to a target RNA, where the oligomeric compound
CC specifically hybridises the target RNA and the oligomeric compound
CC inhibits RNA levels by at least 50% in both single-stranded and double-
CC stranded forms; and an oligomeric compound, 8-80 nucleobases in length
CC targeted to a target RNA, where the oligomeric compound has a least 80%
CC sequence homology to the complement of the target RNA and where the
CC oligomeric compound inhibits RNA levels by at least 60% in both single-
CC stranded and double-stranded forms. The method is useful for identifying
CC a multifunctional oligomeric compound to modulate expression of RNA. This
CC sequence represents an intron targeting allele specific oligonucleotide
CC that can be used to modulate RNA expression.
XX
SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2850 CCTCTGAGTAGCTGGGA 2867
|||||
DB 20 CCTCCCGAGTAGCTGGGA 3
RESULT 2190
ADS94486/c
ID ADS94486 standard; DNA; 20 BP.
XX
```

```
AC ADS94486;
XX
DT 02-DEC-2004 (first entry)
XX
DE Human 5-lipoxygenase activating protein (FLAP) gene PCR primer #112.
XX
KW human; 5-lipoxygenase activating protein; FLAP; chromosome 13q12;
KW single nucleotide polymorphism; SNP; myocardial infarction; PCR; primer;
KW microsatellite marker; ss.
XX
OS Homo sapiens.
XX
PN WO2004035746-A2.
XX
PD 29-APR-2004.
XX
PF 16-OCT-2003; 2003WO-US032805.
XX
PR 17-OCT-2002; 2002US-0419432P.
XX
PA (DECO-) DECODE GENETICS BHP.
XX
PI Helgadottir A, Gulcher JR, Manolescu A;
XX
DR WPI; 2004-348442/32.
XX
PT Novel FLAP (5-lipoxygenase activating protein) nucleic acid useful for
PT diagnosing myocardial infarction and for identifying agent that is useful
PT for treating myocardial infarction.
XX
PS Example; SEQ ID NO 115; 230pp; English.
XX
CC The invention comprises nucleic acid sequences of the human 5-
CC lipoxygenase activating protein (FLAP) gene - present on chromosome
CC 13q12. In particular the invention relates to polymorphisms identified
CC within this gene. The DNA sequences of the invention are useful for
CC diagnosing susceptibility to myocardial infarction and identifying agents
CC that alter expression of FLAP. The present DNA sequence represents a PCR
CC primer that is used to amplify a microsatellite marker from the human
CC FLAP gene.
XX
SQ Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2832 GTGATCTCTCCACCTCAG 2849
|||||
DB 20 GTGATCTCTCCACCTCAG 3
RESULT 2191
ADT01119
ID ADT01119 standard; DNA; 20 BP.
XX
AC ADT01119;
XX
DT 16-DEC-2004 (first entry)
XX
DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID1107.
XX
KW tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
KW tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
KW GUCY2F; MCKK; MLK4; kinase domain; cytoskeletal; tyrosine kinase inhibitor;
KW guanylate cyclase stimulator; ss.
XX
OS Homo sapiens.
XX
PN WO2004082458-A2.
XX
PD 30-SEP-2004.
XX
```

PF 18-FEB-2004; 2004WO-US004452.
 XX
 PR 21-FEB-2003; 2003US-0448537P.
 PR 29-MAY-2003; 2003US-0473895P.
 XX
 PA (UWJO) UNIV JOHNS HOPKINS.
 XX
 PI Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;
 XX WPI; 2004-718702/70.
 XX
 DR Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCCK) and
 XX associated methods for diagnosing cancer and screening for anti-cancer
 PT agents.
 PT
 XX Disclosure; SEQ ID NO 1107; 363pp; English.
 PS
 XX This invention relates to a novel activated mutant protein tyrosine
 CC kinases and associated methods for diagnosing cancer and screening for
 CC anti-cancer agents. Protein kinases are signalling molecules involved in
 CC tumorigenesis. Mutational analysis of the human tyrosine kinase gene
 CC family identified somatic alteration sin 1 in 5 colorectal cancers, with
 CC the majority of mutations occurring in the NTRK3, FES, GUCY2P and
 CC MCCK/MLK4 genes. Most were identified in the kinase domain. The invention
 CC may be useful for the production of compounds with a cytostatic activity
 CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
 CC stimulators. The invention may be useful for developing methods for
 CC detecting mutations involved in cancer or screening for anti-cancer
 CC agents. The present sequence is that of a human-derived oligonucleotide
 CC which is related to the invention.
 XX
 SQ Sequence 20 BP; 6 A; 1 C; 11 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16.4; DB 1; Length 20;
 Best Local Similarity 94.4%; Pred. No. 1.3e+03;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 514 GGGGAGGAGGAGCTGAA 531
 DB 2 GGGGAGGAGGAGCTGTAA 19
 RESULT 2192
 AAX77487/C
 ID AAX77487 standard; DNA; 18 BP.
 XX
 AC AAX77487;
 XX
 DT 05-AUG-1999 (first entry)
 XX
 DE US5912147 primer.31.
 XX
 KW Primer; quantitation; genetic instability; tumour cell; detection;
 KW neoplastic transformation; carcinogenesis; ss.
 XX
 OS Synthetic.
 XX
 PN US5912147-A.
 XX
 PD 15-JUN-1999.
 XX
 PF 22-OCT-1996; 96US-00734973.
 XX
 PR 22-OCT-1996; 96US-00734973.
 XX
 PA (HEAL-) HEALTH RES INC.
 XX
 PI Anderson G, Stoler D, Basik M;
 XX WPI; 1999-357197/30.
 XX
 DR Quantitating genetic instability.
 XX
 PT Claim 4; Col 29-30; 27pp; English.
 XX
 PS This invention describes a novel method for quantitating genetic
 CC instability independent of microsatellite alterations by treating a
 CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC from normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence
 CC (CG)xRG, where R is a purine selected from adenine and guanine and x = 3-
 CC 7, (ii) a nucleotide sequence (CG)xRY, where R is as in (i) and Y is a
 CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
 CC a nucleotide sequence (CG)xRR, where R is as in (i) and x = 3-7, (iv) a
 CC nucleotide sequence (CG)xYY, where Y is a pyrimidine selected from
 CC cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
 CC (CA)xRG, where R is a purine selected from adenine and guanine and x = 6-
 CC 16, (vi) a nucleotide sequence (CA)xRY, where R is a purine selected from
 CC adenine and guanine and Y is a pyrimidine selected from cytosine,
 CC thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xRR,
 CC where R is a purine selected from adenine and guanine and x = 6-16,
 CC (viii) a nucleotide sequence (CA)xYY, where Y is a pyrimidine selected
 CC from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
 CC of the primers. The method is useful for detecting genomic instability
 CC which are commonly associated with the various stages of neoplastic
 CC transformation and carcinogenesis. The method is rapid and simple

PS Claim 4; Col 29-30; 27pp; English.
 XX
 CC This invention describes a novel method for quantitating genetic
 CC instability independent of microsatellite alterations by treating a
 CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC from normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence
 CC (CG)xRG, where R is a purine selected from adenine and guanine and x = 3-
 CC 7, (ii) a nucleotide sequence (CG)xRY, where R is as in (i) and Y is a
 CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
 CC a nucleotide sequence (CG)xRR, where R is as in (i) and x = 3-7, (iv) a
 CC nucleotide sequence (CG)xYY, where Y is a pyrimidine selected from
 CC cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
 CC (CA)xRG, where R is a purine selected from adenine and guanine and x = 6-
 CC 16, (vi) a nucleotide sequence (CA)xRY, where R is a purine selected from
 CC adenine and guanine and Y is a pyrimidine selected from cytosine,
 CC thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xRR,
 CC where R is a purine selected from adenine and guanine and x = 6-16,
 CC (viii) a nucleotide sequence (CA)xYY, where Y is a pyrimidine selected
 CC from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
 CC of the primers. The method is useful for detecting genomic instability
 CC which are commonly associated with the various stages of neoplastic
 CC transformation and carcinogenesis. The method is rapid and simple
 XX
 SQ Sequence 18 BP; 8 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2728 GTGTGTGTGTGTGTGT 2743
 DB 17 GTGTGTGTGTGTGTGT 2
 RESULT 2193
 AAX77486/C
 ID AAX77486 standard; DNA; 18 BP.
 XX
 AC AAX77486;
 XX
 DT 05-AUG-1999 (first entry)
 XX
 DE US5912147 primer 30.
 XX
 KW Primer; quantitation; genetic instability; tumour cell; detection;
 KW neoplastic transformation; carcinogenesis; ss.
 XX
 OS Synthetic.
 XX
 PN US5912147-A.
 XX
 PD 15-JUN-1999.
 XX
 PF 22-OCT-1996; 96US-00734973.
 XX
 PR 22-OCT-1996; 96US-00734973.
 XX
 PA (HEAL-) HEALTH RES INC.
 XX
 PI Anderson G, Stoler D, Basik M;
 XX WPI; 1999-357197/30.
 XX
 DR Quantitating genetic instability.
 XX
 PT Claim 4; Col 29-30; 27pp; English.
 XX
 PS This invention describes a novel method for quantitating genetic
 CC instability independent of microsatellite alterations by treating a
 CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC from normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence

CC (CG)xRG, where R is a purine selected from adenine and guanine and x = 3-7, (ii) a nucleotide sequence (CG)xRY, where R is as in (i) and Y is a pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii) a nucleotide sequence (CG)xRR, where R is as in (i) and x = 3-7, (iv) a nucleotide sequence (CG)xY, where Y is a pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence (CA)xRG, where R is a purine selected from adenine and guanine and x = 6-16, (vi) a nucleotide sequence (CA)xRY, where R is a purine selected from adenine and guanine and Y is a pyrimidine selected from cytosine, thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xRR, where R is a purine selected from adenine and guanine and x = 6-16, (viii) a nucleotide sequence (CA)xY, where Y is a pyrimidine selected from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination of the primers. The method is useful for detecting genomic instability which are commonly associated with the various stages of neoplastic transformation and carcinogenesis. The method is rapid and simple

XX Sequence 18 BP; 8 A; 10 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGT 2743
|||||

Db 17 GTGTGTGTGTGTGTGT 2

RESULT 2194

AAX77488/C

ID AAX77488 standard; DNA; 18 BP.

XX AAX77488;

XX 05-AUG-1999 (first entry)

DE US912147 primer 32.

XX Primer; quantitation; genetic instability; tumour cell; detection; neoplastic transformation; carcinogenesis; DNA/RNA hybrid; ss.

XX Synthetic.

XX Key Location/Qualifiers
FT misc_RNA 18
FT /*tag= a
FT /note= "uracil"

XX US912147-A.

XX 15-JUN-1999.

XX 22-OCT-1996; 96US-00734973.

XX 22-OCT-1996; 96US-00734973.

XX (HEAL-) HEALTH RES INC.

XX Anderson G, Stoler D, Basik M;

XX WPI; 1999-357197/30.

XX Quantitating genetic instability.

XX Claim 4; Col 29-30; 27pp; English.

XX This invention describes a novel method for quantitating genetic instability independent of microsatellite alterations by treating a comparison pair comprising genomic DNA from tumour cells and genomic DNA from normal cells. The method involves the cells from the same individual with oligonucleotide primers selected from (i) a nucleotide sequence (CG)xRG, where R is a purine selected from adenine and guanine and x = 3-7, (ii) a nucleotide sequence (CG)xRY, where R is as in (i) and Y is a

CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii) a nucleotide sequence (CG)xRR, where R is as in (i) and x = 3-7, (iv) a nucleotide sequence (CG)xY, where Y is a pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence (CA)xRG, where R is a purine selected from adenine and guanine and x = 6-16, (vi) a nucleotide sequence (CA)xRY, where R is a purine selected from adenine and guanine and Y is a pyrimidine selected from cytosine, thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xRR, where R is a purine selected from adenine and guanine and x = 6-16, (viii) a nucleotide sequence (CA)xY, where Y is a pyrimidine selected from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination of the primers. The method is useful for detecting genomic instability which are commonly associated with the various stages of neoplastic transformation and carcinogenesis. The method is rapid and simple

XX Sequence 18 BP; 8 A; 9 C; 0 G; 0 T; 1 U; 0 Other;

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGT 2743
|||||

Db 17 GTGTGTGTGTGTGTGT 2

RESULT 2195

ADO48752

ID ADO48752 standard; DNA; 18 BP.

XX ADO48752;

XX 12-AUG-2004 (first entry)

XX Human neuropilin 1 (NRP1) extension PCR primer #54.

XX human; melanoma; single nucleotide polymorphism; SNP; neuropilin 1; NRPL; mannose receptor C type 2; MRC2; extension PCR; primer; ss; genotyping.

XX Homo sapiens.

XX WO2004044163-A2.

XX 27-MAY-2004.

XX 06-NOV-2003; 2003WO-US035876.

XX 06-NOV-2002; 2002US-0424475P.

XX 23-JUL-2003; 2003US-0489703P.

XX (SEQU-) SEQUENOM INC.

XX Roth RB, Nelson MR, Braun A, Kammerer SM;

XX WPI; 2004-411720/38.

XX Identifying a subject at risk of melanoma, useful for treating melanoma, comprises detecting the presence or absence of one or more polymorphic variations associated with melanoma in a nucleic acid sample from a subject.

XX Example 3; Page 78; 176pp; English.

XX The invention comprises a method for identifying a subject at risk of melanoma. The invention involves detecting the presence or absence of one or more polymorphic variations associated with melanoma in the neuropilin 1 (NRP1) or mannose receptor C type 2 (MRC2) genes. The method of the invention is useful for identifying subjects at risk and treating melanoma. The present DNA sequence represents an extension PCR primer that was used to detect single nucleotide polymorphisms within human NRPL.

XX Sequence 18 BP; 2 A; 3 C; 9 G; 3 T; 0 U; 1 Other;

Query Match 0.5%; Score 16; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2775 GGCTGGAGTGCAGTGG 2790
 |||||
 Db 1 GGCTGGAGTGCAGTGG 16

RESULT 2196
 ADR32355
 ID ADR32355 standard; DNA; 18 BP.
 XX AC
 XX ADR32355;
 XX DT
 XX 04-NOV-2004 (first entry)
 XX DE Rat KDR cytosolic domain cloning RT-PCR primer.
 XX KW Rat; receptor tyrosine kinase; KDR; therapy; cancer;
 KW ischaemic ocular disease; proliferative retinopathy; inflammation;
 KW reverse transcription; RT; PCR; primer; ss.
 XX OS Rattus norvegicus.
 XX PN WO2004070004-A2.
 XX PD 19-AUG-2004.
 XX PF 23-JAN-2004; 2004WO-US001928.
 XX PR 29-JAN-2003; 2003US-0443335P.
 XX PA (MERI) MERCK & CO INC.
 XX PI Thomas RA, Pan B, Mcgaughey GB;
 XX WPI; 2004-604429/58.
 XX PT New nucleic acid molecules encoding rat KDR protein, useful for
 PT identifying inhibitors of KDR activity for treating cancer, ischemic
 PT ocular diseases, and inflammation.
 XX PS Example 2; Page 30; 77pp; English.
 XX CC The invention relates to rat receptor tyrosine kinase (KDR) and its
 CC corresponding nucleic acid sequence. The nucleic acid molecules of the
 CC invention are useful for identifying compounds that modulate wild-type
 CC rat KDR activity to evaluate the safety and efficacy of specific
 CC inhibitors of KDR in rats. KDR inhibitors are useful for treating cancer,
 CC ischaemic ocular diseases such as proliferative retinopathy and
 CC inflammation. The present sequence is a reverse transcription (RT) PCR
 CC primer used for cloning rat KDR cytosolic domain. This sequence is used
 CC in the exemplification of the invention.
 XX SQ Sequence 18 BP; 0 A; 0 C; 0 G; 18 T; 0 U; 0 Other;

Query Match 0.5%; Score 16; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
 |||||
 Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 2197
 ADR57967
 ID ADR57967 standard; DNA; 18 BP.
 XX AC
 XX ADR57967;
 XX OS

DT 18-NOV-2004 (first entry)
 XX Nucleotide #4 for signal amplification method.
 XX ss; signal amplification method; gene expression; reverse transcription;
 KW self-assembly reaction; DNA chip.
 XX OS Unidentified.
 XX PN WO2004072302-A1.
 XX PD 26-AUG-2004.
 XX PF 13-FEB-2004; 2004WO-JP001588.
 XX PR 14-FEB-2003; 2003JP-00037212.
 XX PA (PALM-) PALMA BEEZ RES INST CO LTD.
 XX PI Usui M, Fujikawa T;
 XX WPI; 2004-642306/62.
 XX PT Signal amplification method for detecting expressed gene, by using
 PT reverse transcription reaction and self-assembly reaction of
 PT oligonucleotide probes.
 XX PS Disclosure; SEQ ID NO 4; 27pp; Japanese.
 XX CC The invention relates to a signal amplification method (M1) for detecting
 CC expressed gene using reverse transcription reaction and a self-assembly
 CC reaction of forming a self assembly of oligonucleotide probes, thus
 CC improving detection sensitivity of the expressed gene in a DNA chip. (M1)
 CC is useful for signal amplification method (M1) for detecting expressed
 CC gene (claimed). (M1) improves detection sensitivity of the expressed gene
 CC in a DNA chip (claimed). (M1) does not require use of expensive enzymes
 CC and enables detection corresponding to the original RNA length or
 CC expression amount because of using neither linear amplification nor PCR.
 CC This sequence corresponds to a nucleotide used in the method of the
 CC invention.
 XX SQ Sequence 18 BP; 0 A; 0 C; 0 G; 18 T; 0 U; 0 Other;

Query Match 0.5%; Score 16; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 1.6e+03;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
 |||||
 Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 2198
 ADR82260
 ID ADR82260 standard; DNA; 19 BP.
 XX AC
 XX ADR82260;
 XX DT 16-DEC-2004 (first entry)
 XX DE Hepatitis C virus (HCV) oligonucleotide seqid 6759.
 XX KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; IRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
 XX OS Hepatitis C virus.


```

XX PN WO2004080406-A2.
XX PD 23-SEP-2004.
XX PF 08-MAR-2004; 2004WO-US007070.
XX PR 07-MAR-2003; 2003US-0452682P.
XX PR 12-MAR-2003; 2003US-0454265P.
XX PR 13-MAR-2003; 2003US-0454962P.
XX PR 13-MAR-2003; 2003US-0455050P.
XX PR 14-APR-2003; 2003US-0462894P.
XX PR 17-APR-2003; 2003US-0463772P.
XX PR 25-APR-2003; 2003US-0465665P.
XX PR 25-APR-2003; 2003US-0465802P.
XX PR 09-MAY-2003; 2003US-0469612P.
XX PR 08-AUG-2003; 2003US-0493986P.
XX PR 11-AUG-2003; 2003US-0494597P.
XX PR 26-SEP-2003; 2003US-0506341P.
XX PR 09-OCT-2003; 2003US-0510246P.
XX PR 10-OCT-2003; 2003US-0510318P.
XX PR 07-NOV-2003; 2003US-0518453P.
XX PA (ALNY-) ALNYLAM PHARM.
XX PI Manoharan M, Bumcrot D;
XX PF WPI; 2004-677362/66.
XX PT Interference RNA agent useful for treating dyslipidemias, coronary artery
XX PT disease, diabetes, cancer or neurological disease, comprises sense
XX PT sequence and antisense sequence which has specific modifications.
XX PS Example 5; SEQ ID NO 6759; 378pp; English.
XX CC The invention describes a RNA interference (iRNA) agent (I) comprising a
XX CC sense sequence and an antisense sequence, where the sense sequences have
XX CC one or more asymmetrical 2'-O alkyl modifications, the antisense
XX CC sequences have one or more asymmetrical phosphorothioate modifications
XX CC and the antisense sequence targets a human gene sequence. Also described
XX CC are: a pharmaceutical preparation comprising (I); reducing (MI) apoB-100
XX CC levels or glucose-6-phosphatase levels in a subject; producing (I);
XX CC stabilising (I), involves selecting a sequence with activity and
XX CC introducing one or more asymmetrical modification in the sequence, where
XX CC the modification decreases nuclease sensitivity while not decreasing its
XX CC activity; a kit comprising (I) and instruction for its use; and a device
XX CC that can be dispense or administer a composition comprising (I). (I) is
XX CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (MI)
XX CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
XX CC The subject is suffering from a disorder characterised by elevated or
XX CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
XX CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX CC disorder is chosen from the HDL/LDL cholesterol imbalance,
XX CC dyslipidaemias, hypercholesterolaemia, coronary artery disease (CAD), coronary heart
XX CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
XX CC inhibit hepatic glucose production or for treating glucose-metabolism-
XX CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
XX CC lung cancer), neurological disease (e.g., Huntington disease or
XX CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
XX CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
XX CC be used to control HCV gene expression.
XX SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
Query Match 0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.5e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT 16

```

RESULT 2199
 ADR82257
 ID ADR82257 standard; DNA; 19 BP.
 XX
 AC ADR82257;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Hepatitis C virus (HCV) oligonucleotide seqid 6756.
 XX
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 08-MAR-2004; 2004WO-US007070.
 XX
 PR 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX
 (ALNY-) ALNYLAM PHARM.
 XX
 PI Manoharan M, Bumcrot D;
 XX
 PF WPI; 2004-677362/66.
 XX
 PT Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 XX
 PS Example 5; SEQ ID NO 6759; 378pp; English.
 XX
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (MI) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (MI)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
 CC be used to control HCV gene expression.

CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
 CC be used to control HCV gene expression.

XX
 SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.5e+03;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2903 TTTT TTTT TTTT TTTT TTTT 2918
 |||||
 Db 1 TTTT TTTT TTTT TTTT 16

RESULT 2200
 ADR82261
 ID ADR82261 standard; DNA; 19 BP.
 AC ADR82261;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Hepatitis C virus (HCV) oligonucleotide seqid 6760.
 XX
 KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cyostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
 XX
 OS Hepatitis C virus.
 XX
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 PF 08-MAR-2004; 2004WO-US007070.
 XX
 PR 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX
 PA (ALNY-) ALNYLAM PHARM.
 XX
 PI Manoharan M, Bumcrot D;
 XX

WPI; 2004-677362/66.

DR Interference RNA agent useful for treating dyslipidemias, coronary artery
 XX disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.
 PT

XX Example 5; SEQ ID NO 6760; 378pp; English.

XX The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
 CC be used to control HCV gene expression.

XX Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;

Query Match 0.5%; Score 16; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.5e+03;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2903 TTTT TTTT TTTT TTTT TTTT 2918
 |||||
 Db 1 TTTT TTTT TTTT TTTT 16

RESULT 2201
 ADR82258
 ID ADR82258 standard; DNA; 19 BP.
 XX
 AC ADR82258;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Hepatitis C virus (HCV) oligonucleotide seqid 6757.

XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cyostatic; anticonvulsant; nootropic; muscula; anti-HIV;
 KW RNA interference; iRNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
 XX
 OS Hepatitis C virus.

XX
 PN WO2004080406-A2.
 XX
 PD 23-SEP-2004.

```

XX PF 08-MAR-2004; 2004WO-US007070.
XX PF
XX PF 07-MAR-2003; 2003US-0452682P.
XX PR 12-MAR-2003; 2003US-0454265P.
XX PR 13-MAR-2003; 2003US-0454962P.
XX PR 13-MAR-2003; 2003US-0455050P.
XX PR 14-APR-2003; 2003US-0462894P.
XX PR 11-APR-2003; 2003US-0463772P.
XX PR 25-APR-2003; 2003US-0465665P.
XX PR 25-APR-2003; 2003US-0465802P.
XX PR 09-MAY-2003; 2003US-0469612P.
XX PR 08-AUG-2003; 2003US-0493986P.
XX PR 11-AUG-2003; 2003US-0494597P.
XX PR 26-SEP-2003; 2003US-0506341P.
XX PR 09-OCT-2003; 2003US-0510246P.
XX PR 10-OCT-2003; 2003US-0510318P.
XX PR 07-NOV-2003; 2003US-0518453P.
XX PF
XX PA (ALNY-) ALNYLAM PHARM.
XX PF
XX PI Manoharan M, Bumcrot D;
XX PF
XX PF WPI; 2004-677362/66.
XX PF
XX PF Interference RNA agent useful for treating dyslipidemias, coronary artery
XX PT disease, diabetes, cancer or neurological disease, comprises sense
XX PT sequence and antisense sequence which has specific modifications.
XX PF
XX PS Example 5; SEQ ID NO 6757; 378pp; English.
XX PF
XX CC The invention describes a RNA interference (iRNA) agent (I) comprising a
XX CC sense sequence and an antisense sequence, where the sense sequences have
XX CC one or more asymmetrical 2'-O alkyl modifications, the antisense
XX CC sequences have one or more asymmetrical phosphorothioate modifications
XX CC and the antisense sequence targets a human gene sequence. Also described
XX CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
XX CC levels or glucose-6-phosphatase levels in a subject; producing (I);
XX CC stabilising (I); involves selecting a sequence with activity and
XX CC introducing one or more asymmetrical modification in the sequence, where
XX CC the modification decreases nuclease sensitivity while not decreasing its
XX CC activity; a kit comprising (I) and instruction for its use; and a device
XX CC that can be dispense or administer a composition comprising (I). (I) is
XX CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
XX CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
XX CC The subject is suffering from a disorder characterised by elevated or
XX CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
XX CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX CC disorder is chosen from the HDL/LDL cholesterol imbalance,
XX CC dyslipidaemias, hypercholesterolaemia, statin-resistant
XX CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
XX CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
XX CC inhibit hepatic glucose production or for treating glucose-metabolism-
XX CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
XX CC lung cancer), neurological disease (e.g., Huntington disease or
XX CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
XX CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
XX CC be used to control HCV gene expression.
XX PF
XX SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
XX PF
XX PF Query Match 0.5%; Score 16; DB 1; Length 19;
XX PF Best Local Similarity 100.0%; Pred. No. 1.5e+03;
XX PF Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX PF
XX QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
XX DB 1 TTTT TTTT TTTT TTTT TTTT 16
XX PF
XX PF RESULT 2202
XX PF ADR82256

```

```

ID AD82256 standard; DNA; 19 BP.
XX AC
XX AC ADR82256;
XX DT
XX DT 16-DEC-2004 (first entry)
XX DE
XX DE Hepatitis C virus (HCV) oligonucleotide seqid 6755.
XX KW
XX KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
XX KW cytostatic; anticonvulsant; nootropic; muscular; anti-HIV;
XX KW RNA interference; iRNA; antisense technology; lipid metabolism;
XX KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
XX KW coronary artery disease; CAD; coronary heart disease; CHD;
XX KW atherosclerosis; hepatic glucose production;
XX KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
XX KW colon cancer; lung cancer; neurological disease; Huntington disease;
XX KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
XX OS
XX OS Hepatitis C virus.
XX PF
XX PF WO2004080406-A2.
XX PD
XX PD 23-SEP-2004.
XX PF
XX PF 08-MAR-2004; 2004WO-US007070.
XX PF
XX PF 07-MAR-2003; 2003US-0452682P.
XX PR 12-MAR-2003; 2003US-0454265P.
XX PR 13-MAR-2003; 2003US-0454962P.
XX PR 13-MAR-2003; 2003US-0455050P.
XX PR 14-APR-2003; 2003US-0462894P.
XX PR 17-APR-2003; 2003US-0463772P.
XX PR 25-APR-2003; 2003US-0465665P.
XX PR 25-APR-2003; 2003US-0465802P.
XX PR 09-MAY-2003; 2003US-0469612P.
XX PR 08-AUG-2003; 2003US-0493986P.
XX PR 11-AUG-2003; 2003US-0494597P.
XX PR 26-SEP-2003; 2003US-0506341P.
XX PR 09-OCT-2003; 2003US-0510246P.
XX PR 10-OCT-2003; 2003US-0510318P.
XX PR 07-NOV-2003; 2003US-0518453P.
XX PF
XX PF (ALNY-) ALNYLAM PHARM.
XX PF
XX PI Manoharan M, Bumcrot D;
XX PF
XX PF WPI; 2004-677362/66.
XX PT
XX PT Interference RNA agent useful for treating dyslipidemias, coronary artery
XX PT disease, diabetes, cancer or neurological disease, comprises sense
XX PT sequence and antisense sequence which has specific modifications.
XX PF
XX PS Example 5; SEQ ID NO 6755; 378pp; English.
XX PF
XX CC The invention describes a RNA interference (iRNA) agent (I) comprising a
XX CC sense sequence and an antisense sequence, where the sense sequences have
XX CC one or more asymmetrical 2'-O alkyl modifications, the antisense
XX CC sequences have one or more asymmetrical phosphorothioate modifications
XX CC and the antisense sequence targets a human gene sequence. Also described
XX CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
XX CC levels or glucose-6-phosphatase levels in a subject; producing (I);
XX CC stabilising (I); involves selecting a sequence with activity and
XX CC introducing one or more asymmetrical modification in the sequence, where
XX CC the modification decreases nuclease sensitivity while not decreasing its
XX CC activity; a kit comprising (I) and instruction for its use; and a device
XX CC that can be dispense or administer a composition comprising (I). (I) is
XX CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
XX CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
XX CC The subject is suffering from a disorder characterised by elevated or
XX CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
XX CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX CC disorder is chosen from the HDL/LDL cholesterol imbalance,
XX CC dyslipidaemias, hypercholesterolaemia, statin-resistant

```

CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
 CC be used to control HCV gene expression.

XX SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.5e+03;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
 Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 2203
 ADR82259
 ID ADR82259 standard; DNA; 19 BP.
 XX AC ADR82259;
 XX DT 16-DEC-2004 (first entry)
 XX DE Hepatitis C virus (HCV) oligonucleotide seqid 6758.
 XX KW antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
 KW cytostatic; anticonvulsant; nootropic; muscular; anti-HIV;
 KW RNA interference; RNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; hepatitis C virus; HCV; ss.
 XX OS Hepatitis C virus.
 XX PN WO2004080406-A2.
 XX PD 23-SEP-2004.
 XX PF 08-MAR-2004; 2004WO-US007070.
 XX PR 07-MAR-2003; 2003US-0452692P.
 XX PR 12-MAR-2003; 2003US-0454265P.
 XX PR 13-MAR-2003; 2003US-0454962P.
 XX PR 13-MAR-2003; 2003US-0455050P.
 XX PR 14-APR-2003; 2003US-0462894P.
 XX PR 17-APR-2003; 2003US-0463772P.
 XX PR 25-APR-2003; 2003US-0465665P.
 XX PR 25-APR-2003; 2003US-0465802P.
 XX PR 09-MAY-2003; 2003US-0469612P.
 XX PR 08-AUG-2003; 2003US-0493986P.
 XX PR 11-AUG-2003; 2003US-0494597P.
 XX PR 26-SEP-2003; 2003US-0506341P.
 XX PR 09-OCT-2003; 2003US-0510246P.
 XX PR 10-OCT-2003; 2003US-0510318P.
 XX PR 07-NOV-2003; 2003US-0518453P.
 XX PA (ALNY-) ALNYLAM PHARM.
 XX PI Manoharan M, Bumcrot D;
 XX WPI; 2004-677362/66.
 XX DR Interference RNA agent useful for treating dyslipidemias, coronary artery
 XX disease, diabetes, cancer or neurological disease, comprises sense
 PT

PT sequence and antisense sequence which has specific modifications.
 XX Example 5; SEQ ID NO 6758; 378pp; English.
 XX CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instruction for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidaemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a hepatitis C virus (HCV) antisense oligonucleotide that can
 CC be used to control HCV gene expression.

XX SQ Sequence 19 BP; 0 A; 0 C; 0 G; 19 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 1.5e+03;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
 Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 2204
 AAH20694/C
 ID AAH20694 standard; DNA; 20 BP.
 XX AC AAH20694;
 XX DT 13-AUG-2001 (first entry)
 XX DE Human telomeric repeat binding factor 2 oligonucleotide 111422.
 XX KW Antisense; phosphorothioate; human; telomeric repeat binding factor 2;
 KW inhibitor; premature aging; hyperproliferative disorder; cancer;
 KW cytostatic; ss.
 XX OS Homo sapiens.
 XX FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone"
 FT modified_base 1..3
 FT /tag= a
 FT /mod_base= OTHER
 FT /note= "2-O-methoxyethyl"
 FT modified_base 13..20
 FT /tag= c
 FT /mod_base= OTHER
 FT /note= "2-O-methoxyethyl"

```
XX PN WO200143752-A1.
XX FT
XX PD 21-JUN-2001.
XX PF 14-DEC-2000; 2000WO-US033954.
XX PR 17-DEC-1999; 99US-00467642.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Cowser LM;
XX PD WPI; 2001-398071/42.
XX DR
XX PF Antisense compounds targeted to nucleic acid encoding telomeric repeat
XX FT binding factor 2 useful for treating conditions such as premature aging
XX FT and diseases such as cancer.
XX PS Claim 3; Page 81; 108pp; English.
XX CC This invention describes a novel antisense compound (I) 8-30 nucleobases
XX CC in length targeted to a polynucleotide encoding human telomeric repeat
XX CC binding factor 2 (II) which specifically hybridizes with, and inhibits
XX CC the expression of (II). (I) is useful for treating a human having a
XX CC disease or condition associated with (II) such as premature aging or a
XX CC hyperproliferative disorder especially cancer, by inhibiting the
XX CC expression of (II) in human cells or tissues. (I) is useful for
XX CC diagnostics, therapeutics, prophylaxis and as research reagents and kits.
XX CC The products of the invention have cytostatic activity. This sequence
XX CC represents an antisense oligonucleotide used to illustrate the method of
XX CC the invention
XX SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2758 TCTCGCTCTGTACCC 2773
DB 16 TCTCGCTCTGTACCC 1
RESULT 2205
ADM15337/c
ID ADM15337 standard; DNA; 20 BP.
XX AC ADM15337;
XX DT 01-JUL-2004 (first entry)
XX DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1524.
XX KW chimeric; antisense oligonucleotide; phosphorothioate; human;
XX KW microsomal prostaglandin E2 synthase inhibitor; mPGES-1 inhibitor;
XX KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
XX KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
XX KW immunomodulatory; cardiovascular; gene therapy; inflammation;
XX KW Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
XX KW reperfusion injury; ophthalmic disorder; immunological disorder;
XX KW cardiovascular disorder; neurological disorder; ss.
XX OS Homo sapiens.
XX OS Synthetic.
XX PH Key Location/Qualifiers
XX FT modified_base 1..20
XX FT /*tag= b
XX FT /mod_base= OTHER
XX FT /note= "phosphorothioate linkages and all cytidine
XX FT residues are 5-methylcytidines"
```

```
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX PN WO2004028458-A2.
XX XX
XX PD 08-APR-2004.
XX PF 25-SEP-2003; 2003WO-US030374.
XX PR 25-SEP-2002; 2002US-0413549P.
XX PA (PHAA ) PHARMACIA CORP.
XX PI Gierse JK;
XX PD WPI; 2004-305094/28.
XX DR
XX PF New antisense compound, having a sequence targeted to a nucleic acid
XX FT encoding mPGES-1, useful for preparing a composition for treating e.g.,
XX FT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
XX FT ischemia.
XX PS Claim 4; SEQ ID NO 1524; 132pp; English.
XX CC The present sequence represents a chimeric antisense oligonucleotide
XX CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
XX CC human mPGES-1 gene is located on chromosome 9, more specifically to
XX CC 9q34.3. The present invention also describes: (1) antisense compounds,
XX CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
XX CC mPGES-1, which specifically hybridise with the nucleic acid mPGES-1 and
XX CC inhibits its expression; (2) a method of inhibiting the expression of
XX CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
XX CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
XX CC antisense oligonucleotides and antisense compounds have cytostatic,
XX CC antidiabetic, immunomodulator, cardiant, neuroprotective,
XX CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
XX CC ophthalmological, immunomodulatory and cardiovascular activities, and can
XX CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
XX CC can be used for preparing a composition for treating a disease or
XX CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
XX CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
XX CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX SQ Sequence 20 BP; 6 A; 6 C; 4 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2852 TCCTGAGTAGCTGGGA 2867
DB 20 TCCTGAGTAGCTGGGA 5
RESULT 2206
ADM15017/c
ID ADM15017 standard; DNA; 20 BP.
XX AC ADM15017;
XX XX
XX DT 01-JUL-2004 (first entry)
XX DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1204.
XX KW chimeric; antisense oligonucleotide; phosphorothioate; human;
XX KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
XX KW microsomal prostaglandin E2 synthase inhibitor; cytostatic; antidiabetic;
```

KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
 KW neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
 KW immunomodulatory; cardiovascular; gene therapy; inflammation;
 KW Alzheimer's disease; arthritic; diabetes; cancer; ischaemia;
 KW reperfusion injury; ophthalmic disorder; immunological disorder;
 KW cardiovascular disorder; neurological disorder; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "phosphorothioate linkages and all cytidine
 residues are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-O-methoxyethyls"
 FT
 XX WO2004028458-A2.
 XX
 XX
 PD 08-APR-2004.
 XX
 XX 25-SEP-2003; 2003WO-US030374.
 XX
 XX 25-SEP-2002; 2002US-0413549P.
 XX
 XX (PHAA) PHARMACIA CORP.
 XX
 FI Gierse JK;
 XX
 DR WPI; 2004-305094/28.
 XX
 XX New antisense compound, having a sequence targeted to a nucleic acid
 PT encoding mPGES-1, useful for preparing a composition for treating e.g.,
 PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
 PT ischemia.
 XX
 PS Claim 4; SEQ ID NO 1204; 132pp; English.
 XX
 CC The present sequence represents a chimeric antisense oligonucleotide
 CC targeted to human microsomal prostaglandin E2 synthase (mPGES-1). The
 CC human mPGES-1 gene is located on chromosome 9, more specifically to
 CC 9q34.3. The present invention also describes: (1) antisense compounds,
 CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
 CC mPGES-1, which specifically hybridize with the nucleic acid mPGES-1 and
 CC inhibits its expression; (2) a method of inhibiting the expression of
 CC mPGES-1 in cells or tissues; and (3) a method of treating an animal
 CC having a disease or condition associated with mPGES-1. mPGES-1 chimeric
 CC antisense oligonucleotides and antisense compounds have cytostatic,
 CC antidiabetic, immunomodulator, cardiant, neuroprotective,
 CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
 CC ophthalmological, immunomodulatory and cardiovascular activities, and can
 CC be used as mPGES-1 inhibitors and in gene therapy. The antisense compound
 CC can be used for preparing a composition for treating a disease or
 CC condition associated with mPGES-1 e.g., inflammation, Alzheimer's
 CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
 CC ophthalmic, immunological, cardiovascular or neurological disorder.
 XX
 SQ Sequence 20 BP; 8 A; 8 C; 3 G; 1 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+03;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2734 GTGTGTGTGTGTGTGTGT 2749
 ||||||||||||||||

Db 16 GTGTGTGTGTGTGTGT 1
 RESULT 2207
 ADT00407/c
 ID ADT00407 standard; DNA; 20 BP.
 XX
 AC
 ADT00407;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID395.
 XX
 KW tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
 KW tumorigenesis; somatic alteration; colorectal cancer; NTRK3; PES;
 KW GUCY2F; MCKK; MLK4; kinase domain; cytostatic; tyrosine kinase inhibitor;
 KW guanylate cyclase stimulator; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004082458-A2.
 XX
 PD 30-SEP-2004.
 XX
 PF 18-FEB-2004; 2004WO-US004452.
 XX
 XX 21-FEB-2003; 2003US-0448537P.
 PR 29-MAY-2003; 2003US-0473895P.
 XX
 XX (UYJO) UNIV JOHNS HOPKINS.
 PA
 XX
 PI Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;
 XX WPI; 2004-718702/70.
 DR
 XX
 PT Activated mutant protein tyrosine kinases (e.g. NTRK3, PES and MCKK) and
 PT associated methods for diagnosing cancer and screening for anti-cancer
 PT agents.
 XX
 PS Disclosure; SEQ ID NO 395; 363pp; English.
 XX
 CC This invention relates to a novel activated mutant protein tyrosine
 CC kinases and associated methods for diagnosing cancer and screening for
 CC anti-cancer agents. Protein kinases are signalling molecules involved in
 CC tumorigenesis. Mutational analysis of the human tyrosine kinase gene
 CC family identified somatic alteration sin 1 in 5 colorectal cancers, with
 CC the majority of mutations occurring in the NTRK3, PES, GUCY2F and
 CC MCKK/MLK4 genes. Most were identified in the kinase domain. The invention
 CC may be useful for the production of compounds with a cytostatic activity
 CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
 CC stimulators. The invention may be useful for developing methods for
 CC detecting mutations involved in cancer or screening for anti-cancer
 CC agents. The present sequence is that of a human-derived oligonucleotide
 CC which is related to the invention.
 XX
 SQ Sequence 20 BP; 5 A; 4 C; 8 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 16; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+03;
 Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2758 TCTCGTCTGTGTACCC 2773
 ||||||||||||||||
 Db 16 TCTCGTCTGTGTACCC 1
 RESULT 2208
 AAQ82623/c
 ID AAQ82623 standard; DNA; 19 BP.
 XX
 AC AAQ82623;
 XX
 DT 25-MAR-2003 (revised)

```

DT 14-SEP-1995 (first entry)
XX Chromosome 11 (locus D11S964) STS primer UT544a.
DE sequence sampled mapping; genomic analysis; complex genome mapping;
XX cosmid library; chromosome 11; sequence tagged site; STS analysis; ss.
KW Synthetic.
XX WO9429486-A1.
XX 22-DEC-1994.
XX 15-JUN-1994; 94WO-US006810.
XX 15-JUN-1993; 93US-00078471.
XX 07-SEP-1993; 93US-00117952.
XX (SALK ) SALK INST BIOLOGICAL STUDIES.
PA Evans GA, Smith MW;
XX WPI; 1995-036508/05.
XX Sequencing complex genomes, present as fragments in a cosmid library - by
PT sequencing end-specific nucleotides of each clone then correlating with
PT spatial relationship of cosmid, esp. for mammalian chromosomes.
XX Example 4; Page 90; 128pp; English.
XX Sequences were determined from the ends of chromosome 11-specific cosmids
CC by automated sequencing without intermediate subcloning. A sample of 371
CC DNA sequence fragments were determined and of these, 277 were suitable
CC for STS primer prediction by computer analysis (using the "primer"
CC program available from E.Lander, Mir). The STSs and cosmids were mapped
CC by in situ hybridisation, somatic cell hybrid analysis or both. Using
CC this method, 370 STSs specific for human chromosome 11 were generated and
CC most of them were regionally mapped. This procedure illustrates a novel
CC method for sequencing complex genomes, designated "sequence sampled
CC mapping". The sequence sampled mapping method is useful for the
CC completion of high density sequence-based maps, and ultimately, for the
CC complete sequencing of genomic DNA directly from cosmid clones. See
CC AQ82001-Q82706 and AQ91325-Q91358 for STS primers. (Updated on 25-MAR-
CC 2003 to correct PN field.)
XX Sequence 19 BP; 4 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2765 CTGTACCCAGCGTGGAGT 2783
Db 19 CTGTACCCAGCGTGAAGT 1
RESULT 2209
AAZ35377/C
ID AAZ35377 standard; DNA; 19 BP.
XX AAZ35377;
AC AAZ35377;
XX 27-MAR-2000 (first entry)
XX Interspersed repeated sequence PCR primer ALU3'.
DE Human; absorptive hypercalciuria; osteoporosis; nephrolithiasis;
KW osteopathic; anticalciuric; chromosome 1q23.3-q24; therapy; diagnosis;
XX PCR primer; ss.
XX Homo sapiens.
XX WO9967426-A1.
PN

```

```

XX 29-DEC-1999.
XX 23-JUN-1999; 99WO-US014347.
XX 23-JUN-1998; 98US-0090348P.
XX (TEXA ) UNIV TEXAS SYSTEM.
XX Reed-Gitomer BY, Pak CYC;
XX WPI; 2000-116959/10.
XX Novel genomic region useful in screening for absorptive hypercalciuria or
PT osteoporosis with hypercalciuria.
XX Example 3; Page 125; 153pp; English.
XX The present sequence is that of interspersed repeated sequence PCR (IRS-
CC PCR) primer ALU3' used to identify human-specific sequences in yeast
CC artificial chromosomes (YAC) derived from the human chromosome 1q23.3-q24
CC region. The chromosomal region contains the locus associated with
CC absorptive hypercalciuria (AH). IRS-PCR fingerprints were generated, and
CC genes contained within YACs were identified by exon trapping. cDNA
CC corresponding to the AH gene was isolated (see AAZ35376). Identification
CC of the AH genomic region allows genetic screening for increased risk of
CC developing AH or osteoporosis with hypercalciuria
XX Sequence 19 BP; 3 A; 9 C; 4 G; 3 T; 0 U; 0 Other;
SQ Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2779 GGAGTGCAGTGGTGAATC 2797
Db 19 GGAGTGCAGTGGCGGATC 1
RESULT 2210
ADE43498/C
ID ADE43498 standard; DNA; 19 BP.
XX ADE43498;
AC ADE43498;
XX 29-JAN-2004 (first entry)
DT Human IDE PCR primer, SEQ ID 103.
XX Neurodegenerative disease; uPA; SNCG; IDE; KNSLI; LIPA; TNFRSF6;
KW Alzheimer's disease; neuroprotective; nootropic; gene therapy;
XX Chromosome 10; PCR; primer; ss.
XX Homo sapiens.
XX WO2003054143-A2.
XX 03-JUL-2003.
XX 25-OCT-2002; 2002WO-US034679.
XX 25-OCT-2001; 2001US-0339525P.
XX 08-NOV-2001; 2001US-0336929P.
XX 08-NOV-2001; 2001US-0338010P.
XX 09-NOV-2001; 2001US-0338363P.
XX 04-DEC-2001; 2001US-0337052P.
XX 28-MAR-2002; 2002US-0368919P.
XX (NEUR-) NEUROGENETICS INC.
PA (GEO ) GEN HOSPITAL CORP.
XX Becker KD, Velicelebi G, Elliott KJ, Wang X, Tanzi RE, Bertram L;
PI Saunders AJ, Mullin KM, Sampson AJ, Blacker DL;

```

XX DR WPI; 2003-559131/52.
 XX
 PT Determining a predisposition for or the occurrence of neurodegenerative
 PT disease, e.g. Alzheimer's disease by detecting in a target nucleic acid
 PT the presence or absence of an allelic variant of one or more polymorphic
 PT regions.
 XX
 PS Example 3; Page 274; 848pp; English.
 XX
 CC The present invention relates to a method (M1) for determining a
 CC predisposition for or the occurrence of neurodegenerative disease in a
 CC subject. The method comprises detecting in a target nucleic acid obtained
 CC from the subject the presence or absence of an allelic variant of one or
 CC more polymorphic regions of one or more genes selected from UPA
 CC (urokinase plasminogen activator), SNCG (gamma-synuclein), IDE (insulin-
 CC degrading enzyme), KNSL1 (Kinesin-like protein 1), LIPA (lysosomal acid
 CC lyase), and TNFRSF6 (Tumour Necrosis Factor Receptor-SF6), where the
 CC presence of at least one of the allelic variant of one or more
 CC polymorphic regions is indicative of a predisposition for or the
 CC occurrence of neurodegenerative disease. The genes are all located on
 CC chromosome 10. M1 is useful for determining a predisposition for or the
 CC occurrence of, and for treating neurodegenerative disease, particularly
 CC Alzheimer's disease. The present sequence is a PCR primer, which was used
 CC in the method of the invention.
 XX
 SQ Sequence 19 BP; 6 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.6e+03;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 2828 TCAGTGATCTCCCACT 2846
 |||||
 Db 19 TGAATTGATCTCCCACT 1
 RESULT 2211
 ACA88902/c
 ID ACA88902 standard; DNA; 19 BP.
 XX
 AC ACA88902;
 XX
 DT 08-JUL-2003 (first entry)
 XX
 DE Selection and amplification of genetic markers PCR related primer #13.
 XX
 KW Genetic marker selection; multiplex PCR amplification;
 KW prenatal diagnostic testing; foetal sex determination;
 KW genetic identification; DNA profiling; DNA fingerprinting;
 KW forensic analysis; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003031646-A1.
 XX
 PD 17-APR-2003.
 XX
 PF 14-OCT-2002; 2002WO-AU001388.
 XX
 PR 12-OCT-2001; 2001AU-00008234.
 PR 12-OCT-2001; 2001AU-00008235.
 XX
 PA (UYQU) UNIV QUEENSLAND.
 XX
 PI Findlay I, Matthews PL, Mulcahy BK;
 XX
 DR WPI; 2003-381725/36.
 XX
 CC Selecting genetic markers as targets for nucleic acid sequence
 PT amplification, useful for improving genetic testing, e.g. fetal sex
 PT determination, comprises selecting each of the genetic markers according
 PT to a heterozygosity index.

XX
 PS Claim 36; Page 39; 64pp; English.
 XX
 CC The invention describes a method of selecting genetic markers as targets
 CC for nucleic acid sequence amplification comprising selecting each of the
 CC genetic markers according to a heterozygosity index of 0.5 or greater.
 CC Selecting and amplification of genetic markers are useful as targets for
 CC nucleic acid sequence amplification, for genetic testing or facilitating
 CC multiplex PCR amplification from limiting amounts of target nucleic acid.
 CC The methods are also useful for improving genetic diagnostic and
 CC screening methods, such as prenatal diagnostic testing, foetal sex
 CC determination or genetic identification, e.g. DNA profiling or DNA
 CC fingerprinting. The nucleic acid sequence amplification is also useful in
 CC forensic analysis of degraded, old, ancient and difficult samples that
 CC are difficult to amplify and identify. This sequence represents a PCR
 CC primer used in the selection and amplification of genetic markers
 XX
 SQ Sequence 19 BP; 3 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.6e+03;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 2768 TCACCCAGGCTCGAGTCA 2786
 |||||
 Db 19 TCACCCAGGCTCGAGTCA 1
 RESULT 2212
 ACA58281/c
 ID ACA58281 standard; DNA; 19 BP.
 XX
 AC ACA58281;
 XX
 DT 09-JUN-2003 (first entry)
 XX
 DE Human familial bipolar affective disorder chromosome marker primer #229.
 XX
 KW Human; genotype determination; familial bipolar affective disorder;
 KW chromosomal region linked; locus associated with resistance; D4S402;
 KW D4S424; D4S431; D4S404; D11S394; D11S29; chromosome marker; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002192655-A1.
 XX
 PD 19-DEC-2002.
 XX
 PF 13-JUN-2001; 2001US-00881012.
 XX
 PR 29-MAR-1996; 96US-0014334P.
 PR 20-OCT-1997; 97US-0062924P.
 PR 19-OCT-1998; 98US-00175158.
 XX
 PA (GINN/) GINNS E I.
 PA (EGEL/) EGELAND J A.
 PA (PAUL/) PAUL S M.
 XX
 PI Ginn EI, Egeland JA, Paul SM;
 XX
 DR WPI; 2003-352708/33.
 XX
 PT Determining a genotype associated with increased or decreased resistance
 PT to familial bipolar affective disorder in a family comprises determining
 PT the genotype of e.g., chromosomal regions D4S402 and D4S424.
 XX
 PS Disclosure; Page 12; 79pp; English.
 XX
 CC The present invention relates to a method of determining a genotype
 CC associated with increased or decreased resistance to familial bipolar
 CC affective disorder. The method comprises determining the genotype with at
 CC least one marker of at least one chromosomal region linked to a locus
 CC associated with resistance to bipolar affective disorder, where the

CC chromosomal regions are included of and localised between D4S402 and
CC D4S424, D4S431 and D4S404, or D11S394 and D11S29. The invention also
CC discloses a kit for determining a genotype associated with increased or
CC decreased resistance to familial bipolar affective disorder, where the
CC kit comprises markers for two or more of the chromosomal regions cited.
CC The method and kit are useful for determining a genotype associated with
CC increased or decreased resistance to familial bipolar affective disorder
CC in a family affected by bipolar affective disorder, for determining the
CC contribution of these chromosomal regions to bipolar affective disorder
CC in an affective family member, and for assessing an increased or
CC decreased risk of developing bipolar illness for a tested individual from
CC an affected family. ACA58053-ACA58292 represent primers used in the
CC present invention
XX
SQ Sequence 19 BP; 3 A; 5 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2768 TCACCCAGGCTGGAGTCCA 2786
DB 19 TCACCCAGGCTGGAGTCCA 1
RESULT 2213
ADMT77315/C
ID ADM77315 standard; DNA; 19 BP.
XX
AC ADM77315;
XX
DT 03-JUN-2004 (first entry)
DE Human fibrocystin (PKHD1) gene DHPLC PCR primer #23.
XX
XX human; fibrocystin;
KW treating autosomal recessive polycystic kidney disease; PKHD1; DHPLC PCR;
KW ss; primer.
XX
XX Homo sapiens.
XX OS
XX WO2003062453-A2.
XX
XX 31-JUL-2003.
XX
XX 23-JAN-2003; 2003WO-US002038.
XX
XX 23-JAN-2002; 2002US-0351110P.
XX
XX (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
XX
XX Harris PC, Ward CJ, Rossetti S, Torres VE;
XX WPI; 2003-618286/58.
XX
XX New isolated nucleic acid comprising a sequence encoding a fibrocystin
PT polypeptide, useful for diagnosing and treating autosomal recessive
PT polycystic kidney disease.
XX
XX Example 4; SEQ ID NO 70; 136pp; English.
XX
XX The invention comprises the amino acid and coding sequences of
CC fibrocystin proteins. The DNA and protein sequences of the invention are
CC useful for diagnosing and treating autosomal recessive polycystic kidney
CC disease. The present DNA sequence represents a DHPLC PCR primer that was
CC used to screen for mutations in the human fibrocystin (PKHD1) gene.
XX
SQ Sequence 19 BP; 8 A; 9 C; 0 G; 2 T; 0 U; 0 Other;
Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTATG 2746
DB 19 GTATGTGTGTGTGTGTATG 1
RESULT 2214
ADMT4391/C
ID ADM4391 standard; RNA; 19 BP.
XX
XX ADM4391;
XX
DT 01-JUL-2004 (first entry)
DE Human interleukin-2-targeted siNA upper strand SEQ ID NO:126.
XX
XX cytostatic; vasotropic; nephrotropic; cancer; restenosis;
KW polycystic kidney disease; RNA interference;
KW short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW expression modulation; gene therapy; drug screening; diagnosis;
KW therapeutic target identification; pharmacogenomics;
KW gene function analysis; gene mapping; human; interleukin-2; ss.
XX
XX Homo sapiens.
XX
XX WO2003070744-A1.
XX
XX 28-AUG-2003.
XX
XX 11-FEB-2003; 2003WO-US004566.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX McSwiggen J, Beigelman L, Thompson J;
XX WPI; 2003-731546/69.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of an interleukin gene.
XX
XX Example 3; SEQ ID NO 126; 138pp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human interleukin-2 gene by RNA
CC interference. The siNAs may or may not comprise ribonucleotides and may
CC be double or single stranded. They further comprise sense and antisense
CC regions, or alternatively are assembled from a sense oligonucleotide and
CC an antisense oligonucleotide. Specifically, the siNAs include short
CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
CC hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
CC can contain deoxyribonucleotides, and can be chemically synthesised,
CC expressed from a vector or enzymatically synthesised. The invention also
CC relates to kits for the in vitro or in vivo delivery of siRNA; conjugates
CC and/or complexes of siRNA; and vectors that express siNA. The siNAs are
CC used to modulate expression of the interleukin-2 gene in cells, tissue
CC explants or organisms (e.g., by ex vivo gene therapy), or in grafts and
CC transplants for the treatment of a variety of conditions. They may be
CC used for treating cancer, restenosis and polycystic kidney disease. The
CC siNAs are also useful for drug screening, diagnosis, therapeutic target
CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents the upper strand of a
CC human interleukin-2-targeted double-stranded siNA, which is identical to
CC the interleukin-2 transcript target sequence.
XX

```
SQ Sequence 19 BP; 4 A; 8 C; 5 G; 0 T; 2 U; 0 Other;
Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.6e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2767 GTCACCCAGGCTGGAGTGC 2785
DB 19 GTTCCCGAGGCTGGAGTGC 1

RESULT 2215
AD014519
ID AD014519 standard; RNA; 19 BP.
XX
AC AD014519;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human interleukin-2-targeted siNA lower strand SEQ ID NO:254.
XX
KW cytostatic; vasotropic; nephrotropic; cancer; restenosis;
KW polycystic kidney disease; RNA interference;
KW short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW expression modulation; gene therapy; drug screening; diagnosis;
KW therapeutic target identification; pharmacogenomics;
KW gene function analysis; gene mapping; human; interleukin-2; ss.
XX
OS Homo sapiens.
XX
PN WO2003070744-A1.
XX
PD 28-AUG-2003.
XX
PF 11-FEB-2003; 2003WO-US004566.
XX
PR 20-FEB-2002; 2002US-0358580P.
XX
PR 11-MAR-2002; 2002US-0363124P.
XX
PR 06-JUN-2002; 2002US-0386782P.
XX
PR 29-AUG-2002; 2002US-0406784P.
XX
PR 05-SEP-2002; 2002US-0408378P.
XX
PR 09-SEP-2002; 2002US-0409293P.
XX
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Thompson J;
XX
DR WPI; 2003-731546/69.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
diagnosis of cancer, downregulates expression of an interleukin gene.
XX
PS Example 3; SEQ ID NO 254; 138pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
downregulate expression of the human interleukin-2 gene by RNA
interference. The siNAs may or may not comprise ribonucleotides and may
be double or single stranded. They further comprise sense and antisense
regions, or alternatively are assembled from a sense oligonucleotide and
an antisense oligonucleotide. Specifically, the siNAs include short
interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
can contain deoxyribonucleotides, and can be chemically synthesised,
expressed from a vector or enzymatically synthesised. The invention also
relates to kits for the in vitro or in vivo delivery of siRNA; conjugates
and/or complexes of siRNA; and vectors that express siNA. The siNAs are
used to modulate expression of the interleukin-2 gene in cells, tissue
explants or organisms (e.g., by ex vivo gene therapy), or in grafts and
transplants for the treatment of a variety of conditions. They may be
used for treating cancer, restenosis and polycystic kidney disease. The
siNAs are also useful for drug screening, diagnosis, therapeutic target
```

```
CC identification and validation, genetic engineering, pharmacogenomics,
CC studying gene function, and gene mapping (e.g., of single nucleotide
CC polymorphisms). The present sequence represents the lower strand of a
CC human interleukin-2-targeted double-stranded siNA.
XX
SQ Sequence 19 BP; 2 A; 5 C; 8 G; 0 T; 4 U; 0 Other;
Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.6e+03;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2767 GTCACCCAGGCTGGAGTGC 2785
DB 1 GUUGCCCGAGGCTGGAGTGC 19

RESULT 2216
AD014515
ID AD014515 standard; RNA; 19 BP.
XX
AC AD014515;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human interleukin-2-targeted siNA lower strand SEQ ID NO:250.
XX
KW cytostatic; vasotropic; nephrotropic; cancer; restenosis;
KW polycystic kidney disease; RNA interference;
KW short interfering nucleic acid; siNA; short interfering RNA; siRNA;
KW double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
KW expression modulation; gene therapy; drug screening; diagnosis;
KW therapeutic target identification; pharmacogenomics;
KW gene function analysis; gene mapping; human; interleukin-2; ss.
XX
OS Homo sapiens.
XX
PN WO2003070744-A1.
XX
PD 28-AUG-2003.
XX
PF 11-FEB-2003; 2003WO-US004566.
XX
PR 20-FEB-2002; 2002US-0358580P.
XX
PR 11-MAR-2002; 2002US-0363124P.
XX
PR 06-JUN-2002; 2002US-0386782P.
XX
PR 29-AUG-2002; 2002US-0406784P.
XX
PR 05-SEP-2002; 2002US-0408378P.
XX
PR 09-SEP-2002; 2002US-0409293P.
XX
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Mcswiggen J, Beigelman L, Thompson J;
XX
DR WPI; 2003-731546/69.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
diagnosis of cancer, downregulates expression of an interleukin gene.
XX
PS Example 3; SEQ ID NO 250; 138pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
downregulate expression of the human interleukin-2 gene by RNA
interference. The siNAs may or may not comprise ribonucleotides and may
be double or single stranded. They further comprise sense and antisense
regions, or alternatively are assembled from a sense oligonucleotide and
an antisense oligonucleotide. Specifically, the siNAs include short
interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short
hairpin RNA (shRNA). The siNAs can be unmodified or chemically modified,
can contain deoxyribonucleotides, and can be chemically synthesised,
expressed from a vector or enzymatically synthesised. The invention also
relates to kits for the in vitro or in vivo delivery of siRNA; conjugates
and/or complexes of siRNA; and vectors that express siNA. The siNAs are
used to modulate expression of the interleukin-2 gene in cells, tissue
explants or organisms (e.g., by ex vivo gene therapy), or in grafts and
transplants for the treatment of a variety of conditions. They may be
used for treating cancer, restenosis and polycystic kidney disease. The
siNAs are also useful for drug screening, diagnosis, therapeutic target
```

CC used to modulate expression of the interleukin-2 gene in cells, tissue
 CC explants or organisms (e.g., by ex vivo gene therapy), or in grafts and
 CC transplants for the treatment of a variety of conditions. They may be
 CC used for treating cancer, restenosis and polycystic kidney disease. The
 CC siRNAs are also useful for drug screening, diagnosis, therapeutic target
 CC identification and validation, genetic engineering, pharmacogenomics,
 CC studying gene function, and gene mapping (e.g., of single nucleotide
 CC polymorphisms). The present sequence represents the lower strand of a
 CC human interleukin-2-targeted double-stranded siRNA.
 XX

SQ Sequence 19 BP; 2 A; 9 C; 3 G; 0 T; 5 U; 0 Other;
 Query Match 0.5%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 69.4%; Pred. No. 1.6e+03;
 Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
 QY 2839 TCCACCTCAGCCTCCTGA 2857
 :|||:|||||:|||||
 Db 1 UCCUGCCUACGCCUCCUGA 19

RESULT 2217
 AD014387/c
 ID AD014387 standard; RNA; 19 BP.
 XX
 AC AD014387;
 XX
 DT 01-JUL-2004 (first entry)
 XX
 DE Human interleukin-2-targeted siNA upper strand SEQ ID NO:122.
 XX
 KW cytostatic; vasotropic; nephrotropic; cancer; restenosis;
 KW polycystic kidney disease; RNA interference;
 KW short interfering nucleic acid; siNA; short interfering RNA; siRNA;
 KW double-stranded RNA; micro-RNA; miRNA; short hairpin RNA; shRNA;
 KW expression modulation; gene therapy; drug screening; diagnosis;
 KW therapeutic target identification; pharmacogenomics;
 KW gene function analysis; gene mapping; human; interleukin-2; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2003070744-A1.
 XX
 PD 28-AUG-2003.
 XX
 PF 11-FEB-2003; 2003WO-US004566.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J, Beigelman L, Thompson J;
 XX
 DR WPI; 2003-731546/69.
 XX
 PT New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of cancer, downregulates expression of an interleukin gene.
 XX
 PS Example 3; SEQ ID NO 122; 138pp; English.
 XX
 CC The invention relates to short interfering nucleic acids (siNA) which
 CC downregulate expression of the human interleukin-2 gene by RNA
 CC interference. The siRNAs may or may not comprise ribonucleotides and may
 CC be double or single stranded. They further comprise sense and antisense
 CC regions, or alternatively are assembled from a sense oligonucleotide and
 CC an antisense oligonucleotide. Specifically, the siRNAs include short
 CC interfering RNA (siRNA), double-stranded RNA, micro-RNA (miRNA) and short

CC hairpin RNA (shRNA). The siRNAs can be unmodified or chemically modified,
 CC can contain deoxyribonucleotides, and can be chemically synthesised,
 CC expressed from a vector or enzymatically synthesised. The invention also
 CC relates to kits for the in vitro or in vivo delivery of siRNA; conjugates
 CC and/or complexes of siRNA; and vectors that express siNA. The siRNAs are
 CC used to modulate expression of the interleukin-2 gene in cells, tissue
 CC explants or organisms (e.g., by ex vivo gene therapy), or in grafts and
 CC transplants for the treatment of a variety of conditions. They may be
 CC used for treating cancer, restenosis and polycystic kidney disease. The
 CC siRNAs are also useful for drug screening, diagnosis, therapeutic target
 CC identification and validation, genetic engineering, pharmacogenomics,
 CC studying gene function, and gene mapping (e.g., of single nucleotide
 CC polymorphisms). The present sequence represents the upper strand of a
 CC human interleukin-2-targeted double-stranded siRNA, which is identical to
 CC the interleukin-2 transcript target sequence.
 XX

SQ Sequence 19 BP; 5 A; 3 C; 9 G; 0 T; 2 U; 0 Other;
 Query Match 0.5%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.6e+03;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2839 TCCACCTCAGCCTCCTGA 2857
 |||:|||||:|||||
 Db 19 TCCTGCCTCAGCCTCCTGA 1

RESULT 2218
 ADH53976/c
 ID ADH53976 standard; DNA; 19 BP.
 XX
 AC ADH53976;
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Human neurodegenerative disease-related PCR primer SeqID103.
 XX
 KW human; neurodegenerative disease; urokinase plasminogen activator; uPA;
 KW gamma-synuclein; SNCG; insulin degrading enzyme; IDE;
 KW kinesin-like protein 1; KNSL1; lysosomal acid lipase; LIPA;
 KW tumour necrosis factor receptor SF6; TNFRSF6; Alzheimer's disease; PCR;
 KW primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003224380-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 25-OCT-2002; 2002US-00282174.
 XX
 PR 25-OCT-2001; 2001US-0339525P.
 PR 25-OCT-2001; 2001US-0348065P.
 PR 02-NOV-2001; 2001US-0336983P.
 PR 08-NOV-2001; 2001US-0336929P.
 PR 08-NOV-2001; 2001US-0338010P.
 PR 09-NOV-2001; 2001US-0338363P.
 PR 04-DEC-2001; 2001US-0337052P.
 PR 28-MAR-2002; 2002US-0368919P.
 XX
 PA (GEHO) GEN HOSPITAL CORP.
 XX
 PI Becker KD, Velicelebi G, Elliott KJ, Wang X, Tanzi RE;
 PI Bertram L, Saunders AJ, Mullin KM, Sampson AJ;
 XX
 DR WPI; 2004-060538/06.
 XX
 PT Determining a predisposition for or the occurrence of neurodegenerative
 PT disease, particularly Alzheimer's disease, comprises determining the
 PT presence of a polymorphism in the uPA, SNCG, IDE, KNSL1, LIPA or TNFRSF6
 PT gene.
 XX
 PS Example 3; SEQ ID NO 103; 205pp; English.

XX This invention relates to a novel method of determining a predisposition
 CC for or the occurrence of neurodegenerative disease comprising detecting
 CC in a target nucleic acid obtained from the subject the presence of an
 CC allelic variant of polymorphic regions of human genes selected from
 CC urokinase plasminogen activator (uPA), gamma-synuclein (SNCG), insulin
 CC degrading enzyme (IDE), kinesin-like protein 1 (KNSL1), lysosomal acid
 CC lipase (LIPA) and tumour necrosis factor receptor SF6 (TNFRSF6). The
 CC method is useful in determining the presence or predisposition to a
 CC neurodegenerative disease, particularly Alzheimer's disease. The present
 CC sequence is that of a PCR primer which was used for amplification of a
 CC region of the human IDE gene in the exemplification of the invention.
 XX
 SQ Sequence 19 BP; 6 A; 2 C; 7 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.6e+03;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 2828 TCAAGTGATCTCCCACT 2846
 Db 19 TGAATTGATCTCCCACT 1
 RESULT 2219
 ADM66491/C
 ID ADM66491 standard; DNA; 19 BP.
 XX
 AC ADM66491;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE Human short tandem repeat (STR) marker DYS385 PCR primer #1.
 XX
 KW ss; PCR; primer; ethnic origin; human; short tandem repeat; STR marker;
 KW Y-chromosome; Caucasian; Afro-Caribbean; south Asian; African-American;
 KW Japanese; ethnic profiling; rape allegation.
 XX
 OS Homo sapiens.
 XX
 XN US2003224372-A1.
 XX
 PD 04-DEC-2003.
 XX
 XX 31-MAY-2002; 2002US-00160436.
 XX
 XX 31-MAY-2002; 2002US-00160436.
 XX
 PA (SYND/) SYNDERCOMBE-COURT D.
 XX
 PI Syndercombe-Court D;
 XX
 DR WPT; 2004-033952/03.
 XX
 PT Identifying ethnic origin of humans, e.g., Caucasian, Japanese by
 PT assaying biological sample from subject for presence of at least three
 PT short tandem repeat markers in DNA of Y-chromosome of subject.
 XX
 PS Disclosure; Page 2; 6pp; English.
 XX
 CC The invention relates to a method of identifying ethnic origin of human
 CC subject comprising assaying a biological sample from subject for presence
 CC of at least three short tandem repeat (STR) markers in DNA of Y-
 CC chromosome, which are DYS438, DYS385, and DYS390 and ethnic origin is
 CC Caucasian, Afro-Caribbean, or south Asian or STR DYS385 in DNA of Y-
 CC chromosome, where ethnic origin is Caucasian, Afro-Caribbean (African-
 CC American), Japanese or south Asian. The method is useful for identifying
 CC ethnic origin of a human subject, where the ethnic origin is chosen from
 CC Caucasian, Afro-Caribbean (African-American), Japanese or south Asian.
 CC The methods are used to assay a mixed population of human individuals to
 CC determine the ethnic origin of subjects in the mixed population, and also
 CC for identifying an individual subject's ethnic origin by comparison to a
 CC local reference population or with respect to a control population.

CC Ethnic profiling in humans can be improved by the selection of STR
 CC markers from a non-autosomal chromosome, e.g., the Y-chromosome in the
 CC case of male individuals. Y-chromosome markers can provide additional
 CC benefits over autosomal STRs e.g. assisting in complex relationship
 CC studies and providing additional and more sensitive information about
 CC individuals involved in an allegation of rape that can be used for the
 CC intelligence purposes. The STR markers provide a means for identifying
 CC the ethnic origin of an individual in which the statistical model used
 CC provides reasonably accurate results with the advantage of a simple assay
 CC being used with only three markers required. The present sequence
 CC represents a human short tandem repeat (STR) marker DYS385 PCR primer.
 XX
 SQ Sequence 19 BP; 6 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.6e+03;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 2760 TCGCTCTGTCCACCGGCT 2778
 Db 19 TAGCTCTGTCCACCGGCT 1
 RESULT 2220
 ADR80868
 ID ADR80868 standard; DNA; 19 BP.
 XX
 AC ADR80868;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human glucose-6-phosphatase oligonucleotide seqid 5367.
 XX
 KW antilipemic; cardiant; vasotropic; antidiabetic; antidiabetic;
 KW cycostatic; anticonvulsant; nootropic; muscular; anti-HIV;
 KW RNA interference; RNA; antisense technology; lipid metabolism;
 KW cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
 KW coronary artery disease; CAD; coronary heart disease; CHD;
 KW atherosclerosis; hepatic glucose production;
 KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
 KW colon cancer; lung cancer; neurological disease; Huntington disease;
 KW spinocerebellar ataxia; viral disease; AIDS; glucose-6-phosphatase; ss.
 XX
 OS Homo sapiens.
 XX
 XN W02004080406-A2.
 XX
 PD 23-SEP-2004.
 XX
 XX 08-MAR-2004; 2004WO-US007070.
 XX
 PR 07-MAR-2003; 2003US-0452682P.
 PR 12-MAR-2003; 2003US-0454265P.
 PR 13-MAR-2003; 2003US-0454962P.
 PR 13-MAR-2003; 2003US-0455050P.
 PR 14-APR-2003; 2003US-0462894P.
 PR 17-APR-2003; 2003US-0463772P.
 PR 25-APR-2003; 2003US-0465665P.
 PR 25-APR-2003; 2003US-0465802P.
 PR 09-MAY-2003; 2003US-0469612P.
 PR 08-AUG-2003; 2003US-0493986P.
 PR 11-AUG-2003; 2003US-0494597P.
 PR 26-SEP-2003; 2003US-0506341P.
 PR 09-OCT-2003; 2003US-0510246P.
 PR 10-OCT-2003; 2003US-0510318P.
 PR 07-NOV-2003; 2003US-0518453P.
 XX
 PA (ALNY-) ALNYLAM PHARM.
 XX
 PI Manoharan M, Bumcrot D;
 XX
 DR WPI; 2004-677362/66.
 XX

PT Interference RNA agent useful for treating dyslipidemias, coronary artery
 PT disease, diabetes, cancer or neurological disease, comprises sense
 PT sequence and antisense sequence which has specific modifications.

XX Example 5; SEQ ID NO 5367; 378pp; English.

XX
 CC The invention describes a RNA interference (iRNA) agent (I) comprising a
 CC sense sequence and an antisense sequence, where the sense sequences have
 CC one or more asymmetrical 2'-O alkyl modifications, the antisense
 CC sequences have one or more asymmetrical phosphorothioate modifications
 CC and the antisense sequence targets a human gene sequence. Also described
 CC are: a pharmaceutical preparation comprising (I); reducing (M1) apoB-100
 CC levels or glucose-6-phosphatase levels in a subject; producing (I);
 CC stabilising (I), involves selecting a sequence with activity and
 CC introducing one or more asymmetrical modification in the sequence, where
 CC the modification decreases nuclease sensitivity while not decreasing its
 CC activity; a kit comprising (I) and instructions for its use; and a device
 CC that can be dispense or administer a composition comprising (I). (I) is
 CC useful for reducing apoB-100 levels or glucose-6-phosphatase levels. (M1)
 CC is useful for reducing apoB-100 levels or glucose-6-phosphatase levels.
 CC The subject is suffering from a disorder characterised by elevated or
 CC otherwise unwanted expression of apoB-100, elevated or otherwise unwanted
 CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
 CC disorder is chosen from the HDL/LDL cholesterol imbalance,
 CC dyslipidemias, hypercholesterolaemia, statin-resistant
 CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
 CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
 CC inhibit hepatic glucose production or for treating glucose-metabolism-
 CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
 CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
 CC lung cancer), neurological disease (e.g., Huntington disease or
 CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
 CC represents a human glucose-6-phosphatase antisense oligonucleotide that
 CC can be used to control glucose-6-phosphatase gene expression.

XX SQ Sequence 19 BP; 1 A; 1 C; 2 G; 15 T; 0 U; 0 Other;

Query Match 0.5%; Score 15.8; DB 1; Length 19;
 Best Local Similarity 89.5%; Pred. No. 1.6e+03;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2903 TTTTTCCTTTTTCAG 2921

Db 1 TTTTTCCTTTTTCAG 19

RESULT 2221

AAAX77458/c

ID AAX77458 standard; DNA; 18 BP.

XX AC AAX77458;

XX DT 05-AUG-1999 (first entry)

XX DE US5912147 primer 2.

XX KW Primer; quantitation; genetic instability; tumour cell; detection;
 KW neoplastic transformation; carcinogenesis; ss.

XX OS Synthetic.

XX PN US5912147-A.

XX PD 15-JUN-1999.

XX PF 22-OCT-1996; 96US-00734973.

XX PR 22-OCT-1996; 96US-00734973.

XX PA (HEAL-) HEALTH RES INC.

XX PI Anderson G, Stoler D, Basik M;

XX

DR WPI; 1999-357197/30.

XX Quantitating genetic instability.

XX PS Claim 4; Col 17-18; 27pp; English.

XX
 CC This invention describes a novel method for quantitating genetic
 CC instability independent of microsatellite alterations by treating a
 CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC from normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence
 CC (CG)XRG, where R is a purine selected from adenine and guanine and x = 3-
 CC 7, (ii) a nucleotide sequence (CG)XRY, where R is as in (i) and Y is a
 CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
 CC a nucleotide sequence (CG)XRR, where R is as in (i) and x = 3-7, (iv) a
 CC nucleotide sequence (CG)XY, where Y is a pyrimidine selected from
 CC cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
 CC (CA)XRG, where R is a purine selected from adenine and guanine and x = 6-
 CC 16, (vi) a nucleotide sequence (CA)XRY, where R is a purine selected from
 CC adenine and guanine and Y is a pyrimidine selected from cytosine
 CC thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)XRR,
 CC where R is a purine selected from adenine and guanine and x = 6-16,
 CC (viii) a nucleotide sequence (CA)XY, where Y is a pyrimidine selected
 CC from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
 CC of the primers. The method is useful for detecting genomic instability
 CC which are commonly associated with the various stages of neoplastic
 CC transformation and carcinogenesis. The method is rapid and simple

XX SQ Sequence 18 BP; 8 A; 8 C; 2 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 1.8e+03;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2727 CGTGTGTGTGTGTGTGT 2743

Db 18 CCTGTGTGTGTGTGTGT 2

RESULT 2222

AAAX77457/c

ID AAX77457 standard; DNA; 18 BP.

XX AC AAX77457;

XX DT 05-AUG-1999 (first entry)

XX DE US5912147 primer 1.

XX KW Primer; quantitation; genetic instability; tumour cell; detection;
 KW neoplastic transformation; carcinogenesis; ss.

XX OS Synthetic.

XX PN US5912147-A.

XX PD 15-JUN-1999.

XX PF 22-OCT-1996; 96US-00734973.

XX PR 22-OCT-1996; 96US-00734973.

XX PA (HEAL-) HEALTH RES INC.

XX PI Anderson G, Stoler D, Basik M;

XX WPI; 1999-357197/30.

XX Quantitating genetic instability.

XX PS Claim 4; Col 15-16; 27pp; English.

XX This invention describes a novel method for quantitating genetic

CC instability independent of microsatellite alterations by treating a
 CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC from normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence
 CC (CG)XRG, where R is a purine selected from adenine and guanine and x = 3-
 CC 7, (ii) a nucleotide sequence (CG)XRY, where R is as in (i) and Y is a
 CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
 CC a nucleotide sequence (CG)XRR, where R is as in (i) and x = 3-7, (iv) a
 CC nucleotide sequence (CG)XY, where Y is a pyrimidine selected from
 CC cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
 CC (CA)XRG, where R is a purine selected from adenine and guanine and x = 6-
 CC 16, (vi) a nucleotide sequence (CA)XRY, where R is a purine selected from
 CC adenine and guanine and Y is a pyrimidine selected from cytosine,
 CC thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)XRR,
 CC where R is a purine selected from adenine and guanine and x = 6-16,
 CC (viii) a nucleotide sequence (CA)XY, where Y is a pyrimidine selected
 CC from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
 CC of the primers. The method is useful for detecting genomic instability
 CC which are commonly associated with the various stages of neoplastic
 CC transformation and carcinogenesis. The method is rapid and simple
 XX
 SQ Sequence 18 BP; 9 A; 8 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 1.8e+03;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2727 CGTGTGTGTGTGTGTGT 2743
 Db 18 CTTGTGTGTGTGTGTGT 2

RESULT 2223
 ABK27429/C
 ID ABK27429 standard; DNA; 18 BP.
 AC ABK27429;
 XX
 DT 09-APR-2002 (first entry)
 XX
 DE Colon cancer associated cDNA CATX-2, 3' PCR primer.

XX Human; colon cancer; tumour; abnormal cell growth; melanoma;
 KW cervical cancer; colorectal adenocarcinoma; Wilms' tumour; leukaemia;
 KW lymphoma; antisense therapy; CATX; probe; primer; ss.
 XX
 OS Homo sapiens.

XX WO20011047-A2.

XX 15-FEB-2001.

XX 08-AUG-2000; 2000WO-US021606.

XX 09-AUG-1999; 99US-0147933P.

XX (FARB) BAYER CORP.

XX Bowman BM, Wang K;

XX WPI; 2002-121548/16.

XX New isolated nucleic acid involved in growth regulation in human colonic
 PT epithelial cells, termed CATX, for diagnosing and treating abnormal cell
 PT growth, and for use as a probe/primer for detecting tumors.

PS Example; Page 87; 130pp; English.

XX The invention relates to an isolated nucleic acid (I) involved in growth
 CC regulation in human colonic epithelial cells, termed CATX. (I) is useful
 CC as a probe/primer for detecting tumours, preferably colon cancer. The
 CC nucleic acid, encoded polypeptide and antibody are useful in diagnosis
 CC and treatment of abnormal cell growth (such as cervical cancer,

CC melanomas, colorectal adenocarcinomas, Wilms' tumour, leukaemias and
 CC lymphomas), in screening assays for the treatment of abnormal cell
 CC growth, for raising antibodies, and to screen for peptide analogues and
 CC antagonists. (I) is useful as a biomarker for human tumour cells, e.g.,
 CC colon cancer cells, for generating probes and primers designed for
 CC identifying and/or cloning homologues in other cell types, in antisense
 CC therapy, and in tissue profiling. (I) identifies cancer cells at an early
 CC stage of development, so that premalignant cells can be identified prior
 CC to their spreading throughout the human body. (I) allows early detection
 CC of potentially cancerous conditions, and treatment of the cancerous
 CC conditions prior to spread of the cancer cells throughout the body, or
 CC prior to development of an irreversible cancerous condition. ABK27426-
 CC ABK27469 represent human colon cancer associated coding sequences and
 CC primers of the invention
 XX

SQ Sequence 18 BP; 3 A; 8 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 15.4; DB 1; Length 18;
 Best Local Similarity 94.1%; Pred. No. 1.8e+03;
 Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2772 CCAGGCTGGAGTGCAGT 2788
 Db 18 CCAGGCTGGAGTGCAGT 2

RESULT 2224
 ACA62883/C
 ID ACA62883 standard; DNA; 18 BP.

XX ACA62883;

XX 21-AUG-2003 (first entry)

XX Repeated nucleic acid detection method, human probe Alu3L.

XX Repeated nucleic acid detection; human; alu; probe; ss.

XX Homo sapiens.

XX US2003022163-A1.

XX 30-JAN-2003.

XX 15-DEC-2000; 2000US-00739909.

XX 21-JUL-1999; 99US-00358972.

XX 25-AUG-1999; 99US-00383316.

XX (MAND//) MANDREKAR M N.

XX (TERE//) TEREBA A.

XX (SHUL//) SHULTZ J W.

XX Mandrekar MN, Tereba A, Shultz JW;

XX WPI; 2003-479484/45.

XX Determining presence or absence of desired nucleic acids that contain
 PT multiple repeats of predetermined nucleic acid target sequences in a
 PT sample, by using nucleic acid hybridization methods.

PS Claim 1; Page 27; 31pp; English.

XX The invention describes a method of determining presence or absence of a
 CC desired nucleic acid (NA) that contains multiple repeats of a
 CC predetermined NA target sequence in a NA sample. The method involves
 CC providing a treated sample that may contain the desired NA in which
 CC several predetermined repeating NA target sequences are hybridised with a
 CC NA probe, analysing for presence of hybridised NA containing the NA
 CC probe, and thereby the presence or absence of the desired NA. The method
 CC is useful for determining the presence or absence of desired nucleic
 CC acids that contain multiple repeats of a predetermined NA target
 CC sequence, in a NA sample obtained from a biological sample, where the

CC repeated sequence includes several predetermined repeated sequence that
 CC differ in length and/or sequence. The methods can be efficiently used for
 CC distinguishing human and bacterial NA. The method is highly sensitive,
 CC and enables detection and quantification of the presence of a NA without
 CC the need to undergo a NA target sequence enrichment step prior to a NA
 CC hybrid detection step. The method enables rapid and accurate detection of
 CC a desired NA that contains multiple repeats of a NA target sequence. This
 CC sequence represents a probe used to detect the human Alu repeat sequences

XX Sequence 18 BP; 6 A; 3 C; 7 G; 2 T; 0 U; 0 Other;

SQ Query Match 0.5%; Score 15.4; DB 1; Length 18;

Best Local Similarity 94.1%; Pred. No. 1.8e+03;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTACCCA 2774

Db 17 TCTGTCTCTGTACCCA 1

RESULT 2225

AAX90796

ID AAX90796 standard; DNA; 19 BP.

XX AC AAX90796;

XX 13-JAN-2000 (first entry)

XX Human 7SL RNA specific PCR primer-2.

DE PCR primer; human 7SL RNA; amplify; human staufen cDNA; hStau;

XX synthesised; random hexamer primer; Superscript II reverse transcriptase;

KW ss.

XX Synthetic.

OS Homo sapiens.

XX WO9951255-A1.

PN 14-OCT-1999.

PD 06-APR-1999; 99WO-US007533.

PF 06-APR-1998; 98US-0080783P.

PR (UJO) UNIV JOHNS HOPKINS SCHOOL MEDICINE.

XX Greider CW, Le S;

XX WPI; 1999-620168/53.

DR Human staufen polypeptide useful in methods for identifying telomerase

PT inhibitors.

PS Example 1; Page 25; 50pp; English.

XX The present sequence is a PCR primer specific to human 7SL RNA. It is

CC used to amplify human staufen (hStau) cDNA synthesised using random

CC hexamer primers and Superscript II reverse transcriptase

XX Sequence 19 BP; 3 A; 4 C; 8 G; 4 T; 0 U; 0 Other;

SQ Query Match 0.5%; Score 15.4; DB 1; Length 19;

Best Local Similarity 94.1%; Pred. No. 1.7e+03;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2921 GAGACGGGGTCTCGCAA 2937

Db 1 GAGACGGGGTCTCGCTA 17

RESULT 2226

AAT27912/c

ID AAT27912 standard; DNA; 18 BP.

XX AC AAT27912;

XX 28-JAN-1997 (first entry)

XX 5'-anchored simple sequence repeat primer DBD(AC)7.5.

XX Detection; polymorphism; perfect compound simple sequence repeat;

KW adaptor directed primer; genome; genetic; fingerprinting;

KW amplified fragment length polymorphism assay; microsatellite region;

XX genetic trait marking; germplasm comparisons; 5'-anchored; ss.

OS Synthetic.

XX WO9617082-A2.

XX 06-JUN-1996.

XX 21-NOV-1995; 95WO-US015150.

XX 28-NOV-1994; 94US-00346456.

XX (DUPO) DU PONT DE NEMOURS & CO E I.

XX Morgante M, Vogel JM;

XX WPI; 1996-277795/28.

XX Modified amplified fragment length polymorphism assay - for detection of

PT polymorphism esp. in micro:satellite regions.

XX Example 1; Page 76; 173pp; English.

XX Detecting polymorphisms between 2 nucleic acid samples, esp. in

CC microsatellite regions, comprises digesting the nucleic acid to generate

CC fragments, ligating adaptor segments to their ends, amplifying them using

CC primer directed amplification and comparing the prods. to detect

CC differences. The primers used in the amplification comprise a primer

CC consisting of a perfect cpd. simple sequence repeat (SSR), and an adaptor

CC directed primer, comprising a sequence complementary to an adaptor

CC segment. The present sequence is an example of a SSR primer, which is

CC flanked at its 5'-end by degenerate nucleotides. The method represents a

CC modified amplified fragment length polymorphism assay, which is partic.

CC useful for genome fingerprinting, i.e. for genetic trait marking and

CC germplasm comparisons

XX Sequence 18 BP; 8 A; 7 C; 0 G; 0 T; 0 U; 3 Other;

SQ Query Match 0.5%; Score 15.2; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 1.9e+03;

Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTA 2744

Db 18 TGTGTGTGTGTGTGTH 3

RESULT 2227

AAT27915

ID AAT27915 standard; DNA; 18 BP.

XX AC AAT27915;

XX 28-JAN-1997 (first entry)

XX 5'-anchored simple sequence repeat primer VHV(GT)7.5.

XX Detection; polymorphism; perfect compound simple sequence repeat;

KW adaptor directed primer; genome; genetic; fingerprinting;

KW amplified fragment length polymorphism assay; microsatellite region;

XX genetic trait marking; germplasm comparisons; 5'-anchored; ss.

```

OS Synthetic.
PN WO9617082-A2.
XX
XX 06-JUN-1996.
XX
XX 21-NOV-1995; 95WO-US015150.
XX
XX 28-NOV-1994; 94US-00346456.
XX
XX (DUPO ) DU PONT DE NEMOURS & CO E I.
XX
XX Morgante M, Vogel JM;
XX
XX WPI; 1996-277795/28.
XX
XX Modified amplified fragment length polymorphism assay - for detection of
PT polymorphism esp. in micro:satellite regions.
XX
XX Example 1; Page 77; 173pp; English.
XX
XX Detecting polymorphisms between 2 nucleic acid samples, esp. in
CC microsatellite regions, comprises digesting the nucleic acid to generate
CC fragments, ligating adaptor segments to their ends, amplifying them using
CC primer directed amplification and comparing the prods. to detect
CC differences. The primers used in the amplification comprise a primer
CC consisting of a perfect cpd. simple sequence repeat (SSR), and an adaptor
CC segment. The present sequence is an example of a SSR primer, which is
CC flanked at its 5'-end by degenerate nucleotides. The method represents a
CC modified amplified fragment length polymorphism assay, which is partic.
CC useful for genome fingerprinting, i.e. for genetic trait marking and
CC germplasm comparisons
XX
XX Sequence 18 BP; 0 A; 0 C; 8 G; 7 T; 0 U; 3 Other;
SQ
Query Match 0.5%; Score 15.2; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. NO. 1.9e+03;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Oy 2727 CGTGTGTGTGTGTGTG 2742
Db :|||||
3 VGTGTGTGTGTGTGTG 18

RESULT 2228
AAT27913/C
ID AAT27913 standard; DNA; 18 BP.
XX
XX AAT27913;
XX
XX 28-JAN-1997 (first entry)
XX
XX 5'-anchored simple sequence repeat primer BDB(CA)7.5.
XX
XX Detection; polymorphism; perfect compound simple sequence repeat;
XX adaptor directed primer; genome; genetic; fingerprinting;
XX amplified fragment length polymorphism assay; microsatellite region;
XX genetic trait marking; germplasm comparisons; 5'-anchored; ss.
XX
XX Synthetic.
XX
XX WO9617082-A2.
XX
XX 06-JUN-1996.
XX
XX 21-NOV-1995; 95WO-US015150.
XX
XX 28-NOV-1994; 94US-00346456.
XX
XX (DUPO ) DU PONT DE NEMOURS & CO E I.
XX
XX Morgante M, Vogel JM;
XX
XX WPI; 1996-277795/28.
XX
XX Modified amplified fragment length polymorphism assay - for detection of
PT polymorphism esp. in micro:satellite regions.
XX
XX Example 1; Page 77; 173pp; English.
XX
XX Detecting polymorphisms between 2 nucleic acid samples, esp. in
CC microsatellite regions, comprises digesting the nucleic acid to generate
CC fragments, ligating adaptor segments to their ends, amplifying them using
CC primer directed amplification and comparing the prods. to detect
CC differences. The primers used in the amplification comprise a primer
CC consisting of a perfect cpd. simple sequence repeat (SSR), and an adaptor
CC segment. The present sequence is an example of a SSR primer, which is
CC flanked at its 5'-end by degenerate nucleotides. The method represents a
CC modified amplified fragment length polymorphism assay, which is partic.
CC useful for genome fingerprinting, i.e. for genetic trait marking and
CC germplasm comparisons
XX
XX Sequence 18 BP; 0 A; 0 C; 8 G; 7 T; 0 U; 3 Other;
SQ
Query Match 0.5%; Score 15.2; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. NO. 1.9e+03;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

```

XX WPI; 1996-277795/28.
XX
XX Modified amplified fragment length polymorphism assay - for detection of
PT polymorphism esp. in micro:satellite regions.
XX
XX Example 1; Page 76; 173pp; English.
XX
XX Detecting polymorphisms between 2 nucleic acid samples, esp. in
CC microsatellite regions, comprises digesting the nucleic acid to generate
CC fragments, ligating adaptor segments to their ends, amplifying them using
CC primer directed amplification and comparing the prods. to detect
CC differences. The primers used in the amplification comprise a primer
CC consisting of a perfect cpd. simple sequence repeat (SSR), and an adaptor
CC segment. The present sequence is an example of a SSR primer, which is
CC flanked at its 5'-end by degenerate nucleotides. The method represents a
CC modified amplified fragment length polymorphism assay, which is partic.
CC useful for genome fingerprinting, i.e. for genetic trait marking and
CC germplasm comparisons
XX
XX Sequence 18 BP; 7 A; 8 C; 0 G; 0 T; 0 U; 3 Other;
SQ
Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. NO. 2e+03;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 2728 GTGTGTGTGTGTGTG 2742
Db |||||||
18 GTGTGTGTGTGTGTG 4

RESULT 2229
AAT27914
ID AAT27914 standard; DNA; 18 BP.
XX
XX AAT27914;
XX
XX 28-JAN-1997 (first entry)
XX
XX 5'-anchored simple sequence repeat primer HVH(TG)7.5.
XX
XX Detection; polymorphism; perfect compound simple sequence repeat;
XX adaptor directed primer; genome; genetic; fingerprinting;
XX amplified fragment length polymorphism assay; microsatellite region;
XX genetic trait marking; germplasm comparisons; 5'-anchored; ss.
XX
XX Synthetic.
XX
XX WO9617082-A2.
XX
XX 06-JUN-1996.
XX
XX 21-NOV-1995; 95WO-US015150.
XX
XX 28-NOV-1994; 94US-00346456.
XX
XX (DUPO ) DU PONT DE NEMOURS & CO E I.
XX
XX Morgante M, Vogel JM;
XX
XX WPI; 1996-277795/28.
XX
XX Modified amplified fragment length polymorphism assay - for detection of
PT polymorphism esp. in micro:satellite regions.
XX
XX Example 1; Page 77; 173pp; English.
XX
XX Detecting polymorphisms between 2 nucleic acid samples, esp. in
CC microsatellite regions, comprises digesting the nucleic acid to generate
CC fragments, ligating adaptor segments to their ends, amplifying them using
CC primer directed amplification and comparing the prods. to detect
CC differences. The primers used in the amplification comprise a primer
CC consisting of a perfect cpd. simple sequence repeat (SSR), and an adaptor
CC segment. The present sequence is an example of a SSR primer, which is
CC flanked at its 5'-end by degenerate nucleotides. The method represents a
CC modified amplified fragment length polymorphism assay, which is partic.
CC useful for genome fingerprinting, i.e. for genetic trait marking and
CC germplasm comparisons
XX
XX Sequence 18 BP; 7 A; 8 C; 0 G; 0 T; 0 U; 3 Other;
SQ
Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. NO. 2e+03;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```


CC consisting of a perfect cpd. simple sequence repeat (SSR), and an adaptor
 CC directed primer, comprising a sequence complementary to an adaptor
 CC segment. The present sequence is an example of a SSR primer, which is
 CC flanked at its 5'-end by degenerate nucleotides. The method represents a
 CC modified amplified fragment length polymorphism assay, which is partic.
 CC useful for genome fingerprinting, i.e. for genetic trait marking and
 CC germplasm comparisons

XX SQ Sequence 18 BP; 0 A; 0 C; 7 G; 8 T; 0 U; 3 Other;
 Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2729 TGTGTGTGTGTGTGT 2743
 DB 4 TGTGTGTGTGTGTGT 18
 |||||

RESULT 2230
 AAX77462/C
 ID AAX77462 standard; DNA; 18 BP.

XX AC AAX77462;

XX 05-AUG-1999 (first entry)

XX US912147 primer 6.

XX Primer; quantitation; genetic instability; tumour cell; detection;
 XX neoplastic transformation; carcinogenesis; ss.

XX Synthetic.

XX US912147-A.

XX 15-JUN-1999.

XX 22-OCT-1996; 96US-00734973.

XX 22-OCT-1996; 96US-00734973.

XX (HEAL-) HEALTH RES INC.

XX Anderson G, Stoler D, Basik M;

XX WPI; 1999-357197/30.

XX Quantitating genetic instability.

XX Claim 4; Col 17-18; 27pp; English.

XX This invention describes a novel method for quantitating genetic
 CC instability independent of microsatellite alterations by treating a
 CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC from normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence
 CC (CG)XRG, where R is a purine selected from adenine and guanine and x = 3-
 CC 7, (ii) a nucleotide sequence (CG)XRY, where R is as in (i) and Y is a
 CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
 CC a nucleotide sequence (CG)XRR, where R is as in (i) and x = 3-7, (iv) a
 CC nucleotide sequence (CG)XY, where Y is a pyrimidine selected from
 CC cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
 CC (CA)XRG, where R is a purine selected from adenine and guanine and x = 6-
 CC 16, (vi) a nucleotide sequence (CA)XRY, where R is a purine selected from
 CC adenine and guanine and Y is a pyrimidine selected from cytosine,
 CC thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)XRR,
 CC where R is a purine selected from adenine and guanine and x = 6-16,
 CC (viii) a nucleotide sequence (CA)XY, where Y is a pyrimidine selected
 CC from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
 CC of the primers. The method is useful for detecting genomic instability
 CC which are commonly associated with the various stages of neoplastic
 CC transformation and carcinogenesis. The method is rapid and simple

XX SQ Sequence 18 BP; 8 A; 9 C; 1 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 2729 TGTGTGTGTGTGTGT 2743
 DB 16 TGTGTGTGTGTGTGT 2
 |||||

RESULT 2231
 AAX77485/C
 ID AAX77485 standard; DNA; 18 BP.

XX AC AAX77485;

XX 05-AUG-1999 (first entry)

XX US912147 primer 29.

XX Primer; quantitation; genetic instability; tumour cell; detection;
 XX neoplastic transformation; carcinogenesis; ss.

XX Synthetic.

XX US912147-A.

XX 15-JUN-1999.

XX 22-OCT-1996; 96US-00734973.

XX 22-OCT-1996; 96US-00734973.

XX (HEAL-) HEALTH RES INC.

XX Anderson G, Stoler D, Basik M;

XX WPI; 1999-357197/30.

XX Quantitating genetic instability.

XX Claim 4; Col 27-28; 27pp; English.

XX This invention describes a novel method for quantitating genetic
 CC instability independent of microsatellite alterations by treating a
 CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC from normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence
 CC (CG)XRG, where R is a purine selected from adenine and guanine and x = 3-
 CC 7, (ii) a nucleotide sequence (CG)XRY, where R is as in (i) and Y is a
 CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
 CC a nucleotide sequence (CG)XRR, where R is as in (i) and x = 3-7, (iv) a
 CC nucleotide sequence (CG)XY, where Y is a pyrimidine selected from
 CC cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
 CC (CA)XRG, where R is a purine selected from adenine and guanine and x = 6-
 CC 16, (vi) a nucleotide sequence (CA)XRY, where R is a purine selected from
 CC adenine and guanine and Y is a pyrimidine selected from cytosine,
 CC thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)XRR,
 CC where R is a purine selected from adenine and guanine and x = 6-16,
 CC (viii) a nucleotide sequence (CA)XY, where Y is a pyrimidine selected
 CC from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
 CC of the primers. The method is useful for detecting genomic instability
 CC which are commonly associated with the various stages of neoplastic
 CC transformation and carcinogenesis. The method is rapid and simple

XX SQ Sequence 18 BP; 9 A; 8 C; 1 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743.
|||||

Db 16 TGTGTGTGTGTGTGT 2

RESULT 2232
AAAX77494/C
ID AAX77494 standard; DNA; 18 BP.

AC AAX77494;

DT 05-AUG-1999 (first entry)

DE US5912147 primer 38.

Primer; quantitation; genetic instability; tumour cell; detection;
neoplastic transformation; carcinogenesis; DNA/RNA hybrid; ss.

OS Synthetic.

Key Location/Qualifiers
FH 17. .18
FT misc_RNA
FT /*tag= a
FT /note= "uracil"

PN US5912147-A.

PD 15-JUN-1999.

PF 22-OCT-1996; 96US-00734973.

PR 22-OCT-1996; 96US-00734973.

PA (HEAL-) HEALTH RES INC.

PI Anderson G, Stoler D, Basik M;

DR WPI; 1999-357197/30.

PT Quantitating genetic instability.

PS Claim 4; Col 31-32; 27pp; English.

This invention describes a novel method for quantitating genetic instability independent of microsatellite alterations by treating a comparison pair comprising genomic DNA from tumour cells and genomic DNA from normal cells. The method involves the cells from the same individual with oligonucleotide primers selected from (i) a nucleotide sequence (CG)xRG, where R is a purine selected from adenine and guanine and x = 3-7, (ii) a nucleotide sequence (CG)xRY, where R is as in (i) and Y is a pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii) a nucleotide sequence (CG)xRR, where R is as in (i) and x = 3-7, (iv) a nucleotide sequence (CG)xYX, where Y is a pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence (CA)xRG, where R is a purine selected from adenine and guanine and x = 6-16, (vi) a nucleotide sequence (CA)xRY, where R is a purine selected from adenine and guanine and Y is a pyrimidine selected from cytosine, thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xRR, where R is a purine selected from adenine and guanine and x = 6-16, (viii) a nucleotide sequence (CA)xYX, where Y is a pyrimidine selected from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination of the primers. The method is useful for detecting genomic instability which are commonly associated with the various stages of neoplastic transformation and carcinogenesis. The method is rapid and simple

Sequence 18 BP; 8 A; 8 C; 0 G; 0 T; 2 U; 0 Other;

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
|||||

Db 16 TGTGTGTGTGTGTGT 2

RESULT 2233
AAAX77484/C
ID AAX77484 standard; DNA; 18 BP.

AC AAX77484;

DT 05-AUG-1999 (first entry)

DE US5912147 primer 28.

Primer; quantitation; genetic instability; tumour cell; detection;
neoplastic transformation; carcinogenesis; ss.

OS Synthetic.

PN US5912147-A.

PD 15-JUN-1999.

PF 22-OCT-1996; 96US-00734973.

PR 22-OCT-1996; 96US-00734973.

PA (HEAL-) HEALTH RES INC.

PI Anderson G, Stoler D, Basik M;

DR WPI; 1999-357197/30.

PT Quantitating genetic instability.

PS Claim 4; Col 27-28; 27pp; English.

This invention describes a novel method for quantitating genetic instability independent of microsatellite alterations by treating a comparison pair comprising genomic DNA from tumour cells and genomic DNA from normal cells. The method involves the cells from the same individual with oligonucleotide primers selected from (i) a nucleotide sequence (CG)xRG, where R is a purine selected from adenine and guanine and x = 3-7, (ii) a nucleotide sequence (CG)xRY, where R is as in (i) and Y is a pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii) a nucleotide sequence (CG)xRR, where R is as in (i) and x = 3-7, (iv) a nucleotide sequence (CG)xYX, where Y is a pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence (CA)xRG, where R is a purine selected from adenine and guanine and x = 6-16, (vi) a nucleotide sequence (CA)xRY, where R is a purine selected from adenine and guanine and Y is a pyrimidine selected from cytosine, thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xRR, where R is a purine selected from adenine and guanine and x = 6-16, (viii) a nucleotide sequence (CA)xYX, where Y is a pyrimidine selected from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination of the primers. The method is useful for detecting genomic instability which are commonly associated with the various stages of neoplastic transformation and carcinogenesis. The method is rapid and simple

Sequence 18 BP; 10 A; 8 C; 0 G; 0 T; 0 U; 0 Other;

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
|||||

Db 16 TGTGTGTGTGTGTGT 2

RESULT 2234
AAAX77493/C
ID AAX77493 standard; DNA; 18 BP.

XX

AC AAX77493;
 DT 05-AUG-1999 (first entry)
 DE US5912147 primer 37.
 DE US5912147 primer 37.
 KW Primer; quantitation; genetic instability; tumour cell; detection;
 KW neoplastic transformation; carcinogenesis; DNA/RNA hybrid; ss.
 XX OS Synthetic.
 XX FT Key Location/Qualifiers
 FT misc_RNA 17
 FT /*tag= a
 FT /note= "uracil"
 XX US5912147-A.
 XX 15-JUN-1999.
 XX 22-OCT-1996; 96US-00734973.
 XX 22-OCT-1996; 96US-00734973.
 XX (HEAL-) HEALTH RES INC.
 XX Anderson G, Stoler D, Basik M;
 DR WPI; 1999-357197/30.
 XX Quantitating genetic instability.
 PS Claim 4; Col 31-32; 27pp; English.
 CC This invention describes a novel method for quantitating genetic
 CC instability independent of microsatellite alterations by treating a
 CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC from normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence
 CC (CG)XRG, where R is a purine selected from adenine and guanine and x = 3-
 CC 7, (ii) a nucleotide sequence (CG)XRY, where R is as in (i) and Y is a
 CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
 CC a nucleotide sequence (CG)XRR, where R is as in (i) and x = 3-7, (iv) a
 CC nucleotide sequence (CG)XY, where Y is a pyrimidine selected from
 CC cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
 CC (CA)XRG, where R is a purine selected from adenine and guanine and x = 6-
 CC 16, (vi) a nucleotide sequence (CA)XRY, where R is a purine selected from
 CC adenine and guanine and Y is a pyrimidine selected from cytosine,
 CC thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)XRR,
 CC where R is a purine selected from adenine and guanine and x = 6-16,
 CC (viii) a nucleotide sequence (CA)XY, where Y is a pyrimidine selected
 CC from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
 CC of the primers. The method is useful for detecting genomic instability
 CC which are commonly associated with the various stages of neoplastic
 CC transformation and carcinogenesis. The method is rapid and simple
 XX SQ Sequence 18 BP; 8 A; 8 C; 0 G; 1 T; 1 U; 0 Other;
 Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 2729 TGTGTGTGTGTGTGT 2743
 Db 16 TGTGTGTGTGTGTGT 2
 RESULT 2235
 AAX77459/C
 ID AAX77459 standard; DNA; 18 BP.
 XX AC AAX77459;
 XX

DT 05-AUG-1999 (first entry)
 XX US5912147 primer 3.
 DE US5912147 primer 3.
 DE US5912147 primer 3.
 KW Primer; quantitation; genetic instability; tumour cell; detection;
 KW neoplastic transformation; carcinogenesis; ss.
 XX OS Synthetic.
 XX FT Key Location/Qualifiers
 FT misc_RNA 17
 FT /*tag= a
 FT /note= "uracil"
 XX US5912147-A.
 XX 15-JUN-1999.
 XX 22-OCT-1996; 96US-00734973.
 XX 22-OCT-1996; 96US-00734973.
 XX (HEAL-) HEALTH RES INC.
 XX Anderson G, Stoler D, Basik M;
 DR WPI; 1999-357197/30.
 XX Quantitating genetic instability.
 PS Claim 4; Col 17-18; 27pp; English.
 CC This invention describes a novel method for quantitating genetic
 CC instability independent of microsatellite alterations by treating a
 CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC from normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence
 CC (CG)XRG, where R is a purine selected from adenine and guanine and x = 3-
 CC 7, (ii) a nucleotide sequence (CG)XRY, where R is as in (i) and Y is a
 CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
 CC a nucleotide sequence (CG)XRR, where R is as in (i) and x = 3-7, (iv) a
 CC nucleotide sequence (CG)XY, where Y is a pyrimidine selected from
 CC cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
 CC (CA)XRG, where R is a purine selected from adenine and guanine and x = 6-
 CC 16, (vi) a nucleotide sequence (CA)XRY, where R is a purine selected from
 CC adenine and guanine and Y is a pyrimidine selected from cytosine,
 CC thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)XRR,
 CC where R is a purine selected from adenine and guanine and x = 6-16,
 CC (viii) a nucleotide sequence (CA)XY, where Y is a pyrimidine selected
 CC from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
 CC of the primers. The method is useful for detecting genomic instability
 CC which are commonly associated with the various stages of neoplastic
 CC transformation and carcinogenesis. The method is rapid and simple
 XX SQ Sequence 18 BP; 9 A; 9 C; 0 G; 0 T; 0 U; 0 Other;
 Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 2729 TGTGTGTGTGTGTGT 2743
 Db 16 TGTGTGTGTGTGTGT 2
 RESULT 2236
 AAX77464/C
 ID AAX77464 standard; DNA; 18 BP.
 XX AC AAX77464;
 XX 05-AUG-1999 (first entry)
 XX US5912147 primer 8.
 DE US5912147 primer 8.
 DE US5912147 primer 8.
 KW Primer; quantitation; genetic instability; tumour cell; detection;
 KW neoplastic transformation; carcinogenesis; DNA/RNA hybrid; ss.
 XX

```

OS Synthetic.
FH Key Location/Qualifiers
FT misc_RNA 18
FT /*tag= a
FT /note= "uracil"
XX
XX US5912147-A.
XX
XX 15-JUN-1999.
XX
XX 22-OCT-1996; 96US-00734973.
XX
XX 22-OCT-1996; 96US-00734973.
XX
XX (HEAL-) HEALTH RES INC.
XX
XX Anderson G, Stoler D, Basik M;
XX
XX WPI; 1999-357197/30.
XX
XX Quantitating genetic instability.
XX
XX Claim 4; Col 19-20; 27pp; English.
XX
XX This invention describes a novel method for quantitating genetic
XX instability independent of microsatellite alterations by treating a
XX comparison pair comprising genomic DNA from tumour cells and genomic DNA
XX from normal cells. The method involves the cells from the same individual
XX with oligonucleotide primers selected from (i) a nucleotide sequence
XX (CG)xRG, where R is a purine selected from adenine and guanine and x = 3-
XX 7, (ii) a nucleotide sequence (CG)xRY, where R is as in (i) and Y is a
XX pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
XX a nucleotide sequence (CG)xYV, where R is as in (i) and x = 3-7, (iv) a
XX nucleotide sequence (CG)xYV, where Y is a pyrimidine selected from
XX cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
XX (CA)xRG, where R is a purine selected from adenine and guanine and x = 6-
XX 16, (vi) a nucleotide sequence (CA)xRY, where R is a purine selected from
XX adenine and guanine and Y is a pyrimidine selected from cytosine,
XX thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xRR,
XX where R is a purine selected from adenine and guanine and x = 6-16,
XX (viii) a nucleotide sequence (CA)xYV, where Y is a pyrimidine selected
XX from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
XX of the primers. The method is useful for detecting genomic instability
XX which are commonly associated with the various stages of neoplastic
XX transformation and carcinogenesis. The method is rapid and simple
XX
XX Sequence 18 BP; 8 A; 8 C; 1 G; 0 T; 1 U; 0 Other;
XX
Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2729 TGTGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGTGT 2

RESULT 2237
AAX77491/c
ID AAX77491 standard; DNA; 18 BP.
XX
XX AAX77491;
XX
XX 05-AUG-1999 (first entry)
XX
XX US5912147 primer 35.
XX
XX Primer; quantitation; genetic instability; tumour cell; detection;
XX neoplastic transformation; carcinogenesis; DNA/RNA hybrid; ss.
XX
XX Synthetic.
XX
Key Location/Qualifiers
FT misc_RNA 17

```

```

FH Key Location/Qualifiers
FT misc_RNA 18
FT /*tag= a
FT /note= "uracil"
XX
XX US5912147-A.
XX
XX 15-JUN-1999.
XX
XX 22-OCT-1996; 96US-00734973.
XX
XX 22-OCT-1996; 96US-00734973.
XX
XX (HEAL-) HEALTH RES INC.
XX
XX Anderson G, Stoler D, Basik M;
XX
XX WPI; 1999-357197/30.
XX
XX Quantitating genetic instability.
XX
XX Claim 4; Col 31-32; 27pp; English.
XX
XX This invention describes a novel method for quantitating genetic
XX instability independent of microsatellite alterations by treating a
XX comparison pair comprising genomic DNA from tumour cells and genomic DNA
XX from normal cells. The method involves the cells from the same individual
XX with oligonucleotide primers selected from (i) a nucleotide sequence
XX (CG)xRG, where R is a purine selected from adenine and guanine and x = 3-
XX 7, (ii) a nucleotide sequence (CG)xRY, where R is as in (i) and Y is a
XX pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
XX a nucleotide sequence (CG)xRR, where R is as in (i) and x = 3-7, (iv) a
XX nucleotide sequence (CG)xYV, where Y is a pyrimidine selected from
XX cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
XX (CA)xRG, where R is a purine selected from adenine and guanine and x = 6-
XX 16, (vi) a nucleotide sequence (CA)xRY, where R is a purine selected from
XX adenine and guanine and Y is a pyrimidine selected from cytosine,
XX thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xRR,
XX where R is a purine selected from adenine and guanine and x = 6-16,
XX (viii) a nucleotide sequence (CA)xYV, where Y is a pyrimidine selected
XX from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
XX of the primers. The method is useful for detecting genomic instability
XX which are commonly associated with the various stages of neoplastic
XX transformation and carcinogenesis. The method is rapid and simple
XX
XX Sequence 18 BP; 8 A; 8 C; 0 G; 1 T; 1 U; 0 Other;
XX
Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2e+03;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2729 TGTGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGTGT 2

RESULT 2238
AAX77492/c
ID AAX77492 standard; DNA; 18 BP.
XX
XX AAX77492;
XX
XX 05-AUG-1999 (first entry)
XX
XX US5912147 primer 36.
XX
XX Primer; quantitation; genetic instability; tumour cell; detection;
XX neoplastic transformation; carcinogenesis; DNA/RNA hybrid; ss.
XX
XX Synthetic.
XX
Key Location/Qualifiers
FT misc_RNA 17

```

```

FT      /*tag= a
FX      /note= "uracil"
FN      US912147-A.
PD      15-JUN-1999.
XX      22-OCT-1996; 96US-00734973.
XX      22-OCT-1996; 96US-00734973.
XX      (HEAL-) HEALTH RES INC.
PI      Anderson G, Stoler D, Basik M;
DR      WPI; 1999-357197/30.
XX      Quantitating genetic instability.
PT      Claim 4; Col 31-32; 27pp; English.
PS      This invention describes a novel method for quantitating genetic
CC      instability independent of microsatellite alterations by treating a
CC      comparison pair comprising genomic DNA from tumour cells and genomic DNA
CC      from normal cells. The method involves the cells from the same individual
CC      with oligonucleotide primers selected from (i) a nucleotide sequence
CC      (CG)xRG, where R is a purine selected from adenine and guanine and x = 3-
CC      7, (ii) a nucleotide sequence (CG)xRY, where R is as in (i) and x = 3-
CC      7, (iii) a nucleotide sequence (CG)xRR, where R is as in (i) and x = 3-
CC      7, (iv) a nucleotide sequence (CG)xY, where Y is a pyrimidine selected
CC      from cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
CC      (CA)xRG, where R is a purine selected from adenine and guanine and x = 6-
CC      16, (vi) a nucleotide sequence (CA)xRY, where R is a purine selected from
CC      adenine and guanine and Y is a pyrimidine selected from cytosine,
CC      thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xRR,
CC      where R is a purine selected from adenine and guanine and x = 6-16,
CC      (viii) a nucleotide sequence (CA)xY, where Y is a pyrimidine selected
CC      from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
CC      of the primers. The method is useful for detecting genomic instability
CC      which are commonly associated with the various stages of neoplastic
CC      transformation and carcinogenesis. The method is rapid and simple
XX      Sequence 18 BP; 8 A; 9 C; 0 G; 0 T; 1 U; 0 Other;
SQ      Query Match 0.5%; Score 15; DB 1; Length 18;
          Best Local Similarity 100.0%; Pred. No. 2e+03;
          Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2729 TGTGTGTGTGTGTGT 2743
          |||||
Db      16 TGTGTGTGTGTGTGT 2

RESULT 2239
AAX77489/C
ID      AAX77489 standard; DNA; 18 BP.
XX      AAX77489;
AC      AAX77489;
XX      05-AUG-1999 (first entry)
DT      US912147 primer 33.
XX      Primer; quantitation; genetic instability; tumour cell; detection;
XX      neoplastic transformation; carcinogenesis; ss.
OS      Synthetic.
XX      US912147-A.
FN      15-JUN-1999.
PD      22-OCT-1996; 96US-00734973.
XX      22-OCT-1996; 96US-00734973.
XX      (HEAL-) HEALTH RES INC.
PI      Anderson G, Stoler D, Basik M;

```

```

PF      22-OCT-1996; 96US-00734973.
XX      22-OCT-1996; 96US-00734973.
XX      (HEAL-) HEALTH RES INC.
XX      Anderson G, Stoler D, Basik M;
PI      WPI; 1999-357197/30.
DR      Quantitating genetic instability.
XX      Claim 4; Col 29-30; 27pp; English.
PS      This invention describes a novel method for quantitating genetic
CC      instability independent of microsatellite alterations by treating a
CC      comparison pair comprising genomic DNA from tumour cells and genomic DNA
CC      from normal cells. The method involves the cells from the same individual
CC      with oligonucleotide primers selected from (i) a nucleotide sequence
CC      (CG)xRG, where R is a purine selected from adenine and guanine and x = 3-
CC      7, (ii) a nucleotide sequence (CG)xRY, where R is as in (i) and x = 3-
CC      7, (iii) a nucleotide sequence (CG)xRR, where R is as in (i) and x = 3-
CC      7, (iv) a nucleotide sequence (CG)xY, where Y is a pyrimidine selected
CC      from cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
CC      (CA)xRG, where R is a purine selected from adenine and guanine and x = 6-
CC      16, (vi) a nucleotide sequence (CA)xRY, where R is a purine selected from
CC      adenine and guanine and Y is a pyrimidine selected from cytosine,
CC      thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xRR,
CC      where R is a purine selected from adenine and guanine and x = 6-16,
CC      (viii) a nucleotide sequence (CA)xY, where Y is a pyrimidine selected
CC      from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
CC      of the primers. The method is useful for detecting genomic instability
CC      which are commonly associated with the various stages of neoplastic
CC      transformation and carcinogenesis. The method is rapid and simple
XX      Sequence 18 BP; 8 A; 8 C; 0 G; 2 T; 0 U; 0 Other;
SQ      Query Match 0.5%; Score 15; DB 1; Length 18;
          Best Local Similarity 100.0%; Pred. No. 2e+03;
          Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2729 TGTGTGTGTGTGTGT 2743
          |||||
Db      16 TGTGTGTGTGTGTGT 2

RESULT 2240
AAX77490/C
ID      AAX77490 standard; DNA; 18 BP.
XX      AAX77490;
AC      AAX77490;
XX      05-AUG-1999 (first entry)
DT      US912147 primer 34.
XX      Primer; quantitation; genetic instability; tumour cell; detection;
XX      neoplastic transformation; carcinogenesis; ss.
OS      Synthetic.
XX      US912147-A.
FN      15-JUN-1999.
PD      22-OCT-1996; 96US-00734973.
XX      22-OCT-1996; 96US-00734973.
XX      (HEAL-) HEALTH RES INC.
PI      Anderson G, Stoler D, Basik M;

```

XX WPI; 1999-357197/30.
 XX Quantitating genetic instability.
 XX Claim 4; Col 29-30; 27pp; English.
 XX This invention describes a novel method for quantitating genetic
 CC instability independent of microsatellite alterations by treating a
 CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC from normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence
 CC (CG)xxg, where R is a purine selected from adenine and guanine and x = 3-
 CC 7, (ii) a nucleotide sequence (CG)xxy, where R is as in (i) and Y is a
 CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
 CC a nucleotide sequence (CG)xrr, where R is as in (i) and x = 3-7, (iv) a
 CC nucleotide sequence (CG)xyy, where Y is a pyrimidine selected from
 CC cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
 CC (CA)xxg, where R is a purine selected from adenine and guanine and x = 6-
 CC 16, (vi) a nucleotide sequence (CA)xry, where R is a purine selected from
 CC adenine and guanine and Y is a pyrimidine selected from cytosine,
 CC thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xrr,
 CC where R is a purine selected from adenine and guanine and x = 6-16,
 CC (viii) a nucleotide sequence (CA)xyy, where Y is a pyrimidine selected
 CC from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
 CC of the primers. The method is useful for detecting genomic instability
 CC which are commonly associated with the various stages of neoplastic
 CC transformation and carcinogenesis. The method is rapid and simple
 XX Sequence 18 BP; 8 A; 9 C; 0 G; 1 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 2729 TGTGTGTGTGTGTGT 2743
 Db 16 TGTGTGTGTGTGTGT 2

RESULT 2241
 AAX77460/C
 ID AAX77460 standard; DNA; 18 BP.
 AC AAX77460;
 XX 05-AUG-1999 (first entry)
 DT US5912147 primer 4.
 DE Primer; quantitation; genetic instability; tumour cell; detection;
 KW neoplastic transformation; carcinogenesis; ss.
 KW Synthetic.
 OS US5912147-A.
 XX 15-JUN-1999.
 XX 22-OCT-1996; 96US-00734973.
 XX 22-OCT-1996; 96US-00734973.
 XX 22-OCT-1996; 96US-00734973.
 XX (HEAL-) HEALTH RES INC.
 XX Anderson G, Stoler D, Basik M;
 XX WPI; 1999-357197/30.
 XX Quantitating genetic instability.
 XX Claim 4; Col 17-18; 27pp; English.

CC This invention describes a novel method for quantitating genetic
 CC instability independent of microsatellite alterations by treating a
 CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC from normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence
 CC (CG)xxg, where R is a purine selected from adenine and guanine and x = 3-
 CC 7, (ii) a nucleotide sequence (CG)xxy, where R is as in (i) and Y is a
 CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
 CC a nucleotide sequence (CG)xrr, where R is as in (i) and x = 3-7, (iv) a
 CC nucleotide sequence (CG)xyy, where Y is a pyrimidine selected from
 CC cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
 CC (CA)xxg, where R is a purine selected from adenine and guanine and x = 6-
 CC 16, (vi) a nucleotide sequence (CA)xry, where R is a purine selected from
 CC adenine and guanine and Y is a pyrimidine selected from cytosine,
 CC thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xrr,
 CC where R is a purine selected from adenine and guanine and x = 6-16,
 CC (viii) a nucleotide sequence (CA)xyy, where Y is a pyrimidine selected
 CC from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
 CC of the primers. The method is useful for detecting genomic instability
 CC which are commonly associated with the various stages of neoplastic
 CC transformation and carcinogenesis. The method is rapid and simple
 XX Sequence 18 BP; 9 A; 8 C; 0 G; 1 T; 0 U; 0 Other;
 SQ Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 2729 TGTGTGTGTGTGTGT 2743
 Db 16 TGTGTGTGTGTGTGT 2

RESULT 2242
 AAX77461/C
 ID AAX77461 standard; DNA; 18 BP.
 AC AAX77461;
 XX 05-AUG-1999 (first entry)
 DT US5912147 primer 5.
 DE Primer; quantitation; genetic instability; tumour cell; detection;
 KW neoplastic transformation; carcinogenesis; DNA/RNA hybrid; ss.
 KW Synthetic.
 OS US5912147-A.
 XX 15-JUN-1999.
 XX 22-OCT-1996; 96US-00734973.
 XX 22-OCT-1996; 96US-00734973.
 XX (HEAL-) HEALTH RES INC.
 XX Anderson G, Stoler D, Basik M;
 XX WPI; 1999-357197/30.
 XX Quantitating genetic instability.
 XX Claim 4; Col 17-18; 27pp; English.
 XX This invention describes a novel method for quantitating genetic
 CC instability independent of microsatellite alterations by treating a

CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC from normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence
 CC (CG)xRG, where R is a purine selected from adenine and guanine and x = 3-
 CC 7, (ii) a nucleotide sequence (CG)xRY, where R is as in (i) and Y is a
 CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
 CC a nucleotide sequence (CG)xRR, where R is as in (i) and x = 3-7, (iv) a
 CC nucleotide sequence (CG)xXY, where Y is a pyrimidine selected from
 CC cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
 CC (CA)xRG, where R is a purine selected from adenine and guanine and x = 6-
 CC 16, (vi) a nucleotide sequence (CA)xRY, where R is a purine selected from
 CC adenine and guanine and Y is a pyrimidine selected from cytosine,
 CC thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xRR,
 CC where R is a purine selected from adenine and guanine and x = 6-16,
 CC (viii) a nucleotide sequence (CA)xXY, where Y is a pyrimidine selected
 CC from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
 CC of the primers. The method is useful for detecting genomic instability
 CC which are commonly associated with the various stages of neoplastic
 CC transformation and carcinogenesis. The method is rapid and simple

XX SQ Sequence 18 BP; 9 A; 8 C; 0 G; 0 T; 1 U; 0 Other;
 Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2729 TGTGTGTGTGTGTGT 2743
 Db 16 TGTGTGTGTGTGTGT 2

RESULT 2243
 AAX77463/C
 ID AAX77463 standard; DNA; 18 BP.

XX AC AAX77463;
 XX DT 05-AUG-1999 (first entry)
 XX DE US5912147 primer 7.
 XX KW Primer; quantitation; genetic instability; tumour cell; detection;
 XX KW neoplastic transformation; carcinogenesis; ss.
 XX OS Synthetic.

XX XN US5912147-A.

XX PD 15-JUN-1999.

XX PF 22-OCT-1996; 96US-00734973.

XX PR 22-OCT-1996; 96US-00734973.

XX PA (HEAL-) HEALTH RES INC.

XX PI Anderson G, Stoler D, Basik M;

XX DR WPI; 1999-357197/30.

XX PT Quantitating genetic instability.

XX PS Claim 4; Col 19-20; 27pp; English.

XX This invention describes a novel method for quantitating genetic
 CC instability independent of microsatellite alterations by treating a
 CC comparison pair comprising genomic DNA from tumour cells and genomic DNA
 CC from normal cells. The method involves the cells from the same individual
 CC with oligonucleotide primers selected from (i) a nucleotide sequence
 CC (CG)xRG, where R is a purine selected from adenine and guanine and x = 3-
 CC 7, (ii) a nucleotide sequence (CG)xRY, where R is as in (i) and Y is a
 CC pyrimidine selected from cytosine, thymine, and uracil and x = 3-7, (iii)
 CC a nucleotide sequence (CG)xRR, where R is as in (i) and x = 3-7, (iv) a

CC nucleotide sequence (CG)xXY, where Y is a pyrimidine selected from
 CC cytosine, thymine, and uracil and x = 3-7, (v) a nucleotide sequence
 CC (CA)xRG, where R is a purine selected from adenine and guanine and x = 6-
 CC 16, (vi) a nucleotide sequence (CA)xRY, where R is a purine selected from
 CC adenine and guanine and Y is a pyrimidine selected from cytosine,
 CC thymine, and uracil, and x = 6-16, (vii) a nucleotide sequence (CA)xRR,
 CC where R is a purine selected from adenine and guanine and x = 6-16,
 CC (viii) a nucleotide sequence (CA)xXY, where Y is a pyrimidine selected
 CC from cytosine, thymine, and uracil and x = 6-16, and (ix) a combination
 CC of the primers. The method is useful for detecting genomic instability
 CC which are commonly associated with the various stages of neoplastic
 CC transformation and carcinogenesis. The method is rapid and simple

XX SQ Sequence 18 BP; 8 A; 8 C; 1 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 15; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 2e+03;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2729 TGTGTGTGTGTGTGT 2743
 Db 16 TGTGTGTGTGTGTGT 2

RESULT 2244
 AAS13733/C
 ID AAS13733 standard; DNA; 18 BP.

XX AC AAS13733;

XX DT 08-MAY-2002 (first entry)

XX DE Simple sequence repeat, SSR, #30.

XX KW Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
 XX KW cereal profiling; grass profiling; seed batch purity testing.

XX OS Poeae.

XX XN NZ509193-A.

XX PD 25-MAY-2001.

XX PF 03-JAN-2001; 2001NZ-00509193.

XX PR 24-DEC-1999; 99AU-00004906.

XX PR 04-MAY-2000; 2000AU-00007310.

XX PA (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.

XX PA (UYSC-) UNIV SOUTHERN CROSS.

XX PA (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.

XX PA (UYAD-) UNIV ADELAIDE.

XX PA (ITMA-) INT MAIZE & WHEAT IMPROVEMENT CENT.

XX PI Forster JW, Jones ES;

XX DR WPI; 2001-512563/56.

XX New simple sequence repeats having 2 or more tandemly repeated nucleotide
 PT core elements isolated from ryegrass and fescue, useful for selecting of
 PT genes in grass or cereal breeding or profiling grass or cereal species
 PT varieties.

XX PS Claim 6; Page 51; 72pp; English.

XX The invention relates to a substantially purified or isolated nucleic
 CC acid (I) from ryegrass or fescue species including a simple sequence
 CC repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
 CC 2-6 nucleotides in length. Also included are a nucleic acid primer
 CC suitable for amplifying an SSR, identifying (M1) an SSR by preparing a
 CC library of ryegrass or fescue genomic DNA enriched for SSRs and
 CC identifying clones in the library containing SSRs, a library of ryegrass
 CC or fescue genomic DNA enriched for SSRs prepared by the M1, selecting for

CC a gene in grass or cereal breeding by identifying an SSR that is closely
 CC associated with the gene such that the SSR and the gene are
 CC preferentially co-inherited, and selecting for the SSR in the breeding, a
 CC method for DNA profiling grass or cereal species varieties by assessing
 CC variation between SSR varieties and testing the purity of grass or cereal
 CC seed batches by assessing variation within seed batch of an SSR. The SSRs
 CC may be used in the selection of genes in grass or cereal breeding, for
 CC profiling grass or cereal species varieties, for testing the purity of
 CC grass or cereal seed batches, and for DNA profiling to establish the
 CC distinct identity, uniformity and/or stability of a cultivar. The present
 CC sequence is a ryegrass or fescue SSR
 XX
 SQ

Sequence 18 BP; 9 A; 8 C; 0 G; 1 T; 0 U; 0 Other;

Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2735 TGTGTGTGTATGTGT 2749
 |||||
 Db 18 TGTGTGTGTATGTGT 4

RESULT 2245
 AAS13764
 ID AAS13764 standard; DNA; 18 BP.

XX
 AC AAS13764;

DT 08-MAY-2002 (first entry)

XX DE Simple sequence repeat, SSR, #36.

XX KW Simple sequence repeat; plant; ds; SSR; ryegrass; fescue; tandem repeat;
 KW cereal profiling; grass profiling; seed batch purity testing.

XX OS Lolium rigidum.

XX FN NZ509193-A.

XX PD 25-MAY-2001.

XX PF 03-JAN-2001; 2001NZ-00509193.

XX PR 24-DEC-1999; 99AU-00004906.

XX PR 04-MAY-2000; 2000AU-00007310.

XX PA (SAUS-) STATE SOUTH AUSTRALIA SOUTH AUSTRALIAN R.

XX PA (UYSC-) UNIV SOUTHERN CROSS.

XX PA (VICT-) STATE VICTORIA DEPT NATURAL RES & ENVIRO.

XX PA (UYAD-) UNIV ADELAIDE.

XX PA (ITWA-) INT MAIZE & WHEAT IMPROVEMENT CENT.

XX PI Forster JW, Jones ES;

XX DR WPI; 2001-512563/56.

XX PT New simple sequence repeats having 2 or more tandemly repeated nucleotide
 PT core elements isolated from ryegrass and fescue, useful for selecting of
 PT genes in grass or cereal breeding or profiling grass or cereal species
 PT varieties.

XX PS Example 1; Fig 6; 72pp; English.

XX CC The invention relates to a substantially purified or isolated nucleic
 CC acid (1) from ryegrass or fescue species including a simple sequence
 CC repeat (SSR), having 2 or more tandemly repeated nucleotide core elements
 CC 2-6 nucleotides in length. Also included are a nucleic acid primer
 CC suitable for amplifying an SSR, identifying (MI) an SSR by preparing a
 CC library of ryegrass or fescue genomic DNA enriched for SSRs and
 CC identifying clones in the library containing SSRs, a library of ryegrass
 CC or fescue genomic DNA enriched for SSRs prepared by the MI, selecting for
 CC a gene in grass or cereal breeding by identifying an SSR that is closely

CC associated with the gene such that the SSR and the gene are
 CC preferentially co-inherited, and selecting for the SSR in the breeding, a
 CC method for DNA profiling grass or cereal species varieties by assessing
 CC variation between SSR varieties and testing the purity of grass or cereal
 CC seed batches by assessing variation within seed batch of an SSR. The SSRs
 CC may be used in the selection of genes in grass or cereal breeding, for
 CC profiling grass or cereal species varieties, for testing the purity of
 CC grass or cereal seed batches, and for DNA profiling to establish the
 CC distinct identity, uniformity and/or stability of a cultivar. The present
 CC sequence is a ryegrass or fescue SSR
 XX
 SQ

Sequence 18 BP; 0 A; 1 C; 8 G; 9 T; 0 U; 0 Other;

Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
 |||||
 Db 4 TGTGTGTGTGTGTGT 18

RESULT 2246

AAH37514

ID AAH37514 standard; DNA; 18 BP.

XX
 AC AAH37514;

XX DT 14-AUG-2001 (first entry)

XX DE SNP specific lower PCR primer SEQ ID 310.

XX KW Single nucleotide polymorphism; SNP; single nucleotide primer extension;
 KW SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;
 KW Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;
 KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;
 KW acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;
 KW inflammation; forensic investigation; paternity analysis; PCR primer; ss.
 OS Homo sapiens.

XX FN WO200129262-A2.

XX PD 26-APR-2001.

XX PF 13-OCT-2000; 2000WO-US028436.

XX PR 15-OCT-1999; 99US-0160096P.

XX PA (ORCH-) ORCHID BIOSCIENCES INC.

XX PI Picoult-Newburg L, Pohl M;

XX DR WPI; 2001-290930/30.

XX PT New genotyping oligonucleotide, useful for detecting the presence,
 PT absence or identity of single polynucleotide polymorphism in a nucleic
 PT acid sample.

XX PS Claim 1; Page 51; 83pp; English.

XX CC Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide
 CC primer extension (SNPE) primers, and the sequences of regions flanking
 CC sites of single nucleotide polymorphisms SNPs. The present invention
 CC includes kits for determining the presence or absence of a SNP, using the
 CC oligonucleotides of the invention. The PCR primers are used to amplify a
 CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.
 CC The oligonucleotides are useful for genotyping a nucleic acid sample by
 CC performing a single-nucleotide primer extension reaction. The
 CC oligonucleotides are useful for determining the presence, absence or
 CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to
 CC assess by association analysis the genotype of an individual or group of
 CC individuals, having a pathological phenotypic trait suspected of being

CC caused by one or more SNPs. Phenotypic traits include diseases e.g.
 CC agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
 CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,
 CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic
 CC traits also include symptoms of or susceptibility to multifactorial
 CC disease of which a component is or may be genetic such as autoimmune
 CC diseases, including, rheumatoid arthritis, multiple sclerosis,
 CC inflammation, cancer, nervous system diseases and infection by pathogenic
 CC microorganism. The method is also useful in forensic investigations and
 CC paternity analysis. The present sequence represents a PCR primer specific
 CC for a human SNP containing DNA sequence
 XX
 SQ Sequence 18 BP; 0 A; 2 C; 9 G; 7 T; 0 U; 0 Other;

Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTG 2742
 Db 1 GTGTGTGTGTGTGTG 15

RESULT 2247
 ADA73752/C
 ID ADA73752 standard; DNA; 18 BP.

XX AC ADA73752;

XX DT 20-NOV-2003 (first entry)

XX DE Carcinoma associated (CA) polynucleotide #265.

XX KW mouse; ds; vulnery; antiinflammatory; cytostatic; gene therapy;
 KW vaccine; carcinoma associated gene; CA gene; CA protein; carcinoma drug;
 KW breast carcinoma; mammary adenocarcinoma; breast cancer; wound;
 KW inflammation; mouse mammary tumour virus; MMTV.

XX OS Mus sp.

XX PN US2003022255-A1.

XX PD 30-JAN-2003.

XX PF 22-DEC-2000; 2000US-00747377.

XX PR 22-DEC-2000; 2000US-00747377.

XX PA (MORR/) MORRIS D W.
 XX FA (ENGE/) ENGELHARD E K.

XX PI Morris DW, Engelhard EK;

XX DR WPI; 2003-596332/56.

XX Novel recombinant carcinoma associated nucleic acid for diagnosing or
 PT treating breast carcinoma, as probes to determine the number of copies of
 PT carcinoma associated gene in the genome, and in gene therapy.

XX PS Disclosure; Page 42; 61pp; English.

XX The invention describes a recombinant carcinoma associated (CA) nucleic
 CC acid (i). (i) is useful for: evaluating the effect of a candidate
 CC carcinoma drug, by administering the drug to a patient, removing a cell
 CC sample from the patient, and determining alterations in the expression or
 CC activation of a CA gene; diagnosing carcinoma, by determining the
 CC expression of one or more CA genes in a first tissue type of a first
 CC individual, and comparing the expression of the gene(s) from a second
 CC normal tissue type from the first individual or a second unaffected
 CC individual, where a difference in the expression indicates that the first
 CC individual has carcinoma; and diagnosing carcinoma or a propensity to
 CC carcinoma by sequencing at least one CA gene of an individual. A
 CC recombinant CA protein is useful for: screening a bioactive agent capable

CC of binding to an CA protein (CAP); screening a bioactive agent capable of
 CC modulating the activity of CAP; and determining the effect of the
 CC candidate agent on the bioactivity of CAP. The invention also discloses a
 CC method for treating carcinoma. (ii) is useful as probes to determine the
 CC number of copies of CA gene in the genome and to determine the
 CC chromosomal location of CA genes, in gene therapy, as DNA vaccines, and
 CC for generating animal models of carcinomas, particularly breast
 CC carcinomas. This animal model is useful in the screening of bioactive
 CC molecules to treat carcinoma. The recombinant CA protein is useful as
 CC markers of carcinomas, including mammary adenocarcinomas (i.e. breast
 CC cancer), to generate anti-CAP antibody, and for treating wound and
 CC inflammation. This sequence represents a carcinoma associated (CA) gene
 CC discovered using mouse mammary tumour virus (MMTV) infection of mouse
 CC models.

XX SQ Sequence 18 BP; 8 A; 6 C; 2 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2735 TGTGTGTGTGTGTGT 2749
 Db 16 TGTGTGTGTGTGTGT 2

RESULT 2248
 ADA02206/C
 ID ADA02206 standard; DNA; 18 BP.

XX AC ADA02206;

XX DT 06-NOV-2003 (first entry)

XX DE Mouse carcinoma associated nucleic acid, SEQ ID NO:725.

XX KW Mouse; murine; carcinoma associated; oncogene; carcinoma; cancer; breast;
 KW prostate; lymphoma; leukaemia; cytostatic; gene therapy; drug screening;
 KW ds.

XX OS Mus sp.

XX PN WO2003057146-A2.

XX PD 17-JUL-2003.

XX PF 26-DEC-2002; 2002WO-US041414.

XX PR 26-DEC-2001; 2001US-00035832.

XX PA (SAGR-) SAGRES DISCOVERY.

XX PI Morris DW;

XX DR WPI; 2003-587068/55.

XX Novel recombinant nucleic acid encoding carcinoma associated protein,
 PT useful for preparing compositions for treating carcinomas.

XX PS Claim 1; Page 218; 245pp; English.

XX The invention relates to recombinant carcinoma associated (CA) nucleic
 CC acid sequences from mouse and human (ADA01482-ADA03094), and to
 CC recombinant carcinoma associated proteins (CAP) encoded by them. The
 CC invention also encompasses expression vectors and host cells comprising a
 CC CA nucleic acid, a polypeptide (especially an antibody) that specifically
 CC binds to the protein, and a biochip comprising CA nucleic acid or
 CC fragments thereof. The sequences of the invention were identified using
 CC oncogenic retroviruses, which insert into the genome of the host organism
 CC at random. Many of these do not carry transduced host oncogenes or
 CC pathogenic trans-acting viral genes, meaning that cancer incidence is a
 CC direct consequence of the effects of proviral integration into host
 CC protooncogenes. The CA nucleic acid sequences can be used to diagnose

CC carcinoma (especially breast cancer, prostate cancer, lymphoma or
 CC leukaemia) or a propensity to carcinoma by determination of the sequence
 CC of a CA gene, or by determination of CA gene expression in particular
 CC tissues. CA nucleic acids, proteins and antibodies are also useful as
 CC therapeutic agents and in screening and evaluating drug candidates. The
 CC present sequence represents a specifically claimed murine CA nucleic acid
 CC sequence of the invention. Note: The sequence data for this patent is
 CC also available in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 18 BP; 8 A; 6 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2735 TGTGTGTGTGTGTGT 2749
 Db 16 TGTGTGTGTGTGTGT 2

RESULT 2249
 ADB71945/c
 ID ADB71945 standard; DNA; 18 BP.

XX
 AC ADB71945;

XX
 DT 04-DEC-2003 (first entry)

XX
 DE Mouse carcinoma associated gene fragment #725.

XX mouse; ds; cytostatic; gene therapy; vaccine; carcinoma; lymphomas;
 KW cancer; neoplasm; adenocarcinoma; sarcoma.

XX
 OS Mus sp.

XX
 PN WO2003008583-A2.

XX
 PD 30-JAN-2003.

XX
 PF 26-DEC-2001; 2001WO-US051291.

XX
 PR 02-MAR-2001; 2001US-00798586.

XX
 PR 23-OCT-2001; 2001US-00004113.

XX
 PR 08-NOV-2001; 2001US-00052482.

XX
 PR 30-NOV-2001; 2001US-00397722.

XX
 PR 20-DEC-2001; 2001US-00034650.

XX
 PA (SAGR-) SAGRES DISCOVERY.

XX
 PI Morris DW, Engelhard EK;

XX
 DR WPI; 2003-239337/23.

XX
 PT New recombinant nucleic acid, useful for treating carcinomas, lymphomas,
 PT cancers, neoplasm, adenocarcinoma, or sarcomas.

XX
 PS Claim 1; Page 174; 2304pp; English.

XX
 SQ The invention relates to a novel recombinant nucleic acid comprising a
 CC nucleotide sequence selected from any of the 660 sequences fully defined
 CC in the specification. A polynucleotide of the invention has cytostatic
 CC activity, and may have a use in gene therapy, or in a vaccine. The
 CC recombinant nucleic acids and polypeptides are useful for treating
 CC carcinomas, e.g. lymphomas, cancers, neoplasm, adenocarcinoma, and
 CC sarcomas. The sequences shown in ADB71221-ADB72172 represent mouse
 CC sequence tags, or genomic insertion sites, of carcinoma associated (CA)
 CC genes of the invention.

XX
 SQ Sequence 18 BP; 8 A; 6 C; 2 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2e+03;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 2735 TGTGTGTGTGTGTGT 2749
 Db 16 TGTGTGTGTGTGTGT 2

RESULT 2250
 AAQ33786
 ID AAQ33786 standard; DNA; 18 BP.

XX
 AC AAQ33786;

XX
 DT 25-MAR-2003 (revised)

XX
 DT 02-FEB-1993 (first entry)

XX
 DE Microsatellite sequence from clone TGLA189.

XX PCR; selection; primers; OPTIPRIM; breeding; cattle; parentage;
 KW genetic mapping; traits; amplification; ss.

XX
 OS Bos taurus.

XX
 PN WO9213102-A1.

XX
 PD 06-AUG-1992.

XX
 PF 15-JAN-1992; 92WO-US000340.

XX
 PR 15-JAN-1991; 91US-00642342.

XX
 PA (GENM-) GENMARK.

XX
 PI Georges M, Massey JM;

XX
 DR WPI; 1992-284684/34.

XX Polymorphic bovine DNA markers - used in genetic identification, gene
 PT mapping, and selective breeding.

XX
 PS Table 7; Page 244; 517pp; English.

XX The sequence is that of a bovine microsatellite sequence obtd. by
 CC screening a library of bovine MboI DNA fragments of between 250 and 500
 CC bp with an (AC)₁₅ and a (TC)₁₅ oligonucleotide probe. One out of 50
 CC clones cross-hybridised. Assuming independent distribution of
 CC microsatellites and MboI sites, the frequency of (T₆)_n > 9 microsatellites
 CC in the bovine genome is estimated at >100, 000. The sequence information
 CC for ca. 230 such bovine microsatellites is summarised in the
 CC specification and indexed herein (see below). The sequences upstream and
 CC downstream of the microsatellite sequence were used to generate the
 CC required PCR primers for in vitro amplification of the corresp.
 CC microsatellite (using the program OPTIPRIM). The microsatellites may be
 CC used to identify individuals, for parentage testing, and in the genetic
 CC mapping of economic trait loci, or genes involved the determinism of
 CC economically important traits esp. in cattle, to allow selective
 CC breeding. See also AAQ33501-34437. (Updated on 25-MAR-2003 to correct PN
 CC field.)

XX
 SQ Sequence 18 BP; 1 A; 0 C; 9 G; 8 T; 0 U; 0 Other;

Query Match 0.5%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 2e+03;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2726 GCGTGTGTGTGTGTGTGT 2743
 Db 1 GTGTGTGTGTGTGTGT 18

RESULT 2251
 AAV14205/c
 ID AAV14205 standard; DNA; 18 BP.

XX
AC AAV14205;
XX
XX 27-AUG-2003 (revised)
DT 19-MAY-1998 (first entry)
XX
XX Probe HBP145 for genotype specific target of HBV.
XX
XX Probe; hepatitis b virus; HBV detection; RT pol region; genetic analysis;
KW preCore region; HBsAg region; genotype specific target;
KW mutation detection; ss.
XX
XX Synthetic.
OS Hepatitis B virus.
OS
XX WO9740193-A2.
XX
XX 30-OCT-1997.
PD
XX 21-APR-1997; 97WO-EP002002.
PF
XX 19-APR-1996; 96EP-00870053.
XX
XX (INNO-) INNOGENETICS NV.
PA
XX Stuyver L, Rossau R, Maertens G;
FI
XX WPI; 1997-535867/49.
DR
XX
XX
XX Detection and/or genetic analysis of hepatitis B virus - specifically
PT genotype, preCore mutations, vaccine escape mutations and RT gene
PT mutations selected by treatment with drugs.
XX
XX Claim 5; Page 29; 80pp; English.
XX
XX This sequence is a probe for a genotype specific target of hepatitis b
CC virus (HBV). This sequence can be used in the method of the invention for
CC detection and/or genetic analysis of hepatitis B virus (HBV) in a sample.
CC The method comprises: (a) optionally releasing, isolating or
CC concentrating polynucleic acids (I) in the sample, and amplifying the
CC relevant part of a suitable HBV gene in the sample with at least 1
CC suitable primer pair; (b) hybridising (I) with a combination of at least
CC 2 nucleotide probes, which are applied to known locations on a solid
CC support and hybridise specifically to mutant target sequences chosen from
CC the HBV RT pol gene region, HBV preCore region, HBsAg region and/or HBV
CC genotype specific target sequences, or their complements or U for T
CC homologues; (c) detecting the hybrids formed in step (b), and inferring
CC the HBV genotype and/or mutants present in the sample from the
CC differential hybridisation signal(s). The composition can be used to
CC diagnose and/or monitor HBV mutants and/or genotypes in a sample,
CC specifically genotype, preCore mutations, vaccine escape mutations and RT
CC gene mutations selected by treatment with drugs, e.g. lamivudine and
CC penciclovir. (Updated on 27-AUG-2003 to correct OS field.)
XX
SQ Sequence 18 BP; 2 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 216 CCAGCCCAAGTGTGTGGG 233
DB 18 CCAGCCCAAGATGATGGG 1

RESULT 2252
AAX09336
ID AAX09336 standard; DNA; 18 BP.
XX
AC AAX09336;
XX
XX 24-MAR-1999 (first entry)
DT
XX

DE Human biallelic polymorphic marker upstream primer #216.
XX
XX Polymorphism; biallelic; human; forensic; paternity testing; disease;
KW detection; phenotypic typing; characteristic; infection; hereditary;
KW autoimmune disease; cancer; inflammation; drug; therapy; medicament;
KW treatment; marker; primer; ss.
XX
XX Synthetic.
OS Homo sapiens.
OS
XX WO9820165-A2.
XX
XX 14-MAY-1998.
PD
XX 05-NOV-1997; 97WO-US020313.
PF
XX 06-NOV-1996; 96US-0030455P.
XX
XX (WHED) WHITEHEAD INST BIOMEDICAL RES.
PA
XX Lander ES, Wang D, Hudson T;
XX
XX WPI; 1998-286974/25.
DR
XX
XX New isolated nucleic acid segments from the human genome - used for
PT determining polymorphic forms for use in e.g. forensics, paternity
PT testing or phenotypic typing for disease.
XX
XX Claim 15; Page 73; 310pp; English.
XX
XX AAX09121-X10268 are allele-specific oligonucleotide primers used in the
CC isolation of various biallelic polymorphic markers found in the human
CC genome (represented in AAX10269-X12937). These primers can be used in a
CC method for determining polymorphic forms in an individual for use in e.g.
CC forensics, paternity testing or for phenotypic typing for diseases such
CC as acamaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular
CC dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial
CC hypercholesterolemia, polycystic kidney disease, hereditary
CC spherocytosis, von Willebrand's disease, tuberous sclerosis, hereditary
CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
CC syndrome, osteogenesis imperfecta, acute intermittent porphyria,
CC autoimmune diseases, inflammation, cancer, diseases of the nervous
CC system, infection by pathogenic microorganisms, and characteristics such
CC as longevity, appearance (e.g. baldness, obesity), strength, speed,
CC endurance, fertility, and susceptibility or receptivity to particular
CC drugs or therapeutic treatments. The isolated polymorphic nucleic acid
CC segments can also be used to produce medicaments for the treatment or
CC prophylaxis of such diseases
XX
SQ Sequence 18 BP; 4 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2850 CCTCTGAGTAGCTGGGA 2867
DB 1 CCTCCCAAGTAGCTGGGA 18

RESULT 2253
AAX27846/C
ID AAX27846 standard; DNA; 18 BP.
XX
XX AAX27846;
XX
XX 23-DEC-1999 (first entry)
DT
XX
XX PCR primer for human DNA marker clone S110.
DE
XX Tandem repeat sequence; DNA isolation; intermediate tandem repeat;
KW ITR sequence; pentanucleotide tandem repeat; stutter artifact;
KW DNA typing; DNA profiling; linkage analysis; criminal justice;
KW

KW paternity testing; animal lineage analysis; microsatellite loci;
 KW polymorphism detection; PCR primer; ss.

OS Synthetic.
 XX Homo sapiens.

PN WO9940194-A1.

PD 12-AUG-1999.

PF 04-FEB-1999; 99WO-US002345.

PR 04-FEB-1998; 98US-00018584.

PA (PROM-) PROMEGA CORP.

PI Schumm JW, Bacher JW;

DR WPI; 1999-590696/50.

XX Isolating DNA containing intermediate tandem repeat sequences, useful in
 PT DNA profiling.

PS Claim 30; Page 22; 11pp; English.

CC This sequence is a PCR primer for a human DNA marker clone used in the
 CC method of the invention. The method is for isolating a fragment of DNA
 CC containing an intermediate tandem repeat (ITR) sequence using
 CC hybridization selection, and comprises: (a) providing several DNA
 CC fragments, at least one of which contains an ITR sequence, a region of
 CC the DNA fragment which contains at least one repeat unit consisting of a
 CC sequence of five, six or seven bases repeated in tandem at least two
 CC times; (b) providing a stationary support having at least one
 CC oligonucleotide associated with it, where the oligonucleotide includes a
 CC sequence of nucleotides which is complementary to a portion of the ITR
 CC sequence; and (c) combining the DNA fragments with the support under
 CC conditions where the DNA fragments including the DNA fragment containing
 CC the ITR sequence hybridize to the support. The method is particularly
 CC used to isolate DNA containing pentanucleotide tandem repeat sequences as
 CC well as to detect target ITR DNA sequences having a low incidence of
 CC stutter artifacts (no more than 2.4%). The method is useful in DNA
 CC profiling for linkage analysis, criminal justice, paternity testing and
 CC other forensic and medical uses. DNA typing is also useful for confirming
 CC the lineage of horses, dogs and other prize animals. The invention
 CC overcomes problems related to the use of microsatellite loci in DNA
 CC profiling. The method can detect polymorphisms with a low incidence of
 CC stutter artifacts, which has previously been a problem in interpreting
 CC allelic content of loci. The development of markers based on larger
 CC repeat units, enables easier separation of the fragments on
 CC electrophoretic gels. This allows the simultaneous analysis of more loci

XX Sequence 18 BP; 5 A; 4 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 2e+03;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2764 TCTGTACCCAGGCTGGA 2781

DB 18 TTTGTACCCAGACTGGA 1

RESULT 2254

AAZ71414

ID AAZ71414 standard; DNA; 18 BP.

AC AAZ71414;

DT 10-SEP-2001 (first entry)

DE Human biallelic marker upstream amplification primer SEQ ID NO:5770.

XX Human genome; biallelic marker; high density disequilibrium map;

KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 XX diagnosis; ss.

OS Homo sapiens.

XX WO9954500-A2.

PD 28-OCT-1999.

PF 21-APR-1999; 99WO-IB000822.

XX 21-APR-1998; 98US-0082614P.

PR 23-NOV-1998; 98US-0109732P.

XX (GEST) GENSET.

XX Cohen D, Blumenfeld M, Chumakov I;

XX WPI; 2000-013267/01.

XX Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome.

PS Claim 8; Page 1461; 2745pp; English.

CC AAZ65654 to AAZ65978 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AAZ65979 to AAZ77440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the invention
 CC have a variety of uses: they can be used for high density mapping of the
 CC human genome, and in complex association studies and haplotyping studies
 CC which are useful in determining the genetic basis for disease states.
 CC Compositions and methods of the invention can also be useful for the
 CC identification of the targets for the development of pharmaceutical
 CC agents and diagnostic methods, as well as the characterisation of the
 CC differential efficacious responses to and side effects from
 CC pharmaceutical agents acting on a disease as well as other treatment.
 CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
 CC 3367, are not actually given a sequence in the Sequence Listing from the
 CC present invention

XX Sequence 18 BP; 8 A; 7 C; 1 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 2e+03;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1618 ACCCCCATGAACCGAAC 1635

DB 1 ACCCCCATGAACCGAAC 18

RESULT 2255

AAF24249

ID AAF24249 standard; DNA; 18 BP.

AC AAF24249;

XX 27-MAR-2001 (first entry)

XX Human interleukin-1 beta coding sequence PCR primer #1.

XX Human; interleukin-1 receptor; arthritis; retroviral vector;
 KW joint pathology; PCR primer; ss.

XX Homo sapiens.

XX US6156304-A.

XX 05-DEC-2000.

XX

comprising DNA sequences encoding desired genes, infecting in vitro cultured target cells with recombinant vector, resulting in transduced target tissue cells (TTC) and transplanting TTC to the mammalian host, or by introducing DNA sequences encoding desired genes into target cell of a host by employing non-viral system. The method of the invention is useful for treating a connective tissue disorder. The method is also useful for producing an animal model for the study of pathologies, where the gene induces one or more symptoms of a joint pathology. The animal model is useful in studying connective tissue pathologies and indices of systemic inflammation, where the pathologies are leukocytosis, synovitis, oedema, cartilage breakdown, suppression of cartilage matrix synthesis, inflammation of eyes, arthritis or rheumatoid nodules. The indices of systemic inflammation includes elevated erythrocyte sedimentation rate, fever, weight loss and increases in blood levels of C-reactive protein and IL-6 (interleukin-6). The present nucleic acid sequence represents an oligonucleotide that was used in the methods of the invention

XX Sequence 18 BP; 4 A; 6 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1814 GGGGCCATGGTACCTGCA 1831
||| ||||| ||||| |||||
DB 1 GGCACCATGGTACCTGCA 18

RESULT 2259
ABL45073/c
ID ABL45073 standard; DNA; 18 BP.

AC ABL45073;

DT 11-APR-2002 (first entry)

DE Human chromosome 1p36-35 PCR primer SEQ ID NO:2117.

XX Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis; genome;
XX PCR primer; ss.

OS Homo sapiens.

XX JP2001321190-A.

XX 20-NOV-2001.

XX 12-MAR-2001; 2001JP-00068285.

XX 10-MAR-2000; 2000JP-00066716.

XX (RIKA) RIKAGAKU KENKYUSHO.

XX (GENO-) GENOTEX YG.

XX WPI; 2002-144136/19.

XX Arraying genome clones.

XX Claim 4; Page 46; 528pp; Japanese.

The present invention describes a method of arraying genome clones. The method comprises: (a) clones of the genomic libraries contained in multiwell plates numbered for discrimination are mixed in each of the multiwell plates; (b) a primer designed based on the chromosome marker sequence is added to the mixture to carry out an amplification reaction; (c) a signal corresponding to the marker is detected from the resultant amplified product to specify the discrimination Nos. of the multiwell plates containing the clones having said marker sequence; (d) the order of the markers is changed so that the same discrimination Nos. succeed to the maximum in the specified discrimination Nos. to array the multiwell plates; (e) the clones in the multiwell plates of the specified discrimination Nos. are mixed respectively in each wells of longitudinal and lateral directions; (f) the mixed clones are cultured and the

CC resultant cultures are amplified by using the above primer; (g) signals are detected from the amplified products; (h) the clones in the multiwell plates are specified from the detected result; and (i) the clones are reconstituted as the positions on the chromosome and arrayed. The microarray is useful for gene analysis. ABL42957 to ABL45322 represent PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634 represent PCR primers for human chromosome 21q22.1, which are specifically claimed for use in the present invention

XX Sequence 18 BP; 6 A; 1 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2838 CTCCTACCTCAGCTCTCT 2855
||||| ||||| ||||| |||||
DB 18 CTCCTACCTCAGCTCTCT 1

RESULT 2259
ABS66047/c
ID ABS66047 standard; DNA; 18 BP.

AC ABS66047;

XX 07-AUG-2003 (revised)

XX 15-NOV-2002 (first entry)

XX Universal bacteria detection primer #4.

XX Microbe detection; Legionella; Pseudomonas aeruginosa; Mycobacterium;
XX Burkholderia cepacia; Escherichia coli; Acinetobacter; Acanthamoeba;
XX Cryptosporidium parvum; PCR; primer; ss.

OS Rubacteria.

XX JP2002223766-A.

XX 13-AUG-2002.

XX 31-JAN-2001; 2001JP-00023742.

XX 31-JAN-2001; 2001JP-00023742.

XX (BAKA-) RAKAN KK.

XX (GIFU-) GIFU DAIGAKUCHO.

XX WPI; 2002-649521/70.

XX Detection of a microbe and a primer set for the detection.

XX Claim 4; Page 6; 25pp; Japanese.

The invention relates to a method for detection of a microbe by amplifying the gene of the microbe belonging to a specified range of classification by polymerase chain reaction (PCR) using a primer targeting the gene of the microbe. A primer set for the detection of a microbe is included for the detection of Legionella spp, Pseudomonas aeruginosa, Burkholderia cepacia, Escherichia coli, Acinetobacter, Mycobacterium, Acanthamoeba, Cryptosporidium parvum groups. ABS66002-ABS66053 represent primers used to detect the microbes of the invention. (Updated on 07-AUG-2003 to correct OS field.)

XX Sequence 18 BP; 1 A; 10 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 531 ACGGAGCCAGCTGTGGG 548
||||| ||||| ||||| |||||
DB 18 ACGGAGCCAGCTGTGGG 1

RESULT 2260
ADE14203/c
ID ADE14203 standard; DNA; 18 BP.
XX AC ADE14203;
XX DT 29-JAN-2004 (first entry)
XX DE Optineurin promoter motif, repeat element or regulatory region #312.
XX KW Human; optineurin; ds; ophthalmological; single nucleotide polymorphism;
XX KW SNP; glaucoma; progressive ocular hypertensive disorder;
XX KW glaucoma related disorder; motif; repeat element; regulatory region.
XX OS Homo sapiens.
XX US2003190617-A1.
XX PD 09-OCT-2003.
XX PF 06-MAR-2002; 2002US-00091281.
XX PR 06-MAR-2002; 2002US-00091281.
XX PA (SIEE/) SI E.
XX PA (RAYM/) RAYMOND V.
XX PA (MORI/) MORISSETTE J.
XX PI Raymond V, Morissette J, Si E;
XX WPI; 2003-864168/80.
XX New nucleic acid sequences of the optineurin gene are useful to detect
PT polymorphisms particularly single nucleotide polymorphisms in the
PT optineurin promoter to diagnose, prognose and treat glaucoma and related
PT disorders.
XX Claim 11; SEQ ID NO 314; 159pp; English.
XX The invention relates to an isolated nucleic acid (M1) comprising at
CC least 20 but not more than 1500 consecutive nucleotides of the optineurin
CC promoter appearing as ADE13890. Also included are the optineurin promoter
CC operably linked to a heterologous nucleic acid, a nucleic acid capable of
CC detecting a single nucleotide polymorphism (SNP) in the optineurin
CC promoter, a host cell comprising the promoter operably linked to a
CC heterologous sequence, diagnosing or prognosing glaucoma in a sample
CC obtained from a cell or bodily fluid (comprising detecting a polymorphism
CC in a promoter region of the optineurin gene, associated with a glaucoma
CC phenotype), detecting a SNP sequence variation in a sample containing
CC DNA, detecting the presence of an optineurin promoter sequence variation
CC in a sample containing DNA, determining the presence or increased
CC susceptibility to glaucoma or to a progressive ocular hypertensive
CC disorder resulting in loss of visual field in a patient (or the severity
CC or progression of glaucoma in a patient, comprising providing
CC amplification reaction primers that direct amplification of a selected
CC nucleic acid region containing the variation within the optineurin
CC promoter and amplifying the DNA) and detecting a polymorphism (comprising
CC obtaining a sample containing human genomic DNA, providing a nucleic acid
CC capable of detecting a SNP located within an optineurin promoter, and
CC detecting the polymorphism). The invention is used to diagnose and
CC prognose glaucoma and also to treat glaucoma related disorders. The
CC present sequence is an optineurin promoter motif, repeat element or
CC putative regulatory region.
XX SQ Sequence 18 BP; 4 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2766 TGTCACCCAGGCTGGAGT 2783

Db 18 TCTCACCACGCTGGAGT 1
RESULT 2261
ADE43642/c
ID ADE43642 standard; DNA; 18 BP.
XX AC ADE43642;
XX DT 29-JAN-2004 (first entry)
XX DE Human KNSL1 PCR primer, SEQ ID 247.
XX KW Neurodegenerative disease; uPA; SNGC; IDE; KNSL1; LIPA; TNFRSF6;
XX KW Alzheimer's disease; neuroprotective; nootropic; gene therapy;
XX KW Chromosome 10; PCR; primer; ss.
XX OS Homo sapiens.
XX WO2003054143-A2.
XX PD 03-JUL-2003.
XX PF 25-OCT-2002; 2002WO-US034679.
XX PR 25-OCT-2001; 2001US-0339525P.
XX PR 08-NOV-2001; 2001US-0336929P.
XX PR 08-NOV-2001; 2001US-0338010P.
XX PR 09-NOV-2001; 2001US-0338163P.
XX PR 04-DEC-2001; 2001US-0337052P.
XX PR 28-MAR-2002; 2002US-0368919P.
XX (NEUR-) NEUROGENETICS INC.
XX (GEO) GEN HOSPITAL CORP.
XX Becker KD, Velicalebi G, Elliott KJ, Wang X, Tanzi RE, Bertram L;
XX Saunders AJ, Mullin KM, Sampson AJ, Blacker DL;
XX WPI; 2003-559131/52.
XX Determining a predisposition for or the occurrence of neurodegenerative
PT disease, e.g. Alzheimer's disease by detecting in a target nucleic acid
PT the presence or absence of an allelic variant of one or more polymorphic
PT regions.
XX Example 3; Page 288; 848pp; English.
XX The present invention relates to a method (M1) for determining a
CC predisposition for or the occurrence of neurodegenerative disease in a
CC subject. The method comprises detecting in a target nucleic acid obtained
CC from the subject the presence or absence of an allelic variant of one or
CC more polymorphic regions of one or more genes selected from uPA
CC (urokinase plasminogen activator), SNGC (gamma-synuclein), IDE (insulin-
CC degrading enzyme), KNSL1 (Kinesin-like protein 1), LIPA (lysosomal acid
CC lyase), and TNFRSF6 (Tumour Necrosis Factor Receptor-SF6), where the
CC presence of at least one of the allelic variant of one or more
CC polymorphic regions is indicative of a predisposition for or the
CC occurrence of neurodegenerative disease. The genes are all located on
CC chromosome 10. M1 is useful for determining a predisposition for or the
CC occurrence of, and for treating neurodegenerative disease, particularly
CC Alzheimer's disease. The present sequence is a PCR primer, which was used
CC in the method of the invention.
XX SQ Sequence 18 BP; 4 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
Query Match 0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 2e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2755 AGCTCTCGCTCTGTACC 2772
Db 18 AGGTCTCGCACTGTACC 1

RESULT 2262
 ADG89496/c
 ID ADG89496 standard; DNA; 18 BP.
 XX
 AC ADG89496;
 XX
 DT 11-MAR-2004 (first entry)
 XX
 DE Human matrilin-3 PCR primer REMAT3.2J.F SEQ ID NO:71.
 XX
 KW human; matrilin-3; osteopathic; gene therapy; osteoarthritis; MATN3; EGF;
 KW ss; PCR; primer.
 XX
 OS Homo sapiens.
 XX
 PN WO2003062469-A2.
 XX
 PD 31-JUL-2003.
 XX
 PF 23-JAN-2003; 2003WO-IB000342.
 XX
 PR 25-JAN-2002; 2002US-0453705P.
 PR 05-DEC-2002; 2002US-0431538P.
 XX
 PA (DECO-) DECODE GENETICS EHF.
 XX
 PI Stefansson SE;
 XX
 DR WPI; 2003-646073/61.
 XX
 PT New nucleic acid molecule for diagnosing, prognosing or treating
 PT osteoarthritis comprises a matrilin-3 gene or its fragment or variant,
 PT and at least one polymorphism.
 XX
 PS Disclosure; SEQ ID NO 71; 190pp; English.
 XX
 CC The invention relates to a novel nucleic acid molecule comprising a
 CC matrilin-3 gene, or its fragment or variant, a sequence of 137870 bp
 CC fully defined in the specification, and at least one polymorphism given
 CC in the specification. A protein of the invention has osteopathic
 CC activity. A polynucleotide of the invention may have a use in gene
 CC therapy. The composition and methods of the invention are useful in
 CC diagnosing, prognosing or treating osteoarthritis using polymorphisms in
 CC the matrilin-3 gene. The present sequence is used in the exemplification
 CC of the invention.
 XX
 SQ Sequence 18 BP; 5 A; 3 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 2e+03;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 2833 TGATCCTCCACCTTCAGC 2850
 Db 18 TGATCCTCCACCTTCGC 1
 RESULT 2263
 ADL02154
 ID ADL02154 standard; DNA; 18 BP.
 XX
 AC ADL02154;
 XX
 DT 06-MAY-2004 (first entry)
 XX
 DE Human PCR primer P1 #3.
 XX
 KW STR; human; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN CN1401783-A.
 XX
 PD 12-MAR-2003.
 XX
 PF 26-SEP-2002; 2002CN-00133812.
 XX
 PR 26-SEP-2002; 2002CN-00133812.
 XX
 PA (UYSI-) UNIV SICHUAN.
 XX
 PI Hou Y, Li Y, Ying B;
 XX
 DR WPI; 2003-469319/45.
 XX
 PT Design method for compound amplification of STR primer.
 XX
 OS Disclosure; Page 10; 13pp; Chinese.
 XX
 CC The invention relates to a process for designing the primer for the
 CC complex amplification of STR includes respectively adding a non-human
 CC genome sequence to the terminal 5' of the oligonucleotide primer P1 and
 CC P2 able to specifically bind with human genome sequence to obtain long
 CC primers YPA-P1 and YPB-P2, using them as the primer pair for the first
 CC stage of polymerase chain reaction (PCR), and directly using the non-
 CC human genome sequence as the primer pair for the second stage of PCR. The
 CC present sequence represents a human PCR primer.
 XX
 SQ Sequence 18 BP; 3 A; 8 C; 2 G; 5 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 2e+03;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 709 CCCCCCAACTTCTCAGC 726
 Db 1 CCCCCCAACTTCTCAGC 18
 RESULT 2264
 ADH70789/c
 ID ADH70789 standard; DNA; 18 BP.
 XX
 AC ADH70789;
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Human Vbeta gene repeat sequence #579.
 XX
 KW human; T-cell associated disease; Vbeta; autoimmune disease;
 KW degenerative nervous system disease; graft versus host disease;
 KW hypersensitivity disease; infectious disease; neoplastic disease;
 KW Addison's disease; atrophic gastritis;
 KW degenerative nervous system disease; multiple sclerosis;
 KW Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;
 KW allergy; type II hypersensitivity; Goodpasture's syndrome;
 KW type IV hypersensitivity; leprosy; infectious disease; viral infection;
 KW HIV; fungal infection; Candida; parasitic infection; schistosoma;
 KW filaria; bacterial infection; Mycobacterium; neoplastic disease;
 KW lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;
 KW breast cancer; ds.
 XX
 OS Homo sapiens.
 XX
 PN US2002150891-A1.
 XX
 PD 17-OCT-2002.
 XX
 PF 05-MAR-1999; 99US-00263959.
 XX
 PR 19-SEP-1994; 94US-00309335.
 PR 19-SEP-1995; 95US-00531241.
 XX
 PA (HOOD/) HOOD L E.

PA (ROWE/) ROWEN L.
 XX Hood LE, Rowen L;
 PI WPI; 2004-059052/06.
 XX
 XX
 XX
 PT Kit for diagnosing and treating T-cell associated diseases e.g.
 PT autoimmune, degenerative nervous system and infectious disease, comprises
 PT nucleic acid primers specifically priming and allowing amplification of a
 PT Vbeta gene.
 XX
 XX
 PS Disclosure; SEQ ID NO 983; 164pp; English.
 XX
 XX The invention relates to a kit for diagnosing and treating T-cell
 CC associated diseases which comprises a panel of nucleic acid primers
 CC specifically priming and allowing amplification of each Vbeta gene,
 CC VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant
 CC rejection and diagnosing and treating T-cell associated diseases
 CC including autoimmune diseases, degenerative nervous system diseases,
 CC graft versus host disease, hypersensitivity diseases, infectious diseases
 CC and neoplastic diseases. Autoimmune diseases include Addison's disease,
 CC atrophic gastritis. Degenerative nervous system diseases include multiple
 CC sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type
 CC I hypersensitivities such as contact with allergens that lead to
 CC allergies, Type II hypersensitivities such as those present in
 CC Goodpasture's syndrome and Type IV hypersensitivities such as those
 CC manifested in leprosy. Infectious diseases include viral infections
 CC caused by viruses such as HIV, fungal infections such as those caused by
 CC the yeast genus Candida, parasitic infections such as those caused by
 CC schistosomes, filaria and bacterial infections such as those caused by
 CC Mycobacterium. Neoplastic diseases include lymphoproliferative diseases
 CC such as leukaemias, lymphomas and cancers such as cancer of the brain,
 CC breast. The present sequence represents a Vbeta gene repeat sequence.
 XX
 SQ Sequence 18 BP; 9 A; 8 C; 0 G; 1 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 2e+03; Mismatches 0; Gaps 0;
 Matches 16; Conservative 0; Indels 2; Indels 0; Gaps 0;
 QY 2729 TGTGTGTGTGTGTGTGTG 2746
 DB ||||| ||||| |||||
 18 TGTGTGTGTGTGTGTGTG 1
 RESULT 2265
 ADH54120/C
 ID ADH54120 standard; DNA; 18 BP.
 XX
 AC ADH54120;
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Human neurodegenerative disease-related PCR primer SeqID247.
 XX
 KW human; neurodegenerative disease; urokinase plasminogen activator; uPA;
 KW gamma-synuclein; SNGG; insulin degrading enzyme; IDE;
 KW kinsin-like protein 1; KNSL1; lysosomal acid lipase; LIPA;
 KW tumour necrosis factor receptor SF6; TNFRSF6; Alzheimer's disease; PCR;
 KW primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003224380-A1.
 XX
 PD 04-DEC-2003.
 XX
 PF 25-OCT-2002; 2002US-00282174.
 XX
 PR 25-OCT-2001; 2001US-0339525P.
 PR 25-OCT-2001; 2001US-0348065P.
 PR 02-NOV-2001; 2001US-0336983P.
 PR 08-NOV-2001; 2001US-0336929P.

PR 08-NOV-2001; 2001US-0338010P.
 PR 09-NOV-2001; 2001US-0338363P.
 PR 04-DEC-2001; 2001US-0337052P.
 PR 28-MAR-2002; 2002US-0368919P.
 XX
 XX (GEHO) GEN HOSPITAL CORP.
 PA
 XX
 XX Becker KD, Velicelebi G, Elliott KJ, Wang X, Tanzi RE;
 PI Bertram L, Saunders AJ, Mullin KM, Sampson AJ;
 XX
 XX WPI; 2004-060538/06.
 XX
 XX Determining a predisposition for or the occurrence of neurodegenerative
 PT disease, particularly Alzheimer's disease, comprises determining the
 PT presence of a polymorphism in the uPA, SNGG, IDE, KNSL1, LIPA or TNFRSF6
 PT gene.
 XX
 PS Example 3; SEQ ID NO 247; 205pp; English.
 XX
 CC This invention relates to a novel method of determining a predisposition
 CC for or the occurrence of neurodegenerative disease comprising detecting
 CC in a target nucleic acid obtained from the subject the presence of an
 CC allelic variant of polymorphic regions of human genes selected from
 CC urokinase plasminogen activator (uPA), gamma-synuclein (SNGG), insulin
 CC degrading enzyme (IDE), kinsin-like protein 1 (KNSL1), lysosomal acid
 CC lipase (LIPA) and tumour necrosis factor receptor SF6 (TNFRSF6). The
 CC method is useful in determining the presence or predisposition to a
 CC neurodegenerative disease, particularly Alzheimer's disease. The present
 CC sequence is that of a PCR primer which was used for amplification of a
 CC region of the human KNSL1 gene in the exemplification of the invention.
 XX
 SQ Sequence 18 BP; 4 A; 4 C; 7 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 2e+03; Mismatches 0; Gaps 0;
 Matches 16; Conservative 0; Indels 2; Indels 0; Gaps 0;
 QY 2755 AGCTCTCGCTCTGTGTCACC 2772
 DB ||||| ||||| |||||
 18 AGGTCTCGCACTGTGTCACC 1
 RESULT 2266
 ADP45875
 ID ADP45875 standard; DNA; 18 BP.
 XX
 AC ADP45875;
 XX
 DT 26-AUG-2004 (first entry)
 XX
 DE Extend primer 67 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.
 XX
 KW breast cancer; cytostatic; gene therapy; human;
 KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
 KW CD54; cell surface glycoprotein P3.58; ICAM-4;
 KW Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
 KW ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
 XX
 OS Homo sapiens.
 XX
 PN WO2004047623-A2.
 XX
 PD 10-JUN-2004.
 XX
 PF 25-NOV-2003; 2003WO-US037948.
 XX
 PR 25-NOV-2002; 2002US-0429136P.
 PR 24-JUL-2003; 2003US-0490234P.
 XX
 XX (SEQU-) SEQUENOM INC.
 PA
 XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
 XX

DR WPI; 2004-441051/41.

XX Identifying a subject at risk of breast cancer by detecting the presence

PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE

PT regions which are associated with breast cancer in a nucleic acid sample

PT from a subject.

XX Example 4; Page 84; 289pp; English.

XX The invention relates to a novel method for identifying a subject at risk

CC of breast cancer comprising detecting the presence or absence of one or

CC more polymorphic variations associated with breast cancer in a nucleic

CC acid sample from a subject. The method of the invention has cytostatic

CC applications and may be useful for identifying a subject at risk of

CC breast cancer, for early diagnosis, prevention and treatment of breast

CC cancer, possibly via gene therapy, as well as to analyse and predict a

CC response to a breast cancer treatment and in clinical drug trials. The

CC current sequence is that of an Extend primer (also described as probe) of

CC the invention which was used to genotype human intercellular adhesion

CC molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor;BB2

CC ;CD54;cell surface glycoprotein P3.58) has been mapped to chromosomal

CC position 19p13.3-p13.2. ICAM-4 (Landsteiner-Wiener blood group;LW) has

CC been mapped to chromosomal position 19p13.2-cen and ICAM-5

CC (telencephalin) has been mapped to chromosomal position 19p13.2.

XX Sequence 18 BP; 3 A; 4 C; 8 G; 3 T; 0 U; 0 Other;

SQ Query Match 0.5%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 2e+03; Indels 0; Gaps 0;

Matches 16; Conservative 0; Mismatches 2;

OY 455 TACGCTGCACGTGGAGG 472

DB 1 TGGCTGCCAAGTGGAGG 18

RESULT 2267

ADS94251/c

ID ADS94251 standard; DNA; 18 BP.

XX ADS94251;

AC ADS94251;

XX 02-DEC-2004 (first entry)

DT BCL2 probe.

DE CAMP concentration; monocyte cell;

XX granulocyte macrophage colony stimulating factor; GMCSF;

KW immunosuppressive; antianaemic; anabolic; hypertensive; antidiabetic;

KW nephrotropic; muscular; neuroprotective; ophthalmological;

KW antiinflammatory; antiulcer; gastrointestinal; dermatological; CNS;

KW antiarthritic; antirheumatic; thyromimetic; antithyroid; vasotropic;

KW antiallergic; antiasthmatic; virucide; cytostatic;

KW granulysin expression stimulator; interleukin-10 expression stimulator;

KW autoimmune disease; allergic disease; transplant rejection;

KW viral infection; tumour; human; probe; ss.

XX Homo sapiens.

OS Synthetic.

OS WO2004035083-A2.

XX 29-APR-2004.

PD 21-OCT-2003; 2003WO-GB004537.

XX 21-OCT-2002; 2002GB-00024415.

PR (MEDI-) MEDICAL RES COUNCIL.

PA Kelly RW;

XX WPI; 2004-357143/33.

XX Composition useful for treatment of autoimmune disease or condition e.g.

PT primary myxoedema, comprising agent which raises cAMP concentration in

PT monocyte cell, and granulocyte-macrophage colony stimulating factor or

PT its derivative.

XX Example 1; Page 59; 92pp; English.

XX The present invention describes a composition or a therapeutic system

CC comprising an agent which raises cAMP concentration in a monocyte cell,

CC and granulocyte-macrophage colony stimulating factor (GMCSF) or its

CC derivative and optionally a carrier, diluent or excipient. The

CC composition and agent have immunosuppressive, antianaemic, anabolic,

CC hypertensive, antidiabetic, nephrotropic, muscular, neuroprotective,

CC ophthalmological, antiinflammatory, antiulcer, gastrointestinal,

CC dermatological, CNS, antiarthritic, antirheumatic, thyromimetic,

CC antithyroid, vasotropic, antiallergic, antiasthmatic, virucide and

CC cytostatic activities, and can be used as granulysin expression and

CC interleukin-10 expression stimulators. They can be used in the

CC manufacture of a medicament for the treatment of an autoimmune disease or

CC a condition (e.g. primary myxoedema, thyrotoxicosis, pernicious anaemia,

CC autoimmune atrophic gastritis, Addison's disease, insulin dependent

CC diabetes mellitus, Goodpasture's syndrome, myasthenia gravis, sympathetic

CC ophthalmia, multiple sclerosis, autoimmune haemolytic anaemia, idiopathic

CC leucopenia, ulcerative colitis, dermatomyositis, scleroderma, mixed

CC connective tissue disease, rheumatoid arthritis, irritable bowel

CC syndrome, systemic lupus erythematosus, Hashimoto's disease, thyroiditis,

CC Behcet's disease, celiac disease/dermatitis herpetiformis, renal

CC vasculitis and demyelinating disease), allergic diseases such as allergic

CC asthma, for inducing tolerance to an antigen in a patient or treating an

CC aberrant or undesired immune or inflammatory response (e.g. deficiency in

CC interleukin-10 production) to the antigen in the patient, for treating

CC diseases associated with transplant rejection (e.g. graft versus host

CC disease or host versus graft disease), viral infection (e.g. herpes

CC simplex virus infection (such as cold sore) and human papillomas virus

CC infection (e.g. wart)) and tumours. The composition stimulates or

CC enhances granulysin expression in cells of the macrophage/monocyte

CC lineage, and particularly stimulates or enhances interleukin-10

CC expression in, and secretion from cells of, the macrophage/monocyte

CC lineage. The present sequence represents a probe for BCL2, which is used

CC in an example from the present invention.

XX Sequence 18 BP; 4 A; 7 C; 7 G; 0 T; 0 U; 0 Other;

SQ Query Match 0.5%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 2e+03; Indels 0; Gaps 0;

Matches 16; Conservative 0; Mismatches 2;

OY 95 TCTGTGTCCTGCTGGGG 112

DB 18 TCTGTGTCCTGCTGGGG 1

RESULT 2268

ADT00299/c

ID ADT00299 standard; DNA; 18 BP.

XX ADT00299;

AC ADT00299;

XX 16-DEC-2004 (first entry)

DT Novel mutant protein tyrosine kinase-related oligonucleotide SeqID287.

DE tyrosine kinase; cancer; anti-cancer agent; signalling molecule;

XX tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;

KW GUCY2F; MCKK; MLK4; kinase domain; cytostatic; tyrosine kinase inhibitor;

KW guanylate cyclase stimulator; ss.

XX Homo sapiens.

OS WO2004082458-A2.

XX 30-SEP-2004.

XX PF 18-FEB-2004; 2004WO-US004452.
 XX PR 21-FEB-2003; 2003US-0448537P.
 XX PR 29-MAY-2003; 2003US-0473895P.
 XX PA (UWJO) UNIV JOHNS HOPKINS.
 XX PI Bardelli A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;
 XX DR WPI; 2004-718702/70.
 XX CC Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCCK) and
 PT associated methods for diagnosing cancer and screening for anti-cancer
 PT agents.
 XX CC Disclosure; SEQ ID NO 287; 363pp; English.
 XX CC This invention relates to a novel activated mutant protein tyrosine
 CC kinases and associated methods for diagnosing cancer and screening for
 CC anti-cancer agents. Protein kinases are signalling molecules involved in
 CC tumorigenesis. Mutational analysis of the human tyrosine kinase gene
 CC family identified somatic alteration sin 1 in 5 colorectal cancers, with
 CC the majority of mutations occurring in the NTRK3, FES, GUCY2F and
 CC MCCK/MLK4 genes. Most were identified in the kinase domain. The invention
 CC may be useful for the production of compounds with a cytostatic activity
 CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
 CC stimulators. The invention may be useful for developing methods for
 CC detecting mutations involved in cancer or screening for anti-cancer
 CC agents. The present sequence is that of a human-derived oligonucleotide
 CC which is related to the invention.
 XX SQ Sequence 18 BP; 4 A; 5 C; 7 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 2e+03;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Oy 2763 CTCTGTGACCCAGCGCTGG 2780
 Db ||||| ||||| |||||
 18 CTCTGTGCGCCAGACTGG 1
 RESULT 2269
 ADP45859
 ID ADP45859 standard; DNA; 23 BP.
 XX AC ADP45859;
 XX DT 26-AUG-2004 (first entry)
 XX DE Extend primer 51 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.
 XX KW breast cancer; cytostatic; gene therapy; human;
 KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
 KW CD54; cell surface glycoprotein P3.58; ICAM-4;
 KW Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
 KW ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
 XX OS Homo sapiens.
 XX PN WO2004047623-A2.
 XX PD 10-JUN-2004.
 XX PF 25-NOV-2003; 2003WO-US037948.
 XX PR 25-NOV-2002; 2002US-0429136P.
 XX PR 24-JUL-2003; 2003US-0490234P.
 XX PA (SEQU-) SEQUENOM INC.
 XX PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
 XX DR WPI; 2004-441051/41.
 XX PT Identifying a subject at risk of breast cancer by detecting the presence
 PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
 PT regions which are associated with breast cancer in a nucleic acid sample

XX WPI; 2004-441051/41.
 XX PT Identifying a subject at risk of breast cancer by detecting the presence
 PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
 PT regions which are associated with breast cancer in a nucleic acid sample
 PT from a subject.
 XX PS Example 4; Page 83; 289pp; English.
 XX CC The invention relates to a novel method for identifying a subject at risk
 CC of breast cancer comprising detecting the presence or absence of one or
 CC more polymorphic variations associated with breast cancer in a nucleic
 CC acid sample from a subject. The method of the invention has cytostatic
 CC applications and may be useful for identifying a subject at risk of
 CC breast cancer, for early diagnosis, prevention and treatment of breast
 CC cancer, possibly via gene therapy, as well as to analyse and predict a
 CC response to a breast cancer treatment and in clinical drug trials. The
 CC current sequence is that of an Extend primer (also described as probe) of
 CC the invention which was used to genotype human intercellular adhesion
 CC molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor; BB2
 CC ; CD54; cell surface glycoprotein P3.58) has been mapped to chromosomal
 CC position 19p13.3-p13.2, ICAM-4 (Landsteiner-Wiener blood group; LW) has
 CC been mapped to chromosomal position 19p13.2-cen and ICAM-5
 CC (telencephalin) has been mapped to chromosomal position 19p13.2.
 XX SQ Sequence 23 BP; 5 A; 4 C; 6 G; 8 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.8; DB 1; Length 23;
 Best Local Similarity 88.9%; Pred. No. 1.6e+03;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Oy 1464 GGTGACCGTGAATGCTCT 1481
 Db ||||| ||||| |||||
 6 GGTGACCTTGAATGTGAT 23
 RESULT 2270
 ADP45810
 ID ADP45810 standard; DNA; 22 BP.
 XX AC ADP45810;
 XX DT 26-AUG-2004 (first entry)
 XX DE Extend primer 2 used to genotype human ICAM-1/ICAM-4/ICAM-5 polymorphism.
 XX KW breast cancer; cytostatic; gene therapy; human;
 KW intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
 KW CD54; cell surface glycoprotein P3.58; ICAM-4;
 KW Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
 KW ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
 XX OS Homo sapiens.
 XX PN WO2004047623-A2.
 XX PD 10-JUN-2004.
 XX PF 25-NOV-2003; 2003WO-US037948.
 XX PR 25-NOV-2002; 2002US-0429136P.
 XX PR 24-JUL-2003; 2003US-0490234P.
 XX PA (SEQU-) SEQUENOM INC.
 XX PI Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
 XX DR WPI; 2004-441051/41.
 XX PT Identifying a subject at risk of breast cancer by detecting the presence
 PT of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
 PT regions which are associated with breast cancer in a nucleic acid sample

PT from a subject.
 PS Example 4; Page 82; 289pp; English.
 CC The invention relates to a novel method for identifying a subject at risk
 CC of breast cancer comprising detecting the presence or absence of one or
 CC more polymorphic variations associated with breast cancer in a nucleic
 CC acid sample from a subject. The method of the invention has cytostatic
 CC applications and may be useful for identifying a subject at risk of
 CC breast cancer, for early diagnosis, prevention and treatment of breast
 CC cancer, possibly via gene therapy, as well as to analyse and predict a
 CC response to a breast cancer treatment and in clinical drug trials. The
 CC current sequence is that of an extend primer (also described as probe) of
 CC the invention which was used to genotype human intercellular adhesion
 CC molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor; BB2
 CC ; CD54; cell surface glycoprotein P3.58) has been mapped to chromosomal
 CC position 19p13.3-p13.2, ICAM-4 (Landeliner-Wiener blood group; LW) has
 CC been mapped to chromosomal position 19p13.2-cen and ICAM-5
 CC (telencephalin) has been mapped to chromosomal position 19p13.2.
 XX
 SQ Sequence 22 BP; 6 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.6; DB 1; Length 22;
 Best Local Similarity 81.0%; Pred. No. 1.7e+03;
 Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 2249 CATGTCACATTCACAGGTCCACC 2269
 DB 1 CAGAGCACATTCACGGTCCACC 21
 RESULT 2271
 AAC73486
 ID AACT73486 standard; DNA; 18 BP.
 XX
 AC AACT73486;
 XX
 XX
 DT 02-FEB-2001 (first entry)
 XX
 DE Reverse primer #104 used in multiplexing PCR/SBE assay.
 XX
 KW Oligonucleotide array; genotyping; single base extension reaction; SBE;
 KW PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
 XX
 OS Unidentified.
 XX
 PN WO200058516-A2.
 XX
 PD 05-OCT-2000.
 XX
 XX 27-MAR-2000; 2000WO-US008069.
 PF
 XX 26-MAR-1999; 99US-0126473P.
 PR 23-JUN-1999; 99US-0140359P.
 XX
 PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
 PA (AFFY-) AFFYMETRIX INC.
 XX
 XX Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;
 PI Ryder T, Sklar P;
 XX
 XX WPI; 2000-656171/63.
 DR
 XX Universal array of oligonucleotides tags attached to a solid substrate
 PT along with locus-specific tagged oligonucleotides useful in genotyping
 PT using single base extension reactions.
 XX
 XX Example 7; Page 59; 70pp; English.
 PS
 XX The present invention relates to an oligonucleotide array comprising
 CC oligonucleotide tags fixed to a solid substrate. The oligonucleotide
 CC array is useful for genotyping a nucleic acid sample at one or more loci
 CC via single base extension (SBE) reactions. A pair of primers is used to

CC amplify a polymorphic locus in a sample e.g. a single nucleotide
 CC polymorphism (SNP). The present sequence is one of the primers used in
 CC the method of the present invention to amplify a polymorphic sample. The
 CC amplified nucleic acid product is then used as a template in a SBE
 CC reaction with an extension primer. The SBE reaction products are used to
 XX form the oligonucleotide array
 SQ Sequence 18 BP; 5 A; 7 C; 3 G; 3 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 2.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2254 CACATTCACAGGTCCACC 2269
 DB 3 CACATTCACAGGTCCACC 18
 RESULT 2272
 ADS41455
 ID ADS41455 standard; DNA; 18 BP.
 XX
 AC ADS41455;
 XX
 DT 16-DEC-2004 (first entry)
 XX
 DE Human autoimmune disease-related PCR primer - SEQ ID 6669.
 XX
 KW single nucleotide polymorphism detection; SNP detection;
 KW rheumatoid arthritis; type 1 diabetes; multiple sclerosis;
 KW systemic lupus erythematosus; inflammatory bowel disease; psoriasis;
 KW thyroiditis; celiac disease; pernicious anaemia; asthma; vitiligo;
 KW glomerulonephritis; Grave's disease; myocarditis; Sjogren's disease;
 KW primary systemic vasculitis; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO2004083403-A2.
 XX
 PD 30-SEP-2004.
 XX
 XX 18-MAR-2004; 2004WO-US008461.
 PF
 XX 18-MAR-2003; 2003US-0455444P.
 PR 25-APR-2003; 2003US-0465241P.
 XX
 XX (APPL-) APPLERA CORP.
 XX
 XX Cargill M, Begovich AB, Alexander HC;
 XX WPI; 2004-728480/71.
 DR
 XX New isolated nucleic acid molecule comprises at least 8 contiguous
 PT nucleotides where one of the nucleotides is a single nucleotide
 PT polymorphism (SNP), useful for diagnosing or treating autoimmune
 PT diseases, e.g. rheumatoid arthritis.
 XX
 PS Claim 21; SEQ ID NO 6669; 123pp; English.
 XX
 CC The invention comprises amino acid and coding sequences containing
 CC genetic polymorphisms associated with an altered risk of developing an
 CC autoimmune disease (e.g. rheumatoid arthritis). The invention further
 CC comprises a method of identifying an individual that has an altered risk
 CC of developing an autoimmune disease, comprising detecting a single
 CC nucleotide polymorphism (SNP) in a nucleic acid of the invention. The DNA
 CC and protein sequences of the invention are useful for diagnosing and
 CC treating autoimmune diseases, such as: rheumatoid arthritis, type 1
 CC diabetes, multiple sclerosis, systemic lupus erythematosus, inflammatory
 CC bowel diseases, psoriasis, thyroiditis, celiac disease, pernicious
 CC anaemia, asthma, vitiligo, glomerulonephritis, Grave's disease,
 CC myocarditis, Sjogren's disease, or primary systemic vasculitis. The
 CC present DNA sequence represents a human autoimmune disease-related PCR
 CC primer of the invention. NOTE: The present sequence is not shown in the

CC specification, but has been retrieved from the WIPO website.

XX
SQ Sequence 18 BP; 4 A; 8 C; 2 G; 4 T; 0 U; 0 Other;
Query Match 0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 2.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 2254 CACATTCAAGGTCACC 2269
Db 1 CACATTCAAGGTCACC 16
RESULT 2273
ADS41454
ID ADS41454 standard; DNA; 18 BP.
XX
AC ADS41454;
XX
DT 16-DEC-2004 (first entry)
XX
DE Human autoimmune disease-related PCR primer - SEQ ID 6668.
XX
KW single nucleotide polymorphism detection; SNP detection;
KW rheumatoid arthritis; type 1 diabetes; multiple sclerosis;
KW systemic lupus erythematosus; inflammatory bowel disease; psoriasis;
KW thyroiditis; celiac disease; pernicious anaemia; asthma; vitiligo;
KW glomerulonephritis; Grave's disease; myocarditis; Sjogren's disease;
KW primary systemic vasculitis; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN WO2004083403-A2.
XX
PD 30-SEP-2004.
XX
PF 18-MAR-2004; 2004WO-US008461.
XX
PR 18-MAR-2003; 2003US-0455444P.
XX
PS 25-APR-2003; 2003US-0465241P.
XX
PA (APPL-) APPLERA CORP.
XX
PI Cargill M, Begovich AB, Alexander HC;
XX
DR WPI; 2004-728480/71.
XX
PT New isolated nucleic acid molecule comprises at least 8 contiguous
PT nucleotides where one of the nucleotides is a single nucleotide
PT polymorphism (SNP), useful for diagnosing or treating autoimmune
PT diseases, e.g. rheumatoid arthritis.
XX
PS Claim 21; SEQ ID NO 6668; 123pp; English.
XX
CC The invention comprises amino acid and coding sequences containing
CC genetic polymorphisms associated with an altered risk of developing an
CC autoimmune disease (e.g. rheumatoid arthritis). The invention further
CC comprises a method of identifying an individual that has an altered risk
CC of developing an autoimmune disease, comprising detecting a single
CC nucleotide polymorphism (SNP) in a nucleic acid of the invention. The DNA
CC and protein sequences of the invention are useful for diagnosing and
CC treating autoimmune diseases, such as: rheumatoid arthritis, type 1
CC diabetes, multiple sclerosis, systemic lupus erythematosus, inflammatory
CC bowel diseases, psoriasis, thyroiditis, celiac disease, pernicious
CC anaemia, asthma, vitiligo, glomerulonephritis, Grave's disease,
CC myocarditis, Sjogren's disease, or primary systemic vasculitis. The
CC present DNA sequence represents a human autoimmune disease-related PCR
CC primer of the invention. NOTE: The present sequence is not shown in the
CC specification, but has been retrieved from the WIPO website.
XX
SQ Sequence 18 BP; 4 A; 7 C; 2 G; 5 T; 0 U; 0 Other;
Query Match 0.5%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 2.2e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2254 CACATTCAAGGTCACC 2269
Db 1 CACATTCAAGGTCACC 16

RESULT 2274
AAT54732
ID AAT54732 standard; RNA; 18 BP.

XX
AC AAT54732;
XX
DT 25-MAR-2003 (revised)
DT 22-APR-1997 (first entry)
XX
DE Human IL-5 hammerhead ribozyme target sequence (nt. position 151).
XX
KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW translocation; chronic myelogenous leukaemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmune disease;
KW atherosclerosis; myocardial infarction; stroke; restenosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;
KW ss.

XX Homo sapiens.

XX OS

XX PN WO9523225-A2.

XX PD 31-AUG-1995.

XX PF 23-FEB-1995; 95WO-IB000156.

XX PR 23-FEB-1994; 94US-00201109.

XX PR 29-MAR-1994; 94US-00218934.

XX PR 04-APR-1994; 94US-00222795.

XX PR 07-APR-1994; 94US-00224483.

XX PR 15-APR-1994; 94US-00227958.

XX PR 15-APR-1994; 94US-00228041.

XX PR 18-MAY-1994; 94US-00245736.

XX PR 06-JUL-1994; 94US-00271280.

XX PR 15-AUG-1994; 94US-00291932.

XX PR 16-AUG-1994; 94US-00291433.

XX PR 17-AUG-1994; 94US-00292620.

XX PR 19-AUG-1994; 94US-00293520.

XX PR 02-SEP-1994; 94US-00300000.

XX PR 08-SEP-1994; 94US-00303039.

XX PR 23-SEP-1994; 94US-00311486.

XX PR 23-SEP-1994; 94US-00311749.

XX PR 28-SEP-1994; 94US-00314397.

XX PR 28-OCT-1994; 94US-00316771.

XX PR 07-OCT-1994; 94US-00319492.

XX PR 11-OCT-1994; 94US-00321993.

XX PR 04-NOV-1994; 94US-00334847.

XX PR 10-NOV-1994; 94US-00337608.

XX PR 28-NOV-1994; 94US-00345516.

XX PR 16-DEC-1994; 94US-00357577.

XX PR 23-DEC-1994; 94US-00363233.

XX PR 30-JAN-1995; 95US-00380734.

XX (RIBO-) RIBOZYME PHARM INC.

XX PA

XX PI Stinchcomb DT, Chowrira B, Dizenzo A, Draper KG, Dudycz LW;

XX PI Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;

XX PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweetler D, Thompson JD;

XX PI Tracz D, Usman N, Wincott PE, Woolf T;

DR WPI; 1995-351090/45.
 XX Ribozymes having modified bases and methods for producing them - for use
 PT in inhibiting disease related genes.
 XX
 PS Claim 2; Page 222; 407pp; English.
 XX
 CC The present sequence represents a preferred target sequence for an
 CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves interleukin-5 (IL-
 CC 5) mRNA at the nucleotide base position indicated in the DE line. Regions
 CC of the mRNA that do not form secondary folding structures and that
 CC contain potential hammerhead and hairpin ribozyme cleavage sites were
 CC identified by computer analysis. Ribozymes directed against these mRNA
 CC sequences were designed and synthesised with modifications that improve
 CC their nuclease resistance. The ribozymes cleave the IL-5 target sequences
 CC and thereby inhibit IL-5 expression, making them useful for treating
 CC chronic asthma, e.g. by inhibiting the synthesis of IL-5 in lymphocytes
 CC and preventing the recruitment and activation of eosinophils. The
 CC ribozymes can also be used to treat eosinophilia (related to parasitic
 CC infection or with pulmonary infiltration) and L-tryptophan-associated
 CC eosinophilia-myalgia syndrome. (Updated on 25-MAR-2003 to correct PI
 CC field.)
 XX
 SQ Sequence 18 BP; 2 A; 6 C; 3 G; 0 T; 7 U; 0 Other;
 Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 62.5%; Pred. No. 2.2e+03;
 Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;
 QY 2117 GGCACCTGCTGCTACT 2132
 |||||:|:|:|:
 DB 2 GGCACGCUUUCUACU 17
 RESULT 2275
 AAQ95849/C
 ID AAQ95849 standard; DNA; 18 BP.
 XX
 AC AAQ95849;
 XX
 DT 21-FEB-1996 (first entry)
 XX
 XX Primer A (Group 11, set A) for marker D6S344, chromosome 6.
 DE primer; polymerase chain reaction; PCR; linkage study; locus;
 KW microsatellite marker sequence; automated genotyping; allele;
 KW polymorphism; detection; Homo sapiens; ss.
 XX Synthetic.
 OS
 XX WO9515400-A1.
 XX
 PD 08-JUN-1995.
 XX
 XX 05-DEC-1994; 94WO-US013945.
 PF
 XX 03-DEC-1993; 93US-00160837.
 PR
 XX (UJJO) UNIV JOHNS HOPKINS.
 PA
 XX Levitt RC;
 PI
 XX WPI; 1995-215278/28.
 XX
 XX Kit for automated genotyping contg. pairs of PCR primers - designed to
 PT amplify polymorphic nucleotide repeat sequences, arranged in sets each
 PT with a characteristic fluorescence label, useful e.g. in detection of
 PT disease related genetic rearrangement.
 XX
 PS Disclosure; Fig 7K-2; 104pp; English.
 XX
 XX The method aims to provide a collection of highly reproducible
 CC microsatellite marker sequences (MMS) at approx. 10-50 cm intervals

CC throughout the human genome which can be detectably labelled. The MMS are
 CC polymorphic, simple sequence repeats and can be used in automated
 CC genotyping, esp. fluorescence-based. The primers correspond to the unique
 CC DNA sequence surrounding each marker, and PCR is used to detect each
 CC polymorphism. When the MMS show considerable polymorphism (ie. a
 CC difference in the number of repeats) between individuals, the markers can
 CC be particularly informative. The MMS can be ideal for linkage studies.
 CC Kits comprise at least 4 groups, of at least 3 sets, each comprising
 CC labelled primers for PCR amplification of the DNA. Group 11 primer pairs
 CC are shown in AAQ95841-82. The published size range of the D6S344 allele
 CC is 139-159 bp, and the degree of heterozygosity in the population is
 CC about 72%
 XX
 SQ Sequence 18 BP; 3 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 2.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2767 GTCACCCAGGCTGGAG 2782
 |||||:|:|:|:
 DB 16 GTGACCCAGGCTGGAG 1
 RESULT 2276
 AAZ25594
 ID AAZ25594 standard; DNA; 18 BP.
 XX
 AC AAZ25594;
 XX
 DT 21-DEC-1999 (first entry)
 XX
 XX Human RhoG antisense phosphorothioate oligonucleotide #35.
 DE
 XX Human; RhoG; inhibition; antisense; phosphorothioate; expression; GTPase;
 KW mitosis; mitogen; DNA synthesis; cell cycle; cancer;
 KW dynamic organisation; actin cytoskeleton; ras-mediated transformation;
 KW diagnosis; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..18
 FT /*tag= a
 FT /note= "phosphorothioate linkages"
 XX
 PN US9565370-A.
 XX
 XX 12-OCT-1999.
 PD
 XX 25-SEP-1998; 98US-00161015.
 PF
 XX 25-SEP-1998; 98US-00161015.
 PR
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Cowsert LM;
 PI
 XX WPI; 1999-579906/49.
 XX
 XX Antisense oligonucleotides useful for inhibiting the expression of the
 PT human RhoG gene.
 PT
 XX Example 15; Col 27; 24pp; English.
 PS
 XX AAZ25553 to AAZ25582 represent specifically claimed antisense
 CC oligonucleotides targeted to, and capable of inhibiting the expression of
 CC nucleic acids encoding human RhoG. RhoG is a member of the Rho subfamily
 CC of small GTPases the expression of which is associated with the induction
 CC of mitosis by mitogens. RhoG is thought to be required for entry into the
 CC DNA synthesis step of the cell cycle. It also effects the dynamic
 CC organisation of the actin cytoskeleton which regulates changes during

CC cell cycle progression (e.g. cell rounding and pinching off during
 CC mitosis) and with determining the density to which cells will proliferate
 CC (RhoG affects an actin-dependent signal transduction pathway mediating
 CC the level of contact inhibition through surface signals). Additionally,
 CC RhoG is associated with the development of cancers (RhoG participates in
 CC a signalling pathway involving ras-mediated transformation). Antisense
 CC compounds from the present invention may be used for inhibiting the
 CC expression of human RhoG in cells and tissues in vitro and may be used
 CC diagnostically to determine the role of RhoG in various biochemical
 CC pathways (e.g. its role in mitosis, the organisation of the actin
 CC cytoskeleton and in cancer development). AAZ25590 to AAZ25599 represent
 CC more human RhoG antisense oligonucleotides, but they do not inhibit RhoG
 CC as strongly as the specifically claimed sequences

XX SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 2.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1702 GGCAGTGGTGCACAC 1717
 |||||
 Db 3 GGCAGTGGTGCACAC 18

RESULT 2277
 AAZ41033
 ID AAZ41033 standard; DNA; 18 BP.
 XX
 AC AAZ41033;
 XX
 DT 26-JAN-2000 (first entry)
 XX
 DE Cellular inhibitor of apoptosis-2 phosphorothioate antisense oligo #25.
 XX
 KW Identification; genetic target; gene modulation; human; probe;
 KW antisense oligonucleotide; phosphorothioate; PCR primer;
 KW nucleotide sequence-based technology; antisense drug discovery;
 KW target validation; ss.

XX Synthetic.
 OS Homo sapiens.
 XX
 PN W09953101-A1.
 XX
 PD 21-OCT-1999.
 XX
 PF 13-APR-1999; 99WO-US008268.
 XX
 PR 13-APR-1998; 98US-0081483P.
 PR 28-APR-1998; 98US-00067638.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Cowser LM, Baker BF, Mcneil J, Preter SM, Sasnor HM, Brooks DG;
 PI Ohasi C, Wyatt JR, Borchers AH, Vickers TA;
 XX
 DR WPI; 1999-620446/53.

XX Identifying compounds which modulate expression of nucleic acids, used to
 PT provide compounds having defined physical, chemical or bioactive
 PT properties, e.g. antisense activity.
 XX
 PS Example 21; Page 100; 264pp; English.

XX A method has been developed of defining a set of compounds that modulate
 CC the expression of a target nucleic acid (tNA) sequence via binding of the
 CC compounds with the tNA sequence. The method comprises generating a
 CC library of virtual compounds in silico according to defined criteria, and
 CC evaluating in silico the binding of the virtual compounds with the tNA
 CC according to defined criteria. Also described are: (1) a method of
 CC defining a set of oligonucleotides (ONS) that modulate the expression of
 CC a tNA sequence via binding of the ONS with the tNA sequence comprising

CC generating a library of virtual compounds in silico according to defined
 CC criteria, and evaluating in silico the binding of the virtual ONS with
 CC the tNA according to defined criteria; and (2) a method of defining a set
 CC of compounds that modulate the expression of a tNA sequence via binding
 CC of the compounds with the tNA. The methods can be used for the generation
 CC and identification of synthetic compounds having defined physical,
 CC chemical or bioactive properties. Information gathered from assays of
 CC such compounds is used to identify nucleic acid sequences that are
 CC tractable to a variety of nucleotide sequence-based technologies, e.g.
 CC antisense drug discovery and target validation. AAZ40852 to AAZ41220, and
 CC AA52701 to AA52706, represent sequences used in the exemplification of
 CC the present invention

XX SQ Sequence 18 BP; 4 A; 4 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 2.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1499 TTGTCATCATCACTGT 1514
 |||||
 Db 2 TTGACATCATCACTGT 17

RESULT 2278
 AAX36673/C
 ID AAX36673 standard; DNA; 18 BP.
 XX
 AC AAX36673;
 XX
 DT 13-JUL-1999 (first entry)
 XX
 DE PCR primer for marker D6S344.
 XX
 KW PCR primer; detection; glaucoma allele; haplotype analysis; human; GLC1B;
 KW chromosome 2; chromosome 6; GLC6p25; haplotype profile;
 KW presymptomatic glaucoma; symptomatic glaucoma; ss.

XX Synthetic.
 OS Homo sapiens.
 XX
 PN W09916899-A2.
 XX
 PD 08-APR-1999.
 XX
 PF 29-SEP-1998; 98WO-CA000924.
 XX
 PR 30-SEP-1997; 97CA-02217097.
 XX
 PA (UYLA-) UNIV LAVAL.
 XX
 PI Raymond V, Morissette J, Falardeau P, Cote G, Anctil J;
 XX
 DR WPI; 1999-263704/22.
 XX
 PT Haplotype analyses for indirect detection of glaucoma.
 XX
 PS Claim 18; Page 28; 41pp; English.

XX This sequence represents a PCR primer used in the method of the
 CC invention. The method is for detecting the presence of alleles for
 CC glaucoma comprising haplotype analysis of human chromosome 2 and 6
 CC respectively, where the haplotypes are associated with loci GLC1B and
 CC GLC6p25 respectively. The primers are used to amplify gene sequences to
 CC generate information necessary to compile haplotype profiles. The
 CC haplotype profiles can be used to detect presymptomatic and symptomatic
 CC glaucoma. They can also be used to localise, isolate and identify the
 CC GLC1B and GLC6p25 loci so that detection of individuals with glaucoma is
 CC enhanced. The haplotype analyses also provide means for identification
 CC and following of mutant alleles in pedigrees or populations.
 CC Identification of presymptomatic individuals using the methods allows
 CC intervention in the disease process and obviates the impact of inheriting
 CC a mutant allele causing disease, by medically disrupting the initiation

```

CC or progression of the disease
XX Sequence 18 BP; 3 A; 7 C; 4 G; 4 T; 0 U; 0 Other;
SQ
    Query Match      0.5%; Score 14.4; DB 1; Length 18;
    Best Local Similarity 93.8%; Pred. No. 2.2e+03;
    Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2767 GTCACCCAGGCTGGAG 2782
DB 16 GTGACCCAGGCTGGAG 1
    RESULT 2279
    ID AA222127
    AC AA222127 standard; DNA; 18 BP.
XX
XX AA222127;
XX
DT 26-NOV-1999 (first entry)
DE Human c-IAP-2 mRNA inhibiting antisense oligo ISIS #23436.
XX
XX Cellular Inhibitor of Apoptosis-2; antisense; diagnostic; therapeutic;
KW c-IAP-2; prophylaxis; infection; inflammation; tumor formation; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX US958771-A.
PN
XX
XX 28-SEP-1999.
XX
XX 03-DEC-1998; 98US-00205144.
XX
XX 03-DEC-1998; 98US-00205144.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Cowser LM, Ackermann BJ;
PI WPI; 1999-561046/47.
XX
XX
XX Antisense compounds complementary to Cellular Inhibitor of Apoptosis-2
XX useful for e.g. diagnostics, therapeutics, and as research reagents.
XX
XX Claim 3; Col 39; 33pp; English.
XX
XX The invention provides antisense compounds of 8-30 nucleotides that
XX inhibit the expression of human Cellular Inhibitor of Apoptosis-2 (c-IAP-
XX 2). The antisense compounds may be used for diagnostics, therapeutics
XX (for modulating the expression of c-IAP-2), prophylaxis (e.g. to prevent
XX or delay infection, inflammation, or tumor formation), as research
XX reagents (e.g. to distinguish between members of a biological pathway)
XX and in kits. Sequences AA222103-142 represent phosphorothioate
XX oligonucleotides used for antisense inhibition of cellular inhibitor of
XX apoptosis-2
XX
XX Sequence 18 BP; 4 A; 4 C; 2 G; 8 T; 0 U; 0 Other;
SQ
    Query Match      0.5%; Score 14.4; DB 1; Length 18;
    Best Local Similarity 93.8%; Pred. No. 2.2e+03;
    Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1499 TTGTCATCATCACTGT 1514
DB 2 TTGACATCATCACTGT 17
    RESULT 2280
AAC65595
ID AAC65595 standard; DNA; 18 BP.
XX

```

```

AC AAC65595;
XX
XX 14-FEB-2001 (first entry)
XX
XX Human uteroglobin SNP PCR primer HUG-3100TR.
XX
XX Mouse; uteroglobin; immunoglobulin A mediated disease; IgA nephropathy;
KW autoimmune disorder; pulmonary inflammation; Wegener's granulomatosis;
KW Goodpasture's disease; diabetic glomerulosclerosis; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX WO200062795-A2.
XX
XX 26-OCT-2000.
XX
XX 13-APR-2000; 2000WO-US009979.
XX
XX 21-APR-1999; 99US-0130434P.
XX
XX (USSH ) US DEPT HEALTH & HUMAN SERVICES.
XX
XX Mukherjee AB, Zheng F, Zhang Z;
XX
XX WPI; 2000-687100/67.
XX
XX Use of a composition comprising uteroglobin (or a fragment, derivative,
XX mimetic or variant), for inhibiting or treating an immunoglobulin-A
XX mediated autoimmune disorders, e.g. diabetic glomerulosclerosis and
XX pulmonary inflammation.
XX
XX Example 12; Page 43; 60pp; English.
XX
XX The present invention describes the use of uteroglobin in the diagnosis
XX and prevention of IgA mediated diseases, such as IgA nephropathy,
XX Wegener's granulomatosis, Goodpasture's disease and diabetic
XX glomerulosclerosis. This is possible as uteroglobin binds to fibronectin,
XX preventing the complexing of fibronectin with IgA and the deposition of
XX immune complexes in the kidney
XX
XX Sequence 18 BP; 2 A; 9 C; 1 G; 6 T; 0 U; 0 Other;
SQ
    Query Match      0.5%; Score 14.4; DB 1; Length 18;
    Best Local Similarity 93.8%; Pred. No. 2.2e+03;
    Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 412 GCACCCCTCCCTCTT 427
DB 2 GCATCCCTCCCTCTT 17
    RESULT 2281
AAC85531/c
ID AAC85531 standard; cDNA; 18 BP.
XX
XX AAC85531;
XX
XX 16-MAY-2001 (first entry)
XX
XX Primer ZC22,481.
XX
XX Splice variant; zdint2; mammalian adhesion protease peptide; MAPP;
KW testis; ovary; prostate; small intestine; colon; stomach; thyroid;
KW spinal cord; lymph node; trachea; heart; wound healing; apoptosis;
KW neurogenesis; tumor proliferation; ischemia reperfusion; inflammation;
KW immunologic recognition; gamete maturation; platelet aggregation;
KW infection; brain; cancer; Alzheimer's disease; multiple sclerosis;
KW congestive heart failure; PCR; polymerase chain reaction; amplify;
XX primer; ss.
XX
XX Synthetic.
XX
XX WO200109293-A2.
XX

```


XX PD 08-FEB-2001.

XX PF 02-AUG-2000; 2000WO-US021085.

XX PR 03-AUG-1999; 99US-00368070.

XX PA (ZYMO) ZYMOGENETICS INC.

XX PI Sheppard PO, Baidur N, Bishop PD;

XX DR WPI; 2001-202662/20.

XX PT Mammalian adhesion protease peptides useful for delivery of therapeutic agents, for identifying agonists and antagonists and treating disorders of brain, heart tissue and platelet aggregation.

XX PS Example 4; Page 102; 106pp; English.

XX CC The sequences given in AAC85531-32 are primers which were used for mapping mammalian adhesion protease peptide (MAPP). The results showed linkage of MAPP to the framework marker SHGC-11829 with a LOD score of >10 and at a distance of 7 cR 10000 from the marker. The use of surrounding markers positioned MAPP in the 20q13 region on the integrated LDB chromosome 20 map

XX SQ Sequence 18 BP; 3 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 2.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 840 CACAGTCACCTATGGC 855
 |||||
 DB 18 CACAGTCACCCATGGC 3

RESULT 2282

AAF94744

ID AAF94744 standard; DNA; 18 BP.

XX AC AAF94744;

XX DT 23-MAY-2001 (first entry)

XX DE Rho G antisense phosphorothioate oligonucleotide SEQ ID 168.

XX KW Rho; GTP binding protein; phosphorothioate antisense oligonucleotide;
 KW RhoA; RhoB; RhoC; Rac 1; cdc42; hyperproliferative condition;
 KW cancer; wound healing; clotting; ischaemia; reperfusion; reoxygenation;
 KW ss.

XX OS Homo sapiens.

XX PN WO200115739-A1.

XX PD 08-MAR-2001.

XX PF 18-AUG-2000; 2000WO-US022808.

XX PR 31-AUG-1999; 99US-00387341.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Roberts ML, Cowseert LM;

XX DR WPI; 2001-191677/19.

XX PT An antisense compound targeted to a nucleic acid molecule encoding a member of the human Rho family of small GTP binding proteins useful for treating e.g. cancer and ischemia.

XX PS Example 18; Page 81; 156pp; English.

XX CC This invention relates to an antisense compound targeted to a nucleic acid molecule encoding a member of the human Rho family of small GTP binding proteins, where the antisense compound inhibits the expression of the member of the human Rho family. The invention includes antisense oligonucleotides AAF94580 - AAF94637 which target a RhoA nucleotide sequence, AAF94645 - AAF94684 which target a RhoB nucleotide sequence, AAF94686 - AAF94725 which target a RhoC nucleotide sequence, AAF94727 - AAF94766 which target RhoG nucleotide sequence, AAF94769 - AAF94790 which target a Rac 1 nucleotide sequence and AAF94795 - AAF94809 which target cdc42 nucleotide sequence. The antisense compound is useful for treating hyperproliferative conditions, especially cancer, abnormal wound healing or clotting conditions and ischaemia/reperfusion or reoxygenation injury. The compound may also be used to diagnose the above conditions

XX SQ Sequence 18 BP; 4 A; 4 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 2.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 GGCAGTGGTGGCCACAC 1717
 |||||
 DB 3 GGCAGTGGTGGCCACAC 18

RESULT 2283

ABV72145/c

ID ABV72145 standard; DNA; 18 BP.

XX AC ABV72145;

XX DT 05-DEC-2002 (first entry)

XX DE PCR primer used to map human zdint2 gene.

XX KW Human; isoform: zdint2; mammalian adhesion protease peptide; MAPP;
 KW disintegrin-like family member; disintegrin protease; DP; PCR; primer;
 KW anticoagulation; fertilization; muscle fusion; neurogenesis;
 KW chromosome 20; ss.

XX OS Homo sapiens.

XX PN US6420154-B1.

XX PD 16-JUL-2002.

XX PF 02-AUG-2000; 2000US-00632098.

XX PR 03-AUG-1999; 99US-0146968P.

XX PA (ZYMO) ZYMOGENETICS INC.

XX PI Sheppard PO, Baidur N, Bishop PD;

XX DR WPI; 2002-626081/67.

XX PT New Isolated Mammalian Adhesion Protease Peptides (zdint2), which have homology to disintegrin-like family members, useful for preventing, diagnosing and treating fertility, muscular and neurogenic disorders.

XX PS Example 4; Col 77-78; 42pp; English.

XX CC PCR primers ABV72145-46 were used to map human zdint2 gene to chromosome 20. Zdint2 is a mammalian adhesion protease peptide (MAPP), and has homology to disintegrin-like family members (ADAMs, SVMPs and MDCs), referred to as disintegrin proteases (Dps). MAPPs have been found to be involved in anticoagulation, fertilization, muscle fusion, and neurogenesis. Zdint2 may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate MAPP expression. The proteins may be administered to treat disorders associated with decreased expression by rectifying mutations or deletions in a patient's genome that affect the activity of MAPP by expressing inactive proteins or to

CC supplement the patients own production of MAPPS
 XX Sequence 18 BP; 3 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
 SQ

Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 2.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 840 CACAGTCACCTATGCG 855
 DB 18 CACAGTCACCTATGCG 3

RESULT 2284
 ABQ94329/c
 ID ABQ94329 standard; DNA; 18 BP.
 AC ABQ94329;
 XX
 DT 01-NOV-2002 (first entry)
 DE Human BNO1 gene exon 1b primer 2.
 KW Human; BNO1; F-box; PBXO; chromosome 16q24.3; SCF ubiquitin-E3 ligase;
 KW protein ubiquitination; proteasome targeting; breast; prostate; liver;
 KW ovarian; immune disease; inflammatory disease; AIDS;
 KW acquired immunodeficiency syndrome; asthma; Crohn's disease;
 KW multiple sclerosis; neurological disorder; Parkinson's disease;
 KW Alzheimer's disease; cytostatic; immunomodulator; neuroprotective;
 KW gene therapy; diagnosis; prognosis; mutation analysis; SSCP;
 KW single-strand conformation polymorphism; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1 /*tag= a
 FT /mod_base= OTHER
 FT /note= "Labelled with HEX"

PN WO200261081-A1.
 XX
 XX 08-AUG-2002.
 PD
 XX
 PF 31-JAN-2002; 2002WO-AU000096.
 XX
 PR 31-JAN-2001; 2001AU-00002783.
 XX
 PA (BION-) BIONOMICS LTD.
 XX
 PI Callen DF, Powell JA, Kremmidiotis G, Gardner AB, Crawford J;
 PI Bais AJ, Kochetkova M;
 XX
 DR WPI; 2002-619250/66.
 XX
 PT New gene (BNO1) mapping to chromosome 16q24.3, useful in gene therapy,
 PT e.g. for diagnosing or treating cancers (e.g. lymphoma),
 PT immune/inflammatory diseases (e.g. AIDS) or neurological disorders (e.g.
 PT Parkinson's disease).
 XX
 XX Example 8; Page 63; 85pp; English.
 XX
 CC The invention relates to the human and murine BNO1 proteins and nucleic
 CC acids encoding them. The BNO1 protein is a member of the PBXO class of F-
 CC box proteins, containing an F-box motif but no other known protein-
 CC interaction domains. Proteins which contain F-boxes are the substrate
 CC recognition components of SCF ubiquitin-E3 ligases, which are responsible
 CC for ubiquitinating proteins, thereby targeting them for degradation in
 CC the proteasome. In addition, BNO1 is able to interact with Skp1, an
 CC essential component of SCF ubiquitin-E3 ligases, suggesting that it plays
 CC a role in the ubiquitin-proteasome degradation system that is involved in
 CC the regulation of many proteins, particularly those involved in important
 CC cellular processes such as cell cycle regulation. The human BNO1 gene

CC maps to chromosome 16q24.3, and is expressed as two different isoforms.
 CC Isoform 1 consists of 539 amino acids and is encoded by an open reading
 CC frame (ORF) of 1617 bp, while the longer isoform 2 consists of 568 amino
 CC acids encoded by an ORF of 1704 bp. The mRNAs encoding the 2 human BNO1
 CC isoforms are the product of differential splicing: both comprise exons 1-
 CC 9, but the isoform 2 mRNA additionally comprises exon 2.5. Loss of
 CC heterozygosity (LOH) of the long arm of chromosome 16, in which the human
 CC BNO1 gene is situated, is implicated in breast and prostate cancer, and
 CC BNO1 expression is also downregulated in these cancers. BNO1 nucleic
 CC acids, proteins and compounds which modulate BNO1 activity or expression
 CC may be used for treating disorders associated with altered BNO1 activity
 CC or expression. Such disorders include cancers (e.g., breast, prostate,
 CC liver and ovarian cancers), immune/inflammatory diseases (e.g., AIDS
 CC (acquired immunodeficiency syndrome), asthma, Crohn's disease or multiple
 CC sclerosis) or neurological disorders (e.g., Parkinson's disease or
 CC Alzheimer's disease). BNO1 nucleic acids, proteins and antibodies may
 CC also be used to diagnose or prognose disorders associated with BNO1
 CC dysfunction, or a predisposition to these disorders. Additionally, BNO1
 CC nucleic acids and proteins, and transgenic animals comprising human BNO1
 CC nucleic acid sequences or in which BNO1 gene function has been knocked
 CC out are useful in screening potential drugs for treating BNO1-associated
 CC disorders, and the human BNO1 protein isoforms are particularly useful
 CC for identifying BNO1-specific protein substrates that are targeted for
 CC degradation by ubiquitination. Sequences ABQ94326-ABQ94349 represent
 CC human BNO1 gene-specific PCR primers used in SSCP (single-strand
 CC conformation polymorphism) analysis of tumours and cell lines for BNO1
 CC mutations in an exemplification of the invention
 XX
 SQ Sequence 18 BP; 3 A; 7 C; 6 G; 2 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 2.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 457 CGCTGCCAGGTGGAGG 472
 DB 17 CCCTGCCAGGTGGAGG 2

RESULT 2285
 AAD60503
 ID AAD60503 standard; DNA; 18 BP.
 XX
 AC AAD60503;
 XX
 DT 18-DEC-2003 (first entry)
 XX
 DE Human c-IAP-2 antisense oligonucleotide #ISIS #23476.
 XX
 KW Human; antisense; cellular inhibitor of apoptosis-2; c-IAP-2; cancer;
 KW hyperproliferative condition; apoptosis inhibitor 2; autoimmune disease;
 KW API-1; hIAP-1; MHC; gene therapy; phosphorothioate; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..18
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone; All cytidine residues
 FT are 5-methylcytidines"
 FT modified_base 1..4
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 15..18
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
 XX
 XX US2003083300-A1.
 PN
 XX

PD 01-MAY-2003.
 XX
 PF 16-JUL-2002; 2002US-00197290.
 XX
 PR 23-SEP-1999; 99WO-US022083.
 PR 04-OCT-2001; 2001US-00857299.
 XX
 XX (BENN/) BENNETT C F.
 PA (ACKE/) ACKERMANN E J.
 PA (COWS/) COWSERT L M.
 XX
 PI Bennett CF, Ackermann EJ, Cowsert LM;
 XX
 XX WPI; 2003-755119/71.
 DR
 XX
 XX New antisense compound, preferably an oligonucleotide, for inhibiting
 PT expression of human Cellular Inhibitor of Apoptosis-2 in human cells or
 PT tissues, and for treating diseases, such as cancer or an autoimmune
 PT disease.
 XX
 PS Claim 3; Page 22; 34pp; English.
 XX
 XX The invention relates to antisense compounds targetted to a nucleic acid
 CC encoding human cellular inhibitor of apoptosis-2 (also known as c-IAP-2,
 CC apoptosis inhibitor 2, API-1, hIAP-1 and MIHC) to inhibit its expression.
 CC Antisense compounds of the invention are used to induce apoptosis in
 CC human cells or tissues to treat diseases or conditions associated with
 CC insufficient apoptosis. They are used to treat diseases or conditions
 CC associated with c-IAP-2 such as hyperproliferative conditions especially
 CC cancer or autoimmune diseases. The invention is also useful in antisense
 CC gene therapy. The present sequence is an antisense oligonucleotide
 CC targetted to human c-IAP-2 DNA
 XX
 SQ Sequence 18 BP; 4 A; 4 C; 2 G; 8 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 2.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 YQ 1499 TTGTCATCATCACTGT 1514
 DB 2 TTGACATCATCACTGT 17
 RESULT 2286
 ADH62513/c
 ID ADH62513 standard; DNA; 18 BP.
 XX
 AC ADH62513;
 XX
 DT 25-MAR-2004 (first entry)
 XX
 DE Human MAPP DNA specific PCR primer, ZC22481.
 XX
 KW MAPP; disintegrin protease; diagnosis; tumour; gene therapy; PCR; primer;
 KW mammalian adhesion protease peptide; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003175262-A1.
 XX
 PD 18-SEP-2003.
 XX
 XX 21-JUN-2002; 2002US-00177308.
 PF
 XX 03-AUG-1999; 99US-0146969P.
 PR 02-AUG-2000; 2000US-00632098.
 XX
 XX (ZYMO) ZYMOGENETICS INC.
 PA
 XX Sheppard PO, Baidur N, Bishop PD;
 PI
 XX WPI; 2003-898498/82.
 DR

XX
 PT New MAPP polypeptide, useful for preparing a composition for diagnosing
 PT or treating tumor.
 XX
 PS Example 4; SEQ ID NO 12; 46pp; English.
 XX
 CC The present invention relates to novel mammalian adhesion protease
 CC peptide (MAPP), a member of the disintegrin proteases and polynucleotides
 CC encoding such proteins. Sequences of the invention are useful for
 CC preparing a composition for diagnosing or treating tumour. The invention
 CC is also useful in gene therapy. The present sequence is human MAPP DNA
 CC specific PCR primer used in the exemplification of the invention.
 XX
 SQ Sequence 18 BP; 3 A; 3 C; 8 G; 4 T; 0 U; 0 Other;
 Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 2.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 YQ 840 CACAGTCACCTATGCC 855
 DB 18 CACAGTCACCCATGCC 3
 RESULT 2287
 ACAS8053/c
 ID ACAS8053 standard; DNA; 18 BP.
 XX
 AC ACAS8053;
 XX
 DT 09-JUN-2003 (first entry)
 XX
 DE Human familial bipolar affective disorder chromosome marker primer #1.
 XX
 KW Human; genotype determination; familial bipolar affective disorder;
 KW chromosomal region linked; locus associated with resistance; D4S402;
 KW D4S424; D4S431; D4S404; D11S394; D11S29; chromosome marker; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002192655-A1.
 XX
 PD 19-DEC-2002.
 XX
 PF 13-JUN-2001; 2001US-00881012.
 XX
 PR 29-MAR-1996; 96US-0014334P.
 PR 20-OCT-1997; 97US-0062924P.
 PR 19-OCT-1998; 98US-00175158.
 XX
 XX (GINN/) GINNS E I.
 PA (EGEL/) EGELAND J A.
 PA (PAUL/) PAUL S M.
 XX
 PI Ginns EI, Egeland JA, Paul SM;
 XX
 XX WPI; 2003-352708/33.
 DR
 XX
 PT Determining a genotype associated with increased or decreased resistance
 PT to familial bipolar affective disorder in a family comprises determining
 PT the genotype of e.g., chromosomal regions D4S402 and D4S424.
 XX
 XX Disclosure; Page 8; 79pp; English.
 XX
 CC The present invention relates to a method of determining a genotype
 CC associated with increased or decreased resistance to familial bipolar
 CC affective disorder. The method comprises determining the genotype with at
 CC least one marker of at least one chromosomal region linked to a locus
 CC associated with resistance to bipolar affective disorder, where the
 CC chromosomal regions are included of and localised between D4S402 and
 CC D4S424, D4S431 and D4S404, or D11S394 and D11S29. The invention also
 CC discloses a kit for determining a genotype associated with increased or
 CC decreased resistance to familial bipolar affective disorder, where the

CC kit comprises markers for two or more of the chromosomal regions cited.
 CC The method and kit are useful for determining a genotype associated with
 CC increased or decreased resistance to familial bipolar affective disorder
 CC in a family affected by bipolar affective disorder, for determining the
 CC contribution of these chromosomal regions to bipolar affective disorder
 CC in an affective family member, and for assessing an increased or
 CC decreased risk of developing bipolar illness for a tested individual from
 CC an affected family. ACAS8053-ACAS8292 represent primers used in the
 CC present invention

XX SQ Sequence 18 BP; 3 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 2.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2767 GTCACCCAGGCTGGAG 2782
 DB 16 GTGACCCAGGCTGGAG 1

RESULT 2288

ADH76720
 ID ADH76720 standard; DNA; 18 BP.

XX AC ADH76720;

XX DT 22-APR-2004 (first entry)

XX DE MCHRI genomic sequence analysis primer #29.

XX KW melanin-concentrating hormone receptor 1; MCHRI; anorectic; gene therapy;
 XX KW obesity; primer; ss.

XX OS Unidentified.

XX XX WO2003104489-A2.

XX PN 18-DEC-2003.

XX PD 05-JUN-2003; 2003WO-EP005917.

XX PF 05-JUN-2002; 2002EP-00012569.

XX PR (UYPH-) UNIV PHILIPPS MARBURG.

XX PA Platzter M, Platzter C, Gudermann T, Hebebrand J, Hinney A;
 XX PI Reichwald K;

XX DR WPI; 2004-062377/06.

XX PT New diagnostic composition, useful for diagnosing obesity related to the
 XX PT presence of a molecular variant of the MCHRI gene or a susceptibility to
 XX PT the disorder.

XX PS Example 2; Page 43; 76pp; English.

XX CC The invention relates to a novel diagnostic polynucleotide composition.
 XX CC The polynucleotide composition comprises: a sequence encoding a
 XX CC polypeptide with defined sequences given in the specification; a sequence
 XX CC capable of hybridizing to a melanin-concentrating hormone receptor 1
 XX CC (MCHRI) gene; a polynucleotide encoding an MCHRI polypeptide; or a
 XX CC sequence comprising one or more of the nucleotide exchanges (SNP's) given
 XX CC in the specification and at least 8 bases of surrounding sequence of the
 XX CC MCHRI gene. The composition has anorectic activity. The polynucleotide
 XX CC composition may be used in gene therapy to treat the disorders of the
 XX CC invention. The composition is useful for diagnosing obesity related to
 XX CC the presence of a molecular variant of the MCHRI gene or a susceptibility
 XX CC to the disorder. The MCHRI protein or polynucleotide is useful for
 XX CC preparing a medicament for treating or preventing obesity related to the
 XX CC presence of a molecular variant of the MCHRI gene. This polynucleotide
 XX CC represents an MCHRI primer of the invention.

SQ Sequence 18 BP; 2 A; 9 C; 2 G; 5 T; 0 U; 0 Other;

Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 2.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCACCC 2773
 DB 3 TCTCCCTCTGTCACCC 18

RESULT 2289

ADJ94731
 ID ADJ94731 standard; DNA; 18 BP.

XX AC ADJ94731;

XX DT 06-MAY-2004 (first entry)

XX DE RT-PCR primer 7 used to analyse human eIF2C3 expression.

XX KW cytostatic; antiinflammatory; virucide; immunosuppressive; tumour;
 XX KW inflammatory; infectious disease; viral infection; degenerative;
 XX KW autoimmune; gene therapy; Argonaute family;
 XX KW eukaryotic translation initiation factor 2C3; eIF2C3; human; ss; PCR;
 XX KW RT-PCR; primer.

XX OS Homo sapiens.

XX XX WO2004007718-A2.

XX PD 22-JAN-2004.

XX PF 10-JUL-2003; 2003WO-EP007516.

XX PR 10-JUL-2002; 2002EP-00015532.

XX PR 23-AUG-2002; 2002EP-00018906.

XX PA (PLAC) MAX PLANCK GES FOERDERUNG WISSENSCHAFTEN.

XX PI Tuschl T, Martinez J, Patkaniowska A, Urlaub H, Luehrmann R;

XX DR WPI; 2004-122948/12.

XX PT New single-stranded RNA molecule having a length from 14-50 nucleotides,
 XX PT useful for preventing or treating tumor, inflammatory, infectious, e.g.
 XX PT viral infections, degenerative and autoimmune diseases.

XX PS Example; Fig 17A; 73pp; English.

XX CC The invention relates to a novel single-stranded RNA molecule having a
 XX CC length from 14-50 nucleotides where at least 14-20 of the 5'-most
 XX CC nucleotides are substantially complementary to a target transcript. The
 XX CC RNA molecule of the invention demonstrates cytostatic, antiinflammatory,
 XX CC virucide and immunosuppressive activities and may be useful for
 XX CC inhibiting the expression of a target gene in vitro or in vivo,
 XX CC preferably for preventing or treating diseases associated with the
 XX CC overexpression of at least one target transcript. The diseases may be
 XX CC selected from tumor diseases, inflammatory diseases, infectious diseases
 XX CC such as viral infections, degenerative diseases and autoimmune diseases.
 XX CC Furthermore, the molecules of the invention may be utilised during gene
 XX CC therapy. The current sequence is that of the RT-PCR primer of the
 XX CC invention which was used to analyse human eukaryotic translation
 XX CC initiation factor 2C3 (eIF2C3) expression.

XX SQ Sequence 18 BP; 3 A; 7 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 2.2e+03;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 630 CTTGGCGGCCCAAGGG 645
 ||||| |||||

Db 3 CCTGCTGCCCCAAGG 18

RESULT 2290
ADN06374/C

ID ADN06374 standard; DNA; 18 BP.

XX

AC ADN06374;

XX

XX 15-JUL-2004 (first entry)

XX

XX Human FLAP related microsatellite marker SEQ ID NO:22.

DE

XX

XX leukotriene synthesis inhibitor; myocardial infarction;

KW acute coronary syndrome; antiatherosclerotic; cardiant; antianginal;

KW leukotriene biosynthesis inhibitor; leukotriene receptor antagonist;

KW 5-lipoxygenase activating protein; FLAP; human; chromosome 13;

KW chromosome 13q12; polymorphism; 5-lipoxygenase gene promoter;

KW 5-LO gene promoter; diabetes; hypertension; hypercholesterolaemia;

KW obesity; inflammatory marker; low density lipoprotein; cholesterol;

KW high density lipoprotein; angina; atherosclerosis; microsatellite marker;

KW ss.

OS Homo sapiens.

OS Synthetic.

XX

XX WO2004035741-A2.

PN

XX

XX 29-APR-2004.

PD

XX

XX 16-OCT-2003; 2003WO-US032556.

XX

XX 17-OCT-2002; 2002US-0419433P.

PR

XX 21-FEB-2003; 2003US-0449331P.

PR

XX (DECO-) DECODE GENETICS EHF.

PA

XX Helgadottir A, Gurney ME, Gulcher JR;

PI

XX WPI; 2004-357211/33.

DR

XX

XX Use of leukotriene synthesis inhibitor for manufacture of a medicament

PT for treatment for myocardial infarction or susceptibility to myocardial

PT infarction in individual.

XX

PS Disclosure; SEQ ID NO 22; 306pp; English.

XX

XX The present invention describes using a leukotriene synthesis inhibitor

CC (I) for the manufacture of a medicament for the treatment of myocardial

CC infarction or susceptibility to myocardial infarction in an individual.

CC Also described is a method (MI) for the treatment of acute coronary

CC syndrome (ACS) in an individual comprising administering (I). (I) has

CC antiatherosclerotic, cardiant and antianginal activities, and can be used

CC as a leukotriene biosynthesis inhibitor, and a leukotriene receptor

CC antagonist. (I) can be used for the manufacture of a medicament for the

CC treatment of myocardial infarction or susceptibility to myocardial

CC infarction in an individual who has at least one risk factor chosen from

CC an at-risk haplotype for myocardial infarction, an at-risk haplotype in

CC the 5-lipoxygenase activating protein (FLAP) gene, a polymorphism in a

CC FLAP nucleic acid and an at-risk polymorphism in the 5-lipoxygenase (5-

CC LO) gene promoter; in an individual who has at least one risk factor

CC chosen from diabetes, hypertension, hypercholesterolaemia, elevated

CC lpla), obesity, past or current smoker; in an individual having elevated

CC inflammatory marker chosen from C-reactive protein (CRP), serum amyloid

CC A, fibrinogen, leukotriene, leukotriene metabolite, interleukin-6, tissue

CC necrosis factor-alpha, soluble vascular cell adhesion molecule (sVCAM),

CC soluble intervascular adhesion molecule (sICAM), E-selectin, matrix

CC metalloprotease type-1, matrix metalloprotease type-2, matrix

CC metalloprotease type-3 and matrix metalloprotease type-9; in an

CC individual having increased low density lipoprotein (LDL) cholesterol

CC and/or decreased high density lipoprotein (HDL) cholesterol; in an

CC individual having increased leukotriene synthesis; in an individual

CC having previous myocardial infarction or acute coronary syndrome (ACS)

CC event, stable angina; or in an individual who has atherosclerosis or who

CC requires treatment to restore blood flow in arteries. (M1) is useful for

CC treating an individual suffering from acute coronary syndrome chosen from

CC unstable angina, non-ST-elevation myocardial infarction (NSTEMI) and ST-

CC elevation myocardial infarction (STEMI). The human FLAP gene is located

CC on chromosome 13, more specifically to 13q12. The present sequence

CC represents a microsatellite marker used in the exemplification of the

CC present invention.

XX

XX Sequence 18 BP; 1 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

SQ

Query Match 0.5%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 2.2e+03;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2771 CCCAGGCTGGAGTCA 2786

Db 17 CCCAGGCTGGAGAGCA 2

|||||

RESULT 2291

ADN048731

ID ADO48731 standard; DNA; 18 BP.

XX

XX ADO48731;

AC

XX

XX 12-AUG-2004 (first entry)

DT

XX

XX Human neuropilin 1 (NRP1) extension PCR primer #33.

DE

XX

XX human; melanoma; single nucleotide polymorphism; SNP; neuropilin 1; NRP1;

KW mannose receptor C type 2; MRC2; extension PCR; primer; ss; genotyping.

KW

XX Homo sapiens.

OS

XX WO2004044163-A2.

PN

XX 27-MAY-2004.

PD

XX

XX 06-NOV-2003; 2003WO-US035876.

XX

XX 06-NOV-2002; 2002US-0424475P.

PR

XX 23-JUL-2003; 2003US-0489703P.

PR

XX (SEQU-) SEQUENOM INC.

PA

XX

XX Roth RB, Nelson MR, Braun A, Kammerer SM;

PI

XX WPI; 2004-411720/38.

DR

XX

XX Identifying a subject at risk of melanoma, useful for treating melanoma,

PT comprises detecting the presence or absence of one or more polymorphic

PT variations associated with melanoma in a nucleic acid sample from a

PT subject.

XX

XX Example 3; Page 78; 176pp; English.

PS

XX The invention comprises a method for identifying a subject at risk of

CC melanoma. The invention involves detecting the presence or absence of one

CC or more polymorphic variations associated with melanoma in the neuropilin

CC 1 (NRP1) or mannose receptor C type 2 (MRC2) genes. The method of the

CC invention is useful for identifying subjects at risk and treating

CC melanoma. The present DNA sequence represents an extension PCR primer

CC that was used to detect single nucleotide polymorphisms within human

CC NRP1.

XX

XX Sequence 18 BP; 4 A; 1 C; 9 G; 3 T; 0 U; 1 Other;

SQ

Query Match 0.5%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 2.2e+03;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 512 GTGGGAGAGGAGCT 527

```
DB      ||||| 2 GTGGGATAAGGAGCT 17
RESULT 2292
ADP45830
ID      ADP45830 standard; DNA; 18 BP.
XX
AC
XX
DT      ADP45830;
DE      26-AUG-2004 (first entry)
XX
KW      Extend primer 22 used to genotype human ICAM-1/ICAM-4/ICAM-5 SNP.
XX
KW      breast cancer; cytostatic; gene therapy; human;
KW      intercellular adhesion molecule; ICAM-1; human rhinovirus receptor; BB2;
KW      CD54; cell surface glycoprotein P3.58; ICAM-4;
KW      Landsteiner-Wiener blood group; ICAM-5; telencephalin; chromosome 19p13;
KW      ss; primer; PCR; SNP; single nucleotide polymorphism; probe.
XX
OS      Homo sapiens.
XX
PN      WO2004047623-A2.
XX
PD      10-JUN-2004.
XX
PF      25-NOV-2003; 2003WO-US037948.
XX
PR      25-NOV-2002; 2002US-0429136P.
PR      24-JUL-2003; 2003US-0490234P.
XX
PA      (SEQU-) SEQUENOM INC.
XX
PI      Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX      WPI; 2004-441051/41.
XX
PT      Identifying a subject at risk of breast cancer by detecting the presence
PT      of polymorphic variations in the ICAM, MAPK10, KIAA0861, NUMA1 or GALE
PT      regions which are associated with breast cancer in a nucleic acid sample
PT      from a subject.
XX
PS      Example 4; Page 83; 289pp; English.
XX
CC      The invention relates to a novel method for identifying a subject at risk
CC      of breast cancer comprising detecting the presence or absence of one or
CC      more polymorphic variations associated with breast cancer in a nucleic
CC      acid sample from a subject. The method of the invention has cytostatic
CC      applications and may be useful for identifying a subject at risk of
CC      breast cancer, for early diagnosis, prevention and treatment of breast
CC      cancer, possibly via gene therapy, as well as to analyse and predict a
CC      response to a breast cancer treatment and in clinical drug trials. The
CC      current sequence is that of an Extend primer (also described as probe) of
CC      the invention which was used to genotype human intercellular adhesion
CC      molecule ICAM-1/ICAM-4/ICAM-5 gDNA. ICAM-1 (human rhinovirus receptor;BB2
CC      ;CD54;cell surface glycoprotein P3.58) has been mapped to chromosomal
CC      position 19p13.3-p13.2, ICAM-4 (Landsteiner-Wiener blood group;IW) has
CC      been mapped to chromosomal position 19p13.2-cen and ICAM-5
CC      (telencephalin) has been mapped to chromosomal position 19p13.2.
XX
SQ      Sequence 18 BP; 5 A; 5 C; 7 G; 1 T; 0 U; 0 Other;
      Query Match 0.5%; Score 14.4; DB 1; Length 18;
      Best Local Similarity 93.8%; Pred. No. 2.2e+03;
      Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy      2860 AGCTGGGACCATAGGC 2875
      |||||
DB      2 AGCTGGGACCATAGGC 17
RESULT 2293
ADS94393/c
```

```
ID      ADS94393 standard; DNA; 18 BP.
XX
AC      ADS94393;
XX
DT      02-DEC-2004 (first entry)
XX
DE      Human 5-lipoxygenase activating protein (FLAP) gene PCR primer #19.
XX
KW      human; 5-lipoxygenase activating protein; FLAP; chromosome 13q12;
KW      single nucleotide polymorphism; SNP; myocardial infarction; PCR; primer;
KW      microsatellite marker; ss.
XX
OS      Homo sapiens.
XX
PN      WO2004035746-A2.
XX
PD      29-APR-2004.
XX
PF      16-OCT-2003; 2003WO-US032805.
XX
PR      17-OCT-2002; 2002US-0419432P..
XX
PA      (DECO-) DECODE GENETICS EHP.
XX
PI      Helgadottir A, Gulcher JR, Manolescu A;
XX      WPI; 2004-348442/32.
XX
PT      Novel FLAP (5-lipoxygenase activating protein) nucleic acid useful for
PT      diagnosing myocardial infarction and for identifying agent that is useful
PT      for treating myocardial infarction.
XX
PS      Example; SEQ ID NO 22; 230pp; English.
XX
CC      The invention comprises nucleic acid sequences of the human 5-
CC      lipoxygenase activating protein (FLAP) gene - present on chromosome
CC      13q12. In particular the invention relates to polymorphisms identified
CC      within this gene. The DNA sequences of the invention are useful for
CC      diagnosing susceptibility to myocardial infarction and identifying agents
CC      that alter expression of FLAP. The present DNA sequence represents a PCR
CC      primer that is used to amplify a microsatellite marker from the human
CC      FLAP gene.
XX
SQ      Sequence 18 BP; 1 A; 7 C; 5 G; 5 T; 0 U; 0 Other;
      Query Match 0.5%; Score 14.4; DB 1; Length 18;
      Best Local Similarity 93.8%; Pred. No. 2.2e+03;
      Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Oy      2771 CCCAGGCTGGAGTGCA 2786
      |||||
DB      17 CCCAGGCTGGAGAGCA 2
      Search completed: July 26, 2005, 15:13:27
      Job time : 90 secs
```

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 26, 2005, 15:06:36 ; Search time 26 Seconds
(without alignments)
3.568 Million cell updates/sec

Title: nm000201

Perfect score: 2986

Sequence: 1 GGCCCCAGTCGACGCTGAG.....ATTAAGCTTTCTCAACTGCC 2986

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 779 seqs, 1534 residues

Total number of hits satisfying chosen parameters: 1558

Minimum DB seq length: 18

Maximum DB seq length: 26

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 780 summaries

Database : rgs201.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	24	0.8	24	1	AR008538
2	24	0.8	24	1	AR008539
3	24	0.8	24	1	AR013833
4	24	0.8	24	1	AR013834
5	24	0.8	24	1	AR014326
6	24	0.8	24	1	AR014327
7	24	0.8	24	1	AR029111
8	24	0.8	24	1	AR029112
9	24	0.8	24	1	AR033787
10	24	0.8	24	1	AR033788
11	24	0.8	24	1	AR042447
12	24	0.8	24	1	AR042448
13	24	0.8	24	1	AR048728
14	24	0.8	24	1	AR048729
15	24	0.8	24	1	AR058327
16	24	0.8	24	1	AR058328
17	24	0.8	24	1	AR065923
18	24	0.8	24	1	AR065924
19	24	0.8	24	1	AR068085
20	24	0.8	24	1	AR068086
21	24	0.8	24	1	AR088153
22	24	0.8	24	1	AR088154
23	24	0.8	24	1	AR090407
24	24	0.8	24	1	AR090407
25	24	0.8	24	1	AR090407
26	24	0.8	24	1	AR090407
27	24	0.8	24	1	AR090407
28	24	0.8	24	1	AR090407
29	24	0.8	24	1	AR090407
30	24	0.8	24	1	AR090407
31	24	0.8	24	1	AR090407
32	24	0.8	24	1	AR090407
33	24	0.8	24	1	AR090407

ACCESSION:BD064508	24	0.8	24	1	BD064508
ACCESSION:BD064509	24	0.8	24	1	BD064509
ACCESSION:AR364453	35	0.8	23.4	1	AR364453
ACCESSION:AX614112	37	0.8	23.4	1	AX614112
ACCESSION:CQ778235	38	0.8	23	1	CQ778235
ACCESSION:AX797527	39	0.8	22.4	1	AX797527
ACCESSION:CQ771558	40	0.7	22	1	CQ771558
ACCESSION:AX284111	41	0.7	22	1	AX284111
ACCESSION:AX284113	42	0.7	22	1	AX284113
ACCESSION:AX117832	43	0.7	21.8	1	AX117832
ACCESSION:AX117836	44	0.7	21.8	1	AX117836
ACCESSION:AX117828	45	0.7	21.4	1	AX117828
ACCESSION:AR026554	46	0.7	21	1	AR026554
ACCESSION:AR062603	47	0.7	21	1	AR062603
ACCESSION:AR104706	48	0.7	21	1	AR104706
ACCESSION:AR105528	49	0.7	21	1	AR105528
ACCESSION:AR123190	50	0.7	21	1	AR123190
ACCESSION:AR129002	51	0.7	21	1	AR129002
ACCESSION:BD192437	52	0.7	21	1	BD192437
ACCESSION:BD266260	53	0.7	21	1	BD266260
ACCESSION:CQ771255	54	0.7	21	1	CQ771255
ACCESSION:CQ771257	55	0.7	21	1	CQ771257
ACCESSION:CQ778237	56	0.7	21	1	CQ778237
ACCESSION:120605	57	0.7	21	1	120605
ACCESSION:130543	58	0.7	21	1	130543
ACCESSION:130545	59	0.7	21	1	130545
ACCESSION:130546	60	0.7	21	1	130546
ACCESSION:130547	61	0.7	21	1	130547
ACCESSION:130548	62	0.7	21	1	130548
ACCESSION:133298	63	0.7	21	1	133298
ACCESSION:150989	64	0.7	21	1	150989
ACCESSION:AR370528	65	0.7	21	1	AR370528
ACCESSION:AR544734	66	0.7	21	1	AR544734
ACCESSION:AR560504	67	0.7	21	1	AR560504
ACCESSION:AR560512	68	0.7	21	1	AR560512
ACCESSION:AX175258	69	0.7	20.8	1	AX175258
ACCESSION:131234	70	0.7	20.8	1	131234
ACCESSION:AX115976	71	0.7	20.8	1	AX115976
ACCESSION:BD266115	72	0.7	20.6	1	BD266115
ACCESSION:BD266116	73	0.7	20.6	1	BD266116
ACCESSION:BD266117	74	0.7	20.6	1	BD266117
ACCESSION:BD266118	75	0.7	20.6	1	BD266118
ACCESSION:AR529596	76	0.7	20.6	1	AR529596
ACCESSION:AR529597	77	0.7	20.6	1	AR529597
ACCESSION:AX095621	78	0.7	20.6	1	AX095621
ACCESSION:AX095622	79	0.7	20.6	1	AX095622
ACCESSION:AR068108	80	0.7	20.4	1	AR068108
ACCESSION:AR110392	81	0.7	20.4	1	AR110392
ACCESSION:CQ754864	82	0.7	20.4	1	CQ754864
ACCESSION:130040	83	0.7	20.4	1	130040
ACCESSION:131213	84	0.7	20.4	1	131213
ACCESSION:AX674899	85	0.7	20.4	1	AX674899
ACCESSION:AR127801	86	0.7	20.4	1	AR127801
ACCESSION:131542	87	0.7	20.4	1	131542
ACCESSION:131533	88	0.7	20.4	1	131533
ACCESSION:AX104876	89	0.7	20.4	1	AX104876
ACCESSION:AX175257	90	0.7	20.4	1	AX175257
ACCESSION:AX547929	91	0.7	20.4	1	AX547929
ACCESSION:AX384656	92	0.7	20.2	1	AX384656
ACCESSION:AX115164	93	0.7	20.2	1	AX115164
ACCESSION:AX2360	94	0.7	20	1	AX2360
ACCESSION:AX2361	95	0.7	20	1	AX2361
ACCESSION:AX4399	96	0.7	20	1	AX4399
ACCESSION:AX4400	97	0.7	20	1	AX4400
ACCESSION:AX47182	98	0.7	20	1	AX47182
ACCESSION:AX56654	99	0.7	20	1	AX56654
ACCESSION:AX56655	100	0.7	20	1	AX56655
ACCESSION:AX80375	101	0.7	20	1	AX80375
ACCESSION:AX80376	102	0.7	20	1	AX80376
ACCESSION:AR021350	103	0.7	20	1	AR021350
ACCESSION:AR026549	104	0.7	20	1	AR026549
ACCESSION:AR026550	105	0.7	20	1	AR026550
ACCESSION:AR026550	106	0.7	20	1	AR026550

C 107	20	0.7	20	1	AR026551	ACCESSION: AR026551	C 180	20	0.7	20	1	AR120021	ACCESSION: AR120021
C 108	20	0.7	20	1	AR026552	ACCESSION: AR026552	C 181	20	0.7	20	1	AR120117	ACCESSION: AR120117
C 109	20	0.7	20	1	AR026553	ACCESSION: AR026553	C 182	20	0.7	20	1	AR121942	ACCESSION: AR121942
C 110	20	0.7	20	1	AR026554	ACCESSION: AR026554	C 183	20	0.7	20	1	AR123189	ACCESSION: AR123189
C 111	20	0.7	20	1	AR054240	ACCESSION: AR054240	C 184	20	0.7	20	1	AR123194	ACCESSION: AR123194
C 112	20	0.7	20	1	AR062602	ACCESSION: AR062602	C 185	20	0.7	20	1	AR123195	ACCESSION: AR123195
C 113	20	0.7	20	1	AR062607	ACCESSION: AR062607	C 186	20	0.7	20	1	AR123196	ACCESSION: AR123196
C 114	20	0.7	20	1	AR062608	ACCESSION: AR062608	C 187	20	0.7	20	1	AR123197	ACCESSION: AR123197
C 115	20	0.7	20	1	AR062609	ACCESSION: AR062609	C 188	20	0.7	20	1	AR123198	ACCESSION: AR123198
C 116	20	0.7	20	1	AR062610	ACCESSION: AR062610	C 189	20	0.7	20	1	AR123199	ACCESSION: AR123199
C 117	20	0.7	20	1	AR062611	ACCESSION: AR062611	C 190	20	0.7	20	1	AR123200	ACCESSION: AR123200
C 118	20	0.7	20	1	AR062612	ACCESSION: AR062612	C 191	20	0.7	20	1	AR123201	ACCESSION: AR123201
C 119	20	0.7	20	1	AR062613	ACCESSION: AR062613	C 192	20	0.7	20	1	AR123202	ACCESSION: AR123202
C 120	20	0.7	20	1	AR062614	ACCESSION: AR062614	C 193	20	0.7	20	1	AR123203	ACCESSION: AR123203
C 121	20	0.7	20	1	AR062615	ACCESSION: AR062615	C 194	20	0.7	20	1	AR123209	ACCESSION: AR123209
C 122	20	0.7	20	1	AR062616	ACCESSION: AR062616	C 195	20	0.7	20	1	AR123210	ACCESSION: AR123210
C 123	20	0.7	20	1	AR062622	ACCESSION: AR062622	C 196	20	0.7	20	1	AR123211	ACCESSION: AR123211
C 124	20	0.7	20	1	AR062623	ACCESSION: AR062623	C 197	20	0.7	20	1	AR123212	ACCESSION: AR123212
C 125	20	0.7	20	1	AR062624	ACCESSION: AR062624	C 198	20	0.7	20	1	AR123213	ACCESSION: AR123213
C 126	20	0.7	20	1	AR062625	ACCESSION: AR062625	C 199	20	0.7	20	1	AR123271	ACCESSION: AR123271
C 127	20	0.7	20	1	AR062626	ACCESSION: AR062626	C 200	20	0.7	20	1	AR123272	ACCESSION: AR123272
C 128	20	0.7	20	1	AR062627	ACCESSION: AR062627	C 201	20	0.7	20	1	AR123351	ACCESSION: AR123351
C 129	20	0.7	20	1	AR062628	ACCESSION: AR062628	C 202	20	0.7	20	1	AR124879	ACCESSION: AR124879
C 130	20	0.7	20	1	AR062685	ACCESSION: AR062685	C 203	20	0.7	20	1	AR124880	ACCESSION: AR124880
C 131	20	0.7	20	1	AR099490	ACCESSION: AR099490	C 204	20	0.7	20	1	AR128997	ACCESSION: AR128997
C 132	20	0.7	20	1	AR100310	ACCESSION: AR100310	C 205	20	0.7	20	1	AR128998	ACCESSION: AR128998
C 133	20	0.7	20	1	AR100318	ACCESSION: AR100318	C 206	20	0.7	20	1	AR128999	ACCESSION: AR128999
C 134	20	0.7	20	1	AR104705	ACCESSION: AR104705	C 207	20	0.7	20	1	AR129000	ACCESSION: AR129000
C 135	20	0.7	20	1	AR104710	ACCESSION: AR104710	C 208	20	0.7	20	1	AR129001	ACCESSION: AR129001
C 136	20	0.7	20	1	AR104711	ACCESSION: AR104711	C 209	20	0.7	20	1	AR129003	ACCESSION: AR129003
C 137	20	0.7	20	1									

253	20	0.7	20	1	BD242888	ACCESSION:BD242888	C 326	20	0.7	20	1	AR254169	ACCESSION:AR254169
C 254	20	0.7	20	1	BD267999	ACCESSION:BD267999	C 327	20	0.7	20	1	AR367391	ACCESSION:AR367391
C 255	20	0.7	20	1	BD272006	ACCESSION:BD272006	C 328	20	0.7	20	1	AR310708	ACCESSION:AR310708
C 256	20	0.7	20	1	BD272108	ACCESSION:BD272108	C 329	20	0.7	20	1	AR321577	ACCESSION:AR321577
C 257	20	0.7	20	1	BD272196	ACCESSION:BD272196	C 330	20	0.7	20	1	AR342115	ACCESSION:AR342115
C 258	20	0.7	20	1	BD272199	ACCESSION:BD272199	C 331	20	0.7	20	1	AR343042	ACCESSION:AR343042
C 259	20	0.7	20	1	BD272200	ACCESSION:BD272200	C 332	20	0.7	20	1	AR351594	ACCESSION:AR351594
C 260	20	0.7	20	1	BD272205	ACCESSION:BD272205	C 333	20	0.7	20	1	AR351595	ACCESSION:AR351595
C 261	20	0.7	20	1	BD273740	ACCESSION:BD273740	C 334	20	0.7	20	1	AR370527	ACCESSION:AR370527
C 262	20	0.7	20	1	CQ771250	ACCESSION:CQ771250	C 335	20	0.7	20	1	AR370532	ACCESSION:AR370532
C 263	20	0.7	20	1	CQ800973	ACCESSION:CQ800973	C 336	20	0.7	20	1	AR370533	ACCESSION:AR370533
C 264	20	0.7	20	1	CQ831689	ACCESSION:CQ831689	C 337	20	0.7	20	1	AR370534	ACCESSION:AR370534
C 265	20	0.7	20	1	I13817	ACCESSION:I13817	C 338	20	0.7	20	1	AR370535	ACCESSION:AR370535
C 266	20	0.7	20	1	I20604	ACCESSION:I20604	C 339	20	0.7	20	1	AR370536	ACCESSION:AR370536
C 267	20	0.7	20	1	I20609	ACCESSION:I20609	C 340	20	0.7	20	1	AR370537	ACCESSION:AR370537
C 268	20	0.7	20	1	I20610	ACCESSION:I20610	C 341	20	0.7	20	1	AR370538	ACCESSION:AR370538
C 269	20	0.7	20	1	I20611	ACCESSION:I20611	C 342	20	0.7	20	1	AR370539	ACCESSION:AR370539
C 270	20	0.7	20	1	I20612	ACCESSION:I20612	C 343	20	0.7	20	1	AR370540	ACCESSION:AR370540
C 271	20	0.7	20	1	I20613	ACCESSION:I20613	C 344	20	0.7	20	1	AR370541	ACCESSION:AR370541
C 272	20	0.7	20	1	I20614	ACCESSION:I20614	C 345	20	0.7	20	1	AR370547	ACCESSION:AR370547
C 273	20	0.7	20	1	I20615	ACCESSION:I20615	C 346	20	0.7	20	1	AR370548	ACCESSION:AR370548
C 274	20	0.7	20	1	I20616	ACCESSION:I20616	C 347	20	0.7	20	1	AR370549	ACCESSION:AR370549
C 275	20	0.7	20	1	I20617	ACCESSION:I20617	C 348	20	0.7	20	1	AR370550	ACCESSION:AR370550
C 276	20	0.7	20	1	I20618	ACCESSION:I20618	C 349	20	0.7	20	1	AR370551	ACCESSION:AR370551
C 277	20	0.7	20	1	I20624	ACCESSION:I20624	C 350	20	0.7	20	1	AR370609	ACCESSION:AR370609
C 278	20	0.7	20	1	I20625	ACCESSION:I20625	C 351	20	0.7	20	1	AR370610	ACCESSION:AR370610
C 279	20	0.7	20	1	I20626	ACCESSION:I20626	C 352	20	0.7	20	1	AR371570	ACCESSION:AR371570
C 280	20	0.7	20	1	I20627	ACCESSION:I20627	C 353	20	0.7	20	1	AR390753	ACCESSION:AR390753
C 281	20	0.7	20	1	I20628	ACCESSION:I20628	C 354	20	0.7	20	1	AR399186	ACCESSION:AR399186
C 282	20	0.7	20	1	I20686	ACCESSION:I20686	C 355	20	0.7	20	1	AR409506	ACCESSION:AR409506
C 283	20	0.7	20	1	I20687	ACCESSION:I20687	C 356	20	0.7	20	1	AR412367	ACCESSION:AR412367
C 284	20	0.7	20	1	I29010	ACCESSION:I29010	C 357	20	0.7	20	1	AR429267	ACCESSION:AR429267
C 285	20	0.7	20	1	I32393	ACCESSION:I32393	C 358	20	0.7	20	1	AR429273	ACCESSION:AR429273
C 286	20	0.7	20	1	I33297	ACCESSION:I33297	C 359	20	0.7	20	1	AR429276	ACCESSION:AR429276
C 287	20	0.7	20	1	I33302	ACCESSION:I33302	C 360	20	0.7	20	1	AR429282	ACCESSION:AR429282
C 288	20	0.7	20	1	I33303	ACCESSION:I33303	C 361	20	0.7	20	1	AR429287	ACCESSION:AR429287
C 289	20	0.7	20	1	I33304	ACCESSION:I33304	C 362	20	0.7	20	1	AR429288	ACCESSION:AR429288
C 290	20	0.7	20	1	I33305	ACCESSION:I33305	C 363	20	0.7	20	1	AR429290	ACCESSION:AR429290
C 291	20	0.7	20	1	I33306	ACCESSION:I33306	C 364	20	0.7	20	1	AR429296	ACCESSION:AR429296
C 292	20	0.7	20	1	I33307	ACCESSION:I33307	C 365	20	0.7	20	1	AR429298	ACCESSION:AR429298
C 293	20	0.7	20	1	I33308	ACCESSION:I33308	C 366	20	0.7	20	1	AR429303	ACCESSION:AR429303
C 294	20	0.7	20	1	I33309	ACCESSION:I33309	C 367	20	0.7	20	1	AR429305	ACCESSION:AR429305
C 295	20	0.7	20	1	I33310	ACCESSION:I33310	C 368	20	0.7	20	1	AR429311	ACCESSION:AR429311
C 296	20	0.7	20	1	I33311	ACCESSION:I33311	C 369	20	0.7	20	1	AR431224	ACCESSION:AR431224
C 297	20	0.7	20	1	I33317	ACCESSION:I33317	C 370	20	0.7	20	1	AR435738	ACCESSION:AR435738
C 298	20	0.7	20	1	I33318	ACCESSION:I33318	C 371	20	0.7	20	1	AR451258	ACCESSION:AR451258
C 299	20	0.7	20	1	I33319	ACCESSION:I33319	C 372	20	0.7	20	1	AR451259	ACCESSION:AR451259
C 300	20	0.7	20	1	I33320	ACCESSION:I33320	C 373	20	0.7	20	1	AR451261	ACCESSION:AR451261
C 301	20	0.7	20	1	I33321	ACCESSION:I33321	C 374	20	0.7	20	1	AR452808	ACCESSION:AR452808
C 302	20	0.7	20	1	I33451	ACCESSION:I33451	C 375	20	0.7	20	1	AR534798	ACCESSION:AR534798
C 303	20	0.7	20	1	I36646	ACCESSION:I36646	C 376	20	0.7	20	1	AR534799	ACCESSION:AR534799
C 304	20	0.7	20	1	I40395	ACCESSION:I40395	C 377	20	0.7	20	1	AR544732	ACCESSION:AR544732
C 305	20	0.7	20	1	I59717	ACCESSION:I59717	C 378	20	0.7	20	1	AR544733	ACCESSION:AR544733
C 306	20	0.7	20	1	I63126	ACCESSION:I63126	C 379	20	0.7	20	1	AR544785	ACCESSION:AR544785
C 307	20	0.7	20	1	I84733	ACCESSION:I84733	C 380	20	0.7	20	1	AR560503	ACCESSION:AR560503
C 308	20	0.7	20	1	I84734	ACCESSION:I84734	C 381	20	0.7	20	1	AX040559	ACCESSION:AX040559
C 309	20	0.7	20	1	AR179697	ACCESSION:AR179697	C 382	20	0.7	20	1	AX078054	ACCESSION:AX078054
C 310	20	0.7	20	1	AR179818	ACCESSION:AR179818	C 383	20	0.7	20	1	AX081373	ACCESSION:AX081373
C 311	20	0.7	20	1	AR179819	ACCESSION:AR179819	C 384	20	0.7	20	1	AX081374	ACCESSION:AX081374
C 312	20	0.7	20	1	AR182819	ACCESSION:AR182819	C 385	20	0.7	20	1	AX081375	ACCESSION:AX081375
C 313	20	0.7	20	1	AR193525	ACCESSION:AR193525	C 386	20	0.7	20	1	AX090045	ACCESSION:AX090045
C 314	20	0.7	20	1	AR193526	ACCESSION:AR193526	C 387	20	0.7	20	1	AX092653	ACCESSION:AX092653
C 315	20	0.7	20	1	AR199510	ACCESSION:AR199510	C 388	20	0.7	20	1	AX188686	ACCESSION:AX188686
C 316	20	0.7	20	1	AR203443	ACCESSION:AR203443	C 389	20	0.7	20	1	AX235177	ACCESSION:AX235177
C 317	20	0.7	20	1	AR207551	ACCESSION:AR207551	C 390	20	0.7	20	1	AX283203	ACCESSION:AX283203
C 318	20	0.7	20	1	AR212315	ACCESSION:AR212315	C 391	20	0.7	20	1	AX283204	ACCESSION:AX283204
C 319	20	0.7	20	1	AR212329	ACCESSION:AR212329	C 392	20	0.7	20	1	AX283205	ACCESSION:AX283205
C 320	20	0.7	20	1	AR212509	ACCESSION:AR212509	C 393	20	0.7	20	1	AX283272	ACCESSION:AX283272
C 321	20	0.7	20	1	AR224787	ACCESSION:AR224787	C 394	20	0.7	20	1	AX283273	ACCESSION:AX283273
C 322	20	0.7	20	1	AR236090	ACCESSION:AR236090	C 395	20	0.7	20	1	AX283274	ACCESSION:AX283274
C 323	20	0.7	20	1	AR237464	ACCESSION:AR237464	C 396	20	0.7	20	1	AX384657	ACCESSION:AX384657
C 324	20	0.7	20	1	AR237466	ACCESSION:AR237466	C 397	20	0.7	20	1	AX397905	ACCESSION:AX397905
C 325	20	0.7	20	1	AR254168	ACCESSION:AR254168	C 398	20	0.7	20	1	AX397906	ACCESSION:AX397906

C 399	20	0.7	20	1	AX419808	ACCSSION:AX419808	C 472	19	0.6	19	1	AX114983	ACCSSION:AX114983
C 400	20	0.7	20	1	AX419810	ACCSSION:AX419810	C 473	19	0.6	19	1	AX283206	ACCSSION:AX283206
C 401	20	0.7	20	1	AX419811	ACCSSION:AX419811	C 474	19	0.6	19	1	AX283275	ACCSSION:AX283275
C 402	20	0.7	20	1	AX419812	ACCSSION:AX419812	C 475	19	0.6	19	1	AX384658	ACCSSION:AX384658
C 403	20	0.7	20	1	AX593896	ACCSSION:AX593896	C 476	19	0.6	20	1	AR124506	ACCSSION:AR124506
C 404	20	0.7	20	1	AX593900	ACCSSION:AX593900	C 477	19	0.6	20	1	AR152875	ACCSSION:AR152875
C 405	20	0.7	20	1	AX797648	ACCSSION:AX797648	C 478	19	0.6	20	1	BD134331	ACCSSION:BD134331
C 406	20	0.7	20	1	AX797649	ACCSSION:AX797649	C 479	19	0.6	20	1	BD138317	ACCSSION:BD138317
C 407	20	0.7	20	1	AX957374	ACCSSION:AX957374	C 480	19	0.6	20	1	BD225804	ACCSSION:BD225804
C 408	20	0.7	20	1	AX957632	ACCSSION:AX957632	C 481	19	0.6	20	1	AX019553	ACCSSION:AX019553
C 409	20	0.7	20	1	AX957633	ACCSSION:AX957633	C 482	19	0.6	21	1	AR153724	ACCSSION:AR153724
C 410	20	0.7	20	1	AX957726	ACCSSION:AX957726	C 483	19	0.6	21	1	AR212319	ACCSSION:AR212319
C 411	20	0.7	20	1	AX957727	ACCSSION:AX957727	C 484	19	0.6	21	1	AR267381	ACCSSION:AR267381
C 412	20	0.7	20	1	AX958131	ACCSSION:AX958131	C 485	18.4	0.6	20	1	A63570	ACCSSION:A63570
C 413	20	0.7	20	1	AX958132	ACCSSION:AX958132	C 486	18.4	0.6	20	1	AR084543	ACCSSION:AR084543
C 414	20	0.7	20	1	BD014066	ACCSSION:BD014066	C 487	18.4	0.6	20	1	AR123339	ACCSSION:AR123339
C 415	20	0.7	20	1	BD014105	ACCSSION:BD014105	C 488	18.4	0.6	20	1	AR129684	ACCSSION:AR129684
C 416	20	0.7	20	1	BD106485	ACCSSION:BD106485	C 489	18.4	0.6	20	1	BD138316	ACCSSION:BD138316
C 417	20	0.7	21	1	I50990	ACCSSION:I50990	C 490	18.4	0.6	20	1	CQ771252	ACCSSION:CQ771252
C 418	20	0.7	21	1	I50991	ACCSSION:I50991	C 491	18.4	0.6	20	1	I88661	ACCSSION:I88661
C 419	20	0.7	22	1	AR062627	ACCSSION:AR062627	C 492	18.4	0.6	20	1	AR205392	ACCSSION:AR205392
C 420	20	0.7	22	1	AR104730	ACCSSION:AR104730	C 493	18.4	0.6	20	1	AR232228	ACCSSION:AR232228
C 421	20	0.7	22	1	AR105552	ACCSSION:AR105552	C 494	18.4	0.6	20	1	AX092614	ACCSSION:AX092614
C 422	20	0.7	22	1	AR123214	ACCSSION:AR123214	C 495	18.4	0.6	20	1	AX179298	ACCSSION:AX179298
C 423	20	0.7	22	1	I20629	ACCSSION:I20629	C 496	18.4	0.6	20	1	AX179299	ACCSSION:AX179299
C 424	20	0.7	22	1	I33322	ACCSSION:I33322	C 497	18.4	0.6	20	1	AX957175	ACCSSION:AX957175
C 425	20	0.7	23	1	AR370552	ACCSSION:AR370552	C 498	18.4	0.6	20	1	BD016468	ACCSSION:BD016468
C 426	19.8	0.7	23	1	AX926722	ACCSSION:AX926722	C 499	18.4	0.6	20	1	BD097545	ACCSSION:BD097545
C 427	19.8	0.7	24	1	AR154046	ACCSSION:AR154046	C 500	18.4	0.6	20	1	BD105781	ACCSSION:BD105781
C 428	19.8	0.7	24	1	AR565270	ACCSSION:AR565270	C 501	18.4	0.6	21	1	AX398276	ACCSSION:AX398276
C 429	19.8	0.7	24	1	BD130152	ACCSSION:BD130152	C 502	18.4	0.6	21	1	AX398277	ACCSSION:AX398277
C 430	19.6	0.7	21	1	BD266119	ACCSSION:BD266119	C 503	18.4	0.6	22	1	AR242947	ACCSSION:AR242947
C 431	19.4	0.6	21	1	I31248	ACCSSION:I31248	C 504	18.4	0.6	22	1	AX384999	ACCSSION:AX384999
C 432	19.4	0.6	21	1	AR182144	ACCSSION:AR182144	C 505	18.4	0.6	23	1	AX116678	ACCSSION:AX116678
C 433	19.4	0.6	21	1	AX104715	ACCSSION:AX104715	C 506	18.2	0.6	19	1	AR074597	ACCSSION:AR074597
C 434	19.4	0.6	21	1	AX115646	ACCSSION:AX115646	C 507	18.2	0.6	19	1	AR083936	ACCSSION:AR083936
C 435	19.4	0.6	21	1	AX175255	ACCSSION:AX175255	C 508	18.2	0.6	19	1	I23816	ACCSSION:I23816
C 436	19.4	0.6	21	1	AX175256	ACCSSION:AX175256	C 509	18.2	0.6	19	1	I29970	ACCSSION:I29970
C 437	19.4	0.6	21	1	AX547768	ACCSSION:AX547768	C 510	18	0.6	18	1	AR013831	ACCSSION:AR013831
C 438	19.4	0.6	21	1	AX741051	ACCSSION:AX741051	C 511	18	0.6	18	1	AR021351	ACCSSION:AR021351
C 439	19.4	0.6	21	1	AX823486	ACCSSION:AX823486	C 512	18	0.6	18	1	AR030948	ACCSSION:AR030948
C 440	19.4	0.6	24	1	AX116747	ACCSSION:AX116747	C 513	18	0.6	18	1	AR030949	ACCSSION:AR030949
C 441	19.2	0.6	24	1	E32214	ACCSSION:E32214	C 514	18	0.6	18	1	AR030950	ACCSSION:AR030950
C 442	19.2	0.6	24	1	AX060468	ACCSSION:AX060468	C 515	18	0.6	18	1	AR030951	ACCSSION:AR030951
C 443	19.2	0.6	24	1	AX060477	ACCSSION:AX060477	C 516	18	0.6	18	1	AR030952	ACCSSION:AR030952
C 444	19.2	0.6	24	1	AX201810	ACCSSION:AX201810	C 517	18	0.6	18	1	AR033785	ACCSSION:AR033785
C 445	19	0.6	19	1	A42362	ACCSSION:A42362	C 518	18	0.6	18	1	AR042445	ACCSSION:AR042445
C 446	19	0.6	19	1	A44401	ACCSSION:A44401	C 519	18	0.6	18	1	AR054230	ACCSSION:AR054230
C 447	19	0.6	19	1	A47184	ACCSSION:A47184	C 520	18	0.6	18	1	AR054236	ACCSSION:AR054236
C 448	19	0.6	19	1	A56656	ACCSSION:A56656	C 521	18	0.6	18	1	AR058325	ACCSSION:AR058325
C 449	19	0.6	19	1	A80377	ACCSSION:A80377	C 522	18	0.6	18	1	AR062601	ACCSSION:AR062601
C 450	19	0.6	19	1	AR013832	ACCSSION:AR013832	C 523	18	0.6	18	1	AR062604	ACCSSION:AR062604
C 451	19	0.6	19	1	AR033786	ACCSSION:AR033786	C 524	18	0.6	18	1	AR062605	ACCSSION:AR062605
C 452	19	0.6	19	1	AR042446	ACCSSION:AR042446	C 525	18	0.6	18	1	AR062681	ACCSSION:AR062681
C 453	19	0.6	19	1	AR058326	ACCSSION:AR058326	C 526	18	0.6	18	1	AR074312	ACCSSION:AR074312
C 454	19	0.6	19	1	AR088152	ACCSSION:AR088152	C 527	18	0.6	18	1	AR088151	ACCSSION:AR088151
C 455	19	0.6	19	1	AR102942	ACCSSION:AR102942	C 528	18	0.6	18	1	AR102941	ACCSSION:AR102941
C 456	19	0.6	19	1	AR111780	ACCSSION:AR111780	C 529	18	0.6	18	1	AR104704	ACCSSION:AR104704
C 457	19	0.6	19	1	AR119588	ACCSSION:AR119588	C 530	18	0.6	18	1	AR104707	ACCSSION:AR104707
C 458	19	0.6	19	1	AR153771	ACCSSION:AR153771	C 531	18	0.6	18	1	AR104708	ACCSSION:AR104708
C 459	19	0.6	19	1	BD266405	ACCSSION:BD266405	C 532	18	0.6	18	1	AR104784	ACCSSION:AR104784
C 460	19	0.6	19	1	BD266407	ACCSSION:BD266407	C 533	18	0.6	18	1	AR105526	ACCSSION:AR105526
C 461	19	0.6	19	1	BD273666	ACCSSION:BD273666	C 534	18	0.6	18	1	AR105529	ACCSSION:AR105529
C 462	19	0.6	19	1	I21896	ACCSSION:I21896	C 535	18	0.6	18	1	AR105530	ACCSSION:AR105530
C 463	19	0.6	19	1	I23324	ACCSSION:I23324	C 536	18	0.6	18	1	AR105606	ACCSSION:AR105606
C 464	19	0.6	19	1	I50992	ACCSSION:I50992	C 537	18	0.6	18	1	AR105611	ACCSSION:AR105611
C 465	19	0.6	19	1	I63600	ACCSSION:I63600	C 538	18	0.6	18	1	AR105612	ACCSSION:AR105612
C 466	19	0.6	19	1	I71048	ACCSSION:I71048	C 539	18	0.6	18	1	AR105613	ACCSSION:AR105613
C 467	19	0.6	19	1	I84735	ACCSSION:I84735	C 540	18	0.6	18	1	AR105614	ACCSSION:AR105614
C 468	19	0.6	19	1	AR179820	ACCSSION:AR179820	C 541	18	0.6	18	1	AR105615	ACCSSION:AR105615
C 469	19	0.6	19	1	AR193527	ACCSSION:AR193527	C 542	18	0.6	18	1	AR105616	ACCSSION:AR105616
C 470	19	0.6	19	1	AR254170	ACCSSION:AR254170	C 543	18	0.6	18	1	AR105617	ACCSSION:AR105617
C 471	19	0.6	19	1	AX081376	ACCSSION:AX081376	C 544	18	0.6	18	1	AR105618	ACCSSION:AR105618

C 691	16.8	0.6	20	1	BD129936	ACCESSION:BD129936
C 692	16.8	0.6	20	1	AB068830	ACCESSION:AB068830
C 693	16.8	0.6	21	1	AR154017	ACCESSION:AR154017
C 694	16.8	0.6	21	1	AR565241	ACCESSION:AR565241
C 695	16.8	0.6	21	1	AX777492	ACCESSION:AX777492
C 696	16.8	0.6	21	1	BD130123	ACCESSION:BD130123
C 697	16.6	0.6	19	1	AX033910	ACCESSION:AX033910
C 698	16.4	0.5	18	1	AR068107	ACCESSION:AR068107
C 699	16.4	0.5	18	1	AR110391	ACCESSION:AR110391
C 700	16.4	0.5	18	1	AR120115	ACCESSION:AR120115
C 701	16.4	0.5	18	1	AR178165	ACCESSION:AR178165
C 702	16.4	0.5	18	1	AR178166	ACCESSION:AR178166
C 703	16.4	0.5	18	1	AR178166	ACCESSION:AR178166
C 704	16.4	0.5	18	1	CO758961	ACCESSION:CO758961
C 705	16.4	0.5	18	1	CO766223	ACCESSION:CO766223
C 706	16.4	0.5	18	1	I30039	ACCESSION:I30039
C 707	16.4	0.5	18	1	AR182079	ACCESSION:AR182079
C 708	16.4	0.5	18	1	AR261503	ACCESSION:AR261503
C 709	16.4	0.5	18	1	AR371568	ACCESSION:AR371568
C 710	16.4	0.5	18	1	AX116403	ACCESSION:AX116403
C 711	16.4	0.5	18	1	AX175253	ACCESSION:AX175253
C 712	16.4	0.5	18	1	AX175254	ACCESSION:AX175254
C 713	16.4	0.5	18	1	BD087486	ACCESSION:BD087486
C 714	16.4	0.5	18	1	BD088792	ACCESSION:BD088792
C 715	16.4	0.5	18	1	AB068357	ACCESSION:AB068357
C 716	16.4	0.5	19	1	CO824199	ACCESSION:CO824199
C 717	16.4	0.5	20	1	BD138330	ACCESSION:BD138330
C 718	16.4	0.5	20	1	E05497	ACCESSION:E05497
C 719	16.4	0.5	20	1	E32215	ACCESSION:E32215
C 720	16.4	0.5	20	1	I31483	ACCESSION:I31483
C 721	16.4	0.5	20	1	AR242049	ACCESSION:AR242049
C 722	16.4	0.5	20	1	AR370243	ACCESSION:AR370243
C 723	16.4	0.5	20	1	AX770003	ACCESSION:AX770003
C 724	16.2	0.5	19	1	AB069586	ACCESSION:AB069586
C 725	16	0.5	18	1	AR528447	ACCESSION:AR528447
C 726	16	0.5	18	1	AR071801	ACCESSION:AR071801
C 727	16	0.5	18	1	AR071802	ACCESSION:AR071802
C 728	16	0.5	19	1	AR071803	ACCESSION:AR071803
C 729	16	0.5	19	1	AR541350	ACCESSION:AR541350
C 730	16	0.5	19	1	AR541351	ACCESSION:AR541351
C 731	16	0.5	19	1	AR541352	ACCESSION:AR541352
C 732	16	0.5	19	1	AR541353	ACCESSION:AR541353
C 733	16	0.5	20	1	AR370242	ACCESSION:AR370242
C 734	16	0.5	20	1	AR562156	ACCESSION:AR562156
C 735	15.8	0.5	19	1	AR067275	ACCESSION:AR067275
C 736	15.4	0.5	18	1	AR071772	ACCESSION:AR071772
C 737	15.4	0.5	18	1	AR071773	ACCESSION:AR071773
C 738	15.4	0.5	18	1	AX082553	ACCESSION:AX082553
C 739	15.4	0.5	19	1	E10167	ACCESSION:E10167
C 740	15.4	0.5	19	1	AR370177	ACCESSION:AR370177
C 741	15	0.5	18	1	AR071774	ACCESSION:AR071774
C 742	15	0.5	18	1	AR071775	ACCESSION:AR071775
C 743	15	0.5	18	1	AR071776	ACCESSION:AR071776
C 744	15	0.5	18	1	AR071777	ACCESSION:AR071777
C 745	15	0.5	18	1	AR071778	ACCESSION:AR071778
C 746	15	0.5	18	1	AR071779	ACCESSION:AR071779
C 747	15	0.5	18	1	AR071799	ACCESSION:AR071799
C 748	15	0.5	18	1	AR071800	ACCESSION:AR071800
C 749	15	0.5	18	1	AR071804	ACCESSION:AR071804
C 750	15	0.5	18	1	AR071805	ACCESSION:AR071805
C 751	15	0.5	18	1	AR071806	ACCESSION:AR071806
C 752	15	0.5	18	1	AR071807	ACCESSION:AR071807
C 753	15	0.5	18	1	AR071808	ACCESSION:AR071808
C 754	15	0.5	18	1	AR071809	ACCESSION:AR071809
C 755	15	0.5	18	1	AX115187	ACCESSION:AX115187
C 756	15	0.5	18	1	AX695098	ACCESSION:AX695098
C 757	14.8	0.5	18	1	AG9799	ACCESSION:AG9799
C 758	14.8	0.5	18	1	A66978	ACCESSION:A66978
C 759	14.8	0.5	18	1	AR154096	ACCESSION:AR154096
C 760	14.8	0.5	18	1	BD171788	ACCESSION:BD171788
C 761	14.8	0.5	18	1	CO803382	ACCESSION:CO803382
C 762	14.8	0.5	18	1	AR294035	ACCESSION:AR294035
C 763	14.8	0.5	18	1	AR488480	ACCESSION:AR488480
C 764	14.8	0.5	18	1	AR565320	ACCESSION:AR565320
C 765	14.8	0.5	18	1	AX811382	ACCESSION:AX811382
C 766	14.8	0.5	18	1	BD089873	ACCESSION:BD089873
C 767	14.8	0.5	18	1	BD130202	ACCESSION:BD130202
C 768	14.8	0.5	18	1	AB068214	ACCESSION:AB068214
C 769	14.4	0.5	18	1	BD266406	ACCESSION:BD266406
C 770	14.4	0.5	18	1	AR076318	ACCESSION:AR076318
C 771	14.4	0.5	18	1	AR078881	ACCESSION:AR078881
C 772	14.4	0.5	18	1	BD234550	ACCESSION:BD234550
C 773	14.4	0.5	18	1	BD250628	ACCESSION:BD250628
C 774	14.4	0.5	18	1	CO758945	ACCESSION:CO758945
C 775	14.4	0.5	18	1	I39667	ACCESSION:I39667
C 776	14.4	0.5	18	1	AR215620	ACCESSION:AR215620
C 777	14.4	0.5	18	1	AR219241	ACCESSION:AR219241
C 778	14.4	0.5	18	1	AX004441	ACCESSION:AX004441
C 779	14.4	0.5	18	1	AX082162	ACCESSION:AX082162
C 780	14.4	0.5	18	1	AX635770	ACCESSION:AX635770
RESULT 1						
LOCUS	AR008538	24 bp	DNA	linear	PAT 04-DEC-1998	
DEFINITION	Sequence 22 from patent US 5753502.					
ACCESSION	AR008538					
VERSION	AR008538.1	GI:3967647				
KEYWORDS	Unknown.					
ORGANISM	Unknown.					
REFERENCE	1 (bases 1 to 24)					
AUTHORS	Kilgannon,P.D. and Gallatin,W.Michael.					
TITLE	Neuron-specific ICAM-4 promoter					
JOURNAL	Patent: US 5753502-A 22 19-MAY-1998;					
FEATURES	Location/Qualifiers					
source	1..24					
	/organism="unknown"					
	/mol_type="unassigned DNA"					
Query Match	0.8%;	Score 24;	DB 1;	Length 24;		
Best Local Similarity	100.0%;	Pred. No. 57;				
Matches	24;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;	
QY	729	CCGGGTCCTAGAGGTGGACACGCA	752			
Db	1	CCGGGTCCTAGAGGTGGACACGCA	24			
RESULT 2						
LOCUS	AR008539/c	24 bp	DNA	linear	PAT 04-DEC-1998	
DEFINITION	Sequence 23 from patent US 5753502.					
ACCESSION	AR008539					
VERSION	AR008539.1	GI:3967648				
KEYWORDS	Unknown.					
SOURCE	Unknown.					
ORGANISM	Unknown.					
REFERENCE	1 (bases 1 to 24)					
AUTHORS	Kilgannon,P.D. and Gallatin,W.Michael.					
TITLE	Neuron-specific ICAM-4 promoter					
JOURNAL	Patent: US 5753502-A 23 19-MAY-1998;					
FEATURES	Location/Qualifiers					
source	1..24					
	/organism="unknown"					
	/mol_type="unassigned DNA"					
Query Match	0.8%;	Score 24;	DB 1;	Length 24;		
Best Local Similarity	100.0%;	Pred. No. 57;				
Matches	24;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;	

QY 942 GAACACAGCCAGGAGACACTGCA 965
|||||
Db 24 GAACACAGCCAGGAGACACTGCA 1

RESULT 3
LOCUS AR013833 24 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 23 from patent US 5773218.
ACCESSION AR013833
VERSION AR013833.1 GI:3971287
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 24)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Method to identify compounds which modulate ICAM-related protein interactions
JOURNAL Patent: US 5773218-A 23 30-JUN-1998;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCTAGAGGTGACACGCA 752
|||||
Db 1 CCGGGTCTAGAGGTGACACGCA 24

RESULT 4
LOCUS AR013834 24 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 24 from patent US 5773218.
ACCESSION AR013834
VERSION AR013834.1 GI:3971288
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 24)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Method to identify compounds which modulate ICAM-related protein interactions
JOURNAL Patent: US 5773218-A 24 30-JUN-1998;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCTAGAGGTGACACGCA 752
|||||
Db 1 CCGGGTCTAGAGGTGACACGCA 24

RESULT 5
LOCUS AR014326 24 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 22 from patent US 5773293.
ACCESSION AR014326
VERSION AR014326.1 GI:3971780
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 24)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Method to identify compounds which modulate ICAM-related protein interactions
JOURNAL Patent: US 5773218-A 24 30-JUN-1998;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACACAGCCAGGAGACACTGCA 965
|||||
Db 24 GAACACAGCCAGGAGACACTGCA 1

RESULT 6
LOCUS AR014327/c 24 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 23 from patent US 5773293.
ACCESSION AR014327
VERSION AR014327.1 GI:3971781
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 24)
AUTHORS Kilgannon,P.D. and Gallatin,W.Michael.
TITLE Anti-ICAM-4 antibodies and hybridomas
JOURNAL Patent: US 5773293-A 23 30-JUN-1998;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCTAGAGGTGACACGCA 752
|||||
Db 1 CCGGGTCTAGAGGTGACACGCA 24

RESULT 7
LOCUS AR029111 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 3 from patent US 5859212.
ACCESSION AR029111
VERSION AR029111.1 GI:5941084
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 24)
AUTHORS McClelland,A. and Greve,J.M.
TITLE Method of isolating and purifying sICAM-1
JOURNAL Patent: US 5859212-A 3 12-JAN-1999;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1408 CTTGAGGGCACCTACTCTGTGG 1431
|||||
Db 1 CTTGAGGGCACCTACTCTGTGG 24

REFERENCE 1 (bases 1 to 24)
AUTHORS Kilgannon,P.D. and Gallatin,W.Michael.
TITLE Anti-ICAM-4 antibodies and hybridomas
JOURNAL Patent: US 5773293-A 22 30-JUN-1998;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCTAGAGGTGACACGCA 752
|||||
Db 1 CCGGGTCTAGAGGTGACACGCA 24

RESULT 6
LOCUS AR014327/c 24 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 23 from patent US 5773293.
ACCESSION AR014327
VERSION AR014327.1 GI:3971781
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 24)
AUTHORS Kilgannon,P.D. and Gallatin,W.Michael.
TITLE Anti-ICAM-4 antibodies and hybridomas
JOURNAL Patent: US 5773293-A 23 30-JUN-1998;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACACAGCCAGGAGACACTGCA 965
|||||
Db 24 GAACACAGCCAGGAGACACTGCA 1

RESULT 7
LOCUS AR029111 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 3 from patent US 5859212.
ACCESSION AR029111
VERSION AR029111.1 GI:5941084
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 24)
AUTHORS McClelland,A. and Greve,J.M.
TITLE Method of isolating and purifying sICAM-1
JOURNAL Patent: US 5859212-A 3 12-JAN-1999;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1408 CTTGAGGGCACCTACTCTGTGG 1431
|||||
Db 1 CTTGAGGGCACCTACTCTGTGG 24

```

RESULT 8
LOCUS AR029112/c 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 4 from patent US 5859212.
ACCESSION AR029112
VERSION AR029112.1 GI:5941085
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 24)
AUTHORS McClelland A. and Greve J.M.
TITLE Method of isolating and purifying sICAM-1
JOURNAL Patent: US 5859212-A 4 12-JAN-1999;
FEATURES
source
Location/Qualifiers
1. .24
/mol_type="unassigned DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1489 CGGTATGAGATTGTCATCACT 1512
Db 24 CGGTATGAGATTGTCATCACT 1

RESULT 9
LOCUS AR033787 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 23 from patent US 5869262.
ACCESSION AR033787
VERSION AR033787.1 GI:5949392
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 24)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
JOURNAL Patent: US 5869262-A 23 09-FEB-1999;
FEATURES
source
Location/Qualifiers
1. .24
/mol_type="unassigned DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCCTAGAGTGGACACGCA 752
Db 1 CCGGGTCCTAGAGTGGACACGCA 24

RESULT 10
LOCUS AR033788/c 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 24 from patent US 5869262.
ACCESSION AR033788
VERSION AR033788.1 GI:5949393
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 24)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
JOURNAL Patent: US 5869262-A 24 09-FEB-1999;

```

```

FEATURES
source
Location/Qualifiers
1. .24
/mol_type="unassigned DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACCCAGAGCCAGGAGACACTGCA 965
Db 24 GAACCCAGAGCCAGGAGACACTGCA 1

RESULT 11
LOCUS AR042447 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 23 from patent US 5811517.
ACCESSION AR042447
VERSION AR042447.1 GI:5962943
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 24)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE ICAM-related protein variants
JOURNAL Patent: US 5811517-A 23 22-SEP-1998;
FEATURES
source
Location/Qualifiers
1. .24
/mol_type="unassigned DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCCTAGAGTGGACACGCA 752
Db 1 CCGGGTCCTAGAGTGGACACGCA 24

RESULT 12
LOCUS AR042448/c 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 24 from patent US 5811517.
ACCESSION AR042448
VERSION AR042448.1 GI:5962944
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 24)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE ICAM-related protein variants
JOURNAL Patent: US 5811517-A 24 22-SEP-1998;
FEATURES
source
Location/Qualifiers
1. .24
/mol_type="unassigned DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACCCAGAGCCAGGAGACACTGCA 965
Db 24 GAACCCAGAGCCAGGAGACACTGCA 1

RESULT 13
LOCUS AR048728 24 bp DNA linear PAT 29-SEP-1999

```

```
DEFINITION Sequence 3 from patent US 5821341.
ACCESSION AR048728
VERSION AR048728.1 GI:5971071
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS McClelland,A. and Greve,J.M.
TITLE Antibodies to sICAM-1
JOURNAL Patent: US 5821341-A 3 13-OCT-1998;
FEATURES
    source
        Location/Qualifiers
            1..24
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1408 CTTGAGGGCACCTACCTCTGTCGG 1431
Db 1 CTTGAGGGCACCTACCTCTGTCGG 24

RESULT 14
AR048729/c
LOCUS AR048729 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 4 from patent US 5821341.
ACCESSION AR048729
VERSION AR048729.1 GI:5971072
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS McClelland,A. and Greve,J.M.
TITLE Antibodies to sICAM-1
JOURNAL Patent: US 5821341-A 4 13-OCT-1998;
FEATURES
    source
        Location/Qualifiers
            1..24
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1489 CGGTATGAGATTGTCACTCACT 1512
Db 24 CGGTATGAGATTGTCACTCACT 1

RESULT 15
AR058327
LOCUS AR058327 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 23 from patent US 5837822.
ACCESSION AR058327
VERSION AR058327.1 GI:5983904
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Humanized antibodies specific for ICAM related protein
JOURNAL Patent: US 5837822-A 23 17-NOV-1998;
FEATURES
    source
        Location/Qualifiers
            1..24
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1489 CGGTATGAGATTGTCACTCACT 1512
Db 24 CGGTATGAGATTGTCACTCACT 1

RESULT 16
AR058328/c
LOCUS AR058328 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 24 from patent US 5837822.
ACCESSION AR058328
VERSION AR058328.1 GI:5983905
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Humanized antibodies specific for ICAM related protein
JOURNAL Patent: US 5837822-A 24 17-NOV-1998;
FEATURES
    source
        Location/Qualifiers
            1..24
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACACAGCCAGGACACACTGCA 965
Db 24 GAACACAGCCAGGACACACTGCA 1

RESULT 17
AR065923
LOCUS AR065923 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 3 from patent US 5849699.
ACCESSION AR065923
VERSION AR065923.1 GI:5996139
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS McClelland,A. and Greve,J.M.
TITLE Soluble molecule related to but distinct from ICAM-1
JOURNAL Patent: US 5849699-A 3 15-DEC-1998;
FEATURES
    source
        Location/Qualifiers
            1..24
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1408 CTTGAGGGCACCTACCTCTGTCGG 1431
Db 1 CTTGAGGGCACCTACCTCTGTCGG 24

RESULT 18
AR065924/c
LOCUS AR065924 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 4 from patent US 5849699.
ACCESSION AR065924
VERSION AR065924.1 GI:5996140
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1408 CTTGAGGGCACCTACCTCTGTCGG 1431
Db 1 CTTGAGGGCACCTACCTCTGTCGG 24
```



```
Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS McClelland,A. and Greve,J.M.
TITLE Soluble molecule related to but distinct from ICAM-1
JOURNAL Patent: US 5849699-A 4 15-DEC-1998;
FEATURES
    source
        1..24
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1489 CGGTATGAGATTTCATCATCACT 1512
Db 24 CGGTATGAGATTTCATCATCACT 1

RESULT 19
AR068085
LOCUS AR068085 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 22 from patent US 5852170.
ACCESSION AR068085
VERSION AR068085.1 GI:5999307
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Kilgannon,P.D. and Gallatin,W.Michael.
TITLE ICAM-4 materials and methods
JOURNAL Patent: US 5852170-A 22 22-DEC-1998;
FEATURES
    source
        1..24
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCCTAGAGTGGACACGCA 752
Db 1 CCGGGTCCTAGAGTGGACACGCA 24

RESULT 20
AR068086/c
LOCUS AR068086 24 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 23 from patent US 5852170.
ACCESSION AR068086
VERSION AR068086.1 GI:5999308
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Kilgannon,P.D. and Gallatin,W.Michael.
TITLE ICAM-4 materials and methods
JOURNAL Patent: US 5852170-A 23 22-DEC-1998;
FEATURES
    source
        1..24
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACACGAGCCAGGAGACTGCA 965
Db 24 GAACACGAGCCAGGAGACTGCA 1

RESULT 21
AR088153
LOCUS AR088153 24 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 23 from patent US 5989843.
ACCESSION AR088153
VERSION AR088153.1 GI:10014916
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
JOURNAL Patent: US 5989843-A 23 23-NOV-1999;
FEATURES
    source
        1..24
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCCTAGAGTGGACACGCA 752
Db 1 CCGGGTCCTAGAGTGGACACGCA 24

RESULT 22
AR088154/c
LOCUS AR088154 24 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 24 from patent US 5989843.
ACCESSION AR088154
VERSION AR088154.1 GI:10014917
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
JOURNAL Patent: US 5989843-A 24 23-NOV-1999;
FEATURES
    source
        1..24
        /organism="unknown"
        /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACACGAGCCAGGAGACTGCA 965
Db 24 GAACACGAGCCAGGAGACTGCA 1

RESULT 23
AR090407
LOCUS AR090407 24 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 527 from patent US 5994076.
ACCESSION AR090407
VERSION AR090407.1 GI:10017162
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Chenchik,A., Jokhadze,G. and Bibilashvili,R.
TITLE Methods of assaying differential expression
```

```
JOURNAL Patent: US 5994076-A 527 30-NOV-1999;
FEATURES Location/Qualifiers
source
    1..24
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1220 GCGAGTTCCTGCTGCTGATGGCC 1243
Db 1 GCGAGTTCCTGCTGCTGATGGCC 24

RESULT 24
186172
LOCUS 186172 24 bp DNA linear PAT 10-JUN-1998
DEFINITION Sequence 22 from patent US 5700658.
ACCESSION 186172
VERSION 186172.1 GI:3205890
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 24)
AUTHORS Kilgannon,P.D. and Gallatin,W.Michael.
TITLE ICAM-4 materials and methods
JOURNAL Patent: US 5700658-A 22 23-DEC-1997;
FEATURES Location/Qualifiers
source
    1..24
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCCTAGAGGTGGACACGCA 752
Db 1 CCGGGTCCTAGAGGTGGACACGCA 24

RESULT 25
186173/c
LOCUS 186173 24 bp DNA linear PAT 10-JUN-1998
DEFINITION Sequence 23 from patent US 5700658.
ACCESSION 186173
VERSION 186173.1 GI:3205891
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 24)
AUTHORS Kilgannon,P.D. and Gallatin,W.Michael.
TITLE ICAM-4 materials and methods
JOURNAL Patent: US 5700658-A 23 23-DEC-1997;
FEATURES Location/Qualifiers
source
    1..24
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACCCAGAGCCAGGACACTGCA 965
Db 24 GAACCCAGAGCCAGGACACTGCA 1

RESULT 26
186882
LOCUS 186882 24 bp DNA linear PAT 10-JUN-1998
DEFINITION Sequence 22 from patent US 5702917.
ACCESSION 186882
VERSION 186882.1 GI:3206600
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 24)
AUTHORS Kilgannon,P.D. and Gallatin,W.Michael.
TITLE Polynucleotides encoding human ICAM-4
JOURNAL Patent: US 5702917-A 22 30-DEC-1997;
FEATURES Location/Qualifiers
source
    1..24
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCCTAGAGGTGGACACGCA 752
Db 1 CCGGGTCCTAGAGGTGGACACGCA 24

RESULT 27
186883/c
LOCUS 186883 24 bp DNA linear PAT 10-JUN-1998
DEFINITION Sequence 23 from patent US 5702917.
ACCESSION 186883
VERSION 186883.1 GI:3206601
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 24)
AUTHORS Kilgannon,P.D. and Gallatin,W.Michael.
TITLE Polynucleotides encoding human ICAM-4
JOURNAL Patent: US 5702917-A 23 30-DEC-1997;
FEATURES Location/Qualifiers
source
    1..24
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.8%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACCCAGAGCCAGGACACTGCA 965
Db 24 GAACCCAGAGCCAGGACACTGCA 1

RESULT 28
AR197442
LOCUS AR197442 24 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 527 from patent US 6352829.
ACCESSION AR197442
VERSION AR197442.1 GI:20247291
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 24)
AUTHORS Chenchik,A., Jokhadze,G. and Bibilashvilli,R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6352829-A 527 05-MAR-2002;
FEATURES Location/Qualifiers
source
    1..24
    /organism="unknown"
    /mol_type="unassigned DNA"
```

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57; Mismatches 0; Indels 0; Gaps 0;
Matches 24; Conservative 0; Indels 0; Gaps 0;

QY 1220 GGGAGCTTCGTGCTGCTGATGGCC 1243
|||||
Db 1 GGGAGCTTCGTGCTGCTGATGGCC 24

RESULT 29
AX746340
LOCUS AX746340.1 GI:31746276
DEFINITION Sequence 527 from patent US 6489455.
ACCESSION AR259596
VERSION AR259596
KEYWORDS AR259596.1 GI:27310107
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 24)
AUTHORS Chenchik, A., Jolkhadze, G. and Bibilashvili, R.
TITLE Methods of assaying differential expression
JOURNAL Patent: US 6489455-A 527 03-DEC-2002;
FEATURES Location/Qualifiers
source 1..24
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57; Mismatches 0; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1220 GGGAGCTTCGTGCTGCTGATGGCC 1243
|||||
Db 1 GGGAGCTTCGTGCTGCTGATGGCC 24

RESULT 30
AX746339
LOCUS AX746339
DEFINITION Sequence 22 from Patent EP1308514.
ACCESSION AX746339
VERSION AX746339.1 GI:31746275
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Kilgannon, P.D. and Gallatin, M.W.
TITLE ICAM-4 materials and methods
JOURNAL Patent: EP 1308514-A 22 07-MAY-2003;
ICOS CORPORATION (US)
FEATURES Location/Qualifiers
source 1..24
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/notes="sense primer designed complementary to human ICAM-1 domain 3 (H-1/D3 S)"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57; Mismatches 0; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCCTAGAGTGGACACGCA 752
|||||
Db 1 CCGGGTCCTAGAGTGGACACGCA 24

RESULT 31
AX746340/c
LOCUS AX746340.1 GI:31746276
DEFINITION Sequence 23 from Patent EP1308514.

ACCESSION AX746340
VERSION AX746340.1 GI:31746276
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Kilgannon, P.D. and Gallatin, M.W.
TITLE ICAM-4 materials and methods
JOURNAL Patent: EP 1308514-A 23 07-MAY-2003;
ICOS CORPORATION (US)
FEATURES Location/Qualifiers
source 1..24
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="antisense primer designed complementary to human ICAM-1 domain 3 (H-1/D3 AS)"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57; Mismatches 0; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACACAGCCAGGACACTGCA 965
|||||
Db 24 GAACACAGCCAGGACACTGCA 1

RESULT 32
AX816919
LOCUS AX816919
DEFINITION Sequence 22 from Patent EP1338896.
ACCESSION AX816919
VERSION AX816919.1 GI:39647196
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Kilgannon, P.D. and Gallatin, M.W.
TITLE ICAM-4 and diagnostic uses thereof
JOURNAL Patent: EP 1338896-A 22 27-AUG-2003;
ICOS CORPORATION (US)
FEATURES Location/Qualifiers
source 1..24
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 57; Mismatches 0; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCCTAGAGTGGACACGCA 752
|||||
Db 1 CCGGGTCCTAGAGTGGACACGCA 24

RESULT 33
AX816920/c
LOCUS AX816920
DEFINITION Sequence 23 from Patent EP1338896.
ACCESSION AX816920
VERSION AX816920.1 GI:39647197
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Kilgannon, P.D. and Gallatin, M.W.
TITLE ICAM-4 and diagnostic uses thereof
JOURNAL Patent: EP 1338896-A 23 27-AUG-2003;
ICOS CORPORATION (US)

FEATURES
source
1. .24
Location/Qualifiers
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACGAGCCGAGGAGACTGCA 965
Db 24 GAACGAGCCGAGGAGACTGCA 1

RESULT 34
BD064508
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

BD064508
ICAM-4 and diagnostic uses thereof.
BD064508
BD064508.1 GI:22610111
JP 2001508181-A/20.
Vaccinia virus
Vaccinia virus
Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
Orthopoxvirus.
1 (bases 1 to 24)
Kilgannon, P.D. and Gallatin, M.W.
ICAM-4 and diagnostic uses thereof
Patent: JP 2001508181-A 20 19-JUN-2001;
ICOS CORP
PN JP 2001508181-A/20
PD 19-JUN-2001
PF 02-OCT-1998 JP 1999522146
PR 02-OCT-1997 US 08/942867
PC PATRICK D KILGANNON, MICHAEL W GALLATIN
PG GOIN33/68//C07K16/28
PD GOIN33/68//C07K16/28
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers.

Query Match
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACGAGCCGAGGAGACTGCA 965
Db 24 GAACGAGCCGAGGAGACTGCA 1

RESULT 36
AR364453
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

AR364453
Sequence 40 from patent US 5284931.
AR364453
AR364453.1 GI:34427066
Unknown.
Unknown.
Unclassified.
1 (bases 1 to 25)
Springer, T.A., Rothlein, R., Marlin, S.D. and Dustin, M.L.
Intercellular adhesion molecules, and their binding ligands
Patent: US 5284931-A 40 08-FEB-1994;
Location/Qualifiers
1. .25
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1550 TCAGCAGCTACCTCTATACCGCCA 1574
Db 1 TCAGCAGCTACCTCTATACCGCCA 25

RESULT 37
AX614112
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

AX614112
Sequence 5137 from Patent WO02072882.
AX614112
AX614112.1 GI:28409541
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Cullen, P. and Seedorf, U.
Coronary chip
Patent: WO 02072882-A 5137 19-SEP-2002;
OGHAM GmbH (DE)
Location/Qualifiers
1. .25
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGTCCTAGAGTGACACGCA 752
Db 1 CCGGTCCTAGAGTGACACGCA 24

RESULT 35
BD064509/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

BD064509/c
ICAM-4 and diagnostic uses thereof.
BD064509
BD064509.1 GI:22610112
JP 2001508181-A/21.
Vaccinia virus
Vaccinia virus
Viruses; dsDNA viruses, no RNA stage; Poxviridae; Chordopoxvirinae;
Orthopoxvirus.
1 (bases 1 to 24)
Kilgannon, P.D. and Gallatin, M.W.
ICAM-4 and diagnostic uses thereof
Patent: JP 2001508181-A 21 19-JUN-2001;
ICOS CORP
PN JP 2001508181-A/21
PD 19-JUN-2001

PF 02-OCT-1998 JP 1999522146
PR 02-OCT-1997 US 08/942867
PC PATRICK D KILGANNON, MICHAEL W GALLATIN
PG GOIN33/68//C07K16/28
PD GOIN33/68//C07K16/28
CC Strandedness: Single;
CC Topology: Linear;
FH Key Location/Qualifiers.

FEATURES
source
1. .24
/organism="vaccinia virus"
/mol_type="genomic DNA"
/db_xref="taxon:10245"

Query Match
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACGAGCCGAGGAGACTGCA 965
Db 24 GAACGAGCCGAGGAGACTGCA 1

RESULT 36
AR364453
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

AR364453
Sequence 40 from patent US 5284931.
AR364453
AR364453.1 GI:34427066
Unknown.
Unknown.
Unclassified.
1 (bases 1 to 25)
Springer, T.A., Rothlein, R., Marlin, S.D. and Dustin, M.L.
Intercellular adhesion molecules, and their binding ligands
Patent: US 5284931-A 40 08-FEB-1994;
Location/Qualifiers
1. .25
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1550 TCAGCAGCTACCTCTATACCGCCA 1574
Db 1 TCAGCAGCTACCTCTATACCGCCA 25

RESULT 37
AX614112
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source

AX614112
Sequence 5137 from Patent WO02072882.
AX614112
AX614112.1 GI:28409541
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Cullen, P. and Seedorf, U.
Coronary chip
Patent: WO 02072882-A 5137 19-SEP-2002;
OGHAM GmbH (DE)
Location/Qualifiers
1. .25
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 100.0%; Pred. No. 57;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1550 TCAGCAGCTACCTCTATACCGCCA 1574
Db 1 TCAGCAGCTACCTCTATACCGCCA 25

Best Local Similarity 96.0%; Pred. No. 64;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2762 GCTCTGTCAACCCAGGCTGGAGTGCA 2786
|||||
Db 1 GCTCTGTGCGCCAGGCTGGAGTGCA 25

RESULT 38
CQ778235
LOCUS
DEFINITION
ACCESSION
VERSION
QY778235.1 GI:45380953
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE
1
AUTHORS
Ohtani, N., Sugita, Y., Yamaya, M., Kubo, H., Negai, H. and Izuhara, K.
TITLE
Methods of testing for bronchial asthma or chronic obstructive
pulmonary disease
JOURNAL
Patent: EP 1394274-A 1921 03-MAR-2004;
Genox Research, Inc. (JP)
FEATURES
Location/Qualifiers
source
1..23
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="an artificially synthesized primer sequence"

Query Match 0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 77;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 918 GCTGACGTGTCAGTAATACTGG 940
|||||
Db 1 GCTGACGTGTCAGTAATACTGG 23

RESULT 39
AX797527/c
LOCUS
DEFINITION
ACCESSION
VERSION
QY797527.1 GI:37518030
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE
1
AUTHORS
Hayes, I., Cotter, T., Murphy, F. and Seery, L.
TITLE
Tgnp
JOURNAL
Patent: WO 03050302-A 12 19-JUN-2003;
Elix Therapeutics Ltd (IE)
FEATURES
Location/Qualifiers
source
1..24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PCR primer"

Query Match 0.8%; Score 22.4; DB 1; Length 24;
Best Local Similarity 95.8%; Pred. No. 86;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2763 CTCTGTCAACCCAGGCTGGAGTGCA 2786
|||||
Db 24 CTCTGTCAACCCAGGCTGGAGTGCA 1

RESULT 40
CQ771558

LOCUS
DEFINITION
ACCESSION
VERSION
QY771558.1 GI:45125548
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE
1
AUTHORS
Blair, E.D., Clarke, N.J., Johnston, S.L. and Rowlands, D.J.
TITLE
Animal models
JOURNAL
Patent: WO 2004009810-A 19 29-JAN-2004;
GLAXO GROUP LIMITED (GB)
FEATURES
Location/Qualifiers
source
1..22
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer NS 25"

Query Match 0.7%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 352 GGGCAGTCAACAGCTAAACCT 373
|||||
Db 1 GGGCAGTCAACAGCTAAACCT 22

RESULT 41
AX284111
LOCUS
DEFINITION
ACCESSION
VERSION
QY284111.1 GI:17044821
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE
1
AUTHORS
Degitz, K.K. and Besch, R.
TITLE
Polydesoxyribonucleotides for inhibiting the expression of the
ican-1-gene
JOURNAL
Patent: WO 0179487-A 76 25-OCT-2001;
Degitz, Klaus Karl (DE); Besch, Robert (DE)
FEATURES
Location/Qualifiers
source
1..22
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kunstlichen
Sequenz: Polydesoxyribonukleotid"

Query Match 0.7%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 406 GAACGGCACCCCTCCCTCTT 427
|||||
Db 1 GAACGGCACCCCTCCCTCTT 22

RESULT 42
AX284113
LOCUS
DEFINITION
ACCESSION
VERSION
QY284113.1 GI:17044823
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE
1

AUTHORS Degitz, K.K. and Besch, R.
TITLE Polydesoxyribonucleotides for inhibiting the expression of the
icam-1-gene
JOURNAL Patent: WO 0179487-A 78 25-OCT-2001;
Degitz, Klaus Karl (DE); Besch, Robert (DE)
FEATURES Location/Qualifiers

source
1..22
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kunstlichen
Sequenz: Polydesoxyribonukleotid"

Query Match 0.7%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 488 CCAACCTCACCGTGTGCTGCT 509
DB 1 CCAACCTCACCGTGTGCTGCT 22

RESULT 43
AX117832/c
LOCUS AX117832 25 bp DNA linear PAT 11-MAY-2001
DEFINITION Sequence 2955 from Patent WO0129262.
ACCESSION AX117832
VERSION AX117832.1 GI:14034783

KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Picoult-Newburg, L. and Pohl, M.
TITLE Genotyping reagents, kits and methods of use thereof
JOURNAL Patent: WO 0129262-A 2955 26-APR-2001;
Orchid BioSciences, Inc. (US)

FEATURES
source
1..25
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 97;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2724 CCGGTGTGTGTGTGTGTGTGTGTG 2748
DB 25 CCGGTGTGTGTGTGTGTGTGTGTG 1

RESULT 44
AX117836/c
LOCUS AX117836 25 bp DNA linear PAT 11-MAY-2001
DEFINITION Sequence 2959 from Patent WO0129262.
ACCESSION AX117836
VERSION AX117836.1 GI:14034787

KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Picoult-Newburg, L. and Pohl, M.
TITLE Genotyping reagents, kits and methods of use thereof
JOURNAL Patent: WO 0129262-A 2959 26-APR-2001;
Orchid BioSciences, Inc. (US)

FEATURES
source
1..25
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

/note="Primer"

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 97;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2725 CCGGTGTGTGTGTGTGTGTGTGTG 2749
DB 25 CCGGTGTGTGTGTGTGTGTGTGTG 1

RESULT 45
AX117828/c
LOCUS AX117828 25 bp DNA linear PAT 11-MAY-2001
DEFINITION Sequence 2951 from Patent WO0129262.
ACCESSION AX117828
VERSION AX117828.1 GI:14034779

KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Picoult-Newburg, L. and Pohl, M.
TITLE Genotyping reagents, kits and methods of use thereof
JOURNAL Patent: WO 0129262-A 2951 26-APR-2001;
Orchid BioSciences, Inc. (US)

FEATURES
source
1..25
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 1.1e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2727 CCGGTGTGTGTGTGTGTGTGTGTG 2749
DB 23 CCGGTGTGTGTGTGTGTGTGTGTG 1

RESULT 46
AR026554/c
LOCUS AR026554 21 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 17 from patent US 5856103.
ACCESSION AR026554
VERSION AR026554.1 GI:5937394

KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 21)
AUTHORS Gray, D.M. and Clark, C.L.
TITLE Method for selectively ranking sequences for antisense targeting
JOURNAL Patent: US 5856103-A 17 05-JAN-1999;
FEATURES Location/Qualifiers

source
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2176 ACCAGCTATTATTGAGTGTC 2196
DB 21 ACCAGCTATTATTGAGTGTC 1

RESULT 47
AR062603/c
LOCUS AR062603 21 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 3 from patent US 5843738.
ACCESSION AR062603
VERSION AR062603.1 GI:5990294
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 3 01-DEC-1998;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2176 ACCAGCTATTATTGAGTGTC 2196
Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 48
AR104706/c
LOCUS AR104706 21 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 3 from patent US 6093811.
ACCESSION AR104706
VERSION AR104706.1 GI:12817414
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 3 25-JUL-2000;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2176 ACCAGCTATTATTGAGTGTC 2196
Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 49
AR105528/c
LOCUS AR105528 21 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 3 from patent US 6096722.
ACCESSION AR105528
VERSION AR105528.1 GI:12819125
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 3 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2176 ACCAGCTATTATTGAGTGTC 2196
Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 50
AR123190/c
LOCUS AR123190 21 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 3 from patent US 6169079.
ACCESSION AR123190
VERSION AR123190.1 GI:14108156
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 3 02-JAN-2001;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2176 ACCAGCTATTATTGAGTGTC 2196
Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 51
AR129002/c
LOCUS AR129002 21 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 17 from patent US 6183966.
ACCESSION AR129002
VERSION AR129002.1 GI:14116664
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Grav,D.M. and Clark,C.L.
TITLE Apparatus and method for selectively ranking sequences for antisense targeting
JOURNAL Patent: US 6183966-A 17 06-FEB-2001;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2176 ACCAGCTATTATTGAGTGTC 2196
Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 52
BD192437/c
LOCUS BD192437 21 bp DNA linear PAT 17-JUL-2003
DEFINITION Compositions and methods for the delivery of oligonucleotides via the alimentary canal.
ACCESSION BD192437
VERSION BD192437.1 GI:33002176

KEYWORDS JP 2002510319-A/2.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 21)
AUTHORS Teng,C.L. and Hardee,G.
TITLE Compositions and methods for the delivery of oligonucleotides via the alimentary canal
JOURNAL Patent: JP 2002510319-A 2 02-APR-2002;
COMMENT ISIS PHARMACEUTICALS INC
OS Artificial Sequence
PN JP 2002510319-A/2
PD 02-APR-2002
PR 01-JUL-1998 JP 1999507295
PI CHING LEOU TENG GREG HARDEE
PC C12Q1/68,A61K9/127,A61K48/00,C07H21/04
CC Description of Artificial Sequence: Novel Sequence FH Key

FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 43 AACCTCAGCCTCGTATGGCT 63
Db 21 AACCTCAGCCTCGTATGGCT 1
|||||

RESULT 53
BD266260 21 bp DNA linear PAT 17-JUL-2003
LOCUS Universal arrays.
DEFINITION BD266260
ACCESSION BD266260.1 GI:33076028
VERSION JP 2002539849-A/260.
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 21)
AUTHORS Pan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S., Lockhart,D.J., Ryder,T. and Sklar,P.
TITLE Universal arrays
JOURNAL Patent: JP 2002539849-A 260 26-NOV-2002;
COMMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC
PN JP 2002539849-A/260
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI
PI JIAN BING PAN,JOEL N HIRSCHHORN,XIAOHUA
HUANG PAUL,KAPLAN,ERIC
PI S LANDER,
PI DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
PC C12Q1/68,C12M1/00,C12N15/09,C12N15/09,G01N33/53, PC G01N33/566,
PC G01N37/00,C12N15/00,C12N15/00,C12N15/00
CC Primer
FH Key Location/Qualifiers
FT source 1. .21
/organism="Artificial Sequence".
FEATURES
source
1. .21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 27 TGCTACTCAGAGTTGCAACCT 47
Db 1 TGCTACTCAGAGTTGCAACCT 21
|||||

RESULT 54
LOCUS CQ771255 21 bp DNA linear PAT 04-MAR-2004
DEFINITION Sequence 6 from Patent WO2004009845.
ACCESSION CQ771255
VERSION CQ771255.1 GI:45125362
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Mueller,N.
TITLE Methods of screening for schizophrenia
JOURNAL Patent: WO 2004009845-A 6 29-JAN-2004;
Mueller, Norbert (DE)
FEATURES Location/Qualifiers
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer derived from Human ICAM-1 gene"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1403 GAGATCTTGAGGCGACCTTACC 1423
Db 1 GAGATCTTGAGGCGACCTTACC 21
|||||

RESULT 55
LOCUS CQ771257/c 21 bp DNA linear PAT 04-MAR-2004
DEFINITION Sequence 8 from Patent WO2004009845.
ACCESSION CQ771257
VERSION CQ771257.1 GI:45125364
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Mueller,N.
TITLE Methods of screening for schizophrenia
JOURNAL Patent: WO 2004009845-A 8 29-JAN-2004;
Mueller, Norbert (DE)
FEATURES Location/Qualifiers
source
1. .21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="SNAPshot primer for ICAM-1"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1463 AGGTGACCGTGAATGTGCTCT 1483
Db 21 AGGTGACCGTGAATGTGCTCT 1
|||||

RESULT 56
LOCUS CQ778237/c 21 bp DNA linear PAT 11-MAR-2004

DEFINITION Sequence 1923 from Patent EP1394274.
ACCESSION CQ778237
VERSION CQ778237.1 GI:45380955
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Ohtani, N., Sugita, Y., Yamaya, M., Kubo, H., Nagai, H. and Izuohara, K.
TITLE Methods of testing for bronchial asthma or chronic obstructive pulmonary disease
JOURNAL Patent: Ep 1394274-A 1923 03-MAR-2004;
Genox Research, Inc. (JP)
FEATURES
source
1. .21
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="an artificially synthesized primer sequence"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 ACCAAGCCAGAGTCTCAGAA 1029
|||||
Db 21 ACCAAGCCAGAGTCTCAGAA 1

RESULT 57
I30543/c
LOCUS 120605
DEFINITION Sequence 3 from patent US 5514788.
ACCESSION 120605
VERSION 120605.1 GI:1600960
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Bennett, C. Frank. and Mirabelli, C. K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 3 07-MAY-1996;
FEATURES
source
1. .21
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

I20605 21 bp DNA linear PAT 07-OCT-1996
Sequence 3 from patent US 5514788.
120605
120605.1 GI:1600960
Unknown.
Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 21)
AUTHORS Bennett, C. Frank. and Mirabelli, C. K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 3 07-MAY-1996;
FEATURES
source
1. .21
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

I30543 21 bp DNA linear PAT 06-FEB-1997
Sequence 6 from patent US 5580969.
I30543
I30543.1 GI:1821334
Unknown.
Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 21)
AUTHORS Hoke, G. D., Bradley, M. O., Williams, T. J. and Lee, C. -H.
TITLE Antisense oligonucleotides directed against human ICAM-1 RNA
JOURNAL Patent: US 5580969-A 6 03-DEC-1996;
FEATURES
source
1. .21
Location/Qualifiers

/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGTCCTCTGCTACTCAGAG 38
|||||
Db 21 GAGTCCTCTGCTACTCAGAG 1

RESULT 59
I30545/c
LOCUS 130545
DEFINITION Sequence 8 from patent US 5580969.
ACCESSION 130545
VERSION 130545.1 GI:1821336
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Hoke, G. D., Bradley, M. O., Williams, T. J. and Lee, C. -H.
TITLE Antisense oligonucleotides directed against human ICAM-1 RNA
JOURNAL Patent: US 5580969-A 8 03-DEC-1996;
FEATURES
source
1. .21
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2053 CCCTCCATAGACATGTGTAGC 2073
|||||
Db 21 CCCTCCATAGACATGTGTAGC 1

RESULT 60
I30546/c
LOCUS 130546
DEFINITION Sequence 9 from patent US 5580969.
ACCESSION 130546
VERSION 130546.1 GI:1821337
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Hoke, G. D., Bradley, M. O., Williams, T. J. and Lee, C. -H.
TITLE Antisense oligonucleotides directed against human ICAM-1 RNA
JOURNAL Patent: US 5580969-A 9 03-DEC-1996;
FEATURES
source
1. .21
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2494 CCACCCACATACATTTCTGCC 2514
|||||
Db 21 CCACCCACATACATTTCTGCC 1

RESULT 61
I30547/c
LOCUS 130547
DEFINITION Sequence 10 from patent US 5580969.
ACCESSION 130547

VERSION I30547.1 GI:1821338
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
LOCUS Hoke,G.D., Bradley,M.O., Williams,T.J. and Lee,C.-H.
DEFINITION Antisense oligonucleotides directed against human ICAM-1 RNA
AUTHORS Antisense oligonucleotides directed against human ICAM-1 RNA
TITLE Patent: US 5580969-A 10 03-DEC-1996;
JOURNAL Location/Qualifiers
FEATURES
source 1..21
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02; Indels 0; Gaps 0;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
|||||
Db 21 TGTGTGTGTGTGTGTGTGTGT 1
RESULT 62
I30548/c
LOCUS I30548 21 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 11 from patent US 5580969.
AUTHORS
ACCESSION I30548
VERSION I30548.1 GI:1821339
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
LOCUS Hoke,G.D., Bradley,M.O., Williams,T.J. and Lee,C.-H.
DEFINITION Antisense oligonucleotides directed against human ICAM-1 RNA
AUTHORS Antisense oligonucleotides directed against human ICAM-1 RNA
TITLE Patent: US 5580969-A 11 03-DEC-1996;
JOURNAL Location/Qualifiers
FEATURES
source 1..21
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02; Indels 0; Gaps 0;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 43 AACCTAGCCTCGTATGGCT 63
|||||
Db 21 AACCTAGCCTCGTATGGCT 1
RESULT 63
I33298/c
LOCUS I33298 21 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 3 from patent US 5591623.
AUTHORS Bennett,C.F. and Mirabelli,C.K.
DEFINITION Oligonucleotide modulation of cell adhesion
ACCESSION I33298
VERSION I33298.1 GI:1824089
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
LOCUS Bennett,C.F. and Mirabelli,C.K.
DEFINITION Oligonucleotide modulation of cell adhesion
AUTHORS Oligonucleotide modulation of cell adhesion
TITLE Patent: US 5591623-A 3 07-JAN-1997;
JOURNAL Location/Qualifiers
FEATURES
source 1..21
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02; Indels 0; Gaps 0;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2176 ACCAGCTATTATTGAGTGTC 2196
|||||
Db 21 ACCAGCTATTATTGAGTGTC 1
RESULT 64
I50989/c
LOCUS I50989 21 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 4 from patent US 5643780.
AUTHORS
ACCESSION I50989
VERSION I50989.1 GI:2472692
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
LOCUS Baker,B.F.
DEFINITION Compositions and methods for modulating RNA activity through
AUTHORS modification of the 5' cap structure of RNA
TITLE Patent: US 5643780-A 4 01-JUL-1997;
JOURNAL Location/Qualifiers
FEATURES
source 1..21
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02; Indels 0; Gaps 0;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 17 TGAGCTCCTCTGCTACTCAGA 37
|||||
Db 21 TGAGCTCCTCTGCTACTCAGA 1
RESULT 65
AR370528/c
LOCUS AR370528 21 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 3 from patent US 6300491.
AUTHORS
ACCESSION AR370528
VERSION AR370528.1 GI:34607281
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
LOCUS Bennett,C.F. and Mirabelli,C.K.
DEFINITION Oligonucleotide inhibition of cell adhesion
AUTHORS Oligonucleotide inhibition of cell adhesion
TITLE Patent: US 6300491-A 3 09-OCT-2001;
JOURNAL Location/Qualifiers
FEATURES
source 1..21
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02; Indels 0; Gaps 0;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2176 ACCAGCTATTATTGAGTGTC 2196
|||||
Db 21 ACCAGCTATTATTGAGTGTC 1
RESULT 66
AR544734/c
LOCUS AR544734 21 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 3 from patent US 6747014.
AUTHORS
ACCESSION AR544734
VERSION AR544734.1 GI:53937695
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
LOCUS Bennett,C.F. and Mirabelli,C.K.
DEFINITION Oligonucleotide inhibition of cell adhesion
AUTHORS Oligonucleotide inhibition of cell adhesion
TITLE Patent: US 6747014-A 3 09-OCT-2001;
JOURNAL Location/Qualifiers
FEATURES
source 1..21
/organism="unknown"
/mol_type="genomic DNA"

REFERENCE 1 (bases 1 to 21)
AUTHORS Teng,C.-L., Cook,P.D., Tillman,L., Hardee,G.E., Ecker,D.J. and Manoharan,M.
TITLE Compositions and methods for non-parenteral delivery of oligonucleotides
JOURNAL Patent: US 6747014-A 3 08-JUN-2004;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 43 AACCTCAGCTCGCTATGGCT 63
Db 21 AACCTCAGCTCGCTATGGCT 1

RESULT 67
AR560504/c
LOCUS AR560504 21 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 18 from patent US 6753423.
ACCESSION AR560504
VERSION AR560504.1 GI:53972808
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Cook,P.D., Manoharan,M. and Bennett,C.F.
TITLE Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
JOURNAL Patent: US 6753423-A 18 22-JUN-2004;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2100 TGACGGATGCCAGCTTGGCA 2120
Db 21 TGACGGATGCCAGCTTGGCA 1

RESULT 68
AR560512/c
LOCUS AR560512 21 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 26 from patent US 6753423.
ACCESSION AR560512
VERSION AR560512.1 GI:53972816
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Cook,P.D., Manoharan,M. and Bennett,C.F.
TITLE Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
JOURNAL Patent: US 6753423-A 26 22-JUN-2004;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2100 TGACGGATGCCAGCTTGGCA 2120
Db 21 TGACGGATGCCAGCTTGGCA 1

RESULT 69
AR175258
LOCUS AR175258 24 bp DNA linear PAT 03-JUL-2001
DEFINITION Sequence 22 from Patent WO0144465.
ACCESSION AR175258
VERSION AR175258.1 GI:14598626
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Phillips,N.C. and Fillion,M.C.
TITLE Therapeutically useful synthetic oligonucleotides
JOURNAL Patent: WO 0144465-A 22 21-JUN-2001;
Bioniche Life Sciences Inc. (CA)
FEATURES Location/Qualifiers
source 1..24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.7%; Score 20.8; DB 1; Length 24;
Best Local Similarity 91.7%; Pred. No. 1.3e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2726 GCGTGTGTGTGTGTGTGTGTGTGTGT 2749
Db 1 GTGTGTGTGTGTGTGTGTGTGTGTGT 24

RESULT 70
I31234/c
LOCUS I31234 25 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 146 from patent US 5582979.
ACCESSION I31234
VERSION I31234.1 GI:1822025
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 25)
AUTHORS Weber,J.L.
TITLE Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and method of using the same
JOURNAL Patent: US 5582979-A 146 10-DEC-1996;
FEATURES Location/Qualifiers
source 1..25
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 1.2e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2726 GCGTGTGTGTGTGTGTGTGTGTGTGT 2749
Db 24 GTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 71
AX115976
LOCUS AX115976 25 bp DNA linear PAT 11-MAY-2001
DEFINITION Sequence 1099 from Patent WO0129262.
ACCESSION AX115976
VERSION AX115976.1 GI:14032918
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

```

other sequences; artificial sequences.
1
REFERENCE Picoult-Newburg,L. and Pohl,M.
AUTHORS Genotyping reagents, kits and methods of use thereof
TITLE Patent: WO 0129262-A 1099 26-APR-2001;
JOURNAL Orchid Biosciences, Inc. (US)
FEATURES Location/Qualifiers
source
1..25
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.7%; Score 20.6; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 1.2e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGT 2749
Db 1 GTGTGTGTGTGTGTGTGTGTGTGTGT 24

RESULT 72
BD266115 21 bp DNA linear PAT 17-JUL-2003
LOCUS Universal arrays.
DEFINITION BD266115
ACCESSION BD266115
VERSION BD266115.1 GI:33075883
KEYWORDS JP 2002539849-A/115.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 21)
AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
Lockhart,D.J., Ryder,T. and Sklar,P.
TITLE Universal arrays
JOURNAL WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC
COMMENT Patent: JP 2002539849-A 115 26-NOV-2002;
OS Homo sapiens (human)
PN JP 2002539849-A/115
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI
JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
HUANG,PAUL KAPLAN,ERIC
PI S LANDER,
PI DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
PC C12Q1/68,C12M1/00,C12N15/09,C12N15/09,C12N15/09,G01N33/53, PC
G01N33/566,
CC Universal arrays
FH Key Location/Qualifiers
FT source
1..21
/organism='Homo sapiens (human)'.

FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 1.6e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 39 TTGCAACCTTCAGCTCGCTAT 59
Db 1 TTGCAACCTTCAGCTCGCTAT 21

RESULT 74
BD266117 21 bp DNA linear PAT 17-JUL-2003
LOCUS Universal arrays.
DEFINITION BD266117
ACCESSION BD266117
VERSION BD266117.1 GI:33075885
KEYWORDS JP 2002539849-A/117.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 21)
AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
Lockhart,D.J., Ryder,T. and Sklar,P.
TITLE Universal arrays
JOURNAL WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC
COMMENT Patent: JP 2002539849-A 117 26-NOV-2002;
OS Homo sapiens (human)
PN JP 2002539849-A/117
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI
JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
HUANG,PAUL KAPLAN,ERIC
PI S LANDER,
PI DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
PC C12Q1/68,C12M1/00,C12N15/09,C12N15/09,C12N15/09,G01N33/53, PC
G01N33/566,
CC Universal arrays
FH Key Location/Qualifiers
FT source
1..21
/organism='Homo sapiens (human)'.

FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 1.6e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 768 TTCCTGACGGCTGTTC 788
Db 1 TTCCTGACGGCTGTTC 21

RESULT 73
BD266116 21 bp DNA linear PAT 17-JUL-2003
LOCUS Universal arrays.
DEFINITION BD266116
ACCESSION BD266116
VERSION BD266116.1 GI:33075884
KEYWORDS JP 2002539849-A/116.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 21)
AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
Lockhart,D.J., Ryder,T. and Sklar,P.
TITLE Universal arrays
JOURNAL WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC
COMMENT Patent: JP 2002539849-A 116 26-NOV-2002;
OS Homo sapiens (human)
PN JP 2002539849-A/116
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI
JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
HUANG,PAUL KAPLAN,ERIC
PI S LANDER,
PI DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
PC C12Q1/68,C12M1/00,C12N15/09,C12N15/09,C12N15/09,G01N33/53, PC
G01N33/566,
CC Universal arrays
FH Key Location/Qualifiers
FT source
1..21
/organism='Homo sapiens (human)'.

FEATURES
source
1..21
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

```

```

PC  G01N37/00,C12N15/00,C12N15/00,C12N15/00,C12N15/00
CC  Universal arrays
FH  Key
FT  source
FT  Location/Qualifiers
FEATURES
    source
        1..21
            /organism="Homo sapiens (human)"
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
Query Match
Best Local Similarity 0.7%; Score 20.6; DB 1; Length 21;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY  214 GACCAGCCCAAGTTGTTGGGC 234
    |||||:|||||
Db  1 GACCAGCCCAAGTTGTTGGGC 21

RESULT 75
BD266118 21 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION
ACCESSION
BD266118.1 GI:33075886
VERSION
KEYWORDS
SOURCE
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS
Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
Lockhart,D.J., Ryder,T. and Sklar,P.
TITLE
Universal arrays
JOURNAL
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, AFFYMETRIX INC
COMMENT
OS Homo sapiens (human)
PN JP 2002539849-A/118
PD 26-NOV-2002
PR 26-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI
JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
HUANG,PAUL,KAPLAN,ERIC
PI S LANDER,
PI DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
PC C12Q1/68,C12M1/00,C12N15/09,C12N15/09,C12N15/09,G01N33/53,PC
G01N33/566,
PC G01N37/00,C12N15/00,C12N15/00,C12N15/00
CC Universal arrays
FH Key
FT source
FT Location/Qualifiers
FEATURES
    source
        1..21
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
Query Match
Best Local Similarity 0.7%; Score 20.6; DB 1; Length 21;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY  1452 GGTACCCCGAGGTGACCGT 1472
    |||||:|||||
Db  1 GGTACCCCGAGGTGACCGT 21

RESULT 76
AR529596 21 bp DNA linear PAT 08-OCT-2004
LOCUS
DEFINITION
ACCESSION
AR529596
SEQUENCE 799 from patent US 6727063.
SOURCE
Pharmaceuticals, Inc. (US)
LOCATION/Qualifiers
    source
        1..21

```

```

VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
Lander,E.S., Cargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE
Single nucleotide polymorphisms in genes
JOURNAL
Patent: US 6727063-A 799 27-APR-2004;
FEATURES
    Location/Qualifiers
        1..21
            /organism="unknown"
            /mol_type="genomic DNA"
Query Match
Best Local Similarity 0.7%; Score 20.6; DB 1; Length 21;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY  1452 GGTACCCCGAGGTGACCGT 1472
    |||||:|||||
Db  1 GGTACCCCGAGGTGACCGT 21

RESULT 77
AR529597 21 bp DNA linear PAT 08-OCT-2004
LOCUS
DEFINITION
ACCESSION
AR529597
SEQUENCE 800 from patent US 6727063.
VERSION
AR529597.1 GI:53918034
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
Lander,E.S., Cargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE
Single nucleotide polymorphisms in genes
JOURNAL
Patent: US 6727063-A 800 27-APR-2004;
FEATURES
    Location/Qualifiers
        1..21
            /organism="unknown"
            /mol_type="genomic DNA"
Query Match
Best Local Similarity 0.7%; Score 20.6; DB 1; Length 21;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY  214 GACCAGCCCAAGTTGTTGGGC 234
    |||||:|||||
Db  1 GACCAGCCCAAGTTGTTGGGC 21

RESULT 78
AR529562 21 bp DNA linear PAT 30-MAR-2001
LOCUS
DEFINITION
ACCESSION
AR529562
SEQUENCE 799 from Patent WO0118250.
VERSION
AR529562.1 GI:13511824
KEYWORDS
SOURCE
ORGANISM
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS
Lander,E.S., Cargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE
Single nucleotide polymorphisms in genes
JOURNAL
Patent: WO 0118250-A 799 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
Pharmaceuticals, Inc. (US)
FEATURES
    Location/Qualifiers
        1..21

```

```
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 20.6; DB 1; Length 21;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1452 GGTCAACCGCGAGGTGACCGT 1472
Db 1 GGTCAACCGCGAGGTGACCGT 21

RESULT 79
LOCUS AX095622 21 bp DNA linear PAT 30-MAR-2001
DEFINITION Sequence 800 from Patent WO0118250.
ACCESSION AX095622
VERSION AX095622.1 GI:13511825
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
REFERENCE
AUTHORS
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 800 15-MAR-2001;
Pharmaceuticals, Inc. (US)
FEATURES
source
Location/Qualifiers
1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.7%; Score 20.6; DB 1; Length 21;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 214 GACAGCCCAAGTTGTGGGC 234
Db 1 GACAGCCCAAGTTGTGGGC 21

RESULT 80
LOCUS AR068108/c 22 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 4 from patent US 5852182.
ACCESSION AR068108
VERSION AR068108.1 GI:5999330
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 22)
AUTHORS Cook, P. Dan. and Manoharan, M.
TITLE Thiol-derivatized oligonucleosides
JOURNAL Patent: US 5852182-A 4 22-DEC-1998;
Netherlands Organisatie voor Toegepast-Natuurwetenschappelijk
Onderzoek TNO (NL)
FEATURES
source
Location/Qualifiers
1..22
/organism="unassigned DNA"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20.4; DB 1; Length 22;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 16 CTGAGCTCCTCTGCTACTCAGA 37
Db 22 CTTAGCTCCTCTGCTACTCAGA 1

RESULT 78
LOCUS AR110392/c 22 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 4 from patent US 6114513.
ACCESSION AR110392
VERSION AR110392.1 GI:12826668
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 22)
AUTHORS Cook, P. Dan. and Manoharan, M.
TITLE Thiol-derivatized oligonucleosides
JOURNAL Patent: US 6114513-A 4 05-SEP-2000;
Netherlands Organisatie voor Toegepast-Natuurwetenschappelijk
Onderzoek TNO (NL)
FEATURES
source
Location/Qualifiers
1..22
/organism="unassigned DNA"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20.4; DB 1; Length 22;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 16 CTGAGCTCCTCTGCTACTCAGA 37
Db 22 CTTAGCTCCTCTGCTACTCAGA 1

RESULT 82
LOCUS CQ754864/c 22 bp DNA linear PAT 01-MAR-2004
DEFINITION Sequence 11 from Patent EP1375510.
ACCESSION CQ754864
VERSION CQ754864.1 GI:44845892
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS te Koppelaar, J. M. and Bank, R. A.
TITLE Modification of collagenous materials and medical treatment,
diagnosis and monitoring of fibrotic conditions
JOURNAL Patent: EP 1375510-A 11 02-JAN-2004;
Netherlands Organisatie voor Toegepast-Natuurwetenschappelijk
Onderzoek TNO (NL)
FEATURES
source
Location/Qualifiers
1..22
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: forward primer
exon 7"

Query Match
Best Local Similarity 0.7%; Score 20.4; DB 1; Length 22;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2727 CGTGTGTGTGTGTGTGTGTGTG 2748
Db 22 CGTGTGTGTGTGTGTGTGTGTG 1

RESULT 83
LOCUS I30040 22 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 4 from patent US 5578718.
ACCESSION I30040
VERSION I30040.1 GI:1820831
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
```

REFERENCE 1 (bases 1 to 22)
AUTHORS Cook, P.D. and Manoharan, M.
TITLE Thiol-derivatized nucleosides
JOURNAL Patent: US 5578718-A 4 26-NOV-1996;
FEATURES Location/Qualifiers
source 1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 1.6e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 16 CTGAGCTCCTCTGCTACTCAGA 37
Db 22 CTTAGCTCCTCTGCTACTCAGA 1

RESULT 84
I31213/c
LOCUS I31213 22 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 125 from patent US 5582979.
ACCESSION I31213
VERSION I31213.1 GI:1822004
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Weber, J.L.
TITLE Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and method of using the same
JOURNAL Patent: US 5582979-A 125 10-DEC-1996;
FEATURES Location/Qualifiers
source 1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 1.6e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
Db 22 GTGTGTGTGTGTGTGTGTGTGT 1

RESULT 85
AX674899
LOCUS AX674899 22 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 26 from Patent WO03005034.
ACCESSION AX674899
VERSION AX674899.1 GI:29333232
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Macdonald, M.L., Zeisler, J.M., Samuels, M., Goldberg, Y.P., Robataille, J.M. and Hayden, M.R.
TITLE Processes for identifying therapeutic agents useful in treating diseases involving fzd4 gene
JOURNAL Patent: WO 03005034-A 26 16-JAN-2003;
FEATURES Xenon Genetics, Inc. (CA); The University of British Columbia (CA)
source 1..22
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 1.6e+02;

Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TTTGGCTCTGTCAACCAGGCTG 2779
Db 1 TCTTGCTCTGTCAACCAGGCTG 22

RESULT 86
AR127801/c
LOCUS AR127801 23 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 22 from patent US 6180777.
ACCESSION AR127801
VERSION AR127801.1 GI:14114396
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 23)
AUTHORS Horn, T.
TITLE Synthesis of branched nucleic acids
JOURNAL Patent: US 6180777-A 22 30-JAN-2001;
FEATURES Location/Qualifiers
source 1..23
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20.4; DB 1; Length 23;
Best Local Similarity 95.5%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
Db 23 GTGTGTGTGTGTGTGTGTGTGT 2

RESULT 87
I31542/c
LOCUS I31542 23 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 454 from patent US 5582979.
ACCESSION I31542
VERSION I31542.1 GI:1822333
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 23)
AUTHORS Weber, J.L.
TITLE Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and method of using the same
JOURNAL Patent: US 5582979-A 454 10-DEC-1996;
FEATURES Location/Qualifiers
source 1..23
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20.4; DB 1; Length 23;
Best Local Similarity 95.5%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
Db 22 GTGTGTGTGTGTGTGTGTGTGT 1

RESULT 88
I31533/c
LOCUS I31533 24 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 445 from patent US 5582979.
ACCESSION I31533
VERSION I31533.1 GI:1822324
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
REFERENCE 1 (bases 1 to 24)
AUTHORS Weber, J.L.
TITLE Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and method of using the same
JOURNAL Patent: US 5582979-A 445 10-DEC-1996;
FEATURES Location/Qualifiers
source
1..24
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20.4; DB 1; Length 24;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
|||||
Db 23 GTGTGTGTGTGTGTGTGTGTGT 2

RESULT 89
AX104876
LOCUS AX104876 24 bp DNA linear PAT 30-APR-2001
DEFINITION Sequence 1068 from Patent WO0122972.
ACCESSION AX104876
VERSION AX104876.1 GI:13921073
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
1
REFERENCE
AUTHORS Krieg, A.M., Schetter, C. and Vollmer, J.C.
TITLE Immunostimulatory nucleic acids
JOURNAL Patent: WO 0122972-A 1068 05-APR-2001;
UNIVERSITY OF IOWA RESEARCH FOUNDATION (US); Coley Pharmaceutical GmbH (DE)
FEATURES Location/Qualifiers
source
1..24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 0.7%; Score 20.4; DB 1; Length 24;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
|||||
Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 90
AX175257
LOCUS AX175257 24 bp DNA linear PAT 03-JUL-2001
DEFINITION Sequence 21 from Patent WO014465.
ACCESSION AX175257
VERSION AX175257.1 GI:14598625
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
1
REFERENCE
AUTHORS Phillips, N.C. and Filion, M.C.
TITLE Therapeutically useful synthetic oligonucleotides
JOURNAL Patent: WO 014465-A 21 21-JUN-2001;
Bioniche Life Sciences Inc. (CA)
FEATURES Location/Qualifiers
source
1..24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match
0.7%; Score 20.4; DB 1; Length 24;

Best Local Similarity 95.5%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
|||||
Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 91
AX547929
LOCUS AX547929 24 bp DNA linear PAT 01-MAR-2003
DEFINITION Sequence 1068 from Patent WO02053141.
ACCESSION AX547929
VERSION AX547929.1 GI:25813073
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
1
REFERENCE
AUTHORS Bratzler, R.L.
TITLE Inhibition of angiogenesis by nucleic acids
JOURNAL Patent: WO 02053141-A 1068 11-JUL-2002;
Coley Pharmaceutical Group, Inc. (US)
FEATURES Location/Qualifiers
source
1..24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic Sequence"

Query Match
0.7%; Score 20.4; DB 1; Length 24;
Best Local Similarity 95.5%; Pred. No. 1.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
|||||
Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 92
AX384656/c
LOCUS AX384656 21 bp DNA linear PAT 19-MAR-2002
DEFINITION Sequence 28 from Patent EP1182206.
ACCESSION AX384656
VERSION AX384656.1 GI:19577851
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
1
REFERENCE
AUTHORS Peymann, A., Uhlmann, E., Mag, M., Kretschmar, G., Helsenberg, M. and Winkler, I.
TITLE Stabilized oligonucleotides and the use thereof
JOURNAL Patent: EP 1182206-A 28 27-FEB-2002;
HOECHST AKTIENGESELLSCHAFT (DE)
FEATURES Location/Qualifiers
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisense Oligonucleotide"

Query Match
0.7%; Score 20.2; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 1.7e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1937 TCAGAGGGGGAAGTGTGGGGG 1957
|||||
Db 21 BCAGAGGGGGAAGTGTGGGGG 1

RESULT 93
AX115164

LOCUS AX115164 25 bp DNA linear PAT 11-MAY-2001
 DEFINITION Sequence 287 from Patent WO0129262.
 ACCESSION AX115164
 VERSION AX115164.1 GI:14032106
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 other sequences; artificial sequences.
 REFERENCE 1
 AUTHORS Picoult-Newburg, L. and Pohl, M.
 TITLE Genotyping reagents, kits and methods of use thereof
 JOURNAL Patent: WO 0129262-A 287 26-APR-2001;
 Orchid BioSciences, Inc. (US)
 FEATURES
 source 1..25
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Primer"
 Query Match 0.7%; Score 20.2; DB 1; Length 25;
 Best Local Similarity 88.0%; Pred. No. 1.5e+02;
 Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 2829 CAAGTGATCTCCACCTGAGCCTC 2853
 |||||
 Db 1 CAAGTGATCTCTGCCTCAGCCTC 25
 |||||
 RESULT 94
 A42360/c
 LOCUS A42360 20 bp DNA linear PAT 05-MAR-1997
 DEFINITION Sequence 20 from Patent WO9501363.
 ACCESSION A42360
 VERSION A42360.1 GI:2297836
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified
 unclassified.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Uhlmann, E. and Meier, C.
 TITLE METHYLPHOSPHONIC ACID ESTER, PROCESS FOR PREPARING THE SAME AND ITS
 JOURNAL Patent: WO 9501363-A 20 12-JAN-1995;
 HOECHST AG (DE)
 COMMENT Other publication FI 956341 960219
 Other publication CA 2165971 950112
 Other publication NO 955352 960214
 Other publication AU 7073594 950124
 Other publication DE 4321946 950112.
 FEATURES
 source 1..20
 /organism="unidentified"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32644"
 /note="ICAM"
 exon 1..20
 /note="ICAM"
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1940 GAGGGGAAGTGGTGGGGG 1957
 |||||
 Db 20 GAGGGGAAGTGGTGGGGG 1
 |||||
 RESULT 95
 A42361/c
 LOCUS A42361 20 bp DNA linear PAT 05-MAR-1997
 DEFINITION Sequence 21 from Patent WO9501363.
 ACCESSION A42361
 VERSION A42361.1 GI:2297837
 KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified
 unclassified.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Uhlmann, E. and Meier, C.
 TITLE METHYLPHOSPHONIC ACID ESTER, PROCESS FOR PREPARING THE SAME AND ITS
 JOURNAL Patent: WO 9501363-A 20 12-JAN-1995;
 HOECHST AG (DE)
 COMMENT Other publication FI 956341 960219
 Other publication CA 2165971 950112
 Other publication NO 955352 960214
 Other publication AU 7073594 950124
 Other publication DE 4321946 950112.
 FEATURES
 source 1..20
 /organism="unidentified"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32644"
 /note="ICAM"
 exon 1..20
 /note="ICAM"
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1938 GAGAGGGGAAGTGGTGGGG 1957
 |||||
 Db 20 GAGAGGGGAAGTGGTGGGG 1
 |||||
 RESULT 97
 A44400/c
 LOCUS A44400 20 bp DNA linear PAT 07-MAR-1997
 DEFINITION Sequence 29 from Patent EP0653439.
 ACCESSION A44399
 VERSION A44399.1 GI:2299228
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Feynman, A.D., Uhlmann, E.D., Mag, M., Kretschmar, G.D., Helsing, M.D.
 TITLE Stabilized oligonucleotids and the use thereof
 JOURNAL Patent: EP 0653439-A 29 17-MAY-1995;
 HOECHST AG (DE)
 COMMENT Other publication JP 7194385 950801
 Other publication CA 2135591 950513
 Other publication AU 7779594 950518
 Other publication DE 4338704 950518.
 FEATURES
 source 1..20
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 exon 1..20
 /note="ICAM"
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1938 GAGAGGGGAAGTGGTGGGG 1957
 |||||
 Db 20 GAGAGGGGAAGTGGTGGGG 1
 |||||

KEYWORDS
 SOURCE unidentified
 ORGANISM unidentified
 unclassified.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Uhlmann, E. and Meier, C.
 TITLE METHYLPHOSPHONIC ACID ESTER, PROCESS FOR PREPARING THE SAME AND ITS
 JOURNAL Patent: WO 9501363-A 21 12-JAN-1995;
 HOECHST AG (DE)
 COMMENT Other publication FI 956341 960219
 Other publication CA 2165971 950112
 Other publication NO 955352 960214
 Other publication AU 7073594 950124
 Other publication DE 4321946 950112.
 FEATURES
 source 1..20
 /organism="unidentified"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32644"
 exon 1..20
 /note="ICAM"
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1940 GAGGGGAAGTGGTGGGGG 1959
 |||||
 Db 20 GAGGGGAAGTGGTGGGGG 1
 |||||
 RESULT 96
 A44399/c
 LOCUS A44399 20 bp DNA linear PAT 07-MAR-1997
 DEFINITION Sequence 29 from Patent EP0653439.
 ACCESSION A44399
 VERSION A44399.1 GI:2299228
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Feynman, A.D., Uhlmann, E.D., Mag, M., Kretschmar, G.D., Helsing, M.D.
 TITLE Stabilized oligonucleotids and the use thereof
 JOURNAL Patent: EP 0653439-A 29 17-MAY-1995;
 HOECHST AG (DE)
 COMMENT Other publication JP 7194385 950801
 Other publication CA 2135591 950513
 Other publication AU 7779594 950518
 Other publication DE 4338704 950518.
 FEATURES
 source 1..20
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 exon 1..20
 /note="ICAM"
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1938 GAGAGGGGAAGTGGTGGGG 1957
 |||||
 Db 20 GAGAGGGGAAGTGGTGGGG 1
 |||||
 RESULT 97
 A44400/c
 LOCUS A44400 20 bp DNA linear PAT 07-MAR-1997
 DEFINITION Sequence 29 from Patent EP0653439.
 ACCESSION A44399
 VERSION A44399.1 GI:2299228
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Feynman, A.D., Uhlmann, E.D., Mag, M., Kretschmar, G.D., Helsing, M.D.
 TITLE Stabilized oligonucleotids and the use thereof
 JOURNAL Patent: EP 0653439-A 29 17-MAY-1995;
 HOECHST AG (DE)
 COMMENT Other publication JP 7194385 950801
 Other publication CA 2135591 950513
 Other publication AU 7779594 950518
 Other publication DE 4338704 950518.
 FEATURES
 source 1..20
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 exon 1..20
 /note="ICAM"
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1938 GAGAGGGGAAGTGGTGGGG 1957
 |||||
 Db 20 GAGAGGGGAAGTGGTGGGG 1
 |||||

```

DEFINITION Sequence 30 from Patent EP0653439.
ACCESSION A44400
VERSION A44400.1 GI:2299229
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE 1 (bases 1 to 20)
JOURNAL Peyman,A.D., Uhlmann,E.D., Mag,M., Kretzchmar,G.D., Helsenberg,M.D.
COMMENT Seela,F.P. and Lampe,S.D.
Other publication JP 7194385 950801
Other publication CA 213591 950513
Other publication AU 777994 950518
Other publication DE 4338704 950518.
FEATURES
source Location/Qualifiers
1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
1..20
/notes="ICAM"
exon

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGGAG 1959
|||||
Db 20 GAGGGGAAGTGGTGGGGGAG 1

RESULT 98
A47182/c
LOCUS A47182
DEFINITION Sequence 25 from Patent EP0680969.
ACCESSION A47182
VERSION A47182.1 GI:2301224
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE 1 (bases 1 to 20)
JOURNAL Seela,F.P. and Lampe,S.D.
COMMENT Modified oligonucleotides, their preparation and their use
Patent: EP 0680969-A 25 08-NOV-1995;
HOECHST AG (DE)
Other publication JP 8003186 960109
Other publication AU 1778295 951109
Other publication DE 4415370 951109.
FEATURES
source Location/Qualifiers
1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
1..20
/notes="ICAM"
exon

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGGG 1

RESULT 99
A47183/c
LOCUS A47183
DEFINITION Sequence 26 from Patent EP0680969.
ACCESSION A47183
VERSION A47183.1 GI:2301225
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE 1 (bases 1 to 20)
JOURNAL Seela,F.P. and Lampe,S.D.
COMMENT Modified oligonucleotides, their preparation and their use
Patent: EP 0680969-A 26 08-NOV-1995;
HOECHST AG (DE)
Other publication JP 8003186 960109
Other publication AU 1778295 951109
Other publication DE 4415370 951109.
FEATURES
source Location/Qualifiers
1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
1..20
/notes="ICAM"
exon

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGGG 1

```

```

LOCUS A47183
DEFINITION Sequence 26 from Patent EP0680969.
ACCESSION A47183
VERSION A47183.1 GI:2301225
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
TITLE 1 (bases 1 to 20)
JOURNAL Seela,F.P. and Lampe,S.D.
COMMENT Modified oligonucleotides, their preparation and their use
Patent: EP 0680969-A 26 08-NOV-1995;
HOECHST AG (DE)
Other publication JP 8003186 960109
Other publication AU 1778295 951109
Other publication DE 4415370 951109.
FEATURES
source Location/Qualifiers
1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
1..20
/notes="ICAM"
exon

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGGAG 1959
|||||
Db 20 GAGGGGAAGTGGTGGGGGAG 1

RESULT 100
A56654/c
LOCUS A56654
DEFINITION Sequence 21 from Patent EP0739898.
ACCESSION A56654
VERSION A56654.1 GI:3712699
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Peyman,A.D., Uhlmann,E.D., Breipohl,G.D. and Wallmeier,H.D.
TITLE Phosphonomonoester nucleic acids, methods for their preparation and
JOURNAL their use
Patent: EP 0739898-A 21 30-OCT-1996;
HOECHST AG (DE)
COMMENT Other publication CZ 9600743 961016
Other publication CN 1138588 961225
Other publication FL 313207 960916
Other publication JP 8259579 961008
Other publication NO 961006 960916
Other publication CA 2171589 960914
Other publication AU 4802896 960926
Other publication DE 19508923 960919.
FEATURES
source Location/Qualifiers
1..20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
exon

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGGG 1

```

RESULT 101
A56655/c
LOCUS A56655 20 bp DNA linear PAT 03-MAR-1998
DEFINITION Sequence 22 from Patent EP0739898.
ACCESSION A56655
VERSION A56655.1 GI:3712700
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Peyman,A.D., Uhlmann,E.D., Breipohl,G.D. and Wallmeier,H.D.
TITLE Phosphomonoester nucleic acids, methods for their preparation and their use
JOURNAL Patent: EP 0739898-A 22 30-OCT-1996;
COMMENT HOECHST AG (DE)
Other publication CN 9600743 961016
Other publication CN 1138588 961225
Other publication PL 313207 960916
Other publication JP 8259579 961008
Other publication NO 961006 960916
Other publication CA 2171589 960914
Other publication AU 4802896 960926
Other publication DE 19508923 960919.
FEATURES
source
1. .20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1940 GAGGGGAAGTGTGGGGGAG 1959
|||||
Db 20 GAGGGGAAGTGTGGGGGAG 1
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
RESULT 102
A80375/c
LOCUS A80375 20 bp DNA linear PAT 20-OCT-1999
DEFINITION Sequence 21 from Patent EP0726274.
ACCESSION A80375
VERSION A80375.1 GI:6093102
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 20)
AUTHORS Peyman,A.D. and Uhlmann,E.D.
TITLE G-CAP STABILIZED OLIGONUCLEOTIDES
JOURNAL Patent: EP 0726274-A 21 14-AUG-1996;
HOECHST AG (DE)
FEATURES
source
1. .20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAAGTGTGGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGTGGGGG 1
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
RESULT 103
A80376/c
LOCUS A80376 20 bp DNA linear PAT 20-OCT-1999

DEFINITION Sequence 22 from Patent EP0726274.
ACCESSION A80376
VERSION A80376.1 GI:6093103
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 20)
AUTHORS Peyman,A.D. and Uhlmann,E.D.
TITLE G-CAP STABILIZED OLIGONUCLEOTIDES
JOURNAL Patent: EP 0726274-A 22 14-AUG-1996;
HOECHST AG (DE)
FEATURES
source
1. .20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
exon
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1940 GAGGGGAAGTGTGGGGGAG 1959
|||||
Db 20 GAGGGGAAGTGTGGGGGAG 1
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
RESULT 104
A8021350/c
LOCUS A8021350 20 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 1 from patent US 5789573.
ACCESSION A8021350
VERSION A8021350.1 GI:3975965
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Baker,B., Bennett,C.Frank. and Anderson,K.P.
TITLE Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JOURNAL Patent: US 5789573-A 1 04-AUG-1998;
HOECHST AG (DE)
FEATURES
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1
/organism="unknown"
/mol_type="unassigned DNA"
RESULT 105
A8026549/c
LOCUS A8026549 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 12 from patent US 5856103.
ACCESSION A8026549
VERSION A8026549.1 GI:5937389
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Gray,D.M. and Clark,C.L.
TITLE Method for selectively ranking sequences for antisense targeting
JOURNAL Patent: US 5856103-A 12 05-JAN-1999;
HOECHST AG (DE)
FEATURES
source
1. .20
/organism="unknown"

```
/mol_type="unassigned DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
      |||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 106
AR026550/c
LOCUS      AR026550      20 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 13 from patent US 5856103.
ACCESSION  AR026550
VERSION     AR026550.1 GI:5937390
KEYWORDS   Unknown.
SOURCE     Unassigned.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Gray,D.M. and Clark,C.L.
TITLE      Method for selectively ranking sequences for antisense targeting
JOURNAL    Patent: US 5856103-A 13 05-JAN-1999;
FEATURES   Location/Qualifiers
            source
            1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
      |||||
Db 20 TCAAACTGCCCTGATGGCA 1

RESULT 107
AR026551/c
LOCUS      AR026551      20 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 14 from patent US 5856103.
ACCESSION  AR026551
VERSION     AR026551.1 GI:5937391
KEYWORDS   Unknown.
SOURCE     Unassigned.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Gray,D.M. and Clark,C.L.
TITLE      Method for selectively ranking sequences for antisense targeting
JOURNAL    Patent: US 5856103-A 14 05-JAN-1999;
FEATURES   Location/Qualifiers
            source
            1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
      |||||
Db 20 TGAACCTATCCCGGACAGG 1

RESULT 108
AR026552/c
LOCUS      AR026552      20 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 15 from patent US 5856103.
ACCESSION  AR026552
VERSION     AR026552.1 GI:5937392

/mol_type="unassigned DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
      |||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 109
AR026553/c
LOCUS      AR026553      20 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 16 from patent US 5856103.
ACCESSION  AR026553
VERSION     AR026553.1 GI:5937393
KEYWORDS   Unknown.
SOURCE     Unassigned.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Gray,D.M. and Clark,C.L.
TITLE      Method for selectively ranking sequences for antisense targeting
JOURNAL    Patent: US 5856103-A 16 05-JAN-1999;
FEATURES   Location/Qualifiers
            source
            1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TCACGGATCCAGCTGGGC 2119
      |||||
Db 20 TCACGGATCCAGCTGGGC 1

RESULT 110
AR026555/c
LOCUS      AR026555      20 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 18 from patent US 5856103.
ACCESSION  AR026555
VERSION     AR026555.1 GI:5937395
KEYWORDS   Unknown.
SOURCE     Unassigned.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 20)
AUTHORS    Gray,D.M. and Clark,C.L.
TITLE      Method for selectively ranking sequences for antisense targeting
JOURNAL    Patent: US 5856103-A 18 05-JAN-1999;
FEATURES   Location/Qualifiers
            source
            1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
      |||||
Db 20 TGAACCTATCCCGGACAGG 1

RESULT 108
AR026552/c
LOCUS      AR026552      20 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 15 from patent US 5856103.
ACCESSION  AR026552
VERSION     AR026552.1 GI:5937392

/mol_type="unassigned DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
      |||||
Db 20 TGAACCTATCCCGGACAGG 1

RESULT 108
AR026552/c
LOCUS      AR026552      20 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 15 from patent US 5856103.
ACCESSION  AR026552
VERSION     AR026552.1 GI:5937392
```

QY 2962 AGTTAATAAAGCTTTCTCAA 2981
Db 20 AGTTAATAAAGCTTTCTCAA 1

RESULT 111
AR054240/c
LOCUS AR054240 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 11 from patent US 5834607.
ACCESSION AR054240
VERSION AR054240.1 GI:5979102
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Cook,P.Dan.
TITLE Amines and methods of making and using the same
JOURNAL Patent: US 5834607-A 11 10-NOV-1998;
FEATURES
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 112
AR062602/c
LOCUS AR062602 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2 from patent US 5843738.
ACCESSION AR062602
VERSION AR062602.1 GI:5990293
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 2 01-DEC-1998;
FEATURES
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 113
AR062607/c
LOCUS AR062607 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 7 from patent US 5843738.
ACCESSION AR062607
VERSION AR062607.1 GI:5990298
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.

TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 7 01-DEC-1998;
FEATURES
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCTCGCTATG 60
Db 20 GCAACCTCAGCTCGCTATG 1

RESULT 114
AR062608/c
LOCUS AR062608 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 8 from patent US 5843738.
ACCESSION AR062608
VERSION AR062608.1 GI:5990299
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 8 01-DEC-1998;
FEATURES
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCAGCAGCCCCCG 77
Db 20 ATGGCTCCAGCAGCCCCCG 1

RESULT 115
AR062609/c
LOCUS AR062609 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 9 from patent US 5843738.
ACCESSION AR062609
VERSION AR062609.1 GI:5990300
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 9 01-DEC-1998;
FEATURES
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTCTCGGGGCTCT 116
Db 20 CTGGTCTCTCGGGGCTCT 1

RESULT 116

AR062610/c
LOCUS AR062610 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 10 from patent US 5843738.
ACCESSION AR062610
VERSION AR062610.1 GI:5990301
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 10 01-DEC-1998;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAACTGCCCTCATGGGCA 356
|||||
Db 20 TCAACTGCCCTCATGGGCA 1

RESULT 117
AR062611/c
LOCUS AR062611 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 11 from patent US 5843738.
ACCESSION AR062611
VERSION AR062611.1 GI:5990302
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 11 01-DEC-1998;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGACC 894
|||||
Db 20 AGGCCTCAGTCAGTGACC 1

RESULT 118
AR062612/c
LOCUS AR062612 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 12 from patent US 5843738.
ACCESSION AR062612
VERSION AR062612.1 GI:5990303
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 12 01-DEC-1998;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGAGGTCAACCCGCGAG 1464
|||||
Db 20 AAGGGAGGTCAACCCGCGAG 1

RESULT 119
AR062613/c
LOCUS AR062613 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 13 from patent US 5843738.
ACCESSION AR062613
VERSION AR062613.1 GI:5990304
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 13 01-DEC-1998;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCACGCTCCCTCA 1656
|||||
Db 20 CACAAGCCACGCTCCCTCA 1

RESULT 120
AR062614/c
LOCUS AR062614 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 14 from patent US 5843738.
ACCESSION AR062614
VERSION AR062614.1 GI:5990305
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 14 01-DEC-1998;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
|||||
Db 20 TGAACCTATCCCGGACAGG 1

RESULT 121
AR062615/c
LOCUS AR062615 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 15 from patent US 5843738.
ACCESSION AR062615
VERSION AR062615.1 GI:5990306
KEYWORDS

```

SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Bennett,C.Frank. and Mirabelli,C.K.
TITLE        Oligonucleotide modulation of cell adhesion
JOURNAL      Patent: US 5843738-A 15 01-DEC-1998;
FEATURES     Location/Qualifiers
            source
            1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
      ||||||||||||||||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 122
AR062616/c
LOCUS      AR062616          20 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 16 from patent US 5843738.
ACCESSION  AR062616
VERSION     AR062616.1 GI:5990307
KEYWORDS    .
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Bennett,C.Frank. and Mirabelli,C.K.
TITLE        Oligonucleotide modulation of cell adhesion
JOURNAL      Patent: US 5843738-A 16 01-DEC-1998;
FEATURES     Location/Qualifiers
            source
            1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAGCTTTCTCAA 2981
      ||||||||||||||||||
Db 20 AGTTAATAAGCTTTCTCAA 1

RESULT 123
AR062622/c
LOCUS      AR062622          20 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 22 from patent US 5843738.
ACCESSION  AR062622
VERSION     AR062622.1 GI:5990313
KEYWORDS    .
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Bennett,C.Frank. and Mirabelli,C.K.
TITLE        Oligonucleotide modulation of cell adhesion
JOURNAL      Patent: US 5843738-A 22 01-DEC-1998;
FEATURES     Location/Qualifiers
            source
            1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
      ||||||||||||||||||

```

```

Db 20 TGACGGATGCCAGCTTGGGC 1
      ||||||||||||||||||

RESULT 124
AR062623/c
LOCUS      AR062623          20 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 23 from patent US 5843738.
ACCESSION  AR062623
VERSION     AR062623.1 GI:5990314
KEYWORDS    .
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Bennett,C.Frank. and Mirabelli,C.K.
TITLE        Oligonucleotide modulation of cell adhesion
JOURNAL      Patent: US 5843738-A 23 01-DEC-1998;
FEATURES     Location/Qualifiers
            source
            1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
      ||||||||||||||||||
Db 20 GAGGCCACAGACTTACAGA 1

RESULT 125
AR062624/c
LOCUS      AR062624          20 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 24 from patent US 5843738.
ACCESSION  AR062624
VERSION     AR062624.1 GI:5990315
KEYWORDS    .
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Bennett,C.Frank. and Mirabelli,C.K.
TITLE        Oligonucleotide modulation of cell adhesion
JOURNAL      Patent: US 5843738-A 24 01-DEC-1998;
FEATURES     Location/Qualifiers
            source
            1..20
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900
      ||||||||||||||||||
Db 20 CAAGAGGAGGAGCAAGACT 1

RESULT 126
AR062625/c
LOCUS      AR062625          20 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 25 from patent US 5843738.
ACCESSION  AR062625
VERSION     AR062625.1 GI:5990316
KEYWORDS    .
SOURCE      Unknown.
ORGANISM     Unclassified.
REFERENCE    1 (bases 1 to 20)
AUTHORS      Bennett,C.Frank. and Mirabelli,C.K.
TITLE        Oligonucleotide modulation of cell adhesion

```

JOURNAL Patent: US 5843738-A 25 01-DEC-1998;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAGTCTAGCTGATGAG 1940
|||||
Db 20 TTAAGTCTAGCTGATGAG 1

RESULT 127
AR062626/c

LOCUS 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 26 from patent US 5843738.
ACCESSION AR062626
VERSION AR062626.1 GI:5990317
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 26 01-DEC-1998;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCCACCATGAGGACA 1981
|||||
Db 20 ATAGCCCCCACCATGAGGACA 1

RESULT 128
AR062684/c

LOCUS 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 84 from patent US 5843738.
ACCESSION AR062684
VERSION AR062684.1 GI:5990375
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 84 01-DEC-1998;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 129
AR062685/c

LOCUS 20 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 85 from patent US 5843738.
ACCESSION AR062685
VERSION AR062685.1 GI:5990376
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 85 01-DEC-1998;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGGTGGGGGAGACATA 1964
|||||
Db 20 GAAGTGGTGGGGGAGACATA 1

RESULT 130
AR099490/c

LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 17 from patent US 6077833.
ACCESSION AR099490
VERSION AR099490.1 GI:12809256
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Vickers,T.A.
TITLE Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
JOURNAL Patent: US 6077833-A 17 20-JUN-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 131
AR100310/c

LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 41 from patent US 6080580.
ACCESSION AR100310
VERSION AR100310.1 GI:12810758
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Baker,B.F., Bennett,C.Frank., Butler,M.M. and Shanahan,W.R. Jr.
TITLE Antisense oligonucleotide modulation of tumor necrosis factor- α (TNF- α) expression
JOURNAL Patent: US 6080580-A 41 27-JUN-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"


```
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 132
AR100318/c
LOCUS AR100318 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 49 from patent US 6080580.
ACCESSION AR100318
VERSION AR100318.1 GI:12810766
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Baker,B.F., Bennett,C.Frank., Butler,M.M. and Shanahan,W.R. Jr.
TITLE Antisense oligonucleotide modulation of tumor necrosis
factor- $\alpha$ . (TNF- $\alpha$ .) expression
JOURNAL Patent: US 6080580-A 49 27-JUN-2000;
FEATURES Location/Qualifiers
source
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 133
AR104705/c
LOCUS AR104705 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 2 from patent US 6093811.
ACCESSION AR104705
VERSION AR104705.1 GI:12817413
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 2 25-JUL-2000;
FEATURES Location/Qualifiers
source
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
|||||
Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 134
AR104710/c
LOCUS AR104710 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 7 from patent US 6093811.
ACCESSION AR104710
```

```
VERSION AR104710.1 GI:12817418
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 7 25-JUL-2000;
FEATURES Location/Qualifiers
source
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCTCGCTATG 60
|||||
Db 20 GCAACCTCAGCCTCGCTATG 1

RESULT 135
AR104711/c
LOCUS AR104711 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 8 from patent US 6093811.
ACCESSION AR104711
VERSION AR104711.1 GI:12817419
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 8 25-JUL-2000;
FEATURES Location/Qualifiers
source
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCAGCAGCCCCCG 77
|||||
Db 20 ATGGCTCCAGCAGCCCCCG 1

RESULT 136
AR104712/c
LOCUS AR104712 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 9 from patent US 6093811.
ACCESSION AR104712
VERSION AR104712.1 GI:12817420
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 9 25-JUL-2000;
FEATURES Location/Qualifiers
source
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
|||||
Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 134
AR104710/c
LOCUS AR104710 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 7 from patent US 6093811.
ACCESSION AR104710
```

QY 97 CTGGTCTGCTCGGGCTCT 116
|||||
Db 20 CTGGTCTGCTCGGGCTCT 1

RESULT 137
AR104713/c
LOCUS AR104713 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 10 from patent US 6093811.
ACCESSION AR104713
VERSION AR104713.1 GI:12817421
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 10 25-JUL-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAACTGCCCTGATGGCA 356
|||||
Db 20 TCAACTGCCCTGATGGCA 1

RESULT 138
AR104714/c
LOCUS AR104714 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 11 from patent US 6093811.
ACCESSION AR104714
VERSION AR104714.1 GI:12817422
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 11 25-JUL-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGACC 894
|||||
Db 20 AGGCCTCAGTCAGTGACC 1

RESULT 139
AR104715/c
LOCUS AR104715 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 12 from patent US 6093811.
ACCESSION AR104715
VERSION AR104715.1 GI:12817423
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)

AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 12 25-JUL-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGGAGGTCAACCCGCGAG 1464
|||||
Db 20 AAGGGGAGGTCAACCCGCGAG 1

RESULT 140
AR104716/c
LOCUS AR104716 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 13 from patent US 6093811.
ACCESSION AR104716
VERSION AR104716.1 GI:12817424
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 13 25-JUL-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCACGCCCTCCCTGA 1656
|||||
Db 20 CACAAGCCACGCCCTCCCTGA 1

RESULT 141
AR104717/c
LOCUS AR104717 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 14 from patent US 6093811.
ACCESSION AR104717
VERSION AR104717.1 GI:12817425
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 14 25-JUL-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
|||||
Db 20 TGAACCTATCCCGGACAGG 1

```
RESULT 142
AR104718/c
LOCUS       AR104718             20 bp      DNA          linear          PAT 14-FEB-2001
DEFINITION   Sequence 15 from patent US 6093811.
ACCESSION   AR104718
VERSION     AR104718.1  GI:12817426
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Bennett,C.Frank. and Mirabelli,C.K.
TITLE       Oligonucleotide modulation of cell adhesion
JOURNAL     Patent: US 6093811-A 15 25-JUL-2000;
FEATURES
LOCATION/Qualifiers
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 143
AR104719/c
LOCUS       AR104719             20 bp      DNA          linear          PAT 14-FEB-2001
DEFINITION   Sequence 16 from patent US 6093811.
ACCESSION   AR104719
VERSION     AR104719.1  GI:12817427
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Bennett,C.Frank. and Mirabelli,C.K.
TITLE       Oligonucleotide modulation of cell adhesion
JOURNAL     Patent: US 6093811-A 16 25-JUL-2000;
FEATURES
LOCATION/Qualifiers
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAAGCTTTCTCAA 2981
|||||
Db 20 AGTTAATAAAGCTTTCTCAA 1

RESULT 144
AR104725/c
LOCUS       AR104725             20 bp      DNA          linear          PAT 14-FEB-2001
DEFINITION   Sequence 22 from patent US 6093811.
ACCESSION   AR104725
VERSION     AR104725.1  GI:12817433
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Bennett,C.Frank. and Mirabelli,C.K.
TITLE       Oligonucleotide modulation of cell adhesion
JOURNAL     Patent: US 6093811-A 22 25-JUL-2000;
FEATURES
LOCATION/Qualifiers
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAAGCTTTCTCAA 2981
|||||
Db 20 AGTTAATAAAGCTTTCTCAA 1
```

```
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TCACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TCACGGATGCCAGCTTGGGC 1

RESULT 145
AR104726/c
LOCUS       AR104726             20 bp      DNA          linear          PAT 14-FEB-2001
DEFINITION   Sequence 23 from patent US 6093811.
ACCESSION   AR104726
VERSION     AR104726.1  GI:12817434
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Bennett,C.Frank. and Mirabelli,C.K.
TITLE       Oligonucleotide modulation of cell adhesion
JOURNAL     Patent: US 6093811-A 23 25-JUL-2000;
FEATURES
LOCATION/Qualifiers
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
|||||
Db 20 GAGGCCACAGACTTACAGA 1

RESULT 146
AR104727/c
LOCUS       AR104727             20 bp      DNA          linear          PAT 14-FEB-2001
DEFINITION   Sequence 24 from patent US 6093811.
ACCESSION   AR104727
VERSION     AR104727.1  GI:12817435
KEYWORDS
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 20)
AUTHORS     Bennett,C.Frank. and Mirabelli,C.K.
TITLE       Oligonucleotide modulation of cell adhesion
JOURNAL     Patent: US 6093811-A 24 25-JUL-2000;
FEATURES
LOCATION/Qualifiers
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900
|||||
Db 20 CAAGAGGAGGAGCAAGACT 1

RESULT 147
AR104728/c
LOCUS       AR104728             20 bp      DNA          linear          PAT 14-FEB-2001
DEFINITION   Sequence 25 from patent US 6093811.
ACCESSION   AR104728
VERSION     AR104728.1  GI:12817436
```

KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 25 25-JUL-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1921 TTAAGTCTAGCCTGATGAG 1940
Db 20 TTAAGTCTAGCCTGATGAG 1
RESULT 148
AR104729/c
LOCUS AR104729 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 26 from patent US 6093811.
ACCESSION AR104729
VERSION AR104729.1 GI:12817437
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 25 25-JUL-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1962 ATAGCCCCCACCATTGAGGACA 1981
Db 20 ATAGCCCCCACCATTGAGGACA 1
RESULT 149
AR104787/c
LOCUS AR104787 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 84 from patent US 6093811.
ACCESSION AR104787
VERSION AR104787.1 GI:12817495
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 84 25-JUL-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
RESULT 150
AR104788/c
LOCUS AR104788 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 85 from patent US 6093811.
ACCESSION AR104788
VERSION AR104788.1 GI:12817496
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 85 25-JUL-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1945 GAAGTGGTGGGGGAGACATA 1964
Db 20 GAAGTGGTGGGGGAGACATA 1
RESULT 151
AR105527/c
LOCUS AR105527 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 2 from patent US 6096722.
ACCESSION AR105527
VERSION AR105527.1 GI:12819124
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and
treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 2 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 7 GAGTCGACGCTGAGCTCCTC 26
Db 20 GAGTCGACGCTGAGCTCCTC 1
RESULT 152
AR105532/c
LOCUS AR105532 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 7 from patent US 6096722.
ACCESSION AR105532
VERSION AR105532.1 GI:12819129
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)

AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 7 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACTCAGCTCGCTATG 60
|||||
Db 20 GCAACTCAGCTCGCTATG 1

RESULT 153
AR105533/c
LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 8 from patent US 6096722.
ACCESSION AR105533
VERSION AR105533.1 GI:12819130
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 8 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCAGCAGCCCCCG 77
|||||
Db 20 ATGGCTCCAGCAGCCCCCG 1

RESULT 154
AR105534/c
LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 9 from patent US 6096722.
ACCESSION AR105534
VERSION AR105534.1 GI:12819131
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 9 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTGCTCGGGGCTCT 116
|||||

Db 20 CTGGTCTGCTCGGGGCTCT 1

RESULT 155
AR105535/c
LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 10 from patent US 6096722.
ACCESSION AR105535
VERSION AR105535.1 GI:12819132
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 10 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
|||||
Db 20 TCAAACTGCCCTGATGGCA 1

RESULT 156
AR105536/c
LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 11 from patent US 6096722.
ACCESSION AR105536
VERSION AR105536.1 GI:12819133
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 11 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGTGACC 894
|||||
Db 20 AGGCCTCAGTCAGTGTGACC 1

RESULT 157
AR105537/c
LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 12 from patent US 6096722.
ACCESSION AR105537
VERSION AR105537.1 GI:12819134
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.

TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 12 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGAGGTCACCCGCGAG 1464
|||||
Db 20 AAGGGAGGTCACCCGCGAG 1

RESULT 158
AR105538/c
LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 13 from patent US 6096722.
ACCESSION AR105538
VERSION AR105538.1 GI:12819135
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 13 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAGCCAGCGCTCCCTGA 1656
|||||
Db 20 CACAGCCAGCGCTCCCTGA 1

RESULT 159
AR105539/c
LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 14 from patent US 6096722.
ACCESSION AR105539
VERSION AR105539.1 GI:12819136
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 14 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
|||||
Db 20 TGAACCTATCCCGGACAGG 1

RESULT 160
AR105540/c
LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 15 from patent US 6096722.
ACCESSION AR105540
VERSION AR105540.1 GI:12819137
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 15 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 161
AR105541/c
LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 16 from patent US 6096722.
ACCESSION AR105541
VERSION AR105541.1 GI:12819138
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 16 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAAGCTTTCTCAA 2981
|||||
Db 20 AGTTAATAAAGCTTTCTCAA 1

RESULT 162
AR105547/c
LOCUS 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 22 from patent US 6096722.
ACCESSION AR105547
VERSION AR105547.1 GI:12819144
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and

JOURNAL treatment of cell adhesion molecule-associated diseases
FEATURES Patent: US 6096722-A 22 01-AUG-2000;

source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 163

LOCUS AR105548/c 20 bp DNA linear PAT 14-FEB-2001

DEFINITION Sequence 23 from patent US 6096722.

ACCESSION AR105548

VERSION AR105548.1 GI:12819145

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)

AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.

TITLE Antisense modulation of cell adhesion molecule expression and

treatment of cell adhesion molecule-associated diseases

JOURNAL Patent: US 6096722-A 23 01-AUG-2000;

FEATURES

source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGCCCCACAGACTTACAGA 2044

Db 20 GAGCCCCACAGACTTACAGA 1

RESULT 164

LOCUS AR105549/c 20 bp DNA linear PAT 14-FEB-2001

DEFINITION Sequence 24 from patent US 6096722.

ACCESSION AR105549

VERSION AR105549.1 GI:12819146

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)

AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.

TITLE Antisense modulation of cell adhesion molecule expression and

treatment of cell adhesion molecule-associated diseases

JOURNAL Patent: US 6096722-A 24 01-AUG-2000;

FEATURES

source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGACCAAGACT 1900

Db 20 CAAGAGGAGGACCAAGACT 1

RESULT 165

LOCUS AR105550/c

DEFINITION Sequence 25 from patent US 6096722.

ACCESSION AR105550

VERSION AR105550.1 GI:12819147

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)

AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.

TITLE Antisense modulation of cell adhesion molecule expression and

treatment of cell adhesion molecule-associated diseases

JOURNAL Patent: US 6096722-A 25 01-AUG-2000;

FEATURES

source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAAGTCTAGCCTGATGAG 1940

Db 20 TTAAAGTCTAGCCTGATGAG 1

RESULT 166

LOCUS AR105551/c

DEFINITION Sequence 26 from patent US 6096722.

ACCESSION AR105551

VERSION AR105551.1 GI:12819148

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)

AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.

TITLE Antisense modulation of cell adhesion molecule expression and

treatment of cell adhesion molecule-associated diseases

JOURNAL Patent: US 6096722-A 26 01-AUG-2000;

FEATURES

source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCACCATGAGGACA 1981

Db 20 ATAGCCCCACCATGAGGACA 1

RESULT 167

LOCUS AR105609/c

DEFINITION Sequence 84 from patent US 6096722.

ACCESSION AR105609

VERSION AR105609.1 GI:12819206

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)

AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.

TITLE Antisense modulation of cell adhesion molecule expression and

treatment of cell adhesion molecule-associated diseases

JOURNAL Patent: US 6096722-A 84 01-AUG-2000;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 168
LOCUS AR105610 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 85 from patent US 6096722.
ACCESSION AR105610
VERSION AR105610.1 GI:12819207
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 85 01-AUG-2000;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGGTGGGGGAGACATA 1964
|||||
Db 20 GAAGTGGTGGGGGAGACATA 1

RESULT 169
LOCUS AR105622/c 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 97 from patent US 6096722.
ACCESSION AR105622
VERSION AR105622.1 GI:12819219
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 97 01-AUG-2000;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1497 GATTGTCATCATCACTGTGG 1516
|||||
Db 20 GATTGTCATCATCACTGTGG 1

RESULT 170
LOCUS AR105625/c 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 100 from patent US 6096722.
ACCESSION AR105625
VERSION AR105625.1 GI:12819222
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 100 01-AUG-2000;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1587 GAAATACAGACTACACAGG 1606
|||||
Db 20 GAAATACAGACTACACAGG 1

RESULT 171
LOCUS AR108782/c 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 2 from patent US 6111094.
ACCESSION AR108782
VERSION AR108782.1 GI:12824269
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Condon,T.P. and Flournoy,S.Cheng.
TITLE Enhanced antisense modulation of ICAM-1
JOURNAL Patent: US 6111094-A 2 29-AUG-2000;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 172
LOCUS AR108785/c 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 5 from patent US 6111094.
ACCESSION AR108785
VERSION AR108785.1 GI:12824272
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Condon,T.P. and Flournoy,S.Cheng.
TITLE Enhanced antisense modulation of ICAM-1
JOURNAL Patent: US 6111094-A 5 29-AUG-2000;
FEATURES Location/Qualifiers
source 1. .20


```
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2102 ACGGATGCCAGCTTGGGCAC 2121
|||||
Db 20 ACGGATGCCAGCTTGGGCAC 1

RESULT 173
AR108786/c
LOCUS AR108786 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 6 from patent US 6111094.
ACCESSION AR108786
VERSION AR108786.1 GI:12824273
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank,, Condon,T.P. and Flournoy,S.Cheng.
TITLE Enhanced antisense modulation of ICAM-1
JOURNAL Patent: US 6111094-A 6 29-AUG-2000;
FEATURES
Location/Qualifiers
source
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2106 ATGCCAGCTGGGCACGTGCT 2125
|||||
Db 20 ATGCCAGCTGGGCACGTGCT 1

RESULT 174
AR108791/c
LOCUS AR108791 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 11 from patent US 6111094.
ACCESSION AR108791
VERSION AR108791.1 GI:12824278
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank,, Condon,T.P. and Flournoy,S.Cheng.
TITLE Enhanced antisense modulation of ICAM-1
JOURNAL Patent: US 6111094-A 11 29-AUG-2000;
FEATURES
Location/Qualifiers
source
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 175
AR110484/c
LOCUS AR110484 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 2 from patent US 6114519.
ACCESSION AR110484
```

```
VERSION AR110484.1 GI:12826760
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cole,D.L., Ravikumar,V.T. and Cheruvallath,Z.S.
TITLE Synthesis of sulfurized oligonucleotides
JOURNAL Patent: US 6114519-A 2 05-SEP-2000;
FEATURES
Location/Qualifiers
source
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 176
AR110490/c
LOCUS AR110490 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 8 from patent US 6114519.
ACCESSION AR110490
VERSION AR110490.1 GI:12826766
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cole,D.L., Ravikumar,V.T. and Cheruvallath,Z.S.
TITLE Synthesis of sulfurized oligonucleotides
JOURNAL Patent: US 6114519-A 8 05-SEP-2000;
FEATURES
Location/Qualifiers
source
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 177
AR110491/c
LOCUS AR110491 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 9 from patent US 6114519.
ACCESSION AR110491
VERSION AR110491.1 GI:12826767
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cole,D.L., Ravikumar,V.T. and Cheruvallath,Z.S.
TITLE Synthesis of sulfurized oligonucleotides
JOURNAL Patent: US 6114519-A 9 05-SEP-2000;
FEATURES
Location/Qualifiers
source
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1
```

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 178
AR111778/c
LOCUS AR111778 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 21 from patent US 6127346.
ACCESSION AR111778
VERSION AR111778.1 GI:12828626
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Peyman,A., Uhlmann,E., Breipohl,G. and Wallmeier,H.
TITLE Phosphonomonoester nucleic acids process for their preparation and their use
JOURNAL Patent: US 6127346-A 21 03-OCT-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGAAGTGGTGGGG 1957
Db 20 GAGAGGGAAGTGGTGGGG 1

RESULT 179
AR111779/c
LOCUS AR111779 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 22 from patent US 6127346.
ACCESSION AR111779
VERSION AR111779.1 GI:12828627
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Peyman,A., Uhlmann,E., Breipohl,G. and Wallmeier,H.
TITLE Phosphonomonoester nucleic acids process for their preparation and their use
JOURNAL Patent: US 6127346-A 22 03-OCT-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGAG 1959
Db 20 GAGGGGAAGTGGTGGGGAG 1

RESULT 180
AR120021/c
LOCUS AR120021 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 25 from patent US 6153595.
ACCESSION AR120021
VERSION AR120021.1 GI:14102720
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Draper,K.G., Kiser,D.L., Anderson,K.P. and Chapman,S.
TITLE Composition and method for treatment of CMV infections
JOURNAL Patent: US 6153595-A 25 28-NOV-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 181
AR120117/c
LOCUS AR120117 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 17 from patent US 6153737.
ACCESSION AR120117
VERSION AR120117.1 GI:14102816
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M., Cook,P.Dan. and Bennett,C.Frank.
TITLE Derivatized oligonucleotides having improved uptake and other properties
JOURNAL Patent: US 6153737-A 17 28-NOV-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 182
AR121942/c
LOCUS AR121942 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 2 from patent US 6160152.
ACCESSION AR121942
VERSION AR121942.1 GI:14105518
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Capaldi,D.C. and Ravikumar,V.T.
TITLE Process for the synthesis of oligomeric compounds
JOURNAL Patent: US 6160152-A 2 12-DEC-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 183
AR123189/c
LOCUS AR123189 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 2 from patent US 6169079.
ACCESSION AR123189
VERSION AR123189.1 GI:14108155
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 2 02-JAN-2001;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
|||||
Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 184
AR123194/c
LOCUS AR123194 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 7 from patent US 6169079.
ACCESSION AR123194
VERSION AR123194.1 GI:14108160
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 7 02-JAN-2001;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCTCGCTATG 60
|||||
Db 20 GCAACCTCAGCCTCGCTATG 1

RESULT 185
AR123195/c
LOCUS AR123195 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 8 from patent US 6169079.
ACCESSION AR123195
VERSION AR123195.1 GI:14108161
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 8 02-JAN-2001;

FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGTCTCCAGCAGCCCCG 77
|||||
Db 20 ATGGTCTCCAGCAGCCCCG 1

RESULT 186
AR123196/c
LOCUS AR123196 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 9 from patent US 6169079.
ACCESSION AR123196
VERSION AR123196.1 GI:14108162
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 9 02-JAN-2001;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTCTCGGGGCTCT 116
|||||
Db 20 CTGGTCTCTCGGGGCTCT 1

RESULT 187
AR123197/c
LOCUS AR123197 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 10 from patent US 6169079.
ACCESSION AR123197
VERSION AR123197.1 GI:14108163
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 10 02-JAN-2001;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
|||||
Db 20 TCAAACTGCCCTGATGGCA 1

RESULT 188
AR123198/c
LOCUS AR123198 20 bp DNA linear PAT 16-MAY-2001

```
DEFINITION Sequence 11 from patent US 6169079.
ACCESSION AR123198
VERSION AR123198.1 GI:14108164
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 11 02-JAN-2001;
FEATURES
    source
        Location/Qualifiers
            1..20
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 875 AGGCTCAGTCAGTGTGACC 894
    |||||
Db 20 AGGCTCAGTCAGTGTGACC 1

RESULT 189
AR123199/c
LOCUS AR123199 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 12 from patent US 6169079.
ACCESSION AR123199
VERSION AR123199.1 GI:14108165
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 12 02-JAN-2001;
FEATURES
    source
        Location/Qualifiers
            1..20
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1445 AAGGGAGGTACCCGCGAG 1464
    |||||
Db 20 AAGGGAGGTACCCGCGAG 1

RESULT 190
AR123200/c
LOCUS AR123200 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 13 from patent US 6169079.
ACCESSION AR123200
VERSION AR123200.1 GI:14108166
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 13 02-JAN-2001;
FEATURES
    source
        Location/Qualifiers
            1..20
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1637 CACAAGCCAGCCTCCCTGA 1656
    |||||
Db 20 CACAAGCCAGCCTCCCTGA 1

RESULT 191
AR123201/c
LOCUS AR123201 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 14 from patent US 6169079.
ACCESSION AR123201
VERSION AR123201.1 GI:14108167
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 14 02-JAN-2001;
FEATURES
    source
        Location/Qualifiers
            1..20
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1654 TGAACCTATCCCGGACAGG 1673
    |||||
Db 20 TGAACCTATCCCGGACAGG 1

RESULT 192
AR123202/c
LOCUS AR123202 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 15 from patent US 6169079.
ACCESSION AR123202
VERSION AR123202.1 GI:14108168
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 15 02-JAN-2001;
FEATURES
    source
        Location/Qualifiers
            1..20
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1938 GAGAGGGGAAGTGGTGGGG 1957
    |||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 193
AR123203/c
LOCUS AR123203 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 16 from patent US 6169079.
ACCESSION AR123203
VERSION AR123203.1 GI:14108169
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
```

```
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 16 02-JAN-2001;
FEATURES
source
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAGCTTCTCAA 2981
    |||||
Db 20 AGTTAATAAGCTTCTCAA 1

RESULT 194
AR123209/c
LOCUS AR123209 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 22 from patent US 6169079.
ACCESSION AR123209
VERSION AR123209.1 GI:14108175
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 22 02-JAN-2001;
FEATURES
source
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
    |||||
Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 195
AR123210/c
LOCUS AR123210 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 23 from patent US 6169079.
ACCESSION AR123210
VERSION AR123210.1 GI:14108176
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 23 02-JAN-2001;
FEATURES
source
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
    |||||
Db 20 GAGGCCACAGACTTACAGA 1

Unclassified.
REFERENCE 196
AR123211/c
LOCUS AR123211 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 24 from patent US 6169079.
ACCESSION AR123211
VERSION AR123211.1 GI:14108177
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 24 02-JAN-2001;
FEATURES
source
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900
    |||||
Db 20 CAAGAGGAGGAGCAAGACT 1

RESULT 197
AR123212/c
LOCUS AR123212 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 25 from patent US 6169079.
ACCESSION AR123212
VERSION AR123212.1 GI:14108178
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 25 02-JAN-2001;
FEATURES
source
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAAGCTAGCCTGATGAG 1940
    |||||
Db 20 TTAAAGCTAGCCTGATGAG 1

RESULT 198
AR123213/c
LOCUS AR123213 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 26 from patent US 6169079.
ACCESSION AR123213
VERSION AR123213.1 GI:14108179
KEYWORDS
SOURCE
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 26 02-JAN-2001;
FEATURES
source
    1..20
    /organism="unknown"
    /mol_type="unassigned DNA"
```

[illegible]

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTGCTACTCAGA 37
 |||||
 Db 20 GAGCTCCTGCTACTCAGA 1

RESULT 204
 AR128997/c
 LOCUS AR128997 20 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 12 from patent US 6183966.
 ACCESSION AR128997
 VERSION AR128997.1 GI:14116659
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Gray,D.M. and Clark,C.L.
 TITLE Apparatus and method for selectively ranking sequences for antisense targeting
 JOURNAL Patent: US 6183966-A 12 06-FEB-2001;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGG 1957
 |||||
 Db 20 GAGAGGGGAAGTGTGGGG 1

RESULT 205
 AR128998/c
 LOCUS AR128998 20 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 13 from patent US 6183966.
 ACCESSION AR128998
 VERSION AR128998.1 GI:14116660
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Gray,D.M. and Clark,C.L.
 TITLE Apparatus and method for selectively ranking sequences for antisense targeting
 JOURNAL Patent: US 6183966-A 13 06-FEB-2001;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
 |||||
 Db 20 TCAAACTGCCCTGATGGCA 1

RESULT 206
 AR128999/c
 LOCUS AR128999 20 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 14 from patent US 6183966.
 ACCESSION AR128999
 VERSION AR128999.1 GI:14116661
 KEYWORDS
 SOURCE Unknown.

ORGANISM Unknown.
 Unclassified.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Gray,D.M. and Clark,C.L.
 TITLE Apparatus and method for selectively ranking sequences for antisense targeting
 JOURNAL Patent: US 6183966-A 14 06-FEB-2001;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCGGGACAGG 1673
 |||||
 Db 20 TGAACCTATCCGGGACAGG 1

RESULT 207
 AR129000/c
 LOCUS AR129000 20 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 15 from patent US 6183966.
 ACCESSION AR129000
 VERSION AR129000.1 GI:14116662
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Gray,D.M. and Clark,C.L.
 TITLE Apparatus and method for selectively ranking sequences for antisense targeting
 JOURNAL Patent: US 6183966-A 15 06-FEB-2001;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGG 1957
 |||||
 Db 20 GAGAGGGGAAGTGTGGGG 1

RESULT 208
 AR129001/c
 LOCUS AR129001 20 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 16 from patent US 6183966.
 ACCESSION AR129001
 VERSION AR129001.1 GI:14116663
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Gray,D.M. and Clark,C.L.
 TITLE Apparatus and method for selectively ranking sequences for antisense targeting
 JOURNAL Patent: US 6183966-A 16 06-FEB-2001;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGG 1957
 |||||
 Db 20 GAGAGGGGAAGTGTGGGG 1

RESULT 209
 AR129002/c
 LOCUS AR129002 20 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 17 from patent US 6183966.
 ACCESSION AR129002
 VERSION AR129002.1 GI:14116664
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Gray,D.M. and Clark,C.L.
 TITLE Apparatus and method for selectively ranking sequences for antisense targeting
 JOURNAL Patent: US 6183966-A 17 06-FEB-2001;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 209
AR129003/c
LOCUS AR129003 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 18 from patent US 6183966.
ACCESSION AR129003
VERSION AR129003.1 GI:141116665
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Gray,D.M. and Clark,C.L.
TITLE Apparatus and method for selectively ranking sequences for antisense targeting
JOURNAL Patent: US 6183966-A 18 06-FEB-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAAGCTTCTCAA 2981
Db 20 AGTTAATAAAGCTTCTCAA 1

RESULT 210
AR141077/c
LOCUS AR141077 20 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 8 from patent US 6207819.
ACCESSION AR141077
VERSION AR141077.1 GI:14483573
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Maier,M.A.
TITLE Compounds, processes and intermediates for synthesis of mixed backbone oligomeric compounds
JOURNAL Patent: US 6207819-A 8 27-MAR-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 211
AR142473/c
LOCUS AR142473 20 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 3 from patent US 6175004.
ACCESSION AR142473
VERSION AR142473.1 GI:15102772
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Ross,B.S. and Manoharan,M.
TITLE Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
JOURNAL Patent: US 6175004-A 3 16-JAN-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 212
AR149965/c
LOCUS AR149965 20 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 41 from patent US 6228642.
ACCESSION AR149965
VERSION AR149965.1 GI:151114556
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Baker,B.F., Bennett,C.Frank., Butler,M.M. and Shanahan,W.R. Jr.
TITLE Antisense oligonucleotide modulation of tumor necrosis factor-(alpha.) (TNF-alpha.) expression
JOURNAL Patent: US 6228642-A 41 08-MAY-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 213
AR149973/c
LOCUS AR149973 20 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 49 from patent US 6228642.
ACCESSION AR149973
VERSION AR149973.1 GI:151114564
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Baker,B.F., Bennett,C.Frank., Butler,M.M. and Shanahan,W.R. Jr.
TITLE Antisense oligonucleotide modulation of tumor necrosis factor-(alpha.) (TNF-alpha.) expression
JOURNAL Patent: US 6228642-A 49 08-MAY-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 214
AR149973/c
LOCUS AR149973 20 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 49 from patent US 6228642.
ACCESSION AR149973
VERSION AR149973.1 GI:151114564
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Baker,B.F., Bennett,C.Frank., Butler,M.M. and Shanahan,W.R. Jr.
TITLE Antisense oligonucleotide modulation of tumor necrosis factor-(alpha.) (TNF-alpha.) expression
JOURNAL Patent: US 6228642-A 49 08-MAY-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 214
AR152001/c
LOCUS AR152001 20 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 1 from patent US 6232296.
ACCESSION AR152001
VERSION AR152001.1 GI:15118051
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Henry,V.S.
TITLE Inhibition of complement activation and complement modulation by use of modified oligonucleotides
JOURNAL Patent: US 6232296-A 1 15-MAY-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 215
AR153734/c
LOCUS AR153734 20 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 11 from patent US 6235886.
ACCESSION AR153734
VERSION AR153734.1 GI:15121266
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M., and Cook,P.Dan.
TITLE Methods of synthesis and use
JOURNAL Patent: US 6235886-A 11 22-MAY-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 216
AR164169/c
LOCUS AR164169 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 2 from patent US 6271358.
ACCESSION AR164169
VERSION AR164169.1 GI:16235154
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)

AUTHORS Manoharan,M., Mohan,V. and Boswell,H.
TITLE RNA targeted 2'-modified oligonucleotides that are conformationally preorganized
JOURNAL Patent: US 6271358-A 2 07-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 217
AR164170/c
LOCUS AR164170 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 3 from patent US 6271358.
ACCESSION AR164170
VERSION AR164170.1 GI:16235156
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M., Mohan,V. and Boswell,H.
TITLE RNA targeted 2'-modified oligonucleotides that are conformationally preorganized
JOURNAL Patent: US 6271358-A 3 07-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 218
AR164172/c
LOCUS AR164172 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 5 from patent US 6271358.
ACCESSION AR164172
VERSION AR164172.1 GI:16235160
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M., Mohan,V. and Boswell,H.
TITLE RNA targeted 2'-modified oligonucleotides that are conformationally preorganized
JOURNAL Patent: US 6271358-A 5 07-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 219
AR164172/c
LOCUS AR164172 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 5 from patent US 6271358.
ACCESSION AR164172
VERSION AR164172.1 GI:16235160
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M., Mohan,V. and Boswell,H.
TITLE RNA targeted 2'-modified oligonucleotides that are conformationally preorganized
JOURNAL Patent: US 6271358-A 5 07-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 219
AR165297/c

LOCUS AR165297 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 2 from patent US 6274725.
ACCESSION AR165297
VERSION AR165297.1 GI:16238846
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi,Y. and Manoharan,M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 2 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 220
AR165303/c

LOCUS AR165303 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 8 from patent US 6274725.
ACCESSION AR165303
VERSION AR165303.1 GI:16238858
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi,Y. and Manoharan,M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 8 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 221
AR165306/c

LOCUS AR165306 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 11 from patent US 6274725.
ACCESSION AR165306
VERSION AR165306.1 GI:16238864
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi,Y. and Manoharan,M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 11 14-AUG-2001;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 222
AR165317/c

LOCUS AR165317 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 22 from patent US 6274725.
ACCESSION AR165317
VERSION AR165317.1 GI:16238877
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi,Y. and Manoharan,M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 22 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 223
AR165317/c

LOCUS AR165317 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 22 from patent US 6274725.
ACCESSION AR165317
VERSION AR165317.1 GI:16238877
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi,Y. and Manoharan,M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 22 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 224
AR165318/c

LOCUS AR165318 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 18 from patent US 6274725.
ACCESSION AR165318
VERSION AR165318.1 GI:16238877
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi,Y. and Manoharan,M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 18 14-AUG-2001;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 222
AR165312/c

LOCUS AR165312 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 17 from patent US 6274725.
ACCESSION AR165312
VERSION AR165312.1 GI:16238872
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi,Y. and Manoharan,M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 17 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 223
AR165317/c

LOCUS AR165317 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 22 from patent US 6274725.
ACCESSION AR165317
VERSION AR165317.1 GI:16238877
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi,Y. and Manoharan,M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 22 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 224
AR165318/c

LOCUS AR165318 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 18 from patent US 6274725.
ACCESSION AR165318
VERSION AR165318.1 GI:16238877
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi,Y. and Manoharan,M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 18 14-AUG-2001;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

DEFINITION Sequence 23 from patent US 6274725.
ACCESSION AR165318
VERSION AR165318.1 GI:16238878
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi, Y. and Manoharan, M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 23 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTGCTACTCAGA 1

RESULT 225
AR165320/c
LOCUS
DEFINITION Sequence 25 from patent US 6274725.
ACCESSION AR165320
VERSION AR165320.1 GI:16238880
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi, Y. and Manoharan, M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 25 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 226
AR165326/c
LOCUS
DEFINITION Sequence 31 from patent US 6274725.
ACCESSION AR165326
VERSION AR165326.1 GI:16238888
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi, Y. and Manoharan, M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 31 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 227
AR165328/c
LOCUS
DEFINITION Sequence 33 from patent US 6274725.
ACCESSION AR165328
VERSION AR165328.1 GI:16238892
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi, Y. and Manoharan, M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 33 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 228
AR165333/c
LOCUS
DEFINITION Sequence 38 from patent US 6274725.
ACCESSION AR165333
VERSION AR165333.1 GI:16238900
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi, Y. and Manoharan, M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 38 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 229
AR165335/c
LOCUS
DEFINITION Sequence 40 from patent US 6274725.
ACCESSION AR165335
VERSION AR165335.1 GI:16238902
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 227
AR165328/c
LOCUS
DEFINITION Sequence 33 from patent US 6274725.
ACCESSION AR165328
VERSION AR165328.1 GI:16238892
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi, Y. and Manoharan, M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 33 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 228
AR165333/c
LOCUS
DEFINITION Sequence 38 from patent US 6274725.
ACCESSION AR165333
VERSION AR165333.1 GI:16238900
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi, Y. and Manoharan, M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 38 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 229
AR165335/c
LOCUS
DEFINITION Sequence 40 from patent US 6274725.
ACCESSION AR165335
VERSION AR165335.1 GI:16238902
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi,Y. and Manoharan,M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 40 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 230
AR165341/c
LOCUS AR165341 20 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 46 from patent US 6274725.
ACCESSION AR165341
VERSION AR165341.1 GI:16238911
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sanghvi,Y. and Manoharan,M.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6274725-A 46 14-AUG-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 231
AR167436/c
LOCUS AR167436 20 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 2 from patent US 6287591.
ACCESSION AR167436
VERSION AR167436.1 GI:17903216
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Semple,S.C., Klimuk,S.K., Harasym,T., Hope,M.J., Ansell,S.M.,
Cullis,P., Scherrer,P. and Debeyer,D.
TITLE Charged therapeutic agents encapsulated in lipid particles
containing four lipid components
JOURNAL Patent: US 6287591-A 2 11-SEP-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119

Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 232
AR176024/c
LOCUS AR176024 20 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 3 from patent US 6310047.
ACCESSION AR176024
VERSION AR176024.1 GI:17917323
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Farrell,N. and Kloster,M.
TITLE High affinity DNA binding compounds as adjuvants in antisense
technology
JOURNAL Patent: US 6310047-A 3 30-OCT-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 233
AR178771/c
LOCUS AR178771 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 17 from patent US 6319906.
ACCESSION AR178771
VERSION AR178771.1 GI:20219909
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Vickers,T.A.
TITLE Oligonucleotide compositions and methods for the modulation of the
expression of B7 protein
JOURNAL Patent: US 6319906-A 17 20-NOV-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 234
AR179598/c
LOCUS AR179598 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1 from patent US 6326358.
ACCESSION AR179598
VERSION AR179598.1 GI:20221153
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)

AUTHORS Manoharan,M.
TITLE Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages
JOURNAL Patent: US 6326358-A 1 04-DEC-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 235
LOCUS AR179600/c 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 3 from patent US 6326358.
ACCESSION AR179600
VERSION AR179600.1 GI:20221155
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M.
TITLE Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages
JOURNAL Patent: US 6326358-A 3 04-DEC-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 236
LOCUS AR179601/c 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 4 from patent US 6326358.
ACCESSION AR179601
VERSION AR179601.1 GI:20221156
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M.
TITLE Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages
JOURNAL Patent: US 6326358-A 4 04-DEC-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 237
LOCUS AR179602/c 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 5 from patent US 6326358.
ACCESSION AR179602
VERSION AR179602.1 GI:20221157
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M.
TITLE Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages
JOURNAL Patent: US 6326358-A 5 04-DEC-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 238
LOCUS AR179603/c 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 6 from patent US 6326358.
ACCESSION AR179603
VERSION AR179603.1 GI:20221158
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M.
TITLE Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages
JOURNAL Patent: US 6326358-A 6 04-DEC-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 239
LOCUS AR179604/c 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7 from patent US 6326358.
ACCESSION AR179604
VERSION AR179604.1 GI:20221159
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M.

TITLE Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages
JOURNAL Patent: US 6326358-A 7 04-DEC-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 240
AR179605/c
LOCUS
DEFINITION Sequence 8 from patent US 6326358.
ACCESSION AR179605
VERSION AR179605.1 GI:20221160
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M.
TITLE Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages
JOURNAL Patent: US 6326358-A 8 04-DEC-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 241
AR179606/c
LOCUS
DEFINITION Sequence 9 from patent US 6326358.
ACCESSION AR179606
VERSION AR179606.1 GI:20221161
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M.
TITLE Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages
JOURNAL Patent: US 6326358-A 9 04-DEC-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 242
AR179608/c
LOCUS
DEFINITION Sequence 11 from patent US 6326358.
ACCESSION AR179608
VERSION AR179608.1 GI:20221163
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M.
TITLE Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages
JOURNAL Patent: US 6326358-A 11 04-DEC-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 243
AR179610/c
LOCUS
DEFINITION Sequence 13 from patent US 6326358.
ACCESSION AR179610
VERSION AR179610.1 GI:20221165
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M.
TITLE Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages
JOURNAL Patent: US 6326358-A 13 04-DEC-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 244
BD192436/c
LOCUS
DEFINITION Compositions and methods for the delivery of oligonucleotides via the alimentary canal.
ACCESSION BD192436
VERSION BD192436.1 GI:33002175
KEYWORDS JP 2002510319-A/1.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE other sequences; artificial sequences.
AUTHORS 1 (bases 1 to 20)
Teng,C.L. and Hardee,G.

RESULT 242
AR179608/c
LOCUS
DEFINITION Sequence 11 from patent US 6326358.
ACCESSION AR179608
VERSION AR179608.1 GI:20221163
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M.
TITLE Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages
JOURNAL Patent: US 6326358-A 11 04-DEC-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 243
AR179610/c
LOCUS
DEFINITION Sequence 13 from patent US 6326358.
ACCESSION AR179610
VERSION AR179610.1 GI:20221165
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M.
TITLE Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages
JOURNAL Patent: US 6326358-A 13 04-DEC-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 244
BD192436/c
LOCUS
DEFINITION Compositions and methods for the delivery of oligonucleotides via the alimentary canal.
ACCESSION BD192436
VERSION BD192436.1 GI:33002175
KEYWORDS JP 2002510319-A/1.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE other sequences; artificial sequences.
AUTHORS 1 (bases 1 to 20)
Teng,C.L. and Hardee,G.

```

TITLE      Compositions and methods for the delivery of oligonucleotides via
JOURNAL    the alimentary canal
PATENT: JP 2002510319-A 1 02-APR-2002;
COMMENT    ISIS PHARMACEUTICALS INC
OS         Artificial Sequence
PN         JP 2002510319-A/1
PD         02-APR-2002
PF         01-JUL-1998 JP 1999507295
PR         01-JUL-1997 US 08/886829
PI         CHING LEOU TENG,GREG HARDEE
PC         C12Q1/68,A61K9/127,A61K48/00,C07H21/04
CC         Description of Artificial Sequence: Novel Sequence FH Key
           Location/Qualifiers
FEATURES   source
            1..20
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
        |||||||
Db       20 TGACGGATGCCAGCTTGGGC 1

RESULT 245
BD209848/c
LOCUS   BD209848      20 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Compositions and methods for topical delivery of oligonucleotides.
ACCESSION BD209848
VERSION   BD209848.1 GI:33019618
KEYWORDS JP 2002515514-A/1.
SOURCE    synthetic construct
ORGANISM  other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS   Mehta,R., Hardee,G.E., Cook,P.D., Ecker,D.J., Tsai,Y.J. and
           Templin,M.V.
TITLE      Compositions and methods for topical delivery of oligonucleotides
JOURNAL    ISIS PHARMACEUTICALS INC
COMMENT    Patent: JP 2002515514-A 1 28-MAY-2002;
           OS Artificial Sequence
           PN JP 2002515514-A/1
           PD 28-MAY-2002
           PF 20-MAY-1999 JP 2000549773
           PR 21-MAY-1998 US 09/082336
           PI RAHUL MEHTA,GREGORY E HARDEE,PHILLIP D COOK,DAVID J ECKER, PI
           YALI JENNIFER TSAI,MICHAEL V TEMPLIN
           PC A61K48/00,A61K9/107,A61K31/7088,A61K31/7125,A61K47/12,A61K47/
           24,A61K47/38,
           PC C07H21/04,C12N15/09,C12Q1/68,C12N15/00
           CC Antisense Sequence
           FH Key Location/Qualifiers
           FT source 1..20
           FT source /organism='Artificial Sequence'.

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1938 GAGAGGGGAAGTGGTGGGG 1957
        |||||||
Db       20 GAGAGGGGAAGTGGTGGGG 1

RESULT 247
BD222600/c
LOCUS   BD222600      20 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Aminoxy-modified nucleoside compound and oligomer compound
           produced therefrom.
ACCESSION BD222600
VERSION   BD222600.1 GI:33032370
KEYWORDS JP 2002522447-A/18.
SOURCE    synthetic construct
ORGANISM  other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS   Manoharan,M., Cook,P.D., Prakash,T.P. and Kawasaki,A.M.
TITLE      Aminoxy-modified nucleoside compound and oligomer compound
           produced therefrom
JOURNAL    ISIS PHARMACEUTICALS INC
COMMENT    Patent: JP 2002522447-A 18 23-JUL-2002;
           OS Artificial Sequence
           PN JP 2002522447-A/18
           PD 23-JUL-2002
           PF 09-AUG-1999 JP 2000563675
           PR 07-AUG-1998 US 09/130973
           PI MUTHIAH MANOHARAN, PHILIP DAN COOK, THAZHA P PRAKASH, ANDREW M
           PI KAWASAKI
           PC C07H19/167,C07H19/067,C07H19/10,C07H19/20,C07H21/02,C12N15/00,
           PC C12N15/00
           CC Description of Artificial Sequence: antisense sequence FH
           Key Location/Qualifiers

```

```

RESULT 246
BD209849/c
LOCUS   BD209849      20 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Compositions and methods for topical delivery of oligonucleotides.
ACCESSION BD209849
VERSION   BD209849.1 GI:33019619
KEYWORDS JP 2002515514-A/2.
SOURCE    synthetic construct
ORGANISM  other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS   Mehta,R., Hardee,G.E., Cook,P.D., Ecker,D.J., Tsai,Y.J. and
           Templin,M.V.
TITLE      Compositions and methods for topical delivery of oligonucleotides
JOURNAL    ISIS PHARMACEUTICALS INC
COMMENT    Patent: JP 2002515514-A 2 28-MAY-2002;
           OS Artificial Sequence
           PN JP 2002515514-A/2
           PD 28-MAY-2002
           PF 20-MAY-1999 JP 2000549773
           PR 21-MAY-1998 US 09/082336
           PI RAHUL MEHTA,GREGORY E HARDEE,PHILLIP D COOK,DAVID J ECKER, PI
           YALI JENNIFER TSAI,MICHAEL V TEMPLIN
           PC A61K48/00,A61K9/107,A61K31/7088,A61K31/7125,A61K47/12,A61K47/
           24,A61K47/38,
           PC C07H21/04,C12N15/09,C12Q1/68,C12N15/00
           CC Antisense Sequence
           FH Key Location/Qualifiers
           FT source 1..20
           FT source /organism='Artificial Sequence'.

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1938 GAGAGGGGAAGTGGTGGGG 1957
        |||||||
Db       20 GAGAGGGGAAGTGGTGGGG 1

RESULT 247
BD222600/c
LOCUS   BD222600      20 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION Aminoxy-modified nucleoside compound and oligomer compound
           produced therefrom.
ACCESSION BD222600
VERSION   BD222600.1 GI:33032370
KEYWORDS JP 2002522447-A/18.
SOURCE    synthetic construct
ORGANISM  other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS   Manoharan,M., Cook,P.D., Prakash,T.P. and Kawasaki,A.M.
TITLE      Aminoxy-modified nucleoside compound and oligomer compound
           produced therefrom
JOURNAL    ISIS PHARMACEUTICALS INC
COMMENT    Patent: JP 2002522447-A 18 23-JUL-2002;
           OS Artificial Sequence
           PN JP 2002522447-A/18
           PD 23-JUL-2002
           PF 09-AUG-1999 JP 2000563675
           PR 07-AUG-1998 US 09/130973
           PI MUTHIAH MANOHARAN, PHILIP DAN COOK, THAZHA P PRAKASH, ANDREW M
           PI KAWASAKI
           PC C07H19/167,C07H19/067,C07H19/10,C07H19/20,C07H21/02,C12N15/00,
           PC C12N15/00
           CC Description of Artificial Sequence: antisense sequence FH
           Key Location/Qualifiers

```

```

FT source 1. .20
FT /organism='Artificial Sequence'.
FEATURES
  source 1. .20
    Location/Qualifiers
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
   |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 248
BD226785/c
LOCUS BD226785 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Compositions and methods for the pulmonary delivery of nucleic acids.
ACCESSION BD226785
VERSION BD226785.1 GI:33036555
KEYWORDS JP 2002515513-A/1.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F., Ecker,D.J. and Cook,P.D.
TITLE Compositions and methods for the pulmonary delivery of nucleic acids
JOURNAL Patent: JP 2002515513-A 1 28-MAY-2002;
COMMENT ISIS PHARMACEUTICALS INC
OS Artificial Sequence
PN JP 2002515513-A/1
PD 28-MAY-2002
PR 20-MAY-1998 JP 2000549772
PI CLARENCE FRANK BENNETT,DAVID J ECKER,PHILIP DAN COOK PC
A61K48/00,A61K31/712,A61K31/7125,C12N15/09,C12Q1/68, PC
C12N15/00
CC Antisense Sequence
FH Key Location/Qualifiers
FT source 1. .20
FT /organism='Artificial Sequence'.
FEATURES
  source 1. .20
    Location/Qualifiers
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
   |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 249
BD227838/c
LOCUS BD227838 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Antisense oligonucleotide regulation of expression of tumor necrosis factor-alpha (TNF-alpha).
ACCESSION BD227838
VERSION BD227838.1 GI:33037608
KEYWORDS JP 2002526125-A/41.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)

```

```

AUTHORS Baker,B.F., Bennett,F.C., Butler,M.M. and Jr,W.J.S.
TITLE Antisense oligonucleotide regulation of expression of tumor necrosis factor-alpha (TNF-alpha)
JOURNAL Patent: JP 2002526125-A 41 20-AUG-2002;
COMMENT ISIS PHARMACEUTICALS INC
OS Artificial Sequence
PN JP 2002526125-A/41
PD 20-AUG-2002
PR 05-OCT-1999 JP 2000574737
PR 05-OCT-1998 US 09/166186,18-MAY-1999 US 09/313932 PI
BRENDA F BAKER,FRANK C BENNETT,MADELINE M BUTLER,WILLIAM J PI
SHANAHAN JR
PC C12N15/09,A61K31/7115,A61K31/712,A61K31/7125,A61K48/00,A61P1/00,A61P1/16,
PC A61P1/18,A61P3/10,A61P17/00,A61P17/04,A61P29/00,A61P31/00, PC
C07H21/02
PC C07H21/04,C12N15/00
CC control sequence
FH Key Location/Qualifiers
FT source 1. .20
FT /organism='Artificial Sequence'.
FEATURES
  source 1. .20
    Location/Qualifiers
      /organism="synthetic construct"
      /mol_type="genomic DNA"
      /db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
   |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 250
BD227846/c
LOCUS BD227846 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Antisense oligonucleotide regulation of expression of tumor necrosis factor-alpha (TNF-alpha).
ACCESSION BD227846
VERSION BD227846.1 GI:33037616
KEYWORDS JP 2002526125-A/49.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Baker,B.F., Bennett,F.C., Butler,M.M. and Jr,W.J.S.
TITLE Antisense oligonucleotide regulation of expression of tumor necrosis factor-alpha (TNF-alpha)
JOURNAL Patent: JP 2002526125-A 49 20-AUG-2002;
COMMENT ISIS PHARMACEUTICALS INC
OS Artificial Sequence
PN JP 2002526125-A/49
PD 20-AUG-2002
PR 05-OCT-1999 JP 2000574737
PR 05-OCT-1998 US 09/166186,18-MAY-1999 US 09/313932 PI
BRENDA F BAKER,FRANK C BENNETT,MADELINE M BUTLER,WILLIAM J PI
SHANAHAN JR
PC C12N15/09,A61K31/7115,A61K31/712,A61K31/7125,A61K48/00,A61P1/00,A61P1/16,
PC A61P1/18,A61P3/10,A61P17/00,A61P17/04,A61P29/00,A61P31/00, PC
C07H21/02
PC C07H21/04,C12N15/00
CC control sequence
FH Key Location/Qualifiers
FT source 1. .20
FT /organism='Artificial Sequence'.
FEATURES
  source 1. .20
    Location/Qualifiers
      /organism="synthetic construct"
      /mol_type="genomic DNA"

```


/db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
 |||||
 Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 251

BD233827/c BD233827 20 bp DNA linear PAT 17-JUL-2003
 LOCUS
 DEFINITION Fluorescent probe for chromosome painting.
 ACCESSION BD233827
 VERSION BD233827.1 GI:33043597
 KEYWORDS JP 2002527077-A/1.
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Cherif,D.
 TITLE Fluorescent probe for chromosome painting
 JOURNAL Patent: JP 2002527077-A 1 27-AUG-2002;
 GENSET

OS Artificial Sequence
 PN JP 2002527077-A/1
 PD 27-AUG-2002
 PF 15-OCT-1999 JP 2000576054
 PR 15-OCT-1998 FR 98/12957
 PI DORRA CHERIF
 PC C12N15/00, C12N15/09, C12N15/09, G01N21/78, G01N33/58, C12N15/00, PC
 CC primer PCR Alu
 FH Key
 FT primer bind Location/Qualifiers

FEATURES
 source 1..20
 Location/Qualifiers
 /db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTGCAGTGG 2790
 |||||
 Db 20 CCCAGGCTGGAGTGCAGTGG 1

RESULT 252

BD242655/c BD242655 20 bp DNA linear PAT 17-JUL-2003
 LOCUS
 DEFINITION ZINC finger peptide cleavage of nucleic acids.
 ACCESSION BD242655
 VERSION BD242655.1 GI:33052425
 KEYWORDS JP 2002526118-A/9.
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Lima,W.F., Crooke,S.T. and Manoharan,M.
 TITLE ZINC finger peptide cleavage of nucleic acids
 JOURNAL Patent: JP 2002526118-A 9 20-AUG-2002;
 ISIS PHARMACEUTICALS INC
 OS Artificial Sequence
 PN JP 2002526118-A/9
 PD 20-AUG-2002
 PF 06-OCT-1999 JP 2000574714
 PR 06-OCT-1998 US 60/103309
 PI WALT F LIMA, STANLEY T CROOKE, MUTHIAH MANOHARAN PC

FEATURES
 source 1..20
 Location/Qualifiers
 /db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTGCAGTGG 2790
 |||||
 Db 20 CCCAGGCTGGAGTGCAGTGG 1

RESULT 253

BD242888/c BD242888 20 bp DNA linear PAT 17-JUL-2003
 LOCUS
 DEFINITION Secreted proteins and polynucleotides encoding them.
 ACCESSION BD242888
 VERSION BD242888.1 GI:33052658
 KEYWORDS JP 2002536973-A/39.
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Valenzuela,D., Yuan,O., Hoffman,H., Hall,J. and Rapiejko,P.
 TITLE Secreted proteins and polynucleotides encoding them
 JOURNAL Patent: JP 2002536973-A 39 05-NOV-2002;
 ALPHAGEN INC
 OS Artificial Sequence
 PN JP 2002536973-A/39
 PD 05-NOV-2002
 PF 18-FEB-2000 JP 2000599860
 PR 19-FEB-1999 US 60/120680, 23-APR-1999 US 09/298733 PR
 17-AUG-1999 US 60/149639, 23-SEP-1999 US 60/155686 PR
 01-OCT-1999 US 60/157247, 29-NOV-1999 US 60/167823 PR
 29-NOV-1999 US 60/167822, 15-FEB-2000 US 60/182711 PI DARIO
 VALENZUELA, OLIVE YUAN, HEIDI HOFFMAN, JEFF HALL, PETER PI RAPIEJKO
 PC C12N15/09, A61K38/00, A61P3/10, A61P5/14, A61P11/00, A61P11/06, PC
 CC oligonucleotide
 FH Key
 FT source Location/Qualifiers

FEATURES
 source 1..20
 Location/Qualifiers
 /db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTGCAGTGG 2790
 |||||
 Db 20 CCCAGGCTGGAGTGCAGTGG 1

RESULT 254

BD267999/c BD267999 20 bp DNA linear PAT 17-JUL-2003
 LOCUS
 DEFINITION TCAAGTGATCCTCCACCTC 2847
 ACCESSION BD267999
 VERSION BD267999.1 GI:33052425
 KEYWORDS JP 2002526118-A/9.
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Lima,W.F., Crooke,S.T. and Manoharan,M.
 TITLE ZINC finger peptide cleavage of nucleic acids
 JOURNAL Patent: JP 2002526118-A 9 20-AUG-2002;
 ISIS PHARMACEUTICALS INC
 OS Artificial Sequence
 PN JP 2002526118-A/9
 PD 20-AUG-2002
 PF 06-OCT-1999 JP 2000574714
 PR 06-OCT-1998 US 60/103309
 PI WALT F LIMA, STANLEY T CROOKE, MUTHIAH MANOHARAN PC

FEATURES
 source 1..20
 Location/Qualifiers
 /db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2828 TCAAGTGATCCTCCACCTC 2847
 |||||
 Db 1 TCAAGTGATCCTCCACCTC 20

RESULT 254

BD267999/c BD267999 20 bp DNA linear PAT 17-JUL-2003
 LOCUS
 DEFINITION TCAAGTGATCCTCCACCTC 2847
 ACCESSION BD267999
 VERSION BD267999.1 GI:33052425
 KEYWORDS JP 2002526118-A/9.
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Lima,W.F., Crooke,S.T. and Manoharan,M.
 TITLE ZINC finger peptide cleavage of nucleic acids
 JOURNAL Patent: JP 2002526118-A 9 20-AUG-2002;
 ISIS PHARMACEUTICALS INC
 OS Artificial Sequence
 PN JP 2002526118-A/9
 PD 20-AUG-2002
 PF 06-OCT-1999 JP 2000574714
 PR 06-OCT-1998 US 60/103309
 PI WALT F LIMA, STANLEY T CROOKE, MUTHIAH MANOHARAN PC

FEATURES
 source 1..20
 Location/Qualifiers
 /db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2828 TCAAGTGATCCTCCACCTC 2847
 |||||
 Db 1 TCAAGTGATCCTCCACCTC 20

C12N15/09, C12N9/16, C12N15/00
 CC Description of Artificial Sequence: Artificial Sequence FH
 Key Location/Qualifiers
 FT source 1..20
 FT /Organism='Artificial Sequence'.
 FT Location/Qualifiers

FEATURES
 source 1..20
 Location/Qualifiers
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
 |||||
 Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 253

BD242888 LOCUS
 DEFINITION Secreted proteins and polynucleotides encoding them.
 ACCESSION BD242888
 VERSION BD242888.1 GI:33052658
 KEYWORDS JP 2002536973-A/39.
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Valenzuela,D., Yuan,O., Hoffman,H., Hall,J. and Rapiejko,P.
 TITLE Secreted proteins and polynucleotides encoding them
 JOURNAL Patent: JP 2002536973-A 39 05-NOV-2002;
 ALPHAGEN INC
 OS Artificial Sequence
 PN JP 2002536973-A/39
 PD 05-NOV-2002
 PF 18-FEB-2000 JP 2000599860
 PR 19-FEB-1999 US 60/120680, 23-APR-1999 US 09/298733 PR
 17-AUG-1999 US 60/149639, 23-SEP-1999 US 60/155686 PR
 01-OCT-1999 US 60/157247, 29-NOV-1999 US 60/167823 PR
 29-NOV-1999 US 60/167822, 15-FEB-2000 US 60/182711 PI DARIO
 VALENZUELA, OLIVE YUAN, HEIDI HOFFMAN, JEFF HALL, PETER PI RAPIEJKO
 PC C12N15/09, A61K38/00, A61P3/10, A61P5/14, A61P11/00, A61P11/06, PC
 CC oligonucleotide
 FH Key
 FT source Location/Qualifiers

FEATURES
 source 1..20
 Location/Qualifiers
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
 |||||
 Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 254

BD267999/c BD267999 20 bp DNA linear PAT 17-JUL-2003
 LOCUS
 DEFINITION TCAAGTGATCCTCCACCTC 2847
 ACCESSION BD267999
 VERSION BD267999.1 GI:33052425
 KEYWORDS JP 2002526118-A/9.
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Lima,W.F., Crooke,S.T. and Manoharan,M.
 TITLE ZINC finger peptide cleavage of nucleic acids
 JOURNAL Patent: JP 2002526118-A 9 20-AUG-2002;
 ISIS PHARMACEUTICALS INC
 OS Artificial Sequence
 PN JP 2002526118-A/9
 PD 20-AUG-2002
 PF 06-OCT-1999 JP 2000574714
 PR 06-OCT-1998 US 60/103309
 PI WALT F LIMA, STANLEY T CROOKE, MUTHIAH MANOHARAN PC

FEATURES
 source 1..20
 Location/Qualifiers
 /db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2828 TCAAGTGATCCTCCACCTC 2847
 |||||
 Db 1 TCAAGTGATCCTCCACCTC 20

RESULT 254

BD267999/c BD267999 20 bp DNA linear PAT 17-JUL-2003
 LOCUS
 DEFINITION TCAAGTGATCCTCCACCTC 2847
 ACCESSION BD267999
 VERSION BD267999.1 GI:33052425
 KEYWORDS JP 2002526118-A/9.
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Lima,W.F., Crooke,S.T. and Manoharan,M.
 TITLE ZINC finger peptide cleavage of nucleic acids
 JOURNAL Patent: JP 2002526118-A 9 20-AUG-2002;
 ISIS PHARMACEUTICALS INC
 OS Artificial Sequence
 PN JP 2002526118-A/9
 PD 20-AUG-2002
 PF 06-OCT-1999 JP 2000574714
 PR 06-OCT-1998 US 60/103309
 PI WALT F LIMA, STANLEY T CROOKE, MUTHIAH MANOHARAN PC

FEATURES
 source 1..20
 Location/Qualifiers
 /db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2828 TCAAGTGATCCTCCACCTC 2847
 |||||
 Db 1 TCAAGTGATCCTCCACCTC 20

DEFINITION Oligonucleotides having site specific chiral phosphorothioate internucleoside linkages.

ACCESSION BD267999

VERSION BD267999.1 GI:33077767

KEYWORDS JP 2002520420-A/1.

SOURCE synthetic construct

ORGANISM synthetic construct

REFERENCE 1 (bases 1 to 20)

AUTHORS Cook, P.D. and Manoharan, M.

TITLE Oligonucleotides having site specific chiral phosphorothioate internucleoside linkages

JOURNAL Patent: JP 2002520420-A 1 09-JUL-2002;

COMMENT ISIS PHARMACEUTICALS INC

PN JP 2002520420-A/1

PD 09-JUL-2002

PF 14-JUL-1999 JP 2000560140

PR 14-JUL-1998 US 09/115027

PI PHILIP DAN COOK, MUTHIAH MANOHARAN

PC C07H21/04, A61K31/7125, A61K48/00, C07H19/10, C07H19/20, C07H21/02, C12Q1/68

CC Antisense Sequence

FH Key Location/Qualifiers

FT source 1..20

FEATURES Location/Qualifiers

source 1..20

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 255

BD272006/c

LOCUS Multiparticulate formulation. 20 bp DNA linear PAT 17-JUL-2003

DEFINITION

ACCESSION BD272006

VERSION BD272006.1 GI:33081774

KEYWORDS JP 2002537343-A/2.

SOURCE synthetic construct

ORGANISM synthetic construct

REFERENCE 1 (bases 1 to 20)

AUTHORS Hardee, G.E., Tillman, L.G., Mehta, R.C. and Teng, C.L.

TITLE Multiparticulate formulation

JOURNAL Patent: JP 2002537343-A 2 05-NOV-2002;

COMMENT ISIS PHARMACEUTICALS INC

PN JP 2002537343-A/2

PD 05-NOV-2002

PF 23-FEB-2000 JP 2000600661

PR 23-FEB-1999 US 09/256515

PI GREGORY E HARDEE, LLOYD G TILLMAN, RAHUL C MEHTA, CHING LEOU TENG

PC A61K31/711, A61K9/20, A61K9/48, A61K47/12, A61K47/14, PC A61K47/28

CC A61K47/32, A61K47/38, A61K47/48, A61K48/00, A61P35/00 CC Novel

Sequence

FH Key Location/Qualifiers

FT source 1..20

FEATURES Location/Qualifiers

source 1..20

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 256

BD272108/c

LOCUS Fusogenic lipids and vesicles. 20 bp DNA linear PAT 17-JUL-2003

DEFINITION

ACCESSION BD272108

VERSION BD272108.1 GI:33081876

KEYWORDS JP 2002541089-A/2.

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 20)

AUTHORS Leamon, C.P.

TITLE Fusogenic lipids and vesicles

JOURNAL Patent: JP 2002541089-A 2 03-DEC-2002;

COMMENT ISIS PHARMACEUTICALS INC

PN JP 2002541089-A/2

PD 03-DEC-2002

PF 06-APR-2000 JP 2000609038

PR 06-APR-1999 US 09/287175

PI CHRISTOPHER PAUL LEAMON

PC C07C323/52, A61K9/127, A61K47/28, C07C323/60, C07F9/10, C07J9/00 CC

CC Oligonucleotide

FH Key Location/Qualifiers

FT source 1..20

FEATURES Location/Qualifiers

source 1..20

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 257

BD272196/c

LOCUS Strengthened antisense control of ICAM-1. 20 bp DNA linear PAT 17-JUL-2003

DEFINITION

ACCESSION BD272196

VERSION BD272196.1 GI:33081964

KEYWORDS JP 2002531378-A/2.

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 20)

AUTHORS Bennett, F.C., Condon, T.P. and Flournoy, S.C.

TITLE Strengthened antisense control of ICAM-1

JOURNAL Patent: JP 2002531378-A 2 24-SEP-2002;

COMMENT ISIS PHARMACEUTICALS INC

PN JP 2002531378-A/2

PD 24-SEP-2002

PF 15-APR-1999 JP 2000544679

PR 17-APR-1998 US 09/062416

PI FRANK C BENNETT, THOMAS P CONDON, SHIN CHENG FLOURNOY PC

```

C07H21/04,A61K31/711,A61K48/00,A61P9/10,A61P31/12,A61P31/18, PC
A61P43/00,
PC C12N15/09,C12Q1/68,C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Strengthened antisense control of ICAM-1
FH Key Location/Qualifiers
FT source 1..20
/organism='Unidentified'.
FEATURES
    source
        Location/Qualifiers
            1..20
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 258
BD272199/c
LOCUS BD272199 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Strengthened antisense control of ICAM-1.
ACCESSION BD272199
VERSION BD272199.1 GI:33081967
KEYWORDS JP 2002531378-A/5.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,F.C., Condon,T.P. and Flounoy,S.C.
TITLE Strengthened antisense control of ICAM-1
JOURNAL Patent: JP 2002531378-A 5 24-SEP-2002;
COMMENT ISIS PHARMACEUTICALS INC
OS Unidentified
PN JP 2002531378-A/5
PD 24-SEP-2002
PR 15-APR-1999 JP 2000544679
PR 17-APR-1998 US 03/062416
PI FRANK C BENNETT,THOMAS P CONDON,SHIN CHENG FLOURNOY PC
C07H21/04,A61K31/711,A61K48/00,A61P9/10,A61P31/12,A61P31/18, PC
A61P43/00,
PC C12N15/09,C12Q1/68,C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Strengthened antisense control of ICAM-1
FH Key Location/Qualifiers
FT source 1..20
/organism='Unidentified'.
FEATURES
    source
        Location/Qualifiers
            1..20
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2102 ACGGATGCCAGCTTGGGCAC 2121
Db 20 ACGGATGCCAGCTTGGGCAC 1

RESULT 259
BD272200/c
LOCUS BD272200 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Strengthened antisense control of ICAM-1.

```

```

ACCESSION BD272200
VERSION BD272200.1 GI:33081968
KEYWORDS JP 2002531378-A/6.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,F.C., Condon,T.P. and Flounoy,S.C.
TITLE Strengthened antisense control of ICAM-1
JOURNAL Patent: JP 2002531378-A 6 24-SEP-2002;
COMMENT ISIS PHARMACEUTICALS INC
OS Unidentified
PN JP 2002531378-A/6
PD 24-SEP-2002 JP 2000544679
PR 15-APR-1999 JP 2000544679
PR 17-APR-1998 US 09/062416
PI FRANK C BENNETT,THOMAS P CONDON,SHIN CHENG FLOURNOY PC
C07H21/04,A61K31/711,A61K48/00,A61P9/10,A61P31/12,A61P31/18, PC
A61P43/00,
PC C12N15/09,C12Q1/68,C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Strengthened antisense control of ICAM-1
FH Key Location/Qualifiers
FT source 1..20
/organism='Unidentified'.
FEATURES
    source
        Location/Qualifiers
            1..20
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

Query Match
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2106 ATGCCAGCTTGGGCACTGCT 2125
Db 20 ATGCCAGCTTGGGCACTGCT 1

RESULT 260
BD272205/c
LOCUS BD272205 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Strengthened antisense control of ICAM-1.
ACCESSION BD272205
VERSION BD272205.1 GI:33081973
KEYWORDS JP 2002531378-A/11.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,F.C., Condon,T.P. and Flounoy,S.C.
TITLE Strengthened antisense control of ICAM-1
JOURNAL Patent: JP 2002531378-A 11 24-SEP-2002;
COMMENT ISIS PHARMACEUTICALS INC
OS Unidentified
PN JP 2002531378-A/11
PD 24-SEP-2002 JP 2000544679
PR 15-APR-1999 JP 2000544679
PR 17-APR-1998 US 09/062416
PI FRANK C BENNETT,THOMAS P CONDON,SHIN CHENG FLOURNOY PC
C07H21/04,A61K31/711,A61K48/00,A61P9/10,A61P31/12,A61P31/18, PC
A61P43/00,
PC C12N15/09,C12Q1/68,C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Strengthened antisense control of ICAM-1
FH Key Location/Qualifiers
FT source 1..20
/organism='Unidentified'.
FEATURES
    source
        Location/Qualifiers
            1..20
            /organism="unidentified"
            /mol_type="genomic DNA"
            /db_xref="taxon:32644"

```


Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 279 CAACCGGAAGGTGTATGAAC 298
|||||
Db 20 CAACCGGAAGGTGTATGAAC 1

RESULT 265
I13817/c I13817 20 bp DNA linear PAT 26-SEP-1995
LOCUS
DEFINITION Sequence 25 from patent US 5442049.
ACCESSION I13817
VERSION I13817.1 GI:996247

KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Anderson,K., Draper,K. and Baker,B.
TITLE Oligonucleotides for modulating the effects of cytomegalovirus
infections

JOURNAL Patent: US 5442049-A 25 15-AUG-1995;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 266
I20604/c I20604 20 bp DNA linear PAT 07-OCT-1996
LOCUS
DEFINITION Sequence 2 from patent US 5514788.
ACCESSION I20604

VERSION I20604.1 GI:1600959
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion

JOURNAL Patent: US 5514788-A 2 07-MAY-1996;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
|||||
Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 267
I20609/c I20609 20 bp DNA linear PAT 07-OCT-1996
LOCUS
DEFINITION Sequence 7 from patent US 5514788.
ACCESSION I20609

VERSION I20609.1 GI:1600964
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion

JOURNAL Patent: US 5514788-A 7 07-MAY-1996;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCTCGCTATG 60
|||||
Db 20 GCAACCTCAGCCTCGCTATG 1

RESULT 268
I20610/c I20610 20 bp DNA linear PAT 07-OCT-1996
LOCUS
DEFINITION Sequence 8 from patent US 5514788.
ACCESSION I20610

VERSION I20610.1 GI:1600965
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion

JOURNAL Patent: US 5514788-A 8 07-MAY-1996;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCAGCAGCCCCCG 77
|||||
Db 20 ATGGCTCCAGCAGCCCCCG 1

RESULT 269
I20611/c I20611 20 bp DNA linear PAT 07-OCT-1996
LOCUS
DEFINITION Sequence 9 from patent US 5514788.
ACCESSION I20611

VERSION I20611.1 GI:1600966
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion

JOURNAL Patent: US 5514788-A 9 07-MAY-1996;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGTCCTGCTCGGGGCTCT 116

JOURNAL	Patent: US 5514788-A 12 07-MAY-1996;
FEATURES	Location/Qualifiers
source	1..20
	/organism="unknown"
	/mol_type="unassigned DNA"
Query Match	0.7%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 1.9e+02;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1445 AAGGGGAGGTCAACCCCGGAG 1464
Db	20 AAGGGGAGGTCAACCCCGGAG 1
RESULT 273	
LOCUS	I20615 20 bp DNA linear PAT 07-OCT-1996
DEFINITION	Sequence 13 from patent US 5514788.
ACCESSION	I20615
VERSION	I20615.1 GI:1600970
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 20)
AUTHORS	Bennett,C.Frank. and Mirabelli,C.K.
TITLE	Oligonucleotide modulation of cell adhesion
JOURNAL	Patent: US 5514788-A 13 07-MAY-1996;
FEATURES	Location/Qualifiers
source	1..20
	/organism="unknown"
	/mol_type="unassigned DNA"
Query Match	0.7%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 1.9e+02;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1637 CACAAGCCACGGCTCCCTGA 1656
Db	20 CACAAGCCACGGCTCCCTGA 1
RESULT 274	
LOCUS	I20616/20 bp DNA linear PAT 07-OCT-1996
DEFINITION	Sequence 14 from patent US 5514788.
ACCESSION	I20616
VERSION	I20616.1 GI:1600971
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 20)
AUTHORS	Bennett,C.Frank. and Mirabelli,C.K.
TITLE	Oligonucleotide modulation of cell adhesion
JOURNAL	Patent: US 5514788-A 14 07-MAY-1996;
FEATURES	Location/Qualifiers
source	1..20
	/organism="unknown"
	/mol_type="unassigned DNA"
Query Match	0.7%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 1.9e+02;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1654 TGAACCTATCCCGGACAGG 1673
Db	20 TGAACCTATCCCGGACAGG 1
RESULT 275	
LOCUS	I20617/20 bp DNA linear PAT 07-OCT-1996
DEFINITION	Sequence 15 from patent US 5514788.
ACCESSION	I20617
VERSION	I20617.1 GI:1600972
KEYWORDS	.
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 20)
AUTHORS	Bennett,C.Frank. and Mirabelli,C.K.
TITLE	Oligonucleotide modulation of cell adhesion
JOURNAL	Patent: US 5514788-A 15 07-MAY-1996;
FEATURES	Location/Qualifiers
source	1..20
	/organism="unknown"
	/mol_type="unassigned DNA"
Query Match	0.7%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 1.9e+02;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1673 TGAACTTATCCCGGACAGG 1692
Db	20 TGAACTTATCCCGGACAGG 1

LOCUS 120617 20 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 15 from patent US 5514788.
ACCESSION 120617
VERSION 120617.1 GI:1600972
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 15 07-MAY-1996;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 276
120618/c
LOCUS 120618 20 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 16 from patent US 5514788.
ACCESSION 120618
VERSION 120618.1 GI:1600973
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 16 07-MAY-1996;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAAGCTTCTCTCAA 2981
|||||
Db 20 AGTTAATAAAGCTTCTCTCAA 1

RESULT 277
120624/c
LOCUS 120624 20 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 22 from patent US 5514788.
ACCESSION 120624
VERSION 120624.1 GI:1600979
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 22 07-MAY-1996;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TCACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TCACGGATGCCAGCTTGGGC 1

RESULT 278
120625/c
LOCUS 120625 20 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 23 from patent US 5514788.
ACCESSION 120625
VERSION 120625.1 GI:1600980
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 23 07-MAY-1996;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
|||||
Db 20 GAGGCCACAGACTTACAGA 1

RESULT 279
120626/c
LOCUS 120626 20 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 24 from patent US 5514788.
ACCESSION 120626
VERSION 120626.1 GI:1600981
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 24 07-MAY-1996;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900
|||||
Db 20 CAAGAGGAGGAGCAAGACT 1

RESULT 280
120627/c
LOCUS 120627 20 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 25 from patent US 5514788.
ACCESSION 120627
VERSION 120627.1 GI:1600982
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 25 07-MAY-1996;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAGTCTAGCCTGATGAG 1940
|||||
Db 20 TTAAGTCTAGCCTGATGAG 1

RESULT 281
I20628/c
LOCUS 120628 20 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 26 from patent US 5514788.
ACCESSION I20628
VERSION I20628.1 GI:1600983
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 26 07-MAY-1996;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCACCATGAGGACA 1981
|||||
Db 20 ATAGCCCCACCATGAGGACA 1

RESULT 282
I20686/c
LOCUS 120686 20 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 84 from patent US 5514788.
ACCESSION I20686
VERSION I20686.1 GI:1601041
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 84 07-MAY-1996;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||

Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 283
I20687/c
LOCUS 120687 20 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 85 from patent US 5514788.
ACCESSION I20687
VERSION I20687.1 GI:1601042
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 85 07-MAY-1996;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGGTGGGGGAGACATA 1964
|||||
Db 20 GAAGTGGTGGGGGAGACATA 1

RESULT 284
I29010/c
LOCUS 129010 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 6 from patent US 5576302.
ACCESSION I29010
VERSION I29010.1 GI:1819801
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cook,P.D. and Hoke,G.
TITLE Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
JOURNAL Patent: US 5576302-A 6 19-NOV-1996;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 285
I32393/c
LOCUS 132393 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 6 from patent US 5587361.
ACCESSION I32393
VERSION I32393.1 GI:1823184
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cook,P.D. and Hoke,G.
TITLE Oligonucleotides having phosphorothioate linkages of high chiral


```

Purity
JOURNAL Patent: US 5587361-A 6 24-DEC-1996;
FEATURES Location/Qualifiers
source
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 286
I33297/c
LOCUS I33297 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 2 from patent US 5591623.
ACCESSION I33297
VERSION I33297.1 GI:1824088
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 2 07-JAN-1997;
FEATURES Location/Qualifiers
source
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
|||||
Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 287
I33302/c
LOCUS I33302 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 7 from patent US 5591623.
ACCESSION I33302
VERSION I33302.1 GI:1824093
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 7 07-JAN-1997;
FEATURES Location/Qualifiers
source
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCACCTCAGCCTCGCTATG 60
|||||
Db 20 GCACCTCAGCCTCGCTATG 1

RESULT 288
I33297/c
LOCUS I33297 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 2 from patent US 5591623.
ACCESSION I33297
VERSION I33297.1 GI:1824088
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 2 07-JAN-1997;
FEATURES Location/Qualifiers
source
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 286
I33297/c
LOCUS I33297 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 2 from patent US 5591623.
ACCESSION I33297
VERSION I33297.1 GI:1824088
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 2 07-JAN-1997;
FEATURES Location/Qualifiers
source
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
|||||
Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 287
I33302/c
LOCUS I33302 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 7 from patent US 5591623.
ACCESSION I33302
VERSION I33302.1 GI:1824093
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 7 07-JAN-1997;
FEATURES Location/Qualifiers
source
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCACCTCAGCCTCGCTATG 60
|||||
Db 20 GCACCTCAGCCTCGCTATG 1

RESULT 288
I33303/c
LOCUS I33303 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 8 from patent US 5591623.
ACCESSION I33303
VERSION I33303.1 GI:1824094
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 8 07-JAN-1997;
FEATURES Location/Qualifiers
source
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCAGCAGCCCG 77
|||||
Db 20 ATGGCTCCAGCAGCCCG 1

RESULT 289
I33304/c
LOCUS I33304 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 9 from patent US 5591623.
ACCESSION I33304
VERSION I33304.1 GI:1824095
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 9 07-JAN-1997;
FEATURES Location/Qualifiers
source
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTGCTCGGGCTCT 116
|||||
Db 20 CTGGTCTGCTCGGGCTCT 1

RESULT 290
I33305/c
LOCUS I33305 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 10 from patent US 5591623.
ACCESSION I33305
VERSION I33305.1 GI:1824096
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 10 07-JAN-1997;
FEATURES Location/Qualifiers
source
1..20
/mol_type="unknown"
/mol_type="unassigned DNA"
```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAACTGCCTGATGGCA 356
|||||
Db 20 TCAACTGCCTGATGGCA 1

RESULT 291
I33306/c
LOCUS I33306 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 11 from patent US 5591623..
ACCESSION I33306
VERSION I33306.1 GI:1824097
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 11 07-JAN-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGACC 894
|||||
Db 20 AGGCCTCAGTCAGTGACC 1

RESULT 292
I33307/c
LOCUS I33307 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 12 from patent US 5591623.
ACCESSION I33307
VERSION I33307.1 GI:1824098
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 12 07-JAN-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGAGGTCACTCCGCGAG 1464
|||||
Db 20 AAGGGAGGTCACTCCGCGAG 1

RESULT 293
I33308/c
LOCUS I33308 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 13 from patent US 5591623.
ACCESSION I33308
VERSION I33308.1 GI:1824099
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 13 07-JAN-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCAGGCTCCCTGA 1656
|||||
Db 20 CACAAGCCAGGCTCCCTGA 1

RESULT 294
I33309/c
LOCUS I33309 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 14 from patent US 5591623.
ACCESSION I33309
VERSION I33309.1 GI:1824100
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 14 07-JAN-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
|||||
Db 20 TGAACCTATCCCGGACAGG 1

RESULT 295
I33310/c
LOCUS I33310 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 15 from patent US 5591623.
ACCESSION I33310
VERSION I33310.1 GI:1824101
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 15 07-JAN-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957

Db 20 GAGAGGGGAAGTGGTGGGG 1
|||||
RESULT 296
I33311/c
LOCUS I33311 linear PAT 06-FEB-1997
DEFINITION Sequence 16 from patent US 5591623.
ACCESSION I33311
VERSION I33311.1 GI:1824102
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 16 07-JAN-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2962 AGTTAATAAAGCTTCTCAA 2981
|||||
Db 20 AGTTAATAAAGCTTCTCAA 1
|||||
RESULT 297
I33317/c
LOCUS I33317 linear PAT 06-FEB-1997
DEFINITION Sequence 22 from patent US 5591623.
ACCESSION I33317
VERSION I33317.1 GI:1824108
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 22 07-JAN-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTGGGC 1
|||||
RESULT 298
I33318/c
LOCUS I33318 linear PAT 06-FEB-1997
DEFINITION Sequence 23 from patent US 5591623.
ACCESSION I33318
VERSION I33318.1 GI:1824109
KEYWORDS
SOURCE
ORGANISM
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion

JOURNAL Patent: US 5591623-A 23 07-JAN-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2025 GAGGCCACAGACTTACAGA 2044
|||||
Db 20 GAGGCCACAGACTTACAGA 1
|||||
RESULT 299
I33319/c
LOCUS I33319 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 24 from patent US 5591623.
ACCESSION I33319
VERSION I33319.1 GI:1824110
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 24 07-JAN-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1881 CAAGAGGAAGGAGCAAGACT 1900
|||||
Db 20 CAAGAGGAAGGAGCAAGACT 1
|||||
RESULT 300
I33320/c
LOCUS I33320 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 25 from patent US 5591623.
ACCESSION I33320
VERSION I33320.1 GI:1824111
KEYWORDS
SOURCE
ORGANISM
Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 25 07-JAN-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1921 TTAAAGTCTAGCCTGATGAG 1940
|||||
Db 20 TTAAAGTCTAGCCTGATGAG 1
|||||
RESULT 301
I33321/c

LOCUS I33321 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 26 from patent US 5591623.
ACCESSION I33321
VERSION I33321.1 GI:1824112
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett, C. Frank, and Mirabelli, C. K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 26 07-JAN-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCCACCATGAGGACA 1981
Db 20 ATAGCCCCCACCATGAGGACA 1

RESULT 302
I33451/c
LOCUS I33451 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 25 from patent US 5591720.
ACCESSION I33451
VERSION I33451.1 GI:1824242
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Anderson, K. P. and Draper, K. G.
TITLE Oligonucleotides for modulating the effects of cytomegalovirus infections
JOURNAL Patent: US 5591720-A 25 07-JAN-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 303
I36646/c
LOCUS I36646 20 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 6 from patent US 5607923.
ACCESSION I36646
VERSION I36646.1 GI:2086471
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cook, P. D. and Hoke, G.
TITLE Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
JOURNAL Patent: US 5607923-A 6 04-MAR-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 304
I40395/c
LOCUS I40395 20 bp DNA linear PAT 13-MAY-1997
DEFINITION Sequence 6 from patent US 5620963.
ACCESSION I40395
VERSION I40395.1 GI:2082687
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cook, P. D. and Hoke, G.
TITLE Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
JOURNAL Patent: US 5620963-A 6 15-APR-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 305
I59717/c
LOCUS I59717 20 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 6 from patent US 5654284.
ACCESSION I59717
VERSION I59717.1 GI:2478349
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cook, P. D. and Hoke, G.
TITLE Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
JOURNAL Patent: US 5654284-A 6 05-AUG-1997;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 306
I63126/c
LOCUS I63126 20 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 6 from patent US 5661134.

ACCESSION 163126
VERSION 163126.1 GI:2480834
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cook, P. Dan. and Hoke, G.
TITLE Oligonucleotides for modulating Ha-ras or Ki-ras having
phosphorothioate linkages of high chiral purity
JOURNAL Patent: US 5661134-A 6 26-AUG-1997;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 307
184733/c
LOCUS 184733 20 bp DNA linear PAT 04-APR-1998
DEFINITION Sequence 21 from patent US 5696248.
ACCESSION 184733
VERSION 184733.1 GI:3022253
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Peyman, A., Uhlmann, E. and Carolus, C.
TITLE 3'-modified oligonucleotide derivatives
JOURNAL Patent: US 5696248-A 21 09-DEC-1997;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAAGTGGTGGGG 1957
Db 20 GAGAGGGGAAGTGGTGGGG 1
RESULT 308
184734/c
LOCUS 184734 20 bp DNA linear PAT 04-APR-1998
DEFINITION Sequence 22 from patent US 5696248.
ACCESSION 184734
VERSION 184734.1 GI:3022254
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Peyman, A., Uhlmann, E. and Carolus, C.
TITLE 3'-modified oligonucleotide derivatives
JOURNAL Patent: US 5696248-A 22 09-DEC-1997;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1940 GAGGGGAAGTGGTGGGGAG 1959
Db 20 GAGGGGAAGTGGTGGGGAG 1
RESULT 309
AR179697/c
LOCUS AR179697 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 2 from patent US 6326478.
ACCESSION AR179697
VERSION AR179697.1 GI:20221252
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cheruvallath, Z. S., Ravikumar, V. T. and Cole, D. L.
TITLE Process for the synthesis of oligomeric compounds
JOURNAL Patent: US 6326478-A 2 04-DEC-2001;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 310
AR179818/c
LOCUS AR179818 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 21 from patent US 6326487.
ACCESSION AR179818
VERSION AR179818.1 GI:20221373
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Peyman, A., Uhlmann, E. and Carolus, C.
TITLE 3 modified oligonucleotide derivatives
JOURNAL Patent: US 6326487-A 21 04-DEC-2001;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAAGTGGTGGGG 1957
Db 20 GAGAGGGGAAGTGGTGGGG 1
RESULT 311
AR179819/c
LOCUS AR179819 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 22 from patent US 6326487.
ACCESSION AR179819
VERSION AR179819.1 GI:20221374
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Peyman,A., Uhlmann,E. and Carolus,C.
TITLE 3 modified oligonucleotide derivatives
JOURNAL Patent: US 6326487-A 22 04-DEC-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGGAG 1959
|||||
Db 20 GAGGGGAAGTGGTGGGGGAG 1

RESULT 312
AR182819/c
LOCUS AR182819 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 127 from patent US 6339066.
ACCESSION AR182819
VERSION AR182819.1 GI:20226026
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.Frank., Dean,N.M., Cook,F.Dan. and Hoke,G.
TITLE Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate beta.I., beta.II., gamma., delta., .EPSILON., zeta. and .eta. isoforms of human protein kinase C
JOURNAL Patent: US 6339066-A 127 15-JAN-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 313
AR193525/c
LOCUS AR193525 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 29 from patent US 6348312.
ACCESSION AR193525
VERSION AR193525.1 GI:20240117
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Peyman,A., Uhlmann,E., Mag,M., Kretzschmar,G., Helsberg,M. and Winkler,I.
TITLE Stabilized oligonucleotides and their use
JOURNAL Patent: US 6348312-A 29 19-FEB-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGGG 1

RESULT 314
AR193526/c
LOCUS AR193526 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 30 from patent US 6348312.
ACCESSION AR193526
VERSION AR193526.1 GI:20240118
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Peyman,A., Uhlmann,E., Mag,M., Kretzschmar,G., Helsberg,M. and Winkler,I.
TITLE Stabilized oligonucleotides and their use
JOURNAL Patent: US 6348312-A 30 19-FEB-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGGAG 1959
|||||
Db 20 GAGGGGAAGTGGTGGGGGAG 1

RESULT 315
AR199510/c
LOCUS AR199510 20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1 from patent US 6355438.
ACCESSION AR199510
VERSION AR199510.1 GI:20249584
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Baker,B.F., Yu,Z. and Leeds,J.M.
TITLE Method for quantitating oligonucleotides
JOURNAL Patent: US 6355438-A 1 12-MAR-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 316
AR203443/c
LOCUS AR203443 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 10 from patent US 6365379.
ACCESSION AR203443
VERSION AR203443.1 GI:21499833
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Lima,W.F., Crooke,S.T. and Manoharan,M.
TITLE Zinc finger peptide cleavage of nucleic acids
JOURNAL Patent: US 6365373-A 10 02-APR-2002;
FEATURES
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1
RESULT 317
AR207551/c
LOCUS AR207551 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 2 from patent US 6379698.
ACCESSION AR207551
VERSION AR207551.1 GI:21507334
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Leamon,C.Paul.
TITLE Fusogenic lipids and vesicles
JOURNAL Patent: US 6379698-A 2 30-APR-2002;
FEATURES
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 318
AR212315/c
LOCUS AR212315 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 2 from patent US 6399756.
ACCESSION AR212315
VERSION AR212315.1 GI:21515856
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cheruvallath,Z.S., Ravikumar,V.T. and Cole,D.L.
TITLE Process for the synthesis of oligomeric compounds
JOURNAL Patent: US 6399756-A 2 04-JUN-2002;
FEATURES
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 319
AR212329/c
LOCUS AR212329 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 11 from patent US 6399757.
ACCESSION AR212329
VERSION AR212329.1 GI:21515874
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Cook,P.Dan.
TITLE Oligonucleotide and nucleotide amine analogs, methods of synthesis and use
JOURNAL Patent: US 6399757-A 11 04-JUN-2002;
FEATURES
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1
RESULT 320
AR212509/c
LOCUS AR212509 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 1 from patent US 6399765.
ACCESSION AR212509
VERSION AR212509.1 GI:21516103
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Krotz,A.H., McElroy,B.M. and Scozzari,A.N.
TITLE Methods for removing dimethoxytrityl groups from oligonucleotides
JOURNAL Patent: US 6399765-A 1 04-JUN-2002;
FEATURES
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 321
AR224787/c
LOCUS AR224787 20 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 1 from patent US 6440943.
ACCESSION AR224787
VERSION AR224787.1 GI:23333697
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cook,P.D. and Manoharan,M.
TITLE Oligonucleotides having site specific chiral phosphorothioate internucleoside linkages
JOURNAL Patent: US 6440943-A 1 27-AUG-2002;

```
FEATURES
source      Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 322
AR236090/c
LOCUS      AR236090      20 bp      DNA      linear      PAT 20-DEC-2002
DEFINITION Sequence 8 from patent US 6462184.
ACCESSION  AR236090
VERSION     AR236090.1 GI:27279789
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Manoharan,M. and Maier,M.A.
TITLE      Compounds, processes and intermediates for synthesis of mixed
           backbone oligomeric compounds
JOURNAL    Patent: US 6462184-A 8 08-OCT-2002;
FEATURES    Location/Qualifiers
source      1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCGTCTACTCAGA 37
|||||
Db 20 GAGCTCCTCGTCTACTCAGA 1

RESULT 323
AR237464/c
LOCUS      AR237464      20 bp      DNA      linear      PAT 20-DEC-2002
DEFINITION Sequence 2 from patent US 6465628.
ACCESSION  AR237464
VERSION     AR237464.1 GI:27282214
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Ravikumar,V.T., Manoharan,M., Capaldi,D.C., Krotz,A., Cole,D.L. and
           Guzaev,A.
TITLE      Process for the synthesis of oligomeric compounds
JOURNAL    Patent: US 6465628-A 2 15-OCT-2002;
FEATURES    Location/Qualifiers
source      1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 324
AR237466/c
LOCUS      AR237466      20 bp      DNA      linear      PAT 20-DEC-2002
DEFINITION Sequence 4 from patent US 6465628.
ACCESSION  AR237466
VERSION     AR237466.1 GI:27282216
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Ravikumar,V.T., Manoharan,M., Capaldi,D.C., Krotz,A., Cole,D.L. and
           Guzaev,A.
TITLE      Process for the synthesis of oligomeric compounds
JOURNAL    Patent: US 6465628-A 4 15-OCT-2002;
FEATURES    Location/Qualifiers
source      1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 325
AR254168/c
LOCUS      AR254168      20 bp      DNA      linear      PAT 20-DEC-2002
DEFINITION Sequence 20 from patent US 6479651.
ACCESSION  AR254168
VERSION     AR254168.1 GI:27302905
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Seela,F. and Thomas,H.
TITLE      Modified oligonucleotides, their preparation and their use
JOURNAL    Patent: US 6479651-A 20 12-NOV-2002;
FEATURES    Location/Qualifiers
source      1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 326
AR254169/c
LOCUS      AR254169      20 bp      DNA      linear      PAT 20-DEC-2002
DEFINITION Sequence 21 from patent US 6479651.
ACCESSION  AR254169
VERSION     AR254169.1 GI:27302906
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 20)
AUTHORS    Seela,F. and Thomas,H.
TITLE      Modified oligonucleotides, their preparation and their use
JOURNAL    Patent: US 6479651-A 21 12-NOV-2002;
FEATURES    Location/Qualifiers
source      1..20
/organism="unknown"
/mol_type="genomic DNA"
```


/mol_type="genomic DNA"		AR321577.1		GI:33706806
Query Match		Unknown.		
Best Local Similarity		0.7%; Score 20; DB 1; Length 20;		
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Qy	1940 GAGGGGAAGTGGTGGGGAG 1959	Unclassified.		
Db	20 GAGGGGAAGTGGTGGGGAG 1	1 (bases 1 to 20)		
REFERENCE		Cherif,D.		
AUTHORS		Detection of altered expression of genes regulating cell		
TITLE		proliferation		
JOURNAL		Patent: US 6562959-A 1 13-MAY-2003;		
FEATURES		Location/Qualifiers		
source		1..20		
/organism="unknown"		/mol_type="genomic DNA"		
Query Match		0.7%; Score 20; DB 1; Length 20;		
Best Local Similarity		100.0%; Pred. No. 1.9e+02;		
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Qy	2771 CCCAGGCTGGAGTCAGTGG 2790	Unclassified.		
Db	20 CCCAGGCTGGAGTCAGTGG 1	1 (bases 1 to 20)		
REFERENCE		Shukla,A.A., Deshmukh,R.R., Cramer,S.M. and Moore,J.A.		
AUTHORS		High affinity, low molecular weight displacers for oligonucleotide		
TITLE		purification		
JOURNAL		Patent: US 6573373-A 1 03-JUN-2003;		
FEATURES		Location/Qualifiers		
source		1..20		
/organism="unknown"		/mol_type="genomic DNA"		
Query Match		0.7%; Score 20; DB 1; Length 20;		
Best Local Similarity		100.0%; Pred. No. 1.9e+02;		
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Qy	2100 TGACGGATGCCAGCTTGGGC 2119	Unclassified.		
Db	20 TGACGGATGCCAGCTTGGGC 1	1 (bases 1 to 20)		
REFERENCE		Manoharan,M., Lonnberg,H., Salo,H. and Virta,P.		
AUTHORS		Aminoxy functionalized oligomers		
TITLE		Patent: US 6576752-A 5 10-JUN-2003;		
JOURNAL		Location/Qualifiers		
FEATURES		1..20		
source		/organism="unknown"		
/mol_type="genomic DNA"		/mol_type="genomic DNA"		
Query Match		0.7%; Score 20; DB 1; Length 20;		
Best Local Similarity		100.0%; Pred. No. 1.9e+02;		
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Qy	18 GAGCTCCTCGTACTCAGA 37	Unclassified.		
Db	20 GAGCTCCTCGTACTCAGA 1	1 (bases 1 to 20)		
REFERENCE		Manoharan,M. and Guzaev,A.P.		
AUTHORS		Process for preparing peptide derivatized oligomeric compounds		
TITLE		Patent: US 6559279-A 4 06-MAY-2003;		
JOURNAL		Location/Qualifiers		
FEATURES		1..20		
source		/organism="unknown"		
/mol_type="genomic DNA"		/mol_type="genomic DNA"		
Query Match		0.7%; Score 20; DB 1; Length 20;		
Best Local Similarity		100.0%; Pred. No. 1.9e+02;		
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Qy	18 GAGCTCCTCGTACTCAGA 37	Unclassified.		
Db	20 GAGCTCCTCGTACTCAGA 1	1 (bases 1 to 20)		
REFERENCE		Manoharan,M. and Guzaev,A.P.		
AUTHORS		Process for preparing peptide derivatized oligomeric compounds		
TITLE		Patent: US 6559279-A 4 06-MAY-2003;		
JOURNAL		Location/Qualifiers		
FEATURES		1..20		
source		/organism="unknown"		
/mol_type="genomic DNA"		/mol_type="genomic DNA"		
Query Match		0.7%; Score 20; DB 1; Length 20;		
Best Local Similarity		100.0%; Pred. No. 1.9e+02;		
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Qy	18 GAGCTCCTCGTACTCAGA 37	Unclassified.		
Db	20 GAGCTCCTCGTACTCAGA 1	1 (bases 1 to 20)		
REFERENCE		Manoharan,M. and Guzaev,A.P.		
AUTHORS		Process for preparing peptide derivatized oligomeric compounds		
TITLE		Patent: US 6559279-A 4 06-MAY-2003;		
JOURNAL		Location/Qualifiers		
FEATURES		1..20		
source		/organism="unknown"		
/mol_type="genomic DNA"		/mol_type="genomic DNA"		
Query Match		0.7%; Score 20; DB 1; Length 20;		
Best Local Similarity		100.0%; Pred. No. 1.9e+02;		
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Qy	18 GAGCTCCTCGTACTCAGA 37	Unclassified.		
Db	20 GAGCTCCTCGTACTCAGA 1	1 (bases 1 to 20)		
REFERENCE		Manoharan,M. and Guzaev,A.P.		
AUTHORS		Process for preparing peptide derivatized oligomeric compounds		
TITLE		Patent: US 6559279-A 4 06-MAY-2003;		
JOURNAL		Location/Qualifiers		
FEATURES		1..20		
source		/organism="unknown"		
/mol_type="genomic DNA"		/mol_type="genomic DNA"		
Query Match		0.7%; Score 20; DB 1; Length 20;		
Best Local Similarity		100.0%; Pred. No. 1.9e+02;		
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Qy	18 GAGCTCCTCGTACTCAGA 37	Unclassified.		
Db	20 GAGCTCCTCGTACTCAGA 1	1 (bases 1 to 20)		
REFERENCE		Manoharan,M. and Guzaev,A.P.		
AUTHORS		Process for preparing peptide derivatized oligomeric compounds		
TITLE		Patent: US 6559279-A 4 06-MAY-2003;		
JOURNAL		Location/Qualifiers		
FEATURES		1..20		
source		/organism="unknown"		
/mol_type="genomic DNA"		/mol_type="genomic DNA"		
Query Match		0.7%; Score 20; DB 1; Length 20;		
Best Local Similarity		100.0%; Pred. No. 1.9e+02;		
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Qy	18 GAGCTCCTCGTACTCAGA 37	Unclassified.		
Db	2			

Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCTCTGCTACTCAGA 1

RESULT 332
AR351594/c
LOCUS AR351594 20 bp DNA PAT 17-AUG-2003
DEFINITION Sequence 1 from patent US 6586586.
ACCESSION AR351594
VERSION AR351594.1 GI:33753389
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Krotz,A.H. and Ravikumar,V.T.
TITLE Purification of oligonucleotides
JOURNAL Patent: US 6586586-A 1 01-JUL-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 333
AR351595/c
LOCUS AR351595 20 bp DNA PAT 17-AUG-2003
DEFINITION Sequence 2 from patent US 6586586.
ACCESSION AR351595
VERSION AR351595.1 GI:33753390
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Krotz,A.H. and Ravikumar,V.T.
TITLE Purification of oligonucleotides
JOURNAL Patent: US 6586586-A 2 01-JUL-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 334
AR370527/c
LOCUS AR370527 20 bp DNA PAT 12-SEP-2003
DEFINITION Sequence 2 from patent US 6300491.
ACCESSION AR370527
VERSION AR370527.1 GI:34607280
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
1 (bases 1 to 20)
Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 2 09-OCT-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
|||||
Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 335
AR370532/c
LOCUS AR370532 20 bp DNA PAT 12-SEP-2003
DEFINITION Sequence 7 from patent US 6300491.
ACCESSION AR370532
VERSION AR370532.1 GI:34607285
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 7 09-OCT-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCTCGCTATG 60
|||||
Db 20 GCAACCTCAGCCTCGCTATG 1

RESULT 336
AR370533/c
LOCUS AR370533 20 bp DNA PAT 12-SEP-2003
DEFINITION Sequence 8 from patent US 6300491.
ACCESSION AR370533
VERSION AR370533.1 GI:34607286
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 8 09-OCT-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCAGCAGCCCCCG 77
|||||
Db 20 ATGGCTCCAGCAGCCCCCG 1

```
RESULT 337
AR370534/c
LOCUS
DEFINITION Sequence 9 from patent US 6300491.
ACCESSION AR370534
VERSION AR370534.1 GI:34607287
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 9 09-OCT-2001;
FEATURES
source
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTGCTCGGGGCTCT 116
Db 20 CTGGTCTGCTCGGGGCTCT 1

RESULT 338
AR370535/c
LOCUS
DEFINITION Sequence 10 from patent US 6300491.
ACCESSION AR370535
VERSION AR370535.1 GI:34607288
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 10 09-OCT-2001;
FEATURES
source
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAACTGCCCTGATGGCA 356
Db 20 TCAACTGCCCTGATGGCA 1

RESULT 339
AR370536/c
LOCUS
DEFINITION Sequence 11 from patent US 6300491.
ACCESSION AR370536
VERSION AR370536.1 GI:34607289
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 11 09-OCT-2001;
FEATURES
source
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCACGCCTCCCTGA 1656
Db 20 CACAAGCCACGCCTCCCTGA 1

RESULT 340
AR370537/c
LOCUS
DEFINITION Sequence 12 from patent US 6300491.
ACCESSION AR370537
VERSION AR370537.1 GI:34607290
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 12 09-OCT-2001;
FEATURES
source
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGTGACC 894
Db 20 AGGCCTCAGTCAGTGTGACC 1

RESULT 341
AR370538/c
LOCUS
DEFINITION Sequence 13 from patent US 6300491.
ACCESSION AR370538
VERSION AR370538.1 GI:34607291
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 13 09-OCT-2001;
FEATURES
source
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGGAGGTACCCCGCAG 1464
Db 20 AAGGGGAGGTACCCCGCAG 1

RESULT 342
AR370539/c
LOCUS
DEFINITION Sequence 14 from patent US 6300491.
ACCESSION AR370539
VERSION AR370539.1 GI:34607292
KEYWORDS
SOURCE
ORGANISM
REFERENCE
1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 14 09-OCT-2001;
FEATURES
source
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCACGCCTCCCTGA 1656
Db 20 CACAAGCCACGCCTCCCTGA 1
```

ACCESSION AR370539
VERSION AR370539.1 GI:34607292
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 14 09-OCT-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1654 TGAACCTATCCGGGACAGG 1673
Db 20 TGAACCTATCCGGGACAGG 1
RESULT 343
AR370540/c
LOCUS AR370540 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 15 from patent US 6300491.
ACCESSION AR370540
VERSION AR370540.1 GI:34607293
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 15 09-OCT-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAAGTGGTGGGG 1957
Db 20 GAGAGGGGAAGTGGTGGGG 1
RESULT 344
AR370541/c
LOCUS AR370541 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 16 from patent US 6300491.
ACCESSION AR370541
VERSION AR370541.1 GI:34607294
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 16 09-OCT-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2962 AGTTAATAAGCTTCTCAA 2981
Db 20 AGTTAATAAGCTTCTCAA 1
RESULT 345
AR370547/c
LOCUS AR370547 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 22 from patent US 6300491.
ACCESSION AR370547
VERSION AR370547.1 GI:34607300
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 22 09-OCT-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 346
AR370548/c
LOCUS AR370548 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 23 from patent US 6300491.
ACCESSION AR370548
VERSION AR370548.1 GI:34607301
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 23 09-OCT-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2025 GAGGCCACAGACTTACAGA 2044
Db 20 GAGGCCACAGACTTACAGA 1
RESULT 347
AR370549/c
LOCUS AR370549 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 24 from patent US 6300491.
ACCESSION AR370549
VERSION AR370549.1 GI:34607302
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 24 09-OCT-2001;
FEATURES
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGACCAAGACT 1900
|||||
Db 20 CAAGAGGAGGACCAAGACT 1

RESULT 348
AR370550/c
LOCUS AR370550 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 25 from patent US 6300491.
ACCESSION AR370550
VERSION AR370550.1 GI:34607303
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 25 09-OCT-2001;
FEATURES
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAAGTCTAGCCTGATGAG 1940
|||||
Db 20 TTAAAGTCTAGCCTGATGAG 1

RESULT 349
AR370551/c
LOCUS AR370551 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 26 from patent US 6300491.
ACCESSION AR370551
VERSION AR370551.1 GI:34607304
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 26 09-OCT-2001;
FEATURES
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCCACCATGAGGACA 1981
|||||
Db 20 ATAGCCCCCACCATGAGGACA 1

RESULT 350
AR370609/c
LOCUS AR370609 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 84 from patent US 6300491.
ACCESSION AR370609
VERSION AR370609.1 GI:34607362
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 84 09-OCT-2001;
FEATURES
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 351
AR370610/c
LOCUS AR370610 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 85 from patent US 6300491.
ACCESSION AR370610
VERSION AR370610.1 GI:34607363
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 85 09-OCT-2001;
FEATURES
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGGTGGGGGAGACATA 1964
|||||
Db 20 GAAGTGGTGGGGGAGACATA 1

RESULT 352
AR371570/c
LOCUS AR371570 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 17 from patent US 6395492.
ACCESSION AR371570
VERSION AR371570.1 GI:34608551
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M., Cook,P.D. and Bennett,C.F.
TITLE Derivatized oligonucleotides having improved uptake and other properties
JOURNAL Patent: US 6395492-A 17 28-MAY-2002;
FEATURES
Location/Qualifiers

```
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 353
AR390753/c
LOCUS AR390753 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 2 from patent US 6610842.
ACCESSION AR390753
VERSION AR390753.1 GI:40113093
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Ravikumar,V.T., Capaldi,D.C. and Cole,D.L.
TITLE Processes for the synthesis of oligomers using phosphoramidite
compositions
JOURNAL Patent: US 6610842-A 2 26-AUG-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 354
AR399186/c
LOCUS AR399186 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 26 from patent US 6617442.
ACCESSION AR399186
VERSION AR399186.1 GI:40137685
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Crooke,S.T., Lima,W.F., Wu,H. and Monoharan,M.
TITLE Human RNase H1 and oligonucleotide compositions thereof
JOURNAL Patent: US 6617442-A 26 09-SEP-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 355
AR409506/c
LOCUS AR409506 20 bp DNA linear PAT 18-DEC-2003
```

```
DEFINITION Sequence 2 from patent US 6632938.
ACCESSION AR409506
VERSION AR409506.1 GI:40160479
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Moore,M.N., Arthur,J.C., Vanscoy,K. and Scozzari,A.N.
TITLE Processes of purifying oligonucleotides
JOURNAL Patent: US 6632938-A 2 14-OCT-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 356
AR412367/c
LOCUS AR412367 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 18 from patent US 6639062.
ACCESSION AR412367
VERSION AR412367.1 GI:40167477
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M., Cook,P.D., Prakash,T.P. and Kawasaki,A.M.
TITLE Aminoxy-modified nucleosidic compounds and oligomeric compounds
prepared therefrom
JOURNAL Patent: US 6639062-A 18 28-OCT-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 357
AR429267/c
LOCUS AR429267 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 2 from patent US 6642373.
ACCESSION AR429267
VERSION AR429267.1 GI:40189438
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Ravikumar,V.T.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6642373-A 2 04-NOV-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"
```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 358
AR429273/c
LOCUS AR429273 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 8 from patent US 6642373.
ACCESSION AR429273
VERSION AR429273.1 GI:40189444
KEYWORDS
SOURCE
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Ravikumar,V.T.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6642373-A 8 04-NOV-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 359
AR429276/c
LOCUS AR429276 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 11 from patent US 6642373.
ACCESSION AR429276
VERSION AR429276.1 GI:40189447
KEYWORDS
SOURCE
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Ravikumar,V.T.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6642373-A 11 04-NOV-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 360
AR429282/c
LOCUS AR429282 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 17 from patent US 6642373.
ACCESSION AR429282
VERSION AR429282.1 GI:40189453
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Ravikumar,V.T.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6642373-A 17 04-NOV-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 361
AR429287/c
LOCUS AR429287 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 22 from patent US 6642373.
ACCESSION AR429287
VERSION AR429287.1 GI:40189458
KEYWORDS
SOURCE
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Ravikumar,V.T.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6642373-A 22 04-NOV-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 362
AR429288/c
LOCUS AR429288 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 23 from patent US 6642373.
ACCESSION AR429288
VERSION AR429288.1 GI:40189459
KEYWORDS
SOURCE
ORGANISM Unknown.
Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Ravikumar,V.T.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6642373-A 23 04-NOV-2003;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||

Db 20 GAGCTCCTGCTACTCAGA 1

RESULT 363
AR429290/c
LOCUS AR429290 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 25 from patent US 6642373.
ACCESSION AR429290
VERSION AR429290.1 GI:40189461
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Ravikumar,V.T.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6642373-A 25 04-NOV-2003;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 364
AR429296/c
LOCUS AR429296 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 31 from patent US 6642373.
ACCESSION AR429296
VERSION AR429296.1 GI:40189467
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Ravikumar,V.T.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6642373-A 31 04-NOV-2003;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 365
AR429298/c
LOCUS AR429298 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 33 from patent US 6642373.
ACCESSION AR429298
VERSION AR429298.1 GI:40189469
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Ravikumar,V.T.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6642373-A 33 04-NOV-2003;

FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 366
AR429303/c
LOCUS AR429303 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 38 from patent US 6642373.
ACCESSION AR429303
VERSION AR429303.1 GI:40189474
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Ravikumar,V.T.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6642373-A 38 04-NOV-2003;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 367
AR429305/c
LOCUS AR429305 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 40 from patent US 6642373.
ACCESSION AR429305
VERSION AR429305.1 GI:40189476
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Ravikumar,V.T.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6642373-A 40 04-NOV-2003;
FEATURES
source Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 368
AR429311/c
LOCUS AR429311 20 bp DNA linear PAT 18-DEC-2003

DEFINITION Sequence 46 from patent US 6642373.
ACCESSION AR429311
VERSION AR429311.1 GI:40189482
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Ravikumar,V.T.
TITLE Activators for oligonucleotide synthesis
JOURNAL Patent: US 6642373-A 46 04-NOV-2003;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 369
AR4311224/c
LOCUS AR4311224 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 1 from patent US 6649750.
ACCESSION AR4311224
VERSION AR4311224.1 GI:40193122
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Capaldi,D.C., Ravikumar,V.T. and Cole,D.L.
TITLE Process for the preparation of oligonucleotide compounds
JOURNAL Patent: US 6649750-A 1 18-NOV-2003;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 370
AR435738/c
LOCUS AR435738 20 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 4 from patent US 6656730.
ACCESSION AR435738
VERSION AR435738.1 GI:40198820
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M.
TITLE Oligonucleotides conjugated to protein-binding drugs
JOURNAL Patent: US 6656730-A 4 02-DEC-2003;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGTCCTCTGCTACTCAGA 1

RESULT 371
AR451258/c
LOCUS AR451258 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 1 from patent US 6673912.
ACCESSION AR451258
VERSION AR451258.1 GI:42682236
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Cook,P.D.
TITLE 2'-O-aminoethoxyethyl-modified oligonucleotides
JOURNAL Patent: US 6673912-A 1 06-JAN-2004;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGTCCTCTGCTACTCAGA 1

RESULT 372
AR451259/c
LOCUS AR451259 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2 from patent US 6673912.
ACCESSION AR451259
VERSION AR451259.1 GI:42682237
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Cook,P.D.
TITLE 2'-O-aminoethoxyethyl-modified oligonucleotides
JOURNAL Patent: US 6673912-A 2 06-JAN-2004;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGTCCTCTGCTACTCAGA 1

RESULT 373
AR451261/c
LOCUS AR451261 20 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 4 from patent US 6673912.
ACCESSION AR451261
VERSION AR451261.1 GI:42682239
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

TITLE Compositions and methods for non-parenteral delivery of

oligonucleotides
Patent: US 6747014-A 2 08-JUN-2004;JOURNAL
FEATURES
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAGTGGTGGGG 1957

Db 20 GAGAGGGGAGTGGTGGGG 1

RESULT 379

AR544785/c

LOCUS

DEFINITION

Accession

Version

Keywords

Source

Organism

Reference

Authors

Title

Journal

Features

source

1. .20

/organism="unknown"

/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 380

AR560503/c

LOCUS

DEFINITION

Accession

Version

Keywords

Source

Organism

Reference

Authors

Title

Journal

Features

source

1. .20

/organism="unknown"

/mol_type="genomic DNA"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37

Db 18 GAGCTCCTCTGCTACTCAGA 37

Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 381

AX040559/c

LOCUS

DEFINITION

Accession

Version

Keywords

Source

Organism

Reference

Authors

Title

Journal

Features

source

1. .20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Oligonucleotide"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAGTGGTGGGG 1957

Db 20 GAGAGGGGAGTGGTGGGG 1

RESULT 382

AX078054/c

LOCUS

DEFINITION

Accession

Version

Keywords

Source

Organism

Reference

Authors

Title

Journal

Features

source

1. .20

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

/note="ICAM-1"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 383

AX081373/c

LOCUS

DEFINITION

Accession

Version

Keywords

Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 381

AX040559/c

LOCUS

DEFINITION

Accession

Version

Keywords

Source

Organism

Reference

Authors

Title

Journal

Features

source

1. .20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Oligonucleotide"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAGTGGTGGGG 1957

Db 20 GAGAGGGGAGTGGTGGGG 1

RESULT 382

AX078054/c

LOCUS

DEFINITION

Accession

Version

Keywords

Source

Organism

Reference

Authors

Title

Journal

Features

source

1. .20

/organism="Homo sapiens"

/mol_type="unassigned DNA"

/db_xref="taxon:9606"

/note="ICAM-1"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 383

AX081373/c

LOCUS

DEFINITION

Accession

Version

Keywords

```

SOURCE      synthetic construct
ORGANISM    synthetic construct
            other sequences; artificial sequences.
REFERENCE 1
AUTHORS     Uhlmann,E., Greiner,B., Unger,E., Gothe,G. and Schwerdel,M.
TITLE       Conjugates and methods for the production thereof, and their use
            for transporting molecules via biological membranes
JOURNAL     Patent: WO 0108707-A 52 08-FEB-2001;
            Aventis Pharma Deutschland GmbH (DE)
FEATURES
source      Location/Qualifiers
            1..20
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="Oligonucleotide"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 384
AX081374/c
LOCUS      AX081374      20 bp      DNA      linear      PAT 27-FEB-2001
DEFINITION Sequence 53 from Patent WO0108707.
ACCESSION  AX081374
VERSION     AX081374.1 GI:13170216
KEYWORDS    synthetic construct
SOURCE      synthetic construct
            other sequences; artificial sequences.
REFERENCE 1
AUTHORS     Uhlmann,E., Greiner,B., Unger,E., Gothe,G. and Schwerdel,M.
TITLE       Conjugates and methods for the production thereof, and their use
            for transporting molecules via biological membranes
JOURNAL     Patent: WO 0108707-A 53 08-FEB-2001;
            Aventis Pharma Deutschland GmbH (DE)
FEATURES
source      Location/Qualifiers
            1..20
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="Oligonucleotide"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGG 1957
      |||||
Db 20 GAGAGGGGAAGTGTGGGG 1

RESULT 385
AX081375/c
LOCUS      AX081375      20 bp      DNA      linear      PAT 27-FEB-2001
DEFINITION Sequence 54 from Patent WO0108707.
ACCESSION  AX081375
VERSION     AX081375.1 GI:13170217
KEYWORDS    synthetic construct
SOURCE      synthetic construct
            other sequences; artificial sequences.
REFERENCE 1
AUTHORS     Uhlmann,E., Greiner,B., Unger,E., Gothe,G. and Schwerdel,M.
TITLE       Conjugates and methods for the production thereof, and their use
            for transporting molecules via biological membranes
JOURNAL     Patent: WO 0108707-A 54 08-FEB-2001;
            Aventis Pharma Deutschland GmbH (DE)

```

```

FEATURES
source      Location/Qualifiers
            1..20
            /organism="synthetic construct"
            /mol_type="unassigned DNA"
            /db_xref="taxon:32630"
            /note="Oligonucleotide"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGTGGGGGAG 1959
      |||||
Db 20 GAGGGGAAGTGTGGGGGAG 1

RESULT 386
AX090045/c
LOCUS      AX090045      20 bp      DNA      linear      PAT 21-MAR-2001
DEFINITION Sequence 1 from Patent WO0115726.
ACCESSION  AX090045
VERSION     AX090045.1 GI:13444006
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS     Sample,S.C., Haraeym,T.O., Klimuk,S.K., Kojic,L.D., Bramson,J.L.,
            Mui,B. and Hope,M.J.
TITLE       Compositions for stimulating cytokine secretion and inducing an
            immune response
JOURNAL     Patent: WO 0115726-A 1 08-MAR-2001;
            Inex Pharmaceuticals Corp. (CA)
FEATURES
source      Location/Qualifiers
            1..20
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 387
AX092653
LOCUS      AX092653      20 bp      DNA      linear      PAT 21-MAR-2001
DEFINITION Sequence 65 from Patent WO0115676..
ACCESSION  AX092653
VERSION     AX092653.1 GI:13444710
KEYWORDS    Homo sapiens (human)
SOURCE      Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS     Hayden,M.R., Brooks-Wilson,A.R., Pimstone,S.N. and Clee,S.M.
TITLE       Compositions and methods for modulating hdl cholesterol and
            triglyceride levels
JOURNAL     Patent: WO 0115676-A 65 08-MAR-2001;
            University of British Columbia (CA); Xenon Genetics Inc. (CA)
FEATURES
source      Location/Qualifiers
            1..20
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"

Query Match      0.7%; Score 20; DB 1; Length 20;

```

Best Local Similarity 100.0%; Pred. No. 1.9e+02; Indels 0; Gaps 0; Matches 20; Conservative 0; Mismatches 0;

QY 2825 GGCTCAAGTGATCCTCCAC 2844
|||||
Db 1 GGCTCAAGTGATCCTCCAC 20

RESULT 388
AX188696/c
LOCUS
DEFINITION Sequence 3 from Patent WO0147960. 20 bp DNA linear PAT 08-AUG-2001
ACCESSION AX188686
VERSION AX188686.1 GI:15142267
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS O'Hare, P.F., Normand, N.M., Brewis, N.D. and Phelan, A.
TITLE Uses of transport proteins for controlling cell cycle
JOURNAL Patent: WO 0147960-A 3 05-JUL-2001;
Phogen Limited (GB)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02; Indels 0; Gaps 0; Matches 20; Conservative 0; Mismatches 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 389
AX235177/c
LOCUS
DEFINITION Sequence 10 from Patent WO0163282. 20 bp DNA linear PAT 11-SEP-2001
ACCESSION AX235177
VERSION AX235177.1 GI:15593768
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Cuzin, M., Peltie, P., Fontecave, M., Decout, J.L. and Dueymes, C.
TITLE Analysis of biological targets using a biochip comprising a fluorescent marker
JOURNAL Patent: WO 0163282-A 10 30-AUG-2001;
COMMISSARIAT A L'ENERGIE ATOMIQUE (FR)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="sequence synthetic"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02; Indels 0; Gaps 0; Matches 20; Conservative 0; Mismatches 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 390
AX283203/c

LOCUS
DEFINITION Sequence 41 from Patent WO0179216. 20 bp DNA linear PAT 20-NOV-2001
ACCESSION AX283203
VERSION AX283203.1 GI:17044084
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Uhlmann, E., Breipohl, G. and Will, D.W.
TITLE Polyamide nucleic acid derivatives, agents and methods for producing them
JOURNAL Patent: WO 0179216-A 41 25-OCT-2001;
Aventis Pharma Deutschland GmbH (DE)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen Sequenz: Oligonukleotide"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02; Indels 0; Gaps 0; Matches 20; Conservative 0; Mismatches 0;

QY 2100 TGACGGATCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATCCAGCTTGGGC 1

RESULT 391
AX283204/c
LOCUS
DEFINITION Sequence 42 from Patent WO0179216. 20 bp DNA linear PAT 20-NOV-2001
ACCESSION AX283204
VERSION AX283204.1 GI:17044085
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Uhlmann, E., Breipohl, G. and Will, D.W.
TITLE Polyamide nucleic acid derivatives, agents and methods for producing them
JOURNAL Patent: WO 0179216-A 42 25-OCT-2001;
Aventis Pharma Deutschland GmbH (DE)
FEATURES
source Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen Sequenz: Oligonukleotide"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02; Indels 0; Gaps 0; Matches 20; Conservative 0; Mismatches 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 392
AX283205/c
LOCUS
DEFINITION Sequence 43 from Patent WO0179216. 20 bp DNA linear PAT 20-NOV-2001
ACCESSION AX283205
VERSION AX283205.1 GI:17044086
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct

other sequences; artificial sequences.

REFERENCE 1
AUTHORS Uhlmann,E., Breipohl,G. and Will,D.W.
TITLE Polyamide nucleic acid derivatives, agents and methods for producing them
JOURNAL Patent: WO 0179216-A 43 25-OCT-2001;
Aventis Pharma Deutschland GmbH (DE)
FEATURES Location/Qualifiers

source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen Sequenz:Oligonukleotide"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGGAG 1959

Db 20 GAGGGGAAGTGGTGGGGGAG 1

RESULT 393

AX283272/c
LOCUS AX283272 20 bp DNA linear PAT 20-NOV-2001
DEFINITION Sequence 36 from Patent WO0179249.

ACCESSION AX283272

VERSION AX283272.1 GI:17044153

KEYWORDS

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1

AUTHORS Uhlmann,E., Breipohl,G. and Will,D.W.
TITLE Polyamide nucleic acid derivatives, agents and methods for producing the same
JOURNAL Patent: WO 0179249-A 36 25-OCT-2001;
Aventis Pharma Deutschland GmbH (DE)

FEATURES

source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen Sequenz: Oligonukleotide"

Query Match

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGTTGGGC 2119

Db 20 TGACGGATGCCAGTTGGGC 1

RESULT 394

AX283273/c
LOCUS AX283273 20 bp DNA linear PAT 20-NOV-2001
DEFINITION Sequence 37 from Patent WO0179249.

ACCESSION AX283273

VERSION AX283273.1 GI:17044154

KEYWORDS

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1

AUTHORS Uhlmann,E., Breipohl,G. and Will,D.W.
TITLE Polyamide nucleic acid derivatives, agents and methods for producing the same
JOURNAL Patent: WO 0179249-A 37 25-OCT-2001;
Aventis Pharma Deutschland GmbH (DE)

FEATURES

source

1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen Sequenz: Oligonukleotide"

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGGG 1957

Db 20 GAGAGGGGAAGTGGTGGGGG 1

RESULT 395

AX283274/c
LOCUS AX283274 20 bp DNA linear PAT 20-NOV-2001
DEFINITION Sequence 38 from Patent WO0179249.

ACCESSION AX283274

VERSION AX283274.1 GI:17044155

KEYWORDS

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1

AUTHORS Uhlmann,E., Breipohl,G. and Will,D.W.
TITLE Polyamide nucleic acid derivatives, agents and methods for producing the same
JOURNAL Patent: WO 0179249-A 38 25-OCT-2001;
Aventis Pharma Deutschland GmbH (DE)

FEATURES

source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen Sequenz: Oligonukleotide"

Query Match

Best Local Similarity 100.0%; Pred. No. 1.9e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGGAG 1959

Db 20 GAGGGGAAGTGGTGGGGGAG 1

RESULT 396

AX384657/c
LOCUS AX384657 20 bp DNA linear PAT 19-MAR-2002
DEFINITION Sequence 29 from Patent EP1182206.

ACCESSION AX384657

VERSION AX384657.1 GI:19577852

KEYWORDS

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1

AUTHORS Peymann,A., Uhlmann,E., Mag,M., Kretschmar,G., Heleberg,M. and Winkler,I.
TITLE Stabilized oligonucleotids and the use thereof
JOURNAL Patent: EP 1182206-A 29 27-FEB-2002;
HOECHST AKTIENGESSELLSCHAFT (DE)

FEATURES

source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisense Oligonukleotid"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGGAG 1959
|||||
20 GAGGGGAGTGGTGGGGGAG 1

Db

RESULT 397
AX397905/c

LOCUS AX397905 20 bp DNA linear PAT 27-MAY-2002
DEFINITION Sequence 3 from Patent WO0220060.
ACCESSION AX397905
VERSION AX397905.1 GI:21260770
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS O'Hare, P.F., Brewis, N.D., Normand, N.M. and Sunasee, K.R.
TITLE Vp22 protein / nucleic acid aggregates, uses thereof
JOURNAL Patent: WO 0220060-A 3 14-MAR-2002;
Phogen Limited (GB)

FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
20 GAGAGGGGAAGTGGTGGGG 1

Db

RESULT 398
AX397906/c

LOCUS AX397906 20 bp DNA linear PAT 27-MAY-2002
DEFINITION Sequence 4 from Patent WO0220060.
ACCESSION AX397906
VERSION AX397906.1 GI:21260771
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS O'Hare, P.F., Brewis, N.D., Normand, N.M. and Sunasee, K.R.
TITLE Vp22 protein / nucleic acid aggregates, uses thereof
JOURNAL Patent: WO 0220060-A 4 14-MAR-2002;
Phogen Limited (GB)

FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
20 TGACGGATGCCAGCTTGGGC 1

Db

RESULT 399
AX419808/c

LOCUS AX419808 20 bp DNA linear PAT 18-JUN-2002
DEFINITION Sequence 145 from Patent WO0198537.
ACCESSION AX419808
VERSION AX419808.1 GI:21524175
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Lyamichev, V., Allawi, H., Dong, F., Neri, B.P. and Vener, I.T.
TITLE Nucleic acid accessible hybridization sites
JOURNAL Patent: WO 0198537-A 145 27-DEC-2001;
THIRD WAVE TECHNOLOGIES, INC. (US)

FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
20 GAGAGGGGAAGTGGTGGGG 1

Db

RESULT 400
AX419810/c

LOCUS AX419810 20 bp DNA linear PAT 18-JUN-2002
DEFINITION Sequence 147 from Patent WO0198537.
ACCESSION AX419810
VERSION AX419810.1 GI:21524177
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Lyamichev, V., Allawi, H., Dong, F., Neri, B.P. and Vener, I.T.
TITLE Nucleic acid accessible hybridization sites
JOURNAL Patent: WO 0198537-A 147 27-DEC-2001;
THIRD WAVE TECHNOLOGIES, INC. (US)

FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
|||||
20 CAGTCGACGCTGAGCTCCTC 1

Db

RESULT 401
AX419811/c

LOCUS AX419811 20 bp DNA linear PAT 18-JUN-2002
DEFINITION Sequence 148 from Patent WO0198537.
ACCESSION AX419811
VERSION AX419811.1 GI:21524178
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Lyamichev, V., Allawi, H., Dong, F., Neri, B.P. and Vener, I.T.
TITLE Nucleic acid accessible hybridization sites
JOURNAL Patent: WO 0198537-A 148 27-DEC-2001;
THIRD WAVE TECHNOLOGIES, INC. (US)

```

FEATURES
  source
    Location/Qualifiers
      1..20
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
Query Match
  Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 337 TCAAACTGCCCTGATGGCA 356
Db 20 TCAAACTGCCCTGATGGCA 1

RESULT 402
LOCUS AX419812/c
DEFINITION Sequence 149 from Patent WO0198537.
ACCESSION AX419812
VERSION AX419812.1 GI:21524179
KEYWORDS
SOURCE
  ORGANISM
    synthetic construct
    other sequences; artificial sequences.
REFERENCE
  1
  Lyamichev, V., Allawi, H., Dong, F., Neri, B. P. and Vener, I. T.
  Nucleic acid accessible hybridization sites
  Patent: WO 0198537-A 149 27-DEC-2001;
  THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES
  source
    Location/Qualifiers
      1..20
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
Query Match
  Best Local Similarity 0.7%; Score 20; DB 1; Length 20;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 403
LOCUS AX593896/c
DEFINITION Sequence 10 from Patent WO02069369.
ACCESSION AX593896
VERSION AX593896.1 GI:28375155
KEYWORDS
SOURCE
  ORGANISM
    synthetic construct
    other sequences; artificial sequences.
REFERENCE
  1
  Schetter, C. and Vollmer, J.
  Cpg-like nucleic acids and methods of use thereof
  Patent: WO 02069369-A 10 06-SEP-2002;
  Coley Pharmaceutical Group, Ltd (BM)
FEATURES
  source
    Location/Qualifiers
      1..20
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /notes="Synthetic oligonucleotide"
Query Match
  Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

```

```

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 404
LOCUS AX593900/c
DEFINITION Sequence 14 from Patent WO02069369.
ACCESSION AX593900
VERSION AX593900.1 GI:28375159
KEYWORDS
SOURCE
  ORGANISM
    synthetic construct
    other sequences; artificial sequences.
REFERENCE
  1
  Schetter, C. and Vollmer, J.
  Cpg-like nucleic acids and methods of use thereof
  Patent: WO 02069369-A 14 06-SEP-2002;
  Coley Pharmaceutical Group, Ltd (BM)
FEATURES
  source
    Location/Qualifiers
      1..20
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="Synthetic oligonucleotide"
      2..4
        /mod_base=m5c
      8
        /mod_base=m5c
      12
        /mod_base=m5c
      15..16
        /mod_base=m5c
      19
        /mod_base=m5c
Query Match
  Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 405
LOCUS AX797648/c
DEFINITION Sequence 11 from Patent WO03039595.
ACCESSION AX797648
VERSION AX797648.1 GI:37518076
KEYWORDS
SOURCE
  ORGANISM
    Homo sapiens (human)
REFERENCE
  1
  Sample, S., Klimuk, S. and Yuan, Z. N.
  Mucosal adjuvants comprising an oligonucleotide and a cationic
  lipid
  Patent: WO 03039595-A 11 15-MAY-2003;
  Inex Pharmaceuticals Corp. (CA)
FEATURES
  source
    Location/Qualifiers
      1..20
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"
Query Match
  Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 406
LOCUS AX797648/c
DEFINITION Sequence 11 from Patent WO03039595.
ACCESSION AX797648
VERSION AX797648.1 GI:37518076
KEYWORDS
SOURCE
  ORGANISM
    Homo sapiens (human)
REFERENCE
  1
  Sample, S., Klimuk, S. and Yuan, Z. N.
  Mucosal adjuvants comprising an oligonucleotide and a cationic
  lipid
  Patent: WO 03039595-A 11 15-MAY-2003;
  Inex Pharmaceuticals Corp. (CA)
FEATURES
  source
    Location/Qualifiers
      1..20
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"
Query Match
  Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
  Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

```


Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 406
AX797649/c
LOCUS AX797649 20 bp DNA linear PAT 04-OCT-2003
DEFINITION Sequence 12 from Patent WO03039595.
ACCESSION AX797649
VERSION AX797649.1 GI:37518077
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Sample, S., Klimuk, S. and Yuan, Z.N.
TITLE Mucosal adjuvants comprising an oligonucleotide and a cationic lipid
JOURNAL Patent: WO 03039595-A 12 15-MAY-2003;
Inex Pharmaceuticals Corp. (CA)
FEATURES
source Location/Qualifiers
1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 407
AX957632/c
LOCUS AX957632 20 bp DNA linear PAT 08-JAN-2004
DEFINITION Sequence 11 from Patent WO03094963.
ACCESSION AX957632
VERSION AX957632.1 GI:40785505
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Tam, Y.K., Semple, S., Klimuk, S. and Chikh, G.
TITLE Methylated immunostimulatory oligonucleotides and methods of using the same
JOURNAL Patent: WO 03094963-A 12 20-NOV-2003;
Inex Pharmaceuticals Corporation (CA)
FEATURES
source Location/Qualifiers
1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 410
AX957726/c
LOCUS AX957726 20 bp DNA linear PAT 08-JAN-2004
DEFINITION Sequence 11 from Patent WO03094828.
ACCESSION AX957726
VERSION AX957726.1 GI:40785544
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Tam, Y.K., Semple, S., Klimuk, S. and Chikh, G.
TITLE Cancer vaccines and methods of using the same

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 410
AX957726/c
LOCUS AX957726 20 bp DNA linear PAT 08-JAN-2004
DEFINITION Sequence 11 from Patent WO03094828.
ACCESSION AX957726
VERSION AX957726.1 GI:40785544
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Tam, Y.K., Semple, S., Klimuk, S. and Chikh, G.
TITLE Cancer vaccines and methods of using the same

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 408
AX957632/c
LOCUS AX957632 20 bp DNA linear PAT 08-JAN-2004
DEFINITION Sequence 11 from Patent WO03094963.
ACCESSION AX957632

JOURNAL Patent: WO 03094828-A 11 20-NOV-2003;
Inex Pharmaceuticals Corp. (CA)
FEATURES Location/Qualifiers
source 1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 411
AX957727/c
LOCUS AX957727 20 bp DNA linear PAT 08-JAN-2004
DEFINITION Sequence 12 from Patent WO03094828.
ACCESSION AX957727
VERSION AX957727.1 GI:40785545
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Tam, Y.K., Semple, S., Klimuk, S. and Chikh, G.
TITLE Cancer vaccines and methods of using the same
JOURNAL Patent: WO 03094828-A 12 20-NOV-2003;
Inex Pharmaceuticals Corp. (CA)
FEATURES Location/Qualifiers
source 1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 412
AX958131/c
LOCUS AX958131 20 bp DNA linear PAT 08-JAN-2004
DEFINITION Sequence 11 from Patent WO03094829.
ACCESSION AX958131
VERSION AX958131.1 GI:40785795
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Semple, S., Chikh, G., Hope, M.J. and Tam, Y.K.
TITLE Pathogen vaccines and methods for using the same
JOURNAL Patent: WO 03094829-A 11 20-NOV-2003;
Inex Pharmaceuticals Corp. (CA)
FEATURES Location/Qualifiers
source 1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 413
AX958132/c
LOCUS AX958132 20 bp DNA linear PAT 08-JAN-2004
DEFINITION Sequence 12 from Patent WO03094829.
ACCESSION AX958132
VERSION AX958132.1 GI:40785796
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
REFERENCE
AUTHORS Semple, S., Chikh, G., Hope, M.J. and Tam, Y.K.
TITLE Pathogen vaccines and methods for using the same
JOURNAL Patent: WO 03094829-A 12 20-NOV-2003;
Inex Pharmaceuticals Corp. (CA)
FEATURES Location/Qualifiers
source 1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 414
BD014066/c
LOCUS BD014066 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Oligonucleotide having phosphorothioate bond with high chiral purity.
ACCESSION BD014066
VERSION BD014066.1 GI:22554395
KEYWORDS JP 2001103987-A/6.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Cook, P.D. and Hawk, G.
TITLE Oligonucleotide having phosphorothioate bond with high chiral purity
JOURNAL Patent: JP 2001103987-A 6 17-APR-2001;
COMMENT ISIS PHARMACEUTICALS INC
OS Unidentified
PN JP 2001103987-A/6
PD 17-APR-2001
PF 31-AUG-2000 JP 2000262871
PR 06-JUN-1995 US 08/471967, 06-JUN-1995 US 08/467597 PR
06-JUN-1995 US 08/468447, 06-JUN-1995 US 08/468569 PR
06-JUN-1995 US 08/466692, 06-JUN-1995 US 08/471966 PR
06-JUN-1995 US 08/469851, 06-JUN-1995 US 08/470129 PI PHILIP
DAN COOK, GLENN HAWK
PC C12N15/09, A61K31/7125, A61K48/00, A61P27/02, A61P29/00, A61P31/12,
PC A61P31/18,
PC A61P35/00, C07H21/00, C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Oligonucleotide having phosphorothioate bond with high chiral purity
CC Key Location/Qualifiers
FH source 1..20
FT /organism='Unidentified'.

FEATURES
 source Location/Qualifiers
 1. .20
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 |||||
 Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 415
 BD014105/c
 LOCUS 20 bp DNA linear PAT 27-AUG-2002
 DEFINITION High-chimeric purity phosphorothioate bond-containing
 oligonucleotide.
 ACCESSION BD014105
 VERSION BD014105.1 GI:22554434
 KEYWORDS JP 2001114798-A/6.
 SOURCE unidentified
 ORGANISM unidentified
 unclassified.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Cook,P.D. and Hawk,G.
 TITLE High-Chimeric purity phosphorothioate bond-containing
 JOURNAL Patent: JP 2001114798-A 6 24-APR-2001;
 ISIS PHARMACEUTICALS INC
 COMMENT OS Unidentified
 PN JP 2001114798-A/6
 PD 24-APR-2001
 PF 31-AUG-2000 JP 2000262865
 PR 06-JUN-1995 US 08/471967,06-JUN-1995 US 08/467597 PR
 06-JUN-1995 US 08/468447,06-JUN-1995 US 08/468569 PR
 06-JUN-1995 US 08/466592,06-JUN-1995 US 08/471966 PR
 06-JUN-1995 US 08/469851,06-JUN-1995 US 08/470129 PI PHILIP
 DAN COOK,GLENN HAWK
 PC C07H21/00,A61K31/7125,A61K48/00,A61P1/16,A61P27/02,A61P29/00,
 A61P31/14,
 PC A61P31/18,A61P35/00,C12N15/09,C12N15/00
 CC Strandedness: Single;
 CC Topology: Linear;
 CC High-chimeric purity phosphorothioate bond-containing CC
 oligonucleotide
 FH Key Location/Qualifiers
 FT source 1. .20
 FT /organism='Unidentified'.

FEATURES
 source Location/Qualifiers
 1. .20
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 |||||
 Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 416
 BD106485/c
 LOCUS 20 bp DNA linear PAT 18-SEP-2002
 DEFINITION High efficiency encapsulation of charged therapeutic agents in
 lipid vesicles.
 ACCESSION BD106485
 VERSION BD106485.1 GI:23201303
 KEYWORDS JP 2002501511-A/2.

FEATURES
 source Location/Qualifiers
 1. .20
 /organism="Chlamydia sp."
 /mol_type="genomic DNA"
 /db_xref="taxon:35827"

 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.9e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 |||||
 Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 417
 I50990/c
 LOCUS 21 bp DNA linear PAT 07-OCT-1997
 DEFINITION Sequence 5 from patent US 5643780.
 ACCESSION I50990
 VERSION I50990.1 GI:2472693
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.
 REFERENCE 1 (bases 1 to 21)
 AUTHORS Baker,B.F.
 TITLE Compositions and methods for modulating RNA activity through
 modification of the 5' cap structure of RNA
 JOURNAL Patent: US 5643780-A 5 01-JUL-1997;
 FEATURES Location/Qualifiers
 source 1. .21
 /organism="unknown"
 /mol_type="unassigned DNA"

 Query Match 0.7%; Score 20; DB 1; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

 QY 18 GAGCTCCTCTGCTACTCAGA 37
 |||||
 Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 418
 I50991/c
 LOCUS 21 bp DNA linear PAT 07-OCT-1997
 DEFINITION Sequence 6 from patent US 5643780.
 ACCESSION I50991
 VERSION I50991.1 GI:2472694
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 UNCLASSIFIED.

SOURCE Chlamydia sp.
 ORGANISM Chlamydia sp.
 Bacteria; Chlamydiae; Chlamydiales; Chlamydiaceae; Chlamydia.
 REFERENCE 1 (bases 1 to 20)
 AUTHORS Sample,S.C., Klimuk,S.K., Harasym,T., Hope,M.J., Ansel,S.M.,
 Cullis,P., Scherrer,P. and Debeyer,D.S.
 TITLE High efficiency encapsulation of charged therapeutic agents in
 lipid vesicles
 JOURNAL Patent: JP 2002501511-A 2 15-JAN-2002;
 INEX PHARMACEUTICALS CORP
 COMMENT PN JP 2002501511-A/2
 PD 15-JAN-2002
 PP 14-MAY-1998 JP 1998548646
 PI SEAN C SAMPLE,SANDRA K KLIMUK,TROY HARASYM,MICHAEL J HOPE, PI
 STEVEN M ANSELL,
 PI PIETER CULLIS,PETER SCHERRER,DAN SUITE DEBEYER PC A61K9/00
 CC Strandedness: Single;
 CC Topology: Linear;
 FH Key Location/Qualifiers.

REFERENCE 1 (bases 1 to 21)
AUTHORS Baker,B.F.
TITLE Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
JOURNAL Patent: US 5643780-A 6 01-JUL-1997;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 419
AR062627/c
LOCUS AR062627 22 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 27 from patent US 5843738.
ACCESSION AR062627
VERSION AR062627.1 GI:5990318
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Bennett,C.Frank., and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 27 01-DEC-1998;
FEATURES Location/Qualifiers
source 1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 420
AR104730/c
LOCUS AR104730 22 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 27 from patent US 6093811.
ACCESSION AR104730
VERSION AR104730.1 GI:12817438
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Bennett,C.Frank., and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 27 25-JUL-2000;
FEATURES Location/Qualifiers
source 1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 421
AR105552/c
LOCUS AR105552 22 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 27 from patent US 6096722.
ACCESSION AR105552
VERSION AR105552.1 GI:12819149
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 27 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 422
AR123214/c
LOCUS AR123214 22 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 27 from patent US 6169079.
ACCESSION AR123214
VERSION AR123214.1 GI:14108180
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 27 02-JAN-2001;
FEATURES Location/Qualifiers
source 1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 423
I20629/c
LOCUS I20629 22 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 27 from patent US 5514788.
ACCESSION I20629
VERSION I20629.1 GI:1600984
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 22)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 27 07-MAY-1996;

```
FEATURES
  source      Location/Qualifiers
 1..22       /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
    |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 424
LOCUS      I33322
DEFINITION Sequence 27 from patent US 5591623.
ACCESSION  I33322
VERSION     I33322.1 GI:1824113
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 22)
AUTHORS    Bennett,C.Frank. and Mirabelli,C.K.
TITLE      Oligonucleotide modulation of cell adhesion
JOURNAL    Patent: US 5591623-A 27 07-JAN-1997;
FEATURES   Location/Qualifiers
  source      1..22
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
    |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 425
LOCUS      AR370552/c
DEFINITION Sequence 27 from patent US 6300491.
ACCESSION  AR370552
VERSION     AR370552.1 GI:34607305
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 22)
AUTHORS    Bennett,C.F. and Mirabelli,C.K.
TITLE      Oligonucleotide inhibition of cell adhesion
JOURNAL    Patent: US 6300491-A 27 09-OCT-2001;
FEATURES   Location/Qualifiers
  source      1..22
             /organism="unknown"
             /mol_type="genomic DNA"

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
    |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 426
LOCUS      AX926722
DEFINITION Sequence 5 from Patent WO03085133.
ACCESSION  AX926722
VERSION     AX926722.1 GI:40247008
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE  1
AUTHORS    Nagaraju,J.G.
TITLE      Novel fssr-pcr primers and method of identifying genotyping
          diverse genomes of plant and animal systems including rice
          varieties, a kit thereof
JOURNAL    Patent: WO 03085133-A 5 16-OCT-2003;
          Centre for DNA fingerprinting and Diagnostics, Centre for; the
          Department of Biotechnology, Ministry of Science & Technology (IN)
FEATURES   Location/Qualifiers
  source      1..23
             /organism="synthetic construct"
             /mol_type="unassigned DNA"
             /db_xref="taxon:32630"
             /note="A novel FISSR-PCR primer for genotyping eukaryotes"

Query Match
Best Local Similarity 91.3%; Score 19.8; DB 1; Length 23;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2727 CCGTGTGTGTGTGTGTGTGTGTGT 2749
    |||||
Db 1 CGTATGTGTGTGTGTGTGTGTGTGT 23

RESULT 427
LOCUS      AR154046/c
DEFINITION Sequence 96 from patent US 6238863.
ACCESSION  AR154046
VERSION     AR154046.1 GI:15122099
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 24)
AUTHORS    Schumm,J.W. and Bacher,J.W.
TITLE      Materials and methods for indentifying and analyzing intermediate
          tandem repeat DNA markers
JOURNAL    Patent: US 6238863-A 96 29-MAY-2001;
FEATURES   Location/Qualifiers
  source      1..24
             /organism="unknown"
             /mol_type="unassigned DNA"

Query Match
Best Local Similarity 91.3%; Score 19.8; DB 1; Length 24;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2766 TGTACCCAGGCTGGAGTGCAGT 2788
    |||||
Db 23 TATCACCCAGGCTGGAGTGCAGT 1

RESULT 428
LOCUS      AR565270/c
DEFINITION Sequence 96 from patent US 6767703.
ACCESSION  AR565270
VERSION     AR565270.1 GI:53981108
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 24)
AUTHORS    Schumm,J.W. and Bacher,J.W.
TITLE      Materials and methods for indentifying and analyzing intermediate
```


/note="Primer"									
Query Match 0.6%; Score 19.4; DB 1; Length 21;									
Best Local Similarity 95.2%; Pred. No. 2.1e+02;									
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	2826	GCTCAAGTCATCCTCCCACT	2846						
DB	21	GCTCAAGTCATCCTCCCACT	1						
RESULT 435									
AX175255									
LOCUS	AX175255	Sequence 19 from Patent WO0144465.	21 bp	DNA	linear				PAT 03-JUL-2001
DEFINITION	AX175255								
ACCESSION	AX175255.1	GI:14598623							
VERSION									
KEYWORDS		synthetic construct							
SOURCE		synthetic construct							
ORGANISM		other sequences; artificial sequences.							
REFERENCE	1								
AUTHORS		Phillips,N.C. and Filion,M.C.							
TITLE		Therapeutically useful synthetic oligonucleotides							
JOURNAL		Patent: WO 0144465-A 19 21-JUN-2001;							
		Bioniche Life Sciences Inc. (CA)							
FEATURES		Location/Qualifiers							
source		1..21							
		/organism="synthetic construct"							
		/mol_type="unassigned DNA"							
		/db_xref="taxon:32630"							
Query Match 0.6%; Score 19.4; DB 1; Length 21;									
Best Local Similarity 95.2%; Pred. No. 2.1e+02;									
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	2729	TGTGTGTGTGTGTGTGTGT	2749						
DB	1	TGTGTGTGTGTGTGTGTGT	21						
RESULT 436									
AX175256									
LOCUS	AX175256	Sequence 20 from Patent WO0144465.	21 bp	DNA	linear				PAT 03-JUL-2001
DEFINITION	AX175256								
ACCESSION	AX175256.1	GI:14598624							
VERSION									
KEYWORDS		synthetic construct							
SOURCE		synthetic construct							
ORGANISM		other sequences; artificial sequences.							
REFERENCE	1								
AUTHORS		Phillips,N.C. and Filion,M.C.							
TITLE		Therapeutically useful synthetic oligonucleotides							
JOURNAL		Patent: WO 0144465-A 20 21-JUN-2001;							
		Bioniche Life Sciences Inc. (CA)							
FEATURES		Location/Qualifiers							
source		1..21							
		/organism="synthetic construct"							
		/mol_type="unassigned DNA"							
		/db_xref="taxon:32630"							
Query Match 0.6%; Score 19.4; DB 1; Length 21;									
Best Local Similarity 95.2%; Pred. No. 2.1e+02;									
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	2728	GTGTGTGTGTGTGTGTGTG	2748						
DB	1	GTGTGTGTGTGTGTGTGTG	21						
RESULT 437									
AX547768									

LOCUS AX547768 21 bp DNA linear PAT 01-MAR-2003
DEFINITION Sequence 907 from Patent WO02053141.
ACCESSION AX547768
VERSION AX547768.1 GI:25812912
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Bratzler,R.L.
TITLE Inhibition of angiogenesis by nucleic acids
JOURNAL Patent: WO 02053141-A 907 11-JUL-2002;
Coley Pharmaceutical Group, Inc. (US)
FEATURES Location/Qualifiers
source 1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Synthetic Sequence"

Query Match 0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2749
|||||
Db 1 TGTGTGTGTGTGTGTGTGT 21
|||||

RESULT 438
AX741051
LOCUS AX741051 21 bp DNA linear PAT 10-MAY-2003
DEFINITION Sequence 25 from Patent WO03027328.
ACCESSION AX741051
VERSION AX741051.1 GI:30523912
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Kirtsen,N.V., Hyldig-Nielsen,J.J. and Williams,B.F.
TITLE Methods, kits and compositions pertaining to the suppression of
detectable probe binding to randomly distributed repeat sequences
in genomic nucleic acid
JOURNAL Patent: WO 03027328-A 25 03-APR-2003;
Boston Probes, Inc. (US); DakoCytomation Denmark A/S (DK)
FEATURES Location/Qualifiers
source 1..21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="Description of Combined DNA/RNA Molecule:Synthetic
Oligomer Sequence-Synthetic Probe Sequence"

Query Match 0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2766 TGTACCCAGCTGGAGTGCA 2786
|||||
Db 1 TGTGCGCCAGCTGGAGTGCA 21
|||||

RESULT 439
AX823486/c
LOCUS AX823486 21 bp DNA linear PAT 11-DEC-2003
DEFINITION Sequence 259 from Patent WO02068647.
ACCESSION AX823486
VERSION AX823486.1 GI:39749946
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Patent: WO 02068647-A 259 06-SEP-2002;
Curagen Corporation (US)
FEATURES Location/Qualifiers
source 1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Description of Artificial Sequence: PCR Primer
Sequence"

Query Match 0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 AGCTGGAGTGCAGTGTGCA 2794
|||||
Db 21 AGCTGGAGGCGAGTGTGCA 1
|||||

RESULT 440
AX116747/c
LOCUS AX116747 24 bp DNA linear PAT 11-MAY-2001
DEFINITION Sequence 1870 from Patent WO0129262.
ACCESSION AX116747
VERSION AX116747.1 GI:14033689
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Picoult-Newburg,L. and Pohl,M.
TITLE Genotyping reagents, kits and methods of use thereof
JOURNAL Patent: WO 0129262-A 1870 26-APR-2001;
Orchid Biosciences, Inc. (US)
FEATURES Location/Qualifiers
source 1..24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.6%; Score 19.4; DB 1; Length 24;
Best Local Similarity 95.2%; Pred. No. 1.8e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2749
|||||
Db 21 TGTGTGTGTGTGTGTGTGT 1
|||||

RESULT 441
E32214/c
LOCUS E32214 24 bp DNA linear PAT 18-JUN-2001
DEFINITION Method for isolating satellite sequence.
ACCESSION E32214
VERSION E32214.1 GI:13021823
KEYWORDS JP 2000060559-A/16.
SOURCE Haliotis discus discus
ORGANISM Haliotis discus discus
Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;
Vetigastropoda; Haliotoidea; Haliotidae; Haliotis.

REFERENCE 1 (bases 1 to 24)
AUTHORS Hideaki,T. and Masashi,S.
TITLE Method for isolating satellite sequence
JOURNAL Patent: JP 2000060559-A 16 29-FEB-2000;
NATL INST OF AGROBIOLOGICAL RESOURCES
COMMENT OS Haliotis discus discus
PN JP 2000060559-A/16
PD 29-FEB-2000
PF 18-AUG-1998 JP 1998232153
PR

Query Match 0.6%: Score 19: DB 1: Length 19;

Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCGC 69
|||||
Db 19 CCTCGCTATGGCTCCCGC 1

RESULT 446
A44401/c
LOCUS A44401 19 bp DNA linear PAT 07-MAR-1997
DEFINITION Sequence 31 from Patent EP0653439.
ACCESSION A44401
VERSION A44401.1 GI:2299230
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 19)
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE Peyman,A.D., Uhlmann,E.D., Mag,M., Kretzschmar,G.D., Helsenberg,M.D.
JOURNAL Stabilized oligonucleotides and the use thereof
COMMENT Patent: EP 0653439-A 31 17-MAY-1995;
HOECHST AG (DE)
Other publication JP 7194385 950801
Other publication CA 2135591 950513
Other publication AU 7779994 950518
Other publication DE 4338704 950518.
FEATURES
source 1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
exon 1..19
/note="ICAM"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCGC 69
|||||
Db 19 CCTCGCTATGGCTCCCGC 1

RESULT 447
A47184/c
LOCUS A47184 19 bp DNA linear PAT 07-MAR-1997
DEFINITION Sequence 27 from Patent EP0680969.
ACCESSION A47184
VERSION A47184.1 GI:2301226
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 19)
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
TITLE Seel,F.P. and Lampe,S.D.
JOURNAL Modified oligonucleotides, their preparation and their use
COMMENT Patent: EP 0680969-A 27 08-NOV-1995;
HOECHST AG (DE)
Other publication JP 8003186 960109
Other publication AU 1778295 951109
Other publication DE 4415370 951109.
FEATURES
source 1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
exon 1..19
/note="ICAM"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCGC 69
|||||
Db 19 CCTCGCTATGGCTCCCGC 1

RESULT 448
A56656/c
LOCUS A56656 19 bp DNA linear PAT 03-MAR-1998
DEFINITION Sequence 23 from Patent EP0739898.
ACCESSION A56656
VERSION A56656.1 GI:3712701
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1
AUTHORS Peyman,A.D., Uhlmann,E.D., Breipohl,G.D. and Wallmeier,H.D.
TITLE Phosphonomonoester nucleic acids, methods for their preparation and
JOURNAL their use
COMMENT Patent: EP 0739898-A 23 30-OCT-1996;
HOECHST AG (DE)
Other publication CN 9600743 961016
Other publication CZ 1138588 961225
Other publication PL 313207 960916
Other publication JP 8259579 961008
Other publication NO 961006 960916
Other publication CA 2171589 960914
Other publication AU 4802896 960926
Other publication DE 19508923 960919.
FEATURES
source 1..19
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCGC 69
|||||
Db 19 CCTCGCTATGGCTCCCGC 1

RESULT 449
A80377/c
LOCUS A80377 19 bp DNA linear PAT 20-OCT-1999
DEFINITION Sequence 23 from Patent EP0726274.
ACCESSION A80377
VERSION A80377.1 GI:6093104
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 19)
AUTHORS Peyman,A.D. and Uhlmann,E.D.
TITLE G-CAP STABILIZED OLIGONUCLEOTIDES
JOURNAL Patent: EP 0726274-A 23 14-AUG-1996;
HOECHST AG (DE)
FEATURES
source 1..19
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
exon 1..19

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCAGC 69
Db 19 CCTCGCTATGGCTCCAGC 1

RESULT 450
LOCUS AR013832 19 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 22 from patent US 5773218.
ACCESSION AR013832
VERSION AR013832.1 GI:3971286
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Gallatin,W.Michael, and Vazeux,R.
TITLE Method to identify compounds which modulate ICAM-related protein interactions
JOURNAL Patent: US 5773218-A 22 30-JUN-1998;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAAATTC 609
Db 19 TCACCATGGAGCCAAATTC 1

RESULT 451
LOCUS AR033786 19 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 22 from patent US 5869262.
ACCESSION AR033786
VERSION AR033786.1 GI:5949391
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Gallatin,W.Michael, and Vazeux,R.
TITLE Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
JOURNAL Patent: US 5869262-A 22 09-FEB-1999;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAAATTC 609
Db 19 TCACCATGGAGCCAAATTC 1

RESULT 452
LOCUS AR042446 19 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 22 from patent US 5811517.
ACCESSION AR042446
VERSION AR042446.1 GI:5962942
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
1 (bases 1 to 19)
Gallatin,W.Michael, and Vazeux,R.
ICAM-related protein variants
Patent: US 5811517-A 22 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAAATTC 609
Db 19 TCACCATGGAGCCAAATTC 1

RESULT 453
LOCUS AR058326 19 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 22 from patent US 5837822.
ACCESSION AR058326
VERSION AR058326.1 GI:5983903
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Gallatin,W.Michael, and Vazeux,R.
TITLE Humanized antibodies specific for ICAM related protein
JOURNAL Patent: US 5837822-A 22 17-NOV-1998;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAAATTC 609
Db 19 TCACCATGGAGCCAAATTC 1

RESULT 454
LOCUS AR088152/c 19 bp DNA linear PAT 07-SEP-2000
DEFINITION Sequence 22 from patent US 5989843.
ACCESSION AR088152
VERSION AR088152.1 GI:10014915
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Gallatin,W.Michael, and Vazeux,R.
TITLE Methods for identifying modulators of protein kinase C phosphorylation of ICAM-related protein
JOURNAL Patent: US 5989843-A 22 23-NOV-1999;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAAATTC 609
Db 19 TCACCATGGAGCCAAATTC 1

Db 19 TCACCATGGAGCCCAATTC 1

RESULT 455
AR102942/c
LOCUS AR102942 19 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 22 from patent US 6087130.
ACCESSION AR102942
VERSION AR102942.1 GI:12814530
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Antibody substances that bind to ICAM-related protein
JOURNAL Patent: US 6087130-A 22 11-JUL-2000;
FEATURES
source Location/Qualifiers
1. .19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCCAATTC 609
|||||
Db 19 TCACCATGGAGCCCAATTC 1

RESULT 456
AR111780/c
LOCUS AR111780 19 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 23 from patent US 6127346.
ACCESSION AR111780
VERSION AR111780.1 GI:12828628
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Feynman,A., Uhlmann,E., Breipohl,G. and Wallmeier,H.
TITLE Phosphonomonoester nucleic acids process for their preparation and their use
JOURNAL Patent: US 6127346-A 23 03-OCT-2000;
FEATURES
source Location/Qualifiers
1. .19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCCAATTC 609
|||||
Db 19 TCACCATGGAGCCCAATTC 1

RESULT 457
AR119588/c
LOCUS AR119588 19 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 22 from patent US 6153395.
ACCESSION AR119588
VERSION AR119588.1 GI:14102287
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE ICAM-related protein

JOURNAL Patent: US 6153395-A 22 28-NOV-2000;
FEATURES
source Location/Qualifiers
1. .19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCCAATTC 609
|||||
Db 19 TCACCATGGAGCCCAATTC 1

RESULT 458
AR153771
LOCUS AR153771 19 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 6 from patent US 6235889.
ACCESSION AR153771
VERSION AR153771.1 GI:15121303
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Ulanovsky,L.
TITLE Nucleic acid amplification using modular branched primers
JOURNAL Patent: US 6235889-A 6 22-MAY-2001;
FEATURES
source Location/Qualifiers
1. .19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 769 TCCTGGACGGCTGTTC 787
|||||
Db 1 TCCTGGACGGCTGTTC 19

RESULT 459
BD266405/c
LOCUS BD266405 19 bp DNA linear PAT 17-JUL-2003
DEFINITION Universal arrays.
ACCESSION BD266405
VERSION BD266405.1 GI:33076173
KEYWORDS JP 2002539849-A/405.
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE other sequences; artificial sequences.
1 (bases 1 to 19)
AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S., Lockhart,D.J., Ryder,T. and Sklar,P.
TITLE Universal arrays
JOURNAL Patent: JP 2002539849-A 405 26-NOV-2002;
COMMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, AFFYMETRIX INC
OS Artificial Sequence
PN JP 2002539849-A/405
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI
JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
HUANG,PAUL KAPLAN,ERIC
PI S LANDER,
PI DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
PC C1201/68,C12M1/00,C12N15/09,C12N15/09,G01N33/53, PC
G01N33/566,
PC G01N37/00,C12N15/00,C12N15/00,C12N15/00
CC Primer
FH Key Location/Qualifiers

FT source 1..19 /organism='Artificial Sequence'.
 FT Location/Qualifiers

FEATURES
 source
 1..19
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 2.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 226 TTGTTGGCATAGACCC 244
 Db 19 TTGTTGGCATAGACCC 1

RESULT 460
 BD266407/c
 LOCUS 19 bp DNA linear PAT 17-JUL-2003
 DEFINITION Universal arrays.
 ACCESSION BD266407
 VERSION BD266407.1 GI:33076175
 KEYWORDS JP 2002539849-A/407.
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 19)
 AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S.,
 Lockhart,D.J., Ryder,T. and Sklar,P.
 TITLE Universal arrays
 JOURNAL Patent: JP 2002539849-A 407 26-NOV-2002;
 COMMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC

OS Artificial Sequence
 PN JP 2002539849-A/407
 PD 26-NOV-2002
 PE 27-MAR-2000 JP 2000608794
 PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI
 JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
 HUANG,PAUL KAPLAN,ERIC
 PI S LANDER,
 PI DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
 PC C12Q1/68,C12N1/00,C12N15/09,C12N15/09,G01N33/53, PC
 G01N33/566,
 PC G01N37/00,C12N15/00,C12N15/00,C12N15/00
 CC Primer
 FH Key Location/Qualifiers
 FT source 1..19 /organism='Artificial Sequence'.
 FT Location/Qualifiers

FEATURES
 source
 1..19
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 2.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1249 CTGACGAGAGGGATTGTC 1267
 Db 19 CTGACGAGAGGGATTGTC 1

RESULT 461
 BD273666/c
 LOCUS 19 bp DNA linear PAT 17-JUL-2003
 DEFINITION Novel oligomer conjugate facilitating transfer of biological
 molecule into cell.
 ACCESSION BD273666
 VERSION BD273666.1 GI:33083434
 KEYWORDS JP 2002532388-A/2.
 SOURCE synthetic construct

ORGANISM
 REFERENCE 1 (bases 1 to 19)
 AUTHORS Midoux,P., Pichon,C., BelloMroufai,M. and Monsigny,M.
 TITLE Novel oligomer conjugate facilitating transfer of biological
 molecule into cell
 JOURNAL Patent: JP 2002532388-A 2 02-OCT-2002;
 COMMENT IDM IMMUNO-DESIGNED MOLECULES
 OS Artificial Sequence
 PN JP 2002532388-A/2
 PD 02-OCT-2002
 PE 22-NOV-1999 JP 2000585395
 PR 02-DEC-1998 EP 98 403 015.5
 PI PATRICK MIDOUX,CHANTAL PICHON,MAHAJOUB BELLO-ROUFAL,MICHEL PI
 MONSIGNY

PC A61K47/48,A61K31/7088,A61K38/00,A61P29/00,A61P31/12,A61P35/00,
 PC A61P37/06,
 PC A61P37/08,C07K14/00,C08G69/02,C12N15/09,C12N15/00,A61K37/02 CC
 phosphorothioate oligonucleotide ISIS 1939
 FH Key Location/Qualifiers
 FT source 1..19
 FT Location/Qualifiers
 FT /organism='Artificial Sequence'.
 FT Location/Qualifiers
 1..19
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

FEATURES
 source

Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 2.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1939 AGAGGGGAAGTGTGGGG 1957
 Db 19 AGAGGGGAAGTGTGGGG 1

RESULT 462
 I21896/c
 LOCUS 19 bp DNA linear PAT 07-OCT-1996
 DEFINITION Sequence 22 from patent US 5525487.
 ACCESSION I21896
 VERSION I21896.1 GI:1602250
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 19)
 AUTHORS Gallatin,W.Michael. and Vazeux,R.
 TITLE DNA encoding I-CAM related protein
 JOURNAL Patent: US 5525487-A 22 11-JUN-1996;
 FEATURES Location/Qualifiers
 source 1..19
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 2.6e+02;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCAATTC 609
 Db 19 TCACCATGGAGCAATTC 1

RESULT 463
 I23324/c
 LOCUS 19 bp DNA linear PAT 07-OCT-1996
 DEFINITION Sequence 22 from patent US 5532127.
 ACCESSION I23324
 VERSION I23324.1 GI:1603194
 KEYWORDS Unknown.
 SOURCE Unknown.

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Gallatin,W.Michael, and Vazeux,R.
TITLE Assay for l-CAM related protein expression
JOURNAL Patent: US 5532127-A 22 02-JUL-1996;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAATTTC 609
Db 19 TCACCATGGAGCCAATTTC 1

RESULT 464
150992/c
LOCUS 150992 19 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 7 from patent US 5643780.
ACCESSION 150992
VERSION 150992.1 GI:2472695
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Baker,B.F.
TITLE Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
JOURNAL Patent: US 5643780-A 7 01-JUL-1997;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCTCCTCTGCTACTCAGAG 38
Db 19 GCTCCTCTGCTACTCAGAG 1

RESULT 465
163600/c
LOCUS 163600 19 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 22 from patent US 5663293.
ACCESSION 163600
VERSION 163600.1 GI:2481173
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Gallatin,W.Michael, and Vazeux,R.
TITLE ICAM-related protein
JOURNAL Patent: US 5663293-A 22 02-SEP-1997;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAATTTC 609

Db 19 TCACCATGGAGCCAATTTC 1

RESULT 466
171048
LOCUS 171048 19 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 6 from patent US 5681699.
ACCESSION 171048
VERSION 171048.1 GI:3007183
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Rotter,J.I., Targan,S.R., Yang,H., Beaudet,A.L. and Vora,D.
TITLE Methods of diagnosing ulcerative colitis and Crohn's disease
JOURNAL Patent: US 5681699-A 6 28-OCT-1997;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 769 TCCTCGACGGGCTGTTC 787
Db 1 TCCTCGACGGGCTGTTC 19

RESULT 467
184735/c
LOCUS 184735 19 bp DNA linear PAT 04-APR-1998
DEFINITION Sequence 23 from patent US 5696248.
ACCESSION 184735
VERSION 184735.1 GI:3022255
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Peyman,A., Uhlmann,E. and Carolus,C.
TITLE 3'-modified oligonucleotide derivatives
JOURNAL Patent: US 5696248-A 23 09-DEC-1997;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCAGC 69
Db 19 CCTCGCTATGGCTCCAGC 1

RESULT 468
AR179820/c
LOCUS AR179820 19 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 23 from patent US 6326487.
ACCESSION AR179820
VERSION AR179820.1 GI:20221375
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Peyman,A., Uhlmann,E. and Carolus,C.
TITLE 3 modified oligonucleotide derivatives

JOURNAL Patent: US 6326487-A 23 04-DEC-2001;
 FEATURES
 source
 1. .19
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match
 Best Local Similarity 0.6%; Score 19; DB 1; Length 19;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCGC 69
 |||||
 Db 19 CCTCGCTATGGCTCCCGC 1

RESULT 469
 AR193527/c
 LOCUS
 DEFINITION Sequence 31 from patent US 6348312. linear PAT 20-APR-2002
 ACCESSION AR193527
 VERSION AR193527.1 GI:20240119
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE
 1 (bases 1 to 19)
 AUTHORS Feynman,A., Uhlmann,E., Mag,M., Kretzschmar,G., Helsing,M. and Winkler,I.
 TITLE Stabilized oligonucleotides and their use
 JOURNAL Patent: US 6348312-A 31 19-FEB-2002;
 FEATURES
 source
 1. .19
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match
 Best Local Similarity 0.6%; Score 19; DB 1; Length 19;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCGC 69
 |||||
 Db 19 CCTCGCTATGGCTCCCGC 1

RESULT 470
 AR254170/c
 LOCUS
 DEFINITION Sequence 22 from patent US 6479651. linear PAT 20-DEC-2002
 ACCESSION AR254170
 VERSION AR254170.1 GI:27302907
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE
 1 (bases 1 to 19)
 AUTHORS Seela,F. and Thomas,H.
 TITLE Modified oligonucleotides, their preparation and their use
 JOURNAL Patent: US 6479651-A 22 12-NOV-2002;
 FEATURES
 source
 1. .19
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match
 Best Local Similarity 0.6%; Score 19; DB 1; Length 19;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCGC 69
 |||||
 Db 19 CCTCGCTATGGCTCCCGC 1

RESULT 471

AX081376/c
 LOCUS
 DEFINITION Sequence 55 from Patent WO0108707. linear PAT 27-FEB-2001
 ACCESSION AX081376
 VERSION AX081376.1 GI:13170218
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 other sequences; artificial sequences.
 REFERENCE
 1
 AUTHORS Uhlmann,E., Greiner,B., Unger,E., Gothe,G. and Schwerdel,M.
 TITLE Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
 JOURNAL Patent: WO 0108707-A 55 08-FEB-2001;
 FEATURES
 source
 1. .19
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Oligonucleotide"

Query Match
 Best Local Similarity 0.6%; Score 19; DB 1; Length 19;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCGC 69
 |||||
 Db 19 CCTCGCTATGGCTCCCGC 1

RESULT 472
 AX114983/c
 LOCUS
 DEFINITION Sequence 106 from Patent WO0129262. linear PAT 11-MAY-2001
 ACCESSION AX114983
 VERSION AX114983.1 GI:14031925
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 other sequences; artificial sequences.
 REFERENCE
 1
 AUTHORS Picoult-Newburg,L. and Pohl,M.
 TITLE Genotyping reagents, kits and methods of use thereof
 JOURNAL Patent: WO 0129262-A 106 26-APR-2001;
 FEATURES
 source
 1. .19
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Primer"

Query Match
 Best Local Similarity 0.6%; Score 19; DB 1; Length 19;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTCAGTGGT 2791
 |||||
 Db 19 CAGGCTGGAGTCAGTGGT 1

RESULT 473
 AX283206/c
 LOCUS
 DEFINITION Sequence 44 from Patent WO0179216. linear PAT 20-NOV-2001
 ACCESSION AX283206
 VERSION AX283206.1 GI:17044087
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 other sequences; artificial sequences.
 REFERENCE
 1

AUTHORS Uhlmann,E., Breipohl,G. and Will,D.W.
TITLE Polyamide nucleic acid derivatives, agents and methods for
producing them
JOURNAL Patent: WO 0179216-A 44 25-OCT-2001;
Aventis Pharma Deutschland GmbH (DE)
FEATURES Location/Qualifiers
source 1. .19

/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen
Sequenz:Oligonukleotide"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCGC 69
|||||
Db 19 CCTCGCTATGGCTCCCGC 1

RESULT 474
AX283275/c
LOCUS AX283275 19 bp DNA linear PAT 20-NOV-2001
DEFINITION Sequence 39 from Patent WO0179249.
ACCESSION AX283275
VERSION AX283275.1 GI:17044156
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Uhlmann,E., Breipohl,G. and Will,D.W.
TITLE Polyamide nucleic acid derivatives, agents and methods for
producing the same
JOURNAL Patent: WO 0179249-A 39 25-OCT-2001;
Aventis Pharma Deutschland GmbH (DE)
FEATURES Location/Qualifiers
source 1. .19

/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen Sequenz:
Oligonukleotide"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCGC 69
|||||
Db 19 CCTCGCTATGGCTCCCGC 1

RESULT 475
AX384658/c
LOCUS AX384658 19 bp DNA linear PAT 19-MAR-2002
DEFINITION Sequence 30 from Patent EP1182206.
ACCESSION AX384658
VERSION AX384658.1 GI:19577853
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE 1
AUTHORS Feymann,A., Uhlmann,E., Mag,M., Kretschmar,G., Helsberg,M. and
Winkler,I.
TITLE Stabilized oligonucleotids and the use thereof
JOURNAL Patent: EP 1182206-A 30 27-FEB-2002;
HOECHST AKTIENGESELLSCHAFT (DE)
FEATURES Location/Qualifiers
source 1. .19

/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisense Oligonukleotid"

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCGC 69
|||||
Db 19 CCTCGCTATGGCTCCCGC 1

RESULT 476
AR124506/c
LOCUS AR124506 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 75 from patent US 6171860.
ACCESSION AR124506
VERSION AR124506.1 GI:14109867
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Baker,B.F. and Cowsert,L.M.
TITLE Antisense inhibition of rank expression
JOURNAL Patent: US 6171860-A 75 09-JAN-2001;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2830 AAGTGATCTCCACCTCA 2848
|||||
Db 20 AAGTGATCTCCACCTCA 2

RESULT 477
AR152875/c
LOCUS AR152875 20 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 155 from patent US 6235470.
ACCESSION AR152875
VERSION AR152875.1 GI:15120407
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Sidransky,D.
TITLE Detection of neoplasia by analysis of saliva
JOURNAL Patent: US 6235470-A 155 22-MAY-2001;
FEATURES Location/Qualifiers
source 1. .20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2774 AGCTGGAGTCAGTCGTG 2792
|||||
Db 20 AGCTGGAGTCAGTCGTG 2

RESULT 478
BD134331/c
LOCUS BD134331 20 bp DNA linear PAT 18-SEP-2002

DEFINITION Detection of neoplasia by analysis of saliva.

ACCESSION BD134331

VERSION BD134331.1 GI:23229276

KEYWORDS JP 2002505888-A/155.

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 20)

AUTHORS Sidlanski, D.

TITLE Detection of neoplasia by analysis of saliva

JOURNAL Patent: JP 2002505888-A 155 26-FEB-2002;

COMMENT THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE

OS Artificial Sequence

PN JP 2002505888-A/155

PD 26-FEB-2002

PF 10-MAR-1999 JP 2000535774

PR 10-MAR-1998 US 09/038637

PI DAVID SIDLANSKI

PC C12N15/09,C12Q1/68,C12N15/00

CC nucleotide

FT source Location/Qualifiers

1. .20

FT source 1 (bases 1 to 20)

FEATURES Location/Qualifiers

1. .20

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 0.6%; Score 19; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.5e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2774 AGCGTGGAGTGCAGTGGTG 2792

DB 20 AGCGTGGAGTGCAGTGGTG 2

RESULT 479

BD138317/C

LOCUS

DEFINITION Antisense modulation of human MDM2 expression.

ACCESSION BD138317

VERSION BD138317.1 GI:23233262

KEYWORDS JP 2002508944-A/243.

SOURCE unidentified

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 20)

AUTHORS Miraglia, L.J., Nero, P., Graham, M.J., Monia, B.P. and Cowsert, L.M.

TITLE Antisense modulation of human MDM2 expression

JOURNAL Patent: JP 2002508944-A 243 26-MAR-2002;

COMMENT ISIS PHARMACEUTICALS INC

OS Unidentified

PN JP 2002508944-A/243

PD 26-MAR-2002

PF 26-MAR-1999 JP 2000538025

PR 26-MAR-1998 US 09/048810

PI LOREN J MIRAGLIA, PAMELA NERO, MARK J GRAHAM, BRETT P MONIA, LEX M

PI COWSERT

PC C12N15/09,A61K48/00,A61P9/10,A61P17/06,A61P35/00,C07H21/04//

PC C12Q1/68,

PC C12N15/00

CC Strandedness: Single;

CC Topology: Linear;

CC Antisense modulation of human MDM2 expression

FT source 1. .20

FT source Location/Qualifiers

1. .20

FEATURES Location/Qualifiers

1. .20

/organism="unidentified"

/mol_type="genomic DNA"

/db_xref="taxon:32644"

Query Match 0.6%; Score 19; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.5e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTGG 2790

DB 20 CCAGGCTGGAGTGCAGTGG 2

RESULT 480

BD225804/C

LOCUS

DEFINITION Promoter region of mouse and human telomerase RNA component genes.

ACCESSION BD225804

VERSION BD225804.1 GI:33035574

KEYWORDS JP 2002509699-A/7.

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1 (bases 1 to 20)

AUTHORS Keith, W.N.

TITLE Promoter region of mouse and human telomerase RNA component genes

JOURNAL Patent: JP 2002509699-A 7 02-APR-2002;

COMMENT CANCER RESEARCH CAMPAIGN TECHNOLOGY LTD

OS Artificial Sequence

PN JP 2002509699-A/7

PD 02-APR-2002

PF 29-JAN-1999 JP 2000529424

PR 29-JAN-1998 GB 9801902.9

PI WILLIAM NICOL KEITH

PC C12N15/09,A61K31/7105,A61K31/711,A61K38/76,A61K45/00,PC

A61K48/00,

PC A61P35/00,C12N1/15,C12N1/19,C12N1/21,C12N5/10,C12P21/02 PC

,C12Q1/68//C12N9/12,

PC (A61K35/76,A61K31:522),C12N15/00,A61K37/02,C12N5/00 CC

Description of Artificial Sequence: Primer

FT Key Location/Qualifiers

1. .20

FT source 1 (bases 1 to 20)

FEATURES Location/Qualifiers

1. .20

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 0.6%; Score 19; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 2.5e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCT 2863

DB 19 CTCAGCCTCCTGAGTAGCT 1

RESULT 481

AX019553/C

LOCUS

DEFINITION Sequence 7 from Patent WO938964.

ACCESSION AX019553

VERSION AX019553.1 GI:10043467

KEYWORDS

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1

AUTHORS Keith, W.N.

TITLE Promoter regions of the mouse and human telomerase rna component

JOURNAL Patent: WO 938964-A 7 05-AUG-1999;

genes

KEITH WILLIAM NICOL (GB); CANCER RES CAMPAIGN TECH (GB)

FEATURES
source
1. .20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer"

Query Match
Best Local Similarity 100.0%; Pred. No. 2.5e+02; Length 20;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2845 CTCAGCTCTCTGAGTAGCT 2863
|||||
Db 19 CTCAGCTCTCTGAGTAGCT 1

RESULT 482
AR153724/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 100.0%; Pred. No. 2.3e+02; Length 21;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 AGCCTCGCTATGGCTCCCA 67
|||||
Db 19 AGCCTCGCTATGGCTCCCA 1

RESULT 483
AR212319/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 100.0%; Pred. No. 2.3e+02; Length 21;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 AGCCTCGCTATGGCTCCCA 67
|||||
Db 19 AGCCTCGCTATGGCTCCCA 1

RESULT 484
AR267381/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .21
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 100.0%; Pred. No. 2.3e+02; Length 21;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 AGCCTCGCTATGGCTCCCA 67
|||||
Db 19 AGCCTCGCTATGGCTCCCA 1

RESULT 485
A63570
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
FEATURES
source
1. .20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 95.0%; Pred. No. 2.8e+02; Length 20;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2747
|||||
Db 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 20

RESULT 486
AR084543/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
FEATURES
source
1. .20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 100.0%; Pred. No. 2.3e+02; Length 21;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 AGCCTCGCTATGGCTCCCA 67
|||||
Db 19 AGCCTCGCTATGGCTCCCA 1

RESULT 484
AR267381/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1. .21
/organism="unknown"
/mol_type="genomic DNA"

Query Match
Best Local Similarity 100.0%; Pred. No. 2.3e+02; Length 21;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 AGCCTCGCTATGGCTCCCA 67
|||||
Db 19 AGCCTCGCTATGGCTCCCA 1

RESULT 485
A63570
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
FEATURES
source
1. .20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 95.0%; Pred. No. 2.8e+02; Length 20;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2747
|||||
Db 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 20

RESULT 486
AR084543/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT
FEATURES
source
1. .20
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 100.0%; Pred. No. 2.3e+02; Length 21;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 AGCCTCGCTATGGCTCCCA 67
|||||
Db 19 AGCCTCGCTATGGCTCCCA 1

REFERENCE 1 (bases 1 to 20)
 AUTHORS Matson,R.S., Coassin,P.J., Rampal,J.B. and Caskey,C.Thomas.
 TITLE Oligonucleotide repeat arrays
 JOURNAL Patent: US 5981185-A 32 09-NOV-1999;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 2.8e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGT 2747
 |||||
 Db 20 GTGTGTGTGTGTGTGTGT 1

RESULT 487
 AR123339/c
 LOCUS 20 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 5 from patent US 6169176.
 ACCESSION AR123339
 VERSION AR123339.1 GI:14108305
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Bruice,T.C. and Dev,A.P.
 TITLE Deoxynucleic alkyl thiourea compounds and uses thereof
 JOURNAL Patent: US 6169176-A 5 02-JAN-2001;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 2.8e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTG 2748
 |||||
 Db 20 TGTGTGTGTGTGTGTGTG 1

RESULT 488
 AR129684/c
 LOCUS 20 bp DNA linear PAT 16-MAY-2001
 DEFINITION Sequence 88 from patent US 6187545.
 ACCESSION AR129684
 VERSION AR129684.1 GI:14117581
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
 AUTHORS McKay,R., Butler,M.M., Wyatt,J. and Cowser,L.M.
 TITLE Antisense modulation of pepck-cytosolic expression
 JOURNAL Patent: US 6187545-A 88 13-FEB-2001;
 FEATURES Location/Qualifiers
 source 1..20
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 2.8e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGT 2747
 |||||
 Db 20 GTGTGTGTGTGTGTGTGT 1

RESULT 489
 BD138316/c
 LOCUS 20 bp DNA linear PAT 19-SEP-2002
 DEFINITION Antisense modulation of human MDM2 expression.
 ACCESSION BD138316
 VERSION BD138316.1 GI:23233261
 KEYWORDS JP 2002508944-A/242.
 SOURCE unidentified
 ORGANISM unidentified
 unclassified.

REFERENCE 1 (bases 1 to 20)
 AUTHORS Miraglia,L.J., Nero,P., Graham,M.J., Monia,B.P. and Cowser,L.M.
 TITLE Antisense modulation of human MDM2 expression
 JOURNAL Patent: JP 2002508944-A 242 26-MAR-2002;
 COMMENT ISIS PHARMACEUTICALS INC

OS Unidentified
 PN JP 2002508944-A/242
 PD 26-MAR-2002
 PF 26-MAR-1999 JP 2000538025
 PR 26-MAR-1998 US 09/048810
 PI LOREN J MIRAGLIA, PAMELA NERO, MARK J GRAHAM, BRETT P MONIA, LEX M

PI COWSERT
 PC C12N15/09, A61K48/00, A61P9/10, A61P17/06, A61P35/00, C07H21/04//
 PC C12Q1/58,
 PC C12N15/00
 CC Strandedness: Single;
 CC Topology: Linear;
 CC Antisense modulation of human MDM2 expression FH Key
 CC Location/Qualifiers
 FT source 1..20
 FT /organism='Unidentified'.

FEATURES
 source Location/Qualifiers
 1..20
 /organism="unidentified"
 /mol_type="genomic DNA"
 /db_xref="taxon:32644"

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 2.8e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2765 CTGTACCCAGGCTGGAGTG 2784
 |||||
 Db 20 CTGTACCCAGGCTGGAGTG 1

RESULT 490
 CQ771252
 LOCUS 20 bp DNA linear PAT 04-MAR-2004
 DEFINITION Sequence 3 from Patent WO2004009845.
 ACCESSION CQ771252
 VERSION CQ771252.1 GI:45125359
 KEYWORDS
 SOURCE synthetic construct
 ORGANISM synthetic construct
 other sequences; artificial sequences.

REFERENCE 1
 AUTHORS Mueller,N.
 TITLE Methods of screening for schizophrenia
 JOURNAL Patent: WO 2004009845-A 3 29-JAN-2004;
 MueUer, Norbert (DE)

FEATURES Location/Qualifiers
 source 1..20
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="SNAPSHOT primer for ICAM-1"

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 2.8e+02;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 758 CCGTGGTCTCTTCCCTGGAC 777
|||||
Db 1 CCGTGTCTCTTCCCTGGAC 20

RESULT 491
188661/c
LOCUS 188661 20 bp DNA linear PAT 10-AUG-1998
DEFINITION Sequence 43 from patent US 5719026.
ACCESSION 188661
VERSION 188661.1 GI:3408601
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Fukui,T., Katsuragi,K., Kinoshita,M. and Shin,S. deceased.
TITLE Method for detecting polymorphism of human cytochrome P4501A2 gene
JOURNAL Patent: US 5719026-A 43 17-FEB-1998;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2849 GCCTCTCTGAGTAGCTGGAC 2868
|||||
Db 20 GCGTCTCTGAGTAGCTGGAC 1

RESULT 492
AR205392
LOCUS AR205392 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 76 from patent US 6368856.
ACCESSION AR205392
VERSION AR205392.1 GI:21502963
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Wyatt,J.
TITLE Antisense inhibition of Phosphorylase kinase beta expression
JOURNAL Patent: US 6368856-A 76 09-APR-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2764 TCTGTCAACCAGCTGGACT 2783
|||||
Db 1 TCTGTCAACCAGCTGGTGT 20

RESULT 493
AR232228/c
LOCUS AR232228 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 18 from patent US 6455307.
ACCESSION AR232228
VERSION AR232228.1 GI:27274220
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)

AUTHORS McKay,R., Freier,S.M. and Wyatt,J.
TITLE Antisense modulation of casein kinase 2-alpha prime expression
JOURNAL Patent: US 6455307-A 18 24-SEP-2002;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGTG 2792
|||||
Db 20 CAGGCTGGAGTGCAGTGGCG 1

RESULT 494
AX092614
LOCUS AX092614 20 bp DNA linear PAT 21-MAR-2001
DEFINITION Sequence 26 from Patent WO0115676.
ACCESSION AX092614
VERSION AX092614.1 GI:13444671
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Hayden,M.R., Brooks-Wilson,A.R., Pimstone,S.N. and Clee,S.M.
TITLE Compositions and methods for modulating hdl cholesterol and triglyceride levels
JOURNAL Patent: WO 0115676-A 26 08-MAR-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2825 GGCTCAAGTGATCCTCCAC 2844
|||||
Db 1 GGCTCAAGCGATCCTCCAC 20

RESULT 495
AX179298
LOCUS AX179298 20 bp DNA linear PAT 03-JUL-2001
DEFINITION Sequence 1 from Patent WO0141813.
ACCESSION AX179298
VERSION AX179298.1 GI:14598969
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Linnik,M.D. and McNealy,P.A.
TITLE Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
JOURNAL Patent: WO 0141813-A 1 14-JUN-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.8e+02;

```

Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGT 2747
    |||||
Db 1 GTGTGTGTGTGTGTGTGT 20

RESULT 496
AX179299/C
LOCUS AX179299 20 bp DNA linear PAT 03-JUL-2001
DEFINITION Sequence 2 from Patent WO0141813.
ACCESSION AX179299
VERSION AX179299.1 GI:14598970
KEYWORDS
SOURCE
ORGANISM
other sequences; artificial sequences.
REFERENCE
AUTHORS Linnik,M.D. and Mcnealy,P.A.
TITLE Methods of treating lupus based on antibody affinity and screening
JOURNAL Methods and compositions for use thereof
PATENT: WO 0141813-A 2 14-JUN-2001;
LA JOLLA PHARMACEUTICAL COMPANY (CA)
FEATURES
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2748
    |||||
Db 20 TGTGTGTGTGTGTGTGTGT 1

RESULT 497
AX957375/C
LOCUS AX957375 20 bp DNA linear PAT 08-JAN-2004
DEFINITION Sequence 12 from Patent WO03092718.
ACCESSION AX957375
VERSION AX957375.1 GI:40785480
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS Pereira,H.A., Chodosh,J. and Callegan,M.C.
TITLE Treatment and inhibition of ocular infections and wounds by
JOURNAL cap37and cap37 peptides
PATENT: WO 03092718-A 12 13-NOV-2003;
Pereira, Heloise A. (US) ; Chodosh, James (US) ; Callegan, Michelle
C. (US)
FEATURES
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Completely synthesized"

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1073 AGGTGACGCTGAATGGGTT 1092
    |||||
Db 20 ACGTGACGCTGAATGGGTT 1

RESULT 498
BD016468

```

```

LOCUS BD016468 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Method for regulating telomeric length.
ACCESSION BD016468
VERSION BD016468.1 GI:22557644
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS Ota,K. and Shibata,T.
TITLE Method for regulating telomeric length
JOURNAL Patent: JP 2001231567-A 9 28-AUG-2001;
THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, JAPAN SCIENCE AND
TECHNOLOGY CORP
COMMENT
OS Artificial Sequence
PN JP 2001231567-A/9
PD 28-AUG-2001
PF 18-FEB-2000 JP 2000041929
PI KUNIKAZU OTA, TAKEHIKO SHIBATA
PC C12N15/09,A61K35/76,A61K38/00,A61K48/00,A61P35/00,A61P43/00,
PC C07H21/00,
PC C07K14/395,C12N9/16,C12N15/00,A61K37/02
CC Description of Artificial Sequence:synthetic DNA FH Key
Location/Qualifiers
1..20
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGT 2747
    |||||
Db 1 GTGTGTGTGTGTGTGTGT 20

RESULT 499
BD097545
LOCUS BD097545 20 bp DNA linear PAT 27-AUG-2002
DEFINITION Method for regulating telomeric length.
ACCESSION BD097545
VERSION BD097545.1 GI:22643119
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS Ota,K. and Shibata,T.
TITLE Method for regulating telomeric length
JOURNAL Patent: WO 0160996-A 9 23-AUG-2001;
THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, JAPAN SCIENCE AND
TECHNOLOGY CORP.KUNIHIRO OTA, TAKEHIKO SHIBATA
COMMENT
OS Artificial Sequence
PN WO 0160996-A/9
PD 23-AUG-2001
PF 14-FEB-2001 WO 2001JP001024
PI 18-FEB-2000 JP 00P 41929
PI KUNIHIRO OTA, TAKEHIKO SHIBATA
PC C12N15/09,A61K35/76,A61K38/00,A61K48/00,A61P35/00,A61P43/00,
PC C07H21/00,
PC C07K14/395,C12N9/16
CC Description of Artificial Sequence:synthetic DNA FH Key
Location/Qualifiers
1..20
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

FEATURES
source
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

```

```

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTATGT 2747
|||||
Db 1 GTGTGTGTGTGTGTGTGT 20

RESULT 500
AX398276/c
LOCUS
DEFINITION
  Conjugates of biologically stable polymers and polynucleotides for
  treating systemic lupus erythematosus.
ACCESSION
  BD105781
VERSION
  BD105781.1 GI:22651355
KEYWORDS
  JP 2001354569-A/6.
SOURCE
  synthetic construct
ORGANISM
  other sequences; artificial sequences.
REFERENCE
  1 (bases 1 to 20)
AUTHORS
  Conrad,M.J. and Coutts,S.
TITLE
  Conjugates of biologically stable polymers and polynucleotides for
  treating systemic lupus erythematosus
JOURNAL
  Patent: JP 2001354569-A 6 25-DEC-2001;
  LA JOLLA PHARMACEUTICAL CO
COMMENT
  OS Artificial Sequence
  PN JP 2001354569-A/6
  PD 25-DEC-2001
  PR 04-APR-2001 JP 2001106534
  PF 16-JAN-1990 US 466138,13-MAR-1990 US 494118 PI
  PC A61K31/7088,A61K47/48,A61P37/02,C07K14/00,C12N15/00,C12N15/00
  CC Synthetic Construct
  FH Key Location/Qualifiers
  FT source 1..20
  FT Location/Qualifiers
  FT /organism="Artificial Sequence".

FEATURES
  source
  1..20
  /organism="synthetic construct"
  /mol_type="genomic DNA"
  /db_xref="taxon:32630"

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTATGT 2747
|||||
Db 20 GTGTGTGTGTGTGTGTGT 1

RESULT 501
AX398276/c
LOCUS
DEFINITION
  Sequence 1 from Patent WO2020543.
ACCESSION
  AX398276
VERSION
  AX398276.1 GI:21261077
KEYWORDS
  synthetic construct
SOURCE
  synthetic construct
ORGANISM
  other sequences; artificial sequences.
REFERENCE
  1
AUTHORS
  Sinha,N.
TITLE
  Synthons for oligonucleotide synthesis
JOURNAL
  Patent: WO 0220543-A 1 14-MAR-2002;
  Avesia Biotechnology, Inc. (US)
FEATURES
  Location/Qualifiers
  source
  1..21
  /organism="synthetic construct"
  /mol_type="unassigned DNA"
  /db_xref="taxon:32630"

```

```

/note="Sequence prepared in Example 4"

Query Match          0.6%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 2.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGT 2747
|||||
Db 20 GTGTGTGTGTGTGTGTGT 1

RESULT 502
AX398277
LOCUS
DEFINITION
  Sequence 2 from Patent WO2020543.
ACCESSION
  AX398277
VERSION
  AX398277.1 GI:21261078
KEYWORDS
  synthetic construct
SOURCE
  synthetic construct
ORGANISM
  other sequences; artificial sequences.
REFERENCE
  1
AUTHORS
  Sinha,N.
TITLE
  Synthons for oligonucleotide synthesis
JOURNAL
  Patent: WO 0220543-A 2 14-MAR-2002;
  Avesia Biotechnology, Inc. (US)
FEATURES
  Location/Qualifiers
  source
  1..21
  /organism="synthetic construct"
  /mol_type="unassigned DNA"
  /db_xref="taxon:32630"
  /note="Sequence prepared in Example 4"

Query Match          0.6%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 2.7e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGT 2747
|||||
Db 1 GTGTGTGTGTGTGTGTGT 20

RESULT 503
AR242947
LOCUS
DEFINITION
  Sequence 93 from patent US 6475739.
ACCESSION
  AR242947
VERSION
  AR242947.1 GI:27289609
KEYWORDS
  Unknown.
SOURCE
  Unknown.
ORGANISM
  Unclassified.
REFERENCE
  1 (bases 1 to 22)
AUTHORS
  Brunkow,M.E., Proll,S., Paepfer,B. and Staehling-Hampton,K.
TITLE
  Methods for identifying genomic deletions
JOURNAL
  Patent: US 6475739-A 93 05-NOV-2002;
  Location/Qualifiers
FEATURES
  source
  1..22
  /organism="unknown"
  /mol_type="genomic DNA"

Query Match          0.6%; Score 18.4; DB 1; Length 22;
Best Local Similarity 95.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTCAGTGGTG 2792
|||||
Db 1 CAGGCTGGAGTCGAATGGTG 20

RESULT 504
AX384999
LOCUS

```

DEFINITION Sequence 93 from Patent WO0210455.
ACCESSION AX384999
VERSION AX384999.1 GI:19578127
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Brunkow,M.E., Proll,S. and Paepker,B.
TITLE Methods for identifying genomic deletions
JOURNAL Patent: WO 0210455-A 93 07-FEB-2002;
Celltech R & D, Inc. (US) ; Straehling-Hampton, Karen (US)
FEATURES
source
1..22
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PCR primer"
Query Match 0.6%; Score 18.4; DB 1; Length 22;
Best Local Similarity 95.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2773 CAGGCTGGAGTGCAGTGGT 2792
|||||
Db 1 CAGGCTGGAGTGCAGTGGT 20
RESULT 505
AX116678
LOCUS AX116678 23 bp DNA PAT 11-MAY-2001
DEFINITION Sequence 1801 from Patent WO0129262.
ACCESSION AX116678
VERSION AX116678.1 GI:14033620
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Picoult-Newburg,L. and Pohl,M.
TITLE Genotyping reagents, kits and methods of use thereof
JOURNAL Patent: WO 0129262-A 1801 26-APR-2001;
Orchid BioSciences, Inc. (US)
FEATURES
source
1..23
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"
Query Match 0.6%; Score 18.4; DB 1; Length 23;
Best Local Similarity 95.0%; Pred. No. 2.5e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
|||||
Db 4 TGTGTGTGTGTGTGTGTGTG 23
RESULT 506
AR074597/c
LOCUS AR074597 19 bp DNA PAT 28-AUG-2000
DEFINITION Sequence 14 from patent US 5955265.
ACCESSION AR074597
VERSION AR074597.1 GI:10001350
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Brook,J.David., Housman,D.E., Shaw,D.J., Harley,H.G. and Johnson,K.J.
TITLE DNA sequence encoding the myotonic dystrophy gene and uses thereof

JOURNAL Patent: US 5955265-A 14 21-SEP-1999;
FEATURES Location/Qualifiers
source
1..19
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18.2; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 2773 CAGGCTGGAGTGCAGTGGT 2791
|||||
Db 19 CAGGCTGGAGTGCARTGGY 1
RESULT 507
AR083936/c
LOCUS AR083936 19 bp DNA PAT 01-SEP-2000
DEFINITION Sequence 14 from patent US 5977333.
ACCESSION AR083936
VERSION AR083936.1 GI:10010707
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Brook,J.David., Housman,D.E., Shaw,D.J., Harley,H.G. and Johnson,K.J.
TITLE DNA sequence encoding the myotonic dystrophy gene and uses thereof
JOURNAL Patent: US 5977333-A 14 02-NOV-1999;
FEATURES Location/Qualifiers
source
1..19
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18.2; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 2773 CAGGCTGGAGTGCAGTGGT 2791
|||||
Db 19 CAGGCTGGAGTGCARTGGY 1
RESULT 508
I23816/c
LOCUS I23816 19 bp DNA PAT 07-OCT-1996
DEFINITION Sequence 2 from patent US 5538869.
ACCESSION I23816
VERSION I23816.1 GI:1603686
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Siciliano,M.J. and Liu,P.
TITLE In-situ hybridization probes for identification and banding of specific human chromosomes and regions
JOURNAL Patent: US 5538869-A 2 23-JUL-1996;
FEATURES Location/Qualifiers
source
1..19
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18.2; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 2773 CAGGCTGGAGTGCAGTGGT 2791
|||||
Db 19 CAGGCTGGAGTGCARTGGY 1

RESULT 509
LOCUS I29970 19 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 2 from patent US 5578493.
ACCESSION I29970
VERSION I29970.1 GI:1820761
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Gilliam,T.Conrad. and Tanzi,R.E.
TITLE Wilson's disease gene
JOURNAL Patent: US 5578493-A 2 26-NOV-1996;
FEATURES
source
1..19
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18.2; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 2773 CAGCTGGAGTGAGTGCT 2791
|||||
Db 19 CAGCTGGAGTGCACTGGY 1
|||||
RESULT 510
LOCUS AR013831 18 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 21 from patent US 5773218.
ACCESSION AR013831
VERSION AR013831.1 GI:3971285
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Method to identify compounds which modulate ICAM-related protein interactions
JOURNAL Patent: US 5773218-A 21 30-JUN-1998;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 440 GCAAGAACCTTACCCTAC 457
|||||
Db 1 GCAAGAACCTTACCCTAC 18
|||||
RESULT 511
LOCUS AR021351/c 18 bp DNA linear PAT 05-DEC-1998
DEFINITION Sequence 2 from patent US 5789573.
ACCESSION AR021351
VERSION AR021351.1 GI:3975966
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Baker,B., Bennett,C.Frank. and Anderson,K.P.
TITLE Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
JOURNAL Patent: US 5789573-A 2 04-AUG-1998;
FEATURES
source
1..18
Location/Qualifiers

/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 20 GCTCCTCTGCTACTCAGA 37
|||||
Db 18 GCTCCTCTGCTACTCAGA 1
|||||
RESULT 512
LOCUS AR030948/c 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 22 from patent US 5861493.
ACCESSION AR030948
VERSION AR030948.1 GI:5944162
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.Dan., Springer,R.H., Sprankle,K.G. and Ross,B.S.
TITLE Process for the synthesis of 2'-O-substituted pyrimidines
JOURNAL Patent: US 5861493-A 22 19-JAN-1999;
FEATURES
source
1..18
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1
|||||
RESULT 513
LOCUS AR030949/c 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 23 from patent US 5861493.
ACCESSION AR030949
VERSION AR030949.1 GI:5944163
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.Dan., Springer,R.H., Sprankle,K.G. and Ross,B.S.
TITLE Process for the synthesis of 2'-O-substituted pyrimidines
JOURNAL Patent: US 5861493-A 23 19-JAN-1999;
FEATURES
source
1..18
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1
|||||
RESULT 514
LOCUS AR030950/c 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 24 from patent US 5861493.
ACCESSION AR030950
FEATURES
source
1..18
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

VERSION AR030950.1 GI:5944164
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.Dan., Springer,R.H., Sprankle,K.G. and Ross,B.S.
TITLE Process for the synthesis of 2'-O-substituted pyrimidines
JOURNAL Patent: US 5861493-A 24 19-JAN-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1
RESULT 515
LOCUS AR030951/c 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 25 from patent US 5861493.
ACCESSION AR030951
VERSION AR030951.1 GI:5944165
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.Dan., Springer,R.H., Sprankle,K.G. and Ross,B.S.
TITLE Process for the synthesis of 2'-O-substituted pyrimidines
JOURNAL Patent: US 5861493-A 25 19-JAN-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1
RESULT 516
LOCUS AR030952/c 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 26 from patent US 5861493.
ACCESSION AR030952
VERSION AR030952.1 GI:5944166
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.Dan., Springer,R.H., Sprankle,K.G. and Ross,B.S.
TITLE Process for the synthesis of 2'-O-substituted pyrimidines
JOURNAL Patent: US 5861493-A 26 19-JAN-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1
RESULT 517
LOCUS AR033785 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 21 from patent US 5869262.
ACCESSION AR033785
VERSION AR033785.1 GI:5949390
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
JOURNAL Patent: US 5869262-A 21 09-FEB-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 440 GCAAGAACCTTACCCCTAC 457
Db 1 GCAAGAACCTTACCCCTAC 18
RESULT 518
LOCUS AR042445 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 21 from patent US 5811517.
ACCESSION AR042445
VERSION AR042445.1 GI:5962941
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE ICAM-related protein variants
JOURNAL Patent: US 5811517-A 21 22-SEP-1998;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 440 GCAAGAACCTTACCCCTAC 457
Db 1 GCAAGAACCTTACCCCTAC 18
RESULT 519
LOCUS AR054230/c 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5834607.
ACCESSION AR054230
VERSION AR054230.1 GI:5979092
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)
AUTHORS Manoharan,M. and Cook,P.Dan.
TITLE Amines and methods of making and using the same
JOURNAL Patent: US 5834607-A 1 10-NOV-1998;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 520
AR054236/c

LOCUS AR054236 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 7 from patent US 5834607.
ACCESSION AR054236
VERSION AR054236.1 GI:5979098
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)
AUTHORS Manoharan,M. and Cook,P.Dan.
TITLE Amines and methods of making and using the same
JOURNAL Patent: US 5834607-A 7 10-NOV-1998;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 521
AR058325

LOCUS AR058325 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 21 from patent US 5837822.
ACCESSION AR058325
VERSION AR058325.1 GI:5983902
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Humanized antibodies specific for ICAM related protein
JOURNAL Patent: US 5837822-A 21 17-NOV-1998;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCTTAC 457
|||||
Db 1 GCAAGAACCTTACCTTAC 18

RESULT 522

AR062601/c
LOCUS AR062601 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 1 from patent US 5843738.
ACCESSION AR062601
VERSION AR062601.1 GI:5990292
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 1 01-DEC-1998;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 523

AR062604/c
LOCUS AR062604 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 4 from patent US 5843738.
ACCESSION AR062604
VERSION AR062604.1 GI:5990295
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 4 01-DEC-1998;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCACCTCAGCCTC 2853
|||||
Db 18 TCCTCCACCTCAGCCTC 1

RESULT 524

AR062605/c
LOCUS AR062605 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 5 from patent US 5843738.
ACCESSION AR062605
VERSION AR062605.1 GI:5990296
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 5 01-DEC-1998;
FEATURES Location/Qualifiers
source
1. .18

```

/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.6%; Score 18; DB 1; Length 18;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCCATCG 1381
Db 18 CTTTCCCACTGCCCATCG 1

RESULT 525
AR062681
LOCUS AR062681 18 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 81 from patent US 5843738.
ACCESSION AR062681
VERSION AR062681.1 GI:5990372
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5843738-A 81 01-DEC-1998;
FEATURES
source
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.6%; Score 18; DB 1; Length 18;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 1 GCCTCGCTATGGCTCCCA 18

RESULT 526
AR074312/c
LOCUS AR074312 18 bp DNA linear PAT 28-AUG-2000
DEFINITION Sequence 120 from patent US 5952490.
ACCESSION AR074312
VERSION AR074312.1 GI:10001067
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Hanecak,R.C., Anderson,K.P., Bennett,C.Frank., Chiang,M.-Y.,
Brown-Driver,V.L., Ecker,D.J., Vickers,T.A., Wyatt,J.R. and
Imbach,J.Louis.
TITLE Oligonucleotides having a conserved G4 core sequence
JOURNAL Patent: US 5952490-A 120 14-SEP-1999;
FEATURES
source
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.6%; Score 18; DB 1; Length 18;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCCACTCAGCCTC 2853
Db 18 TCCTCCCACTCAGCCTC 1

RESULT 527
AR088151
LOCUS AR088151 18 bp DNA linear PAT 07-SEP-2000
```

```

DEFINITION Sequence 21 from patent US 5989843.
ACCESSION AR088151
VERSION AR088151.1 GI:10014914
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Methods for identifying modulators of protein kinase C
phosphorylation of ICAM-related protein
JOURNAL Patent: US 5989843-A 21 23-NOV-1999;
FEATURES
source
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.6%; Score 18; DB 1; Length 18;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCCTAC 457
Db 1 GCAAGAACCTTACCCCTAC 18

RESULT 528
AR102941
LOCUS AR102941 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 21 from patent US 6087130.
ACCESSION AR102941
VERSION AR102941.1 GI:12814529
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE Antibody substances that bind to ICAM-related protein
JOURNAL Patent: US 6087130-A 21 11-JUL-2000;
FEATURES
source
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.6%; Score 18; DB 1; Length 18;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCCTAC 457
Db 1 GCAAGAACCTTACCCCTAC 18

RESULT 529
AR104704/c
LOCUS AR104704 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 1 from patent US 6093811.
ACCESSION AR104704
VERSION AR104704.1 GI:12817412
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 6093811-A 1 25-JUL-2000;
FEATURES
source
Location/Qualifiers
1..18
/organism="unknown"
/mol_type="unassigned DNA"
```

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
| | | | | | | | | | | | | | | | | |
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 530

AR104707/c AR104707 18 bp DNA linear PAT 14-FEB-2001

LOCUS Sequence 4 from patent US 6093811.

DEFINITION AR104707

ACCESSION AR104707

VERSION AR104707.1 GI:12817415

KEYWORDS

SOURCE

ORGANISM

Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Bennett,C.Frank. and Mirabelli,C.K.

TITLE Oligonucleotide modulation of cell adhesion

JOURNAL Patent: US 6093811-A 4 25-JUL-2000;

FEATURES Location/Qualifiers

1..18

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 3.5e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0;

QY 2836 TCCTCCCACTGAGCCTC 2853

| | | | | | | | | | | | | | | | | |

Db 18 TCCTCCCACTGAGCCTC 1

RESULT 531

AR104708/c AR104708 18 bp DNA linear PAT 14-FEB-2001

LOCUS Sequence 5 from patent US 6093811.

DEFINITION AR104708

ACCESSION AR104708

VERSION AR104708.1 GI:12817416

KEYWORDS

SOURCE

ORGANISM

Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Bennett,C.Frank. and Mirabelli,C.K.

TITLE Oligonucleotide modulation of cell adhesion

JOURNAL Patent: US 6093811-A 5 25-JUL-2000;

FEATURES Location/Qualifiers

1..18

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 3.5e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCCATCG 1381

| | | | | | | | | | | | | | | | | |

Db 18 CTTTCCCACTGCCCATCG 1

RESULT 532

AR104784 AR104784 18 bp DNA linear PAT 14-FEB-2001

LOCUS Sequence 81 from patent US 6093811.

DEFINITION AR104784

ACCESSION AR104784

VERSION AR104784.1 GI:12817492

KEYWORDS

SOURCE

Unknown.

ORGANISM

Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Bennett,C.Frank. and Mirabelli,C.K.

TITLE Oligonucleotide modulation of cell adhesion

JOURNAL Patent: US 6093811-A 81 25-JUL-2000;

FEATURES Location/Qualifiers

1..18

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 3.5e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

| | | | | | | | | | | | | | | | | |

Db 1 GCCTCGCTATGGCTCCCA 18

RESULT 533

AR105526/c

LOCUS Sequence 1 from patent US 6096722.

DEFINITION AR105526

ACCESSION AR105526

VERSION AR105526.1 GI:12819123

KEYWORDS

SOURCE

ORGANISM

Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.

TITLE Antisense modulation of cell adhesion molecule expression and

JOURNAL treatment of cell adhesion molecule-associated diseases

FEATURES Patent: US 6096722-A 1 01-AUG-2000;

Location/Qualifiers

1..18

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 3.5e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

| | | | | | | | | | | | | | | | | |

Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 534

AR105529/c

LOCUS Sequence 4 from patent US 6096722.

DEFINITION AR105529

ACCESSION AR105529

VERSION AR105529.1 GI:12819126

KEYWORDS

SOURCE

ORGANISM

Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.

TITLE Antisense modulation of cell adhesion molecule expression and

JOURNAL treatment of cell adhesion molecule-associated diseases

FEATURES Patent: US 6096722-A 4 01-AUG-2000;

Location/Qualifiers

1..18

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 3.5e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCACCTCAGCCTC 2853
Db 18 TCCTCCACCTCAGCCTC 1

RESULT 535
AR105530/c
LOCUS AR105530 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 5 from patent US 6096722.
ACCESSION AR105530
VERSION AR105530.1 GI:12819127
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 5 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCACTGCCCATCG 1381
Db 18 CTTTCCACTGCCCATCG 1

RESULT 536
AR105606
LOCUS AR105606 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 81 from patent US 6096722.
ACCESSION AR105606
VERSION AR105606.1 GI:12819203
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 81 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCACTGCCCATCG 1381
Db 18 CTTTCCACTGCCCATCG 1

RESULT 536
AR105606
LOCUS AR105606 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 81 from patent US 6096722.
ACCESSION AR105606
VERSION AR105606.1 GI:12819203
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 81 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGTCCCA 67
Db 1 GCCTCGCTATGGTCCCA 18

RESULT 537
AR105611/c
LOCUS AR105611 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 86 from patent US 6096722.
ACCESSION AR105611
VERSION AR105611.1 GI:12819208
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 86 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 86 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1192 GGCCAGCTTATACACAAG 1209
Db 18 GGCCAGCTTATACACAAG 1

RESULT 538
AR105612/c
LOCUS AR105612 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 87 from patent US 6096722.
ACCESSION AR105612
VERSION AR105612.1 GI:12819209
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 87 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1254 CGAGAGGGATTGTCGGG 1271
Db 18 CGAGAGGGATTGTCGGG 1

RESULT 539
AR105613/c
LOCUS AR105613 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 88 from patent US 6096722.
ACCESSION AR105613
VERSION AR105613.1 GI:12819210
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 88 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1286 CAGAAAATTCACGACAGA 1303

|||||
18 CAGAAAATCCAGCAGA 1

RESULT 540
AR105614/c
LOCUS
DEFINITION Sequence 89 from patent US 6096722.
ACCESSION AR105614
VERSION AR105614.1 GI:12819211
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 90 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1296 CCAGCAGACTCCAAATGTG 1313
|||||
18 CCAGCAGACTCCAAATGTG 1

RESULT 541
AR105615/c
LOCUS
DEFINITION Sequence 90 from patent US 6096722.
ACCESSION AR105615
VERSION AR105615.1 GI:12819212
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 90 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1296 CCAGCAGACTCCAAATGTG 1313
|||||
18 CCAGCAGACTCCAAATGTG 1

RESULT 542
AR105616/c
LOCUS
DEFINITION Sequence 91 from patent US 6096722.
ACCESSION AR105616
VERSION AR105616.1 GI:12819213
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)

QY 1324 GGGAACTTCGCGAG 1341
|||||
18 GGGAACTTCGCGAG 1

RESULT 543
AR105617/c
LOCUS
DEFINITION Sequence 92 from patent US 6096722.
ACCESSION AR105617
VERSION AR105617.1 GI:12819214
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 92 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1337 CCGAGCTCAAGTGTCTAA 1354
|||||
18 CCGAGCTCAAGTGTCTAA 1

RESULT 544
AR105618/c
LOCUS
DEFINITION Sequence 93 from patent US 6096722.
ACCESSION AR105618
VERSION AR105618.1 GI:12819215
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 93 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1380 CGGGGAATCAGTGTGT 1397
|||||
18 CGGGGAATCAGTGTGT 1

RESULT 545
AR105619/c
LOCUS
DEFINITION Sequence 94 from patent US 6096722.
ACCESSION AR105619
VERSION AR105619.1 GI:12819216
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 94 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1390 GTGACTGTCACTCGAGAT 1407
|||||
18 GTGACTGTCACTCGAGAT 1

Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
Patent: US 6096722-A 91 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1337 CCGAGCTCAAGTGTCTAA 1354
|||||
18 CCGAGCTCAAGTGTCTAA 1

RESULT 543
AR105617/c
LOCUS
DEFINITION Sequence 92 from patent US 6096722.
ACCESSION AR105617
VERSION AR105617.1 GI:12819214
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 92 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1380 CGGGGAATCAGTGTGT 1397
|||||
18 CGGGGAATCAGTGTGT 1

RESULT 544
AR105618/c
LOCUS
DEFINITION Sequence 93 from patent US 6096722.
ACCESSION AR105618
VERSION AR105618.1 GI:12819215
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 93 01-AUG-2000;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1390 GTGACTGTCACTCGAGAT 1407
|||||
18 GTGACTGTCACTCGAGAT 1

```
Db      18 GTGACTGTCTACTCGAGAT 1
RESULT 545
AR105620/c
LOCUS      18 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 95 from patent US 6096722.
ACCESSION AR105620
VERSION    AR105620.1 GI:12819217
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS   Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE     Antisense modulation of cell adhesion molecule expression and
          treatment of cell adhesion molecule-associated diseases
JOURNAL   Patent: US 6096722-A 95 01-AUG-2000;
FEATURES   Location/Qualifiers
            source
              1..18
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1542 TGCAGGCGCTCAGCAGTA 1559
Db      18 TGCAGGCGCTCAGCAGTA 1
RESULT 548
AR105624/c
LOCUS      18 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 99 from patent US 6096722.
ACCESSION AR105624
VERSION    AR105624.1 GI:12819221
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS   Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE     Antisense modulation of cell adhesion molecule expression and
          treatment of cell adhesion molecule-associated diseases
JOURNAL   Patent: US 6096722-A 99 01-AUG-2000;
FEATURES   Location/Qualifiers
            source
              1..18
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1556 CGTACCTCTATAACCGCC 1573
Db      18 CGTACCTCTATAACCGCC 1
RESULT 549
AR105626/c
LOCUS      18 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 101 from patent US 6096722.
ACCESSION AR105626
VERSION    AR105626.1 GI:12819223
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS   Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE     Antisense modulation of cell adhesion molecule expression and
          treatment of cell adhesion molecule-associated diseases
JOURNAL   Patent: US 6096722-A 101 01-AUG-2000;
FEATURES   Location/Qualifiers
            source
              1..18
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1743 TGCAGCTACCTACCGG 1760
Db      18 TGCAGCTACCTACCGG 1
TITLE     Antisense modulation of cell adhesion molecule expression and
          treatment of cell adhesion molecule-associated diseases
JOURNAL   Patent: US 6096722-A 98 01-AUG-2000;
FEATURES   Location/Qualifiers
            source
              1..18
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1435 AGGAGCACTCAAGGGGAG 1452
Db      18 AGGAGCACTCAAGGGGAG 1
RESULT 546
AR105621/c
LOCUS      18 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 96 from patent US 6096722.
ACCESSION AR105621
VERSION    AR105621.1 GI:12819218
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS   Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE     Antisense modulation of cell adhesion molecule expression and
          treatment of cell adhesion molecule-associated diseases
JOURNAL   Patent: US 6096722-A 96 01-AUG-2000;
FEATURES   Location/Qualifiers
            source
              1..18
                /organism="unknown"
                /mol_type="unassigned DNA"
Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1487 CCCGGTATGAGATTGTCA 1504
Db      18 CCCGGTATGAGATTGTCA 1
RESULT 547
AR105623/c
LOCUS      18 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 98 from patent US 6096722.
ACCESSION AR105623
VERSION    AR105623.1 GI:12819220
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS   Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
```

```

RESULT 550
AR105627/c
LOCUS      18 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 102 from patent US 6096722.
ACCESSION  AR105627
VERSION     AR105627.1  GI:12819224
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE       Antisense modulation of cell adhesion molecule expression and
            treatment of cell adhesion molecule-associated diseases
JOURNAL     Patent: US 6096722-A 102 01-AUG-2000;
FEATURES    Location/Qualifiers
            source
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1791 CTCAGTCAGATACACAG 1808
Db      18 CTCAGTCAGATACACAG 1

RESULT 551
AR105628/c
LOCUS      18 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 103 from patent US 6096722.
ACCESSION  AR105628
VERSION     AR105628.1  GI:12819225
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE       Antisense modulation of cell adhesion molecule expression and
            treatment of cell adhesion molecule-associated diseases
JOURNAL     Patent: US 6096722-A 103 01-AUG-2000;
FEATURES    Location/Qualifiers
            source
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1844 TAGGCCACGCATCTGATC 1861
Db      18 TAGGCCACGCATCTGATC 1

RESULT 552
AR105630/c
LOCUS      18 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 105 from patent US 6096722.
ACCESSION  AR105630
VERSION     AR105630.1  GI:12819227
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE       Antisense modulation of cell adhesion molecule expression and
            treatment of cell adhesion molecule-associated diseases
JOURNAL     Patent: US 6096722-A 105 01-AUG-2000;
FEATURES    Location/Qualifiers
            source
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1844 TAGGCCACGCATCTGATC 1861
Db      18 TAGGCCACGCATCTGATC 1

RESULT 553
AR108787/c
LOCUS      18 bp      DNA      linear      PAT 14-FEB-2001
DEFINITION Sequence 7 from patent US 6111094.
ACCESSION  AR108787
VERSION     AR108787.1  GI:12824274
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Bennett,C.Frank., Condon,T.P. and Flournoy,S.Cheng.
TITLE       Enhanced antisense modulation of ICAM-1
JOURNAL     Patent: US 6111094-A 7 29-AUG-2000;
FEATURES    Location/Qualifiers
            source
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1412 AGGGCACCTACTCTGTC 1429
Db      18 AGGGCACCTACTCTGTC 1

RESULT 554
AR119587
LOCUS      18 bp      DNA      linear      PAT 16-MAY-2001
DEFINITION Sequence 21 from patent US 6153395.
ACCESSION  AR119587
VERSION     AR119587.1  GI:14102286
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Gallatin,W.Michael. and Vazeux,R.
TITLE       ICAM-related protein
JOURNAL     Patent: US 6153395-A 21 28-NOV-2000;
FEATURES    Location/Qualifiers
            source
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGG 2117
Db      18 TGACGGATGCCAGCTTGG 1

RESULT 554
AR119587
LOCUS      18 bp      DNA      linear      PAT 16-MAY-2001
DEFINITION Sequence 21 from patent US 6153395.
ACCESSION  AR119587
VERSION     AR119587.1  GI:14102286
KEYWORDS    Unknown.
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Gallatin,W.Michael. and Vazeux,R.
TITLE       ICAM-related protein
JOURNAL     Patent: US 6153395-A 21 28-NOV-2000;
FEATURES    Location/Qualifiers
            source
            1..18
            /organism="unknown"
            /mol_type="unassigned DNA"

Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      440 GCAAGAACCTTACCCTAC 457
Db      1 GCAAGAACCTTACCCTAC 18

RESULT 555

```


AR120104/c
LOCUS AR120104 18 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 4 from patent US 6153737.
ACCESSION AR120104
VERSION AR120104.1 GI:14102803
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
UNCLASSIFIED.
REFERENCE 1 (bases 1 to 18)
AUTHORS Manoharan,M., Cook,P.Dan. and Bennett,C.Frank.
TITLE Derivatized oligonucleotides having improved uptake and other
properties
JOURNAL Patent: US 6153737-A 4 28-NOV-2000;
FEATURES Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1
RESULT 556
AR123188/c
LOCUS AR123188 18 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1 from patent US 6169079.
ACCESSION AR123188
VERSION AR123188.1 GI:14108154
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
UNCLASSIFIED.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 1 02-JAN-2001;
FEATURES Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1
RESULT 557
AR123191/c
LOCUS AR123191 18 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 4 from patent US 6169079.
ACCESSION AR123191
VERSION AR123191.1 GI:14108157
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
UNCLASSIFIED.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 4 02-JAN-2001;
FEATURES Location/Qualifiers
1. .18
/organism="unknown"

/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2836 TCCTCCACCTCAGCCTC 2853
|||||
Db 18 TCCTCCACCTCAGCCTC 1
RESULT 558
AR123192/c
LOCUS AR123192 18 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 5 from patent US 6169079.
ACCESSION AR123192
VERSION AR123192.1 GI:14108158
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
UNCLASSIFIED.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 5 02-JAN-2001;
FEATURES Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1364 CTTTCCCACTGCCCATCG 1381
|||||
Db 18 CTTTCCCACTGCCCATCG 1
RESULT 559
AR123268
LOCUS AR123268 18 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 81 from patent US 6169079.
ACCESSION AR123268
VERSION AR123268.1 GI:14108234
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
UNCLASSIFIED.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6169079-A 81 02-JAN-2001;
FEATURES Location/Qualifiers
1. .18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 1 GCCTCGCTATGGCTCCCA 18
RESULT 560
AR152356/c
LOCUS AR152356 18 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 1 from patent US 6232463.
ACCESSION AR152356
VERSION AR152356.1 GI:15118406

KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.Dan., Manoharan,M. and Ramasamy,K.S.
TITLE Substituted purines and oligonucleotide cross-linking
JOURNAL Patent: US 6232463-A 1 15-MAY-2001;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 561
AR153730/c
LOCUS AR153730 18 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 7 from patent US 6235886.
ACCESSION AR153730
VERSION AR153730.1 GI:15121262
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)
AUTHORS Manoharan,M. and Cook,P.Dan.
TITLE Methods of synthesis and use
JOURNAL Patent: US 6235886-A 7 22-MAY-2001;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 562
AR153770/c
LOCUS AR153770 18 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 5 from patent US 6235889.
ACCESSION AR153770
VERSION AR153770.1 GI:15121302
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)
AUTHORS Ulanovsky,L.
TITLE Nucleic acid amplification using modular branched primers
JOURNAL Patent: US 6235889-A 5 22-MAY-2001;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 844 GTCACCTATGGCAACGAC 861
Db 18 GTCACCTATGGCAACGAC 1

RESULT 563
BD266259
LOCUS BD266259 18 bp DNA linear PAT 17-JUL-2003
DEFINITION Universal arrays.
ACCESSION BD266259
VERSION BD266259.1 GI:33076027
KEYWORDS JP 2002539849-A/259.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences: artificial sequences.

REFERENCE 1 (bases 1 to 18)
AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S., Lockhart,D.J., Ryder,T. and Sklar,P.
TITLE Universal arrays
JOURNAL Patent: JP 2002539849-A 259 26-NOV-2002;
COMMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC

OS Artificial Sequence
PN JP 2002539849-A/259
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI
JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
HUANG,PAUL KAPLAN,ERIC
PI S LANDER,
PI DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
PC C12Q1/68.C12M1/00.C12N15/09.C12N15/09.C12N15/09.G01N33/53. PC
G01N33/566.
PC G01N37/00.C12N15/00.C12N15/00.C12N15/00
CC Primer
FH Key Location/Qualifiers
FT source 1..18
/organism="Artificial Sequence".

FEATURES
source 1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 759 CGTGGTCTGTTCCCTGGA 776
Db 1 CGTGGTCTGTTCCCTGGA 18

RESULT 564
BD266261
LOCUS BD266261 18 bp DNA linear PAT 17-JUL-2003
DEFINITION Universal arrays.
ACCESSION BD266261
VERSION BD266261.1 GI:33076029
KEYWORDS JP 2002539849-A/261.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences: artificial sequences.

REFERENCE 1 (bases 1 to 18)
AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S., Lockhart,D.J., Ryder,T. and Sklar,P.
TITLE Universal arrays
JOURNAL Patent: JP 2002539849-A 261 26-NOV-2002;
COMMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH,AFFYMETRIX INC

OS Artificial Sequence
PN JP 2002539849-A/261
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI

JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
HUANG,PAUL KAPLAN,ERIC
PI S LANDER,
DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
PC C12Q1/68,C12M1/00,C12N15/09,C12N15/09,G01N33/53, PC
G01N33/566,
PC G01N37/00,C12N15/00,C12N15/00,C12N15/00
CC Primer
FH Key Location/Qualifiers
FT source 1..18
FT Location/Qualifiers
REFERENCE 1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 204 CACCTCCTGTGACGACC 221
|||||
Db 1 CACCTCCTGTGACGACC 18

RESULT 565
BD266403/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1..18
AUTHORS
TITLE
JOURNAL
COMMENT
OS Artificial Sequence
PN JP 2002539849-A/403
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI
JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
HUANG,PAUL KAPLAN,ERIC
PI S LANDER,
DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
PC C12Q1/68,C12M1/00,C12N15/09,C12N15/09,G01N33/53, PC
G01N33/566,
PC G01N37/00,C12N15/00,C12N15/00,C12N15/00
CC Primer
FH Key Location/Qualifiers
FT source 1..18
FT Location/Qualifiers
REFERENCE 1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 782 TGTTCCTCAGTCTCGGAGG 799
|||||
Db 18 TGTTCCTCAGTCTCGGAGG 1

JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
HUANG,PAUL KAPLAN,ERIC
PI S LANDER,
DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
PC C12Q1/68,C12M1/00,C12N15/09,C12N15/09,G01N33/53, PC
G01N33/566,
PC G01N37/00,C12N15/00,C12N15/00,C12N15/00
CC Primer
FH Key Location/Qualifiers
FT source 1..18
FT Location/Qualifiers
REFERENCE 1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 782 TGTTCCTCAGTCTCGGAGG 799
|||||
Db 18 TGTTCCTCAGTCTCGGAGG 1

RESULT 566
BD266406/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 18)
AUTHORS
TITLE
JOURNAL
COMMENT
OS Artificial Sequence
PN JP 2002539849-A/406
PD 26-NOV-2002
PF 27-MAR-2000 JP 2000608794
PR 26-MAR-1999 US 60/126473,23-JUN-1999 US 60/140359 PI
JIAN BING FAN,JOEL N HIRSCHHORN,XIAOHUA
HUANG,PAUL KAPLAN,ERIC
PI S LANDER,
DAVID J LOCKHART,THOMAS RYDER,PAMELA SKLAR
PC C12Q1/68,C12M1/00,C12N15/09,C12N15/09,G01N33/53, PC
G01N33/566,
PC G01N37/00,C12N15/00,C12N15/00,C12N15/00
CC Primer
FH Key Location/Qualifiers
FT source 1..18
FT Location/Qualifiers
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1464 GGTGACCGTGAATGTGCT 1481
|||||
Db 18 GGTGACCGTGAATGTGCT 1

RESULT 567
BD272201/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 18)
AUTHORS
TITLE
JOURNAL
COMMENT
OS Unidentified
PN JP 2002531378-A/7
PD 24-SEP-2002
PF 15-APR-1999 JP 2000544679
PR 17-APR-1998 US 09/062416
PI FRANK C BENNETT,THOMAS P CONDON SHIN CHENG FLOURNOY PC
C07H21/04,A61K31/711,A61K48/00,A61P9/10,A61P31/12,A61P31/18, PC
A61P43/00,
PC C12N15/09,C12Q1/68,C12N15/00
CC Strandedness: Single;
CC Topology: Linear;

CC Strengthened antisense control of ICAM-1
 FH Key Location/Qualifiers
 FT source 1..18
 FT /organism='Unidentified'.
 Location/Qualifiers
 FEATURES source 1..18
 /organism='unidentified'
 /mol_type='genomic DNA'
 /db_xref='taxon:32644'

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 3.5e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGG 2117
 |||||
 Db 18 TGACGGATGCCAGCTTGG 1

RESULT 568
 E09017/c

LOCUS E09017 18 bp DNA linear PAT 29-SEP-1997
 DEFINITION Antisense DNA against human ICAM-1 gene.

ACCESSION E09017
 VERSION E09017.1 GI:22025643
 KEYWORDS JP 199509976-A/1.

SOURCE unidentified
 ORGANISM unidentified.

REFERENCE 1 (bases 1 to 18)
 AUTHORS Iwasa,S., Tada,H. and Doken,K.

TITLE MODIFIED OLIGONUCLEOTIDE
 JOURNAL Patent: JP 199509976-A 1 18-APR-1995;
 TAKEDA CHEM IND LTD

OS None
 OC Artificial sequences.
 PN JP 199509976-A/1

PD 18-APR-1995
 PF 30-SEP-1993 JP 1993244753
 PI IWASA SUSUMU, TADA HIROKO, DOKEN KAZUHIRO
 PC C12N15/09,C07H21/00,C07H21/04,C07K7/06;
 CC strandness: Single;
 CC topology: Linear;
 CC hypothetical: No;
 CC anti-sense: Yes;
 FH Key Location/Qualifiers

FT source 1..18
 FT /organism='Artificial sequences' FT
 misc_feature 1..18 /note='phosphorothioate oligonucleotide'.
 FT Location/Qualifiers

FEATURES source 1..18
 /organism='unidentified'
 /mol_type='genomic DNA'
 /db_xref='taxon:32644'

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 3.5e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 |||||
 Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 569
 E09087/c

LOCUS E09087 18 bp DNA linear PAT 29-SEP-1997
 DEFINITION Antisense oligonucleotide which acts as ICAM-1 inhibitor.

ACCESSION E09087
 VERSION E09087.1 GI:22025713
 KEYWORDS JP 1995112997-A/1.

SOURCE unidentified
 ORGANISM unidentified
 unclassified.
 REFERENCE 1 (bases 1 to 18)
 Tanimura,H., Hayase,Y., Naka,T. and Iwasa,S.
 OLIGONUCLEOTIDE DERIVATIVE, ITS PRODUCTION SYNTHETIC INTERMEDIATE
 THEREFOR AND USE THEREOF
 Patent: JP 1995112997-A 1 02-MAY-1995;
 JOURNAL TAKEDA CHEM IND LTD

COMMENT OS None

OC Artificial sequences.
 PN JP 1995112997-A/1

PD 02-MAY-1995
 PF 04-AUG-1994 JP 1994183306
 PR 06-AUG-1993 JP 93P 196327

PI TANIMURA HIROSHI, HAYASE YOJI, NAKA TATSUHIKO, IWASA SUSUMU PC
 C07H21/04,A61K31/70,A61K31/70,A61K31/70,A61K48/00,C07H21/00; CC
 strandedness: Single;
 CC topology: Linear;

FH Key Location/Qualifiers

FT source 1..18

FT /organism='Artificial sequences' FT

misc_feature 1..18 /note='phosphorothioete antisense FT

FT oligonucleotide,many types of modification are occurred'.
 FT Location/Qualifiers

FEATURES source 1..18
 /organism='unidentified'
 /mol_type='genomic DNA'
 /db_xref='taxon:32644'

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 3.5e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 |||||
 Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 570

I19568/c

LOCUS I19568

DEFINITION Sequence 6 from patent US 5506212.

ACCESSION I19568

VERSION I19568.1 GI:1599923

KEYWORDS

SOURCE Unknown.

ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Hoke,G. and Cook,P.D.

TITLE Oligonucleotides with substantially chirally pure phosphorothioate linkages
 JOURNAL Patent: US 5506212-A 6 09-APR-1996;

FEATURES source Location/Qualifiers

1..18

/organism='unknown'

/mol_type='unassigned DNA'

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 3.5e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

|||||

Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 571

I20603/c

LOCUS 120603 18 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 1 from patent US 5514788.
ACCESSION 120603
VERSION 120603.1 GI:1600958
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 1 07-MAY-1996;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 572
120606/c
LOCUS 120606 18 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 4 from patent US 5514788.
ACCESSION 120606
VERSION 120606.1 GI:1600961
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 4 07-MAY-1996;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2836 TCCTCCACCTCAGCCTC 2853
Db 18 TCCTCCACCTCAGCCTC 1

RESULT 573
120607/c
LOCUS 120607 18 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 5 from patent US 5514788.
ACCESSION 120607
VERSION 120607.1 GI:1600962
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 5 07-MAY-1996;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1364 CTTTCCCACTGCCCATCG 1381
Db 18 CTTTCCCACTGCCCATCG 1

RESULT 574
120683
LOCUS 120683 18 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 81 from patent US 5514788.
ACCESSION 120683
VERSION 120683.1 GI:1601038
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5514788-A 81 07-MAY-1996;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 50 GCCTCGCTATGGCTCCCA 67
Db 1 GCCTCGCTATGGCTCCCA 18

RESULT 575
121594/c
LOCUS 121594 18 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 6 from patent US 5521302.
ACCESSION 121594
VERSION 121594.1 GI:1601948
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.D.
TITLE Process for preparing oligonucleotides having chiral phosphorus linkages
JOURNAL Patent: US 5521302-A 6 28-MAY-1996;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 576
121895
LOCUS 121895 18 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 21 from patent US 5525487.
ACCESSION 121895
VERSION 121895.1 GI:1602249
KEYWORDS

JOURNAL Patent: US 5591623-A 5 07-JAN-1997;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCCATCG 1381
|||||
Db 18 CTTTCCCACTGCCCATCG 1

RESULT 582
I33376
LOCUS 133376 18 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 81 from patent US 5591623.
ACCESSION I33376
VERSION I33376.1 GI:1824167
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank. and Mirabelli,C.K.
TITLE Oligonucleotide modulation of cell adhesion
JOURNAL Patent: US 5591623-A 81 07-JAN-1997;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGTCCCA 67
|||||
Db 1 GCCTCGCTATGGTCCCA 18

RESULT 583
I63599
LOCUS 163599 18 bp DNA linear PAT 07-OCT-1997
DEFINITION Sequence 21 from patent US 5663293.
ACCESSION I63599
VERSION I63599.1 GI:2481172
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Gallatin,W.Michael. and Vazeux,R.
TITLE ICAM-related protein
JOURNAL Patent: US 5663293-A 21 02-SEP-1997;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCTTAC 457
|||||
Db 1 GCAAGAACCTTACCTTAC 18

RESULT 584
I71047/c

LOCUS I71047 18 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 5 from patent US 5681699.
ACCESSION I71047
VERSION I71047.1 GI:3007182
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Rotter,J.I., Targan,S.R., Yang,H., Beaudet,A.L. and Vora,D.
TITLE Methods of diagnosing ulcerative colitis and Crohn's disease
JOURNAL Patent: US 5681699-A 5 28-OCT-1997;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 844 GTCACCTATGGCAACGAC 861
|||||
Db 18 GTCACCTATGGCAACGAC 1

RESULT 585
AR181914/c
LOCUS AR181914 18 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1 from patent US 6335437.
ACCESSION AR181914
VERSION AR181914.1 GI:20224128
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Manoharan,M.
TITLE Methods for the preparation of conjugated oligomers
JOURNAL Patent: US 6335437-A 1 01-JAN-2002;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGTCCCA 67
|||||
Db 18 GCCTCGCTATGGTCCCA 1

RESULT 586
AR181915/c
LOCUS AR181915 18 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 2 from patent US 6335437.
ACCESSION AR181915
VERSION AR181915.1 GI:20224129
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Manoharan,M.
TITLE Methods for the preparation of conjugated oligomers
JOURNAL Patent: US 6335437-A 2 01-JAN-2002;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 587
AR181916/c
LOCUS AR181916 18 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 3 from patent US 6335437.
ACCESSION AR181916
VERSION AR181916.1 GI:20224130
KEYWORDS
SOURCE
ORGANISM Unknown.

REFERENCE 1 (bases 1 to 18)
AUTHORS Manoharan,M.
TITLE Methods for the preparation of conjugated oligomers
JOURNAL Patent: US 6335437-A 3 01-JAN-2002;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 588
AR212325/c
LOCUS AR212325 18 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 7 from patent US 6399757.
ACCESSION AR212325
VERSION AR212325.1 GI:21515869
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Manoharan,M. and Cook,P.Dan.
TITLE Oligonucleotide and nucleotide amine analogs, methods of synthesis and use
JOURNAL Patent: US 6399757-A 7 04-JUN-2002;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 589
AR267387/c
LOCUS AR267387 18 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 7 from patent US 6495671.
ACCESSION AR267387
VERSION AR267387.1 GI:29697416
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Manoharan,M. and Cook,P.D.
TITLE Oligonucleotide and nucleotide amine analogs, methods of synthesis and use
JOURNAL Patent: US 6495671-A 7 17-DEC-2002;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 590
AR270972/c
LOCUS AR270972 18 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 6 from patent US 6500945.
ACCESSION AR270972
VERSION AR270972.1 GI:29702231
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.D.
TITLE Nucleotides having chiral phosphorus linkages
JOURNAL Patent: US 6500945-A 6 31-DEC-2002;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 591
AR364449
LOCUS AR364449 18 bp DNA linear PAT 03-SEP-2003
DEFINITION Sequence 21 from patent US 5284931.
ACCESSION AR364449
VERSION AR364449.1 GI:34427062
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Springer,T.A., Rothlein,R., Marlin,S.D. and Dustin,M.L.
TITLE Intercellular adhesion molecules, and their binding ligands
JOURNAL Patent: US 5284931-A 21 08-FEB-1994;
FEATURES Location/Qualifiers
source
1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 207 CTCCTGTGACGCCCAA 224
Db 1 CTCCTGTGACGCCCAA 18

RESULT 592
AR370526/c
LOCUS AR370526 18 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 1 from patent US 6300491.
ACCESSION AR370526
VERSION AR370526.1 GI:34607279
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 1 09-OCT-2001;
FEATURES
source Location/Qualifiers
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 593
AR370529/c
LOCUS AR370529 18 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 4 from patent US 6300491.
ACCESSION AR370529
VERSION AR370529.1 GI:34607282
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 4 09-OCT-2001;
FEATURES
source Location/Qualifiers
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCACCTCAGCCTC 2853
Db 18 TCCTCCACCTCAGCCTC 1

RESULT 594
AR370530/c
LOCUS AR370530 18 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 5 from patent US 6300491.
ACCESSION AR370530
VERSION AR370530.1 GI:34607283
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.F. and Mirabelli,C.K.

TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 5 09-OCT-2001;
FEATURES
source Location/Qualifiers
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCATCG 1381
Db 18 CTTTCCCACTGCCATCG 1

RESULT 595
AR370606
LOCUS AR370606 18 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 81 from patent US 6300491.
ACCESSION AR370606
VERSION AR370606.1 GI:34607359
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.F. and Mirabelli,C.K.
TITLE Oligonucleotide inhibition of cell adhesion
JOURNAL Patent: US 6300491-A 81 09-OCT-2001;
FEATURES
source Location/Qualifiers
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 1 GCCTCGCTATGGCTCCCA 18

RESULT 596
AR371557/c
LOCUS AR371557 18 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 4 from patent US 6395492.
ACCESSION AR371557
VERSION AR371557.1 GI:34608538
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Manoharan,M., Cook,P.D. and Bennett,C.F.
TITLE Derivatized oligonucleotides having improved uptake and other properties
JOURNAL Patent: US 6395492-A 4 28-MAY-2002;
FEATURES
source Location/Qualifiers
1..18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 597
AR429181/c
LOCUS 18 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 22 from patent US 6642367.
ACCESSION AR429181
VERSION AR429181.1 GI:40189308
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.D., Sanghvi,Y.S., Sprankle,K.G., Ross,B.S., Griffey,R.H. and Springer,R.H.
TITLE Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom
JOURNAL Patent: US 6642367-A 22 04-NOV-2003;
FEATURES
source 1. .18
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 598
AR429182/c
LOCUS 18 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 23 from patent US 6642367.
ACCESSION AR429182
VERSION AR429182.1 GI:40189309
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.D., Sanghvi,Y.S., Sprankle,K.G., Ross,B.S., Griffey,R.H. and Springer,R.H.
TITLE Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom
JOURNAL Patent: US 6642367-A 23 04-NOV-2003;
FEATURES
source 1. .18
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 599
AR429183/c
LOCUS 18 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 24 from patent US 6642367.
ACCESSION AR429183
VERSION AR429183.1 GI:40189310
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.D., Sanghvi,Y.S., Sprankle,K.G., Ross,B.S., Griffey,R.H. and Springer,R.H.

RESULT 600
AR429184/c
LOCUS 18 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 25 from patent US 6642367.
ACCESSION AR429184
VERSION AR429184.1 GI:40189311
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.D., Sanghvi,Y.S., Sprankle,K.G., Ross,B.S., Griffey,R.H. and Springer,R.H.
TITLE Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom
JOURNAL Patent: US 6642367-A 25 04-NOV-2003;
FEATURES
source 1. .18
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 601
AR429185/c
LOCUS 18 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 26 from patent US 6642367.
ACCESSION AR429185
VERSION AR429185.1 GI:40189312
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.D., Sanghvi,Y.S., Sprankle,K.G., Ross,B.S., Griffey,R.H. and Springer,R.H.
TITLE Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom
JOURNAL Patent: US 6642367-A 26 04-NOV-2003;
FEATURES
source 1. .18
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 602
AR429186/c
LOCUS 18 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 27 from patent US 6642367.
ACCESSION AR429186
VERSION AR429186.1 GI:40189313
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Cook,P.D., Sanghvi,Y.S., Sprankle,K.G., Ross,B.S., Griffey,R.H. and Springer,R.H.
TITLE Process for the synthesis of 2'-O-substituted pyrimidines and oligomeric compounds therefrom
JOURNAL Patent: US 6642367-A 27 04-NOV-2003;
FEATURES
source 1. .18
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
|||||

	TITLE	Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
JOURNAL	PATENT:	US 6753423-A 5 22-JUN-2004;
FEATURES	Location/Qualifiers	source 1..18
	/organism=	"unknown"
	/mol_type=	"genomic DNA"
Query Match	Score	18; DB 1; Length 18;
Best Local Similarity	100.0%; Pred.	No. 3.5e+02;
Matches	Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	50 GCCTCGCTATGGTCCCA	67
Db	18 GCCTCGCTATGGTCCCA	1
RESULT 605		
LOCUS	AR560501/c	Sequence 15 from patent US 6753423. 18 bp DNA linear PAT 08-OCT-2004
DEFINITION	AR560501	
ACCESSION	AR560501	
VERSION	AR560501.1	GI:53972805
KEYWORDS	.	
SOURCE	Unknown.	
ORGANISM	Unclassified.	
REFERENCE	1 (bases 1 to 18)	
AUTHORS	Cook,P.D., Manoharan,M. and Bennett,C.F.	
TITLE	Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals	
JOURNAL	PATENT:	US 6753423-A 15 22-JUN-2004;
FEATURES	Location/Qualifiers	source 1..18
	/organism=	"unknown"
	/mol_type=	"genomic DNA"
Query Match	Score	18; DB 1; Length 18;
Best Local Similarity	100.0%; Pred.	No. 3.5e+02;
Matches	Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	50 GCCTCGCTATGGTCCCA	67
Db	18 GCCTCGCTATGGTCCCA	1
RESULT 606		
LOCUS	AR560502/c	Sequence 16 from patent US 6753423. 18 bp DNA linear PAT 08-OCT-2004
DEFINITION	AR560502	
ACCESSION	AR560502	
VERSION	AR560502.1	GI:53972806
KEYWORDS	.	
SOURCE	Unknown.	
ORGANISM	Unclassified.	
REFERENCE	1 (bases 1 to 18)	
AUTHORS	Cook,P.D., Manoharan,M. and Bennett,C.F.	
TITLE	Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals	
JOURNAL	PATENT:	US 6753423-A 16 22-JUN-2004;
FEATURES	Location/Qualifiers	source 1..18
	/organism=	"unknown"
	/mol_type=	"genomic DNA"
Query Match	Score	18; DB 1; Length 18;
Best Local Similarity	100.0%; Pred.	No. 3.5e+02;
Matches	Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	50 GCCTCGCTATGGTCCCA	67
Db	18 GCCTCGCTATGGTCCCA	1
RESULT 604		
LOCUS	AR560491/c	Sequence 5 from patent US 6753423. 18 bp DNA linear PAT 08-OCT-2004
DEFINITION	AR560491	
ACCESSION	AR560491	
VERSION	AR560491.1	GI:53972795
KEYWORDS	.	
SOURCE	Unknown.	
ORGANISM	Unclassified.	
REFERENCE	1 (bases 1 to 18)	
AUTHORS	Cook,P.D., Manoharan,M. and Bennett,C.F.	
TITLE	Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals	
JOURNAL	PATENT:	US 6753423-A 4 22-JUN-2004;
FEATURES	Location/Qualifiers	source 1..18
	/organism=	"unknown"
	/mol_type=	"genomic DNA"
Query Match	Score	18; DB 1; Length 18;
Best Local Similarity	100.0%; Pred.	No. 3.5e+02;
Matches	Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	50 GCCTCGCTATGGTCCCA	67
Db	18 GCCTCGCTATGGTCCCA	1
RESULT 602		
LOCUS	AR482042/c	Sequence 6 from patent US 6699979. 18 bp DNA linear PAT 14-MAY-2004
DEFINITION	AR482042	
ACCESSION	AR482042	
VERSION	AR482042.1	GI:47243989
KEYWORDS	.	
SOURCE	Unknown.	
ORGANISM	Unclassified.	
REFERENCE	1 (bases 1 to 18)	
AUTHORS	Cook,P.D.	
TITLE	Oligonucleotides having chiral phosphorus linkages	
JOURNAL	PATENT:	US 6699979-A 6 02-MAR-2004;
FEATURES	Location/Qualifiers	source 1..18
	/organism=	"unknown"
	/mol_type=	"genomic DNA"
Query Match	Score	18; DB 1; Length 18;
Best Local Similarity	100.0%; Pred.	No. 3.5e+02;
Matches	Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	50 GCCTCGCTATGGTCCCA	67
Db	18 GCCTCGCTATGGTCCCA	1
RESULT 603		
LOCUS	AR560490/c	Sequence 4 from patent US 6753423. 18 bp DNA linear PAT 08-OCT-2004
DEFINITION	AR560490	
ACCESSION	AR560490	
VERSION	AR560490.1	GI:53972794
KEYWORDS	.	
SOURCE	Unknown.	
ORGANISM	Unclassified.	
REFERENCE	1 (bases 1 to 18)	
AUTHORS	Cook,P.D., Manoharan,M. and Bennett,C.F.	
TITLE	Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals	
JOURNAL	PATENT:	US 6753423-A 4 22-JUN-2004;
FEATURES	Location/Qualifiers	source 1..18
	/organism=	"unknown"
	/mol_type=	"genomic DNA"
Query Match	Score	18; DB 1; Length 18;
Best Local Similarity	100.0%; Pred.	No. 3.5e+02;
Matches	Conservative	0; Mismatches 0; Indels 0; Gaps 0;
QY	50 GCCTCGCTATGGTCCCA	67
Db	18 GCCTCGCTATGGTCCCA	1
RESULT 604		
LOCUS	AR560491/c	Sequence 5 from patent US 6753423. 18 bp DNA linear PAT 08-OCT-2004
DEFINITION	AR560491	
ACCESSION	AR560491	
VERSION	AR560491.1	GI:53972795
KEYWORDS	.	
SOURCE	Unknown.	
ORGANISM	Unclassified.	
REFERENCE	1 (bases 1 to 18)	
AUTHORS	Cook,P.D., Manoharan,M. and Bennett,C.F.	
TITLE	Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals	
JOURNAL	PATENT:	US 6753423-A 4 2

```
RESULT 607
AX032674/c
LOCUS AX032674 18 bp DNA linear PAT 20-SEP-2000
DEFINITION Sequence 120 from Patent EP1016715.
ACCESSION AX032674
VERSION AX032674.1 GI:10279612
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Imbach,J.L., Brown-Driver,V.L., Vickers,T.A., Ecker,D.J.,
Bennett,C.F., Chiang,M.Y., Anderson,K.P., Hanecak,R.C. and
Wyatt,J.R.
TITLE Oligonucleotides having a conserved g4 core sequence
JOURNAL Patent: EP 1016715-A 120 05-JUL-2000;
ISIS PHARMACEUTICALS INC (US)
FEATURES
LOCATION/Qualifiers
SOURCE
1..18
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2836 TCCTCCACCTCAGCCTC 2853
DB 18 TCCTCCACCTCAGCCTC 1
RESULT 608
AX419809/c
LOCUS AX419809 18 bp DNA linear PAT 18-JUN-2002
DEFINITION Sequence 146 from Patent WO0198537.
ACCESSION AX419809
VERSION AX419809.1 GI:21524176
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Lyamichev,V., Allawi,H., Dong,F., Neri,B.P. and Vener,I.T.
TITLE Nucleic acid accessible hybridization sites
JOURNAL Patent: WO 0198537-A 146 27-DEC-2001;
THIRD WAVE TECHNOLOGIES, INC. (US)
FEATURES
LOCATION/Qualifiers
SOURCE
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1
RESULT 609
AX708864/c
LOCUS AX708864 18 bp DNA linear PAT 04-APR-2003
DEFINITION Sequence 46 from Patent WO02101045.
ACCESSION AX708864
VERSION AX708864.1 GI:29564594
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Manoharan,M. and Cook,P.Dan.
TITLE Methods of synthesis and use
JOURNAL Patent: US 6235886-A 2 22-MAY-2001;
LOCATION/Qualifiers
SOURCE
1..19
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1
other sequences; artificial sequences.
REFERENCE
1
AUTHORS Patapoutian,A., Song,C., Ganju,P., Peier,A., McIntyre,P. and
Bevan,S.
TITLE Vanilloid receptor-related nucleic acids and polypeptides
JOURNAL Patent: WO 02101045-A 46 19-DEC-2002;
Novartis AG (CH) ; IRM LLC (BM)
FEATURES
LOCATION/Qualifiers
SOURCE
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide primer"
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2766 TGTACCCAGGCTGGAGT 2783
DB 18 TGTACCCAGGCTGGAGT 1
RESULT 610
AR054231/c
LOCUS AR054231 19 bp DNA linear PAT 29-SEP-1999
DEFINITION Sequence 2 from patent US 5834607.
ACCESSION AR054231
VERSION AR054231.1 GI:5979093
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Manoharan,M. and Cook,P.Dan.
TITLE Amines and methods of making and using the same
JOURNAL Patent: US 5834607-A 2 10-NOV-1998;
LOCATION/Qualifiers
SOURCE
1..19
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1
RESULT 611
AR153725/c
LOCUS AR153725 19 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 2 from patent US 6235886.
ACCESSION AR153725
VERSION AR153725.1 GI:15121257
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Manoharan,M. and Cook,P.Dan.
TITLE Methods of synthesis and use
JOURNAL Patent: US 6235886-A 2 22-MAY-2001;
LOCATION/Qualifiers
SOURCE
1..19
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 50 GCCTCGCTATGGCTCCCA 67
 Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 612
 BD222603/c
 LOCUS 19 bp DNA linear PAT 17-JUL-2003
 DEFINITION Aminoxy-modified nucleoside compound and oligomer compound produced therefrom.
 ACCESSION BD222603
 VERSION BD222603.1 GI:33032373
 KEYWORDS JP 2002522447-A/21.
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.
 REFERENCE 1 (bases 1 to 19)
 AUTHORS Manoharan,M., Cook,P.D., Prakash,T.P. and Kawasaki,A.M.
 TITLE Aminoxy-modified nucleoside compound and oligomer compound produced therefrom
 JOURNAL Patent: JP 2002522447-A 21 23-JUL-2002;
 COMMENT ISIS PHARMACEUTICALS INC
 PN JP 2002522447-A/21
 PD 23-JUL-2002
 PF 09-AUG-1999 JP 2000563675
 PR 07-AUG-1998 US 09/130973
 PI MUTHIAH MANOHARAN, PHILIP DAN COOK, THAZHA P PRAKASH, ANDREW M KAWASAKI
 PC C07H19/167, C07H19/067, C07H19/10, C07H19/20, C07H21/02, C12N15/00,
 CC C12N15/00
 CC Description of Artificial Sequence: antisense sequence FH
 Key Location/Qualifiers
 FT source 1..19
 FT /organism='Artificial Sequence'.
 FEATURES
 source 1..19
 Location/Qualifiers
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match 0.6%; Score 18; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCA 35
 Db 19 GAGCTCCTCTGCTACTCA 2

RESULT 613
 AR212320/c
 LOCUS 19 bp DNA linear PAT 20-JUN-2002
 DEFINITION Sequence 2 from patent US 6399757.
 ACCESSION AR212320
 VERSION AR212320.1 GI:21515862
 KEYWORDS .
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 19)
 AUTHORS Manoharan,M., Cook,P.D. and Cook,P.Dan.
 TITLE Oligonucleotide and nucleotide amine analogs, methods of synthesis and use
 JOURNAL Patent: US 6399757-A 2 04-JUN-2002;
 FEATURES Location/Qualifiers
 source 1..19
 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.6%; Score 18; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 614
 AR267382/c
 LOCUS 19 bp DNA linear PAT 10-APR-2003
 DEFINITION Sequence 2 from patent US 6495671.
 ACCESSION AR267382
 VERSION AR267382.1 GI:29697411
 KEYWORDS .
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 19)
 AUTHORS Manoharan,M. and Cook,P.D.
 TITLE Oligonucleotide and nucleotide amine analogs, methods of synthesis and use
 JOURNAL Patent: US 6495671-A 2 17-DEC-2002;
 FEATURES Location/Qualifiers
 source 1..19
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.6%; Score 18; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 615
 AR412370/c
 LOCUS 19 bp DNA linear PAT 18-DEC-2003
 DEFINITION Sequence 21 from patent US 6639062.
 ACCESSION AR412370
 VERSION AR412370.1 GI:40167480
 KEYWORDS .
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 19)
 AUTHORS Manoharan,M., Cook,P.D., Prakash,T.P. and Kawasaki,A.M.
 TITLE Aminoxy-modified nucleosidic compounds and oligomeric compounds prepared therefrom
 JOURNAL Patent: US 6639062-A 21 28-OCT-2003;
 FEATURES Location/Qualifiers
 source 1..19
 /organism="unknown"
 /mol_type="genomic DNA"

Query Match 0.6%; Score 18; DB 1; Length 19;
 Best Local Similarity 100.0%; Pred. No. 3.3e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCA 35
 Db 19 GAGCTCCTCTGCTACTCA 2

RESULT 616
 AR560509/c
 LOCUS 19 bp DNA linear PAT 08-OCT-2004
 DEFINITION Sequence 23 from patent US 6753423.
 ACCESSION AR560509
 VERSION AR560509.1 GI:53972813
 KEYWORDS .
 SOURCE Unknown.

```

ORGANISM      Unknown.
REFERENCE      1 (bases 1 to 19)
AUTHORS        Cook,P.D., Manoharan,M. and Bennett,C.F.
TITLE          Compositions and methods for enhanced biostability and altered
JOURNAL        biodistribution of oligonucleotides in mammals
FEATURES       Patent: US 6753423-A 23 22-JUN-2004;
               Location/Qualifiers
               source
               1..19
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match      0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 19 GCCTCGCTATGGCTCCCA 2

RESULT 617
AX133851
LOCUS          AX133851          19 bp DNA linear PAT 15-MAY-2001
DEFINITION     Sequence 37 from Patent WO0119856.
ACCESSION      AX133851
VERSION        AX133851.1 GI:14139803
KEYWORDS
SOURCE         synthetic construct
ORGANISM       synthetic construct
               other sequences; artificial sequences.
REFERENCE      1
AUTHORS        Shimkets,R.A., Fernandes,E., Herrmann,J.L., Liu,X., Yang,M. and
TITLE          Boldog,F.L.
JOURNAL        Secreted human proteins, polynucleotides encoding them and methods
               of using the same
FEATURES       Patent: WO 0119856-A 37 22-MAR-2001;
               Curagen Corporation (US)
               Location/Qualifiers
               source
               1..19
               /organism="synthetic construct"
               /mol_type="unassigned DNA"
               /db_xref="taxon:32630"
               /note="Agi121 forward primer"

Query Match      0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTG 2789
Db 2 CCAGGCTGGAGTGCAGTG 19

RESULT 618
AR435736/c
LOCUS          AR435736          20 bp DNA linear PAT 18-DEC-2003
DEFINITION     Sequence 2 from patent US 6656730.
ACCESSION      AR435736
VERSION        AR435736.1 GI:40198818
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 20)
AUTHORS        Manoharan,M.
TITLE          Oligonucleotides conjugated to protein-binding drugs
JOURNAL        Patent: US 6656730-A 2 02-DEC-2003;
FEATURES       Location/Qualifiers
               source
               1..20
               /organism="unknown"
               /mol_type="genomic DNA"

```

```

Query Match      0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCTCCTCTGCTACTCAGA 37
Db 18 GCTCCTCTGCTACTCAGA 1

RESULT 619
AR435737/c
LOCUS          AR435737          20 bp DNA linear PAT 18-DEC-2003
DEFINITION     Sequence 3 from patent US 6656730.
ACCESSION      AR435737
VERSION        AR435737.1 GI:40198819
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 20)
AUTHORS        Manoharan,M.
TITLE          Oligonucleotides conjugated to protein-binding drugs
JOURNAL        Patent: US 6656730-A 3 02-DEC-2003;
FEATURES       Location/Qualifiers
               source
               1..20
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match      0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCTCCTCTGCTACTCAGA 37
Db 18 GCTCCTCTGCTACTCAGA 1

RESULT 620
AR542568
LOCUS          AR542568          20 bp DNA linear PAT 08-OCT-2004
DEFINITION     Sequence 80 from patent US 6743909.
ACCESSION      AR542568
VERSION        AR542568.1 GI:53935056
KEYWORDS
SOURCE         Unknown.
ORGANISM       Unclassified.
REFERENCE      1 (bases 1 to 20)
AUTHORS        Cowser,T.L.M. and Dobie,K.W.
TITLE          Antisense modulation of PTPN12 expression
JOURNAL        Patent: US 6743909-A 80 01-JUN-2004;
FEATURES       Location/Qualifiers
               source
               1..20
               /organism="unknown"
               /mol_type="genomic DNA"

Query Match      0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTGCAGT 2788
Db 3 CCCAGGCTGGAGTGCAGT 20

RESULT 621
AX926743
LOCUS          AX926743          20 bp DNA linear PAT 19-DEC-2003
DEFINITION     Sequence 26 from Patent WO03085133.
ACCESSION      AX926743
VERSION        AX926743.1 GI:40247078
KEYWORDS
SOURCE         synthetic construct

```

```

ORGANISM      synthetic construct
              other sequences; artificial sequences.
REFERENCE
AUTHORS      Nagaraaju,J.G.
TITLE        Novel f1ssr-pcr primers and method of identifying genotyping
              diverse genomes of plant and animal systems including rice
              varieties, a kit thereof
JOURNAL      Patent: WO 03085133-A 26 16-OCT-2003;
              Centre for DNA Fingerprinting and Diagnostics, Centre for; the
              Department of Biotechnology, Ministry of Science & Technology (IN)
              Location/Qualifiers
FEATURES
source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="A novel FISSR-PCR primer for genotyping eukaryotes"

Query Match      0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTCTGTGTGTGTGTGTAT 2745
      |||||
Db 1 GTCTGTGTGTGTGTGTAT 18

RESULT 622
AR154010
LOCUS      AR154010 21 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 60 from patent US 6238863.
ACCESSION AR154010
VERSION AR154010.1 GI:15122063
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE
AUTHORS      Schumm,J.W. and Bacher,J.W.
TITLE        Materials and methods for indentifying and analyzing intermediate
              tandem repeat DNA markers
JOURNAL      Patent: US 6238863-A 60 29-MAY-2001;
              Location/Qualifiers
FEATURES
source
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match      0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 3.1e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2837 CCTCCACCTCAGCCTCCTGA 2857
      |||||
Db 1 CCTCCATTTCAGCCTCCTGA 21

RESULT 623
AR565234
LOCUS      AR565234 21 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 60 from patent US 6767703.
ACCESSION AR565234
VERSION AR565234.1 GI:53981072
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE
AUTHORS      Schumm,J.W. and Bacher,J.W.
TITLE        Materials and methods for indentifying and analyzing intermediate
              tandem repeat DNA markers
JOURNAL      Patent: US 6767703-A 60 27-JUL-2004;
              Location/Qualifiers
FEATURES
source
1..21
/organism="unknown"

```

```

/mol_type="genomic DNA"

Query Match      0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 3.1e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2837 CCTCCACCTCAGCCTCCTGA 2857
      |||||
Db 1 CCTCCATTTCAGCCTCCTGA 21

RESULT 624
AX664288/c
LOCUS      AX664288 21 bp DNA linear PAT 22-MAR-2003
DEFINITION Sequence 8 from Patent WO2076507.
ACCESSION AX664288
VERSION AX664288.1 GI:29164218
KEYWORDS
SOURCE      synthetic construct
ORGANISM      synthetic construct
              other sequences; artificial sequences.
REFERENCE
AUTHORS      Grewal,I.
TITLE        Uses of opo ligand to modulate immune responses
JOURNAL      Patent: WO 02076507-A 8 03-OCT-2002;
              GENENTECH, INC. (US)
              Location/Qualifiers
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="sequence is synthesized"

Query Match      0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 3.1e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2834 GATCCTCCACCTCAGCCTCC 2854
      |||||
Db 21 GATCCTCCACCTCAACCTTC 1

RESULT 625
BD130116
LOCUS      BD130116 21 bp DNA linear PAT 18-SEP-2002
DEFINITION Material and method for specifying and analyzing medium-size tandem
              repeat DNA marker.
ACCESSION BD130116
VERSION BD130116.1 GI:23225061
KEYWORDS JP 2002502606-A/60.
SOURCE      unidentified
ORGANISM      unidentified
              unclassified.
REFERENCE
AUTHORS      Schumm,J.W. and Bacher,J.W.
TITLE        Material and method for specifying and analyzing medium-size tandem
              repeat DNA marker
JOURNAL      Patent: JP 2002502606-A 60 29-JAN-2002;
              PROMEGA CORP
COMMENT      OS Unidentified
              PN JP 2002502606-A/60
              PD 29-JAN-2002
              PF 04-FEB-1999 JP 2000530608
              PR JAMES W SCHUMM,JEFFREY W BACHER
              PC C12N15/09,C12Q1/68,C12N15/00
              CC Strandedness: Single;
              CC Topology: Linear;
              CC Material and method for specifying and analyzing medium-size
              CC Material and method repeat
              CC DNA marker
              FT Key Location/Qualifiers
              source 1..21

```

```
FEATURES
source
    /organism='Unidentified'.
    Location/Qualifiers
    1..21
    /organism="unidentified"
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"

Query Match
Best Local Similarity 90.5%; Score 17.8; DB 1; Length 21;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2837 CCTCCACCTCAGCCTCCTGA 2857
||||| |||||||
Db 1 CCTCCATTTCAGCCTCCTGA 21

RESULT 626
AR074777
LOCUS AR074777 19 bp DNA linear PAT 28-AUG-2000
DEFINITION Sequence 74 from patent US 5955276.
ACCESSION AR074777
VERSION AR074777.1 GI:10001530
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Morgante,M. and Vogel,J.Marie.
TITLE Compound microsatellite primers for the detection of genetic
polymorphisms
JOURNAL Patent: US 5955276-A 74 21-SEP-1999;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 94.7%; Score 17.4; DB 1; Length 19;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
||||| |||||||
Db 1 TGTGTGTGTGTGTGTATAT 19

RESULT 627
AR148945
LOCUS AR148945 19 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 2 from patent US 6228345.
ACCESSION AR148945
VERSION AR148945.1 GI:15113536
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Ossowski, L.
TITLE In vivo assay for intravasation
JOURNAL Patent: US 6228345-A 2 08-MAY-2001;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 94.7%; Score 17.4; DB 1; Length 19;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2768 TCACCCAGGCTGGAGTGCA 2786
||||| |||||||
Db 1 TCACCCAGGCTGGAGTGCA 19
```

```
RESULT 628
AR153772
LOCUS AR153772 19 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 7 from patent US 6235889.
ACCESSION AR153772
VERSION AR153772.1 GI:15121304
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Ulanovsky, L.
TITLE Nucleic acid amplification using modular branched primers
JOURNAL Patent: US 6235889-A 7 22-MAY-2001;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 94.7%; Score 17.4; DB 1; Length 19;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 769 TCCTGGACGGCTGTTC 787
||||| |||||||
Db 1 TCCTGGACAGGCTGTTC 19

RESULT 629
I31530/c
LOCUS I31530 19 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 442 from patent US 5582979.
ACCESSION I31530
VERSION I31530.1 GI:1822321
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Weber, J.L.
TITLE Length polymorphisms in (dC-dA).sub.n. (dG-dT).sub.n sequences and
method of using the same
JOURNAL Patent: US 5582979-A 442 10-DEC-1996;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 94.7%; Score 17.4; DB 1; Length 19;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
||||| |||||||
Db 1 TGTGTGTGTGTGTGTGTGT 1

RESULT 630
I71049
LOCUS I71049 19 bp DNA linear PAT 03-APR-1998
DEFINITION Sequence 7 from patent US 5681699.
ACCESSION I71049
VERSION I71049.1 GI:3007184
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Rotter, J.I., Targan, S.R., Yang, H., Beaudet, A.L. and Vora, D.
TITLE Methods of diagnosing ulcerative colitis and Crohn's disease
JOURNAL Patent: US 5681699-A 7 28-OCT-1997;
FEATURES Location/Qualifiers
source 1..19
```



```
AX040468
LOCUS AX040468 19 bp DNA linear PAT 18-NOV-2000
DEFINITION Sequence 8 from Patent WO0063365.
ACCESSION AX040468
VERSION AX040468.1 GI:11230260
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Belotserkovskii,B., Reddy,G. and Zarling,D.
TITLE Locked nucleic acid hybrids and methods of use
JOURNAL Patent: WO 0063365-A 8 26-OCT-2000;
Pangene Corporation (US)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Z-DNA"

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 3.8e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
|||||
Db 1 TGTGTGTGTGTGTGTGTGT 19

RESULT 634
BD090072/C
LOCUS BD090072 19 bp DNA linear PAT 27-AUG-2002
DEFINITION A method of arraying genome clone.
ACCESSION BD090072
VERSION BD090072.1 GI:22635682
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 19)
AUTHORS Soeda,E.
TITLE A method of arraying genome clone
JOURNAL Patent: JP 2001321190-A 2316 20-NOV-2001;
THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
COMMENT
OS Artificial Sequence
PN JP 2001321190-A/2316
PD 20-NOV-2001
PP 12-MAR-2001 JP 2001068285
PI EIICHI SOEDA
PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
C12N15/00,
PC C12N15/00
CC Description of Artificial Sequence:Synthetic DNA FH Key
Location/Qualifiers
FT source 1..19
/organism='Artificial Sequence'.
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 3.8e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2770 ACCCAGGCTGGAGTGCAGT 2788
|||||
Db 19 ACCCAGGCTGGAGTGTAGT 1

RESULT 633
AX040467/C
LOCUS AX040467 19 bp DNA linear PAT 18-NOV-2000
DEFINITION Sequence 7 from Patent WO0063365.
ACCESSION AX040467
VERSION AX040467.1 GI:11230259
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Belotserkovskii,B., Reddy,G. and Zarling,D.
TITLE Locked nucleic acid hybrids and methods of use
JOURNAL Patent: WO 0063365-A 7 26-OCT-2000;
Pangene Corporation (US)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Z-DNA"

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 3.8e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
|||||
Db 19 TGTGTGTGTGTGTGTGTGT 1

RESULT 633
```

```
AX040468
LOCUS AX040468 19 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 86 from patent US 6458532.
ACCESSION AR233457
VERSION AR233457.1 GI:27276048
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 19)
AUTHORS Detera-Wadleigh,S.D., Yoshikawa,T., Sanders,A.R. and Esterling,L.E.
TITLE Polynucleotides encoding IMP.18p myo-inositol monophosphatase and
methods of detecting said polynucleotides
JOURNAL Patent: US 6458532-A 86 01-OCT-2002;
Pangene Corporation (US)
FEATURES
source
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 3.8e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTACCCAGGCT 2778
|||||
Db 19 TTGCTCTGTACCCAGGCT 1

RESULT 632
AX040467/C
LOCUS AX040467 19 bp DNA linear PAT 18-NOV-2000
DEFINITION Sequence 7 from Patent WO0063365.
ACCESSION AX040467
VERSION AX040467.1 GI:11230259
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Belotserkovskii,B., Reddy,G. and Zarling,D.
TITLE Locked nucleic acid hybrids and methods of use
JOURNAL Patent: WO 0063365-A 7 26-OCT-2000;
Pangene Corporation (US)
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Z-DNA"

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 3.8e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
|||||
Db 19 TGTGTGTGTGTGTGTGTGT 1

RESULT 633
```

```

RESULT 635
AB068733/c
LOCUS
DEFINITION
  Synthetic construct DNA, reverse primer for human STS sts-D1S2728
  at 1p36.
ACCESSION
  AB068733
VERSION
  AB068733.1 GI:15129537
KEYWORDS
  synthetic construct
SOURCE
  synthetic construct
  other sequences; artificial sequences.
REFERENCE
  1
  Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K.,
  Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H.,
  Morohashi,A., Ohita,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A.
  and Soeda,E.
  A BAC-based STS-content map spanning a 35-Mb region of human
  chromosome 1p35-p36
JOURNAL
  Genomics 74 (1), 55-70 (2001)
MEDLINE
  21269192
PUBMED
  11374902
REFERENCE
  2 (bases 1 to 19)
AUTHORS
  Horii,A.
TITLE
  Direct Submission
JOURNAL
  Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
  Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
  Miyagi 980-8575, Japan (E-mail:horii@mail.cc.tohoku.ac.jp,
  Tel:81-22-717-8042, Fax:81-22-717-8047)
FEATURES
  Location/Qualifiers
  source
    1..19
    /organism="synthetic construct"
    /mol_type="genomic DNA"
    /db_xref="taxon:32630"
  misc_feature
    1..19
    /notes="reverse primer for human STS sts-D1S2728 at 1p36
    sts-D1S2728 obtained from clones B351N1, B26G13, B26E12,
    B39F12, Human BAC library RPCI-11"
  Query Match
    Best Local Similarity 0.6%; Score 17.4; DB 1; Length 19;
    Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
  QY 2770 ACCCAGGCTGGAGTGCAGT 2788
  Db 19 ACCCAGGCTGGAGTGTAGT 1
  RESULT 636
  AR074792/c
  LOCUS
  DEFINITION
    Sequence 89 from patent US 5955276.
  ACCESSION
    AR074792
  VERSION
    AR074792.1 GI:10001545
  KEYWORDS
    Unknown.
  SOURCE
    Unknown.
  ORGANISM
    Unclassified.
  REFERENCE
    1 (bases 1 to 20)
  AUTHORS
    Morgante,M. and Vogel,J.Marie.
  TITLE
    Compound microsatellite primers for the detection of genetic
    polymorphisms
  JOURNAL
    Patent: US 5955276-A 89 21-SEP-1999;
  FEATURES
    Location/Qualifiers
    source
      1..20
      /organism="unknown"
      /mol_type="unassigned DNA"
  Query Match
    Best Local Similarity 0.6%; Score 17.4; DB 1; Length 20;
    Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
  QY 2729 TGTGTGTGTGTGTGTATGT 2747
    ||||||||||||||||
  
```

```

Db 20 TGTGTGTGTGTGTGTATAT 2
  RESULT 637
  AR124503/c
  LOCUS
  DEFINITION
    Sequence 72 from patent US 6171860.
  ACCESSION
    AR124503
  VERSION
    AR124503.1 GI:14109864
  KEYWORDS
    Unknown.
  SOURCE
    Unknown.
  ORGANISM
    Unclassified.
  REFERENCE
    1 (bases 1 to 20)
  AUTHORS
    Baker,B.F. and Cowseert,L.M.
  TITLE
    Antisense inhibition of rank expression
  JOURNAL
    Patent: US 6171860-A 72 09-JAN-2001;
  FEATURES
    Location/Qualifiers
    source
      1..20
      /organism="unknown"
      /mol_type="unassigned DNA"
  Query Match
    Best Local Similarity 0.6%; Score 17.4; DB 1; Length 20;
    Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
  QY 2775 GGCTGGAGTGCAGTGTGC 2793
  Db 20 GGCTAGAGTGCAGTGTGC 2
  RESULT 638
  AR162414/c
  LOCUS
  DEFINITION
    Sequence 94 from patent US 6258600.
  ACCESSION
    AR162414
  VERSION
    AR162414.1 GI:16229592
  KEYWORDS
    Unknown.
  SOURCE
    Unknown.
  ORGANISM
    Unclassified.
  REFERENCE
    1 (bases 1 to 20)
  AUTHORS
    Zhang,H. and Cowseert,L.M.
  TITLE
    Antisense modulation of caspase 8 expression
  JOURNAL
    Patent: US 6258600-A 94 10-JUL-2001;
  FEATURES
    Location/Qualifiers
    source
      1..20
      /organism="unknown"
      /mol_type="unassigned DNA"
  Query Match
    Best Local Similarity 0.6%; Score 17.4; DB 1; Length 20;
    Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
  QY 2774 AGGCTGGAGTGCAGTGTGC 2792
  Db 20 AGGCTGGAGTGCAGTGGCG 2
  RESULT 639
  E32219/c
  LOCUS
  DEFINITION
    Method for isolating satellite sequence.
  ACCESSION
    E32219
  VERSION
    E32219.1 GI:13021841
  KEYWORDS
    JP 2000060559-A/21.
  SOURCE
    Haliotis discus discus
  ORGANISM
    Haliotis discus discus
  REFERENCE
    Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;
    Vetigastropoda; Haliotidea; Haliotidae; Haliotis.
  AUTHORS
    Hideaki,T. and Masashi,S.
  TITLE
    Method for isolating satellite sequence
  
```

JOURNAL Patent: JP 2000060559-A 21 29-FEB-2000;
OS NATL INST OF AGROBIOLOGICAL RESOURCES
COMMENT PN JP 2000060559-A/21
PD 29-FEB-2000
PF 18-AUG-1998 JP 1998232153
PR HIDEAKI TAKAHASHI,MASASHI SEKINO
PI C12N15/09,C12Q1/68,C12N15/00
PC
CC
FH Key Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
1..20
/organism='Haliotis discus discus'.
FEATURES
source
1..20
/organism="Haliotis discus discus"
/mol_type="genomic DNA"
/sub_species="discus"
/db_xref="taxon:91233"
Query Match 0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2731 TGTGTGTGTGTGTGTGT 2749
Db
20 TGTGTGTGTGTGTGTGT 2
RESULT 640
AR562157
LOCUS AR562157 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 33 from patent US 6759215.
ACCESSION AR562157
VERSION AR562157.1 GI:53976020
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zsebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Method of preparing human stem cell factor polypeptide
JOURNAL Patent: US 6759215-A 33 06-JUL-2004;
FEATURES
source
1..20
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2903 TTTTGTGTGTGTGTGTGTGT 2921
Db
2 TTTTGTGTGTGTGTGTGTGT 20
RESULT 641
AX353616
LOCUS AX353616 20 bp DNA linear PAT 06-FEB-2002
DEFINITION Sequence 14 from Patent WO0204508.
ACCESSION AX353616
VERSION AX353616.1 GI:18618699
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Schweifer,N., Scherl-Mostagier,M., Sommergruber,W. and Absheher,R.
TITLE Tumour-associated antigen (B345), characterised by an amino acid
sequence as in seq. Id. No. 4
JOURNAL Patent: WO 0204508-A 14 17-JAN-2002;
FEATURES
Location/Qualifiers

source
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"
Query Match 0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2835 ATCTCTCCACCTCAGCCTC 2853
Db
2 ATCTCTCCACCTCAGCCTC 20
RESULT 642
AR126570
LOCUS AR126570 21 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 1 from patent US 6180349.
ACCESSION AR126570
VERSION AR126570.1 GI:14113163
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Ginzinger,D.G., Godfrey,T.E., Jensen,R.H. and Gray,J.W.
TITLE Quantitative PCR method to enumerate DNA copy number
JOURNAL Patent: US 6180349-A 1 30-JAN-2001;
FEATURES
source
1..21
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 3.4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2728 GTGTGTGTGTGTGTGTATG 2746
Db
2 GTGTGTGTGTGTGTGTGTG 20
RESULT 643
AR126571
LOCUS AR126571 21 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 2 from patent US 6180349.
ACCESSION AR126571
VERSION AR126571.1 GI:14113164
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 21)
AUTHORS Ginzinger,D.G., Godfrey,T.E., Jensen,R.H. and Gray,J.W.
TITLE Quantitative PCR method to enumerate DNA copy number
JOURNAL Patent: US 6180349-A 2 30-JAN-2001;
FEATURES
source
1..21
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 3.4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2728 GTGTGTGTGTGTGTGTATG 2746
Db
2 GTGTGTGTGTGTGTGTGTG 20
RESULT 644
AR184101/c

```

LOCUS AX184101 21 bp DNA linear PAT 06-AUG-2001
DEFINITION Sequence 1854 from Patent WO0142511.
ACCESSION AX184101
VERSION AX184101.1 GI:15135440
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Daly,M., Hudson,T.J., Lander,E.S., Rioux,J. and Siminovitch,K.
TITLE Ind-related polymorphisms
JOURNAL Pat: WO 0142511-A 1854 14-JUN-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Ellipsis
Biotherapeutics Corporation (CA)
FEATURES
source 1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.6%; Score 17.4; DB 1; Length 21;
Best Local Similarity 90.8%; Pred. No. 3.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2832 GTGATCTCCACCTCAGCC 2851
|||||
Db 20 GTGATCNCCTCTCAGCC 1

RESULT 645
BD089174
LOCUS BD089174 21 bp DNA linear PAT 27-AUG-2002
DEFINITION A method of arraying genome clone.
ACCESSION BD089174
VERSION BD089174.1 GI:22634784
KEYWORDS JP 2001321190-A/1418.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 21)
AUTHORS Soeda,E.
TITLE A method of arraying genome clone
JOURNAL Patent: JP 2001321190-A 1418 20-NOV-2001;
THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
GENOTECHS
COMMENT OS Artificial Sequence
PN JP 2001321190-A/1418
PD 20-NOV-2001
PF 12-MAR-2001 JP 2001068285
PI EIICHI SOEDA
PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
C12N15/00,
PC C12N15/00
CC Description of Artificial Sequence:Synthetic DNA FH Key
Location/Qualifiers
FT source 1..21
/organism='Artificial Sequence'.
FEATURES
source 1..21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.6%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 3.4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2729 TGTGTGTGTGTGTGTGTGT 2747
|||||
Db 1 TGTGTGTGTGTGTGTGTGT 19

LOCUS AX105619 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 94 from patent US 6096722.
ACCESSION AX105619
VERSION AX105619.1 GI:12819216
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and
treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 94 01-AUG-2000;
FEATURES
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1412 AGGCACCTACCTCTGT 1428

```

```

RESULT 646
AB068223
LOCUS AB068223 21 bp DNA linear SYN 21-MAY-2003
DEFINITION Synthetic construct DNA, reverse primer for human STS sts-R12616F
at lp36.
ACCESSION AB068223
VERSION AB068223.1 GI:15129027
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K.,
Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H.,
Morchaishi,A., Ohira,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A.
and Soeda,E.
TITLE A BAC-based STS-content map spanning a 35-Mb region of human
chromosome lp35-p36
JOURNAL Genomics 74 (1), 55-70 (2001)
MEDLINE 21269192
PUBMED 11374902
REFERENCE 2 (bases 1 to 21)
AUTHORS Horii,A.
TITLE Direct Submission
JOURNAL Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
Miyagi 980-8575, Japan (E-mail:horii@mail.cc.tohoku.ac.jp,
Tel:81-22-717-8042, Fax:81-22-717-8047)
FEATURES
source 1..21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
misc_feature 1..21
/note="reverse primer for human STS sts-R12616F at lp36
sts-R12616F obtained from clones B12616, B156A20,
B141IM15, B137L6, B157A17, B157P23, Human BAC library
RPC1-11"
Query Match 0.6%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 3.4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2729 TGTGTGTGTGTGTGTGTGT 2747
|||||
Db 1 TGTGTGTGTGTGTGTGTGT 19

RESULT 647
AX105619/c
LOCUS AX105619/c 18 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 94 from patent US 6096722.
ACCESSION AX105619
VERSION AX105619.1 GI:12819216
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Bennett,C.Frank., Mirabelli,C.K. and Baker,B.
TITLE Antisense modulation of cell adhesion molecule expression and
treatment of cell adhesion molecule-associated diseases
JOURNAL Patent: US 6096722-A 94 01-AUG-2000;
FEATURES
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.6%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1412 AGGCACCTACCTCTGT 1428

```

```
Db          |||||||
18 AGGCACCTACCTCTGT 2

RESULT 648
CQ788011    linear    PAT 24-MAR-2004
LOCUS       18 bp      DNA
DEFINITION  Sequence 317 from Patent WO2004020664.
ACCESSION   CQ788011
VERSION     CQ788011.1 GI:45722969
KEYWORDS    .
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Geldermann,H., Preuss,S. and Han,Y.
TITLE       Polymorphous microsatellite loci in genes for pre-diagnostic
            purposes
JOURNAL     Patent: WO 2004020664-A 317 11-MAR-2004;
            Universitaet Hohenheim (DE)
FEATURES    Location/Qualifiers
            source
            1..18
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="R ckw rts-Primer f r MM03"

Query Match      0.6%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 4.4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2854 CTGAGTAGCTGGGACCA 2870
Db          |||||||
1 CTGAGTAGCTGGGACCA 17

RESULT 649
AR082562/c    linear    PAT 31-AUG-2000
LOCUS       19 bp      DNA
DEFINITION  Sequence 12 from patent US 5973133.
ACCESSION   AR082562
VERSION     AR082562.1 GI:10009284
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 19)
AUTHORS     Hardy,J.A. and Goate,A.M.
TITLE       Mutant S182 genes
JOURNAL     Patent: US 5973133-A 12 26-OCT-1999;
            Location/Qualifiers
FEATURES    Location/Qualifiers
            source
            1..19
                /organism="unknown"
                /mol_type="unassigned DNA"

Query Match      0.6%; Score 17; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.2e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2779 GGAGTCAGTGGTGCAATC 2797
Db          |||||||
19 GGAGTCAGTGGYRATC 1

RESULT 650
AX116706/c    linear    PAT 11-MAY-2001
LOCUS       19 bp      DNA
DEFINITION  Sequence 1829 from Patent WO0129262.
ACCESSION   AX116706
VERSION     AX116706.1 GI:14033648
KEYWORDS    .
SOURCE      synthetic construct
ORGANISM    synthetic construct

other sequences; artificial sequences.
1
Picoult-Newburg,L. and Pohl,M.
Genotyping reagents, kits and methods of use thereof
Patent: WO 0129262-A 1829 26-APR-2001;
Orchid Biosciences, Inc. (US)
FEATURES    Location/Qualifiers
            source
            1..19
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="Primer"

Query Match      0.6%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2776 GCTGGAGTCAGTGGTG 2792
Db          |||||||
19 GCTGGAGTCAGTGGTG 3

RESULT 651
AX670675/c    linear    PAT 26-MAR-2003
LOCUS       19 bp      DNA
DEFINITION  Sequence 2 from Patent WO02068685.
ACCESSION   AX670675
VERSION     AX670675.1 GI:29292060
KEYWORDS    .
SOURCE      synthetic construct
ORGANISM    synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Levett,L.J. and Liddle,S.
TITLE       Diagnostic test for the detection of chromosomal abnormalities in a
            fetus
JOURNAL     Patent: WO 02068685-A 2 06-SEP-2002;
            Cytogenetic DNA Services Ltd (GB)
FEATURES    Location/Qualifiers
            source
            1..19
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="Primer"

Query Match      0.6%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2766 TGTCACCCAGGTGGAG 2782
Db          |||||||
17 TGTCACCCAGGTGGAG 1

RESULT 652
AR054243/c    linear    PAT 29-SEP-1999
LOCUS       20 bp      DNA
DEFINITION  Sequence 14 from patent US 5834607.
ACCESSION   AR054243
VERSION     AR054243.1 GI:5979105
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
            Unclassified.
            1 (bases 1 to 20)
REFERENCE   1
AUTHORS     Manoharan,M. and Cook,P.Dan.
TITLE       Amines and methods of making and using the same
JOURNAL     Patent: US 5834607-A 14 10-NOV-1998;
            Location/Qualifiers
FEATURES    Location/Qualifiers
            source
            1..20
                /organism="unknown"
                /mol_type="unassigned DNA"
```

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCA 67
|||||
Db 17 CCTCGCTATGGCTCCCA 1

RESULT 653
AR153737/c AR153737 20 bp DNA linear PAT 08-AUG-2001
LOCUS
DEFINITION Sequence 14 from patent US 6235886.
ACCESSION AR153737
VERSION AR153737.1 GI:15121269

KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Cook,P.Dan.
TITLE Methods of synthesis and use
JOURNAL Patent: US 6235886-A 14 22-MAY-2001;
FEATURES
Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCA 67
|||||
Db 17 CCTCGCTATGGCTCCCA 1

RESULT 654
CQ818365/c CQ818365 20 bp DNA linear PAT 07-JUN-2004
LOCUS
DEFINITION Sequence 7 from Patent WO2004044581.
ACCESSION CQ818365
VERSION CQ818365.1 GI:48427038

KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE
AUTHORS Mackenzie,I., Rees,C.M., Nikitenko,L.L., Bicknell,R. and Smith,D.M.
TITLE Transcriptional regulation of cfrl and uses thereof
JOURNAL Patent: WO 2004044581-A 7 27-MAY-2004;
ISIS INNOVATION LIMITED (GB)

FEATURES
Location/Qualifiers
source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTG 2742
|||||
Db 17 GCGTGTGTGTGTGTGTG 1

RESULT 655
CQ818387/c CQ818387 20 bp DNA linear PAT 07-JUN-2004
LOCUS
DEFINITION Sequence 29 from Patent WO2004044581.
ACCESSION CQ818387
VERSION CQ818387.1 GI:48427060

KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Mackenzie,I., Rees,C.M., Nikitenko,L.L., Bicknell,R. and Smith,D.M.
TITLE Transcriptional regulation of cfrl and uses thereof
JOURNAL Patent: WO 2004044581-A 29 27-MAY-2004;
ISIS INNOVATION LIMITED (GB)

FEATURES
Location/Qualifiers
source 1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTG 2742
|||||
Db 17 GCGTGTGTGTGTGTGTG 1

RESULT 656
AR212332/c AR212332 20 bp DNA linear PAT 20-JUN-2002
LOCUS
DEFINITION Sequence 14 from patent US 6399757.
ACCESSION AR212332
VERSION AR212332.1 GI:21515878

KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Cook,P.Dan.
TITLE Oligonucleotide and nucleotide amine analogs, methods of synthesis and use

JOURNAL Patent: US 6399757-A 14 04-JUN-2002;
FEATURES
Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCA 67
|||||
Db 17 CCTCGCTATGGCTCCCA 1

RESULT 657
AR267394/c AR267394 20 bp DNA linear PAT 10-APR-2003
LOCUS
DEFINITION Sequence 14 from patent US 6495671.
ACCESSION AR267394
VERSION AR267394.1 GI:29697423

KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 20)
AUTHORS Manoharan,M. and Cook,P.D.
TITLE Oligonucleotide and nucleotide amine analogs, methods of synthesis and use

JOURNAL Patent: US 6495671-A 14 17-DEC-2002;
FEATURES
Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4e+02; 0; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0;

QY 51 CCTCGCTATGGCTCCCA 67
|||||
Db 17 CCTCGCTATGGCTCCCA 1

RESULT 658
AR562158
LOCUS AR562158 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 34 from patent US 6759215.
ACCESSION AR562158
VERSION AR562158.1 GI:53976021
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Zsebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Method of preparing human stem cell factor polypeptide
JOURNAL Patent: US 6759215-A 34 06-JUL-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4e+02; 0; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 0;

QY 2903 TTTTTCCTTTTTC 2919
|||||
Db 3 TTTTTCCTTTTTC 19

RESULT 659
AR011709/c
LOCUS AR011709 20 bp DNA linear PAT 04-DEC-1998
DEFINITION Sequence 19 from patent US 5763168.
ACCESSION AR011709
VERSION AR011709.1 GI:3969699
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Lalouel,J.-M., Jeunemaitre,X., Lifton,R.P., Soubrier,F.,
Kotelevtsev,Y. and Corvol,P.
TITLE Method to determine predisposition to hypertension
JOURNAL Patent: US 5763168-A 19 09-JUN-1998;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTGCAGT 2788
|||||
Db 20 CTCGAGGCTGGAGTGCAGT 1

RESULT 660
AR091933
LOCUS AR091933 20 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 5 from patent US 5998133.
ACCESSION AR091933
VERSION AR091933.1 GI:10018687

KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Blumenfeld,A., Gusella,J.F., Breakefield,X.O. and Slaugenhaupt,S.
TITLE Use of genetic markers to diagnose familial dysautonomia
JOURNAL Patent: US 5998133-A 5 07-DEC-1999;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2853 CCTGAGTAGCTGGACCATA 2872
|||||
Db 1 CCTGAGTAGCTGGACCATA 20

RESULT 661
AR092309/c
LOCUS AR092309 20 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 19 from patent US 5998145.
ACCESSION AR092309
VERSION AR092309.1 GI:10019063
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Lalouel,J.-M., Jeunemaitre,X., Lifton,R.P., Soubrier,F.,
Kotelevtsev,Y. and Corvol,P.
TITLE Method to determine predisposition to hypertension
JOURNAL Patent: US 5998145-A 19 07-DEC-1999;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTGCAGT 2788
|||||
Db 20 CTCGAGGCTGGAGTGCAGT 1

RESULT 662
AR103706/c
LOCUS AR103706 20 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 230 from patent US 6087485.
ACCESSION AR103706
VERSION AR103706.1 GI:12815294
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Brooks-Wilson,A.R., Buckler,A., Cardon,L., Carey,A.H., Galvin,M.,
Miller,A. and North,M.
TITLE Asthma related genes
JOURNAL Patent: US 6087485-A 230 11-JUL-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTGCTCTGTCCAGGCT 2778
| | | | | | | | | |
Db 20 CTGCTCTGTCCAGGCT 1

RESULT 663
AR119526/c
LOCUS AR119526 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 19 from patent US 6153386.
ACCESSION AR119526
VERSION AR119526.1 GI:14102225
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Lalouel,J.-M. and Jeunemaitre,X.
TITLE Method to determine predisposition to hypertension
JOURNAL Patent: US 6153386-A 19 28-NOV-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTGCACT 2788
| | | | | | | | | |
Db 20 CTCGGAGGCTGGAGTGCACT 1

RESULT 664
AR122443/c
LOCUS AR122443 20 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 19 from patent US 6165727.
ACCESSION AR122443
VERSION AR122443.1 GI:14106760
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Lalouel,J.-M., Jeunemaitre,X., Lifton,R.P., Soubrier,F.,
Kotelevtsev,Y. and Corvol,P.
TITLE Method to determine predisposition to hypertension
JOURNAL Patent: US 6165727-A 19 26-DEC-2000;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTGCACT 2788
| | | | | | | | | |
Db 20 CTCGGAGGCTGGAGTGCACT 1

RESULT 665
AR152855/c
LOCUS AR152855 20 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 135 from patent US 6235470.
ACCESSION AR152855
VERSION AR152855.1 GI:15120387
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.

Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sidransky,D.
TITLE Detection of neoplasia by analysis of saliva
JOURNAL Patent: US 6235470-A 135 22-MAY-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTGCTCTGTCCAGGCT 2778
| | | | | | | | | |
Db 20 CTGCTCTGTCCAGGCT 1

RESULT 666
AR152863/c
LOCUS AR152863 20 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 143 from patent US 6235470.
ACCESSION AR152863
VERSION AR152863.1 GI:15120395
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sidransky,D.
TITLE Detection of neoplasia by analysis of saliva
JOURNAL Patent: US 6235470-A 143 22-MAY-2001;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2776 GCTGGAGTCAGTGGTGCAA 2795
| | | | | | | | | |
Db 20 GCTGGAGTCAGTGGTGCAA 1

RESULT 667
BD134311/c
LOCUS BD134311 20 bp DNA linear PAT 18-SEP-2002
DEFINITION Detection of neoplasia by analysis of saliva.
ACCESSION BD134311
VERSION BD134311.1 GI:23229256
KEYWORDS JP 2002505888-A/135.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Sidlanski,D.
TITLE Detection of neoplasia by analysis of saliva
JOURNAL Patent: JP 2002505888-A 135 26-FEB-2002;
COMMENT THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
OS Artificial Sequence
PN JP 2002505888-A/135
PD 26-FEB-2002
PF 10-MAR-1999 JP 2000535774
PR 10-MAR-1998 US 09/038637
PI DAVID SIDLANSKI
PC C12N15/09,C12Q1/68,C12N15/00
CC nucleotide
FH Key Location/Qualifiers
FT source 1..20
FT /organism='Artificial Sequence'.

FEATURES
source
Location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 0.6%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTACCCAGGCT 2778
Db 20 CTTGCTTTGTACCCAGGCT 1

RESULT 668
BD134319/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

BD134319 20 bp DNA linear PAT 18-SEP-2002
Detection of neoplasia by analysis of saliva.
BD134319
BD134319.1 GI:23229264
JP 2002505888-A/143.
synthetic construct
synthetic construct
other sequences; artificial sequences.
1 (bases 1 to 20)
Sidlanski,D.
Detection of neoplasia by analysis of saliva
Patent: JP 2002505888-A 143 26-FEB-2002;
THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE
OS Artificial Sequence
PN JP 2002505888-A/143
PD 26-FEB-2002
PF 10-MAR-1999 JP 2000535774
PR 10-MAR-1998 US 09/038637
PI DAVID SIDLANSKI
PC C12N15/09,C12Q1/68,C12N15/00
CC nucleotide
FH Key Location/Qualifiers
FT source 1..20
/organism='Artificial Sequence'.
FT source 1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match
Best Local Similarity 0.6%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2776 GCTGGAGTGCAGTGTGCA 2795
Db 20 GCTGGAGTATAGTGTGCA 1

RESULT 669
BD138315/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

BD138315 20 bp DNA linear PAT 18-SEP-2002
Antisense modulation of human MDM2 expression.
BD138315
BD138315.1 GI:23233260
JP 2002508944-A/241.
unidentified
unidentified
unclassified.
1 (bases 1 to 20)
Miraglia,L.J., Nero,P., Graham,M.J., Monia,B.P. and Cowsert,L.M.
Antisense modulation of human MDM2 expression
Patent: JP 2002508944-A 241 26-MAR-2002;
ISIS PHARMACEUTICALS INC
OS Unidentified
PN JP 2002508944-A/241

PD 26-MAR-2002
PF 26-MAR-1999 JP 2000538025
PR 26-MAR-1998 US 09/048810
PI LOREN J MIRAGLIA,PAMELA NERO,MARK J GRAHAM,BRETT P MONIA,LEX M

PI COWSERT
PC C12N15/09,A61K48/00,A61P9/10,A61P17/06,A61P35/00,C07H21/04//
PC C12Q1/68,
PC C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Antisense modulation of human MDM2 expression FH Key
CC Location/Qualifiers
FT source 1..20
/organism='Unidentified'.
FT Location/Qualifiers
1..20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.6%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTACCCAGGCTG 2779
Db 20 TTGCTCTGTACCAGGCTG 1

RESULT 670
BD138338/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

BD138338 20 bp DNA linear PAT 18-SEP-2002
Antisense modulation of human MDM2 expression.
BD138338
BD138338.1 GI:23233283
JP 2002508944-A/264.
unidentified
unidentified
unclassified.
1 (bases 1 to 20)
Miraglia,L.J., Nero,P., Graham,M.J., Monia,B.P. and Cowsert,L.M.
Antisense modulation of human MDM2 expression
Patent: JP 2002508944-A 264 26-MAR-2002;
ISIS PHARMACEUTICALS INC
OS Unidentified
PN JP 2002508944-A/264
PD 26-MAR-2002
PF 26-MAR-1999 JP 2000538025
PR 26-MAR-1998 US 09/048810
PI LOREN J MIRAGLIA,PAMELA NERO,MARK J GRAHAM,BRETT P MONIA,LEX M

PI COWSERT
PC C12N15/09,A61K48/00,A61P9/10,A61P17/06,A61P35/00,C07H21/04//
PC C12Q1/68,
PC C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Antisense modulation of human MDM2 expression FH Key
CC Location/Qualifiers
FT source 1..20
/organism='Unidentified'.
FT Location/Qualifiers
1..20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.6%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2833 TGATCTCCACCTCAGCCT 2852

```

Db      20  TGAATCGCCACCTCGGCT 1
||||| ||||| ||||| |||||
RESULT 671
BD217343/c
LOCUS      20 bp DNA linear PAT 17-JUL-2003
DEFINITION Method of quantifying hypertensive constitution.
ACCESSION BD217343
VERSION    BD217343.1 GI:33027113
KEYWORDS   JP 2002519012-A/19.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
REFERENCE  1 (bases 1 to 20)
AUTHORS    Fukuyota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
TITLE       Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
JOURNAL    Lalouel,J.M. and Jeunemaitre,X.
COMMENT    Method of quantifying hypertensive constitution
PATENT: JP 2002519012-A 19 02-JUL-2002;
UNIVERSITY OF UTAH RESEARCH FOUNDATION
OS Homo sapiens (human)
PN JP 2002519012-A/19
PD 02-JUL-2002
PF 15-APR-1999 JP 2000557000
PR 29-JUN-1998 US 09/106216
PI JEAN MARC LALOUEL,XAVIER JEUNEMAIRE
PC C1201/68,C12N15/09,C12N15/00
CC Method of quantifying hypertensive constitution FH Key
FT Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
FT /organism='Homo sapiens (human)'.
FT /organism="Homo sapiens"
FT /mol_type="genomic DNA"
FT /db_xref="taxon:9606"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTCAGT 2788
Db      20  CTCGAGGCTGGAGTCAGT 1
||||| ||||| ||||| |||||
RESULT 672
CQ759610
LOCUS      20 bp DNA linear PAT 01-MAR-2004
DEFINITION Sequence 40 from Patent WO2003106672.
ACCESSION CQ759610
VERSION    CQ759610.1 GI:44849560
KEYWORDS   synthetic construct
SOURCE     other sequences; artificial sequences.
ORGANISM   other sequences; artificial sequences.
REFERENCE  1
AUTHORS    Hayashizaki,Y., Carninci,P. and Harbers,M.T.
TITLE       Method of utilizing the 5' end of transcribed nucleic acid regions
JOURNAL    for cloning and analysis
PATENT: WO 2003106672-A 40 24-DEC-2003;
Riken (JP) ; Kabushiki Kaisha Dnaform (JP)
FEATURES   Location/Qualifiers
source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="tag8"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 2728 GTGTGTGTGTGTGTGTATCT 2747
Db      1  GTGTGTGTGTGTGTGTGT 20
||||| ||||| ||||| |||||
RESULT 673
CQ787993/c
LOCUS      20 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 299 from Patent WO2004020664.
ACCESSION CQ787993
VERSION    CQ787993.1 GI:45722951
KEYWORDS   synthetic construct
SOURCE     other sequences; artificial sequences.
ORGANISM   other sequences; artificial sequences.
REFERENCE  1
AUTHORS    Geldermann,H., Preuss,S. and Han,Y.
TITLE       Polymorphous microsatellite loci in genes for pre-diagnostic
JOURNAL    purposes
PATENT: WO 2004020664-A 299 11-MAR-2004;
UNIVERSITAET HOHENHEIM (DE)
FEATURES   Location/Qualifiers
source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="R ckw rts-Primer f x M06"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2853 CCTGAGTAGCTGGACCATA 2872
Db      20  CCTGAGTAGCTGGACTACA 1
||||| ||||| ||||| |||||

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTCAGT 2788
Db      20  CTCGAGGCTGGAGTCAGT 1
||||| ||||| ||||| |||||
RESULT 675
AR194764
LOCUS      20 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 8 from patent US 6348596.
ACCESSION AR194764
VERSION    AR194764.1 GI:20241356
KEYWORDS   keywords

```


KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L. and Park,S.-J.
TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor
JOURNALS Patent: US 6750016-A 55 15-JUN-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGATTTTTTTTTTTTTTTT 2917
||| |||||||||
Db 20 TTTTTTTTTTTTTTTTTT 1

RESULT 681
AR559411/c
LOCUS AR559411 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 70 from patent US 6750016.
ACCESSION AR559411
VERSION AR559411.1 GI:53968827
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L. and Park,S.-J.
TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor
JOURNALS Patent: US 6750016-A 70 15-JUN-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGATTTTTTTTTTTTTTTT 2917
||| |||||||||
Db 20 TTTTTTTTTTTTTTTTTT 1

RESULT 682
AR561993/c
LOCUS AR561993 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6759199.
ACCESSION AR561993
VERSION AR561993.1 GI:53975645
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J., Elghanian,R. and Taton,T.A.
TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor
JOURNALS Patent: US 6759199-A 55 06-JUL-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGATTTTTTTTTTTTTTTT 2917
||| |||||||||
Db 20 TTTTTTTTTTTTTTTTTT 1

RESULT 683
AR565165/c
LOCUS AR565165 20 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 55 from patent US 6767702.
ACCESSION AR565165
VERSION AR565165.1 GI:53981003
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Mirkin,C.A., Letsinger,R.L., Mucic,R.C., Storhoff,J.J., Elghanian,R., Taton,T.A., Garimella,V. and Li,Z.
TITLE Nanoparticles having oligonucleotides attached thereto and uses therefor
JOURNALS Patent: US 6767702-A 55 27-JUL-2004;
FEATURES Location/Qualifiers
source 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGATTTTTTTTTTTTTTTT 2917
||| |||||||||
Db 20 TTTTTTTTTTTTTTTTTT 1

RESULT 684
AX092615/c
LOCUS AX092615 20 bp DNA linear PAT 21-MAR-2001
DEFINITION Sequence 27 from Patent WO0115676.
ACCESSION AX092615
VERSION AX092615.1 GI:13444672
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Hayden,M.R., Brooks-Wilson,A.R., Pimstone,S.N. and Clee,S.M.
TITLE Compositions and methods for modulating hdl cholesterol and triglyceride levels
JOURNALS Patent: WO 0115676-A 27 08-MAR-2001;
FEATURES University of British Columbia (CA) ; Xenon Genetics Inc. (CA)
Location/Qualifiers
source 1..20
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2782 GTGCAGTGTGCAATCATGG 2801
||| |||||||
Db 20 GTGCAGTGTGCAATCATGG 1

RESULT 685
AX117390

```

LOCUS       AX117390                      20 bp    DNA                linear    PAT 11-MAY-2001
DEFINITION   Sequence 2513 from Patent WO0129262.
ACCESSION   AX117390
VERSION     AX117390.1  GI:114034341
KEYWORDS    .
SOURCE      synthetic construct
            synthetic construct
            other sequences; artificial sequences.
ORGANISM    1
REFERENCE   1
AUTHORS     Picoult-Newburg,L. and Pohl,M.
TITLE       Genotyping reagents, kits and methods of use thereof
JOURNAL     Patent: WO 0129262-A 2513 26-APR-2001;
            Orchid BioSciences, Inc. (US)
FEATURES             Location/Qualifiers
     source          1..20
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer"

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2828  TCAAGTGATCCTCCACCTC 2847
           ||||| ||||| ||||| |||||
Db      1    TCAAGCGATCCTCACACCTC 20

RESULT 686
LOCUS       BD089116                      20 bp    DNA                linear    PAT 27-AUG-2002
DEFINITION   A method of arraying genome clone.
ACCESSION   BD089116
VERSION     BD089116.1  GI:22634726
KEYWORDS    JP 2001321190-A/1360.
SOURCE      synthetic construct
            synthetic construct
            other sequences; artificial sequences.
ORGANISM    1 (bases 1 to 20)
REFERENCE   1
AUTHORS     Soeda,E.
TITLE       A method of arraying genome clone
JOURNAL     Patent: JP 2001321190-A 1360 20-NOV-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
GENOTECHS
COMMENT     OS   Artificial Sequence
            PN   JP 2001321190-A/1360
            PD   20-NOV-2001
            PF   12-MAR-2001 JP 2001068285
            PI   EIICHI SOEDA
            PC   C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
            C12N15/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
            FT   Location/Qualifiers
            FT   source          1..20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2759  CTGCTCTGTACCCAGGCT 2778
           ||||| ||||| ||||| |||||
Db      1    CTCACTCAGTCACCCAGGCT 20

RESULT 687

```

```

BD089273
LOCUS       BD089273                      20 bp    DNA                linear    PAT 27-AUG-2002
DEFINITION   A method of arraying genome clone.
ACCESSION   BD089273
VERSION     BD089273.1  GI:22634883
KEYWORDS    JP 2001321190-A/1517.
SOURCE      synthetic construct
            synthetic construct
            other sequences; artificial sequences.
ORGANISM    1 (bases 1 to 20)
REFERENCE   1
AUTHORS     Soeda,E.
TITLE       A method of arraying genome clone
JOURNAL     Patent: JP 2001321190-A 1517 20-NOV-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
GENOTECHS
COMMENT     OS   Artificial Sequence
            PN   JP 2001321190-A/1517
            PD   20-NOV-2001
            PF   12-MAR-2001 JP 2001068285
            PI   EIICHI SOEDA
            PC   C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
            C12N15/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
            FT   Location/Qualifiers
            FT   source          1..20
                     /organism="Artificial Sequence".
                     Location/Qualifiers
                     1..20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2775  GGCTGGAGTCAGTGGTGCA 2794
           ||||| ||||| ||||| |||||
Db      1    GGCTGGAGTACAGTGTGCA 20

RESULT 688
LOCUS       BD089312/c                   20 bp    DNA                linear    PAT 27-AUG-2002
DEFINITION   A method of arraying genome clone.
ACCESSION   BD089312
VERSION     BD089312.1  GI:22634922
KEYWORDS    JP 2001321190-A/1556.
SOURCE      synthetic construct
            synthetic construct
            other sequences; artificial sequences.
ORGANISM    1 (bases 1 to 20)
REFERENCE   1
AUTHORS     Soeda,E.
TITLE       A method of arraying genome clone
JOURNAL     Patent: JP 2001321190-A 1556 20-NOV-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
GENOTECHS
COMMENT     OS   Artificial Sequence
            PN   JP 2001321190-A/1556
            PD   20-NOV-2001
            PF   12-MAR-2001 JP 2001068285
            PI   EIICHI SOEDA
            PC   C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
            C12N15/00,
            PC   C12N15/00
            CC   Description of Artificial Sequence:Synthetic DNA FH   Key
            FT   Location/Qualifiers
            FT   source          1..20
                     /organism="Artificial Sequence".
                     Location/Qualifiers
                     1..20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2759  CTGCTCTGTACCCAGGCT 2778
           ||||| ||||| ||||| |||||
Db      1    CTCACTCAGTCACCCAGGCT 20

RESULT 687

```

/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCTGAGTAGCTG 2864

Db 20 CTCAGCCTCCCAAGTAGCTG 1

RESULT 689

BD090075/c

LOCUS

BD090075

DEFINITION

A method of arraying genome clone.

ACCESSION

BD090075

VERSION

BD090075.1

KEYWORDS

JP 2001321190-A/2319.

SOURCE

synthetic construct

ORGANISM

other sequences; artificial sequences.

REFERENCE

1 (bases 1 to 20)

AUTHORS

Soeda,E.

TITLE

A method of arraying genome clone

JOURNAL

Patent: JP 2001321190-A 2319 20-NOV-2001;

THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA

GENOTECHS

COMMENT

OS Artificial Sequence

PN JP 2001321190-A/2319

PD 20-NOV-2001

PF 12-MAR-2001

PI EICHHI SOEDA

PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566,PC

C12N15/00,

PC C12N15/00

CC Description of Artificial Sequence:Synthetic DNA

FT Key

FT Location/Qualifiers

1. .20

source

Location/Qualifiers

1. .20

/organism="Artificial Sequence".

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match

Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2830 AAGTAGCTCTCCACCTCAG 2849

Db 20 ACGTAAATCTCCACCTCAG 1

RESULT 690

BD106257/c

LOCUS

BD106257

DEFINITION

Novel LDL-receptor.

ACCESSION

BD106257

VERSION

BD106257.1

KEYWORDS

JP 2002501376-A/272.

SOURCE

Chlamydia sp.

ORGANISM

Chlamydia sp.

Bacteria; Chlamydiae; Chlamydiales; Chlamydiaceae; Chlamydia.

REFERENCE

1 (bases 1 to 20)

AUTHORS

Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D., Hammond,H.

and Hey,P.

TITLE

Novel LDL-receptor

JOURNAL

Patent: JP 2002501376-A 272 15-JAN-2002;

THE WELLCOME TRUST LTD AS TRUSTEE TO THE WELLCOME TRUST, MERCK & CO

INC

COMMENT

PN JP 2002501376-A/272

/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCTGAGTAGCTG 2864

Db 20 CTCAGCCTCCCAAGTAGCTG 1

RESULT 689

BD090075/c

LOCUS

BD090075

DEFINITION

A method of arraying genome clone.

ACCESSION

BD090075

VERSION

BD090075.1

KEYWORDS

JP 2001321190-A/2319.

SOURCE

synthetic construct

ORGANISM

other sequences; artificial sequences.

REFERENCE

1 (bases 1 to 20)

AUTHORS

Soeda,E.

TITLE

A method of arraying genome clone

JOURNAL

Patent: JP 2001321190-A 2319 20-NOV-2001;

THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA

GENOTECHS

COMMENT

OS Artificial Sequence

PN JP 2001321190-A/2319

PD 20-NOV-2001

PF 12-MAR-2001

PI EICHHI SOEDA

PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566,PC

C12N15/00,

PC C12N15/00

CC Description of Artificial Sequence:Synthetic DNA

FT Key

FT Location/Qualifiers

1. .20

source

Location/Qualifiers

1. .20

/organism="Artificial Sequence".

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match

Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2830 AAGTAGCTCTCCACCTCAG 2849

Db 20 ACGTAAATCTCCACCTCAG 1

RESULT 690

BD106257/c

LOCUS

BD106257

DEFINITION

Novel LDL-receptor.

ACCESSION

BD106257

VERSION

BD106257.1

KEYWORDS

JP 2002501376-A/272.

SOURCE

Chlamydia sp.

ORGANISM

Chlamydia sp.

Bacteria; Chlamydiae; Chlamydiales; Chlamydiaceae; Chlamydia.

REFERENCE

1 (bases 1 to 20)

AUTHORS

Todd,J.A., Hess,J.W., Caskey,C.T., Cox,R.D., Gerhold,D., Hammond,H.

and Hey,P.

TITLE

Novel LDL-receptor

JOURNAL

Patent: JP 2002501376-A 272 15-JAN-2002;

THE WELLCOME TRUST LTD AS TRUSTEE TO THE WELLCOME TRUST, MERCK & CO

INC

COMMENT

PN JP 2002501376-A/272

15-JAN-2002
15-APR-1998 JP 1998543635
15-APR-1997 US 60/043553,05-JUN-1997 US 60/048740 PI
JOHN ANDREW TODD,JOHN WILFRED HESS,CHARLES
THOMAS CASKEY,ROGER
DAVID COX,
DAVID GERHOLD,HOLLY HAMMOND,PATRICIA HEY
C12N15/12,C12N15/11,C12Q1/68,C07K14/705,C07K16/28,A61K38/17,
A61K39/395,
A61K48/00
Strandedness: Single;
Topology: Linear;
Location/Qualifiers.
Key Location/Qualifiers
1. .20
/organism="Chlamydia sp."
/mol_type="genomic DNA"
/db_xref="taxon:35827"

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2828 TCAAGTGATCTCCACCTC 2847

Db 20 TCAAGTGATCTCTCGCTC 1

RESULT 691

BD129936/c

LOCUS

BD129936

DEFINITION

Asthma-associated gene.

ACCESSION

BD129936

VERSION

BD129936.1

KEYWORDS

JP 2002500895-A/226.

SOURCE

unidentified

ORGANISM

unclassified.

REFERENCE

1 (bases 1 to 20)

AUTHORS

Wilson,A.R.B., Buckler,A., Cardon,L., Carey,A.H., Galvin,M.,

Miller,A. and North,W.

TITLE

Asthma-associated gene

JOURNAL

Patent: JP 2002500895-A 226 15-JAN-2002;

AXYS PHARMACEUTICALS INC

COMMENT

OS Unidentified

PN JP 2002500895-A/226

PD 15-JAN-2002

PF 21-JAN-1998 JP 2000528715

PI ANGELA R BROOKS WILSON,ALAN BUCKLER,LON

CARDON,ALISOUN H CAREY,

PI MARGARET GALVIN,ANDREW MILLER,MICHAEL NORTH

PC C12Q1/68,A01K67/027,C07K14/47,C12N15/09,C12N15/00 CC

Strandedness: Single;

Topology: Linear;

Asthma-associated gene

Location/Qualifiers

1. .20

source

Location/Qualifiers

1. .20

/organism="Unidentified".

/organism="unidentified"

/mol_type="genomic DNA"

/db_xref="taxon:32644"

Query Match

Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTCGCTCTCTCAGCCAGGCT 2778

Db 20 CTCAGCTCTCTCAGCCAGGCT 1

```

RESULT 692
AB068830/c
LOCUS       Synthetic construct DNA, forward primer for human STS sts-D1S2126
            at lp36.
ACCESSION   AB068830
VERSION     AB068830.1 GI:15129634
KEYWORDS    .
SOURCE      synthetic construct
ORGANISM    synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K.,
            Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H.,
            Morohashi,A., Ohira,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A.
            and Soeda,E.
TITLE       A BAC-based STS-content map spanning a 35-Mb region of human
            chromosome lp35-p36
JOURNAL     Genomics 74 (1), 55-70 (2001)
MEDLINE     21269192
PUBMED      11374902
REFERENCE   2 (bases 1 to 20)
AUTHORS     Horii,A.
TITLE       Direct Submission
JOURNAL     Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
            Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
            Miyagi 980-8575, Japan (E-mail:horii@mail.cc.tohoku.ac.jp,
            Tel:81-22-717-8042, Fax:81-22-717-8047)
FEATURES             Location/Qualifiers
     source          1..20
                     /organism="synthetic construct"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32630"
     misc_feature     1..20
                     /notes="forward primer for human STS sts-D1S2126 at lp36
            sts-D1S2126 obtained from clones B24G6, B27H21, B37N12,
            B88B14, B367J3, B235B9 B143K19, B122B1, Human BAC library
            RPC1-11"

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.1e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2830 AAGTGATCTCCACCTCAG 2849
Db      20 ACGTAATCTCCACCTCAG 1

RESULT 693
AR154017/c
LOCUS       AR154017
DEFINITION   Sequence 67 from patent US 6238863.
ACCESSION   AR154017
VERSION     AR154017.1 GI:15122070
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
            Unclassified.
REFERENCE   1 (bases 1 to 21)
AUTHORS     Schumm,J.W. and Bacher,J.W.
TITLE       Materials and methods for indentifying and analyzing intermediate
            tandem repeat DNA markers
JOURNAL     Patent: US 6238863-A 67 29-MAY-2001;
            Location/Qualifiers
     source          1..21
                     /organism="unknown"
                     /mol_type="unassigned DNA"

Query Match          0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.9e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2760 TCGCTCTGTCCACCGGCTG 2779
Db      20 TCGCTCTGTCCACCGGCTG 1

RESULT 694
AR565241/c
LOCUS       AR565241
DEFINITION   Sequence 67 from patent US 6767703.
ACCESSION   AR565241
VERSION     AR565241.1 GI:53981079
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
            Unclassified.
REFERENCE   1 (bases 1 to 21)
AUTHORS     Schumm,J.W. and Bacher,J.W.
TITLE       Materials and methods for indentifying and analyzing intermediate
            tandem repeat DNA markers
JOURNAL     Patent: US 6767703-A 67 27-JUL-2004;
            Location/Qualifiers
     source          1..21
                     /organism="unknown"
                     /mol_type="genomic DNA"

Query Match          0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.9e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2760 TCGCTCTGTCCACCGGCTG 2779
Db      20 TCGCTCTGTCCACCGGCTG 1

RESULT 695
AX777492/c
LOCUS       AX777492
DEFINITION   Sequence 40 from Patent WO03029458.
ACCESSION   AX777492
VERSION     AX777492.1 GI:32694510
KEYWORDS    .
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
            synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Breitling,F., Moldenhauer,G., Poustka,A. and Kuehlwein,T.
TITLE       Method for producing protein libraries and for selecting proteins
            from said libraries
JOURNAL     Patent: WO 03029458-A 40 10-APR-2003;
            Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts
            (DE)
FEATURES             Location/Qualifiers
     source          1..21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer VH3-11"

Query Match          0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.9e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1766 GGACGCCGGAGGACAGGGCA 1785
Db      21 GGACGCTGGAGGAGGGCA 2

RESULT 696
BD130123/c
LOCUS       BD130123
DEFINITION   Material and method for specifying and analyzing medium-size tandem
            repeat DNA marker.
ACCESSION   BD130123
VERSION     BD130123.1 GI:23225068

```

```

Db      20 TTGCTCTGTCCACAGGCTG 1

RESULT 694
AR565241/c
LOCUS       AR565241
DEFINITION   Sequence 67 from patent US 6767703.
ACCESSION   AR565241
VERSION     AR565241.1 GI:53981079
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unknown.
            Unclassified.
REFERENCE   1 (bases 1 to 21)
AUTHORS     Schumm,J.W. and Bacher,J.W.
TITLE       Materials and methods for indentifying and analyzing intermediate
            tandem repeat DNA markers
JOURNAL     Patent: US 6767703-A 67 27-JUL-2004;
            Location/Qualifiers
     source          1..21
                     /organism="unknown"
                     /mol_type="genomic DNA"

Query Match          0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.9e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2760 TCGCTCTGTCCACCGGCTG 2779
Db      20 TCGCTCTGTCCACAGGCTG 1

RESULT 695
AX777492/c
LOCUS       AX777492
DEFINITION   Sequence 40 from Patent WO03029458.
ACCESSION   AX777492
VERSION     AX777492.1 GI:32694510
KEYWORDS    .
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
            synthetic construct
            other sequences; artificial sequences.
REFERENCE   1
AUTHORS     Breitling,F., Moldenhauer,G., Poustka,A. and Kuehlwein,T.
TITLE       Method for producing protein libraries and for selecting proteins
            from said libraries
JOURNAL     Patent: WO 03029458-A 40 10-APR-2003;
            Deutsches Krebsforschungszentrum Stiftung des Oeffentlichen Rechts
            (DE)
FEATURES             Location/Qualifiers
     source          1..21
                     /organism="synthetic construct"
                     /mol_type="unassigned DNA"
                     /db_xref="taxon:32630"
                     /note="Primer VH3-11"

Query Match          0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 3.9e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1766 GGACGCCGGAGGACAGGGCA 1785
Db      21 GGACGCTGGAGGAGGGCA 2

RESULT 696
BD130123/c
LOCUS       BD130123
DEFINITION   Material and method for specifying and analyzing medium-size tandem
            repeat DNA marker.
ACCESSION   BD130123
VERSION     BD130123.1 GI:23225068

```

KEYWORDS JP 2002502606-A/67.
 SOURCE unidentified
 ORGANISM unclassified
 REFERENCE 1 (bases 1 to 21)
 AUTHORS Schumm,J.W. and Bacher,J.W.
 TITLE Material and method for specifying and analyzing medium-size tandem repeat DNA marker
 JOURNAL Patent: JP 2002502606-A 67 29-JAN-2002;
 COMMENT PROMEGA CORP
 OS Unidentified
 PN JP 2002502606-A/67
 PD 29-JAN-2002
 PF 04-FEB-1999 JP 2000530608
 PR 04-FEB-1998 US 09/018584
 PI JAMES W SCHUMM,JEFFREY W BACHER
 PC C12N15/09,C12Q1/68,C12N15/00
 CC Strandedness: Single;
 CC Topology: Linear;
 CC Material and method for specifying and analyzing medium-size tandem repeat
 CC DNA marker
 FH Key Location/Qualifiers
 FT source 1..21
 FT /organism='Unidentified'.
 FEATURES
 source
 1..21
 Location/Qualifiers
 /organism='unidentified'
 /mol_type='genomic DNA'
 /db_xref='taxon:32644'
 Query Match 0.6%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 3.9e+02;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2760 TCCTCTGTGTCACCAAGCTG 2779
 DB 20 TTGCTCTGTGTCACCAAGCTG 1
 RESULT 697
 AX033910/c 19 bp DNA linear PAT 21-SEP-2000
 LOCUS Sequence 2 from Patent WO9851790.
 DEFINITION AX033910
 ACCESSION AX033910
 VERSION AX033910.1 GI:10280478
 KEYWORDS
 SOURCE unidentified
 ORGANISM unclassified.
 REFERENCE 1
 AUTHORS Cancilla,M.R., Choo,K.H. and Du,S.D.
 TITLE A novel nucleic acid molecule
 JOURNAL Patent: WO 9851790-A 2 19-NOV-1998;
 CANCELLA MICHAEL ROBERT (AU) ; CHOO KONG HONG ANDY (AU) ; SART
 DESIREE DU (AU) ; AMRAD OPERATIONS PTY LTD (AU)
 FEATURES
 source 1..19
 Location/Qualifiers
 /organism='unidentified'
 /mol_type='unassigned DNA'
 /db_xref='taxon:32644'
 Query Match 0.6%; Score 16.6; DB 1; Length 19;
 Best Local Similarity 84.2%; Pred. No. 4.6e+02;
 Matches 16; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 2773 CAGGCTGGAGTGCAGTGGT 2791
 DB 19 CAGGCTGCAGTGCARTGGY 1
 RESULT 698
 AR068107/c

LOCUS AR068107 18 bp DNA linear PAT 29-SEP-1999
 DEFINITION Sequence 3 from patent US 5852182.
 ACCESSION AR068107
 VERSION AR068107.1 GI:5999329
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Cook,P.Dan. and Manoharan,M.
 TITLE Thiol-derivatized oligonucleosides
 JOURNAL Patent: US 5852182-A 3 22-DEC-1998;
 FEATURES Location/Qualifiers
 source 1..18
 /organism='unknown'
 /mol_type='unassigned DNA'
 Query Match 0.5%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 5e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 50 GCCTCGCTATGGCTCCCA 67
 DB 18 GGCTCGCTATGGCTCCCA 1
 RESULT 699
 AR110391/c 18 bp DNA linear PAT 14-FEB-2001
 LOCUS Sequence 3 from patent US 6114513.
 DEFINITION AR110391
 ACCESSION AR110391
 VERSION AR110391.1 GI:12826667
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Cook,P.Dan. and Manoharan,M.
 TITLE Thiol-derivatized oligonucleotides
 JOURNAL Patent: US 6114513-A 3 05-SEP-2000;
 FEATURES Location/Qualifiers
 source 1..18
 /organism='unknown'
 /mol_type='unassigned DNA'
 Query Match 0.5%; Score 16.4; DB 1; Length 18;
 Best Local Similarity 94.4%; Pred. No. 5e+02;
 Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 50 GCCTCGCTATGGCTCCCA 67
 DB 18 GGCTCGCTATGGCTCCCA 1
 RESULT 700
 AR120115/c 18 bp DNA linear PAT 16-MAY-2001
 LOCUS Sequence 15 from patent US 6153737.
 DEFINITION AR120115
 ACCESSION AR120115
 VERSION AR120115.1 GI:14102814
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Manoharan,M., Cook,P.Dan. and Bennett,C.Frank.
 TITLE Derivatized oligonucleotides having improved uptake and other properties
 JOURNAL Patent: US 6153737-A 15 28-NOV-2000;
 FEATURES Location/Qualifiers
 source 1..18
 /organism='unknown'
 /mol_type='unassigned DNA'


```
Query Match      0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
    |||||
Db 18 GCCTCGCTACGGCTCCCA 1

RESULT 701
AR178165/c
LOCUS      AR178165      18 bp      DNA      linear      PAT 18-DEC-2001
DEFINITION Sequence 1 from patent US 6316186.
ACCESSION  AR178165
VERSION     AR178165.1 GI:17921058
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS    Ekins,R.Philip.
TITLE      Binding assay using binding agents with tail groups
JOURNAL    Patent: US 6316186-A 1 13-NOV-2001;
FEATURES   Location/Qualifiers
            source
            1..18
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATG 2746
    |||||
Db 18 TGTGTGTGTGTGTGTGTG 1

RESULT 702
AR178166
LOCUS      AR178166      18 bp      DNA      linear      PAT 18-DEC-2001
DEFINITION Sequence 2 from patent US 6316186.
ACCESSION  AR178166
VERSION     AR178166.1 GI:17921059
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS    Ekins,R.Philip.
TITLE      Binding assay using binding agents with tail groups
JOURNAL    Patent: US 6316186-A 2 13-NOV-2001;
FEATURES   Location/Qualifiers
            source
            1..18
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGT 2743
    |||||
Db 1 GTGTGTGTGTGTGTGTGT 18

RESULT 703
CQ758961/c
LOCUS      CQ758961      18 bp      DNA      linear      PAT 01-MAR-2004
DEFINITION Sequence 85 from Patent WO2003104489.
ACCESSION  CQ758961
VERSION     CQ758961.1 GI:44848965
KEYWORDS   .

Query Match      0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2776 GCTGGAGTGCAGTGGTGC 2793
    |||||
Db 18 GCTGGAGTGCAGTGGCGC 1

RESULT 705
I30039/c
LOCUS      I30039        18 bp      DNA      linear      PAT 06-FEB-1997
DEFINITION Sequence 3 from patent US 5578718.
ACCESSION  I30039
VERSION     I30039.1 GI:1820830
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS    Cook,P.D. and Manoharan,M.
TITLE      Thiol-derivatized nucleosides
JOURNAL    Patent: US 5578718-A 3 26-NOV-1996;
FEATURES   Location/Qualifiers
            source
            1..18
              /organism="unknown"
```

```
SOURCE      synthetic construct
ORGANISM     synthetic construct
REFERENCE    1
AUTHORS      Platzner,M., Platzner,C., Gudermann,T., Hebebrand,J., Hinney,A. and
              Reichwald,K.
TITLE        Mchri variant associated with human obesity
JOURNAL      Patent: WO 2003104489-A 85 18-DEC-2003;
              Philipps-Universitaet Marburg (DE)
FEATURES     Location/Qualifiers
              1..18
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="Primer D1r"

Query Match      0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCCACCAGG 2776
    |||||
Db 18 CTCGTTCTGTCCACCAGG 1

RESULT 704
CQ766223/c
LOCUS      CQ766223      18 bp      DNA      linear      PAT 03-MAR-2004
DEFINITION Sequence 184 from Patent WO2004005547.
ACCESSION  CQ766223
VERSION     CQ766223.1 GI:44908483
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM     synthetic construct
REFERENCE    1
AUTHORS      Weinzierl,R.
TITLE        Method
JOURNAL      IMPERIAL COLLEGE INNOVATIONS LIMITED (GB)
FEATURES     Location/Qualifiers
              1..18
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="HS consensus sequence"

Query Match      0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2776 GCTGGAGTGCAGTGGTGC 2793
    |||||
Db 18 GCTGGAGTGCAGTGGCGC 1

RESULT 705
I30039/c
LOCUS      I30039        18 bp      DNA      linear      PAT 06-FEB-1997
DEFINITION Sequence 3 from patent US 5578718.
ACCESSION  I30039
VERSION     I30039.1 GI:1820830
KEYWORDS   .
SOURCE     Unknown.
ORGANISM   Unclassified.
REFERENCE  1 (bases 1 to 18)
AUTHORS    Cook,P.D. and Manoharan,M.
TITLE      Thiol-derivatized nucleosides
JOURNAL    Patent: US 5578718-A 3 26-NOV-1996;
FEATURES   Location/Qualifiers
            source
            1..18
              /organism="unknown"
```

/mol_type="unassigned DNA"

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5e+02; Mismatches 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
| | | | | | | | | | | | | | | | | |
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 706

AR182079
LOCUS AR182079 18 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 28 from patent US 6337188.

AR182079
ACCESSION AR182079
VERSION AR182079.1 GI:20224995

KEYWORDS

SOURCE

ORGANISM

Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Head,S.R., Golet,P., Karn,J. and Boyce-Jacino,M.

TITLE De novo or 'universal' sequencing array

JOURNAL Patent: US 6337188-A 28 08-JAN-2002;

FEATURES Location/Qualifiers

1..18

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.5%; Score 16.4; DB 1; Length 18;

Best Local Similarity 94.4%; Pred. No. 5e+02; Mismatches 0; Gaps 0;

Matches 17; Conservative 0; Indels 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATG 2746

| | | | | | | | | | | | | | | | | |

Db 1 TGTGTGTGTGTGTGTGTG 18

RESULT 707

AR261503
LOCUS AR261503 18 bp DNA linear PAT 29-JAN-2003
DEFINITION Sequence 28 from patent US 6322968.

AR261503
ACCESSION AR261503
VERSION AR261503.1 GI:28072570

KEYWORDS

SOURCE

ORGANISM

Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Head,S.R., Golet,P., Karn,J. and Boyce-Jacino,M.

TITLE De novo or 'universal' sequencing array

JOURNAL Patent: US 6322968-A 28 27-NOV-2001;

FEATURES Location/Qualifiers

1..18

/organism="unknown"

/mol_type="genomic DNA"

Query Match 0.5%; Score 16.4; DB 1; Length 18;

Best Local Similarity 94.4%; Pred. No. 5e+02; Mismatches 0; Gaps 0;

Matches 17; Conservative 0; Indels 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTATG 2746

| | | | | | | | | | | | | | | | | |

Db 1 TGTGTGTGTGTGTGTGTG 18

RESULT 708

AR371568/c
LOCUS AR371568 18 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 15 from patent US 6395492.

AR371568
ACCESSION AR371568
VERSION AR371568.1 GI:34608549

KEYWORDS

SOURCE

ORGANISM

Unknown.

Unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Manoharan,M., Cook,P.D. and Bennett,C.F.

TITLE Derivatized oligonucleotides having improved uptake and other

properties

JOURNAL Patent: US 6395492-A 15 28-MAY-2002;

FEATURES Location/Qualifiers

1..18

/organism="unknown"

/mol_type="genomic DNA"

Query Match 0.5%; Score 16.4; DB 1; Length 18;

Best Local Similarity 94.4%; Pred. No. 5e+02; Mismatches 0; Gaps 0;

Matches 17; Conservative 0; Indels 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

| | | | | | | | | | | | | | | | | |

Db 18 GCCTCGCTACGGCTCCCA 1

RESULT 709

AX116403/c
LOCUS AX116403 18 bp DNA linear PAT 11-MAY-2001
DEFINITION Sequence 1526 from Patent WO0129262.

AX116403
ACCESSION AX116403
VERSION AX116403.1 GI:14033345

KEYWORDS

SOURCE

ORGANISM

synthetic construct

other sequences; artificial sequences.

REFERENCE 1

AUTHORS Picoult-Newburg,L. and Pohl,M.

TITLE Genotyping reagents, kits and methods of use thereof

JOURNAL Patent: WO 0129262-A 1526 26-APR-2001;

Orchid BioSciences, Inc. (US)

FEATURES Location/Qualifiers

1..18

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="Primer"

Query Match 0.5%; Score 16.4; DB 1; Length 18;

Best Local Similarity 94.4%; Pred. No. 5e+02; Mismatches 0; Gaps 0;

Matches 17; Conservative 0; Indels 1; Indels 0; Gaps 0;

QY 2776 GCTGGAGTGCAGTGTGC 2793

| | | | | | | | | | | | | | | | | |

Db 18 GCTGGAGTGCAGTGTGC 1

RESULT 710

AX175253
LOCUS AX175253 18 bp DNA linear PAT 03-JUL-2001
DEFINITION Sequence 17 from Patent WO0144465.

AX175253
ACCESSION AX175253
VERSION AX175253.1 GI:14598621

KEYWORDS

SOURCE

ORGANISM

synthetic construct

other sequences; artificial sequences.

REFERENCE 1

AUTHORS Phillips,N.C. and Filion,M.C.

TITLE Therapeutically useful synthetic oligonucleotides

JOURNAL Patent: WO 0144465-A 17 21-JUN-2001;

Bioniche Life Sciences Inc. (CA)

FEATURES Location/Qualifiers

1..18

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATG 2746
|||||
Db 1 TGTGTGTGTGTGTGTGTG 18

RESULT 711

AX175254 AX175254 18 bp DNA linear PAT 03-JUL-2001

LOCUS Sequence 18 from Patent WO0144465.

DEFINITION AX175254

ACCESSION AX175254

VERSION AX175254.1 GI:14598622

KEYWORDS synthetic construct

SOURCE other sequences; artificial sequences.

ORGANISM 1

REFERENCE 1

AUTHORS Phillips,N.C. and Filion,M.C.

TITLE Therapeutically useful synthetic oligonucleotides

JOURNAL Patent: WO 0144465-A 18 21-JUN-2001;

COMMENT Bioniche Life Sciences Inc. (CA)

FEATURES Location/Qualifiers

source 1..18

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGT 2743
|||||
Db 1 GTGTGTGTGTGTGTGTGT 18

RESULT 712

BD087486 BD087486 18 bp DNA linear PAT 27-AUG-2002

LOCUS De novo or universal sequencing array.

DEFINITION BD087486

ACCESSION BD087486.1 GI:226333096

VERSION JP 2001524319-A/28.

KEYWORDS synthetic construct

SOURCE other sequences; artificial sequences.

ORGANISM 1 (bases 1 to 18)

REFERENCE Head,S.R., Golet,P., Karn,J. and Jacino,M.B.

AUTHORS De novo or universal sequencing array

TITLE Patent: JP 2001524319-A 28 04-DEC-2001;

JOURNAL ORCHID BIOSCIENCES INC

COMMENT OS Artificial Sequence

PN JP 2001524319-A/28

PD 04-DEC-2001

PF 20-NOV-1998 JP 2000522278

PR 21-NOV-1997 US 08/976427

PI STEVEN R HEAD, PHILIP GOLETT, JONATHAN KARN, MICHAEL BOYCE JACINO

PC C12N15/09, C12N15/09, C12M1/00, C12Q1/68, G01N33/50, C12N15/00, PC

C12N15/00

CC Synthetic primer

FT Key Location/Qualifiers

FT source 1..18

/organism='Artificial Sequence'.

FEATURES Location/Qualifiers

source 1..18

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATG 2746
|||||
Db 1 TGTGTGTGTGTGTGTGTG 18

RESULT 713

BD088792/c BD088792 18 bp DNA linear PAT 27-AUG-2002

LOCUS A method of arraying genome clone.

DEFINITION BD088792

ACCESSION BD088792.1 GI:226344402

VERSION JP 2001321190-A/1036.

KEYWORDS synthetic construct

SOURCE other sequences; artificial sequences.

ORGANISM 1 (bases 1 to 18)

REFERENCE Soeda,E.

AUTHORS A method of arraying genome clone

TITLE Patent: JP 2001321190-A 1036 20-NOV-2001;

JOURNAL THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA

COMMENT GENOTECHS

OS Artificial Sequence

PN JP 2001321190-A/1036

PD 20-NOV-2001

PF 12-MAR-2001 JP 2001068285

PI EIICHI SOEDA

PC C12N15/09, C12N15/09, C12M1/00, C12Q1/68, G01N33/53, G01N33/566, PC

C12N15/00

PC C12N15/00

CC Description of Artificial Sequence:Synthetic DNA FH Key

Location/Qualifiers

FT source 1..18

/organism='Artificial Sequence'.

FEATURES Location/Qualifiers

source 1..18

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2862 CTGGGACCATAGGCTCAC 2879
|||||
Db 18 CTGGGACCATAGGCTCAC 1

RESULT 714

AB068357/c AB068357 18 bp DNA linear SYN 21-MAY-2003

LOCUS Synthetic construct DNA, reverse primer for human STS sts-R24401R

DEFINITION at 1p36.

ACCESSION AB068357

VERSION AB068357.1 GI:15129161

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1

AUTHORS Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K.,

Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H.,

Morohashi,A., Ohira,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A.

and Soeda,E.

A BAC-based STS-content map spanning a 35-Mb region of human

chromosome 1p35-p36

Genomics 74 (1), 55-70 (2001)

JOURNAL 21269192

TITLE

JOURNAL

MEDLINE

PUBMED 11374902
REFERENCE 2 (bases 1 to 18)
AUTHORS Horii, A.
TITLE Direct Submission
JOURNAL Submitted (04-AUG-2001) Akira Horii, Tohoku University School of Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai, Miyagi 980-8575, Japan (E-mail: horii@mail.cc.tohoku.ac.jp, Tel: 81-22-717-8042, Fax: 81-22-717-8047)
FEATURES
source 1..18
/mol_type="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
misc_feature 1..18
/notes="reverse primer for human STS sts-R244O11R at 1p36 sts-R244O11R obtained from clones B244O11, B364C12, B301I9, B220M17, B218I5, B181A23, B319H13, Human BAC library RPCI-11"
Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2862 CTGGACCACTAGGCTCAC 2879
Db 18 CTGGACCACTAGGCTCAC 1
RESULT 715
CQ824199/c
LOCUS CQ824199 19 bp DNA linear PAT 21-JUN-2004
DEFINITION Sequence 52 from Patent EP1428893.
ACCESSION CQ824199
VERSION CQ824199.1 GI:49021151
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Sprecher, E. and Bergman, R.
TITLE p-cadherin modulators for modulating hair growth via
JOURNAL Patent: EP 1428893-A 52 16-JUN-2004;
Sprecher, Eli (IL); Bergman, Reuven (IL)
FEATURES
source 1..19
/mol_type="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Synthetic oligonucleotide"
Query Match 0.5%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 4.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2758 TCTCGCTCTGTACCCAG 2775
Db 18 TCTCACTCTGTACCCAG 1
RESULT 716
BD138330/c
LOCUS BD138330 20 bp DNA linear PAT 18-SEP-2002
DEFINITION Antisense modulation of human MDM2 expression.
ACCESSION BD138330
VERSION BD138330.1 GI:23233275
KEYWORDS JP 2002508944-A/256.
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Miraglia, L.J., Nero, P., Graham, M.J., Monia, B.P. and Cowse, L.M.
TITLE Antisense modulation of human MDM2 expression

JOURNAL Patent: JP 2002508944-A 256 26-MAR-2002;
ISIS PHARMACEUTICALS INC
COMMENT OS Unidentified
PN JP 2002508944-A/256
PD 26-MAR-2002
PF 26-MAR-1999 JP 2000538025
PR 26-MAR-1998 US 05/048810
PI LOREN J MIRAGLIA, PAMELA NERO, MARK J GRAHAM, BRETT P MONIA, LEX M
CONSERT
PI C12N15/09, A61K48/00, A61P9/10, A61P17/06, A61P35/00, C07H21/04//
PC C12Q1/68,
PC C12N15/00
CC Strandedness: Single;
CC Topology: Linear;
CC Antisense modulation of human MDM2 expression PH Key
CC Location/Qualifiers
FT source 1..20
FT /organism="Unidentified".
FEATURES
source 1..20
Location/Qualifiers
/organism="Unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2882 CACCACACCTGGCAATT 2899
Db 18 CACCACACCTGGCAATT 1
RESULT 717
E05497
LOCUS E05497 20 bp DNA linear PAT 29-SEP-1997
DEFINITION PCR primer for detecting polymorphism of Oryza sativa and Zea maize.
ACCESSION E05497
VERSION E05497.1 GI:2173685
KEYWORDS JP 1993244995-A/7.
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1 (bases 1 to 20)
AUTHORS Komatsu, Y. and Kikuchi, Y.
TITLE NEW PRIMER
JOURNAL Patent: JP 1993244995-A 7 24-SEP-1993;
KYOWA HAKKO KOGYO CO LTD
COMMENT OS Artificial gene
OC Artificial sequence; Genes.
OS Zea maize
PN JP 1993244995-A/7
PD 24-SEP-1993
PF 24-SEP-1991 JP 1991243122
PI KOMATSU YUKI, KIKUCHI YASUHIRO
PC C12Q1/68, C12N15/11;
CC Strandedness: Single;
CC Topology: Linear;
CC hypothetical; No;
CC anti-sense; No.
FEATURES
source 1..20
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2729 TGTGTGTGTGTGTATG 2746

Db 1 TGTGTGTGTGTGTGTG 18
|||||
19 TTTCAGACAGGCTTC 2

RESULT 718
E32215/c
LOCUS 20 bp DNA linear PAT 18-JUN-2001
DEFINITION Method for isolating satellite sequence.
ACCESSION E32215
VERSION E32215.1 GI:13021826
KEYWORDS JP 2000060559-A/17.
SOURCE Haliotis discus discus
ORGANISM Haliotis discus discus
Eukaryota; Metazoa; Mollusca; Gastropoda; Orthogastropoda;
Vetigastropoda; Haliotoidea; Haliotidae; Haliotis.
REFERENCE 1 (bases 1 to 20)
AUTHORS Hideaki.T. and Masashi.S.
TITLE Method for isolating satellite sequence
JOURNAL Patent: JP 2000060559-A 17 29-FEB-2000;
NATL INST OF AGROBIOLOGICAL RESOURCES
COMMENT OS Haliotis discus discus
PN JP 2000060559-A/17
PD 29-FEB-2000
PR 18-AUG-1998 JP 1998232153
PI HIDEAKI TAKAHASHI,MASASHI SEKINO
PC C12N15/09,C12Q1/68,C12N15/00
CC
FH Key Location/Qualifiers
FT source 1..20
FT Location/Qualifiers
/organism='Haliotis discus discus'.
FEATURES
source
1..20
/organism="Haliotis discus discus"
/mol_type="genomic DNA"
/sub_species="discus"
/db_xref="taxon:91233"

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2725 CGCGTGTGTGTGTGTG 2742
|||||
18 CGCGGTGTGTGTGTG 1

Db 18 CGCGGTGTGTGTGTG 1

RESULT 719
I31483/c
LOCUS 20 bp DNA linear PAT 06-FEB-1997
DEFINITION Sequence 395 from patent US 5582979.
ACCESSION I31483
VERSION I31483.1 GI:1822274
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Weber,J.L.
TITLE Length polymorphisms in (dC-dA).sub.n.(dG-dT).sub.n sequences and method of using the same
JOURNAL Patent: US 5582979-A 395 10-DEC-1996;
FEATURES
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2916 TTTCAGACAGGCTTC 2933
|||||

Db 19 TTTCAGACAGGCTTC 2

RESULT 720
AR242049/c
LOCUS 20 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 337 from patent US 6472154.
ACCESSION AR242049
VERSION AR242049.1 GI:27287861
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Garner,H.R., Wren,J.D., Minna,J.D. and Fondon,J.W. III.
TITLE Polymorphic repeats in human genes
JOURNAL Patent: US 6472154-A 337 29-OCT-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTG 2743
|||||
18 GCGTGTGTGTGTGTGTG 1

Db 18 GCGTGTGTGTGTGTGTG 1

RESULT 721
AR370243/c
LOCUS 20 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 64 from patent US 6300132.
ACCESSION AR370243
VERSION AR370243.1 GI:34606749
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Cowser,L.M.
TITLE Antisense inhibition of telomeric repeat binding factor 2 expression
JOURNAL Patent: US 6300132-A 64 09-OCT-2001;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2775 GGCTGGAGTGCAGTGGTG 2792
|||||
20 GGCTGGAGTGCAGTGGCG 3

Db 20 GGCTGGAGTGCAGTGGCG 3

RESULT 722
AX770003/c
LOCUS 20 bp DNA linear PAT 02-JUL-2003
DEFINITION Sequence 17 from Patent WO03025010.
ACCESSION AX770003
VERSION AX770003.1 GI:32437625
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Hayes,I., Melino,G., de Laurenzi,V., Barcaroli,D., Candi,E., Bernassola,F., Tobler,A. and Novak,U.

TITLE Human delta-N p73 molecules and uses thereof
JOURNAL Patent: WO 03025010-A 17 27-MAR-2003;
Birn Therapeutics Ltd (IE)
FEATURES Location/Qualifiers
source 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="forward primer for cloning 7S"

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2845 CTCAGCTCTCTGAGTAGC 2862
|||||
Db 18 CTCAGCTCTCCGAGTAGC 1

RESULT 723
AB069586/c
LOCUS Synthetic construct DNA, forward primer for human STS sts-R-361F7F
DEFINITION at lp36.
ACCESSION AB069586
VERSION AB069586.1 GI:15130390
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Chen, Y.Z., Hayashi, Y., Wu, J.G., Takaoka, E., Maekawa, K.,
Watanabe, N., Inazawa, J., Hosoda, F., Atai, Y., Mizushima, H.,
Morohashi, A., Ohira, M., Nakagawa, A., Liu, S., Hoshi, M., Horii, A.
and Soeda, E.
A BAC-based STS-content map spanning a 35-Mb region of human
chromosome lp35-p36
Genomics 74 (1), 55-70 (2001)
PUBMED 11374902
REFERENCE 2 (bases 1 to 20)
AUTHORS Horii, A.
TITLE Direct Submission
JOURNAL Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
Miyagi 980-8575, Japan (E-mail: horii@mail.cc.tohoku.ac.jp,
Tel: 81-22-717-8042, Fax: 81-22-717-8047)

FEATURES Location/Qualifiers
source 1..20
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

misc_feature 1..20
/note="forward primer for human STS sts-R-361F7F at lp36
sts-R-361F7F obtained from clones B250P6, B29601, B361F7,
B90E22, Human BAC library RPCI-11"

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.5e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2760 TCCTCTGTGACCCAGGC 2777
|||||
Db 18 TCCTCTGTGACCCAGGC 1

RESULT 724
AR528447
LOCUS Synthetic construct DNA, forward primer for human STS sts-R-361F7F
DEFINITION Sequence 85 from patent US 6723897.
ACCESSION AR528447
VERSION AR528447.1 GI:53916512
KEYWORDS

SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Brown, S.M., Ellich, T.D., Heck, G.R., Kishore, G.M., Logusch, E.W.,
Logusch, S.J., Piller, K.J., Rao, S., Ream, J.E. and Baerson, S.R.
TITLE Methods for controlling gibberellin levels
JOURNAL Patent: US 6723897-A 85 20-APR-2004;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.5%; Score 16.2; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 5e+02;
Matches 16; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTTTCCTTTTTC 2919
|||||
Db 3 TTTTTCCTTTTTC 19

RESULT 725
AR071801/c
LOCUS Sequence 30 from patent US 5912147.
DEFINITION AR071801 linear
ACCESSION AR071801
VERSION AR071801.1 GI:7222689
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoller, D., Basik, M. and Anderson, G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 30 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGT 2743
|||||
Db 17 GTGTGTGTGTGTGT 2

RESULT 726
AR071802/c
LOCUS Sequence 31 from patent US 5912147.
DEFINITION AR071802 linear
ACCESSION AR071802
VERSION AR071802.1 GI:7222690
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoller, D., Basik, M. and Anderson, G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 31 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGT 2743
Db 17 GTGTGTGTGTGTGTGT 2

RESULT 727
AR071803/c 18 bp DNA linear PAT 18-FEB-2000
LOCUS Sequence 32 from patent US 5912147.
DEFINITION AR071803
ACCESSION AR071803
VERSION AR071803.1 GI:7222691
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability;
JOURNAL Patent: US 5912147-A 32 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.5e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGT 2743
Db 17 GTGTGTGTGTGTGTGT 2

RESULT 728
AR541350 19 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 15 from patent US 6737520.
DEFINITION AR541350
ACCESSION AR541350
VERSION AR541350.1 GI:53932997
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 15 18-MAY-2004;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 729
AR541351 19 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 16 from patent US 6737520.
DEFINITION AR541351
ACCESSION AR541351
VERSION AR541351.1 GI:53932998
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)

AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 16 18-MAY-2004;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 730
AR541352 19 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 17 from patent US 6737520.
DEFINITION AR541352
ACCESSION AR541352
VERSION AR541352.1 GI:53932999
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 17 18-MAY-2004;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 731
AR541353 19 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 18 from patent US 6737520.
DEFINITION AR541353
ACCESSION AR541353
VERSION AR541353.1 GI:53933000
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 18 18-MAY-2004;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 731
AR541353 19 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 18 from patent US 6737520.
DEFINITION AR541353
ACCESSION AR541353
VERSION AR541353.1 GI:53933000
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Manoharan,M. and Mohan,V.
TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry
JOURNAL Patent: US 6737520-A 18 18-MAY-2004;
FEATURES Location/Qualifiers
source 1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 5.2e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16

Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 732

AR541361

LOCUS AR541361 19 bp DNA linear PAT 08-OCT-2004

DEFINITION Sequence 26 from patent US 6737520.

ACCESSION AR541361

VERSION AR541361.1 GI:53933008

KEYWORDS

SOURCE Unknown.

ORGANISM

REFERENCE 1 (bases 1 to 19)

AUTHORS Manoharan,M. and Mohan,V.

TITLE Oligonucleotides having A-DNA form and B-DNA form conformational geometry

JOURNAL Patent: US 6737520-A 26 18-MAY-2004;

FEATURES

source

1. .19

/organism="unknown"

/mol_type="genomic DNA"

Query Match 0.5%; Score 16; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 5.2e+02;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918

Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 733

AR370242/C

LOCUS AR370242 20 bp DNA linear PAT 12-SEP-2003

DEFINITION Sequence 63 from patent US 6300132.

ACCESSION AR370242

VERSION AR370242.1 GI:34606748

KEYWORDS

SOURCE Unknown.

ORGANISM

REFERENCE 1 (bases 1 to 20)

AUTHORS Monia,B.P. and Cowsett,L.M.

TITLE Antisense inhibition of telomeric repeat binding factor 2 expression

JOURNAL Patent: US 6300132-A 63 09-OCT-2001;

FEATURES

source

1. .20

/organism="unknown"

/mol_type="genomic DNA"

Query Match 0.5%; Score 16; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5e+02;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTCTCACCC 2773

Db 16 TCTCGCTCTCTCACCC 1

RESULT 734

AR562156

LOCUS AR562156 20 bp DNA linear PAT 08-OCT-2004

DEFINITION Sequence 32 from patent US 6759215.

ACCESSION AR562156

VERSION AR562156.1 GI:53976019

KEYWORDS

SOURCE Unknown.

ORGANISM

REFERENCE 1 (bases 1 to 20)

AUTHORS Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.

TITLE Method of preparing human stem cell factor polypeptide

JOURNAL Patent: US 6759215-A 32 06-JUL-2004;

FEATURES

source

1. .20

/organism="unknown"

/mol_type="genomic DNA"

Query Match 0.5%; Score 16; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 5e+02;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918

Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 735

AR067275/C

LOCUS AR067275 19 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 623 from patent US 5851760.

ACCESSION AR067275

VERSION AR067275.1 GI:5998497

KEYWORDS

SOURCE Unknown.

ORGANISM

REFERENCE 1 (bases 1 to 19)

AUTHORS Evans,G.A. and Smith,M.W.

TITLE Method for generation of sequence sampled maps of complex genomes

JOURNAL Patent: US 5851760-A 623 22-DEC-1998;

FEATURES

source

1. .19

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.5%; Score 15.8; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 5.4e+02;

Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2765 CTGTCACCCAGGCTGGAGT 2783

Db 19 CTGTCACCCAGGCTGAAGT 1

RESULT 736

AR071772/C

LOCUS AR071772 18 bp DNA linear PAT 18-FEB-2000

DEFINITION Sequence 1 from patent US 5912147.

ACCESSION AR071772

VERSION AR071772.1 GI:7222660

KEYWORDS

SOURCE Unknown.

ORGANISM

REFERENCE 1 (bases 1 to 18)

AUTHORS Stoler,D., Basik,M. and Anderson,G.

TITLE Rapid means of quantitating genomic instability

JOURNAL Patent: US 5912147-A 1 15-JUN-1999;

FEATURES

source

1. .18

/organism="unknown"

/mol_type="unassigned DNA"

Query Match 0.5%; Score 15.4; DB 1; Length 18;

Best Local Similarity 94.1%; Pred. No. 6.3e+02;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2727 CGTGTGTGTGTGTGTGT 2743

Db 18 CTGTGTGTGTGTGTGTGT 2

RESULT 737

AR071773/c
LOCUS AR071773 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 2 from patent US 5912147.
ACCESSION AR071773
VERSION AR071773.1 GI:7222661
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 2 15-JUN-1999;
FEATURES
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 0.5%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 6.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2727 CGTGTGTGTGTGTGTGT 2743
| | | | | | | | | | | | | | | | | | | | | |
Db 18 CCTGTGTGTGTGTGTGT 2

RESULT 738
AX082553/c
LOCUS AX082553 18 bp DNA linear PAT 28-FEB-2001
DEFINITION Sequence 4 from Patent WO0111047.
ACCESSION AX082553
VERSION AX082553.1 GI:13184663
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Bowman,B.M. and Wang,K.
TITLE Dna sequences isolated from human colonic epithelial cells
JOURNAL Patent: WO 0111047-A 4 15-FEB-2001;
Bayer Corporation (US)
FEATURES
source 1..18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.5%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 6.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2772 CCAGGCTGGAGTGCAGT 2788
| | | | | | | | | | | | | | | | | | | | | |
Db 18 CCAGGCTGGAGTGCAGT 2

RESULT 739
E10167
LOCUS E10167 19 bp DNA linear PAT 29-SEP-1997
DEFINITION Primer.
ACCESSION E10167
VERSION E10167.1 GI:22026996
KEYWORDS JP 1995289262-A/8.
SOURCE unidentified
ORGANISM unidentified
REFERENCE 1 (bases 1 to 19)
AUTHORS Hashimoto,T. and Mizuno,T.
TITLE METHOD FOR TRANSDUCTION OF SITE-SPECIFIC MUTATION
JOURNAL Patent: JP 1995289262-A 8 07-NOV-1995;
TAKARA SHUZO CO LTD

COMMENT OS None
OC Artificial sequences.
PN JP 1995289262-A/8
PD 07-NOV-1995
PF 28-FEB-1995 JP 1995063484
PR 02-MAR-1994 JP 94P 54795
PT HASHIMOTO TAMOTSU, MIZUNO TOSHIKI
PC C12N15/09/C12N1/21, (C12N1/21,C12R1:19);
CC strandedness: Single;
CC topology: Linear;
CC hypothetical: No;
FH Key Location/Qualifiers
FT source 1..19
FT /organism='Artificial sequences'.
FEATURES
source Location/Qualifiers
1..19
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 0.5%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 5.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2345 GGCACACCTGCCTTCC 2361
| | | | | | | | | | | | | | | | | | | | | |
Db 2 GGCACACATGCCTTCC 18

RESULT 740
AR370177
LOCUS AR370177 19 bp DNA linear PAT 12-SEP-2003
DEFINITION Sequence 13 from patent US 6300131.
ACCESSION AR370177
VERSION AR370177.1 GI:34606672
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Greider,C.W. and Le,S.
TITLE Telomerase-associated proteins
JOURNAL Patent: US 6300131-A 13 09-OCT-2001;
FEATURES
source 1..19
/organism="unknown"
/mol_type="genomic DNA"
Query Match 0.5%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 5.9e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2921 GAGACGGGGTCTCGCAA 2937
| | | | | | | | | | | | | | | | | | | | | |
Db 1 GAGACGGGGTCTCGCTA 17

RESULT 741
AR071774/c
LOCUS AR071774 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 3 from patent US 5912147.
ACCESSION AR071774
VERSION AR071774.1 GI:7222662
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 3 15-JUN-1999;
FEATURES
source Location/Qualifiers

```
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
|||||
Db 16 TGTGTGTGTGTGTGT 2

RESULT 742
AR071775/c
LOCUS AR071775 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 4 from patent US 5912147.
ACCESSION AR071775
VERSION AR071775.1 GI:7222663
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 4 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
|||||
Db 16 TGTGTGTGTGTGTGT 2

RESULT 743
AR071776/c
LOCUS AR071776 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 5 from patent US 5912147.
ACCESSION AR071776
VERSION AR071776.1 GI:7222664
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 5 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
|||||
Db 16 TGTGTGTGTGTGTGT 2

RESULT 744
AR071777/c
LOCUS AR071777 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 6 from patent US 5912147.
```

```
ACCESSION AR071777
VERSION AR071777.1 GI:7222665
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 6 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
|||||
Db 16 TGTGTGTGTGTGTGT 2

RESULT 745
AR071778/c
LOCUS AR071778 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 7 from patent US 5912147.
ACCESSION AR071778
VERSION AR071778.1 GI:7222666
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 7 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
|||||
Db 16 TGTGTGTGTGTGTGT 2

RESULT 746
AR071779/c
LOCUS AR071779 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 8 from patent US 5912147.
ACCESSION AR071779
VERSION AR071779.1 GI:7222667
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 8 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
|||||
Db 16 TGTGTGTGTGTGTGT 2
```

```
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGTGT 2

RESULT 747
AR071799/c
LOCUS AR071799 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 28 from patent US 5912147.
ACCESSION AR071799
VERSION AR071799.1 GI:7222687
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 28 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGTGT 2

RESULT 750
AR071805/c
LOCUS AR071805 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 34 from patent US 5912147.
ACCESSION AR071805
VERSION AR071805.1 GI:7222693
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 34 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGTGT 2

RESULT 751
AR071806/c
LOCUS AR071806 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 35 from patent US 5912147.
ACCESSION AR071806
VERSION AR071806.1 GI:7222694
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 35 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGTGT 2

RESULT 748
AR071800/c
LOCUS AR071800 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 29 from patent US 5912147.
ACCESSION AR071800
VERSION AR071800.1 GI:7222688
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 29 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGTGT 2

RESULT 749
AR071804/c
LOCUS AR071804 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 33 from patent US 5912147.
ACCESSION AR071804
VERSION AR071804.1 GI:7222692
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 33 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGTGT 2

RESULT 749
AR071804/c
LOCUS AR071804 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 33 from patent US 5912147.
ACCESSION AR071804
VERSION AR071804.1 GI:7222692
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 33 15-JUN-1999;
FEATURES Location/Qualifiers
source 1..18
/mol_type="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGTGT 2
```

```
RESULT 752
AR071807/c
LOCUS AR071807 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 36 from patent US 5912147.
ACCESSION AR071807
VERSION AR071807.1 GI:7222695
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 36 15-JUN-1999;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGTGT 2

RESULT 753
AR071808/c
LOCUS AR071808 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 37 from patent US 5912147.
ACCESSION AR071808
VERSION AR071808.1 GI:7222696
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 37 15-JUN-1999;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGTGT 2

RESULT 754
AR071809/c
LOCUS AR071809 18 bp DNA linear PAT 18-FEB-2000
DEFINITION Sequence 38 from patent US 5912147.
ACCESSION AR071809
VERSION AR071809.1 GI:7222697
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 18)
AUTHORS Stoler,D., Basik,M. and Anderson,G.
TITLE Rapid means of quantitating genomic instability
JOURNAL Patent: US 5912147-A 38 15-JUN-1999;
FEATURES
source
1..18
/organism="unknown"
/mol_type="unassigned DNA"
```

```
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGTGT 2

RESULT 755
AX115187
LOCUS AX115187 18 bp DNA linear PAT 11-MAY-2001
DEFINITION Sequence 310 from Patent WO0129262.
ACCESSION AX115187
VERSION AX115187.1 GI:14032129
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Picoult-Newburg,L. and Pohl,M.
TITLE Genotyping reagents, kits and methods of use thereof
JOURNAL Patent: WO 0129262-A 310 26-APR-2001;
Orchid BioSciences, Inc. (US)
FEATURES
source
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTG 2742
Db 1 GTGTGTGTGTGTGTG 15

RESULT 756
AX695098/c
LOCUS AX695098 18 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 725 from Patent WO03008583.
ACCESSION AX695098
VERSION AX695098.1 GI:29418216
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Morris,D.W. and Engelhard,E.K.
TITLE Novel compositions and methods for cancer
JOURNAL Patent: WO 03008583-A 725 30-JAN-2003;
Sagres Discovery (US)
FEATURES
source
1..18
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 6.8e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2735 TGTGTGTGTGTGTGT 2749
Db 16 TGTGTGTGTGTGTGT 2
```

```

RESULT 757
A09799/c
LOCUS       A09799          18 bp      DNA      linear      PAT 13-AUG-1993
DEFINITION   Nucleotide sequence 7 from patent number EP0368819.
ACCESSION   A09799
VERSION     A09799.1  GI:412019
KEYWORDS    .
SOURCE      unidentified
            unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS    Holmgren,J. and Sanches Castillo,J.
TITLE      Expression of the binding subunit of cholera toxin with the aid of
            foreign promoters and/or leader sequences
JOURNAL    Patent: EP 0368819-A 7 16-MAY-1990;
            Holmgren, Jan; Sanches Castillo, Joaquin
FEATURES    Location/Qualifiers
             source
               1..18
               /organism="unidentified"
               /mol_type="unassigned DNA"
               /db_xref="taxon:32644"

Query Match      0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1217 CCCGGGAGCTTCGTGTC 1234
      |||||
Db 18 CCCGGGAGCTTCGTGTC 1

RESULT 758
A66978/c
LOCUS       A66978          18 bp      DNA      linear      PAT 29-MAR-1999
DEFINITION   Sequence 145 from Patent WO9740193.
ACCESSION   A66978
VERSION     A66978.1  GI:4538349
KEYWORDS    .
SOURCE      unidentified
            unclassified.
REFERENCE   1 (bases 1 to 18)
AUTHORS    Stuyver,L., Rossau,R. and Maertens,G.
TITLE      METHOD FOR TYPING AND DETECTING HBV
JOURNAL    Patent: WO 9740193-A 145 30-OCT-1997;
            INNOGENETICS NV (BE)
FEATURES    Location/Qualifiers
             source
               1..18
               /organism="unidentified"
               /mol_type="unassigned DNA"
               /db_xref="taxon:32644"

Query Match      0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 216 CCAGCCCAAGTTGTGGG 233
      |||||
Db 18 CCAGCCCAAGATGATGGG 1

RESULT 759
AR154096/c
LOCUS       AR154096        18 bp      DNA      linear      PAT 08-AUG-2001
DEFINITION   Sequence 146 from patent US 6238863.
ACCESSION   AR154096
VERSION     AR154096.1  GI:15122149
KEYWORDS    .
SOURCE      Unknown.
            Unclassified.
REFERENCE   1 (bases 1 to 18)

```

```

AUTHORS      Schumm,J.W. and Bacher,J.W.
TITLE        Materials and methods for indentifying and analyzing intermediate
            tandem repeat DNA markers
JOURNAL      Patent: US 6238863-A 146 29-MAY-2001;
FEATURES     Location/Qualifiers
             source
               1..18
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2764 TCTGTCAACCCAGCTGGA 2781
      |||||
Db 18 TTTGTCAACCCAGACTGGA 1

RESULT 760
BD171788/c
LOCUS       BD171788        18 bp      DNA      linear      PAT 18-FEB-2003
DEFINITION   Method for detecting microorganisms, and primer set for detecting
            microorganisms.
ACCESSION   BD171788
VERSION     BD171788.1  GI:28413082
KEYWORDS    JP 200223766-A/46.
SOURCE      synthetic construct
            other sequences; artificial sequences.
REFERENCE   1 (bases 1 to 18)
AUTHORS    Ezaki,T.
TITLE      Method for detecting microorganisms, and primer set for detecting
            microorganisms
JOURNAL    Patent: JP 200223766-A 46 13-AUG-2002;
            RAKAN CO LTD,TAKAYUKI EZAKI,KATSUMI ENDO
COMMENT     OS Artificial Sequence
            PN JP 200223766-A/46
            PD 13-AUG-2002
            PF 31-JAN-2001 JP 2001023742
            PI TAKAYUKI EZAKI
            PC
            C12N15/09,C12Q1/68//(C12N15/09,C12R1:01),(C12N15/09,C12R1:385), PC
            (C12N15/09,C12R1:19),(C12N15/09,C12R1:325),(C12N15/09 PC
            ,C12R1:645),C12N15/00,
            PC
            (C12N15/00,C12R1:01),(C12N15/00,C12R1:385),(C12N15/00,C12R1:19) PC
            ,
            PC (C12N15/00,C12R1:325),(C12N15/00,C12R1:645)
            CC Description of Artificial Sequence:Synthesized Primer Sequence

CC          for
CC          Universal Bacteria
FH          Key          Location/Qualifiers
FT          source      1..18
FT          /organism='Artificial Sequence'.
FEATURES     Location/Qualifiers
             source
               1..18
               /organism="synthetic construct"
               /mol_type="genomic DNA"
               /db_xref="taxon:32630"

Query Match      0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 531 ACGGGAGCCAGCTGTGGG 548
      |||||
Db 18 ACGGGAGCGCAGCTGGG 1

RESULT 761
CQ803382/c
LOCUS       CQ803382        18 bp      DNA      linear      PAT 10-MAY-2004

```

DEFINITION Sequence 11 from Patent WO2004035083.

ACCESSION CQ803382

VERSION CQ803382.1 GI:47110243

KEYWORDS synthetic construct

SOURCE synthetic construct

ORGANISM other sequences; artificial sequences.

REFERENCE 1

AUTHORS Kelly,R.W.

TITLE Compositions for the treatment of autoimmune disorders

JOURNAL Patent: WO 2004035083-A 11 29-APR-2004;

Medical Research Council (GB)

FEATURES

source

1..18

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="ECL2 probe"

Query Match 0.5%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 7.1e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 95 TCCTGTCCTCTCGCGGG 112

Db 18 TCCTGTCCTCTCGCGGG 1

RESULT 762

AR294035

LOCUS

Sequence 5770 from patent US 6537751.

ACCESSION AR294035

VERSION AR294035.1 GI:31681319

KEYWORDS

Unknown.

ORGANISM

Unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.

TITLE Biallelic markers for use in constructing a high density

JOURNAL disequilibrium map of the human genome

Patent: US 6537751-A 5770 25-MAR-2003;

FEATURES

source

1..18

/organism="unknown"

/mol_type="genomic DNA"

Query Match 0.5%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 7.1e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1618 ACCCCATGAACCGAAC 1635

Db 1 ACCCCATGAACCGAAC 18

RESULT 763

AR488480/c

LOCUS

Sequence 145 from patent US 6709812.

ACCESSION AR488480

VERSION AR488480.1 GI:47254532

KEYWORDS

Unknown.

ORGANISM

Unclassified.

REFERENCE 1 (bases 1 to 18)

AUTHORS Stuyver,L., Rossau,R. and Maertens,G.

TITLE Method for typing and detecting HBV

JOURNAL Patent: US 6709812-A 145 23-MAR-2004;

FEATURES

source

1..18

/organism="unknown"

/mol_type="genomic DNA"

Query Match 0.5%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 7.1e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 216 CCAGCCCAAGTGTGGG 233

Db 18 CCAGCCCAAGTGTGGG 1

RESULT 764

AR565320/c

LOCUS

Sequence 146 from patent US 6767703.

ACCESSION AR565320

VERSION AR565320.1 GI:53981158

KEYWORDS

Unknown.

ORGANISM

Unknown.

REFERENCE 1 (bases 1 to 18)

AUTHORS Schumm,J.W. and Bacher,J.W.

TITLE Materials and methods for identifying and analyzing intermediate

JOURNAL tandem repeat DNA markers

Patent: US 6767703-A 146 27-JUL-2004;

FEATURES

source

1..18

/organism="unknown"

/mol_type="genomic DNA"

Query Match 0.5%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 7.1e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2764 TCTGTCAACCCAGCTGGA 2781

Db 18 TCTGTCAACCCAGCTGGA 1

RESULT 765

AX811382/c

LOCUS

Sequence 71 from Patent WO03062469.

ACCESSION AX811382

VERSION AX811382.1 GI:38635604

KEYWORDS

synthetic construct

synthetic construct

other sequences; artificial sequences.

ORGANISM

Unclassified.

REFERENCE 1

AUTHORS Stefansson,S.E.

TITLE Gene matn3 or matrilin-3 linked to osteoarthritis treatment

JOURNAL Patent: WO 03062469-A 71 31-JUL-2003;

FEATURES

source

1..18

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="primer that hybridizes to the human MATN3 gene"

Query Match 0.5%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 7.1e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2833 TGATCTCCACCTCAGC 2850

Db 18 TGATCTCCACCTCAGC 1

RESULT 766

```

BD089873/c
LOCUS       BD089873               18 bp    DNA    linear    PAT 27-AUG-2002
DEFINITION  A method of arraying genome clone.
ACCESSION   BD089873
VERSION     BD089873.1 GI:22635483
KEYWORDS    JP 2001321190-A/2117.
SOURCE      synthetic construct
ORGANISM    other sequences; artificial sequences.
REFERENCE   1 (bases 1 to 18)
AUTHORS     Soeda,E.
TITLE       A method of arraying genome clone
JOURNAL     Patent: JP 2001321190-A 2117 20-NOV-2001;
            THE INSTITUTE OF PHYSICAL AND CHEMICAL RESEARCH, YUGENKAISHA
COMMENT     GENOTECHS
            OS Artificial Sequence
            PN JP 2001321190-A/2117
            PD 20-NOV-2001
            PF 12-MAR-2001 JP 2001068285
            PT EIICHI SOEDA
            PC C12N15/09,C12N15/09,C12M1/00,C12Q1/68,G01N33/53,G01N33/566, PC
              C12N15/00,
            PC C12N15/00
            CC Description of Artificial Sequence:Synthetic DNA FH Key
            CC Location/Qualifiers
            FT source 1..18
            FT /organism='Artificial Sequence'.

FEATURES             source
LOCUS             1..18
DEFINITION        /organism="synthetic construct"
ACCESSION         /mol_type="genomic DNA"
KEYWORDS         /db_xref="taxon:32630"

Query Match      0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred.No.7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2838 CTCACCTCAGCCTCTCT 2855
Db 18 CTCCTACCTCAGCCTTCT 1

RESULT 767
LOCUS       BD130202/c            18 bp    DNA    linear    PAT 18-SEP-2002
DEFINITION  Material and method for specifying and analyzing medium-size tandem
            repeat DNA marker.
ACCESSION   BD130202
VERSION     BD130202.1 GI:23225147
KEYWORDS    JP 2002502606-A/146.
SOURCE      unidentified
ORGANISM    unclassified.
REFERENCE     1 (bases 1 to 18)
AUTHORS      Schumm,J.W. and Bacher,J.W.
TITLE       Material and method for specifying and analyzing medium-size tandem
            repeat DNA marker
JOURNAL     Patent: JP 2002502606-A 146 29-JAN-2002;
            PROMEGA CORP
COMMENT     OS Unidentified
            PN JP 2002502606-A/146
            PD 29-JAN-2002
            PF 04-FEB-1999 JP 2000530608
            PR 04-FEB-1998 US 09/018584
            PT JAMES W SCHUMM,JEFFREY W BACHER
            PC C12N15/09,C12Q1/68,C12N15/00
            CC Strandedness: Single;
            CC Topology: Linear;
            CC Material and method for specifying and analyzing medium-size
            CC tandem repeat
            CC DNA marker
            FH Key Location/Qualifiers
            FT source 1..18

```

```

FT          Location/Qualifiers
FEATURES             source
LOCUS             1..18
DEFINITION        /organism='Unidentified'.
ACCESSION         /mol_type="genomic DNA"
KEYWORDS         /db_xref="taxon:32644"

Query Match      0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred.No.7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2764 TCTGTCACCCAGGCTGGA 2781
Db 18 TTGTGACCCAGACTGGA 1

RESULT 768
LOCUS       AB068214/c            18 bp    DNA    linear    SYN 21-MAY-2003
DEFINITION  Synthetic construct DNA, forward primer for human STS sts-D1S2731
            at 1p36.
ACCESSION   AB068214
VERSION     AB068214.1 GI:15129018
KEYWORDS    .
SOURCE      synthetic construct
ORGANISM    synthetic construct
            other sequences; artificial sequences.
REFERENCE     1
AUTHORS      Chen,Y.Z., Hayashi,Y., Wu,J.G., Takaoka,E., Maekawa,K.,
            Watanabe,N., Inazawa,J., Hosoda,F., Arai,Y., Mizushima,H.,
            Morohashi,A., Ohira,M., Nakagawara,A., Liu,S., Hoshi,M., Horii,A.
            and Soeda,E.
TITLE       A BAC-based STS-content map spanning a 35-Mb region of human
            chromosome 1p35-p36
JOURNAL     Genomics 74 (1), 55-70 (2001)
MEDLINE     21269192
PUBMED      11374902
REFERENCE     2 (bases 1 to 18)
AUTHORS      Horii,A.
TITLE       Direct Submission
JOURNAL     Submitted (04-AUG-2001) Akira Horii, Tohoku University School of
            Medicine, Molecular Pathology; 2-1 Seiryomachi, Aoba-ku, Sendai,
            Miyagi 980-8575, Japan (E-mail:horii@mail.cc.tohoku.ac.jp,
            Tel:81-22-717-8042, Fax:81-22-717-8047)

FEATURES             source
LOCUS             1..18
DEFINITION        /organism="synthetic construct"
ACCESSION         /mol_type="genomic DNA"
KEYWORDS         /db_xref="taxon:32630"

misc_feature      1..18
                /note="forward primer for human STS sts-D1S2731 at 1p36
                sts-D1S2731 obtained from clones B352O13, B68K18, B11M7,
                B26E12, Human BAC library RPC1-11"

Query Match      0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred.No.7.1e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2838 CTCACCTCAGCCTCTCT 2855
Db 18 CTCCTACCTCAGCCTTCT 1

RESULT 769
LOCUS       BD266406            18 bp    DNA    linear    PAT 17-JUL-2003
DEFINITION  Universal arrays.
ACCESSION   BD266406
VERSION     BD266406.1 GI:33076174
KEYWORDS    JP 2002539849-A/406.
SOURCE      synthetic construct
ORGANISM    synthetic construct
            other sequences; artificial sequences.

```

REFERENCE 1 (bases 1 to 18)
 AUTHORS Fan,J.B., Hirschhorn,J.N., Huang,X., Kaplan,P., Lander,E.S., Lockhart,D.J., Ryder,T. and Sklar,P.
 TITLE Universal arrays
 JOURNAL Patent: JP 2002539849-A 406 26-NOV-2002;
 COMMENT WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH, AFFYMETRIX INC
 OS Artificial Sequence
 PN JP 2002539849-A/406
 PD 26-NOV-2002
 PF 27-MAR-2000 JP 2000608794
 PR 26-MAR-1999 US 60/126473, 23-JUN-1999 US 60/140359 PI
 JIAN BING FAN, JOEL N HIRSCHHORN, XIAOHUA HUANG, PAUL KAPLAN, ERIC PI S LANDER,
 PI DAVID J LOCKHART, THOMAS RYDER, PAMELA SKLAR
 PC C12Q1/68, C12M1/00, C12N15/09, C12N15/09, C12N15/09, G01N33/53, PC G01N33/566,
 PC G01N37/00, C12N15/00, C12N15/00, C12N15/00
 CC Primer
 FH Key
 FT source
 FT Location/Qualifiers
 FT 1..18 /organism="Artificial Sequence".
 source Location/Qualifiers
 1..18 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2254 CACATTCAAGGTGACC 2269
 |||||
 Db 3 CACATTCAAGGTGACC 18

RESULT 770
 AR076318
 LOCUS 18 bp DNA linear PAT 30-AUG-2000
 DEFINITION Sequence 32 from patent US 5958771.
 ACCESSION AR076318
 VERSION AR076318.1 GI:10003064
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Bennett,C.Frank., Ackermann,E.J. and Cowsert,L.M.
 TITLE Antisense modulation of cellular inhibitor of Apoptosis-2
 JOURNAL expression
 COMMENT Patent: US 5958771-A 32 28-SEP-1999;
 FEATURES
 source Location/Qualifiers
 1..18 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1499 TTGTCATCATCACTGT 1514
 |||||
 Db 2 TTGACATCATCACTGT 17

RESULT 771
 AR078881
 LOCUS 18 bp DNA linear PAT 31-AUG-2000
 DEFINITION Sequence 25 from patent US 5965370.
 ACCESSION AR078881
 VERSION AR078881.1 GI:10005627
 KEYWORDS

SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Cowsert,L.M.
 TITLE Antisense modulation of RhoG expression
 JOURNAL Patent: US 5965370-A 25 12-OCT-1999;
 FEATURES
 source Location/Qualifiers
 1..18 /organism="unknown"
 /mol_type="unassigned DNA"

Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 GGCAGTGTGGCCACAC 1717
 |||||
 Db 3 GGCAGTGTGGCCACAC 18

RESULT 772
 BD234550
 LOCUS 18 bp DNA linear PAT 17-JUL-2003
 DEFINITION Antisense modulation of expression of cellular inhibitor of apoptosis-2.
 ACCESSION BD234550
 VERSION BD234550.1 GI:33044320
 KEYWORDS JP 2002531102-A/32.
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Bennett,F.C., Ackermann,E.J. and Cowsert,L.M.
 TITLE Antisense modulation of expression of cellular inhibitor of Apoptosis-2
 JOURNAL ISIS PHARMACEUTICALS INC
 COMMENT Patent: JP 2002531102-A 32 24-SEP-2002;
 PN JP 2002531102-A/32
 PD 24-SEP-2002
 PF 23-SEP-1999 JP 2000585449
 PR 03-DEC-1998 US 09/205144
 PI FRANK C BENNETT, ELIZABETH J ACKERMANN, LEX M COWSERT PC C12N15/09, A61K31/7115, A61K31/712, A61K31/7125, A61K31/713, A61K48/00, A61P35/00, A61P37/00, C12N15/00
 CC Synthetic
 FH Key
 FT source
 FT Location/Qualifiers
 FT 1..18 /organism='Artificial Sequence'.
 source Location/Qualifiers
 1..18 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1499 TTGTCATCATCACTGT 1514
 |||||
 Db 2 TTGACATCATCACTGT 17

RESULT 773
 BD250628
 LOCUS 18 bp DNA linear PAT 17-JUL-2003
 DEFINITION Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation.
 ACCESSION BD250628
 VERSION BD250628.1 GI:33060398
 KEYWORDS

KEYWORDS JP 2002511276-A/182.
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Cowsert,L.M., Baker,B.F., Mcneil,J., Freier,S.M., Sasnor,H.M., Brooks,D.G., Ohasi,C., Wyatt,J.R., Borchers,A.H. and Vikkars,T.A.
 TITLE Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
 JOURNAL Patent: JP 2002511276-A 182 16-APR-2002;
 COMMENT ISIS PHARMACEUTICALS INC
 PN JP 2002511276-A/182
 PD 16-APR-2002
 PF 16-APR-1999 JP 2000543647
 PR 13-APR-1998 US 60/081483,28-APR-1998 US 09/067638 PI
 LEX M COWSERT,BRENDA F BAKER,JOHN MCNEIL,SUSAN M FREIER,HENRI PI
 M SASNOR,
 PI DOUGLAS G BROOKS,CARA OHASI,JACQUELINE R WYATT,ALEXANDER H PI
 BORCHERS,
 PI TIMOTHY A VIKKARS
 PC C12N15/09,C07B61/00,C07B61/00,C12Q1/68,G06F17/30,G06F17/50, PC
 C12N15/00
 CC Antisense Oligonucleotide
 FH Key Location/Qualifiers
 FT source 1..18
 FT /organism='Artificial Sequence'.
 FEATURES
 source 1..18
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"
 Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1499 TTGTCATCATCACTGT 1514
 Db 2 TTGACATCATCACTGT 17
 RESULT 774
 LOCUS CQ758945 18 bp DNA linear PAT 01-MAR-2004
 DEFINITION Sequence 69 from Patent WO2003104489.
 ACCESSION CQ758945
 VERSION CQ758945.1 GI:4848949
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM other sequences; artificial sequences.
 REFERENCE 1
 AUTHORS Platzer,M., Platzer,C., Gudermann,T., Hebebrand,J., Hinney,A. and Reichwald,K.
 TITLE Mchrl variant associated with human obesity
 JOURNAL Patent: WO 2003104489-A 69 18-DEC-2003;
 Philippines-Universitaet Marburg (DE)
 FEATURES
 source 1..18
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /notes="Primer B5f2"
 Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2758 TCTCGCTCTGTACCC 2773
 Db 3 TCTCCCTCTGTACCC 18

RESULT 775
 LOCUS I39667 18 bp DNA linear PAT 13-MAY-1997
 DEFINITION Sequence 705 from patent US 5616488.
 ACCESSION I39667
 VERSION I39667.1 GI:2084147
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Sullivan,S., Draper,K.G., McSwiggen,J. and Stinchcomb,D.T.
 TITLE IL-5 targeted ribozymes
 JOURNAL Patent: US 5616488-A 705 01-APR-1997;
 FEATURES
 Location/Qualifiers
 1..18
 /organism="unknown"
 /mol_type="unassigned DNA"
 Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 2117 GGCAGTGGTGTCTACT 2132
 Db 2 GGCAGTGGTGTCTACT 17
 RESULT 776
 LOCUS AR215620 18 bp DNA linear PAT 25-SEP-2002
 DEFINITION Sequence 168 from patent US 6410323.
 ACCESSION AR215620
 VERSION AR215620.1 GI:23313876
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Roberts,M.L. and Cowsert,L.M.
 TITLE Antisense modulation of human Rho family gene expression
 JOURNAL Patent: US 6410323-A 168 25-JUN-2002;
 FEATURES
 Location/Qualifiers
 1..18
 /organism="unknown"
 /mol_type="genomic DNA"
 Query Match 0.5%; Score 14.4; DB 1; Length 18;
 Best Local Similarity 93.8%; Pred. No. 7.7e+02;
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1702 GGCAGTGGTGGCCACAC 1717
 Db 3 GGCAGTGGTGGCCACAC 18
 RESULT 777
 LOCUS AR219241/c 18 bp DNA linear PAT 25-SEP-2002
 DEFINITION Sequence 12 from patent US 6420154.
 ACCESSION AR219241
 VERSION AR219241.1 GI:23320199
 KEYWORDS
 SOURCE Unknown.
 ORGANISM Unknown.
 REFERENCE 1 (bases 1 to 18)
 AUTHORS Sheppard,P.O., Baindur,N. and Bishop,P.D.
 TITLE Mammalian adhesion protease peptides
 JOURNAL Patent: US 6420154-A 12 16-JUL-2002;
 FEATURES
 Location/Qualifiers

```
source 1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 840 CACAGTCACCTATGGC 855
|||||
Db 18 CACAGTCACCCATGGC 3

RESULT 778
AX004441/c
LOCUS 18 bp DNA linear PAT 24-AUG-2000
DEFINITION Sequence 23 from Patent WO9916899.
ACCESSION AX004441
VERSION AX004441.1 GI:9927900
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS Anctil,J.L. and Cote,G.
TITLE Molecular diagnostic of glaucomas associated with chromosomes 2 and 6
JOURNAL ANCTIL JEAN LOUIS (CA); COTE GILLES (CA)
FEATURES
source 1. .18
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="OLIGONUCLEOTIDE"

Query Match 0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2767 GTCAACCCAGCTGGAG 2782
|||
Db 16 GTGACCCAGCTGGAG 1

RESULT 779
AX082162/c
LOCUS 18 bp DNA linear PAT 27-FEB-2001
DEFINITION Sequence 12 from Patent WO0109293.
ACCESSION AX082162
VERSION AX082162.1 GI:13170962
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS Sheppard,P.O., Baidur,N. and Bishop,P.D.
TITLE Mammalian adhesion protease peptides
JOURNAL Patent: WO 0109293-A 12 08-FEB-2001;
Zymogenetics, Inc. (US)
FEATURES
source 1. .18
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide ZC22,481"

Query Match 0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 840 CACAGTCACCTATGGC 855
|||||
```

```
Db 18 CACAGTCACCCATGGC 3

RESULT 780
AX635770
LOCUS 18 bp RNA linear PAT 21-FEB-2003
DEFINITION Sequence 2909 from Patent EP1260586.
ACCESSION AX635770
VERSION AX635770.1 GI:28471384
KEYWORDS
SOURCE unidentified
ORGANISM unidentified
unclassified.
REFERENCE
AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A.,
Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J.,
Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M.,
Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and
Woolf,T.
TITLE Method and reagent for inhibiting the expression of disease related
genes
JOURNAL Patent: EP 1260586-A 2909 27-NOV-2002;
RIBOZYME PHARMACEUTICALS, INC. (US)
FEATURES
source 1. .18
Location/Qualifiers
/organism="unidentified"
/mol_type="unassigned RNA"
/db_xref="taxon:32644"

Query Match 0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.7e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2117 GGCACCTGCTGTCTACT 2132
|||||
Db 2 GGCACCTGCTTCTACT 17

Search completed: July 26, 2005, 15:07:06
Job time : 30 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 26, 2005, 15:12:54 ; Search time 25 Seconds
(without alignments)
3.711 Million cell updates/sec

Title: nm000201

Perfect score: 2986

Sequence: 1 GCGCCCGAGTCGACGCTGAG.....ATAAGCTTCTCACTGCC 2986

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 778 seqs, 15534 residues

Total number of hits satisfying chosen parameters: 1556

Minimum DB seq length: 18
Maximum DB seq length: 26

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 778 summaries

Database : rni201.seq.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	25	0.8	25	1	US-09-396-196G-31947
2	25	0.8	25	1	US-09-396-196G-31948
3	25	0.8	25	1	US-09-396-196G-31949
4	25	0.8	25	1	US-09-396-196G-31950
5	25	0.8	25	1	US-09-396-196G-31951
6	25	0.8	25	1	US-09-396-196G-31952
7	25	0.8	25	1	US-09-396-196G-31953
8	25	0.8	25	1	US-09-396-196G-31954
9	25	0.8	25	1	US-09-396-196G-31955
10	25	0.8	25	1	US-09-396-196G-31956
11	25	0.8	25	1	US-09-396-196G-31957
12	25	0.8	25	1	US-09-396-196G-31958
13	25	0.8	25	1	US-09-396-196G-31959
14	25	0.8	25	1	US-09-396-196G-31960
15	25	0.8	25	1	US-09-396-196G-31961
16	25	0.8	25	1	US-09-396-196G-31962
17	25	0.8	25	1	US-09-396-196G-31963
18	25	0.8	25	1	US-09-396-196G-31964
19	25	0.8	25	1	US-09-396-196G-31965
20	25	0.8	25	1	US-09-396-196G-31966
21	24	0.8	24	1	US-08-245-295-22
22	24	0.8	24	1	US-08-481-130-22
23	24	0.8	24	1	US-08-481-130-22
24	24	0.8	24	1	US-08-481-130-22
25	24	0.8	24	1	US-08-656-984A-22
26	24	0.8	24	1	US-08-656-984A-23
27	24	0.8	24	1	US-08-482-882-23
28	24	0.8	24	1	US-08-482-882-24
29	24	0.8	24	1	US-08-485-604-22
30	24	0.8	24	1	US-08-485-604-23
31	24	0.8	24	1	US-08-483-389-23
32	24	0.8	24	1	US-08-483-389-24
33	24	0.8	24	1	US-08-443-965B-3

US-08-443-965B-4	1	24	0.8	24	34	C 34	Sequence 4, Appli
US-08-487-113D-23	24	24	0.8	24	35	C 35	Sequence 23, Appl
US-08-487-113D-24	24	24	0.8	24	36	C 36	Sequence 24, Appl
US-08-425-989B-3	24	24	0.8	24	37	C 37	Sequence 3, Appli
US-08-425-989B-4	24	24	0.8	24	38	C 38	Sequence 4, Appli
US-08-487-595-22	24	24	0.8	24	39	C 39	Sequence 22, Appl
US-08-487-595-23	24	24	0.8	24	40	C 40	Sequence 23, Appl
US-08-443-966B-3	24	24	0.8	24	41	C 41	Sequence 3, Appli
US-08-443-966B-4	24	24	0.8	24	42	C 42	Sequence 4, Appli
US-08-473-503-23	24	24	0.8	24	43	C 43	Sequence 23, Appl
US-08-473-503-24	24	24	0.8	24	44	C 44	Sequence 24, Appl
US-08-483-932-23	24	24	0.8	24	45	C 45	Sequence 23, Appl
US-08-483-932-24	24	24	0.8	24	46	C 46	Sequence 24, Appl
US-08-720-420A-23	24	24	0.8	24	47	C 47	Sequence 23, Appl
US-08-720-420A-24	24	24	0.8	24	48	C 48	Sequence 24, Appl
US-08-859-998-527	24	24	0.8	24	49	C 49	Sequence 527, App
US-08-714-017-23	24	24	0.8	24	50	C 50	Sequence 23, Appl
US-08-714-017-24	24	24	0.8	24	51	C 51	Sequence 24, Appl
US-08-475-680-23	24	24	0.8	24	52	C 52	Sequence 23, Appl
US-08-475-680-24	24	24	0.8	24	53	C 53	Sequence 24, Appl
US-09-225-928-527	24	24	0.8	24	54	C 54	Sequence 527, App
US-09-225-201B-527	24	24	0.8	24	55	C 55	Sequence 527, App
US-10-083-720A-15	24	24	0.8	24	56	C 56	Sequence 15, Appl
5284931-40	25	23.4	0.8	25	57	C 57	Patent No. 5284931
US-08-063-167A-3	21	21	0.7	21	58	C 58	Sequence 3, Appli
US-08-136-118-6	21	21	0.7	21	59	C 59	Sequence 6, Appli
US-08-136-118-8	21	21	0.7	21	60	C 60	Sequence 8, Appli
US-08-136-118-9	21	21	0.7	21	61	C 61	Sequence 9, Appli
US-08-136-118-10	21	21	0.7	21	62	C 62	Sequence 10, Appl
US-08-136-118-11	21	21	0.7	21	63	C 63	Sequence 11, Appl
US-08-007-997A-3	21	21	0.7	21	64	C 64	Sequence 3, Appli
US-08-327-363-4	21	21	0.7	21	65	C 65	Sequence 4, Appli
US-08-440-740A-3	21	21	0.7	21	66	C 66	Sequence 3, Appli
US-08-808-474A-17	21	21	0.7	21	67	C 67	Sequence 17, Appl
US-08-344-155C-3	21	21	0.7	21	68	C 68	Sequence 3, Appli
US-08-982-845B-3	21	21	0.7	21	69	C 69	Sequence 3, Appli
US-08-991-525B-3	21	21	0.7	21	70	C 70	Sequence 3, Appli
US-09-128-496-3	21	21	0.7	21	71	C 71	Sequence 3, Appli
US-09-128-496-3	21	21	0.7	21	72	C 72	Sequence 3, Appli
US-09-235-614-17	21	21	0.7	21	73	C 73	Sequence 17, Appl
US-09-109-663-37	21	21	0.7	21	74	C 74	Sequence 37, Appl
US-09-009-490A-3	21	21	0.7	21	75	C 75	Sequence 3, Appli
US-10-029-598-3	21	21	0.7	21	76	C 76	Sequence 3, Appli
US-09-546-596A-18	21	21	0.7	21	77	C 77	Sequence 18, Appl
US-09-546-596A-26	21	21	0.7	21	78	C 78	Sequence 26, Appl
US-08-117-363A-18	21	21	0.7	21	79	C 79	Sequence 18, Appl
US-10-083-720A-14	21	21	0.7	21	80	C 80	Sequence 14, Appl
PCT-US93-08101-3	21	21	0.7	21	81	C 81	Sequence 3, Appli
US-08-222-177A-146	25	20.8	0.7	25	82	C 82	Sequence 146, App
US-09-657-472-799	21	20.6	0.7	21	83	C 83	Sequence 799, App
US-09-657-472-800	21	20.6	0.7	21	84	C 84	Sequence 800, App
US-08-116-801C-4	22	20.4	0.7	22	85	C 85	Sequence 4, Appli
US-08-222-177A-125	22	20.4	0.7	22	86	C 86	Sequence 125, App
US-08-458-396-4	22	20.4	0.7	22	87	C 87	Sequence 4, Appli
US-08-924-326-4	22	20.4	0.7	22	88	C 88	Sequence 4, Appli
US-09-383-856-4	22	20.4	0.7	22	89	C 89	Sequence 4, Appli
US-08-222-177A-454	23	20.4	0.7	23	90	C 90	Sequence 454, App
US-08-787-321-22	23	20.4	0.7	23	91	C 91	Sequence 22, Appl
US-08-222-177A-445	24	20.4	0.7	24	92	C 92	Sequence 445, App
US-09-396-196G-73177	25	20.2	0.7	25	93	C 93	Sequence 73177, A
US-08-009-263C-25	20	20	0.7	20	94	C 94	Sequence 25, Appl
US-08-063-167A-2	20	20	0.7	20	95	C 95	Sequence 2, Appli
US-08-063-167A-7	20	20	0.7	20	96	C 96	Sequence 7, Appli
US-08-063-167A-8	20	20	0.7	20	97	C 97	Sequence 8, Appli
US-08-063-167A-9	20	20	0.7	20	98	C 98	Sequence 9, Appli
US-08-063-167A-10	20	20	0.7	20	99	C 99	Sequence 10, Appl
US-08-063-167A-11	20	20	0.7	20	100	C 100	Sequence 11, Appl
US-08-063-167A-12	20	20	0.7	20	101	C 101	Sequence 12, Appl
US-08-063-167A-13	20	20	0.7	20	102	C 102	Sequence 13, Appl
US-08-063-167A-14	20	20	0.7	20	103	C 103	Sequence 14, Appl
US-08-063-167A-15	20	20	0.7	20	104	C 104	Sequence 15, Appl
US-08-063-167A-16	20	20	0.7	20	105	C 105	Sequence 16, Appl
US-08-063-167A-22	20	20	0.7	20	106	C 106	Sequence 22, Appl

c 107 20 0.7 20 1 US-08-063-167A-23 Sequence 23, Appl
c 108 20 0.7 20 1 US-08-063-167A-24 Sequence 24, Appl
c 109 20 0.7 20 1 US-08-063-167A-25 Sequence 25, Appl
c 110 20 0.7 20 1 US-08-063-167A-26 Sequence 26, Appl
c 111 20 0.7 20 1 US-08-063-167A-84 Sequence 84, Appl
c 112 20 0.7 20 1 US-08-063-167A-85 Sequence 85, Appl
c 113 20 0.7 20 1 US-08-468-447-6 Sequence 6, Appl
c 114 20 0.7 20 1 US-08-469-851A-6 Sequence 6, Appl
c 115 20 0.7 20 1 US-08-007-997A-7 Sequence 7, Appl
c 116 20 0.7 20 1 US-08-007-997A-8 Sequence 8, Appl
c 117 20 0.7 20 1 US-08-007-997A-9 Sequence 9, Appl
c 118 20 0.7 20 1 US-08-007-997A-10 Sequence 10, Appl
c 119 20 0.7 20 1 US-08-007-997A-11 Sequence 11, Appl
c 120 20 0.7 20 1 US-08-007-997A-12 Sequence 12, Appl
c 121 20 0.7 20 1 US-08-007-997A-13 Sequence 13, Appl
c 122 20 0.7 20 1 US-08-007-997A-14 Sequence 14, Appl
c 123 20 0.7 20 1 US-08-007-997A-15 Sequence 15, Appl
c 124 20 0.7 20 1 US-08-007-997A-16 Sequence 16, Appl
c 125 20 0.7 20 1 US-08-007-997A-22 Sequence 22, Appl
c 126 20 0.7 20 1 US-08-007-997A-23 Sequence 23, Appl
c 127 20 0.7 20 1 US-08-007-997A-24 Sequence 24, Appl
c 128 20 0.7 20 1 US-08-007-997A-25 Sequence 25, Appl
c 129 20 0.7 20 1 US-08-007-997A-26 Sequence 26, Appl
c 130 20 0.7 20 1 US-08-007-997A-26 Sequence 26, Appl
c 131 20 0.7 20 1 US-07-927-506-25 Sequence 25, Appl
c 132 20 0.7 20 1 US-08-467-597A-6 Sequence 6, Appl
c 133 20 0.7 20 1 US-08-468-569A-6 Sequence 6, Appl
c 134 20 0.7 20 1 US-08-466-692A-6 Sequence 6, Appl
c 135 20 0.7 20 1 US-08-471-966A-6 Sequence 6, Appl
c 136 20 0.7 20 1 US-08-462-305-21 Sequence 21, Appl
c 137 20 0.7 20 1 US-08-462-305-22 Sequence 22, Appl
c 138 20 0.7 20 1 US-08-361-858-11 Sequence 11, Appl
c 139 20 0.7 20 1 US-08-361-858-11 Sequence 11, Appl
c 140 20 0.7 20 1 US-08-440-740A-2 Sequence 2, Appl
c 141 20 0.7 20 1 US-08-440-740A-7 Sequence 7, Appl
c 142 20 0.7 20 1 US-08-440-740A-8 Sequence 8, Appl
c 143 20 0.7 20 1 US-08-440-740A-9 Sequence 9, Appl
c 144 20 0.7 20 1 US-08-440-740A-10 Sequence 10, Appl
c 145 20 0.7 20 1 US-08-440-740A-11 Sequence 11, Appl
c 146 20 0.7 20 1 US-08-440-740A-12 Sequence 12, Appl
c 147 20 0.7 20 1 US-08-440-740A-13 Sequence 13, Appl
c 148 20 0.7 20 1 US-08-440-740A-14 Sequence 14, Appl
c 149 20 0.7 20 1 US-08-440-740A-15 Sequence 15, Appl
c 150 20 0.7 20 1 US-08-440-740A-16 Sequence 16, Appl
c 151 20 0.7 20 1 US-08-440-740A-22 Sequence 22, Appl
c 152 20 0.7 20 1 US-08-440-740A-23 Sequence 23, Appl
c 153 20 0.7 20 1 US-08-440-740A-24 Sequence 24, Appl
c 154 20 0.7 20 1 US-08-440-740A-25 Sequence 25, Appl
c 155 20 0.7 20 1 US-08-440-740A-26 Sequence 26, Appl
c 156 20 0.7 20 1 US-08-440-740A-84 Sequence 84, Appl
c 157 20 0.7 20 1 US-08-440-740A-85 Sequence 85, Appl
c 158 20 0.7 20 1 US-08-808-474A-12 Sequence 12, Appl
c 159 20 0.7 20 1 US-08-808-474A-13 Sequence 13, Appl
c 160 20 0.7 20 1 US-08-808-474A-14 Sequence 14, Appl
c 161 20 0.7 20 1 US-08-808-474A-15 Sequence 15, Appl
c 162 20 0.7 20 1 US-08-808-474A-16 Sequence 16, Appl
c 163 20 0.7 20 1 US-08-808-474A-18 Sequence 18, Appl
c 164 20 0.7 20 1 US-08-469-852A-1 Sequence 1, Appl
c 165 20 0.7 20 1 US-08-613-417A-21 Sequence 21, Appl
c 166 20 0.7 20 1 US-08-613-417A-22 Sequence 22, Appl
c 167 20 0.7 20 1 US-08-344-155C-2 Sequence 2, Appl
c 168 20 0.7 20 1 US-08-344-155C-7 Sequence 7, Appl
c 169 20 0.7 20 1 US-08-344-155C-8 Sequence 8, Appl
c 170 20 0.7 20 1 US-08-344-155C-9 Sequence 9, Appl
c 171 20 0.7 20 1 US-08-344-155C-10 Sequence 10, Appl
c 172 20 0.7 20 1 US-08-344-155C-11 Sequence 11, Appl
c 173 20 0.7 20 1 US-08-344-155C-12 Sequence 12, Appl
c 174 20 0.7 20 1 US-08-344-155C-13 Sequence 13, Appl
c 175 20 0.7 20 1 US-08-344-155C-14 Sequence 14, Appl
c 176 20 0.7 20 1 US-08-344-155C-15 Sequence 15, Appl
c 177 20 0.7 20 1 US-08-344-155C-16 Sequence 16, Appl
c 178 20 0.7 20 1 US-08-344-155C-22 Sequence 22, Appl
c 179 20 0.7 20 1 US-08-344-155C-23 Sequence 23, Appl

20 0.7 20 1 US-08-344-155C-24 Sequence 24, Appl
20 0.7 20 1 US-08-344-155C-25 Sequence 25, Appl
20 0.7 20 1 US-08-344-155C-26 Sequence 26, Appl
20 0.7 20 1 US-08-344-155C-84 Sequence 84, Appl
20 0.7 20 1 US-08-344-155C-85 Sequence 85, Appl
20 0.7 20 1 US-08-594-452-21 Sequence 21, Appl
20 0.7 20 1 US-08-594-452-22 Sequence 22, Appl
20 0.7 20 1 US-08-982-845B-2 Sequence 2, Appl
20 0.7 20 1 US-08-982-845B-7 Sequence 7, Appl
20 0.7 20 1 US-08-982-845B-8 Sequence 8, Appl
20 0.7 20 1 US-08-982-845B-9 Sequence 9, Appl
20 0.7 20 1 US-08-982-845B-10 Sequence 10, Appl
20 0.7 20 1 US-08-982-845B-11 Sequence 11, Appl
20 0.7 20 1 US-08-982-845B-12 Sequence 12, Appl
20 0.7 20 1 US-08-982-845B-13 Sequence 13, Appl
20 0.7 20 1 US-08-982-845B-14 Sequence 14, Appl
20 0.7 20 1 US-08-982-845B-15 Sequence 15, Appl
20 0.7 20 1 US-08-982-845B-16 Sequence 16, Appl
20 0.7 20 1 US-08-982-845B-22 Sequence 22, Appl
20 0.7 20 1 US-08-982-845B-23 Sequence 23, Appl
20 0.7 20 1 US-08-982-845B-24 Sequence 24, Appl
20 0.7 20 1 US-08-982-845B-25 Sequence 25, Appl
20 0.7 20 1 US-08-982-845B-26 Sequence 26, Appl
20 0.7 20 1 US-08-982-845B-84 Sequence 84, Appl
20 0.7 20 1 US-08-982-845B-85 Sequence 85, Appl
20 0.7 20 1 US-08-578-686C-20 Sequence 20, Appl
20 0.7 20 1 US-08-578-686C-21 Sequence 21, Appl
20 0.7 20 1 US-08-281-203-19 Sequence 19, Appl
20 0.7 20 1 US-08-295-509B-1 Sequence 1, Appl
20 0.7 20 1 US-09-094-405-25 Sequence 25, Appl
20 0.7 20 1 US-09-094-405-26 Sequence 26, Appl
20 0.7 20 1 US-08-777-266A-17 Sequence 17, Appl
20 0.7 20 1 US-09-166-186-41 Sequence 41, Appl
20 0.7 20 1 US-09-166-186-49 Sequence 49, Appl
20 0.7 20 1 US-08-991-525B-2 Sequence 2, Appl
20 0.7 20 1 US-08-991-525B-7 Sequence 7, Appl
20 0.7 20 1 US-08-991-525B-8 Sequence 8, Appl
20 0.7 20 1 US-08-991-525B-9 Sequence 9, Appl
20 0.7 20 1 US-08-991-525B-10 Sequence 10, Appl
20 0.7 20 1 US-08-991-525B-11 Sequence 11, Appl
20 0.7 20 1 US-08-991-525B-12 Sequence 12, Appl
20 0.7 20 1 US-08-991-525B-13 Sequence 13, Appl
20 0.7 20 1 US-08-991-525B-14 Sequence 14, Appl
20 0.7 20 1 US-08-991-525B-15 Sequence 15, Appl
20 0.7 20 1 US-08-991-525B-16 Sequence 16, Appl
20 0.7 20 1 US-08-991-525B-23 Sequence 23, Appl
20 0.7 20 1 US-08-991-525B-24 Sequence 24, Appl
20 0.7 20 1 US-08-991-525B-25 Sequence 25, Appl
20 0.7 20 1 US-08-991-525B-26 Sequence 26, Appl
20 0.7 20 1 US-08-991-525B-84 Sequence 84, Appl
20 0.7 20 1 US-08-991-525B-85 Sequence 85, Appl
20 0.7 20 1 US-09-085-759-2 Sequence 2, Appl
20 0.7 20 1 US-09-085-759-7 Sequence 7, Appl
20 0.7 20 1 US-09-085-759-8 Sequence 8, Appl
20 0.7 20 1 US-09-085-759-9 Sequence 9, Appl
20 0.7 20 1 US-09-085-759-10 Sequence 10, Appl
20 0.7 20 1 US-09-085-759-11 Sequence 11, Appl
20 0.7 20 1 US-09-085-759-12 Sequence 12, Appl
20 0.7 20 1 US-09-085-759-13 Sequence 13, Appl
20 0.7 20 1 US-09-085-759-14 Sequence 14, Appl
20 0.7 20 1 US-09-085-759-15 Sequence 15, Appl
20 0.7 20 1 US-09-085-759-16 Sequence 16, Appl
20 0.7 20 1 US-09-085-759-22 Sequence 22, Appl
20 0.7 20 1 US-09-085-759-23 Sequence 23, Appl
20 0.7 20 1 US-09-085-759-24 Sequence 24, Appl
20 0.7 20 1 US-09-085-759-25 Sequence 25, Appl
20 0.7 20 1 US-09-085-759-26 Sequence 26, Appl
20 0.7 20 1 US-09-085-759-84 Sequence 84, Appl
20 0.7 20 1 US-09-085-759-85 Sequence 85, Appl
20 0.7 20 1 US-09-085-759-97 Sequence 97, Appl
20 0.7 20 1 US-09-085-759-100 Sequence 100, Appl
20 0.7 20 1 US-09-062-416-2 Sequence 2, Appl

C 253	20	0.7	20	1	US-09-062-416-5	Sequence 5, Appli	C 326	20	0.7	20	1	US-09-109-663-36	Sequence 36, Appli
C 254	20	0.7	20	1	US-09-062-416-6	Sequence 6, Appli	C 327	20	0.7	20	1	US-09-378-665A-1	Sequence 1, Appli
C 255	20	0.7	20	1	US-09-062-416-11	Sequence 11, Appli	C 328	20	0.7	20	1	US-09-378-665A-2	Sequence 2, Appli
C 256	20	0.7	20	1	US-08-950-779-2	Sequence 2, Appli	C 329	20	0.7	20	1	US-09-378-665A-4	Sequence 4, Appli
C 257	20	0.7	20	1	US-08-950-779-8	Sequence 8, Appli	C 330	20	0.7	20	1	US-09-078-954-2	Sequence 2, Appli
C 258	20	0.7	20	1	US-08-950-779-9	Sequence 9, Appli	C 331	20	0.7	20	1	US-09-009-490A-2	Sequence 2, Appli
C 259	20	0.7	20	1	US-09-258-408-21	Sequence 21, Appli	C 332	20	0.7	20	1	US-09-009-490A-7	Sequence 7, Appli
C 260	20	0.7	20	1	US-09-258-408-22	Sequence 22, Appli	C 333	20	0.7	20	1	US-09-009-490A-8	Sequence 8, Appli
C 261	20	0.7	20	1	US-09-196-132-21	Sequence 21, Appli	C 334	20	0.7	20	1	US-09-009-490A-9	Sequence 9, Appli
C 262	20	0.7	20	1	US-09-196-132-22	Sequence 22, Appli	C 335	20	0.7	20	1	US-09-009-490A-10	Sequence 10, Appli
C 263	20	0.7	20	1	US-09-144-112-20	Sequence 20, Appli	C 336	20	0.7	20	1	US-09-009-490A-11	Sequence 11, Appli
C 264	20	0.7	20	1	US-09-144-112-21	Sequence 21, Appli	C 337	20	0.7	20	1	US-09-009-490A-12	Sequence 12, Appli
C 265	20	0.7	20	1	US-08-838-715B-25	Sequence 25, Appli	C 338	20	0.7	20	1	US-09-009-490A-13	Sequence 13, Appli
C 266	20	0.7	20	1	US-08-211-882-17	Sequence 17, Appli	C 339	20	0.7	20	1	US-09-009-490A-14	Sequence 14, Appli
C 267	20	0.7	20	1	US-09-414-145-2	Sequence 2, Appli	C 340	20	0.7	20	1	US-09-009-490A-15	Sequence 15, Appli
C 268	20	0.7	20	1	US-09-128-496-2	Sequence 2, Appli	C 341	20	0.7	20	1	US-09-009-490A-16	Sequence 16, Appli
C 269	20	0.7	20	1	US-09-128-496-7	Sequence 7, Appli	C 342	20	0.7	20	1	US-09-009-490A-22	Sequence 22, Appli
C 270	20	0.7	20	1	US-09-128-496-8	Sequence 8, Appli	C 343	20	0.7	20	1	US-09-009-490A-23	Sequence 23, Appli
C 271	20	0.7	20	1	US-09-128-496-9	Sequence 9, Appli	C 344	20	0.7	20	1	US-09-009-490A-24	Sequence 24, Appli
C 272	20	0.7	20	1	US-09-128-496-10	Sequence 10, Appli	C 345	20	0.7	20	1	US-09-009-490A-25	Sequence 25, Appli
C 273	20	0.7	20	1	US-09-128-496-11	Sequence 11, Appli	C 346	20	0.7	20	1	US-09-009-490A-26	Sequence 26, Appli
C 274	20	0.7	20	1	US-09-128-496-12	Sequence 12, Appli	C 347	20	0.7	20	1	US-09-009-490A-84	Sequence 84, Appli
C 275	20	0.7	20	1	US-09-128-496-13	Sequence 13, Appli	C 348	20	0.7	20	1	US-09-009-490A-85	Sequence 85, Appli
C 276	20	0.7	20	1	US-09-128-496-14	Sequence 14, Appli	C 349	20	0.7	20	1	US-09-326-186B-17	Sequence 17, Appli
C 277	20	0.7	20	1	US-09-128-496-15	Sequence 15, Appli	C 350	20	0.7	20	1	US-09-349-007A-1	Sequence 1, Appli
C 278	20	0.7	20	1	US-09-128-496-16	Sequence 16, Appli	C 351	20	0.7	20	1	US-09-349-007A-3	Sequence 3, Appli
C 279	20	0.7	20	1	US-09-128-496-22	Sequence 22, Appli	C 352	20	0.7	20	1	US-09-349-007A-4	Sequence 4, Appli
C 280	20	0.7	20	1	US-09-128-496-23	Sequence 23, Appli	C 353	20	0.7	20	1	US-09-349-007A-5	Sequence 5, Appli
C 281	20	0.7	20	1	US-09-128-496-24	Sequence 24, Appli	C 354	20	0.7	20	1	US-09-349-007A-6	Sequence 6, Appli
C 282	20	0.7	20	1	US-09-128-496-25	Sequence 25, Appli	C 355	20	0.7	20	1	US-09-349-007A-7	Sequence 7, Appli
C 283	20	0.7	20	1	US-09-128-496-26	Sequence 26, Appli	C 356	20	0.7	20	1	US-09-349-007A-8	Sequence 8, Appli
C 284	20	0.7	20	1	US-09-128-496-84	Sequence 84, Appli	C 357	20	0.7	20	1	US-09-349-007A-9	Sequence 9, Appli
C 285	20	0.7	20	1	US-09-128-496-85	Sequence 85, Appli	C 358	20	0.7	20	1	US-09-349-007A-11	Sequence 11, Appli
C 286	20	0.7	20	1	US-09-187-995-12	Sequence 12, Appli	C 359	20	0.7	20	1	US-09-349-007A-13	Sequence 13, Appli
C 287	20	0.7	20	1	US-09-130-973-56	Sequence 56, Appli	C 360	20	0.7	20	1	US-09-111-678-2	Sequence 2, Appli
C 288	20	0.7	20	1	US-09-130-973-57	Sequence 57, Appli	C 361	20	0.7	20	1	US-08-895-981-21	Sequence 21, Appli
C 289	20	0.7	20	1	US-09-144-883C-3	Sequence 3, Appli	C 362	20	0.7	20	1	US-08-895-981-22	Sequence 22, Appli
C 290	20	0.7	20	1	US-09-235-614-12	Sequence 12, Appli	C 363	20	0.7	20	1	US-08-829-637A-127	Sequence 127, App
C 291	20	0.7	20	1	US-09-235-614-13	Sequence 13, Appli	C 364	20	0.7	20	1	US-08-337-120A-29	Sequence 29, Appli
C 292	20	0.7	20	1	US-09-235-614-14	Sequence 14, Appli	C 365	20	0.7	20	1	US-08-337-120A-30	Sequence 30, Appli
C 293	20	0.7	20	1	US-09-235-614-15	Sequence 15, Appli	C 366	20	0.7	20	1	US-09-711-050A-1	Sequence 1, Appli
C 294	20	0.7	20	1	US-09-235-614-16	Sequence 16, Appli	C 367	20	0.7	20	1	US-09-412-499A-10	Sequence 10, Appli
C 295	20	0.7	20	1	US-09-235-614-18	Sequence 18, Appli	C 368	20	0.7	20	1	US-09-287-175-2	Sequence 2, Appli
C 296	20	0.7	20	1	US-09-250-075-8	Sequence 8, Appli	C 369	20	0.7	20	1	US-09-633-659-17	Sequence 17, Appli
C 297	20	0.7	20	1	US-09-313-932-41	Sequence 41, Appli	C 370	20	0.7	20	1	US-09-349-659-2	Sequence 2, Appli
C 298	20	0.7	20	1	US-09-313-932-49	Sequence 49, Appli	C 371	20	0.7	20	1	US-09-689-964-11	Sequence 11, Appli
C 299	20	0.7	20	1	US-09-409-816-1	Sequence 1, Appli	C 372	20	0.7	20	1	US-09-689-964-11	Sequence 11, Appli
C 300	20	0.7	20	1	US-08-397-277A-11	Sequence 11, Appli	C 373	20	0.7	20	1	US-09-271-220-1	Sequence 1, Appli
C 301	20	0.7	20	1	US-09-123-108-2	Sequence 2, Appli	C 374	20	0.7	20	1	US-09-352-058A-1	Sequence 1, Appli
C 302	20	0.7	20	1	US-09-123-108-3	Sequence 3, Appli	C 375	20	0.7	20	1	US-09-726-096A-8	Sequence 8, Appli
C 303	20	0.7	20	1	US-09-123-108-5	Sequence 5, Appli	C 376	20	0.7	20	1	US-09-288-679-2	Sequence 2, Appli
C 304	20	0.7	20	1	US-09-177-953-2	Sequence 2, Appli	C 377	20	0.7	20	1	US-09-288-679-4	Sequence 4, Appli
C 305	20	0.7	20	1	US-09-177-953-8	Sequence 8, Appli	C 378	20	0.7	20	1	US-09-643-233-20	Sequence 20, Appli
C 306	20	0.7	20	1	US-09-177-953-11	Sequence 11, Appli	C 379	20	0.7	20	1	US-09-643-233-21	Sequence 21, Appli
C 307	20	0.7	20	1	US-09-177-953-17	Sequence 17, Appli	C 380	20	0.7	20	1	US-10-121-135-1	Sequence 1, Appli
C 308	20	0.7	20	1	US-09-177-953-22	Sequence 22, Appli	C 381	20	0.7	20	1	US-10-121-135-2	Sequence 2, Appli
C 309	20	0.7	20	1	US-09-177-953-23	Sequence 23, Appli	C 382	20	0.7	20	1	US-10-121-135-2	Sequence 2, Appli
C 310	20	0.7	20	1	US-09-177-953-25	Sequence 25, Appli	C 383	20	0.7	20	1	US-10-121-135-4	Sequence 4, Appli
C 311	20	0.7	20	1	US-09-177-953-31	Sequence 31, Appli	C 384	20	0.7	20	1	US-09-658-517C-4	Sequence 4, Appli
C 312	20	0.7	20	1	US-09-177-953-33	Sequence 33, Appli	C 385	20	0.7	20	1	US-09-418-804-1	Sequence 1, Appli
C 313	20	0.7	20	1	US-09-177-953-38	Sequence 38, Appli	C 386	20	0.7	20	1	US-09-343-006-1	Sequence 1, Appli
C 314	20	0.7	20	1	US-09-177-953-40	Sequence 40, Appli	C 387	20	0.7	20	1	US-09-344-260A-5	Sequence 5, Appli
C 315	20	0.7	20	1	US-09-177-953-46	Sequence 46, Appli	C 388	20	0.7	20	1	US-09-495-398-1	Sequence 1, Appli
C 316	20	0.7	20	1	US-09-115-025A-1	Sequence 1, Appli	C 389	20	0.7	20	1	US-09-495-398-2	Sequence 2, Appli
C 317	20	0.7	20	1	US-09-115-025A-3	Sequence 3, Appli	C 390	20	0.7	20	1	US-09-306-278A-2	Sequence 2, Appli
C 318	20	0.7	20	1	US-09-115-025A-4	Sequence 4, Appli	C 391	20	0.7	20	1	US-09-409-926-26	Sequence 26, Appli
C 319	20	0.7	20	1	US-09-115-025A-5	Sequence 5, Appli	C 392	20	0.7	20	1	US-09-876-242-2	Sequence 2, Appli
C 320	20	0.7	20	1	US-09-115-025A-6	Sequence 6, Appli	C 393	20	0.7	20	1	US-09-370-541-18	Sequence 18, Appli
C 321	20	0.7	20	1	US-09-115-025A-7	Sequence 7, Appli	C 394	20	0.7	20	1	US-10-318-628-2	Sequence 2, Appli
C 322	20	0.7	20	1	US-09-115-025A-8	Sequence 8, Appli	C 395	20	0.7	20	1	US-10-318-628-8	Sequence 8, Appli
C 323	20	0.7	20	1	US-09-115-025A-9	Sequence 9, Appli	C 396	20	0.7	20	1	US-10-318-628-11	Sequence 11, Appli
C 324	20	0.7	20	1	US-09-115-025A-11	Sequence 11, Appli	C 397	20	0.7	20	1	US-10-318-628-17	Sequence 17, Appli
C 325	20	0.7	20	1	US-09-115-025A-13	Sequence 13, Appli	C 398	20	0.7	20	1		

C 399	20	0.7	20	1	US-10-318-628-22	Sequence 22, Appl	C 472	19	0.6	19	1	US-08-314-615-22	Sequence 22, Appl
C 400	20	0.7	20	1	US-10-318-628-23	Sequence 23, Appl	C 473	19	0.6	19	1	US-08-314-362-22	Sequence 22, Appl
C 401	20	0.7	20	1	US-10-318-628-25	Sequence 25, Appl	C 474	19	0.6	19	1	US-08-327-363-7	Sequence 7, Appl
C 402	20	0.7	20	1	US-10-318-628-31	Sequence 31, Appl	C 475	19	0.6	19	1	US-08-433-010-22	Sequence 22, Appl
C 403	20	0.7	20	1	US-10-318-628-33	Sequence 33, Appl	C 476	19	0.6	19	1	US-08-196-003-6	Sequence 6, Appl
C 404	20	0.7	20	1	US-10-318-628-38	Sequence 38, Appl	C 477	19	0.6	19	1	US-08-462-305-23	Sequence 23, Appl
C 405	20	0.7	20	1	US-10-318-628-40	Sequence 40, Appl	C 478	19	0.6	19	1	US-08-482-882-22	Sequence 22, Appl
C 406	20	0.7	20	1	US-10-318-628-46	Sequence 46, Appl	C 479	19	0.6	19	1	US-08-483-389-22	Sequence 22, Appl
C 407	20	0.7	20	1	US-09-477-878-1	Sequence 1, Appl	C 480	19	0.6	19	1	US-08-487-1130-22	Sequence 22, Appl
C 408	20	0.7	20	1	US-09-334-130-4	Sequence 4, Appl	C 481	19	0.6	19	1	US-08-473-503-22	Sequence 22, Appl
C 409	20	0.7	20	1	US-10-290-587-2	Sequence 2, Appl	C 482	19	0.6	19	1	US-08-613-417A-23	Sequence 23, Appl
C 410	20	0.7	20	1	US-09-747-772-3	Sequence 3, Appl	C 483	19	0.6	19	1	US-08-483-932-22	Sequence 22, Appl
C 411	20	0.7	20	1	US-09-747-772-4	Sequence 4, Appl	C 484	19	0.6	19	1	US-08-720-420A-22	Sequence 22, Appl
C 412	20	0.7	20	1	US-10-029-598-1	Sequence 1, Appl	C 485	19	0.6	19	1	US-08-933-824-6	Sequence 6, Appl
C 413	20	0.7	20	1	US-10-029-598-2	Sequence 2, Appl	C 486	19	0.6	19	1	US-08-594-452-23	Sequence 23, Appl
C 414	20	0.7	20	1	US-10-029-598-55	Sequence 55, Appl	C 487	19	0.6	19	1	US-08-578-686C-22	Sequence 22, Appl
C 415	20	0.7	20	1	US-09-546-596A-17	Sequence 17, Appl	C 488	19	0.6	19	1	US-08-281-203-20	Sequence 20, Appl
C 416	20	0.7	20	1	US-09-594-387-4	Sequence 4, Appl	C 489	19	0.6	19	1	US-08-714-017-22	Sequence 22, Appl
C 417	20	0.7	20	1	US-09-949-474A-4	Sequence 4, Appl	C 490	19	0.6	19	1	US-09-094-405-27	Sequence 27, Appl
C 418	20	0.7	20	1	US-09-835-370-41	Sequence 41, Appl	C 491	19	0.6	19	1	US-08-863-790-22	Sequence 22, Appl
C 419	20	0.7	20	1	US-09-835-370-42	Sequence 42, Appl	C 492	19	0.6	19	1	US-08-475-680-22	Sequence 22, Appl
C 420	20	0.7	20	1	US-09-835-370-43	Sequence 43, Appl	C 493	19	0.6	19	1	US-09-258-408-23	Sequence 23, Appl
C 421	20	0.7	20	1	US-08-117-363A-17	Sequence 17, Appl	C 494	19	0.6	19	1	US-09-196-132-23	Sequence 23, Appl
C 422	20	0.7	20	1	US-10-103-906-1	Sequence 1, Appl	C 495	19	0.6	19	1	US-09-144-112-22	Sequence 22, Appl
C 423	20	0.7	20	1	US-10-083-720A-13	Sequence 13, Appl	C 496	19	0.6	19	1	US-08-296-749-22	Sequence 22, Appl
C 424	20	0.7	20	1	US-10-234-764-5	Sequence 5, Appl	C 497	19	0.6	19	1	US-09-264-466-6	Sequence 6, Appl
C 425	20	0.7	20	1	US-08-823-031B-12	Sequence 12, Appl	C 498	19	0.6	19	1	US-08-895-981-23	Sequence 23, Appl
C 426	20	0.7	20	1	US-10-192-437-11	Sequence 11, Appl	C 499	19	0.6	19	1	US-08-337-120A-31	Sequence 31, Appl
C 427	20	0.7	20	1	US-10-073-718-17	Sequence 17, Appl	C 500	19	0.6	19	1	US-09-643-233-22	Sequence 22, Appl
C 428	20	0.7	20	1	US-09-654-373-2	Sequence 2, Appl	C 501	19	0.6	19	1	US-09-835-370-44	Sequence 44, Appl
C 429	20	0.7	20	1	PCT-US91-05815-25	Sequence 25, Appl	C 502	19	0.6	19	1	US-08-314-369-22	Sequence 22, Appl
C 430	20	0.7	20	1	PCT-US93-08101-2	Sequence 2, Appl	C 503	19	0.6	20	1	US-09-435-296-75	Sequence 75, Appl
C 431	20	0.7	20	1	PCT-US93-08101-7	Sequence 7, Appl	C 504	19	0.6	20	1	US-09-280-805-243	Sequence 243, App
C 432	20	0.7	20	1	PCT-US93-08101-8	Sequence 8, Appl	C 505	19	0.6	20	1	US-09-038-637-155	Sequence 155, App
C 433	20	0.7	20	1	PCT-US93-08101-9	Sequence 9, Appl	C 506	19	0.6	21	1	US-08-397-277A-1	Sequence 1, Appl
C 434	20	0.7	20	1	PCT-US93-08101-10	Sequence 10, Appl	C 507	19	0.6	21	1	US-09-689-964-1	Sequence 1, Appl
C 435	20	0.7	20	1	PCT-US93-08101-11	Sequence 11, Appl	C 508	19	0.6	21	1	US-09-689-964-1	Sequence 1, Appl
C 436	20	0.7	20	1	PCT-US93-08101-12	Sequence 12, Appl	C 509	19	0.6	21	1	US-10-132-437-1	Sequence 1, Appl
C 437	20	0.7	20	1	PCT-US93-08101-13	Sequence 13, Appl	C 510	19	0.6	21	1	PCT-US93-08367A-1	Sequence 1, Appl
C 438	20	0.7	20	1	PCT-US93-08101-14	Sequence 14, Appl	C 511	19	0.6	21	1	US-08-594-452-92	Sequence 92, Appl
C 439	20	0.7	20	1	PCT-US93-08101-15	Sequence 15, Appl	C 512	19	0.6	22	1	US-09-258-408-92	Sequence 92, Appl
C 440	20	0.7	20	1	PCT-US93-08101-16	Sequence 16, Appl	C 513	18.4	0.6	22	1	US-08-605-089-43	Sequence 43, Appl
C 441	20	0.7	20	1	PCT-US93-08101-22	Sequence 22, Appl	C 514	18.4	0.6	20	1	US-08-863-639A-32	Sequence 32, Appl
C 442	20	0.7	20	1	PCT-US93-08101-23	Sequence 23, Appl	C 515	18.4	0.6	20	1	US-09-289-267-165	Sequence 165, App
C 443	20	0.7	20	1	PCT-US93-08101-24	Sequence 24, Appl	C 516	18.4	0.6	20	1	US-09-407-675-5	Sequence 5, Appl
C 444	20	0.7	20	1	PCT-US93-08101-25	Sequence 25, Appl	C 517	18.4	0.6	20	1	US-09-280-805-242	Sequence 242, App
C 445	20	0.7	20	1	PCT-US93-08101-26	Sequence 26, Appl	C 518	18.4	0.6	20	1	US-09-488-671-88	Sequence 88, Appl
C 446	20	0.7	20	1	PCT-US93-08101-84	Sequence 84, Appl	C 519	18.4	0.6	20	1	US-09-180-903-8	Sequence 8, Appl
C 447	20	0.7	20	1	PCT-US93-08101-85	Sequence 85, Appl	C 520	18.4	0.6	20	1	US-09-662-250A-76	Sequence 76, Appl
C 448	20	0.7	20	1	PCT-US93-08367A-11	Sequence 11, Appl	C 521	18.4	0.6	20	1	US-09-780-173A-18	Sequence 18, Appl
C 449	20	0.7	20	1	PCT-US96-08757A-6	Sequence 6, Appl	C 522	18.4	0.6	22	1	US-09-948-686-93	Sequence 93, Appl
C 450	20	0.7	21	1	US-08-327-363-5	Sequence 5, Appl	C 523	18.2	0.6	19	1	US-08-070-517-2	Sequence 2, Appl
C 451	20	0.7	21	1	US-08-327-363-6	Sequence 6, Appl	C 524	18.2	0.6	19	1	US-08-118-441-2	Sequence 2, Appl
C 452	20	0.7	21	1	US-08-753-147-28	Sequence 28, Appl	C 525	18.2	0.6	19	1	US-08-432-699A-14	Sequence 14, Appl
C 453	20	0.7	22	1	US-08-063-167A-27	Sequence 27, Appl	C 526	18.2	0.6	19	1	US-08-422-706B-14	Sequence 14, Appl
C 454	20	0.7	22	1	US-08-440-740A-27	Sequence 27, Appl	C 527	18.2	0.6	19	1	US-08-338-579A-2	Sequence 2, Appl
C 455	20	0.7	22	1	US-08-344-155C-27	Sequence 27, Appl	C 528	18.2	0.6	19	1	PCT-US94-09851-2	Sequence 2, Appl
C 456	20	0.7	22	1	US-08-982-845B-27	Sequence 27, Appl	C 529	18	0.6	18	1	US-08-297-703-6	Sequence 6, Appl
C 457	20	0.7	22	1	US-08-991-525B-27	Sequence 27, Appl	C 530	18	0.6	18	1	US-08-063-167A-1	Sequence 1, Appl
C 458	20	0.7	22	1	US-09-085-759-27	Sequence 27, Appl	C 531	18	0.6	18	1	US-08-063-167A-5	Sequence 5, Appl
C 459	20	0.7	22	1	US-09-128-496-27	Sequence 27, Appl	C 532	18	0.6	18	1	US-08-063-167A-81	Sequence 81, Appl
C 460	20	0.7	22	1	US-09-009-490A-27	Sequence 27, Appl	C 533	18	0.6	18	1	US-08-058-023-6	Sequence 6, Appl
C 461	20	0.7	22	1	PCT-US93-08101-27	Sequence 27, Appl	C 534	18	0.6	18	1	US-08-314-615-21	Sequence 21, Appl
C 462	20	0.7	22	1	PCT-US93-08101-27	Sequence 27, Appl	C 535	18	0.6	18	1	US-08-314-362-21	Sequence 21, Appl
C 463	20	0.7	24	1	US-08-594-452-88	Sequence 88, Appl	C 536	18	0.6	18	1	US-08-136-118-15	Sequence 15, Appl
C 464	20	0.7	24	1	US-08-594-452-87	Sequence 87, Appl	C 537	18	0.6	18	1	US-08-007-997A-1	Sequence 1, Appl
C 465	20	0.7	24	1	US-09-258-408-87	Sequence 87, Appl	C 538	18	0.6	18	1	US-08-007-997A-4	Sequence 4, Appl
C 466	20	0.7	24	1	US-09-258-408-88	Sequence 88, Appl	C 539	18	0.6	18	1	US-08-007-997A-5	Sequence 5, Appl
C 467	19.8	0.7	24	1	US-09-018-584A-96	Sequence 96, Appl	C 540	18	0.6	18	1	US-08-007-997A-81	Sequence 81, Appl
C 468	19.8	0.7	24	1	US-09-784-423-96	Sequence 96, Appl	C 541	18	0.6	18	1	US-08-433-010-21	Sequence 21, Appl
C 469	19.4	0.6	21	1	US-08-222-177A-160	Sequence 160, App	C 542	18	0.6	18	1	US-08-196-003-5	Sequence 5, Appl
C 470	19.4	0.6	21	1	US-08-529-878B-9	Sequence 9, Appl	C 543	18	0.6	18	1	US-08-475-467-22	Sequence 22, Appl
C 471	19.4	0.6	21	1	US-09-233-086-61	Sequence 61, Appl	C 544	18	0.6	18	1		

c 545	18	0.6	18	1	US-08-475-467-23	Sequence 23, Appl	c 618	18	0.6	18	1	US-09-128-508-1	Sequence 1, Appl
c 546	18	0.6	18	1	US-08-475-467-24	Sequence 24, Appl	c 619	18	0.6	18	1	US-08-397-277A-7	Sequence 7, Appl
c 547	18	0.6	18	1	US-08-475-467-25	Sequence 25, Appl	c 620	18	0.6	18	1	US-09-264-466-5	Sequence 5, Appl
c 548	18	0.6	18	1	US-08-475-467-26	Sequence 26, Appl	c 621	18	0.6	18	1	US-09-009-490A-1	Sequence 1, Appl
c 549	18	0.6	18	1	US-08-482-882-21	Sequence 21, Appl	c 622	18	0.6	18	1	US-03-009-490A-4	Sequence 4, Appl
c 550	18	0.6	18	1	US-08-653-653A-2	Sequence 2, Appl	c 623	18	0.6	18	1	US-09-009-490A-5	Sequence 5, Appl
c 551	18	0.6	18	1	US-08-483-389-21	Sequence 21, Appl	c 624	18	0.6	18	1	US-09-009-490A-81	Sequence 81, Appl
c 552	18	0.6	18	1	US-08-361-855-1	Sequence 1, Appl	c 625	18	0.6	18	1	US-09-149-156B-1	Sequence 1, Appl
c 553	18	0.6	18	1	US-08-361-855-7	Sequence 7, Appl	c 626	18	0.6	18	1	US-09-149-156B-2	Sequence 2, Appl
c 554	18	0.6	18	1	US-08-487-113D-21	Sequence 21, Appl	c 627	18	0.6	18	1	US-09-149-156B-3	Sequence 3, Appl
c 555	18	0.6	18	1	US-08-440-740A-1	Sequence 1, Appl	c 628	18	0.6	18	1	US-09-633-659-4	Sequence 4, Appl
c 556	18	0.6	18	1	US-08-440-740A-4	Sequence 4, Appl	c 629	18	0.6	18	1	US-09-689-964-7	Sequence 7, Appl
c 557	18	0.6	18	1	US-08-440-740A-5	Sequence 5, Appl	c 630	18	0.6	18	1	US-09-689-964-7	Sequence 7, Appl
c 558	18	0.6	18	1	US-08-440-740A-81	Sequence 81, Appl	c 631	18	0.6	18	1	US-09-784-917-6	Sequence 6, Appl
c 559	18	0.6	18	1	US-08-890-084-22	Sequence 22, Appl	c 632	18	0.6	18	1	US-09-747-009A-22	Sequence 22, Appl
c 560	18	0.6	18	1	US-08-890-084-23	Sequence 23, Appl	c 633	18	0.6	18	1	US-09-747-009A-23	Sequence 23, Appl
c 561	18	0.6	18	1	US-08-890-084-24	Sequence 24, Appl	c 634	18	0.6	18	1	US-09-747-009A-24	Sequence 24, Appl
c 562	18	0.6	18	1	US-08-890-084-25	Sequence 25, Appl	c 635	18	0.6	18	1	US-09-747-009A-25	Sequence 25, Appl
c 563	18	0.6	18	1	US-08-890-084-26	Sequence 26, Appl	c 636	18	0.6	18	1	US-09-747-009A-26	Sequence 26, Appl
c 564	18	0.6	18	1	US-08-473-503-21	Sequence 21, Appl	c 637	18	0.6	18	1	US-10-150-696-6	Sequence 6, Appl
c 565	18	0.6	18	1	US-08-689-870-11	Sequence 11, Appl	c 638	18	0.6	18	1	US-09-546-596A-4	Sequence 4, Appl
c 566	18	0.6	18	1	US-08-483-932-21	Sequence 21, Appl	c 639	18	0.6	18	1	US-09-546-596A-5	Sequence 5, Appl
c 567	18	0.6	18	1	US-08-344-155C-1	Sequence 1, Appl	c 640	18	0.6	18	1	US-03-546-596A-15	Sequence 15, Appl
c 568	18	0.6	18	1	US-08-344-155C-4	Sequence 4, Appl	c 641	18	0.6	18	1	US-09-546-596A-16	Sequence 16, Appl
c 569	18	0.6	18	1	US-08-344-155C-5	Sequence 5, Appl	c 642	18	0.6	18	1	US-08-117-363A-4	Sequence 4, Appl
c 570	18	0.6	18	1	US-08-344-155C-81	Sequence 81, Appl	c 643	18	0.6	18	1	US-08-117-363A-15	Sequence 15, Appl
c 571	18	0.6	18	1	US-08-689-873-11	Sequence 11, Appl	c 644	18	0.6	18	1	US-08-117-363A-16	Sequence 16, Appl
c 572	18	0.6	18	1	US-08-403-888A-120	Sequence 120, App	c 645	18	0.6	18	1	US-08-314-369-21	Sequence 21, Appl
c 573	18	0.6	18	1	US-08-720-420A-21	Sequence 21, Appl	c 646	18	0.6	18	1	US-10-192-437-7	Sequence 7, Appl
c 574	18	0.6	18	1	US-08-933-824-5	Sequence 5, Appl	c 647	18	0.6	18	1	US-10-073-718-4	Sequence 4, Appl
c 575	18	0.6	18	1	US-08-982-845B-1	Sequence 1, Appl	c 648	18	0.6	18	1	PCT-US93-08101-1	Sequence 1, Appl
c 576	18	0.6	18	1	US-08-982-845B-4	Sequence 4, Appl	c 649	18	0.6	18	1	PCT-US93-08101-4	Sequence 4, Appl
c 577	18	0.6	18	1	US-08-982-845B-5	Sequence 5, Appl	c 650	18	0.6	18	1	PCT-US93-08101-5	Sequence 5, Appl
c 578	18	0.6	18	1	US-08-982-845B-81	Sequence 81, Appl	c 651	18	0.6	18	1	PCT-US93-08101-81	Sequence 81, Appl
c 579	18	0.6	18	1	US-08-714-017-21	Sequence 21, Appl	c 652	18	0.6	18	1	PCT-US93-08367A-7	Sequence 7, Appl
c 580	18	0.6	18	1	US-08-863-790-21	Sequence 21, Appl	c 653	18	0.6	18	1	5284931-21	Patent No. 5284931
c 581	18	0.6	18	1	US-08-991-525B-1	Sequence 1, Appl	c 654	18	0.6	18	1	5284931-21	Patent No. 5284931
c 582	18	0.6	18	1	US-08-991-525B-4	Sequence 4, Appl	c 655	18	0.6	18	1	US-08-361-858-2	Sequence 2, Appl
c 583	18	0.6	18	1	US-08-991-525B-5	Sequence 5, Appl	c 656	18	0.6	18	1	US-08-397-277A-2	Sequence 2, Appl
c 584	18	0.6	18	1	US-08-991-525B-81	Sequence 81, Appl	c 657	18	0.6	18	1	US-09-689-964-2	Sequence 2, Appl
c 585	18	0.6	18	1	US-09-085-759-1	Sequence 1, Appl	c 658	18	0.6	18	1	US-09-370-541-21	Sequence 21, Appl
c 586	18	0.6	18	1	US-09-085-759-4	Sequence 4, Appl	c 659	18	0.6	18	1	US-09-546-596A-23	Sequence 23, Appl
c 587	18	0.6	18	1	US-09-085-759-5	Sequence 5, Appl	c 660	18	0.6	18	1	US-08-117-363A-23	Sequence 23, Appl
c 588	18	0.6	18	1	US-09-085-759-81	Sequence 81, Appl	c 661	18	0.6	18	1	US-10-192-437-2	Sequence 2, Appl
c 589	18	0.6	18	1	US-09-085-759-86	Sequence 86, Appl	c 662	18	0.6	18	1	PCT-US93-08367A-2	Sequence 2, Appl
c 590	18	0.6	18	1	US-09-085-759-87	Sequence 87, Appl	c 663	18	0.6	18	1	US-09-334-130-2	Sequence 2, Appl
c 591	18	0.6	18	1	US-09-085-759-88	Sequence 88, Appl	c 664	18	0.6	20	1	US-09-334-130-3	Sequence 3, Appl
c 592	18	0.6	18	1	US-09-085-759-89	Sequence 89, Appl	c 665	18	0.6	20	1	US-10-172-911-80	Sequence 80, Appl
c 593	18	0.6	18	1	US-09-085-759-90	Sequence 90, Appl	c 666	18	0.6	20	1	US-09-594-387-2	Sequence 3, Appl
c 594	18	0.6	18	1	US-09-085-759-91	Sequence 91, Appl	c 667	18	0.6	20	1	US-09-594-387-3	Sequence 3, Appl
c 595	18	0.6	18	1	US-09-085-759-92	Sequence 92, Appl	c 668	18	0.6	20	1	US-09-018-584A-60	Sequence 60, Appl
c 596	18	0.6	18	1	US-09-085-759-93	Sequence 93, Appl	c 669	17.8	0.6	21	1	US-09-784-423-60	Sequence 60, Appl
c 597	18	0.6	18	1	US-09-085-759-95	Sequence 95, Appl	c 670	17.8	0.6	21	1	US-09-859-736-6	Sequence 6, Appl
c 598	18	0.6	18	1	US-09-085-759-96	Sequence 96, Appl	c 671	17.8	0.6	21	1	US-08-599-252-52	Sequence 52, Appl
c 599	18	0.6	18	1	US-09-085-759-98	Sequence 98, Appl	c 672	17.8	0.6	22	1	PCT-US96-06352-52	Sequence 52, Appl
c 600	18	0.6	18	1	US-09-085-759-99	Sequence 99, Appl	c 673	17.8	0.6	22	1	PCT-US96-06583-52	Sequence 52, Appl
c 601	18	0.6	18	1	US-09-085-759-101	Sequence 101, App	c 674	17.8	0.6	22	1	US-08-222-177A-442	Sequence 442, App
c 602	18	0.6	18	1	US-09-085-759-102	Sequence 102, App	c 675	17.4	0.6	19	1	US-08-196-003-7	Sequence 7, Appl
c 603	18	0.6	18	1	US-09-085-759-103	Sequence 103, App	c 676	17.4	0.6	19	1	US-08-689-870-9	Sequence 9, Appl
c 604	18	0.6	18	1	US-09-085-759-105	Sequence 105, App	c 677	17.4	0.6	19	1	US-08-689-873-9	Sequence 9, Appl
c 605	18	0.6	18	1	US-08-475-680-21	Sequence 21, Appl	c 678	17.4	0.6	19	1	US-08-849-021-74	Sequence 74, Appl
c 606	18	0.6	18	1	US-09-062-416-7	Sequence 7, Appl	c 679	17.4	0.6	19	1	US-08-933-824-7	Sequence 7, Appl
c 607	18	0.6	18	1	US-08-296-749-21	Sequence 21, Appl	c 680	17.4	0.6	19	1	US-08-915-609-3	Sequence 3, Appl
c 608	18	0.6	18	1	US-08-211-882-4	Sequence 4, Appl	c 681	17.4	0.6	19	1	US-08-915-609-4	Sequence 4, Appl
c 609	18	0.6	18	1	US-09-128-496-1	Sequence 1, Appl	c 682	17.4	0.6	19	1	US-09-366-840-2	Sequence 2, Appl
c 610	18	0.6	18	1	US-09-128-496-4	Sequence 4, Appl	c 683	17.4	0.6	19	1	US-09-264-466-7	Sequence 7, Appl
c 611	18	0.6	18	1	US-09-128-496-5	Sequence 5, Appl	c 684	17.4	0.6	19	1	US-09-091-952A-86	Sequence 86, Appl
c 612	18	0.6	18	1	US-08-894-899-81	Sequence 81, Appl	c 685	17.4	0.6	19	1	US-08-849-021-89	Sequence 89, Appl
c 613	18	0.6	18	1	US-08-894-899-22	Sequence 22, Appl	c 686	17.4	0.6	20	1	US-09-435-296-72	Sequence 72, Appl
c 614	18	0.6	18	1	US-08-894-899-23	Sequence 23, Appl	c 687	17.4	0.6	20	1	US-09-487-445-94	Sequence 94, Appl
c 615	18	0.6	18	1	US-08-894-899-24	Sequence 24, Appl	c 688	17.4	0.6	20	1	US-09-314-246-1	Sequence 1, Appl
c 616	18	0.6	18	1	US-08-894-899-25	Sequence 25, Appl	c 689	17.4	0.6	21	1	US-09-314-246-2	Sequence 2, Appl
c 617	18	0.6	18	1	US-08-894-899-26	Sequence 26, Appl	c 690	17.4	0.6	21	1		

US-09-396-196G-31948

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2543 GTCTGCATGATGTCCTCCAGGGAAT 2567
|||||
DB 1 GTCTGCATGATGTCCTCCAGGGAAT 25

RESULT 3

US-09-396-196G-31949
; Sequence 31949, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31949
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31949

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2603 GCATTTCACTGGGACCTTGCACTAT 2627
|||||
DB 1 GCATTTCACTGGGACCTTGCACTAT 25

RESULT 4

US-09-396-196G-31950
; Sequence 31950, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31950
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31950

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2639 TTTCTGTCAGTATCAGGTCCTGTC 2663
|||||
DB 1 TTTCTGTCAGTATCAGGTCCTGTC 25

RESULT 5

US-09-396-196G-31951
; Sequence 31951, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31951
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31951

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2651 ATCAGGGTCCTGCAAGCAGTGGGA 2675
|||||
DB 1 ATCAGGGTCCTGCAAGCAGTGGGA 25

RESULT 6

US-09-396-196G-31952
; Sequence 31952, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31952
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31952

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2792 GCAATCATGGTTCACTGCAGTCTTG 2816
|||||
DB 1 GCAATCATGGTTCACTGCAGTCTTG 25

RESULT 7

US-09-396-196G-31953
; Sequence 31953, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack

```
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31953
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
; US-09-396-196G-31953

Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2798 ATGGTTCACAGCTTTGACCTTT 2822
Db 1 ATGGTTCACAGCTTTGACCTTT 25

RESULT 8
US-09-396-196G-31954
; Sequence 31954, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31954
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
; US-09-396-196G-31954

Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2816 GACCTTTTGGGCTCAAGTGATCCTC 2840
Db 1 GACCTTTTGGGCTCAAGTGATCCTC 25

RESULT 9
US-09-396-196G-31955
; Sequence 31955, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
```

```
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31955
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
; US-09-396-196G-31955

Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2852 TCCGTAGTAGCTGGACCATAGGCT 2876
Db 1 TCCGTAGTAGCTGGACCATAGGCT 25

RESULT 10
US-09-396-196G-31956
; Sequence 31956, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31956
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
; US-09-396-196G-31956

Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2864 GGGACCATAGGCTCACACACCACA 2888
Db 1 GGGACCATAGGCTCACACACCACA 25

RESULT 11
US-09-396-196G-31957
; Sequence 31957, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31957
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
; US-09-396-196G-31957

Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2927 GGGTCTCGCAACATTGCCAGACTT 2951
|||||
Db 1 GGGTCTCGCAACATTGCCAGACTT 25

RESULT 12

US-09-396-196G-31958
; Sequence 31958, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 60/100,678
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31958
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31958

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2939 ATTGCCCAGACTTCCTTTGTGTAG 2963
|||||
Db 1 ATTGCCCAGACTTCCTTTGTGTAG 25

RESULT 13

US-09-396-196G-31959
; Sequence 31959, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 60/100,678
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31959
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31959

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2546 TGGACATGAGTCCCGAGGAATATG 2570
|||||
Db 1 TGGACATGAGTCCCGAGGAATATG 25

RESULT 14

US-09-396-196G-31960

; Sequence 31960, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 60/100,678
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31960
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31960

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2564 GAATATGCCCAAGCTATGCCTTGTTC 2588
|||||
Db 1 GAATATGCCCAAGCTATGCCTTGTTC 25

RESULT 15

US-09-396-196G-31961
; Sequence 31961, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 60/100,678
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31961
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31961

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2567 TATGCCCAAGCTATGCCTTGTCTC 2591
|||||
Db 1 TATGCCCAAGCTATGCCTTGTCTC 25

RESULT 16

US-09-396-196G-31962
; Sequence 31962, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1

```
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31962
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31962

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2576 GCTATGCTCTGTCTCTTGTCTGT 2600
Db 1 GCTATGCTCTGTCTCTTGTCTGT 25

RESULT 17
US-09-396-196G-31963
; Sequence 31963, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31963
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31963

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2582 CTTGTCTCTTGTCTCTTGTTCAT 2606
Db 1 CTTGTCTCTTGTCTCTTGTTCAT 25

RESULT 18
US-09-396-196G-31964
; Sequence 31964, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31964
; LENGTH: 25
; TYPE: DNA
```

```
; ORGANISM: Mus musculus
US-09-396-196G-31964

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2588 CTTGTCTCTTGTTCATTTCACT 2612
Db 1 CTTGTCTCTTGTTCATTTCACT 25

RESULT 19
US-09-396-196G-31965
; Sequence 31965, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31965
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31965

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2591 CTTGTCTCTTGTTCATTTCACTGG 2615
Db 1 CTTGTCTCTTGTTCATTTCACTGG 25

RESULT 20
US-09-396-196G-31966
; Sequence 31966, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31966
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31966

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 47;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2594 GTCCTGTTCATTTCACTGGAGC 2618
Db 1 GTCCTGTTCATTTCACTGGAGC 2618
```



```

; STREET: 233 South Wacker Drive, 6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/481,130
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/245,295
; FILING DATE: 18-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: WILLIAMS, JR. JOSEPH A.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 27866/32713
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-474-6300
; TELEFAX: 312-474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; US-08-481-130-22

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCTTAGAGTGGACACGCA 752
DB 1 CCGGGTCTTAGAGTGGACACGCA 24

RESULT 24
US-08-481-130-23/c
; Sequence 23, Application US/08481130
; Patent No. 5702917
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Kilgannon, Patrick D.
; TITLE OF INVENTION: ICAM-4 Materials and Methods
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive, 6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America

```

```

; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/481,130
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/245,295
; FILING DATE: 18-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: WILLIAMS, JR. JOSEPH A.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 27866/32713
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-474-6300
; TELEFAX: 312-474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; US-08-481-130-23

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACGAGCCGAGGACACTGCA 965
DB 24 GAACGAGCCGAGGACACTGCA 1

RESULT 25
US-08-656-984A-22
; Sequence 22, Application US/08656984A
; Patent No. 5753502
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Kilgannon, Patrick D.
; TITLE OF INVENTION: ICAM-4 Materials and Methods
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive, 6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible

```

OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/656,984A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/245,295
; FILING DATE: 18-MAY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/485,604
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: WILLIAMS, JR. JOSEPH A.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 27866/33321
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-474-6300
; TELEFAX: 312-474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-656-984A-22

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 729 CCGGTCCTAGAGTGGACGCA 752
|||
Db 1 CCGGTCCTAGAGTGGACGCA 24

RESULT 26
US-08-656-984A-23/c
; Sequence 23, Application US/08656984A
; Patent No. 5753502
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Kilgannon, Patrick D.
; TITLE OF INVENTION: ICAM-4 Materials and Methods
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive, 6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/656,984A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/245,295
; FILING DATE: 18-MAY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/485,604
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: WILLIAMS, JR. JOSEPH A.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 27866/33321
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-474-6300
; TELEFAX: 312-474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-656-984A-23

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 942 GAACGAGCCGAGACACTGCA 965
|||
Db 24 GAACGAGCCGAGACACTGCA 1

RESULT 27
US-08-482-882-23
; Sequence 23, Application US/08482882
; Patent No. 5773218
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25

;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/482,882
;; FILING DATE: 07-JUN-1995
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/286,754
;; FILING DATE:
;; APPLICATION NUMBER: US 08/102,852
;; FILING DATE: 05-AUG-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/009,266
;; FILING DATE: 22-JAN-1993
;; APPLICATION NUMBER: US 07/894,061
;; FILING DATE: 05-JUN-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/889,724
;; FILING DATE: 26-MAY-1992
;; APPLICATION NUMBER: US 07/827,689
;; FILING DATE: 27-JAN-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: No. 5773218and, Greta E.
;; REGISTRATION NUMBER: 35,302
;; REFERENCE/DOCKET NUMBER: 32178
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (312) 474-6300
;; TELEFAX: (312) 474-0448
;; TELEX: 25-3856
;; INFORMATION FOR SEQ ID NO: 23:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 24 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
US-08-482-882-23

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 729 CCGGTCTCTAGAGTGGACACGCA 752
Db 1 CCGGTCTCTAGAGTGGACACGCA 24

RESULT 28
US-08-482-882-24/c
; Sequence 24, Application US/08482882
; Patent No. 5773218
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/482,882
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

;; APPLICATION NUMBER: US 08/286,754
;; FILING DATE:
;; APPLICATION NUMBER: US 08/102,852
;; FILING DATE: 05-AUG-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/009,266
;; FILING DATE: 22-JAN-1993
;; APPLICATION NUMBER: US 07/894,061
;; FILING DATE: 05-JUN-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/889,724
;; FILING DATE: 26-MAY-1992
;; APPLICATION NUMBER: US 07/827,689
;; FILING DATE: 27-JAN-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: No. 5773218and, Greta E.
;; REGISTRATION NUMBER: 35,302
;; REFERENCE/DOCKET NUMBER: 32178
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (312) 474-6300
;; TELEFAX: (312) 474-0448
;; TELEX: 25-3856
;; INFORMATION FOR SEQ ID NO: 24:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 24 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
US-08-482-882-24

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 942 GAACGAGCCAGGACACTGCA 965
Db 24 GAACGAGCCAGGACACTGCA 1

RESULT 29
US-08-485-604-22
; Sequence 22, Application US/08485604
; Patent No. 5773293
; GENERAL INFORMATION:
; APPLICANT: Wp, W. Michael
; APPLICANT: Kilgannon, Patrick D.
; TITLE OF INVENTION: ICAM-4 Materials and Methods
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive, 6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,604
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/894,061
;; FILING DATE: 05-JUN-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/009,266
;; FILING DATE: 22-JAN-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/102,852
;; FILING DATE: 05-AUG-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/245,295
;; FILING DATE: 18-MAY-1994
;; ATTORNEY/AGENT INFORMATION:
;; NAME: WILLIAMS, JR. JOSEPH A.
;; REGISTRATION NUMBER: 38,659
;; REFERENCE/DOCKET NUMBER: 27866/32715
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 312-474-6300
;; TELEFAX: 312-474-0448
;; TELEX: 25-3856
;; INFORMATION FOR SEQ ID NO: 22:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 24 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: cDNA
US-08-485-604-22

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGTCCTAGAGTGACACGCA 752
Db 1 CCGGTCCTAGAGTGACACGCA 24

RESULT 30
US-08-485-604-23/c
; Sequence 23, Application US/08485604
; Patent No. 5773293
; GENERAL INFORMATION:
; APPLICANT: WF, W. Michael
; TITLE OF INVENTION: ICAM-4 Materials and Methods
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive, 6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,604
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:

;; APPLICATION NUMBER: US 08/009,266
;; FILING DATE: 22-JAN-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/102,852
;; FILING DATE: 05-AUG-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/245,295
;; FILING DATE: 18-MAY-1994
;; ATTORNEY/AGENT INFORMATION:
;; NAME: WILLIAMS, JR. JOSEPH A.
;; REGISTRATION NUMBER: 38,659
;; REFERENCE/DOCKET NUMBER: 27866/32715
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 312-474-6300
;; TELEFAX: 312-474-0448
;; TELEX: 25-3856
;; INFORMATION FOR SEQ ID NO: 23:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 24 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: cDNA
US-08-485-604-23

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACGAGCCGAGGACACTGCA 965
Db 24 GAACGAGCCGAGGACACTGCA 1

RESULT 31
US-08-483-389-23
; Sequence 23, Application US/08483389
; Patent No. 5811517
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; TITLE OF INVENTION: ICAM-RELATED PROTEIN
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive/6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,389
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689

```
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Suh, Young J.
; REGISTRATION NUMBER: P-41,337
; REFERENCE/DOCKET NUMBER: 27866/32760
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: (312) 474-6600
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-483-389-23

Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 729 CCGGTCCTCAGAGTGGACACGCA 752
Db 1 CCGGTCCTCAGAGTGGACACGCA 24

RESULT 32
US-08-483-389-24/c
; Sequence 24, Application US/08483389
; Patent No. 5811517
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-RELATED PROTEIN
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive/6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,389
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Suh, Young J.
; REGISTRATION NUMBER: P-41,337
; REFERENCE/DOCKET NUMBER: 27866/32760
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
```

```
; TELEFAX: (312) 474-0448
; TELEX: (312) 474-6600
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-483-389-24

Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 942 GAACGAGCCAGGAGACACTGCA 965
Db 24 GAACGAGCCAGGAGACACTGCA 1

RESULT 33
US-08-443-965B-3
; Sequence 3, Application US/08443965B
; Patent No. 5821341
; GENERAL INFORMATION:
; APPLICANT: McClelland, Alan
; APPLICANT: Greve, Jeffrey M.
; TITLE OF INVENTION: Soluble Molecule Related to but
; TITLE OF INVENTION: Distinct from ICAM-1
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bayer Corporation
; STREET: 400 Morgan Lane
; CITY: West Haven
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06516
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" diskette, 1.44 MB storage
; COMPUTER: IBM ThinkPad 760ED
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/443,965B
; FILING DATE: 18-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/425,989
; FILING DATE: 20-APR-1995
; APPLICATION NUMBER: 08/156,653
; FILING DATE: 22-NOV-1993
; APPLICATION NUMBER: 08/005,204
; FILING DATE: 15-JAN-1993
; APPLICATION NUMBER: 07/449,356
; FILING DATE: 21-DEC-1989
; APPLICATION NUMBER: 07/445,951
; FILING DATE: 13-DEC-1989
; APPLICATION NUMBER: 07/301,192
; FILING DATE: 24-JAN-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Barbara A. Shimei
; REGISTRATION NUMBER: 29,862
; REFERENCE/DOCKET NUMBER: MTI 209.2C3D2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203) 812-2786
; TELEFAX: (203) 812-5492
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
```

```

; ANTI-SENSE: no
; FEATURE:
; NAME/KEY: PCR 5.4 (5' PCR primer)
; LOCATION: nucleotides 1351 to 1374 of sICAM
US-08-443-965B-3

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels

QY 1408 CTTGAGGGCACCTACCTCTGTCGG 1431
DB 1 CTTGAGGGCACCTACCTCTGTCGG 24

RESULT 34
US-08-443-965B-4/c
; Sequence 4, Application US/08443965B
; Patent No. 5821341
; GENERAL INFORMATION:
; APPLICANT: McClelland, Alan
; APPLICANT: Greve, Jeffrey M.
; TITLE OF INVENTION: Soluble Molecule Related to but
; TITLE OF INVENTION: Distinct from ICAM-1
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bayer Corporation
; STREET: 400 Morgan Lane
; CITY: West Haven
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06516
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" diskette, 1.44 MB storage
; COMPUTER: IBM ThinkPad 760ED
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/443,965B
; FILING DATE: 18-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/425,989
; FILING DATE: 20-APR-1995
; APPLICATION NUMBER: 08/156,653
; FILING DATE: 22-NOV-1993
; APPLICATION NUMBER: 08/005,204
; FILING DATE: 15-JAN-1993
; APPLICATION NUMBER: 07/449,356
; FILING DATE: 21-DEC-1989
; APPLICATION NUMBER: 07/445,951
; FILING DATE: 13-DEC-1989
; APPLICATION NUMBER: 07/301,192
; FILING DATE: 24-JAN-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Barbara A. Shime1
; REGISTRATION NUMBER: 29,862
; REFERENCE/DOCKET NUMBER: MTI 209.2C3D2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203) 812-2786
; TELEFAX: (203) 812-5492
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: yes
; FEATURE:
; NAME/KEY: 3' PCR primer
; LOCATION: complementary to nucleotides 1432 -
; LOCATION: 1455 of sICAM

```

```

US-08-443-965B--4
Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels

Qy 1489 CGGTATGAGATTGTCATCATCACT 1512
Db 24 CGGTATGAGATTGTCATCATCACT 1

RESULT 35
US-08-487-113D-23
; Sequence 23, Application US/08487113D
; Patent No. 5837822
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/487,113D
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5837822and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32744
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-487-113D-23
Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;

```

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 729 CCGGTCCTAGAGTGGACACGCA 752
Db 1 CCGGTCCTAGAGTGGACACGCA 24

RESULT 36

US-08-487-113D-24/c
; Sequence 24, Application US/08487113D
; Patent No. 5837822
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/487,113D
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5837822and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32744
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-487-113D-24

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 942 GAACGAGCCAGGACACTGCA 965

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 24 GAACGAGCCAGGACACTGCA 1

RESULT 37

US-08-425-989B-3
; Sequence 3, Application US/08425989B
; Patent No. 5849699
; GENERAL INFORMATION:
; APPLICANT: McClelland, Alan
; APPLICANT: Greve, Jeffrey M.
; TITLE OF INVENTION: Soluble Molecule Related to but
; TITLE OF INVENTION: Distinct from ICAM-1
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bayer Corporation
; STREET: 400 Morgan Lane
; CITY: West Haven
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06516
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" diskette, 1.44 MB storage
; COMPUTER: IBM ThinkPad 760ED
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/425,989B
; FILING DATE: 20-APR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/156,653
; FILING DATE: 22-NOV-1993
; APPLICATION NUMBER: 08/005,204
; FILING DATE: 15-JAN-1993
; APPLICATION NUMBER: 07/449,356
; FILING DATE: 21-DEC-1989
; APPLICATION NUMBER: 07/445,951
; FILING DATE: 13-DEC-1989
; APPLICATION NUMBER: 07/301,192
; FILING DATE: 24-JAN-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Barbara A. Shimei
; REGISTRATION NUMBER: 29,862
; REFERENCE/DOCKET NUMBER: MTI 209.2C3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203) 812-2786
; TELEFAX: (203) 812-5492
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: no
; FEATURE:
; NAME/KEY: PCR 5.4 (5' PCR primer)
; LOCATION: nucleotides 1351 to 1374 of sICAM
US-08-425-989B-3

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1408 CTTGAGGGCACCTACTCTGTCGG 1431

Db 1 CTTGAGGGCACCTACTCTGTCGG 24

RESULT 38

US-08-425-989B-4/c
; Sequence 4, Application US/08425989B
; Patent No. 5849699

GENERAL INFORMATION:
APPLICANT: McClelland, Alan
APPLICANT: Greve, Jeffrey M.
TITLE OF INVENTION: Soluble Molecule Related to but
TITLE OF INVENTION: Distinct from ICAM-1
NUMBER OF SEQUENCES: 13
CORRESPONDENCE ADDRESS:
ADDRESSEE: Bayer Corporation
STREET: 400 Morgan Lane
CITY: West Haven
STATE: Connecticut
COUNTRY: USA
ZIP: 06516

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" diskette, 1.44 MB storage
COMPUTER: IBM ThinkPad 760ED
OPERATING SYSTEM: Windows 95
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/425,989B
FILING DATE: 20-APR-1995

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/156,653
FILING DATE: 22-NOV-1993
APPLICATION NUMBER: 08/005,204
FILING DATE: 15-JAN-1993
APPLICATION NUMBER: 07/449,356
FILING DATE: 21-DEC-1989
APPLICATION NUMBER: 07/445,951
FILING DATE: 13-DEC-1989
APPLICATION NUMBER: 07/301,192
FILING DATE: 24-JAN-1989

ATTORNEY/AGENT INFORMATION:
NAME: Barbara A. Shinei
REGISTRATION NUMBER: 29,862
REFERENCE/DOCKET NUMBER: MTI 209.2C3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (203) 812-2786
TELEFAX: (203) 812-5492
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 bases
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
HYPOTHETICAL: no
ANTI-SENSE: yes
FEATURE:

NAME/KEY: 3' PCR primer
LOCATION: complementary to nucleotides 1432 -
LOCATION: 1455 of sICAM

US-08-425-989B-4
Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
NAME/KEY: 3' PCR primer
LOCATION: complementary to nucleotides 1432 -
LOCATION: 1455 of sICAM

US-08-425-989B-4
Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1489 CGGTATGAGATTGTCATCATCACT 1512
DB 24 CGGTATGAGATTGTCATCATCACT 1

RESULT 39
US-08-487-595-22
Sequence 22, Application US/08487595
Patent No. 5852170
GENERAL INFORMATION:
APPLICANT: Gallatin, W. Michael
APPLICANT: Kilgannon, Patrick D.
TITLE OF INVENTION: ICAM-4 Materials and Methods
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:

ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 233 South Wacker Drive, 6300 Sears Tower
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/487,595
FILING DATE:

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,689
FILING DATE: 27-JAN-1992

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/889,724
FILING DATE: 26-MAY-1992

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/894,061
FILING DATE: 05-JUN-1992

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/009,266
FILING DATE: 22-JAN-1993

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/102,852
FILING DATE: 05-AUG-1993

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/245,295
FILING DATE: 18-MAY-1994

ATTORNEY/AGENT INFORMATION:
NAME: WILLIAMS, JR. JOSEPH A.
REGISTRATION NUMBER: 38,659
REFERENCE/DOCKET NUMBER: 27866/32714
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312-474-6300
TELEFAX: 312-474-0448
TELEX: 25-3856

INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-487-595-22

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCTCTAGAGGTGGACACGCA 752
DB 1 CCGGGTCTCTAGAGGTGGACACGCA 24

RESULT 40
US-08-487-595-23/c
Sequence 23, Application US/08487595
Patent No. 5852170
GENERAL INFORMATION:
APPLICANT: Gallatin, W. Michael
APPLICANT: Kilgannon, Patrick D.
TITLE OF INVENTION: ICAM-4 Materials and Methods
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 233 South Wacker Drive, 6300 Sears Tower
CITY: Chicago
STATE: Illinois

; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/487,595
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/245,295
; FILING DATE: 18-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: WILLIAMS, JR. JOSEPH A.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 27866/32714
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-474-6300
; TELEFAX: 312-474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-487-595-23

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 942 GAACCAAGCCAGGACACTGCA 965
Db 24 GAACCAAGCCAGGACACTGCA 1

RESULT 41
US-08-443-966B-3
; Sequence 3, Application US/08443966B
; Patent No. 5859212
; GENERAL INFORMATION:
; APPLICANT: McClelland, Alan
; APPLICANT: Greve, Jeffrey M.
; TITLE OF INVENTION: Soluble Molecule Related to but
; TITLE OF INVENTION: Distinct from ICAM-1
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bayer Corporation
; STREET: 400 Morgan Lane
; CITY: West Haven
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06516
; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" diskette, 1.44 MB storage
; COMPUTER: IBM ThinkPad 760ED
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/443,966B
; FILING DATE: 18-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/425,989
; FILING DATE: 20-APR-1995
; APPLICATION NUMBER: 08/156,653
; FILING DATE: 22-NOV-1993
; APPLICATION NUMBER: 08/005,204
; FILING DATE: 15-JAN-1993
; APPLICATION NUMBER: 07/449,356
; FILING DATE: 21-DEC-1989
; APPLICATION NUMBER: 07/445,951
; FILING DATE: 13-DEC-1989
; APPLICATION NUMBER: 07/301,192
; FILING DATE: 24-JAN-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Barbara A. Shime1
; REGISTRATION NUMBER: 29,862
; REFERENCE/DOCKET NUMBER: MTI 209.2C3D1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203) 812-2786
; TELEFAX: (203) 812-5492
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: no
; FEATURE:
; NAME/KEY: PCR 5.4 (5' PCR primer)
; LOCATION: nucleotides 1351 to 1374 of sICAM
; US-08-443-966B-3

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1408 CTTGAGGCGACCTACTCTGCGG 1431
Db 1 CTTGAGGCGACCTACTCTGCGG 24

RESULT 42
US-08-443-966B-4/c
; Sequence 4, Application US/08443966B
; Patent No. 5859212
; GENERAL INFORMATION:
; APPLICANT: McClelland, Alan
; APPLICANT: Greve, Jeffrey M.
; TITLE OF INVENTION: Soluble Molecule Related to but
; TITLE OF INVENTION: Distinct from ICAM-1
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bayer Corporation
; STREET: 400 Morgan Lane
; CITY: West Haven
; STATE: Connecticut
; COUNTRY: USA
; ZIP: 06516
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" diskette, 1.44 MB storage
; COMPUTER: IBM ThinkPad 760ED
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:

```

; APPLICATION NUMBER: US/08/443,966B
; FILING DATE: 18-MAY-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/425,989
; FILING DATE: 20-APR-1995
; APPLICATION NUMBER: 08/156,653
; FILING DATE: 22-NOV-1993
; APPLICATION NUMBER: 08/005,204
; FILING DATE: 15-JAN-1993
; APPLICATION NUMBER: 07/449,356
; FILING DATE: 21-DEC-1989
; APPLICATION NUMBER: 07/445,951
; FILING DATE: 13-DEC-1989
; APPLICATION NUMBER: 07/301,192
; FILING DATE: 24-JAN-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Barbara A. Shimek
; REGISTRATION NUMBER: 29,862
; REFERENCE/DOCKET NUMBER: MTI 209.2C3D1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (203) 812-2786
; TELEFAX: (203) 812-5492
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: yes
; FEATURE:
; NAME/KEY: 3' PCR primer
; LOCATION: complementary to nucleotides 1432 -
; LOCATION: 1455 of sICAM
US-08-443-966B-4

```

```

Query Match          0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1489 CGGTATGAGATGTCTATCATCTACT 1512
DB 24 CGGTATGAGATGTCTATCATCTACT 1

```

```

RESULT 43
US-08-473-503-23
; Sequence 23, Application US/08473503
; Patent No. 5869262
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/473,503
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754

```

```

; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5869262and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-473-503-23

```

```

Query Match          0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 729 CCGGGTCTAGAGGTGGACACGCA 752
DB 1 CCGGGTCTAGAGGTGGACACGCA 24

```

```

RESULT 44
US-08-473-503-24/c
; Sequence 24, Application US/08473503
; Patent No. 5869262
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/473,503
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266

```


; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 586262and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-473-503-24

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 942 GAACAGAGCCAGGAGACACTGCA 965
Db 24 GAACAGAGCCAGGAGACACTGCA 1

RESULT 45
US-08-483-932-23
; Sequence 23, Application US/08483932
; Patent No. 5880268
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,932
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5880268and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-483-932-23

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 729 CCGGTCCTAGAGGTGGACACGCA 752
Db 1 CCGGTCCTAGAGGTGGACACGCA 24

RESULT 46
US-08-483-932-24/c
; Sequence 24, Application US/08483932
; Patent No. 5880268
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,932
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992

ATTORNEY/AGENT INFORMATION:
NAME: No. 5880268and, Greta E.
REGISTRATION NUMBER: 35,302
REFERENCE/DOCKET NUMBER: 32178
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-483-932-24

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACACAGCCAGGAGACTGCA 965
|||||
DB 24 GAACACAGCCAGGAGACTGCA 1

RESULT 47
US-08-720-420A-23
Sequence 23, Application US/08720420A
Patent No. 5989843
GENERAL INFORMATION:
APPLICANT: Gallatin, W. Michael
APPLICANT: Vazeux, Rosemay
TITLE OF INVENTION: ICAM-Related Materials and Methods
NUMBER OF SEQUENCES: 120
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION NUMBER: US/08/720,420A
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/487,113
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/286,754
FILING DATE: 05-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/102,852
FILING DATE: 05-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/009,266
FILING DATE: 22-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/894,061
FILING DATE: 05-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/889,724
FILING DATE: 26-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,689
FILING DATE: 27-JAN-1992
ATTORNEY/AGENT INFORMATION:

NAME: Williams, Joseph A., Jr.
REGISTRATION NUMBER: 38,659
REFERENCE/DOCKET NUMBER: 33282
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-720-420A-23

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGTCCTAGAGTGGACACGCA 752
|||||
DB 1 CCGGTCCTAGAGTGGACACGCA 24

RESULT 48
US-08-720-420A-24/c
Sequence 24, Application US/08720420A
Patent No. 5989843
GENERAL INFORMATION:
APPLICANT: Gallatin, W. Michael
APPLICANT: Vazeux, Rosemay
TITLE OF INVENTION: ICAM-Related Materials and Methods
NUMBER OF SEQUENCES: 120
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION NUMBER: US/08/720,420A
FILING DATE:
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/487,113
FILING DATE: 07-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/286,754
FILING DATE: 05-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/102,852
FILING DATE: 05-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/009,266
FILING DATE: 22-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/894,061
FILING DATE: 05-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/889,724
FILING DATE: 26-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,689
FILING DATE: 27-JAN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Joseph A., Jr.

```
;
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 33282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-720-420A-24

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 942 GAACGAGCCGAGGAGACTGCA 965
Db 24 GAACGAGCCGAGGAGACTGCA 1

RESULT 49
US-08-859-998-527
; Sequence 527, Application US/08859998
; Patent No. 5994076
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; APPLICANT: Jokhadze, George
; APPLICANT: Bibilashvili, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: Fast-Seq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 527:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; US-08-859-998-527

Query Match 0.8%; Score 24; DB 1; Length 24;
```

```
;
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 33282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-720-420A-24

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1220 GGGAGCTTCGTGCTCTGTATGGCC 1243
Db 1 GGGAGCTTCGTGCTCTGTATGGCC 24

RESULT 50
US-08-714-017-23
; Sequence 23, Application US/08714017
; Patent No. 6040176
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/714,017
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6040176and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-714-017-23

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 729 CCGGCTCTAGAGTGGACACGCA 752
```

Db 1 CCGGGTCCTAGAGTGGACACGCA 24

RESULT 51
US-08-714-017-24/c
; Sequence 24, Application US/08714017
; Patent No. 6040176
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/714,017
; FILING DATE: 05-AUG-1993
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION DATA:
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6040176and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-714-017-24

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 942 GAACGAGCCGAGGAGCACTGCA 965
|||||
Db 24 GAACGAGCCGAGGAGCACTGCA 1

RESULT 52
US-08-475-680-23

; Sequence 23, Application US/08475680
; Patent No. 6100383
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/475,680
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION DATA:
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6100383and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-475-680-23

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 729 CCGGGTCCTAGAGTGGACACGCA 752
|||||
Db 1 CCGGGTCCTAGAGTGGACACGCA 24

RESULT 53
US-08-475-680-24/c
; Sequence 24, Application US/08475680
; Patent No. 6100383
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay

```

; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/475,680
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6100383and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-475-680-24

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 942 GAACGAGCCGAGACACTGCA 965
Db 24 GAACGAGCCGAGACACTGCA 1

RESULT 54
US-09-225-928-527
; Sequence 527, Application US/09225928
; Patent No. 6352829
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,201B
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>

```

```

; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,928
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
; INFORMATION FOR SEQ ID NO: 527:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 527:
US-09-225-928-527

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 63;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1220 GGGAGCTTCGTGCTCTGTATGGCC 1243
Db 1 GGGAGCTTCGTGCTCTGTATGGCC 24

RESULT 55
US-09-225-201B-527
; Sequence 527, Application US/09225201B
; Patent No. 6489455
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,201B
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>

```


; SEQUENCE CHARACTERISTICS:

; LENGTH: 21

; TYPE: Nucleic Acid

; STRANDEDNESS: Single

; TOPOLOGY: Linear

; ANTI-SENSE: Yes

US-08-043-167A-3

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2176 ACCAGCTATTATTGAGTGTC 2196

Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 59

US-08-136-118-6/c

; Sequence 6, Application US/08136118

; Patent No. 5580969

; GENERAL INFORMATION:

; APPLICANT: HOKE, Glenn D

; APPLICANT: BRADLEY, Matthews O

; APPLICANT: WILLIAMS, Taffy J

; APPLICANT: LEE, Che-Hung

; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES DIRECTED

; TITLE OF INVENTION: AGAINST HUMAN ICAM-1

; NUMBER OF SEQUENCES: 15

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Naval Medical Res. & Dev. Cmd.

; STREET: 8901 Wisconsin Ave.

; CITY: Bethesda

; STATE: Maryland

; COUNTRY: USA

; ZIP: 20889-5606

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/136,118

; FILING DATE:

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 07/918,259

; FILING DATE: 24-JUL-1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Spevack, A. David

; REGISTRATION NUMBER: 24,743

; REFERENCE/DOCKET NUMBER: N.C. 75,776

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 295-6759

; TELEFAX: (202) 295-1022

; INFORMATION FOR SEQ ID NO: 6:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 21 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; HYPOTHETICAL: NO

; ANTI-SENSE: YES

US-08-136-118-6

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 18 GAGCTCCTCTGCTACTACAG 38

Db 21 GAGCTCCTCTGCTACTACAG 1

RESULT 60

US-08-136-118-8/c

; Sequence 8, Application US/08136118

; Patent No. 5580969

; GENERAL INFORMATION:

; APPLICANT: HOKE, Glenn D

; APPLICANT: BRADLEY, Matthews O

; APPLICANT: WILLIAMS, Taffy J

; APPLICANT: LEE, Che-Hung

; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES DIRECTED

; TITLE OF INVENTION: AGAINST HUMAN ICAM-1

; NUMBER OF SEQUENCES: 15

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Naval Medical Res. & Dev. Cmd.

; STREET: 8901 Wisconsin Ave.

; CITY: Bethesda

; STATE: Maryland

; COUNTRY: USA

; ZIP: 20889-5606

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/136,118

; FILING DATE:

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 07/918,259

; FILING DATE: 24-JUL-1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Spevack, A. David

; REGISTRATION NUMBER: 24,743

; REFERENCE/DOCKET NUMBER: N.C. 75,776

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (202) 295-6759

; TELEFAX: (202) 295-1022

; INFORMATION FOR SEQ ID NO: 8:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 21 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; HYPOTHETICAL: NO

; ANTI-SENSE: YES

US-08-136-118-8

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2053 CCCTCCATAGACATGTGTAGC 2073

Db 21 CCCTCCATAGACATGTGTAGC 1

RESULT 61

US-08-136-118-9/c

; Sequence 9, Application US/08136118

; Patent No. 5580969

; GENERAL INFORMATION:

; APPLICANT: HOKE, Glenn D

; APPLICANT: BRADLEY, Matthews O

; APPLICANT: WILLIAMS, Taffy J

; APPLICANT: LEE, Che-Hung

; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES DIRECTED

; TITLE OF INVENTION: AGAINST HUMAN ICAM-1

; NUMBER OF SEQUENCES: 15

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Naval Medical Res. & Dev. Cmd.

; STREET: 8901 Wisconsin Ave.

```

; CITY: Bethesda
; STATE: Maryland
; COUNTRY: USA
; ZIP: 20889-5606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/136,118
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/918,259
; FILING DATE: 24-JUL-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Spevack, A. David
; REGISTRATION NUMBER: 24,743
; REFERENCE/DOCKET NUMBER: N.C. 75,776
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 295-6759
; TELEFAX: (202) 295-1022
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-08-136-118-9

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2494 CCACCCACATACATTTCTGCC 2514
Db 21 CCACCCACATACATTTCTGCC 1

RESULT 62
US-08-136-118-10/c
; Sequence 10, Application US/08136118
; Patent No. 5580969
; GENERAL INFORMATION:
; APPLICANT: HOKE, Glenn D
; APPLICANT: BRADLEY, Matthews O
; APPLICANT: WILLIAMS, Taffy J
; APPLICANT: LEE, Che-Hung
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES DIRECTED
; AGAINST HUMAN ICAM-1
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Naval Medical Res. & Dev. Cmd.
; STREET: 8901 Wisconsin Ave.
; CITY: Bethesda
; STATE: Maryland
; COUNTRY: USA
; ZIP: 20889-5606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/136,118
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/918,259
; FILING DATE: 24-JUL-1992

```

```

; ATTORNEY/AGENT INFORMATION:
; NAME: Spevack, A. David
; REGISTRATION NUMBER: 24,743
; REFERENCE/DOCKET NUMBER: N.C. 75,776
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 295-6759
; TELEFAX: (202) 295-1022
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-08-136-118-10

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
Db 21 TGTGTGTGTGTGTGTGTGTGT 1

RESULT 63
US-08-136-118-11/c
; Sequence 11, Application US/08136118
; Patent No. 5580969
; GENERAL INFORMATION:
; APPLICANT: HOKE, Glenn D
; APPLICANT: BRADLEY, Matthews O
; APPLICANT: WILLIAMS, Taffy J
; APPLICANT: LEE, Che-Hung
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES DIRECTED
; AGAINST HUMAN ICAM-1
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Naval Medical Res. & Dev. Cmd.
; STREET: 8901 Wisconsin Ave.
; CITY: Bethesda
; STATE: Maryland
; COUNTRY: USA
; ZIP: 20889-5606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/136,118
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/918,259
; FILING DATE: 24-JUL-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Spevack, A. David
; REGISTRATION NUMBER: 24,743
; REFERENCE/DOCKET NUMBER: N.C. 75,776
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 295-6759
; TELEFAX: (202) 295-1022
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-08-136-118-11

```



```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 43 AACCTCAGCCTCGTATGGCT 63
Db 21 AACCTCAGCCTCGTATGGCT 1

RESULT 64
US-08-007-997A-3/c
; Sequence 3, Application US/08007997A
; Patent No. 5591623
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: Of Cell Adhesion
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 5591623ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/007,997A
; FILING DATE: 19930121
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0709
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-007-997A-3
```

```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2176 ACCAGCTATTTATTCAGTGTC 2196
Db 21 ACCAGCTATTTATTCAGTGTC 1

RESULT 65
US-08-327-363-4/c
; Sequence 4, Application US/08327363
```

```
; Patent No. 5643780
; GENERAL INFORMATION:
; APPLICANT: ISIS Pharmaceuticals and
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Compositions and Methods for Modulating
; TITLE OF INVENTION: RNA Activity Through Modification of the 5' Cap Structure of
; TITLE OF INVENTION: RNA
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5643780ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/327,363
; FILING DATE: herewith
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 847,054
; FILING DATE: April 3, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathryn Leary, Ph.D.
; REGISTRATION NUMBER: 36,317
; REFERENCE/DOCKET NUMBER: ISIS-1719
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: unknown
US-08-327-363-4

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 17 TGAGCTCCTCTGCTACTCAGA 37
Db 21 TGAGCTCCTCTGCTACTCAGA 1

RESULT 66
US-08-440-740A-3/c
; Sequence 3, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
```

```

; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-440-740A-3

```

```

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

OY      2176 ACCAGCTATTATTGAGTGTC 2196
      |||||
Db      21 ACCAGCTATTATTGAGTGTC 1

```

```

RESULT 67
US-08-808-474A-17/c
; Sequence 17, Application US/08808474A
; Patent No. 5856103
; GENERAL INFORMATION:
; APPLICANT: Gray, Donald M.
; APPLICANT: Clark, Chris L.
; TITLE OF INVENTION: METHOD FOR SELECTIVELY RANKING SEQUENCES
; TITLE OF INVENTION: FOR ANTISENSE TARGETING
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Locke Putnell Rain Harrell
; STREET: 2200 Ross Avenue, Suite 2200
; CITY: Dallas
; STATE: Texas
; COUNTRY: USA
; ZIP: 75201-6776
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/808,474A
; FILING DATE: 03-MAR-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Mayfield, Denise L.
; REGISTRATION NUMBER: 33,732
; REFERENCE/DOCKET NUMBER: UTDAL:001
; TELECOMMUNICATION INFORMATION:

```

```

; TELEPHONE: (214) 740-8000
; TELEFAX: (214) 740-8800
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-808-474A-17

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      2176 ACCAGCTATTATTGAGTGTC 2196
      |||||
Db      21 ACCAGCTATTATTGAGTGTC 1

RESULT 68
US-08-344-155C-3/c
; Sequence 3, Application US/08344155C
; Patent No. 5883082
; GENERAL INFORMATION:
; APPLICANT: Bennett and Stepkowski
; TITLE OF INVENTION: Compositions and Methods for Preventing
; TITLE OF INVENTION: and Treating Allograft Rejection
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,155C
; FILING DATE: No. 5883082ember 23, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/063,167
; FILING DATE: 5/17/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/007,997
; FILING DATE: 1/21/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/939,855
; FILING DATE: 9/2/92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/567,286
; FILING DATE: 8/14/90
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0098
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21
; TYPE: Nucleic Acid

```

STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-344-155C-3

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2176 ACCAGCTATTATTGAGTGTC 2196
|||||
Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 69

US-08-982-845B-3/c
; Sequence 3, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053

COMPUTER READABLE FORM:

MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: Windows 95
SOFTWARE: WORDPERFECT 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/982.845B
FILING DATE: December 2, 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/440.740
FILING DATE: May 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 063.167
FILING DATE: May 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 969.151
FILING DATE: February 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 007.997
FILING DATE: January 21, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939.855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567.286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0243
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 21
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes

US-08-982-845B-3

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2176 ACCAGCTATTATTGAGTGTC 2196
|||||
Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 70

US-08-991-525B-3/c
; Sequence 3, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053

COMPUTER READABLE FORM:

MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: Windows 95
SOFTWARE: WORDPERFECT 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/991.525B
FILING DATE: December 16, 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 440.740
FILING DATE: May 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 063.167
FILING DATE: May 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 969.151
FILING DATE: February 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 007.997
FILING DATE: January 21, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939.855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567.286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (856) 810-1515
TELEFAX: (856) 810-1454
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 21
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes

US-08-991-525B-3

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2176 ACCAGCTATTATTGAGTGTC 2196

Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 71
US-09-085-759-3/c
; Sequence 3, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-085-759-3

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2176 ACCAGCTATTATTGAGTGTC 2196
Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 72
US-09-128-496-3/c
; Sequence 3, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-128-496-3

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy 2176 ACCAGCTATTATTGAGTGTC 2196
Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 73
US-09-235-614-17/c
; Sequence 17, Application US/09235614
; Patent No. 6183966
; GENERAL INFORMATION:
; APPLICANT: GRAY, DONALD M.
; APPLICANT: CLARK, CHRISTOPHER L.

;; TITLE OF INVENTION: AN APPARATUS AND METHOD FOR SELECTIVELY RANKING
;; TITLE OF INVENTION: SEQUENCES FOR ANTISENSE TARGETING

;; FILE REFERENCE: 91556/66384
;; CURRENT APPLICATION NUMBER: US/09/235,614
;; CURRENT FILING DATE: 1999-01-22
;; PRIOR APPLICATION NUMBER: 08/808,474
;; PRIOR FILING DATE: 1997-03-03
;; PRIOR APPLICATION NUMBER: 08/320,507
;; PRIOR FILING DATE: 1994-10-07
;; NUMBER OF SEQ ID NOS: 38
;; SOFTWARE: PatentIn Ver. 2.1
;; SEQ ID NO 17
;; LENGTH: 21
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: S-ASO
US-09-235-614-17

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2176 ACCAGCTATTATTGAGTGTC 2196
|||||
Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 74
US-09-109-663-37/c
; Sequence 37, Application US/09109663
; Patent No. 6277961
; GENERAL INFORMATION:
; APPLICANT: Tu, Guang-Chou
; APPLICANT: Israel, Yedy
; TITLE OF INVENTION: AN IMPROVED METHOD FOR DESIGN AND SELECTION OF
; TITLE OF INVENTION: EFFICACIOUS ANTISENSE OLIGONUCLEOTIDES
; FILE REFERENCE: 9855-3U1
; CURRENT APPLICATION NUMBER: US/09/109,663
; CURRENT FILING DATE: 1998-07-03
; EARLIER APPLICATION NUMBER: 60/051,705
; EARLIER FILING DATE: 1997-07-03
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 37
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Known
; OTHER INFORMATION: Effective ASO
US-09-109-663-37

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1937 TCAGAGGGGAAGTGGTGGGG 1957
|||||
Db 21 TCAGAGGGGAAGTGGTGGGG 1

RESULT 75
US-09-009-490A-3/c
; Sequence 3, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: Of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata

;; STREET: 66 East Main Street
;; CITY: Marlton
;; STATE: NJ
;; COUNTRY: USA
;; ZIP: 08053
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;; COMPUTER: IBM PS/2
;; OPERATING SYSTEM: Windows 95
;; SOFTWARE: WORDPERFECT 6.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/009,490A
;; FILING DATE: January 20, 1998
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 440,740
;; FILING DATE: May 12, 1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 063,167
;; FILING DATE: May 17, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 20, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0268
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 810-1515
;; TELEFAX: (609) 810-1454
;; INFORMATION FOR SEQ ID NO: 3:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 21
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-09-009-490A-3

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2176 ACCAGCTATTATTGAGTGTC 2196
|||||
Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 76
US-10-029-598-3/c
; Sequence 3, Application US/10029598
; Patent No. 6747014
; GENERAL INFORMATION:
; APPLICANT: Teng, Ching-Leou
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Tillman, Lloyd
; APPLICANT: Hardee, Gregory E.
; APPLICANT: Ecker, David J.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Compositions And Methods For No. 6747014-Parental Delivery Of Oli
; FILE REFERENCE: ISIS4945
; CURRENT APPLICATION NUMBER: US/10/029,598
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 08/082,624

;
; PRIOR FILING DATE: 1998-05-21
; PRIOR APPLICATION NUMBER: 09/315,298
; PRIOR FILING DATE: 1999-05-20
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Sequence
US-10-029-598-3

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 43 AACCTCAGCTCGCTATGGCT 63
Db 21 AACCTCAGCTCGCTATGGCT 1

RESULT 77
US-09-546-596A-18/c
; Sequence 18, Application US/09546596A
; Patent No. 6753423
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Cook, Phillip D.
; Bennett, C. Frank

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
; ENHANCED BIOTABILITY AND ALTERED BIODISTRIBUTION OF
; OLIGONUCLEOTIDES IN MAMMALS

NUMBER OF SEQUENCES: 63
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
and No. 6753423ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/546,596A
FILING DATE: 10-Apr-2000
CLASSIFICATION: <Unknown>

ATTORNEY/AGENT INFORMATION:
NAME: Lucci, Joseph
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2707
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-09-546-596A-18

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2100 TGACGGATGCCAGCTTGGCA 2120

Db 21 TGACGGATGCCAGCTTGGCA 1

RESULT 78

US-09-546-596A-26/c
; Sequence 26, Application US/09546596A
; Patent No. 6753423
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Cook, Phillip D.
; Bennett, C. Frank

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
; ENHANCED BIOTABILITY AND ALTERED BIODISTRIBUTION OF
; OLIGONUCLEOTIDES IN MAMMALS

NUMBER OF SEQUENCES: 63
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
and No. 6753423ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/546,596A
FILING DATE: 10-Apr-2000
CLASSIFICATION: <Unknown>

ATTORNEY/AGENT INFORMATION:
NAME: Lucci, Joseph
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2707
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 26:
US-09-546-596A-26

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2100 TGACGGATGCCAGCTTGGCA 2120
Db 21 TGACGGATGCCAGCTTGGCA 1

RESULT 79

US-08-117-363A-18/c
; Sequence 18, Application US/08117363A
; Patent No. 6783931
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Cook, Phillip D.

; TITLE OF INVENTION: AMINE-DERIVATIZED NUCLEOSIDES AND
; OLIGONUCLEOSIDES
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
and No. 6783931ris
STREET: One Liberty Place - 46th Floor

; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/117,363A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Lucci, Joseph
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-1169
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-117-363A-18

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2100 TGACGGATGCCAGCTTGCGCA 2120
Db 21 TGACGGATGCCAGCTTGCGCA 1

RESULT 80
US-10-083-720A-14/c
; Sequence 14, Application US/10083720A
; Patent No. 6797813
; GENERAL INFORMATION:
; APPLICANT: de Waal Malefyt, Rene
; APPLICANT: Fickenscher, Helmut
; APPLICANT: Fleckenstein, Bernhard
; APPLICANT: Knappe, Andrea
; TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS
; FILE REFERENCE: DX0644KBK
; CURRENT APPLICATION NUMBER: US/10/083,720A
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 09/363,993
; PRIOR FILING DATE: 1999-07-29
; PRIOR APPLICATION NUMBER: 08/934,959
; PRIOR FILING DATE: 1997-09-22
; PRIOR APPLICATION NUMBER: 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: 60/302,176
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: 60/027,368
; PRIOR FILING DATE: 1996-09-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ICAM-reverse.
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(21)
; OTHER INFORMATION: ICAM reverse.

US-10-083-720A-14
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 997 AACGTGATTCTGACGAAGCCA 1017
Db 21 AACGTGATTCTGACGAAGCCA 1

RESULT 81
PCT-US93-08101-3/c
; Sequence 3, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; PCT-US93-08101-3

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2176 ACCAGCTATTATTGAGTGTC 2196
Db 21 ACCAGCTATTATTGAGTGTC 1

RESULT 82

```
US-08-222-177A-146/c
; Sequence 146, Application US/08222177A
; Patent No. 5582979
; GENERAL INFORMATION:
; APPLICANT: Weber, James L.
; TITLE OF INVENTION: LENGTH POLYMORPHISMS IN
; TITLE OF INVENTION: (dc-da)n. (dg-dt)n SEQUENCES AND METHODS OF USING SAME
; NUMBER OF SEQUENCES: 460
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dewitt Ross & Stevens, S.C.
; STREET: 8000 Excelsior Drive, Suite 401
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: USA
; ZIP: 53717-1914
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/222,177A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/341,562
; FILING DATE: 21-APR-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 09865.601
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 831-2100
; TELEFAX: (608) 831-2106
; TELEX:
; INFORMATION FOR SEQ ID NO: 146:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 25 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; IMMEDIATE SOURCE:
; CLONE: mfd32rs
US-08-222-177A-146

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
Db 24 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 83
US-09-657-472-799
; Sequence 799, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolz, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 800
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-800

Query Match 0.7%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 1.7e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 214 GACCAGCCCAAGTTGTTGGGC 234
Db 1 GACCAGCCCAAGTTGTTGGGC 21

RESULT 85
US-08-116-801C-4/c
; Sequence 4, Application US/08116801C
; Patent No. 5578718
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: Thiol-Derivatized Nucleosides
; TITLE OF INVENTION: And Oligonucleosides
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5578718ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
```

```
US-09-657-472-799
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 799
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-799

Query Match 0.7%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 1.7e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1452 GGTCAACCGCGAGGTGACCGT 1472
Db 1 GGTCAACCGCGAGGTGACCGT 21

RESULT 84
US-09-657-472-800
; Sequence 800, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolz, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 800
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-800

Query Match 0.7%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 1.7e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 214 GACCAGCCCAAGTTGTTGGGC 234
Db 1 GACCAGCCCAAGTTGTTGGGC 21

RESULT 85
US-08-116-801C-4/c
; Sequence 4, Application US/08116801C
; Patent No. 5578718
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: Thiol-Derivatized Nucleosides
; TITLE OF INVENTION: And Oligonucleosides
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5578718ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
```



```
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/116,801C
; FILING DATE: September 3, 1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-0784
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 20
; OTHER INFORMATION: /note=
; OTHER INFORMATION: "2'-O-thiol modified-2'-deoxyadenosine"
; US-08-116-801C-4
Query Match 0.7%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 1.7e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 16 CTGAGCTCCTCTGCTACTCAGA 37
Db 22 CTTAGCTCCTCTGCTACTCAGA 1

RESULT 86
US-08-222-177A-125/c
; Sequence 125, Application US/08222177A
; Patent No. 5582979
; GENERAL INFORMATION:
; APPLICANT: Weber, James L.
; TITLE OF INVENTION: LENGTH POLYMORPHISMS IN
; TITLE OF INVENTION: (dC-dA)n (dG-dT)n SEQUENCES AND METHODS OF USING SAME
; NUMBER OF SEQUENCES: 460
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dewitt Ross & Stevens, S.C.
; STREET: 8000 Excelsior Drive, Suite 401
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: USA
; ZIP: 53717-1914
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/222,177A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/341,562
; FILING DATE: 21-APR-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
```

```
; REFERENCE/DOCKET NUMBER: 09865.501
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 831-2100
; TELEFAX: (608) 831-2106
; TELEX:
; INFORMATION FOR SEQ ID NO: 125:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; IMMEDIATE SOURCE:
; CLONE: mfd25rs
; US-08-222-177A-125
Query Match 0.7%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 1.7e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGT 2749
Db 22 GTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 87
US-08-458-396-4/c
; Sequence 4, Application US/08458396
; Patent No. 5852182
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: Thiol-Derivatized Nucleosides
; TITLE OF INVENTION: And Oligonucleosides
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5852182ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/458,396
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-1992
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 20
; OTHER INFORMATION: /note=
; OTHER INFORMATION: "2'-O-thiol modified-2'-deoxyadenosine"
; US-08-458-396-4
```

Query Match 0.7%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 1.7e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 16 CTGAGCTCCTCTGCTACTCAGA 37
Db 22 CTTAGCTCCTCTGCTACTCAGA 1

RESULT 88

US-08-924-326-4/c
; Sequence 4, Application US/08924326
; Patent No. 6114513
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Thiol-Derivatized Nucleosides
; TITLE OF INVENTION: And Oligonucleosides
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/924,326
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/458,396
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-1992
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 20
; OTHER INFORMATION: /note=
; OTHER INFORMATION: "2'-O-thiol modified-2'-deoxyadenosine"
US-08-924-326-4

Query Match 0.7%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 1.7e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 16 CTGAGCTCCTCTGCTACTCAGA 37
Db 22 CTTAGCTCCTCTGCTACTCAGA 1

RESULT 89

US-09-383-856-4/c
; Sequence 4, Application US/09383856
; Patent No. 626558

; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: Thiol-Derivatized Nucleosides
; TITLE OF INVENTION: And Oligonucleosides
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 626558ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT 4.0
; SOFTWARE: WordPerfect 8.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/383,856
; FILING DATE: 26-AUG-99
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/924,326
; FILING DATE: 05-SEP-97
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-4100
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 20
; OTHER INFORMATION: /note=
; OTHER INFORMATION: "2'-O-thiol modified-2'-deoxyadenosine"
US-09-383-856-4

Query Match 0.7%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 1.7e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 16 CTGAGCTCCTCTGCTACTCAGA 37
Db 22 CTTAGCTCCTCTGCTACTCAGA 1

RESULT 90

US-08-222-177A-454/c
; Sequence 454, Application US/08222177A
; Patent No. 5582979
; GENERAL INFORMATION:
; APPLICANT: Weber, James L.
; TITLE OF INVENTION: LENGTH POLYMORPHISMS IN
; TITLE OF INVENTION: (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
; NUMBER OF SEQUENCES: 460
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DeWitt Ross & Stevens, S.C.
; STREET: 8000 Excelsior Drive, Suite 401
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: USA
; ZIP: 53717-1914

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels

Qy	2729	TGTGTGTGTGTGTATGTAGAC	2753
Db	25	TGTGTGTGTGTGTAGTCGAC	1

RESULT 94
US-08-009-263C-25/c
; Sequence 25, Application US/08009263C
; Patent No. 5442049
; GENERAL INFORMATION:
; APPLICANT: Kevin Anderson, Kenneth Draper, Brenda Baker
; TITLE OF INVENTION: Oligonucleotides for Modulating the
; TITLE OF INVENTION: Effects of Cytomegalovirus Infections
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 5442049ris
; STREET: One Liberty Place -- 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA

```
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels
```

Qy 18 GAGTCCTCTGCTACTCAGA 37
|||
Db 20 GAGTCCTCTGCTACTCAGA 1

RESULT 95
US-08-063-167A-2/c
; Sequence 2, Application US/08063167A
; Patent No. 5514788
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation

```

; TITLE OF INVENTION: of Cell Adhesion
;
; NUMBER OF SEQUENCES: 85
;
; CORRESPONDENCE ADDRESS:
;
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
;

```

```
Query Match          0.78; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 7 CAGTCGACGCTGAGCTCCTC 26
|||
Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 96
US-08-063-167A-7/C
; Sequence 7, Application US/08063167A
; Patent No. 5514788
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB
; STORING

REFERENCE/DOCKET NUMBER: ISPH-0002
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-063-167A-9

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTGCTCGGGCTCT 116
DB 20 CTGGTCTGCTCGGGCTCT 1

RESULT 99
US-08-063-167A-10/c

Sequence 10, Application US/08063167A
Patent No. 5514788
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
TITLE OF INVENTION: of Cell Adhesion
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/063,167A
FILING DATE: 19930517
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0002
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes

US-08-063-167A-10

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAACTGCCTGATGGCA 356
DB 20 TCAACTGCCTGATGGCA 1

RESULT 100

US-08-063-167A-11/c
Sequence 11, Application US/08063167A
Patent No. 5514788
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
TITLE OF INVENTION: of Cell Adhesion
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/063,167A
FILING DATE: 19930517
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0002
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes

US-08-063-167A-11

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCTCAGTCAGTGACC 894
DB 20 AGGCTCAGTCAGTGACC 1

```
RESULT 101
US-08-063-167A-12/c
; Sequence 12, Application US/08063167A
; Patent No. 5514788
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/063,167A
; FILING DATE: 19930517
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-063-167A-12
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGAGGTCACCCGCGAG 1464
|||||
DB 20 AAGGGAGGTCACCCGCGAG 1

RESULT 102
US-08-063-167A-13/c
; Sequence 13, Application US/08063167A
; Patent No. 5514788
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
```

```
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/063,167A
; FILING DATE: 19930517
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-063-167A-13
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCACGCTCCCTGA 1656
|||||
DB 20 CACAAGCCACGCTCCCTGA 1

RESULT 103
US-08-063-167A-14/c
; Sequence 14, Application US/08063167A
; Patent No. 5514788
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
```

APPLICATION NUMBER: US/08/063,167A
FILING DATE: 19930517
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0002
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-063-167A-14

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1654 TGAACCTATCCCGGACAGG 1673
Db 20 TGAACCTATCCCGGACAGG 1

RESULT 104
US-08-063-167A-15/c
Sequence 15, Application US/08063167A
Patent No. 5514788
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
TITLE OF INVENTION: of Cell Adhesion
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/063,167A
FILING DATE: 19930517
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286

FILING DATE: August 14, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0002
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-063-167A-15

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1938 GACAGGGAGTGTGGGG 1957
Db 20 GACAGGGAGTGTGGGG 1

RESULT 105
US-08-063-167A-16/c
Sequence 16, Application US/08063167A
Patent No. 5514788
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
TITLE OF INVENTION: of Cell Adhesion
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/063,167A
FILING DATE: 19930517
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0002
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439


```
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20
;   TYPE: Nucleic Acid
;   STRANDEDNESS: Single
;   TOPOLOGY: Linear
;   ANTI-SENSE: Yes
US-08-063-167A-16

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTAAATAAAGCTTCTCAA 2981
Db 20 AGTAAATAAAGCTTCTCAA 1

RESULT 106
US-08-063-167A-22/c
; Sequence 22, Application US/08063167A
; Patent No. 5514788
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/063,167A
; FILING DATE: 19930517
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20
;   TYPE: Nucleic Acid
;   STRANDEDNESS: Single
;   TOPOLOGY: Linear
;   ANTI-SENSE: Yes
US-08-063-167A-22

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
Db 20 GAGGCCACAGACTTACAGA 1

RESULT 108
US-08-063-167A-24/c
; Sequence 24, Application US/08063167A
; Patent No. 5514788
```



```
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
US-08-063-167A-26

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1962 ATAGCCCCCACCATGAGGACA 1981
Db 20 ATAGCCCCCACCATGAGGACA 1

RESULT 111
US-08-063-167A-84/c
; Sequence 84, Application US/08063167A
; Patent No. 5514788
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/063.167A
; FILING DATE: 19930517
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
US-08-063-167A-84
```

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 84:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
US-08-063-167A-84

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 112
US-08-063-167A-85/c
; Sequence 85, Application US/08063167A
; Patent No. 5514788
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/063.167A
; FILING DATE: 19930517
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 85:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
US-08-063-167A-85
```

STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-063-167A-85

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGGTGGGAGACATA 1964
|||||
DB 20 GAAGTGGTGGGAGACATA 1

RESULT 113

US-08-468-447-6/c
Sequence 6, Application US/08468447
Patent No. 5576302

GENERAL INFORMATION:

APPLICANT: Phillip Dan Cook and Glenn Hoke
TITLE OF INVENTION: Oligonucleotides For Modulating
HEPATITIS C VIRUS HAVING PHOSPHOROTHIOATE LINKAGES OF HIGH CHIRAL PURITY
TITLE OF INVENTION: Purity
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5576302ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/468,447
FILING DATE: 06-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 297,703
FILING DATE: 29-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucci
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2008
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-468-447-6

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
|||||
DB 20 TGACGGATGCCAGCTTGGC 1

RESULT 114

US-08-469-851A-6/c
Sequence 6, Application US/08469851A
Patent No. 5587361
GENERAL INFORMATION:

APPLICANT: Cook and Hoke
TITLE OF INVENTION: OLIGONUCLEOTIDES HAVING PHOSPHOROTHIOATE
LINKAGES OF HIGH CHIRAL PURITY
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5587361ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/469,851A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 297,703
FILING DATE: 29-AUG-1994
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucci
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-2012
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-469-851A-6

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
|||||
DB 20 TGACGGATGCCAGCTTGGC 1

RESULT 115

US-08-007-997A-2/c
Sequence 2, Application US/08007997A
Patent No. 5591623

GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
OF CELL ADHESION
NUMBER OF SEQUENCES: 82
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz
ADDRESSEE: Mackiewicz & No. 5591623ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/007,997A
FILING DATE: 19930121

```

; CLASSIFICATION: 514
; PRIOR APPLICATION NUMBER: 939,855
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0709
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-007-997A-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
DB 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 116
US-08-007-997A-7/c
; Sequence 7, Application US/08007997A
; Patent No. 5591623
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 5591623ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/007,997A
; FILING DATE: 19930121
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0709
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-007-997A-8

; REFERENCE/DOCKET NUMBER: ISIS-0709
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-007-997A-7

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCTCGCTATG 60
DB 20 GCAACCTCAGCTCGCTATG 1

RESULT 117
US-08-007-997A-8/c
; Sequence 8, Application US/08007997A
; Patent No. 5591623
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 5591623ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/007,997A
; FILING DATE: 19930121
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0709
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-007-997A-8
```



```

;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/007,997A
; FILING DATE: 19930121
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0709
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-007-997A-11

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGACC 894
DB 20 AGGCCTCAGTCAGTGACC 1

RESULT 121
US-08-007-997A-12/c
; Sequence 12, Application US/08007997A
; Patent No. 5591623
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 5591623ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/007,997A
; FILING DATE: 19930121
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0709
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-007-997A-13

```

```

;
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0709
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-007-997A-12

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGGAGGTACCCGCGAG 1464
DB 20 AAGGGGAGGTACCCGCGAG 1

RESULT 122
US-08-007-997A-13/c
; Sequence 13, Application US/08007997A
; Patent No. 5591623
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 5591623ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/007,997A
; FILING DATE: 19930121
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0709
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-007-997A-13

```

; SEQUENCE CHARACTERISTICS:

; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-007-997A-13

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCAGCCTCCCTGA 1656

Db 20 CACAAGCCAGCCTCCCTGA 1

RESULT 123

US-08-007-997A-14/c
; Sequence 14, Application US/08007997A
; Patent No. 5591623
; GENERAL INFORMATION:

; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 5591623ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103

; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2

; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/007,997A
; FILING DATE: 19930121

; PRIOR APPLICATION DATA:
; CLASSIFICATION: 514
; APPLICATION NUMBER: 939,855

; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209

; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286

; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata

; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0709

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439

; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20

; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear

; ANTI-SENSE: Yes
; US-08-007-997A-14

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673

Db 20 TGAACCTATCCCGGACAGG 1

RESULT 124

US-08-007-997A-15/c
; Sequence 15, Application US/08007997A
; Patent No. 5591623
; GENERAL INFORMATION:

; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 5591623ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103

; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2

; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/007,997A
; FILING DATE: 19930121
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:

; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0709

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439

; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20

; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear

; ANTI-SENSE: Yes
; US-08-007-997A-15

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957

Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 125

US-08-007-997A-16/c
; Sequence 16, Application US/08007997A
; Patent No. 5591623
; GENERAL INFORMATION:

; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 82

CORRESPONDENCE ADDRESS:
 ADDRESSEE: Woodcock Washburn Kurtz
 ADDRESSEE: Mackiewicz & No. 5591623ris
 STREET: One Liberty Place - 46th Floor
 CITY: Philadelphia
 STATE: PA
 COUNTRY: USA
 ZIP: 19103
 COMPUTER READABLE FORM:
 MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
 COMPUTER: IBM PS/2
 OPERATING SYSTEM: PC-DOS
 SOFTWARE: WORDPERFECT 5.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/007,997A
 FILING DATE: 19930121
 CLASSIFICATION: 514
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 939,855
 FILING DATE: September 2, 1992
 PRIOR APPLICATION NUMBER: PCT/US91/05209
 FILING DATE: July 23, 1991
 NAME: Jane Massey Licata
 REGISTRATION NUMBER: 32,257
 REFERENCE/DOCKET NUMBER: ISIS-0709
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (215) 568-3100
 TELEFAX: (215) 568-3439
 INFORMATION FOR SEQ ID NO: 16:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 20
 TYPE: Nucleic Acid
 STRANDEDNESS: Single
 TOPOLOGY: Linear
 ANTI-SENSE: Yes
 US-08-007-997A-16
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.le+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2962 AGTAAATGAAGCTTTCTCAA 2981
 DB 20 AGTAAATGAAGCTTTCTCAA 1
 RESULT 126
 US-08-007-997A-22/c
 Sequence 22, Application US/08007997A
 Patent No. 5591623
 GENERAL INFORMATION:
 APPLICANT: Bennett and Mirabelli
 TITLE OF INVENTION: Oligonucleotide Modulation
 TITLE OF INVENTION: of Cell Adhesion
 NUMBER OF SEQUENCES: 82
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Woodcock Washburn Kurtz
 ADDRESSEE: Mackiewicz & No. 5591623ris
 STREET: One Liberty Place - 46th Floor
 CITY: Philadelphia
 STATE: PA
 COUNTRY: USA
 ZIP: 19103
 COMPUTER READABLE FORM:
 MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
 COMPUTER: IBM PS/2
 OPERATING SYSTEM: PC-DOS
 SOFTWARE: WORDPERFECT 5.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/007,997A
 FILING DATE: 19930121
 CLASSIFICATION: 514
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 939,855
 FILING DATE: September 2, 1992
 PRIOR APPLICATION NUMBER: PCT/US91/05209
 FILING DATE: July 23, 1991
 NAME: Jane Massey Licata
 REGISTRATION NUMBER: 32,257
 REFERENCE/DOCKET NUMBER: ISIS-0709
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (215) 568-3100
 TELEFAX: (215) 568-3439
 INFORMATION FOR SEQ ID NO: 16:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 20
 TYPE: Nucleic Acid
 STRANDEDNESS: Single
 TOPOLOGY: Linear
 ANTI-SENSE: Yes
 US-08-007-997A-16
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.le+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2962 AGTAAATGAAGCTTTCTCAA 2981
 DB 20 AGTAAATGAAGCTTTCTCAA 1
 RESULT 126
 US-08-007-997A-22/c
 Sequence 22, Application US/08007997A
 Patent No. 5591623
 GENERAL INFORMATION:
 APPLICANT: Bennett and Mirabelli
 TITLE OF INVENTION: Oligonucleotide Modulation
 TITLE OF INVENTION: of Cell Adhesion
 NUMBER OF SEQUENCES: 82
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Woodcock Washburn Kurtz
 ADDRESSEE: Mackiewicz & No. 5591623ris
 STREET: One Liberty Place - 46th Floor
 CITY: Philadelphia
 STATE: PA
 COUNTRY: USA
 ZIP: 19103
 COMPUTER READABLE FORM:
 MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
 COMPUTER: IBM PS/2
 OPERATING SYSTEM: PC-DOS
 SOFTWARE: WORDPERFECT 5.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/007,997A
 FILING DATE: 19930121
 CLASSIFICATION: 514
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 939,855
 FILING DATE: September 2, 1992
 PRIOR APPLICATION NUMBER: PCT/US91/05209
 FILING DATE: July 23, 1991
 NAME: Jane Massey Licata
 REGISTRATION NUMBER: 32,257
 REFERENCE/DOCKET NUMBER: ISIS-0709
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (215) 568-3100
 TELEFAX: (215) 568-3439
 INFORMATION FOR SEQ ID NO: 22:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 20
 TYPE: Nucleic Acid
 STRANDEDNESS: Single
 TOPOLOGY: Linear
 ANTI-SENSE: Yes
 US-08-007-997A-22
 Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.le+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 2100 TGACGGATGCCAGCTTGGGC 2119
 DB 20 TGACGGATGCCAGCTTGGGC 1
 RESULT 127
 US-08-007-997A-23/c
 Sequence 23, Application US/08007997A
 Patent No. 5591623
 GENERAL INFORMATION:
 APPLICANT: Bennett and Mirabelli
 TITLE OF INVENTION: Oligonucleotide Modulation
 TITLE OF INVENTION: of Cell Adhesion
 NUMBER OF SEQUENCES: 82
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Woodcock Washburn Kurtz
 ADDRESSEE: Mackiewicz & No. 5591623ris
 STREET: One Liberty Place - 46th Floor
 CITY: Philadelphia
 STATE: PA
 COUNTRY: USA
 ZIP: 19103
 COMPUTER READABLE FORM:
 MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
 COMPUTER: IBM PS/2
 OPERATING SYSTEM: PC-DOS
 SOFTWARE: WORDPERFECT 5.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/007,997A
 FILING DATE: 19930121
 CLASSIFICATION: 514
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 939,855
 FILING DATE: September 2, 1992
 PRIOR APPLICATION NUMBER: PCT/US91/05209
 FILING DATE: July 23, 1991
 NAME: Jane Massey Licata
 REGISTRATION NUMBER: 32,257
 REFERENCE/DOCKET NUMBER: ISIS-0709
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (215) 568-3100
 TELEFAX: (215) 568-3439
 INFORMATION FOR SEQ ID NO: 22:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 20
 TYPE: Nucleic Acid
 STRANDEDNESS: Single
 TOPOLOGY: Linear
 ANTI-SENSE: Yes
 US-08-007-997A-22

```
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Jane Massey Licata
/ REGISTRATION NUMBER: 32,257
/ REFERENCE/DOCKET NUMBER: ISIS-0709
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (215) 568-3100
/ TELEFAX: (215) 568-3439
/ INFORMATION FOR SEQ ID NO: 23:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20
/ TYPE: Nucleic Acid
/ STRANDEDNESS: Single
/ TOPOLOGY: Linear
/ ANTI-SENSE: Yes
US-08-007-997A-23

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
Db 20 GAGGCCACAGACTTACAGA 1

RESULT 128
US-08-007-997A-24/c
/ Sequence 24, Application US/08007997A
/ Patent No. 5591623
/ GENERAL INFORMATION:
/ APPLICANT: Bennett and Mirabelli
/ TITLE OF INVENTION: Oligonucleotide Modulation
/ TITLE OF INVENTION: of Cell Adhesion
/ NUMBER OF SEQUENCES: 82
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Woodcock Washburn Kurtz
/ ADDRESSEE: Mackiewicz & No. 5591623ris
/ STREET: One Liberty Place - 46th Floor
/ CITY: Philadelphia
/ STATE: PA
/ COUNTRY: USA
/ ZIP: 19103
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
/ COMPUTER: IBM PS/2
/ OPERATING SYSTEM: PC-DOS
/ SOFTWARE: WORDPERFECT 5.0
/ CURRENT APPLICATION DATA:
/ FILING DATE: 19930121
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 939,855
/ FILING DATE: September 2, 1992
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US91/05209
/ FILING DATE: July 23, 1991
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 567,286
/ FILING DATE: August 14, 1990
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Jane Massey Licata
/ REGISTRATION NUMBER: 32,257
/ REFERENCE/DOCKET NUMBER: ISIS-0709
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (215) 568-3100
/ TELEFAX: (215) 568-3439
/ INFORMATION FOR SEQ ID NO: 24:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20
/ TYPE: Nucleic Acid
/ STRANDEDNESS: Single
/ TOPOLOGY: Linear
/ ANTI-SENSE: Yes
US-08-007-997A-25

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAGTCTAGCCTGATGAG 1940
Db 20 TTAAGTCTAGCCTGATGAG 1

RESULT 130
```

```

US-08-007-997A-26/c
; Sequence 26, Application US/08007997A
; Patent No. 5591623
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 5591623ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/007,997A
; FILING DATE: 19930121
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0709
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-007-997A-26
;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e-02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCCACCATGAGACA 1981
Db 20 ATAGCCCCCACCATGAGACA 1

RESULT 131
US-07-927-506-25/c
; Sequence 25, Application US/07927506
; Patent No. 5591720
; GENERAL INFORMATION:
; APPLICANT: Anderson, Kevin P.
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: Oligonucleotides for Modulating
; TITLE OF INVENTION: the Effects of Cytomegalovirus Infections
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz &
; ADDRESSEE: No. 5591720ris
; STREET: One Liberty Place -- 46th floor

```

```

; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb
; MEDIUM TYPE: STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/927,506
; FILING DATE: 19921119
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Licata, Jane M.
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0408
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-07-927-506-25
;
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e-02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 132
US-08-467-597A-6/c
; Sequence 6, Application US/08467597A
; Patent No. 5607923
; GENERAL INFORMATION:
; APPLICANT: Phillip Dan Cook and Glenn Hoke
; TITLE OF INVENTION: Oligonucleotides For Modulating
; TITLE OF INVENTION: Cytomegalovirus Having Phosphorothioate Linkages Of High Chir
; TITLE OF INVENTION: Purity
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5607923ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/467,597A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 297,703
; FILING DATE: 29-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307

```

;; REFERENCE/DOCKET NUMBER: ISIS-2007
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 215-568-3100
;; TELEFAX: 215-568-3439
;; INFORMATION FOR SEQ ID NO: 6:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
US-08-467-597A-6

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 133
US-08-468-569A-6/c
;; Sequence 6, Application US/08468569A
;; Patent No. 5620963
;; GENERAL INFORMATION:
;; APPLICANT: Cook and Hoke
;; TITLE OF INVENTION: OLIGONUCLEOTIDES FOR MODULATING PROTEIN
;; TITLE OF INVENTION: KINASE C HALVING PHOSPHOROTHIOATE LINKAGES
;; TITLE OF INVENTION: AND HIGH CHIRAL PURITY
;; NUMBER OF SEQUENCES: 16
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5620963ris
;; STREET: One Liberty Place - 46th Floor
;; CITY: Philadelphia
;; STATE: PA
;; COUNTRY: U.S.A.
;; ZIP: 19103
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5 inch disk, 720 Kb
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: WordPerfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/468,569A
;; FILING DATE: 06-JUN-1995
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 297,703
;; FILING DATE: 29-AUG-1994
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Joseph Lucci
;; REGISTRATION NUMBER: 33,307
;; REFERENCE/DOCKET NUMBER: ISIS-2009
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 215-568-3100
;; TELEFAX: 215-568-3439
;; INFORMATION FOR SEQ ID NO: 6:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
US-08-468-569A-6

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
|||||

Db 20 TGACGGATGCCAGCTTGGC 1
RESULT 134
US-08-466-692A-6/c
;; Sequence 6, Application US/08466692A
;; Patent No. 5654284
;; GENERAL INFORMATION:
;; APPLICANT: Cook and Hoke
;; TITLE OF INVENTION: OLIGONUCLEOTIDES FOR MODULATING RAF KINASE
;; TITLE OF INVENTION: HAVING PHOSPHOROTHIOATE LINKAGES OF HIGH
;; TITLE OF INVENTION: CHIRAL PURITY
;; NUMBER OF SEQUENCES: 16
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5654284ris
;; STREET: One Liberty Place - 46th Floor
;; CITY: Philadelphia
;; STATE: PA
;; COUNTRY: U.S.A.
;; ZIP: 19103
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5 inch disk, 720 Kb
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: WordPerfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/466,692A
;; FILING DATE: 06-JUN-1995
;; CLASSIFICATION: 536
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 297,703
;; FILING DATE: 29-AUG-1994
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Joseph Lucci
;; REGISTRATION NUMBER: 33,307
;; REFERENCE/DOCKET NUMBER: ISIS-2010
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 215-568-3100
;; TELEFAX: 215-568-3439
;; INFORMATION FOR SEQ ID NO: 6:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
US-08-466-692A-6

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 135
US-08-471-966A-6/c
;; Sequence 6, Application US/08471966A
;; Patent No. 5661134
;; GENERAL INFORMATION:
;; APPLICANT: Phillip Dan Cook and Glenn Hoke
;; TITLE OF INVENTION: Oligonucleotides For Modulating Ha-ras or
;; TITLE OF INVENTION: Ki-ras Having Phosphorothioate Linkages Of High Chiral Purity
;; NUMBER OF SEQUENCES: 16
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5661134ris
;; STREET: One Liberty Place - 46th Floor
;; CITY: Philadelphia
;; STATE: PA
;; COUNTRY: U.S.A.
;; ZIP: 19103

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
|||||

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3 5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/471,966A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 297,703
; FILING DATE: 29-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2011
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-471-966A-6

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 136
US-08-462-305-21/c
; Sequence 21, Application US/08462305
; Patent No. 5696248
; GENERAL INFORMATION:
; APPLICANT: Peyman, Anuschirwan
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Carolus, Carolin
; TITLE OF INVENTION: 3'-Modified Oligonucleotide Derivatives
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoechst Marion Roussel, Inc.
; STREET: 2110 E. Galbraith Road, P.O. Box 156300
; CITY: Cincinnati
; STATE: Ohio
; COUNTRY: USA
; ZIP: 45215-6300
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,305
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Payne, T. Helen
; REGISTRATION NUMBER: 36,889
; REFERENCE/DOCKET NUMBER: HOE94/F161K US
; TELEPHONE: 513-948-7183
; TELEFAX: 513-948-7960 or 4681
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:

; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; US-08-462-305-21

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 137
US-08-462-305-22/c
; Sequence 22, Application US/08462305
; Patent No. 5696248
; GENERAL INFORMATION:
; APPLICANT: Peyman, Anuschirwan
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Carolus, Carolin
; TITLE OF INVENTION: 3'-Modified Oligonucleotide Derivatives
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoechst Marion Roussel, Inc.
; STREET: 2110 E. Galbraith Road, P.O. Box 156300
; CITY: Cincinnati
; STATE: Ohio
; COUNTRY: USA
; ZIP: 45215-6300
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,305
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Payne, T. Helen
; REGISTRATION NUMBER: 36,889
; REFERENCE/DOCKET NUMBER: HOE94/F161K US
; TELEPHONE: 513-948-7183
; TELEFAX: 513-948-7960 or 4681
; TELETYPE: 214320
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; US-08-462-305-22

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGG 1959
Db 20 GAGGGGAAGTGGTGGGG 1

RESULT 138
US-08-653-653A-1/c
; Sequence 1, Application US/08653653A
; Patent No. 5789573
; GENERAL INFORMATION:

```
; APPLICANT: Brenda P. Baker, C. Frank Bennett and Kevin P.
; APPLICANT: Anderson
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
; TITLE OF INVENTION: ANTISENSE INHIBITION OF PROTEIN
; TITLE OF INVENTION: TRANSLATION
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jane Massey Licata, Esq.
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM 486
; OPERATING SYSTEM: WINDOWS FOR WORKGROUPS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/653,653A
; FILING DATE: May 24, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/927,506
; FILING DATE: No. 5789573ember 19, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/568,366
; FILING DATE: August 16, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0146
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; ANTI-SENSE: yes
; US-08-653-653A-1
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
```

RESULT 139

```
US-08-361-858-11/c
; Sequence 11, Application US/08361858
; Patent No. 5834607
; GENERAL INFORMATION:
```

```
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; TITLE OF INVENTION: MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5834607ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/361,858
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/943,516
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumont, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-0484
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 20
; OTHER INFORMATION: /note= "2'-aminopropoxy
; OTHER INFORMATION: cytosine"
; US-08-361-858-11
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
```

RESULT 140

```
US-08-440-740A-2/c
; Sequence 2, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
```

```
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
```

```
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 2:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-440-740A-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 141
US-08-440-740A-7/c
; Sequence 7, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
```

```
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 7:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-440-740A-7

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCTCGCTATG 60
Db 20 GCAACCTCAGCTCGCTATG 1

RESULT 142
US-08-440-740A-8/c
; Sequence 8, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
```

; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-440-740A-8

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCCGAGCCCGG 77
Db 20 ATGGCTCCCGAGCCCGG 1

RESULT 143

US-08-440-740A-9/c
; Sequence 9, Application US/08440740A
; Patent No. 5843738

; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257

; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-440-740A-9

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTCTCGGGGCTCT 116
Db 20 CTGGTCTCTCGGGGCTCT 1

RESULT 144

US-08-440-740A-10/c
; Sequence 10, Application US/08440740A
; Patent No. 5843738

; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid


```
; Sequence 13, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-440-740A-13
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1637 CACAAGCCAGCCTCCCTGA 1656
Db 20 CACAAGCCAGCCTCCCTGA 1
```

```
RESULT 148
US-08-440-740A-14/c
; Sequence 14, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
```

```
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-440-740A-14
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1654 TGAACCTATCCCGGACAGG 1673
Db 20 TGAACCTATCCCGGACAGG 1
```

```
RESULT 149
US-08-440-740A-15/c
; Sequence 15, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
```

```
;
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-440-740A-15

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGG 1957
Db 20 GAGAGGGGAAGTGTGGGG 1

RESULT 150
US-08-440-740A-16/c
; Sequence 16, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-440-740A-16

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAAGCTTCTCAA 2981
Db 20 AGTTAATAAAGCTTCTCAA 1

RESULT 151
US-08-440-740A-22/c
; Sequence 22, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
```

;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER: 939,855
;/ FILING DATE: September 2, 1992
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER: 567,286
;/ FILING DATE: August 14, 1990
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Jane Massey Licata
;/ REGISTRATION NUMBER: 32,257
;/ REFERENCE/DOCKET NUMBER: ISPH-0133
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (609) 779-2400
;/ TELEFAX: (609) 779-8488
;/ INFORMATION FOR SEQ ID NO: 22:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 20
;/ TYPE: Nucleic Acid
;/ STRANDEDNESS: Single
;/ TOPOLOGY: Linear
;/ ANTI-SENSE: Yes
;/ US-08-440-740A-22

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db |||||||||||||||||||

RESULT 152
US-08-440-740A-23/c
; Sequence 23, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata

;/ REGISTRATION NUMBER: 32,257
;/ REFERENCE/DOCKET NUMBER: ISPH-0133
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (609) 779-2400
;/ TELEFAX: (609) 779-8488
;/ INFORMATION FOR SEQ ID NO: 23:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 20
;/ TYPE: Nucleic Acid
;/ STRANDEDNESS: Single
;/ TOPOLOGY: Linear
;/ ANTI-SENSE: Yes
;/ US-08-440-740A-23

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
Db |||||||||||||||||||

RESULT 153
US-08-440-740A-24/c
; Sequence 24, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (609) 779-2400
;/ TELEFAX: (609) 779-8488
;/ INFORMATION FOR SEQ ID NO: 24:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 20

; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-440-740A-24

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900
|||||
DB 20 CAAGAGGAGGAGCAAGACT 1

RESULT 154

US-08-440-740A-25/c
; Sequence 25, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 32,257
; FILING DATE: September 2, 1992
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-440-740A-25

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1921 TTAAAGTCTAGCCTGATGAG 1940
|||||
DB 20 TTAAAGTCTAGCCTGATGAG 1

RESULT 155

US-08-440-740A-26/c
; Sequence 26, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-440-740A-26

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCCACCATGAGGACA 1981
|||||
DB 20 ATAGCCCCCACCATGAGGACA 1

RESULT 156

US-08-440-740A-84/c
; Sequence 84, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 84:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-440-740A-84

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCTCTGCTACTCAGA 37
Db 20 GAGCTCTCTGCTACTCAGA 1

RESULT 157
US-08-440-740A-85/c
; Sequence 85, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 85:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-440-740A-85
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1945 GAAGTGGTGGGGGAGACATA 1964
Db 20 GAAGTGGTGGGGGAGACATA 1
RESULT 158
US-08-808-474A-12/c
; Sequence 12, Application US/08808474A
; Patent No. 5856103
; GENERAL INFORMATION:
; APPLICANT: Gray, Donald M.
; APPLICANT: Clark, Chris L.
; TITLE OF INVENTION: METHOD FOR SELECTIVELY RANKING SEQUENCES
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Locke Purnell Rain Harrell
; STREET: 2200 Ross Avenue, Suite 2200
; CITY: Dallas
; STATE: Texas
; COUNTRY: USA
; ZIP: 75201-6776

```
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/808,474A
; FILING DATE: 03-MAR-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Mayfield, Denise L.
; REGISTRATION NUMBER: 33,732
; REFERENCE/DOCKET NUMBER: UTDAL:001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (214) 740-8000
; TELEFAX: (214) 740-8800
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-808-474A-12

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGG 1957
Db 20 GAGAGGGGAAGTGTGGGG 1

RESULT 159
US-08-808-474A-13/c
; Sequence 13, Application US/08808474A
; Patent No. 5856103
; GENERAL INFORMATION:
; APPLICANT: Gray, Donald M.
; APPLICANT: Clark, Chris L.
; TITLE OF INVENTION: METHOD FOR SELECTIVELY RANKING SEQUENCES
; TITLE OF INVENTION: FOR ANTISENSE TARGETING
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Locke Purnell Rain Harrell
; STREET: 2200 Ross Avenue, Suite 2200
; CITY: Dallas
; STATE: Texas
; COUNTRY: USA
; ZIP: 75201-6776
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/808,474A
; FILING DATE: 03-MAR-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Mayfield, Denise L.
; REGISTRATION NUMBER: 33,732
; REFERENCE/DOCKET NUMBER: UTDAL:001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (214) 740-8000
; TELEFAX: (214) 740-8800
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-808-474A-13

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGG 1957
Db 20 GAGAGGGGAAGTGTGGGG 1

RESULT 159
US-08-808-474A-13/c
; Sequence 13, Application US/08808474A
; Patent No. 5856103
; GENERAL INFORMATION:
; APPLICANT: Gray, Donald M.
; APPLICANT: Clark, Chris L.
; TITLE OF INVENTION: METHOD FOR SELECTIVELY RANKING SEQUENCES
; TITLE OF INVENTION: FOR ANTISENSE TARGETING
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Locke Purnell Rain Harrell
; STREET: 2200 Ross Avenue, Suite 2200
; CITY: Dallas
; STATE: Texas
; COUNTRY: USA
; ZIP: 75201-6776
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/808,474A
; FILING DATE: 03-MAR-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Mayfield, Denise L.
; REGISTRATION NUMBER: 33,732
; REFERENCE/DOCKET NUMBER: UTDAL:001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (214) 740-8000
; TELEFAX: (214) 740-8800
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-808-474A-13

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
Db 20 TCAAACTGCCCTGATGGCA 1

RESULT 160
US-08-808-474A-14/c
; Sequence 14, Application US/08808474A
; Patent No. 5856103
; GENERAL INFORMATION:
; APPLICANT: Gray, Donald M.
; APPLICANT: Clark, Chris L.
; TITLE OF INVENTION: METHOD FOR SELECTIVELY RANKING SEQUENCES
; TITLE OF INVENTION: FOR ANTISENSE TARGETING
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Locke Purnell Rain Harrell
; STREET: 2200 Ross Avenue, Suite 2200
; CITY: Dallas
; STATE: Texas
; COUNTRY: USA
; ZIP: 75201-6776
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/808,474A
; FILING DATE: 03-MAR-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Mayfield, Denise L.
; REGISTRATION NUMBER: 33,732
; REFERENCE/DOCKET NUMBER: UTDAL:001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (214) 740-8000
; TELEFAX: (214) 740-8800
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-808-474A-14

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
Db 20 TGAACCTATCCCGGACAGG 1

RESULT 161
US-08-808-474A-15/c
; Sequence 15, Application US/08808474A
; Patent No. 5856103
; GENERAL INFORMATION:
; APPLICANT: Gray, Donald M.
; APPLICANT: Clark, Chris L.
; TITLE OF INVENTION: METHOD FOR SELECTIVELY RANKING SEQUENCES
; TITLE OF INVENTION: FOR ANTISENSE TARGETING
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Locke Purnell Rain Harrell
; STREET: 2200 Ross Avenue, Suite 2200
; CITY: Dallas
; STATE: Texas
; COUNTRY: USA
```

ZIP: 75201-6776
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/808,474A
FILING DATE: 03-MAR-1997
ATTORNEY/AGENT INFORMATION:
NAME: Mayfield, Denise L.
REGISTRATION NUMBER: 33,732
REFERENCE/DOCKET NUMBER: UTDAL:001
TELEPHONE: (214) 740-8000
TELEFAX: (214) 740-8800
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-808-474A-15

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 162
US-08-808-474A-16/c
Sequence 16, Application US/08808474A
Patent No. 5856103
GENERAL INFORMATION:
APPLICANT: Gray, Donald M.
APPLICANT: Clark, Chris L.
TITLE OF INVENTION: METHOD FOR SELECTIVELY RANKING SEQUENCES
TITLE OF INVENTION: FOR ANTISENSE TARGETING
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: Locke Purnell Rain Harrell
STREET: 2200 Ross Avenue, Suite 2200
CITY: Dallas
STATE: Texas
COUNTRY: USA
ZIP: 75201-6776
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/808,474A
FILING DATE: 03-MAR-1997
ATTORNEY/AGENT INFORMATION:
NAME: Mayfield, Denise L.
REGISTRATION NUMBER: 33,732
REFERENCE/DOCKET NUMBER: UTDAL:001
TELEPHONE: (214) 740-8000
TELEFAX: (214) 740-8800
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-808-474A-16

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATCCAGCTTGGGC 2119
Db 20 TGACGGATCCAGCTTGGGC 1

RESULT 163
US-08-808-474A-18/c
Sequence 18, Application US/08808474A
Patent No. 5856103
GENERAL INFORMATION:
APPLICANT: Gray, Donald M.
APPLICANT: Clark, Chris L.
TITLE OF INVENTION: METHOD FOR SELECTIVELY RANKING SEQUENCES
TITLE OF INVENTION: FOR ANTISENSE TARGETING
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: Locke Purnell Rain Harrell
STREET: 2200 Ross Avenue, Suite 2200
CITY: Dallas
STATE: Texas
COUNTRY: USA
ZIP: 75201-6776
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/808,474A
FILING DATE: 03-MAR-1997
ATTORNEY/AGENT INFORMATION:
NAME: Mayfield, Denise L.
REGISTRATION NUMBER: 33,732
REFERENCE/DOCKET NUMBER: UTDAL:001
TELEPHONE: (214) 740-8000
TELEFAX: (214) 740-8800
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-808-474A-18

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAGCTTTCTCAA 2981
Db 20 AGTTAATAAGCTTTCTCAA 1

RESULT 164
US-08-469-852A-1/c
Sequence 1, Application US/08469852A
Patent No. 5874213
GENERAL INFORMATION:
APPLICANT: Cummins, Lendell L.
APPLICANT: Freier, Susan M.
APPLICANT: Griffey, Richard
APPLICANT: Srivatsa, Susan G.
TITLE OF INVENTION: Capillary Electrophoretic Detection of
TITLE OF INVENTION: Nucleic Acids
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5874213ris LLP
STREET: One Liberty Place - 46th Floor


```
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/469,852A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/295,509
; FILING DATE: 24-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Michael P. Straher
; REGISTRATION NUMBER: 38,325
; REFERENCE/DOCKET NUMBER: ISIS-2015
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-469-852A-1

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      18 GAGCTCCTCTGCTACTCAGA 37
        |||||
Db       20 GAGCTCCTCTGCTACTCAGA 1

RESULT 165
US-08-613-417A-21/c
; Sequence 21, Application US/08613417A
; Patent No. 5874553
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Phosphonomonoester nucleic acids,
; and their use
; NUMBER OF SEQUENCES: 33
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0. Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/613,417A
; FILING DATE:
; CLASSIFICATION: 514
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: yes
; FEATURE:
; NAME/KEY: exon
; LOCATION: 1..20
; US-08-613-417A-21

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1940 GAGGGGAAAGTGTGGGGGAG 1959
        |||||
Db       20 GAGGGGAAAGTGTGGGGGAG 1

RESULT 167
US-08-344-155C-2/c
; Sequence 2, Application US/08344155C
; Patent No. 5883082
; GENERAL INFORMATION:
; APPLICANT: Bennett and Stepkowski
; TITLE OF INVENTION: Compositions and Methods for Preventing
; and Treating Allograft Rejection
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,155C
; FILING DATE: NO. 5883082ember 23, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; US-08-613-417A-21

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1938 GAGAGGGGAAAGTGTGGGGG 1957
        |||||
Db       20 GAGAGGGGAAAGTGTGGGGG 1

RESULT 166
US-08-613-417A-22/c
; Sequence 22, Application US/08613417A
; Patent No. 5874553
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Phosphonomonoester nucleic acids,
; and their use
; NUMBER OF SEQUENCES: 33
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0. Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/613,417A
; FILING DATE:
; CLASSIFICATION: 514
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: yes
; FEATURE:
; NAME/KEY: exon
; LOCATION: 1..20
; US-08-613-417A-22

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1940 GAGGGGAAAGTGTGGGGGAG 1959
        |||||
Db       20 GAGGGGAAAGTGTGGGGGAG 1

RESULT 167
US-08-344-155C-2/c
; Sequence 2, Application US/08344155C
; Patent No. 5883082
; GENERAL INFORMATION:
; APPLICANT: Bennett and Stepkowski
; TITLE OF INVENTION: Compositions and Methods for Preventing
; and Treating Allograft Rejection
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,155C
; FILING DATE: NO. 5883082ember 23, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; US-08-613-417A-21
```

APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/063,167
FILING DATE: 5/17/93
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/007,997
FILING DATE: 1/21/93
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/939,855
FILING DATE: 9/2/92
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/567,286
FILING DATE: 8/14/90
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0098
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-344-155C-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
|||||
DB 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 168
US-08-344-155C-7/c
Sequence 7, Application US/08344155C
Patent No. 5883082
GENERAL INFORMATION:
APPLICANT: Bennett and Stepkowski
TITLE OF INVENTION: Compositions and Methods for Preventing
TITLE OF INVENTION: and Treating Allograft Rejection
NUMBER OF SEQUENCES: 99
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/344,155C
FILING DATE: No. 5883082ember 23, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/063,167
FILING DATE: 5/17/93
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/007,997
FILING DATE: 1/21/93
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/939,855
FILING DATE: 9/2/92
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/567,286
FILING DATE: 8/14/90
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0098
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-344-155C-7

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCTCGCTATG 60
|||||
DB 20 GCAACCTCAGCCTCGCTATG 1

RESULT 169
US-08-344-155C-8/c
Sequence 8, Application US/08344155C
Patent No. 5883082
GENERAL INFORMATION:
APPLICANT: Bennett and Stepkowski
TITLE OF INVENTION: Compositions and Methods for Preventing
TITLE OF INVENTION: and Treating Allograft Rejection
NUMBER OF SEQUENCES: 99
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/344,155C
FILING DATE: No. 5883082ember 23, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/063,167
FILING DATE: 5/17/93
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/007,997

;/ FILING DATE: 1/21/93
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER: 07/939,855
;/ FILING DATE: 9/2/92
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER: 07/567,286
;/ FILING DATE: 8/14/90
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Jane Massey Licata
;/ REGISTRATION NUMBER: 32,257
;/ REFERENCE/DOCKET NUMBER: ISPH-0098
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (609) 779-2400
;/ TELEFAX: (609) 779-8498
;/ INFORMATION FOR SEQ ID NO: 8:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 20
;/ TYPE: Nucleic Acid
;/ STRANDEDNESS: Single
;/ TOPOLOGY: Linear
;/ ANTI-SENSE: Yes
;/ US-08-344-155C-8

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 58 ATGGCTCCCGAGCAGCCCGG 77
Db 20 ATGGCTCCCGAGCAGCCCGG 1

RESULT 170
US-08-344-155C-9/c
; Sequence 9, Application US/08344155C
; Patent No. 5883082
; GENERAL INFORMATION:
; APPLICANT: Bennett and Stepkowski
; TITLE OF INVENTION: Compositions and Methods for Preventing
; TITLE OF INVENTION: and Treating Allograft Rejection
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,155C
; FILING DATE: No. 5883082ember 23, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/063,167
; FILING DATE: 5/17/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/007,997
; FILING DATE: 1/21/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/939,855
; FILING DATE: 9/2/92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/567,286
; FILING DATE: 8/14/90
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257

;/ APPLICATION NUMBER: 07/567,286
;/ FILING DATE: 8/14/90
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Jane Massey Licata
;/ REGISTRATION NUMBER: 32,257
;/ REFERENCE/DOCKET NUMBER: ISPH-0098
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (609) 779-2400
;/ TELEFAX: (609) 779-8498
;/ INFORMATION FOR SEQ ID NO: 9:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 20
;/ TYPE: Nucleic Acid
;/ STRANDEDNESS: Single
;/ TOPOLOGY: Linear
;/ ANTI-SENSE: Yes
;/ US-08-344-155C-9
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 97 CTGCTCCTGCTCGGGCTCT 116
Db 20 CTGCTCCTGCTCGGGCTCT 1

RESULT 171
US-08-344-155C-10/c
; Sequence 10, Application US/08344155C
; Patent No. 5883082
; GENERAL INFORMATION:
; APPLICANT: Bennett and Stepkowski
; TITLE OF INVENTION: Compositions and Methods for Preventing
; TITLE OF INVENTION: and Treating Allograft Rejection
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,155C
; FILING DATE: No. 5883082ember 23, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/063,167
; FILING DATE: 5/17/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/007,997
; FILING DATE: 1/21/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/939,855
; FILING DATE: 9/2/92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/567,286
; FILING DATE: 8/14/90
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257

REFERENCE/DOCKET NUMBER: ISPH-0098
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-344-155C-10

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
Db 20 TCAAACTGCCCTGATGGCA 1

RESULT 172

US-08-344-155C-11/c
Sequence 11, Application US/08344155C
Patent No. 5883082

GENERAL INFORMATION:

APPLICANT: Bennett and Stepkowski
TITLE OF INVENTION: Compositions and Methods for Preventing
and Treating Allograft Rejection

NUMBER OF SEQUENCES: 99

CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodland Falls Corporate Park

STREET: 210 Lake Drive East, Suite 201

CITY: Cherry Hill

STATE: NJ

COUNTRY: USA

ZIP: 08002

COMPUTER READABLE FORM:

MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE

COMPUTER: IBM PS/2

OPERATING SYSTEM: PC-DOS

SOFTWARE: WORDPERFECT 5.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/344,155C

FILING DATE: No. 5883082ember 23, 1994

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 939,855

FILING DATE: September 2, 1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/US91/05209

FILING DATE: July 23, 1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/063,167

FILING DATE: 5/17/93

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/007,997

FILING DATE: 1/21/93

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/939,855

FILING DATE: 9/2/92

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/567,286

FILING DATE: 8/14/90

ATTORNEY/AGENT INFORMATION:

NAME: Jane Massey Licata

REGISTRATION NUMBER: 32,257

REFERENCE/DOCKET NUMBER: ISPH-0098

TELECOMMUNICATION INFORMATION:

TELEPHONE: (609) 779-2400

TELEFAX: (609) 779-8488

INFORMATION FOR SEQ ID NO: 11:

SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-344-155C-11

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGTGACC 894
Db 20 AGGCCTCAGTCAGTGTGACC 1

RESULT 173

US-08-344-155C-12/c
Sequence 12, Application US/08344155C
Patent No. 5883082

GENERAL INFORMATION:

APPLICANT: Bennett and Stepkowski

TITLE OF INVENTION: Compositions and Methods for Preventing
and Treating Allograft Rejection

NUMBER OF SEQUENCES: 99

CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodland Falls Corporate Park

STREET: 210 Lake Drive East, Suite 201

CITY: Cherry Hill

STATE: NJ

COUNTRY: USA

ZIP: 08002

COMPUTER READABLE FORM:

MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE

COMPUTER: IBM PS/2

OPERATING SYSTEM: PC-DOS

SOFTWARE: WORDPERFECT 5.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/344,155C

FILING DATE: No. 5883082ember 23, 1994

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 939,855

FILING DATE: September 2, 1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: PCT/US91/05209

FILING DATE: July 23, 1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/063,167

FILING DATE: 5/17/93

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/007,997

FILING DATE: 1/21/93

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/939,855

FILING DATE: 9/2/92

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/567,286

FILING DATE: 8/14/90

ATTORNEY/AGENT INFORMATION:

NAME: Jane Massey Licata

REGISTRATION NUMBER: 32,257

REFERENCE/DOCKET NUMBER: ISPH-0098

TELECOMMUNICATION INFORMATION:

TELEPHONE: (609) 779-2400

TELEFAX: (609) 779-8488

INFORMATION FOR SEQ ID NO: 12:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: Nucleic Acid

STRANDEDNESS: Single

TOPOLOGY: Linear

; ANTI-SENSE: Yes		Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
US-08-344-155C-12			
Query Match 0.7%; Score 20; DB 1; Length 20;			
Best Local Similarity 100.0%; Pred. No. 2.1e+02;			
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY 1445	AAGGGAGGTCACCCCGAG 1464	QY 1637	CACAAGCCACGCTCCCTGA 1656
Db 20	AAGGGAGGTCACCCCGAG 1	Db 20	CACAAGCCACGCTCCCTGA 1
RESULT 174		RESULT 175	
US-08-344-155C-13/c		US-08-344-155C-14/c	
; Sequence 13, Application US/08344155C		; Sequence 14, Application US/08344155C	
; Patent No. 5883082		; Patent No. 5883082	
; GENERAL INFORMATION:		; GENERAL INFORMATION:	
; APPLICANT: Bennett and Stepkowski		; APPLICANT: Bennett and Stepkowski	
; TITLE OF INVENTION: Compositions and Methods for Preventing		; TITLE OF INVENTION: Compositions and Methods for Preventing	
; TITLE OF INVENTION: and Treating Alllograft Rejection		; TITLE OF INVENTION: and Treating Alllograft Rejection	
; NUMBER OF SEQUENCES: 99		; NUMBER OF SEQUENCES: 99	
; CORRESPONDENCE ADDRESS:		; CORRESPONDENCE ADDRESS:	
; ADDRESSEE: Woodland Falls Corporate Park		; ADDRESSEE: Woodland Falls Corporate Park	
; STREET: 210 Lake Drive East, Suite 201		; STREET: 210 Lake Drive East, Suite 201	
; CITY: Cherry Hill		; CITY: Cherry Hill	
; STATE: NJ		; STATE: NJ	
; COUNTRY: USA		; COUNTRY: USA	
; ZIP: 08002		; ZIP: 08002	
; COMPUTER READABLE FORM:		; COMPUTER READABLE FORM:	
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE		; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE	
; COMPUTER: IBM PS/2		; COMPUTER: IBM PS/2	
; OPERATING SYSTEM: PC-DOS		; OPERATING SYSTEM: PC-DOS	
; SOFTWARE: WORDPERFECT 5.0		; SOFTWARE: WORDPERFECT 5.0	
; CURRENT APPLICATION DATA:		; CURRENT APPLICATION DATA:	
; APPLICATION NUMBER: US/08/344,155C		; APPLICATION NUMBER: US/08/344,155C	
; FILING DATE: No. 5883082ember 23, 1994		; FILING DATE: No. 5883082ember 23, 1994	
; CLASSIFICATION: 514		; CLASSIFICATION: 514	
; PRIOR APPLICATION DATA:		; PRIOR APPLICATION DATA:	
; APPLICATION NUMBER: 939,855		; APPLICATION NUMBER: 939,855	
; FILING DATE: September 2, 1992		; FILING DATE: September 2, 1992	
; PRIOR APPLICATION DATA:		; PRIOR APPLICATION DATA:	
; APPLICATION NUMBER: PCT/US91/05209		; APPLICATION NUMBER: PCT/US91/05209	
; FILING DATE: July 23, 1991		; FILING DATE: July 23, 1991	
; PRIOR APPLICATION DATA:		; PRIOR APPLICATION DATA:	
; APPLICATION NUMBER: 08/063,167		; APPLICATION NUMBER: 08/063,167	
; FILING DATE: 5/17/93		; FILING DATE: 5/17/93	
; PRIOR APPLICATION DATA:		; PRIOR APPLICATION DATA:	
; APPLICATION NUMBER: 08/007,997		; APPLICATION NUMBER: 08/007,997	
; FILING DATE: 1/21/93		; FILING DATE: 1/21/93	
; PRIOR APPLICATION DATA:		; PRIOR APPLICATION DATA:	
; APPLICATION NUMBER: 07/939,855		; APPLICATION NUMBER: 07/939,855	
; FILING DATE: 9/2/92		; FILING DATE: 9/2/92	
; PRIOR APPLICATION DATA:		; PRIOR APPLICATION DATA:	
; APPLICATION NUMBER: 07/567,286		; APPLICATION NUMBER: 07/567,286	
; FILING DATE: 8/14/90		; FILING DATE: 8/14/90	
; ATTORNEY/AGENT INFORMATION:		; ATTORNEY/AGENT INFORMATION:	
; NAME: Jane Massey Licata		; NAME: Jane Massey Licata	
; REGISTRATION NUMBER: 32,257		; REGISTRATION NUMBER: 32,257	
; REFERENCE/DOCKET NUMBER: ISPH-0098		; REFERENCE/DOCKET NUMBER: ISPH-0098	
; TELECOMMUNICATION INFORMATION:		; TELECOMMUNICATION INFORMATION:	
; TELEPHONE: (609) 779-2400		; TELEPHONE: (609) 779-2400	
; TELEFAX: (609) 779-8488		; TELEFAX: (609) 779-8488	
; INFORMATION FOR SEQ ID NO: 13:		; INFORMATION FOR SEQ ID NO: 14:	
; SEQUENCE CHARACTERISTICS:		; SEQUENCE CHARACTERISTICS:	
; LENGTH: 20		; LENGTH: 20	
; TYPE: Nucleic Acid		; TYPE: Nucleic Acid	
; STRANDEDNESS: Single		; STRANDEDNESS: Single	
; TOPOLOGY: Linear		; TOPOLOGY: Linear	
; ANTI-SENSE: Yes		; ANTI-SENSE: Yes	
US-08-344-155C-13		US-08-344-155C-14	
Query Match 0.7%; Score 20; DB 1; Length 20;		Query Match 0.7%; Score 20; DB 1; Length 20;	
Best Local Similarity 100.0%; Pred. No. 2.1e+02;		Best Local Similarity 100.0%; Pred. No. 2.1e+02;	
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY 1654	TGAACCTATCCCGGACAGG 1673	QY 1654	TGAACCTATCCCGGACAGG 1673
Db 20	TGAACCTATCCCGGACAGG 1	Db 20	TGAACCTATCCCGGACAGG 1


```
;
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,155C
; FILING DATE: No. 5883082ember 23, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/063,167
; FILING DATE: 5/17/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/007,997
; FILING DATE: 1/21/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/939,855
; FILING DATE: 9/2/92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/567,286
; FILING DATE: 8/14/90
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0098
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-344-155C-22

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
DB 20 TGACGGATGCCAGCTTGGC 1

RESULT 179
US-08-344-155C-23/c
; Sequence 23, Application US/08344155C
; Patent No. 5883082
; GENERAL INFORMATION:
; APPLICANT: Bennett and Stepkowski
; TITLE OF INVENTION: Compositions and Methods for Preventing
; and Treating Allograft Rejection
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
```

```
;
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,155C
; FILING DATE: No. 5883082ember 23, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/063,167
; FILING DATE: 5/17/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/007,997
; FILING DATE: 1/21/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/939,855
; FILING DATE: 9/2/92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/567,286
; FILING DATE: 8/14/90
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0098
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-344-155C-23

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
DB 20 GAGGCCACAGACTTACAGA 1

RESULT 180
US-08-344-155C-24/c
; Sequence 24, Application US/08344155C
; Patent No. 5883082
; GENERAL INFORMATION:
; APPLICANT: Bennett and Stepkowski
; TITLE OF INVENTION: Compositions and Methods for Preventing
; and Treating Allograft Rejection
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
```

COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/344,155C
FILING DATE: No. 5883082ember 23, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/063,167
FILING DATE: 5/17/93
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/007,997
FILING DATE: 1/21/93
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/939,855
FILING DATE: 9/2/92
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/567,286
FILING DATE: 8/14/90
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0098
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-344-155C-24

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900
DB 20 CAAGAGGAGGAGCAAGACT 1

RESULT 181
US-08-344-155C-25/c
Sequence 25, Application US/08344155C
Patent No. 5883082
GENERAL INFORMATION:
APPLICANT: Bennett and Stepkowski
TITLE OF INVENTION: Compositions and Methods for Preventing
TITLE OF INVENTION: and Treating Allograft Rejection
NUMBER OF SEQUENCES: 99
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/344,155C

FILING DATE: No. 5883082ember 23, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/063,167
FILING DATE: 5/17/93
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/007,997
FILING DATE: 1/21/93
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/939,855
FILING DATE: 9/2/92
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/567,286
FILING DATE: 8/14/90
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0098
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-344-155C-25

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAAGTCTAGCCTGATGAG 1940
DB 20 TTAAAGTCTAGCCTGATGAG 1

RESULT 182
US-08-344-155C-26/c
Sequence 26, Application US/08344155C
Patent No. 5883082
GENERAL INFORMATION:
APPLICANT: Bennett and Stepkowski
TITLE OF INVENTION: Compositions and Methods for Preventing
TITLE OF INVENTION: and Treating Allograft Rejection
NUMBER OF SEQUENCES: 99
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/344,155C
FILING DATE: No. 5883082ember 23, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992

APPLICATION NUMBER: 07/939,855
FILING DATE: 9/2/92
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/567,286
FILING DATE: 8/14/90
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0098
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 85:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-344-155C-85

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGGTGGGGGAGACATA 1964
|||||
DB 20 GAAGTGGTGGGGGAGACATA 1

RESULT 185

US-08-594-452-21/c
Sequence 21, Application US/08594452
Patent No. 6013639
GENERAL INFORMATION:
APPLICANT: PEYMAN, Anushirwan
APPLICANT: UHLMANN, Eugen
TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 105
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/594,452
FILING DATE: 31-JAN-1996
CLASSIFICATION: 536

PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE 195 02 912.7
FILING DATE: 31-JAN-1995
ATTORNEY/AGENT INFORMATION:
NAME: SANDERCOCK, Colin G.
REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 18748/264/HOCE
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399
TELEX: 904136

INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-594-452-21

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAAGTGGTGGGGG 1957
|||||
DB 20 GAGAGGGGAAGTGGTGGGGG 1

RESULT 186

US-08-594-452-22/c
Sequence 22, Application US/08594452
Patent No. 6013639
GENERAL INFORMATION:
APPLICANT: PEYMAN, Anushirwan
APPLICANT: UHLMANN, Eugen
TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 105
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/594,452
FILING DATE: 31-JAN-1996
CLASSIFICATION: 536

PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE 195 02 912.7
FILING DATE: 31-JAN-1995
ATTORNEY/AGENT INFORMATION:
NAME: SANDERCOCK, Colin G.
REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 18748/264/HOCE
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-594-452-22

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGGAG 1959
|||||
DB 20 GAGGGGAAGTGGTGGGGGAG 1

RESULT 187

US-08-982-845B-2/c
Sequence 2, Application US/08982845B
Patent No. 6015894
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
TITLE OF INVENTION: of Cell Adhesion
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:

```

; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8498
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
; US-08-982-845B-2

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 7 CAGTCGACGCTGAGCTCCTC 26
Db 20 CAGTCGACGCTGAGCTCCTC 1

```

```

RESULT 188
US-08-982-845B-7/c
; Sequence 7, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA

```

```

; ZIP: 08053
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8498
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
; US-08-982-845B-7

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 41 GCAACCTCAGCCTCGCTATG 60
Db 20 GCAACCTCAGCCTCGCTATG 1

```

```

RESULT 189
US-08-982-845B-8/c
; Sequence 8, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95

```

```

; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-982-845B-8

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 58 ATGGCTCCCGAGCCGCCG 77
DB 20 ATGGCTCCCGAGCCGCCG 1

```

```

RESULT 190
US-08-982-845B-9/c
; Sequence 9, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514

```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-982-845B-9

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 97 CTGGTCTCTCTCGGGCTCT 116
DB 20 CTGGTCTCTCTCGGGCTCT 1

```

```

RESULT 191
US-08-982-845B-10/c
; Sequence 10, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167

```

; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA: 969,151
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-982-845B-10

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
|||||
Db 20 TCAAACTGCCCTGATGGCA 1

RESULT 192
US-08-982-845B-11/c
; Sequence 11, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-982-845B-11

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGTGACC 894
|||||
Db 20 AGGCCTCAGTCAGTGTGACC 1

RESULT 193
US-08-982-845B-12/c
; Sequence 12, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: AUGUST 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-982-845B-12

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGAGGTCACCCGGAG 1464
Db 20 AAGGGAGGTCACCCGGAG 1

RESULT 194
US-08-982-845B-13/c
; Sequence 13, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; NAME: Jane Massey Licata
```

```

; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-982-845B-13

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAGCCACGGCTCCCTGA 1656
Db 20 CACAGCCACGGCTCCCTGA 1

RESULT 195
US-08-982-845B-14/c
; Sequence 14, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; NAME: Jane Massey Licata
```

```
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20
;   TYPE: Nucleic Acid
;   STRANDEDNESS: Single
;   TOPOLOGY: Linear
;   ANTI-SENSE: Yes
; US-08-982-845B-14
;
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
Db 20 TGAACCTATCCCGGACAGG 1

RESULT 196
US-08-982-845B-15/c
; Sequence 15, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20
;   TYPE: Nucleic Acid
;   STRANDEDNESS: Single
;   TOPOLOGY: Linear
;   ANTI-SENSE: Yes
; US-08-982-845B-16

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
Db 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 197
US-08-982-845B-16/c
; Sequence 16, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20
;   TYPE: Nucleic Acid
;   STRANDEDNESS: Single
;   TOPOLOGY: Linear
;   ANTI-SENSE: Yes
; US-08-982-845B-16

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAAGCTTCTCA 2981
|||||
Db 20 AGTTAATAAAGCTTCTCA 1

RESULT 198
US-08-982-845B-22/c
; Sequence 22, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-982-845B-22

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGATGCCAGCTTGGC 2119
|||||

Db 20 TGACGATGCCAGCTTGGC 1

RESULT 199
US-08-982-845B-23/c
; Sequence 23, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-982-845B-23

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
|||||

Db 20 GAGGCCACAGACTTACAGA 1

RESULT 200
US-08-982-845B-24/c


```
; Sequence 24, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-982-845B-24

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900
Db 20 CAAGAGGAGGAGCAAGACT 1

RESULT 201
US-08-982-845B-25/c
; Sequence 25, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
```

```
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-982-845B-25

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAGTCTAGCCTGATGAG 1940
Db 20 TTAAGTCTAGCCTGATGAG 1

RESULT 202
US-08-982-845B-26/c
; Sequence 26, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
```

;; CITY: Marlton
;; STATE: NJ
;; COUNTRY: USA
;; ZIP: 08053
;;
;; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;;
;; COMPUTER: IBM PS/2
;; OPERATING SYSTEM: Windows 95
;; SOFTWARE: WORDPERFECT 6.0
;;
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/982,845B
;; FILING DATE: December 2, 1997
;; CLASSIFICATION: 514
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/440,740
;; FILING DATE: May 12, 1995
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 063,167
;; FILING DATE: May 17, 1993
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 21, 1993
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;;
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;;
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0243
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 779-8488
;; INFORMATION FOR SEQ ID NO: 26:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
;;
US-08-982-845B-26

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCCAGGAGCA 1981
Db 20 ATAGCCCCCAGGAGCA 1

RESULT 203
US-08-982-845B-84/c
; Sequence 84, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:

;; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;;
;; COMPUTER: IBM PS/2
;; OPERATING SYSTEM: Windows 95
;; SOFTWARE: WORDPERFECT 6.0
;;
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/982,845B
;; FILING DATE: December 2, 1997
;; CLASSIFICATION: 514
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/440,740
;; FILING DATE: May 12, 1995
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 063,167
;; FILING DATE: May 17, 1993
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 21, 1993
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;;
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;;
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0243
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 779-8488
;; INFORMATION FOR SEQ ID NO: 84:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
;;
US-08-982-845B-84

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 204
US-08-982-845B-85/c
; Sequence 85, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:

```
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA: 063,167
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA: 007,997
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA: 567,286
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 85:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-982-845B-85

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGTGGGGGAGACATA 1964
Db 20 GAAGTGTGGGGGAGACATA 1

RESULT 205
US-08-578-686C-20/c
; Sequence 20, Application US/08578686C
; Patent No. 6028182
; GENERAL INFORMATION:
; APPLICANT: Uhlmann, Eugen
; TITLE OF INVENTION: Methylphosphonic Acid Ester, Process For
; PREPARING THE SAME AND ITS USE
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; STREET: 1300 I. Street, N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: January 2, 1996
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
```

```
; NAME: Johnson, Lori-Ann
; REGISTRATION NUMBER: 34,498
; REFERENCE/DOCKET NUMBER: 2481.1481-00000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-408-4000
; TELEFAX: 202-408-4400
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-578-686C-20

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
Db 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 206
US-08-578-686C-21/c
; Sequence 21, Application US/08578686C
; Patent No. 6028182
; GENERAL INFORMATION:
; APPLICANT: Uhlmann, Eugen
; TITLE OF INVENTION: Methylphosphonic Acid Ester, Process For
; PREPARING THE SAME AND ITS USE
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; STREET: 1300 I. Street, N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: January 2, 1996
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Johnson, Lori-Ann
; REGISTRATION NUMBER: 34,498
; REFERENCE/DOCKET NUMBER: 2481.1481-00000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-408-4000
; TELEFAX: 202-408-4400
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-578-686C-21

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGTGGGGGAG 1959
Db 20 GAGGGGAAGTGTGGGGGAG 1
```

```
RESULT 207
US-08-281-203-19/c
; Sequence 19, Application US/08281203
; Patent No. 6033909
; GENERAL INFORMATION:
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Peyman, Anuschirwan
; APPLICANT: O'Malley, Gerard
; APPLICANT: Heisberg, Mathias
; APPLICANT: Winkler, Irvin
; TITLE OF INVENTION: Oligonucleotide Analogs, Their
; TITLE OF INVENTION: Preparation and Use
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner
; STREET: 1300 I Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/281,203
; FILING DATE: 27-JULY-1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/003,972
; FILING DATE: 19-JAN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Einaudi, Carol P.
; REGISTRATION NUMBER: 32,220
; REFERENCE/DOCKET NUMBER: 02481.1269-01000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-408-4000
; TELEFAX: 202-408-4400
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-281-203-19
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGTGGGGGAG 1959
Db 20 GAGGGGAAGTGTGGGGGAG 1

RESULT 208
US-08-295-509B-1/c
; Sequence 1, Application US/08295509B
; Patent No. 6045995
; GENERAL INFORMATION:
; APPLICANT: Cummins, Lendell L.
; APPLICANT: Freier, Susan M.
; APPLICANT: Griffey, Richard
; APPLICANT: Srivatsa, Susan G.
; TITLE OF INVENTION: Capillary Electrophoretic Detection of
; TITLE OF INVENTION: Nucleic Acids
; NUMBER OF SEQUENCES: 4
```

```
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6045995ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/295,509B
; FILING DATE: 24-AUG-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Michael P. Straher
; REGISTRATION NUMBER: 38,325
; REFERENCE/DOCKET NUMBER: ISIS-1395
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-295-509B-1
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGTCTCTCTGCTACTCAGA 37
Db 20 GAGTCTCTCTGCTACTCAGA 1

RESULT 209
US-09-094-405-25/c
; Sequence 25, Application US/09094405
; Patent No. 6066720
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Modified oligonucleotides, their preparation
; TITLE OF INVENTION: and use
; NUMBER OF SEQUENCES: 30
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/094,405
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/940,196
; FILING DATE:
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; ORIGINAL SOURCE:
; ORGANISM: human
; FEATURE:
```

```
; NAME/KEY: exon
; LOCATION: 1..20
; OTHER INFORMATION: /note= "ICAM"
US-09-094-405-25

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

QY 1938 GAGAGGGGAAGTGGTGGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGGG 1

RESULT 210
US-09-094-405-26/c
; Sequence 26, Application US/09094405
; Patent No. 6066720
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Modified oligonucleotides, their preparation
; TITLE OF INVENTION: and use
; NUMBER OF SEQUENCES: 30
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/094,405
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/940,196
; FILING DATE:
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; ORIGINAL SOURCE:
; ORGANISM: human
; FEATURE:
; NAME/KEY: exon
; LOCATION: 1..20
; OTHER INFORMATION: /note= "ICAM"
US-09-094-405-26

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

QY 1940 GAGGGGAAGTGGTGGGGGAG 1959
|||||
Db 20 GAGGGGAAGTGGTGGGGGAG 1

RESULT 211
US-08-777-266A-17/c
; Sequence 17, Application US/08777266A
; Patent No. 6077833
; GENERAL INFORMATION:
; APPLICANT: Clarence Frank Bennett
; APPLICANT: Timothy A. Vickers
; TITLE OF INVENTION: Oligonucleotide Compositions and
; TITLE OF INVENTION: Methods for the Modulation of the Expression of B7 Proteins
; NUMBER OF SEQUENCES: 125
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata

; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/777,266A
; FILING DATE: December 31, 1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0201
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; PUBLICATION INFORMATION:
; DOCUMENT NUMBER: US 5514788
; FILING DATE: 17-MAY-1993
; PUBLICATION DATE: 07-MAY-1996
; ANTI-SENSE: Yes
; US-08-777-266A-17

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 212
US-09-166-186-41/c
; Sequence 41, Application US/09166186A
; Patent No. 6080580
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TNF-a EXPRESSION
; FILE REFERENCE: ISPH-0322
; CURRENT APPLICATION NUMBER: US/09/166,186A
; CURRENT FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 250
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: control sequence
US-09-166-186-41

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
```

Db 20 TGACGGATGCCAGCTGGGC 1
|||||

RESULT 213
US-09-166-186-49/c
; Sequence 49, Application US/09166186A
; Patent No. 6080580
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TNF-a EXPRESSION
; FILE REFERENCE: ISPH-0322
; CURRENT APPLICATION NUMBER: US/09/166,186A
; CURRENT FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 250
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: control sequence
US-09-166-186-49

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||

Db 20 GAGCTCCTCTGCTACTCAGA 1
|||||

RESULT 214
US-08-991-525B-2/c
; Sequence 2, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990

; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (856) 810-1515
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-991-525B-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 7 CAGTCGACGCTGAGCTCCTC 26
|||||

Db 20 CAGTCGACGCTGAGCTCCTC 1
|||||

RESULT 215
US-08-991-525B-7/c
; Sequence 7, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (856) 810-1515
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-991-525B-7

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCTCGCTATG 60
Db 20 GCAACCTCAGCTCGCTATG 1

RESULT 216
US-08-991-525B-8/c
; Sequence 8, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELEPHONE: (856) 810-1515
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-991-525B-8

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCAGCAGCCCCG 77
Db 20 ATGGCTCCAGCAGCCCCG 1

RESULT 217
US-08-991-525B-9/c
; Sequence 9, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELEPHONE: (856) 810-1515
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-991-525B-8
```

;
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-991-525B-9

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTGCTCGGGGCTCT 116
DB 20 CTGGTCTGCTCGGGGCTCT 1

RESULT 218
US-08-991-525B-10/C
; Sequence 10, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELEPHONE: (856) 810-1515
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-991-525B-10

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
DB 20 TCAAACTGCCCTGATGGCA 1

RESULT 219
US-08-991-525B-11/c
; Sequence 11, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELEPHONE: (856) 810-1515
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-991-525B-11

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCACTGACG 894
|||||
Db 20 AGGCCTCACTGACG 1

RESULT 220
US-08-991-525B-12/c
; Sequence 12, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (856) 810-1515
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-991-525B-12

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1445 AAGGGAGGTCACCGCGAG 1464
|||||
Db 20 AAGGGAGGTCACCGCGAG 1

RESULT 221
US-08-991-525B-13/c
; Sequence 13, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (856) 810-1515
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-991-525B-13

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCACGCTCCCTGA 1656
|||||
Db 20 CACAAGCCACGCTCCCTGA 1

RESULT 222
US-08-991-525B-14/c
; Sequence 14, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:

APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: Windows 95
SOFTWARE: WORDPERFECT 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/991,525B
FILING DATE: December 16, 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 440,740
FILING DATE: May 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 063,167
FILING DATE: May 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 969,151
FILING DATE: February 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 007,997
FILING DATE: January 21, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0247
TELEPHONE: (856) 810-1515
TELEFAX: (856) 810-1454
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-991-525B-14

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
DB 20 TGAACCTATCCCGGACAGG 1

RESULT 223
US-08-991-525B-15/c
Sequence 15, Application US/08991525B
Patent No. 6093811
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:

ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: Windows 95
SOFTWARE: WORDPERFECT 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/991,525B
FILING DATE: December 16, 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 440,740
FILING DATE: May 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 063,167
FILING DATE: May 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 969,151
FILING DATE: February 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 007,997
FILING DATE: January 21, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0247
TELEPHONE: (856) 810-1515
TELEFAX: (856) 810-1454
INFORMATION FOR SEQ ID NO: 15:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-991-525B-15

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
DB 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 224
US-08-991-525B-16/c
Sequence 16, Application US/08991525B
Patent No. 6093811
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA

```

; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (856) 810-1454
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
US-08-991-525B-16

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAAGCTTCTCAA 2981
Db 20 AGTTAATAAAGCTTCTCAA 1

RESULT 225
US-08-991-525B-22/c
; Sequence 22, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95

```

```

; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (856) 810-1515
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
US-08-991-525B-22

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 226
US-08-991-525B-23/c
; Sequence 23, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514

```

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 440,740
;; FILING DATE: May 12, 1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 063,167
;; FILING DATE: May 17, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 21, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0247
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (856) 810-1515
;; TELEFAX: (856) 810-1454
;; INFORMATION FOR SEQ ID NO: 23:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-08-991-525B-23

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
US-08-991-525B-23

QY 2025 GAGGCCACAGACTTACAGA 2044
DB 20 GAGGCCACAGACTTACAGA 1

RESULT 227
US-08-991-525B-24/c
; Sequence 24, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167

;; FILING DATE: May 17, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 21, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0247
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (856) 810-1515
;; TELEFAX: (856) 810-1454
;; INFORMATION FOR SEQ ID NO: 24:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-08-991-525B-24

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
US-08-991-525B-24

QY 1881 CAAGAGGAGGAGCAAGACT 1900
DB 20 CAAGAGGAGGAGCAAGACT 1

RESULT 228
US-08-991-525B-25/c
; Sequence 25, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (856) 810-1515
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-991-525B-25
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAAGTCTAGCCTGATGAG 1940
Db 20 TTAAAGTCTAGCCTGATGAG 1
```

```
RESULT 229
US-08-991-525B-26/c
; Sequence 26, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
```

```
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (856) 810-1515
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-991-525B-26

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCACCATGAGGACA 1981
Db 20 ATAGCCCCACCATGAGGACA 1

RESULT 230
US-08-991-525B-84/c
; Sequence 84, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
```

REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (856) 810-1515
TELEFAX: (856) 810-1454
INFORMATION FOR SEQ ID NO: 84:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-991-525B-84

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTGCTACTCAGA 37
|||||
DB 20 GAGCTCCTGCTACTCAGA 1

RESULT 231

US-08-991-525B-85/c
Sequence 85, Application US/08991525B
Patent No. 6093811
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
TITLE OF INVENTION: of Cell Adhesion
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: Windows 95
SOFTWARE: WORDPERFECT 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/991,525B
FILING DATE: December 16, 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 440,740
FILING DATE: May 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 063,167
FILING DATE: May 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 969,151
FILING DATE: February 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 007,997
FILING DATE: January 21, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (856) 810-1515
TELEFAX: (856) 810-1454

INFORMATION FOR SEQ ID NO: 85:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-991-525B-85

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGTGGGGGAGACATA 1964
|||||
DB 20 GAAGTGTGGGGGAGACATA 1

RESULT 232

US-09-085-759-2/c
Sequence 2, Application US/09085759
Patent No. 6096722
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett, Christopher Mirabelli,
APPLICANT: Brenda Baker
TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
TITLE OF INVENTION: Molecule-Associated Diseases
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/085,759
FILING DATE: herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/440,740
FILING DATE: May 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 063,167
FILING DATE: May 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 969,151
FILING DATE: February 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 007,997
FILING DATE: January 20, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0311
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 20

```
;
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-085-759-2
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
    |||||
Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 233
US-09-085-759-7/c
; Sequence 7, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-8488
; TELEFAX: (609) 779-2400
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-085-759-8
```

```
;
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-085-759-7
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCACCTCAGCTCGCTATG 60
    |||||
Db 20 GCACCTCAGCTCGCTATG 1

RESULT 234
US-09-085-759-8/c
; Sequence 8, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-085-759-8
```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCCGAGAGCCCGG 77
DB 20 ATGGCTCCCGAGAGCCCGG 1

RESULT 235
US-09-085-759-9/c
; Sequence 9, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-085-759-9

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTCTGCTCGGGCTCT 116
DB 20 CTGGTCTCTGCTCGGGCTCT 1

RESULT 236
US-09-085-759-10/c
; Sequence 10, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-085-759-10

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAGAACTGCTGATGGCA 356


```
Db      20 TCAACTGCCCTGATGGCA 1

RESULT 237
US-09-085-759-11/c
; Sequence 11, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
US-09-085-759-11
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      875 AGCCTCAGTCAGTGTGACC 894
        |||||
Db      20 AGCCTCAGTCAGTGTGACC 1

RESULT 238
US-09-085-759-12/c
; Sequence 12, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
US-09-085-759-12
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1445 AAGGGGAGGTCAACCGCGAG 1464
        |||||
Db      20 AAGGGGAGGTCAACCGCGAG 1

RESULT 239
US-09-085-759-13/c
; Sequence 13, Application US/09085759
```

Patent No. 6096722
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett, Christopher Mirabelli,
APPLICANT: Brenda Baker
TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
TITLE OF INVENTION: Molecule-Associated Diseases
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/085,759
FILING DATE: herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/440,740
FILING DATE: May 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 063,167
FILING DATE: May 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 969,151
FILING DATE: February 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 007,997
FILING DATE: January 20, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0311
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-09-085-759-13

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCAGCGCTCCCTGA 1656
|||||
Db 20 CACAAGCCAGCGCTCCCTGA 1

RESULT 240
US-09-085-759-14/c
Sequence 14, Application US/09085759
Patent No. 6096722
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett, Christopher Mirabelli,

APPLICANT: Brenda Baker
TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
TITLE OF INVENTION: Molecule-Associated Diseases
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/085,759
FILING DATE: herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/440,740
FILING DATE: May 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 063,167
FILING DATE: May 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 969,151
FILING DATE: February 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 007,997
FILING DATE: January 20, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0311
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-09-085-759-14

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
|||||
Db 20 TGAACCTATCCCGGACAGG 1

RESULT 241
US-09-085-759-15/c
Sequence 15, Application US/09085759
Patent No. 6096722
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett, Christopher Mirabelli,
APPLICANT: Brenda Baker
TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion

;; TITLE OF INVENTION: Molecule-Associated Diseases
;; NUMBER OF SEQUENCES: 109
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Law Offices of Jane Massey Licata
;; STREET: 66 East Main Street
;; CITY: Marlton
;; STATE: NJ
;; COUNTRY: USA
;; ZIP: 08053
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;; COMPUTER: IBM PS/2
;; OPERATING SYSTEM: PC-DOS
;; SOFTWARE: WORDPERFECT 5.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/085,759
;; FILING DATE: herewith
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/440,740
;; FILING DATE: May 12, 1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 063,167
;; FILING DATE: May 17, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 20, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0311
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 779-8488
;; INFORMATION FOR SEQ ID NO: 15:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-09-085-759-15

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAAGTGTGGGG 1957
Db 20 GAGAGGGGAAGTGTGGGG 1

RESULT 242
US-09-085-759-16/c
; Sequence 16, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:

;; ADDRESSEE: Law Offices of Jane Massey Licata
;; STREET: 66 East Main Street
;; CITY: Marlton
;; STATE: NJ
;; COUNTRY: USA
;; ZIP: 08053
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;; COMPUTER: IBM PS/2
;; OPERATING SYSTEM: PC-DOS
;; SOFTWARE: WORDPERFECT 5.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/085,759
;; FILING DATE: herewith
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/440,740
;; FILING DATE: May 12, 1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 063,167
;; FILING DATE: May 17, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 20, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0311
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 779-8488
;; INFORMATION FOR SEQ ID NO: 16:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-09-085-759-16

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2962 AGTTAATRAAGCTTTCTCAA 2981
Db 20 AGTTAATRAAGCTTTCTCAA 1

RESULT 243
US-09-085-759-22/c
; Sequence 22, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton

STATE: NJ
 COUNTRY: USA
 ZIP: 08053
 COMPUTER READABLE FORM:
 MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
 COMPUTER: IBM PS/2
 OPERATING SYSTEM: PC-DOS
 SOFTWARE: WORDPERFECT 5.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/085,759
 FILING DATE: herewith

CLASSIFICATION:
 PRIOR APPLICATION DATA: 08/440,740
 FILING DATE: May 12, 1995
 PRIOR APPLICATION DATA: 063,167
 FILING DATE: May 17, 1993
 PRIOR APPLICATION DATA: 969,151
 FILING DATE: February 10, 1993
 PRIOR APPLICATION DATA: 007,997
 FILING DATE: January 20, 1993
 PRIOR APPLICATION DATA: 939,855
 FILING DATE: September 2, 1992
 PRIOR APPLICATION DATA: 567,286
 FILING DATE: August 14, 1990
 ATTORNEY/AGENT INFORMATION:
 NAME: Jane Massey Licata
 REGISTRATION NUMBER: 32,257
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (609) 779-2400
 INFORMATION FOR SEQ ID NO: 22:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 20
 TYPE: Nucleic Acid
 STRANDEDNESS: Single
 TOPOLOGY: Linear
 ANTI-SENSE: Yes
 US-09-085-759-22

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
 Db |||||

RESULT 244
 US-09-085-759-23/c
 Sequence 23, Application US/09085759
 Patent No. 6096722
 GENERAL INFORMATION:
 APPLICANT: C. Frank Bennett, Christopher Mirabelli,
 APPLICANT: Brenda Baker
 TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
 TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
 TITLE OF INVENTION: Molecule-Associated Diseases
 NUMBER OF SEQUENCES: 109
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Law Offices of Jane Massey Licata
 STREET: 66 East Main Street
 CITY: Marlton
 STATE: NJ
 COUNTRY: USA
 ZIP: 08053

COMPUTER READABLE FORM:
 MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
 COMPUTER: IBM PS/2
 OPERATING SYSTEM: PC-DOS
 SOFTWARE: WORDPERFECT 5.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/09/085,759
 FILING DATE: herewith
 CLASSIFICATION:
 PRIOR APPLICATION DATA: 08/440,740
 FILING DATE: May 12, 1995
 PRIOR APPLICATION DATA: 063,167
 FILING DATE: May 17, 1993
 PRIOR APPLICATION DATA: 969,151
 FILING DATE: February 10, 1993
 PRIOR APPLICATION DATA: 007,997
 FILING DATE: January 20, 1993
 PRIOR APPLICATION DATA: 939,855
 FILING DATE: September 2, 1992
 PRIOR APPLICATION DATA: 567,286
 FILING DATE: August 14, 1990
 ATTORNEY/AGENT INFORMATION:
 NAME: Jane Massey Licata
 REGISTRATION NUMBER: 32,257
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (609) 779-2400
 INFORMATION FOR SEQ ID NO: 23:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 20
 TYPE: Nucleic Acid
 STRANDEDNESS: Single
 TOPOLOGY: Linear
 ANTI-SENSE: Yes
 US-09-085-759-23

Query Match 0.7%; Score 20; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
 Db |||||

RESULT 245
 US-09-085-759-24/c
 Sequence 24, Application US/09085759
 Patent No. 6096722
 GENERAL INFORMATION:
 APPLICANT: C. Frank Bennett, Christopher Mirabelli,
 APPLICANT: Brenda Baker
 TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
 TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
 TITLE OF INVENTION: Molecule-Associated Diseases
 NUMBER OF SEQUENCES: 109
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Law Offices of Jane Massey Licata
 STREET: 66 East Main Street
 CITY: Marlton
 STATE: NJ
 COUNTRY: USA
 ZIP: 08053
 COMPUTER READABLE FORM:
 MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
 COMPUTER: IBM PS/2

```

; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-085-759-24

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1881 CAAGAGGAGGAGCAAGACT 1900
Db 20 CAAGAGGAGGAGCAAGACT 1

RESULT 246
US-09-085-759-25/c
; Sequence 25, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:

```

```

; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-085-759-25

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1921 TTAAGTCTAGCCTGATGAG 1940
Db 20 TTAAGTCTAGCCTGATGAG 1

RESULT 247
US-09-085-759-26/c
; Sequence 26, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:

```


;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 20, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 32,257
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0311
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 779-8488
;; INFORMATION FOR SEQ ID NO: 85:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
;;
US-09-085-759-85

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGGTGGGAGACATA 1964
Db 20 GAAGTGGTGGGAGACATA 1

RESULT 250
US-09-085-759-97/c
; Sequence 97, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 20, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0311
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 779-8488
;; INFORMATION FOR SEQ ID NO: 97:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;;
US-09-085-759-97

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1497 GATTGTCATCATCTGTTGG 1516
Db 20 GATTGTCATCATCTGTTGG 1

RESULT 251
US-09-085-759-100/c
; Sequence 100, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:

APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0311
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8486
INFORMATION FOR SEQ ID NO: 100:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-09-085-759-100

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1587 GAAATACAGACTACACAGG 1606
|||||
Db 20 GAAATACAGACTACACAGG 1

RESULT 252
US-09-062-416-2/c
Sequence 2, Application US/09062416
Patent No. 6111094
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett, Thomas P. Condon,
APPLICANT: Shin Cheng Flournoy
TITLE OF INVENTION: ENHANCED ANTISENSE MODULATION OF ICAM-1
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 EAST MAIN STREET
CITY: MARLTON
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/062,416
FILING DATE: Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/440,740
FILING DATE: MAY 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/063,167
FILING DATE: MAY 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/969,151
FILING DATE: FEB 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/007,997
FILING DATE: JAN 21, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/939,855
FILING DATE: SEP 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/567,286
FILING DATE: AUG 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0306
TELEPHONE: (609) 779-2400

NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0306
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400
TELEFAX: (609) 810-1454
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-09-062-416-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 253
US-09-062-416-5/c
Sequence 5, Application US/09062416
Patent No. 6111094
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett, Thomas P. Condon,
APPLICANT: Shin Cheng Flournoy
TITLE OF INVENTION: ENHANCED ANTISENSE MODULATION OF ICAM-1
NUMBER OF SEQUENCES: 33
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 EAST MAIN STREET
CITY: MARLTON
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/062,416
FILING DATE: Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/440,740
FILING DATE: MAY 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/063,167
FILING DATE: MAY 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/969,151
FILING DATE: FEB 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/007,997
FILING DATE: JAN 21, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/939,855
FILING DATE: SEP 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/567,286
FILING DATE: AUG 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0306
TELEPHONE: (609) 779-2400


```
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-062-416-5

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2102 ACGGATGCCAGCTTGGGCAC 2121
Db 20 ACGGATGCCAGCTTGGGCAC 1

RESULT 254
US-09-062-416-6/c
; Sequence 6, Application US/09062416
; Patent No. 6111094
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Thomas P. Condon,
; APPLICANT: Shin Cheng Flournoy
; TITLE OF INVENTION: ENHANCED ANTISENSE MODULATION OF ICAM-1
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 EAST MAIN STREET
; CITY: MARLTON
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/062,416
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: MAY 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/063,167
; FILING DATE: MAY 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/969,151
; FILING DATE: FEB 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/007,997
; FILING DATE: JAN 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/939,855
; FILING DATE: SEP 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/567,286
; FILING DATE: AUG 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0306
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
```

```
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-062-416-6

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2106 ATGCCAGCTTGGGCACCTGCT 2125
Db 20 ATGCCAGCTTGGGCACCTGCT 1

RESULT 255
US-09-062-416-11/c
; Sequence 11, Application US/09062416
; Patent No. 6111094
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Thomas P. Condon,
; APPLICANT: Shin Cheng Flournoy
; TITLE OF INVENTION: ENHANCED ANTISENSE MODULATION OF ICAM-1
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 EAST MAIN STREET
; CITY: MARLTON
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/062,416
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: MAY 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/063,167
; FILING DATE: MAY 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/969,151
; FILING DATE: FEB 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/007,997
; FILING DATE: JAN 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/939,855
; FILING DATE: SEP 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/567,286
; FILING DATE: AUG 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0306
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-062-416-11
```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 256

US-08-950-779-2/c
; Sequence 2, Application US/08950779
; Patent No. 6114519
; GENERAL INFORMATION:
; APPLICANT: Cole, Douglas L.
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Cheruvallath, Zacharia S.
; TITLE OF INVENTION: Synthesis of Sulfurized Oligonucleotides
; FILE REFERENCE: ISIS2585
; CURRENT APPLICATION NUMBER: US/08/950,779
; CURRENT FILING DATE: 1997-10-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: No. 6114519el Sequence
US-08-950-779-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 257

US-08-950-779-8/c
; Sequence 8, Application US/08950779
; Patent No. 6114519
; GENERAL INFORMATION:
; APPLICANT: Cole, Douglas L.
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Cheruvallath, Zacharia S.
; TITLE OF INVENTION: Synthesis of Sulfurized Oligonucleotides
; FILE REFERENCE: ISIS2585
; CURRENT APPLICATION NUMBER: US/08/950,779
; CURRENT FILING DATE: 1997-10-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule: No. 6114519el
; OTHER INFORMATION: Sequence
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: No. 6114519el Sequence
US-08-950-779-8

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 258

US-08-950-779-9/c
; Sequence 9, Application US/08950779
; Patent No. 6114519
; GENERAL INFORMATION:
; APPLICANT: Cole, Douglas L.
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Cheruvallath, Zacharia S.
; TITLE OF INVENTION: Synthesis of Sulfurized Oligonucleotides
; FILE REFERENCE: ISIS2585
; CURRENT APPLICATION NUMBER: US/08/950,779
; CURRENT FILING DATE: 1997-10-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule: No. 6114519el
; OTHER INFORMATION: Sequence
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: No. 6114519el Sequence
US-08-950-779-9

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 259

US-09-258-408-21/c
; Sequence 21, Application US/09258408
; Patent No. 6121434
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anushirwan
; APPLICANT: UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/258,408
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/594,452
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:

```
;
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-258-408-21

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
Db 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 260
US-09-258-408-22/c
; Sequence 22, Application US/09258408
; Patent No. 6121434
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anuschirwan
; APPLICANT: UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/258,408
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/594,452
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-258-408-22

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGTGGGGGAG 1959
Db 20 GAGGGGAAGTGTGGGGGAG 1

RESULT 261
US-09-196-132-21/c
; Sequence 21, Application US/09196132
; Patent No. 6127346
; GENERAL INFORMATION:
```

```
;
; APPLICANT:
; TITLE OF INVENTION: Phosphonomonoester nucleic acids,
; TITLE OF INVENTION: process for their preparation, and their use
; NUMBER OF SEQUENCES: 33
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/196,132
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/613,417
; FILING DATE:
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: yes
; FEATURE:
; NAME/KEY: exon
; LOCATION: 1..20
US-09-196-132-21

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
Db 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 262
US-09-196-132-22/c
; Sequence 22, Application US/09196132
; Patent No. 6127346
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Phosphonomonoester nucleic acids,
; TITLE OF INVENTION: process for their preparation, and their use
; NUMBER OF SEQUENCES: 33
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/196,132
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/613,417
; FILING DATE:
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: yes
; FEATURE:
; NAME/KEY: exon
; LOCATION: 1..20
US-09-196-132-22

Query Match 0.7%; Score 20; DB 1; Length 20;
```

Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGGAG 1959
|||||
Db 20 GAGGGGAAGTGGTGGGGGAG 1

RESULT 263
US-09-144-112-20/c
; Sequence 20, Application US/09144112
; Patent No. 6150510
; GENERAL INFORMATION:
; APPLICANT: SEELA, Frank
; APPLICANT: THOMAS, Horst
; TITLE OF INVENTION: MODIFIED OLIGONUCLEOTIDES, THEIR PREPARATION AND THEIR
; TITLE OF INVENTION: USE
; FILE REFERENCE: 026083/0181
; CURRENT APPLICATION NUMBER: US/09/144,112
; CURRENT FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: DE P 44 38 918.3
; PRIOR FILING DATE: 1994-11-04
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Antisense
; OTHER INFORMATION: Oligonucleotide
US-09-144-112-20

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGGG 1

RESULT 264
US-09-144-112-21/c
; Sequence 21, Application US/09144112
; Patent No. 6150510
; GENERAL INFORMATION:
; APPLICANT: SEELA, Frank
; APPLICANT: THOMAS, Horst
; TITLE OF INVENTION: MODIFIED OLIGONUCLEOTIDES, THEIR PREPARATION AND THEIR
; TITLE OF INVENTION: USE
; FILE REFERENCE: 026083/0181
; CURRENT APPLICATION NUMBER: US/09/144,112
; CURRENT FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: DE P 44 38 918.3
; PRIOR FILING DATE: 1994-11-04
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Antisense
; OTHER INFORMATION: Oligonucleotide
US-09-144-112-21

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGGAG 1959
|||||

Db 20 GAGGGGAAGTGGTGGGGGAG 1

RESULT 265
US-08-838-715B-25/c
; Sequence 25, Application US/08838715B
; Patent No. 6153595
; GENERAL INFORMATION:
; APPLICANT: Draper, Chapman, Kisner, Anderson
; TITLE OF INVENTION: Composition and Method for Treatment
; TITLE OF INVENTION: of CMV Infection
; NUMBER OF SEQUENCES: 90
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jane Massey Licata, Esq.
; STREET: 66 E. Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM 486
; OPERATING SYSTEM: WINDOWS FOR WORKGROUPS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/838,715B
; FILING DATE: April 9, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/568,366
; FILING DATE: 8/16/90
; APPLICATION NUMBER: 07/927,506
; FILING DATE: 11/19/92
; APPLICATION NUMBER: 08/009,263
; FILING DATE: 1/25/93
; APPLICATION NUMBER: 08/233,711
; FILING DATE: 4/26/94
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0204
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
US-08-838-715B-25

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCTCTGCTACTCAGA 1

RESULT 266
US-08-211-882-17/c
; Sequence 17, Application US/08211882
; Patent No. 6153737
; GENERAL INFORMATION:
; APPLICANT: Manoharan et al.
; TITLE OF INVENTION: Derivatized Oligonucleotides Having
; TITLE OF INVENTION: Improved Uptake And Other Properties
; NUMBER OF SEQUENCES: 18

```
;
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6153737ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/211,882
; FILING DATE: 22-APR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/782,374
; FILING DATE: 24-OCT-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-0649
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-211-882-17

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 267
US-09-414-145-2/c
; Sequence 2, Application US/09414145
; Patent No. 6160152
; GENERAL INFORMATION:
; APPLICANT: Capaldi, Daniel C
; TITLE OF INVENTION: Improved Process For The Synthesis Of Oligomeric
; FILE REFERENCE: ISIS4179
; CURRENT APPLICATION NUMBER: US/09/414,145
; CURRENT FILING DATE: 1999-10-07
; PRIOR APPLICATION NUMBER: 08/021,277
; PRIOR FILING DATE: 1993-02-22
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6160152el
;
US-09-414-145-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
```

```
Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 268
US-09-128-496-2/c
; Sequence 2, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
US-09-128-496-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCTC 26
Db 20 CAGTCGACGCTGAGCTCTC 1

RESULT 269
US-09-128-496-7/c
; Sequence 7, Application US/09128496
; Patent No. 6169079
```

```
;
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-8488
; TELEFAX: (609) 779-2400
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
; US-09-128-496-7
;
; Query Match 0.7%; Score 20; DB 1; Length 20;
; Best Local Similarity 100.0%; Pred. No. 2.1e+02;
; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 41 GCAACCTCAGCCTCGCTATG 60
; Db 20 GCAACCTCAGCCTCGCTATG 1
;
; RESULT 270
; US-09-128-496-8/c
; Sequence 8, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
```

```
;
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
; US-09-128-496-8
;
; Query Match 0.7%; Score 20; DB 1; Length 20;
; Best Local Similarity 100.0%; Pred. No. 2.1e+02;
; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 58 ATGGCTCCCGAGCAGCCCG 77
; Db 20 ATGGCTCCCGAGCAGCCCG 1
;
; RESULT 271
; US-09-128-496-9/c
; Sequence 9, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
```

```

; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-128-496-9

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 97 CTGGTCTCTGCTCGGGGCTCT 116
Db 20 CTGGTCTCTGCTCGGGGCTCT 1

```

```

RESULT 272
US-09-128-496-10/c
; Sequence 10, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:

```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-128-496-10
; Query Match 0.7%; Score 20; DB 1; Length 20;
; Best Local Similarity 100.0%; Pred. No. 2.1e+02;
; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
; QY 337 TCAAACTGCCCTGATGGCA 356
; Db 20 TCAAACTGCCCTGATGGCA 1
; RESULT 273
; US-09-128-496-11/c
; Sequence 11, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855

```

;; FILING DATE: September 2, 1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0133
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 779-8488
;; INFORMATION FOR SEQ ID NO: 11:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-09-128-496-11

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGTGACC 894
|||
DB 20 AGGCCTCAGTCAGTGTGACC 1

RESULT 274

US-09-128-496-12/c
; Sequence 12, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133

;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 779-8488
;; INFORMATION FOR SEQ ID NO: 12:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-09-128-496-12

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGGAGGTCAACCCGCGAG 1464
|||
DB 20 AAGGGGAGGTCAACCCGCGAG 1

RESULT 275

US-09-128-496-13/c
; Sequence 13, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single

; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-128-496-13

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCACGGCTCCCTGA 1656
|||
Db 20 CACAAGCCACGGCTCCCTGA 1

RESULT 276

US-09-128-496-14/c
; Sequence 14, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes

US-09-128-496-14

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGACCTATCCGGGACAGG 1673
|||
Db 20 TGACCTATCCGGGACAGG 1

RESULT 277

US-09-128-496-15/c
; Sequence 15, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-128-496-15

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
|||
Db 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 278

US-09-128-496-16/c
; Sequence 16, Application US/09128496

```
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-128-496-16
;
; Query Match 0.7%; Score 20; DB 1; Length 20;
; Best Local Similarity 100.0%; Pred. No. 2.1e+02;
; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTAAATGAAGCTTCTCA 2981
Db 20 AGTAAATGAAGCTTCTCA 1

RESULT 279
US-09-128-496-22/c
; Sequence 22, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
```

```
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-128-496-22
;
; Query Match 0.7%; Score 20; DB 1; Length 20;
; Best Local Similarity 100.0%; Pred. No. 2.1e+02;
; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACCGATGCCAGCTTGGC 2119
Db 20 TGACCGATGCCAGCTTGGC 1

RESULT 280
US-09-128-496-23/c
; Sequence 23, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
```

```

; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
US-09-128-496-23

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e-02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 2025 GAGGCCACAGACTTACAGA 2044
DB 20 GAGGCCACAGACTTACAGA 1

```

```

RESULT 281
US-09-128-496-24/c
; Sequence 24, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740

```

```

; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
US-09-128-496-24

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1881 CAAGAGGAGGAGCAAGACT 1900
DB 20 CAAGAGGAGGAGCAAGACT 1

```

```

RESULT 282
US-09-128-496-25/c
; Sequence 25, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:

```

; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-128-496-25

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAAGTCTAGCCTGATGAG 1940
|||||
Db 20 TTAAAGTCTAGCCTGATGAG 1

RESULT 283

US-09-128-496-26/c
; Sequence 26, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257

; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-128-496-26

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCCAGGAGGACA 1981
|||||
Db 20 ATAGCCCCCAGGAGGACA 1

RESULT 284

US-09-128-496-84/c
; Sequence 84, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 84:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid

;
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-128-496-84

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 285

US-09-128-496-85/c
; Sequence 85, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 85:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes

US-09-128-496-85

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGGTGGGGGACACATA 1964
|||
Db 20 GAAGTGGTGGGGGACACATA 1

RESULT 286

US-09-187-995-12/c
; Sequence 12, Application US/09187995
; Patent No. 6169177
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Improved Processes For The Synthesis Of Oligomeric
; TITLE OF INVENTION: Compounds
; FILE REFERENCE: ISIS3298
; CURRENT APPLICATION NUMBER: US/09/187,995
; CURRENT FILING DATE: 1998-11-06
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6169177e1
; OTHER INFORMATION: Sequence
US-09-187-995-12

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 287

US-09-130-973-56/c
; Sequence 56, Application US/09130973
; Patent No. 6172209
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Prakash, Thazha P
; APPLICANT: Kawasaki, Andrew M
; TITLE OF INVENTION: Aminoxy-Modified Oligonucleotides And Methods For
; TITLE OF INVENTION: Making Same
; FILE REFERENCE: ISIS2955
; CURRENT APPLICATION NUMBER: US/09/130,973
; CURRENT FILING DATE: 1998-08-07
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)
; OTHER INFORMATION: 2'-O-DMAOE T
; NAME/KEY: misc_feature
; LOCATION: (2)
; OTHER INFORMATION: 2'-O-DMAOE C
; NAME/KEY: misc_feature
; LOCATION: (3)
; OTHER INFORMATION: 2'-O-DMAOE T
; NAME/KEY: misc_feature
; LOCATION: (4)
; OTHER INFORMATION: 2'-O-DMAOE G
; NAME/KEY: misc_feature
; LOCATION: (5)
; OTHER INFORMATION: 2'-O-DMAOE A

```
NAME/KEY: misc_feature
LOCATION: (6)
OTHER INFORMATION: 2'-O-DMAOE G
NAME/KEY: misc_feature
LOCATION: (7)
OTHER INFORMATION: 2'-O-DMAOE T
NAME/KEY: misc_feature
LOCATION: (8)
OTHER INFORMATION: 2'-O-DMAOE A
NAME/KEY: misc_feature
LOCATION: (9)
OTHER INFORMATION: 2'-O-DMAOE G
NAME/KEY: misc_feature
LOCATION: (10)
OTHER INFORMATION: 2'-O-DMAOE C
NAME/KEY: misc_feature
LOCATION: (11)
OTHER INFORMATION: 2'-O-DMAOE A
NAME/KEY: misc_feature
LOCATION: (12)
OTHER INFORMATION: 2'-O-DMAOE G
NAME/KEY: misc_feature
LOCATION: (13)
OTHER INFORMATION: 2'-O-DMAOE A
NAME/KEY: misc_feature
LOCATION: (14)
OTHER INFORMATION: 2'-O-DMAOE G
NAME/KEY: misc_feature
LOCATION: (15)
OTHER INFORMATION: 2'-O-DMAOE G
NAME/KEY: misc_feature
LOCATION: (16)
OTHER INFORMATION: 2'-O-DMAOE A
NAME/KEY: misc_feature
LOCATION: (17)
OTHER INFORMATION: 2'-O-DMAOE G
NAME/KEY: misc_feature
LOCATION: (18)
OTHER INFORMATION: 2'-O-DMAOE C
NAME/KEY: misc_feature
LOCATION: (19)
OTHER INFORMATION: 2'-O-DMAOE T
NAME/KEY: misc_feature
LOCATION: (20)
OTHER INFORMATION: 2'-O-DMAOE C
OTHER INFORMATION: Description of Artificial Sequence: No. 6172209e1
US-09-130-973-56
```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 18 GAGCTCCTGCTACTCAGA 37
    |||||
Db 20 GAGCTCCTGCTACTCAGA 1
```

RESULT 288
US-09-130-973-57/c
Sequence 57, Application US/09130973
Patent No. 6172209
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Cook, Phillip Dan
APPLICANT: Prakash, Thazha P
APPLICANT: Kawasaki, Andrew M
TITLE OF INVENTION: Aminoxy-Modified Oligonucleotides And Methods For
FILE REFERENCE: ISIS2955
CURRENT APPLICATION NUMBER: US/09/130,973
CURRENT FILING DATE: 1998-08-07
NUMBER OF SEQ ID NOS: 58

```
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 57
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
NAME/KEY: misc_feature
LOCATION: (1)
OTHER INFORMATION: 2'-O-DMAOE T
NAME/KEY: misc_feature
LOCATION: (2)
OTHER INFORMATION: 2'-O-DMAOE C
NAME/KEY: misc_feature
LOCATION: (3)
OTHER INFORMATION: 2'-O-DMAOE T
NAME/KEY: misc_feature
LOCATION: (4)
OTHER INFORMATION: 2'-O-DMAOE G
NAME/KEY: misc_feature
LOCATION: (5)
OTHER INFORMATION: 2'-O-DMAOE A
NAME/KEY: misc_feature
LOCATION: (6)
OTHER INFORMATION: 2'-O-DMAOE G
NAME/KEY: misc_feature
LOCATION: (7)
OTHER INFORMATION: 2'-O-DMAOE T
NAME/KEY: misc_feature
LOCATION: (8)
OTHER INFORMATION: 2'-O-DMAOE A
NAME/KEY: misc_feature
LOCATION: (9)
OTHER INFORMATION: 2'-DMAOE G
NAME/KEY: misc_feature
LOCATION: (10)
OTHER INFORMATION: 2'-O-DMAOE C
NAME/KEY: misc_feature
LOCATION: (11)
OTHER INFORMATION: 2'-O-DMAOE A
NAME/KEY: misc_feature
LOCATION: (12)
OTHER INFORMATION: 2'-O-DMAOE G
NAME/KEY: misc_feature
LOCATION: (13)
OTHER INFORMATION: 2'-O-DMAOE A
NAME/KEY: misc_feature
LOCATION: (14)
OTHER INFORMATION: 2'-O-DMAOE G
NAME/KEY: misc_feature
LOCATION: (15)
OTHER INFORMATION: 2'-O-DMAOE G
NAME/KEY: misc_feature
LOCATION: (16)
OTHER INFORMATION: 2'-O-DMAOE A
NAME/KEY: misc_feature
LOCATION: (17)
OTHER INFORMATION: 2'-O-DMAOE G
NAME/KEY: misc_difference
LOCATION: (18)
OTHER INFORMATION: 2'-O-DMAOE C
NAME/KEY: misc_feature
LOCATION: (19)
OTHER INFORMATION: 2'-O-DMAPO T
NAME/KEY: misc_feature
LOCATION: (20)
OTHER INFORMATION: 2'-O-DMAOE C
OTHER INFORMATION: Description of Artificial Sequence: No. 6172209e1
US-09-130-973-57
```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
; 18 GAGCTCCTGCTACTCAGA 37
; |||||
; 20 GAGCTCCTGCTACTCAGA 1
;

RESULT 289
US-09-144-883C-3/c
; Sequence 3, Application US/09144883C
; Patent No. 6175004
; GENERAL INFORMATION:
; APPLICANT: Ross, Bruce S
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Improved Process for the Synthesis of Oligonucleotides
; TITLE OF INVENTION: Incorporating 2-Aminoadenosine
; FILE REFERENCE: ISIS3158
; CURRENT APPLICATION NUMBER: US/09/144,883C
; CURRENT FILING DATE: 1998-09-01
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 5-methyl
; NAME/KEY: modified_base
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2-aminoadenosine
; NAME/KEY: misc_feature
; LOCATION: (8)
; OTHER INFORMATION: 5-methyl
; NAME/KEY: misc_feature
; LOCATION: (12)
; OTHER INFORMATION: 5-methyl
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: 2-aminoadenosine
; NAME/KEY: misc_feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 5-methyl
; NAME/KEY: misc_feature
; LOCATION: (19)
; OTHER INFORMATION: 5-methyl
; NAME/KEY: modified_base
; LOCATION: (20)
; OTHER INFORMATION: 2-aminoadenosine
; OTHER INFORMATION: Description of Artificial Sequence: No. 6175004el Sequence
US-09-144-883C-3

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
; |||||
; 20 TGACGGATGCCAGCTTGGGC 1
;

RESULT 290
US-09-235-614-12/c
; Sequence 12, Application US/09235614
; Patent No. 6183966
; GENERAL INFORMATION:
; APPLICANT: GRAY, DONALD M.
; APPLICANT: CLARK, CHRISTOPHER L.
; TITLE OF INVENTION: AN APPARATUS AND METHOD FOR SELECTIVELY RANKING
; TITLE OF INVENTION: SEQUENCES FOR ANTISENSE TARGETING
; FILE REFERENCE: 91556/66384
; CURRENT APPLICATION NUMBER: US/09/235,614
; CURRENT FILING DATE: 1999-01-22
```

```
; PRIOR APPLICATION NUMBER: 08/808,474
; PRIOR FILING DATE: 1997-03-03
; PRIOR APPLICATION NUMBER: 08/320,507
; PRIOR FILING DATE: 1994-10-07
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: ASO
US-09-235-614-12

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
; |||||
; 20 GAGAGGGGAAGTGGTGGGG 1
;

RESULT 291
US-09-235-614-13/c
; Sequence 13, Application US/09235614
; Patent No. 6183966
; GENERAL INFORMATION:
; APPLICANT: GRAY, DONALD M.
; APPLICANT: CLARK, CHRISTOPHER L.
; TITLE OF INVENTION: AN APPARATUS AND METHOD FOR SELECTIVELY RANKING
; TITLE OF INVENTION: SEQUENCES FOR ANTISENSE TARGETING
; FILE REFERENCE: 91556/66384
; CURRENT APPLICATION NUMBER: US/09/235,614
; CURRENT FILING DATE: 1999-01-22
; PRIOR APPLICATION NUMBER: 08/808,474
; PRIOR FILING DATE: 1997-03-03
; PRIOR APPLICATION NUMBER: 08/320,507
; PRIOR FILING DATE: 1994-10-07
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: S-ASO
US-09-235-614-13

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
; |||||
; 20 TCAAACTGCCCTGATGGCA 1
;

RESULT 292
US-09-235-614-14/c
; Sequence 14, Application US/09235614
; Patent No. 6183966
; GENERAL INFORMATION:
; APPLICANT: GRAY, DONALD M.
; APPLICANT: CLARK, CHRISTOPHER L.
; TITLE OF INVENTION: AN APPARATUS AND METHOD FOR SELECTIVELY RANKING
; TITLE OF INVENTION: SEQUENCES FOR ANTISENSE TARGETING
; FILE REFERENCE: 91556/66384
; CURRENT APPLICATION NUMBER: US/09/235,614
; CURRENT FILING DATE: 1999-01-22
; PRIOR APPLICATION NUMBER: 08/808,474
; PRIOR FILING DATE: 1997-03-03
; PRIOR APPLICATION NUMBER: 08/320,507
```

; PRIOR FILING DATE: 1994-10-07
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence
US-09-235-614-14

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCCGGACAGG 1673
Db 20 TGAACCTATCCCGGACAGG 1

RESULT 293

US-09-235-614-15/c
; Sequence 15, Application US/09235614
; Patent No. 6183966
; GENERAL INFORMATION:
; APPLICANT: GRAY, DONALD M.
; TITLE OF INVENTION: AN APPARATUS AND METHOD FOR SELECTIVELY RANKING
; FILE REFERENCE: 91556/66384
; CURRENT FILING DATE: 1999-01-22
; PRIOR APPLICATION NUMBER: US/09/235,614
; PRIOR FILING DATE: 1997-03-03
; PRIOR APPLICATION NUMBER: 08/808,474
; PRIOR FILING DATE: 1994-10-07
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: S-ASO
US-09-235-614-15

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAGTGGTGGGG 1957
Db 20 GAGAGGGGAGTGGTGGGG 1

RESULT 294

US-09-235-614-16/c
; Sequence 16, Application US/09235614
; Patent No. 6183966
; GENERAL INFORMATION:
; APPLICANT: GRAY, DONALD M.
; TITLE OF INVENTION: AN APPARATUS AND METHOD FOR SELECTIVELY RANKING
; FILE REFERENCE: 91556/66384
; CURRENT FILING DATE: 1999-01-22
; PRIOR APPLICATION NUMBER: US/09/235,614
; PRIOR FILING DATE: 1997-03-03
; PRIOR APPLICATION NUMBER: 08/808,474
; PRIOR FILING DATE: 1994-10-07
; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: S-ASO
US-09-235-614-16

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATCCGACTTGGGC 2119
Db 20 TGACGGATCCGACTTGGGC 1

RESULT 295

US-09-235-614-18/c
; Sequence 18, Application US/09235614
; Patent No. 6183966
; GENERAL INFORMATION:
; APPLICANT: GRAY, DONALD M.
; TITLE OF INVENTION: AN APPARATUS AND METHOD FOR SELECTIVELY RANKING
; FILE REFERENCE: 91556/66384
; CURRENT FILING DATE: 1999-01-22
; PRIOR APPLICATION NUMBER: US/09/235,614
; PRIOR FILING DATE: 1997-03-03
; PRIOR APPLICATION NUMBER: 08/808,474
; PRIOR FILING DATE: 1994-10-07
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: S-ASO
US-09-235-614-18

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAAGCTTCTCAA 2981
Db 20 AGTTAATAAAGCTTCTCAA 1

RESULT 296

US-09-250-075-8/c
; Sequence 8, Application US/09250075
; Patent No. 6207819
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Compounds Processes And Intermediates For Synthesis Of
; FILE REFERENCE: ISIS3299
; CURRENT FILING DATE: 1999-02-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (1)-(20)

; OTHER INFORMATION: 2'-methoxyethoxy (MOE)
; OTHER INFORMATION: Description of Artificial Sequence: No. 6207819el
; OTHER INFORMATION: Sequence
US-09-250-075-8

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 297

US-09-313-932-41/c
; Sequence 41, Application US/09313932A

; Patent No. 6228642

; GENERAL INFORMATION:

; APPLICANT: Baker, Brenda

; APPLICANT: Bennett, C. Frank

; APPLICANT: Butler, Madeline M.

; APPLICANT: Shanahan, William R.

; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TNF-

; FILE REFERENCE: ISPH-0356

; CURRENT APPLICATION NUMBER: US/09/313,932A

; CURRENT FILING DATE: 1999-05-18

; NUMBER OF SEQ ID NOS: 501

; SEQ ID NO 41

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: control sequence

US-09-313-932-41

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 298

US-09-313-932-49/c

; Sequence 49, Application US/09313932A

; Patent No. 6228642

; GENERAL INFORMATION:

; APPLICANT: Baker, Brenda

; APPLICANT: Bennett, C. Frank

; APPLICANT: Butler, Madeline M.

; APPLICANT: Shanahan, William R.

; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TNF-

; FILE REFERENCE: ISPH-0356

; CURRENT APPLICATION NUMBER: US/09/313,932A

; CURRENT FILING DATE: 1999-05-18

; NUMBER OF SEQ ID NOS: 501

; SEQ ID NO 49

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: control sequence

US-09-313-932-49

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 299

US-09-409-816-1/c

; Sequence 1, Application US/09409816A

; Patent No. 6232296

; GENERAL INFORMATION:

; APPLICANT: Henry, Scott

; APPLICANT: Manoharan, Nulthiah

; TITLE OF INVENTION: Inhibition of Complement Activation and Complement

; FILE REFERENCE: ISPH-0384

; CURRENT APPLICATION NUMBER: US/09/409,816A

; CURRENT FILING DATE: 1999-08-30

; NUMBER OF SEQ ID NOS: 1

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 1

; LENGTH: 20

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic

US-09-409-816-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 300

US-08-397-277A-11/c

; Sequence 11, Application US/08397277A

; Patent No. 6235886

; GENERAL INFORMATION:

; APPLICANT: Manoharan, Muthiah

; APPLICANT: Phillip D. Cook

; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF

; TITLE OF INVENTION: MAKING AND USING THE SAME

; NUMBER OF SEQUENCES: 16

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz

; ADDRESS: and No. 6235886ris

; STREET: One Liberty Place - 46th Floor

; CITY: Philadelphia

; STATE: PA

; COUNTRY: U.S.A.

; ZIP: 19103

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: WordPerfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/397,277A

; FILING DATE: 09-MAR-1995

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 07/943,516

; FILING DATE: 11-SEP-1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Gaumont, Rebecca R.

; REGISTRATION NUMBER: 35,152

; REFERENCE/DOCKET NUMBER: ISIS-1198

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 215-568-3100

; TELEFAX: 215-568-3439

```
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;   MOLECULE TYPE: DNA (genomic)
;   FEATURE:
;     NAME/KEY: misc_feature
;     LOCATION: 20
;     OTHER INFORMATION: /note= "2'-aminopropoxy
;     OTHER INFORMATION: cytosine"
US-08-397-277A-11
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
|||||
```

```
RESULT 301
US-09-123-108-2/c
; Sequence 2, Application US/09123108
; Patent No. 6271358
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Boswell, Herb
; TITLE OF INVENTION: RNA TARGETED 2'-MODIFIED OLIGONUCLEOTIDES THAT ARE
; FILE REFERENCE: ISIS-3147 sequence listing
; CURRENT APPLICATION NUMBER: US/09/123,108
; CURRENT FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6271358el sequence
US-09-123-108-2
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
|||||
```

```
RESULT 302
US-09-123-108-3/c
; Sequence 3, Application US/09123108
; Patent No. 6271358
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Boswell, Herb
; TITLE OF INVENTION: RNA TARGETED 2'-MODIFIED OLIGONUCLEOTIDES THAT ARE
; FILE REFERENCE: ISIS-3147 sequence listing
; CURRENT APPLICATION NUMBER: US/09/123,108
; CURRENT FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6271358el sequence
US-09-123-108-3
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
|||||
```

```
RESULT 303
US-09-123-108-5/c
; Sequence 5, Application US/09123108
; Patent No. 6271358
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Mohan, Venkatraman
; APPLICANT: Boswell, Herb
; TITLE OF INVENTION: RNA TARGETED 2'-MODIFIED OLIGONUCLEOTIDES THAT ARE
; FILE REFERENCE: ISIS-3147 sequence listing
; CURRENT APPLICATION NUMBER: US/09/123,108
; CURRENT FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6271358el sequence
US-09-123-108-5
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATCCAGCTTGGGC 2119
Db 20 TGACGGATCCAGCTTGGGC 1
|||||
```

```
RESULT 304
US-09-177-953-2/c
; Sequence 2, Application US/09177953
; Patent No. 6274725
; GENERAL INFORMATION:
; APPLICANT: Sanghvi, Yogesh
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS3148
; CURRENT APPLICATION NUMBER: US/09/177,953
; CURRENT FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6274725el Sequence
US-09-177-953-2
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 305
US-09-177-953-8/c
; Sequence 8, Application US/09177953
; Patent No. 6274725
; GENERAL INFORMATION:
; APPLICANT: Sanghvi, Yogesh
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS3148
; CURRENT APPLICATION NUMBER: US/09/177,953
; CURRENT FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Oligonucleotide
; OTHER INFORMATION: Description of Artificial Sequence: No. 6274725el Sequence

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 306
US-09-177-953-11/c
; Sequence 11, Application US/09177953
; Patent No. 6274725
; GENERAL INFORMATION:
; APPLICANT: Sanghvi, Yogesh
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS3148
; CURRENT APPLICATION NUMBER: US/09/177,953
; CURRENT FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6274725el Sequence

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 307
US-09-177-953-17/c
; Sequence 17, Application US/09177953
; Patent No. 6274725
; GENERAL INFORMATION:
; APPLICANT: Sanghvi, Yogesh
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS3148
; CURRENT APPLICATION NUMBER: US/09/177,953
; CURRENT FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Oligonucleotide
; OTHER INFORMATION: Description of Artificial Sequence: No. 6274725el Sequence

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

; NAME/KEY: misc_feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2' O MOE
; NAME/KEY: misc_feature
; LOCATION: (14)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (15)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (16)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (18)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (19)
; OTHER INFORMATION: 5 methyl U
; US-09-177-953-17

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 308

US-09-177-953-22/c
; Sequence 22, Application US/09177953
; Patent No. 6274725
; GENERAL INFORMATION:
; APPLICANT: Sanghvi, Yogesh
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS3148
; CURRENT APPLICATION NUMBER: US/09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6274725el Sequence
; NAME/KEY: misc_feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2' O MOE, phosphorothioate linkage
; NAME/KEY: misc_feature
; LOCATION: (20)
; OTHER INFORMATION: 2' O MOE linkage
; US-09-177-953-22

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 309

US-09-177-953-23/c
; Sequence 23, Application US/09177953
; Patent No. 6274725
; GENERAL INFORMATION:

; APPLICANT: Sanghvi, Yogesh
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS3148
; CURRENT APPLICATION NUMBER: US/09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6274725el Sequence
; NAME/KEY: misc_feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2' O MOE linkage
; US-09-177-953-23

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 310

US-09-177-953-25/c
; Sequence 25, Application US/09177953
; Patent No. 6274725
; GENERAL INFORMATION:
; APPLICANT: Sanghvi, Yogesh
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS3148
; CURRENT APPLICATION NUMBER: US/09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6274725el Sequence
; US-09-177-953-25

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 311

US-09-177-953-31/c
; Sequence 31, Application US/09177953
; Patent No. 6274725
; GENERAL INFORMATION:
; APPLICANT: Sanghvi, Yogesh
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis

```
; FILE REFERENCE: ISIS3148
; CURRENT APPLICATION NUMBER: US/09/177,953
; CURRENT FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6274725el Sequence
; NAME/KEY: misc_feature
; LOCATION: (2)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (3)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (4)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (8)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (12)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2' O MOE
; NAME/KEY: misc_feature
; LOCATION: (14)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (15)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (16)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (18)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (19)
; OTHER INFORMATION: 5 methyl U
; US-09-177-953-31

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
Db       20 TGACGGATGCCAGCTTGGGC 1

RESULT 312
US-09-177-953-33/c
; Sequence 33, Application US/09177953
; Patent No. 6274725
; GENERAL INFORMATION:
; APPLICANT: Sanghvi, Yogesh
; APPLICANT: Ravikumar, Vasulunga T.
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS3148
; CURRENT APPLICATION NUMBER: US/09/177,953
; CURRENT FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Oligonucleotide
; OTHER INFORMATION: Description of Artificial Sequence: No. 6274725el Sequence
; NAME/KEY: misc_feature
; LOCATION: (2)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (3)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (4)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (8)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (12)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2' MOE
; NAME/KEY: misc_feature
; LOCATION: (14)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (15)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (16)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (18)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (19)
; OTHER INFORMATION: 5 methyl U
; US-09-177-953-33

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
Db       20 TGACGGATGCCAGCTTGGGC 1

RESULT 313
US-09-177-953-38/c
; Sequence 38, Application US/09177953
; Patent No. 6274725
; GENERAL INFORMATION:
; APPLICANT: Sanghvi, Yogesh
; APPLICANT: Ravikumar, Vasulunga T.
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS3148
; CURRENT APPLICATION NUMBER: US/09/177,953
; CURRENT FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Oligonucleotide
; OTHER INFORMATION: Description of Artificial Sequence: No. 6274725el Sequence
; NAME/KEY: misc_feature
; LOCATION: (2)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (3)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (4)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (8)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (12)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2' MOE
; NAME/KEY: misc_feature
; LOCATION: (14)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (15)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (16)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (18)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (19)
; OTHER INFORMATION: 5 methyl U
; US-09-177-953-31

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
Db       20 TGACGGATGCCAGCTTGGGC 1

RESULT 312
US-09-177-953-33/c
; Sequence 33, Application US/09177953
; Patent No. 6274725
; GENERAL INFORMATION:
; APPLICANT: Sanghvi, Yogesh
; APPLICANT: Ravikumar, Vasulunga T.
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS3148
; CURRENT APPLICATION NUMBER: US/09/177,953
; CURRENT FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
```

; NAME/KEY: misc_feature
; LOCATION: (19)
; OTHER INFORMATION: 5 methyl U
US-09-177-953-38

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 314

US-09-177-953-40/c
; Sequence 40, Application US/09177953
; Patent No. 6274725
; GENERAL INFORMATION:
; APPLICANT: Sanghvi, Yogesh
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS3148
; CURRENT APPLICATION NUMBER: US/09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6274725el Sequence
US-09-177-953-40

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 315

US-09-177-953-46/c
; Sequence 46, Application US/09177953
; Patent No. 6274725
; GENERAL INFORMATION:
; APPLICANT: Sanghvi, Yogesh
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS3148
; CURRENT APPLICATION NUMBER: US/09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Oligonucleotide
; OTHER INFORMATION: Description of Artificial Sequence: No. 6274725el Sequence
; NAME/KEY: misc_feature
; LOCATION: (2)

; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (3)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (4)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (8)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (12)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc_feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2' O MOE
; NAME/KEY: misc_feature
; LOCATION: (14)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (15)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (16)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (18)
; OTHER INFORMATION: 5 methyl U
; NAME/KEY: misc_feature
; LOCATION: (19)
; OTHER INFORMATION: 5 methyl U
US-09-177-953-46

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 316

US-09-115-025A-1/c
; Sequence 1, Application US/09115025A
; Patent No. 6277967
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS2951
; CURRENT APPLICATION NUMBER: US/09/115,025A
; CURRENT FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Alternating phosphodiester/phosphorothioate
; OTHER INFORMATION: linkages
; NAME/KEY: modified base
; LOCATION: (2)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6277967el Sequence
US-09-115-025A-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 317

US-09-115-025A-3/c
; Sequence 3, Application US/09115025A
; Patent No. 6277967
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS2951
; CURRENT APPLICATION NUMBER: US/09/115,025A
; CURRENT FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Alternating phosphodiester/phosphorothioate
; NAME/KEY: linkages
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6277967el Sequence
US-09-115-025A-3

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 318

US-09-115-025A-4/c
; Sequence 4, Application US/09115025A
; Patent No. 6277967
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS2951
; CURRENT APPLICATION NUMBER: US/09/115,025A
; CURRENT FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6277967el Sequence
US-09-115-025A-4

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 319

US-09-115-025A-5/c
; Sequence 5, Application US/09115025A
; Patent No. 6277967
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS2951
; CURRENT APPLICATION NUMBER: US/09/115,025A
; CURRENT FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: All phosphorothioate linkages
; OTHER INFORMATION: Description of Artificial Sequence: No. 6277967el Sequence
US-09-115-025A-5

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 320

US-09-115-025A-6/c
; Sequence 6, Application US/09115025A
; Patent No. 6277967
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS2951
; CURRENT APPLICATION NUMBER: US/09/115,025A
; CURRENT FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: All phosphorothioate linkages
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6277967el Sequence
US-09-115-025A-6

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 321

US-09-115-025A-7/c
; Sequence 7, Application US/09115025A
; Patent No. 6277967

```
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; FILE REFERENCE: ISIS2951
; CURRENT APPLICATION NUMBER: US/09/115,025A
; CURRENT FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6277967el Sequence
US-09-115-025A-7

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
|||||

RESULT 322
US-09-115-025A-8/c
; Sequence 8, Application US/09115025A
; Patent No. 6277967
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; FILE REFERENCE: ISIS2951
; CURRENT APPLICATION NUMBER: US/09/115,025A
; CURRENT FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Alternating phosphodiester/phosphorothioate
; OTHER INFORMATION: linkages
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Staggered 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6277967el Sequence
US-09-115-025A-8

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
|||||

RESULT 323
US-09-115-025A-9/c
; Sequence 9, Application US/09115025A
; Patent No. 6277967
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
```

```
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS2951
; CURRENT APPLICATION NUMBER: US/09/115,025A
; CURRENT FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; NAME/KEY: modified_base
; LOCATION: (2)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (18)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (20)
; OTHER INFORMATION: c=5-methyl
; OTHER INFORMATION: Description of Artificial Sequence: No. 6277967el Sequence
US-09-115-025A-9

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
|||||

RESULT 324
US-09-115-025A-11/c
; Sequence 11, Application US/09115025A
; Patent No. 6277967
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; FILE REFERENCE: ISIS2951
; CURRENT APPLICATION NUMBER: US/09/115,025A
; CURRENT FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: All phosphorothioate linkages
; NAME/KEY: modified_base
; LOCATION: (2)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (18)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (20)
```



```
; OTHER INFORMATION: c=5-methyl
; OTHER INFORMATION: Description of Artificial Sequence: No. 6277967el Sequence
US-09-115-025A-11

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
   |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 325
US-09-115-025A-13/c
; Sequence 13, Application US/09115025A
; Patent No. 6277967
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; FILE REFERENCE: ISIS2951
; CURRENT APPLICATION NUMBER: US/09/115,025A
; CURRENT FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-methoxyethoxy
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Alternating phosphodiester/phosphorothioate
; OTHER INFORMATION: linkages
; NAME/KEY: modified_base
; LOCATION: (2)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (18)
; OTHER INFORMATION: c=5-methyl
; OTHER INFORMATION: Description of Artificial Sequence: No. 6277967el Sequence
US-09-115-025A-13

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
   |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 326
US-09-109-663-36/c
; Sequence 36, Application US/09109663
; Patent No. 6277981
; GENERAL INFORMATION:
; APPLICANT: Tu, Guang-Chou
; APPLICANT: Israel, Yedy
; TITLE OF INVENTION: AN IMPROVED METHOD FOR DESIGN AND SELECTION OF
; FILE REFERENCE: 9855-3U1
; CURRENT APPLICATION NUMBER: US/09/109,663
; CURRENT FILING DATE: 1998-07-03
; EARLIER APPLICATION NUMBER: 60/051,705
; EARLIER FILING DATE: 1997-07-03
```

```
; NUMBER OF SEQ ID NOS: 81
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Known
; OTHER INFORMATION: Effective ASO
US-09-109-663-36

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
   |||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 327
US-09-378-665A-1/c
; Sequence 1, Application US/09378665A
; Patent No. 6277982
; GENERAL INFORMATION:
; APPLICANT: Fraser, Allister S.
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Jung, Michael E.
; APPLICANT: Kawasaki, Andrew M.
; TITLE OF INVENTION: Alkylation of Alcohols, Amines, Thiols and Their
; FILE REFERENCE: ISIS4072
; CURRENT APPLICATION NUMBER: US/09/378,665A
; CURRENT FILING DATE: 1999-08-20
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6277982el Sequence
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: a phosphorothioate linkage
; NAME/KEY: misc_feature
; LOCATION: (2)
; OTHER INFORMATION: 5-methyl-C
; NAME/KEY: misc_feature
; LOCATION: (10)
; OTHER INFORMATION: 5-methyl-C
; NAME/KEY: misc_feature
; LOCATION: (18)
; OTHER INFORMATION: 5-methyl-C
US-09-378-665A-1

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
   |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 328
US-09-378-665A-2/c
; Sequence 2, Application US/09378665A
; Patent No. 6277982
; GENERAL INFORMATION:
; APPLICANT: Fraser, Allister S.
; APPLICANT: Manoharan, Muthiah
```

```
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Jung, Michael E.
; APPLICANT: Kawasaki, Andrew M.
; TITLE OF INVENTION: Alkylation of Alcohols, Amines, Thiols and Their
; FILE REFERENCE: IS154072
; CURRENT APPLICATION NUMBER: US/09/378,665A
; CURRENT FILING DATE: 1999-08-20
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6277982el Sequence
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: a phosphodiester linkage
; NAME/KEY: misc_feature
; LOCATION: (2)
; NAME/KEY: misc_feature
; LOCATION: (10)
; OTHER INFORMATION: 5-methyl-C
; NAME/KEY: misc_feature
; LOCATION: (18)
; OTHER INFORMATION: 5-methyl-C
; US-09-378-665A-2

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
   |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 329
US-09-378-665A-4/c
; Sequence 4, Application US/09378665A
; Patent No. 6277982
; GENERAL INFORMATION:
; APPLICANT: Fraser, Allister S.
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Jung, Michael E.
; APPLICANT: Kawasaki, Andrew M.
; TITLE OF INVENTION: Alkylation of Alcohols, Amines, Thiols and Their
; FILE REFERENCE: IS154072
; CURRENT APPLICATION NUMBER: US/09/378,665A
; CURRENT FILING DATE: 1999-08-20
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6277982el Sequence
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: a phosphorothioate linkage
; NAME/KEY: misc_feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 5-methyl-C
; NAME/KEY: misc_feature
; LOCATION: (8)
; OTHER INFORMATION: 5-methyl-C
; NAME/KEY: misc_feature
; LOCATION: (12)
```

```
; OTHER INFORMATION: 5-methyl-C
; NAME/KEY: misc_feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 5-methyl-C
; NAME/KEY: misc_feature
; LOCATION: (19)
; OTHER INFORMATION: 5-methyl-C
; US-09-378-665A-4

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
   |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 330
US-09-078-954-2/c
; Sequence 2, Application US/09078954
; Patent No. 6287591
; GENERAL INFORMATION:
; APPLICANT: SEMPLE, Sean C.
; APPLICANT: Klimuk, Sandra K.
; APPLICANT: Harasym, Troy
; APPLICANT: Hope, Michael J.
; APPLICANT: Ansell, Steven M.
; APPLICANT: Cullis, Pieter
; APPLICANT: Scherrer, Peter
; APPLICANT: Geiser, Timothy
; APPLICANT: Zon, Gerald
; APPLICANT: Debever, Dan
; TITLE OF INVENTION: High Efficiency Encapsulation of Charged Therapeutic Agents
; TITLE OF INVENTION: Lipid Vesicles
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oppedahl & Larson
; STREET: PO Box 5270
; CITY: Frisco
; STATE: CO
; COUNTRY: USA
; ZIP: 80443-5270
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS 5.0
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/078,954
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/856,374
; FILING DATE: 14-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Marina T. Larson
; REGISTRATION NUMBER: 32,038
; REFERENCE/DOCKET NUMBER: INEX.P-003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (970) 668-2050
; TELEFAX: (970) 668-2082
; TELEX:
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: yes
; US-09-078-954-2
```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
Db |||||

RESULT 331
US-09-009-490A-2/c
; Sequence 2, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-009-490A-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGAGCTGAGCTCTC 26
Db |||||

RESULT 332
US-09-009-490A-7/c
; Sequence 7, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-009-490A-7

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCTCGCTATG 60
Db |||||

RESULT 333
US-09-009-490A-8/c
; Sequence 8, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-009-490A-8

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCCGAGGAGCCCG 77
|||||
Db 20 ATGGCTCCCGAGGAGCCCG 1

RESULT 334
US-09-009-490A-9/c
; Sequence 9, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:

; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-009-490A-9

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTGCTCGGGCTCT 116
|||||
Db 20 CTGGTCTGCTCGGGCTCT 1

RESULT 335
US-09-009-490A-10/c
; Sequence 10, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:

```

; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
; US-09-009-490A-10

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 337 TCAAACTGCCGTGATGGCA 356
Db 20 TCAAACTGCCGTGATGGCA 1

```

```

RESULT 336
US-09-009-490A-11/c
; Sequence 11, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA

```

```

; ZIP: 08053
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
; US-09-009-490A-11

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 875 AGGCCTCAGTCAGTGTGACC 894
Db 20 AGGCCTCAGTCAGTGTGACC 1

```

```

RESULT 337
US-09-009-490A-12/c
; Sequence 12, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95

```

```

; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-009-490A-12

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGGAGGTACCCCGGAG 1464
|||||
Db 20 AAGGGGAGGTACCCCGGAG 1

RESULT 338
US-09-009-490A-13/c
; Sequence 13, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514

```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-009-490A-13

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCACGCTCCCTGA 1656
|||||
Db 20 CACAAGCCACGCTCCCTGA 1

RESULT 339
US-09-009-490A-14/c
; Sequence 14, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167

```

```
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA: 969,151
; APPLICATION NUMBER: 939,855
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 32,257
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-009-490A-14

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1654 TGAACCTATCCGGGACAGG 1673
Db 20 TGAACCTATCCGGGACAGG 1

RESULT 340
US-09-009-490A-15/c
; Sequence 15, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-009-490A-15

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
Db 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 341
US-09-009-490A-16/c
; Sequence 16, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
```

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0268
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 810-1515
;; TELEFAX: (609) 810-1454
;; INFORMATION FOR SEQ ID NO: 16:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-09-009-490A-16

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAAGCTTTCTCAA 2981
Db 20 AGTTAATAAAGCTTTCTCAA 1

RESULT 342
US-09-009-490A-22/c
; Sequence 22, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata

;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0268
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 810-1515
;; TELEFAX: (609) 810-1454
;; INFORMATION FOR SEQ ID NO: 22:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-09-009-490A-22

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 343
US-09-009-490A-23/c
; Sequence 23, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454

Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAGTCTAGCCTGATGAG 1940
Db 20 TTAAGTCTAGCCTGATGAG 1

RESULT 346

US-09-009-490A-26/c
; Sequence 26, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-009-490A-26

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCCAGGAGGACA 1981
Db 20 ATAGCCCCCAGGAGGACA 1

Db 20 ATAGCCCCCAGGAGGACA 1

RESULT 347

US-09-009-490A-84/c
; Sequence 84, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 84:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-009-490A-84

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 348
US-09-009-490A-85/c

Sequence 85, Application US/09009490A
Patent No. 6300491
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
TITLE OF INVENTION: of Cell Adhesion
NUMBER OF SEQUENCES: 95
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Office of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: Windows 95
SOFTWARE: WORDPERFECT 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/009,490A
FILING DATE: January 20, 1998
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 440,740
FILING DATE: May 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 063,167
FILING DATE: May 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 969,151
FILING DATE: February 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 007,997
FILING DATE: January 20, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0268
TELEPHONE: (609) 810-1515
TELEFAX: (609) 810-1454
INFORMATION FOR SEQ ID NO: 85:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-09-009-490A-85
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1945 GAAGTGGTGGGGAGACATA 1964
|||||
Db 20 GAAGTGGTGGGGAGACATA 1
RESULT 349
US-09-379-718-3/c
Sequence 3, Application US/09379718
Patent No. 6310047
GENERAL INFORMATION:
APPLICANT: Farrell, Nicholas
TITLE OF INVENTION: Alternating Internucleoside Linkages
FILE REFERENCE: ISIS3863
CURRENT APPLICATION NUMBER: US/09/349,007A
CURRENT FILING DATE: 1999-07-07
; TITLE OF INVENTION: High Affinity DNA Binding Compounds as Adjuvants in
; TITLE OF INVENTION: Antisense technology
; FILE REFERENCE: farrell/kloster
; CURRENT APPLICATION NUMBER: US/09/379,718
; CURRENT FILING DATE: 1999-08-24
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: synthetic
; OTHER INFORMATION: oligonucleotides for gene therapy
US-09-379-718-3
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps
QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 350
US-09-326-186B-17/c
Sequence 17, Application US/09326186B
Patent No. 6319906
GENERAL INFORMATION:
APPLICANT: Bennett, Clarence Frank
APPLICANT: Vickers, Timothy A.
TITLE OF INVENTION: Oligonucleotide Compositions and Methods for the
TITLE OF INVENTION: Modulation of the Expression of B7 Protein
FILE REFERENCE: ISPH-0376
CURRENT APPLICATION NUMBER: US/09/326,186B
CURRENT FILING DATE: 1999-06-04
PRIOR APPLICATION NUMBER: 08/777,266
PRIOR FILING DATE: 1996-12-31
NUMBER OF SEQ ID NOS: 226
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 17
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
PUBLICATION INFORMATION:
PATENT DOCUMENT NUMBER: US 5514788
PATENT FILING DATE: 1993-05-17
PUBLICATION DATE: 1996-05-07
US-09-326-186B-17
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps
QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1
RESULT 351
US-09-349-007A-1/c
Sequence 1, Application US/09349007A
Patent No. 6326358
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
TITLE OF INVENTION: Alternating Internucleoside Linkages
FILE REFERENCE: ISIS3863
CURRENT APPLICATION NUMBER: US/09/349,007A
CURRENT FILING DATE: 1999-07-07

; PRIOR APPLICATION NUMBER: 09/115,025
; PRIOR FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Alternating phosphodiester/phosphorothioate
; NAME/KEY: linkages
; NAME/KEY: modified base
; LOCATION: (2)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6326358el Sequence
US-09-349-007A-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 352

US-09-349-007A-3/c
; Sequence 3, Application US/09349007A
; Patent No. 6326358
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/349,007A
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: 09/115,025
; PRIOR FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Alternating phosphodiester/phosphorothioate
; NAME/KEY: linkages
; NAME/KEY: modified base
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6326358el Sequence
US-09-349-007A-3

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 353

US-09-349-007A-4/c
; Sequence 4, Application US/09349007A
; Patent No. 6326358
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah

; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/349,007A
; CURRENT FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: 09/115,025
; PRIOR FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6326358el Sequence
US-09-349-007A-4

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 354

US-09-349-007A-5/c
; Sequence 5, Application US/09349007A
; Patent No. 6326358
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/349,007A
; CURRENT FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: 09/115,025
; PRIOR FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: All phosphorothioate linkages
; OTHER INFORMATION: Description of Artificial Sequence: No. 6326358el Sequence
US-09-349-007A-5

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 355

US-09-349-007A-6/c
; Sequence 6, Application US/09349007A
; Patent No. 6326358
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/349,007A
; CURRENT FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: 09/115,025

```
; PRIOR FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: All phosphorothioate linkages
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6326358el Sequence
US-09-349-007A-6
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1
```

RESULT 356

```
US-09-349-007A-7/c
; Sequence 7, Application US/09349007A
; Patent No. 6326358
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/349,007A
; CURRENT FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: 09/115,025
; PRIOR FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6326358el Sequence
US-09-349-007A-7
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1
```

RESULT 357

```
US-09-349-007A-8/c
; Sequence 8, Application US/09349007A
; Patent No. 6326358
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/349,007A
; CURRENT FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: 09/115,025
```

```
; PRIOR FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Alternating phosphodiester/phosphorothioate
; OTHER INFORMATION: linkages
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Staggered 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. 6326358el Sequence
US-09-349-007A-8
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1
```

RESULT 358

```
US-09-349-007A-9/c
; Sequence 9, Application US/09349007A
; Patent No. 6326358
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/349,007A
; CURRENT FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: 09/115,025
; PRIOR FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; NAME/KEY: modified base
; LOCATION: (2)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (18)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (20)
; OTHER INFORMATION: c=5-methyl
; OTHER INFORMATION: Description of Artificial Sequence: No. 6326358el Sequence
US-09-349-007A-9
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1
```

```
RESULT 359
US-09-349-007A-11/c
; Sequence 11, Application US/09349007A
; Patent No. 6326358
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/349,007A
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: 09/115,025
; PRIOR FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: All phosphorothioate linkages
; NAME/KEY: modified_base
; LOCATION: (2)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (18)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (20)
; OTHER INFORMATION: c=5-methyl
; OTHER INFORMATION: Description of Artificial Sequence: No. 6326358el Sequence
US-09-349-007A-11

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 361
US-09-111-678-2/c
; Sequence 2, Application US/09111678
; Patent No. 6326478
; GENERAL INFORMATION:
; APPLICANT: Cheruvallath, Zacharia S
; APPLICANT: Ravikumar, Vasulunga T
; APPLICANT: Cole, Douglas L
; TITLE OF INVENTION: Process For The Synthesis Of Oligomeric Compounds
; FILE REFERENCE: ISIS2853
; CURRENT APPLICATION NUMBER: US/09/111,678
; CURRENT FILING DATE: 1998-07-08
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6326478el
US-09-111-678-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGTTGGGC 2119
Db 20 TGACGGATGCCAGTTGGGC 1

RESULT 362
US-08-895-981-21/c
; Sequence 21, Application US/08895981
; Patent No. 6326487
; GENERAL INFORMATION:
; APPLICANT: Peyman, Anuschirwan
; APPLICANT: Unimann, Eugen
; APPLICANT: Carolus, Carolin
; TITLE OF INVENTION: 3'-Modified Oligonucleotide Derivatives
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoechst Marion Roussel, Inc.
; STREET: 2110 E. Galbraith Road, P.O. Box 156300
; CITY: Cincinnati
; STATE: Ohio
```

```
RESULT 359
US-09-349-007A-11/c
; Sequence 11, Application US/09349007A
; Patent No. 6326358
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/349,007A
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: 09/115,025
; PRIOR FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: All phosphorothioate linkages
; NAME/KEY: modified_base
; LOCATION: (2)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (18)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (20)
; OTHER INFORMATION: c=5-methyl
; OTHER INFORMATION: Description of Artificial Sequence: No. 6326358el Sequence
US-09-349-007A-11

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 360
US-09-349-007A-13/c
; Sequence 13, Application US/09349007A
; Patent No. 6326358
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/349,007A
; PRIOR FILING DATE: 1999-07-07
; PRIOR APPLICATION NUMBER: 09/115,025
; PRIOR FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
```

```
;
; COUNTRY: USA
; ZIP: 45215-6300
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/895,981
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,305
; FILING DATE: 05-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Payne, T. Helen
; REGISTRATION NUMBER: 36,889
; REFERENCE/DOCKET NUMBER: HOE94/F161K US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 513-948-7960 or 4681
; TELEFAX: 513-948-7960 or 4681
; TELEX: 214320
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; US-08-895-981-21
;
; Query Match 0.7%; Score 20; DB 1; Length 20;
; Best Local Similarity 100.0%; Pred. No. 2.1e+02;
; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 1938 GAGAGGGGAAGTGTGGGGG 1957
; Db 20 GAGAGGGGAAGTGTGGGGG 1
;
; RESULT 363
; US-08-895-981-22/c
; Sequence 22, Application US/08895981
; Patent No. 6326487
; GENERAL INFORMATION:
; APPLICANT: Peyman, Anuschirwan
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Carolus, Carolin
; TITLE OF INVENTION: 3'-Modified Oligonucleotide Derivatives
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoechst Marion Roussel, Inc.
; STREET: 2110 E. Galbraith Road, P.O. Box 156300
; CITY: Cincinnati
; STATE: Ohio
; COUNTRY: USA
; ZIP: 45215-6300
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/895,981
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,305
; FILING DATE: 05-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Payne, T. Helen
; REGISTRATION NUMBER: 36,889
; REFERENCE/DOCKET NUMBER: HOE94/F161K US
;
; COUNTRY: USA
; ZIP: 45215-6300
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/895,981
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,305
; FILING DATE: 05-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Payne, T. Helen
; REGISTRATION NUMBER: 36,889
; REFERENCE/DOCKET NUMBER: HOE94/F161K US
;
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 513-948-7183
; TELEFAX: 513-948-7960 or 4681
; TELEX: 214320
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; US-08-895-981-22
;
; Query Match 0.7%; Score 20; DB 1; Length 20;
; Best Local Similarity 100.0%; Pred. No. 2.1e+02;
; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 1940 GAGGGGAAGTGTGGGGGAG 1959
; Db 20 GAGGGGAAGTGTGGGGGAG 1
;
; RESULT 364
; US-08-829-637A-127/c
; Sequence 127, Application US/08829637A
; Patent No. 6339066
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Phillip Dan Cook
; APPLICANT: Nicholas Dean
; APPLICANT: Glenn Hoke
; TITLE OF INVENTION: OLIGONUCLEOTIDES WHICH HAVE
; TITLE OF INVENTION: PHOSPHOROTHIORATE LINKAGES OF HIGH CHIRAL PURITY AND
; TITLE OF INVENTION: WHICH MODULATE al, ail, , k, n, AND ISOFORMS OF
; NUMBER OF SEQUENCES: 136
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: John W. Caldwell (28,937) Woodcock
; ADDRESSEE: Washburn Kurtz Mackiewicz & No. 6339066ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/829,637A
; FILING DATE: herewith
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/481,066
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/470,129
; FILING DATE: 06-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/469,851
; FILING DATE: 06-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/468,569
; FILING DATE: 06-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/089,996
; FILING DATE: 09-JUL-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/058,023
; FILING DATE: 05-MAY-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/777,007
```

;; FILING DATE: 16-OCT-1991
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/777,760
;; FILING DATE: 15-OCT-1991
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/852,852
;; FILING DATE: 16-MAR-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: PCT/US91/00243
;; FILING DATE: 11-JAN-1991
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/566,977
;; FILING DATE: 13-AUG-1990
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/436,358
;; FILING DATE: 11-JAN-1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME:
;; REGISTRATION NUMBER:
;; REFERENCE/DOCKET NUMBER: ISIS-
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (215) 568-3100
;; TELEFAX: (215) 568-3439
;; INFORMATION FOR SEQ ID NO: 127:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; ANTI-SENSE: yes
US-08-829-637A-127

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTGGGC 1

RESULT 365
US-08-337-120A-29/c
; Sequence 29, Application US/08337120A
; Patent No. 6348312
; GENERAL INFORMATION:
; APPLICANT: Peyman, Anuschirwan
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Mag, Matthias
; APPLICANT: Kretzschmar, Gerhard
; APPLICANT: Helsenberg, Mathias
; APPLICANT: Winkler, Irvin
; TITLE OF INVENTION: Stabilized Oligonucleotides And Their
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner, L.L.P.
; STREET: 1300 I Street, N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/337,120A
; FILING DATE: 12-NOV-1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/337,120A
; FILING DATE: 12-NOV-1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:

;; APPLICATION NUMBER: DE P 43 38 704.7
;; FILING DATE: 12-NOV-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Einaudi, Carol P.
;; REGISTRATION NUMBER: 32,220
;; REFERENCE/DOCKET NUMBER: 02481.1409-00000
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (202) 408-4000
;; TELEFAX: (202) 408-4400
;; INFORMATION FOR SEQ ID NO: 29:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
US-08-337-120A-29

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 366
US-08-337-120A-30/c
; Sequence 30, Application US/08337120A
; Patent No. 6348312
; GENERAL INFORMATION:
; APPLICANT: Peyman, Anuschirwan
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Mag, Matthias
; APPLICANT: Kretzschmar, Gerhard
; APPLICANT: Helsenberg, Mathias
; APPLICANT: Winkler, Irvin
; TITLE OF INVENTION: Stabilized Oligonucleotides And Their
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner, L.L.P.
; STREET: 1300 I Street, N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/337,120A
; FILING DATE: 12-NOV-1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DE P 43 38 704.7
; FILING DATE: 12-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Einaudi, Carol P.
; REGISTRATION NUMBER: 32,220
; REFERENCE/DOCKET NUMBER: 02481.1409-00000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single


```
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-337-120A-30

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGTGGGGGAG 1959
Db 20 GAGGGGAAGTGTGGGGGAG 1

RESULT 367
US-09-711-050A-1/c
; Sequence 1, Application US/09711050A
; Patent No. 6355438
; GENERAL INFORMATION:
; APPLICANT: Yu, Zhengrong
; APPLICANT: Baker, Brenda F.
; APPLICANT: Leeds, Janet M.
; TITLE OF INVENTION: Method for Quantitating Oligonucleotides
; FILE REFERENCE: ISPH-0516
; CURRENT APPLICATION NUMBER: US/09/711,050A
; CURRENT FILING DATE: 2000-11-11
; PRIOR APPLICATION NUMBER: 60/165,184
; PRIOR FILING DATE: 1999-11-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-711-050A-1

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 368
US-09-412-499A-10/c
; Sequence 10, Application US/09412499A
; Patent No. 6365379
; GENERAL INFORMATION:
; APPLICANT: Lima, Walt F.
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Zinc Finger Peptide Cleavage of Nucleic Acids
; FILE REFERENCE: ISIS4182
; CURRENT APPLICATION NUMBER: US/09/412,499A
; CURRENT FILING DATE: 1999-10-05
; PRIOR APPLICATION NUMBER: 60/103,309
; PRIOR FILING DATE: 1998-10-06
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6365379el Sequence
US-09-412-499A-10

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-337-120A-30

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 369
US-09-287-175-2/c
; Sequence 2, Application US/09287175
; Patent No. 6379698
; GENERAL INFORMATION:
; APPLICANT: LEAMON, Christopher P
; TITLE OF INVENTION: FUSOGENIC LIPIDS AND VESICLES
; FILE REFERENCE: 049202/2002
; CURRENT APPLICATION NUMBER: US/09/287,175
; CURRENT FILING DATE: 1999-04-06
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Oligonucleotide
US-09-287-175-2

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 370
US-09-633-659-17/c
; Sequence 17, Application US/09633659
; Patent No. 6395492
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Bennett, Clarence Frank
; TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake And
; TITLE OF INVENTION: Other Properties
; FILE REFERENCE: ISIS4470
; CURRENT APPLICATION NUMBER: US/09/633,659
; CURRENT FILING DATE: 2000-08-07
; PRIOR APPLICATION NUMBER: 08/211,882
; PRIOR FILING DATE: 1994-04-22
; PRIOR APPLICATION NUMBER: 07/782,374
; PRIOR FILING DATE: 1991-10-24
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6395492el Sequence
US-09-633-659-17

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 371
```

US-09-349-659-2/c
; Sequence 2, Application US/09349659
; Patent No. 6399756
; GENERAL INFORMATION:
; APPLICANT: Cheruvallath, Zacharia S
; APPLICANT: Ravikumar, Vasulinga T
; APPLICANT: Cole, Douglas L
; TITLE OF INVENTION: Improved Process For The Synthesis Of Oligomeric
; FILE REFERENCE: ISIS3837
; CURRENT APPLICATION NUMBER: US/09/349,659
; CURRENT FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: 09/111,678
; PRIOR FILING DATE: 1998-07-08
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6399756el
; OTHER INFORMATION: Sequence
US-09-349-659-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 372

US-09-689-964-11/c
; Sequence 11, Application US/09689964
; Patent No. 6399757
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. 6399757ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/689,964
; FILING DATE: 12-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/397,277
; FILING DATE: 09-MAR-1995
; APPLICATION NUMBER: 07/943,516
; FILING DATE: 11-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumont, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1198
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439

; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 20
; OTHER INFORMATION: /note= "2'-aminopropoxy
; cytosine"
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-689-964-11

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 373

US-09-689-964-11/c
; Sequence 11, Application US/09689964
; Patent No. 6495671
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. 6495671ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/689,964
; FILING DATE: 12-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/397,277
; FILING DATE: 09-MAR-1995
; APPLICATION NUMBER: 07/943,516
; FILING DATE: 11-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumont, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1198
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 20

;
; OTHER INFORMATION: /note= "2'-aminopropoxy
; cytosine"
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-09-689-964-11

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
|||||

RESULT 374

US-09-271-220-1/c
; Sequence 1, Application US/09271220
; Patent No. 6399765
; GENERAL INFORMATION:
; APPLICANT: Krotz, Achim H.
; APPLICANT: McElroy, Bethany M.
; TITLE OF INVENTION: Methods for Removing Dimethoxytrityl Groups From
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: ISIS-3349
; CURRENT APPLICATION NUMBER: US/09/271,220
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-09-271-220-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
|||||

RESULT 375

US-09-352-058A-1/c
; Sequence 1, Application US/09352058A
; Patent No. 6440943
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Oligonucleotides Having Site Specific Chiral Phosphorothioate
; TITLE OF INVENTION: Internucleoside Linkages
; FILE REFERENCE: ISIS3890
; CURRENT APPLICATION NUMBER: US/09/352,058A
; CURRENT FILING DATE: 1999-07-14
; PRIOR APPLICATION NUMBER: 09/115,027
; PRIOR FILING DATE: 1998-07-14
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Sequence
US-09-352-058A-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
|||||

RESULT 376

US-09-726-096A-8/c
; Sequence 8, Application US/09726096A
; Patent No. 6462184
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Maier, Martin A.
; TITLE OF INVENTION: Compounds Processes And Intermediates For Synthesis Of Mixed Back
; TITLE OF INVENTION: Oligomeric Compounds
; FILE REFERENCE: ISIS4528
; CURRENT APPLICATION NUMBER: US/09/726,096A
; CURRENT FILING DATE: 2000-11-29
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-methoxyethoxy (MOE)
US-09-726-096A-8

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
|||||

RESULT 377

US-09-288-679-2/c
; Sequence 2, Application US/09288679
; Patent No. 6465628
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulinga
; APPLICANT: Manoharan, Muthia
; APPLICANT: Capaldi, Daniel
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: Improved Process for the Synthesis of Oligomeric Compounds
; FILE REFERENCE: ISIS3380
; CURRENT APPLICATION NUMBER: US/09/288,679
; CURRENT FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: No. 6465628el Sequence
US-09-288-679-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||

```
Db      20 TGACGGATGCCAGCTGGGC 1

RESULT 378
US-09-288-679-4/c
; Sequence 4, Application US/09288679
; Patent No. 6465628
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulinga
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Capaldi, Daniel
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: Improved Process for the Synthesis of Oligomeric Compounds
; FILE REFERENCE: ISIS3380
; CURRENT APPLICATION NUMBER: US/09/288,679
; CURRENT FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Phosphorothioate backbone
US-09-288-679-4

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1938 GAGAGGGGAAGTGGTGGGG 1957
Db      20 GAGAGGGGAAGTGGTGGGG 1

RESULT 379
US-09-643-233-20/c
; Sequence 20, Application US/09643233
; Patent No. 6479651
; GENERAL INFORMATION:
; APPLICANT: SEELA, Frank
; APPLICANT: THOMAS, Horst
; TITLE OF INVENTION: MODIFIED OLIGONUCLEOTIDES, THEIR PREPARATION AND THEIR
; FILE REFERENCE: 026083/0181
; CURRENT APPLICATION NUMBER: US/09/643,233
; CURRENT FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 09/144,112
; PRIOR FILING DATE: 1998-08-31
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Antisense
; OTHER INFORMATION: Oligonucleotide
US-09-643-233-20

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1938 GAGAGGGGAAGTGGTGGGG 1957
Db      20 GAGAGGGGAAGTGGTGGGG 1
```

```
RESULT 380
US-09-643-233-21/c
; Sequence 21, Application US/09643233
; Patent No. 6479651
; GENERAL INFORMATION:
; APPLICANT: SEELA, Frank
; APPLICANT: THOMAS, Horst
; TITLE OF INVENTION: MODIFIED OLIGONUCLEOTIDES, THEIR PREPARATION AND THEIR
; FILE REFERENCE: 026083/0181
; CURRENT APPLICATION NUMBER: US/09/643,233
; CURRENT FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 09/144,112
; PRIOR FILING DATE: 1998-08-31
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Antisense
; OTHER INFORMATION: Oligonucleotide
US-09-643-233-21

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1940 GAGGGGAAGTGGTGGGGAG 1959
Db      20 GAGGGGAAGTGGTGGGGAG 1

RESULT 381
US-10-121-135-1/c
; Sequence 1, Application US/10121135
; Patent No. 6673912
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; TITLE OF INVENTION: 2'-O-Aminoethyloxethyl-Modified Oligonucleotides
; FILE REFERENCE: ISIS-5036
; CURRENT APPLICATION NUMBER: US/10/121,135
; CURRENT FILING DATE: 2002-04-11
; PRIOR APPLICATION NUMBER: 09/370,625
; PRIOR FILING DATE: 1999-08-06
; PRIOR APPLICATION NUMBER: 09/130,566
; PRIOR FILING DATE: 1998-08-07
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-O-[2-(2-N,N-dimethylaminoethyl) oxyethyl]-5-methyl; phosphoro-
; OTHER INFORMATION: hioate linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 5-methyl-C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 5-methyl-C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
```

; OTHER INFORMATION: 5-methyl-C
US-10-121-135-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 382

US-10-121-135-2/c
; Sequence 2, Application US/10121135
; Patent No. 6673912
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; TITLE OF INVENTION: 2'-O-Aminoethyloxyethyl-Modified Oligonucleotides
; FILE REFERENCE: ISIS-5036
; CURRENT APPLICATION NUMBER: US/10/121,135
; CURRENT FILING DATE: 2002-04-11
; PRIOR APPLICATION NUMBER: 09/370,625
; PRIOR FILING DATE: 1999-08-06
; PRIOR APPLICATION NUMBER: 09/130,566
; PRIOR FILING DATE: 1998-08-07
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-O-(2-N,N-dimethylaminoethyl) oxyethyl]-5-methyl; phosphodiester linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 5-methyl-C
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 5-methyl-C
US-10-121-135-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 383

US-10-121-135-2/c
; Sequence 2, Application US/10121135
; Patent No. 6552178
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; TITLE OF INVENTION: 2'-O-Aminoethyloxyethyl-Modified Oligonucleotides
; FILE REFERENCE: ISIS-5036
; CURRENT APPLICATION NUMBER: US/10/121,135

; CURRENT FILING DATE: 2002-04-11
; PRIOR APPLICATION NUMBER: 09/370,625
; PRIOR FILING DATE: 1999-08-06
; PRIOR APPLICATION NUMBER: 09/130,566
; PRIOR FILING DATE: 1998-08-07
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-O-(2-N,N-dimethylaminoethyl) oxyethyl]-5-methyl; phosphodiester linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 5-methyl-C
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 5-methyl-C
US-10-121-135-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 384

US-10-121-135-4/c
; Sequence 4, Application US/10121135
; Patent No. 6673912
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; TITLE OF INVENTION: 2'-O-Aminoethyloxyethyl-Modified Oligonucleotides
; FILE REFERENCE: ISIS-5036
; CURRENT APPLICATION NUMBER: US/10/121,135
; CURRENT FILING DATE: 2002-04-11
; PRIOR APPLICATION NUMBER: 09/370,625
; PRIOR FILING DATE: 1999-08-06
; PRIOR APPLICATION NUMBER: 09/130,566
; PRIOR FILING DATE: 1998-08-07
; NUMBER OF SEQ ID NOS: 28
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2'-O-(2-N,N-dimethylaminoethyl) oxyethyl]-5-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: phosphorothioate linkage
; FEATURE:

```
; NAME/KEY: misc_feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 5-methyl-C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(18)
; OTHER INFORMATION: 5-methyl-C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 5-methyl-C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 5-methyl-C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 5-methyl-C
US-10-121-135-4
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
```

RESULT 385

```
US-09-658-517C-4/c
; Sequence 4, Application US/09658517C
; Patent No. 6559279
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Guzaev, Andrei P.
; TITLE OF INVENTION: Process For Preparing Peptide Derivatized Oligomeric Compounds
; FILE REFERENCE: ISIS4501
; CURRENT APPLICATION NUMBER: US/09/658,517C
; CURRENT FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-09-658-517C-4
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCTCTGCTACTCAGA 37
Db 20 GAGCTCTCTGCTACTCAGA 1
```

RESULT 386

```
US-09-418-804-1/c
; Sequence 1, Application US/09418804A
; Patent No. 6562959
; GENERAL INFORMATION:
; APPLICANT: CHERIF, Dorra
; TITLE OF INVENTION: FLUORESCENT PROBES FOR CHROMOSOME PAINTING
; FILE REFERENCE: GENSET.069AUS
; CURRENT APPLICATION NUMBER: US/09/418,804A
; CURRENT FILING DATE: 1999-10-15
; EARLIER APPLICATION NUMBER: FR 98/12957
; EARLIER FILING DATE: 1998-10-15
; NUMBER OF SEQ ID NOS: 3
```

```
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: primer PCR Alu
US-09-418-804-1
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2771 CCCAGGCTGGAGTGCAGTGG 2790
Db 20 CCCAGGCTGGAGTGCAGTGG 1
```

RESULT 387

```
US-09-343-006-1/c
; Sequence 1, Application US/09343006
; Patent No. 6573373
; GENERAL INFORMATION:
; APPLICANT: Shukla, Abhinav A.
; APPLICANT: Deshmukh, Ranjit R.
; APPLICANT: Cramer, Steven M.
; APPLICANT: Moore, James A.
; TITLE OF INVENTION: High Affinity, Low Molecular Weight Displacers For Oligonucleotides
; FILE REFERENCE: ISIS3682
; CURRENT APPLICATION NUMBER: US/09/343,006
; CURRENT FILING DATE: 1999-06-29
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. 6573373el Sequence
US-09-343-006-1
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
```

RESULT 388

```
US-09-344-260A-5/c
; Sequence 5, Application US/09344260A
; Patent No. 6576752
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Lonnberg, Harri
; APPLICANT: Salo, Harri
; APPLICANT: Virta, Pasi
; TITLE OF INVENTION: Aminoalkoxy Functionalized Oligomers
; FILE REFERENCE: ISIS-3508
; CURRENT APPLICATION NUMBER: US/09/344,260A
; CURRENT FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/016,520
; PRIOR FILING DATE: 1998-01-30
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: No. 6576752el Sequence
US-09-344-260A-5

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
    |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 389
US-09-495-398-1/c
; Sequence 1, Application US/09495398
; Patent No. 6586586
; GENERAL INFORMATION:
; APPLICANT: Krotz, Achim H.
; APPLICANT: Ravikumar, Vasulunga T.
; TITLE OF INVENTION: Purification of Oligonucleotides
; FILE REFERENCE: ISIS-4287
; CURRENT APPLICATION NUMBER: US/09/495,398
; CURRENT FILING DATE: 2000-01-31
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-495-398-1

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
    |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 390
US-09-495-398-2/c
; Sequence 2, Application US/09495398
; Patent No. 6586586
; GENERAL INFORMATION:
; APPLICANT: Krotz, Achim H.
; APPLICANT: Ravikumar, Vasulunga T.
; TITLE OF INVENTION: Purification of Oligonucleotides
; FILE REFERENCE: ISIS-4287
; CURRENT APPLICATION NUMBER: US/09/495,398
; CURRENT FILING DATE: 2000-01-31
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-495-398-2

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
    |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: No. 6576752el Sequence
US-09-344-260A-5

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
    |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 391
US-09-306-278A-2/c
; Sequence 2, Application US/09306278A
; Patent No. 6610842
; GENERAL INFORMATION:
; APPLICANT: Capaldi, Daniel C
; APPLICANT: Ravikumar, Vasulunga T
; APPLICANT: Cole, Douglas L
; TITLE OF INVENTION: Processes For The Synthesis Of Oligomers Using Phosphoramidite
; FILE REFERENCE: ISIS3481
; CURRENT APPLICATION NUMBER: US/09/306,278A
; CURRENT FILING DATE: 1999-05-06
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. 6610842el Sequence
US-09-306-278A-2

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
    |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 392
US-09-409-926-26/c
; Sequence 26, Application US/09409926
; Patent No. 6617442
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Lima, Walter F.
; APPLICANT: Wu, Hongjiang
; TITLE OF INVENTION: Human RNase H1 and Oligonucleotide Compositions Thereof
; FILE REFERENCE: ISIS4186
; CURRENT APPLICATION NUMBER: US/09/409,926
; CURRENT FILING DATE: 1999-09-30
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6617442el Sequence
US-09-409-926-26

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
    |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 393
US-09-409-926-26/c
; Sequence 26, Application US/09409926
; Patent No. 6617442
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Lima, Walter F.
; APPLICANT: Wu, Hongjiang
; TITLE OF INVENTION: Human RNase H1 and Oligonucleotide Compositions Thereof
; FILE REFERENCE: ISIS4186
; CURRENT APPLICATION NUMBER: US/09/409,926
; CURRENT FILING DATE: 1999-09-30
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6617442el Sequence
US-09-409-926-26

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
    |||||
Db 20 TGACGGATGCCAGCTTGGGC 1
```

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 393
US-09-876-242-2/c
; Sequence 2, Application US/09876242
; Patent No. 6632938
; GENERAL INFORMATION:
; APPLICANT: Moore, Max N.
; APPLICANT: Arthur, John Charles
; APPLICANT: VanSooy, Kent
; APPLICANT: Scozzari, Anthony N.
; TITLE OF INVENTION: Processes Of Purifying Oligonucleotides
; FILE REFERENCE: ISIS4728
; CURRENT APPLICATION NUMBER: US/09/876,242
; CURRENT FILING DATE: 2001-06-07
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-09-876-242-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 394
US-09-370-541-18/c
; Sequence 18, Application US/09370541
; Patent No. 6639062
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Prakash, Thazha P
; APPLICANT: Kawasaki, Andrew M
; TITLE OF INVENTION: Aminoxy-Modified Nucleosidic Compounds And Oligomeric
; FILE REFERENCE: ISIS3993
; CURRENT APPLICATION NUMBER: US/09/370,541
; CURRENT FILING DATE: 1999-08-09
; EARLIER APPLICATION NUMBER: 09/130,973
; EARLIER FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 09/016,520
; EARLIER FILING DATE: 1998-01-30
; EARLIER APPLICATION NUMBER: 60/037,143
; EARLIER FILING DATE: 1997-02-14
; EARLIER APPLICATION NUMBER: 09/344,260
; EARLIER FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: antisense
US-09-370-541-18

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 395
US-10-318-628-2/c
; Sequence 2, Application US/10318628
; Patent No. 6642373
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-318-628-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 396
US-10-318-628-8/c
; Sequence 8, Application US/10318628
; Patent No. 6642373
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; NAME/KEY: misc feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 5 methyl C
; NAME/KEY: misc feature
; LOCATION: (8)..(8)


```
; OTHER INFORMATION: 5 methyl C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 5 methyl C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2' methoxyethyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(16)
; OTHER INFORMATION: 5 methyl U
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 5 methyl U
US-10-318-628-8

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
   |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 397
US-10-318-628-11/c
; Sequence 11, Application US/10318628
; Patent No. 6642373
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulunga T.
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-318-628-11

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
   |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 399
US-10-318-628-22/c
; Sequence 22, Application US/10318628
; Patent No. 6642373
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-318-628-11

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
   |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 398
US-10-318-628-17/c
; Sequence 17, Application US/10318628
; Patent No. 6642373
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
```

```
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2' O MOE, phosphorothioate linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: 2' O MOE linkage
US-10-318-628-22
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCAGA 37
      |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1
```

RESULT 400

```
US-10-318-628-23/c
; Sequence 23, Application US/10318628
; Patent No. 6642373
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; PRIOR FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2' O MOE linkage
US-10-318-628-23
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCAGA 37
      |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1
```

RESULT 401

```
US-10-318-628-25/c
; Sequence 25, Application US/10318628
; Patent No. 6642373
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; PRIOR FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
```

```
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-318-628-25
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
Db 20 TGACGGATGCCAGCTTGGGC 1
```

RESULT 402

```
US-10-318-628-31/c
; Sequence 31, Application US/10318628
; Patent No. 6642373
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 5 methyl C
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 5 methyl C
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 5 methyl C
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 5 methyl C
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (14)..(16)
; OTHER INFORMATION: 2' O MOE
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2' O MOE
US-10-318-628-31
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 403
US-10-318-628-33/c
; Sequence 33, Application US/10318628
; Patent No. 6642373
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-318-628-33

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 404
US-10-318-628-38/c
; Sequence 38, Application US/10318628
; Patent No. 6642373
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-318-628-38

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 405
US-10-318-628-40/c
; Sequence 40, Application US/10318628
; Patent No. 6642373
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-318-628-40

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 406
US-10-318-628-46/c
; Sequence 46, Application US/10318628
; Patent No. 6642373
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; NAME/KEY: misc_feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 5 Methyl C
; NAME/KEY: misc_feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 5 Methyl C
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)

OTHER INFORMATION: 5 Methyl C
FEATURE:
NAME/KEY: misc feature
LOCATION: (13)..(20)
OTHER INFORMATION: 2' O MOE
FEATURE:
NAME/KEY: misc feature
LOCATION: (14)..(16)
OTHER INFORMATION: 5 Methyl U
FEATURE:
NAME/KEY: misc feature
LOCATION: (19)..(19)
OTHER INFORMATION: 5 Methyl U
US-10-318-628-46

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 407

US-09-477-878-1/c
Sequence 1, Application US/09477878
Patent No. 6649750
GENERAL INFORMATION:
APPLICANT: Capaldi, Daniel C
APPLICANT: Ravikumar, Vasulunga T
APPLICANT: Cole, Douglas L
TITLE OF INVENTION: Process for the Preparation of Oligomeric Compounds
FILE REFERENCE: IS154308
CURRENT APPLICATION NUMBER: US/09/477,878
CURRENT FILING DATE: 2000-01-05
NUMBER OF SEQ ID NOS: 2
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 1
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: No. 6649750el Sequence
US-09-477-878-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 408

US-09-334-130-4/c
Sequence 4, Application US/09334130
Patent No. 6656730
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
TITLE OF INVENTION: Drug-Conjugated Oligomeric Compounds
FILE REFERENCE: IS153758
CURRENT APPLICATION NUMBER: US/09/334,130
CURRENT FILING DATE: 1999-06-15
NUMBER OF SEQ ID NOS: 9
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 4
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: No. 6656730el

OTHER INFORMATION: Sequence
US-09-334-130-4

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 409

US-10-290-587-2/c
Sequence 2, Application US/10290587
Patent No. 667471
GENERAL INFORMATION:
APPLICANT: Cheruvallath, Zacharia S.
APPLICANT: Ravikumar, Vasulunga T.
APPLICANT: Cole, Douglas L.
TITLE OF INVENTION: Process For The Synthesis Of Oligomeric Compounds
FILE REFERENCE: ISIS-5108
CURRENT APPLICATION NUMBER: US/10/290,587
CURRENT FILING DATE: 2002-11-08
PRIOR APPLICATION NUMBER: 10/016,465
PRIOR FILING DATE: 2001-12-11
PRIOR APPLICATION NUMBER: 09/349,659
PRIOR FILING DATE: 1999-07-08
NUMBER OF SEQ ID NOS: 4
SOFTWARE: PatentIn version 3.2
SEQ ID NO 2
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic construct
US-10-290-587-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 410

US-09-747-772-3/c
Sequence 3, Application US/09747772
Patent No. 6734167
GENERAL INFORMATION:
APPLICANT: O'Hare, Peter Francis Joseph
APPLICANT: No. 6734167mand, Nadia Michelle
APPLICANT: Brewis, Neil Douglas
APPLICANT: Phelan, Anne
TITLE OF INVENTION: Uses of Transport Proteins
FILE REFERENCE: 5759-56969
CURRENT APPLICATION NUMBER: US/09/747,772
CURRENT FILING DATE: 2000-12-20
NUMBER OF SEQ ID NOS: 5
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3
LENGTH: 20
TYPE: DNA
ORGANISM: synthetic construct
US-09-747-772-3

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957

Db 20 GAGAGGGGAAGTGGTGGGG 1

```
RESULT 411
US-09-747-772-4/c
; Sequence 4, Application US/09747772
; Patent No. 6734167
; GENERAL INFORMATION:
; APPLICANT: O'Hare, Peter Francis Joseph
; APPLICANT: No. 6734167mand, Nadia Michelle
; APPLICANT: Brewis, Neil Douglas
; APPLICANT: Phelan, Anne
; TITLE OF INVENTION: Uses of Transport Proteins
; FILE REFERENCE: 5759-56969
; CURRENT APPLICATION NUMBER: US/09/747,772
; CURRENT FILING DATE: 2000-12-20
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: synthetic construct
US-09-747-772-4
```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
Db 20 GAGAGGGGAAGTGGTGGGG 1

```
RESULT 412
US-10-029-598-1/c
; Sequence 1, Application US/10029598
; Patent No. 6747014
; GENERAL INFORMATION:
; APPLICANT: Teng, Ching-Leou
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Tillman, Lloyd
; APPLICANT: Hardee, Gregory E.
; APPLICANT: Ecker, David J.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Compositions And Methods For No. 6747014-Parental Delivery Of Oligonucleotides
; FILE REFERENCE: ISIS4945
; CURRENT APPLICATION NUMBER: US/10/029,598
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 08/082,624
; PRIOR FILING DATE: 1998-05-21
; PRIOR APPLICATION NUMBER: 09/315,298
; PRIOR FILING DATE: 1999-05-20
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Sequence
; NAME/KEY: misc.feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: Phosphorothioate linkage
US-10-029-598-1
```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTGGGC 2119
Db 20 TGACGGATGCCAGCTGGGC 1

```
RESULT 413
US-10-029-598-2/c
; Sequence 2, Application US/10029598
; Patent No. 6747014
; GENERAL INFORMATION:
; APPLICANT: Teng, Ching-Leou
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Tillman, Lloyd
; APPLICANT: Hardee, Gregory E.
; APPLICANT: Ecker, David J.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Compositions And Methods For No. 6747014-Parental Delivery Of Oligonucleotides
; FILE REFERENCE: ISIS4945
; CURRENT APPLICATION NUMBER: US/10/029,598
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 08/082,624
; PRIOR FILING DATE: 1998-05-21
; PRIOR APPLICATION NUMBER: 09/315,298
; PRIOR FILING DATE: 1999-05-20
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Sequence
; NAME/KEY: misc.feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: Phosphorothioate linkage
US-10-029-598-2
```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
Db 20 GAGAGGGGAAGTGGTGGGG 1

```
RESULT 414
US-10-029-598-55/c
; Sequence 55, Application US/10029598
; Patent No. 6747014
; GENERAL INFORMATION:
; APPLICANT: Teng, Ching-Leou
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Tillman, Lloyd
; APPLICANT: Hardee, Gregory E.
; APPLICANT: Ecker, David J.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Compositions And Methods For No. 6747014-Parental Delivery Of Oligonucleotides
; FILE REFERENCE: ISIS4945
; CURRENT APPLICATION NUMBER: US/10/029,598
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 08/082,624
; PRIOR FILING DATE: 1998-05-21
; PRIOR APPLICATION NUMBER: 09/315,298
; PRIOR FILING DATE: 1999-05-20
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Sequence
; NAME/KEY: misc.feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 5'-methyl
US-10-029-598-55
```

```

; NAME/KEY: misc feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 5'-methyl
; NAME/KEY: misc feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 5'-methyl
; NAME/KEY: misc feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 5'-methyl
; NAME/KEY: misc feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 5'-methyl
; NAME/KEY: misc feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: Phosphorothioate linkage
; US-10-029-598-55

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTGGGC 2119
      |||||
Db      20 TGACGGATGCCAGCTGGGC 1

RESULT 415
US-09-546-596A-17/c
; Sequence 17, Application US/09546596A
; Patent No. 6753423
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Cook, Phillip D.
; Bennett, C. Frank
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
; ENHANCED BIOTABILITY AND ALTERED BIODISTRIBUTION OF
; OLIGONUCLEOTIDES IN MAMMALS
; NUMBER OF SEQUENCES: 63
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. 6753423ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/546,596A
; FILING DATE: 10-Apr-2000
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Lucci, Joseph
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2707
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 17:

```

```

US-09-546-596A-17
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      18 GAGTCCTCTGCTACTCAGA 37
      |||||
Db      20 GAGTCCTCTGCTACTCAGA 1

RESULT 416
US-09-594-387-4/c
; Sequence 4, Application US/09594387
; Patent No. 6762169
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Ligand-Conjugated Oligomeric Compounds
; FILE REFERENCE: ISIS4390
; CURRENT APPLICATION NUMBER: US/09/594,387
; CURRENT FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: USSN 09/334,130
; PRIOR FILING DATE: 1999-06-15
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6762169el Sequence
; US-09-594-387-4

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      18 GAGTCCTCTGCTACTCAGA 37
      |||||
Db      20 GAGTCCTCTGCTACTCAGA 1

RESULT 417
US-09-949-474A-4/c
; Sequence 4, Application US/09949474A
; Patent No. 6762281
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Guzaev, Andrei P.
; TITLE OF INVENTION: Process for Preparing Peptide Derivatized Oligomeric Compounds
; FILE REFERENCE: ISIS4850
; CURRENT APPLICATION NUMBER: US/09/949,474A
; CURRENT FILING DATE: 2001-09-07
; PRIOR APPLICATION NUMBER: 09/658,517
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; US-09-949-474A-4

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      18 GAGTCCTCTGCTACTCAGA 37
      |||||
Db      20 GAGTCCTCTGCTACTCAGA 1

```

```
RESULT 418
US-09-835-370-41/c
; Sequence 41, Application US/09835370
; Patent No. 6777544
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; APPLICANT: WILL, DAVID W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
; FILE REFERENCE: 02481.1742 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/09/835,370
; CURRENT FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: nucleotide
; OTHER INFORMATION: base sequence of PNA derivatives that bind to
; OTHER INFORMATION: viral and cellular targets
US-09-835-370-41

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 419
US-09-835-370-42/c
; Sequence 42, Application US/09835370
; Patent No. 6777544
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; APPLICANT: WILL, DAVID W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
; FILE REFERENCE: 02481.1742 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/09/835,370
; CURRENT FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: nucleotide
; OTHER INFORMATION: base sequence of PNA derivatives that bind to
; OTHER INFORMATION: viral and cellular targets
US-09-835-370-42

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 420
US-09-835-370-43/c
; Sequence 43, Application US/09835370
; Patent No. 6777544
```

```
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; APPLICANT: WILL, DAVID W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
; FILE REFERENCE: 02481.1742 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/09/835,370
; CURRENT FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: nucleotide
; OTHER INFORMATION: base sequence of PNA derivatives that bind to
; OTHER INFORMATION: viral and cellular targets
US-09-835-370-43

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGGAG 1959
Db 20 GAGGGGAAGTGGTGGGGGAG 1

RESULT 421
US-08-117-363A-17/c
; Sequence 17, Application US/08117363A
; Patent No. 6783931
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: AMINE-DERIVATIZED NUCLEOSIDES AND
; TITLE OF INVENTION: OLIGONUCLEOSIDES
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 6783931ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/117,363A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Lucci, Joseph
; REGISTRATION NUMBER: 33,307
; REFERENCES/DOCKET NUMBER: ISIS-1169
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-117-363A-17
```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
|||||

RESULT 422

US-10-103-906-1/c
; Sequence 1, Application US/10103906
; Patent No. 6794502
; GENERAL INFORMATION:
; APPLICANT: Krotz, Achim H.
; APPLICANT: McElroy, Bethany M.
; TITLE OF INVENTION: Methods for Removing Dimethoxytrityl Groups From
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: ISIS-3349
; CURRENT APPLICATION NUMBER: US/10/103,906
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: US/09/271,220
; PRIOR FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-10-103-906-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTGGGC 2119
Db 20 TGACGGATGCCAGCTGGGC 1
|||||

RESULT 423

US-10-083-720A-13
; Sequence 13, Application US/10083720A
; Patent No. 6797813
; GENERAL INFORMATION:
; APPLICANT: de Waal Malefyt, Rene
; APPLICANT: Fickenscher, Helmut
; APPLICANT: Fleckenstein, Bernhard
; APPLICANT: Knappe, Andrea
; TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS
; FILE REFERENCE: DX0644K8K
; CURRENT APPLICATION NUMBER: US/10/083,720A
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 09/363,993
; PRIOR FILING DATE: 1999-07-29
; PRIOR APPLICATION NUMBER: 08/934,959
; PRIOR FILING DATE: 1997-09-22
; PRIOR APPLICATION NUMBER: 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: 60/302,176
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: 60/027,368
; PRIOR FILING DATE: 1996-09-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ICAM-1 forward.

; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)-(20)
; OTHER INFORMATION: ICAM-1 forward.
US-10-083-720A-13

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 950 GCCAGGAGACATGTCAGACA 969
Db 1 GCCAGGAGACATGTCAGACA 20
|||||

RESULT 424

US-10-234-764-5/c
; Sequence 5, Application US/10234764
; Patent No. 6825331
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Lonnberg, Harri
; APPLICANT: Salo, Harri
; APPLICANT: Virta, Pasi
; TITLE OF INVENTION: Aminoxy Functionalized Oligomers
; FILE REFERENCE: ISIS5089
; CURRENT APPLICATION NUMBER: US/10/234,764
; CURRENT FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: 09/016,520
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 09/344,260
; PRIOR FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-234-764-5

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1
|||||

RESULT 425

US-09-823-031B-12/c
; Sequence 12, Application US/09823031B
; Patent No. 6825338
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Guzaev, Andrei P.
; TITLE OF INVENTION: Labeled Oligonucleotides, Methods For Making Same, And Compounds
; FILE REFERENCE: ISIS-4723
; CURRENT APPLICATION NUMBER: US/09/823,031B
; CURRENT FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Sequence
; NAME/KEY: misc_feature


```
; LOCATION: (1)..(1)
; OTHER INFORMATION: cholesterol and linker or dialkylglycerol and linker
US-09-823-031B-12

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 426
US-10-192-437-11/c
; Sequence 11, Application US/10192437
; Patent No. 6828434
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6828434r18
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/192,437
; FILING DATE: 10-Jul-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/397,277A
; FILING DATE: 09-MAR-1995
; APPLICATION NUMBER: 07/943,516
; FILING DATE: 11-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumond, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1198
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 20
; OTHER INFORMATION: /note= "2'-aminopropoxy cytosine"
; SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-10-192-437-11

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
```

```
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 427
US-10-073-718-17/c
; Sequence 17, Application US/10073718
; Patent No. 6831166
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Bennett, Clarence Frank
; TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake and Other Properties
; FILE REFERENCE: ISIS-5024
; CURRENT APPLICATION NUMBER: US/10/073,718
; CURRENT FILING DATE: 2002-05-08
; PRIOR APPLICATION NUMBER: 09/633659
; PRIOR FILING DATE: 2000-08-07
; PRIOR APPLICATION NUMBER: 6153737
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 08/211882
; PRIOR FILING DATE: 1994-04-22
; PRIOR APPLICATION NUMBER: PCT/US92/09196
; PRIOR FILING DATE: 1992-10-23
; PRIOR APPLICATION NUMBER: 07/782374
; PRIOR FILING DATE: 1991-10-24
; PRIOR APPLICATION NUMBER: 07/566977
; PRIOR FILING DATE: 1990-08-13
; PRIOR APPLICATION NUMBER: PCT/US91/000243
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 08/463358
; PRIOR FILING DATE: 1990-01-11
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. 6831166el Sequence
US-10-073-718-17

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 428
US-09-654-373-2/c
; Sequence 2, Application US/09654373
; Patent No. 6835395
; GENERAL INFORMATION:
; APPLICANT: SEMPLE, Sean C.
; APPLICANT: Klimuk, Sandra K.
; APPLICANT: Harasym, Troy O.
; APPLICANT: Dos Santos, Nancy
; APPLICANT: Ansell, Steven M.
; APPLICANT: Cullis, Pieter R.
; APPLICANT: Hope, Michael J.
; APPLICANT: Scherrer, Peter
; APPLICANT: McIntosh, Deidre
; APPLICANT: Wong, Kim F.
; TITLE OF INVENTION: Small Multilamellar Oligodeoxynucleotide-Containing Lipid Vesicles and Method of Making Same
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oppedahl & Larson LLP
; STREET: PO Box 5068
; CITY: Dillon
; STATE: MT
; COUNTRY: U.S.A.
; ZIP: 59715
```

```
;
; STATE: CO
; COUNTRY: USA
; ZIP: 80435-5068
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS 5.0
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/654,373
; FILING DATE: 01-Sep-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/152,179
; FILING DATE: SEPTEMBER 2, 1999
; APPLICATION NUMBER: 09/078,954
; FILING DATE: MAY 14, 1998
; APPLICATION NUMBER: 08/856,374
; FILING DATE: MAY 14, 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Marina T. Larson
; REGISTRATION NUMBER: 32,038
; REFERENCE/DOCKET NUMBER: INEX.P-007
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (970) 468-6600
; TELEFAX: (970) 468-0104
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-654-373-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTGGGC 2119
Db 20 TGACGGATGCCAGCTGGGC 1

RESULT 429
PCT-US91-05815-25/c
; Sequence 25, Application PC/TUS9105815
; GENERAL INFORMATION:
; APPLICANT: Anderson, Kevin P.
; TITLE OF INVENTION: Oligonucleotides for Modulating
; TITLE OF INVENTION: the Effects of Cytomegalovirus Infections
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz &
; ADDRESSEE: Norris
; STREET: One Liberty Place -- 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb
; MEDIUM TYPE: STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05815
```

```
;
; FILING DATE: 19910814
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Licata, Jane M.
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0408
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; PCT-US91-05815-25

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 430
PCT-US93-08101-2/c
; Sequence 2, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 2:
```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
PCT-US93-08101-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
DB 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 431

PCT-US93-08101-7/c
; Sequence 7, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
PCT-US93-08101-7

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCTCGCTATG 60
DB 20 GCAACCTCAGCCTCGCTATG 1

RESULT 432

PCT-US93-08101-8/c
; Sequence 8, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
PCT-US93-08101-8

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCCGAGGAGCCCCG 77
DB 20 ATGGCTCCCGAGGAGCCCCG 1

RESULT 433

PCT-US93-08101-9/c
; Sequence 9, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion

```

; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; PCT-US93-08101-9

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 97 CTGGTCTGCTCGGGGCTCT 116
Db 20 CTGGTCTGCTCGGGGCTCT 1

RESULT 434
PCT-US93-08101-10/c
; Sequence 10, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:

```

```

; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; PCT-US93-08101-10

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
Db 20 TCAAACTGCCCTGATGGCA 1

RESULT 435
PCT-US93-08101-11/c
; Sequence 11, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:

```

```
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
PCT-US93-08101-11

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCTTCAGTCAGTGACC 894
Db 20 AGGCTTCAGTCAGTGACC 1

RESULT 436
PCT-US93-08101-12/c
; Sequence 12, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
PCT-US93-08101-13

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
PCT-US93-08101-12

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGGAGGTACCCGCGAG 1464
Db 20 AAGGGGAGGTACCCGCGAG 1

RESULT 437
PCT-US93-08101-13/c
; Sequence 13, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
PCT-US93-08101-13

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1637 CACAAGCCAGCCTCCCTGA 1656
|||||
Db 20 CACAAGCCAGCCTCCCTGA 1

RESULT 438
PCT-US93-08101-14/c
; Sequence 14, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
PCT-US93-08101-14

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1654 TGAACCTATCCCGGACAGG 1673
|||||
Db 20 TGAACCTATCCCGGACAGG 1

RESULT 439
PCT-US93-08101-15/c
; Sequence 15, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation

; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
PCT-US93-08101-15

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAAGTGGTGGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGGG 1

RESULT 440
PCT-US93-08101-16/c
; Sequence 16, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2

```

; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA: 567,286
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
PCT-US93-08101-16

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 2962 AGTTAATAAAGCTTTCTCAA 2981
Db 20 AGTTAATAAAGCTTTCTCAA 1

```

```

RESULT 441
PCT-US93-08101-22/c
; Sequence 22, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439

```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
PCT-US93-08101-22

```

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

```

```

RESULT 442
PCT-US93-08101-23/c
; Sequence 23, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100

```

TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
PCT-US93-08101-23

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
|||||
DB 20 GAGGCCACAGACTTACAGA 1

RESULT 443

PCT-US93-08101-24/c
Sequence 24, Application PC/TUS9308101
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/08101
FILING DATE: Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
PRIOR APPLICATION DATA:
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0002
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 24:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
PCT-US93-08101-24

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1881 CAAGGGAAGGAGCAAGACT 1900
|||||
DB 20 CAAGGGAAGGAGCAAGACT 1

RESULT 444

PCT-US93-08101-25/c
Sequence 25, Application PC/TUS9308101
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/08101
FILING DATE: Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
PRIOR APPLICATION DATA:
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0002
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
PCT-US93-08101-25

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1921 TTAAGTCTAGCCTGATGAG 1940
|||||
DB 20 TTAAGTCTAGCCTGATGAG 1

RESULT 445

PCT-US93-08101-26/c
Sequence 26, Application PC/TUS9308101
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli


```
;
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; PCT-US93-08101-26

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCCACCATGAGGACA 1981
   |||||||
Db 20 ATAGCCCCCACCATGAGGACA 1

RESULT 446
PCT-US93-08101-84/c
; Sequence 84, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
```

```
;
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 84:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; PCT-US93-08101-84

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
   |||||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 447
PCT-US93-08101-85/c
; Sequence 85, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
```

```
/ FILING DATE: July 23, 1991
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 567,286
/ FILING DATE: August 14, 1990
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER:
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Jane Massey Licata
/ REGISTRATION NUMBER: 32,257
/ REFERENCE/DOCKET NUMBER: ISPH-0002
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (215) 568-3100
/ TELEFAX: (215) 568-3439
/ INFORMATION FOR SEQ ID NO: 85:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20
/ TYPE: Nucleic Acid
/ STRANDEDNESS: Single
/ TOPOLOGY: Linear
/ ANTI-SENSE: Yes
PCT-US93-08101-85

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGGTGGGGGAGACATA 1964
Db 20 GAAGTGGTGGGGGAGACATA 1

RESULT 448
PCT-US93-08367A-11/c
/ Sequence 11, Application PC/TUS9308367A
/ GENERAL INFORMATION:
/ APPLICANT: Manoharan, Muthiah
/ APPLICANT: Phillip D. Cook
/ TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
/ TITLE OF INVENTION: MAKING AND USING THE SAME
/ NUMBER OF SEQUENCES: 16
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
/ STREET: One Liberty Place - 46th Floor
/ CITY: Philadelphia
/ STATE: PA
/ COUNTRY: U.S.A.
/ ZIP: 19103
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US93/08367A
/ FILING DATE:
/ CLASSIFICATION:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Gaumont, Rebecca R.
/ REGISTRATION NUMBER: 35,152
/ REFERENCE/DOCKET NUMBER: ISIS-1171
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 215-568-3100
/ TELEFAX: 215-568-3439
/ INFORMATION FOR SEQ ID NO: 11:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ FEATURE:

/ NAME/KEY: misc_feature
/ LOCATION: 20
/ OTHER INFORMATION: /note= "2'-aminopropoxy
/ OTHER INFORMATION: cytosine"
PCT-US93-08367A-11

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 449
PCT-US96-08757A-6/c
/ Sequence 6, Application PC/TUS9608757A
/ GENERAL INFORMATION:
/ APPLICANT: ISIS Pharmaceuticals, Inc., et al.
/ TITLE OF INVENTION: Oligonucleotides Having Phosphorothioate
/ TITLE OF INVENTION: Linkages Of High Chiral Purity
/ NUMBER OF SEQUENCES: 17
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & Norris
/ STREET: One Liberty Place - 46th Floor
/ CITY: Philadelphia
/ STATE: PA
/ COUNTRY: U.S.A.
/ ZIP: 19103
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5 inch disk, 720 Kb
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: WordPerfect 6.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US96/08757A
/ FILING DATE: 05-JUN-1996
/ CLASSIFICATION:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/471,967
/ FILING DATE: 06-JUN-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/467,597
/ FILING DATE: 06-JUN-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/468,447
/ FILING DATE: 06-JUN-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/468,569
/ FILING DATE: 06-JUN-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/466,692
/ FILING DATE: 06-JUN-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/471,966
/ FILING DATE: 06-JUN-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/469,851
/ FILING DATE: 06-JUN-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/470,129
/ FILING DATE: 06-JUN-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Joseph Luccl
/ REGISTRATION NUMBER: 33,307
/ REFERENCE/DOCKET NUMBER: ISIS-2298
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 215-568-3100
/ TELEFAX: 215-568-3439
/ INFORMATION FOR SEQ ID NO: 6:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20
```

```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
PCT-US96-08757A-6

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.1e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 450
US-08-327-363-5/c
; Sequence 5, Application US/08327363
; Patent No. 5643780
; GENERAL INFORMATION:
; APPLICANT: ISIS Pharmaceuticals and
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Compositions and Methods for Modulating
; TITLE OF INVENTION: RNA Activity Through Modification of the 5' Cap Structure of
; TITLE OF INVENTION: RNA
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5643780ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/327,363
; FILING DATE: herewith
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 847,054
; FILING DATE: April 3, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathryn Leary, Ph.D.
; REGISTRATION NUMBER: 36,317
; REFERENCE/DOCKET NUMBER: ISIS-1719
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: unknown
US-08-327-363-5

Query Match          0.7%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
      |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 452
US-08-753-147-28/c
; Sequence 28, Application US/08753147
; Patent No. 5770372
; GENERAL INFORMATION:
; APPLICANT: Concannon, Patrick
; TITLE OF INVENTION: Detection of Mutations in the Human ATM Gene
; NUMBER OF SEQUENCES: 196
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Christensen O'Connor Johnson and Kindness
; STREET: 1420 5th Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98101-2347
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/753,147
; FILING DATE:

```

```

; GENERAL INFORMATION:
; APPLICANT: ISIS Pharmaceuticals and
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Compositions and Methods for Modulating
; TITLE OF INVENTION: RNA Activity Through Modification of the 5' Cap Structure of
; TITLE OF INVENTION: RNA
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5643780ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/327,363
; FILING DATE: herewith
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 847,054
; FILING DATE: April 3, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Kathryn Leary, Ph.D.
; REGISTRATION NUMBER: 36,317
; REFERENCE/DOCKET NUMBER: ISIS-1719
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: unknown
US-08-327-363-6

Query Match          0.7%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
      |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 452
US-08-753-147-28/c
; Sequence 28, Application US/08753147
; Patent No. 5770372
; GENERAL INFORMATION:
; APPLICANT: Concannon, Patrick
; TITLE OF INVENTION: Detection of Mutations in the Human ATM Gene
; NUMBER OF SEQUENCES: 196
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Christensen O'Connor Johnson and Kindness
; STREET: 1420 5th Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98101-2347
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/753,147
; FILING DATE:

```

CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Sheiness, Diana K.
REGISTRATION NUMBER: 35,356
REFERENCE/DOCKET NUMBER: WRC-1-9714
TELEPHONE: (206) 743-4387
TELEFAX: (206) 224 0779
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
US-08-753-147-28

Query Match 0.7%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTGCAGTGG 2790
|||||
DB 21 CCCAGGCTGGAGTGCAGTGG 2

RESULT 453

US-08-063-167A-27/c
Sequence 27, Application US/08063167A
Patent No. 5514788
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
TITLE OF INVENTION: of Cell Adhesion
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002

COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/063,167A
FILING DATE: 19930517
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0002
TELEPHONE: (215) 568-3100

TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 22
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-063-167A-27

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 454

US-08-007-997A-27/c
Sequence 27, Application US/08007997A
Patent No. 5591623
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
TITLE OF INVENTION: of Cell Adhesion
NUMBER OF SEQUENCES: 82
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz
ADDRESSEE: Mackiewicz & No. 5591623ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/007,997A
FILING DATE: 19930121
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISIS-0709
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 27:
SEQUENCE CHARACTERISTICS:
LENGTH: 22
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-007-997A-27

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 455
US-08-440-740A-27/c
; Sequence 27, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-440-740A-27

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 456
US-08-344-155C-27/c
; Sequence 27, Application US/08344155C
; Patent No. 5883082
; GENERAL INFORMATION:
; APPLICANT: Bennett and Stepkowski
; TITLE OF INVENTION: Compositions and Methods for Preventing
; and Treating Allograft Rejection
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,155C
; FILING DATE: No. 5883082ember 23, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/063,167
; FILING DATE: 5/17/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/007,997
; FILING DATE: 1/21/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/939,855
; FILING DATE: 9/2/92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/567,286
; FILING DATE: 8/14/90
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0098
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-344-155C-27

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 457
US-08-982-845B-27/c
; Sequence 27, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
```

;; TITLE OF INVENTION: of Cell Adhesion
;; NUMBER OF SEQUENCES: 87
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Law Offices of Jane Massey Licata
;; STREET: 66 East Main Street
;; CITY: Marlton
;; STATE: NJ
;; COUNTRY: USA
;; ZIP: 08053
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;; COMPUTER: IBM PS/2
;; OPERATING SYSTEM: Windows 95
;; SOFTWARE: WORDPERFECT 6.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/982,845B
;; FILING DATE: December 2, 1997
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/440,740
;; FILING DATE: May 12, 1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 063,167
;; FILING DATE: May 17, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 21, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0243
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 779-8488
;; INFORMATION FOR SEQ ID NO: 27:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 22
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
;; US-08-982-845B-27

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 458
US-08-991-525B-27/c
; Sequence 27, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street

;; CITY: Marlton
;; STATE: NJ
;; COUNTRY: USA
;; ZIP: 08053
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;; COMPUTER: IBM PS/2
;; OPERATING SYSTEM: Windows 95
;; SOFTWARE: WORDPERFECT 6.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/991,525B
;; FILING DATE: December 16, 1997
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 440,740
;; FILING DATE: May 12, 1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 063,167
;; FILING DATE: May 17, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 21, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0247
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (856) 810-1515
;; TELEFAX: (856) 810-1454
;; INFORMATION FOR SEQ ID NO: 27:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 22
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
;; US-08-991-525B-27

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 459
US-09-085-759-27/c
; Sequence 27, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA

```
;
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-085-759-27

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 460
US-09-128-496-27/c
; Sequence 27, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
```

```
;
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-128-496-27

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 461
US-09-009-490A-27/c
; Sequence 27, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
US-09-009-490A-27

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 462
PCT-US93-08101-27/c
; Sequence 27, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
;
PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
```

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
PCT-US93-08101-27

Query Match 0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 463
US-08-594-452-87/c
; Sequence 87, Application US/08594452
; Patent No. 6013639
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anuschirwan
; APPLICANT: UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/594,452
; FILING DATE: 31-JAN-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DE 195 02 912.7
; FILING DATE: 31-JAN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 87:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-594-452-87

Query Match 0.7%; Score 20; DB 1; Length 24;
```



```
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
    |||||
    24 GAGAGGGGAAGTGTGGGGG 5

Db

RESULT 464
US-08-594-452-88/c
; Sequence 86, Application US/08594452
; Patent No. 6013639
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anuschirwan
; APPLICANT: UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/594,452
; FILING DATE: 31-JAN-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DE 195 02 912.7
; FILING DATE: 31-JAN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 88:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-594-452-88

Query Match 0.7%; Score 20; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
    |||||
    24 GAGAGGGGAAGTGTGGGGG 5

Db

RESULT 466
US-09-258-408-88/c
; Sequence 88, Application US/09258408
; Patent No. 6121434
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anuschirwan
; APPLICANT: UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/258,408
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/594,452
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 88:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-594-452-88

Query Match 0.7%; Score 20; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
    |||||
    20 GAGAGGGGAAGTGTGGGGG 1

Db

RESULT 465
US-09-258-408-87/c
; Sequence 87, Application US/09258408
; Patent No. 6121434
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anuschirwan
; APPLICANT: UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
```

TELECOMMUNICATION INFORMATION:
TELEPHONE: (202)672-5300
TELEFAX: (202)672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 88:
SEQUENCE CHARACTERISTICS:
LENGTH: 24 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-258-408-88

Query Match 0.7%; Score 20; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAGTGTGGGG 1957
|||||
Db 20 GAGAGGGGAGTGTGGGG 1

RESULT 467

US-09-018-584A-96/c
Sequence 96, Application US/09018584A
Patent No. 6238863
GENERAL INFORMATION:
APPLICANT: Schumm, James W.
APPLICANT: Bacher, Jeffery W.
TITLE OF INVENTION: MATERIALS AND METHODS FOR
IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM
REPEAT DNA MARKERS
TITLE OF INVENTION: REPEAT DNA MARKERS
NUMBER OF SEQUENCES: 147
CORRESPONDENCE ADDRESS:
ADDRESSEE: Promega Corporation
STREET: 2800 Woods Hollow Road
CITY: Madison
STATE: Wisconsin
COUNTRY: U.S.A.
ZIP: 53711-5399

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb
COMPUTER: IBM compatible PC
OPERATING SYSTEM: Windows 95
SOFTWARE: Word 97 (DOS text format)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/018,584A
FILING DATE: 04-Feb-1998
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Grady J. Frenchick
REGISTRATION/DOCKET NUMBER: 16026.9180
REFERENCE/DOCKET NUMBER: 16026.9180
TELECOMMUNICATION INFORMATION:
TELEPHONE: (608) 257-3501
TELEFAX: (608) 257-2275
INFORMATION FOR SEQ ID NO: 96:
SEQUENCE CHARACTERISTICS:
LENGTH: 24
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-09-018-584A-96

Query Match 0.7%; Score 19.8; DB 1; Length 24;
Best Local Similarity 91.3%; Pred. No. 1.8e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2766 TGTACCCAGGCTGGAGTGCAGT 2788
|||||
Db 23 TATCACCAGGCTGGAGTGCAT 1

RESULT 468

US-09-784-423-96/c
Sequence 96, Application US/097844423
Patent No. 6767703
GENERAL INFORMATION:
APPLICANT: Schumm, James W.
APPLICANT: Bacher, Jeffery W.
TITLE OF INVENTION: MATERIALS AND METHODS FOR
IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM
REPEAT DNA MARKERS
NUMBER OF SEQUENCES: 147
CORRESPONDENCE ADDRESS:
ADDRESSEE: Promega Corporation
STREET: 2800 Woods Hollow Road
CITY: Madison
STATE: Wisconsin
COUNTRY: U.S.A.
ZIP: 53711-5399

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb
COMPUTER: IBM compatible PC
OPERATING SYSTEM: Windows 95
SOFTWARE: Word 97 (DOS text format)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/784,423
FILING DATE: 15-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/018,584
FILING DATE: 04-Feb-1998
ATTORNEY/AGENT INFORMATION:
NAME: Grady J. Frenchick
REGISTRATION/DOCKET NUMBER: 29,018
REFERENCE/DOCKET NUMBER: 16026.9180
TELECOMMUNICATION INFORMATION:
TELEPHONE: (608) 257-3501
TELEFAX: (608) 257-2275
INFORMATION FOR SEQ ID NO: 96:
SEQUENCE CHARACTERISTICS:
LENGTH: 24
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-09-784-423-96

Query Match 0.7%; Score 19.8; DB 1; Length 24;
Best Local Similarity 91.3%; Pred. No. 1.8e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2766 TGTACCCAGGCTGGAGTGCAGT 2788
|||||
Db 23 TATCACCAGGCTGGAGTGCAT 1

RESULT 469

US-08-222-177A-160/c
Sequence 160, Application US/08222177A
Patent No. 5582979
GENERAL INFORMATION:
APPLICANT: Weber, James L.
TITLE OF INVENTION: LENGTH POLYMORPHISMS IN
(dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
NUMBER OF SEQUENCES: 460
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dewitt Ross & Stevens, S.C.
STREET: 8000 Excelsior Drive, Suite 401
CITY: Madison
STATE: Wisconsin
COUNTRY: USA
ZIP: 53717-1914
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible

```
;
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/222,177A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/341,562
; FILING DATE: 21-APR-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 09865.601
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 831-2100
; TELEFAX: (608) 831-2106
; TELEX:
; INFORMATION FOR SEQ ID NO: 160:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; IMMEDIATE SOURCE:
; CLONE: mfd37rs
; US-08-222-177A-160

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2729 TGTGTGTGTGTGTGTGTGTGT 2749
Db      21 TGTGTGTGTGTGTGTGTGTGT 1

;
; RESULT 470
; US-08-529-878B-9
; Sequence 9, Application US/08529878B
; Patent No. 5932556
; GENERAL INFORMATION:
; APPLICANT: Tam, Robert C.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: REGULATION OF CD28 EXPRESSION
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Crockett & Fish
; STREET: 3000 S. Augusta Court
; CITY: La Habra
; STATE: California
; COUNTRY: United States of America
; ZIP: 90631
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/529,878B
; FILING DATE: 13-SEP-1995
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: Fish, Robert D.
; REGISTRATION NUMBER: 33,880
; REFERENCE/DOCKET NUMBER: 213/003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 714-525-3433
; TELEFAX: 714-525-3303
; TELEX:
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; US-08-529-878B-9

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2728 GTGTGTGTGTGTGTGTGTGTG 2748
Db      1 GTGTGTGTGTGTGTGTGTGTG 21

;
; RESULT 471
; US-09-233-086-61
; Sequence 61, Application US/09233086
; Patent No. 6337192
; GENERAL INFORMATION:
; APPLICANT: Bartel, Paul L.
; APPLICANT: Tavtigian, Sean V.
; APPLICANT: Myriad Genetics, Inc.
; TITLE OF INVENTION: MMSC1 - An MMAC1 Interacting Protein
; FILE REFERENCE: MMSC1 Gene
; CURRENT APPLICATION NUMBER: US/09/233,086
; CURRENT FILING DATE: 1999-01-19
; EARLIER FILING DATE: 1998-01-20
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 61
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:MMSC1 Primers
; US-09-233-086-61

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 2.3e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2759 CTCGCTCTGTCACCAGGCTG 2779
Db      1 CTTGCTCTGTCACCAGGCTG 21

;
; RESULT 472
; US-08-314-615-22/c
; Sequence 22, Application US/08314615
; Patent No. 5525487
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: I-CAM Related Protein
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; ADDRESSEE: Bicknell
; STREET: Two First National Plaza, 20 South Clark
; STREET: Street
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/314,615
```

/ FILING DATE:
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/07/827,689
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Borun, Michael F.
/ REGISTRATION NUMBER: 25,447
/ REFERENCE/DOCKET NUMBER: 27866/30704
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (312)346-5750
/ TELEFAX: (312)984-9740
/ TELEX: 25-3856

/ INFORMATION FOR SEQ ID NO: 22:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
US-08-314-615-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAAATTC 609
|||||
Db 19 TCACCATGGAGCCAAATTC 1

RESULT 473

US-08-314-362-22/c
/ Sequence 22, Application US/08314362
/ Patent No. 5532127

/ GENERAL INFORMATION:
/ APPLICANT: Gallatin, W. Michael
/ APPLICANT: Vazeux, Rosemay
/ TITLE OF INVENTION: I-CAM Related Protein
/ NUMBER OF SEQUENCES: 22
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
/ ADDRESSEE: Bicknell
/ STREET: Two First National Plaza, 20 South Clark
/ STREET: Street
/ CITY: Chicago
/ STATE: Illinois
/ COUNTRY: USA
/ ZIP: 60603

/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/314,362
/ FILING DATE:

/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/07/894,061
/ FILING DATE:
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/827,689
/ FILING DATE: 27-JAN-1992

/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US
/ FILING DATE: 26-MAY-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: No. 5532127 and, Greta E.
/ REGISTRATION NUMBER: 35,302
/ REFERENCE/DOCKET NUMBER: 27866/30918
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (312)346-5750

/ TELEFAX: (312)984-9740
/ TELEX: 25-3856
/ INFORMATION FOR SEQ ID NO: 22:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
US-08-314-362-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAAATTC 609
|||||
Db 19 TCACCATGGAGCCAAATTC 1

RESULT 474

US-08-327-363-7/c
/ Sequence 7, Application US/08327363
/ Patent No. 5643780

/ GENERAL INFORMATION:
/ APPLICANT: ISIS Pharmaceuticals and
/ APPLICANT: Brenda Baker
/ TITLE OF INVENTION: Compositions and Methods for Modulating
/ TITLE OF INVENTION: RNA Activity Through Modification of the 5' Cap Structure of
/ TITLE OF INVENTION: RNA
/ NUMBER OF SEQUENCES: 7
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5643780ris
/ STREET: One Liberty Place - 46th Floor
/ CITY: Philadelphia
/ STATE: PA
/ COUNTRY: USA
/ ZIP: 19103

/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
/ COMPUTER: IBM PS/2
/ OPERATING SYSTEM: PC-DOS
/ SOFTWARE: WORDPERFECT 5.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/327,363
/ FILING DATE: herewith
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 847,054
/ FILING DATE: April 3, 1992

/ ATTORNEY/AGENT INFORMATION:
/ NAME: Kathryn Leary, Ph.D.
/ REGISTRATION NUMBER: 36,317
/ REFERENCE/DOCKET NUMBER: ISIS-1719
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (215) 568-3100
/ TELEFAX: (215) 568-3439
/ INFORMATION FOR SEQ ID NO: 7:

/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: unknown

US-08-327-363-7

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCTCCTCTGCTACTCAGAG 38
|||||
Db 19 GCTCCTCTGCTACTCAGAG 1

```
RESULT 475
US-08-433-010-22/c
; Sequence 22, Application US/08433010
; Patent No. 5663293
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Protein
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; ADDRESSEE: Bicknell
; STREET: Two First National Plaza, 20 South Clark
; STREET: Street
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/433,010
; FILING DATE:
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/009,266
; FILING DATE:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5663293and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 31218
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312)346-5750
; TELEFAX: (312)984-9740
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-433-010-22
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 591 TCACCATGGAGCAATTC 609
Db 19 TCACCATGGAGCAATTC 1

RESULT 476
US-08-196-003-6
; Sequence 6, Application US/08196003
; Patent No. 5681699
; GENERAL INFORMATION:
; APPLICANT: BEAUDET M.D., ARTHUR L
; APPLICANT: ROTTER M.D., JEROME I
; APPLICANT: TARGAN M.D., STEPHAN R

; APPLICANT: VORA M.D., DEVENDRA
; APPLICANT: YANG M.D., HUIYING
; TITLE OF INVENTION: METHODS OF SCREENING FOR ULCERATIVE
; TITLE OF INVENTION: COLITIS AND CROHN'S DISEASE
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
; STREET: 444 SOUTH FLOWER STREET, SUITE 2000
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/196,003
; FILING DATE: 11-FEB-1994
; CLASSIFICATION: 424
; ATTORNEY/AGENT INFORMATION:
; NAME: WHITEFORD ESQ, WENDY A
; REGISTRATION NUMBER: 36,964
; REFERENCE/DOCKET NUMBER: P07 32056
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-4442
; TELEFAX: (213) 489-4210
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-196-003-6
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 769 TCCCTGGACGGGCTGTTC 787
Db 1 TCCCTGGACGGGCTGTTC 19

RESULT 477
US-08-462-305-23/c
; Sequence 23, Application US/08462305
; Patent No. 5696248
; GENERAL INFORMATION:
; APPLICANT: Peyman, Anuschirwan
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Carolus, Carolin
; TITLE OF INVENTION: 3'-Modified Oligonucleotide Derivatives
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoechst Marion Roussel, Inc.
; STREET: 2110 E. Galbraith Road, P.O. Box 156300
; CITY: Cincinnati
; STATE: Ohio
; COUNTRY: USA
; ZIP: 45215-6300
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,305
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
```

NAME: Payne, T. Helen
REGISTRATION NUMBER: 36,889
REFERENCE/DOCKET NUMBER: HOE94/F161K US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 513-948-7183
TELEFAX: 513-948-7960 or 4681
TELEX: 214320
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
US-08-462-305-23

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCGCAG 69
|||||
Db 19 CCTCGCTATGGCTCCCGCAG 1

RESULT 478
US-08-482-882-22/c
Sequence 22, Application US/08482882
Patent No. 5773218
GENERAL INFORMATION:
APPLICANT: Gallatin, W. Michael
APPLICANT: Vazeux, Rosemay
TITLE OF INVENTION: ICAM-Related Materials and Methods
NUMBER OF SEQUENCES: 116
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 S. Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,882
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/286,754
FILING DATE:
APPLICATION NUMBER: US 08/102,852
FILING DATE: 05-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/009,266
FILING DATE: 22-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/894,061
FILING DATE: 05-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/889,724
FILING DATE: 26-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,689
FILING DATE: 27-JAN-1992
ATTORNEY/AGENT INFORMATION:
NAME: No. 5773218and, Greta B.
REGISTRATION NUMBER: 35,302
REFERENCE/DOCKET NUMBER: 32178
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300

TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-482-882-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAAATTC 609
|||||
Db 19 TCACCATGGAGCCAAATTC 1

RESULT 479
US-08-483-389-22/c
Sequence 22, Application US/08483389
Patent No. 5811517
GENERAL INFORMATION:
APPLICANT: Gallatin, W. Michael
APPLICANT: Vazeux, Rosemay
TITLE OF INVENTION: ICAM-RELATED PROTEIN
NUMBER OF SEQUENCES: 118
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 233 South Wacker Drive/6300 Sears Tower
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/483,389
FILING DATE: 07-JUN-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/102,852
FILING DATE: 05-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/009,266
FILING DATE: 22-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/894,061
FILING DATE: 05-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/889,724
FILING DATE: 26-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,689
FILING DATE: 27-JAN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Suh, Young J.
REGISTRATION NUMBER: P-41,337
REFERENCE/DOCKET NUMBER: 27866/32760
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: (312) 474-6600
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-483-389-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAATTC 609
Db 19 TCACCATGGAGCCAATTC 1

RESULT 480
US-08-487-113D-22/c
; Sequence 22, Application US/08487113D
; Patent No. 5837822
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 5300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/487,113D
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5837822and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32744
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-487-113D-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAATTC 609
Db 19 TCACCATGGAGCCAATTC 1

RESULT 481
US-08-473-503-22/c
; Sequence 22, Application US/08473503
; Patent No. 5869262
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/473,503
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5869262and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-473-503-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCAATTC 609

```
Db      19 TCACCATGGAGCCCAATTC 1
|||||
RESULT 482
US-08-613-417A-23/c
; Sequence 23, Application US/08613417A
; Patent No. 5874553
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Phosphonomonoester nucleic acids,
; TITLE OF INVENTION: process for their preparation, and their use
; NUMBER OF SEQUENCES: 33
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0. Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/613,417A
; FILING DATE:
; CLASSIFICATION: 514
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: yes
; FEATURE:
; NAME/KEY: exon
; LOCATION: 1..19
US-08-613-417A-23

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      51 CCTCGCTATGCTCCCGC 69
|||||
Db      19 CCTCGCTATGCTCCCGC 1

RESULT 483
US-08-483-932-22/c
; Sequence 22, Application US/08483932
; Patent No. 5880268
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0. Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,932
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      591 TCACCATGGAGCCCAATTC 609
|||||
Db      19 TCACCATGGAGCCCAATTC 1

RESULT 484
US-08-720-420A-22/c
; Sequence 22, Application US/08720420A
; Patent No. 5989843
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0. Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/720,420A
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/487,113
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
```


;; PRIOR APPLICATION DATA: US 08/009,266
;; FILING DATE: 22-JAN-1993
;; PRIOR APPLICATION DATA:
;; FILING DATE: 05-JUN-1992
;; PRIOR APPLICATION DATA: US 07/894,061
;; FILING DATE: 05-JUN-1992
;; PRIOR APPLICATION DATA: US 07/889,724
;; FILING DATE: 26-MAY-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/827,689
;; FILING DATE: 27-JAN-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Williams, Joseph A., Jr.
;; REGISTRATION NUMBER: 38,659
;; REFERENCE/DOCKET NUMBER: 33282
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (312) 474-6300
;; TELEFAX: (312) 474-0448
;; TELEX: 25-3856
;; INFORMATION FOR SEQ ID NO: 22:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 19 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
US-08-720-420A-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 591 TCACCATGGAGCCCAATTC 609
Db 19 TCACCATGGAGCCCAATTC 1

RESULT 485
US-08-933-824-6
; Sequence 6, Application US/08933824
; Patent No. 6008335
; GENERAL INFORMATION:
; APPLICANT: BEAUDET M.D., AURTHUR L
; APPLICANT: ROTTER M.D., JEROME I
; APPLICANT: TARGAN M.D., STEPHAN R
; APPLICANT: VORA M.D., DEVENDRA
; APPLICANT: YANG M.D., HUIYING
; TITLE OF INVENTION: METHODS OF SCREENING FOR ULCERATIVE
; TITLE OF INVENTION: COLITIS AND CROHN'S DISEASE
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
; STREET: 444 SOUTH FLOWER STREET, SUITE 2000
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/933,824
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/196,003
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: WHITEFORD ESQ, WENDY A
; REGISTRATION NUMBER: 36,964

;; REFERENCE/DOCKET NUMBER: P07 32056
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-4442
;; TELEFAX: (213) 489-4210
;; INFORMATION FOR SEQ ID NO: 6:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 19 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
US-08-933-824-6

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 769 TCCCTGGACGGCTGTTC 787
Db 1 TCCCTGGACGGCTGTTC 19

RESULT 486
US-08-594-452-23/c
; Sequence 23, Application US/08594452
; Patent No. 6013639
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anuschirwan
; APPLICANT: UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/594,452
; FILING DATE: 31-JAN-1996
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DE 195 02 912.7
; FILING DATE: 31-JAN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 672-5300
; TELEFAX: (202) 672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-594-452-23

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 51 CCTCGCTATGGCTCCAGC 69
Db 19 CCTCGCTATGGCTCCAGC 1

```

RESULT 487
US-08-578-686C-22/c
; Sequence 22, Application US/08578686C
; Patent No. 6028182
; GENERAL INFORMATION:
; APPLICANT: Uhlmann, Eugen
; TITLE OF INVENTION: Methylphosphonic Acid Ester, Process For
; PREPARING THE SAME AND ITS USE
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner, L.L.P.
; STREET: 1300 I. Street, N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/578,686C
; FILING DATE: January 2, 1996
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Johnson, Lori-Ann
; REGISTRATION NUMBER: 34,498
; REFERENCE/DOCKET NUMBER: 2481.1481-00000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-408-4000
; TELEFAX: 202-408-4400
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-578-686C-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCAGC 69
DB 19 CCTCGCTATGGCTCCAGC 1

RESULT 488
US-08-281-203-20/c
; Sequence 20, Application US/08281203
; Patent No. 6033909
; GENERAL INFORMATION:
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Peyman, Anuschirwan
; APPLICANT: O'Malley, Gerard
; APPLICANT: Helsing, Matthias
; APPLICANT: Winkler, Irvin
; TITLE OF INVENTION: Oligonucleotide Analogs, Their
; PREPARATION AND USE
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner
; STREET: 1300 I Street, N.W.
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA

```

```

; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/281,203
; FILING DATE: 27-JULY-1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/003,972
; FILING DATE: 19-JAN-1993
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Binaudi, Carol P.
; REGISTRATION NUMBER: 32,220
; REFERENCE/DOCKET NUMBER: 02481.1269-01000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-408-4000
; TELEFAX: 202-408-4400
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-281-203-20

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCAGC 69
DB 19 CCTCGCTATGGCTCCAGC 1

RESULT 489
US-08-714-017-22/c
; Sequence 22, Application US/08714017
; Patent No. 6040176
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemary
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/714,017
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:

```

```
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6040176and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-714-017-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCCAATTC 609
Db 19 TCACCATGGAGCCCAATTC 1

RESULT 490
US-09-094-405-27/c
; Sequence 27, Application US/09094405
; Patent No. 6066720
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Modified oligonucleotides, their preparation
; NUMBER OF SEQUENCES: 30
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/094,405
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/940,196
; FILING DATE:
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; ORIGINAL SOURCE:
; ORGANISM: human
; FEATURE:
; NAME/KEY: exon
; LOCATION: 1..19
; OTHER INFORMATION: /note= "ICAM"
US-09-094-405-27

Query Match 0.6%; Score 19; DB 1; Length 19;
```

```
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCGAGC 69
Db 19 CCTCGCTATGGCTCCGAGC 1

RESULT 491
US-08-863-790-22/c
; Sequence 22, Application US/08863790
; Patent No. 6087130
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Protein
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; ADDRESSEE: Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,790
; FILING DATE:
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6087130and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 31570
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-863-790-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCCCAATTC 609
Db 19 TCACCATGGAGCCCAATTC 1

RESULT 492
```

US-08-475-680-22/c
; Sequence 22, Application US/08475680
; Patent No. 6100383
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/475,680
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6100383and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-475-680-22
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 591 TCACCATGGAGCCCAATTC 609
Db 19 TCACCATGGAGCCCAATTC 1
RESULT 493
US-09-258-408-23/c
; Sequence 23, Application US/09258408
; Patent No. 6121434
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anuschirwan

; APPLICANT: UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/258,408
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/594,452
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-258-408-23
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 51 CCTCGCTATGGCTCCGAGC 69
Db 19 CCTCGCTATGGCTCCGAGC 1
RESULT 494
US-09-196-132-23/c
; Sequence 23, Application US/09196132
; Patent No. 6127346
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Phosphonomonoester nucleic acids,
; TITLE OF INVENTION: process for their preparation, and their use
; NUMBER OF SEQUENCES: 33
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/196,132
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/613,417
; FILING DATE:
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

```
;
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: yes
; FEATURE:
; NAME/KEY: exon
; LOCATION: 1..19
;
US-09-196-132-23

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGTCCCGC 69
DB 19 CCTCGCTATGGTCCCGC 1

RESULT 495
US-09-144-112-22/c
; Sequence 22, Application US/09144112
; Patent No. 6150510
; GENERAL INFORMATION:
; APPLICANT: SEELA, Frank
; APPLICANT: THOMAS, Horst
; TITLE OF INVENTION: MODIFIED OLIGONUCLEOTIDES, THEIR PREPARATION AND THEIR
; TITLE OF INVENTION: USE
; FILE REFERENCE: 026083/0181
; CURRENT APPLICATION NUMBER: US/09/144,112
; CURRENT FILING DATE: 1998-08-31
; PRIOR APPLICATION NUMBER: DE P 44 38 918.3
; PRIOR FILING DATE: 1994-11-04
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Antisense
; OTHER INFORMATION: Oligonucleotide
US-09-144-112-22

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGTCCCGC 69
DB 19 CCTCGCTATGGTCCCGC 1

RESULT 496
US-08-296-749-22/c
; Sequence 22, Application US/08296749
; Patent No. 6153395
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Protein
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; ADDRESSEE: Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25

;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/296,749
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6153395and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 31570
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312)474-6300
; TELEFAX: (312)474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-296-749-22

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGAGCCAAATTC 609
DB 19 TCACCATGAGCCAAATTC 1

RESULT 497
US-09-264-466-6
; Sequence 6, Application US/09264466
; Patent No. 6235889
; GENERAL INFORMATION:
; APPLICANT: BEAUDET M.D., AURTHUR L
; ROTTER M.D., JEROME I
; TARGAN M.D., STEPHAN R
; VORA M.D., DEVENDRA
; YANG M.D., HUIYING
; TITLE OF INVENTION: METHODS OF SCREENING FOR ULCERATIVE
; COLITIS AND CROHN'S DISEASE
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
; STREET: 444 SOUTH FLOWER STREET, SUITE 2000
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/09/264,466
; APPLICATION NUMBER: US/09/264,466
; FILING DATE: 08-Mar-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/196,003
```

;; FILING DATE: 11-FEB-1994
;; ATTORNEY/AGENT INFORMATION:
;; NAME: WHITEFORD ESQ. WENDY A
;; REGISTRATION NUMBER: 36,964
;; REFERENCE/DOCKET NUMBER: P07 32056
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-4442
;; TELEFAX: (213) 489-4210
;; INFORMATION FOR SEQ ID NO: 6:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 19 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; SEQUENCE DESCRIPTION: SEQ ID NO: 6:
US-09-264-466-6

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 769 TCCCTGGACGGGCTGTTC 787
Db 1 TCCCTGGACGGGCTGTTC 19

RESULT 498
US-08-895-981-23/c
; Sequence 23, Application US/08895981
; Patent No. 6326487
; GENERAL INFORMATION:
; APPLICANT: Peyman, Anuschirwan
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Carolus, Carolin
; TITLE OF INVENTION: 3'-Modified Oligonucleotide Derivatives
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoechst Marion Roussel, Inc.
; STREET: 2110 E. Galbraith Road, P.O. Box 156300
; CITY: Cincinnati
; STATE: Ohio
; COUNTRY: USA
; ZIP: 45215-6300
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/895,981
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,305
; FILING DATE: 05-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Payne, T. Helen
; REGISTRATION NUMBER: 36,889
; REFERENCE/DOCKET NUMBER: HOE94/F161K US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 513-948-7183
; TELEFAX: 513-948-7960 or 4681
; TELEX: 214320
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
US-08-895-981-23

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGTCCGAGC 69
Db 19 CCTCGCTATGGTCCGAGC 1

RESULT 499
US-08-337-120A-31/c
; Sequence 31, Application US/08337120A
; Patent No. 6348312
; GENERAL INFORMATION:
; APPLICANT: Peyman, Anuschirwan
; APPLICANT: Uhlmann, Eugen
; APPLICANT: Meg, Matthias
; APPLICANT: Kretschmar, Gerhard
; APPLICANT: Helsing, Matthias
; APPLICANT: Winkler, Irvin
; TITLE OF INVENTION: Stabilized Oligonucleotides And Their
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner, L.L.P.
; STREET: 1300 I Street, N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/337,120A
; FILING DATE: 12-NOV-1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: DE P 43 38 704.7
; FILING DATE: 12-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Binaudi, Carol P.
; REGISTRATION NUMBER: 32,220
; REFERENCE/DOCKET NUMBER: 02481.1409-00000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)408-4000
; TELEFAX: (202)408-4400
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-337-120A-31

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGTCCGAGC 69
Db 19 CCTCGCTATGGTCCGAGC 1

RESULT 500
US-09-643-233-22/c
; Sequence 22, Application US/09643233
; Patent No. 6479651
; GENERAL INFORMATION:

```
; APPLICANT: SEELA, Frank
; APPLICANT: THOMAS, Horst
; TITLE OF INVENTION: MODIFIED OLIGONUCLEOTIDES, THEIR PREPARATION AND THEIR
; TITLE OF INVENTION: USE
; FILE REFERENCE: 026083/0181
; CURRENT APPLICATION NUMBER: US/09/643,233
; CURRENT FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 09/144,112
; PRIOR FILING DATE: 1998-08-31
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Antisense
; OTHER INFORMATION: Oligonucleotide
US-09-643-233-22

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCGAGC 69
Db 19 CCTCGCTATGGCTCCGAGC 1

RESULT 501
US-09-835-370-44/c
; Sequence 44, Application US/09835370
; Patent No. 6777544
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; APPLICANT: WILL, DAVID W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
; TITLE OF INVENTION: PROCESSES FOR PREPARING THEM
; FILE REFERENCE: 02481.1742 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/09/835,370
; CURRENT FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 44
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: nucleotide
; OTHER INFORMATION: base sequence of PNA derivatives that bind to
; OTHER INFORMATION: viral and cellular targets
US-09-835-370-44

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCGAGC 69
Db 19 CCTCGCTATGGCTCCGAGC 1

RESULT 502
US-08-314-369-22/c
; Sequence 22, Application US/08314369
; Patent No. 6818743
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: I-CAM Related Protein
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
```

```
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; ADDRESSEE: Bicknell
; STREET: Two First National Plaza, 20 South Clark
; STREET: Street
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/314,369
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/889,724
; FILING DATE:
; APPLICATION NUMBER: US 07/827,689
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6818743and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 27866/30902
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312)346-5750
; TELEFAX: (312)984-9740
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-314-369-22

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCAATTC 609
Db 19 TCACCATGGAGCAATTC 1

RESULT 503
US-09-435-296-75/c
; Sequence 75, Application US/09435296
; Patent No. 6171860
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Lex M. Cowert
; TITLE OF INVENTION: ANTISENSE MODULATION OF RANK EXPRESSION
; FILE REFERENCE: RTS-0116
; CURRENT APPLICATION NUMBER: US/09/435,296
; CURRENT FILING DATE: 1999-11-05
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-435-296-75

Query Match          0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2830 AAGTGATCTCCACCTCA 2848
|||||
```

Db 20 AAGTGATCTCCCACTCA 2

RESULT 504
US-09-280-805-243/c
; Sequence 243, Application US/09280805
; Patent No. 6184212
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PC
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/280,805
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/048,810
; FILING DATE: March 26, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Licata, Jane Massey
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0346
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-810-1515
; TELEFAX: 609-810-1454
; INFORMATION FOR SEQ ID NO: 243:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-280-805-243

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTCAGTGG 2790
Db 20 CCAGGCTGGAGTCAGTGG 2

RESULT 505
US-09-038-637-155/c
; Sequence 155, Application US/09038637
; Patent No. 6235470
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: DETECTION OF NEOPLASM BY ANALYSIS OF SALIVA
; NUMBER OF SEQUENCES: 195
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 4225 Executive Square, Suite 1400
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037
; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,637
; FILING DATE: 10-MAR-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/579,233
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/152,313
; FILING DATE: 12-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Haile, Lisa A.
; REGISTRATION NUMBER: 38,347
; REFERENCE/DOCKET NUMBER: 07265/146001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/678-5070
; TELEFAX: 619/678-5099
; INFORMATION FOR SEQ ID NO: 155:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
US-09-038-637-155

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2774 AGCGTGGAGTCAGTGGTG 2792
Db 20 AGCGTGGAGTCAGTGGTG 2

RESULT 506
US-08-397-277A-1/c
; Sequence 1, Application US/08397277A
; Patent No. 6235886
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; TITLE OF INVENTION: MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 6235886ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/397,277A
; FILING DATE: 09-MAR-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/943,516
; FILING DATE: 11-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumond, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1198
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100

; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-397-277A-1

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 AGCCTCGCTATGGCTCCCA 67
|||
Db 19 AGCCTCGCTATGGCTCCCA 1

RESULT 507
US-09-689-964-1/c
; Sequence 1, Application US/09689964
; Patent No. 6399757
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. 6399757ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/689,964
FILING DATE: 12-Oct-2000
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/397,277
FILING DATE: 09-MAR-1995
APPLICATION NUMBER: 07/943,516
FILING DATE: 11-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Gaumont, Rebecca R.
REGISTRATION NUMBER: 35,152
REFERENCE/DOCKET NUMBER: ISIS-1198
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 1:

US-09-689-964-1
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 AGCCTCGCTATGGCTCCCA 67

Db 19 AGCCTCGCTATGGCTCCCA 1
|||
|||

RESULT 508
US-09-689-964-1/c
; Sequence 1, Application US/09689964
; Patent No. 6495671
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. 6495671ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/689,964
FILING DATE: 12-Oct-2000
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/397,277
FILING DATE: 09-MAR-1995
APPLICATION NUMBER: 07/943,516
FILING DATE: 11-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Gaumont, Rebecca R.
REGISTRATION NUMBER: 35,152
REFERENCE/DOCKET NUMBER: ISIS-1198
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-09-689-964-1

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 AGCCTCGCTATGGCTCCCA 67
|||
Db 19 AGCCTCGCTATGGCTCCCA 1

RESULT 509
US-10-192-437-1/c
; Sequence 1, Application US/10192437
; Patent No. 6828434
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
and No. 6828434ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/192,437
FILING DATE: 10-Jul-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/397,277A
FILING DATE: 09-MAR-1995
APPLICATION NUMBER: 07/943,516
FILING DATE: 11-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Gaumont, Rebecca R.
REGISTRATION NUMBER: 35,152
REFERENCE/DOCKET NUMBER: ISIS-1198
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-10-192-437-1

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 AGCCTCGCTATGCTCCCA 67
Db 19 AGCCTCGCTATGCTCCCA 1

RESULT 510
PCT-US93-08367A-1/c
Sequence 1, Application PC/TUS9308367A
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Phillip D. Cook
TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
TITLE OF INVENTION: MAKING AND USING THE SAME
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/08367A
FILING DATE:
CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:
NAME: Gaumont, Rebecca R.
REGISTRATION NUMBER: 35,152
REFERENCE/DOCKET NUMBER: ISIS-1171
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US93-08367A-1

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 49 AGCCTCGCTATGCTCCCA 67
Db 19 AGCCTCGCTATGCTCCCA 1

RESULT 511
US-08-594-452-92/c
Sequence 92, Application US/08594452
Patent No. 6013639
GENERAL INFORMATION:
APPLICANT: PEYMAN, Anushirwan
APPLICANT: UHLMANN, Eugen
TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 105
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/594,452
FILING DATE: 31-JAN-1996
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE 195 02 912.7
FILING DATE: 31-JAN-1995
ATTORNEY/AGENT INFORMATION:
NAME: SANDERCOCK, Colin G.
REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 18748/264/HOCE
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202)672-5300
TELEFAX: (202)672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 92:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-594-452-92

Query Match 0.6%; Score 19; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCAGC 69
| | | | | | | | | | | | | | | | | | | | | |
Db 22 CCTCGCTATGGCTCCAGC 4

RESULT 512
US-09-258-408-92/c
; Sequence 92, Application US/09258408
; Patent No. 6121434
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anuschirwan
; APPLICANT: UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/258,408
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/594,452
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136

; INFORMATION FOR SEQ ID NO: 92:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-258-408-92

Query Match 0.6%; Score 19; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 51 CCTCGCTATGGCTCCAGC 69
| | | | | | | | | | | | | | | | | | | | | |
Db 22 CCTCGCTATGGCTCCAGC 4

RESULT 513
US-09-258-408-92/c
; Sequence 43, Application US/08605089
; Patent No. 5719026
; GENERAL INFORMATION:
; APPLICANT: Takafumi FUKUI
; APPLICANT: Kiyonori KATSURAGI
; APPLICANT: Moritooshi KINOSHITA
; APPLICANT: Sadahiro SHIN
; TITLE OF INVENTION: METHOD FOR DETECTING POLYMORPHISM OF
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SUGHRUE, MION, ZINN, MACPEAK & SEAS
; STREET: 2100 Pennsylvania Avenue, N.W.

Query Match 0.6%; Score 19; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCAGC 69
| | | | | | | | | | | | | | | | | | | | | |
Db 22 CCTCGCTATGGCTCCAGC 4

RESULT 512
US-09-258-408-92/c
; Sequence 92, Application US/09258408
; Patent No. 6121434
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anuschirwan
; APPLICANT: UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/258,408
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/594,452
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136

; INFORMATION FOR SEQ ID NO: 92:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-258-408-92

; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy Disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/605,089
; FILING DATE: 06-MAR-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JPA-6-154571
; FILING DATE: 06-JUL-1994
; APPLICATION NUMBER: PCT/JP95/01352
; FILING DATE: 06-JUL-1995
; INFORMATION FOR SEQ ID NO: 43:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 BASES
; TYPE: NUCLEOTIDE
; STRANDEDNESS: SINGLE
; TOPOLOGY: LINEAR
; MOLECULE TYPE: DNA
US-08-605-089-43

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2849 GCGTCTGAGTAGCTGGGAC 2868
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GCGTCTGAGTAGCTGGGAC 1

RESULT 514
US-08-863-639A-32/c
; Sequence 32, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
; APPLICANT: Matson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
; ZIP: 91101

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel WordPerfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Mueth
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

QY 2849 GCGTCTGAGTAGCTGGGAC 2868
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GCGTCTGAGTAGCTGGGAC 1

RESULT 514
US-08-863-639A-32/c
; Sequence 32, Application US/08863639A
; Patent No. 5981185
; GENERAL INFORMATION:
; APPLICANT: Matson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. T.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
; ZIP: 91101

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel WordPerfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Mueth
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

; SEQ ID NO 88
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-488-671-88

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGT 2747
|||
20 GTGTGTGTGTGTGTGTGT 1

RESULT 519
US-09-180-903-8
; Sequence 8, Application US/09180903
; Patent No. 6316190
; GENERAL INFORMATION:
; APPLICANT: Rein, Alan
; Casas-Finet, Jose
; Fisher, Robert
; Fivash, Matthew
; Henderson, Louis E.
; TITLE OF INVENTION: Oligonucleotides Which Specifically Bind
; Retroviral Nucleocapsid Proteins
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/180,903
; FILING DATE: 12-Jul-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/017,128
; FILING DATE: 20-MAY-1996
; APPLICATION NUMBER: WO PCT/US97/08936
; FILING DATE: 19-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Choi, Kathleen L.
; REGISTRATION NUMBER: 43,433
; REFERENCE/DOCKET NUMBER: 015280-279100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-09-180-903-8

Query Match 0.8%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTATGT 2748

Db 1 TGTGTGTGTGTGTGTGTG 20
|||||
|||||

RESULT 520
US-09-662-250A-76
; Sequence 76, Application US/09662250A
; Patent No. 6368856
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHORYLASE KINASE BETA EXPRESSION
; FILE REFERENCE: RTS-0129
; CURRENT APPLICATION NUMBER: US/09/662,250A
; CURRENT FILING DATE: 2000-09-14
; NUMBER OF SEQ ID NOS: 102
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-662-250A-76

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2764 TCTGTACCCAGGCTGGAGT 2783
|||||
1 TCTGTACCCAGGCTGGTGT 20

Db 1 TCTGTACCCAGGCTGGTGT 20

RESULT 521
US-09-780-173A-18/c
; Sequence 18, Application US/09780173A
; Patent No. 6455307
; GENERAL INFORMATION:
; APPLICANT: Robert McKay
; APPLICANT: Susan M. Freier
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CASEIN KINASE 2-ALPHA PRIME EXPRESSION
; FILE REFERENCE: RTS-0165
; CURRENT APPLICATION NUMBER: US/09/780,173A
; CURRENT FILING DATE: 2001-02-08
; NUMBER OF SEQ ID NOS: 95
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-780-173A-18

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 3e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTCAGTGGTG 2792
|||||
20 CAGGCTGGAGTCAGTGGCG 1

Db 20 CAGGCTGGAGTCAGTGGCG 1

RESULT 522
US-09-918-686-93
; Sequence 93, Application US/09918686
; Patent No. 6475739
; GENERAL INFORMATION:
; APPLICANT: Brunkow, Mary
; APPLICANT: Prolli, Sean
; APPLICANT: Paepfer, Bryan
; APPLICANT: Staehling-Hampton, Karen
; TITLE OF INVENTION: METHODS FOR IDENTIFYING

;; TITLE OF INVENTION: GENOMIC DELETIONS
;; FILE REFERENCE: 240083.515
;; CURRENT APPLICATION NUMBER: US/09/918,686
;; CURRENT FILING DATE: 2001-07-30
;; NUMBER OF SEQ ID NOS: 105
;; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 93
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-09-918-686-93

Query Match 0.6%; Score 18.4; DB 1; Length 22;
Best Local Similarity 95.0%; Pred. No. 2.8e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGTG 2792
|||||
Db 1 CAGGCTGGAGTGCAGTGGTG 20

RESULT 523
US-08-070-517-2/c
; Sequence 2, Application US/08070517
; Patent No. 5538869
; GENERAL INFORMATION:
; APPLICANT: Michael J. Siciliano
; APPLICANT: Pu Liu
; TITLE OF INVENTION: In-Situ Hybridization Probes for
; TITLE OF INVENTION: Identification and Banding of
; TITLE OF INVENTION: Specific Human Chromosomes and
; TITLE OF INVENTION: Regions
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy Disk
COMPUTER: IBM PC Compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: ASCII-DOS
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/070,517
FILING DATE: 19930601
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Barbara S. Kitchell
REGISTRATION NUMBER: 33,928
REFERENCE/DOCKET NUMBER: UTSC:290/KIT
TELEPHONE: (512) 320-7200
TELEFAX: (512) 474-7577
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acids
STRANDEDNESS: single
TOPOLOGY: linear

US-08-070-517-2
Query Match 0.6%; Score 18.2; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGTG 2791
|||||
Db 19 CAGGCTGGAGTGCAGTGGTG 1

RESULT 524
US-08-118-441-2/c
; Sequence 2, Application US/08118441
; Patent No. 5578493
; GENERAL INFORMATION:
; APPLICANT: Gilliam, T. Conrad
; APPLICANT: Tanzi, Rudolph E.
; TITLE OF INVENTION: ISOLATION AND USES OF A WILSON'S DISEASE
; TITLE OF INVENTION: GENE
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10112

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/118,441
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 0575/44011
TELEPHONE: (212) 977-9550
TELEFAX: (212) 664-0525
TELEX: 422523 COOP UI
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
US-08-118-441-2

Query Match 0.6%; Score 18.2; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGTG 2791
|||||
Db 19 CAGGCTGGAGTGCAGTGGTG 1

RESULT 525
US-08-422-699A-14/c
; Sequence 14, Application US/08422699A
; Patent No. 5955265
; GENERAL INFORMATION:
; APPLICANT: Brook, J. David
; APPLICANT: Housman, David E.
; APPLICANT: Shaw, Duncan J.
; APPLICANT: Harley, Helen G.
; APPLICANT: Johnson, Keith J.
; TITLE OF INVENTION: DNA SEQUENCE ENCODING THE MYOTONIC
; TITLE OF INVENTION: DYSTROPHY GENE AND USES THEREOF
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
; STREET: Two Militia Drive
; CITY: Lexington
; STATE: Massachusetts

COUNTRY: US
ZIP: 02713
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/422,699A
FILING DATE:

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/422,706
FILING DATE:
PRIOR APPLICATION NUMBER: US 08/023,612
FILING DATE: 26-FEB-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/839,255
FILING DATE: 20-FEB-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/01545
FILING DATE: 19-FEB-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB93/00253
FILING DATE: 05-FEB-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB9202485.0
FILING DATE: 06-FEB-1992
ATTORNEY/AGENT INFORMATION:
NAME: Granahan, Patricia
REGISTRATION NUMBER: 32,227
REFERENCE/DOCKET NUMBER: MIT-5830A2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-861-6240
TELEFAX: 617-861-9540
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-422-699A-14

Query Match 0.6%; Score 18.2; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGT 2791
|||||:|||||:|||||:
Db 19 CAGGCTGGAGTGCARTGGY 1

RESULT 526
US-08-422-706B-14/c
Sequence 14, Application US/08422706B
Patent No. 5977333
GENERAL INFORMATION:
APPLICANT: Brook, J. David
APPLICANT: Housman, David E.
APPLICANT: Shaw, Duncan J.
APPLICANT: Harley, Helen G.
APPLICANT: Johnson, Keith J.
TITLE OF INVENTION: DNA SEQUENCE ENCODING THE MYOTONIC
DYSSTROPHY GENE AND USES THEREOF
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
STREET: Two Militia Drive
CITY: Lexington
STATE: Massachusetts
COUNTRY: US

ZIP: 02713
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/422,706B
FILING DATE: 14-APR-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/284,543
FILING DATE: 08-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/023,612
FILING DATE: 26-FEB-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/839,255
FILING DATE: 20-FEB-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/01545
FILING DATE: 19-FEB-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/GB93/00253
FILING DATE: 05-FEB-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB9202485.0
FILING DATE: 06-FEB-1992
ATTORNEY/AGENT INFORMATION:
NAME: Granahan, Patricia
REGISTRATION NUMBER: 32,227
REFERENCE/DOCKET NUMBER: MIT-5830A2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-861-6240
TELEFAX: 617-861-9540
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-422-706B-14

Query Match 0.6%; Score 18.2; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGT 2791
|||||:|||||:|||||:
Db 19 CAGGCTGGAGTGCARTGGY 1

RESULT 527
US-08-338-579A-2/c
Sequence 2, Application US/08338579A
Patent No. 6068975
GENERAL INFORMATION:
APPLICANT: Gilliam, T. Conrad
APPLICANT: Tanzi, Rudolph E.
TITLE OF INVENTION: ISOLATION AND USES OF A WILSON'S
DISEASE GENE
NUMBER OF SEQUENCES: 107
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/338,579A
FILING DATE: June 17, 1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 0575/44011-A-PCT-US
TELEPHONE: (212) 278-0400
TELEFAX: (212) 391-0525
TELEX:
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
US-08-338-579A-2

Query Match 0.6%; Score 18.2; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGT 2791
DB 19 CAGGCTGGAGTGCARTGGY 1

RESULT 528
PCT-US94-09851-2/c
Sequence 2, Application PC/TUS9409851
GENERAL INFORMATION:
APPLICANT: Gilliam, T. Conrad
TITLE OF INVENTION: ISOLATION AND USES OF A WILSON'S
TITLE OF INVENTION: DISEASE GENE
NUMBER OF SEQUENCES: 92
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cooper & Dunham
STREET: 30 Rockefeller Plaza
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10112
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/09851
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 0575/44011-PCT
TELEPHONE: (212) 977-9550
TELEFAX: (212) 664-0525
TELEX: 422523 COOP UI
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)

HYPOTHETICAL: NO
PCT-US94-09851-2

Query Match 0.6%; Score 18.2; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 3.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGT 2791
DB 19 CAGGCTGGAGTGCARTGGY 1

RESULT 529
US-08-297-703-6/c
Sequence 6, Application US/08297703
Patent No. 5506212
GENERAL INFORMATION:
APPLICANT: Hake,, Glenn
TITLE OF INVENTION: Stereoisomerically Pure
TITLE OF INVENTION: Phosphorothioate
TITLE OF INVENTION: Oligonucleotides
NUMBER OF SEQUENCES: 10
CORRESPONDENCE ADDRESS:
ADDRESSEE: John W. Caldwell
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/297,703
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/777,007
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Caldwell, John W.
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-0015
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-368-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
US-08-297-703-6

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 530
US-08-063-167A-1/c
Sequence 1, Application US/08063167A
Patent No. 5514788
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation


```
;
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/063,167A
; FILING DATE: 19930517
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
; US-08-063-167A-1
;
; Query Match 0.6%; Score 18; DB 1; Length 18;
; Best Local Similarity 100.0%; Pred. No. 3.7e+02;
; Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 50 GCCTCGCTATGGCTCCCA 67
; DB 18 GCCTCGCTATGGCTCCCA 1
;
; RESULT 531
; US-08-063-167A-4/c
; Sequence 4, Application US/08063167A
; Patent No. 5514788
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/063,167A
; FILING DATE: 19930517
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
```

```
;
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/063,167A
; FILING DATE: 19930517
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
; US-08-063-167A-4
;
; Query Match 0.6%; Score 18; DB 1; Length 18;
; Best Local Similarity 100.0%; Pred. No. 3.7e+02;
; Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 2836 TCCTCCACCTCAGCCTC 2853
; DB 18 TCCTCCACCTCAGCCTC 1
;
; RESULT 532
; US-08-063-167A-5/c
; Sequence 5, Application US/08063167A
; Patent No. 5514788
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/063,167A
; FILING DATE: 19930517
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
```

APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0002
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-063-167A-5

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCCATCG 1381
DB 18 CTTTCCCACTGCCCATCG 1

RESULT 533
US-08-063-167A-81
Sequence 81, Application US/08063167A
Patent No. 5514788
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
TITLE OF INVENTION: of Cell Adhesion
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/063,167A
FILING DATE: 19930517
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257

REFERENCE/DOCKET NUMBER: ISPH-0002
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 81:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-063-167A-81

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 1 GCCTCGCTATGGCTCCCA 18

RESULT 534
US-08-058-023-6/c
Sequence 6, Application US/08058023
Patent No. 5521302
GENERAL INFORMATION:
APPLICANT: Cook, Phillip D.
TITLE OF INVENTION: OLIGONUCLEOTIDES HAVING CHIRAL
TITLE OF INVENTION: PHOSPHORUS LINKAGES
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
ADDRESSEE: and No. 5521302ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/058,023
FILING DATE: 05-MAY-1993
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Joseph Lucci
REGISTRATION NUMBER: 33,307
REFERENCE/DOCKET NUMBER: ISIS-1053
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-058-023-6

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1

```
RESULT 535
US-08-314-615-21
; Sequence 21, Application US/08314615
; Patent No. 5525487
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: I-CAM Related Protein
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; STREET: Two First National Plaza, 20 South Clark
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/314,615
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/827,689
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Borun, Michael F.
; REGISTRATION NUMBER: 25,447
; REFERENCE/DOCKET NUMBER: 27866/30704
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312)346-5750
; TELEFAX: (312)984-9740
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-314-615-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCCTTACCCTAC 457
Db 1 GCAAGAACCCTTACCCTAC 18

RESULT 536
US-08-314-362-21
; Sequence 21, Application US/08314362
; Patent No. 5532127
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: I-CAM Related Protein
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; STREET: Two First National Plaza, 20 South Clark
; CITY: Chicago
```

```
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60603
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/314,362
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/894,061
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/827,689
; FILING DATE: 27-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US
; FILING DATE: 26-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5532127and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 27866/30918
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312)346-5750
; TELEFAX: (312)984-9740
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-314-362-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCCTTACCCTAC 457
Db 1 GCAAGAACCCTTACCCTAC 18

RESULT 537
US-08-136-118-15/c
; Sequence 15, Application US/08136118
; Patent No. 5580969
; GENERAL INFORMATION:
; APPLICANT: HOKE, Glenn D
; APPLICANT: BRADLEY, Matthews O
; APPLICANT: WILLIAMS, Taffy J
; APPLICANT: LEE, Che-Hung
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDES DIRECTED
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Naval Medical Res. & Dev. Cmd.
; STREET: 8901 Wisconsin Ave.
; CITY: Bethesda
; STATE: Maryland
; COUNTRY: USA
; ZIP: 20889-5606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/136,118
```

FILING DATE: 514
 PRIOR APPLICATION DATA: US 07/918,259
 APPLICATION NUMBER: 24-JUL-1992
 FILING DATE: 24-JUL-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Spevack, A. David
 REGISTRATION NUMBER: 24,743
 REFERENCE/DOCKET NUMBER: N.C. 75,776
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (202) 295-6759
 TELEFAX: (202) 295-1022
 INFORMATION FOR SEQ ID NO: 15:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 18 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 HYPOTHETICAL: NO
 ANTI-SENSE: YES
 US-08-136-118-15

```

Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2038 TTACAGAAAGTGGCCC 2055
Db 18 TTACAGAAAGTGGCCC 1

```

```

RESULT 538
US-08-007-997A-1/c
; Sequence 1, Application US/08007997A
; Patent No. 5591623
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 5591623ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/007,997A
; FILING DATE: 19930121
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA: PCT/US91/05209
; APPLICATION NUMBER: July 23, 1991
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISIS-0709
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439

```

```

; INFORMATION FOR SEQ ID NO: 1:
;
; SEQUENCE CHARACTERISTICS:
;
; LENGTH: 18
;
; TYPE: Nucleic Acid
;
; STRANDEDNESS: Single
;
; TOPOLOGY: Linear
;
; ANTI-SENSE: Yes
;
; US-08-007-997A-1

```

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels

Qy 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

```

RESULT 539
US-08-007-997A-4/c
; Sequence 4, Application US/08007997A
; Patent No. 5591623
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz
; ADDRESSEE: Mackiewicz & No. 5591623-ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
;

```

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels

QY 2836 TCCTCCACCTCAGCTC 2853
 Db 18 TCCTCCACCTCAGCTC 1

RESULT 540

US-08-007-997A-5/G
 ; Sequence 5, Application US/08007997A
 ; Patent No. 5591623
 ; GENERAL INFORMATION:
 ; APPLICANT: Bennett and Mirabelli
 ; TITLE OF INVENTION: Oligonucleotide Modulation
 ; TITLE OF INVENTION: of Cell Adhesion
 ; NUMBER OF SEQUENCES: 82
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Woodcock Washburn Kurtz
 ; ADDRESSEE: Mackiewicz & No. 5591623ris
 ; STREET: One Liberty Place - 46th Floor
 ; CITY: Philadelphia
 ; STATE: PA
 ; COUNTRY: USA
 ; ZIP: 19103
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
 ; COMPUTER: IBM PS/2
 ; OPERATING SYSTEM: PC-DOS
 ; SOFTWARE: WORDPERFECT 5.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/007,997A
 ; FILING DATE: 19930121
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 939,855
 ; FILING DATE: September 2, 1992
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: PCT/US91/05209
 ; FILING DATE: July 23, 1991
 ; APPLICATION NUMBER: 567,286
 ; FILING DATE: August 14, 1990
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Jane Massey Licata
 ; REGISTRATION NUMBER: 32,257
 ; REFERENCE/DOCKET NUMBER: ISIS-0709
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (215) 568-3100
 ; TELEFAX: (215) 568-3439
 ; INFORMATION FOR SEQ ID NO: 5:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 18
 ; TYPE: Nucleic Acid
 ; STRANDEDNESS: Single
 ; TOPOLOGY: Linear
 ; ANTI-SENSE: Yes
 ; US-08-007-997A-5

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 3.7e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCATCG 1381
 Db 18 CTTTCCCACTGCCATCG 1

RESULT 541

US-08-007-997A-81
 ; Sequence 81, Application US/08007997A
 ; Patent No. 5591623
 ; GENERAL INFORMATION:
 ; APPLICANT: Bennett and Mirabelli
 ; TITLE OF INVENTION: Oligonucleotide Modulation
 ; TITLE OF INVENTION: of Cell Adhesion

; NUMBER OF SEQUENCES: 82
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Woodcock Washburn Kurtz
 ; ADDRESSEE: Mackiewicz & No. 5591623ris
 ; STREET: One Liberty Place - 46th Floor
 ; CITY: Philadelphia
 ; STATE: PA
 ; COUNTRY: USA
 ; ZIP: 19103
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
 ; COMPUTER: IBM PS/2
 ; OPERATING SYSTEM: PC-DOS
 ; SOFTWARE: WORDPERFECT 5.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/007,997A
 ; FILING DATE: 19930121
 ; CLASSIFICATION: 514
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 939,855
 ; FILING DATE: September 2, 1992
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: PCT/US91/05209
 ; FILING DATE: July 23, 1991
 ; APPLICATION NUMBER: 567,286
 ; FILING DATE: August 14, 1990
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Jane Massey Licata
 ; REGISTRATION NUMBER: 32,257
 ; REFERENCE/DOCKET NUMBER: ISIS-0709
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (215) 568-3100
 ; TELEFAX: (215) 568-3439
 ; INFORMATION FOR SEQ ID NO: 81:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 18
 ; TYPE: Nucleic Acid
 ; STRANDEDNESS: Single
 ; TOPOLOGY: Linear
 ; ANTI-SENSE: Yes
 ; US-08-007-997A-81

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 3.7e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 Db 1 GCCTCGCTATGGCTCCCA 18

RESULT 542
 US-08-433-010-21
 ; Sequence 21, Application US/08433010
 ; Patent No. 5663293
 ; GENERAL INFORMATION:
 ; APPLICANT: Gallatin, W. Michael
 ; APPLICANT: Vazeux, Rosemary
 ; TITLE OF INVENTION: ICAM-Related Protein
 ; NUMBER OF SEQUENCES: 34
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
 ; ADDRESSEE: Bicknell
 ; STREET: Two First National Plaza, 20 South Clark
 ; STREET: Street
 ; CITY: Chicago
 ; STATE: Illinois
 ; COUNTRY: USA
 ; ZIP: 60603
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/433,010
FILING DATE:
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/009,266
FILING DATE:
FILING DATE: 27-JAN-1992
APPLICATION NUMBER: US 07/827,689
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/889,724
FILING DATE: 26-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/894,061
FILING DATE: 05-JUN-1992
ATTORNEY/AGENT INFORMATION:
NAME: No. 5663293and, Greta E.
REGISTRATION NUMBER: 35,302
REFERENCE/DOCKET NUMBER: 31218
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312)346-5750
TELEFAX: (312)984-9740
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-433-010-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCTAC 457
|||||
DB 1 GCAAGAACCTTACCCTAC 18

RESULT 543
US-08-196-003-5/c
Sequence 5, Application US/08196003
Patent No. 5681699
GENERAL INFORMATION:
APPLICANT: BEAUDET M.D., ARTHUR L
APPLICANT: ROTTER M.D., JEROME I
APPLICANT: TARGAN M.D., STEPHAN R
APPLICANT: VORA M.D., DEVENDRA
APPLICANT: YANG M.D., HUIYING
TITLE OF INVENTION: METHODS OF SCREENING FOR ULCERATIVE
DISEASE
TITLE OF INVENTION: COLITIS AND CROHN'S DISEASE
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
STREET: 444 SOUTH FLOWER STREET, SUITE 2000
CITY: LOS ANGELES
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/196,003
FILING DATE: 11-FEB-1994
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:

NAME: WHITEFORD ESQ, WENDY A
REGISTRATION NUMBER: 36,964
REFERENCE/DOCKET NUMBER: P07 32056
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-4442
TELEFAX: (213) 489-4210
INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-196-003-5

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 844 GTCACCTATGGCAACGAC 861
|||||
DB 18 GTCACCTATGGCAACGAC 1

RESULT 544
US-08-475-467-22/c
Sequence 22, Application US/08475467
Patent No. 5760202
GENERAL INFORMATION:
APPLICANT: Cook, Philip Dan
APPLICANT: Sprankle, Kelly G.
APPLICANT: Ross, Bruce S.
APPLICANT: Springer, Robert, H.
TITLE OF INVENTION: Improved process for the
synthesis of 2'-O-substituted
pyrimidines
TITLE OF INVENTION: 26
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
ADDRESSEE: and No. 5760202ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/475,467
FILING DATE: Herewith
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-1965
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-475-467-22

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 3.7e+02; Indels 0; Gaps 0; Mismatches 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 |||||
 Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 545

US-08-475-467-23/c
 ; Sequence 23, Application US/08475467
 ; Patent No. 5760202
 ; GENERAL INFORMATION:
 ; APPLICANT: Cook, Philip Dan
 ; APPLICANT: Sprankle, Kelly G.
 ; APPLICANT: Ross, Bruce S.
 ; APPLICANT: Springer, Robert, H.
 ; TITLE OF INVENTION: Improved process for the
 ; TITLE OF INVENTION: synthesis of 2'-O-substituted
 ; TITLE OF INVENTION: pyrimidines
 ; NUMBER OF SEQUENCES: 26
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
 ; ADDRESSEE: and No. 5760202ris
 ; STREET: One Liberty Place - 46th Floor
 ; CITY: Philadelphia
 ; STATE: PA
 ; COUNTRY: U.S.A.
 ; ZIP: 19103
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5 inch disk, 720 Kb
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: WordPerfect 5.1
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/475,467
 ; FILING DATE: herewith
 ; CLASSIFICATION: 536
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER:
 ; FILING DATE:
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: John W. Caldwell
 ; REGISTRATION NUMBER: 28,937
 ; REFERENCE/DOCKET NUMBER: ISIS-1965
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 215-568-3100
 ; TELEFAX: 215-568-3439
 ; INFORMATION FOR SEQ ID NO: 23:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 18 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-475-467-23

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 3.7e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 |||||
 Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 546

US-08-475-467-24/c
 ; Sequence 24, Application US/08475467
 ; Patent No. 5760202
 ; GENERAL INFORMATION:
 ; APPLICANT: Cook, Philip Dan
 ; APPLICANT: Sprankle, Kelly G.
 ; APPLICANT: Ross, Bruce S.

; APPLICANT: Springer, Robert, H.
 ; TITLE OF INVENTION: Improved process for the
 ; TITLE OF INVENTION: synthesis of 2'-O-substituted
 ; TITLE OF INVENTION: pyrimidines
 ; NUMBER OF SEQUENCES: 26
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
 ; ADDRESSEE: and No. 5760202ris
 ; STREET: One Liberty Place - 46th Floor
 ; CITY: Philadelphia
 ; STATE: PA
 ; COUNTRY: U.S.A.
 ; ZIP: 19103
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5 inch disk, 720 Kb
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: WordPerfect 5.1
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/475,467
 ; FILING DATE: herewith
 ; CLASSIFICATION: 536
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER:
 ; FILING DATE:
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: John W. Caldwell
 ; REGISTRATION NUMBER: 28,937
 ; REFERENCE/DOCKET NUMBER: ISIS-1965
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 215-568-3100
 ; TELEFAX: 215-568-3439
 ; INFORMATION FOR SEQ ID NO: 24:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 18 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-475-467-24

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 3.7e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 |||||
 Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 547

US-08-475-467-25/c
 ; Sequence 25, Application US/08475467
 ; Patent No. 5760202
 ; GENERAL INFORMATION:
 ; APPLICANT: Cook, Philip Dan
 ; APPLICANT: Sprankle, Kelly G.
 ; APPLICANT: Ross, Bruce S.
 ; APPLICANT: Springer, Robert, H.
 ; TITLE OF INVENTION: Improved process for the
 ; TITLE OF INVENTION: synthesis of 2'-O-substituted
 ; TITLE OF INVENTION: pyrimidines
 ; NUMBER OF SEQUENCES: 26
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
 ; ADDRESSEE: and No. 5760202ris
 ; STREET: One Liberty Place - 46th Floor
 ; CITY: Philadelphia
 ; STATE: PA
 ; COUNTRY: U.S.A.
 ; ZIP: 19103
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5 inch disk, 720 Kb
 ; COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/475,467
FILING DATE: herewith
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-1965
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-475-467-25

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 548
US-08-475-467-26/c
Sequence 26, Application US/08475467
Patent No. 5760202
GENERAL INFORMATION:
APPLICANT: Cook, Philip Dan
APPLICANT: Sprankle, Kelly G.
APPLICANT: Ross, Bruce S.
APPLICANT: Springer, Robert, H.
TITLE OF INVENTION: Improved process for the
TITLE OF INVENTION: synthesis of 2'-O-substituted
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
ADDRESSEE: and No. 5760202ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 720 Kb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/475,467
FILING DATE: herewith
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: John W. Caldwell
REGISTRATION NUMBER: 28,937
REFERENCE/DOCKET NUMBER: ISIS-1965
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-475-467-26

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 549
US-08-482-882-21
Sequence 21, Application US/08482882
Patent No. 5773218
GENERAL INFORMATION:
APPLICANT: Gallatin, W. Michael
APPLICANT: Vazeux, Rosemay
TITLE OF INVENTION: ICAM-Related Materials and Methods
NUMBER OF SEQUENCES: 116
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 S. Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,882
FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/286,754
FILING DATE:
APPLICATION NUMBER: US 08/102,852
FILING DATE: 05-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/009,266
FILING DATE: 22-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/894,061
FILING DATE: 05-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/889,724
FILING DATE: 26-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,689
FILING DATE: 27-JAN-1992
ATTORNEY/AGENT INFORMATION:
NAME: No. 5773218and, Greta E.
REGISTRATION NUMBER: 35,302
REFERENCE/DOCKET NUMBER: 32178
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear


```

; MOLECULE TYPE: DNA
US-08-482-882-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCCTAC 457
Db 1 GCAAGAACCTTACCCCTAC 18

RESULT 550
US-08-653-653A-2/c
; Sequence 2, Application US/08653653A
; Patent No. 5789573
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker, C. Frank Bennett and Kevin P.
; APPLICANT: Anderson
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
; TITLE OF INVENTION: ANTISENSE INHIBITION OF PROTEIN
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jane Massey Licata, Esq.
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM 486
; OPERATING SYSTEM: WINDOWS FOR WORKGROUPS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/653,653A
; FILING DATE: May 24, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/927,506
; FILING DATE: No. 5789573ember 19, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/568,366
; FILING DATE: August 16, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0146
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

; ANTI-SENSE: yes
US-08-653-653A-2

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCTCCTCTGCTACTCAGA 37
Db 18 GCTCCTCTGCTACTCAGA 1

RESULT 551
US-08-483-389-21
; Sequence 21, Application US/08483389
; Patent No. 5811517
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-RELATED PROTEIN
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive/6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,389
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Suh, Young J.
; REGISTRATION NUMBER: P-41,337
; REFERENCE/DOCKET NUMBER: 27866/32760
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: (312) 474-6600
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-483-389-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```


;
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5837822and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32744
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-487-113D-21

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 3.7e+02; Indels 0; Gaps 0; Mismatches 0; Conservative 0;

QY 440 GCAAGAACCTTACCTAC 457
Db 1 GCAAGAACCTTACCTAC 18
|||||

RESULT 555

US-08-440-740A-1/c
; Sequence 1, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; FILING DATE: September 2, 1992

;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-440-740A-1

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 3.7e+02; Indels 0; Gaps 0; Mismatches 0; Conservative 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1
|||||

RESULT 556

US-08-440-740A-4/c
; Sequence 4, Application US/08440740A
; Patent No. 5843738
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/440,740A
; FILING DATE: May 12, 1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:

```
/ TELEPHONE: (609) 779-2400
/ TELEFAX: (609) 779-8488
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18
/ TYPE: Nucleic Acid
/ STRANDEDNESS: Single
/ TOPOLOGY: Linear
/ ANTI-SENSE: Yes
US-08-440-740A-4

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCCACTGAGCCTC 2853
Db 18 TCCTCCCACTGAGCCTC 1

RESULT 557
US-08-440-740A-5/c
/ Sequence 5, Application US/08440740A
/ Patent No. 5843738
/ GENERAL INFORMATION:
/ APPLICANT: Bennett and Mirabelli
/ TITLE OF INVENTION: Oligonucleotide Modulation
/ TITLE OF INVENTION: of Cell Adhesion
/ NUMBER OF SEQUENCES: 85
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Law Offices of Jane Massey Licata
/ STREET: 66 East Main Street
/ CITY: Marlton
/ STATE: NJ
/ COUNTRY: USA
/ ZIP: 08053
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
/ COMPUTER: IBM PS/2
/ OPERATING SYSTEM: PC-DOS
/ SOFTWARE: WORDPERFECT 5.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/440,740A
/ FILING DATE: May 12, 1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 063,167
/ FILING DATE: May 17, 1993
/ OPERATING SYSTEM: PC-DOS
/ SOFTWARE: WORDPERFECT 5.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: 969,151
/ FILING DATE: February 10, 1993
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 007,997
/ FILING DATE: January 20, 1993
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 939,855
/ FILING DATE: September 2, 1992
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 567,286
/ FILING DATE: August 14, 1990
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Jane Massey Licata
/ REGISTRATION NUMBER: 32,257
/ REFERENCE/DOCKET NUMBER: ISPH-0133
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (609) 779-2400
/ TELEFAX: (609) 779-8488
/ INFORMATION FOR SEQ ID NO: 5:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18
/ TYPE: Nucleic Acid
/ STRANDEDNESS: Single
/ TOPOLOGY: Linear
/ ANTI-SENSE: Yes
US-08-440-740A-81

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 CTTTCCCACTGCCATCG 1

RESULT 558
US-08-440-740A-81
/ Sequence 81, Application US/08440740A
/ Patent No. 5843738
/ GENERAL INFORMATION:
/ APPLICANT: Bennett and Mirabelli
/ TITLE OF INVENTION: Oligonucleotide Modulation
/ TITLE OF INVENTION: of Cell Adhesion
/ NUMBER OF SEQUENCES: 85
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Law Offices of Jane Massey Licata
/ STREET: 66 East Main Street
/ CITY: Marlton
/ STATE: NJ
/ COUNTRY: USA
/ ZIP: 08053
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
/ COMPUTER: IBM PS/2
/ OPERATING SYSTEM: PC-DOS
/ SOFTWARE: WORDPERFECT 5.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/440,740A
/ FILING DATE: May 12, 1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 063,167
/ FILING DATE: May 17, 1993
/ OPERATING SYSTEM: PC-DOS
/ SOFTWARE: WORDPERFECT 5.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: 969,151
/ FILING DATE: February 10, 1993
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 007,997
/ FILING DATE: January 20, 1993
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 939,855
/ FILING DATE: September 2, 1992
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 567,286
/ FILING DATE: August 14, 1990
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Jane Massey Licata
/ REGISTRATION NUMBER: 32,257
/ REFERENCE/DOCKET NUMBER: ISPH-0133
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (609) 779-2400
/ TELEFAX: (609) 779-8488
/ INFORMATION FOR SEQ ID NO: 81:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18
/ TYPE: Nucleic Acid
/ STRANDEDNESS: Single
/ TOPOLOGY: Linear
/ ANTI-SENSE: Yes
US-08-440-740A-81

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Db      1  GCCTCGCTATGGCTCCCA 18
|||||
RESULT 559
US-08-890-084-22/c
; Sequence 22, Application US/088900084
; Patent No. 5861493
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Sprankle, Kelly G.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Springer, Robert, H.
; TITLE OF INVENTION: Improved process for the
; TITLE OF INVENTION: synthesis of 2'-O-substituted
; TITLE OF INVENTION: pyrimidines
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5861493ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,084
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/475,467
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-1965
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-890-084-23
;
; Query Match      0.6%; Score 18; DB 1; Length 18;
; Best Local Similarity 100.0%; Pred. No. 3.7e+02;
; Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY      50  GCCTCGCTATGGCTCCCA 67
|||||
Db      18  GCCTCGCTATGGCTCCCA 1
|||||
RESULT 561
US-08-890-084-24/c
; Sequence 24, Application US/088900084
; Patent No. 5861493
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Sprankle, Kelly G.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Springer, Robert, H.
; TITLE OF INVENTION: Improved process for the
; TITLE OF INVENTION: synthesis of 2'-O-substituted
; TITLE OF INVENTION: pyrimidines
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5861493ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,084
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/475,467
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-1965
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-890-084-22
;
; Query Match      0.6%; Score 18; DB 1; Length 18;
; Best Local Similarity 100.0%; Pred. No. 3.7e+02;
; Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
QY      50  GCCTCGCTATGGCTCCCA 67
|||||
Db      18  GCCTCGCTATGGCTCCCA 1
|||||
RESULT 560
US-08-890-084-23/c
; Sequence 23, Application US/088900084
; Patent No. 5861493
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Sprankle, Kelly G.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Springer, Robert, H.
; TITLE OF INVENTION: Improved process for the
; TITLE OF INVENTION: synthesis of 2'-O-substituted
; TITLE OF INVENTION: pyrimidines
```

```
;
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/475,467
;
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-1965
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-890-084-24
;
; Query Match 0.6%; Score 18; DB 1; Length 18;
; Best Local Similarity 100.0%; Pred. No. 3.7e+02;
; Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 50 GCCTCGCTATGGCTCCCA 67
; Db 18 GCCTCGCTATGGCTCCCA 1
;
; RESULT 563
; US-08-890-084-26/c
; Sequence 26, Application US/08890084
; Patent No. 5861493
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Sprankle, Kelly G.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Springer, Robert, H.
; TITLE OF INVENTION: Improved process for the
; TITLE OF INVENTION: synthesis of 2'-O-substituted
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5861493ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/890,084
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/475,467
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: John W. Caldwell
; REGISTRATION NUMBER: 28,937
; REFERENCE/DOCKET NUMBER: ISIS-1965
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
; US-08-890-084-26
;
; Query Match 0.6%; Score 18; DB 1; Length 18;
; Best Local Similarity 100.0%; Pred. No. 3.7e+02;
; Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; QY 50 GCCTCGCTATGGCTCCCA 67
; Db 18 GCCTCGCTATGGCTCCCA 1
;
; RESULT 564
; US-08-473-503-21
; Sequence 21, Application US/08473503
```

```
; Patent No. 5869262
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/473,503
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 5869262and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-473-503-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCTAC 457
Db 1 GCAAGAACCTTACCCTAC 18

RESULT 565
US-08-689-870-11/c
; Sequence 11, Application US/08689870
; Patent No. 5874233
; GENERAL INFORMATION:
; APPLICANT: Targan, Stephan R.
; APPLICANT: Vasiliauskas, Eric A.
; APPLICANT: Plevy, Scott E.
```

```
; APPLICANT: Yang, Huiying
; APPLICANT: Rotter, Jerome I.
; TITLE OF INVENTION: Methods of Diagnosing a Clinical Subtype
; of Crohn's Disease with Features of Ulcerative Colitis
; NUMBER OF SEQUENCES: 12
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Campbell & Flores LLP
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: United States
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/689,870
; FILING DATE: 15-AUG-1996
; CLASSIFICATION: 436
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-CE 2224
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-689-870-11

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 844 GTCACCTATGCGAACGAC 861
Db 18 GTCACCTATGCGAACGAC 1

RESULT 566
US-08-483-932-21
; Sequence 21, Application US/08483932
; Patent No. 5880268
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/483,932
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE: 05-AUG-1994
```

APPLICATION NUMBER: US 08/102,852
FILING DATE: 05-AUG-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/009,266
FILING DATE: 22-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/894,061
FILING DATE: 05-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/889,724
FILING DATE: 26-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,689
FILING DATE: 27-JAN-1992
ATTORNEY/AGENT INFORMATION:
NAME: No. 5880268and, Greta E.
REGISTRATION NUMBER: 35,302
REFERENCE/DOCKET NUMBER: 32178
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-483-932-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCTTAC 457
|||||
Db 1 GCAAGAACCTTACCTTAC 18

RESULT 567
US-08-344-155C-1/c
Sequence 1, Application US/08344155C
Patent No. 5883082
GENERAL INFORMATION:
APPLICANT: Bennett and Stepkowski
TITLE OF INVENTION: Compositions and Methods for Preventing
TITLE OF INVENTION: and Treating Allograft Rejection
NUMBER OF SEQUENCES: 99
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/344,155C
FILING DATE: No. 5883082ember 23, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/063,167

FILING DATE: 5/17/93
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/007,997
FILING DATE: 1/21/93
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/939,855
FILING DATE: 9/2/92
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/567,286
FILING DATE: 8/14/90
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0098
TELECOMMUNICATION INFORMATION:
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-344-155C-1

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGCTCCCA 67
|||||
Db 18 GCCTCGCTATGCTCCCA 1

RESULT 568
US-08-344-155C-4/c
Sequence 4, Application US/08344155C
Patent No. 5883082
GENERAL INFORMATION:
APPLICANT: Bennett and Stepkowski
TITLE OF INVENTION: Compositions and Methods for Preventing
TITLE OF INVENTION: and Treating Allograft Rejection
NUMBER OF SEQUENCES: 99
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodland Falls Corporate Park
STREET: 210 Lake Drive East, Suite 201
CITY: Cherry Hill
STATE: NJ
COUNTRY: USA
ZIP: 08002
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/344,155C
FILING DATE: No. 5883082ember 23, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/05209
FILING DATE: July 23, 1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/063,167
FILING DATE: 5/17/93
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/007,997
FILING DATE: 1/21/93
PRIOR APPLICATION DATA:


```
; APPLICATION NUMBER: 07/939,855
; FILING DATE: 9/2/92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/567,286
; FILING DATE: 8/14/90
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0098
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-344-155C-4

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2836 TCCTCCCACTCAGCCTC 2853
Db 18 TCCTCCCACTCAGCCTC 1
```

```
RESULT 569
US-08-344-155C-5/c
; Sequence 5, Application US/08344155C
; Patent No. 5883082
; GENERAL INFORMATION:
; APPLICANT: Bennett and Stepkowski
; TITLE OF INVENTION: Compositions and Methods for Preventing
; TITLE OF INVENTION: and Treating Allograft Rejection
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,155C
; FILING DATE: No. 5883082ember 23, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/063,167
; FILING DATE: 5/17/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/007,997
; FILING DATE: 1/21/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/939,855
; FILING DATE: 9/2/92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/567,286
; FILING DATE: 8/14/90
```

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0098
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-344-155C-5

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCCATCG 1381
Db 18 CTTTCCCACTGCCCATCG 1

RESULT 570
US-08-344-155C-81
; Sequence 81, Application US/08344155C
; Patent No. 5883082
; GENERAL INFORMATION:
; APPLICANT: Bennett and Stepkowski
; TITLE OF INVENTION: Compositions and Methods for Preventing
; TITLE OF INVENTION: and Treating Allograft Rejection
; NUMBER OF SEQUENCES: 99
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/344,155C
; FILING DATE: No. 5883082ember 23, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/063,167
; FILING DATE: 5/17/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/007,997
; FILING DATE: 1/21/93
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/939,855
; FILING DATE: 9/2/92
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/567,286
; FILING DATE: 8/14/90
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0098
; TELECOMMUNICATION INFORMATION:
```

TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 81:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-344-155C-81

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 1 GCCTCGCTATGGCTCCCA 18

RESULT 571
US-08-689-873-11/c
Sequence 11, Application US/08699873
Patent No. 5916748
GENERAL INFORMATION:
APPLICANT: Targan, Stephan R.
APPLICANT: Vasiliuskas, Eric A.
APPLICANT: Plevy, Scott E.
APPLICANT: Yang, Huiying
APPLICANT: Rotter, Jerome I.
TITLE OF INVENTION: METHODS OF DIAGNOSING A CLINICAL SUBTYPE
OF CROHN'S DISEASE WITH FEATURES OF ULCERATIVE COLITIS
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pretty, Schroeder & Poplawski
STREET: 444 S. Flower Street, Suite 2000
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/689,873
FILING DATE: 15-AUG-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/630,672
FILING DATE: 12-APR-1996
ATTORNEY/AGENT INFORMATION:
NAME: Fujita, Sharon M.
REGISTRATION NUMBER: 38,459
REFERENCE/DOCKET NUMBER: P07 37278
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 622-7700
TELEFAX: (213) 489-4210

INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
US-08-689-873-11

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 844 GTCACCTATGGCAACGAC 861
DB 18 GTCACCTATGGCAACGAC 1

RESULT 572
US-08-403-888A-120/c
Sequence 120, Application US/08403888A
Patent No. 5952490
GENERAL INFORMATION:
APPLICANT: Hanecak et al.
TITLE OF INVENTION: Oligonucleotides Having A Conserved G4 Core
NUMBER OF SEQUENCES: 146
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5952490ris LLP
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch disk, 1.44 Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 6.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/403,888A
FILING DATE: 12-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/954,185
FILING DATE: 29-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Paul K. Legaard
REGISTRATION NUMBER: 38,534
REFERENCE/DOCKET NUMBER: ISIS-1229
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 120:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-403-888A-120

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCACCTCAGCCTC 2853
DB 18 TCCTCCACCTCAGCCTC 1

RESULT 573
US-08-720-420A-21
Sequence 21, Application US/08720420A
Patent No. 5989843
GENERAL INFORMATION:
APPLICANT: Gallatin, W. Michael
APPLICANT: Vazeux, Rosemay
TITLE OF INVENTION: ICAM-Related Materials and Methods
NUMBER OF SEQUENCES: 120
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402

```

;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/720,420A
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/487,113
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams, Joseph A., Jr.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 33282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-720-420A-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCTTAC 457
Db 1 GCAAGAACCTTACCTTAC 18

RESULT 574
US-08-933-824-5/c
; Sequence 5, Application US/08933824
; Patent No. 6008335
; GENERAL INFORMATION:
; APPLICANT: BEAUDET M.D., AURTHUR L
; APPLICANT: ROTTEN M.D., JEROME I
; APPLICANT: TARGAN M.D., STEPHAN R
; APPLICANT: VORA M.D., DEVENDRA
; APPLICANT: YANG M.D., HUIYING
; TITLE OF INVENTION: METHODS OF SCREENING FOR ULCERATIVE
; TITLE OF INVENTION: COLITIS AND CROHN'S DISEASE
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
; STREET: 444 SOUTH FLOWER STREET, SUITE 2000
; CITY: LOS ANGELES

;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/720,420A
; FILING DATE:
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/487,113
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: WHITEFORD ESQ, WENDY A
; REGISTRATION NUMBER: 36,964
; REFERENCE/DOCKET NUMBER: P07 32056
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-4442
; TELEFAX: (213) 489-4210
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-933-824-5

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 844 GTCACCTATGGCAACGAC 861
Db 18 GTCACCTATGGCAACGAC 1

RESULT 575
US-08-982-845B-1/c
; Sequence 1, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151

```

; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELEPHONE: (609) 779-8486
; TELEFAX: (609) 779-2400
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-982-845B-1

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 50 GCCTCGCTATGGTCCCA 67
Db 18 GCCTCGCTATGGTCCCA 1

RESULT 576
US-08-982-845B-4/c
; Sequence 4, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8486
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-982-845B-4

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2836 TCCTCCACCTCAGCCTC 2853
Db 18 TCCTCCACCTCAGCCTC 1

RESULT 577
US-08-982-845B-5/c
; Sequence 5, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990

```

; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-982-845B-5

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCCATCG 1381
Db 18 CTTTCCCACTGCCCATCG 1

RESULT 578
US-08-982-845B-81
; Sequence 81, Application US/08982845B
; Patent No. 6015894
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/982,845B
; FILING DATE: December 2, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0243
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-08-982-845B-81

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 1 GCCTCGCTATGGCTCCCA 18

RESULT 579
US-08-714-017-21
; Sequence 21, Application US/08714017
; Patent No. 6040176
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 116
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/714,017
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/286,754
; FILING DATE:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6040176and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 32178
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs

```

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-714-017-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCTAC 457
Db 1 GCAAGAACCTTACCCTAC 18

RESULT 580

US-08-863-790-21
Sequence 21, Application US/08863790
Patent No. 6087130
GENERAL INFORMATION:
APPLICANT: Gallatin, W. Michael
APPLICANT: Vazeux, Rosemay
TITLE OF INVENTION: ICAM-Related Protein
NUMBER OF SEQUENCES: 45
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Getstein, Murray &
ADDRESS: Borun
STREET: 6300 Sears Tower, 233 S. Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60606
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/863,790
FILING DATE:
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/827,689
FILING DATE: 27-JAN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/889,724
FILING DATE: 26-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/894,061
FILING DATE: 05-JUN-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/009,266
FILING DATE: 22-JAN-1993
ATTORNEY/AGENT INFORMATION:
NAME: No. 6087130and, Greta E.
REGISTRATION NUMBER: 35,302
REFERENCE/DOCKET NUMBER: 31570
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312)474-6300
TELEFAX: (312)474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-863-790-21.

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCTAC 457
Db 1 GCAAGAACCTTACCCTAC 18

RESULT 581

US-08-991-525B-1/c
Sequence 1, Application US/08991525B
Patent No. 6093811
GENERAL INFORMATION:
APPLICANT: Bennett and Mirabelli
TITLE OF INVENTION: Oligonucleotide Modulation
of Cell Adhesion
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: Windows 95
SOFTWARE: WORDPERFECT 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/991,525B
FILING DATE: December 16, 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 440,740
FILING DATE: May 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 063,167
FILING DATE: May 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 969,151
FILING DATE: February 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 007,997
FILING DATE: January 21, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (856) 810-1515
TELEFAX: (856) 810-1454
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-991-525B-1

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

```
RESULT 582
US-08-991-525B-4/c
; Sequence 4, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (856) 810-1515
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-991-525B-4
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCCACTCAGCCTC 2853
Db 18 TCCTCCCACTCAGCCTC 1

RESULT 583
US-08-991-525B-5/c
; Sequence 5, Application US/08991525B
; Patent No. 6093811
```

```
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/991,525B
; FILING DATE: December 16, 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 21, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (856) 810-1515
; TELEFAX: (856) 810-1454
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-08-991-525B-5
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCCATCG 1381
Db 18 CTTTCCCACTGCCCATCG 1

RESULT 584
US-08-991-525B-81
; Sequence 81, Application US/08991525B
; Patent No. 6093811
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 87
```

```

CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: Windows 95
SOFTWARE: WORDPERFECT 6.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/991.525B
FILING DATE: December 16, 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 440,740
FILING DATE: May 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 063,167
FILING DATE: May 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 969,151
FILING DATE: February 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 007,997
FILING DATE: January 21, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0247
TELEPHONE: (856) 810-1515
TELEFAX: (856) 810-1454
INFORMATION FOR SEQ ID NO: 81:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-08-991-525B-81

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTGCTATGGCTCCCA 67
Db 1 GCCTGCTATGGCTCCCA 18

RESULT 585
US-08-985-759-1/c
Sequence 1, Application US/09085759
Patent No. 6096722
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett, Christopher Mirabelli,
APPLICANT: Brenda Baker
TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
TITLE OF INVENTION: Molecule-Associated Diseases
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street

```

```

CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/085,759
FILING DATE: herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/440,740
FILING DATE: May 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 063,167
FILING DATE: May 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 969,151
FILING DATE: February 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 007,997
FILING DATE: January 20, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0311
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
ANTI-SENSE: Yes
US-09-085-759-1

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTGCTATGGCTCCCA 67
Db 18 GCCTGCTATGGCTCCCA 1

RESULT 586
US-09-085-759-4/c
Sequence 4, Application US/09085759
Patent No. 6096722
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett, Christopher Mirabelli,
APPLICANT: Brenda Baker
TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
TITLE OF INVENTION: Molecule-Associated Diseases
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA

```



```
;
;
; ZIP: 08053
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
; US-09-085-759-4
;
; Query Match 0.6%; Score 18; DB 1; Length 18;
; Best Local Similarity 100.0%; Pred. No. 3.7e+02;
; Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; Qy 2836 TCCTCCACCTCAGCCTC 2853
; Db 18 TCCTCCACCTCAGCCTC 1
;
; RESULT 587
; US-09-085-759-5/c
; Sequence 5, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
```

```
;
;
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
;
; US-09-085-759-5
;
; Query Match 0.6%; Score 18; DB 1; Length 18;
; Best Local Similarity 100.0%; Pred. No. 3.7e+02;
; Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
;
; Qy 1364 CTTTCCACTGCCCATCG 1381
; Db 18 CTTTCCACTGCCCATCG 1
;
; RESULT 588
; US-09-085-759-81
; Sequence 81, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
```

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-085-759-81

```

```

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 50 GCCTCGCTATGGCTCCCA 67
Db 1 GCCTCGCTATGGCTCCCA 18

```

```

RESULT 589
US-09-085-759-86/c
; Sequence 86, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith

```

```

; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 86:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; US-09-085-759-86

```

```

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1192 GCCCAGCTTATACACAAG 1209
Db 18 GCCCAGCTTATACACAAG 1

```

```

RESULT 590
US-09-085-759-87/c
; Sequence 87, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995

```

```

; PRIOR APPLICATION DATA: 063,167
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 87:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-09-085-759-87

```

```

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1254 CGAGAGGGATTGTCGGG 1271
Db 18 CGAGAGGGATTGTCGGG 1

```

```

RESULT 591
US-09-085-759-88/c
; Sequence 88, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:

```

```

; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 88:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-09-085-759-88

```

```

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1286 CAGAAAATTCAGCAGCA 1303
Db 18 CAGAAAATTCAGCAGCA 1

```

```

RESULT 592
US-09-085-759-89/c
; Sequence 89, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997

```

;; FILING DATE: January 20, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; PRIOR APPLICATION DATA: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0311
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 779-8488
;; INFORMATION FOR SEQ ID NO: 89:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
US-09-085-759-89

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1296 CCAGCAGACTCCCAATGTG 1313
Db 18 CCAGCAGACTCCCAATGTG 1

RESULT 593
US-09-085-759-90/c
; Sequence 90, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0311
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 779-8488
;; INFORMATION FOR SEQ ID NO: 90:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
US-09-085-759-90

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1324 GCGAACCCATTCCCGGAG 1341
Db 18 GCGAACCCATTCCCGGAG 1

RESULT 594
US-09-085-759-91/c
; Sequence 91, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:

```
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 91:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-09-085-759-91
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1337 CCGAGCTCAAGTGCTTAA 1354
Db 18 CCGAGCTCAAGTGCTTAA 1

RESULT 595
US-09-085-759-92/c
; Sequence 92, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 93:
; TELECOMMUNICATION INFORMATION:
```

```
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 92:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-09-085-759-92
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1380 CGGGGAATCAGTACTGT 1397
Db 18 CGGGGAATCAGTACTGT 1

RESULT 596
US-09-085-759-93/c
; Sequence 93, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 93:
; SEQUENCE CHARACTERISTICS:
```

```
;
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-09-085-759-93

Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1390 GTGACTGTCTCACTCGAGAT 1407
    |||||
Db 18 GTGACTGTCTCACTCGAGAT 1

RESULT 597
US-09-085-759-95/c
; Sequence 95, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; APPLICATION DATA:
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 95:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-09-085-759-96

Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1435 AGGAGCACTCAAGGGGAG 1452
    |||||
Db 18 AGGAGCACTCAAGGGGAG 1

RESULT 598
US-09-085-759-96/c
; Sequence 96, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; APPLICATION DATA:
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 96:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-09-085-759-96

Query Match      0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
```

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1487 CCGGTATGAGATTGTCA 1504
|||||
Db 18 CCGGTATGAGATTGTCA 1

RESULT 599

US-09-085-759-98/c
; Sequence 98, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; NAME: Jane Massey Licata
; ATTORNEY/AGENT INFORMATION:
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 98:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-09-085-759-98

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1542 TGCAGGCCTCAGCACGTA 1559
|||||

Db 18 TGCAGGCCTCAGCACGTA 1

RESULT 600

US-09-085-759-99/c
; Sequence 99, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 99:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-09-085-759-99

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1556 CGTACTCTATAACGCC 1573
|||||
Db 18 CGTACTCTATAACGCC 1

RESULT 601

US-09-085-759-101/c
; Sequence 101, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 101:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-09-085-759-101
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1743 TGCAGCTACCTACCGG 1760
Db 18 TGCAGCTACCTACCGG 1
RESULT 602
US-09-085-759-102/c
; Sequence 102, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 101:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear

APPLICANT: C. Frank Bennett, Christopher Mirabelli,
APPLICANT: Brenda Baker
TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
TITLE OF INVENTION: Molecule-Associated Diseases
NUMBER OF SEQUENCES: 109
CORRESPONDENCE ADDRESS:
ADDRESSEE: Law Offices of Jane Massey Licata
STREET: 66 East Main Street
CITY: Marlton
STATE: NJ
COUNTRY: USA
ZIP: 08053
COMPUTER READABLE FORM:
MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: WORDPERFECT 5.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/085,759
FILING DATE: herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/440,740
FILING DATE: May 12, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 063,167
FILING DATE: May 17, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 969,151
FILING DATE: February 10, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 007,997
FILING DATE: January 20, 1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 939,855
FILING DATE: September 2, 1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 567,286
FILING DATE: August 14, 1990
ATTORNEY/AGENT INFORMATION:
NAME: Jane Massey Licata
REGISTRATION NUMBER: 32,257
REFERENCE/DOCKET NUMBER: ISPH-0311
TELEPHONE: (609) 779-2400
TELEFAX: (609) 779-8488
INFORMATION FOR SEQ ID NO: 102:
SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-09-085-759-102
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1791 CTCAGCTACGATACACAG 1808
Db 18 CTCAGCTACGATACACAG 1
RESULT 603
US-09-085-759-103/c
; Sequence 103, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 102:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear

;; TITLE OF INVENTION: Molecule-Associated Diseases
;; NUMBER OF SEQUENCES: 109
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Law Offices of Jane Massey Licata
;; STREET: 66 East Main Street
;; CITY: Marlton
;; STATE: NJ
;; COUNTRY: USA
;; ZIP: 08053
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;; COMPUTER: IBM PS/2
;; OPERATING SYSTEM: PC-DOS
;; SOFTWARE: WORDPERFECT 5.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/085,759
;; FILING DATE: herewith
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/440,740
;; FILING DATE: May 12, 1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 063,167
;; FILING DATE: May 17, 1993
;; APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 20, 1993
;; APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0311
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 779-8488
;; INFORMATION FOR SEQ ID NO: 103:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;;
US-09-085-759-103

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1844 TAGCCACGCATCTGATC 1861
Db 18 TAGCCACGCATCTGATC 1

RESULT 604
US-09-085-759-105/C
;; Sequence 105, Application US/09085759
;; Patent No. 6096722
;; GENERAL INFORMATION:
;; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
;; APPLICANT: Brenda Baker
;; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
;; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
;; TITLE OF INVENTION: Molecule-Associated Diseases
;; NUMBER OF SEQUENCES: 109
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Law Offices of Jane Massey Licata

;; STREET: 66 East Main Street
;; CITY: Marlton
;; STATE: NJ
;; COUNTRY: USA
;; ZIP: 08053
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;; COMPUTER: IBM PS/2
;; OPERATING SYSTEM: PC-DOS
;; SOFTWARE: WORDPERFECT 5.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/085,759
;; FILING DATE: herewith
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/440,740
;; FILING DATE: May 12, 1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 063,167
;; FILING DATE: May 17, 1993
;; APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 20, 1993
;; APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0311
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 779-8488
;; INFORMATION FOR SEQ ID NO: 105:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;;
US-09-085-759-105

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1412 AGGCACCTACTCTGTC 1429
Db 18 AGGCACCTACTCTGTC 1

RESULT 605
US-08-475-680-21
;; Sequence 21, Application US/08475680
;; Patent No. 6100383
;; GENERAL INFORMATION:
;; APPLICANT: Gallatin, W. Michael
;; APPLICANT: Vazeux, Rosemary
;; TITLE OF INVENTION: ICAM-Related Materials and Methods
;; NUMBER OF SEQUENCES: 116
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
;; STREET: 6300 Sears Tower, 233 S. Wacker Drive
;; CITY: Chicago
;; STATE: Illinois
;; COUNTRY: USA
;; ZIP: 60606
;;
;; COMPUTER READABLE FORM:

;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/475,680
;; FILING DATE: 07-JUN-1995
;; CLASSIFICATION: 530
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/286,754
;; FILING DATE: 05-AUG-1994
;; APPLICATION NUMBER: US 08/102,852
;; FILING DATE: 05-AUG-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/009,266
;; FILING DATE: 22-JAN-1993
;; APPLICATION NUMBER: US 07/894,061
;; FILING DATE: 05-JUN-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/889,724
;; FILING DATE: 26-MAY-1992
;; APPLICATION NUMBER: US 07/827,689
;; FILING DATE: 27-JAN-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: No. 6100383and, Greta E.
;; REGISTRATION NUMBER: 35,302
;; REFERENCE/DOCKET NUMBER: 32178
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (312) 474-6300
;; TELEFAX: (312) 474-0448
;; TELEX: 25-3856
;; INFORMATION FOR SEQ ID NO: 21:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
US-08-475-680-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCTAC 457
Db 1 GCAAGAACCTTACCCTAC 18

RESULT 606
US-09-062-416-7/c
; Sequence 7, Application US/09062416
; Patent No. 6111094
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Thomas P. Condon,
; APPLICANT: Shin Cheng Flournoy
; TITLE OF INVENTION: ENHANCED ANTISENSE MODULATION OF ICAM-1
; NUMBER OF SEQUENCES: 33
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 EAST MAIN STREET
; CITY: MARLTON
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:

;; APPLICATION NUMBER: US/09/062,416
;; FILING DATE: Herewith
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA: 08/440,740
;; FILING DATE: MAY 12, 1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/063,167
;; FILING DATE: MAY 17, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 07/969,151
;; FILING DATE: FEB 10, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/007,997
;; FILING DATE: JAN 21, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 07/939,855
;; FILING DATE: SEP 2, 1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 07/567,286
;; FILING DATE: AUG 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0306
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 779-2400
;; TELEFAX: (609) 810-1454
;; INFORMATION FOR SEQ ID NO: 7:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18 base pairs
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-09-062-416-7

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TCACGGATGCCAGTTGG 2117
Db 18 TCACGGATGCCAGTTGG 1

RESULT 607
US-08-296-749-21
; Sequence 21, Application US/08296749
; Patent No. 6153395
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Protein
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
; ADDRESSEE: Borun
; STREET: 6300 Sears Tower, 233 S. Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: USA
; ZIP: 60606
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/296,749
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: No. 6153395and, Greta E.
; REGISTRATION NUMBER: 35,302
; REFERENCE/DOCKET NUMBER: 31570
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312)474-6300
; TELEFAX: (312)474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-296-749-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCTTAC 457
Db 1 GCAAGAACCTTACCTTAC 18

RESULT 608
US-08-211-882-4/c
; Sequence 4, Application US/08211882
; Patent No. 6153737
; GENERAL INFORMATION:
; APPLICANT: Manoharan et al.
; TITLE OF INVENTION: Derivatized Oligonucleotides Having
; TITLE OF INVENTION: Improved Uptake And Other Properties
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 61537377ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/211,882
; FILING DATE: 22-APR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/782,374
; FILING DATE: 24-OCT-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-0649
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-128-496-1

Query Match 0.6%; Score 18; DB 1; Length 18;
```

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-211-882-4

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTGCTATGCTCCCA 67
Db 18 GCCTGCTATGCTCCCA 1

RESULT 609
US-09-128-496-1/c
; Sequence 1, Application US/09128496
; Patent No. 6159079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-128-496-1

Query Match 0.6%; Score 18; DB 1; Length 18;
```

Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 610

US-09-128-496-4/c
; Sequence 4, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-128-496-4

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCCACTGAGCCTC 2853
Db 18 TCCTCCCACTGAGCCTC 1

RESULT 611

US-09-128-496-5/c
; Sequence 5, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/128,496
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-128-496-5

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCATCG 1381
Db 18 CTTTCCCACTGCCATCG 1

RESULT 612

US-09-128-496-81
; Sequence 81, Application US/09128496
; Patent No. 6169079
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion

; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; FILING DATE: US/09/128,496
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/440,740
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0133
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-128-496-81

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 1 GCCTCGCTATGGCTCCCA 18

RESULT 613
US-08-894-899-22/c
; Sequence 22, Application US/08894899
; Patent No. 622025
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
; APPLICANT: Spranger, Robert H.
; APPLICANT: Sprankle, Kelly G.
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidi
; FILE REFERENCE: ISIS-2167
; CURRENT FILING DATE: 1998-01-07

; PRIOR APPLICATION NUMBER: PCT/US96/03174
; PRIOR FILING DATE: 1996-03-06
; PRIOR APPLICATION NUMBER: 08/475,467
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/398,901
; PRIOR FILING DATE: 1995-03-06
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 22
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: No. 622025el Sequence
US-08-894-899-22

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 614

US-08-894-899-23/c
; Sequence 23, Application US/08894899
; Patent No. 622025
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
; APPLICANT: Spranger, Robert H.
; APPLICANT: Sprankle, Kelly G.
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidi
; FILE REFERENCE: ISIS-2167
; CURRENT APPLICATION NUMBER: US/08/894,899
; CURRENT FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: PCT/US96/03174
; PRIOR FILING DATE: 1996-03-06
; PRIOR APPLICATION NUMBER: 08/475,467
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/398,901
; PRIOR FILING DATE: 1995-03-06
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 23
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: No. 622025el Sequence
US-08-894-899-23

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 615

US-08-894-899-24/c
; Sequence 24, Application US/08894899
; Patent No. 622025
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.

; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
; APPLICANT: Springer, Robert H.
; APPLICANT: Sprankle, Kelly G.
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidin
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidin
; FILE REFERENCE: ISIS-2167
; CURRENT APPLICATION NUMBER: US/08/894,899
; CURRENT FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: PCT/US96/03174
; PRIOR FILING DATE: 1996-03-06
; PRIOR APPLICATION NUMBER: 08/475,467
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/398,901
; PRIOR FILING DATE: 1995-03-06
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 24
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: No. 6222025el Sequence
; US-08-894-899-24

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 616
US-08-894-899-25/c
; Sequence 25, Application US/08894899
; Patent No. 6222025
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
; APPLICANT: Springer, Robert H.
; APPLICANT: Sprankle, Kelly G.
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidin
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidin
; FILE REFERENCE: ISIS-2167
; CURRENT APPLICATION NUMBER: US/08/894,899
; CURRENT FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: PCT/US96/03174
; PRIOR FILING DATE: 1996-03-06
; PRIOR APPLICATION NUMBER: 08/475,467
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/398,901
; PRIOR FILING DATE: 1995-03-06
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 25
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: No. 6222025el Sequence
; US-08-894-899-25

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 617
US-08-894-899-26/c
; Sequence 26, Application US/08894899
; Patent No. 6222025
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
; APPLICANT: Springer, Robert H.
; APPLICANT: Sprankle, Kelly G.
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidin
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidin
; FILE REFERENCE: ISIS-2167
; CURRENT APPLICATION NUMBER: US/08/894,899
; CURRENT FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: PCT/US96/03174
; PRIOR FILING DATE: 1996-03-06
; PRIOR APPLICATION NUMBER: 08/475,467
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/398,901
; PRIOR FILING DATE: 1995-03-06
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 26
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: No. 6222025el Sequence
; US-08-894-899-26

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 618
US-09-128-508-1/c
; Sequence 1, Application US/09128508
; Patent No. 6232463
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ramasamy, Kanda S.
; TITLE OF INVENTION: Substituted Purines and Oligonucleotide Cross-Linking
; FILE REFERENCE: ISIS3152
; CURRENT APPLICATION NUMBER: US/09/128,508
; CURRENT FILING DATE: 1998-08-04
; PRIOR APPLICATION NUMBER: PCT/US91/00243
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 07/463,358
; PRIOR FILING DATE: 1990-01-11
; PRIOR APPLICATION NUMBER: 08/189,792
; PRIOR FILING DATE: 1994-02-01
; PRIOR APPLICATION NUMBER: 08/948,151
; PRIOR FILING DATE: 1997-10-09
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn ver. 2.1
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6232463el
; US-09-128-508-1

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 619
US-08-397-277A-7/c
; Sequence 7, Application US/08397277A
; Patent No. 6235886
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; TITLE OF INVENTION: MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 6235886ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/397,277A
; FILING DATE: 09-MAR-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/943,516
; FILING DATE: 11-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumont, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1198
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-397-277A-7

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 620
US-09-264-466-5/c
; Sequence 5, Application US/09264466
; Patent No. 6235889
; GENERAL INFORMATION:
; APPLICANT: BEAUDET M.D., AURTHUR L
; ROTTER M.D., JEROME I
; TARGAN M.D., STEPHAN R

VORA M.D., DEVENDRA
YANG M.D., HUIYING
; TITLE OF INVENTION: METHODS OF SCREENING FOR ULCERATIVE
; COLITIS AND CROHN'S DISEASE
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
; STREET: 444 SOUTH FLOWER STREET, SUITE 2000
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/264,466
; FILING DATE: 08-Mar-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/196,003
; FILING DATE: 11-FEB-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: WHITEFORD ESQ, WENDY A
; REGISTRATION NUMBER: 36,964
; REFERENCE/DOCKET NUMBER: P07 32056
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-4442
; TELEFAX: (213) 489-4210

INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-264-466-5

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 844 GTCACCTATGCAACGAC 861
|||||
DB 18 GTCACCTATGCAACGAC 1

RESULT 621
US-09-009-490A-1/c
; Sequence 1, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A

;; FILING DATE: January 20, 1998
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 440,740
;; FILING DATE: May 12, 1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 063,167
;; FILING DATE: May 17, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 20, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 20, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0268
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 810-1515
;; TELEFAX: (609) 810-1454
;; INFORMATION FOR SEQ ID NO: 1:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-09-009-490A-1

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGTATGGTCCCA 67
DB 18 GCCTCGTATGGTCCCA 1

RESULT 622
US-09-009-490A-4/c
; Sequence 4, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 063,167
;; FILING DATE: May 17, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 969,151
;; FILING DATE: February 10, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 007,997
;; FILING DATE: January 20, 1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 939,855
;; FILING DATE: September 2, 1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 567,286
;; FILING DATE: August 14, 1990
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Jane Massey Licata
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0268
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (609) 810-1515
;; TELEFAX: (609) 810-1454
;; INFORMATION FOR SEQ ID NO: 4:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 18
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-09-009-490A-4

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCACCTCAGCCTC 2853
DB 18 TCCTCCACCTCAGCCTC 1

RESULT 623
US-09-009-490A-5/c
; Sequence 5, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151


```
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA: 007,997
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-009-490A-5

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCCATCG 1381
DB 18 CTTTCCCACTGCCCATCG 1

RESULT 624
US-09-009-490A-81
; Sequence 81, Application US/09009490A
; Patent No. 6300491
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Office of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,490A
; FILING DATE: January 20, 1998
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:

; FILING DATE: September 2, 1992
; APPLICATION NUMBER: 939,855
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 810-1515
; TELEFAX: (609) 810-1454
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-009-490A-81

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 1 GCCTCGCTATGGCTCCCA 18

RESULT 625
US-09-149-156B-1/c
; Sequence 1, Application US/09149156B
; Patent No. 6335437
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Methods For The Preparation Of Conjugated Oligomers
; FILE REFERENCE: ISIS3073
; CURRENT APPLICATION NUMBER: US/09/149,156B
; CURRENT FILING DATE: 1998-09-07
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: No. 6335437el Sequence
; US-09-149-156B-1

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 626
US-09-149-156B-2/c
; Sequence 2, Application US/09149156B
; Patent No. 6335437
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Methods For The Preparation Of Conjugated Oligomers
; FILE REFERENCE: ISIS3073
; CURRENT APPLICATION NUMBER: US/09/149,156B
; CURRENT FILING DATE: 1998-09-07
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
```

; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: No. 6335437el Sequence
US-09-149-156B-2

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
| | | | | | | | | | | | | | | | | |
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 627
US-09-149-156B-3/c
; Sequence 3, Application US/09149156B
; Patent No. 6335437
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Methods For The Preparation Of Conjugated Oligomers
; FILE REFERENCE: ISIS3073
; CURRENT APPLICATION NUMBER: US/09/149,156B
; CURRENT FILING DATE: 1998-09-07
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 3
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: No. 6335437el Sequence
US-09-149-156B-3

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
| | | | | | | | | | | | | | | | | |
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 628
US-09-633-659-4/c
; Sequence 4, Application US/09633659
; Patent No. 6395492
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Bennett, Clarence Frank
; TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake And
; TITLE OF INVENTION: Other Properties
; FILE REFERENCE: ISIS4470
; CURRENT APPLICATION NUMBER: US/09/633,659
; CURRENT FILING DATE: 2000-08-07
; PRIOR APPLICATION NUMBER: 08/211,882
; PRIOR FILING DATE: 1994-04-22
; PRIOR APPLICATION NUMBER: 07/782,374
; PRIOR FILING DATE: 1991-10-24
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6395492el Sequence
US-09-633-659-4

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
| | | | | | | | | | | | | | | | | |
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 629
US-09-689-964-7/c
; Sequence 7, Application US/09689964
; Patent No. 6399757
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. 6399757ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/689,964
; FILING DATE: 12-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/397,277
; FILING DATE: 09-MAR-1995
; APPLICATION NUMBER: 07/943,516
; FILING DATE: 11-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumont, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1198
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 7:
US-09-689-964-7

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
| | | | | | | | | | | | | | | | | |
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 630
US-09-689-964-7/c
; Sequence 7, Application US/09689964
; Patent No. 6495671
; GENERAL INFORMATION:

```
; APPLICANT: Manoharan, Muthiah
; Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. 6495671r18
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/689,964
; FILING DATE: 12-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/397,277
; FILING DATE: 09-MAR-1995
; APPLICATION NUMBER: 07/943,516
; FILING DATE: 11-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumont, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1198
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE DESCRIPTION: SEQ ID NO: 7:
US-09-689-964-7

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 631
US-09-784-917-6/c
; Sequence 6, Application US/09784917
; Patent No. 6500945
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; TITLE OF INVENTION: Oligonucleotides Having Chiral Phosphorus Linkages
; FILE REFERENCE: ISI84732
; CURRENT APPLICATION NUMBER: US/09/784,917
; CURRENT FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: 09/208,533
; PRIOR FILING DATE: 1998-12-09
; PRIOR APPLICATION NUMBER: 08/635,009
; PRIOR FILING DATE: 1996-04-19
; PRIOR APPLICATION NUMBER: 08/058,023
; PRIOR FILING DATE: 1993-05-05
; PRIOR APPLICATION NUMBER: PCT/US91/00243
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 07/777,670
; PRIOR FILING DATE: 1991-10-15
```

```
; PRIOR APPLICATION NUMBER: 07/463,358
; PRIOR FILING DATE: 1990-01-11
; PRIOR APPLICATION NUMBER: 07/566,977
; PRIOR FILING DATE: 1990-08-13
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-784-917-6

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 632
US-09-747-009A-22/c
; Sequence 22, Application US/09747009A
; Patent No. 6642367
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
; APPLICANT: Springer, Robert H.
; APPLICANT: Sprankie, Kelly G.
; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidine
; FILE REFERENCE: ISIS-4684
; CURRENT APPLICATION NUMBER: US/09/747,009A
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 08/894,899
; PRIOR FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: PCT/US96/03174
; PRIOR FILING DATE: 1996-01-07
; PRIOR APPLICATION NUMBER: 08/475,467
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: 08/398,901
; PRIOR FILING DATE: 1995-03-06
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 22
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. 6642367e1 Sequence
US-09-747-009A-22

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 633
US-09-747-009A-23/c
; Sequence 23, Application US/09747009A
; Patent No. 6642367
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
```

APPLICANT: Springer, Robert H.
APPLICANT: Sprankle, Kelly G.
TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidine
TITLE OF INVENTION: Oligomeric Compounds Therefrom
FILE REFERENCE: ISIS-4684
CURRENT APPLICATION NUMBER: US/09/747,009A
CURRENT FILING DATE: 2000-12-22
PRIOR APPLICATION NUMBER: 08/894,899
PRIOR FILING DATE: 1998-01-07
PRIOR APPLICATION NUMBER: PCT/US96/03174
PRIOR FILING DATE: 1996-01-07
PRIOR APPLICATION NUMBER: 08/475,467
PRIOR FILING DATE: 1995-06-07
PRIOR APPLICATION NUMBER: 08/398,901
PRIOR FILING DATE: 1995-03-06
NUMBER OF SEQ ID NOS: 31
SOFTWARE: PatentIn version 3.1
SEQ ID NO 23
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: No. 6642367el Sequence
US-09-747-009A-23

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 634
US-09-747-009A-24/c
Sequence 24, Application US/09747009A
Patent No. 6642367
GENERAL INFORMATION:
APPLICANT: Cook, Phillip Dan
APPLICANT: Sanghvi, Yogesh S.
APPLICANT: Ross, Bruce S.
APPLICANT: Griffey, Rich H.
APPLICANT: Springer, Robert H.
APPLICANT: Sprankle, Kelly G.
TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidine
TITLE OF INVENTION: Oligomeric Compounds Therefrom
FILE REFERENCE: ISIS-4684
CURRENT APPLICATION NUMBER: US/09/747,009A
CURRENT FILING DATE: 2000-12-22
PRIOR APPLICATION NUMBER: 08/894,899
PRIOR FILING DATE: 1998-01-07
PRIOR APPLICATION NUMBER: PCT/US96/03174
PRIOR FILING DATE: 1996-01-07
PRIOR APPLICATION NUMBER: 08/475,467
PRIOR FILING DATE: 1995-06-07
PRIOR APPLICATION NUMBER: 08/398,901
PRIOR FILING DATE: 1995-03-06
NUMBER OF SEQ ID NOS: 31
SOFTWARE: PatentIn version 3.1
SEQ ID NO 24
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: No. 6642367el Sequence
US-09-747-009A-24

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

Db 18 GCCTCGCTATGGCTCCCA 1
|||||

RESULT 635
US-09-747-009A-25/c
Sequence 25, Application US/09747009A
Patent No. 6642367
GENERAL INFORMATION:
APPLICANT: Cook, Phillip Dan
APPLICANT: Sanghvi, Yogesh S.
APPLICANT: Ross, Bruce S.
APPLICANT: Griffey, Rich H.
APPLICANT: Springer, Robert H.
APPLICANT: Sprankle, Kelly G.
TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidine
TITLE OF INVENTION: Oligomeric Compounds Therefrom
FILE REFERENCE: ISIS-4684
CURRENT APPLICATION NUMBER: US/09/747,009A
CURRENT FILING DATE: 2000-12-22
PRIOR APPLICATION NUMBER: 08/894,899
PRIOR FILING DATE: 1998-01-07
PRIOR APPLICATION NUMBER: PCT/US96/03174
PRIOR FILING DATE: 1996-01-07
PRIOR APPLICATION NUMBER: 08/475,467
PRIOR FILING DATE: 1995-06-07
PRIOR APPLICATION NUMBER: 08/398,901
PRIOR FILING DATE: 1995-03-06
NUMBER OF SEQ ID NOS: 31
SOFTWARE: PatentIn version 3.1
SEQ ID NO 25
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: No. 6642367el Sequence
US-09-747-009A-25

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 636
US-09-747-009A-26/c
Sequence 26, Application US/09747009A
Patent No. 6642367
GENERAL INFORMATION:
APPLICANT: Cook, Phillip Dan
APPLICANT: Sanghvi, Yogesh S.
APPLICANT: Ross, Bruce S.
APPLICANT: Griffey, Rich H.
APPLICANT: Springer, Robert H.
APPLICANT: Sprankle, Kelly G.
TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidine
TITLE OF INVENTION: Oligomeric Compounds Therefrom
FILE REFERENCE: ISIS-4684
CURRENT APPLICATION NUMBER: US/09/747,009A
CURRENT FILING DATE: 2000-12-22
PRIOR APPLICATION NUMBER: 08/894,899
PRIOR FILING DATE: 1998-01-07
PRIOR APPLICATION NUMBER: PCT/US96/03174
PRIOR FILING DATE: 1996-01-07
PRIOR APPLICATION NUMBER: 08/475,467
PRIOR FILING DATE: 1995-06-07
PRIOR APPLICATION NUMBER: 08/398,901
PRIOR FILING DATE: 1995-03-06
NUMBER OF SEQ ID NOS: 31
SOFTWARE: PatentIn version 3.1

SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-546-596A-5

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 640

US-09-546-596A-15/c
Sequence 15, Application US/09546596A
Patent No. 6753423
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
Bennett, C. Frank
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
ENHANCED BIOTABILITY AND ALTERED BIODISTRIBUTION OF
OLIGONUCLEOTIDES IN MAMMALS

NUMBER OF SEQUENCES: 63

CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz

and No. 6753423ris

STREET: One Liberty Place - 46th Floor

CITY: Philadelphia

STATE: PA

COUNTRY: U.S.A.

ZIP: 19103

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/546,596A

FILING DATE: 10-Apr-2000

CLASSIFICATION: <Unknown>

ATTORNEY/AGENT INFORMATION:

NAME: Lucci, Joseph

REGISTRATION NUMBER: 33,307

REFERENCE/DOCKET NUMBER: ISIS-2707

TELECOMMUNICATION INFORMATION:

TELEPHONE: 215-568-3100

TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 15:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

SEQUENCE DESCRIPTION: SEQ ID NO: 15:

US-09-546-596A-15

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 641

US-09-546-596A-16/c

Sequence 16, Application US/09546596A

Patent No. 6753423

GENERAL INFORMATION:

APPLICANT: Manoharan, Muthiah

Cook, Phillip D.

Bennett, C. Frank

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR

ENHANCED BIOTABILITY AND ALTERED BIODISTRIBUTION OF

OLIGONUCLEOTIDES IN MAMMALS

NUMBER OF SEQUENCES: 63

CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz

and No. 6753423ris

STREET: One Liberty Place - 46th Floor

CITY: Philadelphia

STATE: PA

COUNTRY: U.S.A.

ZIP: 19103

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/546,596A

FILING DATE: 10-Apr-2000

CLASSIFICATION: <Unknown>

ATTORNEY/AGENT INFORMATION:

NAME: Lucci, Joseph

REGISTRATION NUMBER: 33,307

REFERENCE/DOCKET NUMBER: ISIS-2707

TELECOMMUNICATION INFORMATION:

TELEPHONE: 215-568-3100

TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 16:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

SEQUENCE DESCRIPTION: SEQ ID NO: 16:

US-09-546-596A-16

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 642

US-08-117-363A-4/c

Sequence 4, Application US/08117363A

Patent No. 6783931

GENERAL INFORMATION:

APPLICANT: Manoharan, Muthiah

APPLICANT: Phillip D. Cook

TITLE OF INVENTION: AMINE-DERIVATIZED NUCLEOSIDES AND

OLIGONUCLEOSIDES

NUMBER OF SEQUENCES: 23

CORRESPONDENCE ADDRESS:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz

and No. 6783931ris

STREET: One Liberty Place - 46th Floor

CITY: Philadelphia

STATE: PA

COUNTRY: U.S.A.

ZIP: 19103

```
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/117,363A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Lucci, Joseph
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-1169
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-117-363A-4

Query Match          0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 643
US-08-117-363A-15/c
; Sequence 15, Application US/08117363A
; Patent No. 6783931
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: AMINE-DERIVATIZED NUCLEOSIDES AND
; TITLE OF INVENTION: OLIGONUCLEOSIDES
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 6783931ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/117,363A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Lucci, Joseph
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-1169
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-117-363A-16

Query Match          0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 645
US-08-117-369-21
; Sequence 21, Application US/08314369
; Patent No. 6818743
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: I-CAM Related Protein
```

NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray &
ADDRESSEE: Bicknell
STREET: Two First National Plaza, 20 South Clark
CITY: Chicago
STATE: Illinois
COUNTRY: USA
ZIP: 60603
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/314,369
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/889,724
FILING DATE:
APPLICATION NUMBER: US 07/827,689
ATTORNEY/AGENT INFORMATION:
NAME: No. 6818743and, Greta E.
REGISTRATION NUMBER: 35,302
REFERENCE/DOCKET NUMBER: 27866/30902
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312)346-5750
TELEFAX: (312)984-9740
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-314-369-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCTAC 457
|||||
Db 1 GCAAGAACCTTACCCTAC 18

RESULT 646
US-10-192-437-7/c
Sequence 7, Application US/10192437
Patent No. 6828434
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
and Philip D. Cook
TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
MAKING AND USING THE SAME
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
and No. 6828434ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/10/192,437
FILING DATE: 10-Jul-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/397,277A
FILING DATE: 09-MAR-1995
APPLICATION NUMBER: 07/943,516
FILING DATE: 11-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Gaumond, Rebecca R.
REGISTRATION NUMBER: 35,152
REFERENCE/DOCKET NUMBER: ISIS-1198
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 7:
US-10-192-437-7

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 647

US-10-073-718-4/c
Sequence 4, Application US/10073718
Patent No. 6831166
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Cook, Phillip Dan
APPLICANT: Bennett, Clarence Frank
TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake and Other Pr
FILE REFERENCE: ISIS-5024
CURRENT APPLICATION NUMBER: US/10/073,718
CURRENT FILING DATE: 2002-05-08
PRIOR APPLICATION NUMBER: 09/633659
PRIOR FILING DATE: 2000-08-07
PRIOR APPLICATION NUMBER: 6153737
PRIOR FILING DATE: 2000-11-28
PRIOR APPLICATION NUMBER: 08/211882
PRIOR FILING DATE: 1994-04-22
PRIOR APPLICATION NUMBER: PCT/US92/09196
PRIOR FILING DATE: 1992-10-23
PRIOR APPLICATION NUMBER: 07/782374
PRIOR FILING DATE: 1991-10-24
PRIOR APPLICATION NUMBER: 07/566977
PRIOR FILING DATE: 1990-08-13
PRIOR APPLICATION NUMBER: PCT/US91/000243
PRIOR FILING DATE: 1991-01-11
PRIOR APPLICATION NUMBER: 08/463358
PRIOR FILING DATE: 1990-01-11
NUMBER OF SEQ ID NOS: 18
SOFTWARE: PatentIn version 3.1
SEQ ID NO 4
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: No. 6831166el Sequence
US-10-073-718-4

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 3.7e+02; Indels 0; Gaps 0; Matches 18; Conservative 0; Mismatches 0;

QY 50 GCCTCGCTATGGTCCCA 67
 |||||
 Db 18 GCCTCGCTATGGTCCCA 1

RESULT 648

PCT-US93-08101-1/c
 ; Sequence 1, Application PC/TUS9308101
 ; GENERAL INFORMATION:
 ; APPLICANT: Bennett and Mirabelli
 ; TITLE OF INVENTION: Oligonucleotide Modulation
 ; NUMBER OF SEQUENCES: 85
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Woodland Falls Corporate Park
 ; STREET: 210 Lake Drive East, Suite 201
 ; CITY: Cherry Hill
 ; STATE: NJ
 ; COUNTRY: USA
 ; ZIP: 08002
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
 ; COMPUTER: IBM PS/2
 ; OPERATING SYSTEM: PC-DOS
 ; SOFTWARE: WORDPERFECT 5.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: PCT/US93/08101
 ; FILING DATE: Herewith
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 939,855
 ; FILING DATE: September 2, 1992
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: PCT/US91/05209
 ; FILING DATE: July 23, 1991
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 567,286
 ; FILING DATE: August 14, 1990
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER:
 ; FILING DATE:
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Jane Massey Licata
 ; REGISTRATION NUMBER: 32,257
 ; REFERENCE/DOCKET NUMBER: ISPH-0002
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (215) 568-3100
 ; TELEFAX: (215) 568-3439
 ; INFORMATION FOR SEQ ID NO: 1:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 18
 ; TYPE: Nucleic Acid
 ; STRANDEDNESS: Single
 ; TOPOLOGY: Linear
 ; ANTI-SENSE: Yes
 ; PCT-US93-08101-1

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 3.7e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGTCCCA 67
 |||||
 Db 18 GCCTCGCTATGGTCCCA 1

RESULT 649

PCT-US93-08101-4/c
 ; Sequence 4, Application PC/TUS9308101
 ; GENERAL INFORMATION:

; APPLICANT: Bennett and Mirabelli
 ; TITLE OF INVENTION: Oligonucleotide Modulation
 ; NUMBER OF SEQUENCES: 85
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Woodland Falls Corporate Park
 ; STREET: 210 Lake Drive East, Suite 201
 ; CITY: Cherry Hill
 ; STATE: NJ
 ; COUNTRY: USA
 ; ZIP: 08002
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
 ; COMPUTER: IBM PS/2
 ; OPERATING SYSTEM: PC-DOS
 ; SOFTWARE: WORDPERFECT 5.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: PCT/US93/08101
 ; FILING DATE: Herewith
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 939,855
 ; FILING DATE: September 2, 1992
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: PCT/US91/05209
 ; FILING DATE: July 23, 1991
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 567,286
 ; FILING DATE: August 14, 1990
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER:
 ; FILING DATE:
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Jane Massey Licata
 ; REGISTRATION NUMBER: 32,257
 ; REFERENCE/DOCKET NUMBER: ISPH-0002
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (215) 568-3100
 ; TELEFAX: (215) 568-3439
 ; INFORMATION FOR SEQ ID NO: 4:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 18
 ; TYPE: Nucleic Acid
 ; STRANDEDNESS: Single
 ; TOPOLOGY: Linear
 ; ANTI-SENSE: Yes
 ; PCT-US93-08101-4

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 3.7e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCACCTCAGCCTC 2853
 |||||
 Db 18 TCCTCCACCTCAGCCTC 1

RESULT 650
 PCT-US93-08101-5/c
 ; Sequence 5, Application PC/TUS9308101
 ; GENERAL INFORMATION:
 ; APPLICANT: Bennett and Mirabelli
 ; TITLE OF INVENTION: Oligonucleotide Modulation
 ; NUMBER OF SEQUENCES: 85
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Woodland Falls Corporate Park
 ; STREET: 210 Lake Drive East, Suite 201
 ; CITY: Cherry Hill
 ; STATE: NJ
 ; COUNTRY: USA
 ; ZIP: 08002
 ; COMPUTER READABLE FORM:

```

; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; APPLICATION DATA:
; FILING DATE: Herewith
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; PCT-US93-08101-5

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCATCG 1381
DB 18 CTTTCCCACTGCCATCG 1

RESULT 651
PCT-US93-08101-81
; Sequence 81, Application PC/TUS9308101
; GENERAL INFORMATION:
; APPLICANT: Bennett and Mirabelli
; TITLE OF INVENTION: Oligonucleotide Modulation
; TITLE OF INVENTION: of Cell Adhesion
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodland Falls Corporate Park
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08101
; FILING DATE: Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; APPLICATION DATA:

```

```

; APPLICATION NUMBER: PCT/US91/05209
; FILING DATE: July 23, 1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 81:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; PCT-US93-08101-81

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 1 GCCTCGCTATGGCTCCCA 18

RESULT 652
PCT-US93-08367A-7/c
; Sequence 7, Application PC/TUS9308367A
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSER: and Norris
; STREET: One Liberty Place-- 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08367A
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumont, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1171
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)

```

PCT-US93-08367A-7

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 653

5284931-21

; Patent No. 5284931
; APPLICANT: SPRINGER, TIMOTHY A.; ROTHLEIN, ROBERT; MARLIN,
; STEVEN D.; DUSTIN, MICHAEL L.
; TITLE OF INVENTION: INTERCELLULAR ADHESION MOLECULES AND
; THEIR BINDING LIGANDS
; NUMBER OF SEQUENCES: 41
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/515,478
; FILING DATE: 27-APR-1990
; SEQ ID NO: 21:
; LENGTH: 18

5284931-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 207 CTCCTGTGACCGCCCAA 224
|||||
Db 1 CTCCTGTGACCGCCCAA 18

RESULT 654

5284931-21

; Patent No. 5284931
; APPLICANT: SPRINGER, TIMOTHY A.; ROTHLEIN, ROBERT; MARLIN,
; STEVEN D.; DUSTIN, MICHAEL L.
; TITLE OF INVENTION: INTERCELLULAR ADHESION MOLECULES AND
; THEIR BINDING LIGANDS
; NUMBER OF SEQUENCES: 41
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/515,478
; FILING DATE: 27-APR-1990
; SEQ ID NO: 21:
; LENGTH: 18

5284931-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 3.7e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 207 CTCCTGTGACCGCCCAA 224
|||||
Db 1 CTCCTGTGACCGCCCAA 18

RESULT 655

US-08-361-858-2/c

; Sequence 2, Application US/08361858
; Patent No. 5834607
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; TITLE OF INVENTION: MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5834607ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia

; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/361,858
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/943,516
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumont, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-0484
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 19
; OTHER INFORMATION: /note= "abasic, aldehydic
; OTHER INFORMATION: species"
US-08-361-858-2

Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 656

US-08-397-277A-2/c

; Sequence 2, Application US/08397277A
; Patent No. 6235886
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; TITLE OF INVENTION: MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 6235886ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/397,277A
; FILING DATE: 09-MAR-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/943,516
FILING DATE: 11-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Gaumond, Rebecca R.
REGISTRATION NUMBER: 35,152
REFERENCE/DOCKET NUMBER: ISIS-1198
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 19
OTHER INFORMATION: /note= "abasic, aldehydic
species"
US-08-397-277A-2

Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 657

US-09-689-964-2/c
Sequence 2, Application US/09689964
Patent No. 6395757
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
Phillip D. Cook
TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
MAKING AND USING THE SAME
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
and No. 6395757ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/689,964
FILING DATE: 12-Oct-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/397,277
FILING DATE: 09-MAR-1995
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/689,964
FILING DATE: 12-Oct-2000
CLASSIFICATION: <Unknown>
APPLICATION DATA:
APPLICATION NUMBER: 08/397,277
FILING DATE: 09-MAR-1995
APPLICATION NUMBER: 07/943,516
FILING DATE: 11-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Gaumond, Rebecca R.
REGISTRATION NUMBER: 35,152
REFERENCE/DOCKET NUMBER: ISIS-1198
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:

LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 19
OTHER INFORMATION: /note= "abasic, aldehydic
species"
US-09-689-964-2

Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 658

US-09-689-964-2/c
Sequence 2, Application US/09689964
Patent No. 6495671
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
Phillip D. Cook
TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
MAKING AND USING THE SAME
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
and No. 6495671ris
STREET: One Liberty Place - 46th Floor
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/689,964
FILING DATE: 12-Oct-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/397,277
FILING DATE: 09-MAR-1995
APPLICATION NUMBER: 07/943,516
FILING DATE: 11-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Gaumond, Rebecca R.
REGISTRATION NUMBER: 35,152
REFERENCE/DOCKET NUMBER: ISIS-1198
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 19
OTHER INFORMATION: /note= "abasic, aldehydic
species"

```
/
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-689-964-2

Query Match          0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 659
US-09-370-541-21/c
; Sequence 21, Application US/09370541
; Patent No. 6639062
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Prakash, Thazha P
; APPLICANT: Kawasaki, Andrew M
; TITLE OF INVENTION: Aminoxy-Modified Nucleosidic Compounds And Oligomeric
; FILE REFERENCE: ISI83993
; CURRENT APPLICATION NUMBER: US/09/370,541
; CURRENT FILING DATE: 1999-08-09
; EARLIER APPLICATION NUMBER: 09/130,973
; EARLIER FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 09/016,520
; EARLIER FILING DATE: 1998-01-30
; EARLIER APPLICATION NUMBER: 60/037,143
; EARLIER FILING DATE: 1997-02-14
; EARLIER APPLICATION NUMBER: 09/344,260
; EARLIER FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 21
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: antisense
; OTHER INFORMATION: sequence
US-09-370-541-21

Query Match          0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCA 35
Db 19 GAGCTCCTCTGCTACTCA 2

RESULT 660
US-09-546-596A-23/c
; Sequence 23, Application US/09546596A
; Patent No. 6753423
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip D.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
; ENHANCED BIOSTABILITY AND ALTERED BIODISTRIBUTION OF
; OLIGONUCLEOTIDES IN MAMMALS
; NUMBER OF SEQUENCES: 63
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. 6753423ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
```

```
/
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/546,596A
; FILING DATE: 10-Apr-2000
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Lucchi, Joseph
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2707
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 23:
US-09-546-596A-23

Query Match          0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 19 GCCTCGCTATGGCTCCCA 2

RESULT 661
US-08-117-363A-23/c
; Sequence 23, Application US/08117363A
; Patent No. 6783931
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: AMINE-DERIVATIZED NUCLEOSIDES AND
; TITLE OF INVENTION: OLIGONUCLEOSIDES
; NUMBER OF SEQUENCES: 23
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. 6783931ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/117,363A
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Lucchi, Joseph
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-1169
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
```

;
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-117-363A-23

Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
| | | | | | | | | | | | | | | | | | | | | |
Db 19 GCCTCGCTATGGCTCCCA 2

RESULT 662

US-10-192-437-2/c
; Sequence 2, Application US/10192437
; Patent No. 6828434
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. 6828434ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/192,437
; FILING DATE: 10-Jul-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/397,277A
; FILING DATE: 09-MAR-1995
; APPLICATION NUMBER: 07/943,516
; FILING DATE: 11-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumont, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1198
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 19
; OTHER INFORMATION: /note= "abasic, aldehydic
; species"
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-192-437-2

Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
| | | | | | | | | | | | | | | | | | | | | |
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 663

PCT-US93-08367A-2/c
; Sequence 2, Application PC/TUS9308367A
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and Norris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/08367A
; FILING DATE:
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumont, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1171
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 19
; OTHER INFORMATION: /note= "abasic, aldehydic
; OTHER INFORMATION: species"
PCT-US93-08367A-2

Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
| | | | | | | | | | | | | | | | | | | | | |
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 664

US-09-334-130-2/c
; Sequence 2, Application US/09334130
; Patent No. 6656730
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Drug-Conjugated Oligomeric Compounds
; FILE REFERENCE: ISIS3758
; CURRENT APPLICATION NUMBER: US/09/334,130
; CURRENT FILING DATE: 1999-06-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Oligonucleotide
; OTHER INFORMATION: Description of Artificial Sequence: No. 6656730el
; OTHER INFORMATION: Sequence
US-09-334-130-2

Query Match 0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCTCCTCTGCTACTCAGA 37
|||||
Db 18 GCTCCTCTGCTACTCAGA 1

RESULT 665
US-09-334-130-3/c
; Sequence 3, Application US/09334130
; Patent No. 6656730
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Drug-Conjugated Oligomeric Compounds
; FILE REFERENCE: ISIS3758
; CURRENT APPLICATION NUMBER: US/09/334,130
; CURRENT FILING DATE: 1999-06-15
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6656730el
; OTHER INFORMATION: Sequence
US-09-334-130-3

Query Match 0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCTCCTCTGCTACTCAGA 37
|||||
Db 18 GCTCCTCTGCTACTCAGA 1

RESULT 666
US-10-172-911-80
; Sequence 80, Application US/10172911
; Patent No. 6743909
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTPN12 EXPRESSION
; FILE REFERENCE: PTS-0016
; CURRENT APPLICATION NUMBER: US/10/172,911
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 123
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-172-911-80

Query Match 0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTGCAGT 2788
|||||
Db 3 CCCAGGCTGGAGTGCAGT 20

RESULT 667
US-09-594-387-2/c
; Sequence 2, Application US/09594387
; Patent No. 6762169
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Ligand-Conjugated Oligomeric Compounds
; FILE REFERENCE: ISIS4390
; CURRENT APPLICATION NUMBER: US/09/594,387
; CURRENT FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: USSN 09/334,130
; PRIOR FILING DATE: 1999-06-15
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Oligonucleotide
; OTHER INFORMATION: Description of Artificial Sequence: No. 6762169el Sequence
US-09-594-387-2

Query Match 0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCTCCTCTGCTACTCAGA 37
|||||
Db 18 GCTCCTCTGCTACTCAGA 1

RESULT 668
US-09-594-387-3/c
; Sequence 3, Application US/09594387
; Patent No. 6762169
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Ligand-Conjugated Oligomeric Compounds
; FILE REFERENCE: ISIS4390
; CURRENT APPLICATION NUMBER: US/09/594,387
; CURRENT FILING DATE: 2000-06-15
; PRIOR APPLICATION NUMBER: USSN 09/334,130
; PRIOR FILING DATE: 1999-06-15
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6762169el Sequence
US-09-594-387-3

Query Match 0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 20 GCTCCTCTGCTACTCAGA 37
|||||
Db 18 GCTCCTCTGCTACTCAGA 1

RESULT 669
US-09-018-584A-60
; Sequence 60, Application US/09018584A

Patent No. 6238863
GENERAL INFORMATION:
APPLICANT: Schumm, James W.
APPLICANT: Bacher, Jeffery W.
TITLE OF INVENTION: MATERIALS AND METHODS FOR
IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM
REPEAT DNA MARKERS
TITLE OF INVENTION: REPEAT DNA MARKERS
NUMBER OF SEQUENCES: 147
CORRESPONDENCE ADDRESS:
ADDRESSEE: Promega Corporation
STREET: 2800 Woods Hollow Road
CITY: Madison
STATE: Wisconsin
COUNTRY: U.S.A.
ZIP: 53711-5399
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb
COMPUTER: IBM compatible PC
OPERATING SYSTEM: Windows 95
SOFTWARE: Word 97 (DOS text format)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/018,584A
FILING DATE: 04-Feb-1998
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Grady J. Frenchick
REGISTRATION/DOCKET NUMBER: 16026.9180
TELEPHONE: (608) 257-3501
TELEFAX: (608) 257-2275
INFORMATION FOR SEQ ID NO: 60:
SEQUENCE CHARACTERISTICS:
LENGTH: 21
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-09-018-584A-60

Query Match 0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 3.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2837 CCTCCACCTCAGCTCCTGA 2857
|||||
Db 1 CCTCCATTTCAGCTCCTGA 21

RESULT 670
US-09-784-423-60
Sequence 60, Application US/09784423
Patent No. 6767703
GENERAL INFORMATION:
APPLICANT: Schumm, James W.
Bacher, Jeffery W.
TITLE OF INVENTION: MATERIALS AND METHODS FOR
IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM
REPEAT DNA MARKERS
NUMBER OF SEQUENCES: 147
CORRESPONDENCE ADDRESS:
ADDRESSEE: Promega Corporation
STREET: 2800 Woods Hollow Road
CITY: Madison
STATE: Wisconsin
COUNTRY: U.S.A.
ZIP: 53711-5399
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb
COMPUTER: IBM compatible PC
OPERATING SYSTEM: Windows 95
SOFTWARE: Word 97 (DOS text format)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/784,423

FILING DATE: 15-Feb-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/018,584
FILING DATE: 04-Feb-1998
ATTORNEY/AGENT INFORMATION:
NAME: Grady J. Frenchick
REGISTRATION/DOCKET NUMBER: 29,018
REFERENCE/DOCKET NUMBER: 16026.9180
TELECOMMUNICATION INFORMATION:
TELEPHONE: (608) 257-3501
TELEFAX: (608) 257-2275
INFORMATION FOR SEQ ID NO: 60:
SEQUENCE CHARACTERISTICS:
LENGTH: 21
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
SEQUENCE DESCRIPTION: SEQ ID NO: 60
US-09-784-423-60

Query Match 0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 3.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2837 CCTCCACCTCAGCTCCTGA 2857
|||||
Db 1 CCTCCATTTCAGCTCCTGA 21

RESULT 671
US-09-859-736-6
Sequence 6, Application US/09859736
Patent No. 6838244
GENERAL INFORMATION:
APPLICANT: LI, WAN-LIANG ROBERT
APPLICANT: ZHOU, JIAN S.
TITLE OF INVENTION: FLUORESCENT OLIGONUCLEOTIDES AND USES THEREOF
FILE REFERENCE: 16517-248
CURRENT APPLICATION NUMBER: US/09/859,736
CURRENT FILING DATE: 2001-05-18
PRIOR APPLICATION NUMBER: 60/205,452
PRIOR FILING DATE: 2000-05-19
NUMBER OF SEQ ID NOS: 7
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 6
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: dT oligonucleotide
US-09-859-736-6

Query Match 0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 3.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTTGATTTTTTTTTTTTTTTT 2918
|||||
Db 1 TTTTATTTTTTTTTTTTTTTT 21

RESULT 672
US-08-599-252-52/c
Sequence 52, Application US/08599252
Patent No. 5705343
GENERAL INFORMATION:
APPLICANT: DRAYNA, DENNIS T.
APPLICANT: FEDER, JOHN N.
APPLICANT: GNIKKE, ANDREAS
APPLICANT: KIMMEL, BRUCE E.
APPLICANT: THOMAS, WINSTON J.

APPLICANT: WOLFF, ROGER K.
TITLE OF INVENTION: METHOD TO DIAGNOSE HEREDITARY
TITLE OF INVENTION: HEMOCHROMATOSIS
NUMBER OF SEQUENCES: 124
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORRISON & FOERSTER
STREET: 2000 Pennsylvania Ave. N.W., Suite 5500
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20006-1888
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/599,252
FILING DATE: 09-FEB-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: MURASHIGE, KATE H.
REGISTRATION NUMBER: 29,959
REFERENCE/DOCKET NUMBER: 9053-0001.21
TELEPHONE: (202) 887-1500
TELEFAX: (202) 887-0763
TELEX: 90-4030
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-599-252-52

Query Match 0.6%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 3.2e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCCACCCAGGCTG 2779
|||||
Db 21 CTCACCTCTGTCTCCAGGCTG 1

RESULT 673
PCT-US96-06352-52/c
Sequence 52, Application PC/TUS9606352
GENERAL INFORMATION:
APPLICANT: DRAYNA, DENNIS T.
APPLICANT: FEDER, JOHN N.
APPLICANT: GNIKKE, ANDREAS
APPLICANT: KIMMEL, BRUCE E.
APPLICANT: THOMAS, WINSTON J.
APPLICANT: WOLFF, ROGER K.
TITLE OF INVENTION: METHOD TO DIAGNOSE HEREDITARY
TITLE OF INVENTION: HEMOCHROMATOSIS
NUMBER OF SEQUENCES: 124
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORRISON & FOERSTER
STREET: 2000 Pennsylvania Ave. N.W., Suite 5500
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20006-1888
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/06352
FILING DATE:

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/599,252
FILING DATE: 09-FEB-1996
ATTORNEY/AGENT INFORMATION:
NAME: MURASHIGE, KATE H.
REGISTRATION NUMBER: 29,959
REFERENCE/DOCKET NUMBER: 9053-0001.21
TELEPHONE: (202) 887-1500
TELEFAX: (202) 887-0763
TELEX: 90-4030
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US96-06352-52

Query Match 0.6%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 3.2e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCCACCCAGGCTG 2779
|||||
Db 21 CTCACCTCTGTCTCCAGGCTG 1

RESULT 674
PCT-US96-06583-52/c
Sequence 52, Application PC/TUS9606583
GENERAL INFORMATION:
APPLICANT: DRAYNA, DENNIS T.
APPLICANT: FEDER, JOHN N.
APPLICANT: GNIKKE, ANDREAS
APPLICANT: KIMMEL, BRUCE E.
APPLICANT: THOMAS, WINSTON J.
APPLICANT: WOLFF, ROGER K.
TITLE OF INVENTION: METHOD TO DIAGNOSE HEREDITARY
TITLE OF INVENTION: HEMOCHROMATOSIS
NUMBER OF SEQUENCES: 124
CORRESPONDENCE ADDRESS:
ADDRESSEE: MORRISON & FOERSTER
STREET: 2000 Pennsylvania Ave. N.W., Suite 5500
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20006-1888
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/06583
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/599,252
FILING DATE: 09-FEB-1996
ATTORNEY/AGENT INFORMATION:
NAME: MURASHIGE, KATE H.
REGISTRATION NUMBER: 29,959
REFERENCE/DOCKET NUMBER: 9053-0001.21
TELEPHONE: (202) 887-1500
TELEFAX: (202) 887-0763
TELEX: 90-4030
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 base pairs
TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
PCT-US96-06583-52

Query Match 0.6%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 3.2e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCACCCAGGCTG 2779
DB 21 CTCACCTCTGCTCCAGGCTG 1

RESULT 675

US-08-222-177A-442/c
Sequence 442, Application US/08222177A
Patent No. 5582979
GENERAL INFORMATION:
APPLICANT: Weber, James L.
TITLE OF INVENTION: LENGTH POLYMORPHISMS IN
TITLE OF INVENTION: (dC-dA)n.(dG-dT)n SEQUENCES AND METHODS OF USING SAME
NUMBER OF SEQUENCES: 460
CORRESPONDENCE ADDRESS:

ADDRESSEE: Dewitt Ross & Stevens, S.C.
STREET: 8000 Excelsior Drive, Suite 401
CITY: Madison
STATE: Wisconsin
COUNTRY: USA
ZIP: 53717-1914

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/222,177A
FILING DATE:

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/341,562
FILING DATE: 21-APR-1989
ATTORNEY/AGENT INFORMATION:
NAME: Sara, Charles S.
REGISTRATION NUMBER: 30,492
REFERENCE/DOCKET NUMBER: 09865.601
TELECOMMUNICATION INFORMATION:
TELEPHONE: (608) 831-2100
TELEFAX: (608) 831-2106
TELEX:

INFORMATION FOR SEQ ID NO: 442:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-222-177A-442

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
DB 19 TGTGTGTGTGTGTGTGTGT 1

RESULT 676

US-08-196-003-7
Sequence 7, Application US/08196003
Patent No. 5681699
GENERAL INFORMATION:
APPLICANT: BEAUDET M.D., AURTHUR L

APPLICANT: ROTTER M.D., JEROME I
APPLICANT: TARGAN M.D., STEPHAN R
APPLICANT: VORA M.D., DEVENDRA
APPLICANT: YANG M.D., HUIYING
TITLE OF INVENTION: METHODS OF SCREENING FOR ULCERATIVE
TITLE OF INVENTION: COLITIS AND CROHN'S DISEASE
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:

ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
STREET: 444 SOUTH FLOWER STREET, SUITE 2000
CITY: LOS ANGELES
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/196,003
FILING DATE: 11-FEB-1994
CLASSIFICATION: 424

ATTORNEY/AGENT INFORMATION:
NAME: WHITEFORD ESQ, WENDY A
REGISTRATION NUMBER: 36,964
REFERENCE/DOCKET NUMBER: P07 32056
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-4442
TELEFAX: (213) 489-4210

INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-196-003-7

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 769 TCCCTGGACGGCTGTTC 787
DB 1 TCCCTGGACGGCTGTTC 19

RESULT 677

US-08-689-870-9
Sequence 9, Application US/08689870
Patent No. 5874233
GENERAL INFORMATION:
APPLICANT: Targan, Stephan R.
APPLICANT: Vasiliaskas, Eric A.
APPLICANT: Plevy, Scott E.
APPLICANT: Yang, Huiying
APPLICANT: Rotter, Jerome I.

TITLE OF INVENTION: Methods of Diagnosing a Clinical Subtype
TITLE OF INVENTION: of Crohn's Disease with Features of Ulcerative Colitis
NUMBER OF SEQUENCES: 12
CORRESPONDENCE ADDRESS:

ADDRESSEE: Campbell & Flores LLP
STREET: 4370 La Jolla Village Drive, Suite 700
CITY: San Diego
STATE: California
COUNTRY: United States
ZIP: 92122

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25

```
;
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/689,870
; FILING DATE: 15-AUG-1996
; CLASSIFICATION: 436
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-CE 2224
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-689-870-9

Query Match      0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 769 TCCTGGACGGCTGTTC 787
Db 1 TCCTGGACGGCTGTTC 19

RESULT 678
US-08-689-873-9
; Sequence 9, Application US/08689873
; Patent No. 5916748
; GENERAL INFORMATION:
; APPLICANT: Targan, Stephan R.
; APPLICANT: Vasiliauskas, Eric A.
; APPLICANT: Plevy, Scott E.
; APPLICANT: Yang, Huiying
; APPLICANT: Rotter, Jerome I.
; TITLE OF INVENTION: METHODS OF DIAGNOSING A CLINICAL SUBTYPE
; TITLE OF INVENTION: OF CROHN'S DISEASE WITH FEATURES OF ULCERATIVE COLITIS
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pretty, Schroeder & Poplawski
; STREET: 444 S. Flower Street, Suite 2000
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
;
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/689,873
FILING DATE: 15-AUG-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/630,672
FILING DATE: 12-APR-1996
ATTORNEY/AGENT INFORMATION:
NAME: Fujita, Sharon M.
REGISTRATION NUMBER: 38,459
REFERENCE/DOCKET NUMBER: P07 37278
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 622-7700
TELEFAX: (213) 489-4210
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
;
```

```
;
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
;
US-08-689-873-9

Query Match      0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 769 TCCTGGACGGCTGTTC 787
Db 1 TCCTGGACGGCTGTTC 19

RESULT 679
US-08-849-021-74
; Sequence 74, Application US/08849021
; Patent No. 5955276
; GENERAL INFORMATION:
; APPLICANT: MORGANTE, MICHELE
; APPLICANT: VOGEL, JULIE M.
; TITLE OF INVENTION: COMPOUND MICROSATELLITE
; TITLE OF INVENTION: PRIMERS FOR THE
; TITLE OF INVENTION: DETECTION OF GENETIC
; TITLE OF INVENTION: POLYMORPHISMS
; NUMBER OF SEQUENCES: 89
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: E. I. DU PONT DE NEMOURS AND
; ADDRESSEE: COMPANY
; STREET: 1007 MARKET STREET
; CITY: WILMINGTON
; STATE: DELAWARE
; COUNTRY: U.S.A.
; ZIP: 19898
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PATENT IN RELEASE #1.0, VERSION 1.25
;
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/849,021
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/346,456
FILING DATE: 28 NOVEMBER 1994
ATTORNEY/AGENT INFORMATION:
NAME: FLOYD, LINDA AXAMETHY
REGISTRATION NUMBER: 33,692
REFERENCE/DOCKET NUMBER: BB-1064-A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 302-892-8112
TELEFAX: 302-992-7949
INFORMATION FOR SEQ ID NO: 74:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
;
US-08-849-021-74

Query Match      0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTATGT 2747
Db 1 TGTGTGTGTGTGTATAT 19

RESULT 680
US-08-933-824-7
; Sequence 7, Application US/08933824
;
```

; Patent No. 6008335
; GENERAL INFORMATION:
; APPLICANT: BEAUDET M.D., ARTHUR L
; APPLICANT: ROTTER M.D., JEROME I
; APPLICANT: TARGAN M.D., STEPHAN R
; APPLICANT: VORA M.D., DEVENDRA
; APPLICANT: YANG M.D., HUIYING
; TITLE OF INVENTION: METHODS OF SCREENING FOR ULCERATIVE
; TITLE OF INVENTION: COLITIS AND CROHN'S DISEASE
; NUMBER OF SEQUENCES: 7
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
; STREET: 444 SOUTH FLOWER STREET, SUITE 2000
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/933,824
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/196,003
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: WHITEFORD ESQ. WENDY A
; REGISTRATION NUMBER: 36,964
; REFERENCE/DOCKET NUMBER: P07 32056
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-4442
; TELEFAX: (213) 489-4210
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-933-824-7

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 769 TCCTGGACGGCTGTTC 787
Db 1 TCCTGGACGGCTGTTC 19

RESULT 681
US-08-915-609-3/c
; Sequence 3, Application US/08915609
; Patent No. 6054300
; GENERAL INFORMATION:
; APPLICANT: McKendree Jr., William L.
; TITLE OF INVENTION: Single-Site Amplification (SSA) Method for Accelerated
; TITLE OF INVENTION: Development of Nucleic Acid Marker
; FILE REFERENCE: 0115,97
; CURRENT APPLICATION NUMBER: US/08/915,609
; CURRENT FILING DATE: 1997-08-21
; EARLIER APPLICATION NUMBER: 60/028,775
; EARLIER FILING DATE: 1996-08-23
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.0 - beta
; SEQ ID NO 3
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence

; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
; FEATURE:
; NAME/KEY: primer bind
; LOCATION: (1)..(19)
; FEATURE:
; NAME/KEY: primer bind
; LOCATION: (1)..(19)
US-08-915-609-3

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATG 2746
Db 1 GTGTGTGTGTGTGTGTG 1

RESULT 682
US-08-915-609-4
; Sequence 4, Application US/08915609
; Patent No. 6054300
; GENERAL INFORMATION:
; APPLICANT: McKendree Jr., William L.
; TITLE OF INVENTION: Single-Site Amplification (SSA) Method for Accelerated
; TITLE OF INVENTION: Development of Nucleic Acid Marker
; FILE REFERENCE: 0115,97
; CURRENT APPLICATION NUMBER: US/08/915,609
; CURRENT FILING DATE: 1997-08-21
; EARLIER APPLICATION NUMBER: 60/028,775
; EARLIER FILING DATE: 1996-08-23
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.0 - beta
; SEQ ID NO 4
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
; FEATURE:
; NAME/KEY: primer bind
; LOCATION: (1)..(19)
; FEATURE:
; NAME/KEY: primer bind
; LOCATION: (1)..(19)
US-08-915-609-4

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATG 2746
Db 1 GTGTGTGTGTGTGTGTG 19

RESULT 683
US-09-366-840-2
; Sequence 2, Application US/09366840
; Patent No. 6228345
; GENERAL INFORMATION:
; APPLICANT: Ossowski, Liliana
; TITLE OF INVENTION: In Vivo Assay for Intravasation
; FILE REFERENCE: A32590 70165.0550
; CURRENT APPLICATION NUMBER: US/09/366,840
; CURRENT FILING DATE: 1999-08-04
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Human

US-09-366-840-2

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2768 TCACCCAGGCTGGAGTGCA 2786
Db 1 TCGCCAGGCTGGAGTGCA 19

RESULT 684

US-09-264-466-7

; Sequence 7, Application US/09264466
; Patent No. 6235889

GENERAL INFORMATION:

APPLICANT: BEAUDET M.D., AURTHUR L
; ROTTER M.D., JEROME I
; TARGAN M.D., STEPHAN R
; VORA M.D., DEVENDRA
; YANG M.D., HUIYING

TITLE OF INVENTION: METHODS OF SCREENING FOR ULCERATIVE
; COLITIS AND CROHN'S DISEASE

NUMBER OF SEQUENCES: 7

CORRESPONDENCE ADDRESS:

ADDRESSEE: PRETTY, SCHROEDER, BRUEGEMANN & CLARK
; STREET: 444 SOUTH FLOWER STREET, SUITE 2000
; CITY: LOS ANGELES
; STATE: CALIFORNIA
; COUNTRY: USA

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/264,466

FILING DATE: 08-Mar-1999

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/196,003

FILING DATE: 11-FEB-1994

ATTORNEY/AGENT INFORMATION:

NAME: WHITEFORD ESQ, WENDY A

REGISTRATION NUMBER: 36,964

REFERENCE/DOCKET NUMBER: P07 32056

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-4442

TELEFAX: (213) 489-4210

INFORMATION FOR SEQ ID NO: 7:

SEQUENCE CHARACTERISTICS:

LENGTH: 19 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

SEQUENCE DESCRIPTION: SEQ ID NO: 7:

US-09-264-466-7
Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 769 TCCTGGAGGGCTGTTC 787
Db 1 TCCTGGAGGGCTGTTC 19

RESULT 685

US-09-091-952A-86/c

; Sequence 86, Application US/09091952A

; Patent No. 6458532

GENERAL INFORMATION:

APPLICANT: Detera-Wadleigh, Sevilla D.

Gershon, Elliot S.

Badner, Judith A.

Goldin, Lynn R.

Berrettini, Wade H.

Yoshikawa, Takeo

Sanders, Alan R.

Esterling, Lisa E.

TITLE OF INVENTION: Chromosomal Markers and Diagnostic
; Tests for Manic-Depressive Illness

NUMBER OF SEQUENCES: 197

CORRESPONDENCE ADDRESS:

ADDRESSEE: Townsend and Townsend and Crew LLP

STREET: Two Embarcadero Center, Eighth Floor

CITY: San Francisco

STATE: CA

COUNTRY: USA

ZIP: 94111-3834

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FastSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/091,952A

FILING DATE: 19-Apr-1999

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 60/029,278

FILING DATE: 28-OCT-1996

APPLICATION NUMBER: PCT/US97/19381

FILING DATE: 28-OCT-1997

ATTORNEY/AGENT INFORMATION:

NAME: Smith, Timothy L.

REGISTRATION NUMBER: 35,367

REFERENCE/DOCKET NUMBER: 015280-297100US

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 576-0200

TELEFAX: (415) 576-0300

TELEX: <Unknown>

INFORMATION FOR SEQ ID NO: 86:

SEQUENCE CHARACTERISTICS:

LENGTH: 19 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA

FEATURE:

NAME/KEY: -

LOCATION: 1...19

OTHER INFORMATION: D18S378 forward primer

SEQUENCE DESCRIPTION: SEQ ID NO: 86:

US-09-091-952A-86

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 4e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTCTACCCAGGCT 2778
Db 19 TTGCTCTGTCTACCCAGGCT 1

RESULT 686

US-08-849-021-89/c

; Sequence 89, Application US/08849021

; Patent No. 5955276

GENERAL INFORMATION:

APPLICANT: MORGANTE, MICHELE

APPLICANT: VOGEL, JULIE M.

TITLE OF INVENTION: COMPOUND MICROSATELLITE

TITLE OF INVENTION: PRIMERS FOR THE

;; TITLE OF INVENTION: DETECTION OF GENETIC
;; TITLE OF INVENTION: POLYMORPHISMS
;; NUMBER OF SEQUENCES: 89
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: E. I. DU PONT DE NEMOURS AND
;; ADDRESSEE: COMPANY
;; STREET: 1007 MARKET STREET
;; CITY: WILMINGTON
;; STATE: DELAWARE
;; COUNTRY: U.S.A.
;; ZIP: 19898
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: FLOPPY DISK
;; COMPUTER: IBM PC COMPATIBLE
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PATENT IN RELEASE #1.0, VERSION 1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/849,021
;; FILING DATE:
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/346,456
;; FILING DATE: 28 NOVEMBER 1994
;; ATTORNEY/AGENT INFORMATION:
;; NAME: FLOYD, LINDA AXAMETHY
;; REGISTRATION NUMBER: 33,692
;; REFERENCE/DOCKET NUMBER: BB-1064-A
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 302-892-8112
;; TELEFAX: 302-992-7949
;; INFORMATION FOR SEQ ID NO: 89:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; US-08-849-021-89

Query Match 0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 3.8e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
|||||

Db 20 TGTGTGTGTGTGTGTATAT 2

RESULT 687
US-09-435-296-72/c
; Sequence 72, Application US/09435296
; Patent No. 6171860
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF RANK EXPRESSION
; FILE REFERENCE: RTS-0116
; CURRENT APPLICATION NUMBER: US/09/435,296
; CURRENT FILING DATE: 1999-11-05
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-435-296-72

Query Match 0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 3.8e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2775 GGCTGAGTGCAGTGTGTC 2793

Db 20 GGCTAGAGTGCAGTGTGC 2
|||||

RESULT 688
US-09-487-445-94/c
; Sequence 94, Application US/09487445
; Patent No. 6258600
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 8 EXPRESSION
; FILE REFERENCE: RTS-0107
; CURRENT APPLICATION NUMBER: US/09/487,445
; CURRENT FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-487-445-94

Query Match 0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 3.8e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 AGCTGGAGTGCAGTGTG 2792
|||||

Db 20 AGCTGGAGTGCAGTGTGCG 2

RESULT 689
US-09-314-246-1
; Sequence 1, Application US/09314246
; Patent No. 6180349
; GENERAL INFORMATION:
; APPLICANT: Ginzinger, David G.
; APPLICANT: Godfrey, Tony E.
; APPLICANT: Jensen, Ronald H.
; APPLICANT: Gray, Joe W.
; APPLICANT: The Regents of the University of California
; TITLE OF INVENTION: A Quantitative PCR Method to Enumerate DNA Copy Number
; FILE REFERENCE: 2307AA-096200US
; CURRENT APPLICATION NUMBER: US/09/314,246
; CURRENT FILING DATE: 1999-05-18
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: TM-TaqMan
; OTHER INFORMATION: dual-labeled fluorogenic oligonucleotide probe
; OTHER INFORMATION: complementary to amplification products of
; OTHER INFORMATION: CA-repeat
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: 5'-t attached to 6-carboxy fluorescein (FAM)
; NAME/KEY: modified_base
; LOCATION: (21)
; OTHER INFORMATION: 3'-t attached to 6-carboxy tetramethyl rhodamine
; OTHER INFORMATION: (TAMRA)
US-09-314-246-1

Query Match 0.6%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATG 2746
|||||

```
Db      2 GTGTGTGTGTGTGTGTG 20

RESULT 690
US-09-314-246-2
; Sequence 2, Application US/09314246
; Patent No. 6180349
; GENERAL INFORMATION:
; APPLICANT: Ginzinger, David G.
; APPLICANT: Godfrey, Tony E.
; APPLICANT: Jensen, Ronald H.
; APPLICANT: Gray, Joe W.
; APPLICANT: The Regents of the University of California
; TITLE OF INVENTION: A Quantitative PCR Method to Enumerate DNA Copy Number
; FILE REFERENCE: 2307AA-096200US
; CURRENT APPLICATION NUMBER: US/09/314,246
; CURRENT FILING DATE: 1999-05-18
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:TM-TaqMan
; OTHER INFORMATION: dual-labeled fluorogenic oligonucleotide probe
; OTHER INFORMATION: complementary to amplification products of
; OTHER INFORMATION: CA-repeat
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: 5'-t attached to reporter dye
; NAME/KEY: modified_base
; LOCATION: (21)
; OTHER INFORMATION: 3'-t attached to quenching dye
US-09-314-246-2

Query Match      0.6%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred.No. 3.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2728 GTGTGTGTGTGTGTGTG 2746
          |||||
Db      2 GTGTGTGTGTGTGTGTG 20

RESULT 691
US-09-085-759-94/c
; Sequence 94, Application US/09085759
; Patent No. 6096722
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett, Christopher Mirabelli,
; APPLICANT: Brenda Baker
; TITLE OF INVENTION: Antisense Modulation of Cell Adhesion
; TITLE OF INVENTION: Molecule Expression and Treatment of Cell Adhesion
; TITLE OF INVENTION: Molecule-Associated Diseases
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PS/2
; OPERATING SYSTEM: PC-DOS
; SOFTWARE: WORDPERFECT 5.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/085,759
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/440,740
; FILING DATE: May 12, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 063,167
; FILING DATE: May 17, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 969,151
; FILING DATE: February 10, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 007,997
; FILING DATE: January 20, 1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 939,855
; FILING DATE: September 2, 1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 567,286
; FILING DATE: August 14, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0311
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 94:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
US-09-085-759-94

Query Match      0.6%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred.No. 4.6e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1412 AGGGCACCTACCTCTGT 1428
          |||||
Db      18 AGGGCACCTACCTCTGT 2

RESULT 692
US-08-670-479-12/c
; Sequence 12, Application US/08670479
; Patent No. 5973133
; GENERAL INFORMATION:
; APPLICANT: Hardy, John A.
; APPLICANT: Goate, Alison M.
; TITLE OF INVENTION: MUTANT S182 GENES
; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SmithKline Beecham Corporation
; STREET: 709 Swedeland Road
; CITY: King of Prussia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19406-0939
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: Fast-Seq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/670,479
; FILING DATE: 26-JUN-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,500
; FILING DATE: 18-JUL-1996
; APPLICATION NUMBER: 60/001,800
; FILING DATE: 02-AUG-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Han, William T
```

REGISTRATION NUMBER: 34,344
REFERENCE/DOCKET NUMBER: P50361
TELECOMMUNICATION INFORMATION:
TELEPHONE: 610-270-5219
TELEFAX: 610-270-5090
TELEX:
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
FRAGMENT TYPE:
ORIGINAL SOURCE:
US-08-670-479-12

Query Match 0.6%; Score 17; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 4.4e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2779 GGAGTGCAGTGGTGCATC 2797
|||||:||||:||||:
Db 19 GGAGTGCATGGYRATC 1

RESULT 693
US-08-361-858-14/c
; Sequence 14, Application US/08361858
; Patent No. 5834607
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; TITLE OF INVENTION: MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5834607ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/361,858
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/943,516
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumond, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-0484
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 18
; OTHER INFORMATION: /note="2'deoxyuridine
; OTHER INFORMATION: residue"
US-08-361-858-14

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCA 67
|||||:|||||:|||||:
Db 17 CCTCGCTATGGCTCCCA 1

RESULT 694
US-08-397-277A-14/c
; Sequence 14, Application US/08397277A
; Patent No. 6235886
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; TITLE OF INVENTION: MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 6235886ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/397,277A
; FILING DATE: 09-MAR-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/943,516
; FILING DATE: 11-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumond, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1198
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 18
; OTHER INFORMATION: /note="2'deoxyuridine
; OTHER INFORMATION: residue"
US-08-397-277A-14

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCA 67
|||||:|||||:|||||:
Db 17 CCTCGCTATGGCTCCCA 1

RESULT 695
US-09-689-964-14/c
; Sequence 14, Application US/09689964
; Patent No. 6399757

;
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. 639571ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/689,964
; FILING DATE: 12-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/397,277
; FILING DATE: 09-MAR-1995
; APPLICATION NUMBER: 07/943,516
; FILING DATE: 11-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumond, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1198
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 18
; OTHER INFORMATION: /note= "2'deoxyuridine
; residue"
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-689-964-14

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 51 CCTCGCTATGGCTCCCA 67
Db 17 CCTCGCTATGGCTCCCA 1

RESULT 696
US-09-689-964-14/c
; Sequence 14, Application US/09689964
; Patent No. 6495671
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. 6495671ris
; STREET: One Liberty Place - 46th Floor

;
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/689,964
; FILING DATE: 12-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/397,277
; FILING DATE: 09-MAR-1995
; APPLICATION NUMBER: 07/943,516
; FILING DATE: 11-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumond, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1198
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 18
; OTHER INFORMATION: /note= "2'deoxyuridine
; residue"
; SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-09-689-964-14

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 51 CCTCGCTATGGCTCCCA 67
Db 17 CCTCGCTATGGCTCCCA 1

RESULT 697
US-10-192-437-14/c
; Sequence 14, Application US/10192437
; Patent No. 6828434
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. 6828434ria
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:

```
/
/ APPLICATION NUMBER: US/10/192,437
/ FILING DATE: 10-Jul-2002
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/08/397,277A
/ FILING DATE: 09-MAR-1995
/ APPLICATION NUMBER: 07/943,516
/ FILING DATE: 11-SEP-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Gaumont, Rebecca R.
/ REGISTRATION NUMBER: 35,152
/ REFERENCE/DOCKET NUMBER: ISIS-1198
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 215-568-3100
/ TELEFAX: 215-568-3439
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: 18
/ OTHER INFORMATION: /note= "2'-deoxyuridine
/ residue"
/ SEQUENCE DESCRIPTION: SEQ ID NO: 14:
US-10-192-437-14

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCA 67
DB 17 CCTCGCTATGGCTCCCA 1

RESULT 698
PCT-US93-08367A-14/c
/ Sequence 14, Application PC/TUS9308367A
/ GENERAL INFORMATION:
/ APPLICANT: Manoharan, Mathiah
/ APPLICANT: Phillip D. Cook
/ TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
/ MAKING AND USING THE SAME
/ NUMBER OF SEQUENCES: 16
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
/ ADDRESS: One Liberty Place - 46th Floor
/ CITY: Philadelphia
/ STATE: PA
/ COUNTRY: U.S.A.
/ ZIP: 19103
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: PCT/US93/08367A
/ FILING DATE:
/ CLASSIFICATION:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Gaumont, Rebecca R.
/ REGISTRATION NUMBER: 35,152
/ REFERENCE/DOCKET NUMBER: ISIS-1171
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 215-568-3100
/ TELEFAX: 215-568-3439
/ INFORMATION FOR SEQ ID NO: 14:
```

```
/
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: 18
/ OTHER INFORMATION: /note= "2'-deoxyuridine
/ residue"
/ SEQUENCE DESCRIPTION: SEQ ID NO: 14:
PCT-US93-08367A-14

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.2e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCCA 67
DB 17 CCTCGCTATGGCTCCCA 1

RESULT 699
US-07-952-442-19/c
/ Sequence 19, Application US/07952442
/ Patent No. 5374525
/ GENERAL INFORMATION:
/ APPLICANT: Lalouel, Jean-Marc
/ APPLICANT: Jeunemaitre, Xavier
/ APPLICANT: Lifton, Richard P.
/ APPLICANT: Soubrier, Florent
/ APPLICANT: Kotelevtsev, Youri
/ APPLICANT: Corval, Pierre
/ TITLE OF INVENTION: Angiotensinogen Gene Variants and
/ DISPOSITION TO ESSENTIAL HYPERTENSION
/ NUMBER OF SEQUENCES: 22
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Venable, Baetjer, Howard & Civiletti
/ STREET: 1201 New York Avenue N.W., Suite 1000
/ CITY: Washington
/ STATE: DC
/ ZIP: 20005
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/07/952,442
/ FILING DATE: 19920930
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Ihnen, Jeffrey L.
/ REGISTRATION NUMBER: 28,957
/ REFERENCE/DOCKET NUMBER: 19780-104502
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 202-962-4810
/ TELEX: 202-962-8300
/ INFORMATION FOR SEQ ID NO: 19:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: NUCLEIC ACID
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ HYPOTHETICAL: NO
/ ANTI-SENSE: NO
/ ORIGINAL SOURCE:
/ ORGANISM: Homo sapiens
US-07-952-442-19

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
```


Qy	2769	CACCCAGGCTGGAGTGCAGT	2788
D _b	20	CTCCGAGGCTGGAGTGCAGT	1

RESULT 702
US-08-319-545A-19/c
; Sequence 19, Application US/08319545A
; Patent No. 5763168
; GENERAL INFORMATION:
; APPLICANT: Lalouel, Jean-Marc
; APPLICANT: Jeunemaitre, Xavier
; APPLICANT: Lifton, Richard P.
; APPLICANT: Soubrier, Florent
; APPLICANT: Kotelevtsev, Youri
; APPLICANT: Corvol, Pierre
; TITLE OF INVENTION: Method to Determine Predisposition
; TITLE OF INVENTION: to Hypertension
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti
; STREET: 1201 New York Avenue N.W., Suite 1000
; CITY: Washington
; STATE: DC
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Wordperfect 5.1/5.2 Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,545A
; FILING DATE: 7-OCT-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/952,442
; FILING DATE: 30-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 19780-104502-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-4810
; TELEX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
US-08-319-545A-19

RESULT 703
US-08-480-655-5
; Sequence 5, Application US/08480655
; Patent No. 5998133
; GENERAL INFORMATION:
; APPLICANT: BLUMENFELD, ANAT; GUSELLA, JAMES F;
; APPLICANT: BREAKFIELD, XANDRA, O;
;

APPLICANT: SLAUGENHAUPT, SUSAN
 TITLE OF INVENTION: USE OF GENETIC MARKERS TO
 TITLE OF INVENTION: DIAGNOSE FAMILIAL DYSAUTONOMIA
 NUMBER OF SEQUENCES: 34
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
 STREET: 345 PARK AVENUE
 CITY: NEW YORK
 STATE: NEW YORK
 COUNTRY: USA
 ZIP: 10154
 COMPUTER READABLE FORM:
 MEDIUM TYPE: FLOPPY DISK
 COMPUTER: IBM PC COMPATIBLE
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: ASCII
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/480,655
 FILING DATE: 07-JUNE-1995
 CLASSIFICATION: 435
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 08/049,678
 FILING DATE: 16-APRIL-1993
 CLASSIFICATION: 435
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: US/07/890,719
 FILING DATE: 29-MAY-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: KENNETH H. SONNENFELD
 REGISTRATION NUMBER: 33,285
 REFERENCE/DOCKET NUMBER: 1829-4001US1
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 212-451-8513
 TELEFAX: 212-751-6849
 INFORMATION FOR SEQ ID NO: 5:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 20
 TYPE: NUCLEIC ACID
 STRANDEDNESS: SINGLE
 TOPOLOGY: UNKNOWN
 MOLECULE TYPE: OLIGONUCLEOTIDE
 HYPOTHETICAL: NO
 FEATURE:
 NAME/KEY: PRIMER SEQUENCE FOR D9S58 LOCUS
 LOCATION: CHROMOSOME 9
 IDENTIFICATION METHOD:
 OTHER INFORMATION:
 PUBLICATION INFORMATION:
 AUTHORS: KWIAKOWSKI, DAVID J;
 AUTHORS: HENSKE, ELIZABETH P; WEIMER, KIM;
 AUTHORS: OZELIUS, LAURIE; GUSELLA, JAMES J;
 AUTHORS: HAINES, JONATHAN
 TITLE: CONSTRUCTION OF A GT POLYMORPHISM
 TITLE: MAP OF HUMAN 9Q
 JOURNAL: GENOMICS
 VOLUME: 12
 ISSUE:
 PAGES: 229-240
 DATE: 1992
 DOCUMENT NUMBER:
 FILING DATE:
 PUBLICATION DATE:
 RELEVANT RESIDUES IN SEQ ID NO:
 US-08-480-655-5

```
RESULT 704
US-09-092-988-19/c
; Sequence 19, Application US/09092988
; Patent No. 5998145
; GENERAL INFORMATION:
; APPLICANT: Lalouel, Jean-Marc
; APPLICANT: Jeunemaitre, Xavier
; APPLICANT: Lifton, Richard P.
; APPLICANT: Soubrier, Florent
; APPLICANT: Kotelevtsev, Youri
; APPLICANT: Corvol, Pierre
; TITLE OF INVENTION: Method to Determine Predisposition
; TITLE OF INVENTION: to Hypertension
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Venable, Baetjer, Howard & Civiletti
; STREET: 1201 New York Avenue N.W., Suite 1000
; CITY: Washington
; STATE: DC
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1/5.2 Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/092,988
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/319,545
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Ihnen, Jeffrey L.
; REGISTRATION NUMBER: 28,957
; REFERENCE/DOCKET NUMBER: 19780-104502-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-962-4810
; TELEX: 202-962-8300
; INFORMATION FOR SEQ ID NO: 19:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
US-09-092-988-19

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTGCAGT 2788
Db 20 CTCGAGGCTGGAGTGCAGT 1

RESULT 705
US-09-289-267-162/c
; Sequence 162, Application US/09289267A
; Patent No. 6046320
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF MDMX EXPRESSION
; FILE REFERENCE: RTS-0049
; CURRENT APPLICATION NUMBER: US/09/289,267A
; CURRENT FILING DATE: 1999-04-04
```

```
; NUMBER OF SEQ ID NOS: 166
; SEQ ID NO 162
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-289-267-162

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2764 TCTGTCAACCAGGCTGGAGT 2783
Db 20 TCTGTCTCCAGGCTGAAGT 1

RESULT 706
US-09-289-267-164
; Sequence 164, Application US/09289267A
; Patent No. 6046320
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF MDMX EXPRESSION
; FILE REFERENCE: RTS-0049
; CURRENT APPLICATION NUMBER: US/09/289,267A
; CURRENT FILING DATE: 1999-04-04
; NUMBER OF SEQ ID NOS: 166
; SEQ ID NO 164
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-289-267-164

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2776 GCTGGAGTGCAGTGGTGCAG 2795
Db 1 GCTGGAGTGCAGTGGTGCAG 20

RESULT 707
US-09-009-913-230/c
; Sequence 230, Application US/09009913
; Patent No. 6087485
; GENERAL INFORMATION:
; APPLICANT: Axy's Pharmaceuticals, Inc.
; TITLE OF INVENTION: Asthma Related Genes
; NUMBER OF SEQUENCES: 339
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bozicevic & Reed, LLP
; STREET: 285 Hamilton Ave, Suite 200
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,913
; FILING DATE: 21-JAN-1998
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
```

Query Match 0.6%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTGCACT 2788
| | | | | | | | | | | | | | | | | | | | | |
Db 20 CTCGAGGCTGGAGTGCACT 1

RESULT 710

US-09-280-805-241/c
; Sequence 241, Application US/09280805
; Patent No. 6184212
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PC
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/280,805
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/048,810
; FILING DATE: March 26, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Licata, Jane Massey
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0346
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-810-1515
; TELEFAX: 609-810-1454
; INFORMATION FOR SEQ ID NO: 241:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTACCCAGGCTG 2779
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TTGCTCTGTATACCCAGGCTG 1

RESULT 711

US-09-280-805-264/c
; Sequence 264, Application US/09280805
; Patent No. 6184212
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PC
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/280,805
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/048,810
; FILING DATE: March 26, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Licata, Jane Massey
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0346
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-810-1515
; TELEFAX: 609-810-1454
; INFORMATION FOR SEQ ID NO: 264:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes

US-09-280-805-264
Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2833 TGATCCTCCACCTCAGCCT 2852
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TGATCCTCCACCTCAGCCT 1

RESULT 712

US-09-038-637-135/c
; Sequence 135, Application US/09038637
; Patent No. 6235470
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: DETECTION OF NEOPLASIM BY ANALYSIS OF SALIVA
; NUMBER OF SEQUENCES: 195
; CORRESPONDENCE ADDRESS:
; ADDRESSES: Fish & Richardson P.C.
; STREET: 4225 Executive Square, Suite 1400
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: FastSEQ for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,637
; FILING DATE: 10-MAR-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/579,233
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/152,313
; FILING DATE: 12-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Haile, Lisa A.

REGISTRATION NUMBER: 38,347
REFERENCE/DOCKET NUMBER: 07265/146001
TELEPHONE: 619/678-5070
TELEFAX: 619/678-5099

INFORMATION FOR SEQ ID NO: 135:

SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: Genomic DNA

US-09-038-637-135

Query Match 0.6%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 4.4e+02;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCAACCCAGGCT 2778

|||||
20 CTGCTTTGTCAACCCAGGCT 1

RESULT 713

US-09-038-637-143/c

Sequence 143, Application US/09038637

Patent No. 6235470

GENERAL INFORMATION:

APPLICANT: Sidransky, David

TITLE OF INVENTION: DETECTION OF NEOPLASIM BY ANALYSIS OF SALIVA

NUMBER OF SEQUENCES: 195

CORRESPONDENCE ADDRESS:

ADDRESSEE: Fish & Richardson P.C.

STREET: 4225 Executive Square, Suite 1400

CITY: La Jolla

STATE: CA

COUNTRY: USA

ZIP: 92037

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: Windows 95

SOFTWARE: FastSeq for Windows Version 2.0b

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/038,637

FILING DATE: 10-MAR-1998

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/579,233

FILING DATE: 28-DEC-1995

APPLICATION NUMBER: 08/152,313

FILING DATE: 12-NOV-1993

ATTORNEY/AGENT INFORMATION:

NAME: Halle, Lisa A.

REGISTRATION NUMBER: 38,347

REFERENCE/DOCKET NUMBER: 07265/146001

TELEPHONE: 619/678-5070

TELEFAX: 619/678-5099

INFORMATION FOR SEQ ID NO: 143:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Genomic DNA

US-09-038-637-143

Query Match 0.6%; Score 16.8; DB 1; Length 20;

Best Local Similarity 90.0%; Pred. No. 4.4e+02;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2776 GCTGGAGTGTAGTGGTGCAA 2795

|||||

Db 20 GCTGGAGTATAGTGGTGCAA 1

RESULT 714

US-09-455-683-5

Sequence 5, Application US/09455683

Patent No. 6262250

GENERAL INFORMATION:

APPLICANT: BLUMENFELD, ANAT; GUSELLA, JAMES F;

BREKKEFIELD, XANDRA, O;

SLAUGENHAUPT, SUSAN

TITLE OF INVENTION: USE OF GENETIC MARKERS TO

DIAGNOSE FAMILIAL DYSAUTONOMIA

NUMBER OF SEQUENCES: 34

CORRESPONDENCE ADDRESS:

ADDRESSER: MORGAN & FINNEGAN, L.L.P.

STREET: 345 PARK AVENUE

CITY: NEW YORK

STATE: NEW YORK

COUNTRY: USA

ZIP: 10154

COMPUTER READABLE FORM:

MEDIUM TYPE: FLOPPY DISK

COMPUTER: IBM PC COMPATIBLE

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: ASCII

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/455,683

FILING DATE: 07-DEC-1999

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/480,655

FILING DATE: 07-JUNE-1995

APPLICATION NUMBER: 08/049,678

FILING DATE: 16-APRIL-1993

APPLICATION NUMBER: US/07/890,719

FILING DATE: 29-MAY-1992

ATTORNEY/AGENT INFORMATION:

NAME: KENNETH H. SONNENFELD

REGISTRATION NUMBER: 33,285

REFERENCE/DOCKET NUMBER: 1829-4001US2

TELEPHONE: 212-451-8513

TELEFAX: 212-751-6849

INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 BASE PAIRS

TYPE: NUCLEIC ACID

STRANDEDNESS: SINGLE

TOPOLOGY: UNKNOWN

MOLECULE TYPE: OLIGONUCLEOTIDE

HYPOTHETICAL: NO

FEATURE:

NAME/KEY: PRIMER SEQUENCE FOR D9S58 LOCUS

LOCATION: CHROMOSOME 9

PUBLICATION INFORMATION:

AUTHORS: KWIAKOWSKI, DAVID J;

HENSKE, ELIZABETH P; WEIMER, KIM;

OZELIUS, LAURIE; GUSELLA, JAMES J;

HAINES, JONATHAN

TITLE: CONSTRUCTION OF A GT POLYMORPHISM

MAP OF HUMAN 9Q

JOURNAL: GENOMICS

VOLUME: 12

ISSUE:

PAGES: 229-240

DATE: 1992

SEQUENCE DESCRIPTION: SEQ ID NO: 5:

US-09-455-683-5

Query Match

Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2853 CCTGAGTACTGGACCATTA 2872
Db 1 CCTGAGTACCGGGACTATA 20

RESULT 715
US-09-357-740-8
; Sequence 8, Application US/09357740
; Patent No. 6348596
; GENERAL INFORMATION:
; APPLICANT: Lee, Linda G.
; APPLICANT: Graham, Ronald J.
; APPLICANT: Mullah, Khairuzzaman B.
; APPLICANT: Haxo, Francis T.
; TITLE OF INVENTION: ASYMMETRIC CYANINE DYE QUENCHERS
; FILE REFERENCE: 9584-007
; CURRENT FILING DATE: 1999-07-20
; EARLIER APPLICATION NUMBER: US/09/357,740
; EARLIER FILING DATE: 1999-07-20
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Probe
US-09-357-740-8

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2833 TGATCCTCCACCTCAGCCT 2852
Db 1 TGATCCACCGGCTCAGCCT 20

RESULT 716
US-09-060-299-300/c
; Sequence 300, Application US/09060299
; Patent No. 6545137
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; APPLICANT: Hess, John W
; APPLICANT: Caskey, Charles T
; APPLICANT: Cox, Roger D
; APPLICANT: Gerhold, David
; APPLICANT: Hammond, Holly
; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L
; TITLE OF INVENTION: No. 6545137el Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6545137th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; ZIP: VA 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/060,299
; FILING DATE: 15-APR-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/043,553

; FILING DATE: 15-APR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-35
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 300:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-060-299-300
Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2828 TCAAGTGATCCTCCACCTC 2847
Db 20 TCAAGTGATCCTCTGCCTC 1
RESULT 717
US-09-402-923A-300/c
; Sequence 300, Application US/09402923A
; Patent No. 6555654
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; APPLICANT: Hess, John W
; APPLICANT: Caskey, Charles T
; APPLICANT: Cox, Roger D
; APPLICANT: Gerhold, David
; APPLICANT: Hammond, Holly
; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L
; TITLE OF INVENTION: No. 6555654el LDL-Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6555654th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; ZIP: VA 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/402,923A
; FILING DATE: 14-FEB-2001
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB98/01102
; FILING DATE: 15-APR-1998
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-81
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091

```
;
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 300:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 300:
US-09-402-923A-300

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2828 TCAAGTGATCTCCACCTC 2847
      ||| ||||| ||||| |||||
Db       20 TCAAGTGATCTCTGCCTC 1

RESULT 718
US-09-976-618A-55/c
; Sequence 55, Application US/09976618A
; Patent No. 6812334
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-121
; CURRENT APPLICATION NUMBER: US/09/976,618A
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-121
; CURRENT APPLICATION NUMBER: US/09/976,618A
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:random
US-09-976-618A-55

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2898 TTGTGATTTTTTTTTTTT 2917
      ||| ||||| ||||| |||||
Db       20 TTTTGTTTTTTTTTTTTTT 1

RESULT 720
US-10-234-764-10
; Sequence 10, Application US/10234764
; Patent No. 6825331
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Lonnberg, Harri
; APPLICANT: Salo, Harri
; APPLICANT: Virta, Pasi
; TITLE OF INVENTION: Aminoxy Functionalized Oligomers
; FILE REFERENCE: ISIS5089
; CURRENT APPLICATION NUMBER: US/10/234,764
; CURRENT FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: 09/016,520
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 09/344,260
; PRIOR FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-234-764-10

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2898 TTGTGATTTTTTTTTTTT 2917
      ||| ||||| ||||| |||||
Db       20 TTTTGTTTTTTTTTTTTTT 1

RESULT 719
US-09-976-968A-55/c
; Sequence 55, Application US/09976968A
; Patent No. 6818753
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
```

```
QY 2898 TTTGATTTTTTTTTTTTTTT 2917
Db 1 TTTTGTGTGTGTGTGTGTGTGT 20

RESULT 721
US-09-975-059A-55/c
; Sequence 55, Application US/09975059A
; Patent No. 6828432
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storchoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-115
; CURRENT APPLICATION NUMBER: US/09/975,059A
; CURRENT FILING DATE: 2001-10-11
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
; OTHER INFORMATION: synthetic sequence
US-09-975-059A-55

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTTGATTTTTTTTTTTTTTT 2917
Db 20 TTTTGTGTGTGTGTGTGTGTGT 1

RESULT 722
US-09-975-059A-55/c
; Sequence 55, Application US/09975059A
; Patent No. 6828432
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storchoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; FILE REFERENCE: 00-713-115
; CURRENT APPLICATION NUMBER: US/09/975,059A
; CURRENT FILING DATE: 2001-10-11
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
; OTHER INFORMATION: synthetic sequence
US-09-975-059A-55

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTTGATTTTTTTTTTTTTTT 2917
Db 20 TTTTGTGTGTGTGTGTGTGTGT 1

RESULT 723
US-09-859-736-4
; Sequence 67, Application US/09018584A
; Patent No. 6238863
; GENERAL INFORMATION:
; APPLICANT: Schumm, James W.
; APPLICANT: Bacher, Jeffery W.
; TITLE OF INVENTION: MATERIALS AND METHODS FOR IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM REPEAT DNA MARKERS
; TITLE OF INVENTION: REPEAT DNA MARKERS
; NUMBER OF SEQUENCES: 147
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Promega Corporation
; STREET: 2800 Woods Hollow Road
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: U.S.A.
; ZIP: 53711-5399
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Word 97 (DOS text format)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/018,584A
; FILING DATE: 04-Feb-1998
; CLASSIFICATION:

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 4.4e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTTGATTTTTTTTTTTTTTT 2917
Db 1 TTTTGTGTGTGTGTGTGTGTGT 20

RESULT 724
US-09-018-584A-67/c
; Sequence 67, Application US/09018584A
; Patent No. 6238863
; GENERAL INFORMATION:
; APPLICANT: Schumm, James W.
; APPLICANT: Bacher, Jeffery W.
; TITLE OF INVENTION: MATERIALS AND METHODS FOR IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM REPEAT DNA MARKERS
; TITLE OF INVENTION: REPEAT DNA MARKERS
; NUMBER OF SEQUENCES: 147
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Promega Corporation
; STREET: 2800 Woods Hollow Road
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: U.S.A.
; ZIP: 53711-5399
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Word 97 (DOS text format)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/018,584A
; FILING DATE: 04-Feb-1998
; CLASSIFICATION:
```

```
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Grady J. Frenchick
/ REGISTRATION NUMBER: 29,018
/ REFERENCE/DOCKET NUMBER: 16026.9180
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (608) 257-3501
/ TELEFAX: (608) 257-2275
/ INFORMATION FOR SEQ ID NO: 67:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 21
/ TYPE: Nucleic Acid
/ STRANDEDNESS: Single
/ TOPOLOGY: Linear
/ US-09-018-584A-67

Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 4.2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTCCACCGAGCTG 2779
Db 20 TTGCTCTGTCCACCGAGCTG 1

RESULT 725
US-09-784-423-67/c
; Sequence 67, Application US/09784423
; Patent No. 6767703
; GENERAL INFORMATION:
; APPLICANT: Schumm, James W.
; Bacher, Jeffery W.
; TITLE OF INVENTION: MATERIALS AND METHODS FOR
; IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM
; REPEAT DNA MARKERS
; NUMBER OF SEQUENCES: 147
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Promega Corporation
; STREET: 2800 Woods Hollow Road
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: U.S.A.
; ZIP: 53711-5399
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb
; COMPUTER: IBM compatible PC
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Word 97 (DOS text format)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/784,423
; FILING DATE: 15-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/018,584
; FILING DATE: 04-Feb-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Grady J. Frenchick
; REGISTRATION NUMBER: 29,018
; REFERENCE/DOCKET NUMBER: 16026.9180
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 257-3501
; TELEFAX: (608) 257-2275
; INFORMATION FOR SEQ ID NO: 67:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 67
US-09-784-423-67

Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 4.2e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 2760 TCGCTCTGTCCACCGAGCTG 2779
Db 20 TTGCTCTGTCCACCGAGCTG 1

RESULT 726
US-09-078-294-2/c
; Sequence 2, Application US/09078294
; Patent No. 6265211
; GENERAL INFORMATION:
; APPLICANT: Choo, Kong-Hong Andy
; APPLICANT: Du Sart, Desiree
; APPLICANT: Cancilla, Michael R.
; TITLE OF INVENTION: A NOVEL NUCLEIC ACID MOLECULE
; FILE REFERENCE: Davies Col
; CURRENT APPLICATION NUMBER: US/09/078,294
; CURRENT FILING DATE: 1998-05-13
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 19
; TYPE: DNA
; ORGANISM: DNA primer
; US-09-078-294-2

Query Match 0.6%; Score 16.6; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 4.8e+02;
Matches 16; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGT 2791
Db 19 CAGGCTGGAGTGCAGTGGY 1

RESULT 727
US-08-116-801C-3/c
; Sequence 3, Application US/08116801C
; Patent No. 5578718
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: Thiol-Derivatized Nucleosides
; TITLE OF INVENTION: And Oligonucleosides
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5578718r18
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/116,801C
; FILING DATE: September 3, 1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-0784
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
```

```
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 5
; OTHER INFORMATION: /note=
; OTHER INFORMATION: "2'-O-thiol modified-2'-deoxyadenosine"
US-08-116-801C-3

Query Match          0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GGCTCGCTATGGCTCCCA 1

RESULT 728
US-08-458-396-3/c
; Sequence 3, Application US/08458396
; Patent No. 5852182
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: Thiol-Derivatized Nucleosides
; TITLE OF INVENTION: And Oligonucleosides
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 5852182ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/458,396
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/458,396
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-1992
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 5
; OTHER INFORMATION: /note=
; OTHER INFORMATION: "2'-O-thiol modified-2'-deoxyadenosine"
US-08-458-396-3

Query Match          0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GGCTCGCTATGGCTCCCA 1
```

```
Db 18 GGCTCGCTATGGCTCCCA 1

RESULT 729
US-08-924-326-3/c
; Sequence 3, Application US/08924326
; Patent No. 6114513
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: Thiol-Derivatized Nucleosides
; TITLE OF INVENTION: And Oligonucleosides
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 6114513ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/924,326
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/458,396
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-1992
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 5
; OTHER INFORMATION: /note=
; OTHER INFORMATION: "2'-O-thiol modified-2'-deoxyadenosine"
US-08-924-326-3

Query Match          0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GGCTCGCTATGGCTCCCA 1

RESULT 730
US-08-211-882-15/c
; Sequence 15, Application US/08211882
; Patent No. 6153737
; GENERAL INFORMATION:
; APPLICANT: Manoharan et al.
; TITLE OF INVENTION: Derivatized Oligonucleotides Having
; TITLE OF INVENTION: Improved Uptake And Other Properties
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
```

```
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6153737ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/211,882
; FILING DATE: 22-APR-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/782,374
; FILING DATE: 24-OCT-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-0649
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-211-882-15

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTACGGCTCCCA 1

RESULT 731
US-09-383-856-3/c
; Sequence 3, Application US/09383856
; Patent No. 6265558
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: Thiol-Derivatized Nucleosides
; TITLE OF INVENTION: And Oligonucleosides
; NUMBER OF SEQUENCES: 5
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; ADDRESSEE: and No. 6265558ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT 4.0
; SOFTWARE: WordPerfect 8.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/383,856
; FILING DATE: 26-AUG-99
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/924,326
; FILING DATE: 05-SEP-97
; CLASSIFICATION:
```

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-4100
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 5
; OTHER INFORMATION: /note=
; OTHER INFORMATION: "2'-O-thiol modified-2'-deoxyadenosine"
; US-09-383-856-3

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 732
US-08-700-530-1/c
; Sequence 1, Application US/08700530
; Patent No. 6316186
; GENERAL INFORMATION:
; APPLICANT: EKINS, Roger P
; TITLE OF INVENTION: Binding assay using binding agents with tail groups
; FILE REFERENCE: 0380-P01180US0
; CURRENT APPLICATION NUMBER: US/08/700,530
; CURRENT FILING DATE: 1996-10-23
; PRIOR APPLICATION NUMBER: PCT/GB95/00521
; PRIOR FILING DATE: 1995-03-10
; PRIOR APPLICATION NUMBER: GB 9404709.9
; PRIOR FILING DATE: 1994-03-11
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Oligonucleotide
; US-08-700-530-1

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATG 2746
Db 18 TGTGTGTGTGTGTGTGTG 1

RESULT 733
US-08-700-530-2
; Sequence 2, Application US/08700530
; Patent No. 6316186
; GENERAL INFORMATION:
; APPLICANT: EKINS, Roger P
; TITLE OF INVENTION: Binding assay using binding agents with tail groups
; FILE REFERENCE: 0380-P01180US0
; CURRENT APPLICATION NUMBER: US/08/700,530
```

```
; CURRENT FILING DATE: 1996-10-23
; PRIOR APPLICATION NUMBER: PCT/GB95/00521
; PRIOR FILING DATE: 1995-03-10
; PRIOR APPLICATION NUMBER: GB 9404709.9
; PRIOR FILING DATE: 1994-03-11
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Oligonucleotide
US-08-700-530-2

Query Match          0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGT 2743
Db 1 GTGTGTGTGTGTGTGTGT 18

RESULT 734
US-08-976-427-28
; Sequence 28, Application US/08976427A
; Patent No. 6322968
; GENERAL INFORMATION:
; APPLICANT: Head, Steven R.
; APPLICANT: Goelet, Philip
; APPLICANT: Karn, Jonathan
; APPLICANT: Boyce-Jacino, Michael
; TITLE OF INVENTION: De No. 6322968o or "Universal" Sequencing Array
; FILE REFERENCE: 04990.0049
; CURRENT APPLICATION NUMBER: US/08/976,427A
; CURRENT FILING DATE: 1997-11-21
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic primer
US-08-976-427-28

Query Match          0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATG 2746
Db 1 TGTGTGTGTGTGTGTGTG 18

RESULT 735
US-09-648-312-28
; Sequence 28, Application US/09648312
; Patent No. 6337188
; GENERAL INFORMATION:
; APPLICANT: Head, Steven R.
; APPLICANT: Goelet, Philip
; APPLICANT: Karn, Jonathan
; APPLICANT: Boyce-Jacino, Michael
; TITLE OF INVENTION: De No. 6337188o or "Universal" Sequencing Array
; FILE REFERENCE: 04990.0049
; CURRENT APPLICATION NUMBER: US/09/648,312
; CURRENT FILING DATE: 2000-08-25
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 28
```

```
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic primer
US-09-648-312-28

Query Match          0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATG 2746
Db 1 TGTGTGTGTGTGTGTGTG 18

RESULT 736
US-09-633-659-15/c
; Sequence 15, Application US/09633659
; Patent No. 6395492
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Bennett, Clarence Frank
; TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake And
; TITLE OF INVENTION: Other Properties
; FILE REFERENCE: ISIS4470
; CURRENT APPLICATION NUMBER: US/09/633,659
; CURRENT FILING DATE: 2000-08-07
; PRIOR APPLICATION NUMBER: 08/211,882
; PRIOR FILING DATE: 1994-04-22
; PRIOR APPLICATION NUMBER: 07/782,374
; PRIOR FILING DATE: 1991-10-24
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6395492e1 Sequence
US-09-633-659-15

Query Match          0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTACGGCTCCCA 1

RESULT 737
US-10-073-718-15/c
; Sequence 15, Application US/10073718
; Patent No. 6831166
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Bennett, Clarence Frank
; TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake and Other Pri
; FILE REFERENCE: ISIS-5024
; CURRENT APPLICATION NUMBER: US/10/073,718
; CURRENT FILING DATE: 2002-05-08
; PRIOR APPLICATION NUMBER: 09/633659
; PRIOR FILING DATE: 2000-08-07
; PRIOR APPLICATION NUMBER: 6153737
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 08/211882
; PRIOR FILING DATE: 1994-04-22
; PRIOR APPLICATION NUMBER: PCT/US92/09196
; PRIOR FILING DATE: 1992-10-23
; PRIOR APPLICATION NUMBER: 07/782374
```

;; PRIOR FILING DATE: 1991-10-24
;; PRIOR APPLICATION NUMBER: 07/566977
;; PRIOR FILING DATE: 1990-08-13
;; PRIOR APPLICATION NUMBER: PCT/US91/000243
;; PRIOR FILING DATE: 1991-01-11
;; PRIOR APPLICATION NUMBER: 08/463358
;; PRIOR FILING DATE: 1990-01-11
;; NUMBER OF SEQ ID NOS: 18
;; SOFTWARE: PatentIn version 3.1
;; SEQ ID NO 15
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: No. 6831166el Sequence
US-10-073-718-15

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 5.3e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTACGGCTCCCA 1

RESULT 738
US-08-222-177A-395/c
; Sequence 395, Application US/08222177A
; Patent No. 5582979
; GENERAL INFORMATION:
; APPLICANT: Weber, James L.
; TITLE OF INVENTION: LENGTH POLYMORPHISMS IN
; TITLE OF INVENTION: (dc-da)n (gg-dt)n SEQUENCES AND METHODS OF USING SAME
; NUMBER OF SEQUENCES: 460
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DeWitt Ross & Stevens, S.C.
; STREET: 8000 Excelsior Drive, Suite 401
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: USA
; ZIP: 53717-1914
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: US/08/222,177A
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/341,562
; FILING DATE: 21-APR-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 09865.601
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 831-2100
; TELEFAX: (608) 831-2106
; TELEX:
; INFORMATION FOR SEQ ID NO: 395:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; IMMEDIATE SOURCE:
; CLONE: mfd125p1
US-08-222-177A-395

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2916 TTTCAGAGACGGGGTCTC 2933
Db 19 TTTCAGAGACAGGGTCTC 2

RESULT 739
US-09-280-805-256/c
; Sequence 256, Application US/09280805
; Patent No. 6184212
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PC
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/280,805
; FILING DATE: herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/048,810
; FILING DATE: March 26, 1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Licata, Jane Massey
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0346
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-810-1515
; TELEFAX: 609-810-1454
; INFORMATION FOR SEQ ID NO: 256:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-280-805-256

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2882 CACCACACCTGGCAATT 2899
Db 18 CACCACACCTGGCTAATT 1

RESULT 740
US-09-467-642-64/c
; Sequence 64, Application US/09467642
; Patent No. 6300132
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowart
; TITLE OF INVENTION: ANTISENSE MODULATION OF TELOMERIC REPEAT BINDING FACTOR 2 EXPRES
; FILE REFERENCE: RTS-0106
; CURRENT APPLICATION NUMBER: US/09/467,642

; CURRENT FILING DATE: 1999-12-20
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-467-642-64

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2775 GGCTGGAGTGCAGTGTGTG 2792
| | | | | | | | | | | | | | | | | | | | | |
DB 20 GGCTGGAGTGCAGTGGCG 3

RESULT 741
US-09-475-947A-337/c
; Sequence 337, Application US/09475947A
; Patent No. 6472154
; GENERAL INFORMATION:
; APPLICANT: Garner, Harold R.
; APPLICANT: Wren, Jonathan D.
; APPLICANT: Minna, John D.
; TITLE OF INVENTION: Polymorphic Repeats in Human Genes
; FILE REFERENCE: UTSD0667
; CURRENT APPLICATION NUMBER: US/09/475,947A
; CURRENT FILING DATE: 1999-12-31
; NUMBER OF SEQ ID NOS: 346
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 337
; LENGTH: 20
; TYPE: DNA
; ORGANISM: human
US-09-475-947A-337

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 4.8e+02;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 GGCTGTGTGTGTGTGTGT 2743
| | | | | | | | | | | | | | | | | | | | | |
DB 18 GGCTGTGTGTGTGTGTGT 1

RESULT 742
US-08-734-973-30/c
; Sequence 30, Application US/08734973
; Patent No. 5912147
; GENERAL INFORMATION:
; APPLICANT: Stoler, Daniel L.
; APPLICANT: Basik, Mark
; APPLICANT: Anderson, Garth R.
; TITLE OF INVENTION: A Rapid Means For Quantitating
; TITLE OF INVENTION: Genomic Instability
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One M&T Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: MS-DOS/ Microsoft Windows
; SOFTWARE: Wordperfect for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/734,973

; FILING DATE: October 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 03551.0021
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 30 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
US-08-734-973-30

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGT 2743
| | | | | | | | | | | | | | | | | | | | | |
DB 17 GTGTGTGTGTGTGTGT 2

RESULT 743
US-08-734-973-31/c
; Sequence 31, Application US/08734973
; Patent No. 5912147
; GENERAL INFORMATION:
; APPLICANT: Stoler, Daniel L.
; APPLICANT: Basik, Mark
; APPLICANT: Anderson, Garth R.
; TITLE OF INVENTION: A Rapid Means For Quantitating
; TITLE OF INVENTION: Genomic Instability
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One M&T Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: MS-DOS/ Microsoft Windows
; SOFTWARE: Wordperfect for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/734,973
; FILING DATE: October 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 03551.0021
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 31 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
US-08-734-973-31

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGT 2743
Db 17 GTGTGTGTGTGTGTGT 2

RESULT 744
US-08-734-973-32/c
; Sequence 32, Application US/08734973
; Patent No. 5913147
; GENERAL INFORMATION:
; APPLICANT: Stoler, Daniel L.
; APPLICANT: Basik, Mark
; APPLICANT: Anderson, Garth R.
; TITLE OF INVENTION: A Rapid Means For Quantitating
; TITLE OF INVENTION: Genomic Instability
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One Met Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: MS-DOS/ Microsoft Windows
; SOFTWARE: Wordperfect for Windows
; CURRENT APPLICATION DATA:
; FILING DATE: October 1996
; APPLICATION NUMBER: US/08/734,973
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 03551.0021
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 32 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
US-08-734-973-32

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGT 2743
Db 17 GTGTGTGTGTGTGTGT 2

RESULT 745
US-09-809-545A-84
; Sequence 84, Application US/09809545A
; Patent No. 6800455
; GENERAL INFORMATION:
; APPLICANT: Stanton, Lawrence W.
; APPLICANT: White, R. Tyler
; TITLE OF INVENTION: SECRETED FACTORS
; FILE REFERENCE: SCIOS.017A
; CURRENT APPLICATION NUMBER: US/09/809,545A
; CURRENT FILING DATE: 2001-03-14
; NUMBER OF SEQ ID NOS: 84
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 84
; LENGTH: 18

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligos corresponding to polylinker sequence.
US-09-809-545A-84

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 746
US-10-352-704-12
; Sequence 12, Application US/10352704
; Patent No. 6825339
; GENERAL INFORMATION:
; APPLICANT: Chatelain, Francois
; TITLE OF INVENTION: Process for Preparing Polynucleotides on
; a Solid Support and Apparatus Permitting its
; Implementation
; NUMBER OF SEQUENCES: 31
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C.
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/352,704
; FILING DATE: 28-Jan-2003
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/358,556A
; FILING DATE: 14-DEC-1994
; APPLICATION NUMBER: FR 9315164
; FILING DATE: 16-DEC-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Player, William E.
; REGISTRATION NUMBER: 31,409
; REFERENCE/DOCKET NUMBER: 10577/P58418
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)638-6666
; TELEFAX: (202) 393-5350
; TELEX: RCA 248593 IDEA UR
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; FRAGMENT TYPE: N-terminal
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..18
; SEQUENCE DESCRIPTION: SEQ ID NO: 12:
US-10-352-704-12
Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 5.8e+02;

NUMBER OF SEQUENCES: 797
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
STREET: 444 South Flower Street, Suite 2000
CITY: Los Angeles
STATE: CA
COUNTRY: USA
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/117,952
FILING DATE: 07-SEP-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/078,471
FILING DATE: 15-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: Reiter, Stephen E.
REGISTRATION NUMBER: 31,192
REFERENCE/DOCKET NUMBER: P41 9423
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-546-4737
TELEFAX: 619-546-9392
INFORMATION FOR SEQ ID NO: 623:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Oligonucleotide
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-117-952-623

Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 5.7e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2765 CTGTCACCCAGGCTGGAGT 2783
Db 19 CTGTCACCCAGGCTGAAGT 1

RESULT 751
US-08-734-973-1/c
Sequence 1, Application US/08734973
Patent No. 5912147
GENERAL INFORMATION:
APPLICANT: Stoler, Daniel L.
APPLICANT: Basik, Mark
APPLICANT: Anderson, Garth R.
TITLE OF INVENTION: A Rapid Means For Quantitating
TITLE OF INVENTION: Genomic Instability
NUMBER OF SEQUENCES: 38
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
STREET: 1800 One M&T Plaza
CITY: Buffalo
STATE: New York
COUNTRY: United States
ZIP: 14203-2391
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS/ Microsoft Windows
SOFTWARE: Wordperfect for Windows
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/734,973
FILING DATE: October 1996

ATTORNEY/AGENT INFORMATION:
NAME: Nelson, M. Bud
REGISTRATION NUMBER: 35,300
REFERENCE/DOCKET NUMBER: 03551.0021
TELECOMMUNICATION INFORMATION:
TELEPHONE: (716) 856-4000
TELEFAX: (716) 849-0349
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single-stranded
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
US-08-734-973-1

Query Match 0.5%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 6.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2727 CGTGTGTGTGTGTGTGT 2743
Db 18 CTGTGTGTGTGTGTGTGT 2

RESULT 752
US-08-734-973-2/c
Sequence 2, Application US/08734973
Patent No. 5912147
GENERAL INFORMATION:
APPLICANT: Stoler, Daniel L.
APPLICANT: Basik, Mark
APPLICANT: Anderson, Garth R.
TITLE OF INVENTION: A Rapid Means For Quantitating
TITLE OF INVENTION: Genomic Instability
NUMBER OF SEQUENCES: 38
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
STREET: 1800 One M&T Plaza
CITY: Buffalo
STATE: New York
COUNTRY: United States
ZIP: 14203-2391
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS/ Microsoft Windows
SOFTWARE: Wordperfect for Windows
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/734,973
FILING DATE: October 1996
ATTORNEY/AGENT INFORMATION:
NAME: Nelson, M. Bud
REGISTRATION NUMBER: 35,300
REFERENCE/DOCKET NUMBER: 03551.0021
TELECOMMUNICATION INFORMATION:
TELEPHONE: (716) 856-4000
TELEFAX: (716) 849-0349
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single-stranded
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
US-08-734-973-2

Query Match 0.5%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 6.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```
QY 2727 CCGTGTGTGTGTGTGTGT 2743
Db 18 CCTGTGTGTGTGTGTGT 2

RESULT 753
US-09-904-744-2
; Sequence 2, Application US/09904744
; Patent No. 6828142
; GENERAL INFORMATION:
; APPLICANT: Barbera-Guillem, Emilio
; APPLICANT: Nelson, M. Bud
; APPLICANT: Castro, Stephanie
; TITLE OF INVENTION: Nanocrystals having polynucleotide strands and their use to form
; TITLE OF INVENTION: dendrimers in a signal amplification system
; FILE REFERENCE: B-73
; CURRENT APPLICATION NUMBER: US/09/904,744
; CURRENT FILING DATE: 2001-07-13
; PRIOR APPLICATION NUMBER: 09/437076
; PRIOR FILING DATE: 1999-11-09
; PRIOR APPLICATION NUMBER: 60/107828
; PRIOR FILING DATE: 1998-11-10
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthesized
US-09-904-744-2

Query Match 0.5%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 6.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2901 GATTTTGTGTGTGTGT 2917
Db 2 GGTGTGTGTGTGTGT 18

RESULT 754
US-09-286-959B-13
; Sequence 13, Application US/09286959B
; Patent No. 6300131
; GENERAL INFORMATION:
; APPLICANT: Johns Hopkins University
; APPLICANT: Greider, Carol W.
; APPLICANT: Le, Siyuan
; TITLE OF INVENTION: TELOMERASE-ASSOCIATED PROTEINS
; FILE REFERENCE: 07265/157001
; CURRENT APPLICATION NUMBER: US/09/286,959B
; CURRENT FILING DATE: 1999-04-06
; PRIOR APPLICATION NUMBER: 60/080,783
; PRIOR FILING DATE: 1998-04-06
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-286-959B-13

Query Match 0.5%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 6.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2921 GAGACGGGGTCTCGCAA 2937
Db 1 GAGACGGGGTCTCGCTA 17
```

```
RESULT 755
US-08-734-973-3/c
; Sequence 3, Application US/08734973
; Patent No. 5912147
; GENERAL INFORMATION:
; APPLICANT: Stoler, Daniel L.
; APPLICANT: Basik, Mark
; APPLICANT: Anderson, Garth R.
; TITLE OF INVENTION: A Rapid Means For Quantitating
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One M&T Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: MS-DOS/ Microsoft Windows
; SOFTWARE: Wordperfect for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/734,973
; FILING DATE: October 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 03551.0021
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 3 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
US-08-734-973-3

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGTGT 2

RESULT 756
US-08-734-973-4/c
; Sequence 4, Application US/08734973
; Patent No. 5912147
; GENERAL INFORMATION:
; APPLICANT: Stoler, Daniel L.
; APPLICANT: Basik, Mark
; APPLICANT: Anderson, Garth R.
; TITLE OF INVENTION: A Rapid Means For Quantitating
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One M&T Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
```

```
/
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: MS-DOS/ Microsoft Windows
/ SOFTWARE: Wordperfect for Windows
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/734,973
/ FILING DATE: October 1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Nelson, M. Bud
/ REGISTRATION NUMBER: 35,300
/ REFERENCE/DOCKET NUMBER: 03551.0021
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (716) 856-4000
/ TELEFAX: (716) 849-0349
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 nucleotides
/ TYPE: nucleic acid
/ STRANDEDNESS: single-stranded
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
/ HYPOTHETICAL: NO
/
/ US-08-734-973-4
/
/ Query Match 0.5%; Score 15; DB 1; Length 18;
/ Best Local Similarity 100.0%; Pred. No. 7.1e+02;
/ Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
/
/ QY 2729 TGTGTGTGTGTGTGT 2743
/ Db 16 TGTGTGTGTGTGTGT 2
/
/ RESULT 757
/ US-08-734-973-5/C
/ Sequence 5, Application US/08734973
/ Patent No. 5912147
/ GENERAL INFORMATION:
/ APPLICANT: Stoler, Daniel L.
/ APPLICANT: Basik, Mark
/ APPLICANT: Anderson, Garth R.
/ TITLE OF INVENTION: A Rapid Means For Quantitating
/ TITLE OF INVENTION: Genomic Instability
/ NUMBER OF SEQUENCES: 38
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
/ STREET: 1800 One Mkt Plaza
/ CITY: Buffalo
/ STATE: New York
/ COUNTRY: United States
/ ZIP: 14203-2391
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette, 3.5 inch
/ OPERATING SYSTEM: MS-DOS/ Microsoft Windows
/ SOFTWARE: Wordperfect for Windows
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/734,973
/ FILING DATE: October 1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Nelson, M. Bud
/ REGISTRATION NUMBER: 35,300
/ REFERENCE/DOCKET NUMBER: 03551.0021
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (716) 856-4000
/ TELEFAX: (716) 849-0349
/ INFORMATION FOR SEQ ID NO: 5:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 nucleotides
/ TYPE: nucleic acid
/ STRANDEDNESS: single-stranded
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
/ HYPOTHETICAL: NO
/
/ US-08-734-973-6
/
/ Query Match 0.5%; Score 15; DB 1; Length 18;
/ Best Local Similarity 100.0%; Pred. No. 7.1e+02;
/ Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
/
/ QY 2729 TGTGTGTGTGTGTGT 2743
/ Db 16 TGTGTGTGTGTGTGT 2
/
/ RESULT 757
/ US-08-734-973-7/c
/ Sequence 7, Application US/08734973
/ Patent No. 5912147
/ GENERAL INFORMATION:
/ APPLICANT: Stoler, Daniel L.
/ APPLICANT: Basik, Mark
/ APPLICANT: Anderson, Garth R.
/ TITLE OF INVENTION: A Rapid Means For Quantitating
/ TITLE OF INVENTION: Genomic Instability
```

```
US-08-734-973-5
/
/ Query Match 0.5%; Score 15; DB 1; Length 18;
/ Best Local Similarity 100.0%; Pred. No. 7.1e+02;
/ Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
/
/ QY 2729 TGTGTGTGTGTGTGT 2743
/ Db 16 TGTGTGTGTGTGTGT 2
/
/ RESULT 758
/ US-08-734-973-6/c
/ Sequence 6, Application US/08734973
/ Patent No. 5912147
/ GENERAL INFORMATION:
/ APPLICANT: Stoler, Daniel L.
/ APPLICANT: Basik, Mark
/ APPLICANT: Anderson, Garth R.
/ TITLE OF INVENTION: A Rapid Means For Quantitating
/ TITLE OF INVENTION: Genomic Instability
/ NUMBER OF SEQUENCES: 38
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
/ STREET: 1800 One Mkt Plaza
/ CITY: Buffalo
/ STATE: New York
/ COUNTRY: United States
/ ZIP: 14203-2391
/
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Diskette, 3.5 inch
/ OPERATING SYSTEM: MS-DOS/ Microsoft Windows
/ SOFTWARE: Wordperfect for Windows
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/734,973
/ FILING DATE: October 1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Nelson, M. Bud
/ REGISTRATION NUMBER: 35,300
/ REFERENCE/DOCKET NUMBER: 03551.0021
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (716) 856-4000
/ TELEFAX: (716) 849-0349
/ INFORMATION FOR SEQ ID NO: 6:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 18 nucleotides
/ TYPE: nucleic acid
/ STRANDEDNESS: single-stranded
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
/ HYPOTHETICAL: NO
/
/ US-08-734-973-6
/
/ Query Match 0.5%; Score 15; DB 1; Length 18;
/ Best Local Similarity 100.0%; Pred. No. 7.1e+02;
/ Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
/
/ QY 2729 TGTGTGTGTGTGTGT 2743
/ Db 16 TGTGTGTGTGTGTGT 2
/
/ RESULT 759
/ US-08-734-973-7/c
/ Sequence 7, Application US/08734973
/ Patent No. 5912147
/ GENERAL INFORMATION:
/ APPLICANT: Stoler, Daniel L.
/ APPLICANT: Basik, Mark
/ APPLICANT: Anderson, Garth R.
/ TITLE OF INVENTION: A Rapid Means For Quantitating
/ TITLE OF INVENTION: Genomic Instability
```

```
;
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One M&t Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
; OPERATING SYSTEM: MS-DOS/ Microsoft Windows
; SOFTWARE: Wordperfect for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/734,973
; FILING DATE: October 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 03551.0021
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 7 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: No
; US-08-734-973-7

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
DB 16 TGTGTGTGTGTGTGT 2

RESULT 760
US-08-734-973-8/c
; Sequence 8, Application US/08734973
; Patent No. 5912147
; GENERAL INFORMATION:
; APPLICANT: Stoler, Daniel L.
; APPLICANT: Basik, Mark
; APPLICANT: Anderson, Garth R.
; TITLE OF INVENTION: A Rapid Means For Quantitating
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One M&t Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
; OPERATING SYSTEM: MS-DOS/ Microsoft Windows
; SOFTWARE: Wordperfect for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/734,973
; FILING DATE: October 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 03551.0021
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 28 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: No
; US-08-734-973-28

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
DB 16 TGTGTGTGTGTGTGT 2

RESULT 760
US-08-734-973-8/c
; Sequence 8, Application US/08734973
; Patent No. 5912147
; GENERAL INFORMATION:
; APPLICANT: Stoler, Daniel L.
; APPLICANT: Basik, Mark
; APPLICANT: Anderson, Garth R.
; TITLE OF INVENTION: A Rapid Means For Quantitating
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One M&t Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
; OPERATING SYSTEM: MS-DOS/ Microsoft Windows
; SOFTWARE: Wordperfect for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/734,973
; FILING DATE: October 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 03551.0021
; TELECOMMUNICATION INFORMATION:
```

```
;
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 8 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: No
; US-08-734-973-8

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
DB 16 TGTGTGTGTGTGTGT 2

RESULT 761
US-08-734-973-28/c
; Sequence 28, Application US/08734973
; Patent No. 5912147
; GENERAL INFORMATION:
; APPLICANT: Stoler, Daniel L.
; APPLICANT: Basik, Mark
; APPLICANT: Anderson, Garth R.
; TITLE OF INVENTION: A Rapid Means For Quantitating
; TITLE OF INVENTION: Genomic Instability
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One M&t Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
; OPERATING SYSTEM: MS-DOS/ Microsoft Windows
; SOFTWARE: Wordperfect for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/734,973
; FILING DATE: October 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 03551.0021
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 28 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: No
; US-08-734-973-28

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
DB 16 TGTGTGTGTGTGTGT 2
```

RESULT 762
US-08-734-973-29/c
; Sequence 29, Application US/08734973
; Patent No. 5912147
; GENERAL INFORMATION:
; APPLICANT: Stoler, Daniel L.
; APPLICANT: Basik, Mark
; APPLICANT: Anderson, Garth R.
; TITLE OF INVENTION: A Rapid Means For Quantitating
; TITLE OF INVENTION: Genomic Instability
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One M&T Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: MS-DOS/ Microsoft Windows
; SOFTWARE: Wordperfect for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/734,973
; FILING DATE: October 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 03551.0021
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 29 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
US-08-734-973-29

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGT 2

RESULT 763
US-08-734-973-33/c
; Sequence 33, Application US/08734973
; Patent No. 5912147
; GENERAL INFORMATION:
; APPLICANT: Stoler, Daniel L.
; APPLICANT: Basik, Mark
; APPLICANT: Anderson, Garth R.
; TITLE OF INVENTION: A Rapid Means For Quantitating
; TITLE OF INVENTION: Genomic Instability
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One M&T Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: MS-DOS/ Microsoft Windows
; SOFTWARE: Wordperfect for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/734,973
; FILING DATE: October 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 03551.0021
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 34 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
US-08-734-973-34

; OPERATING SYSTEM: MS-DOS/ Microsoft Windows
; SOFTWARE: Wordperfect for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/734,973
; FILING DATE: October 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 03551.0021
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 33 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
US-08-734-973-33

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGT 2743
Db 16 TGTGTGTGTGTGT 2

RESULT 764
US-08-734-973-34/c
; Sequence 34, Application US/08734973
; Patent No. 5912147
; GENERAL INFORMATION:
; APPLICANT: Stoler, Daniel L.
; APPLICANT: Basik, Mark
; APPLICANT: Anderson, Garth R.
; TITLE OF INVENTION: A Rapid Means For Quantitating
; TITLE OF INVENTION: Genomic Instability
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One M&T Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: MS-DOS/ Microsoft Windows
; SOFTWARE: Wordperfect for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/734,973
; FILING DATE: October 1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 03551.0021
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 34 :
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
US-08-734-973-34

Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 7.1e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGT 2743
 |||||

Db 16 TGTGTGTGTGTGT 2

RESULT 765

US-08-734-973-35/c

; Sequence 35, Application US/08734973

; Patent No. 5912147

; GENERAL INFORMATION:

; APPLICANT: Stoler, Daniel L.

; APPLICANT: Basik, Mark

; APPLICANT: Anderson, Garth R.

; TITLE OF INVENTION: A Rapid Means For Quantitating

; NUMBER OF SEQUENCES: 38

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear

; STREET: 1800 One M&T Plaza

; CITY: Buffalo

; STATE: New York

; COUNTRY: United States

; ZIP: 14203-2391

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette, 3.5 inch

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: MS-DOS/ Microsoft Windows

; SOFTWARE: Wordperfect for Windows

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/734,973

; FILING DATE: October 1996

; ATTORNEY/AGENT INFORMATION:

; NAME: Nelson, M. Bud

; REGISTRATION NUMBER: 35,300

; REFERENCE/DOCKET NUMBER: 03551.0021

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (716) 856-4000

; TELEFAX: (716) 849-0349

; INFORMATION FOR SEQ ID NO: 35 :

; SEQUENCE CHARACTERISTICS:

; LENGTH: 18 nucleotides

; TYPE: nucleic acid

; STRANDEDNESS: single-stranded

; TOPOLOGY: linear

; MOLECULE TYPE: DNA

; HYPOTHETICAL: No

US-08-734-973-35

Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 7.1e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGT 2743
 |||||

Db 16 TGTGTGTGTGTGT 2

RESULT 766

US-08-734-973-36/c

; Sequence 36, Application US/08734973

; Patent No. 5912147

; GENERAL INFORMATION:

; APPLICANT: Stoler, Daniel L.

; APPLICANT: Basik, Mark

; APPLICANT: Anderson, Garth R.

; TITLE OF INVENTION: A Rapid Means For Quantitating

; NUMBER OF SEQUENCES: 38

; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
 ; STREET: 1800 One M&T Plaza
 ; CITY: Buffalo
 ; STATE: New York
 ; COUNTRY: United States
 ; ZIP: 14203-2391

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette, 3.5 inch

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: MS-DOS/ Microsoft Windows

; SOFTWARE: Wordperfect for Windows

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/734,973

; FILING DATE: October 1996

; ATTORNEY/AGENT INFORMATION:

; NAME: Nelson, M. Bud

; REGISTRATION NUMBER: 35,300

; REFERENCE/DOCKET NUMBER: 03551.0021

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (716) 856-4000

; TELEFAX: (716) 849-0349

; INFORMATION FOR SEQ ID NO: 36 :

; SEQUENCE CHARACTERISTICS:

; LENGTH: 18 nucleotides

; TYPE: nucleic acid

; STRANDEDNESS: single-stranded

; TOPOLOGY: linear

; MOLECULE TYPE: DNA

; HYPOTHETICAL: No

US-08-734-973-36

Query Match 0.5%; Score 15; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 7.1e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGT 2743
 |||||

Db 16 TGTGTGTGTGTGT 2

RESULT 767

US-08-734-973-37/c

; Sequence 37, Application US/08734973

; Patent No. 5912147

; GENERAL INFORMATION:

; APPLICANT: Stoler, Daniel L.

; APPLICANT: Basik, Mark

; APPLICANT: Anderson, Garth R.

; TITLE OF INVENTION: A Rapid Means For Quantitating

; NUMBER OF SEQUENCES: 38

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear

; STREET: 1800 One M&T Plaza

; CITY: Buffalo

; STATE: New York

; COUNTRY: United States

; ZIP: 14203-2391

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette, 3.5 inch

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: MS-DOS/ Microsoft Windows

; SOFTWARE: Wordperfect for Windows

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/734,973

; FILING DATE: October 1996

; ATTORNEY/AGENT INFORMATION:

; NAME: Nelson, M. Bud

; REGISTRATION NUMBER: 35,300

; REFERENCE/DOCKET NUMBER: 03551.0021

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (716) 856-4000

TELEFAX: (716) 849-0349
INFORMATION FOR SEQ ID NO: 37 :
SEQUENCE CHARACTERISTICS:
LENGTH: 18 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single-stranded
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
US-08-734-973-37

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
|||||
DB 16 TGTGTGTGTGTGTGT 2

RESULT 768

US-08-734-973-38/c
Sequence 38, Application US/08734973
Patent No. 5912147

GENERAL INFORMATION:
APPLICANT: Stoler, Daniel L.
APPLICANT: Basik, Mark
APPLICANT: Anderson, Garth R.
TITLE OF INVENTION: A Rapid Means For Quantitating
TITLE OF INVENTION: Genomic Instability
NUMBER OF SEQUENCES: 38
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
STREET: 1800 One M&T Plaza
CITY: Buffalo

STATE: New York
COUNTRY: United States
ZIP: 14203-2391
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS/ Microsoft Windows
SOFTWARE: Wordperfect for Windows
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/734,973
FILING DATE: October 1996
ATTORNEY/AGENT INFORMATION:

NAME: Nelson, M. Bud
REGISTRATION NUMBER: 35,300
REFERENCE/DOCKET NUMBER: 03551.0021
TELEPHONE: (716) 856-4000
TELEFAX: (716) 849-0349

INFORMATION FOR SEQ ID NO: 38 :
SEQUENCE CHARACTERISTICS:
LENGTH: 18 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single-stranded
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
US-08-734-973-38

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 7.1e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGT 2743
|||||
DB 16 TGTGTGTGTGTGTGT 2

RESULT 769

US-09-018-584A-146/c
Sequence 146, Application US/09018584A
Patent No. 6218863
GENERAL INFORMATION:

APPLICANT: Schumm, James W.
APPLICANT: Bacher, Jeffery W.
TITLE OF INVENTION: MATERIALS AND METHODS FOR
TITLE OF INVENTION: IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM
TITLE OF INVENTION: REPEAT DNA MARKERS
NUMBER OF SEQUENCES: 147
CORRESPONDENCE ADDRESS:

ADDRESSEE: Promega Corporation
STREET: 2800 Woods Hollow Road
CITY: Madison

STATE: Wisconsin
COUNTRY: U.S.A.
ZIP: 53711-5399

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb
COMPUTER: IBM compatible PC
OPERATING SYSTEM: Windows 95
SOFTWARE: Word 97 (DOS text format)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/018,584A
FILING DATE: 04-Feb-1998

CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:

NAME: Grady J. Frenchick
REGISTRATION NUMBER: 29,018
REFERENCE/DOCKET NUMBER: 16026.9180
TELEPHONE: (608) 257-3501
TELEFAX: (608) 257-2275
INFORMATION FOR SEQ ID NO: 146:

SEQUENCE CHARACTERISTICS:
LENGTH: 18
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-09-018-584A-146

Query Match 0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 7.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2764 TGTGTACCCAGCTGGA 2781
|||||
DB 18 TTGTGACCCAGACTGGA 1

RESULT 770

US-09-422-978-5770
Sequence 5770, Application US/09422978
Patent No. 6537751

GENERAL INFORMATION:

APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilya
TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
FILE REFERENCE: GENSET.020CPI
CURRENT APPLICATION NUMBER: US/09/422,978
CURRENT FILING DATE: 1999-10-20
EARLIER APPLICATION NUMBER: US 09/298,850
EARLIER FILING DATE: 1999-04-21
EARLIER APPLICATION NUMBER: US 60/109,732
EARLIER FILING DATE: 1998-11-23
EARLIER APPLICATION NUMBER: US 60/082,614
EARLIER FILING DATE: 1998-04-21
NUMBER OF SEQ ID NOS: 11796
SEQ ID NO 5770

LENGTH: 18
TYPE: DNA
ORGANISM: Homo Sapiens

```
;
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-6753 for SEQ 1836,
US-09-422-978-5770
;
; Query Match          0.5%; Score 14.8; DB 1; Length 18;
; Best Local Similarity 88.9%; Pred. No. 7.4e+02;
; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
QY 1618 ACCCCCATGAACCGAAC 1635
      ||||| ||||| |||||
Db 1 ACCCCCATGAACCGAAC 18
;
; RESULT 771
; US-09-155-885A-145/c
; Sequence 145, Application US/09155885A
; Patent No. 6709812
; GENERAL INFORMATION:
; APPLICANT: STUYVER, LIEVEN
; ROSSAU, RUDI
; MAERTENS, GEERT
; TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
; NUMBER OF SEQUENCES: 313
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: NIXON & VANDERHYE P.C.
; STREET: 1100 NORTH GLEBE ROAD
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: U.S.A.
; ZIP: 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/155,885A
; FILING DATE: 08-Oct-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP97/02002
; FILING DATE: 21-APR-1997
; APPLICATION NUMBER: EP 96870053.4
; FILING DATE: 19-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: SADOFF, B.J.
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 2551-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703) 816-4000
; TELEFAX: (703) 816-4100
; INFORMATION FOR SEQ ID NO: 145:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; SEQUENCE DESCRIPTION: SEQ ID NO: 145:
US-09-155-885A-145
;
; Query Match          0.5%; Score 14.8; DB 1; Length 18;
; Best Local Similarity 88.9%; Pred. No. 7.4e+02;
; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
QY 216 CCAGCCCAAGTTGTTGGG 233
      ||||| ||||| |||||
Db 18 CCAGCCCAAGATGATGGG 1
;
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-6753 for SEQ 1836,
US-09-422-978-5770
;
; Query Match          0.5%; Score 14.8; DB 1; Length 18;
; Best Local Similarity 88.9%; Pred. No. 7.4e+02;
; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
QY 1618 ACCCCCATGAACCGAAC 1635
      ||||| ||||| |||||
Db 1 ACCCCCATGAACCGAAC 18
;
; RESULT 772
; US-09-784-423-146/c
; Sequence 146, Application US/09784423
; Patent No. 6767703
; GENERAL INFORMATION:
; APPLICANT: Schumm, James W.
; Bacher, Jeffery W.
; TITLE OF INVENTION: MATERIALS AND METHODS FOR
; IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM
; REPEAT DNA MARKERS
; NUMBER OF SEQUENCES: 147
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Promega Corporation
; STREET: 2800 Woods Hollow Road
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: U.S.A.
; ZIP: 53711-5399
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb
; COMPUTER: IBM compatible PC
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Word 97 (DOS text format)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/784,423
; FILING DATE: 15-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/018,584
; FILING DATE: 04-Feb-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Grady J. Frenchick
; REGISTRATION NUMBER: 29,018
; REFERENCE/DOCKET NUMBER: 16026.9180
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 257-3501
; TELEFAX: (608) 257-2275
; INFORMATION FOR SEQ ID NO: 146
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 146
US-09-784-423-146
;
; Query Match          0.5%; Score 14.8; DB 1; Length 18;
; Best Local Similarity 88.9%; Pred. No. 7.4e+02;
; Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
QY 2764 TGTGTACCCAGGCTGGA 2781
      ||||| ||||| |||||
Db 18 TTTGTACCCAGACTGGA 1
;
; RESULT 773
; US-08-319-492B-705
; Sequence 705, Application US/08319492B
; Patent No. 5616488
; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS
; OF IL-5
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; SUITE: Suite 4700
```

CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
FILING DATE: US/08/319,492B
FILING DATE: October 7, 1994
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Watburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/276
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 488-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 705:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-319-492B-705

Query Match 0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 62.5%; Pred. No. 7.9e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 2117 GGCAGTCTGTCTACT 2132
Db 2 GGCACGUCUUCUUCU 17

RESULT 774
US-09-205-144-32
; Sequence 32, Application US/09205144
; Patent No. 5958771
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Elizabeth J. Ackermann
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF CELLULAR INHIBITOR OF APOPTOSIS-2 EXPRES
; FILE REFERENCE: RTS-0021
; CURRENT APPLICATION NUMBER: US/09/205,144
; CURRENT FILING DATE: 1998-12-03
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 32
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-144-32

Query Match 0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1499 TTGTCACTCATCTGT 1514
Db 2 TTGACATCATCTACTGT 17

RESULT 775
US-09-161-015-25
; Sequence 25, Application US/09161015A
; Patent No. 5965370
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF Rhog EXPRESSION
; FILE REFERENCE: RTS-0015
; CURRENT APPLICATION NUMBER: US/09/161,015A
; CURRENT FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 25
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-161-015-25

Query Match 0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 GGCAGTGTGTCACAC 1717
Db 3 GGCAGTGTGTCACAC 18

RESULT 776
US-09-387-341-168
; Sequence 168, Application US/09387341
; Patent No. 6410323
; GENERAL INFORMATION:
; APPLICANT: Roberts, M. Luisa
; APPLICANT: Cowsett, Lex M.
; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
; FILE REFERENCE: ISPH-0404
; CURRENT APPLICATION NUMBER: US/09/387,341
; CURRENT FILING DATE: 1999-08-31
; EARLIER APPLICATION NUMBER: 09/156,424
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,979
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,807
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/161,015
; EARLIER FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 233
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 168
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Synthetic
US-09-387-341-168

Query Match 0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 GGCAGTGTGTCACAC 1717
Db 3 GGCAGTGTGTCACAC 18

RESULT 777
US-09-632-098-12/C
; Sequence 12, Application US/09632098
; Patent No. 6420154

```
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Bairdur, Nand
; APPLICANT: Bishop, Paul D.
; TITLE OF INVENTION: MAMMALIAN ADHESION PROTEASE PEPTIDES
; FILE REFERENCE: 99-39
; CURRENT APPLICATION NUMBER: US/09/632,098
; CURRENT FILING DATE: 2000-08-02
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 12
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide ZC22,481
US-10-632-098-12

Query Match      0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      840 CACAGTCACCTATGGC 855
      |||||
Db      18 CACAGTCACCCATGGC 3

RESULT 778
US-10-177-308-12/c
; Sequence 12, Application US/10177308
; Patent No. 6762044
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.
; APPLICANT: Bairdur, Nand
; APPLICANT: Bishop, Paul D.
; TITLE OF INVENTION: MAMMALIAN ADHESION PROTEASE PEPTIDES
; FILE REFERENCE: 99-39
; CURRENT APPLICATION NUMBER: US/10/177,308
; CURRENT FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: US/09/632,098
; PRIOR FILING DATE: 2000-08-02
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 12
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide ZC22,481
US-10-177-308-12

Query Match      0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 7.9e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      840 CACAGTCACCTATGGC 855
      |||||
Db      18 CACAGTCACCCATGGC 3

Search completed: July 26, 2005, 15:13:25
Job time : 30 secs
```

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 26, 2005, 15:20:36 ; Search time 55 Seconds
(without alignments)
3.717 Million cell updates/sec

Title: nm000201

Perfect score: 2986

Sequence: 1 GCGCCCGAGTCGACGCTGAG.....ATAAGCTTCTCACTGCC 2986

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1638 seqs, 34233 residues

Total number of hits satisfying chosen parameters: 3276

Minimum DB seq length: 18

Maximum DB seq length: 26

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 1640 summaries

Database : rnpb201.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	25	0.8	25	1	US-10-719-900-9820
2	25	0.8	25	1	US-10-719-900-25042
3	25	0.8	25	1	US-10-719-900-64720
4	25	0.8	25	1	US-10-719-900-97347
5	25	0.8	25	1	US-10-719-900-112518
6	25	0.8	25	1	US-10-719-900-166224
7	25	0.8	25	1	US-10-719-900-179201
8	25	0.8	25	1	US-10-719-900-197837
9	25	0.8	25	1	US-10-719-900-321240
10	25	0.8	25	1	US-10-719-900-374103
11	25	0.8	25	1	US-10-719-900-475751
12	25	0.8	25	1	US-10-719-900-529450
13	25	0.8	25	1	US-10-719-900-544968
14	25	0.8	25	1	US-10-719-900-635363
15	25	0.8	25	1	US-10-719-900-652192
16	25	0.8	25	1	US-10-719-900-671642
17	25	0.8	25	1	US-10-719-900-677592
18	25	0.8	25	1	US-10-719-900-687621
19	25	0.8	25	1	US-10-719-900-705390
20	25	0.8	25	1	US-10-719-900-778514
21	25	0.8	25	1	US-10-719-900-864263
22	25	0.8	25	1	US-10-809-189-944980
23	25	0.8	25	1	US-10-809-189-31947
24	25	0.8	25	1	US-10-809-189-31948
25	25	0.8	25	1	US-10-809-189-31949
26	25	0.8	25	1	US-10-809-189-31950
27	25	0.8	25	1	US-10-809-189-31951
28	25	0.8	25	1	US-10-809-189-31952
29	25	0.8	25	1	US-10-809-189-31953
30	25	0.8	25	1	US-10-809-189-31954
31	25	0.8	25	1	US-10-809-189-31955
32	25	0.8	25	1	US-10-809-189-31956
33	25	0.8	25	1	US-10-809-189-31957

34	25	0.8	25	1	US-10-809-189-31958	Sequence 31958, A
35	25	0.8	25	1	US-10-809-189-31959	Sequence 31959, A
36	25	0.8	25	1	US-10-809-189-31960	Sequence 31960, A
37	25	0.8	25	1	US-10-809-189-31961	Sequence 31961, A
38	25	0.8	25	1	US-10-809-189-31962	Sequence 31962, A
39	25	0.8	25	1	US-10-809-189-31963	Sequence 31963, A
40	25	0.8	25	1	US-10-809-189-31964	Sequence 31964, A
41	25	0.8	25	1	US-10-809-189-31965	Sequence 31965, A
42	25	0.8	25	1	US-10-809-189-31966	Sequence 31966, A
43	25	0.8	25	1	US-10-956-157-147622	Sequence 147622, A
44	25	0.8	25	1	US-10-956-157-173784	Sequence 173784, A
45	25	0.8	25	1	US-10-956-157-186274	Sequence 186274, A
46	25	0.8	25	1	US-10-956-157-186275	Sequence 186275, A
47	25	0.8	25	1	US-10-956-157-186276	Sequence 186276, A
48	25	0.8	25	1	US-10-956-157-188294	Sequence 188294, A
49	25	0.8	25	1	US-10-956-157-189026	Sequence 189026, A
50	25	0.8	25	1	US-10-956-157-236121	Sequence 236121, A
51	25	0.8	25	1	US-10-956-157-237070	Sequence 237070, A
52	25	0.8	25	1	US-10-956-157-250153	Sequence 250153, A
53	25	0.8	25	1	US-10-956-157-267202	Sequence 267202, A
54	25	0.8	25	1	US-10-956-157-274130	Sequence 274130, A
55	25	0.8	25	1	US-10-956-157-280750	Sequence 280750, A
56	25	0.8	25	1	US-10-956-157-293226	Sequence 293226, A
57	25	0.8	25	1	US-10-956-157-298048	Sequence 298048, A
58	24	0.8	24	1	US-10-083-720A-15	Sequence 15, Appl
59	24	0.8	24	1	US-09-753-436-23	Sequence 23, Appl
60	24	0.8	24	1	US-09-753-436-24	Sequence 24, Appl
61	24	0.8	24	1	US-10-025-524-22	Sequence 22, Appl
62	24	0.8	24	1	US-10-025-524-23	Sequence 23, Appl
63	24	0.8	24	1	US-10-186-180-25	Sequence 25, Appl
64	24	0.8	24	1	US-10-163-942-23	Sequence 23, Appl
65	24	0.8	24	1	US-10-163-942-24	Sequence 24, Appl
66	24	0.8	24	1	US-10-745-115-23	Sequence 23, Appl
67	24	0.8	24	1	US-10-745-115-24	Sequence 24, Appl
68	24	0.8	24	1	US-10-916-256-15	Sequence 15, Appl
69	24	0.8	25	1	US-10-956-157-149908	Sequence 149908, A
70	24	0.8	25	1	US-10-956-157-149909	Sequence 149909, A
71	24	0.8	25	1	US-10-956-157-194300	Sequence 194300, A
72	24	0.8	25	1	US-10-956-157-204929	Sequence 204929, A
73	23.4	0.8	25	1	US-10-719-900-9819	Sequence 9819, Ap
74	23.4	0.8	25	1	US-10-719-900-25041	Sequence 25041, A
75	23.4	0.8	25	1	US-10-719-900-64719	Sequence 64719, A
76	23.4	0.8	25	1	US-10-719-900-97348	Sequence 97348, A
77	23.4	0.8	25	1	US-10-719-900-112517	Sequence 112517, A
78	23.4	0.8	25	1	US-10-719-900-166223	Sequence 166223, A
79	23.4	0.8	25	1	US-10-719-900-179202	Sequence 179202, A
80	23.4	0.8	25	1	US-10-719-900-197838	Sequence 197838, A
81	23.4	0.8	25	1	US-10-719-900-321241	Sequence 321241, A
82	23.4	0.8	25	1	US-10-719-900-374102	Sequence 374102, A
83	23.4	0.8	25	1	US-10-719-900-475750	Sequence 475750, A
84	23.4	0.8	25	1	US-10-719-900-529451	Sequence 529451, A
85	23.4	0.8	25	1	US-10-719-900-544967	Sequence 544967, A
86	23.4	0.8	25	1	US-10-719-900-635362	Sequence 635362, A
87	23.4	0.8	25	1	US-10-719-900-652193	Sequence 652193, A
88	23.4	0.8	25	1	US-10-719-900-671643	Sequence 671643, A
89	23.4	0.8	25	1	US-10-719-900-687622	Sequence 687622, A
90	23.4	0.8	25	1	US-10-719-900-705391	Sequence 705391, A
91	23.4	0.8	25	1	US-10-719-900-778515	Sequence 778515, A
92	23.4	0.8	25	1	US-10-719-900-864264	Sequence 864264, A
93	23.4	0.8	25	1	US-10-719-900-944979	Sequence 944979, A
94	23.4	0.8	25	1	US-10-956-157-134268	Sequence 134268, A
95	23.4	0.8	25	1	US-10-956-157-149515	Sequence 149515, A
96	23.4	0.8	25	1	US-10-956-157-149516	Sequence 149516, A
97	23.4	0.8	25	1	US-10-956-157-149712	Sequence 149712, A
98	23.4	0.8	25	1	US-10-956-157-150170	Sequence 150170, A
99	23.4	0.8	25	1	US-10-956-157-172502	Sequence 172502, A
100	23.4	0.8	25	1	US-10-956-157-172503	Sequence 172503, A
101	23.4	0.8	25	1	US-10-956-157-172504	Sequence 172504, A
102	23.4	0.8	25	1	US-10-956-157-172905	Sequence 172905, A
103	23.4	0.8	25	1	US-10-956-157-173075	Sequence 173075, A
104	23.4	0.8	25	1	US-10-956-157-173076	Sequence 173076, A
105	23.4	0.8	25	1	US-10-956-157-173079	Sequence 173079, A
106	23.4	0.8	25	1	US-10-956-157-173079	Sequence 173079, A

C 399	20.4	0.7	25	1	US-10-956-157-283686	Sequence 283686,	C 472	20.2	0.7	25	1	US-10-681-773-35331	Sequence 35331, A
C 400	20.4	0.7	25	1	US-10-956-157-287539	Sequence 287539,	C 473	20.2	0.7	25	1	US-10-681-773-69661	Sequence 69661, A
C 401	20.4	0.7	25	1	US-10-956-157-287740	Sequence 287740,	C 474	20.2	0.7	25	1	US-10-681-773-70701	Sequence 70701, A
C 402	20.4	0.7	25	1	US-10-956-157-292068	Sequence 292068,	C 475	20.2	0.7	25	1	US-10-719-956-575924	Sequence 575924, A
C 403	20.4	0.7	25	1	US-10-956-157-297564	Sequence 297564,	C 476	20	0.7	20	1	US-09-726-096A-8	Sequence 8, Appl1
C 404	20.4	0.7	25	1	US-10-956-157-299664	Sequence 299664,	C 477	20	0.7	20	1	US-09-876-242-2	Sequence 2, Appl1
C 405	20.4	0.7	25	1	US-10-956-157-299666	Sequence 299666,	C 478	20	0.7	20	1	US-09-370-541-18	Sequence 18, Appl1
C 406	20.4	0.7	25	1	US-10-956-157-299668	Sequence 299668,	C 479	20	0.7	20	1	US-10-318-628-2	Sequence 2, Appl1
C 407	20.2	0.7	25	1	US-10-719-900-717061	Sequence 717061,	C 480	20	0.7	20	1	US-10-318-628-8	Sequence 8, Appl1
C 408	20.2	0.7	25	1	US-10-809-189-731177	Sequence 731177, A	C 481	20	0.7	20	1	US-10-318-628-11	Sequence 11, Appl1
C 409	20.2	0.7	25	1	US-10-956-157-10472	Sequence 10472, A	C 482	20	0.7	20	1	US-10-318-628-17	Sequence 17, Appl1
C 410	20.2	0.7	25	1	US-10-956-157-26478	Sequence 26478, A	C 483	20	0.7	20	1	US-10-318-628-22	Sequence 22, Appl1
C 411	20.2	0.7	25	1	US-10-956-157-26689	Sequence 26689, A	C 484	20	0.7	20	1	US-10-318-628-23	Sequence 23, Appl1
C 412	20.2	0.7	25	1	US-10-956-157-26689	Sequence 26689, A	C 485	20	0.7	20	1	US-10-318-628-25	Sequence 25, Appl1
C 413	20.2	0.7	25	1	US-10-956-157-67008	Sequence 67008, A	C 486	20	0.7	20	1	US-10-318-628-31	Sequence 31, Appl1
C 414	20.2	0.7	25	1	US-10-956-157-69904	Sequence 69904, A	C 487	20	0.7	20	1	US-10-318-628-33	Sequence 33, Appl1
C 415	20.2	0.7	25	1	US-10-956-157-72784	Sequence 72784, A	C 488	20	0.7	20	1	US-10-318-628-38	Sequence 38, Appl1
C 416	20.2	0.7	25	1	US-10-956-157-79341	Sequence 79341, A	C 489	20	0.7	20	1	US-10-318-628-40	Sequence 40, Appl1
C 417	20.2	0.7	25	1	US-10-956-157-79352	Sequence 79352, A	C 490	20	0.7	20	1	US-10-318-628-46	Sequence 46, Appl1
C 418	20.2	0.7	25	1	US-10-956-157-90103	Sequence 90103, A	C 491	20	0.7	20	1	US-10-318-628-58	Sequence 2, Appl1
C 419	20.2	0.7	25	1	US-10-956-157-90111	Sequence 90111, A	C 492	20	0.7	20	1	US-09-747-772-3	Sequence 3, Appl1
C 420	20.2	0.7	25	1	US-10-956-157-90114	Sequence 90114, A	C 493	20	0.7	20	1	US-09-747-772-4	Sequence 4, Appl1
C 421	20.2	0.7	25	1	US-10-956-157-128291	Sequence 128291,	C 494	20	0.7	20	1	US-10-029-598-1	Sequence 1, Appl1
C 422	20.2	0.7	25	1	US-10-956-157-134266	Sequence 134266,	C 495	20	0.7	20	1	US-10-029-598-2	Sequence 2, Appl1
C 423	20.2	0.7	25	1	US-10-956-157-134267	Sequence 134267,	C 496	20	0.7	20	1	US-10-029-598-55	Sequence 55, Appl1
C 424	20.2	0.7	25	1	US-10-956-157-135196	Sequence 135196,	C 497	20	0.7	20	1	US-09-835-370-41	Sequence 41, Appl1
C 425	20.2	0.7	25	1	US-10-956-157-135335	Sequence 135335,	C 498	20	0.7	20	1	US-09-835-370-42	Sequence 42, Appl1
C 426	20.2	0.7	25	1	US-10-956-157-136947	Sequence 136947,	C 499	20	0.7	20	1	US-09-835-370-43	Sequence 43, Appl1
C 427	20.2	0.7	25	1	US-10-956-157-137117	Sequence 137117,	C 500	20	0.7	20	1	US-10-103-906-1	Sequence 1, Appl1
C 428	20.2	0.7	25	1	US-10-956-157-137483	Sequence 137483,	C 501	20	0.7	20	1	US-10-083-720A-13	Sequence 13, Appl1
C 429	20.2	0.7	25	1	US-10-956-157-146704	Sequence 146704,	C 502	20	0.7	20	1	US-10-234-764-5	Sequence 5, Appl1
C 430	20.2	0.7	25	1	US-10-956-157-149517	Sequence 149517,	C 503	20	0.7	20	1	US-10-192-437-11	Sequence 11, Appl1
C 431	20.2	0.7	25	1	US-10-956-157-149711	Sequence 149711,	C 504	20	0.7	20	1	US-10-073-718-17	Sequence 17, Appl1
C 432	20.2	0.7	25	1	US-10-956-157-173066	Sequence 173066,	C 505	20	0.7	20	1	US-09-808-680-1	Sequence 9, Appl1
C 433	20.2	0.7	25	1	US-10-956-157-173077	Sequence 173077,	C 506	20	0.7	20	1	US-09-808-680-9	Sequence 9, Appl1
C 434	20.2	0.7	25	1	US-10-956-157-173078	Sequence 173078,	C 507	20	0.7	20	1	US-09-808-680-10	Sequence 10, Appl1
C 435	20.2	0.7	25	1	US-10-956-157-173080	Sequence 173080,	C 508	20	0.7	20	1	US-09-794-824-1	Sequence 1, Appl1
C 436	20.2	0.7	25	1	US-10-956-157-174133	Sequence 174133,	C 509	20	0.7	20	1	US-09-794-824-5	Sequence 5, Appl1
C 437	20.2	0.7	25	1	US-10-956-157-175078	Sequence 175078,	C 510	20	0.7	20	1	US-09-794-824-7	Sequence 7, Appl1
C 438	20.2	0.7	25	1	US-10-956-157-177069	Sequence 177069,	C 511	20	0.7	20	1	US-09-949-093-3	Sequence 3, Appl1
C 439	20.2	0.7	25	1	US-10-956-157-177126	Sequence 177126,	C 512	20	0.7	20	1	US-09-949-093-4	Sequence 4, Appl1
C 440	20.2	0.7	25	1	US-10-956-157-177127	Sequence 177127,	C 513	20	0.7	20	1	US-09-860-784-21	Sequence 21, Appl1
C 441	20.2	0.7	25	1	US-10-956-157-177128	Sequence 177128,	C 514	20	0.7	20	1	US-09-860-784-22	Sequence 22, Appl1
C 442	20.2	0.7	25	1	US-10-956-157-177525	Sequence 177525,	C 515	20	0.7	20	1	US-09-949-474-4	Sequence 4, Appl1
C 443	20.2	0.7	25	1	US-10-956-157-180784	Sequence 180784,	C 516	20	0.7	20	1	US-09-965-551-1	Sequence 1, Appl1
C 444	20.2	0.7	25	1	US-10-956-157-184259	Sequence 184259,	C 517	20	0.7	20	1	US-09-965-551-3	Sequence 3, Appl1
C 445	20.2	0.7	25	1	US-10-956-157-186418	Sequence 186418,	C 518	20	0.7	20	1	US-09-965-551-4	Sequence 4, Appl1
C 446	20.2	0.7	25	1	US-10-956-157-199807	Sequence 199807,	C 519	20	0.7	20	1	US-09-965-551-5	Sequence 5, Appl1
C 447	20.2	0.7	25	1	US-10-956-157-199808	Sequence 199808,	C 520	20	0.7	20	1	US-09-965-551-6	Sequence 6, Appl1
C 448	20.2	0.7	25	1	US-10-956-157-201830	Sequence 201830,	C 521	20	0.7	20	1	US-09-965-551-7	Sequence 7, Appl1
C 449	20.2	0.7	25	1	US-10-956-157-206905	Sequence 206905,	C 522	20	0.7	20	1	US-09-965-551-8	Sequence 8, Appl1
C 450	20.2	0.7	25	1	US-10-956-157-228954	Sequence 228954,	C 523	20	0.7	20	1	US-09-965-551-9	Sequence 9, Appl1
C 451	20.2	0.7	25	1	US-10-956-157-231367	Sequence 231367,	C 524	20	0.7	20	1	US-09-965-551-11	Sequence 11, Appl1
C 452	20.2	0.7	25	1	US-10-956-157-235192	Sequence 235192,	C 525	20	0.7	20	1	US-09-965-551-13	Sequence 13, Appl1
C 453	20.2	0.7	25	1	US-10-956-157-236289	Sequence 236289,	C 526	20	0.7	20	1	US-09-835-371-41	Sequence 41, Appl1
C 454	20.2	0.7	25	1	US-10-956-157-237035	Sequence 237035,	C 527	20	0.7	20	1	US-09-835-371-42	Sequence 42, Appl1
C 455	20.2	0.7	25	1	US-10-956-157-237036	Sequence 237036,	C 528	20	0.7	20	1	US-09-835-371-43	Sequence 43, Appl1
C 456	20.2	0.7	25	1	US-10-956-157-252918	Sequence 252918,	C 529	20	0.7	20	1	US-09-824-322B-41	Sequence 41, Appl1
C 457	20.2	0.7	25	1	US-10-956-157-255341	Sequence 255341,	C 530	20	0.7	20	1	US-09-824-322B-49	Sequence 49, Appl1
C 458	20.2	0.7	25	1	US-10-956-157-266272	Sequence 266272,	C 531	20	0.7	20	1	US-09-933-300-36	Sequence 36, Appl1
C 459	20.2	0.7	25	1	US-10-956-157-266967	Sequence 266967,	C 532	20	0.7	20	1	US-09-982-262B-2	Sequence 2, Appl1
C 460	20.2	0.7	25	1	US-10-956-157-267711	Sequence 267711,	C 533	20	0.7	20	1	US-09-982-262B-7	Sequence 7, Appl1
C 461	20.2	0.7	25	1	US-10-956-157-268065	Sequence 268065,	C 534	20	0.7	20	1	US-09-982-262B-8	Sequence 8, Appl1
C 462	20.2	0.7	25	1	US-10-956-157-268263	Sequence 268263,	C 535	20	0.7	20	1	US-09-982-262B-9	Sequence 9, Appl1
C 463	20.2	0.7	25	1	US-10-956-157-268264	Sequence 268264,	C 536	20	0.7	20	1	US-09-982-262B-10	Sequence 10, Appl1
C 464	20.2	0.7	25	1	US-10-956-157-274587	Sequence 274587,	C 537	20	0.7	20	1	US-09-982-262B-11	Sequence 11, Appl1
C 465	20.2	0.7	25	1	US-10-956-157-274588	Sequence 274588,	C 538	20	0.7	20	1	US-09-982-262B-12	Sequence 12, Appl1
C 466	20.2	0.7	25	1	US-10-956-157-278091	Sequence 278091,	C 539	20	0.7	20	1	US-09-982-262B-13	Sequence 13, Appl1
C 467	20.2	0.7	25	1	US-10-956-157-283255	Sequence 283255,	C 540	20	0.7	20	1	US-09-982-262B-14	Sequence 14, Appl1
C 468	20.2	0.7	25	1	US-10-956-157-285780	Sequence 285780,	C 541	20	0.7	20	1	US-09-982-262B-15	Sequence 15, Appl1
C 469	20.2	0.7	25	1	US-10-956-157-295898	Sequence 295898,	C 542	20	0.7	20	1	US-09-982-262B-16	Sequence 16, Appl1
C 470	20.2	0.7	25	1	US-10-956-157-297532	Sequence 297532,	C 543	20	0.7	20	1	US-09-982-262B-22	Sequence 22, Appl1
C 471	20.2	0.7	25	1	US-10-956-157-319011	Sequence 319011,	C 544	20	0.7	20	1	US-09-982-262B-23	Sequence 23, Appl1

c 545	20	0.7	20	1	US-09-982-362B-24	Sequence 24, Appl	c 618	20	0.7	20	1	US-10-454-663-16	Sequence 16, Appl
c 546	20	0.7	20	1	US-09-982-362B-25	Sequence 25, Appl	c 619	20	0.7	20	1	US-10-454-663-22	Sequence 22, Appl
c 547	20	0.7	20	1	US-09-982-362B-26	Sequence 26, Appl	c 620	20	0.7	20	1	US-10-454-663-23	Sequence 23, Appl
c 548	20	0.7	20	1	US-09-982-362B-84	Sequence 84, Appl	c 621	20	0.7	20	1	US-10-454-663-24	Sequence 24, Appl
c 549	20	0.7	20	1	US-09-982-362B-85	Sequence 85, Appl	c 622	20	0.7	20	1	US-10-454-663-25	Sequence 25, Appl
c 550	20	0.7	20	1	US-09-935-316-1	Sequence 1, Appl	c 623	20	0.7	20	1	US-10-454-663-26	Sequence 26, Appl
c 551	20	0.7	20	1	US-09-935-316-2	Sequence 2, Appl	c 624	20	0.7	20	1	US-10-454-663-84	Sequence 84, Appl
c 552	20	0.7	20	1	US-09-902-953-1	Sequence 1, Appl	c 625	20	0.7	20	1	US-10-454-663-85	Sequence 85, Appl
c 553	20	0.7	20	1	US-09-902-953-2	Sequence 2, Appl	c 626	20	0.7	20	1	US-10-636-452-1	Sequence 1, Appl
c 554	20	0.7	20	1	US-09-970-971A-25	Sequence 25, Appl	c 627	20	0.7	20	1	US-10-636-452-5	Sequence 5, Appl
c 555	20	0.7	20	1	US-09-944-493-1	Sequence 1, Appl	c 628	20	0.7	20	1	US-10-636-452-7	Sequence 7, Appl
c 556	20	0.7	20	1	US-09-944-493-2	Sequence 2, Appl	c 629	20	0.7	20	1	US-10-636-452-7	Sequence 7, Appl
c 557	20	0.7	20	1	US-09-895-480A-2	Sequence 2, Appl	c 630	20	0.7	20	1	US-10-671-395-1144	Sequence 1144, Ap
c 558	20	0.7	20	1	US-09-946-172A-1	Sequence 1, Appl	c 631	20	0.7	20	1	US-10-671-395-1268	Sequence 1268, Ap
c 559	20	0.7	20	1	US-09-882-945A-145	Sequence 145, App	c 632	20	0.7	20	1	US-10-671-395-1453	Sequence 1453, Ap
c 560	20	0.7	20	1	US-09-882-945A-147	Sequence 147, App	c 633	20	0.7	20	1	US-10-671-395-1543	Sequence 1543, Ap
c 561	20	0.7	20	1	US-09-882-945A-148	Sequence 148, App	c 634	20	0.7	20	1	US-10-745-377-65	Sequence 1550, Ap
c 562	20	0.7	20	1	US-09-882-945A-149	Sequence 149, App	c 635	20	0.7	20	1	US-10-745-377-65	Sequence 65, Appl
c 563	20	0.7	20	1	US-09-851-871-17	Sequence 17, Appl	c 636	20	0.7	20	1	US-10-664-639A-1	Sequence 1, Appl
c 564	20	0.7	20	1	US-09-793-146-20	Sequence 20, Appl	c 637	20	0.7	20	1	US-10-664-639A-2	Sequence 2, Appl
c 565	20	0.7	20	1	US-09-793-146-21	Sequence 21, Appl	c 638	20	0.7	20	1	US-10-664-639A-3	Sequence 3, Appl
c 566	20	0.7	20	1	US-09-823-031-12	Sequence 12, Appl	c 639	20	0.7	20	1	US-10-664-639A-4	Sequence 4, Appl
c 567	20	0.7	20	1	US-10-071-822A-2	Sequence 2, Appl	c 640	20	0.7	20	1	US-10-664-639A-5	Sequence 5, Appl
c 568	20	0.7	20	1	US-10-117-267-8	Sequence 8, Appl	c 641	20	0.7	20	1	US-10-664-639A-6	Sequence 6, Appl
c 569	20	0.7	20	1	US-10-085-306-302	Sequence 302, App	c 642	20	0.7	20	1	US-10-664-639A-7	Sequence 7, Appl
c 570	20	0.7	20	1	US-10-154-993-17	Sequence 17, Appl	c 643	20	0.7	20	1	US-10-664-639A-8	Sequence 8, Appl
c 571	20	0.7	20	1	US-10-232-881-2	Sequence 2, Appl	c 644	20	0.7	20	1	US-10-664-639A-9	Sequence 9, Appl
c 572	20	0.7	20	1	US-10-232-881-4	Sequence 4, Appl	c 645	20	0.7	20	1	US-10-664-639A-10	Sequence 10, Appl
c 573	20	0.7	20	1	US-10-251-699-1	Sequence 1, Appl	c 646	20	0.7	20	1	US-10-664-639A-11	Sequence 11, Appl
c 574	20	0.7	20	1	US-10-086-477A-1	Sequence 1, Appl	c 647	20	0.7	20	1	US-10-664-639A-12	Sequence 12, Appl
c 575	20	0.7	20	1	US-10-186-180-23	Sequence 23, Appl	c 648	20	0.7	20	1	US-10-664-639A-13	Sequence 13, Appl
c 576	20	0.7	20	1	US-10-012-010B-2	Sequence 2, Appl	c 649	20	0.7	20	1	US-10-664-639A-14	Sequence 14, Appl
c 577	20	0.7	20	1	US-10-290-545-11	Sequence 11, Appl	c 650	20	0.7	20	1	US-10-664-639A-15	Sequence 15, Appl
c 578	20	0.7	20	1	US-10-290-545-12	Sequence 12, Appl	c 651	20	0.7	20	1	US-10-664-639A-16	Sequence 16, Appl
c 579	20	0.7	20	1	US-10-262-318-2	Sequence 2, Appl	c 652	20	0.7	20	1	US-10-664-639A-17	Sequence 17, Appl
c 580	20	0.7	20	1	US-10-337-004-1	Sequence 1, Appl	c 653	20	0.7	20	1	US-10-664-639A-18	Sequence 18, Appl
c 581	20	0.7	20	1	US-10-337-004-2	Sequence 2, Appl	c 654	20	0.7	20	1	US-10-664-639A-19	Sequence 19, Appl
c 582	20	0.7	20	1	US-10-203-780-12	Sequence 12, Appl	c 655	20	0.7	20	1	US-10-664-639A-20	Sequence 20, Appl
c 583	20	0.7	20	1	US-10-365-623-2	Sequence 2, Appl	c 656	20	0.7	20	1	US-10-664-639A-21	Sequence 21, Appl
c 584	20	0.7	20	1	US-10-284-742-17	Sequence 17, Appl	c 657	20	0.7	20	1	US-10-664-639A-22	Sequence 22, Appl
c 585	20	0.7	20	1	US-10-140-013-10	Sequence 10, Appl	c 658	20	0.7	20	1	US-10-664-639A-23	Sequence 23, Appl
c 586	20	0.7	20	1	US-10-140-013-14	Sequence 14, Appl	c 659	20	0.7	20	1	US-10-664-639A-24	Sequence 24, Appl
c 587	20	0.7	20	1	US-10-084-839-3896	Sequence 3896, Ap	c 660	20	0.7	20	1	US-10-664-639A-25	Sequence 25, Appl
c 588	20	0.7	20	1	US-10-119-432A-1	Sequence 1, Appl	c 661	20	0.7	20	1	US-10-664-639A-26	Sequence 26, Appl
c 589	20	0.7	20	1	US-10-080-979-17	Sequence 17, Appl	c 662	20	0.7	20	1	US-10-664-639A-27	Sequence 27, Appl
c 590	20	0.7	20	1	US-10-323-591-3	Sequence 3, Appl	c 663	20	0.7	20	1	US-10-664-639A-28	Sequence 28, Appl
c 591	20	0.7	20	1	US-10-423-311-11	Sequence 11, Appl	c 664	20	0.7	20	1	US-10-664-639A-29	Sequence 29, Appl
c 592	20	0.7	20	1	US-10-181-200-2	Sequence 2, Appl	c 665	20	0.7	20	1	US-10-664-639A-30	Sequence 30, Appl
c 593	20	0.7	20	1	US-10-181-200-8	Sequence 8, Appl	c 666	20	0.7	20	1	US-10-664-639A-31	Sequence 31, Appl
c 594	20	0.7	20	1	US-10-181-200-9	Sequence 9, Appl	c 667	20	0.7	20	1	US-10-664-639A-32	Sequence 32, Appl
c 595	20	0.7	20	1	US-10-181-200-14	Sequence 14, Appl	c 668	20	0.7	20	1	US-10-664-639A-33	Sequence 33, Appl
c 596	20	0.7	20	1	US-10-444-445-2	Sequence 2, Appl	c 669	20	0.7	20	1	US-10-664-639A-34	Sequence 34, Appl
c 597	20	0.7	20	1	US-10-445-996-2	Sequence 2, Appl	c 670	20	0.7	20	1	US-10-664-639A-35	Sequence 35, Appl
c 598	20	0.7	20	1	US-10-359-328-1	Sequence 1, Appl	c 671	20	0.7	20	1	US-10-664-639A-36	Sequence 36, Appl
c 599	20	0.7	20	1	US-10-359-328-2	Sequence 2, Appl	c 672	20	0.7	20	1	US-10-664-639A-37	Sequence 37, Appl
c 600	20	0.7	20	1	US-10-359-328-4	Sequence 4, Appl	c 673	20	0.7	20	1	US-10-664-639A-38	Sequence 38, Appl
c 601	20	0.7	20	1	US-10-437-263-11	Sequence 11, Appl	c 674	20	0.7	20	1	US-10-664-639A-39	Sequence 39, Appl
c 602	20	0.7	20	1	US-10-437-263-12	Sequence 12, Appl	c 675	20	0.7	20	1	US-10-664-639A-40	Sequence 40, Appl
c 603	20	0.7	20	1	US-10-437-275-11	Sequence 11, Appl	c 676	20	0.7	20	1	US-10-652-795-41	Sequence 41, Appl
c 604	20	0.7	20	1	US-10-437-275-12	Sequence 12, Appl	c 677	20	0.7	20	1	US-10-652-795-49	Sequence 49, Appl
c 605	20	0.7	20	1	US-10-437-258-11	Sequence 11, Appl	c 678	20	0.7	20	1	US-10-780-439-17	Sequence 17, Appl
c 606	20	0.7	20	1	US-10-437-258-12	Sequence 12, Appl	c 679	20	0.7	20	1	US-10-789-113-3	Sequence 3, Appl
c 607	20	0.7	20	1	US-10-444-206-17	Sequence 17, Appl	c 680	20	0.7	20	1	US-10-789-113-4	Sequence 4, Appl
c 608	20	0.7	20	1	US-10-454-663-2	Sequence 2, Appl	c 681	20	0.7	20	1	US-10-647-918-41	Sequence 41, Appl
c 609	20	0.7	20	1	US-10-454-663-7	Sequence 7, Appl	c 682	20	0.7	20	1	US-10-647-918-49	Sequence 49, Appl
c 610	20	0.7	20	1	US-10-454-663-8	Sequence 8, Appl	c 683	20	0.7	20	1	US-10-777-838-1	Sequence 1, Appl
c 611	20	0.7	20	1	US-10-454-663-9	Sequence 9, Appl	c 684	20	0.7	20	1	US-10-777-838-2	Sequence 2, Appl
c 612	20	0.7	20	1	US-10-454-663-10	Sequence 10, Appl	c 685	20	0.7	20	1	US-10-727-109-1	Sequence 1, Appl
c 613	20	0.7	20	1	US-10-454-663-11	Sequence 11, Appl	c 686	20	0.7	20	1	US-10-727-109-6	Sequence 6, Appl
c 614	20	0.7	20	1	US-10-454-663-12	Sequence 12, Appl	c 687	20	0.7	20	1	US-10-727-109-9	Sequence 9, Appl
c 615	20	0.7	20	1	US-10-454-663-13	Sequence 13, Appl	c 688	20	0.7	20	1	US-10-760-940-2	Sequence 2, Appl
c 616	20	0.7	20	1	US-10-454-663-14	Sequence 14, Appl	c 689	20	0.7	20	1	US-10-760-940-4	Sequence 4, Appl
c 617	20	0.7	20	1	US-10-454-663-15	Sequence 15, Appl	c 690	20	0.7	20	1	US-10-872-113-65	Sequence 65, Appl

C 691	20	0.7	20	1	US-10-793-497-1	Sequence 1, Appli	764	19	0.6	19	1	US-10-759-878-9	Sequence 9, Appli
C 692	20	0.7	20	1	US-10-793-497-2	Sequence 2, Appli	765	19	0.6	19	1	US-10-759-878-10	Sequence 10, Appl
C 693	20	0.7	20	1	US-10-793-497-55	Sequence 55, Appl	766	19	0.6	19	1	US-10-759-878-11	Sequence 11, Appl
C 694	20	0.7	20	1	US-10-807-114-145	Sequence 145, App	767	19	0.6	19	1	US-10-759-878-12	Sequence 12, Appl
C 695	20	0.7	20	1	US-10-807-114-147	Sequence 147, App	768	19	0.6	19	1	US-10-759-878-13	Sequence 13, Appl
C 696	20	0.7	20	1	US-10-807-114-148	Sequence 148, App	769	19	0.6	19	1	US-10-759-878-14	Sequence 14, Appl
C 697	20	0.7	20	1	US-10-807-114-149	Sequence 149, App	770	19	0.6	19	1	US-10-759-878-15	Sequence 15, Appl
C 698	20	0.7	20	1	US-10-841-962-17	Sequence 17, Appl	771	19	0.6	19	1	US-10-759-878-16	Sequence 16, Appl
C 699	20	0.7	20	1	US-10-863-999-41	Sequence 41, Appl	772	19	0.6	19	1	US-10-759-878-17	Sequence 17, Appl
C 700	20	0.7	20	1	US-10-863-999-42	Sequence 42, Appl	773	19	0.6	19	1	US-10-759-878-18	Sequence 18, Appl
C 701	20	0.7	20	1	US-10-863-999-43	Sequence 43, Appl	774	19	0.6	19	1	US-10-759-878-19	Sequence 19, Appl
C 702	20	0.7	20	1	US-10-925-734-2	Sequence 2, Appli	c 775	19	0.6	19	1	US-10-745-115-22	Sequence 22, Appl
C 703	20	0.7	20	1	US-10-858-658-41	Sequence 41, Appl	c 776	19	0.6	19	1	US-10-863-999-44	Sequence 44, Appl
C 704	20	0.7	20	1	US-10-858-658-42	Sequence 42, Appl	c 777	19	0.6	19	1	US-10-858-658-44	Sequence 44, Appl
C 705	20	0.7	20	1	US-10-858-658-43	Sequence 43, Appl	c 778	19	0.6	19	1	US-10-858-658-44	Sequence 44, Appl
C 706	20	0.7	20	1	US-10-916-256-13	Sequence 13, Appl	c 779	19	0.6	19	1	US-10-741-600-73889	Sequence 73889, A
C 707	20	0.7	20	1	US-10-624-570-1	Sequence 1, Appli	780	19	0.6	19	1	US-10-939-214-22	Sequence 22, Appl
C 708	20	0.7	20	1	US-10-858-917-1	Sequence 1, Appli	781	19	0.6	19	1	US-10-800-487-1	Sequence 1, Appli
C 709	20	0.7	20	1	US-10-858-917-4	Sequence 4, Appli	782	19	0.6	19	1	US-10-800-487-2	Sequence 2, Appli
C 710	20	0.7	20	1	US-10-939-214-20	Sequence 20, Appl	783	19	0.6	19	1	US-10-800-487-3	Sequence 3, Appli
C 711	20	0.7	20	1	US-10-939-214-21	Sequence 21, Appl	784	19	0.6	19	1	US-10-800-487-4	Sequence 4, Appli
C 712	20	0.7	20	1	US-10-755-166-17	Sequence 17, Appl	785	19	0.6	19	1	US-10-800-487-5	Sequence 5, Appli
C 713	20	0.7	20	1	US-10-770-970-41	Sequence 41, Appl	786	19	0.6	19	1	US-10-800-487-6	Sequence 6, Appli
C 714	20	0.7	20	1	US-10-770-970-49	Sequence 49, Appl	787	19	0.6	19	1	US-10-800-487-7	Sequence 7, Appli
C 715	20	0.7	20	1	US-10-792-374-3	Sequence 3, Appli	788	19	0.6	19	1	US-10-800-487-8	Sequence 8, Appli
C 716	20	0.7	20	1	US-10-876-962A-1	Sequence 1, Appli	789	19	0.6	19	1	US-10-800-487-9	Sequence 9, Appli
C 717	20	0.7	20	1	US-10-876-962A-2	Sequence 2, Appli	790	19	0.6	19	1	US-10-800-487-10	Sequence 10, Appl
C 718	20	0.7	20	1	US-10-940-360-2	Sequence 2, Appli	791	19	0.6	19	1	US-10-800-487-11	Sequence 11, Appl
C 719	20	0.7	20	1	US-10-940-360-4	Sequence 4, Appli	792	19	0.6	19	1	US-10-800-487-12	Sequence 12, Appl
C 720	20	0.7	21	1	US-10-084-839-3887	Sequence 3887, Ap	793	19	0.6	19	1	US-10-800-487-13	Sequence 13, Appl
C 721	20	0.7	22	1	US-09-982-262B-27	Sequence 27, Appl	794	19	0.6	19	1	US-10-800-487-14	Sequence 14, Appl
C 722	20	0.7	22	1	US-10-454-663-27	Sequence 27, Appl	795	19	0.6	19	1	US-10-800-487-15	Sequence 15, Appl
C 723	20	0.7	24	1	US-09-860-784-87	Sequence 87, Appl	796	19	0.6	19	1	US-10-800-487-16	Sequence 16, Appl
C 724	20	0.7	24	1	US-09-860-784-88	Sequence 88, Appl	797	19	0.6	19	1	US-10-800-487-17	Sequence 17, Appl
C 725	20	0.7	25	1	US-10-956-157-26681	Sequence 26681, A	798	19	0.6	19	1	US-10-800-487-18	Sequence 18, Appl
C 726	20	0.7	25	1	US-10-956-157-26683	Sequence 26683, A	799	19	0.6	19	1	US-10-800-487-19	Sequence 19, Appl
C 727	20	0.7	25	1	US-10-956-157-206690	Sequence 206690	800	19	0.6	19	1	US-10-800-487-20	Sequence 20, Appl
C 728	20	0.7	25	1	US-10-956-157-216381	Sequence 216381,	801	19	0.6	19	1	US-10-800-487-21	Sequence 21, Appl
C 729	20	0.7	25	1	US-10-956-157-216382	Sequence 216382,	802	19	0.6	19	1	US-10-800-487-22	Sequence 22, Appl
C 730	20	0.7	25	1	US-10-956-157-292271	Sequence 292271,	803	19	0.6	19	1	US-10-800-487-23	Sequence 23, Appl
C 731	19.8	0.7	23	1	US-10-357-488-5	Sequence 5, Appli	804	19	0.6	19	1	US-10-800-487-24	Sequence 24, Appl
C 732	19.8	0.7	24	1	US-09-784-423-96	Sequence 96, Appl	805	19	0.6	19	1	US-10-800-487-25	Sequence 25, Appl
C 733	19.6	0.7	21	1	US-10-730-771-119	Sequence 119, App	806	19	0.6	19	1	US-10-800-487-26	Sequence 26, Appl
C 734	19.4	0.6	21	1	US-09-735-363A-19	Sequence 19, Appl	807	19	0.6	19	1	US-10-800-487-27	Sequence 27, Appl
C 735	19.4	0.6	21	1	US-09-735-363A-20	Sequence 20, Appl	808	19	0.6	19	1	US-10-800-487-28	Sequence 28, Appl
C 736	19.4	0.6	21	1	US-09-998-425-61	Sequence 61, Appl	809	19	0.6	19	1	US-10-800-487-29	Sequence 29, Appl
C 737	19.4	0.6	21	1	US-09-997-977-61	Sequence 61, Appl	810	19	0.6	19	1	US-10-800-487-30	Sequence 30, Appl
C 738	19.4	0.6	21	1	US-09-776-479-907	Sequence 907, App	811	19	0.6	19	1	US-10-800-487-31	Sequence 31, Appl
C 739	19.4	0.6	21	1	US-09-776-479-907	Sequence 907, App	812	19	0.6	19	1	US-10-800-487-32	Sequence 32, Appl
C 740	19.4	0.6	21	1	US-10-112-653-876	Sequence 876, App	813	19	0.6	19	1	US-10-800-487-33	Sequence 33, Appl
C 741	19.4	0.6	21	1	US-10-017-995-907	Sequence 907, App	814	19	0.6	19	1	US-10-800-487-34	Sequence 34, Appl
C 742	19.4	0.6	21	1	US-10-255-434-25	Sequence 25, Appl	815	19	0.6	19	1	US-10-800-487-35	Sequence 35, Appl
C 743	19.4	0.6	21	1	US-10-314-578-907	Sequence 907, App	816	19	0.6	19	1	US-10-800-487-36	Sequence 36, Appl
C 744	19.4	0.6	21	1	US-10-051-874-259	Sequence 259, App	817	19	0.6	19	1	US-10-800-487-37	Sequence 37, Appl
C 745	19.4	0.6	21	1	US-10-786-720-20230	Sequence 20230, A	818	19	0.6	19	1	US-10-800-487-38	Sequence 38, Appl
C 746	19.4	0.6	21	1	US-10-831-778-907	Sequence 907, App	819	19	0.6	19	1	US-10-800-487-39	Sequence 39, Appl
C 747	19.2	0.6	24	1	US-09-769-207A-19	Sequence 19, Appl	820	19	0.6	19	1	US-10-800-487-40	Sequence 40, Appl
C 748	19.2	0.6	24	1	US-10-196-095-3	Sequence 3, Appli	821	19	0.6	19	1	US-10-800-487-41	Sequence 41, Appl
C 749	19.2	0.6	24	1	US-10-196-095-12	Sequence 12, Appl	822	19	0.6	19	1	US-10-800-487-42	Sequence 42, Appl
C 750	19.2	0.6	24	1	US-10-268-311-19	Sequence 19, Appl	823	19	0.6	19	1	US-10-800-487-43	Sequence 43, Appl
C 751	19.2	0.6	24	1	US-10-474-553-10	Sequence 10, Appl	824	19	0.6	19	1	US-10-800-487-44	Sequence 44, Appl
C 752	19	0.6	19	1	US-09-835-370-44	Sequence 44, Appl	825	19	0.6	19	1	US-10-800-487-45	Sequence 45, Appl
C 753	19	0.6	19	1	US-09-753-436-22	Sequence 22, Appl	826	19	0.6	19	1	US-10-800-487-46	Sequence 46, Appl
C 754	19	0.6	19	1	US-09-860-784-23	Sequence 23, Appl	827	19	0.6	19	1	US-10-800-487-47	Sequence 47, Appl
C 755	19	0.6	19	1	US-09-835-371-44	Sequence 44, Appl	828	19	0.6	19	1	US-10-800-487-48	Sequence 48, Appl
C 756	19	0.6	19	1	US-09-793-146-22	Sequence 22, Appl	829	19	0.6	19	1	US-10-800-487-49	Sequence 49, Appl
C 757	19	0.6	19	1	US-10-145-181C-4	Sequence 4, Appli	830	19	0.6	19	1	US-10-800-487-50	Sequence 50, Appl
C 758	19	0.6	19	1	US-10-084-839-3892	Sequence 3892, Ap	831	19	0.6	19	1	US-10-800-487-51	Sequence 51, Appl
C 759	19	0.6	19	1	US-10-119-432A-2	Sequence 2, Appli	832	19	0.6	19	1	US-10-800-487-52	Sequence 52, Appl
C 760	19	0.6	19	1	US-10-323-591-4	Sequence 4, Appli	833	19	0.6	19	1	US-10-800-487-53	Sequence 53, Appl
C 761	19	0.6	19	1	US-10-163-942-22	Sequence 22, Appl	834	19	0.6	19	1	US-10-800-487-54	Sequence 54, Appl
C 762	19	0.6	19	1	US-10-759-878-3	Sequence 3, Appli	835	19	0.6	19	1	US-10-800-487-55	Sequence 55, Appl
C 763	19	0.6	19	1	US-10-759-878-8	Sequence 8, Appli	836	19	0.6	19	1	US-10-800-487-56	Sequence 56, Appl
												US-10-800-487-57	Sequence 57, Appl

1129	19	0.6	21	1	US-10-800-487-344	Sequence 344, App	cl202	19	0.6	21	1	US-10-800-487-417	Sequence 417, App
1130	19	0.6	21	1	US-10-800-487-345	Sequence 345, App	cl203	19	0.6	21	1	US-10-800-487-418	Sequence 418, App
1131	19	0.6	21	1	US-10-800-487-346	Sequence 346, App	cl204	19	0.6	21	1	US-10-800-487-419	Sequence 419, App
1132	19	0.6	21	1	US-10-800-487-347	Sequence 347, App	cl205	19	0.6	21	1	US-10-800-487-420	Sequence 420, App
1133	19	0.6	21	1	US-10-800-487-348	Sequence 348, App	cl206	19	0.6	21	1	US-10-800-487-430	Sequence 430, App
cl1134	19	0.6	21	1	US-10-800-487-349	Sequence 349, App	cl207	19	0.6	21	1	US-10-800-487-431	Sequence 431, App
cl1135	19	0.6	21	1	US-10-800-487-350	Sequence 350, App	cl208	19	0.6	21	1	US-10-800-487-432	Sequence 432, App
cl1136	19	0.6	21	1	US-10-800-487-351	Sequence 351, App	cl209	19	0.6	21	1	US-10-800-487-433	Sequence 433, App
cl1137	19	0.6	21	1	US-10-800-487-352	Sequence 352, App	cl210	19	0.6	21	1	US-10-800-487-434	Sequence 434, App
cl1138	19	0.6	21	1	US-10-800-487-353	Sequence 353, App	cl211	19	0.6	21	1	US-10-800-487-435	Sequence 435, App
cl1139	19	0.6	21	1	US-10-800-487-354	Sequence 354, App	cl212	19	0.6	21	1	US-10-800-487-436	Sequence 436, App
cl1140	19	0.6	21	1	US-10-800-487-355	Sequence 355, App	cl213	19	0.6	21	1	US-10-800-487-437	Sequence 437, App
cl1141	19	0.6	21	1	US-10-800-487-356	Sequence 356, App	cl214	19	0.6	21	1	US-10-800-487-438	Sequence 438, App
1142	19	0.6	21	1	US-10-800-487-357	Sequence 357, App	cl215	19	0.6	22	1	US-09-860-784-92	Sequence 92, Appl
1143	19	0.6	21	1	US-10-800-487-358	Sequence 358, App	cl216	18.8	0.6	23	1	US-09-263-959-774	Sequence 774, App
1144	19	0.6	21	1	US-10-800-487-359	Sequence 359, App	cl217	18.8	0.6	23	1	US-10-401-194-30	Sequence 30, Appl
1145	19	0.6	21	1	US-10-800-487-360	Sequence 360, App	cl218	18.4	0.6	20	1	US-09-752-983-242	Sequence 242, App
1146	19	0.6	21	1	US-10-800-487-361	Sequence 361, App	cl219	18.4	0.6	20	1	US-09-516-369A-4	Sequence 4, Appl
1147	19	0.6	21	1	US-10-800-487-362	Sequence 362, App	cl220	18.4	0.6	20	1	US-09-964-059B-100	Sequence 100, App
1148	19	0.6	21	1	US-10-800-487-363	Sequence 363, App	cl221	18.4	0.6	20	1	US-09-845-742B-1	Sequence 1, Appl
1149	19	0.6	21	1	US-10-800-487-364	Sequence 364, App	cl222	18.4	0.6	20	1	US-09-845-742B-2	Sequence 2, Appl
cl1150	19	0.6	21	1	US-10-800-487-365	Sequence 365, App	cl223	18.4	0.6	20	1	US-10-085-906-33	Sequence 33, Appl
cl1151	19	0.6	21	1	US-10-800-487-366	Sequence 366, App	cl224	18.4	0.6	20	1	US-10-165-854-1	Sequence 1, Appl
cl1152	19	0.6	21	1	US-10-800-487-367	Sequence 367, App	cl225	18.4	0.6	20	1	US-10-165-854-2	Sequence 2, Appl
cl1153	19	0.6	21	1	US-10-800-487-368	Sequence 368, App	cl226	18.4	0.6	20	1	US-10-222-334-14	Sequence 14, Appl
cl1154	19	0.6	21	1	US-10-800-487-369	Sequence 369, App	cl227	18.4	0.6	20	1	US-10-219-238-1	Sequence 1, Appl
cl1155	19	0.6	21	1	US-10-800-487-370	Sequence 370, App	cl228	18.4	0.6	20	1	US-10-219-238-2	Sequence 2, Appl
cl1156	19	0.6	21	1	US-10-800-487-371	Sequence 371, App	cl229	18.4	0.6	20	1	US-10-005-344-242	Sequence 242, App
cl1157	19	0.6	21	1	US-10-800-487-372	Sequence 372, App	cl230	18.4	0.6	20	1	US-10-423-311-12	Sequence 12, Appl
1158	19	0.6	21	1	US-10-800-487-373	Sequence 373, App	cl231	18.4	0.6	20	1	US-10-199-676-38	Sequence 38, Appl
1159	19	0.6	21	1	US-10-800-487-374	Sequence 374, App	cl232	18.4	0.6	20	1	US-10-199-676-74	Sequence 74, Appl
1160	19	0.6	21	1	US-10-800-487-375	Sequence 375, App	cl233	18.4	0.6	20	1	US-10-303-325-84	Sequence 84, Appl
cl1161	19	0.6	21	1	US-10-800-487-376	Sequence 376, App	cl234	18.4	0.6	20	1	US-10-303-325-150	Sequence 150, App
1162	19	0.6	21	1	US-10-800-487-377	Sequence 377, App	cl235	18.4	0.6	20	1	US-10-671-395-138	Sequence 138, App
cl1163	19	0.6	21	1	US-10-800-487-378	Sequence 378, App	cl236	18.4	0.6	20	1	US-10-671-395-139	Sequence 139, App
1164	19	0.6	21	1	US-10-800-487-379	Sequence 379, App	cl237	18.4	0.6	20	1	US-10-671-395-140	Sequence 140, App
1165	19	0.6	21	1	US-10-800-487-380	Sequence 380, App	cl238	18.4	0.6	20	1	US-10-671-395-141	Sequence 141, App
cl1166	19	0.6	21	1	US-10-800-487-381	Sequence 381, App	cl239	18.4	0.6	20	1	US-10-671-395-142	Sequence 142, App
cl1167	19	0.6	21	1	US-10-800-487-382	Sequence 382, App	cl240	18.4	0.6	20	1	US-10-671-395-175	Sequence 175, App
cl1168	19	0.6	21	1	US-10-800-487-383	Sequence 383, App	cl241	18.4	0.6	20	1	US-10-671-395-176	Sequence 176, App
cl1169	19	0.6	21	1	US-10-800-487-384	Sequence 384, App	cl242	18.4	0.6	20	1	US-10-671-395-316	Sequence 316, App
cl1170	19	0.6	21	1	US-10-800-487-385	Sequence 385, App	cl243	18.4	0.6	20	1	US-10-671-395-317	Sequence 317, App
cl1171	19	0.6	21	1	US-10-800-487-386	Sequence 386, App	cl244	18.4	0.6	20	1	US-10-671-395-318	Sequence 318, App
cl1172	19	0.6	21	1	US-10-800-487-387	Sequence 387, App	cl245	18.4	0.6	20	1	US-10-671-395-319	Sequence 319, App
cl1173	19	0.6	21	1	US-10-800-487-388	Sequence 388, App	cl246	18.4	0.6	20	1	US-10-671-395-320	Sequence 320, App
1174	19	0.6	21	1	US-10-800-487-389	Sequence 389, App	cl247	18.4	0.6	20	1	US-10-671-395-321	Sequence 321, App
1175	19	0.6	21	1	US-10-800-487-390	Sequence 390, App	cl248	18.4	0.6	20	1	US-10-671-395-353	Sequence 353, App
1176	19	0.6	21	1	US-10-800-487-391	Sequence 391, App	cl249	18.4	0.6	20	1	US-10-671-395-354	Sequence 354, App
1177	19	0.6	21	1	US-10-800-487-392	Sequence 392, App	cl250	18.4	0.6	20	1	US-10-671-395-482	Sequence 482, App
1178	19	0.6	21	1	US-10-800-487-393	Sequence 393, App	cl251	18.4	0.6	20	1	US-10-671-395-483	Sequence 483, App
1179	19	0.6	21	1	US-10-800-487-394	Sequence 394, App	cl252	18.4	0.6	20	1	US-10-671-395-484	Sequence 484, App
1180	19	0.6	21	1	US-10-800-487-395	Sequence 395, App	cl253	18.4	0.6	20	1	US-10-671-395-485	Sequence 485, App
cl1181	19	0.6	21	1	US-10-800-487-396	Sequence 396, App	cl254	18.4	0.6	20	1	US-10-671-395-531	Sequence 531, App
cl1182	19	0.6	21	1	US-10-800-487-397	Sequence 397, App	cl255	18.4	0.6	20	1	US-10-671-395-532	Sequence 532, App
cl1183	19	0.6	21	1	US-10-800-487-398	Sequence 398, App	cl256	18.4	0.6	20	1	US-10-671-395-533	Sequence 533, App
cl1184	19	0.6	21	1	US-10-800-487-399	Sequence 399, App	cl257	18.4	0.6	20	1	US-10-671-395-586	Sequence 586, App
cl1185	19	0.6	21	1	US-10-800-487-400	Sequence 400, App	cl258	18.4	0.6	20	1	US-10-671-395-600	Sequence 600, App
cl1186	19	0.6	21	1	US-10-800-487-401	Sequence 401, App	cl259	18.4	0.6	20	1	US-10-671-395-613	Sequence 613, App
cl1187	19	0.6	21	1	US-10-800-487-402	Sequence 402, App	cl260	18.4	0.6	20	1	US-10-671-395-614	Sequence 614, App
cl1188	19	0.6	21	1	US-10-800-487-403	Sequence 403, App	cl261	18.4	0.6	20	1	US-10-671-395-653	Sequence 653, App
cl1189	19	0.6	21	1	US-10-800-487-404	Sequence 404, App	cl262	18.4	0.6	20	1	US-10-671-395-658	Sequence 658, App
1190	19	0.6	21	1	US-10-800-487-405	Sequence 405, App	cl263	18.4	0.6	20	1	US-10-671-395-733	Sequence 733, App
1191	19	0.6	21	1	US-10-800-487-406	Sequence 406, App	cl264	18.4	0.6	20	1	US-10-671-395-753	Sequence 753, App
1192	19	0.6	21	1	US-10-800-487-407	Sequence 407, App	cl265	18.4	0.6	20	1	US-10-671-395-882	Sequence 882, App
1193	19	0.6	21	1	US-10-800-487-408	Sequence 408, App	cl266	18.4	0.6	20	1	US-10-671-395-959	Sequence 959, App
1194	19	0.6	21	1	US-10-800-487-409	Sequence 409, App	cl267	18.4	0.6	20	1	US-10-671-395-1001	Sequence 1001, App
1195	19	0.6	21	1	US-10-800-487-410	Sequence 410, App	cl268	18.4	0.6	20	1	US-10-671-395-1267	Sequence 1267, App
1196	19	0.6	21	1	US-10-800-487-411	Sequence 411, App	cl269	18.4	0.6	20	1	US-10-671-395-1423	Sequence 1423, App
1197	19	0.6	21	1	US-10-800-487-412	Sequence 412, App	cl270	18.4	0.6	20	1	US-10-671-395-1595	Sequence 1595, App
cl1198	19	0.6	21	1	US-10-800-487-413	Sequence 413, App	cl271	18.4	0.6	20	1	US-10-671-395-1640	Sequence 1640, App
cl1199	19	0.6	21	1	US-10-800-487-414	Sequence 414, App	cl272	18.4	0.6	20	1	US-10-671-395-1665	Sequence 1665, App
cl1200	19	0.6	21	1	US-10-800-487-415	Sequence 415, App	cl273	18.4	0.6	20	1	US-10-671-395-1685	Sequence 1685, App
cl201	19	0.6	21	1	US-10-800-487-416	Sequence 416, App	1274	18.4	0.6	20	1	US-10-745-377-26	Sequence 26, Appl

c1275	18.4	0.6	20	1	US-10-661-088-16	Sequence 16, Appl	1348	18	0.6	18	1	US-10-745-115-21	Sequence 21, Appl
1276	18.4	0.6	20	1	US-10-661-088-19	Sequence 19, Appl	1349	18	0.6	18	1	US-10-872-984-7	Sequence 7, Appl
c1277	18.4	0.6	20	1	US-10-661-097-16	Sequence 16, Appl	c1350	18	0.6	18	1	US-10-755-166-4	Sequence 4, Appl
1278	18.4	0.6	20	1	US-10-661-097-19	Sequence 19, Appl	c1351	18	0.6	18	1	US-10-699-240A-22	Sequence 22, Appl
c1279	18.4	0.6	20	1	US-10-661-355-16	Sequence 16, Appl	c1352	18	0.6	18	1	US-10-699-240A-23	Sequence 23, Appl
1280	18.4	0.6	20	1	US-10-661-355-19	Sequence 19, Appl	c1353	18	0.6	18	1	US-10-699-240A-24	Sequence 24, Appl
c1281	18.4	0.6	20	1	US-10-661-099-16	Sequence 16, Appl	c1354	18	0.6	18	1	US-10-699-240A-25	Sequence 25, Appl
1282	18.4	0.6	20	1	US-10-661-099-19	Sequence 19, Appl	c1355	18	0.6	18	1	US-10-699-240A-26	Sequence 26, Appl
1283	18.4	0.6	20	1	US-10-407-818-13	Sequence 13, Appl	c1356	18	0.6	18	1	US-10-730-771-259	Sequence 259, App
c1284	18.4	0.6	20	1	US-10-407-818-14	Sequence 14, Appl	c1357	18	0.6	18	1	US-10-730-771-261	Sequence 261, App
1285	18.4	0.6	20	1	US-10-407-818-16	Sequence 16, Appl	c1358	18	0.6	18	1	US-10-730-771-403	Sequence 403, App
1286	18.4	0.6	20	1	US-10-748-541-1	Sequence 1, Appl	c1359	18	0.6	18	1	US-10-730-771-406	Sequence 406, App
c1287	18.4	0.6	20	1	US-10-748-541-2	Sequence 2, Appl	c1360	18	0.6	18	1	US-10-913-280-642	Sequence 642, App
1288	18.4	0.6	20	1	US-10-872-113-26	Sequence 26, Appl	c1361	18	0.6	18	1	US-10-700-971C-23	Sequence 23, Appl
c1289	18.4	0.6	20	1	US-10-661-415-16	Sequence 16, Appl	c1362	18	0.6	18	1	US-09-370-541-21	Sequence 21, Appl
1290	18.4	0.6	20	1	US-10-661-415-19	Sequence 19, Appl	c1363	18	0.6	19	1	US-10-192-437-2	Sequence 2, Appl
1291	18.4	0.6	20	1	US-10-814-555-1	Sequence 1, Appl	c1364	18	0.6	19	1	US-09-881-012-160	Sequence 160, App
c1292	18.4	0.6	20	1	US-10-814-555-2	Sequence 2, Appl	c1365	18	0.6	19	1	US-09-881-012-160	Sequence 160, App
1293	18.4	0.6	20	1	US-10-624-570-3	Sequence 3, Appl	c1366	18	0.6	19	1	US-10-098-871-37	Sequence 37, Appl
1294	18.4	0.6	20	1	US-10-639-300-38	Sequence 38, Appl	c1367	18	0.6	19	1	US-10-780-433-23	Sequence 23, Appl
c1295	18.4	0.6	20	1	US-10-639-300-74	Sequence 74, Appl	c1368	18	0.6	20	1	US-10-172-911-80	Sequence 80, Appl
c1296	18.4	0.6	20	1	US-10-913-280-643	Sequence 643, App	c1369	18	0.6	20	1	US-09-993-731-22	Sequence 22, Appl
c1297	18.4	0.6	21	1	US-10-385-193-1	Sequence 1, Appl	c1370	18	0.6	20	1	US-09-843-377-88	Sequence 88, Appl
1298	18.4	0.6	21	1	US-10-385-193-2	Sequence 2, Appl	c1371	18	0.6	20	1	US-10-357-488-26	Sequence 26, Appl
c1299	18.4	0.6	21	1	US-10-786-720-20232	Sequence 20232, A	c1372	18	0.6	20	1	US-10-671-395-1629	Sequence 1629, Ap
1300	18.4	0.6	21	1	US-10-751-736-5457	Sequence 5457, Ap	c1373	18	0.6	20	1	US-10-819-244-88	Sequence 88, Appl
c1301	18.4	0.6	21	1	US-10-847-918-11896	Sequence 11896, A	c1374	17.8	0.6	20	1	US-09-784-423-60	Sequence 60, Appl
1302	18.4	0.6	21	1	US-10-847-918-11898	Sequence 11898, A	c1375	17.8	0.6	21	1	US-09-964-059B-70	Sequence 70, Appl
1303	18.4	0.6	22	1	US-09-918-686-93	Sequence 93, Appl	c1376	17.8	0.6	21	1	US-09-964-059B-143	Sequence 143, App
1304	18.4	0.6	22	1	US-10-353-150-93	Sequence 93, Appl	c1377	17.8	0.6	21	1	US-09-964-059B-144	Sequence 144, App
c1305	18.2	0.6	19	1	US-10-831-819-7	Sequence 7, Appl	c1378	17.8	0.6	21	1	US-09-964-059B-145	Sequence 145, App
c1306	18	0.6	18	1	US-09-784-917-6	Sequence 6, Appl	c1379	17.8	0.6	21	1	US-10-085-906-432	Sequence 432, App
c1307	18	0.6	18	1	US-10-150-696-6	Sequence 6, Appl	c1380	17.8	0.6	21	1	US-10-252-819-5	Sequence 5, Appl
c1308	18	0.6	18	1	US-10-192-437-7	Sequence 7, Appl	c1381	17.8	0.6	21	1	US-10-126-103-235	Sequence 235, App
c1309	18	0.6	18	1	US-10-073-718-4	Sequence 4, Appl	c1382	17.8	0.6	21	1	US-10-431-096-235	Sequence 235, App
1310	18	0.6	18	1	US-09-753-436-21	Sequence 21, Appl	c1383	17.8	0.6	21	1	US-10-786-720-20231	Sequence 20231, A
c1311	18	0.6	18	1	US-09-808-680-2	Sequence 2, Appl	c1384	17.8	0.6	21	1	US-10-831-778-912	Sequence 912, A
c1312	18	0.6	18	1	US-09-808-680-12	Sequence 12, Appl	c1385	17.8	0.6	21	1	US-10-751-736-4630	Sequence 4630, Ap
c1313	18	0.6	18	1	US-09-747-009-23	Sequence 23, Appl	c1386	17.8	0.6	21	1	US-10-751-736-5107	Sequence 5107, Ap
c1314	18	0.6	18	1	US-09-747-009-25	Sequence 25, Appl	c1387	17.8	0.6	21	1	US-10-751-736-23296	Sequence 23296, A
c1315	18	0.6	18	1	US-09-747-009-24	Sequence 24, Appl	c1388	17.8	0.6	21	1	US-10-129-595-8	Sequence 8, Appl
c1316	18	0.6	18	1	US-09-747-009-25	Sequence 25, Appl	c1389	17.8	0.6	21	1	US-10-830-287A-7	Sequence 7, Appl
c1317	18	0.6	18	1	US-09-747-009-26	Sequence 26, Appl	c1390	17.8	0.6	21	1	US-10-601-140A-43	Sequence 43, Appl
c1318	18	0.6	18	1	US-09-982-262B-1	Sequence 1, Appl	c1391	17.8	0.6	21	1	US-10-847-918-11897	Sequence 11897, A
c1319	18	0.6	18	1	US-09-982-262B-4	Sequence 4, Appl	c1392	17.8	0.6	22	1	US-09-770-107-123	Sequence 123, App
c1320	18	0.6	18	1	US-09-982-262B-5	Sequence 5, Appl	c1393	17.4	0.6	19	1	US-09-557-423-7	Sequence 7, Appl
c1321	18	0.6	18	1	US-09-982-262B-81	Sequence 81, Appl	c1394	17.4	0.6	19	1	US-09-557-423-8	Sequence 8, Appl
c1322	18	0.6	18	1	US-09-864-636A-1698	Sequence 1698, Ap	c1395	17.4	0.6	19	1	US-09-969-373-3086	Sequence 3086, Ap
c1323	18	0.6	18	1	US-09-882-945A-146	Sequence 146, App	c1396	17.4	0.6	19	1	US-09-263-959-1278	Sequence 1278, Ap
c1324	18	0.6	18	1	US-09-864-426A-1698	Sequence 1698, Ap	c1397	17.4	0.6	19	1	US-10-251-598-86	Sequence 86, Appl
c1325	18	0.6	18	1	US-10-154-993-4	Sequence 4, Appl	c1398	17.4	0.6	19	1	US-10-665-951-389	Sequence 389, App
c1326	18	0.6	18	1	US-10-171-319-46	Sequence 46, Appl	c1399	17.4	0.6	19	1	US-10-665-951-816	Sequence 816, App
c1327	18	0.6	18	1	US-10-284-742-4	Sequence 4, Appl	c1400	17.4	0.6	19	1	US-10-758-155-389	Sequence 389, App
c1328	18	0.6	18	1	US-10-084-839-1698	Sequence 1698, Ap	c1401	17.4	0.6	19	1	US-10-758-155-816	Sequence 816, App
c1329	18	0.6	18	1	US-10-084-839-3880	Sequence 3880, Ap	c1402	17.4	0.6	19	1	US-10-871-222-390	Sequence 390, App
c1330	18	0.6	18	1	US-10-080-979-4	Sequence 4, Appl	c1403	17.4	0.6	19	1	US-10-871-222-494	Sequence 494, App
c1331	18	0.6	18	1	US-10-080-979-5	Sequence 5, Appl	c1404	17.4	0.6	19	1	US-10-863-973-923	Sequence 923, App
c1332	18	0.6	18	1	US-10-080-979-15	Sequence 15, Appl	c1405	17.4	0.6	19	1	US-10-863-973-1146	Sequence 1146, Ap
c1333	18	0.6	18	1	US-10-080-979-16	Sequence 16, Appl	c1406	17.4	0.6	19	1	US-10-831-620-389	Sequence 389, App
c1334	18	0.6	18	1	US-10-080-979-23	Sequence 23, Appl	c1407	17.4	0.6	19	1	US-10-831-620-816	Sequence 816, App
c1335	18	0.6	18	1	US-10-080-979-66	Sequence 66, Appl	c1408	17.4	0.6	20	1	US-09-899-569A-14	Sequence 14, Appl
c1336	18	0.6	18	1	US-10-080-979-68	Sequence 68, Appl	c1409	17.4	0.6	20	1	US-09-771-933-107	Sequence 107, App
c1337	18	0.6	18	1	US-10-080-979-69	Sequence 69, Appl	c1410	17.4	0.6	20	1	US-10-181-177-94	Sequence 94, Appl
1338	18	0.6	18	1	US-10-163-942-21	Sequence 21, Appl	c1411	17.4	0.6	20	1	US-10-671-395-862	Sequence 862, App
c1339	18	0.6	18	1	US-10-454-663-1	Sequence 1, Appl	c1412	17.4	0.6	20	1	US-10-671-395-967	Sequence 967, App
c1340	18	0.6	18	1	US-10-454-663-4	Sequence 4, Appl	c1413	17.4	0.6	20	1	US-10-671-395-1098	Sequence 1098, Ap
c1341	18	0.6	18	1	US-10-454-663-5	Sequence 5, Appl	c1414	17.4	0.6	20	1	US-10-671-395-1333	Sequence 1333, Ap
1342	18	0.6	18	1	US-10-454-663-81	Sequence 81, Appl	c1415	17.4	0.6	20	1	US-10-671-395-1343	Sequence 1343, Ap
c1343	18	0.6	18	1	US-10-780-439-4	Sequence 4, Appl	c1416	17.4	0.6	20	1	US-10-671-395-1505	Sequence 1505, Ap
c1344	18	0.6	18	1	US-10-780-439-5	Sequence 5, Appl	c1417	17.4	0.6	20	1	US-10-671-395-1627	Sequence 1627, Ap
c1345	18	0.6	18	1	US-10-780-439-15	Sequence 15, Appl	c1418	17.4	0.6	20	1	US-10-620-642-33	Sequence 33, Appl
c1346	18	0.6	18	1	US-10-780-439-16	Sequence 16, Appl	c1419	17.4	0.6	21	1	US-10-786-720-20999	Sequence 20999, A
c1347	18	0.6	18	1	US-10-807-114-146	Sequence 146, App	c1420	17.4	0.6	21	1	US-10-751-736-5468	Sequence 5468, Ap

c1421	17.4	21	1	US-10-751-736-23297	Sequence 23297, A	1494	16.8	0.6	20	1	US-10-876-086-49	Sequence 49, Appl
c1422	17.2	18	1	US-10-463-981B-2	Sequence 2, Appl1	1495	16.8	0.6	20	1	US-10-831-901A-29732	Sequence 29732, A
c1423	17.2	18	1	US-10-741-600-73887	Sequence 73887, A	1496	16.8	0.6	20	1	US-10-831-901A-29733	Sequence 29733, A
c1424	17	17	0.6	US-10-669-962-28	Sequence 28, Appl	1497	16.8	0.6	20	1	US-10-831-901A-29734	Sequence 29734, A
c1425	17	0.6	20	US-10-192-437-14	Sequence 14, Appl	1498	16.8	0.6	20	1	US-10-831-901A-29735	Sequence 29735, A
c1426	17	0.6	20	US-09-908-147-138	Sequence 138, App	1499	16.8	0.6	20	1	US-10-831-901A-29736	Sequence 29736, A
c1427	17	0.6	20	US-10-728-509-138	Sequence 138, App	c1500	16.8	0.6	20	1	US-10-789-831-22	Sequence 22, Appl
c1428	17	0.6	20	US-10-671-395-1187	Sequence 1187, Ap	c1501	16.8	0.6	20	1	US-10-789-831-22	Sequence 22, Appl
c1429	17	0.6	20	US-10-671-395-1609	Sequence 1609, Ap	c1502	16.8	0.6	20	1	US-10-789-831-24	Sequence 24, Appl
c1430	17	0.6	20	US-10-620-642-34	Sequence 34, Appl	c1503	16.8	0.6	20	1	US-10-705-715-95	Sequence 95, Appl
c1431	17	0.6	21	US-10-786-720-20626	Sequence 20626, A	c1504	16.8	0.6	21	1	US-09-784-423-67	Sequence 67, Appl
c1432	17	0.6	21	US-10-786-720-20628	Sequence 20628, A	c1505	16.8	0.6	21	1	US-09-964-059B-71	Sequence 71, Appl
c1433	17	0.6	21	US-10-786-720-20998	Sequence 20998, A	c1506	16.8	0.6	21	1	US-10-642-763-5	Sequence 5, Appl1
c1434	17	0.6	21	US-10-786-720-21000	Sequence 21000, A	c1507	16.8	0.6	21	1	US-10-751-736-4631	Sequence 4631, Ap
c1435	16.8	0.6	20	US-09-752-983-241	Sequence 241, App	c1508	16.8	0.6	21	1	US-10-751-736-23527	Sequence 23527, A
c1436	16.8	0.6	20	US-09-752-983-264	Sequence 264, App	c1509	16.8	0.6	21	1	US-10-751-736-23854	Sequence 23854, A
c1437	16.8	0.6	20	US-09-907-190-5	GENERAL INFORMA	c1510	16.8	0.6	21	1	US-10-751-736-38571	Sequence 38571, A
c1438	16.8	0.6	20	US-09-263-959-1214	Sequence 1214, Ap	c1511	16.8	0.6	21	1	US-10-751-736-38782	Sequence 38782, A
c1439	16.8	0.6	20	US-09-863-806-135	Sequence 135, App	c1512	16.8	0.6	21	1	US-10-751-736-38784	Sequence 38784, A
c1440	16.8	0.6	20	US-09-863-806-143	Sequence 143, App	c1513	16.8	0.6	21	1	US-10-751-736-52502	Sequence 52502, A
c1441	16.8	0.6	20	US-09-888-361-95	Sequence 95, Appl	c1514	16.8	0.6	21	1	US-10-751-736-53051	Sequence 53051, A
c1442	16.8	0.6	20	US-09-908-147-137	Sequence 137, App	c1515	16.8	0.6	21	1	US-10-913-246-23	Sequence 23, Appl
c1443	16.8	0.6	20	US-09-964-059B-68	Sequence 68, Appl	c1516	16.8	0.6	21	1	US-10-934-890-23	Sequence 23, Appl
c1444	16.8	0.6	20	US-09-964-059B-69	Sequence 69, Appl	c1517	16.8	0.6	21	1	US-10-491-653-40	Sequence 40, Appl
c1445	16.8	0.6	20	US-09-964-059B-79	Sequence 79, Appl	c1518	16.8	0.6	21	1	US-10-847-918-11027	Sequence 11027, A
c1446	16.8	0.6	20	US-09-964-059B-80	Sequence 80, Appl	c1519	16.6	0.6	19	1	US-09-728-552-2	Sequence 2, Appl1
c1447	16.8	0.6	20	US-09-964-059B-81	Sequence 81, Appl	c1520	16.4	0.5	18	1	US-10-073-718-15	Sequence 15, Appl
c1448	16.8	0.6	20	US-09-976-900A-55	Sequence 55, Appl	c1521	16.4	0.5	18	1	US-09-735-363A-17	Sequence 17, Appl
c1449	16.8	0.6	20	US-10-085-908-352	Sequence 352, App	c1522	16.4	0.5	18	1	US-09-735-363A-18	Sequence 18, Appl
c1450	16.8	0.6	20	US-10-007-078-81	Sequence 81, Appl	c1523	16.4	0.5	18	1	US-09-896-650A-28	Sequence 28, Appl
c1451	16.8	0.6	20	US-10-024-396-90	Sequence 90, Appl	c1524	16.4	0.5	18	1	US-09-263-953-1276	Sequence 1276, Ap
c1452	16.8	0.6	20	US-10-331-907-300	Sequence 300, App	c1525	16.4	0.5	18	1	US-10-011-204-1	Sequence 1, Appl1
c1453	16.8	0.6	20	US-10-005-344-241	Sequence 241, App	c1526	16.4	0.5	18	1	US-10-011-204-2	Sequence 2, Appl1
c1454	16.8	0.6	20	US-10-005-344-264	Sequence 264, App	c1527	16.4	0.5	18	1	US-10-154-993-15	Sequence 15, Appl
c1455	16.8	0.6	20	US-10-189-268-71	Sequence 71, Appl	c1528	16.4	0.5	18	1	US-10-284-742-15	Sequence 15, Appl
c1456	16.8	0.6	20	US-10-210-723-78	Sequence 78, Appl	c1529	16.4	0.5	18	1	US-10-755-166-15	Sequence 15, Appl
c1457	16.8	0.6	20	US-10-210-723-136	Sequence 136, App	c1530	16.4	0.5	18	1	US-10-669-962-27	Sequence 27, Appl
c1458	16.8	0.6	20	US-10-728-509-137	Sequence 137, App	c1531	16.4	0.5	18	1	US-10-751-235-59	Sequence 59, Appl
c1459	16.8	0.6	20	US-10-648-593-516	Sequence 516, App	c1532	16.4	0.5	19	1	US-10-678-160A-52	Sequence 52, Appl
c1460	16.8	0.6	20	US-10-671-395-515	Sequence 515, App	c1533	16.4	0.5	20	1	US-09-752-983-256	Sequence 256, App
c1461	16.8	0.6	20	US-10-671-395-597	Sequence 597, App	c1534	16.4	0.5	20	1	US-09-454-394-34	Sequence 34, Appl
c1462	16.8	0.6	20	US-10-671-395-678	Sequence 678, App	c1535	16.4	0.5	20	1	US-09-454-394-35	Sequence 35, Appl
c1463	16.8	0.6	20	US-10-671-395-782	Sequence 782, App	c1536	16.4	0.5	20	1	US-09-771-993-1325	Sequence 125, App
c1464	16.8	0.6	20	US-10-671-395-837	Sequence 837, App	c1537	16.4	0.5	20	1	US-09-865-866-146	Sequence 146, App
c1465	16.8	0.6	20	US-10-671-395-881	Sequence 881, App	c1538	16.4	0.5	20	1	US-09-920-671-82	Sequence 82, Appl
c1466	16.8	0.6	20	US-10-671-395-950	Sequence 950, App	c1539	16.4	0.5	20	1	US-09-993-721-23	Sequence 23, Appl
c1467	16.8	0.6	20	US-10-671-395-950	Sequence 1068, Ap	c1540	16.4	0.5	20	1	US-09-846-863-34	Sequence 34, Appl
c1468	16.8	0.6	20	US-10-671-395-1191	Sequence 1191, Ap	c1541	16.4	0.5	20	1	US-10-085-906-323	Sequence 323, App
c1469	16.8	0.6	20	US-10-671-395-1366	Sequence 1366, Ap	c1542	16.4	0.5	20	1	US-10-085-906-323	Sequence 323, App
c1470	16.8	0.6	20	US-10-745-377-27	Sequence 27, Appl	c1543	16.4	0.5	20	1	US-10-005-344-256	Sequence 256, App
c1471	16.8	0.6	20	US-10-872-113-27	Sequence 27, Appl	c1544	16.4	0.5	20	1	US-10-148-355A-64	Sequence 64, Appl
c1472	16.8	0.6	20	US-10-661-415-12	Sequence 12, Appl	c1545	16.4	0.5	20	1	US-10-317-277A-85	Sequence 85, Appl
c1473	16.8	0.6	20	US-10-661-415-15	Sequence 15, Appl	c1546	16.4	0.5	20	1	US-10-317-277A-160	Sequence 160, App
c1474	16.8	0.6	20	US-10-831-778-226	Sequence 226, App	c1547	16.4	0.5	20	1	US-10-671-395-1171	Sequence 1171, Ap
c1475	16.8	0.6	20	US-10-831-778-556	Sequence 556, App	c1548	16.4	0.5	20	1	US-10-671-395-1374	Sequence 1374, Ap
c1476	16.8	0.6	20	US-10-831-778-560	Sequence 560, App	c1549	16.4	0.5	20	1	US-10-671-395-1427	Sequence 1427, Ap
c1477	16.8	0.6	20	US-10-806-573-5	GENERAL INFORMA	c1550	16.4	0.5	20	1	US-10-671-395-1597	Sequence 1597, Ap
c1478	16.8	0.6	20	US-10-754-478-135	Sequence 135, App	c1551	16.4	0.5	20	1	US-10-671-395-1641	Sequence 1641, Ap
c1479	16.8	0.6	20	US-10-754-478-143	Sequence 143, App	c1552	16.4	0.5	20	1	US-10-664-639A-77	Sequence 77, Appl
c1480	16.8	0.6	20	US-10-728-078-23	Sequence 23, Appl	c1553	16.4	0.5	20	1	US-10-728-078-14	Sequence 14, Appl
c1481	16.8	0.6	20	US-10-601-140A-1	Sequence 1, Appl1	c1554	16.4	0.5	20	1	US-10-831-901A-29726	Sequence 29726, A
c1482	16.8	0.6	20	US-10-601-140A-2	Sequence 2, Appl1	c1555	16.4	0.5	20	1	US-10-831-901A-29728	Sequence 29728, A
c1483	16.8	0.6	20	US-10-601-140A-3	Sequence 3, Appl1	c1556	16.4	0.5	20	1	US-10-828-674-103	Sequence 103, App
c1484	16.8	0.6	20	US-10-601-140A-4	Sequence 4, Appl1	c1557	16.4	0.5	20	1	US-10-830-477-103	Sequence 103, App
c1485	16.8	0.6	20	US-10-601-140A-6	Sequence 6, Appl1	c1558	16.4	0.5	20	1	US-10-643-038-146	Sequence 146, App
c1486	16.8	0.6	20	US-10-601-140A-7	Sequence 7, Appl1	c1559	16.4	0.5	20	1	US-10-849-072-21	Sequence 21, Appl
c1487	16.8	0.6	20	US-10-601-140A-8	Sequence 8, Appl1	c1560	16	0.5	18	1	US-10-849-072-21	Sequence 21, Appl
c1488	16.8	0.6	20	US-10-601-140A-9	Sequence 9, Appl1	c1561	16	0.5	18	1	US-10-831-778-913	Sequence 913, App
c1489	16.8	0.6	20	US-10-601-140A-10	Sequence 10, Appl	c1562	16	0.5	18	1	US-10-831-778-939	Sequence 939, App
c1490	16.8	0.6	20	US-10-601-140A-23	Sequence 23, Appl	c1563	16	0.5	18	1	US-10-776-933-150	Sequence 150, App
c1491	16.8	0.6	20	US-10-601-140A-34	Sequence 34, Appl	c1564	16	0.5	18	1	US-10-674-159A-112	Sequence 112, App
c1492	16.8	0.6	20	US-10-601-140A-40	Sequence 40, Appl	c1565	16	0.5	18	1	US-10-776-917-141	Sequence 141, App
c1493	16.8	0.6	20	US-10-601-140A-44	Sequence 44, Appl	c1566	16	0.5	18	1		

1567	16	0.5	18	1	US-10-766-096-9	Sequence 9, Appli
1568	16	0.5	18	1	US-10-872-984-5	Sequence 5, Appli
1569	16	0.5	18	1	US-10-872-984-6	Sequence 6, Appli
1570	16	0.5	18	1	US-10-638-141-10	Sequence 10, Appl
1571	16	0.5	18	1	US-10-776-934-741	Sequence 741, App
1572	16	0.5	18	1	US-10-601-140A-24	Sequence 24, Appl
1573	16	0.5	18	1	US-10-884-617-2	Sequence 2, Appli
1574	16	0.5	18	1	US-10-669-962-29	Sequence 29, Appl
1575	16	0.5	18	1	US-10-503-120-1	Sequence 1, Appli
1576	16	0.5	18	1	US-10-503-120-8	Sequence 8, Appli
1577	16	0.5	18	1	US-10-503-120-9	Sequence 9, Appli
1578	16	0.5	18	1	US-10-503-120-10	Sequence 10, Appl
1579	16	0.5	18	1	US-10-503-120-21	Sequence 21, Appl
1580	16	0.5	18	1	US-11-024-428-7	Sequence 7, Appli
1581	16	0.5	19	1	US-10-760-940-1	Sequence 1, Appli
1582	16	0.5	19	1	US-10-913-246-22	Sequence 22, Appl
1583	16	0.5	19	1	US-10-913-246-24	Sequence 24, Appl
1584	16	0.5	19	1	US-10-934-890-22	Sequence 22, Appl
1585	16	0.5	19	1	US-10-934-890-24	Sequence 24, Appl
1586	16	0.5	19	1	US-10-700-884-23	Sequence 23, Appl
1587	16	0.5	19	1	US-10-871-222-391	Sequence 391, App
1588	16	0.5	19	1	US-10-871-222-495	Sequence 495, App
1589	16	0.5	19	1	US-10-940-360-1	Sequence 1, Appli
1590	16	0.5	20	1	US-10-148-355A-63	Sequence 63, Appl
1591	16	0.5	20	1	US-10-671-395-1204	Sequence 1204, Ap
1592	16	0.5	20	1	US-10-671-395-1524	Sequence 1524, Ap
1593	16	0.5	20	1	US-10-845-667-118	Sequence 118, App
1594	16	0.5	20	1	US-10-620-642-32	Sequence 32, Appl
1595	16	0.5	20	1	US-10-831-901A-29729	Sequence 29729, A
1596	16	0.5	20	1	US-10-831-901A-29730	Sequence 29730, A
1597	16	0.5	20	1	US-10-831-901A-29731	Sequence 29731, A
1598	15.8	0.5	19	1	US-09-881-012-229	Sequence 229, App
1599	15.8	0.5	19	1	US-09-881-012-229	Sequence 229, App
1600	15.8	0.5	19	1	US-10-160-436-1	Sequence 1, Appli
1601	15.8	0.5	19	1	US-10-282-174-103	Sequence 103, App
1602	15.8	0.5	19	1	US-10-600-009-103	Sequence 103, App
1603	15.8	0.5	19	1	US-10-673-575-1	Sequence 1, Appli
1604	15.8	0.5	19	1	US-10-883-218-387	Sequence 387, App
1605	15.8	0.5	19	1	US-10-883-218-789	Sequence 789, App
1606	15.8	0.5	19	1	US-10-984-919-562	Sequence 562, App
1607	15.8	0.5	19	1	US-10-863-973-918	Sequence 918, App
1608	15.8	0.5	19	1	US-10-863-973-1141	Sequence 1141, Ap
1609	15.4	0.5	18	1	US-09-739-909-9	Sequence 9, Appli
1610	15.4	0.5	18	1	US-10-089-887-4	Sequence 4, Appli
1611	15.4	0.5	19	1	US-10-871-222-150	Sequence 150, App
1612	15.4	0.5	19	1	US-10-871-222-300	Sequence 300, App
1613	15.4	0.5	19	1	US-10-863-973-922	Sequence 922, App
1614	15.4	0.5	19	1	US-10-863-973-1145	Sequence 1145, Ap
1615	15	0.5	18	1	US-09-747-377-265	Sequence 265, App
1616	15	0.5	18	1	US-10-105-613-265	Sequence 265, App
1617	14.8	0.5	18	1	US-09-784-423-146	Sequence 146, App
1618	14.8	0.5	18	1	US-09-731-175-7	Sequence 7, Appli
1619	14.8	0.5	18	1	US-09-263-959-983	Sequence 983, App
1620	14.8	0.5	18	1	US-10-085-906-135	Sequence 135, App
1621	14.8	0.5	18	1	US-10-091-281-314	Sequence 314, App
1622	14.8	0.5	18	1	US-10-351-951-71	Sequence 71, Appl
1623	14.8	0.5	18	1	US-10-282-174-247	Sequence 247, App
1624	14.8	0.5	18	1	US-10-349-143-5770	Sequence 5770, Ap
1625	14.8	0.5	18	1	US-10-453-792-145	Sequence 145, App
1626	14.8	0.5	18	1	US-10-600-009-247	Sequence 247, App
1627	14.8	0.5	18	1	US-10-856-122-82	Sequence 82, Appl
1628	14.8	0.5	18	1	US-10-984-919-561	Sequence 561, App
1629	14.6	0.5	25	1	US-10-956-157-173783	Sequence 173783,
1630	14.4	0.5	18	1	US-10-177-308-12	Sequence 12, Appl
1631	14.4	0.5	18	1	US-10-730-771-406	Sequence 406, App
1632	14.4	0.5	18	1	US-09-969-373-3402	Sequence 3402, Ap
1633	14.4	0.5	18	1	US-09-881-012-1	Sequence 1, Appli
1634	14.4	0.5	18	1	US-09-881-012-1	Sequence 1, Appli
1635	14.4	0.5	18	1	US-10-197-290-32	Sequence 32, Appl
1636	14.4	0.5	18	1	US-10-178-325-168	Sequence 168, App
1637	14.4	0.5	18	1	US-10-388-263-185	Sequence 185, App
1638	14.4	0.5	18	1	US-10-853-665-12	Sequence 12, Appl
1639	14.4	0.5	18	1	US-10-829-674-38	Sequence 38, Appl

c164014.40.5181US-10-830-477-38Sequence 38, Appl

ALIGNMENTS

RESULT 1
US-10-719-900-9820
; Sequence 9820, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 9820
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-9820

Query Match0.8%; Score 25; DB 1; Length 25;
Best Local Similarity100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY2467AAACTGACACCTTCTGTAGCCACCT2491
|||||
Db1AAACTGACACCTTCTGTAGCCACCT25

RESULT 2
US-10-719-900-25042/c
; Sequence 25042, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 25042
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-25042

Query Match0.8%; Score 25; DB 1; Length 25;
Best Local Similarity100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY584GGAGAGATCACCATGGAGCCAATTT608
|||||
Db25GGAGAGATCACCATGGAGCCAATTT1

RESULT 3
US-10-719-900-64720/c
; Sequence 64720, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900

```
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 64720
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-64720
```

```
Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 350 ATGGCGAGTCAACAGCTAAACCTT 374
Db 25 ATGGCGAGTCAACAGCTAAACCTT 1
```

```
RESULT 4
US-10-719-900-97347
; Sequence 97347, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 97347
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-97347
```

```
Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2528 ACATCAGCGGTATCTCTGGACAT 2552
Db 1 ACATCAGCGGTATCTCTGGACAT 25
```

```
RESULT 5
US-10-719-900-112518
; Sequence 112518, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 112518
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-112518
```

```
Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2496 ACCACATACATTTCTGCCAGTGTT 2520
Db 1 ACCACATACATTTCTGCCAGTGTT 25
```

```
RESULT 6
US-10-719-900-166224/c
; Sequence 166224, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 166224
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-166224
```

```
Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 554 CCGCTGAGGTACGACCGCGTGCT 578
Db 25 CCGCTGAGGTACGACCGCGTGCT 1
```

```
RESULT 7
US-10-719-900-179201
; Sequence 179201, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 179201
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-179201
```

```
Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2631 AGCTCCAGTTTCTCGAGTGATCAG 2655
Db 1 AGCTCCAGTTTCTCGAGTGATCAG 25
```

```
RESULT 8
US-10-719-900-197837
; Sequence 197837, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
```

Db		 CTTACCCTACGCTGCCAGGTGGAG 1
RESULT 11		
US-10-719-900-475751 ; Sequence 475751, Application US/10719900 ; Publication No. US20050026164A1 ; GENERAL INFORMATION: ; APPLICANT: Xue Mei Zhou ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse ; FILE REFERENCE: 3528.1 ; CURRENT APPLICATION NUMBER: US/10/719,900 ; PRIOR FILING DATE: 2003-11-20 ; PRIOR APPLICATION NUMBER: 60/427,808 ; PRIOR FILING DATE: 2002 11 20 ; NUMBER OF SEQ ID NOS: 982914 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1 ; SEQ ID NO 475751 ; LENGTH: 25 ; TYPE: DNA ; ORGANISM: Mus musculus US-10-719-900-475751		
Query Match 0.8%; Score 25; DB 1; Length 25; Best Local Similarity 100.0%; Pred.No.1.le+02; Matches 25; Conservative 0; Mismatches 0; Indels		
QY	2428	GAGATTACCAGTGAGGCCTTTATTC 2452 1 GAGATTACCAGTGAGGCCTTTATTC 25
Db		
RESULT 12		
US-10-719-900-529450 ; Sequence 529450, Application US/10719900 ; Publication No. US20050026164A1 ; GENERAL INFORMATION: ; APPLICANT: Xue Mei Zhou ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse ; FILE REFERENCE: 3528.1 ; CURRENT APPLICATION NUMBER: US/10/719,900 ; PRIOR FILING DATE: 2003-11-20 ; PRIOR APPLICATION NUMBER: 60/427,808 ; PRIOR FILING DATE: 2002 11 20 ; NUMBER OF SEQ ID NOS: 982914 ; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1 ; SEQ ID NO 529450 ; LENGTH: 25 ; TYPE: DNA ; ORGANISM: Mus musculus US-10-719-900-529450		
Query Match 0.8%; Score 25; DB 1; Length 25; Best Local Similarity 100.0%; Pred.No.1.le+02; Matches 25; Conservative 0; Mismatches 0; Indels		
QY	2792	GCAATCATGTTCTACTGCGACTCTTG 2816 1 GCAATCATGTTCTACTGCGACTCTTG 25
Db		
RESULT 13		
US-10-719-900-544968 ; Sequence 544968, Application US/10719900 ; Publication No. US20050026164A1 ; GENERAL INFORMATION: ; APPLICANT: Xue Mei Zhou ; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse ; FILE REFERENCE: 3528.1 ; CURRENT APPLICATION NUMBER: US/10/719,900 ; PRIOR FILING DATE: 2003-11-20 ; PRIOR APPLICATION NUMBER: 60/427,808		

; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 544968
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-544968

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2603 GCATTTCACTGGAGCTTGCACTAT 2627
|||||
Db 1 GCATTTCACTGGAGCTTGCACTAT 25

RESULT 14
US-10-719-900-635363/c
; Sequence 635363, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 635363
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-635363

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 649 GAGCTGTTTGGAGACACCTCGGCC 673
|||||
Db 25 GAGCTGTTTGGAGACACCTCGGCC 1

RESULT 15
US-10-719-900-652192/c
; Sequence 652192, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 652192
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-652192

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 392 CTCAGAACGGTGGAACTGGCACC 416
|||||

Db 25 CTCAGAACGGTGGAACTGGCACC 1
RESULT 16
US-10-719-900-671642
; Sequence 671642, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 671642
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-671642

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2858 GTAGCTGGGACCATAGGCTCACAC 2882
|||||
Db 1 GTAGCTGGGACCATAGGCTCACAC 25

RESULT 17
US-10-719-900-677592
; Sequence 677592, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 677592
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-677592

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2742 GTATGCTAGACAACTCTCGCTCT 2766
|||||
Db 1 GTATGCTAGACAACTCTCGCTCT 25

RESULT 18
US-10-719-900-687621/c
; Sequence 687621, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20

```
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 687621
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-687621
```

```
Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 879 CTCAGTCAGTGCAGCGCAGAGAC 903
    |||||
Db 25 CTCAGTCAGTGCAGCGCAGAGAC 1
```

```
RESULT 19
US-10-719-900-705390/c
; Sequence 705390, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 705390
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-705390
```

```
Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 596 ATGGAGCCAAATTTCTCGTCCGCAC 620
    |||||
Db 25 ATGGAGCCAAATTTCTCGTCCGCAC 1
```

```
RESULT 20
US-10-719-900-778514/c
; Sequence 778514, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 778514
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-778514
```

```
Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 432 GCCAGTGGGCAAGAACCTTACCCTA 456
    |||||
Db 25 GCCAGTGGGCAAGAACCTTACCCTA 1
```

```
RESULT 21
US-10-719-900-864263
; Sequence 864263, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 864263
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-864263
```

```
Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2807 TGCAGTCTTGACCTTTTGGGCTCAA 2831
    |||||
Db 1 TGCAGTCTTGACCTTTTGGGCTCAA 25
```

```
RESULT 22
US-10-719-900-944980/c
; Sequence 944980, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 944980
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-944980
```

```
Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 422 CCTCTTGGCAGCCAGTGGGCAAGAA 446
    |||||
Db 25 CCTCTTGGCAGCCAGTGGGCAAGAA 1
```

```
RESULT 23
US-10-809-189-31947
; Sequence 31947, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
```

; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31947
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31947

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2528 ACACTGAGCGGTGATGCTGGACAT 2552
Db 1 ACACTGAGCGGTGATGCTGGACAT 25

RESULT 24

US-10-809-189-31948
; Sequence 31948, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31948
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31948

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2543 GTCTGACATGAGTCCCGAGGAAT 2567
Db 1 GTCTGACATGAGTCCCGAGGAAT 25

RESULT 25

US-10-809-189-31949
; Sequence 31949, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806

; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31949
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31949

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2603 GCATTTCACTGGGAGCTTGCACTAT 2627
Db 1 GCATTTCACTGGGAGCTTGCACTAT 25

RESULT 26

US-10-809-189-31950
; Sequence 31950, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31950
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31950

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2639 TTTCTGCACTGATCAGGTCCTGC 2663
Db 1 TTTCTGCACTGATCAGGTCCTGC 25

RESULT 27

US-10-809-189-31951
; Sequence 31951, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31951
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus

US-10-809-189-31951

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2651 ATCAGGGTCTGCAAGCAGTGGGA 2675
|||||
Db 1 ATCAGGGTCTGCAAGCAGTGGGA 25

RESULT 28

US-10-809-189-31952
; Sequence 31952, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31952
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31952

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2792 GCAATCATGTTCACTGCAGTCTTG 2816
|||||
Db 1 GCAATCATGTTCACTGCAGTCTTG 25

RESULT 29

US-10-809-189-31953
; Sequence 31953, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31953
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31953

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2798 ATGGTTCACTGCAGTCTTGACCTTT 2822
|||||
Db 1 ATGGTTCACTGCAGTCTTGACCTTT 25

RESULT 30

US-10-809-189-31954
; Sequence 31954, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31954
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31954

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2816 GACCTTTTGGGCTCAAGTGATCCTC 2840
|||||
Db 1 GACCTTTTGGGCTCAAGTGATCCTC 25

RESULT 31

US-10-809-189-31955
; Sequence 31955, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31955
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31955

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2852 TCCTGAGTAGCTGGGACCATAGGCT 2876
|||||
Db 1 TCCTGAGTAGCTGGGACCATAGGCT 25

RESULT 32
US-10-809-189-31956
; Sequence 31956, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; PRIOR FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31956
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31956

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2864 GGGACCATAGGCTCACACACACCA 2888
Db 1 GGGACCATAGGCTCACACACACCA 25

RESULT 33
US-10-809-189-31957
; Sequence 31957, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; PRIOR FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31957
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31957

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2927 GGGTCTCGCAACATTGCCAGACTT 2951
Db 1 GGGTCTCGCAACATTGCCAGACTT 25

RESULT 34
US-10-809-189-31958
; Sequence 31958, Application US/10809189
; Publication No. US20050048531A1

; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; PRIOR FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31958
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31958

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2939 ATTGCCCAGACTTCCTTTGTGTAG 2963
Db 1 ATTGCCCAGACTTCCTTTGTGTAG 25

RESULT 35
US-10-809-189-31959
; Sequence 31959, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; PRIOR FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31959
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31959

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2546 TGGACATGATGCCCGGGAATATG 2570
Db 1 TGGACATGATGCCCGGGAATATG 25

RESULT 36
US-10-809-189-31960
; Sequence 31960, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.


```
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31960
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31960
```

```
Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2564 GAATATGCCCAAGCTATGCTTGTGTC 2588
      |||||||
Db 1 GAATATGCCCAAGCTATGCTTGTGTC 25
```

RESULT 37

```
US-10-809-189-31961
; Sequence 31961, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31961
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31961
```

```
Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2567 TATGCCCAAGCTATGCTTGTGCTC 2591
      |||||||
Db 1 TATGCCCAAGCTATGCTTGTGCTC 25
```

RESULT 38

```
US-10-809-189-31962
; Sequence 31962, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
```

```
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31962
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31962
```

```
Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2576 GCTATGCCTTGTCTCTTGTGCTGT 2600
      |||||||
Db 1 GCTATGCCTTGTCTCTTGTGCTGT 25
```

RESULT 39

```
US-10-809-189-31963
; Sequence 31963, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31963
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31963
```

```
Query Match          0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2582 CCTTGTCTCTTGTCTCTTGTGTCAT 2606
      |||||||
Db 1 CCTTGTCTCTTGTCTCTTGTGTCAT 25
```

RESULT 40

```
US-10-809-189-31964
; Sequence 31964, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
```

; SEQ ID NO 31964
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31964

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2588 CCTCTGCTGCTGTTGCATTTCACT 2612
DB 1 CCTCTGCTGCTGTTGCATTTCACT 25

RESULT 41

US-10-809-189-31965
; Sequence 31965, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; PRIOR FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31965
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31965

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2591 CTGTGCTGTTGTCATTTCACTGGG 2615
DB 1 CTGTGCTGTTGTCATTTCACTGGG 25

RESULT 42

US-10-809-189-31966
; Sequence 31966, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; PRIOR FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31966
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31966

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2594 GTCTGTTTGCACTTTCACTGGGAGC 2618
DB 1 GTCTGTTTGCACTTTCACTGGGAGC 25

RESULT 43

US-10-956-157-147622
; Sequence 147622, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 147622
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-147622

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2770 ACCCAGGCTGGAGTGCAGTGTGCA 2794
DB 1 ACCCAGGCTGGAGTGCAGTGTGCA 25

RESULT 44

US-10-956-157-173784
; Sequence 173784, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 173784
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-173784

Query Match 0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTGCAGTGTGC 2793
DB 1 CACCCAGGCTGGAGTGCAGTGTGC 25

RESULT 45

US-10-956-157-186274
; Sequence 186274, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

```
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186274
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-186274

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2763 CTCTGTCACCCAGGCTGGAGTGCAG 2787
Db 1 CTCTGTCACCCAGGCTGGAGTGCAG 25

RESULT 46
US-10-956-157-186275
; Sequence 186275, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186275
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-186275

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2763 CTCTGTCACCCAGGCTGGAGTGCAG 2787
Db 1 CTCTGTCACCCAGGCTGGAGTGCAG 25

RESULT 47
US-10-956-157-186276
; Sequence 186276, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186276
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-186276
```

```
Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2763 CTCTGTCACCCAGGCTGGAGTGCAG 2787
Db 1 CTCTGTCACCCAGGCTGGAGTGCAG 25

RESULT 48
US-10-956-157-188294/c
; Sequence 188294, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 188294
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-188294

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2825 GGCTCAAGTGATCCTCCACCTCAG 2849
Db 25 GGCTCAAGTGATCCTCCACCTCAG 1

RESULT 49
US-10-956-157-189026
; Sequence 189026, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 189026
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-189026

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2765 CTGTACCCAGGCTGGAGTGCAGTG 2789
Db 1 CTGTACCCAGGCTGGAGTGCAGTG 25

RESULT 50
US-10-956-157-236121/c
; Sequence 236121, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 236121
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-236121

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2823 TGGGCTCAAGTGATCTCCACCTC 2847
      |||||
Db 25 TGGGCTCAAGTGATCTCCACCTC 1

RESULT 51
US-10-956-157-237070/c
; Sequence 237070, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 237070
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-237070

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2829 CAAGTGATCTCCACCTCAGCTC 2853
      |||||
Db 25 CAAGTGATCTCCACCTCAGCTC 1

RESULT 52
US-10-956-157-250153
; Sequence 250153, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 250153
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-250153

Query Match      0.8%; Score 25; DB 1; Length 25;

```

```

Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2767 GTCACCCAGGCTGGAGTGCAGTGGT 2791
      |||||
Db 1 GTCACCCAGGCTGGAGTGCAGTGGT 25

RESULT 53
US-10-956-157-267202/c
; Sequence 267202, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 267202
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-267202

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2830 AAGTGATCTCTCCACCTCAGCTCC 2854
      |||||
Db 25 AAGTGATCTCTCCACCTCAGCTCC 1

RESULT 54
US-10-956-157-274130/c
; Sequence 274130, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 274130
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-274130

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2827 CTCAGTGATCTCTCCACCTCAGCC 2851
      |||||
Db 25 CTCAGTGATCTCTCCACCTCAGCC 1

RESULT 55
US-10-956-157-280750
; Sequence 280750, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Mounts, William

```

```
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 280750
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-280750

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2766 TGTCAACCCAGGCTGGAGTGCAGTGG 2790
      |||||
Db 1 TGTCAACCCAGGCTGGAGTGCAGTGG 25

RESULT 56
US-10-956-157-293226
; Sequence 293226, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 293226
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-293226

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2764 TCTGTCAACCCAGGCTGGAGTGCAGT 2788
      |||||
Db 1 TCTGTCAACCCAGGCTGGAGTGCAGT 25

RESULT 57
US-10-956-157-298048
; Sequence 298048, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 298048
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-298048

Query Match      0.8%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
```

```
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2768 TCACCCAGGCTGGAGTGCAGTGGTG 2792
      |||||
Db 1 TCACCCAGGCTGGAGTGCAGTGGTG 25

RESULT 58
US-10-083-720A-15
; Sequence 15, Application US/10083720A
; Publication No. US20030073199A1
; GENERAL INFORMATION:
; APPLICANT: de Waal Malefyt, Rene
; APPLICANT: Fickenscher, Helmut
; APPLICANT: Fleckenstein, Bernhard
; APPLICANT: Knappe, Andrea
; TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS
; FILE REFERENCE: DX0644KBK
; CURRENT APPLICATION NUMBER: US/10/083,720A
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 09/363,993
; PRIOR FILING DATE: 1999-07-29
; PRIOR APPLICATION NUMBER: 08/934,959
; PRIOR FILING DATE: 1997-09-22
; PRIOR APPLICATION NUMBER: 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: 60/302,176
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: 60/027,368
; PRIOR FILING DATE: 1996-09-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ICAM-1 probe.
; NAME/KEY: misc_feature
; LOCATION: (1)..(24)
; OTHER INFORMATION: ICAM-1 probe.
US-10-083-720A-15

Query Match      0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 971 TGACCATCTACAGCTTTCGGCGC 994
      |||||
Db 1 TGACCATCTACAGCTTTCGGCGC 24

RESULT 59
US-09-753-436-23
; Sequence 23, Application US/09753436
; Patent No. US20010029293A1
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
```

;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/753,436
;; FILING DATE:
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; PRIOR APPLICATION NUMBER: 09/382,289
;; FILING DATE:
;; APPLICATION NUMBER: US 08/487,113
;; FILING DATE: 07-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/286,754
;; FILING DATE: 05-AUG-1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/102,852
;; FILING DATE: 05-AUG-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/009,266
;; FILING DATE: 22-JAN-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/894,061
;; FILING DATE: 05-JUN-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/889,724
;; FILING DATE: 26-MAY-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/827,689
;; FILING DATE: 27-JAN-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Williams, Joseph A., Jr.
;; REGISTRATION NUMBER: 38,659
;; REFERENCE/DOCKET NUMBER: 33282
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (312) 474-6300
;; TELEFAX: (312) 474-0448
;; TELEX: 25-3856
;; INFORMATION FOR SEQ ID NO: 23:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 24 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
US-09-753-436-23

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGGTCCTAGAGGTGGACACGCA 752
Db 1 CCGGGTCCTAGAGGTGGACACGCA 24

RESULT 60
US-09-753-436-24/c
; Sequence 24, Application US/09753436
; Patent No. US200100293A1
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemary
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible

;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/753,436
;; FILING DATE:
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; PRIOR APPLICATION NUMBER: 09/382,289
;; FILING DATE:
;; APPLICATION NUMBER: US 08/487,113
;; FILING DATE: 07-JUN-1995
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/286,754
;; FILING DATE: 05-AUG-1994
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/102,852
;; FILING DATE: 05-AUG-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/009,266
;; FILING DATE: 22-JAN-1993
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/894,061
;; FILING DATE: 05-JUN-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/889,724
;; FILING DATE: 26-MAY-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/827,689
;; FILING DATE: 27-JAN-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Williams, Joseph A., Jr.
;; REGISTRATION NUMBER: 38,659
;; REFERENCE/DOCKET NUMBER: 33282
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (312) 474-6300
;; TELEFAX: (312) 474-0448
;; TELEX: 25-3856
;; INFORMATION FOR SEQ ID NO: 24:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 24 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
US-09-753-436-24

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACCAGAGCCAGGAGACACTGCA 965
Db 24 GAACCAGAGCCAGGAGACACTGCA 1

RESULT 61
US-10-025-524-22
; Sequence 22, Application US/10025524
; Publication No. US2003006859A1
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Kilgannon, Patrick D.
; TITLE OF INVENTION: ICAM-4 Materials and Methods
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive, 6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk

```

;
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/025,524
; FILING DATE: 18-Dec-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; APPLICATION NUMBER: US 08/245,295
; FILING DATE: 18-MAY-1994
; APPLICATION NUMBER: US 08/485,604
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: WILLIAMS, JR. JOSEPH A.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 27866/33321
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-474-6300
; TELEFAX: 312-474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-10-025-524-22

```

```

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGTCCTAGAGTGGACACGCA 752
Db 1 CCGGTCCTAGAGTGGACACGCA 24

```

```

RESULT 62
US-10-025-524-23/c
; Sequence 23, Application US/10025524
; Publication No. US20030068659A1
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; TITLE OF INVENTION: ICAM-4 Materials and Methods
; NUMBER OF SEQUENCES: 42
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 233 South Wacker Drive, 6300 Sears Tower
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/025,524
; FILING DATE: 18-Dec-2001

```

```

;
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; APPLICATION NUMBER: US 08/245,295
; FILING DATE: 18-MAY-1994
; APPLICATION NUMBER: US 08/485,604
; FILING DATE: 07-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: WILLIAMS, JR. JOSEPH A.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 27866/33321
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312-474-6300
; TELEFAX: 312-474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 23:
US-10-025-524-23

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACGAGCGCCAGGAGACACTGCA 965
Db 24 GAACGAGCGCCAGGAGACACTGCA 1

RESULT 63
US-10-186-180-25
; Sequence 25, Application US/10186180
; Publication No. US20030108958A1
; GENERAL INFORMATION:
; APPLICANT: De Waal Malefyt, Rene
; APPLICANT: Nagalakshmi, Marehalli
; APPLICANT: Moore, Kevin
; APPLICANT: Fickensher, Helmut
; TITLE OF INVENTION: BIOLOGICAL ACTIVITY OF AKI55
; FILE REFERENCE: DX01168
; CURRENT APPLICATION NUMBER: US/10/186,180
; CURRENT FILING DATE: 2002-06-27
; PRIOR APPLICATION NUMBER: U.S. Provisional 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: U.S. Provisional 60/302,176
; PRIOR FILING DATE: 2001-06-28
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Probe for ICAM-1.
US-10-186-180-25

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 971 TGACCATCTACAGCTTTCCGGCGC 994
Db 1 TGACCATCTACAGCTTTCCGGCGC 24

RESULT 64
US-10-163-942-23
; Sequence 23, Application US/10163942
; Publication No. US20030199423A1
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/163,942
; FILING DATE: 05-JUN-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/753,436
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 09/382,289
; FILING DATE: <Unknown>
; APPLICATION NUMBER: US 08/487,113
; FILING DATE: 07-JUN-1995
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams, Joseph A., Jr.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 33282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 23:
US-10-163-942-23

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 729 CCGGTCCTAGAGGTGGACACGCA 752

Db 1 CCGGTCCTAGAGGTGGACACGCA 24

RESULT 65
US-10-163-942-24/c
; Sequence 24, Application US/10163942
; Publication No. US20030199423A1
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/163,942
; FILING DATE: 05-JUN-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/753,436
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 09/382,289
; FILING DATE: <Unknown>
; APPLICATION NUMBER: US 08/487,113
; FILING DATE: 07-JUN-1995
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams, Joseph A., Jr.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 33282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 24:
US-10-163-942-24

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 942 GAACAGAGCCAGGAGACTGCA 965

Db 24 GAACAGAGCCAGGAGACTGCA 1

RESULT 66
US-10-745-115-23
; Sequence 23, Application US/10745115
; Publication No. US20040248211A1
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; City: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/745,115
; FILING DATE: 23-Dec-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/163,942
; FILING DATE: 05-Jun-2002
; APPLICATION NUMBER: US/09/753,436
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 09/382,289
; FILING DATE: <Unknown>
; APPLICATION NUMBER: US 08/487,113
; FILING DATE: 07-JUN-1995
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams, Joseph A., Jr.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 33282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 23:
US-10-745-115-23

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 729 CCGGGTCTAGAGGTGGACACGCA 752
Db 1 CCGGGTCTAGAGGTGGACACGCA 24

RESULT 67
US-10-745-115-24/c
; Sequence 24, Application US/10745115
; Publication No. US20040248211A1
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; City: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/745,115
; FILING DATE: 23-Dec-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/163,942
; FILING DATE: 05-Jun-2002
; APPLICATION NUMBER: US/09/753,436
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 09/382,289
; FILING DATE: <Unknown>
; APPLICATION NUMBER: US 08/487,113
; FILING DATE: 07-JUN-1995
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams, Joseph A., Jr.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 33282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 24:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 24:
US-10-745-115-24

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 942 GAACGAGCCGAGGAGACTGCA 965
Db 24 GAACGAGCCGAGGAGACTGCA 1

RESULT 68
US-10-916-256-15
; Sequence 15, Application US/10916256
; Publication No. US2005009106A1
; GENERAL INFORMATION:
; APPLICANT: de Waal Malefyt, Rene
; APPLICANT: Fickenscher, Helmut
; APPLICANT: Fleckenstein, Bernhard
; APPLICANT: Knappe, Andrea
; TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS
; FILE REFERENCE: DX0644KBK
; CURRENT APPLICATION NUMBER: US/10/916,256
; CURRENT FILING DATE: 2004-08-10
; PRIOR APPLICATION NUMBER: US/10/083,720
; PRIOR FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 09/363,993
; PRIOR FILING DATE: 1999-07-29
; PRIOR APPLICATION NUMBER: 08/934,959
; PRIOR FILING DATE: 1997-09-22
; PRIOR APPLICATION NUMBER: 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: 60/302,176
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: 60/027,368
; PRIOR FILING DATE: 1996-09-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ICAM-1 probe.
; NAME/KEY: misc_feature
; LOCATION: (1)..(24)
; OTHER INFORMATION: ICAM-1 probe.
US-10-916-256-15

Query Match 0.8%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 971 TGACCATCTACAGCTTCCGGCGC 994
Db 1 TGACCATCTACAGCTTCCGGCGC 24

RESULT 69
US-10-956-157-149908
; Sequence 149908, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 149908
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-149908

Query Match 0.8%; Score 24; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2763 CTCTGTCAACCCAGGCTGGAGTGCA 2786
Db 2 CTCTGTCAACCCAGGCTGGAGTGCA 25

RESULT 70
US-10-956-157-149909
; Sequence 149909, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 149909
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-149909

Query Match 0.8%; Score 24; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2763 CTCTGTCAACCCAGGCTGGAGTGCA 2786
Db 2 CTCTGTCAACCCAGGCTGGAGTGCA 25

RESULT 71
US-10-956-157-194300
; Sequence 194300, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 194300
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-194300

Query Match 0.8%; Score 24; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTGCAGTGGTGCA 2794
Db 1 CCCAGGCTGGAGTGCAGTGGTGCA 24

RESULT 72
US-10-956-157-204929
; Sequence 204929, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 204929
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-204929

Query Match 0.8%; Score 24; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCTCAGTAGCTGGGA 2867
|||||
Db 2 CCTCAGCCTCTCAGTAGCTGGGA 25

RESULT 73
US-10-719-900-9819
; Sequence 9819, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 9819
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-9819

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2467 AAATGACACCTTGTAGCCACCT 2491
|||||
Db 1 AAATGACACCTATGTAGCCACCT 25

RESULT 74
US-10-719-900-25041/c
; Sequence 25041, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 25041
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-25041

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 584 GGAGAGATCACCATGGAGCAATTT 608
|||||
Db 25 GGAGAGATCACCTTGGAGCAATTT 1

RESULT 75
US-10-719-900-64719/c
; Sequence 64719, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 64719
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-64719

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 350 ATGGCGAGTCAACAGCTAAACCTT 374
|||||
Db 25 ATGGCGAGTCAAGAGCTAAACCTT 1

RESULT 76
US-10-719-900-97348
; Sequence 97348, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 97348
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-97348

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2528 ACACTCAGCGGTGTCGTGGACAT 2552
|||||
Db 1 ACACTCAGCGGTGATGTCGTGGACAT 25

RESULT 77
US-10-719-900-112517
; Sequence 112517, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 112517
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-112517

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2496 ACCACATACATTTGCCAGTGCT 2520
|||||
Db 1 ACCACATACATATCTGCCAGTGCT 25

RESULT 78
US-10-719-900-166223/c
; Sequence 166223, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 166223
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-166223

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 554 CCCTGAGGTCAGACACCGTGCT 578
|||||
Db 25 CCCTGAGGTCAGACACCGTGCT 1

RESULT 79
US-10-719-900-179202
; Sequence 179202, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 179202
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-179202

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2631 AGTCCAGTTTCTCGAGTGATCAG 2655

Db 1 AGTCCAGTTTCTCGAGTGATCAG 25
|||||

RESULT 80
US-10-719-900-197838
; Sequence 197838, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 197838
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-197838

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2561 AGGGAATATGCCAAGCTATGCCTT 2585
|||||
Db 1 AGGGAATATGCCAAGCTATGCCTT 25

RESULT 81
US-10-719-900-321241/c
; Sequence 321241, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 321241
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-321241

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 609 CTCGTGCCGCACTGAACCTGGACCTG 633
|||||
Db 25 CTCGTGCCGCACTGAACCTGGACCTG 1

RESULT 82
US-10-719-900-374102/c
; Sequence 374102, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808

```
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 374102
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-374102
```

```
Query Match          0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 447 CCTTACCCTACGCTGCCAGGTGGAG 471
      |||||
Db 25 CCTTACCCTACGCTGCCAGGTGGAG 1
```

RESULT 83

```
US-10-719-900-475750
; Sequence 475750, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 475750
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-475750
```

```
Query Match          0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2428 GAGATTACCCAGAGGCGCTTATTC 2452
      |||||
Db 1 GAGATTACCCAGAGGCGCTTATTC 25
```

RESULT 84

```
US-10-719-900-529451
; Sequence 529451, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 529451
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-529451
```

```
Query Match          0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2792 GCAATCATGTTCACTGCAGTCTTG 2816
      |||||
```

```
Db 1 GCAATCATGTTGACTGCAGTCTTG 25
```

RESULT 85

```
US-10-719-900-544967
; Sequence 544967, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 544967
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-544967
```

```
Query Match          0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2603 GCATTTCACTGGGAGCTTGCACTAT 2627
      |||||
Db 1 GCATTTCACTGGGAGCTTGCACTAT 25
```

RESULT 86

```
US-10-719-900-635362/c
; Sequence 635362, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 635362
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-635362
```

```
Query Match          0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 649 GAGCTGTTTGAGAACACCTCGGCC 673
      |||||
Db 25 GAGCTGTTTGAGTACACCTCGGCC 1
```

RESULT 87

```
US-10-719-900-652193/c
; Sequence 652193, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
```

```
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 652193
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-652193
```

```
Query Match      0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 392 CTCAGAACGGTGGAACTGGCCAC 416
    |||||||
Db 25 CTCAGAACGGGAGGAACCTGGCCAC 1
```

```
RESULT 88
US-10-719-900-671643
; Sequence 671643, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 671643
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-671643
```

```
Query Match      0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2858 GTAGCTGGGACCATAGCTCACAAC 2882
    |||||||
Db 1 GTAGCTGGGACCTTAGCTCACAAC 25
```

```
RESULT 89
US-10-719-900-677593
; Sequence 677593, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 677593
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-677593
```

```
Query Match      0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2742 GTATGTGTAGACAAGCTCTCGCTCT 2766
    |||||||
Db 1 GTATGTGTAGACTAGCTCTCGCTCT 25
```

```
RESULT 90
US-10-719-900-687622/c
; Sequence 687622, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 687622
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-687622
```

```
Query Match      0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 879 CTCAGTCAGTGTACCGCAGAGGAC 903
    |||||||
Db 25 CTCAGTCAGTGTACCGCAGAGGAC 1
```

```
RESULT 91
US-10-719-900-705391/c
; Sequence 705391, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 705391
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-705391
```

```
Query Match      0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 596 ATGGAGCCAAATTCTCGTCCGCAC 620
    |||||||
Db 25 ATGGAGCCAAATTCTCGTCCGCAC 1
```

```
RESULT 92
US-10-719-900-778515/c
; Sequence 778515, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
```

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 778515
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-778515

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 432 GCACGTGGCAGAACCTTACCCCTA 456
|||||
Db 25 GCACGTGGCAGAACCTTACCCCTA 1

RESULT 93
US-10-719-900-864264
; Sequence 864264, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 864264
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-864264

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2807 TGCAGTCTTGACCTTTGGGCTCAA 2831
|||||
Db 1 TGCAGTCTTGACCTTTGGGCTCAA 25

RESULT 94
US-10-719-900-944979/c
; Sequence 944979, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 944979
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-944979

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 422 CCTCTTGGCAGCGAGTGGGCAAGAA 446
|||||
Db 25 CCTCTTGGCAGCGAGTGGGCAAGAA 1

RESULT 95
US-10-956-157-134268/c
; Sequence 134268, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 134268
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-134268

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2828 TCAAGTGATCTCTCCACCTCAGCCT 2852
|||||
Db 25 TCAAGTGATCTCTCCGCTCAGCCT 1

RESULT 96
US-10-956-157-149515/c
; Sequence 149515, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 149515
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-149515

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2764 TCTGTCAACCCAGGCTGAGTGCACT 2788
|||||
Db 25 TCTGTCAACCCAGGCTAGAGTGCACT 1

RESULT 97
US-10-956-157-149516/c
; Sequence 149516, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2

; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-173133

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2765 CTGTCAACCCAGGCTGGAGTGCAGTG 2789
|||||
DB 25 CTGTGCCCCAGGCTGGAGTGCAGTG 1

RESULT 108

US-10-956-157-173783
; Sequence 173783, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 173783
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-173783

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGGAGTGCAGTGGTGC 2793
|||||
DB 1 CACCCAGGCTGGAGTGCAGTGGTGC 25

RESULT 109

US-10-956-157-178223
; Sequence 178223, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 178223
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-178223

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGTGCATC 2797
|||||
DB 1 CAGGCTGGAGTGCAGTGGTGCATC 25

RESULT 110

US-10-956-157-187293/c

; Sequence 187293, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 187293
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-187293

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCAACCCAGGCTGGAG 2782
|||||
DB 25 TCTCACTCTGTCAACCCAGGCTGGAG 1

RESULT 111

US-10-956-157-187294/c
; Sequence 187294, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 187294
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-187294

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCAACCCAGGCTGGAG 2782
|||||
DB 25 TCTCGCTCTGTCAACCCAGGCTGGAG 1

RESULT 112

US-10-956-157-188388/c
; Sequence 188388, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 188388
; LENGTH: 25
; TYPE: DNA

```
; ORGANISM: Probe Sequence
US-10-956-157-188388

Query Match      0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2763 CTCTGTCAACCCAGGCTGGAGTGCAG 2787
      ||||| ||||| ||||| ||||| |||||
DB 25 CTCTGTGCGCCAGGCTGGAGTGCAG 1

RESULT 113
US-10-956-157-188389/c
; Sequence 188389, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 188389
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-188389

Query Match      0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2763 CTCTGTCAACCCAGGCTGGAGTGCAG 2787
      ||||| ||||| ||||| ||||| |||||
DB 25 CTCTGTCAACCCAGGCTGGAGTGCAG 1

RESULT 114
US-10-956-157-201642/c
; Sequence 201642, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 201642
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-201642

Query Match      0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2841 CCACCTCAGCCTCTCTGAGTAGCTGG 2865
      ||||| ||||| ||||| ||||| |||||
DB 25 CCACCTCAGCCTCTCTGAGTAGCTGG 1

RESULT 115
US-10-956-157-216383/c
; Sequence 216383, Application US/10956157
```

```
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216383
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-216383

Query Match      0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2761 CGCTCTGTCAACCCAGGCTGGAGTGC 2785
      ||||| ||||| ||||| ||||| |||||
DB 25 CGCTCTGTGCGCCAGGCTGGAGTGC 1

RESULT 116
US-10-956-157-216384/c
; Sequence 216384, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216384
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-216384

Query Match      0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2761 CGCTCTGTCAACCCAGGCTGGAGTGC 2785
      ||||| ||||| ||||| ||||| |||||
DB 25 CACTCTGTCAACCCAGGCTGGAGTGC 1

RESULT 117
US-10-956-157-216385/c
; Sequence 216385, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216385
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
```


Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2830 AAGTGATCTCCACCTCAGCCTCC 2854
|||||
Db 25 AAGTCATCTCCACCTCAGCCTCC 1

RESULT 123

US-10-956-157-286029/c
; Sequence 286029, Application US/10956157
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 286029

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-286029

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2762 GCTCTGTCAACCCAGGCTGGAGTGCA 2786
|||||
Db 25 GCTCTGTCAACCCAGGCTGGAGTGCA 1

RESULT 124

US-10-956-157-286030/c
; Sequence 286030, Application US/10956157
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 286030

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-286030

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2762 GCTCTGTCAACCCAGGCTGGAGTGCA 2786
|||||
Db 25 GCTCTGTCAACCCAGGCTGGAGTGCA 1

RESULT 125

US-10-956-157-293223

; Sequence 293223, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 293223

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-293223

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2764 TCTGTCAACCCAGGCTGGAGTGCA 2788
|||||
Db 1 TCTGTCAACCCAGGCTGGAGTGCA 25

RESULT 126

US-10-956-157-293224

; Sequence 293224, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 293224

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-293224

Query Match 0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2764 TCTGTCAACCCAGGCTGGAGTGCA 2788
|||||
Db 1 TCTGTCAACCCAGGCTGGAGTGCA 25

RESULT 127

US-10-956-157-293225

; Sequence 293225, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 293225

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-293225

```
Query Match          0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2764 TCTGTACCCAGGCTGGAGTGCACT 2788
      ||||| ||||| ||||| ||||| |||||
Db 1 TCTGTCCGCCAGGCTGGAGTGCACT 25

RESULT 128
US-10-956-157-298378
; Sequence 298378, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 298378
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-298378

Query Match          0.8%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1.7e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2760 TCCTCTGTCTACCCAGGCTGGAGTG 2784
      ||||| ||||| ||||| ||||| |||||
Db 1 TCACCTGTCTACCCAGGCTGGAGTG 25

RESULT 129
US-10-664-639A-87
; Sequence 87, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; TITLE OF INVENTION: Double-Stranded Oligomeric Compounds
; FILE REFERENCE: ISIS0001-100 (COR000027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 87
; LENGTH: 23
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-664-639A-87

Query Match          0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 265 CTCCTGCTGGGAACACCGGAA 287
      ||||| ||||| ||||| ||||| |||||
Db 1 CTCCTGCTGGGAACACCGGAA 23
```

```
RESULT 130
US-10-800-487-333
; Sequence 333, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 333
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-333

Query Match          0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 2e+02;
Matches 21; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 953 AGGAGACACTGCAGACAGTGACC 975
      ||||| ||||| ||||| ||||| |||||
Db 1 AGGAGACACUGCAGACAGUGACC 23

RESULT 131
US-10-800-487-334
; Sequence 334, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
```

```
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 334
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-334

Query Match      0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 73.9%; Pred. No. 2e+02;
Matches 17; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 968 CAGTGACCATCTACAGCTTCCG 990
      |||:|||||:|:|||||:|||||
Db 1 CAGUGACCAUCUACAGCUUCCG 23

RESULT 132
US-10-800-487-335
; Sequence 335, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 335
; LENGTH: 23
```

```
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-335

Query Match      0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 78.3%; Pred. No. 2e+02;
Matches 18; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1550 TCAGCAGCTACCTCTATAACGCG 1572
      :|||||:|:|:|:|:|:|:|:|
Db 1 UCAGCAGCUACGCUUAUAACGCG 23

RESULT 133
US-10-800-487-336
; Sequence 336, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 336
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-336

Query Match      0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 95.7%; Pred. No. 2e+02;
Matches 22; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1875 CTAAGCCAAAGAGGAGGACGAAG 1897
      |:|||||:|:|:|:|:|:|:|
Db 1 CUAAGCCAAAGAGGAGGAGGACGAAG 23

RESULT 134
US-10-800-487-337
; Sequence 337, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 337
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-337

Query Match 0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 47.8%; Pred. No. 2e+02;
Matches 11; Conservative 12; Mismatches 0; Indels 0; Gaps 0;

QY 2587 TCCTGTGCTGTTTGCAATTC 2609
      :||:||||:||||:||||:
Db 1 UCCUUGUCCUGUUGCAUUC 23

RESULT 135
US-10-800-487-338
; Sequence 338, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 337
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-337
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 338
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-338

Query Match 0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 65.2%; Pred. No. 2e+02;
Matches 15; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 2796 TCATGTTCACTGCAGTCTTGAC 2818
      :||:||||:||||:||||:
Db 1 UCAUGGUUACUCGACGACUUGAC 23

RESULT 136
US-10-800-487-339
; Sequence 339, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 339
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-339

Query Match 0.8%; Score 23; DB 1; Length 23;
```



```
; Best Local Similarity 60.9%; Pred. No. 2e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 14; Conservative 9;

QY 2799 TGGTTCACGTCAGCTTGACCTT 2821
      :||:||||:||||:||||:||||:
Db 1 UGGUUCACUGCAGUCUUGACCU 23

RESULT 137
US-10-800-487-340
; Sequence 340, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 340
; LENGTH: 23
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-340

Query Match 0.8%; Score 23; DB 1; Length 23;
Best Local Similarity 87.0%; Pred. No. 2e+02;
Matches 20; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2869 CATAGGCTCACACACACACCTT 2891
      ||:||||:||||:||||:||||:
Db 1 CAUAGGCUACAACACACACCU 23

RESULT 138
US-09-864-636A-1697/c
; Sequence 1697, Application US/09864636A
; Publication No. US20030104378A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allwai, Hatim
; APPLICANT: Bartholomay, Christian
; TITLE OF INVENTION: Detection of RNA Sequences
; FILE REFERENCE: FORS-04944
; CURRENT APPLICATION NUMBER: US/09/864,636A
```

```
; CURRENT FILING DATE: 2002-10-15
; NUMBER OF SEQ ID NOS: 2640
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1697
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-636A-1697

Query Match 0.8%; Score 23; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1645 ACGCCTCCCTGAACCTATCCCGG 1667
      |||||:||||:||||:||||:
Db 23 ACGCCTCCCTGAACCTATCCCGG 1

RESULT 139
US-09-864-426A-1697/c
; Sequence 1697, Application US/09864426A
; Publication No. US20040018489A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Ma, Wu Po
; APPLICANT: Lyamichiev, Victor
; APPLICANT: Saïser, Michael
; TITLE OF INVENTION: Enzymes for the Detection of RNA Sequences
; FILE REFERENCE: FORS-04946
; CURRENT APPLICATION NUMBER: US/09/864,426A
; CURRENT FILING DATE: 2001-05-24
; NUMBER OF SEQ ID NOS: 2640
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1697
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-426A-1697

Query Match 0.8%; Score 23; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1645 ACGCCTCCCTGAACCTATCCCGG 1667
      |||||:||||:||||:||||:
Db 23 ACGCCTCCCTGAACCTATCCCGG 1

RESULT 140
US-10-084-839-1697/c
; Sequence 1697, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allwai, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichiev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
```

; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tsetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1697
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-1697

Query Match 0.8%; Score 23; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1645 ACGCTCCCTCGAACCTATCCCGG 1667
|||
DB 23 ACGCTCCCTCGAACCTATCCCGG 1

RESULT 141

US-10-084-839-3879/c
; Sequence 3879, Application US/10084839
; Publication No. US20030186238A1

GENERAL INFORMATION:

; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tsetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3879
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-3879

Query Match 0.8%; Score 23; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1645 ACGCTCCCTCGAACCTATCCCGG 1667
|||
DB 23 ACGCTCCCTCGAACCTATCCCGG 1

RESULT 142

US-10-956-157-209504
; Sequence 209504, Application US/10956157
; Publication No. US20050118625A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH HUMAN OSTEOARTHRITIS
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 209504
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-209504

Query Match 0.8%; Score 23; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2762 GCTCTGTCAACCCAGGCTGGAGTG 2784
|||
DB 1 GCTCTGTCAACCCAGGCTGGAGTG 23

RESULT 143

US-10-956-157-262753/c
; Sequence 262753, Application US/10956157
; Publication No. US20050118625A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH HUMAN OSTEOARTHRITIS
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 262753
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-262753

Query Match 0.8%; Score 23; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2823 TGGGCTCAAGTGATCCTCCACC 2845
|||
DB 23 TGGGCTCAAGTGATCCTCCACC 1

RESULT 144

US-10-956-157-303903/c
; Sequence 303903, Application US/10956157
; Publication No. US20050118625A1

GENERAL INFORMATION:

```

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 303903
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-130393

Query Match      0.8%; Score 23; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2763 CTCTGTCACCCAGGCTGGAGTGC 2785
Db 25 CTCTGTCACCCAGGCTGGAGTGC 3

RESULT 145
US-10-323-463-12/c
; Sequence 12, Application US/10323463
; Publication No. US20030157693A1
; GENERAL INFORMATION:
; APPLICANT: VERDIN, ERIC
; APPLICANT: JORDAN, ALBERT
; TITLE OF INVENTION: CELL LINES WITH LATENT IMMUNODEFICIENCY
; TITLE OF INVENTION: VIRUS AND METHODS OF USE THEREOF
; FILE REFERENCE: UCAL-261
; CURRENT APPLICATION NUMBER: US/10/323,463
; CURRENT FILING DATE: 2002-12-18
; PRIOR APPLICATION NUMBER: US 60/341,727
; PRIOR FILING DATE: 2001-12-19
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-323-463-12

Query Match      0.8%; Score 22.4; DB 1; Length 24;
Best Local Similarity 95.8%; Pred. No. 2.2e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCCTGAGTAGCTGGGA 2867
Db 24 CCTCAGCCTCCCGAGTAGCTGGGA 1

RESULT 146
US-10-956-157-130041/c
; Sequence 130041, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 130041
; LENGTH: 25

```

```

; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-130041

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCCTGAGTAGCTGGGA 2867
Db 25 CCTCAGCCTCCCGAGTAGCTGGGA 2

RESULT 147
US-10-956-157-134576
; Sequence 134576, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 134576
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-134576

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 AGGCTGGAGTGCAGTGGTGCATC 2797
Db 1 AGGCTGGAGTGCAGTGGTGCATC 24

RESULT 148
US-10-956-157-137807/c
; Sequence 137807, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 137807
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-137807

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTGGGAC 2868
Db 25 CTCAGCCTCCTGAGTAGCTGGGAC 2

RESULT 149
US-10-956-157-137808/c

```

```
/ Sequence 137808, Application US/10956157
/ Publication No. US20050118625A1
/ GENERAL INFORMATION:
/ APPLICANT: Mounts, William
/ TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
/ TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
/ FILE REFERENCE: 031896-043000 (AM 101081)
/ CURRENT APPLICATION NUMBER: US/10/956,157
/ CURRENT FILING DATE: 2004-10-04
/ NUMBER OF SEQ ID NOS: 319805
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 137808
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: Probe Sequence
US-10-956-157-137808

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2845 CTCAGCCTCCTGAGTAGCTGGGAC 2868
Db      25 CTCAGTCTCCTGAGTAGCTGGGAC 2

RESULT 150
US-10-956-157-138446/c
/ Sequence 138446, Application US/10956157
/ Publication No. US20050118625A1
/ GENERAL INFORMATION:
/ APPLICANT: Mounts, William
/ TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
/ TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
/ FILE REFERENCE: 031896-043000 (AM 101081)
/ CURRENT APPLICATION NUMBER: US/10/956,157
/ CURRENT FILING DATE: 2004-10-04
/ NUMBER OF SEQ ID NOS: 319805
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 138446
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: Probe Sequence
US-10-956-157-138446

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2845 CTCAGCCTCCTGAGTAGCTGGGAC 2868
Db      25 CTCAGTCTCCTGAGTAGCTGGGAC 2

RESULT 151
US-10-956-157-138447/c
/ Sequence 138447, Application US/10956157
/ Publication No. US20050118625A1
/ GENERAL INFORMATION:
/ APPLICANT: Mounts, William
/ TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
/ TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
/ FILE REFERENCE: 031896-043000 (AM 101081)
/ CURRENT APPLICATION NUMBER: US/10/956,157
/ CURRENT FILING DATE: 2004-10-04
/ NUMBER OF SEQ ID NOS: 319805
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 138447
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: Probe Sequence
US-10-956-157-138447
```

```
/ ORGANISM: Probe Sequence
US-10-956-157-138447

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2845 CTCAGCCTCCTGAGTAGCTGGGAC 2868
Db      25 CTCAGCCTCCTGAGTAGCTGGGAC 2

RESULT 152
US-10-956-157-172501/c
/ Sequence 172501, Application US/10956157
/ Publication No. US20050118625A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
/ TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
/ FILE REFERENCE: 031896-043000 (AM 101081)
/ CURRENT APPLICATION NUMBER: US/10/956,157
/ CURRENT FILING DATE: 2004-10-04
/ NUMBER OF SEQ ID NOS: 319805
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 172501
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: Probe Sequence
US-10-956-157-172501

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2766 TGTCAACCCAGGCTGGAGTGCAGTG 2789
Db      24 TGTCAACCCAGGCTGGAGTGCAGTG 1

RESULT 153
US-10-956-157-173134/c
/ Sequence 173134, Application US/10956157
/ Publication No. US20050118625A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
/ TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
/ FILE REFERENCE: 031896-043000 (AM 101081)
/ CURRENT APPLICATION NUMBER: US/10/956,157
/ CURRENT FILING DATE: 2004-10-04
/ NUMBER OF SEQ ID NOS: 319805
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 173134
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: Probe Sequence
US-10-956-157-173134

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2766 TGTCAACCCAGGCTGGAGTGCAGTG 2789
Db      24 TGTCAACCCAGGCTGGAGTGCAGTG 1

RESULT 154
US-10-956-157-285778/c
/ Sequence 285778, Application US/10956157
```

```
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 285778
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-285778

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2763 CTCTGTCAACAGGCTGGAGTGCA 2786
      ||||| ||||| ||||| ||||| |||||
Db 24 CTCTGTCAACAGGCTGGAGTGCA 1

RESULT 155
US-10-956-157-285779/c
; Sequence 285779, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 285779
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-285779

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2763 CTCTGTCAACAGGCTGGAGTGCA 2786
      ||||| ||||| ||||| ||||| |||||
Db 24 CTCTGTCAACAGGCTGGAGTGCA 1

RESULT 156
US-10-956-157-289288/c
; Sequence 289288, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 289288
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-289288
```

```
US-10-956-157-289288

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCAACAGGCTGGA 2781
      ||||| ||||| ||||| ||||| |||||
Db 24 TCTCGCTCTGTCAACAGGCTGGA 1

RESULT 157
US-10-956-157-289296/c
; Sequence 289296, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 289296
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-289296

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCAACAGGCTGGA 2781
      ||||| ||||| ||||| ||||| |||||
Db 24 TCTCGCTCTGTCAACAGGCTGGA 1

RESULT 158
US-10-956-157-289297/c
; Sequence 289297, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 289297
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-289297

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCAACAGGCTGGA 2781
      ||||| ||||| ||||| ||||| |||||
Db 24 TCTCGCTCTGTCAACAGGCTGGA 1

RESULT 159
US-10-956-157-291920/c
; Sequence 291920, Application US/10956157
; Publication No. US20050118625A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 291920
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-291920

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCCTCAGTAGCTGGGA 2867
DB 24 CCTCCGCTCCTCAGTAGCTGGGA 1

RESULT 160
US-10-956-157-291921/c
; Sequence 291921, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 291921
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-291921

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCCTCAGTAGCTGGGA 2867
DB 24 CCTCCGCTCCTCAGTAGCTGGGA 1

RESULT 161
US-10-956-157-298049
; Sequence 298049, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 298049
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-298049
```

```
Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2768 TCACCCAGCGCTGGAGTGCAGTGGT 2791
DB 1 TCACCCAGCGCTGGAGTGCAGTGGT 24

RESULT 162
US-10-956-157-316357/c
; Sequence 316357, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 316357
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-316357

Query Match      0.8%; Score 22.4; DB 1; Length 25;
Best Local Similarity 95.8%; Pred. No. 2.1e+02;
Matches 23; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCCACCCAGGCTGGA 2781
DB 25 TCTCGCTTTGTCCACCCAGGCTGGA 2

RESULT 163
US-10-655-579-34
; Sequence 34, Application US/10655579
; Publication No. US20040126789A1
; GENERAL INFORMATION:
; APPLICANT: Park, Kyusung
; TITLE OF INVENTION: Compositions and Methods For Synthesizing Nucleic Acids
; FILE REFERENCE: 0942.5580002
; CURRENT APPLICATION NUMBER: US/10/655,579
; PRIOR FILING DATE: 2003-09-05
; PRIOR APPLICATION NUMBER: 60/408,609
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: 60/427,867
; PRIOR FILING DATE: 2002-11-19
; NUMBER OF SEQ ID NOS: 164
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Tms1-44, forward primer
US-10-655-579-34

Query Match      0.7%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2775 GGCTGGAGTGCAGTGTGCAAT 2796
DB 1 GGCTGGAGTGCAGTGTGCAAT 22
```

RESULT 164

US-10-664-639A-85

; Sequence 85, Application US/10564639A

; Publication No. US20040137471A1

; GENERAL INFORMATION:

; APPLICANT: Vickers, Timothy

; APPLICANT: Koo, Seongjoon

; APPLICANT: Bennett, C. Frank

; APPLICANT: Crooke, Stanley T.

; APPLICANT: Dean, Nicholas, M.

; APPLICANT: Baker, Brenda F.

; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and

; FILE REFERENCE: Double-Stranded Oligomeric Compounds

; CURRENT APPLICATION NUMBER: US/10/664,639A

; CURRENT FILING DATE: 2003-09-18

; PRIOR APPLICATION NUMBER: US 60/411,780

; PRIOR FILING DATE: 2002-09-18

; NUMBER OF SEQ ID NOS: 121

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 85

; LENGTH: 22

; TYPE: DNA

; ORGANISM: artificial sequence

; FEATURE:

; OTHER INFORMATION: oligonucleotide

US-10-664-639A-85

Query Match

Best Local Similarity 0.7%; Score 22; DB 1; Length 22;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 234 CATAGAGACCCGTTGCCTAAA 255

Db 1 CATAGAGACCCGTTGCCTAAA 22

RESULT 165

US-10-664-639A-86/c

; Sequence 86, Application US/10664639A

; Publication No. US20040137471A1

; GENERAL INFORMATION:

; APPLICANT: Vickers, Timothy

; APPLICANT: Koo, Seongjoon

; APPLICANT: Bennett, C. Frank

; APPLICANT: Crooke, Stanley T.

; APPLICANT: Dean, Nicholas, M.

; APPLICANT: Baker, Brenda F.

; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and

; FILE REFERENCE: Double-Stranded Oligomeric Compounds

; CURRENT APPLICATION NUMBER: US/10/664,639A

; CURRENT FILING DATE: 2003-09-18

; PRIOR APPLICATION NUMBER: US 60/411,780

; PRIOR FILING DATE: 2002-09-18

; NUMBER OF SEQ ID NOS: 121

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 86

; LENGTH: 22

; TYPE: DNA

; ORGANISM: artificial sequence

; FEATURE:

; OTHER INFORMATION: oligonucleotide

US-10-664-639A-86

Query Match

Best Local Similarity 0.7%; Score 22; DB 1; Length 22;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 302 GCAATGTCAGAGATAGCCA 323

Db 22 GCAATGTCAGAGATAGCCA 1

RESULT 166

US-10-792-374-2

; Sequence 2, Application US/10792374

; Publication No. US20050079513A1

; GENERAL INFORMATION:

; APPLICANT: Applied Biosystems

; APPLICANT: Lossos, Izidore

; APPLICANT: Tibshirani, Rob

; APPLICANT: Wechsner, Mark

; APPLICANT: Alizadeh, Ash

; APPLICANT: Botstein, David

; APPLICANT: Levy, Ronald

; TITLE OF INVENTION: CLASSIFICATION OF PATIENTS HAVING DIFFUSE LARGE B-CELL LYMPHOMA

; FILE REFERENCE: BASED UPON GENE EXPRESSION

; CURRENT APPLICATION NUMBER: US/10/792,374

; CURRENT FILING DATE: 2004-03-03

; PRIOR APPLICATION NUMBER: 60/510,822

; PRIOR FILING DATE: 2003-10-14

; NUMBER OF SEQ ID NOS: 114

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 2

; LENGTH: 22

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-792-374-2

Query Match

Best Local Similarity 0.7%; Score 22; DB 1; Length 22;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 ACGCTGAGCTCCTCTGCTACTC 34

Db 1 ACGCTGAGCTCCTCTGCTACTC 22

RESULT 167

US-10-084-839-3891/c

; Sequence 3891, Application US/10084839

; Publication No. US20030186238A1

; GENERAL INFORMATION:

; APPLICANT: Third Wave Technologies

; APPLICANT: Allawi, Hatim

; APPLICANT: Argue, Brad T.

; APPLICANT: Bartholomay, Christian T.

; APPLICANT: Chehak, LuAnne

; APPLICANT: Curtis, Michelle L.

; APPLICANT: Bis, Peggy S.

; APPLICANT: Hall, Jeff G.

; APPLICANT: Ip, Hon S.

; APPLICANT: Ji, Lin

; APPLICANT: Kaiser, Michael

; APPLICANT: Kwiatkowski, Jr., Robert W.

; APPLICANT: Lukowiak, Andrew A.

; APPLICANT: Lyamichev, Victor

; APPLICANT: Lymaicheva, Natalie E.

; APPLICANT: Ma, WuPo

; APPLICANT: Neri, Bruce P.

; APPLICANT: Olson, Sarah M.

; APPLICANT: Olson-Munoz, Marilyn C.

; APPLICANT: Schaefer, James J.

; APPLICANT: Skrzypczynski, Zbigniew

; APPLICANT: Takova, Tsetska Y.

; APPLICANT: Thompson, Lisa C.

; APPLICANT: Vedvik, Kevin L.

; TITLE OF INVENTION: RNA Detection Assays

; FILE REFERENCE: FORS-06666

; CURRENT APPLICATION NUMBER: US/10/084,839

; CURRENT FILING DATE: 2002-02-26

; NUMBER OF SEQ ID NOS: 4004

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 3891

```
/ LENGTH: 23
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic
US-10-084-839-3891

Query Match      0.7%; Score 22; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1825 ACCTGCACACCTAAACACTAG 1846
Db 22 ACCTGCACACCTAAACACTAG 1

RESULT 168
US-10-084-839-3895/c
/ Sequence 3895, Application US/10084839
/ Publication No. US20030186238A1
/ GENERAL INFORMATION:
/ APPLICANT: Third Wave Technologies
/ APPLICANT: Allawi, Hatim
/ APPLICANT: Argue, Brad T.
/ APPLICANT: Bartholomay, Christian T.
/ APPLICANT: Chehak, LuAnne
/ APPLICANT: Curtis, Michelle L.
/ APPLICANT: Ejs, Peggy S.
/ APPLICANT: Hall, Jeff G.
/ APPLICANT: Ip, Hon S.
/ APPLICANT: Ji, Lin
/ APPLICANT: Kaiser, Michael
/ APPLICANT: Kwiatkowski, Jr., Robert W.
/ APPLICANT: Lukowiak, Andrew A.
/ APPLICANT: Lyamichev, Victor
/ APPLICANT: Lymaicheva, Natalie E.
/ APPLICANT: Ma, WuPo
/ APPLICANT: Neri, Bruce P.
/ APPLICANT: Olson, Sarah M.
/ APPLICANT: Olson-Munoz, Marilyn C.
/ APPLICANT: Schaefer, James J.
/ APPLICANT: Skrzypczynski, Zbigniew
/ APPLICANT: Takova, Tsetska Y.
/ APPLICANT: Thompson, Lisa C.
/ APPLICANT: Vedvik, Kevin L.
/ TITLE OF INVENTION: RNA Detection Assays
/ FILE REFERENCE: FORS-06666
/ CURRENT FILING DATE: 2002-02-26
/ NUMBER OF SEQ ID NOS: 4004
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 3895
/ LENGTH: 23
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic
US-10-084-839-3895

Query Match      0.7%; Score 22; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1825 ACCTGCACACCTAAACACTAG 1846
Db 22 ACCTGCACACCTAAACACTAG 1

RESULT 169
US-10-956-157-183478/c
/ Sequence 183478, Application US/10956157
/ Publication No. US20050118625A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Wyeth
/ APPLICANT: Mounts, William
/ TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
/ TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
/ FILE REFERENCE: 031896-043000 (AM 101081)
/ CURRENT APPLICATION NUMBER: US/10/956,157
/ CURRENT FILING DATE: 2004-10-04
/ NUMBER OF SEQ ID NOS: 319805
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 183478
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: Probe Sequence
US-10-956-157-183478

Query Match      0.7%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2764 TCTGTCACCCAGGCTGGAGTGC 2785
Db 25 TCTGTCACCCAGGCTGGAGTGC 4

RESULT 170
US-10-956-157-257269/c
/ Sequence 257269, Application US/10956157
/ Publication No. US20050118625A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Mounts, William
/ TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
/ TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
/ FILE REFERENCE: 031896-043000 (AM 101081)
/ CURRENT APPLICATION NUMBER: US/10/956,157
/ CURRENT FILING DATE: 2004-10-04
/ NUMBER OF SEQ ID NOS: 319805
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 257269
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: Probe Sequence
US-10-956-157-257269

Query Match      0.7%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2823 TGGGCTCAAGTGATCCTCCAC 2844
Db 22 TGGGCTCAAGTGATCCTCCAC 1

RESULT 171
US-10-956-157-26674/c
/ Sequence 26674, Application US/10956157
/ Publication No. US20050118625A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: Mounts, William
/ TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
/ TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
/ FILE REFERENCE: 031896-043000 (AM 101081)
/ CURRENT APPLICATION NUMBER: US/10/956,157
/ CURRENT FILING DATE: 2004-10-04
/ NUMBER OF SEQ ID NOS: 319805
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 26674
/ LENGTH: 25
/ TYPE: DNA
/ ORGANISM: Probe Sequence
US-10-956-157-26674
```



```
Query Match          0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2850 CTTCTGAGTAGTGGGACCATAGG 2874
Db 25 CTTCTGAGTAGTGGGACTATAGG 1

RESULT 172
US-10-956-157-26682
; Sequence 26682, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26682
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-26682

Query Match          0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTATGTGA 2750
Db 1 GTGTATGTGTGTGTGTATGTGA 25

RESULT 173
US-10-956-157-69111/c
; Sequence 69111, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 69111
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-69111

Query Match          0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGTGTAGA 2752
Db 25 GTGTGTGTGTGTGTGTGTGTATA 1

RESULT 174
US-10-956-157-136238/c
; Sequence 136238, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 136238
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-136238

Query Match          0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2822 TTGGGCTCAAGTGATCTCCACCAT 2846
Db 25 TTAGGCTCAAGCGATCTCCACCAT 1

RESULT 175
US-10-956-157-145010
; Sequence 145010, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 145010
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-145010

Query Match          0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2848 AGCTCTCTGAGTAGCTGGGACCATA 2872
Db 1 AGCTCTCTGAGTAGCTGGGATTATA 25

RESULT 176
US-10-956-157-145011
; Sequence 145011, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 145011
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-145011

Query Match          0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2848 AGCTCTCTGAGTAGCTGGGACCATA 2872
Db 1 AGCTCTCTGAGTAGCTGGGATTATA 25
```

```
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2848 AGCCTCTGAGTAGCTGGGACCATTA 2872
      |||||
Db 1 AGCCTCTGAGTAGCTGGGACTACA 25

RESULT 177
US-10-956-157-150177/c
; Sequence 150177, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 150177
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-150177

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2764 TCTGTCAACCAGCTGGAGTGAGT 2788
      |||||
Db 25 TCTATCACCAGCTGGAGTGAGT 1

RESULT 178
US-10-956-157-173064/c
; Sequence 173064, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 173064
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-173064

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTCAACCAGCTGGAGTG 2784
      |||||
Db 25 TTGCTCTATCAACCAGCTGGAGTG 1

RESULT 179
US-10-956-157-173065/c
; Sequence 173065, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

```
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 173065
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-173065

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTCAACCAGCTGGAGTG 2784
      |||||
Db 25 TTGCTCTGCCACCAGCTGGAGTG 1

RESULT 180
US-10-956-157-187292/c
; Sequence 187292, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 187292
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-187292

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2758 TTCGCTCTGTCAACCAGCTGGAG 2782
      |||||
Db 25 TTTCACCTCTGTCAACCAGCTGGAG 1

RESULT 181
US-10-956-157-189773/c
; Sequence 189773, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 189773
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-189773

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
```

```
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2849 GCCTCTGAGTAGCTGGGACCATAG 2873
|||||
Db 25 GCCTCTGAATAGCTGGGACCACAG 1

RESULT 182
US-10-956-157-198817
; Sequence 198817, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 198817
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-198817

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2840 CCCACCTCAGCTCTCTGAGTAGCTG 2864
|||
Db 1 CCTACCTCAGCCTCTTGTAGTAGCTG 25

RESULT 183
US-10-956-157-201601/c
; Sequence 201601, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 201601
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-201601

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2766 TGTCACCCAGGCTGGAGTCAGTGG 2790
|||
Db 25 TATCACCCAGGCTGGAGTGTAGTGG 1

RESULT 184
US-10-956-157-204126/c
; Sequence 204126, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

```
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 204126
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-204126

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2851 CTCCTGAGTAGCTGGGACCATAGGC 2875
|||||
Db 25 CTCCTGAGTAGCTGGGATTATAGGC 1

RESULT 185
US-10-956-157-208666
; Sequence 208666, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 208666
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-208666

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2776 GCTGGAGTCAGTGGTGCATCATG 2800
|||||
Db 1 GCTGGAGTCAGTGGTGCAGTCTTG 25

RESULT 186
US-10-956-157-211313/c
; Sequence 211313, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 211313
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-211313

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 2838 CTCCACCTCAGCCTCTCAGTAGC 2862
|||
Db 25 CTCCACCTCAGCCTCTCAGTAGC 1

RESULT 187

US-10-956-157-211314/c
; Sequence 211314, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 211314
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-211314

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2838 CTCCACCTCAGCCTCTCAGTAGC 2862
|||
Db 25 CTCCACCTCAGCCTCTCAGTAGC 1

RESULT 188

US-10-956-157-211315/c
; Sequence 211315, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 211315
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-211315

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2838 CTCCACCTCAGCCTCTCAGTAGC 2862
|||
Db 25 CTCCACCTCAGCCTCTCAGTAGC 1

RESULT 189

US-10-956-157-216386/c
; Sequence 216386, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216386
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-216386

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2761 CGCTCTGTCAACCCAGGCTGGAGTGC 2785
|||
Db 25 CACCTGTCAACCCAGGCTGGAGTGC 1

RESULT 190

US-10-956-157-216388/c
; Sequence 216388, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216388
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-216388

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2761 CGCTCTGTCAACCCAGGCTGGAGTGC 2785
|||
Db 25 CTCACCTGTCAACCCAGGCTGGAGTGC 1

RESULT 191

US-10-956-157-237034/c
; Sequence 237034, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 237034
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-237034

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2823 TGGGCTCAAGTGATCTCCACCTC 2847
Db 25 TGGGCTCAAGTGATCTCTCGCTC 1

RESULT 192

US-10-956-157-240074/c
; Sequence 240074, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 240074
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-240074

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2813 CTTGACCTTTTGGGCTCAAGTGATC 2837
Db 25 CTTGATCTTCTGGGCTCAAGTGATC 1

RESULT 193

US-10-956-157-248564/c
; Sequence 248564, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 248564
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-248564

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2761 CGCTCTGTCAACCAGGCTGGAGTGC 2785
Db 25 CGCTCTGTCAACCAGGCTAGAGTAC 1

RESULT 194

US-10-956-157-253556/c
; Sequence 253556, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 253556
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-253556

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCTCCTAGTAGCTGGAC 2868
Db 25 CCTCAGCCTCTCTAAGTAGCTTGGAC 1

RESULT 195

US-10-956-157-267200/c
; Sequence 267200, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 267200
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-267200

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2830 AAGTGATCTCTCCACCTCAGCTCC 2854
Db 25 AAGCCATCTCTCCACCTCAGCTCC 1

RESULT 196

US-10-956-157-273579
; Sequence 273579, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 273579
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-273579

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2775 GGCTGGAGTGACAGTGGTGCATCAT 2799

Db 1 GCGTGGAGTGCAGTGGTGCAGTCTT 25
|||||

RESULT 197

US-10-956-157-274129/c
; Sequence 274129, Application US/10956157
; Publication No. US20050118625A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 274129
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-274129

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2827 CTCAGTGATCTCCACCTCAGCC 2851
|||||

Db 25 CTCAGTGATCCACCCGCTCAGCC 1
|||||

RESULT 198

US-10-956-157-274131/c
; Sequence 274131, Application US/10956157
; Publication No. US20050118625A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 274131
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-274131

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2827 CTCAGTGATCTCCACCTCAGCC 2851
|||||

Db 25 CTCAGGAAATCTCCACCTCAGCC 1
|||||

RESULT 199

US-10-956-157-281557/c
; Sequence 281557, Application US/10956157
; Publication No. US20050118625A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 281557
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-281557

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2848 AGCCTCTCAGTAGCTGGGACCATA 2872
|||||

Db 25 AGCCTCTCAGTAGCTGGGACTACA 1
|||||

RESULT 200

US-10-956-157-281558/c
; Sequence 281558, Application US/10956157
; Publication No. US20050118625A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 281558
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-281558

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2848 AGCCTCTCAGTAGCTGGGACCATA 2872
|||||

Db 25 AGCCTCTCAGTAGCTGGGACTACA 1
|||||

RESULT 201

US-10-956-157-293352
; Sequence 293352, Application US/10956157
; Publication No. US20050118625A1

GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 293352
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-293352

Query Match 0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2764 TCTGTCAACCCAGCTGGAGTGCAGT 2788
|||||

```
Db      1  TCTGTGCCCCAGCTTGGAGTGCACT 25

RESULT 202
US-10-956-157-293353
; Sequence 293353, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 293353
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-293353

Query Match      0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2764  TCTGTCACCAGCTCGAGTGCACT 2788
          ||||| ||||| ||||| ||||| |||||
Db      1  TCTGTGCCCCAGCTGAGGGCAGT 25

RESULT 203
US-10-956-157-297528
; Sequence 297528, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 297528
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-297528

Query Match      0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2846  TCAGCCTCTCGAGTAGCTGGGACCA 2870
          ||||| ||||| ||||| ||||| |||||
Db      1  TCAGCCTCCCGAGTAGCTGGGACTA 25

RESULT 204
US-10-956-157-297529
; Sequence 297529, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
```

```
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 297529
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-297529

Query Match      0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2846  TCAGCCTCTCGAGTAGCTGGGACCA 2870
          ||||| ||||| ||||| ||||| |||||
Db      1  TCAGCCTCCCGAGTAGCTGGGACTA 25

RESULT 205
US-10-956-157-297530
; Sequence 297530, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 297530
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-297530

Query Match      0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2846  TCAGCCTCTCGAGTAGCTGGGACCA 2870
          ||||| ||||| ||||| ||||| |||||
Db      1  TCAGCCTCCCGAGTAGCTGGGACTA 25

RESULT 206
US-10-956-157-297531
; Sequence 297531, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 297531
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-297531

Query Match      0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2846  TCAGCCTCTCGAGTAGCTGGGACCA 2870
          ||||| ||||| ||||| ||||| |||||
Db      1  TCAGCCTCCCGAGTAGCTGGGACTA 25

RESULT 207
US-10-956-157-297532
; Sequence 297532, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 297532
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-297532

Query Match      0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2846  TCAGCCTCTCGAGTAGCTGGGACCA 2870
          ||||| ||||| ||||| ||||| |||||
Db      1  TCAGCCTCCCGAGTAGCTGGGACTA 25
```

```
RESULT 207
US-10-956-157-302162/c
; Sequence 302162, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 302162
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-302162

Query Match          0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2846 TCAGCCTCCTGAGTAGCTGGGACCA 2870
      |||||
Db 25 TCAGCCTCCTGAGTAGCTGGGGCTA 1

RESULT 208
US-10-956-157-302207/c
; Sequence 302207, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 302207
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-302207

Query Match          0.7%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 2.5e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2762 GCTCTGTACCCAGGCTGGAGTGCA 2786
      |||||
Db 25 GCTCTATCACCCAGGCTGGAGTGTA 1

RESULT 209
US-10-956-157-26679
; Sequence 26679, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26679
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-26679

Query Match          0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGTGTA 2750
      |||||
Db 1 GTATGTGTGTGTGTATGTGTA 23

RESULT 210
US-10-956-157-26680
; Sequence 26680, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26680
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-26680

Query Match          0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGTGTA 2750
      |||||
Db 2 GTATGTGTGTGTGTATGTGTA 24

RESULT 211
US-10-956-157-146232/c
; Sequence 146232, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 146232
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-146232

Query Match          0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2852 TCCTGAGTAGCTGGGACCATAGG 2874
      |||||
Db 24 TCCTGAGTAGCTGGGACTATAGG 2
```



```
RESULT 212
US-10-956-157-166115/c
; Sequence 166115, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 166115
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-166115

Query Match      0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTGGGA 2867
    |||||||
Db 25 CTCAGCCTCCCGAGTAGCTGGGA 3

RESULT 213
US-10-956-157-166116/c
; Sequence 166116, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 166116
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-166116

Query Match      0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTGGGA 2867
    |||||||
Db 25 CTCAGCCTCCCGAGTAGCTGGGA 3

RESULT 214
US-10-956-157-166117/c
; Sequence 166117, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 166117
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-166117

Query Match      0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTGGGA 2867
    |||||||
Db 25 CTCAGCCTCCTGAGTAGCTAGGA 3

RESULT 215
US-10-956-157-184309
; Sequence 184309, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 184309
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-184309

Query Match      0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTGGGA 2867
    |||||||
Db 1 CTCAGCCTCCCGAGTAGCTGGGA 23

RESULT 216
US-10-956-157-184310
; Sequence 184310, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 184310
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-184310

Query Match      0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTGGGA 2867
    |||||||
Db 1 CTCAGCCTCCCGAGTAGCTGGGA 23
```

```
RESULT 217
US-10-956-157-184311/c
; Sequence 184311, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 184311
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-184311

Query Match      0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTGGGA 2867
    |||||||
Db 1 CTCAGCCTCCCGAGTAGCTGGGA 23
```

```
RESULT 217
US-10-956-157-185024
; Sequence 185024, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 185024
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-185024
Query Match      0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2845 CTCAGCCTCCTGAGTAGCTGGG 2867
      |||||
DB      1 CTCAGCCTCCTGAGTAGCTGTA 23

RESULT 218
US-10-956-157-193927/c
; Sequence 193927, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193927
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-193927
Query Match      0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2844 CTCAGCCTCCTGAGTAGCTGGG 2866
      |||||
DB      23 CCTCAGCCTCCGAGTAGCTGGG 1

RESULT 219
US-10-956-157-194036/c
; Sequence 194036, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 194036
```

```
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-194036
Query Match      0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2844 CCTCAGCCTCCTGAGTAGCTGGG 2866
      |||||
DB      23 CCTCAGCCTCCTGAGTAGCTGGG 1

RESULT 220
US-10-956-157-194037/c
; Sequence 194037, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 194037
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-194037
Query Match      0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2844 CCTCAGCCTCCTGAGTAGCTGGG 2866
      |||||
DB      23 CGTCAGCCTCCTGAGTAGCTGGG 1

RESULT 221
US-10-956-157-201831/c
; Sequence 201831, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 201831
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-201831
Query Match      0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      2758 TCTCGCTCTGTCCAGCAGCTGG 2780
      |||||
DB      23 TCTCGCTCTGTCCAGCAGCTGG 1

RESULT 222
```

```
US-10-956-157-249727/c
; Sequence 249727, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 249727
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-249727

Query Match          0.7%; Score 21.4; DB 1; Length 25;
Best Local Similarity 95.7%; Pred. No. 2.7e+02;
Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2767 GTCACCCAGCGCTGAGTGCAGTG 2789
DB 25 GTCACCCAGCGCTGAGTGCAGTG 3

RESULT 223
US-10-029-598-3/c
; Sequence 3, Application US/10029598
; Publication No. US20030040497A1
; GENERAL INFORMATION:
; APPLICANT: Teng, Ching-Leou
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Tillman, Lloyd
; APPLICANT: Hardee, Gregory E.
; APPLICANT: Ecker, David J.
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Compositions And Methods For No. US20030040497A1-Parental Delivered
; FILE REFERENCE: ISI84945
; CURRENT APPLICATION NUMBER: US/10/029,598
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 08/082,624
; PRIOR FILING DATE: 1998-05-21
; PRIOR APPLICATION NUMBER: 09/315,298
; PRIOR FILING DATE: 1999-05-20
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Sequence
US-10-029-598-3

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 AACCTCAGCCTCGCTATGGCT 63
DB 21 AACCTCAGCCTCGCTATGGCT 1

RESULT 224
US-10-083-720A-14/c
; Sequence 14, Application US/10083720A
; Publication No. US20030073199A1
; GENERAL INFORMATION:
; APPLICANT: de Waal Malefyt, Rene
; APPLICANT: Fickenscher, Helmut
```

```
; APPLICANT: Fleckenstein, Bernhard
; APPLICANT: Knappe, Andrea
; TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS
; FILE REFERENCE: DX0644KBK
; CURRENT APPLICATION NUMBER: US/10/083,720A
; CURRENT FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 09/363,993
; PRIOR FILING DATE: 1999-07-29
; PRIOR APPLICATION NUMBER: 08/934,959
; PRIOR FILING DATE: 1997-09-22
; PRIOR APPLICATION NUMBER: 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: 60/302,176
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: 60/027,368
; PRIOR FILING DATE: 1996-09-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ICAM-reverse.
; NAME/KEY: misc_feature
; LOCATION: (1)..(21)
; OTHER INFORMATION: ICAM reverse.
US-10-083-720A-14

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 997 AACGTGATTCTGACGAAGCCA 1017
DB 21 AACGTGATTCTGACGAAGCCA 1

RESULT 225
US-09-932-300-37/c
; Sequence 37, Application US/09932300
; Publication No. US20030032788A1
; GENERAL INFORMATION:
; APPLICANT: GARVER, Eric
; APPLICANT: TU, Guang-Chou
; APPLICANT: ISRAEL, Yedy
; TITLE OF INVENTION: METHODS OF INHIBITING ALCOHOL CONSUMPTION
; FILE REFERENCE: 9855-3U2
; CURRENT APPLICATION NUMBER: US/09/932,300
; CURRENT FILING DATE: 2001-08-20
; PRIOR APPLICATION NUMBER: US 60/051,705
; PRIOR FILING DATE: 1997-07-03
; PRIOR APPLICATION NUMBER: US 09/109,663
; PRIOR FILING DATE: 1998-07-02
; NUMBER OF SEQ ID NOS: 111
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 37
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Known
; OTHER INFORMATION: effective ASO
US-09-932-300-37

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1937 TGAGAGGGGGAAGTGGTGGGG 1957
DB 21 TGAGAGGGGGAAGTGGTGGGG 1
```

RESULT 226
US-09-982-262B-3/c
; Sequence 3, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-3

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2176 ACCAGCTATTATTGAGTGTC 2196
DB 21 ACCAGCTATTATTGAGTGTC 1

RESULT 227
US-10-186-180-24/c
; Sequence 24, Application US/10186180
; Publication No. US20030108958A1
; GENERAL INFORMATION:
; APPLICANT: De Waal Malefyt, Rene
; APPLICANT: Nagalakshmi, Marehalli
; APPLICANT: Moore, Kevin
; APPLICANT: Fickensher, Helmut
; TITLE OF INVENTION: BIOLOGICAL ACTIVITY OF AK155
; FILE REFERENCE: DX01168
; CURRENT APPLICATION NUMBER: US/10/186,180
; CURRENT FILING DATE: 2002-06-27
; PRIOR APPLICATION NUMBER: U.S. Provisional 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: U.S. Provisional 60/302,176
; PRIOR FILING DATE: 2001-06-28
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 24
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Reverse primer for ICAM-1.
US-10-186-180-24

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 997 AACGTGATTCTGACGAAGCCA 1017
DB 21 AACGTGATTCTGACGAAGCCA 1

RESULT 228
US-10-109-349A-172
; Sequence 172, Application US/10109349A
; Publication No. US20030186246A1
; GENERAL INFORMATION:
; APPLICANT: Medical College of Ohio
; APPLICANT: Willey, James C.
; APPLICANT: Crawford, Brin L.
; TITLE OF INVENTION: MULTIPLEX STANDARDIZED REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION
; FILE REFERENCE: 01154/2001-203
; CURRENT APPLICATION NUMBER: US/10/109,349A
; CURRENT FILING DATE: 2002-06-12
; NUMBER OF SEQ ID NOS: 282
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 172
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-109-349A-172

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 674 CCTACCAGCTCCAGACCTTTG 694
DB 1 CCTACCAGCTCCAGACCTTTG 21

RESULT 229
US-10-109-349A-173/c
; Sequence 173, Application US/10109349A
; Publication No. US20030186246A1
; GENERAL INFORMATION:
; APPLICANT: Medical College of Ohio
; APPLICANT: Willey, James C.
; APPLICANT: Crawford, Brin L.
; TITLE OF INVENTION: MULTIPLEX STANDARDIZED REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION
; FILE REFERENCE: 01154/2001-203
; CURRENT APPLICATION NUMBER: US/10/109,349A
; CURRENT FILING DATE: 2002-06-12
; NUMBER OF SEQ ID NOS: 282
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 173
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-109-349A-173

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 997 AACGTGATTCTGACGAAGCCA 1017
DB 21 AACGTGATTCTGACGAAGCCA 1

RESULT 230
US-10-080-979-18/c
; Sequence 18, Application US/10080979
; Publication No. US20030191075A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Manoharan, Muthiah

```
; APPLICANT: Bennett, Frank C.
; TITLE OF INVENTION: Oligonucleotide Conjugates For Hepatic Delivery
; FILE REFERENCE: Isis-5028
; CURRENT APPLICATION NUMBER: US/10/080,979
; CURRENT FILING DATE: 2002-02-22
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 78
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-modified phosphoramidite
US-10-080-979-18

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGCA 2120
|||||
Db 21 TGACGGATGCCAGCTTGGGCA 1

RESULT 231
US-10-080-979-70/c
; Sequence 70, Application US/10080979
; Publication No. US20030191075A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bennett, Frank C.
; TITLE OF INVENTION: Oligonucleotide Conjugates For Hepatic Delivery
; FILE REFERENCE: Isis-5028
; CURRENT APPLICATION NUMBER: US/10/080,979
; CURRENT FILING DATE: 2002-02-22
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 70
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-modified phosphoramidite
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: non-nucleoside 6-carbon amino linker
US-10-080-979-70

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGCA 2120
|||||
Db 21 TGACGGATGCCAGCTTGGGCA 1

RESULT 232
US-10-080-979-73/c
; Sequence 73, Application US/10080979
; Publication No. US20030191075A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bennett, Frank C.
; TITLE OF INVENTION: Oligonucleotide Conjugates For Hepatic Delivery
```

```
; FILE REFERENCE: Isis-5028
; CURRENT APPLICATION NUMBER: US/10/080,979
; CURRENT FILING DATE: 2002-02-22
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 73
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-modified phosphoramidite
US-10-080-979-73

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGCA 2120
|||||
Db 21 TGACGGATGCCAGCTTGGGCA 1

RESULT 233
US-10-388-578-76
; Sequence 76, Application US/10388578
; Publication No. US20030224411A1
; GENERAL INFORMATION:
; APPLICANT: Geron Corporation
; APPLICANT: Stanton, Lawrence
; APPLICANT: Ralph, Brandenberger
; APPLICANT: Joseph, Gold D.
; APPLICANT: John, Irving
; APPLICANT: Mandalam, Ramkumar
; APPLICANT: Mok, Michael
; APPLICANT: Shelton, Dawne
; TITLE OF INVENTION: Genes that are Up- or Down-Regulated During Differentiation of H
; FILE REFERENCE: 135/001
; CURRENT APPLICATION NUMBER: US/10/388,578
; CURRENT FILING DATE: 2003-03-13
; NUMBER OF SEQ ID NOS: 139
; SOFTWARE: Custom
; SEQ ID NO 76
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-388-578-76

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 ACTCCAGACGGGTGGAACGTG 411
|||||
Db 1 ACTCCAGACGGGTGGAACGTG 21

RESULT 234
US-10-388-578-77
; Sequence 77, Application US/10388578
; Publication No. US20030224411A1
; GENERAL INFORMATION:
; APPLICANT: Geron Corporation
; APPLICANT: Stanton, Lawrence
; APPLICANT: Ralph, Brandenberger
; APPLICANT: Joseph, Gold D.
; APPLICANT: John, Irving
; APPLICANT: Mandalam, Ramkumar
; APPLICANT: Mok, Michael
; APPLICANT: Shelton, Dawne
```

```
; TITLE OF INVENTION: Genes that are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells
; FILE REFERENCE: 135/001
; CURRENT APPLICATION NUMBER: US/10/388,578
; CURRENT FILING DATE: 2003-03-13
; NUMBER OF SEQ ID NOS: 139
; SOFTWARE: Custom
; SEQ ID NO 77
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-388-578-77

Query Match      0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 414 ACCCTCCCTCTTGGCAGCC 434
      |||
Db 1 ACCCTCCCTCTTGGCAGCC 21

RESULT 235
US-10-388-578-78/c
; Sequence 78, Application US/10388578
; Publication No. US20030224411A1
; GENERAL INFORMATION:
; APPLICANT: Geron Corporation
; APPLICANT: Stanton, Lawrence
; APPLICANT: Ralph, Brandenberger
; APPLICANT: Joseph, Gold D.
; APPLICANT: John, Irving
; APPLICANT: Mandalam, Ramkumar
; APPLICANT: Mok, Michael
; APPLICANT: Shelton, Dawne
; TITLE OF INVENTION: Genes that are Up- or Down-Regulated During Differentiation of Human Embryonic Stem Cells
; FILE REFERENCE: 135/001
; CURRENT APPLICATION NUMBER: US/10/388,578
; CURRENT FILING DATE: 2003-03-13
; NUMBER OF SEQ ID NOS: 139
; SOFTWARE: Custom
; SEQ ID NO 78
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-388-578-78

Query Match      0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 438 GGGCAAGACCTTACCTACG 458
      |||
Db 21 GGGCAAGACCTTACCTACG 1

RESULT 236
US-10-454-663-3/c
; Sequence 3, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
```

```
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-3

Query Match      0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2176 ACCAGCTATTATTGAGTGC 2196
      |||
Db 21 ACCAGCTATTATTGAGTGC 1

RESULT 237
US-10-050-888A-13/c
; Sequence 13, Application US/10050888A
; Publication No. US20040073376A1
; GENERAL INFORMATION:
; APPLICANT: Gesteland, Raymond F.
; APPLICANT: Atkins, John F.
; APPLICANT: Matveeva, Olga V.
; APPLICANT: Giddings, Michael C.
; TITLE OF INVENTION: Finding Active Antisense Oligonucleotides Using Artificial Neural Networks
; FILE REFERENCE: T9479.B
; CURRENT APPLICATION NUMBER: US/10/050,888A
; CURRENT FILING DATE: 2002-01-14
; PRIOR APPLICATION NUMBER: US 60/262,993
; PRIOR FILING DATE: 2001-01-19
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-050-888A-13

Query Match      0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1937 TGAGAGGGGGAAGTGGTGGGG 1957
      |||
Db 21 TGAGAGGGGGAAGTGGTGGGG 1

RESULT 238
US-10-780-439-18/c
; Sequence 18, Application US/10780439
; Publication No. US20040142899A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D.
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR ENHANCED BIOSTABILITY AND ALTERED BIODISTRIBUTION OF OLIGONUCLEOTIDES IN MAMMALS
; NUMBER OF SEQUENCES: 63
; CORRESPONDENCE ADDRESS:
```

ADDRESSER: Cozen O'Connor
STREET: 1900 Market Street
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/780,439
FILING DATE: 17-Feb-2004
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Nguyen, Quan L.
REGISTRATION NUMBER: 46,957
REFERENCE/DOCKET NUMBER: ISIC0006-102
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-665-2000
TELEFAX: 215-665-2013
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 18:
US-10-780-439-18
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGCA 2120
Db 21 TGACGGATGCCAGCTTGGCA 1
RESULT 239
US-10-780-439-26/c
Sequence 26, Application US/10780439
Publication No. US20040142899A1
GENERAL INFORMATION:
APPLICANT: Cook, Phillip D.
Manoharan, Muthiah
Bennett, C. Frank
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
ENHANCED BIOSTABILITY AND ALTERED BIODISTRIBUTION OF
OLIGONUCLEOTIDES IN MAMMALS
NUMBER OF SEQUENCES: 63
CORRESPONDENCE ADDRESS:
ADDRESSER: Cozen O'Connor
STREET: 1900 Market Street
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/780,439
FILING DATE: 17-Feb-2004
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Nguyen, Quan L.
REGISTRATION NUMBER: 46,957
REFERENCE/DOCKET NUMBER: ISIC0006-102

TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-665-2000
TELEFAX: 215-665-2013
INFORMATION FOR SEQ ID NO: 26:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 26:
US-10-780-439-26
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGCA 2120
Db 21 TGACGGATGCCAGCTTGGCA 1
RESULT 240
US-10-777-838-3/c
Sequence 3, Application US/10777838
Publication No. US20040162259A1
GENERAL INFORMATION:
APPLICANT: Wedel, Mark K.
TITLE OF INVENTION: Compositions and Methods for Treatment of Pouchitis
FILE REFERENCE: ISIC0008-100
CURRENT APPLICATION NUMBER: US/10/777,838
CURRENT FILING DATE: 2004-02-12
PRIOR APPLICATION NUMBER: 60/518,053
PRIOR FILING DATE: 2003-11-07
PRIOR APPLICATION NUMBER: 60/477,215
PRIOR FILING DATE: 2003-02-13
NUMBER OF SEQ ID NOS: 53
SEQ ID NO 3
LENGTH: 21
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: antisense sequence
US-10-777-838-3
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 43 AACCTCAGCTCGCTATGGCT 63
Db 21 AACCTCAGCTCGCTATGGCT 1
RESULT 241
US-10-389-431-76
Sequence 76, Application US/10389431
Publication No. US20040180347A1
GENERAL INFORMATION:
APPLICANT: Geron Corporation
APPLICANT: Stanton, Lawrence
APPLICANT: Ralph, Brandenberger
APPLICANT: Joseph, Gold D.
APPLICANT: John, Irving
APPLICANT: Mandalam, Ramkumar
APPLICANT: Mok, Michael
TITLE OF INVENTION: A Marker System for Preparing and Characterizing High-Quality Human
FILING DATE: 135/002
FILE REFERENCE: 135/002
CURRENT APPLICATION NUMBER: US/10/389,431
CURRENT FILING DATE: 2003-03-13
NUMBER OF SEQ ID NOS: 100

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 76

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-389-431-76

Query Match

Best Local Similarity 100.0%; Score 21; DB 1; Length 21;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 391 ACTCCAGACGGGTGGAACGTG 411

Db 1 ACTCCAGACGGGTGGAACGTG 21

RESULT 242

US-10-389-431-77

; Sequence 77, Application US/10389431

; Publication No. US20040180347A1

; GENERAL INFORMATION:

; APPLICANT: Geron Corporation

; APPLICANT: Stanton, Lawrence

; APPLICANT: Ralph, Brandenberger

; APPLICANT: Joseph, Gold D.

; APPLICANT: John, Irving

; APPLICANT: Mandalam, Ramkumar

; APPLICANT: Mok, Michael

; TITLE OF INVENTION: A Marker System for Preparing and Characterizing High-Quality Human Embryonic Stem Cells

; FILE REFERENCE: 135/002

; CURRENT APPLICATION NUMBER: US/10/389,431

; CURRENT FILING DATE: 2003-03-13

; NUMBER OF SEQ ID NOS: 100

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 77

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-389-431-77

Query Match

Best Local Similarity 100.0%; Score 21; DB 1; Length 21;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 414 ACCCTCCCTCTTGGCAGCC 434

Db 1 ACCCTCCCTCTTGGCAGCC 21

RESULT 243

US-10-389-431-78/c

; Sequence 78, Application US/10389431

; Publication No. US20040180347A1

; GENERAL INFORMATION:

; APPLICANT: Geron Corporation

; APPLICANT: Stanton, Lawrence

; APPLICANT: Ralph, Brandenberger

; APPLICANT: Joseph, Gold D.

; APPLICANT: John, Irving

; APPLICANT: Mandalam, Ramkumar

; APPLICANT: Mok, Michael

; TITLE OF INVENTION: A Marker System for Preparing and Characterizing High-Quality Human Embryonic Stem Cells

; FILE REFERENCE: 135/002

; CURRENT APPLICATION NUMBER: US/10/389,431

; CURRENT FILING DATE: 2003-03-13

; NUMBER OF SEQ ID NOS: 100

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 78

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Homo sapiens

US-10-389-431-78

Query Match

Best Local Similarity 100.0%; Score 21; DB 1; Length 21;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 438 GGGCAAGAACCTTACCCTACG 458

Db 21 GGGCAAGAACCTTACCCTACG 1

RESULT 244

US-10-759-878-5/c

; Sequence 5, Application US/10759878

; Publication No. US20040220129A1

; GENERAL INFORMATION:

; APPLICANT: Samuel Jotham Reich

; APPLICANT: Michael J. Tolentino

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA

; FILE REFERENCE: 43826-0003 US

; CURRENT APPLICATION NUMBER: US/10/759,878

; CURRENT FILING DATE: 2004-01-16

; PRIOR APPLICATION NUMBER: US 60/440,579

; NUMBER OF SEQ ID NOS: 94

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 5

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: siRNA antisense strand

US-10-759-878-5

Query Match

Best Local Similarity 100.0%; Score 21; DB 1; Length 21;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 223 AAGTTGTTGGCATAGAGACC 243

Db 21 AAGTTGTTGGCATAGAGACC 1

RESULT 245

US-10-759-878-7/c

; Sequence 7, Application US/10759878

; Publication No. US20040220129A1

; GENERAL INFORMATION:

; APPLICANT: Samuel Jotham Reich

; APPLICANT: Michael J. Tolentino

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA

; FILE REFERENCE: 43826-0003 US

; CURRENT APPLICATION NUMBER: US/10/759,878

; CURRENT FILING DATE: 2004-01-16

; PRIOR APPLICATION NUMBER: US 60/440,579

; NUMBER OF SEQ ID NOS: 94

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 7

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: siRNA antisense strand

; NAME/KEY: misc RNA

; LOCATION: (1)-(19)

; OTHER INFORMATION: ribonucleotide bases

US-10-759-878-7

Query Match

Best Local Similarity 100.0%; Score 21; DB 1; Length 21;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;


```
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 223 AAGTTGTTGGCATAGAGACC 243
    |||||
Db 21 AAGTTGTTGGCATAGAGACC 1

RESULT 246
US-10-759-878-20
; Sequence 20, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 20
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-20

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 133 AATGCCACACATCTGTGTC 153
    |||||
Db 1 AATGCCACACATCTGTGTC 21

RESULT 247
US-10-759-878-21
; Sequence 21, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 21
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-21

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 159 AAAAGTCATCTGCCCCGGG 179
    |||||
Db 1 AAAAGTCATCTGCCCCGGG 21

RESULT 248
US-10-759-878-22
; Sequence 22, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-22

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 160 AAAGTCATCTGCCCCGGGA 180
    |||||
Db 1 AAAGTCATCTGCCCCGGGA 21

RESULT 249
US-10-759-878-23
; Sequence 23, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-23

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 161 AAGTCATCTGCCCCGGGAG 181
    |||||
Db 1 AAGTCATCTGCCCCGGGAG 21

RESULT 250
US-10-759-878-24
; Sequence 24, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
```

```
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-24
```

```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 223 AAGTTGTTGGCATAGACC 243
Db 1 AAGTTGTTGGCATAGACC 21
```

```
RESULT 251
US-10-759-878-25
; Sequence 25, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 25
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-25
```

```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 253 AAAAGGAGTTGCTCTGCTCT 273
Db 1 AAAAGGAGTTGCTCTGCTCT 21
```

```
RESULT 252
US-10-759-878-26
; Sequence 26, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
```

```
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-26
```

```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 254 AAAAGGAGTTGCTCTGCTCTG 274
Db 1 AAAAGGAGTTGCTCTGCTCTG 21
```

```
RESULT 253
US-10-759-878-27
; Sequence 27, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-27
```

```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 255 AAAAGGAGTTGCTCTGCTCTG 275
Db 1 AAAAGGAGTTGCTCTGCTCTG 21
```

```
RESULT 254
US-10-759-878-28
; Sequence 28, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 28
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
;
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-28

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 256 AAGGAGTTGCTCCTCCTGGG 276
Db 1 AAGGAGTTGCTCCTCCTGGG 21

RESULT 255
US-10-759-878-29
; Sequence 29, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-29

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 277 AACACCGGAAGGTGTATGAA 297
Db 1 AACACCGGAAGGTGTATGAA 21

RESULT 256
US-10-759-878-30
; Sequence 30, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 30
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-30

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AACCGAAGGTGTATGAACTG 300
Db 1 AACCGAAGGTGTATGAACTG 21

RESULT 257
US-10-759-878-31
; Sequence 31, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-31

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 286 AAGGTGTATGAACTGAGCAAT 306
Db 1 AAGGTGTATGAACTGAGCAAT 21

RESULT 258
US-10-759-878-32
; Sequence 32, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 32
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-32

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 296 AACTGAGCAATGTGCAAGAG 316
Db 1 AACTGAGCAATGTGCAAGAG 21

RESULT 259
```

US-10-759-878-33
; Sequence 33, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 33
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-33

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 304 AATGTGCAAGATAGCCAA 324
|||||
Db 1 AATGTGCAAGATAGCCAA 21

RESULT 260
US-10-759-878-34
; Sequence 34, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 34
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-34

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 311 AAGAAGATAGCCAACTGCT 331
|||||
Db 1 AAGAAGATAGCCAACTGCT 21

RESULT 261
US-10-759-878-35
; Sequence 35, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA

; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 35
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-35

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 314 AAGATAGCCAACTGCT 334
|||||
Db 1 AAGATAGCCAACTGCT 21

RESULT 262
US-10-759-878-36
; Sequence 36, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 36
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-36

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 323 AACCAATGTGCTTCAAACT 343
|||||
Db 1 AACCAATGTGCTTCAAACT 21

RESULT 263
US-10-759-878-37
; Sequence 37, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 37
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-37

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 327 AATGTGCTATTCAAACTGCC 347
Db 1 AATGTGCTATTCAAACTGCC 21

RESULT 264
US-10-759-878-38
; Sequence 38, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 38
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-38

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 339 AAACCTGCCCTGATGGGCAGTC 359
Db 1 AAACCTGCCCTGATGGGCAGTC 21

RESULT 265
US-10-759-878-39
; Sequence 39, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-39

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 339 AAACCTGCCCTGATGGGCAGTC 359
Db 1 AAACCTGCCCTGATGGGCAGTC 21

RESULT 266
US-10-759-878-40
; Sequence 40, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 40
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-40

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 340 AACTGCCCTGATGGGCAGTCA 360
Db 1 AACTGCCCTGATGGGCAGTCA 21

RESULT 267
US-10-759-878-41
; Sequence 41, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 41
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-41

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 360 AACAGCTAAACCTTCCTCAC 380
Db 1 AACAGCTAAACCTTCCTCAC 21

RESULT 267
US-10-759-878-41
; Sequence 41, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 41
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-41

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 367 AAAACCTTCCTCACCGGTGAC 387
```

Db 1 AAAACCTTCTCCACCGTGAC 21
|||||

RESULT 268

US-10-759-878-42

; Sequence 42, Application US/10759878

; Publication No. US20040220129A1

; GENERAL INFORMATION:

; APPLICANT: Samuel J. Tolentino

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA

; FILE REFERENCE: 43826-0003 US

; CURRENT FILING DATE: 2004-01-16

; PRIOR APPLICATION NUMBER: US 60/440,579

; PRIOR FILING DATE: 2003-01-16

; NUMBER OF SEQ ID NOS: 94

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 42

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: target sequence

US-10-759-878-42

Query Match 0.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 3.5e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 368 AAACCTTCTCCACCGTGACT 388

Db 1 AAACCTTCTCCACCGTGACT 21

RESULT 269

US-10-759-878-43

; Sequence 43, Application US/10759878

; Publication No. US20040220129A1

; GENERAL INFORMATION:

; APPLICANT: Samuel J. Tolentino

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA

; FILE REFERENCE: 43826-0003 US

; CURRENT FILING DATE: 2004-01-16

; PRIOR APPLICATION NUMBER: US 60/440,579

; PRIOR FILING DATE: 2003-01-16

; NUMBER OF SEQ ID NOS: 94

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 43

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: target sequence

US-10-759-878-43

Query Match 0.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 3.5e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 369 AACCTTCTCCACCGTGACTG 389

Db 1 AACCTTCTCCACCGTGACTG 21

RESULT 270

US-10-759-878-44

; Sequence 44, Application US/10759878

; Publication No. US20040220129A1

; GENERAL INFORMATION:

; APPLICANT: Samuel J. Tolentino

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA

; FILE REFERENCE: 43826-0003 US

; CURRENT FILING DATE: 2004-01-16

; PRIOR APPLICATION NUMBER: US 60/440,579

; PRIOR FILING DATE: 2003-01-16

; NUMBER OF SEQ ID NOS: 94

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 44

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: target sequence

US-10-759-878-44

Query Match 0.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 3.5e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 398 AACGGGTGGAAGTGGCACCCC 418

Db 1 AACGGGTGGAAGTGGCACCCC 21

RESULT 271

US-10-759-878-45

; Sequence 45, Application US/10759878

; Publication No. US20040220129A1

; GENERAL INFORMATION:

; APPLICANT: Samuel J. Tolentino

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA

; FILE REFERENCE: 43826-0003 US

; CURRENT FILING DATE: 2004-01-16

; PRIOR APPLICATION NUMBER: US 60/440,579

; PRIOR FILING DATE: 2003-01-16

; NUMBER OF SEQ ID NOS: 94

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 45

; LENGTH: 21

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: target sequence

US-10-759-878-45

Query Match 0.7%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 3.5e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 AACTGGCACCCCTCCCTCTT 427

Db 1 AACTGGCACCCCTCCCTCTT 21

RESULT 272

US-10-759-878-46

; Sequence 46, Application US/10759878

; Publication No. US20040220129A1

; GENERAL INFORMATION:

; APPLICANT: Samuel J. Tolentino

; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA

; FILE REFERENCE: 43826-0003 US

```
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 46
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-46
```

```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      442 AAGAACCTTACCCTACGCTGC 462
Db       1 AAGAACCTTACCCTACGCTGC 21
|||||
```

RESULT 273

```
US-10-759-878-47
; Sequence 47, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 47
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-47
```

```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      445 AACCTTACCCTACGCTGCCAG 465
Db       1 AACCTTACCCTACGCTGCCAG 21
|||||
```

RESULT 274

```
US-10-759-878-48
; Sequence 48, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 48
```

```
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-48
```

```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      490 AACCTCACCGTGGTCTGCTC 510
Db       1 AACCTCACCGTGGTCTGCTC 21
|||||
```

RESULT 275

```
US-10-759-878-49
; Sequence 49, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 49
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-49
```

```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      520 AAGGAGCTGAACGGGAGCCA 540
Db       1 AAGGAGCTGAACGGGAGCCA 21
|||||
```

RESULT 276

```
US-10-759-878-50
; Sequence 50, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 50
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-50
```

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 529 AAACGGAGCCAGCTGTGGGG 549
|||||
Db 1 AAACGGAGCCAGCTGTGGGG 21

RESULT 277

US-10-759-878-51
; Sequence 51, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-51

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 530 AACGGAGCCAGCTGTGGGG 550
|||||
Db 1 AACGGAGCCAGCTGTGGGG 21

RESULT 278

US-10-759-878-52
; Sequence 52, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 52
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-52

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 604 AATTCTCGGCGGCGACTGAA 624
|||||
Db 1 AATTCTCGGCGGCGACTGAA 21

RESULT 279

US-10-759-878-53
; Sequence 53, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 53
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-53

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 623 AACTGGACCTGGGCCCCAAG 643
|||||
Db 1 AACTGGACCTGGGCCCCAAG 21

RESULT 280

US-10-759-878-54
; Sequence 54, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 54
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-54

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 641 AAGGCTGGAGCTGTTTGA 661
|||||
Db 1 AAGGCTGGAGCTGTTTGA 21

RESULT 281

US-10-759-878-55
; Sequence 55, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:


```
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US 60/440,579
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 55
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-55

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 661 AACACCTCGGCCCTACCAG 681
Db 1 AACACCTCGGCCCTACCAG 21

RESULT 282
US-10-759-878-56
; Sequence 56, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US 60/440,579
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 56
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-56

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 716 AACTTGTGAGCCCGGGTCC 736
Db 1 AACTTGTGAGCCCGGGTCC 21

RESULT 283
US-10-759-878-57
; Sequence 57, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US 60/440,579
; CURRENT FILING DATE: 2004-01-16
```

```
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 57
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-57

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 835 AACCCACAGTCACCTATGCC 855
Db 1 AACCCACAGTCACCTATGCC 21

RESULT 284
US-10-759-878-58
; Sequence 58, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US 60/440,579
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 58
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-58

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 856 AACGACTCTTCTCGGCCAAG 876
Db 1 AACGACTCTTCTCGGCCAAG 21

RESULT 285
US-10-759-878-59
; Sequence 59, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US 60/440,579
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 59
; LENGTH: 21
; TYPE: DNA
```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-59

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 874 AAGGCCTCAGTGTGACC 894
|||||
Db 1 AAGGCCTCAGTGTGACC 21

RESULT 286

US-10-759-878-60
; Sequence 60, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 60
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-60

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 933 AATACTGGGGAACCAAGCCA 953
|||||
Db 1 AATACTGGGGAACCAAGCCA 21

RESULT 287

US-10-759-878-61
; Sequence 61, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 61
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-61

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;

Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 943 AACACAGCCAGGACACTG 963
|||||
Db 1 AACACAGCCAGGACACTG 21

RESULT 288

US-10-759-878-62
; Sequence 62, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 62
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-62

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 997 AACGTGATTCGACCAAGCCA 1017
|||||
Db 1 AACGTGATTCGACCAAGCCA 21

RESULT 289

US-10-759-878-63
; Sequence 63, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 63
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-63

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1012 AAGCCAGAGTCTCAGAAGGG 1032
|||||
Db 1 AAGCCAGAGTCTCAGAAGGG 21

```
RESULT 290
US-10-759-878-64
; Sequence 64, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 64
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-64

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1028 AAGGGACCGAGGTGACAGTGA 1048
      |||||||
Db 1 AAGGGACCGAGGTGACAGTGA 21

RESULT 291
US-10-759-878-65
; Sequence 65, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 65
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-65

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1048 AAGTGTGAGGCCACCTTAGA 1068
      |||||||
Db 1 AAGTGTGAGGCCACCTTAGA 21

RESULT 292
US-10-759-878-66
; Sequence 66, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 66
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-66

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1084 RATGGGTTCCAGCCGACCCA 1104
      |||||||
Db 1 AATGGGGTTCCAGCCGACCCA 21

RESULT 294
US-10-759-878-68
; Sequence 68, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 67
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-67

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1084 RATGGGTTCCAGCCGACCCA 1104
      |||||||
Db 1 AATGGGGTTCCAGCCGACCCA 21

RESULT 294
US-10-759-878-68
; Sequence 68, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 68
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-68

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1084 RATGGGTTCCAGCCGACCCA 1104
      |||||||
Db 1 AATGGGGTTCCAGCCGACCCA 21
```

; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 68
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-68

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1132 AAGGCCACCCAGGACAC 1152
Db 1 AAGGCCACCCAGGACAC 21

RESULT 295
US-10-759-878-69
; Sequence 69, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 69
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-69

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1150 AAGCGCGCAGCTTCTCTGC 1170
Db 1 AAGCGCGCAGCTTCTCTGC 21

RESULT 296
US-10-759-878-70
; Sequence 70, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 70
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: target sequence
US-10-759-878-70

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1176 AACCCCTGGAGGTGGCGGCCA 1196
Db 1 AACCCCTGGAGGTGGCGGCCA 21

RESULT 297
US-10-759-878-71
; Sequence 71, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 71
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-71

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1207 AAGAACCCAGCCCGGAGCTT 1227
Db 1 AAGAACCCAGCCCGGAGCTT 21

RESULT 298
US-10-759-878-72
; Sequence 72, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 72
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-72

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 1210 AACACACCCGGGAGCTTCGT 1230
Db 1 AACACACCCGGGAGCTTCGT 21

RESULT 299
US-10-759-878-73
; Sequence 73, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 73
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-73

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1272 AAATGGACGTGCCAGAAAA 1292
Db 1 AAATGGACGTGCCAGAAAA 21

RESULT 300
US-10-759-878-74
; Sequence 74, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 74
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-74

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1273 AAATGGACGTGCCAGAAAAT 1293
Db 1 AAATGGACGTGCCAGAAAAT 21

RESULT 301
US-10-759-878-75
; Sequence 75, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 75
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-75

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1289 AAAATTCACGACGACTCCAA 1309
Db 1 AAAATTCACGACGACTCCAA 21

RESULT 302
US-10-759-878-76
; Sequence 76, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 76
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-76

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1290 AAAATTCACGACGACTCCAA 1310
Db 1 AAAATTCACGACGACTCCAA 21

RESULT 303
US-10-759-878-77
; Sequence 77, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
```

```
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 77
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-77
```

```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1291 AATTCCCGAGGACTCCCAATG 1311
      |||||
Db 1 AATTCCCGAGGACTCCCAATG 21
```

```
RESULT 304
US-10-759-878-78
; Sequence 78, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 78
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-78
```

```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1308 AATGTCCAGGCTTGGGGGAA 1328
      |||||
Db 1 AATGTCCAGGCTTGGGGGAA 21
```

```
RESULT 305
US-10-759-878-79
; Sequence 79, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 79
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-79
```

```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1327 AACCCATTGCCGAGCTCAAG 1347
      |||||
Db 1 AACCCATTGCCGAGCTCAAG 21
```

```
RESULT 306
US-10-759-878-80
; Sequence 80, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 80
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-80
```

```
Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1345 AAGTCTCTAAAGGATGGCACT 1365
      |||||
Db 1 AAGTCTCTAAAGGATGGCACT 21
```

```
RESULT 307
US-10-759-878-81
; Sequence 81, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 81
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-81
```

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1353 AAGGATGGCACTTTCCCACTG 1373

Db 1 AAGGATGGCACTTTCCCACTG 21

RESULT 308

US-10-759-878-82
; Sequence 82, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 82
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-82

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1354 AAGGATGGCACTTTCCCACTG 1374

Db 1 AAGGATGGCACTTTCCCACTG 21

RESULT 309

US-10-759-878-83
; Sequence 83, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 83
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-83

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1385 AATCAGTGACTGTCTCACTCGAG 1405

|||||

Db 1 AATCAGTGACTGTCTCACTCGAG 21

RESULT 310

US-10-759-878-84
; Sequence 84, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 84
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-84

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGAGGTCACTCCCGGAGG 1465

Db 1 AAGGGAGGTCACTCCCGGAGG 21

RESULT 311

US-10-759-878-85
; Sequence 85, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 85
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-85

Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1474 AATGTGCTCTCCCCCGGTAT 1494

Db 1 AATGTGCTCTCCCCCGGTAT 21

RESULT 312

US-10-759-878-86
; Sequence 86, Application US/10759878
; Publication No. US20040220129A1

```
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 86
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-86
```

```
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1533 AATGGGCACTGCAGGCTCAG 1553
|||||
Db 1 AATGGGCACTGCAGGCTCAG 21
```

```
RESULT 313
US-10-759-878-87
; Sequence 87, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 87
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-87
```

```
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1567 AACCGCCAGCGGAATCAAG 1587
|||||
Db 1 AACCGCCAGCGGAATCAAG 21
```

```
RESULT 314
US-10-759-878-88
; Sequence 88, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
```

```
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 88
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-88
```

```
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1579 AAGATCAAGAAATACAGACTA 1599
|||||
Db 1 AAGATCAAGAAATACAGACTA 21
```

```
RESULT 315
US-10-759-878-89
; Sequence 89, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 89
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-89
```

```
Query Match 0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1585 AAGAAATACAGACTACACAG 1605
|||||
Db 1 AAGAAATACAGACTACACAG 21
```

```
RESULT 316
US-10-759-878-90
; Sequence 90, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 90
; LENGTH: 21
```



```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-90

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1588 AATACAGACTACACAGGCC 1608
      |||||
Db 1 AATACAGACTACACAGGCC 21

RESULT 317
US-10-759-878-91
; Sequence 91, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 91
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-91

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1589 AATACAGACTACACAGGCC 1609
      |||||
Db 1 AATACAGACTACACAGGCC 21

RESULT 318
US-10-759-878-92
; Sequence 92, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 92
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-92

Query Match          0.7%; Score 21; DB 1; Length 21;

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-90

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1601 AACAGGCCCAAAAGGGACCC 1621
      |||||
Db 1 AACAGGCCCAAAAGGGACCC 21

RESULT 319
US-10-759-878-93
; Sequence 93, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 93
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-93

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1610 AAAAGGGACCCCATGAAC 1630
      |||||
Db 1 AAAAGGGACCCCATGAAC 21

RESULT 320
US-10-759-878-94
; Sequence 94, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 94
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-94

Query Match          0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1611 AAAAGGGACCCCATGAAC 1631
      |||||
Db 1 AAAAGGGACCCCATGAAC 21
```

```
RESULT 321
US-10-793-497-3/c
; Sequence 3, Application US/10793497
; Publication No. US20040229831A1
; GENERAL INFORMATION:
; APPLICANT: Teng, Ching-Leou
; APPLICANT: Cook, Phillip D
; APPLICANT: Tillman, Lloyd
; APPLICANT: Hardee, Gregory E
; APPLICANT: Ecker, David J
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Compositions and Methods for Non-Parenteral Delivery of
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: ISIC0001-104
; CURRENT APPLICATION NUMBER: US/10/793,497
; CURRENT FILING DATE: 2004-03-05
; PRIOR APPLICATION NUMBER: 09/082,624
; PRIOR FILING DATE: 1999-05-21
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-10-793-497-3

Query Match      0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 AACCTCAGCCTCGCTATGGCT 63
Db 21 AACCTCAGCCTCGCTATGGCT 1

RESULT 322
US-10-916-256-14/c
; Sequence 14, Application US/10916256
; Publication No. US20050009106A1
; GENERAL INFORMATION:
; APPLICANT: de Waal Malefyt, Rene
; APPLICANT: Fickenscher, Helmut
; APPLICANT: Fleckenstein, Bernhard
; APPLICANT: Knappe, Andrea
; TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS
; FILE REFERENCE: DX0644KBK
; CURRENT APPLICATION NUMBER: US/10/916,256
; PRIOR APPLICATION NUMBER: US/10/083,720
; PRIOR FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 09/363,993
; PRIOR FILING DATE: 1999-07-29
; PRIOR APPLICATION NUMBER: 08/934,959
; PRIOR FILING DATE: 1997-09-22
; PRIOR APPLICATION NUMBER: 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: 60/302,176
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: 60/027,368
; PRIOR FILING DATE: 1996-09-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ICAM-reverse.
; NAME/KEY: misc_feature
```

```
; LOCATION: (1)..(21)
; OTHER INFORMATION: ICAM reverse.
US-10-916-256-14

Query Match      0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 997 AACGTGATTCTGACGAAGCCA 1017
Db 21 AACGTGATTCTGACGAAGCCA 1

RESULT 323
US-10-624-570-6
; Sequence 6, Application US/10624570
; Publication No. US20050026152A1
; GENERAL INFORMATION:
; APPLICANT: Muller, Norbert
; TITLE OF INVENTION: Method of Screening Schizophrenia
; FILE REFERENCE: 03-1039
; CURRENT APPLICATION NUMBER: US/10/624,570
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: US 60/397,611
; PRIOR FILING DATE: 2002-07-23
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Primer derived from human ICAM-1 gene
US-10-624-570-6

Query Match      0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1403 GAGATCTTGAGGGCACCTACC 1423
Db 1 GAGATCTTGAGGGCACCTACC 21

RESULT 324
US-10-624-570-8/c
; Sequence 8, Application US/10624570
; Publication No. US20050026152A1
; GENERAL INFORMATION:
; APPLICANT: Muller, Norbert
; TITLE OF INVENTION: Method of Screening Schizophrenia
; FILE REFERENCE: 03-1039
; CURRENT APPLICATION NUMBER: US/10/624,570
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: US 60/397,611
; PRIOR FILING DATE: 2002-07-23
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Snapshot primer for ICAM-1
US-10-624-570-8

Query Match      0.7%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 3.5e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 AGGTGACCGTGAATGTGCTCT 1483
Db 21 AGGTGACCGTGAATGTGCTCT 1
```



```
Best Local Similarity   91.7%;    Pred. NO. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Y      2729 TGTGTGTGTGTGTATGTTAGA 2752
          |||||
b      2 TGTGTGTGTGTGTGTGTATA 25
          |||||

RESULT 332
S-10-956-157-26481
Sequence 26481, Application US/10956157
Publication NO. US20050118625A1
GENERAL INFORMATION:
```

APPLICANT: Wyeth
APPLICANT'S ADDRESS: Mount Pleasant, South Carolina 29568
INVENTOR: William J. Meade
INVENTOR'S ADDRESS: 10000 E. 1st Avenue, Suite 100, Denver, Colorado 80231
ATTORNEY: The Law Firm of Williams, Meade & Associates, P.C., 10000 E. 1st Avenue, Suite 100, Denver, Colorado 80231
DATE OF FILING: 10/1/98
DATE OF PUBLICATION: 10/1/98
DATE OF INVENTION: 10/1/98
TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
ABSTRACT: The present invention relates to the use of nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases.

FILE REFERENCE: 051930 083000 (RM 10010817)
CURRENT APPLICATION NUMBER: US/10/956,157
CURRENT FILING DATE: 2004-10-04
NUMBER OF SEQ ID NOS: 319805

SEQ ID NO 26481
LENGTH: 25
TYPE: DNA
ORGANISM: Probe Sequence
S-10-956-157-26481

```
Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

y 2729 TGTGTGTGTGTGTATGTTAGA 2752
|||||
b 1 TGTGTGTGTGTGTGTGTATA 24

RESULT 333
S-10-956-157-26686
Sequence 26686, Application US/10956157
Publication No. US20050118625A1
GENERAL INFORMATION:

APPLICANT: Mycell
APPLICANT: Mounts, William
TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

FILE REFERENCE: 651856 083000 AM 20100817
CURRENT APPLICATION NUMBER: US/10/956,157
CURRENT FILING DATE: 2004-10-04
NUMBER OF SEQ ID NOS: 319805

SEQ ID NO 26686
LENGTH: 25
TYPE: DNA
ORGANISM: Probe Sequence
S-10-956-157-26686

```

Query Match      0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. NO. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

y      2726 GCGTGTGTGTGTGTGTGTGTGTGT 2749
          | | | | | | | | | | | | | |
b      2 GTGTATGTGTGTGTGTGTGTGTGT 25

RESULT 334
S-10-956-157-69107/c
Sequence 69107, Application US/10956157
Publication No. US20050118625A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Mounts, William

```

```
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 69107
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-69107

Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATGTGTAG 2752
      |||||||||||||||||||
Db 25 TGTGTGTGTGTGTGTGTGTGTATA 2

RESULT 335
US-10-956-157-69108/c
; Sequence 69108, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 69108
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-69108

Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGTGTAG 2751
      |||||||||||||||||||
Db 25 GTGTGTGTGTGTGTGTGTATAG 2

RESULT 336
US-10-956-157-69908/c
; Sequence 69908, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 69908
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-69908

Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGTGTAG 2751
      |||||||||||||||||||
Db 25 GTGTGTGTGTGTGTGTGTATAG 2

RESULT 337
US-10-956-157-69909/c
; Sequence 69909, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 69909
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-69909

Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGTGTAG 2751
      |||||||||||||||||||
Db 25 GTGTGTGTGTGTGTGTGTATAG 2

RESULT 338
US-10-956-157-85148/c
; Sequence 85148, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 85148
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-85148

Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2814 TTGACCTTTTGGGCTCAAGTGATC 2837
      |||||||
Db 25 TTGATCTTCTGGGCTCAAGTGATC 2

RESULT 339
US-10-956-157-99876/c
; Sequence 99876, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

```
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTATGTGTAGA 2752
      |||||||||||||||||||
Db 25 TGTGTGTGTGTGTGTGTGTGTATA 2

RESULT 337
US-10-956-157-69909/c
; Sequence 69909, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 69909
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-69909

Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGTGTAG 2751
      |||||||||||||||||||
Db 25 GTGTGTGTGTGTGTGTGTATAG 2

RESULT 338
US-10-956-157-85148/c
; Sequence 85148, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 85148
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-85148

Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2814 TTGACCTTTTGGGCTCAAGTGATC 2837
      |||||||
Db 25 TTGATCTTCTGGGCTCAAGTGATC 2

RESULT 339
US-10-956-157-99876/c
; Sequence 99876, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 99876
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-99876

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGT 2749
Db 25 -GTGTGTGTGTGTGTGTGTGTGTATGTAT 2

RESULT 340
US-10-956-157-99878/c
; Sequence 99878, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 99878
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-99878

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGT 2749
Db 24 GTGTGTGTGTGTGTGTGTGTGTATGTAT 1

RESULT 341
US-10-956-157-128314/c
; Sequence 128314, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 128314
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-128314

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCCTGAGTAGCTGGGA 2867
Db 25 CCTAGCCTCCTGAGTAGCTGAGA 2

RESULT 342
US-10-956-157-137800/c
; Sequence 137800, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 137800
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-137800

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTGGGAC 2868
Db 25 CTCAGCCTCCTGAGTAGCTGGGAC 2

RESULT 343
US-10-956-157-137802/c
; Sequence 137802, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 137802
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-137802

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTGGGAC 2868
Db 25 CTCAGCCTCCTGAGTAGCTGGGAC 2

RESULT 344
US-10-956-157-137803/c
; Sequence 137803, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 137803
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-137803

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 137803
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-137803

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTGGGAC 2868
Db 25 CTCAGCCTCCCAAGTAGCTGGGAC 2

RESULT 345

US-10-956-157-137804/c
; Sequence 137804, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 137804
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-137804

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTGGGAC 2868
Db 25 CTCAGCCTCCCAAGTAGCTGGGAC 2

RESULT 346

US-10-956-157-137805/c
; Sequence 137805, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 137805
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-137805

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTGGGAC 2868
Db 25 CTCAGCCTCCCAAGTAGCTGGGAC 2

RESULT 347

US-10-956-157-137806/c
; Sequence 137806, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 137806
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-137806

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTGGGAC 2868
Db 25 CTCAGCCTCCCAAGTAGCTGGGAC 2

RESULT 348

US-10-956-157-162473/c
; Sequence 162473, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 162473
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-162473

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2776 GCTGGAGTGCAGTGGTGCAATCAT 2799
Db 24 GCTGGAGTGCAGTGGTGCAATCTT 1

RESULT 349

US-10-956-157-174048
; Sequence 174048, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)

```

: CURRENT APPLICATION NUMBER: US/10/956,157
:
: CURRENT FILING DATE: 2008-10-04
:
: NUMBER OF SEQ ID NOS: 319805
:
: SOFTWARE: Patentin version 3.2
:
: SEQ ID NO 174048
:
: LENGTH: 25
:
: TYPE: DNA
:
: ORGANISM: Probe Sequence
:
: US-10-956-157-174048

```

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2847 CAGCCTCCTGAGTAGCTGGGACCA 2870
|||||
Db 1 CAGCCTCCAGAGTAGCTGGGACTA 24

RESULT 350
US-10-956-157-185025
; Sequence 185025, Application US/10956157
; Publication No. US20050118625A1

```
Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Qy 2845 CTCAGCCTCCTGAGTAGCTGGGAC 2868
|||
Db 1 CTCAGCCTCAGAGTAGCTGGGAC 24

RESULT 351
US-10-956-157-185762
; Sequence 185762, Application US/10956157
; Publication No. US20050118625A1

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2763 CTCTGTCACCCAGGCTGGAGTGCA 2786

```

Db      1  CTCTGTTGCCAGCGCTGGAGTGCA  24
|||||  |||||||
RESULT 352
US-10-956-157-198969
; Sequence 198969, Application US/10956157
; Publication No. US20050118625A1

```

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2844 CCTCAGCCTCCTGAGTAGCTGGGA 2867
|||
Db 1 CCTCAGCCTCCCAAGTAGCTGGGA 24

RESULT 353
US-10-956-157-198970
; Sequence 198970, Application US/10956157
; Publication No. US20050118625A1

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2844 CCTCAGCCTCCTGAGTAGCTGGGA 2867
|||||
pb 1 CCTCAGCCTCCTCAGTAGCTGGGA 24
|||||

RESULT 354
US-10-956-157-204490/c.
; Sequence 204490, Application US/10956157
; Publication No. US20050118625A1


```
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 204490
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Probe Sequence
US-10-956-157-204490

Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2767 GTCACCCAGGCTGGAGTGCAGTGG 2790
      ||||| ||||| ||||| ||||| |||||
Db 25 GTCACCCAGACTGGAGTGCATGG 2
      ||||| ||||| ||||| ||||| |||||

RESULT 355
US-10-956-157-208929
; Sequence 208929, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 208929
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Probe Sequence
US-10-956-157-208929

Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2765 CTGTACCCAGGCTGGAGTGCAGT 2788
      ||||| ||||| ||||| ||||| |||||
Db 2 CTGTGCCAGGCTGGAGTGCAGT 25
      ||||| ||||| ||||| ||||| |||||

RESULT 356
US-10-956-157-243873/c
; Sequence 243873, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 243873
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Probe Sequence
US-10-956-157-243873

Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2795 ATCATGGTTCACGTCAGTCTTGAC 2818
      ||||| ||||| ||||| ||||| |||||
```

```
Db 24 ATCATGGTTCACGTCAGCCTTAAC 1

RESULT 357
US-10-956-157-247763/c
; Sequence 247763, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 247763
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Probe Sequence
US-10-956-157-247763

Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2847 CAGCCTCCTGAGTAGCTGGGACCA 2870
      ||||| ||||| ||||| ||||| |||||
Db 25 CAGTCTCCTGAGTAGCTGGGACTA 2
      ||||| ||||| ||||| ||||| |||||

RESULT 358
US-10-956-157-252710
; Sequence 252710, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 252710
;   LENGTH: 25
;   TYPE: DNA
;   ORGANISM: Probe Sequence
US-10-956-157-252710

Query Match          0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2767 GTCACCCAGGCTGGAGTGCAGTGG 2790
      ||||| ||||| ||||| ||||| |||||
Db 1 GTCGCCAGGCTGGAGGCGAGTGG 24
      ||||| ||||| ||||| ||||| |||||

RESULT 359
US-10-956-157-260201/c
; Sequence 260201, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
```

; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 260201
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-260201

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2831 AGTGATCTCCACCTCAGCTCC 2854
|||
Db 25 AGCAATCTCCACCTCAGCTCC 2

RESULT 360

US-10-956-157-260460/c
; Sequence 260460, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 260460
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-260460

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2819 CTCTGGGCTCAAGTCAAGTCTCC 2842
|||
Db 24 CTCTGGGCTCAAGTCAAGTCTCC 1

RESULT 361

US-10-956-157-266968/c
; Sequence 266968, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266968
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-266968

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2831 AGTGATCTCCACCTCAGCTCC 2854
|||
Db 24 AATGATCTCCACCTCAGCTCC 1

RESULT 362

US-10-956-157-277502
; Sequence 277502, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 277502
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-277502

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2778 TGGAGTGCAGTGTGCAATCATGG 2801
|||
Db 1 TGGAGTGCAGTGTGCAATCATGG 24

RESULT 363

US-10-956-157-287943/c
; Sequence 287943, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 287943
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-287943

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2852 TCCTGAGTAGCTGGGACTACAGGC 2875
|||
Db 25 TCCTGAGTAGCTGGGACTACAGGC 2

RESULT 364

US-10-956-157-287944/c
; Sequence 287944, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 287944
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-287944

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2852 TCTGAGTAGCTGGGACCATAGGC 2875
|||||
Db 25 TCTGAGTAGCTGGGACTACAGGC 2

RESULT 365
US-10-956-157-287945/c
; Sequence 287945, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 287945
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-287945

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2852 TCTGAGTAGCTGGGACCATAGGC 2875
|||||
Db 25 TCTGAGTAGCTGGGACTACAGGC 2

RESULT 366
US-10-956-157-289295/c
; Sequence 289295, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 289295
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-289295

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2758 TCTCGTCTGTCAACCCAGGCTGGA 2781
|||||
Db 24 TCTGTCTCTATCAACCCAGGCTGGA 1

RESULT 367
US-10-956-157-289298/c
; Sequence 289298, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 289298
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-289298

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2758 TCTCGTCTGTCAACCCAGGCTGGA 2781
|||||
Db 24 TCTGTCTCTGTCAACCAAGCTGGA 1

RESULT 368
US-10-956-157-293989/c
; Sequence 293989, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 293989
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-293989

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCTGAGTAGCTGGGA 2867
|||||
Db 24 CCTAGCCTCTGAGTAGCTGAGA 1

RESULT 369
US-10-956-157-315149/c
; Sequence 315149, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2

Query Match 0.7%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 3.1e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCTGAGTAGCTGGGA 2867
|||||
Db 24 CCTAGCCTCTGAGTAGCTGAGA 1


```
; PRIOR FILING DATE: 1999-03-26
; PRIOR APPLICATION NUMBER: US 60/140,359
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/536,841
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 590
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 117
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Template sequence
US-10-730-771-117
```

```
Query Match 0.7%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 3.9e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 214 GACCAGCCCAAGTGTGGGC 234
Db 1 GACCAGCCCAAGTGTGGGC 21
|||||:|||||
```

```
RESULT 374
US-10-730-771-118
; Sequence 118, Application US/10730771
; Publication No. US20050074787A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Hirschhorn, Joel N.
; APPLICANT: Huang, Xiaohua
; APPLICANT: Kaplan, Paul
; APPLICANT: Lander, Eric S.
; APPLICANT: Lockhart, David J.
; APPLICANT: Ryder, Thomas
; APPLICANT: Sklar, Pamela
; TITLE OF INVENTION: UNIVERSAL ARRAYS
; FILE REFERENCE: 2825.1016-007
; CURRENT APPLICATION NUMBER: US/10/730,771
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: US 60/126,473
; PRIOR FILING DATE: 1999-03-26
; PRIOR APPLICATION NUMBER: US 60/140,359
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/536,841
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 590
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 118
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Template sequence
US-10-730-771-118
```

```
Query Match 0.7%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 3.9e+02;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1452 GGTACCCCGGAGGTGACCGT 1472
Db 1 GGTACCCCGGAGGTGACCGT 21
|||||:|||||
```

```
RESULT 375
US-10-184-372-11/c
; Sequence 11, Application US/10184372
; Publication No. US20030219852A1
; GENERAL INFORMATION:
; APPLICANT: Bank, Rudolf A.
; APPLICANT: Van der Slot, Annemarie J.
```

```
; APPLICANT: Zuurmond, Anne-Marie
; APPLICANT: Te Koppele, Johannes M.
; TITLE OF INVENTION: Modification of collagenous materials and medical treatment, diag
; FILE REFERENCE: P60187US00
; CURRENT APPLICATION NUMBER: US/10/184,372
; CURRENT FILING DATE: 2003-06-19
; PRIOR APPLICATION NUMBER: US 09/450,209
; PRIOR FILING DATE: 1999-11-29
; NUMBER OF SEQ ID NOS: 59
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-184-372-11
```

```
Query Match 0.7%; Score 20.4; DB 1; Length 22;
Best Local Similarity 95.5%; Pred. No. 3.9e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2727 CGTGTGTGTGTGTGTATGTG 2748
Db 22 CGTGTGTGTGTGTGTATGTG 1
|||||:|||||
```

```
RESULT 376
US-09-735-363A-21
; Sequence 21, Application US/09735363A
; Patent No. US20010041681A1
; GENERAL INFORMATION:
; APPLICANT: Fillon, Mario
; APPLICANT: Phillip, Nigel
; TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
; FILE REFERENCE: 02811-0181
; CURRENT APPLICATION NUMBER: US/09/735,363A
; CURRENT FILING DATE: 2000-12-12
; PRIOR APPLICATION NUMBER: 60/170,325
; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: 60/228,925
; PRIOR FILING DATE: 2000-08-29
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 21
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-21
```

```
Query Match 0.7%; Score 20.4; DB 1; Length 24;
Best Local Similarity 95.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2728 GTGTGTGTGTGTGTATGTGT 2749
Db 2 GTGTGTGTGTGTGTGTGTGTGT 23
|||||:|||||
```

```
RESULT 377
US-09-776-479-1068
; Sequence 1068, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
```

; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1068
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-1068

Query Match 0.7%; Score 20.4; DB 1; Length 24;
Best Local Similarity 95.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
|||||
Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 378

US-09-776-479-1068
; Sequence 1068, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fourn, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1068
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-1068

Query Match 0.7%; Score 20.4; DB 1; Length 24;
Best Local Similarity 95.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
|||||
Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 379

US-09-909-317-6/c
; Sequence 6, Application US/09909317
; Publication No. US20040152075A1
; GENERAL INFORMATION:
; APPLICANT: Betty P. Tsao (Inventor)
; APPLICANT: Rita M. Cantor (Inventor)
; APPLICANT: Jerome I. Rotter (Inventor)
; TITLE OF INVENTION: Genetic Marker Test for Lupus
; FILE REFERENCE: 18810-82152
; CURRENT APPLICATION NUMBER: US/09/909,317
; CURRENT FILING DATE: 2001-07-18
; PRIOR APPLICATION NUMBER: 09/280,181
; PRIOR FILING DATE: 1999-03-29
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 6
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-909-317-6

Query Match 0.7%; Score 20.4; DB 1; Length 24;
Best Local Similarity 95.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
|||||
Db 23 GTGTGTGTGTGTGTGTGTGTGT 2

RESULT 380

US-10-112-653-1012
; Sequence 1012, Application US/10112653
; Publication No. US20030050268A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Daniel J.
; APPLICANT: Berg, Arthur M.
; TITLE OF INVENTION: IMMUNOSTIMULATORY NUCLEIC ACID FOR
; TITLE OF INVENTION: TREATMENT OF NON-ALLERGIC INFLAMMATORY DISEASES
; FILE REFERENCE: C01039/70060(AWS)
; CURRENT APPLICATION NUMBER: US/10/112,653
; CURRENT FILING DATE: 2002-03-29
; PRIOR APPLICATION NUMBER: US 60/279,642
; PRIOR FILING DATE: 2001-03-29
; NUMBER OF SEQ ID NOS: 1040
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1012
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-112-653-1012

Query Match 0.7%; Score 20.4; DB 1; Length 24;
Best Local Similarity 95.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749
|||||
Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 381

US-10-017-995-1068
; Sequence 1068, Application US/10017995
; Publication No. US20030055014A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; TITLE OF INVENTION: Inhibition of Angiogenesis by Nucleic Acids
; FILE REFERENCE: C1037/7025 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/017,995
; CURRENT FILING DATE: 2001-12-18
; PRIOR APPLICATION NUMBER: US 60/255,534
; PRIOR FILING DATE: 2000-12-14
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1068
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-017-995-1068

Query Match 0.7%; Score 20.4; DB 1; Length 24;
Best Local Similarity 95.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTATGTGT 2749
DB 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 382
US-10-314-578-1068
; Sequence 1068, Application US/10314578
; Publication No. US20030212026A1
; GENERAL INFORMATION:
; APPLICANT: Krieg, Arthur M.
; APPLICANT: Schetter, Christian
; APPLICANT: Vollmer, Jorg
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids
; FILE REFERENCE: C1039/7035 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/314,578
; CURRENT FILING DATE: 2002-12-09
; PRIOR APPLICATION NUMBER: US 60/156,113
; PRIOR FILING DATE: 1999-09-25
; PRIOR APPLICATION NUMBER: US 60/156,135
; PRIOR FILING DATE: 1999-09-27
; PRIOR APPLICATION NUMBER: US 60/227,436
; PRIOR FILING DATE: 2000-08-23
; NUMBER OF SEQ ID NOS: 1145
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1068
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-314-578-1068

Query Match 0.7%; Score 20.4; DB 1; Length 24;
Best Local Similarity 95.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTATGTGT 2749
DB 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 383
US-10-831-778-1068
; Sequence 1068, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 1068
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-1068

Query Match 0.7%; Score 20.4; DB 1; Length 24;
Best Local Similarity 95.5%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTATGTGT 2749

DB 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 384
US-10-956-157-10484
; Sequence 10484, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10484
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-10484
Query Match 0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATGTGTA 2750
DB 4 TGTGTGTGTGTGTGTGTGTGTA 25

RESULT 385
US-10-956-157-26678
; Sequence 26678, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26678
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-26678

Query Match 0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATGTGTA 2750
DB 1 TATGTGTGTGTGTGTATGTGTA 22

RESULT 386
US-10-956-157-99874/c
; Sequence 99874, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 99874
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-99874

Query Match 0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
|||||

Db 25 GTGTGTGTGTGTGTGTGTGTGTGTGTGTAT 4

RESULT 387

US-10-956-157-99877/c
; Sequence 99877, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 99877
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-99877

Query Match 0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
|||||

Db 24 GTGTGTGTGTGTGTGTGTGTGTGTGTGTAT 3

RESULT 388

US-10-956-157-99880/c
; Sequence 99880, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 99880
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-99880

Query Match 0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 GCCTGTGTGTGTGTGTGTGTGTGTGTGTGT 2747
|||||

Db 23 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2

RESULT 389
US-10-956-157-136632/c
; Sequence 136632, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 136632
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-136632

Query Match 0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2823 TGGGCTCAAGTGATCTCTCCAC 2844
|||||

Db 23 TGGGCTGAAGTGATCTCTCCAC 2

RESULT 390

US-10-956-157-174794/c
; Sequence 174794, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 174794
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-174794

Query Match 0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCAACCCAGGCTG 2779
|||||

Db 22 TCTTGCTCTGTCAACCCAGGCTG 1

RESULT 391

US-10-956-157-174796/c
; Sequence 174796, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 214644
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-214644

Query Match 0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2847 CAGCTCTCTGAGTAGCTGGAC 2868
||| ||||| ||||| ||||| |||||
Db 25 CAGTCTCTGAGTAGCTGGAC 4

RESULT 397

US-10-956-157-216380/c
; Sequence 216380, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216380
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-216380

Query Match 0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2764 TCTGTCAACCAGCTGGAGTGC 2785
||| ||||| ||||| ||||| |||||
Db 22 TCTGTCTCCAGCTGGAGTGC 1

RESULT 398

US-10-956-157-216387/c
; Sequence 216387, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216387
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-216387

Query Match 0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2764 TCTGTCAACCAGCTGGAGTGC 2785
||| ||||| ||||| ||||| |||||
Db 22 TCCGTCAACCAGCTGGAGTGC 1

RESULT 399

US-10-956-157-283686/c
; Sequence 283686, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 283686
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-283686

Query Match 0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2776 GCTGGAGTGCAGTGGTGCATC 2797
||| ||||| ||||| ||||| |||||
Db 25 GCTGGAGTGCATGTCGATC 4

RESULT 400

US-10-956-157-287539
; Sequence 287539, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 287539
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-287539

Query Match 0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2844 CCTCAGCTCTCTGAGTAGCTGG 2865
||| ||||| ||||| ||||| |||||
Db 3 CCTCAGCTCTCAGAGTAGCTGG 24

RESULT 401

US-10-956-157-287740
; Sequence 287740, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2

```
; SEQ ID NO 287740
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-287740

Query Match          0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2771 CCAGGCTGGAGTGCAGTGGTG 2792
    |||||||
Db 3 CCAGGCTGGAGTGCAGTGGCG 24

RESULT 402
US-10-956-157-292068
; Sequence 292068, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 292068
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-292068

Query Match          0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2768 TCACCCAGGCTGGAGTGCAGTG 2789
    |||||||
Db 1 TCGCCAGGCTGGAGTGCAGTG 22

RESULT 403
US-10-956-157-297564
; Sequence 297564, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 297564
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-297564

Query Match          0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2846 TCAGCCTCCTGAGTAGCTGGGA 2867
    |||||||
Db 1 TCAGCCTCCTGAGTAGCTGGGA 22
```

```
RESULT 404
US-10-956-157-299664/c
; Sequence 299664, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 299664
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-299664

Query Match          0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2846 TCAGCCTCCTGAGTAGCTGGGA 2867
    |||||||
Db 25 TCAGCCTCCTGAGTAGCTGGGA 4

RESULT 405
US-10-956-157-299666/c
; Sequence 299666, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 299666
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-299666

Query Match          0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2846 TCAGCCTCCTGAGTAGCTGGGA 2867
    |||||||
Db 25 TCAGCCTCCCGAGTAGCTGGGA 4

RESULT 406
US-10-956-157-299668/c
; Sequence 299668, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 299668
```

; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-299668

Query Match 0.7%; Score 20.4; DB 1; Length 25;
Best Local Similarity 95.5%; Pred. No. 3.4e+02;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2846 TCAGCCTCTGACTAGCTGGGA 2867
Db 25 TCAGCCTCTGACGAGCTGGGA 4

RESULT 407

US-10-719-900-717061
; Sequence 717061, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 717061
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-717061

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2192 GTGCTTTTATGTAGGCTAAATGAA 2216
Db 1 GTGCTTTTATGGCGCTAGCTGAA 25

RESULT 408

US-10-809-189-73177/c
; Sequence 73177, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 73177
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
US-10-809-189-73177

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTATGTAGTAC 2753

Db 25 TGTGTGTGTGTGTAGTGCAGAC 1

RESULT 409

US-10-956-157-10472
; Sequence 10472, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10472
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-10472

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTATGTGTAGA 2752
Db 1 GTGTGTGTGTGTGTGTATATA 25

RESULT 410

US-10-956-157-26478
; Sequence 26478, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26478
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-26478

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTATGTGTAGA 2752
Db 1 GTGTGTGTGTGTGTGTATATA 25

RESULT 411

US-10-956-157-26689
; Sequence 26689, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157

; SEQ ID NO 137117
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-137117

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2781 AGTGCAGTGGTCAATCATGTTCA 2805
|||||
DB 1 AGTGCAGTGGTCAATGCTTGGCTCA 25

RESULT 427

US-10-956-157-137482/c
; Sequence 137482, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 137482
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-137482

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2783 TGCAGTGGTCAATCATGTTCTACT 2807
|||||
DB 25 TGCAGTGGCGCAATCTTGGCTACT 1

RESULT 428

US-10-956-157-137483/c
; Sequence 137483, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 137483
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-137483

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2783 TGCAGTGGTCAATCATGTTCTACT 2807
|||||
DB 25 TGCAGTGGCGCTATCATGGCTACT 1

RESULT 429

US-10-956-157-146704
; Sequence 146704, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 146704
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-146704

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2843 ACCTCAGCCTCTGAGTAGCTGGGA 2867
|||||
DB 1 ACCTCAGCCTTCGAGTAGCTGGAA 25

RESULT 430

US-10-956-157-149517/c
; Sequence 149517, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 149517
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-149517

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2764 TCTGTACCCAGGCTGGAGTGCACT 2788
|||||
DB 25 TCTGTGCCAGGCTGGAATGCAGT 1

RESULT 431

US-10-956-157-149711/c
; Sequence 149711, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 149711

; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-174133

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2768 TCACCCAGGCTGAGTGAGTGGTG 2792
|||||
DB 25 TCACCCAGGCTAGATCCCGTGGTG 1

RESULT 437

US-10-956-157-175078/c
; Sequence 175078, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 175078
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-175078

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2840 CCACCTCAGCCTCCTGAGTAGCTG 2864
|||||
DB 25 CCGCCTCAGCCTCCTGAGCAGCTG 1

RESULT 438

US-10-956-157-177069/c
; Sequence 177069, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 177069
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-177069

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2784 GCAGTGGTGCAATCATGGTCTACTG 2808
|||||
DB 25 GCAGTGGTGATCATGGCTCACTG 1

RESULT 439

US-10-956-157-177126/c

; Sequence 177126, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 177126
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-177126

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2784 GCAGTGGTGCAATCATGGTCTACTG 2808
|||||
DB 25 GCAGTGGTGCAATCTCGGCTCACTG 1

RESULT 440

US-10-956-157-177127/c
; Sequence 177127, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 177127
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-177127

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2784 GCAGTGGTGCAATCATGGTCTACTG 2808
|||||
DB 25 GCAGTGGTGCAATCTCGGCTCACTG 1

RESULT 441

US-10-956-157-177128/c
; Sequence 177128, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 177128
; LENGTH: 25
; TYPE: DNA

```

; ORGANISM: Probe Sequence
US-10-956-157-177128

Query Match          0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2784 GCAGTGGTGCATCATCGTTCACGTG 2808
      |||||
Db 25 GCAGTGGTGCATCTGTGGCTCACTG 1

RESULT 442
US-10-956-157-177525
; Sequence 177525, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 177525
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-177525

Query Match          0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGCGCATC 2797
      |||||
Db 1 CAGGTTGGAGTGCAGTGGCGCGATC 25

RESULT 443
US-10-956-157-180784/c
; Sequence 180784, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 180784
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-180784

Query Match          0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2765 CTGTACCCAGGCTGAGTGCAGTG 2789
      |||||
Db 25 CTGTACCCAGGCTAGTACATG 1

RESULT 444
US-10-956-157-184259/c
; Sequence 184259, Application US/10956157
```

```

; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 184259
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-184259

Query Match          0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2763 CTCTGTACCCAGGCTGGAGTGACG 2787
      |||||
Db 25 CTCTGTGCCCAGGCTGGAGTGTAG 1

RESULT 445
US-10-956-157-186418
; Sequence 186418, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 186418
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-186418

Query Match          0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2838 CTCCACCTCAGCCCTCCTGAGTAGC 2862
      |||||
Db 1 CTCCACATTAGCCTCATGAGTAGC 25

RESULT 446
US-10-956-157-199807/c
; Sequence 199807, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 199807
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
```

US-10-956-157-199807

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2766 TGTACCCAGGCTGGAGTGCAGTGG 2790
|||||
Db 25 TGTACCCAGGCTAGAGTACAATGG 1

RESULT 447
US-10-956-157-199808/c
; Sequence 199808, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 199808
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-199808

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2766 TGTACCCAGGCTGGAGTGCAGTGG 2790
|||||
Db 25 TGTACCCAGGCTAGAGTACAATGG 1

RESULT 448
US-10-956-157-201830/c
; Sequence 201830, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 201830
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-201830

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2756 GCTCTCGCTCTGTCAACCCAGGCTGG 2780
|||||
Db 25 GGTATTGCTCTGTCAACCCAGGCTGG 1

RESULT 449
US-10-956-157-206905/c
; Sequence 206905, Application US/10956157
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 206905
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-206905

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2803 TCACTGCAGCTCTTGACCTTTTGGGC 2827
|||||
Db 25 TCACTGCAGCCTTGATCTTCTGGGC 1

RESULT 450

US-10-956-157-228954/c
; Sequence 228954, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 228954
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-228954

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2827 CTCAGTGTATCTCCACCTCAGCC 2851
|||||
Db 25 CTCAGTGTATCTCTGCTCAGTC 1

RESULT 451

US-10-956-157-231367/c
; Sequence 231367, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 231367
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-231367

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2805 ACTGCAGTCTTGACCTTTGGGCTC 2829
|||||
Db 25 ACTGCAGCCTTGATCTTCTGGGCTC 1

RESULT 452

US-10-956-157-235192
; Sequence 235192, Application US/10956157
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 235192

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-235192

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2780 GAGTGCAGTGGTGCAATCATGTTTC 2804
|||||
Db 1 GAGTGCAGTGGTGCACTTTGGCTC 25

RESULT 453

US-10-956-157-236289/c
; Sequence 236289, Application US/10956157
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 236289

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-236289

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2816 GACCTTTTGGGCTCAAGTGATCCTC 2840
|||||
Db 25 GATCTCTGGGCTCAAGTGATCCTC 1

RESULT 454

US-10-956-157-237035/c

; Sequence 237035, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 237035
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-237035

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2823 TGGGCTCAAGTGATCCTCCACCTC 2847
|||||
Db 25 TGGGCTCAAGTGATCTCTCGCTC 1

RESULT 455

US-10-956-157-237036/c

; Sequence 237036, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 237036

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-237036

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2823 TGGGCTCAAGTGATCCTCCACCTC 2847
|||||
Db 25 TGGGCTCAAGTGATCTCTCGCTC 1

RESULT 456

US-10-956-157-252918/c

; Sequence 252918, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 252918

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-252918

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCCTCAGTAGCTGGAC 2868
|||||
Db 25 CCTCAGCTTCCCAAGTAGCTGGAC 1
|||||

RESULT 457

US-10-956-157-255341/c
; Sequence 255341, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 255341
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-255341

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2782 GTGCAGTGTGCAATCATGTTGCTCAC 2806
|||||
Db 25 GTGCAGTGTGCAATCATGTTGCTCAC 1
|||||

RESULT 458

US-10-956-157-266272/c
; Sequence 266272, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266272
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-266272

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2814 TTGACCTTTGGGCTCAAGTGATCC 2838
|||||
Db 25 TTGATCTCTCGGGCTCAAGTGATCC 1
|||||

RESULT 459

US-10-956-157-266967/c
; Sequence 266967, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCCTCAGTAGCTGGAC 2868
|||||
Db 25 CCTCAGCTTCCCAAGTAGCTGGAC 1
|||||

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2782 GTGCAGTGTGCAATCATGTTGCTCAC 2806
|||||
Db 25 GTGCAGTGTGCAATCATGTTGCTCAC 1
|||||

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2814 TTGACCTTTGGGCTCAAGTGATCC 2838
|||||
Db 25 TTGATCTCTCGGGCTCAAGTGATCC 1
|||||

APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 266967
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-266967

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2830 AAGTGATCTCCACCTCAGCTCC 2854
|||||
Db 25 AAGCAATCTCCACCTCGGCTCC 1
|||||

RESULT 460

US-10-956-157-267711
; Sequence 267711, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 267711
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-267711

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2779 GGAGTGCAGTGTGCAATCATGTT 2803
|||||
Db 1 GGAGTGCAGTGTGCAATCATGTTGCT 25
|||||

RESULT 461

US-10-956-157-268065/c
; Sequence 268065, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 268065
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-268065

Query Match 0.7%; Score 20.2; DB 1; Length 25;

```

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 274587
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-274587

Query Match      0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2830 AAGTGATCTCCACCTCAGCTCC 2854
      |||||
Db 25 AAGTGATCTCTCGCTCAGTCTCC 1

RESULT 462
US-10-956-157-268263/c
; Sequence 268263, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 268263
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-268263

Query Match      0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2817 ACCTTTGGGCTCAAGTGATCTCC 2841
      |||||
Db 25 ACCTCTGGGCTCAAGTGATCTCC 1

RESULT 463
US-10-956-157-268264/c
; Sequence 268264, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 268264
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-268264

Query Match      0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2817 ACCTTTGGGCTCAAGTGATCTCC 2841
      |||||
Db 25 ACCTCTGGGCTCAAGTGATCTCC 1

RESULT 464
US-10-956-157-274587/c
; Sequence 274587, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
```

```

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 274587
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-274587

Query Match      0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2827 CTCAAGTGATCTCCACCTCAGCC 2851
      |||||
Db 25 CTCAAGCAATCTCCACCTCGGCC 1

RESULT 465
US-10-956-157-274588/c
; Sequence 274588, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 274588
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-274588

Query Match      0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2827 CTCAAGTGATCTCCACCTCAGCC 2851
      |||||
Db 25 CTCAAGCAATCTCCACCTCGGCC 1

RESULT 466
US-10-956-157-278091/c
; Sequence 278091, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 278091
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-278091

Query Match      0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
```

```
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2846 TCAGCTCTCTGAGTAGCTGGGACCA 2870
|||||
Db 25 TCAGCTCTCCCAAGAGCTGGGACCA 1
|||||

RESULT 467
US-10-956-157-283255/c
; Sequence 283255, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 283255
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-283255
Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2824 GGCTCAAGTAGTCTCCCACTCA 2848
|||||
Db 25 GGCTCCAGGATCCTCCCACTCA 1
|||||

RESULT 468
US-10-956-157-285780/c
; Sequence 285780, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 285780
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-285780
Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2762 GCTCTCTACCCAGGCTGGAGTCA 2786
|||||
Db 25 GCTCTGTGCCCAAGCTGGAGTCA 1
|||||

RESULT 469
US-10-956-157-295898
; Sequence 295898, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

```
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 295898
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-295898
Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2760 TCGCTCTGTCACCAGGCTGGAGTG 2784
|||||
Db 1 TCATTCTATCACCCAGGCTGGAGTG 25
|||||

RESULT 470
US-10-956-157-297532
; Sequence 297532, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 297532
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-297532
Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 2846 TCAGCTCTCTGAGTAGCTGGGACCA 2870
|||||
Db 1 TCAGCTCTCCGAGTAGCTAGGACTA 25
|||||

RESULT 471
US-10-956-157-319011/c
; Sequence 319011, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 319011
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-319011
Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```


QY 2807 TGCAGCTTTGACCTTTTGGGCTCAA 2831
||||| ||||| ||||| ||||| |||||
Db 25 TGCAGCCTTGATCTTCTGGGCTCAA 1

RESULT 472
US-10-681-773-35331/c
; Sequence 35331, Application US/10681773
; Publication No. US20040146890A1
; GENERAL INFORMATION:
; APPLICANT: Matsuzaki, Hajime
; APPLICANT: Mei, Rui
; APPLICANT: Shen, Mei-Mei
; APPLICANT: Kennedy, Giulia
; TITLE OF INVENTION: Methods for Genotyping Polymorphisms in Humans
; FILE REFERENCE: 3522.2
; CURRENT APPLICATION NUMBER: US/10/681,773
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: 60/470,475
; PRIOR FILING DATE: 2002-05-14
; PRIOR APPLICATION NUMBER: 60/417,190
; PRIOR FILING DATE: 2002-10-08
; NUMBER OF SEQ ID NOS: 124031
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 35331
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-681-773-35331

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTGGTGCAT 2796
||||| ||||| ||||| ||||| |||||
Db 25 CCAGGCTATAGTCAGAGGTGCAT 1

RESULT 473
US-10-681-773-69661/c
; Sequence 69661, Application US/10681773
; Publication No. US20040146890A1
; GENERAL INFORMATION:
; APPLICANT: Matsuzaki, Hajime
; APPLICANT: Mei, Rui
; APPLICANT: Shen, Mei-Mei
; APPLICANT: Kennedy, Giulia
; TITLE OF INVENTION: Methods for Genotyping Polymorphisms in Humans
; FILE REFERENCE: 3522.2
; CURRENT APPLICATION NUMBER: US/10/681,773
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: 60/470,475
; PRIOR FILING DATE: 2002-05-14
; PRIOR APPLICATION NUMBER: 60/417,190
; PRIOR FILING DATE: 2002-10-08
; NUMBER OF SEQ ID NOS: 124031
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 69661
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-681-773-69661

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGTGCATC 2797
||||| ||||| ||||| ||||| |||||
Db 25 CAGGCTATAGTCAGAGGTGCATC 1

RESULT 474
US-10-681-773-70701/c
; Sequence 70701, Application US/10681773
; Publication No. US20040146890A1
; GENERAL INFORMATION:
; APPLICANT: Matsuzaki, Hajime
; APPLICANT: Mei, Rui
; APPLICANT: Shen, Mei-Mei
; APPLICANT: Kennedy, Giulia
; TITLE OF INVENTION: Methods for Genotyping Polymorphisms in Humans
; FILE REFERENCE: 3522.2
; CURRENT APPLICATION NUMBER: US/10/681,773
; CURRENT FILING DATE: 2003-10-07
; PRIOR APPLICATION NUMBER: 60/470,475
; PRIOR FILING DATE: 2002-05-14
; PRIOR APPLICATION NUMBER: 60/417,190
; PRIOR FILING DATE: 2002-10-08
; NUMBER OF SEQ ID NOS: 124031
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 70701
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-681-773-70701

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGCAGTGCAGTGGC 2793
||||| ||||| ||||| ||||| |||||
Db 25 CACCCAGGCTATAGTCAGAGGTGC 1

RESULT 475
US-10-719-956-575924
; Sequence 575924, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 575924
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-575924

Query Match 0.7%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 3.6e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 722 TCAGCCCCCGGGTCCCTAGAGGTGGA 746
||| ||||| ||||| ||||| |||||
Db 1 TCACCTCCCGGGTCCCGAGAGGTGGA 25

RESULT 476
US-09-726-096A-8/c
; Sequence 8, Application US/09726096A
; Publication No. US20010016652A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Maier, Martin A.
; TITLE OF INVENTION: Compounds Processes And Intermediates For Synthesis Of Mixed Bac
; TITLE OF INVENTION: Oligomeric Compounds

FILE REFERENCE: ISIS4528
CURRENT APPLICATION NUMBER: US/09/726,096A
EARLIER FILING DATE: 2000-11-29
NUMBER OF SEQ ID NOS: 12
SOFTWARE: PatentIn version 3.0
SEQ ID NO 8
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
NAME/KEY: misc feature
OTHER INFORMATION: Oligonucleotide
NAME/KEY: misc feature
LOCATION: (1)..(20)
OTHER INFORMATION: 2'-methoxyethoxy (MOE)
US-09-726-096A-8

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 477

US-09-876-242-2/c
Sequence 2, Application US/09876242
Publication No. US20030055241A1
GENERAL INFORMATION:
APPLICANT: Moore, Max N.
APPLICANT: Arthur, John Charles
APPLICANT: VanSooy, Kent
APPLICANT: Scozzari, Anthony N.
TITLE OF INVENTION: Processes Of Purifying Oligonucleotides
FILE REFERENCE: ISIS4728
CURRENT APPLICATION NUMBER: US/09/876,242
EARLIER FILING DATE: 2001-06-07
NUMBER OF SEQ ID NOS: 8
SOFTWARE: PatentIn version 3.1
SEQ ID NO 2
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide
US-09-876-242-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 478

US-09-370-541-18/c
Sequence 18, Application US/09370541
Publication No. US20030088079A1
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Cook, Phillip Dan
APPLICANT: Prakash, Thazha P
APPLICANT: Kawasaki, Andrew M
TITLE OF INVENTION: Aminoxy-Modified Nucleosidic Compounds And Oligomeric
TITLE OF INVENTION: Compounds Prepared Therefrom
FILE REFERENCE: ISIS3993
CURRENT APPLICATION NUMBER: US/09/370,541
EARLIER FILING DATE: 1999-08-09
CURRENT APPLICATION NUMBER: 09/130,973

EARLIER FILING DATE: 1998-08-07
EARLIER APPLICATION NUMBER: 09/016,520
EARLIER FILING DATE: 1998-01-30
EARLIER APPLICATION NUMBER: 60/037,143
EARLIER FILING DATE: 1997-02-14
EARLIER APPLICATION NUMBER: 09/344,260
EARLIER FILING DATE: 1999-06-25
NUMBER OF SEQ ID NOS: 21
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 18
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: antisense
OTHER INFORMATION: sequence
US-09-370-541-18

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 479

US-10-318-628-2/c
Sequence 2, Application US/10318628
Publication No. US20030191304A1
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Ravikumar, Vasulinga T.
APPLICANT: Sanghvi, Yogesh
TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
FILE REFERENCE: ISIS4855
CURRENT APPLICATION NUMBER: US/10/318,628
CURRENT FILING DATE: 2002-12-12
PRIOR APPLICATION NUMBER: 09/177,953
PRIOR FILING DATE: 1998-10-23
PRIOR APPLICATION NUMBER: 60/087,757
PRIOR FILING DATE: 1998-06-02
NUMBER OF SEQ ID NOS: 47
SOFTWARE: PatentIn version 3.2
SEQ ID NO 2
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic construct
US-10-318-628-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 480

US-10-318-628-8/c
Sequence 8, Application US/10318628
Publication No. US20030191304A1
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Ravikumar, Vasulinga T.
APPLICANT: Sanghvi, Yogesh
TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
FILE REFERENCE: ISIS4855
CURRENT APPLICATION NUMBER: US/10/318,628

```
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; NAME/KEY: misc_feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 5 methyl C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 5 methyl C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 5 methyl C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2' methoxyethyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(16)
; OTHER INFORMATION: 5 methyl U
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 5 methyl U
; US-10-318-628-8
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
```

```
RESULT 481
US-10-318-628-11/c
; Sequence 11, Application US/10318628
; Publication No. US20030191304A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulunga T.
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; US-10-318-628-11
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
```

```
RESULT 482
US-10-318-628-17/c
; Sequence 17, Application US/10318628
; Publication No. US20030191304A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; NAME/KEY: misc_feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 5 methyl C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 5 methyl C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 5 methyl C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2' O MOE
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(16)
; OTHER INFORMATION: 5 methyl U
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 5 methyl U
; US-10-318-628-17
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
```

```
RESULT 483
US-10-318-628-22/c
; Sequence 22, Application US/10318628
; Publication No. US20030191304A1
```

GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Ravikumar, Vasulinga T.
APPLICANT: Sanghvi, Yogesh
TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
FILE REFERENCE: ISIS4855
CURRENT APPLICATION NUMBER: US/10/318,628
CURRENT FILING DATE: 2002-12-12
PRIOR APPLICATION NUMBER: 09/177,953
PRIOR FILING DATE: 1998-10-23
PRIOR APPLICATION NUMBER: 60/087,757
PRIOR FILING DATE: 1998-06-02
NUMBER OF SEQ ID NOS: 47
SOFTWARE: PatentIn version 3.2
SEQ ID NO 22
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic construct
NAME/KEY: misc feature
LOCATION: (1)..(20)
OTHER INFORMATION: 2' O MOE, phosphorothioate linkage
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: 2' O MOE linkage
US-10-318-628-22

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 484

US-10-318-628-23/c
Sequence 23, Application US/10318628
Publication No. US20030191304A1
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Ravikumar, Vasulinga T.
APPLICANT: Sanghvi, Yogesh
TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
FILE REFERENCE: ISIS4855
CURRENT APPLICATION NUMBER: US/10/318,628
CURRENT FILING DATE: 2002-12-12
PRIOR APPLICATION NUMBER: 09/177,953
PRIOR FILING DATE: 1998-10-23
PRIOR APPLICATION NUMBER: 60/087,757
PRIOR FILING DATE: 1998-06-02
NUMBER OF SEQ ID NOS: 47
SOFTWARE: PatentIn version 3.2
SEQ ID NO 23
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic construct
NAME/KEY: misc feature
LOCATION: (1)..(20)
OTHER INFORMATION: 2' O MOE linkage
US-10-318-628-23

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
DB 20 GAGCTCCTCTGCTACTCAGA 1
RESULT 485
US-10-318-628-25/c
Sequence 25, Application US/10318628
Publication No. US20030191304A1
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Ravikumar, Vasulinga T.
APPLICANT: Sanghvi, Yogesh
TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
FILE REFERENCE: ISIS4855
CURRENT APPLICATION NUMBER: US/10/318,628
CURRENT FILING DATE: 2002-12-12
PRIOR APPLICATION NUMBER: 09/177,953
PRIOR FILING DATE: 1998-10-23
PRIOR APPLICATION NUMBER: 60/087,757
PRIOR FILING DATE: 1998-06-02
NUMBER OF SEQ ID NOS: 47
SOFTWARE: PatentIn version 3.2
SEQ ID NO 25
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic construct
US-10-318-628-25

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TCACGGATGCCAGCTTGGGC 2119
|||||
DB 20 TCACGGATGCCAGCTTGGGC 1

RESULT 486

US-10-318-628-31/c
Sequence 31, Application US/10318628
Publication No. US20030191304A1
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Ravikumar, Vasulinga T.
APPLICANT: Sanghvi, Yogesh
TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
FILE REFERENCE: ISIS4855
CURRENT APPLICATION NUMBER: US/10/318,628
CURRENT FILING DATE: 2002-12-12
PRIOR APPLICATION NUMBER: 09/177,953
PRIOR FILING DATE: 1998-10-23
PRIOR APPLICATION NUMBER: 60/087,757
PRIOR FILING DATE: 1998-06-02
NUMBER OF SEQ ID NOS: 47
SOFTWARE: PatentIn version 3.2
SEQ ID NO 31
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic construct
NAME/KEY: misc feature
LOCATION: (2)..(4)
OTHER INFORMATION: 5 methyl C
FEATURE:
NAME/KEY: misc feature
LOCATION: (8)..(8)
OTHER INFORMATION: 5 methyl C
FEATURE:

```

; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 5 methyl C
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 5 methyl C
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (14)..(16)
; OTHER INFORMATION: 2' O MOE
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2' O MOE
;
US-10-318-628-31

```

```
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels
```

Qy 2100 TGACGGATGCCAGCTTGGGC 2119

Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 487

```

US-10-318-628-33/c
; Sequence 33, Application US/10318628
; Publication No. US20030191304A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For O
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/31
; CURRENT FILING DATE: 2002-12-12
; PRIORITY FILING DATE: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic constr
US-10-318-628-33

```

```
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels
```

Qy 2100 TGACGGATGCCAGCTTGGGC 2119
|||
pb 20 TGACGGATGCCAGCTTGGGC 1

RESULT 488

```

US-10-318-628-38/C
; Sequence 38, Application US/10318628
; Publication No. US20030191304A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318, 628
; CURRENT FILING DATE: 2002-12-12

```

```

, PRIOR APPLICATION NUMBER: 09/177,953
, PRIOR FILING DATE: 1998-10-23
, PRIOR APPLICATION NUMBER: 60/087,757
, PRIOR FILING DATE: 1998-06-02
, NUMBER OF SEQ ID NOS: 47
, SOFTWARE: PatentIn version 3.2
, SEQ ID NO 38
, LENGTH: 20
, TYPE: DNA
, ORGANISM: Artificial Sequence
, FEATURE:
, OTHER INFORMATION: Synthetic construct
US-10-318-628-38

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels

Qy 2100 TGACGGATGCCAGCTTGGGC 2119
pB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 489

```

US-10-318-628-40/c
; Sequence 40, Application US/10318628
; Publication No. US20030191304A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Olig
; FILE REFERENCE: IS184855
; CURRENT APPLICATION NUMBER: US/10/318,6
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757
; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-318-628-40

```

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels

Qy	2100	TGACGGATGCCAGCTTGGGC	2119
ph	20	TGACGGATGCCAGCTTGGGC	1

RESULT, T 490

```

US-10-318-628-46/c
; Sequence 46, Application US/10318628
; Publication No. US20030191304A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Sanghvi, Yogesh
; TITLE OF INVENTION: Activators For Oligonucleotide Synthesis
; FILE REFERENCE: ISIS4855
; CURRENT APPLICATION NUMBER: US/10/318,628
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: 09/177,953
; PRIOR FILING DATE: 1998-10-23
; PRIOR APPLICATION NUMBER: 60/087,757

```

```

; PRIOR FILING DATE: 1998-06-02
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; NAME/KEY: misc feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 5 Methyl C
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 5 Methyl C
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 5 Methyl C
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2' O MOE
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (14)..(16)
; OTHER INFORMATION: 5 Methyl U
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 5 Methyl U
; US-10-318-628-46

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 491
US-10-290-587-2/c
; Sequence 2, Application US/10290587
; Publication No. US20030149260A1
; GENERAL INFORMATION:
; APPLICANT: Cheruvallath, Zacharia S.
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Cole, Douglas L.
; TITLE OF INVENTION: Process For The Synthesis Of Oligomeric Compounds
; FILE REFERENCE: ISIS-5108
; CURRENT APPLICATION NUMBER: US/10/290,587
; CURRENT FILING DATE: 2002-11-08
; PRIOR APPLICATION NUMBER: 10/016,465
; PRIOR FILING DATE: 2001-12-11
; PRIOR APPLICATION NUMBER: 09/349,659
; PRIOR FILING DATE: 1999-07-08
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; US-10-290-587-2

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
```

```

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 492
US-09-747-772-3/c
; Sequence 3, Application US/09747772
; Patent No. US20020155988A1
; GENERAL INFORMATION:
; APPLICANT: O'Hare, Peter Francis Joseph
; APPLICANT: No. US20020155988Almand, Nadia Michelle
; APPLICANT: Brewis, Neil Douglas
; APPLICANT: Phelan, Anne
; TITLE OF INVENTION: Uses of Transport Proteins
; FILE REFERENCE: 5759-56969
; CURRENT APPLICATION NUMBER: US/09/747,772
; CURRENT FILING DATE: 2000-12-20
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: synthetic construct
; US-09-747-772-3

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
Db 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 493
US-09-747-772-4/c
; Sequence 4, Application US/09747772
; Patent No. US20020155988A1
; GENERAL INFORMATION:
; APPLICANT: O'Hare, Peter Francis Joseph
; APPLICANT: No. US20020155988Almand, Nadia Michelle
; APPLICANT: Brewis, Neil Douglas
; APPLICANT: Phelan, Anne
; TITLE OF INVENTION: Uses of Transport Proteins
; FILE REFERENCE: 5759-56969
; CURRENT APPLICATION NUMBER: US/09/747,772
; CURRENT FILING DATE: 2000-12-20
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: synthetic construct
; US-09-747-772-4

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
Db 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 494
US-10-029-598-1/c
; Sequence 1, Application US/10029598
; Publication No. US20030040497A1
; GENERAL INFORMATION:
; APPLICANT: Teng, Ching-Leou
; APPLICANT: Cook, Phillip Dan
```

APPLICANT: Tillman, Lloyd
APPLICANT: Hardee, Gregory E.
APPLICANT: Ecker, David J.
APPLICANT: Manoharan, Muthiah
TITLE OF INVENTION: Compositions And Methods For No. US20030040497A1-Parental Deliver
FILE REFERENCE: ISIS4945
CURRENT APPLICATION NUMBER: US/10/029,598
CURRENT FILING DATE: 2001-12-21
PRIOR APPLICATION NUMBER: 08/082,624
PRIOR FILING DATE: 1998-05-21
PRIOR APPLICATION NUMBER: 09/315,298
PRIOR FILING DATE: 1999-05-20
NUMBER OF SEQ ID NOS: 58
SOFTWARE: PatentIn version 3.1
SEQ ID NO 1
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Sequence
NAME/KEY: misc_feature
LOCATION: (1)..(20)
OTHER INFORMATION: Phosphorothioate linkage
US-10-029-598-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 495
US-10-029-598-2/c
Sequence 2, Application US/10029598
Publication No. US20030040497A1
GENERAL INFORMATION:
APPLICANT: Teng, Ching-Leou
APPLICANT: Cook, Phillip Dan
APPLICANT: Tillman, Lloyd
APPLICANT: Hardee, Gregory E.
APPLICANT: Ecker, David J.
APPLICANT: Manoharan, Muthiah
TITLE OF INVENTION: Compositions And Methods For No. US20030040497A1-Parental Deliver
FILE REFERENCE: ISIS4945
CURRENT APPLICATION NUMBER: US/10/029,598
CURRENT FILING DATE: 2001-12-21
PRIOR APPLICATION NUMBER: 08/082,624
PRIOR FILING DATE: 1998-05-21
PRIOR APPLICATION NUMBER: 09/315,298
PRIOR FILING DATE: 1999-05-20
NUMBER OF SEQ ID NOS: 58
SOFTWARE: PatentIn version 3.1
SEQ ID NO 2
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Sequence
NAME/KEY: misc_feature
LOCATION: (1)..(20)
OTHER INFORMATION: Phosphorothioate linkage
US-10-029-598-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
DB 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 496
US-10-029-598-55/c
Sequence 55, Application US/10029598
Publication No. US20030040497A1
GENERAL INFORMATION:
APPLICANT: Teng, Ching-Leou
APPLICANT: Cook, Phillip Dan
APPLICANT: Tillman, Lloyd
APPLICANT: Hardee, Gregory E.
APPLICANT: Ecker, David J.
APPLICANT: Manoharan, Muthiah
TITLE OF INVENTION: Compositions And Methods For No. US20030040497A1-Parental Deliver
FILE REFERENCE: ISIS4945
CURRENT APPLICATION NUMBER: US/10/029,598
CURRENT FILING DATE: 2001-12-21
PRIOR APPLICATION NUMBER: 08/082,624
PRIOR FILING DATE: 1998-05-21
PRIOR APPLICATION NUMBER: 09/315,298
PRIOR FILING DATE: 1999-05-20
NUMBER OF SEQ ID NOS: 58
SOFTWARE: PatentIn version 3.1
SEQ ID NO 55
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Sequence
NAME/KEY: misc_feature
LOCATION: (2)..(4)
OTHER INFORMATION: 5'-methyl
NAME/KEY: misc_feature
LOCATION: (8)..(8)
OTHER INFORMATION: 5'-methyl
NAME/KEY: misc_feature
LOCATION: (12)..(12)
OTHER INFORMATION: 5'-methyl
NAME/KEY: misc_feature
LOCATION: (15)..(16)
OTHER INFORMATION: 5'-methyl
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 5'-methyl
NAME/KEY: misc_feature
LOCATION: (13)..(20)
OTHER INFORMATION: 2'-O-methoxyethyl
NAME/KEY: misc_feature
LOCATION: (1)..(20)
OTHER INFORMATION: Phosphorothioate linkage
US-10-029-598-55

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 497
US-09-835-370-41/c
Sequence 41, Application US/09835370
Publication No. US20030022172A1
GENERAL INFORMATION:
APPLICANT: BREIPOHL, EUGEN
APPLICANT: UHLMANN, GERHARD
APPLICANT: WILL, DAVID W
TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
TITLE OF INVENTION: PROCESSES FOR PREPARING THEM
FILE REFERENCE: 02481.1742 SEQUENCE LISTING
CURRENT APPLICATION NUMBER: US/09/835,370

```
/ CURRENT FILING DATE: 2001-04-17
/ NUMBER OF SEQ ID NOS: 64
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 41
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: nucleotide
/ OTHER INFORMATION: base sequence of PNA derivatives that bind to
/ OTHER INFORMATION: viral and cellular targets
US-09-835-370-41

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
Db      20 TGACGGATGCCAGCTTGGGC 1
|||||

RESULT 498
US-09-835-370-42/c
/ Sequence 42, Application US/09835370
/ Publication No. US20030022172A1
/ GENERAL INFORMATION:
/ APPLICANT: BREIPOHL, EUGEN
/ APPLICANT: WILL, DAVID W
/ TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
/ TITLE OF INVENTION: PROCESSES FOR PREPARING THEM
/ FILE REFERENCE: 02481.1742 SEQUENCE LISTING
/ CURRENT APPLICATION NUMBER: US/09/835,370
/ CURRENT FILING DATE: 2001-04-17
/ NUMBER OF SEQ ID NOS: 64
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 42
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: nucleotide
/ OTHER INFORMATION: base sequence of PNA derivatives that bind to
/ OTHER INFORMATION: viral and cellular targets
US-09-835-370-42

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1938 GAGAGGGGAAGTGGTGGGG 1957
Db      20 GAGAGGGGAAGTGGTGGGG 1
|||||

RESULT 499
US-09-835-370-43/c
/ Sequence 43, Application US/09835370
/ Publication No. US20030022172A1
/ GENERAL INFORMATION:
/ APPLICANT: BREIPOHL, EUGEN
/ APPLICANT: WILL, DAVID W
/ TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
/ TITLE OF INVENTION: PROCESSES FOR PREPARING THEM
/ FILE REFERENCE: 02481.1742 SEQUENCE LISTING
/ CURRENT APPLICATION NUMBER: US/09/835,370
/ CURRENT FILING DATE: 2001-04-17
/ NUMBER OF SEQ ID NOS: 64
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 43
/ LENGTH: 20

/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: nucleotide
/ OTHER INFORMATION: base sequence of PNA derivatives that bind to
/ OTHER INFORMATION: viral and cellular targets
US-09-835-370-43

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
Db      20 TGACGGATGCCAGCTTGGGC 1
|||||

RESULT 501
US-10-083-720A-13
/ Sequence 13, Application US/10083720A
/ Publication No. US20030073199A1
/ GENERAL INFORMATION:
/ APPLICANT: de Waal Malefyt, Rene
/ APPLICANT: Fickenscher, Helmut
/ APPLICANT: Fleckenstein, Bernhard
/ APPLICANT: Knappe, Andrea
/ TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS
/ FILE REFERENCE: DX0644KBK
/ CURRENT APPLICATION NUMBER: US/10/083,720A
/ CURRENT FILING DATE: 2002-02-28
/ PRIOR APPLICATION NUMBER: 09/363,993
/ PRIOR FILING DATE: 1999-07-29
/ PRIOR APPLICATION NUMBER: 08/934,959
/ PRIOR FILING DATE: 1997-09-22
/ PRIOR APPLICATION NUMBER: 60/345,690
/ PRIOR FILING DATE: 2002-01-03
/ PRIOR APPLICATION NUMBER: 60/302,176
/ PRIOR FILING DATE: 2001-06-28
/ PRIOR APPLICATION NUMBER: 60/027,368
/ PRIOR FILING DATE: 1996-09-23

/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: nucleotide
/ OTHER INFORMATION: base sequence of PNA derivatives that bind to
/ OTHER INFORMATION: viral and cellular targets
US-09-835-370-43

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1940 GAGGGGAAGTGGTGGGGAG 1959
Db      20 GAGGGGAAGTGGTGGGGAG 1
|||||

RESULT 500
US-10-103-906-1/c
/ Sequence 1, Application US/10103906
/ Publication No. US20020156268A1
/ GENERAL INFORMATION:
/ APPLICANT: Krotz, Achim H.
/ APPLICANT: McElroy, Bethany M.
/ TITLE OF INVENTION: Methods for Removing Dimethoxytrityl Groups From
/ TITLE OF INVENTION: Oligonucleotides
/ FILE REFERENCE: ISIS-3349
/ CURRENT APPLICATION NUMBER: US/10/103,906
/ CURRENT FILING DATE: 2002-03-22
/ PRIOR APPLICATION NUMBER: US/09/271,220
/ PRIOR FILING DATE: 1999-03-17
/ NUMBER OF SEQ ID NOS: 4
/ SOFTWARE: PatentIn Ver. 2.0
/ SEQ ID NO 1
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: antisense sequence
US-10-103-906-1

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
Db      20 TGACGGATGCCAGCTTGGGC 1
|||||
```



```

; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ICAM-1 forward.
;
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: ICAM-1 forward.
US-08-3720A-13

```

```
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels
```

Qy 950 GCCAGGAGACACTGCAGACA 969
|||||
D'b 1 GCCAGGAGACACTGCAGACA 20

```

RESULT 502
US-10-234-764-5/c
; Sequence 5, Application US/10234764
; Publication No. US20030113769A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Lomberg, Harri
; APPLICANT: Salo, Harri
; APPLICANT: Virta, Pasi
; TITLE OF INVENTION: Aminooxy Functionalized Oligomers
; FILE REFERENCE: ISIS089
; CURRENT APPLICATION NUMBER: US/10/234,764
; CURRENT FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: 09/016,520
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 09/344,260
; PRIOR FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-234-764-5

```

```
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels
```

Qy 18 GAGCTCCTCTGCTACTCAGA 37
|||
Dy 20 GAGCTCCTCTGCTACTCAGA 1

```

RESULT 503
US-10-192-437-11/c
; Sequence 11, Application US/10192437
; Publication No. US20030153737A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. US20030153737A1r18
; STREET: One Liberty Place - 46th Floor
;

```

```

CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/192,437
FILING DATE: 10-Jul-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/397,277A
FILING DATE: 09-MAR-1995
APPLICATION NUMBER: 07/943,516
FILING DATE: 11-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Gaumont, Rebecca R.
REGISTRATION NUMBER: 35,152
REFERENCE/DOCKET NUMBER: ISIS-1198
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: misc_feature
LOCATION: 20
OTHER INFORMATION: /note= "2'-aminopropoxy
cytosine"
SEQUENCE DESCRIPTION: SEQ ID NO: 11:
US-10-192-437-11

```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20: Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 18 GAGCTCCTCTGCTACTCAGA 37
|||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 504
US-10-073-718-17/c
Sequence 17, Application US/10073718
Publication No. US20020177150A1
GENERAL INFORMATION:
APPLICANT: Manoharan, Muthiah
APPLICANT: Cook, Phillip Dan
APPLICANT: Bennett, Clarence Frank
TITLE OF INVENTION: Derivatized Oligonucle
FILE REFERENCE: ISIS-5024
CURRENT APPLICATION NUMBER: US/10/073,718
CURRENT FILING DATE: 2002-05-08
PRIORITY APPLICATION NUMBER: 09/633659
PRIORITY FILING DATE: 2000-08-07
PRIORITY APPLICATION NUMBER: 6153737
PRIORITY FILING DATE: 2000-11-28
PRIORITY APPLICATION NUMBER: 08/211882
PRIORITY FILING DATE: 1994-04-22
PRIORITY APPLICATION NUMBER: PCT/US92/09196
PRIORITY FILING DATE: 1992-10-23
PRIORITY APPLICATION NUMBER: 07/782374
PRIORITY FILING DATE: 1991-10-24
PRIORITY APPLICATION NUMBER: 07/566977
PRIORITY FILING DATE: 1990-08-13

```
; PRIOR APPLICATION NUMBER: PCT/US91/000243
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 08/463358
; PRIOR FILING DATE: 1990-01-11
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. US20020177150A1el Sequence
US-10-073-718-17

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
      |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 505
US-09-808-680-1/c
; Sequence 1, Application US/09808680
; Patent No. US20020052331A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda F
; APPLICANT: Bennett, C. Frank
; APPLICANT: Anderson, Kevin P
; APPLICANT: Condon, Thomas P
; TITLE OF INVENTION: Compositions and Methods for Antisense Inhibition of
; FILE REFERENCE: ISPH-0557
; CURRENT APPLICATION NUMBER: US/09/808,680
; PRIOR FILING DATE: 1997-04-29
; PRIOR APPLICATION NUMBER: 08/653,653
; PRIOR FILING DATE: 1996-05-24
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; PRIOR APPLICATION NUMBER: 07/939,855
; PRIOR FILING DATE: 1992-09-02
; PRIOR APPLICATION NUMBER: 07/567,286
; PRIOR FILING DATE: 1990-08-14
; PRIOR APPLICATION NUMBER: 07/927,506
; PRIOR FILING DATE: 1992-11-19
; PRIOR APPLICATION NUMBER: 07/568,366
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-808-680-9

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 33 TCAGAGTTGCAACCTCAGCC 52
      |||||
Db 20 TCAGAGTTGCAACCTCAGCC 1

RESULT 507
US-09-808-680-10/c
; Sequence 10, Application US/09808680
; Patent No. US20020052331A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda F
; APPLICANT: Bennett, C. Frank
; APPLICANT: Anderson, Kevin P
; APPLICANT: Condon, Thomas P
; TITLE OF INVENTION: Compositions and Methods for Antisense Inhibition of
; FILE REFERENCE: ISPH-0557
; CURRENT APPLICATION NUMBER: US/09/808,680
; PRIOR FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/194,230
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: PCT/US97/07132
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-808-680-10
```

```
; PRIOR FILING DATE: 1997-04-29
; PRIOR APPLICATION NUMBER: 08/553,653
; PRIOR FILING DATE: 1998-05-24
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; PRIOR APPLICATION NUMBER: 07/939,855
; PRIOR FILING DATE: 1992-09-02
; PRIOR APPLICATION NUMBER: 07/567,286
; PRIOR FILING DATE: 1990-08-14
; PRIOR APPLICATION NUMBER: 07/927,506
; PRIOR FILING DATE: 1992-11-19
; PRIOR APPLICATION NUMBER: 07/568,366
; PRIOR FILING DATE: 1990-08-16
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-808-680-10
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 23 CCTCTGCTACTCAGATTGC 42
Db 20 CCTCTGCTACTCAGATTGC 1
|||||
```

RESULT 508

```
US-09-794-824-1/c
; Sequence 1, Application US/09794824
; Patent No. US20020082227A1
; GENERAL INFORMATION:
; APPLICANT: Scott Henry
; TITLE OF INVENTION: Use of Oligonucleotides for Inhibition of Complement Activation
; FILE REFERENCE: ISPH-0504
; CURRENT APPLICATION NUMBER: US/09/794,824
; CURRENT FILING DATE: 2001-02-24
; PRIOR APPLICATION NUMBER: 09/409,816
; PRIOR FILING DATE: 1999-09-30
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
US-09-794-824-1
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGC 2119
Db 20 TGACGGATGCCAGCTTGGC 1
|||||
```

RESULT 509

```
US-09-794-824-5/c
; Sequence 5, Application US/09794824
; Patent No. US20020082227A1
; GENERAL INFORMATION:
; APPLICANT: Scott Henry
```

```
; TITLE OF INVENTION: Use of Oligonucleotides for Inhibition of Complement Activation
; FILE REFERENCE: ISPH-0504
; CURRENT APPLICATION NUMBER: US/09/794,824
; CURRENT FILING DATE: 2001-02-24
; PRIOR APPLICATION NUMBER: 09/409,816
; PRIOR FILING DATE: 1999-09-30
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
US-09-794-824-5
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGC 2119
Db 20 TGACGGATGCCAGCTTGGC 1
|||||
```

RESULT 510

```
US-09-794-824-7/c
; Sequence 7, Application US/09794824
; Patent No. US20020082227A1
; GENERAL INFORMATION:
; APPLICANT: Scott Henry
; TITLE OF INVENTION: Use of Oligonucleotides for Inhibition of Complement Activation
; FILE REFERENCE: ISPH-0504
; CURRENT APPLICATION NUMBER: US/09/794,824
; CURRENT FILING DATE: 2001-02-24
; PRIOR APPLICATION NUMBER: 09/409,816
; PRIOR FILING DATE: 1999-09-30
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
US-09-794-824-7
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGC 2119
Db 20 TGACGGATGCCAGCTTGGC 1
|||||
```

RESULT 511

```
US-09-949-093-3/c
; Sequence 3, Application US/09949093
; Patent No. US20020142960A1
; GENERAL INFORMATION:
; APPLICANT: PHOGEN LIMITED
; APPLICANT: O'Hare, Peter Francis Joseph
; APPLICANT: Brewis, Neil Douglas
; APPLICANT: No. US20020142960A1mand, Nadia Michelle
; APPLICANT: Sunassee, Kavitha Regna
; TITLE OF INVENTION: DELIVERY OF SUBSTANCES TO CELLS
; FILE REFERENCE: 5759-61121
; CURRENT APPLICATION NUMBER: US/09/949,093
; CURRENT FILING DATE: 2002-06-24
; PRIOR APPLICATION NUMBER: GB 0022101.0
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 5
```

SOFTWARE: PatentIn version 3.1
SEQ ID NO 3
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide primer
US-09-949-093-3

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 512

US-09-949-093-4/c
Sequence 4, Application US/09949093
Patent No. US20020142960A1
GENERAL INFORMATION:

APPLICANT: PHOGEN LIMITED
APPLICANT: O'Hare, Peter Francis Joseph
APPLICANT: Brewis, Neil Douglas
APPLICANT: No. US20020142960A1mand, Nadia Michelle
APPLICANT: Sunassee, Kavitha Regna
TITLE OF INVENTION: DELIVERY OF SUBSTANCES TO CELLS
FILE REFERENCE: 5759-61121
CURRENT APPLICATION NUMBER: US/09/949,093
CURRENT FILING DATE: 2002-06-24
PRIOR APPLICATION NUMBER: GB 0022101.0
PRIOR FILING DATE: 2000-09-08

NUMBER OF SEQ ID NOS: 5

SOFTWARE: PatentIn version 3.1

SEQ ID NO 4

LENGTH: 20

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Oligonucleotide primer

US-09-949-093-4

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 513

US-09-860-784-21/c
Sequence 21, Application US/09860784
Patent No. US20020151512A1
GENERAL INFORMATION:

APPLICANT: PEYMAN, Anuschirwan

UHLMANN, Eugen

TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES

NUMBER OF SEQUENCES: 105

CORRESPONDENCE ADDRESS:

ADDRESSEE: Foley & Lardner

STREET: 3000 K Street, N.W., Suite 500

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20007-5109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA: US/09/860,784
APPLICATION NUMBER: US/09/860,784
FILING DATE: 21-May-2001
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/594,452

FILING DATE: 04-APR-1996

ATTORNEY/AGENT INFORMATION:

NAME: SANDERCOCK, Colin G.

REGISTRATION NUMBER: 31,298

REFERENCE/DOCKET NUMBER: 18748/264/HOCE

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202) 672-5300

TELEFAX: (202) 672-5399

TELEX: 904136

INFORMATION FOR SEQ ID NO: 21:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 21:

US-09-860-784-21

Query Match

0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 4.7e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957

|||||

Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 514

US-09-860-784-22/c

Sequence 22, Application US/09860784

Patent No. US20020151512A1

GENERAL INFORMATION:

APPLICANT: PEYMAN, Anuschirwan

UHLMANN, Eugen

TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES

NUMBER OF SEQUENCES: 105

CORRESPONDENCE ADDRESS:

ADDRESSEE: Foley & Lardner

STREET: 3000 K Street, N.W., Suite 500

CITY: Washington

STATE: D.C.

COUNTRY: USA

ZIP: 20007-5109

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA: US/09/860,784

APPLICATION NUMBER: US/09/860,784

FILING DATE: 21-May-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/594,452

FILING DATE: 04-APR-1996

ATTORNEY/AGENT INFORMATION:

NAME: SANDERCOCK, Colin G.

REGISTRATION NUMBER: 31,298

REFERENCE/DOCKET NUMBER: 18748/264/HOCE

TELECOMMUNICATION INFORMATION:

TELEPHONE: (202) 672-5300

TELEFAX: (202) 672-5399

TELEX: 904136

INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs

```
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-09-860-784-22

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGTGGGGGAG 1959
      |||||
Db 20 GAGGGGAAGTGTGGGGGAG 1

RESULT 515
US-09-949-474-4/c
; Sequence 4, Application US/09949474
; Patent No. US20020156235A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Process for Preparing Peptide Derivatized Oligomeric Compounds
; FILE REFERENCE: ISIS4850
; CURRENT APPLICATION NUMBER: US/09/949,474
; CURRENT FILING DATE: 2001-09-07
; PRIOR APPLICATION NUMBER: 09/658,517
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. US20020156235A1e1 Sequence
US-09-949-474-4

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
      |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 516
US-09-965-551-1/c
; Sequence 1, Application US/09965551
; Patent No. US20020165181A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/965,551
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/349,007
; PRIOR FILING DATE: 1999-07-07
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Alternating phosphodiester/phosphorothioate
; OTHER INFORMATION: linkages
; NAME/KEY: modified base
; LOCATION: (2)..(20)
```

```
; OTHER INFORMATION: 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. US20020165181A1e1 Sequence:
US-09-965-551-1

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
      |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 517
US-09-965-551-3/c
; Sequence 3, Application US/09965551
; Patent No. US20020165181A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/965,551
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/349,007
; PRIOR FILING DATE: 1999-07-07
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Alternating phosphodiester/phosphorothioate
; OTHER INFORMATION: linkages
; NAME/KEY: modified base
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. US20020165181A1e1 Sequence:
US-09-965-551-3

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 518
US-09-965-551-4/c
; Sequence 4, Application US/09965551
; Patent No. US20020165181A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/965,551
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/349,007
; PRIOR FILING DATE: 1999-07-07
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: No. US20020165181A1e1 Sequence:
```

US-09-965-551-4

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 519

US-09-965-551-5/c
; Sequence 5, Application US/09965551
; Patent No. US20020165181A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/965,551
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/349,007
; PRIOR FILING DATE: 1999-07-07
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: All phosphorothioate linkages
; OTHER INFORMATION: Description of Artificial Sequence: No. US20020165181A1
US-09-965-551-5

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 520

US-09-965-551-6/c
; Sequence 6, Application US/09965551
; Patent No. US20020165181A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/965,551
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/349,007
; PRIOR FILING DATE: 1999-07-07
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: All phosphorothioate linkages
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. US20020165181A1
US-09-965-551-6

US-09-965-551-6

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 521

US-09-965-551-7/c
; Sequence 7, Application US/09965551
; Patent No. US20020165181A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/965,551
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/349,007
; PRIOR FILING DATE: 1999-07-07
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; OTHER INFORMATION: Description of Artificial Sequence: No. US20020165181A1
US-09-965-551-7

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 522

US-09-965-551-8/c
; Sequence 8, Application US/09965551
; Patent No. US20020165181A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; TITLE OF INVENTION: Alternating Internucleoside Linkages
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/965,551
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/349,007
; PRIOR FILING DATE: 1999-07-07
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Alternating phosphodiester/phosphorothioate
; NAME/KEY: modified base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Staggered 2'-Methoxyethoxy
US-09-965-551-8

```
; OTHER INFORMATION: Description of Artificial Sequence: No. US20020165181A1e1 Sequenc
US-09-965-551-8

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 523
US-09-965-551-9/c
; Sequence 9, Application US/09965551
; Patent No. US20020165181A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/965,551
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/349,007
; PRIOR FILING DATE: 1999-07-07
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; NAME/KEY: modified_base
; LOCATION: (2)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (18)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (20)
; OTHER INFORMATION: c=5-methyl
; OTHER INFORMATION: Description of Artificial Sequence: No. US20020165181A1e1 Sequenc
US-09-965-551-9

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 524
US-09-965-551-11/c
; Sequence 11, Application US/09965551
; Patent No. US20020165181A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/965,551
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/349,007
; PRIOR FILING DATE: 1999-07-07
; NUMBER OF SEQ ID NOS: 13
```

```
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-Methoxyethoxy
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: All phosphorothioate linkages
; NAME/KEY: modified_base
; LOCATION: (2)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (18)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (20)
; OTHER INFORMATION: c=5-methyl
; OTHER INFORMATION: Description of Artificial Sequence: No. US20020165181A1e1 Sequenc
US-09-965-551-11

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 525
US-09-965-551-13/c
; Sequence 13, Application US/09965551
; Patent No. US20020165181A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Carbohydrate or 2'-Modified Oligonucleotides Having
; FILE REFERENCE: ISIS3863
; CURRENT APPLICATION NUMBER: US/09/965,551
; CURRENT FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 09/349,007
; PRIOR FILING DATE: 1999-07-07
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-methoxyethoxy
; NAME/KEY: modified_base
; LOCATION: (1)..(20)
; OTHER INFORMATION: Alternating phosphodiester/phosphorothioate
; NAME/KEY: modified_base
; LOCATION: (2)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: c=5-methyl
; NAME/KEY: modified_base
; LOCATION: (18)
; OTHER INFORMATION: c=5-methyl
; OTHER INFORMATION: Description of Artificial Sequence: No. US20020165181A1e1 Sequenc
```

US-09-965-551-13

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCTCTGCTACTCAGA 1

RESULT 526

US-09-835-371-41/c
; Sequence 41, Application US/09835371
; Publication No. US20020187473A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, Eugen
; APPLICANT: BREIPOHL, Gerhard
; APPLICANT: WILL, David W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES, AND AGENTS AND
; FILE REFERENCE: 02481.1743 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/09/835,371
; CURRENT FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: base sequence
; OTHER INFORMATION: of PNA targeting CMV
US-09-835-371-41

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 527

US-09-835-371-42/c
; Sequence 42, Application US/09835371
; Publication No. US20020187473A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, Eugen
; APPLICANT: BREIPOHL, Gerhard
; APPLICANT: WILL, David W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES, AND AGENTS AND
; FILE REFERENCE: 02481.1743 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/09/835,371
; CURRENT FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: base sequence
; OTHER INFORMATION: of PNA targeting CMV
US-09-835-371-42

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGAAGTGGTGGGG 1957

Db 20 GAGAGGGAAGTGGTGGGG 1
|||||

RESULT 528

US-09-835-371-43/c
; Sequence 43, Application US/09835371
; Publication No. US20020187473A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, Eugen
; APPLICANT: BREIPOHL, Gerhard
; APPLICANT: WILL, David W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES, AND AGENTS AND
; FILE REFERENCE: 02481.1743 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/09/835,371
; CURRENT FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: base sequence
; OTHER INFORMATION: of PNA targeting CMV
US-09-835-371-43

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGG 1959
|||||
Db 20 GAGGGGAAGTGGTGGGG 1

RESULT 529

US-09-824-322B-41/c
; Sequence 41, Application US/09824322B
; Publication No. US20030022848A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-ALPHA EXPRESSION
; FILE REFERENCE: ISPH-0501
; CURRENT APPLICATION NUMBER: US/09/824,322B
; CURRENT FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: US 09/313,932
; PRIOR FILING DATE: 1999-05-18
; PRIOR APPLICATION NUMBER: US 09/166,186
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 503
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: control sequence
US-09-824-322B-41

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 530

US-09-824-322B-49/c
; Sequence 49, Application US/09824322B
; Publication No. US20030022848A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-ALPHA
; FILE REFERENCE: ISPH-0501
; CURRENT APPLICATION NUMBER: US/09/824,322B
; CURRENT FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: US 09/313,932
; PRIOR FILING DATE: 1999-05-18
; PRIOR APPLICATION NUMBER: US 09/166,186
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 503
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: control sequence
US-09-824-322B-49

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCTCTGCTACTCAGA 37
DB 20 GAGCTCTCTGCTACTCAGA 1

RESULT 531

US-09-932-300-36/c
; Sequence 36, Application US/09932300
; Publication No. US20030032788A1
; GENERAL INFORMATION:
; APPLICANT: Garver, Eric
; APPLICANT: TU, Guang-Chou
; APPLICANT: ISRAEL, Yedy
; TITLE OF INVENTION: METHODS OF INHIBITING ALCOHOL CONSUMPTION
; FILE REFERENCE: 9855-302
; CURRENT APPLICATION NUMBER: US/09/932,300
; CURRENT FILING DATE: 2001-08-20
; PRIOR APPLICATION NUMBER: US 60/051,705
; PRIOR FILING DATE: 1997-07-03
; PRIOR APPLICATION NUMBER: US 09/109,663
; PRIOR FILING DATE: 1998-07-02
; NUMBER OF SEQ ID NOS: 111
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Known
; OTHER INFORMATION: effective ASO
US-09-932-300-36

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGAGTGGTGGGG 1957
DB 20 GAGAGGGAGTGGTGGGG 1

RESULT 532

US-09-982-262B-2/c
; Sequence 2, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
DB 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 533

US-09-982-262B-7/c
; Sequence 7, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-7

Query Match 0.7%; Score 20; DB 1; Length 20;

```
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 41 GCAACCTCAGCCTCGCTATG 60
    |||||
Db 20 GCAACCTCAGCCTCGCTATG 1

RESULT 534
US-09-982-262B-8/c
; Sequence 8, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-8

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 58 ATGGCTCCAGCAGCCCG 77
    |||||
Db 20 ATGGCTCCAGCAGCCCG 1

RESULT 535
US-09-982-262B-9/c
; Sequence 9, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
    |||||
Db 20 TCAAACTGCCCTGATGGCA 1

RESULT 537
US-09-982-262B-11/c
; Sequence 11, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
```

```

; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1993-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-11

```

```

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 875 AGGCCTCAGTCAGTGTGACC 894
      |||||
Db 20 AGGCCTCAGTCAGTGTGACC 1

```

```

RESULT 538
US-09-982-262B-12/c
; Sequence 12, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1993-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-12

```

```

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1445 AAGGGAGGTCACCCCGCAG 1464
      |||||
Db 20 AAGGGAGGTCACCCCGCAG 1

```

```

RESULT 539
US-09-982-262B-13/c
; Sequence 13, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett

```

```

; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1993-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-13

```

```

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1637 CACAGCCACGCTCCCTGA 1656
      |||||
Db 20 CACAGCCACGCTCCCTGA 1

```

```

RESULT 540
US-09-982-262B-14/c
; Sequence 14, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1993-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-14

```

```

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1654 TGAACCTATCCCGGACAGG 1673
      |||||

```

```
Db      20 TGAACCTATCCCGGACAGG 1
;
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-16

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2962 AGTTAATAAAGCTTCTCAA 2981
      |||||||
Db      20 AGTTAATAAAGCTTCTCAA 1

RESULT 543
US-09-982-262B-22/c
; Sequence 22, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-15

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1938 GAGAGGGGAAGTGTGGGG 1957
      |||||||
Db      20 GAGAGGGGAAGTGTGGGG 1

RESULT 542
US-09-982-262B-16/c
; Sequence 16, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-16

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
      |||||||
Db      20 TGACGGATGCCAGCTTGGGC 1

RESULT 544
US-09-982-262B-23/c
; Sequence 23, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
```

```
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-23
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2025 GAGGCCACAGACTTACAGA 2044
    |||||G|||G|||G|||G|||G|||
DB 20 GAGGCCACAGACTTACAGA 1
```

```
RESULT 545
US-09-982-262B-24/c
; Sequence 24, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-24
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1881 CAAGAGGAAGGAGCAAGACT 1900
    |||||G|||G|||G|||G|||
DB 20 CAAGAGGAAGGAGCAAGACT 1
```

```
RESULT 546
US-09-982-262B-25/c
; Sequence 25, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
```

```
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-25
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1921 TTAAAGTCTAGCCTGATGAG 1940
    |||||G|||G|||G|||G|||
DB 20 TTAAAGTCTAGCCTGATGAG 1
```

```
RESULT 547
US-09-982-262B-26/c
; Sequence 26, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-26
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1962 ATAGCCCCACCATGAGGACA 1981
    |||||G|||G|||G|||G|||
DB 20 ATAGCCCCACCATGAGGACA 1
```

```
RESULT 548
US-09-982-262B-84/c
```

; Sequence 84, Application US/09982262B
; Publication No. US2003007565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-84

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 549

US-09-982-262B-85/c
; Sequence 85, Application US/09982262B
; Publication No. US2003007565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-85

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1945 GAAGTGGTGGGGGAGACATA 1964
|||||
DB 20 GAAGTGGTGGGGGAGACATA 1

RESULT 550

US-09-935-316-1/c
; Sequence 1, Application US/09935316
; Publication No. US20030083286A1
; GENERAL INFORMATION:
; APPLICANT: Weinbach, Susan
; APPLICANT: Tillman, Lloyd G.
; APPLICANT: Geary, Richard H.
; APPLICANT: Hardee, Gregory E.
; TITLE OF INVENTION: Pulsatile Release Compositions And Methods For Enhanced Intestin
; FILE REFERENCE: ISIS4823
; CURRENT APPLICATION NUMBER: US/09/935,316
; CURRENT FILING DATE: 2001-08-22
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-935-316-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
DB 20 TGACGGATGCCAGCTTGGGC 1

RESULT 551

US-09-935-316-2/c
; Sequence 2, Application US/09935316
; Publication No. US20030083286A1
; GENERAL INFORMATION:
; APPLICANT: Weinbach, Susan
; APPLICANT: Tillman, Lloyd G.
; APPLICANT: Geary, Richard H.
; APPLICANT: Hardee, Gregory E.
; TITLE OF INVENTION: Pulsatile Release Compositions And Methods For Enhanced Intestin
; FILE REFERENCE: ISIS4823
; CURRENT APPLICATION NUMBER: US/09/935,316
; CURRENT FILING DATE: 2001-08-22
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-935-316-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
DB 20 GAGAGGGGAAGTGGTGGGG 1

```
RESULT 552
US-09-902-953-1/c
; Sequence 1, Application US/09902953
; Publication No. US20030096770A1
; GENERAL INFORMATION:
; APPLICANT: Krotz, Achim
; APPLICANT: Mehta, Rahul
; TITLE OF INVENTION: Enhancement Of The Stability Of Oligonucleotides Comprising
; FILE REFERENCE: ISIS-4797
; CURRENT APPLICATION NUMBER: US/09/902,953
; CURRENT FILING DATE: 2001-07-11
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-902-953-1
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 553
US-09-902-953-2/c
; Sequence 2, Application US/09902953
; Publication No. US20030096770A1
; GENERAL INFORMATION:
; APPLICANT: Krotz, Achim
; APPLICANT: Mehta, Rahul
; TITLE OF INVENTION: Enhancement Of The Stability Of Oligonucleotides Comprising
; FILE REFERENCE: ISIS-4797
; CURRENT APPLICATION NUMBER: US/09/902,953
; CURRENT FILING DATE: 2001-07-11
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-902-953-2
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 554
US-09-970-971A-25/c
; Sequence 25, Application US/09970971A
; Publication No. US20030096979A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Mohan, Venkatraman
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Kawasaki, Andrew M.
```

```
; TITLE OF INVENTION: Oligonucleotides Having DNA Form and B-DNA Form Conformational C
; FILE REFERENCE: ISIS4789
; CURRENT APPLICATION NUMBER: US/09/970,971A
; CURRENT FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. US20030096979A1e1 Sequence
; NAME/KEY: misc_feature
; LOCATION: (1)..(19)
; OTHER INFORMATION: phosphorothioate linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 5-methyl C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 5-methyl C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 5-methyl C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 5-methyl C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 5-methyl C
US-09-970-971A-25
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 555
US-09-944-493-1/c
; Sequence 1, Application US/09944493
; Publication No. US20030124196A1
; GENERAL INFORMATION:
; APPLICANT: Weinbach, Susan
; APPLICANT: Tillman, Lloyd G.
; APPLICANT: Geary, Richard H.
; APPLICANT: Hardee, Gregory E.
; TITLE OF INVENTION: Pulsatile Release Compositions And Methods For Enhanced Intestin
; FILE REFERENCE: ISIS4823
; CURRENT APPLICATION NUMBER: US/09/944,493
; CURRENT FILING DATE: 2001-08-21
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-944-493-1
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
```

```
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 556
US-09-944-493-2/c
; Sequence 2, Application US/09944493
; Publication No. US20030124196A1
; GENERAL INFORMATION:
; APPLICANT: Weinbach, Susan
; APPLICANT: Tillman, Lloyd G.
; APPLICANT: Geary, Richard H.
; APPLICANT: Hardee, Gregory E.
; TITLE OF INVENTION: Pulsatile Release Compositions And Methods For Enhanced Intestinal
; TITLE OF INVENTION: Absorption
; FILE REFERENCE: ISI84823
; CURRENT APPLICATION NUMBER: US/09/944,493
; CURRENT FILING DATE: 2001-08-21
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-944-493-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1938 GAGAGGGGAGTGTGGGGG 1957
Db 20 GAGAGGGGAGTGTGGGGG 1

RESULT 557
US-09-895-480A-2/c
; Sequence 2, Application US/09895480A
; Publication No. US20030129221A1
; GENERAL INFORMATION:
; APPLICANT: Inex Pharmaceuticals Inc.
; TITLE OF INVENTION: High Efficiency Encapsulation of Charged Therapeutic
; Agents in
; Lipid Vesicles
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oppedahl & Larson LLP
; STREET: PO Box 5068
; CITY: Dillon
; STATE: CO
; COUNTRY: US
; ZIP: 80435
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS 5.0
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/895,480A
; FILING DATE: 29-Jun-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: <Unknown>
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: <Unknown>
; REGISTRATION NUMBER: <Unknown>
; REFERENCE/DOCKET NUMBER: <Unknown>
```

```
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: <Unknown>
; TELEFAX: <Unknown>
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-09-895-480A-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 558
US-09-946-172A-1/c
; Sequence 1, Application US/09946172A
; Publication No. US20030129593A1
; GENERAL INFORMATION:
; APPLICANT: University Technologies International Inc.
; TITLE OF INVENTION: Process For Producing Multiple Oligonucleotides on a Solid Suppo
; FILE REFERENCE: 213202.00326
; CURRENT APPLICATION NUMBER: US/09/946,172A
; CURRENT FILING DATE: 2001-09-05
; PRIOR APPLICATION NUMBER:
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
; NAME/KEY: misc_structure
; LOCATION: (1)..(20)
; OTHER INFORMATION: Synthetic
US-09-946-172A-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 559
US-09-882-945A-145/c
; Sequence 145, Application US/09882945A
; Publication No. US20030143535A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/09/882,945A
```



```
; CURRENT FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 145
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-882-945A-145
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1938 GAGAGGGGAAGTGGTGGGGG 1957
      |||||||
Db 20 GAGAGGGGAAGTGGTGGGGG 1
```

```
RESULT 560
US-09-882-945A-147/c
; Sequence 147, Application US/09882945A
; Publication No. US20030143535A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/09/882,945A
; CURRENT FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 147
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-882-945A-147
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 7 CAGTCGACGCTGAGCTCCTC 26
      |||||||
Db 20 CAGTCGACGCTGAGCTCCTC 1
```

```
RESULT 561
US-09-882-945A-148/c
; Sequence 148, Application US/09882945A
; Publication No. US20030143535A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/09/882,945A
; CURRENT FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 148
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-882-945A-148
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 337 TCAAACTGCCCTGATGGGCA 356
      |||||||
Db 20 TCAAACTGCCCTGATGGGCA 1
```

```
RESULT 562
US-09-882-945A-149/c
; Sequence 149, Application US/09882945A
; Publication No. US20030143535A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/09/882,945A
; CURRENT FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 149
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-882-945A-149
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||||
Db 20 TGACGGATGCCAGCTTGGGC 1
```

```
RESULT 563
US-09-851-871-17/c
; Sequence 17, Application US/09851871
; Publication No. US20030176374A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, Clarence Frank
; APPLICANT: Vickers, Timothy A.
; APPLICANT: Karras, James G.
; TITLE OF INVENTION: Oligonucleotide Compositions and Methods for the
; FILE REFERENCE: ISPH-0343
; CURRENT APPLICATION NUMBER: US/09/851,871
; CURRENT FILING DATE: 2001-05-09
; PRIOR APPLICATION NUMBER: PCT/US00/14471
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: 09/326,186
; PRIOR FILING DATE: 1993-06-04
; PRIOR APPLICATION NUMBER: 08/777,266
; PRIOR FILING DATE: 1996-12-31
; NUMBER OF SEQ ID NOS: 284
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
```

; PUBLICATION INFORMATION:
; PATENT DOCUMENT NUMBER: US 5514788
; PATENT FILING DATE: 1993-05-17
; PUBLICATION DATE: 1996-05-07
US-09-851-871-17

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 564

US-09-793-146-20/c
; Sequence 20, Application US/09793146
; Publication No. US20030203359A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; PREPARATION AND USE
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/09/793,146
; CURRENT FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14
; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-09-793-146-20

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGG 1957
Db 20 GAGAGGGGAAGTGTGGGG 1

RESULT 565

US-09-793-146-21/c
; Sequence 21, Application US/09793146
; Publication No. US20030203359A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; PREPARATION AND USE
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/09/793,146
; CURRENT FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14
; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA

; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-09-793-146-21

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGTGGGGGAG 1959
Db 20 GAGGGGAAGTGTGGGGGAG 1

RESULT 566

US-09-823-031-12/c
; Sequence 12, Application US/09823031
; Publication No. US20030208061A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Guzaev, Andrei P.
; TITLE OF INVENTION: Labeled Oligonucleotides, Methods For Making Same And Compounds
; TITLE OF INVENTION: Therefor
; FILE REFERENCE: ISIS4723
; CURRENT APPLICATION NUMBER: US/09/823,031
; CURRENT FILING DATE: 2001-03-30
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: Oligonucleotide
US-09-823-031-12

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 567

US-10-071-822A-2/c
; Sequence 2, Application US/10071822A
; Publication No. US20030027780A1
; GENERAL INFORMATION:
; APPLICANT: Hardee, Gregory E.
; APPLICANT: Tillman, Lloyd G.
; APPLICANT: Gonzales-Ferreiro, Maria
; APPLICANT: Mehta, Rahul C.
; APPLICANT: Teng, Ching-Leeu
; TITLE OF INVENTION: Multiparticulate Formulation
; FILE REFERENCE: ISIS4947
; CURRENT APPLICATION NUMBER: US/10/071,822A
; CURRENT FILING DATE: 2002-02-08
; PRIOR APPLICATION NUMBER: US/09/256,515
; PRIOR FILING DATE: 1999-02-23
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide Sequence
US-10-071-822A-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGATCCAGCTTGGGC 2119
Db 20 TGACGATCCAGCTTGGGC 1

RESULT 568

US-10-117-267-8/c
; Sequence 8, Application US/10117267
; Publication No. US20030045698A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Maier, Ph.D., Martin A.
; TITLE OF INVENTION: Compounds, Processes And Intermediates For Synthesis Of Mixed Back
; FILE REFERENCE: ISIS-5039
; CURRENT APPLICATION NUMBER: US/10/117,267
; CURRENT FILING DATE: 2002-04-05
; PRIOR APPLICATION NUMBER: 09/726,096
; PRIOR FILING DATE: 2000-11-29
; PRIOR APPLICATION NUMBER: 09/250,075
; PRIOR FILING DATE: 1999-02-12
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-methoxyethoxy (MOE)
US-10-117-267-8

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 569

US-10-085-906-302/c
; Sequence 302, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
; APPLICANT: Ying, Vincent
; APPLICANT: Wu, Paul
; APPLICANT: Gray, Gary S.
; TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
; TITLE OF INVENTION: COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
; FILE REFERENCE: GNN-5343CP2
; CURRENT APPLICATION NUMBER: US/10/085,906
; CURRENT FILING DATE: 2002-02-27
; PRIOR APPLICATION NUMBER: US 60/126,215
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 09/534,061
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: PCT/US00/07938
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 545
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 302
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-085-906-302

Query Match 0.7%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2771 CCCAGGCTGGAGTGCAGTGG 2790
Db 20 CCCAGGCTGGAGTGCAGTGG 1

RESULT 570

US-10-154-993-17/c
; Sequence 17, Application US/10154993
; Publication No. US20030064492A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Bennet, Clarence Frank
; TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake
; TITLE OF INVENTION: And
; TITLE OF INVENTION: Other Properties
; FILE REFERENCE: ISIS4470
; CURRENT APPLICATION NUMBER: US/10/154,993
; CURRENT FILING DATE: 2002-05-23
; PRIOR APPLICATION NUMBER: US/09/633,659
; PRIOR FILING DATE: 2000-08-07
; PRIOR APPLICATION NUMBER: 08/211,882
; PRIOR FILING DATE: 1994-04-22
; PRIOR APPLICATION NUMBER: 07/782,374
; PRIOR FILING DATE: 1991-10-24
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Novel Sequence
US-10-154-993-17

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 571

US-10-232-881-2/c
; Sequence 2, Application US/10232881
; Publication No. US20030080888A1
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulinga
; APPLICANT: Manoharan, Muthia
; APPLICANT: Capaldi, Daniel
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: Improved Process for the Synthesis of Oligomeric
; TITLE OF INVENTION: Compounds
; FILE REFERENCE: ISIS3380
; CURRENT APPLICATION NUMBER: US/10/232,881
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US/09/288,679
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial

; FEATURE:
; OTHER INFORMATION: No. US20030088088A1el Sequence
US-10-232-881-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 572

US-10-232-881-4/c
; Sequence 4, Application US/10232881
; Publication No. US20030088088A1
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulunga
; APPLICANT: Manoharan, Muthia
; APPLICANT: Capaldi, Daniel
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: Improved Process for the Synthesis of Oligomeric
; FILE REFERENCE: ISIS3380
; CURRENT APPLICATION NUMBER: US/10/232,881
; CURRENT FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US/09/288,679
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Phosphorothioate backbone
US-10-232-881-4

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 573

US-10-251-699-1/c
; Sequence 1, Application US/10251699
; Publication No. US2003009989A1
; GENERAL INFORMATION:
; APPLICANT: CHERIF, Dorra
; TITLE OF INVENTION: FLUORESCENT PROBES FOR CHROMOSOME PAINTING
; FILE REFERENCE: GENSET.069AUS
; CURRENT APPLICATION NUMBER: US/10/251,699
; CURRENT FILING DATE: 2002-09-19
; PRIOR APPLICATION NUMBER: US/09/418,804
; PRIOR FILING DATE: 1999-10-15
; NUMBER OF SEQ ID NOS: 3
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: primer bind
; LOCATION: 1..20
; OTHER INFORMATION: primer PCR Alu

US-10-251-699-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGCTGGAGTGCAGTGG 2790
|||||
Db 20 CCCAGCTGGAGTGCAGTGG 1

RESULT 574

US-10-086-477A-1/c
; Sequence 1, Application US/10086477A
; Publication No. US2003010404A1
; GENERAL INFORMATION:
; APPLICANT: Sempie, Sean
; APPLICANT: Harasym, Troy
; APPLICANT: Klimuk, Sandra
; APPLICANT: Kojic, Ijljiana
; APPLICANT: Branson, Jonathan
; APPLICANT: Mui, Barbara
; APPLICANT: Hope, Michael
; TITLE OF INVENTION: COMPOSITIONS FOR STIMULATING CYTOKINE SECRETION AND INDUCING
; FILE REFERENCE: INEXP006US
; CURRENT APPLICATION NUMBER: US/10/086,477A
; CURRENT FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: 60/176,406
; PRIOR FILING DATE: 2000-01-13
; PRIOR APPLICATION NUMBER: 60/151,211
; PRIOR FILING DATE: 1999-08-27
; NUMBER OF SEQ ID NOS: 11
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: human
; FEATURE:
; NAME/KEY: 3' untranslated region of human ICAM-1 mRNA
; LOCATION: (1)..(20)
US-10-086-477A-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TCACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TCACGGATGCCAGCTTGGGC 1

RESULT 575

US-10-186-180-23
; Sequence 23, Application US/10186180
; Publication No. US20030108958A1
; GENERAL INFORMATION:
; APPLICANT: De Waal Malefyt, Rene
; APPLICANT: Nagalakshmi, Marehalli
; APPLICANT: Moore, Kevin
; APPLICANT: Fickensher, Helmut
; TITLE OF INVENTION: BIOLOGICAL ACTIVITY OF AK155
; FILE REFERENCE: DX01168
; CURRENT APPLICATION NUMBER: US/10/186,180
; CURRENT FILING DATE: 2002-06-27
; PRIOR APPLICATION NUMBER: U.S. Provisional 60/345,690
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: U.S. Provisional 60/302,176
; PRIOR FILING DATE: 2001-06-28
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 23
; LENGTH: 20

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Forward primer for ICAM-1.
US-10-186-180-23

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 950 GCCAGGAGACTGTCAGACA 969
Db 1 GCCAGGAGACTGTCAGACA 20

RESULT 576
US-10-012-010B-2/c
; Sequence 2, Application US/10012010B
; Publication No. US20030119768A1
; GENERAL INFORMATION:
; APPLICANT: Madden, Thomas D
; APPLICANT: Webb, Murray S
; TITLE OF INVENTION: Therapeutic Oligonucleotides of Reduced Toxicity
; FILE REFERENCE: INEX.P-009
; CURRENT APPLICATION NUMBER: US/10/012,010B
; CURRENT FILING DATE: 2002-11-14
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: antisense for ICAM-1 mRNA
; NAME/KEY: misc feature
; FEATURE:
; OTHER INFORMATION: antisense for ICAM-1
US-10-012-010B-2

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 577
US-10-290-545-11/c
; Sequence 11, Application US/10290545
; Publication No. US20030125292A1
; GENERAL INFORMATION:
; APPLICANT: Semple, Sean
; APPLICANT: Klimuk, Sandy
; APPLICANT: Yuan, Zuan-Ning
; TITLE OF INVENTION: Improved Mucosal Vaccines and Methods for Using the Same
; FILE REFERENCE: A-71854/TAL/AXG
; CURRENT APPLICATION NUMBER: US/10/290,545
; CURRENT FILING DATE: 2002-11-07
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-290-545-11

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
```

```
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 578
US-10-290-545-12/c
; Sequence 12, Application US/10290545
; Publication No. US20030125292A1
; GENERAL INFORMATION:
; APPLICANT: Semple, Sean
; APPLICANT: Klimuk, Sandy
; APPLICANT: Yuan, Zuan-Ning
; TITLE OF INVENTION: Improved Mucosal Vaccines and Methods for Using the Same
; FILE REFERENCE: A-71854/TAL/AXG
; CURRENT APPLICATION NUMBER: US/10/290,545
; CURRENT FILING DATE: 2002-11-07
; NUMBER OF SEQ ID NOS: 30
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-290-545-12

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 579
US-10-262-318-2/c
; Sequence 2, Application US/10262318
; Publication No. US20030144198A1
; GENERAL INFORMATION:
; APPLICANT: Copharos
; APPLICANT: Collins, Douglas A.
; TITLE OF INVENTION: ADMINISTRATION OF TRANSPORT PROTEINS WITH CONJUGATED COBALAMIN
; FILE REFERENCE: DELIVER AGENTS
; FILE REFERENCE: COPI012
; CURRENT APPLICATION NUMBER: US/10/262,318
; CURRENT FILING DATE: 2002-09-30
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide-- ISIS 2302
US-10-262-318-2

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 580
US-10-337-004-1/c
; Sequence 1, Application US/10337004
; Publication No. US20030153742A1
; GENERAL INFORMATION:
; APPLICANT: Krotz, Achim H.
; APPLICANT: Ravikumar, Vasalinga T.
; TITLE OF INVENTION: Purification Of Oligonucleotides
; FILE REFERENCE: ISIS5111
```

; CURRENT APPLICATION NUMBER: US/10/337,004
; PRIOR FILING DATE: 2003-01-02
; PRIOR APPLICATION NUMBER: 09/495,398
; PRIOR FILING DATE: 2000-01-31
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-337-004-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 581
US-10-337-004-2/c
; Sequence 2, Application US/10337004
; Publication No. US20030153742A1
; GENERAL INFORMATION:
; APPLICANT: Krotz, Achim H.
; TITLE OF INVENTION: Purification of Oligonucleotides
; FILE REFERENCE: ISIS111
; CURRENT APPLICATION NUMBER: US/10/337,004
; CURRENT FILING DATE: 2003-01-02
; PRIOR APPLICATION NUMBER: 09/495,398
; PRIOR FILING DATE: 2000-01-31
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
US-10-337-004-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 582
US-10-203-780-12/c
; Sequence 12, Application US/10203780
; Publication No. US20030165914A1
; GENERAL INFORMATION:
; APPLICANT: CUZIN, MARC
; APPLICANT: PELTIE, PHILIPPE
; APPLICANT: FONTECAVE, MARC
; APPLICANT: DECOU, JEAN-LUC
; APPLICANT: DUEYMES, CECILE
; TITLE OF INVENTION: ANALYSIS OF BIOLOGICAL TARGETS USING A BIOCHIP COMPRISING A FLUOR
; FILE REFERENCE: 226286USXPCT
; CURRENT APPLICATION NUMBER: US/10/203,780
; CURRENT FILING DATE: 2002-11-25
; PRIOR APPLICATION NUMBER: PCT/FR01/00516
; PRIOR FILING DATE: 2001-02-22
; PRIOR APPLICATION NUMBER: FR 00 02236

; PRIOR FILING DATE: 2000-02-23
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: ARTIFICIAL SEQUENCE
; FEATURE:
; OTHER INFORMATION: SYNTHETIC DNA
; NAME/KEY: modified_base
; LOCATION: (1)..(1)
; OTHER INFORMATION: c is modified with a covalent linkage to flavin
US-10-203-780-12

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 583
US-10-365-623-2/c
; Sequence 2, Application US/10365623
; Publication No. US20030166512A1
; GENERAL INFORMATION:
; APPLICANT: Xie, Dong
; TITLE OF INVENTION: Protein Carrier System for Therapeutic Oligonucleotides
; FILE REFERENCE: 63024.000001
; CURRENT APPLICATION NUMBER: US/10/365,623
; CURRENT FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide directed against human ICAM-1
US-10-365-623-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 584
US-10-284-742-17/c
; Sequence 17, Application US/10284742
; Publication No. US20030175751A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Bennett, Clarence Frank
; TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake And Other Pr
; FILE REFERENCE: ISIS109
; CURRENT APPLICATION NUMBER: US/10/284,742
; CURRENT FILING DATE: 2003-01-17
; PRIOR APPLICATION NUMBER: 10/154,993
; PRIOR FILING DATE: 2002-05-23
; PRIOR APPLICATION NUMBER: 09/633,659
; PRIOR FILING DATE: 2000-08-07
; PRIOR APPLICATION NUMBER: 08/211,882
; PRIOR FILING DATE: 1994-04-22
; PRIOR APPLICATION NUMBER: PCT/US92/09196
; PRIOR FILING DATE: 1992-10-23

```
; PRIOR APPLICATION NUMBER: 07/782,374
; PRIOR FILING DATE: 1991-10-24
; PRIOR APPLICATION NUMBER: PCT/US91/00243
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 07/463,358
; PRIOR FILING DATE: 1990-01-11
; PRIOR APPLICATION NUMBER: 07/566,977
; PRIOR FILING DATE: 1990-08-13
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: nucleotide functionalized to incorporate
; OTHER INFORMATION: a propyl-N-phthalimido functionality
US-10-284-742-17
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTGTGCTACTCAGA 37
Db 20 GAGCTCCTGTGCTACTCAGA 1
|||||
```

RESULT 585

```
US-10-140-013-10/c
; Sequence 10, Application US/10140013
; Publication No. US20030181406A1
; GENERAL INFORMATION:
; APPLICANT: Christian Schetter
; APPLICANT: Jorg Vollmer
```

```
; TITLE OF INVENTION: CpG-LIKE NUCLEIC ACIDS AND METHODS OF
; TITLE OF INVENTION: USE THEREOF
; FILE REFERENCE: C01041/70019 (AWS)
; CURRENT APPLICATION NUMBER: US/10/140,013
; CURRENT FILING DATE: 2002-05-06
; PRIOR APPLICATION NUMBER: US 60/254,341
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: PCT/US01/48281
; PRIOR FILING DATE: 2001-12-10
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-10-140-013-10
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
|||||
```

RESULT 586

```
US-10-140-013-14/c
; Sequence 14, Application US/10140013
; Publication No. US20030181406A1
; GENERAL INFORMATION:
; APPLICANT: Christian Schetter
```

```
; APPLICANT: Jorg Vollmer
; TITLE OF INVENTION: CpG-LIKE NUCLEIC ACIDS AND METHODS OF
; TITLE OF INVENTION: USE THEREOF
; FILE REFERENCE: C01041/70019 (AWS)
; CURRENT APPLICATION NUMBER: US/10/140,013
; CURRENT FILING DATE: 2002-05-06
; PRIOR APPLICATION NUMBER: US 60/254,341
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: PCT/US01/48281
; PRIOR FILING DATE: 2001-12-10
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
; NAME/KEY: modified base
; LOCATION: (2)..(4)
; OTHER INFORMATION: m5c
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (8)...(8)
; OTHER INFORMATION: m5c
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (12)...(12)
; OTHER INFORMATION: m5c
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (15)...(16)
; OTHER INFORMATION: m5c
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (19)...(19)
; OTHER INFORMATION: m5c
US-10-140-013-14
```

Query Match

```
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
|||||
```

RESULT 587

```
US-10-084-839-3896/c
; Sequence 3896, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
```

; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tseteka Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3896
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-3896

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1796 TCAGATACACAGCATTGG 1815
|||
Db 20 TCAGATACACAGCATTGG 1

RESULT 588
US-10-119-432A-1/c
; Sequence 1, Application US/10119432A
; Publication No. US20030190626A1
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulunga
; TITLE OF INVENTION: Phosphorothioate Monoester Modified Oligomers
; FILE REFERENCE: ISIS4790
; CURRENT APPLICATION NUMBER: US/10/119,432A
; CURRENT FILING DATE: 2002-08-15
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-10-119-432A-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGC 2119
|||
Db 20 TGACGGATGCCAGCTTGGC 1

RESULT 589
US-10-080-979-17/c
; Sequence 17, Application US/10080979
; Publication No. US20030191075A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Manoharan, Nuthiah
; APPLICANT: Bennett, Frank C.
; TITLE OF INVENTION: Oligonucleotide Conjugates For Hepatic Delivery
; FILE REFERENCE: Isis-5028
; CURRENT APPLICATION NUMBER: US/10/080,979
; CURRENT FILING DATE: 2002-02-22
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-modified phosphoramidite
; NAME/KEY: misc_feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-O-methyl
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: non-nucleoside 6-carbon amino linker
US-10-080-979-17

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 590
US-10-323-591-3
; Sequence 3, Application US/10323591
; Publication No. US20030195248A1
; GENERAL INFORMATION:
; APPLICANT: Serhan, Charles N.
; APPLICANT: Colgan, Sean P.
; TITLE OF INVENTION: No. US20030195248A1el Approach to Anti-Microbial Host Defense w
; TITLE OF INVENTION: Lipoxin Analogs
; FILE REFERENCE: 14149.01
; CURRENT APPLICATION NUMBER: US/10/323,591
; CURRENT FILING DATE: 2002-12-18
; PRIOR APPLICATION NUMBER: US 60/342,138
; PRIOR FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-323-591-3

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 840 CACAGTCACCTATGCGAACG 859
|||
Db 1 CACAGTCACCTATGCGAACG 20

RESULT 591
US-10-423-311-11
; Sequence 11, Application US/10423311
; Publication No. US20030206938A1
; GENERAL INFORMATION:
; APPLICANT: Pereira, Heloise Anne
; APPLICANT: Chodosh, James
; APPLICANT: Callegan, Michelle C.
; TITLE OF INVENTION: TREATMENT AND INHIBITION OF OCULAR INFECTIONS AND WOUNDS BY CAP3
; TITLE OF INVENTION: CAP37 PEPTIDES
; FILE REFERENCE: 6267.002
; CURRENT APPLICATION NUMBER: US/10/423,311
; CURRENT FILING DATE: 2003-04-25
; PRIOR APPLICATION NUMBER: 60/378,295
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20


```
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Completely synthesized
US-10-423-311-11
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 150 GTCCCTCAAAAGTCATCC 169
      |||||
Db 1 GTCCCTCAAAAGTCATCC 20
```

```
RESULT 592
US-10-181-200-2/c
; Sequence 2, Application US/10181200
; Publication No. US20030212267A1
; GENERAL INFORMATION:
; APPLICANT: Cole, Douglas L.
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Cheruvallath, Zacharia S.
; TITLE OF INVENTION: IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES
; FILE REFERENCE: ISIS-4709
; CURRENT APPLICATION NUMBER: US/10/181,200
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: PCT/US01/00715
; PRIOR FILING DATE: 2001-01-10
; PRIOR APPLICATION NUMBER: US 09/481,486
; PRIOR FILING DATE: 2000-01-11
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: phosphorothioate 20-mer
US-10-181-200-2
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
Db 20 TGACGGATGCCAGCTTGGGC 1
```

```
RESULT 593
US-10-181-200-8/c
; Sequence 8, Application US/10181200
; Publication No. US20030212267A1
; GENERAL INFORMATION:
; APPLICANT: Cole, Douglas L.
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Cheruvallath, Zacharia S.
; TITLE OF INVENTION: IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES
; FILE REFERENCE: ISIS-4709
; CURRENT APPLICATION NUMBER: US/10/181,200
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: PCT/US01/00715
; PRIOR FILING DATE: 2001-01-10
; PRIOR APPLICATION NUMBER: US 09/481,486
; PRIOR FILING DATE: 2000-01-11
```

```
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(13)
; OTHER INFORMATION: 2'-methoxyethyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: phosphorothioate 20-mer
US-10-181-200-8
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
Db 20 TGACGGATGCCAGCTTGGGC 1
```

```
RESULT 594
US-10-181-200-9/c
; Sequence 9, Application US/10181200
; Publication No. US20030212267A1
; GENERAL INFORMATION:
; APPLICANT: Cole, Douglas L.
; APPLICANT: Ravikumar, Vasulunga T.
; APPLICANT: Cheruvallath, Zacharia S.
; TITLE OF INVENTION: IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES
; FILE REFERENCE: ISIS-4709
; CURRENT APPLICATION NUMBER: US/10/181,200
; CURRENT FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: PCT/US01/00715
; PRIOR FILING DATE: 2001-01-10
; PRIOR APPLICATION NUMBER: US 09/481,486
; PRIOR FILING DATE: 2000-01-11
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(13)
; OTHER INFORMATION: 2'-methoxyethyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: phosphorothioate 20-mer
US-10-181-200-9
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
Db 20 TGACGGATGCCAGCTTGGGC 1
```

```
RESULT 595
US-10-181-200-14/c
; Sequence 14, Application US/10181200
```

```
; Publication No. US20030212267A1
; GENERAL INFORMATION:
; APPLICANT: Cole, Douglas L.
; APPLICANT: Ravikumar, Vasulinga T.
; APPLICANT: Cheruvallath, Zacharia S.
; TITLE OF INVENTION: IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES
; FILE REFERENCE: ISIS-4709
; CURRENT APPLICATION NUMBER: US/10/181,200
; PRIOR FILING DATE: 2002-12-12
; PRIOR APPLICATION NUMBER: PCT/US01/00715
; PRIOR FILING DATE: 2001-01-10
; PRIOR APPLICATION NUMBER: US 09/481,486
; PRIOR FILING DATE: 2000-01-11
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc feature
; LOCATION: (12)..(13)
; OTHER INFORMATION: 2'-O'-methoxyethyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: phosphorothioate 20-mer
; OTHER INFORMATION: phosphorothioate 20-mer
; US-10-181-200-14

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 596
US-10-444-445-2/c
; Sequence 2, Application US/10444445
; Publication No. US20030229220A1
; GENERAL INFORMATION:
; APPLICANT: Capaldi, Daniel C
; APPLICANT: Ravikumar, Vasulinga T
; TITLE OF INVENTION: Processes For The Synthesis Of Oligomers Using Phosphoramidite
; TITLE OF INVENTION: Compositions
; FILE REFERENCE: ISIS196
; CURRENT APPLICATION NUMBER: US/10/444,445
; CURRENT FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: 09/306,278
; PRIOR FILING DATE: 1999-05-06
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; US-10-444-445-2

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1
```

```
RESULT 597
US-10-445-996-2/c
; Sequence 2, Application US/10445996
; Publication No. US20040005618A1
; GENERAL INFORMATION:
; APPLICANT: Zhengrong Yu
; APPLICANT: Brenda F. Baker
; APPLICANT: John Wu
; TITLE OF INVENTION: Nuclease-Based Method for Detecting and Quantitating
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: ISPH-0500
; CURRENT APPLICATION NUMBER: US/10/445,996
; CURRENT FILING DATE: 2003-05-27
; PRIOR APPLICATION NUMBER: US/09/705,587
; PRIOR FILING DATE: 2000-11-03
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
; US-10-445-996-2

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 598
US-10-359-328-1/c
; Sequence 1, Application US/10359328
; Publication No. US2004000938A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; TITLE OF INVENTION: METHODS OF ENHANCING RENAL UPTAKE OF OLIGONUCLEOTIDES
; FILE REFERENCE: ISIS-5140
; CURRENT APPLICATION NUMBER: US/10/359,328
; CURRENT FILING DATE: 2003-02-06
; PRIOR APPLICATION NUMBER: US 09/370,625
; PRIOR FILING DATE: 1999-08-06
; PRIOR APPLICATION NUMBER: US 09/130,566
; PRIOR FILING DATE: 1998-08-07
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: 2'-O-[2-(2-N-dimethylaminoethyl)oxyethyl]-5-methyl-
; OTHER INFORMATION: phosphorothioate linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 5-methyl-C
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 5-methyl-C
; FEATURE:
; NAME/KEY: misc feature
```

```
; LOCATION: (18)..(18)
; OTHER INFORMATION: 5-methyl-C
US-10-359-328-1

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
   |||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 599
US-10-359-328-2/c
; Sequence 2, Application US/10359328
; Publication No. US20040009938A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; TITLE OF INVENTION: METHODS OF ENHANCING RENAL UPTAKE OF OLIGONUCLEOTIDES
; FILE REFERENCE: ISIS-5140
; CURRENT APPLICATION NUMBER: US/10/359,328
; CURRENT FILING DATE: 2003-02-06
; PRIOR APPLICATION NUMBER: US 09/370,625
; PRIOR FILING DATE: 1999-08-06
; PRIOR APPLICATION NUMBER: US 09/130,566
; PRIOR FILING DATE: 1998-08-07
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: phosphorothioate linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 5-Methyl-C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 5-Methyl-C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 5-Methyl-C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(20)
; OTHER INFORMATION: 2'-O-[2-N,N-dimethylaminoethyl]oxyethyl]-5-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 5-Methyl-C
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 5-Methyl-C
US-10-359-328-4

Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
   |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 601
US-10-437-263-11/c
; Sequence 11, Application US/10437263
; Publication No. US20040009943A1
; GENERAL INFORMATION:
; APPLICANT: Semple, Sean
; APPLICANT: Tam, Ying K.
; APPLICANT: Chikh, Ghania
; APPLICANT: Hope, Michael J.
; TITLE OF INVENTION: PATHOGEN VACCINES AND METHODS FOR USING THE SAME
; FILE REFERENCE: A-72216/TAL
; CURRENT APPLICATION NUMBER: US/10/437,263
; CURRENT FILING DATE: 2003-05-12
; PRIOR APPLICATION NUMBER: 60/379,343
; PRIOR FILING DATE: 2002-05-10
; PRIOR APPLICATION NUMBER: 60/460,646
; PRIOR FILING DATE: 2003-04-04
; PRIOR APPLICATION NUMBER: 60/454,298
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 34
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-437-263-11
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
Db 20 TGACGGATGCCAGCTTGGGC 1
```

RESULT 602

```
US-10-437-263-12/c
; Sequence 12, Application US/10437263
; Publication No. US20040009943A1
```

GENERAL INFORMATION:

```
; APPLICANT: Sample, Sean
; APPLICANT: Tam, Ying K.
; APPLICANT: Chikh, Ghania
; TITLE OF INVENTION: PATHOGEN VACCINES AND METHODS FOR USING THE SAME
; FILE REFERENCE: A-72216/TAL
; CURRENT APPLICATION NUMBER: US/10/437,263
; CURRENT FILING DATE: 2003-05-12
; PRIOR APPLICATION NUMBER: 60/379,343
; PRIOR FILING DATE: 2002-05-10
; PRIOR APPLICATION NUMBER: 60/460,646
; PRIOR FILING DATE: 2003-04-04
; PRIOR APPLICATION NUMBER: 60/454,298
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-437-263-12
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
Db 20 TGACGGATGCCAGCTTGGGC 1
```

RESULT 603

```
US-10-437-275-11/c
; Sequence 11, Application US/10437275
; Publication No. US20040009944A1
```

GENERAL INFORMATION:

```
; APPLICANT: Sample, Sean
; APPLICANT: Tam, Ying K.
; APPLICANT: Klimuk, Sandra
; APPLICANT: Chikh, Ghania
; TITLE OF INVENTION: METHYLATED IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND METHODS OF
; FILE REFERENCE: A-72158/TAL
; CURRENT APPLICATION NUMBER: US/10/437,275
; CURRENT FILING DATE: 2003-05-12
; PRIOR APPLICATION NUMBER: 60/379,343
; PRIOR FILING DATE: 2002-05-10
; PRIOR APPLICATION NUMBER: 60/460,646
; PRIOR FILING DATE: 2003-04-04
; PRIOR APPLICATION NUMBER: 10/290,545
; PRIOR FILING DATE: 2002-11-07
; NUMBER OF SEQ ID NOS: 32
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-437-275-11
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
Db 20 TGACGGATGCCAGCTTGGGC 1
```

RESULT 604

```
US-10-437-275-12/c
; Sequence 12, Application US/10437275
; Publication No. US20040009944A1
```

GENERAL INFORMATION:

```
; APPLICANT: Sample, Sean
; APPLICANT: Tam, Ying K.
; APPLICANT: Klimuk, Sandra
; APPLICANT: Chikh, Ghania
; TITLE OF INVENTION: METHYLATED IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND METHODS OF
; FILE REFERENCE: A-72158/TAL
; CURRENT APPLICATION NUMBER: US/10/437,275
; CURRENT FILING DATE: 2003-05-12
; PRIOR APPLICATION NUMBER: 60/379,343
; PRIOR FILING DATE: 2002-05-10
; PRIOR APPLICATION NUMBER: 60/460,646
; PRIOR FILING DATE: 2003-04-04
; PRIOR APPLICATION NUMBER: 10/290,545
; PRIOR FILING DATE: 2002-11-07
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-437-275-12
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
Db 20 TGACGGATGCCAGCTTGGGC 1
```

RESULT 605

```
US-10-437-258-11/c
; Sequence 11, Application US/10437258
; Publication No. US20040013649A1
```

GENERAL INFORMATION:

```
; APPLICANT: Sample, Sean
; APPLICANT: Tam, Ying K.
; APPLICANT: Klimuk, Sandra
; APPLICANT: Chikh, Ghania
; TITLE OF INVENTION: CANCER VACCINES AND METHODS OF USING THE SAME
; FILE REFERENCE: A-72252/TAL
; CURRENT APPLICATION NUMBER: US/10/437,258
; CURRENT FILING DATE: 2003-05-12
; PRIOR APPLICATION NUMBER: 60/379,343
; PRIOR FILING DATE: 2002-05-10
; PRIOR APPLICATION NUMBER: 60/460,646
; PRIOR FILING DATE: 2003-04-04
; PRIOR APPLICATION NUMBER: 60/454,298
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 34
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-437-258-11

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 606
US-10-437-258-12/c
; Sequence 12, Application US/10437258
; Publication No. US20040013649A1
; GENERAL INFORMATION:
; APPLICANT: Tam, Ying K.
; APPLICANT: Semple, Sean
; APPLICANT: Klimuk, Sandra
; APPLICANT: Chikh, Ghania
; TITLE OF INVENTION: CANCER VACCINES AND METHODS OF USING THE SAME
; FILE REFERENCE: A-72252/TAL
; CURRENT APPLICATION NUMBER: US/10/437,258
; CURRENT FILING DATE: 2003-05-12
; PRIOR APPLICATION NUMBER: 60/379,343
; PRIOR FILING DATE: 2002-05-10
; PRIOR APPLICATION NUMBER: 60/460,646
; PRIOR FILING DATE: 2003-04-04
; PRIOR APPLICATION NUMBER: 60/454,298
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 34
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-437-258-12

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 607
US-10-444-206-17/c
; Sequence 17, Application US/10444206
; Publication No. US20040023917A1
; GENERAL INFORMATION:
; APPLICANT: Bennett, Clarence Frank
; APPLICANT: Vickers, Timothy A.
; APPLICANT: Karras, James G.
; TITLE OF INVENTION: Oligonucleotide Compositions and Methods for the
; TITLE OF INVENTION: Modulation of the Expression of B7 Protein
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/10/444,206
; CURRENT FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: 09/851,871
; PRIOR FILING DATE: 2001-05-09
; PRIOR APPLICATION NUMBER: PCT/US00/14471
; PRIOR FILING DATE: 2000-05-25
; PRIOR APPLICATION NUMBER: 09/326,186
; PRIOR FILING DATE: 1999-06-04
; PRIOR APPLICATION NUMBER: 08/777,266
; PRIOR FILING DATE: 1996 12 31

; NUMBER OF SEQ ID NOS: 444
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
; PUBLICATION INFORMATION:
; PATENT DOCUMENT NUMBER: US 5514788
; PATENT FILING DATE: 1993 05 17
; PUBLICATION DATE: 1996 05 07
US-10-444-206-17

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 608
US-10-454-663-2/c
; Sequence 2, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-2

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 609
US-10-454-663-7/c
; Sequence 7, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
```

```
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-7

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      41  GCAACCTCAGCTCGCTATG 60
          |||||
Db       20  GCAACCTCAGCTCGCTATG 1

RESULT 610
US-10-454-663-8/c
; Sequence 8, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-8

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      58  ATGGCTCCAGCAGCCCCG 77
          |||||
Db       20  ATGGCTCCAGCAGCCCCG 1

RESULT 611
US-10-454-663-9/c
; Sequence 9, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-9

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      97  CTGGTCTGCTCGGGGCTCT 116
          |||||
Db       20  CTGGTCTGCTCGGGGCTCT 1

RESULT 612
US-10-454-663-10/c
; Sequence 10, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-10
```

```
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-10

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGCA 356
Db 20 TCAAACTGCCCTGATGGCA 1

RESULT 613
US-10-454-663-11/c
; Sequence 11, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-11

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGGCCTCAGTCAGTGTGACC 894
Db 20 AGGCCTCAGTCAGTGTGACC 1

RESULT 614
US-10-454-663-12/c
; Sequence 12, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
```

```
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-12

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1445 AAGGGAGGTACCCGCGAG 1464
Db 20 AAGGGAGGTACCCGCGAG 1

RESULT 615
US-10-454-663-13/c
; Sequence 13, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-13

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1637 CACAAGCCACGCTCCCTGA 1656
Db 20 CACAAGCCACGCTCCCTGA 1
```

```
RESULT 616
US-10-454-663-14/c
; Sequence 14, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-14
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1654 TGAACCTATCCCGGACAGG 1673
DB 20 TGAACCTATCCCGGACAGG 1
```

```
RESULT 617
US-10-454-663-15/c
; Sequence 15, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 15
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-15

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
DB 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 618
US-10-454-663-16/c
; Sequence 16, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-16

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2962 AGTTAATAAAGCTTTCTCAA 2981
DB 20 AGTTAATAAAGCTTTCTCAA 1

RESULT 619
US-10-454-663-22/c
; Sequence 22, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
```



```
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-22

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 620
US-10-454-663-23/c
; Sequence 23, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-23

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2025 GAGGCCACAGACTTACAGA 2044
      |||||
Db 20 GAGGCCACAGACTTACAGA 1

RESULT 621
US-10-454-663-24/c
```

```
; Sequence 24, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-24

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1881 CAAGAGGAGGAGCAAGACT 1900
      |||||
Db 20 CAAGAGGAGGAGCAAGACT 1

RESULT 622
US-10-454-663-25/c
; Sequence 25, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
```

US-10-454-663-25

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1921 TTAAAGTCTAGCCTGATGAG 1940
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TTAAAGTCTAGCCTGATGAG 1

RESULT 623

US-10-454-663-26/c
; Sequence 26, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-26

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1962 ATAGCCCCCACCATGAGGACA 1981
| | | | | | | | | | | | | | | | | | | | | |
Db 20 ATAGCCCCCACCATGAGGACA 1

RESULT 624

US-10-454-663-84/c
; Sequence 84, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12

; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-84

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 18 GAGCTCCTCTGCTACTCAGA 37
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 625

US-10-454-663-85/c
; Sequence 85, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-85

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1945 GAAGTGGTGGGGGAGACATA 1964
| | | | | | | | | | | | | | | | | | | | | |
Db 20 GAAGTGGTGGGGGAGACATA 1

RESULT 626

US-10-636-452-1/c
; Sequence 1, Application US/10636452
; Publication No. US20040038925A1
; GENERAL INFORMATION:
; APPLICANT: Scott Henry

```
; TITLE OF INVENTION: Use of Oligonucleotides for Inhibition of Complement Activation
; FILE REFERENCE: ISPH-0504
; CURRENT APPLICATION NUMBER: US/10/636,452
; CURRENT FILING DATE: 2003-08-07
; PRIOR APPLICATION NUMBER: 09/794,824
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: 09/409,816
; PRIOR FILING DATE: 1999-09-30
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
US-10-636-452-1

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
        |||||||
Db       20 TGACGGATGCCAGCTTGGGC 1

RESULT 627
US-10-636-452-5/c
; Sequence 5, Application US/10636452
; Publication No. US20040038925A1
; GENERAL INFORMATION:
; APPLICANT: Scott Henry
; TITLE OF INVENTION: Use of Oligonucleotides for Inhibition of Complement Activation
; FILE REFERENCE: ISPH-0504
; CURRENT APPLICATION NUMBER: US/10/636,452
; CURRENT FILING DATE: 2003-08-07
; PRIOR APPLICATION NUMBER: 09/794,824
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: 09/409,816
; PRIOR FILING DATE: 1999-09-30
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
US-10-636-452-5

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
        |||||||
Db       20 TGACGGATGCCAGCTTGGGC 1

RESULT 628
US-10-636-452-7/c
; Sequence 7, Application US/10636452
; Publication No. US20040038925A1
; GENERAL INFORMATION:
; APPLICANT: Scott Henry
; TITLE OF INVENTION: Use of Oligonucleotides for Inhibition of Complement Activation
; FILE REFERENCE: ISPH-0504
; CURRENT APPLICATION NUMBER: US/10/636,452
; CURRENT FILING DATE: 2003-08-07
; PRIOR APPLICATION NUMBER: 09/794,824
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: 09/409,816
```

```
; PRIOR FILING DATE: 1999-09-30
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
US-10-636-452-7

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
        |||||||
Db       20 TGACGGATGCCAGCTTGGGC 1

RESULT 629
US-10-050-888A-7/c
; Sequence 7, Application US/10050888A
; Publication No. US20040073376A1
; GENERAL INFORMATION:
; APPLICANT: Gesteland, Raymond F.
; APPLICANT: Atkins, John F.
; APPLICANT: Matveeva, Olga V.
; APPLICANT: Giddings, Michael C.
; TITLE OF INVENTION: Finding Active Antisense Oligonucleotides Using Artificial Neural
; TITLE OF INVENTION: Networks
; FILE REFERENCE: T9479.B
; CURRENT APPLICATION NUMBER: US/10/050,888A
; CURRENT FILING DATE: 2002-01-14
; PRIOR APPLICATION NUMBER: US 60/262,993
; PRIOR FILING DATE: 2001-01-19
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-050-888A-7

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1938 GAGAGGGGAAGTGGTGGGGG 1957
        |||||||
Db       20 GAGAGGGGAAGTGGTGGGGG 1

RESULT 630
US-10-671-395-1144/c
; Sequence 1144, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1144
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
```

; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1144

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2848 AGCCTCCTGAGTAGCTGGGA 2867
|||||
DB 20 AGCCTCCTGAGTAGCTGGGA 1

RESULT 631
US-10-671-395-1268/c
; Sequence 1268, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1268
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1268

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2847 CAGCCTCCTGAGTAGCTGGG 2866
|||||
DB 20 CAGCCTCCTGAGTAGCTGGG 1

RESULT 632
US-10-671-395-1453/c
; Sequence 1453, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR FILING DATE: 2002-09-25
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1453
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1453

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCCTGAGTAGCT 2863
|||||
DB 20 CCTCAGCCTCCTGAGTAGCT 1

RESULT 633
US-10-671-395-1543/c
; Sequence 1543, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1543
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1543

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2846 TCAGCCTCCTGAGTAGCTGG 2865
|||||
DB 20 TCAGCCTCCTGAGTAGCTGG 1

RESULT 634
US-10-671-395-1550/c
; Sequence 1550, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1550
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1550

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTG 2864
|||||
DB 20 CTCAGCCTCCTGAGTAGCTG 1

RESULT 635

```
US-10-745-377-65
; Sequence 65, Application US/10745377
; Publication No. US20040137423A1
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
; APPLICANT: Pimstone, Simon
; APPLICANT: Brooks-Wilson, Angela R.
; APPLICANT: Clee, Susanne M.
; TITLE OF INVENTION: Compositions and Methods for Modulating
; TITLE OF INVENTION: HDL Cholesterol and Triglyceride Levels
; FILE REFERENCE: 760050-109
; CURRENT FILING DATE: 2003-12-23
; PRIOR APPLICATION NUMBER: US/10/745,377
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: US 60/124,702
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: US 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: US 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: US 60/151,977
; PRIOR FILING DATE: 1999-09-01
; PRIOR APPLICATION NUMBER: US 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: US 60/213,958
; PRIOR FILING DATE: 2000-06-23
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: Word for Windows Version 6.0 (ASCII Text)
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: homo sapien
US-10-745-377-65
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2825 GGCTCAAGTGATCCTCCAC 2844
      |||||||
Db 1 GGCTCAAGTGATCCTCCAC 20
```

```
RESULT 636
US-10-664-639A-1/c
; Sequence 1, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; TITLE OF INVENTION: Double-Stranded Oligomeric Compounds
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(6)
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
```

```
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-1
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 8 AGTCGACGCTGAGCTCCTCT 27
      |||||||
Db 20 AGTCGACGCTGAGCTCCTCT 1
```

```
RESULT 637
US-10-664-639A-2/c
; Sequence 2, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; TITLE OF INVENTION: Double-Stranded Oligomeric Compounds
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; NAME/KEY: misc feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-2
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 33 TCAGAGTTGCAACCTCAGCC 52
      |||||||
Db 20 TCAGAGTTGCAACCTCAGCC 1
```

```
RESULT 638
US-10-664-639A-3/c
; Sequence 3, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
```

;; TITLE OF INVENTION: Double-Stranded Oligomeric Compounds
;; FILE REFERENCE: ISIS0001-100 (CORE00027US)
;; CURRENT APPLICATION NUMBER: US/10/664,639A
;; PRIOR FILING DATE: 2003-09-18
;; PRIOR APPLICATION NUMBER: US 60/411,780
;; PRIOR FILING DATE: 2002-09-18
;; NUMBER OF SEQ ID NOS: 121
;; SOFTWARE: PatentIn version 3.2
;; SEQ ID NO 3
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: artificial sequence
;; FEATURE:
;; OTHER INFORMATION: oligonucleotide
;; NAME/KEY: misc feature
;; LOCATION: (1)..(6)
;; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (15)..(20)
;; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-3

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 256 AAGGAGTTGCTCTGCTGG 275
Db 20 AAGGAGTTGCTCTGCTGG 1

RESULT 639

US-10-664-639A-4/c
;; Sequence 4, Application US/10664639A
;; Publication No. US20040137471A1
;; GENERAL INFORMATION:
;; APPLICANT: Vickers, Timothy
;; APPLICANT: Koo, Seongjoon
;; APPLICANT: Bennett, C. Frank
;; APPLICANT: Crooke, Stanley T.
;; APPLICANT: Dean, Nicholas, M.
;; APPLICANT: Baker, Brenda F.
;; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
;; FILE REFERENCE: ISIS0001-100 (CORE00027US)
;; CURRENT APPLICATION NUMBER: US/10/664,639A
;; PRIOR FILING DATE: 2003-09-18
;; PRIOR APPLICATION NUMBER: US 60/411,780
;; NUMBER OF SEQ ID NOS: 121
;; SOFTWARE: PatentIn version 3.2
;; SEQ ID NO 4
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: artificial sequence
;; FEATURE:
;; OTHER INFORMATION: oligonucleotide
;; NAME/KEY: misc feature
;; LOCATION: (1)..(6)
;; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (15)..(20)
;; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-4

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 321 CCAACCAATGTGCTATTCAA 340
Db 20 CCAACCAATGTGCTATTCAA 1

RESULT 640

US-10-664-639A-5/c
;; Sequence 5, Application US/10664639A
;; Publication No. US20040137471A1
;; GENERAL INFORMATION:
;; APPLICANT: Vickers, Timothy
;; APPLICANT: Koo, Seongjoon
;; APPLICANT: Bennett, C. Frank
;; APPLICANT: Crooke, Stanley T.
;; APPLICANT: Dean, Nicholas, M.
;; APPLICANT: Baker, Brenda F.
;; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
;; FILE REFERENCE: ISIS0001-100 (CORE00027US)
;; CURRENT APPLICATION NUMBER: US/10/664,639A
;; CURRENT FILING DATE: 2003-09-18
;; PRIOR APPLICATION NUMBER: US 60/411,780
;; PRIOR FILING DATE: 2002-09-18
;; NUMBER OF SEQ ID NOS: 121
;; SOFTWARE: PatentIn version 3.2
;; SEQ ID NO 5
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: artificial sequence
;; FEATURE:
;; OTHER INFORMATION: oligonucleotide
;; NAME/KEY: misc feature
;; LOCATION: (1)..(6)
;; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
;; FEATURE:
;; NAME/KEY: misc feature
;; LOCATION: (15)..(20)
;; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-5

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 422 CCTCTGGCAGCCAGTGGC 441
Db 20 CCTCTGGCAGCCAGTGGC 1

RESULT 641

US-10-664-639A-6/c
;; Sequence 6, Application US/10664639A
;; Publication No. US20040137471A1
;; GENERAL INFORMATION:
;; APPLICANT: Vickers, Timothy
;; APPLICANT: Koo, Seongjoon
;; APPLICANT: Bennett, C. Frank
;; APPLICANT: Crooke, Stanley T.
;; APPLICANT: Dean, Nicholas, M.
;; APPLICANT: Baker, Brenda F.
;; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
;; FILE REFERENCE: ISIS0001-100 (CORE00027US)
;; CURRENT APPLICATION NUMBER: US/10/664,639A
;; CURRENT FILING DATE: 2003-09-18
;; PRIOR APPLICATION NUMBER: US 60/411,780
;; PRIOR FILING DATE: 2002-09-18
;; NUMBER OF SEQ ID NOS: 121
;; SOFTWARE: PatentIn version 3.2
;; SEQ ID NO 6
;; LENGTH: 20
;; TYPE: DNA

```
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-6
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 571 ACGTGCTGCTGAGGAGAGA 590
|||||
Db 20 ACGTGCTGCTGAGGAGAGA 1
```

RESULT 642

```
US-10-664-639A-7/c
; Sequence 7, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-7
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 674 CCTACCAGCTCCAGACCTTT 693
|||||
Db 20 CCTACCAGCTCCAGACCTTT 1
```

RESULT 643

```
US-10-664-639A-8/c
; Sequence 8, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
```

```
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-8
```

```
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 732 GGTCTAGAGGTGGACGCG 751
|||||
Db 20 GGTCTAGAGGTGGACGCG 1
```

RESULT 644

```
US-10-664-639A-9/c
; Sequence 9, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
```

US-10-664-639A-9

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 801 CCAGGTCACCTGGCACTGG 820
|||||
DB 20 CCAGGTCACCTGGCACTGG 1

RESULT 645

US-10-664-639A-10/c
; Sequence 10, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: Double-Stranded Oligomeric Compounds
; CURRENT APPLICATION NUMBER: US/10/664, 639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-10

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 921 GAGGTGCGAGTAATCTGG 940
|||||
DB 20 GAGGTGCGAGTAATCTGG 1

RESULT 646

US-10-664-639A-11/c
; Sequence 11, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: Double-Stranded Oligomeric Compounds
; CURRENT APPLICATION NUMBER: US/10/664, 639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780

; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-11

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1002 GATTCTGACGAGCCAGAGG 1021
|||||
DB 20 GATTCTGACGAGCCAGAGG 1

RESULT 647

US-10-664-639A-12/c
; Sequence 12, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: Double-Stranded Oligomeric Compounds
; CURRENT APPLICATION NUMBER: US/10/664, 639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-12

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 AGCTCTGCTGAAGGCCACC 1140
|||||
DB 20 AGCTCTGCTGAAGGCCACC 1


```
RESULT 648
US-10-664-639A-13/c
; Sequence 13, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: Double-Stranded Oligomeric Compounds
; CURRENT APPLICATION NUMBER: US/10/664,639A
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-13

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1221 GGAGCTTCGTGCTCTGTATG 1240
      |||||
Db 20 GGAGCTTCGTGCTCTGTATG 1

RESULT 649
US-10-664-639A-14/c
; Sequence 14, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: Double-Stranded Oligomeric Compounds
; CURRENT APPLICATION NUMBER: US/10/664,639A
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-14
```

```
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-14

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1341 GCTCAAGTGTCTAAAGGATG 1360
      |||||
Db 20 GCTCAAGTGTCTAAAGGATG 1

RESULT 650
US-10-664-639A-15/c
; Sequence 15, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: Double-Stranded Oligomeric Compounds
; CURRENT APPLICATION NUMBER: US/10/664,639A
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-15

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1421 ACCTCTGTGGGCCAGGAGC 1440
      |||||
Db 20 ACCTCTGTGGGCCAGGAGC 1

RESULT 651
US-10-664-639A-16/c
; Sequence 16, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
```

```
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE OF INVENTION: Double-Stranded Oligomeric Compounds
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; US-10-664-639A-16

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1501 GTCATCATCACTGTGTAGC 1520
Db 20 GTCATCATCACTGTGTAGC 1

RESULT 652
US-10-664-639A-17/c
; Sequence 17, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; US-10-664-639A-17

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1622 CCATGAACCCGAACACACAA 1641
Db 20 CCATGAACCCGAACACACAA 1

RESULT 653
US-10-664-639A-18/c
; Sequence 18, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; US-10-664-639A-18

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1633 AACACACAGCCAGCCTCC 1652
Db 20 AACACACAGCCAGCCTCC 1

RESULT 654
US-10-664-639A-19/c
; Sequence 19, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
; LENGTH: 20
```


; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-22

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1781 GGGCAATGTCTCAGTCAGA 1800
|||||
DB 20 GGGCAATGTCTCAGTCAGA 1

RESULT 658

US-10-664-639A-23/c
; Sequence 23, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: Double-Stranded Oligomeric Compounds
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; FEATURE: oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-23

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1818 CCATGGTACTGCACACCTA 1837
|||||
DB 20 CCATGGTACTGCACACCTA 1

RESULT 659

US-10-664-639A-24/c
; Sequence 24, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: Double-Stranded Oligomeric Compounds
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18

; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; FEATURE: oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-24

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1924 AAGTCTAGCCTGATGAGG 1943
|||||
DB 20 AAGTCTAGCCTGATGAGG 1

RESULT 660

US-10-664-639A-25/c
; Sequence 25, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: Double-Stranded Oligomeric Compounds
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; FEATURE: oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-25

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1971 CCATGAGGACATACAACTGG 1990
|||||
DB 20 CCATGAGGACATACAACTGG 1

```
RESULT 661
US-10-664-639A-26/c
; Sequence 26, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; TITLE OF INVENTION: Double-Stranded Oligomeric Compounds
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-26

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2012 TATTGGGTATGCTGAGGCC 2031
Db 20 TATTGGGTATGCTGAGGCC 1

RESULT 662
US-10-664-639A-27/c
; Sequence 27, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; TITLE OF INVENTION: Double-Stranded Oligomeric Compounds
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; FEATURE:
```

```
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-27

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2056 TCCATAGACATGCTGAGCAT 2075
Db 20 TCCATAGACATGCTGAGCAT 1

RESULT 663
US-10-664-639A-28/c
; Sequence 28, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; TITLE OF INVENTION: Double-Stranded Oligomeric Compounds
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-28

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 664
US-10-664-639A-29/c
; Sequence 29, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
```



```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-32

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2341 CATTGCCCAACCTGCGCTTTC 2360
DB 20 CATTGCCCAACCTGCGCTTTC 1

RESULT 668
US-10-664-639A-33/c
; Sequence 33, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; PRIOR FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-33

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2417 TCACAGTTTCAGAGATTACC 2436
DB 20 TCACAGTTTCAGAGATTACC 1

RESULT 669
US-10-664-639A-34/c
; Sequence 34, Application US/10664639A
; Publication No. US20040137471A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; PRIOR FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-34

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2531 CTCACGGTCATGCTCTGGAC 2550
DB 20 CTCACGGTCATGCTCTGGAC 1

RESULT 670
US-10-664-639A-35/c
; Sequence 35, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; PRIOR FILING DATE: 2003-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
US-10-664-639A-35
```

```

; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; TITLE OF INVENTION: Double-Stranded Oligomeric Compounds
; FILE REFERENCE: ISIS0001-100 (CORE00027U5)
; CURRENT APPLICATION NUMBER: US/10/664,639A

```



```
RESULT 674
US-10-664-639A-39/c
; Sequence 39, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: Double-Stranded Oligomeric Compounds
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: misc feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; US-10-664-639A-39

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2944 CCAGACTTCCTTGTGCTTAG 2963
Db 20 CCAGACTTCCTTGTGCTTAG 1

RESULT 675
US-10-664-639A-40/c
; Sequence 40, Application US/10664639A
; Publication No. US20040137471A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas, M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: Double-Stranded Oligomeric Compounds
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
```

```
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(6)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl substituted bases
; US-10-664-639A-40

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2104 GGATGCCAGCTTGGGCACTG 2123
Db 20 GGATGCCAGCTTGGGCACTG 1

RESULT 676
US-10-652-795-41/c
; Sequence 41, Application US/10652795
; Publication No. US20040142346A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-ALPHA EXPRESSION
; FILE REFERENCE: ISPH-0501
; CURRENT APPLICATION NUMBER: US/10/652,795
; CURRENT FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US/09/824,322B
; PRIOR FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: US 09/313,932
; PRIOR FILING DATE: 1999-05-18
; PRIOR APPLICATION NUMBER: US 09/166,186
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 503
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: control sequence
; US-10-652-795-41

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 677
US-10-652-795-49/c
; Sequence 49, Application US/10652795
; Publication No. US20040142346A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-ALPHA EXPRESSION
; FILE REFERENCE: ISPH-0501
; CURRENT APPLICATION NUMBER: US/10/652,795
; CURRENT FILING DATE: 2003-08-29
; PRIOR APPLICATION NUMBER: US/09/824,322B
; PRIOR FILING DATE: 2001-04-02
```

;; PRIOR APPLICATION NUMBER: US 09/313,932
;; PRIOR FILING DATE: 1999-05-18
;; PRIOR APPLICATION NUMBER: US 09/166,186
;; PRIOR FILING DATE: 1998-10-05
;; NUMBER OF SEQ ID NOS: 503
;; SEQ ID NO 49
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: control sequence
US-10-652-795-49

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 678

US-10-780-439-17/c
;; Sequence 17, Application US/10780439
;; Publication No. US20040142899A1
;; GENERAL INFORMATION:
;; APPLICANT: Cook, Phillip D.
;; Manoharan, Muthiah
;; Bennett, C. Frank

;; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
;; ENHANCED BIOTABILITY AND ALTERED BIODISTRIBUTION OF
;; OLIGONUCLEOTIDES IN MANIMALS
;; NUMBER OF SEQUENCES: 63
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Cozen O'Connor
;; STREET: 1900 Market Street
;; CITY: Philadelphia
;; STATE: PA
;; COUNTRY: U.S.A.
;; ZIP: 19103

COMPUTER READABLE FORM:

;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA: US/10/780,439
;; FILING DATE: 17-Feb-2004
;; CLASSIFICATION: <Unknown>
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Nguyen, Quan L.
;; REGISTRATION NUMBER: 46,957
;; REFERENCE/DOCKET NUMBER: ISIC0006-102

;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 215-665-2000
;; TELEFAX: 215-665-2013
;; INFORMATION FOR SEQ ID NO: 17:

;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; SEQUENCE DESCRIPTION: SEQ ID NO: 17:
US-10-780-439-17

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||

DB 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 679

US-10-789-113-3/c
;; Sequence 3, Application US/10789113
;; Publication No. US20040142900A1
;; GENERAL INFORMATION:
;; APPLICANT: O'Hare, Peter Francis Joseph
;; APPLICANT: Normand, Nadia Michelle
;; APPLICANT: Brewis, Neil Douglas
;; APPLICANT: Phelan, Anne
;; TITLE OF INVENTION: Uses of Transport Proteins
;; FILE REFERENCE: 5759-56969
;; CURRENT APPLICATION NUMBER: US/10/789,113
;; CURRENT FILING DATE: 2004-02-26
;; PRIOR APPLICATION NUMBER: US/09/747,772
;; PRIOR FILING DATE: 2000-12-20
;; NUMBER OF SEQ ID NOS: 5
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 3
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: synthetic construct
US-10-789-113-3

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
|||||
DB 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 680

US-10-789-113-4/c
;; Sequence 4, Application US/10789113
;; Publication No. US20040142900A1
;; GENERAL INFORMATION:
;; APPLICANT: O'Hare, Peter Francis Joseph
;; APPLICANT: Normand, Nadia Michelle
;; APPLICANT: Brewis, Neil Douglas
;; APPLICANT: Phelan, Anne
;; TITLE OF INVENTION: Uses of Transport Proteins
;; FILE REFERENCE: 5759-56969
;; CURRENT APPLICATION NUMBER: US/10/789,113
;; CURRENT FILING DATE: 2004-02-26
;; PRIOR APPLICATION NUMBER: US/09/747,772
;; PRIOR FILING DATE: 2000-12-20
;; NUMBER OF SEQ ID NOS: 5
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 4
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: synthetic construct
US-10-789-113-4

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGGGGG 1957
|||||
DB 20 GAGAGGGGAAGTGTGGGGG 1

RESULT 681

US-10-647-918-41/c
;; Sequence 41, Application US/10647918
;; Publication No. US20040152652A1
;; GENERAL INFORMATION:
;; APPLICANT: Baker, Brenda

```
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-ALPHA
; FILE REFERENCE: ISPH-0501
; CURRENT APPLICATION NUMBER: US/10/647,918
; CURRENT FILING DATE: 2003-08-26
; PRIOR APPLICATION NUMBER: US/09/824,322B
; PRIOR FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: US 09/313,932
; PRIOR FILING DATE: 1999-05-18
; PRIOR APPLICATION NUMBER: US 09/166,186
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 503
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: control sequence
US-10-647-918-41

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 682
US-10-647-918-49/c
; Sequence 49, Application US/10647918
; Publication No. US20040152652A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; APPLICANT: Butler, Madeline M.
; APPLICANT: Shanahan, William R.
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-ALPHA
; FILE REFERENCE: ISPH-0501
; CURRENT APPLICATION NUMBER: US/10/647,918
; CURRENT FILING DATE: 2003-08-26
; PRIOR APPLICATION NUMBER: US/09/824,322B
; PRIOR FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: US 09/313,932
; PRIOR FILING DATE: 1999-05-18
; PRIOR APPLICATION NUMBER: US 09/166,186
; PRIOR FILING DATE: 1998-10-05
; NUMBER OF SEQ ID NOS: 503
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: control sequence
US-10-647-918-49

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 683
US-10-777-838-1/c
; Sequence 1, Application US/10777838
```

```
; Publication No. US20040162259A1
; GENERAL INFORMATION:
; APPLICANT: Wedel, Mark K.
; APPLICANT: Miner, Philip B.
; TITLE OF INVENTION: Compositions and Methods for Treatment of Pouchitis
; FILE REFERENCE: ISIC0008-100
; CURRENT APPLICATION NUMBER: US/10/777,838
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/518,053
; PRIOR FILING DATE: 2003-11-07
; PRIOR APPLICATION NUMBER: 60/477,215
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 53
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-10-777-838-1

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 684
US-10-777-838-2/c
; Sequence 2, Application US/10777838
; Publication No. US20040162259A1
; GENERAL INFORMATION:
; APPLICANT: Wedel, Mark K.
; APPLICANT: Miner, Philip B.
; TITLE OF INVENTION: Compositions and Methods for Treatment of Pouchitis
; FILE REFERENCE: ISIC0008-100
; CURRENT APPLICATION NUMBER: US/10/777,838
; CURRENT FILING DATE: 2004-02-12
; PRIOR APPLICATION NUMBER: 60/518,053
; PRIOR FILING DATE: 2003-11-07
; PRIOR APPLICATION NUMBER: 60/477,215
; PRIOR FILING DATE: 2003-02-13
; NUMBER OF SEQ ID NOS: 53
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-10-777-838-2

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGTGTGGGG 1957
Db 20 GAGAGGGGAAGTGTGTGGGG 1

RESULT 685
US-10-727-109-1/c
; Sequence 1, Application US/10727109
; Publication No. US20040171044A1
; GENERAL INFORMATION:
; APPLICANT: PHOGEN, LIMITED
; APPLICANT: O'Hare, Peter Francis Joseph
; APPLICANT: Normand, Nadia Michelle
; TITLE OF INVENTION: DELIVERY OF SUBSTANCES TO CELLS
; FILE REFERENCE: 5759-54451
```

```
; CURRENT APPLICATION NUMBER: US/10/727,109
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: US/09/522,278B
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: GB 9930499.0
; PRIOR FILING DATE: 1999-12-24
; PRIOR APPLICATION NUMBER: GB 9905444.7
; PRIOR FILING DATE: 1999-03-10
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-727-109-1
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1938 GAGAGGGGAAGTGGTGGGG 1957
      |||||
DB 20 GAGAGGGGAAGTGGTGGGG 1
```

RESULT 686

```
US-10-727-109-6/c
; Sequence 6, Application US/10727109
; Publication No. US20040171044A1
; GENERAL INFORMATION:
; APPLICANT: PHOGEN, LIMITED
; APPLICANT: O'Hare, Peter Francis Joseph
; APPLICANT: Normand, Nadia Michelle
; TITLE OF INVENTION: DELIVERY OF SUBSTANCES TO CELLS
; FILE REFERENCE: 5759-54451
; CURRENT APPLICATION NUMBER: US/10/727,109
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: US/09/522,278B
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: GB 9930499.0
; PRIOR FILING DATE: 1999-12-24
; PRIOR APPLICATION NUMBER: GB 9905444.7
; PRIOR FILING DATE: 1999-03-10
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-727-109-6
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1938 GAGAGGGGAAGTGGTGGGG 1957
      |||||
DB 20 GAGAGGGGAAGTGGTGGGG 1
```

RESULT 687

```
US-10-727-109-9/c
; Sequence 9, Application US/10727109
; Publication No. US20040171044A1
; GENERAL INFORMATION:
; APPLICANT: PHOGEN, LIMITED
; APPLICANT: O'Hare, Peter Francis Joseph
; APPLICANT: Normand, Nadia Michelle
; TITLE OF INVENTION: DELIVERY OF SUBSTANCES TO CELLS
```

```
; FILE REFERENCE: 5759-54451
; CURRENT APPLICATION NUMBER: US/10/727,109
; CURRENT FILING DATE: 2003-12-02
; PRIOR APPLICATION NUMBER: US/09/522,278B
; PRIOR FILING DATE: 2000-03-09
; PRIOR APPLICATION NUMBER: GB 9930499.0
; PRIOR FILING DATE: 1999-12-24
; PRIOR APPLICATION NUMBER: GB 9905444.7
; PRIOR FILING DATE: 1999-03-10
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-10-727-109-9
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1938 GAGAGGGGAAGTGGTGGGG 1957
      |||||
DB 20 GAGAGGGGAAGTGGTGGGG 1
```

RESULT 688

```
US-10-760-940-2/c
; Sequence 2, Application US/10760940
; Publication No. US20040219577A1
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulinga
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Capaldi, Daniel C.
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas L.
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS
; FILE REFERENCE: ISIS-5422
; CURRENT APPLICATION NUMBER: US/10/760,940
; CURRENT FILING DATE: 2004-01-20
; PRIOR APPLICATION NUMBER: US 10/232,881
; PRIOR FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US 09/288,679
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: US 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-760-940-2
```

```
Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2100 TGACGGATGCCAGCTTGGGC 2119
      |||||
DB 20 TGACGGATGCCAGCTTGGGC 1
```

RESULT 689

```
US-10-760-940-4/c
; Sequence 4, Application US/10760940
; Publication No. US20040219577A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ravikumar, Vasulinga
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Capaldi, Daniel C.
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas L.
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS
; FILE REFERENCE: ISIS-5422
; CURRENT APPLICATION NUMBER: US/10/760,940
; CURRENT FILING DATE: 2004-01-20
; PRIOR APPLICATION NUMBER: US/10/232,881
; PRIOR FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US 09/288,679
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: US 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Phosphorothioate backbone
US-10-760-940-4

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 690
US-10-872-113-65
; Sequence 65, Application US/10872113
; Publication No. US20040229275A1
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
; APPLICANT: Pimstone, Simon
; APPLICANT: Brooks-Wilson, Angela R.
; APPLICANT: Clee, Susanne M.
; TITLE OF INVENTION: Compositions and Methods for Modulating
; TITLE OF INVENTION: HDL Cholesterol and Triglyceride Levels
; FILE REFERENCE: 760050-138
; CURRENT APPLICATION NUMBER: US/10/872,113
; CURRENT FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 09/654,323
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: US 60/124,702
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: US 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: US 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: US 60/151,977
; PRIOR FILING DATE: 1999-09-01
; PRIOR APPLICATION NUMBER: US 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: US 60/213,958
; PRIOR FILING DATE: 2000-06-23
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: word for Windows Version 6.0 (ASCII Text)
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: homo sapien
US-10-872-113-65

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2825 GGCTCAAGTGATCTCTCCAC 2844
Db 1 GGCTCAAGTGATCTCTCCAC 20

RESULT 691
US-10-793-497-1/c
; Sequence 1, Application US/10793497
; Publication No. US20040229831A1
; GENERAL INFORMATION:
; APPLICANT: Teng, Ching-Leou
; APPLICANT: Cook, Phillip D
; APPLICANT: Tillman, Lloyd
; APPLICANT: Hardee, Gregory E
; APPLICANT: Ecker, David J
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Compositions and Methods for Non-Parenteral Delivery of
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: ISIC0001-104
; CURRENT APPLICATION NUMBER: US/10/793,497
; CURRENT FILING DATE: 2004-03-05
; PRIOR APPLICATION NUMBER: 09/082,624
; PRIOR FILING DATE: 1999-05-21
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-10-793-497-1

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 692
US-10-793-497-2/c
; Sequence 2, Application US/10793497
; Publication No. US20040229831A1
; GENERAL INFORMATION:
; APPLICANT: Teng, Ching-Leou
; APPLICANT: Cook, Phillip D
; APPLICANT: Tillman, Lloyd
; APPLICANT: Hardee, Gregory E
; APPLICANT: Ecker, David J
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Compositions and Methods for Non-Parenteral Delivery of
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: ISIC0001-104
; CURRENT APPLICATION NUMBER: US/10/793,497
; CURRENT FILING DATE: 2004-03-05
; PRIOR APPLICATION NUMBER: 09/082,624
; PRIOR FILING DATE: 1999-05-21
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-10-793-497-2

Query Match          0.7%; Score 20; DB 1; Length 20;
```

```
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
    |||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 693
US-10-793-497-55/c
; Sequence 55, Application US/10793497
; Publication No. US20040229831A1
; GENERAL INFORMATION:
; APPLICANT: Teng, Ching-Leou
; APPLICANT: Cook, Phillip D
; APPLICANT: Tillman, Lloyd
; APPLICANT: Hardee, Gregory E
; APPLICANT: Becker, David J
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: Compositions and Methods for Non-Parenteral Delivery of
; FILE REFERENCE: Oligonucleotides
; CURRENT APPLICATION NUMBER: US/10/793,497
; CURRENT FILING DATE: 2004-03-05
; PRIOR APPLICATION NUMBER: 09/082,624
; PRIOR FILING DATE: 1999-05-21
; NUMBER OF SEQ ID NOS: 58
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-10-793-497-55

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
    |||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 694
US-10-807-114-145/c
; Sequence 145, Application US/10807114
; Publication No. US20040235024A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/10/807,114
; CURRENT FILING DATE: 2004-03-23
; PRIOR APPLICATION NUMBER: US/09/882,945
; PRIOR FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 145
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-807-114-145

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
    |||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 695
US-10-807-114-147/c
; Sequence 147, Application US/10807114
; Publication No. US20040235024A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/10/807,114
; CURRENT FILING DATE: 2004-03-23
; PRIOR APPLICATION NUMBER: US/09/882,945
; PRIOR FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 147
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-807-114-147

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 7 CAGTCGACGCTGAGCTCCTC 26
    |||||
Db 20 CAGTCGACGCTGAGCTCCTC 1

RESULT 696
US-10-807-114-148/c
; Sequence 148, Application US/10807114
; Publication No. US20040235024A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/10/807,114
; CURRENT FILING DATE: 2004-03-23
; PRIOR APPLICATION NUMBER: US/09/882,945
; PRIOR FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 148
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-807-114-148

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 337 TCAAACTGCCCTGATGGGCA 356
```

```
Db      20 TCACAACTGCCCTGATGGGCA 1
|||||
RESULT 697
US-10-807-114-149/c
; Sequence 149, Application US/10807114
; Publication No. US20040235024A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Venzel, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/10/807,114
; CURRENT FILING DATE: 2004-03-23
; PRIOR APPLICATION NUMBER: US/09/882,945
; PRIOR FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 149
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-807-114-149
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db      20 TGACGGATGCCAGCTTGGGC 1

RESULT 698
US-10-641-962-17/c
; Sequence 17, Application US/10641962
; Publication No. US20040235164A1
; GENERAL INFORMATION:
; APPLICANT: Bennett et al.
; TITLE OF INVENTION: Oligonucleotide Compositions and Methods for the
; FILE REFERENCE: Modulation of the Expression of B7 Protein
; FILE REFERENCE: 30566/39578
; CURRENT APPLICATION NUMBER: US/10/641,962
; CURRENT FILING DATE: 2003-08-15
; NUMBER OF SEQ ID NOS: 444
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic primer
; PUBLICATION INFORMATION:
; PATENT DOCUMENT NUMBER: US 5514788
; PATENT FILING DATE: 1993 05 17
; PUBLICATION DATE: 1996 05 07
US-10-641-962-17
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db      20 TGACGGATGCCAGCTTGGGC 1

RESULT 699
US-10-863-999-41/c
; Sequence 41, Application US/10863999
; Publication No. US20040265885A1
; GENERAL INFORMATION:
; APPLICANT: BREIPOHL, GERHARD
; APPLICANT: WILL, DAVID W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
; FILE REFERENCE: 02481.1742 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/10/863,999
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: US/09/835,370
; PRIOR FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: nucleotide
; OTHER INFORMATION: base sequence of PNA derivatives that bind to
; OTHER INFORMATION: viral and cellular targets
US-10-863-999-41
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db      20 TGACGGATGCCAGCTTGGGC 1

RESULT 700
US-10-863-999-42/c
; Sequence 42, Application US/10863999
; Publication No. US20040265885A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; APPLICANT: WILL, DAVID W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
; FILE REFERENCE: 02481.1742 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/10/863,999
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: US/09/835,370
; PRIOR FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: nucleotide
; OTHER INFORMATION: base sequence of PNA derivatives that bind to
; OTHER INFORMATION: viral and cellular targets
US-10-863-999-42
Query Match      0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db      20 GAGAGGGGAAGTGGTGGGG 1

RESULT 701
```

US-10-863-999-43/c
; Sequence 43, Application US/10863999
; Publication No. US20040265885A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; APPLICANT: WILL, DAVID W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
; TITLE OF INVENTION: PROCESSES FOR PREPARING THEM
; FILE REFERENCE: 02481.1742 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/10/863,999
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: US/09/835,370
; PRIOR FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: nucleotide
; OTHER INFORMATION: base sequence of PNA derivatives that bind to
; OTHER INFORMATION: viral and cellular targets
US-10-863-999-43
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1940 GAGGGGAAGTGTGGGGGAG 1959
|||||
DB 20 GAGGGGAGTGTGGGGGAG 1
RESULT 702
US-10-925-734-2/c
; Sequence 2, Application US/10925734
; Publication No. US20050008689A1
; GENERAL INFORMATION:
; APPLICANT: Inex Pharmaceuticals Inc.
; TITLE OF INVENTION: High Efficiency Encapsulation of Charged
; Therapeutic Agents in Lipid Vesicles
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Oppedahl & Larson LLP
; STREET: PO Box 5068
; CITY: Dillon
; STATE: CO
; COUNTRY: US
; ZIP: 80435
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS 5.0
; SOFTWARE: Word Perfect
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/925,734
; FILING DATE: 24-Aug-2004
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/895,480
; FILING DATE: 29-Jun-2001
; ATTORNEY/AGENT INFORMATION:
; NAME: <Unknown>
; REGISTRATION NUMBER: <Unknown>
; REFERENCE/DOCKET NUMBER: <Unknown>
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: <Unknown>
; TELEFAX: <Unknown>
; TELEX: <Unknown>

; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; HYPOTHETICAL: no
; ANTI-SENSE: yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-925-734-2
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
DB 20 TGACGGATGCCAGCTTGGGC 1
RESULT 703
US-10-858-658-41/c
; Sequence 41, Application US/10858658
; Publication No. US20050009073A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; APPLICANT: WILL, DAVID W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES, AND AGENTS AND
; TITLE OF INVENTION: PROCESSES FOR PREPARING THEM
; FILE REFERENCE: 02481.1743 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/10/858,658
; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: US/09/835,371
; PRIOR FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: base sequence
; OTHER INFORMATION: of PNA targeting CMV
US-10-858-658-41
Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
DB 20 TGACGGATGCCAGCTTGGGC 1
RESULT 704
US-10-858-658-42/c
; Sequence 42, Application US/10858658
; Publication No. US20050009073A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; APPLICANT: WILL, DAVID W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES, AND AGENTS AND
; TITLE OF INVENTION: PROCESSES FOR PREPARING THEM
; FILE REFERENCE: 02481.1743 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/10/858,658
; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: US/09/835,371
; PRIOR FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.1


```
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: base sequence
; OTHER INFORMATION: of PNA targeting CMV
US-10-858-658-42

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
      |||||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 705
US-10-858-658-43/c
; Sequence 43, Application US/10858658
; Publication No. US2005009073A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, Eugen
; APPLICANT: BREIPOHL, Gerhard
; APPLICANT: WILL, David W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES, AND AGENTS AND
; TITLE OF INVENTION: PROCESSES FOR PREPARING THEM
; FILE REFERENCE: 02481.1743 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/10/858,658
; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: US/09/835,371
; PRIOR FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: base sequence
; OTHER INFORMATION: of PNA targeting CMV
US-10-858-658-43

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGAG 1959
      |||||||
Db 20 GAGGGGAAGTGGTGGGGAG 1

RESULT 706
US-10-916-256-13
; Sequence 13, Application US/10916256
; Publication No. US2005009106A1
; GENERAL INFORMATION:
; APPLICANT: de Waal Malefyt, Rene
; APPLICANT: Fickenscher, Helmut
; APPLICANT: Fleckenstein, Bernhard
; APPLICANT: Knappe, Andrea
; TITLE OF INVENTION: MAMMALIAN CYTOKINE; RELATED REAGENTS
; FILE REFERENCE: DX0644KEK
; CURRENT APPLICATION NUMBER: US/10/916,256
; CURRENT FILING DATE: 2004-08-10
; PRIOR APPLICATION NUMBER: US/10/083,720
; PRIOR FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 09/363,993
; PRIOR FILING DATE: 1999-07-29
; PRIOR APPLICATION NUMBER: 08/934,959
; PRIOR FILING DATE: 1997-09-22
; PRIOR APPLICATION NUMBER: 60/345,690
```

```
; PRIOR FILING DATE: 2002-01-03
; PRIOR APPLICATION NUMBER: 60/302,176
; PRIOR FILING DATE: 2001-06-28
; PRIOR APPLICATION NUMBER: 60/027,368
; PRIOR FILING DATE: 1996-09-23
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: ICAM-1 forward.
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: ICAM-1 forward.
US-10-916-256-13

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 950 GCCAGGAGACACTGCAGACA 969
      |||||||
Db 1 GCCAGGAGACACTGCAGACA 20

RESULT 707
US-10-624-570-1
; Sequence 1, Application US/10624570
; Publication No. US20050026152A1
; GENERAL INFORMATION:
; APPLICANT: Muller, Norbert
; TITLE OF INVENTION: Method of Screening Schizophrenia
; FILE REFERENCE: 03-1039
; CURRENT APPLICATION NUMBER: US/10/624,570
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: US 60/397,611
; PRIOR FILING DATE: 2002-07-23
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Primer derived from human ICAM-1 gene
US-10-624-570-1

Query Match          0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 706 ACTCCCCCACAACCTGTCTCAG 725
      |||||||
Db 1 ACTCCCCCACAACCTGTCTCAG 20

RESULT 708
US-10-858-917-1/c
; Sequence 1, Application US/10858917
; Publication No. US20050026192A1
; GENERAL INFORMATION:
; APPLICANT: Moore, Max N.
; APPLICANT: Andrade, Mark
; APPLICANT: Carty, Recaldo
; APPLICANT: Scozzari, Anthony
; APPLICANT: Krotz, Achim
; TITLE OF INVENTION: OLIGONUCLEOTIDE SYNTHESIS WITH ALTERNATIVE SOLVENTS
; FILE REFERENCE: ISIC0014-100 (DVCW0003US)
; CURRENT APPLICATION NUMBER: US/10/858,917
; CURRENT FILING DATE: 2004-06-02
```

; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-858-917-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 709

US-10-858-917-4/c
; Sequence 4, Application US/10858917
; Publication No. US20050026192A1
; GENERAL INFORMATION:
; APPLICANT: Moore, Max N.
; APPLICANT: Andrade, Mark
; APPLICANT: Carthy, Recaldo
; APPLICANT: Scozzari, Anthony
; APPLICANT: Krotz, Achim
; TITLE OF INVENTION: OLIGONUCLEOTIDE SYNTHESIS WITH ALTERNATIVE SOLVENTS
; FILE REFERENCE: ISIC0014-100 (DVCN0003US)
; CURRENT APPLICATION NUMBER: US/10/858,917
; CURRENT FILING DATE: 2004-06-02
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-O-methoxyethyl-2'-deoxyribonucleosyl residue
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (16)..(20)
; OTHER INFORMATION: 2'-O-methoxyethyl-2'-deoxyribonucleosyl residue
US-10-858-917-4

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 710

US-10-939-214-20/c
; Sequence 20, Application US/10939214
; Publication No. US20050026817A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/10/939,214
; CURRENT FILING DATE: 2004-09-10
; PRIOR APPLICATION NUMBER: US/09/793,146

; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14
; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-10-939-214-20

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 711

US-10-939-214-21/c
; Sequence 21, Application US/10939214
; Publication No. US20050026817A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/10/939,214
; CURRENT FILING DATE: 2004-09-10
; PRIOR APPLICATION NUMBER: US/09/793,146
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14
; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-10-939-214-21

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1940 GAGGGGAAGTGGTGGGGAG 1959
|||||
Db 20 GAGGGGAAGTGGTGGGGAG 1

RESULT 712

US-10-755-166-17/c
; Sequence 17, Application US/10755166
; Publication No. US20050043219A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Bennett, Clarence Frank
; TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake and Other Pr
; FILE REFERENCE: ISIS-5024
; CURRENT APPLICATION NUMBER: US/10/755,166
; CURRENT FILING DATE: 2004-01-09

; PRIOR APPLICATION NUMBER: US/10/073,718
; PRIOR FILING DATE: 2002-02-11
; PRIOR APPLICATION NUMBER: 09/633659
; PRIOR FILING DATE: 2000-08-07
; PRIOR APPLICATION NUMBER: 6153737
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 08/211882
; PRIOR FILING DATE: 1994-04-22
; PRIOR APPLICATION NUMBER: PCT/US92/09196
; PRIOR FILING DATE: 1992-10-23
; PRIOR APPLICATION NUMBER: 07/782374
; PRIOR FILING DATE: 1991-10-24
; PRIOR APPLICATION NUMBER: 07/566977
; PRIOR FILING DATE: 1990-08-13
; PRIOR APPLICATION NUMBER: PCT/US91/000243
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 08/463358
; PRIOR FILING DATE: 1990-01-11
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Novel Sequence
US-10-755-166-17

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 713

US-10-770-970-41/c
; Sequence 41, Application US/10770970
; Publication No. US20050053965A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-?
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0826
; CURRENT APPLICATION NUMBER: US 10/770,970
; CURRENT FILING DATE: 2004-02-02
; PRIOR APPLICATION NUMBER: US 10/647,918
; PRIOR FILING DATE: 2003-08-26
; PRIOR APPLICATION NUMBER: US 10/652,795
; PRIOR FILING DATE: 2003-08-29
; NUMBER OF SEQ ID NOS: 566
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: control sequence
US-10-770-970-41

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 714

US-10-770-970-49/c

; Sequence 49, Application US/10770970
; Publication No. US20050053965A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE MODULATION OF TUMOR NECROSIS FACTOR-?
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: ISPH-0826
; CURRENT APPLICATION NUMBER: US/10/770,970
; CURRENT FILING DATE: 2004-02-02
; PRIOR APPLICATION NUMBER: US 10/647,918
; PRIOR FILING DATE: 2003-08-26
; PRIOR APPLICATION NUMBER: US 10/652,795
; PRIOR FILING DATE: 2003-08-29
; NUMBER OF SEQ ID NOS: 566
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: control sequence
US-10-770-970-49

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
|||||
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 715

US-10-792-374-3/c
; Sequence 3, Application US/10792374
; Publication No. US20050079513A1
; GENERAL INFORMATION:
; APPLICANT: Applied Biosystems
; APPLICANT: Lossos, Izidore
; APPLICANT: Tibshirani, Rob
; APPLICANT: Wechsler, Mark
; APPLICANT: Alizadeh, Ash
; APPLICANT: Botstein, David
; APPLICANT: Levy, Ronald
; TITLE OF INVENTION: CLASSIFICATION OF PATIENTS HAVING DIFFUSE LARGE B-CELL LYMPHOMA
; TITLE OF INVENTION: BASED UPON GENE EXPRESSION
; FILE REFERENCE: 9692-000042
; CURRENT APPLICATION NUMBER: US/10/792,374
; CURRENT FILING DATE: 2004-03-03
; PRIOR APPLICATION NUMBER: 60/510,822
; PRIOR FILING DATE: 2003-10-14
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-792-374-3

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 131 GCAATGCCCAGACATCTGTG 150
|||||
Db 20 GCAATGCCCAGACATCTGTG 1

RESULT 716

US-10-876-962A-1/c
; Sequence 1, Application US/10876962A
; Publication No. US20050096287A1
; GENERAL INFORMATION:

; APPLICANT: MEHTA, RAHUL
; APPLICANT: HARDEE, GREGORY E.
; APPLICANT: COOK, PHILLIP DAN
; APPLICANT: ECKER, DAVID J.
; APPLICANT: TSAI, YALI JENNIFER
; APPLICANT: TEMPLIN, MICHAEL V.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF OLIGONUCLEOTIDES
; FILE REFERENCE: ISIC0003-102 (ISIS-3535US)
; CURRENT APPLICATION NUMBER: US/10/876,962A
; CURRENT FILING DATE: 2004-06-25
; PRIOR APPLICATION NUMBER: US 09/315,294
; PRIOR FILING DATE: 1999-05-20
; PRIOR APPLICATION NUMBER: US 09/082,336
; PRIOR FILING DATE: 1998-05-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense
US-10-876-962A-1

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 717

US-10-876-962A-2/c

; Sequence 2, Application US/10876962A
; Publication No. US20050096287A1
; GENERAL INFORMATION:
; APPLICANT: MEHTA, RAHUL
; APPLICANT: HARDEE, GREGORY E.
; APPLICANT: COOK, PHILLIP DAN
; APPLICANT: ECKER, DAVID J.
; APPLICANT: TSAI, YALI JENNIFER
; APPLICANT: TEMPLIN, MICHAEL V.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR TOPICAL DELIVERY OF OLIGONUCLEOTIDES
; FILE REFERENCE: ISIC0003-102 (ISIS-3535US)
; CURRENT APPLICATION NUMBER: US/10/876,962A
; CURRENT FILING DATE: 2004-06-25
; PRIOR APPLICATION NUMBER: US 09/315,294
; PRIOR FILING DATE: 1999-05-20
; PRIOR APPLICATION NUMBER: US 09/082,336
; PRIOR FILING DATE: 1998-05-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense
US-10-876-962A-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 718

US-10-940-360-2/c

; Sequence 2, Application US/10940360
; Publication No. US20050137391A1
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulinga
; APPLICANT: Manoharan, Muthia
; APPLICANT: Capaldi, Daniel
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: Improved Process for the Synthesis of Oligomeric Compounds
; FILE REFERENCE: ISIS3380
; CURRENT APPLICATION NUMBER: US/10/940,360
; CURRENT FILING DATE: 2004-09-14
; PRIOR APPLICATION NUMBER: US/09/288,679
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Novel Sequence
US-10-940-360-2

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2100 TGACGGATGCCAGCTTGGGC 2119
|||||
Db 20 TGACGGATGCCAGCTTGGGC 1

RESULT 719

US-10-940-360-4/c

; Sequence 4, Application US/10940360
; Publication No. US20050137391A1
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulinga
; APPLICANT: Manoharan, Muthia
; APPLICANT: Capaldi, Daniel
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: Improved Process for the Synthesis of Oligomeric Compounds
; FILE REFERENCE: ISIS3380
; CURRENT APPLICATION NUMBER: US/10/940,360
; CURRENT FILING DATE: 2004-09-14
; PRIOR APPLICATION NUMBER: US/09/288,679
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Phosphorothioate backbone
US-10-940-360-4

Query Match 0.7%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
|||||
Db 20 GAGAGGGGAAGTGGTGGGG 1

```
RESULT 720
US-10-084-839-3887/c
; Sequence 3887, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lymaicheva, Victor
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilynn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tsatska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 3887
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-3887

Query Match          0.7%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1594 AGACTACAAAGGCCCAAAA 1613
Db 20 AGACTACAAAGGCCCAAAA 1

RESULT 721
US-09-982-2628-27/c
; Sequence 27, Application US/099822628
; Publication No. US2003007565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,2628
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
```

```
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 27
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-2628-27

Query Match          0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 722
US-10-454-663-27/c
; Sequence 27, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 27
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-27

Query Match          0.7%; Score 20; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 18 GAGCTCCTCTGCTACTCAGA 37
Db 20 GAGCTCCTCTGCTACTCAGA 1

RESULT 723
US-09-860-784-87/c
; Sequence 87, Application US/09860784
; Patent No. US200201512A1
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anushirwan
; APPLICANT: UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
```

;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Foley & Lardner
;; STREET: 3000 K Street, N.W., Suite 500
;; CITY: Washington
;; STATE: D.C.
;; COUNTRY: USA
;; ZIP: 20007-5109
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.30
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/860,784
;; FILING DATE: 21-May-2001
;; CLASSIFICATION: <Unknown>
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/594,452
;; FILING DATE: 04-APR-1996
;; ATTORNEY/AGENT INFORMATION:
;; NAME: SANDERCOCK, Colin G.
;; REGISTRATION NUMBER: 31,298
;; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (202)672-5300
;; TELEFAX: (202)672-5399
;; TELEX: 904136
;; INFORMATION FOR SEQ ID NO: 87:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 24 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; SEQUENCE DESCRIPTION: SEQ ID NO: 87:
US-09-860-784-87

Query Match 0.7%; Score 20; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
DB 24 GAGAGGGGAAGTGGTGGGG 5

RESULT 724
US-09-860-784-88/c
; Sequence 88, Application US/09860784
; Patent No. US200201512A1
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anuschirwan
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/860,784
; FILING DATE: 21-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/594,452
; FILING DATE: 04-APR-1996

;; ATTORNEY/AGENT INFORMATION:
;; NAME: SANDERCOCK, Colin G.
;; REGISTRATION NUMBER: 31,298
;; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (202)672-5300
;; TELEFAX: (202)672-5399
;; TELEX: 904136
;; INFORMATION FOR SEQ ID NO: 88:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 24 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; SEQUENCE DESCRIPTION: SEQ ID NO: 88:
US-09-860-784-88

Query Match 0.7%; Score 20; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1938 GAGAGGGGAAGTGGTGGGG 1957
DB 20 GAGAGGGGAAGTGGTGGGG 1

RESULT 725
US-10-956-157-26681
; Sequence 26681, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 26681
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-26681

Query Match 0.7%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2731 TGTGTGTGTGTGTGTGTGT 2750
DB 2 TGTGTGTGTGTGTGTGTGT 21

RESULT 726
US-10-956-157-26683
; Sequence 26683, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO: 26683
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence

US-10-956-157-26683

Query Match 0.7%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2731 TGTGTGTGTGTGTATGTGTA 2750
|||||
Db 1 TGTGTGTGTGTATGTGTA 20

RESULT 727

US-10-956-157-206690
; Sequence 206690, Application US/10956157
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 206690

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-206690

Query Match 0.7%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTGCAGTGG 2790
|||||
Db 2 CCCAGGCTGGAGTGCAGTGG 21

RESULT 728

US-10-956-157-216381/c
; Sequence 216381, Application US/10956157
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 216381

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-216381

Query Match 0.7%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2766 TGTCACCCAGGCTGGAGTGC 2785
|||||
Db 20 TGTCACCCAGGCTGGAGTGC 1

RESULT 729

US-10-956-157-216382/c
; Sequence 216382, Application US/10956157
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 216382

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-216382

Query Match 0.7%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2766 TGTCACCCAGGCTGGAGTGC 2785
|||||
Db 20 TGTCACCCAGGCTGGAGTGC 1

RESULT 730

US-10-956-157-292271/c
; Sequence 292271, Application US/10956157
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 292271

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-292271

Query Match 0.7%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2766 TGTCACCCAGGCTGGAGTGC 2785
|||||
Db 22 TGTCACCCAGGCTGGAGTGC 3

RESULT 731

US-10-357-488-5
; Sequence 5, Application US/10357488
; Publication No. US20030194730A1

; GENERAL INFORMATION:

; APPLICANT: Centre For DNA Fingerprinting and Diagnostics

; TITLE OF INVENTION: No. US20030194730A1el FISRR-PCR primers and markers and a method

; TITLE OF INVENTION: primers and markers for identifying genetic constitution and br

; FILE REFERENCE: 782-indian

; CURRENT APPLICATION NUMBER: US/10/357,488

; CURRENT FILING DATE: 2003-02-04

; PRIOR APPLICATION NUMBER: 260/MAS/2002

; PRIOR FILING DATE: 2002-04-08

; NUMBER OF SEQ ID NOS: 37

; SOFTWARE: PatentIn version 3.1

; SEQ ID NO 5

; LENGTH: 23

; TYPE: DNA

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: A novel FISSR-PCR primer for genotyping eukaryotes
US-10-357-488-5

Query Match          0.7%; Score 19.8; DB 1; Length 23;
Best Local Similarity 91.3%; Pred. No. 4.3e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2727 CGTGTGTGTGTGTGTGTGTGT 2749
Db 1 CGTATGTGTGTGTGTGTGTGT 23

RESULT 732
US-09-784-423-96/c
; Sequence 96, Application US/09784423
; Patent No. US20020012924A1
; GENERAL INFORMATION:
; APPLICANT: Schumm, James W.
; Bacher, Jeffery W.
; TITLE OF INVENTION: MATERIALS AND METHODS FOR
; IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM
; REPEAT DNA MARKERS
; NUMBER OF SEQUENCES: 147
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Promega Corporation
; STREET: 2800 Woods Hollow Road
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: U.S.A.
; ZIP: 53711-5399
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb
; COMPUTER: IBM compatible PC
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Word 97 (DOS text format)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/784,423
; FILING DATE: 15-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/018,584
; FILING DATE: 04-Feb-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Grady J. Frenchick
; REGISTRATION NUMBER: 29,018
; REFERENCE/DOCKET NUMBER: 16026.9180
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 257-3501
; TELEFAX: (608) 257-2275
; INFORMATION FOR SEQ ID NO: 96
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 96
US-09-784-423-96

Query Match          0.7%; Score 19.8; DB 1; Length 24;
Best Local Similarity 91.3%; Pred. No. 4.1e+02;
Matches 21; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2766 TGTACCCAGGCTGGAGTGCAGT 2788
Db 23 TATCACCCAGGCTGGAGTGCAT 1

RESULT 733
US-10-730-771-119
; Sequence 119, Application US/10730771
; Publication No. US20050074787A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Hirschhorn, Joel N.
; APPLICANT: Huang, Xiaohua
; APPLICANT: Kaplan, Paul
; APPLICANT: Lander, Eric S.
; APPLICANT: Lockhart, David J.
; APPLICANT: Ryder, Thomas
; APPLICANT: Sklar, Pamela
; TITLE OF INVENTION: UNIVERSAL ARRAYS
; FILE REFERENCE: 2825.1016-007
; CURRENT APPLICATION NUMBER: US/10/730,771
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: US 60/126,473
; PRIOR FILING DATE: 1999-03-26
; PRIOR APPLICATION NUMBER: US 60/140,359
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/536,841
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 590
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 119
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Template sequence
US-10-730-771-119

Query Match          0.7%; Score 19.6; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 4.9e+02;
Matches 19; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1238 ATGGCCCCGACTGACGACG 1257
Db 2 ATGGCCCCCRACTGGACGAG 21

RESULT 734
US-09-735-363A-19
; Sequence 19, Application US/09735363A
; Patent No. US20010041681A1
; GENERAL INFORMATION:
; APPLICANT: Fillion, Mario
; APPLICANT: Phillip, Nigel
; TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
; FILE REFERENCE: 02811-0181
; CURRENT APPLICATION NUMBER: US/09/735,363A
; CURRENT FILING DATE: 2000-12-12
; PRIOR APPLICATION NUMBER: 60/170,325
; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: 60/228,925
; PRIOR FILING DATE: 2000-08-29
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 19
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-19

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 5.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2749
Db 1 TGTGTGTGTGTGTGTGTGT 21

RESULT 735
```



```
US-09-735-363A-20
; Sequence 20, Application US/09735363A
; Patent No. US20010041681A1
; GENERAL INFORMATION:
; APPLICANT: Filion, Mario
; APPLICANT: Phillip, Nigel
; TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
; FILE REFERENCE: 02811-0181
; CURRENT APPLICATION NUMBER: US/09/735,363A
; PRIOR FILING DATE: 2000-12-12
; PRIOR APPLICATION NUMBER: 60/170,325
; PRIOR FILING DATE: 1999-12-13
; PRIOR APPLICATION NUMBER: 60/228,925
; PRIOR FILING DATE: 2000-08-29
; NUMBER OF SEQ ID NOS: 87
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 20
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-20

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 5.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTATGTG 2748
|||
1 GTGTGTGTGTGTGTGTGTGTG 21
Db

RESULT 736
US-09-998-425-61
; Sequence 61, Application US/09998425
; Publication No. US20030008346A1
; GENERAL INFORMATION:
; APPLICANT: Bartel, Paul L.
; APPLICANT: Tavtigian, Sean V.
; TITLE OF INVENTION: MMSC1 - An MMAC1 Interacting Protein
; FILE REFERENCE: MMSC1 Gene
; CURRENT APPLICATION NUMBER: US/09/998,425
; CURRENT FILING DATE: 2001-12-03
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: 09/233,086
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-01-19
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/071,861
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-01-20
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 61
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:MMSC1 Primers
US-09-998-425-61

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 5.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTGTCACCCAGGCTG 2779
|||
1 CTTGCTCTGTGTCACCCAGGCTG 21
Db

RESULT 737
US-09-997-977-61
; Sequence 61, Application US/09997977
; Publication No. US20030027228A1
; GENERAL INFORMATION:
; APPLICANT: Bartel, Paul L.
; APPLICANT: Tavtigian, Sean V.
; TITLE OF INVENTION: MMSC1 - An MMAC1 Interacting Protein
; FILE REFERENCE: MMSC1 Gene
; CURRENT APPLICATION NUMBER: US/09/997,977
; CURRENT FILING DATE: 2001-12-03
; PRIOR APPLICATION NUMBER: 09/233,086
; PRIOR FILING DATE: 1999-01-19
; PRIOR APPLICATION NUMBER: US 60/071,861
; PRIOR FILING DATE: 1998-01-20
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 61
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:MMSC1 Primers
US-09-997-977-61

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 5.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTGTCACCCAGGCTG 2779
|||
1 CTTGCTCTGTGTCACCCAGGCTG 21
Db

RESULT 738
US-09-776-479-907
; Sequence 907, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 907
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-907

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 5.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATGTGT 2749
|||
1 TGTGTGTGTGTGTGTGTGTGT 21
Db

RESULT 739
US-09-776-479-907
; Sequence 907, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
```

```
; APPLICANT: Bartel, Paul L.
; APPLICANT: Tavtigian, Sean V.
; APPLICANT: Myriad Genetics, Inc.
; TITLE OF INVENTION: MMSC1 - An MMAC1 Interacting Protein
; FILE REFERENCE: MMSC1 Gene
; CURRENT APPLICATION NUMBER: US/09/997,977
; CURRENT FILING DATE: 2001-12-03
; PRIOR APPLICATION NUMBER: 09/233,086
; PRIOR FILING DATE: 1999-01-19
; PRIOR APPLICATION NUMBER: US 60/071,861
; PRIOR FILING DATE: 1998-01-20
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 61
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:MMSC1 Primers
US-09-997-977-61

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 5.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTGTCACCCAGGCTG 2779
|||
1 CTTGCTCTGTGTCACCCAGGCTG 21
Db

RESULT 738
US-09-776-479-907
; Sequence 907, Application US/09776479
; Publication No. US20030087848A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/776,479
; CURRENT FILING DATE: 2001-02-02
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 907
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-09-776-479-907

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 5.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATGTGT 2749
|||
1 TGTGTGTGTGTGTGTGTGTGT 21
Db

RESULT 739
US-09-776-479-907
; Sequence 907, Application US/09776479
; Publication No. US20040067902A9
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
```

US-09-776-479-907

Quercus: Monticola

DEC 10 1967

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

1. THE STATE OF TEXAS, County of EL PASO, do hereby certify that JOSEPH A. GARCIA is the duly qualified and authorized representative of the EL PASO COUNTY in the SEVENTH Congressional District of the State of Texas.

; SEQ ID NO 307

; SEQ ID NO 307

```
; SEQ ID NO 907
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-314-578-907

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 5.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TCTGTGTGTGTGTGTGTGTGTGT 2749
Db 1 TCTGTGTGTGTGTGTGTGTGTGT 21

RESULT 744
US-10-051-874-259/c
; Sequence 259, Application US/10051874
; Publication No. US20040005557A1
; GENERAL INFORMATION:
; APPLICANT: Padigar, Muralidhara
; APPLICANT: Alsobrook II, John P
; APPLICANT: Coleman, Steven D
; APPLICANT: Spytek, Kimberly A
; APPLICANT: Boldog, Ferenc
; APPLICANT: Vernet, Corine AM
; APPLICANT: Li, Li
; APPLICANT: Shenoy, Suresh G
; APPLICANT: Casman, Stacie J
; APPLICANT: Guo, Xiaojia Sasha
; APPLICANT: Edinger, Shlomit R
; APPLICANT: MacDougall, John R
; APPLICANT: Malyankar, Uriel M
; APPLICANT: Patturajan, Meera
; APPLICANT: Shinkets, Richard A
; APPLICANT: Pena, Carol EA
; APPLICANT: Tchernev, Velizar T
; APPLICANT: Zerhusen, Bryan D
; APPLICANT: Millet, Isabelle
; APPLICANT: Miller, Charles E
; APPLICANT: Lepley, Denise M
; APPLICANT: Smithson, Glenna
; APPLICANT: Baumgartner, Jason C
; APPLICANT: Herrman, John L
; APPLICANT: Peyman, John A
; APPLICANT: Gorman, Linda
; APPLICANT: Mezes, Peter D
; APPLICANT: Kekuda, Ramesh
; APPLICANT: Taupier Jr, Raymond J
; APPLICANT: Gerlach, Valerie
; APPLICANT: Grosse, William M
; APPLICANT: Liu, Xiaohong
; APPLICANT: Ellerman, Karen
; APPLICANT: Rothenberg, Mark
; APPLICANT: Stone, David J
; APPLICANT: Burgess, Catherine E
; TITLE OF INVENTION: PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF
; FILE REFERENCE: 21402-245
; CURRENT APPLICATION NUMBER: US/10/051,874
; CURRENT FILING DATE: 2002-09-25
; PRIOR APPLICATION NUMBER: 60/268,595
; PRIOR FILING DATE: 2001-02-14
; PRIOR APPLICATION NUMBER: 60/325,306
; PRIOR FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 60/262,587
; PRIOR FILING DATE: 2001-01-18
; PRIOR APPLICATION NUMBER: 60/272,409
; PRIOR FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 60/262,454
; PRIOR FILING DATE: 2001-01-18

; SEQ ID NO 907
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-314-578-907

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 5.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TCTGTGTGTGTGTGTGTGTGTGT 2749
Db 1 TCTGTGTGTGTGTGTGTGTGTGT 21

RESULT 744
US-10-051-874-259/c
; Sequence 259, Application US/10051874
; Publication No. US20040005557A1
; GENERAL INFORMATION:
; APPLICANT: Padigar, Muralidhara
; APPLICANT: Alsobrook II, John P
; APPLICANT: Coleman, Steven D
; APPLICANT: Spytek, Kimberly A
; APPLICANT: Boldog, Ferenc
; APPLICANT: Vernet, Corine AM
; APPLICANT: Li, Li
; APPLICANT: Shenoy, Suresh G
; APPLICANT: Casman, Stacie J
; APPLICANT: Guo, Xiaojia Sasha
; APPLICANT: Edinger, Shlomit R
; APPLICANT: MacDougall, John R
; APPLICANT: Malyankar, Uriel M
; APPLICANT: Patturajan, Meera
; APPLICANT: Shinkets, Richard A
; APPLICANT: Pena, Carol EA
; APPLICANT: Tchernev, Velizar T
; APPLICANT: Zerhusen, Bryan D
; APPLICANT: Millet, Isabelle
; APPLICANT: Miller, Charles E
; APPLICANT: Lepley, Denise M
; APPLICANT: Smithson, Glenna
; APPLICANT: Baumgartner, Jason C
; APPLICANT: Herrman, John L
; APPLICANT: Peyman, John A
; APPLICANT: Gorman, Linda
; APPLICANT: Mezes, Peter D
; APPLICANT: Kekuda, Ramesh
; APPLICANT: Taupier Jr, Raymond J
; APPLICANT: Gerlach, Valerie
; APPLICANT: Grosse, William M
; APPLICANT: Liu, Xiaohong
; APPLICANT: Ellerman, Karen
; APPLICANT: Rothenberg, Mark
; APPLICANT: Stone, David J
; APPLICANT: Burgess, Catherine E
; TITLE OF INVENTION: PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND METHODS OF
; FILE REFERENCE: 21402-245
; CURRENT APPLICATION NUMBER: US/10/051,874
; CURRENT FILING DATE: 2002-09-25
; PRIOR APPLICATION NUMBER: 60/268,595
; PRIOR FILING DATE: 2001-02-14
; PRIOR APPLICATION NUMBER: 60/325,306
; PRIOR FILING DATE: 2001-09-27
; PRIOR APPLICATION NUMBER: 60/262,587
; PRIOR FILING DATE: 2001-01-18
; PRIOR APPLICATION NUMBER: 60/272,409
; PRIOR FILING DATE: 2001-02-28
; PRIOR APPLICATION NUMBER: 60/262,454
; PRIOR FILING DATE: 2001-01-18

; PRIOR APPLICATION NUMBER: 60/276,777
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: 60/291,672
; PRIOR FILING DATE: 2001-05-17
; PRIOR APPLICATION NUMBER: 60/330,336
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 60/265,530
; PRIOR FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: 60/261,376
; PRIOR FILING DATE: 2001-01-16
; NUMBER OF SEQ ID NOS: 269
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 259
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: PCR Primer
; OTHER INFORMATION: Sequence
US-10-051-874-259

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 5.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 AGGCTGGAGTGCAGTGGTGCA 2794
Db 21 AGGCTGGAGGCGCAGTGGTGCA 1

RESULT 745
US-10-786-720-20230
; Sequence 20230, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20230
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-20230

Query Match          0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 5.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2769 CACCCAGGCTGCAGTGCAGTG 2789
Db 1 CACCTAGGCTGGAGTGCAGTG 21

RESULT 746
US-10-831-778-907
; Sequence 907, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
```

; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 907
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-907

Query Match 0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 5.2e+02;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
DB 1 TGTGTGTGTGTGTGTGTGTGT 21

RESULT 747

US-09-769-207A-19
; Sequence 19, Application US/09769207A
; Patent No. US20020132234A1
; GENERAL INFORMATION:
; APPLICANT: DZGenes, LLC
; TITLE OF INVENTION: NITRIC OXIDE SYNTHASE GENE DIAGNOSTIC POLYMORPHISMS
; FILE REFERENCE: DZG 2165.1
; CURRENT APPLICATION NUMBER: US/09/769,207A
; PRIOR FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: US 60/177,775
; PRIOR FILING DATE: 2000-01-24
; PRIOR APPLICATION NUMBER: US 60/220,662
; PRIOR FILING DATE: 2000-07-25
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 19
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)-(24)
; OTHER INFORMATION: Reverse primer
US-09-769-207A-19

Query Match 0.6%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 4.8e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2781 AGTGCAGTGTGCAATCATGGTTC 2804
DB 1 AGTGCAGTGTGATGATTTGGTTC 24

RESULT 748

US-10-196-095-3/c
; Sequence 3, Application US/10196095
; Publication No. US20030158081A1
; GENERAL INFORMATION:
; APPLICANT: Thorton, Sarah M.
; TITLE OF INVENTION: CHEMICAL COMPOUNDS
; FILE REFERENCE: 009901/0270771 - APG/PHM70556/UST
; CURRENT APPLICATION NUMBER: US/10/196,095
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: US/09/597,835
; PRIOR FILING DATE: 2000-06-19
; PRIOR APPLICATION NUMBER: GB 9914440.4
; PRIOR FILING DATE: 1999-06-22
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: MS Word

; SEQ ID NO 3
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-196-095-3

Query Match 0.6%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 4.8e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCAACCCAGGCTGGAG 2782
DB 24 CTCACCTCTGTGGCCCGAGGCTGGAG 1

RESULT 749

US-10-196-095-12/c
; Sequence 12, Application US/10196095
; Publication No. US20030158081A1
; GENERAL INFORMATION:
; APPLICANT: March, Ruth E.
; TITLE OF INVENTION: CHEMICAL COMPOUNDS
; FILE REFERENCE: 009901/0270771 - APG/PHM70556/UST
; CURRENT APPLICATION NUMBER: US/10/196,095
; CURRENT FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: US/09/597,835
; PRIOR FILING DATE: 2000-06-19
; PRIOR APPLICATION NUMBER: GB 9914440.4
; PRIOR FILING DATE: 1999-06-22
; NUMBER OF SEQ ID NOS: 54
; SOFTWARE: MS Word
; SEQ ID NO 12
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-196-095-12

Query Match 0.6%; Score 19.2; DB 1; Length 24;
Best Local Similarity 87.5%; Pred. No. 4.8e+02;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCAACCCAGGCTGGAG 2782
DB 24 CTCACCTCTGTGGCCCGAGGCTGGAG 1

RESULT 750

US-10-268-311-19
; Sequence 19, Application US/10268311
; Publication No. US20030170674A1
; GENERAL INFORMATION:
; APPLICANT: DZGenes, LLC
; TITLE OF INVENTION: NITRIC OXIDE SYNTHASE GENE DIAGNOSTIC POLYMORPHISMS
; FILE REFERENCE: DZG 2165.3
; CURRENT APPLICATION NUMBER: US/10/268,311
; CURRENT FILING DATE: 2002-10-10
; PRIOR APPLICATION NUMBER: US 60/177,775
; PRIOR FILING DATE: 2000-01-24
; PRIOR APPLICATION NUMBER: US 09/769,207
; PRIOR FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: US 60/220,662
; PRIOR FILING DATE: 2000-07-25
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 19
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Reverse Primer
; NAME/KEY: misc_feature

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCAATTC 609
|||||
Db 19 TCACCATGGAGCAATTC 1

RESULT 754

US-09-860-784-23/c
; Sequence 23, Application US/09860784
; Patent No. US20020151512A1
; GENERAL INFORMATION:
; APPLICANT: PEYMAN, Anushirwan
; UHLMANN, Eugen
; TITLE OF INVENTION: G CAP-STABILIZED OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Foley & Lardner
; STREET: 3000 K Street, N.W., Suite 500
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20007-5109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/860,784
; FILING DATE: 21-May-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/594,452
; FILING DATE: 04-APR-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: SANDERCOCK, Colin G.
; REGISTRATION NUMBER: 31,298
; REFERENCE/DOCKET NUMBER: 18748/264/HOCE
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202)672-5300
; TELEFAX: (202)672-5399
; TELEX: 904136
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 23:
US-09-860-784-23

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCGAG 69
|||||
Db 19 CCTCGCTATGGCTCCGAG 1

RESULT 755

US-09-835-371-44/c
; Sequence 44, Application US/09835371
; Publication No. US20020187473A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, Eugen
; APPLICANT: BREIPOHL, Gerhard
; APPLICANT: WILL, David W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES, AND AGENTS AND
; PROCESSES FOR PREPARING THEM
; FILE REFERENCE: 02481.1743 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/09/835,371

; CURRENT FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 44
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: base sequence
; OTHER INFORMATION: of PNA targeting CMV
US-09-835-371-44

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCGAG 69
|||||
Db 19 CCTCGCTATGGCTCCGAG 1

RESULT 756

US-09-793-146-22/c
; Sequence 22, Application US/09793146
; Publication No. US20030203359A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, Eugen
; APPLICANT: BREIPOHL, Gerhard
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/09/793,146
; CURRENT FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14
; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-09-793-146-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCGAG 69
|||||
Db 19 CCTCGCTATGGCTCCGAG 1

RESULT 757

US-10-145-181C-4/c
; Sequence 4, Application US/10145181C
; Publication No. US20030176379A1
; GENERAL INFORMATION:
; APPLICANT: Raoof, Araz A.
; APPLICANT: Gudipati, Mangaraju
; APPLICANT: Bibby, David C.
; APPLICANT: Weindach Reingold, Susan
; TITLE OF INVENTION: ANTISENSE PERMEATION ENHANCERS
; FILE REFERENCE: 24,045-B USA
; CURRENT APPLICATION NUMBER: US/10/145,181C
; CURRENT FILING DATE: 2002-05-13
; PRIOR APPLICATION NUMBER: US 60/290,436
; PRIOR FILING DATE: 2001-05-11
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.1

```
; SEQ ID NO 4
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
; NAME/KEY: Modified base
; LOCATION: (1)..(19)
; OTHER INFORMATION: Phosphorothioate oligonucleotide
US-10-145-181C-4
```

```
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1938 GAGAGGGGAAGTGGTGGG 1956
      |||||
Db 19 GAGAGGGGAAGTGGTGGG 1
```

```
RESULT 758
US-10-084-839-3892/c
; Sequence 3892, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, Wupo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tsetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3892
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-3892
```

```
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1798 AGATACACAGCATTGGG 1816
      |||||
Db 19 AGATACACAGCATTGGG 1
```

```
RESULT 759
US-10-119-432A-2/c
; Sequence 2, Application US/10119432A
; Publication No. US20030190626A1
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulinga
; TITLE OF INVENTION: Phosphorothioate Monoester Modified Oligomers
; FILE REFERENCE: ISIS4790
; CURRENT APPLICATION NUMBER: US/10/119,432A
; CURRENT FILING DATE: 2002-08-15
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Oligonucleotide
US-10-119-432A-2
```

```
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2101 GACGGATGCCAGCTTGGGC 2119
      |||||
Db 19 GACGGATGCCAGCTTGGGC 1
```

```
RESULT 760
US-10-323-591-4/c
; Sequence 4, Application US/10323591
; Publication No. US20030195248A1
; GENERAL INFORMATION:
; APPLICANT: Serhan, Charles N.
; APPLICANT: Colgan, Sean P.
; TITLE OF INVENTION: No. US20030195248A1el Approach to Anti-Microbial Host Defense wit
; TITLE OF INVENTION: Lipoxin Analogs
; FILE REFERENCE: 14149.01
; CURRENT APPLICATION NUMBER: US/10/323,591
; CURRENT FILING DATE: 2002-12-18
; PRIOR APPLICATION NUMBER: US 60/342,138
; PRIOR FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-323-591-4
```

```
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1571 GCCAGCGGAAGATCAAGAA 1589
      |||||
Db 19 GCCAGCGGAAGATCAAGAA 1
```

```
RESULT 761
US-10-163-942-22/c
; Sequence 22, Application US/10163942
; Publication No. US20030199423A1
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemary
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
```

STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/163,942
FILING DATE: 05-Jun-2002
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/753,436
FILING DATE: <Unknown>
APPLICATION NUMBER: 09/382,289
FILING DATE: <Unknown>
APPLICATION NUMBER: US 08/487,113
FILING DATE: 07-JUN-1995
APPLICATION NUMBER: US 08/286,754
FILING DATE: 05-AUG-1994
APPLICATION NUMBER: US 08/102,852
FILING DATE: 05-AUG-1993
APPLICATION NUMBER: US 08/009,266
FILING DATE: 22-JAN-1993
APPLICATION NUMBER: US 07/894,061
FILING DATE: 05-JUN-1992
APPLICATION NUMBER: US 07/889,724
FILING DATE: 26-MAY-1992
APPLICATION NUMBER: US 07/827,689
FILING DATE: 27-JAN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Joseph A., Jr.
REGISTRATION NUMBER: 38,659
REFERENCE/DOCKET NUMBER: 33282
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-10-163-942-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 591 TCACCATGGAGCAATTTC 609
DB 19 TCACCATGGAGCAATTTC 1

RESULT 762
US-10-759-878-3
Sequence 3, Application US/10759878
Publication No. US20040220129A1
GENERAL INFORMATION:
APPLICANT: Samuel J. Tolentino
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
TITLE OF INVENTION: INHIBITION OF ICAM-1
FILE REFERENCE: 43826-0003 US
CURRENT APPLICATION NUMBER: US/10/759,878
PRIOR APPLICATION NUMBER: US/10/759,878
CURRENT FILING DATE: 2004-01-16
PRIOR FILING DATE: 2004-01-16
PRIOR APPLICATION NUMBER: US 60/440,579

PRIOR FILING DATE: 2003-01-16
NUMBER OF SEQ ID NOS: 94
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 3
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: target sequence
US-10-759-878-3

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 225 GTGTGGGCATAGAGACC 243
DB 1 GTGTGGGCATAGAGACC 19

RESULT 763
US-10-759-878-8
Sequence 8, Application US/10759878
Publication No. US20040220129A1
GENERAL INFORMATION:
APPLICANT: Samuel J. Tolentino
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
TITLE OF INVENTION: INHIBITION OF ICAM-1
FILE REFERENCE: 43826-0003 US
CURRENT APPLICATION NUMBER: US/10/759,878
CURRENT FILING DATE: 2004-01-16
PRIOR APPLICATION NUMBER: US 60/440,579
PRIOR FILING DATE: 2003-01-16
NUMBER OF SEQ ID NOS: 94
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 8
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: target sequence
US-10-759-878-8

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 258 GGAGTTGCTCTCCCTGGG.276
DB 1 GGAGTTGCTCTCCCTGGG 19

RESULT 764
US-10-759-878-9
Sequence 9, Application US/10759878
Publication No. US20040220129A1
GENERAL INFORMATION:
APPLICANT: Samuel J. Tolentino
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
TITLE OF INVENTION: INHIBITION OF ICAM-1
FILE REFERENCE: 43826-0003 US
CURRENT APPLICATION NUMBER: US/10/759,878
CURRENT FILING DATE: 2004-01-16
PRIOR APPLICATION NUMBER: US 60/440,579
PRIOR FILING DATE: 2003-01-16
NUMBER OF SEQ ID NOS: 94
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 9
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence


```
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-9

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 282 CCGGAAGGTGTATGAAC TG 300
Db 1 CCGGAAGGTGTATGAAC TG 19

RESULT 765
US-10-759-878-10
; Sequence 10, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-10

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 298 CTGAGCAATGTCAGAGAAG 316
Db 1 CTGAGCAATGTCAGAGAAG 19

RESULT 766
US-10-759-878-11
; Sequence 11, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 11
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-11

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 329 TGTGCTATTCAAAC TGCCCC 347
Db 1 TGTGCTATTCAAAC TGCCCC 19

RESULT 767
US-10-759-878-12
; Sequence 12, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 12
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-12

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 371 CCTTCTCACC GTGACTG 389
Db 1 CCTTCTCACC GTGACTG 19

RESULT 768
US-10-759-878-13
; Sequence 13, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 13
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-13

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 400 CCGGTGGAAC TGCGACCCC 418
Db 1 CCGGTGGAAC TGCGACCCC 19

RESULT 769
```

US-10-759-878-14
; Sequence 14, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-14

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 447 CCTTACCCTACGCTGCCAG 465
DB 1 CCTTACCCTACGCTGCCAG 19

RESULT 770
US-10-759-878-15
; Sequence 15, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-15

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 492 CCTCACCGTGGTGTCTC 510
DB 1 CCTCACCGTGGTGTCTC 19

RESULT 771
US-10-759-878-16
; Sequence 16, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA

; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 16
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-16

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 532 CGGAGCCAGCTGTGGGG 550
DB 1 CGGAGCCAGCTGTGGGG 19

RESULT 772
US-10-759-878-17
; Sequence 17, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 17
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-17

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 606 TTTCCTGCGCGCACTGAA 624
DB 1 TTTCCTGCGCGCACTGAA 19

RESULT 773
US-10-759-878-18
; Sequence 18, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 18
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-18

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      625 CTGGACCTCGGCCCAAG 643
Db      1 CTGGACCTCGGCCCAAG 19

RESULT 774
US-10-759-878-19
; Sequence 19, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: target sequence
US-10-759-878-19

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      876 GGCTCAGTCAGTGTGACC 894
Db      1 GGCTCAGTCAGTGTGACC 19

RESULT 775
US-10-745-115-22/c
; Sequence 22, Application US/10745115
; Publication No. US20040248211A1
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESS: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/10/745,115
; FILING DATE: 23-Dec-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/163,942
; FILING DATE: 05-Jun-2002
; APPLICATION NUMBER: US/09/753,436
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 09/382,289
; FILING DATE: <Unknown>
; APPLICATION NUMBER: US 08/487,113
; FILING DATE: 07-JUN-1995
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams, Joseph A., Jr.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 33282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-10-745-115-22

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      591 TCACCATGGAGCAATTC 609
Db      19 TCACCATGGAGCAATTC 1

RESULT 776
US-10-863-999-44/c
; Sequence 44, Application US/10863999
; Publication No. US20040265885A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, EUGEN
; APPLICANT: BREIPOHL, GERHARD
; APPLICANT: WILL, DAVID W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES AND AGENTS AND
; PROCESSES FOR PREPARING THEM
; FILE REFERENCE: 02481.1742 SEQUENCE LISTING
; CURRENT APPLICATION NUMBER: US/10/863,999
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: US/09/835,370
; PRIOR FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 44
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

; OTHER INFORMATION: Description of Artificial Sequence: nucleotide
; OTHER INFORMATION: base sequence of PNA derivatives that bind to
; OTHER INFORMATION: viral and cellular targets
US-10-863-999-44

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCACG 69
|||||
DB 19 CCTCGCTATGGCTCCACG 1

RESULT 777
US-10-858-658-44/c
; Sequence 44, Application US/10858658
; Publication No. US2005009073A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, Eugen
; APPLICANT: BREIPOHL, Gerhard
; APPLICANT: WILL, David W
; TITLE OF INVENTION: POLYAMIDE NUCLEIC ACID DERIVATIVES, AND AGENTS AND
; TITLE OF INVENTION: PROCESSES FOR PREPARING THEM
; FILE REFERENCE: 02481.1743 SEQUENCE LISTING
; CURRENT FILING DATE: 2004-06-02
; PRIOR APPLICATION NUMBER: US/09/835,371
; PRIOR FILING DATE: 2001-04-17
; NUMBER OF SEQ ID NOS: 53
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 44
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: base sequence
; OTHER INFORMATION: of PNA targeting CMV
US-10-858-658-44

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCACG 69
|||||
DB 19 CCTCGCTATGGCTCCACG 1

RESULT 778
US-10-741-600-73889/c
; Sequence 73889, Application US/10741600
; Publication No. US20050026169A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
; TITLE OF INVENTION: MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001499
; CURRENT APPLICATION NUMBER: US/10/741,600
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 73997
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 73889
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-741-600-73889

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 879 CTCAGTCAGTGTGACCGCA 897

DB 19 CTCAGTCAGTGTGACCGCA 1
|||||
RESULT 779
US-10-939-214-22/c
; Sequence 22, Application US/10939214
; Publication No. US20050026817A1
; GENERAL INFORMATION:
; APPLICANT: UHLMANN, Eugen
; APPLICANT: BREIPOHL, Gerhard
; TITLE OF INVENTION: POLYAMIDE-OLIGONUCLEOTIDE DERIVATIVES, THEIR
; TITLE OF INVENTION: PREPARATION AND USE
; FILE REFERENCE: 02481.1437-02
; CURRENT APPLICATION NUMBER: US/10/939,214
; CURRENT FILING DATE: 2004-09-10
; PRIOR APPLICATION NUMBER: US/09/793,146
; PRIOR FILING DATE: 2001-02-27
; PRIOR APPLICATION NUMBER: P 44 08 528.1
; PRIOR FILING DATE: 1994-03-14
; PRIOR APPLICATION NUMBER: 08/402,838
; PRIOR FILING DATE: 1995-03-13
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic PNA
US-10-939-214-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGCTCCACG 69
|||||
DB 19 CCTCGCTATGGCTCCACG 1

RESULT 780
US-10-800-487-1
; Sequence 1, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MEH804-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782

;
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.

;
; NUMBER OF SEQ ID NOS: 438

;
; SOFTWARE: PatentIn version 3.3

;
; SEQ ID NO 1

;
; LENGTH: 19

;
; TYPE: RNA

;
; ORGANISM: Artificial Sequence

;
; FEATURE:

;
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-1

Query Match 0.6%; Score 19; DB 1; Length 19;

Best Local Similarity 89.5%; Pred. No. 6.3e+02;

Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCCCAGTCGACGCTGAGC 21

|||||:|||||:|||||

Db 1 GCCCCAGACGACGUCAGC 19

RESULT 781

US-10-800-487-2

; Sequence 2, Application US/10800487

; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; TITLE OF INVENTION: Acid (siNA)

; FILE REFERENCE: 400/148 (MBHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; PRIOR FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/427,160

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 2

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-2

Query Match 0.6%; Score 19; DB 1; Length 19;

Best Local Similarity 68.4%; Pred. No. 6.3e+02;

Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 21 CTCCTCTGCTACTCAGAGT 39

|||||:|||||:|||||

Db 1 CUCCUCUGCUCACGAGU 19

RESULT 782

US-10-800-487-3

; Sequence 3, Application US/10800487

; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; TITLE OF INVENTION: Acid (siNA)

; FILE REFERENCE: 400/148 (MBHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; PRIOR FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/427,160

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 3

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-3

Query Match 0.6%; Score 19; DB 1; Length 19;

Best Local Similarity 73.7%; Pred. No. 6.3e+02;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 39 TTGCAACCTCAGCTCGCT 57

:::|||||:|||||:|||||

Db 1 UUGCAACCCUCAGCCUCGCU 19

RESULT 783

US-10-800-487-4

; Sequence 4, Application US/10800487

; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; TITLE OF INVENTION: Acid (siNA)

; FILE REFERENCE: 400/148 (MBHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; PRIOR FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

```
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 4
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-4

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 57 TATGGCTCCAGAGCCCC 75
Db 1 UAUGGCUCCAGAGCCCC 19

RESULT 784
US-10-800-487-5
; Sequence 5, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 5
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-4
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-5

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 75 CCGGCCCGCGCTGCCGCA 93
Db 1 CCGGCCCGCGCGGCCGCA 19

RESULT 785
US-10-800-487-6
; Sequence 6, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 6
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-6

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 93 ACTCCTGGTCTGCTCGGG 111
Db 1 ACUCCUGGCUCCUGCCGGG 19

RESULT 786
US-10-800-487-7
; Sequence 7, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
```



```
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 147 TGTGTCCTCCCTCAAAAGTC 165
Db 1 UGUGUCCCCCUCAAAAGUC 19

RESULT 789
US-10-800-487-10
; Sequence 10, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 10
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-10

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY 165 CATCTGCCCCGGGAGGC 183
Db 1 CAUCCUGCCCCGGGAGGC 19

RESULT 790
US-10-800-487-11
; Sequence 11, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
```

```
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 11
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-11

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY 183 CTCCTGCTGTGTGACATGC 201
Db 1 CUCCGUGUGUGACAGC 19

RESULT 791
US-10-800-487-12
; Sequence 12, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
```


; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 12
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-12

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 201 CAGCACCTCTGTGACCAG 219
|||||:|:|:|:|:|:|
Db 1 CAGCACCCUGUGACCAG 19

RESULT 792

US-10-800-487-13
; Sequence 13, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 13
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-13

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 219 GCCCAAGTTGTTGGGCAATA 237
|||||:|:|:|:|:|:|
Db 1 GCCCAAGUUGUGGCAUA 19

RESULT 793

US-10-800-487-14
; Sequence 14, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 14
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-14

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 237 AGAGACCCCGTTGCCTAAA 255
|||||:|:|:|:|:|:|
Db 1 AGAGACCCCGUUGCCUAAA 19

RESULT 794

US-10-800-487-15
; Sequence 15, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853

```
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 15
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-15

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      255 AAAGGAGTTCCTCTCGCT 273
Db      1 AAAGGAGUUGCUCUGCCU 19

RESULT 795
US-10-800-487-16
; Sequence 16, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 16
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-16

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      273 TGGGACACCGGAGGTG 291
Db      1 UGGGAACAACCGGAGGUG 19

RESULT 796
US-10-800-487-17
; Sequence 17, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 17
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-17

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      291 GTATGAACCTGAGCAATGTG 309
Db      1 GUUAGAACUGAGCAATGUG 19

RESULT 797
US-10-800-487-18
; Sequence 18, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
```

```
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 18
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-18

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      309 GCAAGAAGATAGCCACCA 327
        |||||:|||||
Db       1 GCAGAAGAUGCCACCA 19

RESULT 798
US-10-800-487-19
; Sequence 19, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 18
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-18
```

```
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 19
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-19

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      327 AATGCTATTCAAACCTGC 345
        ||:|:|:|:|:|:|:|
Db       1 AAUGGCUAUUCAACUGC 19

RESULT 799
US-10-800-487-20
; Sequence 20, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 20
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-20

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

QY 345 CCTGTATGGCAGTCAACA 363
||||:||||:||||:
Db 1 CCUGAUGGCGACUCAACA 19

RESULT 800
US-10-800-487-21
; Sequence 21, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 21
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-21

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 363 AGCTAAACCTTCTCACC 381
||||:||||:||||:
Db 1 AGCUAAACCUUCCUACAC 19

RESULT 801
US-10-800-487-22
; Sequence 22, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 21
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-21

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 381 CGGTACTGGACTCCAGAA 399
||||:||||:||||:
Db 1 CGUGUACUGGACUCCAGAA 19

RESULT 802
US-10-800-487-23
; Sequence 23, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 22
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-22

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 381 CGGTACTGGACTCCAGAA 399
||||:||||:||||:
Db 1 CGUGUACUGGACUCCAGAA 19

RESULT 802
US-10-800-487-23
; Sequence 23, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.

```
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-23

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 399 ACGGTTGGAACCTGGCACCC 417
      |||||:||||:|||||
Db 1 ACGGGUGGAACUUGGCACCC 19

RESULT 803
US-10-800-487-24
; Sequence 24, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 24
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 2
US-10-800-487-24

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 417 CCTCCCTCTTGGCAGCCA 435
      ||:||||:|||||
Db 1 CCUCCCCCUUGGCAGCCA 19

RESULT 804
```

```
US-10-800-487-25
; Sequence 25, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 25
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-25

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 435 AGTGGGCAAGAACCTTACC 453
      ||:|||||:|||||
Db 1 AGUGGGCAAGAACCUUACC 19

RESULT 805
US-10-800-487-26
; Sequence 26, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
```

```
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 25
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-26

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 453 CCTACGCTGCCAGTGGAG 471
      ||:||||:||||:||||:
Db 1 CCUACGCGCCAGGUGGAG 19

RESULT 806
US-10-800-487-27
; Sequence 27, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 27
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-27

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 471 GGGTGGGGCACCCTGGGCC 489
      |||:||||:||||:||||:
Db 1 GGGUGGGGCACCCCGGGCC 19

RESULT 807
US-10-800-487-28
; Sequence 28, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 28
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-28

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 489 CAACCTCACCGTGGTGTG 507
      |||:||||:||||:||||:
Db 1 CAACCCACCGUGUGUGUG 19

RESULT 808
US-10-800-487-29
; Sequence 29, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
```

```
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 29
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-29

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 507 GTCCTGGTGGGAGAGGAG 525
||:|||||
Db 1 GCUCCGUGGGAGAGGAG 19

RESULT 809
US-10-800-487-30
; Sequence 30, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 30
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 2
US-10-800-487-29
```

```
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 30
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-30

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 525 GCTGAACGGGAGCCAGCT 543
||:|||||
Db 1 GCUGAAACGGGAGCCAGCU 19

RESULT 810
US-10-800-487-31
; Sequence 31, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 31
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 2
US-10-800-487-31

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

QY 543 TGTGGGGGACCGCTGAG 561
:|||||||:|
Db 1 UGUGGGGAGCCCGCUGAG 19

RESULT 811

US-10-800-487-32
; Sequence 32, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 32
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-32

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 561 GGTCCAGCACCGTGCTG 579
:|||||||:|
Db 1 GGUCACGACCGGUGCUG 19

RESULT 812

US-10-800-487-33
; Sequence 33, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 33
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-33

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 579 GGTGAGGAGAGATCACCAT 597
:|||||||:|
Db 1 GGUGAGGAGAGAUCCACAU 19

RESULT 813

US-10-800-487-34
; Sequence 34, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438


```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 34
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-34

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 597 TCGAGCCAAATTTCTGCTGC 615
      :|||||:||||:||||:
Db 1 UGGAGCCAAUUUCUGUGC 19

RESULT 814
US-10-800-487-35
; Sequence 35, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 36
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-36

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 615 CCGCACTGACTGCACCTG 633
      :|||||:||||:||||:
Db 1 CCGCACTGACUGGACUG 19

RESULT 815
US-10-800-487-36
```

```
; Sequence 36, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 36
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-36

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 633 GCGGCCCAAGGCTGGAG 651
      :|||||:||||:||||:
Db 1 GCGGCCCAAGGCTGGAG 19

RESULT 816
US-10-800-487-37
; Sequence 37, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
```

```
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 37
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-37

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 651 GCTGTTTGAGAACACCTCG 669
||.:.:|||:|||||:|
Db 1 GCUGUUGAGAACACCUUG 19

RESULT 817
US-10-800-487-38
/ Sequence 38, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MEHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 39
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-39

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 651 GCTGTTTGAGAACACCTCG 669
||.:.:|||:|||||:|
Db 1 GCUGUUGAGAACACCUUG 19

RESULT 817
US-10-800-487-38
/ Sequence 38, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MEHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 38
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-38
```

```
US-10-800-487-38

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 669 GGCCCCCTTACCAGCTCCAG 687
|||:|:|:|:|:|:|:|
Db 1 GGCCCCCUACGACCUCCAG 19

RESULT 818
US-10-800-487-39
/ Sequence 39, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MEHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 39
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-39

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 687 GACCTTTGCTGCGCAGCG 705
|||:|:|:|:|:|:|
Db 1 GACCUUGUCGCGCAGCG 19

RESULT 819
US-10-800-487-40
/ Sequence 40, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
```

```
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 40
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-40

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 705 GACTCCCCCACAACACTGTC 723
    |||:|||||:|||||:|
Db 1 GACUCCCCCACAACUUGUC 19

RESULT 820
US-10-800-487-41
; Sequence 41, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 40
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-41

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 705 GACTCCCCCACAACACTGTC 723
    |||:|||||:|||||:|
Db 1 GACUCCCCCACAACUUGUC 19

RESULT 820
US-10-800-487-41
; Sequence 41, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 42
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-42

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 723 CAGCCCCCGGTCCTAGAG 741
    |||:|||||:|||||:|
Db 1 CAGCCCCCGGCUUAGAG 19

RESULT 821
US-10-800-487-42
; Sequence 42, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 42
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-42

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 741 GGTGGACACGCGGGGACC 759
```

```
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 41
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-41

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 723 CAGCCCCCGGTCCTAGAG 741
    |||:|||||:|||||:|
Db 1 CAGCCCCCGGCUUAGAG 19

RESULT 821
US-10-800-487-42
; Sequence 42, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 42
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-42

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 741 GGTGGACACGCGGGGACC 759
```

Db 1 GGUGGACACGCGGGGACC 19
||:||||||||||||||||||

RESULT 822

US-10-800-487-43

; Sequence 43, Application US/10800487

; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; TITLE OF INVENTION: Acid (siRNA)

; FILE REFERENCE: 400/148 (MBHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; CURRENT FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/427,160

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 43

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense

US-10-800-487-43

Query Match

Best Local Similarity 0.6%; Score 19; DB 1; Length 19;

Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 759 CGTGGCTGTTCCCTCGAC 777

||:||||||||||||||||||

Db 1 CGUGGUCUGUCCCGGAC 19

RESULT 823

US-10-800-487-44

; Sequence 44, Application US/10800487

; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; TITLE OF INVENTION: Acid (siRNA)

; FILE REFERENCE: 400/148 (MBHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; CURRENT FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 44
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-44

Query Match

Best Local Similarity 0.6%; Score 19; DB 1; Length 19;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 777 CGGGCTGTTCCCGACTCG 795

||||:|||||:|:|

Db 1 CGGGCUGUCCCGAGUCUG 19

RESULT 824

US-10-800-487-45

; Sequence 45, Application US/10800487

; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; TITLE OF INVENTION: Acid (siRNA)

; FILE REFERENCE: 400/148 (MBHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; CURRENT FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/427,160

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438

; SOFTWARE: PatentIn version 3.3

```
; SEQ ID NO 45
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-45

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 795 GGAGGCCAGGTCACCTG 813
    |||||:|||||:|||||:|
Db 1 GGAGGCCAGGCCACCUG 19

RESULT 825
US-10-800-487-46
; Sequence 46, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 47
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-47

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 831 GTTGAACCCACAGTCACC 849
    |:|||||:|||||:|||||
Db 1 GUUGAACCCACAGUCACC 19

RESULT 827
US-10-800-487-48
; Sequence 48, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 46
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-46

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 813 GGCACUGGGGACACGAGG 831
    |||||:|||||:|||||:|
Db 1 GGCACUGGGGACACGAGG 19

RESULT 826
US-10-800-487-47
; Sequence 47, Application US/10800487
```

```
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 47
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-47

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 831 GTTGAACCCACAGTCACC 849
    |:|||||:|||||:|||||
Db 1 GUUGAACCCACAGUCACC 19

RESULT 827
US-10-800-487-48
; Sequence 48, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 46
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-46
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 48
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-48

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      849 CTATGGCAAGCACTCTCTC 867
      ||:|||||:|||||:|:|
Db      1 CUAUGGCAAGCAGCUCCUUC 19

RESULT 828
US-10-800-487-49
; Sequence 49, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 49
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-49

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      849 CTATGGCAAGCACTCTCTC 867
      ||:|||||:|||||:|:|
Db      1 CUAUGGCAAGCAGCUCCUUC 19
```

```
Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      867 CTCGGCCAAAGGCGCTAGTC 885
      ||:|||||:|||||:|:|
Db      1 CUCGGCCAAAGGCGCUCAGUC 19

RESULT 829
US-10-800-487-50
; Sequence 50, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 50
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-50

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      885 CAGTGTGACCGCAGAGGAC 903
      |||:|||||:|||||:|
Db      1 CAGUGUGACCGCAGAGGAC 19

RESULT 830
US-10-800-487-51
; Sequence 51, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siNA)
```

```
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 51
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense i
US-10-800-487-51

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 903 CGAGGGCACCCAGCGGCTG 921
Db 1 CGAGGGCACCCAGCGGCGUG 19

RESULT 831
US-10-800-487-52
/ Sequence 52, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 51
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense i
US-10-800-487-51
```

```
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 52
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense i
US-10-800-487-52

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 921 GACGTTGTCAGTAATACCTG 939
Db 1 GACGUGUGCAGUAUACUG 19

RESULT 832
US-10-800-487-53
/ Sequence 53, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 53
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense i
US-10-800-487-53

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 939 GGGGAACCCAGAGCCAGGAG 957
Db 1 GGGGAACCCAGAGCCAGGAG 957
```

Db 1 GGGGAACAGAGCCAGGAG 19

RESULT 833

US-10-800-487-54
; Sequence 54, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 54
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-54

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 957 GACACTGCACAGTGACC 975

Db 1 GACACUGCAGACAGUGACC 19

RESULT 834

US-10-800-487-55
; Sequence 55, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 55
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-55

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 975 CATCTACAGCTTTCGGCG 993

Db 1 CAUCUACAGCUUCCGGCG 19

RESULT 835

US-10-800-487-56
; Sequence 56, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 56


```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-56

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 993 GCCCACGGTATTCTGACG 1011
Db 1 GCCCAACGAGUUCUGACG 19

RESULT 836
US-10-800-487-57
; Sequence 57, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 57
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-57

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAAGCCAGAGGTCTCAGAA 1029
Db 1 GAAGCCAGAGGUUCUCAGAA 19

RESULT 837
US-10-800-487-58
; Sequence 58, Application US/10800487
; Publication No. US20050048529A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 58
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-58

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1029 AGGACCCGAGGTGACAGTG 1047
Db 1 AGGACCCGAGGUGACAGUG 19

RESULT 838
US-10-800-487-59
; Sequence 59, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 59
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-59

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1047 GAAGTGTGAGGCCACCCT 1065
      |||||:|||||:|||||:
Db 1 GAAGUGUGAGGCCACCCTU 19

RESULT 839
US-10-800-487-60
; Sequence 60, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 60
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-60

```

```

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1065 TAGAGCCAAAGTGAGCTG 1083
      :|||||:|||||:|||||:
Db 1 UAGAGCCAAAGGUGAGCCUG 19

RESULT 840
US-10-800-487-61
; Sequence 61, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 61
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-61

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1083 GAATGGGTTCCAGCCAG 1101
      |||||:|||||:|||||:
Db 1 GAAUGGGGUUCCAGCCAG 19

RESULT 841
US-10-800-487-62
; Sequence 62, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)

```

```
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 62
; TYPE: RNA
; LENGTH: 19
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-62

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1101 GCCACTGGGCGCGAGGGCC 1119
Db 1 GCCACUGGGCGCGAGGGCC 19

RESULT 842
US-10-800-487-63
; Sequence 63, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
```

```
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 63
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-63

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1119 CCAGCTCCTGCTGAAGGCC 1137
Db 1 CCAGCUCUCCUGCUGAAGGCC 19

RESULT 843
US-10-800-487-64
; Sequence 64, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 64
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-64

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1137 CACCCGAGGAGGACACGGG 1155
Db 1 CACCCGAGGAGGACACGGG 19
```

```
RESULT 844
US-10-800-487-65
; Sequence 65, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 65
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-65

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1155 GCGCAGCTTCTCTGCTCT 1173
Db 1 GCGCAGCUCUCCUGCUCU 19

RESULT 845
US-10-800-487-66
; Sequence 66, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
```

```
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 66
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-66

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1173 TGAACCCCTGGAGGTGGCC 1191
Db 1 UGCAACCCUGGAGUGGCC 19

RESULT 846
US-10-800-487-67
; Sequence 67, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 67
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-67

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1191 CGCCAGCTTATACACAAG 1209
      |||||:::|||||
Db 1 CGCCAGCUUACACAAG 19

RESULT 847
US-10-800-487-68
; Sequence 68, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 68
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-69

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1209 GAACACACCCGGAGCTT 1227
      |||||:::|||||
Db 1 GAACACACCCGGAGCUU 19

RESULT 848
US-10-800-487-69
; Sequence 69, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 69
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-70

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1227 TCGTGTCTGTATGCCCC 1245
      :||:|::|::|::|
Db 1 UCGUGUCCUGUAUGGCCCC 19

RESULT 849
US-10-800-487-70
; Sequence 70, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 70
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-70

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1245 CCGACTGGACGAGGGAT 1263
Db      1 CCGACUGGACGAGAGGGAU 19

RESULT 850
US-10-800-487-71
; Sequence 71, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 71
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-71

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1263 TTGTCCGGGAAACTGGACG 1281
Db      1 UUGUCGGGAAACUGGACG 19

RESULT 851
US-10-800-487-72
; Sequence 72, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 72
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-72

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      1281 GTGGCCAGAAATTCGCCAG 1299
Db      1 GUGGCCAGAAAAUCCGAG 19

RESULT 852
US-10-800-487-73
; Sequence 73, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
```

```
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 73
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-73

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1299 GCAGACTCCAATGTGCCAG 1317
      |||||:||||:||||:||||
Db 1 GCAGACUCCAUGUGCCAG 19

RESULT 853
US-10-800-487-74
; Sequence 74, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 73
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-73

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1299 GCAGACTCCAATGTGCCAG 1317
      |||||:||||:||||:||||
Db 1 GCAGACUCCAUGUGCCAG 19

RESULT 853
US-10-800-487-74
; Sequence 74, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
```

```
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 74
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-74

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1317 GGCTTGGGGGAACCCCAATTG 1335
      ||||:|||||:||||:||||
Db 1 GGCUGUGGGGAACCCCAUUG 19

RESULT 854
US-10-800-487-75
; Sequence 75, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 75
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-75

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1335 GCCCGAGCTCAAGTGCTTA 1353
      |||||:||||:||||:||||
Db 1 GCCCGAGCTCAAGUGUCUA 19
```

```
RESULT 855
US-10-800-487-76
; Sequence 76, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 76
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-76

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.3%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1353 AAAGGATGGCCTTCCCA 1371
|||||:|||||:|||||
Db 1 AAAGGAUGGCACUUCCCA 19

RESULT 856
US-10-800-487-77
; Sequence 77, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 77
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-77

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.3%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1353 AAAGGATGGCCTTCCCA 1371
|||||:|||||:|||||
Db 1 AAAGGAUGGCACUUCCCA 19

RESULT 857
US-10-800-487-78
; Sequence 78, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 78
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-78

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1371 ACTGCCCATCGGGAATCA 1389
|||||:|||||:|||||
Db 1 ACUGCCCAUCGGGGAUCA 19

RESULT 857
US-10-800-487-78
; Sequence 78, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 78
; LENGTH: 19
; TYPE: RNA
```



```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense i
US-10-800-487-78

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1389 AGTGACTGTCACTCGAGAT 1407
      ||:||||:||||:||||:
Db 1 AGUGACUGACUCCGAGAU 19

RESULT 858
US-10-800-487-79
; Sequence 79, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 79
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense i
US-10-800-487-79

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 1407 TCTTGAGGGCACTACTC 1425
      ||:||||:||||:||||:
Db 1 UCUGAGGGCACCUACCUC 19

RESULT 859
US-10-800-487-80
; Sequence 80, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
```

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 80
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense i
US-10-800-487-80

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1425 CTGTCGGCCAGGAGCACT 1443
      ||:||||:||||:||||:
Db 1 CUGUCGGCCAGGAGCACU 19

RESULT 860
US-10-800-487-81
; Sequence 81, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
```

```
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 81
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-81

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.9%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1443 TCACGGGGAGGTACCCGC 1461
Db      1 UCAAGGGGAGGUCACCCGC 19

RESULT 861
US-10-800-487-82
/ Sequence 82, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ PRIOR FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 82
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-82

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1443 TCACGGGGAGGTACCCGC 1461
Db      1 UCAAGGGGAGGUCACCCGC 19
```

```
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1461 CGAGGTGACCGTGAATGTG 1479
Db      1 CGAGGUGACCGGUAUGUG 19

RESULT 862
US-10-800-487-83
/ Sequence 83, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 83
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-83

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1479 GCTCTCCCCCGGTATGAG 1497
Db      1 GCUCUCCCCCGGUAUGAG 19

RESULT 863
US-10-800-487-84
/ Sequence 84, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
```

```
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 84
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-84

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 6.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1497 GATTGTCATCATCATCGTGT 1515
Db 1 GAUGGUCAUCACUGUG 19

RESULT 864
US-10-800-487-85
; Sequence 85, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
```

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 85
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-85

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1515 GGTAGCAGCCGAGTCATA 1533
Db 1 GGUAGCAGCCGACAGUCAUA 19

RESULT 865
US-10-800-487-86
; Sequence 86, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 86
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-86

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1533 AATGGGCACTGCAGGCCTC 1551
Db 1 AAUGGGCACUGAGGCCUC 19
```

```

; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,590
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 88
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-88

Query Match 0.8%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1569 CCGCCAGCGGAGATCAAG 1587
Db 1 CCGCCAGCGGAGAUCAAG 19

RESULT 868
US-10-800-487-89
; Sequence 89, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,590
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 89
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence

```

```
;
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-89

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

Qy 1587 GAAATACAGACTACACAG 1605
      ||||:|||||:|||||
Db 1 GAAAUACAGACUACAACAG 19

RESULT 869
US-10-800-487-90
; Sequence 90, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 91
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-91

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1623 CATGAACCGAACACACAA 1641
      ||:|||||:|||||
Db 1 CAUGAAACCGAACACACAA 19

RESULT 871
US-10-800-487-92
; Sequence 92, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 90
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-90

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1605 GGCACAAAAGGGACCCCC 1623
      |||||:|||||:|||||
Db 1 GGCACAAAAGGGACCCCC 19

RESULT 870
US-10-800-487-91
; Sequence 91, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
```

```
;
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 91
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-91

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1623 CATGAACCGAACACACAA 1641
      ||:|||||:|||||
Db 1 CAUGAAACCGAACACACAA 19

RESULT 871
US-10-800-487-92
; Sequence 92, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 91
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-91
```

```
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 92
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-92

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1641 AGCCACGCTCCCTGAACC 1659
Db 1 AGCCACGCCUCCUGAAC 19

RESULT 872
US-10-800-487-93
/ Sequence 93, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MEHB04-218)
/ CURRENT APPLICATION NUMBER: US 10/800,487
/ PRIOR FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 94
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-94

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 1641 AGCCACGCTCCCTGAACC 1659
Db 1 AGCCACGCCUCCUGAAC 19

RESULT 872
US-10-800-487-93
/ Sequence 93, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MEHB04-218)
/ CURRENT APPLICATION NUMBER: US 10/800,487
/ PRIOR FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 93
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-93

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1659 CTATCCCGGCACAGGCGCT 1677
Db 1 CUAUCCCGGCACAGGCGCU 19

RESULT 873
US-10-800-487-94
/ Sequence 94, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ ORGANISM: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MEHB04-218)
/ CURRENT APPLICATION NUMBER: US 10/800,487
/ PRIOR FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 94
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-94

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 6.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 1677 TCTTCTCGGCTTCCCAT 1695
Db 1 UCUCUCCGCGCCUCCCAU 19

RESULT 874
US-10-800-487-95
/ Sequence 95, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ ORGANISM: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MEHB04-218)
/ CURRENT APPLICATION NUMBER: US 10/800,487
/ PRIOR FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
```

```
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 95
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-95

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1695 TATTGGTGGCAGTGGGCC 1713
Db       1 UAUUGGUGGACAGUGGUGCC 19

RESULT 875
US-10-800-487-96
; Sequence 96, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 96
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-96

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1695 TATTGGTGGCAGTGGGCC 1713
Db       1 UAUUGGUGGACAGUGGUGCC 19

RESULT 876
US-10-800-487-97
; Sequence 97, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 97
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-97

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1731 ACACATATGCCATGCAGCT 1749
Db       1 AGACAUAUGCCAUGCAGCU 19

RESULT 877
```

```
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 96
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-96

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1713 CACACTGAACAGAGTGGAA 1731
Db       1 CACACUGAACACAGUGGAA 19

RESULT 876
US-10-800-487-97
; Sequence 97, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 97
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-97

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1731 ACACATATGCCATGCAGCT 1749
Db       1 AGACAUAUGCCAUGCAGCU 19

RESULT 877
```

```
US-10-800-487-98
; Sequence 98, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-03-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 98
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-98

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1749 TACACCTACCGCCCTGGG 1767
      :||||:|||||:|||||
Db 1 UACACCUACCGGCCUUGG 19

RESULT 878
US-10-800-487-99
; Sequence 99, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 99
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-99

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1749 TACACCTACCGCCCTGGG 1767
      :||||:|||||:|||||
Db 1 UACACCUACCGGCCUUGG 19

RESULT 879
US-10-800-487-100
; Sequence 100, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 100
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-99

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1767 GACGCCGAGGACAGGCA 1785
      |||:|||||:|||||
Db 1 GACGCCGAGGACAGGCA 19

RESULT 879
US-10-800-487-100
; Sequence 100, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 100
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-99
```



```
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-100

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 1785 ATTGTCCTCAGTCAGATAC 1803
    |::|::|::|::|::|::|::|
Db 1 AUUGUCCUGAGUGGCAUAC 19

RESULT 880
US-10-800-487-101
; Sequence 101, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 101
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-101

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1803 CAACAGCATTTGGGGCAT 1821
    |||||::|::|::|::|::|
Db 1 CAACAGCAUUGGGGCAU 19

RESULT 881
US-10-800-487-102
; Sequence 102, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
```

```
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 102
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-102

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1821 TGTACCTGCACACCTAAA 1839
    :||::|::|::|::|::|
Db 1 UGGUACCUCCGACACCUAAA 19

RESULT 882
US-10-800-487-103
; Sequence 103, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
```

```
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 103
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-103

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.4%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1839 AACACTAGGCCAGCATCT 1857
      |||||:|||||||:|:|
Db 1 AACACUAGGCCAGCAUCU 19

RESULT 883
US-10-800-487-104
; Sequence 104, Application US/108000487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 104
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-104

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1857 TGATCTGTAGTCACATGAC 1875
      |||:|:|:|:|:|:|:|
Db 1 UGAUCUGAGUCACAUAGAC 19

RESULT 884
US-10-800-487-105
; Sequence 105, Application US/108000487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 105
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-105

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1875 CTAAGCCAGAGGAGGAG 1893
      |:|:|:|:|:|:|:|
Db 1 CUAAGCCAGAGGAGGAG 19

RESULT 885
US-10-800-487-106
; Sequence 106, Application US/108000487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
```



```
; Sequence 109, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 109
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-109
```

```
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1947 AGTGTGGGGGACATAG 1965
||:|||||:|||||:|
Db 1 AGUGUGGGGGACAUAG 19
```

```
RESULT 889
US-10-800-487-110
; Sequence 110, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
```

```
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 110
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-110
```

```
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1965 GCCCACCATGAGGACATA 1983
|||||:|||||:|
Db 1 GCCCACCACGAGGACAU 19
```

```
RESULT 890
US-10-800-487-111
; Sequence 111, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 111
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
```

US-10-800-487-111

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1983 ACAACTGGGAATACTGAA 2001
||||:||||:||||:||||:
Db 1 ACAACUGGGAUAUCUGAA 19

RESULT 891

US-10-800-487-112
; Sequence 112, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 112
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense

US-10-800-487-111
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 112
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-112
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 112
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 6.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 2001 AACCTGCTGCTATTGGGT 2019
||||:||||:||||:||||:
Db 1 AACUUGCUGCCUAUUGGU 19

RESULT 892

US-10-800-487-113
; Sequence 113, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 113
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-113
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 113
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2019 TATGCTGAGGCCACAGAC 2037
:||||:||||:||||:||||:
Db 1 UAUGCUGAGGCCACAGAC 19

RESULT 893

US-10-800-487-114
; Sequence 114, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20

;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 438
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 114
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-114

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.7%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2037 CTTACAGAGAAGTGGCCC 2055
|:|||||:|||||:|||||
Db 1 CUUACAGAGAGUGGCC 19

RESULT 894
US-10-800-487-115
;; Sequence 115, Application US/10800487
;; Publication No. US20050048529A1
;; GENERAL INFORMATION:
;; APPLICANT: McSwiggen, James
;; APPLICANT: Sirna Therapeutics, Inc.
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;; FILE REFERENCE: 400/148 (MBH04-218)
;; CURRENT APPLICATION NUMBER: US/10/800,487
;; CURRENT FILING DATE: 2004-03-15
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-15
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: US 10/427,160
;; PRIOR FILING DATE: 2003-04-30
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 438
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 115
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-115

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2055 CTCCATAGACATGTGAGC 2073

Db 1 CUCCAAGACAGUGGAGC 19
|:|||||:|||||:|||||

RESULT 895
US-10-800-487-116
;; Sequence 116, Application US/10800487
;; Publication No. US20050048529A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;; FILE REFERENCE: 400/148 (MBH04-218)
;; CURRENT APPLICATION NUMBER: US/10/800,487
;; CURRENT FILING DATE: 2004-03-15
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-15
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: US 10/427,160
;; PRIOR FILING DATE: 2003-04-30
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 438
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 116
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-116

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 6.3e+02;
Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2073 CATCAAAACACAAGGCC 2091
|:|||||:|||||:|||||

Db 1 CAUCAAAACACAAGGCC 19
|:|||||:|||||:|||||
RESULT 896
US-10-800-487-117
;; Sequence 117, Application US/10800487
;; Publication No. US20050048529A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;; FILE REFERENCE: 400/148 (MBH04-218)
;; CURRENT APPLICATION NUMBER: US/10/800,487
;; CURRENT FILING DATE: 2004-03-15
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-15
;; PRIOR APPLICATION NUMBER: US 10/720,448

```
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 117
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-117

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred.No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      2091 CACACTTCTGACGGATGC 2109
      |||::|||:|||||:|
Db      1 CACACUUCUGACGGAUGC 19

RESULT 897
US-10-800-487-118
; Sequence 118, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 118
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-119

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred.No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      2109 CCAGCTTGGGCACTGCTGT 2127
      |||::|||:|||||:|
Db      1 CCAGCUUGGGCACUGCUGU 19

RESULT 898
US-10-800-487-119
; Sequence 119, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 119
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-119

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred.No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      2127 TCTACTGACCCCAACCCCTT 2145
      :|::|:|||||:|
Db      1 UCUACUGACCCCAACCCUU 19

RESULT 899
US-10-800-487-120
; Sequence 120, Application US/10800487
```

```
; SEQ ID NO 118
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-118

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred.No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      2109 CCAGCTTGGGCACTGCTGT 2127
      |||::|||:|||||:|
Db      1 CCAGCUUGGGCACUGCUGU 19

RESULT 898
US-10-800-487-119
; Sequence 119, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 119
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-119

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred.No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY      2127 TCTACTGACCCCAACCCCTT 2145
      :|::|:|||||:|
Db      1 UCUACUGACCCCAACCCUU 19

RESULT 899
US-10-800-487-120
; Sequence 120, Application US/10800487
```

```
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 120
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-120

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 47.4%; Pred. No. 6.3e+02;
Matches 9; Conservative 10; Mismatches 0; Indels 0; Gaps 0;

QY      2145 TGATGATATCTATTATTC 2163
Db      1 UGAUGAUGAUUUUAUUC 19

RESULT 900
US-10-800-487-121
; Sequence 121, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 120
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-120
```

```
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 121
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-121

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 6.3e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY      2163 CATTGTTATTTTACCAGC 2181
Db      1 CAUUGUUAUUUACCAGC 19

RESULT 901
US-10-800-487-122
; Sequence 122, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 122
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-122
```



```
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 124
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-124

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 42.1%; Pred. No. 6.3e+02;
Matches 8; Conservative 11; Mismatches 0; Indels 0; Gaps 0;

QY 2181 CTATTATTGAGTGCTTT 2199
Db 1 CUUUUUUUGUGUCUUU 19

RESULT 902
US-10-800-487-123
; Sequence 123, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 123
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-123

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2199 TTATGTAGGCTAAATGAAC 2217
Db 1 UUAUGAGGCUAAUGAAC 19

RESULT 903
US-10-800-487-124
; Sequence 124, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
```

```
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 124
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-124

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2217 CATAGGTCTGTGGCTCACC 2235
Db 1 CAUAGGUCUCUGGCCUCAC 19

RESULT 904
US-10-800-487-125
; Sequence 125, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
```

```

; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.

```

Query Match	0.6%;	Score 19;	DB 1;	Length 19;
Best Local Similarity	78.9%;	Pred. No. 6.3e+02;		
Matches 15;	Conservative	4;	Mismatches 0;	Indels 0;
Gaps	0;			

RESULT 905
US-10-800-487-126
; Sequence 126, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference
; TITLE OF INVENTION: Molecule (ICAM)
; TITLE OF INVENTION: Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic

```
Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

Db 1 UCACAUUCAAGGUCACCAG 19

RESULT 906
US-10-800-487-127
; Sequence 127, Application US/10800487
; Publication No. US20050048529A1

```
Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

RESULT 907
US-10-800-487-128
; Sequence 128, Application US/10800487
; Publication No. US20050048529A1

```
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 128
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-128

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      2289 GTACACTGCAGGAGAGTGC 2307
Db      1   GUACACUGCAGGAGAGUGC 19

RESULT 908
US-10-800-487-129
; Sequence 129, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 129
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-129

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY      2307 CCTGGCAAAAAGATCAAAAT 2325
Db      1   CCUGGCAAAAAGAUCAAU 19

RESULT 909
US-10-800-487-130
; Sequence 130, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 130
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-130

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      2325 TGGGGCTGGGACTTCTCAT 2343
Db      1   UGGGGCUGGGACUUCUAU 19

RESULT 910
US-10-800-487-131
; Sequence 131, Application US/10800487
; Publication No. US20050048529A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siRNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ PRIOR FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 131
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-131

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2343 TTGCCCAACTGCGCTTCC 2361
Db 1 UUGGCCAACCGCCUUC 19

RESULT 911
US-10-800-487-132
/ Sequence 132, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ PRIOR FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 131
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-131

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2343 TTGCCCAACTGCGCTTCC 2361
Db 1 UUGGCCAACCGCCUUC 19

RESULT 911
US-10-800-487-132
/ Sequence 132, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ PRIOR FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 132
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-132

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2361 CCCAGAAGGAGTGATTTT 2379
Db 1 CCCAGAGGAGUGAUUUU 19

RESULT 912
US-10-800-487-133
/ Sequence 133, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ PRIOR FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 133
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-133
```

```
Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02; Indels 0; Gaps 0;
Matches 16; Conservative 3; Mismatches 0;

QY 2379 TCTATCGGCACAAAAGCAC 2397
Db 1 UCUAUGGCGACAAAAGCAC 19

RESULT 913
US-10-800-487-134
; Sequence 134, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 134
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-134

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02; Indels 0; Gaps 0;
Matches 16; Conservative 3; Mismatches 0;

QY 2397 CTATATGGACTGGTAATGG 2415
Db 1 CUAAUAGGACUGGUAUGG 19

RESULT 914
US-10-800-487-135
; Sequence 135, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
```

```
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 135
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-135

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2415 GTTCACAGGTTCCAGAGATT 2433
Db 1 GUUCACAGGUUCAGAGAUU 19

RESULT 915
US-10-800-487-136
; Sequence 136, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 136
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-136
```

;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 438
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 136
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-136

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2433 TACCCAGTAGGCGCTTATT 2451
Db 1 UACCCAGUGAGGCCUUAU 19

RESULT 916
US-10-800-487-137
;; Sequence 137, Application US/10800487
;; Publication No. US20050048529A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;; FILE REFERENCE: 400/148 (MBHB04-218)
;; CURRENT APPLICATION NUMBER: US/10/800,487
;; CURRENT FILING DATE: 2004-03-15
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-15
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: US 10/427,160
;; PRIOR FILING DATE: 2003-04-30
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 137
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-137

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2451 TCCTCCCTTCCCCCAAAA 2469
Db 1 UCCUCCCUCCCCCAAAA 19

RESULT 917
US-10-800-487-138
;; Sequence 138, Application US/10800487
;; Publication No. US20050048529A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;; FILE REFERENCE: 400/148 (MBHB04-218)
;; CURRENT APPLICATION NUMBER: US/10/800,487
;; CURRENT FILING DATE: 2004-03-15
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-15
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: US 10/427,160
;; PRIOR FILING DATE: 2003-04-30
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 138
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-138

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2469 ACTGACACCTTGTGTAGCC 2487
Db 1 ACUGACACCUUGUUGAGCC 19

RESULT 918
US-10-800-487-139
;; Sequence 139, Application US/10800487
;; Publication No. US20050048529A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;; FILE REFERENCE: 400/148 (MBHB04-218)
;; CURRENT APPLICATION NUMBER: US/10/800,487
;; CURRENT FILING DATE: 2004-03-15
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-15
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059

```
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 139
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-139

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2487 CACCTCCCCACCACATAC 2505
Db 1 CACCUCUCCACCACCAUAC 19

RESULT 919
US-10-800-487-140
; Sequence 140, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 140
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-140

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 63.2%; Pred. No. 6.3e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 2505 CATTTCGCCAGTGTTCAC 2523
Db 1 CAUUCUGCCAGUGUUCAC 19

RESULT 920
US-10-800-487-141
; Sequence 141, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 141
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-141

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 6.3e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 2523 CAATGACACTCAGCGGTCA 2541
Db 1 CAAUGACACUCACGCGUCA 19

RESULT 921
US-10-800-487-142
; Sequence 142, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
```

```
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 142
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-142

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2541 ATGCTGTGGACATGAGTGCC 2559
||:|||||:|||||
Db 1 AUGUCUGGACAUAGUGCC 19

RESULT 922
US-10-800-487-143
/ Sequence 143, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 142
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-142
```

```
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 143
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-143

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2559 CCAGGGAATATGCCCAAGC 2577
|||||:|||||
Db 1 CCAGGGAAUAGCCCAAGC 19

RESULT 923
US-10-800-487-144
/ Sequence 144, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 144
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-144

Query Match 0.6%; Score 19; DB 1; Length 19;
```



```
; Best Local Similarity 52.6%; Pred. No. 6.3e+02; Mismatches 9; Indels 0; Gaps 0;
Matches 10; Conservative
QY 2577 CTATGCTTGCTCTCTGT 2595
   |||::|::|::|::|::|::|
Db 1 CUAGCCUUGCCUUCUGU 19

RESULT 924
US-10-800-487-145
; Sequence 145, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 145
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-145

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 6.3e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 2595 TCCTGTTGCTTCTACTG 2613
   |||::|::|::|::|::|::|
Db 1 UCCUGUUGCAUUCACUG 19

RESULT 925
US-10-800-487-146
; Sequence 146, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 146
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-146

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 52.6%; Pred. No. 6.3e+02;
Matches 10; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 2595 TCCTGTTGCTTCTACTG 2613
   |||::|::|::|::|::|::|
Db 1 UCCUGUUGCAUUCACUG 19

RESULT 926
US-10-800-487-147
; Sequence 147, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 147
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-147

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2613 GGGAGCTTGCACTATTGCA 2631
   |||::|::|::|::|::|::|
Db 1 GGGAGCUUGCACUUGCA 19

RESULT 926
US-10-800-487-147
; Sequence 147, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 148
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-147
```

;; PRIOR FILING DATE: 2002-06-06
;; Remaining Prior Application data removed - See File Wrapper or PALM.

;; NUMBER OF SEQ ID NOS: 438
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 147
;; LENGTH: 19

;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:

;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-147

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2631 AGCTCCAGTTCTCTGCAGT 2649
|||:||||:||||:||||:
Db 1 AGCUCCAGUUUCCUGCAGU 19

RESULT 927

US-10-800-487-148
; Sequence 148, Application US/10800487
; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; FILE OF INVENTION: Acid (siRNA)

; FILE REFERENCE: 400/148 (MBHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; CURRENT FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/427,160

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 148

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-148

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2649 TGATCAGGTCCTGCAAGC 2667
:||||:||||:||||:
Db 1 UGAUCAGGUCUCCUGCAAGC 19

RESULT 928

US-10-800-487-149

; Sequence 149, Application US/10800487

; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; FILE OF INVENTION: Acid (siRNA)

; FILE REFERENCE: 400/148 (MBHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; CURRENT FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/427,160

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 149

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense

US-10-800-487-149

Query Match 0.6%; Score 19; DB 1; Length 19;

Best Local Similarity 94.7%; Pred. No. 6.3e+02;

Matches 18; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 2667 CAGTGGGGAAGGGGGCCAA 2685

||||:||||:||||:||||:
Db 1 CAGUGGGGAGGGGGCCAA 19

RESULT 929

US-10-800-487-150

; Sequence 150, Application US/10800487

; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; FILE OF INVENTION: Acid (siRNA)

; FILE REFERENCE: 400/148 (MBHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; CURRENT FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; Publication No. US20050048529A1
 ;
 ; GENERAL INFORMATION:
 ;
 ; APPLICANT: Sirna Therapeutics, Inc.
 ;
 ; APPLICANT: McSwiggen, James
 ;
 ; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
 ;
 ; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nuclei
 ;
 ; TITLE OF INVENTION: Acid (siRNA)

```

; NUMBER OF SEQ ID NOS: 436
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 155
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-155

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;

```

```
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2775 GCGTGGAGTGCAGTGGTC 2793
    |||:||||:||||:||||:
Db 1 GGCUGAGUGCAGUGGUC 19

RESULT 935
US-10-800-487-156
; Sequence 156, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.3
; NUMBER OF SEQ ID NOS: 438
; SEQ ID NO 156
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-156

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 73.7%; Pred.No. 6.3e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 2793 CAATCATGTTTCACTCCAG 2811
    |||:||||:||||:||||:
Db 1 CAAUCAUGGUACACUGCAG 19

RESULT 936
US-10-800-487-157
; Sequence 157, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
```

```
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.3
; NUMBER OF SEQ ID NOS: 438
; SEQ ID NO 157
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense 1
US-10-800-487-157

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred.No. 6.3e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 2811 GCTTGACCTTTTGGGCTC 2829
    |:::||||:||||:
Db 1 GUCUGACCUUUGGGCUC 19

RESULT 937
US-10-800-487-158
; Sequence 158, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2002-06-06
```

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 158
; LENGTH: 19

; TYPE: RNA
; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-158

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2829 CAAGTGATCTCCACCTC 2847

Db 1 CAAGUGAUCCUCCACCUC 19

RESULT 938

US-10-800-487-159
; Sequence 159, Application US/10800487
; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; TITLE OF INVENTION: Acid (siRNA)

; FILE REFERENCE: 400/148 (MBHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; CURRENT FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/427,160

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 159

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-800-487-159

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 2847 CAGCCTCCTGAGTAGCTGG 2865

Db 1 CAGCCUCCUGAGUAGUCGG 19

```
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 161
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-161

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 6.3e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      2883 ACCACACCTGGCAAATTTG 2901
        |||||:|||||:|||||:|
Db       1 ACCACACCGGCAAAUUUG 19

RESULT 941
US-10-800-487-162
; Sequence 162, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 162
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-162

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 15.8%; Pred. No. 6.3e+02;
Matches 3; Conservative 16; Mismatches 0; Indels 0; Gaps 0;

QY      2901 GATTTTTCCTTTTTCCTTC 2919
        |||:|||||:|||||:|
Db       1 GAUUUUUUUUUUUUUUUC 19

RESULT 942
US-10-800-487-163
; Sequence 163, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 163
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-163

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 6.3e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      2919 CAGACACGGGTCTCGCAA 2937
        |||||:|||||:|||||:|
Db       1 CAGACACGGGGUCUCGCAA 19

RESULT 943
US-10-800-487-164
; Sequence 164, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
```

;; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;; FILE REFERENCE: 400/148 (MEHB04-218)
;; CURRENT APPLICATION NUMBER: US/10/800,487
;; CURRENT FILING DATE: 2004-03-15
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-15
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: US 10/427,160
;; PRIOR FILING DATE: 2003-04-30
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 438
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 164
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-164

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2937 ACATTGCCAGACTTCCTT 2955
|||||:|||||:|||||:
DB 1 ACAUUGCCCGAGACUCCUU 19

RESULT 944
US-10-800-487-165
;; Sequence 165, Application US/10800487
;; Publication No. US20050048529A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;; FILE REFERENCE: 400/148 (MEHB04-218)
;; CURRENT APPLICATION NUMBER: US/10/800,487
;; CURRENT FILING DATE: 2004-03-15
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-15
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: US 10/427,160
;; PRIOR FILING DATE: 2003-04-30
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 438
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 164
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-165

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 438
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 165
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-165

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 57.9%; Pred. No. 6.3e+02;
Matches 11; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 2955 TTGTGTTAGTTAATAAGC 2973
::|:|:|:|:|:|:|:|:|:|:
DB 1 UUGUGUGUAGUUAUAAAGC 19

RESULT 945
US-10-800-487-166
;; Sequence 166, Application US/10800487
;; Publication No. US20050048529A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;; FILE REFERENCE: 400/148 (MEHB04-218)
;; CURRENT APPLICATION NUMBER: US/10/800,487
;; CURRENT FILING DATE: 2004-03-15
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-15
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: US 10/427,160
;; PRIOR FILING DATE: 2003-04-30
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 438
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 166
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-800-487-166

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 6.3e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2966 AATAAGCTTCTCAACTG 2984
||:|||||:::|:|||||:
Db 1 AAUAAAGCUUUCUACAUG 19

RESULT 946

US-10-800-487-167/c
; Sequence 167, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 167
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-167

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCCCCAGTCGACGCTGAGC 21
|||||:|||||:|||||:
Db 19 GCCCCAGTCGACGCTGAGC 1

RESULT 947

US-10-800-487-168/c
; Sequence 168, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 168
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-168

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 CTCCTCTGCTACTCAGAGT 39
|||||:|||||:|||||:
Db 19 CTCCTCTGCTACTCAGAGT 1

RESULT 948

US-10-800-487-169/c
; Sequence 169, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.

```
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 169
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-169

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 39 TTGCAACCTCAGCTCGCT 57
      |||||
Db 19 TTGCAACCTCAGCTCGCT 1

RESULT 949
US-10-800-487-170/c
; Sequence 170, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 170
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-170

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 57 TATGGCTCCAGCAGCC 75
      |||||
Db 19 TATGGCTCCAGCAGCC 1

RESULT 950
```

```
US-10-800-487-171/c
; Sequence 171, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 171
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-171

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 75 CCGGCCCGCGCTGCCGCA 93
      |||||
Db 19 CCGGCCCGCGCTGCCGCA 1

RESULT 951
US-10-800-487-172/c
; Sequence 172, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
```

```
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 172
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-172

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 93 ACTCCTGGTCTGCTCGGG 111
Db 19 ACTCCTGGTCTGCTCGGG 1

RESULT 952
US-10-800-487-173/c
; Sequence 173, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 173
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-173/c
```

```
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-173

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 111 GGCTCTGTTCACGACCT 129
Db 19 GGCTCTGTTCACGACCT 1

RESULT 953
US-10-800-487-174/c
; Sequence 174, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 174
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-174

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 129 TGGCAATGCCAGACATCT 147
Db 19 TGGCAATGCCAGACATCT 1

RESULT 954
US-10-800-487-175/c
; Sequence 175, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
```

```
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 175
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-175

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 147 TGTGTCCTCCCTCAAAAGTC 165
Db 19 TGTGTCCTCCCTCAAAAGTC 1

RESULT 955
US-10-800-487-176/c
; Sequence 176, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 177
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-177

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 176
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-176

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 165 CATCTGCCCCCGGGGAGGC 183
Db 19 CATCTGCCCCCGGGGAGGC 1

RESULT 956
US-10-800-487-177/c
; Sequence 177, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 177
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-177

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 179
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-179

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 219 GCCCAAGTTGTTGGGCATA 237
Db 19 GCCCAAGTTGTTGGGCATA 1

RESULT 959
US-10-800-487-180/c
; Sequence 180, Application US/108000487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/1148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438

```

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 180
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-180

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 237 AGAGACCCCGTTCCTAA 255
    |||||
Db 19 AGAGACCCCGTTCCTAAA 1

RESULT 960
US-10-800-487-181/c
; Sequence 181, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT:  Sirna Therapeutics, Inc.
; TITLE OF INVENTION:  RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION:  Acid (sRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 181
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-181

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 255 AAAGGAGTTCCTCCTG 273
    |||||
Db 19 AAAGGAGTTCCTCCTCT 1

RESULT 961
US-10-800-487-182/c
; Sequence 182, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT:  Sirna Therapeutics, Inc.
; TITLE OF INVENTION:  RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION:  Acid (sRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 181
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-182
```

```
; Sequence 182, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT:  Sirna Therapeutics, Inc.
; TITLE OF INVENTION:  RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION:  Acid (sRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 182
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-182

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 273 TCGGAACCAACCGAAGGTG 291
    |||||
Db 19 TCGGAACCAACCGAAGGTG 1

RESULT 962
US-10-800-487-183/c
; Sequence 183, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT:  Sirna Therapeutics, Inc.
; TITLE OF INVENTION:  RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION:  Acid (sRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 183
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-183
```

```
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 183
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
US-10-800-487-183

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 291 GTATGAAGTGCATGTG 309
Db 19 GTATGAAGTGCATGTG 1

RESULT 963
US-10-800-487-184/c
; Sequence 184, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 184
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
```

```
US-10-800-487-184

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 309 GCAAGAAGATAGCCAAACCA 327
Db 19 GCAAGAAGATAGCCAAACCA 1

RESULT 964
US-10-800-487-185/c
; Sequence 185, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 185
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
US-10-800-487-185

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 327 AATGTGCTATTCAAACCTGC 345
Db 19 AATGTGCTATTCAAACCTGC 1

RESULT 965
US-10-800-487-186/c
; Sequence 186, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
```

;; TITLE OF INVENTION: Acid (siRNA)
;; FILE REFERENCE: 400/148 (MEHB04-218)
;; CURRENT APPLICATION NUMBER: US/10/800,487
;; CURRENT FILING DATE: 2004-03-15
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-15
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: US 10/427,160
;; PRIOR FILING DATE: 2003-04-30
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 438
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 186
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-186

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 345 CCTGTATGGCAGTCAACA 363
DB 19 CCTGTATGGCAGTCAACA 1

RESULT 966
US-10-800-487-187/c
;; Sequence 187, Application US/10800487
;; Publication No. US20050048529A1
;; GENERAL INFORMATION:
;; APPLICANT: McSwiggen, James
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;; FILE REFERENCE: 400/148 (MEHB04-218)
;; CURRENT APPLICATION NUMBER: US/10/800,487
;; CURRENT FILING DATE: 2004-03-15
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-15
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: US 10/427,160
;; PRIOR FILING DATE: 2003-04-30
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; Remaining Prior Application data removed - See File Wrapper or PALM.

;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 438
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 187
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-187

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 363 AGCTAAACCTTCCTCACC 381
DB 19 AGCTAAACCTTCCTCACC 1

RESULT 967
US-10-800-487-188/c
;; Sequence 188, Application US/10800487
;; Publication No. US20050048529A1
;; GENERAL INFORMATION:
;; APPLICANT: Sirna Therapeutics, Inc.
;; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
;; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
;; TITLE OF INVENTION: Acid (siNA)
;; FILE REFERENCE: 400/148 (MEHB04-218)
;; CURRENT APPLICATION NUMBER: US/10/800,487
;; CURRENT FILING DATE: 2004-03-15
;; PRIOR APPLICATION NUMBER: US 10/757,803
;; PRIOR FILING DATE: 2004-01-15
;; PRIOR APPLICATION NUMBER: US 10/720,448
;; PRIOR FILING DATE: 2003-11-24
;; PRIOR APPLICATION NUMBER: US 10/693,059
;; PRIOR FILING DATE: 2003-10-23
;; PRIOR APPLICATION NUMBER: US 10/444,853
;; PRIOR FILING DATE: 2003-05-23
;; PRIOR APPLICATION NUMBER: US 10/427,160
;; PRIOR FILING DATE: 2003-04-30
;; PRIOR APPLICATION NUMBER: PCT/US03/05346
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: PCT/US03/05028
;; PRIOR FILING DATE: 2003-02-20
;; PRIOR APPLICATION NUMBER: US 60/358,580
;; PRIOR FILING DATE: 2002-02-20
;; PRIOR APPLICATION NUMBER: US 60/363,124
;; PRIOR FILING DATE: 2002-03-11
;; PRIOR APPLICATION NUMBER: US 60/386,782
;; PRIOR FILING DATE: 2002-06-06
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 438
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 188
;; LENGTH: 19
;; TYPE: RNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-188

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 381 CGTGACTGGACTCCAGAA 399


```
Db      19  CGGTGACTGGACTCCAGAA 1
|||||
RESULT 968
US-10-800-487-189/c
; Sequence 189, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sRNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 189
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-800-487-189

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      399  ACGGGTGGAACTGGCACCC 417
|||||
Db      19  ACGGGTGGAACTGGCACCC 1
|||||
RESULT 969
US-10-800-487-190/c
; Sequence 190, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sRNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
```

```
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 190
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-800-487-190

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      417  CCTCCCCCTTTGGCAGCCA 435
|||||
Db      19  CCTCCCCCTTTGGCAGCCA 1
|||||
RESULT 970
US-10-800-487-191/c
; Sequence 191, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sRNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 191
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-800-487-191
```

```
; SEQ ID NO 191
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-191

Query Match
Best Local Similarity 0.6%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 435 AGTGGGCAAGACCTTACC 453
Db 19 AGTGGGCAAGACCTTACC 1

RESULT 971
US-10-800-487-192/c
; Sequence 192, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 192
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-193

Query Match
Best Local Similarity 0.6%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 471 GCGTGGGCACCCCGGCC 489
Db 19 GCGTGGGCACCCCGGCC 1

RESULT 973
US-10-800-487-194/c
; Sequence 194, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
```

```
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 193
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-193

Query Match
Best Local Similarity 0.6%; Score 19; DB 1; Length 19;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 471 GCGTGGGCACCCCGGCC 489
Db 19 GCGTGGGCACCCCGGCC 1

RESULT 973
US-10-800-487-194/c
; Sequence 194, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
```

```

; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 194
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-194
```

```

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY 489 CAACCTCACCGTGGTGCTG 507
      |||||
Db 19 CAACCTCACCGTGGTGCTG 1
```

```

RESULT 974
US-10-800-487-195/c
; Sequence 195, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 195
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-195
```

```

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY 507 GCTCCGTGGGAGAGGAG 525
      |||||
Db 19 GCTCCGTGGGAGAGGAG 1
```

```

RESULT 975
US-10-800-487-196/c
; Sequence 196, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 196
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-196
```

```

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY 525 GCTGAAACGGGAGCCAGCT 543
      |||||
Db 19 GCTGAAACGGGAGCCAGCT 1
```

```

RESULT 976
US-10-800-487-197/c
; Sequence 197, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 195
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-195
```

FILE REFERENCE: 400/148 (MBHB04-218)
CURRENT APPLICATION NUMBER: US/10/800,487
PRIORITY FILING DATE: 2004-03-15
PRIORITY FILING DATE: 2004-01-15
PRIORITY FILING DATE: 2004-01-15
PRIORITY FILING DATE: 2003-11-24
PRIORITY FILING DATE: 2003-11-24
PRIORITY FILING DATE: 2003-10-23
PRIORITY FILING DATE: 2003-10-23
PRIORITY FILING DATE: 2003-05-23
PRIORITY FILING DATE: 2003-05-23
PRIORITY FILING DATE: 2003-04-30
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2002-02-20
PRIORITY FILING DATE: 2002-03-11
PRIORITY FILING DATE: 2002-06-06
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 438
SOFTWARE: PatentIn version 3.3
SEQ ID NO 197
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-197

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 543 TGTGGGGGAGCCCGCTGAG 561
Db 19 TGTGGGGGAGCCCGCTGAG 1

RESULT 977
US-10-800-487-198/c
Sequence 198, Application US/10800487
Publication No. US20050048529A1
GENERAL INFORMATION:
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/148 (MBHB04-218)
CURRENT APPLICATION NUMBER: US/10/800,487
PRIORITY FILING DATE: 2004-03-15
PRIORITY FILING DATE: 2004-01-15
PRIORITY FILING DATE: 2003-11-24
PRIORITY FILING DATE: 2003-11-24
PRIORITY FILING DATE: 2003-10-23
PRIORITY FILING DATE: 2003-05-23
PRIORITY FILING DATE: 2003-04-30
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2002-02-20
PRIORITY FILING DATE: 2002-02-20
PRIORITY FILING DATE: 2002-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 438
SOFTWARE: PatentIn version 3.3
SEQ ID NO 198
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-198

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 579 GGTGAGGAGATCACCAT 597
Db 19 GGTGAGGAGATCACCAT 1

PRIORITY FILING DATE: 2002-03-11
PRIORITY FILING DATE: 2002-06-06
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 438
SOFTWARE: PatentIn version 3.3
SEQ ID NO 198
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-198

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 561 GGTGAGGAGATCACCAT 597
Db 19 GGTGAGGAGATCACCAT 1

RESULT 978
US-10-800-487-199/c
Sequence 199, Application US/10800487
Publication No. US20050048529A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/148 (MBHB04-218)
CURRENT APPLICATION NUMBER: US/10/800,487
PRIORITY FILING DATE: 2004-03-15
PRIORITY FILING DATE: 2004-01-15
PRIORITY FILING DATE: 2004-01-15
PRIORITY FILING DATE: 2003-11-24
PRIORITY FILING DATE: 2003-10-23
PRIORITY FILING DATE: 2003-10-23
PRIORITY FILING DATE: 2003-05-23
PRIORITY FILING DATE: 2003-04-30
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2003-02-20
PRIORITY FILING DATE: 2002-02-20
PRIORITY FILING DATE: 2002-03-11
PRIORITY FILING DATE: 2002-06-06
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 438
SOFTWARE: PatentIn version 3.3
SEQ ID NO 199
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-199

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 579 GGTGAGGAGATCACCAT 597
Db 19 GGTGAGGAGATCACCAT 1


```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
US-10-800-487-202

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 633 GCGGCCCCCAAGGCTGGAG 651
Db 19 GCGGCCCCCAAGGCTGGAG 1

RESULT 982
US-10-800-487-203/c
; Sequence 203, Application US/108000487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT:  McSwiggen, James
; TITLE OF INVENTION:  RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE:  400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER:  US 10/800,487
; PRIOR FILING DATE:  2004-03-15
; PRIOR APPLICATION NUMBER:  US 10/757,803
; PRIOR FILING DATE:  2004-01-15
; PRIOR APPLICATION NUMBER:  US 10/720,448
; PRIOR FILING DATE:  2003-11-24
; PRIOR APPLICATION NUMBER:  US 10/693,059
; PRIOR FILING DATE:  2003-11-24
; PRIOR APPLICATION NUMBER:  US 10/444,853
; PRIOR FILING DATE:  2003-05-23
; PRIOR APPLICATION NUMBER:  US 10/427,160
; PRIOR FILING DATE:  2003-04-30
; PRIOR APPLICATION NUMBER:  PCT/US03/05346
; PRIOR FILING DATE:  2003-02-20
; PRIOR APPLICATION NUMBER:  PCT/US03/05028
; PRIOR FILING DATE:  2003-02-20
; PRIOR APPLICATION NUMBER:  US 60/358,580
; PRIOR FILING DATE:  2002-02-20
; PRIOR APPLICATION NUMBER:  US 60/363,124
; PRIOR FILING DATE:  2002-03-11
; PRIOR APPLICATION NUMBER:  US 60/386,782
; PRIOR FILING DATE:  2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS:  438
; SOFTWARE:  PatentIn version 3.3
; SEQ ID NO 203
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
US-10-800-487-203

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 651 GCTGTTTGAGAACACCTCG 669
Db 19 GCTGTTTGAGAACACCTCG 1

RESULT 983
US-10-800-487-204/c
; Sequence 204, Application US/108000487
; Publication No. US20050048529A1
```

```
; GENERAL INFORMATION:
; APPLICANT:  McSwiggen, James
; TITLE OF INVENTION:  RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE:  400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER:  US 10/800,487
; PRIOR FILING DATE:  2004-03-15
; PRIOR APPLICATION NUMBER:  US 10/757,803
; PRIOR FILING DATE:  2004-01-15
; PRIOR APPLICATION NUMBER:  US 10/720,448
; PRIOR FILING DATE:  2003-11-24
; PRIOR APPLICATION NUMBER:  US 10/693,059
; PRIOR FILING DATE:  2003-10-23
; PRIOR APPLICATION NUMBER:  US 10/444,853
; PRIOR FILING DATE:  2003-05-23
; PRIOR APPLICATION NUMBER:  US 10/427,160
; PRIOR FILING DATE:  2003-04-30
; PRIOR APPLICATION NUMBER:  PCT/US03/05346
; PRIOR FILING DATE:  2003-02-20
; PRIOR APPLICATION NUMBER:  PCT/US03/05028
; PRIOR FILING DATE:  2003-02-20
; PRIOR APPLICATION NUMBER:  US 60/358,580
; PRIOR FILING DATE:  2002-02-20
; PRIOR APPLICATION NUMBER:  US 60/363,124
; PRIOR FILING DATE:  2002-03-11
; PRIOR APPLICATION NUMBER:  US 60/386,782
; PRIOR FILING DATE:  2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS:  438
; SOFTWARE:  PatentIn version 3.3
; SEQ ID NO 204
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
US-10-800-487-204

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 GGCCCCCTACCAGCTCCAG 687
Db 19 GGCCCCCTACCAGCTCCAG 1

RESULT 984
US-10-800-487-205/c
; Sequence 205, Application US/108000487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT:  McSwiggen, James
; TITLE OF INVENTION:  RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE:  400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER:  US 10/800,487
; PRIOR FILING DATE:  2004-03-15
; PRIOR APPLICATION NUMBER:  US 10/757,803
; PRIOR FILING DATE:  2004-01-15
; PRIOR APPLICATION NUMBER:  US 10/720,448
; PRIOR FILING DATE:  2003-11-24
; PRIOR APPLICATION NUMBER:  US 10/693,059
; PRIOR FILING DATE:  2003-10-23
; PRIOR APPLICATION NUMBER:  US 10/444,853
; PRIOR FILING DATE:  2003-05-23
; PRIOR APPLICATION NUMBER:  US 10/427,160
; PRIOR FILING DATE:  2003-04-30
; PRIOR APPLICATION NUMBER:  PCT/US03/05346
```

```
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 205
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-205

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      687 GACCTTTGTCCTGCCAGCG 705
      |||||
Db      19 GACCTTTGTCCTGCCAGCG 1

RESULT 985
US-10-800-487-206/c
; Sequence 206, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 206
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-206
```

```
Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      705 GACTCCCCCACAACCTTGTC 723
      |||||
Db      19 GACTCCCCCACAACCTTGTC 1

RESULT 986
US-10-800-487-207/c
; Sequence 207, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 207
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-207

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      723 CAGCCCCCGGCTCCTAGAG 741
      |||||
Db      19 CAGCCCCCGGCTCCTAGAG 1

RESULT 987
US-10-800-487-208/c
; Sequence 208, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
```

; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 208
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-800-487-208

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 GGTGGACACGACGGGACC 759
|||||
Db 19 GGTGGACACGACGGGACC 1

RESULT 988
US-10-800-487-209/c
; Sequence 209, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 209
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-800-487-209

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 759 CGTGGTCTCTCCCTGGAC 777
|||||
Db 19 CGTGGTCTCTCCCTGGAC 1

RESULT 989
US-10-800-487-210/c
; Sequence 210, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 210
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-800-487-210

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 741 GGTGGACACGACGGGACC 759
|||||
Db 19 GGTGGACACGACGGGACC 1

RESULT 988
US-10-800-487-209/c
; Sequence 209, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 210
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
US-10-800-487-210

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 777 CGGGCTGTTCACGTCG 795
|||||
Db 19 CGGGCTGTTCACGTCG 1

RESULT 990

US-10-800-487-211/c
; Sequence 211, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 211
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-211

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 795 GGAGGCCCGGTCCACCTG 813

Db 19 CGAGGCCCGGTCCACCTG 1

RESULT 991

US-10-800-487-212/c
; Sequence 212, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 212
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-212

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 813 GGCACCTGGGGACACGAGG 831

Db 19 GGCACCTGGGGACACGAGG 1

RESULT 992

US-10-800-487-213/c
; Sequence 213, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 213
; LENGTH: 19

```
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-213

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 831 GTTGAACCCACAGTCACC 849
Db 19 GTTGAACCCACAGTCACC 1

RESULT 993
US-10-800-487-214/c
; Sequence 214, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 214
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-214

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 849 CTATGGCAACGACTCCTTC 867
Db 19 CTATGGCAACGACTCCTTC 1

RESULT 994
US-10-800-487-215/c
; Sequence 215, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 214
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-214
```

```
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 215
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-215

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 867 CTCGGCCAAAGGCTCAGTC 885
Db 19 CTCGGCCAAAGGCTCAGTC 1

RESULT 995
US-10-800-487-216/c
; Sequence 216, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
```

```
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 216
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-216

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      885 CAGTGTGACCGCAGAGGAC 903
        |||||
Db       19 CAGTGTGACCGCAGAGGAC 1

RESULT 996
US-10-800-487-217/c
/ Sequence 217, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 217
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-217

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      885 CAGTGTGACCGCAGAGGAC 903
        |||||
Db       19 CAGTGTGACCGCAGAGGAC 1

RESULT 997
US-10-800-487-218/c
/ Sequence 218, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 218
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-218

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      921 GACGTGTGCAGTAATACTG 939
        |||||
Db       19 GACGTGTGCAGTAATACTG 1

RESULT 998
US-10-800-487-219/c
/ Sequence 219, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
```

```
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      903 CGAGGGCACCCAGCGGCTG 921
        |||||
Db       19 CGAGGGCACCCAGCGGCTG 1

RESULT 997
US-10-800-487-218/c
/ Sequence 218, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 218
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-218

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      921 GACGTGTGCAGTAATACTG 939
        |||||
Db       19 GACGTGTGCAGTAATACTG 1

RESULT 998
US-10-800-487-219/c
/ Sequence 219, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
```

```
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 219
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-219

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 939 GGGGAACAGAGCCAGGAG 957
DB 19 GGGGAACAGAGCCAGGAG 1

RESULT 999
US-10-800-487-220/c
; Sequence 220, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 221
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-221

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 975 CATCTACAGCTTTCGGCG 993
DB 19 CATCTACAGCTTTCGGCG 1
```

```
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 220
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-220

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 957 GACACTGCAGACAGTGACC 975
DB 19 GACACTGCAGACAGTGACC 1

RESULT 1000
US-10-800-487-221/c
; Sequence 221, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 221
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-221

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 975 CATCTACAGCTTTCGGCG 993
DB 19 CATCTACAGCTTTCGGCG 1
```

```
RESULT 1001
US-10-800-487-222/c
; Sequence 222, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 222
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-222

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 993 GCCCAACGTGATTCGACG 1011
DB 19 GCCCAACGTGATTCGACG 1

RESULT 1002
US-10-800-487-223/c
; Sequence 223, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 223
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-223

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 993 GCCCAACGTGATTCGACG 1011
DB 19 GCCCAACGTGATTCGACG 1
```

```
RESULT 1003
US-10-800-487-224/c
; Sequence 224, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 224
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-223

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1011 GAAGCCAGAGGTCAGAA 1029
DB 19 GAAGCCAGAGGTCAGAA 1

RESULT 1003
US-10-800-487-224/c
; Sequence 224, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 224
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-223
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-224

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1029 AGGACCGAGGTGACAGTG 1047
      |||||
Db 19 AGGACCGAGGTGACAGTG 1

RESULT 1004
US-10-800-487-225/c
; Sequence 225, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 225
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-225

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1047 GAAGTGTGAGGCCACCT 1065
      |||||
Db 19 GAAGTGTGAGGCCACCT 1

RESULT 1005
US-10-800-487-226/c
; Sequence 226, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 225
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-225
```

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 226
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-226

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1065 TAGAGCCCAAGGTGACGCTG 1083
      |||||
Db 19 TAGAGCCCAAGGTGACGCTG 1

RESULT 1006
US-10-800-487-227/c
; Sequence 227, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 227
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-227

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1083 GAATGGGTTCCAGCCAG 1101
Db 19 GAATGGGTTCCAGCCAG 1

RESULT 1007
US-10-800-487-228/c
; Sequence 228, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAME) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 228
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-228

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1083 GAATGGGTTCCAGCCAG 1101
Db 19 GAATGGGTTCCAGCCAG 1

RESULT 1007
US-10-800-487-228/c
; Sequence 228, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAME) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 228
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-228

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1101 GCCACTGGCCCGAGGGCC 1119
Db 19 GCCACTGGCCCGAGGGCC 1

RESULT 1008
US-10-800-487-229/c
; Sequence 229, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAME) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 229
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-229

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1119 CCAGCTCCTGCTGAAGGCC 1137
Db 19 CCAGCTCCTGCTGAAGGCC 1

RESULT 1009
US-10-800-487-230/c
; Sequence 230, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAME) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
```

```
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 230
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-230

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1137 CACCCAGAGGACACACGGG 1155
      |||||
Db 19 CACCCAGAGGACACACGGG 1

RESULT 1010
US-10-800-487-231/c
/ Sequence 231, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MEHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 231
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-231
```

```
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 231
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-231
```

```
Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1155 GCGCAGCTTCTCTGCTCT 1173
      |||||
Db 19 GCGCAGCTTCTCTGCTCT 1
```

```
RESULT 1011
US-10-800-487-232/c
/ Sequence 232, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MEHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 232
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-232
```

```
Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1173 TCGAACCCCTGGAGGTGGCC 1191
      |||||
Db 19 TCGAACCCCTGGAGGTGGCC 1
```



```
RESULT 1012
US-10-800-487-233/c
; Sequence 233, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 233
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-233

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1191 CGGCCAGCTTATACACAAG 1209
Db 19 CGGCCAGCTTATACACAAG 1

RESULT 1013
US-10-800-487-234/c
; Sequence 234, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
```

```
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 234
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-234

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1209 GAACACAGACCCGGAGCTT 1227
Db 19 GAACACAGACCCGGAGCTT 1

RESULT 1014
US-10-800-487-235/c
; Sequence 235, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 235
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
```

```
;
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-800-487-235

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1227 TCCTGTCCTGTATGGCCCC 1245
    |||||
Db 19 TCCTGTCCTGTATGGCCCC 1

RESULT 1015
US-10-800-487-236/c
; Sequence 236, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT:  McSwiggen, James
; TITLE OF INVENTION:  RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION:  Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 236
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-800-487-236

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1245 CCGACTGGACGAGGGAT 1263
    |||||
Db 19 CCGACTGGACGAGGGAT 1

RESULT 1016
US-10-800-487-237/c
; Sequence 237, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT:  McSwiggen, James
; TITLE OF INVENTION:  RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION:  Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 236
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-800-487-236
```

```
;
; TITLE OF INVENTION:  RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION:  Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 237
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  siNA antisense region
US-10-800-487-237

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1263 TTGTCGGGAAACTGGACG 1281
    |||||
Db 19 TTGTCGGGAAACTGGACG 1

RESULT 1017
US-10-800-487-238/c
; Sequence 238, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT:  Sirna Therapeutics, Inc.
; APPLICANT:  McSwiggen, James
; TITLE OF INVENTION:  RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION:  Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION:  Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
```

```
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 238
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
US-10-800-487-238

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1281 GTGGCAGAAATTCACG 1299
Db 19 GTGGCAGAAATTCACG 1

RESULT 1018
US-10-800-487-239/c
; Sequence 239, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (s1NA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 239
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
US-10-800-487-239

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1299 GCAGACTCCAATGTCACG 1317
Db 19 GCAGACTCCAATGTCACG 1
```

RESULT 1019

```
US-10-800-487-240/c
; Sequence 240, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (s1NA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 240
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
US-10-800-487-240
```

```
Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1317 GGCTTGGGGGAACCCATTG 1335
Db 19 GGCTTGGGGGAACCCATTG 1
```

RESULT 1020

```
US-10-800-487-241/c
; Sequence 241, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (s1NA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
```

```
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 241
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-241

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1335 GCCCGAGCTCAAGTGCTA 1353
Db 19 GCCCGAGCTCAAGTGCTA 1

RESULT 1021
US-10-800-487-242/c
; Sequence 242, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 241
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-241
```

```
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 242
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-242

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1353 AAAGGATGGCACTTTCCCA 1371
Db 19 AAAGGATGGCACTTTCCCA 1

RESULT 1022
US-10-800-487-243/c
; Sequence 243, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 243
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-243

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1371 ACTGCCCATCGGGGAATCA 1389
Db 19 ACTGCCCATCGGGGAATCA 1

RESULT 1023
```

```
US-10-800-487-244/c
; Sequence 244, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 244
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-244

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1389 AGTGACTGTCACTCGAGAT 1407
Db 19 AGTGACTGTCACTCGAGAT 1

RESULT 1024
US-10-800-487-245/c
; Sequence 245, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 244
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-244

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1389 AGTGACTGTCACTCGAGAT 1407
Db 19 AGTGACTGTCACTCGAGAT 1

RESULT 1024
US-10-800-487-245/c
; Sequence 245, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 245
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-245

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1407 TCTTGAGGGCACCTACCTC 1425
Db 19 TCTTGAGGGCACCTACCTC 1

RESULT 1025
US-10-800-487-246/c
; Sequence 246, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 246
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-245
```

OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-246

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1425 CTCTCGGGCCAGGAGCACT 1443
|||||
Db 19 CTGTGGGCCAGGAGCACT 1

RESULT 1026

US-10-800-487-247/c
Sequence 247, Application US/10800487
Publication No. US20050048529A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/148 (MBHB04-218)

CURRENT APPLICATION NUMBER: US/10/800,487
CURRENT FILING DATE: 2004-03-15
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-15
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: US 10/427,160
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 438
SOFTWARE: PatentIn version 3.3
SEQ ID NO 247
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-247

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1443 TCAAGGGGAGGTCAACCGC 1461
|||||
Db 19 TCAAGGGGAGGTCAACCGC 1

RESULT 1027

US-10-800-487-248/c
Sequence 248, Application US/10800487
Publication No. US20050048529A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
TITLE OF INVENTION: Acid (siNA)
FILE REFERENCE: 400/148 (MBHB04-218)
CURRENT APPLICATION NUMBER: US/10/800,487
CURRENT FILING DATE: 2004-03-15
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-15
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: US 10/427,160
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 438
SOFTWARE: PatentIn version 3.3
SEQ ID NO 248
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-248

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1461 CGAGGTGACCGTGAATGTG 1479
|||||
Db 19 CGAGGTGACCGTGAATGTG 1

RESULT 1028

US-10-800-487-249/c
Sequence 249, Application US/10800487
Publication No. US20050048529A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.

TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/148 (MBHB04-218)
CURRENT APPLICATION NUMBER: US/10/800,487
CURRENT FILING DATE: 2004-03-15
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-15
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: US 10/427,160
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580

```
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 249
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-249

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1479 GCTCTCCCCCGGTATGAG 1497
Db 19 GCTCTCCCCCGGTATGAG 1

RESULT 1029
US-10-800-487-250/c
; Sequence 250, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 250
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-250

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1497 GATTGTCATCATCTG 1515
Db 19 GATTGTCATCATCTG 1

RESULT 1030
US-10-800-487-251/c
; Sequence 251, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 251
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-251

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1515 GGTAGCAGCCGCGATCATA 1533
Db 19 GGTAGCAGCCGCGATCATA 1

RESULT 1031
US-10-800-487-252/c
; Sequence 252, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
```

```
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 252
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-252

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1533 AATGGGCACTGCAGGCTC 1551
      |||
      19 AATGGGCACTGCAGGCTC 1

RESULT 1032
US-10-800-487-253/c
/ Sequence 253, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 254
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-254

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1569 CGCCGAGCGGAGATCAAG 1587
      |||
      19 CGCCGAGCGGAGATCAAG 1

RESULT 1034
US-10-800-487-255/c
```

```
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 253
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-253

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1551 CAGCAGCTACTCTATAAC 1569
      |||
      19 CAGCAGCTACTCTATAAC 1

RESULT 1033
US-10-800-487-254/c
/ Sequence 254, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 254
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-254

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1569 CGCCGAGCGGAGATCAAG 1587
      |||
      19 CGCCGAGCGGAGATCAAG 1

RESULT 1034
US-10-800-487-255/c
```



```
/ Sequence 255, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siRNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ PRIORITY FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 255
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-255

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1587 GAAATACAGACTACACAG 1605
      |||||
Db 19 GAAATACAGACTACACAG 1

RESULT 1035
US-10-800-487-256/c
/ Sequence 256, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siRNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ PRIORITY FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
```

```
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 256
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-256

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1605 GGCCCCAAAAGGACCCCC 1623
      |||||
Db 19 GGCCCCAAAAGGACCCCC 1

RESULT 1036
US-10-800-487-257/c
/ Sequence 257, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 257
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
```

US-10-800-487-257

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1623 CATGAACCGACACACAA 1641
|||||
DB 19 CATGAACCGACACACAA 1

RESULT 1037

US-10-800-487-258/c
; Sequence 258, Application US/10800487
; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/427,160

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 258

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region

US-10-800-487-258

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1641 AGCCAGCCTCCTGAACC 1659
|||||
DB 19 AGCCAGCCTCCTGAACC 1

RESULT 1038

US-10-800-487-259/c
; Sequence 259, Application US/10800487
; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; TITLE OF INVENTION: Acid (sirna)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 259
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: sirna antisense region

US-10-800-487-259

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1659 CTATCCCGGACAGGGCCT 1677
|||||
DB 19 CTATCCCGGACAGGGCCT 1

RESULT 1039

US-10-800-487-260/c
; Sequence 260, Application US/10800487
; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/427,160

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 260
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-260

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1677 TCTTCTCGGCTTCCCAT 1695
|||||
DB 19 TCTTCTCGGCTTCCCAT 1

RESULT 1040
US-10-800-487-261/c
; Sequence 261, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 261
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-261

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1695 TATGGTGGCAGTGGGCC 1713

DB 19 TATGGTGGCAGTGGGCC 1
|||||

RESULT 1041
US-10-800-487-262/c
; Sequence 262, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 262
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-262

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1713 CACACTGAACAGAGTGGAA 1731
|||||

DB 19 CACACTGAACAGAGTGGAA 1
|||||

RESULT 1042
US-10-800-487-263/c
; Sequence 263, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448

```
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 263
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-263

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1731 AGACATATGCCATGCAGCT 1749
Db 19 AGACATATGCCATGCAGCT 1

RESULT 1043
US-10-800-487-264/c
/ Sequence 264, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 265
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-265

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1731 GACGCCGGGAGGACAGGCA 1785
Db 19 GACGCCGGGAGGACAGGCA 1

RESULT 1045
US-10-800-487-266/c
/ Sequence 266, Application US/10800487
```

```
/ SEQ ID NO 264
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-264

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1749 TACACTACCGCCCTGGG 1767
Db 19 TACACTACCGCCCTGGG 1

RESULT 1044
US-10-800-487-265/c
/ Sequence 265, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 265
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-265

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1767 GACGCCGGGAGGACAGGCA 1785
Db 19 GACGCCGGGAGGACAGGCA 1

RESULT 1045
US-10-800-487-266/c
/ Sequence 266, Application US/10800487
```

```
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 266
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-266

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1785 ATTGTCCTCAGTCAGATAC 1803
Db 19 ATTGTCCTCAGTCAGATAC 1

RESULT 1046
US-10-800-487-267/c
; Sequence 267, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 266
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-266
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 267
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-267

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1803 CAACAGCATTGGGGCCAT 1821
Db 19 CAACAGCATTGGGGCCAT 1

RESULT 1047
US-10-800-487-268/c
; Sequence 268, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 268
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-268
```

```
Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1821 TGGTACTGCGACACCTAAA 1839
    |||||
Db 19 TGGTACTGCGACACCTAAA 1

RESULT 1048
US-10-800-487-269/c
; Sequence 269, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 269
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-269

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1839 AACACTAGGCGCGCATCT 1857
    |||||
Db 19 AACACTAGGCGCGCATCT 1

RESULT 1049
US-10-800-487-270/c
; Sequence 270, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 269
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-269
```

```
FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 270
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-270

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1857 TGATCTGTAGTCACATGAC 1875
    |||||
Db 19 TGATCTGTAGTCACATGAC 1

RESULT 1050
US-10-800-487-271/c
; Sequence 271, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
```

; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 271
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-271

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1875 CTAAGCCAAAGAGGAG 1893

Db 19 CTAAGCCAAAGAGGAG 1

RESULT 1051
US-10-800-487-272/c
; Sequence 272, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR FILING DATE: 2003-11-24
; PRIOR FILING DATE: 2003-10-20
; PRIOR FILING DATE: 2003-10-23
; PRIOR FILING DATE: 2003-05-23
; PRIOR FILING DATE: 2003-04-30
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2002-02-20
; PRIOR FILING DATE: 2002-03-11
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 272
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-272

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1893 GCAAGACTCAAGACATGAT 1911
; Sequence 274, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR FILING DATE: 2003-11-24
; PRIOR FILING DATE: 2003-10-20
; PRIOR FILING DATE: 2003-10-23
; PRIOR FILING DATE: 2003-05-23
; PRIOR FILING DATE: 2003-04-30
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2003-02-20
; PRIOR FILING DATE: 2002-02-20
; PRIOR FILING DATE: 2002-03-11
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 272
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-272

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1893 GCAAGACTCAAGACATGAT 1911
; Sequence 274, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24

Db 19 GCAGACTCAAGACATGAT 1

RESULT 1052

US-10-800-487-273/c
; Sequence 273, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/593,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 273
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-273

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1911 TTGATGGATGTTAAAGTCT 1929

Db 19 TTGATGGATGTTAAAGTCT 1

RESULT 1053

US-10-800-487-274/c
; Sequence 274, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24

```
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 274
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-274

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1929 TAGCCTGATGAGAGGGGAA 1947
      |||||
Db 19 TAGCCTGATGAGAGGGGAA 1

RESULT 1054
US-10-800-487-275/c
; Sequence 275, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 275
```

```
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-275

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1947 ACTGGTGGGGAGACATAG 1965
      |||||
Db 19 ACTGGTGGGGAGACATAG 1

RESULT 1055
US-10-800-487-276/c
; Sequence 276, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 276
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-276

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1965 GCCCCACCATGAGGACATA 1983
      |||||
Db 19 GCCCCACCATGAGGACATA 1

RESULT 1056
US-10-800-487-277/c
; Sequence 277, Application US/10800487
; Publication No. US20050048529A1
```



```
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-01-15
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 277
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-277

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1983 ACAACTGGGAATACTGAA 2001
      |||||
Db 19 ACAACTGGGAATACTGAA 1

RESULT 1057
US-10-800-487-278/c
; Sequence 278, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-01-15
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 277
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-277

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1983 ACACTGGGAATACTGAA 2001
      |||||
Db 19 ACAACTGGGAATACTGAA 1

RESULT 1057
US-10-800-487-278/c
; Sequence 278, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-01-15
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 278
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-278

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2001 AACTTGCTGCCCTATTGGGT 2019
      |||||
Db 19 AACTTGCTGCCCTATTGGGT 1

RESULT 1058
US-10-800-487-279/c
; Sequence 279, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/800,487
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 279
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-279
```

```
Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2019 TATGCTGAGCCACACAG 2037
   |||||
Db 19 TATGCTGAGCCACACAG 1

RESULT 1059
US-10-800-487-280/c
; Sequence 280, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 280
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-280

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2037 CTTACAGAGAGTGCC 2055
   |||||
Db 19 CTTACAGAGAGTGCC 1

RESULT 1060
US-10-800-487-281/c
; Sequence 281, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
```

```
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 281
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-281

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2055 CTCCTAGACATGTGTAGC 2073
   |||||
Db 19 CTCCTAGACATGTGTAGC 1

RESULT 1061
US-10-800-487-282/c
; Sequence 282, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
```

```

; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 282
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-282

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2073 CATCAAAACACAAAGGCC 2091
Db 19 CATCAAAACACAAAGGCC 1

RESULT 1062
US-10-800-487-283/c
; Sequence 283, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBH04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 284
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-284

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2109 CCAGCTTGGGCACTGCTGT 2127
Db 19 CCAGCTTGGGCACTGCTGT 1

RESULT 1064
US-10-800-487-285/c
; Sequence 285, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBH04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 283
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-283

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2091 CACACTTCTCGACGGATGC 2109
Db 19 CACACTTCTCGACGGATGC 1
```

```

RESULT 1063
US-10-800-487-284/c
; Sequence 284, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBH04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 284
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-284

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2109 CCAGCTTGGGCACTGCTGT 2127
Db 19 CCAGCTTGGGCACTGCTGT 1

RESULT 1064
US-10-800-487-285/c
; Sequence 285, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBH04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 283
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-283
```

```
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 285
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-285

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2127 TCTACTGACCCCAACCCCTT 2145
Db 19 TCTACTGACCCCAACCCCTT 1

RESULT 1065
US-10-800-487-286/c
; Sequence 286, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 286
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-286

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2145 TCATGATATGTTTATTC 2163
Db 19 TCATGATATGTTTATTC 1

RESULT 1066
US-10-800-487-287/c
; Sequence 287, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 287
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-287

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2163 CATTGTTATTTTACCAGC 2181
Db 19 CATTGTTATTTTACCAGC 1

RESULT 1067
US-10-800-487-288/c
; Sequence 288, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 288
; LENGTH: 19
```

```
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 288
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-288

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2181 CTATTATTAGTGTCCTTT 2199
|||
DB 19 CTATTATTAGTGTCCTTT 1

RESULT 1068
US-10-800-487-289/c
; Sequence 289, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 288
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-288
```

```
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 290
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-289

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2199 TTATGTAGCTAAATGAAC 2217
|||
DB 19 TTATGTAGCTAAATGAAC 1

RESULT 1069
US-10-800-487-290/c
; Sequence 290, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 290
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-290

Query Match 0.6%; Score 19; DB 1; Length 19;
```

```
Best Local Similarity 100.0%; Pred. No. 6.3e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;

QY 2217 CATAGGTCTCTGGCCTCAC 2235
|||||
Db 19 CATAGGTCTCTGGCCTCAC 1

RESULT 1070
US-10-800-487-291/c
; Sequence 291, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 291
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-291

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2253 TCACATTCAAGGTCCACG 2271
|||||
Db 19 TCACATTCAAGGTCCACG 1

RESULT 1071
US-10-800-487-293/c
; Sequence 293, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 291
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-291

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2235 CGGAGCTCCAGTCCATGT 2253
|||||
Db 19 CGGAGCTCCAGTCCATGT 1

RESULT 1071
US-10-800-487-292/c
; Sequence 292, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
```

```
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 292
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-292

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2253 TCACATTCAAGGTCCACG 2271
|||||
Db 19 TCACATTCAAGGTCCACG 1

RESULT 1072
US-10-800-487-293/c
; Sequence 293, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
```

; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 293
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-293

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;

QY 2271 GGTACAGTTGTACAGTTG 2289
|||||
Db 19 GGTACAGTTGTACAGTTG 1

RESULT 1073

US-10-800-487-294/c

; Sequence 294, Application US/10800487

; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)

; FILE REFERENCE: 400/148 (MEHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; CURRENT FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/427,160

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 294

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

US-10-800-487-294

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;

QY 2289 GTACACTGCAGGAGTGC 2307
|||||
Db 19 GTACACTGCAGGAGTGC 1

RESULT 1074

US-10-800-487-295/c

; Sequence 295, Application US/10800487

; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; TITLE OF INVENTION: Acid (siNA)

; FILE REFERENCE: 400/148 (MEHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; CURRENT FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/427,160

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 295

; LENGTH: 19

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

US-10-800-487-295

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;

QY 2307 CCTGGCAAAAAGATCAAAAT 2325
|||||
Db 19 CCTGGCAAAAAGATCAAAAT 1

RESULT 1075

US-10-800-487-296/c

; Sequence 296, Application US/10800487

; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; TITLE OF INVENTION: Acid (siNA)

; FILE REFERENCE: 400/148 (MEHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; CURRENT FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

```
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 296
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-296

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2325 TGGGGCTGGGACTTCTCAT 2343
Db 19 TGGGGCTGGGACTTCTCAT 1

RESULT 1076
US-10-800-487-297/c
; Sequence 297, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 297
; LENGTH: 19
; TYPE: RNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-297

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2343 TTGGCCAACTGCGCTTCC 2361
Db 19 TTGGCCAACTGCGCTTCC 1

RESULT 1077
US-10-800-487-298/c
; Sequence 298, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 298
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-298

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2361 CCCAGAAGGAGTGATTTT 2379
Db 19 CCCAGAAGGAGTGATTTT 1

RESULT 1078
US-10-800-487-299/c
; Sequence 299, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
```



```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 300
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense
US-10-800-487-300

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0

Qy 2397 CTATATGACTGGTAATGG 2415
|||||
Db 19 CTATATGACTGGTAATGG 1

RESULT 1080
US-10-800-487-301/c
; Sequence 301, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Interferon
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Int
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 301
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense
US-10-800-487-301

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;

```



```
/
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 307
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-307

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2523 CAATGACACTCAGCGGTCA 2541
Db 19 CAATGACACTCAGCGGTCA 1

RESULT 1087
US-10-800-487-308/c
/ Sequence 308, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ PRIOR FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 308
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
```

```
/
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-308

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2541 ATGTCTGGACATGAGTGCC 2559
Db 19 ATGTCTGGACATGAGTGCC 1

RESULT 1088
US-10-800-487-309/c
/ Sequence 309, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ PRIOR FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 309
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-309

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2559 CCAGGGAATATGCCCAAGC 2577
Db 19 CCAGGGAATATGCCCAAGC 1

RESULT 1089
US-10-800-487-310/c
/ Sequence 310, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, James
```

```
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 310
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-310
```

```
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2577 CTATGCTTGTCTCTTGT 2595
Db 19 CTATGCTTGTCTCTTGT 1
```

```
RESULT 1090
US-10-800-487-311/c
; Sequence 311, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 312
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-312
```

```
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 311
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-311
```

```
Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2595 TCCTGTTTGCATTTCACTG 2613
Db 19 TCCTGTTTGCATTTCACTG 1
```

```
RESULT 1091
US-10-800-487-312/c
; Sequence 312, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 312
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-312
```

QY 2613 GGGAGCTTGCACTATTGCA 2631
|||||
Db 19 GGGAGCTTGCACTATTGCA 1

RESULT 1092

US-10-800-487-313/c
; Sequence 313, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sina)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 313
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sina antisense region
US-10-800-487-313

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2631 AGCTCCAGTTTCTCGAGT 2649
|||||
Db 19 AGCTCCAGTTTCTCGAGT 1

RESULT 1093

US-10-800-487-314/c
; Sequence 314, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sina)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 314
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sina antisense region
US-10-800-487-314

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2649 TGATCAGGTCTCTGCAAGC 2667
|||||
Db 19 TGATCAGGTCTCTGCAAGC 1

RESULT 1094

US-10-800-487-315/c
; Sequence 315, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sina)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.


```
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 318
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-318

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2721 CATCCGCGTGTGTGTGTGT 2739
      |||||
Db 19 CATCCGCGTGTGTGTGTGT 1

RESULT 1098
US-10-800-487-319/c
; Sequence 319, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 319
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-319
```

```
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-319

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2739 TGTGTATGTGTAGACAAGC 2757
      |||||
Db 19 TGTGTATGTGTAGACAAGC 1

RESULT 1099
US-10-800-487-320/c
; Sequence 320, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 320
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-320

Query Match      0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2757 CTCTCGCTCTGTCAACCAG 2775
      |||||
Db 19 CTCTCGCTCTGTCAACCAG 1

RESULT 1100
US-10-800-487-321/c
; Sequence 321, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
```



```
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 321
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-321

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2775 GGCTGGAGTGCAGTGGTGC 2793
Db 19 GGCTGGAGTGCAGTGGTGC 1

RESULT 1101
US-10-800-487-322/c
; Sequence 322, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 321
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-321
```

```
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 322
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-322
```

```
Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2793 CAATCATGGTTCACCTGCAG 2811
Db 19 CAATCATGGTTCACCTGCAG 1
```

```
RESULT 1102
US-10-800-487-323/c
; Sequence 323, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 323
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-323
```

```
Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 2811 GTCTTGACCTTTGGGCTC 2829
|||||
Db 19 GTCTTGACCTTTGGGCTC 1

RESULT 1103

US-10-800-487-324/c
; Sequence 324, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 324
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-324

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2829 CAAGTGATCTCCCACTC 2847
|||||
Db 19 CAAGTGATCTCCCACTC 1

RESULT 1104

US-10-800-487-325/c
; Sequence 325, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 325
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-325

Query Match 0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2847 CAGCCTCTGAGTAGCTGG 2865
|||||
Db 19 CAGCCTCTGAGTAGCTGG 1

RESULT 1105

US-10-800-487-326/c
; Sequence 326, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 326
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-326

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2865 GGACCATAGGCTCACAA 2883
DB 19 GGACCATAGGCTCACAA 1

RESULT 1106
US-10-800-487-327/c
; Sequence 327, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 327
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-327

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2883 ACCACACCTGGCAAAATTG 2901
DB 19 ACCACACCTGGCAAAATTG 1

RESULT 1107
US-10-800-487-328/c
; Sequence 328, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 327
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-327

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2883 ACCACACCTGGCAAAATTG 2901
DB 19 ACCACACCTGGCAAAATTG 1

RESULT 1107
US-10-800-487-328/c
; Sequence 328, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 328
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-328

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2901 GATTTTTCATTTTTC 2919
DB 19 GATTTTTCATTTTTC 1

RESULT 1108
US-10-800-487-329/c
; Sequence 329, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 329
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-329
```

```
Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2901 GATTTTTCATTTTTC 2919
DB 19 GATTTTTCATTTTTC 1
```

```
RESULT 1108
US-10-800-487-329/c
; Sequence 329, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 329
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-800-487-329
```

```
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 329
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-329

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2919 CAGACGCGGTCGCAA 2937
      |||||
Db 19 CAGACGCGGTCGCAA 1

RESULT 1109
US-10-800-487-330/c
/ Sequence 330, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MEHB04-218)
/ CURRENT APPLICATION NUMBER: US 10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 331
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-331
```

```
US-10-800-487-330

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2937 ACATTGCCGACAGCTTCCTT 2955
      |||||
Db 19 ACATTGCCGACAGCTTCCTT 1

RESULT 1110
US-10-800-487-331/c
/ Sequence 331, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MEHB04-218)
/ CURRENT APPLICATION NUMBER: US 10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 331
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-800-487-331

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred.No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2955 TTGTGTTAGTTAATAAAGC 2973
      |||||
Db 19 TTGTGTTAGTTAATAAAGC 1

RESULT 1111
US-10-800-487-332/c
/ Sequence 332, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
```

```
; TITLE OF INVENTION: Acid (sina)
; FILE REFERENCE: 400/148 (MEH04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: Patent in version 3.3
; SEQ ID NO 332
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sina antisense region
US-10-800-487-332

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2966 AATAAGCTTTCTCAACTG 2984
Db      19 AATAAGCTTTCTCAACTG 1

RESULT 1112
US-10-730-771-405/c
; Sequence 405, Application US/10730771
; Publication No. US20050074787A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Hirschhorn, Joel N.
; APPLICANT: Huang, Xiaohua
; APPLICANT: Kaplan, Paul
; APPLICANT: Lander, Eric S.
; APPLICANT: Lockhart, David J.
; APPLICANT: Ryder, Thomas
; APPLICANT: Sklar, Pamela
; TITLE OF INVENTION: UNIVERSAL ARRAYS
; FILE REFERENCE: 2825.1016-007
; CURRENT APPLICATION NUMBER: US/10/730,771
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: US 60/126,473
; PRIOR FILING DATE: 1999-03-26
; PRIOR APPLICATION NUMBER: US 60/140,359
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/536,841
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 590
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 405
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Template sequence
US-10-730-771-407

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1249 CTGGACGAGAGGATGTC 1267
Db      19 CTGGACGAGAGGATGTC 1

RESULT 1114
US-09-752-983-243/c
; Sequence 243, Application US/09752983
; Patent No. US20010016575A1
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDW2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
```

```
; FEATURE:
; OTHER INFORMATION: Template sequence
US-10-730-771-405

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      226 TTGTTGGCATAGAGACCC 244
Db      19 TTGTTGGCATAGAGACCC 1

RESULT 1113
US-10-730-771-407/c
; Sequence 407, Application US/10730771
; Publication No. US20050074787A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Hirschhorn, Joel N.
; APPLICANT: Huang, Xiaohua
; APPLICANT: Kaplan, Paul
; APPLICANT: Lander, Eric S.
; APPLICANT: Lockhart, David J.
; APPLICANT: Ryder, Thomas
; APPLICANT: Sklar, Pamela
; TITLE OF INVENTION: UNIVERSAL ARRAYS
; FILE REFERENCE: 2825.1016-007
; CURRENT APPLICATION NUMBER: US/10/730,771
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: US 60/126,473
; PRIOR FILING DATE: 1999-03-26
; PRIOR APPLICATION NUMBER: US 60/140,359
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/536,841
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 590
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 407
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Template sequence
US-10-730-771-407

Query Match          0.6%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 6.3e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1249 CTGGACGAGAGGATGTC 1267
Db      19 CTGGACGAGAGGATGTC 1

RESULT 1114
US-09-752-983-243/c
; Sequence 243, Application US/09752983
; Patent No. US20010016575A1
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDW2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
```

;/ MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
;/ COMPUTER: IBM PC
;/ OPERATING SYSTEM: WINDOWS 95
;/ SOFTWARE: WORDPERECT 6.0
;/ CURRENT APPLICATION DATA:
;/ APPLICATION NUMBER: US/09/752,983
;/ FILING DATE: 02-Jan-2001
;/ CLASSIFICATION:
;/ PRIOR APPLICATION DATA:
;/ APPLICATION NUMBER: 09/280,805
;/ FILING DATE: <Unknown>
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Licata, Jane Massey
;/ REGISTRATION NUMBER: 32,257
;/ REFERENCE/DOCKET NUMBER: ISPH-0346
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: 609-810-1515
;/ TELEFAX: 609-810-1454
;/ INFORMATION FOR SEQ ID NO: 243:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 20 base pairs
;/ TYPE: Nucleic Acid
;/ STRANDEDNESS: Single
;/ TOPOLOGY: Linear
;/ ANTI-SENSE: Yes
;/ US-09-752-983-243

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6e+02; 0; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTGG 2790
|||||
DB 20 CCAGGCTGGAGTGCAGTGG 2

RESULT 1115
US-09-863-806-155/c
; Sequence 155, Application US/09863806
; Publication No. US20020197608A1
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: DETECTION OF NEOPLASIM BY ANALYSIS OF SALIVA
; NUMBER OF SEQUENCES: 195
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 4225 Executive Square, Suite 1400
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/863,806
; FILING DATE: 22-May-2001
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/038,637
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/152,313
; FILING DATE: 12-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Haile, Lisa A.
; REGISTRATION NUMBER: 38,347
; REFERENCE/DOCKET NUMBER: 07265/146001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/678-5070
; TELEFAX: 619/678-5099
; INFORMATION FOR SEQ ID NO: 155:
; SEQUENCE CHARACTERISTICS:

;/ LENGTH: 20 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: Genomic DNA
;/ SEQUENCE DESCRIPTION: SEQ ID NO: 155:
US-09-863-806-155

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6e+02; 0; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2774 AGGCTGGAGTGCAGTGGTG 2792
|||||
DB 20 AGGCTGGAGTGCAGTGGTG 2

RESULT 1116
US-10-084-839-3883/c
; Sequence 3883, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Taetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3883
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-3883

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1645 AGGCTCCCTGAACCTATC 1663
|||||
DB 19 AGGCTCCCTGAACCTATC 1

RESULT 1117
US-10-005-344-243/c
; Sequence 243, Application US/10005344
; Publication No. US20030203862A1

GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia
; APPLICANT: Pamela Nero
; APPLICANT: Mark J. Graham
; APPLICANT: Brett P. Monia
; APPLICANT: Brich Koller
; APPLICANT: Mingyi Chiang
; APPLICANT: Mano Manoharan
; TITLE OF INVENTION: Antisense Modulation of mdm2 expression.
; FILE REFERENCE: ISPH-0622
; CURRENT APPLICATION NUMBER: US/10/005,344
; CURRENT FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: US 09/048,810
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/280,805
; PRIOR FILING DATE: 1999-03-26
; NUMBER OF SEQ ID NOS: 379
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 243
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-005-344-243

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTGG 2790
DB 20 CCAGGCTGGAGTGCAGTGG 2

RESULT 1118

US-10-343-303-10
; Sequence 10, Application US/10343303
; Publication No. US20040038394A1
; GENERAL INFORMATION:
; APPLICANT: Mogam Biotechnology Research Institute
; APPLICANT: Pan-Gen Biotech Laboratories Inc.
; TITLE OF INVENTION: Expression vector for animal cell
; FILE REFERENCE: opp010629kr
; CURRENT APPLICATION NUMBER: US/10/343,303
; CURRENT FILING DATE: 2003-08-04
; PRIOR APPLICATION NUMBER: KR10-2000-43996
; PRIOR FILING DATE: 2000-07-29
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: KopatentIn 1.55
; SEQ ID NO 10
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: BM1 primer for human beta globin nuclear matrix attachment region
; OTHER INFORMATION: element
; FEATURE:
; NAME/KEY: primer
; LOCATION: (1)..(20)
; OTHER INFORMATION: primer
US-10-343-303-10

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2850 CCTCCTGAGTAGCTGGGAC 2868
DB 1 CCTCCTGAGTAGCTGGGAC 19

RESULT 1119

US-10-671-395-1199/c
; Sequence 1199, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1199
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1199

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2849 GCCTCCTGAGTAGCTGGGA 2867
DB 20 GCCTCCTGAGTAGCTGGGA 2

RESULT 1120

US-10-671-395-1448/c
; Sequence 1448, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1448
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1448

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCCTGAGTAGC 2862
DB 19 CCTCAGCCTCCTGAGTAGC 1

RESULT 1121

US-10-754-478-155/c
; Sequence 155, Application US/10754478
; Publication No. US20050009040A1
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: DETECTION OF NEOPLASIM BY ANALYSIS OF SALIVA
; NUMBER OF SEQUENCES: 195

;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Fish & Richardson P.C.
;; STREET: 4225 Executive Square, Suite 1400
;; CITY: La Jolla
;; STATE: CA
;; COUNTRY: USA
;; ZIP: 92037
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Diskette
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: Windows 95
;; SOFTWARE: FastSeq for Windows Version 2.0b
;;
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/10/754,478
;; FILING DATE: 09-Jan-2004
;;
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/09/038,637
;; FILING DATE: 10-MAR-1998
;; APPLICATION NUMBER: 08/579,233
;; FILING DATE: 28-DEC-1995
;; APPLICATION NUMBER: 08/152,313
;; FILING DATE: 12-NOV-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Hallie, Lisa A.
;; REGISTRATION NUMBER: 38,347
;; REFERENCE/DOCKET NUMBER: 07265/146001
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 619/678-5070
;; TELEFAX: 619/678-5099
;;
;; INFORMATION FOR SEQ ID NO: 155:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: Genomic DNA
;; SEQUENCE DESCRIPTION: SEQ ID NO: 155:
US-10-754-478-155

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;

QY 2774 AGGCTGGAGTGCAGTGGTG 2792
Db 20 AGGCTGGAGTGCAGTGGTG 2

RESULT 1122
US-10-496-626-9
; Sequence 9, Application US/10496626
; Publication No. US20050089862A1
; GENERAL INFORMATION:
; APPLICANT: Therianos, Stavros
; APPLICANT: Coleman, Paul
; APPLICANT: Zhu, Min
; TITLE OF INVENTION: MULTIPLEX REAL-TIME QUANTITATIVE PCR
; FILE REFERENCE: 21108.000903
; CURRENT APPLICATION NUMBER: US/10/496,626
; CURRENT FILING DATE: 2004-05-23
; PRIOR APPLICATION NUMBER: PCT/US02/38806
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: 60/397,475
; PRIOR FILING DATE: 2002-07-19
; PRIOR APPLICATION NUMBER: 60/336,095
; PRIOR FILING DATE: 2001-11-30
; NUMBER OF SEQ ID NOS: 109
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

;; OTHER INFORMATION: Description of Artificial Sequence:/note =
;; OTHER INFORMATION: synthetic construct
US-10-496-626-9

Query Match 0.6%; Score 19; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 6e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;

QY 596 ATGGAGCCCAATTCTCGTG 614
Db 1 ATGGAGCCCAATTCTCGTG 19

RESULT 1123
US-10-192-437-1/c
; Sequence 1, Application US/10192437
; Publication No. US20030153737A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. US20030153737A1ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/192,437
; FILING DATE: 10-Jul-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/397,277A
; FILING DATE: 09-MAR-1995
; APPLICATION NUMBER: 07/943,516
; FILING DATE: 11-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumond, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-11198
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 1:
US-10-192-437-1

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02; Indels 0; Gaps 0;
Matches 19; Conservative 0; Mismatches 0;

QY 49 AGCCTCGCTATGCTCCCA 67
Db 19 AGCCTCGCTATGCTCCCA 1

RESULT 1124
US-10-759-878-4


```
; Sequence 4, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; PRIOR FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: siRNA sense strand
US-10-759-878-4
```

```
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.7e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 225 GTTGTGGGCATAGAGACC 243
Db 1 GUUGUUGGCAUAGAGACC 19
|:::|||||:|||||
```

```
RESULT 1125
US-10-759-878-6
; Sequence 6, Application US/10759878
; Publication No. US20040220129A1
; GENERAL INFORMATION:
; APPLICANT: Samuel Jotham Reich
; APPLICANT: Michael J. Tolentino
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR siRNA
; TITLE OF INVENTION: INHIBITION OF ICAM-1
; FILE REFERENCE: 43826-0003 US
; CURRENT APPLICATION NUMBER: US/10/759,878
; CURRENT FILING DATE: 2004-01-16
; PRIOR APPLICATION NUMBER: US 60/440,579
; PRIOR FILING DATE: 2003-01-16
; NUMBER OF SEQ ID NOS: 94
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: siRNA sense strand
; FEATURE:
; NAME/KEY: misc_RNA
; LOCATION: (1)...(19)
; OTHER INFORMATION: ribonucleotide bases
US-10-759-878-6
```

```
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 5.7e+02;
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 225 GTTGTGGGCATAGAGACC 243
Db 1 GUUGUUGGCAUAGAGACC 19
|:::|||||:|||||
```

```
RESULT 1126
US-10-800-487-341
; Sequence 341, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 341
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-341
```

```
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 955 GAGACACTGCAGACAGTGA 973
Db 1 GAGACACUGCAGACAGAGA 19
|||||:|||||:|
```

```
RESULT 1127
US-10-800-487-342
; Sequence 342, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
```

```
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 342
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-800-487-342

Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      970 GTGACCATCTACAGCTTTC 988
Db      1 GUGACCAUCUACGCUUUC 19

RESULT 1128
US-10-800-487-343
/ Sequence 343, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MEHB04-218)
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 343
```

```
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
/ NAME/KEY: misc feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-800-487-343

Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.7e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1552 AGCAGGTACTCTATAACC 1570
Db      1 AGCAGGUACCUAUUACC 19

RESULT 1129
US-10-800-487-344
/ Sequence 344, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MEHB04-218)
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/800,487
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 344
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
/ NAME/KEY: misc feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-800-487-344

Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1877 AAGCCAAGGAGGAGCA 1895
```



```
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 347
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: s1NA sense region
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-800-487-347

Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2801 GTTCACTGCAGCTTGCACC 2819
   |||||:|||||:|||||
Db 1 GUUCACUGCAGUCUGACC 19

RESULT 1133
US-10-800-487-348
/ Sequence 348, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 348
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: s1NA sense region
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-800-487-348

Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2801 GTTCACTGCAGCTTGCACC 2819
   |||||:|||||:|||||
Db 1 GUUCACUGCAGUCUGACC 19

RESULT 1133
US-10-800-487-348
/ Sequence 348, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 348
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: s1NA sense region
/ NAME/KEY: misc_feature
```

```
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-800-487-348

Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2871 TAGGCTCACACACACACAC 2889
   |||||:|||||:|||||
Db 1 UAGGCUACACACACACAC 19

RESULT 1134
US-10-800-487-349/c
/ Sequence 349, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 349
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: s1NA antisense region
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-800-487-349

Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 955 GAGACACTGCAGACAGTGA 973
   |||||:|||||:|||||
Db 19 GAGACACTGCAGACAGTGA 1

RESULT 1135
US-10-800-487-350/c
/ Sequence 350, Application US/10800487
```

```
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US 10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 350
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-350

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 970 GTGACCATCTACAGCTTTC 988
Db 19 GTGACCATCTACAGCTTTC 1
|||||
RESULT 1136
US-10-800-487-351/c
; Sequence 351, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 350
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-350

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 970 GTGACCATCTACAGCTTTC 988
Db 19 GTGACCATCTACAGCTTTC 1
|||||
RESULT 1136
US-10-800-487-352/c
; Sequence 352, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 351
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-351

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1552 AGCAGCTACCTCTATAACC 1570
Db 19 AGCAGCTACCTCTATAACC 1
|||||
RESULT 1137
US-10-800-487-352/c
; Sequence 352, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
```

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 352
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-352
```

```
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1877 AAGCCAGAGGAGGAGCA 1895
Db 19 AAGCCAGAGGAGGAGCA 1
```

```
RESULT 1138
US-10-800-487-353/c
; Sequence 353, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 353
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
```

```
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-353
```

```
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1877 AAGCCAGAGGAGGAGCA 1895
Db 19 AAGCCAGAGGAGGAGCA 1
```

```
RESULT 1138
US-10-800-487-353/c
; Sequence 353, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/366,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 353
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
```

```
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-353
```

```
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2589 CTCCTGCTCTGTTTGCAAT 2607
Db 19 CTCCTGCTCTGTTTGCAAT 1
```

RESULT 1139

```
US-10-800-487-354/c
; Sequence 354, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Sirna Therapeutics, Inc.
```

```
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
```

```
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
```

```
; FILE REFERENCE: 400/148 (MBHB04-218)
```

```
; CURRENT APPLICATION NUMBER: US/10/800,487
```

```
; PRIOR FILING DATE: 2004-03-15
```

```
; PRIOR APPLICATION NUMBER: US 10/757,803
```

```
; PRIOR FILING DATE: 2004-01-15
```

```
; PRIOR APPLICATION NUMBER: US 10/720,448
```

```
; PRIOR FILING DATE: 2003-11-24
```

```
; PRIOR APPLICATION NUMBER: US 10/693,059
```

```
; PRIOR FILING DATE: 2003-10-23
```

```
; PRIOR APPLICATION NUMBER: US 10/444,853
```

```
; PRIOR FILING DATE: 2003-05-23
```

```
; PRIOR APPLICATION NUMBER: US 10/427,160
```

```
; PRIOR FILING DATE: 2003-04-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```
; PRIOR FILING DATE: 2003-02-20
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```
; PRIOR FILING DATE: 2003-02-20
```

```
; PRIOR APPLICATION NUMBER: US 60/358,580
```

```
; PRIOR FILING DATE: 2002-02-20
```

```
; PRIOR APPLICATION NUMBER: US 60/363,124
```

```
; PRIOR FILING DATE: 2002-03-11
```

```
; PRIOR APPLICATION NUMBER: US 60/386,782
```

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; NUMBER OF SEQ ID NOS: 438
```

```
; SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 354
```

```
; LENGTH: 21
```

```
; TYPE: RNA
```

```
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
```

```
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
```

```
; NAME/KEY: misc feature
```

```
; LOCATION: (20)..(21)
```

```
; OTHER INFORMATION: n stands for thymidine
```

```
US-10-800-487-354
```

```
Query Match 0.6%; Score 19; DB 1; Length 21;
```

```
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
```

```
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2798 ATGTTTCACTGCAGTCTTG 2816
Db 19 ATGTTTCACTGCAGTCTTG 1
```

RESULT 1140

```
US-10-800-487-355/c
```

```
; Sequence 355, Application US/10800487
```

```
; Publication No. US20050048529A1
```

```
; GENERAL INFORMATION:
```

```
; APPLICANT: Sirna Therapeutics, Inc.
```

```
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
```

```
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
```

```
; FILE REFERENCE: 400/148 (MBHB04-218)
```

```
; CURRENT APPLICATION NUMBER: US/10/800,487
```

```
; PRIOR FILING DATE: 2004-03-15
```

```
; PRIOR APPLICATION NUMBER: US 10/757,803
```

```
; PRIOR FILING DATE: 2004-01-15
```

```
; PRIOR APPLICATION NUMBER: US 10/720,448
```

```
; PRIOR FILING DATE: 2003-11-24
```

```
; PRIOR APPLICATION NUMBER: US 10/693,059
```

```
; PRIOR FILING DATE: 2003-10-23
```

```
; PRIOR APPLICATION NUMBER: US 10/444,853
```

```
; PRIOR FILING DATE: 2003-05-23
```

```
; PRIOR APPLICATION NUMBER: US 10/427,160
```

```
; PRIOR FILING DATE: 2003-04-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```
; PRIOR FILING DATE: 2003-02-20
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```
; PRIOR FILING DATE: 2003-02-20
```

```
; PRIOR APPLICATION NUMBER: US 60/358,580
```

```
; PRIOR FILING DATE: 2002-02-20
```

```
; PRIOR APPLICATION NUMBER: US 60/363,124
```

```
; PRIOR FILING DATE: 2002-03-11
```

```
; PRIOR APPLICATION NUMBER: US 60/366,782
```

```
; Remaining Prior Application data removed - See File Wrapper or PALM.
```

```
; NUMBER OF SEQ ID NOS: 438
```

```
; SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 355
```

```
; LENGTH: 21
```

```
; TYPE: RNA
```

```
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
```

```
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
```

```
; NAME/KEY: misc feature
```

```
; LOCATION: (20)..(21)
```

```
; OTHER INFORMATION: n stands for thymidine
```

```
US-10-800-487-355
```

```
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 355
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc.feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-355
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2801 GTTCACTGCAGTCTTGACC 2819
Db 19 GTTCACTGCAGTCTTGACC 1

RESULT 1141
US-10-800-487-356/c
; Sequence 356, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 355
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc.feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-355
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2801 GTTCACTGCAGTCTTGACC 2819
Db 19 GTTCACTGCAGTCTTGACC 1

RESULT 1141
US-10-800-487-356/c
; Sequence 356, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
```

```
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 356
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc.feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-356
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2871 TAGGCTCACACACACAC 2889
Db 19 TAGGCTCACACACACAC 1

RESULT 1142
US-10-800-487-357
; Sequence 357, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 357
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
```

```
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (1)..(1)
;/ OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (5)..(5)
;/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (7)..(8)
;/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (10)..(10)
;/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (14)..(14)
;/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (17)..(17)
;/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (20)..(20)
;/ OTHER INFORMATION: n stands for thymidine
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (21)..(21)
;/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-357
```

```
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 955 GAGACACTGCAGACACTGA 973
Db 1 GAGACACUGCAGACAGUGA 19
```

```
RESULT 1143
US-10-800-487-358
; Sequence 358, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
```

```
;/ PRIOR FILING DATE: 2002-03-11
;/ PRIOR APPLICATION NUMBER: US 60/386,782
;/ PRIOR FILING DATE: 2002-06-06
;/ Remaining Prior Application data removed - See File Wrapper or PALM.
;/ NUMBER OF SEQ ID NOS: 438
;/ SOFTWARE: PatentIn version 3.3
;/ SEQ ID NO 358
;/ LENGTH: 21
;/ TYPE: RNA
;/ ORGANISM: Artificial Sequence
;/ FEATURE:
;/ OTHER INFORMATION: Description of Artificial Sequence: sina sense region
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (1)..(1)
;/ OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (2)..(2)
;/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (5)..(6)
;/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (8)..(10)
;/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (12)..(12)
;/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (15)..(19)
;/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (20)..(20)
;/ OTHER INFORMATION: n stands for thymidine
;/ FEATURE:
;/ NAME/KEY: misc_feature
;/ LOCATION: (21)..(21)
;/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-358

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 970 GTGACCATCTACAGCTTTC 988
Db 1 GUGACCAUCUACAGCUUUC 19

RESULT 1144
US-10-800-487-359
; Sequence 359, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
```



```
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 359
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: 5'-3' attached terminal deoxyabasic moiety
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; LOCATION: (3)..(3)
; NAME/KEY: misc_feature
; LOCATION: (3)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-359
```

```
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.7e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1552 AGCAGCTACTCTCTATACC 1570
|||||:|:|:|:|:|:|:|:|:|
Db 1 AGCAGGUACCUUAUACC 19
```

```
RESULT 1145
US-10-800-487-360
```

```
; Sequence 360, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MEH04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 360
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: 5'-3 attached terminal deoxyabasic moiety
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-360
```

```
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1877 AAGCCAAGAGGAGGAGCA 1895
|||||:|:|:|:|:|:|:|:|:|
Db 1 AAGCCAAGAGGAGGAGCA 19
```

```
RESULT 1146
US-10-800-487-361
```

```

; Sequence 361, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 361
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxybasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxybasic moiety
; US-10-800-487-361

```



```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sina sense region
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (14)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (17)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-364

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2871 TAGGCTCACACACACAC 2889
Db 1 UAGGCUACACACACAC 19

RESULT 1150
US-10-800-487-365/c
; Sequence 365, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23

```

```

; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: Patent version 3.3
; SEQ ID NO 365
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sina antisense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (4)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (11)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-365

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 955 GAGACACTGCAGACAGTGA 973
Db 19 GAGACACTGCAGACAGTGA 1

RESULT 1151
US-10-800-487-366/c
; Sequence 366, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James

```

```
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 366
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (6)..(7)
; FEATURE:
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; NAME/KEY: misc_feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
; US-10-800-487-366
```

```
Query Match 0.6% Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 970 GTGACCATCTACAGCTTTC 988

Db 19 GTGACCATCTACAGCTTTC 1

```
RESULT 1152
US-10-800-487-367/c
; Sequence 367, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 367
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (3)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
```

; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-367

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1552 AGCAGTACTCTATTAACC 1570
|||||
Db 19 AGCAGTACTCTATTAACC 1

RESULT 1153

US-10-800-487-368/c
; Sequence 368, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 368
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature

; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-368

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1877 AAGCCAAAGAGGAGGAGCA 1895
|||||
Db 19 AAGCCAAAGAGGAGGAGCA 1

RESULT 1154

US-10-800-487-369/c
; Sequence 369, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 369
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature

; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-369

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2589 CTCCTGCTCTGTTGCATT 2607
|||||
Db 19 CTCCTGCTCTGTTGCATT 1

RESULT 1155
US-10-800-487-370/c
; Sequence 370, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 370
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature

; LOCATION: (12)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-370

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2798 ATGGTTCACTGCAGTCTTG 2816
|||||
Db 19 ATGGTTCACTGCAGTCTTG 1

RESULT 1156
US-10-800-487-371/c
; Sequence 371, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 371
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature

```
/ LOCATION: (3)..(4)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (9)..(10)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (12)..(12)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (15)..(15)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (19)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-800-487-371
```

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 2801 GTTCACTGCGAGTCTTGACC 2819
Db 19 GTTCACTGCGAGTCTTGACC 1
```

```
RESULT 1157
US-10-800-487-372/c
/ Sequence 372, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
```

```
/ SEQ ID NO 372
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (2)..(2)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (4)..(4)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (7)..(7)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (9)..(10)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (12)..(12)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (16)..(18)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-800-487-372
```

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 2871 TAGGCTCACAACACCACAC 2889
Db 19 TAGGCTCACAACACCACAC 1
```

```
RESULT 1158
US-10-800-487-373
/ Sequence 373, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR FILING DATE: 2004-03-15
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
```



```
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 373
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(4)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(13)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
```

```
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-373
Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
QY      955 GAGACACTGCAGACAGTGA 973
Db      1 GAGACACUGCAGACAGUGA 19
          |||||:|||||:|
RESULT 1159
US-10-800-487-374
; Sequence 374, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBH04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 374
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(4)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(6)
```

OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (7)..(7)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (8)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (11)..(11)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (12)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (13)..(14)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (15)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-374

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 970 GTGACCATCTACAGCTTTC 988
|:|||||:|||||:|
Db 1 GUGACCAUCUACAGCUUUC 19

RESULT 1160
US-10-800-487-375
Sequence 375, Application US/10800487
Publication No. US20050048529A1
GENERAL INFORMATION:
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
FILE OF INVENTION: Acid (siRNA)
FILE REFERENCE: 400/148 (MEHB04-218)
CURRENT APPLICATION NUMBER: US/10/800,487
CURRENT FILING DATE: 2004-03-15
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-15
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: US 10/427,160
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20

PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 438
SOFTWARE: PatentIn version 3.3
SEQ ID NO 375
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)..(1)
OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (3)..(3)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (4)..(4)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (5)..(5)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (7)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (8)..(8)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (9)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (14)..(14)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety

US-10-800-487-375

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.7e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1552 AGCAGCTACCTCTATAACC 1570
|||||:||||:|:|:|
Db 1 AGCAGGUACCUUAUACC 19

RESULT 1161

US-10-800-487-376
; Sequence 376, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBH04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 376
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(3)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(17)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro

; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-376

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1877 AAGCCAAGAGGAAGGAGCA 1895
|||||:||||:|:|:|
Db 1 AAGCCAAGAGGAAGGAGCA 19

RESULT 1162

US-10-800-487-377
; Sequence 377, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBH04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 377
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro


```
; NAME/KEY: misc feature
; LOCATION: (6)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (8)..(8)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (10)..(11)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (12)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: n stands for thymidine
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-379
```

```
Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred.No. 5.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0;
```

```
Qy      2801 GTTCACTGCAGTCCTTGACC 2819
         ||::|||:|||||:|||||
Db       1 GUUCACUGCAGUUGACC 19
```

```
RESULT 1165
US-10-800-487-380
Sequence 380, Application US/10800487
Publication No. US20050048529A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of I...
TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Sh...
TITLE OF INVENTION: Acid (siRNA)
FILE REFERENCE: 400/148 (MBHB04-218)
CURRENT APPLICATION NUMBER: US/10/800,487
CURRENT FILING DATE: 2004-03-15
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-15
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: US 10/427,160
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
```

```
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 380
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(11)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
```

```
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; US-10-800-487-380

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2871 TAGGCTCACACACCACAC 2889
Db 1 UAAGGCUCAACACCACAC 19

RESULT 1166
US-10-800-487-381/c
; Sequence 381, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Inter cellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEH804-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 381
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(3)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
```

```
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(13)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
;
US-10-800-487-381
```

Query Match 0.6%; Score 19; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 5.7e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 955 GAGACACTGCAGACAGTGA 973

Db 19 GAGACACTGCAGACAGTGA 1

RESULT 1167

US-10-800-487-382/c

; Sequence 382, Application US/10800487

; Publication No. US20050048529A1

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; FILE REFERENCE: 400/148 (MBHB04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; PRIOR FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/427,160

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: PCT/US03/05346

```
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 382
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sinA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(12)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(15)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
;
US-10-800-487-382
```

Query Match

0.6%; Score 19; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 5.7e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 970 GTGACCATCTACAGCTTTC 988

```
Db      19 GTGACCATCTACGCTTC 1
|||||
RESULT 1169
US-10-800-487-383/c
; Sequence 383, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 383
; LENGTH: 21
; TYPE: RNA.
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(11)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(13)
```

```
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(17)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-383
Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1552 AGCAGCTACCTCTATAACC 1570
Db      19 AGCAGCTACCTCTATAACC 1
|||||
RESULT 1169
US-10-800-487-384/c
; Sequence 384, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
```



```
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 384
;   LENGTH: 21
;   TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
;
US-10-800-487-384

Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1877 AGCCAAAGAGGAGGAGCA 1895
Db      19  AGCCAAAGAGGAGGAGCA 1

RESULT 1170
US-10-800-487-385/c
; Sequence 385, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (s1NA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
```

```
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 385
;   LENGTH: 21
;   TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(13)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(19)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
;
US-10-800-487-385

Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      2589 CTCCTGTCTCTGTTCATT 2607
Db      19  CTCCTGTCTCTGTTCATT 1

RESULT 1171
```

```
US-10-800-487-386/c
; Sequence 386, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 386
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (2)..(5)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (10)..(11)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (13)..(15)
; OTHER INFORMATION: 2'-deoxy
```

```
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-386

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2798 ATGGTTCACTGCAGTCTTG 2816
|||||
DB 19 ATGGTTCACTGCAGTCTTG 1

RESULT 1172
US-10-800-487-387/c
; Sequence 387, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 387
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
```

```

FEATURE:
NAME/KEY: misc feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (3)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (5)..(8)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (9)..(10)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (11)..(11)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (12)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (13)..(14)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (16)..(18)
OTHER INFORMATION: 2'-deoxy
FEATURE:
NAME/KEY: misc feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
FEATURE:
NAME/KEY: misc feature
LOCATION: (21)..(21)
OTHER INFORMATION: n stands for thymidine
US-10-800-487-387
Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches   19; Conservative    0; Mismatches    0; Indels    0; Gaps    0;

Qy      2801 GTTCACGCGAGCTGTGACC 2819
Db       |||||||||
        19 GTTCACTGCAGTCTTGACC 1

RESULT 1173
US-10-800-487-388/c
Sequence 388, Application US/10800487
Publication No. US20050048529A1
GENERAL INFORMATION:
APPLICANT: McSwigen, James
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short interfering Nucleic
Acid (siNA)
FILE REFERENCE: 400/148 (MHB04-218)
CURRENT APPLICATION NUMBER: US/10/800,487
CURRENT FILING DATE: 2004-03-15
PRIORITY APPLICATION NUMBER: US 10/757,803

```

```

; NAME/KEY: misc_feature
; LOCATION: (16)..(18)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-388

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2871 TAGGCTCACACACACAC 2889
Db 19 TAGGCTCACACACACAC 1

RESULT 1174
US-10-800-487-389
; Sequence 389, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 389
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:

```

```

; NAME/KEY: misc_feature
; LOCATION: (1)..(4)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(13)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(16)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-389

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 955 GAGACACTGCACACAGTGA 973
Db 1 GAGACACUGCAGACAGUGA 19

RESULT 1175
US-10-800-487-390
; Sequence 390, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)

```

```
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 390
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(4)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(11)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(14)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
```

```
; LOCATION: (15)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-390

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      970 GTGACCATCTACAGCTTTC 988
      |:|||||:|:|||||:|:|
Db      1 GUGACCAUCUACAGCUUUC 19

RESULT 1176
US-10-800-487-391
; Sequence 391, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (iCAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MEHE04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 391
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
```

```

; LOCATION: (3)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-O-methyl
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-O-methyl
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 2'-O-methyl
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (9)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-O-methyl
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (16)..(17)
; OTHER INFORMATION: 2'-O-methyl
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymid
;
; FEATURE:
;
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached termi
US-10-800-487-391

```

```

; LOCATION: (3)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (9)..(13)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(17)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-391

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred.No. 5.7e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1552 AGCAGTACCTCTATAACC 1570
Db       |||||:|||:|||
         1 AGCAGUACCUAUARACC 19

RESULT 1177
US-10-800-487-392
; Sequence 392, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
```


RESULT 1180
 -10-800-487-395
 Sequence 395, Application US/10800487
 Publication No. US20050048529A1
 GENERAL INFORMATION:
 APPLICANT: Sirna Therapeutics, Inc.
 APPLICANT: McSwigen, James
 TITLE OF INVENTION: RNA Interference
 TITLE OF INVENTION: Molecule (ICAM)


```
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-395

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2801 GTTCACTGCAGTCTTGACC 2819
Db 1 GUUCACUGCAGUCUGACC 19

RESULT 1181
US-10-800-487-396
; Sequence 396, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 396
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
```

```
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (2)..(4)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (10)..(11)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (13)..(13)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (14)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (17)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-396

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2871 TAGGCTCACACACCACAC 2889
Db 1 UAGGCUCACACACCACAC 19

RESULT 1182
US-10-800-487-397/c
; Sequence 397, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
```

```
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 397
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(3)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(6)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(13)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
```

```
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-397

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 955 GAGACACTGCACACAGTGA 973
DB 19 GAGACACTGCACACAGTGA 1

RESULT 1183
US-10-800-487-398/c
; Sequence 398, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 398
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sRNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(5)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
```

NAME/KEY: misc_feature
LOCATION: (6)..(7)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (8)..(8)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (9)..(9)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (10)..(12)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(15)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(17)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(18)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (19)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
FEATURE:
NAME/KEY: misc_feature
LOCATION: (21)..(21)
OTHER INFORMATION: n stands for thymidine
US-10-800-487-398

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 970 GTGACCATCTACAGCTTTC 988
|||||
Db 19 GTGACCATCTACAGCTTTC 1

RESULT 1184
US-10-800-487-399/c
Sequence 399, Application US/10800487
Publication No. US20050048529A1
GENERAL INFORMATION:
APPLICANT: McSwiggen, James
APPLICANT: Sirna Therapeutics, Inc.
TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
TITLE OF INVENTION: Molecule (ICM) Gene Expression Using Short Interfering Nucleic
FILE REFERENCE: 400/148 (MBHB04-218)
CURRENT APPLICATION NUMBER: US/10/800,487
CURRENT FILING DATE: 2004-03-15
PRIORITY APPLICATION NUMBER: US 10/757,803
PRIORITY FILING DATE: 2004-01-15
PRIORITY APPLICATION NUMBER: US 10/720,448
PRIORITY FILING DATE: 2003-11-24
PRIORITY APPLICATION NUMBER: US 10/693,059
PRIORITY FILING DATE: 2003-10-23

PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: US 10/427,160
PRIOR FILING DATE: 2003-04-30
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 438
SOFTWARE: PatentIn version 3.3
SEQ ID NO 399
LENGTH: 21
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: SINA antisense region
NAME/KEY: misc_feature
LOCATION: (1)..(2)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (3)..(4)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (5)..(5)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (6)..(6)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (7)..(11)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (12)..(12)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (13)..(13)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (14)..(14)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (15)..(15)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (16)..(16)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature
LOCATION: (17)..(17)
OTHER INFORMATION: 2'-O-methyl
FEATURE:
NAME/KEY: misc_feature
LOCATION: (18)..(19)
OTHER INFORMATION: 2'-deoxy-2'-fluoro
FEATURE:
NAME/KEY: misc_feature

```
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-800-487-399
```

```
Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1552 AGCACGTACTCTTATAACC 1570
      |||||||
Db 19 AGCACGTACTCTTATAACC 1
```

```
RESULT 1185
US-10-800-487-400/c
; Sequence 400, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 400
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
```

```
/ LOCATION: (15)..(16)
/ OTHER INFORMATION: 2'-O-methyl
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (17)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: n stands for thymidine
US-10-800-487-400
```

```
Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1877 AAGCCAAAGAGGAGGAGCA 1895
      |||||||
Db 19 AAGCCAAAGAGGAGGAGCA 1
```

```
RESULT 1186
US-10-800-487-401/c
; Sequence 401, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 401
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
```

```
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(13)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(19)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-401
```

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 2589 CTCCTGTCTCTGTTCATT 2607
    |||||
Db 19 CTCCTGTCTCTGTTCATT 1
```

RESULT 1187

```
US-10-800-487-402/c
; Sequence 402, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sina Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (sina)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 402
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: sina antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(5)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(11)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(15)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-402

Query Match 0.6%; Score 19; DB 1; Length 21;
```



```

; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(3)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(6)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(7)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (8)..(8)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (9)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (11)..(11)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(12)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (13)..(15)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(18)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
; US-10-800-487-404

```

```

Query Match      0.8%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      2871 TAGGCTCACAACACCACAC 2889
          |||||||

```

```

Db      19 TAGGCTCACAACACCACAC 1
RESULT 1190
US-10-800-487-405
; Sequence 405, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 405
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; US-10-800-487-405

```

```

Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      955 GAGACACTGCAGACAGTGA 973
          |||||||
Db      1 GAGACACUGCAGACAGAGA 19
RESULT 1191
US-10-800-487-406
; Sequence 406, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:

```

```

; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 407
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: s1NA sense
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-407

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 78.9%; Pred. No. 5.7e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1552 AGCACGTACCTCTATAACC 1570
Db 1 AGCACGTACCTCTATAACC 19

```

RESULT 1193
US-10-800-487-408
; Sequence 408, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sinna Therapeutics, Inc.

```

, TITLE OF INVENTION: RNA interference mediated inhibition of intercellular adhesion
, TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
, TITLE OF INVENTION: Acid (siala)
, FILE REFERENCE: 400/1148 (MBHB04-218)
, CURRENT APPLICATION NUMBER: US/10/800,487
, CURRENT FILING DATE: 2004-03-15
, PRIOR APPLICATION NUMBER: US 10/757,803
, PRIOR FILING DATE: 2004-01-15
, PRIOR APPLICATION NUMBER: US 10/720,448
, PRIOR FILING DATE: 2003-11-24
, PRIOR APPLICATION NUMBER: US 10/693,059
, PRIOR FILING DATE: 2003-10-23
, PRIOR APPLICATION NUMBER: US 10/444,853
, PRIOR FILING DATE: 2003-05-23

```



```
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 408
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
;
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; US-10-800-487-408

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1877 AAGCCAAGAGGAAGGAGCA 1895
      |||||
Db 1 AAGCCAAGAGGAAGGAGCA 19

RESULT 1194
US-10-800-487-409
; Sequence 409, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 410
```

```
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 409
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
;
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
; US-10-800-487-409

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 47.4%; Pred. No. 5.7e+02;
Matches 9; Conservative 10; Mismatches 0; Indels 0; Gaps 0;

QY 2589 CTCCTGTCTCTGTTCATT 2607
      |:::|:::|:::|:::|
Db 1 CUCUUGUCCUGUUGCAU 19

RESULT 1195
US-10-800-487-410
; Sequence 410, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 410
```

```
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence:  s1NA sense region
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(1)
/ OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-410

Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 63.2%; Pred. No. 5.7e+02;
Matches 12; Conservative 7; Mismatches 0; Indels 0; Gaps 0;

QY 2798 ATGCTTCACTGCAGTCTTG 2816
Db 1 AUGGUUACUGCAGUCUUG 19

RESULT 1196
US-10-800-487-411
; Sequence 411, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-03-11
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 411
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
```

```
/ OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-411

Query Match      0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 5.7e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY 2801 GTTCACTGCAGTCTTGACC 2819
Db 1 GUUCACUGCAGUCUUGACC 19

RESULT 1197
US-10-800-487-412
; Sequence 412, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; FILE REFERENCE: 400/148 (MEHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 412
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
/ OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: n stands for thymidine
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
```

; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-800-487-412

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 5.7e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2871 TAGGCTCACAACACCAC 2889
Db 1 UAGGCUCAACACCACAC 19

RESULT 1198
US-10-800-487-413/c
; Sequence 413, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; PRIOR FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 10/693,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 413
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-413

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 955 GAGACACTGCAGACACTGA 973
Db 19 GAGACACTGCAGACACTGA 1

RESULT 1199
US-10-800-487-414/c
; Sequence 414, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 414
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-414

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 970 GTGACCATCTACAGCTTTC 988
Db 19 GTGACCATCTACAGCTTTC 1

RESULT 1200
US-10-800-487-415/c
; Sequence 415, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siRNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487

```
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 415
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
/ NAME/KEY: misc feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ US-10-800-487-415
```

```
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1552 AGCAGTACTCTATAACC 1570
Db |||||
19 AGCAGTACTCTATAACC 1

RESULT 1201
US-10-800-487-416/c
/ Sequence 416, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion.
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 416
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
/ NAME/KEY: misc feature
/ LOCATION: (20)..(20)
/ OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (21)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ US-10-800-487-416
```

```
Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1877 AGCCCAAGAGGAGGAGCA 1895
Db |||||
19 AGCCCAAGAGGAGGAGCA 1
```

```
RESULT 1202
US-10-800-487-417/c
/ Sequence 417, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion.
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ FILE REFERENCE: 400/148 (MBHB04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
```

```
; SEQ ID NO 417
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
; US-10-800-487-417

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2589 CTCCTGCTCTGTTTGATT 2607
      |||||
Db 19 CTCCTGCTCTGTTTGATT 1

RESULT 1203
US-10-800-487-418/c
; Sequence 418, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBH04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 418
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
```

```
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
; US-10-800-487-418

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2798 ATGGTTCACGTCAGTCTTG 2816
      |||||
Db 19 ATGGTTCACGTCAGTCTTG 1

RESULT 1204
US-10-800-487-419/c
; Sequence 419, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBH04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 419
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
; US-10-800-487-419

Query Match          0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2801 GTTCACTGCAGTCTTGACC 2819
      |||||
Db 19 GTTCACTGCAGTCTTGACC 1
```

```
RESULT 1205
US-10-800-487-420/c
; Sequence 420, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 420
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-420

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2871 TAGGCTCACACACACAC 2889
Db 19 TAGGCTCACACACACAC 1

RESULT 1206
US-10-800-487-430
; Sequence 430, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
```

```
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 430
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxybasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxybasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-800-487-430

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 5.7e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1893 GCAAGACTCAAGACATGAT 1911
Db 1 GCAAGACTCAAGACATGAT 19

RESULT 1207
US-10-800-487-431/c
; Sequence 431, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
```

```
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 431
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal glyceryl moiety
US-10-800-487-431

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1893 GCAAGACTCAAGACATGAT 1911
Db 19 GCAAGACTCAAGACATGAT 1

RESULT 1208
US-10-800-487-432
; Sequence 432, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
```

```
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 432
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (3)..(6)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (10)..(13)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(18)
; OTHER INFORMATION: 2'-O-Methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (2)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (7)..(9)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (14)..(14)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; OTHER INFORMATION:
US-10-800-487-432

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 5.7e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1893 GCAAGACTCAAGACATGAT 1911
Db 1 GCAAGACTCAAGACATGAT 19
```



```
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:   siNA sense region  
;  
; FEATURE:  
; NAME/KEY: misc_feature  
; LOCATION: (2)..(2)  
; OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro  
;  
; FEATURE:  
; NAME/KEY: misc_feature  
; LOCATION: (7)..(9)  
; OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro  
;  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (14)..(14)  
; OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro  
;  
; FEATURE:  
; NAME/KEY: misc_feature  
; LOCATION: (16)..(16)  
; OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro  
;  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (19)..(19)  
; OTHER INFORMATION: 2'-O-Methyl or 2'-deoxy-2'-Fluoro  
;  
; FEATURE:  
; NAME/KEY: misc_feature  
; LOCATION: (1)..(1)  
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety  
;  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (21)..(21)  
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety  
;  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (20)..(21)  
; OTHER INFORMATION: n stands for thymidine  
;  
US-10-800-487-434
```

```
Query Match      0.6%; Score 19; DB 1; Length 21;  
Best Local Similarity    84.2%; Pred.No. 5.7e+02;  
Matches    16; Conservative     3; Mismatches    0; Indels    0; Gaps    0;
```

```
QY      1893 GCACGACTCAAGCATGCAT 1911  
           |||||||  
DB       1 GCAAAGCUCUACAAGAUGAU 19
```

```
RESULT 1211  
US-10-800-487-435/c  
; Sequence 435, Application US/108000487  
; Publication No. US20050048529A1  
; GENERAL INFORMATION:  
; APPLICANT: McSwiggen, James  
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion  
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic Acids  
; TITLE OF INVENTION: Acid (siNA)  
; FILE REFERENCE: 400/148 (MBHB04-218)  
; CURRENT APPLICATION NUMBER: US/10/800,487  
; CURRENT FILING DATE: 2004-03-15  
; PRIOR APPLICATION NUMBER: US 10/757,803  
; PRIOR FILING DATE: 2004-01-15  
; PRIOR APPLICATION NUMBER: US 10/720,448  
; PRIOR FILING DATE: 2003-11-24  
; PRIOR APPLICATION NUMBER: US 10/693,059  
; PRIOR FILING DATE: 2003-10-23  
; PRIOR APPLICATION NUMBER: US 10/444,853  
; PRIOR FILING DATE: 2003-05-23  
; PRIOR APPLICATION NUMBER: US 10/427,160  
; PRIOR FILING DATE: 2003-04-30  
; PRIOR APPLICATION NUMBER: PCT/US03/05346  
; PRIOR FILING DATE: 2003-02-20  
; PRIOR APPLICATION NUMBER: PCT/US03/05028  
; PRIOR FILING DATE: 2003-02-20  
; PRIOR APPLICATION NUMBER: US 60/358,580
```

```

; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 438
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 435
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
;
; NAME/KEY: misc feature
; LOCATION: (2)..(3)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (7)..(10)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (14)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (19)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-Fluoro
;
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
;
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate or Phosphorodithioate 3'-Internucleotide 1
;
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal glyceryl moiety
;
US-10-800-487-435

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 5.7e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1893 GCAAGACTCAAGACATGAT 1911
      |||||
Db 19 GCAAGACTCAAGACATGAT 1

RESULT 1212
US-10-800-487-436
; Sequence 436, Application US/10800487
; Publication No. US20050048529A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Inter cellular Adhe
; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering N
; TITLE OF INVENTION: Acid (siNA)
; FILE REFERENCE: 400/148 (MBHB04-218)
; CURRENT APPLICATION NUMBER: US/10/800,487
; CURRENT FILING DATE: 2004-03-15
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-15
; PRIOR APPLICATION NUMBER: US 10/720,448

```

```
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 436
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(1)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (3)..(6)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (10)..(13)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (15)..(15)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (17)..(18)
/ OTHER INFORMATION: 2'-deoxy
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (2)..(2)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (7)..(9)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (14)..(14)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (16)..(16)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (19)..(19)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (1)..(1)
/ OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (21)..(21)
```

```
/ OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (20)..(21)
/ OTHER INFORMATION: n stands for thymidine
/ US-10-800-487-436

Query Match
Best Local Similarity 0.6%; Score 19; DB 1; Length 21;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 1893 GCAAGACTCAAGACATGAT 1911
    |||||:|||||:|:
Db 1 GCAAGACUCACAGACAUGAU 19

RESULT 1213
US-10-800-487-437
/ Sequence 437, Application US/10800487
/ Publication No. US20050048529A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, James
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Intercellular Adhesion
/ TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic
/ TITLE OF INVENTION: Acid (siNA)
/ FILE REFERENCE: 400/148 (MHR04-218)
/ CURRENT APPLICATION NUMBER: US/10/800,487
/ CURRENT FILING DATE: 2004-03-15
/ PRIOR APPLICATION NUMBER: US 10/757,803
/ PRIOR FILING DATE: 2004-01-15
/ PRIOR APPLICATION NUMBER: US 10/720,448
/ PRIOR FILING DATE: 2003-11-24
/ PRIOR APPLICATION NUMBER: US 10/693,059
/ PRIOR FILING DATE: 2003-10-23
/ PRIOR APPLICATION NUMBER: US 10/444,853
/ PRIOR FILING DATE: 2003-05-23
/ PRIOR APPLICATION NUMBER: US 10/427,160
/ PRIOR FILING DATE: 2003-04-30
/ PRIOR APPLICATION NUMBER: PCT/US03/05346
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: PCT/US03/05028
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 438
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 437
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (2)..(2)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (7)..(9)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (14)..(14)
/ OTHER INFORMATION: 2'-deoxy-2'-Fluoro
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: (16)..(16)
```

```

, OTHER INFORMATION: 2'-deoxy-2'-Fluoro
,
, FEATURE:
, NAME/KEY: misc_feature
, LOCATION: (19)..(19)
, OTHER INFORMATION: 2'-deoxy-2'-Fluoro
,
, FEATURE:
, NAME/KEY: misc_feature
, LOCATION: (1)..(1)
, OTHER INFORMATION: 5'-3 attached term
,
, FEATURE:
, NAME/KEY: misc_feature
, LOCATION: (21)..(21)
, OTHER INFORMATION: 3'-3 attached term
,
, FEATURE:
, NAME/KEY: misc_feature
, LOCATION: (20)..(21)
, OTHER INFORMATION: n stands for thymine
,
, US-10-800-447-437

```

Query Match 0.6%; Score 19; DB 1; Length 21;
Best Local Similarity 84.2%; Pred. No. 5.7e+02;
Matches 16; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

Qy 1893 GCAAGACTCAAGACATGAT 1911
 |||||:|||||:
 pb 1 GCAAGACUCAAGACAUGAU 19

RESULT 1214

US-10-800-487-438/c

; Sequence 438, Application US/10800487

; Publication No. US2005048529A1

; GENERAL INFORMATION:

; APPLICANT: Sitna Therapeutics, Inc.

; APPLICANT: McSwigen, James

; TITLE OF INVENTION: RNA interference Mediated Inhibition Of Intercellular Adhesion

; TITLE OF INVENTION: Molecule (ICAM) Gene Expression Using Short Interfering Nucleic

; TITLE OF INVENTION: Acid (siNA)

; FILE REFERENCE: 400/148 (MBH04-218)

; CURRENT APPLICATION NUMBER: US/10/800,487

; CURRENT FILING DATE: 2004-03-15

; PRIOR APPLICATION NUMBER: US 10/757,803

; PRIOR FILING DATE: 2004-01-15

; PRIOR APPLICATION NUMBER: US 10/720,448

; PRIOR FILING DATE: 2003-11-24

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2003-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/427,160

; PRIOR FILING DATE: 2003-04-30

; PRIOR APPLICATION NUMBER: PCT/US03/05346

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: PCT/US03/05028

; PRIOR FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; Remaining Prior Application data removed - See File Wrapper or PALM.

; NUMBER OF SEQ ID NOS: 438

; SOFTWARE: PatentIn version 3.3

; SEQ ID NO 438

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

; FEATURE:

; NAME/KEY: misc feature

; LOCATION: (1)..(1)

STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/860,784
FILING DATE: 21-May-2001
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/594,452
FILING DATE: 04-APR-1996
ATTORNEY/AGENT INFORMATION:
NAME: SANDERCOCK, Colin G.
REGISTRATION NUMBER: 31,298
REFERENCE/DOCKET NUMBER: 18748/264/HOCE
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202)672-5300
TELEFAX: (202)672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 92:
SEQUENCE CHARACTERISTICS:
LENGTH: 22 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
SEQUENCE DESCRIPTION: SEQ ID NO: 92:
US-09-860-784-92

Query Match 0.6%; Score 19; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 5.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 51 CCTCGCTATGGTCCCGC 69
DB 22 CCTCGCTATGGTCCCGC 4

RESULT 1216
US-09-263-959-774/c
; Sequence 774, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSES: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900

TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 774:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-263-959-774

Query Match 0.6%; Score 18.8; DB 1; Length 23;
Best Local Similarity 90.9%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGT 2749
DB 22 GTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 1217
US-10-401-194-30
; Sequence 30, Application US/10401194
; Publication No. US20030219810A1
; GENERAL INFORMATION:
; APPLICANT: Millennium Pharmaceuticals, Inc.
; APPLICANT: Barnes, Glenn T.
; APPLICANT: Bertin, John
; TITLE OF INVENTION: POLYMORPHISMS IN THE HUMAN CARD4 GENE
; FILE REFERENCE: MPI02-041P1RM
; CURRENT APPLICATION NUMBER: US/10/401,194
; CURRENT FILING DATE: 2003-03-27
; PRIOR APPLICATION NUMBER: US 60/368,184
; PRIOR FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 30
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-401-194-30

Query Match 0.6%; Score 18.8; DB 1; Length 23;
Best Local Similarity 90.9%; Pred. No. 5.4e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2795 ATCATCGTTCACGTCAGCTCTTG 2816
DB 2 ATCATCGTTCACGTCAGCTCTTG 23

RESULT 1218
US-09-752-983-242/c
; Sequence 242, Application US/09752983
; Patent No. US20010016575A1
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSES: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PC
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/752,983

```
; FILING DATE: 02-Jan-2001
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/280,805
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Licata, Jane Massey
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0346
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-810-1515
; TELEFAX: 609-810-1454
; INFORMATION FOR SEQ ID NO: 242:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-752-983-242

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2765 CTGTCACCCAGCGTGGATG 2784
Db 20 CTGTTACCCAGCGTGGATG 1

RESULT 1219
US-09-916-369A-4
; Sequence 4, Application US/09916369A
; Publication No. US20020058802A1
; GENERAL INFORMATION:
; APPLICANT: Dellinger, Douglas J
; APPLICANT: Perboost, Michael GM
; APPLICANT: Caruthers, Marvin H
; APPLICANT: Betley, Jason R
; TITLE OF INVENTION: Synthesis of Polynucleotides Using Combined Oxidation/Deprotection
; FILE REFERENCE: 10003869-1
; CURRENT APPLICATION NUMBER: US/09/916,369A
; PRIOR FILING DATE: 2001-07-21
; PRIOR APPLICATION NUMBER: US 09/627,249
; PRIOR FILING DATE: 2000-07-28
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: synthetic sequence
US-09-916-369A-4

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATGTG 2748
Db 1 TGTGTGTGTGTGTGTGTGTG 20

RESULT 1220
US-09-964-059B-100
; Sequence 100, Application US/09964059B
; Publication No. US20030171875A1
; GENERAL INFORMATION:
; APPLICANT: Frudakis, Tony
; TITLE OF INVENTION: Efficient Methods and Apparatus for High-Throughput Processing of
```

```
; FILE REFERENCE: 0201-0001
; CURRENT APPLICATION NUMBER: US/09/964,059B
; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: US 60/274,686
; PRIOR FILING DATE: 2000-03-08
; NUMBER OF SEQ ID NOS: 239
; SEQ ID NO 100
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-964-059B-100

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2828 TCAAGTGATCTCCACCTC 2847
Db 1 TCAAGTGATCCACCCACCTC 20

RESULT 1221
US-09-845-742B-1
; Sequence 1, Application US/09845742B
; Publication No. US20030215801A1
; GENERAL INFORMATION:
; APPLICANT: Pieken, Wolfgang
; APPLICANT: Wolter, Andreas
; APPLICANT: Sebesta P, David
; APPLICANT: Leuck, Michael
; APPLICANT: Latham-Timmons A, Hallie
; APPLICANT: Pilon, John
; APPLICANT: Husar M, Gregory
; TITLE OF INVENTION: METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES EMPLOYING THE
; FILE REFERENCE: PRO. 03
; CURRENT APPLICATION NUMBER: US/09/845,742B
; CURRENT FILING DATE: 2001-05-01
; PRIOR APPLICATION NUMBER: 60/201,561
; PRIOR FILING DATE: 2000-05-01
; PRIOR APPLICATION NUMBER: 60/265,020
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: 09/341,337
; PRIOR FILING DATE: 1999-07-08
; PRIOR APPLICATION NUMBER: PCT/US98/00649
; PRIOR FILING DATE: 1998-01-08
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-845-742B-1

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTATGTG 2748
Db 1 TGTGTGTGTGTGTGTGTGTG 20

RESULT 1222
US-09-845-742B-2/c
; Sequence 2, Application US/09845742B
; Publication No. US20030215801A1
; GENERAL INFORMATION:
; APPLICANT: Pieken, Wolfgang
; APPLICANT: Wolter, Andreas
```

APPLICANT: Sebesta P, David
APPLICANT: Leuck, Michael
APPLICANT: Latham-Timmons A, Hallie
APPLICANT: Pilon, John
APPLICANT: Husar M, Gregory
TITLE OF INVENTION: METHOD FOR IMMOBILIZING OLIGONUCLEOTIDES EMPLOYING THE
TITLE OF INVENTION: CYCLOADDITION BIOCONJUGATION METHOD
FILE REFERENCE: PRO. 03
CURRENT APPLICATION NUMBER: US/09/845,742B
PRIOR FILING DATE: 2001-05-01
PRIOR APPLICATION NUMBER: 60/201,561
PRIOR FILING DATE: 2000-05-01
PRIOR APPLICATION NUMBER: 60/265,020
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: 09/341,337
PRIOR FILING DATE: 1999-07-08
PRIOR APPLICATION NUMBER: PCT/US98/00649
PRIOR FILING DATE: 1998-01-08
NUMBER OF SEQ ID NOS: 2
SOFTWARE: Patent In Ver. 2.0
SEQ ID NO 2
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: Nucleic Acid Ligand
NAME/KEY: modified_base
LOCATION: (1)
OTHER INFORMATION: C at position 1 is substituted at the 5' position
OTHER INFORMATION: with a fluorescein.
US-09-845-742B-2

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
DB 20 TGTGTGTGTGTGTGTGTGTG 1

RESULT 1223
US-10-085-906-33
Sequence 33, Application US/10085906
Publication No. US20030054371A1
GENERAL INFORMATION:
APPLICANT: Ying, Vincent
APPLICANT: Wu, Paul
APPLICANT: Gray, Gary S.
TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
TITLE OF INVENTION: COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
FILE REFERENCE: GNN-5343CP2
CURRENT APPLICATION NUMBER: US/10/085,906
CURRENT FILING DATE: 2002-02-27
PRIOR FILING DATE: 2002-02-27
PRIOR APPLICATION NUMBER: US 60/126,215
PRIOR FILING DATE: 1999-03-25
PRIOR APPLICATION NUMBER: US 09/534,061
PRIOR FILING DATE: 2000-03-24
PRIOR APPLICATION NUMBER: PCT/US00/07938
PRIOR FILING DATE: 2000-03-24
NUMBER OF SEQ ID NOS: 545
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 33
LENGTH: 20
TYPE: DNA
ORGANISM: Homo sapiens
US-10-085-906-33

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTG 2747
DB 1 GTGTGTGTGTGTGTGTGTGTG 20

RESULT 1224
US-10-165-854-1/c
Sequence 1, Application US/10165854
Publication No. US20030059807A1
GENERAL INFORMATION:
APPLICANT: Roach, Jeffrey Shawn
TITLE OF INVENTION: MICROCALORIMETRIC DETECTION OF ANALYTES AND BINDING EVENTS
FILE REFERENCE: PRO06
CURRENT APPLICATION NUMBER: US/10/165,854
CURRENT FILING DATE: 2002-06-07
PRIOR APPLICATION NUMBER: 60/296,685
PRIOR FILING DATE: 2001-06-07
NUMBER OF SEQ ID NOS: 4
SOFTWARE: Patent In version 3.1
SEQ ID NO 1
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Nucleic Acid Ligand
US-10-165-854-1

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
DB 20 TGTGTGTGTGTGTGTGTGTG 1

RESULT 1225
US-10-165-854-2
Sequence 2, Application US/10165854
Publication No. US20030059807A1
GENERAL INFORMATION:
APPLICANT: Roach, Jeffrey Shawn
APPLICANT: Wolter, Andreas
TITLE OF INVENTION: MICROCALORIMETRIC DETECTION OF ANALYTES AND BINDING EVENTS
FILE REFERENCE: PRO06
CURRENT APPLICATION NUMBER: US/10/165,854
CURRENT FILING DATE: 2002-06-07
PRIOR APPLICATION NUMBER: 60/296,685
PRIOR FILING DATE: 2001-06-07
NUMBER OF SEQ ID NOS: 4
SOFTWARE: Patent In version 3.1
SEQ ID NO 2
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Nucleic Acid Ligand
US-10-165-854-2

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
DB 1 TGTGTGTGTGTGTGTGTGTG 20

RESULT 1226
US-10-222-334-14/c
Sequence 14, Application US/10222334

```
; Publication No. US20030073116A1
; GENERAL INFORMATION:
; APPLICANT: Ginsburg, David
; APPLICANT: Levy, Gallia
; APPLICANT: Tsai, Han-Mou
; TITLE OF INVENTION: ADAMTS13 Genes and Proteins and Variants, and Uses Thereof
; FILE REFERENCE: UM-07288
; CURRENT APPLICATION NUMBER: US/10/222,334
; CURRENT FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: 60/312,834
; PRIOR FILING DATE: 2001-08-16
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-222-334-14

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCACCCAGGCT 2778
Db 20 CTCACCTCTGTCACCCAGGCT 1

RESULT 1227
US-10-219-238-1
; Sequence 1, Application US/10219238
; Publication No. US20030114405A1
; GENERAL INFORMATION:
; APPLICANT: Linnik, Matthew D.
; APPLICANT: Hepburn, Bonnie
; TITLE OF INVENTION: METHODS OF TREATING SYSTEMIC LUPUS
; TITLE OF INVENTION: ERYTHEMATOSUS IN INDIVIDUALS HAVING
; TITLE OF INVENTION: SIGNIFICANTLY IMPAIRED RENAL FUNCTION
; FILE REFERENCE: 252312007800
; CURRENT APPLICATION NUMBER: US/10/219,238
; CURRENT FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: US 60/314,281
; PRIOR FILING DATE: 2001-08-22
; PRIOR APPLICATION NUMBER: US 60/311,858
; PRIOR FILING DATE: 2001-08-13
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-219-238-1

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTATGCT 2747
Db 1 GTGTGTGTGTGTGTGTGTGT 20

RESULT 1228
US-10-219-238-2/c
; Sequence 2, Application US/10219238
; Publication No. US20030114405A1
; GENERAL INFORMATION:
; APPLICANT: Linnik, Matthew D.
; APPLICANT: Hepburn, Bonnie
```

```
; TITLE OF INVENTION: METHODS OF TREATING SYSTEMIC LUPUS
; TITLE OF INVENTION: ERYTHEMATOSUS IN INDIVIDUALS HAVING
; TITLE OF INVENTION: SIGNIFICANTLY IMPAIRED RENAL FUNCTION
; FILE REFERENCE: 252312007800
; CURRENT APPLICATION NUMBER: US/10/219,238
; CURRENT FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: US 60/314,281
; PRIOR FILING DATE: 2001-08-22
; PRIOR APPLICATION NUMBER: US 60/311,858
; PRIOR FILING DATE: 2001-08-13
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-219-238-2

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATGCTG 2748
Db 20 TGTGTGTGTGTGTGTGTGTG 1

RESULT 1229
US-10-005-344-242/c
; Sequence 242, Application US/10005344
; Publication No. US20030203862A1
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia
; APPLICANT: Pamela Nero
; APPLICANT: Mark J. Graham
; APPLICANT: Brett P. Monia
; APPLICANT: Erich Koller
; APPLICANT: Mingyi Chiang
; APPLICANT: Mano Manoharan
; TITLE OF INVENTION: Antisense Modulation of mdm2 expression.
; FILE REFERENCE: ISPH-0622
; CURRENT APPLICATION NUMBER: US/10/005,344
; CURRENT FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: US 09/048,810
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/280,805
; PRIOR FILING DATE: 1999-03-26
; NUMBER OF SEQ ID NOS: 379
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 242
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-005-344-242

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2765 CTGTCACCCAGGCTGGAGTG 2784
Db 20 CTGTTACCCAGGCTGGAGTG 1

RESULT 1230
US-10-423-311-12/c
; Sequence 12, Application US/10423311
; Publication No. US20030206938A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Pereira, Heloise Anne
; APPLICANT: Chodosh, James
; APPLICANT: Callegan, Michelle C.
; TITLE OF INVENTION: TREATMENT AND INHIBITION OF OCULAR INFECTIONS AND WOUNDS BY CAP37 PEPTIDES
; FILE REFERENCE: 6267.002
; CURRENT APPLICATION NUMBER: US/10/423,311
; CURRENT FILING DATE: 2003-04-25
; PRIOR APPLICATION NUMBER: 60/378,295
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Completely synthesized
US-10-423-311-12

Query Match      0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1073 AGGTGACGCTGAATGGGTT 1092
      |||||
Db 20 ACGTGACGCTGAATGGGTT 1

RESULT 1231
US-10-199-676-38
; Sequence 38, Application US/10199676
; Publication No. US20040014051A1
; GENERAL INFORMATION:
; APPLICANT: Vickie L. Brown-Driver
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF BREAST CANCER-1 EXPRESSION
; FILE REFERENCE: PTS-0017
; CURRENT APPLICATION NUMBER: US/10/199,676
; CURRENT FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 84
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-199-676-38

Query Match      0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2763 CTCTGTCAACCCAGGCTGGAG 2782
      |||||
Db 1 CTCTGTGCGCCAGGCTGGAG 20

RESULT 1232
US-10-199-676-74/c
; Sequence 74, Application US/10199676
; Publication No. US20040014051A1
; GENERAL INFORMATION:
; APPLICANT: Vickie L. Brown-Driver
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF BREAST CANCER-1 EXPRESSION
; FILE REFERENCE: PTS-0017
; CURRENT APPLICATION NUMBER: US/10/199,676
; CURRENT FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 84
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: H. sapiens
; FEATURE:
US-10-199-676-74

Query Match      0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2763 CTCTGTCAACCCAGGCTGGAG 2782
      |||||
Db 20 CTCTGTGCGCCAGGCTGGAG 1

RESULT 1233
US-10-303-325-84
; Sequence 84, Application US/10303325
; Publication No. US20040102395A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF IAP-LIKE EXPRESSION
; FILE REFERENCE: RTS-0434
; CURRENT APPLICATION NUMBER: US/10/303,325
; CURRENT FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 156
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-303-325-84

Query Match      0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCAACCCAGGC 2777
      |||||
Db 1 TCTCGCTCTGTCAACCCAGGC 20

RESULT 1234
US-10-303-325-150/c
; Sequence 150, Application US/10303325
; Publication No. US20040102395A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF IAP-LIKE EXPRESSION
; FILE REFERENCE: RTS-0434
; CURRENT APPLICATION NUMBER: US/10/303,325
; CURRENT FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 156
; SEQ ID NO 150
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-303-325-150

Query Match      0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCAACCCAGGC 2777
      |||||
Db 20 TCTCGCTCTGTCAACCCAGGC 1

RESULT 1235
US-10-671-395-138/c
; Sequence 138, Application US/10671395
```



```
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 138
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-138

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 2747
Db 20 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 1236
US-10-671-395-139/c
; Sequence 139, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 139
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-139

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 2748
Db 20 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 1

RESULT 1237
US-10-671-395-140/c
; Sequence 140, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 140
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-140

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 2748
Db 20 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 1

RESULT 1238
US-10-671-395-141/c
; Sequence 141, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 141
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-141

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 2748
Db 20 TGTGTGTGTGTGTGTGTGTGTGTGTGTG 1

RESULT 1239
US-10-671-395-142/c
; Sequence 142, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 142
```

; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-142

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGT 2747
DB 20 GTGTGTGTGTGTGTGTGT 1

RESULT 1240
US-10-671-395-175/c
; Sequence 175, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 175
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-175

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGT 2747
DB 20 GTGTGTGTGTGTGTGTGT 1

RESULT 1241
US-10-671-395-176/c
; Sequence 176, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 176
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-176

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGT 2747
DB 20 GTGTGTGTGTGTGTGTGT 1

RESULT 1242
US-10-671-395-316/c
; Sequence 316, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 316
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-316

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGT 2747
DB 20 GTGTGTGTGTGTGTGTGT 1

RESULT 1243
US-10-671-395-317/c
; Sequence 317, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 317
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-317

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2748
DB 20 TGTGTGTGTGTGTGTGTGT 1

; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 353
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-353

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGT 2747
DB 20 GTGTGTGTGTGTGTGTGT 1

RESULT 1249

US-10-671-395-354/c
; Sequence 354, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 354
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-354

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGT 2747
DB 20 GTGTGTGTGTGTGTGTGT 1

RESULT 1250

US-10-671-395-482/c
; Sequence 482, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 482
; LENGTH: 20
; TYPE: DNA

; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-482

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2748
DB 20 TGTGTGTGTGTGTGTGTGT 1

RESULT 1251

US-10-671-395-483/c
; Sequence 483, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 483
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-483

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2748
DB 20 TGTGTGTGTGTGTGTGTGT 1

RESULT 1252

US-10-671-395-484/c
; Sequence 484, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 484
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-484

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;


```
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 586
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-586

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2727 CGTGTGTGTGTGTGTATG 2746
Db 20 CGTGTGTGTGTGTGTGTG 1

RESULT 1258
US-10-671-395-600/c
; Sequence 600, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 600
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-600

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTATGTG 2748
Db 20 TGTGTGTGTGTGTGTGTG 1

RESULT 1259
US-10-671-395-613/c
; Sequence 613, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
```

```
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 613
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-613

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGT 2747
Db 20 GTGTGTGTGTGTGTGTGT 1

RESULT 1260
US-10-671-395-614/c
; Sequence 614, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 614
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-614

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGT 2747
Db 20 GTGTGTGTGTGTGTGTGT 1

RESULT 1261
US-10-671-395-653/c
; Sequence 653, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 653
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
```

```
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-653

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGT 2747
DB 20 GTGTGTGTGTGTGTGTGTGT 1

RESULT 1262
US-10-671-395-688/c
; Sequence 688, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 688
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-688

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2838 CTCGCCCTCAGCCTCCTCGA 2857
DB 20 CTCGCCCTCAGCCTCCTCGA 1

RESULT 1263
US-10-671-395-733/c
; Sequence 733, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 733
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-733

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2723 TCCGGTGTGTGTGTGTGTG 2742
DB 20 TCCGGTGTGTGTGTGTGTG 1

RESULT 1264
US-10-671-395-753/c
; Sequence 753, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 753
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-753

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2839 TCCACCTCAGCCTCCTCGAG 2858
DB 20 TCCCGCCTCAGCCTCCTCGAG 1

RESULT 1265
US-10-671-395-882/c
; Sequence 882, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 882
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-882

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2840 CCCACCTCAGCCTCCTCGAGT 2859
DB 20 CCCGCCTCAGCCTCCTCGAGT 1

RESULT 1266
US-10-671-395-959/c
```

```
; Sequence 959, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; CURRENT FILING DATE: 2002-09-25
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 959
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-959

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2722 ATCCGCGTGTGTGTGTGT 2741
Db 20 ATCCGCGTGTGTGTGTGT 1

RESULT 1267
US-10-671-395-1001/c
; Sequence 1001, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; CURRENT FILING DATE: 2002-09-25
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1001
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1001

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2841 CCACCTCAGCCTCTCGAGTA 2860
Db 20 CCACCTCAGCCTCTCGAGTA 1

RESULT 1268
US-10-671-395-1267/c
; Sequence 1267, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; CURRENT FILING DATE: 2002-09-25
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1267
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1267

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2842 CACCTCAGCCTCTCGAGTAG 2861
Db 20 CGCCTCAGCCTCTCGAGTAG 1

RESULT 1269
US-10-671-395-1423/c
; Sequence 1423, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; CURRENT FILING DATE: 2002-09-25
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1423
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1423

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGT 2747
Db 20 GTGTGTGTGTGTGTGTGTGT 1

RESULT 1270
US-10-671-395-1595/c
; Sequence 1595, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; CURRENT FILING DATE: 2002-09-25
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1595
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1595
```



```
; SEQ ID NO 1595
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1595

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2727 CGTGTGTGTGTGTGTATG 2746
Db 20 CGTGTGTGTGTGTGTATG 1

RESULT 1271
US-10-671-395-1640/c
; Sequence 1640, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1640
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1640

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2730 GTGTGTGTGTGTGTATGT 2749
Db 20 GTGTGTGTGTGTGTATGT 1

RESULT 1272
US-10-671-395-1665/c
; Sequence 1665, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1665
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1665

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGT 2747
Db 20 GTGTGTGTGTGTGTATGT 1

RESULT 1273
US-10-671-395-1685/c
; Sequence 1685, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1685
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1685

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTATGTG 2748
Db 20 TGTGTGTGTGTGTATGTG 1

RESULT 1274
US-10-745-377-26
; Sequence 26, Application US/10745377
; Publication No. US20040137423A1
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
; APPLICANT: Pimstone, Simon
; APPLICANT: Brooks-Wilson, Angela R.
; APPLICANT: Clee, Susanne M.
; TITLE OF INVENTION: Compositions and Methods for Modulating
; TITLE OF INVENTION: HDL Cholesterol and Triglyceride Levels
; FILE REFERENCE: 760050-109
; CURRENT APPLICATION NUMBER: US/10/745,377
; CURRENT FILING DATE: 2003-12-23
; PRIOR APPLICATION NUMBER: 09/654,323
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: US 60/124,702
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: US 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: US 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: US 60/151,977
; PRIOR FILING DATE: 1999-09-01
; PRIOR APPLICATION NUMBER: US 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: US 60/213,958
; PRIOR FILING DATE: 2000-06-23
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: Word for Windows Version 6.0 (ASCII Text)
```

```
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: homo sapien
US-10-745-377-26

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2825 GGCTCAAGTCATCTCCAC 2844
Db 1 GGCTCAAGCGATCTCCAC 20

RESULT 1275
US-10-661-088-16/c
; Sequence 16, Application US/10661088
; Publication No. US20040162253A1
; GENERAL INFORMATION:
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
; FILE REFERENCE: 029849/0206
; CURRENT APPLICATION NUMBER: US/10/661,088
; PRIOR FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-088-16

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGT 2747
Db 20 GTGTGTGTGTGTGTGTGT 1

RESULT 1276
US-10-661-088-19
; Sequence 19, Application US/10661088
; Publication No. US20040162253A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
; FILE REFERENCE: 029849/0206
; CURRENT APPLICATION NUMBER: US/10/661,088
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 19
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-088-19

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTATGTG 2748
Db 1 TGTGTGTGTGTGTGTGTG 20

RESULT 1277
US-10-661-097-16/c
; Sequence 16, Application US/10661097
; Publication No. US20040162254A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
; FILE REFERENCE: 029849/0204
; CURRENT APPLICATION NUMBER: US/10/661,097
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-097-16

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGT 2747
Db 20 GTGTGTGTGTGTGTGTGT 1

RESULT 1278
US-10-661-097-19
; Sequence 19, Application US/10661097
; Publication No. US20040162254A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HSV
; FILE REFERENCE: 029849/0204
; CURRENT APPLICATION NUMBER: US/10/661,097
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 19
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-097-19
```

```
Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2729 TGTGTGTGTGTGTGTATGTG 2748
      |||||
Db 1 TGTGTGTGTGTGTGTGTGTG 20
```

```
RESULT 1279
US-10-661-355-16/c
; Sequence 16, Application US/10661355
; Publication No. US20040170959A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
; FILE REFERENCE: 029849/0208
; CURRENT APPLICATION NUMBER: US/10/661,355
; PRIOR FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-355-16
```

```
Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2728 GTGTGTGTGTGTGTATGT 2747
      |||||
Db 20 GTGTGTGTGTGTGTGTGT 1
```

```
RESULT 1280
US-10-661-355-19
; Sequence 19, Application US/10661355
; Publication No. US20040170959A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES
; FILE REFERENCE: 029849/0208
; CURRENT APPLICATION NUMBER: US/10/661,355
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
```

```
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-355-19
```

```
Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2729 TGTGTGTGTGTGTATGTG 2748
      |||||
Db 1 TGTGTGTGTGTGTGTGTGTG 20
```

```
RESULT 1281
US-10-661-099-16/c
; Sequence 16, Application US/10661099
; Publication No. US20040171568A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HIV
; FILE REFERENCE: 029849/0203
; CURRENT APPLICATION NUMBER: US/10/661,099
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-099-16
```

```
Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2728 GTGTGTGTGTGTATGT 2747
      |||||
Db 20 GTGTGTGTGTGTGTGTGT 1
```

```
RESULT 1282
US-10-661-099-19
; Sequence 19, Application US/10661099
; Publication No. US20040171568A1
; GENERAL INFORMATION:
; APPLICANT: VAILLANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING HIV
; FILE REFERENCE: 029849/0203
; CURRENT APPLICATION NUMBER: US/10/661,099
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
```

; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-099-19

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
|||||
Db 1 TGTGTGTGTGTGTGTGTG 20

RESULT 1283
US-10-407-818-13
; Sequence 13, Application US/10407818
; Publication No. US20040198971A1
; GENERAL INFORMATION:
; APPLICANT: RABBANI, ELAZAR
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: DONEGAN, JAMES J.
; TITLE OF INVENTION: MULTISIGNAL LABELING REAGENTS, AND PROCESSES AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: ENZ-65
; CURRENT APPLICATION NUMBER: US/10/407,818
; CURRENT FILING DATE: 2003-04-03
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-407-818-13

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
|||||
Db 1 TGTGTGTGTGTGTGTGTG 20

RESULT 1284
US-10-407-818-14/c
; Sequence 14, Application US/10407818
; Publication No. US20040198971A1
; GENERAL INFORMATION:
; APPLICANT: RABBANI, ELAZAR
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: DONEGAN, JAMES J.
; TITLE OF INVENTION: MULTISIGNAL LABELING REAGENTS, AND PROCESSES AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: ENZ-65
; CURRENT APPLICATION NUMBER: US/10/407,818
; CURRENT FILING DATE: 2003-04-03
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-407-818-14

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTG 2747
|||||
Db 20 GTGTGTGTGTGTGTGTG 1

RESULT 1285
US-10-407-818-16
; Sequence 16, Application US/10407818
; Publication No. US20040198971A1
; GENERAL INFORMATION:
; APPLICANT: RABBANI, ELAZAR
; APPLICANT: STAVRIANOPOULOS, JANNIS G.
; APPLICANT: DONEGAN, JAMES J.
; TITLE OF INVENTION: MULTISIGNAL LABELING REAGENTS, AND PROCESSES AND USES
; TITLE OF INVENTION: THEREFOR
; FILE REFERENCE: ENZ-65
; CURRENT APPLICATION NUMBER: US/10/407,818
; CURRENT FILING DATE: 2003-04-03
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Combined DNA/RNA Molecule:
; OTHER INFORMATION: Synthetic oligonucleotide
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-407-818-16

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 6.9e+02;
Matches 17; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
|||||
Db 1 TGTGTGTGTGTGTGTGTG 20

RESULT 1286
US-10-748-541-1
; Sequence 1, Application US/10748541
; Publication No. US20040208864A1
; GENERAL INFORMATION:
; APPLICANT: Strand, Vibeke
; APPLICANT: Linnik, Matthew D.
; APPLICANT: Joh, Tenshang
; TITLE OF INVENTION: METHODS OF IMPROVING HEALTH-RELATED
; TITLE OF INVENTION: QUALITY OF LIFE IN INDIVIDUALS WITH SYSTEMIC LUPUS
; TITLE OF INVENTION: ERYTHEMATOSUS
; FILE REFERENCE: 252312007900
; CURRENT APPLICATION NUMBER: US/10/748,541
; CURRENT FILING DATE: 2003-12-29
; PRIOR APPLICATION NUMBER: US 60/436,906
; PRIOR FILING DATE: 2002-12-27
; PRIOR APPLICATION NUMBER: US 60/478,128
; PRIOR FILING DATE: 2003-06-11
; NUMBER OF SEQ ID NOS: 2

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-748-541-1

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  2728 GTGTGTGTGTGTGTATGT 2747
      |||||
Db   1 GTGTGTGTGTGTGTGTGT 20

RESULT 1287
US-10-748-541-2/c
; Sequence 2, Application US/10748541
; Publication No. US20040208864A1
; GENERAL INFORMATION:
; APPLICANT: Strand, Vibeke
; APPLICANT: Linnik, Matthew D.
; APPLICANT: Joh, Tenshang
; TITLE OF INVENTION: METHODS OF IMPROVING HEALTH-RELATED
; TITLE OF INVENTION: QUALITY OF LIFE IN INDIVIDUALS WITH SYSTEMIC LUPUS
; TITLE OF INVENTION: ERYTHEMATOSUS
; FILE REFERENCE: 252312007900
; CURRENT APPLICATION NUMBER: US/10/748,541
; CURRENT FILING DATE: 2003-12-29
; PRIOR APPLICATION NUMBER: US 60/436,906
; PRIOR FILING DATE: 2002-12-27
; PRIOR APPLICATION NUMBER: US 60/478,128
; PRIOR FILING DATE: 2003-06-11
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-748-541-2

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  2729 TGTGTGTGTGTGTATGTG 2748
      |||||
Db   20 TGTGTGTGTGTGTGTGTG 1

RESULT 1288
US-10-872-113-26
; Sequence 26, Application US/10872113
; Publication No. US20040229275A1
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
; APPLICANT: Rimstone, Simon
; APPLICANT: Brooks-Wilson, Angela R.
; APPLICANT: Clee, Susanne M.
; TITLE OF INVENTION: Compositions and Methods for Modulating
; TITLE OF INVENTION: HDL Cholesterol and Triglyceride Levels
; FILE REFERENCE: 760050-138
; CURRENT APPLICATION NUMBER: US/10/872,113
; CURRENT FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 09/654,323
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: US 60/124,702
; PRIOR FILING DATE: 1999-03-15

; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-748-541-1

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  2825 GGCTCAAGTGATCTCTCCAC 2844
      |||||
Db   1 GGCTCAAGCGATCTCTCCAC 20

RESULT 1289
US-10-661-415-16/c
; Sequence 16, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: VAILLIANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
; FILE REFERENCE: 029849/0205
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: Patent In Ver. 3.2
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-415-16

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  2728 GTGTGTGTGTGTGTATGT 2747
      |||||
Db   20 GTGTGTGTGTGTGTGTGT 1

RESULT 1290
US-10-661-415-19
; Sequence 19, Application US/10661415
; Publication No. US20040229828A1
; GENERAL INFORMATION:
; APPLICANT: VAILLIANT, ANDREW
; APPLICANT: JUTEAU, JEAN-MARC
; TITLE OF INVENTION: ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV
; FILE REFERENCE: 029849/0205
```

```
; CURRENT APPLICATION NUMBER: US/10/661,415
; CURRENT FILING DATE: 2003-09-12
; PRIOR APPLICATION NUMBER: PCT/IB03/04573
; PRIOR FILING DATE: 2003-09-11
; PRIOR APPLICATION NUMBER: 60/430,934
; PRIOR FILING DATE: 2002-12-05
; PRIOR APPLICATION NUMBER: 60/410,264
; PRIOR FILING DATE: 2002-09-13
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-661-415-19
```

```
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2729 TGTGTGTGTGTGTGTATGTG 2748
|||||
DB 1 TGTGTGTGTGTGTGTGTGTG 20
```

```
RESULT 1291
US-10-814-555-1
; Sequence 1, Application US/10814555
; Publication No. US20040258683A1
; GENERAL INFORMATION:
; APPLICANT: Linnik, Matthew D.
; TITLE OF INVENTION: METHODS OF TREATING AND MONITORING
; FILE REFERENCE: 252312008000
; CURRENT APPLICATION NUMBER: US/10/814,555
; CURRENT FILING DATE: 2004-03-30
; PRIOR APPLICATION NUMBER: US 60/459,470
; PRIOR FILING DATE: 2003-03-30
; PRIOR APPLICATION NUMBER: US 60/478,127
; PRIOR FILING DATE: 2003-06-11
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-814-555-1
```

```
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2728 GTGTGTGTGTGTGTGTATGT 2747
|||||
DB 1 GTGTGTGTGTGTGTGTGTGT 20
```

```
RESULT 1292
US-10-814-555-2/c
; Sequence 2, Application US/10814555
; Publication No. US20040258683A1
; GENERAL INFORMATION:
; APPLICANT: Linnik, Matthew D.
; APPLICANT: Joh, Tenshang
; TITLE OF INVENTION: METHODS OF TREATING AND MONITORING
; FILE REFERENCE: 252312008000
```

```
; CURRENT APPLICATION NUMBER: US/10/814,555
; CURRENT FILING DATE: 2004-03-30
; PRIOR APPLICATION NUMBER: US 60/459,470
; PRIOR FILING DATE: 2003-03-30
; PRIOR APPLICATION NUMBER: US 60/478,127
; PRIOR FILING DATE: 2003-06-11
; NUMBER OF SEQ ID NOS: 3
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-814-555-2
```

```
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2729 TGTGTGTGTGTGTGTATGTG 2748
|||||
DB 20 TGTGTGTGTGTGTGTGTGTG 1
```

```
RESULT 1293
US-10-624-570-3
; Sequence 3, Application US/10624570
; Publication No. US20050026152A1
; GENERAL INFORMATION:
; APPLICANT: Muller, Norbert
; TITLE OF INVENTION: Method of Screening Schizophrenia
; FILE REFERENCE: 03-1039
; CURRENT APPLICATION NUMBER: US/10/624,570
; CURRENT FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: US 60/397,611
; PRIOR FILING DATE: 2002-07-23
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Snapshot primer for ICAM-1
US-10-624-570-3
```

```
Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 758 CCGTGTCTGTTCCTGGAC 777
|||||
DB 1 CCGTGTCTGTTCCTGGAC 20
```

```
RESULT 1294
US-10-639-300-38
; Sequence 38, Application US/10639300
; Publication No. US20050026857A1
; GENERAL INFORMATION:
; APPLICANT: Vickie L. Brown-Driver
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF BREAST CANCER-1 EXPRESSION
; FILE REFERENCE: PTS-0017
; CURRENT APPLICATION NUMBER: US/10/639,300
; CURRENT FILING DATE: 2003-08-12
; PRIOR APPLICATION NUMBER: US/10/199,676
; PRIOR FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 84
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-639-300-38

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2763 CTCTGTACCCAGGTGGAG 2782
Db 1 CTCTGTGCGCCAGGTGGAG 20

RESULT 1295
US-10-639-300-74/c
; Sequence 74, Application US/10639300
; Publication No. US20050026857A1
; GENERAL INFORMATION:
; APPLICANT: Vickie L. Brown-Driver
; TITLE OF INVENTION: ANTISENSE MODULATION OF BREAST CANCER-1 EXPRESSION
; FILE REFERENCE: PTS-0017
; CURRENT APPLICATION NUMBER: US/10/639,300
; CURRENT FILING DATE: 2003-08-12
; PRIOR APPLICATION NUMBER: US/10/199,676
; PRIOR FILING DATE: 2002-07-18
; NUMBER OF SEQ ID NOS: 84
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
; OTHER INFORMATION: Primer
US-10-639-300-74

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2763 CTCTGTACCCAGGTGGAG 2782
Db 20 CTCTGTGCGCCAGGTGGAG 1

RESULT 1296
US-10-913-280-643/c
; Sequence 643, Application US/10913280
; Publication No. US20050089894A1
; GENERAL INFORMATION:
; APPLICANT: Ginns, Edward I.
; TITLE OF INVENTION: SYSTEMS AND METHODS FOR ANALYZING
; TITLE OF INVENTION: NUCLEIC ACID SEQUENCES
; FILE REFERENCE: 07917-238001
; CURRENT APPLICATION NUMBER: US/10/913,280
; CURRENT FILING DATE: 2004-08-06
; PRIOR APPLICATION NUMBER: US 60/493,238
; PRIOR FILING DATE: 2003-08-06
; PRIOR APPLICATION NUMBER: US 60/568,958
; PRIOR FILING DATE: 2004-05-07
; NUMBER OF SEQ ID NOS: 920
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 643
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-913-280-643

Query Match          0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 6.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 776 ACGGCTGTTCCCACTCTCG 795
Db 20 ACCGGCTGTTCCCACTCTCG 1

RESULT 1297
US-10-385-193-1/c
; Sequence 1, Application US/10385193
; Publication No. US20030229218A1
; GENERAL INFORMATION:
; APPLICANT: Nanda D. Sinha
; TITLE OF INVENTION: Synthons for Oligonucleotide Synthesis
; FILE REFERENCE: 2733.1001-001
; CURRENT APPLICATION NUMBER: US/10/385,193
; CURRENT FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/230,685
; PRIOR FILING DATE: 2000-09-07
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-385-193-1

Query Match          0.6%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 6.5e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGT 2747
Db 20 GTGTGTGTGTGTGTGTGT 1

RESULT 1298
US-10-385-193-2
; Sequence 2, Application US/10385193
; Publication No. US20030229218A1
; GENERAL INFORMATION:
; APPLICANT: Nanda D. Sinha
; TITLE OF INVENTION: Synthons for Oligonucleotide Synthesis
; FILE REFERENCE: 2733.1001-001
; CURRENT APPLICATION NUMBER: US/10/385,193
; CURRENT FILING DATE: 2003-03-07
; PRIOR APPLICATION NUMBER: US 60/230,685
; PRIOR FILING DATE: 2000-09-07
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-385-193-2

Query Match          0.6%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 6.5e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATGT 2747
Db 1 GTGTGTGTGTGTGTGTGT 20

RESULT 1299
US-10-786-720-20232/c
; Sequence 20232, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20232
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-20232

Query Match          0.6%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 6.5e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2770 ACCAGGCTGGAGTGCAGTG 2789
DB 20 ACTAGGCTGGAGTGCAGTG 1

RESULT 1300
US-10-751-736-5467
; Sequence 5467, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5467
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-5467

Query Match          0.6%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 6.5e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2848 AGCCTCTGAGTAGCTGGGA 2867
DB 2 AGCCTCTGAGTAGCTGTGA 21

RESULT 1301
US-10-847-918-11896/c
; Sequence 11896, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
```

```
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11896
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-847-918-11896

Query Match          0.6%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 6.5e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTGGT 2791
DB 21 CCAGGCTGGAGTGTAGTGGT 2

RESULT 1302
US-10-847-918-11898
; Sequence 11898, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11898
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-847-918-11898

Query Match          0.6%; Score 18.4; DB 1; Length 21;
Best Local Similarity 75.0%; Pred. No. 6.5e+02;
Matches 15; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTGGT 2791
DB 1 CCAGGCTGGAGUGUGUGGU 20

RESULT 1303
US-09-918-686-93
; Sequence 93, Application US/09918686
; Patent No. US2002076720A1
; GENERAL INFORMATION:
; APPLICANT: Brunkow, Mary
; APPLICANT: Proll, Sean
; APPLICANT: Paepker, Bryan
; APPLICANT: Staehling-Hampton, Karen
; TITLE OF INVENTION: METHODS FOR IDENTIFYING
; TITLE OF INVENTION: GENOMIC DELETIONS
; FILE REFERENCE: 240083.515
; CURRENT APPLICATION NUMBER: US/09/918,686
; CURRENT FILING DATE: 2001-07-30
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 93
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
```


US-09-918-686-93

Query Match 0.6%; Score 18.4; DB 1; Length 22;
Best Local Similarity 95.0%; Pred. No. 6.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGT 2792
|||||
Db 1 CAGGCTGGAGTGCAGTGGT 20

RESULT 1304

US-10-353-150-93
; Sequence 93, Application US/10353150
; Publication No. US20030157543A1
; GENERAL INFORMATION:
; APPLICANT: Brunkow, Mary E.
; APPLICANT: Prohl, Sean
; APPLICANT: Paepfer, Bryan
; APPLICANT: Staehling-Hampton, Karen
; TITLE OF INVENTION: METHODS FOR IDENTIFYING
; FILE REFERENCE: GENOMIC DELETIONS
; FILE REFERENCE: 240083.515C1
; CURRENT APPLICATION NUMBER: US/10/353,150
; CURRENT FILING DATE: 2003-01-27
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 93
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-353-150-93

Query Match 0.6%; Score 18.4; DB 1; Length 22;
Best Local Similarity 95.0%; Pred. No. 6.2e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGT 2792
|||||
Db 1 CAGGCTGGAGTGCAGTGGT 20

RESULT 1305

US-10-831-819-7/c
; Sequence 7, Application US/10831819
; Publication No. US20050112613A1
; GENERAL INFORMATION:
; APPLICANT: KRAHE, RALF
; APPLICANT: ZHANG, SHANXIANG
; APPLICANT: DE LA CHAPELLE, ALBERT
; TITLE OF INVENTION: METHODS AND REAGENTS FOR PREDICTING THE LIKELIHOOD OF
; FILE REFERENCE: DEVELOPING SHORT STATURE CAUSED BY FRAXG
; FILE REFERENCE: 18525/04053
; CURRENT APPLICATION NUMBER: US/10/831,819
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/320,146
; PRIOR FILING DATE: 2003-04-25
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-831-819-7

Query Match 0.6%; Score 18.2; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 7.5e+02;
Matches 17; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGGT 2791
|||||
Db 19 CAGGCTGGAGTGCAGTGGT 1

RESULT 1306

US-09-784-917-6/c
; Sequence 6, Application US/09784917
; Publication No. US20010008936A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; TITLE OF INVENTION: Oligonucleotides Having Chiral Phosphorus Linkages
; FILE REFERENCE: ISIS4732
; CURRENT APPLICATION NUMBER: US/09/784,917
; CURRENT FILING DATE: 2002-05-07
; PRIOR APPLICATION NUMBER: 09/208,533
; PRIOR FILING DATE: 1998-12-09
; PRIOR APPLICATION NUMBER: 08/635,009
; PRIOR FILING DATE: 1996-04-19
; PRIOR APPLICATION NUMBER: 08/058,023
; PRIOR FILING DATE: 1993-05-05
; PRIOR APPLICATION NUMBER: PCT/US91/00243
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 07/777,670
; PRIOR FILING DATE: 1991-10-15
; PRIOR APPLICATION NUMBER: 07/463,358
; PRIOR FILING DATE: 1990-01-11
; PRIOR APPLICATION NUMBER: 07/566,977
; PRIOR FILING DATE: 1990-08-13
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-784-917-6

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1307

US-10-150-696-6/c
; Sequence 6, Application US/10150696
; Publication No. US20020137921A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; TITLE OF INVENTION: OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES
; FILE REFERENCE: ISIS-5033
; CURRENT APPLICATION NUMBER: US/10/150,696
; CURRENT FILING DATE: 2002-05-17
; PRIOR APPLICATION NUMBER: US 09/784,917
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: US 09/208,533
; PRIOR FILING DATE: 1998-12-09
; PRIOR APPLICATION NUMBER: US 08/635,009
; PRIOR FILING DATE: 1996-04-19
; PRIOR APPLICATION NUMBER: US 08/058,023
; PRIOR FILING DATE: 1993-05-05
; PRIOR APPLICATION NUMBER: US 07/777,670
; PRIOR FILING DATE: 1991-10-15
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-150-696-6

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1308

US-10-192-437-7/c
; Sequence 7, Application US/10192437
; Publication No. US20030153737A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz
; and No. US20030153737A1ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Wordperfect 5.1
CURRENT APPLICATION DATA: US/10/192,437
FILING DATE: 10-Jul-2002
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/397,277A
FILING DATE: 09-MAR-1995
APPLICATION NUMBER: 07/943,516
FILING DATE: 11-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Gaumont, Rebecca R.
REGISTRATION NUMBER: 35,152
REFERENCE/DOCKET NUMBER: ISIS-1198
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-568-3100
TELEFAX: 215-568-3439

INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 7:

US-10-192-437-7

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1309

US-10-073-718-4/c
; Sequence 4, Application US/10073718
; Publication No. US20020177150A1
; GENERAL INFORMATION:

; APPLICANT: Manoharan, Muthiah
; Cook, Phillip Dan
; APPLICANT: Bennett, Clarence Frank
; TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake and Other Pr
; FILE REFERENCE: ISIS-5024
; CURRENT APPLICATION NUMBER: US/10/073,718
; CURRENT FILING DATE: 2002-05-08
; PRIOR APPLICATION NUMBER: 09/633659
; PRIOR FILING DATE: 2000-08-07
; PRIOR APPLICATION NUMBER: 6153737
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 08/211882
; PRIOR FILING DATE: 1994-04-22
; PRIOR APPLICATION NUMBER: PCT/US92/09196
; PRIOR FILING DATE: 1992-10-23
; PRIOR APPLICATION NUMBER: 07/782374
; PRIOR FILING DATE: 1991-10-24
; PRIOR APPLICATION NUMBER: 07/566977
; PRIOR FILING DATE: 1990-08-13
; PRIOR APPLICATION NUMBER: PCT/US91/000243
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 08/463358
; PRIOR FILING DATE: 1990-01-11
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. US20020177150A1el Sequence
US-10-073-718-4

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1310

US-09-753-436-21
; Sequence 21, Application US/09753436
; Patent No. US20010029293A1
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; APPLICANT: Vazeux, Rosemary
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/753,436
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/382,289
; FILING DATE:
; APPLICATION NUMBER: US 08/487,113
; FILING DATE: 07-JUN-1995
; PRIOR APPLICATION DATA:

```
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams, Joseph A., Jr.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 33282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-09-753-436-21
```

```
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 440 GCAAGAACCTTACCCCTAC 457
Db 1 GCAAGAACCTTACCCCTAC 18
```

```
RESULT 1311
US-09-808-680-2/c
; Sequence 2, Application US/09808680
; Patent No. US20020052331A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda F
; APPLICANT: Bennett, C. Frank
; APPLICANT: Anderson, Kevin P
; APPLICANT: Condon, Thomas P
; TITLE OF INVENTION: Compositions and Methods for Antisense Inhibition of
; FILE REFERENCE: ISPH-0557
; CURRENT APPLICATION NUMBER: US/09/808,680
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/194,230
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: PCT/US97/07132
; PRIOR FILING DATE: 1997-04-29
; PRIOR APPLICATION NUMBER: 08/653,653
; PRIOR FILING DATE: 1996-05-24
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; PRIOR APPLICATION NUMBER: 07/939,855
; PRIOR FILING DATE: 1993-01-21
; PRIOR APPLICATION NUMBER: 07/567,286
; PRIOR FILING DATE: 1992-11-19
; PRIOR APPLICATION NUMBER: 07/927,506
; PRIOR FILING DATE: 1992-11-19
; PRIOR APPLICATION NUMBER: 07/568,366
; PRIOR FILING DATE: 1990-08-16
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-808-680-12
```

```
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCA 35
Db 18 GAGCTCCTCTGCTACTCA 35
```

```
; PRIOR APPLICATION NUMBER: 07/927,506
; PRIOR FILING DATE: 1992-11-19
; PRIOR APPLICATION NUMBER: 07/568,366
; PRIOR FILING DATE: 1990-08-16
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-808-680-2
```

```
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 20 GCTCCTCTGCTACTCAGA 37
Db 18 GCTCCTCTGCTACTCAGA 1
```

```
RESULT 1312
US-09-808-680-12/c
; Sequence 12, Application US/09808680
; Patent No. US20020052331A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda F
; APPLICANT: Bennett, C. Frank
; APPLICANT: Anderson, Kevin P
; APPLICANT: Condon, Thomas P
; TITLE OF INVENTION: Compositions and Methods for Antisense Inhibition of
; FILE REFERENCE: ISPH-0557
; CURRENT APPLICATION NUMBER: US/09/808,680
; CURRENT FILING DATE: 2001-03-15
; PRIOR APPLICATION NUMBER: 09/194,230
; PRIOR FILING DATE: 1999-02-24
; PRIOR APPLICATION NUMBER: PCT/US97/07132
; PRIOR FILING DATE: 1997-04-29
; PRIOR APPLICATION NUMBER: 08/653,653
; PRIOR FILING DATE: 1996-05-24
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; PRIOR APPLICATION NUMBER: 07/939,855
; PRIOR FILING DATE: 1992-09-02
; PRIOR APPLICATION NUMBER: 07/567,286
; PRIOR FILING DATE: 1990-08-14
; PRIOR APPLICATION NUMBER: 07/927,506
; PRIOR FILING DATE: 1992-11-19
; PRIOR APPLICATION NUMBER: 07/568,366
; PRIOR FILING DATE: 1990-08-16
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 12
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-808-680-12
```

```
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCA 35
Db 18 GAGCTCCTCTGCTACTCA 35
```

Db 18 GAGCTCCTCTGCTACTCA 1

RESULT 1313

US-09-747-009-22/c

; Sequence 22, Application US/09747009

; Publication No. US20030050454A1

; GENERAL INFORMATION:

; APPLICANT: Cook, Phillip Dan

; APPLICANT: Sanghvi, Yogesh S.

; APPLICANT: Ross, Bruce S.

; APPLICANT: Griffey, Rich H.

; APPLICANT: Springer, Robert H.

; APPLICANT: Sprankle, Kelly G.

; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidine

; TITLE OF INVENTION: Oligomeric Compounds Therefrom

; FILE REFERENCE: ISIS-4684

; CURRENT APPLICATION NUMBER: US/09/747,009

; PRIOR FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 08/894,899

; PRIOR FILING DATE: 1998-01-07

; PRIOR APPLICATION NUMBER: PCT/US96/03174

; PRIOR FILING DATE: 1996-01-07

; PRIOR APPLICATION NUMBER: 08/475,467

; PRIOR FILING DATE: 1995-06-07

; PRIOR APPLICATION NUMBER: 08/398,901

; PRIOR FILING DATE: 1995-03-06

; NUMBER OF SEQ ID NOS: 29

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 22

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; NAME/KEY: misc_feature

; OTHER INFORMATION: No. US20030050454A1el Sequence

US-09-747-009-22

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 8.3e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

|||||

Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1314

US-09-747-009-23/c

; Sequence 23, Application US/09747009

; Publication No. US20030050454A1

; GENERAL INFORMATION:

; APPLICANT: Cook, Phillip Dan

; APPLICANT: Sanghvi, Yogesh S.

; APPLICANT: Ross, Bruce S.

; APPLICANT: Griffey, Rich H.

; APPLICANT: Springer, Robert H.

; APPLICANT: Sprankle, Kelly G.

; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidine

; TITLE OF INVENTION: Oligomeric Compounds Therefrom

; FILE REFERENCE: ISIS-4684

; CURRENT APPLICATION NUMBER: US/09/747,009

; PRIOR FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 08/894,899

; PRIOR FILING DATE: 1998-01-07

; PRIOR APPLICATION NUMBER: PCT/US96/03174

; PRIOR FILING DATE: 1996-01-07

; PRIOR APPLICATION NUMBER: 08/475,467

; PRIOR FILING DATE: 1995-06-07

; PRIOR APPLICATION NUMBER: 08/398,901

; PRIOR FILING DATE: 1995-03-06

; NUMBER OF SEQ ID NOS: 29

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 23

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; NAME/KEY: misc_feature

; OTHER INFORMATION: No. US20030050454A1el Sequence

US-09-747-009-23

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 8.3e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

|||||

Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1315

US-09-747-009-24/c

; Sequence 24, Application US/09747009

; Publication No. US20030050454A1

; GENERAL INFORMATION:

; APPLICANT: Cook, Phillip Dan

; APPLICANT: Sanghvi, Yogesh S.

; APPLICANT: Ross, Bruce S.

; APPLICANT: Griffey, Rich H.

; APPLICANT: Springer, Robert H.

; APPLICANT: Sprankle, Kelly G.

; TITLE OF INVENTION: Improved Process For The Synthesis Of 2'-O-Substituted Pyrimidin

; TITLE OF INVENTION: Oligomeric Compounds Therefrom

; FILE REFERENCE: ISIS-4684

; CURRENT APPLICATION NUMBER: US/09/747,009

; PRIOR FILING DATE: 2000-12-22

; PRIOR APPLICATION NUMBER: 08/894,899

; PRIOR FILING DATE: 1998-01-07

; PRIOR APPLICATION NUMBER: PCT/US96/03174

; PRIOR FILING DATE: 1996-01-07

; PRIOR APPLICATION NUMBER: 08/475,467

; PRIOR FILING DATE: 1995-06-07

; PRIOR APPLICATION NUMBER: 08/398,901

; PRIOR FILING DATE: 1995-03-06

; NUMBER OF SEQ ID NOS: 29

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 24

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; NAME/KEY: misc_feature

; OTHER INFORMATION: No. US20030050454A1el Sequence

US-09-747-009-24

Query Match 0.6%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 8.3e+02;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

|||||

Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1316

US-09-747-009-25/c

; Sequence 25, Application US/09747009

; Publication No. US20030050454A1

; GENERAL INFORMATION:

; APPLICANT: Cook, Phillip Dan

; APPLICANT: Sanghvi, Yogesh S.

; APPLICANT: Ross, Bruce S.

; APPLICANT: Griffey, Rich H.

; APPLICANT: Springer, Robert H.

; APPLICANT: Sprankle, Kelly G.

```

; FAJOUR FILING DATE: 1999 01 21
;
; NUMBER OF SEQ ID NOS: 86
;
; SEQ ID NO 4
;     LENGTH: 18
;     TYPE: DNA
;
; ORGANISM: Artificial sequence
;

```

;
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-4

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCACCTCAGCCTC 2853
|||||
DB 18 TCCTCCACCTCAGCCTC 1

RESULT 1320

US-09-982-262B-5/c
; Sequence 5, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-5

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCATCG 1381
|||||
DB 18 CTTTCCCACTGCCATCG 1

RESULT 1321

US-09-982-262B-81
; Sequence 81, Application US/09982262B
; Publication No. US20030077565A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0612
; CURRENT APPLICATION NUMBER: US/09/982,262B
; CURRENT FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17

;
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 86
; SEQ ID NO 81
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-982-262B-81

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
DB 1 GCCTCGCTATGGCTCCCA 18

RESULT 1322

US-09-864-636A-1698/c
; Sequence 1698, Application US/09864636A
; Publication No. US20030104378A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allwai, Hatim
; APPLICANT: Bartholomay, Christian
; APPLICANT: Chehak, LuAnne
; TITLE OF INVENTION: Detection of RNA Sequences
; FILE REFERENCE: FORS-04944
; CURRENT APPLICATION NUMBER: US/09/864,636A
; CURRENT FILING DATE: 2002-10-15
; NUMBER OF SEQ ID NOS: 2640
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1698
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-864-636A-1698

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1614 AGGGACCCCCCATGAAACC 1631
|||||
DB 18 AGGGACCCCCCATGAAACC 1

RESULT 1323

US-09-882-945A-146/c
; Sequence 146, Application US/09882945A
; Publication No. US20030143535A1
; GENERAL INFORMATION:
; APPLICANT: Lyamichiev, Victor
; APPLICANT: Allawi, Hatim
; APPLICANT: Dong, Fang
; APPLICANT: Neri, Bruce
; APPLICANT: Vener, Tatiana
; TITLE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
; FILE REFERENCE: FORS-04586
; CURRENT APPLICATION NUMBER: US/09/882,945A
; CURRENT FILING DATE: 2001-06-15
; NUMBER OF SEQ ID NOS: 334
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 146
; LENGTH: 18
; TYPE: DNA

;; PRIOR APPLICATION NUMBER: 09/633,659
;; PRIOR FILING DATE: 2000-08-07
;; PRIOR APPLICATION NUMBER: 08/211,882
;; PRIOR FILING DATE: 1994-04-22
;; PRIOR APPLICATION NUMBER: PCT/US92/09196
;; PRIOR FILING DATE: 1992-10-23
;; PRIOR APPLICATION NUMBER: 07/782,374
;; PRIOR FILING DATE: 1991-10-24
;; PRIOR APPLICATION NUMBER: PCT/US91/00243
;; PRIOR FILING DATE: 1991-01-11
;; PRIOR APPLICATION NUMBER: 07/463,358
;; PRIOR FILING DATE: 1990-01-11
;; PRIOR APPLICATION NUMBER: 07/566,977
;; PRIOR FILING DATE: 1990-08-13
;; NUMBER OF SEQ ID NOS: 18
;; SOFTWARE: PatentIn version 3.1
;; SEQ ID NO 4
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; FEATURE:
;; NAME/KEY: misc.feature
;; LOCATION: (1)..(17)
;; OTHER INFORMATION: phosphorothioate inter-nucleotide backbone linkage
US-10-284-742-4

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1328
US-10-084-839-1698/c
; Sequence 1698, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichiev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tssetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1698

;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic
US-10-084-839-1698

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1614 AGGACCCCCCATGAACC 1631
DB 18 AGGACCCCCCATGAACC 1

RESULT 1329
US-10-084-839-3880/c
; Sequence 3880, Application US/10084839
; Publication No. US20030186238A1
; GENERAL INFORMATION:
; APPLICANT: Third Wave Technologies
; APPLICANT: Allawi, Hatim
; APPLICANT: Argue, Brad T.
; APPLICANT: Bartholomay, Christian T.
; APPLICANT: Chehak, LuAnne
; APPLICANT: Curtis, Michelle L.
; APPLICANT: Eis, Peggy S.
; APPLICANT: Hall, Jeff G.
; APPLICANT: Ip, Hon S.
; APPLICANT: Ji, Lin
; APPLICANT: Kaiser, Michael
; APPLICANT: Kwiatkowski, Jr., Robert W.
; APPLICANT: Lukowiak, Andrew A.
; APPLICANT: Lyamichiev, Victor
; APPLICANT: Lymaicheva, Natalie E.
; APPLICANT: Ma, WuPo
; APPLICANT: Neri, Bruce P.
; APPLICANT: Olson, Sarah M.
; APPLICANT: Olson-Munoz, Marilyn C.
; APPLICANT: Schaefer, James J.
; APPLICANT: Skrzypczynski, Zbigniew
; APPLICANT: Takova, Tssetska Y.
; APPLICANT: Thompson, Lisa C.
; APPLICANT: Vedvik, Kevin L.
; TITLE OF INVENTION: RNA Detection Assays
; FILE REFERENCE: FORS-06666
; CURRENT APPLICATION NUMBER: US/10/084,839
; CURRENT FILING DATE: 2002-02-26
; NUMBER OF SEQ ID NOS: 4004
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3880
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-084-839-3880

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1614 AGGACCCCCCATGAACC 1631
DB 18 AGGACCCCCCATGAACC 1

RESULT 1330
US-10-080-979-4/c
; Sequence 4, Application US/10080979
; Publication No. US20030191075A1
; GENERAL INFORMATION:


```
; APPLICANT: Cook, Philip Dan
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bennett, Frank C.
; TITLE OF INVENTION: Oligonucleotide Conjugates For Hepatic Delivery
; FILE REFERENCE: Isis-5028
; CURRENT APPLICATION NUMBER: US/10/080,979
; CURRENT FILING DATE: 2002-02-22
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc.feature
; LOCATION: (1)..(18)
; OTHER INFORMATION: phosphorothioate inter-nucleotide linkage
; NAME/KEY: misc.feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: nucleotide functionalized to incorporate a pentyl-N-phthalimido
; OTHER INFORMATION: unctonality
US-10-080-979-4
```

```
Query Match          0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 50 GCCTCGCTATGGCTCCCA 67
   |||||||
Db 18 GCCTCGCTATGGCTCCCA 1
```

RESULT 1331

```
US-10-080-979-5/c
; Sequence 5, Application US/10080979
; Publication No. US20030191075A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bennett, Frank C.
; TITLE OF INVENTION: Oligonucleotide Conjugates For Hepatic Delivery
; FILE REFERENCE: Isis-5028
; CURRENT APPLICATION NUMBER: US/10/080,979
; CURRENT FILING DATE: 2002-02-22
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc.feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-modified phosphoramidite
; NAME/KEY: misc.feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 2'-O-modified phosphoramidite
US-10-080-979-5
```

```
Query Match          0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 50 GCCTCGCTATGGCTCCCA 67
   |||||||
Db 18 GCCTCGCTATGGCTCCCA 1
```

RESULT 1332

```
US-10-080-979-15/c
; Sequence 15, Application US/10080979
```

```
; Publication No. US20030191075A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bennett, Frank C.
; TITLE OF INVENTION: Oligonucleotide Conjugates For Hepatic Delivery
; FILE REFERENCE: Isis-5028
; CURRENT APPLICATION NUMBER: US/10/080,979
; CURRENT FILING DATE: 2002-02-22
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc.feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 2'-O-modified phosphoramidite
; NAME/KEY: misc.feature
; LOCATION: (18)..(18)
; OTHER INFORMATION: non-nucleoside 6-carbon amino linker
US-10-080-979-15
```

```
Query Match          0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 50 GCCTCGCTATGGCTCCCA 67
   |||||||
Db 18 GCCTCGCTATGGCTCCCA 1
```

RESULT 1333

```
US-10-080-979-16/c
; Sequence 16, Application US/10080979
; Publication No. US20030191075A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Philip Dan
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bennett, Frank C.
; TITLE OF INVENTION: Oligonucleotide Conjugates For Hepatic Delivery
; FILE REFERENCE: Isis-5028
; CURRENT APPLICATION NUMBER: US/10/080,979
; CURRENT FILING DATE: 2002-02-22
; NUMBER OF SEQ ID NOS: 78
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc.feature
; LOCATION: (10)..(10)
; OTHER INFORMATION: 2'-O-modified phosphoramidite
US-10-080-979-16
```

```
Query Match          0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 50 GCCTCGCTATGGCTCCCA 67
   |||||||
Db 18 GCCTCGCTATGGCTCCCA 1
```

RESULT 1334

```
US-10-080-979-23/c
; Sequence 23, Application US/10080979
; Publication No. US20030191075A1
; GENERAL INFORMATION:
```

APPLICANT: Cook, Philip Dan
APPLICANT: Manoharan, Muthiah
APPLICANT: Bennett, Frank C.
TITLE OF INVENTION: Oligonucleotide Conjugates For Hepatic Delivery
FILE REFERENCE: Isis-5028
CURRENT APPLICATION NUMBER: US/10/080,979
CURRENT FILING DATE: 2002-02-22
NUMBER OF SEQ ID NOS: 78
SOFTWARE: PatentIn version 3.1
SEQ ID NO 23
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide
NAME/KEY: misc feature
LOCATION: (1)..(1)
OTHER INFORMATION: U2' modified with fluorescein
US-10-080-979-23

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1335
US-10-080-979-66/c
Sequence 66, Application US/10080979
Publication No. US20030191075A1
GENERAL INFORMATION:
APPLICANT: Cook, Philip Dan
APPLICANT: Manoharan, Muthiah
APPLICANT: Bennett, Frank C.
TITLE OF INVENTION: Oligonucleotide Conjugates For Hepatic Delivery
FILE REFERENCE: Isis-5028
CURRENT APPLICATION NUMBER: US/10/080,979
CURRENT FILING DATE: 2002-02-22
NUMBER OF SEQ ID NOS: 78
SOFTWARE: PatentIn version 3.1
SEQ ID NO 66
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide
NAME/KEY: misc feature
LOCATION: (1)..(18)
OTHER INFORMATION: phosphorothioate inter-nucleotide linkage
NAME/KEY: misc feature
LOCATION: (5)..(5)
OTHER INFORMATION: nucleotide functionalized to incorporate a pentyl-N-phthalimido
OTHER INFORMATION: unctonality
NAME/KEY: misc feature
LOCATION: (9)..(9)
OTHER INFORMATION: nucleotide functionalized to incorporate a pentyl-N-phthalimido
OTHER INFORMATION: unctonality
NAME/KEY: misc feature
LOCATION: (11)..(11)
OTHER INFORMATION: nucleotide functionalized to incorporate a pentyl-N-phthalimido
NAME/KEY: misc feature
LOCATION: (15)..(15)
OTHER INFORMATION: nucleotide functionalized to incorporate a pentyl-N-phthalimido
OTHER INFORMATION: unctonality
US-10-080-979-66

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
DB 18 GCCTCGCTATGGCTCCCA 1
RESULT 1336
US-10-080-979-68/c
Sequence 68, Application US/10080979
Publication No. US20030191075A1
GENERAL INFORMATION:
APPLICANT: Cook, Philip Dan
APPLICANT: Manoharan, Muthiah
APPLICANT: Bennett, Frank C.
TITLE OF INVENTION: Oligonucleotide Conjugates For Hepatic Delivery
FILE REFERENCE: Isis-5028
CURRENT APPLICATION NUMBER: US/10/080,979
CURRENT FILING DATE: 2002-02-22
NUMBER OF SEQ ID NOS: 78
SOFTWARE: PatentIn version 3.1
SEQ ID NO 68
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide
NAME/KEY: misc feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-O-modified phosphoramidite
US-10-080-979-68

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
|||||
DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1337
US-10-080-979-69/c
Sequence 69, Application US/10080979
Publication No. US20030191075A1
GENERAL INFORMATION:
APPLICANT: Cook, Philip Dan
APPLICANT: Manoharan, Muthiah
APPLICANT: Bennett, Frank C.
TITLE OF INVENTION: Oligonucleotide Conjugates For Hepatic Delivery
FILE REFERENCE: Isis-5028
CURRENT APPLICATION NUMBER: US/10/080,979
CURRENT FILING DATE: 2002-02-22
NUMBER OF SEQ ID NOS: 78
SOFTWARE: PatentIn version 3.1
SEQ ID NO 69
LENGTH: 18
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Oligonucleotide
NAME/KEY: misc feature
LOCATION: (1)..(1)
OTHER INFORMATION: 2'-O-modified phosphoramidite
NAME/KEY: misc feature
LOCATION: (18)..(18)
OTHER INFORMATION: non-nucleoside 6-carbon amino linker
NAME/KEY: misc feature
LOCATION: (10)..(10)
OTHER INFORMATION: 2'-O-modified phosphoramidite
US-10-080-979-69

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCGTCGCTATGGCTCCCA 67
Db 18 GCGTCGCTATGGCTCCCA 1

RESULT 1338
US-10-163-942-21
; Sequence 21, Application US/10163942
; Publication No. US20030199423A1
; GENERAL INFORMATION:
; APPLICANT: Gallatin, W. Michael
; Vazeux, Rosemay
; TITLE OF INVENTION: ICAM-Related Materials and Methods
; NUMBER OF SEQUENCES: 120
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/163,942
; FILING DATE: 05-Jun-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/753,436
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 09/382,289
; FILING DATE: <Unknown>
; APPLICATION NUMBER: US 08/487,113
; FILING DATE: 07-JUN-1995
; APPLICATION NUMBER: US 08/286,754
; FILING DATE: 05-AUG-1994
; APPLICATION NUMBER: US 08/102,852
; FILING DATE: 05-AUG-1993
; APPLICATION NUMBER: US 08/009,266
; FILING DATE: 22-JAN-1993
; APPLICATION NUMBER: US 07/894,061
; FILING DATE: 05-JUN-1992
; APPLICATION NUMBER: US 07/889,724
; FILING DATE: 26-MAY-1992
; APPLICATION NUMBER: US 07/827,689
; FILING DATE: 27-JAN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Williams, Joseph A., Jr.
; REGISTRATION NUMBER: 38,659
; REFERENCE/DOCKET NUMBER: 33282
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (312) 474-6300
; TELEFAX: (312) 474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-10-163-942-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCTAC 457

Db 1 GCAAGAACCTTACCCTAC 18
RESULT 1339
US-10-454-663-1/c
; Sequence 1, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-1

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCGTCGCTATGGCTCCCA 67
Db 18 GCGTCGCTATGGCTCCCA 1

RESULT 1340
US-10-454-663-4/c
; Sequence 4, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Christopher K. Mirabelli
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-4

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2836 TCCTCCCACTCAGCCTC 2853
| | | | | | | | | | | | | | | | | | | | | |
DB 18 TCCTCCCACTCAGCCTC 1

RESULT 1341
US-10-454-663-5/c
; Sequence 5, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18
; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-5

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1364 CTTTCCCACTGCCATCG 1381
| | | | | | | | | | | | | | | | | | | | | |
DB 18 CTTTCCCACTGCCATCG 1

RESULT 1342
US-10-454-663-81
; Sequence 81, Application US/10454663
; Publication No. US20040033977A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: OLIGONUCLEOTIDE MODULATION OF CELL ADHESION
; FILE REFERENCE: ISPH-0744
; CURRENT APPLICATION NUMBER: US/10/454,663
; CURRENT FILING DATE: 2003-06-04
; PRIOR APPLICATION NUMBER: 09/982,262
; PRIOR FILING DATE: 2001-10-18

; PRIOR APPLICATION NUMBER: 09/659,288
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 09/128,496
; PRIOR FILING DATE: 1998-08-03
; PRIOR APPLICATION NUMBER: 08/440,740
; PRIOR FILING DATE: 1995-05-12
; PRIOR APPLICATION NUMBER: 08/063,167
; PRIOR FILING DATE: 1993-05-17
; PRIOR APPLICATION NUMBER: 07/969,151
; PRIOR FILING DATE: 1993-02-10
; PRIOR APPLICATION NUMBER: 08/007,997
; PRIOR FILING DATE: 1993-01-21
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 81
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-454-663-81

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02; Indels 0; Gaps 0;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
| | | | | | | | | | | | | | | | | | | | | |
DB 1 GCCTCGCTATGGCTCCCA 18

RESULT 1343
US-10-780-439-4/c
; Sequence 4, Application US/10780439
; Publication No. US20040142899A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D.
; Manoharan, Muthiah
; Bennett, C. Frank
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
; ENHANCED BIOTABILITY AND ALTERED BIODISTRIBUTION OF
; OLIGONUCLEOTIDES IN MAMMALS

NUMBER OF SEQUENCES: 63
CORRESPONDENCE ADDRESS:
ADDRESSEE: Cozen O'Connor
STREET: 1900 Market Street
CITY: Philadelphia
STATE: PA
COUNTRY: U.S.A.
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/780,439
FILING DATE: 17-Feb-2004
CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Nguyen, Quan L.
REGISTRATION NUMBER: 46,957
REFERENCE/DOCKET NUMBER: ISIC0006-102
TELECOMMUNICATION INFORMATION:
TELEPHONE: 215-665-2000
TELEFAX: 215-665-2013
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 4:

US-10-780-439-4

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 8.3e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 |||||
 DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1344
 US-10-780-439-5/c
 ; Sequence 5, Application US/10780439
 ; Publication No. US20040142899A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Cook, Phillip D.
 ; Manoharan, Muthiah
 ; Bennett, C. Frank

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
 ENHANCED BIOTABILITY AND ALTERED BIODISTRIBUTION OF
 OLIGONUCLEOTIDES IN MAMMALS

NUMBER OF SEQUENCES: 63
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Cozen O'Connor
 STREET: 1900 Market Street
 CITY: Philadelphia
 STATE: PA
 COUNTRY: U.S.A.
 ZIP: 19103

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/10780,439
 FILING DATE: 17-Feb-2004
 CLASSIFICATION: <Unknown>
 ATTORNEY/AGENT INFORMATION:
 NAME: Nguyen, Quan L.
 REGISTRATION NUMBER: 46,957
 REFERENCE/DOCKET NUMBER: ISIC0006-102
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 215-665-2000
 TELEFAX: 215-665-2013

INFORMATION FOR SEQ ID NO: 15:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 18 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 SEQUENCE DESCRIPTION: SEQ ID NO: 15:
 US-10-780-439-15

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 8.3e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 |||||
 DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1346
 US-10-780-439-16/c
 ; Sequence 16, Application US/10780439
 ; Publication No. US20040142899A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Cook, Phillip D.
 ; Manoharan, Muthiah
 ; Bennett, C. Frank

TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
 ENHANCED BIOTABILITY AND ALTERED BIODISTRIBUTION OF
 OLIGONUCLEOTIDES IN MAMMALS

NUMBER OF SEQUENCES: 63
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Cozen O'Connor
 STREET: 1900 Market Street
 CITY: Philadelphia
 STATE: PA
 COUNTRY: U.S.A.
 ZIP: 19103

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/10780,439
 FILING DATE: 17-Feb-2004
 CLASSIFICATION: <Unknown>
 ATTORNEY/AGENT INFORMATION:
 NAME: Nguyen, Quan L.
 REGISTRATION NUMBER: 46,957
 REFERENCE/DOCKET NUMBER: ISIC0006-102
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: 215-665-2000
 TELEFAX: 215-665-2013

INFORMATION FOR SEQ ID NO: 5:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 18 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 SEQUENCE DESCRIPTION: SEQ ID NO: 5:
 US-10-780-439-5

Query Match 0.6%; Score 18; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 8.3e+02;
 Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
 |||||
 DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1345
 US-10-780-439-15/c
 ; Sequence 15, Application US/10780439
 ; Publication No. US20040142899A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Cook, Phillip D.
 ; Manoharan, Muthiah
 ; Bennett, C. Frank

CLASSIFICATION: <Unknown>
ATTORNEY/AGENT INFORMATION:
NAME: Nguyen, Quan L.
REGISTRATION NUMBER: 46,957
REFERENCE/DOCKET NUMBER: ISIC0006-102
TELEPHONE: 215-665-2000
TELEFAX: 215-665-2013
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 16:

US-10-780-439-16
Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
| | | | | | | | | | | | | | | | | |
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1347
US-10-807-114-146/c
Sequence 146, Application US/10807114
Publication No. US20040235024A1
GENERAL INFORMATION:
APPLICANT: Lyamichev, Victor
APPLICANT: Allawi, Hatim
APPLICANT: Dong, Fang
APPLICANT: Vener, Tatiana
FILE OF INVENTION: Nucleic Acid Accessible Hybridization Sites
CURRENT APPLICATION NUMBER: US/10/807,114
CURRENT FILING DATE: 2004-03-23
PRIOR APPLICATION NUMBER: US/09/882,945
PRIOR FILING DATE: 2001-06-15
NUMBER OF SEQ ID NOS: 334
SOFTWARE: PatentIn version 3.0
SEQ ID NO 146
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic
US-10-807-114-146

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
| | | | | | | | | | | | | | | | | |
Db. 18 GCCTCGCTATGGCTCCCA 1

RESULT 1348
US-10-745-115-21
Sequence 21, Application US/10745115
Publication No. US20040248211A1
GENERAL INFORMATION:
APPLICANT: Gallatin, W. Michael
TITLE OF INVENTION: ICAM-Related Materials and Methods
NUMBER OF SEQUENCES: 120
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun

STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-8402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/745,115
FILING DATE: 23-Dec-2003
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/10/163,942
FILING DATE: 05-Jun-2002
APPLICATION NUMBER: US/09/753,436
FILING DATE: <Unknown>
APPLICATION NUMBER: 09/382,289
FILING DATE: <Unknown>
APPLICATION NUMBER: US 08/487,113
FILING DATE: 07-JUN-1995
APPLICATION NUMBER: US 08/286,754
FILING DATE: 05-AUG-1994
APPLICATION NUMBER: US 08/102,852
FILING DATE: 05-AUG-1993
APPLICATION NUMBER: US 08/009,266
FILING DATE: 22-JAN-1993
APPLICATION NUMBER: US 07/894,061
FILING DATE: 05-JUN-1992
APPLICATION NUMBER: US 07/889,724
FILING DATE: 26-MAY-1992
APPLICATION NUMBER: US 07/827,689
FILING DATE: 27-JAN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Williams, Joseph A., Jr.
REGISTRATION NUMBER: 38,659
REFERENCE/DOCKET NUMBER: 33282
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312) 474-6300
TELEFAX: (312) 474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 21:
US-10-745-115-21

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 440 GCAAGAACCTTACCCCTAC 457
| | | | | | | | | | | | | | | | | |
Db 1 GCAAGAACCTTACCCCTAC 18

RESULT 1349
US-10-872-984-7
Sequence 7, Application US/10872984
Publication No. US20040265888A1
GENERAL INFORMATION:
APPLICANT: Kaufman, Joseph C.
APPLICANT: Roth, Matthew E.
APPLICANT: Lizardi, Paul M.
APPLICANT: Feng, Li
APPLICANT: Latimer, Darin R.
TITLE OF INVENTION: Binary Encoded Sequence Tags

```
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/10/872,984
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US/09/994,311
; PRIOR FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-7
```

```
Query Match          0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2903 TTTTCTTTTCTTTTCTCA 2920
      |||||
Db 1 TTTTCTTTTCTTTTCTCA 18
```

```
RESULT 1350
US-10-755-166-4/c
; Sequence 4, Application US/10/755166
; Publication No. US20050043219A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Bennett, Clarence Frank
; TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake and Other Pro
; FILE REFERENCE: ISIS-5024
; CURRENT APPLICATION NUMBER: US/10/755,166
; CURRENT FILING DATE: 2004-01-09
; PRIOR APPLICATION NUMBER: US/10/073,718
; PRIOR FILING DATE: 2002-02-11
; PRIOR APPLICATION NUMBER: 09/633659
; PRIOR FILING DATE: 2000-08-07
; PRIOR APPLICATION NUMBER: 6153737
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 08/211882
; PRIOR FILING DATE: 1994-04-22
; PRIOR APPLICATION NUMBER: PCT/US92/09196
; PRIOR FILING DATE: 1992-10-23
; PRIOR APPLICATION NUMBER: 07/782374
; PRIOR FILING DATE: 1991-10-24
; PRIOR APPLICATION NUMBER: 07/566977
; PRIOR FILING DATE: 1990-08-13
; PRIOR APPLICATION NUMBER: PCT/US91/000243
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 08/463358
; PRIOR FILING DATE: 1990-01-11
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Novel Sequence
US-10-755-166-4
```

```
Query Match          0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 50 GCCTCGCTATGGCTCCCA 67
      |||||
Db 18 GCCTCGCTATGGCTCCCA 1
```

```
RESULT 1351
US-10-699-240A-22/c
; Sequence 22, Application US/10699240A
; Publication No. US20050059815A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
; APPLICANT: Springer, Robert H.
; APPLICANT: Sprankle, Kelly G.
; TITLE OF INVENTION: PROCESSES FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS THEREFROM
; FILE REFERENCE: ISIS-5320
; CURRENT APPLICATION NUMBER: US/10/699,240A
; CURRENT FILING DATE: 2003-10-31
; PRIOR APPLICATION NUMBER: US 09/747,009
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: US 08/894,899
; PRIOR FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: PCT/US96/03174
; PRIOR FILING DATE: 1996-03-06
; PRIOR APPLICATION NUMBER: US 08/475,467
; PRIOR FILING DATE: 1995-06-07
; PRIOR APPLICATION NUMBER: US 08/398,901
; PRIOR FILING DATE: 1995-03-06
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 22
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc feature
; LOCATION: (1)..(17)
; OTHER INFORMATION: phosphorothioate linkage, 2'-deoxy
US-10-699-240A-22

Query Match          0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
      |||||
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1352
US-10-699-240A-23/c
; Sequence 23, Application US/10699240A
; Publication No. US20050059815A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Sanghvi, Yogesh S.
; APPLICANT: Ross, Bruce S.
; APPLICANT: Griffey, Rich H.
; APPLICANT: Springer, Robert H.
; APPLICANT: Sprankle, Kelly G.
; TITLE OF INVENTION: PROCESSES FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS THEREFROM
; FILE REFERENCE: ISIS-5320
; CURRENT APPLICATION NUMBER: US/10/699,240A
; CURRENT FILING DATE: 2003-10-31
; PRIOR APPLICATION NUMBER: US 09/747,009
; PRIOR FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: US 08/894,899
; PRIOR FILING DATE: 1998-01-07
; PRIOR APPLICATION NUMBER: PCT/US96/03174
; PRIOR FILING DATE: 1996-03-06
```

;; PRIOR APPLICATION NUMBER: US 08/475,467
;; PRIOR FILING DATE: 1995-06-07
;; PRIOR APPLICATION NUMBER: US 08/398,901
;; PRIOR FILING DATE: 1995-03-06
;; NUMBER OF SEQ ID NOS: 31
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 23
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial
;; FEATURE:
;; OTHER INFORMATION: Synthetic Construct
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (1)..(17)
;; OTHER INFORMATION: phosphorothioate linkage, methyl
US-10-699-240A-23

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1353

US-10-699-240A-24/C
;; Sequence 24, Application US/10699240A
;; Publication No. US20050059815A1
;; GENERAL INFORMATION:
;; APPLICANT: Cook, Phillip Dan
;; APPLICANT: Sanghvi, Yogesh S.
;; APPLICANT: Ross, Bruce S.
;; APPLICANT: Griffey, Robert H.
;; APPLICANT: Sprankle, Kelly G.
;; TITLE OF INVENTION: PROCESSES FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND
;; FILE REFERENCE: ISIS-5320
;; CURRENT APPLICATION NUMBER: US/10/699,240A
;; CURRENT FILING DATE: 2003-10-31
;; PRIOR APPLICATION NUMBER: US 09/747,009
;; PRIOR FILING DATE: 2000-12-22
;; PRIOR APPLICATION NUMBER: US 08/894,899
;; PRIOR FILING DATE: 1998-01-07
;; PRIOR APPLICATION NUMBER: PCT/US96/03174
;; PRIOR FILING DATE: 1996-03-06
;; PRIOR APPLICATION NUMBER: US 08/475,467
;; PRIOR FILING DATE: 1995-06-07
;; PRIOR APPLICATION NUMBER: US 08/398,901
;; PRIOR FILING DATE: 1995-03-06
;; NUMBER OF SEQ ID NOS: 31
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 24
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial
;; FEATURE:
;; OTHER INFORMATION: Synthetic Construct
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (1)..(17)
;; OTHER INFORMATION: phosphorothioate linkage, propyl
US-10-699-240A-24

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

|||||

DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1354

US-10-699-240A-25/C
;; Sequence 25, Application US/10699240A
;; Publication No. US20050059815A1
;; GENERAL INFORMATION:
;; APPLICANT: Cook, Phillip Dan
;; APPLICANT: Sanghvi, Yogesh S.
;; APPLICANT: Ross, Bruce S.
;; APPLICANT: Griffey, Robert H.
;; APPLICANT: Sprankle, Kelly G.
;; TITLE OF INVENTION: PROCESSES FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND
;; FILE REFERENCE: ISIS-5320
;; CURRENT APPLICATION NUMBER: US/10/699,240A
;; CURRENT FILING DATE: 2003-10-31
;; PRIOR APPLICATION NUMBER: US 09/747,009
;; PRIOR FILING DATE: 2000-12-22
;; PRIOR APPLICATION NUMBER: US 08/894,899
;; PRIOR FILING DATE: 1998-01-07
;; PRIOR APPLICATION NUMBER: PCT/US96/03174
;; PRIOR FILING DATE: 1996-03-06
;; PRIOR APPLICATION NUMBER: US 08/475,467
;; PRIOR FILING DATE: 1995-06-07
;; PRIOR APPLICATION NUMBER: US 08/398,901
;; PRIOR FILING DATE: 1995-03-06
;; NUMBER OF SEQ ID NOS: 31
;; SOFTWARE: PatentIn version 3.3
;; SEQ ID NO 25
;; LENGTH: 18
;; TYPE: DNA
;; ORGANISM: Artificial
;; FEATURE:
;; OTHER INFORMATION: Synthetic Construct
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: (1)..(17)
;; OTHER INFORMATION: phosphorothioate linkage, pentyl
US-10-699-240A-25

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67

DB 18 GCCTCGCTATGGCTCCCA 1

RESULT 1355

US-10-699-240A-26/C
;; Sequence 26, Application US/10699240A
;; Publication No. US20050059815A1
;; GENERAL INFORMATION:
;; APPLICANT: Cook, Phillip Dan
;; APPLICANT: Sanghvi, Yogesh S.
;; APPLICANT: Ross, Bruce S.
;; APPLICANT: Griffey, Robert H.
;; APPLICANT: Sprankle, Kelly G.
;; TITLE OF INVENTION: PROCESSES FOR THE SYNTHESIS OF 2'-O-SUBSTITUTED PYRIMIDINES AND
;; FILE REFERENCE: ISIS-5320
;; CURRENT APPLICATION NUMBER: US/10/699,240A
;; CURRENT FILING DATE: 2003-10-31
;; PRIOR APPLICATION NUMBER: US 09/747,009
;; PRIOR FILING DATE: 2000-12-22
;; PRIOR APPLICATION NUMBER: US 08/894,899
;; PRIOR FILING DATE: 1998-01-07
;; PRIOR APPLICATION NUMBER: PCT/US96/03174


```
; PRIOR FILING DATE: 1996-03-06
; PRIOR APPLICATION NUMBER: US 08/475,467
; PRIOR FILING DATE: 1999-06-07
; PRIOR APPLICATION NUMBER: US 08/398,901
; PRIOR FILING DATE: 1995-03-06
; NUMBER OF SEQ ID NOS: 31
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 26
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; NAME/KEY: misc_feature
; LOCATION: (1)..(17)
; OTHER INFORMATION: phosphorothioate linkage, RNA
US-10-699-240A-26

Query Match          0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1

RESULT 1356
US-10-730-771-259
; Sequence 259, Application US/10730771
; Publication No. US20050074787A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Hirschhorn, Joel N.
; APPLICANT: Huang, Xiaohua
; APPLICANT: Kaplan, Paul
; APPLICANT: Lander, Eric S.
; APPLICANT: Lockhart, David J.
; APPLICANT: Ryder, Thomas
; APPLICANT: Sklar, Pamela
; TITLE OF INVENTION: UNIVERSAL ARRAYS
; FILE REFERENCE: 2825.1016-007
; CURRENT APPLICATION NUMBER: US/10/730,771
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: US 60/126,473
; PRIOR FILING DATE: 1999-03-26
; PRIOR APPLICATION NUMBER: US 60/140,359
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/536,841
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 590
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 259
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Template sequence
US-10-730-771-259

Query Match          0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 759 CGTGGTCTGCTCCCTGGA 776
Db 1 CGTGGTCTGCTCCCTGGA 18

RESULT 1357
US-10-730-771-261
; Sequence 261, Application US/10730771
```

```
; Publication No. US20050074787A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Hirschhorn, Joel N.
; APPLICANT: Huang, Xiaohua
; APPLICANT: Kaplan, Paul
; APPLICANT: Lander, Eric S.
; APPLICANT: Lockhart, David J.
; APPLICANT: Ryder, Thomas
; APPLICANT: Sklar, Pamela
; TITLE OF INVENTION: UNIVERSAL ARRAYS
; FILE REFERENCE: 2825.1016-007
; CURRENT APPLICATION NUMBER: US/10/730,771
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: US 60/126,473
; PRIOR FILING DATE: 1999-03-26
; PRIOR APPLICATION NUMBER: US 60/140,359
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/536,841
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 590
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 261
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Template sequence
US-10-730-771-261

Query Match          0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 204 CACCTCCTGTGACCAGCC 221
Db 1 CACCTCCTGTGACCAGCC 18

RESULT 1358
US-10-730-771-403/c
; Sequence 403, Application US/10730771
; Publication No. US20050074787A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Hirschhorn, Joel N.
; APPLICANT: Huang, Xiaohua
; APPLICANT: Kaplan, Paul
; APPLICANT: Lander, Eric S.
; APPLICANT: Lockhart, David J.
; APPLICANT: Ryder, Thomas
; APPLICANT: Sklar, Pamela
; TITLE OF INVENTION: UNIVERSAL ARRAYS
; FILE REFERENCE: 2825.1016-007
; CURRENT APPLICATION NUMBER: US/10/730,771
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: US 60/126,473
; PRIOR FILING DATE: 1999-03-26
; PRIOR APPLICATION NUMBER: US 60/140,359
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/536,841
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 590
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 403
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Template sequence
US-10-730-771-403

Query Match          0.6%; Score 18; DB 1; Length 18;
```

Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 782 TGTTCCTGCTCGGAGG 799
Db 18 TGTTCCTGCTCGGAGG 1

RESULT 1359

US-10-730-771-406/c
; Sequence 406, Application US/10730771
; Publication No. US20050074787A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Hirschhorn, Joel N.
; APPLICANT: Huang, Xiaohua
; APPLICANT: Kaplan, Paul
; APPLICANT: Langer, Eric S.
; APPLICANT: Lockhart, David J.
; APPLICANT: Ryder, Thomas
; APPLICANT: Sklar, Pamela
; TITLE OF INVENTION: UNIVERSAL ARRAYS
; FILE REFERENCE: 2825.1016-007
; CURRENT APPLICATION NUMBER: US/10/730,771
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: US 60/126,473
; PRIOR FILING DATE: 1999-03-26
; PRIOR APPLICATION NUMBER: US 60/140,359
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/536,841
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 590
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 406
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Template sequence
US-10-730-771-406

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1464 GGTGACCGGATGTGCT 1481
Db 18 GGTGACCGGATGTGCT 1

RESULT 1360

US-10-913-280-642/c
; Sequence 642, Application US/10913280
; Publication No. US20050089894A1
; GENERAL INFORMATION:
; APPLICANT: Ginns, Edward I.
; APPLICANT: Galdzicka, Marzena
; TITLE OF INVENTION: SYSTEMS AND METHODS FOR ANALYZING
; FILE REFERENCE: 07917-238001
; CURRENT APPLICATION NUMBER: US/10/913,280
; CURRENT FILING DATE: 2004-08-06
; PRIOR APPLICATION NUMBER: US 60/493,238
; PRIOR FILING DATE: 2003-08-06
; PRIOR APPLICATION NUMBER: US 60/568,958
; PRIOR FILING DATE: 2004-05-07
; NUMBER OF SEQ ID NOS: 920
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 642
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

OTHER INFORMATION: Primer
US-10-913-280-642

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 778 GGGCTGTTCCAGTCTCG 795
Db 18 GGGCTGTTCCAGTCTCG 1

RESULT 1361

US-10-700-971C-23/c
; Sequence 23, Application US/10700971C
; Publication No. US20050119470A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Baker, Brenda
; APPLICANT: Eldrup, Ann
; APPLICANT: Bhat, Balkrishen
; APPLICANT: Griffey, Richard H.
; APPLICANT: Swayze, Eric E.
; APPLICANT: Crooke, Stanley T.
; TITLE OF INVENTION: Conjugated Oligomeric Compounds and Their Use in Gene
; FILE REFERENCE: ISIC-0009-101
; CURRENT APPLICATION NUMBER: US/10/700,971C
; CURRENT FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: US 10/616,241
; PRIOR FILING DATE: 2003-07-09
; PRIOR APPLICATION NUMBER: US 60/423,760
; PRIOR FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 10/078,949
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/479,783
; PRIOR FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 08/870,608
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: US 08/559,440
; PRIOR FILING DATE: 1996-06-06
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense oligonucleotide
US-10-700-971C-23

Query Match 0.6%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 8.3e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCGCTGCTATGGCTCCCA 67
Db 18 GCGCTGCTATGGCTCCCA 1

RESULT 1362

US-09-370-541-21/c
; Sequence 21, Application US/09370541
; Publication No. US20030088079A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Prakash, Thazha P
; APPLICANT: Kawasaki, Andrew M
; TITLE OF INVENTION: Aminoxy-Modified Nucleosidic Compounds And Oligomeric
; FILE REFERENCE: ISIS3993
; CURRENT APPLICATION NUMBER: US/09/370,541

```
; CURRENT FILING DATE: 1999-08-09
; EARLIER APPLICATION NUMBER: 09/130,973
; EARLIER FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 09/016,520
; EARLIER FILING DATE: 1998-01-30
; EARLIER APPLICATION NUMBER: 60/037,143
; EARLIER FILING DATE: 1997-02-14
; EARLIER APPLICATION NUMBER: 09/344,260
; EARLIER FILING DATE: 1999-06-25
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 21
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: antisense
; OTHER INFORMATION: sequence
US-09-370-541-21
```

```
Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 18 GAGCTCCTCTGCTACTCA 35
Db 19 GAGCTCCTCTGCTACTCA 2
```

```
RESULT 1363
US-10-192-437-2/c
; Sequence 2, Application US/10192437
; Publication No. US20030153737A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF
; MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Woodcock Washburn Kurtz Mackiewicz
; and No. US20030153737A1ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/192,437
; FILING DATE: 10-Jul-2002
; CLASSIFICATION: <unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/397,277A
; FILING DATE: 09-MAR-1995
; APPLICATION NUMBER: 07/943,516
; FILING DATE: 11-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Gaumond, Rebecca R.
; REGISTRATION NUMBER: 35,152
; REFERENCE/DOCKET NUMBER: ISIS-1198
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
```

```
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 19
; OTHER INFORMATION: /note= "abasic, aldehydic
; species"
; SEQUENCE DESCRIPTION: SEQ ID NO: 2:
US-10-192-437-2
```

```
Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTATGGCTCCCA 1
```

```
RESULT 1364
US-09-881-012-160/c
; Sequence 160, Application US/09881012
; Publication No. US20020192655A1
; GENERAL INFORMATION:
; APPLICANT: Ginns, Edward I.
; APPLICANT: Egeland, Janice A.
; APPLICANT: Paul, Steven M.
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by The Secretary of the
; APPLICANT: Department of Health and Human Services
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Susceptibility and Resistance Genes for
; TITLE OF INVENTION: Bipolar Affective Disorder
; FILE REFERENCE: 015280-248110US
; CURRENT APPLICATION NUMBER: US/09/881,012
; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US/09/175,158
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: US 60/062,924
; PRIOR FILING DATE: 1997-10-20
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 160
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: D4S1575 reverse primer
US-09-881-012-160
```

```
Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 2767 GTCACCCAGGCTGGAGTG 2784
Db 19 GTCACCCAGGCTGGAGTG 2
```

```
RESULT 1365
US-09-881-012-160/c
; Sequence 160, Application US/09881012
; Publication No. US20040248086A9
; GENERAL INFORMATION:
; APPLICANT: Ginns, Edward I.
; APPLICANT: Egeland, Janice A.
; APPLICANT: Paul, Steven M.
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by The Secretary of the
; APPLICANT: Department of Health and Human Services
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Susceptibility and Resistance Genes for
; TITLE OF INVENTION: Bipolar Affective Disorder
; FILE REFERENCE: 015280-248110US
; CURRENT APPLICATION NUMBER: US/09/881,012
```

; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US/09/175,158
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: US 60/062,924
; PRIOR FILING DATE: 1997-10-20
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 160
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: D4S1575 reverse primer
US-09-881-012-160

Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2767 GTCACCCAGGCTGGAGTG 2784
|||||
Db 19 GTCACCCAGGCTGGAGTG 2

RESULT 1366
US-10-098-871-37
; Sequence 37, Application US/10098871
; Publication No. US20030198958A1
; GENERAL INFORMATION:
; APPLICANT: Shimkets, Richard A.
; APPLICANT: Fernandes, Elma
; APPLICANT: Herrmann, John
; APPLICANT: Liu, Xiaohong
; APPLICANT: Yang, Meijia
; APPLICANT: Boldog, Ference
; APPLICANT: Smithson, Glennda
; APPLICANT: Rastelli, Luca
; TITLE OF INVENTION: NOVEL HUMAN PROTEINS, POLYNUCLEOTIDES ENCODING THEM AND
; FILE REFERENCE: CURA-65 CIP
; CURRENT APPLICATION NUMBER: US/10/098,871
; CURRENT FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: 09/659,634
; PRIOR FILING DATE: 2000-09-12
; PRIOR APPLICATION NUMBER: 60/153,629
; PRIOR FILING DATE: 1999-09-13
; PRIOR APPLICATION NUMBER: 60/154,520
; PRIOR FILING DATE: 1999-09-16
; PRIOR APPLICATION NUMBER: 60/154,762
; PRIOR FILING DATE: 1999-09-20
; PRIOR APPLICATION NUMBER: 60/159,231
; PRIOR FILING DATE: 2000-10-31
; PRIOR APPLICATION NUMBER: 60/276,960
; PRIOR FILING DATE: 2001-03-19
; NUMBER OF SEQ ID NOS: 80
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 37
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Ag121 forward primer
US-10-098-871-37

Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTG 2789
|||||
Db 2 CCAGGCTGGAGTGCAGTG 19

RESULT 1367
US-10-780-439-23/c
; Sequence 23, Application US/10780439
; Publication No. US20040142899A1
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D.
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR
; ENHANCED BIOTABILITY AND ALTERED BIODISTRIBUTION OF
; OLIGONUCLEOTIDES IN MAMMALS
; NUMBER OF SEQUENCES: 63
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cozen O'Connor
; STREET: 1900 Market Street
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/780,439
; FILING DATE: 17-Feb-2004
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Nguyen, Quan L.
; REGISTRATION NUMBER: 46,957
; REFERENCE/DOCKET NUMBER: ISIC0006-102
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-665-2000
; TELEFAX: 215-665-2013
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 23:
US-10-780-439-23

Query Match 0.6%; Score 18; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 7.9e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 50 GCCTGCTATGGCTCCCA 67
|||||
Db 19 GCCTGCTATGGCTCCCA 2

RESULT 1368
US-10-172-911-80
; Sequence 80, Application US/10172911
; Publication No. US2003023434A1
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowser
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTPN12 EXPRESSION
; FILE REFERENCE: PUS-0016
; CURRENT APPLICATION NUMBER: US/10/172,911
; CURRENT FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 123
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-172-911-80

```
; APPLICANT: Centre For DNA Fingerprinting and Diagnostics
; TITLE OF INVENTION: No. US20030194730A1el FISSR-PCR primers and markers and a method
; TITLE OF INVENTION: primers and markers for identifying genetic constitution and bre
; FILE OF INVENTION: varieties.
; FILE REFERENCE: 782-indian
; CURRENT APPLICATION NUMBER: US/10/357,488
; CURRENT FILING DATE: 2003-02-04
; PRIOR APPLICATION NUMBER: 260/MAS/2002
; PRIOR FILING DATE: 2002-04-08
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: A novel FISSR-PCR primer for genotyping eukaryotes
US-10-357-488-26

Query Match          0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTGCAGT 2788
Db 3 CCCAGGCTGGAGTGCAGT 20

RESULT 1369
US-09-993-731-22
; Sequence 22, Application US/09993731
; Publication No. US20030105040A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION
; FILE REFERENCE: RTS-0302
; CURRENT APPLICATION NUMBER: US/09/993,731
; CURRENT FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-993-731-22

Query Match          0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTGCAGTGG 2790
Db 1 CAGGCTGGAGTGCAGTGG 18

RESULT 1370
US-09-843-377-88
; Sequence 88, Application US/09843377
; Publication No. US20030176371A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; TITLE OF INVENTION: ANTISENSE MODULATION OF INTERFERON GAMMA RECEPTOR 2 EXPRESSION
; FILE REFERENCE: RTS-0235
; CURRENT APPLICATION NUMBER: US/09/843,377
; CURRENT FILING DATE: 2001-04-26
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 88
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-843-377-88

Query Match          0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2762 GCTCTGTCACCCAGGCTG 2779
Db 1 GCTCTGTCACCCAGGCTG 18

RESULT 1371
US-10-357-488-26
; Sequence 26, Application US/10357488
; Publication No. US20030194730A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Centre For DNA Fingerprinting and Diagnostics
; TITLE OF INVENTION: No. US20030194730A1el FISSR-PCR primers and markers and a method
; TITLE OF INVENTION: primers and markers for identifying genetic constitution and bre
; FILE OF INVENTION: varieties.
; FILE REFERENCE: 782-indian
; CURRENT APPLICATION NUMBER: US/10/357,488
; CURRENT FILING DATE: 2003-02-04
; PRIOR APPLICATION NUMBER: 260/MAS/2002
; PRIOR FILING DATE: 2002-04-08
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: A novel FISSR-PCR primer for genotyping eukaryotes
US-10-357-488-26

Query Match          0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTAT 2745
Db 1 GTGTGTGTGTGTGTGTAT 18

RESULT 1372
US-10-671-395-1629/c
; Sequence 1629, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1629
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1629

Query Match          0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2850 CCTCCTGAGTAGCTGGGA 2867
Db 20 CCTCCTGAGTAGCTGGGA 3

RESULT 1373
US-10-819-244-88
; Sequence 88, Application US/10819244
; Publication No. US20040171575A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INTERFERON GAMMA RECEPTOR 2 EXPRESSION
; FILE REFERENCE: RTS-0235
; CURRENT APPLICATION NUMBER: US/10/819,244
; CURRENT FILING DATE: 2004-04-06
; PRIOR APPLICATION NUMBER: US/09/843,377
```

;; PRIOR FILING DATE: 2001-04-26
;; NUMBER OF SEQ ID NOS: 89
;; SEQ ID NO 88
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Antisense Oligonucleotide
US-10-819-244-88

Query Match 0.6%; Score 18; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 7.5e+02;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2762 GCTCTGTCACCCAGGCTG 2779
|||||
Db 1 GCTCTGTCACCCAGGCTG 18

RESULT 1374

US-09-784-423-60
; Sequence 60, Application US/097844423
; Patent No. US20020012924A1
; GENERAL INFORMATION:

;; APPLICANT: Schumm, James W.
;; Bacher, Jeffery W.

;; TITLE OF INVENTION: MATERIALS AND METHODS FOR

;; IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM
;; REPEAT DNA MARKERS

;; NUMBER OF SEQUENCES: 147

;; CORRESPONDENCE ADDRESS:

;; ADDRESSEE: Promega Corporation

;; STREET: 2800 Woods Hollow Road

;; CITY: Madison

;; STATE: Wisconsin

;; COUNTRY: U.S.A.

;; ZIP: 53711-5399

;; COMPUTER READABLE FORM:

;; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb

;; COMPUTER: IBM compatible PC

;; OPERATING SYSTEM: Windows 95

;; SOFTWARE: Word 97 (DOS text format)

;; CURRENT APPLICATION DATA:

;; APPLICATION NUMBER: US/09/784,423

;; FILING DATE: 15-Feb-2001

;; CLASSIFICATION: <Unknown>

;; PRIOR APPLICATION DATA:

;; APPLICATION NUMBER: 09/018,584

;; FILING DATE: 04-Feb-1998

;; ATTORNEY/AGENT INFORMATION:

;; NAME: Grady J. Frenchick

;; REGISTRATION NUMBER: 29,018

;; REFERENCE/DOCKET NUMBER: 16026.9180

;; TELEPHONE: (608) 257-3501

;; TELEFAX: (608) 257-2275

;; INFORMATION FOR SEQ ID NO: 60

;; SEQUENCE CHARACTERISTICS:

;; LENGTH: 21

;; TYPE: Nucleic Acid

;; STRANDEDNESS: Single

;; TOPOLOGY: Linear

;; SEQUENCE DESCRIPTION: SEQ ID NO: 60

US-09-784-423-60

Query Match 0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 7.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2837 CCTCCCACTGACGCTCCTGA 2857
|||||
Db 1 CCTCCCACTGACGCTCCTGA 21

RESULT 1375

US-09-964-059B-70

; Sequence 70, Application US/09964059B

; Publication No. US20030171875A1

; GENERAL INFORMATION:

;; APPLICANT: Frudakis, Tony

;; TITLE OF INVENTION: Efficient Methods and Apparatus for High-Throughput Processing o

;; FILE REFERENCE: 0201-0001

;; CURRENT APPLICATION NUMBER: US/09/964,059B

;; CURRENT FILING DATE: 2002-12-23

;; PRIOR APPLICATION NUMBER: US 60/274,686

;; PRIOR FILING DATE: 2000-03-08

;; NUMBER OF SEQ ID NOS: 239

;; SEQ ID NO 70

;; LENGTH: 21

;; TYPE: DNA

;; ORGANISM: Homo Sapiens

US-09-964-059B-70

Query Match 0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 7.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2777 CTGGAGTGCAGTGTGCAATC 2797

|||||

Db 1 CTGGAGTGCAGTGTGCAATC 21

RESULT 1376

US-09-964-059B-143

; Sequence 143, Application US/09964059B

; Publication No. US20030171875A1

; GENERAL INFORMATION:

;; APPLICANT: Frudakis, Tony

;; TITLE OF INVENTION: Efficient Methods and Apparatus for High-Throughput Processing o

;; FILE REFERENCE: 0201-0001

;; CURRENT APPLICATION NUMBER: US/09/964,059B

;; CURRENT FILING DATE: 2002-12-23

;; PRIOR APPLICATION NUMBER: US 60/274,686

;; PRIOR FILING DATE: 2000-03-08

;; NUMBER OF SEQ ID NOS: 239

;; SEQ ID NO 143

;; LENGTH: 21

;; TYPE: DNA

;; ORGANISM: Homo Sapiens

US-09-964-059B-143

Query Match 0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 7.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2780 GAGTGCAGTGTGCAATCATG 2800

|||||

Db 1 GAGTGCAGTGTGCAATCATG 21

RESULT 1377

US-09-964-059B-144/c

; Sequence 144, Application US/09964059B

; Publication No. US20030171875A1

; GENERAL INFORMATION:

;; APPLICANT: Frudakis, Tony

;; TITLE OF INVENTION: Efficient Methods and Apparatus for High-Throughput Processing o

;; FILE REFERENCE: 0201-0001

;; CURRENT APPLICATION NUMBER: US/09/964,059B

;; CURRENT FILING DATE: 2002-12-23

;; PRIOR APPLICATION NUMBER: US 60/274,686

;; PRIOR FILING DATE: 2000-03-08

;; NUMBER OF SEQ ID NOS: 239

;; SEQ ID NO 143

;; LENGTH: 21

;; TYPE: DNA

;; ORGANISM: Homo Sapiens

US-09-964-059B-143


```
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5107
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-5107

Query Match          0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 7.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2780 GAGTGCAGTGGTGCAATCATG 2800
DB 1 GAGTGCAGTGGTGCAATCTTG 21

RESULT 1387
US-10-751-736-23296/c
; Sequence 23296, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23296
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-23296

Query Match          0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 7.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2180 GCTATTATTAGTGTCTTTT 2200
DB 21 GCTGTTATTAGTGTCTGTT 1

RESULT 1388
US-10-129-595-8/c
; Sequence 8, Application US/10129595
; Publication No. US20050031583A1
; GENERAL INFORMATION:
; APPLICANT: Genentech, Inc. et al.
; TITLE OF INVENTION: Uses of ORG Ligand to Modulate Immune Responses
; FILE REFERENCE: P1830R1
; CURRENT APPLICATION NUMBER: US/10/129,595
; CURRENT FILING DATE: 2002-05-08
; PRIOR APPLICATION NUMBER: US 60/278,215
; PRIOR FILING DATE: 2001-03-23
; NUMBER OF SEQ ID NOS: 18
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: sequence is synthesized

US-10-129-595-8

Query Match          0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 7.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2834 GATCCTCCACCTCAGCCTCC 2854
DB 21 GATCCTCCACCTCAACCTTC 1

RESULT 1389
US-10-830-287A-7
; Sequence 7, Application US/10830287A
; Publication No. US20050038238A1
; GENERAL INFORMATION:
; APPLICANT: Kriesel, John D.
; APPLICANT: Jones, Brandt B.
; APPLICANT: Grissom, Charles B.
; APPLICANT: Herpin, Geoff
; APPLICANT: Glazer, Peter M.
; TITLE OF INVENTION: OLIGONUCLEOTIDE COMPLEXES FOR USE AS ANTI-VIRAL THERAPEUTICS
; FILE REFERENCE: 007180-19
; CURRENT APPLICATION NUMBER: US/10/830,287A
; CURRENT FILING DATE: 2004-04-21
; PRIOR APPLICATION NUMBER: 60/464,270
; PRIOR FILING DATE: 2003-04-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Variola virus
US-10-830-287A-7

Query Match          0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 7.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGTGATTTTTTTTTTTTTT 2918
DB 1 TTTTGTGATTTTTTTTTTTTTT 21

RESULT 1390
US-10-601-140A-43/c
; Sequence 43, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 43
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-601-140A-43

Query Match          0.6%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 7.5e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGTGATTTTTTTTTTTTTT 2918
```



```
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 3086
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-3086

Query Match          0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGT 2747
Db 19 TGTGTGTGTGTGTGTGT 1

RESULT 1396
US-09-263-959-1278
; Sequence 1278 Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTIL
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESS: Seed and Berry LLP
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: McMasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 1278:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-263-959-1278

Query Match          0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2846 TCAGCCTCTCTGAGTACTG 2864
Db 1 TCAGCCTCTCTGAGTACTG 19

RESULT 1397
```

```
US-10-251-598-86/C
; Sequence 86 Application US/10251598
; Publication No. US20030170668A1
; GENERAL INFORMATION:
; APPLICANT: Detera-Wadleigh, Sevilla D.
; Gershon, Elliot S.
; Badner, Judith A.
; Goldin, Lynn R.
; Berrettini, Wade H.
; Yoshikawa, Takeo
; Sanders, Alan R.
; Esterling, Lisa E.
; TITLE OF INVENTION: Chromosomal Markers and Diagnostic
; NUMBER OF SEQUENCES: 197
; CORRESPONDENCE ADDRESS:
; ADDRESS: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/251,598
; FILING DATE: 19-Sep-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/091,952
; FILING DATE: 19-Apr-1999
; APPLICATION NUMBER: US 60/029,278
; FILING DATE: 28-OCT-1996
; APPLICATION NUMBER: PCT/US97/19381
; FILING DATE: 28-OCT-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, Timothy L.
; REGISTRATION NUMBER: 35,367
; REFERENCE/DOCKET NUMBER: 015280-297100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 86:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: -
; LOCATION: 1...19
; OTHER INFORMATION: D18S378 forward primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 86:
US-10-251-598-86

Query Match          0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTGCACCCAGGCT 2778
Db 19 TTGCTCTGTGCACCCAGGCT 1

RESULT 1398
US-10-665-951-389
; Sequence 389 Application US/10665951
; Publication No. US20040138163A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Beigelman, Leonid
/ APPLICANT: Pavco, Pamela
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
/ TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
/ TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
/ FILE REFERENCE: 400/131 (MBHB02-742-F)
/ CURRENT APPLICATION NUMBER: US/10/665,951
/ CURRENT FILING DATE: 2003-09-18
/ PRIOR APPLICATION NUMBER: US 10/664,668
/ PRIOR FILING DATE: 2003-09-18
/ PRIOR APPLICATION NUMBER: PCT/US 03/05022
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/399,348
/ PRIOR FILING DATE: 2002-07-29
/ PRIOR APPLICATION NUMBER: US 60/393,796
/ PRIOR FILING DATE: 2002-07-03
/ PRIOR APPLICATION NUMBER: US 10/287,949
/ PRIOR FILING DATE: 2002-11-04
/ PRIOR APPLICATION NUMBER: US 10/306,747
/ PRIOR FILING DATE: 2002-11-27
/ PRIOR APPLICATION NUMBER: PCT/US 02/17674
/ PRIOR FILING DATE: 2002-05-29
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 60/386,782
/ PRIOR FILING DATE: 2002-06-06
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 2455
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 389
/ LENGTH: 19
/ TYPE: RNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-665-951-389

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 42.1%; Pred. No. 9e+02;
Matches 8; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
Db 1 UGUGUGUGUGUGUGUGUGU 19

RESULT 1399
US-10-665-951-816/c
/ Sequence 816, Application US/10665951
/ Publication No. US20040138163A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Beigelman, Leonid
/ APPLICANT: Pavco, Pamela
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
/ TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
/ TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
/ FILE REFERENCE: 400/131 (MBHB02-742-F)
/ CURRENT APPLICATION NUMBER: US/10/665,951
/ CURRENT FILING DATE: 2003-09-18
/ PRIOR APPLICATION NUMBER: US 10/664,668
/ PRIOR FILING DATE: 2003-09-18
/ PRIOR APPLICATION NUMBER: PCT/US 03/05022
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/399,348
/ PRIOR FILING DATE: 2002-07-29
/ PRIOR APPLICATION NUMBER: US 60/393,796
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Beigelman, Leonid
/ APPLICANT: Pavco, Pamela
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
/ TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
/ TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
/ FILE REFERENCE: 400/141 (MEHB02742-N)
/ CURRENT APPLICATION NUMBER: US/10/758,155
/ CURRENT FILING DATE: 2004-01-12
/ PRIOR APPLICATION NUMBER: US 10/665,951
/ PRIOR FILING DATE: 2003-09-18
/ PRIOR APPLICATION NUMBER: US 10/664,668
/ PRIOR FILING DATE: 2003-09-18
/ PRIOR APPLICATION NUMBER: PCT/US 03/05022
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/399,348
/ PRIOR FILING DATE: 2002-07-29
/ PRIOR APPLICATION NUMBER: US 60/393,796
/ PRIOR FILING DATE: 2002-07-03
/ PRIOR APPLICATION NUMBER: US 10/287,949
/ PRIOR FILING DATE: 2002-11-04
/ PRIOR APPLICATION NUMBER: US 10/306,747
/ PRIOR FILING DATE: 2002-11-27
/ PRIOR APPLICATION NUMBER: PCT/US 02/17674
/ PRIOR FILING DATE: 2002-05-29
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 2751
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 389
/ LENGTH: 19

RESULT 1400
US-10-758-155-389
/ Sequence 389, Application US/10758155
/ Publication No. US20050075304A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Beigelman, Leonid
/ APPLICANT: Pavco, Pamela
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
/ TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
/ TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
/ FILE REFERENCE: 400/141 (MEHB02742-N)
/ CURRENT APPLICATION NUMBER: US/10/758,155
/ CURRENT FILING DATE: 2004-01-12
/ PRIOR APPLICATION NUMBER: US 10/665,951
/ PRIOR FILING DATE: 2003-09-18
/ PRIOR APPLICATION NUMBER: US 10/664,668
/ PRIOR FILING DATE: 2003-09-18
/ PRIOR APPLICATION NUMBER: PCT/US 03/05022
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/399,348
/ PRIOR FILING DATE: 2002-07-29
/ PRIOR APPLICATION NUMBER: US 60/393,796
/ PRIOR FILING DATE: 2002-07-03
/ PRIOR APPLICATION NUMBER: US 10/287,949
/ PRIOR FILING DATE: 2002-11-04
/ PRIOR APPLICATION NUMBER: US 10/306,747
/ PRIOR FILING DATE: 2002-11-27
/ PRIOR APPLICATION NUMBER: PCT/US 02/17674
/ PRIOR FILING DATE: 2002-05-29
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 2751
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 389
/ LENGTH: 19

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
Db 19 TGTGTGTGTGTGTGTGTGT 1

RESULT 1400
US-10-758-155-389
/ Sequence 389, Application US/10758155
/ Publication No. US20050075304A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: McSwiggen, James
/ APPLICANT: Beigelman, Leonid
/ APPLICANT: Pavco, Pamela
/ TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
/ TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
/ TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
/ FILE REFERENCE: 400/141 (MEHB02742-N)
/ CURRENT APPLICATION NUMBER: US/10/758,155
/ CURRENT FILING DATE: 2004-01-12
/ PRIOR APPLICATION NUMBER: US 10/665,951
/ PRIOR FILING DATE: 2003-09-18
/ PRIOR APPLICATION NUMBER: US 10/664,668
/ PRIOR FILING DATE: 2003-09-18
/ PRIOR APPLICATION NUMBER: PCT/US 03/05022
/ PRIOR FILING DATE: 2003-02-20
/ PRIOR APPLICATION NUMBER: US 60/399,348
/ PRIOR FILING DATE: 2002-07-29
/ PRIOR APPLICATION NUMBER: US 60/393,796
/ PRIOR FILING DATE: 2002-07-03
/ PRIOR APPLICATION NUMBER: US 10/287,949
/ PRIOR FILING DATE: 2002-11-04
/ PRIOR APPLICATION NUMBER: US 10/306,747
/ PRIOR FILING DATE: 2002-11-27
/ PRIOR APPLICATION NUMBER: PCT/US 02/17674
/ PRIOR FILING DATE: 2002-05-29
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 2751
/ SOFTWARE: PatentIn version 3.3
/ SEQ ID NO 389
/ LENGTH: 19
```



```
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/444853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 706
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 494
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-871-222-494

Query Match          0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGCTGTGCTGTATGT 2747
      |||||
Db 19 TGTGCTGTGCTGTATGT 1

RESULT 1404
US-10-863-973-923/C
; Sequence 923, Application US/10863973
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Polisky, Barry
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBHB03-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1832
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 923
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-863-973-923/C

Query Match          0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGCTGTGCTGTATGT 2747
      |||||
Db 19 TGTGCTGTGCTGTATGT 1

RESULT 1404
US-10-863-973-923/C
; Sequence 923, Application US/10863973
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Polisky, Barry
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBHB03-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1832
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 923
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-863-973-923/C
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-863-973-923

Query Match          0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 9e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTGTGTCACCCAGG 2776
      |||||
Db 19 TCTGTCTGTGTCACCCAGG 1

RESULT 1405
US-10-863-973-1146
; Sequence 1146, Application US/10863973
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: Polisky, Barry
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBHB03-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1832
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1146
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-863-973-1146

Query Match          0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 9e+02;
Matches 13; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTGTGTCACCCAGG 2776
      |||||
Db 1 UCUCGUCUCUGACCCAGG 19

RESULT 1406
US-10-831-620-389
; Sequence 389, Application US/10831620
; Publication No. US20050148530A1
```



```
RESULT 1409
US-09-771-933-107/c
; Sequence 107, Application US/09771933
; Publication No. US2003002387A1
; GENERAL INFORMATION:
; APPLICANT: Gill-Garrison, Rosalynn D
; APPLICANT: Martin, Christopher J
; APPLICANT: Sanchez-Felix, Manuel V
; TITLE OF INVENTION: Computer-assisted Means for Assessing Lifestyle Risk
; TITLE OF INVENTION: Factors
; FILE REFERENCE: 620-130
; CURRENT APPLICATION NUMBER: US/09/771,933
; CURRENT FILING DATE: 2001-01-30
; NUMBER OF SEQ ID NOS: 205
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 107
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-771-933-107

Query Match          0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 8.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2835 ATCTCCACCTCAGCCTC 2853
Db 20 ATCTCCACCTCAGCCTC 2

RESULT 1410
US-10-181-177-94/c
; Sequence 94, Application US/10181177
; Publication No. US20030083296A1
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Lex M. Cowbert
; TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 8 EXPRESSION
; FILE REFERENCE: RTSP-0334
; CURRENT APPLICATION NUMBER: US/10/181,177
; CURRENT FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: PCT/US01/00955
; PRIOR FILING DATE: 2001-01-11
; PRIOR APPLICATION NUMBER: 09/487,445
; PRIOR FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 176
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-181-177-94

Query Match          0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 8.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2774 AGGCTGAGTGCAGTGGTG 2792
Db 20 AGGCTGAGTGCAGTGGCG 2

RESULT 1411
US-10-671-395-862/c
; Sequence 862, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
```

```
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 862
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-862

Query Match          0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 8.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2838 CTCCACCTCAGCCTCCTG 2856
Db 19 CTCCACCTCAGCCTCCTG 1

RESULT 1412
US-10-671-395-967/c
; Sequence 967, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 967
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-967

Query Match          0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 8.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
Db 20 TGTGTGTGTGTGTGTGTGT 2

RESULT 1413
US-10-671-395-1098/c
; Sequence 1098, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
```



```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1098
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1098

Query Match      0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 8.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2722 ATCCGCGTGTGTGTGTG 2740
Db 19 ATCCGCGTGTGTGTGTG 1

RESULT 1414
US-10-671-395-1333/c
; Sequence 1333, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1333
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1333

Query Match      0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 8.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2727 CGTGTGTGTGTGTGTAT 2745
Db 19 CGTGTGTGTGTGTGTAT 1

RESULT 1415
US-10-671-395-1343/c
; Sequence 1343, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1343
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1343

Query Match      0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 8.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2727 CGTGTGTGTGTGTGTAT 2745
Db 19 CGTGTGTGTGTGTGTAT 1

RESULT 1416
US-10-671-395-1505/c
; Sequence 1505, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1505
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1505

Query Match      0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 8.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATG 2746
Db 19 GTGTGTGTGTGTGTATG 1

RESULT 1417
US-10-671-395-1627/c
; Sequence 1627, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1627
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1627

Query Match      0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 8.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2731 TGTGTGTGTGTGTGTGT 2749
```

Db 20 TGTGTGTGTGTGTGTGT 2
||||| |||||||

RESULT 1418
US-10-620-642-33
; Sequence 33, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; Bosselman, Robert A.
; Suggs, Sidney V.
; Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-MAY-1995
; APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-DEC-1993
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-APR-1991
; APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-OCT-1991
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 33:
US-10-620-642-33

Query Match 0.6%; Score 17.4; DB 1; Length 20;
Best Local Similarity 94.7%; Pred. No. 8.6e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2903 TTTTTCAG 2921
Db 2 TTTTTCAG 20

RESULT 1419
US-10-786-720-20999
; Sequence 20999, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20999
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-20999

Query Match 0.6%; Score 17.4; DB 1; Length 21;
Best Local Similarity 47.4%; Pred. No. 8.2e+02;
Matches 9; Conservative 9; Mismatches 1; Indels 0; Gaps 0;

QY 2727 CGGTGTGTGTGTGTAT 2745
Db 3 CGUGUGUGUGUGUGUUU 21

RESULT 1420
US-10-751-736-5468
; Sequence 5468, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5468
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-5468

Query Match 0.6%; Score 17.4; DB 1; Length 21;
Best Local Similarity 73.7%; Pred. No. 8.2e+02;
Matches 14; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2849 GCCTCCTAGTAGCTGGGA 2867
Db 1 GCCCUCGAGUAGCUGUGA 19

RESULT 1421
US-10-751-736-23297/c
; Sequence 23297, Application US/10751736
; Publication No. US20040265230A1

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; TITLE OF INVENTION: CANCERS
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 23297
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-23297

Query Match          0.6%; Score 17.4; DB 1; Length 21;
Best Local Similarity 94.7%; Pred. No. 8.2e+02;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2179 AGCTATTATTGAGTGCT 2197
      ||||| ||||| ||||| |||||
DB 20 AGCTGTTATTGAGTGCT 2

RESULT 1422
US-10-463-981B-2/c
; Sequence 2, Application US/10463981B
; Publication No. US20040081982A1
; GENERAL INFORMATION:
; APPLICANT: Choo, Kong-Hong Andy
; APPLICANT: Wong, Lee Hwa
; APPLICANT: Saffery, Richard Eric
; TITLE OF INVENTION: Neocentromere-based mini-chromosomes or artificial chromosomes
; FILE REFERENCE: A35869-PCT-USA-A (071838.0140)
; CURRENT APPLICATION NUMBER: US/10/463,981B
; CURRENT FILING DATE: 2003-06-17
; PRIOR APPLICATION NUMBER: PCT/AU01/01644
; PRIOR FILING DATE: 2001-12-20
; PRIOR APPLICATION NUMBER: AU PR2247
; PRIOR FILING DATE: 2000-12-21
; PRIOR APPLICATION NUMBER: AU PR8909
; PRIOR FILING DATE: 2001-11-16
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide primer
US-10-463-981B-2

Query Match          0.6%; Score 17.2; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 9.9e+02;
Matches 16; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 2774 AGCTGGAGTGAGTGCT 2791
      ||||| ||||| ||||| |||||
DB 18 AGCTGGAGTGAGTGCT 1

RESULT 1423
US-10-741-600-73887
; Sequence 73887, Application US/10741600
; Publication No. US20050026169A1
; GENERAL INFORMATION:
; APPLICANT: CARGILL, Michele et al.
; TITLE OF INVENTION: GENETIC POLYMORPHISMS ASSOCIATED WITH
```

```
; TITLE OF INVENTION: MYOCARDIAL INFARCTION, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001499
; CURRENT APPLICATION NUMBER: US/10/741,600
; CURRENT FILING DATE: 2003-12-22
; NUMBER OF SEQ ID NOS: 73997
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 73887
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-741-600-73887

Query Match          0.6%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 761 TGGTCTGTTCCTGGAC 777
      ||||| ||||| ||||| |||||
DB 1 TGGTCTGTTCCTGGAC 17

RESULT 1424
US-10-669-962-28
; Sequence 28, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
; APPLICANT: Brugliera, Filippa
; APPLICANT: Holton, Timothy A.
; APPLICANT: Michael, Michael Z.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/10/669,962
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US/09/142,108C
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: PN8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: Patent in Ver. 2.1
; SEQ ID NO 28
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
US-10-669-962-28

Query Match          0.6%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1e+03;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTTTCCTTTTTCCTTC 2919
      ||||| ||||| ||||| |||||
DB 2 TTTTTCCTTTTTCCTTC 18

RESULT 1425
US-10-192-437-14/c
; Sequence 14, Application US/10192437
; Publication No. US20030153737A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Phillip D. Cook
; TITLE OF INVENTION: NOVEL AMINES AND METHODS OF MAKING AND USING THE SAME
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. US20030153737A1R1S
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
```

```
/
/ COUNTRY: U.S.A.
/ ZIP: 19103
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: WordPerfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/10/192,437
/ FILING DATE: 10-Jul-2002
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/08/397,277A
/ FILING DATE: 09-MAR-1995
/ APPLICATION NUMBER: 07/943,516
/ FILING DATE: 11-SEP-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Gaumond, Rebecca R.
/ REGISTRATION NUMBER: 35,152
/ REFERENCE/DOCKET NUMBER: ISIS-1198
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 215-568-3100
/ TELEFAX: 215-568-3439
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ FEATURE:
/ NAME/KEY: misc_feature
/ LOCATION: 18
/ OTHER INFORMATION: /note= "2'-deoxyuridine
/ residue"
/ SEQUENCE DESCRIPTION: SEQ ID NO: 14:
/ US-10-192-437-14
/
/ Query Match 0.6%; Score 17; DB 1; Length 20;
/ Best Local Similarity 100.0%; Pred. No. 9.3e+02;
/ Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
/
/ QY 51 CCTCGCTATGGCTCCCA 67
/ Db 17 CCTCGCTATGGCTCCCA 1
/
/ RESULT 1426
/ US-09-908-147-138/c
/ Sequence 138, Application US/09908147
/ Publication No. US20030144221A1
/ GENERAL INFORMATION:
/ APPLICANT: Hong Zhang
/ APPLICANT: Andrew T. Watt
/ TITLE OF INVENTION: ANTISENSE MODULATION OF BCL2-ASSOCIATED X PROTEIN EXPRESSION
/ FILE REFERENCE: RTS-0185
/ CURRENT APPLICATION NUMBER: US/09/908,147
/ CURRENT FILING DATE: 2001-07-17
/ NUMBER OF SEQ ID NOS: 168
/ SEQ ID NO 138
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
/ US-09-908-147-138
/
/ Query Match 0.6%; Score 17; DB 1; Length 20;
/ Best Local Similarity 100.0%; Pred. No. 9.3e+02;
/ Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
/
/ QY 963 GCAGACAGTGACCATCT 979
/ Db 17 GTGTGTGTGTATGTGTA 1
/
/ RESULT 1429
/ US-10-671-395-1187/c
/ Sequence 1187, Application US/10671395
/ Publication No. US20040132063A1
/ GENERAL INFORMATION:
/ APPLICANT: Pharmacia Corp.
/ APPLICANT: Gierse, James K
/ TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
/ FILE REFERENCE: 1179/1/US
/ CURRENT APPLICATION NUMBER: US/10/671,395
/ CURRENT FILING DATE: 2003-09-25
/ PRIOR APPLICATION NUMBER: 60/413,549
/ PRIOR FILING DATE: 2002-09-25
/ NUMBER OF SEQ ID NOS: 1809
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 1187
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: artificial
/ FEATURE:
/ OTHER INFORMATION: Human PGE2 antisense
/ US-10-671-395-1187
/
/ Query Match 0.6%; Score 17; DB 1; Length 20;
/ Best Local Similarity 100.0%; Pred. No. 9.3e+02;
/ Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
/
/ QY 2734 GTGTGTGTGTATGTGTA 2750
/ Db 17 GTGTGTGTGTATGTGTA 1
/
/ RESULT 1429
/ US-10-671-395-1609/c
/ Sequence 1609, Application US/10671395
/ Publication No. US20040132063A1
/ GENERAL INFORMATION:
/ APPLICANT: Pharmacia Corp.
/ APPLICANT: Pharmacia Corp.
```

; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1609
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1609

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2851 CTCCTGAGTAGCTGGGA 2867
|||||
Db 20 CTCCTGAGTAGCTGGGA 4

RESULT 1430
US-10-620-642-34
; Sequence 34, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; Bosselman, Robert A.
; Suggs, Sidney V.
; Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-MAY-1995
; APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-DEC-1993
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-APR-1991
; APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-OCT-1991
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990

; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 34:
US-10-620-642-34

Query Match 0.6%; Score 17; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 9.3e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTTTCCTTTTTCCTTC 2919
|||||
Db 3 TTTTTCCTTTTTCCTTC 19

RESULT 1431
US-10-786-720-20626
; Sequence 20626, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20626
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-20626

Query Match 0.6%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 8.9e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2774 AGGCTGGAGTGCAGTGG 2790
|||||
Db 2 AGGCTGGAGTGCAGTGG 18

RESULT 1432
US-10-786-720-20628/c
; Sequence 20628, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20628
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-786-720-20628

Query Match      0.6%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 8.9e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2774 AGCGTGAGTGCAGTGC 2790
Db 20 AGCGTGAGTGCAGTGC 4

RESULT 1433
US-10-786-720-20998
; Sequence 20998, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20998
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-786-720-20998

Query Match      0.6%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 8.9e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2727 CGTGTGTGTGTGTGTGT 2743
Db 5 CGTGTGTGTGTGTGTGT 21

RESULT 1434
US-10-786-720-21000/c
; Sequence 21000, Application US/10786720
; Publication No. US2004019181A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; TITLE OF INVENTION: DISEASES
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 21000
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNai-antisense strand
US-10-786-720-21000

Query Match      0.6%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 8.9e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2727 CGTGTGTGTGTGTGTGT 2743
|||||
```

```
Db 17 CGTGTGTGTGTGTGTGT 1

RESULT 1435
US-09-752-983-241/c
; Sequence 241, Application US/09752983
; Patent No. US20010016575A1
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PC
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/752,983
; FILING DATE: 02-Jan-2001
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/280,905
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Licata, Jane Massey
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0346
; TELEPHONE: 609-810-1515
; TELEFAX: 609-810-1454
; INFORMATION FOR SEQ ID NO: 241:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-752-983-241

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TCGTCTGTCTACCCAGGCTG 2779
Db 20 TTGCTCTGTCTACCCAGGCTG 1

RESULT 1436
US-09-752-983-264/c
; Sequence 264, Application US/09752983
; Patent No. US20010016575A1
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
```

;
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PC
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/752,983
; FILING DATE: 02-Jan-2001
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/280,805
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Licata, Jane Massey
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0346
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-810-1515
; TELEFAX: 609-810-1454
; INFORMATION FOR SEQ ID NO: 264:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; US-09-752-983-264

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2833 TGATCTCCCACTAGCCT 2852
||||| ||||| ||||| |||||
Db 20 TGATCGCCCACTCGCCT 1

RESULT 1437
US-09-907-190-5
; GENERAL INFORMATION:
; APPLICANT: BLUMENFELD, ANAT; GUSELLA, JAMES F;
; BREAKFIELD, XANDRA, O;
; SLAUGENHAUPT, SUSAN
; TITLE OF INVENTION: USE OF GENETIC MARKERS TO
; DIAGNOSE FAMILIAL DYSAUTONOMIA
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/907,190
; FILING DATE: 17-Jul-2001
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/480,655
; FILING DATE: 07-JUNE-1995
; APPLICATION NUMBER: 08/049,678
; FILING DATE: 16-APRIL-1993
; APPLICATION NUMBER: US/07/890,719
; FILING DATE: 29-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: KENNETH H. SONNENFELD
; REGISTRATION NUMBER: 33,285

;
;
; REFERENCE/DOCKET NUMBER: 1829-4001US1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-451-8513
; TELEFAX: 212-751-6849
; JOURNAL: GENOMICS
; VOLUME: 12
; ISSUE:
; PAGES: 229-240
; DATE: 1992
; DOCUMENT NUMBER:
; FILING DATE:
; PUBLICATION DATE:
; RELEVANT RESIDUES IN SEQ ID NO:
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-09-907-190-5

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2853 CCTGAGTAGCTGGGACCAT 2872
||||| ||||| ||||| |||||
Db 1 CCTGAGTAGCGGGACTATA 20

RESULT 1438
US-09-263-959-1214/c
; Sequence 1214, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTILIZE
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 1214:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-263-959-1214

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCCAGGC 2777
||||| ||||| ||||| |||||
Db 20 TCTTGTCTGTCTCCAGGC 1

```
RESULT 1439
US-09-863-806-135/c
; Sequence 135, Application US/09863806
; Publication No. US20020197608A1
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: DETECTION OF NEOPLASIM BY ANALYSIS OF SALIVA
; NUMBER OF SEQUENCES: 195
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 4225 Executive Square, Suite 1400
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/863,806
; FILING DATE: 22-May-2001
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/038,637
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/152,313
; FILING DATE: 12-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Haile, Lisa A.
; REGISTRATION NUMBER: 39,347
; REFERENCE/DOCKET NUMBER: 07265/146001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/678-5099
; TELEFAX: 619/678-5099
; INFORMATION FOR SEQ ID NO: 135:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 135:
US-09-863-806-135

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTCGCTCTCTCACCAGGCT 2778
DB 20 CTTGCTTTGTCACCCAGGCT 1

RESULT 1440
US-09-863-806-143/c
; Sequence 143, Application US/09863806
; Publication No. US20020197608A1
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: DETECTION OF NEOPLASIM BY ANALYSIS OF SALIVA
; NUMBER OF SEQUENCES: 195
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 4225 Executive Square, Suite 1400
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
```

```
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: FastSeq for Windows Version 2.0b
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/863,806
FILING DATE: 22-May-2001
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/038,637
FILING DATE: <Unknown>
APPLICATION NUMBER: 08/152,313
FILING DATE: 12-NOV-1993
ATTORNEY/AGENT INFORMATION:
NAME: Haile, Lisa A.
REGISTRATION NUMBER: 38,347
REFERENCE/DOCKET NUMBER: 07265/146001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619/678-5070
TELEFAX: 619/678-5099
INFORMATION FOR SEQ ID NO: 143:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Genomic DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 143:
US-09-863-806-143

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2776 GCTGGAGTCAGTGTGTGCAA 2795
DB 20 GCTGGAGTATAGTGTGTGCAA 1

RESULT 1441
US-09-888-361-95
; Sequence 95, Application US/09888361
; Publication No. US20030064944A1
; GENERAL INFORMATION:
; APPLICANT: Susan Murray
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA RECEPTOR
; FILE REFERENCE: RTS-0158
; CURRENT APPLICATION NUMBER: US/09/888,361
; CURRENT FILING DATE: 2001-06-21
; NUMBER OF SEQ ID NOS: 163
; SEQ ID NO 95
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-888-361-95

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2843 ACCTCAGCCTCTCTGAGTAGC 2862
DB 1 ACCTCAGCCTCCCAAGTAGC 20

RESULT 1442
US-09-908-147-137/c
; Sequence 137, Application US/09908147
; Publication No. US20030144221A1
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
```



```
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF BCL2-ASSOCIATED X PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0185
; CURRENT APPLICATION NUMBER: US/09/908,147
; CURRENT FILING DATE: 2001-07-17
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 137
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-908-147-137

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  958 ACATGCACACAGTGACCAT 977
    ||| ||||| ||||| |||||
Db   20 ACATGGCAGACAGTGACCAT 1

RESULT 1443
US-09-964-059B-68
; Sequence 68, Application US/09964059B
; Publication No. US20030171875A1
; GENERAL INFORMATION:
; APPLICANT: Frudakis, Tony
; TITLE OF INVENTION: Efficient Methods and Apparatus for High-Throughput Processing of
; FILE REFERENCE: 0201-0001
; CURRENT APPLICATION NUMBER: US/09/964,059B
; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: US 60/274,686
; PRIOR FILING DATE: 2000-03-08
; NUMBER OF SEQ ID NOS: 239
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-964-059B-68

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  2773 CAGGCTGGAGTGCAGTGGTG 2792
    ||||| ||||| ||||| |||||
Db   1 CAGGCTGGAGTACAGTGATG 20

RESULT 1444
US-09-964-059B-69
; Sequence 69, Application US/09964059B
; Publication No. US20030171875A1
; GENERAL INFORMATION:
; APPLICANT: Frudakis, Tony
; TITLE OF INVENTION: Efficient Methods and Apparatus for High-Throughput Processing of
; FILE REFERENCE: 0201-0001
; CURRENT APPLICATION NUMBER: US/09/964,059B
; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: US 60/274,686
; PRIOR FILING DATE: 2000-03-08
; NUMBER OF SEQ ID NOS: 239
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-964-059B-69

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  2773 CAGGCTGGAGTGCAGTGGTG 2792
    ||||| ||||| ||||| |||||
Db   1 CAGGCTGGAGTACAGTGATG 20
```

```
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  2774 AGGCTGGAGTGCAGTGGTGC 2793
    ||||| ||||| ||||| |||||
Db   1 AGGCTGGAGTACAGTGATGC 20

RESULT 1445
US-09-964-059B-79
; Sequence 79, Application US/09964059B
; Publication No. US20030171875A1
; GENERAL INFORMATION:
; APPLICANT: Frudakis, Tony
; TITLE OF INVENTION: Efficient Methods and Apparatus for High-Throughput Processing of
; FILE REFERENCE: 0201-0001
; CURRENT APPLICATION NUMBER: US/09/964,059B
; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: US 60/274,686
; PRIOR FILING DATE: 2000-03-08
; NUMBER OF SEQ ID NOS: 239
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-964-059B-79

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  2828 TCAAGTGATCTCCACCTC 2847
    ||||| ||||| ||||| |||||
Db   1 TCAAGCGATCATCCACCTC 20

RESULT 1446
US-09-964-059B-80
; Sequence 80, Application US/09964059B
; Publication No. US20030171875A1
; GENERAL INFORMATION:
; APPLICANT: Frudakis, Tony
; TITLE OF INVENTION: Efficient Methods and Apparatus for High-Throughput Processing of
; FILE REFERENCE: 0201-0001
; CURRENT APPLICATION NUMBER: US/09/964,059B
; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: US 60/274,686
; PRIOR FILING DATE: 2000-03-08
; NUMBER OF SEQ ID NOS: 239
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-964-059B-80

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  2830 AAGTGATCTCCACCTCAG 2849
    ||||| ||||| ||||| |||||
Db   1 AAGCGATCATCCACCTCAG 20

RESULT 1447
US-09-964-059B-81
; Sequence 81, Application US/09964059B
; Publication No. US20030171875A1
; GENERAL INFORMATION:
; APPLICANT: Frudakis, Tony
; TITLE OF INVENTION: Efficient Methods and Apparatus for High-Throughput Processing of
```

```
; TITLE OF INVENTION: Sequence Data
; FILE REFERENCE: 0201-0001
; CURRENT APPLICATION NUMBER: US/09/964,059B
; CURRENT FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: US 60/274,686
; PRIOR FILING DATE: 2000-03-08
; NUMBER OF SEQ ID NOS: 239
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; US-09-964-059B-81

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2834 GATCTCCACCTCAGCTC 2853
Db 1 GATCATCCACCTCAGCTTC 20

RESULT 1448
US-09-976-900A-55/c
; Sequence 55, Application US/09976900A
; Publication No. US20040219520A1
; GENERAL INFORMATION:
; APPLICANT: Mirkin, Chad A.
; APPLICANT: Letsinger, Robert L.
; APPLICANT: Mucic, Robert C.
; APPLICANT: Storhoff, James J.
; APPLICANT: Elghanian, Robert
; APPLICANT: Taton, Thomas A.
; TITLE OF INVENTION: NANOPARTICLES HAVING OLIGONUCLEOTIDES ATTACHED THERETO
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 00-713-123
; CURRENT APPLICATION NUMBER: US/09/976,900A
; CURRENT FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 09/603,830
; PRIOR FILING DATE: 2000-06-26
; PRIOR APPLICATION NUMBER: 09/344,667
; PRIOR FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: 09/240,755
; PRIOR FILING DATE: 1999-01-29
; PRIOR APPLICATION NUMBER: PCT/US97/12783
; PRIOR FILING DATE: 1997-07-21
; PRIOR APPLICATION NUMBER: 60/031,809
; PRIOR FILING DATE: 1996-07-29
; PRIOR APPLICATION NUMBER: 60/200,161
; PRIOR FILING DATE: 2000-04-26
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: Microsoft Word 2000
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: random
; US-09-976-900A-55

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGATTTTTTTTTTTTTT 2917
Db 20 TTTTTTTTTTTTTTTTTTTT 1

RESULT 1449
US-10-085-906-352/c
; Sequence 352, Application US/10085906
```

```
; Publication No. US20030054371A1
; GENERAL INFORMATION:
; APPLICANT: Ying, Vincent
; APPLICANT: Wu, Paul
; APPLICANT: Gray, Gary S.
; TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
; TITLE OF INVENTION: COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
; FILE REFERENCE: GNN-5343CP2
; CURRENT APPLICATION NUMBER: US/10/085,906
; CURRENT FILING DATE: 2002-02-27
; PRIOR APPLICATION NUMBER: US 60/126,215
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 09/534,061
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: PCT/US00/07938
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 545
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 352
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-085-906-352

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2767 GTCACCCAGGCTGGAGTGCA 2786
Db 20 GTCGCTCAGGCTGGAGTGCA 1

RESULT 1450
US-10-007-078-81/c
; Sequence 81, Application US/10007078
; Publication No. US20030105042A1
; GENERAL INFORMATION:
; APPLICANT: Donna T. Ward
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF EIF2C1 EXPRESSION
; FILE REFERENCE: RTS-0236
; CURRENT APPLICATION NUMBER: US/10/007,078
; CURRENT FILING DATE: 2001-11-08
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-10-007-078-81

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2768 TCACCCAGGCTGGAGTGCGAG 2787
Db 20 TCGTCCAGGCTGGAGTGCGAG 1

RESULT 1451
US-10-024-396-90
; Sequence 90, Application US/10024396
; Publication No. US20030147864A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CD36L1 EXPRESSION
; FILE REFERENCE: RTS-0339
; CURRENT APPLICATION NUMBER: US/10/024,396
; CURRENT FILING DATE: 2001-12-18
; NUMBER OF SEQ ID NOS: 91
```

; SEQ ID NO 90
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-024-396-90

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCACCCAGGCT 2778
Db 1 CTCCTCTGTCGCCAGGCT 20

RESULT 1452
US-10-331-907-300/c
; Sequence 300, Application US/10331907
; Publication No. US20030181660A1
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; Hesse, John W
; Caskey, Charles T
; Cox, Roger D
; Gerhold, David
; Hammond, Holly
; Hey, Patricia
; Kawaguchi, Yoshihiko
; Merriman, Tony R
; Metzker, Michael L
; TITLE OF INVENTION: No. US20030181660A1e1 LDL-Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESS: Nixon and Vanderhye
; STREET: 1100 No. US20030181660A1th Glebe Road, Eighth Floor
; City: Arlingtoncon
; STATE: Virginia
; COUNTRY: US
; ZIP: VA 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/331,907
; FILING DATE: 31-Dec-2002
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/402,923A
; FILING DATE: 14-Feb-2001
; APPLICATION NUMBER: PCT/GB98/01102
; FILING DATE: 15-APR-1998
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B. J. Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-81
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 300:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 300:
US-10-331-907-300

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2828 TCAAGTGATCTCTCCACCTC 2847
Db 20 TCAAGTGATCTCTCGCTC 1

RESULT 1453
US-10-005-344-241/c
; Sequence 241, Application US/10005344
; Publication No. US20030203862A1
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia
; APPLICANT: Pamela Nero
; APPLICANT: Mark J. Graham
; APPLICANT: Brett P. Monia
; APPLICANT: Erich Koller
; APPLICANT: Mingyi Chiang
; APPLICANT: Mano Manoharan
; TITLE OF INVENTION: Antisense Modulation of mdm2 expression.
; FILE REFERENCE: ISPH-0622
; CURRENT APPLICATION NUMBER: US/10/005,344
; PRIOR FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: US 09/048,810
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/280,805
; PRIOR FILING DATE: 1999-03-26
; NUMBER OF SEQ ID NOS: 379
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 241
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-005-344-241

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTCACCCAGGCTG 2779
Db 20 TTGCTCTGTTACCCAGGCTG 1

RESULT 1454
US-10-005-344-264/c
; Sequence 264, Application US/10005344
; Publication No. US20030203862A1
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia
; APPLICANT: Pamela Nero
; APPLICANT: Mark J. Graham
; APPLICANT: Brett P. Monia
; APPLICANT: Erich Koller
; APPLICANT: Mingyi Chiang
; APPLICANT: Mano Manoharan
; TITLE OF INVENTION: Antisense Modulation of mdm2 expression.
; FILE REFERENCE: ISPH-0622
; CURRENT APPLICATION NUMBER: US/10/005,344
; PRIOR FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: US 09/048,810
; PRIOR FILING DATE: 1998-03-26
; PRIOR APPLICATION NUMBER: US 09/280,805
; PRIOR FILING DATE: 1999-03-26
; NUMBER OF SEQ ID NOS: 379
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 264
; LENGTH: 20

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-005-344-264

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2833 TGATCTCCCACTCAGCCT 2852
||||| ||||||| |||||
Db 20 TGATCCGCCCACTCGGCT 1

RESULT 1455
US-10-189-268-71
; Sequence 71, Application US/10189268
; Publication No. US20040005570A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF GERANYLERANYL DIPHOSPHATE SYNTHASE 1 EXP
; FILE REFERENCE: PTS-0021
; CURRENT APPLICATION NUMBER: US/10/189,268
; CURRENT FILING DATE: 2002-07-02
; NUMBER OF SEQ ID NOS: 131
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-189-268-71

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2766 TGTACCCAGGCTGGAGTGC 2785
||| ||||||| |||||||
Db 1 TGTGTCCCAAGCTGGAGTGC 20

RESULT 1456
US-10-210-723-78
; Sequence 78, Application US/10210723
; Publication No. US20040023382A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPP3CB EXPRESSION
; FILE REFERENCE: PTS-0028
; CURRENT APPLICATION NUMBER: US/10/210,723
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 141
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-723-78

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCTGAGTAGCT 2863
||||| ||||||| |||||||
Db 1 CCTCAGCCTCCCAAGTAGCT 20
```

```
RESULT 1457
US-10-210-723-136/c
; Sequence 136, Application US/10210723
; Publication No. US20040023382A1
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF PPP3CB EXPRESSION
; FILE REFERENCE: PTS-0028
; CURRENT APPLICATION NUMBER: US/10/210,723
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 141
; SEQ ID NO 136
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-723-136

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCTGAGTAGCT 2863
||||| ||||||| |||||||
Db 20 CCTCAGCCTCCCAAGTAGCT 1

RESULT 1458
US-10-728-509-137/c
; Sequence 137, Application US/10728509
; Publication No. US20040077583A1
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF BCL2-ASSOCIATED X PROTEIN EXPRESSION
; FILE REFERENCE: RTS-0185
; CURRENT APPLICATION NUMBER: US/10/728,509
; CURRENT FILING DATE: 2003-12-05
; PRIOR APPLICATION NUMBER: US/09/908,147
; PRIOR FILING DATE: 2001-07-17
; NUMBER OF SEQ ID NOS: 168
; SEQ ID NO 137
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-728-509-137

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 958 ACATGCGACAGACGTGACCAT 977
||||| ||||||| |||||||
Db 20 ACATGCGACAGACGTGACCAT 1

RESULT 1459
US-10-648-593-516/c
; Sequence 516, Application US/10648593
; Publication No. US20040106132A1
; GENERAL INFORMATION:
; APPLICANT: Bristol-Myers Squibb Company
; TITLE OF INVENTION: IDENTIFICATION OF GENES FOR PREDICTING ACTIVITY OF COMPOUNDS THAT
; TITLE OF INVENTION: INTERACT WITH AND/OR MODULATE PROTEIN TYROSINE KINASES AND/OR
; TITLE OF INVENTION: PROTEIN TYROSINE KINASE PATHWAYS IN BREAST CELLS
; FILE REFERENCE: D0273 NP
```

```
; CURRENT APPLICATION NUMBER: US/10/648,593
; CURRENT FILING DATE: 2003-08-26
; PRIOR APPLICATION NUMBER: 60/406,385
; PRIOR FILING DATE: 2002-08-27
; NUMBER OF SEQ ID NOS: 557
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 516
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-648-593-516

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2845 CTCAGCCTCCTGAGTAGCTG 2864
DB 20 CTCAGCCTCCCAAGTAGCTG 1

RESULT 1460
US-10-671-395-515/c
; Sequence 515, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 515
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-515

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2836 TCCTCCCACTCAGCCTCCT 2855
DB 20 TCCTCCCGCCTCAGCCTCCT 1

RESULT 1461
US-10-671-395-597/c
; Sequence 597, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 597
; LENGTH: 20
; TYPE: DNA

; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-597

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2835 ATCCTCCCACTCAGCCTCC 2854
DB 20 ATCTCTCCGCTCAGCCTCC 1

RESULT 1462
US-10-671-395-678/c
; Sequence 678, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; PRIOR FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 678
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-678

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2834 GATCCTCCCACTCAGCCTC 2853
DB 20 GATCTCCGCTCAGCCTC 1

RESULT 1463
US-10-671-395-782/c
; Sequence 782, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 782
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-782

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2834 GATCCTCCCACTCAGCCTC 2853
DB 20 GATCTCCGCTCAGCCTC 1

RESULT 1463
US-10-671-395-782/c
; Sequence 782, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 782
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-782

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2778 TGGAGTGCAGTGGTGCATC 2797
|||||
Db 20 TGGAGTGAAGTGGTACATC 1

RESULT 1464

US-10-671-395-837/c
; Sequence 837, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 837
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-837

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGTGT 2791
|||||
Db 20 CCAAGCTGGAGTGAAGTGT 1

RESULT 1465

US-10-671-395-881/c
; Sequence 881, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 881
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-881

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2776 GCTGGAGTGCAGTGGTGCAC 2795
|||||
Db 20 GCTGGAGTGAAGTGGTACAA 1

RESULT 1466

US-10-671-395-950/c
; Sequence 950, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 950
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-950

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2771 CCCAGCTGGAGTGCAGTGG 2790
|||||
Db 20 CCCAAGCTGGAGTGAAGTGG 1

RESULT 1467

US-10-671-395-1068/c
; Sequence 1068, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1068
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1068

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2777 CTGGAGTGCAGTGGTGCAT 2796
|||||
Db 20 CTGGAGTGAAGTGGTACAT 1

RESULT 1468

US-10-671-395-1191/c
; Sequence 1191, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K

```
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1191
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1191

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTAT 2745
Db 20 GTGTGTGTGTGTGTGTGTTT 1

RESULT 1469
US-10-671-395-1366/c
; Sequence 1366, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1366
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1366

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2730 GTGTGTGTGTGTGTGTGTGT 2749
Db 20 GTATGTGTGTGTGTGTGTTT 1

RESULT 1470
US-10-745-377-27/c
; Sequence 27, Application US/10745377
; Publication No. US20040137423A1
; GENERAL INFORMATION:
; APPLICANT: Pimstone, Simon
; APPLICANT: Hayden, Michael R.
; APPLICANT: Brooks-Wilson, Angela R.
; TITLE OF INVENTION: Compositions and Methods for Modulating
; TITLE OF INVENTION: HDL Cholesterol and Triglyceride Levels
; FILE REFERENCE: 760050-109
; CURRENT APPLICATION NUMBER: US/10/745,377
; CURRENT FILING DATE: 2003-12-23
```

```
; PRIOR APPLICATION NUMBER: 09/654,323
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: US 60/124,702
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: US 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: US 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: US 60/151,977
; PRIOR FILING DATE: 1999-09-01
; PRIOR APPLICATION NUMBER: US 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: US 60/213,958
; PRIOR FILING DATE: 2000-06-23
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: Word for Windows Version 6.0 (ASCII Text)
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: homo sapien
US-10-745-377-27

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2782 GTGCAGTGTGTGCAATCATGG 2801
Db 20 GTGCAGTGTGTGCAATCATGG 1

RESULT 1471
US-10-872-113-27/c
; Sequence 27, Application US/10872113
; Publication No. US20040229275A1
; GENERAL INFORMATION:
; APPLICANT: Hayden, Michael R.
; APPLICANT: Pimstone, Simon
; APPLICANT: Brooks-Wilson, Angela R.
; APPLICANT: Clee, Susanne M.
; TITLE OF INVENTION: Compositions and Methods for Modulating
; TITLE OF INVENTION: HDL Cholesterol and Triglyceride Levels
; FILE REFERENCE: 760050-138
; CURRENT APPLICATION NUMBER: US/10/872,113
; CURRENT FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: 09/654,323
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: US 60/124,702
; PRIOR FILING DATE: 1999-03-15
; PRIOR APPLICATION NUMBER: US 60/138,048
; PRIOR FILING DATE: 1999-06-08
; PRIOR APPLICATION NUMBER: US 60/139,600
; PRIOR FILING DATE: 1999-06-17
; PRIOR APPLICATION NUMBER: US 60/151,977
; PRIOR FILING DATE: 1999-09-01
; PRIOR APPLICATION NUMBER: US 09/526,193
; PRIOR FILING DATE: 2000-03-15
; PRIOR APPLICATION NUMBER: US 60/213,958
; PRIOR FILING DATE: 2000-06-23
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: Word for Windows Version 6.0 (ASCII Text)
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: homo sapien
US-10-872-113-27

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2782 GTGCAGTGTGTGCAATCATGG 2801
```



```
US-10-831-778-560/c
; Sequence 560, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouton, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/WAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 60/179,991
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 560
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-560

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGATTTTTTTTTTTTTT 2917
Db 20 TTTTTTTTTTTTTTTTTT 1

RESULT 1477
US-10-806-573-5
; GENERAL INFORMATION:
; APPLICANT: BLUMENFELD, ANAT; GUSELLA, JAMES F;
; BREAKFIELD, XANDRA, O;
; SLAUGENHAUPT, SUSAN
; TITLE OF INVENTION: DIAGNOSE FAMILIAL DYSAUTONOMIA
; NUMBER OF SEQUENCES: 34
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/806,573
; FILING DATE: 22-Mar-2004
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/480,655
; FILING DATE: 07-JUNE-1995
; APPLICATION NUMBER: 08/049,678
; FILING DATE: 16-APRIL-1993
; APPLICATION NUMBER: US/07/890,719
; FILING DATE: 29-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: KENNETH H. SONNENFELD
; REGISTRATION NUMBER: 33,285
; REFERENCE/DOCKET NUMBER: 1829-4001US1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-451-8513
; TELEFAX: 212-751-6849
; JOURNAL: GENOMICS

US-10-806-573-5
; VOLUME: 12
; ISSUE:
; PAGES: 229-240
; DATE: 1992
; DOCUMENT NUMBER:
; FILING DATE:
; PUBLICATION DATE:
; RELEVANT RESIDUES IN SEQ ID NO:
; SEQUENCE DESCRIPTION: SEQ ID NO: 5:
US-10-806-573-5

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2853 CTTGAGTAGCTGGGACCATA 2872
Db 1 CTTGAGTAGCTGGGACCATA 20

RESULT 1478
US-10-754-478-135/c
; Sequence 135, Application US/10754478
; Publication No. US2005009040A1
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: DETECTION OF NEOPLASIM BY ANALYSIS OF SALIVA
; NUMBER OF SEQUENCES: 195
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 4225 Executive Square, Suite 1400
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/754,478
; FILING DATE: 09-Jan-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,637
; FILING DATE: 10-MAR-1998
; APPLICATION NUMBER: 08/579,233
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/152,313
; FILING DATE: 12-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Halle, Lisa A.
; REGISTRATION NUMBER: 38,347
; REFERENCE/DOCKET NUMBER: 07265/146001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/678-5070
; TELEFAX: 619/678-5099
; INFORMATION FOR SEQ ID NO: 135:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 135:
US-10-754-478-135

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2759 CTCGCTCTGTCCACCCAGGCT 2778
Db 1 CTCGCTCTGTCTCCACCCAGGCT 20
```

Db 20 CTTGCTTTTGTACCCAGGCT 1

RESULT 1479
US-10-754-478-143/c
; Sequence 143, Application US/10754478
; Publication No. US2005009040A1
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: DETECTION OF NEOPLASIM BY ANALYSIS OF SALIVA
; NUMBER OF SEQUENCES: 195
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 4225 Executive Square, Suite 1400
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: FastSeq for Windows Version 2.0b
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10754,478
; FILING DATE: 09-Jan-2004
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,637
; FILING DATE: 10-MAR-1998
; APPLICATION NUMBER: 08/579,233
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/152,313
; FILING DATE: 12-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Haile, Lisa A.
; REGISTRATION NUMBER: 38,347
; REFERENCE/DOCKET NUMBER: 07265/146001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619/678-5070
; TELEFAX: 619/678-5099
; INFORMATION FOR SEQ ID NO: 143:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Genomic DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 143:
US-10-754-478-143

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2776 GCTGGAGTGCAGTGGTGCAA 2795
|||||
Db 20 GCTGGAGTATAGTGGTGCAA 1

RESULT 1480
US-10-728-078-23
; Sequence 23, Application US/10728078
; Publication No. US20050038229A1
; GENERAL INFORMATION:
; APPLICANT: Lipovsek, Dasa
; APPLICANT: Wagner, Richard W
; APPLICANT: Kuimelis, Robert G
; TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
; TITLE OF INVENTION: AND OTHER BINDING PROTEINS
; FILE REFERENCE: 50036/021004
; CURRENT APPLICATION NUMBER: US/10/728,078
; CURRENT FILING DATE: 2003-12-03
; PRIOR APPLICATION NUMBER: US/09/688,566

; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: US 60/111,737
; PRIOR FILING DATE: 1998-12-10
; PRIOR APPLICATION NUMBER: US 09/456,693
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: US 09/515,260
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 202
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-728-078-23

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGTATTTTTTTTTTTTTTT 2917
|||||
Db 1 TTTTITTTTTTTTTTTTTTT 20

RESULT 1481
US-10-601-140A-1
; Sequence 1, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 1
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-601-140A-1

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGTATTTTTTTTTTTTTTT 2917
|||||
Db 1 TTTTITTTTTTTTTTTTTTT 20

RESULT 1482
US-10-601-140A-2
; Sequence 2, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45

```
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-2
```

```
Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 2898 TTGATTTTTTTTTTTTTT 2917
||| ||||| ||||| ||||| |||||
Db 1 TTTTTTTTTTTTTTTTTT 20
```

```
RESULT 1483
US-10-601-140A-3
; Sequence 3, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
```

```
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 3
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-3
```

```
Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
Qy 2898 TTGATTTTTTTTTTTTTT 2917
||| ||||| ||||| ||||| |||||
Db 1 TTTTTTTTTTTTTTTTTT 20
```

```
RESULT 1484
US-10-601-140A-4
; Sequence 4, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (10)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (16)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-4
```

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGTGATTTTTTTTTTTTTTTT 2917
||| ||||| ||||| ||||| |||||
Db 1 TTTT TTTT TTTT TTTT TTTT 20

RESULT 1485
US-10-601-140A-6
; Sequence 6, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-6

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGTGATTTTTTTTTTTTTTTT 2917
||| ||||| ||||| ||||| |||||
Db 1 TTTT TTTT TTTT TTTT TTTT 20

RESULT 1486
US-10-601-140A-7
; Sequence 7, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)

; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (14)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-7

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGTGATTTTTTTTTTTTTTTT 2917
||| ||||| ||||| ||||| |||||
Db 1 TTTT TTTT TTTT TTTT TTTT 20

RESULT 1487
US-10-601-140A-8
; Sequence 8, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; NAME/KEY: modified_base
; LOCATION: (1)..
; OTHER INFORMATION: LNA monomer
US-10-601-140A-8

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGTGATTTTTTTTTTTTTTTT 2917
||| |||||
Db 1 TTTTGTGTGTGTGTGTGTGT 20

RESULT 1488

US-10-601-140A-9
; Sequence 9, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 9
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (3)..(4)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (8)..(9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (13)..(14)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (18)..(19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-9

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGTGATTTTTTTTTTTTTTTT 2917
||| |||||
Db 1 TTTTGTGTGTGTGTGTGTGT 20

RESULT 1489

US-10-601-140A-10
; Sequence 10, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 10
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; NAME/KEY: modified_base
; LOCATION: (3)..(5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (10)..(12)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)..(19)
; OTHER INFORMATION: LNA monomer
US-10-601-140A-10

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGTGATTTTTTTTTTTTTTTT 2917
||| |||||
Db 1 TTTTGTGTGTGTGTGTGTGT 20

RESULT 1490

US-10-601-140A-23
; Sequence 23, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 23
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide capture probe
; NAME/KEY: modified_base
; LOCATION: (1)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (3)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (5)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (7)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (9)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base

; LOCATION: (11)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (15)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (17)
; OTHER INFORMATION: LNA monomer
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: (19)
; OTHER INFORMATION: LNA monomer
; US-10-601-140A-23

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGATTTTTTTTTTTTTTTT 2917
||| |||||
Db 1 TTTTTTTTTTTTTTTTTT 20

RESULT 1491

US-10-601-140A-34/c
; Sequence 34, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide linker
US-10-601-140A-34

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGATTTTTTTTTTTTTTTT 2917
||| |||||
Db 20 TTTTTTTTTTTTTTTTTT 1

RESULT 1492

US-10-601-140A-40
; Sequence 40, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide linker
US-10-601-140A-40

; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-40

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGATTTTTTTTTTTTTTTT 2917
||| |||||
Db 1 TTTTTTTTTTTTTTTTTT 20

RESULT 1493

US-10-601-140A-44/c
; Sequence 44, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; PRIOR FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 44
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
US-10-601-140A-44

Query Match 0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2898 TTGATTTTTTTTTTTTTTTT 2917
||| |||||
Db 20 TTTTTTTTTTTTTTTTTT 1

RESULT 1494

US-10-876-086-49
; Sequence 49, Application US/10876086
; Publication No. US20050066389A1
; GENERAL INFORMATION:
; APPLICANT: Gallie, Daniel R.
; APPLICANT: Young, Todd E.
; APPLICANT: The Regents of the University of California
; TITLE OF INVENTION: Genes Which Produce Staygreen Characteristics in Maize
; FILE REFERENCE: 023070-137010US
; CURRENT APPLICATION NUMBER: US/10/876,086
; CURRENT FILING DATE: 2004-06-23
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
US-10-876-086-49

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligo-dt(20)
US-10-876-086-49

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  2898 TTGTGATTTTTCCTTTTTCCTTTT 2917
Db   1 TTTTTCCTTTTTCCTTTTTCCTTTT 20

RESULT 1495
US-10-831-901A-29732
; Sequence 29732, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29732
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29732

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  2898 TTGTGATTTTTCCTTTTTCCTTTT 2917
Db   1 TTTTTCCTTTTTCCTTTTTCCTTTT 20

RESULT 1496
US-10-831-901A-29733
; Sequence 29733, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
```

```
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29733
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29733

Query Match          0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 9.8e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY  2898 TTGTGATTTTTCCTTTTTCCTTTT 2917
Db   1 TTTTTCCTTTTTCCTTTTTCCTTTT 20

RESULT 1497
US-10-831-901A-29734
; Sequence 29734, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL000808US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
```

RESULT 1499

```

; FEATURE:
; OTHER INFORMATION: detection probe
; FEATURE:

```


ATTORNEY/AGENT INFORMATION:
NAME: Grady J. Frenchick
REGISTRATION NUMBER: 29,018
REFERENCE/DOCKET NUMBER: 16026.9180
TELECOMMUNICATION INFORMATION:
TELEPHONE: (608) 257-3501
TELEFAX: (608) 257-2275
INFORMATION FOR SEQ ID NO: 67
SEQUENCE CHARACTERISTICS:
LENGTH: 21
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
SEQUENCE DESCRIPTION: SEQ ID NO: 67
US-09-784-423-67

Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 9.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTGACCCAGGCTG 2779
| | | | | | | | | | | | | | | | | | | | | |
Db 20 TTGCTCTGTGACCAAGCTG 1

RESULT 1505
US-09-964-059B-71
Sequence 71, Application US/09964059B
Publication No. US20030171875A1
GENERAL INFORMATION:
APPLICANT: Frudakis, Tony
TITLE OF INVENTION: Efficient Methods and Apparatus for High-Throughput Processing of
FILE REFERENCE: 0201-0001
CURRENT APPLICATION NUMBER: US/09/964,059B
PRIOR FILING DATE: 2002-12-23
PRIOR APPLICATION NUMBER: US 60/274,686
PRIOR FILING DATE: 2000-03-08
NUMBER OF SEQ ID NOS: 239
SEQ ID NO 71
LENGTH: 21
TYPE: DNA
ORGANISM: Homo Sapiens
US-09-964-059B-71

Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 9.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2779 GGAGTGCACTGGTGCAATCA 2798
| | | | | | | | | | | | | | | | | | | | | |
Db 1 GGAGTGCACTGGTGCAATCA 20

RESULT 1506
US-10-642-763-5/c
Sequence 5, Application US/10642763
Publication No. US20040076640A1
GENERAL INFORMATION:
APPLICANT: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD)
TITLE OF INVENTION: Immunogenic Compositions for Use as Vaccines
FILE REFERENCE: IRD - VEAS
CURRENT APPLICATION NUMBER: US/10/642,763
CURRENT FILING DATE: 2003-08-19
PRIOR APPLICATION NUMBER: US/09/913,525
PRIOR FILING DATE: 2001-08-15
PRIOR APPLICATION NUMBER: 99/01794
PRIOR FILING DATE: 1999-02-15
NUMBER OF SEQ ID NOS: 22
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 5
LENGTH: 21
TYPE: DNA

ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Bac-CCRS
US-10-642-763-5

Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 9.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1283 GCCCAGAAATTCACAGCAG 1302
| | | | | | | | | | | | | | | | | | | | | |
Db 21 GCCCAGAGAAATTCACACAG 2

RESULT 1507
US-10-751-736-4631
Sequence 4631, Application US/10751736
Publication No. US20040265230A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Martinez, Robert
APPLICANT: Brown, Eugene
APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
FILE REFERENCE: AM100927 (031896-002000)
CURRENT APPLICATION NUMBER: US/10/751,736
CURRENT FILING DATE: 2003-01-06
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
PRIOR FILING DATE: 2003-01-06
NUMBER OF SEQ ID NOS: 54873
SOFTWARE: PatentIn version 3.2
SEQ ID NO 4631
LENGTH: 21
TYPE: RNA
ORGANISM: RNAi
US-10-751-736-4631

Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 65.0%; Pred. No. 9.3e+02;
Matches 13; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 2844 CCTCAGCCTCTCTGAGTAGCT 2863
| | | | | | | | | | | | | | | | | | | | | |
Db 1 CUUAGCCUCCUGAGUAGCU 20

RESULT 1508
US-10-751-736-23527/c
Sequence 23527, Application US/10751736
Publication No. US20040265230A1
GENERAL INFORMATION:
APPLICANT: Wyeth
APPLICANT: Martinez, Robert
APPLICANT: Brown, Eugene
APPLICANT: Liu, Wei
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
FILE REFERENCE: AM100927 (031896-002000)
CURRENT APPLICATION NUMBER: US/10/751,736
CURRENT FILING DATE: 2003-01-06
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
PRIOR FILING DATE: 2003-01-06
NUMBER OF SEQ ID NOS: 54873
SOFTWARE: PatentIn version 3.2
SEQ ID NO 23527
LENGTH: 21
TYPE: DNA
ORGANISM: homo sapiens
US-10-751-736-23527

Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 9.3e+02;

```
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2184 TTTATTGAGTGCTTTTATG 2203
Db 20 TTTATTGAGTGCTGCTCTG 1

RESULT 1509
US-10-751-736-23854/c
; Sequence 23854, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23854
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-23854

Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 9.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2181 CTATTATTGAGTGCTTTT 2200
Db 21 CTGTTATTGAGTGCTGTGT 2

RESULT 1510
US-10-751-736-38571/c
; Sequence 38571, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38571
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-38571

Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 9.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2733 TGTGTGTGTGTATGTGTAGA 2752
Db 21 TGTGTGTGTGTGTGTCTAGA 2
```

```
RESULT 1511
US-10-751-736-38782
; Sequence 38782, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38782
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-38782

Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 9.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2722 ATCCGCGTGTGTGTGTGTGT 2741
Db 2 ATCTGTGTGTGTGTGTGTGT 21

RESULT 1512
US-10-751-736-38784/c
; Sequence 38784, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38784
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-38784

Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 9.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2731 TGTGTGTGTGTGTATGTGTA 2750
Db 21 TGTGTGTGTGTGTGTGTCTA 2

RESULT 1513
US-10-751-736-52502
; Sequence 52502, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
```



```
; TITLE OF INVENTION: From Said Libraries
; FILE REFERENCE: 4121-162
; CURRENT APPLICATION NUMBER: US/10/491,653
; CURRENT FILING DATE: 2004-04-01
; PRIOR APPLICATION NUMBER: EP 01123596.7
; PRIOR FILING DATE: 2001-10-01
; PRIOR APPLICATION NUMBER: PCT/EP02/10852
; PRIOR FILING DATE: 2002-09-27
; NUMBER OF SEQ ID NOS: 151
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-491-653-40
```

```
Query Match          0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 9.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1766 GGACGCCGAGGACGAGGCA 1785
Db 21 GGACGCTGAGGAGAGGGCA 2
```

```
RESULT 1518
US-10-847-918-11027/c
; Sequence 11027, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
; PRIOR APPLICATION NUMBER: US 60/471,729
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 14937
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11027
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-847-918-11027
```

```
Query Match          0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 9.3e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1585 AAGAAATACAGACTCAACA 1604
Db 20 AAGAAATACAGACTCCAGCA 1
```

```
RESULT 1519
US-09-728-552-2/c
; Sequence 2, Application US/09728552
; Publication No. US20030096398A1
; GENERAL INFORMATION:
; APPLICANT: Choo, Kong-Hong Andy
; APPLICANT: Du Sart, Desirée
; APPLICANT: Cancilla, Michael R.
; TITLE OF INVENTION: A NOVEL NUCLEIC ACID MOLECULE
; FILE REFERENCE: Davies Col
; CURRENT APPLICATION NUMBER: US/09/728,552
; CURRENT FILING DATE: 2000-12-02
; PRIOR APPLICATION NUMBER: 09/078,294
```

```
; PRIOR FILING DATE: 1998-05-13
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2
; LENGTH: 19
; TYPE: DNA
; ORGANISM: DNA primer
US-09-728-552-2
```

```
Query Match          0.6%; Score 16.6; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1.1e+03;
Matches 16; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2773 CAGCGTGCAGTGCAGTGGT 2791
Db 19 CAGCGTGCAGTGCARTGGY 1
```

```
RESULT 1520
US-10-073-718-15/c
; Sequence 15, Application US/10073718
; Publication No. US2002017150A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Bennett, Clarence Frank
; TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake and Other Properties
; FILE REFERENCE: ISIS-5024
; CURRENT APPLICATION NUMBER: US/10/073,718
; CURRENT FILING DATE: 2002-05-08
; PRIOR APPLICATION NUMBER: 09/633659
; PRIOR FILING DATE: 2000-08-07
; PRIOR APPLICATION NUMBER: 6153737
; PRIOR FILING DATE: 2000-11-28
; PRIOR APPLICATION NUMBER: 08/211882
; PRIOR FILING DATE: 1994-04-22
; PRIOR APPLICATION NUMBER: PCT/US92/09196
; PRIOR FILING DATE: 1992-10-23
; PRIOR APPLICATION NUMBER: 07/782374
; PRIOR FILING DATE: 1991-10-24
; PRIOR APPLICATION NUMBER: 07/566977
; PRIOR FILING DATE: 1990-08-13
; PRIOR APPLICATION NUMBER: PCT/US91/000243
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 08/463358
; PRIOR FILING DATE: 1990-01-11
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. US2002017150A1el Sequence
US-10-073-718-15
```

```
Query Match          0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.2e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTACGGCTCCCA 1
```

```
RESULT 1521
US-09-735-363A-17
; Sequence 17, Application US/09735363A
; Patent No. US20010041681A1
; GENERAL INFORMATION:
; APPLICANT: Fillion, Mario
; APPLICANT: Phillip, Nigel
; TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
```

FILE REFERENCE: 02811-0181
CURRENT APPLICATION NUMBER: US/09/735,363A
CURRENT FILING DATE: 2000-12-12
PRIOR APPLICATION NUMBER: 60/170,325
PRIOR FILING DATE: 1999-12-13
PRIOR APPLICATION NUMBER: 60/228,925
PRIOR FILING DATE: 2000-08-29
NUMBER OF SEQ ID NOS: 87
SOFTWARE: PatentIn version 3.0
SEQ ID NO 17
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-17

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.2e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTG 2746
Db 1 TGTGTGTGTGTGTGTGTG 18

RESULT 1522

US-09-735-363A-18
Sequence 18, Application US/09735363A
Patent No. US20010041681A1
GENERAL INFORMATION:
APPLICANT: Phillip, Nigel
TITLE OF INVENTION: Therapeutically Useful Synthetic Oligonucleotides
FILE REFERENCE: 02811-0181
CURRENT APPLICATION NUMBER: US/09/735,363A
CURRENT FILING DATE: 2000-12-12
PRIOR APPLICATION NUMBER: 60/170,325
PRIOR FILING DATE: 1999-12-13
PRIOR APPLICATION NUMBER: 60/228,925
PRIOR FILING DATE: 2000-08-29
NUMBER OF SEQ ID NOS: 87
SOFTWARE: PatentIn version 3.0
SEQ ID NO 18
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide
US-09-735-363A-18

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.2e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTG 2743
Db 1 GTGTGTGTGTGTGTGTGTG 18

RESULT 1523

US-09-896-650A-28
Sequence 28, Application US/09896650A
Patent No. US20020146704A1
GENERAL INFORMATION:
APPLICANT: Head, Steven
APPLICANT: Boyce-Jacino, Michael
APPLICANT: Karn, Jonathan
APPLICANT: Golet, Philip
TITLE OF INVENTION: De No. US20020146704A1 or "Universal" Sequencing Array
FILE REFERENCE: 13019-2
CURRENT APPLICATION NUMBER: US/09/896,650A
CURRENT FILING DATE: 2001-06-29

NUMBER OF SEQ ID NOS: 31
SOFTWARE: PatentIn version 3.1
SEQ ID NO 28
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Reagent Sequence
US-09-896-650A-28

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.2e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTG 2746
Db 1 TGTGTGTGTGTGTGTGTG 18

RESULT 1524

US-09-263-959-1276/c
Sequence 1276, Application US/09263959
Patent No. US20020150891A1
GENERAL INFORMATION:
APPLICANT: Hood, Leroy E.
APPLICANT: Koop, Ben F.
TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
NUMBER OF SEQUENCES: 1279
CORRESPONDENCE ADDRESS:
ADDRESSEE: Seed and Berry LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: US
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC Compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/263,959
FILING DATE: 05-MAR-1999
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Mcmasters, David D.
REGISTRATION NUMBER: 33,963
REFERENCE/DOCKET NUMBER: 920010.426C2
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 1276:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-263-959-1276

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.2e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2769 CACCCAGCGTGGAGTGCA 2786
Db 18 CATCCAGCGTGGAGTGCA 1

RESULT 1525

US-10-011-204-1/c
Sequence 1, Application US/10011204
Publication No. US20020182617A1

```
; GENERAL INFORMATION:
; APPLICANT: EXKINS, Roger P
; TITLE OF INVENTION: Binding assay using binding agents with tail groups
; FILE REFERENCE: 0380-P01180US0
; CURRENT APPLICATION NUMBER: US/10/011,204
; PRIOR FILING DATE: 2001-11-08
; PRIOR APPLICATION NUMBER: US/08/700,530
; PRIOR FILING DATE: 1996-10-23
; PRIOR APPLICATION NUMBER: PCT/GB95/00521
; PRIOR FILING DATE: 1995-03-10
; PRIOR APPLICATION NUMBER: GB 9404709.9
; PRIOR FILING DATE: 1994-03-11
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Oligonucleotide
US-10-011-204-1

Query Match          0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.2e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTG 2746
Db 18 TGTGTGTGTGTGTGTGTG 1

RESULT 1526
US-10-011-204-2
; Sequence 2, Application US/10011204
; Publication No. US20020182617A1
; GENERAL INFORMATION:
; APPLICANT: EXKINS, Roger P
; TITLE OF INVENTION: Binding assay using binding agents with tail groups
; FILE REFERENCE: 0380-P01180US0
; CURRENT APPLICATION NUMBER: US/10/011,204
; PRIOR FILING DATE: 2001-11-08
; PRIOR APPLICATION NUMBER: US/08/700,530
; PRIOR FILING DATE: 1996-10-23
; PRIOR APPLICATION NUMBER: PCT/GB95/00521
; PRIOR FILING DATE: 1995-03-10
; PRIOR APPLICATION NUMBER: GB 9404709.9
; PRIOR FILING DATE: 1994-03-11
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: Oligonucleotide
US-10-011-204-2

Query Match          0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.2e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2726 GCCTGTGTGTGTGTGTGTG 2743
Db 1 GTGTGTGTGTGTGTGTGTG 18

RESULT 1527
US-10-154-993-15/c
; Sequence 15, Application US/10154993
; Publication No. US20030064492A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake
; TITLE OF INVENTION: And
; FILE REFERENCE: ISIS4470
; CURRENT APPLICATION NUMBER: US/10/154,993
; CURRENT FILING DATE: 2002-05-23
; PRIOR APPLICATION NUMBER: US/09/633,659
; PRIOR FILING DATE: 2000-08-07
; PRIOR APPLICATION NUMBER: 08/211,882
; PRIOR FILING DATE: 1994-04-22
; PRIOR APPLICATION NUMBER: 07/782,374
; PRIOR FILING DATE: 1991-10-24
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 15
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Novel Sequence
US-10-154-993-15

Query Match          0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 1.2e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 50 GCCTCGCTATGGCTCCCA 67
Db 18 GCCTCGCTACGGCTCCCA 1

RESULT 1528
US-10-284-742-15/c
; Sequence 15, Application US/10284742
; Publication No. US20030175751A1
; GENERAL INFORMATION:
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Cook, Phillip Dan
; TITLE OF INVENTION: Derivatized Oligonucleotides Having Improved Uptake And Other Pro
; FILE REFERENCE: ISIS5109
; CURRENT APPLICATION NUMBER: US/10/284,742
; CURRENT FILING DATE: 2003-01-17
; PRIOR APPLICATION NUMBER: 10/154,993
; PRIOR FILING DATE: 2002-05-23
; PRIOR APPLICATION NUMBER: 09/633,659
; PRIOR FILING DATE: 2000-08-07
; PRIOR APPLICATION NUMBER: 08/211,882
; PRIOR FILING DATE: 1994-04-22
; PRIOR APPLICATION NUMBER: PCT/US92/09196
; PRIOR FILING DATE: 1992-10-23
; PRIOR APPLICATION NUMBER: 07/782,374
; PRIOR FILING DATE: 1991-10-24
; PRIOR APPLICATION NUMBER: PCT/US91/00243
; PRIOR FILING DATE: 1991-01-11
; PRIOR APPLICATION NUMBER: 07/463,358
; PRIOR FILING DATE: 1990-01-11
; PRIOR APPLICATION NUMBER: 07/566,977
; PRIOR FILING DATE: 1990-08-13
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 15
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic construct
; NAME/KEY: misc feature
; LOCATION: (1)..(18)
```

```

US-10-678-160A-52/c
; Sequence 52, Application US/10678160A
; Publication No. US20040247555A1
; GENERAL INFORMATION:
; APPLICANT: Sprecher, Eli
; APPLICANT: Bergman, Reuven
; TITLE OF INVENTION: METHODS OF AND C
; TITLE OF INVENTION: P-CADHERIN MODUL
; FILE REFERENCE: 26465
; CURRENT APPLICATION NUMBER: US/10/678
; CURRENT FILING DATE: 2003-10-06
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 52
; LENGTH: 19
; TYPE: DNA

```



```
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide
US-10-678-160A-52

Query Match          0.5%; Score 16.4; DB 1; Length 19;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCCACCCAG 2775
Db 18 TCTCACTCTGTCCACCCAG 1

RESULT 1533
US-09-752-983-256/c
; Sequence 256, Application US/09752983
; Patent No. US20010016575A1
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM PC
; OPERATING SYSTEM: WINDOWS 95
; SOFTWARE: WORDPERFECT 6.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/752,983
; FILING DATE: 02-Jan-2001
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/280,805
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Licata, Jane Massey
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0346
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-810-1515
; TELEFAX: 609-810-1454
; INFORMATION FOR SEQ ID NO: 256:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
US-09-752-983-256

Query Match          0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2882 CACCACACCTGGCAATTT 2899
Db 18 CACCACACCTGGCTAATT 1

RESULT 1534
US-09-454-394-34
; Sequence 34, Application US/09454394
; Patent No. US20020094525A1
; GENERAL INFORMATION:
; APPLICANT: Tina McIntosh
; APPLICANT: Steven Head
; APPLICANT: Philip Goelet
; APPLICANT: Michael T. Boyce-Jacino
; TITLE OF INVENTION: Methods for the Detection of Multiple
; FILE REFERENCE: 04990.0029
; CURRENT APPLICATION NUMBER: US/09/454,394
; CURRENT FILING DATE: 1999-12-03
; EARLIER APPLICATION NUMBER: 08/216,538
; EARLIER FILING DATE: 1994-03-23
; EARLIER APPLICATION NUMBER: 08/145,145
; EARLIER FILING DATE: 1993-11-03
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Equus caballus
US-09-454-394-34

Query Match          0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2731 TGTGTGTGTGTGTATGTG 2748
Db 20 TGTGTGTGTGTGTATTTG 3

RESULT 1535
US-09-454-394-35/c
; Sequence 35, Application US/09454394
; Patent No. US20020094525A1
; GENERAL INFORMATION:
; APPLICANT: Tina McIntosh
; APPLICANT: Steven Head
; APPLICANT: Philip Goelet
; APPLICANT: Michael T. Boyce-Jacino
; TITLE OF INVENTION: Methods for the Detection of Multiple
; FILE REFERENCE: 04990.0029
; CURRENT APPLICATION NUMBER: US/09/454,394
; CURRENT FILING DATE: 1999-12-03
; EARLIER APPLICATION NUMBER: 08/216,538
; EARLIER FILING DATE: 1994-03-23
; EARLIER APPLICATION NUMBER: 08/145,145
; EARLIER FILING DATE: 1993-11-03
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Equus caballus
US-09-454-394-35

Query Match          0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2731 TGTGTGTGTGTGTATGTG 2748
Db 20 TGTGTGTGTGTGTATTTG 3

RESULT 1536
US-09-771-933-125/c
; Sequence 125, Application US/09771933
; Publication NO. US20030023387A1
; GENERAL INFORMATION:
; APPLICANT: Gill-Garrison, Rosalynn D.
; APPLICANT: Martin, Christopher J.
; APPLICANT: Sanchez-Felix, Manuel V
```

;; TITLE OF INVENTION: Computer-assisted Means for Assessing Lifestyle Risk

;; FILE OF INVENTION: Factors

;; FILE REFERENCE: 620-130

;; CURRENT APPLICATION NUMBER: US/09/771,933

;; CURRENT FILING DATE: 2001-01-30

;; NUMBER OF SEQ ID NOS: 205

;; SOFTWARE: Patentin Ver. 2.1

;; SEQ ID NO 125

;; LENGTH: 20

;; TYPE: DNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Description of Artificial Sequence: Primer

US-09-771-933-125

Query Match

Best Local Similarity 0.5%; Score 16.4; DB 1; Length 20;

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2836 TCTCCACCTCAGCCTC 2853

Db 20 TTCTCCACCTCAGCCTC 3

RESULT 1537

US-09-865-866-146/c

;; Sequence 146, Application US/09865866

;; Publication No. US20030045487A1

;; GENERAL INFORMATION:

;; APPLICANT: C. Frank Bennett

;; APPLICANT: Jacqueline Wyatt

;; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPASE A2, GROUP IIA (SYNOVIAL) EX

;; FILE REFERENCE: RTS-0221

;; CURRENT APPLICATION NUMBER: US/09/865,866

;; CURRENT FILING DATE: 2001-05-25

;; NUMBER OF SEQ ID NOS: 173

;; SEQ ID NO 146

;; LENGTH: 20

;; TYPE: DNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Antisense Oligonucleotide

US-09-865-866-146

Query Match

Best Local Similarity 0.5%; Score 16.4; DB 1; Length 20;

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1060 CACCCTAGAGCAAGGTG 1077

Db 20 CACCCTAGAGCAAGGTG 3

RESULT 1538

US-09-920-671-82/c

;; Sequence 82, Application US/09920671

;; Publication No. US20030083283A1

;; GENERAL INFORMATION:

;; APPLICANT: C. Frank Bennett

;; APPLICANT: Susan M. Freier

;; TITLE OF INVENTION: ANTISENSE MODULATION OF COREST EXPRESSION

;; FILE REFERENCE: RTS-0297

;; CURRENT APPLICATION NUMBER: US/09/920,671

;; CURRENT FILING DATE: 2001-08-01

;; NUMBER OF SEQ ID NOS: 91

;; SEQ ID NO 82

;; LENGTH: 20

;; TYPE: DNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Antisense Oligonucleotide

US-09-920-671-82

Query Match

Best Local Similarity 0.5%; Score 16.4; DB 1; Length 20;

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2850 CCTCTGAGTAGCTGGGA 2867

Db 20 CCTCCGAGTAGCTGGGA 3

RESULT 1539

US-09-993-731-23

;; Sequence 23, Application US/09993731

;; Publication No. US20030105040A1

;; GENERAL INFORMATION:

;; APPLICANT: Brett P. Monia

;; APPLICANT: Andrew T. Watt

;; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B-R EXPRESSION

;; FILE REFERENCE: RTS-0302

;; CURRENT APPLICATION NUMBER: US/09/993,731

;; CURRENT FILING DATE: 2001-11-13

;; NUMBER OF SEQ ID NOS: 89

;; SEQ ID NO 23

;; LENGTH: 20

;; TYPE: DNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Antisense Oligonucleotide

US-09-993-731-23

Query Match

Best Local Similarity 0.5%; Score 16.4; DB 1; Length 20;

Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2773 CAGGCTGGAGTCAGTGG 2790

Db 2 CAGGTTGGAGTCAGTGG 19

RESULT 1540

US-09-846-863-34

;; Sequence 34, Application US/09846863

;; Publication No. US20030170624A1

;; GENERAL INFORMATION:

;; APPLICANT: GOBLET, PHILIP

;; APPLICANT: KNAPP, MICHAEL R.

;; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS AND

;; CORRESPONDENCE ADDRESS: THEIR USE IN GENETIC ANALYSIS

;; NUMBER OF SEQUENCES: 95

;; ADDRESS: HOWREY & SIMON

;; STREET: 1299 PENNSYLVANIA AVENUE, N.W.

;; CITY: WASHINGTON

;; STATE: D.C.

;; COUNTRY: US

;; ZIP: 20004

;; MEDIUM TYPE: Floppy disk

;; COMPUTER: IBM PC compatible

;; OPERATING SYSTEM: PC-DOS/MS-DOS

;; SOFTWARE: PatentIn Release #1.0, Version #1.25

;; CURRENT APPLICATION DATA:

;; APPLICATION NUMBER: US/09/846,863

;; FILING DATE: 01-May-2001

;; CLASSIFICATION: <Unknown>

;; PRIORITY APPLICATION DATA:

;; APPLICATION NUMBER: 08/216,538

;; FILING DATE: <Unknown>

;; ATTORNEY/AGENT INFORMATION:

;; NAME: AUERBACH, JEFFREY I

;; REGISTRATION NUMBER: 32,680

;; REFERENCE/DOCKET NUMBER: 683-104-CIP

;; TELECOMMUNICATION INFORMATION:

;; TELEPHONE: (202) 383-7451

```
;/ TELEFAX: (202) 383-6610
;/ INFORMATION FOR SEQ ID NO: 34:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 20 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: DNA (genomic)
;/ HYPOTHETICAL: NO
;/ ANTI-SENSE: NO
;/ ORIGINAL SOURCE:
;/ ORGANISM: Equus caballus
;/ IMMEDIATE SOURCE:
;/ CLONE: 595-1
;/ SEQUENCE DESCRIPTION: SEQ ID NO: 34:
```

```
US-09-846-863-34
```

```
Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2731 TGTGTGTGTGTGTATGTG 2748
Db 1 TGTGTGTGTGTATTTG 18
```

RESULT 1541

```
US-09-846-863-35/c
; Sequence 35, Application US/09846863
; Publication No. US20030170624A1
; GENERAL INFORMATION:
```

```
; APPLICANT: GOLETT, PHILIP
```

```
; KNAPP, MICHAEL R.
```

```
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS AND
; THEIR USE IN GENETIC ANALYSIS
```

```
; NUMBER OF SEQUENCES: 95
```

```
; CORRESPONDENCE ADDRESS:
```

```
; ADDRESSEE: HOWREY & SIMON
```

```
; STREET: 1299 PENNSYLVANIA AVENUE, N.W.
```

```
; CITY: WASHINGTON
```

```
; STATE: D.C.
```

```
; COUNTRY: US
```

```
; ZIP: 20004
```

```
; COMPUTER READABLE FORM:
```

```
; MEDIUM TYPE: Floppy disk
```

```
; COMPUTER: IBM PC compatible
```

```
; OPERATING SYSTEM: PC-DOS/MS-DOS
```

```
; SOFTWARE: PatentIn Release #1.0, Version #1.25
```

```
; CURRENT APPLICATION DATA:
```

```
; APPLICATION NUMBER: US/09/846,863
```

```
; FILING DATE: 01-May-2001
```

```
; CLASSIFICATION: <Unknown>
```

```
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: 08/216,538
```

```
; FILING DATE: <Unknown>
```

```
; ATTORNEY/AGENT INFORMATION:
```

```
; NAME: AUERBACH, JEFFREY I
```

```
; REGISTRATION NUMBER: 32,680
```

```
; REFERENCE/DOCKET NUMBER: 683-104-CIP
```

```
; TELECOMMUNICATION INFORMATION:
```

```
; TELEPHONE: (202) 383-7451
```

```
; TELEFAX: (202) 383-6610
```

```
; INFORMATION FOR SEQ ID NO: 35:
```

```
; SEQUENCE CHARACTERISTICS:
```

```
; LENGTH: 20 base pairs
```

```
; TYPE: nucleic acid
```

```
; STRANDEDNESS: single
```

```
; TOPOLOGY: linear
```

```
; MOLECULE TYPE: DNA (genomic)
```

```
; HYPOTHETICAL: NO
```

```
; ANTI-SENSE: NO
```

```
; ORIGINAL SOURCE:
```

```
; ORGANISM: Equus caballus
```

```
;/ IMMEDIATE SOURCE:
;/ CLONE: 595-1
;/ SEQUENCE DESCRIPTION: SEQ ID NO: 35:
```

```
US-09-846-863-35
```

```
Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2731 TGTGTGTGTGTGTATGTG 2748
Db 20 TGTGTGTGTGTGTATTTG 3
```

RESULT 1542

```
US-10-085-906-323/c
```

```
; Sequence 323, Application US/10085906
```

```
; Publication No. US20030054371A1
```

```
; GENERAL INFORMATION:
```

```
; APPLICANT: Ying, Vincent
```

```
; APPLICANT: Wu, Paul
```

```
; APPLICANT: Gray, Gary S.
```

```
; TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
```

```
; FILE REFERENCE: GNN-5343CP2
```

```
; CURRENT APPLICATION NUMBER: US/10/085,906
```

```
; CURRENT FILING DATE: 2002-02-27
```

```
; PRIOR APPLICATION NUMBER: US 60/126,215
```

```
; PRIOR FILING DATE: 1999-03-25
```

```
; PRIOR APPLICATION NUMBER: US 09/534,061
```

```
; PRIOR FILING DATE: 2000-03-24
```

```
; PRIOR APPLICATION NUMBER: PCT/US00/07938
```

```
; PRIOR FILING DATE: 2000-03-24
```

```
; NUMBER OF SEQ ID NOS: 545
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 323
```

```
; LENGTH: 20
```

```
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
```

```
US-10-085-906-323
```

```
Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2769 CACCCAGGCTGGAGTGCA 2786
Db 20 CGCCCGAGGCTGGAGTGCA 3
```

RESULT 1543

```
US-10-005-344-256/c
```

```
; Sequence 256, Application US/10005344
```

```
; Publication No. US20030203862A1
```

```
; GENERAL INFORMATION:
```

```
; APPLICANT: Loren J. Miraglia
```

```
; APPLICANT: Pamela Nero
```

```
; APPLICANT: Mark J. Graham
```

```
; APPLICANT: Brett P. Monia
```

```
; APPLICANT: Erich Koller
```

```
; APPLICANT: Mingyi Chiang
```

```
; APPLICANT: Mano Manoharan
```

```
; TITLE OF INVENTION: Antisense Modulation of mdm2 expression.
```

```
; FILE REFERENCE: ISPH-0622
```

```
; CURRENT APPLICATION NUMBER: US/10/005,344
```

```
; CURRENT FILING DATE: 2001-12-04
```

```
; PRIOR APPLICATION NUMBER: US 09/048,810
```

```
; PRIOR FILING DATE: 1998-03-26
```

```
; PRIOR APPLICATION NUMBER: US 09/280,805
```

```
; PRIOR FILING DATE: 1999-03-26
```

```
; NUMBER OF SEQ ID NOS: 379
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 256
```

; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-005-344-256

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2882 CACCACACTGGCAATT 2899
Db 18 CACCACACTGGCTAATT 1

RESULT 1544
US-10-148-355A-64/c
; Sequence 64, Application US/10148355A
; Publication No. US20030207831A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; APPLICANT: ISIS PHARMACEUTICALS, INC.
; TITLE OF INVENTION: ANTISENSE MODULATION OF TELOMERIC REPEAT BINDING FACTOR 2
; FILE REFERENCE: RTSP-0082
; CURRENT APPLICATION NUMBER: US/10/148,355A
; CURRENT FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: 09/467,642
; PRIOR FILING DATE: 1999-12-17
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-148-355A-64

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2775 GGCTGAGTGCAGTGTGTG 2792
Db 20 GGCTGAGTGCAGTGTGCG 3

RESULT 1545
US-10-317-277A-85
; Sequence 85, Application US/10317277A
; Publication No. US20040110159A1
; GENERAL INFORMATION:
; APPLICANT: Dobie, Kenneth W.
; TITLE OF INVENTION: Modulation of Estrogen-Responsive Finger Protein Expression
; FILE REFERENCE: RTS-0473
; CURRENT APPLICATION NUMBER: US/10/317,277A
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 168
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-317-277A-85

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGAAGGCCACCCACAG 1146
Db 1 CTGAAGGCTACCCACAG 18

RESULT 1546
US-10-317-277A-160/c
; Sequence 160, Application US/10317277A
; Publication No. US20040110159A1
; GENERAL INFORMATION:
; APPLICANT: Dobie, Kenneth W.
; TITLE OF INVENTION: Modulation of Estrogen-Responsive Finger Protein Expression
; FILE REFERENCE: RTS-0473
; CURRENT APPLICATION NUMBER: US/10/317,277A
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 168
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 160
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-317-277A-160

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1129 CTGAAGGCCACCCACAG 1146
Db 20 CTGAAGGCTACCCACAG 3

RESULT 1547
US-10-671-395-1171/c
; Sequence 1171, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1171
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1171

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2722 ATCCGCGTGTGTGTGTGT 2739
Db 18 ATCCGTGTGTGTGTGTGT 1

RESULT 1548
US-10-671-395-1374/c
; Sequence 1374, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE

```
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1374
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1374

Query Match          0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTAT 2745
Db 19 GTGTGTGTGTGTGTTT 2

RESULT 1549
US-10-671-395-1427/c
; Sequence 1427, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1427
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1427

Query Match          0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTAT 2745
Db 20 GTGTGTGTGTGTGTTT 3

RESULT 1550
US-10-671-395-1597/c
; Sequence 1597, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1597
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1597

Query Match          0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTAT 2745
Db 18 GTGTATGTGTGTGTAT 1

RESULT 1551
US-10-671-395-1641/c
; Sequence 1641, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1641
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1641

Query Match          0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2732 GTGTGTGTGTGTGTGT 2749
Db 20 GTGTGTATGTGTATGTGT 3

RESULT 1552
US-10-664-639A-77/c
; Sequence 77, Application US/10664639A
; Publication No. US2004013747A1
; GENERAL INFORMATION:
; APPLICANT: Vickers, Timothy
; APPLICANT: Koo, Seongjoon
; APPLICANT: Bennett, C. Frank
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Dean, Nicholas M.
; APPLICANT: Baker, Brenda F.
; TITLE OF INVENTION: Efficient Reduction of Target RNA's by Single- and
; FILE REFERENCE: ISIS0001-100 (CORE00027US)
; CURRENT APPLICATION NUMBER: US/10/664,639A
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 60/411,780
; PRIOR FILING DATE: 2002-09-18
; NUMBER OF SEQ ID NOS: 121
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 77
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: oligonucleotide
US-10-664-639A-77

Query Match          0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2850 CCTCTGAGTAGTGGGA 2867
      ||||| ||||| |||||
Db 20 CCTCCGAGTAGTGGGA 3

RESULT 1553
US-10-728-078-14/c
; Sequence 14, Application US/10728078
; Publication No. US20050038229A1
; GENERAL INFORMATION:
; APPLICANT: Lipovsek, Dasa
; APPLICANT: Wagner, Richard W
; APPLICANT: Kuimelis, Robert G
; TITLE OF INVENTION: PROTEIN SCAFFOLDS FOR ANTIBODY MIMICS
; FILE OF INVENTION: AND OTHER BINDING PROTEINS
; FILE REFERENCE: 50036/021004
; CURRENT APPLICATION NUMBER: US/10/728,078
; CURRENT FILING DATE: 2003-12-03
; PRIOR APPLICATION NUMBER: US/09/688,566
; PRIOR FILING DATE: 2000-10-16
; PRIOR APPLICATION NUMBER: US 60/111,737
; PRIOR FILING DATE: 1998-12-10
; PRIOR APPLICATION NUMBER: US 09/456,693
; PRIOR FILING DATE: 1999-12-09
; PRIOR APPLICATION NUMBER: US 09/515,260
; PRIOR FILING DATE: 2000-02-29
; NUMBER OF SEQ ID NOS: 202
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Puromycin linker oligonucleotide
US-10-728-078-14

Query Match          0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2901 GATTTTCTTTTCTTTT 2918
      ||||| ||||| |||||
Db 20 GGTCTTTTCTTTTCTTTT 3

RESULT 1554
US-10-831-901A-29726
; Sequence 29726, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29727
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound

; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29726
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29726

Query Match          0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2903 TTTTCTTTTCTTTTCTCA 2920
      ||||| ||||| |||||
Db 1 TTTTCTTTTCTTTTCTCA 18

RESULT 1555
US-10-831-901A-29727
; Sequence 29727, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29727
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
```

US-10-831-901A-29727

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2903 TTTTCTTTTCTTTTCTCA 2920
|||||
Db 2 TTTTCTTTTCTTTTCTCA 19

RESULT 1556

US-10-831-901A-29728
; Sequence 29728, Application US/10831901A
; Publication No. US2005010085A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; TITLE OF INVENTION: Acute Respiratory Syndrome (SARS)
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29728
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29728

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2903 TTTTCTTTTCTTTTCTCA 2920
|||||
Db 3 TTTTCTTTTCTTTTCTCA 20

RESULT 1557

US-10-829-674-103/c
; Sequence 103, Application US/10829674
; Publication No. US2005011261A1
; GENERAL INFORMATION:
; APPLICANT: Anna Helgadottir
; TITLE OF INVENTION: SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION AND STROKE
; FILE REFERENCE: 30847/2048-004
; CURRENT APPLICATION NUMBER: US/10/829,674
; CURRENT FILING DATE: 2004-04-22
; PRIOR APPLICATION NUMBER: 10/769,542

; PRIOR FILING DATE: 2004-01-30
; PRIOR APPLICATION NUMBER: PCT/US03/32805
; PRIOR FILING DATE: 2003-10-16
; PRIOR APPLICATION NUMBER: 60/419,432
; PRIOR FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 717
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 103
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-829-674-103

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2832 GTGATCCTCCACCTCAG 2849
|||||
Db 20 GTGATCCTCCACCTGAG 3

RESULT 1558

US-10-830-477-103/c
; Sequence 103, Application US/10830477
; Publication No. US20050113408A1
; GENERAL INFORMATION:
; APPLICANT: Helgadottir et al.
; TITLE OF INVENTION: SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION, STROKE, AND PAOD;
; TITLE OF INVENTION: METHODS OF TREATMENT
; FILE REFERENCE: 30847/2051-005
; CURRENT APPLICATION NUMBER: US/10/830,477
; CURRENT FILING DATE: 2004-04-22
; PRIOR APPLICATION NUMBER: 10/769,744
; PRIOR FILING DATE: 2004-01-30
; PRIOR APPLICATION NUMBER: PCT/US03/32556
; PRIOR FILING DATE: 2003-10-16
; PRIOR APPLICATION NUMBER: 60/419,433
; PRIOR FILING DATE: 2002-10-17
; PRIOR APPLICATION NUMBER: 60/449,331
; PRIOR FILING DATE: 2003-02-21
; NUMBER OF SEQ ID NOS: 717
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 103
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-830-477-103

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2832 GTGATCCTCCACCTCAG 2849
|||||
Db 20 GTGATCCTCCACCTGAG 3

RESULT 1559

US-10-643-038-146/c
; Sequence 146, Application US/10643038
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PHOSPHOLIPASE A2, GROUP IIA (SYNOVIAL) EN
; FILE REFERENCE: RTS-0221
; CURRENT APPLICATION NUMBER: US/10/643,038
; CURRENT FILING DATE: 2003-08-18
; PRIOR APPLICATION NUMBER: US/09/865,866
; PRIOR FILING DATE: 2001-05-25
; NUMBER OF SEQ ID NOS: 173
; SEQ ID NO 146

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-038-146

Query Match      0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 1.1e+03;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1060 CACCCTAGAGCCAGGTG 1077
Db 20 CACCCTAGAGCCAGGTG 3

RESULT 1560
US-10-849-072-21/c
; Sequence 21, Application US/10849072
; Publication No. US20040214221A1
; GENERAL INFORMATION:
; APPLICANT: Roche Diagnostics GmbH
; TITLE OF INVENTION: High density labeling of DNA with modified or
; TITLE OF INVENTION: "chromophore" carrying nucleotides and DNA polymerases
; FILE REFERENCE: 4780/00/WO
; CURRENT FILING DATE: 2004-05-19
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 21
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: second
; OTHER INFORMATION: fragment of SEQ ID NO: 6
US-10-849-072-21

Query Match      0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 18 TTTT TTTT TTTT TTTT TTTT 3

RESULT 1561
US-10-849-072-23
; Sequence 23, Application US/10849072
; Publication No. US20040214221A1
; GENERAL INFORMATION:
; APPLICANT: Roche Diagnostics GmbH
; TITLE OF INVENTION: High density labeling of DNA with modified or
; TITLE OF INVENTION: "chromophore" carrying nucleotides and DNA polymerases
; FILE REFERENCE: 4780/00/WO
; CURRENT FILING DATE: 2004-05-19
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 23
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: second
; OTHER INFORMATION: fragment of SEQ ID NO: 6
US-10-849-072-23

Query Match      0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 1562
US-10-831-778-913
; Sequence 913, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 913
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-913

Query Match      0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 1563
US-10-831-778-939
; Sequence 939, Application US/10831778
; Publication No. US20040235774A1
; GENERAL INFORMATION:
; APPLICANT: Bratzler, Robert L.
; APPLICANT: Petersen, Deanna M.
; APPLICANT: Fouron, Yves
; TITLE OF INVENTION: Immunostimulatory Nucleic Acids for the
; TITLE OF INVENTION: Treatment of Asthma and Allergy
; FILE REFERENCE: C1037/7013 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/10/831,778
; CURRENT FILING DATE: 2004-04-23
; PRIOR FILING DATE: 2000-02-03
; NUMBER OF SEQ ID NOS: 1093
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 939
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Sequence
US-10-831-778-939

Query Match      0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16
```


RESULT 1564
US-10-776-933-150
; Sequence 150, Application US/10776933
; Publication No. US2004024171A1
; GENERAL INFORMATION:
; APPLICANT: HANSEN, BO
; APPLICANT: THRU, CHARLOTTE ALBAEK
; APPLICANT: WESTERGAARD, MAJKEN
; APPLICANT: PETERSEN, KAMILLE DUMONG
; APPLICANT: WISSENBACH, MARGIT
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF THIOREDOXIN
; FILE REFERENCE: 58614(71432)
; CURRENT APPLICATION NUMBER: US/10/776,933
; PRIOR FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: 60/446,374
; PRIOR FILING DATE: 2003-02-10
; NUMBER OF SEQ ID NOS: 150
; SOFTWARE: Patentin Ver. 3.2
; SEQ ID NO 150
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: poly-T oligonucleotide
; FEATURE:
; OTHER INFORMATION: This sequence may encompass 12-18 nucleotides
; OTHER INFORMATION: according to the specification as filed
US-10-776-933-150

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 1565
US-10-674-159A-112
; Sequence 112, Application US/10674159A
; Publication No. US20040242518A1
; GENERAL INFORMATION:
; APPLICANT: Chen, Jianzhu
; APPLICANT: Ge, Qing
; APPLICANT: Eissen, Herman
; TITLE OF INVENTION: Influenza Therapeutic
; FILE REFERENCE: 0492611-0506
; CURRENT APPLICATION NUMBER: US/10/674,159A
; CURRENT FILING DATE: 2003-09-29
; NUMBER OF SEQ ID NOS: 271
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 112
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: mRNA
US-10-674-159A-112

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 1566
US-10-776-917-141
; Sequence 141, Application US/10776917
; Publication No. US20040248840A1
; GENERAL INFORMATION:
; APPLICANT: HANSEN, BO
; APPLICANT: THRU, CHARLOTTE ALBAEK
; APPLICANT: WESTERGAARD, MAJKEN
; APPLICANT: PETERSEN, KAMILLE DUMONG
; APPLICANT: WISSENBACH, MARGIT
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF RAS EXPRESSION
; FILE REFERENCE: 58609(71432)
; CURRENT APPLICATION NUMBER: US/10/776,917
; CURRENT FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: 60/446,363
; PRIOR FILING DATE: 2003-02-10
; PRIOR APPLICATION NUMBER: DK 2003-01539
; PRIOR FILING DATE: 2003-10-20
; NUMBER OF SEQ ID NOS: 201
; SOFTWARE: Patentin Ver. 3.2
; SEQ ID NO 141
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: poly-T oligonucleotide
; FEATURE:
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according to the
; OTHER INFORMATION: specification as filed
US-10-776-917-141

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 1567
US-10-766-096-9
; Sequence 9, Application US/10766096
; Publication No. US20040265786A1
; GENERAL INFORMATION:
; APPLICANT: Lin, Ching-I Patsy
; Wallace, Robert Bruce
; Cossman, Jeffrey
; French, Cynthia
; TITLE OF INVENTION: Lyophilization of Cultured Human Cells
; to Preserve RNA and DNA
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/766,096
; FILING DATE: 27-Jan-2004
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/884,029
; FILING DATE: 27-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Parent, Annette S.

```
;/
;/ REGISTRATION NUMBER: 42,058
;/ REFERENCE/DOCKET NUMBER: 02558B-059100US
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (415) 576-0200
;/ TELEFAX: (415) 576-0300
;/ INFORMATION FOR SEQ ID NO: 9:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 18 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ MOLECULE TYPE: DNA
;/ FEATURE:
;/ NAME/KEY: modified_base
;/ LOCATION: 13..18
;/ OTHER INFORMATION: /mod_base= OTHER
;/ /note: "t at positions 13-18 may be
;/ present or absent"
;/ SEQUENCE DESCRIPTION: SEQ ID NO: 9:
US-10-766-096-9
```

```
Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2903 TTTT TTTT TTTT TTTT TTTT 2918
||| ||| ||| ||| ||| |||
Db 1 TTTT TTTT TTTT TTTT TTTT 16
```

```
RESULT 1568
US-10-872-984-5
; Sequence 5, Application US/10872984
; Publication No. US20040265888A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
; APPLICANT: Roth, Matthew E.
; APPLICANT: Lizardi, Paul M.
; APPLICANT: Feng, Li
; APPLICANT: Latimer, Darin R.
; TITLE OF INVENTION: Binary Encoded Sequence Tags
; FILE REFERENCE: AGL 100
; CURRENT APPLICATION NUMBER: US/10/872,984
; CURRENT FILING DATE: 2004-06-21
; PRIOR APPLICATION NUMBER: US/09/994,311
; PRIOR FILING DATE: 2001-11-26
; PRIOR APPLICATION NUMBER: US/09/637,751
; PRIOR FILING DATE: 2000-08-11
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-5
```

```
Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2903 TTTT TTTT TTTT TTTT TTTT 2918
||| ||| ||| ||| ||| |||
Db 1 TTTT TTTT TTTT TTTT TTTT 16
```

```
RESULT 1569
US-10-872-984-6
; Sequence 6, Application US/10872984
; Publication No. US20040265888A1
; GENERAL INFORMATION:
; APPLICANT: Kaufman, Joseph C.
```

```
;/
;/ APPLICANT: Roth, Matthew E.
;/ APPLICANT: Lizardi, Paul M.
;/ APPLICANT: Feng, Li
;/ APPLICANT: Latimer, Darin R.
;/ TITLE OF INVENTION: Binary Encoded Sequence Tags
;/ FILE REFERENCE: AGL 100
;/ CURRENT APPLICATION NUMBER: US/10/872,984
;/ CURRENT FILING DATE: 2004-06-21
;/ PRIOR APPLICATION NUMBER: US/09/994,311
;/ PRIOR FILING DATE: 2001-11-26
;/ PRIOR APPLICATION NUMBER: US/09/637,751
;/ PRIOR FILING DATE: 2000-08-11
;/ NUMBER OF SEQ ID NOS: 10
;/ SOFTWARE: PatentIn Ver. 2.1
;/ SEQ ID NO 6
;/ LENGTH: 18
;/ TYPE: DNA
;/ ORGANISM: Artificial Sequence
;/ FEATURE:
;/ OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-872-984-6
```

```
Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2903 TTTT TTTT TTTT TTTT TTTT 2918
||| ||| ||| ||| ||| |||
Db 1 TTTT TTTT TTTT TTTT TTTT 16
```

```
RESULT 1570
US-10-638-141-10
; Sequence 10, Application US/10638141
; Publication No. US20050003364A1
; GENERAL INFORMATION:
; APPLICANT: Stanton, Lawrence W.
; APPLICANT: Kapoun, Ann Marie
; TITLE OF INVENTION: SECRETED FACTORS
; FILE REFERENCE: SCIOS.013A
; CURRENT APPLICATION NUMBER: US/10/638,141
; CURRENT FILING DATE: 2003-08-07
; PRIOR APPLICATION NUMBER: US/09/665,728
; PRIOR FILING DATE: 2000-09-20
; PRIOR APPLICATION NUMBER: 60/156,277
; PRIOR FILING DATE: 1999-09-27
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-638-141-10
```

```
Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 2903 TTTT TTTT TTTT TTTT TTTT 2918
||| ||| ||| ||| ||| |||
Db 1 TTTT TTTT TTTT TTTT TTTT 16
```

```
RESULT 1571
US-10-776-934-741
; Sequence 741, Application US/10776934
; Publication No. US20050014712A1
; GENERAL INFORMATION:
; APPLICANT: HANSEN, BO
; APPLICANT: THRU, CHARLOTTE ALBAEK
; APPLICANT: WESTERGAARD, MAJKEN
```

```

; APPLICANT: PETERSEN, KAMILLE DUMONG
; APPLICANT: WISENBACH, MARGIT
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS FOR THE MODULATION OF SURVIVIN EXPRESSION
; FILE REFERENCE: 58610(71432)
; CURRENT APPLICATION NUMBER: US/10/776,934
; PRIOR FILING DATE: 2004-02-10
; PRIOR APPLICATION NUMBER: 60/446,372
; PRIOR FILING DATE: 2003-02-10
; PRIOR APPLICATION NUMBER: 60/523,591
; PRIOR FILING DATE: 2003-11-19
; NUMBER OF SEQ ID NOS: 741
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 741
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: poly-T oligonucleotide
; FEATURE:
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides according to the
; OTHER INFORMATION: specification as filed
US-10-776-934-741

```

```

Query Match          0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
      ||||| ||||| ||||| ||||| |||||
DB 1 TTTT TTTT TTTT TTTT TTTT 16

```

RESULT 1572

```

US-10-601-140A-24
; Sequence 24, Application US/10601140A
; Publication No. US20050053942A1
; GENERAL INFORMATION:
; APPLICANT: KAUPPINEN, SAKARI
; APPLICANT: JACOBSEN, NANA
; TITLE OF INVENTION: METHODS AND SYSTEMS FOR DETECTION AND ISOLATION OF A
; TITLE OF INVENTION: NUCLEOTIDE SEQUENCE
; FILE REFERENCE: 57764(71994)
; CURRENT APPLICATION NUMBER: US/10/601,140A
; CURRENT FILING DATE: 2003-06-20
; PRIOR APPLICATION NUMBER: US 60/390,928
; PRIOR FILING DATE: 2002-06-24
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 24
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(18)
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides
US-10-601-140A-24

```

```

Query Match          0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
      ||||| ||||| ||||| ||||| |||||
DB 1 TTTT TTTT TTTT TTTT TTTT 16

```

RESULT 1573

```

US-10-884-617-2
; Sequence 2, Application US/10884617
; Publication No. US20050054730A1

```

```

; GENERAL INFORMATION:
; APPLICANT: Fu, Jin
; APPLICANT: Gaetani, Silvana
; APPLICANT: Piomelli, Daniele
; APPLICANT: The Regents of the University of California
; TITLE OF INVENTION: Compounds, Compositions and Treatments of
; TITLE OF INVENTION: Oleoylthanolamide-Like Modulators of PPARalpha
; FILE REFERENCE: 02307E-133310US
; CURRENT APPLICATION NUMBER: US/10/884,617
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: US 60/279,542
; PRIOR FILING DATE: 2001-03-27
; PRIOR APPLICATION NUMBER: US 60/336,289
; PRIOR FILING DATE: 2001-10-31
; PRIOR APPLICATION NUMBER: US 10/112,509
; PRIOR FILING DATE: 2002-03-27
; PRIOR APPLICATION NUMBER: US 60/485,062
; PRIOR FILING DATE: 2003-07-02
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Oligo(dT)-12-18
; OTHER INFORMATION: primer for reverse transcription of total RNA
; FEATURE:
; NAME/KEY: modified base
; LOCATION: (13)..(18)
; OTHER INFORMATION: t at positions 13-18 may be present or absent
US-10-884-617-2

```

```

Query Match          0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
      ||||| ||||| ||||| ||||| |||||
DB 1 TTTT TTTT TTTT TTTT TTTT 16

```

RESULT 1574

```

US-10-669-962-29
; Sequence 29, Application US/10669962
; Publication No. US20050081264A1
; GENERAL INFORMATION:
; APPLICANT: Brugliera, Filippo
; APPLICANT: Holton, Timothy A.
; APPLICANT: Michael, Michael Z.
; TITLE OF INVENTION: GENETIC SEQUENCES ENCODING FLAVONOID PATHWAY ENZYMES
; TITLE OF INVENTION: AND USES THEREFOR
; FILE REFERENCE: 11658
; CURRENT APPLICATION NUMBER: US/10/669,962
; CURRENT FILING DATE: 2003-09-24
; PRIOR APPLICATION NUMBER: US/09/142,108C
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: PN8386
; PRIOR FILING DATE: 1996-03-01
; NUMBER OF SEQ ID NOS: 45
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:oligonucleotide
US-10-669-962-29

```

```

Query Match          0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
| | | | | | | | | | | | | | | |
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 1575
US-10-503-120-1
; Sequence 1, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; CURRENT FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-503-120-1

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
| | | | | | | | | | | | | | | |
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 1576
US-10-503-120-8
; Sequence 8, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; CURRENT FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(17)
; OTHER INFORMATION: Residues 1, 3, 5, 7, 9, 11, 13, 15 and 17 are 2'-O-methyl-D-uridine
US-10-503-120-8

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 50.0%; Pred. No. 1.3e+03;
Matches 8; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
: |: |: |: |: |: |: |: |: |: |: |
Db 1 UTUTUTUTUTUTUTUT 16

RESULT 1577

US-10-503-120-9
; Sequence 9, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; CURRENT FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(15)
; OTHER INFORMATION: Residues 1-3, 7-9, and 13-15 are 2'-O-methyl-D-uridine
US-10-503-120-9

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 43.8%; Pred. No. 1.3e+03;
Matches 7; Conservative 9; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
: |: |: |: |: |: |: |: |: |: |: |
Db 1 UUUUUUUUUUUUUU 16

RESULT 1578
US-10-503-120-10
; Sequence 10, Application US/10503120
; Publication No. US20050142535A1
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; CURRENT FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
; NAME/KEY: misc_feature
; LOCATION: (1)..(18)
; OTHER INFORMATION: Residues 1-6 and 13-18 are 2'-O-methyl-D-uridine
US-10-503-120-10

Query Match 0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 37.5%; Pred. No. 1.3e+03;
Matches 6; Conservative 10; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
: |: |: |: |: |: |: |: |: |: |: |
Db 1 UUUUUUUUUUUUUU 16

RESULT 1579
US-10-503-120-21/c
; Sequence 21, Application US/10503120
; Publication No. US20050142535A1

```
; GENERAL INFORMATION:
; APPLICANT: MCGILL UNIVERSITY ET AL.
; TITLE OF INVENTION: OLIGONUCLEOTIDES COMPRISING ALTERNATING SEGMENTS AND USES THEREOF
; FILE REFERENCE: 85827-63
; CURRENT APPLICATION NUMBER: US/10/503,120
; CURRENT FILING DATE: 2004-07-30
; PRIOR APPLICATION NUMBER: US 60/352,873
; PRIOR FILING DATE: 2002-02-01
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 21
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Target RNA oligonucleotide
US-10-503-120-21

Query Match          0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
      |||||
Db 18 TTTT TTTT TTTT TTTT TTTT 3

RESULT 1580
US-11-024-428-7
; Sequence 7, Application US/11024428
; Publication No. US20050106676A1
; GENERAL INFORMATION:
; APPLICANT: NAGAI, HIROSHI
; APPLICANT: KURODA, KYOKO
; APPLICANT: NAKAJIMA, TERUMI
; TITLE OF INVENTION: NOVEL PROTEINS HAVING HEMOLYTIC ACTIVITY AND GENES
; TITLE OF INVENTION: ENCODING THE PROTEIN
; FILE REFERENCE: 037181.50611US
; CURRENT APPLICATION NUMBER: US/11/024,428
; CURRENT FILING DATE: 2004-12-30
; PRIOR APPLICATION NUMBER: US/09/979,275
; PRIOR FILING DATE: 2003-05-27
; PRIOR APPLICATION NUMBER: PCT/JP01/02209
; PRIOR FILING DATE: 2001-03-21
; PRIOR APPLICATION NUMBER: JP 2000-78967
; PRIOR FILING DATE: 2000-03-21
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 7
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: oligonucleotide
; FEATURE:
; OTHER INFORMATION: this sequence may encompass 12-18 nucleotides
US-11-024-428-7

Query Match          0.5%; Score 16; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.3e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
      |||||
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 1581
US-10-760-940-1
; Sequence 1, Application US/10760940
; Publication No. US20040219577A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Ravikumar, Vasulinga
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Capaldi, Daniel C.
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas L.
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: IMPROVED PROCESS FOR THE SYNTHESIS OF OLIGOMERIC COMPOUNDS
; FILE REFERENCE: ISIS-5422
; CURRENT APPLICATION NUMBER: US/10/760,940
; CURRENT FILING DATE: 2004-01-20
; PRIOR APPLICATION NUMBER: US 10/232,881
; PRIOR FILING DATE: 2002-08-30
; PRIOR APPLICATION NUMBER: US 09/288,679
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: US 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 5
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 1
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-760-940-1

Query Match          0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
      |||||
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 1582
US-10-913-246-22/c
; Sequence 22, Application US/10913246
; Publication No. US20050003441A1
; GENERAL INFORMATION:
; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: AMPLIFICATION OF RNA SEQUENCES
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/913,246
; CURRENT FILING DATE: 2004-08-05
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-913-246-22

Query Match          0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
      |||||
Db 19 TTTT TTTT TTTT TTTT TTTT 4
```

RESULT 1583

US-10-913-246-24/c
; Sequence 24, Application US/10913246
; Publication No. US20050003441A1
; GENERAL INFORMATION:

; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/913,246
; CURRENT FILING DATE: 2004-08-05
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-913-246-24

Query Match 0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
| | | | | | | | | | | | | | | | | |
DB 19 TTTT TTTT TTTT TTTT TTTT 4

RESULT 1584

US-10-934-890-22/c
; Sequence 22, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:

; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: n = A,T,C or G
US-10-934-890-22

Query Match 0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
| | | | | | | | | | | | | | | | | |
DB 19 TTTT TTTT TTTT TTTT TTTT 4

RESULT 1585

US-10-934-890-24/c
; Sequence 24, Application US/10934890
; Publication No. US20050014192A1
; GENERAL INFORMATION:

; APPLICANT: Kurn, Nurith
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; FILE REFERENCE: 492692000500
; CURRENT APPLICATION NUMBER: US/10/934,890
; CURRENT FILING DATE: 2004-09-03
; PRIOR APPLICATION NUMBER: US/10/100,321
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/274,550
; PRIOR FILING DATE: 2001-03-09
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-934-890-24

Query Match 0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTT TTTT TTTT TTTT TTTT 2918
| | | | | | | | | | | | | | | | | |
DB 19 TTTT TTTT TTTT TTTT TTTT 4

RESULT 1586

US-10-700-884-23
; Sequence 23, Application US/10700884
; Publication No. US20050118605A9
; GENERAL INFORMATION:

; APPLICANT: Baker, Brenda F.
; APPLICANT: Eldrup, Anne B.
; APPLICANT: Manoharan, Muthiah
; APPLICANT: Bhat, Balkrishen
; APPLICANT: Griffey, Richard
; APPLICANT: Swayze, Eric E.
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Prakash, Thazha P.
; APPLICANT: Rajeev, Kallanthottathil G.
; TITLE OF INVENTION: OLIGOMERIC COMPOUNDS HAVING MODIFIED BASES FOR BINDING TO ADENINE
; FILE REFERENCE: ISIS-5317
; CURRENT APPLICATION NUMBER: US/10/700,884
; CURRENT FILING DATE: 2003-11-04
; PRIOR APPLICATION NUMBER: US 10/635,380
; PRIOR FILING DATE: 2003-08-06
; PRIOR APPLICATION NUMBER: US 60/423,760
; PRIOR FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 10/078,949
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 09/479,783
; PRIOR FILING DATE: 2000-01-07
; PRIOR APPLICATION NUMBER: US 08/870,608
; PRIOR FILING DATE: 1997-06-06
; PRIOR APPLICATION NUMBER: US 08/659,440
; PRIOR FILING DATE: 1996-06-06
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 23
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
; FEATURE:

```
; NAME/KEY: misc.feature
; LOCATION: (16)..(19)
; OTHER INFORMATION: 2'-O-[2-(methoxy)ethyl]-2-thio-5-methyluridine
US-10-700-884-23

Query Match          0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTTGTGTGTGTATG 2746
Db 1 TTTTGTGTGTGTATG 16

RESULT 1587
US-10-871-222-391
; Sequence 391, Application US/10871222
; Publication No. US20050119212A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acid
; TITLE OF INVENTION: Synthase Ligand (FASL) Gene Expression Using Short Interfering
; FILE REFERENCE: 400/164 (MEHB04-487)
; CURRENT APPLICATION NUMBER: US/10/871,222
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/757803
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US10/720448
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 706
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 391
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siRNA sense
US-10-871-222-391

Query Match          0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 50.0%; Pred. No. 1.2e+03;
Matches 8; Conservative 8; Mismatches 0; Indels 0; Gaps 0;

QY 2731 TGTGTGTGTGTATG 2746
Db 1 UGUGUGUGUGAUG 16

RESULT 1588
US-10-871-222-495/c
; Sequence 495, Application US/10871222
; Publication No. US20050119212A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acid
; TITLE OF INVENTION: Synthase Ligand (FASL) Gene Expression Using Short Interfering
; FILE REFERENCE: 400/164 (MEHB04-487)
; CURRENT APPLICATION NUMBER: US/10/871,222
; PRIOR FILING DATE: 2004-06-18
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US10/826966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US10/757803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US10/720448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US10/693059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US10/444853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US60/358580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US60/363124
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 706
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 495
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
US-10-871-222-495

Query Match          0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2731 TGTGTGTGTGTATG 2746
Db 19 TGTGTGTGTGTATG 4

RESULT 1589
US-10-940-360-1
; Sequence 1, Application US/10940360
; Publication No. US2005013791A1
; GENERAL INFORMATION:
; APPLICANT: Ravikumar, Vasulinga
; APPLICANT: Manoharan, Muthia
; APPLICANT: Capaldi, Daniel
; APPLICANT: Krotz, Achim
; APPLICANT: Cole, Douglas
; APPLICANT: Guzaev, Andrei
; TITLE OF INVENTION: Improved Process for the Synthesis of Oligomeric Compounds
; FILE REFERENCE: ISIS3380
; CURRENT APPLICATION NUMBER: US/10/940,360
; CURRENT FILING DATE: 2004-09-14
; PRIOR APPLICATION NUMBER: US/09/288,679
; PRIOR FILING DATE: 1999-04-09
; PRIOR APPLICATION NUMBER: 60/118,564
; PRIOR FILING DATE: 1999-02-04
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1
; LENGTH: 19
; TYPE: DNA
```

; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Novel Sequence
US-10-940-360-1

Query Match 0.5%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTTCTTTTCTTTTCTTTT 2918
Db 1 TTTTCTTTTCTTTTCTTTT 16

RESULT 1590
US-10-148-355A-63/c
; Sequence 63, Application US/10148355A
; Publication No. US20030207831A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsett
; APPLICANT: ISIS PHARMACEUTICALS, INC.
; TITLE OF INVENTION: ANTISENSE MODULATION OF TELOMERIC REPEAT BINDING FACTOR 2
; FILE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTSP-0082
; CURRENT APPLICATION NUMBER: US/10/148,355A
; CURRENT FILING DATE: 2002-09-30
; PRIOR APPLICATION NUMBER: 09/467,642
; PRIOR FILING DATE: 1999-12-17
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-148-355A-63

Query Match 0.5%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2758 TCTCGCTCTGTCTACCC 2773
Db 16 TCTCGCTCTGTCTACCC 1

RESULT 1591
US-10-671-395-1204/c
; Sequence 1204, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1204
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1204

Query Match 0.5%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2734 GTCTGTGTGTATGTGT 2749
Db 16 GTCTGTGTGTATGTGT 1

RESULT 1592
US-10-671-395-1524/c
; Sequence 1524, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOMAL PROSTAGLANDIN E2 SYNTHASE
; FILE OF INVENTION: EXPRESSION
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1524
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human PGE2 antisense
US-10-671-395-1524

Query Match 0.5%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2852 TCCTGAGTAGCTGGGA 2867
Db 20 TCCTGAGTAGCTGGGA 5

RESULT 1593
US-10-845-667-118/c
; Sequence 118, Application US/10845667
; Publication No. US20050026183A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing
; APPLICANT: Bibikova, Marina
; TITLE OF INVENTION: Methods and Compositions For Diagnosing
; FILE OF INVENTION: Conditions Associated With Specific DNA Methylation Patterns
; FILE REFERENCE: 67234-091
; CURRENT APPLICATION NUMBER: US/10/845,667
; CURRENT FILING DATE: 2004-05-14
; PRIOR APPLICATION NUMBER: 60/471,488
; PRIOR FILING DATE: 2003-05-15
; NUMBER OF SEQ ID NOS: 1506
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 118
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo sapeins
US-10-845-667-118

Query Match 0.5%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2727 CGTGTGTGTGTGTGTG 2742
Db 20 CGTGTGTGTGTGTGTG 5

RESULT 1594
US-10-620-642-32

; Sequence 32, Application US/10620642
; Publication No. US20050080250A1
; GENERAL INFORMATION:
; APPLICANT: Zsebo, Krisztina M.
; Bosselman, Robert A.
; Suggs, Sidney V.
; Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION NUMBER: US/10/620,642
; FILING DATE: 16-Jul-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/10/175,608
; FILING DATE: 16-Oct-2002
; APPLICATION NUMBER: 09/635,249
; FILING DATE: 07-AUG-2000
; APPLICATION NUMBER: 09/486,546
; FILING DATE: 24-MAY-1995
; APPLICATION NUMBER: 08/172,329
; FILING DATE: 21-DEC-1993
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; APPLICATION NUMBER: 07/684,535
; FILING DATE: 10-APR-1991
; APPLICATION NUMBER: 09/589,701
; FILING DATE: 10-OCT-1991
; APPLICATION NUMBER: 07/573,616
; FILING DATE: 24-AUG-1990
; APPLICATION NUMBER: 07/537,198
; FILING DATE: 11-JUN-1990
; APPLICATION NUMBER: 07/422,383
; FILING DATE: 16-OCT-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Clough, David W.
; REGISTRATION NUMBER: 36,107
; REFERENCE/DOCKET NUMBER: 01017/35199
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-10-620-642-32

Query Match 0.5%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 1595
US-10-831-901A-29729
; Sequence 29729, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq For Windows Version 4.0
; SEQ ID NO 29729
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29729

Query Match 0.5%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2903 TTTT TTTT TTTT TTTT TTTT 2918
Db 1 TTTT TTTT TTTT TTTT TTTT 16

RESULT 1596
US-10-831-901A-29730
; Sequence 29730, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28

```

; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29730
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29730

Query Match      0.5%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTTTCCTTTTTCCTTTT 2918
Db 1 TTTTTCCTTTTTCCTTTT 16

RESULT 1597
US-10-831-901A-29731
; Sequence 29731, Application US/10831901A
; Publication No. US20050100895A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Becker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISI00083-100 (BIOL000808)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29731
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29731

Query Match      0.5%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2e+03;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTTTCCTTTTTCCTTTT 2918
Db 1 TTTTTCCTTTTTCCTTTT 16

RESULT 1597
US-10-831-901A-29731
; Sequence 29731, Application US/10831901A
; Publication No. US20050100895A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Becker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISI00083-100 (BIOL000808)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; CURRENT FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 29731
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-29731
```

```

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2903 TTTTTCCTTTTTCCTTTT 2918
Db 1 TTTTTCCTTTTTCCTTTT 16

RESULT 1598
US-09-881-012-229/c
; Sequence 229, Application US/09881012
; Publication No. US20020192655A1
; GENERAL INFORMATION:
; APPLICANT: Ginns, Edward I.
; APPLICANT: Egeland, Janice A.
; APPLICANT: Paul, Steven M.
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by The Secretary of the
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Susceptibility and Resistance Genes for
; FILE REFERENCE: 015280-248110US
; CURRENT APPLICATION NUMBER: US/09/881,012
; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US/09/175,158
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: US 60/062,924
; PRIOR FILING DATE: 1997-10-20
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 229
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: UT1585 primer
US-09-881-012-229

Query Match      0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2768 TCACCCAGGCTGGAGTGCA 2786
Db 19 TCACCCAGGCTGGAGTGCA 1

RESULT 1599
US-09-881-012-229/c
; Sequence 229, Application US/09881012
; Publication No. US20040248086A9
; GENERAL INFORMATION:
; APPLICANT: Ginns, Edward I.
; APPLICANT: Egeland, Janice A.
; APPLICANT: Paul, Steven M.
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by The Secretary of the
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Susceptibility and Resistance Genes for
; FILE REFERENCE: 015280-248110US
; CURRENT APPLICATION NUMBER: US/09/881,012
; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US/09/175,158
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: US 60/062,924
; PRIOR FILING DATE: 1997-10-20
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 229
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Artificial Sequence
```

```
; OTHER INFORMATION: UT1585 primer
US-09-881-012-229

Query Match          0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2768 TCACCCAGCGTCGAGTGCA 2786
Db 19 TCACCCAGCGCGGAGTGCA 1

RESULT 1600
US-10-160-436-1/c
; Sequence 1, Application US/10160436
; Publication No. US20030224372A1
; GENERAL INFORMATION:
; APPLICANT: Syndercombe-Court, Denise
; TITLE OF INVENTION: Method for determining ethnic origin by means of STR
; TITLE OF INVENTION: profile
; FILE REFERENCE: 04630/017001
; CURRENT APPLICATION NUMBER: US/10/160,436
; CURRENT FILING DATE: 2002-09-10
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 1
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-160-436-1

Query Match          0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2760 TCGCTCTGTCCACCCAGGCT 2778
Db 19 TAGCTCTGTCCACCCATGCT 1

RESULT 1601
US-10-282-174-103/c
; Sequence 103, Application US/10282174
; Publication No. US20030224380A1
; GENERAL INFORMATION:
; APPLICANT: Becker, Kenneth David
; APPLICANT: Vellicelebi, Gonul
; APPLICANT: Elliot, Kathryn J.
; APPLICANT: Wang, Xin
; APPLICANT: Bertram, Lars
; APPLICANT: Tanzi, Rudolph E.
; APPLICANT: Saunders, Aleister J.
; APPLICANT: Sampson, Andrew Johnson
; TITLE OF INVENTION: GENES AND POLYMORPHISMS ON CHROMOSOME 10
; TITLE OF INVENTION: ASSOCIATED WITH ALZHEIMER'S DISEASE AND OTHER
; TITLE OF INVENTION: NEURODEGENERATIVE DISEASES
; FILE REFERENCE: 37481-3308
; CURRENT APPLICATION NUMBER: US/10/282,174
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: US 60/339,525
; PRIOR FILING DATE: 2001-10-25
; PRIOR APPLICATION NUMBER: US 60/338,010
; PRIOR FILING DATE: 2001-11-08
; PRIOR APPLICATION NUMBER: US 60/336,929
; PRIOR FILING DATE: 2001-11-08
; PRIOR APPLICATION NUMBER: US 60/338,363
; PRIOR FILING DATE: 2001-11-09
; PRIOR APPLICATION NUMBER: US 60/337,052
; PRIOR FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: US 60/368,919
; PRIOR FILING DATE: 2002-03-28
; PRIOR APPLICATION NUMBER: US 10/282,174
; PRIOR FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 103
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-600-009-103

Query Match          0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2828 TCAAGTGATCCTCCACCT 2846
Db 19 TGAATTGATCCTCCACCT 1

RESULT 1602
US-10-600-009-103/c
; Sequence 103, Application US/10600009
; Publication No. US20050009031A1
; GENERAL INFORMATION:
; APPLICANT: Becker, Kenneth David
; APPLICANT: Vellicelebi, Gonul
; APPLICANT: Elliot, Kathryn J.
; APPLICANT: Wang, Xin
; APPLICANT: Tanzi, Rudolph E.
; APPLICANT: Bertram, Lars
; APPLICANT: Saunders, Aleister J.
; APPLICANT: Mullin, Kristina M.
; APPLICANT: Sampson, Andrew Johnson
; APPLICANT: Blacker, Deborah Lynne
; TITLE OF INVENTION: GENES AND POLYMORPHISMS ON CHROMOSOME 10
; TITLE OF INVENTION: ASSOCIATED WITH ALZHEIMER'S DISEASE AND OTHER
; TITLE OF INVENTION: NEURODEGENERATIVE DISEASES
; FILE REFERENCE: 37481-3308B
; CURRENT APPLICATION NUMBER: US/10/600,009
; CURRENT FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: US 60/339,525
; PRIOR FILING DATE: 2001-10-25
; PRIOR APPLICATION NUMBER: US 60/338,010
; PRIOR FILING DATE: 2001-11-08
; PRIOR APPLICATION NUMBER: US 60/336,929
; PRIOR FILING DATE: 2001-11-08
; PRIOR APPLICATION NUMBER: US 60/338,363
; PRIOR FILING DATE: 2001-11-09
; PRIOR APPLICATION NUMBER: US 60/337,052
; PRIOR FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: US 60/368,919
; PRIOR FILING DATE: 2002-03-28
; PRIOR APPLICATION NUMBER: US 10/282,174
; PRIOR FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 103
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-600-009-103

Query Match          0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2828 TCAAGTGATCCTCCACCT 2846
Db 19 TGAATTGATCCTCCACCT 1
```

```
RESULT 1603
US-10-673-575-1/c
; Sequence 1, Application US/10673575
; Publication No. US20050069902A1
; GENERAL INFORMATION:
; APPLICANT: Sinha, Sudhir K
; APPLICANT: Walker, Jerilyn A
; APPLICANT: Batzer, Mark A
; TITLE OF INVENTION: Assay for Quantitation of Human DNA Using Alu Elements
; FILE REFERENCE: P56885
; CURRENT APPLICATION NUMBER: US/10/673,575
; CURRENT FILING DATE: 2003-09-30
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Primer (Alu3) for inter-Alu PCR
US-10-673-575-1
Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2779 GGAGTCAGTGGTGCATC 2797
DB 19 GGAGTCAGTGGCGCATC 1
|||||
RESULT 1604
US-10-883-218-387
; Sequence 387, Application US/10883218
; Publication No. US20050124567A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of TRPM7 Gene Expression
; FILE REFERENCE: 400/195 (MBH04-535)
; CURRENT APPLICATION NUMBER: US/10/883,218
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2003-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 930
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 789
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-883-218-789
Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2899 TTGATTTTTCCTTTT 2917
DB 19 TTAATTTTTCCTTTT 1
|||||
RESULT 1606
US-10-984-919-562/c
; Sequence 562, Application US/10984919
; Publication No. US20050130927A1
; GENERAL INFORMATION:
; APPLICANT: Schlingsiefen, Karl-Hermann
; APPLICANT: Brysch, Wolfgang
```

```
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-883-218-387
Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 5.3%; Pred. No. 1.3e+03;
Matches 1; Conservative 16; Mismatches 2; Indels 0; Gaps 0;

QY 2899 TTGATTTTTCCTTTT 2917
DB 1 UUAUUUUUUUUUUUUUU 19
|||||
RESULT 1605
US-10-883-218-789/c
; Sequence 789, Application US/10883218
; Publication No. US20050124567A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Haerberli, Peter
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of TRPM7 Gene Expression
; FILE REFERENCE: 400/195 (MBH04-535)
; CURRENT APPLICATION NUMBER: US/10/883,218
; CURRENT FILING DATE: 2004-07-01
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2003-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/427,160
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 930
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 789
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-883-218-789
Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2899 TTGATTTTTCCTTTT 2917
DB 19 TTAATTTTTCCTTTT 1
|||||
RESULT 1606
US-10-984-919-562/c
; Sequence 562, Application US/10984919
; Publication No. US20050130927A1
; GENERAL INFORMATION:
; APPLICANT: Schlingsiefen, Karl-Hermann
; APPLICANT: Brysch, Wolfgang
```

```
/ ; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
/ ; FILE REFERENCE: 10496/P63763USO
/ ; CURRENT APPLICATION NUMBER: US/10/984,919
/ ; CURRENT FILING DATE: 2004-11-10
/ ; PRIOR APPLICATION NUMBER: US/09/341,700
/ ; PRIOR FILING DATE: 1999-09-24
/ ; PRIOR APPLICATION NUMBER: PCT/EP98/00497
/ ; PRIOR FILING DATE: 1998-01-30
/ ; PRIOR APPLICATION NUMBER: EP 97 101 531.8
/ ; PRIOR FILING DATE: 1997-01-31
/ ; NUMBER OF SEQ ID NOS: 1764
/ ; SOFTWARE: PatentIn Ver. 2.1
/ ; SEQ ID NO 562
/ ; LENGTH: 19
/ ; TYPE: DNA
/ ; ORGANISM: Artificial Sequence
/ ; FEATURE:
/ ; OTHER INFORMATION: Description of Artificial Sequence:
/ ; OTHER INFORMATION: antisense oligonucleotide
US-10-984-919-562

Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2899 TTGATTTTCTTTTCTTTT 2917
Db 19 TTGATTTCTTTTCTTTTATT 1

RESULT 1607
US-10-863-973-918/c
/ ; Sequence 918, Application US/10863973
/ ; Publication No. US2005014333A1
/ ; GENERAL INFORMATION:
/ ; APPLICANT: Sirna Therapeutics, Inc.
/ ; APPLICANT: Richards, Ivan
/ ; APPLICANT: Polisky, Barry
/ ; APPLICANT: McSwiggen, James
/ ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
/ ; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
/ ; TITLE OF INVENTION: Nucleic Acid (siNA)
/ ; FILE REFERENCE: 400/163 (MEHB03-084-D)
/ ; CURRENT APPLICATION NUMBER: US/10/863,973
/ ; CURRENT FILING DATE: 2004-06-09
/ ; PRIOR APPLICATION NUMBER: PCT/US03/04566
/ ; PRIOR FILING DATE: 2003-02-14
/ ; PRIOR APPLICATION NUMBER: PCT/US04/16390
/ ; PRIOR FILING DATE: 2004-05-24
/ ; PRIOR APPLICATION NUMBER: US 10/826,966
/ ; PRIOR FILING DATE: 2004-04-16
/ ; PRIOR APPLICATION NUMBER: US 10/757,803
/ ; PRIOR FILING DATE: 2004-01-14
/ ; PRIOR APPLICATION NUMBER: US 10/720,448
/ ; PRIOR FILING DATE: 2003-11-24
/ ; PRIOR APPLICATION NUMBER: US 10/693,059
/ ; PRIOR FILING DATE: 2003-10-23
/ ; PRIOR APPLICATION NUMBER: US 10/444,853
/ ; PRIOR FILING DATE: 2003-05-23
/ ; PRIOR APPLICATION NUMBER: PCT/US03/05346
/ ; PRIOR FILING DATE: 2003-02-20
/ ; PRIOR APPLICATION NUMBER: PCT/US03/05028
/ ; PRIOR FILING DATE: 2003-02-20
/ ; PRIOR APPLICATION NUMBER: US 60/358,580
/ ; Remaining Prior Application data removed - See File Wrapper or PALM.
/ ; SOFTWARE: PatentIn version 3.3
/ ; SEQ ID NO 918
/ ; LENGTH: 19
/ ; TYPE: RNA
/ ; ORGANISM: Artificial Sequence
/ ; FEATURE:
/ ; OTHER INFORMATION: Description of Artificial Sequence:
/ ; OTHER INFORMATION: antisense region
US-10-863-973-918
```

```
/ ; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-863-973-918

Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.3e+03;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2848 AGCTTCTTGAGTAGCTGGG 2866
Db 19 AGCTTCCCGAGTAGCTGGG 1

RESULT 1608
US-10-863-973-1141
/ ; Sequence 1141, Application US/10863973
/ ; Publication No. US2005014333A1
/ ; GENERAL INFORMATION:
/ ; APPLICANT: Sirna Therapeutics, Inc.
/ ; APPLICANT: Richards, Ivan
/ ; APPLICANT: Polisky, Barry
/ ; APPLICANT: McSwiggen, James
/ ; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
/ ; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
/ ; TITLE OF INVENTION: Nucleic Acid (siNA)
/ ; FILE REFERENCE: 400/163 (MEHB03-084-D)
/ ; CURRENT APPLICATION NUMBER: US/10/863,973
/ ; CURRENT FILING DATE: 2004-06-09
/ ; PRIOR APPLICATION NUMBER: PCT/US03/04566
/ ; PRIOR FILING DATE: 2003-02-14
/ ; PRIOR APPLICATION NUMBER: PCT/US04/16390
/ ; PRIOR FILING DATE: 2004-05-24
/ ; PRIOR APPLICATION NUMBER: US 10/826,966
/ ; PRIOR FILING DATE: 2004-04-16
/ ; PRIOR APPLICATION NUMBER: US 10/757,803
/ ; PRIOR FILING DATE: 2004-01-14
/ ; PRIOR APPLICATION NUMBER: US 10/720,448
/ ; PRIOR FILING DATE: 2003-11-24
/ ; PRIOR APPLICATION NUMBER: US 10/693,059
/ ; PRIOR FILING DATE: 2003-10-23
/ ; PRIOR APPLICATION NUMBER: US 10/444,853
/ ; PRIOR FILING DATE: 2003-05-23
/ ; PRIOR APPLICATION NUMBER: PCT/US03/05346
/ ; PRIOR FILING DATE: 2003-02-20
/ ; PRIOR APPLICATION NUMBER: PCT/US03/05028
/ ; PRIOR FILING DATE: 2003-02-20
/ ; PRIOR APPLICATION NUMBER: US 60/358,580
/ ; Remaining Prior Application data removed - See File Wrapper or PALM.
/ ; SOFTWARE: PatentIn version 3.3
/ ; SEQ ID NO 1141
/ ; LENGTH: 19
/ ; TYPE: RNA
/ ; ORGANISM: Artificial Sequence
/ ; FEATURE:
/ ; OTHER INFORMATION: Description of Artificial Sequence:
/ ; OTHER INFORMATION: siNA antisense region
US-10-863-973-1141

Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 73.7%; Pred. No. 1.3e+03;
Matches 14; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 2848 AGCTTCTTGAGTAGCTGGG 2866
Db 1 AGCUUCCCGAGUAGCTUGG 19

RESULT 1609
US-09-739-909-9/c
/ ; Sequence 9, Application US/09739909
/ ; Publication No. US20030022163A1
/ ; GENERAL INFORMATION:
/ ; APPLICANT: Mandrekar, Michelle N.
```

APPLICANT: Tereba, Allan
TITLE OF INVENTION: Detection of Repetitive Nucleic Acid Sequences
FILE REFERENCE: US CIP of PRO-104.0
CURRENT APPLICATION NUMBER: US/09/739,909
CURRENT FILING DATE: 2000-12-15
PRIORITY APPLICATION NUMBER: 09/358,972
PRIOR FILING DATE: 1999-07-21
PRIOR APPLICATION NUMBER: 09/383,316
PRIOR FILING DATE: 1999-08-25
NUMBER OF SEQ ID NOS: 30
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 9
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens
US-09-739-909-9

Query Match 0.5%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.4e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2758 TCTGCTCTGTACCCCA 2774
|||||
DB 17 TCTGCTCTGTACCCCA 1

RESULT 1610

US-10-089-887-4/c
Sequence 4, Application US/10089887
Publication No. US20030219740A1
GENERAL INFORMATION:
APPLICANT: Bayer Corporation et al.
TITLE OF INVENTION: DNA Sequences Isolated from Human Colonic Epithelial Cells
FILE REFERENCE: 1657/1020
CURRENT APPLICATION NUMBER: US/10/089,887
CURRENT FILING DATE: 2000-08-08
PRIOR APPLICATION NUMBER: US 60/147,933
PRIOR FILING DATE: 1999-08-09
NUMBER OF SEQ ID NOS: 61
SOFTWARE: PatentIn version 3.1
SEQ ID NO 4
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens
US-10-089-887-4

Query Match 0.5%; Score 15.4; DB 1; Length 18;
Best Local Similarity 94.1%; Pred. No. 1.4e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2772 CCAGGCTGGAGTGCAGT 2788
|||||
DB 18 CCAGGCTGGAGTGCAGT 2

RESULT 1611

US-10-871-222-150/c
Sequence 150, Application US/10871222
Publication No. US20050119212A1
GENERAL INFORMATION:
APPLICANT: Haerberli, Peter
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acids
TITLE OF INVENTION: Synthase Ligand (FASL) Gene Expression Using Short Interfering
FILE REFERENCE: 400/164 (MBHB04-487)
CURRENT APPLICATION NUMBER: US/10/871,222
CURRENT FILING DATE: 2004-06-18
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US10/826966

PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US10/757803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US10/720448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US10/693059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US10/444853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US60/358580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US60/363124
PRIOR FILING DATE: 2002-03-11
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 706
SOFTWARE: PatentIn version 3.3
SEQ ID NO 150
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-871-222-150

Query Match 0.5%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.4e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2903 TTTTTCCTTTTTCCTTTC 2919
|||||
DB 19 TTTTTCCTTTTTCCTTTC 3

RESULT 1612

US-10-871-222-300
Sequence 300, Application US/10871222
Publication No. US20050119212A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: Haerberli, Peter
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RNA Mediated Inhibition Fatty Acid Synthase (FAS) and Fatty Acid
TITLE OF INVENTION: Synthase Ligand (FASL) Gene Expression Using Short Interfering
FILE REFERENCE: 400/164 (MBHB04-487)
CURRENT APPLICATION NUMBER: US/10/871,222
CURRENT FILING DATE: 2004-06-18
PRIOR APPLICATION NUMBER: PCT/US04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US10/826966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US10/757803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US10/720448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US10/693059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US10/444853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: PCT/US03/05028
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US60/358580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US60/363124
PRIOR FILING DATE: 2002-03-11
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 706

```
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 300
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-871-222-300
```

```
Query Match          0.5%; Score 15.4; DB 1; Length 19;
Best Local Similarity 5.9%; Pred. No. 1.4e+03;
Matches 1; Conservative 15; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2903 TTTTCTTTTCTTTTCTTTC 2919
      ::::::::::::::: |
DB 1 UUUUUUUUUUUUUUUUAC 17
```

```
RESULT 1613
US-10-863-973-922/c
; Sequence 922, Application US/10863973
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: Polisky, Barry
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBHB03-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1832
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 922
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  Target Sequence/sRNA sense
```

```
Query Match          0.5%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.4e+03;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 2776 GCTGGAGTGCAGTGGTG 2792
      ||| |||||
DB 19 GCTAGAGTGCAGTGGTG 3
```

```
RESULT 1614
US-10-863-973-1145
; Sequence 1145, Application US/10863973
; Publication No. US2005014333A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: Polisky, Barry
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Interleukin and
; TITLE OF INVENTION: Interleukin Receptor Gene Expression Using Short Interfering
; FILE REFERENCE: 400/163 (MBHB03-084-D)
; CURRENT APPLICATION NUMBER: US/10/863,973
; CURRENT FILING DATE: 2004-06-09
; PRIOR APPLICATION NUMBER: PCT/US03/04566
; PRIOR FILING DATE: 2003-02-14
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1832
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 1145
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:  sRNA antisense region
US-10-863-973-1145

Query Match          0.5%; Score 15.4; DB 1; Length 19;
Best Local Similarity 70.6%; Pred. No. 1.4e+03;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 2776 GCTGGAGTGCAGTGGTG 2792
      ||| |||||
DB 1 GCUAGAGUGCAGUGGUG 17
```

```
RESULT 1615
US-09-747-377-265/c
; Sequence 265, Application US/09747377
; Publication No. US2003002255A1
; GENERAL INFORMATION:
; APPLICANT: Morris, David
; TITLE OF INVENTION: NOVEL COMPOSITIONS AND METHODS FOR BREAST CANCER
; FILE REFERENCE: A-6959/RMS/BCF
; CURRENT APPLICATION NUMBER: US/09/747,377
; CURRENT FILING DATE: 2000-12-22
; NUMBER OF SEQ ID NOS: 493
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 265
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Mus sp.
US-09-747-377-265
```

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2735 TGTGTGTGTGTGTGT 2749
Db 16 TGTGTGTGTGTGTGT 2

RESULT 1616
US-10-105-613-265/c
; Sequence 265, Application US/10105613
; Publication No. US2003009963A1
; GENERAL INFORMATION:
; APPLICANT: Morris, David
; TITLE OF INVENTION: NOVEL COMPOSITIONS AND METHODS FOR BREAST CANCER
; FILE REFERENCE: A-69959/RMS/DCF
; CURRENT APPLICATION NUMBER: US/10/105,613
; CURRENT FILING DATE: 2002-03-20
; PRIOR APPLICATION NUMBER: US/09/747,377
; PRIOR FILING DATE: 2000-12-22
; NUMBER OF SEQ ID NOS: 493
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 265
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Mus sp.
US-10-105-613-265

Query Match 0.5%; Score 15; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.6e+03;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2735 TGTGTGTGTGTGTGT 2749
Db 16 TGTGTGTGTGTGTGT 2

RESULT 1617
US-09-784-423-146/c
; Sequence 146, Application US/09784423
; Patent No. US20020012924A1
; GENERAL INFORMATION:
; APPLICANT: Schumm, James W.
; Bacher, Jeffery W.
; TITLE OF INVENTION: MATERIALS AND METHODS FOR IDENTIFYING AND ANALYZING INTERMEDIATE TANDEM REPEAT DNA MARKERS
; NUMBER OF SEQUENCES: 147
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Promega Corporation
; STREET: 2800 Woods Hollow Road
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: U.S.A.
; ZIP: 53711-5399
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette - 3.5 inch, 1.44 Mb
; COMPUTER: IBM compatible PC
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Word 97 (DOS text format)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/784,423
; FILING DATE: 15-Feb-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/018,584
; FILING DATE: 04-Feb-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Grady J. Frenchick
; REGISTRATION NUMBER: 29,018
; REFERENCE/DOCKET NUMBER: 16026.9180
; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (608) 257-3501
; TELEFAX: (608) 257-2275
; INFORMATION FOR SEQ ID NO: 146
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 146
US-09-784-423-146

Query Match 0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2764 TGTGTCAACCCAGCTGGA 2781
Db 18 TTGTGACCCAGACTGGA 1

RESULT 1618
US-09-731-175-7
; Sequence 7, Application US/09731175
; Patent No. US20020098168A1
; GENERAL INFORMATION:
; APPLICANT: Glorioso, Joseph C.
; Evans, Christopher H.
; Robbins, Paul D.
; TITLE OF INVENTION: Gene Transfer for Studying and Treating
; a Connective Tissue of a Mammalian Host
; NUMBER OF SEQUENCES: 8
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/731,175
; FILING DATE: 05-Dec-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/924,777
; FILING DATE: 2000-01-31
; APPLICATION NUMBER: US 07/963,928
; FILING DATE: 20-OCT-1992
; APPLICATION NUMBER: US 08/027,750
; FILING DATE: 08-MAR-1993
; APPLICATION NUMBER: US 08/183,563
; FILING DATE: 18-JAN-1994
; APPLICATION NUMBER: US 08/381,603
; FILING DATE: 27-JAN-1995
; APPLICATION NUMBER: US 08/567,710
; FILING DATE: 05-DEC-1995
; APPLICATION NUMBER: US 08/685,212
; FILING DATE: 23-JUL-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Bastian, Kevin L.
; REGISTRATION NUMBER: 34,774
; REFERENCE/DOCKET NUMBER: 018484-002280US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 7
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid


```
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 7:
US-09-731-175-7

Query Match          0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1814 GGGGCCATGCTACCTGCA 1831
Db      1 GGCACCATGCTACCTGCA 18

RESULT 1619
US-09-263-959-983/c
; Sequence 983, Application US/09263959
; Patent No. US20020150891A1
; GENERAL INFORMATION:
; APPLICANT: Hood, Leroy E.
; APPLICANT: Rowen, Lee
; APPLICANT: Koop, Ben F.
; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI
; NUMBER OF SEQUENCES: 1279
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Seed and Berry LLP
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: US
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: PC-DOS/MS-DOS
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/263,959
; FILING DATE: 05-MAR-1999
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 920010.426C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 983:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-263-959-983

Query Match          0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2729 TGTGTGTGTGTGTGTATG 2746
Db      18 TGTGTGTATGTGTGTGTG 1

RESULT 1620
US-10-085-906-135
; Sequence 135, Application US/10085906
; Publication No. US20030054371A1
; GENERAL INFORMATION:
; APPLICANT: Ying, Vincent
; APPLICANT: Wu, Paul
; APPLICANT: Gray, Gary S.
```

```
; TITLE OF INVENTION: POLYMORPHIC ELEMENTS IN THE
; TITLE OF INVENTION: COSTIMULATORY RECEPTOR LOCUS AND USES THEREOF
; FILE REFERENCE: GNN-5343CF2
; CURRENT APPLICATION NUMBER: US/10/085,906
; CURRENT FILING DATE: 2002-02-27
; PRIOR APPLICATION NUMBER: US 60/126,215
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 09/534,061
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: PCT/US00/07938
; PRIOR FILING DATE: 2000-03-24
; NUMBER OF SEQ ID NOS: 545
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 135
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-085-906-135

Query Match          0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2726 GCGTGTGTGTGTGTGTGT 2743
Db      1 GTGTCCGTGTGTGTGTGT 18

RESULT 1621
US-10-091-281-314/c
; Sequence 314, Application US/10091281
; Publication No. US20030190617A1
; GENERAL INFORMATION:
; APPLICANT: RAYMOND, VINCENT
; APPLICANT: SI, ERWIN
; APPLICANT: MORISSETTE, JEAN
; TITLE OF INVENTION: OPTINEURIN NUCLEIC ACID MOLECULES AND USES THEREOF
; FILE REFERENCE: 13587.338
; CURRENT APPLICATION NUMBER: US/10/091,281
; CURRENT FILING DATE: 2002-03-06
; NUMBER OF SEQ ID NOS: 463
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 314
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Putative AHRR/AHR.01 motif
US-10-091-281-314

Query Match          0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2766 TGTCAACCCAGCTGGAGT 2783
Db      18 TCTCACCAGCTGGAGT 1

RESULT 1622
US-10-351-951-71/c
; Sequence 71, Application US/10351951
; Publication No. US20030203380A1
; GENERAL INFORMATION:
; APPLICANT: Stefansson, Stefan E.
; TITLE OF INVENTION: GENE LINKED TO OSTEOARTHRITIS
; FILE REFERENCE: 2345.2043-004
; CURRENT APPLICATION NUMBER: US/10/351,951
; CURRENT FILING DATE: 2003-01-24
; PRIOR APPLICATION NUMBER: 10/057,312
; PRIOR FILING DATE: 2002-01-25
; PRIOR APPLICATION NUMBER: 60/431,538
; PRIOR FILING DATE: 2002-12-05
```

```
/ NUMBER OF SEQ ID NOS: 132
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 71
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: primer that hybridizes to the human MATN3 gene
US-10-351-951-71

Query Match          0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2833 TGATCTCCACCTGACC 2850
Db 18 TGATCTCCACCTGGC 1

RESULT 1623
US-10-282-174-247/c
/ Sequence 247, Application US/10282174
/ Publication No. US20030224380A1
/ GENERAL INFORMATION:
/ APPLICANT: Becker, Kenneth David
/ APPLICANT: Velicelebi, Gonul
/ APPLICANT: Elliot, Kathryn J.
/ APPLICANT: Wang, Xin
/ APPLICANT: Tanzi, Rudolph E.
/ APPLICANT: Bertram, Lars
/ APPLICANT: Saunders, Aleister J.
/ APPLICANT: Mullin, Kristina M.
/ APPLICANT: Sampson, Andrew Johnson
/ APPLICANT: Blacker, Deborah Lynne
/ TITLE OF INVENTION: GENES AND POLYMORPHISMS ON CHROMOSOME 10
/ TITLE OF INVENTION: ASSOCIATED WITH ALZHEIMER'S DISEASE AND OTHER
/ FILE REFERENCE: 37481-3308
/ CURRENT APPLICATION NUMBER: US/10/282,174
/ CURRENT FILING DATE: 2002-10-25
/ PRIOR APPLICATION NUMBER: US 60/339,525
/ PRIOR FILING DATE: 2001-10-25
/ PRIOR APPLICATION NUMBER: US 60/338,010
/ PRIOR FILING DATE: 2001-11-08
/ PRIOR APPLICATION NUMBER: US 60/336,929
/ PRIOR FILING DATE: 2001-11-08
/ PRIOR APPLICATION NUMBER: US 60/338,363
/ PRIOR FILING DATE: 2001-11-09
/ PRIOR APPLICATION NUMBER: US 60/337,052
/ PRIOR FILING DATE: 2001-12-04
/ PRIOR APPLICATION NUMBER: US 60/368,919
/ PRIOR FILING DATE: 2002-03-28
/ NUMBER OF SEQ ID NOS: 564
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 247
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Primer
US-10-282-174-247

Query Match          0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2755 AGCTCTCGCTCTGCTGACC 2772
Db 18 AGGCTCTGCACTGCTGACC 1

RESULT 1624
US-10-349-143-5770
```

```
/ Sequence 5770, Application US/10349143
/ Publication No. US20040005584A1
/ GENERAL INFORMATION:
/ APPLICANT: Cohen, Daniel
/ APPLICANT: Blumenfeld, Marta
/ APPLICANT: Chumakov, Ilya
/ TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
/ FILE REFERENCE: GENSET.020CPI
/ CURRENT APPLICATION NUMBER: US/10/349,143
/ CURRENT FILING DATE: 2003-01-21
/ PRIOR APPLICATION NUMBER: US/09/422,978
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
/ PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
/ PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
/ PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
/ PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
/ PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
/ NUMBER OF SEQ ID NOS: 11796
/ SEQ ID NO 5770
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Homo Sapiens
/ FEATURE:
/ NAME/KEY: primer_bind
/ LOCATION: 1..18
/ OTHER INFORMATION: upstream amplification primer 99-6753 for SEQ 1836,
US-10-349-143-5770

Query Match          0.5%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1618 ACCCCCATGAACCGAAC 1635
Db 1 ACCCCCATGAACCGAAC 18

RESULT 1625
US-10-453-792-145/c
/ Sequence 145, Application US/10453792
/ Publication No. US20040029110A1
/ GENERAL INFORMATION:
/ APPLICANT: STUYVER, LIEVEN
/ APPLICANT: ROSSAU, RUDI
/ APPLICANT: MAERTENS, GEERT
/ TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
/ NUMBER OF SEQUENCES: 313
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: NIXON & VANDERHYE P.C.
/ STREET: 1100 NORTH GLEBE ROAD
/ CITY: ARLINGTON
/ STATE: VIRGINIA
/ COUNTRY: U.S.A.
/ ZIP: 22201-4714
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/10/453,792
/ FILING DATE: 04-Jun-2003
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US/09/155,885A
/ FILING DATE: 08-Oct-1998
/ APPLICATION NUMBER: PCT/EP97/02002
/ FILING DATE: 21-APR-1997
/ APPLICATION NUMBER: EP 96870053.4
/ FILING DATE: 19-APR-1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: SADOFF, B.J.
```

```
;
;   REGISTRATION NUMBER: 36,663
;   REFERENCE/DOCKET NUMBER: 2551-5
;   TELECOMMUNICATION INFORMATION:
;   TELEPHONE: (703) 816-4000
;   TELEFAX: (703) 816-4100
;   INFORMATION FOR SEQ ID NO: 145:
;   SEQUENCE CHARACTERISTICS:
;   LENGTH: 18 base pairs
;   TYPE: nucleic acid
;   STRANDEDNESS: single
;   TOPOLOGY: linear
;   MOLECULE TYPE: DNA (genomic)
;   HYPOTHETICAL: NO
;   ANTI-SENSE: NO
;   SEQUENCE DESCRIPTION: SEQ ID NO: 145:
US-10-453-792-145

      Query Match          0.5%;   Score 14.8;   DB 1;   Length 18;
      Best Local Similarity 88.9%;   Pred. No. 1.6e+03;
      Matches 16;   Conservative 0;   Mismatches 2;   Indels 0;   Gaps 0;

QY      216 CCAGCCCAAGTTGTTGGG 233
Db      18 CCAGCCCAAGATGATGGG 1

RESULT 1626
US-10-600-009-247/c
; Sequence 247, Application US/10600009
; Publication No. US2005009031A1
; GENERAL INFORMATION:
; APPLICANT: Becker, Kenneth David
; APPLICANT: Velicelebi, Gonul
; APPLICANT: Elliot, Kathryn J.
; APPLICANT: Wang, Xin
; APPLICANT: Tanzi, Rudolph E.
; APPLICANT: Bertram, Lars
; APPLICANT: Saunders, Aleister J.
; APPLICANT: Mullin, Kristina M.
; APPLICANT: Sampson, Andrew Johnson
; APPLICANT: Blacker, Deborah Lynne
; TITLE OF INVENTION: GENES AND POLYMORPHISMS ON CHROMOSOME 10
; TITLE OF INVENTION: ASSOCIATED WITH ALZHEIMER'S DISEASE AND OTHER
; TITLE OF INVENTION: NEURODEGENERATIVE DISEASES
; FILE REFERENCE: 37481-3308B
; CURRENT APPLICATION NUMBER: US/10/600,009
; CURRENT FILING DATE: 2003-06-18
; PRIOR APPLICATION NUMBER: US 60/339,525
; PRIOR FILING DATE: 2001-10-25
; PRIOR APPLICATION NUMBER: US 60/338,010
; PRIOR FILING DATE: 2001-11-08
; PRIOR APPLICATION NUMBER: US 60/336,929
; PRIOR FILING DATE: 2001-11-08
; PRIOR APPLICATION NUMBER: US 60/338,363
; PRIOR FILING DATE: 2001-11-09
; PRIOR APPLICATION NUMBER: US 60/337,052
; PRIOR FILING DATE: 2001-12-04
; PRIOR APPLICATION NUMBER: US 60/368,919
; PRIOR FILING DATE: 2002-03-28
; PRIOR APPLICATION NUMBER: US 10/282,174
; PRIOR FILING DATE: 2002-10-25
; NUMBER OF SEQ ID NOS: 564
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 247
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-600-009-247

      Query Match          0.5%;   Score 14.8;   DB 1;   Length 18;
      Best Local Similarity 88.9%;   Pred. No. 1.6e+03;
      Matches 16;   Conservative 0;   Mismatches 2;   Indels 0;   Gaps 0;

QY      2755 AGCTCTGCTCTGTCAACC 2772
Db      18 AGGTCTGCACTGTCAACC 1

Matches 16;   Conservative 0;   Mismatches 2;   Indels 0;   Gaps 0;

RESULT 1627
US-10-856-122-82/c
; Sequence 82, Application US/10856122
; Publication No. US20050074850A1
; GENERAL INFORMATION:
; APPLICANT: NADLER, MONICA J.S.
; APPLICANT: KINET, JEAN-PIERRE
; APPLICANT: LAUNAY, JEROME
; APPLICANT: MAHIOU, JEROME
; TITLE OF INVENTION: NOVEL CALCIUM CHANNELS AND USES THEREOF
; FILE REFERENCE: 290058.120 US2
; CURRENT APPLICATION NUMBER: US/10/856,122
; CURRENT FILING DATE: 2004-05-28
; PRIOR APPLICATION NUMBER: 60/474,245
; PRIOR FILING DATE: 2003-05-28
; NUMBER OF SEQ ID NOS: 126
; SOFTWARE: PatentIn Ver. 3.2
; SEQ ID NO 82
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-856-122-82

      Query Match          0.5%;   Score 14.8;   DB 1;   Length 18;
      Best Local Similarity 88.9%;   Pred. No. 1.6e+03;
      Matches 16;   Conservative 0;   Mismatches 2;   Indels 0;   Gaps 0;

QY      745 GACAGCGAGGGGACGGTG 762
Db      18 GACATGCGAGGGGACGGTG 1

Matches 16;   Conservative 0;   Mismatches 2;   Indels 0;   Gaps 0;

RESULT 1628
US-10-984-919-561/c
; Sequence 561, Application US/10984919
; Publication No. US20050130927A1
; GENERAL INFORMATION:
; APPLICANT: Schlingensiepen, Karl-Hermann
; APPLICANT: Brysch, Wolfgang
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD
; FILE REFERENCE: 10496/P63763USO
; CURRENT APPLICATION NUMBER: US/10/984,919
; CURRENT FILING DATE: 2004-11-10
; PRIOR APPLICATION NUMBER: US/09/341,700
; PRIOR FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: PCT/EP98/00497
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: EP 97 101 531.8
; PRIOR FILING DATE: 1997-01-31
; NUMBER OF SEQ ID NOS: 1764
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 561
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: antisense oligonucleotide
US-10-984-919-561

      Query Match          0.5%;   Score 14.8;   DB 1;   Length 18;
      Best Local Similarity 88.9%;   Pred. No. 1.6e+03;
      Matches 16;   Conservative 0;   Mismatches 2;   Indels 0;   Gaps 0;
```

QY 2899 TTGATTTTTCCTTTTTCCTT 2916
Db 18 TTGATTTTTCCTTTTTCCTT 1

RESULT 1629

US-10-956-157-173783/c
; Sequence 173783, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 173783
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
; OTHER INFORMATION: Probe Sequence
US-10-956-157-173783

Query Match 0.5%; Score 14.6; DB 1; Length 25;

Best Local Similarity 81.0%; Pred. No. 1.2e+03;

Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 385 TACTGCACTCCAGACGGGTG 405

Db 21 TACTGCACTCCAGCCTGGGTG 1

RESULT 1630

US-10-177-308-12/c
; Sequence 12, Application US/10177308
; Publication No. US20030175262A1
; GENERAL INFORMATION:
; APPLICANT: Sheppard, Paul O.

; APPLICANT: Baidur, Nand
; APPLICANT: Bishop, Paul D.
; TITLE OF INVENTION: MAMMALIAN ADHESION PROTEASE PEPTIDES
; FILE REFERENCE: 99-39
; CURRENT APPLICATION NUMBER: US/10/177,308
; CURRENT FILING DATE: 2002-06-21
; PRIOR FILING DATE: 2000-08-02
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 12
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide ZC22,481
US-10-177-308-12

Query Match 0.5%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 1.8e+03;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 840 CACAGTCACCTATGCC 855

Db 18 CACAGTCACCCATGCC 3

RESULT 1631

US-10-730-771-406
; Sequence 406, Application US/10730771
; Publication No. US20050074787A1
; GENERAL INFORMATION:
; APPLICANT: Fan, Jian-Bing

; APPLICANT: Hirschhorn, Joel N.
; APPLICANT: Huang, Xiachua
; APPLICANT: Kaplan, Paul
; APPLICANT: Lander, Eric S.
; APPLICANT: Lockhart, David J.
; APPLICANT: Ryder, Thomas
; APPLICANT: Sklar, Pamela
; TITLE OF INVENTION: UNIVERSAL ARRAYS
; FILE REFERENCE: 2825.1016-007
; CURRENT APPLICATION NUMBER: US/10/730,771
; CURRENT FILING DATE: 2003-12-08
; PRIOR APPLICATION NUMBER: US 60/126,473
; PRIOR FILING DATE: 1999-03-26
; PRIOR APPLICATION NUMBER: US 60/140,359
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: US 09/536,841
; PRIOR FILING DATE: 2000-03-27
; NUMBER OF SEQ ID NOS: 590
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 406
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Template sequence
US-10-730-771-406

Query Match 0.5%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 1.8e+03;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2254 CACATTCACGGTCACC 2269

Db 3 CACATTCACGGTCACC 18

RESULT 1632

US-09-969-373-3402/c
; Sequence 3402, Application US/09969373
; Patent No. US20020133852A1
; GENERAL INFORMATION:
; APPLICANT: Effertz, Roger J.
; APPLICANT: Hauge, Brian M.
; TITLE OF INVENTION: Soybean SSRs and Methods of Genotyping
; FILE REFERENCE: 38-10(52679)A
; CURRENT APPLICATION NUMBER: US/09/969,373
; CURRENT FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: US 09/754,853
; PRIOR FILING DATE: 2001-01-05
; PRIOR APPLICATION NUMBER: US 09/760,427
; PRIOR FILING DATE: 2001-01-13
; PRIOR APPLICATION NUMBER: US 09/855,768
; PRIOR FILING DATE: 2001-05-15
; NUMBER OF SEQ ID NOS: 4593
; SEQ ID NO 3402
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Glycine max
US-09-969-373-3402

Query Match 0.5%; Score 14.4; DB 1; Length 18;

Best Local Similarity 93.8%; Pred. No. 1.8e+03;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1627 AAACCGAACACACAG 1642

Db 18 AAACCGAACACACAG 3

RESULT 1633

US-09-881-012-1/c
; Sequence 1, Application US/09881012
; Publication No. US20020192655A1

```
; GENERAL INFORMATION:
; APPLICANT: Ginns, Edward I.
; APPLICANT: Egeland, Janice A.
; APPLICANT: Paul, Steven M.
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by The Secretary of the
; APPLICANT: Department of Health and Human Services
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Susceptibility and Resistance Genes for
; TITLE OF INVENTION: Bipolar Affective Disorder
; FILE REFERENCE: 015280-248110US
; CURRENT APPLICATION NUMBER: US/09/881,012
; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US/09/175,158
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: US 60/062,924
; PRIOR FILING DATE: 1997-10-20
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: D6S344 forward primer
US-09-881-012-1

Query Match          0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.8e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2767 GTACCCAGGCTGGAG 2782
   ||| ||||| ||||| |||||
Db 16 GTGACCCAGGCTGGAG 1

RESULT 1634
US-09-881-012-1/c
; Sequence 1, Application US/09881012
; Publication No. US20040248086A9
; GENERAL INFORMATION:
; APPLICANT: Ginns, Edward I.
; APPLICANT: Egeland, Janice A.
; APPLICANT: Paul, Steven M.
; APPLICANT: The Government of the United States of America
; APPLICANT: as represented by The Secretary of the
; APPLICANT: Department of Health and Human Services
; TITLE OF INVENTION: Susceptibility and Resistance Genes for
; TITLE OF INVENTION: Bipolar Affective Disorder
; FILE REFERENCE: 015280-248110US
; CURRENT APPLICATION NUMBER: US/09/881,012
; CURRENT FILING DATE: 2001-06-13
; PRIOR APPLICATION NUMBER: US/09/175,158
; PRIOR FILING DATE: 1998-10-19
; PRIOR APPLICATION NUMBER: US 60/062,924
; PRIOR FILING DATE: 1997-10-20
; NUMBER OF SEQ ID NOS: 240
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: D6S344 forward primer
US-09-881-012-1

Query Match          0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.8e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2767 GTACCCAGGCTGGAG 2782
   ||| ||||| ||||| |||||
Db 16 GTGACCCAGGCTGGAG 1

RESULT 1635
US-10-197-290-32
; Sequence 32, Application US/10197290
; Publication No. US20030083300A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Elizabeth J. Ackermann
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF CELLULAR INHIBITOR OF APOPTOSIS-2
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTSP-0421
; CURRENT APPLICATION NUMBER: US/10/197,290
; CURRENT FILING DATE: 2002-07-16
; PRIOR APPLICATION NUMBER: 09/857,299
; PRIOR FILING DATE: 2001-20-04
; PRIOR APPLICATION NUMBER: PCT/US99/22083
; PRIOR FILING DATE: 1999-09-23
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 32
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-197-290-32

Query Match          0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.8e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1499 TTGTCATCATCACTGT 1514
   ||| ||||| ||||| |||||
Db 2 TTGACATCATCACTGT 17

RESULT 1636
US-10-178-325-168
; Sequence 168, Application US/10178325
; Publication No. US20030199467A1
; GENERAL INFORMATION:
; APPLICANT: Roberts, M. Luisa
; APPLICANT: Cowsett, Lex M.
; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
; TITLE OF INVENTION: Expression
; FILE REFERENCE: ISPH-0404
; CURRENT APPLICATION NUMBER: US/10/178,325
; CURRENT FILING DATE: 2002-06-21
; PRIOR APPLICATION NUMBER: US/09/387,341
; PRIOR FILING DATE: 1999-08-31
; PRIOR APPLICATION NUMBER: 09/156,424
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 09/156,979
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 09/156,807
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 09/161,015
; PRIOR FILING DATE: 1998-09-25
; NUMBER OF SEQ ID NOS: 233
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 168
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-178-325-168

Query Match          0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.8e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1702 GGACGTGGTGCCACAC 1717
```

Db 3 GGCAAGTGGTGGCACAC 18
|||||

RESULT 1637

US-10-388-263-185

; Sequence 185, Application US/10388263

; Publication No. US20030228597A1

; GENERAL INFORMATION:

; APPLICANT: Cowsert, Lex M.

; APPLICANT: Baker, Brenda F.

; APPLICANT: McNeil, John

; APPLICANT: Freier, Susan M.

; APPLICANT: Sasmor, Henri M.

; APPLICANT: Brooks, Douglas G.

; APPLICANT: Ohashi, Cara

; APPLICANT: Wyatt, Jacqueline R.

; APPLICANT: Borchers, Alexander

; APPLICANT: Vickers, Timothy A.

; TITLE OF INVENTION: IDENTIFICATION OF GENETIC TARGETS FOR

; MODULATION BY OLIGONUCLEOTIDES AND

; TITLE OF INVENTION: GENERATION OF OLIGONUCLEOTIDES FOR GENE MODULATION

; FILE REFERENCE: IS18-4503

; CURRENT APPLICATION NUMBER: US/10/388,263

; CURRENT FILING DATE: 2003-03-12

; NUMBER OF SEQ ID NOS: 947

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 185

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-10-388-263-185

Query Match 0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.8e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1499 TTGTATCATCACTGT 1514

|||

Db 2 TTGACATCACTGT 17

RESULT 1638

US-10-853-665-12/c

; Sequence 12, Application US/10853665

; Publication No. US20040259163A1

; GENERAL INFORMATION:

; APPLICANT: Sheppard, Paul O.

; APPLICANT: Baidur, Nand D.

; APPLICANT: Bishop, Paul D.

; TITLE OF INVENTION: MAMMALIAN ADHESION PROTEASE PEPTIDES

; FILE REFERENCE: 99-39

; CURRENT APPLICATION NUMBER: US/10/853,665

; PRIOR FILING DATE: 2004-05-25

; PRIOR APPLICATION NUMBER: US/10/177,308

; PRIOR FILING DATE: 2002-06-21

; PRIOR APPLICATION NUMBER: US/09/632,098

; PRIOR FILING DATE: 2000-08-02

; NUMBER OF SEQ ID NOS: 26

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 12

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Oligonucleotide ZC22,481

US-10-853-665-12

Query Match 0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.8e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 840 CACAGTCACCTATGGC 855

|||||

Db 18 CACAGTCACCTATGGC 3

RESULT 1639

US-10-829-674-38/c

; Sequence 38, Application US/10829674

; Publication No. US20050112611A1

; GENERAL INFORMATION:

; APPLICANT: Anna Helgadottir

; TITLE OF INVENTION: SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION AND STROKE

; FILE REFERENCE: 30847/2048-004

; CURRENT APPLICATION NUMBER: US/10/829,674

; CURRENT FILING DATE: 2004-04-22

; PRIOR APPLICATION NUMBER: 10/769,542

; PRIOR FILING DATE: 2004-01-30

; PRIOR APPLICATION NUMBER: PCT/US03/32805

; PRIOR FILING DATE: 2003-10-16

; PRIOR APPLICATION NUMBER: 60/419,432

; PRIOR FILING DATE: 2002-10-17

; NUMBER OF SEQ ID NOS: 717

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 38

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Homo sapiens

; US-10-829-674-38

Query Match 0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.8e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTGCA 2786

|||||

Db 17 CCCAGGCTGGAGTGCA 2

RESULT 1640

US-10-830-477-38/c

; Sequence 38, Application US/10830477

; Publication No. US20050113408A1

; GENERAL INFORMATION:

; APPLICANT: Helgadottir et al.

; TITLE OF INVENTION: SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION, STROKE, AND PAOD;

; METHODS OF TREATMENT

; FILE REFERENCE: 30847/2051-005

; CURRENT APPLICATION NUMBER: US/10/830,477

; CURRENT FILING DATE: 2004-04-22

; PRIOR APPLICATION NUMBER: 10/769,744

; PRIOR FILING DATE: 2004-01-30

; PRIOR APPLICATION NUMBER: PCT/US03/32556

; PRIOR FILING DATE: 2003-10-16

; PRIOR APPLICATION NUMBER: 60/419,433

; PRIOR FILING DATE: 2002-10-17

; PRIOR APPLICATION NUMBER: 60/449,331

; PRIOR FILING DATE: 2003-02-21

; NUMBER OF SEQ ID NOS: 717

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 38

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Homo sapiens

; US-10-830-477-38

Query Match 0.5%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 1.8e+03;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2771 CCCAGGCTGGAGTGCA 2786

|||||

Db 17 CCCAGGCTGGAGTGCA 2

Search completed: July 26, 2005, 15:21:41
Job time : 64 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: July 26, 2005, 15:29:59 ; Search time 3 seconds
(without alignments)
4.242 Million cell updates/sec

Title: mm000201
Perfect score: 2986
Sequence: 1 GCGCCCGAGTCAGCGTCAG.....ATAGAGCTTCTCAACTGCC 2986

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 95 seqs, 2131 residues

Total number of hits satisfying chosen parameters: 190

Minimum DB seq length: 18
Maximum DB seq length: 26

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 95 summaries

Database : rst201.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	26	0.9	26	1	T97446
2	24	0.8	25	1	H93534
3	21.8	0.7	25	1	AZ467470
4	21.8	0.7	25	1	AZ762101
5	21.8	0.7	26	1	AZ646850
6	21.8	0.7	26	1	AZ830951
7	21.4	0.7	24	1	AZ647335
8	21.4	0.7	26	1	AZ774981
9	21.4	0.7	26	1	AZ781130
10	21.2	0.7	26	1	R15830
11	20.8	0.7	24	1	AZ846178
12	20.8	0.7	24	1	TA163H1LP
13	20.8	0.7	25	1	BX563211
14	20.8	0.7	25	1	AZ339866
15	20.8	0.7	25	1	AZ345553
16	20.8	0.7	25	1	AZ404057
17	20.8	0.7	25	1	AZ769873
18	20.8	0.7	25	1	AZ771881
19	20.8	0.7	26	1	BX569116
20	20.8	0.7	26	1	AZ307889
21	20.8	0.7	26	1	AZ345505
22	20.8	0.7	26	1	AZ494537
23	20.8	0.7	26	1	AZ503652
24	20.8	0.7	26	1	AZ795803
25	20.8	0.7	26	1	AZ806004
26	20.8	0.7	26	1	AZ975568
27	20.4	0.7	22	1	AZ985497
28	20.4	0.7	23	1	BX557786
29	20.4	0.7	23	1	AZ328763
30	20.4	0.7	23	1	AZ483624
31	20.4	0.7	23	1	AZ637290
32	20.4	0.7	23	1	AZ789907
33	20.4	0.7	23	1	AZ828969

ALIGNMENTS

C	34	20.4	0.7	23	1	AZ829195	ACCESSION:AZ829195
	35	20.4	0.7	24	1	BX559963	ACCESSION:BX559963
	36	20.4	0.7	24	1	AZ19602	ACCESSION:AZ19602
	37	20.4	0.7	24	1	AZ446429	ACCESSION:AZ446429
	38	20.4	0.7	24	1	AZ621455	ACCESSION:AZ621455
	39	20.4	0.7	24	1	AZ807762	ACCESSION:AZ807762
C	40	20.4	0.7	24	1	AZ813106	ACCESSION:AZ813106
	41	20.4	0.7	25	1	AZ459694	ACCESSION:AZ459694
	42	20	0.7	20	1	AZ482421	ACCESSION:AZ482421
	43	20	0.7	21	1	AZ415089	ACCESSION:AZ415089
C	44	20	0.7	25	1	N77071	ACCESSION:N77071
C	45	19.8	0.7	23	1	AZ309945	ACCESSION:AZ309945
	46	19.4	0.6	21	1	AZ310642	ACCESSION:AZ310642
	47	19.4	0.6	21	1	AZ333309	ACCESSION:AZ333309
	48	19.4	0.6	21	1	AZ635627	ACCESSION:AZ635627
	49	19.4	0.6	21	1	AZ641805	ACCESSION:AZ641805
	50	19.4	0.6	21	1	AZ762904	ACCESSION:AZ762904
	51	19.4	0.6	21	1	AZ854856	ACCESSION:AZ854856
	52	19.4	0.6	22	1	AZ464442	ACCESSION:AZ464442
	53	19.4	0.6	22	1	AZ484090	ACCESSION:AZ484090
C	54	19.4	0.6	22	1	AZ780002	ACCESSION:AZ780002
	55	19.4	0.6	23	1	AZ371475	ACCESSION:AZ371475
	56	19.4	0.6	23	1	AZ620203	ACCESSION:AZ620203
	57	19.4	0.6	23	1	AZ824638	ACCESSION:AZ824638
	58	18.8	0.6	22	1	AZ500466	ACCESSION:AZ500466
	59	18.8	0.6	22	1	AZ793094	ACCESSION:AZ793094
C	60	18.8	0.6	23	1	AZ356191	ACCESSION:AZ356191
	61	18.4	0.6	20	1	AZ368875	ACCESSION:AZ368875
	62	18.4	0.6	20	1	AZ465453	ACCESSION:AZ465453
	63	18.4	0.6	20	1	AZ470768	ACCESSION:AZ470768
	64	18.4	0.6	20	1	AZ580200	ACCESSION:AZ580200
	65	18.4	0.6	20	1	AZ634201	ACCESSION:AZ634201
C	66	18.4	0.6	20	1	AZ946508	ACCESSION:AZ946508
	67	18.4	0.6	20	1	AZ959039	ACCESSION:AZ959039
C	68	18.4	0.6	21	1	AZ991225	ACCESSION:AZ991225
	69	18.4	0.6	22	1	AZ514387	ACCESSION:AZ514387
C	70	18.4	0.6	22	1	AZ780118	ACCESSION:AZ780118
	71	18.4	0.6	23	1	AZ452951	ACCESSION:AZ452951
C	72	18	0.6	19	1	AZ995094	ACCESSION:AZ995094
	73	18	0.6	19	1	AZ491644	ACCESSION:AZ491644
C	74	17.8	0.6	21	1	AZ513902	ACCESSION:AZ513902
	75	17.8	0.6	21	1	AZ621072	ACCESSION:AZ621072
C	76	17.8	0.6	21	1	AZ818214	ACCESSION:AZ818214
	77	17.8	0.6	22	1	AZ784203	ACCESSION:AZ784203
	78	17.8	0.6	22	1	AZ801266	ACCESSION:AZ801266
	79	17.4	0.6	19	1	AZ431700	ACCESSION:AZ431700
C	80	17.4	0.6	19	1	AZ649147	ACCESSION:AZ649147
	81	17.4	0.6	19	1	AZ774954	ACCESSION:AZ774954
C	82	17.4	0.6	19	1	AZ795767	ACCESSION:AZ795767
	83	17.4	0.6	19	1	AZ822936	ACCESSION:AZ822936
	84	17.4	0.6	19	1	AZ827177	ACCESSION:AZ827177
C	85	17.4	0.6	19	1	CR786637	ACCESSION:CR786637
	86	17	0.6	18	1	AZ786779	ACCESSION:AZ786779
	87	17	0.6	19	1	AZ654458	ACCESSION:AZ654458
	88	16.8	0.6	20	1	AZ785549	ACCESSION:AZ785549
	89	16.8	0.6	20	1	AZ629111	ACCESSION:AZ629111
	90	16.8	0.6	21	1	AJ725584	ACCESSION:AJ725584
C	91	16.4	0.5	18	1	AZ793887	ACCESSION:AZ793887
	92	16.4	0.5	20	1	AZ398474	ACCESSION:AZ398474
C	93	16	0.5	20	1	AZ772074	ACCESSION:AZ772074
	94	16	0.5	20	1	CL693868	ACCESSION:CL693868
C	95	15.8	0.5	19	1		

RESULT 1

T97446

LOCUS

DEFINITION

T97446

yes7903.r1 Soares fetal liver spleen INFLS Homo sapiens cDNA clone

IMAGE:121876 5', similar to gb:M23892 ARACHIDONATE 15-LIPOXYGENASE

(HUMAN);, mRNA sequence.

26 bp

mrna

linear

EST 29-MAR-1995

Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLCC, UT
84112, USA

Insert Length: 10000 Std Error: 0.00
 Plate: 0019 row: A column: 07
 Seq primer: CGTTGTAACACGCGCCAGT
 Class: plasmid ends
 High quality sequence stop: 26.
 Location/Qualifiers

FEATURES

source

```

1..26
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0019A07"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

Query Match 0.7%; Score 21.4; DB 1; Length 26;

Best Local Similarity 95.7%; Pred. No. 18; Matches 22; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGA 2750

Db 2 GTGTGTGTGTGTGTGTGTGTGA 24

RESULT 10

R15830/c

LOCUS

DEFINITION

Y445f05.r1 Soares infant brain INTB Homo sapiens cDNA clone IMAGE:53108 5', similar to gb|M87929|HUMALU146 Human carcinoma cell-derived alu RNA transcript, (rRNA); gb:M29874 CYTOCHROME P450 I1B6 (HUMAN); mRNA sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Homo sapiens (human)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

1 (bases 1 to 26)

Hillier,L., Clark,N., Dubuque,T., Elliston,K., Hawkins,M.,

Holman,M., Hultman,M., Kucaba,T., Le,M., Lennon,G., Marra,M.,

Parsons,J., Rifkin,L., Rohlffing,T., Soares,M., Tan,F.,

Trevaskis,E., Waterson,R., Williamson,A., Wohlmann,P. and

Wilson.R.

The WashU-Merck EST Project

Unpublished (1995)

Contact: Wilson RK

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800

Fax: 314 286 1810

Email: est@watson.wustl.edu

High quality sequence starts: 1

High qality sequence stops: 1
 Source: IMAGE Consortium, LLNL
 This clone is available royalty-free through LLNL ; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.
 Trace considered overall poor quality
 Seq primer: M13RP1
 High quality sequence stop: 1.
 Location/Qualifiers

FEATURES

source

```

1..26
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:426044"
/db_xref="taxon:9606"
/clone="IMAGE:53108"
/sex="female"
/dev_stages="73 days post natal"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares infant brain INIB"
/note="Organ: whole brain; Vector: Lafmid BA; Site 1: Not I; Site 2: Hind III; 1st strand cDNA was primed with a Not I - oligo(dT) primer [5' AACTGGAAGAATCGCGCCGAGGAATTTTTTTTTTTTTTTT 3']; double-stranded cDNA was ligated to Hind III adaptors (Pharmacia), digested with Not I and directionally cloned into the Not I and Hind III sites of the Lafmid BA vector. Library went through one round of normalization. Library constructed by Bento Soares and M.Fatima Bonaldo."

```

Query Match 0.7%; Score 21.2; DB 1; Length 26;

Best Local Similarity 88.5%; Pred. No. 19; Matches 23; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2771 CCCAGCTGGAGTCGACGTGTGCAAT 2796

Db 26 CCCAGCTGGAGTCGACGTGTGAT 1

RESULT 11

AZ846178

LOCUS

DEFINITION

2M0146F14F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0146F14 F, genomic survey sequence.

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

Mus musculus

1 (bases 1 to 24)

Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,

Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,

Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von

Niederhausern,A. and Wright,D., Weiss,R.

Mouse whole genome scaffolding with paired end reads from 10kb

Plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah

Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0146 row: F column: 14

Seq primer: CGTTGTAACACGCGCCAGT

Class: plasmid ends

High quality sequence stop: 24.

Location/Qualifiers

1..24

/organism="Mus musculus"

/mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="JUGC2M0146F14"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, Tl-resistant, P-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male); was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.7%; Score 20.8; DB 1; Length 24;
 Best Local Similarity 91.7%; Pred. No. 19;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 24

RESULT 12
 TAl63H11P/C
 LOCUS
 DEFINITION T. brucei sheared genomic DNA clone 163h11, forward sequence, genomic survey sequence.
 ACCESSION AL472248
 VERSION AL472248.1 GI:11837597
 KEYWORDS GSS.
 SOURCE Trypanosoma brucei
 ORGANISM Trypanosoma brucei
 Eukaryota; Euglenozoa; Kinetoplastida; Trypanosomatidae;
 Trypanosoma.
 REFERENCE 1 (bases 1 to 24)
 AUTHORS Hall N., Bowman, S., Lennard, N.J., Doggett, J., Atkin, R., Chillingworth, C., Ormond, D., Harris, B., El-Sayed, N., Hou, L., Melville, S.E., Rajandream, M.A. and Barrell, B.G.
 TITLE Direct Submission
 JOURNAL Submitted (10-DEC-2000) Trypanosoma brucei genome sequencing project, Sanger Centre, The Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SA, E-mail: barrell@sanger.ac.uk and rhi@sanger.ac.uk
 COMMENT Constructed at the Institute for Genomic Research (TIGR), Rockville, MD. Genomic DNA isolated from a cloned population of Trypanosoma brucei (TREU927/4 GUTAT 10.1) was mechanically sheared to give a tight size distribution (4 kb). The v + i method used for the library construction is described in detail in Smith, H. and Venter, J.C. (Making small insert libraries for whole genome shotgun sequencing projects. In Genome Sequencing: A Practical Approach, eds. M. Vaudin and B. Barrell, Oxford University Press, 1999).
 Email: nelsayed@tigr.org
 Details of T. brucei sequencing at the Sanger Centre are available at http://www.sanger.ac.uk/projects/T-brucei/.

FEATURES
 source
 1..24
 Location/Qualifiers
 /organism="Trypanosoma brucei"
 /mol_type="genomic DNA"

/strain="TREU927"
 /db_xref="taxon:5691"
 /clone="163h11"

Query Match 0.7%; Score 20.8; DB 1; Length 24;
 Best Local Similarity 91.7%; Pred. No. 19;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 24 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 13
 BX563211
 LOCUS
 DEFINITION BX563211 Glossina morsitans morsitans adult infected gut Glossina morsitans morsitans cdna clone Tse65b06_plc, mRNA sequence.
 ACCESSION BX563211
 VERSION BX563211.1 GI:33430473
 KEYWORDS EST.
 SOURCE Glossina morsitans morsitans
 ORGANISM Glossina morsitans morsitans
 Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Hippoboscidae; Glossinidae; Glossina.
 REFERENCE 1 (bases 1 to 25)
 AUTHORS Lehane, M.J., Aksoy, S., Gibson, W., Kerhornou, A., Berriman, M., Hamilton, J., Soares, M.B., Donald, M.F., Lehane, S. and Hall, N.
 TITLE Adult midgut expressed sequence tags from the tsetse fly Glossina morsitans morsitans and expression analysis of putative immune response genes
 JOURNAL Genome Biol. 4 (10), R63 (2003)
 MEDLINE 22881942
 PUBMED 14519198
 COMMENT Contact: Hall N
 Pathogen Sequencing Unit
 The Sanger Institute The Wellcome Trust Genome Campus
 Hinxton, Cambridge, CB10 1SA, UK
 Request for clones, please contact: Mike Lehane
 Prof. M.J.Lehane
 School of Biological Sciences,
 University of Wales,
 Bangor LL57 2UW
 All clones with suffix q1c are reverse primer reads starting at 5' end of the cDNA all plc reads are from the 3' end.

FEATURES
 source
 1..25
 Location/Qualifiers
 /organism="Glossina morsitans morsitans"
 /mol_type="mRNA"
 /sub_species="morsitans"
 /db_xref="taxon:37546"
 /clone="Tse65b06_plc"
 /tissue_type="adult infected gut"
 /clone_lib="Glossina morsitans morsitans adult infected gut"
 /note="country: Zimbabwe; EST from adult gut infected with T.brucei"

Query Match 0.7%; Score 20.8; DB 1; Length 25;
 Best Local Similarity 91.7%; Pred. No. 20;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 2 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 25

RESULT 14
 AZ339866
 LOCUS
 DEFINITION AZ339866
 1M0071H01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic

SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1 (bases 1 to 25)
 AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
 TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 JOURNAL Unpublished (2000)
 COMMENT Contact: Robert B. Weiss
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0574 row: F column: 23
 Seq primer: CGTTGTAACACGCGCCAGT
 Class: plasmid ends
 High quality sequence stop: 25.
 FEATURES
 source Location/Qualifiers
 1..25
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="JUGC1M0574P23"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.7%; Score 20.8; DB 1; Length 25;
 Best Local Similarity 91.7%; Pred. No. 20;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGT 2749
 Db 1 GTGTGTGTGTGTGTGTGTGTGT 24

RESULT 19
 BX569116
 LOCUS BX569116 Glossina morsitans morsitans adult infected gut Glossina morsitans morsitans cDNA clone Tse97f02_plc, mRNA sequence.
 DEFINITION BX569116
 ACCESSION BX569116
 VERSION BX569116.1 GI:33437055
 KEYWORDS EST.
 SOURCE Glossina morsitans morsitans

ORGANISM Glossina morsitans morsitans
 Eukaryota; Metazoa; Arthropoda; Insecta; Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Hippoboscoidae; Glossinidae; Glossina.
 REFERENCE 1 (bases 1 to 26)
 AUTHORS Lehane,M.J., Aksoy,S., Gibson,W., Kerhornou,A., Berriman,M., Hamilton,J., Soares,M.B., Bonaldo,M.F., Lehane,S. and Hall,N.
 TITLE Adult midgut expressed sequence tags from the tsetse fly Glossina morsitans morsitans and expression analysis of putative immune response genes
 JOURNAL Genome Biol. 4 (10), R63 (2003)
 MEDLINE 22881942
 PUBMED 14519198
 COMMENT Contact: Hall N
 Pathogen Sequencing Unit
 The Sanger Institute The Wellcome Trust Genome Campus
 Hinxton, Cambridge, CB10 1SA, UK
 Request for clones, please contact: Mike Lehane
 Prof. M.J. Lehane
 School of Biological Sciences,
 University of Wales,
 Bangor LL57 2UW
 All clones with suffix q1c are reverse primer reads starting at 5' end of the cDNA all plc reads are from the 3' end.
 FEATURES
 source Location/Qualifiers
 1..26
 /organism="Glossina morsitans morsitans"
 /mol_type="mRNA"
 /sub_species="morsitans"
 /db_xref="taxon:37546"
 /clone="Tse97f02_plc"
 /tissue_type="adult infected gut"
 /clone_lib="Glossina morsitans morsitans adult infected gut"
 /note="country: Zimbabwe; EST from adult gut infected with T.brucei"

Query Match 0.7%; Score 20.8; DB 1; Length 26;
 Best Local Similarity 91.7%; Pred. No. 21;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 1 GTGTGTGTGTGTGTGTGTGTGTGT 24

RESULT 20
 AZ307889
 LOCUS AZ307889 26 bp DNA linear GSS 29-SEP-2000
 DEFINITION clone UUGC1M0010u18 F, genomic survey sequence.
 ACCESSION AZ307889
 VERSION AZ307889.1 GI:10347331
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 REFERENCE 1 (bases 1 to 26)
 AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
 TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 JOURNAL Unpublished (2000)
 COMMENT Contact: Robert B. Weiss
 University of Utah Genome Center
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606

Seq primer: CGTTGTAACACGACGGCCAGT
 Class: plasmid ends
 High quality sequence stop: 26.

FEATURES

Location/Qualifiers

1..26
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC2M0051P11"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.7%; Score 20.8; DB 1; Length 26;
 Best Local Similarity 91.7%; Pred. No. 21;
 Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 Db 2 GGTGTGTGTGTGTGTGTGTGTGTGTGTGT 25

RESULT 25

AZ806004

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

26 bp DNA linear GSS 20-FEB-2001

clone UUGC2M0067H16 R, genomic survey sequence.

GI:12966815

Mus musculus (house mouse)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 26)

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,

Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,

Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von

Niederhausern, A., and Wright, D., Weiss, R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0067 row: H column: 16

Seq primer: CACACAGGAACACAGCTATGACC

Class: plasmid ends

High quality sequence stop: 26.

Location/Qualifiers

1..26

/organism="Mus musculus"

/mol_type="genomic DNA"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC2M0067H16"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"

/clone_lib="Mouse 10kb plasmid UUGC1M library"

/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.7%; Score 20.8; DB 1; Length 26;

Best Local Similarity 91.7%; Pred. No. 21;

Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749

Db 1 GTGTGTGTGTGTGTGTGTGTGTGTGTGT 24

RESULT 26

AZ975568/c

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

26 bp DNA linear GSS 27-APR-2001

clone UUGC2M0250L12 R, genomic survey sequence.

GI:13846795

Mus musculus (house mouse)

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 26)

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,

Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,

Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von

Niederhausern, A., and Wright, D., Weiss, R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0250 row: L column: 12

Seq primer: CACACAGGAACACAGCTATGACC

FEATURES source Location/Qualifiers
 1. .23
 /organism="Glossina morsitans morsitans"
 /mol_type="mRNA"
 /sub_species="morsitans"
 /db_xref="taxon:37546"
 /clone="Tse34f11_pic"
 /tissue_type="adult infected gut"
 /clone_lib="Glossina morsitans morsitans adult infected gut"
 /notes="country: Zimbabwe; EST from adult gut infected with T.brucei"

Query Match 0.7%; Score 20.4; DB 1; Length 23;
 Best Local Similarity 95.5%; Pred. No. 21;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749

Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 29
 AZ328763
 LOCUS
 DEFINITION
 1M0052L12R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 clone UUGC1M0052L12 R, genomic survey sequence.

ACCESSION
 AZ328763
 VERSION
 AZ328763.1 GI:10388815

KEYWORDS
 GSS.

SOURCE
 Mus musculus (house mouse)

ORGANISM
 Mus musculus

REFERENCE
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

AUTHORS
 1 (bases 1 to 23)

TITLE
 Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
 Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
 Niederhausern,A. and Wright,D., Weiss,R.

JOURNAL
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts

COMMENT
 Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0052 row: L column: 12
 Seq primer: CACACAGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 23.

FEATURES source Location/Qualifiers
 1. .23
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0052L12"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="Vector: PWD42nv; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were

ligated to the blunt ends in high molar excess. The
 adaptor DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
 inducible derivative of plasmid R1. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells
 and selected for ampicillin resistance."

Query Match 0.7%; Score 20.4; DB 1; Length 23;
 Best Local Similarity 95.5%; Pred. No. 21;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749

Db 1 GTGTGTGTGTGTGTGTGTGTGT 22

RESULT 30
 AZ483624
 LOCUS
 DEFINITION
 1M0309C01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 clone UUGC1M0309C01 R, genomic survey sequence.

ACCESSION
 AZ483624
 VERSION
 AZ483624.1 GI:10647786

KEYWORDS
 GSS.

SOURCE
 Mus musculus (house mouse)

ORGANISM
 Mus musculus

REFERENCE
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

AUTHORS
 1 (bases 1 to 23)

TITLE
 Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
 Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
 Niederhausern,A. and Wright,D., Weiss,R.

JOURNAL
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts

COMMENT
 Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0309 row: C column: 01
 Seq primer: CACACAGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 23.

FEATURES source Location/Qualifiers
 1. .23
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0309C01"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="Vector: PWD42nv; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The

adaptored DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

Query Match      0.7%; Score 20.4; DB 1; Length 23;
Best Local Similarity 95.5%; Pred. No. 21;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTATGTGT 2749
      |||||
Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

```

```

RESULT 31
AZ637290/c
LOCUS
DEFINITION
  23 bp DNA linear GSS 13-DEC-2000
  clone UUGC1M0496005 R, genomic survey sequence.
ACCESSION
  AZ637290
VERSION
  GSS.
KEYWORDS
  Mus musculus (house mouse)
ORGANISM
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
  1 (bases 1 to 23)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0496 row: 0 column: 05
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 23.
Location/Qualifiers
  1..23
  /organism="Mus musculus"
  /mol_type="genomic DNA"
  /strain="C57BL/6J"
  /db_xref="taxon:10090"
  /clone="UUGC1M0496005"
  /sex="Male"
  /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
  /clone_lib="Mouse 10kb plasmid UUGC1M library"
  /note="Vector: PWD42nv; Purified genomic DNA from M.
  musculus C57BL/6J (male) was obtained from the Jackson
  Laboratory Mouse DNA Resource
  (http://www.jax.org/resources/documents/dnares/). The DNA
  was hydrodynamically sheared by repeated passage through a
  0.005 inch orifice at constant velocity. The sheared DNA
  was blunt end-repaired with T4 DNA polymerase and T4
  polynucleotide kinase. Adaptor oligonucleotides were
  ligated to the blunt ends in high molar excess. The
  adaptored DNA was purified and size-selected for a 9.5 to

```

```

FEATURES
  source
    1..23
    /organism="Mus musculus"
    /mol_type="genomic DNA"
    /strain="C57BL/6J"
    /db_xref="taxon:10090"
    /clone="UUGC1M0496005"
    /sex="Male"
    /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
    /clone_lib="Mouse 10kb plasmid UUGC1M library"
    /note="Vector: PWD42nv; Purified genomic DNA from M.
    musculus C57BL/6J (male) was obtained from the Jackson
    Laboratory Mouse DNA Resource
    (http://www.jax.org/resources/documents/dnares/). The DNA
    was hydrodynamically sheared by repeated passage through a
    0.005 inch orifice at constant velocity. The sheared DNA
    was blunt end-repaired with T4 DNA polymerase and T4
    polynucleotide kinase. Adaptor oligonucleotides were
    ligated to the blunt ends in high molar excess. The
    adaptored DNA was purified and size-selected for a 9.5 to

```

10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptored mouse DNA was annealed to adaptored vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

Query Match      0.7%; Score 20.4; DB 1; Length 23;
Best Local Similarity 95.5%; Pred. No. 21;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTATGTGT 2749
      |||||
Db 2 GTGTGTGTGTGTGTGTGTGTGT 1

```

```

RESULT 32
AZ789907/c
LOCUS
DEFINITION
  23 bp DNA linear GSS 16-FEB-2001
  clone UUGC2M0038G13 F, genomic survey sequence.
ACCESSION
  AZ789907
VERSION
  GSS.
KEYWORDS
  Mus musculus (house mouse)
ORGANISM
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
  1 (bases 1 to 23)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0038 row: G column: 13
Seq primer: CGTTCTAAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 23.
Location/Qualifiers
  1..23
  /organism="Mus musculus"
  /mol_type="genomic DNA"
  /strain="C57BL/6J"
  /db_xref="taxon:10090"
  /clone="UUGC2M0038G13"
  /sex="Male"
  /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
  /clone_lib="Mouse 10kb plasmid UUGC1M library"
  /note="Vector: PWD42nv; Purified genomic DNA from M.
  musculus C57BL/6J (male) was obtained from the Jackson
  Laboratory Mouse DNA Resource
  (http://www.jax.org/resources/documents/dnares/). The DNA
  was hydrodynamically sheared by repeated passage through a
  0.005 inch orifice at constant velocity. The sheared DNA
  was blunt end-repaired with T4 DNA polymerase and T4
  polynucleotide kinase. Adaptor oligonucleotides were
  ligated to the blunt ends in high molar excess. The
  adaptored DNA was purified and size-selected for a 9.5 to

```

```

FEATURES
  source
    1..23
    /organism="Mus musculus"
    /mol_type="genomic DNA"
    /strain="C57BL/6J"
    /db_xref="taxon:10090"
    /clone="UUGC2M0038G13"
    /sex="Male"
    /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
    /clone_lib="Mouse 10kb plasmid UUGC1M library"
    /note="Vector: PWD42nv; Purified genomic DNA from M.
    musculus C57BL/6J (male) was obtained from the Jackson
    Laboratory Mouse DNA Resource
    (http://www.jax.org/resources/documents/dnares/). The DNA
    was hydrodynamically sheared by repeated passage through a
    0.005 inch orifice at constant velocity. The sheared DNA
    was blunt end-repaired with T4 DNA polymerase and T4
    polynucleotide kinase. Adaptor oligonucleotides were
    ligated to the blunt ends in high molar excess. The
    adaptored DNA was purified and size-selected for a 9.5 to

```

electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.7%; Score 20.4; DB 1; Length 23;
Best Local Similarity 95.5%; Pred. No. 21;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGT 2749
|||||
Db 22 GTGTGTGTGTGTGTGTGTGTGTGTGT 1

RESULT 33
AZ828969/c
LOCUS 23 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0106013F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0106013 F, genomic survey sequence.

ACCESSION AZ828969
VERSION AZ828969.1 GI:12998877
KEYWORDS GSS.

SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 23)

AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0106 row: 0 column: 13
Seq primer: CGTTGTAAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 23.

Location/Qualifiers
1..23

FEATURES
source
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0106013"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative

of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.7%; Score 20.4; DB 1; Length 23;
Best Local Similarity 95.5%; Pred. No. 21;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGT 2749
|||||
Db 23 GTGTGTGTGTGTGTGTGTGTGTGTGT 2

RESULT 34
AZ829195/c

LOCUS 23 bp DNA linear GSS 20-FEB-2001
DEFINITION 2M0106M12R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0106M12 R, genomic survey sequence.

ACCESSION AZ829195
VERSION AZ829195.1 GI:12999103
KEYWORDS GSS.

SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. 1 (bases 1 to 23)

AUTHORS Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0106 row: M column: 12
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 23.

Location/Qualifiers
1..23

FEATURES
source
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0106M12"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.7%; Score 20.4; DB 1; Length 23;
Best Local Similarity 95.5%; Pred. No. 21;
Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749

Db 22 GTGTGTGTGTGTGTGTGTGTGT 1

RESULT 35

LOCUS BX559963 24 bp mRNA linear EST 10-OCT-2003
DEFINITION BX559963 Glossina morsitans morsitans adult infected gut Glossina morsitans morsitans cDNA clone Tse47a03_p1c, mRNA sequence.

ACCESSION BX559963

VERSION BX559963.1 GI:333367923

KEYWORDS EST

ORGANISM Glossina morsitans morsitans

Source: Glossina morsitans morsitans
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota; Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha; Hippoboscidae; Glossinidae; Glossina.

REFERENCE 1 (bases 1 to 24)

AUTHORS Lehane,M.J., Aksoy,S., Gibson,W., Kexhornou,A., Berrinan,M., Hamilton,J., Soares,M.B., Bonaldo,M.F., Lehane,S. and Hall,N.
TITLE Adult midgut expressed sequence tags from the tsetse fly Glossina morsitans morsitans and expression analysis of putative immune response genes

JOURNAL Genome Biol. 4 (10), R63 (2003)

MEDLINE 22881942

PUBMED 14519198

COMMENT Contact: Hall N

Pathogen Sequencing Unit

The Sanger Institute The Wellcome Trust Genome Campus

Hinxton, Cambridge, CB10 1SA, UK

Request for clones, please contact: Mike Lehane

Prof. M.J.Lehane

School of Biological Sciences,

University of Wales,

Bangor LL57 2UW

All clones with suffix q1c are reverse primer reads starting at 5' end of the cDNA all p1c reads are from the 3' end.

FEATURES

Location/Qualifiers

1..24

/organism="Glossina morsitans morsitans"

/mol_type="mRNA"

/sub_species="morsitans"

/db_xref="taxon:37546"

/clone="Tse47a03_p1c"

/tissue_type="adult infected gut"

/clone_lib="Glossina morsitans morsitans adult infected gut"

/note="country: Zimbabwe; EST from adult gut infected with T.brucei"

Query Match

Best Local Similarity 0.7%; Score 20.4; DB 1; Length 24;

Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749

Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 36

AZ419602

LOCUS

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0196 row: L column: 12

Seq primer: CGTTGTAACGACGCGCAGT

Class: plasmid ends

High quality sequence stop: 24.

Location/Qualifiers

1..24

/organism="Mus musculus"

/mol_type="genomic DNA"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUC1W0196L12"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"

/clone_lib="Mouse 10kb plasmid UUC1W library"

/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match

Best Local Similarity 0.7%; Score 20.4; DB 1; Length 24;

Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749

Db 2 GTGTGTGTGTGTGTGTGTGTGT 23

RESULT 37

AZ446429

LOCUS
 DEFINITION 1M0242A24R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 clone UUGC1M0242A24 R, genomic survey sequence.

ACCESSION AZ446429
 VERSION AZ446429
 KEYWORDS AZ446429.1 GI:10597224
 GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus

REFERENCE
 AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 24)
 Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
 Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
 Niederhausern,A. and Wright,D. Weiss,R.
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts

TITLE Unpublished (2000)
 JOURNAL Contact: Robert B. Weiss
 COMMENT University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0242 row: A column: 24
 Seq primer: CACACAGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 24.

FEATURES
 Location/Qualifiers
 1..24
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0242A24"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="Vector: PWD42nv; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 adaptor DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
 inducible derivative of plasmid R1. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells
 and selected for ampicillin resistance."

Query Match 0.7%; Score 20.4; DB 1; Length 24;
 Best Local Similarity 95.5%; Pred. No. 22;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 |||||
 Db 3 GTGTGTGTGTGTGTGTGTGTGTGTGT 24

RESULT 38
 AZ621455
 LOCUS 24 bp DNA linear GSS 13-DEC-2000

DEFINITION
 ACCESSION
 VERSION
 KEYWORDS
 SOURCE
 ORGANISM

REFERENCE
 AUTHORS

TITLE

JOURNAL
 COMMENT

FEATURES
 Location/Qualifiers

1M0454K11R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 clone UUGC1M0454K11 R, genomic survey sequence.

ACCESSION AZ621455
 VERSION AZ621455.1 GI:11743645
 GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus

REFERENCE
 AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 24)
 Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
 Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
 Niederhausern,A. and Wright,D. Weiss,R.
 Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts

TITLE Unpublished (2000)
 JOURNAL Contact: Robert B. Weiss
 COMMENT University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0454 row: K column: 11
 Seq primer: CACACAGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 24.

FEATURES
 Location/Qualifiers
 1..24
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0454K11"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="Vector: PWD42nv; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 adaptor DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
 inducible derivative of plasmid R1. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells
 and selected for ampicillin resistance."

Query Match 0.7%; Score 20.4; DB 1; Length 24;
 Best Local Similarity 95.5%; Pred. No. 22;
 Matches 21; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 |||||
 Db 2 GTGTGTGTGTGTGTGTGTGTGTGTGT 23

RESULT 39
 AZ807762
 LOCUS 24 bp DNA linear GSS 20-FEB-2001
 DEFINITION 2M0070014R Mouse 10kb plasmid UUGC1M library Mus musculus genomic


```

SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens
REFERENCE
AUTHORS         Hillier, L., Lennon, G., Becker, M., Bonaldo, M.F., Chiapelli, B.,
                Chissole, S., Dietrich, N., DuBuque, T., Favello, A., Gish, W.,
                Hawkins, M., Hultman, M., Kucaba, T., Lacy, M., Le, M., Le, N.,
                Mardis, E., Moore, B., Morris, M., Parsons, J., Prange, C., Rifkin, L.,
                Rohlfing, T., Schellenberg, K., Soares, M.B., Tan, F., Thierry-Mieg, J.,
                Trevaaskis, E., Underwood, K., Wohldmann, P., Waterston, R., Wilson, R.,
                and Marra, M.
TITLE           Generation and analysis of 280,000 human expressed sequence tags
JOURNAL         Genome Res. 5 (9), 807-828 (1996)
MEDLINE         97044478
PUBMED         8889549
COMMENT         Contact: Wilson RK
                Washington University School of Medicine
                4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
                Tel: 314 286 1800
                Fax: 314 286 1810
                Email: est@watson.wustl.edu
                This clone is available royalty-free through LNL ; contact the
                IMAGE Consortium (info@image.llnl.gov) for further information.
                Trace considered overall poor quality
                Insert Length: 1416 Std Error: 0.00
                Seq primer: reverse ET
                High quality sequence stop: 1.
                Location/Qualifiers
                1..25
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="GDB:3795466"
                /db_xref="taxon:9606"
                /clone="IMAGE:246220"
                /sex="male"
                /dev_stage="20 week-post conception fetus"
                /lab_host="DH10B (ampicillin resistant)"
                /clone_lib="Soares fetal liver spleen 1NFLS"
                /note="Organ: Liver and Spleen; Vector: pT73D (Pharmacia)
                with a modified polylinker; Site_1: Pac I; Site_2: Eco RI;
                1st strand cDNA was primed with a Pac I - oligo(dT) primer
                [5', AACTGGAAGATTAATTAAGATCTTTTTTTTTTTTTTTT 3'],
                double-stranded cDNA was ligated to Eco RI adaptors
                (Pharmacia), digested with Pac I and cloned into the Pac I
                and Eco RI sites of the modified pT73 vector. Library
                went through one round of normalization. Library
                constructed by Bento Soares and M.Fatima Bonaldo."

Query Match          0.7%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGCTGGAGTGCAGTGG 2790
      |||||
Db 24 CCCAGCTGGAGTGCAGTGG 5

RESULT 45
LOCUS      A2309945/c
DEFINITION clone UUGC1M0017K22 F, genomic survey sequence.
ACCESSION  A2309945
VERSION     A2309945.1 GI:10351443
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1 (bases 1 to 23)
AUTHORS     Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
                Islam, H., Longacre, S., Mahmood, M., Meenen, E., Pedersen, T.,
                Reilly, M., Rose, R., Stokes, R., Tingey, A., von
                Niederhausern, A. and Wright, D., Weiss, R.
TITLE       Mouse whole genome scaffolding with paired end reads from 10kb
                plasmid inserts
JOURNAL     Unpublished (2000)
COMMENT     Contact: Robert B. Weiss
                University of Utah Genome Center
                Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
                84112, USA
                Tel: 801 585 5606
                Fax: 801 585 7177
                Email: dunn@genetics.utah.edu
                Insert Length: 10000 Std Error: 0.00
                Plate: 0189 row: G column: 17
                Seq primer: CACACAGGAACAGCTATGACC
                Class: plasmid ends
                High quality sequence stop: 21.
                Location/Qualifiers
                1..21
                /organism="Mus musculus"
                /mol_type="genomic DNA"
                /strain="C57BL/6J"
                /db_xref="taxon:10090"
                /clone="UUGC1M0189G17"
                /sex="Male"
                /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
                /clone_lib="Mouse 10kb plasmid UUGC1M library"
                /note="Vector: PWD42nv; Purified genomic DNA from M.
                musculus C57BL/6J (male) was obtained from the Jackson
                Laboratory Mouse DNA Resource
                (http://www.jax.org/resources/documents/dnares/). The DNA
                was hydrodynamically sheared by repeated passage through a
                0.005 inch orifice at constant velocity. The sheared DNA
                was blunt end-repaired with T4 DNA polymerase and T4
                polynucleotide kinase. Adaptor oligonucleotides were
                ligated to the blunt ends in high molar excess. The
                adaptor DNA was purified and size-selected for a 9.5 to
                10.5 kb range using preparative agarose gel
                electrophoresis. Vector DNA was prepared from a derivative
                of PWD42 (gi|4732114|gb|AF129072.1), a copy-number
                inducible derivative of plasmid R1. The vector was ligated
                with adaptors complementary to the insert adaptors and
                purified. The sheared, adaptor mouse DNA was annealed to
                adaptor vector DNA, and transformed into
                chemically-competent E. coli XL10-Gold (Stratagene) cells
                and selected for ampicillin resistance."

Query Match          0.7%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 22;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2730 GTGTGTGTGTGTGTGTGTGT 2749
      |||||
Db 1 GTGTGTGTGTGTGTGTGTGT 20

RESULT 44
LOCUS      N77071/c
DEFINITION yv51a03.r1 Soares fetal liver spleen 1NFLS Homo sapiens cDNA clone
                IMAGE:246220 5', similar to gb|J01853|DOGSRP RNA Dog signal
                recognition particle (rRNA); mRNA sequence.
ACCESSION  N77071
VERSION     N77071.1 GI:1239649
KEYWORDS    EST.

```

```

SOURCE          Homo sapiens (human)
ORGANISM        Homo sapiens
REFERENCE
AUTHORS         Hillier, L., Lennon, G., Becker, M., Bonaldo, M.F., Chiapelli, B.,
                Chissole, S., Dietrich, N., DuBuque, T., Favello, A., Gish, W.,
                Hawkins, M., Hultman, M., Kucaba, T., Lacy, M., Le, M., Le, N.,
                Mardis, E., Moore, B., Morris, M., Parsons, J., Prange, C., Rifkin, L.,
                Rohlfing, T., Schellenberg, K., Soares, M.B., Tan, F., Thierry-Mieg, J.,
                Trevaaskis, E., Underwood, K., Wohldmann, P., Waterston, R., Wilson, R.,
                and Marra, M.
TITLE           Generation and analysis of 280,000 human expressed sequence tags
JOURNAL         Genome Res. 5 (9), 807-828 (1996)
MEDLINE         97044478
PUBMED         8889549
COMMENT         Contact: Wilson RK
                Washington University School of Medicine
                4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
                Tel: 314 286 1800
                Fax: 314 286 1810
                Email: est@watson.wustl.edu
                This clone is available royalty-free through LNL ; contact the
                IMAGE Consortium (info@image.llnl.gov) for further information.
                Trace considered overall poor quality
                Insert Length: 1416 Std Error: 0.00
                Seq primer: reverse ET
                High quality sequence stop: 1.
                Location/Qualifiers
                1..25
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="GDB:3795466"
                /db_xref="taxon:9606"
                /clone="IMAGE:246220"
                /sex="male"
                /dev_stage="20 week-post conception fetus"
                /lab_host="DH10B (ampicillin resistant)"
                /clone_lib="Soares fetal liver spleen 1NFLS"
                /note="Organ: Liver and Spleen; Vector: pT73D (Pharmacia)
                with a modified polylinker; Site_1: Pac I; Site_2: Eco RI;
                1st strand cDNA was primed with a Pac I - oligo(dT) primer
                [5', AACTGGAAGATTAATTAAGATCTTTTTTTTTTTTTTTT 3'],
                double-stranded cDNA was ligated to Eco RI adaptors
                (Pharmacia), digested with Pac I and cloned into the Pac I
                and Eco RI sites of the modified pT73 vector. Library
                went through one round of normalization. Library
                constructed by Bento Soares and M.Fatima Bonaldo."

Query Match          0.7%; Score 20; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2771 CCCAGCTGGAGTGCAGTGG 2790
      |||||
Db 24 CCCAGCTGGAGTGCAGTGG 5

RESULT 45
LOCUS      A2309945/c
DEFINITION clone UUGC1M0017K22 F, genomic survey sequence.
ACCESSION  A2309945
VERSION     A2309945.1 GI:10351443
KEYWORDS    GSS.
SOURCE      Mus musculus (house mouse)
ORGANISM    Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE   1 (bases 1 to 23)
AUTHORS     Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
                Islam, H., Longacre, S., Mahmood, M., Meenen, E., Pedersen, T.,

```


TITLE Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0062 row: P column: 13
Seq primer: CGTTGTAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 21.
Location/Qualifiers
1. .21
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0062P13"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and 14
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

Query Match 0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
|||||
Db 1 TGTGTGTGTGTGTGTGTGTGT 21

RESULT 48
AZ635627
LOCUS 21 bp DNA linear GSS 13-DEC-2000
DEFINITION IM0493D06F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0493D06 F, genomic survey sequence.
ACCESSION AZ635627
VERSION AZ635627.1 GI:11757817
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 21)
REFERENCE
AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Reilly, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausern, A. and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb

TITLE Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
JOURNAL Unpublished (2000)
COMMENT Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0062 row: P column: 13
Seq primer: CGTTGTAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 21.
Location/Qualifiers
1. .21
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0493D06"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and 14
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

Query Match 0.6%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 25;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2748
|||||
Db 1 GTGTGTGTGTGTGTGTGTGTGT 21

RESULT 49
AZ641805
LOCUS 21 bp DNA linear GSS 14-DEC-2000
DEFINITION IM0504J04R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0504J04 R, genomic survey sequence.
ACCESSION AZ641805
VERSION AZ641805.1 GI:11766140
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 21)
REFERENCE
AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Reilly, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausern, A. and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0310 row: 1 column: 15
 Seq primer: CGTTGTAACGACGCGCCAGT
 Class: plasmid ends
 High quality sequence stop: 22.

FEATURES

source

```
1..22
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0310115"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
```

Query Match 0.6%; Score 19.4; DB 1; Length 22;
 Best Local Similarity 95.2%; Pred. No. 26;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
 |||||
 Db 1 TGTGTGTGTGTGTGTGTGTGT 21

RESULT 54

AZ780002/c
 LOCUS AZ780002 22 bp DNA linear GSS 16-FEB-2001
 DEFINITION clone UUGC2M001620 R, genomic survey sequence.

ACCESSION AZ780002
 VERSION AZ780002.1 GI:12911227
 KEYWORDS GSS.

SOURCE Mus musculus (house mouse)

ORGANISM

Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 22)

AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, R., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)

COMMENT Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0016 row: J column: 20
 Seq primer: CACACAGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 22.

FEATURES

Location/Qualifiers

```
1..22
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M001620"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
```

Query Match 0.6%; Score 19.4; DB 1; Length 22;
 Best Local Similarity 95.2%; Pred. No. 26;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTG 2748
 |||||
 Db 22 GTGTGTGTGTGTGTGTGTGTG 2

RESULT 55

LOCUS

AZ371475 23 bp DNA linear GSS 02-OCT-2000
 DEFINITION 1M0122K19R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0122K19 R, genomic survey sequence.

ACCESSION AZ371475
 VERSION AZ371475.1 GI:10485175
 KEYWORDS GSS.

SOURCE Mus musculus (house mouse)

ORGANISM

Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 23)

AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, R., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

JOURNAL Unpublished (2000)

COMMENT Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

Tel: 801 585 5606
 Fax: 801 585 7177
 Email: dunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0122 row: K column: 19
 Seq primer: CACACAGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 23.
 Location/Qualifiers
 1. .23

FEATURES

source

```

/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0122K19"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

Query Match 0.6%; Score 19.4; DB 1; Length 23;
 Best Local Similarity 95.2%; Pred. No. 27;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 |||||
 Db 3 TGTGTGTGTGTGTGTGTGTGTGTGTGT 23

RESULT 56
 AZ602037
 LOCUS 23 bp DNA linear GSS 13-DEC-2000
 DEFINITION 1M0420A10R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0420A10 R, genomic survey sequence.
 ACCESSION AZ602037
 VERSION AZ602037.1 GI:11724227
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 23)
 REFERENCE
 AUTHORS Dunn,D., Aoyagi,A., Barber,M., Becorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,R., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
 TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 JOURNAL Unpublished (2000)
 COMMENT Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606

Fax: 801 585 7177
 Email: dunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0420 row: A column: 10
 Seq primer: CACACAGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 23.
 Location/Qualifiers
 1. .23

FEATURES

source

```

/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0420A10"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

Query Match 0.6%; Score 19.4; DB 1; Length 23;
 Best Local Similarity 95.2%; Pred. No. 27;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGTGTGT 2748
 |||||
 Db 3 GTGTGTGTGTGTGTGTGTGTGTGTGT 23

RESULT 57
 AZ824638
 LOCUS 23 bp DNA linear GSS 20-FEB-2001
 DEFINITION 2M0099A22F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0099A22 F, genomic survey sequence.
 ACCESSION AZ824638
 VERSION AZ824638.1 GI:12994546
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 23)
 REFERENCE
 AUTHORS Dunn,D., Aoyagi,A., Barber,M., Becorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,R., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.
 TITLE Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 JOURNAL Unpublished (2000)
 COMMENT Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177

Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0099 row: A column: 22
 Seq primer: CGTTGTAACAGCGCCAGT
 Class: plasmid ends
 High quality sequence stop: 23.

FEATURES

source

1. .23
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC2M0099A22"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.6%; Score 19.4; DB 1; Length 23;
 Best Local Similarity 95.2%; Pred. No. 27;
 Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2749
 |||||
 DB 2 TGTGTGTGTGTGTGTGTGTGTGTGTGTGT 22

RESULT 58
 AZ500466
 LOCUS 22 bp DNA linear GSS 05-OCT-2000
 DEFINITION IM0338A23R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0338A23 R, genomic survey sequence.
 ACCESSION AZ500466
 VERSION AZ500466.1 GI:10680306
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 22)
 DUNN, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, R., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.
 Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
 Plate: 0338 row: A column: 23
 Seq primer: CACACAGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 22.

FEATURES

source

1. .22
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0338A23"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.6%; Score 18.8; DB 1; Length 22;
 Best Local Similarity 90.9%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2722 ATCCCGTGTGTGTGTGTGTGTGTGTGTGTGTGT 2743
 |||||
 DB 1 ATGCACGTGTGTGTGTGTGTGTGTGTGTGTGT 22

RESULT 59
 AZ793094
 LOCUS 22 bp DNA linear GSS 16-FEB-2001
 DEFINITION 2M0045H20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC2M0045H20 R, genomic survey sequence.
 ACCESSION AZ793094
 VERSION AZ793094.1 GI:12937525
 KEYWORDS GSS.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 22)
 DUNN, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, R., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.
 Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts
 Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00

Plate: 0045 row: H column: 20
 Seq primer: CACACAGGAACAGTATGACC
 Class: plasmid ends
 High quality sequence stop: 22.

FEATURES

source

```

1..22
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0045H20"
/sex="Male"
/lab host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
```

Query Match 0.6%; Score 18.8; DB 1; Length 22;
 Best Local Similarity 90.9%; Pred. No. 31;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749

Db 1 GTGTGTGTGTGTGTGTGTGTGT 22

RESULT 60

AZ356191/c

LOCUS

DEFINITION 23 bp DNA linear GSS 02-OCT-2000
 clone UUGC1M0097L07 F, genomic survey sequence.

ACCESSION AZ356191

VERSION AZ356191.1

KEYWORDS GSS.

SOURCE Mus musculus (house mouse)

ORGANISM

REFERENCE 1 (bases 1 to 23)
 Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, R., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.

Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0097 row: L column: 07

Seq primer: CGTTGTAACGACGCGCAGT
 Class: plasmid ends
 High quality sequence stop: 23.

FEATURES

source

```

1..23
/location/Qualifiers
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0097L07"
/sex="Male"
/lab host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
```

Query Match 0.6%; Score 18.8; DB 1; Length 23;
 Best Local Similarity 90.9%; Pred. No. 32;
 Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGTGT 2749

Db 23 GTGTGTGTGTGTGTGTGTGTGT 2

RESULT 61

AZ368875

LOCUS

DEFINITION 20 bp DNA linear GSS 02-OCT-2000
 clone UUGC1M0119112 F, genomic survey sequence.

ACCESSION AZ368875

VERSION AZ368875.1

KEYWORDS GSS.

SOURCE Mus musculus (house mouse)

ORGANISM

REFERENCE 1 (bases 1 to 20)
 Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C., Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T., Reilly, M., Rose, R., Rose, R., Stokes, R., Tingey, A., von Niederhausern, A. and Wright, D., Weiss, R.

Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0119 row: I column: 12

Seq primer: CGTTGTAACGACGCGCAGT

```

Class: plasmid ends
High quality sequence stop: 20.
Location/Qualifiers
1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0119112"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrotynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid RI. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 32;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGT 2747
Db 1 GTGTGTGTGTGTGTGTGTGT 20

RESULT 62
AZ465453
LOCUS
DEFINITION
1M0275F24F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0275F24 F, genomic survey sequence.
ACCESSION
AZ465453
VERSION
AZ465453.1 GI:10623578
KEYWORDS
GSS.
SOURCE
Mus musculus (house mouse)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 20)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0275 row: F column: 24
Seq primer: CGTTGTAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 20.

Class: plasmid ends
High quality sequence stop: 20.
Location/Qualifiers
1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0119112"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrotynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid RI. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 32;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGTGT 2747
Db 1 GTGTGTGTGTGTGTGTGTGT 20

RESULT 62
AZ465453
LOCUS
DEFINITION
1M0275F24F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0275F24 F, genomic survey sequence.
ACCESSION
AZ465453
VERSION
AZ465453.1 GI:10623578
KEYWORDS
GSS.
SOURCE
Mus musculus (house mouse)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 20)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0275 row: F column: 24
Seq primer: CGTTGTAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 20.

```

FEATURES

source

Location/Qualifiers

```

1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clones="UUGC1M0285H09"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/vector="PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 32;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2729 TGTGTGTGTGTGTATGTG 2748
 |||||
 Db 1 TGTGTGTGTGTGTGTGTG 20

RESULT 64

AZ580200

LOCUS

DEFINITION 20 bp DNA linear GSS 13-DEC-2000
 clone UUGC1M0368A20 F, genomic survey sequence.

ACCESSION

AZ580200

VERSION

AZ580200.1

GI:11694629

GSS.

KEYWORDS

SOURCE

Mus musculus

Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.

1 (bases 1 to 20)

Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,

Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,

Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von

Niederhausern,A. and Wright,D.,Weiss,R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0368 row: A column: 20

Seq primer: CGTTGTAACACGCGCCAGT

Class: plasmid ends

High quality sequence stop: 20.

FEATURES

Location/Qualifiers

source

```

1. .20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clones="UUGC1M0368A20"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/vector="PMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

Query Match 0.6%; Score 18.4; DB 1; Length 20;
 Best Local Similarity 95.0%; Pred. No. 32;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2729 TGTGTGTGTGTGTATGTG 2748
 |||||
 Db 1 TGTGTGTGTGTGTGTGTG 20

RESULT 65

AZ634201

LOCUS

DEFINITION 20 bp DNA linear GSS 13-DEC-2000
 clone UUGC1M0489C19 R, genomic survey sequence.

ACCESSION

AZ634201

VERSION

AZ634201.1

GI:11756391

GSS.

KEYWORDS

SOURCE

Mus musculus

Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.

1 (bases 1 to 20)

Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,

Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,

Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von

Niederhausern,A. and Wright,D.,Weiss,R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0489 row: C column: 19

Seq primer: CACACAGGAACAGGTATGACC

Class: plasmid ends

High quality sequence stop: 20.

FEATURES

Location/Qualifiers

```
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0489C19"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excesses. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match      0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 32;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY    2728 GTGTGTTGTGTGTATCT 2747
       |||||
Db     1 GTGTGTTGTGTGTGTGT 20

RESULT 66
AZ946508/c
LOCUS          20 bp   DNA        linear   GSS 27-APR-2001
DEFINITION    2M0208P13F Mouse 10kb plasmid UUGC2M library Mus musculus genomic
               clone UUGC2M0208P13 F, genomic survey sequence.
ACCESSION     AZ946508
VERSION       AZ946508.1 GI:13815584
KEYWORDS      GSS.
SOURCE        Mus musculus (house mouse)
ORGANISM      Mus musculus
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE     1 (bases 1 to 20)
AUTHORS       Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
              Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
              Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
              Niederhausern,A. and Wright,D.,Weiss,R.
              Mouse whole genome scaffolding with paired end reads from 10kb
              plasmid inserts
              Unpublished (2000)
JOURNAL       Unpublished (2000)
COMMENT       Contact: Robert B. Weiss
              University of Utah Genome Center
              Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLCC, UT
              84112, USA
              Tel: 801 585 5606
              Fax: 801 585 7177
              Email: ddunn@genetics.utah.edu
              Insert Length: 10000 Std Error: 0.00
              Plate: 0208 row: P column: 13
              Seq primer: CGTGTGAACAGCGCCAGT
              Class: plasmid ends
              High quality sequence stop: 20.
              Location/Qualifiers
                source             1..20
                  /organism="Mus musculus"
                  /mol_type="genomic DNA"

/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0489C19"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excesses. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match      0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 32;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY    2728 GTGTGTTGTGTGTATCT 2747
       |||||
Db     1 GTGTGTTGTGTGTGTGT 20

RESULT 66
AZ946508/c
LOCUS          20 bp   DNA        linear   GSS 27-APR-2001
DEFINITION    2M0208P13F Mouse 10kb plasmid UUGC2M library Mus musculus genomic
               clone UUGC2M0208P13 F, genomic survey sequence.
ACCESSION     AZ946508
VERSION       AZ946508.1 GI:13815584
KEYWORDS      GSS.
SOURCE        Mus musculus (house mouse)
ORGANISM      Mus musculus
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE     1 (bases 1 to 20)
AUTHORS       Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
              Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
              Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
              Niederhausern,A. and Wright,D.,Weiss,R.
              Mouse whole genome scaffolding with paired end reads from 10kb
              plasmid inserts
              Unpublished (2000)
JOURNAL       Unpublished (2000)
COMMENT       Contact: Robert B. Weiss
              University of Utah Genome Center
              Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLCC, UT
              84112, USA
              Tel: 801 585 5606
              Fax: 801 585 7177
              Email: ddunn@genetics.utah.edu
              Insert Length: 10000 Std Error: 0.00
              Plate: 0208 row: P column: 13
              Seq primer: CGTGTGAACAGCGCCAGT
              Class: plasmid ends
              High quality sequence stop: 20.
              Location/Qualifiers
                source             1..20
                  /organism="Mus musculus"
                  /mol_type="genomic DNA"
```



```

/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0226L05"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC2M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match      0.6%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 32;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  2729 TGTGTGTGTGTGTGTGTGTG 2748
      |||||
Db   20 TGTGTGTGTGTGTGTGTGTG 1

```

```

RESULT 68
AZ991225/c
LOCUS      21 bp      DNA      linear      GSS 27-APR-2001
DEFINITION 2M0275K17F Mouse 10kb plasmid UUGC2M library Mus musculus genomic
clone UUGC2M0275K17 F, genomic survey sequence.
ACCESSION  AZ991225
VERSION     AZ991225.1  GI:13862452
KEYWORDS   GSS.
SOURCE     Mus musculus (house mouse)
ORGANISM   Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 21)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0275 row: K column: 17
Seq primer: CGTTGTAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 21.
Location/Qualifiers
1. .21
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"

```

```

/db_xref="taxon:10090"
/clone="UUGC2M0275K17"
/sex="Female"
/lab_host="E. coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC2M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (female) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match      0.6%; Score 18.4; DB 1; Length 21;
Best Local Similarity 95.0%; Pred. No. 33;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY  2728 GTGTGTGTGTGTGTGTGTGTG 2747
      |||||
Db   21 GTGTGTGTGTGTGTGTGTGTG 2

```

RESULT 69

AZ514387/c

LOCUS 22 bp DNA linear GSS 05-OCT-2000

DEFINITION 1M0361H03F Mouse 10kb plasmid UUGC1M library Mus musculus genomic clone UUGC1M0361H03 F, genomic survey sequence.

ACCESSION AZ514387

VERSION AZ514387.1 GI:10695703

KEYWORDS GSS.

SOURCE Mus musculus (house mouse)

ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 22)

Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C., Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T., Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von Niederhausern,A. and Wright,D.,Weiss,R.

Mouse whole genome scaffolding with paired end reads from 10kb plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT 84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0361 row: H column: 03

Seq primer: CGTTGTAACGACGCCAGT

Class: plasmid ends

High quality sequence stop: 22.

Location/Qualifiers

1. .22

/organism="Mus musculus"

/mol_type="genomic DNA"

/strain="C57BL/6J"

/db_xref="taxon:10090"

FEATURES

source

/lab host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /clone lib="Mouse 10kb plasmid UUGC1M library"
 /note="Vector: PWD42nv; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA
 was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 adaptor DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative
 of pWD42 [gi|4732114|gb|AF129072.1|], a copy-number
 inducible derivative of plasmid R1. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells
 and selected for ampicillin resistance."

Query Match 0.6%; Score 18.4; DB 1; Length 23;
 Best Local Similarity 95.0%; Pred. No. 35;
 Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGTGT 2747
 |||||
 Db 4 GTGTGTGTGTGTGTGTGT 23

RESULT 72
 AA995094/c
 LOCUS
 DEFINITION
 ou89g09.s1 NCI CGAP Kid3 Homo sapiens cDNA clone IMAGE:1635040 3'
 similar to TR:Q69566 Q69566 ;contains TAR1.t2 MER35 repetitive
 element ;, mRNA sequence.

ACCESSION
 AA995094 GI:3181583
 VERSION
 EST.

SOURCE
 Homo sapiens (human)

ORGANISM
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
 1 (bases 1 to 19)
 NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.

AUTHORS
 National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index

JOURNAL
 Unpublished (1997)

COMMENT
 Contact: Robert Strausberg, Ph.D.

Email: cgapps-r@mail.nih.gov

Tissue procurement: Christopher Moskaluk, M.D., Ph.D., Michael R.

Emmert-Buck, M.D., Ph.D.

CDNA Library Prepared by: M. Bento Soares, Ph.D.

CDNA Library Arrayed by: Greg Lennon, Ph.D.

DNA Sequencing by: Washington University Genome Sequencing Center
 Clone distribution: NCI-CGAP clone distribution information can be
 found through the I.M.A.G.E. Consortium/LINL at:

www.bio.llnl.gov/bbrp/image/image.html

Trace considered overall poor quality

Insert Length: 1087 Std Error: 0.00

Seq primer: -40ml3 fwd. ET from Amersham

High quality sequence stop: 1.

Location/Qualifiers

1..19

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="IMAGE:1635040"

/lab_host="DH10B"

/clone lib="NCI CGAP Kid3"

/note="Organ: Kidney; Vector: pT73D-Pac (Pharmacia) with

a modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st
 strand cDNA was primed with a Not I - oligo(dT) primer,
 double-stranded cDNA was ligated to Eco RI adaptors
 (Pharmacia), digested with Not I and cloned into the Not
 I and Eco RI sites of the modified pT73 vector. mRNA
 source: 2 pooled kidneys. Library went through one round
 of normalization. Library constructed by Bento Soares and
 M. Fatima Bonaldo. "

Query Match 0.6%; Score 18; DB 1; Length 19;

Best Local Similarity 100.0%; Pred. No. 34;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2726 GCGTGTGTGTGTGTGTGT 2743
 |||||
 Db 19 GCGTGTGTGTGTGTGTGT 2

RESULT 73

AZ491644

LOCUS

DEFINITION

1M0325A20F Mouse 10kb plasmid UUGC1M library Mus musculus genomic

clone UUGC1M0325A20 F, genomic survey sequence.

ACCESSION

AZ491644

VERSION

AZ491644.1 GI:10663543

KEYWORDS

GSS.

SOURCE

Mus musculus

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

1 (bases 1 to 19)

AUTHORS

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,

Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,

Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von

Niederhausern, A. and Wright, D., Weiss, R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0325 row: A column: 20

Seq primer: CGTTGTAAACGACGCCAGT

Class: plasmid ends

High quality sequence stop: 19.

Location/Qualifiers

1..19

/organism="Mus musculus"

/mol_type="genomic DNA"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC1M0325A20"

/sex="Male"

/lab host="E. Coli strain XL10-Gold, T1-resistant, F-"

/clone lib="Mouse 10kb plasmid UUGC1M library"

/note="Vector: PWD42nv; Purified genomic DNA from M.

musculus C57BL/6J (male) was obtained from the Jackson

Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA

was hydrodynamically sheared by repeated passage through a

0.005 inch orifice at constant velocity. The sheared DNA

was blunt end-repaired with T4 DNA polymerase and T4

polynucleotide kinase. Adaptor oligonucleotides were

ligated to the blunt ends in high molar excess. The

adapted DNA was purified and size-selected for a 9.5 to

10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative

FEATURES

source

adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.6%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 40;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGTGT 2749
|||||
Db 1 TGTGTGTGTGTGTGTGTGT 21

RESULT 78
AZ801266
LOCUS
DEFINITION
2M0059107R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0059107 R, genomic survey sequence.
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Mus musculus
(house mouse)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 22)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Reilly, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausern, A. and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0059 row: I column: 07
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 22.

FEATURES
source
1..22
Location/Qualifiers
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0059107"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M.
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into

chemically-competent *E. coli* XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

Query Match 0.6%; Score 17.8; DB 1; Length 22;
Best Local Similarity 90.5%; Pred. No. 40;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2723 TCGCGTGTGTGTGTGTGTGTGT 2743
|||||
Db 2 TCTGTGTGTGTGTGTGTGTGT 22

RESULT 79
AZ431700
LOCUS
DEFINITION
1M0216G18R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0216G18 R, genomic survey sequence.
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Mus musculus
(house mouse)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 19)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Reilly, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausern, A. and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0216 row: G column: 18
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 19.

FEATURES
source
1..19
Location/Qualifiers
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0216G18"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M.
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent *E. coli* XL10-Gold (Stratagene) cells

and selected for ampicillin resistance."

```

Query Match          0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 40;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATG 2746
      |||||
Db 1 GTGTGTGTGTGTGTG 19

```

```

RESULT 80
AZ461642/c
LOCUS          19 bp      DNA      linear      GSS 04-OCT-2000
DEFINITION    LM0267P06R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
               clone UUGC1M0267P06 R, genomic survey sequence.
ACCESSION     AZ461642
VERSION       AZ461642.1 GI:10619767
KEYWORDS      GSS.
SOURCE        Mus musculus (house mouse)
ORGANISM      Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 19)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0267 row: P column: 06
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 19.
Location/Qualifiers
1..19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0267P06"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptored DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptored mouse DNA was annealed to
adaptored vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

```

```

FEATURES
source
1..19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0267P06"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptored DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptored mouse DNA was annealed to
adaptored vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

```

```

Query Match          0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 40;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATG 2746
      |||||
Db 19 GTGTGTGTGTGTGTGTG 1

```

```

RESULT 81
AZ649147
LOCUS          19 bp      DNA      linear      GSS 14-DEC-2000
DEFINITION    1M0519B17R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
               clone UUGC1M0519B17 R, genomic survey sequence.
ACCESSION     AZ649147
VERSION       AZ649147.1 GI:11782334
KEYWORDS      GSS.
SOURCE        Mus musculus (house mouse)
ORGANISM      Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 19)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0518 row: B column: 17
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 19.
Location/Qualifiers
1..19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0519B17"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptored DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptored mouse DNA was annealed to
adaptored vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

```

```

FEATURES
source
1..19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0519B17"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptored DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptored mouse DNA was annealed to
adaptored vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

```

Query Match 0.6%; Score 17.4; DB 1; Length 19;
 Best Local Similarity 94.7%; Pred. No. 40;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
 |||||
 DB 1 TGTGTGTGTGTGTGTGT 19

RESULT 82

AZ774954/c
 LOCUS AZ774954 19 bp DNA linear GSS 16-FEB-2001
 DEFINITION 2M0004N15R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 clone UUGC2M0004N15 R, genomic survey sequence.

ACCESSION AZ774954
 VERSION AZ774954.1 GI:12900943
 KEYWORDS GSS.

SOURCE Mus musculus (house mouse)

ORGANISM

Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

1 (bases 1 to 19)

AUTHORS

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
 Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
 Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von
 Niederhausern, A. and Wright, D., Weiss, R.

TITLE

Mouse whole genome scaffolding with paired end reads from 10kb

JOURNAL

COMMENT

Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0004 row: N column: 15

Seq primer: CACACAGGAACAGCTATGACC

Class: plasmid ends

High quality sequence stop: 19.

FEATURES

source

1..19
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC2M0004N15"
 /sex="Male"

/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="Vector: PWD42nv; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA

was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 adaptor DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative

of PWD42 (gi|4732114|gb|AF129072.1), a copy-number
 inducible derivative of plasmid R1. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells
 and selected for ampicillin resistance."

Query Match

0.6%; Score 17.4; DB 1; Length 19;

Best Local Similarity 94.7%; Pred. No. 40;
 Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GGTGTGTGTGTGTGTGTGTG 2746
 |||||
 DB 19 GGTGTGTGTGTGTGTGTG 1

RESULT 83

AZ795767

LOCUS

AZ795767 19 bp DNA linear GSS 16-FEB-2001
 DEFINITION 2M0051112F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 clone UUGC2M0051112 F, genomic survey sequence.

ACCESSION AZ795767

VERSION AZ795767.1 GI:12943132

KEYWORDS GSS.

SOURCE Mus musculus (house mouse)

ORGANISM

Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

1 (bases 1 to 19)

AUTHORS

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
 Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
 Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von
 Niederhausern, A. and Wright, D., Weiss, R.

TITLE

Mouse whole genome scaffolding with paired end reads from 10kb

JOURNAL

COMMENT

Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0051 row: I column: 12

Seq primer: CGTTGTAACAGCAGCGCCAGT

Class: plasmid ends

High quality sequence stop: 19.

FEATURES

source

1..19
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC2M0051112"
 /sex="Male"

/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="Vector: PWD42nv; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource
 (http://www.jax.org/resources/documents/dnares/). The DNA

was hydrodynamically sheared by repeated passage through a
 0.005 inch orifice at constant velocity. The sheared DNA
 was blunt end-repaired with T4 DNA polymerase and T4
 polynucleotide kinase. Adaptor oligonucleotides were
 ligated to the blunt ends in high molar excess. The
 adaptor DNA was purified and size-selected for a 9.5 to
 10.5 kb range using preparative agarose gel
 electrophoresis. Vector DNA was prepared from a derivative

of PWD42 (gi|4732114|gb|AF129072.1), a copy-number
 inducible derivative of plasmid R1. The vector was ligated
 with adaptors complementary to the insert adaptors and
 purified. The sheared, adaptor mouse DNA was annealed to
 adaptor vector DNA, and transformed into
 chemically-competent E. coli XL10-Gold (Stratagene) cells
 and selected for ampicillin resistance."

Query Match

0.6%; Score 17.4; DB 1; Length 19;

Best Local Similarity 94.7%; Pred. No. 40;

Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATG 2746
|||||
Db 1 GTGTGTGTGTGTGTG 19

RESULT 84
AZ822936 19 bp DNA linear GSS 20-FEB-2001
LOCUS 2M0096E08R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC2M0096E08 R, genomic survey sequence.
ACCESSION AZ822936
VERSION
KEYWORDS
SOURCE GSS.
ORGANISM Mus musculus (house mouse)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 19)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0096 Row: E Column: 08
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 19.

FEATURES
source
1. .19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0096E08"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptored DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptored mouse DNA was annealed to
adaptored vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 40;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTATG 2746
|||||
Db 1 GTGTGTGTGTGTGTG 19

RESULT 85
AZ827177 19 bp DNA linear GSS 20-FEB-2001
LOCUS 2M0103A05R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
DEFINITION clone UUGC2M0103A05 R, genomic survey sequence.
ACCESSION AZ827177
VERSION
KEYWORDS
SOURCE GSS.
ORGANISM Mus musculus (house mouse)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 19)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0103 row: A column: 05
Seq primer: CACACAGGAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 19.

FEATURES
source
1. .19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0103A05"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptored DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptored mouse DNA was annealed to
adaptored vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

Query Match 0.6%; Score 17.4; DB 1; Length 19;
Best Local Similarity 94.7%; Pred. No. 40;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 2729 TGTGTGTGTGTGTGTGTGT 2747
Db 1 TGTGTGTGTGTGTGTGTGT 19

RESULT 86
CR786637/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

18 bp mRNA linear EST 01-OCT-2004
DKFZp468J2331.r1 468 (synonym: phrt1) Pongo pygmaeus cDNA clone
DKFZp468J2331_5', mRNA sequence.
CR786637
CR786637.1 GI:53705634
EST.
Pongo pygmaeus (orangutan)
Pongo pygmaeus
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.
1 (bases 1 to 18)
Koehler, K., Beyer, A., Mewes, H.W., Weil, B., Amid, C., Osanger, A.,
Fobo, G., Han, M. and Wiemann, S.
Pongo pygmaeus mRNA (Koehler, K., Beyer, A., Mewes, H.W., et al.)
Unpublished (2004)
Contact: MIPS
MIPS
Ingolstaedter Landstr.1, D-85764 Neuherberg, Germany
This is the 5' sequence of the clone insert. Clone from S. Wiemann,
Molecular Genome Analysis, German Cancer Research Center (DKFZ);
Email: s.wiemann@dkfz-heidelberg.de; mforschung GmbH in Berlin,
Germany. Please contact RZPD for ordering:
http://www.rzpd.de/cgi-bin/products/ci.cgi?CloneID=DKFZp468J2331
Further information about the clone and the sequencing project is
available at http://mips.gsf.de/projects/cdna/.

FEATURES
source
1..18
/organism="Pongo pygmaeus"
/mol_type="mRNA"
/db_xref="taxon:9600"
/clone="DKFZp468J2331"
/tissue_type="heart"
/dev_stage="adult"
/lab_host="DHI08"
/clone_lib="468 (synonym: phrt1)"
/notes="Vector: pSport1_Sfi; Site 1: SfiI; Site 2: SfiIb"

Query Match 0.6%; Score 17; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 42;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2902 ATTTTGTGTGTGTGTGT 2918
Db 17 ATTTTGTGTGTGTGTGT 1

RESULT 87
AZ7866779
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL

19 bp DNA linear GSS 16-FEB-2001
2M0032C01R Mouse 10kb plasmid UGCLIM library Mus musculus genomic
clone UGC2M0032C01 R, genomic survey sequence.
AZ786779
AZ786779.1 GI:12924882
GSS.
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 19)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausern, A. and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss

Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0032 row: C column: 01
Seq primer: CACACAGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 19.

FEATURES
Location/Qualifiers
1..19
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0032C01"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UGCLIM library"
/notes="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adaptored DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adaptored mouse DNA was annealed to
adaptored vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

Query Match 0.6%; Score 17; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 44;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGT 2744
Db 3 GTGTGTGTGTGTGTGT 19

RESULT 88
AZ654458
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

20 bp DNA linear GSS 14-DEC-2000
1M0528G10R Mouse 10kb plasmid UGCLIM library Mus musculus genomic
clone UGC1M0528G10 R, genomic survey sequence.
AZ654458
AZ654458.1 GI:11791604
GSS.
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 20)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausern, A. and Wright, D., Weiss, R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss

```

University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0528 row: G column: 10
 Seq primer: CACACAGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 20.

FEATURES

source

```

1..20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0528G10"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notice="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 [gi|4732114|gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

```

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 48;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
      |||||
Db 1 TGTGTGTGTGTGTGTGTGTG 20

```

```

RESULT 89
AZ785549
LOCUS
DEFINITION
2M0029F01R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0029F01 R, genomic survey sequence.
ACCESSION
AZ785549
VERSION
AZ785549.1 GI:12922419
KEYWORDS
SOURCE
Mus musculus (house mouse)
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 20)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center

```

University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA
 Tel: 801 585 5606
 Fax: 801 585 7177
 Email: ddunn@genetics.utah.edu
 Insert Length: 10000 Std Error: 0.00
 Plate: 0029 row: F column: 01
 Seq primer: CACACAGGAACAGCTATGACC
 Class: plasmid ends
 High quality sequence stop: 20.

FEATURES

source

```

1..20
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0029F01"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notice="Vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pWD42 [gi|4732114|gb|AF129072.1], a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

```

Query Match      0.6%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 48;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 2729 TGTGTGTGTGTGTGTGTGTG 2748
      |||||
Db 1 TTTGTGTGTGTGTGTGTGTG 20

```

```

RESULT 90
AZ629111
LOCUS
DEFINITION
1M0481D22R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0481D22 R, genomic survey sequence.
ACCESSION
AZ629111
VERSION
AZ629111.1 GI:11751301
KEYWORDS
SOURCE
Mus musculus (house mouse)
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 21)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D.,Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center

```

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00
Plate: 0481 row: D column: 22
Seq primer: CACACAGGAACAGCTATGACC

Class: plasmid ends
High quality sequence stop: 21.

FEATURES

source
1..21
Location/Qualifiers
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0481D22"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF125072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated
with adaptors complementary to the insert adaptors and
purified. The sheared, adapted mouse DNA was annealed to
adapted vector DNA, and transformed into
chemically-competent E. coli XL10-Gold (Stratagene) cells
and selected for ampicillin resistance."

Query Match 0.6%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 49;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Query

2729 TGTGTGTGTGTGTGTGTG 2748
|||||
1 TGTGTGTGTGTGTGTAAAGG 20

RESULT 91

AJ725584/c 18 bp mRNA linear EST 07-OCT-2004
LOCUS AJ725584 riken1 Gallus gallus cdna clone 2c16r4, mRNA sequence.
DEFINITION AJ725584
ACCESSION AJ725584.1 GI:53890998
VERSION EST.
KEYWORDS Gallus gallus (chicken)

SOURCE

ORGANISM Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
1 (bases 1 to 18)
Caldwell, R.B., Kierzek, A.M., Arakawa, H., Bezubov, Y., Zaim, J.,
Fiedler, P., Kutter, S., Blagodatki, A., Kostovska, D., Kotar, M.,
Plachy, J., Carninci, P., Hayashizaki, Y., and Buerstedde, J.M.,
Full-length cDNAs from bursal lymphocytes to facilitate gene
function analysis
Unpublished (2004)
Contact: Caldwell RB
GSF - Forschungszentrum, Institut fuer Molekulare Strahlenbiologie
Ingolstaedter Landstr. 1, D-85764 Neuherberg, GERMANY.

REFERENCE

AUTHORS
TITLE
JOURNAL
COMMENT

FEATURES

source
1..18
Location/Qualifiers

/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
/clone="2c16r4"
/cell_type="bursal lymphocyte"
/dev_stage="2-3 weeks old"
/clone_lib="riken1"
/note="CB inbred strain"

Query Match 0.5%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 49;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY

2903 TTTTITTTTTTTTTTCA 2920

Db

18 TTTTITTTTTTTTTTGA 1

RESULT 92

AZ793887/c

LOCUS AZ793887/c

DEFINITION

ACCESSION

VERSION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

TITLE

JOURNAL

COMMENT

AZ793887 20 bp DNA linear GSS 16-FEB-2001
2M0047021F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0047021 F, genomic survey sequence.

ACCESSION AZ793887
VERSION GSS.
KEYWORDS Mus musculus (house mouse)

ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 20)

AUTHORS Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Reilly, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausern, A. and Wright, D., Weiss, R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)

JOURNAL
COMMENT Contact: Robert B. Weiss
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLIC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0047 row: G column: 21
Seq primer: CGTTGTAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 20.

FEATURES

source
1..20
Location/Qualifiers
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC2M0047G21"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative

of pWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 52;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTAT 2745
|||||
Db 18 GTGTGTGTGTGTGT 1

RESULT 93
AZ398474
LOCUS
DEFINITION
IM0163G20R Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0163G20 R, genomic survey sequence.
ACCESSION
VERSION
AZ398474
KEYWORDS
GSS.
SOURCE
Mus musculus (house mouse)

ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
1 (bases 1 to 20)

AUTHORS
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausern, A. and Wright, D., Weiss, R.

TITLE
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

JOURNAL
COMMENT
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0163 row: G column: 20
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 20.

FEATURES
source
1..20
Location/Qualifiers

/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0163G20"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2732 GTGTGTGTGTGTATGT 2747
|||||
Db 5 GTGTGTGTGTGTATGT 20

RESULT 94
AZ772074
LOCUS
DEFINITION
AZ772074
ACCESSION
VERSION
AZ772074.1
KEYWORDS
GSS.
SOURCE
Mus musculus (house mouse)

ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
1 (bases 1 to 20)

AUTHORS
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausern, A. and Wright, D., Weiss, R.

TITLE
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts

JOURNAL
COMMENT
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0574 row: M column: 10
Seq primer: CACACAGGAAACAGCTATGACC
Class: plasmid ends
High quality sequence stop: 20.

FEATURES
source
1..20
Location/Qualifiers

/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUGC1M0574M10"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA
was hydrodynamically sheared by repeated passage through a
0.005 inch orifice at constant velocity. The sheared DNA
was blunt end-repaired with T4 DNA polymerase and T4
polynucleotide kinase. Adaptor oligonucleotides were
ligated to the blunt ends in high molar excess. The
adapted DNA was purified and size-selected for a 9.5 to
10.5 kb range using preparative agarose gel
electrophoresis. Vector DNA was prepared from a derivative
of pWD42 (gi|4732114|gb|AF129072.1), a copy-number
inducible derivative of plasmid R1. The vector was ligated

with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

Query Match 0.5%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 58;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2728 GTGTGTGTGTGTGTGT 2743
|||||
Db 5 GTGTGTGTGTGTGT 20

RESULT 95
CL693868/c
LOCUS
DEFINITION
CL693868 19 bp DNA linear GSS 10-JUL-2004
PRI0162d_A05_2 - PRI0162d.BR (19) Mixed stage fosmid library of *P. pacificus* var. California *Pristionchus pacificus* genomic, genomic survey sequence.
CL693868
CL693868.1 GI:50215776
GSS.
PRISTIONCHUS PACIFICUS
PRISTIONCHUS PACIFICUS
PRISTIONCHUS PACIFICUS
Eukaryota; Metazoa; Nematoda; Chromadorea; Diplogasterida; Neodiplogasteridae; *Pristionchus*.
1 (bases 1 to 19)
Srinivasan,J., Otto,G.W., Kahlow,U., Geisler,R. and Sommer,R.J.
AppADB: an AcedB database for the nematode satellite organism *Pristionchus pacificus*
Nucleic Acids Res. 32 (1), D421-D422 (2004)
Contact: Sommer RJ
Evolutionary Biology
Max-Planck-Institute for Developmental Biology
Spemannstr. 37-39, Tuebingen D-72076, Germany
Tel: 00497071601371
Fax: 00497071601498
Email: ralf.sommer@tuebingen.mpg.de
This library was generated at Caltech, Pasadena, USA and end sequenced at Vancouver, Canada.
Seq primer: T7
Class: fosmid ends.

FEATURES
Source
1..19
Location/Qualifiers
/organism="Pristionchus pacificus"
/mol_type="genomic DNA"
/strain="California"
/db_xref="taxon:54126"
/clone_lib="Mixed stage fosmid library of *P. pacificus* var. California"
/notes="Vector: pEpifos-5 Fosmid vector"

Query Match 0.5%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 59;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2630 CAGCTCCAGTTCTTCGAC 2648
|||||
Db 19 CAGCTCCAGTATCCAGCAG 1

Search completed: July 26, 2005, 15:30:03
Job time : 4 secs

This Page Blank (uspto)